P00001606T0076|17 38|alkaline phosphatases
P00001606T0076|43 57|5-nucleotidase
P00008997A0472|32 40|function
P00008997A0472|76 80|rats
P00008997A0472|11 15|HCO3
P00008997A0472|44 52|CSF PCO2
P00012653T0045|15 21|agents
P00015731A0090|103 119|dichlorphenamide
P00015731A0090|229 234|p CO2
P00015731A0090|73 86|acetazolamide
P00015731A0090|220 221|p
P00015731A0090|159 163|rise
P00015731A0090|176 177|p
P00015731A0090|88 101|methazolamide
P00023348A0601|12 18|polyps
P00025557A0100|10 21|CO2 content
P00025557A0100|73 84|body weight
P00027967A0207|118 127|formation
P00027967A0207|4 12|contrast
P00027967A0207|76 83|illness
P00027967A0207|24 37|HI antibodies
P00027967A0207|193 197|days
P00029953T0045|1 16|Characteristics
P00030937A0119|17 52|alkaline phosphatase concentrations
P00030937A0119|1 5|SGPT
P00034935A0545|1 9|Patients
P00034935A0545|27 34|disease
P00034935A0545|90 104|drug treatment
P00034935A0545|15 24|Parkinson
P00039271T0000|56 67|application
P00039271T0000|75 78|rat
P00048373A0377|39 45|mucoas
P00048373A0377|73 80|absence
P00052597T0000|1 8|Studies
P00052597T0000|46 53|sojourn
P00055040A0000|272 275|HPF
P00055040A0000|278 290|cryoglobulin
P00055040A0000|106 115|technique
P00055040A0000|326 331|blood
P00055040A0000|262 270|fraction
P00055040A0000|82 100|immunofluorescence
P00055040A0000|301 318|plasma fibrinogen
P00056901A0308|35 55|hydroxy-ethyl-starch
P00056901A0308|3 10|mixture
P00056901A0308|83 91|dilution
P00061478T0000|55 64|nutrition
P00061478T0000|6 19|complications
P00064414A1098|43 57|erythropoiesis
P00072928T0000|32 48|haemochromatosis
P00074758T0000|1 9|Patients
P00074758T0000|13 17|risk
P00088391A0181|54 72|coumarin treatment
P00088391A0181|29 37|activity
P00088391A0181|14 25|hand factor
P00092689A0352|8 9|%
P00096241A0087|1 3|T4
P00096241A0087|175 187|term infants
P00096241A0087|189 190|P
P00096241A0087|8 12|FT4I
P00096241A0087|47 53|groups
P00096241A0087|75 79|days
P00100540T0000|1 20|Aspirin intolerance
P00100540T0000|92 99|aspirin
P00101300A0257|35 42|cancers
P00101300A0257|4 9|cases
P00101300A0257|111 116|years
P00101300A0257|94 99|years
P00101300A0257|123 129|months
P00101300A0257|60 62|N1
P00105903A0288|36 47|possibility
P00105903A0288|13 21|research
P00112627A0542|35 40|mg/kg
P00112627A0542|184 192|fentanyl
P00112627A0542|172 177|mg/kg
P00112627A0542|198 203|mg/kg
P00112627A0542|94 99|doses
P00112627A0542|61 72|combination
P00114144A0189|68 83|result emphasis
P00114144A0189|103 113|hypotheses
P00114144A0189|33 38|study
P00114144A0189|189 197|Andersen
P00117748T0000|1 13|Erythromycin
P00117748T0000|77 89|skin lesions
P00118810T0001|11 18|disease
P00122718A0500|17 26|MRF units
P00122718A0500|142 150|behavior
P00130573T0054|1 4|VII
P00133214T0064|48 52|USSR
P00137671A0896|119 130|coagulation
P00137671A0896|92 101|indicator
P00139827A0000|1 18|Radioimmunoassays
P00139827A0000|101 108|estriol
P00139827A0000|143 148|total
P00139827A0000|74 77|DHA
P00139827A0000|223 231|delivery
P00139827A0000|114 122|cortisol
P00139827A0000|82 99|alpha-hydroxy-DHA
P00146327A0147|17 23|tumors
P00146327A0147|111 117|larynx
P00146327A0147|131 143|stem bronchi
P00150066A0100|40 51|coagulation
P00150066A0100|14 24|fibrinogen
P00154430A0906|5 23|Southern technique
P00154430A0906|110 112|kb
P00154430A0906|62 68|region
P00159600A0871|175 180|curve
P00159600A0871|67 77|compliance
P00159600A0871|108 117|ventricle
P00167544A0067|186 212|surface specimen technique
P00167544A0067|76 83|regions
P00167544A0067|132 151|electron microscopy
P00168431T0000|1 21|Steroid glucuronides
P00173860A0475|1 11|Riboflavin
P00173860A0475|208 213|acids
P00173860A0475|63 70|animals
P00173860A0475|151 163|disturbances
P00183063A0300|68 75|cancers
P00183063A0300|169 177|patients
P00183063A0300|5 14|incidence
P00183063A0300|161 165|cent
P00183063A0300|220 226|cancer
P00183063A0300|18 32|DNCB reactions
P00183063A0300|53 58|Stage
P00193088A0196|38 39|g
P00193088A0196|43 53|Metyrapone
P00196255A0000|205 216|bizarreness
P00196255A0000|1 18|REM dream content
P00196255A0000|162 172|hemisphere
P00196255A0000|72 81|influence
P00196255A0000|180 185|music
P00199012T0000|37 54|thyroid carcinoma
P00205074A0000|65 72|rickets
P00205074A0000|45 49|type
P00210220X0000|11 25|neurochemistry
P00216939T0001|99 103|rats
P00216939T0001|127 135|chloride
P00216939T0001|11 19|succimer
P00219565A0172|48 59|transfusion
P00219565A0172|5 14|incidence
P00221136A0984|49 55|humans
P00222102A0227|85 113|alpha-Hydroxycholecalciferol
P00222102A0227|16 24|patients
P00222102A0227|67 78|vitamin-D-3
P00222102A0227|167 173|regard
P00222102A0227|30 59|pseudohypoparathyroidism type
P00224013A0661|33 39|groups
P00224013A0661|174 184|resistance
P00224013A0661|66 74|limb VO2
P00224013A0661|7 10|VO2
P00224013A0661|312 322|comparison
P00224013A0661|502 509|hypoxia
P00224013A0661|108 113|group
P00224013A0661|392 400|pressure
P00224013A0661|54 61|hypoxia
P00224013A0661|158 162|limb
P00227393T0000|1 11|Modulation
P00227393T0000|54 67|aminophylline
P00231555T0001|51 68|combination drugs
P00231555T0001|83 87|ACTH
P00232456T0000|103 111|leukemia
P00232456T0000|16 19|RNA
P00232456T0000|168 173|genes
P00232456T0000|127 135|evidence
P00232456T0000|146 151|class
P00232456T0000|75 88|tumor viruses
P00234264A0164|101 109|children
P00234264A0164|92 97|limit
P00234264A0164|63 68|times
P00239014A0000|95 99|acid
P00239014A0000|45 58|determination
P00240016T0033|1 3|V.
P00242427T0001|42 47|nurse
P00261981A0434|70 74|rats
P00261981A0434|89 96|litters
P00265964A0562|43 57|grain boundary
P00294502T0001|37 45|Class II
P00294502T0001|15 33|treatment planning
P00303189A0247|19 22|way
P00303189A0247|57 72|serum chemistry
P00303189A0247|47 54|patient
P00304310A0000|133 137|time
P00304310A0000|89 102|stabilization
P00304310A0000|122 129|periods
P00313766A0666|101 108|control
P00313766A0666|4 12|patients
P00313766A0666|110 115|range
P00313766A0666|78 86|function
P00321261A0104|221 226|women
P00321261A0104|53 74|prostaglandin F2alpha
P00321261A0104|43 47|PGE2
P00321261A0104|13 21|response
P00331128A0000|16 32|serum calcitonin
P00331128A0000|47 55|patients
P00336354A0543|17 25|serum GH
P00336354A0543|89 101|hypoglycemia
P00337102T0058|1 9|Williams
P00340692T0033|2 10|Emeritus
P00352569A0000|101 106|mg/kg
P00352569A0000|82 87|rates
P00352569A0000|124 133|endotoxin
P00358945A0225|23 32|treatment
P00361340A0529|217 236|hyperparathyroidism
P00361340A0529|246 253|failure
P00361340A0529|77 97|vitamin D deficiency
P00361340A0529|13 22|phenomena
P00361340A0529|121 131|deficiency
P00369683T0000|36 44|schedule
P00369683T0000|88 101|breast cancer
P00369683T0000|75 84|treatment
P00378492A0475|118 139|plasma renin activity
P00378492A0475|82 92|recipients
P00378492A0475|62 75|control group
P00378492A0475|105 114|elevation
P00383169A0000|86 92|agents
P00383169A0000|127 136|piribedil
P00383169A0000|229 239|properties
P00383169A0000|56 73|dopamine receptor
P00383169A0000|31 38|actions
P00385457A0187|49 54|juice
P00385457A0187|124 129|ulcer
P00385457A0187|104 111|healing
P00397806T0039|7 21|Algerian cases
P00401676A0414|82 94|radiotherapy
P00409927A0570|1 9|Neomycin
P00409927A0570|144 153|organisms
P00414575T0000|32 39|calculi
P00416758T0001|68 86|laboratory animals
P00416758T0001|38 43|Zaire
P00416758T0001|14 34|T. gambiense strains
P00417301T0001|35 46|brucellosis
P00420460A0291|168 169|r
P00420460A0291|112 126|blood pressure
P00420460A0291|42 56|drug treatment
P00420460A0291|58 92|log baseline plasma renin activity
P00425547A0000|4 12|patients
P00425547A0000|57 59|os
P00425547A0000|105 115|cephalexin
P00429151T0000|52 56|unit
P00429151T0000|31 43|practitioner
P00429949A0000|139 147|ampoules
P00429949A0000|189 224|International Reference Preparation
P00429949A0000|126 135|prolactin
P00429949A0000|73 99|Biological Standardization
P00429949A0000|105 116|preparation
P00432615A0541|155 167|interference
P00432615A0541|55 65|literature
P00432615A0541|13 24|differences
P00432615A0541|105 118|gammaglobulin
P00437749A0242|65 75|psychology
P00437749A0242|124 128|pain
P00439716T0001|36 55|blood flow velocity
P00439716T0001|76 83|fistula
P00445720A0263|33 36|SPG
P00445720A0263|66 68|LV
P00445720A0263|79 85|atrium
P00450559A0269|19 26|patient
P00450559A0269|54 63|Clinitemp
P00450559A0269|8 13|basis
P00451192A0248|1 5|Data
P00451192A0248|43 59|computer program
P00454780A0340|102 103|V
P00454780A0340|143 152|corrosion
P00454780A0340|123 136|fatigue limit
P00454780A0340|44 62|cast cobalt alloys
P00463973A0000|138 141|age
P00463973A0000|143 146|SGA
P00463973A0000|199 212|birth weights
P00463973A0000|148 155|infants
P00463973A0000|166 171|women
P00465223A0373|84 92|delta PM
P00465223A0373|71 79|delta PU
P00465223A0373|23 42|difference betweent
P00465223A0373|61 67|values
P00465829T0000|48 62|state membrane
P00465829T0000|72 82|potentials
P00473249T0000|1 7|Effect
P00473249T0000|46 60|streptolysin O
P00476020T0000|5 17|biochemistry
P00476020T0000|30 35|fluid
P00477794T0000|1 8|Effects
P00477794T0000|49 66|response patterns
P00477794T0000|31 41|tractotomy
P00479222A0682|207 212|years
P00479222A0682|100 110|properties
P00479222A0682|76 85|retention
P00479222A0682|41 52|environment
P00481612A1121|119 125|action
P00481612A1121|129 137|fentanyl
P00484177A0242|118 121|VT.
P00484177A0242|6 16|expression
P00484177A0242|91 99|CT value
P00488534A0308|4 12|addition
P00488534A0308|173 180|MR rats
P00488534A0308|133 140|MR rats
P00493818A0422|80 83|fit
P00493818A0422|145 154|insertion
P00493818A0422|132 138|months
P00495097A0663|48 56|activity
P00495097A0663|7 22|characteristics
P00499588T0000|1 24|Carbohydrate metabolism
P00499588T0000|48 55|glucose
P00499588T0000|57 64|insulin
P00506559A0000|76 84|hamsters
P00509703A0581|64 73|textbooks
P00512215A0000|69 70|L
P00512215A0000|71 76|f2-f1
P00512215A0000|174 176|L1
P00512215A0000|162 164|L1
P00512215A0000|46 67|difference tone level
P00512215A0000|166 168|L2
P00512215A0000|157 159|f1
P00512215A0000|123 128|input
P00513284A1255|96 101|blood
P00513284A1255|82 91|functions
P00513284A1255|30 43|DOTC infusion
P00517890A0468|141 146|onset
P00517890A0468|36 40|mode
P00517890A0468|150 158|jaundice
P00517890A0468|44 56|transmission
P00521732T0000|55 63|oestriol
P00521732T0000|22 30|oestrone
P00521732T0000|94 123|steroid sulphatase deficiency
P00528144T0000|16 27|transferrin
P00528144T0000|56 67|tumor cells
P00535520A0239|87 102|cholangiography
P00535520A0239|14 24|exceptions
P00541752A1032|82 88|adults
P00541752A1032|161 166|ng/ml
P00541752A1032|10 24|determinations
P00541752A1032|46 53|samples
P00553858A0000|256 265|operation
P00553858A0000|55 60|world
P00553858A0000|112 122|literature
P00553858A0000|10 15|Grice
P00553858A0000|193 198|terms
P00555495T0000|118 127|ovulation
P00555495T0000|101 114|re-appearance
P00555495T0000|10 26|re-establishment
P00555495T0000|134 142|abortion
P00555495T0000|30 39|ovulation
P00557559A0170|110 115|agent
P00557559A0170|58 85|N-methylnitrone 1,4-dioxide
P00564943A0444|85 93|SBO-milk
P00564943A0444|1 7|Calves
P00564943A0444|12 20|MCT-milk
P00565314A0293|1 12|Guinea pigs
P00574222T0000|19 31|implications
P00574222T0000|59 69|prostheses
P00575231A0422|1 5|None
P00575231A0422|13 28|cystometrograms
P00578648T0048|12 19|effects
P00580151A0706|100 111|se-T levels
P00580151A0706|161 168|patient
P00580151A0706|198 202|cost
P00580151A0706|75 87|testosterone
P00583522T0001|60 72|inflammation
P00589073A0000|100 105|phase
P00589073A0000|206 217|infertility
P00589073A0000|130 135|women
P00589073A0000|165 173|patients
P00592887T0000|48 60|lymphography
P00592887T0000|10 18|reaction
P00594466T0001|18 26|seizures
P00594466T0001|5 14|induction
P00594466T0001|31 42|Papio papio
P00597715A0256|1 10|One-third
P00597715A0256|48 61|sperm density
P00597715A0256|143 147|work
P00597715A0256|27 38|azoospermia
P00599601A0260|155 165|physiology
P00599601A0260|123 134|alterations
P00599601A0260|194 197|rat
P00601401A0181|87 98|Bohr effect
P00601401A0181|9 28|hemoglobin solution
P00602702A0309|101 109|function
P00602702A0309|129 150|estriol concentration
P00602702A0309|176 184|diarrhea
P00602702A0309|28 36|diarrhea
P00606849T0000|66 73|rabbits
P00616575A0000|66 72|action
P00616575A0000|42 58|brain structures
P00616575A0000|95 100|field
P00616575A0000|121 124|EMF
P00616575A0000|14 25|sensitivity
P00618078A0367|3 11|decrease
P00618078A0367|94 104|meningitis
P00619782A0058|6 10|tans
P00619782A0058|42 52|volunteers
P00619782A0058|88 109|ultraviolet radiation
P00621626T0000|49 57|subjects
P00621626T0000|95 111|behavior pattern
P00623361A0221|35 47|contribution
P00623361A0221|61 72|dysfunction
P00627039T0000|1 12|Elimination
P00627202T0000|1 10|Diuretics
P00627202T0000|56 59|use
P00630713T0000|19 48|Du Pont aca ammonia procedure
P00635143T0001|40 55|Cyprinus carpio
P00635143T0001|28 36|metaphos
P00636526T0033|28 37|diagnosis
P00639410T0000|19 31|bone changes
P00639410T0000|40 48|response
P00641395A0441|23 31|patients
P00641395A0441|37 55|hyperbilirubinemia
P00641395A0441|146 152|levels
P00641395A0441|105 116|fluorimeter
P00644539A0783|66 70|FEV1
P00644539A0783|144 153|reactions
P00644539A0783|161 175|test solutions
P00644539A0783|89 90|%
P00646193T0000|1 8|Potency
P00646193T0000|12 21|enflurane
P00646193T0000|61 71|isoflurane
P00657551T0000|16 36|magnesium absorption
P00657551T0000|67 73|tracer
P00657551T0000|40 43|man
P00663166A0000|206 228|Eisenmenger physiology
P00663166A0000|144 152|shunting
P00663166A0000|43 55|body imaging
P00663166A0000|14 25|angiography
P00665053A0276|53 56|K13
P00665053A0276|40 44|type
P00665336A0908|52 67|EEG-information
P00669800A0579|50 59|infection
P00669800A0579|8 12|mice
P00676790T0000|33 39|kidney
P00681571T0028|12 20|findings
P00685922A0451|84 87|IHB
P00685922A0451|78 82|tree
P00693987T0001|102 109|history
P00693987T0001|49 54|blood
P00693987T0001|144 148|year
P00693987T0001|124 134|infarction
P00693987T0001|61 75|administration
P00696858A0000|48 57|endocrine
P00696858A0000|82 91|secretion
P00701462A0722|1 17|Urine antibodies
P00703350A0418|50 57|sulfide
P00703350A0418|16 29|198Au colloid
P00704675A0199|155 162|trachea
P00704675A0199|39 46|bronchi
P00704675A0199|143 147|mass
P00704675A0199|109 119|inhalation
P00710372A0302|144 152|features
P00710372A0302|26 37|dysfunction
P00713525A0268|82 94|presentation
P00713525A0268|128 132|data
P00713525A0268|108 122|stimulus words
P00713525A0268|46 56|stutterers
P00715753A0241|139 144|CK-MB
P00715753A0241|4 27|biopsies CK-MB fraction
P00715753A0241|58 59|%
P00722298A0619|306 311|males
P00722298A0619|236 241|field
P00722298A0619|76 87|differences
P00722298A0619|282 288|groups
P00722298A0619|11 19|analysis
P00722298A0619|188 195|females
P00722298A0619|147 159|significance
P00725257A0452|51 54|DHE
P00725257A0452|67 69|M.
P00725534A0888|205 212|atrophy
P00725534A0888|48 57|M. leprae
P00725534A0888|81 96|IgA immunocytes
P00725534A0888|231 236|villi
P00725534A0888|244 252|patients
P00725534A0888|166 180|IgA deficiency
P00729003A1182|1 9|Residues
P00729003A1182|23 34|transcripts
P00736376A0371|53 61|ischemia
P00736376A0371|122 127|skill
P00736376A0371|90 97|urgency
P00740409A0000|5 19|histochemistry
P00740409A0000|24 38|ultrastructure
P00743335T0001|48 55|stimuli
P00747722A0486|119 129|parameters
P00747722A0486|48 60|B1 injection
P00747722A0486|5 9|data
P00747722A0486|63 68|Phase
P00753237A0000|549 560|prophylaxis
P00753237A0000|143 146|fig
P00753237A0000|192 195|PPU
P00753237A0000|346 353|process
P00753237A0000|157 158|B
P00753237A0000|93 104|body weight
P00753237A0000|267 274|patient
P00753237A0000|26 36|phenomenon
P00753237A0000|510 527|blood circulation
P00753237A0000|381 397|PNEUMATIC INSOLE
P00753237A0000|160 167|Plantar
P00753237A0000|227 240|INSENSITIVITY
P00753237A0000|378 379|D
P00753237A0000|540 544|cure
P00753237A0000|486 495|attrition
P00753237A0000|245 254|TRAUMATIS
P00753237A0000|180 190|ulceration
P00755671A0485|48 69|recalcification times
P00755671A0485|78 89|development
P00756511T0036|38 46|diabetes
P00759049A0185|70 99|bathophenanthroline chromogen
P00759049A0185|52 61|ferrozine
P00759049A0185|107 111|ICSH
P00762763A0253|26 30|SIDS
P00767155T0001|20 26|revolt
P00767155T0001|57 66|personnel
P00768220X0000|5 15|motor unit
P00775582T0000|12 22|properties
P00780639X0000|18 25|antigen
P00780639X0000|56 66|evaluation
P00799988A0554|114 121|placebo
P00799988A0554|26 45|assessment patients
P00799988A0554|74 84|preference
P00803867A0315|1 9|Patients
P00803867A0315|97 103|cancer
P00803867A0315|122 130|patients
P00807356T0001|34 42|activity
P00808898A0000|38 45|patient
P00808898A0000|26 30|data
P00812183T0000|12 27|transfer factor
P00818380A0239|80 89|reactions
P00818380A0239|12 18|factor
P00821833A0000|114 125|field study
P00821833A0000|142 148|Panama
P00821833A0000|77 94|Alouatta palliata
P00821833A0000|61 75|howler monkeys
P00823087A0608|1 9|Deflunia
P00827364A0000|7 17|instrument
P00827364A0000|40 57|freeze-fracturing
P00832096T0000|10 28|calcium metabolism
P00836637A0000|201 214|reinforcement
P00836637A0000|248 258|reinforcer
P00836637A0000|228 238|preference
P00836637A0000|107 117|reinforcer
P00837811A0675|69 100|fluid gamma globulin elevations
P00837811A0675|3 12|diagnosis
P00837811A0675|142 149|testing
P00839378A0649|68 85|airway resistance
P00839378A0649|50 58|increase
P00839378A0649|121 128|therapy
P00842522T0000|87 96|emphysema
P00842522T0000|39 49|management
P00843670T0000|14 18|self
P00847967T0000|20 24|uses
P00851286A0375|1 7|Deaths
P00851286A0375|168 173|death
P00851286A0375|147 152|hours
P00851286A0375|31 52|copper concentrations
P00863184T0043|69 73|load
P00863184T0043|81 84|rat
P00866577A0579|69 75|agents
P00866577A0579|1 10|Treatment
P00866577A0579|140 147|patient
P00866577A0579|109 117|function
P00868903A0000|1 9|Amikacin
P00868903A0000|64 74|infections
P00871237A0601|8 16|activity
P00871237A0601|44 50|angina
P00872922A0204|96 104|activity
P00872922A0204|60 66|esters
P00875778T0000|23 46|Gravigard IUCD inserter
P00877857A0763|87 96|mEq/liter
P00877857A0763|47 56|CU/100 ml
P00879829A0564|1 8|Infants
P00879829A0564|128 135|symptom
P00879829A0564|150 156|apnoea
P00885562A0281|20 30|components
P00885562A0281|112 118|method
P00885562A0281|160 167|culture
P00885562A0281|56 65|depletion
P00891370A0000|97 106|injection
P00891370A0000|110 125|contrast-medium
P00891370A0000|62 77|xeroradiography
P00898500A0246|69 71|HD
P00898500A0246|38 46|patients
P00898500A0246|5 9|sera
P00898500A0246|197 202|mites
P00898500A0246|75 90|mites skin test
P00909114A0000|222 227|doses
P00909114A0000|21 24|DAN
P00909114A0000|42 54|nitrosamines
P00909114A0000|125 134|incidence
P00909114A0000|150 162|tract tumors
P00911590T0000|95 103|children
P00911590T0000|41 57|bocurarine block
P00911590T0000|14 23|responses
P00915090A0536|71 75|rads
P00915090A0536|83 89|testis
P00915090A0536|131 132|%
P00915090A0536|41 44|mCi
P00915090A0536|105 115|sperm hads
P00917572T0001|32 38|method
P00917572T0001|56 70|hypothyroidism
P00918556A0000|48 53|HBsAg
P00918556A0000|114 141|radio-immunoassay technique
P00918556A0000|59 67|anti-HBs
P00918556A0000|147 153|series
P00920381T0000|19 27|glycogen
P00921911A0159|102 112|dilatation
P00921911A0159|1 7|Levels
P00921911A0159|80 86|labour
P00921911A0159|24 28|PGFM
P00926604A0504|153 159|effect
P00926604A0504|184 198|strophanthin K
P00926604A0504|115 126|development
P00926604A0504|96 101|heart
P00926604A0504|41 45|dose
P00927633T0001|86 99|Rattus rattus
P00927633T0001|53 62|formation
P00927633T0001|10 18|electron
P00929418T0001|1 5|Role
P00929418T0001|13 42|infectious-disease specialist
P00931089T0001|27 41|operating room
P00932817A0499|103 113|MTF values
P00932817A0499|52 55|MEC
P00932817A0499|90 94|turn
P00935526A0000|169 171|ng
P00935526A0000|5 17|difficulties
P00935526A0000|214 221|columns
P00935526A0000|63 77|chromatography
P00935526A0000|45 47|PG
P00941050T0000|23 46|procainamide absorption
P00947834X0000|16 26|IgE levels
P00947834X0000|36 44|tendency
P00952734T0000|49 54|cause
P00952734T0000|77 88|elastolysis
P00952734T0000|105 109|PECL
P00956364A0138|19 37|S. mutans serotype
P00956364A0138|56 62|growth
P00958550T0001|27 36|community
P00961711T0000|34 38|band
P00961711T0000|42 45|seg
P00962277T0000|34 40|bypass
P00962277T0000|49 68|gelatine derivative
P00967223T0059|1 3|I.
P00970320A0000|40 70|chemical cartridge respirators
P00970320A0000|122 136|copper smelter
P00970839A0118|85 92|feeding
P00970839A0118|128 133|weeks
P00970839A0118|47 57|trout farm
P00975314T0001|80 82|xy
P00975314T0001|97 111|gonadoblastoma
P00980255T0000|1 12|Application
P00980255T0000|52 60|coupling
P00980255T0000|73 83|metabolism
P00985110T0001|113 116|cat
P00985110T0001|37 44|portion
P00985110T0001|10 21|projections
P00985279A0493|1 5|Mean
P00985279A0493|96 102|groups
P00985279A0493|108 117|CO2 group
P00986925A0002|35 41|amount
P00986925A0002|5 11|effect
P00986925A0002|67 79|pentagastrin
P00986925A0002|45 52|calcium
P00988572A0000|221 227|oxygen
P00988572A0000|1 15|Oxygen tension
P00988572A0000|199 203|data
P00988572A0000|57 73|rabbit hind limb
P00988572A0000|44 48|PLO2
P00992316A0178|113 121|criteria
P00992316A0178|24 39|pressure curves
P00996272A0397|19 26|sources
P00996272A0397|120 132|instructions
P00996272A0397|30 35|error
P00999494A0000|5 13|patients
P00999494A0000|42 47|mania
P01003819A0498|50 60|refraction
P01003819A0498|83 100|corneal curvature
P01003819A0498|10 14|help
P01009451A0728|123 131|drinking
P01009451A0728|28 30|UB
P01009451A0728|90 99|reduction
P01009841T0001|36 49|trunk muscles
P01009841T0001|26 32|fibers
P01012640T0001|93 101|syndrome
P01012640T0001|9 24|characteristics
P01012640T0001|28 39|eye changes
P01019207A0232|38 48|conditions
P01019207A0232|88 100|betaI% value
P01019207A0232|105 108|lgC
P01035457A0623|8 14|tumour
P01035457A0623|26 42|nipple discharge
P01035457A0623|75 84|diagnosis
P01044338A0240|67 74|heating
P01044338A0240|26 45|temperature changes
P01047895T0001|69 74|value
P01047895T0001|4 13|criticism
P01047895T0001|120 132|patient care
P01048968A0152|100 112|erythromycin
P01048968A0152|54 67|staphylococci
P01048968A0152|127 141|beta-lactamase
P01050400T0000|1 12|Improvement
P01050400T0000|55 59|time
P01050400T0000|63 72|discharge
P01064124A0560|77 86|specimens
P01064124A0560|14 24|subsurface
P01071715A0903|41 66|blood pressure recordings
P01078982A0227|82 105|antilymphocyte globulin
P01078982A0227|177 193|cyclophosphamide
P01078982A0227|63 79|cyclophosphamide
P01081904A0198|52 60|patients
P01081904A0198|130 138|symptoms
P01082833A0000|288 292|rats
P01082833A0000|273 284|peritonitis
P01082833A0000|39 44|agent
P01082833A0000|172 183|guinea pigs
P01082833A0000|76 86|inhibition
P01082833A0000|160 168|erythema
P01083375T0000|1 20|Alpha-1 antitrypsin
P01084413A0271|3 8|range
P01084413A0271|31 43|measurements
P01088654T0001|33 41|ceramics
P01092248T0000|19 34|zinc deficiency
P01092248T0000|9 15|status
P01093845A0208|1 15|Modern studies
P01093845A0208|32 43|Delta-9-THC
P01093845A0208|110 118|identity
P01093845A0208|56 67|voluntaries
P01093845A0208|164 169|sleep
P01096741X0000|64 78|chickpea haulm
P01096741X0000|12 18|growth
P01098179A0167|238 247|ointments
P01098179A0167|49 61|preparations
P01098179A0167|143 158|chloramphenicol
P01098179A0167|210 216|creams
P01099693T0000|1 7|Letter
P01099693T0000|9 21|Perspectives
P01103390A0149|16 25|behaviour
P01103390A0149|65 75|occurrence
P01103390A0149|104 109|phase
P01113908A0475|38 49|transferrin
P01113908A0475|52 54|hr
P01113908A0475|63 69|tablet
P01116466A0185|51 64|thrombin time
P01116466A0185|155 169|platelet count
P01116466A0185|144 145|X
P01116466A0185|131 132|V
P01116466A0185|134 138|VIII
P01119586A0337|1 21|Glycogen utilization
P01119586A0337|144 148|flow
P01119586A0337|78 81|ATP
P01119586A0337|120 126|hearts
P01122015A0467|99 108|mg/100 ml
P01122015A0467|36 42|values
P01122015A0467|10 13|vol
P01124944A0830|35 47|protein diet
P01124944A0830|53 57|g/kg
P01128985A0000|100 105|apnea
P01128985A0000|89 96|periods
P01130531A0224|102 109|percent
P01130531A0224|87 95|decrease
P01130531A0224|66 76|reductions
P01138215T0001|1 5|Risk
P01138215T0001|9 18|infection
P01140184A0342|51 52|%
P01140184A0342|139 155|liver microsomes
P01140184A0342|165 168|rat
P01140184A0342|60 84|epoxide hydrase activity
P01147502T0000|1 11|Vitrectomy
P01150658A0683|83 85|M.
P01150658A0683|6 14|sequence
P01156814T0000|1 10|Editorial
P01156814T0000|37 47|prevention
P01157614T0000|1 8|Effects
P01157614T0000|23 31|salience
P01158838A0438|58 67|flow rate
P01168607A0672|101 117|prothrombin time
P01168607A0672|43 51|vitamins
P01168607A0672|122 136|serum vitamins
P01168956A0552|187 188|h
P01168956A0552|23 27|drug
P01168956A0552|178 183|organ
P01168956A0552|77 88|sensitivity
P01168956A0552|13 17|date
P01171020A0711|5 12|effects
P01172734T0035|23 27|W-27
P01174873T0000|19 24|study
P01174873T0000|65 70|cases
P01178153A0056|1 3|D.
P01185956A0722|99 106|changes
P01185956A0722|5 12|authors
P01190120A0832|18 31|% lengthening
P01190120A0832|47 66|thromboplastin time
P01191955A0077|20 24|test
P01191955A0077|88 95|varices
P01193458T0001|39 56|Tc sulfur colloid
P01193458T0001|104 110|reflux
P01193458T0001|75 84|follow-up
P01194673A0652|44 55|chemography
P01202616A0466|141 145|loss
P01202616A0466|11 24|retransfusion
P01206896T0001|35 48|resuscitation
P01206896T0001|20 30|anesthesia
P01209618A0409|1 11|Tobramycin
P01209618A0409|58 67|dibecacin
P01209618A0409|72 74|mg
P01209618A0409|120 126|action
P01215067A0000|117 137|meningitis purulenta
P01215067A0000|142 147|cases
P01215067A0000|213 221|subjects
P01215067A0000|57 62|fluid
P01215067A0000|182 194|encephalitis
P01215067A0000|151 168|meningitis serosa
P01224116A0576|43 64|serum immunoglobulins
P01224116A0576|95 100|Busey
P01224116A0576|74 77|IgG
P01228258A0000|137 148|Mitomycin-C
P01228258A0000|159 179|Cytosine arabinoside
P01228258A0000|43 47|type
P01228258A0000|28 34|OK-432
P01228258A0000|120 131|combination
P01233561T0001|10 19|lactation
P01241437A0152|51 57|NLA II
P01241437A0152|86 94|morphine
P01241437A0152|5 13|patients
P01241866A0682|71 76|serum
P01241866A0682|53 67|administration
P01241866A0682|91 97|rabbit
P01243628A0286|48 53|level
P01243628A0286|97 98|%
P01243628A0286|9 14|cases
P01243628A0286|30 38|exposure
P01245162A0262|37 48|taste sense
P01245162A0262|133 152|transaminase levels
P01247475A0000|100 113|deterioration
P01247475A0000|8 17|diagnosis
P01247475A0000|57 61|fact
P01249198A1097|81 90|pregnancy
P01249198A1097|5 28|serum FT3 concentration
P01249198A1097|127 142|hyperthyroidism
P01253191T0000|63 80|action potentials
P01259027A0416|204 213|procedure
P01259027A0416|65 73|analysis
P01259027A0416|93 109|model parameters
P01259027A0416|226 235|extension
P01259027A0416|28 43|identifiability
P01262596T0000|14 24|compromise
P01265443A0159|153 158|pouch
P01265443A0159|172 179|stomach
P01265443A0159|214 220|effect
P01265443A0159|12 19|glucose
P01267446A0210|53 57|acid
P01275335A0158|80 85|phase
P01275335A0158|57 60|end
P01276105A0313|68 73|value
P01276105A0313|4 12|contrast
P01276105A0313|88 91|day
P01279197T0000|53 78|Mason-Pfizer monkey virus
P01279197T0000|89 111|saturation mutagenesis
P01279352A0473|187 195|proteins
P01279352A0473|216 232|target sequences
P01279352A0473|59 69|cell lines
P01279352A0473|108 116|proteins
P01279352A0473|88 99|mouse liver
P01279374A0396|39 44|genes
P01279374A0396|75 86|suppressors
P01280413T0001|1 10|Treatment
P01280413T0001|38 46|sections
P01280413T0001|15 23|staining
P01281322A0604|22 34|relationship
P01281322A0604|91 97|muscle
P01281771T0000|68 86|expression pattern
P01281771T0000|31 35|gene
P01282638A0934|201 208|quality
P01282638A0934|163 180|health care costs
P01282638A0934|280 288|schedule
P01282638A0934|44 52|patients
P01282638A0934|355 362|patient
P01282638A0934|127 136|estimates
P01282638A0934|297 309|interruption
P01282638A0934|29 39|medication
P01284595A0102|103 112|sequences
P01284595A0102|114 125|HTF islands
P01284595A0102|23 27|gene
P01284595A0102|94 97|CpG
P01285009A0000|1 16|Gene constructs
P01285009A0000|140 156|thymidine kinase
P01285009A0000|128 131|mMT
P01285009A0000|105 126|mouse metallothionein
P01285009A0000|220 224|gene
P01285009A0000|292 301|micropyle
P01285009A0000|53 56|hGH
P01285009A0000|93 101|sequence
P01285009A0000|215 218|cBA
P01285554T0000|1 10|Prospects
P01286732A0572|204 216|complication
P01286732A0572|98 106|patients
P01286732A0572|8 20|hepatomegaly
P01286732A0572|146 155|hepatitis
P01286732A0572|123 128|liver
P01292230A0283|52 59|filling
P01292230A0283|28 32|rate
P01295373A0651|114 115|B
P01295373A0651|83 85|SE
P01295373A0651|59 72|% baseline RL
P01295373A0651|56 57|A
P01295373A0651|132 133|C
P01295373A0651|74 78|mean
P01296815A0059|40 44|LD78
P01296815A0059|123 133|pseudogene
P01297332T0000|82 92|cell cycle
P01297332T0000|26 38|DNA sequence
P01298398A0461|49 67|nadolol racemate A
P01298398A0461|5 11|method
P01298398A0461|90 107|phase composition
P01300914A1066|8 15|absence
P01300914A1066|469 477|exercise
P01300914A1066|152 158|biopsy
P01300914A1066|323 334|arrhythmias
P01300914A1066|397 404|feature
P01300914A1066|813 819|stasis
P01300914A1066|89 100|variability
P01300914A1066|32 40|criteria
P01300914A1066|798 806|vaulting
P01300914A1066|502 512|potentials
P01300914A1066|104 111|results
P01300914A1066|430 441|sensitivity
P01300914A1066|484 493|existence
P01300914A1066|420 426|degree
P01302765A0999|67 70|R2s
P01302765A0999|131 141|components
P01304809T0001|64 68|Jena
P01304809T0001|31 60|Friedrich Schiller University
P01309593A0095|5 22|UCR core sequence
P01309593A0095|62 68|factor
P01309593A0095|105 127|MuLV promoter activity
P01309815A0972|113 124|maintenance
P01309815A0972|142 148|arrest
P01309815A0972|15 30|scr1-1 mutation
P01309894A0807|70 80|nucleotide
P01309894A0807|39 51|AAV sequence
P01310154A0879|34 35|N
P01310154A0879|235 246|FBR protein
P01310154A0879|189 209|protein modification
P01310154A0879|7 14|results
P01310154A0879|105 116|FBR protein
P01310879A0000|3 20|patient suffering
P01310879A0000|128 137|treatment
P01310879A0000|63 66|HAT
P01310935T0000|96 115|protein degradation
P01310935T0000|12 17|UbcD1
P01313715A0461|101 109|rp47phox
P01313715A0461|67 77|retrovirus
P01313715A0461|186 191|virus
P01313715A0461|117 121|HL60
P01313715A0461|25 30|study
P01313715A0461|270 281|CGD patient
P01313894A1179|18 25|pattern
P01313894A1179|143 149|tumors
P01313894A1179|178 184|levels
P01313894A1179|133 139|subset
P01314457T0000|1 9|Analysis
P01314457T0000|86 91|L-DNA
P01314457T0000|53 56|kbp
P01314457T0000|125 137|organization
P01314457T0000|13 32|nucleotide sequence
P01314953A1266|137 146|complexes
P01314953A1266|80 84|HAP3
P01314953A1266|94 100|domain
P01314953A1266|14 44|gel mobility shift experiments
P01316125A0176|64 72|radicals
P01316125A0176|174 178|YHPD
P01316125A0176|226 228|OH
P01316125A0176|87 91|YHPD
P01316125A0176|80 82|OH
P01316125A0176|189 193|BHPD
P01316125A0176|148 155|ability
P01316476A0842|16 30|TATA sequences
P01316476A0842|63 66|VZV
P01316680A0643|169 177|H-X2-4-C
P01316680A0643|64 75|amino acids
P01316680A0643|178 179|H
P01316680A0643|77 90|CAYWCCLGHAFAC
P01316680A0643|31 36|EHV-1
P01316903A0296|22 26|form
P01316903A0296|62 65|IIA
P01317376A0981|1 22|Fructokinase activity
P01317376A0981|54 64|Z. mobilis
P01317376A0981|78 86|fructose
P01318739A0410|69 74|VM-26
P01318739A0410|83 96|neurotoxicity
P01320640A0336|1 12|Tumor cells
P01320640A0336|92 95|VIP
P01320640A0336|61 68|enolase
P01321277A0664|96 102|domain
P01321277A0664|40 48|deletion
P01321277A0664|12 13|R
P01321332A0970|187 195|presence
P01321332A0970|216 231|transactivation
P01321332A0970|159 179|hepatoma HepG2 cells
P01321332A0970|43 49|site A
P01321332A0970|124 134|apoAI gene
P01321332A0970|284 289|ARP-1
P01321336A0731|5 20|splice variants
P01321336A0731|24 33|ALF1 cDNA
P01321337A1161|32 46|MATa cna1 cna2
P01321337A1161|63 80|MATa cnb1 mutants
P01321337A1161|105 112|ability
P01324385A0329|1 8|METHODS
P01324385A0329|236 244|subjects
P01324385A0329|10 24|IgG antibodies
P01324385A0329|105 109|IVDA
P01324385A0329|263 276|control group
P01324385A0329|177 182|stage
P01324385A0329|151 156|HIV-1
P01324404A1208|1 11|HNF-3 beta
P01324404A1208|162 182|region II-III domain
P01324404A1208|27 36|sequences
P01324404A1208|88 103|transactivation
P01324639T0000|139 150|clindamycin
P01324639T0000|96 119|amoxicillin-clavulanate
P01324639T0000|121 133|temafloxacin
P01325386A0766|5 20|hit1-1 mutation
P01325386A0766|61 79|heat shock protein
P01326557T0000|85 117|chondroitin sulfate proteoglycan
P01326557T0000|1 8|Cloning
P01326557T0000|121 126|brain
P01327758A0000|71 84|gene products
P01327758A0000|23 39|papillomavirus-1
P01327758A0000|121 131|E2 protein
P01328197A0985|33 71|MAP kinase activator/MAP kinase system
P01328197A0985|108 140|ras signal transduction pathways
P01328681A0149|103 116|transcription
P01328681A0149|20 28|proteins
P01328681A0149|56 77|c-myc hyperexpression
P01328681A0149|226 228|A.
P01328854T0000|184 196|muscle cells
P01328854T0000|110 117|subunit
P01328854T0000|10 20|MEF-2 site
P01329039A0239|154 162|proteins
P01329039A0239|54 60|CANNTG
P01329039A0239|14 29|E-box consensus
P01330077A0000|1 21|T-cell receptor beta
P01330077A0000|33 52|gene rearrangements
P01330077A0000|79 85|B-cell
P01330975T0000|52 59|myeloma
P01331060A0768|5 14|structure
P01331060A0768|59 69|comparison
P01331292A1425|118 125|variola
P01331292A1425|129 143|vaccinia virus
P01331292A1425|92 98|region
P01331516A0103|137 149|C2 myoblasts
P01331516A0103|101 106|virus
P01331516A0103|110 133|coinfection experiments
P01332964A0247|29 42|RII beta gene
P01333047A0404|186 204|threonine residues
P01333047A0404|174 180|serine
P01333047A0404|63 88|growth factor stimulation
P01333047A0404|149 160|Nck protein
P01333125A0000|153 159|region
P01333125A0000|3 14|combination
P01333125A0000|66 73|methods
P01333125A0000|161 164|UTR
P01333125A0000|30 47|sequence analysis
P01334428A1102|1 3|Km
P01334428A1102|99 115|mumol min-1 mg-1
P01334428A1102|8 12|Vmax
P01334428A1102|57 61|poly
P01334428A1102|62 65|Glu
P01334518T0000|16 31|blood screening
P01334518T0000|76 98|immunodeficiency virus
P01334518T0000|107 118|risk groups
P01338867A0503|1 11|Comparison
P01338867A0503|38 45|results
P01338867A0503|179 185|extent
P01338867A0503|131 139|blockade
P01338867A0503|15 19|data
P01339373T0000|92 111|SNF1 protein kinase
P01339373T0000|73 80|protein
P01339373T0000|15 25|expression
P01339468A0272|187 195|proteins
P01339468A0272|115 123|proteins
P01339468A0272|95 99|ORF2
P01339773A0778|140 167|ventilation-perfusion ratio
P01339773A0778|5 18|relationships
P01339773A0778|124 132|increase
P01340470A0000|16 28|protein gene
P01340470A0000|78 99|RNA recognition motif
P01340470A0000|121 123|RS
P01346262A0377|205 212|protein
P01346262A0377|155 162|protein
P01346262A0377|94 98|UC21
P01347476T0000|16 31|mouse ornithine
P01347476T0000|54 69|sequence family
P01347908T0000|5 14|rationale
P01347908T0000|43 54|stimulation
P01348504A0757|82 90|distance
P01348590A0000|32 36|data
P01348590A0000|66 74|lymphoma
P01348590A0000|227 239|radiotherapy
P01348590A0000|195 198|use
P01348590A0000|20 28|analysis
P01348590A0000|261 268|outcome
P01348590A0000|176 185|diagnosis
P01348590A0000|150 153|CD4
P01349705T0000|1 8|Effects
P01349705T0000|12 19|dioxins
P01350780A0184|101 123|gamma-glutamyl kinases
P01350780A0184|53 61|homology
P01352113A0002|68 76|exposure
P01352113A0002|21 27|events
P01352113A0002|97 100|rat
P01352113A0002|45 61|nitrogen dioxide
P01353478T0000|1 12|Interaction
P01353478T0000|30 49|IAP retrotransposon
P01357190A0726|116 123|ability
P01357190A0726|10 19|exception
P01357190A0726|89 102|glycoproteins
P01358190A0654|1 13|Substitution
P01358190A0654|21 35|DR1 beta chain
P01358190A0654|79 90|recognition
P01358190A0654|135 141|effect
P01358758A0000|142 153|combination
P01358758A0000|27 45|rat insulin I gene
P01358758A0000|106 119|FLAT elements
P01358758A0000|75 92|sequence elements
P01359588A0375|6 17|computation
P01360180A1568|33 51|P68 amino terminus
P01360180A1568|162 183|reporter gene product
P01360180A1568|210 213|RNA
P01363080A0710|142 151|diuretics
P01363080A0710|67 72|error
P01363080A0710|166 186|anhydrase inhibitors
P01364100A0377|4 12|addition
P01364100A0377|67 71|unit
P01370446A0818|7 12|sites
P01371272A1167|17 27|dNTP pools
P01371272A1167|46 65|frameshift fidelity
P01371413A0742|18 29|hGCSFR gene
P01371413A0742|173 183|cDNA probe
P01371413A0742|91 110|segregation pattern
P01372365A1202|16 18|%T
P01372365A1202|43 45|Cl
P01372365A1202|131 141|conditions
P01372365A1202|47 61|concentrations
P01372802A1481|372 374|C3
P01372802A1481|413 422|fragments
P01372802A1481|131 139|epitopes
P01372802A1481|47 66|amino acid residues
P01372802A1481|17 25|segments
P01372802A1481|257 265|segments
P01372802A1481|321 329|epitopes
P01372802A1481|29 31|C3
P01372900A1017|119 156|polymerase chain reaction experiments
P01372900A1017|45 57|organization
P01374331A0636|9 13|gene
P01374398A0951|48 52|cDNA
P01374398A0951|63 66|kDa
P01374398A0951|13 32|translation protein
P01374398A0951|150 151|%
P01375224A0152|48 53|v-Crk
P01375224A0152|83 109|chicken embryo fibroblasts
P01375224A0152|25 33|evidence
P01376319T0000|51 79|mannose 6-phosphate receptor
P01376319T0000|10 20|pseudogene
P01377764A0309|5 14|carcinoma
P01377764A0309|106 111|layer
P01377962A1012|64 68|size
P01377962A1012|76 82|organs
P01377962A1012|14 26|tobacco GS-2
P01378127A0841|111 120|responses
P01378127A0841|14 21|effects
P01378506A0884|114 128|virus assembly
P01378506A0884|96 98|NC
P01379032A0495|152 155|day
P01379032A0495|49 57|steroids
P01379032A0495|114 122|steroids
P01379032A0495|131 133|mg
P01379032A0495|75 87|steroid dose
P01380062A0097|101 108|targets
P01380062A0097|143 146|Y-5
P01380062A0097|66 69|CTL
P01380062A0097|129 132|Y-2
P01380454A0451|205 226|transcription factors
P01380454A0451|237 247|NF-kappa B
P01380454A0451|257 264|members
P01380454A0451|249 252|Myb
P01380454A0451|79 99|DNA binding activity
P01380454A0451|30 45|protein product
P01380825A0622|113 120|tissues
P01380825A0622|61 66|mRNAs
P01380825A0622|151 158|protein
P01383695A0100|69 75|embryo
P01383695A0100|96 105|IgM kappa
P01384165A0000|101 113|regeneration
P01384165A0000|175 192|tracheal grafting
P01384165A0000|39 46|omentum
P01384165A0000|129 139|epithelium
P01384165A0000|63 78|vascularization
P01385462A0151|118 136|acid determination
P01385462A0151|66 70|runs
P01386897A0000|69 73|form
P01386897A0000|155 159|CLN2
P01386897A0000|39 49|cell cycle
P01386897A0000|161 164|ref
P01386897A0000|10 21|yeast cells
P01388160A1102|83 98|epsilon peptide
P01388160A1102|7 22|residue Glu-381
P01388160A1102|198 205|Ser-108
P01388160A1102|26 30|beta
P01389573A1071|103 105|P2
P01389573A1071|98 100|P1
P01389573A1071|113 115|A2
P01389573A1071|77 88|measurement
P01389573A1071|90 94|TBPf
P01391001A0583|49 54|total
P01391001A0583|31 45|yeasts species
P01392277A0000|68 73|water
P01392277A0000|1 9|Comments
P01392277A0000|96 101|baths
P01392277A0000|179 187|standard
P01392277A0000|133 148|KOK regulations
P01392277A0000|45 56|regulations
P01394200A0592|101 122|rebound lymphocytosis
P01394200A0592|127 139|upregulation
P01394200A0592|196 202|CD45RO
P01394200A0592|41 58|T-cell activation
P01394200A0592|75 86|lymphopenia
P01395755A1023|193 199|ml/min
P01395755A1023|164 179|oxygen delivery
P01395755A1023|288 293|L/min
P01395755A1023|295 296|p
P01395755A1023|247 253|output
P01395755A1023|27 38|differences
P01395755A1023|123 129|ml/min
P01396444A0934|153 161|activity
P01396444A0934|5 16|experiments
P01396444A0934|56 63|alveoli
P01396444A0934|72 81|condition
P01396583A0204|19 31|tumour cells
P01396583A0204|81 86|probe
P01396601A0986|55 60|Stl2p
P01396601A0986|83 87|size
P01396601A0986|26 33|domains
P01396601A0986|45 50|Stl1p
P01398071A0526|68 76|extracts
P01398071A0526|39 46|strains
P01398071A0526|179 182|III
P01398074A0697|65 74|yeast RNA
P01398074A0697|52 55|RNA
P01398098A0770|34 38|mRNA
P01398098A0770|87 98|polypeptide
P01398106A0754|205 214|overhangs
P01398106A0754|1 9|Cleavage
P01398106A0754|223 233|OH termini
P01398106A0754|112 116|exon
P01398106A0754|57 59|bp
P01398106A0754|79 100|intron insertion site
P01399206A0375|5 12|results
P01399206A0375|133 154|epidermolysis bullosa
P01399206A0375|91 108|blister formation
P01400396A1265|112 122|activation
P01400396A1265|126 147|protein kinase C beta
P01400401A0854|1 22|Western blot analyses
P01400401A0854|46 62|immunoreactivity
P01402647A0114|50 60|cell lines
P01402647A0114|129 142|phage surface
P01403391T0000|9 20|hepatitis B
P01404612A0303|84 92|proteins
P01404612A0303|61 64|HIV
P01406630A0965|137 144|binding
P01406630A0965|115 122|protein
P01406630A0965|37 50|kappa B motif
P01406630A0965|181 199|NF-kappa B complex
P01406677A0000|236 246|start site
P01406677A0000|172 192|nucleotide positions
P01406677A0000|161 170|sequences
P01406677A0000|268 283|luciferase gene
P01406703A1435|178 183|cells
P01406703A1435|58 64|region
P01406703A1435|72 80|H-2RIIBP
P01408090A0572|5 14|technique
P01408219A0670|102 107|nodes
P01408219A0670|69 72|PGL
P01408219A0670|147 158|hyperplasia
P01408219A0670|120 128|analysis
P01409581A0206|80 89|factor PU
P01409581A0206|24 27|E26
P01410071T0000|17 26|melatonin
P01410071T0000|39 47|cortisol
P01410071T0000|53 62|prolactin
P01410071T0000|28 37|serotonin
P01414219A0319|101 105|time
P01414219A0319|114 127|concentration
P01414219A0319|177 180|ERY
P01414219A0319|14 24|volunteers
P01418494T0000|31 39|function
P01418834A0987|87 101|blood pressure
P01418834A0987|177 178|P
P01418834A0987|46 47|H
P01419945A1386|1 13|Localization
P01419945A1386|135 140|sites
P01419945A1386|30 36|plexus
P01420223T0000|1 13|Significance
P01420223T0000|40 63|latissimus dorsi muscle
P01420363T0000|16 19|AP1
P01420363T0000|71 87|tissue inhibitor
P01420363T0000|24 42|PEA3 binding sites
P01420363T0000|91 111|metalloproteinases-1
P01421145A1190|1 14|Fractionation
P01421145A1190|155 166|leaf tissue
P01421145A1190|90 96|PCAT-1
P01421609A1067|7 11|data
P01421609A1067|77 80|CPB
P01423454A0309|103 113|vasculitis
P01423454A0309|16 20|ANCA
P01423454A0309|184 197|effectiveness
P01423454A0309|144 152|activity
P01423454A0309|160 167|disease
P01424674A0000|50 57|disease
P01424674A0000|13 23|pemphigoid
P01425921A1286|20 28|features
P01425921A1286|177 183|region
P01425921A1286|44 62|amino acid changes
P01426635A0496|108 124|dopamine neurons
P01426635A0496|94 103|serotonin
P01426635A0496|44 47|CNS
P01427457A0000|118 133|calcium heparin
P01427457A0000|115 116|h
P01427457A0000|176 185|treatment
P01427457A0000|89 91|SC
P01428513A0440|54 61|persons
P01429624A0328|32 43|temperature
P01429624A0328|5 10|shift
P01429624A0328|74 80|guanyl
P01429724A0664|99 105|Gly451
P01429724A0664|108 114|Leu455
P01429724A0664|89 94|Phe96
P01429768T0000|71 76|alloy
P01429768T0000|7 26|neutrophil response
P01429836A1205|87 102|protein sorting
P01429836A1205|18 23|Vps1p
P01429836A1205|10 14|form
P01431602A0229|110 127|microliters HClO4
P01431602A0229|12 18|method
P01431602A0229|45 62|sensitivity range
P01432453T0000|1 11|Validation
P01433502A1163|84 89|cells
P01433502A1163|7 14|results
P01433502A1163|107 111|part
P01433502A1163|194 203|repressor
P01435698A0000|81 88|changes
P01435698A0000|157 169|implantation
P01435698A0000|92 104|prostacyclin
P01435698A0000|106 110|PGI2
P01435698A0000|29 48|blood compatibility
P01437562A0462|119 138|nucleotide sequence
P01437562A0462|36 43|protein
P01437562A0462|59 72|C.fasciculata
P01437562A0462|10 20|antibodies
P01438287T0000|16 31|vaccinia vector
P01441818T0001|1 16|Interferon type
P01441818T0001|67 87|Klebsiella infection
P01443745T0000|53 61|sedation
P01443745T0000|13 24|interaction
P01446132A0328|46 52|filter
P01447139A0208|1 3|V.
P01447189T0000|100 120|killer cell leukemia
P01447189T0000|54 63|RNK-Met-1
P01447189T0000|88 91|rat
P01448806A0135|50 56|growth
P01448806A0135|19 33|growth hormone
P01448932T0000|1 48|Rice dwarf phytoreovirus segment S12 transcript
P01449301A0710|71 76|hours
P01449301A0710|57 64|minutes
P01451771A0619|238 243|wives
P01451771A0619|16 24|analyses
P01451771A0619|203 216|health scores
P01451771A0619|178 181|MDS
P01451771A0619|134 137|PCA
P01452584T0000|48 59|retardation
P01452584T0000|40 44|role
P01454518A0336|205 211|probes
P01454518A0336|36 43|domains
P01454518A0336|160 185|stringency hybridizations
P01454518A0336|225 235|ERCC3 cDNA
P01456888A0074|70 81|HIV-1 group
P01456888A0074|39 47|capacity
P01456888A0074|10 16|reason
P01456888A0074|190 198|bacteria
P01456888A0074|22 30|particle
P01456888A0074|265 281|core protein p55
P01456888A0074|91 111|core antigen p55 gag
P01457695T0000a|53 67|hemofiltration
P01457695T0000a|76 80|year
P01458170A0155|1 11|Adapromine
P01458170A0155|39 47|decrease
P01458170A0155|197 210|wave activity
P01458170A0155|225 230|range
P01458170A0155|117 130|power spectra
P01458170A0155|81 85|peak
P01458170A0155|179 187|increase
P01458170A0155|149 155|cortex
P01459451A0478|20 34|antirepression
P01459451A0478|57 63|factor
P01459921A0000|219 224|acids
P01459921A0000|126 146|linoleoyl methionine
P01459921A0000|193 197|flow
P01459921A0000|151 168|calcium linoleate
P01460054A0968|76 84|activity
P01460054A0968|12 17|ICSBP
P01462786T0000|32 39|control
P01464606A0344|190 194|EDTA
P01464606A0344|38 46|integrin
P01464606A0344|23 28|alpha
P01464606A0344|148 172|fragment affinity column
P01464606A0344|72 77|cells
P01464606A0344|31 35|beta
P01467828A0542|35 46|involvement
P01467828A0542|7 14|results
P01467828A0542|132 143|reperfusion
P01467828A0542|164 173|receptors
P01468625A1080|37 42|times
P01468625A1080|14 18|ACT1
P01469047A1606|168 186|acid decarboxylase
P01469047A1606|18 25|portion
P01469047A1606|72 102|% amino acid sequence identity
P01469047A1606|46 48|aa
P01470741T0062|41 47|course
P01473196A1016|62 71|clearance
P01473234A1001|71 85|acid formation
P01475381T0001|1 12|Brucellosis
P01477021A0394|136 137|P
P01477021A0394|52 81|serum prolactin concentration
P01477021A0394|122 123|P
P01480183A0000|98 105|library
P01480470A0323|1 7|BiP670
P01480470A0323|26 29|Ca2
P01483755A0000|119 129|metabolism
P01483755A0000|153 159|muscle
P01483755A0000|140 149|structure
P01483755A0000|52 55|MRI
P01483755A0000|10 32|resonance spectroscopy
P01485648A0000|84 108|Pharmacia Diagnostics AB
P01485648A0000|236 244|patients
P01485648A0000|200 210|comparison
P01485648A0000|56 60|test
P01485648A0000|226 232|groups
P01485648A0000|62 82|Pharmacia CAP System
P01487144A0505|19 31|gene segment
P01487144A0505|131 155|transcription terminator
P01487144A0505|182 200|L cell fibroblasts
P01487144A0505|164 177|myeloma cells
P01492463T0001|50 55|wages
P01492463T0001|21 27|Prague
P01492463T0001|12 17|nurse
P01495069A0392|1 5|DIBA
P01495069A0392|95 105|percentage
P01496784A0939|85 90|death
P01496784A0939|21 26|study
P01496784A0939|44 60|strongyloidiasis
P01498607A0000|95 129|parsley chalcone synthase promoter
P01498607A0000|73 87|responsiveness
P01499616A0136|35 43|foreskin
P01499616A0136|168 169|%
P01499616A0136|10 20|blood flow
P01499616A0136|132 142|anesthesia
P01504178T0000|17 22|years
P01504178T0000|56 65|visionary
P01504178T0000|47 54|country
P01505488A0231|64 70|period
P01505488A0231|92 96|July
P01506705A0282|20 32|hemodynamics
P01509798A0520|85 86|%
P01509798A0520|4 12|rest AFF
P01509798A0520|78 81|UEA
P01509798A0520|47 48|%
P01511950T0000|153 163|population
P01511950T0000|70 75|Japan
P01511950T0000|77 89|significance
P01511950T0000|13 30|hepatitis B virus
P01512654A0503|143 158|threshold level
P01512654A0503|176 183|latency
P01512654A0503|73 75|ES
P01512654A0503|28 37|phosphate
P01513114A1133|84 92|ABSTRACT
P01513114A1133|54 58|year
P01513114A1133|77 81|mg/d
P01513114A1133|60 63|SPK
P01516427T0000|26 36|tomography
P01516829A0460|103 113|activation
P01516829A0460|117 129|target genes
P01516829A0460|78 82|SNF2
P01516829A0460|94 98|SNF6
P01518833A0397|87 94|spinach
P01518833A0397|3 27|lambda gt10 cDNA library
P01518833A0397|77 83|leaves
P01518926T0000|10 16|topics
P01523111A0769|1 8|Factors
P01523111A0769|64 75|temperature
P01523111A0769|44 47|age
P01525153A0359|156 163|Gilbert
P01525153A0359|64 82|monomer structures
P01525153A0359|37 41|form
P01525153A0359|28 29|d
P01525153A0359|150 152|D.
P01525153A0359|30 35|T2G4T
P01526658A0454|1 4|IFI
P01526658A0454|8 12|mRNA
P01526658A0454|79 89|cell lines
P01527020A0511|138 142|gene
P01527020A0511|111 116|exons
P01527020A0511|89 98|positions
P01531086A0127|84 91|protein
P01531086A0127|22 35|reading frame
P01531632A0000|204 211|glycine
P01531632A0000|216 233|arginine residues
P01531632A0000|97 106|nucleolin
P01531632A0000|108 119|fibrillarin
P01531632A0000|121 125|SSB1
P01531632A0000|15 23|proteins
P01532796A0107|50 54|step
P01532796A0107|70 72|F1
P01532796A0107|21 25|gene
P01532796A0107|96 109|beta subunits
P01532796A0107|58 66|assembly
P01533760T0000|34 38|risk
P01533760T0000|42 55|breast cancer
P01533760T0000|72 85|meta-analyses
P01536153A0574|35 45|difference
P01536153A0574|233 236|IgE
P01536153A0574|249 256|dyspnea
P01536153A0574|104 123|animal food workers
P01537334A0507|19 29|TRP-2 maps
P01537334A0507|5 9|gene
P01537334A0507|75 101|coat colour mutation slaty
P01538401A1244|6 31|base-pair oligonucleotide
P01538401A1244|41 52|nucleotides
P01538401A1244|120 127|binding
P01539996A0588|273 281|sequence
P01539996A0588|319 327|residues
P01539996A0588|48 70|T. thermophilus enzyme
P01539996A0588|353 375|T. thermophilus enzyme
P01539996A0588|127 128|%
P01539996A0588|297 305|presence
P01539996A0588|242 248|enzyme
P01541577A0000|115 121|Morgan
P01541577A0000|99 104|Scale
P01541577A0000|106 110|SHCS
P01541577A0000|44 64|volunteer hearing Ss
P01542565T0000|100 107|protein
P01542565T0000|39 50|protein L12
P01542565T0000|126 143|sequence analysis
P01542565T0000|73 89|characterization
P01542686A0000|158 169|NF-kappa B.
P01542686A0000|147 154|subunit
P01542686A0000|11 18|cloning
P01543909A0787|137 152|characteristics
P01543909A0787|237 253|ferritin subunit
P01543909A0787|52 54|Lg
P01543909A0787|63 68|clone
P01544918A1240|1 17|Characterization
P01544918A1240|203 222|gel electrophoresis
P01544918A1240|165 179|sodium dodecyl
P01544918A1240|87 103|immunoreactivity
P01544918A1240|262 270|RII beta
P01544918A1240|321 324|kDa
P01544918A1240|147 161|mobility shift
P01545523A0000|20 35|quantifications
P01545523A0000|57 65|testings
P01545523A0000|89 96|protein
P01545792A0000|35 40|MLC-2
P01545792A0000|159 169|expression
P01545792A0000|106 115|sequences
P01545797A0587|51 60|SLK1 gene
P01545797A0587|1 21|Disruption mutations
P01545797A0587|72 79|mutants
P01545797A0587|151 161|degrees C.
P01545818A0696|188 204|v-Src SH2 domain
P01545818A0696|159 166|binding
P01545818A0696|133 144|Rat-2 cells
P01545818A0696|14 17|p62
P01547775A1024|7 11|data
P01547775A1024|179 193|PLRV replicase
P01547775A1024|167 171|site
P01547775A1024|90 98|position
P01547942A0120|143 150|CHOP-10
P01547942A0120|56 68|zipper probe
P01547942A0120|15 18|LAP
P01548756A1102|184 201|rhesus monkey DNA
P01548756A1102|112 115|DNA
P01548756A1102|146 160|chimpanzee DNA
P01548756A1102|11 24|hybridization
P01549118A0000|68 73|stage
P01549118A0000|96 106|regulation
P01549118A0000|62 65|sex
P01549125A0140|112 122|expression
P01549125A0140|127 145|DNA binding assays
P01549125A0140|27 35|portions
P01549346A0000|81 84|DNA
P01549346A0000|30 53|transcription activator
P01551176A0000|1 9|GR63178A
P01551176A0000|29 37|analogue
P01551898A1084|153 167|culture medium
P01551898A1084|116 122|levels
P01551898A1084|133 135|mg
P01551898A1084|105 112|protein
P01551910A0978|6 15|DNA motif
P01552457T0000|1 25|Intrapocket chemotherapy
P01552457T0000|80 86|insert
P01552853A1377|71 82|yop regulon
P01552853A1377|23 27|virF
P01554334A0000|153 162|Committee
P01554334A0000|189 198|Australia
P01554334A0000|42 51|IFN-gamma
P01554334A0000|94 106|tuberculosis
P01554334A0000|166 177|Agriculture
P01556068A0000|5 35|Klebsiella aerogenes gene maoA
P01556068A0000|158 168|catabolite
P01556068A0000|62 71|synthesis
P01556068A0000|75 92|monoamine oxidase
P01557217A0272|89 95|h p.i.
P01558942A1369|9 21|observations
P01560021A0379|40 51|differences
P01560021A0379|26 31|basis
P01562659A0676|304 316|confirmation
P01562659A0676|140 153|dexamethasone
P01562659A0676|229 243|CNS vasculitis
P01562659A0676|320 340|C. immitis infection
P01562659A0676|355 358|CNS
P01562659A0676|247 259|encephalitis
P01563635T0000|34 50|characterization
P01563635T0000|1 15|Overproduction
P01563635T0000|88 103|deletion mutant
P01565093A0179|102 106|BLLs
P01565093A0179|6 11|March
P01565093A0179|22 29|October
P01565093A0179|46 53|persons
P01565093A0179|164 191|disease surveillance system
P01566576A0605|7 11|C.J.
P01568960A1129|96 106|blood flow
P01568960A1129|79 85|output
P01568960A1129|12 21|mechanism
P01569102A0708|70 77|repeats
P01569102A0708|125 134|cysteines
P01569581A0482|220 252|translation initiation frequency
P01569581A0482|33 38|model
P01569581A0482|80 91|nucleotides
P01569581A0482|145 154|base-pair
P01569581A0482|166 195|translation initiation region
P01569945A0529|5 14|SEN1 gene
P01569945A0529|46 59|reading frame
P01573270A0000|152 158|killer
P01573270A0000|5 12|IA4 mAb
P01573270A0000|67 78|BALB/c mice
P01573270A0000|177 198|EBV-B lymphocyte line
P01573270A0000|46 56|antibodies
P01577740A1111|36 55|S1 nuclease mapping
P01577740A1111|131 148|Northern analyses
P01579472A1018|20 36|enhancer element
P01579472A1018|88 94|manner
P01580738T0001|48 55|ascites
P01581577A1186|1 6|PSI-G
P01581577A1186|11 16|PSI-K
P01582413A0192|100 106|region
P01582413A0192|202 213|DNA binding
P01582413A0192|127 134|helices
P01582413A0192|45 53|clusters
P01582500A0178|30 35|sleep
P01584812T0000|17 27|expression
P01584812T0000|64 76|localization
P01584812T0000|37 46|structure
P01586901A0000|101 106|drugs
P01586901A0000|52 60|patients
P01587763A0402|84 93|fractions
P01587763A0402|71 77|scheme
P01587763A0402|110 113|day
P01588315A0356|1 7|AgMNPV
P01588315A0356|71 89|promoter structure
P01588315A0356|39 45|OpMNPV
P01588315A0356|213 221|relation
P01588315A0356|94 104|polyhedrin
P01588315A0356|62 67|terms
P01588961A0000|152 161|pre-tRNAs
P01588961A0000|1 5|STP1
P01588961A0000|108 116|families
P01588965A0000|1 19|GCR1 gene function
P01592545A0726|101 102|p
P01592545A0726|66 74|patients
P01592545A0726|124 125|%
P01592545A0726|61 62|%
P01596007A0908|273 278|WORDS
P01596007A0908|71 81|proportion
P01596007A0908|247 255|ABSTRACT
P01596007A0908|228 231|SWS
P01596007A0908|149 164|control studies
P01596007A0908|195 196|%
P01597272A0077|4 9|women
P01600531A0483|32 33|%
P01600531A0483|10 14|flow
P01600531A0483|75 88|control group
P01601869A1389|175 185|activation
P01601869A1389|37 43|region
P01601869A1389|10 17|segment
P01605038T0001|1 10|Influence
P01605038T0001|21 31|regulation
P01608239T0001|17 25|barriers
P01612085A0624|32 46|concentrations
P01612085A0624|76 82|U.ml-1
P01612085A0624|58 69|triathletes
P01612085A0624|27 30|EPO
P01615049A0000|5 11|eating
P01615049A0000|77 89|h light/12 h
P01615049A0000|95 100|cycle
P01615493A0408|5 7|HC
P01615493A0408|24 38|antigen levels
P01615493A0408|11 19|activity
P01616475A0756|103 117|family history
P01616475A0756|38 46|validity
P01616475A0756|178 205|panic disorder presentation
P01616475A0756|147 155|patients
P01616475A0756|121 135|panic disorder
P01617776A0343|238 243|heart
P01617776A0343|257 267|infarction
P01617776A0343|216 223|reentry
P01617776A0343|246 250|days
P01617776A0343|58 69|arrhythmias
P01618027A1108|17 28|transcripts
P01618027A1108|200 206|region
P01618027A1108|176 185|remainder
P01618027A1108|41 45|size
P01618256A0521|5 9|mean
P01618256A0521|94 95|%
P01618256A0521|31 44|concentration
P01619642A0131|6 13|parents
P01620129A0417|83 99|promoter element
P01620129A0417|163 168|cells
P01620129A0417|46 59|factor HiNF-D
P01620781A0611|171 178|stimuli
P01620781A0611|234 241|members
P01620781A0611|78 85|control
P01620781A0611|106 108|A1
P01620781A0611|220 228|sequence
P01620781A0611|118 120|A3
P01620781A0611|112 114|B2
P01620781A0611|124 126|B4
P01623900A0670|103 112|excretion
P01623900A0670|311 335|norepinephrine excretion
P01623900A0670|77 90|plasma levels
P01623900A0670|195 201|supine
P01623900A0670|116 130|norepinephrine
P01623900A0670|62 69|changes
P01623900A0670|362 367|month
P01625131A0452|19 25|biopsy
P01625131A0452|79 88|rejection
P01626372T0000|55 61|growth
P01626372T0000|124 153|trimethoprim-sulfamethoxazole
P01626372T0000|13 21|exudates
P01626372T0000|75 83|bacteria
P01626440A0449|9 30|application solutions
P01627106A0320|154 173|isolation frequency
P01627106A0320|39 67|nitrofurazone administration
P01627106A0320|72 96|S. enteritidis challenge
P01627830A0000|101 105|CKI2
P01627830A0000|5 10|cDNAs
P01627830A0000|62 80|yeast cDNA library
P01628806A1347|52 55|ORF
P01628806A1347|14 32|sequence variation
P01629768A0131|51 55|acid
P01629768A0131|65 68|SOC
P01629768A0131|106 124|glass micropipette
P01630455A0448|48 57|NF beta A
P01630455A0448|99 111|DNA sequence
P01630455A0448|149 163|TATA box motif
P01633816A0667|119 127|opn gene
P01633816A0667|16 21|clone
P01633816A0667|83 85|kb
P01633816A0667|29 43|EcoRI fragment
P01633816A0667|105 111|region
P01634400A1101|64 87|replacement stock costs
P01634400A1101|27 31|feed
P01634861A1336|12 20|contrast
P01634861A1336|104 121|lactate clearance
P01636714A0845|170 173|CLP
P01636714A0845|81 87|cortex
P01636714A0845|162 163|h
P01636714A0845|57 60|MBF
P01636714A0845|47 52|areas
P01639092A0776|8 10|N.
P01640778A0485|25 31|method
P01642060A0471|85 93|patients
P01642060A0471|140 148|FIGO III
P01642060A0471|14 25|application
P01644751A0590|80 97|sequence analysis
P01644814A0068|68 83|immortalization
P01644814A0068|5 10|virus
P01644814A0068|28 35|protein
P01644831A0824|117 127|accordance
P01644831A0824|4 15|examination
P01644831A0824|158 165|mutants
P01644831A0824|67 73|NGFI-B
P01644831A0824|147 156|receptors
P01645905A0341|68 72|TGEV
P01645905A0341|1 14|Nucleoprotein
P01645905A0341|141 152|degradation
P01645905A0341|189 207|breakdown products
P01645905A0341|104 106|Mr
P01646487A0874|103 104|T
P01646487A0874|142 150|activity
P01646487A0874|77 84|content
P01646487A0874|154 165|neutrophils
P01646487A0874|93 96|IgG
P01646487A0874|88 91|IgA
P01646487A0874|181 189|patients
P01647070A0232|12 26|JCV T antigens
P01647070A0232|60 75|DNA replication
P01647813A0512|64 74|complexity
P01647813A0512|146 153|control
P01647813A0512|91 95|need
P01648530A0000|136 146|expression
P01648530A0000|217 221|eggs
P01648530A0000|160 191|actin-beta-globin reporter gene
P01649318A0734|27 39|CD23 element
P01649318A0734|62 66|mRNA
P01649539T0000|36 58|myeloperoxidase levels
P01649539T0000|73 80|surgery
P01650524A0837|103 107|dose
P01650524A0837|184 187|ICI
P01650524A0837|172 178|A63162
P01650524A0837|72 78|cavity
P01650524A0837|224 234|colchicine
P01651232A0152|102 105|UTP
P01651232A0152|110 118|thio-UTP
P01651232A0152|91 98|mixture
P01652372A0153|35 54|localization signal
P01652372A0153|142 149|protein
P01652372A0153|89 93|cell
P01652755A1492|137 139|RB
P01652755A1492|252 261|promoters
P01652755A1492|22 46|transfection experiments
P01652755A1492|286 290|IL-6
P01652755A1492|225 235|beta-actin
P01652755A1492|344 353|promoters
P01653236A0895|19 22|p50
P01653236A0895|77 84|L cells
P01653236A0895|26 37|association
P01653238A1715|48 58|activities
P01653238A1715|73 79|enzyme
P01654349A0327|48 70|NaHCO3 supplementation
P01654349A0327|41 44|KCl
P01654349A0327|90 94|gain
P01655713A0294|113 116|Tn1
P01655713A0294|83 92|phenotype
P01655713A0294|148 156|mutation
P01655713A0294|107 111|exs1
P01656221A1319|1 10|Alignment
P01656221A1319|95 100|FGFRs
P01656221A1319|166 177|FGFR family
P01656221A1319|120 137|tyrosine residues
P01656675A0236|1 19|Capnography curves
P01656675A0236|26 38|HVS patients
P01657249A1019|48 51|VH4
P01657249A1019|140 158|region determinant
P01657249A1019|58 64|chains
P01657249A1019|167 175|VH4-HV2a
P01657594A0472|83 87|cgs1
P01657594A0472|29 36|mutants
P01658356A1369|191 197|levels
P01658356A1369|80 97|FeLV recombinants
P01658356A1369|66 76|generation
P01658356A1369|226 231|mRNAs
P01658375A0854|236 257|consensus sequence GT
P01658375A0854|140 145|genes
P01658375A0854|218 220|GC
P01658375A0854|95 106|transcripts
P01658375A0854|193 196|end
P01658741A1047|5 13|strategy
P01658741A1047|58 77|nucleotide sequence
P01660486A1756|239 254|gene expression
P01660486A1756|48 57|cell type
P01660486A1756|5 12|results
P01660486A1756|59 74|gene cotransfer
P01660486A1756|225 235|activation
P01661369A0825|138 146|moieties
P01661369A0825|25 35|strE genes
P01661369A0825|61 67|probes
P01662794A0640|1 11|Expression
P01662794A0640|173 181|antisera
P01662794A0640|58 69|COS-1 cells
P01662884A1029|18 27|mg b.i.d.
P01662884A1029|92 101|treatment
P01669611A0142|119 127|diseases
P01669611A0142|5 12|patient
P01669611A0142|73 78|aorta
P01671675A0905|34 60|Northern blotting analysis
P01671675A0905|6 16|conclusion
P01674177T0001|1 21|Histamine-2 blockade
P01674369A0417|65 81|restriction site
P01674369A0417|91 98|cloning
P01674817A0862|96 106|data banks
P01674817A0862|41 46|RNA15
P01674817A0862|31 36|RNA14
P01675154T0000|26 34|patients
P01675637T0033|50 56|region
P01675637T0033|99 123|receptor dimer formation
P01678287A1308|19 45|Antp TATAA binding protein
P01678287A1308|189 197|function
P01678287A1308|121 134|homeobox gene
P01679068A0000|185 195|Klebsiella
P01679068A0000|66 71|value
P01679068A0000|56 57|%
P01679068A0000|73 78|range
P01679749A1171|93 98|RFLPs
P01679749A1171|128 135|studies
P01679749A1171|58 64|genome
P01679749A1171|73 85|availability
P01682484A0680|34 42|contrary
P01682484A0680|204 222|lactate metabolism
P01682484A0680|179 191|hemodynamics
P01682484A0680|58 68|procaterol
P01682542A0690|139 150|individuals
P01682542A0690|55 63|strategy
P01682542A0690|6 13|country
P01686909A0299|34 43|excretion
P01686909A0299|94 103|bretylium
P01686909A0299|123 127|acid
P01688841A0430|50 54|invJ
P01688841A0430|32 36|ipaC
P01688841A0430|38 42|invE
P01688841A0430|107 121|regulator virF
P01688841A0430|60 64|invK
P01690703A0285|1 11|Venkatesan
P01690812A0000|116 121|S RNA
P01690812A0000|160 164|type
P01690812A0000|149 153|type
P01690812A0000|47 52|units
P01692135A0783|169 181|mRNA species
P01692135A0783|112 125|CRNK-16 cells
P01692135A0783|150 158|Fc gamma
P01692962A0980|35 40|alpha
P01692962A0980|8 18|expression
P01692962A0980|128 142|cAMP synthesis
P01692962A0980|72 85|hamster ovary
P01694014A0716|1 10|Treatment
P01694014A0716|116 117|h
P01694014A0716|127 133|levels
P01694014A0716|92 95|PMA
P01694014A0716|28 44|cell lines HL-60
P01694525A0000|97 116|amino acid sequence
P01694525A0000|28 37|epimerase
P01695116A0078|52 55|CR1
P01695116A0078|41 50|remission
P01695314T0000|1 21|Platelet aggregation
P01695314T0000|96 100|type
P01695314T0000|104 121|diabetes mellitus
P01695378A1406|117 126|FKBP mRNA
P01695378A1406|108 113|level
P01695378A1406|14 20|Jurkat
P01697683T0000|1 15|Identification
P01697683T0000|61 76|cytotactin gene
P01698761A1059|186 196|conversion
P01698761A1059|206 212|mucoid
P01698761A1059|114 121|histone
P01698761A1059|143 147|AlgP
P01698761A1059|230 239|phenotype
P01699944A1538|137 153|promoter element
P01699944A1538|175 186|alpha-actin
P01699944A1538|161 165|VLC1
P01701088A1335|34 42|elements
P01701088A1335|54 62|elements
P01701088A1335|92 101|CCAAT box
P01702426A0196|23 29|region
P01702426A0196|74 84|regulation
P01702432A1296|1 27|Northern blotting analysis
P01702432A1296|43 53|expression
P01702432A1296|90 96|clones
P01703335T0000|84 96|observations
P01703335T0000|108 129|transplant population
P01707800A0354|115 130|conduction time
P01707800A0354|172 175|N20
P01707800A0354|72 86|parallel shift
P01707800A0354|164 167|N11
P01708771A1215|1 23|Sequence determination
P01708771A1215|143 149|others
P01708771A1215|94 100|Asn109
P01708771A1215|60 66|Asn120
P01709486A0000|46 47|W
P01709486A0000|75 80|c-kit
P01710766A0349|5 13|proteins
P01710766A0349|131 147|initiation codon
P01710766A0349|28 36|presence
P01710979T0000|5 8|SH2
P01710979T0000|109 113|p110
P01710979T0000|13 24|SH3 domains
P01711041A0348|102 103|%
P01711041A0348|54 58|gene
P01711041A0348|111 121|beta-chain
P01711048T0000|34 42|position
P01711048T0000|113 125|RNA splicing
P01711048T0000|63 72|pro-alpha
P01711048T0000|14 22|mutation
P01713213A0000|5 12|protein
P01713213A0000|110 142|serine/threonine protein kinases
P01713213A0000|215 247|protein tyrosine kinase activity
P01713213A0000|30 38|sequence
P01714322A0969|6 12|report
P01714322A0969|111 116|genes
P01714452A0559|1 9|Homology
P01714452A0559|138 143|sites
P01714452A0559|59 72|repeat domain
P01714452A0559|43 44|%
P01714452A0559|105 112|serines
P01715593A0838|66 78|brain levels
P01715593A0838|82 93|desipramine
P01716292A0000|221 229|DR alpha
P01716292A0000|33 40|regions
P01716292A0000|233 243|H-2E alpha
P01716292A0000|161 169|products
P01716292A0000|13 21|analysis
P01716292A0000|44 51|HLA-DR1
P01717718A1255|38 55|Gag-Pol PR domain
P01717718A1255|80 82|RT
P01717718A1255|172 179|Gag-Pol
P01717718A1255|214 216|RT
P01717718A1255|107 109|PR
P01717833T0000|102 121|rat granulosa cells
P01717833T0000|1 11|Regulation
P01717833T0000|48 57|adenosine
P01717994T0000|1 8|Cloning
P01717994T0000|49 55|kinase
P01717994T0000|59 74|complementation
P01718983A1640|103 107|Cell
P01718983A1640|5 12|Hession
P01718983A1640|67 76|Chi-Rosso
P01718983A1640|78 80|G.
P01718983A1640|51 53|R.
P01718983A1640|18 22|Goff
P01718983A1640|92 94|R.
P01718983A1640|63 65|B.
P01720555A1087|64 78|alfalfa organs
P01721261T0000|1 17|Pharmacokinetics
P01721261T0000|31 50|transplant patients
P01722319A0849|1 9|Analysis
P01722319A0849|178 179|N
P01722319A0849|25 44|amino acid sequence
P01723619A0766|139 140|F
P01723619A0766|21 33|F absorption
P01723619A0766|179 185|factor
P01723619A0766|13 17|rate
P01723619A0766|105 113|emptying
P01724982A0237|51 62|HCV EIA kit
P01724982A0237|92 94|IL
P01725622A0292|69 72|CCI
P01725622A0292|11 22|transfusion
P01726631T0001|1 13|Epidemiology
P01726631T0001|32 51|hospital infections
P01726631T0001|18 28|prevention
P01726631T0001|110 120|resistance
P01726631T0001|89 96|profile
P01727494A0000|1 15|Vaccinia virus
P01727494A0000|115 123|response
P01727494A0000|131 135|host
P01727494A0000|90 100|activation
P01730747A0205|19 21|G1
P01730747A0205|25 32|S phase
P01731933T0000a|1 3|Zn
P01731933T0000a|8 35|coordination domain mutants
P01731979A1408|27 42|gene expression
P01732736A1076|1 12|Transcripts
P01732736A1076|155 167|gastrulation
P01732736A1076|27 42|POU-domain gene
P01732736A1076|44 50|Oct-25
P01733105A0127|5 11|genome
P01733105A0127|15 28|Thogoto virus
P01734020A1318|169 178|PKC alpha
P01734020A1318|19 24|cells
P01734020A1318|143 149|nuclei
P01734570T0000|115 128|translocation
P01734570T0000|97 101|rate
P01734570T0000|12 45|thromboxane synthetase inhibition
P01735447A0271|5 9|size
P01735447A0271|76 85|precursor
P01735447A0271|177 186|reticulum
P01735721A0185|152 160|identity
P01735721A0185|139 144|TyrTS
P01735721A0185|233 234|%
P01735721A0185|47 57|% identity
P01735721A0185|15 34|amino acid sequence
P01736651A0104|50 61|Minneapolis
P01736651A0104|63 68|Minn.
P01737741A0000|34 62|monoamine oxidase inhibitors
P01737741A0000|1 11|BACKGROUND
P01737741A0000|94 104|depression
P01738470A0441|85 90|order
P01738470A0441|1 9|Patients
P01738470A0441|24 29|PDDAT
P01738936A0292|50 52|pM
P01738936A0292|5 13|patients
P01739956A0638|71 78|type IC
P01739956A0638|27 31|beta
P01739956A0638|62 67|drugs
P01740448A1735|18 39|transmembrane regions
P01740448A1735|83 103|amino acid stretches
P01740448A1735|225 234|membranes
P01741249A0177|1 5|W.G.
P01742606A0000|101 109|antibody
P01742606A0000|148 173|kDa spectrin beta-subunit
P01744039A0511|48 73|polymerase chain reaction
P01744039A0511|23 29|region
P01744039A0511|90 109|gel electrophoresis
P01744119A0757|116 124|proteins
P01744119A0757|5 16|constraints
P01744119A0757|172 176|gene
P01744119A0757|179 186|protein
P01744119A0757|94 101|effects
P01748067A0000|98 103|women
P01748067A0000|78 81|age
P01748067A0000|225 233|fracture
P01748067A0000|119 124|years
P01748067A0000|253 258|femur
P01748067A0000|212 221|arthritis
P01748067A0000|241 245|neck
P01748287T0000|77 84|targets
P01748630A0125|1 26|Growth factor stimulation
P01748630A0125|236 244|Gonzalez
P01748630A0125|141 147|region
P01748630A0125|47 62|phosphorylation
P01748630A0125|113 118|Ser62
P01748630A0125|246 248|F.
P01748630A0125|179 186|members
P01748630A0125|30 35|cells
P01751255A0529|9 15|output
P01751255A0529|74 84|MBBF group
P01752441A0000|35 52|HIV-1 Tat protein
P01752441A0000|138 165|TAR RNA stem-loop structure
P01752441A0000|111 130|trinucleotide bulge
P01752441A0000|195 201|leader
P01753317A0879|7 14|results
P01753317A0879|95 109|bone formation
P01753317A0879|60 71|combination
P01756195A1117|38 46|increase
P01756195A1117|97 100|age
P01756195A1117|120 121|r
P01757341A0591|103 107|area
P01757341A0591|53 64|capillaries
P01757341A0591|42 44|Na
P01757341A0591|30 40|number/mm2
P01760166A0963|1 11|CONCLUSION
P01760166A0963|42 53|septum site
P01760166A0963|124 132|patients
P01762053A0557|65 70|space
P01762053A0557|89 98|particles
P01762917A0615|16 19|Ser
P01762917A0615|67 84|TGEK tetrapeptide
P01762917A0615|24 29|Gly69
P01762917A0615|132 143|DNA binding
P01763106A0070|100 112|test session
P01763106A0070|59 69|locomotion
P01765095A0680|84 94|expression
P01765095A0680|98 103|mRNAs
P01765095A0680|148 156|myogenin
P01765269A0308|94 113|consensus sequences
P01765269A0308|46 62|pre-mRNA introns
P01765386A0305|100 102|kb
P01765386A0305|32 44|DNA sequence
P01765386A0305|127 136|junctions
P01765386A0305|146 148|bp
P01765386A0305|106 110|exon
P01766666A0788|118 129|interaction
P01766666A0788|49 72|nucleoprotein complexes
P01766666A0788|96 101|sites
P01766666A0788|148 155|factors
P01766999A0000|59 61|AE
P01766999A0000|123 131|allergen
P01767592A0682|103 143|HAP2/HAP3 consensus recognition sequence
P01767592A0682|168 203|BAF1 consensus recognition sequence
P01767592A0682|40 60|DNA binding proteins
P01767592A0682|26 35|sequences
P01768648A0853|64 76|dimerization
P01768648A0853|107 111|cRel
P01769919A0393|10 26|threshold shifts
P01769919A0393|63 81|brainstem response
P01771593A1152|18 20|TA
P01771593A1152|93 96|PCD
P01771959A0442|70 71|p
P01771959A0442|168 172|PTCA
P01771959A0442|67 68|%
P01771959A0442|13 30|ejection fraction
P01771959A0442|54 55|%
P01771959A0442|212 220|segments
P01771959A0442|151 160|deviation
P01772341A0852|55 87|thromboxane synthetase inhibitor
P01772341A0852|7 11|data
P01772341A0852|144 154|protection
P01774063A0161|186 191|Actcl
P01774063A0161|221 231|chromosome
P01774063A0161|97 99|F1
P01774063A0161|193 196|Ltk
P01774063A0161|180 184|Fshb
P01774063A0161|61 68|matings
P01774822A0289|102 107|cycle
P01774822A0289|46 68|LV time-density curves
P01776715A0489|87 91|loss
P01776715A0489|4 9|delay
P01776715A0489|95 98|CO2
P01776715A0489|135 146|gas mixture
P01776715A0489|31 45|centrifugation
P01779299A0000|49 58|cockroach
P01779299A0000|99 114|acanthocephalan
P01779299A0000|60 79|Periplaneta brunnea
P01779769A0000|71 76|phage
P01779769A0000|38 39|c
P01779769A0000|5 13|sequence
P01779769A0000|78 85|phi C31
P01781923A0744|34 36|DB
P01781923A0744|168 198|barbiturate brain distribution
P01781923A0744|203 214|elimination
P01781923A0744|78 80|DB
P01781923A0744|226 231|lines
P01782669A0496|68 74|A23187
P01782669A0496|56 64|addition
P01783088A1136|307 312|WORDS
P01783088A1136|272 279|disease
P01783088A1136|92 93|%
P01783088A1136|95 105|hyaluronan
P01783088A1136|194 208|micrograms.l-1
P01783088A1136|15 23|patients
P01784589A0000|82 85|rat
P01784589A0000|42 46|role
P01786094T0001|28 34|copper
P01788002T0001|1 15|Magnetotherapy
P01788002T0001|40 48|children
P01791754T0000|125 135|haemolysin
P01791754T0000|88 104|secretion signal
P01792914T0000|16 23|relapse
P01797467A0000|1 6|RU486
P01797467A0000|11 14|ONO
P01797467A0000|75 86|termination
P01804671A1001|256 264|ml.min-1
P01804671A1001|223 231|gas data
P01804671A1001|4 8|line
P01804671A1001|24 30|values
P01804671A1001|130 134|lung
P01808049A0262|1 17|CT abnormalities
P01808049A0262|101 112|hypodensity
P01808049A0262|97 98|%
P01808049A0262|76 77|%
P01808049A0262|48 58|hemorrhage
P01808049A0262|212 213|%
P01808049A0262|123 124|%
P01808186A0984|1 5|Pigs
P01808186A0984|78 81|Exp
P01808829A0510|85 96|hemorrhages
P01808829A0510|15 31|brain congestion
P01810108A0000|71 83|inactivation
P01810108A0000|146 150|cows
P01810108A0000|31 45|heat exchanger
P01811243A0000|1 9|Regional
P01811243A0000|253 267|rCBF technique
P01811243A0000|66 73|ratings
P01811243A0000|37 49|measurements
P01811243A0000|228 235|ratings
P01811243A0000|31 35|rCBF
P01812102A0101|102 111|trimester
P01812102A0101|153 164|NPN complex
P01812102A0101|64 80|pattern reversal
P01812102A0101|82 87|VEP-P
P01812102A0101|13 26|study reports
P01814182A0000|119 129|treatments
P01814182A0000|103 110|heifers
P01814182A0000|158 163|cycle
P01814182A0000|133 136|day
P01814182A0000|75 85|luteolysis
P01817497A0715|1 11|Resolution
P01817497A0715|58 65|Delta T
P01817497A0715|29 38|asymmetry
P01822995T0000|41 58|sequence elements
P01823524A0238|87 97|complexity
P01823524A0238|33 41|examples
P01823524A0238|110 118|exposure
P01823524A0238|225 239|susceptibility
P01823524A0238|181 190|influence
P01824944A0988|119 122|IgE
P01824944A0988|39 52|transfectants
P01824944A0988|7 16|treatment
P01826003A0694|19 29|base pairs
P01826003A0694|57 64|members
P01826003A0694|88 100|beta TG gene
P01827068T0000|36 56|transcription factor
P01827068T0000|76 86|expression
P01828248A0189|50 62|UvrB protein
P01828248A0189|115 126|association
P01828248A0189|173 190|helicase activity
P01828248A0189|79 89|activities
P01829460A0329|51 65|phosphoprotein
P01829460A0329|79 94|kappa B element
P01830928A0361|111 119|proteins
P01830928A0361|79 90|superfamily
P01832152A0000|5 40|incompatibility group W plasmid pSa
P01832152A0000|92 94|J.
P01832197T0001|12 32|D2 dopamine receptor
P01833637A0531|18 29|transcripts
P01833637A0531|53 58|genes
P01833637A0531|162 172|transcript
P01833637A0531|183 193|HSP82 gene
P01833637A0531|75 82|cdc68-1
P01837787T0000|37 41|cDNA
P01839414T0000|65 70|Sabah
P01839414T0000|52 61|neoplasms
P01840607A0294|127 130|PFP
P01840607A0294|47 51|type
P01840711A0000|19 25|rabbit
P01840711A0000|5 15|RNA genome
P01842498A0000|118 135|phorbol myristate
P01842498A0000|113 116|PHA
P01842498A0000|231 248|blood lymphocytes
P01842498A0000|77 89|cDNA library
P01842498A0000|9 19|cDNA clone
P01844017A0410|50 54|drop
P01844017A0410|110 125|vitamin E level
P01844017A0410|58 102|glucose-6-phosphatase dehydrogenase activity
P01844017A0410|148 156|duration
P01844982A0324|1 7|Chagas
P01844982A0324|9 16|disease
P01844982A0324|109 117|controls
P01844982A0324|91 97|factor
P01845885A1003|116 122|family
P01845885A1003|76 83|protein
P01845885A1003|366 370|unit
P01845885A1003|28 32|unit
P01845885A1003|91 102|amino acids
P01845885A1003|45 49|UL26
P01846206A0665|82 88|assays
P01846206A0665|10 16|region
P01846491A0459|117 121|ORFs
P01846491A0459|190 193|DNA
P01846491A0459|23 32|positions
P01846491A0459|125 128|SFV
P01846491A0459|130 150|genus Leporipoxvirus
P01846491A0459|164 186|complex rearrangements
P01847464A0856|34 50|pFRTK-CAT target
P01847464A0856|127 132|ori-P
P01847464A0856|92 102|EBV origin
P01847464A0856|106 125|plasmid replication
P01847464A0856|15 30|cotransfections
P01848300A0910|59 78|peptide utilization
P01849509T0000|1 15|Identification
P01849509T0000|143 148|ISRm3
P01849509T0000|43 86|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|88 98|similarity
P01849734A1063|69 75|levels
P01849734A1063|83 96|neuroblastoma
P01849734A1063|177 187|cell lines
P01849734A1063|105 121|cell line LA-N-1
P01850105A1093|16 21|c-myc
P01850105A1093|5 12|effects
P01850105A1093|127 136|regulator
P01850105A1093|61 66|c-myc
P01850893A0286|20 30|antibodies
P01851527T0000|86 89|APP
P01851527T0000|111 117|blocks
P01851527T0000|44 84|Alzheimer beta-amyloid precursor protein
P01851862A0273|51 54|LTR
P01851862A0273|1 21|Nucleotide sequences
P01852438A0928|51 55|case
P01852438A0928|65 72|percent
P01853796T0000|1 7|Review
P01853796T0000|66 84|insulin resistance
P01853796T0000|9 22|deterioration
P01855255T0000|50 54|RCC1
P01855255T0000|25 32|mitosis
P01855255T0000|73 79|GTPase
P01857143A0351|5 12|patient
P01857143A0351|44 56|skin lesions
P01860846A0663|97 122|MARCKS gene transcription
P01860846A0663|150 173|leukemia cell line HL60
P01861188A0000|17 26|technique
P01861188A0000|1 13|Plate luting
P01861188A0000|175 184|stability
P01861188A0000|197 205|fixation
P01861188A0000|331 354|ASIF compression plates
P01861188A0000|61 65|PMMA
P01862455T0000|1 17|Thyroid lymphoma
P01863887A0174|119 128|substance
P01863887A0174|155 162|insulin
P01863887A0174|219 233|blood products
P01863887A0174|146 153|thyroid
P01863887A0174|41 47|review
P01863887A0174|180 194|erythropoietin
P01864821A0000|205 218|blood vessels
P01864821A0000|115 125|conditions
P01864821A0000|158 166|sickling
P01864821A0000|59 66|feature
P01864821A0000|13 18|forms
P01865010A0000|51 62|integration
P01865010A0000|117 124|tracers
P01865010A0000|202 217|representations
P01865010A0000|142 151|diamidino
P01865010A0000|126 137|Fluoro-Gold
P01865010A0000|13 24|connections
P01869565A1254|50 68|translation system
P01869565A1254|87 99|ADH promoter
P01869968A0000|54 68|administration
P01869968A0000|10 31|radioactivity content
P01870194A0302|101 112|homogeneity
P01870194A0302|7 34|immunodeficiency virus type
P01870500A0276|1 14|Contributions
P01870500A0276|190 195|tumor
P01870500A0276|82 90|S values
P01870500A0276|29 35|source
P01870500A0276|151 161|host organ
P01871135A0295|50 52|bp
P01871135A0295|5 9|cDNA
P01871135A0295|162 183|rat liver glucokinase
P01871135A0295|148 158|% identity
P01871135A0295|134 141|protein
P01872856A0277|138 144|testis
P01872856A0277|64 65|%
P01872856A0277|76 79|hrs
P01872856A0277|128 133|liver
P01872856A0277|54 60|faeces
P01872856A0277|159 167|recovery
P01872856A0277|91 92|%
P01874195A0139|115 145|signal transduction mechanisms
P01874195A0139|53 58|liver
P01874195A0139|29 40|GH receptor
P01875922A0770|71 77|region
P01875922A0770|112 118|effect
P01878489A0959|146 157|neutrophils
P01878489A0959|78 87|magnitude
P01878489A0959|166 175|monocytes
P01881595A0476|118 123|phase
P01881595A0476|174 175|n
P01881595A0476|189 195|phases
P01881595A0476|197 198|n
P01881595A0476|76 87|NS neurones
P01881595A0476|89 90|n
P01882240A0526|114 123|behaviors
P01882240A0526|78 85|quality
P01882240A0526|133 144|communities
P01883992A0922|113 127|beta-zein gene
P01883992A0922|7 14|results
P01883992A0922|78 87|regulator
P01884998A1135|71 80|promoters
P01884998A1135|52 65|transcription
P01885613A1298|1 12|Information
P01885613A1298|59 66|studies
P01885613A1298|108 121|collagen gene
P01885915A0000|51 72|Pasteurella multocida
P01885915A0000|32 43|bacteraemia
P01885915A0000|120 134|P. haemolytica
P01886368A0000|98 108|nerve head
P01886368A0000|43 70|recess type microelectrodes
P01886368A0000|122 126|pigs
P01888896A0505|116 131|initiation site
P01888896A0505|38 44|region
P01890362A0305|85 93|patients
P01890362A0305|11 19|patients
P01890362A0305|73 80|leprosy
P01892680A0907|1 9|Toxicity
P01892680A0907|97 98|p
P01893927A0704|153 159|output
P01893927A0704|64 70|levels
P01893927A0704|131 141|reductions
P01893927A0704|26 34|pressure
P01895358A0000|1 7|Limits
P01895358A0000|81 86|terms
P01895358A0000|198 213|energy turnover
P01895358A0000|11 26|energy turnover
P01895358A0000|30 38|relation
P01895384A0746|5 21|IE0 gene product
P01895384A0746|46 58|IE1 promoter
P01895555T0001|1 11|Evaluation
P01895555T0001|71 78|imaging
P01897515A0348|142 148|anemia
P01897515A0348|77 90|understanding
P01897515A0348|30 37|Hodgkin
P01898164A0839|118 122|arch
P01898164A0839|38 44|repair
P01898164A0839|78 83|group
P01899209A0883|118 131|contractility
P01899209A0883|48 59|perfusate H
P01899209A0883|156 158|r2
P01899409T0000a|1 13|Determinants
P01899409T0000a|76 88|thrombolysis
P01899409T0000a|41 69|revascularisation procedures
P01900194T0000|1 13|Relationship
P01900194T0000|91 102|hydrogenase
P01901443A0297|82 93|hepatitis C
P01901443A0297|132 143|hepatitis C
P01901443A0297|15 23|patients
P01901859A0000|1 8|UDP-Gal
P01901859A0000|80 99|glycosyltransferase
P01901859A0000|42 65|3-galactosyltransferase
P01901859A0000|177 186|exception
P01901859A0000|195 199|apes
P01901950T0000|1 22|Sequence requirements
P01901950T0000|89 105|mouse c-fos gene
P01903841A0125|115 121|eIF-5A
P01903841A0125|43 53|spermidine
P01903841A0125|62 70|hypusine
P01904154A0164|113 126|understanding
P01904154A0164|22 36|identification
P01904154A0164|61 72|transcripts
P01904546A0671|1 11|Disruption
P01904546A0671|111 127|a/alpha diploids
P01904546A0671|44 49|alpha
P01905517A1076|103 113|homologies
P01905517A1076|5 8|ORF
P01906166A0119|1 12|Mitomycin-C
P01906166A0119|43 53|ulceration
P01906166A0119|105 112|tissues
P01906692A0321|34 39|rt-PA
P01906692A0321|1 14|INTERVENTIONS
P01906692A0321|41 48|heparin
P01907941A0275|39 54|I kappa B alpha
P01907941A0275|75 82|binding
P01909621A0119|22 34|hemodialyses
P01909621A0119|79 85|ranges
P01910505A0000|50 56|effect
P01910505A0000|8 26|wuzi yanzong pills
P01913955A0177|102 108|artery
P01913955A0177|71 79|increase
P01913955A0177|143 158|precursor cells
P01913955A0177|40 46|artery
P01913955A0177|407 413|amount
P01913955A0177|187 192|cells
P01913955A0177|253 257|wall
P01913955A0177|321 332|hypertrophy
P01913955A0177|124 139|muscularization
P01913955A0177|449 457|collagen
P01916168A0969|17 41|correlation coefficients
P01916168A0969|140 150|delta ISO2
P01916168A0969|179 187|observer
P01916168A0969|209 217|learners
P01916632A0431|24 28|PBMC
P01916632A0431|61 65|case
P01917943A0621b|49 58|sequences
P01917943A0621b|201 209|plasmids
P01917943A0621b|219 261|chloramphenicol acetyltransferase reporter
P01917943A0621b|126 150|transfection experiments
P01917943A0621b|26 31|sMtCK
P01918010A0000|1 19|Lipoprotein lipase
P01918010A0000|21 24|LPL
P01918010A0000|130 140|expression
P01918070A0281|17 24|binding
P01918070A0281|37 54|T3 receptor alpha
P01918070A0281|56 65|T3R alpha
P01918070A0281|132 141|mutations
P01919831T0000|13 32|management casebook
P01922082A0149|19 38|mouse TSH beta gene
P01922082A0149|57 61|rise
P01922739A0336|274 281|average
P01922739A0336|402 411|pia mater
P01922739A0336|163 167|days
P01922739A0336|40 46|number
P01922739A0336|285 295|electrodes
P01922739A0336|50 62|fluctuations
P01922739A0336|246 250|ROSP
P01922739A0336|148 154|course
P01922739A0336|361 371|electrodes
P01923628T0001|36 50|flow cytometry
P01923628T0001|106 113|myxomas
P01923628T0001|74 82|findings
P01923803A0609|1 9|Position
P01923803A0609|83 92|AUA codon
P01924315A0158|65 72|control
P01924315A0158|8 13|yeast
P01924315A0158|91 106|SOD1 expression
P01925092A0000|55 60|blood
P01925092A0000|10 23|investigators
P01927421A0181|87 96|nystagmus
P01927421A0181|109 118|nystagmus
P01928923A0000|187 194|portion
P01928923A0000|1 14|Equine amnion
P01928923A0000|202 207|limbs
P01928923A0000|166 172|wounds
P01930660T0000|46 54|patients
P01930660T0000|14 27|growth factor
P01932650A0435|116 129|concentration
P01932650A0435|99 108|operation
P01932650A0435|60 74|drainage blood
P01933614A0406|71 83|osteoporosis
P01933614A0406|39 44|spray
P01933614A0406|15 32|salmon calcitonin
P01934378T0000|10 50|muscle metaboreceptor exercise responses
P01936348A0155|40 46|groups
P01936348A0155|60 68|AmF/SnF2
P01937790A0292|5 12|vaccine
P01938178T0000|35 43|analysis
P01938178T0000|60 64|P300
P01939199A0588|84 92|extracts
P01939199A0588|142 152|HeLa cells
P01939199A0588|46 59|transcription
P01939878A0765|69 75|casein
P01939878A0765|159 166|acidity
P01939906A0233|259 278|parameter landscape
P01939906A0233|309 322|cost function
P01939906A0233|6 20|generalization
P01939906A0233|77 90|cost function
P01939906A0233|146 152|source
P01939906A0233|167 176|solutions
P01943184A1050|96 97|%
P01943184A1050|73 79|trypan
P01943184A1050|31 41|University
P01943184A1050|45 63|Wisconsin solution
P01947449A0191|187 198|unit volume
P01947449A0191|54 59|terms
P01947449A0191|233 236|PO2
P01947449A0191|129 133|area
P01947449A0191|240 243|PO2
P01948783A0000|32 39|Estulic
P01948783A0000|22 28|effect
P01954355A0997|1 20|Monitoring patients
P01954355A0997|99 106|disease
P01954355A0997|128 134|causes
P01954355A0997|89 95|course
P01956285A0000|5 13|sequence
P01956285A0000|37 48|nucleotides
P01958368A0556|103 129|vitelliform classification
P01958368A0556|59 70|progression
P01958368A0556|14 21|lesions
P01960974A0000|1 8|Toluene
P01960974A0000|77 85|solvents
P01961747A0000|3 34|herpesvirus proteinase activity
P01961747A0000|143 162|transfection assays
P01963419A0501|129 130|p
P01963419A0501|73 78|water
P01963419A0501|186 187|n
P01963419A0501|114 117|13N
P01963419A0501|159 171|fluoride ion
P01963419A0501|179 182|18O
P01963419A0501|183 184|p
P01963858T0001|53 56|rat
P01963858T0001|25 45|adrenaline secretion
P01967130A0645|50 62|acid protein
P01967130A0645|15 29|pair EFIA cDNA
P01968224A0119|274 281|repeats
P01968224A0119|5 20|coding sequence
P01968224A0119|233 250|PCNA polypeptides
P01968224A0119|42 61|residue polypeptide
P01968224A0119|193 197|PCNA
P01968224A0119|155 174|amino acid sequence
P01968224A0119|121 123|bp
P01970801A0925|168 171|end
P01970801A0925|55 59|CD20
P01970801A0925|196 201|mouse
P01970801A0925|46 50|Ly-1
P01970801A0925|30 35|genes
P01970984A0668|71 72|T
P01970984A0668|77 78|E
P01970984A0668|60 68|groups E
P01972379T0042|35 45|CPS domain
P01972379T0042|18 27|evolution
P01974550A0362|17 20|CBF
P01974550A0362|38 59|hexamethonium bromide
P01974550A0362|162 170|% saline
P01974550A0362|63 71|mg/kg iv
P01975157A0836|54 61|results
P01975157A0836|31 33|pH
P01976638A1135|82 91|sequences
P01977856A1036|71 76|terms
P01977856A1036|80 89|diagnosis
P01977856A1036|125 132|infarct
P01977856A1036|104 110|extent
P01978857A0504|48 58|monitoring
P01978857A0504|11 14|use
P01982061T0000|1 17|Characterization
P01982061T0000|28 31|end
P01982997A1104|136 146|expression
P01982997A1104|32 63|transcription factor expression
P01982997A1104|201 206|c-Fos
P01982997A1104|211 222|Jun-B mRNAs
P01984665T0000|1 11|Processing
P01984665T0000|77 109|dengue-2 virus envelope proteins
P01984665T0000|28 44|immunoreactivity
P01984665T0000|151 164|baculoviruses
P01985920A0156|55 76|oligonucleotide probe
P01985920A0156|9 18|screening
P01985920A0156|181 202|SCP2 protein sequence
P01985924A0554|152 160|presence
P01985924A0554|5 13|addition
P01985924A0554|197 216|initiation activity
P01985924A0554|227 232|delta
P01985924A0554|164 168|urea
P01986241A0117|103 112|CUP1 gene
P01986241A0117|80 95|promoter region
P01986241A0117|24 41|ACE1 gene product
P01986360A0000|260 265|probe
P01986360A0000|7 13|clones
P01986360A0000|196 254|oligoadenylate synthetase gene interferon response element
P01986360A0000|183 188|mouse
P01989561A0100|5 16|application
P01989561A0100|146 150|apex
P01989561A0100|26 37|instruments
P01989561A0100|45 54|occlusion
P01990254A0791|27 32|cases
P01990254A0791|60 71|cell origin
P01991521A0481|66 74|activity
P01991521A0481|89 99|G4 content
P01992742A0000|17 24|records
P01992742A0000|52 60|neuritis
P01992953T0000|1 25|Alanine aminotransferase
P01993656A1860|85 92|guanine
P01993656A1860|9 18|ARF cDNAs
P01996312A0454|54 77|lambda gt11 cDNA clones
P01996312A0454|10 13|PCR
P01999035A0383|99 108|Speedwell
P01999035A0383|46 54|interval
P01999035A0383|120 130|IHD events
P01999999T0001|32 38|injury
P01999999T0001|11 19|luxation
P02001033A1907|138 143|drugs
P02001033A1907|4 11|summary
P02001033A1907|264 272|pressure
P02001033A1907|167 175|reflexes
P02001033A1907|62 72|isoflurane
P02001033A1907|31 45|concentrations
P02002051T0000|1 15|Isoform C beta
P02002051T0000|30 34|form
P02004521A0266|32 48|CT abnormalities
P02005547A0121|258 263|child
P02005547A0121|234 240|family
P02005547A0121|173 181|jaundice
P02005547A0121|58 66|pathways
P02005547A0121|135 153|hyperbilirubinemia
P02007045A0092|49 59|irrigation
P02007045A0092|5 12|authors
P02010912A0366|50 59|structure
P02010912A0366|37 42|study
P02010912A0366|79 83|role
P02010912A0366|91 109|MalT binding sites
P02012097T0000|37 48|parasitemia
P02014928T0000|50 60|inhalation
P02014928T0000|25 44|rhinoconjunctivitis
P02016053A0752|119 138|amino acid residues
P02016053A0752|196 216|DNA binding activity
P02016053A0752|90 96|region
P02017159A0646|13 15|A.
P02017414A0307|50 59|Line RBC2
P02017414A0307|1 4|Age
P02020082A0356|68 73|value
P02020082A0356|200 210|parameters
P02020082A0356|159 171|relationship
P02020082A0356|77 82|AaDO2
P02020082A0356|280 283|PCW
P02020082A0356|134 139|AaDO2
P02021630A1104|169 200|DNA phosphodiester conformation
P02021630A1104|53 65|interactions
P02021630A1104|212 227|protein binding
P02021630A1104|78 85|protein
P02021630A1104|105 121|guanine N7 sites
P02022188A1463|48 57|chromatin
P02022188A1463|22 35|gene products
P02022188A1463|120 132|prerequisite
P02023097A0000|159 176|virus replication
P02023097A0000|125 140|gene expression
P02023097A0000|11 38|immunodeficiency virus type
P02023904A0120|115 123|proteins
P02023904A0120|5 14|CDC7 gene
P02024488A0506|1 5|HeLa
P02024488A0506|127 146|neomycin resistance
P02024488A0506|10 27|Jurkat cell lines
P02024791A0582|1 13|MEASUREMENTS
P02024791A0582|18 30|MAIN RESULTS
P02024791A0582|158 159|P
P02024791A0582|40 46|groups
P02024791A0582|63 68|entry
P02025515A0979|22 26|t1/2
P02026147A0000|152 156|type
P02026147A0000|32 35|CaM
P02026147A0000|160 171|CaM kinases
P02026147A0000|47 61|protein kinase
P02026147A0000|15 18|Ca2
P02026491A0399|5 13|patients
P02026491A0399|123 127|pain
P02028125A0101|33 42|infection
P02028125A0101|5 15|prevalence
P02028125A0101|131 145|cancer therapy
P02028125A0101|181 189|examples
P02030910A0000|100 112|organization
P02030910A0000|9 15|clones
P02033038A0309|86 92|pellet
P02033038A0309|128 130|E3
P02034655A1224|48 56|promoter
P02034655A1224|13 17|gene
P02034655A1224|30 36|region
P02034669A0293|17 27|transcript
P02034669A0293|50 57|tissues
P02035805T0000|1 29|Angina haemorrhagica bullosa
P02038293A0919|1 11|Conclusion
P02038293A0919|47 55|type TOF
P02038293A0919|105 111|bundle
P02038784A0317|21 24|ARC
P02044785A0000|50 65|retroperitoneal
P02044785A0000|10 14|case
P02044785A0000|120 124|cyst
P02044975A0380|155 166|application
P02044975A0380|201 202|%
P02044975A0380|173 179|volume
P02044975A0380|27 31|flow
P02044975A0380|11 17|volume
P02045524A0000|153 160|ratings
P02045524A0000|184 189|drugs
P02045524A0000|235 248|drug sponsors
P02045524A0000|218 229|conferences
P02045524A0000|82 101|Drug Administration
P02045524A0000|61 67|agents
P02046202A0625|20 21|%
P02052592A0000|34 38|cell
P02052592A0000|276 287|interleukin
P02052592A0000|76 83|changes
P02052592A0000|436 442|factor
P02052592A0000|153 165|osteoporosis
P02052592A0000|87 100|bone turnover
P02052592A0000|223 243|estrogen replacement
P02052592A0000|352 370|phytohemagglutinin
P02052592A0000|486 491|cells
P02052592A0000|123 134|development
P02054754A0919|119 128|disorders
P02054754A0919|37 47|management
P02054754A0919|14 24|principles
P02056553T0000|52 63|swine model
P02061282A0447|117 128|orientation
P02061282A0447|5 13|sequence
P02061282A0447|162 168|middle
P02061282A0447|94 100|repeat
P02061282A0447|61 67|region
P02061333A1359|154 163|reference
P02061333A1359|200 210|production
P02061333A1359|39 49|occurrence
P02061333A1359|7 19|observations
P02062933A0738|16 22|choice
P02062933A0738|83 86|AOF
P02062933A0738|147 154|partner
P02065022A0747|117 125|deletion
P02065022A0747|156 162|effect
P02065022A0747|142 148|region
P02065022A0747|12 21|deletions
P02068085A1273|52 59|element
P02068085A1273|108 127|activation sequence
P02069873X0000|51 54|vav
P02069873X0000|117 122|cells
P02069873X0000|140 146|origin
P02069873X0000|167 190|differentiation lineage
P02072238T0000|1 18|Menetrier disease
P02073222A0269|84 97|week protocol
P02073222A0269|24 39|amitriptyline n
P02073222A0269|14 22|patients
P02075876T0001|1 9|Analysis
P02075876T0001|97 100|cat
P02075876T0001|43 46|EER
P02076620T0000|32 40|patients
P02076620T0000|93 100|actions
P02077560T0000|42 59|safety assessment
P02078570A0287|8 13|cases
P02078570A0287|60 69|integrins
P02080902A0183|99 107|controls
P02080902A0183|20 24|rats
P02083199A1175|80 87|EGFR-IC
P02083199A1175|121 125|EGFR
P02083253A1512|5 29|TCF-1 alpha binding site
P02083253A1512|108 116|extracts
P02083253A1512|122 128|Jurkat
P02088781A0653|98 107|influence
P02088781A0653|157 169|compensation
P02088781A0653|142 149|absence
P02088781A0653|25 28|fog
P02088781A0653|57 60|fog
P02091890A0614|118 129|interaction
P02091890A0614|197 204|measure
P02091890A0614|94 104|aggression
P02091890A0614|183 193|inactivity
P02091890A0614|134 145|exploration
P02093033T0001|33 40|effects
P02093033T0001|59 78|hexachlorobutadiene
P02093033T0001|109 121|thymus gland
P02093888A0293|50 54|DBMS
P02093888A0293|99 108|computers
P02094257T0000|65 74|effusions
P02099622A1046|1 21|Immuno-cytochemistry
P02099622A1046|163 172|organisms
P02099622A1046|124 129|cells
P02099622A1046|46 66|Campylobacter jejuni
P02102831A1282|70 78|features
P02102831A1282|8 15|regions
P02102831A1282|94 101|repeats
P02102831A1282|90 92|CT
P02103403A0149|18 25|history
P02103403A0149|65 71|intake
P02103403A0149|97 105|steroids
P02106287A0478|36 42|coupon
P02107548A0727|70 73|RNA
P02107548A0727|114 121|homolog
P02107548A0727|9 26|transcription-PCR
P02107548A0727|78 82|cDNA
P02107548A0727|44 49|clone
P02110145T0000|1 11|Sequencing
P02110145T0000|99 106|TAL2480
P02110145T0000|59 65|enzyme
P02110145T0000|122 132|similarity
P02111015A0574|69 75|domain
P02111015A0574|20 31|amino acids
P02111015A0574|167 172|IRF-2
P02113174A0064|70 94|transcription factor Sp1
P02113174A0064|14 21|protein
P02113455A0207|65 78|consideration
P02113455A0207|40 50|parameters
P02113901A0000|155 165|difference
P02113901A0000|22 29|changes
P02113901A0000|44 55|normocapnia
P02115115A1053|153 164|yeast genes
P02115115A1053|39 49|suggestion
P02115115A1053|123 130|regions
P02115118A0565|6 8|Mr
P02115118A0565|133 177|sucrose density gradient ultracentrifugation
P02115122A0562|32 42|repression
P02115122A0562|144 149|c-Fos
P02115122A0562|108 113|v-Fos
P02115122A0562|10 18|residues
P02115889A0436|65 73|Gx alpha
P02115889A0436|9 14|paper
P02116537A1237|71 74|AMK
P02116537A1237|8 17|influence
P02117799T0000b|1 5|Uses
P02117799T0000b|9 24|orthoclone OKT3
P02117799T0000b|79 90|nonfunction
P02117799T0000b|44 53|rejection
P02118525A0737|116 129|transcription
P02118525A0737|4 12|addition
P02118525A0737|229 235|manner
P02118525A0737|30 38|fragment
P02119530T0000|1 10|Influence
P02119530T0000|14 34|metoprolol treatment
P02119946T0000|33 45|care setting
P02120833A0000|69 77|TAH-NANB
P02120833A0000|4 11|Denmark
P02120833A0000|53 67|hepatitis NANB
P02122454A1042|85 91|lambda
P02122454A1042|39 42|Ser
P02122454A1042|146 155|transport
P02122454A1042|12 23|replacement
P02123293A0227|1 6|Petko
P02123300T0000|87 100|hemophilia A.
P02123300T0000|113 136|Factor VIII Study Group
P02123300T0000|74 83|treatment
P02123467A0811|218 223|MyoD1
P02123467A0811|78 83|cells
P02123467A0811|94 99|MyoD1
P02123467A0811|104 107|Sp1
P02123875A0223|342 353|+1 position
P02123875A0223|99 109|efficiency
P02123875A0223|234 247|COOH terminus
P02123875A0223|282 295|substitutions
P02123875A0223|86 94|fidelity
P02123875A0223|113 138|signal peptidase cleavage
P02123875A0223|58 66|c-region
P02123875A0223|360 365|model
P02123875A0223|303 315|NH2 terminus
P02124433A0235|168 171|MMC
P02124433A0235|232 239|surgery
P02124433A0235|142 147|cases
P02124433A0235|42 53|description
P02124433A0235|119 123|5-FU
P02124433A0235|191 194|PSK
P02124433A0235|158 165|surgery
P02124433A0235|57 64|patient
P02124433A0235|124 136|chemotherapy
P02124433A0235|181 187|OK-432
P02124710A1624|51 66|Fos-Jun complex
P02124710A1624|36 43|binding
P02124710A1624|73 82|AP-1 site
P02125153A0410|119 130|Z5 patients
P02125153A0410|19 26|relapse
P02125153A0410|83 85|R3
P02125153A0410|37 46|treatment
P02125153A0410|176 185|isoniazid
P02125153A0410|61 66|years
P02126504A0602|92 101|Rh-system
P02126504A0602|13 26|Rh-antibodies
P02131652A0883|170 180|ng.l-1 min
P02131652A0883|202 208|VTP-HM
P02131652A0883|110 125|gastrin release
P02131902A0000|153 162|ventricle
P02131902A0000|6 11|study
P02131902A0000|41 49|location
P02131902A0000|90 93|TEE
P02133731A1572|39 40|%
P02133731A1572|6 8|S3
P02133731A1572|59 62|1/T
P02133731A1572|10 13|CBF
P02133731A1572|26 28|S5
P02135536A0621|139 141|Hk
P02135536A0621|81 89|strength
P02135536A0621|9 13|case
P02135536A0621|124 132|hardness
P02135536A0621|192 213|expansion coefficient
P02135536A0621|165 179|micrograms/mm3
P02137704A0000|414 433|target organ damage
P02137704A0000|336 350|blood pressure
P02137704A0000|286 300|blood pressure
P02137704A0000|625 644|wall thickness/left
P02137704A0000|20 25|group
P02137704A0000|265 277|office visit
P02137704A0000|447 455|diameter
P02137704A0000|382 389|indices
P02137704A0000|591 595|mass
P02137704A0000|49 57|patients
P02137704A0000|667 681|diameter ratio
P02137704A0000|183 197|blood pressure
P02137704A0000|120 147|blood pressure measurements
P02138915A1060|35 41|length
P02138915A1060|5 13|p36 gene
P02138915A1060|127 135|ABSTRACT
P02138915A1060|29 31|kb
P02139473A1603|70 74|entC
P02139473A1603|188 211|Shine-Dalgarno sequence
P02139473A1603|62 66|site
P02141425A0175|19 37|fingertip-to-floor
P02141425A0175|39 43|MFTF
P02141425A0175|133 141|patients
P02141425A0175|104 116|measurements
P02141425A0175|45 51|method
P02142486A0367|87 98|bacteraemia
P02142486A0367|108 117|one-third
P02142955A0248|171 177|delays
P02142955A0248|4 15|Experiments
P02142955A0248|189 193|days
P02142955A0248|108 118|appearance
P02142955A0248|75 82|objects
P02143023A0729|23 39|octamer elements
P02143023A0729|47 64|adenovirus genome
P02143186A1306|1 23|Northern blot analysis
P02143186A1306|156 168|shoot tissue
P02143186A1306|127 138|root tissue
P02143961A0400|35 49|pain threshold
P02143961A0400|83 87|pCPA
P02143961A0400|108 117|analgesia
P02144558A1022|29 37|families
P02145195A0253|102 114|binding site
P02145195A0253|57 64|species
P02145268A1454|7 13|losses
P02145268A1454|63 79|cyanogen bromide
P02145268A1454|30 40|resistance
P02146495A0706|101 122|leucine zipper domain
P02146495A0706|11 19|peptides
P02147422A0000|36 40|gene
P02148291A0173|66 72|clones
P02148291A0173|57 62|types
P02148291A0173|88 107|HSE binding domains
P02148508A1478|39 48|principle
P02148508A1478|113 121|patterns
P02148508A1478|52 55|TCM
P02149487A0348|79 110|dehydroepiandrosterone-sulphate
P02149487A0348|132 133|%
P02149487A0348|165 187|androstenedione levels
P02149570T0000|36 56|protein S deficiency
P02151229A0000|239 261|fasting plasma glucose
P02151229A0000|101 109|emission
P02151229A0000|200 205|NIDDM
P02151229A0000|224 229|years
P02151229A0000|19 29|blood flow
P02151229A0000|320 326|mmol/L
P02151229A0000|266 272|mmol/L
P02151229A0000|215 218|age
P02153243A0965|7 11|data
P02153243A0965|144 150|factor
P02153243A0965|42 49|product
P02153977A0364|119 121|hr
P02153977A0364|140 151|culmination
P02153977A0364|67 78|development
P02153977A0364|108 112|peak
P02154474A1504|129 140|P-450 genes
P02154474A1504|26 35|sequences
P02154599T0000|156 171|target promoter
P02154599T0000|5 23|zta transactivator
P02154599T0000|36 45|induction
P02154599T0000|108 119|lymphocytes
P02154686A0185|1 10|Fragments
P02154686A0185|154 163|fragments
P02154686A0185|39 52|repeat region
P02154686A0185|77 82|virus
P02155017A1106|85 105|hypertriglyceridemia
P02155017A1106|70 81|alleviation
P02155017A1106|247 255|dialyses
P02155017A1106|166 184|observation period
P02155017A1106|14 22|benefits
P02157067A0610|1 8|Summers
P02157764A1115|51 58|peptide
P02157764A1115|123 136|cDNA sequence
P02158099A0487|118 124|effect
P02158099A0487|42 59|Chang liver cells
P02158099A0487|150 174|pSV2CAT reporter plasmid
P02158099A0487|14 35|cotransfection assays
P02159470A1432|154 167|transcription
P02159470A1432|113 117|role
P02159470A1432|179 184|genes
P02159470A1432|10 17|binding
P02159470A1432|194 202|subunits
P02160502A0471|4 34|recombination signal sequences
P02160955A0899|1 11|Constructs
P02160955A0899|121 123|bp
P02162103A0000|68 82|phosphoprotein
P02162103A0000|206 207|A
P02162103A0000|96 114|parainfluenza type
P02162103A0000|51 54|RNA
P02162103A0000|117 122|virus
P02162103A0000|156 159|RNA
P02162103A0000|246 260|reading frames
P02162103A0000|124 129|PIV-2
P02162103A0000|29 34|cDNAs
P02162754A0339|38 57|amino acid sequence
P02162754A0339|106 111|mouse
P02162835A0989|96 114|heme binding sites
P02162835A0989|124 143|copper binding site
P02163382A0169|239 259|target DNA sequences
P02163382A0169|100 122|transposon mutagenesis
P02163382A0169|52 67|cosmids pJHCV31
P02163382A0169|167 177|lac operon
P02163382A0169|226 233|fusions
P02164585A0416|5 17|TraD protein
P02164585A0416|26 28|Da
P02164588A0266|16 24|HN genes
P02164588A0266|65 73|residues
P02164588A0266|144 152|assembly
P02164588A0266|135 139|tail
P02164604A1574|125 140|acceptor mutant
P02164604A1574|61 71|cell lines
P02164604A1574|164 169|modes
P02165181A0299|16 24|patients
P02165181A0299|63 68|stage
P02165589A0888|102 106|turn
P02165589A0888|3 10|portion
P02165589A0888|39 43|part
P02165589A0888|176 179|jun
P02165589A0888|14 23|Region II
P02166416A0419|78 82|ARDS
P02166416A0419|26 38|tuberculosis
P02167321T0000|221 234|phorbol ester
P02167321T0000|207 217|activation
P02167321T0000|185 195|expression
P02167321T0000|72 91|activator protein-2
P02167784A0109|70 71|%
P02167784A0109|48 51|min
P02167784A0109|82 85|min
P02167784A0109|109 112|min
P02169887A0360|69 81|capstructure
P02169887A0360|5 16|transcripts
P02169887A0360|150 160|initiation
P02172672T0001|25 33|syndrome
P02173405A0270|16 27|abnormality
P02173405A0270|89 103|calcifications
P02174427A1574|6 13|strains
P02174427A1574|125 171|ubiquinol-cytochrome c oxidoreductase activity
P02174974A0000|1 14|Transcription
P02174974A0000|65 72|enzymes
P02174974A0000|28 34|operon
P02175908A0805|139 146|element
P02175908A0805|174 182|mutation
P02175908A0805|91 96|locus
P02176152A0896|137 152|HSV tk promoter
P02176152A0896|66 79|reporter gene
P02176152A0896|93 96|TPA
P02176232T0001|84 88|IIIA
P02176232T0001|1 13|Risk factors
P02176232T0001|26 48|lymph nodes metastasis
P02179052A1044|98 119|sequence interactions
P02179052A1044|135 144|evolution
P02179815A0582|48 51|CEF
P02179815A0582|201 209|sequence
P02179815A0582|37 44|protein
P02179815A0582|93 101|p68c-rel
P02179815A0582|267 275|sequence
P02179815A0582|125 128|CEF
P02181760A0311|137 157|cotyledon resistance
P02181760A0311|1 11|Blood flow
P02181760A0311|41 59|Doppler ultrasound
P02181760A0311|181 185|fold
P02182323A0121|48 51|Val
P02182323A0121|175 181|region
P02182323A0121|58 62|gene
P02182323A0121|125 134|degrees C
P02183467A0668|237 238|W
P02183467A0668|40 46|region
P02183467A0668|166 169|rev
P02183467A0668|152 155|vif
P02183467A0668|20 24|ORFs
P02183467A0668|145 150|genes
P02183467A0668|243 244|Y
P02185250A0726|35 46|amino acids
P02185250A0726|112 125|translocation
P02187871T0000|5 15|ANB1 locus
P02188168A0000|1 11|Serum beta
P02188168A0000|304 309|years
P02188168A0000|36 44|beta-2-M
P02188168A0000|104 112|carriers
P02188168A0000|223 228|serum
P02188168A0000|208 214|P.G.L.
P02188168A0000|121 137|HIV-1 antibodies
P02190134A0572|4 11|therapy
P02190134A0572|54 61|disease
P02190134A0572|93 125|laser photocoagulation treatment
P02190134A0572|180 187|attempt
P02194273A0913|35 44|pathogens
P02194273A0913|65 75|influenzae
P02195025T0000|1 11|Regulation
P02195715T0000|24 44|protein C deficiency
P02196311A1034|103 106|RNL
P02196311A1034|7 14|results
P02196311A1034|30 38|KE X 3/W
P02196565A0606|113 119|factor
P02196565A0606|202 206|PYK1
P02196565A0606|92 103|translation
P02196565A0606|160 180|MAT alpha expression
P02196565A0606|26 34|factor I
P02196565A0606|121 124|TUF
P02198259A0685|1 9|Deletion
P02198259A0685|143 152|initiator
P02198259A0685|43 47|ends
P02198259A0685|26 27|N
P02199311A0620|86 119|transcription termination signals
P02199311A0620|38 50|ret1-1 cells
P02199311A0620|167 181|tRNA templates
P02200315A0278|1 4|IgG
P02200315A0278|76 81|serum
P02200315A0278|104 115|A60 antigen
P02201770A0188|51 66|Anomiopsyllinae
P02201770A0188|128 134|adults
P02201770A0188|30 49|genus Anomiopsyllus
P02201905A1004|38 50|ABFI protein
P02201905A1004|133 143|regulation
P02201905A1004|14 21|results
P02204621T0000|1 10|Isolation
P02204621T0000|157 162|yeast
P02204621T0000|108 112|gene
P02204621T0000|61 88|tRNA nucleotidyltransferase
P02204625A1130|6 10|gene
P02204625A1130|77 85|response
P02204625A1130|107 115|mitogens
P02206789A0002|49 72|anaesthetic preparation
P02206789A0002|5 13|efficacy
P02206789A0002|82 93|amethocaine
P02208762A0228|117 120|ear
P02208762A0228|141 147|meatus
P02208762A0228|25 38|granddaughter
P02208762A0228|89 97|daughter
P02209243A0237|22 35|serum albumin
P02209243A0237|74 85|improvement
P02209605A0510|154 158|mass
P02209605A0510|101 108|protein
P02209605A0510|26 35|MSAS gene
P02209605A0510|74 87|reading frame
P02212540A0473|69 75|ulcers
P02212540A0473|22 36|wall specimens
P02213566A0000|119 123|rats
P02213566A0000|169 179|infarction
P02213566A0000|5 12|effects
P02213566A0000|73 85|hemodynamics
P02213566A0000|30 33|CoQ
P02217741T0001|5 18|interrelation
P02217741T0001|56 63|insulin
P02217741T0001|91 98|animals
P02219751A0517|64 68|FEMs
P02219751A0517|11 19|saccades
P02220304A0501|84 90|thesis
P02220304A0501|5 10|study
P02220304A0501|160 175|MS distribution
P02220304A0501|26 30|area
P02223773A0000|1 40|Chick brain actin depolymerizing factor
P02223773A0000|42 45|ADF
P02223773A0000|105 119|actin monomers
P02225687A0546|1 19|Comprehensive care
P02225687A0546|81 91|discussion
P02225687A0546|27 34|patient
P02228615A0974|184 192|reaction
P02228615A0974|5 9|85Sr
P02228615A0974|106 116|indication
P02229072A1012|68 78|conditions
P02229072A1012|52 58|medium
P02229072A1012|134 144|metabolism
P02229541T0000|18 27|carcinoma
P02229541T0000|40 46|review
P02231479A0585|119 131|conversation
P02231479A0585|6 12|parent
P02231479A0585|59 67|daughter
P02233680A1115|84 91|control
P02233680A1115|157 163|region
P02233680A1115|172 176|gene
P02233680A1115|145 147|kb
P02233729A1065|6 15|mutations
P02233729A1065|25 29|Dhfr
P02233729A1065|79 89|startpoint
P02234731A0503|103 111|findings
P02234731A0503|115 126|condylomata
P02234731A0503|36 42|smears
P02236022A0000|175 180|genes
P02236022A0000|43 63|transcription factor
P02236022A0000|78 81|DNA
P02236064A1178|1 21|S6 kinase activation
P02236064A1178|63 70|segment
P02237431A0000|137 146|kilobases
P02237431A0000|76 77|T
P02237431A0000|25 40|T cell receptor
P02237431A0000|108 116|enhancer
P02237431A0000|47 57|alpha gene
P02241742A0766|59 61|HD
P02241742A0766|10 14|flow
P02242222T0000|14 21|address
P02243386A0113|34 40|serial
P02243386A0113|76 82|DI RNA
P02243386A0113|63 66|MHV
P02246447A0460|112 123|food groups
P02246447A0460|161 174|portion sizes
P02246447A0460|134 143|r2 values
P02247069A0261|64 75|mating type
P02247069A0261|77 81|V.L.
P02247081A0223|34 45|VPS34 locus
P02247081A0223|117 127|VPS34 gene
P02247081A0223|82 95|growth defect
P02248732A1113|171 179|turnover
P02248732A1113|202 215|DOPAC changes
P02248732A1113|97 108|firing rate
P02248732A1113|126 127|%
P02248732A1113|44 55|haloperidol
P02250919A0404|16 37|illness intrusiveness
P02250919A0404|178 191|muscle cramps
P02250919A0404|91 108|headache symptoms
P02252891T0000|100 105|sites
P02252891T0000|130 135|sites
P02252891T0000|15 22|protein
P02253274A0000|5 17|Mauriceville
P02253274A0000|43 51|plasmids
P02253274A0000|107 109|kb
P02253274A0000|135 150|characteristics
P02254282T0000|1 9|Sequence
P02254282T0000|92 99|enzymes
P02254749A0133|32 35|60K
P02254749A0133|37 40|87K
P02254749A0133|163 171|sequence
P02254749A0133|108 123|ATG start codon
P02254749A0133|132 136|cDNA
P02254749A0133|152 155|60K
P02254749A0133|179 182|TAA
P02257251T0000|20 29|bone loss
P02258918A0242|58 67|disectors
P02258918A0242|13 17|lung
P02259795A0570|69 81|calculations
P02259795A0570|190 194|skin
P02259795A0570|163 169|uptake
P02259795A0570|123 128|mm Hg
P02262439A0508|1 13|MCh infusion
P02262439A0508|89 92|QBA
P02265055A0417|68 83|micrograms ml-1
P02265055A0417|98 113|micrograms ml-1
P02265055A0417|129 146|CSF concentration
P02265055A0417|26 36|atracurium
P02268461A0224|35 43|patients
P02268461A0224|5 13|survival
P02269426A0428|119 127|activity
P02269426A0428|1 4|IST
P02269426A0428|163 174|RNA targets
P02269426A0428|179 199|Tat trans-activation
P02269426A0428|107 114|factors
P02269426A0428|210 221|requirement
P02270587A0000|16 30|treatment need
P02272095A0832|68 83|pain modulation
P02272095A0832|53 64|enkephalins
P02272095A0832|110 126|cluster headache
P02274343A0064|70 78|clawtoes
P02274343A0064|55 65|hammertoes
P02274343A0064|158 170|neuropathies
P02274343A0064|8 24|foot pathologies
P02274343A0064|40 53|metatarsalgia
P02274343A0064|29 38|heel pain
P02276891T0000|1 13|Coenzyme Q10
P02276891T0000|15 27|blood levels
P02277319A0211|22 35|preservatives
P02277319A0211|122 138|bioburden levels
P02278217A0372|80 90|medication
P02278217A0372|29 47|management failure
P02278217A0372|105 117|section lead
P02280777T0000|70 77|element
P02281330A0556|17 37|oxygen concentration
P02281330A0556|111 117|manner
P02281330A0556|149 155|trauma
P02282815T0000|1 13|Significance
P02282815T0000|65 73|children
P02283378A0385|12 21|procedure
P02283873A0308|100 111|involvement
P02283873A0308|20 31|adolescents
P02283873A0308|11 16|group
P02284573A0943|116 119|BAL
P02284573A0943|129 146|brushing material
P02284573A0943|121 124|TBB
P02289102A0114|33 43|headphones
P02289102A0114|10 28|audiotape cassette
P02290216T0001|35 46|cholangitis
P02290216T0001|19 30|obstruction
P02291628A0264|87 90|NMR
P02291628A0264|110 118|examples
P02291628A0264|25 30|paper
P02291628A0264|183 196|endocrinology
P02293019A0000|85 92|tissues
P02293019A0000|175 186|cathepsin-G
P02293019A0000|22 25|ALP
P02293019A0000|107 117|activities
P02293019A0000|61 68|protein
P02294048A0881|25 59|% amino acid sequence similarities
P02296509A0997|54 66|seronegative
P02296509A0997|22 39|household members
P02300577A0852|119 129|beta chain
P02300577A0852|49 68|glycosylation sites
P02300577A0852|149 156|complex
P02303158T0000|81 93|trk oncogene
P02303158T0000|37 41|gene
P02303874A1643|69 73|dose
P02303874A1643|18 34|titration period
P02303874A1643|144 161|micrograms/24 hrs
P02303874A1643|90 95|doses
P02306539T0000|38 48|Microfeast
P02306539T0000|8 33|Selenastrum capricornutum
P02307371A0263|207 214|Burkitt
P02307371A0263|133 141|lymphoma
P02307371A0263|15 24|mechanism
P02307371A0263|184 192|transfer
P02307371A0263|155 177|transcription patterns
P02307371A0263|217 239|lymphoma c-myc alleles
P02307371A0263|123 130|Burkitt
P02307848A0347|63 66|DNA
P02307848A0347|12 21|sequences
P02307848A0347|134 149|Eco-R1 fragment
P02307850A0000|9 35|RNK-16 lambda-gt11 library
P02307850A0000|122 137|characteristics
P02308496A0000|70 74|ACTH
P02308496A0000|33 37|data
P02308496A0000|200 208|% oxygen
P02308496A0000|96 98|T3
P02308496A0000|41 47|change
P02308496A0000|185 192|mixture
P02308496A0000|55 66|blood level
P02308496A0000|149 160|respiration
P02310300A0298|6 20|% lymphography
P02310496X0000|69 73|band
P02310496X0000|306 310|band
P02310496X0000|77 82|Broca
P02310496X0000|187 193|degree
P02310496X0000|222 231|cell loss
P02310496X0000|112 116|rats
P02310496X0000|266 268|NB
P02310496X0000|367 383|reference memory
P02310496X0000|122 136|memory defects
P02312470A0774|237 248|circulation
P02312470A0774|5 18|BAL-to-plasma
P02312470A0774|135 137|Na
P02312470A0774|257 261|time
P02312470A0774|267 273|lavage
P02312470A0774|180 184|time
P02312470A0774|90 94|urea
P02315151T0020|39 46|illness
P02315151T0020|28 34|health
P02317413A0364|187 195|patients
P02317413A0364|32 42|infarction
P02317413A0364|54 75|plasma concentrations
P02317413A0364|173 183|volunteers
P02317413A0364|120 125|diene
P02318208A0817|16 23|element
P02318208A0817|39 50|CACGTGACCCG
P02318208A0817|165 182|promoter sequence
P02320008A0651|136 147|amino acids
P02320008A0651|33 57|muscle alpha-tropomyosin
P02320008A0651|63 74|amino acids
P02322535A0658|17 19|kb
P02322535A0658|42 47|sizes
P02324102A1157|1 11|Comparison
P02324102A1157|163 176|Vanden Berghe
P02324102A1157|193 195|C.
P02324102A1157|15 28|transmembrane
P02324102A1157|134 136|P.
P02324102A1157|159 161|J.
P02324102A1157|145 147|J.
P02324102A1157|149 157|Cassiman
P02324104A0516|16 26|C subunits
P02324104A0516|79 85|stages
P02324104A1195|17 21|exon
P02324104A1195|185 196|CeCAT alpha
P02324104A1195|218 229|nucleotides
P02324104A1195|43 60|carboxyl terminus
P02325895T0000b|141 161|squirrel monkey hand
P02325895T0000b|96 108|displacement
P02325895T0000b|24 49|mechanoreceptor discharge
P02325895T0000b|75 80|force
P02326946T0000|1 44|Plasma lecithin/cholesterol acyltransferase
P02326946T0000|79 85|donors
P02326946T0000|46 50|LCAT
P02328328A0419|16 22|status
P02328328A0419|157 160|yrs
P02328328A0419|188 191|yrs
P02328328A0419|193 201|patients
P02330041A0335|1 11|Expression
P02330041A0335|117 123|factor
P02330041A0335|22 34|localization
P02330041A0335|196 214|rRNA gene promoter
P02330041A0335|227 240|transcription
P02330041A0335|164 179|control element
P02330333A0325|1 14|Accumulations
P02330333A0325|18 22|Tl+1
P02330333A0325|111 117|plasma
P02330333A0325|44 49|times
P02332018A0538|187 188|P
P02332018A0538|49 52|EIA
P02332018A0538|128 146|mean GH increments
P02332018A0538|88 96|patients
P02332018A0538|180 185|ng/ml
P02333239T0000|12 15|age
P02333749A0411|70 80|occurrence
P02333749A0411|55 64|RAST data
P02333749A0411|108 121|P. orbiculare
P02333749A0411|150 155|value
P02335034A0584|86 93|minutes
P02335034A0584|40 51|heat stress
P02335713A0905|8 19|correlation
P02335713A0905|75 91|stearate workers
P02336338A0931|101 108|account
P02336338A0931|5 12|effects
P02339447A0162|101 109|9,11-2H2
P02339447A0162|310 319|pregnancy
P02339447A0162|163 181|serum level 19-OHA
P02339447A0162|290 298|subjects
P02339447A0162|48 65|deuterium content
P02339447A0162|190 192|E1
P02339447A0162|94 95|A
P02341669A0000|103 108|types
P02341669A0000|139 163|maximum length sequences
P02341669A0000|174 192|Legendre sequences
P02341669A0000|37 47|brain-stem
P02341669A0000|194 197|LGS
P02343033A0000|102 111|placentae
P02343033A0000|19 32|dates infants
P02343033A0000|9 14|light
P02347102A0000|117 121|rash
P02347102A0000|5 28|pseudolymphoma syndrome
P02347655A0193|65 72|tissues
P02347655A0193|172 183|composition
P02347655A0193|74 87|gas exchanges
P02347655A0193|45 49|lung
P02347655A0193|19 23|lung
P02347655A0193|191 202|gas mixture
P02347655A0193|212 223|ventilation
P02348408A0126|59 69|dimensions
P02349827A0193|33 42|Videoplan
P02349998A0297|34 44|electrodes
P02349998A0297|87 97|electrodes
P02351297A0000|238 242|cent
P02351297A0000|172 176|cent
P02351297A0000|77 114|atmosphere metal corrosion inhibitors
P02353875A0800|102 109|type Ib
P02353875A0800|84 98|hypersecretion
P02353875A0800|5 12|results
P02353875A0800|57 68|neutrophils
P02353875A0800|120 125|cases
P02355293A0749|157 173|bath environment
P02355293A0749|212 220|strength
P02355293A0749|130 136|grafts
P02355293A0749|62 85|failure characteristics
P02355920A0681|34 58|transcription factor SP1
P02355920A0681|77 83|intron
P02357537A0451|85 90|mg/kg
P02357537A0451|53 56|pHa
P02357537A0451|73 81|naloxone
P02357537A0451|44 49|paCO2
P02360336A0574|10 25|personnel costs
P02360336A0574|151 156|vials
P02361575T0000|21 36|carcinogenicity
P02361575T0000|92 103|B6C3F1 mice
P02361575T0000|75 87|Fischer rats
P02362161T0000|56 75|anhydrase inhibitor
P02371273A0144|81 84|kbp
P02371273A0144|65 79|kilobase pairs
P02372496A0782|187 205|5FU administration
P02372496A0782|222 228|artery
P02372496A0782|178 183|ratio
P02372496A0782|27 38|angiotensin
P02372496A0782|46 58|microspheres
P02373686T0000|171 188|receptor isoforms
P02373686T0000|146 155|mechanism
P02373686T0000|11 21|expression
P02374886A0305|220 229|admission
P02374886A0305|103 110|ability
P02374886A0305|168 182|symptomatology
P02374886A0305|5 31|Community Adjustment Scale
P02374886A0305|79 85|degree
P02374886A0305|148 164|presence/absence
P02378615A0807|141 151|attachment
P02378615A0807|56 75|glycosylation sites
P02378615A0807|104 110|region
P02383693A0301|84 93|lucigenin
P02383693A0301|64 72|solution
P02383693A0301|140 145|pumps
P02383693A0301|165 191|chemiluminescence detector
P02384265A0947|55 61|cancer
P02384265A0947|7 14|results
P02384265A0947|160 166|cancer
P02384265A0947|91 102|possibility
P02386485A0554|5 24|nucleotide sequence
P02386485A0554|129 135|region
P02386485A0554|77 79|bp
P02386485A0554|151 158|bp poly
P02386485A0554|90 96|region
P02388685A0577|5 12|results
P02388685A0577|231 232|%
P02388685A0577|252 259|calcium
P02388685A0577|188 200|coefficients
P02388685A0577|264 282|phosphorus content
P02388685A0577|300 305|tibia
P02390633T0000|64 71|disease
P02390633T0000|25 32|patient
P02391344T0000|93 97|gene
P02391344T0000|11 18|cloning
P02392511T0000|100 108|disorder
P02392511T0000|58 63|state
P02393895A0918|170 177|authors
P02393895A0918|201 216|differentiation
P02393895A0918|5 14|RF values
P02393895A0918|244 258|regurgitations
P02393895A0918|79 87|severity
P02394718A0130|155 174|amino acid sequence
P02394718A0130|93 120|deoxyoligonucleotide probes
P02394718A0130|12 17|genes
P02396415T0001|1 8|Results
P02396415T0001|42 51|treatment
P02396415T0001|26 37|observation
P02399053A0153|100 104|days
P02399053A0153|77 79|RA
P02399053A0153|108 112|life
P02399053A0153|30 31|n
P02400070T0000|1 11|Comparison
P02400070T0000|28 39|thiopentone
P02402678A0463|237 253|mosquito control
P02402678A0463|175 182|fogging
P02402678A0463|43 44|%
P02402678A0463|107 110|ULV
P02402678A0463|50 69|% lambdacyhalothrin
P02402678A0463|260 267|g ai/ha
P02402678A0463|147 162|diesel/kerosene
P02403634A0788|1 18|Sequence analysis
P02403634A0788|175 183|CArG box
P02403634A0788|130 140|regulation
P02403634A0788|166 171|genes
P02403634A0788|293 295|bp
P02403634A0788|246 269|binding site homologies
P02403634A0788|361 369|cap site
P02403634A0788|60 66|GC box
P02403926A0307|1 11|Antibodies
P02403926A0307|168 176|tyrosine
P02403926A0307|146 152|serine
P02403926A0307|211 223|NIH3T3 cells
P02405393T0000|78 90|c-ets-2 gene
P02405393T0000|62 66|ETS2
P02405818A0550|139 149|infarction
P02405818A0550|21 28|Heubner
P02405818A0550|126 135|mechanism
P02406570A0898|170 180|activation
P02406570A0898|113 123|initiation
P02406570A0898|37 46|sequences
P02406570A0898|59 63|ARS1
P02406570A0898|95 99|ABFI
P02408248A0414|42 48|action
P02411513A0667|7 22|characteristics
P02411513A0667|89 94|event
P02411513A0667|180 190|positivity
P02417669A0218|84 91|taurine
P02417669A0218|117 127|asparagine
P02417669A0218|158 178|amino acid aspartate
P02417669A0218|44 55|amino acids
P02419327A0998|116 126|incubation
P02419327A0998|5 21|priming activity
P02419327A0998|228 232|site
P02419327A0998|194 197|DNA
P02420432A1060|185 194|pregnancy
P02420432A1060|159 168|diagnosis
P02420432A1060|125 143|serum PAPP-A level
P02423533A1790|69 80|chicken DNA
P02423533A1790|53 56|rat
P02423533A1790|95 98|DNA
P02423533A1790|104 108|frog
P02423850A0292|1 18|Deletion analysis
P02423850A0292|108 114|region
P02423850A0292|44 48|part
P02427024X0000|117 138|fenfluramine anorexia
P02427024X0000|157 164|respect
P02427024X0000|78 88|laboratory
P02427024X0000|94 100|regard
P02427024X0000|61 69|findings
P02427024X0000|45 52|fiction
P02427812A0865|51 57|6-OHDA
P02427812A0865|67 75|alpha-MD
P02427812A0865|7 14|results
P02427812A0865|90 105|pressor actions
P02431314A0834|107 113|Wright
P02431314A0834|60 71|recognition
P02437625A0197|50 73|histoplasmosis syndrome
P02437625A0197|24 28|eyes
P02437625A0197|75 79|POHS
P02437895A0000|273 275|RH
P02437895A0000|234 240|stroke
P02437895A0000|172 178|adults
P02437895A0000|16 36|potentials procedure
P02437895A0000|154 160|groups
P02437895A0000|185 195|hemisphere
P02437895A0000|296 304|patients
P02437895A0000|209 217|aphasics
P02442837A0060|233 239|period
P02442837A0060|246 253|minutes
P02442837A0060|213 229|bypass procedure
P02442837A0060|43 52|dauricine
P02442837A0060|63 86|calcium channel blocker
P02443924A0083|9 17|patients
P02445751A0925|86 104|cytochrome oxidase
P02445751A0925|113 125|beta subunit
P02445751A0925|161 172|hem2 mutant
P02445751A0925|63 68|mRNAs
P02445751A0925|47 59|state levels
P02449431A1121|71 75|dATP
P02449431A1121|66 69|ATP
P02449431A1121|88 93|ddATP
P02452313A0114|1 9|ASL-8123
P02452313A0114|188 194|tissue
P02452313A0114|232 233|X
P02452313A0114|198 212|concentrations
P02452313A0114|90 112|guinea pig right atria
P02454976A0944|16 23|results
P02454976A0944|48 55|systems
P02454976A0944|99 104|gyrus
P02454976A0944|196 201|gyrus
P02454976A0944|133 144|possibility
P02454976A0944|150 159|divisions
P02456827A0899|16 18|mM
P02456827A0899|20 26|effect
P02456827A0899|110 113|Ba2
P02458080T0000|1 10|Prognosis
P02458699A0650|1 9|Svensson
P02461368A0162|68 77|structure
P02461368A0162|42 46|time
P02461368A0162|133 137|cDNA
P02461368A0162|150 153|DNA
P02462305A1071|53 68|phosphorylation
P02462305A1071|142 153|polypeptide
P02462305A1071|72 76|Ag35
P02463050A0514|55 60|mg/kg
P02463050A0514|94 98|rise
P02463050A0514|122 127|level
P02466414A0000|228 242|weight dextran
P02466414A0000|105 107|Ea
P02466414A0000|262 270|% wt/vol
P02466414A0000|244 247|mol
P02466414A0000|88 103|blood viscosity
P02466414A0000|183 189|plasma
P02468795A1086|17 40|acid phosphatase levels
P02468795A1086|1 6|Serum
P02468795A1086|147 156|parameter
P02470955A0101|84 96|meningitides
P02470955A0101|7 14|studies
P02470955A0101|44 52|increase
P02473198A0613|1 9|Dopamine
P02473198A0613|129 135|glands
P02473198A0613|108 114|effect
P02473693A0174|48 55|protein
P02473693A0174|57 63|HGB F.
P02473907A1338|137 140|IgE
P02473907A1338|101 105|site
P02473907A1338|36 39|IgE
P02473907A1338|9 14|C mAb
P02474093T0000|1 12|Angiotensin
P02474093T0000|83 92|diuretics
P02474093T0000|132 139|effects
P02474204A0105|116 122|marker
P02474204A0105|42 51|Grimelius
P02474204A0105|11 16|cells
P02474204A0105|60 68|staining
P02475506A0878|53 88|polymerase chain reaction technique
P02476030A0000|85 110|laser scanning tomography
P02476030A0000|22 29|surface
P02477373A0930|69 98|transcription initiation site
P02477373A0930|13 21|TATA box
P02479823A0727|38 44|region
P02479823A0727|91 99|TATA box
P02480959A0470|157 161|days
P02480959A0470|36 47|consequence
P02480959A0470|214 224|modulation
P02480959A0470|133 137|days
P02480959A0470|268 272|cAMP
P02481429T0000|32 52|Leishmania parasites
P02481429T0000|73 79|smears
P02482293A1518|67 105|EGF-R tyrosine protein kinase activity
P02482293A1518|179 187|activity
P02482293A1518|47 50|TNF
P02482293A1518|120 123|EGF
P02483210A0000|70 77|trypsin
P02483210A0000|81 94|exacerbations
P02483210A0000|58 64|lipase
P02484714T0000|29 39|expression
P02484714T0000|47 70|mouse estrogen receptor
P02485188A0415|33 46|ABC digestion
P02485188A0415|229 237|diabetes
P02485188A0415|133 141|diabetes
P02485188A0415|104 120|dermatan sulfate
P02485188A0415|152 157|group
P02485188A0415|261 267|levels
P02485188A0415|94 100|levels
P02487898A0315|96 114|NGF administration
P02487898A0315|88 92|ways
P02489032A0000|34 43|diversity
P02489032A0000|187 202|diversification
P02489032A0000|64 71|chicken
P02489032A0000|129 131|VL
P02489032A0000|29 32|IgL
P02489032A0000|75 88|recombination
P02489895T0001|82 89|muscles
P02489895T0001|41 47|rhythm
P02492111A0868|171 177|safety
P02492111A0868|54 62|children
P02492111A0868|43 50|effects
P02492111A0868|299 312|micrograms/dl
P02492111A0868|268 292|blood lead concentration
P02492111A0868|194 200|safety
P02495745T0000|18 25|effects
P02495745T0000|111 121|thrombosis
P02496100T0000|115 120|study
P02496100T0000|95 99|feed
P02497340A0989|102 104|Vk
P02497340A0989|23 37|antibody genes
P02497340A0989|95 97|Jk
P02497340A0989|73 85|chain probes
P02498652A0460|7 19|transfection
P02498652A0460|30 56|TSH beta promoter activity
P02502096A0462|23 33|blood flow
P02505087A1037|48 51|Fos
P02505087A1037|109 113|GCN4
P02506740A0742|119 129|blood flow
P02506740A0742|81 87|effect
P02506740A0742|44 52|recovery
P02507815A0000|32 38|cortex
P02507815A0000|40 42|VC
P02508726A0498|137 148|instability
P02508726A0498|233 243|population
P02508726A0498|197 206|potential
P02508726A0498|50 55|LiCO3
P02508726A0498|114 122|behavior
P02508726A0498|271 282|conjunction
P02508726A0498|211 224|neurotoxicity
P02510242A0313|115 121|HBs Ag
P02510242A0313|66 83|hepatitis B virus
P02510242A0313|161 168|viruses
P02510242A0313|209 214|tests
P02511150T0025|9 15|status
P02511430A0000|68 96|immunoglobulin gene enhancer
P02511430A0000|18 20|bp
P02511430A0000|172 179|factors
P02511430A0000|128 135|binding
P02512010A0801|99 105|return
P02512010A0801|42 53|compression
P02512010A0801|121 132|circulation
P02515953A0459|37 45|patients
P02515953A0459|11 16|study
P02518645T0001|10 24|Chagas disease
P02518645T0001|72 76|life
P02520622A0200|168 175|placebo
P02520622A0200|7 15|patients
P02520622A0200|226 238|group design
P02520622A0200|104 112|symptoms
P02521674T0000|102 109|lesions
P02521674T0000|65 96|complementation group F mutants
P02521674T0000|113 117|nsP4
P02521674T0000|12 15|RNA
P02523800A1178|175 188|BAR1 promoter
P02523800A1178|96 122|TGAAACA consensus sequence
P02523800A1178|28 36|sequence
P02523800A1178|60 68|fragment
P02526165X0000|5 9|sign
P02526165X0000|130 140|malignancy
P02526165X0000|13 25|Leser-Trelat
P02527745A0865|80 84|gene
P02527745A0865|59 70|copy number
P02527745A0865|89 101|conservation
P02528730A1073|108 126|donor splice sites
P02528730A1073|147 151|gene
P02528730A1073|88 91|use
P02530413A0195|68 73|pg/ml
P02530413A0195|4 19|supine position
P02530413A0195|54 59|pg/ml
P02531203A0241|84 93|negatives
P02531203A0241|57 66|responses
P02532210A0000|35 42|protein
P02532210A0000|88 93|genes
P02535460A1443|58 62|gene
P02536160A0518|38 43|Ren1d
P02536160A0518|145 152|pUTKAT1
P02536160A0518|130 141|TK promoter
P02536160A0518|106 120|CAT expression
P02537485A0841|103 108|mg/kg
P02537485A0841|169 174|mg/kg
P02537485A0841|52 70|morphine analgesia
P02537485A0841|126 144|morphine analgesia
P02538656A0172|70 79|R regions
P02538656A0172|64 65|M
P02538656A0172|127 133|region
P02538656A0172|148 169|transforming activity
P02541251A1327|49 54|sites
P02541251A1327|114 118|TATA
P02541251A1327|192 200|features
P02541251A1327|13 20|T2 gene
P02542194A1496|84 89|grade
P02542194A1496|97 109|astrocytomas
P02542194A1496|161 169|survival
P02542194A1496|29 37|patients
P02542612A0530|216 231|RNA transcripts
P02542612A0530|25 28|RNA
P02542612A0530|147 164|Z transactivation
P02542612A0530|104 128|NotI repeat promoter-CAT
P02543621A0788|17 20|DNA
P02543621A0788|1 9|Analysis
P02543621A0788|92 99|changes
P02543621A0788|121 145|translocation breakpoint
P02543734A0414|84 92|activity
P02543734A0414|48 62|bp repeat unit
P02543734A0414|11 27|oligonucleotides
P02545357A0000|55 63|bp group
P02545357A0000|76 82|intron
P02546234A1382|65 72|efforts
P02547611A0318|16 18|bp
P02547611A0318|33 39|region
P02547611A0318|112 114|bp
P02547706T0001|1 9|Validity
P02547706T0001|142 151|pneumonia
P02547706T0001|88 113|cytomegalovirus pneumonia
P02547706T0001|75 84|diagnosis
P02548683T0001|9 16|account
P02548683T0001|29 36|seminar
P02549343A1008|369 377|reaction
P02549343A1008|38 43|cells
P02549343A1008|337 358|neutralizing activity
P02549343A1008|286 293|rabbits
P02549343A1008|21 24|gpI
P02549343A1008|397 407|complement
P02549343A1008|219 225|weight
P02549343A1008|265 273|antibody
P02550118A0610|65 69|days
P02551886A0332|32 40|plasmids
P02551886A0332|73 80|inserts
P02552316A0526|59 66|average
P02552316A0526|149 156|percent
P02552316A0526|31 41|caretakers
P02555177A0488|17 21|LEU2
P02555177A0488|202 218|mRNA translation
P02555177A0488|148 168|COX3 gene expression
P02555177A0488|91 113|COX1 introns aI5 alpha
P02555519A0798|238 252|hapten binding
P02555519A0798|69 73|CDR3
P02555519A0798|173 191|D-region structure
P02555519A0798|111 119|peptides
P02555519A0798|75 109|complementarity determining region
P02556264A0278|138 143|cells
P02556264A0278|48 61|kappa B motif
P02556264A0278|199 215|cell specificity
P02556603A0606|76 82|cancer
P02556603A0606|120 136|bile duct cancer
P02557217A0398|93 124|corticotrophin-cortisol release
P02557217A0398|60 68|increase
P02559630A0270|115 125|fibrinogen
P02559630A0270|80 97|prothrombin times
P02559630A0270|58 78|thromboplastin times
P02562787A0637|48 52|CNBP
P02562787A0637|24 31|protein
P02565405T0000|13 27|trauma victims
P02565807A1198|170 175|WORDS
P02565807A1198|18 36|neu proto-oncogene
P02565807A1198|82 92|properties
P02565807A1198|129 142|NIH 3T3 cells
P02566613T0000|1 29|Somatostatin gene expression
P02566613T0000|44 55|islet cells
P02567030A0482|83 93|difficulty
P02567030A0482|56 64|controls
P02569411A0151|22 32|medication
P02569411A0151|78 94|nucleus amygdala
P02572777T0000|46 63|distress syndrome
P02573303A0000|35 37|LV
P02573303A0000|5 13|decrease
P02573303A0000|131 133|LV
P02573829T0000|50 55|sites
P02573829T0000|66 75|sequences
P02573829T0000|14 26|conservation
P02574016A0428|136 149|micrograms/kg
P02574016A0428|59 60|%
P02574016A0428|108 121|micrograms/kg
P02574016A0428|26 29|TOF
P02574193A0663|1 10|Selection
P02574193A0663|340 359|regression analysis
P02574193A0663|308 326|contingency tables
P02574193A0663|259 266|placebo
P02574193A0663|292 300|subjects
P02574193A0663|92 98|CIWA-B
P02574193A0663|271 279|diazepam
P02575174A0229|170 188|airflow limitation
P02575174A0229|33 41|efficacy
P02575174A0229|97 102|alpha
P02575174A0229|46 52|safety
P02575567T0001|69 74|wires
P02576405A0223|68 77|melphalan
P02576405A0223|98 125|cyclophosphamide-BCNU-VP-16
P02576405A0223|4 12|patients
P02576405A0223|199 207|patients
P02576405A0223|41 50|therapies
P02576405A0223|133 145|EDAP regimen
P02577867T0000|35 48|oncogene jun.
P02582240A1009|137 147|dCCC sites
P02582240A1009|96 110|ATP/GTP ratios
P02582240A1009|44 64|RNA primer synthesis
P02582240A1009|30 40|initiation
P02584969A0119|18 24|design
P02584969A0119|108 117|end point
P02584969A0119|121 122|%
P02586485A0511|21 24|SB3
P02590097A0093|154 157|IgA
P02590097A0093|33 37|lung
P02590097A0093|142 152|gammopathy
P02590097A0093|9 20|involvement
P02590391A0442|34 48|heart contents
P02590391A0442|136 158|diphosphatidylglycerol
P02590391A0442|110 134|phosphatidylethanolamine
P02590391A0442|74 87|phospholipids
P02590391A0442|22 32|parameters
P02590391A0442|89 108|phosphatidylcholine
P02590391A0442|60 66|lipids
P02590615A0636|38 44|timing
P02590615A0636|177 184|tablets
P02590615A0636|28 33|state
P02591078A0000|238 242|time
P02591078A0000|156 171|OKT6 antibodies
P02591078A0000|76 103|contact dermatitis reaction
P02591078A0000|176 195|electron microscopy
P02592640A0466|70 77|cheeses
P02592640A0466|6 12|values
P02592640A0466|230 231|g
P02592640A0466|165 170|cream
P02592640A0466|187 193|cheese
P02592640A0466|263 270|retinol
P02592640A0466|91 96|cream
P02595451A1136|87 91|TCL2
P02595451A1136|38 41|AN2
P02595451A1136|7 11|data
P02595451A1136|59 85|T-cell leukemia breakpoint
P02597484A0624|115 126|differences
P02597484A0624|53 55|De
P02597484A0624|42 51|platelets
P02597484A0624|94 95|K
P02598034A0000|136 142|cortex
P02598034A0000|32 42|potentials
P02598034A0000|81 89|patients
P02599995A1031|171 172|%
P02599995A1031|71 81|penicillin
P02599995A1031|157 165|survival
P02599995A1031|15 31|activity studies
P02601707A0986|1 23|Gel retardation assays
P02601707A0986|38 43|DNase
P02601707A0986|163 177|BC3H1 myocytes
P02601707A0986|63 97|diethyl pyrocarbonate interference
P02601707A0986|120 126|factor
P02603374A0383|9 18|rhinotomy
P02603374A0383|45 61|dorsal rhinotomy
P02604420A0234|19 27|rebiopsy
P02604420A0234|42 62|reticulin antibodies
P02604420A0234|89 94|years
P02604420A0234|121 124|end
P02605182A0936|146 157|polypeptide
P02607766A0000|411 416|salts
P02607766A0000|141 148|cadmium
P02607766A0000|72 96|quality control material
P02607766A0000|326 339|micrograms/dL
P02607766A0000|219 224|blood
P02607766A0000|264 276|micrograms/L
P02607766A0000|34 45|preparation
P02607766A0000|432 434|Pb
P02607766A0000|379 396|spiking-solutions
P02607766A0000|424 426|Hg
P02607766A0000|353 358|blood
P02607766A0000|298 310|micrograms/L
P02607766A0000|182 184|Pb
P02607766A0000|241 244|QCM
P02614668A0971|58 63|serum
P02617623A0740|50 56|LON-10
P02617623A0740|1 7|LON-72
P02617623A0740|97 98|m
P02617623A0740|122 129|village
P02621983T0001|1 13|Significance
P02621983T0001|38 51|acid analysis
P02627159A0899|71 84|immunotherapy
P02630543A0210|49 59|antibodies
P02630543A0210|141 148|changes
P02630543A0210|20 37|staining affinity
P02630543A0210|111 112|T
P02630543A0210|242 248|tissue
P02630543A0210|107 108|T
P02631566A0151|102 127|chloromethyl alkyl ethers
P02631566A0151|1 15|Alkoxymetgyl-3
P02631566A0151|251 278|chloromethyl alkyl sulfides
P02631566A0151|208 217|reactions
P02631887A0000|55 64|lymphomas
P02631887A0000|31 35|HGGM
P02634490A0186|80 91|sialography
P02634490A0186|36 46|affections
P02634490A0186|72 78|course
P02636920T0001|33 80|Pharmacopoeia Heparin Sodium Reference Standard
P02638964A0372|81 87|kg/mm2
P02638964A0372|110 115|water
P02638964A0372|132 141|composite
P02638964A0372|91 102|equilibrium
P02642466T0000|55 73|membrane immunogen
P02644735A0427|4 13|FP mutant
P02644735A0427|83 86|end
P02644735A0427|163 181|host cell sequence
P02644735A0427|15 24|AcFP875-2
P02645431A1562|64 72|acidosis
P02645431A1562|25 39|hypocitraturia
P02645431A1562|89 95|defect
P02647403A0000|43 58|psychopathology
P02647918A0588|1 12|Application
P02647918A0588|139 159|somatomedin-C values
P02647918A0588|234 238|OGTT
P02647918A0588|72 73|%
P02647918A0588|192 206|GH suppression
P02647918A0588|220 225|ng/ml
P02647918A0588|259 260|%
P02647918A0588|247 255|patients
P02647918A0588|176 177|%
P02647918A0588|26 34|criteria
P02647918A0588|60 68|patients
P02648396A0565|101 108|agarose
P02648396A0565|4 16|Rat-1a cells
P02648396A0565|76 83|ability
P02648396A0565|133 137|mice
P02648646A0216|156 164|capacity
P02648646A0216|78 93|airway response
P02648646A0216|124 139|expiratory flow
P02648646A0216|166 170|Vp30
P02649445A0412|6 8|BG
P02649445A0412|67 80|body builders
P02649445A0412|92 100|controls
P02649445A0412|13 31|IRI concentrations
P02650663A0178|100 108|dementia
P02650663A0178|189 198|diagnosis
P02650663A0178|43 51|subjects
P02650663A0178|75 85|impairment
P02651487A0000|32 56|calcium channel blockers
P02651487A0000|141 147|effect
P02651487A0000|232 239|insulin
P02651487A0000|124 133|knowledge
P02656257A0000|19 43|DNA inversion system Cin
P02656257A0000|158 166|enhancer
P02656257A0000|90 101|recombinase
P02657883A0000|1 11|US-Doppler
P02657883A0000|113 121|fistulas
P02657883A0000|123 126|FAV
P02664229A0138|185 199|Arap procedure
P02664229A0138|37 42|scope
P02664229A0138|10 18|cosmesis
P02664229A0138|148 155|fistula
P02664229A0138|225 235|advantages
P02664229A0138|91 97|repair
P02666404A0220|272 291|arabinose permeases
P02666404A0220|5 26|galactose transporter
P02666404A0220|78 89|superfamily
P02666404A0220|198 207|rat brain
P02666404A0220|324 331|maltose
P02666404A0220|93 111|sugar transporters
P02666404A0220|62 70|homology
P02667259A0331|87 96|dizziness
P02667259A0331|40 49|reactions
P02667259A0331|26 30|cent
P02669199A0000|1 22|Tumor necrosis factor
P02669199A0000|24 27|TNF
P02669199A0000|106 109|LPS
P02674141A1202|93 102|proenzyme
P02674141A1202|60 85|activation peptide region
P02674671A0601|130 136|allele
P02674671A0601|61 72|replacement
P02674679A1237|152 162|expression
P02674679A1237|17 48|S1 nuclease protection analysis
P02674679A1237|82 95|mouse tissues
P02674679A1237|8 13|basis
P02674679A1237|121 126|genes
P02677429A0366|68 69|%
P02677429A0366|207 208|%
P02677429A0366|339 346|complex
P02677429A0366|142 143|%
P02677429A0366|312 320|subjects
P02677429A0366|288 289|%
P02677429A0366|222 228|months
P02677429A0366|83 89|months
P02677429A0366|265 269|AIDS
P02677429A0366|363 378|treatment group
P02679804A2000|87 110|orotidine monophosphate
P02679804A2000|5 13|products
P02684159A0870|1 23|Hybridization analysis
P02684159A0870|52 56|mRNA
P02685331A0523|5 30|R. meliloti nifH promoter
P02685331A0523|43 45|K.
P02685331A0523|78 83|sigma
P02685331A0523|123 139|guanine residues
P02685331A0523|180 191|nucleotides
P02685565A0165|36 40|form
P02685565A0165|58 62|mRNA
P02686749A0000|100 107|workers
P02686749A0000|54 61|changes
P02686749A0000|76 84|exposure
P02686749A0000|145 154|discovery
P02686749A0000|88 95|cadmium
P02686749A0000|15 34|health significance
P02686985A0811|101 107|stages
P02686985A0811|66 79|PCF1 mutation
P02686985A0811|244 251|complex
P02686985A0811|194 201|effects
P02689136A1851|15 22|effects
P02689439A0402|34 41|regions
P02689439A0402|169 177|homology
P02689439A0402|112 124|rat Yb1 gene
P02689439A0402|199 205|region
P02689439A0402|79 87|homology
P02691557A0273|190 196|period
P02691557A0273|98 101|age
P02691557A0273|5 14|incidence
P02691557A0273|57 58|h
P02691998A0672|153 157|ET-1
P02691998A0672|129 149|bolus administration
P02691998A0672|75 78|bed
P02693208A0166|169 178|sequences
P02693208A0166|81 85|rad1
P02693208A0166|107 127|repeat recombination
P02694731A0241|204 211|testing
P02694731A0241|20 29|knowledge
P02694731A0241|37 49|epidemiology
P02694731A0241|133 143|hypotheses
P02694731A0241|14 18|hand
P02700977A0444|35 46|penetration
P02700977A0444|83 96|XR bond/Silus
P02702849A0418|100 101|g
P02702849A0418|217 229|micrograms/l
P02702849A0418|231 232|p
P02703925A0359|341 347|weight
P02703925A0359|948 952|zone
P02703925A0359|464 481|cartilage samples
P02703925A0359|75 101|sedimentation coefficients
P02703925A0359|154 165|conclusions
P02703925A0359|261 289|cartilage matrix degradation
P02703925A0359|571 581|HW regions
P02703925A0359|756 764|distance
P02703925A0359|505 512|pattern
P02703925A0359|858 864|amount
P02703925A0359|40 52|subgroupings
P02703925A0359|377 383|values
P02703925A0359|728 748|proteoglycan content
P02703925A0359|671 690|cartilage thickness
P02703925A0359|838 843|cases
P02703925A0359|531 549|matrix degradation
P02703925A0359|780 787|surface
P02703925A0359|967 974|samples
P02703925A0359|302 310|S values
P02705072A0464|1 11|End points
P02705072A0464|72 74|MI
P02705556A1049|35 41|supply
P02705556A1049|6 8|RV
P02705556A1049|12 18|demand
P02708288A0139|113 123|metabolism
P02708288A0139|178 189|soybean oil
P02708288A0139|146 161|fluazifop-butyl
P02708288A0139|165 173|soybeans
P02708353A1080|103 107|gene
P02708353A1080|49 78|transcription initiation site
P02708353A1080|91 99|position
P02709081T0000|19 25|survey
P02709081T0000|29 40|work styles
P02711145T0000|1 19|HIV infectiousness
P02711601A0601|118 119|%
P02711601A0601|86 97|guinea pigs
P02711601A0601|107 108|%
P02712450A0989|170 174|Type
P02712450A0989|110 114|Type
P02712450A0989|193 204|hypercapnia
P02712450A0989|44 49|drive
P02712450A0989|221 226|drive
P02712450A0989|251 257|groups
P02712450A0989|177 185|response
P02713520T0000|76 91|ptilochronology
P02713520T0000|9 21|dose effects
P02713520T0000|45 55|nuthatches
P02714525A0529|1 14|Kidney weight
P02714525A0529|138 149|dose levels
P02714525A0529|110 115|weeks
P02717133T0001|34 56|development conditions
P02717133T0001|60 86|summary oxygen consumption
P02718683A0142|57 65|patients
P02721169A0171|71 77|manner
P02721169A0171|36 46|data items
P02724227T0000|70 78|ischemia
P02725513A0617|85 89|rule
P02725513A0617|155 163|position
P02725513A0617|95 118|metazoan RNA polymerase
P02729666A0267|70 83|dentoskeletal
P02729666A0267|13 35|intergroup differences
P02731671A0000|110 115|Ni3S2
P02731671A0000|46 72|nickel sulfate hexahydrate
P02731671A0000|166 185|inhalation exposure
P02731671A0000|14 22|toxicity
P02731671A0000|220 225|weeks
P02731671A0000|26 38|nickel oxide
P02731671A0000|91 108|nickel subsulfide
P02733116T0000|10 29|National Institutes
P02735364A1330|71 72|p
P02735364A1330|114 115|p
P02735364A1330|160 161|p
P02735364A1330|62 69|results
P02735364A1330|150 158|variable
P02739739T0000|1 26|COUP transcription factor
P02739739T0000|46 74|steroid receptor superfamily
P02740347A0644|1 14|Cosmid clones
P02740347A0644|31 45|VNTR sequences
P02740874A0957|67 74|tissues
P02740874A0957|12 18|damage
P02743842A0000|408 413|ml/kg
P02743842A0000|309 319|blood flow
P02743842A0000|371 377|mM HCl
P02743842A0000|281 295|back-diffusion
P02743842A0000|81 87|mucosa
P02743842A0000|398 403|shock
P02743842A0000|178 194|prostaglandin E2
P02743842A0000|267 276|tissue pH
P02743842A0000|421 424|min
P02743842A0000|150 159|influence
P02744123A0237|115 123|branches
P02744123A0237|66 79|rhesus monkey
P02744123A0237|163 167|time
P02745280A0276|100 121|lactate concentration
P02745280A0276|18 22|PaO2
P02745280A0276|80 91|blood gases
P02745280A0276|179 188|phosphate
P02745280A0276|229 232|31P
P02745280A0276|211 214|ATP
P02745666A0000|118 144|replacement therapy cycles
P02745666A0000|71 77|levels
P02745666A0000|67 69|P4
P02745666A0000|167 174|failure
P02745666A0000|45 47|E2
P02747653A0910|81 89|tadpoles
P02747653A0910|23 30|protein
P02747653A0910|72 77|serum
P02748595A0492|71 78|lineage
P02748595A0492|42 45|ADH
P02751080A0176|17 21|shot
P02751080A0176|59 74|intensity level
P02751080A0176|44 51|minutes
P02752629A0163|20 31|scintigrams
P02752629A0163|53 76|methylene diphosphonate
P02756731T0001|1 15|Prostaglandins
P02757033A0905|152 167|position effect
P02757033A0905|172 185|transcription
P02757033A0905|111 126|heterochromatin
P02757033A0905|195 200|genes
P02758382A0478|184 194|proportion
P02758382A0478|163 167|SHBG
P02758382A0478|92 101|estradiol
P02758382A0478|209 218|estradiol
P02761008X0000|1 30|Brain cholinesterase activity
P02761008X0000|143 151|activity
P02761008X0000|199 204|death
P02761008X0000|49 55|egrets
P02761008X0000|155 160|birds
P02761008X0000|88 100|night-herons
P02761492A0124|51 58|genesis
P02761492A0124|96 104|patients
P02761492A0124|74 85|involvement
P02761540A0873|1 18|Deletion analysis
P02761540A0873|55 69|AP-1 sequences
P02762198T0001|1 5|Reye
P02762198T0001|8 16|syndrome
P02762198T0001|31 36|cases
P02764797A0182|1 6|PULSE
P02764797A0182|173 187|rf pulse shape
P02764797A0182|27 30|NMR
P02764797A0182|63 68|delay
P02764797A0182|73 81|duration
P02764797A0182|45 55|parameters
P02765214A0486|23 29|demand
P02765214A0486|15 20|Kurti
P02766508A0421|3 26|correlation coefficient
P02766508A0421|73 84|map pattern
P02767166A0368|85 93|cataract
P02767166A0368|154 166|pathogenesis
P02767166A0368|111 122|consequence
P02767166A0368|63 74|development
P02772495A0641|1 7|Asthma
P02772495A0641|96 97|%
P02772495A0641|53 62|ASA group
P02772495A0641|74 75|%
P02773930T0000|41 56|hyperfiltration
P02773930T0000|60 66|humans
P02774808A0194|84 101|micrograms/100 ml
P02774808A0194|37 38|P
P02775333A1137|84 89|mg/kg
P02775333A1137|100 107|changes
P02775333A1137|64 70|output
P02775333A1137|125 130|mg/kg
P02775333A1137|13 17|i.v.
P02775333A1137|44 52|increase
P02776742A0000|1 11|Heart rate
P02776742A0000|38 41|Tre
P02776742A0000|314 318|self
P02776742A0000|109 117|clothing
P02776742A0000|44 58|blood pressure
P02776742A0000|85 101|humidity changes
P02776742A0000|253 255|SU
P02776742A0000|300 308|clothing
P02776742A0000|243 251|uniforms
P02776742A0000|60 71|temperature
P02777797A0720|1 23|DNA blot hybridization
P02777797A0720|42 52|rat genome
P02778873A0761|102 111|sequences
P02778873A0761|113 118|DR-A1
P02778873A0761|57 74|enhancer function
P02779752A0776|4 18|m-Chlorophenyl
P02779752A0776|199 205|effect
P02779752A0776|258 268|ketanserin
P02779752A0776|19 29|piperazine
P02779752A0776|59 82|m-trifluoromethylphenyl
P02779752A0776|31 35|mCPP
P02779752A0776|241 245|1-NP
P02781495T0001|67 74|failure
P02781495T0001|12 37|xanthine oxidase activity
P02783181A0000|98 105|effects
P02783181A0000|52 70|antacid magaldrate
P02783181A0000|72 81|ES Riopan
P02787430A0124|64 80|cytophagocytosis
P02787430A0124|13 25|panniculitis
P02789062A1420|3 7|cDNA
P02789062A1420|130 145|oligonucleotide
P02789217A1323|55 70|polyadenylation
P02789217A1323|9 25|IL6 mRNA species
P02789217A1323|74 79|sites
P02790009A1052|133 141|residues
P02790009A1052|105 131|serine protease inhibitors
P02792430A0000|238 249|guinea pigs
P02792430A0000|100 110|inhibition
P02792430A0000|114 138|prostaglandins synthesis
P02792430A0000|25 29|rats
P02792430A0000|226 234|vagotomy
P02793620A0214|64 75|parturition
P02793620A0214|25 29|cows
P02793620A0214|79 88|Charolais
P02794828A0214|5 11|system
P02794828A0214|122 131|pacemaker
P02796216A0063|5 12|disease
P02796216A0063|111 118|roseola
P02796216A0063|74 87|enterorrhagia
P02797877A0475|5 20|combination PIP
P02797877A0475|43 53|micrograms
P02797877A0475|108 113|hours
P02799892A0154|17 20|use
P02799892A0154|103 114|transfusion
P02799892A0154|49 54|WRBCs
P02799892A0154|132 135|PNH
P02800435A0000|155 161|system
P02800435A0000|7 18|experiments
P02800435A0000|126 131|field
P02800435A0000|44 48|cats
P02805945A0000|306 314|degree C
P02805945A0000|140 168|Scripsiella trochoidea Stein
P02805945A0000|128 136|cultures
P02805945A0000|317 325|lighting
P02805945A0000|284 295|temperature
P02805945A0000|364 372|seawater
P02805945A0000|330 346|microEin m-2 s-1
P02807780A0143|154 163|diagnosis
P02807780A0143|81 84|min
P02807780A0143|5 8|use
P02807780A0143|58 59|%
P02807780A0143|133 136|CIS
P02809116A0237|86 94|husbands
P02809116A0237|147 152|wives
P02809116A0237|75 82|effects
P02809722A0926|35 46|improvement
P02809722A0926|79 91|GH secretion
P02810911A0372|5 15|accuracies
P02810911A0372|108 121|tumor markers
P02810911A0372|31 38|absence
P02811378A0379|157 170|cell epulides
P02811378A0379|125 129|none
P02811378A0379|60 72|S100 protein
P02813404T0000|90 105|spermatogenesis
P02814820A0967|201 208|minutes
P02814820A0967|130 143|Billroth dogs
P02814820A0967|44 54|pacemakers
P02814820A0967|86 93|liquids
P02814820A0967|157 161|Roux
P02814820A0967|145 149|t1/2
P02814820A0967|210 211|p
P02816251A0397|169 179|ventricles
P02816251A0397|29 40|capillaries
P02818122A0000|49 59|morphology
P02818122A0000|197 203|nuclei
P02818122A0000|131 143|distribution
P02818122A0000|88 102|animal species
P02820128A1333|4 9|terms
P02820128A1333|59 65|copies
P02820128A1333|125 138|dyad symmetry
P02820128A1333|13 33|sequence repetitions
P02821340A0434|20 28|exercise
P02821340A0434|161 169|workload
P02821340A0434|41 48|UT dogs
P02821340A0434|135 155|mm Hg X ml-1 X min-1
P02821340A0434|194 199|grade
P02824334A0972|7 11|data
P02824334A0972|29 50|G-protein gene family
P02825750A0260|50 51|%
P02825750A0260|30 43|response rate
P02826717A0179|50 55|water
P02826717A0179|93 103|water flow
P02826717A0179|40 44|gill
P02828926A1870|25 32|factors
P02828926A1870|194 216|muscle differentiation
P02830214A0000|48 50|Cl
P02830214A0000|5 11|effect
P02830214A0000|72 81|ear fluid
P02830214A0000|15 28|acetazolamide
P02830282A0155|48 56|fragment
P02830282A0155|143 155|polypeptides
P02830282A0155|62 73|UP1 protein
P02831556A0173|85 91|adults
P02831556A0173|42 49|mothers
P02831556A0173|131 139|morphine
P02832149A1009|255 265|activation
P02832149A1009|115 118|myb
P02832149A1009|174 185|amino acids
P02832149A1009|52 60|products
P02832149A1009|27 32|ratio
P02832149A1009|225 236|consequence
P02832744A0403|59 62|RNA
P02832744A0403|77 84|chicken
P02832744A0403|107 113|testes
P02832744A0403|13 28|mos transcripts
P02833021A1185|187 204|promoter function
P02833021A1185|112 123|enhancement
P02833021A1185|57 62|units
P02833049A1041|156 164|products
P02833049A1041|126 137|transcripts
P02833049A1041|199 210|RD-114 mRNA
P02833049A1041|177 185|majority
P02833049A1041|269 273|loci
P02833517A0467|74 81|element
P02834843A0000|170 180|rifampicin
P02834843A0000|38 59|rifamycin derivatives
P02834843A0000|337 342|H37Rv
P02834843A0000|78 81|FCE
P02834843A0000|131 134|CGP
P02834843A0000|291 305|phase cultures
P02834843A0000|262 270|activity
P02834843A0000|95 106|rifapentine
P02834843A0000|215 224|log phase
P02834843A0000|182 185|RMP
P02834843A0000|61 70|rifabutin
P02837575A0979|1 15|Sodium dodecyl
P02837575A0979|142 145|DNA
P02837575A0979|56 69|topoisomerase
P02838246A0225|102 113|specificity
P02838246A0225|206 214|patients
P02838246A0225|130 143|proliferation
P02838246A0225|194 202|findings
P02838246A0225|220 236|rejection crises
P02838246A0225|264 265|P
P02838246A0225|151 167|T8 subpopulation
P02838710A0299|5 11|levels
P02838710A0299|15 21|NPY-ir
P02839716A0673|58 64|effect
P02839716A0673|88 96|activity
P02840034A1266|115 122|factors
P02840034A1266|10 20|evaluation
P02840034A1266|28 37|treatment
P02843495A0544|1 13|Introduction
P02843495A0544|53 73|macrophage cell line
P02843495A0544|106 120|tumorigenicity
P02844767A0191|174 180|Kallas
P02844767A0191|106 112|plants
P02844767A0191|195 197|S.
P02844767A0191|134 142|proteins
P02844767A0191|50 61|petCA genes
P02844767A0191|27 42|cotranscription
P02844767A0191|211 213|R.
P02844767A1022|159 169|gene probe
P02844767A1022|79 86|subunit
P02844767A1022|46 50|mRNA
P02845654A0510|1 13|Substitution
P02845654A0510|129 141|substitution
P02845654A0510|111 119|cleavage
P02845654A0510|75 77|P2
P02845654A0510|19 36|threonine residue
P02845654A0510|218 220|P1
P02845654A0510|147 163|tyrosine residue
P02846852A1459|50 67|E strand promoter
P02846852A1459|116 133|L strand promoter
P02846852A1459|97 108|polymerases
P02849100A0441|83 91|molecule
P02849100A0441|22 30|sequence
P02849100A0441|120 126|anchor
P02850472A0112|53 68|DNA replication
P02850971A0180|136 148|Vitreoscilla
P02850971A0180|65 89|VtHb amino acid sequence
P02850971A0180|10 30|oligodeoxynucleotide
P02852894T0000|1 7|Causes
P02852894T0000|73 86|Thai villages
P02852894T0000|45 50|study
P02853922A0596|10 13|IOP
P02853922A0596|30 38|patients
P02859434T0000|20 30|laboratory
P02859434T0000|43 48|range
P02861144A0242|9 17|analysis
P02861144A0242|26 38|DNA fragment
P02862656T0000|1 8|Changes
P02862656T0000|12 41|dopamine receptor sensitivity
P02863747T0000|1 12|Replacement
P02863747T0000|21 34|histone genes
P02868446A0184|38 56|RPase beta subunit
P02868446A0184|25 29|CTDs
P02868446A0184|227 233|enzyme
P02868446A0184|271 291|core enzyme subunits
P02868446A0184|61 72|DNA primase
P02869125A0120|34 50|receptor agonist
P02869125A0120|184 194|tachypnoea
P02869125A0120|124 133|analgesia
P02869125A0120|211 218|arousal
P02870720A0188|142 157|tracheal muscle
P02870720A0188|121 137|guinea pig atria
P02870720A0188|75 85|pA2 values
P02872786A0147|22 30|equation
P02872786A0147|121 130|sandflies
P02872786A0147|90 97|foregut
P02874078A0252|77 85|patients
P02875224A1059|170 171|%
P02875224A1059|1 12|Reperfusion
P02875224A1059|38 45|beating
P02875224A1059|25 30|blood
P02875224A1059|106 112|reflow
P02876820A0841|82 84|mV
P02876820A0841|14 22|acidosis
P02877124A0000|143 159|chlorpheniramine
P02877124A0000|72 88|promethazine HCl
P02877124A0000|405 428|methylene diphosphonate
P02877124A0000|16 21|B6AF1
P02877124A0000|458 473|bone metabolism
P02877124A0000|26 37|B6D2F1 mice
P02877124A0000|524 531|weights
P02877124A0000|380 394|body retention
P02877124A0000|497 504|studies
P02877124A0000|535 540|femur
P02877124A0000|251 265|drinking water
P02877124A0000|59 68|tap water
P02877124A0000|542 547|ilium
P02877124A0000|302 322|bone mineral content
P02879906A0000|169 173|tone
P02879906A0000|110 148|beta adrenoceptor subtype distribution
P02879906A0000|62 73|rabbit face
P02880841A0313|232 236|beta
P02880841A0313|128 140|beta subunit
P02880841A0313|315 327|mitochondria
P02880841A0313|286 295|membranes
P02880841A0313|51 60|structure
P02880841A0313|189 193|gene
P02880841A0313|24 27|TF1
P02880841A0313|268 270|F1
P02883327A0413|70 76|region
P02883327A0413|5 26|polyadenylation sites
P02883327A0413|67 68|E
P02883327A0413|132 138|region
P02883963A0000|5 13|patients
P02883963A0000|25 31|T-cell
P02883963A0000|130 137|methods
P02883963A0000|45 55|virus type
P02885517T0000|9 21|blood donors
P02889495A0000|139 143|dose
P02889495A0000|80 88|pimozide
P02889495A0000|46 68|episode schizophrenics
P02889495A0000|164 175|mg pimozide
P02889495A0000|30 35|study
P02892762A0296|76 78|nt
P02892762A0296|90 103|promoter site
P02894741A0000|36 46|vecuronium
P02894741A0000|61 78|muscle relaxation
P02895472A0178|23 31|colonies
P02895472A0178|62 70|plasmids
P02895754A0000|275 283|syndrome
P02895754A0000|141 145|rate
P02895754A0000|261 264|eye
P02895754A0000|266 272|Horner
P02895754A0000|56 96|phosphodiesterase inhibitor theophylline
P02898752A0683|103 121|platelets recovery
P02898752A0683|52 58|CFU-GM
P02898752A0683|10 21|correlation
P02899792T0000|1 10|Oestrogen
P02901498A0354|100 112|erbB protein
P02901498A0354|5 17|biosynthesis
P02901498A0354|22 31|stability
P02902615A0000|51 64|polyarteritis
P02902615A0000|77 85|advances
P02902615A0000|149 157|patients
P02902844A1219|37 41|gene
P02902844A1219|145 158|bacterium PS3
P02902844A1219|121 132|atp operons
P02903500A0278|170 184|immunoglobulin
P02903500A0278|64 67|neu
P02903500A0278|82 93|fusion gene
P02903500A0278|27 37|properties
P02903500A0278|45 52|protein
P02906027A0553|38 46|homology
P02906027A0553|112 122|CpG island
P02906027A0553|28 34|blocks
P02906249A1195|87 92|hours
P02906249A1195|25 35|% Prazosin
P02906249A1195|104 115|application
P02907308T0001|33 57|Richner-Hanhart syndrome
P02907308T0001|20 31|tyrosinosis
P02907533T0000|1 8|Effects
P02907533T0000|52 68|diazepam binding
P02910496A0583|69 77|sequence
P02910496A0583|3 19|decamer sequence
P02910496A0583|24 37|CGA-CCCCUCC-3
P02911540A0478|137 141|care
P02911540A0478|54 58|area
P02911540A0478|67 71|feet
P02911540A0478|28 33|wound
P02914422A0409|1 18|Computer analysis
P02914422A0409|177 182|slurs
P02914422A0409|132 147|frequency range
P02914422A0409|90 105|frequency bands
P02916764A0253|55 72|diabetes mellitus
P02916764A0253|96 113|cigarette smoking
P02916764A0253|125 135|life-style
P02916764A0253|74 94|hypercholesterolemia
P02919483A0091|27 32|girls
P02919483A0091|15 19|boys
P02919832A0144|39 45|M-mode
P02923687A0218|87 95|patients
P02923687A0218|112 124|cleft palate
P02923687A0218|73 83|cleft side
P02925568A0460|152 168|family stressors
P02925568A0460|84 91|samples
P02925568A0460|22 36|father absence
P02925568A0460|181 196|psychopathology
P02927391A0238|267 275|lineages
P02927391A0238|160 167|tissues
P02927391A0238|121 130|germ line
P02928376A0312|137 138|%
P02928376A0312|70 72|H2
P02928376A0312|80 85|gases
P02928376A0312|30 35|water
P02930623A0404|97 99|ms
P02930623A0404|106 112|impact
P02930623A0404|30 36|torque
P02934889A0558|87 94|grazing
P02934889A0558|96 99|May
P02934889A0558|78 83|start
P02934889A0558|124 138|cent reduction
P02934889A0558|195 206|D viviparus
P02935638A0000|42 51|structure
P02936284A0357|117 138|elimination half-life
P02936284A0357|71 82|elimination
P02936284A0357|42 48|plasma
P02936284A0357|28 38|atracurium
P02939260A1553|253 270|Edman degradation
P02939260A1553|65 68|43K
P02939260A1553|96 106|methionine
P02939260A1553|208 221|39K T antigen
P02939260A1553|73 87|42K T antigens
P02941237A0160|205 220|pyrophosphatase
P02941237A0160|142 151|vitamin A
P02941237A0160|131 140|vitamin D
P02941237A0160|15 23|instance
P02941237A0160|58 88|phosphorous ion concentrations
P02941237A0160|28 36|addition
P02941237A0160|90 99|tissue pH
P02947866A1416|116 125|perfusion
P02947866A1416|20 28|analysis
P02947866A1416|56 63|washout
P02950216A0084|114 117|BCF
P02950216A0084|82 95|output signal
P02950216A0084|145 150|volts
P02950216A0084|62 65|LDF
P02958204A0175|279 292|acne vulgaris
P02958204A0175|99 112|apoprotein A1
P02958204A0175|226 238|isotretinoin
P02958204A0175|259 268|treatment
P02958204A0175|216 222|course
P02958204A0175|114 121|apo A-1
P02958204A0175|244 253|mg/kg/day
P02958204A0175|31 43|isotretinoin
P02958660A1094|117 127|experiment
P02958660A1094|55 72|conversion factor
P02958660A1094|77 87|LDF signal
P02958660A1094|40 49|existence
P02960012A0838|18 30|PPNG strains
P02960012A0838|5 14|frequency
P02963517A0453|39 47|stenosis
P02963517A0453|92 102|dilatation
P02963517A0453|78 82|PTCA
P02965149A0727|22 28|Brandl
P02965149A0727|15 20|study
P02966671A0551|97 101|days
P02966671A0551|133 144|enhancement
P02966671A0551|222 233|enhancement
P02966671A0551|322 334|radiotherapy
P02966671A0551|294 299|start
P02966671A0551|123 129|degree
P02967915A0000|152 166|target tissues
P02967915A0000|141 148|variety
P02967915A0000|74 84|expression
P02968055A0984|35 43|increase
P02968055A0984|47 50|ANF
P02969819A0814|36 58|TcR gene recombination
P02969819A0814|74 86|T cell lines
P02970640A0341|188 192|zinc
P02970640A0341|111 123|acid protein
P02970640A0341|134 142|zinc ion
P02971710A0734|163 165|CO
P02971710A0734|10 12|RV
P02971710A0734|107 108|%
P02971710A0734|14 16|LV
P02971710A0734|19 20|S
P02971710A0734|94 104|hematocrit
P02973304A0000|16 22|course
P02973304A0000|26 46|Budd-Chiari syndrome
P02973304A0000|63 73|thrombosis
P02975753A1333|137 148|yeast cells
P02975753A1333|70 80|importance
P02975753A1333|122 133|E3 promoter
P02979426T0000|1 22|Organ transplantation
P02981457A0368|1 3|D.
P02982332T0001|19 24|VP-16
P02982332T0001|26 33|capsule
P02983331T0000|16 20|role
P02983331T0000|112 118|stress
P02983331T0000|59 65|factor
P02985820A1287|68 78|c-myc gene
P02985820A1287|97 104|genesis
P02985820A1287|144 148|MC29
P02985820A1287|11 28|sequence elements
P02987220A0472|1 11|Subcloning
P02987220A0472|66 71|pAVO4
P02987220A0472|131 134|FBP
P02987220A0472|56 62|insert
P02988457A0650|69 87|Bestatin treatment
P02988457A0650|5 9|data
P02988457A0650|107 117|malignancy
P02989786A0328|81 97|CATase synthesis
P02989786A0328|43 62|adenovirus E1A gene
P02993630A1190|81 92|nuclease S1
P02993630A1190|66 75|digestion
P02993630A1190|142 150|sequence
P02993630A1190|22 38|nucleotide level
P02993630A1190|166 173|message
P02994336A0864|1 3|FK
P02994336A0864|143 149|change
P02994336A0864|36 44|analogue
P02994336A0864|74 75|%
P02995999A0000|5 22|sequence analysis
P02995999A0000|163 167|site
P02995999A0000|315 335|recombination events
P02995999A0000|75 95|recombination events
P02995999A0000|54 57|phi
P02995999A0000|146 156|attachment
P02995999A0000|241 260|recombination event
P02997777A0609|274 284|treatments
P02997777A0609|184 190|blocks
P02997777A0609|218 225|top2 ts
P02997777A0609|142 156|top2 ts strain
P02997777A0609|57 62|cells
P02997777A0609|107 109|ts
P02998043A1199|138 142|acid
P02998043A1199|20 28|sequence
P02998043A1199|144 160|carboxy-proximal
P02998043A1199|107 116|sequences
P02999267A0885|102 113|hypertrophy
P02999267A0885|237 245|patients
P02999267A0885|5 14|intensity
P02999267A0885|199 201|GS
P02999267A0885|29 35|uptake
P02999267A0885|150 156|echoes
P03000489A0822|139 140|%
P03000489A0822|96 97|%
P03000489A0822|142 147|range
P03000489A0822|78 82|mean
P03000489A0822|160 168|criteria
P03000489A0822|152 153|%
P03000489A0822|58 66|patients
P03001084A0406|85 87|bp
P03001084A0406|98 106|cap site
P03001084A0406|5 13|sequence
P03001084A0406|125 127|bp
P03001084A0406|45 49|pair
P03001110A0546|35 53|peptide substrates
P03001110A0546|217 225|receptor
P03001110A0546|189 192|mol
P03001110A0546|72 80|function
P03001645A0785|5 10|pet56
P03001645A0785|107 109|bp
P03001952A0958|186 192|effect
P03001952A0958|80 83|HSV
P03001952A0958|106 117|determinant
P03001952A0958|132 143|recurrences
P03001952A0958|60 66|herpes
P03002786A0143|86 93|mg i.m.
P03002786A0143|56 63|mg kg-1
P03002786A0143|12 13|n
P03004364A0775|100 105|FULIP
P03004364A0775|43 53|activities
P03004364A0775|57 61|5-FU
P03004364A0775|107 113|ADRLIP
P03004982A0199|5 24|nucleotide sequence
P03004982A0199|109 119|genes fbcF
P03004982A0199|73 76|DNA
P03005231A0649|220 229|sequences
P03005231A0649|126 139|transcription
P03005231A0649|28 37|sequences
P03005231A0649|164 173|promoters
P03007281A0905|98 102|loci
P03007281A0905|39 41|kb
P03007281A0905|112 119|maximum
P03007281A0905|128 130|kb
P03008405A0532|9 18|outbreaks
P03008405A0532|73 78|HVC-1
P03009826A0201|75 81|repeat
P03011793A0582|34 38|rbsA
P03011793A0582|10 24|reading frames
P03011793A0582|28 32|rbsD
P03013841A0207|1 9|Cattaneo
P03014593A0681|35 37|Ro
P03014593A0681|92 97|mg/kg
P03014593A0681|13 18|mg/kg
P03015628A1078|239 247|subjects
P03015628A1078|142 155|bone turnover
P03015628A1078|26 40|hydroxyproline
P03015628A1078|194 229|serum alkaline phosphatase activity
P03016301A0605|139 144|c-myc
P03016301A0605|114 120|codons
P03016301A0605|11 23|v-myc codons
P03016883A0000|4 7|men
P03016883A0000|127 134|samples
P03016883A0000|73 78|HSV-2
P03016883A0000|44 69|herpes simplex virus type
P03017996A0731|157 167|mutants X2
P03017996A0731|179 192|cleavage site
P03017996A0731|63 77|signal peptide
P03017996A0731|45 57|polypeptides
P03019505A0390|36 42|spread
P03020513T0000|85 91|gyrase
P03020513T0000|16 23|subunit
P03021088A0135|103 114|gastrectomy
P03021088A0135|53 63|occurrence
P03021088A0135|172 176|days
P03021088A0135|131 135|type
P03021088A0135|79 85|ulcers
P03021088A0135|183 188|years
P03023067A0779|34 39|genes
P03023067A0779|73 84|transcripts
P03023682A0271|1 10|Insertion
P03023682A0271|92 95|CAT
P03023682A0271|27 31|SV40
P03023887A0470|154 168|sequence motif
P03023887A0470|182 184|Sa
P03023887A0470|121 128|borders
P03024343A0372|58 64|origin
P03025606T0000|17 32|control signals
P03025606T0000|38 63|herpes simplex virus type
P03025606T0000|72 77|gamma
P03025606T0000|134 142|terminus
P03025661A0260|10 17|EMBO J.
P03026915A1024|22 31|sequences
P03026915A1024|77 88|yeast genes
P03027779A0000|1 18|SPECT examination
P03027779A0000|67 75|patients
P03027779A0000|26 29|TMJ
P03027779A0000|134 138|disc
P03029111A0155|48 73|pet complementation group
P03032143A0218|220 237|yeast kinetochore
P03032143A0218|119 136|sequence elements
P03032143A0218|185 197|conformation
P03032143A0218|55 58|DNA
P03032143A0218|160 168|proteins
P03033283A0837|184 191|maximum
P03033283A0837|116 128|DNA sequence
P03033283A0837|83 88|Towne
P03033283A0837|78 82|HCMV
P03033283A0837|133 171|competition filter binding experiments
P03033283A0837|90 93|DNA
P03034570A0943|223 230|vectors
P03034570A0943|65 98|chloramphenicol acetyltransferase
P03034570A0943|22 35|gene segments
P03034570A0943|130 140|resistance
P03034570A0943|13 18|genes
P03035056T0000|71 79|leukemia
P03035056T0000|56 63|Abelson
P03035658A0355|171 174|VO2
P03035658A0355|130 151|plasma concentrations
P03035658A0355|105 109|dose
P03035658A0355|220 229|ml/kg/min
P03035658A0355|57 66|ml/kg/min
P03035658A0355|88 99|epinephrine
P03035658A0355|120 126|manner
P03036817A0213|108 116|yeast R.
P03036817A0213|60 81|NdeI restriction site
P03037334A0932|40 56|promoter element
P03038891A0935|50 60|cell lines
P03038891A0935|32 45|mouse tissues
P03038891A0935|76 91|p11 mRNA levels
P03039387A0920|34 50|cyclophosphamide
P03039387A0920|178 181|BCG
P03039387A0920|160 172|methotrexate
P03039387A0920|208 218|levamisole
P03040403A0155|5 13|PSS gene
P03040403A0155|58 67|yeast DNA
P03041802A0975|220 228|disorder
P03041802A0975|5 13|presence
P03041802A0975|199 211|pathogenesis
P03041802A0975|29 48|platelet aggregates
P03041802A0975|165 175|deposition
P03045725A0872|142 159|tumor sensitivity
P03045725A0872|163 175|chemotherapy
P03045725A0872|46 62|prolactin levels
P03046931A0247|99 120|nucleotide difference
P03046931A0247|75 79|cDNA
P03049570A1242|7 19|similarities
P03050147A1520|152 161|mRNA site
P03050147A1520|6 17|observation
P03050147A1520|74 84|initiation
P03052641A0204|71 76|gases
P03052641A0204|42 50|vehicles
P03057259A0514|5 17|relationship
P03057259A0514|60 67|thyroid
P03060846T0000|47 55|23S rRNA
P03061301A0624|254 259|smoke
P03061301A0624|138 154|radioimmunoassay
P03061301A0624|212 218|period
P03061301A0624|42 56|excretion rate
P03061301A0624|165 180|urine specimens
P03061383A0000|64 68|acid
P03061383A0000|142 147|Oxa-1
P03061383A0000|94 101|strains
P03061383A0000|192 197|broth
P03061383A0000|14 22|activity
P03062370A0384|119 142|amino acid availability
P03062370A0384|76 86|activation
P03062370A0384|90 105|GCN4 expression
P03064811A0485|169 172|Asp
P03064811A0485|5 24|amino acid sequence
P03065141A0448|137 163|Tn3411 nucleotide sequence
P03065141A0448|103 111|promoter
P03065141A0448|32 37|genes
P03065141A0448|191 197|pMS185
P03065141A0448|5 12|results
P03065621T0000|1 10|Structure
P03065621T0000|87 92|MRP13
P03065621T0000|96 103|protein
P03065621T0000|15 25|regulation
P03066208A0310|56 60|cyst
P03067505A0688|70 81|ear vessels
P03067505A0688|7 19|prostacyclin
P03069980T0000|1 8|Factors
P03069980T0000|77 84|cements
P03069980T0000|47 66|glass polyalkenoate
P03072580A0455|15 17|R.
P03073091A0449|237 246|mg/kg/min
P03073091A0449|278 284|mmol/l
P03073091A0449|143 144|K
P03073091A0449|12 19|glucose
P03073091A0449|132 141|treatment
P03073091A0449|254 267|indomethacine
P03073091A0449|190 204|spironolactone
P03073091A0449|296 305|mg/kg/min
P03073091A0449|328 329|K
P03073091A0449|269 270|K
P03075154T0000|63 84|ciclosporin A therapy
P03075154T0000|15 33|oxalate deposition
P03078268A0529|33 40|aspects
P03078268A0529|219 223|role
P03078268A0529|147 171|amphotericin B treatment
P03078268A0529|107 122|acidosis models
P03080793T0000|1 10|Statement
P03080793T0000|18 29|development
P03080793T0000|52 62|prevention
P03088643A0000|119 131|control rats
P03088643A0000|87 89|CS
P03088643A0000|78 85|stimuli
P03090372A0607|86 89|CyA
P03090372A0607|13 36|glucose tolerance tests
P03097509A0654|54 61|regions
P03097509A0654|91 101|base pairs
P03098018A0139|87 101|P2-A2 pilosity
P03098018A0139|80 85|limbs
P03098018A0139|25 31|height
P03098018A0139|10 18|findings
P03104245A0402|186 192|months
P03104245A0402|101 109|survival
P03104245A0402|203 209|months
P03104245A0402|163 169|months
P03104245A0402|26 31|Ir192
P03104245A0402|224 230|months
P03104914T0000|1 10|Mechanism
P03104914T0000|114 122|partners
P03104914T0000|39 52|translocation
P03108171A0088|1 11|Ritanserin
P03108171A0088|53 70|blocking activity
P03108171A0088|74 86|S2 receptors
P03109147T0127|1 9|Research
P03109147T0127|13 28|ethylene glycol
P03110119A0267|185 191|carina
P03110119A0267|76 81|l/min
P03110119A0267|145 148|tip
P03110119A0267|130 138|catheter
P03110119A0267|15 25|ventilator
P03110692A0156|309 317|patients
P03110692A0156|279 285|months
P03110692A0156|381 393|urine volume
P03110692A0156|15 19|mg/l
P03110692A0156|288 295|beta 2m
P03110692A0156|357 361|year
P03110692A0156|115 125|bone cysts
P03110692A0156|188 196|dialysis
P03110692A0156|176 184|duration
P03110692A0156|61 68|beta 2m
P03110794A0991|53 60|effects
P03111946A0309|33 41|behavior
P03112412A0985|119 140|thr operon expression
P03112412A0985|4 12|addition
P03112412A0985|163 174|temperature
P03112412A0985|215 221|change
P03114829T0000|39 51|panic states
P03115087A0515|21 38|height velocities
P03115087A0515|10 16|weight
P03115087A0515|47 48|%
P03117046T0000|1 10|Isolation
P03117046T0000|15 31|characterization
P03118631A0140|4 15|differences
P03118631A0140|58 66|cochleas
P03118631A0140|90 99|perfusion
P03119485A0476|222 239|distress syndrome
P03119485A0476|55 63|patients
P03119485A0476|5 16|requirement
P03119485A0476|143 150|respect
P03119485A0476|108 114|injury
P03119485A0476|194 200|sepsis
P03123310A0000|93 99|purine
P03123310A0000|63 73|activities
P03125420A0421|1 5|Biol
P03126531T0000|1 9|Reversal
P03126531T0000|64 74|aggression
P03126531T0000|78 87|REM sleep
P03127463A1017|175 191|cord blood cells
P03127463A1017|158 163|My-10
P03127463A1017|82 90|cultures
P03127463A1017|94 111|bone marrow cells
P03127463A1017|26 36|COS7 cells
P03133250A0000|100 112|gonadotropin
P03133250A0000|114 117|hMG
P03133250A0000|159 163|hFSH
P03133250A0000|215 221|IVF-ET
P03133250A0000|180 193|fertilization
P03134872T0029|1 8|Apropos
P03137346A0319|70 75|exons
P03137346A0319|5 19|nucleolin gene
P03137346A0319|123 130|protein
P03138190A0347|144 155|inoculation
P03138190A0347|13 20|amounts
P03139750A0000|69 75|rabbit
P03139750A0000|27 37|expression
P03143048A1091|69 70|P
P03143048A1091|86 100|concentrations
P03143048A1091|66 67|%
P03143048A1091|44 62|apolipoprotein A-I
P03144705A0859|102 110|gradient
P03144705A0859|169 170|X
P03144705A0859|5 17|distribution
P03144705A0859|25 30|sites
P03146150T0000|34 42|efficacy
P03146150T0000|70 83|Pro-urokinase
P03146150T0000|88 95|heparin
P03147912A0422|53 58|sighs
P03147912A0422|95 103|baseline
P03147912A0422|79 91|fluctuations
P03147912A0422|120 124|time
P03150015T0001|22 27|non-A
P03154072A0862|5 21|protein mixtures
P03154072A0862|25 37|sesame flour
P03166458A1356|65 76|nucleotides
P03168709A0000|50 63|glaucoma eyes
P03168709A0000|20 26|fields
P03171279A0158|205 211|dorsal
P03171279A0158|222 226|vein
P03171279A0158|87 93|grafts
P03171279A0158|48 54|artery
P03171279A0158|74 80|toe MP
P03175942A0706|65 69|dams
P03175942A0706|93 103|experiment
P03175942A0706|41 46|doses
P03178161A0000|99 108|vitamin A
P03178161A0000|110 111|E
P03178161A0000|161 167|adults
P03178161A0000|133 143|methionine
P03178161A0000|191 200|carcinoma
P03178161A0000|113 116|B12
P03178161A0000|124 128|acid
P03178161A0000|30 39|screening
P03179496T0000|32 60|modified-hemoglobin solution
P03179496T0000|90 114|blood volume replacement
P03181276A0422|67 68|h
P03181276A0422|92 110|allergen challenge
P03181276A0422|75 76|h
P03183127A0068|50 68|imaging modalities
P03183127A0068|96 115|CT ventriculography
P03183127A0068|79 81|CT
P03185322A1305|139 140|%
P03185322A1305|144 158|class-2 smears
P03185322A1305|126 135|diagnosis
P03185322A1305|91 96|class
P03186091T0000|1 7|Change
P03186091T0000|11 39|plasma cystyl aminopeptidase
P03186091T0000|90 99|predictor
P03190481A0292|156 167|correlation
P03190481A0292|5 9|test
P03190481A0292|219 224|width
P03190481A0292|42 54|quantitation
P03190481A0292|58 69|macrophages
P03190481A0292|131 138|abscess
P03192537A0370|71 72|Y
P03192537A0370|65 70|HMG-I
P03192537A0370|111 130|amino acid sequence
P03192537A0370|214 221|protein
P03192537A0370|74 78|cDNA
P03192799T0000|18 34|American Academy
P03194410A0771|4 15|UOxase mRNA
P03194410A0771|95 105|expression
P03194410A0771|46 53|tissues
P03198436T0000|84 91|iridium
P03198436T0000|56 66|cystectomy
P03199043A0248|1 10|Existence
P03199043A0248|176 198|diffusion coefficients
P03199043A0248|106 110|case
P03199043A0248|209 219|resistance
P03199043A0248|120 145|permeability coefficients
P03200488A0439|119 133|administration
P03200488A0439|155 159|mice
P03200488A0439|36 39|TIQ
P03200488A0439|145 151|period
P03207975A0709|55 76|plasma concentrations
P03207975A0709|43 53|vitamin K1
P03209019A0662|155 160|weeks
P03209019A0662|38 44|groups
P03209019A0662|113 117|DMBA
P03209019A0662|92 102|microliter
P03209019A0662|56 65|CD-1 mice
P03209019A0662|123 128|mg/ml
P03212929A0000|4 19|ELISA procedure
P03212929A0000|62 74|IgE response
P03216131A0559|10 17|isolate
P03219107A0212|33 44|convulsions
P03219107A0212|5 14|incidence
P03223123T0001|32 39|methods
P03223123T0001|93 98|fluid
P03223123T0001|72 80|maturity
P03227568T0001|49 64|dermatoglyphics
P03227568T0001|66 74|patterns
P03227568T0001|40 45|types
P03227568T0001|105 111|cattle
P03228785A1047|1 9|Recovery
P03228785A1047|140 144|area
P03228785A1047|37 48|improvement
P03228785A1047|197 198|p
P03228785A1047|72 82|parameters
P03232410A1467|84 88|year
P03232410A1467|110 117|smoking
P03234790T0001|84 92|toxicity
P03234790T0001|54 76|methyl isobutyl ketone
P03234790T0001|15 22|methods
P03237446A0377|1 5|None
P03237446A0377|75 86|lymphopenia
P03243027T0000|92 116|Dictyostelium discoideum
P03243027T0000|46 69|protein gene expression
P03246999A0483|35 41|b-wave
P03246999A0483|53 70|adaptation period
P03246999A0483|106 114|subjects
P03249840A0411|234 239|entry
P03249840A0411|202 206|FEV1
P03249840A0411|166 170|SGaw
P03249840A0411|75 93|airway conductance
P03249840A0411|251 258|subject
P03249840A0411|95 99|SGaw
P03249840A0411|208 212|PD20
P03249840A0411|269 276|smoking
P03253219T0000|49 77|anthracycline cardiomyopathy
P03253219T0000|40 45|leads
P03257146A1037|84 90|number
P03257146A1037|175 186|neutropenia
P03257146A1037|7 14|results
P03257146A1037|95 103|maturity
P03257146A1037|29 34|CSFHU
P03259437A0140|292 300|neonates
P03259437A0140|142 147|value
P03259437A0140|79 92|starch method
P03259437A0140|123 131|controls
P03259437A0140|166 170|IU/l
P03261223A0644|93 96|TCT
P03261223A0644|77 82|SPECT
P03263357A0112|220 228|activity
P03263357A0112|170 186|leukocyte counts
P03263357A0112|81 97|body temperature
P03263357A0112|214 218|IL-1
P03263357A0112|192 210|plasma interleukin
P03263357A0112|121 142|plasma concentrations
P03264073A0224|39 45|series
P03264073A0224|83 91|activity
P03264073A0224|12 23|derivatives
P03264886A0000|9 19|population
P03264886A0000|132 133|%
P03264886A0000|115 122|Germany
P03264886A0000|178 191|months period
P03264886A0000|92 97|areas
P03264886A0000|63 69|medium
P03268555T0000|70 93|millipore filter method
P03268555T0000|10 20|assessment
P03274204A0642|69 78|dentition
P03274204A0642|1 13|Dentalplaque
P03275873A0379|35 49|RNA polymerase
P03275873A0379|5 12|effects
P03275873A0379|53 61|activity
P03275873A0379|110 115|genes
P03275873A0379|193 198|cells
P03276924A0090|70 79|insertion
P03276924A0090|93 108|MoMuLV provirus
P03280021A1615|118 151|measure alpha log Kobsd/alpha log
P03280021A1615|203 206|T/O
P03280021A1615|53 60|buffers
P03280021A1615|107 113|M NaBr
P03280807A1447|254 262|activity
P03280807A1447|17 33|suf12-null/SUF12
P03280807A1447|115 120|suf12
P03280807A1447|5 13|behavior
P03280807A1447|215 224|variation
P03280946A0375|171 175|gene
P03280946A0375|136 156|lac promoter control
P03280946A0375|100 109|minicells
P03280946A0375|79 87|proteins
P03280946A0375|14 30|immunity protein
P03282813A0794|34 37|QO2
P03282813A0794|207 208|p
P03282813A0794|86 90|ARDS
P03282813A0794|178 179|r
P03282813A0794|161 166|slope
P03282813A0794|72 80|patients
P03285764A0675|170 178|cofactor
P03285764A0675|292 300|failures
P03285764A0675|143 147|role
P03285764A0675|59 71|neuropathies
P03285764A0675|244 251|factors
P03287597T0000|27 41|prostate gland
P03292082A0486|102 108|system
P03292082A0486|142 154|glioblastoma
P03292082A0486|124 134|meningioma
P03292082A0486|72 78|tumors
P03296019T0000|35 48|bond strength
P03296019T0000|66 76|Silicoater
P03296254A0556|35 44|latamoxef
P03296254A0556|158 168|factor VII
P03296254A0556|144 150|factor
P03298134A0000|116 129|cell leukemia
P03298134A0000|6 12|report
P03298134A0000|43 61|interferon alfa-2b
P03298134A0000|63 71|Intron A
P03304015T0000|10 19|chemistry
P03305875T0000|25 35|management
P03308909A0485|32 41|cartilage
P03311954A0000|152 160|mg nocte
P03311954A0000|85 93|efficacy
P03311954A0000|98 104|safety
P03311954A0000|41 53|institutions
P03311954A0000|181 200|reflux oesophagitis
P03312514A0756|171 178|animals
P03312514A0756|5 12|N3 wave
P03312514A0756|230 231|%
P03312514A0756|194 195|%
P03312514A0756|117 118|%
P03312514A0756|218 223|group
P03312514A0756|247 262|control animals
P03317796A0853|8 21|control group
P03319646T0000|1 22|Plasma renin activity
P03319646T0000|61 69|efficacy
P03320875A2090|52 58|record
P03320875A2090|107 116|infection
P03325081A0524|96 107|keratopathy
P03325081A0524|109 112|PBK
P03325081A0524|151 162|keratopathy
P03329716A0187|152 162|calf serum
P03329716A0187|5 13|activity
P03329716A0187|129 142|phorbol ester
P03329716A0187|63 74|E1A protein
P03331525T0001|99 109|isocyanate
P03331525T0001|89 95|groups
P03331525T0001|60 78|urethane molecules
P03332022A1094|70 75|c-raf
P03332022A1094|281 298|cysteine clusters
P03332022A1094|56 62|region
P03332022A1094|135 161|cysteine clustering region
P03334950A0000|84 97|Sarcoma Study
P03334950A0000|64 81|Cooperative Ewing
P03334950A0000|5 19|German Society
P03334950A0000|126 137|combination
P03334950A0000|193 200|surgery
P03335398A0568|84 87|NVS
P03335398A0568|22 38|immunoglobulin G
P03335398A0568|94 106|immunization
P03335651A0000|220 222|T2
P03335651A0000|204 211|indexes
P03335651A0000|143 154|sensitivity
P03335651A0000|36 55|parameter weighting
P03335651A0000|79 81|MR
P03335651A0000|13 19|method
P03337024A0000|205 212|testing
P03337024A0000|168 176|practice
P03337024A0000|147 153|mg/min
P03337024A0000|13 20|studies
P03337024A0000|74 86|procainamide
P03340548A1018|87 90|Zn2
P03340548A1018|81 84|Cd2
P03340548A1018|93 96|Cu2
P03340548A1018|73 79|metals
P03340774A0328|153 155|Gy
P03340774A0328|143 146|rad
P03340774A0328|89 91|Gy
P03340774A0328|12 21|estimates
P03344586T0000|1 17|New technologies
P03344586T0000|53 63|malignancy
P03345706A0561|5 16|correlation
P03345706A0561|25 30|PaCO2
P03346210A0000|35 43|receptor
P03346210A0000|138 167|self-phosphorylation reaction
P03346210A0000|30 33|EGF
P03351478A0371|54 66|% G residues
P03351478A0371|29 33|runs
P03352439T0000|7 36|cord abduction rehabilitation
P03352947T0001|33 40|ARC/LAS
P03352947T0001|24 31|complex
P03354341A0177|16 31|filtration rate
P03354341A0177|52 63|plasma flow
P03354341A0177|94 110|clearance method
P03359860A0000|185 189|data
P03359860A0000|98 105|anxiety
P03359860A0000|178 181|use
P03359860A0000|63 78|characteristics
P03359860A0000|135 139|mood
P03360948A0477|82 94|relationship
P03360948A0477|58 66|behavior
P03360948A0477|132 140|MHI Loss
P03360948A0477|120 123|CAP
P03366720A1335|133 143|glycolysis
P03366720A1335|88 92|acid
P03366720A1335|45 56|utilization
P03368701A0113|82 88|choice
P03368701A0113|107 125|imaging techniques
P03371139A0829|77 83|groups
P03371139A0829|45 53|material
P03371894A0355|72 82|components
P03373755T0001|69 74|ulcer
P03373755T0001|8 20|developments
P03373755T0001|108 135|gastrin receptor blockaders
P03377864A0000|17 23|fields
P03377864A0000|112 126|Maxwell stress
P03377864A0000|94 107|Lorentz force
P03378994T0000|55 71|extraction ratio
P03378994T0000|27 41|sodium cyanate
P03380547A0169|1 4|SPA
P03380547A0169|10 19|PAG sites
P03382310A0903|38 43|scans
P03382310A0903|198 206|outcomes
P03382310A0903|47 55|patients
P03382855A0368|85 94|adhesions
P03382855A0368|5 16|artery cuff
P03384033A0155|187 188|%
P03384033A0155|65 69|cm/s
P03384033A0155|131 132|%
P03384033A0155|57 59|Hz
P03384033A0155|208 218|modalities
P03387665A0000|21 33|distribution
P03387665A0000|158 186|Glossina morsitans centralis
P03387665A0000|37 48|Trypanosoma
P03387665A0000|89 93|skin
P03387665A0000|61 68|T vivax
P03395009A1750|272 278|T11-12
P03395009A1750|131 137|ratios
P03395009A1750|317 329|intervention
P03395009A1750|226 235|locations
P03395009A1750|251 253|L1
P03395009A1750|298 304|region
P03395009A1750|244 247|T12
P03395009A1750|91 103|group-1 dogs
P03395249A1044|70 74|type
P03395249A1044|218 223|WORDS
P03395249A1044|93 97|dams
P03395249A1044|182 190|neonates
P03395249A1044|192 200|ABSTRACT
P03396628A0207|205 210|spots
P03396628A0207|41 46|weeks
P03396628A0207|135 140|weeks
P03396628A0207|81 90|ventricle
P03396628A0207|248 252|mice
P03396628A0207|94 105|BALB/c mice
P03396628A0207|150 154|mice
P03398714A0594|100 107|radical
P03398714A0594|42 51|solvation
P03398714A0594|28 29|%
P03400694A0245|154 162|patients
P03400694A0245|115 127|dipyridamole
P03400694A0245|23 35|Thallium-201
P03400694A0245|77 81|rest
P03400694A0245|14 21|METHODS
P03402183A0171|216 235|voltage stimulation
P03402183A0171|200 202|Hz
P03402183A0171|5 14|TA muscle
P03402183A0171|282 293|circulation
P03402183A0171|264 276|contractions
P03402183A0171|133 144|circulation
P03403412A0000|69 79|efficiency
P03403412A0000|5 12|effects
P03403412A0000|37 41|rate
P03403412A0000|43 54|composition
P03403826T0000|103 120|stenosis severity
P03403826T0000|230 279|exercise/redistribution thallium-201 scintigraphy
P03403826T0000|176 189|cineangiogram
P03403826T0000|151 159|analysis
P03404495A0172|46 56|admissions
P03413681A0659|138 146|function
P03413681A0659|111 121|predictors
P03413681A0659|88 93|woman
P03413681A0659|60 64|fact
P03417104A0536|21 28|results
P03417104A0536|42 58|chlorphentermine
P03417668A1233|156 159|Ca2
P03417668A1233|173 177|form
P03417668A1233|7 15|findings
P03417668A1233|135 148|CaM-kinase II
P03417668A1233|61 74|alpha subunit
P03420266A0000|137 149|animal model
P03420266A0000|170 176|cancer
P03420266A0000|20 29|radiation
P03420266A0000|106 120|adenocarcinoma
P03420466A0000|18 35|cryptosporidiosis
P03420466A0000|72 80|staining
P03420466A0000|45 53|children
P03423732A0341|1 9|Addition
P03423732A0341|141 154|HCO3 response
P03423732A0341|179 185|dmPGE2
P03423732A0341|109 110|%
P03423732A0341|13 23|sucralfate
P03427613A0659|53 60|vessels
P03427613A0659|129 134|brain
P03428274A0000|33 40|protein
P03428274A0000|115 130|DNA replication
P03428274A0000|110 113|Ad2
P03428274A0000|9 15|factor
P03428274A0000|46 56|HeLa cells
P03428274A0000|91 106|adenovirus type
P03429371A1051|18 39|cephalothin clearance
P03429371A1051|79 89|phagocytes
P03434347A0358|1 10|Mean rCBF
P03434347A0358|54 61|surgery
P03434347A0358|29 37|patients
P03436529A1066|223 231|enhancer
P03436529A1066|5 14|structure
P03436529A1066|197 205|template
P03436529A1066|62 66|pair
P03439248A0000|19 26|methods
P03439248A0000|86 103|perfusion imaging
P03439248A0000|53 74|exercise thallium-201
P03441587A0000|84 89|means
P03441587A0000|139 151|erythrocytes
P03441587A0000|114 125|polystyrene
P03441587A0000|59 64|serum
P03441587A0000|72 80|patients
P03441587A0000|44 51|factors
P03443566A0675|36 40|gain
P03443566A0675|88 90|CR
P03443609A0000|103 111|products
P03443609A0000|5 9|role
P03443609A0000|161 179|column methodology
P03448035T0000|19 28|pregnancy
P03450438A0446|35 39|need
P03450438A0446|66 72|method
P03452920T0001|17 21|past
P03452920T0001|9 15|insect
P03459385T0000|24 32|syndrome
P03463537T0001|38 43|Class
P03463537T0001|25 34|treatment
P03463537T0001|56 65|anomalies
P03473253A0000|32 54|cohort mortality study
P03473253A0000|143 173|chloromethyl ether manufacture
P03476002A0148|137 143|months
P03476002A0148|55 78|placebo supplementation
P03476002A0148|10 23|blood samples
P03479897A0961|36 45|angle ANB
P03479897A0961|77 82|angle
P03479897A0961|14 18|hand
P03484894A0782|110 118|biotypes
P03484894A0782|57 64|biotype
P03484894A0782|14 22|isolates
P03486405A0341|112 116|form
P03486405A0341|165 170|exons
P03486405A0341|90 95|exons
P03488532A0235|100 119|acyclovir treatment
P03488532A0235|65 81|dermatomal signs
P03493240T0000|68 73|drugs
P03493240T0000|15 25|properties
P03499608A1054|7 11|data
P03499608A1054|92 101|diagnosis
P03499608A1054|108 135|beta-hydroxylase deficiency
P03499822A0182|138 146|employee
P03499822A0182|23 42|regression analysis
P03499822A0182|160 165|birth
P03499822A0182|149 156|country
P03507689A0000|221 244|beta-galactosidase gene
P03507689A0000|117 122|ssDNA
P03507689A0000|112 115|DNA
P03507689A0000|124 130|origin
P03507689A0000|134 145|replication
P03513989A1149|68 79|disturbance
P03513989A1149|83 103|porphyrin metabolism
P03513989A1149|228 234|agents
P03513989A1149|26 34|disorder
P03516189A0406|5 13|patients
P03516189A0406|28 41|suxamethonium
P03520729A0381|53 66|plasma levels
P03520729A0381|24 34|heart rate
P03520729A0381|13 20|changes
P03526279T0000|27 39|nursing R.N.
P03531317A0930|21 25|loss
P03531317A0930|29 39|recessives
P03536682A0572|1 10|Ovulation
P03536682A0572|36 44|patients
P03537686A0099|154 163|frequency
P03537686A0099|20 29|placement
P03537686A0099|37 55|mutagenesis marker
P03537686A0099|179 188|mutations
P03537686A0099|11 15|size
P03537686A0099|61 86|supF suppressor tRNA gene
P03537721A0491|99 113|chromosome XVI
P03537721A0491|29 54|recombination experiments
P03537727A0243|5 9|poly
P03537727A0243|10 11|A
P03537727A0243|13 20|segment
P03540853A0652|16 35|amino acid sequence
P03540853A0652|39 42|Mop
P03542945T0000|1 14|Ciprofloxacin
P03542945T0000|39 50|experiences
P03543936A0000|52 58|family
P03543936A0000|92 111|ras oncogene family
P03545955A0751|169 174|Study
P03545955A0751|33 42|ingestion
P03545955A0751|5 18|glucose areas
P03545955A0751|199 204|juice
P03545955A0751|318 328|mmol X h/l
P03545955A0751|50 55|foods
P03545955A0751|292 296|milk
P03545955A0751|157 167|mmol X h/l
P03545955A0751|178 185|glucose
P03545955A0751|126 134|fructose
P03545955A0751|62 67|Study
P03549045A0878|1 4|SCL
P03549045A0878|113 120|animals
P03549045A0878|45 57|sinus arrest
P03552363A0568|239 259|blood pressure level
P03552363A0568|96 117|blood pressure levels
P03552363A0568|166 174|subjects
P03552363A0568|121 124|men
P03553439A0404|39 43|Type
P03553439A0404|52 64|tumor tissue
P03553439A0404|132 144|tumor tissue
P03553439A0404|181 192|tumor cells
P03556834T0000|7 26|inhalation toxicity
P03556834T0000|30 43|T-2 mycotoxin
P03559232T0000|15 20|study
P03561036T0000|70 80|lipofundin
P03561036T0000|57 68|oil extract
P03563399A0534|35 37|ms
P03563399A0534|52 56|SoNo
P03563399A0534|61 78|S pi No threshold
P03567017A0000|101 105|drug
P03567017A0000|22 27|times
P03567017A0000|40 44|days
P03567017A0000|130 134|t1/2
P03567017A0000|181 189|subjects
P03568311A1361|70 87|stroke work index
P03568311A1361|128 129|r
P03568311A1361|28 51|pericardiocentesis data
P03568311A1361|104 115|correlation
P03571135T0000|38 46|language
P03571135T0000|26 34|features
P03575656A0120|156 160|time
P03575656A0120|114 121|portion
P03575656A0120|89 93|bone
P03575656A0120|31 44|chemical form
P03577670A0236|48 51|MLD
P03577670A0236|111 117|levels
P03577670A0236|106 109|ASA
P03577670A0236|150 157|sisters
P03581160A0583|152 163|TH subjects
P03581160A0583|172 180|controls
P03582184A0448|1 6|Drugs
P03582184A0448|41 50|reactions
P03583001A0111|169 174|fluid
P03583001A0111|23 32|procedure
P03583001A0111|146 154|drainage
P03586925T0001|118 121|use
P03586925T0001|52 71|descriptor language
P03586925T0001|77 112|Roentgenology and Medical Radiology
P03591464A0840a|18 22|test
P03591464A0840a|46 62|disease activity
P03592297A0138|138 145|changes
P03592297A0138|203 208|TcpO2
P03592297A0138|314 326|vasodilation
P03592297A0138|228 237|electrode
P03592297A0138|184 198|vasomotor tone
P03592297A0138|295 304|degrees C
P03592297A0138|212 216|skin
P03592297A0138|56 66|electrodes
P03595418A0688|5 25|nucleotide sequences
P03595418A0688|91 101|% homology
P03597269A0409|34 45|exponential
P03597269A0409|82 83|b
P03597269A0409|11 16|model
P03600705T0000|50 67|cryptosporidiosis
P03600705T0000|24 40|oocyst excretion
P03601533T0001|69 77|children
P03601533T0001|94 105|thyroiditis
P03605895A0888|118 128|population
P03605895A0888|49 55|excess
P03605895A0888|7 15|patients
P03607961T0001|34 48|zhuang qi gong
P03607961T0001|58 67|mechanism
P03608989A0668|19 30|amino acids
P03608989A0668|6 12|region
P03608989A0668|62 74|interactions
P03610674T0000|23 38|zinc deficiency
P03610674T0000|78 93|rat hippocampus
P03612648A0085|108 116|antibody
P03612648A0085|120 131|cardiolipin
P03615550A1094|21 28|effects
P03615550A1094|109 117|naloxone
P03616174A1069|100 110|blood flow
P03616174A1069|25 36|temperature
P03616174A1069|215 226|circulation
P03616174A1069|15 21|change
P03618039A0126|48 58|adrenaline
P03618039A0126|22 30|patients
P03618039A0126|107 117|disruption
P03622423A0000|171 174|ppm
P03622423A0000|39 43|rats
P03622423A0000|197 200|MIC
P03622423A0000|11 15|male
P03622423A0000|45 56|B6C3F1 mice
P03622423A0000|178 195|methyl isocyanate
P03622423A0000|62 81|Hartley guinea pigs
P03625688A0372|48 58|cuff sling
P03625688A0372|37 43|collar
P03626129T0001|1 8|Effects
P03626129T0001|43 48|cells
P03628532A0000|5 9|role
P03628532A0000|79 90|experiments
P03628532A0000|13 19|saliva
P03628713A0961|86 90|days
P03628713A0961|142 156|radiation dose
P03628713A0961|10 21|experiments
P03628713A0961|208 210|Rb
P03628713A0961|31 34|AIB
P03629973A0240|1 3|W.
P03632739T0000|40 52|polymyositis
P03637037T0000|47 55|patients
P03649340A1119|36 46|precursors
P03649340A1119|165 181|splicing process
P03651840A0266|68 73|MAO-B
P03651840A0266|39 45|DPGPEA
P03651840A0266|126 141|tranylcypromine
P03651840A0266|88 94|effect
P03653226A0833|26 51|tissue-distribution study
P03659603A0797|85 93|increase
P03659603A0797|21 30|amplitude
P03659603A0797|8 15|evening
P03659994A0150|171 187|signal intensity
P03659994A0150|191 193|T2
P03659994A0150|97 105|increase
P03659994A0150|7 14|changes
P03659994A0150|59 70|abnormality
P03659994A0150|30 39|injection
P03664038A0000|21 26|study
P03664038A0000|5 12|purpose
P03664038A0000|77 108|Gudjonsson Suggestibility Scale
P03664038A0000|180 194|suggestibility
P03668003T0000|25 35|microscopy
P03668736A0177|125 130|count
P03668736A0177|147 154|element
P03668736A0177|31 43|X-ray counts
P03673640A0533|5 17|MAO subjects
P03673640A0533|142 148|scores
P03673640A0533|107 114|Anxiety
P03673640A0533|45 51|scores
P03673640A0533|119 131|Irritability
P03673640A0533|184 204|personality profiles
P03673640A0533|27 34|pattern
P03673640A0533|214 224|alcoholics
P03676054A0865|100 101|E
P03676054A0865|33 37|Vinj
P03676054A0865|4 9|group
P03676054A0865|42 44|VT
P03676054A0865|160 176|injector cannula
P03678269A0633|1 6|Today
P03678269A0633|19 24|doubt
P03678269A0633|39 64|plasma cholesterol levels
P03678269A0633|166 171|years
P03679407A0556|187 201|bladder cancer
P03679407A0556|86 93|bladder
P03679407A0556|178 182|risk
P03680791A0230|16 21|grade
P03680791A0230|98 103|sites
P03680791A0230|44 48|site
P03684378A0653|157 168|cholesterol
P03684378A0653|189 199|vitamin K1
P03684378A0653|176 185|secretion
P03684378A0653|148 152|role
P03684378A0653|44 55|correlation
P03685073A0200|19 23|dose
P03685073A0200|92 103|combination
P03685073A0200|122 136|atropine doses
P03687148T0187|16 25|September
P03688202A0377|5 11|models
P03688202A0377|44 54|boundaries
P03688676A0487|83 89|spread
P03688676A0487|93 102|infection
P03688676A0487|28 30|mm
P03691316A0560|41 45|K-CG
P03693543A0405|153 172|Nocardia asteroides
P03693543A0405|141 149|patterns
P03693543A0405|83 91|patterns
P03693543A0405|231 237|number
P03693543A0405|40 59|Rhodococcus species
P03693543A0405|241 246|peaks
P03696899T0001|77 87|adaptation
P03696899T0001|107 114|infants
P03697798T0001|81 88|trachea
P03697798T0001|29 35|muscle
P03698251T0000|1 16|Oxygen delivery
P03698251T0000|37 40|P50
P03698251T0000|75 85|infarction
P03701640A1178|201 206|WORDS
P03701640A1178|97 107|FR30 FI600
P03701640A1178|47 54|isomers
P03704087A0394|8 16|subjects
P03704087A0394|108 119|Spielberger
P03704087A0394|193 219|State Anger Reaction Scale
P03704087A0394|122 155|State-Trait Personality Inventory
P03709627A0247|186 197|metabolites
P03709627A0247|70 84|concentrations
P03709627A0247|36 43|mg dose
P03709627A0247|145 146|h
P03709627A0247|88 94|plasma
P03709627A0247|150 155|order
P03712050T0000|33 41|patients
P03712153T0000|18 55|Haemophilus influenzae type b disease
P03712153T0000|90 102|risk factors
P03714348A0833|101 115|CIC population
P03714348A0833|33 44|correlation
P03714348A0833|57 60|CIC
P03714348A0833|210 219|serum IgG
P03717475A0208|1 4|New
P03717475A0208|82 99|immunoprophylaxis
P03717475A0208|63 76|immunotherapy
P03720615A0434|21 25|part
P03720615A0434|58 69|birthweight
P03720615A0434|74 83|gestation
P03721594A0000|1 9|Adhesion
P03721594A0000|277 284|rabbits
P03721594A0000|313 334|Shwartzman phenomenon
P03721594A0000|109 128|exudate neutrophils
P03721594A0000|164 172|gelation
P03721594A0000|259 270|New Zealand
P03721594A0000|364 371|animals
P03722016A0797|35 36|P
P03722016A0797|57 70|meal interval
P03732252A0556|307 318|combination
P03732252A0556|339 344|delta
P03732252A0556|200 206|extent
P03732252A0556|230 236|amount
P03732252A0556|18 26|analyses
P03732252A0556|83 84|P
P03732252A0556|248 253|delta
P03732252A0556|240 246|change
P03733563A0820|1 9|Liver TG
P03736081A0465|170 180|blood flow
P03736081A0465|408 409|%
P03736081A0465|339 347|increase
P03736081A0465|313 314|p
P03736081A0465|45 49|torr
P03736081A0465|19 33|sinus pressure
P03736081A0465|431 432|p
P03736081A0465|417 429|% saturation
P03736081A0465|95 100|index
P03736081A0465|271 279|pressure
P03743683A0000|69 71|PP
P03743683A0000|6 12|series
P03743683A0000|120 123|age
P03743683A0000|60 67|plaques
P03744168T0001|39 42|l-1
P03744168T0001|27 37|eptazocine
P03746053A0670|1 9|Findings
P03746053A0670|66 70|area
P03746053A0670|147 160|dorsal column
P03746053A0670|121 127|column
P03746508A0390|1 9|Failures
P03746508A0390|62 72|conditions
P03746896A0890|159 166|effects
P03746896A0890|89 94|means
P03746896A0890|28 35|results
P03747493A0000|82 92|infections
P03750700T0001|19 26|outlook
P03750700T0001|31 36|wrist
P03753022A0000|11 19|lymphoma
P03755673A0054|16 21|cases
P03758250A0000|116 122|bursts
P03758250A0000|126 138|EMG activity
P03759731A0992|80 88|ml/min/1
P03759731A0992|52 54|m2
P03759731A0992|92 94|m2
P03759731A0992|56 61|group
P03761523A0000|66 77|utilization
P03761523A0000|95 103|emulsion
P03761523A0000|28 33|study
P03763836T0001|32 38|tumors
P03763836T0001|12 28|electron therapy
P03765731A0918|55 74|angina pectoris und
P03765731A0918|43 53|infarction
P03768208A0879|69 89|bone formation rates
P03768208A0879|7 14|results
P03768208A0879|56 65|increases
P03770143A1209|33 41|disorder
P03770143A1209|142 149|lesions
P03770143A1209|61 67|defect
P03771703A0000|101 109|analysis
P03771703A0000|15 39|trimethylsilylcarbamates
P03772471A1054|117 126|diagnosis
P03772471A1054|58 70|tumor biopsy
P03772471A1054|29 37|Group II
P03772471A1054|15 23|patients
P03776080A0400|17 40|post-mortem examination
P03776080A0400|106 113|animals
P03776779A0238|51 59|steroids
P03779182A0370|81 92|hepatitis B
P03779182A0370|72 77|cases
P03779182A0370|13 25|drug problem
P03780248A0274|87 94|changes
P03780248A0274|217 225|hospital
P03780248A0274|249 260|PCO2 values
P03780248A0274|125 136|ventilation
P03780248A0274|242 244|pH
P03780248A0274|44 51|infants
P03780704A0573|21 34|serum ketones
P03780704A0573|179 181|CC
P03780704A0573|95 103|quotient
P03780704A0573|166 168|CW
P03780704A0573|74 82|exercise
P03781948T0000|54 58|rats
P03785212A0091|19 48|hamster S14 protein sequences
P03788231A0802|222 232|ventricles
P03788231A0802|77 83|animal
P03788231A0802|198 207|placement
P03788231A0802|26 33|aspects
P03791645A1124|85 88|MAL
P03791645A1124|7 15|findings
P03791645A1124|44 56|relationship
P03799323A0501|16 26|hematocrit
P03799323A0501|149 154|cells
P03799323A0501|120 132|sickle cells
P03802195A0481|118 130|ToxR protein
P03802195A0481|7 22|fusion proteins
P03802195A0481|40 52|localization
P03806696A0000|35 40|HgCl2
P03806696A0000|98 106|Coturnix
P03806696A0000|55 62|CH3HgCl
P03806696A0000|266 271|trial
P03806696A0000|124 141|Coturnix japonica
P03806696A0000|166 171|hatch
P03810867A0305|55 59|T3-4
P03810867A0305|93 103|TNM system
P03810867A0305|124 136|Sisson-Jesse
P03810867A0305|105 122|Lederman-Gadeberg
P03814493T0000|18 28|interferon
P03814493T0000|57 65|lymphoma
P03818866A0116|69 83|blood pressure
P03818866A0116|19 27|behavior
P03818866A0116|123 128|women
P03824908A0116|48 56|sequence
P03824908A0116|5 20|M reading frame
P03824908A0116|215 230|paramyxoviruses
P03824908A0116|164 180|carboxy-terminus
P03828500T0001|1 16|Intensification
P03828500T0001|73 84|blood serum
P03830147A0000|475 477|mM
P03830147A0000|544 555|performance
P03830147A0000|282 287|level
P03830147A0000|261 263|mM
P03830147A0000|456 469|concentration
P03830147A0000|91 94|VO2
P03830147A0000|517 523|VO2max
P03830147A0000|169 174|level
P03830147A0000|235 248|blood lactate
P03830147A0000|381 407|blood lactate accumulation
P03830147A0000|312 339|blood lactate concentration
P03830147A0000|45 61|lactate increase
P03830147A0000|532 535|min
P03830147A0000|419 422|VO2
P03830147A0000|367 369|mM
P03835413A0616|84 96|difficulties
P03835413A0616|5 16|observation
P03835413A0616|132 137|risks
P03835413A0616|61 74|space flights
P03836853A0204|19 38|year survival rates
P03836853A0204|56 57|%
P03837609T0000|49 60|blood cells
P03837609T0000|75 88|mononucleosis
P03840480T0000|53 70|peptide sequences
P03843496A0919|112 121|chemicals
P03843496A0919|43 49|models
P03843496A0919|133 140|ability
P03848527T0020|1 14|Hisako Minowa
P03848527T0020|47 57|counsellor
P03860162A0000|1 14|Incorporation
P03860162A0000|22 29|polyene
P03860162A0000|95 104|reduction
P03860162A0000|130 134|loss
P03860162A0000|149 156|potency
P03862898A0563|203 213|components
P03862898A0563|131 150|risk classification
P03862898A0563|15 33|IgE concentrations
P03863561A0405|136 143|respect
P03863561A0405|19 31|mutans group
P03863561A0405|82 87|Strep
P03863561A0405|63 73|difference
P03866085A0795|33 56|suppository formulation
P03866085A0795|83 92|treatment
P03866085A0795|110 118|children
P03866085A0795|195 200|drugs
P03866085A0795|60 65|CZX-S
P03871298A0217|169 172|CAD
P03871298A0217|49 54|SPECT
P03871298A0217|8 23|photon emission
P03871298A0217|88 102|representation
P03873141A0304|103 111|patients
P03873141A0304|7 24|patients vagotomy
P03873141A0304|135 136|%
P03875231A0627|153 158|fluid
P03875231A0627|1 4|MRI
P03875231A0627|97 101|loss
P03875231A0627|214 218|cyst
P03875231A0627|122 137|differentiation
P03875231A0627|44 57|abnormalities
P03878585A0507|101 102|r
P03878585A0507|234 238|BFRI
P03878585A0507|67 78|correlation
P03878585A0507|193 194|r
P03878585A0507|254 260|volume
P03878585A0507|115 137|oxygen flow rate index
P03878585A0507|300 327|machine/min CPB time/m2 bsa
P03878585A0507|211 232|blood flow rate index
P03881260A0000|3 21|yeast DNA fragment
P03881260A0000|65 72|subunit
P03883052T0001|14 33|Magdelaine Comtesse
P03885983A0254|72 80|activity
P03885983A0254|28 37|indoramin
P03887769A0093|28 45|micrograms J/g Cr
P03888621A0185|16 20|gene
P03888621A0185|76 80|mass
P03888621A0185|47 62|protein product
P03891766A1473|81 85|sera
P03891766A1473|62 67|ELISA
P03896991T0000|1 15|New techniques
P03896991T0000|24 41|mass spectrometry
P03904004A1577|32 38|energy
P03904004A1577|101 119|keV 123I photopeak
P03904004A1577|147 167|breakthrough signals
P03904004A1577|74 80|window
P03908196T0000|55 68|glass ionomer
P03910310A0666|34 47|understanding
P03910310A0666|8 15|concept
P03911702A0530|50 55|means
P03911702A0530|175 179|pigs
P03911702A0530|165 171|trauma
P03912247A0282|184 193|flap ages
P03912247A0282|142 148|change
P03912247A0282|166 176|blood flow
P03912247A0282|90 94|flap
P03912247A0282|15 20|blood
P03920700A0491|100 105|alpha
P03920700A0491|108 121|adrenoceptors
P03922116A0197|5 17|distribution
P03922116A0197|131 146|lymphadenectomy
P03922116A0197|46 51|group
P03922116A0197|21 29|patients
P03922116A0197|294 299|cases
P03922116A0197|242 263|luc type installation
P03922116A0197|89 94|group
P03922116A0197|151 156|cases
P03923976T0001|32 40|embolism
P03928357A0340|1 21|Laboratory pyrolyses
P03928357A0340|67 73|yields
P03928357A0340|123 128|PCDDs
P03928357A0340|45 49|PCBs
P03928678T0000|39 50|contraction
P03929610A0268|42 50|patients
P03930894T0000|102 110|allergen
P03930894T0000|1 8|Changes
P03930894T0000|23 46|acetylcholine receptors
P03930894T0000|67 74|effects
P03930894T0000|130 135|drugs
P03931797A0134|50 53|men
P03931797A0134|27 36|psoriasis
P03931797A0134|13 23|prevalence
P03933784A0420|33 46|CSF prolactin
P03933784A0420|14 20|origin
P03935117T0000|41 74|prostaglandin E2 pharmacokinetics
P03935117T0000|31 37|oedema
P03935797A0183|257 261|beta
P03935797A0183|250 255|order
P03935797A0183|217 224|regions
P03935797A0183|110 117|embryos
P03937294A0404|136 150|acid secretion
P03937294A0404|49 63|administration
P03937294A0404|67 84|ethanol solutions
P03937294A0404|93 98|delay
P03939317A0352|36 43|regions
P03939317A0352|73 84|HS promoter
P03940733A0755|50 55|doses
P03940733A0755|32 42|absorption
P03940733A0755|109 117|approach
P03940733A0755|121 131|assessment
P03944212A0166|155 159|MCAO
P03944212A0166|66 72|matter
P03944212A0166|126 139|MCA territory
P03944212A0166|88 92|core
P03946125T0000|1 5|Drug
P03953361A0000|275 279|dogs
P03953361A0000|229 240|sinus blood
P03953361A0000|198 200|LA
P03953361A0000|17 24|effects
P03953361A0000|185 196|lactic acid
P03953361A0000|80 91|reperfusion
P03953361A0000|127 142|creatine kinase
P03953361A0000|178 180|CK
P03956695A0617|1 19|Cortisol excretion
P03956695A0617|124 130|stress
P03963860A0137|3 8|total
P03963860A0137|90 95|group
P03964855A0254|1 12|Angiography
P03964855A0254|70 79|vasospasm
P03964855A0254|60 66|degree
P03966687A0000|70 75|Vance
P03966687A0000|110 116|Annals
P03966687A0000|131 136|years
P03966687A0000|15 21|impact
P03970191A0275|114 123|potential
P03970191A0275|12 20|activity
P03970191A0275|61 79|electrocorticogram
P03972185A0137|66 79|plasma levels
P03972185A0137|112 125|hyperglycemia
P03972185A0137|46 64|insulin deficiency
P03972185A0137|14 19|state
P03976323A0821|61 71|SCR-change
P03977603A0326|1 10|Piroxicam
P03977603A0326|81 93|indomethacin
P03977603A0326|28 37|incidence
P03978132A0108|43 61|surface reflection
P03978132A0108|63 88|photoacceptor sensitivity
P03980386A0000|187 192|lambs
P03980386A0000|126 140|perfusion lung
P03980386A0000|62 70|infusion
P03980386A0000|74 86|distribution
P03980386A0000|15 22|effects
P03981640A0168|28 32|ends
P03982288T0000|1 16|Doctor Berglund
P03985849A0221|102 116|rhinosinusitis
P03985849A0221|17 31|rhinosinusitis
P03985849A0221|197 206|condition
P03985849A0221|182 188|nature
P03985849A0221|135 143|patients
P03987857A0733|35 47|floor region
P03987857A0733|131 140|intensity
P03987857A0733|104 113|mass unit
P03989827T0000|5 14|frequency
P03995513T0000|68 77|treatment
P03995513T0000|27 38|vincristine
P03995513T0000|44 60|cyclophosphamide
P03998071T0000|1 26|Electrochemical detection
P03998071T0000|76 88|osteoporosis
P03999219A0463|102 117|alum irrigation
P03999219A0463|1 15|Ultrastructure
P03999219A0463|23 28|tumor
P03999219A0463|192 199|changes
P03999219A0463|90 95|weeks
P04001413A0093|143 148|scans
P04001413A0093|10 17|purpose
P04002131A0506|53 66|GAG secretion
P04002131A0506|41 49|increase
P04002131A0506|91 107|hyperheparinuria
P04004168A0000|5 13|siblings
P04004168A0000|213 237|motor neuron involvement
P04004168A0000|148 157|movements
P04004168A0000|29 35|anemia
P04004168A0000|120 128|syndrome
P04011338A0620|39 45|degree
P04011338A0620|99 100|%
P04011338A0620|11 19|patients
P04011338A0620|49 60|steatorrhea
P04011338A0620|251 258|taurine
P04011338A0620|147 148|p
P04011338A0620|243 247|loss
P04013576A0981|169 175|lipids
P04013576A0981|185 194|exception
P04013576A0981|263 276|phospholipids
P04013576A0981|229 241|carbon atoms
P04013576A0981|13 26|investigation
P04013576A0981|134 146|distribution
P04014833A0400|65 73|response
P04014833A0400|147 155|mitogens
P04014833A0400|132 144|concanavalin
P04015988T0000|1 21|Marrow cell necrosis
P04015988T0000|58 68|starvation
P04018444A0000|18 22|acid
P04018444A0000|24 29|cheno
P04018444A0000|72 94|cholesterol gallstones
P04021281T0001|23 35|heart muscle
P04021281T0001|90 98|training
P04021431A0000|188 203|blood pressures
P04021431A0000|22 28|method
P04021431A0000|40 50|assessment
P04021431A0000|88 101|determination
P04021431A0000|151 157|system
P04024685A0650|305 308|RBV
P04024685A0650|341 342|p
P04024685A0650|337 339|ml
P04024685A0650|281 283|ml
P04024685A0650|108 113|mVolt
P04024685A0650|285 286|p
P04024685A0650|134 137|EDD
P04024685A0650|87 92|mVolt
P04024685A0650|263 265|ml
P04024685A0650|189 191|HV
P04024685A0650|24 34|parameters
P04025179A0955|33 42|variables
P04025179A0955|12 18|adults
P04028871A0133|174 177|day
P04028871A0133|113 118|doses
P04028871A0133|148 162|mg doxycycline
P04028871A0133|46 51|serum
P04032268A0358|33 35|nm
P04032268A0358|99 100|V
P04032268A0358|10 21|UV detector
P04032268A0358|63 71|detector
P04032716A0299|70 83|concentration
P04032716A0299|55 62|tissues
P04032716A0299|260 267|oviduct
P04032716A0299|108 113|blood
P04032716A0299|133 147|transfer ratio
P04034220A0205|84 91|strains
P04034220A0205|21 29|spectrum
P04034220A0205|215 223|children
P04034220A0205|63 73|ampicillin
P04036838A0918|171 172|r
P04036838A0918|98 99|p
P04036838A0918|56 61|RV/LV
P04036838A0918|149 169|pressure differences
P04036838A0918|47 51|data
P04038454A0984|170 187|cancer recurrence
P04038454A0984|140 147|mg dl-1
P04038454A0984|67 70|RBP
P04038454A0984|245 260|micrograms dl-1
P04038454A0984|104 112|patients
P04039109A0139|32 37|power
P04039109A0139|115 123|diameter
P04039109A0139|6 11|laser
P04039109A0139|109 111|mm
P04039439A0000|69 71|Mn
P04039439A0000|54 67|ppm manganese
P04039439A0000|88 103|manganese oxide
P04039439A0000|105 110|Mn3O4
P04039525A0475|239 242|DDP
P04039525A0475|80 83|DDP
P04039525A0475|196 201|order
P04039525A0475|214 222|toxicity
P04039525A0475|125 135|urinalysis
P04039744A0141|153 159|period
P04039744A0141|67 71|pups
P04039744A0141|163 172|lactation
P04039744A0141|106 116|supplement
P04039744A0141|90 97|mothers
P04040307A0145|95 104|NE levels
P04040858A0000|54 62|patients
P04040858A0000|76 82|cancer
P04041346T0000|18 29|arrhythmias
P04041346T0000|31 38|digoxin
P04048245A0331|1 10|Treatment
P04048245A0331|82 98|serum CPN levels
P04050771A0474|55 59|data
P04050771A0474|97 104|factors
P04050771A0474|63 68|order
P04051521T0001|1 9|Duration
P04051521T0001|92 95|MTX
P04051521T0001|13 22|remission
P04055593A0523|114 125|corrections
P04055593A0523|53 65|flow signals
P04055593A0523|176 187|temperature
P04055593A0523|28 38|processing
P04056256A0416|1 21|Histamine reactivity
P04056256A0416|154 172|airway conductance
P04056256A0416|92 96|mean
P04056256A0416|198 203|mg/ml
P04056256A0416|135 141|% fall
P04061342A0512|155 156|p
P04061342A0512|37 46|elevation
P04061342A0512|148 153|state
P04061342A0512|75 91|min postexercise
P04063732A0509|66 70|type
P04063732A0509|92 93|%
P04063732A0509|73 81|activity
P04066274A0265|126 130|S.P.
P04066274A0265|147 149|En
P04066274A0265|13 21|patients
P04066274A0265|105 111|T.C.P.
P04068663A0452|84 91|animals
P04068663A0452|48 54|values
P04068663A0452|172 179|rabbits
P04068663A0452|124 137|unsuitability
P04068969A0300|1 6|L3-L4
P04068969A0300|97 103|system
P04068969A0300|75 80|trunk
P04070725A0442|68 75|latency
P04070725A0442|123 132|generator
P04070725A0442|46 56|negativity
P04073848T0000|55 72|myasthenia gravis
P04073848T0000|12 34|stapedius reflexometry
P04075021T0000|87 91|cats
P04075021T0000|2 5|14C
P04075021T0000|112 140|monoamine oxidase inhibitors
P04075021T0000|77 83|routes
P04079738A0677|32 36|mean
P04079738A0677|20 30|energy use
P04079738A0677|159 169|degrees C.
P04079738A0677|75 85|kJ X min-1
P04082267A0720|23 33|incubation
P04082267A0720|73 75|Ae
P04082267A0720|121 126|virus
P04084607A0663|5 17|imino proton
P04084607A0663|37 38|T
P04084607A0663|75 80|helix
P04084607A0663|21 23|T3
P04084607A0663|158 163|field
P04084607A0663|176 179|ppm
P04084607A0663|210 233|Watson-Crick base pairs
P04085589A0264a|34 49|secretor status
P04085589A0264a|71 94|spirometry measurements
P04085589A0264a|63 69|status
P04085589A0264a|134 139|rates
P04086403A1016|1 6|Gains
P04086403A1016|20 21|%
P04086403A1016|109 117|% AS-VFA
P04086403A1016|132 136|gain
P04086403A1016|164 171|control
P04086993T0000|69 78|compounds
P04086993T0000|100 108|hamsters
P04086993T0000|39 50|methylation
P04086993T0000|129 139|conditions
P04088396A0145|36 37|%
P04088396A0145|106 114|patients
P04088936T0001|103 119|thrombophlebitis
P04088936T0001|89 97|patients
P04088936T0001|13 20|studies
P04101003T0001|1 10|Relations
P04101003T0001|39 47|activity
P04101003T0001|92 95|dog
P04103248T0000|1 12|Improvement
P04103248T0000|20 31|CRT display
P04114211T0000|7 16|excretion
P04123217T0000|1 10|Formation
P04123217T0000|43 65|Cryptococcus laurentii
P04138224T0095|34 43|vitamin A
P04138224T0095|101 108|rabbits
P04138224T0095|82 97|blood clearance
P04139943T0001|1 14|Demonstration
P04139943T0001|93 108|silver staining
P04139943T0001|72 80|electron
P04143528A0394|32 44|nomenclature
P04152725T0001|22 34|liver injury
P04164595T0020|1 9|Evidence
P04172166T0000|1 14|Poliomyelitis
P04176249T0001|50 59|diptheria
P04176249T0001|37 46|diagnosis
P04176625T0000|1 6|Value
P04176625T0000|25 34|diagnosis
P04176625T0000|14 17|EMG
P04189158T0000|24 40|Rh sensitization
P04196986T0000|36 43|studies
P04196986T0000|89 95|system
P04214345T0000|87 109|Zambian African adults
P04214345T0000|66 83|xylose absorption
P04214345T0000|26 49|serum IgG concentration
P04239041T0045|81 89|potassim
P04239041T0045|93 99|cortex
P04239041T0045|15 30|anticonvulsants
P04247472T0001|23 27|rats
P04247472T0001|61 70|Kirghizia
P04262268T0001|24 30|matrix
P04281856T0001|1 4|Age
P04281856T0001|52 78|Ornithodoros tatarovski Ol
P04284435T0000|16 34|calcium absorption
P04284435T0000|42 47|chick
P04291759T0048|49 61|chemotherapy
P04291759T0048|36 45|reference
P04305850T0000|15 21|growth
P04311951T0001|71 84|instillations
P04311951T0001|13 19|action
P04316696T0001|54 58|body
P04316696T0001|22 30|findings
P04323641T0000|12 31|swine enteroviruses
P04328746T0073|26 53|cytochrome oxidase activity
P04350410T0000|33 37|rats
P04350410T0000|12 22|foam cells
P04350410T0000|44 58|administration
P04369884T0000|1 11|Conditions
P04369884T0000|61 67|factor
P04377003A0000|236 244|patients
P04377003A0000|96 104|spermine
P04377003A0000|129 132|CSF
P04377003A0000|154 165|CSF samples
P04377003A0000|81 91|spermidine
P04377003A0000|212 215|CNS
P04377003A0000|122 127|fluid
P04385060T0000|33 40|effects
P04392584T0000|21 29|malarias
P04407649T0000|43 48|fossa
P04407649T0000|14 28|arachnoid cyst
P04423347T0001|59 64|women
P04423347T0001|46 51|women
P04428981T0000|1 9|Kinetics
P04437406T0000|16 27|description
P04437406T0000|43 65|reflection coefficient
P04437406T0000|90 101|pore theory
P04446923T0001|10 25|characteristics
P04468264T0053|35 49|anesthesiology
P04468264T0053|20 30|pediatrics
P04488232T0001|1 8|Effects
P04488232T0001|30 36|family
P04495034T0000|57 77|Ancylostomum caninum
P04495034T0000|14 27|methylbenzene
P04510102T0000|27 32|month
P04512496T0000|11 18|disease
P04518624T0000|37 42|cells
P04518624T0000|46 52|health
P04533208T0083|31 38|surgery
P04539552T0001|15 22|studies
P04544430T0001|1 12|Proceedings
P04544430T0001|56 63|surgery
P04546974T0000|19 25|timing
P04546974T0000|29 40|deflections
P04548483T0001|87 92|shock
P04548483T0001|54 67|organ changes
P04552263T0000|16 23|schools
P04552263T0000|27 34|nursing
P04563045T0000|71 87|cancer treatment
P04563045T0000|39 43|bcnu
P04563045T0000|26 37|nitrosourea
P04579436T0000|110 117|pigment
P04579436T0000|45 66|Brevibacterium linens
P04583791T0000|20 31|dermatology
P04583791T0000|9 16|history
P04600603T0001|20 29|detection
P04615525T0001|86 94|immunity
P04615525T0001|38 47|formation
P04615525T0001|30 34|sera
P04621188T0000|33 51|Klebsiella bacilli
P04624863T0001|1 10|Mechanism
P04624863T0001|98 107|shigellae
P04624863T0001|31 42|vaccination
P04632967T0000|50 62|patas monkey
P04632967T0000|20 28|pressure
P04632967T0000|79 93|administration
P04640155T0045|14 19|birth
P04646045T0001|33 42|esophagus
P04654249T0000|1 12|Measurement
P04654249T0000|26 35|responses
P04661961T0001|34 39|blood
P04661961T0001|79 86|hamster
P04679438T0001|35 40|heviz
P04679438T0001|12 18|effect
P04704137T0001|38 49|prophylaxis
P04704137T0001|23 30|studies
P04712626T0000|62 71|xanthones
P04712626T0000|30 44|gentianaceae V
P04727344T0000|38 46|steroids
P04730467T0000|1 8|Effects
P04730467T0000|39 46|rickets
P04730467T0000|12 21|cortisone
P04730467T0000|60 77|enzyme activities
P04746559T0053|1 11|Estimation
P04746559T0053|15 35|renin secretion rate
P04753073T0000|11 17|vessel
P04757217T0000|37 47|bile acids
P04757217T0000|12 25|lipoprotein-X
P04759722T0000|1 18|Polycythemia-1973
P04778129T0000|1 19|9,11-Seco steroids
P04784432T0001|69 76|animals
P04784432T0001|55 65|substances
P04787716T0000|1 13|Observations
P04787716T0000|42 64|Chrysops caecutiens L.
P04789916T0001|37 49|bengal-I-131
P04794218T0001|13 21|K agents
P04803629T0001|15 21|system
P04813394T0000|59 78|acid determinations
P04813394T0000|15 34|1,10-phenanthroline
P04824747T0000|39 47|potatoes
P04824747T0000|22 26|rats
P04828587T0000|1 10|Isolation
P04828587T0000|14 17|tha
P04839176T0001|28 37|SHF field
P04852635T0000|68 78|absorption
P04852635T0000|53 55|BC
P04852635T0000|82 103|isonicotinylhydrazine
P04871589T0001|33 42|ankylosis
P04871589T0001|9 17|solution
P04884060T0000|34 60|Pomeranian Medical Academy
P04909355T0000|18 33|Actinomycetales
P04919613T0001|70 87|collagen diseases
P04919613T0001|40 66|immunofluorescence technic
P04941951T0000|1 4|Dr.
P04947347T0000|1 14|Spleen weight
P04947347T0000|30 43|tumour growth
P04959816T0000|23 32|detection
P04970131T0001|51 56|study
P04970131T0001|73 82|embolisms
P04973523T0000|38 46|antigens
P04976988T0000|24 37|serum albumin
P04990556T0000|1 13|Reactivities
P04999086T0001|116 119|man
P04999086T0001|37 40|end
P04999086T0001|104 111|monkeys
P05005311T0000|1 15|Immunogenicity
P05005311T0000|72 88|cross-protection
P05005311T0000|62 68|levels
P05015678T0000|49 57|chlorins
P05021912T0000|19 30|sensitivity
P05027295T0034|1 15|Cholinesterase
P05028628T0001|43 60|occlusion disease
P05031659T0000|42 57|transfer factor
P05031659T0000|12 21|treatment
P05045351T0000|10 19|breathing
P05060388T0000|19 26|studies
P05060388T0000|41 47|tumors
P05066316T0001|38 47|materials
P05066316T0001|83 92|synthesis
P05066316T0001|52 63|composition
P05075857T0000|1 32|Oscilloscope triggering circuit
P05075857T0000|52 62|transients
P05083872T0000|71 80|audiology
P05083872T0000|29 46|training programs
P05091970T0000|11 17|agents
P05095988T0001|14 23|treatment
P05114515T0000|18 32|enzyme release
P05114515T0000|41 54|normalization
P05120197T0000|30 34|pigs
P05124707T0001|37 51|ulcer patients
P05128149T0001|34 39|scars
P05128149T0001|54 61|infarct
P05133723T0000|53 62|rat liver
P05133723T0000|11 21|phenformin
P05138738T0001|11 27|M hemoglobinosis
P05152314T0001|30 52|gas dilution indicator
P05170106T0034|1 8|Results
P05170106T0034|25 35|inspection
P05170106T0034|72 91|enzyme preparations
P05170106T0034|120 127|trypsin
P05172970T0001|5 12|problem
P05172970T0001|144 149|years
P05172970T0001|130 136|Gdansk
P05172970T0001|94 101|history
P05177935T0001|34 39|group
P05177935T0001|67 76|hospitals
P05177935T0001|14 27|authorization
P05210791T0001|14 22|children
P05274128T0001|49 55|tartar
P05274128T0001|5 12|content
P05276380T0000|40 63|blood coagulation tests
P05285978T0076|32 46|Cancer Society
P05303700T0066|1 13|SAM-TR-68-54
P05316745T0000|16 18|L.
P05316745T0000|52 66|Singapore City
P05316745T0000|24 40|Aedes albopictus
P05322747T0034|33 41|overload
P05322747T0034|64 74|tolazamide
P05344097T0000|69 84|Vibrio cholerae
P05344097T0000|30 65|skin permeability factor production
P05356107T0001|54 67|tritium oxide
P05356107T0001|23 31|kinetics
P05362866T0000|1 16|Renin secretion
P05364951T0001|50 57|viroses
P05364951T0001|20 32|pathogenesis
P05388567T0000|16 26|taloximine
P05388567T0000|5 12|effects
P05394352T0000|1 13|Genitography
P05410590T0000|34 44|prevention
P05410590T0000|5 9|role
P05412122T0000|64 66|,7
P05412122T0000|67 80|benzomorphans
P05412122T0000|12 20|8-methyl
P05413428T0000|5 17|distribution
P05413428T0000|43 53|hemorrhage
P05417431T0001|48 56|patients
P05417431T0001|36 40|cent
P05424220T0001|1 20|Lipid concentration
P05424220T0001|113 127|sodium content
P05424220T0001|25 40|lipase activity
P05437405T0000|86 100|salt retention
P05437405T0000|104 107|man
P05445187T0000|17 30|heat exchange
P05445187T0000|70 75|water
P05445187T0000|60 66|effect
P05456002T0000|18 33|doctor shortage
P05463837T0023|31 34|C-2
P05471866T0000|55 59|lamb
P05474466T0001|66 72|factor
P05474466T0001|46 51|assay
P05492285T0000|5 12|biology
P05497793T0000|20 41|metaraminol treatment
P05497793T0000|61 69|activity
P05501347T0001|70 80|rat kidney
P05501347T0001|54 62|function
P05501347T0001|5 11|effect
P05525652T0064|13 19|report
P05532854T0001|45 54|sclerosis
P05536803T0001|19 34|rhodanide space
P05536803T0001|7 17|body water
P05552149T0000|50 63|arthropathies
P05552149T0000|33 38|study
P05553261T0000|1 7|Health
P05556977T0001|1 14|Morphogenesis
P05556977T0001|22 32|trochanter
P05567721T0000|1 14|Sensitivities
P05567721T0000|37 58|factor VII deficiency
P05572662T0000|1 8|Central
P05593469T0001|17 25|injuries
P05595036T0001|20 28|teachers
P05595036T0001|11 18|parents
P05627251T0000|10 16|shifts
P05671267T0000|4 23|Dimethylaminopropyl
P05671267T0000|52 58|pyrido
P05683363T0001|34 38|Ca45
P05683363T0001|80 95|analysis method
P05683363T0001|60 64|rats
P05684081T0001|17 25|activity
P05684081T0001|75 90|osimeter VA-J18
P05692759T0001|24 30|cattle
P05693605T0001|18 31|transaminases
P05718386T0001|83 89|hernia
P05718386T0001|9 13|cyst
P05718386T0001|60 69|treatment
P05718994T0000|80 85|aorta
P05718994T0000|13 28|fibro-elastosis
P05719746T0001|25 31|vision
P05725509T0000|39 43|rats
P05732641T0001|35 50|mosquito larvae
P05732641T0001|11 26|sevine activity
P05733953T0001|71 80|Paramecia
P05733953T0001|59 67|activity
P05740389T0001|55 62|effects
P05749438T0001|77 83|CI-581
P05749438T0001|47 75|methyl-amino cyclohexane HCL
P05751819T0000|50 59|frequency
P05751819T0000|86 94|calvings
P05751819T0000|39 46|calving
P05751819T0000|27 35|sequence
P05760665T0000|1 18|Caries prevention
P05763347T0000|71 82|propranolol
P05763347T0000|56 65|receptors
P05774062T0000|1 12|Measurement
P05774062T0000|24 38|acid secretion
P05781385T0000|103 119|Nocardia species
P05781385T0000|5 17|significance
P05787318T0000|34 43|Atromid-S
P05787318T0000|64 67|man
P05787318T0000|11 18|effects
P05792868T0000|59 65|phloem
P05794247T0000|1 7|Effect
P05794247T0000|42 66|serum lipoprotein lipase
P05794247T0000|11 18|heparin
P05797287T0069|1 3|I.
P05799686T0001|5 16|possibility
P05799686T0001|76 85|carcinoma
P05799686T0001|120 133|incorporation
P05806615T0001|100 105|value
P05806615T0001|114 121|control
P05806615T0001|26 46|adrenaline solutions
P05806615T0001|74 80|stages
P05819249T0000|1 7|Mining
P05823624T0031|5 9|need
P05833022T0001|86 94|epilepsy
P05833022T0001|36 51|enzyme activity
P05833022T0001|8 17|character
P05837169T0001|26 34|function
P05847772T0001|29 35|ureter
P05857301T0000|50 54|rats
P05857301T0000|87 101|administration
P05857301T0000|77 83|routes
P05859016T0000|50 66|embedding medium
P05859016T0000|71 90|electron microscopy
P05881833T0001|8 17|diagnosis
P05881833T0001|45 52|control
P05890093T0000|51 62|x-radiation
P05890093T0000|98 116|hypervitaminosis-A
P05890093T0000|144 153|pregnancy
P05890093T0000|29 40|mouse fetus
P05890093T0000|73 79|trypan
P05896996T0001|4 14|catabolism
P05902458T0001|17 36|paradichlorobenzene
P05902458T0001|49 59|toxicology
P05909034T0000|21 33|preparations
P05919308T0001|1 13|Interactions
P05919308T0001|22 33|adrenergics
P05933228T0000|37 51|neurosecretion
P05939748T0000|19 28|Pap smear
P05947377T0001|71 88|growth deficiency
P05947377T0001|57 65|children
P05947377T0001|12 23|test iodine
P05959588T0000|12 28|Coxsackie B Type
P05967610T0000|52 72|noradrenaline uptake
P05967610T0000|92 100|membrane
P05967610T0000|107 126|reserpine treatment
P05982700T0000|1 6|Study
P05982700T0000|14 25|evagination
P05992157T0001|5 18|pathogenicity
P05992157T0001|79 86|animals
P05995140T0001|19 31|significance
P05995140T0001|8 14|amount
P06012827T0000|84 88|rats
P06035001T0000|39 50|guinea pigs
P06035001T0000|9 21|observations
P06035001T0000|75 86|trypan blue
P06051644T0000|9 13|Slot
P06051644T0000|40 53|determination
P06065507T0000|46 50|rats
P06073427T0001|51 61|interferon
P06073427T0001|69 74|blood
P06073427T0001|88 95|rabbits
P06074640T0001|31 47|encephalopathies
P06084810A0169|33 49|polysome complex
P06084810A0169|97 99|D.
P06085839A0721|23 34|possibility
P06089575A0464|152 157|level
P06089575A0464|1 12|Stimulation
P06089575A0464|163 166|min
P06089575A0464|56 65|elevation
P06090458A0407|102 109|TK gene
P06090458A0407|65 76|orientation
P06090458A0407|129 140|orientation
P06092048A1111|64 72|fibrosis
P06092048A1111|45 51|burden
P06093354A0000|51 65|leukemia virus
P06093354A0000|141 148|library
P06093354A0000|67 71|MuLV
P06094591A0000|51 54|RSV
P06094591A0000|191 197|domain
P06094591A0000|173 177|acid
P06094591A0000|92 100|membrane
P06094591A0000|133 139|domain
P06094591A0000|31 49|Rous sarcoma virus
P06095774T0001|14 21|aspects
P06096380A0662|141 145|mRNA
P06096380A0662|83 92|kilobases
P06096380A0662|27 60|phosphoenolpyruvate carboxykinase
P06096380A0662|180 183|rat
P06097027A0000|99 110|comparisons
P06097027A0000|40 66|erythroblastosis virus E26
P06097027A0000|165 178|tumor viruses
P06098719A0369|66 70|drug
P06099656T0000|103 119|cotransformation
P06099656T0000|64 99|adenovirus DNA binding protein gene
P06099656T0000|129 142|HSV-1 tk gene
P06108610A0518|39 60|modality shift effect
P06110026T0000|19 27|approach
P06113084T0000|9 23|taurine levels
P06113084T0000|89 103|cardiomyopathy
P06119262T0000|42 51|pregnancy
P06121577A0280|102 104|mg
P06121577A0280|117 119|mg
P06121577A0280|185 194|decreases
P06121577A0280|213 234|plasma renin activity
P06121577A0280|198 208|heart rate
P06121577A0280|89 94|doses
P06131038A0000|1 7|Plasma
P06131038A0000|141 150|incidence
P06131038A0000|72 90|postheparin plasma
P06131038A0000|192 196|beds
P06136374A0151|68 85|swimming velocity
P06136374A0151|29 32|VO2
P06141764A0339|1 29|Hybrid-selection experiments
P06141764A0339|81 92|plasmid DNA
P06141764A0339|106 112|clones
P06143734T0000|10 20|metabolism
P06150069A0422|50 55|weeks
P06150069A0422|83 96|neurotoxicity
P06150069A0422|61 78|dose modification
P06151942A0235|16 20|acid
P06151942A0235|191 198|obesity
P06151942A0235|54 65|association
P06151942A0235|128 142|blood pressure
P06151942A0235|150 161|cholesterol
P06152844T0000|1 7|Effect
P06152844T0000|11 21|bromazepam
P06152844T0000|44 63|prolactin secretion
P06155967A1132|51 69|reporting terminal
P06155967A1132|5 17|radiologists
P06155967A1132|28 35|machine
P06161823A0129|50 67|ethinyl estradiol
P06161823A0129|12 20|capsules
P06163433T0000|1 7|Effect
P06163433T0000|113 122|rat brain
P06163433T0000|29 45|cyclopropylamine
P06165132A0000|103 114|spray lento
P06165132A0000|4 14|experiment
P06165132A0000|173 183|pseodopest
P06165132A0000|129 137|vaccines
P06165132A0000|242 247|virus
P06165132A0000|211 223|pseudoplague
P06167806A0000|32 51|dimethylpropranolol
P06167806A0000|5 12|ability
P06167806A0000|113 129|tachyarrhythmias
P06167806A0000|24 30|UM-272
P06167806A0000|160 163|dog
P06173860A0000|35 45|infarction
P06173860A0000|97 116|contralateral leads
P06181216A0070|39 47|patients
P06181216A0070|61 85|serum IgA concentrations
P06184276T0001|9 15|course
P06185014A0642|114 122|increase
P06185014A0642|59 60|%
P06189698A0246|154 156|N2
P06189698A0246|161 174|P3 amplitudes
P06189698A0246|106 115|amplitude
P06193351A1010|69 78|incidence
P06193351A1010|19 33|administration
P06193351A1010|129 145|artery occlusion
P06198532A0982|119 122|RHD
P06198532A0982|196 211|thromboembolism
P06198532A0982|89 91|MS
P06198532A0982|150 156|causes
P06198532A0982|45 53|tendency
P06200300A0409|67 83|scalp electrodes
P06200300A0409|10 20|electrodes
P06204120T0001|42 56|identification
P06204120T0001|12 37|immunofluorescence method
P06208477A0000|115 124|Acids Res
P06208477A0000|57 60|DNA
P06208477A0000|29 36|library
P06209499A0682|69 72|MAP
P06209499A0682|23 42|transmitter release
P06209499A0682|125 136|bradycardia
P06209499A0682|61 65|fall
P06214605A0123|34 39|sizes
P06214605A0123|5 11|number
P06214605A0123|15 23|elements
P06217859T0000|21 27|tensor
P06223586A0000|1 19|Immunochemotherapy
P06223586A0000|127 140|mouse systems
P06223586A0000|25 38|schizophyllan
P06224974A0833|69 72|CPA
P06224974A0833|55 65|metabolite
P06224974A0833|40 52|beta-hydroxy
P06227570A0523|4 12|contrast
P06227570A0523|57 76|suppressor response
P06230499A0128|140 152|summary dose
P06230499A0128|203 207|days
P06230499A0128|43 54|irradiation
P06230499A0128|106 110|dose
P06230499A0128|344 351|results
P06230499A0128|257 268|performance
P06230499A0128|159 161|Gy
P06230499A0128|384 402|dose fractionation
P06234369T0000|13 24|vaccination
P06237518A0117|98 102|CNCl
P06237518A0117|43 47|acid
P06237518A0117|135 141|system
P06237518A0117|15 31|coupling reagent
P06238704T0001|27 44|acid diethylamide
P06240448A0652|139 145|output
P06240448A0652|276 294|pretreatment level
P06240448A0652|348 358|resistance
P06240448A0652|319 327|decrease
P06240448A0652|15 24|treatment
P06240448A0652|153 159|change
P06240448A0652|59 65|phases
P06240448A0652|91 100|reduction
P06241980A0855|136 145|diffusion
P06241980A0855|115 121|models
P06241980A0855|63 72|diffusion
P06244732T0000|21 54|serum creatine kinase B isoenzyme
P06244732T0000|62 71|diagnosis
P06246254A0676|87 100|src sequences
P06246254A0676|191 197|length
P06246254A0676|24 45|heteroduplex analyses
P06246254A0676|121 127|center
P06252520T0000|1 15|Catecholamines
P06252520T0000|29 37|learning
P06254403A0000|39 54|SA-11 rotavirus
P06254403A0000|27 35|chickens
P06258699T0000|16 21|trial
P06258699T0000|59 80|GU bladder irrigation
P06259220A0000|152 157|shock
P06259220A0000|255 269|shock exposure
P06259220A0000|234 236|hr
P06259220A0000|6 17|experiments
P06259220A0000|225 230|shock
P06259220A0000|211 221|reexposure
P06259389A0000|24 27|May
P06259389A0000|12 18|period
P06259389A0000|90 94|HFMD
P06259389A0000|60 64|hand
P06272844A0000|117 121|rate
P06272844A0000|158 163|MNase
P06272844A0000|93 104|chromosomes
P06272844A0000|148 156|nuclease
P06272844A0000|30 34|SV40
P06278424A0145|117 125|gamma 2b
P06278424A0145|26 38|requirements
P06278424A0145|151 157|MPC-11
P06279309A0000|5 11|genome
P06279309A0000|95 101|v-erbA
P06279309A0000|106 112|v-erbB
P06279309A0000|120 130|activities
P06281786A1222|21 31|lambda HHG
P06281786A1222|82 88|region
P06281786A1222|146 157|nucleotides
P06281786A1222|14 19|clone
P06286191T0000|1 12|Restoration
P06286549A0000|205 227|gamma-radiation injury
P06286549A0000|111 114|gut
P06286549A0000|195 199|mice
P06286549A0000|17 33|aminopropylamino
P06286549A0000|116 120|lung
P06286549A0000|92 99|ability
P06286549A0000|145 157|fibrosarcoma
P06287231A0914|51 62|nucleosomes
P06287231A0914|4 12|addition
P06287231A0914|121 141|bulk yeast chromatin
P06290859A0426|136 137|%
P06290859A0426|49 50|%
P06290859A0426|8 28|hepatitis B patients
P06290859A0426|40 46|months
P06291369A0000|272 280|pressure
P06291369A0000|217 221|RVEF
P06291369A0000|7 15|patients
P06291369A0000|148 156|portions
P06295429A0412|170 180|protection
P06295429A0412|20 24|MISO
P06295429A0412|58 66|response
P06295429A0412|29 36|WR-2721
P06295429A0412|88 92|drug
P06298014A0647|125 132|columns
P06298014A0647|56 64|activity
P06300662T0000|50 62|cDNA inserts
P06300662T0000|36 46|expression
P06304771A1284|69 83|polyomaviruses
P06304771A1284|141 156|DNA replication
P06304771A1284|9 17|sequence
P06304771A1284|133 137|role
P06304771A1284|164 177|transcription
P06307099A1005|75 82|animals
P06308607A0375|168 187|polymerase sequence
P06308607A0375|5 14|junctions
P06308607A0375|147 158|nucleotides
P06309855T0000|1 22|Gel route preparation
P06309855T0000|30 36|fusing
P06310159A0000|64 71|protein
P06310159A0000|40 43|DNA
P06310553T0000|11 20|structure
P06314276T0000|118 131|gene promoter
P06314276T0000|1 9|Plasmids
P06314276T0000|99 103|SV40
P06314276T0000|30 40|expression
P06316347A0852|38 43|genes
P06316347A0852|23 31|rnh-lacZ
P06318078T0000|1 11|Expression
P06318078T0000|113 131|alpha gene product
P06318078T0000|45 56|gamma genes
P06318322A0350|69 82|recombination
P06318322A0350|116 123|sarcoma
P06318322A0350|145 154|proto-sis
P06318322A0350|225 238|messenger RNA
P06318322A0350|164 171|introns
P06319071A0173|64 85|calcium stone-formers
P06319071A0173|234 247|units mumol/g
P06319071A0173|8 16|subjects
P06319071A0173|210 213|AMP
P06319421A0937|70 76|uptake
P06319421A0937|5 11|effect
P06319421A0937|89 102|amitriptyline
P06319421A0937|47 57|inhibition
P06320380T0001|1 19|Surgical treatment
P06321634A0123|119 124|bases
P06321634A0123|23 28|mRNAs
P06321634A0123|72 77|bases
P06322183A1070|1 17|NPT II synthesis
P06322183A1070|80 99|immunoprecipitation
P06322183A1070|52 72|kanamycin resistance
P06322183A1070|107 121|NPT II protein
P06324089A0453|116 121|genes
P06324089A0453|47 53|region
P06324089A0453|30 34|GAL7
P06325415A0757|158 169|Ad5 protein
P06325415A0757|96 107|amino acids
P06325415A0757|77 88|Ad7 protein
P06325415A0757|14 24|difference
P06327292A0846|17 41|Shine-Dalgarno sequences
P06328002A0000|71 92|Moloney sarcoma virus
P06328002A0000|112 116|mice
P06328002A0000|94 101|Mo-MuSV
P06328504A0161|1 4|USA
P06328504A0161|48 66|clone lambda PGK-1
P06328504A0161|80 87|portion
P06330478A0304|38 47|mg q.i.d.
P06330478A0304|5 13|patients
P06330478A0304|72 74|mg
P06333433A0000|184 202|lipopolysaccharide
P06333433A0000|8 16|isolates
P06333433A0000|167 174|profile
P06336045A0261a|153 156|TRP
P06336045A0261a|169 174|phase
P06336045A0261a|81 87|spikes
P06336045A0261a|188 193|spike
P06336045A0261a|127 151|threshold response phase
P06336045A0261a|62 64|SA
P06340643A0598|1 5|DMCM
P06340643A0598|81 93|donor organs
P06341139A0213|1 14|Blood glucose
P06341139A0213|207 215|potatoes
P06341139A0213|172 173|g
P06341139A0213|160 167|g honey
P06341139A0213|133 141|fructose
P06341139A0213|19 33|plasma insulin
P06341139A0213|145 152|lactose
P06341139A0213|122 131|g glucose
P06342141A0226|347 363|value judgements
P06342141A0226|154 160|safety
P06342141A0226|563 570|queries
P06342141A0226|331 338|members
P06342141A0226|90 101|sensitivity
P06342141A0226|444 471|health care delivery system
P06342141A0226|583 592|questions
P06342141A0226|106 117|specificity
P06342141A0226|254 258|type
P06342141A0226|488 492|care
P06342141A0226|59 81|family pathophysiology
P06342141A0226|480 484|type
P06342141A0226|539 546|attempt
P06346427A0000|110 120|test-meals
P06350092A0916|84 88|VPBs
P06350092A0916|190 201|possibility
P06350092A0916|59 69|occurrence
P06350092A0916|167 174|disease
P06350092A0916|30 33|AMI
P06355483A0134|117 122|locus
P06355483A0134|99 109|base-pairs
P06355483A0134|131 141|base-pairs
P06361318A0440|71 76|cases
P06361318A0440|83 88|group
P06361318A0440|163 174|KS-R1 group
P06361318A0440|95 100|cases
P06361318A0440|46 51|cases
P06361318A0440|14 28|efficacy rates
P06362143A0565|1 22|Plasma renin activity
P06362143A0565|41 49|response
P06362602T0001|1 12|Enhancement
P06362602T0001|110 115|swine
P06362602T0001|27 35|response
P06362602T0001|94 106|immunization
P06367414A0000|1 9|Bepridil
P06367414A0000|94 101|placebo
P06367414A0000|13 31|calcium antagonist
P06369954T0000|58 70|hemodynamics
P06372563T0000|19 28|captopril
P06372563T0000|39 52|heart failure
P06372563T0000|76 87|natriuresis
P06372563T0000|62 72|furosemide
P06373855A0000|137 142|acuta
P06373855A0000|83 91|patients
P06373855A0000|8 24|biopsy specimens
P06373855A0000|199 224|immunoperoxidase technics
P06373855A0000|47 52|dusky
P06374418A0877|33 37|cyst
P06374418A0877|96 103|hormone
P06379363A0415|152 160|practice
P06379363A0415|41 47|HDL-2M
P06379363A0415|14 19|tests
P06382374A0206|32 54|insulin administration
P06382374A0206|235 251|control subjects
P06382374A0206|188 196|patients
P06382374A0206|126 134|patients
P06382374A0206|60 64|rate
P06385474T0001|23 31|children
P06388818A0000|65 74|lymphomas
P06388818A0000|37 44|Hodgkin
P06388818A0000|212 218|rescue
P06388818A0000|268 272|ABMT
P06388818A0000|181 193|chemotherapy
P06394228T0073|25 30|study
P06395804A0382|1 16|Urease activity
P06395804A0382|22 23|%
P06401749T0000|5 11|effect
P06401749T0000|15 22|lithium
P06402859A0000|139 150|coagulation
P06402859A0000|112 121|modulator
P06402859A0000|75 84|inhibitor
P06406060A0000|16 25|cisplatin
P06406060A0000|76 80|mice
P06406060A0000|89 96|Sarcoma
P06411659A0264|19 31|measurements
P06411659A0264|4 14|facilities
P06412385A0356|200 209|increases
P06412385A0356|314 325|ventilators
P06412385A0356|286 296|likelihood
P06412385A0356|344 353|pneumonia
P06412385A0356|327 338|atelectasis
P06412385A0356|222 228|volume
P06412385A0356|266 271|PaCO2
P06412385A0356|242 264|carbon dioxide tension
P06414990A0057|51 57|sample
P06414990A0057|100 110|evaluation
P06414990A0057|145 165|thyrotropin response
P06414990A0057|72 82|volunteers
P06414990A0057|181 185|area
P06419251T0000|33 46|understanding
P06428116T0000|38 52|hypothyroidism
P06428116T0000|60 66|course
P06433442T0000|37 42|yield
P06433442T0000|46 52|factor
P06434587A0551|118 121|LRH
P06434587A0551|101 114|FSH responses
P06434587A0551|6 13|patient
P06434587A0551|29 31|LH
P06437579A0727|16 18|mg
P06437579A0727|57 59|mg
P06437579A0727|109 127|patient compliance
P06439135A0250|1 13|Regional CBF
P06439135A0250|106 116|procedures
P06439135A0250|90 96|bypass
P06443550T0000|33 40|patient
P06443714T0001|12 34|Rhodnius prolixus Stal
P06446048A0356|38 45|by-pass
P06446048A0356|120 127|problem
P06452461A0930|49 53|PWVn
P06452461A0930|23 34|correlation
P06453290A0000|116 124|material
P06453290A0000|37 49|organization
P06453290A0000|74 79|ducts
P06459831T0001|48 57|reactions
P06460889A0512|152 163|LVdP/dt max
P06460889A0512|34 39|SG-75
P06460889A0512|19 32|.3 mg/kg i.v.
P06460889A0512|143 146|LVP
P06460889A0512|104 114|blood flow
P06466804A0686|69 83|tape recording
P06466804A0686|101 115|flow waveforms
P06466804A0686|200 205|shear
P06466804A0686|133 142|flowmeter
P06466804A0686|164 170|injury
P06467797A0233|200 201|P
P06467797A0233|65 81|10-hydroxylation
P06467797A0233|135 144|Ghanaians
P06467797A0233|158 159|P
P06467797A0233|59 61|NT
P06467797A0233|121 126|urine
P06467797A0233|90 91|D
P06468632A0135|87 101|artery forceps
P06468632A0135|131 137|vessel
P06468632A0135|28 38|ear artery
P06468694A0441|101 110|dophamine
P06468694A0441|217 226|behaviour
P06468694A0441|83 97|administration
P06468694A0441|131 140|phenamine
P06468694A0441|148 161|deterioration
P06468694A0441|74 79|means
P06473252A1073|98 104|factor
P06473252A1073|6 16|experiment
P06473252A1073|132 137|WORDS
P06479976A0386|223 224|P
P06479976A0386|96 109|survival time
P06479976A0386|22 33|differences
P06479976A0386|133 140|illness
P06479976A0386|120 129|diagnosis
P06482179A0497|1 16|Catch-up growth
P06482179A0497|78 86|bone age
P06482665A0735|152 167|pigtail monkeys
P06482665A0735|296 302|animal
P06482665A0735|133 148|caudate nucleus
P06482665A0735|73 81|increase
P06482665A0735|31 50|AMPH administration
P06486932A0000|68 71|age
P06486932A0000|139 147|symptoms
P06486932A0000|52 58|people
P06486932A0000|26 27|%
P06486932A0000|107 114|Nigeria
P06492188A0615|66 74|implants
P06492188A0615|56 62|number
P06494215A0248|5 19|response chain
P06494215A0248|56 73|food presentation
P06494766A0241|22 32|dispersion
P06494766A0241|46 67|Hiss bundle fragments
P06497671T0001|1 8|Changes
P06497671T0001|12 33|plasma cortisol level
P06503132A0784|1 4|SFP
P06503885A0342|220 230|blood flow
P06503885A0342|184 198|overestimation
P06503885A0342|53 57|rise
P06503885A0342|232 236|rCBF
P06503885A0342|316 335|interscan intervals
P06503885A0342|75 86|temperature
P06506074A0456|98 99|X
P06506074A0456|110 112|X.
P06506074A0456|44 46|PL
P06506074A0456|50 51|X
P06506074A0456|92 94|PL
P06506074A0456|89 90|X
P06508393T0000|1 14|Serodiagnosis
P06508393T0000|62 89|card agglutination test set
P06508393T0000|91 103|Testryp CATT
P06516369T0001|55 63|problems
P06516977T0000|19 27|organism
P06520418A0325|118 122|type
P06520418A0325|169 177|patients
P06520418A0325|191 192|p
P06520418A0325|183 187|type
P06520418A0325|134 160|LVIT flow velocity pattern
P06521999A0677|76 87|enucleation
P06524727A0601|136 137|C
P06524727A0601|48 57|responses
P06524727A0601|97 101|hour
P06524727A0601|147 161|blood dilution
P06527379T0044|86 98|DNA sequence
P06527379T0044|13 37|proline/alanine sequence
P06531286A0382|1 8|Removal
P06531286A0382|54 60|hexane
P06531286A0382|31 48|plant extractions
P06539738T0000|33 51|chlorofluorocarbon
P06541932A0000|1 8|Methods
P06541932A0000|38 49|algesimetry
P06542918A1131|136 148|P3 latencies
P06542918A1131|82 92|evaluation
P06546392A0542|85 115|erythrocyte sedimentation rate
P06546392A0542|159 172|antiproteases
P06546392A0542|73 83|cell count
P06546392A0542|121 132|temperature
P06555107A1227|108 117|treatment
P06555107A1227|123 136|beta-mimetics
P06571587T0000|1 8|Effects
P06571587T0000|81 85|dogs
P06571587T0000|40 49|functions
P06579152A1061|118 135|feed-back control
P06579152A1061|37 40|NPF
P06579152A1061|63 73|activation
P06584416A0157|51 55|data
P06584416A0157|7 19|radiologists
P06584416A0157|41 49|patients
P06584416A0157|105 117|examinations
P06588306A0076|50 57|therapy
P06588306A0076|65 77|meningopathy
P06588306A0076|22 44|prophylactic treatment
P06591992A0569|4 16|anisotropism
P06594105A0560|42 51|degrees C
P06594105A0560|287 297|degrees C.
P06594105A0560|119 125|tongue
P06594105A0560|155 160|gland
P06594105A0560|250 261|temperature
P06594105A0560|26 35|lambda tb
P06599282T0001|34 48|cell carcinoma
P06599282T0001|14 21|pattern
P06602580A0664|38 51|complications
P06602580A0664|124 154|alpha 1-antitrypsin deficiency
P06602580A0664|88 97|frequency
P06606043A0598|85 97|phenyl group
P06606043A0598|141 149|activity
P06606043A0598|66 77|replacement
P06606043A0598|11 18|changes
P06607714T0000|20 24|rats
P06610347A0581|102 109|AV node
P06610347A0581|27 38|AV junction
P06610347A0581|12 19|periods
P06615053A0202|117 121|RVEF
P06615053A0202|9 17|patients
P06615053A0202|107 115|ejection
P06625058A0666|81 87|capita
P06625058A0666|72 76|cost
P06627569T0001|7 33|type oculomotor stimulator
P06630319A0244|142 162|halothane anesthesia
P06630319A0244|42 50|ischemia
P06630319A0244|73 78|value
P06643612A0000|70 77|studies
P06643612A0000|95 101|plasma
P06643612A0000|28 35|methods
P06652293A0353|68 79|sensitivity
P06652293A0353|122 123|%
P06652293A0353|105 116|specificity
P06654047A0694|38 45|variant
P06654047A0694|162 166|case
P06654047A0694|180 196|rhabdomyosarcoma
P06655634A0195|101 105|rate
P06655634A0195|76 95|cesarean deliveries
P06655634A0195|12 18|series
P06655634A0195|45 48|TOL
P06657559A0489|1 6|Trial
P06657559A0489|101 105|time
P06657559A0489|142 144|hr
P06657559A0489|9 25|broiler chickens
P06657559A0489|79 84|weeks
P06657559A0489|187 191|feed
P06657559A0489|299 301|hr
P06658445A0140|32 35|man
P06658445A0140|20 27|animals
P06658445A0140|91 97|intake
P06659982A0231|38 50|sleep period
P06659982A0231|5 13|analysis
P06659982A0231|173 183|parameters
P06659982A0231|135 137|QS
P06659982A0231|117 122|stage
P06659982A0231|352 356|year
P06659982A0231|218 223|phase
P06659982A0231|334 338|ones
P06667015A0832|156 173|serum CK-MB level
P06667015A0832|80 89|ischaemia
P06667015A0832|124 132|recovery
P06667015A0832|13 21|findings
P06668316A0178|51 67|phosphate buffer
P06668316A0178|69 81|acetonitrile
P06668316A0178|22 43|reversed-phase column
P06668316A0178|89 94|phase
P06668316A0178|135 146|metabolites
P06670732A0000|71 82|anaesthesia
P06670732A0000|203 211|Atropine
P06670732A0000|40 43|ASA
P06670732A0000|187 197|Thalamonal
P06670732A0000|218 228|mg/kg b.w.
P06670732A0000|159 169|Droperidol
P06670732A0000|58 67|induction
P06670732A0000|122 133|combination
P06670732A0000|151 153|mg
P06671065A0000|1 13|Serum lipids
P06671065A0000|64 72|children
P06671065A0000|123 129|status
P06671925T0000|101 111|impairment
P06671925T0000|38 51|blister fluid
P06671925T0000|28 33|serum
P06674374T0000|87 109|hepatitis B endemicity
P06674374T0000|63 70|country
P06674977A1181|53 58|table
P06674977A1181|27 28|%
P06674977A1181|14 22|families
P06683807A0160|49 59|prevalence
P06683807A0160|14 22|patients
P06684624A0298|96 104|diet 41B
P06685004A0000|156 161|women
P06685004A0000|5 17|associations
P06685004A0000|145 148|men
P06685004A0000|94 97|BMI
P06685004A0000|46 63|globulin capacity
P06685536A0502|52 56|ewes
P06685536A0502|91 102|enucleation
P06686454A0585|117 125|Shigella
P06686454A0585|20 28|activity
P06686454A0585|92 115|Klebsiella-Enterobacter
P06689413A0174|86 91|mm2 X
P06689413A0174|5 14|apparatus
P06689413A0174|178 184|iodine
P06689413A0174|94 96|mm
P06689413A0174|132 138|x-rays
P06691304A0284|154 164|age groups
P06691304A0284|97 104|analyte
P06691304A0284|56 62|values
P06691304A0284|132 139|females
P06691304A0284|14 34|serum concentrations
P06692631A0129|39 45|stress
P06692631A0129|82 86|bone
P06694778A0000|119 125|course
P06694778A0000|129 141|hemodialysis
P06694778A0000|14 35|hemodialysis patients
P06700231A0259|82 87|sizes
P06700231A0259|57 70|tumor nodules
P06702257T0001|1 17|Antithrombin III
P06704467A0539|17 28|sensitivity
P06704467A0539|80 87|mammals
P06704467A0539|108 120|pineal gland
P06707357A0180|187 192|types
P06707357A0180|33 41|patients
P06707357A0180|105 122|valve replacement
P06709700A0230|115 132|Melancholia Scale
P06709700A0230|65 73|subscale
P06709700A0230|52 62|depression
P06709700A0230|176 186|perfection
P06709700A0230|27 36|dimension
P06712314A0148|24 29|cases
P06712314A0148|62 74|institutions
P06713204A0867|5 18|AD components
P06713204A0867|78 81|rat
P06714354A0194|1 8|Monkeys
P06716977A0136|69 75|losses
P06716977A0136|113 122|mg% range
P06716977A0136|25 32|decline
P06719057A0181|100 114|filing defects
P06719057A0181|5 15|importance
P06719057A0181|60 70|evaluation
P06721188A0200|41 47|F test
P06721188A0200|60 68|Snedecor
P06726257A1179|160 166|cortex
P06726257A1179|14 23|reduction
P06726257A1179|48 53|5-HTP
P06726257A1179|296 301|WORDS
P06726257A1179|27 46|5-hydroxytryptophan
P06726257A1179|91 102|differences
P06726257A1179|120 132|methiothepin
P06728580A0291|33 40|El Paso
P06728580A0291|43 45|TX
P06728580A0291|89 97|criteria
P06728580A0291|13 20|measles
P06732946A0281|55 67|fibrinolysis
P06732946A0281|172 181|Videoplan
P06732946A0281|92 97|times
P06732946A0281|147 148|X
P06732946A0281|44 50|tissue
P06735247A0803|80 88|patients
P06735247A0803|59 66|minutes
P06735247A0803|14 49|plasma enteroglucagon concentration
P06740373A0891|98 104|rhesus
P06740373A0891|124 142|drug testing model
P06740919A0162|70 80|heartwater
P06740919A0162|96 99|Bos
P06740919A0162|7 24|Amblyomma lepidum
P06744024A0000|1 9|Morphine
P06744024A0000|36 45|ventricle
P06744024A0000|77 86|analgesia
P06749072A0116|32 41|clearance
P06749072A0116|112 127|water immersion
P06749072A0116|9 24|urate excretion
P06749072A0116|150 154|hour
P06751455A0117|114 121|placebo
P06751455A0117|66 75|remainder
P06754662T0001|9 34|angiolymphoid hyperplasia
P06755986A0382|16 23|strains
P06755986A0382|38 44|humans
P06755986A0382|56 73|toxico-infections
P06762025A0171|51 61|PGF2 alpha
P06762025A0171|110 116|effect
P06763897A0216|102 106|Ile8
P06763897A0216|5 17|hypertension
P06763897A0216|83 86|AII
P06763897A0216|108 111|ALL
P06767648A0734|17 26|perfusion
P06767648A0734|80 87|therapy
P06772612A0000|85 112|carotid body chemoreceptors
P06772612A0000|116 123|hypoxia
P06772612A0000|128 139|hypercapnia
P06772612A0000|177 181|cats
P06772612A0000|12 20|dopamine
P06781728A0690|139 144|rates
P06781728A0690|39 60|osteoprogenitor cells
P06781728A0690|5 16|alterations
P06781728A0690|229 233|rats
P06781728A0690|91 105|mineralization
P06782869A0263|157 166|serum LDH
P06782869A0263|112 132|creatinine clearance
P06782869A0263|94 110|serum creatinine
P06782869A0263|46 59|complications
P06782869A0263|134 143|serum CO2
P06784123A0771|138 145|mu chin
P06784123A0771|12 20|C mu RNA
P06785113A0337|88 93|mucus
P06785113A0337|45 53|activity
P06788388A0000|175 183|interest
P06788388A0000|37 45|ICRF-159
P06788388A0000|14 23|mechanism
P06791500A0622|5 15|evaluation
P06791500A0622|28 45|fluid delta OD450
P06794480A0785|71 77|others
P06794480A0785|30 40|difference
P06795119T0000|52 61|cataracts
P06795832A0148|39 50|HBe-antigen
P06795832A0148|8 14|course
P06795832A0148|74 77|IgG
P06795971A0000|33 45|model system
P06795971A0000|5 16|rat incisor
P06797063A0000|36 57|antigen concentration
P06797063A0000|145 153|patients
P06797063A0000|89 108|ristocetin cofactor
P06797063A0000|13 34|procoagulant activity
P06801778T0001|115 129|commissurotomy
P06801778T0001|91 104|effectiveness
P06803634A0810|49 57|patients
P06803634A0810|86 93|respect
P06803634A0810|214 223|responses
P06803634A0810|177 185|patients
P06803634A0810|227 231|sons
P06803634A0810|62 66|sons
P06805537T0001|64 75|concentrate
P06805537T0001|13 33|hemophilia treatment
P06807149T0000|1 11|Comparison
P06807149T0000|107 119|bronchospasm
P06807149T0000|31 43|preparations
P06807659T0001|37 48|macrophages
P06808529A0167|18 37|isoniazid solutions
P06808529A0167|5 14|stability
P06808529A0167|73 76|NTA
P06809586T0000|39 58|diabetes management
P06810694A0328|49 67|VLDL-triglycerides
P06810694A0328|5 13|decrease
P06812389A0658|1 6|TEMTU
P06812389A0658|11 15|DPTU
P06816053A0849|35 49|drug reactions
P06816053A0849|8 16|patients
P06816442T0001|21 36|serum myoglobin
P06816442T0001|63 70|disease
P06817410A0982|84 95|hepatitis A
P06817410A0982|169 173|type
P06817410A0982|33 38|study
P06817410A0982|193 205|drug addicts
P06817410A0982|151 160|incidence
P06821147A0468|51 59|isolates
P06821147A0468|27 30|g N
P06823837A0562|39 49|wavefronts
P06823837A0562|122 135|outflow tract
P06826813A0264|59 62|UVA
P06829082A0187|237 248|hypothermia
P06829082A0187|140 163|incubation temperatures
P06829082A0187|41 50|degrees C
P06829082A0187|183 192|degrees C
P06829082A0187|90 124|brain tissues glutaminase activity
P06830351A0397|87 88|%
P06830351A0397|110 114|Type
P06830351A0397|24 38|classification
P06830351A0397|74 81|Type Ib
P06830351A0397|90 94|Type
P06833422T0000|21 41|alpha-hydroxy-9 beta
P06833422T0000|95 109|ion monitoring
P06833422T0000|45 59|alpha-pregna-4
P06835914A0192|1 18|Copper treatments
P06835914A0192|188 196|industry
P06835914A0192|59 65|levels
P06838388A0896|186 194|function
P06838388A0896|206 209|day
P06838388A0896|20 31|development
P06838388A0896|113 129|parenchyma areas
P06838388A0896|164 169|organ
P06842629A0446|13 28|GMBF reductions
P06849842T0000|1 34|Penicillin-G degradation products
P06851327A0000|20 24|type
P06851327A0000|124 130|period
P06851327A0000|45 54|infection
P06854957T0066|1 10|Detection
P06856669A1004|51 61|metabolism
P06856669A1004|82 88|efflux
P06856669A1004|144 155|circulation
P06856669A1004|92 98|5-HIAA
P06858640A0262|49 55|origin
P06858640A0262|8 13|basis
P06858967A0167|1 28|Serum lactate dehydrogenase
P06858967A0167|75 84|bilirubin
P06864837T0000|22 50|spine immobilization methods
P06868345A0000|32 37|Italy
P06868345A0000|5 13|presence
P06869986A0000|66 74|collagen
P06869986A0000|13 22|platelets
P06873504T0000|96 111|liver cirrhosis
P06873504T0000|14 27|relationships
P06876006A0930|101 102|%
P06876006A0930|79 89|sonography
P06880563A0516|50 54|type
P06880563A0516|19 23|CPAF
P06880563A0516|5 15|prevalence
P06880563A0516|202 216|chlorpropamide
P06880563A0516|146 161|administrations
P06880650A0316|55 66|researchers
P06880650A0316|41 45|work
P06883385A0509|38 47|remission
P06883385A0509|66 86|neopterine excretion
P06886031A0898|97 102|hours
P06886031A0898|76 89|patient group
P06886031A0898|133 141|tolmetin
P06886031A0898|30 35|fluid
P06890622A0067|116 124|ischemia
P06890622A0067|41 49|platelet
P06890622A0067|62 69|effects
P06891051A0587|100 114|platelet count
P06891051A0587|71 79|patients
P06895559A0000|170 179|gestation
P06895559A0000|1 12|Terbutaline
P06895559A0000|163 166|day
P06895559A0000|62 89|phosphodiesterase inhibitor
P06897114A0240|16 21|motif
P06897114A0240|60 84|DNA sequence recognition
P06911559T0000|1 11|Statistics
P06919347T0001|33 54|Laboratory Assistants
P06919347T0001|66 75|Stockholm
P06919347T0001|95 116|laboratory assistants
P06931124A0109|51 60|NH4Mg PO4
P06931124A0109|76 85|reactants
P06931124A0109|62 65|H2O
P06931124A0109|15 20|place
P06938948T0001|65 73|immunity
P06938948T0001|108 117|leukemias
P06938948T0001|44 51|indices
P06946693T0000|32 42|PGF2 alpha
P06946693T0000|47 53|cattle
P06948493T0026|1 6|Range
P06950004T0047|1 6|Study
P06950004T0047|39 44|teeth
P06950004T0047|56 69|iontophoresis
P06957125T0000|17 27|blood flow
P06957125T0000|36 42|effect
P06959130A0996|51 61|conversion
P06959130A0996|98 108|factor XIa
P06959130A0996|128 141|Arg145-Ala146
P06959130A0996|91 94|IXa
P06962634A0190|39 50|information
P06962634A0190|57 80|porphyrin binding sites
P06966678A0523|68 75|portion
P06966678A0523|169 175|lipids
P06966678A0523|138 142|acid
P06966678A0523|234 239|index
P06966678A0523|312 313|r
P06966678A0523|289 290|n
P06966678A0523|322 323|n
P06966678A0523|355 356|n
P06966678A0523|335 343|ear vein
P06966678A0523|271 277|atrium
P06972179A0556|85 90|range
P06972501A0615|1 12|Correlation
P06972501A0615|58 65|outcome
P06975206A0279|53 58|weeks
P06975206A0279|94 101|calcium
P06975206A0279|106 115|phosphate
P06978566A0197|16 20|days
P06978566A0197|4 12|necropsy
P06978566A0197|39 48|F344 rats
P06978566A0197|149 160|M. pulmonis
P06984225A0367|1 6|REV I
P06984225A0367|12 19|vessels
P06992600A0405|65 78|contamination
P06992600A0405|89 96|outflow
P06994035T0001|4 20|line calculation
P06997203A0325|152 171|antibody conversion
P06997203A0325|190 198|patients
P06997203A0325|36 48|confirmation
P06997203A0325|89 94|rises
P06997203A0325|107 108|%
P06997203A0325|134 142|PHA test
P07007181T0000|39 43|diet
P07007181T0000|15 31|sodium saccharin
P07015018A0395|13 21|extracts
P07016141A0238|86 95|clearance
P07016141A0238|76 81|Xenon
P07016141A0238|26 29|RBF
P07021505A0510|7 18|acclimation
P07021505A0510|47 50|DPB
P07021505A0510|91 95|mmHg
P07034479A1050|83 91|AC group
P07034479A1050|13 16|RMI
P07038189A2301|98 102|drug
P07038189A2301|59 65|safety
P07038189A2301|15 22|results
P07040659A0212|21 34|control group
P07040659A0212|77 81|PEFR
P07040659A0212|56 67|improvement
P07044562T0000|6 9|Pap
P07045156A0204|154 162|antibody
P07045156A0204|112 126|immunoglobulin
P07045156A0204|58 67|rat model
P07053251A0666|84 89|heart
P07053251A0666|43 54|bone marrow
P07061263A0293|101 103|Px
P07061263A0293|66 71|cmH2O
P07061263A0293|75 88|air inflation
P07062036A0072|1 5|Rats
P07062036A0072|30 35|% JIB
P07063606T0000|44 63|barrier alterations
P07064923T0000|52 67|phenylketonuria
P07068493A0414|119 131|CO2 pressure
P07068493A0414|35 46|breaths/min
P07068493A0414|81 86|cycle
P07068493A0414|96 107|inspiration
P07068493A0414|60 61|%
P07068496A0000|70 81|water space
P07068496A0000|176 186|techniques
P07068496A0000|88 94|sodium
P07072635A0000|93 95|DF
P07072635A0000|58 72|administration
P07075024A0540|19 24|cases
P07075024A0540|36 41|fever
P07076222A0543|1 16|Recommendations
P07079595A0848|71 72|r
P07079595A0848|66 69|spg
P07079595A0848|25 36|correlation
P07079595A0848|162 170|sections
P07081327A0546|139 146|samples
P07081327A0546|24 29|fluid
P07081327A0546|46 60|concentrations
P07084617A0204|16 25|follow-up
P07084617A0204|54 62|patients
P07084617A0204|108 117|treatment
P07088195T0019|16 28|consequences
P07088195T0019|3 7|note
P07094856A0115|69 78|intervals
P07094856A0115|19 24|study
P07094856A0115|96 105|gestation
P07096587A0267|64 80|training program
P07096587A0267|148 156|strategy
P07105635A0412|1 8|Samples
P07105635A0412|76 84|patients
P07105635A0412|107 113|asthma
P07105635A0412|30 40|volunteers
P07106534A0160|100 108|increase
P07106534A0160|143 151|increase
P07106534A0160|92 98|length
P07106534A0160|124 129|curve
P07106534A0160|44 59|growth function
P07107462A0202|116 117|n
P07107462A0202|5 14|steepness
P07107462A0202|109 113|Hill
P07109788A0333|18 26|patients
P07109788A0333|4 11|concept
P07112320A0086|1 33|CSF adenosine deaminase activity
P07112654A0388|71 81|prevalence
P07112654A0388|125 139|hospital staff
P07112654A0388|91 99|carriage
P07113897A0285|283 293|exercise r
P07113897A0285|78 82|rest
P07113897A0285|118 119|p
P07113897A0285|115 116|%
P07113897A0285|158 159|%
P07113897A0285|179 180|p
P07113897A0285|176 177|%
P07113897A0285|183 185|NS
P07113897A0285|268 274|rest r
P07116298A1079|273 277|DTIC
P07116298A1079|99 108|stage IVA
P07116298A1079|233 239|months
P07116298A1079|72 80|interval
P07116298A1079|85 93|survival
P07116298A1079|352 358|months
P07116298A1079|248 256|patients
P07116298A1079|189 197|patients
P07116298A1079|267 270|BCG
P07116298A1079|208 211|BCG
P07119890T0000|1 3|Re
P07119890T0000|39 47|labeling
P07119890T0000|72 78|Tc-99m
P07125064T0000|34 42|findings
P07125064T0000|77 98|Schistosoma japonicum
P07126067T0000|59 70|Bali cattle
P07130335A1081|68 73|times
P07130335A1081|1 15|Administration
P07130335A1081|23 53|dopamine agonist bromocriptine
P07130335A1081|59 61|mg
P07130335A1081|104 105|P
P07134924A0640|66 73|coeloms
P07134924A0640|45 56|eye defects
P07136524A0180|141 165|retinoblastoma survivors
P07136524A0180|114 126|osteosarcoma
P07136524A0180|74 82|contrast
P07137927A0000|8 12|past
P07137927A0000|28 37|Singapore
P07137927A0000|14 24|immunology
P07140493A1045|38 49|bicarbonate
P07140493A1045|25 34|secretion
P07140493A1045|63 70|stomach
P07143347T0000|1 7|Cramps
P07149047A0260|34 38|Q/Dk
P07149047A0260|62 63|X
P07154928T0001|50 57|therapy
P07154928T0001|25 35|resorption
P07158726T0001|30 36|policy
P07162146A0000|65 74|detection
P07162146A0000|20 35|ultrafiltration
P07162146A0000|97 112|ethylene glycol
P07162146A0000|79 93|quantification
P07168531T0001|7 25|Onchocerca species
P07168531T0001|61 68|Senegal
P07172690A0547|141 143|Ca
P07172690A0547|12 18|factor
P07172690A0547|44 50|system
P07172690A0547|184 187|SPR
P07172690A0547|127 139|calcium pump
P07172690A0547|92 114|creatine phosphokinase
P07172690A0547|215 223|decrease
P07172690A0547|241 251|properties
P07174046T0000|19 33|group F vibrio
P07174437A0181|1 10|Organisms
P07174437A0181|65 73|counties
P07179412A1131|52 54|US
P07179412A1131|57 58|X
P07181985A0107|71 76|water
P07181985A0107|108 115|bladder
P07181985A0107|11 29|mg mitomycin/20 ml
P07181985A0107|180 183|min
P07183576A0157|207 211|bone
P07183576A0157|98 100|SD
P07183576A0157|37 51|flucloxacillin
P07183576A0157|119 124|fluid
P07183576A0157|255 259|bone
P07183576A0157|156 164|synovium
P07183576A0157|83 96|micrograms/ml
P07184598T0001|23 38|hyperthyroidism
P07184795A0517|34 41|control
P07184795A0517|82 86|I.U.
P07184795A0517|14 28|determinations
P07190869A0316|1 5|CDDP
P07191804A0000|136 144|activity
P07191804A0000|162 169|h sleep
P07191804A0000|106 112|course
P07191804A0000|120 121|h
P07192369T0000|3 9|method
P07192369T0000|76 90|administration
P07194905A0332|1 4|TCZ
P07194905A0332|133 149|brain maturation
P07194905A0332|60 75|tissue necrosis
P07195880A0621|59 66|leprosy
P07202525A0200|51 58|seconds
P07202525A0200|138 146|stimulus
P07202525A0200|110 117|seconds
P07202525A0200|95 100|shock
P07203410T0000|34 43|treatment
P07203410T0000|19 30|involvement
P07203410T0000|61 75|state hospital
P07205967T0000|67 78|improvement
P07205967T0000|108 115|partner
P07214230T0000|1 11|Inhibition
P07214230T0000|80 92|pitch canker
P07214230T0000|41 53|subglutinans
P07217329A0000|171 182|normethadol
P07217329A0000|206 215|biofluids
P07217329A0000|279 285|column
P07217329A0000|311 313|nm
P07217329A0000|161 169|methadol
P07217329A0000|86 90|LAAM
P07217329A0000|188 201|dinormethadol
P07217329A0000|121 138|noracetylmethadol
P07218008T0000|67 72|areas
P07218008T0000|8 27|response properties
P07218008T0000|92 109|Aotus trivirgatus
P07219821T0028|25 39|considerations
P07221354T0000|59 68|symposium
P07221354T0000|28 40|pulse dosing
P07225540A0193|17 20|gas
P07225540A0193|93 107|plasma samples
P07228955A0000|81 93|paraxanthine
P07228955A0000|9 16|authors
P07228955A0000|95 115|1,7-dimethylxanthine
P07228955A0000|56 77|theophylline analysis
P07234755A0838|5 14|monocytes
P07235317T0000|10 18|accuracy
P07235317T0000|30 37|version
P07236351A0812|83 87|loss
P07236351A0812|91 100|areas CA3
P07237560A1038|186 196|gene units
P07237560A1038|207 220|transcription
P07237560A1038|101 106|genes
P07237560A1038|160 176|Hind III linkers
P07237560A1038|63 67|tRNA
P07240343A0000|1 13|Strontium-90
P07240343A0000|76 80|p.c.
P07240343A0000|25 29|i.v.
P07243380A0327|116 120|torr
P07243380A0327|62 70|decrease
P07243380A0327|74 77|P50
P07249497A0688|118 130|estrogen use
P07249497A0688|99 104|risks
P07249497A0688|7 12|women
P07249497A0688|134 137|PPI
P07249660T0000|1 14|Determination
P07249660T0000|48 58|variations
P07251564A0569|100 113|ASDC nosology
P07251564A0569|23 29|sample
P07253335T0000|119 123|rats
P07253335T0000|1 8|Effects
P07253335T0000|79 91|stroke-prone
P07253335T0000|44 49|onset
P07259325A0394|39 43|date
P07259325A0394|47 52|onset
P07260987A0336|139 146|rabbits
P07260987A0336|5 21|plasma half-life
P07260987A0336|130 135|hours
P07260987A0336|165 175|impairment
P07262625A0000|1 23|Corticosteroid therapy
P07262625A0000|66 82|occult infection
P07262625A0000|224 237|Giardia muris
P07262625A0000|288 294|number
P07262625A0000|352 361|infection
P07262625A0000|52 60|patients
P07262625A0000|298 307|parasites
P07262625A0000|91 100|mechanism
P07263421A0351|6 10|Sair
P07263421A0351|31 39|capacity
P07264787A0351|115 116|%
P07264787A0351|148 149|%
P07264787A0351|122 137|hyperthyroidism
P07267675A0000|85 91|number
P07267675A0000|130 140|infections
P07267675A0000|44 47|CGP
P07270163A0684|223 231|controls
P07270163A0684|158 164|lining
P07270163A0684|144 149|villi
P07270163A0684|215 218|CNF
P07274042A0249|1 4|DMI
P07274042A0249|18 32|concentrations
P07274482A0000|51 55|body
P07274482A0000|109 117|movement
P07274482A0000|29 32|cat
P07274482A0000|180 185|deg/s
P07274482A0000|14 21|neurons
P07276210T0000|1 6|Assay
P07276210T0000|10 15|serum
P07276210T0000|74 83|detection
P07278104T0001|1 26|Leukocyte enzyme activity
P07278104T0001|31 68|blood lymphocyte blast transformation
P07280654A0000|65 81|averaging method
P07280654A0000|46 57|application
P07282552A0990|156 170|subendocardium
P07282552A0990|112 117|ratio
P07282552A0990|26 32|tissue
P07283110A0000|68 76|exercise
P07283110A0000|16 26|deficiency
P07293100T0001|1 18|Gastrin secretion
P07293100T0001|26 42|food stimulation
P07295033A0513|21 25|days
P07295033A0513|37 41|dose
P07295033A0513|73 79|faeces
P07296303A0418|1 10|Responses
P07296303A0418|53 72|lateralis posterior
P07296303A0418|27 33|nuclei
P07297576A0454|23 48|drinking water ad libitum
P07297576A0454|75 82|Aludrox
P07298209A0291|139 148|work load
P07298209A0291|5 18|determination
P07298209A0291|74 75|%
P07298523T0000|69 74|swine
P07298523T0000|54 65|parturition
P07298523T0000|28 50|prostaglandin F2 alpha
P07304905A0336|71 89|Heparin-ACD-B etc.
P07304905A0336|43 56|Heparin-ACD-B
P07308849A0817|93 97|data
P07308849A0817|41 44|gut
P07310206A0154|51 58|regions
P07310206A0154|80 108|scanning electron microscopy
P07310206A0154|120 140|resin casting method
P07312707T0000|1 9|Chordoma
P07323063A0000|100 104|rats
P07323063A0000|217 223|degree
P07323063A0000|228 239|time course
P07323063A0000|287 295|recovery
P07323063A0000|166 170|dose
P07326596A0061|41 44|IgE
P07328000T0000|26 39|timber wolves
P07337609A0531|48 63|antibody titers
P07337609A0531|65 68|GMT
P07337609A0531|227 236|challenge
P07337609A0531|15 19|mean
P07341346A0174|112 118|system
P07347728T0000|1 15|Arachnoid cyst
P07354367A0162|37 41|tilt
P07356273T0022|56 63|tissues
P07369183T0000|32 51|coagulation testing
P07372433A0000|87 94|animals
P07372433A0000|129 132|age
P07372433A0000|106 112|months
P07372433A0000|120 125|years
P07375836T0000|77 86|carcinoma
P07375836T0000|14 21|work-up
P07376165T0001|18 25|disease
P07377954A0117|442 453|extremities
P07377954A0117|138 156|oxygen consumption
P07377954A0117|46 52|effect
P07377954A0117|15 22|aspects
P07377954A0117|85 90|terms
P07377954A0117|158 161|VO2
P07377954A0117|112 120|pressure
P07377954A0117|420 428|diseases
P07377954A0117|122 132|pulse rate
P07380615A0478|250 260|efficiency
P07380615A0478|76 87|collar jobs
P07380615A0478|111 115|loss
P07380615A0478|130 136|tissue
P07380615A0478|61 67|nature
P07385920A0189|115 124|excretion
P07385920A0189|128 139|delta amino
P07385920A0189|75 92|blood haemoglobin
P07386500A0174|114 128|determinations
P07386500A0174|52 62|deficiency
P07387242A0236|35 44|intervals
P07387242A0236|71 80|operation
P07387242A0236|145 153|elements
P07387242A0236|104 119|plasma proteins
P07393856A0314|99 110|Experiments
P07393856A0314|37 53|acid ethyl ester
P07393856A0314|14 24|beta-apo-8
P07394364A0738|222 232|adaptation
P07394364A0738|110 118|organism
P07394364A0738|73 80|mammals
P07394364A0738|31 54|gas exchange parenchyma
P07396545A0217|66 74|disorder
P07401318A0823|19 30|temperature
P07401318A0823|88 97|staircase
P07406527A0212|102 106|skin
P07406527A0212|19 29|experiment
P07406527A0212|178 190|HCB controls
P07406527A0212|8 11|end
P07406527A0212|91 97|lijver
P07410037A0752|255 265|propensity
P07410037A0752|173 182|magnesium
P07410037A0752|125 138|control group
P07410037A0752|215 221|factor
P07410037A0752|160 169|excretion
P07413242A0000|21 26|study
P07413242A0000|72 77|T1-L3
P07413781A0169|168 179|preexposure
P07413781A0169|79 90|attenuation
P07413781A0169|13 24|stimulation
P07414817T0001|1 20|Cataract extraction
P07416204A0437|239 241|t0
P07416204A0437|76 91|pacing interval
P07416204A0437|133 135|t1
P07416204A0437|15 21|animal
P07416204A0437|119 131|extrasystole
P07416204A0437|257 269|potentiation
P07416204A0437|214 216|t1
P07418829A0191|38 48|pediatrics
P07423803T0001|1 10|Treatment
P07426101A0124|119 138|alcohol consumption
P07426101A0124|140 154|smoking habits
P07426101A0124|20 52|lipoprotein lipid concentrations
P07426101A0124|163 174|mileage run
P07426101A0124|179 190|performance
P07426745A0177|87 91|rats
P07426745A0177|108 124|gamma-irradiaton
P07426745A0177|149 151|Gy
P07429009T0121|25 49|cell population dynamics
P07432288A0218|1 21|Serum antibody titre
P07432288A0218|64 79|recurrence rate
P07434456A0286|117 135|% glycerol content
P07434456A0286|48 59|blood cells
P07434456A0286|20 25|units
P07434456A0286|188 193|fluid
P07436187A0147|33 40|studies
P07436187A0147|5 10|study
P07436187A0147|128 133|range
P07436187A0147|105 109|time
P07436702A0156|5 20|control persons
P07438346A0381|21 45|lidocaine concentrations
P07438346A0381|112 121|amplitude
P07438346A0381|126 127|%
P07438346A0381|133 137|Vmax
P07440085T0061|1 19|Arm function tests
P07445971A0241|92 96|week
P07445971A0241|72 86|nerve ligation
P07449253A0411|18 23|group
P07449253A0411|112 120|diuresis
P07449253A0411|162 163|%
P07449253A0411|133 141|decrease
P07450388A0406|4 12|patients
P07450388A0406|42 50|movement
P07450388A0406|79 88|bile duct
P07450388A0406|28 34|CCK-PZ
P07455042A0457|291 303|measurements
P07455042A0457|83 112|Dynamic Spatial Reconstructor
P07455042A0457|179 188|injection
P07455042A0457|192 206|contrast agent
P07456774A0448|30 35|drugs
P07458171A0086|55 63|Nematoda
P07458171A0086|73 82|Crustacea
P07461848A0230|64 77|tobacco smoke
P07461848A0230|97 99|NO
P07461848A0230|46 56|components
P07461848A0230|105 108|ppb
P07461848A0230|83 85|CO
P07461848A0230|24 38|concentrations
P07461848A0230|124 132|nicotine
P07463294A1216|139 149|responders
P07463294A1216|18 31|tumor relapse
P07463294A1216|52 57|group
P07463294A1216|151 152|p
P07463294A1216|60 70|responders
P07466831A0714|35 40|onset
P07466831A0714|147 158|disturbance
P07466831A0714|44 57|HCB porphyria
P07469692A0000|84 95|inheritance
P07469692A0000|5 27|term osteomesopycnosis
P07469692A0000|57 69|bone disease
P07472582A0993|185 192|defects
P07472582A0993|116 122|degree
P07472582A0993|142 151|reduction
P07472582A0993|73 78|201Tl
P07473169A0133|119 138|catalase activities
P07473169A0133|67 74|complex
P07474078A0838|186 206|integration activity
P07474078A0838|141 147|mutant
P07474078A0838|76 86|alteration
P07474078A0838|13 21|contrast
P07474124A1360|49 60|PI3 viruses
P07474124A1360|80 105|parainfluenza virus genus
P07474124A1360|172 184|requirements
P07474124A1360|41 44|PI2
P07474124A1360|150 157|respect
P07474451A0000|110 126|signal intensity
P07474451A0000|10 27|resonance imaging
P07474772A0274|157 165|function
P07474772A0274|97 107|comparison
P07474772A0274|58 69|examination
P07475793T0000|9 20|farmworkers
P07476701A0654|19 25|levels
P07476701A0654|29 43|IgE antibodies
P07476971A0381|41 57|SKUT-1B-20 cells
P07477245A0625|17 31|A. parasiticus
P07477245A0625|6 13|strains
P07477245A0625|144 154|aflatoxins
P07477245A0625|104 109|AF B1
P07478523A0551|152 171|RET protein isoform
P07478523A0551|112 123|amino acids
P07479004A0421|102 110|proteins
P07479004A0421|86 88|P2
P07479004A0421|20 41|mobility shift assays
P07479004A0421|93 95|P3
P07479004A0421|122 130|extracts
P07483276A0139|1 9|Analysis
P07483276A0139|109 112|UL3
P07483276A0139|47 61|reading frames
P07483276A0139|221 234|herpesvirus-1
P07483276A0139|188 206|pseudorabies virus
P07483276A0139|95 98|UL2
P07483276A0139|63 67|ORFs
P07483276A0139|180 185|HSV-1
P07483857A0350|85 90|water
P07483857A0350|1 25|Correlation coefficients
P07483857A0350|38 55|reference methods
P07483857A0350|60 63|NIT
P07487363A0447|21 24|IgE
P07487363A0447|40 45|IgG-4
P07487908A0230|118 123|cells
P07487908A0230|138 144|origin
P07487908A0230|6 14|sequence
P07487908A0230|37 50|transcription
P07487908A0230|110 114|gene
P07487908A0230|165 170|cells
P07488291A0934|17 29|observations
P07488291A0934|64 87|triamcinolone acetonide
P07488291A0934|132 142|structures
P07489502A0000|136 140|poly
P07489502A0000|100 110|inhibition
P07489502A0000|5 32|influenza virus NS1 protein
P07489502A0000|126 132|export
P07489502A0000|164 174|inhibition
P07490079T0000|32 39|homolog
P07490079T0000|76 80|STEP
P07490079T0000|63 74|phosphatase
P07490156A0647|17 35|nicotine treatment
P07490156A0647|54 63|increases
P07490156A0647|120 131|correlation
P07490742A0636|118 128|subdomains
P07490742A0636|6 13|finding
P07490770A0267|119 129|intron aI4
P07490770A0267|1 11|Comparison
P07490770A0267|82 90|homology
P07490770A0267|108 113|yeast
P07491305A0102|137 149|sinus rhythm
P07491305A0102|221 228|reports
P07491305A0102|185 204|delta wave polarity
P07491305A0102|157 168|surface ECG
P07491305A0102|52 69|accessory pathway
P07493327A0507|67 69|U4
P07493327A0507|75 84|U6 snRNAs
P07494244A0335|55 68|transcription
P07494244A0335|8 15|absence
P07494244A0335|109 126|ATF/CREB proteins
P07494293A0585|32 35|tip
P07494293A0585|66 100|T-cell signal transduction cascade
P07494293A0585|7 14|results
P07494306A0240|153 161|fraction
P07494306A0240|116 120|VP16
P07494306A0240|96 101|cells
P07494306A0240|56 68|interactions
P07495059T0078|16 48|ECAT Angina Pectoris Study Group
P07495726A1189|117 137|Bcl-2 proto-oncogene
P07495726A1189|81 109|recombination hotspot region
P07495726A1189|7 13|motifs
P07495726A1189|163 174|breakpoints
P07496400A0525|186 196|expression
P07496400A0525|221 230|seedlings
P07496400A0525|54 65|HMGR1S mRNA
P07496400A0525|42 52|HMGR1 mRNA
P07496400A0525|130 141|HMGR1L mRNA
P07496400A0525|242 256|inflorescences
P07498791A0680|68 74|allele
P07498791A0680|92 96|PBS2
P07498791A0680|12 20|mutation
P07499252A0150|137 148|association
P07499252A0150|70 77|binding
P07499252A0150|4 20|hGM-CSF receptor
P07499252A0150|172 183|PI 3-kinase
P07499252A0150|94 98|hGMR
P07499401A0444|35 36|H
P07499401A0444|64 65|%
P07499401A0444|5 13|identity
P07499401A0444|43 44|%
P07499401A0444|90 91|%
P07499421A0237|16 21|study
P07499421A0237|129 138|sequences
P07499421A0237|59 67|cultures
P07500386A0870|84 91|domains
P07500386A0870|179 183|IRA1
P07500386A0870|160 167|ability
P07500950A0000|119 142|Nicotiana tabacum L. cv
P07500950A0000|53 88|Agrobacterium rhizogenes Ri-plasmid
P07500950A0000|22 27|trolC
P07501016T0000|41 60|galaxy TXFS2226-184
P07501700A0000|5 12|effects
P07501700A0000|58 80|monophosphoryl lipid A
P07501700A0000|165 175|occlusions
P07504171A0715|119 133|Src SH2 domain
P07504171A0715|20 42|growth factor receptor
P07504171A0715|78 85|Tyr-857
P07504171A0715|44 50|PDGF-R
P07504712A0843|25 46|actin plaque assembly
P07505798A0000|69 73|H2N2
P07505798A0000|40 67|type A influenza A/Japan/57
P07505798A0000|210 214|CTLs
P07505798A0000|134 160|histocompatibility complex
P07505798A0000|90 92|HA
P07507187T0000|103 113|adenovirus
P07507187T0000|129 140|plasmid DNA
P07507187T0000|29 43|DNA expression
P07507458A0250|85 95|prevalence
P07507458A0250|154 166|RIBA methods
P07507458A0250|144 149|ELISA
P07507458A0250|62 65|aim
P07508140A0448|1 28|Hepatitis B surface antigen
P07508140A0448|47 55|patients
P07508441A0487|171 186|56K cDNA shares
P07508441A0487|204 212|homology
P07508441A0487|235 236|%
P07508441A0487|412 434|binding protein family
P07508441A0487|282 292|annexin XI
P07508441A0487|314 322|56K cDNA
P07508441A0487|194 200|degree
P07508441A0487|221 231|nucleotide
P07508441A0487|267 268|%
P07509053A0139|19 28|processes
P07509053A0139|59 64|c-Myb
P07509053A0139|130 137|lineage
P07509450A0705|100 117|cytosine residues
P07509450A0705|175 181|effect
P07509450A0705|129 148|nucleotide sequence
P07509450A0705|62 73|HSV tk gene
P07509624T0000|84 90|tumors
P07509624T0000|27 39|11q23 region
P07509624T0000|107 126|gel electrophoresis
P07509624T0000|134 139|yeast
P07510461A0731|26 44|test abnormalities
P07510724A1208|87 94|sarcoid
P07510724A1208|190 199|arthritis
P07510724A1208|143 154|association
P07510724A1208|58 67|arthritis
P07511444T0000|84 91|disease
P07511444T0000|1 28|Hepatitis C virus infection
P07511818A0485|171 176|cells
P07511818A0485|34 50|cell populations
P07511818A0485|291 298|protein
P07511818A0485|243 260|IFN-beta sequence
P07511818A0485|105 108|IFN
P07512258A0441|1 22|Liver transplantation
P07512258A0441|57 70|complications
P07512258A0441|91 100|PMN count
P07513703T0000|34 62|protein tyrosine phosphatase
P07513703T0000|1 11|Activation
P07513703T0000|125 153|insulin receptor substrate-1
P07514301A0000|155 163|addition
P07514301A0000|38 52|protein kinase
P07514301A0000|248 258|properties
P07514301A0000|192 213|tumor suppressor gene
P07516466A1054|100 104|PP2A
P07516466A1054|4 12|contrast
P07516466A1054|53 58|virus
P07516466A1054|145 170|phosphoprotein substrates
P07516466A1054|29 36|plasmid
P07516466A1054|120 128|activity
P07516597A1017|140 158|antigen processing
P07516597A1017|22 28|effect
P07516597A1017|183 186|MVE
P07516597A1017|62 65|MVE
P07517544A0515|234 239|L-364
P07517544A0515|282 291|mg/kg/day
P07517544A0515|214 220|period
P07517544A0515|177 185|pancreas
P07517544A0515|135 143|recovery
P07517544A0515|105 117|pancreatitis
P07518257A0351|55 57|P1
P07518257A0351|145 147|bp
P07518257A0351|79 81|bp
P07518460A0771|102 113|mutagenesis
P07518460A0771|141 152|phosphatase
P07518460A0771|20 25|cells
P07518578A0000|305 311|matrix
P07518578A0000|84 91|homolog
P07518578A0000|18 25|protein
P07518578A0000|173 185|localization
P07518578A0000|93 102|pp60c-src
P07519463A0000|85 96|consumption
P07519463A0000|43 58|work efficiency
P07519606A1269|1 14|Anti-NPROSP-C
P07519606A1269|80 93|proSP-C forms
P07519606A1269|56 67|appearances
P07521009A0377|111 119|plasmids
P07521009A0377|193 198|1989a
P07521009A0377|16 20|pms1
P07521009A0377|22 26|pms2
P07521009A0377|59 67|MW104-1B
P07521009A0377|149 152|G/T
P07521601A0000|108 120|chemotherapy
P07521601A0000|63 71|recovery
P07521601A0000|15 29|growth factors
P07522163T0000|19 45|horse cytochrome c peptide
P07522163T0000|173 181|presence
P07522163T0000|110 119|molecules
P07522163T0000|58 68|H-2b class
P07522163T0000|194 212|MHC anchor residue
P07523710T0000|1 10|Diagnosis
P07523710T0000|39 44|yield
P07523710T0000|24 33|carcinoma
P07523710T0000|72 79|antigen
P07525548A1380|84 92|activity
P07525548A1380|37 54|ligand affinities
P07525548A1380|94 102|rsVCAM-1
P07525548A1380|105 125|fibronectin variants
P07525843A0859|1 10|Dilutions
P07525843A0859|369 378|H-2d mice
P07525843A0859|402 404|NP
P07525843A0859|14 18|H-2b
P07525843A0859|187 197|affinities
P07525843A0859|358 365|removal
P07525843A0859|58 62|logs
P07525843A0859|150 155|lysis
P07525843A0859|268 276|peptides
P07527168A0524|50 53|mm2
P07527168A0524|32 42|x200 field
P07527168A0524|62 66|area
P07528325A0165|253 268|gene expression
P07528325A0165|8 15|studies
P07528325A0165|227 240|DNA sequences
P07528325A0165|134 142|tyrosine
P07528667A0834|7 23|initiation sites
P07528772A0616|305 311|region
P07528772A0616|277 285|sequence
P07528772A0616|229 235|ZAP-70
P07528772A0616|376 398|CD3 epsilon TAM motifs
P07528772A0616|51 69|ZAP-70 interaction
P07528772A0616|188 191|NH2
P07528772A0616|214 225|SH2 domains
P07529124A0119|171 174|kDa
P07529124A0119|80 91|heterodimer
P07529124A0119|23 32|structure
P07529124A0119|228 236|residues
P07529124A0119|149 156|weights
P07529516A0474|71 75|EDXR
P07529516A0474|63 67|dose
P07530502A0974|99 115|c-kit expression
P07530502A0974|124 143|protein degradation
P07530502A0974|73 82|reduction
P07530549A0956|1 9|Analysis
P07530549A0956|203 212|sequences
P07530549A0956|144 153|sequences
P07530549A0956|46 60|GRAIL programs
P07530549A0956|240 245|genes
P07532278A0833|1 8|Horvath
P07533758A1038|141 151|similarity
P07533758A1038|5 25|amino acid sequences
P07533758A1038|126 127|%
P07533758A1038|133 134|%
P07533758A1038|73 83|identities
P07533880T0000|68 74|target
P07533880T0000|21 34|IncF plasmids
P07533880T0000|76 85|traJ mRNA
P07533880T0000|41 45|FinP
P07534286A0842|3 24|chicken paxillin cDNA
P07534286A0842|94 95|%
P07534306A0444|186 207|amino acid activation
P07534306A0444|154 161|studies
P07534306A0444|108 124|deletion mutants
P07534306A0444|209 237|carboxyl thioester formation
P07534306A0444|90 100|properties
P07535768A1076|21 39|expression pattern
P07535768A1076|54 59|CL100
P07535768A1076|67 76|homologue
P07537362A1112|84 105|coimmunoprecipitation
P07537362A1112|63 67|Eps8
P07537851A0000|85 90|cells
P07537851A0000|207 216|TNF-alpha
P07537851A0000|178 205|tumor necrosis factor alpha
P07537851A0000|57 63|VCAM-1
P07537851A0000|105 123|lipopolysaccharide
P07538068A1094|16 23|results
P07538068A1094|36 51|control element
P07538068A1094|130 145|Hoxa-7 enhancer
P07538173A0307|1 10|MBP-Rep68
P07538173A0307|101 105|ions
P07538173A0307|26 51|DNA-RNA helicase activity
P07539119A0291|236 243|reasons
P07539119A0291|218 223|cells
P07539119A0291|43 52|mutations
P07539119A0291|181 193|G128R mutant
P07539314T0000|103 115|nifurpirinol
P07539314T0000|1 8|Changes
P07539314T0000|67 78|fingerlings
P07539314T0000|24 29|gills
P07540773A0576|34 38|IJVB
P07540773A0576|5 11|levels
P07540773A0576|15 18|NSE
P07541589A0652|32 45|cancer volume
P07541589A0652|95 111|vesicle invasion
P07541589A0652|74 85|penetration
P07542577A0438|115 121|nature
P07542577A0438|5 20|fusion proteins
P07542577A0438|129 137|epitopes
P07542577A0438|46 56|reactivity
P07542616A0486|256 261|steps
P07542616A0486|203 225|translation initiation
P07542616A0486|147 152|eIF-3
P07542616A0486|13 16|RNA
P07542616A0486|60 68|evidence
P07543684A1027|18 22|cAMP
P07543684A1027|79 99|CFTR gene expression
P07543684A1027|151 161|cell types
P07544357A0808|186 191|CD44v
P07544357A0808|16 29|ALVA-31 cells
P07544357A0808|6 11|PPC-1
P07544357A0808|172 184|CD44 variant
P07544357A0808|77 81|mice
P07544357A0808|193 203|expression
P07545920A1336|43 53|hsiggll295
P07545920A1336|94 97|DNA
P07546293A0968|86 96|expression
P07546293A0968|58 67|sequences
P07546794A0100|1 17|Echocardiography
P07546794A0100|65 69|RVDC
P07546794A0100|105 114|tamponade
P07547500A0066|139 142|p40
P07547500A0066|114 137|chicken l kappa B-alpha
P07547500A0066|92 96|GAL4
P07547500A0066|29 43|fusion protein
P07548425A0000|102 107|nerve
P07548425A0000|222 231|lesioning
P07548425A0000|161 184|tail muscle motoneurons
P07548425A0000|27 34|effects
P07548425A0000|47 53|inputs
P07549005A0530|53 61|collapse
P07549005A0530|10 31|parallax measurements
P07551787A0917|69 82|investigation
P07551787A0917|5 12|outcome
P07551787A0917|52 56|plan
P07553942A0810|115 136|Marchantia rps10 gene
P07553942A0810|5 21|pea rps10 intron
P07553942A0810|146 152|intron
P07553942A0810|60 64|cox3
P07555373A0000|70 79|cisplatin
P07555373A0000|47 56|neoplasms
P07557276A0526|1 25|Alanine aminotransferase
P07557276A0526|65 71|months
P07557276A0526|92 103|hepatitis B
P07557276A0526|79 87|patients
P07557424A0124|81 95|fusion library
P07557424A0124|62 66|lacZ
P07557717A0184|95 99|pain
P07557717A0184|26 44|chest wall muscles
P07558583A0562|103 121|peptide substrates
P07558583A0562|139 148|detection
P07558583A0562|32 41|synthesis
P07558583A0562|5 10|study
P07558583A0562|244 249|class
P07558583A0562|165 189|tyrosine kinase activity
P07559347A0000|32 44|operon bglPH
P07559347A0000|114 121|fusions
P07559347A0000|93 97|lacZ
P07559356T0000|5 20|hypBFCDE operon
P07559356T0000|26 63|Rhizobium leguminosarum biovar viciae
P07559430A0909|1 3|R.
P07559488A0440|1 20|Control experiments
P07559488A0440|38 52|fusion protein
P07559488A0440|161 166|yeast
P07559524A0000|19 28|oncogenes
P07559524A0000|56 76|G1 phase progression
P07559555A0557|96 103|complex
P07559555A0557|9 12|ERM
P07559639A0996|4 12|addition
P07559639A0996|97 110|consensus HSE
P07559650A0558|70 73|E2F
P07559650A0558|55 66|target gene
P07560662A0496|7 15|recovery
P07563072A0773|16 39|rrnB P1-lacZ expression
P07563072A0773|53 65|ppGpp levels
P07563072A0773|94 99|P504L
P07563072A0773|89 93|rpoD
P07563090A0124|207 215|pol gene
P07563090A0124|71 88|yeast Ty1 element
P07563090A0124|174 178|PPT1
P07563090A0124|193 199|middle
P07563090A0124|166 172|repeat
P07563994A0488|102 105|OLB
P07563994A0488|5 13|patients
P07563994A0488|202 204|ml
P07563994A0488|158 162|VTLB
P07563994A0488|127 128|p
P07563994A0488|94 97|min
P07563994A0488|122 125|min
P07564210A0557|103 104|h
P07564210A0557|39 46|regimen
P07564210A0557|130 135|signs
P07565049A1032|184 190|weight
P07565049A1032|145 149|term
P07565049A1032|211 213|g.
P07565113A0000|171 179|excision
P07565113A0000|98 119|parent plasmid plP401
P07565113A0000|123 146|Clostridium perfringens
P07565672A0798|51 56|arg-2
P07565672A0798|96 101|cox-5
P07565672A0798|37 47|expression
P07565672A0798|61 66|cpc-1
P07565688A0797|35 62|cell fractionation analyses
P07565688A0797|87 94|protein
P07565688A0797|203 208|cells
P07565709A0000|1 18|T-cell hybridomas
P07565709A0000|80 90|cell death
P07565709A0000|36 43|T cells
P07565713A0634|1 15|Overexpression
P07565713A0634|48 65|HSP60-null allele
P07565713A0634|127 141|Hsp60 activity
P07565723A0200|5 11|kinase
P07565723A0200|67 70|CTD
P07565736A2134|107 112|cells
P07565736A2134|30 41|C/EBP alpha
P07565775A1265|138 151|EpG formation
P07565775A1265|110 114|rate
P07565775A1265|161 169|transfer
P07565775A1265|192 195|RNA
P07565775A1265|25 31|motifs
P07565775A1265|63 70|effects
P07565775A1265|90 96|enzyme
P07565776A0612|19 23|HOG1
P07565776A0612|143 147|Hog1
P07565776A0612|110 115|cells
P07565776A0612|125 139|overproduction
P07565776A0612|198 204|levels
P07565776A0612|75 93|HSP12 inducibility
P07567079A0014|32 51|Cryptosporidium spp
P07567079A0014|143 149|choice
P07567079A0014|133 139|method
P07567079A0014|105 121|density gradient
P07567079A0014|216 229|contamination
P07567079A0014|83 90|percoll
P07567830A0072|69 75|curves
P07567830A0072|117 123|tremor
P07567830A0072|93 101|patients
P07567830A0072|147 150|age
P07567980T0000|86 89|DNA
P07567980T0000|6 9|p53
P07568116A0902|102 116|signal peptide
P07568116A0902|77 84|absence
P07568576A0074|49 64|Type A behavior
P07568576A0074|6 12|report
P07569075A0585|137 154|chest radiography
P07569075A0585|86 88|PR
P07569075A0585|96 97|%
P07569075A0585|160 163|FBS
P07569075A0585|72 73|%
P07569075A0585|44 46|CR
P07569640A0539|84 90|values
P07569640A0539|65 71|groups
P07569640A0539|94 96|G2
P07571766A0122|219 227|arteries
P07571766A0122|95 110|catheterization
P07571766A0122|73 74|%
P07572582A0000|1 11|Mibefradil
P07572582A0000|36 54|calcium antagonist
P07572582A0000|13 15|Ro
P07574682T0000|58 78|alkaline phosphatase
P07575416A1970|65 71|choice
P07575416A1970|43 53|importance
P07575416A1970|75 90|oligonucleotide
P07575947T0000|5 11|debate
P07576179A0781|31 40|frequency
P07576307A1654|32 38|motifs
P07576307A1654|181 184|ENK
P07576307A1654|134 149|tumor cell line
P07579023A0214|141 154|liver enzymes
P07579023A0214|12 24|dose-finding
P07579023A0214|30 38|patients
P07579328A0653|50 68|GAL4 binding sites
P07579328A0653|93 111|cell lines NIH 3T3
P07579683A0660|84 94|activation
P07579683A0660|64 71|regions
P07579683A0660|181 189|activity
P07579695A0693|153 158|order
P07579695A0693|23 27|data
P07579695A0693|73 78|Cep1p
P07580058A0000|136 139|PAI
P07580058A0000|16 35|Codonopsis pilosula
P07580058A0000|201 213|blood stasis
P07580058A0000|93 97|t-PA
P07580058A0000|161 169|patients
P07580058A0000|182 195|heart disease
P07580782T0000|1 17|Imaging features
P07580782T0000|61 72|correlation
P07582316A0696|33 41|isolates
P07582316A0696|43 47|case
P07582316A0696|63 67|case
P07583190A0306|251 258|lesions
P07583190A0306|188 215|phrase structure violations
P07583190A0306|283 293|impairment
P07583190A0306|24 33|processes
P07583190A0306|78 83|parts
P07585246T0000|1 19|SL1 trans-splicing
P07585246T0000|74 77|end
P07586403A0765|36 63|risk factor-selection scale
P07586403A0765|144 155|risk factor
P07586403A0765|8 13|basis
P07588245T0000|1 11|Repression
P07588245T0000|64 74|activation
P07588245T0000|122 124|TR
P07588608A1687|102 117|i.e.gag-myb-ets
P07588608A1687|155 160|genes
P07588608A1687|20 42|ERF repressor function
P07588608A1687|66 73|members
P07588608A1687|144 151|control
P07588633A0362|98 105|protein
P07588633A0362|213 216|Mos
P07588633A0362|14 19|c-Fos
P07588777A1524|119 138|p44mapk MAP kinases
P07588777A1524|32 40|proposal
P07588777A1524|7 19|observations
P07588777A1524|107 114|p42mapk
P07590264A0373|139 145|allele
P07590264A0373|233 237|gene
P07590264A0373|111 116|mRNAs
P07590264A0373|290 295|level
P07590264A0373|263 264|A
P07590264A0373|266 271|sites
P07590264A0373|299 314|gene expression
P07590268A0740|156 164|germline
P07590268A0740|52 63|development
P07590268A0740|10 27|MAPKAPK-2 message
P07590525A0811|77 81|dogs
P07590525A0811|13 19|values
P07590744A0829|5 14|integrity
P07590744A0829|22 35|cDNA sequence
P07592220A0846|32 50|minute ventilation
P07592220A0846|54 72|oxygen consumption
P07592220A0846|126 127|P
P07592220A0846|121 124|Hyp
P07592439A0000|51 73|Listeria monocytogenes
P07592439A0000|38 46|myovirus
P07592485A0734|100 104|case
P07592485A0734|115 130|NCR sensitivity
P07592485A0734|179 198|ure2 delta mutation
P07592647T0000|1 12|Association
P07592647T0000|22 31|Pur alpha
P07592647T0000|41 63|retinoblastoma protein
P07592676A0466|97 107|NIP region
P07592676A0466|15 25|conditions
P07592710T0000|89 114|immunoglobulin kappa gene
P07592721A0827|34 45|amino acids
P07592721A0827|80 88|contacts
P07592730A0204|1 7|Levels
P07592730A0204|100 109|injection
P07592730A0204|203 207|bulk
P07592730A0204|11 25|TSG-14 protein
P07592730A0204|87 93|humans
P07592730A0204|270 275|liver
P07592730A0204|183 197|phase proteins
P07592790A1457|35 39|PEDF
P07592790A1457|81 88|serpins
P07592790A1457|113 119|region
P07592790A1457|164 171|protein
P07592946A0997|102 110|AP-2 box
P07592946A0997|206 209|Sp1
P07592946A0997|313 317|MyoD
P07592946A0997|286 291|Ets-1
P07592946A0997|226 240|binding factor
P07592946A0997|116 124|Malt box
P07592946A0997|249 256|CTF-NF1
P07592946A0997|264 267|Myb
P07592946A0997|361 369|factor-5
P07592946A0997|88 96|AP-1 box
P07593896A1053|79 95|P0.1 measurement
P07593896A1053|150 160|lung model
P07594592A0755|1 9|Deletion
P07594592A0755|79 90|interaction
P07595374A1215|16 21|EBNA2
P07595374A1215|5 12|domains
P07595374A1215|162 169|domains
P07595374A1215|242 255|LMP1 promoter
P07596283A0396|85 95|tributyrin
P07596283A0396|49 62|triglycerides
P07596283A0396|19 25|enzyme
P07596287A1724|116 132|mutagenesis data
P07596287A1724|83 87|ORF3
P07596287A1724|75 79|size
P07596697A0971|118 126|children
P07596697A0971|29 40|polypeptide
P07596697A0971|45 62|motilin responses
P07597488T0000|27 42|G6PD deficiency
P07598106A0709|1 20|Mean growth changes
P07598106A0709|38 44|sample
P07598106A0709|99 107|subjects
P07598106A0709|231 237|groups
P07598106A0709|149 159|age period
P07599449A0445|71 80|menopause
P07599449A0445|59 64|years
P07600111A0000|239 245|cohort
P07600111A0000|5 15|prevalence
P07600111A0000|77 82|HIV-1
P07600111A0000|135 144|HTLV-I/II
P07600111A0000|20 29|incidence
P07600111A0000|249 264|police officers
P07600111A0000|181 192|association
P07601078A1003|100 104|risk
P07601078A1003|142 152|hypoergy I
P07601078A1003|199 201|OR
P07601078A1003|47 60|dioxin burden
P07601078A1003|186 194|hypoergy
P07601078A1003|23 40|postexposure time
P07601445A0207|85 92|protein
P07601445A0207|69 76|rat p47
P07601445A0207|236 249|RNA helicases
P07601445A0207|98 125|WM6 Drosophila gene product
P07601445A0207|22 46|BAT1 translation product
P07601828A0095|33 49|characterization
P07601828A0095|72 87|flagellar genes
P07601828A0095|105 120|orfX-fliP locus
P07603956A0115|69 79|treatments
P07603956A0115|99 105|levels
P07603956A0115|145 146|%
P07603956A0115|109 122|incorporation
P07604783A0952|55 71|acid composition
P07604783A0952|127 131|bile
P07605990A1110|239 256|promoter activity
P07605990A1110|18 25|studies
P07605990A1110|173 178|ratio
P07605990A1110|123 131|findings
P07605990A1110|192 206|PEBP2 isoforms
P07606587A0266|1 24|Piperacillin-tazobactam
P07606587A0266|132 140|bacteria
P07607213A0140|129 137|peptides
P07607213A0140|176 186|expression
P07607213A0140|27 58|structure/activity relationship
P07607342A0703|83 110|aldose reductase inhibitors
P07607342A0703|202 210|patients
P07607342A0703|160 167|results
P07607342A0703|73 79|trials
P07607607T0000|1 9|Increase
P07607607T0000|21 28|calcium
P07608268A0194|152 153|n
P07608268A0194|39 54|GnRH deficiency
P07608268A0194|163 165|DP
P07608268A0194|26 35|disorders
P07608268A0194|167 168|n
P07608968A0836|100 114|transactivator
P07608968A0836|156 169|transcription
P07608968A0836|79 91|core domains
P07609079A0387|221 231|activation
P07609079A0387|37 46|T3R alpha
P07609079A0387|24 33|HIV-1 LTR
P07609079A0387|133 142|T3R alpha
P07609079A0387|285 294|sequences
P07610052A1064|140 156|EMSA experiments
P07610052A1064|53 56|C30
P07610052A1064|246 262|rat APP promoter
P07610052A1064|125 136|SAA element
P07610052A1064|227 238|functioning
P07610052A1064|61 74|C35 complexes
P07610716A0117|21 38|prevalence values
P07610716A0117|142 150|latitude
P07612174A1064|81 88|effects
P07612174A1064|10 18|primates
P07614762A0224|56 75|latex agglutination
P07615634A0535|48 54|region
P07615634A0535|72 80|sequence
P07616563A0532|116 125|stretches
P07616563A0532|37 57|carAB control region
P07616563A0532|10 14|CarP
P07616802A0315|119 120|p
P07616802A0315|201 211|responders
P07616802A0315|6 9|day
P07616802A0315|40 54|platelet count
P07616802A0315|28 36|increase
P07618548T0000|5 28|Babcock Surgical Clinic
P07622058A0411|112 134|segmentation gene runt
P07622058A0411|56 62|region
P07622521A0418|65 73|beta ARK
P07622521A0418|142 148|series
P07622521A0418|109 118|PH domain
P07622521A0418|152 159|mutants
P07622521A0418|250 262|G beta gamma
P07622521A0418|267 279|PIP2 binding
P07623807A0162|137 142|v-Ras
P07623807A0162|185 194|membranes
P07623807A0162|115 131|plasma membranes
P07623807A0162|166 171|cells
P07623821A0649|93 98|motif
P07623821A0649|14 21|factors
P07623825T0000|23 45|transactivation domain
P07623840A0352|139 143|tRNA
P07623840A0352|93 99|kinase
P07623840A0352|58 62|GCN2
P07624119A0528|34 67|PAX3-FKHR transactivation domains
P07624119A0528|175 188|reporter gene
P07624119A0528|159 169|activation
P07624119A0528|124 128|GAL4
P07624615A0267|69 73|mmHg
P07624615A0267|174 175|H
P07624615A0267|37 39|TB
P07624615A0267|109 114|mEq/L
P07624615A0267|255 265|phosphorus
P07624615A0267|49 54|PaCO2
P07624615A0267|219 222|SID
P07624615A0267|127 130|pHa
P07624615A0267|267 269|PT
P07624615A0267|208 214|effect
P07626469A1341|81 105|mouse Leydig tumor cells
P07626469A1341|7 24|promoter activity
P07627317A1502|100 103|end
P07627317A1502|111 116|shift
P07627317A1502|79 92|concentration
P07627317A1502|13 21|exposure
P07628438T0000|16 40|insulin receptor homolog
P07628438T0000|130 149|signaling potential
P07628438T0000|44 48|gene
P07628456A0000|118 126|proteins
P07628456A0000|21 39|RNA binding domain
P07628456A0000|197 202|RNase
P07628456A0000|167 170|RNA
P07629113A0726|1 4|SCA
P07629113A0726|36 42|serine
P07629113A0726|58 74|metalloproteases
P07629123A0885|102 120|heterodimerization
P07629123A0885|154 164|activation
P07629123A0885|20 28|mutation
P07629123A0885|122 133|DNA binding
P07629163A0770|1 4|NH2
P07629163A0770|65 67|PH
P07629163A0770|146 160|zinc butterfly
P07630687A0010|239 261|protein S deficiencies
P07630687A0010|101 121|catheter association
P07630687A0010|143 153|evaluation
P07630687A0010|79 93|family history
P07630687A0010|225 234|protein C
P07630687A0010|291 299|children
P07630687A0010|155 166|development
P07630687A0010|22 27|study
P07630687A0010|95 99|site
P07631267T0001|1 13|Radiotherapy
P07631267T0001|58 67|carcinoma
P07633756A0690|238 249|information
P07633756A0690|306 326|artefact propagation
P07633756A0690|200 216|reference signal
P07633756A0690|40 46|signal
P07633756A0690|165 170|noise
P07633756A0690|187 194|version
P07633756A0690|268 273|sweep
P07635312A0692|81 87|domain
P07635312A0692|43 52|mutations
P07636179A0000|137 144|kinases
P07636179A0000|156 166|inhibitors
P07636179A0000|47 56|molecules
P07636337A0687|51 56|doses
P07636337A0687|7 14|results
P07636337A0687|111 114|HRT
P07636648A1229|21 45|DTaP booster vaccination
P07636648A1229|52 58|groups
P07636648A1229|127 135|antigens
P07636648A1229|241 242|p
P07636648A1229|90 119|serum antibody concentrations
P07636962A1883b|101 114|BHV-alpha TIF
P07636962A1883b|39 57|DNA binding domain
P07636962A1883b|130 135|amino
P07636962A1883b|61 65|GAL4
P07637718A0218|136 151|trypomastigotes
P07637718A0218|43 59|trans-sialidases
P07639106A0678|71 74|age
P07639106A0678|3 8|model
P07639106A0678|22 28|weight
P07639106A0678|128 138|body TBBMC
P07639106A0678|88 94|height
P07640309A0000|186 191|exons
P07640309A0000|154 171|splice mechanisms
P07640309A0000|93 123|box transcription factor TCF-1
P07640309A0000|88 91|HMG
P07642490A0318|56 64|analysis
P07642538A0744|49 55|levels
P07642538A0744|4 12|contrast
P07642538A0744|109 120|stimulation
P07642633T0000|139 170|transcription enhancer factor-1
P07642633T0000|172 177|TEF-1
P07642633T0000|93 97|cell
P07642633T0000|62 83|transcription factors
P07644466A0578|187 198|translation
P07644466A0578|247 257|substrates
P07644466A0578|146 159|NS4A cofactor
P07644466A0578|132 135|NS3
P07644466A0578|75 99|serine proteinase domain
P07646439A0535|18 26|proteins
P07646439A0535|78 92|chromatography
P07647570A0713|17 28|explanation
P07647570A0713|144 148|Type
P07647570A0713|106 112|cortex
P07647570A0713|151 161|deiodinase
P07649098A0676|338 352|IGF-I promoter
P07649098A0676|677 680|PKA
P07649098A0676|327 334|context
P07649098A0676|157 160|UTR
P07649098A0676|144 146|nt
P07649098A0676|268 276|presence
P07649098A0676|515 529|protein kinase
P07649098A0676|43 55|observations
P07649098A0676|105 116|nucleotides
P07649098A0676|359 373|cotransfection
P07649098A0676|666 673|subunit
P07649098A0676|430 437|plasmid
P07649098A0676|125 133|promoter
P07649098A0676|62 84|transfection construct
P07649098A0676|482 489|subunit
P07651131A1407|168 175|protein
P07651131A1407|23 28|DNase
P07651131A1407|12 18|assays
P07651131A1407|31 55|footprinting experiments
P07651340A0286|84 97|transformants
P07651340A0286|21 35|uvsH77 mutants
P07651340A0286|110 121|restoration
P07651340A0286|165 171|levels
P07651398A0257|4 9|flies
P07651398A0257|162 170|tyrosine
P07651398A0257|90 120|growth factor receptor homolog
P07651398T0000|48 57|signaling
P07651398T0000|65 93|DER receptor tyrosine kinase
P07651424A0487|156 164|proteins
P07651424A0487|143 147|pool
P07651424A0487|13 21|analysis
P07651734A0961|51 62|LIMK-1 mRNA
P07651734A0961|1 23|Northern blot analysis
P07651734A0961|112 123|LIMK-2 mRNA
P07651734A0961|150 153|rat
P07652066A0677|186 199|system repair
P07652066A0677|141 147|fascia
P07652066A0677|260 265|scars
P07652066A0677|8 13|basis
P07652066A0677|58 67|procedure
P07652066A0677|227 231|risk
P07652582A0000|68 71|CML
P07652582A0000|55 64|treatment
P07653812T0000|102 111|clonidine
P07653812T0000|54 63|analgesia
P07653812T0000|13 45|acetyl cholinesterase inhibitors
P07654239A0698|65 87|cell cycle progression
P07654740A0563|152 170|inclusion criteria
P07654740A0563|1 10|Key areas
P07654740A0563|248 262|co-morbidities
P07654740A0563|67 79|alternatives
P07654740A0563|225 243|disease etiologies
P07654740A0563|284 301|contraindications
P07655505A0527|188 195|pattern
P07655505A0527|110 116|stages
P07655505A0527|199 228|phytochrome A gene expression
P07655505A0527|160 164|role
P07656588A0101|235 242|D19S412
P07656588A0101|198 208|FUT2 genes
P07656588A0101|13 34|DNA sequence analysis
P07656588A0101|87 89|kb
P07656588A0101|115 121|region
P07656588A0101|266 268|cM
P07656588A0101|244 253|lod score
P07657668A0642|1 15|TH-SH3 binding
P07657668A0642|58 82|amino acid substitutions
P07658262A0944|1 17|Protein S levels
P07658262A0944|158 170|procoagulant
P07658262A0944|53 57|time
P07658262A0944|122 128|plasma
P07658777A0400|5 9|test
P07658777A0400|56 73|contraindications
P07659515T0000|97 134|Crithidia fasciculata miniexon arrays
P07659515T0000|15 30|retrotransposon
P07659746A1464|69 89|proteolipid messages
P07659746A1464|123 138|d post-anthesis
P07660712A0118|5 14|character
P07660712A0118|133 136|VHB
P07660712A0118|122 129|respect
P07663160A0287|119 128|avoidance
P07663160A0287|223 229|accord
P07663160A0287|174 185|codon usage
P07663160A0287|65 77|base pairing
P07663160A0287|151 160|structure
P07663998T0000|16 22|repair
P07663998T0000|26 30|type
P07665172A0000|1 22|Transcription factors
P07665172A0000|157 164|systems
P07665172A0000|126 132|number
P07665187A0824|175 191|initiation sites
P07665187A0824|111 117|Nramp1
P07665187A0824|135 143|presence
P07665567A0495|273 277|AP-1
P07665567A0495|99 111|TATA element
P07665567A0495|199 216|binding sequences
P07665567A0495|75 83|presence
P07665567A0495|115 125|base pairs
P07665567A0495|266 271|Egr-1
P07665567A0495|148 177|transcription initiation site
P07665633A0284|115 133|National Committee
P07665633A0284|147 167|Laboratory Standards
P07666414A0614|119 139|immunohistochemistry
P07666414A0614|84 109|promoter/lacZ fusion gene
P07666414A0614|64 78|microinjection
P07666523T0000|1 14|Investigation
P07666523T0000|112 127|RNA transcripts
P07666523T0000|56 74|mRNA transcription
P07666966A0207|70 78|segments
P07666966A0207|45 51|lesion
P07667195A0146|1 6|L-735
P07667195A0146|97 109|dosage forms
P07667195A0146|76 84|solution
P07668009A0172|29 49|hepatitis A diseases
P07669351A1278|5 15|properties
P07669351A1278|30 47|SSB-ssDNA complex
P07670943A0308|16 20|male
P07670943A0308|143 150|sibling
P07670943A0308|106 114|families
P07672822T0000|51 56|mouse
P07672822T0000|9 18|structure
P07673154A0688|98 106|response
P07673154A0688|66 80|trypsinization
P07673154A0688|29 34|state
P07674649A0508|42 57|baseline design
P07675449A0848|49 53|p190
P07675449A0848|8 30|glioblastoma cell line
P07676587T0000|30 46|livestock export
P07677573A0000|118 125|changes
P07677573A0000|80 89|secretion
P07677573A0000|179 188|gastritis
P07677573A0000|91 100|incretion
P07677836A1356|153 160|absence
P07677836A1356|93 101|deficits
P07677836A1356|164 176|chemotherapy
P07678006A0901|68 75|medulla
P07678006A0901|99 105|spleen
P07678006A0901|129 132|RNA
P07678006A0901|77 82|liver
P07678242A0473|19 30|correlation
P07678242A0473|92 96|rate
P07678242A0473|109 115|growth
P07678602A0153|155 162|parents
P07678602A0153|131 138|disease
P07678602A0153|26 50|B lymphoblast cell lines
P07679390A0721|103 117|DDT1 aFGF mRNA
P07679390A0721|22 45|primer extension assays
P07679390A0721|79 83|exon
P07679390A0721|181 183|bp
P07680035A0221|40 43|AMP
P07680035A0221|14 28|phorbol esters
P07680629T0000|23 39|characterization
P07680629T0000|62 67|gp138
P07680629T0000|135 159|Dictyostelium discoideum
P07681513A0000|1 11|Piroximone
P07681513A0000|21 38|phosphodiesterase
P07682842A0294|34 52|fMLF-R transcripts
P07682842A0294|113 123|regulation
P07682842A0294|127 149|fMLF-R gene expression
P07682842A0294|245 253|sequence
P07682842A0294|89 103|receptor genes
P07682842A0294|194 202|location
P07683131A0885|142 148|family
P07683131A0885|46 56|SRC-family
P07683131A0885|31 38|members
P07685263A0503|96 102|genome
P07685263A0503|110 127|Whipple bacterium
P07685263A0503|11 36|polymerase chain reaction
P07685874A0258|18 25|calcium
P07685874A0258|145 154|potassium
P07685874A0258|89 101|SLE patients
P07685874A0258|165 187|protein concentrations
P07687320A0526|72 100|complement B-band expression
P07687320A0526|104 107|ge6
P07687541A0992|51 57|GTPase
P07687541A0992|138 142|CNR1
P07687541A0992|65 80|ras superfamily
P07687541A0992|147 151|CNR2
P07687541A0992|30 33|Ran
P07688112A0274|19 26|antigen
P07688112A0274|98 114|acid phosphatase
P07689501A0420|10 18|carriers
P07691885T0000|19 28|mutations
P07691885T0000|43 51|sequence
P07691885T0000|147 157|activation
P07692668A0326|48 51|RNA
P07692668A0326|96 100|RNAs
P07692668A0326|163 181|blot hybridization
P07692668A0326|265 269|ORFs
P07693132A0100|48 57|Zm-ERabp1
P07693132A0100|10 17|cloning
P07693672A0259|1 6|DNase
P07693672A0259|9 21|footprinting
P07693672A0259|61 68|regions
P07693708A0000|36 45|protein-2
P07693708A0000|57 70|transcription
P07693708A0000|74 83|rat liver
P07693975A1418|139 150|proteolysis
P07693975A1418|98 108|N terminus
P07693975A1418|66 73|residue
P07693975A1418|44 54|methionine
P07695629A0489|4 12|addition
P07696450A0271|1 9|PATIENTS
P07696450A0271|100 107|disease
P07696450A0271|140 144|feed
P07696450A0271|14 21|METHODS
P07696450A0271|153 161|TGF-beta
P07696450A0271|86 97|bowel Crohn
P07696450A0271|59 67|children
P07697294A0329|19 31|HSP81-1 mRNA
P07697294A0329|9 15|amount
P07698727A0386|25 30|tumor
P07698727A0386|10 21|destruction
P07699632A0715|50 61|populations
P07699632A0715|5 20|data complement
P07699632A0715|109 112|SPA
P07700361A0125|65 70|types
P07700361A0125|132 136|type
P07702327T0000|52 80|tissue plasminogen activator
P07702752A0545|220 236|rat P450c17 gene
P07702752A0545|207 210|DNA
P07702752A0545|353 362|Y-1 cells
P07702752A0545|277 301|reporter gene luciferase
P07702752A0545|127 146|deletion constructs
P07702752A0545|379 397|Leydig MA-10 cells
P07704040A0000|34 49|mouse NMO1 cDNA
P07704040A0000|142 156|oxidoreductase
P07704040A0000|196 209|DT diaphorase
P07704040A0000|75 76|H
P07704040A0000|185 194|reductase
P07704040A0000|158 175|quinone reductase
P07704040A0000|121 122|H
P07704456A1014|8 17|mechanism
P07704456A1014|109 119|prevalence
P07704456A1014|149 161|HMS subjects
P07704730T0000|35 41|future
P07704730T0000|6 19|contraception
P07705627A1107|99 110|development
P07705627A1107|25 30|Medea
P07706287A0698|34 37|RNA
P07706287A0698|62 71|cytoplasm
P07706287A0698|104 109|phase
P07706299A0563|1 18|Inhibition assays
P07706299A0563|172 180|features
P07706299A0563|193 224|oligosaccharide-protein binding
P07706396T0000|32 46|SEC1 homologue
P07706396T0000|83 90|defects
P07706396T0000|111 128|membrane vesicles
P07707531A0550|19 25|design
P07707531A0550|112 122|repression
P07707531A0550|52 58|effect
P07707531A0550|92 104|binding site
P07707531A0550|134 152|gene transcription
P07708058A0178|48 52|cGRE
P07708058A0178|80 99|activator protein-1
P07708058A0178|43 46|GRE
P07708058A0178|107 112|motif
P07708497A0000|17 27|activation
P07708497A0000|48 50|T3
P07708497A0000|129 133|TREs
P07708497A0000|182 188|AGGTCA
P07708497A0000|61 73|interactions
P07708497A0000|151 157|copies
P07711730A0000|33 36|CPT
P07711730A0000|129 135|muscle
P07711730A0000|41 51|deficiency
P07713421A1435b|80 87|ability
P07713421A1435b|26 50|gain-of-function mutants
P07714608A1252|16 27|differences
P07714608A1252|97 107|heart rate
P07714608A1252|52 58|groups
P07714608A1252|109 126|brain temperature
P07715200A0000|1 18|Anesthesiologists
P07715200A0000|43 47|drug
P07715200A0000|74 89|target response
P07715922A0188|81 86|cells
P07715922A0188|52 57|shape
P07715922A0188|147 150|PRK
P07715922A0188|61 68|corneal
P07719527T0000|35 46|hirudin CGP
P07719527T0000|54 60|REVASC
P07720572A1584|18 28|difference
P07720572A1584|232 242|mechanisms
P07720572A1584|246 258|10T1/2 cells
P07720572A1584|58 70|10T1/2 cells
P07720572A1584|151 169|myoD core enhancer
P07720710A0861|13 26|HMG2 proteins
P07721422A0241|1 29|Primer extension experiments
P07721422A0241|106 116|mouse type
P07723247A0187|252 258|inflow
P07723247A0187|263 276|outflow ports
P07723247A0187|36 45|magnitude
P07723247A0187|133 145|computerized
P07723247A0187|107 116|dialysate
P07724452A0344|84 86|d.
P07724452A0344|73 76|pen
P07724452A0344|14 23|treatment
P07728201A0660|4 12|contrast
P07728201A0660|178 200|penicillin prophylaxis
P07728201A0660|58 85|sickle-hemoglobin C disease
P07728201A0660|44 52|children
P07730273A1309|33 57|amino acid substitutions
P07730273A1309|5 9|NarX
P07730336A0606|69 72|CRE
P07730336A0606|114 122|kappa E3
P07730336A0606|124 127|CRE
P07730336A0606|45 67|cAMP response elements
P07730337T0000|33 37|gene
P07730337T0000|94 105|neurogranin
P07730337T0000|15 25|regulation
P07731686A0000|5 15|TTG-2 gene
P07731686A0000|106 111|T-ALL
P07733075A1200|34 38|mg/b
P07733075A1200|64 68|mg/b
P07733075A1200|39 43|i.d.
P07733075A1200|79 82|CBS
P07733075A1200|45 59|clarithromycin
P07733075A1200|155 173|% eradication rate
P07733075A1200|20 30|omeprazole
P07733075A1200|92 96|i.d.
P07733075A1200|123 134|combination
P07735833A1078|34 56|LysU crystal structure
P07735833A1078|1 12|CONCLUSIONS
P07735833A1078|66 76|structures
P07737118A0317|119 129|constructs
P07737118A0317|5 9|MPS1
P07737118A0317|89 100|GST protein
P07737944A0000|69 89|transfusion practice
P07737944A0000|59 65|impact
P07737944A0000|121 125|need
P07737944A0000|181 187|states
P07737944A0000|15 29|growth factors
P07738839A0173|84 87|PET
P07738839A0173|33 35|EC
P07738839A0173|8 18|IC breaths
P07738839A0173|88 91|CO2
P07739382A0457|108 116|proteins
P07739382A0457|63 76|protein types
P07739382A0457|166 174|ancestor
P07739542A1419|50 59|cyclin D1
P07739542A1419|82 97|G1/S transition
P07739542A1419|106 111|cells
P07739566A1076|168 179|differences
P07739566A1076|130 136|domain
P07739566A1076|195 206|specificity
P07740490T0000|39 43|time
P07740490T0000|12 21|estrogens
P07740490T0000|75 84|serotonin
P07742024A0121|169 174|types
P07742024A0121|82 88|places
P07742024A0121|214 220|extent
P07742024A0121|125 130|tumor
P07742024A0121|31 47|imaging features
P07742363A0941|35 52|yeast eIF-2 alpha
P07742363A0941|111 116|yeast
P07742363A0941|10 13|Ser
P07742917T0001|1 8|Icterus
P07742917T0001|43 51|children
P07743515A0223|155 181|colon adenocarcinoma cells
P07743515A0223|6 14|analysis
P07743515A0223|111 127|cytotrophoblasts
P07743515A0223|45 49|AAMP
P07744763A0514|175 184|receptors
P07744763A0514|39 47|extracts
P07744763A0514|231 236|HNF-4
P07744763A0514|95 133|electromobility supershift experiments
P07744763A0514|210 217|CYP2C11
P07744846A1006|171 176|Bcl-2
P07744846A1006|341 350|C domains
P07744846A1006|161 166|model
P07744846A1006|107 113|method
P07744846A1006|326 336|carboxyl B
P07744846A1006|252 260|A domain
P07744846A1006|218 227|sequences
P07744846A1006|123 131|evidence
P07744846A1006|90 95|yeast
P07745008A0892|74 84|constructs
P07745684T0000|36 51|gene expression
P07745684T0000|110 124|RNA processing
P07745693A0914|153 162|component
P07745693A0914|1 8|Studies
P07745693A0914|96 107|translation
P07745693A0914|40 53|Lb proteinase
P07745726A0960|50 52|E2
P07745726A0960|113 121|distance
P07745726A0960|93 111|expression vectors
P07745726A0960|167 171|role
P07746397A0233|1 8|METHODS
P07746397A0233|64 68|July
P07746397A0233|96 104|patients
P07746397A0233|78 86|December
P07746397A0233|195 214|thromboplastin time
P07746397A0233|216 220|aPTT
P07746397A0233|122 131|embolisms
P07746937A0100|51 59|patients
P07746937A0100|66 72|period
P07746937A0100|89 95|months
P07748451A0343|19 30|discrepancy
P07748451A0343|5 9|mean
P07748451A0343|126 130|poly
P07748451A0343|46 58|restorations
P07748502A0794|102 112|water maze
P07748502A0794|19 28|8-OH-DPAT
P07748502A0794|56 63|ability
P07748952A0462|48 53|P1hfq
P07748952A0462|4 12|addition
P07748952A0462|27 36|promoters
P07749088A0119|10 12|T1
P07749461A1022|202 212|expression
P07749461A1022|97 111|sGTH alpha/CAT
P07749461A1022|73 85|transfection
P07749461A1022|135 148|rainbow trout
P07751848A0222|51 61|activities
P07751848A0222|5 35|carnitine palmitoyltransferase
P07751848A0222|213 221|subjects
P07751848A0222|167 186|nmol/min/mg protein
P07752454A0341|27 30|CNS
P07752454A0341|75 86|methicillin
P07752886A0595|115 119|FecR
P07752886A0595|93 101|residues
P07753030A0173|99 121|Rhodobacter capsulatus
P07753030A0173|53 57|DNAs
P07753030A0173|89 97|phaseoli
P07753796A0743|1 11|Expression
P07753796A0743|20 24|cDNA
P07753796A0743|43 50|peptide
P07754713A0227|39 44|SPP91
P07754713A0227|53 57|CRY2
P07754713A0227|111 115|gene
P07754713A0227|47 51|CDC6
P07754713A0227|14 18|NUC1
P07755914A0000|138 142|AIDS
P07755914A0000|189 193|DMAC
P07755914A0000|59 73|clarithromycin
P07755914A0000|78 90|azithromycin
P07755914A0000|124 132|patients
P07758167A1488|119 129|clone ME10
P07758167A1488|1 14|Growth curves
P07758167A1488|78 85|% serum
P07758167A1488|30 43|proliferation
P07758459A1277|16 25|AAC2 gene
P07758459A1277|96 106|activators
P07758459A1277|150 177|core HAP2/3/4 binding motif
P07759094A0634|109 134|microsatellite PCR marker
P07759094A0634|61 72|NHE5 cosmid
P07759529A0288|65 74|repressor
P07759529A0288|13 23|approaches
P07760819A0731|68 97|PDGF beta receptor activation
P07760819A0731|131 149|cell proliferation
P07760819A0731|13 23|activation
P07760841A0647|100 104|ADH2
P07760841A0647|191 202|copy number
P07760841A0647|66 70|UAS1
P07760841A0647|178 189|orientation
P07760841A0647|145 160|gene activation
P07760841A0647|208 219|helix phase
P07761091A0294|17 28|MAP kinases
P07761091A0294|64 69|MKP-1
P07761420A0909|48 53|CCaMK
P07761467A0666|51 69|protein components
P07761467A0666|91 98|protein
P07762504A0648|68 77|mg/kg/day
P07762504A0648|114 118|dose
P07762504A0648|53 63|amiodarone
P07762504A0648|30 44|administration
P07765118A0967|141 143|h.
P07765118A0967|5 22|maximum induction
P07765118A0967|26 49|ACC-oxidase transcripts
P07767011A0689|1 7|Repair
P07767011A0689|83 93|hprt locus
P07767011A0689|40 53|recombination
P07768836A1126|1 29|Primer extension experiments
P07768836A1126|115 125|start site
P07768898A0492|34 44|divergence
P07768898A0492|48 65|apobec1 sequences
P07768898A0492|82 89|numbers
P07768898A0492|161 168|apobec1
P07768898A0492|123 136|suhstitutions
P07770033A0978|136 140|acid
P07770033A0978|100 103|ORF
P07770033A0978|54 59|clone
P07770033A0978|29 35|clones
P07770033A0978|181 189|homology
P07771745A0442|33 37|face
P07771745A0442|114 124|cheekbones
P07771745A0442|78 86|forehead
P07774137A0000|50 54|test
P07774137A0000|99 106|group A
P07774137A0000|199 205|clinic
P07774137A0000|72 81|detection
P07774925A0084|153 160|T cells
P07774925A0084|87 92|pools
P07774925A0084|96 101|cDNAs
P07774925A0084|37 49|BRCA1 region
P07774925A0084|131 141|HeLa cells
P07776685A0000|171 180|resection
P07776685A0000|185 190|stage
P07776685A0000|6 11|study
P07776685A0000|128 141|interleukin-2
P07776685A0000|148 156|patients
P07776685A0000|210 221|lung cancer
P07776882A0000|33 53|cell volume dynamics
P07776882A0000|83 91|ischemia
P07777518A0483|1 15|DNA sequencing
P07777518A0483|20 42|Southern blot analyses
P07779811A0901|17 28|Sp1 element
P07779811A0901|82 91|reduction
P07779811A0901|46 57|Sp1 binding
P07780148A1153|64 72|M phases
P07780148A1153|112 120|G1 phase
P07780148A1153|44 49|level
P07780719A0477|30 37|driving
P07782087A0559|98 106|position
P07782087A0559|196 209|RACE analyses
P07782087A0559|131 142|combination
P07782302A0479|119 139|affinity interaction
P07782302A0479|159 166|protein
P07782302A0479|73 76|Ran
P07782302A0479|31 46|DEDDDL sequence
P07783064A0452|96 102|levels
P07783064A0452|92 94|CK
P07783822A0000|1 10|OBJECTIVE
P07783822A0000|93 101|beriberi
P07783822A0000|45 57|presentation
P07784078A1064|34 38|lack
P07784078A1064|87 96|RAR alpha
P07784078A1064|42 57|gene expression
P07784197A0827|207 235|BALB/c 3T3 mouse fibroblasts
P07784197A0827|141 149|TGF-beta
P07784197A0827|174 185|band shifts
P07784197A0827|111 118|HeLa S3
P07784197A0827|11 19|extracts
P07784870A0119|17 24|reports
P07784870A0119|257 269|microbiology
P07784870A0119|59 67|findings
P07784870A0119|229 249|immunohistochemistry
P07784870A0119|107 118|information
P07786820A0284|102 108|saline
P07786820A0284|117 122|weeks
P07786820A0284|59 63|dose
P07786820A0284|40 53|i.v. infusion
P07787179A0312|19 28|X1 region
P07787179A0312|37 52|PRB-1b promoter
P07787179A0312|120 143|ethylene responsiveness
P07789342A1352|71 87|affinity binding
P07789342A1352|42 47|TSH-R
P07789342A1352|28 34|domain
P07789809A1246|51 56|types
P07789809A1246|158 175|vesicle transport
P07789809A1246|11 24|Western blots
P07789809A1246|122 141|household functions
P07789809A1246|60 63|Ypt
P07790271A1185|29 44|Gy/25 fractions
P07790719A0098|70 85|family violence
P07790719A0098|21 27|effort
P07791763T0000|35 61|insulin receptor substrate
P07791763T0000|93 122|phosphatidylinositol 3-kinase
P07791763T0000|11 18|cloning
P07791768A0930|103 107|swi6
P07791768A0930|21 42|cell cycle regulators
P07791768A0930|66 71|rap1s
P07791768A0930|215 224|silencing
P07791768A0930|109 113|swi4
P07791768A0930|75 95|hmr delta A mutation
P07791771A0183|7 10|Mol
P07791783A0000|80 100|leucine zipper motif
P07791783A0000|123 129|SOX-LZ
P07791783A0000|13 17|cDNA
P07794556A0000|85 92|disease
P07794556A0000|37 43|Leuven
P07794556A0000|8 14|Center
P07794556A0000|56 67|DNA-testing
P07794556A0000|134 142|November
P07795576A0126|1 12|Examination
P07795576A0126|94 102|increase
P07795576A0126|29 36|factors
P07797077A0842|100 107|domains
P07797077A0842|111 118|members
P07797077A0842|198 203|ICSBP
P07797077A0842|184 189|IRF-1
P07797077A0842|191 196|IRF-2
P07797077A0842|148 154|factor
P07797077A0842|62 68|degree
P07797476A1001|5 18|RAP74 subunit
P07797476A1001|148 156|residues
P07797476A1001|60 68|activity
P07798134T0000|5 22|hsp70 gene family
P07798134T0000|26 43|Neurospora crassa
P07798134T0000|135 141|member
P07798217T0000|84 91|control
P07798217T0000|43 49|Ser129
P07798217T0000|13 28|phosphorylation
P07798271A0330|59 67|proteins
P07798271A0330|11 17|region
P07798271A0330|134 147|Ets-1 protein
P07799925A0526|139 163|tyrosine phosphorylation
P07799925A0526|223 229|p59fyn
P07799925A0526|80 90|HeLa cells
P07799925A0526|40 43|p62
P07799925A0526|208 219|SH2 domains
P07799931A1232|4 12|contrast
P07799931A1232|62 75|c-Maf actions
P07799948A0777|139 144|Raf-1
P07799948A0777|114 117|Src
P07799948A0777|43 47|site
P07799948A0777|79 91|Raf-1 kinase
P07799948A0777|165 175|mechanisms
P07800479A0201|137 145|proteins
P07800479A0201|155 162|nucleus
P07800479A0201|124 133|transport
P07800479A0201|63 70|protein
P07801180A0197|65 81|study approaches
P07801180A0197|41 52|limitations
P07802655T0000|1 17|Characterization
P07802655T0000|33 47|Xenopus laevis
P07802655T0000|114 117|L14
P07802655T0000|128 141|protein genes
P07806492A1162|85 94|precursor
P07806492A1162|6 15|structure
P07806532A0659|87 89|nM
P07806532A0659|47 50|DNA
P07806820A0091|43 50|pedicle
P07808210A1510|54 61|NCEP I.
P07808210A1510|25 30|value
P07809410A0606|34 40|lesion
P07809410A0606|113 119|iodine
P07809410A0606|92 104|131I protein
P07809410A0606|121 129|131I-PBI
P07809410A0606|60 86|serum thyroglobulin values
P07811964A1252|143 155|dimerization
P07811964A1252|26 40|repeat element
P07813466A0074|68 73|trout
P07813466A0074|18 23|mouse
P07813466A0074|173 178|hsc70
P07813466A0074|93 100|introns
P07813466A0074|56 63|Xenopus
P07814321A0850|1 9|Deletion
P07814321A0850|59 65|growth
P07814321A0850|72 81|reduction
P07814388A0662|70 79|receptors
P07814388A0662|11 27|L-cell membranes
P07814388A0662|120 154|pertussis toxin substrate activity
P07814405A1170|185 193|proteins
P07814405A1170|144 153|formation
P07814405A1170|45 60|point mutations
P07815546A0411|1 6|Virol
P07816025A0196|1 11|Comparison
P07816025A0196|157 164|domains
P07816025A0196|83 92|sequences
P07816025A0196|27 46|amino acid sequence
P07816049A1157|69 73|copy
P07816049A1157|216 221|roots
P07816049A1157|53 61|presence
P07816049A1157|127 149|Northern blot analysis
P07816049A1157|107 121|haploid genome
P07816619A0000|24 56|Arabidopsis thaliana cDNA clones
P07816619A0000|165 187|cAMP phosphodiesterase
P07816630A1333|35 43|sequence
P07816630A1333|112 116|BTU2
P07816630A1333|62 88|translation terminator TGA
P07816630A1333|151 157|region
P07818416A0895|103 106|g/L
P07818416A0895|162 171|instances
P07818416A0895|28 54|haemoglobin concentrations
P07820057A0000|102 115|cell leukemia
P07820057A0000|1 28|Tumor necrosis factor alpha
P07820057A0000|127 131|bone
P07822161A1172|17 29|monkey opsin
P07822161A1172|142 153|differences
P07822161A1172|58 66|sequence
P07822161A1172|74 84|nucleotide
P07823951A1100|85 102|globin expression
P07823951A1100|32 36|EKLF
P07823951A1100|173 178|CACCC
P07823951A1100|129 133|idea
P07823951A1100|160 169|regulator
P07823964A0922|102 108|Pho81p
P07823964A0922|25 33|activity
P07823964A0922|91 98|segment
P07824464A0169|207 213|colour
P07824464A0169|173 185|haemorrhages
P07824464A0169|97 120|artery wall dissections
P07824464A0169|122 137|plaque ruptures
P07824464A0169|31 43|tissue flaps
P07824726A0454|70 74|body
P07824726A0454|32 41|subgroups
P07824726A0454|6 10|type
P07824726A0454|79 83|tail
P07824726A0454|91 99|pancreas
P07824726A0454|134 138|type
P07826412T0112|69 83|gamma-subunits
P07826412T0112|7 17|hypothesis
P07826412T0112|88 98|activation
P07828584A0681|16 19|IM1
P07828584A0681|33 40|ability
P07828584A0681|44 49|c-Fos
P07828811A0556|6 13|failure
P07828811A0556|75 92|thermosensitivity
P07828852A0153|25 34|telomeres
P07829057T0000|1 28|Integrated mapping analysis
P07829057T0000|62 72|chromosome
P07829102T0000|48 64|mouse Nramp gene
P07829102T0000|73 87|susceptibility
P07829102T0000|120 129|parasites
P07829554A0257|273 281|antibody
P07829554A0257|135 144|corrosion
P07829554A0257|16 25|knowledge
P07829554A0257|115 133|protein conjugates
P07829554A0257|261 268|testing
P07829554A0257|243 248|ELISA
P07831310A0000|82 92|polymerase
P07831310A0000|77 80|TEV
P07831310A0000|57 75|tobacco etch virus
P07831310A0000|11 33|complementation system
P07831829A1324|1 11|Comparison
P07831829A1324|64 75|furoviruses
P07831829A1324|36 41|BNYVV
P07831829A1324|47 52|SBWMV
P07832779A0719|1 16|Deglycosylation
P07832779A0719|22 39|endoglycosidase H
P07835088A0238|16 28|HSD3B2 genes
P07835088A0238|5 11|HSD3B1
P07835088A0238|42 47|types
P07835273A0000|71 87|insulin receptor
P07835273A0000|41 51|adipocytes
P07835710T0000|13 22|structure
P07835886A0894|70 90|chromosome 14q31-q32
P07835886A0894|5 21|kallistatin gene
P07835886A0894|176 195|alpha 1-antitrypsin
P07835886A0894|47 60|hybridization
P07836218A0128|17 25|exercise
P07836218A0128|157 164|release
P07836218A0128|6 13|studies
P07836218A0128|130 138|acidosis
P07836364A0000|119 128|molecules
P07836364A0000|1 5|Self
P07836364A0000|111 116|class
P07836364A0000|78 104|histocompatibility complex
P07836364A0000|56 68|presentation
P07836364A0000|106 109|MHC
P07836406A0884|33 41|peptides
P07836406A0884|188 202|chromatography
P07836406A0884|57 62|MHC-B
P07838156A0789|69 82|transcription
P07838156A0789|93 117|hormone response element
P07838156A0789|133 146|reporter gene
P07841230T0000|1 13|Dissociation
P07841230T0000|54 68|antimicrobials
P07841663A0845|175 187|sperm motion
P07841663A0845|7 14|studies
P07841663A0845|91 105|oxygen species
P07844155A0327|187 196|processes
P07844155A0327|114 126|LAR isoforms
P07844155A0327|208 211|LAR
P07844155A0327|47 68|tyrosine phosphatases
P07844425A0289|84 93|eggs/10ml
P07844425A0289|20 25|count
P07844425A0289|42 52|eggs/10 ml
P07845672A0368|1 11|Comparison
P07845672A0368|116 122|region
P07845672A0368|74 95|% amino acid identity
P07846163A0422|5 10|mRNAs
P07846163A0422|47 52|exons
P07846942A0717|25 50|beta-receptor antagonists
P07846942A0717|149 154|drugs
P07846942A0717|105 117|fibrillation
P07847036A0353|19 24|times
P07847036A0353|9 14|doses
P07851643A1365|102 116|germline cells
P07851643A1365|133 155|oocyte differentiation
P07851643A1365|13 20|studies
P07852037A0548|64 67|TBF
P07852400A0519|1 31|Rho GDP/GTP exchange inhibitor
P07852400A0519|81 85|Rac1
P07852400A0519|58 62|Rac2
P07853476A0159|10 12|J.
P07853524A1944|1 8|Removal
P07853524A1944|32 39|GST-Tax
P07853524A1944|67 74|ability
P07853524A1944|43 51|thrombin
P07854130T0000|139 143|type
P07854130T0000|5 22|pilE gene product
P07854130T0000|146 163|prepilin proteins
P07854324A0742|118 135|growth conditions
P07854324A0742|82 96|cell phenotype
P07854324A0742|62 68|causes
P07857086A0949|19 20|%
P07857086A0949|98 99|D
P07857086A0949|25 32|Insulin
P07857086A0949|61 62|%
P07857344A0591|55 56|h
P07857344A0591|96 129|pidotimod administration schedule
P07857344A0591|8 17|half-life
P07858986A0310|141 147|Valcor
P07858986A0310|36 50|interferometry
P07858986A0310|196 220|glutaraldehyde treatment
P07858986A0310|94 116|Carpentier-Edwards SAV
P07858986A0310|15 20|study
P07859301A0325|138 165|transcription factor family
P07859301A0325|6 12|region
P07859665A0498|5 16|mean jitter
P07859665A0498|25 38|fiber density
P07859665A0498|124 127|day
P07859777A0000|34 38|rHSA
P07859777A0000|99 103|form
P07859777A0000|178 192|technetium-99m
P07859777A0000|227 235|chloride
P07859777A0000|135 142|microns
P07860646A1363|112 117|FGF-2
P07860646A1363|9 21|intervention
P07860646A1363|45 48|use
P07862108A0987|70 74|mass
P07862108A0987|40 43|TEP
P07862141A0317|80 89|inability
P07862141A0317|63 72|cAPK lead
P07862150A0429|136 161|TGF-beta binding activity
P07862150A0429|6 12|mutant
P07862150A0429|76 82|series
P07862150A0429|227 235|TGF-beta
P07862162A0408|33 40|choline
P07862162A0408|59 66|product
P07862162A0408|124 138|UASINO element
P07862162A0408|74 83|OPI1 gene
P07862168A0000|54 58|gene
P07862168A0000|127 134|stimuli
P07862168A0000|41 52|IL-2R alpha
P07863047A0229|51 59|patients
P07863047A0229|117 131|oxygen therapy
P07863047A0229|172 183|correlation
P07863047A0229|133 137|CAOT
P07863047A0229|192 195|ACE
P07863992A0908|185 192|syncope
P07863992A0908|71 78|testing
P07863992A0908|143 148|years
P07863992A0908|42 48|result
P07863992A0908|214 224|medication
P07863992A0908|109 122|heart disease
P07864652A1901|158 167|processes
P07864652A1901|94 99|roles
P07865129A0293|32 56|TBP/TATA sequence motifs
P07865129A0293|73 79|region
P07865787A1086|32 39|hexamer
P07865787A1086|5 12|results
P07865787A1086|93 103|regulation
P07865787A1086|164 174|expression
P07865888A1309|112 118|import
P07865888A1309|145 155|maturation
P07865888A1309|124 136|mitochondria
P07865917A0191|138 145|results
P07865917A0191|112 126|ACE inhibitors
P07865917A0191|92 106|plasmapheresis
P07865917A0191|72 84|cyclosporine
P07867622X0000|1 16|Promoter region
P07867622X0000|110 117|protein
P07867622X0000|40 44|unit
P07867622X0000|243 249|events
P07867622X0000|122 128|p21rac
P07869721A0000|35 43|dynamics
P07869721A0000|9 14|paper
P07869721A0000|72 80|occluder
P07869937A1142|103 106|RMR
P07869937A1142|86 87|%
P07869937A1142|163 170|P group
P07869937A1142|145 146|%
P07869937A1142|47 50|GIT
P07871718A1132|111 115|beta
P07871718A1132|149 159|activation
P07871718A1132|62 75|ICP4 promoter
P07871721A0392|179 190|cysteine994
P07871721A0392|106 110|p223
P07871721A0392|135 152|proteinase domain
P07871755A0521|20 24|VLPs
P07871755A0521|42 52|quantities
P07871891A0227|1 6|SUP46
P07871891A0227|24 44|translation fidelity
P07872788A1717|187 198|duplication
P07872788A1717|20 37|sequence identity
P07872788A1717|158 175|carboxylesterases
P07872788A1717|10 16|degree
P07872788A1717|133 138|genes
P07873831T0000|37 54|mycosis fungoides
P07873831T0000|89 93|mass
P07874060A0810|99 113|stomach tissue
P07874060A0810|10 15|doses
P07874060A0810|133 147|administration
P07874060A0810|30 35|mg/kg
P07876134A0348|139 152|reading frame
P07876134A0348|21 37|characterization
P07876134A0348|76 84|AFAP-110
P07876192A0443|39 50|amino acids
P07876192A0443|125 143|ICE autoprocessing
P07876210A0275|171 189|Barbie box element
P07876210A0275|94 101|regions
P07876300A0994|18 24|nuclei
P07877308A1175|51 52|%
P07877308A1175|39 47|patients
P07878029A0721|65 84|CBF-A-CBF-C complex
P07878029A0721|94 99|CBF-B
P07878029A0721|183 202|CBF-A-CBF-C complex
P07878029A0721|14 19|CBF-A
P07879204T0000|118 125|results
P07879204T0000|71 79|patients
P07879204T0000|95 107|cyclosporine
P07880449A0091|185 195|cGy X-rays
P07880449A0091|157 173|body irradiation
P07880449A0091|112 123|suppression
P07880449A0091|89 93|mice
P07881077A0195|1 34|Supplementary Phase Contraste RSE
P07881077A0195|54 64|Excitation
P07883168A0090|1 10|Mutations
P07883168A0090|58 63|mRNAs
P07883168A0090|148 153|mRNAs
P07883168A0090|14 23|UPF1 lead
P07883754A0993|49 56|extract
P07883754A0993|7 29|gel retardation assays
P07883754A0993|78 86|presence
P07885999A0000|87 108|mouse tyrosinase gene
P07885999A0000|131 141|band shift
P07885999A0000|44 53|sequences
P07887226A0858|117 125|addition
P07887226A0858|250 253|IDA
P07887226A0858|39 64|hemoglobin determinations
P07887226A0858|143 150|surveys
P07887226A0858|208 223|iron deficiency
P07887859A0998|83 99|ulcer management
P07888156T0000|19 32|telepathology
P07888623A0721|1 15|PMEK1 displays
P07888623A0721|114 115|%
P07888623A0721|58 70|tobacco NTF3
P07888623A0721|75 101|Arabidopsis ATMPK1 kinases
P07888788A1010|17 21|type
P07888788A1010|206 219|aspergillomas
P07888788A1010|99 108|component
P07888788A1010|58 71|aspergillomas
P07888788A1010|46 54|subgroup
P07890485A0827|172 177|g.min
P07890485A0827|42 55|photoreceptor
P07890485A0827|57 60|QO2
P07890485A0827|123 126|QO2
P07890674A0916|156 164|catenins
P07890674A0916|5 13|catenins
P07890674A0916|22 25|APC
P07890674A0916|133 141|presence
P07890674A0916|30 40|E-cadherin
P07890740A0997|143 155|PSD activity
P07890740A0997|95 106|baculovirus
P07890740A0997|60 77|Sf-9 insect cells
P07891685A1051|136 141|Mig1p
P07891685A1051|69 76|binding
P07891685A1051|7 14|results
P07891685A1051|93 102|synthesis
P07891708A1192|136 150|HNF-4 delta C.
P07891708A1192|31 41|expression
P07891713T0000|71 81|repressors
P07891713T0000|40 43|Fos
P07892076A0578|16 27|development
P07892076A0578|54 57|P-2
P07892076A0578|43 52|infection
P07894021A1130|7 11|data
P07894021A1130|29 37|function
P07894021A1130|45 48|DS2
P07894761A0000|5 8|aim
P07894761A0000|129 136|success
P07894761A0000|148 154|vision
P07894761A0000|31 36|study
P07896291A0693|96 112|characterization
P07896291A0693|150 163|WAGR syndrome
P07896817A0204|119 128|PLC-gamma
P07896817A0204|84 92|antisera
P07896817A0204|96 117|phospholipase C-gamma
P07896817A0204|74 78|BAEC
P07896817A0204|45 52|control
P07896852T0000|54 90|apolipoprotein AI gene transcription
P07897696A0000|34 50|acid dehydratase
P07897696A0000|1 12|Erythrocyte
P07897696A0000|234 247|lead exposure
P07897696A0000|282 288|excess
P07897696A0000|106 116|heme ratio
P07897696A0000|295 308|micrograms/dl
P07897696A0000|266 278|blood levels
P07897696A0000|146 148|UC
P07898275A0254|205 211|1H MRS
P07898275A0254|237 249|test objects
P07898275A0254|7 14|classes
P07898275A0254|310 314|ISIS
P07898275A0254|318 346|volume localization sequence
P07898275A0254|18 30|test objects
P07898275A0254|268 279|performance
P07898840X0000|32 58|artery Doppler velocimetry
P07898840X0000|66 75|criterion
P07898840X0000|282 300|growth restriction
P07898840X0000|186 195|gestation
P07898840X0000|259 271|hypertension
P07898840X0000|320 328|analysis
P07898840X0000|384 395|assessments
P07898840X0000|91 100|OBJECTIVE
P07898840X0000|448 455|results
P07899634A0000|1 8|PURPOSE
P07899634A0000|159 161|mu
P07899634A0000|26 31|study
P07901121T0000|1 25|Cooperative dimerization
P07901121T0000|59 62|DNA
P07902532A0312|98 106|promoter
P07902532A0312|36 43|BOX DNA
P07902532A0312|9 14|study
P07902583A0545|152 157|Grf10
P07902583A0545|116 125|complexes
P07902583A0545|144 148|Swi5
P07902583A0545|13 33|disassociation rates
P07903670A1202|12 18|allele
P07905453A0281|1 8|Results
P07905453A0281|109 112|ORF
P07906616A0191|141 152|anaesthesia
P07906616A0191|26 34|response
P07906616A0191|60 71|stimulation
P07907846A0623|222 233|stimulation
P07907846A0623|38 48|mg/kg i.v.
P07907846A0623|140 145|Group
P07907846A0623|97 100|min
P07907846A0623|108 134|bupivacaine administration
P07908187T0000|8 21|possibilities
P07909936A0672|114 131|radiochemotherapy
P07909936A0672|144 169|stem-cell transplantation
P07909936A0672|47 56|disorders
P07909936A0672|194 203|cytokines
P07910946A0323|175 181|region
P07910946A0323|55 74|transfection assays
P07910946A0323|113 123|luciferase
P07910946A0323|196 213|promoter activity
P07910946A0323|15 18|set
P07913891A0174|238 256|tissue specificity
P07913891A0174|49 58|molecules
P07913891A0174|173 194|transcription factors
P07913891A0174|15 22|targets
P07914192A0211|53 58|DNase
P07914192A0211|247 260|HER2 promoter
P07914192A0211|124 144|ets response element
P07914192A0211|166 183|bases down-stream
P07914507A1029|103 107|poly
P07914507A1029|96 99|use
P07914507A1029|76 82|result
P07914507A1029|108 109|A
P07915144A0000|1 15|High-frequency
P07915144A0000|27 38|stimulation
P07915144A0000|91 99|efficacy
P07916326A0000|116 120|gene
P07916326A0000|20 32|organization
P07916326A0000|122 127|Msx-1
P07916577A0190|141 150|sequences
P07916577A0190|96 111|gene expression
P07916577A0190|60 69|disorders
P07916685A0455|139 151|purification
P07916685A0455|65 89|prephenate dehydrogenase
P07916685A0455|165 175|activities
P07916689A1407|85 93|sequence
P07916689A1407|103 106|kbp
P07916689A1407|110 113|DNA
P07916689A1407|27 36|POT1 gene
P07916983A0623|22 24|CT
P07916983A0623|130 142|prescription
P07917540A0000|186 195|treatment
P07917540A0000|4 12|patients
P07917540A0000|161 171|interferon
P07917540A0000|73 83|mg/m2/week
P07917540A0000|120 125|times
P07917540A0000|60 69|vindesine
P07918128A0000|1 11|BACKGROUND
P07918128A0000|97 116|receptor antagonist
P07918128A0000|124 132|patients
P07918128A0000|28 33|phase
P07919540A0240|118 127|AUG codon
P07919540A0240|131 135|exon
P07919540A0240|41 50|synthesis
P07922709T0000|84 95|application
P07922709T0000|12 22|activities
P07925097A1205|76 84|exposure
P07925097A1205|88 97|8-Br-cAMP
P07926729A0000|43 73|signal transduction mechanisms
P07926729A0000|9 20|alterations
P07926729A0000|149 157|programs
P07926748A0383|1 5|NOT4
P07926748A0383|64 78|overexpression
P07926748A0383|53 58|assay
P07926748A0383|106 110|not1
P07926748A0383|30 34|NOT3
P07926774A0652|65 68|MCB
P07926774A0652|77 80|SCB
P07926789A0960|101 109|products
P07926789A0960|82 94|fusion genes
P07927267T0000|18 26|drainage
P07927267T0000|128 139|hepatectomy
P07927267T0000|44 52|drainage
P07927838A0000|187 196|stiffness
P07927838A0000|20 28|subjects
P07927838A0000|159 162|VWF
P07927838A0000|178 182|pain
P07927838A0000|107 123|prevalence rates
P07929165T0000|35 47|actVI region
P07929165T0000|18 27|functions
P07929165T0000|55 67|actinorhodin
P07929411A0087|3 13|comparison
P07929411A0087|112 117|mouse
P07929411A0087|122 127|yeast
P07929411A0087|195 202|regions
P07929559A0000|202 212|organelles
P07929559A0000|77 83|enzyme
P07929559A0000|149 158|movements
P07931490A0237|1 9|PATIENTS
P07931490A0237|233 245|chemotherapy
P07931490A0237|162 179|granisetron doses
P07931490A0237|198 211|micrograms/kg
P07932943A0113|102 110|strategy
P07932943A0113|156 173|control condition
P07932943A0113|41 50|influence
P07933076A0211|22 27|EBNA2
P07933076A0211|47 56|promoters
P07933101A0131|10 17|studies
P07933116A0412|50 51|B
P07933116A0412|93 102|cell line
P07933116A0412|104 108|U937
P07934666A0158|101 103|T2
P07934666A0158|81 83|T2
P07934666A0158|110 113|T2s
P07935370A0000|17 27|expression
P07935370A0000|39 42|CD8
P07935370A0000|121 127|T cell
P07935379A0347|70 77|changes
P07935379A0347|96 101|cells
P07935395A0094|51 69|zinc finger motifs
P07935395A0094|5 12|protein
P07935395A0094|28 31|kDa
P07935418A0447|37 41|cDNA
P07935418A0447|9 21|v-erbA probe
P07935418A0447|79 86|protein
P07935447A0972|238 248|expression
P07935447A0972|173 182|component
P07935447A0972|135 146|PRE B sites
P07935447A0972|186 203|protein complexes
P07935447A0972|49 55|member
P07935447A0972|86 107|leucine zipper family
P07935447A0972|124 129|HF-1a
P07935468T0000|69 91|growth factor receptor
P07935468T0000|15 36|c-fos gene expression
P07935472A0276|32 37|Ets-1
P07935472A0276|237 248|LVc element
P07935472A0276|77 94|expression assays
P07935472A0276|281 298|enhancer activity
P07935472A0276|46 51|sites
P07935472A0276|125 127|E1
P07935472A0276|182 199|enhancer activity
P07935491A0495|7 19|RZR subtypes
P07935491A0495|47 53|family
P07935577A0305|35 46|flucytosine
P07935577A0305|1 10|Treatment
P07935577A0305|54 65|improvement
P07935577A0305|147 152|fluid
P07935997A0000|186 190|IIIB
P07935997A0000|204 208|year
P07935997A0000|49 70|serum immunoglobulins
P07935997A0000|5 15|parameters
P07935997A0000|131 139|patients
P07936640A0900|205 215|cell lines
P07936640A0900|184 193|rat liver
P07936640A0900|260 266|levels
P07936640A0900|244 248|gene
P07936640A0900|124 131|portion
P07936640A0900|44 49|sites
P07936650A1752|129 138|evidences
P07936650A1752|40 45|ets-1
P07936650A1752|46 56|ets-2 gene
P07937108A0325|25 30|mRNAs
P07937127A0645|175 186|herpesvirus
P07937127A0645|145 163|pseudorabies virus
P07937127A0645|123 136|herpesviruses
P07937147A0205|153 163|Filutowicz
P07937147A0205|114 118|Gene
P07937147A0205|144 148|York
P07937147A0205|165 167|J.
P07937147A0205|120 124|Amst
P07937841A0790|100 108|pathways
P07937841A0790|23 31|evidence
P07937841A0790|7 14|results
P07937841A0790|78 88|cell cycle
P07937965T0000|25 30|virus
P07937965T0000|40 45|tumor
P07937965T0000|62 75|DNA synthesis
P07941174T0001|25 34|carcinoma
P07941750A0344|103 107|half
P07941750A0344|111 127|hydatoinase HyuB
P07942448A1227|50 55|class
P07942448A1227|26 36|NYHA class
P07942448A1227|60 68|ABSTRACT
P07943556A0694|35 36|%
P07944542T0000|1 21|Vibrio cholerae O139
P07945330A0103|68 78|Rex-1 gene
P07945330A0103|6 21|differentiation
P07945330A0103|47 60|transcription
P07947930A0499|84 85|%
P07947930A0499|33 47|sodium heparin
P07947930A0499|52 60|membrane
P07947930A0499|76 78|Cm
P07948921A0051|17 24|library
P07948921A0051|62 84|stilbene synthase cDNA
P07949137A0532|19 26|regimen
P07949137A0532|79 95|body irradiation
P07949205A0286|65 82|aminoglutethimide
P07949205A0286|104 120|breast carcinoma
P07949770T0000|25 35|blood flow
P07949770T0000|74 95|liver transplantation
P07951410A0647|101 110|formation
P07951410A0647|38 51|participation
P07951410A0647|161 168|factors
P07951410A0647|119 128|complexes
P07951410A0647|184 189|E2F-1
P07951410A0647|82 84|RB
P07951410A0647|26 36|A549 cells
P07951874A0320|69 75|effect
P07951874A0320|32 45|host organism
P07951874A0320|120 126|system
P07954475A0714|1 9|Analyses
P07954475A0714|234 244|chromosome
P07954475A0714|42 46|mice
P07954475A0714|111 116|AC3F1
P07954475A0714|191 203|inactivation
P07954475A0714|247 268|tumor suppressor gene
P07954475A0714|211 217|allele
P07956578A0851|87 94|factors
P07956578A0851|37 39|mm
P07957085A0207|1 5|Cbf3
P07957085A0207|38 43|Cbf3b
P07957085A0207|31 36|Cbf3a
P07957106A0875|43 49|region
P07957106A0875|60 83|HSV transactivator VP16
P07957243A1316|16 24|residues
P07957632A0000|32 34|2S
P07957632A0000|37 38|R
P07957632A0000|128 147|glutamate receptors
P07957632A0000|227 237|dose range
P07957632A0000|85 91|DCG-IV
P07957632A0000|187 195|recovery
P07957632A0000|18 27|injection
P07958865A1152|156 168|interactions
P07958865A1152|112 115|Tek
P07958865A1152|57 74|heart development
P07958911A0500|156 163|complex
P07958911A0500|10 32|trithorax binding site
P07958911A0500|121 125|gene
P07958920A1157|168 179|RNase P RNA
P07958920A1157|65 78|RNase MRP RNA
P07959011A0379b|1 12|C/EBP alpha
P07959011A0379b|32 40|promoter
P07959011A0379b|115 119|Arch
P07959734A0194|51 56|amino
P07959734A0194|118 136|glycoprotein Gp135
P07959734A0194|10 15|brain
P07959952A1446|3 7|cDNA
P07959952A1446|183 197|mast cell line
P07959952A1446|31 41|pseudogene
P07960608A0228|1 8|Courses
P07961545A1314|117 128|nervousness
P07961545A1314|82 91|dizziness
P07961545A1314|27 37|incidences
P07961545A1314|15 21|events
P07961957A1565|115 140|alpha-MHC gene EM element
P07961957A1565|83 89|factor
P07963540A0795|99 104|c-Rel
P07963540A0795|214 237|kappa B oligonucleotide
P07963540A0795|72 87|factor-kappa B1
P07963540A0795|165 178|cross-linking
P07963540A0795|121 128|studies
P07964162A0941|54 72|MAP kinase cascade
P07964162A0941|145 154|responses
P07964459A0845|48 58|LIM domain
P07964459A0845|67 85|RING finger family
P07964770A0172|19 27|patients
P07964770A0172|47 51|year
P07964918A0000|5 14|influence
P07964918A0000|106 111|signs
P07966565A0901|171 180|infection
P07966565A0901|59 68|agreement
P07966565A0901|27 31|mRNA
P07966565A0901|91 94|RNA
P07966583A1268|118 128|expression
P07966583A1268|55 69|RNA transcript
P07966583A1268|97 106|D17 cells
P07966583A1268|146 160|fusion protein
P07966583A1268|135 143|Env/Mlvi
P07966873A0693|1 9|Articles
P07966873A0693|47 60|heart failure
P07966873A0693|105 111|Chagas
P07967725A0262|152 169|carboxyl terminus
P07967725A0262|177 185|receptor
P07967725A0262|123 144|ligand binding domain
P07969115A0000|222 233|DNA origins
P07969115A0000|83 95|mitochondria
P07969115A0000|161 170|intervals
P07969115A0000|242 258|promoter regions
P07969132A0268|118 127|histidine
P07969132A0268|157 170|gcn2 deletion
P07969132A0268|43 48|genes
P07969132A0268|95 100|cells
P07969132A0268|135 143|plasmids
P07969136A0273|17 38|mobility shift assays
P07969136A0273|158 163|kappa
P07969136A0273|58 67|sequences
P07969136A0273|133 148|NF-kappa B site
P07969181A0313|32 38|levels
P07969181A0313|142 149|amounts
P07969181A0313|176 186|HeLa cells
P07971282A0000|1 11|Regulators
P07971282A0000|107 116|metazoans
P07972012A0956|118 132|amino terminus
P07972012A0956|145 151|domain
P07972012A0956|268 286|phosphatase domain
P07972012A0956|224 241|carboxyl terminus
P07972831A0563|1 13|PAI-1 levels
P07972831A0563|41 49|patients
P07973397T0001|1 14|Determination
P07973397T0001|52 56|salt
P07975763A0000|141 158|detection methods
P07975763A0000|38 41|HCV
P07975763A0000|58 63|cause
P07975763A0000|75 88|liver disease
P07977239A1283|35 40|juice
P07977239A1283|140 144|type
P07977239A1283|199 206|papilla
P07977239A1283|323 334|dorsal duct
P07977239A1283|191 195|type
P07977239A1283|126 134|patients
P07977239A1283|177 185|patients
P07978229T0000|42 49|patient
P07979810A0340|33 40|density
P07979810A0340|67 83|penetration test
P07979810A0340|145 154|pregnancy
P07980440A0138|137 151|phorbol esters
P07980440A0138|4 28|H4IIE rat hepatoma cells
P07980440A0138|77 81|cAMP
P07980440A0138|56 60|acid
P07980440A0138|30 45|glucocorticoids
P07980669A0373|7 24|plasma AVP levels
P07980669A0373|56 62|change
P07981246A0112|35 50|pertussis toxin
P07981246A0112|52 55|IAP
P07981246A0112|132 147|differentiation
P07981246A0112|91 100|G-protein
P07981246A0112|181 196|c-fos induction
P07982995A0000|69 82|growth factor
P07982995A0000|5 11|effect
P07982995A0000|129 130|H
P07982995A0000|46 51|mouse
P07982995A0000|132 141|exchanger
P07982995A0000|217 230|hamster ovary
P07982995A0000|29 38|mutations
P07982995A0000|90 103|beta-receptor
P07983704A0330|207 215|sequence
P07983704A0330|185 192|genomes
P07983704A0330|178 182|type
P07983704A0330|128 148|retrovirus ancestors
P07983715A0996|258 282|luciferase reporter gene
P07983715A0996|190 193|USF
P07983715A0996|131 142|P4 promoter
P07983715A0996|167 184|complex formation
P07983715A0996|46 53|binding
P07983744A0920|137 141|form
P07983744A0920|32 37|IE110
P07983744A0920|98 117|punctate structures
P07983744A0920|178 183|forms
P07983744A0920|79 84|IE175
P07984105A1509|103 118|mouse virulence
P07984105A1509|37 51|WA fyuA mutant
P07984105A1509|14 29|complementation
P07985305T0001|5 14|treatment
P07988559A0836|25 36|RBP-J kappa
P07988559A0836|46 54|affinity
P07988731A0002|207 212|G-box
P07988731A0002|115 123|presence
P07988731A0002|214 222|CCACGTGG
P07988945T0000|16 26|strategies
P07988945T0000|73 83|antibodies
P07991437A1032|1 12|Propafenone
P07991437A1032|56 64|patients
P07992027A0485|3 11|patients
P07992027A0485|56 60|days
P07994021A1223|191 198|protein
P07994021A1223|140 151|association
P07994021A1223|41 45|tail
P07994021A1223|75 91|PECAM-1 isoforms
P07995910A0119|140 150|laparotomy
P07995910A0119|6 15|technique
P07995910A0119|40 51|specificity
P07999066A0238|5 9|role
P07999066A0238|172 180|tat gene
P07999066A0238|230 242|Jurkat cells
P07999066A0238|79 89|regulation
P07999066A0238|154 164|expression
P07999066A0238|290 327|acetyltransferase reporter constructs
P07999066A0238|93 116|IL-2 gene transcription
P07999604A0139|26 34|patients
P07999995A0000|17 31|protein kinase
P07999995A0000|62 66|rice
P08000112T0000|33 39|effect
P08000112T0000|58 85|membrane oxygenator support
P08000497A0179|1 8|METHODS
P08000497A0179|140 143|gas
P08000497A0179|29 39|spirometry
P08000497A0179|45 74|methacholine provocation test
P08001792A0284|38 49|git10 genes
P08001792A0284|66 83|adenylate cyclase
P08001792A0284|108 144|adenylate cyclase activation pathway
P08001792A0284|29 33|git8
P08002564A0249|1 22|DNA sequence analysis
P08002564A0249|156 165|histidine
P08002564A0249|79 85|region
P08002564A0249|47 55|mutation
P08003700T0000|156 165|atpA loci
P08003700T0000|41 55|cDNA libraries
P08003700T0000|14 23|screening
P08005230A0222|72 82|activation
P08005230A0222|151 160|elevation
P08005438A1185|1 6|SPP41
P08005438A1185|160 175|gene expression
P08005438A1185|105 120|suppressor srn1
P08006772A0000|13 27|pulse oximeter
P08006772A0000|91 96|women
P08007835A0538|153 158|event
P08007835A0538|32 41|variables
P08007835A0538|163 168|level
P08007835A0538|58 67|formation
P08007835A0538|198 202|news
P08007975A0000|5 14|IPL1 gene
P08007975A0000|31 67|high-fidelity chromosome segregation
P08011017A0169|99 107|arousals
P08011017A0169|94 97|EEG
P08011017A0169|47 55|evidence
P08012448T0000|1 5|INO2
P08012448T0000|93 114|bud pattern formation
P08012448T0000|47 59|biosynthesis
P08013348A0143|54 62|affinity
P08013348A0143|11 15|ABPs
P08013348A0143|31 43|sex steroids
P08014228A0278|137 147|extraction
P08014228A0278|1 17|Sample treatment
P08014228A0278|77 103|labetalol diastereoisomers
P08014919A0530|116 120|body
P08014919A0530|42 47|units
P08014919A0530|176 179|DGR
P08014919A0530|57 68|progression
P08015850A1076|152 159|barrier
P08015850A1076|80 89|preinjury
P08015850A1076|110 122|availability
P08015850A1076|126 128|Ga
P08015850A1076|61 78|Ga administration
P08015850A1076|211 219|compound
P08016189A0741|1 12|Granisetron
P08016189A0741|53 59|nausea
P08016189A0741|40 48|vomiting
P08018361A0636|65 70|n/cm2
P08020702A0137|156 164|efficacy
P08020702A0137|5 10|study
P08020702A0137|129 144|dog experiments
P08020702A0137|41 48|lipid A
P08020702A0137|30 37|ability
P08020962A1226|16 22|region
P08020962A1226|156 164|elements
P08020962A1226|63 69|number
P08020962A1226|30 42|V beta locus
P08021175A0486|139 162|integration host factor
P08021175A0486|114 134|AMP receptor protein
P08021175A0486|5 9|pexB
P08021175A0486|40 51|nucleotides
P08021225A0000|173 175|A.
P08021225A0000|58 79|Alcaligenes eutrophus
P08021225A0000|122 138|dihydrolipoamide
P08023662T0000|49 68|thromboplastin time
P08023662T0000|73 89|prothrombin time
P08025074A0000|141 145|shot
P08025074A0000|163 169|Dacron
P08025074A0000|109 121|suture lysis
P08028671A0687|51 60|antiserum
P08028671A0687|66 77|fibroblasts
P08028671A0687|111 115|cAMP
P08029334T0000|1 8|Cloning
P08029334T0000|39 55|acid desaturases
P08030243A1011|101 109|activity
P08030243A1011|30 47|RNA capture assay
P08031424T0000|1 9|Ketamine
P08031424T0000|30 42|bronchospasm
P08034318A0724|156 167|NF-1 family
P08034318A0724|21 29|sequence
P08034318A0724|110 120|similarity
P08034318A0724|91 99|UBE site
P08034680A0180|157 160|kDa
P08034680A0180|5 14|mechanism
P08034680A0180|42 52|NF-kappa B
P08034680A0180|135 139|mass
P08034708A0000|81 91|mechanisms
P08034708A0000|25 35|commitment
P08034708A0000|58 76|eosinophil lineage
P08034708A0000|15 20|basis
P08034742A0307|9 11|D.
P08035499A0941|168 177|complexes
P08035499A0941|36 45|stability
P08035499A0941|57 62|kinds
P08035499A0941|91 95|fact
P08035517A0753|37 42|IEP86
P08035517A0753|91 96|IEP72
P08035833A1556|102 118|import machinery
P08035833A1556|39 43|RMIP
P08035833A1556|7 11|YMIP
P08037338A0000|137 147|EPO levels
P08037338A0000|1 8|PURPOSE
P08037338A0000|86 98|pathogenesis
P08037338A0000|54 57|EPO
P08037338A0000|59 69|production
P08037338A0000|26 34|kinetics
P08040336A0435|35 51|collagen element
P08040336A0435|98 121|LAP binding cis-element
P08040336A0435|129 145|albumin promoter
P08040468A0303|19 42|mast cell degranulation
P08040468A0303|66 78|pathogenesis
P08040468A0303|106 132|fibroblast enzyme activity
P08041793A0242|114 124|repression
P08041793A0242|148 153|COX5b
P08041793A0242|91 101|activation
P08044794A0000|42 52|factor p53
P08044802A0462|155 158|p53
P08044802A0462|78 85|changes
P08044802A0462|160 170|cell lines
P08044802A0462|132 140|p53 gene
P08045834A0783|85 98|ATP synthesis
P08045834A0783|5 25|PCr resynthesis rate
P08045834A0783|63 67|rate
P08048582A0821|139 149|LAD region
P08048582A0821|206 209|g-1
P08048582A0821|52 58|extent
P08048582A0821|104 121|ml O2.min-1 times
P08049401A0428|87 93|cortex
P08049401A0428|52 75|glucocorticoid activity
P08049401A0428|40 48|increase
P08049521T0000|97 106|pp60v-src
P08049521T0000|10 33|protein phosphorylation
P08051019A0365|10 22|biosynthesis
P08051074A0000|170 179|digestion
P08051074A0000|116 121|HIV-1
P08051074A0000|108 112|type
P08051074A0000|45 51|region
P08051151A0347|154 164|cell lines
P08051151A0347|142 149|tissues
P08051151A0347|14 23|abundance
P08054281A0731|48 57|indicator
P08054281A0731|5 20|retention index
P08054281A0731|24 35|201Tl SPECT
P08054281A0731|108 118|prediction
P08054281A0731|122 131|prognosis
P08055939A0707|206 210|exon
P08055939A0707|5 13|location
P08055939A0707|77 83|tomato
P08055939A0707|88 105|Arabidopsis genes
P08055939A0707|164 168|exon
P08056474A0438|34 35|%
P08056474A0438|10 14|NMSC
P08056474A0438|107 108|%
P08056474A0438|75 76|%
P08057356A1824|115 127|orientations
P08057356A1824|132 139|spacing
P08057762A0878|153 154|%
P08057762A0878|66 68|T2
P08057762A0878|145 147|T2
P08057762A0878|63 64|%
P08057762A0878|134 136|T1
P08058326A0463|68 84|tal-1 expression
P08058326A0463|168 180|counterparts
P08058326A0463|106 115|sequences
P08062824A0626|35 42|FKBP-33
P08062824A0626|139 149|activities
P08062824A0626|155 162|FKBP-12
P08063108A0109|81 83|aa
P08063108A0109|31 33|nt
P08063775T0000|52 57|PTHrP
P08063775T0000|43 50|protein
P08063836A0904|18 23|c-Abl
P08063836A0904|73 84|requirement
P08065310A1144|159 168|inhibitor
P08065310A1144|126 137|interaction
P08065310A1144|182 188|member
P08065327A0000|96 118|germ line micronucleus
P08065327A0000|11 28|DNA rearrangement
P08065327A0000|74 86|macronucleus
P08065338T0000|43 61|activation domains
P08065338T0000|132 145|transcription
P08065366A0918|21 25|data
P08065366A0918|72 94|chromosome segregation
P08065901A0997|84 93|ZFP genes
P08065901A0997|201 211|components
P08065901A0997|158 170|interactions
P08065901A0997|183 196|KRAB-A domain
P08067013T0001|16 28|significance
P08067013T0001|81 87|muscle
P08067546A0000|17 27|hypothesis
P08067546A0000|86 94|propofol
P08067546A0000|80 83|ETO
P08067546A0000|163 170|effects
P08067546A0000|125 128|STP
P08067546A0000|106 123|sodium thiopental
P08069298A0492|154 174|leptomeningeal cells
P08069298A0492|52 55|RNA
P08069298A0492|146 150|line
P08069298A0492|105 126|leptomeningeal tissue
P08069481A0736|29 37|phantoms
P08070393A0631|54 62|time lag
P08070393A0631|13 19|effect
P08070654A0574|69 76|protein
P08070654A0574|23 38|SPB duplication
P08070654A0574|179 183|body
P08070654A0574|109 127|caltractin/centrin
P08072547A0690|34 49|protein kinases
P08072547A0690|1 4|Ras
P08072547A0690|78 93|serine residues
P08072547T0000|1 6|c-Fos
P08072547T0000|23 31|activity
P08072547T0000|91 94|JNK
P08075070A1632|64 69|helix
P08075070A1632|178 181|HTH
P08075070A1632|11 19|features
P08075070A1632|28 33|model
P08075070A1632|211 219|proteins
P08075421A0621b|50 60|C terminus
P08075421A0621b|13 16|ORF
P08076937A0851|103 118|mismatch primer
P08076937A0851|96 99|DNA
P08076937A0851|25 33|mutation
P08078167A0000|34 45|hepatitis A
P08078167A0000|101 109|measures
P08078167A0000|63 72|travelers
P08078473A1107|53 67|ste13 mutation
P08078473A1107|15 25|ME31B cDNA
P08082286A0748|109 115|effect
P08082286A0748|28 37|receptors
P08082360A0411|1 16|Smoking history
P08082360A0411|46 50|SaO2
P08083011A0584|117 119|RH
P08083011A0584|189 194|males
P08083011A0584|196 204|estrogen
P08083011A0584|29 36|weights
P08083011A0584|14 15|R
P08083963A0795|118 123|DNase
P08083963A0795|36 42|a1/EBP
P08083963A0795|126 138|footprinting
P08083963A0795|107 116|gel shift
P08083998A1723b|50 75|coronavirus transcription
P08083998A1723b|142 151|sequences
P08083998A1723b|28 46|leader-mRNA fusion
P08084339A0907|155 164|beginning
P08084339A0907|172 190|TCR C alpha region
P08084339A0907|125 136|nucleotides
P08084339A0907|28 38|transcript
P08085228A0000|102 114|distribution
P08085228A0000|139 161|immunodeficiency virus
P08085228A0000|163 166|HIV
P08085228A0000|176 179|use
P08085228A0000|183 193|counseling
P08085228A0000|61 68|clients
P08085782A0164|37 42|tumor
P08086453T0000|1 10|Structure
P08086453T0000|46 56|assignment
P08088022A1417|36 43|disease
P08088022A1417|67 80|heart disease
P08088022A1417|104 109|links
P08088777A0754|101 105|Rxra
P08088777A0754|131 136|Grp78
P08088777A0754|73 79|D2Mit1
P08088777A0754|85 91|Notch1
P08088777A0754|154 157|Gsn
P08088777A0754|159 163|Acra
P08088777A0754|148 150|.2
P08088777A0754|62 69|crosses
P08089184A0825|50 60|dagA locus
P08089184A0825|4 12|addition
P08089887A0742|61 71|evaluation
P08090746A1288|19 27|ATTTCAAA
P08090746A1288|76 84|homology
P08090746A1288|122 145|ethylene responsiveness
P08091655A0000|69 85|EcoRI-B fragment
P08091655A0000|52 57|genes
P08091655A0000|89 95|MDV-GA
P08091655A0000|104 107|DNA
P08091669A0828|65 72|absence
P08091669A0828|144 156|ie1 promoter
P08091669A0828|76 79|IE1
P08091669A0828|45 57|39k promoter
P08093616A1214|70 80|DRE region
P08093616A1214|9 30|footprinting analysis
P08093616A1214|88 113|DNA polymerase alpha gene
P08093642A0600|187 199|lambda clone
P08093642A0600|16 50|microsatellite repeat polymorphism
P08093642A0600|4 12|addition
P08093642A0600|58 72|heterozygosity
P08093642A0600|270 285|linkage mapping
P08093642A0600|151 165|heterozygosity
P08094464A2014|81 85|mRNA
P08094464A2014|96 109|configuration
P08094464A2014|177 184|regions
P08094464A2014|12 16|span
P08094927A0311|10 17|studies
P08094927A0311|74 81|release
P08095872A1672|51 59|inotropy
P08095872A1672|19 24|study
P08095872A1672|155 165|transition
P08095872A1672|94 105|contraction
P08096066A0623|5 18|RFLP patterns
P08096066A0623|128 132|band
P08096066A0623|146 157|development
P08097666A1135|1 7|A23187
P08097666A1135|77 85|ampullar
P08097666A1135|27 40|modifications
P08098228A0625|49 52|PPO
P08098228A0625|25 27|kb
P08099443A0359|116 128|GCN2 protein
P08099443A0359|22 30|dsRNA-PK
P08099443A0359|14 17|HRI
P08100765A0361|71 81|cerebellum
P08100765A0361|89 94|lines
P08101134A0376|71 72|%
P08101134A0376|5 19|concentrations
P08101134A0376|79 93|MPTP treatment
P08101839A0000|34 44|expression
P08101839A0000|126 144|cell proliferation
P08101839A0000|106 113|signals
P08101839A0000|73 81|response
P08102364A0000|40 61|Nicotiana tabacum var
P08103935T0000|35 57|SRF accessory proteins
P08103935T0000|15 31|characterization
P08105727A0099|98 107|perfusion
P08105727A0099|15 40|dopamine receptor agonist
P08106087A0139|37 50|kDa zein gene
P08106087A0139|130 138|sequence
P08106087A0139|88 96|sequence
P08106313A1492|5 12|results
P08106313A1492|67 74|cascade
P08106313A1492|130 134|HrpL
P08106313A1492|107 117|expression
P08106313A1492|93 97|HrpS
P08106313A1492|147 159|sigma factor
P08106369A0000|1 12|Vasopressin
P08106369A0000|206 208|V2
P08106369A0000|37 44|hormone
P08106369A0000|126 144|membrane receptors
P08106369A0000|182 190|subtypes
P08106369A0000|14 17|AVP
P08106512A0522|173 183|interferon
P08106512A0522|162 167|gamma
P08106512A0522|10 25|promoter region
P08106512A0522|90 105|promoter region
P08107208A0673|103 106|EBV
P08107208A0673|5 13|approach
P08107208A0673|121 125|DNAs
P08108343A0000|66 70|GnRH
P08108343A0000|43 51|niftolid
P08108343A0000|13 21|analysis
P08108343A0000|185 193|patients
P08108343A0000|113 121|patients
P08108343A0000|264 269|order
P08111035A0098|204 224|oleosin promoter-GUS
P08111035A0098|175 189|tobacco plants
P08111035A0098|145 148|GUS
P08111035A0098|27 37|properties
P08111035A0098|74 95|B. napus oleosin gene
P08112341A1128|17 23|Carter
P08112341A1128|5 10|Greer
P08112341A1128|12 14|J.
P08112601T0000|86 95|synthesis
P08112601T0000|56 65|lipocalin
P08112870A0484|1 17|Western blotting
P08112870A0484|113 121|proteins
P08112870A0484|43 52|antiserum
P08112870A0484|167 170|kDa
P08114702A0000|1 8|Members
P08114702A0000|140 155|control regions
P08114702A0000|76 97|transcription factors
P08114702A0000|60 64|MEF2
P08114745A0953|54 68|RNA production
P08114745A0953|188 211|transcription complexes
P08114745A0953|7 14|results
P08114745A0953|215 218|pol
P08114745A0953|181 184|use
P08115744A0846|16 22|method
P08115744A0846|62 68|method
P08118044A0318|1 12|GATA-1 mRNA
P08118044A0318|64 74|cell lines
P08118044A0318|89 94|level
P08119907A0000|86 101|growth factor-I
P08119907A0000|43 57|p21ras protein
P08119907A0000|61 68|insulin
P08119995A0814|102 112|half-sites
P08119995A0814|136 147|orientation
P08119995A0814|245 254|half-site
P08119995A0814|195 200|parts
P08120029A0864|23 46|decay reaction mixtures
P08120029A0864|108 121|stabilization
P08122370A0331|69 74|HSV-1
P08122370A0331|20 32|counterparts
P08122370A0331|77 95|pseudorabies virus
P08122370A0331|46 65|herpes simplex type
P08124785A0445|170 174|flow
P08124785A0445|1 8|METHODS
P08124785A0445|185 197|flow reserve
P08124785A0445|141 147|artery
P08124785A0445|28 38|open-chest
P08124785A0445|224 250|mean transit time Tmicro-1
P08124956T0000|99 103|pigs
P08125319A1085|119 133|data libraries
P08125319A1085|98 107|sequences
P08125319A1085|53 61|proteins
P08125949A1162|204 210|copies
P08125949A1162|50 66|spinach L12 mRNA
P08125949A1162|169 179|mechanisms
P08125949A1162|214 238|L12/chloroplast ribosome
P08126096A1071|50 61|nucleotides
P08126096A1071|5 22|alpha 7A form RNA
P08126096A1071|126 137|B form RNAs
P08126096A1071|120 121|A
P08128629A1164|1 13|CRS function
P08128629A1164|129 136|LTR RNA
P08128629A1164|75 82|ability
P08130942A0051|70 77|problem
P08130942A0051|20 33|drug delivery
P08131746A0140|100 103|mos
P08131746A0140|93 98|c-raf
P08131746A0140|29 51|serine phosphorylation
P08132574A0831|98 101|RP1
P08132574A0831|40 58|complement C2 gene
P08132574A0831|109 112|HLA
P08133502T0105|1 30|European Community Huntington
P08134115A1161|119 122|H-P
P08134115A1161|153 156|H-P
P08134115A1161|207 216|A/TCTA/TA
P08134115A1161|115 118|myc
P08134115A1161|53 56|GST
P08134115A1161|166 175|consensus
P08138180A0593|143 152|functions
P08138180A0593|27 34|alleles
P08138180A0593|74 85|growth rate
P08139001A1235|32 37|amino
P08139001A1235|5 12|results
P08139001A1235|146 162|tubule formation
P08139001A1235|107 115|residues
P08139017A1465|216 224|provirus
P08139017A1465|80 96|primer extension
P08139017A1465|232 243|Tpl-1 locus
P08139017A1465|123 126|end
P08139017A1465|45 55|initiation
P08139539A0446|4 16|Rat 1a cells
P08139539A0446|37 57|phospholipase C beta
P08139539A0446|95 102|calcium
P08139539A0446|132 141|synthesis
P08139539A0446|121 124|AMP
P08139542T0000|86 94|arginine
P08139542T0000|54 63|CPA1 gene
P08139542T0000|72 82|repression
P08139543A1520|87 91|SLT2
P08139543A1520|58 72|NHP6B function
P08139577T0000|140 145|genes
P08139577T0000|11 21|components
P08139577T0000|89 102|transcription
P08139928T0000|43 48|yeast
P08142875A0877|137 142|cases
P08142875A0877|21 31|dissection
P08143236A1055|69 83|g ethanol.kg-1
P08143236A1055|114 121|percent
P08143236A1055|46 57|alternation
P08144035A0387|85 95|C terminus
P08144035A0387|62 72|N terminus
P08144470A0711|118 130|substitution
P08144470A0711|25 39|asgB480 allele
P08144504T0064|38 52|ATP hydrolysis
P08144504T0064|9 17|coupling
P08144615A0533|1 10|Digestion
P08144615A0533|80 83|TCD
P08144615A0533|158 165|absence
P08144615A0533|56 62|domain
P08144615A0533|106 110|NFBD
P08144668A0802|140 144|GPHe
P08144668A0802|145 147|P2
P08144668A0802|63 67|exon
P08144668A0802|91 96|shift
P08144668A0802|30 36|exon V
P08145646T0000|136 158|nifU2-rpoN superoperon
P08145646T0000|59 63|RpoN
P08145646T0000|45 57|sigma factor
P08148463A0000|33 37|CSFs
P08148463A0000|81 92|neutrophils
P08148463A0000|67 77|production
P08148463A0000|24 31|factors
P08148463A0000|151 154|CSF
P08149484A0151|77 86|PKC delta
P08149484A0151|46 59|kinase domain
P08149484A0151|104 115|PKC delta K
P08150970A0434|49 54|pg/ml
P08150970A0434|25 31|TSST-1
P08150970A0434|111 117|TSST-1
P08151787T0000|1 8|Mapping
P08151787T0000|64 91|colocalization interactions
P08151787T0000|128 151|transactivator proteins
P08151787T0000|104 109|IE110
P08152800A0709|51 62|ERM protein
P08152800A0709|1 19|Gel shift analysis
P08152800A0709|129 168|consensus nucleotide core sequence GGAA
P08153146A0327|1 11|Dotarizine
P08153146A0327|201 210|pressures
P08153146A0327|234 243|pressures
P08153146A0327|30 38|dilation
P08154182A0955|23 34|lambda PG15
P08154182A0955|109 141|Neurospora crassa cDNA libraries
P08157009A0264|168 202|plasma membrane AP-2 sigma subunit
P08157009A0264|114 126|AP-1 complex
P08157009A0264|132 137|Aps2p
P08157663A0882|217 226|evolution
P08157663A0882|114 130|membrane protein
P08157663A0882|59 71|organization
P08157663A0882|146 154|envelope
P08159174A0581|51 68|Southern analysis
P08159174A0581|29 33|gene
P08160387T0000|129 140|deprivation
P08160387T0000|107 114|rearing
P08160387T0000|75 79|role
P08163183T0000|118 130|XylA enzymes
P08163183T0000|5 11|xylose
P08163183T0000|46 79|Clostridium thermosaccharolyticum
P08163183T0000|105 114|phylogeny
P08163528T0000|15 44|Mas70p signal anchor sequence
P08164302A0547|18 31|TPN solutions
P08164302A0547|106 116|difference
P08164679A0809|68 88|runt homology region
P08164679A0809|109 120|Runt domain
P08164684A1266|5 11|ligand
P08164684A1266|59 65|effect
P08167396A0154|23 30|neurons
P08169201A0291|56 68|carA product
P08169201A0291|135 144|organisms
P08169201A0291|181 192|amino acids
P08170400T0000|96 99|FNR
P08170400T0000|74 94|transcription factor
P08172598A0237|102 117|kb mRNA species
P08172598A0237|77 81|xynB
P08172598A0237|15 23|analysis
P08172905A0000|156 158|G3
P08172905A0000|159 172|U70 base pair
P08172905A0000|109 121|acceptor end
P08173693A0390|93 114|angina pectoris class
P08173693A0390|10 21|study group
P08175031A0566|1 10|Treatment
P08176742A0190|56 63|studies
P08178446A1160|54 66|ras activity
P08178446A1160|23 28|ICP10
P08178446A1160|135 153|signaling pathways
P08178572A1118|116 122|region
P08178572A1118|6 37|concensus poly A addition sites
P08180129A1256|1 9|Exposure
P08180129A1256|20 38|TPA concentrations
P08182041A1067|69 74|PEPCK
P08182041A1067|155 174|PEPCK TATA sequence
P08182041A1067|39 51|requirements
P08182041A1067|202 216|hepatoma cells
P08182041A1067|124 146|CREB activation domain
P08182171A0000|68 85|coliform mastitis
P08182171A0000|55 64|treatment
P08182171A0000|123 131|infusion
P08183915A0000|206 217|amino acids
P08183915A0000|125 146|p70 I kappa B protein
P08183915A0000|40 44|p105
P08183915A0000|63 74|p50 subunit
P08183915A0000|31 38|protein
P08184923A0829|54 58|CoBF
P08184923A0829|42 50|increase
P08184923A0829|9 14|L-NNA
P08187085A0086|102 105|ret
P08187085A0086|7 21|rearrangements
P08187085A0086|58 63|genes
P08187085A0086|151 156|genes
P08187177A0405|48 62|sorting signal
P08187177A0405|10 27|amino acid change
P08188290A0544|49 67|TCRAC/TCRDC region
P08188290A0544|11 24|sequence data
P08188290A0544|120 125|assay
P08188606A1034|170 177|strains
P08188606A1034|144 151|strains
P08188606A1034|26 48|Southern hybridization
P08188606A1034|74 80|Tn5422
P08189174A0148|1 7|DESIGN
P08189174A0148|66 71|years
P08189174A0148|144 151|Utrecht
P08189174A0148|122 128|living
P08189503A0000|156 165|mechanism
P08189503A0000|192 206|mRNA synthesis
P08189503A0000|28 38|cDNA clone
P08189503A0000|44 76|mouse hepatitis virus strain A59
P08189533A0919|1 20|Gel electrophoresis
P08189533A0919|70 79|fractions
P08189533A0919|213 219|matrix
P08189533A0919|128 135|amounts
P08190633A0273|65 71|region
P08190633A0273|40 45|exons
P08190633A0273|12 21|AP-2 mRNA
P08192140A0209|71 80|Amsterdam
P08192140A0209|82 83|n
P08192140A0209|106 107|n
P08192140A0209|91 104|New York City
P08192795T0000|49 68|lupus erythematosus
P08194139A0498|50 53|age
P08194139A0498|95 98|men
P08194139A0498|14 44|Serum prolactin concentrations
P08194753A0157|115 122|element
P08194753A0157|93 96|DNA
P08194753A0157|26 34|sequence
P08195186A0000|305 307|K.
P08195186A0000|239 253|Tea expression
P08195186A0000|309 315|Kakuda
P08195186A0000|282 289|MacLeod
P08195186A0000|317 319|D.
P08195186A0000|74 78|gene
P08195186A0000|291 295|C.L.
P08195186A0000|80 83|Tea
P08195186A0000|95 102|protein
P08195217A0799|23 30|protein
P08195217A0799|56 95|reticulocyte lysate translation product
P08195217A0799|133 140|protein
P08196607A0280|1 18|Deletion analysis
P08196607A0280|231 244|reporter gene
P08196607A0280|110 117|UASICL1
P08196607A0280|26 39|ICL1 promoter
P08196618A0473|34 60|phosphotyrosine substrates
P08196618A0473|66 74|mutation
P08196618A0473|94 110|cysteine residue
P08198524A1134|20 23|kDa
P08199878T0000|86 100|brain ischemia
P08199878T0000|25 46|glucose concentration
P08201352A0239|49 70|vitamin K antagonists
P08201352A0239|27 47|protein C deficiency
P08201932A0355|77 83|joints
P08201932A0355|44 57|polyarthritis
P08203260A1204|66 76|ventilator
P08204403A0000|17 22|males
P08204403A0000|3 8|total
P08204403A0000|83 88|study
P08204403A0000|29 36|females
P08204403A0000|150 155|I-131
P08204824A0000|76 83|S phase
P08204824A0000|145 164|Catharanthus roseus
P08204824A0000|11 16|clone
P08204824A0000|166 171|cells
P08206848A0296|33 45|polypeptides
P08206848A0296|96 99|kDa
P08206848A0296|14 24|pyrP genes
P08206991A0466|100 115|N-myristylation
P08206991A0466|172 177|Cys-6
P08206991A0466|77 84|alanine
P08206991A0466|193 199|serine
P08207232A0503|17 40|mobility shift analysis
P08207232A0503|159 172|IL-8 promoter
P08207232A0503|106 112|family
P08207795A0409|100 122|mutagenesis procedures
P08207795A0409|25 33|location
P08208247T0030|83 106|acid decarboxylase gene
P08208247T0030|52 58|region
P08208540A0417|220 235|ankyrin repeats
P08208540A0417|1 8|Cloning
P08208540A0417|190 200|rel domain
P08208540A0417|296 310|ankyrin repeat
P08208540A0417|108 118|gene codes
P08208540A0417|13 23|sequencing
P08208618A1334|69 80|Sp1 binding
P08208618A1334|7 13|HR21ap
P08209423T0000|86 94|evidence
P08209423T0000|111 115|mRNA
P08209423T0000|133 150|glycoprotein gene
P08209423T0000|14 20|frames
P08212571A0597|116 122|levels
P08212571A0597|22 25|tat
P08212571A0597|79 96|tat ORF mutations
P08212571A0597|182 189|mutants
P08212571A0597|194 197|tat
P08212897A0404|101 122|transmembrane domains
P08212897A0404|5 27|hydrophobicity profile
P08213747A0000|577 588|Los Angeles
P08213747A0000|548 550|DC
P08213747A0000|340 348|analysis
P08213747A0000|526 546|Baltimore/Washington
P08213747A0000|552 562|Pittsburgh
P08213747A0000|224 231|history
P08213747A0000|289 298|behaviors
P08213747A0000|564 571|Chicago
P08213747A0000|53 80|immunodeficiency virus type
P08213747A0000|386 404|HIV-1 risk factors
P08213747A0000|183 194|differences
P08213747A0000|482 485|men
P08217862A1336|216 223|strains
P08217862A1336|125 139|nerve activity
P08217862A1336|11 22|development
P08217862A1336|30 55|rat conditioning paradigm
P08218230A1505|16 22|region
P08218230A1505|114 124|hepatocyte
P08218230A1505|92 112|transcription factor
P08218230A1505|133 139|factor
P08219227A0830|50 59|AP-1 site
P08219227A0830|98 106|activity
P08219227A0830|20 23|CRE
P08219227A0830|178 187|AP-1 site
P08219227A0830|209 217|activity
P08219227A0830|195 198|CRE
P08220621T0000|11 22|manuscripts
P08222384A0455|1 6|SIN-1
P08222384A0455|92 95|ECG
P08222384A0455|14 23|influence
P08222618A0000|35 55|logit transformation
P08222618A0000|11 28|computer programs
P08223554A0574|5 12|lengths
P08223554A0574|112 120|residues
P08223592A0424|1 5|TATA
P08223592A0424|140 151|nucleotides
P08223592A0424|10 21|CCAAT boxes
P08223592A0424|209 230|polyadenylation sites
P08223613A0519|204 208|TPS3
P08223613A0519|188 202|TSL1 homologue
P08223613A0519|58 66|products
P08223613A0519|150 176|trehalose synthase complex
P08223875A0711|171 175|CD45
P08223875A0711|39 56|CD3 cross-linking
P08223875A0711|161 167|p59fyn
P08223875A0711|20 33|PA production
P08223875A0711|94 99|cells
P08223875A0711|63 64|%
P08223875A0711|149 157|activity
P08224907A0000|77 86|subunit A
P08224907A0000|124 147|cDNA subfragment probes
P08224907A0000|45 74|gene encoding enhancer factor
P08226616A0000|140 152|assimilation
P08226616A0000|76 85|reductase
P08226616A0000|91 97|enzyme
P08226777A0936|45 51|DdPTPa
P08226794A0501|42 50|activity
P08226956A1397|100 111|type plants
P08226956A1397|23 29|effect
P08226956A1397|72 78|levels
P08228805A0540|174 183|mechanism
P08228805A0540|99 105|p21ras
P08228805A0540|131 134|TCR
P08229102A0768|50 59|potential
P08229102A0768|22 40|QLMI questionnaire
P08229102A0768|91 93|QL
P08229826A1145|176 183|objects
P08229826A1145|28 32|taps
P08230445A0000|117 124|protein
P08230445A0000|5 12|product
P08230445A0000|52 79|immunodeficiency virus type
P08230445A0000|161 171|quantities
P08230445A0000|194 197|Gag
P08230452A1489|4 12|contrast
P08230452A1489|67 86|valine substitution
P08230452A1489|94 108|amino terminus
P08230452A1489|47 59|P1 precursor
P08231577A1027|1 5|Acid
P08231577A1027|42 49|rabbits
P08232304A1166|16 25|deletions
P08232304A1166|159 202|chloramphenicol acetyltransferase construct
P08232304A1166|73 76|TSS
P08234166A0425|137 150|RT conditions
P08234166A0425|38 46|capsules
P08234166A0425|5 20|bioavailability
P08234166A0425|24 32|etodolac
P08234308T0000|1 7|Notice
P08237171A0000|100 113|hydrocephalus
P08237171A0000|18 22|case
P08237171A0000|60 66|recess
P08238626A0248|18 22|mmHg
P08238626A0248|126 129|g-1
P08238626A0248|130 135|min-1
P08239586T0000|1 8|Effects
P08239586T0000|62 69|rabbits
P08241139A0378|86 90|none
P08241139A0378|9 10|%
P08241139A0378|62 70|presence
P08241139A0378|30 41|DNA binding
P08242861A0368|6 17|4,8-DiMeIQx
P08244034T0000|69 98|baculovirus expression system
P08244034T0000|13 49|Leishmania surface glycoprotein GP63
P08245125A0822|1 9|Addition
P08245125A0822|54 64|phalloidin
P08245125A0822|74 85|L266D actin
P08245461A0700|53 71|T cell tumor lines
P08245461A0700|110 119|phenotype
P08245461A0700|132 143|development
P08246984A0512|1 9|Northern
P08246984A0512|77 84|tissues
P08246984A0512|11 14|RNA
P08246987A0260|69 81|Src homology
P08246987A0260|99 102|SH3
P08246987A0260|52 58|p56lck
P08246987A0260|104 111|domains
P08247043T0000|17 38|liver transplantation
P08248253A1785|16 28|observations
P08248253A1785|38 46|promoter
P08249319A0578|32 47|mislocalization
P08249319A0578|55 63|position
P08251506A0503|263 274|cross-links
P08251506A0503|172 191|DRE oligonucleotide
P08251506A0503|13 20|complex
P08251506A0503|224 233|complexes
P08252067A0917|18 29|comparisons
P08252067A0917|37 44|domains
P08252067A0917|90 96|degree
P08253386A0800|153 171|splicing complexes
P08253386A0800|49 78|fibronectin splicing enhancer
P08253386A0800|218 226|U2 snRNP
P08253386A0800|22 31|mechanism
P08253386A0800|135 143|assembly
P08253387A1291|18 27|sequences
P08253387A1291|43 55|hLEF HMG box
P08253387A1291|147 159|interactions
P08253387A1291|91 101|activation
P08253958A0000|86 108|serum immunoglobulin G
P08253958A0000|110 113|IgG
P08253958A0000|57 69|Helicobacter
P08255022A0827|71 72|%
P08255022A0827|65 69|FEV1
P08255022A0827|82 86|PaO2
P08255022A0827|91 99|increase
P08255022A0827|15 28|hypoperfusion
P08255758A0000|113 121|sequence
P08255758A0000|43 49|region
P08255758A0000|74 89|retrotransposon
P08257754A0711|49 50|%
P08257754A0711|36 43|results
P08257754A0711|177 182|IU/ml
P08257754A0711|12 16|dose
P08257754A0711|105 110|IU/ml
P08259650A0640|1 29|Nucleotide sequence analysis
P08259650A0640|37 44|HA gene
P08261398A0392|85 106|alpha mRNA transcript
P08261398A0392|20 41|cell lines P388/ADR/3
P08261398A0392|77 81|topo
P08261398A0392|46 56|P388/ADR/7
P08262041A0727|5 19|phi AP3 factor
P08262041A0727|67 82|phosphorylation
P08262067A1608|16 24|homology
P08262067A1608|38 43|Cdc43
P08262067A1608|196 218|cell wall biosynthesis
P08262067A1608|146 152|events
P08262067A1608|89 102|cell polarity
P08264579A1209|16 20|PTR2
P08264579A1209|42 49|example
P08264579A1209|75 91|characterization
P08264583A0520|97 104|variety
P08264583A0520|166 189|test plasmid substrates
P08264583A0520|28 33|basis
P08264617A0000|50 58|receptor
P08264617A0000|38 47|EGFR/ErbB
P08264617A0000|62 81|NIH 3T3 fibroblasts
P08264617A0000|120 126|events
P08264631A0746|16 22|region
P08264631A0746|81 85|ADR1
P08264631A0746|31 44|ADR1 activity
P08264664A0128|114 118|gene
P08264664A0128|52 70|AP-1 binding sites
P08265955T0000|25 28|NHS
P08267667A0748|275 295|h memory acquisition
P08267667A0748|141 145|rate
P08267667A0748|312 313|p
P08267667A0748|10 24|administration
P08267667A0748|224 225|p
P08267667A0748|461 479|h memory retrieval
P08267667A0748|297 298|F
P08267667A0748|481 482|F
P08267667A0748|183 184|d
P08268833T0000|17 23|action
P08268833T0000|42 51|Sandimmun
P08268833T0000|27 40|cyclosporin A
P08269424A0339|49 52|TRH
P08269424A0339|99 109|tumor side
P08269424A0339|41 44|CRF
P08270257A0551|168 175|species
P08270257A0551|80 83|rat
P08270257A0551|120 130|boundaries
P08270985A0590|1 19|Response durations
P08274774A0958|118 125|tobacco
P08274774A0958|4 12|addition
P08274774A0958|199 220|ribgrass mosaic virus
P08274774A0958|165 171|tomato
P08274774A0958|181 193|mosaic virus
P08276234A0119|68 75|protein
P08276234A0119|143 149|effect
P08276234A0119|12 20|evidence
P08276234A0119|91 99|activity
P08276732A0799|5 9|rate
P08276732A0799|132 138|trauma
P08276732A0799|90 97|measure
P08276851A0347|205 215|biogenesis
P08276851A0347|253 271|cell cycle control
P08276851A0347|64 71|domains
P08276851A0347|234 251|protein transport
P08276851A0347|15 29|Pay4p sequence
P08276865A1188|85 91|growth
P08276865A1188|39 45|microM
P08276865A1188|108 118|activation
P08276865A1188|133 143|MAP kinase
P08276900A0543|1 3|S.
P08278423A0147|1 8|Mothers
P08278423A0147|81 83|TB
P08278423A0147|93 101|children
P08278548A0597|17 21|psaH
P08278548A0597|100 110|mobilities
P08278548A0597|5 9|psaD
P08278548A0597|27 40|psaL products
P08278548A0597|180 188|isoforms
P08279098T0001|47 62|myopia patients
P08280925A0261|64 76|C57Bl/6 mice
P08280925A0261|140 146|groups
P08280925A0261|95 99|mice
P08280925A0261|46 55|responses
P08281536A0626|1 14|Interleukin-6
P08281536A0626|61 67|myxoma
P08281740A0000|18 46|Plowright Rinderpest vaccine
P08281740A0000|53 59|calves
P08281740A0000|162 167|weeks
P08281740A0000|125 139|IgG antibodies
P08282576A0297|16 26|cavum oris
P08282576A0297|82 87|cases
P08282576A0297|45 53|T1-stage
P08283292A0779|17 49|liver cholesterol concentrations
P08283292A0779|84 91|control
P08283292A0779|155 160|diets
P08283292A0779|172 178|pectin
P08283292A0779|9 12|LDL
P08284227A0336|54 72|kb mRNA transcript
P08284227A0336|22 27|cells
P08284227A0336|89 97|contrast
P08285710A0634|137 141|site
P08285710A0634|49 57|Northern
P08285710A0634|64 77|blot analysis
P08285710A0634|59 62|RNA
P08285710A0634|94 98|maps
P08288240A0304|54 62|stathmin
P08288240A0304|126 131|genes
P08288554A0295|137 158|mouse BALBc/3T3 cells
P08288554A0295|126 133|protein
P08288554A0295|13 32|amino acid sequence
P08288606A0240|117 130|placenta mRNA
P08288606A0240|234 246|cDNA library
P08288606A0240|9 25|polymerase chain
P08288606A0240|41 49|approach
P08288606A0240|166 171|clone
P08288633A0144|118 123|CeGAP
P08288633A0144|154 173|sequence similarity
P08288633A0144|39 61|Caenorhabditis elegans
P08288633A0144|142 148|domain
P08288633A0144|77 88|polypeptide
P08288633A0144|241 244|Bcr
P08289341A1202|86 92|copies
P08289341A1202|62 66|E2-C
P08289357A0724|85 93|elements
P08289357A0724|5 12|results
P08289357A0724|27 30|rep
P08289783A0000|5 10|Oct-3
P08289783A0000|95 104|candidate
P08289783A0000|13 25|gene product
P08289831A0290|84 89|mouse
P08289831A0290|100 109|cell line
P08289831A0290|149 156|element
P08289831A0290|74 77|RAW
P08290278A0374|21 24|Mad
P08290278A0374|63 95|candidate tumor suppressor genes
P08291233A0000|34 61|chicken embryo cDNA library
P08291233A0000|3 13|cDNA clone
P08291233A0000|124 133|U3 region
P08291761A0416|16 19|sex
P08291761A0416|71 94|serum IgG concentration
P08291761A0416|110 113|age
P08293412T0000|214 220|emesis
P08293412T0000|27 32|study
P08293412T0000|166 174|cocktail
P08293412T0000|60 72|tolerability
P08293993A0948|64 100|alpha-factor prepro secretion leader
P08293993A0948|28 39|P. pastoris
P08294429A0153|1 9|Analysis
P08294429A0153|52 55|DNA
P08294429A0153|24 32|hGH gene
P08294429A0153|79 87|hGh cDNA
P08294429A0153|60 62|FR
P08294511A0639|49 56|protein
P08294511A0639|176 187|interaction
P08294906A1315|152 161|transport
P08294906A1315|6 18|distribution
P08294906A1315|73 82|aspartate
P08297376A0236|1 16|Co-transfection
P08297376A0236|82 87|alpha
P08297376A0236|92 102|C/EBP beta
P08297376A0236|167 176|sequences
P08297376A0236|75 80|C/EBP
P08298129T0000|70 74|beta
P08298129T0000|47 55|promoter
P08299568A1401|101 118|glucose transport
P08299568A1401|7 11|data
P08299568A1401|46 53|enzymes
P08299896A0626|1 12|Concordance
P08300463A0581|119 126|effects
P08300463A0581|71 89|neurocysticercosis
P08300463A0581|158 163|drugs
P08300463A0581|58 67|treatment
P08300601A0745|86 107|E12/MyoD heterodimers
P08300601A0745|67 81|E12 homodimers
P08300601A0745|43 54|DNA binding
P08300605A0671|48 55|element
P08300605A0671|14 22|elements
P08300611T0000|36 43|domains
P08300611T0000|94 102|relaxase
P08300611T0000|72 80|reaction
P08301702A1083|101 111|microsomes
P08301702A1083|40 64|rat cytochrome P-450 1A1
P08301702A1083|211 225|immunoblotting
P08301702A1083|134 143|cormorant
P08302589A1132|116 129|phorbol ester
P08302589A1132|147 156|ionophore
P08304301A0331|1 8|METHODS
P08304301A0331|65 68|HCC
P08304301A0331|79 90|examination
P08305058T0000|34 44|dissection
P08305058T0000|66 72|hiatus
P08306834A0866|1 11|T2 cancers
P08307338A0227|1 10|Mutations
P08307338A0227|113 125|cytochrome b
P08307338A0227|147 152|cells
P08307338A0227|132 135|RNA
P08308008A0201|71 75|GABP
P08308008A0201|158 168|activation
P08308008A0201|9 14|paper
P08308008A0201|62 69|protein
P08309912A0306|1 11|Amiodarone
P08309912A0306|83 87|drug
P08309957A0000|53 66|jaw movements
P08309957A0000|78 82|rats
P08312243A0177|103 105|Cu
P08312243A0177|87 94|Na2EDTA
P08312243A0177|39 44|NaFe3
P08312243A0177|110 123|Ca metabolism
P08312243A0177|26 35|influence
P08312243A0177|45 49|EDTA
P08314922A0941|112 125|tissue damage
P08314922A0941|11 17|system
P08316209A0000|141 146|genes
P08316209A0000|55 59|CYS3
P08316209A0000|111 117|family
P08316209A0000|46 53|protein
P08317092A0304|16 22|region
P08317092A0304|253 265|tobraviruses
P08317092A0304|38 45|protein
P08317092A0304|176 184|proteins
P08317092A0304|105 111|region
P08319396A0448|307 313|matter
P08319396A0448|65 73|striatum
P08319396A0448|109 116|capsule
P08319396A0448|16 22|images
P08319396A0448|176 195|cerebellar peduncle
P08319396A0448|88 92|limb
P08319396A0448|150 165|intensity areas
P08320120A0361|85 96|capillaries
P08320120A0361|55 61|fields
P08320120A0361|203 210|nodules
P08320120A0361|12 27|microangiopathy
P08321203A0840|1 15|NF-kappa B p65
P08321203A0840|71 81|C/EBP beta
P08321203A0840|26 29|Rel
P08321741A0396|68 81|myelofibrosis
P08321741A0396|189 206|Metaplasia-AMM-in
P08321741A0396|56 64|progress
P08321741A0396|132 140|Myelosis
P08321741A0396|269 281|increase-CML
P08322823A0839|20 31|correlation
P08322823A0839|72 85|UTS phenotype
P08324107A0000|86 100|plasma protein
P08324107A0000|46 50|g/dl
P08324792T0000|67 79|infarct size
P08324792T0000|95 107|rabbit heart
P08325639A0129|204 213|breakdown
P08325639A0129|217 225|proteins
P08325639A0129|67 71|core
P08325639A0129|95 102|complex
P08325639A0129|79 82|26S
P08325883A0368|69 90|RNA recognition motif
P08325883A0368|96 115|glutamine stretches
P08325883A0368|56 62|copies
P08325883A0368|30 42|RBP1 protein
P08331064A0440|69 79|resolution
P08331064A0440|99 109|structures
P08331728A0686|1 8|Binding
P08331728A0686|12 14|U2
P08332492A0145|38 44|GATA-3
P08332492A0145|173 184|replication
P08332492A0145|78 91|T lymphocytes
P08332492A0145|104 110|target
P08333643A0000|1 14|Pneumoscrotum
P08333643A0000|79 84|texts
P08333643A0000|88 95|urology
P08334304A0473|18 23|cells
P08334304A0473|80 102|peptide growth factors
P08334304A0473|133 145|p21 rasVal12
P08335710A0338|5 14|influence
P08335710A0338|31 39|strength
P08336543A0243|136 144|terminus
P08336543A0243|98 103|basis
P08336543A0243|4 8|mice
P08336543A0243|111 119|sequence
P08336738A1273|5 15|equivalent
P08336738A1273|58 80|PSTAIRE sequence motif
P08336738A1273|29 35|ligand
P08337841A0612|137 155|consensus sequence
P08337841A0612|238 242|CATG
P08337841A0612|44 53|GNS genes
P08337841A0612|290 319|GNS protein termination codon
P08337841A0612|23 28|cells
P08337841A0612|214 236|polyadenylation signal
P08342703A0966|115 122|product
P08342703A0966|178 184|vessel
P08342703A0966|10 15|power
P08342703A0966|148 156|pressure
P08343216A0883|62 76|IgG subclasses
P08344248A0910|1 6|GAP-N
P08344248A0910|88 93|cells
P08347677A0308|290 296|microM
P08347677A0308|139 146|residue
P08347677A0308|5 31|phosphorylation efficiency
P08347677A0308|282 284|Km
P08347677A0308|198 219|4-Ala-Ala-Ser-Val-Ala
P08347677A0308|194 197|Arg
P08349104A0000|69 77|response
P08349104A0000|115 122|glucose
P08349104A0000|203 208|sites
P08349104A0000|161 169|proteins
P08349499A1169|1 4|Sex
P08349499A1169|8 12|calf
P08349499A1169|78 82|head
P08350061A0209|32 42|activation
P08350061A0209|5 15|mechanisms
P08350061A0209|46 57|suppression
P08352066A0000|103 117|bone formation
P08352066A0000|43 45|E2
P08352066A0000|151 155|rats
P08355062A0000|196 206|impairment
P08355062A0000|146 156|blood flow
P08355062A0000|57 93|99mTc-hexamethylpropyleneamine oxime
P08355062A0000|45 50|SPECT
P08355539A0133|1 8|METHODS
P08355539A0133|173 181|etiology
P08355539A0133|310 313|EAI
P08355539A0133|119 128|diagnosis
P08355539A0133|221 229|etiology
P08355539A0133|21 29|patients
P08355539A0133|298 306|etiology
P08355696A0236|21 26|c-jun
P08355696A0236|123 129|region
P08355696A0236|91 100|sequences
P08355857A1293|82 93|subgroup B.
P08355857A1293|40 41|%
P08355857A1293|46 56|subgroup A
P08356792T0000|37 47|proviruses
P08357834A0285|103 119|mouse homologues
P08357834A0285|306 318|counterparts
P08357834A0285|140 146|degree
P08357834A0285|267 285|PKC family members
P08357834A0285|95 98|rat
P08357834A0285|150 169|sequence divergence
P08360180A1041|119 129|similarity
P08360180A1041|235 249|cyanobacterial
P08360180A1041|37 42|PSI-G
P08360180A1041|61 75|PSI-K sequence
P08361755A0734|139 150|Tax binding
P08361755A0734|99 102|SRF
P08361755A0734|76 97|serum response factor
P08361755A0734|57 71|NF-kappa B p50
P08361755A0734|122 123|s
P08361755A0734|44 49|cDNAs
P08363332A0365|115 121|bundle
P08363332A0365|244 263|activation sequence
P08363332A0365|183 199|mapping catheter
P08363332A0365|134 140|atrium
P08363332A0365|60 85|surface electrocardiogram
P08366034A0637|81 90|formation
P08366034A0637|110 125|disulfide bonds
P08366034A0637|13 22|existence
P08367487A1014|256 264|extracts
P08367487A1014|23 31|addition
P08367487A1014|226 248|mRNA-splicing activity
P08367487A1014|44 57|17S U2 snRNPs
P08370119A0642|100 108|addition
P08370119A0642|32 36|exon
P08370119A0642|127 140|reading frame
P08370275A0290|124 134|preference
P08370275A0290|107 113|chimps
P08370275A0290|45 52|numeral
P08371713T0000|13 23|transcript
P08373274A0546|1 12|Polymyxin B
P08373274A0546|43 56|week postburn
P08374753A0335|50 71|diffusion coefficient
P08374753A0335|33 35|T2
P08376397A0788|100 109|E2F sites
P08376397A0788|33 40|protein
P08376397A0788|113 124|competitors
P08377199A1432|53 65|conformation
P08377199A1432|73 77|site
P08380736A0895|70 77|protein
P08380736A0895|10 14|mRNA
P08381121A0773|11 32|transmembrane regions
P08382296A0766|1 11|McCann III
P08382303A0507|16 31|transport motif
P08382303A0507|143 151|E1 genes
P08382303A0507|59 65|animal
P08382359A0469|342 357|tumor induction
P08382359A0469|206 215|T antigen
P08382359A0469|4 9|order
P08382359A0469|188 196|sequence
P08382359A0469|283 290|effects
P08382359A0469|319 329|activities
P08382778A0891|50 58|homology
P08382778A0891|101 108|feature
P08382778A0891|3 9|region
P08382778A0891|25 39|protein shares
P08383214A0389|71 75|form
P08383214A0389|99 113|RNase H domain
P08383214A0389|11 19|cleavage
P08383287A0611|21 28|element
P08383287A0611|122 146|hormone response element
P08383492A1205|84 90|region
P08383492A1205|98 109|differences
P08383492A1205|127 132|terms
P08383492A1205|149 157|affinity
P08383622T0000|23 28|NRF-2
P08383622T0000|108 112|role
P08383622T0000|150 159|promoters
P08383622T0000|45 54|activator
P08384309A0000|185 204|DNA binding protein
P08384309A0000|112 147|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08384309A0000|25 48|region/helix-loop-helix
P08384309A0000|104 110|dioxin
P08385337A0282|101 119|DNA binding region
P08385337A0282|159 164|bZIP2
P08385337A0282|179 185|region
P08385337A0282|149 154|bZIP1
P08386279A1621|119 134|HIV-1 infection
P08386279A1621|64 68|HeLa
P08386279A1621|5 29|transactivation function
P08386279A1621|111 114|EBV
P08386317T0000|100 104|CREB
P08386317T0000|81 85|CREB
P08386317T0000|121 132|stimulation
P08386319A1229|1 9|Mutation
P08386319A1229|57 75|threonine residues
P08386319A1229|79 84|Mpk1p
P08386637A1220|154 163|receptors
P08386637A1220|4 12|contrast
P08386637A1220|76 83|agonist
P08386637A1220|43 48|cells
P08386637A1220|60 68|exposure
P08387507A1015|103 110|signals
P08387507A1015|190 197|nucleus
P08387507A1015|142 164|peptide growth factors
P08387507A1015|63 70|pathway
P08387507A1015|226 233|factors
P08387519A0000|51 68|desmin expression
P08387519A0000|39 44|level
P08387519A0000|112 120|enhancer
P08387743A0624|1 12|Replacement
P08387743A0624|101 108|element
P08387743A0624|135 145|expression
P08388496A1117|288 297|BamHI-C/W
P08388496A1117|257 266|infection
P08388496A1117|231 234|day
P08388496A1117|59 80|virus producer status
P08388496A1117|92 103|consequence
P08388496A1117|27 31|LCLs
P08388543A1263|64 69|sites
P08388543A1263|23 31|receptor
P08388543A1263|127 143|protein kinase C
P08388543A1263|214 217|Ras
P08388543A1263|46 49|PLC
P08388543A1263|183 189|effect
P08389074A1227|119 126|effects
P08389074A1227|40 48|EIAV Tat
P08389074A1227|26 36|C-terminus
P08389453A0193|1 23|Uracil DNA glycosylase
P08389453A0193|108 114|uracil
P08389453A0193|120 130|duplex DNA
P08390665A0000|175 183|electron
P08390665A0000|36 45|prototype
P08390665A0000|25 29|LiPc
P08390831A0143|171 184|risk patients
P08390831A0143|155 161|stages
P08390831A0143|98 103|phase
P08390831A0143|42 51|remission
P08391748A0452|1 6|Drugs
P08391748A0452|308 309|%
P08391748A0452|276 291|QT prolongation
P08391748A0452|380 395|QT prolongation
P08391748A0452|185 186|%
P08391748A0452|218 234|QRS prolongation
P08391748A0452|27 28|%
P08392623A1374|85 90|motif
P08392623A1374|39 45|domain
P08392623A1374|122 125|IE2
P08394019A0695|137 147|SH3 domain
P08394019A0695|100 111|PI 3-kinase
P08394019A0695|21 40|GST fusion proteins
P08394019A0695|61 64|SH3
P08394464A1080|102 106|p176
P08394464A1080|71 74|kDa
P08394464A1080|142 149|species
P08394464A1080|14 26|Rev proteins
P08395004A0141|5 12|ability
P08395004A0141|63 75|interference
P08395004A0141|90 130|delta promoter insertion his-4-912 delta
P08395010T0000|32 38|heptad
P08395010T0000|42 57|thyroid hormone
P08395010T0000|146 165|homodimer formation
P08395654T0000|115 122|tissues
P08395654T0000|43 51|receptor
P08396120A0690|69 74|start
P08396120A0690|78 89|translation
P08396657A0452|6 8|B.
P08396713A0305|203 207|ARNT
P08396713A0305|179 198|Ah receptor protein
P08396713A0305|160 164|TCDD
P08396713A0305|123 158|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08396713A0305|61 69|receptor
P08396749A1112b|100 101|P
P08396749A1112b|116 121|apo B
P08396749A1112b|78 83|weeks
P08396749A1112b|164 165|P
P08397123T0000|48 55|element
P08397123T0000|131 139|features
P08400240A0166|103 111|A gamma*
P08400240A0166|50 70|locus control region
P08400240A0166|146 156|transcript
P08400240A0166|193 210|gamma-globin mRNA
P08401570A0828|174 195|transcription factors
P08401570A0828|96 105|sequences
P08401570A0828|28 41|binding sites
P08403245A1234|84 91|piglets
P08403245A1234|43 48|group
P08405433A0000|69 78|promoters
P08405433A0000|80 82|P1
P08405433A0000|24 37|growth factor
P08405433A0000|88 90|P3
P08406352A0172|1 14|Army veterans
P08406352A0172|234 241|respect
P08406352A0172|167 176|carcinoma
P08406352A0172|28 41|fever vaccine
P08406352A0172|269 276|vaccine
P08406352A0172|60 77|hepatitis B virus
P08406497A0000|32 54|glycoprotein component
P08406497A0000|76 87|microfibril
P08406497A0000|12 21|fibrillin
P08408194T0000|116 118|Na
P08408194T0000|83 91|adhesion
P08408194T0000|125 145|ATPase distributions
P08408194T0000|120 121|K
P08408841A0281|9 22|abnormalities
P08408841A0281|74 87|abnormalities
P08409284A0262|87 88|Y
P08409284A0262|25 36|amino acids
P08409284A0262|208 217|diarrhoea
P08409284A0262|132 143|PHE carrier
P08409284A0262|44 55|NBB carrier
P08410042T0000|19 26|disease
P08410042T0000|43 60|dura mater grafts
P08411024T0000|59 83|fibrosis carrier testing
P08411024T0000|12 18|people
P08412120A0839|33 36|DO2
P08412120A0839|10 20|bowel TPO2
P08412662A0333|98 104|257DH4
P08412662A0333|20 26|cosmid
P08412662A0333|124 127|Tn5
P08413186A0077|252 259|pathway
P08413186A0077|139 146|factors
P08413186A0077|52 62|regulation
P08413186A0077|24 34|mechanisms
P08413205A0733|155 161|copies
P08413205A0733|82 83|c
P08413205A0733|131 139|promoter
P08413205A0733|88 89|d
P08413215A0327|86 99|transcription
P08413215A0327|110 123|IL-8 promoter
P08413239A0490|137 150|end formation
P08413239A0490|35 46|sequence CA
P08413239A0490|48 49|N
P08413239A0490|203 206|box
P08413239A0490|76 85|plant Pol
P08413274A0452|50 59|complexes
P08413274A0452|65 87|X-box oligonucleotides
P08413274A0452|142 152|MDBP sites
P08414410A0270|220 226|damage
P08414410A0270|250 267|nerve fiber layer
P08414410A0270|197 205|measures
P08414410A0270|58 62|eyes
P08414410A0270|240 245|nerve
P08415637A0000|35 41|family
P08415637A0000|5 28|ADP-ribosylation factor
P08415637A0000|128 136|proteins
P08415637A0000|109 115|weight
P08415712A1153|205 229|Huntington disease locus
P08415712A1153|36 54|chromosome mapping
P08415712A1153|9 31|Southern blot analysis
P08415712A1153|183 187|GPRK
P08416977A0892|68 82|chromatography
P08416977A0892|7 18|CTD kinases
P08416977A0892|31 36|CTDK1
P08417330A0149|168 170|N.
P08417330A0149|82 105|heat shock inducibility
P08417349A1633|117 128|replication
P08417349A1633|140 157|mutation fixation
P08417349A1633|14 18|data
P08419338A0273|68 75|Palacin
P08419338A0273|32 37|Biber
P08419338A0273|5 11|Stange
P08419338A0273|43 49|Testar
P08419338A0273|13 15|G.
P08419338A0273|17 26|Markovich
P08419338A0273|55 62|Zorzano
P08419338A0273|28 30|D.
P08420230A0544|100 111|angioplasty
P08420230A0544|78 83|month
P08421687A0397|5 28|selenocysteine residues
P08421897A0000|35 40|types
P08421897A0000|66 75|sequences
P08421897A0000|107 113|genome
P08422975A1205|49 75|kinetoplastid mitochondria
P08422975A1205|83 92|formation
P08422975A1205|109 114|mRNAs
P08425050A0898|98 108|PE operons
P08425050A0898|122 126|date
P08425050A0898|47 51|rpeA
P08427501A0221|7 18|differences
P08427501A0221|195 200|types
P08427501A0221|211 217|polyps
P08428750T0000|85 105|chromosome 10p13-ter
P08428750T0000|32 36|gene
P08428940A1763|50 57|hexamer
P08428940A1763|114 128|RNA polymerase
P08428940A1763|10 16|mutant
P08428940A1763|61 63|PR
P08428940A1763|105 109|MerR
P08428952A1957|35 42|fimbrin
P08428952A1957|21 29|evidence
P08428965A1868|5 14|half-life
P08428965A1868|92 94|h.
P08428965A1868|121 126|WORDS
P08429019A2022|201 206|WORDS
P08429019A2022|76 93|protein B binding
P08429019A2022|135 165|yeast ABF-1 consensus sequence
P08429568A0000|1 19|Rhizobium meliloti
P08429568A0000|55 91|nodulation competitiveness locus nfe
P08429568A0000|161 171|strain GR4
P08429568A0000|150 157|ability
P08430095A0161|27 41|identification
P08430095A0161|73 77|SMD1
P08430095A0161|105 110|PRP38
P08431100A0108|187 201|children group
P08431100A0108|113 118|years
P08431100A0108|129 133|loss
P08431100A0108|214 217|age
P08431100A0108|167 172|hours
P08432526A0580|7 12|exons
P08432526A0580|44 60|sequencing cDNAs
P08435755A0938|86 87|h
P08435755A0938|4 14|Experiment
P08435755A0938|149 164|stage-3 seizure
P08435794A0658|1 12|CONCLUSIONS
P08437521A0000|1 10|Mutations
P08437521A0000|48 56|residues
P08437521A0000|174 182|nidulans
P08437521A0000|231 243|areA product
P08437521A0000|287 299|areA control
P08438584A0524|68 75|C2 ORFs
P08438584A0524|101 109|promoter
P08438584A0524|77 87|C1-C2 gene
P08438584A0524|45 53|promoter
P08439564A0883|85 88|rat
P08439564A0883|99 105|factor
P08439564A0883|113 129|transcobalamin I
P08439564A0883|181 189|homology
P08439597A0176|103 120|screening centres
P08439597A0176|52 64|study design
P08440688A1509|112 127|differentiation
P08440688A1509|37 44|G alpha
P08440688A1509|133 148|hormone signals
P08440688A1509|104 110|growth
P08441379A0912|252 272|IL-1 beta expression
P08441379A0912|21 37|proIL-1 beta cap
P08441379A0912|203 213|HeLa cells
P08441379A0912|127 132|virus
P08441411A1260|228 232|IL-2
P08441411A1260|132 133|h
P08441411A1260|186 192|events
P08441411A1260|291 293|G1
P08441411A1260|82 93|stimulation
P08441411A1260|242 250|receptor
P08441411A1260|301 308|S phase
P08441869A0334|56 64|relation
P08442384T0000|5 29|SCH9 protein kinase mRNA
P08443339A1374|156 160|root
P08443339A1374|140 148|cylinder
P08443339A1374|104 111|bundles
P08443339A1374|31 34|GUS
P08443339A1374|15 27|localization
P08443341A0384|1 23|Southern blot analysis
P08443341A0384|49 57|portions
P08443341A0384|93 107|MB cDNA clones
P08443341A0384|241 249|B. napus
P08443341A0384|30 36|probes
P08444344A0000|1 13|Zinc fingers
P08444344A0000|15 17|Zf
P08445299T0000|20 32|insufflation
P08445299T0000|76 80|rats
P08445729A0657|1 12|Replacement
P08445729A0657|83 91|sequence
P08445729A0657|72 79|stretch
P08446579A0784|140 157|activating domain
P08446579A0784|109 118|variation
P08446579A0784|165 189|herpesvirus protein VP16
P08447005T0001|1 12|Elimination
P08447005T0001|63 75|introduction
P08449943A0225|152 166|leukemia cells
P08449943A0225|87 97|regulation
P08449943A0225|126 131|HL-60
P08449943A0225|47 56|mechanism
P08449986A0455|84 95|mouse brain
P08449986A0455|13 19|clones
P08451187A0267|29 40|differences
P08453101A0128|1 17|Pokeweed mitogen
P08453101A0128|19 22|PWM
P08453101A0128|97 104|T cells
P08454077A0956|141 152|reperfusion
P08454077A0956|414 422|ABSTRACT
P08454077A0956|351 359|controls
P08454077A0956|286 300|muscle salvage
P08454077A0956|14 18|rats
P08454077A0956|87 104|revascularisation
P08454077A0956|386 393|normals
P08454077A0956|29 36|U74500A
P08454077A0956|440 445|WORDS
P08454077A0956|309 310|%
P08454077A0956|160 163|min
P08454077A0956|187 190|min
P08454077A0956|125 129|GMBF
P08454591A1322|49 52|TNF
P08454591A1322|114 119|IRF-1
P08454591A1322|5 11|region
P08454591A1322|25 37|inducibility
P08454591A1322|41 45|IL-1
P08455598A0000|157 171|mating ability
P08455598A0000|9 16|mutants
P08455598A0000|125 145|alpha mating ability
P08455598A0000|89 112|a/alpha aar1-6 genotype
P08455611A0154|103 107|zeta
P08455611A0154|138 148|K562 cells
P08455611A0154|110 134|globin promoter activity
P08455611A0154|27 43|expression assay
P08455629A0335|1 10|Breitbart
P08456879A0000|118 123|blood
P08456879A0000|1 10|OBJECTIVE
P08456879A0000|58 72|concentrations
P08457291A0170|117 124|regions
P08457291A0170|52 67|proto-oncogenes
P08458849A0364|186 190|ftr3
P08458849A0364|170 174|ftr2
P08458849A0364|18 28|regulation
P08458849A0364|81 89|promoter
P08458849A0364|180 184|+120
P08459012T0000|9 16|dimelia
P08460270A0205|48 54|larvae
P08460918A0252|1 6|Group
P08460918A0252|202 212|IU liter-1
P08460918A0252|41 49|patients
P08460918A0252|359 377|hyperbilirubinemia
P08460918A0252|320 328|patients
P08460918A0252|176 196|alkaline phosphatase
P08460918A0252|384 397|mumol liter-1
P08460918A0252|147 156|bilirubin
P08461981A0882|49 55|months
P08461981A0882|64 69|study
P08461981A0882|28 35|animals
P08463320A1219|252 261|structure
P08463320A1219|230 239|formation
P08463320A1219|9 43|copper-phenanthroline footprinting
P08463320A1219|124 130|G4oric
P08464056A0000|1 7|Finger
P08464056A0000|28 43|finger proteins
P08464056A0000|45 53|FAX-ZFPs
P08464924A0243|115 128|eIF-5 protein
P08468320A0941|8 10|J.
P08469831T0001|157 166|rat model
P08469831T0001|58 69|nicardipine
P08469831T0001|130 135|state
P08469831T0001|90 99|reactions
P08470895A1617|49 64|mRNA start site
P08470895A1617|104 122|enhancer sequences
P08471629A0816|171 180|substrate
P08471629A0816|153 160|peptide
P08471629A0816|1 16|Pseudosubstrate
P08471629A0816|93 101|beta-PKC
P08472750A0999|117 128|oxygenation
P08472750A0999|55 67|hypertension
P08472750A0999|177 187|activation
P08472750A0999|150 161|attenuation
P08473967T0000|43 70|Myers-Briggs Type Indicator
P08474439A0877|1 10|Mutations
P08474439A0877|279 288|CArG site
P08474439A0877|338 344|muscle
P08474439A0877|316 326|expression
P08474439A0877|49 55|muscle
P08474439A0877|250 256|muscle
P08474439A0877|188 193|E-box
P08474439A0877|145 157|muscle types
P08474439A0877|121 127|effect
P08474464A0348|70 86|TR binding sites
P08474464A0348|42 44|TR
P08476087A0814|18 28|influences
P08476087A0814|108 112|mmHg
P08479742A0985|81 99|cell proliferation
P08479742A0985|133 142|processes
P08479742A0985|45 52|ability
P08482539A0913|114 119|xylan
P08482539A0913|42 45|RNA
P08483479A1056|103 107|mice
P08483479A1056|174 194|elements down-stream
P08483479A1056|203 212|kilobases
P08483479A1056|129 134|alpha
P08483479A1056|281 285|bone
P08483479A1056|226 229|PTH
P08483479A1056|22 25|PTH
P08484689T0000|68 76|evidence
P08484689T0000|1 11|Prevalence
P08484689T0000|91 98|decline
P08485317A0000|5 23|fission yeast dsk1
P08485317A0000|43 53|suppressor
P08485317A0000|73 85|dis1 mutants
P08486276A0419|206 208|Cm
P08486276A0419|232 242|resistance
P08486276A0419|44 47|ORF
P08486276A0419|154 162|proteins
P08486276A0419|189 204|chloramphenicol
P08486276A0419|214 226|tetracycline
P08488700A0283|102 114|immunization
P08488700A0283|5 15|strategies
P08488700A0283|189 198|education
P08488700A0283|267 274|disease
P08488700A0283|214 223|awareness
P08488700A0283|167 184|blood derivatives
P08491124A0517|87 102|instrumentation
P08491124A0517|125 134|materials
P08491124A0517|165 181|mouth protectors
P08491383A1291|22 35|alpha-subunit
P08491383A1291|148 167|interaction domains
P08492164T0000|50 56|cortex
P08492164T0000|58 61|age
P08492164T0000|29 32|cat
P08492164T0000|91 97|effect
P08495786A0085|37 42|media
P08495786A0085|105 110|donor
P08496184A0772|55 58|min
P08496184A0772|124 140|type counterpart
P08496184A0772|105 113|sequence
P08496475T0000|1 14|Calcification
P08496475T0000|52 67|Corynebacterium
P08496601A1153|35 47|muMIP-1 beta
P08496601A1153|3 13|comparison
P08496601A1153|172 181|fragments
P08496601A1153|376 399|consensus CK-1 sequence
P08496601A1153|86 98|CK-1 element
P08496601A1153|216 229|muMIP-1 alpha
P08496601A1153|321 338|promoter segments
P08496601A1153|146 157|macrophages
P08497190T0079|23 37|identification
P08497190T0079|45 48|hyp
P08497259A0452|18 39|SUP4A53T61 transcript
P08497259A0452|5 10|level
P08497273T0000|19 28|repressor
P08497273T0000|8 12|BSAP
P08497273T0000|107 129|B-cell differentiation
P08497280A1397|67 85|SWI4 transcription
P08497280A1397|40 47|pathway
P08498570A1118|16 23|changes
P08498570A1118|111 116|Pcrit
P08498570A1118|78 86|hindlimb
P08498570A1118|121 123|Ra
P08499903A0883|55 63|deletion
P08499903A0883|7 15|patients
P08500524A0424|34 44|gamma gene
P08500524A0424|78 82|exon
P08500524A0424|105 121|splicing signals
P08501030A0456|86 90|narL
P08501030A0456|36 56|.5 operon expression
P08503348A0226|5 33|HMG CoA reductase inhibitors
P08504928T0000|68 91|cell cycle gene product
P08504928T0000|114 125|DNA binding
P08504928T0000|133 137|TATA
P08504928T0000|150 157|subunit
P08504933A0000|1 6|Pit-1
P08504933A0000|127 132|gland
P08505312A0285|1 5|Biol
P08505495A0253|5 14|retention
P08506317A0000|16 28|C/EBP family
P08506317A0000|87 99|heterodimers
P08506317A0000|116 124|CAAT box
P08506317A0000|60 81|transcription factors
P08507921A1021|222 227|death
P08507921A1021|156 165|prognosis
P08507921A1021|53 67|stratification
P08507921A1021|92 108|plasma ANF level
P08507921A1021|134 140|method
P08508778A0112|1 14|Yeast mutants
P08508778A0112|95 106|temperature
P08508778A0112|75 86|fibrillarin
P08509051A0316|41 55|mortality rate
P08509335T0000|1 5|SSG1
P08509335T0000|46 64|1,3-beta-glucanase
P08509430A0372|84 91|CC-2341
P08509430A0372|20 35|complementation
P08509430A0372|93 103|ac-u-g-2.3
P08509430A0372|213 219|medium
P08509430A0372|160 169|selection
P08510320A1249|185 197|beta-lactams
P08510320A1249|65 70|Japan
P08510320A1249|166 176|resistance
P08510924A0490|41 56|transactivation
P08512728A0991|238 239|p
P08512728A0991|100 106|number
P08512728A0991|200 202|RR
P08512728A0991|142 154|fibrillation
P08512728A0991|110 118|patients
P08512728A0991|160 170|conduction
P08514757A1100|48 65|receptor assembly
P08514757A1100|6 19|immunophilins
P08514757A1100|132 142|modulators
P08515619A0184|34 43|ventricle
P08515619A0184|1 20|Tl-201 uptake ratio
P08515619A0184|141 145|dose
P08515619A0184|66 71|ratio
P08515619A0184|81 87|counts
P08515619A0184|261 269|controls
P08515619A0184|149 155|Tl-201
P08516301A0080|6 10|gene
P08516301A0080|47 52|exons
P08516324A0000|237 243|domain
P08516324A0000|23 36|translocation
P08516324A0000|132 140|molecule
P08516324A0000|60 73|Ewing sarcoma
P08518797T0000|62 76|candidate gene
P08518797T0000|30 42|localization
P08519862T0001|25 39|IgM antibodies
P08521414A1384|216 226|cell lines
P08521414A1384|189 196|E1 beta
P08521414A1384|146 150|mRNA
P08521414A1384|88 96|p16INK4A
P08521414A1384|28 39|methylation
P08521414A1384|120 126|levels
P08522511A1250|10 13|PLB
P08522511A1250|47 49|pH
P08522530A1342|87 97|transcript
P08522530A1342|203 208|sigma
P08522530A1342|6 15|nifA mRNA
P08522530A1342|163 173|transcript
P08522530A1342|130 139|anaerobox
P08523545T0000|34 44|E7 protein
P08523545T0000|57 72|adenovirus type
P08523545T0000|11 30|papillomavirus type
P08523545T0000|123 138|adenovirus type
P08523545T0000|75 78|E1A
P08524036A0747|139 158|insertion/deletions
P08524036A0747|115 134|point substitutions
P08524036A0747|53 58|level
P08524036A0747|88 103|enhancer region
P08524036A0747|13 25|expectations
P08524235A0695|1 8|Cloning
P08524235A0695|138 144|region
P08524235A0695|54 62|deletion
P08524235A0695|93 98|helix
P08524235A0695|162 168|result
P08524235A0695|13 23|sequencing
P08524260A0835|32 38|LTBP-2
P08524260A0835|98 106|examples
P08524260A0835|203 218|calcium binding
P08524260A0835|131 137|growth
P08524260A0835|180 198|consensus sequence
P08524260A0835|284 294|fibrillins
P08524272T0000|65 81|Jak/Stat pathway
P08524272T0000|89 92|SH2
P08524292A1022|1 8|Results
P08524292A1022|175 186|DNA binding
P08524292A1022|163 171|activity
P08524292A1022|111 114|AP1
P08524292A1022|134 141|protein
P08524314A0216|34 47|gene sequence
P08524314A0216|190 198|proteins
P08524314A0216|59 66|protein
P08524314A0216|11 32|Ty enhancer activator
P08524314A0216|75 78|kDa
P08526620A1344|50 75|SC5b-9 complement complex
P08526620A1344|163 169|bypass
P08526620A1344|104 114|evaluation
P08528796A1470|5 8|MCA
P08528796A1470|46 55|deviation
P08529630A0840|72 77|roots
P08529630A0840|31 45|P protein mRNA
P08529662A0507|100 108|labeling
P08529662A0507|43 47|form
P08530107A1003|43 53|expression
P08530107A1003|57 66|histidase
P08530342T0000|11 24|gp39 promoter
P08530369A0099|5 9|site
P08530369A0099|112 139|Src family tyrosine kinases
P08530418A1182|101 111|activation
P08530418A1182|66 82|master regulator
P08530418A1182|129 138|RARE beta
P08530418A1182|123 127|HREs
P08530503A1004|17 37|ARP immunoreactivity
P08530503A1004|82 89|cytosol
P08530503A1004|106 118|3T3-L1 cells
P08531669A0950|1 12|Competition
P08531669A0950|100 105|study
P08531669A0950|92 96|kind
P08532536A0925|171 180|induction
P08532536A0925|1 16|TIEG expression
P08532536A0925|20 30|hFOB cells
P08532536A0925|143 156|growth factor
P08532536A0925|66 70|bone
P08532536A0925|120 129|induction
P08533472A0777|35 45|ORFs N2417
P08533472A0777|217 223|factor
P08533472A0777|113 122|organisms
P08533472A0777|128 176|Candida maltosa cycloheximide-resistance protein
P08533472A0777|225 230|ILF-2
P08533757A0204|18 42|Ashkenazi Jewish descent
P08533757A0204|6 14|families
P08533757A0204|93 102|haplotype
P08533757A0204|165 170|BRCA1
P08534367A0984|1 7|PTP-S3
P08534367A0984|21 27|PTP-S4
P08534848A0188b|40 42|cv
P08535138A0857|84 93|treatment
P08535138A0857|33 43|leaf cells
P08535138A0857|99 113|plant hormones
P08535138A0857|67 80|cell division
P08536694A0000|1 16|Protein kinases
P08536694A0000|30 35|roles
P08537403A0336|142 145|VIB
P08537403A0336|41 46|LIMK2
P08537403A0336|165 171|insert
P08537403A0336|90 128|sequence motif Asp-Leu-Asn-Ser-His-Asn
P08538382A1012|1 15|Erythrocyte AA
P08538382A1012|19 25|FO+EPO
P08538382A1012|82 89|placebo
P08538702A0214|86 94|gp15/400
P08538702A0214|55 69|ABA-1 allergen
P08538702A0214|96 102|ladder
P08538702A0214|73 80|Ascaris
P08538702A0214|195 214|Dirofilaria immitis
P08541793A0796|48 51|hrs
P08541793A0796|13 21|recovery
P08542027A1471|64 72|LU genes
P08542027A1471|93 103|expression
P08543173A0314|49 61|start points
P08543173A0314|63 66|tsp
P08543595A1093|17 27|efficacies
P08543595A1093|4 11|summary
P08544820T0000|1 17|Characterization
P08544820T0000|112 122|Lsp-2 gene
P08546707T0000|85 90|c-Rel
P08546707T0000|103 116|NF-kappa Bp50
P08546707T0000|75 79|RelA
P08548291A1059|102 123|serum response factor
P08548291A1059|34 39|SAPKs
P08548291A1059|20 30|activation
P08548291A1059|95 100|Elk-1
P08549859A1604|35 39|odds
P08549859A1604|5 9|gene
P08550460A0374|141 177|membrane lipoprotein leader sequence
P08550460A0374|58 60|bp
P08550460A0374|45 49|pilP
P08550462A0815|17 25|dra gene
P08550462A0815|55 66|amino acids
P08550470A1021|56 65|receptors
P08550470A1021|13 17|CheW
P08550564T0000|136 143|domains
P08550564T0000|39 63|selectivity determinants
P08551577A0000|139 155|envelope protein
P08551577A0000|99 102|DNA
P08551577A0000|126 130|mRNA
P08551577A0000|63 74|transcripts
P08552045A0973|85 96|GCACGTTTT-3
P08552045A0973|235 254|centromere function
P08552045A0973|203 226|methionine biosynthesis
P08552045A0973|146 159|Cpflp protein
P08552045A0973|194 199|genes
P08552086A0150|68 72|VDRE
P08552086A0150|93 98|c-fos
P08552093A0657|1 16|Differentiation
P08552093A0657|49 59|expression
P08552093A0657|141 150|Gq family
P08552093A0657|89 97|alpha i2
P08552095A0758|18 28|abundances
P08552095A0758|159 163|PAF1
P08552095A0758|93 100|strains
P08552095A0758|121 126|genes
P08552096A0151|168 183|cdc34 mutations
P08552096A0151|133 151|cell cycle defects
P08552096A0151|74 78|UBS1
P08552643A0261|141 144|VSV
P08552643A0261|23 26|DBD
P08552643A0261|146 155|infection
P08552643A0261|123 139|stomatitis virus
P08552670T0000|1 15|Identification
P08552670T0000|113 126|fission yeast
P08554069A0743|85 99|T transversion
P08554069A0743|81 82|G
P08554069A0743|5 12|patient
P08554069A0743|111 131|acceptor splice site
P08554723A0187|84 87|PBN
P08554723A0187|64 76|acid lesions
P08554723A0187|157 166|l-alanine
P08554723A0187|172 173|M
P08554723A0187|89 93|PBNx
P08554723A0187|150 153|CTA
P08555168A0390|35 40|sites
P08555168A0390|71 79|affinity
P08555446A0000|139 145|levels
P08555446A0000|173 179|leaves
P08555446A0000|12 26|tobacco plants
P08555446A0000|105 122|35S CaMV promoter
P08555597A0808|1 10|Hb levels
P08555597A0808|30 32|Hb
P08556707A1390|35 41|218leu
P08556707A1390|168 180|p53 function
P08556707A1390|219 231|SNU-C5 cells
P08556707A1390|126 138|temperatures
P08556707A1390|209 215|allele
P08561607A1443|9 14|class
P08561897A0604|1 9|Mobility
P08561897A0604|163 171|CREB/ATF
P08561897A0604|176 180|AP-1
P08561897A0604|79 82|USF
P08561897A0604|88 91|Sp1
P08563483A0094|51 63|gonadotropin
P08563483A0094|70 76|levels
P08563483A0094|65 68|hCG
P08563483A0094|10 15|cases
P08564588A1318|53 61|analysis
P08564588A1318|150 155|WORDS
P08565548A0196|155 162|DA rats
P08565548A0196|54 66|silicone gel
P08565548A0196|112 115|BII
P08565548A0196|133 145|silicone gel
P08566751A0455|172 181|Hox genes
P08566751A0455|29 37|question
P08566751A0455|120 129|sequences
P08566754A0783|116 134|ribonucleoproteins
P08566754A0783|9 29|splice site sequence
P08566754A0783|56 71|polyadenylation
P08566773A1023|34 36|Ci
P08566773A1023|98 109|observation
P08566773A1023|83 93|chitinases
P08566773A1023|41 48|members
P08567683A0401|92 94|Mr
P08567683A0401|11 20|purH cDNA
P08567683A0401|75 90|acid polypeptic
P08567847A1005|52 64|shortcomings
P08567847A1005|126 137|examination
P08567847A1005|177 185|features
P08567847A1005|72 86|user-interface
P08569680A0636|92 96|GATA
P08569680A0636|134 142|function
P08570615T0000|1 11|Disruption
P08570615T0000|80 93|S-phase entry
P08570615T0000|24 35|interaction
P08570615T0000|15 21|RB/E2F
P08573083A0645|143 146|USF
P08573083A0645|93 113|transcription factor
P08573083A0645|24 29|motif
P08573083A0645|61 73|binding site
P08574414A1037|7 14|primers
P08574414A1037|25 36|PCR product
P08575609A0526|118 119|%
P08575609A0526|55 59|eyes
P08575609A0526|127 135|patients
P08575609A0526|45 50|cases
P08575618A1138|70 76|dorsal
P08575618A1138|110 146|pigmentation/phaeomelanin phenotypes
P08575618A1138|60 66|levels
P08576042A0765|272 279|amounts
P08576042A0765|283 287|mRNA
P08576042A0765|74 81|plasmid
P08576042A0765|19 31|HrcA protein
P08576042A0765|83 88|phrcA
P08576042A0765|94 105|B. subtilis
P08576042A0765|215 228|transcription
P08576042A0765|120 138|delta hrcA strains
P08576131A0685|96 107|association
P08576131A0685|124 132|subunits
P08576245A0000|170 177|calcium
P08576245A0000|114 130|stress responses
P08576245A0000|144 151|glucose
P08576245A0000|199 223|glycoprotein trafficking
P08576546A0975|23 34|experiments
P08576546A0975|40 48|efficacy
P08576546A0975|105 119|dose regiments
P08580671A0137|153 165|hypertension
P08580671A0137|185 193|patients
P08580671A0137|199 212|liver disease
P08580671A0137|132 140|bleeding
P08582143A0614|170 195|beta-lactamase production
P08582143A0614|7 14|studies
P08582143A0614|124 134|nitrocefin
P08582143A0614|45 49|test
P08583783A0870|10 13|ANP
P08583783A0870|41 51|filtration
P08583846A0807|87 93|marker
P08583846A0807|125 132|setting
P08584035A0740|103 121|binding properties
P08584035A0740|201 210|complexes
P08584035A0740|64 72|proteins
P08584035A0740|212 214|R1
P08584530A0545|84 89|MEF50
P08584530A0545|42 46|FEV1
P08584530A0545|94 99|MEF25
P08584530A0545|13 25|correlations
P08585324A0823|85 96|tau element
P08585324A0823|56 65|precursor
P08585324A0823|29 33|gene
P08585883A0381|1 7|Hybrid
P08585883A0381|21 32|C57BL x CBA
P08585883A0381|66 70|CD-1
P08585883A0381|198 204|period
P08585883A0381|106 109|day
P08585883A0381|15 19|mice
P08585994A0567|155 158|arm
P08585994A0567|36 45|standards
P08585994A0567|7 23|reference probes
P08585994A0567|121 139|band interval 89A1
P08586874T0000|16 26|life cycle
P08586874T0000|128 134|stages
P08586874T0000|63 68|Looss
P08588852A0236|69 74|fetus
P08588852A0236|49 56|studies
P08588852A0236|95 104|gestation
P08588852A0236|166 170|toes
P08588852A0236|121 133|micrognathia
P08589358A0235|112 117|weeks
P08589358A0235|59 64|rhEPO
P08589358A0235|13 21|units/kg
P08589735A0577|51 67|promoter regions
P08589735A0577|22 36|GUS expression
P08589735A0577|144 148|Ubi1
P08589735A0577|10 20|constructs
P08589735A0577|120 124|Adh1
P08591700A0972|81 86|women
P08591700A0972|27 30|BMI
P08591700A0972|91 94|men
P08592713T0001|11 22|enantiomers
P08595012A0817|86 90|rest
P08595012A0817|21 29|response
P08595012A0817|76 82|values
P08595414A0000|259 270|orientation
P08595414A0000|138 151|model genomes
P08595414A0000|5 13|assembly
P08595414A0000|58 62|maps
P08595414A0000|105 112|contigs
P08595658A0961|5 18|DNA sequences
P08595658A0961|37 44|termini
P08595658A0961|165 179|RNA processing
P08595878A0201|50 64|PP2A functions
P08595878A0201|175 201|R7 photoreceptor cell fate
P08595878A0201|25 33|evidence
P08595878A0201|132 159|signal transduction pathway
P08597177T0000|1 8|Effects
P08597177T0000|55 58|rat
P08597636A0000|33 39|family
P08597636A0000|66 74|features
P08597636A0000|43 48|genes
P08597636A0000|11 16|motif
P08598359X0000|204 211|factors
P08598359X0000|310 316|larynx
P08598359X0000|163 172|treatment
P08598359X0000|280 294|cell carcinoma
P08598359X0000|44 70|treatment energy influence
P08598359X0000|252 261|treatment
P08598359X0000|177 184|patient
P08598359X0000|88 93|T1-T2
P08599945T0000|117 129|RNA cleavage
P08599945T0000|65 72|subunit
P08599945T0000|43 49|domain
P08600028A1129|140 151|Myc protein
P08600028A1129|23 39|trans-activation
P08600028A1129|91 101|reflection
P08601283A0875|171 174|ORF
P08601283A0875|16 24|presence
P08601283A0875|71 75|ORFs
P08601283A0875|4 8|view
P08601283A0875|28 42|SECIS elements
P08601283A0875|121 128|effects
P08601490A0659|7 14|animals
P08601806A0875|97 105|amacrine
P08601806A0875|110 124|ganglion cells
P08601806A0875|78 93|differentiation
P08602608A1056|59 65|CD3500
P08602608A1056|28 33|cases
P08604338A0198|136 153|promoter elements
P08604338A0198|20 34|FLI-1 proteins
P08604338A0198|95 108|ets sequences
P08604708A1086|157 160|BTG
P08604708A1086|57 76|cellulose dialyzers
P08604708A1086|106 122|blood flow rates
P08605324A0434|11 14|LTR
P08605705A0676|16 29|IgM class CIC
P08605705A0676|4 14|conclusion
P08605705A0676|62 73|hepatitis A
P08606267A0740|136 148|registration
P08606267A0740|80 96|exercise testing
P08606267A0740|59 63|data
P08606267A0740|26 32|number
P08606267A0740|225 230|scans
P08608222T0000|49 60|granulocyte
P08608222T0000|80 95|factor receptor
P08608222T0000|126 151|STAT1 homodimer formation
P08608448A0353|50 66|dimethylsulphate
P08608448A0353|71 79|kethoxal
P08608448A0353|83 90|regions
P08608448A0353|146 161|structure model
P08610328A0228|35 43|criteria
P08610328A0228|116 123|studies
P08610328A0228|145 150|world
P08610328A0228|12 18|REVIEW
P08611280A0820|109 115|cm3/m2
P08611280A0820|13 20|volumes
P08611280A0820|221 227|cm3/m2
P08611280A0820|191 192|p
P08611280A0820|146 153|systole
P08611280A0820|61 69|subjects
P08614403A0557|32 51|Rev-erbA alpha mRNA
P08614403A0557|112 117|cells
P08614403A0557|165 173|myotubes
P08614410A0000|115 119|mice
P08614410A0000|5 25|alpha T3-1 cell line
P08614410A0000|195 202|activin
P08615025A1214|275 278|Env
P08615025A1214|338 341|CD4
P08615025A1214|406 409|CD4
P08615025A1214|14 27|glycosylation
P08615025A1214|254 259|gp120
P08615025A1214|352 365|membrane gp41
P08615025A1214|385 400|membrane fusion
P08615025A1214|146 149|Env
P08615025A1214|298 311|cell membrane
P08615025A1214|31 34|Env
P08616743T0000|8 13|trail
P08617237A0489|19 31|phosphoforms
P08617237A0489|93 103|reactivity
P08617237A0489|164 176|localization
P08617243A0336|97 101|site
P08617243A0336|26 33|protein
P08617800A0150|33 44|erbB-2 gene
P08617800A0150|12 25|transcription
P08617802A0993|49 67|SH2/SH3/SH2 region
P08617802A0993|71 79|p120 GAP
P08617802A0993|7 14|results
P08618433A1720|168 181|cell lineages
P08618433A1720|4 12|contrast
P08618433A1720|58 71|FL expression
P08618433A1720|94 95|%
P08618882A0343|34 54|transfection studies
P08618882A0343|109 119|inhibition
P08618882A0343|72 90|DNA binding domain
P08619910A0000|239 248|treatment
P08619910A0000|38 52|motor symptoms
P08619910A0000|129 148|dopamine deficiency
P08619910A0000|105 111|result
P08619910A0000|81 89|akinesia
P08619910A0000|267 275|relation
P08619910A0000|301 309|findings
P08619910A0000|60 68|rigidity
P08620856A1172|65 73|antibody
P08620856A1172|286 292|stages
P08620856A1172|112 119|portion
P08620856A1172|127 146|mouse c-kit protein
P08620856A1172|208 221|reading frame
P08620856A1172|31 55|western blot experiments
P08621017A1186|1 9|LY290181
P08621017A1186|191 194|TRE
P08621017A1186|125 136|uPA PEA3/12
P08621017A1186|182 189|element
P08621017A1186|90 97|binding
P08621420A1166|70 80|antibodies
P08621420A1166|97 115|NF-kappaB proteins
P08621420A1166|123 129|effect
P08621451A0552|1 5|Biol
P08621542A0535|139 157|CD28 costimulation
P08621542A0535|79 94|protein kinases
P08621542A0535|11 26|protein kinases
P08621542A0535|28 33|c-Jun
P08621659A0189|1 5|Gas6
P08621659A0189|88 95|repeats
P08621659A0189|120 127|domains
P08621664A1430|1 15|Polymerization
P08621664A1430|115 118|PKN
P08621719A0000|42 70|c-cbl proto-oncogene product
P08621719A0000|94 101|targets
P08621719A0000|105 129|tyrosine phosphorylation
P08621730T0000|4 25|AP-1 binding sequence
P08621730T0000|129 147|growth factor-beta
P08621730T0000|43 53|regulation
P08621730T0000|74 75|I
P08622070A0889|55 59|time
P08622070A0889|23 24|%
P08622070A0889|72 83|progression
P08622645A1026|18 21|VDR
P08622645A1026|104 111|element
P08622675A0587|98 108|similarity
P08622675A0587|125 137|factor Lef-1
P08622887A1026|254 264|affinities
P08622887A1026|168 171|DBD
P08622887A1026|40 45|EMSAs
P08622887A1026|106 109|DBD
P08622887A1026|269 272|DBD
P08623554A1058|49 58|infection
P08623554A1058|62 68|plants
P08625806A0263|1 8|Krox-20
P08625806A0263|53 60|pattern
P08625806A0263|127 138|maintenance
P08625806A0263|12 28|zinc finger gene
P08625924A0411|1 11|Clones 33F
P08625924A0411|168 173|mRNAs
P08625924A0411|38 56|aromatase proteins
P08626065A0000|96 100|nrdA
P08626065A0000|129 136|degrees
P08626065A0000|40 57|Bacillus subtilis
P08626065A0000|105 115|citB genes
P08626313A1037|56 64|msp gene
P08626437A0332|171 178|p34cdc2
P08626437A0332|1 11|Lyn kinase
P08626437A0332|114 117|GST
P08626437A0332|58 61|BCP
P08626529A0000|186 188|J.
P08626529A0000|190 193|Toh
P08626529A0000|7 21|autoantibodies
P08626529A0000|29 36|Sjogren
P08626529A0000|180 184|Kooy
P08626539T0000|71 75|homo
P08626539T0000|25 35|modulation
P08626539T0000|105 114|receptors
P08626596A0000|116 124|stresses
P08626596A0000|18 26|evidence
P08626596A0000|72 76|AMPK
P08626596A0000|105 110|cells
P08626667A1517|136 152|motifs functions
P08626667A1517|114 124|conclusion
P08626667A1517|24 32|promoter
P08626777A0537|34 49|Col2a1 enhancer
P08626777A0537|172 186|cartilage gene
P08626777A0537|145 162|link protein gene
P08626777A0537|94 100|motifs
P08626809A0729|16 20|pPKR
P08626809A0729|111 125|characteristic
P08627649A0734|205 212|members
P08627649A0734|65 76|FREJ4 cells
P08627649A0734|110 111|s
P08627649A0734|134 155|transcription factors
P08627649A0734|51 59|extracts
P08627649A0734|220 230|Sp1 family
P08627649A0734|240 243|Sp3
P08627649A0734|120 130|Ets family
P08627688A1520|6 12|result
P08628251A1455|1 8|CM-ACO3
P08628251A1455|25 32|flowers
P08628255A0932|173 187|H2A.1 promoter
P08628255A0932|43 62|luciferase activity
P08628255A0932|95 108|DNA synthesis
P08628255A0932|134 142|presence
P08628284A0181|18 39|yeast reporter strain
P08628284A0181|126 132|copies
P08628284A0181|75 82|control
P08628681A0364|97 110|X.laevis cDNA
P08628681A0364|58 72|Northern blots
P08629348A0237|32 39|history
P08629348A0237|185 190|cysts
P08629348A0237|160 169|processes
P08630548A0000|152 161|TNF-alpha
P08630548A0000|116 120|IL-1
P08630548A0000|86 93|potency
P08630548A0000|9 18|cytokines
P08630599A0534|206 215|policemen
P08630599A0534|4 14|difference
P08630599A0534|234 247|micrograms/ml
P08630599A0534|83 91|patients
P08630599A0534|159 167|patients
P08630599A0534|123 125|SD
P08631685A0000|16 20|gene
P08631685A0000|174 184|chromosome
P08631685A0000|25 31|copper
P08631685A0000|61 78|monoamine oxidase
P08631797A0982|174 177|NDF
P08631797A0982|121 128|ligands
P08631797A0982|181 192|EGF binding
P08631820A0755|68 83|complementation
P08631820A0755|168 173|Karst
P08631820A0755|5 9|cDNA
P08631820A0755|146 148|D.
P08631820A0755|122 134|FPS activity
P08631820A0755|31 40|FPS1 gene
P08631908A0224|48 51|DR5
P08631908A0224|40 43|DR4
P08631944A0663|87 94|M2 exon
P08631944A0663|4 12|contrast
P08631944A0663|23 30|isoform
P08631944A0663|46 63|C epsilon4 domain
P08631944A0663|224 233|secretion
P08632009A1067|99 105|factor
P08632009A1067|5 16|specificity
P08632009A1067|146 168|DNA binding affinities
P08632009A1067|121 140|expression profiles
P08632009A1067|30 50|C/EBP family members
P08632015A1226|249 254|genes
P08632015A1226|58 74|DREF polypeptide
P08632015A1226|78 84|nuclei
P08632015A1226|166 170|DREF
P08632015A1226|150 162|accumulation
P08632463A1508|50 57|subunit
P08632463A1508|113 137|transcription elongation
P08632463A1508|77 81|role
P08632463A1508|44 48|beta
P08633855A1064|5 14|lacS gene
P08633855A1064|162 168|strain
P08633855A1064|180 186|NZ6091
P08634357A0527|5 24|extraction recovery
P08634357A0527|89 90|%
P08634423A0498|155 170|differentiation
P08634423A0498|64 73|lacZ gene
P08634423A0498|5 14|frequency
P08634423A0498|43 56|transcription
P08634423A0498|106 118|integrations
P08635771A0000|207 212|study
P08635771A0000|3 8|study
P08635771A0000|38 44|ONLINE
P08635771A0000|162 167|urine
P08635771A0000|134 158|methaqualone metabolites
P08636124A0410|98 112|phosphoprotein
P08636124A0410|57 64|p150TSP
P08636124A0410|182 191|evolution
P08636211A0983|1 8|EMBO J.
P08637006A0000|100 108|elements
P08637006A0000|40 48|promoter
P08637006A0000|149 158|E2F sites
P08637006A0000|135 143|TBP site
P08637717A0817|137 150|cyclin E/Cdk2
P08637717A0817|116 119|p21
P08637717A0817|78 85|peptide
P08637717A0817|105 112|ability
P08638435A0522|1 8|Results
P08638435A0522|122 135|A. hydrophila
P08639521A1032|32 48|protein fragment
P08639521A1032|133 139|motion
P08639742T0000|69 76|petunia
P08639742T0000|81 107|wheat zinc finger proteins
P08639742T0000|39 49|pea petals
P08639742T0000|14 17|PCR
P08640866A0473|49 57|subjects
P08640866A0473|142 146|MAPK
P08640866A0473|24 37|blood T cells
P08640866A0473|61 64|PHA
P08642282A1009|102 106|gene
P08642282A1009|19 30|description
P08642282A1009|64 72|elements
P08642282A1009|135 143|molecule
P08642313A0770|139 146|fashion
P08642313A0770|38 47|cell line
P08642313A0770|66 71|kappa
P08642313A0770|183 190|protein
P08642693T0000|108 119|mutagenesis
P08642693T0000|72 95|protease cleavage sites
P08643382A0752|70 74|poly
P08643382A0752|96 106|cDNA clone
P08643382A0752|24 39|transit peptide
P08643382A0752|75 76|A
P08643557A0259|18 26|question
P08643557A0259|74 86|target genes
P08643578A0532|67 76|G protein
P08643578A0532|95 104|regulator
P08643578A0532|120 126|growth
P08643646A0479|85 97|biosynthesis
P08643646A0479|233 243|conditions
P08643646A0479|22 26|verA
P08643646A0479|41 45|gene
P08643759A0338|17 22|phase
P08643759A0338|52 73|personality variables
P08645214A1052|18 22|BL21
P08645214A1052|83 107|catalase-peroxidase gene
P08645214A1052|24 27|DE3
P08645214A1052|165 173|SDS/PAGE
P08647086A0622|1 5|Cdk2
P08647086A0622|28 37|cyclin D1
P08647086T0000|137 150|Cdk7-cyclin-H
P08647086T0000|18 26|kinase-2
P08647086T0000|65 74|cyclin D1
P08647086T0000|28 32|Cdk2
P08647264T0000|187 195|cleavage
P08647264T0000|1 9|Ligation
P08647264T0000|203 217|substrate PARP
P08647264T0000|40 56|lymphoma B cells
P08647264T0000|13 17|CD40
P08647451A0663|110 117|tissues
P08647451A0663|47 54|HEP-COP
P08647822T0000|116 130|reductase gene
P08647822T0000|37 60|element binding protein
P08647822T0000|105 113|coenzyme
P08648408A0792|114 120|CSA-GO
P08648408A0792|10 13|PHT
P08648408A0792|88 94|PHT-GO
P08648665A1320|1 16|ORF E8 colinear
P08648665A1320|22 28|ORF E6
P08648665A1320|148 162|pZipNeo vector
P08649372A0501|69 75|factor
P08649372A0501|111 118|M phase
P08649372A0501|43 53|repression
P08649373T0000|69 78|chromatin
P08649373T0000|26 38|cis elements
P08649389A0000|185 195|% identity
P08649389A0000|37 53|CTCF cDNA clones
P08649393A0000|118 121|CEN
P08649393A0000|139 160|readthrough phenotype
P08649393A0000|37 40|ctf
P08649393A0000|106 116|centromere
P08649405T0000|1 4|Sp1
P08649405T0000|101 104|AP1
P08649405T0000|75 80|cells
P08649425A0373|69 74|DNase
P08649425A0373|101 119|B-cell development
P08649425A0373|29 37|enhancer
P08649427A0689|20 34|identification
P08649427A0689|110 116|family
P08649427A0689|120 137|GTPase regulators
P08649440T0000|35 39|VIII
P08649440T0000|29 33|IgG2
P08649841A0956|204 212|decrease
P08649841A0956|216 224|CAT mRNA
P08649841A0956|157 167|inhibition
P08649841A0956|109 113|SV40
P08651853A0607|17 26|sclerosis
P08651853A0607|222 230|patients
P08651853A0607|64 68|loss
P08651853A0607|143 144|%
P08651853A0607|130 138|patients
P08651853A0607|192 193|%
P08652081A1953|152 156|IL-3
P08652081A1953|168 178|congestion
P08652081A1953|112 116|IL-1
P08652081A1953|95 106|hypotension
P08652081A1953|211 215|IL-4
P08654375A0544|185 190|Oct-2
P08654375A0544|54 65|amino acids
P08654375A0544|93 103|N-terminus
P08654375A0544|107 111|Bob1
P08654375A0544|14 22|analysis
P08654435A0540|35 39|WM12
P08654435A0540|178 184|assays
P08654435A0540|111 117|effect
P08654435A0540|72 87|Erk2 activation
P08654946A0986|5 30|transcription start point
P08654946A0986|47 55|promoter
P08654946A0986|120 126|region
P08654983A0000|100 102|Bs
P08654983A0000|18 45|signal recognition particle
P08654983A0000|81 98|Bacillus subtilis
P08654983A0000|203 208|Oguro
P08654983A0000|52 64|SRP receptor
P08654983A0000|47 50|SRP
P08655555A0772|116 135|% promoter activity
P08655555A0772|191 208|promoter activity
P08655555A0772|161 168|hexamer
P08656672A0678|153 184|cervix carcinoma cell line HeLa
P08656672A0678|13 36|ufo mRNA overexpression
P08657150A1049|5 9|role
P08657150A1049|83 92|SIN5 gene
P08657150A1049|41 45|NCE3
P08657183A0145|69 74|genes
P08657183A0145|96 100|gene
P08657183A0145|76 80|DHFR
P08657183A0145|10 16|strand
P08659545A0000|35 49|transcript map
P08659545A0000|81 94|understanding
P08659545A0000|7 13|effort
P08659545A0000|199 204|genes
P08659545A0000|121 128|trisomy
P08660748X0000|80 91|predictions
P08660748X0000|24 31|essence
P08660892A1044|17 25|blockade
P08660892A1044|153 160|factors
P08660892A1044|179 185|Mef-2C
P08660892A1044|74 95|SRF expression vector
P08661007T0000|69 78|structure
P08661007T0000|7 18|MN/CA9 gene
P08661007T0000|91 119|protein domain relationships
P08661101A0396|1 22|DNA sequence analysis
P08661101A0396|40 44|gene
P08661114A0564|37 54|sequence homology
P08661114A0564|15 22|domains
P08661119A0085|28 54|EP4 receptor gene sequence
P08661119A0085|134 151|blood lymphocytes
P08662193A0404|143 147|NIT4
P08662193A0404|89 94|yeast
P08662617A2051|170 180|cell lines
P08662617A2051|80 87|protein
P08662617A2051|40 43|HIP
P08662852A1297|102 109|beta2AR
P08662852A1297|168 177|rhodopsin
P08662852A1297|77 94|carboxyl terminus
P08662852A1297|149 164|phosphorylation
P08662928T0000|49 58|cytokines
P08662928T0000|127 149|IL-6 response elements
P08662928T0000|105 118|transcription
P08662980A0762|221 227|effect
P08662980A0762|33 44|DNA binding
P08662980A0762|6 16|phenomenon
P08663120T0000|65 72|protein
P08663120T0000|27 40|p70 S6 kinase
P08663141T0000|100 108|response
P08663141T0000|142 162|angiotensinogen gene
P08663141T0000|123 132|sequences
P08663219A0246|152 169|CAT reporter gene
P08663219A0246|21 35|rat PGS-2 gene
P08663219A0246|93 101|CAAT box
P08663219A0246|193 205|E-box region
P08663219A0246|120 140|hormone inducibility
P08663326A0000|103 110|enzymes
P08663326A0000|54 67|transcription
P08663326A0000|29 43|DmpR activator
P08664229T0000|50 63|autorefractor
P08664229T0000|72 99|Nidek AR-1000 autorefractor
P08664462A1404|169 173|hand
P08664462A1404|223 234|hypothermia
P08664462A1404|67 78|sensitivity
P08664462A1404|179 185|result
P08664462A1404|130 150|muscle contractility
P08665853A0228|34 39|cells
P08665853A0228|98 110|combinations
P08665853A0228|126 132|ErbB-3
P08665853A0228|245 253|activity
P08666238T0000|37 45|ribosome
P08666238T0000|11 33|translation initiation
P08666383A1252|55 67|fluorescence
P08666383A1252|7 15|findings
P08666383A1252|182 188|genome
P08666383A1252|121 129|approach
P08666404A0311|87 123|protein serine-threonine phosphatase
P08666404A0311|219 226|rat PPT
P08666404A0311|131 154|tetratricopeptide motif
P08666404A0311|182 187|PPP5C
P08668124A0744|76 82|strain
P08668124A0744|61 70|phenotype
P08668158A0765|5 9|data
P08668158A0765|66 76|substrates
P08668158A0765|78 82|tRNA
P08668158A0765|153 157|gene
P08668158A0765|93 100|tRNAPro
P08668158A0765|215 223|promoter
P08668158A0765|265 269|RPM1
P08668190A1364|101 106|Hum1p
P08668190A1364|156 161|yeast
P08668190A1364|142 143|H
P08668190A1364|133 136|Ca2
P08668190A1364|121 129|exchange
P08668203A1230|1 4|FTF
P08668203A1230|128 132|SF-1
P08668203A1230|150 157|tissues
P08668210A0000|101 123|protein kinase pathway
P08668210A0000|42 46|role
P08668210A0000|13 21|evidence
P08669676A1644|70 71|n
P08669676A1644|142 151|midazolam
P08669676A1644|161 162|P
P08669676A1644|194 210|treatment groups
P08669676A1644|153 154|n
P08669676A1644|113 122|Q wave MI
P08669676A1644|26 31|death
P08669676A1644|88 89|n
P08670853A0000|1 18|Cluster formation
P08670853A0000|22 32|E-cadherin
P08670853A0000|105 113|adhesion
P08672242A0517|79 90|P1 promoter
P08672242A0517|107 114|regions
P08675026A0420|108 130|Caenorhabditis elegans
P08675026A0420|94 102|function
P08675026A0420|149 153|Homo
P08675608T0000|1 8|Outcome
P08675769A0158|274 287|AI technician
P08675769A0158|201 205|rate
P08675769A0158|112 127|conception rate
P08675769A0158|244 248|bull
P08675769A0158|11 16|rates
P08676266A0838|71 82|test groups
P08676266A0838|5 16|mean values
P08676266A0838|95 108|control group
P08676454A0731|49 54|ICP35
P08676454A0731|42 47|ICP35
P08676454A0731|27 29|N0
P08676454A0731|75 84|B capsids
P08676495A0129|206 211|warts
P08676495A0129|98 113|BPV-1 pre-mRNAs
P08676495A0129|79 89|processing
P08676495A0129|135 145|C127 cells
P08676858A1084|65 71|plants
P08676858A1084|24 31|members
P08677678A0258|204 213|phenomena
P08677678A0258|185 195|mechanisms
P08677678A0258|112 121|retention
P08677678A0258|125 132|feeding
P08679131T0000|8 15|allergy
P08680706A0889|102 107|mm Hg
P08680706A0889|257 262|mm Hg
P08680706A0889|190 195|mm Hg
P08680706A0889|9 10|h
P08680706A0889|226 244|Donor Aerosol dogs
P08680706A0889|14 25|reperfusion
P08682317A0900|137 139|HS
P08682317A0900|53 78|HS transcription factor-1
P08682317A0900|79 84|HSF-1
P08682317A0900|30 33|HSE
P08683106A0374|138 149|STAT1 alpha
P08683106A0374|39 50|STAT1 alpha
P08683106A0374|62 66|IL-2
P08683106A0374|91 96|STAT5
P08683108A1501|112 115|mIg
P08683108A1501|126 144|junB transcription
P08683983A1163|103 108|mouse
P08683983A1163|5 12|results
P08683983A1163|25 38|participation
P08683983A1163|242 261|cell growth control
P08683983A1163|88 98|c-myb gene
P08684742A0000|50 55|women
P08684742A0000|154 163|gestation
P08684742A0000|23 46|pregnancy complications
P08684742A0000|124 137|amniocentesis
P08688190A0000|102 118|beta-D-glucoside
P08688190A0000|65 95|nevadensin 5-O-beta-D-glucosyl
P08688190A0000|29 60|nevadensin 5-O-beta-D-glucoside
P08689520T0000|1 20|Reproductive period
P08689520T0000|29 41|water intake
P08690198A0346|1 8|METHODS
P08690198A0346|48 56|infusion
P08690198A0346|217 226|beginning
P08690198A0346|83 98|supplementation
P08690198A0346|10 14|Rats
P08691962T0000|51 58|disease
P08691962T0000|9 13|role
P08691962T0000|28 37|diagnosis
P08692892A0330|115 128|maximum level
P08692892A0330|5 12|Pro-258
P08692892A0330|27 35|mutation
P08692892A0330|106 107|%
P08692892A0330|15 18|Leu
P08697728A1199|49 50|%
P08700531A1420|169 181|localization
P08700531A1420|231 237|notion
P08700531A1420|327 346|hamster fibroblasts
P08700531A1420|156 163|viruses
P08700531A1420|59 70|alterations
P08700531A1420|247 259|cph oncogene
P08700531A1420|268 272|role
P08702543A0000|33 36|Ras
P08702543A0000|157 163|Cullen
P08702543A0000|99 133|inositol 1,3,4,5-tetrakisphosphate
P08702543A0000|6 11|IP4BP
P08702543A0000|135 138|IP4
P08702633A0164|65 89|tyrosine phosphorylation
P08702633A0164|97 116|Shc adapter protein
P08702633A0164|24 34|Gbetagamma
P08702633A0164|165 212|Ras guanine nucleotide exchange factor activity
P08702728A1325|70 80|HIRc cells
P08702728A1325|41 44|Shc
P08702807A0964|32 49|signaling pathway
P08702807A0964|53 63|expression
P08702807A0964|126 153|cyclin D1 promoter activity
P08702807A0964|13 23|activation
P08702845A0000|34 40|motifs
P08702845A0000|4 9|order
P08702845A0000|142 144|3H
P08702845A0000|251 255|DATs
P08702845A0000|145 169|dopamine uptake kinetics
P08702845A0000|62 70|affinity
P08702845A0000|269 282|COOH terminus
P08702936A0984|81 88|T cells
P08702936A0984|53 65|T cell lines
P08703010A0905|156 166|expression
P08703010A0905|219 227|proteins
P08703010A0905|57 65|E1 E-box
P08703010A0905|44 51|element
P08703959A0659|35 52|proton resonances
P08703959A0659|203 211|spectrum
P08703959A0659|76 83|segment
P08703959A0659|164 177|sugar protons
P08704240A1111|96 103|minutes
P08704240A1111|59 79|CREB phosphorylation
P08704240A1111|13 23|TF-1 cells
P08706368A1024|1 8|RESULTS
P08706368A1024|55 60|curve
P08706368A1024|125 129|FIO2
P08706368A1024|89 101|correlations
P08706368A1024|14 35|LV maximum brightness
P08706731A1303|334 339|roles
P08706731A1303|111 129|ribonuclease genes
P08706731A1303|95 106|Ypr10 genes
P08706731A1303|300 310|prediction
P08706731A1303|271 285|PR-10 proteins
P08707516A0194|93 110|handicap services
P08707516A0194|78 82|need
P08707516A0194|61 68|receipt
P08707840A0753|65 68|p54
P08707840A0753|112 124|pore complex
P08707840A0753|91 96|sides
P08707922A0334|191 195|gene
P08707922A0334|53 61|III beta
P08707922A0334|67 86|O beta-globin genes
P08707922A0334|177 180|ATG
P08707922A0334|124 126|bp
P08709224T0000|80 95|SNF-SWI complex
P08709224T0000|97 107|hSNF5/Ini1
P08709224T0000|28 35|protein
P08709251A0000|69 87|polyhedrosis virus
P08709251A0000|38 60|Autographa californica
P08709251A0000|202 220|polyhedrosis virus
P08709251A0000|161 178|DNA helicase gene
P08709251A0000|182 188|Bombyx
P08709251A0000|12 25|recombination
P08709831A0599|71 77|tumors
P08709831A0599|18 25|potency
P08710371A0000|156 161|virus
P08710371A0000|197 207|mechanisms
P08710371A0000|27 38|interaction
P08710371A0000|62 77|polyomavirus BK
P08710377A0577|1 4|Cbl
P08710377A0577|141 144|Shc
P08710377A0577|39 50|SH3 domains
P08710377A0577|124 127|way
P08711631A0989|1 10|Treatment
P08711631A0989|30 40|prednisone
P08713933A0606|70 81|obstruction
P08713933A0606|105 113|drainage
P08717391A0466|85 91|fusion
P08717391A0466|99 109|N-terminus
P08717391A0466|212 226|immunogenicity
P08717391A0466|43 49|linker
P08717391A0466|121 131|C-terminus
P08719155A0105|305 307|CS
P08719155A0105|309 316|protein
P08719155A0105|130 142|similarities
P08719155A0105|287 303|circumsporozoite
P08719155A0105|247 251|TRAP
P08719155A0105|183 193|Plasmodium
P08719155A0105|30 37|cloning
P08719697A0221|1 8|METHODS
P08719697A0221|127 130|KCS
P08719697A0221|10 13|DSF
P08719697A0221|60 62|CF
P08720407A1386|1 11|CONCLUSION
P08720407A1386|64 79|disc herniation
P08720407A1386|162 189|prostaglandin E2 production
P08721989A1012|68 86|cytokine receptors
P08721989A1012|136 144|evidence
P08721989A1012|161 180|IL-2R beta function
P08721989A1012|150 156|beta c
P08721999A0727|1 4|U24
P08721999A0727|82 90|28S rRNA
P08721999A0727|73 78|tract
P08722568A1001|1 21|Chromatin repression
P08722568A1001|31 48|replacement genes
P08723365T0000|78 93|nephrosclerosis
P08723365T0000|63 74|hypertrophy
P08723883A1684|48 57|vitamin E
P08723883A1684|5 19|concentrations
P08723883A1684|188 196|vitamins
P08723883A1684|178 184|source
P08723883A1684|213 220|species
P08723883A1684|121 127|llamas
P08726024A0532|170 179|H. pylori
P08726024A0532|36 43|primers
P08726024A0532|231 237|plaque
P08726024A0532|199 203|cats
P08726024A0532|109 119|weeks p.t.
P08726024A0532|132 145|fluid samples
P08728040T0000|139 163|fibroblast growth factor
P08728040T0000|86 112|Janus kinase-Stat pathways
P08728040T0000|189 202|sarcoma cells
P08728040T0000|180 186|Kaposi
P08731155A0499|17 31|reconstruction
P08731155A0499|5 10|weeks
P08731511A0625|87 91|HCII
P08731511A0625|5 11|levels
P08731511A0625|37 49|antithrombin
P08731511A0625|93 103|activities
P08733123A0000|152 156|face
P08733123A0000|87 95|disorder
P08733123A0000|125 133|weakness
P08733123A0000|41 45|FSHD
P08733874A0000|137 148|preparation
P08733874A0000|153 157|131I
P08733874A0000|197 205|serum TG
P08733874A0000|182 193|measurement
P08733874A0000|47 64|thyroid carcinoma
P08734538A0613|143 145|AM
P08734538A0613|56 64|textures
P08734538A0613|122 130|textures
P08739209A0700|54 58|rate
P08739209A0700|82 87|ratio
P08739209A0700|149 157|ligation
P08739209A0700|195 199|dogs
P08740416A0239|117 127|C-terminus
P08740416A0239|146 161|signal sequence
P08740416A0239|15 22|protein
P08741206A1551|107 119|vasodilation
P08741206A1551|31 40|afferents
P08742135A0000|84 90|effect
P08742135A0000|98 105|outcome
P08742135A0000|147 161|corticosterone
P08742135A0000|30 42|hormone ACTH
P08745669A0000|205 215|bleomocyin
P08745669A0000|217 235|methyl prednisolon
P08745669A0000|93 101|lymphoma
P08745669A0000|11 19|patients
P08745669A0000|180 191|cisplatinum
P08746981A0154|21 25|diet
P08746981A0154|63 83|mg probiotic/kg food
P08747343A0790|54 62|profiles
P08747343A0790|74 79|films
P08749393A0783|5 18|PI3K_68D cDNA
P08749393A0783|93 110|p110 PI 3-kinases
P08749393A0783|210 221|SH3 domains
P08749393A0783|61 70|sequences
P08750173A0000|170 174|rats
P08750173A0000|1 13|AIMS/METHODS
P08750173A0000|67 76|clearance
P08750173A0000|94 102|bacteria
P08750702A0183|119 139|chloroethylclonidine
P08750702A0183|19 26|control
P08750702A0183|145 155|mg/kg i.v.
P08752714A0000|153 158|years
P08752714A0000|5 15|occurrence
P08752714A0000|123 133|department
P08754802T0000|17 24|control
P08754802T0000|38 42|gene
P08754802T0000|133 142|receptors
P08754802T0000|164 182|adipose expression
P08754834A1097|16 25|fragments
P08754834A1097|43 60|response elements
P08754852A0960|85 92|protein
P08754852A0960|4 26|gel retardation assays
P08754852A0960|111 120|RCS cells
P08754852A0960|183 189|18-mer
P08756332A0000|51 59|proteins
P08756332A0000|1 8|Members
P08756332A0000|233 240|Ral-GEF
P08756332A0000|124 142|effector molecules
P08756556A0406|5 9|cDNA
P08756556A0406|42 53|amino acids
P08756609A0498|137 145|protozoa
P08756609A0498|70 75|range
P08756609A0498|161 165|gene
P08756609A0498|13 32|amino acid sequence
P08756609A0498|91 102|vertebrates
P08756636T0000|61 74|relationships
P08756636T0000|14 23|mutations
P08756712A0227|65 72|subunit
P08756712A0227|10 17|studies
P08756712A0227|135 142|domains
P08757943A0876|109 121|inducibility
P08757943A0876|30 37|element
P08760286A0696|207 210|Ras
P08760286A0696|142 156|identification
P08760286A0696|229 236|GTPases
P08760286A0696|107 115|proteins
P08760286A0696|16 26|similarity
P08760286A0696|296 306|components
P08760286A0696|269 273|MAPK
P08760872A0696|5 12|results
P08760872A0696|108 118|cell cycle
P08760872A0696|94 100|stages
P08760889A0531|1 11|Comparison
P08760889A0531|163 174|amino acids
P08760889A0531|193 204|amino acids
P08760889A0531|257 267|divergence
P08760889A0531|179 183|H2A1
P08760889A0531|88 92|H2As
P08760889A0531|150 155|total
P08761480A0331|1 12|Interaction
P08761480A0331|278 291|splice region
P08761480A0331|110 117|RPDE-39
P08761480A0331|231 234|rat
P08761480A0331|345 356|association
P08761480A0331|224 227|RD1
P08761480A0331|398 412|fusion protein
P08761480A0331|57 70|splice region
P08761480A0331|89 101|PDE4A splice
P08762172A0178|205 210|boxes
P08762172A0178|141 144|box
P08762172A0178|7 25|strain differences
P08762172A0178|164 175|transitions
P08762172A0178|45 54|variables
P08763207A0402|103 106|DPV
P08763207A0402|179 182|CPE
P08763207A0402|11 25|oxidation peak
P08763207A0402|75 76|V
P08763925A0588|116 126|immunoblot
P08763925A0588|55 59|unit
P08763925A0588|173 181|proteins
P08763925A0588|128 136|analyses
P08763925A0588|61 67|c-gvpD
P08766049A0000|221 231|Vancomycin
P08766049A0000|184 186|ml
P08766049A0000|217 219|mg
P08766049A0000|76 84|reaction
P08766049A0000|108 115|patient
P08766049A0000|211 213|ml
P08768374A0765|5 9|P-wr
P08768374A0765|14 33|P-rr cDNA sequences
P08769132A0000|342 352|insertions
P08769132A0000|139 145|hMSH-2
P08769132A0000|309 324|base mismatches
P08769132A0000|278 281|DNA
P08769132A0000|11 29|MSH-2 gene product
P08769132A0000|74 82|proteins
P08769132A0000|223 228|MSH-1
P08769132A0000|430 436|cancer
P08769132A0000|361 371|base pairs
P08769132A0000|329 338|deletions
P08769566A0000|188 191|ZD2
P08769566A0000|42 62|transcription factor
P08769566A0000|126 133|protein
P08769566A0000|180 183|ZD1
P08769566A0000|224 235|homeodomain
P08770021T0000|33 57|tyrosine kinase oncogene
P08770021T0000|59 66|Tpr-Met
P08770920A1220|102 110|proteins
P08770920A1220|16 28|coexpression
P08770920A1220|138 143|IDX-1
P08770920A1220|89 94|IDX-1
P08771781A0103|139 141|L.
P08771781A0103|98 111|reading frame
P08771781A0103|113 118|ORFII
P08771781A0103|7 14|attempt
P08771781A0103|123 137|Brassica napus
P08771787T0000|1 17|Characterization
P08771787T0000|21 24|LRP
P08771787T0000|67 80|tomato plants
P08771787T0000|106 118|pathogenesis
P08775674A0000|1 11|OBJECTIVES
P08775674A0000|108 116|patients
P08775674A0000|122 139|hydatidiform mole
P08775674A0000|28 33|study
P08776748T0000|9 24|P300 amplitudes
P08776793A0811|5 13|patients
P08777374A1471|102 111|exposures
P08777374A1471|158 172|concentrations
P08778700A0476|17 21|case
P08778700A0476|37 43|rarity
P08781119A0723|17 23|region
P08781119A0723|77 84|regions
P08781119A0723|88 96|identity
P08783180A0000|96 105|fruit bat
P08783180A0000|167 174|setting
P08784787A0383|34 38|PAR2
P08784787A0383|63 74|hexapeptide
P08784787A0383|15 32|thrombin receptor
P08789441A0339|71 81|breakpoint
P08789441A0339|112 116|CMPD
P08789441A0339|246 252|region
P08789441A0339|28 41|hybridization
P08789441A0339|181 194|translocation
P08790291A1022|5 9|data
P08790291A1022|47 51|thi1
P08792217A1407|119 129|germ cells
P08792217A1407|49 66|TIMP-2 mRNA level
P08792217A1407|138 148|germ cells
P08792217A1407|9 17|increase
P08792217A1407|89 95|result
P08793693A0237|1 7|DESIGN
P08794326A0405|136 141|SFV-1
P08794326A0405|86 89|end
P08794326A0405|97 105|gag gene
P08794326A0405|44 51|element
P08794348A1067|77 82|trans
P08794348A1067|14 35|complementation assay
P08794547A0648|5 9|rCBF
P08794547A0648|14 24|vasomotion
P08794601A0000|39 53|clarithromycin
P08794601A0000|93 111|ulcer healing rate
P08794601A0000|126 152|H. pylori eradication rate
P08794601A0000|12 23|combination
P08795304T0000|51 64|complications
P08795304T0000|26 32|marker
P08798420A0207|223 226|src
P08798420A0207|201 211|activation
P08798420A0207|5 21|characterization
P08798420A0207|145 164|PRDII/kappaB domain
P08798420A0207|29 44|promoter region
P08798443A1218|170 176|effect
P08798443A1218|21 47|multimerization activities
P08798443A1218|143 149|serine
P08798443A1218|124 139|phosphorylation
P08798443A1218|226 231|c-Myb
P08798610A0843|1 5|PIP2
P08798610A0843|185 192|protein
P08798610A0843|125 132|Cdc42Hs
P08798610A0843|89 96|guanine
P08798610A0843|30 66|phosphatidylcholine carrier vesicles
P08798648A1816|1 8|Cys-757
P08798648A1816|77 92|enzyme activity
P08798762A1279|17 24|results
P08798762A1279|71 83|Cut proteins
P08798893A0611|49 60|lactalbumin
P08798893A0611|80 91|maintenance
P08798893A0611|108 117|viability
P08798893A0611|151 158|respect
P08803710A0701|50 51|%
P08803710A0701|66 67|%
P08803710A0701|43 44|%
P08803710A0701|11 20|survivals
P08803710A0701|91 94|IVA
P08804012A0662|70 80|recreation
P08804012A0662|64 68|work
P08804012A0662|95 110|home management
P08804012A0662|31 34|SIP
P08805338A1061|65 93|OG glycosylase/lyase protein
P08805338A1061|10 20|disruption
P08805338A1061|41 46|yeast
P08805338A1061|180 182|G.
P08806491A0542|84 95|transcripts
P08806491A0542|67 78|TAAG motifs
P08806491A0542|128 135|hr p.i.
P08806817A0244|142 154|TR2 receptor
P08806817A0244|43 48|clone
P08807245A0843|65 75|undercalls
P08807245A0843|56 57|%
P08807408A0524|117 124|pathway
P08807408A0524|36 41|woman
P08807408A0524|126 141|AV modification
P08807408A0524|13 20|RESULTS
P08808275A1193|83 88|genes
P08808275A1193|122 131|phenotype
P08808756A0587|204 209|bases
P08808756A0587|251 255|mRNA
P08808756A0587|163 171|products
P08808756A0587|79 82|RNA
P08808756A0587|225 237|accumulation
P08808927A0417|10 17|HindIII
P08808927A0417|63 76|M. bovis PG45
P08809680T0000|40 43|gap
P08810278A0682|137 145|tyrosine
P08810278A0682|43 50|protein
P08810278A0682|281 288|samples
P08810278A0682|105 108|CAS
P08810278A0682|116 119|CAS
P08810278A0682|294 302|controls
P08810278A0682|189 218|BCR/ABL expressing cell lines
P08810278A0682|181 185|CRKL
P08812012T0000|53 67|Stroop effects
P08812106T0000|85 89|eggs
P08812106T0000|19 22|UTR
P08812106T0000|94 101|embryos
P08812490A0542|55 62|primers
P08812490A0542|174 178|exon
P08812490A0542|76 80|hKID
P08812490A0542|106 116|expression
P08812490A0542|88 96|sequence
P08813766A0605|201 212|yeast Mig1p
P08813766A0605|77 85|residues
P08813766A0605|228 239|Aspergillus
P08813766A0605|45 47|kb
P08813766A0605|187 195|homology
P08813766A0605|27 37|transcript
P08813766A0605|241 251|Emericella
P08814651A0000|139 145|tremor
P08814651A0000|168 177|paradigms
P08814651A0000|43 51|presence
P08814651A0000|56 64|severity
P08816438A0316|154 169|DNA replication
P08816438A0316|191 213|plasmid loss phenotype
P08816438A0316|26 44|plasmid loss rates
P08816438A0316|74 82|plasmids
P08816452A0936|118 128|regulation
P08816452A0936|158 164|tissue
P08816452A0936|7 15|findings
P08816452A0936|91 98|protein
P08816459A0090|102 113|corepressor
P08816459A0090|32 49|repression domain
P08816459A0090|144 146|TR
P08816459A0090|161 174|acid receptor
P08816459A0090|91 96|N-CoR
P08816461A0892|5 13|analysis
P08816461A0892|123 143|nonsense suppression
P08816461A0892|105 118|mRNA turnover
P08816482A0234|33 38|Stat5
P08816482A0234|83 88|genes
P08816498A0000|69 96|signal transduction cascade
P08816498A0000|5 34|serine/threonine kinase Raf-1
P08816498A0000|59 63|Rats
P08816507A1125|51 59|activity
P08816507A1125|233 242|induction
P08816507A1125|67 79|p53 promoter
P08816507A1125|165 168|YY1
P08816507A1125|14 33|cotransfections E1A
P08816507A1125|90 95|level
P08816792A0000|67 74|protein
P08816792A0000|111 119|DNA-PKcs
P08816792A0000|15 29|protein kinase
P08817324A1070|117 141|CAGGG pentamer sequences
P08817324A1070|157 176|paralogy boundaries
P08817324A1070|74 82|presence
P08818718A1229|100 109|liposomes
P08818718A1229|71 77|vector
P08818718A1229|42 51|injection
P08818718A1229|125 129|mice
P08820642A0173|207 215|bacteria
P08820642A0173|48 54|operon
P08820642A0173|113 117|part
P08820642A0173|147 156|hrp genes
P08820642A0173|73 105|Hrp secretion pathway components
P08822208A1364|50 58|isoforms
P08822208A1364|121 131|regulation
P08823163T0000|34 60|diphtheria toxin repressor
P08823163T0000|154 158|role
P08823163T0000|175 189|co-corepressor
P08823163T0000|162 171|phosphate
P08823260A1161|1 5|FEV1
P08823260A1161|36 44|patients
P08823260A1161|105 113|patients
P08823709A0220|39 66|triglyceride lowering drugs
P08823709A0220|93 101|symptoms
P08823709A0220|79 89|resolution
P08824585A0260|138 143|cells
P08824585A0260|24 38|protein kinase
P08824585A0260|61 78|progenitor kinase
P08824800A0808|5 14|fragments
P08824881A0133|76 91|chromosome 9q34
P08824881A0133|57 65|TSC gene
P08825087A0213|1 22|DNA sequence analysis
P08825087A0213|81 95|reading frames
P08825087A0213|128 139|orientation
P08825554A0000|1 16|Tristetraprolin
P08825554A0000|64 85|transcription factors
P08825554A0000|30 39|prototype
P08825633A0304|1 9|Analysis
P08825633A0304|92 99|G alpha
P08825633A0304|74 82|homology
P08825639A0827|128 136|cap site
P08825639A0827|13 31|Alu repeat element
P08828142A0000|99 110|cat species
P08828142A0000|8 24|leukemia viruses
P08828152A1825|118 129|polymerases
P08828152A1825|54 58|RPO1
P08828152A1825|36 46|similarity
P08828152A1825|62 66|IIV6
P08829393A0083|35 41|spikes
P08829393A0083|74 82|patients
P08832146A0959|119 120|p
P08832146A0959|71 72|r
P08832146A0959|108 109|r
P08832146A0959|44 69|bone alkaline phosphatase
P08833653A0304|114 130|islet cell lines
P08833653A0304|23 56|LIM domain homeobox protein isl-1
P08835393A2829|112 138|promoter response elements
P08835393A2829|25 33|pathways
P08835969A0000|170 181|conjunction
P08835969A0000|283 292|detection
P08835969A0000|316 319|EPs
P08835969A0000|155 165|sonography
P08835969A0000|115 117|EP
P08835969A0000|83 92|diagnosis
P08835969A0000|265 273|beta-hCG
P08836172A1382|1 4|RVR
P08836172A1382|87 98|RVR delta E
P08836172A1382|6 10|loss
P08836172A1382|131 143|p21Cip1/Waf1
P08836172A1382|121 127|levels
P08837503A0392|137 142|group
P08837503A0392|84 90|domain
P08837503A0392|112 119|SbHRGP3
P08837503A0392|146 154|proteins
P08837503A0392|166 179|repeat motifs
P08838144A0107|49 59|subdomains
P08838144A0107|79 98|signal transduction
P08838144A0107|120 143|S1 or/and S2 subdomains
P08838314A0129|201 207|AVPR1A
P08838314A0129|142 154|localization
P08838314A0129|111 128|tissue expression
P08838314A0129|94 109|characteristics
P08838805T0000|35 52|beta-catenin gene
P08838805T0000|9 21|organization
P08839832A0729|67 73|region
P08839911A0716|5 6|%
P08840506A0544|51 55|ones
P08840506A0544|12 16|ORFs
P08842143A0000|103 109|viciae
P08842143A0000|99 101|bv
P08842143A0000|54 63|H2 uptake
P08842143A0000|123 130|cluster
P08843412A0543|33 53|40-amino acid region
P08843412A0543|83 85|TR
P08843412A0543|245 256|DNA binding
P08843412A0543|91 108|chicken ovalbumin
P08843412A0543|181 189|identity
P08844448A0000|100 110|volunteers
P08844448A0000|168 176|orlistat
P08844448A0000|277 291|weight control
P08844448A0000|197 213|lipase inhibitor
P08844448A0000|325 333|vitamins
P08844448A0000|295 302|obesity
P08844712A0000|1 7|Effect
P08844712A0000|144 160|alpha-chloralose
P08844712A0000|26 29|N2O
P08844712A0000|165 173|urethane
P08846775A0110|19 23|Swi4
P08846775A0110|8 15|absence
P08846775A0110|106 115|G1 cyclin
P08846775A0110|88 98|expression
P08847403T0000|33 41|patients
P08847403T0000|10 17|embryos
P08848013A1469|64 68|role
P08848013A1469|111 122|promoter A.
P08848013A1469|30 40|promoter B
P08849208A1022|52 59|stature
P08849778A0226|85 91|duplex
P08849778A0226|116 120|CopA
P08849778A0226|43 52|repA mRNA
P08849834A0000|3 9|system
P08849834A0000|67 73|vessel
P08849834A0000|105 138|colour Doppler ultrasound imaging
P08851337A1092|96 111|angina patients
P08851337A1092|74 83|infection
P08853303A0431|169 178|beginning
P08853303A0431|272 275|min
P08853303A0431|140 144|Tmax
P08853303A0431|196 199|Vss
P08853303A0431|44 50|values
P08853303A0431|255 264|T1/2 beta
P08853303A0431|222 228|ml/min
P08853303A0431|114 116|IA
P08853303A0431|182 194|MMC infusion
P08854459A0000|69 80|earthquakes
P08854459A0000|55 65|casualties
P08854459A0000|6 11|paper
P08854459A0000|44 51|pattern
P08855804A1528|139 145|months
P08855804A1528|112 114|mg
P08855804A1528|79 82|men
P08855804A1528|121 126|times
P08856132T0000|54 67|kinin release
P08856132T0000|121 129|abortion
P08858268A1307|171 174|CLZ
P08858268A1307|219 226|effects
P08858268A1307|73 83|cilazapril
P08858268A1307|150 158|patients
P08858268A1307|164 167|CHF
P08861955A0927|118 122|ARF1
P08861955A0927|32 37|motif
P08861955A0927|190 210|GTP binding proteins
P08861955A0927|53 67|amino-terminus
P08861955A0927|130 137|members
P08861963T0000|1 41|Transcription factor recognition surface
P08861963T0000|110 130|DNA enhancer element
P08862743A0603|35 38|age
P08862743A0603|53 59|nmol/L
P08862743A0603|15 29|erythrocyte Mn
P08864061A0000|61 66|cells
P08864061A0000|15 36|thymidine kinase gene
P08866485A0125|169 174|cells
P08866485A0125|96 100|cell
P08866485A0125|7 15|bacteria
P08866485A0125|28 43|export proteins
P08868473A1287|155 165|cell cycle
P08868473A1287|76 85|cleavages
P08868473A1287|44 48|role
P08868954A0648|33 40|effects
P08868954A0648|143 154|angiotensin
P08868954A0648|166 183|enzyme inhibitors
P08869763A0378|69 77|morphine
P08869763A0378|98 109|differences
P08869763A0378|128 139|sensitivity
P08869763A0378|57 65|response
P08870266A0651|68 79|amino acids
P08870266A0651|23 35|observations
P08870266A0651|176 196|secretion efficiency
P08871567A0000|68 75|element
P08871567A0000|79 84|c-myc
P08871635A0000|1 24|B cell antigen receptor
P08871635A0000|39 48|apoptosis
P08871635A0000|26 29|BCR
P08872671A0573|218 227|equations
P08872671A0573|108 131|amplitude perturbations
P08872671A0573|193 198|blood
P08872671A0573|30 55|blood flow shunt fraction
P08873063A0875|139 167|LpS1 RNA accumulation levels
P08873063A0875|116 131|control embryos
P08873063A0875|64 91|USF RNA accumulation levels
P08873063A0875|56 60|drop
P08874399A0277|141 147|groups
P08874399A0277|22 34|intervention
P08874399A0277|127 129|Ca
P08874399A0277|130 131|o
P08876167A0322|35 42|subunit
P08876701A0177|31 43|UmuC-homolog
P08877818A0184|70 93|TRH progenitor sequence
P08877818A0184|127 134|Arg-Arg
P08877818A0184|111 126|His-Pro-Gly-Lys
P08878037A0000|5 14|gene ccpA
P08878045A0606|119 124|group
P08878045A0606|49 57|contacts
P08878045A0606|178 191|transcription
P08878045A0606|78 91|alpha subunit
P08878045A0606|164 174|initiation
P08879080A0265|33 38|order
P08879080A0265|54 57|fit
P08879080A0265|12 17|ACOAs
P08880405A1170|17 23|SC EPD
P08880405A1170|81 84|age
P08880405A1170|59 68|selection
P08881542T0000|1 39|Sodium polystyrene sulfonate treatment
P08881542T0000|62 69|effects
P08882710A0000|1 11|Interferon
P08882710A0000|138 142|beta
P08882710A0000|23 34|gene factor
P08882710A0000|93 102|treatment
P08882710A0000|106 111|cells
P08884757A0653|34 38|item
P08884757A0653|64 74|Impression
P08884757A0653|143 147|SCAG
P08884757A0653|76 79|CGI
P08884757A0653|192 197|nurse
P08884757A0653|105 111|Sandoz
P08884757A0653|324 340|Performance Test
P08884757A0653|92 97|score
P08884757A0653|360 363|SKT
P08884757A0653|121 141|Assessment Geriatric
P08886845A1274|221 230|myoblasts
P08886845A1274|81 87|copies
P08886845A1274|145 153|myotubes
P08887647T0000|1 19|Fission yeast mal2
P08887659A0753|1 10|Mutations
P08887659A0753|52 61|threonine
P08887659A0753|30 35|sites
P08887661A1061|4 12|contrast
P08887661A1061|53 66|NIH 3T3 cells
P08887661A1061|42 47|IRF-1
P08887661A1061|14 28|cotransfection
P08887674A0630|19 45|DMP1 recognition sequences
P08887674A0630|59 81|GGA trinucleotide core
P08887678A0000|32 43|protein Bax
P08887678A0000|142 152|cell death
P08891131A0000|239 240|%
P08891131A0000|204 212|chickens
P08891131A0000|232 236|pigs
P08891131A0000|118 128|intestines
P08891131A0000|184 188|dogs
P08891131A0000|191 192|%
P08891131A0000|90 108|enrichment culture
P08891341A0724|81 88|lengths
P08891341A0724|213 226|reporter gene
P08891341A0724|11 30|transfection assays
P08891341A0724|195 205|expression
P08891341A0724|105 114|sequences
P08891346A1217|169 174|FGF8e
P08891346A1217|143 147|cDNA
P08891346A1217|159 164|FGF8b
P08891346A1217|46 64|isoform expression
P08892755A0186|115 118|JH1
P08892755A0186|4 12|addition
P08892755A0186|145 155|% identity
P08892755A0186|14 23|carp JAK1
P08892757T0000|35 41|member
P08892757T0000|101 109|analysis
P08892757T0000|77 96|mouse embryogenesis
P08892757T0000|133 152|repression activity
P08893779A0229|143 150|failure
P08893779A0229|167 173|strain
P08893779A0229|85 91|values
P08893779A0229|186 187|p
P08893779A0229|359 367|junction
P08893779A0229|295 304|interface
P08893779A0229|124 130|energy
P08893779A0229|245 253|location
P08894144A0330|238 241|CsA
P08894144A0330|160 164|p.o.
P08894144A0330|104 120|CsA vehicle p.o.
P08894144A0330|253 257|p.o.
P08894144A0330|263 265|FB
P08894144A0330|219 224|mg/kg
P08894144A0330|126 139|FB vehicle sc
P08894144A0330|94 98|days
P08894144A0330|211 213|FB
P08894826A0228|1 12|Individuals
P08894826A0228|200 204|NSGI
P08894826A0228|160 166|herpes
P08894826A0228|222 230|syphilis
P08894826A0228|189 198|infection
P08894826A0228|27 41|GUM Department
P08895579A0583|68 75|tissues
P08895579A0583|101 106|mRNAs
P08895579A0583|111 115|MDMX
P08896272A0000|50 53|arm
P08896272A0000|5 24|nucleotide sequence
P08896402A0587|186 187|N
P08896402A0587|84 86|kD
P08896402A0587|202 208|sugars
P08896402A0587|148 159|kD subunits
P08896590T0000|34 38|RNAs
P08896590T0000|55 60|snRNP
P08896590T0000|9 14|exons
P08896804A0000|409 414|% g/v
P08896804A0000|368 373|% v/v
P08896804A0000|280 298|alcohol-preferring
P08896804A0000|13 18|study
P08896804A0000|392 401|saccharin
P08896804A0000|116 123|agonist
P08896804A0000|52 71|time course effects
P08896804A0000|416 424|solution
P08896804A0000|125 134|RO19-4603
P08896804A0000|330 341|choice test
P08896804A0000|240 243|CGS
P08897721A0000|16 25|Neisseria
P08897721A0000|115 129|polysaccharide
P08897721A0000|39 46|group B
P08898365A0274|1 6|Rss1p
P08898365A0274|33 40|protein
P08898365A0274|148 162|pore complexes
P08898365A0274|164 168|NPCs
P08898893A0202|50 55|genes
P08898893A0202|156 177|phosphatase inhibitor
P08898893A0202|143 146|PMA
P08898893A0202|244 249|cells
P08899719A0318|87 94|operons
P08899719A0318|99 103|ORFs
P08899719A0318|63 67|ORFs
P08899719A0318|47 61|reading frames
P08900190A0430|1 15|Growth factors
P08900190A0430|27 37|expression
P08900190A0430|61 99|gene products MAP kinase phosphatase-1
P08901135A1132|117 138|nitrogen derepression
P08901135A1132|201 205|NIT2
P08901135A1132|191 197|import
P08901135A1132|142 161|nitrogen repression
P08901658A0498|48 61|flow increase
P08901658A0498|144 147|GTN
P08901658A0498|10 19|responses
P08902548A0144|17 31|administration
P08902548A0144|117 127|defecation
P08902548A0144|58 65|L-5-HTP
P08902548A0144|89 94|mg/kg
P08902847A1946|238 247|degrees C
P08902847A1946|5 13|evidence
P08902847A1946|108 116|subunits
P08902847A1946|17 24|support
P08902847A1946|156 175|order rate constant
P08902847A1946|80 91|interaction
P08902847A1946|261 266|order
P08902847A1946|215 220|min-1
P08902847A1946|270 279|magnitude
P08903339A0264|59 68|structure
P08903339A0264|75 78|RNA
P08906056A1290|7 15|patients
P08906056A1290|132 155|health care utilization
P08909546A0810|102 109|protein
P08909546A0810|20 24|PEA2
P08910373A0315|50 62|mouse Y4/PP1
P08910373A0315|40 48|mouse Y1
P08910373A0315|73 85|Y2 receptors
P08910567A2269|103 111|enhancer
P08910567A2269|11 24|gene fragment
P08912807A0411|64 80|tyrosine residue
P08912807A0411|147 157|activation
P08913387A1010|1 10|Rifabutin
P08913387A1010|61 67|agents
P08914388A1645|35 41|medium
P08914388A1645|197 201|LVFX
P08914388A1645|227 235|sequence
P08914388A1645|132 136|SPFX
P08914388A1645|87 97|activities
P08914388A1645|24 25|H
P08914388A1645|56 62|author
P08914388A1645|151 159|AM-1155*
P08914532A0598|46 73|endohydrolase isoenzyme X-I
P08915508A0000|171 181|expression
P08915508A0000|32 36|MMLV
P08915508A0000|311 324|transcriptase
P08915508A0000|281 284|Gag
P08915508A0000|287 295|protease
P08915508A0000|326 328|RT
P08915508A0000|190 210|hammerhead ribozymes
P08915508A0000|417 420|RNA
P08915508A0000|266 279|group antigen
P08915508A0000|245 254|sequences
P08915508A0000|122 125|Tat
P08916928A0950|84 107|thymidine incorporation
P08916928A0950|52 58|effect
P08916928A0950|10 17|ligands
P08916960A1331|184 197|translocation
P08916960A1331|174 175|t
P08916960A1331|53 64|alterations
P08916960A1331|214 228|transformation
P08916960A1331|29 31|FL
P08916960A1331|151 161|bcl-2 gene
P08917435A0481|87 97|PAI-1 gene
P08917435A0481|66 79|transcription
P08917435A0481|144 149|c-jun
P08917435A0481|121 128|finding
P08917696A0485|305 308|fos
P08917696A0485|238 243|serum
P08917696A0485|276 288|hydrocarbons
P08917696A0485|313 322|jun genes
P08917696A0485|135 159|reporter gene constructs
P08917696A0485|51 55|TCDD
P08917696A0485|16 25|mechanism
P08917696A0485|257 260|CRE
P08917696A0485|114 131|expression assays
P08917696A0485|385 389|SV40
P08917696A0485|29 47|fos/jun activation
P08918464A0225|32 37|cells
P08918464A0225|39 46|BaF/STK
P08918464A0225|143 146|STK
P08918464A0225|72 78|growth
P08918885A0811|1 5|Kss1
P08918885A0811|74 87|yeast protein
P08918918T0000|103 119|trans-activation
P08918918T0000|11 21|activation
P08918918T0000|61 72|Tat protein
P08919289A0402|19 25|report
P08919289A0402|59 62|MFH
P08919986A1262|70 83|disadvantages
P08919986A1262|55 65|advantages
P08919986A1262|174 184|literature
P08919986A1262|29 34|range
P08919986A1262|91 95|drug
P08921387A1182|1 9|Analysis
P08921387A1182|67 71|EZH1
P08921387A1182|42 56|splicing event
P08921387A1182|94 103|gene GPR2
P08921865A1293|87 105|terminase proteins
P08921865A1293|40 42|ss
P08921865A1293|44 61|DNA binding motif
P08922384A0466|1 15|Immunoblotting
P08922384A0466|116 128|carboxyl end
P08922384A0466|41 49|proteins
P08922390A0361|110 118|paxillin
P08922390A0361|72 80|paxillin
P08922390A0361|61 68|domains
P08922390A2076|100 108|vinculin
P08922390A2076|174 185|LIM domains
P08922390A2076|82 94|interactions
P08922390A2076|246 258|localization
P08922390A2076|29 37|paxillin
P08922390A2076|268 277|adhesions
P08922488A0187|36 45|treatment
P08922488A0187|75 82|effects
P08923460A0565|1 12|RUSH-1 beta
P08923460A0565|109 113|exon
P08923460A0565|46 58|RUSH-1 alpha
P08923470A0458|1 23|PPAR gamma mRNA levels
P08923470A0458|42 43|%
P08924381T0000|67 89|breast cancer patients
P08927169A0178|65 70|times
P08927169A0178|22 31|infection
P08927169A0178|77 85|patients
P08927169A0178|104 112|homeless
P08927841A0053|17 21|data
P08927841A0053|89 97|activity
P08929563T0000|1 19|Rat liver catalase
P08929563T0000|63 85|tripeptide Ala-Asn-Leu
P08931991A1026|103 113|regulation
P08931991A1026|127 144|myosin expression
P08931991A1026|41 44|E2F
P08932385T0000|7 19|Maf proteins
P08933640A0000|49 76|energy sweetener erythritol
P08933640A0000|5 11|effect
P08933640A0000|24 33|ingestion
P08934540A0673|81 90|cell line
P08934540A0673|42 56|activity ratio
P08935991A0844|169 174|sizes
P08935991A0844|65 70|shows
P08935991A0844|59 61|CA
P08935991A0844|182 189|introns
P08935991A0844|73 83|% identity
P08936640A0105|38 54|research studies
P08936640A0105|126 137|lung cancer
P08936640A0105|56 71|review articles
P08937631A1223|103 109|period
P08937631A1223|138 147|relevance
P08937631A1223|62 72|hemorrhage
P08937631A1223|181 192|vasculature
P08937989A1365|5 12|results
P08937989A1365|63 70|regions
P08937989A1365|74 79|talin
P08937989A1365|45 46|N
P08938420A0862|35 45|LHA2 mRNAs
P08938420A0862|86 92|sugars
P08938420A0862|64 72|addition
P08938420A0862|189 206|3-O-methylglucose
P08938420A0862|26 30|LHA4
P08939966A0816|103 115|mRNA decline
P08939966A0816|71 77|levels
P08939966A0816|8 12|rate
P08940134A0705|171 180|reticulum
P08940134A0705|100 104|p130
P08940134A0705|4 7|3Y1
P08940134A0705|110 121|co-sediment
P08940134A0705|12 15|3Y1
P08942999T0000|100 110|resistance
P08942999T0000|43 48|codon
P08942999T0000|11 30|G-to-A substitution
P08943354A0295|68 95|Jak family tyrosine kinases
P08943354A0295|36 41|SHP-1
P08943354A0295|247 252|SHP-1
P08943354A0295|147 158|Tyk2 kinase
P08943354A0295|167 187|hyperphosphorylation
P08943934A0604|55 63|exposure
P08943934A0604|9 18|Theriault
P08945479T0000|69 93|tyrosine phosphorylation
P08945479T0000|42 63|lymphocyte kinase Lck
P08946166A0568|55 64|FRDS gene
P08946166A0568|44 47|ORF
P08947028A0992|7 14|results
P08947028A0992|89 94|Bni1p
P08950144A0172|119 127|interval
P08950144A0172|139 142|sec
P08950144A0172|18 21|CNV
P08950144A0172|11 13|P3
P08951815A0465|1 11|Regulation
P08951815A0465|139 146|absence
P08951815A0465|111 116|times
P08951815A0465|24 39|ASN2 expression
P08952796A0743|18 23|years
P08953340A0000|50 59|mg/kg/day
P08953340A0000|64 77|anthropometry
P08953340A0000|21 36|vanadyl sulfate
P08953340A0000|178 183|trial
P08953340A0000|194 220|weight-training volunteers
P08955071T0000|65 69|ORC1
P08955071T0000|73 86|fission yeast
P08955136A0606|36 47|PIP5KIalpha
P08955136A0606|58 72|PIP5K activity
P08955189A1198|71 76|cells
P08955189A1198|108 115|element
P08955189A1198|13 32|NheI/BglII promoter
P08955402A0288|16 25|mutations
P08955402A0288|157 166|mutations
P08955402A0288|189 206|HOL1-1 background
P08955402A0288|106 113|ability
P08955402A0288|75 81|region
P08958137A0534|80 85|study
P08958137A0534|31 37|plasma
P08959062A0372|101 114|immunodeficit
P08959062A0372|76 85|discovery
P08959062A0372|149 157|syndrome
P08959778A0292|99 102|EGF
P08959778A0292|83 97|graft function
P08959778A0292|42 56|graft survival
P08959778A0292|27 38|differences
P08961873T0000|18 39|coproporphyrin levels
P08961873T0000|43 51|patients
P08964067A0188|1 11|Thrombosis
P08964067A0188|25 29|vein
P08967870A0000|26 49|postmortem examinations
P08969495A0256|223 228|locus
P08969495A0256|98 107|lethality
P08969495A0256|158 164|region
P08969495A0256|42 57|mutation ts-A13
P08969495A0256|123 132|mutations
P08970352A0880|38 41|LDD
P08970352A0880|52 56|risk
P08970352A0880|31 34|use
P08970352A0880|60 71|progression
P08970979A1246|138 146|promoter
P08970979A1246|37 44|virions
P08970979A1246|109 117|template
P08970991A0747|100 101|%
P08970991A0747|67 76|apoptosis
P08970991A0747|41 52|temperature
P08971721A1314|8 13|basis
P08971721A1314|29 36|studies
P08972182A0000|102 107|hours
P08972182A0000|5 17|Fas receptor
P08972182A0000|72 82|cell death
P08972211A0059|168 176|sequence
P08972211A0059|219 228|enhancers
P08972211A0059|95 104|transgene
P08972211A0059|150 152|kb
P08972211A0059|120 122|kb
P08973185T0061|51 66|phosphorylation
P08973185T0061|71 85|AAC expression
P08973630A0923|118 132|Rac activation
P08973630A0923|92 108|Cdc42 activation
P08973630A0923|57 71|Rho activation
P08973917T0000|102 114|gene mapping
P08973917T0000|1 10|Isolation
P08973917T0000|23 32|structure
P08973917T0000|74 92|tryptophan protein
P08974135A0052|205 218|control group
P08974135A0052|138 146|patients
P08974135A0052|20 28|thiamine
P08974135A0052|192 199|members
P08974135A0052|30 40|vitamin B1
P08975713A0454|16 28|cDNA library
P08975713A0454|83 99|p53p2 start site
P08975713A0454|159 163|mRNA
P08977013A0788|71 82|differences
P08977013A0788|22 31|estimates
P08977013A0788|109 115|foveal
P08977013A0788|90 105|specializations
P08977235A0588|1 8|Mutants
P08977235A0588|201 234|receptor tyrosine phosphorylation
P08977235A0588|157 162|STAT5
P08977235A0588|110 115|STAT1
P08977235A0588|167 183|STAT1 activation
P08978690A0262|18 27|Rad3/Mec1
P08978690A0262|88 113|DNA structure checkpoints
P08978996A0000|184 190|impact
P08978996A0000|5 19|identification
P08978996A0000|163 175|epidemiology
P08978996A0000|146 155|attention
P08978996A0000|89 106|dialysis patients
P08979828A1561|19 31|interactions
P08980522A0280|5 9|cDNA
P08980522A0280|44 51|protein
P08980536A1196|115 121|motifs
P08980536A1196|59 72|CHS promoters
P08980536A1196|90 100|importance
P08981371A2049a|78 93|CSF-1 treatment
P08981371A2049a|14 26|PIP2 content
P08985109A1285|50 54|apex
P08985109A1285|98 104|aspect
P08985122A0501|239 249|CpG island
P08985122A0501|5 20|promoter region
P08985122A0501|227 233|domain
P08985122A0501|164 188|transcription factor SP1
P08985122A0501|216 217|G
P08985122A0501|22 24|P1
P08985122A0501|61 91|transcription initiation sites
P08986190A0927|32 41|reduction
P08986190A0927|94 105|LDH release
P08986228A0000|1 9|Children
P08986228A0000|80 87|effects
P08986770A0268|153 167|splice variant
P08986770A0268|39 59|I-POU/tI-POU message
P08986770A0268|93 98|phase
P08987009A0400|101 114|psychoanalyst
P08987009A0400|5 12|patient
P08987009A0400|15 19|role
P08988257A1256|1 10|Silencing
P08988257A1256|71 89|reporter construct
P08988257A1256|97 106|insertion
P08988257A1256|160 164|site
P08988257A1256|120 125|yeast
P08989025A0359|85 99|concentrations
P08989025A0359|71 80|midazolam
P08989025A0359|23 26|Ca2
P08989025A0359|59 69|nifedipine
P08990168A0688|71 76|STAT1
P08990168A0688|10 28|p48 gene induction
P08990168A0688|45 50|STAT1
P08990397A1437|64 75|photosystem
P08990397A1437|28 35|mutants
P08993393A0498|48 56|findings
P08993393A0498|92 105|hPACAP-R gene
P08993831A0000|17 35|muscle development
P08993831A0000|109 121|combinations
P08993831A0000|47 52|types
P08994825A0000|83 87|form
P08994825A0000|42 52|maturation
P08994825A0000|13 20|Mitosis
P08994968A0926|97 104|subunit
P08994968A0926|29 36|subunit
P08994968A0926|75 81|domain
P08995054A1368|17 22|HeT-A
P08995054A1368|100 106|codons
P08995054A1368|71 91|insertions/deletions
P08995054A1368|30 39|sequences
P08995410A1109|169 172|p40
P08995410A1109|5 9|data
P08995410A1109|129 133|p116
P08995410A1109|135 140|hPrt1
P08995410A1109|154 157|p48
P08995410A1109|113 121|subunits
P08995410A1109|123 127|p170
P08995410A1109|149 152|p66
P08995652A0812|340 351|interaction
P08995652A0812|143 157|UL80.5 protein
P08995652A0812|198 209|amino acids
P08995652A0812|742 761|scaffold structures
P08995652A0812|624 635|sequences N
P08995652A0812|217 231|UL80.5 protein
P08995652A0812|690 696|UL26.5
P08995652A0812|652 676|maturation cleavage site
P08995652A0812|379 382|VP5
P08995652A0812|499 513|UL80.5 protein
P08995652A0812|288 302|UL26.5 protein
P08995652A0812|531 544|RRIFVA ALNKLE
P08995652A0812|422 429|capsids
P08995681A0518|6 11|ICP27
P08995681A0518|59 63|ICP4
P08997490A1127|100 116|oligonucleotides
P08997490A1127|156 163|albumin
P08997490A1127|55 66|C/EBP sites
P08997490A1127|45 51|subset
P08998115A0114|1 24|SUMMARY BACKGROUND DATA
P08998115A0114|155 162|disease
P08998115A0114|26 39|Melanoma care
P08999857A0801|155 177|collagen gene promoter
P08999857A0801|54 60|region
P08999857A0801|145 151|alpha1
P08999857A0801|14 19|E-box
P09000049A1341|70 73|Myc
P09000049A1341|74 88|Max activities
P09000049A1341|30 39|complexes
P09000146T0000|53 64|c-src genes
P09000146T0000|12 19|changes
P09000632A2341|68 77|direction
P09000632A2341|8 19|p51 subunit
P09001245A0187|1 7|NUP145
P09001667A0312|18 29|antigenemia
P09001667A0312|8 13|cases
P09002648A0202|55 65|cell types
P09002648A0202|11 20|inhibitor
P09002648A0202|44 51|variety
P09003001A1593|88 95|factors
P09003311A0478|103 110|regions
P09003311A0478|79 84|porCa
P09003410A0000|85 90|virus
P09003410A0000|53 64|coactivator
P09003463A0198|116 130|RII alpha gene
P09003463A0198|6 12|report
P09003463A0198|40 56|characterization
P09003463A0198|88 90|kb
P09004304A0000|153 162|51Cr-EDTA
P09004304A0000|203 225|blood sample technique
P09004304A0000|147 151|acid
P09004304A0000|107 134|chromium-51 ethylenediamine
P09004987T0001|84 92|syndrome
P09004987T0001|32 37|blood
P09004987T0001|41 49|patients
P09005273A1558|18 35|Gulf War veterans
P09005273A1558|96 104|exposure
P09005273A1558|147 168|butyrylcholinesterase
P09005273A1558|73 82|syndromes
P09005836A0977|54 68|antibody level
P09005836A0977|28 31|age
P09006007A0997|239 252|compatibility
P09006007A0997|100 110|conditions
P09006007A0997|213 224|interaction
P09006007A0997|132 144|SelB protein
P09006022A0252|21 34|gene products
P09006022A0252|40 49|cvaA gene
P09006555A0738|1 22|MAIN OUTCOME MEASURES
P09006555A0738|111 125|lavage protein
P09006555A0738|130 148|neutrophil content
P09006555A0738|210 227|scanning electron
P09006555A0738|241 248|studies
P09006910A0000|100 115|gene expression
P09006910A0000|95 98|RXR
P09006910A0000|63 70|control
P09006914A1127|50 75|JNK/p38 signaling pathway
P09006914A1127|5 12|effects
P09006914A1127|37 42|forms
P09006936T0000|85 91|domain
P09006936T0000|23 29|region
P09006936T0000|47 54|protein
P09009208A0337|82 90|Tf1 mRNA
P09009208A0337|30 38|cleavage
P09010223A1850|49 52|SRF
P09010223A1850|66 75|mechanism
P09010223A1850|163 188|ETS transcription factors
P09010223A1850|196 206|regulation
P09010223A1850|109 117|EWS-FLI1
P09011744A0790|279 289|C57BL/6JxM
P09011744A0790|142 149|epsilon
P09011744A0790|229 252|backcross mapping panel
P09011744A0790|133 139|Grin2c
P09011744A0790|153 159|Grin2d
P09011744A0790|113 119|Grin2b
P09011744A0790|266 273|crosses
P09011744A0790|24 33|locations
P09011744A0790|122 129|epsilon
P09012405A0785|18 23|TTD-A
P09012405A0785|88 108|transcription factor
P09012405A0785|28 40|XP-D defects
P09012405A0785|61 69|subunits
P09013499A0198|259 267|controls
P09013499A0198|18 22|pups
P09013499A0198|234 238|odor
P09013499A0198|76 123|N-methyl-D-aspartate receptor antagonist MK-801
P09013499A0198|44 53|injection
P09015543A0210|40 47|forearm
P09015799T0000|51 61|depression
P09015799T0000|24 39|suicide victims
P09017443A0734|18 31|marker screen
P09017443A0734|158 159|p
P09017443A0734|142 156|stratification
P09018133A0244|137 156|alpha-Herpesvirinae
P09018133A0244|109 129|Varicellovirus genus
P09018133A0244|167 178|herpesvirus
P09018133A0244|28 36|evidence
P09020138A0833|33 40|complex
P09020138A0833|6 10|HEF1
P09020138A0833|107 115|tyrosine
P09020138A0833|90 95|RAFTK
P09020172A0964|1 10|Complexes
P09020172A0964|174 183|complexes
P09020172A0964|162 164|Kd
P09020172A0964|215 218|DNA
P09020172A0964|135 160|nM dissociation constants
P09020172A0964|45 51|strand
P09021684A1418|168 182|NF-kappa B2p52
P09021684A1418|46 54|proteins
P09021684A1418|14 18|data
P09023378A0959|186 197|DNA element
P09023378A0959|136 154|activator sequence
P09023378A0959|25 29|CBF1
P09023378A0959|78 92|reporter genes
P09023378A0959|61 74|transcription
P09024097A0000|16 20|goal
P09024097A0000|138 146|ligation
P09024097A0000|65 70|women
P09024805A0905b|187 207|beta-globin TATA box
P09024805A0905b|16 34|promoter construct
P09024805A0905b|65 83|consensus Sp1 site
P09024805A0905b|113 117|copy
P09024805A0905b|52 59|repeats
P09024805A0905b|130 134|CREB
P09025549A0000|236 242|fields
P09025549A0000|217 224|mentors
P09025549A0000|96 109|practitioners
P09025549A0000|52 62|competence
P09025549A0000|124 161|Vancouver sex therapist Bianca Rucker
P09025549A0000|271 280|continent
P09027506T0000|1 13|cDNA cloning
P09027506T0000|112 114|4F
P09027506T0000|52 64|localization
P09027506T0000|108 111|iso
P09028308A0590|204 214|completion
P09028308A0590|237 249|chemotherapy
P09028308A0590|43 56|mitroxantrone
P09028308A0590|130 137|cohorts
P09028308A0590|13 21|patients
P09028308A0590|194 197|day
P09028998A0143|4 9|order
P09028998A0143|97 110|breast tissue
P09028998A0143|74 81|outcome
P09029104A0226|70 76|manner
P09029104A0226|10 15|IGLL1
P09029713A1120|48 55|control
P09029713A1120|63 70|amounts
P09029713A1120|15 19|data
P09030581A0990|19 30|COS-7 cells
P09030581A0990|80 95|selectivity ERK
P09030581A0990|104 112|JNK/SAPK
P09030781A0734|6 13|kinases
P09030781A0734|277 288|roscovitine
P09030781A0734|77 90|cdk2/cyclin A
P09030781A0734|49 60|roscovitine
P09030781A0734|191 197|microM
P09030781A0734|214 228|cdk4/cyclin D1
P09030781A0734|301 307|microM
P09032233T0000|1 12|Interaction
P09032233T0000|60 65|Pit-1
P09032250A0257|117 143|CCAAT binding protein NF-Y
P09032250A0257|49 57|proteins
P09032250A0257|78 82|Tax1
P09032250A0257|28 34|system
P09032258A0395|84 110|NF-AT DNA binding activity
P09032258A0395|139 157|B7-1 costimulation
P09032258A0395|15 32|HLA-DR-B7-1-LFA-3
P09032259A0972|48 57|induction
P09032259A0972|40 43|SRF
P09032259A0972|14 29|Rac1 activation
P09032275A1133|68 88|AHC deletion mutants
P09032328A0650|204 212|proteins
P09032328A0650|84 88|DL-B
P09032328A0650|1 15|DNA sequencing
P09032328A0650|127 135|presence
P09032328A0650|108 113|ORF17
P09032328A0650|150 154|ORFs
P09035307A0000|112 156|99mTc-methoxyisobutylisonitrile scintigraphy
P09035307A0000|88 95|adenoma
P09036529A0343|171 185|Apis mellifera
P09036529A0343|67 78|measurement
P09036529A0343|41 53|microgram/ml
P09036529A0343|132 136|CAST
P09036529A0343|116 125|Pharmacia
P09036529A0343|55 64|Pharmacia
P09036529A0343|219 230|Aquagen ALK
P09036529A0343|148 162|concentrations
P09037064A0183|68 86|vaccine immunogens
P09037064A0183|174 183|vaccinees
P09037064A0183|57 64|vectors
P09037064A0183|133 146|CTL responses
P09037064A0183|90 95|HIV-1
P09038166A0818|1 10|Exons A1a
P09038202A1951|171 180|promoters
P09038202A1951|99 107|promoter
P09038202A1951|7 11|data
P09038202A1951|88 95|species
P09040011A1316|17 20|lck
P09040011A1316|115 127|transduction
P09040011A1316|96 110|cell viability
P09040011A1316|144 162|activation signals
P09040011A1316|177 187|components
P09040011A1316|195 215|Ras/Raf/MAPK pathway
P09042078A0202|22 25|MBF
P09042078A0202|46 55|direction
P09042078A0202|90 102|jaw openings
P09042683A0492|64 80|symptoms profile
P09042683A0492|160 173|schizophrenia
P09042911A0626|100 105|liver
P09042911A0626|142 152|expression
P09042911A0626|41 55|glucocorticoid
P09043768A0139|21 32|biokinetics
P09043768A0139|53 63|indium-111
P09045805A0945|85 97|acoK mutants
P09045805A0945|191 203|gene product
P09045805A0945|113 120|plasmid
P09045805A0945|37 51|acoABCD operon
P09045919A1250|228 235|control
P09045919A1250|107 110|p50
P09045919A1250|45 54|existence
P09045919A1250|115 129|c-Rel proteins
P09045919A1250|147 177|transcription factor machinery
P09045919A1250|243 252|IgH locus
P09046090T0000|87 106|glucose transporter
P09046090T0000|5 10|genes
P09046090T0000|59 71|G4p1 protein
P09046090T0000|131 146|kb DNA fragment
P09046384A0403|55 58|CD4
P09046384A0403|106 118|DDI subgroup
P09047344A0000|152 160|affinity
P09047344A0000|20 27|peptide
P09047344A0000|37 44|peptide
P09047344A0000|76 89|muscle myosin
P09047344A0000|29 32|CBP
P09049198A0289|35 46|involvement
P09049198A0289|80 90|expression
P09049198A0289|179 188|specimens
P09049198A0289|146 152|models
P09049198A0289|57 74|liver cell growth
P09049304A1193|187 211|VPF/VEGF gene expression
P09049304A1193|32 36|AP-2
P09049304A1193|4 27|co-transfection studies
P09049304A1193|127 139|AP-2 protein
P09049313A0116|81 90|proteases
P09049313A0116|109 117|cleavage
P09050847A0180|171 182|selectivity
P09050847A0180|202 210|promoter
P09050847A0180|106 148|transcription initiation factor TIF-IB/SL1
P09050847A0180|72 78|murine
P09050849A1459|67 74|ARF-GEP
P09050867A0542|113 137|POU-homeodomain proteins
P09050867A0542|27 39|binding site
P09050867A0542|44 57|Krox proteins
P09050867A0542|75 81|factor
P09053309A1103|100 123|floor plate inducer shh
P09053309A1103|25 48|floor plate development
P09053835A0865|77 91|protein levels
P09053835A0865|61 69|p53 mRNA
P09055221A0288|101 116|signal contrast
P09055221A0288|22 27|SSTEs
P09055221A0288|43 52|magnitude
P09057325A0177|103 126|complementation studies
P09057325A0177|81 98|deletion analysis
P09057325A0177|41 66|pathogenicity locus pat-1
P09057703A1389|50 70|treatment conditions
P09057841T0000|17 32|gene expression
P09057841T0000|100 118|Candida tropicalis
P09057841T0000|61 67|region
P09058250A0128|66 69|NO2
P09058250A0128|95 102|therapy
P09058250A0128|47 55|analysis
P09058373A0670|101 106|liver
P09058373A0670|44 52|presence
P09058378A1134|102 117|transrepression
P09058378A1134|63 87|transactivation function
P09058378A1134|91 94|p53
P09060045A0576|68 76|settings
P09060045A0576|12 27|review analyses
P09060622A1679|85 86|A
P09060622A1679|55 69|alphavirus RNA
P09060622A1679|106 115|infection
P09060676A1634|18 38|virus entry features
P09060676A1634|7 14|changes
P09061697A0629|275 279|dose
P09061697A0629|201 223|stress imaging studies
P09061697A0629|283 300|99Tcm-tetrofosmin
P09061697A0629|192 196|rest
P09061697A0629|49 52|MBq
P09061697A0629|18 26|patients
P09061697A0629|113 116|MBq
P09061697A0629|179 187|patients
P09061697A0629|56 59|mCi
P09061697A0629|270 273|mCi
P09061697A0629|61 78|99Tcm-tetrofosmin
P09061698A0177|1 14|99Tcm-DMP-HSA
P09061698A0177|42 51|behaviour
P09061698A0177|132 150|reference standard
P09064659A1055|103 116|nonsense mRNA
P09064659A1055|189 193|UPF1
P09064659A1055|93 99|levels
P09064659A1055|147 154|protein
P09064659A1055|45 52|homolog
P09065170A0853|17 27|zidovudine
P09065690A0463|119 122|URS
P09065690A0463|1 6|Ume6p
P09065690A0463|141 162|nitrogen availability
P09065690A0463|77 92|CAR1 expression
P09067577A0307|48 56|tyrosine
P09067577A0307|39 43|CRKL
P09067577A0307|30 37|BCR/ABL
P09068989T0000|80 86|system
P09068989T0000|45 57|leaf extract
P09071407T0000|95 104|condition
P09071407T0000|30 41|guinea pigs
P09073074T0000|37 54|FGFR-3 psuedogene
P09074508A0397|35 40|exons
P09074508A0397|82 88|genome
P09076336A0281|1 14|GH deficiency
P09076336A0281|156 164|spectrum
P09076336A0281|130 138|findings
P09076336A0281|181 195|GH sufficiency
P09077108A0458|86 95|TNF-alpha
P09077108A0458|65 71|levels
P09077108A0458|127 132|fluid
P09077108A0458|75 78|IgG
P09077438A0076|40 53|RNA synthesis
P09079638A0883|205 206|%
P09079638A0883|185 191|ligand
P09079638A0883|173 181|response
P09079638A0883|52 59|Ser-346
P09079638A0883|79 86|alanine
P09079638A0883|29 34|CXCR2
P09079689A0472|118 124|domain
P09079689A0472|1 5|MOP5
P09079689A0472|146 159|reading frame
P09079878A0000|20 52|Lactobacillus sake plasmid pCIM1
P09079878A0000|145 149|lasA
P09079878A0000|123 127|ORFs
P09079904A0995|153 163|Bvg system
P09079904A0995|72 84|DNA topology
P09079904A0995|12 27|iron regulation
P09079904A0995|61 68|changes
P09079928A0525|70 79|oxyR-ahpC
P09079928A0525|55 62|binding
P09080250A0212|136 139|PCR
P09080250A0212|100 105|means
P09080250A0212|156 160|P815
P09080250A0212|109 134|polymerase chain reaction
P09081389A1088|1 6|Grade
P09081389A1088|11 20|mucositis
P09082335A0730|1 5|None
P09082335A0730|23 37|manifestations
P09083345A0851|236 248|presentation
P09083345A0851|128 135|respect
P09083345A0851|14 19|range
P09083345A0851|253 271|treatment efficacy
P09083345A0851|217 225|symptoms
P09083345A0851|188 203|characteristics
P09084174A0667|236 246|Vibrio spp
P09084174A0667|200 210|similarity
P09084174A0667|173 177|orfA
P09084174A0667|163 166|Asd
P09084174A0667|43 54|nucleotides
P09084174A0667|91 104|dehydrogenase
P09084227A0833|1 12|Hovenitin I
P09084227A0833|21 31|ampelopsin
P09084227A0833|159 167|activity
P09084227A0833|88 97|fractions
P09084621A2567|34 38|rCBF
P09084621A2567|117 124|caudate
P09084621A2567|67 79|motor cortex
P09085842A1559|95 123|protein/protein interactions
P09085842A1559|30 41|27K protein
P09087430A1046|19 30|U1A peptide
P09088416A0000|222 230|etiology
P09088416A0000|86 94|syndrome
P09088416A0000|112 130|migraine headaches
P09088416A0000|179 185|branch
P09088416A0000|132 140|tinnitus
P09088416A0000|151 163|hearing loss
P09089093A0373|80 97|enhancer elements
P09089653A1112|51 71|DNase-I footprinting
P09089653A1112|101 111|protection
P09089653A1112|26 38|interactions
P09090054A0186|85 93|permease
P09090054A0186|221 228|cluster
P09090054A0186|157 179|alpha-glucosidase gene
P09090054A0186|26 30|loci
P09090054A0186|74 83|regulator
P09091010A1003|86 93|disease
P09091010A1003|7 12|women
P09091403T0001|69 74|mouse
P09091403T0001|55 61|intron
P09091403T0001|24 37|DNA sequences
P09092580A1354|141 146|sites
P09092580A1354|7 14|studies
P09092580A1354|73 83|activation
P09092580A1354|28 39|involvement
P09092675A0283|3 21|P22 R17 derivative
P09092675A0283|57 58|U
P09092675A0283|90 99|infection
P09094093A0578|32 40|TATA box
P09094093A0578|57 62|cells
P09094671A1192|1 33|Candidate tumor suppressor genes
P09094671A1192|55 59|Mts2
P09094671A1192|97 103|region
P09094671A1192|150 159|deletions
P09096234T0000|65 89|DNA sequence specificity
P09096234T0000|42 50|subunits
P09096234T0000|91 119|operator site discrimination
P09098066A0119|274 277|crl
P09098066A0119|87 100|proteins HMW1
P09098066A0119|48 53|genes
P09098066A0119|231 242|designation
P09098066A0119|162 170|proteins
P09098066A0119|105 109|HMW3
P09098899A0435|39 47|shoulder
P09098899A0435|197 210|delta epsilon
P09098899A0435|105 132|charge-transfer transitions
P09098899A0435|55 57|nm
P09098899A0435|261 266|Cys-S
P09098899A0435|244 252|presence
P09098899A0435|269 275|center
P09099702A0000|32 39|cloning
P09099702A0000|123 126|RTR
P09099702A0000|75 100|orphan receptor germ cell
P09099743A0585|169 181|polypeptides
P09099743A0585|81 89|particle
P09099743A0585|246 255|nucleolin
P09099743A0585|195 198|kDa
P09099743A0585|224 227|kDa
P09100202A0000|8 13|Class
P09100202A0000|46 54|patients
P09101910A0394|36 44|patients
P09101910A0394|59 68|mortality
P09101910A0394|95 100|years
P09103382T0000|37 52|cancer stage IA
P09103382T0000|56 64|critique
P09105042A1497|238 248|sarcomeres
P09105042A1497|6 11|study
P09105042A1497|161 168|failure
P09105042A1497|183 189|myosin
P09105042A1497|44 65|myofibrillar disarray
P09105042A1497|120 129|mutations
P09105530A0000|4 15|egg protein
P09108029A0399|119 124|Ref-1
P09108029A0399|103 115|redox factor
P09108029A0399|40 57|activator protein
P09108029A0399|61 65|AP-1
P09108207A0306|50 74|oropharyngeal irritation
P09108451A0160|1 8|Results
P09108451A0160|89 110|G1-phase accumulation
P09108451A0160|61 67|UCN-01
P09111004A0732|118 124|length
P09111004A0732|230 249|autophosphorylation
P09111004A0732|182 188|length
P09111004A0732|210 214|role
P09111059A0327|103 106|DNA
P09111059A0327|24 30|domain
P09111314A0970|1 10|Cyclin D1
P09111314A0970|61 82|184A1L5R cell lysates
P09111331A0119|101 105|Mpk1
P09111331A0119|54 75|transcription factors
P09111331A0119|113 120|pathway
P09111367A1098|410 423|tal-1 effects
P09111367A1098|336 341|c-myc
P09111367A1098|199 208|apoptosis
P09111367A1098|14 25|experiments
P09111367A1098|220 225|tal-1
P09111367A1098|562 567|T-ALL
P09111367A1098|90 106|tal-1 expression
P09111367A1098|168 174|effect
P09111367A1098|507 519|N-terminally
P09111367A1098|595 602|effects
P09111367A1098|530 543|tal-1 variant
P09111367A1098|57 66|p53 cells
P09111367A1098|363 368|tal-1
P09112400A1155|89 94|cells
P09112400A1155|13 21|activity
P09114972A1366|6 15|induction
P09115247A2069|220 224|site
P09115247A2069|169 180|recognition
P09115247A2069|81 95|alkyl backbone
P09115247A2069|265 278|beta-hydroxyl
P09115247A2069|124 132|distance
P09115247A2069|195 201|enzyme
P09115279A0345|103 110|partner
P09115279A0345|1 21|Cdc2 co-precipitates
P09115279A0345|67 71|Cdc2
P09115279A0345|44 56|cell lysates
P09115365A0000|53 58|hsp70
P09115365A0000|25 43|heat shock protein
P09115365A0000|91 97|stress
P09115989A0993|36 56|psoralen cross-links
P09115989A0993|26 34|location
P09118196A0281|186 198|correlations
P09118196A0281|1 12|Performance
P09118196A0281|213 222|education
P09118196A0281|40 54|National Adult
P09118196A0281|164 170|WAIS-R
P09118704A0771|1 8|RESULTS
P09118704A0771|20 28|patients
P09118704A0771|112 114|CI
P09118704A0771|177 195|bleomycin toxicity
P09119112A1350|34 39|model
P09119112A1350|49 55|GATA-5
P09119112A1350|110 118|function
P09121424A0296|71 79|evidence
P09121424A0296|53 57|Swh3
P09121424A0296|133 137|Sthl
P09121430A1075|4 12|contrast
P09121430A1075|72 85|c-myc message
P09121433A0463|139 143|SMP1
P09121433A0463|198 202|4TAG
P09121433A0463|166 184|consensus sequence
P09121433A0463|194 197|T/A
P09121433A0463|186 193|ACTACTA
P09121433A0463|113 117|MEF2
P09121433A0463|58 71|specificities
P09121452A0538|103 120|activation domain
P09121452A0538|81 95|leucine zipper
P09121452A0538|232 240|promoter
P09121452A0538|124 135|C/EBP alpha
P09121476T0000|1 6|PRH75
P09121476T0000|82 88|plants
P09121774T0000|3 7|role
P09121774T0000|22 32|GTPase Rac
P09121774T0000|123 142|cell transformation
P09122168A1427|49 53|role
P09122168A1427|159 165|system
P09122168A1427|58 69|G betagamma
P09122168A1427|106 119|translocation
P09122168A1427|132 136|GRK3
P09122168A1427|30 43|demonstration
P09122198A0478|80 88|receptor
P09122198A0478|127 138|conclusions
P09123055T0000|16 22|injury
P09123055T0000|64 66|UW
P09123055T0000|30 42|preservation
P09124054A1164|93 101|patients
P09124054A1164|24 32|patients
P09126622A0466|69 86|CAL transformants
P09126622A0466|5 22|pigment intensity
P09126622A0466|120 124|type
P09129147A0644|64 69|motif
P09129147A0644|83 91|homology
P09129147A0644|95 102|Fos/Jun
P09130700A0676|85 93|toxicity
P09130700A0676|52 58|Spc98p
P09130700A0676|177 182|SPC98
P09130700A0676|63 69|Spc97p
P09130700A0676|45 50|Tub4p
P09130720A0417|140 158|intron recognition
P09130720A0417|11 17|screen
P09130720A0417|44 62|branch site region
P09132011A0298|68 78|% homology
P09132011A0298|19 31|p50 sequence
P09132011A0298|142 179|Drosophila cell cycle control protein
P09132011A0298|126 136|% homology
P09132061A0828|154 158|ESTs
P09132061A0828|5 8|atp
P09132061A0828|134 144|peroxidase
P09132061A0828|15 18|atp
P09135066A0653|43 47|Mek1
P09135066A0653|63 70|p96h2bk
P09135772T0000|41 47|roller
P09135772T0000|73 78|foods
P09136015A0529|67 74|cluster
P09136015A0529|28 34|copies
P09138076A1099|153 158|E-box
P09138076A1099|4 29|gel mobility shift assays
P09138076A1099|58 66|extracts
P09138076A1099|165 170|E-box
P09139665A0784|64 74|Gbetagamma
P09139721A0183|103 114|lymphocytes
P09139721A0183|70 88|tolerance subjects
P09139721A0183|161 170|apoptosis
P09139721A0183|45 51|system
P09139892A1150|139 143|dorf
P09139892A1150|79 90|orientation
P09139892A1150|120 131|orientation
P09139910A1572|4 12|contrast
P09139910A1572|89 94|R229I
P09140474T0000|33 39|island
P09140474T0000|4 17|leishmaniasis
P09140474T0000|77 81|case
P09140474T0000|107 114|Minorca
P09143328A1002|38 49|utilization
P09143328A1002|6 13|finding
P09144165A0614|103 110|feature
P09144165A0614|6 11|model
P09144165A0614|40 47|segment
P09144165A0614|167 175|sequence
P09144165A0614|51 55|NFAT
P09144165A0614|155 159|size
P09144165A0614|95 98|RIR
P09144195A1051|65 71|cycles
P09144195A1051|11 22|association
P09144958A0047|152 162|regulation
P09144958A0047|86 114|chlorophyll a/b protein gene
P09144958A0047|42 50|promoter
P09144958A0047|166 177|phytochrome
P09146071T0001|65 83|pontine hemorrhage
P09146071T0001|10 18|movement
P09147420T0000|1 4|TAR
P09147420T0000|76 87|Tat protein
P09147420T0000|95 103|presence
P09147420T0000|44 47|HIV
P09147832A0174|1 9|Children
P09147832A0174|54 58|Time
P09147832A0174|124 134|conscience
P09147832A0174|183 191|measures
P09148903A1715|220 231|degradation
P09148903A1715|58 76|HIV-1 LTR activity
P09148903A1715|106 119|translocation
P09148903A1715|180 215|IkappaBalpha serine phosphorylation
P09148935A0805|187 190|FAK
P09148935A0805|55 74|type FAK expression
P09148935A0805|132 142|expression
P09148935A0805|15 33|c-Src PTK activity
P09149929A0750|110 120|separation
P09149929A0750|57 65|children
P09149929A0750|149 156|control
P09150566A0316|99 105|clouds
P09150566A0316|42 51|formation
P09150595T0000|50 81|Erwinia carotovora hrpNEcc gene
P09150595T0000|32 42|expression
P09150595T0000|11 27|characterization
P09150774A0616|49 52|N2O
P09150774A0616|57 67|inhalation
P09151376A0000|175 184|arthritis
P09151376A0000|195 199|gout
P09151376A0000|14 18|case
P09151376A0000|30 54|hyperbetalipoproteinemia
P09151828A0919|168 176|residues
P09151828A0919|203 209|region
P09151828A0919|127 133|region
P09151828A0919|13 32|amino acid residues
P09151925A0479|152 156|PEIT
P09151925A0479|69 72|TAE
P09151925A0479|5 10|C-LIP
P09151925A0479|125 150|ethanol injection therapy
P09153010A0499|34 42|analysis
P09153010A0499|309 325|reference values
P09153010A0499|281 288|results
P09153010A0499|78 82|MUPs
P09153010A0499|258 273|reproducibility
P09153010A0499|216 220|bias
P09153010A0499|58 69|acquisition
P09153010A0499|123 127|MUPs
P09153319A1332|186 214|control phosphorothioate ODN
P09153319A1332|1 25|Transfection experiments
P09153319A1332|42 51|triplexes
P09153319A1332|151 164|transcription
P09153795A0298|39 47|evidence
P09153795A0298|24 28|RDFS
P09154621A1475|136 153|serum cholesterol
P09154621A1475|36 59|safflower phospholipids
P09154621A1475|7 14|results
P09154621A1475|78 88|ingredient
P09154797A0777|117 121|Vmax
P09154797A0777|41 53|lacZ mutants
P09154797A0777|90 98|affinity
P09154822T0000|19 31|Raf-1 kinase
P09154822T0000|42 54|AMP agonists
P09155015A0140|116 119|ANF
P09155015A0140|55 79|reporter gene expression
P09155015A0140|108 114|factor
P09155015A0140|181 192|hypertrophy
P09156883A0294|34 36|HR
P09156883A0294|116 128|pulsoximetry
P09156883A0294|64 67|ABP
P09156883A0294|22 32|heart rate
P09157337A0545|85 93|etiology
P09157337A0545|100 122|Infectology Department
P09157337A0545|59 68|hepatitis
P09159111A0437|55 64|dichroism
P09159111A0437|66 68|CD
P09159111A0437|127 135|proteins
P09159183A0119|1 6|Genes
P09159183A0119|115 136|transcription factors
P09159183A0119|172 178|plants
P09159183A0119|40 44|OBFs
P09159183A0119|11 38|ocs element binding factors
P09160881A0491|54 59|yeast
P09160881A0491|24 48|co-precipitation studies
P09162092A0675|1 25|MKK3 autophosphorylation
P09162092A0675|92 96|MKK3
P09162092A0675|44 47|p38
P09162097A1258|17 21|data
P09162097A1258|4 11|summary
P09162097A1258|110 119|homologue
P09162097A1258|176 184|MAdCAM-1
P09164543A0219|119 123|mean
P09164543A0219|190 198|vagotomy
P09164543A0219|77 84|surgery
P09164543A0219|94 99|years
P09164543A0219|149 157|vagotomy
P09164543A0219|14 21|METHODS
P09165004A1700|1 13|SRE activity
P09165004A1700|36 46|activation
P09165004A1700|122 137|complex factors
P09165039A0728|36 37|%
P09165039A0728|46 63|sequence homology
P09165118A0311|67 72|input
P09165118A0311|163 168|input
P09165118A0311|176 179|VAs
P09165118A0311|10 17|mutants
P09165118A0311|47 54|pattern
P09168083A0987|55 60|group
P09168083A0987|4 11|patient
P09168218A0216|69 87|pain syndrome type
P09168218A0216|110 119|dystrophy
P09168218A0216|14 23|responses
P09168218A0216|134 139|grill
P09168623A0614|117 127|one-carbon
P09168623A0614|190 199|succinate
P09168623A0614|129 131|C1
P09168623A0614|161 171|expression
P09168623A0614|133 142|compounds
P09168892A1016|85 101|trans-activation
P09168892A1016|59 67|elements
P09168892A1016|13 24|nucleotides
P09169420A0000|50 59|p110alpha
P09169420A0000|100 112|Src homology
P09169420A0000|116 119|SH2
P09169420A0000|156 164|p85alpha
P09169420A0000|43 48|PI3Ks
P09169420A0000|15 41|phosphoinositide 3-kinases
P09169475A0772|21 46|cytokine response element
P09169475A0772|123 135|binding site
P09169475A0772|150 164|STAT complexes
P09169852A0235|69 76|alleles
P09169852A0235|206 215|histidine
P09169852A0235|115 127|zinc fingers
P09169852A0235|166 177|zinc finger
P09170159A0348|35 40|cells
P09170159A0348|124 131|protein
P09171038A0219|17 24|Sjogren
P09171038A0219|145 153|patients
P09171038A0219|27 35|syndrome
P09171038A0219|135 142|Sjogren
P09171235A0851|76 92|COUP-TFI delta35
P09171235A0851|147 153|TRbeta
P09171235A0851|12 26|overexpression
P09171239A2146|54 58|acid
P09171239A2146|78 83|SRC-1
P09171239A2146|91 104|RXR component
P09171389A0549|155 167|Thermus PyrR
P09171389A0549|36 57|transcription signals
P09171389A0549|144 145|%
P09171389A0549|176 201|PyrR attenuation proteins
P09171389A0549|104 134|amino acid sequence identities
P09171389A0549|329 336|Thermus
P09171969A1165|140 155|training effect
P09171969A1165|173 177|COPD
P09171969A1165|37 40|VO2
P09171969A1165|74 92|work rate exercise
P09172414A0000|138 143|serum
P09172414A0000|65 71|method
P09172414A0000|59 63|HPLC
P09172812A0660|53 58|agent
P09172812A0660|62 65|CLL
P09174049A1788|98 108|cell lines
P09174049A1788|172 182|cell death
P09175858A1449|220 227|account
P09175858A1449|290 295|GAPDH
P09175858A1449|67 73|GAPDHs
P09175858A1449|11 21|B-S mutant
P09176837A0211|1 18|Computer software
P09176837A0211|71 76|PN Ca
P09176837A0211|77 89|P solubility
P09176837A0211|104 108|data
P09177857A0000|5 15|conditions
P09177857A0000|143 148|steel
P09177857A0000|94 100|oxygen
P09177857A0000|30 46|titanium dioxide
P09178491A0262|101 109|TATA box
P09178491A0262|37 63|preS2/S gene transcription
P09178752A0574|118 120|ER
P09178752A0574|1 4|EGF
P09178752A0574|83 110|transactivation domain AF-2
P09181130A1067|136 138|r5
P09181130A1067|21 28|Krox-20
P09181130A1067|43 56|recombination
P09181130A1067|60 68|ES cells
P09182281A0197|92 96|drug
P09182707A0254|84 87|FAK
P09182707A0254|143 152|adhesions
P09182707A0254|79 83|p125
P09182707A0254|28 52|tyrosine phosphorylation
P09183145T0001|157 167|infarction
P09183145T0001|124 135|angioplasty
P09185183A0089|84 99|motor abilities
P09185183A0089|36 41|years
P09185586A0000|17 22|mRNAs
P09185586A0000|44 61|scanning ribosome
P09186056A0514|17 31|overexpression
P09186056A0514|40 47|protein
P09186056A0514|123 131|E12/MyoD
P09186507A0882|152 156|TATA
P09186507A0882|54 62|sequence
P09186507A0882|332 336|gene
P09186507A0882|280 284|site
P09186507A0882|134 144|CpG island
P09187277A0118|153 160|neurons
P09187277A0118|1 5|Type
P09187277A0118|114 118|type
P09187277A0118|125 129|type
P09187637A1199|69 72|OP4
P09187637A1199|48 57|amplitude
P09188699A1388|118 131|SDS-PAGE gels
P09188699A1388|14 31|rat SP-A isoforms
P09189783A0000|217 225|exercise
P09189783A0000|6 19|investigation
P09189783A0000|208 212|rest
P09189783A0000|165 178|blood glucose
P09190202A0166|137 143|Sec13p
P09190202A0166|87 93|Sec24p
P09190202A0166|6 18|coat protein
P09190202A0166|42 64|Sec23p protein complex
P09190202A0166|164 171|protein
P09190940A0127|32 52|germline transcripts
P09190940A0127|96 109|recombination
P09192732A1384|127 131|part
P09192732A1384|46 55|homologue
P09192786T0000|68 70|Lu
P09192786T0000|49 54|basis
P09192786T0000|27 34|LU gene
P09192786T0000|74 98|blood group polymorphism
P09192998A0356|81 82|T
P09192998A0356|20 27|enzymes
P09192998A0356|93 100|rrnB T2
P09192998A0356|160 167|rrnB T1
P09192998A0356|73 79|T7 DNA
P09193077A0000|18 22|unit
P09193077A0000|128 131|CHS
P09193077A0000|26 30|LRU1
P09193671A0347|35 45|hydrolysis
P09193671A0347|79 86|ARF-GDP
P09195923A0125|254 259|hsp90
P09195923A0125|87 92|hsp90
P09195923A0125|206 218|immunophilin
P09195923A0125|39 44|FK506
P09195923A0125|127 130|TPR
P09195923A0125|132 138|domain
P09197342T0000|84 91|Oriodol
P09197342T0000|38 46|transfer
P09197342T0000|62 66|oils
P09199167A0942|1 15|Overexpression
P09199167A0942|33 39|growth
P09199167A0942|47 54|absence
P09199292A0536|68 81|cyclin E-cdk2
P09199292A0536|111 121|activities
P09199292A0536|131 138|kinases
P09199322T0000|1 13|Denaturation
P09199322T0000|77 99|replication protein A.
P09199322T0000|28 33|virus
P09199328T0000|69 74|Oct-1
P09199328T0000|16 24|residues
P09199328T0000|40 46|region
P09199353A1924|16 23|results
P09199353A1924|217 228|replication
P09199353A1924|80 99|chromatin structure
P09199353A1924|67 76|regulator
P09199353A1924|160 168|proteins
P09199626A0613|33 38|stage
P09199626A0613|7 12|cases
P09199970A1101|38 51|transmembrane
P09199970A1101|80 86|factor
P09199970A1101|198 201|MCP
P09200498T0000|19 38|muscle coactivation
P09200498T0000|9 14|zones
P09200811T0000|96 124|pGKL1-plasmid DNA polymerase
P09200811T0000|12 25|plasmid pDHL1
P09201980A0910|39 46|mammals
P09201980A0910|60 68|homology
P09202669A0614|154 173|neomycin resistance
P09202669A0614|99 128|herpes virus thymidine kinase
P09202669A0614|145 149|gene
P09202669A0614|63 74|integration
P09202859A0091|21 31|beta-human
P09202859A0091|97 101|PLAP
P09202859A0091|56 59|HCG
P09203586A1197|102 106|step
P09203586A1197|114 132|activation process
P09203586A1197|59 72|rRNA promoter
P09204566T0000|27 35|analysis
P09204566T0000|47 53|copies
P09205113A0587|98 114|selection marker
P09205113A0587|6 9|E14
P09205113A0587|11 16|TG3B1
P09205113A0587|29 41|ES cell line
P09205113A0587|60 72|mouse genome
P09205965A1249|71 86|bladder filling
P09205965A1249|42 53|micturition
P09205965A1249|134 146|transmission
P09206968A0000|16 28|regeneration
P09206968A0000|55 64|condition
P09206968A0000|82 88|damage
P09206968A0000|111 115|loss
P09206968A0000|123 131|function
P09208930T0000|87 98|enzyme gene
P09208930T0000|130 139|proteases
P09209312A0968|175 177|nt
P09209312A0968|55 57|nt
P09209312A0968|42 53|nucleotides
P09209312A0968|165 167|nt
P09209312A0968|104 111|complex
P09209406A1021|113 121|proteins
P09209406A1021|43 50|regions
P09210012A0000|5 11|impact
P09210012A0000|22 29|support
P09211354A0000|68 81|endopeptidase
P09211354A0000|1 14|Stromelysin-1
P09211354A0000|124 137|organ tissues
P09211675A0392|1 13|Surveillance
P09211675A0392|273 288|hospitalization
P09211675A0392|349 366|outpatient visits
P09211675A0392|133 147|blood pressure
P09211675A0392|85 96|assignments
P09211675A0392|18 30|preeclampsia
P09211675A0392|293 301|delivery
P09211675A0392|249 261|measurements
P09211934A0722|51 57|region
P09211934A0722|9 27|footprint analysis
P09212059A1356|82 86|PR-A
P09212059A1356|148 163|hLBD constructs
P09212063A0425|84 86|kb
P09212063A0425|96 99|DNA
P09212063A0425|45 58|cosmid clones
P09215525A0581|35 45|cell cycle
P09215525A0581|111 125|C2C12 myocytes
P09215525A0581|62 78|E2F/DP complexes
P09216017A0621|36 47|risk factor
P09218436A0443|98 111|transcription
P09218436A0443|6 15|promoters
P09218436A0443|57 68|MED-1 class
P09218436A0443|72 81|promoters
P09218520A0075|19 26|studies
P09218520A0075|110 112|cd
P09218775A0000|129 137|alginate
P09218775A0000|111 125|overproduction
P09218775A0000|94 103|phenotype
P09218775A0000|73 75|CF
P09219526A0383|97 114|peptide sequences
P09219526A0383|76 87|observation
P09219526A0383|41 55|cDNA construct
P09220177A0564|32 51|percentage increase
P09220177A0564|5 21|CPK-MB isoenzyme
P09220177A0564|78 79|%
P09220177A0564|107 108|h
P09222115A0545|1 8|Results
P09222115A0545|185 189|pups
P09222115A0545|216 225|isolation
P09222115A0545|158 181|response characteristic
P09222115A0545|72 78|factor
P09223122A0774|56 62|groups
P09223475A0898|184 188|RNAs
P09223475A0898|175 180|class
P09223475A0898|234 246|IE86 protein
P09223475A0898|140 144|HCMV
P09223475A0898|67 71|IE86
P09223475A0898|151 159|promoter
P09223506T0000|133 150|virus infectivity
P09223506T0000|60 87|immunodeficiency virus type
P09223667A0139|19 31|transfection
P09223667A0139|214 228|CTCCC sequence
P09223667A0139|63 88|gel mobility shift assays
P09223667A0139|105 117|binding site
P09224655T0000|138 144|ClC-6c
P09224655T0000|115 123|isoforms
P09224655T0000|77 88|transcripts
P09225151T0000|5 13|behavior
P09225151T0000|36 59|polytetrafluoroethylene
P09225151T0000|126 138|wall defects
P09225151T0000|61 65|PTFE
P09225682A0579|169 175|Fisher
P09225682A0579|5 14|frequency
P09225682A0579|97 100|PEN
P09225682A0579|104 112|isolates
P09225682A0579|211 219|isolates
P09225998A0000|1 37|NF-kappa B/Rel transcription factors
P09225998A0000|174 192|adhesion molecules
P09225998A0000|57 67|activation
P09225998A0000|105 128|regulation/inflammation
P09226345A0436|191 202|requirement
P09226345A0436|36 43|% group
P09226345A0436|111 112|p
P09226345A0436|180 181|%
P09227332A1798|102 109|effects
P09227332A1798|4 11|summary
P09227332A1798|25 34|receptors
P09227332A1798|72 81|receptors
P09227332A1798|13 16|DDC
P09228042A0109|259 264|steps
P09228042A0109|235 242|chelate
P09228042A0109|80 88|biglycan
P09228042A0109|197 211|gel permeation
P09228042A0109|111 121|extraction
P09228202A0581|69 76|KAE-393
P09228202A0581|140 167|5-HT4 receptor agonist/5-HT
P09228202A0581|128 138|benzamides
P09228202A0581|15 52|5-HT3 receptor antagonists ramosetron
P09228202A0581|54 59|YM060
P09228202A0581|95 106|ondansetron
P09228202A0581|62 67|YM114
P09229595A0618|5 20|corneal buttons
P09230216T0000|19 35|glycosylase maps
P09230216T0000|80 84|loss
P09230216T0000|39 59|chromosome 12q22-q24
P09230384A0725|84 86|TB
P09230384A0725|115 119|days
P09230384A0725|66 68|MB
P09230384A0725|10 15|times
P09230894A0422|23 30|KmMig1p
P09230986A0000|96 104|children
P09230986A0000|61 72|neutropenia
P09233487A1386|118 131|ear selection
P09233487A1386|142 151|Prom-EABR
P09233487A1386|107 114|benefit
P09233801A1180|69 92|TGF-beta responsiveness
P09233801A1180|32 49|kinase subdomains
P09233801A1180|11 23|L45 sequence
P09233809A0815|238 245|stomach
P09233809A0815|136 142|region
P09233809A0815|25 35|transgenes
P09233809A0815|228 236|pancreas
P09233809A0815|73 89|Hnf3g gene locus
P09234677A0770|137 148|respiration
P09234677A0770|51 62|transcripts
P09234677A0770|25 35|hypothesis
P09234696A0238|77 84|protein
P09234696A0238|91 98|kinases
P09234713A0754|65 68|PCR
P09234713A0754|83 92|formation
P09234713A0754|142 162|double-strand breaks
P09234713A0754|9 14|study
P09234713A0754|31 37|notion
P09234720A1015|169 172|MEK
P09234720A1015|115 126|H19-7 cells
P09234720A1015|128 140|coexpression
P09234720A1015|177 182|v-Src
P09234725A1892|38 53|transactivation
P09234725A1892|108 123|transrepression
P09234736A0999|87 94|pattern
P09234736A0999|114 122|drm mRNA
P09234736A0999|9 31|hybridization analysis
P09234736A0999|208 215|neurons
P09234736A0999|240 252|goblet cells
P09235073A0000|17 23|months
P09235073A0000|5 10|years
P09235073A0000|53 62|diagnosis
P09235618A0000|174 184|antibodies
P09235618A0000|196 208|IgM subtypes
P09235618A0000|85 100|demyelinization
P09235618A0000|257 269|thrombocytes
P09235618A0000|188 191|IgG
P09235618A0000|247 253|member
P09235618A0000|30 44|neuroinfection
P09235998A0788|36 41|alpha
P09235998A0788|92 110|17-ketocholesterol
P09235998A0788|13 32|membrane expression
P09236224A0939|152 167|differentiation
P09236224A0939|25 39|p21 expression
P09236224A0939|11 21|activation
P09236224A0939|75 82|feature
P09236656A0124|50 58|baseline
P09236656A0124|22 32|cell count
P09236656A0124|105 107|SD
P09237862A0782|100 106|nerves
P09237862A0782|114 118|iris
P09237862A0782|46 55|reduction
P09238850A0785|14 18|ICER
P09238860A0175|175 181|manner
P09238860A0175|37 42|cells
P09238860A0175|161 169|CREM tau
P09239635A0477|50 55|mg/ml
P09239635A0477|125 130|mg/ml
P09239635A0477|28 37|serum IgG
P09241232A0653|69 76|AP site
P09241232A0653|5 17|Ogg1 protein
P09241232A0653|40 50|DNA duplex
P09242375A1313|170 176|effect
P09242375A1313|139 147|capacity
P09242375A1313|42 57|mutations E768D
P09242375A1313|123 134|RET isoform
P09242375A1313|62 67|V804L
P09242506A1033|24 31|complex
P09242506A1033|75 86|DP proteins
P09243267A0401|1 8|METHODS
P09243267A0401|96 102|cavity
P09243267A0401|167 171|RPCI
P09243267A0401|47 56|diagnosis
P09243505A1194|170 177|complex
P09243505A1194|306 317|specificity
P09243505A1194|230 236|region
P09243505A1194|244 255|MADS domain
P09243505A1194|269 274|cases
P09243505A1194|30 41|experiments
P09243840A0663|43 54|week period
P09243840A0663|107 119|autopsy room
P09243840A0663|74 82|HLA-DQA1
P09244282A1371|87 97|insertions
P09244282A1371|113 128|pec-1 phenotype
P09244282A1371|56 64|presence
P09244430A0693|17 29|splice sites
P09244430A0693|64 70|beta-3
P09244430A0693|47 62|adducin isoform
P09246585T0000|32 43|cancer pain
P09248639A0152|35 46|fibroblasts
P09248639A0152|216 220|FPCL
P09248639A0152|6 18|cell strains
P09248639A0152|76 83|samples
P09248639A0152|176 186|fibroblast
P09249070A0989|1 5|Cell
P09250554A0402|1 9|Patients
P09250554A0402|43 45|mg
P09250554A0402|107 114|therapy
P09252397A0081|171 177|repair
P09252397A0081|115 123|JUN gene
P09252397A0081|77 98|nucleotide resolution
P09252397A0081|44 73|cyclobutane pyrimidine dimers
P09252397A0081|134 145|fibroblasts
P09252879A0470|86 103|methacholine PC20
P09252879A0470|52 60|features
P09252879A0470|105 110|PC20M
P09254709T0000|18 46|Bacillus subtilis catabolite
P09254709T0000|75 91|amyO target site
P09256973A0455|68 83|itraconazole/kg
P09256973A0455|5 7|E2
P09256973A0455|58 60|G2
P09256973A0455|14 17|cat
P09257651T0000|39 52|90kD proteins
P09257651T0000|126 131|Prp3p
P09258439A1001|68 74|SsEF-2
P09258439A1001|59 64|forms
P09258439A1001|120 124|gene
P09259052A0568|34 44|Fos family
P09259052A0568|155 170|c-jun AP-1 site
P09259052A0568|189 207|Jun family members
P09259052A0568|26 29|Jun
P09259052A0568|209 213|JunD
P09259052A0568|61 71|antibodies
P09259315A0809|1 9|Mutation
P09259315A0809|218 226|GC cells
P09259315A0809|82 90|enhancer
P09259315A0809|13 17|Enh4
P09259315A0809|60 67|context
P09259328A0440|171 178|regions
P09259328A0440|207 226|luciferase activity
P09259328A0440|78 86|activity
P09259328A0440|50 59|sequences
P09259328A0440|257 259|bp
P09259328A0440|127 129|bp
P09259328A0440|90 101|MSC-1 cells
P09261178T0000|5 10|mouse
P09261200T0001|1 11|MR imaging
P09261200T0001|45 60|FLAIR technique
P09263010T0000|1 10|Induction
P09263010T0000|82 92|regulation
P09263010T0000|14 30|B cell apoptosis
P09263856A0563|96 107|prothrombin
P09263856A0563|52 65|EGF-1 modules
P09263856A0563|44 47|Gla
P09263856A0563|75 77|PS
P09265534A0455|5 9|dose
P09265932A0575|38 49|bupivacaine
P09265932A0575|9 14|women
P09267431A0000|5 24|soybean cDNA clones
P09267431A0000|26 31|SPK-3
P09267542A0126|1 11|Naltrexone
P09267542A0126|96 114|alcohol dependence
P09267542A0126|46 50|Food
P09268387A0293|118 132|RNA polymerase
P09268387A0293|77 84|domains
P09268387A0293|62 65|ELL
P09268631A0316|5 13|position
P09268631A0316|56 62|status
P09268652A0116|102 107|dsRNA
P09268652A0116|42 51|dsRBP-ZFa
P09269879A0266|68 70|iv
P09269879A0266|81 101|elimination profiles
P09269879A0266|57 58|%
P09271393A1333|70 85|HTLV-1 promoter
P09271393A1333|185 195|remodeling
P09271393A1333|200 211|recruitment
P09271393A1333|227 250|transcription machinery
P09271397A1596|139 147|Sp1 site
P09271397A1596|22 27|model
P09271397A1596|209 216|fashion
P09271417A0585|84 94|adipocytes
P09271417A0585|96 103|tissues
P09271417A0585|67 72|heart
P09271417A0585|14 19|mouse
P09271496T0000|1 17|Mapping features
P09271496T0000|115 122|complex
P09271496T0000|126 145|photo-cross-linking
P09272108A1295b|87 91|TATA
P09272108A1295b|66 74|presence
P09272108A1295b|29 35|region
P09275159T0000|82 88|region
P09275990A0938|170 176|diesel
P09275990A0938|26 31|study
P09275990A0938|74 85|TA98 strain
P09275990A0938|45 57|mutagenicity
P09277472A1070|99 108|DC shocks
P09277472A1070|58 67|mechanism
P09278441A1777|1 15|Overexpression
P09278441A1777|95 115|factor transcription
P09278441A1777|61 71|troponin C
P09278450A1338|43 66|competition experiments
P09278450A1338|106 117|NF1 protein
P09278475A0465|88 101|Ino-phenotype
P09278475A0465|105 113|rpo26-31
P09278758A1636|80 88|evidence
P09278758A1636|213 220|failure
P09278758A1636|167 178|lymph nodes
P09278758A1636|132 138|spread
P09278758A1636|194 198|risk
P09280747A0195|85 93|survival
P09280747A0195|174 180|effect
P09280747A0195|5 16|combination
P09280747A0195|125 133|regimens
P09280747A0195|106 116|comparison
P09282911A0277|168 178|regulation
P09282911A0277|18 23|study
P09282911A0277|76 91|RC3/neurogranin
P09283828A0484|17 26|responses
P09285789A0712|158 170|repeat units
P09285789A0712|7 10|Duo
P09285789A0712|58 61|GEF
P09285789A0712|133 139|domain
P09286981A0147|1 5|ArgR
P09286981A0147|24 29|dimer
P09286981A0147|75 79|mass
P09287352A0930|235 236|%
P09287352A0930|96 106|activation
P09287352A0930|17 24|effects
P09287352A0930|156 166|expression
P09287352A0930|53 69|SHP-1 expression
P09287352A0930|212 215|MEK
P09287352A0930|177 180|Cys
P09288848A0780|19 31|HbO2 changes
P09290207A0731|53 69|mating type loci
P09290571A0799|33 34|n
P09290571A0799|40 43|VTs
P09290571A0799|60 64|msec
P09291098A0452|53 68|kb GGT mRNA V-2
P09291098A0452|29 40|kb mRNA V-1
P09291098A0452|90 98|splicing
P09292499A0887|112 116|HeLa
P09292499A0887|125 133|extracts
P09292499A0887|104 107|PTB
P09294139A0729|17 37|core homology region
P09294139A0729|49 63|HS12 enhancers
P09294139A0729|250 271|sequence conservation
P09294139A0729|189 197|function
P09294139A0729|212 220|enhancer
P09294139A0729|284 295|possibility
P09294161A1103|38 47|mechanism
P09294161A1103|59 70|recruitment
P09294161A1103|107 118|globin loci
P09294422A1223|84 93|formation
P09294422A1223|54 60|region
P09294422A1223|9 26|cysteine residues
P09294452A2107|21 29|operator
P09294471A1198|139 142|fit
P09294471A1198|159 163|data
P09294471A1198|9 19|Cox models
P09294471A1198|28 37|CD4 count
P09294471A1198|90 92|I0
P09297698A0933|49 61|UbCRBP mRNAs
P09297698A0933|7 18|transcripts
P09297698A0933|78 84|UbCRBP
P09300323A1182|65 73|ENDO/EPI
P09300323A1182|111 127|control stenosis
P09300323A1182|182 186|i.v.
P09300323A1182|151 154|ITF
P09300698A1219|4 11|support
P09300698A1219|126 134|peptides
P09301350A0946|237 245|capacity
P09301350A0946|98 119|% confidence interval
P09301350A0946|203 204|%
P09301350A0946|135 140|pg/ml
P09301350A0946|155 162|placebo
P09301350A0946|260 263|sex
P09301350A0946|333 358|mean treatment difference
P09301350A0946|182 197|expiratory flow
P09301350A0946|268 274|height
P09301350A0946|329 331|pp
P09303635A0000|69 73|lack
P09303635A0000|101 107|enzyme
P09303635A0000|11 18|disease
P09305592A0000|22 50|translocation characteristic
P09305592A0000|106 120|fusion protein
P09305755A0540|138 143|C/EBP
P09305755A0540|231 234|AP2
P09305755A0540|198 216|activator proteins
P09305755A0540|226 229|AP1
P09305755A0540|165 172|factors
P09305755A0540|83 86|Sp1
P09305755A0540|112 136|CAAT-box binding protein
P09305755A0540|182 186|HNF1
P09305944A0621|157 163|domain
P09305944A0621|232 246|GTP hydrolysis
P09305944A0621|130 138|sequence
P09307312A0172|1 9|Evidence
P09307312A0172|98 110|microphonics
P09307312A0172|276 280|data
P09307312A0172|24 30|shifts
P09307312A0172|165 170|cells
P09307312A0172|75 87|nerve fibers
P09308738A1216|142 150|decrease
P09308738A1216|124 126|MW
P09310836A1019|51 64|SV40 promoter
P09310836A1019|78 109|phorbol 12-myristate 13-acetate
P09310836A1019|12 19|repeats
P09311568A0595|5 24|cleavage dipeptides
P09311568A0595|58 59|A
P09311568A0595|28 46|C1YVV NIa protease
P09311808A0341|39 50|p4 molecule
P09311835A0147|39 55|characterization
P09311835A0147|63 73|T antigens
P09312025T0000|119 130|cell growth
P09312025T0000|1 23|Protein phosphatase 2A
P09312025T0000|95 99|SV40
P09312025T0000|135 155|NF-kappaB activation
P09312032A0165|7 14|introns
P09312032A0165|58 68|processing
P09312032A0165|108 114|snoRNA
P09313755A0816|36 50|risk variables
P09314487T0000|1 10|Detection
P09314487T0000|23 49|Mycobacterium tuberculosis
P09314554A0149|235 273|influenza A PR/8/34 nucleoprotein gene
P09314554A0149|159 171|presentation
P09314554A0149|42 53|translation
P09314554A0149|183 191|epitopes
P09315631A1064|68 74|yeasts
P09315631A1064|17 26|POR2 gene
P09315631A1064|1 9|Deletion
P09315631A1064|169 178|degrees C
P09315631A1064|80 89|deletions
P09315633A0333|99 106|factors
P09315633A0333|108 112|IRFs
P09315633A0333|13 32|amino acid sequence
P09315678A0278|207 216|shuttling
P09315678A0278|10 15|Cbf5p
P09315678A0278|135 142|Nopp140
P09317131A0000|1 3|Ig
P09317131A0000|66 79|transcription
P09317131A0000|47 56|cytokines
P09317757T0000|77 87|ENERGETICS
P09317757T0000|91 101|LOCOMOTION
P09321406T0000|5 31|pheromone response pathway
P09321406T0000|42 55|transcription
P09321930A0567|69 72|MCC
P09321930A0567|168 172|loss
P09321930A0567|198 202|loss
P09321930A0567|74 79|BRCA1
P09321930A0567|85 94|WAF1/CIP1
P09321930A0567|54 57|p53
P09321930A0567|59 62|DCC
P09321930A0567|126 137|frequencies
P09321930A0567|150 160|mechanisms
P09322872A0745|59 70|gancyclovir
P09322872A0745|106 119|recombination
P09322872A0745|44 53|selection
P09323366A0299|68 73|sites
P09323366A0299|117 129|derepression
P09323366A0299|29 48|MLS1 control region
P09324720A0317|55 61|Alzoon
P09324720A0317|40 51|tablespoons
P09324922T0065|1 21|Fermentation process
P09324922T0065|72 85|acid bacteria
P09325022A0192|68 73|study
P09325022A0192|82 85|C3H
P09325022A0192|27 32|group
P09325022A0192|132 138|microm
P09325022A0192|15 22|animals
P09325273A1240|204 222|protein substrates
P09325273A1240|7 14|results
P09325273A1240|344 369|ubiquitin fusion proteins
P09325273A1240|81 90|ubiquitin
P09325273A1240|261 270|ubiquitin
P09325273A1240|94 104|hydrolysis
P09325273A1240|242 252|production
P09325284A0469|77 93|progelatinase B.
P09325284A0469|41 53|acid protein
P09326163A0942|1 8|RESULTS
P09326163A0942|67 76|neoplasms
P09326163A0942|44 47|SMR
P09326263A0410|232 234|1A
P09326263A0410|109 117|placenta
P09326263A0410|226 230|exon
P09326263A0410|84 93|sequences
P09326263A0410|264 268|exon
P09326263A0410|182 187|exons
P09326727T0000|5 18|regurgitation
P09328341A1449|1 12|Attenuation
P09328341A1449|160 175|transactivation
P09328341A1449|75 86|DNA binding
P09328349A1679|127 139|trophoblasts
P09328349A1679|46 61|characteristics
P09328476A0374|16 27|kDa protein
P09328476A0374|81 102|splicing factor Prp3p
P09328833A0588|52 70|MCF-7 cDNA library
P09328833A0588|40 43|HET
P09331864A0230|171 178|control
P09331864A0230|273 283|Finaplix-H
P09331864A0230|230 236|mg TBA
P09331864A0230|318 321|MGA
P09331864A0230|253 262|Revalor-H
P09331864A0230|54 55|d
P09331864A0230|25 27|E2
P09331864A0230|215 224|Revalor-H
P09331864A0230|183 186|MGA
P09333018A0000|1 11|Interferon
P09333018A0000|23 29|Factor
P09333018A0000|31 34|IRF
P09333026A0851|34 44|expression
P09333026A0851|223 231|response
P09333026A0851|93 104|fibroblasts
P09333026A0851|245 258|growth factor
P09333026A0851|134 139|cells
P09333231T0018|22 29|species
P09334330A0252|6 15|mutations
P09334330A0252|281 288|tissues
P09334330A0252|47 52|genes
P09334330A0252|220 224|DPC4
P09334330A0252|19 24|daf-3
P09334330A0252|88 97|receptors
P09334475A0327|68 85|National Registry
P09334475A0327|313 314|h
P09334475A0327|42 50|patients
P09334475A0327|133 143|resolution
P09334475A0327|165 182|segment elevation
P09334475A0327|190 191|%
P09334475A0327|212 215|min
P09334475A0327|247 263|T wave inversion
P09334475A0327|241 242|h
P09335298A0529|55 82|plasmid partitioning system
P09335298A2129|16 21|basis
P09335298A2129|113 134|transformation assays
P09335298A2129|214 232|ParE toxin protein
P09335298A2129|72 79|killing
P09335619A0583|68 78|R1 plasmid
P09335619A0583|170 176|source
P09335619A0583|279 285|region
P09335619A0583|108 119|maize races
P09335619A0583|255 263|sequence
P09335619A0583|296 307|orf221 gene
P09335619A0583|146 156|M1 plasmid
P09335619A0583|211 215|atp9
P09337861T0000|1 8|Cloning
P09337861T0000|53 62|C2 domain
P09339900A0939|237 246|cyclin D2
P09339900A0939|169 172|Sp1
P09339900A0939|141 145|PEA3
P09339900A0939|134 139|C/EBP
P09339900A0939|223 233|expression
P09339900A0939|24 41|promoter activity
P09339900A0939|61 67|region
P09341139A0690|138 142|GRK2
P09341139A0690|113 127|overexpression
P09341139A0690|146 159|beta-arrestin
P09341139A0690|14 29|resensitization
P09341182A0605|96 108|PLZF-BTB/POZ
P09341193A0362|34 44|NGFI-A/Egr
P09341193A0362|70 91|transcription factors
P09341193A0362|25 28|Sp3
P09343210A1112|171 186|VCAM-1 promoter
P09343210A1112|338 355|adhesion molecule
P09343210A1112|142 145|Tax
P09343210A1112|244 264|VCAM-1 gene promoter
P09343210A1112|319 329|expression
P09343210A1112|14 22|deletion
P09343398A1193|1 13|Processivity
P09343398A1193|98 100|dA
P09343398A1193|110 112|dT
P09343398A1193|180 189|structure
P09343432A0209|87 98|amino acids
P09343432A0209|5 8|Scm
P09343432A0209|111 121|SPM domain
P09343432A0209|13 24|ph proteins
P09343433A0360|84 94|genes URA3
P09343433A0360|99 103|ADE2
P09343433A0360|30 39|silencing
P09344650A0967|18 38|transmembrane domain
P09344650A0967|53 61|Casr-rs3
P09345495A0000|1 23|PET activation studies
P09346621A1181|49 56|results
P09346621A1181|8 15|context
P09346621A1181|160 169|APACHE II
P09346621A1181|73 76|ELT
P09346935A0459|16 24|analysis
P09346935A0459|80 85|ZNF74
P09346935A0459|162 169|subunit
P09346935A0459|192 199|pol IIo
P09346938A1680|1 34|Ki-ras4BVal-12 transfectant cells
P09346938A1680|147 174|cathepsin B mRNA expression
P09348226A0852|16 19|EGF
P09348226A0852|77 82|c-cbl
P09348226A0852|29 36|insulin
P09349501A0196|118 127|MLL-LTG19
P09349501A0196|42 49|portion
P09349501A0196|146 152|nuclei
P09349501A0196|105 113|MLL-LTG9
P09351242A0719|222 238|ABA biosynthesis
P09351242A0719|246 269|aba1 Arabidopsis mutant
P09351242A0719|56 65|seedlings
P09351242A0719|132 146|ABA signalling
P09352016A1110|35 37|ml
P09352016A1110|9 23|AF G-CSF level
P09352016A1110|31 33|pg
P09353247A0922|154 170|over-replication
P09353247A0922|141 150|inhibitor
P09353296A0510|35 51|amino acid level
P09353296A0510|5 16|CNXA domain
P09353296A0510|132 144|moaC product
P09353296A0510|164 172|products
P09353328A0736|22 28|kinase
P09353328A0736|76 83|zippers
P09353343T0000|1 11|Modulation
P09353343T0000|71 91|ribonucleoprotein A1
P09354644A0124|7 19|biosynthesis
P09354644A0124|40 50|precursors
P09354644A0124|104 109|IGnT6
P09354684A1158|4 12|addition
P09354684A1158|14 22|mutation
P09356645A0672|69 78|procedure
P09356645A0672|18 25|patient
P09358055A0590|102 105|LTR
P09358055A0590|6 14|sequence
P09358055A0590|131 142|A-particles
P09358055A0590|63 79|promoter element
P09358837T0000|29 43|albumin levels
P09358837T0000|13 17|rise
P09359887A1168|39 52|Rat7p/Nup159p
P09359887A1168|124 133|sequences
P09360953A1057|17 23|Ile244
P09360953A1057|156 159|Leu
P09360953A1057|7 15|residues
P09360953A1057|132 136|loop
P09360953A1057|164 167|Ile
P09360993T0000|51 61|chromosome
P09360993T0000|65 71|family
P09360993T0000|133 143|mast cells
P09362105X0422|33 36|PVR
P09362105X0422|65 73|% O2/PVR
P09362105X0422|127 143|vasoconstriction
P09362105X0422|47 55|% O2-PVR
P09362480A0452|115 125|C-terminus
P09362480A0452|46 55|sequences
P09363759A0000|50 60|regulation
P09363759A0000|38 42|role
P09363759A0000|79 89|cell cycle
P09364440A2206|81 87|motifs
P09364440A2206|53 70|FSH receptor gene
P09364440A2206|122 131|effectors
P09365201A2018|50 66|characterization
P09365201A2018|7 14|studies
P09365201A2018|146 150|ASCs
P09365431A0314|21 32|combination
P09365431A0314|60 104|acetylcholinesterase inhibitor physostigmine
P09366517A0835|1 4|PKA
P09366517A0835|140 148|activity
P09366517A0835|20 23|WT1
P09366517A0835|27 34|Ser-365
P09366628T0000|33 42|causality
P09366628T0000|62 69|studies
P09367392A0567|138 150|accumulation
P09367392A0567|96 116|template recognition
P09367392A0567|43 54|nucleotides
P09367392A0567|31 39|sequence
P09367392A0567|75 78|end
P09367676A0275|1 27|Restriction enzyme mapping
P09367676A0275|200 203|DNA
P09367676A0275|125 130|exons
P09367676A0275|151 164|mouse TS mRNA
P09368006A1332|21 26|study
P09368006A1332|83 94|interaction
P09368006A1332|40 58|NF-kappaB activity
P09368006A1332|104 114|cell cycle
P09368026A0000|83 95|odontoblasts
P09368026A0000|67 78|osteoblasts
P09368026A0000|107 121|mineralization
P09368057A1083|49 61|SRF activity
P09368057A1083|20 28|proteins
P09368057A1083|179 190|SRF binding
P09368097T0000|5 8|pen
P09368190A1053|188 199|stimulation
P09368190A1053|77 96|DNA binding pattern
P09368190A1053|131 139|exposure
P09368190A1053|224 233|IFN-gamma
P09368419A0628|113 119|region
P09368419A0628|125 130|probe
P09368419A0628|31 50|DNA binding protein
P09369450A1358|136 146|HNF-1 site
P09369450A1358|155 158|GRE
P09369450A1358|23 30|effects
P09369450A1358|313 341|steroid receptor coactivator
P09369450A1358|284 307|transcription machinery
P09369453A0273|19 26|members
P09369453A0273|96 110|death enhancer
P09369453A0273|213 221|envelope
P09369453A0273|130 150|transmembrane domain
P09370276A0781|49 67|amino acid protein
P09370276A0781|31 33|bp
P09371431A1172|1 14|Strain CFN037
P09371431A1172|80 95|promoter region
P09371455A0000|50 63|lipase operon
P09371455A0000|126 144|Vibrio cholerae O1
P09371566A1384|155 162|protein
P09371566A1384|6 13|protein
P09371566A1384|92 112|protein preparations
P09371612A1964|1 5|Acad
P09371626A1345|100 106|domain
P09371626A1345|55 58|VP2
P09371626A1345|144 147|VP2
P09371626A1345|210 223|mRNA template
P09371626A1345|135 139|role
P09371626A1345|151 162|replication
P09371698A1254|1 13|Transfection
P09371698A1254|143 163|bp promoter fragment
P09371698A1254|27 40|SK-N-MC cells
P09371698A1254|91 100|fragments
P09372287A0296|137 141|MVST
P09372287A0296|190 195|axons
P09372287A0296|179 186|pathway
P09372287A0296|150 160|C1 segment
P09372908A1068|186 193|complex
P09372908A1068|197 201|PREs
P09372908A1068|149 158|inclusion
P09372908A1068|28 37|Sex Combs
P09372937T0000|18 53|information regulator Sir4p anchors
P09372937T0000|58 77|partitions plasmids
P09372960A0456|1 18|Polysome analyses
P09372960A0456|113 119|number
P09372960A0456|123 126|40S
P09372968A0996|17 21|HeLa
P09372968A0996|130 135|Dlc-1
P09373155T0000|1 15|Identification
P09373155T0000|19 25|dynein
P09373155T0000|93 105|localization
P09374082A0504|171 177|9alpha
P09374082A0504|143 157|prostaglandins
P09374082A0504|76 80|MEHP
P09374082A0504|229 234|lungs
P09374082A0504|14 23|mechanism
P09374082A0504|51 63|2-ethylhexyl
P09374082A0504|117 121|DEHP
P09374082A0504|334 340|asthma
P09374082A0504|27 40|effect states
P09374082A0504|209 221|thromboxanes
P09374541T0000|100 122|cell cycle progression
P09374541T0000|28 53|E2F recognition sequences
P09376626A0737|35 37|T4
P09376626A0737|87 88|h
P09376626A0737|42 44|T3
P09376626A0737|56 57|h
P09376626A0737|73 80|group A
P09376626A0737|61 68|group C
P09377355A0362|49 54|study
P09377355A0362|98 107|disorders
P09377355A0362|5 11|author
P09377355A0362|149 152|use
P09379301A2036|86 96|proglottis
P09379301A2036|5 12|microns
P09379301A2036|75 81|testes
P09380507A0514|33 36|E2F
P09380507A0514|129 163|DNA polymerase alpha gene promoter
P09380507A0514|28 31|GST
P09380707A0714|43 47|SMRT
P09380707A0714|122 126|dots
P09381950A0209|1 10|Ischaemia
P09381950A0209|32 41|flow rate
P09382850A0000|1 11|BACKGROUND
P09382850A0000|80 91|DNA lesions
P09382850A0000|13 32|Checkpoint pathways
P09382924A0131|233 241|subunits
P09382924A0131|78 87|IFN-gamma
P09382924A0131|133 137|LMP7
P09382924A0131|253 258|PSMB6
P09382924A0131|127 131|LMP2
P09382924A0131|271 276|PSMB7
P09383188A0654|81 82|O
P09383188A0654|6 16|difference
P09383188A0654|56 73|ARG box consensus
P09386074A0694|35 49|LV dysfunction
P09386074A0694|62 82|LV ejection fraction
P09387999A1053|70 86|hair cell losses
P09387999A1053|5 15|amplitudes
P09387999A1053|125 129|ears
P09388199A0948|139 157|DNA binding domain
P09388199A0948|55 66|DNA binding
P09388199A0948|37 41|FadR
P09388199A0948|111 126|protein fusions
P09388199A0948|26 33|domains
P09388201A1027|35 39|TATA
P09388201A1027|43 54|CAAT motifs
P09388271A1243|116 123|protein
P09388271A1243|37 45|proteins
P09388271A1243|160 173|kinase kinase
P09388271A1243|91 94|PKC
P09389198A0363|25 35|excitation
P09389198A0363|94 107|A delta units
P09389198A0363|166 175|threshold
P09389198A0363|60 65|nerve
P09389666A0538|96 108|mouse embryo
P09389666A0538|160 166|embryo
P09389666A0538|63 88|anteroposterior asymmetry
P09389666A0538|181 191|conversion
P09389982A1383|1 12|CONCLUSIONS
P09389982A1383|149 168|regression analysis
P09389982A1383|91 108|log reference INR
P09390183A1027|184 191|tissues
P09390183A1027|173 176|kDa
P09390183A1027|41 48|tissues
P09392979T0000|27 41|histoplasmosis
P09392979T0000|45 58|San Francisco
P09393717A1517|35 42|support
P09393717A1517|172 176|mutA
P09393717A1517|7 19|observations
P09393717A1517|61 71|expression
P09393875A0873|239 257|Fos protein levels
P09393875A0873|49 54|mRNAs
P09393875A0873|86 92|copies
P09393875A0873|267 281|papillomavirus
P09393875A0873|133 138|cells
P09394650A0121|17 22|study
P09394650A0121|5 8|aim
P09395470A0294|1 13|CKbeta4GT-II
P09395470A0294|39 43|type
P09395470A0294|47 73|transmembrane glycoprotein
P09396402A0264|86 88|HD
P09396402A0264|173 180|effects
P09396402A0264|142 153|sperm count
P09396402A0264|228 240|chemotherapy
P09396402A0264|14 21|METHODS
P09396437A0878|116 124|subjects
P09396437A0878|8 18|BMI cutoff
P09396437A0878|58 59|%
P09396796A1173|138 143|CDF-1
P09396796A1173|113 134|cell cycle regulation
P09396796A1173|37 42|CDF-1
P09396796A1173|148 151|E2F
P09397261A0940|50 56|course
P09398267A0440|1 23|Southern blot analysis
P09398267A0440|142 146|gene
P09398267A0440|166 173|species
P09398267A0440|120 124|MEK2
P09398598A0256|175 184|molecules
P09398598A0256|143 150|domains
P09398598A0256|94 106|CD4 fragment
P09400613A0594|171 174|PKR
P09400613A0594|41 45|Gal4
P09400613A0594|17 26|mouse PKR
P09400613A0594|254 288|PKR-Gal4 activation domain fusions
P09400613A0594|58 71|domain fusion
P09400613A0594|301 311|activation
P09400613A0594|181 191|K64E/K296R
P09400738A1046|72 84|instillation
P09400738A1046|30 38|response
P09402088A2250|18 23|doubt
P09402088A2250|7 14|defects
P09403059A0209|140 147|element
P09403059A0209|66 71|LINES
P09403059A0209|73 78|SINES
P09405195A0320|54 59|locus
P09405195A0320|173 188|intron excision
P09405195A0320|161 164|DNA
P09405195A0320|106 115|sequences
P09405195A0320|15 25|constructs
P09405536A0777|187 207|conditioning stimuli
P09405536A0777|156 167|application
P09405536A0777|242 251|responses
P09405536A0777|225 234|magnitude
P09407026A0426|275 284|templates
P09407026A0426|308 313|nuc-1
P09407026A0426|161 180|protein acetylation
P09407026A0426|50 73|enhancer factor binding
P09407026A0426|185 205|chromatin remodeling
P09407026A0426|294 304|remodeling
P09407026A0426|125 144|chromatin templates
P09407031A0974|38 42|Chk1
P09407031A0974|58 68|phenotypes
P09407090T0000|1 10|Structure
P09407090T0000|41 45|gene
P09408516T0000|1 10|Stability
P09408516T0000|40 58|dosage formulation
P09409416A0111|17 25|arteries
P09409416A0111|79 82|MHz
P09409416A0111|90 108|Doppler instrument
P09409821T0000|83 87|umuC
P09409821T0000|149 181|postreplication repair mechanism
P09409821T0000|44 53|homologue
P09412079T0001|1 13|Diet therapy
P09412079T0001|44 58|stomach ulcers
P09414074A0827|1 20|Resistance training
P09414074A0827|188 204|performance task
P09414074A0827|77 89|measurements
P09414074A0827|214 217|SSP
P09414319A1442|17 23|Surf-4
P09414319A1442|1 7|Y15170
P09414319A1442|42 48|Surf-1
P09414319A1442|26 32|Y15171
P09416467A0959|50 55|model
P09416467A0959|235 241|effect
P09416467A0959|82 93|arrhythmias
P09416467A0959|57 71|ACE inhibitors
P09416467A0959|104 124|ischemia-reperfusion
P09417082A0127|14 31|signaling cascade
P09417493A0823|4 14|accordance
P09417493A0823|142 158|prostaglandin E2
P09417493A0823|123 140|alpha 2-globuline
P09417493A0823|29 40|improvement
P09417928A0980|1 12|Replacement
P09417928A0980|98 105|fingers
P09417928A0980|57 59|+2
P09417928A0980|28 37|positions
P09418040T0000|1 13|Mg-chelatase
P09418040T0000|202 217|enzyme activity
P09418040T0000|46 65|Chl D cDNA sequence
P09418040T0000|17 24|tobacco
P09418040T0000|257 262|CHL H
P09418040T0000|83 90|subunit
P09418040T0000|92 100|analysis
P09418040T0000|180 194|reconstitution
P09418861A0623|17 26|structure
P09418861A0623|52 57|motif
P09418861A0623|78 94|protein kinase C
P09418905A1396|168 183|gene expression
P09418905A1396|202 212|activation
P09418905A1396|7 14|results
P09418905A1396|58 68|activation
P09418905A1396|150 163|S-phase entry
P09419421A0385|55 59|TKC1
P09419421A0385|92 99|plateau
P09419421A0385|107 114|S phase
P09420219A0284|136 155|beta-actin minigene
P09420219A0284|99 104|cells
P09420219A0284|315 318|Ad5
P09420219A0284|166 173|control
P09420219A0284|19 32|investigation
P09420219A0284|296 311|adenovirus type
P09420234A0654|1 10|MpB GroEL
P09420234A0654|25 44|sequence similarity
P09420234A0654|73 78|GroEL
P09420251A1363|1 3|C.
P09420269A0000|100 106|leader
P09420269A0000|8 11|end
P09420269A0000|108 117|ss-leader
P09420269A0000|289 297|promoter
P09420269A0000|250 252|SL
P09420269A0000|80 82|nt
P09420269A0000|147 156|structure
P09420269A0000|302 311|synthesis
P09420275A1111|32 36|CBF2
P09420275A1111|4 12|addition
P09420275A1111|63 68|LMP-2
P09421507A0000|65 82|pre-mRNA splicing
P09421507A0000|145 154|organisms
P09421511A0827|170 187|template sequence
P09421511A0827|154 162|position
P09421511A0827|70 96|RNA-polymerase specificity
P09421521T0000|1 28|Holliday junction resolvase
P09421521T0000|72 93|endonuclease activity
P09422727A0196|188 192|CREB
P09422727A0196|77 111|protein kinase A signaling pathway
P09422727A0196|265 272|process
P09422727A0196|148 158|activation
P09422727A0196|209 231|transcription factor-2
P09423310A0251|1 20|Histopathologically
P09423310A0251|203 212|reactions
P09423310A0251|228 233|cells
P09423310A0251|166 173|antigen
P09423310A0251|241 246|cysts
P09423968A0039|153 160|defense
P09423968A0039|295 299|rats
P09423968A0039|246 255|processes
P09423968A0039|215 222|defense
P09423968A0039|167 171|pain
P09423968A0039|75 86|interaction
P09425036A0649|4 12|addition
P09425036A0649|39 46|version
P09425036A0649|73 76|Lck
P09425676A0000|117 128|experiments
P09425676A0000|10 20|mechanisms
P09425676A0000|72 95|S-R compatibility tasks
P09426143A1358|304 316|target genes
P09426143A1358|143 153|mechanisms
P09426143A1358|172 183|competition
P09426143A1358|286 296|DNA region
P09426143A1358|105 123|pectinolysis genes
P09426143A1358|21 25|data
P09426143A1358|56 63|effects
P09426239A0386|69 77|addition
P09426239A0386|5 15|cglIM gene
P09426239A0386|43 49|operon
P09426907A0391|21 34|investigation
P09426907A0391|97 102|water
P09426907A0391|57 68|formulation
P09427544A0000|119 130|DNA library
P09427544A0000|5 13|pel gene
P09427544A0000|62 64|EC
P09427544A0000|90 98|activity
P09427627A0802|141 147|manner
P09427627A0802|83 91|mesoderm
P09427627A0802|109 117|explants
P09427627T0000|71 75|role
P09427627T0000|27 34|insulin
P09428389A1805|1 12|CONCLUSIONS
P09428389A1805|114 120|LHRH-A
P09428389A1805|97 102|agent
P09428389A1805|227 238|monotherapy
P09428389A1805|210 214|drug
P09428389A1805|134 152|serum testosterone
P09428799A0897|59 64|genes
P09428799A0897|166 173|P450scc
P09430461A0742|548 558|infarction
P09430461A0742|368 382|quantification
P09430461A0742|203 204|r
P09430461A0742|520 524|risk
P09430461A0742|104 112|infarcts
P09430461A0742|17 22|study
P09430461A0742|289 294|group
P09430461A0742|154 163|risk area
P09430461A0742|114 115|p
P09430461A0742|213 214|p
P09430461A0742|176 201|contrast ventriculography
P09430461A0742|333 346|BMIPP imaging
P09430668A0172a|70 76|sterol
P09430668A0172a|114 120|SREBPs
P09430668A0172a|56 61|sites
P09431812A0576|136 146|activation
P09431812A0576|98 103|level
P09431812A0576|42 45|Ptc
P09431812A0576|150 158|S2 cells
P09432752A0109|138 149|application
P09432752A0109|77 100|treatment possibilities
P09432752A0109|121 127|moment
P09434160A2078|48 52|CD34
P09434160A2078|106 116|stem cells
P09434979A0790|169 178|isocenter
P09434979A0790|156 157|%
P09434979A0790|5 12|results
P09434979A0790|113 123|collimator
P09434979A0790|160 161|%
P09435116A0437|1 8|Isomers
P09435116A0437|60 98|trofluoroacetyl-biphenylol derivatives
P09435806T0001|37 52|growth kinetics
P09435806T0001|109 113|time
P09435806T0001|72 90|cancer recurrences
P09436706A0168|152 163|stimulation
P09436706A0168|185 196|combination
P09436706A0168|212 251|gonadotrophin-releasing hormone agonist
P09436706A0168|135 142|mistake
P09436706A0168|90 101|spermatozoa
P09436989A1011|71 78|mitosis
P09436989A1011|54 62|function
P09436989A1011|12 20|addition
P09436989A1011|31 35|part
P09438165A0405|18 23|day-8
P09438165A0405|8 16|baseline
P09438165A0405|78 86|patients
P09438165A0405|123 126|day
P09438427T0000|102 112|Hoxa1 gene
P09438427T0000|52 58|somite
P09440616A0422|25 35|activities
P09441746A0546|3 13|cDNA clone
P09441746A0546|61 65|gene
P09442024A0236|5 11|Peyron
P09442031A0586|102 108|series
P09442031A0586|33 43|estimation
P09442031A0586|6 17|information
P09442031A0586|159 179|places cleavage Site
P09442031A0586|226 233|residue
P09442080A0856|50 56|source
P09442080A0856|185 188|GHR
P09442080A0856|201 216|domain residues
P09442080A0856|109 114|SHP-2
P09442080A0856|242 248|fusion
P09442080A0856|60 65|SHP-1
P09443948A0000|250 259|Argentina
P09443948A0000|232 246|trichinellosis
P09443948A0000|162 185|immunofluorescence test
P09443948A0000|77 86|technique
P09443948A0000|88 91|EIT
P09443973A1028|1 5|CES4
P09443973A1028|52 61|tif1-A79V
P09444316A0388|81 83|F0
P09444316A0388|109 112|sex
P09445488A0230|119 130|chromosomes
P09445488A0230|70 76|region
P09445488A0230|7 13|effort
P09445488A0230|146 157|combination
P09445488A0230|91 98|markers
P09446600A0260|138 144|manner
P09446600A0260|65 68|Ahr
P09446600A0260|91 100|cytoplasm
P09446815A1021|4 12|addition
P09446815A1021|73 75|bp
P09447962A0452|12 22|transcript
P09447963A0223|1 5|Sip1
P09447963A0223|99 105|family
P09447963A0223|73 88|splicing factor
P09447979A1430|65 78|sequestration
P09447979A1430|52 61|phenotype
P09448268A0186|85 89|gene
P09448268A0186|18 24|kinase
P09448268A0186|26 29|Nlk
P09449018T0000|49 57|drug use
P09451003A0894|51 58|protein
P09451003A0894|7 25|Esigma54 promoters
P09451003A0894|133 139|result
P09451003A0894|183 199|CRP-cAMP complex
P09451003A0894|44 47|CRP
P09451857T0001|1 14|Demonstration
P09451857T0001|83 98|creatine kinase
P09451857T0001|53 62|injection
P09452444A0000|1 14|Interleukin-6
P09452444A0000|111 126|phase reactions
P09452444A0000|132 145|hematopoiesis
P09453537A0863|101 118|recognition sites
P09453537A0863|6 12|region
P09453537A0863|60 70|complement
P09454719A0181|237 247|properties
P09454719A0181|39 50|transcripts
P09454719A0181|282 288|vector
P09454719A0181|61 78|LTR R/U5 junction
P09455695A0762|1 11|ALT levels
P09455695A0762|79 80|%
P09455695A0762|90 95|weeks
P09458021A1373|5 6|%
P09458021A1373|8 9|P
P09459241A0707|34 37|kPa
P09459241A0707|1 5|Pao2
P09459241A0707|89 94|mm Hg
P09459835A0297|81 86|FPMPA
P09459835A0297|6 10|cats
P09459835A0297|92 98|dosage
P09459835A0297|105 122|mg/kg body weight
P09461594A0000|103 106|EMF
P09461594A0000|32 40|exposure
P09461594A0000|217 247|inositol phospholipid turnover
P09461594A0000|161 182|phospholipase Cgamma2
P09461594A0000|73 79|energy
P09461594A0000|44 65|DT40 lymphoma B cells
P09463380A1050|57 78|mesoderm marker genes
P09463380A1050|90 95|Smad1
P09463964A0243|5 10|assay
P09463964A0243|131 137|mg l-1
P09463964A0243|47 61|micrograms l-1
P09464248A0289|13 21|TATA box
P09465035A1032|96 104|activity
P09465035A1032|89 94|alpha
P09465035A1032|61 69|fraction
P09466267A1192|39 42|IHF
P09466267A1192|97 117|dmsA-lacZ expression
P09467044A0973|17 42|breast tumor relapse rate
P09467044A0973|76 88|MGDET groups
P09467900A0701|205 215|EF-hand Ca
P09467900A0701|157 167|N-terminus
P09467900A0701|126 134|X domain
P09467900A0701|78 85|stretch
P09468386A0594|1 6|Pet-1
P09468386A0594|78 91|transcription
P09468386A0594|105 124|promoter constructs
P09468514A1065|76 86|expression
P09468514A1065|94 99|heart
P09469415A1337|273 280|beta 2m
P09469415A1337|55 62|peptide
P09469415A1337|188 201|CTL responses
P09469415A1337|232 241|injection
P09469415A1337|212 228|DNA immunization
P09469833A0533|68 84|deletion mutants
P09469833A0533|42 58|site specificity
P09469833A0533|61 64|set
P09471984A0000|86 104|contact dermatitis
P09471984A0000|60 67|ability
P09472608A0253|51 63|protein YB-1
P09472608A0253|97 111|HIV-1 promoter
P09472608A0253|145 151|U-87MG
P09472608A0253|27 34|ability
P09472608A0253|165 174|cell line
P09473040A1303a|55 84|siderophore system activities
P09473040A1303a|12 21|alcR gene
P09473317X2131|1 10|Copyright
P09473755A0318|48 52|June
P09473755A0318|31 38|January
P09474648A0298|17 24|P-SAECG
P09474648A0298|64 72|patients
P09474648A0298|41 57|frequency domain
P09475724T0000|1 5|TOR2
P09475724T0000|29 47|signaling pathways
P09476399A0141|50 55|Kandy
P09476399A0141|12 20|division
P09477316A0140|4 9|order
P09477316A0140|26 33|pathway
P09477316A0140|123 166|leucine zipper transcription factor MafB/Kr
P09478971A1896|154 178|mouse embryo fibroblasts
P09478971A1896|144 150|Cyp1B1
P09478971A1896|74 78|role
P09478976T0000|1 13|Oncostatin M
P09478976T0000|114 142|metalloproteinase-1 promoter
P09478976T0000|94 110|tissue inhibitor
P09480831A0272|103 109|region
P09480831A0272|113 120|AM gene
P09480831A0272|79 87|elements
P09480929T0000|103 111|proteins
P09480929T0000|48 58|production
P09480929T0000|29 35|domain
P09482107A0551|205 217|NIH3T3 cells
P09482107A0551|221 226|cells
P09482107A0551|175 187|growth rates
P09482107A0551|5 15|inhibition
P09482107A0551|244 258|plasmid vector
P09482107A0551|63 66|C3G
P09482902A0942|369 374|INK4a
P09482902A0942|36 39|p16
P09482902A0942|173 186|kinase assays
P09482902A0942|406 417|Pctr1 locus
P09482902A0942|46 51|A134C
P09482902A0942|155 169|cyclin D2/CDK4
P09482902A0942|365 368|p16
P09482902A0942|299 313|susceptibility
P09482902A0942|29 34|DBA/2
P09482902A0942|90 93|p16
P09484463T0000|1 8|Cloning
P09484463T0000|74 81|tobacco
P09484463T0000|60 68|proteins
P09485308A1165|52 59|subunit
P09485308A1165|29 35|3Fe-4S
P09486035A0051|1 8|METHODS
P09486035A0051|82 92|prevalence
P09486035A0051|133 140|Lebanon
P09486035A0051|120 129|blindness
P09486890A0234|42 55|inoperability
P09486890A0234|10 21|laparoscopy
P09486890A0234|63 68|cases
P09487590A0657|22 33|pain relief
P09488441A0615|275 280|Bcl-3
P09488441A0615|139 142|Sp1
P09488441A0615|40 54|immunoglobulin
P09488441A0615|152 171|P-selectin promoter
P09488441A0615|116 130|p50 homodimers
P09488441A0615|292 302|expression
P09488441A0615|183 199|site competition
P09488486A0000|155 158|III
P09488486A0000|5 9|TATA
P09488486A0000|126 137|polymerases
P09488486A0000|63 76|transcription
P09488491A0000|1 13|E2F activity
P09488491A0000|42 63|retinoblastoma family
P09488725A0904|33 41|identity
P09488725A0904|45 48|SFD
P09489670A1157|103 108|yeast
P09489670A1157|4 15|C. albicans
P09489670A1157|82 92|cell types
P09489670A1157|282 290|function
P09489670A1157|299 316|Hst6p transporter
P09490727A1041|39 47|triplets
P09490727A1041|125 134|apparatus
P09490727A1041|90 97|bundles
P09492038A0352|16 21|study
P09492038A0352|189 203|binding assays
P09492038A0352|107 111|exon
P09492038A0352|60 68|elements
P09495283A0000|18 31|reporter gene
P09495283A0000|43 53|expression
P09495283A0000|72 104|heat shock transcription factors
P09495283A0000|150 155|yeast
P09498553A0702|169 179|CYP51 gene
P09498553A0702|4 12|TATA box
P09498553A0702|188 197|existence
P09498553A0702|214 244|transcription initiation sites
P09498769A0095|50 51|B
P09498769A0095|5 23|expression pattern
P09498769A0095|163 170|B cells
P09498769A0095|123 133|activation
P09499048A1003|141 158|replication cycle
P09499048A1003|125 133|function
P09499254A1309|5 16|DSF regimen
P09499254A1309|57 65|patients
P09499254A1309|123 140|patient tolerance
P09499254A1309|45 53|activity
P09501169A0000|112 124|deacetylases
P09501169A0000|89 107|histone acetylases
P09502627A0705|1 8|RESULTS
P09502627A0705|71 96|wall motion abnormalities
P09502627A0705|277 281|LVEF
P09502627A0705|10 18|Patients
P09502627A0705|152 164|infarct area
P09502627A0705|22 29|Group A
P09502627A0705|219 220|p
P09502627A0705|331 339|Group B.
P09502720T0000|93 111|complex expression
P09502720T0000|72 79|element
P09503526A0614|18 25|myalgia
P09503526A0614|37 45|syndrome
P09503526A0614|125 133|patients
P09503526A0614|47 62|skin vasculitis
P09504514T0000|140 149|remission
P09504514T0000|162 169|MRC AML
P09504514T0000|12 22|comparison
P09504514T0000|151 158|results
P09504906A0099|152 157|Hap1p
P09504906A0099|1 9|Analysis
P09504906A0099|24 34|revertants
P09504906A0099|75 85|amino acid
P09505733A0246|86 93|factors
P09505733A0246|175 180|group
P09505733A0246|53 58|shows
P09505733A0246|13 20|studies
P09506959T0000|1 15|Identification
P09506959T0000|97 116|Myc/Max/Mad network
P09506959T0000|61 70|complexes
P09506983A0304|1 8|Primers
P09506983A0304|83 96|RACE products
P09507032A1144|102 107|cells
P09507032A1144|82 98|CSF-1 protection
P09507032A1144|60 68|CSF1R/IR
P09508377A0863|274 282|melanoma
P09508377A0863|101 117|eumelanin levels
P09508377A0863|249 253|risk
P09508377A0863|229 240|individuals
P09508377A0863|41 55|UV sensitivity
P09508775A0293|186 196|expression
P09508775A0293|173 178|level
P09508775A0293|133 139|growth
P09508775A0293|30 37|pathway
P09510189A0192|69 78|CD58 gene
P09510189A0192|36 48|organization
P09510582A0157|102 104|mg
P09510582A0157|142 145|HBB
P09510582A0157|24 32|patients
P09510582A0157|106 112|geG-25
P09510582A0157|47 51|DCBM
P09511724A0483|68 75|calcium
P09511724A0483|127 132|media
P09511724A0483|40 58|Dsg protein levels
P09511724A0483|104 111|calcium
P09512416A0460|16 27|information
P09512416A0460|206 214|features
P09512416A0460|233 246|7TM receptors
P09512416A0460|93 118|Arabidopsis thaliana gene
P09512416A0460|120 124|GCR1
P09512559T0000|101 106|yeast
P09512559T0000|44 88|nerve growth factor-luciferase reporter gene
P09514156A1147|16 21|DNase
P09514156A1147|154 162|promoter
P09514156A1147|54 68|element region
P09514156A1147|82 84|GC
P09514260A1083|171 187|protein families
P09514260A1083|138 144|origin
P09514260A1083|72 79|results
P09514260A1083|256 264|intein N
P09514260A1083|20 27|inteins
P09514260A1083|266 267|C
P09514260A1083|149 161|relationship
P09514962A0841|77 81|EL-4
P09514962A0841|28 35|protein
P09515032A1230|118 124|stages
P09515032A1230|169 174|stage
P09515858A0000|1 11|BACKGROUND
P09515858A0000|129 140|neutrophils
P09515858A0000|13 22|Defensins
P09515924A0104|87 91|U/mg
P09515924A0104|36 38|mg
P09515924A0104|95 102|protein
P09515924A0104|15 20|cells
P09516472A0292|35 43|elements
P09517989A0476|48 51|CMV
P09517989A0476|112 119|cells/l
P09517989A0476|79 88|CD4 count
P09518808T0000|1 23|National certification
P09518808T0000|46 63|quality assurance
P09519828A0809|138 163|E2 transactivation domain
P09519828A0809|11 28|VP16-E2 molecules
P09520398A0124|42 50|increase
P09520398A0124|89 102|core histones
P09521909A0081|103 119|stamen primordia
P09521909A0081|158 164|region
P09521909A0081|59 65|region
P09521909A0081|183 194|development
P09522297A0744|92 100|analysis
P09522297A0744|57 63|tumors
P09523478A0572|35 43|children
P09523478A0572|4 12|addition
P09523478A0572|14 17|IgM
P09524122A0336|16 22|allele
P09524122A0336|79 88|RAS genes
P09524122A0336|47 53|growth
P09524222A1113|138 143|cells
P09524222A1113|98 109|bone marrow
P09524222A1113|38 58|beta-adducin isoform
P09524222A1113|91 96|liver
P09524250A0767|15 23|elements
P09524267A1023|103 122|localization signal
P09524267A1023|48 55|domains
P09524267A1023|5 18|plant protein
P09524267A1023|213 240|RNA transcription apparatus
P09524267A1023|75 83|proteins
P09524276A0939|153 173|bacterium protection
P09524276A0939|115 119|OxyR
P09524276A0939|43 49|urease
P09524276A0939|75 78|NAC
P09525598A0325|1 11|Regulation
P09525598A0325|19 29|Raf kinase
P09525598A0325|81 91|cell lines
P09525598A0325|126 129|Raf
P09525598A0325|130 141|delta26-303
P09525891T0000|16 21|meis1
P09525891T0000|96 104|sequence
P09525891T0000|26 58|pbx homeodomain protein families
P09528758T0000|152 159|protein
P09528758T0000|70 76|embryo
P09528758T0000|127 139|octamer site
P09528758T0000|95 100|Oct-3
P09528758T0000|26 46|transcription factor
P09528768A0000|1 6|Cells
P09528768A0000|156 174|chaperone proteins
P09528768A0000|129 134|genes
P09528768A0000|47 55|proteins
P09528784A0000|5 9|mei4
P09528784A0000|11 15|gene
P09528858A0205|70 77|regions
P09528858A0205|89 100|suppression
P09528858A0205|104 117|gene activity
P09528987A1348|1 24|Cotransfection analyses
P09528987A1348|216 219|rat
P09528987A1348|230 251|T/EBP gene expression
P09528987A1348|165 179|autoregulation
P09529216A0644|1 14|Flap survival
P09529216A0644|53 59|number
P09529216A0644|148 155|vessels
P09529216A0644|30 41|development
P09529721A0000|274 284|assessment
P09529721A0000|168 180|malnutrition
P09529721A0000|128 138|management
P09529721A0000|314 323|follow-up
P09529721A0000|82 94|malnutrition
P09529721A0000|298 309|counselling
P09531538A0983|48 65|splicing activity
P09531538A0983|13 24|requirement
P09531559A1153|65 72|protein
P09531559A1153|10 27|affinity analyses
P09531559A1153|122 128|domain
P09533109A0449|100 114|administration
P09533109A0449|39 45|volume
P09533109A0449|24 36|theophylline
P09533109A0449|12 20|decrease
P09535579A1105|141 142|l
P09535579A1105|157 159|kJ
P09535579A1105|133 137|EPOC
P09535579A1105|107 125|energy expenditure
P09535835A0279|100 106|manner
P09535835A0279|23 28|mDia2
P09535835A0279|47 57|type forms
P09535892A0000|85 100|plasma membrane
P09535892A0000|200 207|Trp-Asp
P09535892A0000|66 73|signals
P09535892A0000|40 50|G proteins
P09535892A0000|209 216|repeats
P09536028A0945|184 215|signal pathway probe inhibitors
P09536028A0945|4 12|contrast
P09536028A0945|142 144|TF
P09536028A0945|149 152|EGF
P09536901A0362|69 71|T2
P09536901A0362|144 154|assessment
P09536901A0362|28 30|T1
P09536901A0362|120 128|relation
P09537295T0000|119 131|protein gene
P09537295T0000|98 101|rat
P09537295T0000|26 34|androgen
P09537295T0000|13 21|promoter
P09537375A0198|66 77|lacZ fusion
P09537375A0198|159 163|gntT
P09537375A0198|125 129|GntR
P09537651A0366|17 21|PEA3
P09537651A0366|190 193|PMA
P09537651A0366|10 15|sites
P09537651A0366|72 77|v-src
P09537651A0366|132 141|induction
P09538220A0000|200 206|genome
P09538220A0000|106 109|DNA
P09538220A0000|149 160|replication
P09538220A0000|135 145|regulation
P09538220A0000|30 36|region
P09539421A0970|54 63|silencing
P09539421A0970|129 135|themes
P09539421A0970|40 45|roles
P09539746A0781|1 11|Expression
P09539746A0781|36 47|association
P09539746A0781|15 21|Bcl-XL
P09540062A0755|116 123|ability
P09540062A0755|59 63|Site
P09540062A0755|31 38|ability
P09540062A0755|134 136|H4
P09541636T0000|1 24|Creatine kinase release
P09541636T0000|39 58|artery embolization
P09543227A0815|170 182|risk factors
P09543227A0815|21 26|years
P09543227A0815|110 122|risk factors
P09543227A0815|128 129|C
P09543227A0815|62 74|risk factors
P09544991A0483|1 13|PRL receptor
P09544991A0483|29 34|SHP-2
P09545146A0884|1 12|CONCLUSIONS
P09545146A0884|168 188|regression equations
P09545146A0884|67 76|estimates
P09545146A0884|107 119|comedication
P09545146A0884|91 99|CBZ Cl/F
P09545312A1197|99 112|transcription
P09545312A1197|178 189|interaction
P09545312A1197|77 81|role
P09545312A1197|31 38|members
P09545332A0137|35 38|Phe
P09545332A0137|112 116|IRS1
P09545332A0137|25 31|Tyr497
P09545332A0137|133 146|proliferation
P09545638A0330a|36 65|yeast hnRNP methyltransferase
P09545638A0836|77 103|methyltransferase activity
P09545638T0000|1 15|Identification
P09545638T0000|20 36|characterization
P09545638T0000|88 95|HRMT1L1
P09547311A1394|171 177|domain
P09547311A1394|279 286|domains
P09547311A1394|144 154|desmoglein
P09547311A1394|196 204|evidence
P09547311A1394|104 114|E-cadherin
P09548481A0000|119 134|IL-5Ralpha gene
P09548481A0000|96 104|promoter
P09548481A0000|43 51|promoter
P09549398A1463|117 159|rest/reinjection thallium-201 SPET studies
P09549398A1463|175 183|presence
P09549398A1463|9 18|agreement
P09549398A1463|215 216|%
P09549398A1463|94 113|rest/redistribution
P09549660A0782|23 32|data sets
P09550591A0454|138 152|blood pressure
P09550591A0454|53 68|airway pressure
P09550591A0454|95 99|days
P09550591A0454|121 129|decrease
P09551096A0108|100 107|factors
P09551096A0108|58 66|subunits
P09551938A0318|32 39|factors
P09552469A0225|102 104|IR
P09552469A0225|86 89|XRD
P09552469A0225|39 48|poloxamer
P09552469A0225|172 182|dispersion
P09552469A0225|25 34|piroxicam
P09552469A0225|211 218|mixture
P09553134A0596|108 111|PP1
P09553686A0000|305 309|days
P09553686A0000|33 42|estradiol
P09553686A0000|203 208|patch
P09553686A0000|160 171|application
P09553686A0000|73 76|CAS
P09553686A0000|221 227|matrix
P09553686A0000|331 339|patch 7D
P09553686A0000|181 190|estradiol
P09556566A0174|100 121|T cell line MT2 cells
P09556566A0174|55 75|acid Xalpha receptor
P09556566A0174|13 31|vitamin D receptor
P09556861A1018|38 48|mechanisms
P09556861A1018|142 153|respiration
P09556861A1018|77 79|OA
P09556861A1018|194 204|inhibition
P09556861A1018|114 124|inhibition
P09556861A1018|249 266|protein synthesis
P09557682A0490|168 177|DNA motif
P09557682A0490|38 42|beta
P09557682A0490|76 88|combinations
P09557682A0490|179 184|TRE2S
P09557682A0490|44 49|gamma
P09557682A0490|15 23|isoforms
P09557912A0699|304 306|SD
P09557912A0699|173 177|mmHg
P09557912A0699|197 218|muscle fasciculations
P09557912A0699|230 243|suxamethonium
P09557912A0699|79 81|SD
P09557912A0699|106 113|eyelash
P09557912A0699|327 337|resumption
P09557912A0699|184 193|cessation
P09557912A0699|48 57|induction
P09557912A0699|144 157|methohexitone
P09557912A0699|270 279|cessation
P09557912A0699|61 71|anesthesia
P09560325A1285|42 55|glycosylation
P09560325A1285|107 119|explanations
P09560430A0000|34 44|initiation
P09560430A0000|48 55|meiosis
P09560430A0000|59 66|a/alpha
P09561616A0142|171 176|mg/m2
P09561616A0142|49 56|surface
P09561616A0142|160 164|dose
P09561616A0142|121 126|weeks
P09562558T0000|101 107|family
P09562558T0000|61 69|subgroup
P09564860A2315|153 156|GGH
P09564860A2315|99 103|q/11
P09564860A2315|7 11|data
P09564860A2315|129 140|selectivity
P09564860A2315|244 262|Gs protein pathway
P09564860A2315|62 72|rat GnRH-R
P09565576T0000|34 54|DNA topoisomerase I.
P09565606A0520|87 94|rCGCC-3
P09565606A0520|96 104|sequence
P09565606A0520|59 63|repY
P09565606A0520|135 139|site
P09566871A0343|170 179|integrase
P09566871A0343|155 161|levels
P09566871A0343|22 28|levels
P09566871A0343|125 137|FUS3 strains
P09566871A0343|193 215|transcriptase proteins
P09566876A0000|87 90|TBP
P09566876A0000|39 44|TFIIA
P09566876A0000|13 37|transcription factor IIA
P09566918A1115|1 13|Substitution
P09566918A1115|157 166|promoters
P09566918A1115|178 189|PRDI-PRDIII
P09566918A1115|59 62|Asp
P09566918A1115|209 217|elements
P09568549A0188|101 107|routes
P09568549A0188|20 26|effect
P09568549A0188|144 153|histamine
P09568549A0188|111 115|mice
P09568549A0188|62 67|doses
P09570107A0355|33 36|ESP
P09570107A0355|12 29|PCDFs/PCDDs ratio
P09570944T0000|55 57|Mb
P09570944T0000|111 128|chromosome 7q21.1
P09570944T0000|31 41|YAC contig
P09571563A0000|87 90|PRK
P09571563A0000|26 40|image analysis
P09571563A0000|133 146|determination
P09571563A0000|150 157|changes
P09572491A1044|35 52|missense mutation
P09572491A1044|83 86|p53
P09572491A1044|124 131|glycine
P09572491A1044|60 68|p53 gene
P09572965A1235|116 126|regulation
P09572965A1235|9 12|ORF
P09572965A1235|26 34|homology
P09572965A1235|134 153|virulence phenotype
P09573187T0000|50 64|regulator CatR
P09573244A0523|53 79|polyadenylation site usage
P09573378A0761|17 18|D
P09573378A0761|99 102|RNA
P09573378A0761|62 77|complementarity
P09574799A1072|205 218|helminthiases
P09574799A1072|1 16|Echinostomiasis
P09574799A1072|64 71|poverty
P09574799A1072|243 253|conditions
P09574799A1072|73 85|malnutrition
P09575187A1558|21 30|NF-kappaB
P09575187A1558|163 172|apoptosis
P09575187A1558|123 132|sAPPalpha
P09575187A1558|195 211|kappaB decoy DNA
P09575187A1558|45 54|apoptosis
P09575217A0971|117 127|C terminus
P09575217A0971|101 109|deletion
P09575217A0971|89 93|Jak2
P09576915A0269|32 35|HMR
P09576915A0269|78 79|E
P09576915A0269|15 28|recombination
P09577395A0000|55 63|response
P09577395A0000|179 186|degrees
P09577395A0000|193 202|rotations
P09577395A0000|47 50|VOR
P09578570A0200|36 40|gene
P09578570A0200|162 171|isolation
P09578570A0200|9 14|study
P09578570A0200|123 140|PCR amplification
P09578570A0200|60 72|organization
P09579789A0974|190 198|controls
P09579789A0974|140 160|discrimination tasks
P09579789A0974|110 117|variety
P09579789A0974|121 135|odor detection
P09580062A0100|117 131|cyclosporine A
P09580062A0100|49 65|cyclophosphamide
P09580062A0100|7 15|patients
P09580700A0841|170 175|DNase
P09580700A0841|5 27|DNA binding activities
P09580700A0841|178 190|footprinting
P09580700A0841|146 152|region
P09580700A0841|104 108|CIRs
P09581775A0185|69 87|NF-kappaB activity
P09581775A0185|206 215|signaling
P09581775A0185|163 170|PLB-985
P09581775A0185|182 187|cells
P09581872A0000|23 37|cell structure
P09581872A0000|15 21|tissue
P09582306T0000|33 41|Galphai1
P09582306T0000|21 28|Galphao
P09582306T0000|79 107|G protein signaling proteins
P09582326A0151|18 20|E.
P09582331A0506|17 23|region
P09582331A0506|64 68|TATA
P09582331A0506|111 114|SP1
P09582331A0506|30 40|nucleotide
P09582350A0165|18 51|type IA maple syrup urine disease
P09582350A0165|111 113|E1
P09582350A0165|133 155|ketoacid dehydrogenase
P09582953A0000|1 11|OBJECTIVES
P09582953A0000|66 67|C
P09582953A0000|161 184|coagulation factors VII
P09582953A0000|73 94|C1-esterase inhibitor
P09582953A0000|48 57|coagulant
P09582953A0000|321 326|colic
P09582953A0000|261 281|acute-phase response
P09582953A0000|127 156|acute-phase reactant proteins
P09582953A0000|24 47|coagulation factor VIII
P09582953A0000|331 355|hemostasis abnormalities
P09582953A1670|51 57|C1-INH
P09582953A1670|5 9|data
P09582953A1670|23 34|plasminogen
P09583208A0171|21 36|creatine kinase
P09583208A0171|56 69|serum albumin
P09583823A0238|102 103|n
P09583823A0238|138 142|wall
P09583823A0238|193 198|laser
P09583823A0238|74 82|arteries
P09583823A0238|84 100|infarction group
P09583823A0238|185 187|Ho
P09583823A0238|113 117|TMLR
P09583823A0238|159 183|yttrium-aluminium garnet
P09583823A0238|24 28|pigs
P09584179A0673|1 18|Peptide sequences
P09584179A0673|26 49|zinc finger protein Ttk
P09584194A0000|65 81|docking proteins
P09584194A0000|22 29|Efs/Sin
P09584194A0000|128 138|regulation
P09584194A0000|12 15|Cas
P09585253A1147|168 175|pathway
P09585253A1147|5 9|data
P09585253A1147|77 90|TF expression
P09585253A1147|94 116|breast carcinoma cells
P09585253A1147|149 159|activation
P09586285A0551|27 57|H. influenza type b meningitis
P09587549T0001|79 90|hepatitis C
P09587549T0001|12 19|seizure
P09590294A0453|9 16|studies
P09590294A0453|47 61|identification
P09591221A0137|1 17|Control subjects
P09591221A0137|38 41|EPs
P09591221A0137|76 86|positivity
P09591221A0137|26 36|potentials
P09592168T0000|56 64|M98-F219
P09592168T0000|75 113|nucleotide excision repair protein XPA
P09592219A0652|59 71|intervention
P09594299A0468|1 8|RESULTS
P09594299A0468|147 158|dislocation
P09594299A0468|166 169|hip
P09594299A0468|105 109|year
P09596536A0219|66 81|ACL transection
P09596638T0000|72 83|Arabidopsis
P09596638T0000|13 20|mapping
P09598205A0430|68 80|beta-alanine
P09598205A0430|97 106|formation
P09598205A0430|25 40|monosaccharides
P09599102A1191|152 170|copper sensitivity
P09599102A1191|1 9|Analysis
P09599102A1191|79 81|Cu
P09599102A1191|132 147|CUP1 expression
P09599102A1191|61 71|repression
P09599724A0193|68 93|phenoxy herbicide workers
P09599724A0193|200 204|PCDD
P09599724A0193|131 135|PCDD
P09599724A0193|255 263|exposure
P09599724A0193|21 27|sample
P09599724A0193|158 170|blood lipids
P09599724A0193|58 64|cohort
P09601007A0223|32 36|data
P09601007A0223|196 207|respiration
P09601007A0223|12 21|community
P09601007A0223|73 90|CO2 concentration
P09601007A0223|180 194|photosynthesis
P09601516A0695|35 43|residues
P09601516A0695|156 174|surface expression
P09601516A0695|113 122|S protein
P09601516A0695|73 77|PEP1
P09601940A0280|119 127|NF-IL2-A
P09601940A0280|54 68|binding motifs
P09601940A0280|132 138|NF-IL6
P09603345A1257|1 8|GLRaV-2
P09603345A1257|21 34|closterovirus
P09603345A1257|176 182|member
P09603345A1257|88 99|type member
P09605137A0677|34 37|p65
P09605137A0677|162 174|Jurkat cells
P09605137A0677|10 20|expression
P09605137A0677|72 85|IL-2 promoter
P09605934A0801|50 65|binding element
P09605934A0801|138 144|family
P09605934A0801|6 20|E box sequence
P09605934A0801|148 169|transcription factors
P09606924T0000|137 166|matrix solid-phase dispersion
P09606924T0000|35 43|analysis
P09606924T0000|116 130|infant formula
P09606924T0000|47 79|all-rac-alpha-tocopheryl acetate
P09609705A0895|1 12|Examination
P09609705A0895|87 98|Shulmeister
P09609705A0895|83 85|L.
P09609705A0895|72 74|Z.
P09610755A1731|86 95|degrees/s
P09610755A1731|97 98|p
P09611229A1664|86 95|existence
P09611229A1664|5 12|ability
P09611229A1664|25 35|expression
P09611229A1664|147 166|expression/activity
P09611229A1664|107 127|transcription factor
P09611877A0455|16 24|isolates
P09611877A0455|28 31|CSF
P09611877A0455|75 79|ECHO
P09612775A0726|5 21|ParaSight-F test
P09612775A0726|75 84|treatment
P09613946A0194|64 79|HPLC separation
P09614106T0000|32 41|sequences
P09614106T0000|59 72|pair enhancer
P09614106T0000|12 20|mobility
P09617807A0929|139 146|element
P09617807A0929|230 236|plants
P09617807A0929|95 105|assessment
P09617807A0929|124 127|pea
P09618150A1464|100 108|presence
P09618150A1464|112 127|MEK-1 inhibitor
P09618150A1464|14 21|insulin
P09618475A0747|50 65|down-regulation
P09618475A0747|112 116|Nrd1
P09618475A0747|9 17|deletion
P09619631A0344|55 62|protein
P09619631A0344|24 39|C. elegans cDNA
P09620273A0189|17 27|Rb protein
P09620273A0189|130 155|E2F transcription factors
P09620273A0189|107 114|binding
P09620873A1710|86 95|pregnancy
P09620873A1710|157 175|PKC family members
P09620873A1710|15 26|observation
P09621062A0810|115 141|promoter function analysis
P09621062A0810|25 30|sites
P09621062A0810|91 102|mutagenesis
P09621893A0000|69 83|responsiveness
P09621893A0000|96 116|alpha2-adrenoceptors
P09622121A0525|52 55|PTB
P09622121A0525|10 20|antibodies
P09622121A0525|89 117|supershift RNA-PTB complexes
P09623830A0000|65 75|popularity
P09623830A0000|41 46|Botox
P09625807A0000|39 53|display method
P09625807A0000|77 82|mRNAs
P09627285A0160|1 8|SETTING
P09627285A0160|46 69|care infertility center
P09627598A0384|1 8|RESULTS
P09627598A0384|65 71|values
P09627598A0384|108 117|OVAR test
P09627598A0384|180 188|subjects
P09628419A0812|55 64|durations
P09628419A0812|79 83|ISIs
P09628890A0455|34 43|mutations
P09628890A0455|107 116|HA trimer
P09630245A0102|1 15|Yeast U1 snRNP
P09630245A0102|147 162|splicing events
P09630245A0102|63 74|counterpart
P09631366A0951|17 22|cycle
P09631366A0951|110 120|dose level
P09631366A0951|27 32|cases
P09632637A0361|205 209|CCl4
P09632637A0361|156 161|cells
P09632637A0361|9 14|study
P09632637A0361|63 84|M6P/IGFIIR expression
P09632637A0361|44 59|cell regulation
P09632734A0081|114 139|GDP/GTP exchange proteins
P09632734A0081|52 58|region
P09632734A0081|148 159|Rab3 family
P09632785A0000|98 104|factor
P09632785A0000|5 34|pre-mRNA splicing factor U2AF
P09632785A0000|36 38|U2
P09632785A0000|134 155|splice site selection
P09633274A0000|73 95|heart failure patients
P09633879A0246|138 143|years
P09633879A0246|113 120|veteran
P09633879A0246|58 79|serum ferritin levels
P09633879A0246|122 127|group
P09635276A1608|1 11|Regulation
P09635276A1608|63 83|subunit interactions
P09635276A1608|15 42|myosin phosphatase activity
P09636358A0000|172 181|infection
P09636358A0000|22 29|VAI RNA
P09636358A0000|160 165|times
P09636708A0460|119 126|protein
P09636708A0460|200 206|domain
P09636708A0460|142 161|amino acid residues
P09636708A0460|105 111|YccA11
P09638342T0000|22 24|L1
P09638342T0000|13 17|role
P09638650A0169|237 241|ORF3
P09638650A0169|169 173|ORF1
P09638650A0169|203 207|ORF2
P09638650A0169|315 318|NCR
P09638650A0169|47 58|nucleotides
P09638650A0169|153 167|RNA polymerase
P09638650A0169|86 90|ORFs
P09638650A0169|247 267|kDa movement protein
P09638650A0169|126 127|M
P09638650A0169|299 303|OFR5
P09638650A0169|28 34|region
P09639074A0707|1 4|Sp1
P09639074A0707|92 101|complexes
P09639558A0957|80 92|erythrocytes
P09639558A0957|56 59|IgG
P09640162A0242|70 79|treatment
P09640162A0242|161 163|yr
P09640162A0242|12 19|patient
P09641167A1359|1 11|CONCLUSION
P09641167A1359|43 51|IL-1beta
P09641167A1359|62 82|LDLr gene expression
P09642200A0956|48 52|size
P09642200A0956|217 225|membrane
P09642200A0956|78 100|M. thermoautotrophicum
P09642200A0956|268 274|lipids
P09642200A0956|105 118|M. jannaschii
P09642227A0000|1 13|Osteoadherin
P09642227A0000|67 82|keratan sulfate
P09642238A1285|51 57|GATA-1
P09642238A1285|110 121|COS-1 cells
P09642238A1285|79 106|transactivation experiments
P09642238A1285|14 29|enhancer region
P09642764A0469|118 124|thanks
P09642764A0469|64 82|Sauerbrey equation
P09642764A0469|218 222|mass
P09642764A0469|182 187|assay
P09642764A0469|164 168|case
P09643546A0436|1 25|Transcription initiation
P09643546A0436|82 90|promoter
P09645576A0148|1 4|RNA
P09645576A0148|39 47|patients
P09645576A0148|8 13|GBV-C
P09645961A1158|112 122|activation
P09645961A1158|42 50|CBF/NF-Y
P09645961A1158|31 38|binding
P09647240A0000|187 200|Val135 mutant
P09647240A0000|98 123|hepatoma Hep3B cell lines
P09647240A0000|44 71|Janus kinase-STAT signaling
P09649265A1575|50 60|ultrasound
P09649265A1575|163 178|biopsy strategy
P09649265A1575|230 241|examination
P09649265A1575|123 135|office visit
P09649265A1575|30 34|sets
P09649426A0636|49 55|strain
P09649426A0636|74 88|Msn4p activity
P09649438A0182|223 229|P-TEFb
P09649438A0182|86 94|cyclin T
P09649438A0182|157 160|Tat
P09649438A0182|172 186|Tat activation
P09649537A0000|43 71|yeast GCN2 eIF-2alpha kinase
P09649537A0000|13 24|cDNA clones
P09650186A1043|54 60|scheme
P09650186A1043|25 34|positives
P09650299A0000|1 6|VirD2
P09650299A0000|25 59|Agrobacterium tumefaciens proteins
P09650403A0868|5 17|DHEAS levels
P09650403A0868|25 31|stages
P09650403A0868|45 48|BMD
P09651321A0000|156 161|stage
P09651321A0000|109 122|keratinocytes
P09651321A0000|60 78|precursor proteins
P09651375T0000|34 39|RGS12
P09651375T0000|19 30|specificity
P09651375T0000|97 103|PSD-95
P09651375T0000|104 110|Dlg/ZO
P09652737A1244|119 130|progression
P09652737A1244|138 145|changes
P09652737A1244|219 223|AP-1
P09652737A1244|26 34|analysis
P09652737A1244|224 243|DNA binding complex
P09653182A1298|35 45|virus RNAs
P09653182A1298|112 125|transcription
P09653182A1298|145 151|plants
P09653648A0445|1 11|Comparison
P09653648A0445|32 41|sequences
P09653648A0445|131 136|exons
P09653648A0445|227 233|region
P09653648A0445|15 19|cDNA
P09655248A0000|154 160|uptake
P09655248A0000|25 32|protein
P09655248A0000|164 176|lipoproteins
P09656414A0220|16 21|cases
P09656414A0220|30 34|g/m2
P09657003T0000|202 206|RNAs
P09657003T0000|128 146|elm disease fungus
P09657003T0000|244 250|genome
P09657003T0000|148 168|Ophiostoma novo-ulmi
P09658122T0000|69 73|PC-1
P09658122T0000|117 133|nematode protein
P09658122T0000|95 102|homolog
P09658405A0000|81 87|orphan
P09658405A0000|96 116|receptor superfamily
P09658405A0000|26 33|protein
P09660823A0934|66 79|p70 S6 kinase
P09660838A0920|119 134|phosphorylation
P09660838A0920|1 11|Regulation
P09660838A0920|18 27|degrees C
P09660838A0920|53 59|action
P09660838A0920|106 110|HSF1
P09662339A0744|67 76|induction
P09662339A0744|10 15|cells
P09662339A0744|29 39|transition
P09663062A0175|1 23|Tensile bond strengths
P09663062A0175|203 211|students
P09663062A0175|128 152|Scotchbond Multi-Purpose
P09663062A0175|154 156|MP
P09663062A0175|158 173|bonding systems
P09663062A0175|59 65|dentin
P09663062A0175|121 123|LB
P09665361T0000|13 20|therapy
P09665720A0325|39 55|exonuclease site
P09665720A0325|8 15|absence
P09665720A0325|75 90|polymerase site
P09666103A0496|51 59|function
P09666103A0496|116 121|S269L
P09666103A0496|66 74|degreesC
P09666103A0496|22 27|P236S
P09666103A0496|43 47|loss
P09666103A0496|150 161|temperature
P09667482A0978|190 224|stress system disorder perspective
P09667482A0978|5 11|report
P09667482A0978|52 66|stress factors
P09667482A0978|132 139|results
P09668063A0274|137 152|Ets2 constructs
P09668063A0274|50 68|Ras transformation
P09668063A0274|172 178|NIH3T3
P09668063A0274|95 102|effects
P09668063A0274|180 182|DT
P09668098A0868|80 83|TPA
P09668098A0868|95 103|elements
P09668098A0868|167 191|transcription start site
P09668119A0496|69 84|protein binding
P09668119A0496|199 204|bases
P09668119A0496|225 232|CTCCT-3
P09670034A0340|21 26|Ddc1p
P09670034A0340|61 66|Mec3p
P09670943T0000|55 74|SHP-2-pp120 complex
P09670943T0000|97 126|Fc gamma RIIB1-BCR coligation
P09670943T0000|26 29|BCR
P09671464A0316|80 87|glucose
P09671464A0316|25 32|meiosis
P09671464A0316|120 127|meiosis
P09671576A0900|35 43|endoderm
P09671791T0000|51 73|growth factor receptor
P09671791T0000|161 168|L cells
P09671791T0000|149 157|activity
P09673436A0898|70 86|sodium excretion
P09673436A0898|233 243|hypocapnia
P09673436A0898|131 132|P
P09673436A0898|23 27|rats
P09673436A0898|57 66|increases
P09673436A0898|88 92|FENA
P09675896A0959|16 31|carboxyl region
P09675896A0959|65 75|activation
P09676419A0158|139 155|family histories
P09676419A0158|308 317|serum IgE
P09676419A0158|281 284|IgE
P09676419A0158|45 51|months
P09676419A0158|87 92|study
P09676419A0158|321 345|solid-phase immunoassays
P09676419A0158|24 32|children
P09676419A0158|209 218|allergens
P09677405A0856|79 90|mutagenesis
P09678579A0768|65 78|blot analysis
P09678579A0768|26 36|expression
P09679066A1352|101 110|pre-mRNAs
P09679066A1352|80 88|splicing
P09679066A1352|58 65|protein
P09680994A0169|118 123|basis
P09680994A0169|39 54|P. hybrida gene
P09680994A0169|97 104|protein
P09680994A0169|24 33|isolation
P09680994A0169|149 170|intron/exon structure
P09682897A0218|39 45|search
P09682897A0218|59 77|electrocardiograms
P09685021A0127|410 416|extent
P09685021A0127|169 175|microm
P09685021A0127|279 284|layer
P09685021A0127|472 482|attachment
P09685021A0127|350 356|cornea
P09685021A0127|195 212|surface roughness
P09685021A0127|327 333|pocket
P09685021A0127|127 146|membrane pore sizes
P09685021A0127|245 254|membranes
P09685021A0127|420 437|epithelialization
P09685346A0419|136 155|transfection assays
P09685346A0419|114 132|prolactin promoter
P09685346A0419|5 16|combination
P09685346A0419|59 64|Pit-1
P09686603A0124|127 135|promoter
P09686603A0124|148 167|germline expression
P09686603A0124|75 85|mechanisms
P09687511A1091|19 33|FUS expression
P09687511A1091|230 239|potential
P09687511A1091|56 68|32Dcl3 cells
P09687511A1091|89 100|suppression
P09688264A1029|6 15|repressor
P09688264A1029|107 122|rat hepatocytes
P09689919A1192|18 27|PEDF cDNA
P09691037A0355|70 79|N. crassa
P09691037A0355|59 66|strains
P09691037A0355|90 108|Neurospora species
P09693035T0000|21 44|serine/threonine kinase
P09693035T0000|7 11|ULK1
P09693035T0000|56 69|UNC-51 kinase
P09693306T0000|36 44|patients
P09693306T0000|61 72|schwannomas
P09694514A0000|184 193|responses
P09694514A0000|5 42|complement C3a anaphylatoxin receptor
P09694514A0000|297 308|eosinophils
P09694514A0000|228 238|mast cells
P09694514A0000|284 293|migration
P09694725A0500|68 75|element
P09694725A0500|84 99|oligonucleotide
P09694725A0500|141 145|site
P09694725A0500|12 18|assays
P09694869A0932|4 12|addition
P09694869A0932|97 111|overexpression
P09694869A0932|230 251|STAT response element
P09694869A0932|44 48|role
P09694869A0932|21 28|support
P09694869A0932|83 95|p21 promoter
P09694869A0932|52 57|STATs
P09695194T0000|33 44|proportions
P09695194T0000|8 18|comparison
P09696819A0450|184 191|complex
P09696819A0450|99 108|formation
P09696819A0450|125 134|reticulum
P09696819A0450|45 47|gE
P09698457A0976|186 202|target sequences
P09698457A0976|278 285|binding
P09698457A0976|96 115|tissue distribution
P09698457A0976|214 217|DNA
P09698457A0976|12 19|protein
P09700644T0000|32 51|brain abnormalities
P09700644T0000|93 103|correlates
P09701616A0108|50 56|RT-PCR
P09701616A0108|112 141|sand shrimp Metapenaeus ensis
P09701616A0108|78 86|eyestalk
P09701895A0119|39 50|months-3 yr
P09701895A0119|106 116|prevalence
P09701895A0119|132 139|anaemia
P09703213A0280|113 125|facilitation
P09703213A0280|72 82|depression
P09703816A0139|32 43|doxorubicin
P09703816A0139|108 122|iliac arteries
P09703816A0139|47 49|mg
P09704296T0000|35 42|purpura
P09704296T0000|76 92|immunoglobulin E
P09704296T0000|61 72|serum level
P09704857T0000|1 12|Correlation
P09704857T0000|61 69|patients
P09705258A0837|152 161|lacZ gene
P09705258A0837|5 21|IE13.1 cell line
P09705258A0837|59 64|virus
P09705324A1602|68 72|HNF1
P09705324A1602|380 385|OCT-1
P09705324A1602|128 140|rat Std gene
P09705324A1602|13 20|studies
P09705324A1602|194 202|presence
P09705324A1602|322 328|effect
P09705324A1602|217 222|OCT-1
P09705324A1602|364 376|interference
P09705324A1602|176 180|gene
P09705497A0227|65 100|methyl methanesulfonate sensitivity
P09705497A0227|5 20|yeast MMS2 gene
P09705497A0227|160 187|DNA post-replication repair
P09706565A1072|1 11|Anesthesia
P09706565A1072|72 83|atipamezole
P09707498A0262|1 22|MK-801 administration
P09707498A0262|46 54|response
P09708450A0648|139 146|regimen
P09708450A0648|33 39|period
P09708450A0648|108 115|control
P09710131A0374|6 13|methods
P09710131A0374|62 90|image intensifier tube modes
P09710589A1111|143 153|HTLV-1 LTR
P09710589A1111|77 81|V89A
P09710589A1111|47 53|domain
P09710589A1111|30 38|residues
P09710599A0310|34 39|CSF-1
P09710599A0310|141 151|expression
P09710599A0310|56 69|response gene
P09710599A0310|90 95|ets-2
P09710614T0000|34 42|sequence
P09710614T0000|50 53|CD2
P09710614T0000|86 96|regulation
P09710614T0000|145 170|phosphoinositide 3-kinase
P09710621A0598|103 127|Neu juxtamembrane domain
P09710621A0598|146 158|dimerization
P09710621A0598|177 190|interreceptor
P09710621A0598|63 69|series
P09712037A0470|238 243|ITAMs
P09712037A0470|54 57|Fyn
P09712037A0470|248 271|lymphocyte Ag receptors
P09712037A0470|189 203|immunoreceptor
P09712037A0470|79 94|lysine residues
P09712037A0470|62 71|integrity
P09712644T0000|84 93|promoters
P09712644T0000|110 118|elements
P09712898A0911|32 46|p38 activation
P09712898A0911|96 99|RIP
P09712898A0911|7 12|TRAF2
P09712915A0672|70 81|combination
P09712915A0672|143 147|NF-Y
P09712915A0672|29 37|promoter
P09712915A0672|134 137|Sp3
P09713584A1193|130 136|groups
P09713584A1193|90 100|BMI status
P09713996A0262|1 15|Overexpression
P09713996A0262|71 85|patient tumors
P09713996A0262|93 103|cell lines
P09713996A0262|120 127|variety
P09714109A0000|43 50|smoking
P09714109A0000|124 127|SNA
P09714109A0000|61 75|blood pressure
P09714835A0345|170 185|characteristics
P09714835A0345|201 211|duck gp180
P09714835A0345|232 236|L.D.
P09714835A0345|142 145|CPE
P09714835A0345|40 43|CPD
P09714835A0345|122 140|carboxypeptidase E
P09715278A1526|5 19|histopathology
P09715278A1526|108 128|FGF4 over-expressing
P09716095T0000|1 16|Pressure ulcers
P09716183A1036|1 4|TBP
P09716183A1036|200 206|domain
P09716183A1036|110 131|phosphorylation sites
P09716183A1036|181 184|TBP
P09717246A0526|117 122|day-1
P09717246A0526|76 90|rate constants
P09717246A0526|11 14|ILC
P09717246A0526|150 153|ILC
P09717887A0239|186 196|predictors
P09717887A0239|216 226|population
P09717887A0239|144 156|claudication
P09717887A0239|92 109|occlusive disease
P09717887A0239|13 18|study
P09718671A0000|17 29|Injury Scale
P09718671A0000|113 119|system
P09718671A0000|128 136|analysis
P09718671A0000|63 80|TRISS methodology
P09721207A0637|17 25|analysis
P09721207A0637|32 37|exons
P09721207A0637|124 138|vacillans gene
P09722043A2070|84 91|enzymes
P09722043A2070|42 50|increase
P09722508A0953|136 144|proteins
P09722508A0953|100 124|tyrosine phosphorylation
P09722508A0953|61 87|Src family kinase activity
P09723896A0000|1 11|Peroxisome
P09723896A0000|141 145|PPRE
P09723896A0000|213 216|RXR
P09723896A0000|198 211|acid receptor
P09723896A0000|61 74|transcription
P09724654A1120|33 39|S-CDKs
P09724654A1120|55 59|Mcms
P09724654A1120|44 53|Dbf4/Cdc7
P09724763T0000|115 118|DNA
P09724763T0000|73 85|substitution
P09724763T0000|15 27|substitution
P09725292A1473|1 11|CONCLUSION
P09725292A1473|81 86|liver
P09725854A1060|68 73|genes
P09725854A1060|217 223|orf107
P09725854A1060|20 30|similarity
P09725854A1060|95 106|differences
P09725854A1060|165 181|maintainer lines
P09726979T0000|11 18|cloning
P09726988A0275|1 7|Oleate
P09726988A0275|29 35|levels
P09727045A0817|102 106|HREs
P09727045A0817|158 171|AR N terminus
P09727045A0817|56 67|cooperation
P09727045A0817|11 20|mechanism
P09727046A0784|39 44|sites
P09727046A0784|82 88|GATA-1
P09727046A0784|63 73|regulators
P09729481A1177|1 16|Co-transfection
P09729481A1177|24 46|Sp1 expression plasmid
P09729481A1177|147 153|kinase
P09729481A1177|94 109|Schneider cells
P09729481A1177|210 214|site
P09731354A0963|84 91|maximum
P09731354A0963|98 100|hr
P09731354A0963|63 73|NH2 groups
P09731704A0000|101 109|estrogen
P09731704A0000|143 167|U2-OS osteosarcoma cells
P09731704A0000|37 44|effects
P09731704A0000|124 139|gene activation
P09731704A0000|90 97|isoform
P09731705A2126|1 8|Studies
P09731705A2126|81 90|formation
P09731705A2126|96 102|VDR-TR
P09733647A1960|16 51|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
P09733647A1960|116 125|organisms
P09733647A1960|6 14|sequence
P09733647A1960|59 63|part
P09733647A1960|105 112|variety
P09733815T0000|97 107|regulation
P09733815T0000|124 137|virus latency
P09734808A0000|187 193|phases
P09734808A0000|158 165|stimuli
P09734808A0000|148 154|number
P09735366A1180|186 190|mice
P09735366A1180|85 89|Epc1
P09735366A1180|52 67|mouse homologue
P09735366A1180|93 106|yeast protein
P09735366A1180|73 75|Pc
P09735366A1180|120 124|EPL1
P09735371A0227|174 189|differentiation
P09735371A0227|197 208|touch cells
P09735371A0227|77 87|production
P09736697A0783|69 73|ERKs
P09736697A0783|96 100|ERK2
P09736697A0783|110 114|JNK1
P09736697A0783|78 92|overexpression
P09736715A0729|184 187|ILK
P09736715A0729|83 91|activity
P09736715A0729|126 134|membrane
P09736715A0729|41 54|trisphosphate
P09736715A0729|14 34|phosphatidylinositol
P09737453A0557|49 51|SD
P09737453A0557|191 196|assay
P09737453A0557|93 100|complex
P09737453A0557|198 203|ELISA
P09738010A0305|38 45|insulin
P09738010A0305|67 92|insulin response sequence
P09738010A0305|107 118|E-box motif
P09738693T0000|1 8|Effects
P09738693T0000|23 43|neutrophil functions
P09738693T0000|60 66|sepsis
P09739913A0194|39 50|skin defect
P09741783A0000|102 109|acetate
P09741783A0000|1 12|Anastrozole
P09741783A0000|26 45|aromatase inhibitor
P09743128A0969|1 8|Moritta
P09743720A0268|16 20|dogs
P09743720A0268|47 49|DM
P09745797A0943|115 121|impact
P09745797A0943|46 50|pain
P09747873T0000|20 41|adapter protein GRB10
P09748286A0000|84 99|factor receptor
P09748286A0000|64 72|leukemia
P09748286A0000|167 180|pair enhancer
P09748286A0000|194 205|nucleotides
P09748669A0414|34 43|dichotomy
P09748669A0414|59 62|VaD
P09749988A0000|1 8|Badcock
P09749988A0000|131 140|repulsion
P09749988A0000|167 174|results
P09749988A0000|47 51|3-11
P09749988A0000|284 291|contour
P09749988A0000|116 126|attraction
P09749988A0000|147 152|study
P09750540A0000|69 77|symptoms
P09750540A0000|110 127|chemical exposure
P09750540A0000|10 30|chemical sensitivity
P09751114A0967|22 26|MyoD
P09751114A0967|63 65|E1
P09751166A1460|19 26|results
P09751166A1460|52 60|Sp1 site
P09751166A1460|90 106|TH transcription
P09753241A0524|169 173|week
P09753241A0524|55 58|WBC
P09753241A0524|43 53|blood cell
P09753241A0524|176 187|% DSS model
P09753241A0524|108 111|MPO
P09753241A0524|12 24|examinations
P09753769A0362|5 12|primers
P09753769A0362|29 33|sets
P09753774A2246|102 135|plant fructosyl transferase genes
P09753774A2246|76 81|1-fft
P09753774A2246|198 219|plant invertase genes
P09753774A2246|14 24|comparison
P09754571A0169|146 156|cell lines
P09754571A0169|10 20|transcript
P09755191A0553|101 107|chc1-5
P09755191A0553|22 28|swa5-1
P09755191A0553|126 145|frameshift mutation
P09755191A0553|74 82|clathrin
P09755199A0559|68 78|mbt repeat
P09755199A0559|33 46|Scm mutations
P09755199A0559|94 107|PcG mutations
P09756687A0981|81 95|rate constants
P09756687A0981|147 153|values
P09757012A0942|17 20|PDZ
P09757012A0942|96 103|adaptor
P09757012A0942|145 172|signal transduction pathway
P09757012A0942|44 55|KS5 protein
P09759691A1051|206 208|SD
P09759691A1051|368 378|nonsmokers
P09759691A1051|39 48|variables
P09759691A1051|433 448|body mass index
P09759691A1051|284 289|mg/dL
P09759691A1051|18 25|control
P09759691A1051|219 233|blood pressure
P09759691A1051|298 322|plasma cholesterol level
P09759691A1051|420 425|kg/m2
P09759691A1051|269 277|1.0-mmol
P09760243A0970|1 16|Cotransfections
P09760243A0970|22 27|ATF-2
P09761711A0000|1 21|Pseudocontact shifts
P09761711A0000|140 148|presence
P09761711A0000|161 186|susceptibility anisotropy
P09761711A0000|63 70|average
P09761791A0489|20 26|U1-70K
P09761791A0489|36 48|SRZ proteins
P09763446A0000|22 36|Ypt/Rab family
P09763446A0000|57 67|regulation
P09763470A0000|160 180|neuroendocrine cells
P09763470A0000|73 86|noradrenaline
P09763470A0000|28 31|DBH
P09763522A2545|137 144|studies
P09763522A2545|19 27|antibody
P09763522A2545|36 43|N-SMase
P09763522A2545|148 157|apoptosis
P09764741A0092|128 133|basis
P09764741A0092|57 80|cell division machinery
P09764741A0092|107 113|hearts
P09765271A1108|200 225|tyrosine aminotransferase
P09765271A1108|266 273|protein
P09765271A1108|88 94|region
P09765271A1108|104 109|genes
P09765285A0998|103 108|AaUSP
P09765285A0998|97 102|AaEcR
P09765285A0998|226 233|IRper-5
P09765285A0998|86 93|binding
P09765285A0998|23 32|half-site
P09765285A0998|215 222|IRper-0
P09765285A0998|183 208|spacer length requirement
P09765372A0669|101 109|papillae
P09765372A0669|113 127|dorsal surface
P09765372A0669|93 97|type
P09765372A0669|10 17|density
P09765394A0000|18 42|virus transactivator Zta
P09765394A0000|58 73|gene expression
P09765394A0000|120 126|origin
P09765411A0991|101 107|genome
P09765411A0991|190 223|structure NH2-ubiquitin-S27a-COOH
P09765411A0991|78 87|sequences
P09765411A0991|150 154|mRNA
P09765754A1727|26 33|studies
P09765754A1727|44 47|PVI
P09767575A0657|54 65|SD sequence
P09767575A0657|142 148|domain
P09767575A0657|132 138|region
P09767687T0000|53 70|Chlamydophyceaeas
P09767687T0000|95 103|18S rDNA
P09767687T0000|30 41|Phacotaceae
P09769910A1700|20 26|injury
P09769910A1700|59 62|TNF
P09769910A1700|89 98|cytokines
P09770378A0641|1 12|EGFR levels
P09770493A0499|175 191|postimplantation
P09770493A0499|36 45|functions
P09770493A0499|144 151|embryos
P09770493A0499|210 213|day
P09771555A0499|57 62|rhein
P09771985A0238|18 25|repatch
P09771985A0238|113 123|L-cysteine
P09771985A0238|59 65|EtHgCl
P09771985A0238|95 101|EtHgCl
P09773981A0415b|110 119|induction
P09773981A0415b|60 65|Stat5
P09774444A0351|34 38|UKLF
P09774444A0351|54 66|zinc fingers
P09774444A0351|166 190|Sp1 recognition sequence
P09774444A0351|134 154|beta-globin promoter
P09774484T0000|32 42|efficiency
P09774484T0000|46 74|selenocysteine incorporation
P09774662A0958|117 126|RNA level
P09774662A0958|60 75|E2F1 expression
P09776360A0620|24 40|binding activity
P09777477A0000|137 140|air
P09777477A0000|1 10|Observers
P09777477A0000|33 53|control participants
P09777477A0000|144 147|air
P09777999A0796|1 8|RESULTS
P09777999A0796|110 111|%
P09777999A0796|77 87|hypocapnia
P09777999A0796|63 75|PaCO2 levels
P09778068A1129|68 69|%
P09778068A1129|71 79|presence
P09778068A1129|129 137|ablation
P09778068A1129|179 190|performance
P09778068A1129|47 58|baseline EF
P09778068A1129|241 251|predictors
P09778197A0415|232 242|coenzyme A
P09778197A0415|133 138|costs
P09778197A0415|285 290|costs
P09778197A0415|49 54|means
P09778197A0415|157 164|therapy
P09778197A0415|266 273|statins
P09778197A0415|181 188|therapy
P09780228A0122|23 34|DNA segment
P09780336A0771|220 248|messenger ribonucleoproteins
P09780336A0771|158 174|round spermatids
P09780336A0771|178 187|cell type
P09780336A0771|89 100|populations
P09780336A0771|13 33|Msy2 mRNA expression
P09781871A0404|1 19|Glycogen synthesis
P09781871A0404|340 358|Erwinia carotovora
P09781871A0404|36 51|gluconeogenesis
P09781871A0404|130 134|csrA
P09781871A0404|75 98|cell surface properties
P09781871A0404|53 63|glycolysis
P09781871A0404|332 336|rsmA
P09781871A0404|303 314|metabolites
P09784063A0621|1 18|Deletion analysis
P09784063A0621|126 137|nucleotides
P09784063A0621|47 53|domain
P09784245T0000|83 121|protein kinase C phosphorylation sites
P09784245T0000|62 78|protein kinase A
P09786197A0322|68 88|transposon insertion
P09786197A0322|1 9|Analysis
P09786197A0322|145 149|csrS
P09786197A0322|167 186|sequence similarity
P09786926A0095|255 258|rat
P09786926A0095|263 268|cells
P09786926A0095|114 128|overexpression
P09786926A0095|42 70|fatty-acid synthase promoter
P09786926A0095|28 34|region
P09786932A1042|168 173|IRF-7
P09786932A1042|217 237|IFNA gene expression
P09786932A1042|112 117|cells
P09786932A1042|94 99|IRF-7
P09786932A1042|123 132|cell type
P09786932A1042|194 198|role
P09787323A0000|1 8|PURPOSE
P09787323A0000|47 56|treatment
P09789025A0149|1 8|Galphaq
P09789025A0149|24 32|Galpha13
P09789025A0149|72 76|RhoA
P09790499A0545|119 124|index
P09790499A0545|38 54|hBub1 mRNA level
P09790499A0545|93 98|cells
P09790768A0621|80 92|liver testis
P09790768A0621|73 78|brain
P09790771A1032|87 92|locus
P09790771A1032|59 63|Gng3
P09792439T0000|1 11|Inhibition
P09792439T0000|67 83|hnRNP C1 protein
P09792630A1127|68 70|+1
P09792630A1127|38 67|transcription start site CTCA
P09792630A1127|128 138|nucleoside
P09792630A1127|119 120|N
P09792630A1127|217 223|number
P09792630A1127|95 109|consensus CTCA
P09792630A1127|183 210|deoxynucleotidyltransferase
P09792702A0754|1 11|Expression
P09792702A0754|94 109|JNK1 activation
P09792702A0754|45 49|JNK1
P09794414T0000|53 70|DRA transcription
P09795130A0742|84 106|translation efficiency
P09795130A0742|74 80|effect
P09795213A0129|343 348|TFIID
P09795213A0129|32 40|hTAFII68
P09795213A0129|173 175|Y.
P09795213A0129|315 318|EWS
P09795213A0129|78 85|protein
P09795213A0129|135 150|TFIID complexes
P09795213A0129|105 108|TAF
P09795213A0129|255 262|protein
P09795213A0129|184 188|D.J.
P09795213A0129|353 367|RNA polymerase
P09795213A0129|177 182|Heard
P09795213A0129|268 276|homology
P09797189A0559|14 28|shift analysis
P09797456A0883|71 77|levels
P09797456A0883|41 46|cells
P09797456A0883|165 170|cells
P09797456A0883|105 110|cells
P09798100A0705|4 7|Day
P09798100A0705|42 65|micrograms cloprostenol
P09799086A0725|137 139|Gs
P09799086A0725|49 56|patient
P09799086A0725|200 211|LN patients
P09799086A0725|123 129|repeat
P09799362A0507|101 120|Zinc Finger protein
P09799362A0507|66 83|abbreviation AZF1
P09799634A0161|21 35|computer model
P09799634A0161|131 135|UmuD
P09799634A0161|72 81|repressor
P09800187A0100|251 256|Trp53
P09800187A0100|65 68|Tk1
P09800187A0100|145 153|exposure
P09800187A0100|9 14|Trp53
P09800187A0100|72 82|chromosome
P09801333A0174|17 23|N gene
P09801333A0174|99 103|PA-8
P09802902A0225|103 127|ARF6 nucleotide exchange
P09802902A0225|31 35|ARNO
P09804779A0000|60 75|protein kinases
P09804836A0000|309 317|pressure
P09804836A0000|203 211|fraction
P09804836A0000|129 156|colony stimulating factor-1
P09804836A0000|287 289|C4
P09804836A0000|224 225|P
P09804836A0000|252 281|size exclusion chromatography
P09804836A0000|158 163|CSF-1
P09805977A0143|87 97|sperm fall
P09805977A0143|158 163|class
P09805977A0143|167 177|substances
P09806516A1689|1 11|CONCLUSION
P09806516A1689|174 182|excision
P09806516A1689|112 118|Postop
P09806516A1689|122 130|patients
P09806826A0244|59 68|mouse Chr
P09806826A0244|104 107|Chr
P09806826A0244|31 37|defect
P09806830X1174|1 10|Copyright
P09806858T0000|69 78|rnaI gene
P09806858T0000|25 29|gene
P09807755A0146|53 62|viability
P09808216A0000|1 11|BACKGROUND
P09808216A0000|65 67|EB
P09808216A0000|77 84|balance
P09808216A0000|57 63|energy
P09808216A0000|13 20|Studies
P09808441A0320|186 197|coexistence
P09808441A0320|219 233|cell carcinoma
P09808441A0320|133 142|character
P09808441A0320|91 102|singularity
P09808441A0320|15 23|analysis
P09811695A1146|103 126|MuLV TM Env protein p15
P09811695A1146|127 128|E
P09811730A1396|68 76|proteins
P09811730A1396|87 98|KCS element
P09811730A1396|112 140|KCS protein binding activity
P09813041A1122|1 3|GH
P09813041A1122|24 39|phosphorylation
P09813041A1122|89 99|conditions
P09813093A0624|35 42|YCL024W
P09813093A0624|80 88|deletion
P09813093A0624|63 74|combination
P09813110A0982|36 41|CBP90
P09813110A0982|13 32|amino acid sequence
P09813110A0982|120 126|domain
P09813207A0434|273 281|TATA box
P09813207A0434|193 203|transcript
P09813207A0434|49 57|presence
P09813207A0434|290 301|nucleotides
P09813207A0434|144 155|nucleotides
P09813207A0434|333 337|lef2
P09813259A1097|70 81|sensitivity
P09813259A1097|43 51|blockade
P09813259A1097|122 125|GBP
P09814637A1214|55 71|microhemorrhages
P09814637A1214|95 98|MRI
P09815578A1245|103 118|prostate cancer
P09815578A1245|141 164|prostate carcinogenesis
P09815578A1245|44 49|CDKN2
P09817131A0296|16 33|SF-36 survey form
P09817373A0000|186 189|NOS
P09817373A0000|1 8|PURPOSE
P09817373A0000|115 128|insufficiency
P09817373A0000|191 199|activity
P09817373A0000|215 231|tissue synthesis
P09819038A0448|71 87|room temperature
P09819038A0448|37 50|infusion pump
P09819038A0448|13 18|FVIIa
P09819216A0220|8 20|Biochemistry
P09819377A1209|98 109|C2U4 repeat
P09819377A1209|178 183|range
P09819377A1209|78 87|mutations
P09819377A1209|62 68|snR13F
P09819411A0897|38 49|PNR element
P09819411A0897|53 63|palindrome
P09819411A0897|12 30|footprint analysis
P09819421A0000|1 13|Cyclophilins
P09819421A0000|111 124|cyclosporin A
P09819430A0000|17 24|GTPases
P09819430A0000|101 105|form
P09819430A0000|130 135|state
P09819440A0783|108 113|cells
P09819440A0783|12 15|RMP
P09820163A0565|54 74|restriction analysis
P09820611T0000|147 158|nephropathy
P09820611T0000|13 16|use
P09820611T0000|44 52|infusion
P09821978A1255|17 25|deficits
P09821978A1255|79 81|SE
P09822602A1172|33 39|import
P09822602A1172|179 189|HIF-1alpha
P09822602A1172|147 152|roles
P09822602A1172|44 59|transactivation
P09822652A1118|86 89|Sp1
P09822652A1118|15 21|effect
P09822685A0596|9 17|analyses
P09822685A0596|91 97|region
P09822685A0596|120 133|reading frame
P09822825A0141|154 160|medium
P09822825A0141|108 116|addition
P09822825A0141|135 146|amino acids
P09823561T0001|19 32|MALT lymphoma
P09823561T0001|62 85|Gastrospirillum hominis
P09824001A1665|64 72|survival
P09824001A1665|78 80|Ag
P09824001A1665|74 77|vWF
P09824158A1336|58 69|interaction
P09824158A1336|14 40|BCL-6 POZ domain mutations
P09826658A0691|157 172|BPV-1 pre-mRNAs
P09826658A0691|6 19|core sequence
P09826658A0691|132 140|assembly
P09827446T0001|35 48|C4 deficiency
P09827878A0091|204 211|workers
P09827878A0091|86 90|role
P09827878A0091|40 60|superoxide dismutase
P09827878A0091|62 65|SOD
P09827878A0091|120 127|defence
P09828137A0000|115 123|response
P09828137A0000|37 71|cell cycle checkpoint control gene
P09828137A0000|88 95|S-phase
P09829836A0815|33 43|inhibition
P09829836A0815|112 128|yeast LEU2 genes
P09829843A0819|141 151|rHu GM-CSF
P09829843A0819|370 394|chemiluminescence system
P09829843A0819|229 238|microg kg
P09829843A0819|19 22|CSF
P09829843A0819|251 256|level
P09829843A0819|58 69|neutropenia
P09829843A0819|215 218|day
P09829843A0819|243 246|day
P09832099A0000|137 158|color kinesis imaging
P09832099A0000|71 79|patients
P09832099A0000|41 52|wall motion
P09832099A0000|60 67|systole
P09832436T0000|23 39|characterization
P09832436T0000|93 99|family
P09832436T0000|11 18|cloning
P09832436T0000|88 91|PRL
P09832505A0903|101 122|transcription complex
P09832505A0903|29 46|activation target
P09832518A0615|98 106|sequence
P09832518A0615|5 22|repression domain
P09832518A0615|182 199|database searches
P09832518A0615|46 59|Cdc68 protein
P09833740A1112|253 258|modes
P09833740A1112|55 64|inhibitor
P09833740A1112|97 115|cytokine responses
P09833740A1112|131 142|ACH-2 cells
P09833740A1112|124 126|U1
P09834521A0000|46 50|site
P09836881A0441|71 95|Bruininks-Oseretsky Test
P09836881A0441|46 63|motor performance
P09837715A0581|68 73|level
P09837715A0581|117 121|mRNA
P09837715A0581|190 204|leukemia virus
P09837715A0581|112 115|CAT
P09837715A0581|59 62|DNA
P09837715A0581|211 243|SL3-3 LTR-CAT reporter construct
P09837907A0857|17 30|TNF receptors
P09837907A0857|111 123|cytotoxicity
P09837907A0857|199 215|kinase induction
P09837907A0857|125 145|caspase-3 activation
P09837907A0857|182 187|c-Jun
P09837913A0419|103 106|UTR
P09837913A0419|124 127|hD2
P09837913A0419|120 122|D2
P09837920A0222|140 143|JNK
P09837920A0222|59 71|consequences
P09837920A0222|130 135|c-Jun
P09837945A0820|1 19|Immunolocalization
P09837945A0820|172 180|fraction
P09837945A0820|198 206|material
P09837945A0820|134 139|Sop1p
P09838122A0489|79 83|MPP3
P09840928A0884|119 129|histone H3
P09840928A0884|69 72|H2A
P09840928A0884|93 103|substrates
P09840928A0884|160 168|extracts
P09840934A0435|100 104|G12V
P09840934A0435|9 15|Ha-Ras
P09840934A0435|17 21|G12V
P09840934A0435|23 27|T35S
P09840934A0435|219 228|apoptosis
P09840934A0435|149 163|RalGDS pathway
P09840934A0435|30 42|Ha-RasV12S35
P09842517A0497|33 43|technology
P09842517A0497|111 113|CT
P09842517A0497|95 102|methods
P09843412A0130|37 41|form
P09843412A0130|74 81|species
P09843577A0000|53 64|deprivation
P09843577A0000|27 32|cells
P09844106A0835|50 53|FLG
P09844106A0835|99 104|cells
P09844106A0835|37 46|adherence
P09845043A0000|152 159|problem
P09845043A0000|237 246|component
P09845043A0000|5 26|US National Institute
P09845043A0000|82 87|forms
P09845043A0000|122 135|alcohol abuse
P09845043A0000|30 43|Alcohol Abuse
P09845856A0560|64 78|ulcer diseases
P09846482A0441|4 8|turn
P09846482A0441|27 34|complex
P09846482A0441|123 143|actin polymerization
P09847371A0000|1 23|Jembrana disease virus
P09847371A0000|25 28|JDV
P09847371A0000|132 135|BIV
P09848653A0597|1 6|Nhp2p
P09848653A0597|25 32|protein
P09849722A0797|221 234|brain regions
P09849722A0797|64 79|signal increase
P09849722A0797|37 48|expressions
P09849722A0797|214 219|gyrus
P09849965A0000|68 72|role
P09849965A0000|112 133|progesterone receptor
P09849965A0000|46 52|system
P09849965A0000|90 102|dimerization
P09851700A0000|5 9|gene
P09851700A0000|60 64|t-PA
P09852005A1287|1 12|Competition
P09852005A1287|292 304|OP4 sequence
P09852005A1287|162 193|MADS box consensus binding site
P09852005A1287|198 219|serum response factor
P09852109A1475|256 260|role
P09852109A1475|278 285|control
P09852109A1475|43 59|profile analysis
P09852109A1475|195 207|transcript D
P09852109A1475|75 88|transcripts C
P09852136A0507|1 18|Wild type HA-p190
P09852136A0507|111 123|Rho function
P09852136A0507|74 84|extensions
P09854034A0536|27 35|promoter
P09854034A0536|45 56|G+C content
P09856397A0099|1 18|Dry matter intake
P09856397A0099|55 79|serum chemistry profiles
P09856397A0099|129 132|FB1
P09857038A1374|1 3|E.
P09857038A1374|12 14|J.
P09857265A0669|207 208|%
P09857265A0669|174 180|intake
P09857265A0669|129 133|oils
P09857265A0669|193 194|%
P09857265A0669|135 145|vegetables
P09857265A0669|50 59|mg RE/day
P09857265A0669|188 189|%
P09857265A0669|120 124|fats
P09858531A1017|99 104|c-fos
P09858531A1017|14 34|RING1 overexpression
P09858572A0000|5 30|yeast retrotransposon Ty5
P09858581A0183|53 57|gene
P09858581A0183|161 168|prp38-1
P09858581A0183|94 100|growth
P09858581A0183|105 121|splicing defects
P09858593A0334|139 151|neurogenesis
P09858593A0334|58 79|Xenopus NeuroD1/BETA2
P09858619A0356|36 40|Y319
P09858714A1171|50 76|shares sequence similarity
P09858714A1171|82 89|sigma70
P09858714A1171|106 109|srd
P09858714A1171|45 48|dda
P09858745A2033|76 84|fumarate
P09858745A2033|10 30|transcription assays
P09860979A0521|1 11|Expression
P09860979A0521|20 23|Cas
P09860979A0521|40 55|binding protein
P09860979A0521|148 151|Crk
P09861365A0000|39 44|assay
P09861365A0000|96 103|antigen
P09861365A0000|46 51|ELISA
P09862481A0000|81 86|yeast
P09862481A0000|59 77|glucose repression
P09863624A0629|84 89|CRF1s
P09863624A0629|217 221|CRF1
P09863624A0629|202 207|ovine
P09863624A0629|27 36|structure
P09863624A0629|149 155|domain
P09863720T0000|48 53|onset
P09863720T0000|31 38|disease
P09864335A1226|197 209|inactivation
P09864335A1226|111 122|C. albicans
P09864335A1226|79 88|regulator
P09864335A1226|226 232|factor
P09864335A1226|241 246|Fcr1p
P09865775A0162|6 11|study
P09865775A0162|62 71|placement
P09867159A1444|98 99|%
P09867159A1444|6 12|regard
P09867159A1444|46 57|sensitivity
P09867159A1444|105 112|FDG PET
P09867159A1444|82 83|%
P09867159A1444|94 95|%
P09867159A1444|62 73|specificity
P09867855T0000|37 54|promoter activity
P09869297A1807|34 37|CE1
P09869297A1807|98 109|development
P09869297A1807|15 20|roles
P09869400A0203|54 62|proteins
P09869400A0203|127 139|wheat germin
P09871353A0174|119 123|fish
P09871353A0174|33 41|evidence
P09871353A0174|45 70|A. salmonicida infections
P09872337A0000|32 43|clindamycin
P09872337A0000|280 293|% clindamycin
P09872337A0000|132 141|tretinoin
P09872337A0000|155 159|gels
P09872337A0000|249 277|clindamycin phosphate lotion
P09872337A0000|125 130|% w/v
P09873060A0901|1 25|Phosphorylation analyses
P09873060A0901|114 118|JunD
P09873060A0901|41 51|inhibition
P09874803A0000|191 207|disease episodes
P09874803A0000|22 53|bacterium group A Streptococcus
P09874803A0000|123 133|exotoxin B
P09876794T0000|1 10|Improving
P09876794T0000|15 28|evidence base
P09878256A0000|168 179|retardation
P09878256A0000|5 36|peroxisome biogenesis disorders
P09878256A0000|72 80|diseases
P09878256A0000|120 132|deficiencies
P09878542A1151|65 74|silencing
P09878542A1151|89 92|VDR
P09880029A0703|238 239|%
P09880029A0703|100 101|%
P09880029A0703|282 284|C6
P09880029A0703|14 33|MDV genome products
P09880029A0703|217 219|C3
P09880029A0703|182 194|Rep proteins
P09880327A0322|20 27|variety
P09880327A0322|78 89|yeast Uso1p
P09880327A0322|165 173|vesicles
P09880513A1013|6 14|proteins
P09880544A0693|152 161|apoptosis
P09880544A0693|272 280|btk gene
P09880544A0693|96 104|btk gene
P09880544A0693|78 88|disruption
P09880544A0693|15 37|DT-40 lymphoma B-cells
P09881692A0094|65 67|b9
P09881692A0094|58 60|b6
P09881692A0094|121 139|Ckappa1 gene locus
P09882303A1413|1 6|TRAF2
P09882303A1413|178 183|cells
P09882303A1413|45 55|expression
P09882303T0000|68 79|JNK pathway
P09882303T0000|117 126|mechanism
P09882303T0000|147 152|TRAF2
P09882334A0822|17 25|passages
P09882334A0822|252 257|virus
P09882334A0822|98 101|BLV
P09882334A0822|83 92|infection
P09882334A0822|202 207|motif
P09882334A0822|167 183|tyrosine residue
P09882348A0611|136 147|fibroblasts
P09882348A0611|112 131|Shc adapter protein
P09882348A0611|30 52|phosphorylation status
P09882489A0451|200 207|signals
P09882489A0451|9 14|study
P09882489A0451|120 125|array
P09882593A0996|174 185|hand eczema
P09882593A0996|52 56|61Ni
P09882593A0996|193 207|pompholyx type
P09882593A0996|135 143|controls
P09883639A0000|103 108|years
P09883639A0000|49 61|mycobacteria
P09883639A0000|63 66|NTM
P09884275T0000|98 115|organ transplants
P09884275T0000|78 88|recipients
P09885431A0000|118 126|silicone
P09885431A0000|1 10|OBJECTIVE
P09885431A0000|185 195|stock tray
P09885431A0000|176 181|types
P09886843A0339|119 123|NRGN
P09886843A0339|168 172|gene
P09886843A0339|46 52|target
P09886843A0339|31 35|gene
P09887544A0000|1 11|BACKGROUND
P09887544A0000|162 170|epilepsy
P09887544A0000|124 130|relief
P09887544A0000|107 115|sedation
P09887544A0000|134 141|anxiety
P09888994A0858|21 25|gene
P09888994A0858|63 81|mesoderm formation
P09889306A0321|18 28|regulation
P09889306A0321|145 181|ape leukemia virus envelope proteins
P09889306A0321|121 128|vectors
P09889306A0321|224 234|cell types
P09891009T0000|22 45|mouse glycolate oxidase
P09891046A0554|25 36|protein L18
P09891046A0554|40 51|interaction
P09891061A0373|184 195|cis element
P09891061A0373|53 61|fragment
P09891061A0373|31 41|regulators
P09891065A1493|87 96|PKC-alpha
P09891065A1493|28 42|SRE activation
P09891092A1000|52 62|structures
P09891092A1000|29 33|site
P09892017A2151|71 75|ELE1
P09892017A2151|63 67|role
P09892422A1096|207 218|termination
P09892422A1096|76 87|contraction
P09892422A1096|95 105|myocardium
P09892422A1096|226 240|purkinje fibre
P09892662A0334|102 104|Gs
P09892662A0334|144 151|cyclase
P09892662A0334|88 98|activation
P09893060A0767|70 72|kb
P09893913A0656|1 10|Induction
P09893913A0656|111 116|mg/kg
P09893913A0656|56 69|micrograms/kg
P09893913A0656|44 52|fentanyl
P09895323T0000|84 95|Hoxb3 genes
P09895323T0000|24 29|roles
P09895323T0000|45 55|regulation
P09900679T0000|88 97|phenomena
P09904139T0000|42 51|operators
P09913308T0000|67 73|energy
P09913308T0000|41 48|Ti ions
P09913308T0000|62 63|J
P09914500A0000|205 208|TNF
P09914500A0000|81 86|genes
P09914500A0000|52 72|transcription factor
P09914500A0000|9 23|factor kappa B
P09914500A0000|182 203|tumor necrosis factor
P09914525A0890|48 56|degreesC
P09914525A0890|13 16|Ffh
P09915798A1077|16 21|hsp90
P09915798A1077|80 105|hsp90 dimerization domain
P09915798A1077|131 139|elements
P09915860A0119|1 4|Sp1
P09915860A0119|83 98|Schneider cells
P09915860A0119|15 30|transactivation
P09916809A0405|99 106|protein
P09916809A0405|7 10|MGP
P09916809A0405|45 51|matrix
P09917387T0000|80 88|TATA box
P09917387T0000|113 123|start site
P09917391A0380|1 26|Transcription readthrough
P09917391A0380|79 84|event
P09918096A0520|34 38|cyst
P09918715A1158|68 72|TAFs
P09918715A1158|153 166|transcription
P09918715A1158|96 99|TBP
P09918715A1158|127 134|binding
P09918715A1158|26 30|AsiA
P09918842A0184|118 128|initiation
P09918842A0184|80 88|assembly
P09918842A0184|10 22|conservation
P09918842A0184|61 67|region
P09920775A0075|25 27|bp
P09920775A0075|167 176|P19 cells
P09920775A0075|44 68|transcription start site
P09920896A1230|138 145|protein
P09920896A1230|111 123|substitution
P09920896A1230|61 74|type peptides
P09920930A0521|70 82|Luc activity
P09920930A0521|95 101|effect
P09920930A0521|120 136|c-Fos expression
P09920982A0253|5 8|aim
P09920982A0253|196 215|Rap ID ANA II panel
P09920982A0253|24 29|study
P09920982A0253|63 77|susceptibility
P09922230A1482|21 28|results
P09922230A1482|46 50|CAP1
P09923245A0482|84 92|patients
P09923245A0482|25 47|interrater reliability
P09924987A0000|175 184|ribosomes
P09924987A0000|131 139|28S rRNA
P09924987A0000|104 120|adenine residues
P09924987A0000|81 94|N-glycosidase
P09924987A0000|144 149|A2660
P09924987A0000|208 219|prokaryotes
P09925372A0458|17 21|ZFPs
P09925372A0458|80 97|sequence homology
P09925372A0458|46 50|HFHZ
P09925372A0458|31 39|ZFP cDNA
P09925777A1195|162 163|%
P09925777A1195|41 45|site
P09925777A1195|90 93|Rev
P09927449A0421|102 106|CLN1
P09927449A0421|1 15|Overexpression
P09927449A0421|54 63|G1 arrest
P09927585A0796|153 163|factor Sp1
P09927585A0796|1 34|Competitionsupershift EMSA assays
P09927585A0796|58 66|proteins
P09929088A0000|1 8|CONTEXT
P09929088A0000|81 92|sensitivity
P09929088A0000|20 27|AutoPap
P09929088A0000|10 18|ThinPrep
P09931118A1072|28 39|JNK pathway
P09931118A1072|60 66|action
P09931216A0566|71 76|cable
P09931216A0566|107 113|module
P09931391A0944|48 55|surgery
P09931391A0944|10 18|recovery
P09932288A0378|32 35|XT3
P09932288A0378|92 100|sequence
P09932288A0378|72 78|kidney
P09933641A0241|16 25|sequences
P09933641A0241|86 94|analysis
P09933641A0241|114 119|clone
P09933641A0241|176 189|amplification
P09934611A1054|100 108|pressure
P09934611A1054|6 16|dependence
P09934611A1054|73 84|min LVdP/dt
P09936001T0000|68 81|Sc impurities
P09936001T0000|25 30|delta
P09936001T0000|56 58|Al
P09936001T0000|60 62|Ga
P09940132T0000|9 15|theory
P09944066T0073|1 3|II
P09947191T0000|1 32|Neutron scattering measurements
P09947191T0000|58 65|CsMnBr3
P09949178A0264|68 74|factor
P09949178A0264|55 59|IL-6
P09949178A0264|9 19|expression
P09949178A0264|122 126|line
P09950213A1660|117 125|TGF-beta
P09950213A1660|138 151|participation
P09950213A1660|39 51|goblet cells
P09952378A0529|87 97|serostatus
P09952378A0529|5 15|odds ratio
P09952378A0529|110 124|IgG antibodies
P09952378A0529|131 141|adjustment
P09959737T0000|29 37|SN 1987A
P09961682T0000|1 6|Model
P09961682T0000|25 33|dynamics
P09964770T0000|49 68|laminate composites
P09965909T0000|33 54|soliton perturbations
P09965909T0000|24 29|study
P09971790A0856|33 45|endonuclease
P09971790A0856|9 18|mutations
P09971790A0856|89 118|amino-terminal-charge cluster
P09971815A2094|239 244|sites
P09971815A2094|310 320|v-GCR gene
P09971815A2094|376 385|gammaHV68
P09971815A2094|326 330|gene
P09971815A2094|358 365|latency
P09971815A2094|398 416|gammaherpesviruses
P09971815A2094|113 118|genes
P09971815A2094|296 308|v-bcl-2 gene
P09971815A2094|267 274|regions
P09973351A1522|62 72|substrates
P09974642T0000|80 88|dynamics
P09974642T0000|27 31|heat
P09980944T0000|70 83|NQR spin-echo
P09980944T0000|91 100|resonance
P09983871T0000|24 47|YBa2-xLaxCu3O7 ceramics
P09985302T0000|63 70|antidot
P09987176A0260|32 43|vaccination
P09987176A0260|110 116|levels
P09987176A0260|120 128|anti-HAV
P09987961A0093|41 53|angiomatosis
P09987961A0093|107 118|fibroblasts
P09987961A0093|90 102|synoviocytes
P09988767A1496|65 81|mouse 3Ost genes
P09988767A1496|160 174|identification
P09988767A1496|56 60|loci
P09989334A0964|157 163|intron
P09989334A0964|56 66|transcript
P09989334A0964|30 48|processing signals
P09990057T0000|1 14|Recombination
P09990057T0000|19 32|transcription
P09990057T0000|158 183|matrix attachment regions
P09990057T0000|91 93|Ig
P09990060A0937|169 178|induction
P09990060A0937|21 58|coactivator CREB binding protein/p300
P09990060A0937|200 207|T cells
P09990060A0937|182 196|IL-16 promoter
P09990060A0937|107 116|GABPalpha
P09990507A0000|1 11|BACKGROUND
P09990507A0000|140 151|degradation
P09990507A0000|40 59|proteolysis pathway
P09990507A0000|63 79|ubiquitin ligase
P09994942T0000|5 16|NMR studies
P09995897T0000|70 87|Si/SiO2 interface
P09995897T0000|45 56|Pb0 defects
P09999742T0000|9 23|NO interaction
P09999742T0000|45 53|surfaces
P10001333T0038|20 23|Pr3
P10002245T0000|83 96|delta crystal
P10002245T0000|42 52|CuO chains
P10007469T0000|32 39|phonons
P10007469T0000|20 27|librons
P10008261T0000|71 80|YBa2Cu3O6
P10008261T0000|31 41|sublattice
P10013227T0000|58 62|m pi
P10021333A0674|86 97|interaction
P10021333A0674|9 20|experiments
P10021333A0674|60 65|bruno
P10022032A0000|222 225|DTZ
P10022032A0000|49 71|vasodilator nicorandil
P10022032A0000|4 11|support
P10022032A0000|159 167|atenolol
P10022032A0000|73 76|NIC
P10022850A0929|87 99|coactivation
P10022850A0929|4 12|contrast
P10022850A0929|56 67|C/H1 domain
P10022867A1069a|16 20|ETH1
P10022867A1069a|64 78|mutation rates
P10022867A1069a|24 36|apn1 strains
P10022867A1069a|149 156|adenine
P10022875A1265|7 11|data
P10022875A1265|31 44|Ras effectors
P10022905A0446|39 50|stop codons
P10022905A0446|77 84|alleles
P10022905A0446|160 170|mog-1 mRNA
P10022905A0446|150 158|activity
P10022925A0870|65 71|motifs
P10024383T0000|119 124|mouse
P10024383T0000|81 91|osteopenia
P10024383T0000|126 133|twy/twy
P10024882A0541|32 36|cdk7
P10024882A0541|110 117|absence
P10024882A0541|92 99|RNA pol
P10025506A0079|34 50|plastin isoforms
P10026146A0680|137 141|PrKX
P10026146A0680|5 15|inhibition
P10026146A0680|108 110|nM
P10026146A0680|54 62|addition
P10026146A0680|218 237|cAMP concentrations
P10026146A0680|267 281|Calpha subunit
P10026146A0680|94 98|cAMP
P10026211A0543|171 195|H4IIE rat hepatoma cells
P10026211A0543|6 15|construct
P10026211A0543|46 56|C/EBPalpha
P10026211A0543|61 65|beta
P10026784A0929|116 131|POU-homeodomain
P10026784A0929|44 76|POU domain transcription factors
P10026824A0309|174 179|Gq/11
P10026824A0309|23 31|analysis
P10026824A0309|162 170|coupling
P10026824A0309|280 282|Gs
P10026824A0309|225 236|V2 receptor
P10029860A0605|20 27|aspects
P10029860A0605|52 62|categories
P10031854T0000|1 23|New Langevin equations
P10032581T0000|51 62|synchrotron
P10032581T0000|65 74|radiation
P10034615T0000|1 24|Structure determination
P10034615T0000|60 74|reconstruction
P10036181A0603|1 14|Northern blot
P10036181A0603|27 49|hybridization analyses
P10037004A0000|114 121|relapse
P10037004A0000|110 112|BM
P10037004A0000|63 71|leukemia
P10037004A0000|13 21|patients
P10037460A0221|54 69|memory function
P10037460A0221|8 13|brain
P10037460A0221|73 84|interaction
P10037681A0494|171 181|RhoAVal-14
P10037681A0494|35 44|PKC-alpha
P10037681A0494|108 112|PLD1
P10037681A0494|123 125|D4
P10037681A0494|165 169|RhoA
P10041728T0000|1 22|Vacuum Rabi splitting
P10041728T0000|39 63|linear-dispersion theory
P10041728T0000|91 103|observations
P10044519T0000|6 15|reduction
P10047970T0013|9 25|world literature
P10049359A1073|55 58|PTB
P10049359A1073|13 16|unr
P10049775T0000|40 62|Anion Channel isoforms
P10050883A0967|158 167|viability
P10050883A0967|72 78|effect
P10050883A0967|15 44|phosphatidylinositol-3 kinase
P10051400A0000|32 37|model
P10051400A0000|66 77|tube defect
P10051488A1610|35 50|TIMP-1 promoter
P10051488A1610|18 27|AP-1 site
P10051488A1610|66 75|formation
P10051488A1610|79 85|HMAP-1
P10052878A0135|17 32|set-up accuracy
P10054976T0000|69 90|Raman coupling regime
P10054976T0000|53 63|detachment
P10059496T0000|38 53|Penrose lattice
P10063739A0601|186 189|EVS
P10063739A0601|141 145|mmHg
P10063739A0601|76 87|study group
P10063739A0601|27 56|esophageal sphincter pressure
P10063739A0601|89 93|mean
P10065176A0657|68 73|cases
P10065176A0657|32 55|hormone receptor status
P10065176A0657|82 103|lymph node metastases
P10066790A0497|102 111|component
P10066790A0497|255 262|epsilon
P10066790A0497|237 240|mu4
P10066790A0497|206 230|adaptor subunit homologs
P10066790A0497|130 137|complex
P10066790A0497|91 96|beta4
P10066815T0000|155 180|B cell receptor signaling
P10066815T0000|71 82|p85 subunit
P10066815T0000|39 50|phosphatase
P10066815T0000|52 56|SHIP
P10068418A1194|152 160|estrogen
P10068418A1194|100 110|raloxifene
P10068418A1194|57 60|hip
P10068418A1194|44 49|spine
P10068637A1320|16 24|Csx/Nkx2
P10068834A0713|32 34|PE
P10068834A0713|36 38|DM
P10068834A0713|59 61|DM
P10070158A0573|64 78|cassette exons
P10070158A0573|13 28|splicing events
P10071806A0377|5 9|rate
P10071806A0377|45 53|survival
P10072774A0537|154 162|Bge cDNA
P10072774A0537|127 149|beta integrin subunits
P10072774A0537|90 111|ligand binding domain
P10073940A0335|23 29|d-axin
P10074135T0000|34 42|elements
P10074135T0000|83 94|dwarf virus
P10074135T0000|106 110|RNA1
P10074425A0729|154 162|p27 gene
P10074425A0729|110 114|MEFs
P10074425A0729|60 68|response
P10074903A0915|55 66|possibility
P10074903A0915|144 148|IFNs
P10074903A0915|182 200|p21 protein levels
P10074903A0915|104 136|cell growth retardation activity
P10075415A1178|81 92|ru/AB genes
P10075415A1178|126 139|plasmid pPSR1
P10075415A1178|27 33|region
P10077188A1172|220 224|mRNA
P10077188A1172|207 216|synthesis
P10077188A1172|97 105|proteins
P10077188A1172|63 75|biosynthesis
P10077188A1172|120 125|genes
P10078734A0480|116 137|flexor carpi radialis
P10078734A0480|97 106|recording
P10078734A0480|14 28|recovery curve
P10079173A0000|58 80|RNA recognition motifs
P10080875A0772|274 278|CREB
P10080875A0772|70 91|transcription factors
P10080875A0772|5 12|results
P10080875A0772|282 291|C/EBPbeta
P10080875A0772|224 227|p52
P10080875A0772|16 35|supershift analysis
P10080875A0772|293 299|NF-IL6
P10080875A0772|144 168|NF-kappaB components p50
P10080875A0772|120 129|complexes
P10082137A0262|101 104|IRF
P10082137A0262|108 112|mRNA
P10082137A0262|155 165|inhibition
P10082137A0262|25 34|IFN-gamma
P10082137A0262|179 206|procollagen mRNA expression
P10082137A0262|56 68|accumulation
P10082570A0440|31 41|gene UBP43
P10082585A0512|32 39|factors
P10082585A0512|52 66|rDNA silencing
P10082585A0512|195 199|rDNA
P10085088A0918|84 100|initiation phase
P10085088A0918|33 44|p33 subunit
P10085088A0918|178 186|activity
P10085088A0918|72 76|role
P10085140A1004|51 55|role
P10085140A1004|59 77|TGF-beta signaling
P10085140A1004|123 127|Smad
P10085140A1004|132 145|TAK1 pathways
P10085505A1184|67 71|peak
P10085505A1184|14 18|peak
P10086725A0000|1 10|MDS1/EVI1
P10086725A0000|80 103|transcription activator
P10086725A0000|23 33|chromosome
P10087549A0720|5 14|JTc delta
P10087549A0720|79 87|VT group
P10087549A0720|105 107|ms
P10087549A0720|190 203|control group
P10087549A0720|159 163|msec
P10087549A0720|147 151|msec
P10087549A0720|31 37|groups
P10087993A1352|38 43|sites
P10087993A1352|114 130|beta globin gene
P10087993A1352|52 74|repressor proteins BP1
P10087993A1352|79 82|BP2
P10087993A1352|15 26|mutagenesis
P10090146T0000|83 93|repression
P10090146T0000|42 50|AP-2beta
P10090146T0000|28 37|AP-2alpha
P10090943A1426|85 87|SD
P10090943A1426|98 104|donors
P10090943A1426|23 28|CD79b
P10090943A1426|10 15|value
P10090943A1426|61 66|ratio
P10091594A0284|168 175|epitope
P10091594A0284|229 238|anti-K159
P10091594A0284|180 195|helix formation
P10091594A0284|74 90|NMR spectroscopy
P10091594A0284|105 117|ELISA assays
P10092132A0285|187 192|13q34
P10092132A0285|19 23|HLGs
P10092132A0285|162 169|11p11.2
P10092132A0285|109 113|case
P10092132A0285|149 151|.2
P10092856A0798|5 9|cDNA
P10092856A0798|62 69|control
P10094396A0000|1 17|Topoisomerase II
P10094396A0000|29 35|target
P10095059A1003|5 12|numbers
P10095059A1003|60 76|HIV-1 transcript
P10095062A0558|53 79|topoisomerase IIalpha gene
P10095062A0558|30 39|structure
P10096573A0207|155 174|MGSA/GRO-alpha gene
P10096573A0207|81 83|NF
P10096573A0207|182 184|bp
P10097932A0915|69 76|mg/24 h
P10097932A0915|200 209|follow-up
P10097932A0915|174 181|mg/24 h
P10097932A0915|163 167|UAER
P10097932A0915|78 79|n
P10098744A0630|70 76|clones
P10098744A0630|233 243|morphology
P10098744A0630|198 206|survival
P10098744A0630|17 23|change
P10098744A0630|83 90|respect
P10098744A0630|264 287|differentiation markers
P10098744A0630|149 158|monolayer
P10099576A0666|119 124|valve
P10099576A0666|103 111|geometry
P10099576A0666|27 30|aim
P10099576A0666|61 66|shear
P10101159A0742|69 78|mutations
P10101159A0742|142 147|mRNAs
P10101159A0742|26 35|SOC1 gene
P10101198A0946|138 143|mTERF
P10101198A0946|172 175|DNA
P10101198A0946|58 66|homology
P10101198A0946|148 155|protein
P10101198A0946|181 188|monomer
P10102000A1206|69 82|ERA-III group
P10102000A1206|43 55|ERA-II group
P10102136A0646|85 90|cysts
P10102136A0646|35 40|ratio
P10102136A0646|8 13|cysts
P10102136A0646|27 28|K
P10103002A0705|102 123|carbohydrate analysis
P10103002A0705|42 54|chicken gp42
P10103002A0705|92 100|proteins
P10103002A0705|193 197|site
P10119827T0000|17 20|bid
P10119827T0000|25 41|Chicago hospital
P10125354T0000|19 31|price breaks
P10134977T0000|16 25|hospitals
P10134977T0000|27 35|patience
P10153759A0360|55 77|NHBC organ procurement
P10181397A0641|138 151|United States
P10181397A0641|36 58|life expectancy ratios
P10181397A0641|92 101|countries
P10181397A0641|15 21|trends
P10187317T0000|25 41|AHERF physicians
P10187842A1155|142 147|sites
P10187842A1155|106 111|motif
P10187842A1155|165 174|PPARalpha
P10190324A0000|140 148|families
P10190324A0000|96 100|SVAS
P10190324A0000|178 182|SVAS
P10192134A1088|115 125|vitamin D3
P10192134A1088|65 74|use level
P10192134A1088|42 48|health
P10192638T0000|1 25|Methanesulfonyl fluoride
P10192638T0000|77 83|safety
P10192638T0000|124 132|dementia
P10192638T0000|104 113|treatment
P10194225A1132|66 73|alanine
P10194225A1132|11 16|wheel
P10194451A0000|169 177|leukemia
P10194451A0000|32 44|relationship
P10194451A0000|80 112|protein tyrosine kinase activity
P10194451A0000|266 283|chronic-phase CML
P10194451A0000|298 314|progenitor cells
P10194451A0000|210 214|goal
P10194769A0146|19 21|1P
P10194769A0146|174 181|protein
P10194769A0146|39 44|clone
P10194769A0146|142 145|PRL
P10194769A0146|10 17|element
P10195690A0000|50 55|PPARs
P10195690A0000|5 15|peroxisome
P10196127A1059|70 78|residues
P10196127A1059|27 36|S1 pocket
P10196266A0000|101 104|MCF
P10196266A0000|125 141|leukemia viruses
P10196266A0000|106 114|subgroup
P10196266A0000|75 99|mink cell focus-inducing
P10196318T0000|68 87|papillomavirus type
P10196318T0000|94 96|E7
P10197763A0580|55 75|AMP response element
P10197763A0580|126 127|%
P10198003A1505|34 41|fusions
P10198003A1505|70 75|sites
P10198003A1505|112 116|rsmB
P10198061A0339|32 44|beta-catenin
P10198061A0339|71 78|nucleus
P10198061A0339|113 120|cytosol
P10198061A0339|122 125|Ran
P10200473A0171|137 144|FLAME-1
P10200473A0171|116 120|CASH
P10200473A0171|58 65|Usurpin
P10200473A0171|146 150|FLIP
P10200473A0171|122 128|Casper
P10200473A0171|164 168|MRIT
P10202006A0546|18 25|product
P10202006A0546|54 62|B domain
P10203611T0000|85 98|breast masses
P10203611T0000|62 72|evaluation
P10205176A0000|20 23|NRs
P10205176A0000|9 18|receptors
P10205176A0000|57 72|transregulators
P10205588A0000|205 213|features
P10205588A0000|136 144|beta HSA
P10205588A0000|1 10|OBJECTIVE
P10205588A0000|116 134|Lancefield group A
P10205588A0000|173 188|characteristics
P10206152A1024|49 56|maximum
P10206152A1024|113 123|expression
P10206152A1024|37 44|protein
P10206152A1024|72 79|minimum
P10206959A0368|1 7|Pathol
P10207049A0693|5 14|GAC1 gene
P10207049A0693|59 102|serine/threonine phosphoprotein phosphatase
P10207087A0956|1 4|MEF
P10207087A0956|128 131|MEF
P10207087A0956|176 184|AML1/ETO
P10207087A0956|151 154|MEF
P10207092A0924|119 137|sea urchin nucleus
P10207092A0924|6 21|phosphorylation
P10208865A1246|114 128|dentine slices
P10208865A1246|95 110|resorption pits
P10209021A0212|34 39|Gle2p
P10209021A0212|62 82|interaction function
P10209119A0076|221 232|proteolysis
P10209119A0076|201 216|inhibitor Sic1p
P10209119A0076|23 36|protein Skp1p
P10209119A0076|79 108|F-box/WD-repeat protein Cdc4p
P10209119A0076|12 17|yeast
P10209759T0000|1 17|Antithrombin III
P10209759T0000|30 33|min
P10211329A0457|49 57|serum CA
P10211329A0457|66 73|Sjogren
P10211329A0457|7 19|observations
P10211329A0457|76 84|syndrome
P10211919A0846|221 239|CGI Severity scale
P10211919A0846|99 102|end
P10211919A0846|36 37|p
P10211919A0846|212 216|NIMH
P10211919A0846|106 110|week
P10211919A0846|120 126|Y-BOCS
P10212284A0000|84 97|proliferation
P10212284A0000|29 32|TGF
P10212284A0000|14 27|growth factor
P10212426A1067|1 6|Group
P10212426A1067|115 121|values
P10212426A1067|76 84|decrease
P10212426A1067|88 99|performance
P10214610A0900|67 70|age
P10214610A0900|15 24|variation
P10215594A1728|68 78|CRE2 sites
P10215594A1728|23 35|LUC activity
P10215594A1728|59 63|CRE1
P10215594A1728|124 144|2SV40-LUC constructs
P10215803T0000|52 69|calcium gluconate
P10215850A0754|119 121|kb
P10215850A0754|36 48|organization
P10215850A0754|95 100|exons
P10216052A1682|238 246|glaucoma
P10216052A1682|203 208|score
P10216052A1682|135 142|measure
P10216052A1682|256 264|subgroup
P10216052A1682|216 225|variables
P10216052A1682|179 189|field loss
P10216052A1682|268 277|questions
P10217683A0509|1 23|Canalith repositioning
P10217683A0509|31 39|mainstay
P10218200A0534|7 11|eyes
P10218200A0534|74 102|tissue plasminogen activator
P10219091A0246|52 58|enzyme
P10220364A0087|7 17|afterglows
P10221820A0902|158 161|AMT
P10221820A0902|93 103|clinicians
P10221820A0902|149 153|APBD
P10221820A0902|134 145|coexistence
P10223338A2186|81 90|HIV-2 gag
P10223338A2186|54 60|clades
P10223338A2186|27 38|V3 peptides
P10224244T0000|18 29|involvement
P10224244T0000|37 58|Glc7-Reg1 phosphatase
P10224244T0000|105 123|INO1 transcription
P10224289T0000|1 10|Induction
P10224289T0000|39 42|HIV
P10224289T0000|14 35|Fas ligand expression
P10224293A2021|54 59|basis
P10224293A2021|26 39|brain regions
P10224758A0202|78 89|pregnancies
P10225945A0436|18 22|loss
P10225945A0436|4 12|contrast
P10225945A0436|83 105|microtubule attachment
P10225945A0436|26 39|MAD2 staining
P10225945A0436|211 218|meiosis
P10226074A0637|32 39|regions
P10226074A0637|80 102|translation start site
P10228009A0600|84 92|factor-6
P10228009A0600|1 10|Induction
P10228009A0600|110 115|TRAF2
P10228009A0600|44 55|IEC-6 cells
P10228157T0000|84 89|yeast
P10228157T0000|60 72|Dbf2p kinase
P10228795A0842|115 118|IAS
P10228795A0842|22 28|nerves
P10228795A0842|56 66|regulation
P10229668A0190|20 33|cdc33 mutants
P10229682A1151|87 95|sequence
P10229682A1151|97 108|kappaB site
P10229682A1151|12 18|motifs
P10231454A0731|84 89|mg/dl
P10231454A0731|159 166|U/liter
P10231454A0731|7 20|serum calcium
P10231454A0731|91 101|phosphorus
P10231513T0000|76 81|study
P10231513T0000|30 58|granulation tissue formation
P10231862A1117|156 165|synthesis
P10231862A1117|20 27|infants
P10231862A1117|76 81|acids
P10231862A1117|179 185|plasma
P10232600T0000|68 78|expression
P10232600T0000|82 105|sodium iodide symporter
P10232600T0000|28 31|PSA
P10233147A0218|190 197|pathway
P10233147A0218|174 188|Cyr1p/cAMP/PKA
P10233147A0218|128 135|cascade
P10233147A0218|26 32|growth
P10233946A0000|81 85|LTRs
P10233946A0000|53 56|SNV
P10233946A0000|249 256|element
P10233946A0000|146 156|expression
P10233946A0000|167 185|leukemia virus RNA
P10233946A0000|30 51|spleen necrosis virus
P10235265A0197|65 71|system
P10235265A0197|8 17|mechanism
P10240361T0000|36 51|dissatisfaction
P10240361T0000|10 16|survey
P10271171A0458|83 87|unit
P10271171A0458|106 121|resource center
P10271171A0458|60 67|library
P10318806A0000|34 41|protein
P10318806A0000|136 141|c-Jun
P10318806A0000|232 246|growth factors
P10318806A0000|167 170|p38
P10318806A0000|16 23|mitogen
P10318806A0000|48 61|kinase family
P10318806A0000|248 257|cytokines
P10318806A0000|94 100|kinase
P10318806A0918|38 52|PDGF receptors
P10318806A0918|96 104|proteins
P10318806A0918|287 290|Crk
P10318806A0918|13 21|tyrosine
P10318806A0918|115 133|Src family kinases
P10318806A0918|260 281|phospholipase C-gamma
P10318806A0918|63 75|Src homology
P10318806A0918|241 258|phosphatase SHP-2
P10318900A0637|84 91|binding
P10318900A0637|99 102|Fab
P10318900A0637|132 144|conformation
P10318900A0637|104 110|8H2/G5
P10318900A0637|30 37|studies
P10319320A1022|98 108|antagonism
P10319320A1022|172 179|control
P10319320A1022|77 91|Ras activation
P10319955A0941|35 50|occlusion rates
P10319955A0941|64 74|chi-square
P10319955A0941|128 129|P
P10319955A0941|15 26|differences
P10320480A0451|99 111|beta subunit
P10320480A0451|123 137|RNA polymerase
P10321158T0000|69 73|core
P10321158T0000|55 64|cast post
P10321158T0000|94 99|dowel
P10322629A0198|100 105|Pax-2
P10322629A0198|32 48|characterization
P10322629A0198|20 27|cloning
P10322629A0198|110 121|gene family
P10323463T0000a|67 81|manifestations
P10323463T0000a|94 100|effect
P10323863A0852|71 81|telomerase
P10323863A0852|4 12|addition
P10323863A0852|93 99|factor
P10326221A0531|78 87|fulminans
P10326221A0531|28 36|children
P10326856T0000|57 76|purse-string device
P10328351A0443|1 14|Blood samples
P10328351A0443|47 69|supplementation period
P10329566A0610|143 153|pseudoknot
P10329566A0610|212 224|tetraviruses
P10329566A0610|8 16|terminus
P10329566A0610|24 30|genome
P10329566A0610|125 134|structure
P10329586A0414|16 27|fibronectin
P10329586A0414|10 14|gene
P10329586A0414|148 163|prostate cancer
P10329586A0414|73 86|LNCaP-r cells
P10329736A0681|97 126|phosphatidylinositol 3-kinase
P10329736A0681|46 52|system
P10330134A0765|5 20|mRNA expression
P10330134A0765|24 28|RFX1
P10330134A0765|40 44|RFX3
P10330134A0765|79 108|transient-transfection assays
P10330134A0765|123 140|RFX binding sites
P10330159A1258|205 208|DNA
P10330159A1258|118 123|NFAT1
P10330159A1258|39 49|components
P10330159A1258|7 10|VDR
P10330396A0387|101 113|pore complex
P10330396A0387|5 26|RanQ69L preincubation
P10330396A0387|52 56|CRM1
P10330396A0387|76 85|periphery
P10330396A0387|123 134|association
P10331646A0595|66 70|ART5
P10331646A0595|108 122|lymphoma cells
P10331646A0595|75 87|transferases
P10331646A0595|223 238|signal sequence
P10331646A0595|189 203|amino terminus
P10331646A0595|145 154|abundance
P10331646A0595|26 45|amino acid sequence
P10331875A0523|184 191|trimers
P10331875A0523|6 21|dimer interface
P10331875A0523|122 125|HSF
P10333481A1102|119 136|promoter activity
P10333481A1102|157 159|nt
P10333481A1102|59 69|constructs
P10333481A1102|192 200|enhancer
P10333481A1102|15 32|deletion analysis
P10333529A0277|23 35|Abeta levels
P10336495A0547|85 96|interaction
P10336495A0547|49 57|receptor
P10336495A0547|6 16|repression
P10336495A0547|124 132|RXRalpha
P10336495A0547|30 38|agonists
P10339566A0602|100 106|Cnm67p
P10339566A0602|33 42|component
P10339566A0602|60 74|SPB subcomplex
P10340883A1266|38 39|%
P10340883A1266|12 14|OS
P10342511A0909|35 37|r2
P10342511A0909|5 16|coefficient
P10342829A0236|17 27|importance
P10342829A0236|4 9|light
P10342829A0236|125 131|hGnRHR
P10342829A0236|133 137|gene
P10342829A0236|31 36|GnRHR
P10343189A0911|1 6|Grade
P10343189A0911|9 18|mucositis
P10347144A0516|99 103|size
P10347144A0516|131 139|sequence
P10347144A0516|107 110|kDa
P10347203A0832|101 116|pertussis toxin
P10347203A0832|159 168|increases
P10347203A0832|27 32|STAT3
P10347839A0434|86 87|M
P10347839A0434|5 16|IC50 values
P10347839A0434|41 48|bladder
P10349084T0000|102 110|children
P10349084T0000|5 14|influence
P10349084T0000|31 51|virus seropositivity
P10350027A0942|51 62|psychomotor
P10350027A0942|103 114|performance
P10350027A0942|128 131|day
P10350484A0346|68 72|CheA
P10350484A0346|5 13|kinetics
P10350484A0346|124 126|KM
P10350484A0346|46 55|complexes
P10350484A0346|150 158|increase
P10353073A0118|1 20|Regression analyses
P10355085A1119|1 8|Subsets
P10355085A1119|53 61|severity
P10355085A1119|145 154|survivors
P10355085A1119|12 20|patients
P10355910A0369|34 39|years
P10355910A0369|15 24|follow-up
P10358031A0303|103 111|division
P10358031A0303|4 12|addition
P10358031A0303|58 64|nuclei
P10358031A0303|123 129|defect
P10358079A0391|71 76|ErbB4
P10358079A0391|61 66|ErbB2
P10358080T0000|1 11|Modulation
P10358080T0000|60 73|linker domain
P10358138A0672|32 41|phenotype
P10358138A0672|159 162|SAP
P10358138A0672|123 145|cell surface molecules
P10358138A0672|45 48|XLP
P10359575A0317|155 159|hIgA
P10359575A0317|81 85|hIgA
P10359575A0317|76 79|IgA
P10359575A0317|124 134|bFcgamma2R
P10359663A0425|100 105|front
P10359663A0425|64 71|regions
P10359663A0425|126 130|SV40
P10359663A0425|132 140|promoter
P10359663A0425|211 226|enhancer region
P10359664A0579|19 24|sites
P10359664A0579|106 122|electrospray MS.
P10359792A0610|103 129|dCtBP corepressor proteins
P10359792A0610|41 53|Rpd3 mutants
P10359792A0610|165 176|recruitment
P10360839A1338|84 106|KRAB zinc finger genes
P10360839A1338|4 12|addition
P10360839A1338|56 63|members
P10361038A0281|82 95|protein genes
P10361038A0281|45 54|promoters
P10362652A1456|101 107|effect
P10362652A1456|111 114|EGF
P10362652A1456|120 121|%
P10363517A0401|36 41|cases
P10363517A0401|60 75|ultrasonography
P10364159A0813|18 27|questions
P10364159A0813|43 60|FRAP/mTOR protein
P10364202A0646|119 127|increase
P10364202A0646|64 67|DBP
P10364202A0646|5 17|coexpression
P10364202A0646|246 253|process
P10364202A0646|131 141|activation
P10364319A0109|1 3|Cp
P10364319A0109|127 139|control loop
P10364319A0109|79 85|EBNA3C
P10364523A0826|153 161|vicinity
P10364523A0826|139 145|contig
P10364523A0826|6 19|exon trapping
P10365883A1355|17 32|characteristics
P10365883A1355|67 81|vancomycin use
P10365883A1355|132 143|coinfection
P10365883A1355|121 130|infection
P10366503A0812|1 19|Binding affinities
P10366503A0812|140 162|co-immunoprecipitation
P10366503A0812|177 186|terminase
P10366503A0812|243 270|terminase interaction sites
P10366503A0812|210 216|nature
P10366559A0605|5 19|hybrid viruses
P10366559A0605|95 102|virions
P10367240A1354|51 57|medium
P10367240A1354|185 209|fertilization procedures
P10367240A1354|95 105|substances
P10367240A1354|132 146|cryoprotection
P10367240A1354|14 30|cryopreservation
P10367460A0191|118 130|microseconds
P10367460A0191|40 50|kW maximum
P10367460A0191|62 79|power consumption
P10367460A0191|181 193|Hz frequency
P10369418A0644|238 241|p65
P10369418A0644|69 74|CD40L
P10369418A0644|154 169|NF-kappaB sites
P10369418A0644|197 200|p50
P10369418A0644|228 233|c-Rel
P10369757A0000|307 320|transcription
P10369757A0000|368 392|plasmid dimer resolution
P10369757A0000|282 287|genes
P10369757A0000|11 32|transcription factors
P10369757A0000|117 121|AhrC
P10369757A0000|248 261|transcription
P10369757A0000|89 106|Bacillus subtilis
P10369926A0251|138 157|CXC chemokine genes
P10369926A0251|5 9|exon
P10369926A0251|30 41|chicken IL8
P10370675A0649|64 81|hepatitis C virus
P10370675A0649|41 49|patients
P10370675A0649|55 58|HCC
P10370675A0649|83 86|HCV
P10370675A0649|95 108|alcohol abuse
P10370675A0649|147 160|alcohol abuse
P10371097A0963|85 99|identification
P10371097A0963|38 42|tool
P10371097A0963|159 169|Turbuhaler
P10371097A0963|133 153|inhalation technique
P10371097A0963|14 23|Turbutest
P10373029A0204|33 39|soleus
P10373029A0204|44 65|gastrocnemius muscles
P10373523A0924|22 28|p50E4F
P10374632A0897|1 11|CONCLUSION
P10374632A0897|79 87|striatum
P10374632A0897|91 101|RMCAO rats
P10375638A0859|38 54|NRF-1 expression
P10375638A0859|24 28|UTR1
P10375638A0859|120 125|cells
P10375694T0000|112 122|comparison
P10375694T0000|40 51|input zones
P10375694T0000|132 143|input zones
P10376065A0881|100 101|n
P10376065A0881|6 13|filters
P10376065A0881|93 98|mm Hg
P10376065A0881|73 79|median
P10376873A0706|37 40|UTR
P10376877A0611|1 8|Removal
P10376877A0611|200 210|production
P10376877A0611|66 70|half
P10376877A0611|37 45|segments
P10376877A0611|214 222|18S rRNA
P10377345A0740|34 41|UNC-49B
P10377345A0740|82 94|muscle cells
P10377345A0740|46 62|UNC-49C subunits
P10378989A0000|184 190|period
P10378989A0000|141 146|years
P10378989A0000|5 8|aim
P10378989A0000|58 65|reports
P10378989A0000|123 131|patients
P10378989A0000|150 153|age
P10379899A0446|78 85|signals
P10379899A0446|109 118|follicles
P10379942T0000|1 15|Identification
P10379942T0000|20 29|structure
P10379942T0000|131 151|Herpesviridae family
P10379942T0000|91 101|comparison
P10380659A0545|1 14|Baseline data
P10380878A0542|137 156|histone deacetylase
P10380878A0542|22 33|possibility
P10380878A0542|88 107|repression function
P10381257A0000|69 94|preprotein import complex
P10381257A0000|22 29|protein
P10381257A0000|31 38|metaxin
P10381570A1355|118 129|ftz stripes
P10381570A1355|1 5|Slp1
P10381570A1355|55 66|yeast cells
P10381570A1355|133 152|interstripe regions
P10381570A1355|165 171|stages
P10383966A0000|34 38|PBPs
P10383966A0000|93 102|component
P10383966A0000|120 129|cell wall
P10385384A0654|65 90|pentose phosphate pathway
P10385384A0654|9 16|results
P10385915A1341|101 106|locus
P10385915A1341|76 83|D3S1766
P10385915A1341|46 56|MITF locus
P10385915A1341|121 123|cM
P10390158A1150|82 104|tiGH promoter activity
P10390158A1150|45 58|Pit-1 binding
P10391075A0000|21 33|autopsy case
P10391075A0000|132 144|MRI findings
P10391277A0000|1 11|BACKGROUND
P10391277A0000|42 51|treatment
P10392266A0111|102 110|activity
P10392266A0111|5 13|presence
P10392266A0111|27 36|xanthomas
P10392710A1000|1 16|Lung mesenchyme
P10392710A1000|91 113|peptide growth factors
P10392903A0000|155 174|papillomavirus type
P10392903A0000|54 67|proliferation
P10392903A0000|12 37|papillomavirus E2 protein
P10392914A0000|69 73|duct
P10392914A0000|173 189|tract malignancy
P10392914A0000|31 42|arrangement
P10393197A0543|1 5|DDP1
P10393197A0543|43 60|interphase nuclei
P10393251A0283|71 91|restriction analysis
P10393251A0283|5 14|PAC clone
P10393422A0476|96 106|pseudogene
P10393422A0476|25 30|LAMB2
P10393422A0476|10 12|kb
P10393969A0000|34 38|ICP0
P10393969A0000|83 97|transactivator
P10393969A0000|43 63|herpes simplex virus
P10393969A0000|165 174|infection
P10394900A1166|50 58|presence
P10394900A1166|116 120|CaMV
P10394900A1166|122 134|35S promoter
P10394900A1166|30 36|leaves
P10395199A0792|340 348|Teillaud
P10395199A0792|336 338|F.
P10395199A0792|79 83|scFv
P10395199A0792|135 146|mAb Y13-259
P10395199A0792|256 258|M.
P10395199A0792|219 230|mouse model
P10395199A0792|270 272|I.
P10395199A0792|306 313|Fridman
P10395199A0792|315 319|W.H.
P10395199A0792|44 55|experiments
P10395199A0792|288 290|A.
P10395199A0792|364 366|B.
P10395199A0792|300 304|M.C.
P10395378A1198|100 107|ligands
P10395378A1198|65 89|HA envelope glycoprotein
P10395378A1198|130 133|end
P10395908A0236|158 167|G-protein
P10395908A0236|43 50|protein
P10395908A0236|105 136|amino acid motif characteristic
P10395920A1424|100 110|regulation
P10395920A1424|191 198|element
P10395920A1424|43 53|ATF family
P10395920A1424|130 138|response
P10396343T0000|34 38|card
P10396343T0000|71 86|trypanosomiasis
P10396343T0000|88 102|TrypTect CIATT
P10397257A1142|116 124|activity
P10397257A1142|59 65|region
P10397257A1142|79 90|combination
P10397257A1142|133 134|%
P10397257A1142|181 203|cell cycle periodicity
P10398682A0365|5 22|crystal structure
P10400032A0304|49 58|vena cava
P10400032A0304|12 18|method
P10400712A0000|112 123|RNA viruses
P10400712A0000|58 80|Paramyxoviridae family
P10400712A0000|31 34|SV5
P10400757A0000|1 6|CXCR4
P10400757A0000|37 47|coreceptor
P10400757A0000|72 74|X4
P10400757A0000|105 132|immunodeficiency virus type
P10400760A0663|49 59|proteinase
P10400760A0663|115 126|E1345-T1346
P10400760A0663|158 177|cleavage efficiency
P10400760A0663|132 143|E1419-G1420
P10400785A0912|114 124|GTPase Ran
P10400785A0912|78 92|export pathway
P10400785A0912|72 75|CRM
P10402022A0432|10 16|clicks
P10403575A1401|103 117|control levels
P10403575A1401|98 99|%
P10403575A1401|5 15|inhibition
P10403839A0140|87 97|laboratory
P10403839A0140|191 197|mBMAL1
P10403839A0140|39 44|BMAL1
P10403839A0140|178 189|mouse BMAL1
P10403839A0140|46 52|hBMAL1
P10405635A0374|51 59|promoter
P10405635A0374|21 31|activities
P10406122T0000|103 117|responsiveness
P10406122T0000|39 51|LTR promoter
P10406122T0000|24 31|element
P10406122T0000|121 135|tissue culture
P10406462A1127|18 26|evidence
P10406462A1127|42 46|role
P10406465A0589|36 60|vitamin D responsiveness
P10406465A0589|79 87|promoter
P10406843A1265|1 11|Expression
P10406843A1265|67 73|RT-PCR
P10407184A0149|50 55|areas
P10407184A0149|142 144|AD
P10407184A0149|124 138|neuropathology
P10407184A0149|63 71|AD brain
P10407269A0000a|82 85|arm
P10407269A0000a|8 10|bp
P10407269A0000a|63 68|cdc14
P10407269A0000a|151 165|European Union
P10407985A0574|118 124|cycles
P10407985A0574|39 43|s.c.
P10407985A0574|78 93|micrograms s.c.
P10409699A0292|17 36|sequence tag clones
P10409699A0292|252 265|amplification
P10409699A0292|337 341|cDNA
P10409699A0292|126 138|mannosidases
P10409699A0292|160 173|coding region
P10409699A0292|269 278|cDNA ends
P10409730A0597|27 35|RP genes
P10409730A0597|56 75|Rap1p binding sites
P10409730A0597|88 90|bp
P10409749T0000|32 46|discrimination
P10409749T0000|82 92|activators
P10411139A0887|1 13|Accumulation
P10411139A0887|78 84|Prp44p
P10411140A0499|103 108|mRNAs
P10411140A0499|89 95|region
P10413604A0063|48 55|kinases
P10413604A0063|83 89|growth
P10413604A0063|124 133|mechanism
P10413662A0193|103 110|plasmid
P10413662A0193|126 149|iron acquisition system
P10413662A0193|40 65|pMJ101 replication region
P10413662A0193|180 194|V. anguillarum
P10413676A0595|1 11|Expression
P10413676A0595|65 84|FAK kinase activity
P10413676A0595|42 45|FAK
P10413676A0595|117 121|site
P10413676A0595|257 271|cell migration
P10413676A0595|191 197|domain
P10413676A0595|176 179|FAK
P10413676A0595|90 97|Tyr-397
P10414451A0093|35 37|yr
P10414451A0093|101 111|resistance
P10414451A0093|228 237|protein S
P10414451A0093|17 25|patients
P10414451A0093|217 226|protein C
P10414451A0093|144 163|lupus anticoagulant
P10414451A0093|125 134|protein C
P10416558A0000|305 311|health
P10416558A0000|38 43|study
P10416558A0000|107 123|exercise program
P10416558A0000|14 22|purposes
P10416558A0000|153 167|CD4 cell count
P10416558A0000|82 92|laboratory
P10416558A0000|332 348|exercise relapse
P10417703A1326|65 79|20S proteasome
P10417703A1326|23 30|results
P10417703A1326|163 181|plant RPT subunits
P10417703A1326|194 212|yeast counterparts
P10419521A0136|70 84|RNA polymerase
P10419521A0136|20 39|elongation activity
P10419521A0136|41 44|ELL
P10419521A0136|62 66|type
P10422342A0535|5 21|radiation burden
P10422342A0535|142 158|radiation burden
P10422342A0535|78 86|medicine
P10422342A0535|252 256|67Ga
P10422342A0535|114 118|dose
P10422342A0535|178 190|examinations
P10423156A0265|1 14|TaV particles
P10423156A0265|108 111|kDa
P10423156A0265|47 52|g/cm3
P10423292A0782|87 107|transcription factor
P10423292A0782|116 121|sites
P10423292A0782|26 32|region
P10423292A0782|134 137|CRE
P10425445T0000|33 98|mouse growth hormone receptor/growth hormone binding protein gene
P10426878A0367|68 77|Trialists
P10426878A0367|5 12|results
P10426878A0367|108 115|aspirin
P10426878A0367|41 45|data
P10426878A0367|132 140|patients
P10428091A0322|80 91|disparities
P10428091A0322|37 41|MMRs
P10428759A0743|3 11|decrease
P10428759A0743|31 55|receptor kinase activity
P10428811A1067|1 13|Cat proteins
P10428811A1067|63 68|cells
P10429184A0000|136 145|mechanism
P10429184A0000|82 98|plant cell walls
P10429184A0000|60 69|extension
P10429946A0473|139 148|sequences
P10429946A0473|97 99|bp
P10429946A0473|126 128|bp
P10429946A0473|41 54|collagen gene
P10429946A0473|74 82|fragment
P10430421T0000|1 20|APOE-epsilon4 count
P10430421T0000|39 49|prevalence
P10430421T0000|30 33|age
P10430583A0000|7 22|DNA repair gene
P10430886A0838|16 23|mutants
P10430886A0838|123 132|activator
P10430944A1298|69 81|malignancies
P10430944A1298|5 9|data
P10433729A1559|1 3|A.
P10433729A1559|5 11|Bowers
P10433729A1559|13 16|K.E
P10435595A0203|15 24|mechanism
P10437043A0164|1 8|METHODS
P10437043A0164|24 29|cases
P10438593A0000|49 60|Tat protein
P10438593A0000|42 47|HIV-1
P10438627A0885|84 91|pfTrm1p
P10438627A0885|169 173|tRNA
P10438627A0885|55 64|reactions
P10438627A0885|22 26|tRNA
P10438627A0885|161 164|Asp
P10438627A0885|183 188|yeast
P10438924T0000|48 64|protein kinase B
P10438924T0000|5 28|B cell antigen receptor
P10438924T0000|43 46|Akt
P10438950A0580|1 5|IL-1
P10438950A0580|10 47|TNF increase AND-34 transcript levels
P10440923A0684|174 178|kip1
P10440923A0684|233 248|kinase activity
P10440923A0684|318 321|pRb
P10440923A0684|153 173|kinase inhibitor p27
P10440923A0684|81 94|control cells
P10440923A0684|53 73|lovastatin treatment
P10440923A0684|214 220|cyclin
P10440923A0684|181 191|inhibition
P10441449X1212|1 10|Copyright
P10441506A0098|307 320|CZ region/HR1
P10441506A0098|339 345|domain
P10441506A0098|172 185|CZ region/HR1
P10441506A0098|129 135|region
P10441506A0098|41 49|PKNalpha
P10441506A0098|18 35|sequence homology
P10441506A0098|113 118|amino
P10443990A0000|84 95|bone health
P10443990A0000|21 40|alcohol consumption
P10444813A0448|46 52|growth
P10444813A0448|28 38|inhibition
P10445506A0073|66 77|body length
P10445506A0073|45 50|times
P10446131A0132|1 20|PDGF A-chain levels
P10446131A0132|72 76|SMCs
P10446206A0000|1 17|Deletion mapping
P10446206A0000|86 94|fragment
P10446206A0000|172 177|study
P10446206A0000|132 156|transcription start site
P10446206A0000|45 48|PS1
P10446910A0147|17 35|E2F1 gene promoter
P10446910A0147|253 258|sites
P10446910A0147|64 70|region
P10446910A0147|296 298|E2
P10446998A0375|18 33|differentiation
P10446998A0375|64 69|cells
P10446998A0375|97 111|responsiveness
P10446998T0000|1 15|Transformation
P10446998T0000|47 57|inhibition
P10447597A1004|5 18|Cr.psbA-4 ORF
P10447597A1004|59 72|GIY-YIG motif
P10448095A0865|5 30|STAT protein accumulation
P10448095A0865|162 180|expression profile
P10448095A0865|46 62|C/EBP expression
P10448440T0020|100 120|personality disorder
P10448440T0020|76 89|schizophrenia
P10448440T0020|40 62|understanding patients
P10449072A0560|50 61|arrangement
P10449072A0560|12 16|goal
P10450815A0180|169 184|tobacco smoking
P10450815A0180|203 211|calculus
P10450815A0180|110 115|years
P10450815A0180|225 232|account
P10450815A0180|254 261|factors
P10450815A0180|94 103|age range
P10450815A0180|270 273|age
P10452306A0502|168 176|diameter
P10452306A0502|97 105|peak Vo2
P10452306A0502|193 225|heart catheterization parameters
P10452306A0502|135 141|M-mode
P10452306A0502|61 89|norepinephrine concentration
P10452991A0331|82 95|T cell clones
P10453006A0478|16 26|homologues
P10453006A0478|4 12|addition
P10453006A0478|93 99|PSMB12
P10453006A0478|160 165|genes
P10453006A0478|60 65|PSMB9
P10453371A0640|63 75|BMD z-scores
P10454533A0859|16 19|HRI
P10454533A0859|139 142|HRI
P10454533A0859|82 98|Hsc70 antagonist
P10454533A0859|25 30|Hsc70
P10454533A0859|167 179|conformation
P10454550A0960|51 55|Reg1
P10454550A0960|23 31|evidence
P10454557A0975|222 232|components
P10454557A0975|200 203|cis
P10454557A0975|83 93|inactivity
P10454557A0975|37 52|HML ARS cluster
P10454557A0975|145 154|silencing
P10454557A0975|180 189|silencers
P10454568A0815|170 173|EGF
P10454568A0815|155 168|growth factor
P10454568A0815|36 40|cDNA
P10454568A0815|78 95|expression system
P10454568A0815|183 196|DNA synthesis
P10454568A0815|14 30|Grb10 expression
P10455087A1400|113 122|threshold
P10455087A1400|44 68|body insulin sensitivity
P10455183A0530|4 12|contrast
P10455183A0530|127 135|capacity
P10455183A0530|24 27|Sec
P10455183A0530|44 51|binding
P10455189A0104|4 11|B cells
P10455189A0104|13 17|HEF1
P10457075A1198|154 155|P
P10457075A1198|80 81|P
P10457075A1198|52 54|VI
P10457075A1198|77 78|%
P10457075A1198|106 111|Pcrit
P10458907A0543|22 51|mouse Rad30b mRNA transcripts
P10458907A0543|11 17|RAD30B
P10459809A1262|78 85|biofilm
P10459809A1262|44 56|cell density
P10460171A0842|118 122|step
P10460171A0842|87 95|chemical
P10460171A0842|40 64|fragment kinase reaction
P10463057A0534|45 53|plasmids
P10464185T0000|11 27|characterization
P10464291A0597|1 9|IL-1beta
P10464291A0597|86 99|protein delta
P10464291A0597|113 124|mRNA levels
P10464291A0597|130 134|time
P10464310A0218|290 296|FGFR-1
P10464310A0218|175 189|Crk SH2 domain
P10464310A0218|203 209|FGFR-1
P10464310A0218|282 285|Crk
P10464310A0218|161 167|FGFR-1
P10464310A0218|123 153|juxtamembrane tyrosine residue
P10466825T0000|1 5|Role
P10466825T0000|96 101|genes
P10466825T0000|74 84|expression
P10467004A0683|184 186|bp
P10467004A0683|66 75|EBS1/IBS1
P10467004A0683|26 34|splicing
P10467465T0000|20 40|significance testing
P10467465T0000|42 56|misconceptions
P10468585A0980|137 144|portion
P10468585A0980|87 106|amino acid residues
P10468585A0980|178 195|hsp70 interaction
P10469174A0678|34 50|NMR measurements
P10469174A0678|70 78|fragment
P10469174A0678|113 121|residues
P10469174A0678|125 129|MBF1
P10470220A1011|68 69|%
P10470220A1011|5 16|arrangement
P10470220A1011|202 205|LIA
P10470220A1011|166 177|specificity
P10470220A1011|51 62|sensitivity
P10470220A1011|92 93|%
P10470220A1011|183 184|%
P10471587A0239|253 265|erythromycin
P10471587A0239|216 222|RT-PCR
P10471587A0239|39 56|triplicate assays
P10471587A0239|197 201|MICs
P10471587A0239|135 144|technique
P10471721A0141|100 105|genes
P10471721A0141|18 26|analysis
P10471721A0141|161 162|s
P10471721A0141|182 187|genes
P10471746A1102|55 75|chromatin remodeling
P10471746A1102|10 14|MyoD
P10472836A0189|85 87|M.
P10472836A0189|1 12|Feed intake
P10472836A0189|63 73|treatments
P10473598A0691|138 153|transactivation
P10473598A0691|99 107|promoter
P10473598A0691|31 37|region
P10474898A0629|168 174|assays
P10474898A0629|111 124|hybridization
P10474898A0629|56 65|synthesis
P10474898A0629|29 38|structure
P10474898A0629|73 89|CMT1A-REP repeat
P10475972A0269|55 66|vaccination
P10475972A0269|42 47|delay
P10477545T0000|100 113|HIV-1 strains
P10477545T0000|5 15|B-oligomer
P10477545T0000|47 68|CC chemokine receptor
P10477583A0000b|55 67|Fc receptors
P10477583A0000b|77 87|Fc gamma R
P10477583A0000b|106 117|progression
P10477599T0000|81 85|site
P10477599T0000|159 165|factor
P10477599T0000|128 140|interactions
P10477599T0000|44 53|C motif-1
P10477748A1076|59 66|spindle
P10478844A1604|85 95|repression
P10478844A1604|207 218|competition
P10478844A1604|175 186|PPARalphatr
P10478844A1604|99 110|PPARalphawt
P10478844A1604|23 34|coactivator
P10479025A0528|17 26|locations
P10479025A0528|138 147|responses
P10479025A0528|105 116|spectrogram
P10479492A0000|68 72|data
P10479492A0000|1 10|OBJECTIVE
P10479492A0000|116 154|corpus uteri adenocarcinoma FIGO stage
P10479492A0000|89 90|%
P10479492A0000|31 43|Epidemiology
P10482516A1158|54 73|structure functions
P10482516A1158|110 118|deletion
P10482516A1158|146 154|increase
P10482565A0469|94 100|fusion
P10482565A0469|60 67|effects
P10483124T0000|168 188|cDNA scanning method
P10483124T0000|22 33|mutagenesis
P10483124T0000|59 79|CIC5F11/CIC2B9 locus
P10483124T0000|46 51|genes
P10484695A0791|7 25|NART-R performance
P10484695A0791|123 142|language impairment
P10484695A0791|45 53|estimate
P10485353T0000|48 73|polysaccharide antibodies
P10485353T0000|93 101|children
P10485353T0000|107 118|West Africa
P10485353T0000|120 132|Burkina-Faso
P10485585A0175|1 8|Galoyan
P10485585A0175|28 35|results
P10487040A0453|21 29|staining
P10487040A0453|75 76|%
P10487307A0768|84 86|mg
P10487307A0768|20 36|surgery patients
P10487307A0768|90 97|placebo
P10487753A0788|18 31|XDRP1 protein
P10487753A0788|79 92|cell division
P10487760A0336|82 88|mutant
P10487760A0336|111 116|yeast
P10487760A0336|29 38|cofactors
P10487921A0132|1 19|ATF1 transcription
P10487921A0132|75 81|oxygen
P10488087A0340|1 9|Mutation
P10488087A0340|54 65|combination
P10488087A0340|113 117|SP-A
P10488087A0340|183 202|SP-A gene sequences
P10488129T0058|1 10|Synthesis
P10488129T0058|24 27|RNA
P10488129T0058|61 74|E2F complexes
P10488148A0111|1 10|NF-kappaB
P10488148A0111|159 165|switch
P10488148A0111|95 102|stimuli
P10488148A0111|28 32|role
P10488148T0000|1 38|ERK MAP kinase links cytokine signals
P10488148T0000|108 119|interaction
P10488148T0000|63 78|HIV-1 infection
P10488875A0000|66 71|palsy
P10488875A0000|10 25|differentiation
P10488875A0000|73 75|CP
P10489822T0000|1 12|Montelukast
P10489822T0000|57 63|asthma
P10489822T0000|90 95|trial
P10490604A0601|80 96|ZAP-70 block 70Z
P10490604A0601|110 125|NFAT activation
P10490604A0601|27 38|kinase-dead
P10490639A0000|187 202|cyclin partners
P10490639A0000|160 171|association
P10490639A0000|79 82|Cdk
P10490639A0000|30 35|PHO85
P10490662A0819|4 8|fact
P10490662A0819|60 64|Lace
P10490822A1167|81 89|approach
P10490822A1167|7 14|results
P10490835T0000|1 24|Protein kinase A-Ialpha
P10490835T0000|109 142|tyrosine kinase signaling pathway
P10490835T0000|74 92|cancer cell growth
P10490955T0000|155 180|thrombospondin-1 peptides
P10490955T0000|8 16|integrin
P10490955T0000|44 55|stimulation
P10491187T0000|32 35|PTS
P10491187T0000|5 30|phosphotransferase system
P10491187T0000|95 103|analysis
P10492127A0914|49 59|devazepide
P10492127A0914|174 187|saline intake
P10492127A0914|208 210|hr
P10492127A0914|12 17|study
P10492127A0914|31 45|administration
P10493203T0000|23 47|treadmill exercise score
P10493203T0000|63 71|patients
P10493580A1126|17 22|Gly84
P10493580A1126|145 167|esterase/lipase family
P10493580A1126|130 137|C group
P10493580A1126|46 59|oxyanion hole
P10495573A0365|174 180|course
P10495573A0365|65 69|MUSE
P10495573A0365|56 61|place
P10495573A0365|149 153|MUSE
P10495573A0365|121 128|results
P10495573A0365|30 36|market
P10496284A0115|38 49|CSF protein
P10496284A0115|77 83|levels
P10496284A0115|132 150|IgG synthesis rate
P10496388A1956a|119 126|concern
P10496388A1956a|49 56|vessels
P10496388A1956a|12 24|nonperfusion
P10496553A1004|34 42|patients
P10496553A1004|98 103|weeks
P10496553A1004|5 17|healing rate
P10496553A1004|67 72|weeks
P10496553A1004|123 130|figures
P10497199A0559|100 104|GlRE
P10497199A0559|21 26|yeast
P10497199A0559|78 92|factor binding
P10497199A0559|165 171|factor
P10497800A0000|51 55|MMPI
P10497800A0000|57 65|Hathaway
P10497800A0000|13 20|Butcher
P10498616A0157|205 211|growth
P10498616A0157|3 14|G22V mutant
P10498616A0157|162 170|survival
P10498616A0157|75 88|interleukin-3
P10498616A0157|189 193|IL-3
P10498616A0157|58 68|expression
P10498616A0157|90 94|IL-3
P10498706A1219|55 59|pelD
P10498706A1219|39 43|PecS
P10498706A1219|109 118|repressor
P10499121A0542|81 98|input compression
P10499121A0542|129 139|enrollment
P10499121A0542|148 153|study
P10501034A0839|55 59|hmg2
P10501034A0839|199 213|pigment glands
P10501034A0839|149 162|morphogenesis
P10501936T0000|153 167|protein import
P10501936T0000|100 114|point mutation
P10501936T0000|21 38|Neurospora crassa
P10501936T0000|59 81|membrane protein TOM70
P10501969A1329|5 12|results
P10501969A1329|79 85|GATA-4
P10501969A1329|62 69|targets
P10502402A0129|84 103|mouse T lymphocytes
P10502402A0129|24 29|TRAIL
P10502402A0129|177 189|cytotoxicity
P10502434A0367|174 183|treatment
P10502434A0367|23 29|August
P10502434A0367|40 48|patients
P10502522A0000|119 130|individuals
P10502522A0000|93 104|lymphocytes
P10502522A0000|11 27|provirus genomes
P10503812A1450|3 13|population
P10503812A1450|54 79|organ transplant patients
P10503812A1450|129 134|years
P10503812A1450|192 220|cyclosporin pharmacokinetics
P10505694A0000|17 22|IL-12
P10505694A0000|86 90|PBMC
P10505694A0000|79 84|cells
P10505694A0000|133 143|production
P10505694A0000|122 131|IFN-gamma
P10505694A0000|61 66|blood
P10506143A0610|170 173|EGF
P10506143A0610|175 184|TNF-alpha
P10506143A0610|231 256|GTP binding proteins Rac1
P10506143A0610|186 196|anisomycin
P10506143A0610|113 117|JNK1
P10506143A0610|214 219|MEKK1
P10508522A1598|48 54|target
P10508522A1598|23 35|TGF-beta RII
P10510295A0606|49 52|ERA
P10510295A0606|82 99|repressor element
P10510295A0606|77 80|TAB
P10510295A0606|14 47|ethanol repression autoregulation
P10511216A0654|64 69|cause
P10512699A0364|48 61|SECIS element
P10512699A0364|141 149|position
P10512699A0364|37 46|structure
P10512699A0364|162 165|UGA
P10512699A0364|167 172|codon
P10512699A0364|194 205|termination
P10512857A0000|116 137|transcription factors
P10512857A0000|36 47|plakoglobin
P10512857A0000|89 101|interactions
P10513756A0584|68 85|8-predictor model
P10513756A0584|43 44|%
P10513756A0584|150 155|alpha
P10514493A0199|136 150|reporter genes
P10514493A0199|161 185|NTR-1 promoter sequences
P10514493A0199|121 131|Ntr-1 gene
P10516011A0471|118 122|sets
P10516011A0471|36 51|peptide mapping
P10516011A0471|126 151|pAP phosphorylation sites
P10516072A0146|1 5|Duch
P10516878T0000|17 46|dopamine D2 receptor activity
P10516878T0000|1 13|Modification
P10516878T0000|63 72|Parkinson
P10516878T0000|75 82|disease
P10517672A1417|137 140|NF1
P10517672A1417|101 127|CCAAT transcription factor
P10517672A1417|146 183|Drosophila Schneider SL2 insect cells
P10517672A1417|215 231|trans-activation
P10518496A0952|152 178|periimplantation lethality
P10518496A0952|223 236|organogenesis
P10518496A0952|42 52|stem cells
P10518496A0952|135 142|tissues
P10518561A0261|33 51|Tec family kinases
P10518561A0261|121 130|effectors
P10518822A1037|1 11|CONCLUSION
P10518822A1037|39 46|eotaxin
P10518822A1037|113 122|biomarker
P10518822A1037|91 97|asthma
P10518956A0137|155 160|gland
P10518956A0137|7 30|thyroid hormone changes
P10518956A0137|128 140|hypothalamus
P10518956A0137|166 179|thyroid gland
P10520800A0307|171 174|ECG
P10520800A0307|84 89|years
P10520800A0307|1 8|METHODS
P10520800A0307|115 124|reduction
P10520800A0307|59 62|men
P10521443A0486|257 280|NF-kappaB c-Rel subunit
P10521443A0486|81 90|tyrosines
P10521443A0486|66 77|IR mutation
P10521443A0486|197 210|IkappaB-alpha
P10521443A0486|26 39|IR activation
P10521447A1190|32 46|AML3/CBFalpha1
P10521447A1190|14 28|overexpression
P10521509A0000|139 146|domains
P10521509A0000|41 49|proteins
P10521509A0000|227 232|RGS11
P10521509A0000|104 107|GGL
P10521509A0000|154 163|subfamily
P10521509A0000|80 86|EGL-10
P10521509A0000|88 98|pleckstrin
P10521796A0872|5 8|ORs
P10521796A0872|336 345|gastritis
P10521796A0872|37 40|sex
P10521796A0872|382 385|CAG
P10521796A0872|12 14|GC
P10521796A0872|166 168|IM
P10521796A0872|75 93|baseline diagnoses
P10521796A0872|188 191|DYS
P10521796A0872|177 186|dysplasia
P10521796A0872|390 398|baseline
P10523520A0986|51 63|Hh molecules
P10523520A0986|11 25|nematode genes
P10523640A0367|119 134|gene regulation
P10523640A0367|80 88|tyrosine
P10523640A0367|162 184|serine phosphorylation
P10523640A0367|14 33|Src tyrosine kinase
P10523647A1001|49 58|regulator
P10523647A1001|108 120|AP-1 factors
P10523647A1001|135 152|AP-1 target genes
P10523674A0000|1 10|RNase MRP
P10523674A0000|79 84|roles
P10524258T0000|1 11|Regulation
P10524258T0000|21 54|fibroblast growth factor receptor
P10524258T0000|58 64|FGFR-1
P10526670A0236|1 4|Rac
P10526670A0236|42 49|F-actin
P10526670A0236|77 97|phosphatidylinositol
P10526670A0236|146 163|membrane ruffling
P10527106A0384|186 193|deficit
P10527106A0384|169 178|depiction
P10527106A0384|42 50|findings
P10527106A0384|57 64|support
P10527180A0869|205 207|CI
P10527180A0869|1 8|RESULTS
P10527180A0869|544 549|liver
P10527180A0869|679 683|lung
P10527180A0869|10 17|Factors
P10527180A0869|74 91|treatment failure
P10527180A0869|222 249|Karnofsky performance score
P10527180A0869|765 773|response
P10527180A0869|812 824|chemotherapy
P10527180A0869|391 395|% CI
P10527180A0869|329 333|% CI
P10527180A0869|715 722|disease
P10527180A0869|786 794|response
P10527180A0869|526 536|metastases
P10527180A0869|834 838|% CI
P10527180A0869|670 674|bone
P10527180A0869|49 50|P
P10527180A0869|732 736|% CI
P10527180A0869|353 356|use
P10527180A0869|662 668|tissue
P10527180A0869|302 319|hormone receptors
P10527475A0643|4 6|PC
P10527475A0643|13 18|MNGCs
P10529198A0068|26 32|domain
P10529198A0068|73 88|homologues p140
P10529354A0375|66 76|structures
P10529354A0375|144 157|26S particles
P10529354A0375|94 99|PA700
P10529354A0375|90 93|19S
P10531340A1275|18 20|R.
P10531340A1275|22 28|Venter
P10531342A1111|4 12|contrast
P10531342A1111|41 61|proteophosphoglycans
P10531446A0203|1 11|Neuregulin
P10531446A0203|23 28|ErbB2
P10531446A0203|41 46|ErbB4
P10531446A0203|30 35|ErbB3
P10532805A0792|4 14|PC12 cells
P10532805A0792|53 68|differentiation
P10533066A0758|1 15|TSC1 mutations
P10533066A0758|37 46|mutations
P10534048A0297|50 70|projection algorithm
P10534048A0297|235 250|attenuation map
P10534048A0297|22 30|FOREPROJ
P10534048A0297|106 136|attenuation correction factors
P10534048A0297|285 295|projection
P10534402A0659|171 186|pachytene stage
P10534402A0659|1 7|RT-PCR
P10534402A0659|48 59|time course
P10534402A0659|146 154|Prophase
P10534402A0659|105 121|Spo11 expression
P10535715A0268|36 41|phase
P10535715A0268|112 119|kJ/24 h
P10535715A0268|129 135|luteal
P10536369A0662|103 110|element
P10536369A0662|43 51|evidence
P10536788A0931|169 171|PL
P10536788A0931|158 159|%
P10536788A0931|10 11|d
P10536788A0931|74 80|breeds
P10540292A1179|201 207|inputs
P10540292A1179|7 11|data
P10540292A1179|130 144|spv expression
P10540292A1179|26 45|spv virulence genes
P10540915A0697|71 80|reduction
P10540915A0697|43 51|ligation
P10540915A0697|88 89|%
P10541550A0487|143 161|DmORC localization
P10541550A0487|58 73|chorion element
P10541550A0487|88 99|information
P10541550A0487|120 133|amplification
P10542237A0357|155 158|LPS
P10542237A0357|65 69|mice
P10542237A0357|27 35|explants
P10542260A0832|50 55|FVIIa
P10542260A0832|5 16|requirement
P10542260A0832|60 63|FXa
P10542274A1376|19 29|activation
P10542274A1376|97 126|caveolin-1 protein expression
P10542274A1376|56 65|signaling
P10542281A0382|103 108|motif
P10542281A0382|35 45|hyaluronan
P10542281A0382|133 145|repeat loops
P10543270A1054|68 76|recovery
P10543270A1054|32 37|NOexh
P10543270A1054|131 134|ppb
P10543270A1054|94 95|p
P10543728A0358|17 20|E1A
P10543728A0358|115 123|contrast
P10543728A0358|23 36|cHa-ras cells
P10543728A0358|106 110|AP-1
P10543949A0686|24 40|specificity site
P10544088A0308|5 14|NF-kappaB
P10544088A0308|111 120|NF-kappaB
P10544088A0308|26 44|reporter construct
P10544088A0308|134 137|Tat
P10544113A0293|114 117|LTR
P10544113A0293|76 84|enhancer
P10545248A0567|87 113|homeodomain protein Tinman
P10545248A0567|115 118|Tin
P10545248A0567|5 9|core
P10548434A1549|156 169|p38 signaling
P10548434A1549|53 63|T antigens
P10548434A1549|145 152|JNK/SPK
P10548434A1549|132 135|ERK
P10548722A0099|5 9|loci
P10548722A0099|142 150|sequence
P10548722A0099|25 37|organization
P10548722A0099|194 201|element
P10549354A2371|129 135|cancer
P10549354A2371|47 71|Tcf target gene activity
P10549354A2371|120 125|forms
P10550139A0191|1 9|PATIENTS
P10550139A0191|65 86|bone marrow aspirates
P10550139A0191|97 102|sides
P10550574A1038|140 141|%
P10550574A1038|6 12|regard
P10550574A1038|145 151|cycles
P10550574A1038|106 111|grade
P10551796T0000|1 11|Regulation
P10551848A0000|34 46|Kurzydlowski
P10551848A0000|66 75|MacLennan
P10551848A0000|22 28|Kimura
P10551848A0000|58 60|M.
P10551848A0000|15 20|study
P10551879T0000|48 75|A-kinase anchoring proteins
P10551879T0000|95 133|fluorescence resonance energy transfer
P10553551A0000|85 92|pathway
P10553551A0000|52 60|disorder
P10554946A0082|173 179|breast
P10554946A0082|142 150|emphasis
P10554946A0082|52 61|tamoxifen
P10554946A0082|127 135|faslodex
P10554946A0082|198 204|lipids
P10554946A0082|181 187|uterus
P10555285A1065|33 51|duplication events
P10555285A1065|6 18|organization
P10556028A0292|185 189|BD-2
P10556028A0292|5 15|cop region
P10556028A0292|66 69|inc
P10556028A0292|111 124|repA promoter
P10556028A0292|41 64|plasmid incompatibility
P10556033A0000|100 107|systems
P10556033A0000|55 61|humans
P10556033A0000|167 173|region
P10556033A0000|46 51|yeast
P10556046A0328|63 80|signaling pathway
P10556089A0901|102 106|role
P10556089A0901|5 9|data
P10556089A0901|199 211|conservation
P10556089A0901|215 228|gene function
P10556089A0901|240 246|CUG-bp
P10556263A1035|1 12|CONCLUSIONS
P10556263A1035|26 31|value
P10556263A1035|45 50|space
P10556751A0758|18 22|view
P10556751A0758|92 104|immunization
P10556751A0758|106 109|HGV
P10556751A0758|74 78|lack
P10557072A0127|47 52|cDNAs
P10557072A0127|31 36|mouse
P10557072A1218|77 94|signaling pathway
P10557072A1218|28 32|ULK2
P10559207A0207|170 175|genes
P10559207A0207|197 206|evolution
P10559207A0207|27 42|ATP sulfurylase
P10559207A0207|12 21|organisms
P10559207A0207|151 157|fusion
P10559320A0080|55 65|alphavirus
P10559320A0080|20 24|half
P10559320A0080|44 51|homolog
P10559364A0846|168 172|UL44
P10559364A0846|232 259|UL112-113 accessory protein
P10559364A0846|46 47|h
P10559364A0846|284 301|bromodeoxyuridine
P10559364A0846|49 52|IE2
P10559364A0846|25 33|HF cells
P10559364A0846|303 307|BrdU
P10560997A1072|1 11|CONCLUSION
P10560997A1072|12 13|S
P10561153A0225|136 143|failure
P10561153A0225|39 45|breast
P10561153A0225|14 18|case
P10561460A0615|138 152|signal peptide
P10561460A0615|65 70|level
P10561460A0615|78 89|polypeptide
P10562418A0238|49 54|cells
P10562495A0188|101 105|gene
P10562495A0188|78 88|SFV genome
P10562495A0188|123 133|production
P10562495A0188|15 24|SFV genes
P10563605A0773|49 53|IENF
P10563605A0773|83 98|fiber densities
P10563605A0773|29 40|association
P10563836A1234|115 134|AP-2 protein levels
P10563836A1234|4 12|contrast
P10563836A1234|144 149|cells
P10564280A0140|187 200|Src substrate
P10564280A0140|219 226|mitosis
P10564280A0140|132 170|component scaffold attachment factor B
P10564474T0000|57 67|expression
P10564474T0000|107 129|polymyxin B resistance
P10564484A0859|70 78|promoter
P10564484A0859|6 16|constructs
P10564484A0859|129 141|requirements
P10564484A0859|195 203|promoter
P10564593A0428|137 145|S1-M1-80
P10564593A0428|1 5|FISH
P10564593A0428|33 38|paint
P10564593A0428|121 129|MCF-7 MX
P10564593A0428|181 194|translocation
P10564939A0981|5 11|effect
P10564939A0981|15 22|smoking
P10566862A0000|1 11|BACKGROUND
P10566862A0000|52 61|distances
P10566862A0000|128 138|evaluation
P10566862A0000|28 40|stereoacuity
P10567524T0000|69 74|yeast
P10567524T0000|40 57|signaling network
P10567538A1028|18 44|acetyltransferase activity
P10567538A1028|158 164|region
P10567538A1028|135 138|CH3
P10567582A1334|93 106|embryogenesis
P10567582A1334|60 65|CtBP2
P10568275A0679|98 106|subgroup
P10568275A0679|110 116|GEOMAR
P10568275A0679|26 33|sea ice
P10568275A0679|61 73|Arctic Ocean
P10568728A1445|5 10|level
P10568728A1445|61 65|days
P10570262A0000|1 11|Activation
P10570262A0000|59 68|receptors
P10570262A0000|90 108|signaling cascades
P10571047A1009|102 119|HindIII fragments
P10571047A1009|59 66|spacers
P10571047A1009|26 35|sequences
P10572087A0326|86 91|yeast
P10572087A0326|52 74|anemia group C protein
P10572131A0000|1 19|Klebsiella oxytoca
P10572131A0000|64 71|enzymes
P10573781A0631|32 43|involvement
P10573781A0631|56 60|loci
P10573781A0631|88 94|excess
P10574929A0583|22 35|fractionation
P10574992A0901|138 149|irradiation
P10574992A0901|109 134|cell death susceptibility
P10574992A0901|192 232|PARP chemical inhibitor 3-aminobenzamide
P10575545A0147|19 24|CACCC
P10576177A0308|6 17|distinction
P10576177A0308|126 137|implication
P10576177A0308|45 54|diagnosis
P10578528A0730|38 43|focus
P10578528A0730|24 32|location
P10578528A0730|95 108|manifestation
P10579722T0000|1 16|Phosphorylation
P10579722T0000|74 84|Rho-kinase
P10580438A0508|137 150|preadipocytes
P10580438A0508|20 40|mobility shift assay
P10580438A0508|79 83|G4RE
P10580438A0508|165 175|adipocytes
P10584138T0001|51 69|radio-chemotherapy
P10584138T0001|1 15|Cytoprotection
P10584138T0001|82 93|neck tumors
P10585311A0494|153 159|biopsy
P10585311A0494|1 9|Patients
P10585311A0494|98 106|interval
P10585311A0494|142 151|diagnosis
P10585311A0494|130 138|symptoms
P10585311A0494|31 35|MPGN
P10585417A1412|17 28|differences
P10585417A1412|32 41|signaling
P10585417A1412|46 63|tissue expression
P10585453A1029|32 51|hGH-N gene promoter
P10585453A1029|188 195|hGH LCR
P10585453A1029|109 113|data
P10585453A1029|13 24|Pit-1 sites
P10585480A0157|49 52|Sos
P10585480A0157|56 90|guanine nucleotide exchange factor
P10585491A0945|35 51|binding activity
P10585491A0945|374 383|seedlings
P10585491A0945|76 98|AtpC promoter sequence
P10585491A0945|287 295|extracts
P10585491A0945|319 341|AtpC expression levels
P10585491A0945|155 177|AtpC expression levels
P10585491A0945|250 266|binding activity
P10585491A0945|125 133|extracts
P10585491A0945|301 308|tissues
P10586074A0129|143 161|encephalitis virus
P10586074A0129|10 17|purpose
P10586074A0129|121 131|flavivirus
P10586115A0477|204 211|inducer
P10586115A0477|175 180|cells
P10586115A0477|55 64|cytokines
P10586115A0477|96 105|TNF-alpha
P10586115A0477|110 114|IL-6
P10586115A0477|75 84|IL-1alpha
P10587460A0302|175 182|Delta60
P10587460A0302|162 169|Delta80
P10587460A0302|153 160|Delta84
P10587460A0302|23 42|VDRE binding domain
P10587460A0302|144 151|Delta90
P10587460A0302|124 132|Delta113
P10587576A0596|84 88|ESTs
P10587576A0596|39 43|loci
P10587576A0596|56 58|kb
P10587576A0596|63 69|harbor
P10589562A1208|101 122|RF power requirements
P10589562A1208|28 37|inability
P10590092A0124|32 53|HIV-1 gene expression
P10590092A0124|61 64|CNS
P10591633A0138|21 28|process
P10591633A0138|65 80|target membrane
P10591633A0138|7 12|event
P10591633A0138|125 151|SNARE protein interactions
P10591633A0138|88 95|vesicle
P10591976A0317|32 39|LWS lat
P10591976A0317|55 63|triangle
P10591976A0317|92 100|patients
P10592791A0370|440 452|practicality
P10592791A0370|307 321|RIDASCREEN kit
P10592791A0370|4 14|conclusion
P10592791A0370|200 207|ability
P10592791A0370|501 518|research purposes
P10592791A0370|108 123|RIDASCREEN kits
P10592791A0370|377 392|test procedures
P10592791A0370|285 295|background
P10592791A0370|250 257|testing
P10592791A0370|157 170|investigation
P10592791A0370|456 467|SET-EIA kit
P10592824A1157|171 172|%
P10592824A1157|39 48|infection
P10592824A1157|76 88|JEV antibody
P10592824A1157|128 135|vaccine
P10592824A1157|255 266|JE vaccines
P10592824A1157|184 185|%
P10592824A1157|293 303|Chi-square
P10592824A1157|247 251|dose
P10593950A1113|38 40|dT
P10593950A1113|65 71|U2AF65
P10593950A1113|126 134|hnRNP A1
P10593950A1113|109 121|protein p116
P10594239A0614|137 140|Ipl
P10594239A0614|1 10|Tih1 maps
P10594239A0614|65 72|regions
P10594239A0614|93 101|evidence
P10594239A0614|125 133|contrast
P10594903A0000|35 48|nanoparticles
P10594903A0000|5 14|potential
P10594903A0000|112 122|substances
P10594903A0000|165 167|VX
P10596955A1032|103 109|levels
P10596955A1032|80 92|Axsym method
P10596955A1032|24 40|failure patients
P10596955A1032|45 53|troponin
P10597223A0339|221 242|transcription factors
P10597223A0339|112 124|p21 promoter
P10597223A0339|192 205|binding sites
P10597223A0339|62 72|activation
P10597317A1156|1 10|Apoptosis
P10597317A1156|231 240|apoptosis
P10597317A1156|199 209|inhibition
P10597317A1156|50 65|co-transfection
P10597317A1156|20 25|cells
P10597317A1156|213 216|JNK
P10597317A1156|89 97|addition
P10598101A0754|87 95|pentamer
P10598101A0754|65 73|promoter
P10598101A0754|159 172|transcription
P10598101A0754|214 230|expression assay
P10598101A0754|181 198|kDa zein promoter
P10600171A1066|84 91|binding
P10600171A1066|95 102|COUP-TF
P10600171A1066|47 53|CYP3A2
P10601280A0674|35 42|element
P10601280A0674|121 131|activation
P10601335A0892|19 30|mannosidase
P10601335A0892|76 86|degrees C.
P10601410A0977|51 55|IVIg
P10601410A0977|20 24|data
P10601410A0977|42 46|role
P10601747A0482|86 95|anomalies
P10601747A0482|113 124|N400 effect
P10601747A0482|167 177|word onset
P10602502A0422|38 60|cell cycle progression
P10602502A0422|10 21|Tob protein
P10602516A0182|32 40|homology
P10602516A0182|99 105|AT1-46
P10602516A0182|123 131|function
P10602516A0182|44 55|microtubule
P10603349A1667|204 217|mesencephalon
P10603349A1667|100 116|progenitor cells
P10603349A1667|157 166|viscinity
P10603349A1667|83 87|Myf5
P10603349A1667|41 49|hedgehog
P10604583T0000|117 138|liver transplantation
P10604583T0000|146 157|possibility
P10604583T0000|29 36|removal
P10604583T0000|195 201|toxins
P10606245A0906|85 105|OC promoter activity
P10606245A0906|19 26|CDP/cut
P10606245A0906|112 122|repression
P10606245A0906|148 157|OC box I.
P10606515A0389|154 160|strand
P10606515A0389|6 13|domains
P10606515A0389|41 52|DNA binding
P10607566A0880|171 174|RAR
P10607566A0880|115 121|manner
P10607566A0880|189 192|TCF
P10607566A0880|197 217|beta-catenin binding
P10607566A0880|73 84|RA receptor
P10607900T0000|1 26|Sak kinase gene structure
P10608893A0727|39 42|DNA
P10608893A0727|57 65|strength
P10608893A0727|12 17|Hp140
P10611225A1127|101 112|translation
P10611225A1127|67 73|region
P10611225A1127|126 137|interaction
P10611225A1127|193 197|role
P10611225A1127|45 50|eIF4A
P10611235A1927|118 132|relocalization
P10611235A1927|54 64|activation
P10611235A1927|95 96|G
P10611235A1927|72 82|MAPK Fus3p
P10611235A1927|28 32|step
P10611320A0816|149 153|Cdk7
P10611320A0816|74 82|CAK gene
P10612044A1180|159 173|Aal-rpL8 genes
P10612044A1180|79 90|nucleotides
P10612044A1180|31 43|conservation
P10612773A1210|1 12|CONCLUSIONS
P10612773A1210|107 114|surgery
P10612773A1210|30 39|S-100beta
P10612918A0318|53 59|screws
P10613843A0107|37 55|duplication events
P10613843A0107|123 125|Ca
P10613874A0663|186 199|GlnA proteins
P10613874A0663|84 88|ORFs
P10613874A0663|1 8|Cloning
P10613874A0663|40 46|region
P10613874A0663|106 108|bp
P10613874A0663|165 173|homology
P10614857A0584|35 40|blood
P10614857A0584|229 239|rhinovirus
P10614857A0584|75 81|months
P10614857A0584|85 88|age
P10614857A0584|217 218|P
P10614857A0584|150 158|children
P10614857A0584|181 191|adenovirus
P10617126A1005|221 225|rats
P10617126A1005|118 122|area
P10617126A1005|201 204|CA3
P10617126A1005|157 170|dentate gyrus
P10617126A1005|193 196|CA1
P10617126A1005|14 22|analysis
P10617232A0393|138 146|patients
P10617232A0393|22 30|serology
P10617232A0393|122 131|treatment
P10618645A0750|65 71|nmol/L
P10618645A0750|44 57|concentration
P10619169A0411|1 5|Rams
P10619169A0411|23 34|testis size
P10619353T0000|1 5|Role
P10619353T0000|93 110|chicken ovalbumin
P10619353T0000|9 33|estrogen receptor ligand
P10619353T0000|120 149|promoter transcription factor
P10620335A0749|40 47|COUP-TF
P10622574A0000|19 36|hepatitis C virus
P10622574A0000|99 115|prevalence rates
P10622574A0000|143 148|world
P10622574A0000|43 52|infection
P10623758A0947|137 142|cells
P10623758A0947|71 78|footpad
P10623758A0947|8 15|latency
P10623758A0947|89 107|beta-galactosidase
P10623758A0947|44 51|ganglia
P10624787A0432|204 219|body mass index
P10624787A0432|37 46|functions
P10624787A0432|75 76|P
P10624787A0432|254 255|P
P10624787A0432|221 222|P
P10624787A0432|179 183|Type
P10625494A1059|7 14|results
P10625494A1059|73 86|MDR1 promoter
P10625721T0101|35 39|HACA
P10625721T0101|27 33|Arrest
P10627532A0739|32 33|Z
P10627532A0739|112 115|JNK
P10627532A0739|95 102|kinases
P10627532A0739|56 62|stress
P10627532A0739|104 107|p38
P10627532A0739|90 93|MAP
P10628490T0000|24 30|artery
P10628748A0746|154 157|CRE
P10628748A0746|58 62|SF-1
P10628748A0746|28 39|mutagenesis
P10628750T0000|1 12|Angiotensin
P10628750T0000|156 176|NF-kappaB activation
P10628750T0000|40 42|NF
P10628750T0000|44 60|kappaB1 isoforms
P10628971A0824|19 26|mutants
P10628971A0824|80 89|mutations
P10628971A0824|67 74|members
P10628971A0824|124 145|protein sorting genes
P10629035A0827|85 92|G tails
P10629035A0827|217 226|synthesis
P10629035A0827|126 136|telomerase
P10629035A0827|12 24|strandedness
P10629938A1352|152 162|cell cycle
P10629938A1352|141 148|studies
P10629938A1352|67 79|compartments
P10629938A1352|125 129|tool
P10630630A0614|35 44|inhibitor
P10630630A0614|10 22|calphostin C
P10630630A0614|91 106|CFI mRNA levels
P10633499A1306|1 25|Arhythmacanthus Yamaguti
P10633499A1306|203 208|hooks
P10633499A1306|121 131|hook types
P10635209A0419|42 50|adhesive
P10637230A0332|23 28|c-myc
P10637230A0332|9 19|expression
P10637230A0332|88 93|cells
P10637337A0545|19 29|DNA repair
P10637337A0545|45 49|TFA1
P10639585A0157|99 114|differentiation
P10639585A0157|12 31|MPO gene regulation
P10640683A0670|37 46|P19 cells
P10640683A0670|286 296|derivative
P10640683A0670|164 172|enhancer
P10640683A0670|157 162|RIPE3
P10640683A0670|364 377|transcription
P10640683A0670|330 338|increase
P10640683A0670|210 223|co-expression
P10640734A0190|69 72|SH2
P10640734A0190|174 187|cell activity
P10640734A0190|127 149|tyrosine phosphatase-1
P10641688A0341|1 10|Alignment
P10641688A0341|63 75|disc changes
P10642531A2322|1 24|Competition experiments
P10642531A2322|59 71|relationship
P10643313A0345|34 50|mg acetazolamide
P10643313A0345|55 67|disinfection
P10643313A0345|132 138|ml SF6
P10643313A0345|75 86|conjunctiva
P10644414T0000|43 61|20-hydroxyecdysone
P10644414T0000|14 24|expression
P10644760A0000|86 97|interaction
P10644760A0000|42 68|neurotransmitter phenotype
P10644760A0000|111 115|cues
P10645921A0000|1 11|BACKGROUND
P10645921A0000|30 41|hypertrophy
P10646820T0000|96 108|hysterectomy
P10646820T0000|29 44|lymphadenectomy
P10647177A0599|136 141|sites
P10647177A0599|175 184|formation
P10647177A0599|53 57|pair
P10647177A0599|106 110|fold
P10647817T0000|40 55|monkey platelet
P10647817T0000|29 35|gibbon
P10647817T0000|60 85|T cell activation antigen
P10648020A0151|33 36|vWF
P10648020A0151|278 280|RA
P10648020A0151|10 31|Von Willebrand factor
P10648020A0151|187 197|fibrinogen
P10648020A0151|216 223|markers
P10648020A0151|176 185|platelets
P10648489A1117|69 72|sum
P10648489A1117|117 136|peak concentrations
P10648489A1117|37 41|dose
P10648489A1117|106 112|trough
P10649449A0413|32 42|homologies
P10649449A0413|5 14|sequences
P10649449A0413|76 83|enzymes
P10649449A0413|91 97|number
P10649738A0953|85 99|patient-months
P10649738A0953|48 55|patient
P10649738A0953|5 13|episodes
P10650938T0000|5 22|estrogen receptor
P10650938T0000|52 73|estrogen dependencies
P10650938T0000|28 36|isoforms
P10650939A1542|64 68|PR-B
P10650939A1542|25 33|isoforms
P10650939A1542|73 77|PR-A
P10650939A1542|15 18|SMC
P10651076T0000|6 16|resolution
P10651076T0000|26 36|tomography
P10651805T0000|1 17|Characterization
P10651805T0000|76 83|carrier
P10652102A0620|117 123|growth
P10652102A0620|67 77|inhibition
P10652102A0620|46 50|Fus3
P10652324A0177|14 27|participation
P10652800A0984|48 57|evolution
P10652800A0984|200 207|control
P10652800A0984|5 28|insulin therapy regimen
P10652800A0984|212 218|height
P10652800A0984|93 105|relationship
P10652800A0984|133 142|diagnosis
P10653400A0000|54 57|LDN
P10653400A0000|94 99|donor
P10653693A0429|25 31|issues
P10653693A0429|73 77|KRAB
P10653697A0133|27 32|forms
P10653697A0133|47 57|processing
P10654032A1133|87 98|performance
P10655230A0685|35 54|mouse GCN2 isoforms
P10655230A0685|12 29|yeast counterpart
P10655230A0685|105 111|kinase
P10656161A0316|83 88|serum
P10656161A0316|29 40|Cmax values
P10657238A0541|153 162|construct
P10657238A0541|237 245|activity
P10657238A0541|124 141|mouse NMuMG cells
P10657238A0541|107 120|transcription
P10657899A0685|17 22|cells
P10657899A0685|100 110|activation
P10657899A0685|173 177|mice
P10657899A0685|26 36|mouse skin
P10657899A0685|122 131|JB6 cells
P10658445A0208|1 8|METHODS
P10658445A0208|158 164|latter
P10658445A0208|36 44|patients
P10658445A0208|182 197|reference group
P10660069A0819|117 126|RRD genes
P10660069A0819|65 69|HOG1
P10660069A0819|93 104|interaction
P10660069A0819|135 168|Hog1p signal transduction pathway
P10660604A0748|59 96|HD-PPRE luciferase reporter construct
P10662550A0679|64 85|retardation phenotype
P10662550A0679|7 11|SOX8
P10662614A0972|68 70|CI
P10662614A0972|16 21|assay
P10662614A0972|80 82|P1
P10662614A0972|92 94|CP
P10664876A0000|34 48|corticosteroid
P10664876A0000|207 216|molecules
P10664876A0000|277 284|group C
P10664876A0000|286 308|betamethasone type-non
P10664876A0000|255 262|group B
P10664876A0000|325 332|group D
P10664876A0000|58 66|patients
P10664876A0000|182 188|groups
P10665798A0598|98 120|creatine phosphokinase
P10665798A0598|20 25|level
P10665798A0598|52 74|aspartate transaminase
P10665798A0598|29 42|serum enzymes
P10665798A0598|210 214|cell
P10665798A0598|181 192|albino rats
P10666222A0330|36 56|survivin cDNA clones
P10666253A1291|35 42|hairpin
P10666253A1291|55 61|amount
P10666253A1291|14 27|stabilization
P10667597A0668|38 53|splice variants
P10667597A0668|9 20|HZF16 genes
P10669319A1722|59 65|number
P10669319A1722|13 24|conclusions
P10669594A0969|50 63|SefA proteins
P10669594A0969|97 105|fimbriae
P10669594A0969|29 33|none
P10669633A0391|100 110|flt-1 gene
P10669633A0391|9 14|study
P10669633A0391|122 132|activation
P10669751T0000|128 142|transformation
P10669751T0000|74 89|cot oncoprotein
P10671519A0641|100 111|amino acids
P10671519A0641|162 179|membrane proteins
P10671519A0641|40 51|MAN1 shares
P10671519A0641|73 79|domain
P10671554A0492|64 77|porcine cDNAs
P10671554A0492|112 131|amino acid residues
P10671554A0492|13 33|amino acid sequences
P10672433A0199|98 101|TIB
P10672433A0199|65 72|bedtime
P10672433A0199|202 212|percentage
P10672433A0199|10 15|night
P10672433A0199|132 139|minutes
P10672433A0199|85 89|time
P10672433A0199|50 61|measurement
P10672433A0199|216 223|morning
P10672433A0199|93 96|bed
P10672433A0199|122 128|number
P10673335X0782|1 10|Copyright
P10674395A0262|153 180|signal transduction pathway
P10674395A0262|263 278|cell line GT1-7
P10674395A0262|142 145|GMP
P10674395A0262|147 151|cGMP
P10675154T0000|20 35|botulinum toxin
P10675610A0279|1 6|MSSPs
P10675610A0279|32 47|DNA replication
P10675610A0279|126 139|C-MYC protein
P10677214A2842|85 99|N HSQC spectra
P10677214A2842|52 56|E44D
P10677214A2842|79 80|H
P10677214A2842|166 172|Glu-44
P10678144A0509|7 11|i.v.
P10679015A0216|39 44|yeast
P10679015A0216|58 63|class
P10679015A0216|28 35|studies
P10679065A1217|85 98|reporter gene
P10679065A1217|80 83|CAT
P10679065A1217|106 109|BCR
P10679649A0311|1 8|METHODS
P10679649A0311|170 173|CMF
P10679649A0311|10 26|TBN measurements
P10679649A0311|195 205|median age
P10679649A0311|154 168|5-fluorouracil
P10679649A0311|217 222|range
P10679649A0311|181 193|chemotherapy
P10679922A1110|86 114|tumor suppressor gene target
P10679922A1110|72 76|ING1
P10679922A1110|47 54|samples
P10681562A0263|145 161|PPARgamma action
P10681588A0899b|1 5|EMSA
P10681588A0899b|174 186|protein beta
P10681588A0899b|199 203|PC12
P10681588A0899b|224 232|extracts
P10681588A0899b|118 138|transcription factor
P10681588A0899b|59 69|Rat2 cells
P10681588A0899b|26 34|proteins
P10681588A0899b|208 215|C6 cell
P10681588A0899b|151 156|CCAAT
P10682570A0453|71 80|operation
P10682570A0453|9 19|SOD levels
P10683244A0939|38 50|NBF2 protein
P10683244A0939|23 32|R protein
P10683244A0939|77 85|proteins
P10683244A0939|160 167|mixture
P10683244A0939|135 154|sieve chomatography
P10683244X2359|1 10|Copyright
P10683989A0251|36 43|results
P10683989A0251|144 145|P
P10683989A0251|88 89|P
P10683989A0251|14 30|oxide inhalation
P10684097A0175|19 21|SD
P10684097A0175|188 192|g B.
P10684097A0175|29 33|rats
P10684097A0175|151 168|ethinyl estradiol
P10684265T0000|70 85|cytomegalovirus
P10684265T0000|10 22|modification
P10684265T0000|149 155|hSMT3b
P10684304A1242|5 16|interaction
P10684304A1242|27 28|L
P10684646A0224|112 120|caveolin
P10684646A0224|9 14|study
P10684941A0722|80 87|results
P10684941A0722|23 38|complementarity
P10684941A0722|95 108|nt insertions
P10684941A0722|45 62|ligation reaction
P10687366A0000|117 120|age
P10687366A0000|61 67|foetus
P10687855T0000|1 48|Mouse growth hormone transcription factor Zn-16
P10687855T0000|67 76|structure
P10687945A0000|1 12|Deglutition
P10688646A0535|102 114|alpha-globin
P10688646A0535|24 34|K562 cells
P10688646A0535|131 150|hormone hybrid gene
P10688661A0237|118 127|lethality
P10688661A0237|57 77|transcription factor
P10688661A0237|13 28|binding protein
P10688661A0237|180 190|expression
P10688666A1010|27 42|ASK1 activation
P10688666A1010|62 82|homo-oligomerization
P10690725A1037|11 19|patients
P10691972T0000|1 17|Characterization
P10691972T0000|67 85|resistance protein
P10691972T0000|179 183|gene
P10691972T0000|95 99|gene
P10691972T0000|122 140|comparison withthe
P10692374A1873|255 258|PAN
P10692374A1873|32 45|M. jannaschii
P10692374A1873|7 14|results
P10692374A1873|129 132|PAN
P10692374A1873|165 175|hydrolysis
P10693246A0252|20 30|dissection
P10693246A0252|36 46|components
P10693246A0252|194 205|mediastinum
P10694189A0469|5 11|effect
P10694189A0469|15 18|MIB
P10694511A0570|55 60|cells
P10694511A0570|23 27|yam8
P10694511A0570|43 47|mid1
P10694511A0570|31 35|cDNA
P10694609A0309|50 59|induction
P10694609A0309|154 160|return
P10694609A0309|20 30|compliance
P10694609A0309|143 147|hour
P10694609A0309|122 139|operating theater
P10696007A1325|33 54|C2-C3 disk morphology
P10696007A1325|13 24|correlation
P10698937T0000|53 66|up-regulation
P10698937T0000|24 39|kinase activity
P10699354A0557|16 18|RT
P10699354A0557|24 28|P300
P10699684A0661|22 28|method
P10699684A0661|92 98|groups
P10699684A0661|62 70|patients
P10700262A0000|103 119|brain structures
P10700262A0000|75 90|control systems
P10702241A0357|71 73|a2
P10702241A0357|99 101|a3
P10702241A0357|132 138|spleen
P10702241A0357|105 110|liver
P10702241A0357|87 93|kidney
P10702241A0357|112 116|lung
P10702241A0357|125 130|brain
P10702285A0855|65 94|phosphatidylinositol 3-kinase
P10702285A0855|41 42|G
P10702285A0855|166 173|subunit
P10702285A0855|105 112|pathway
P10702285A0855|114 124|expression
P10702285A0855|246 247|q
P10702285A0855|151 154|p85
P10702794A1495|118 123|HePTP
P10702794A1495|71 76|HePTP
P10702794A1495|162 166|part
P10702794A1495|61 67|target
P10703633A0747|171 175|mean
P10703633A0747|307 318|time points
P10703633A0747|279 299|irritation sensation
P10703633A0747|39 43|acid
P10703633A0747|73 77|acid
P10703633A0747|257 271|mean magnitude
P10703633A0747|178 181|SEM
P10703633A0747|95 96|p
P10703633A0747|183 186|min
P10704283A0649a|1 9|Analysis
P10704283A0649a|86 105|chromosome 5q31-q33
P10704283A0649a|160 165|genes
P10704283A0649a|120 135|gene candidates
P10704338A0354|205 218|alpha-helices
P10704338A0354|272 287|leucine residue
P10704338A0354|42 46|role
P10704338A0354|289 301|P-position-L
P10704338A0354|83 86|p24
P10704338A0354|25 32|insight
P10704338A0354|182 187|turns
P10704338A0354|91 98|protein
P10704499A0682|202 211|activator
P10704499A0682|220 251|phorbol-12-myristate-13-acetate
P10704499A0682|16 29|PC12-E2 cells
P10704499A0682|48 57|treatment
P10704499A0682|191 194|MEK
P10704499A0682|178 181|PLC
P10704499A0682|63 73|antibodies
P10704499A0682|183 186|PKC
P10704975A0479|1 19|Thiopentone sodium
P10704975A0479|83 91|exposure
P10704975A0479|46 49|min
P10705783A0433|32 42|neurectomy
P10705783A0433|113 137|concentration gentamicin
P10705783A0433|142 147|mg/mL
P10705783A0433|14 19|cases
P10706513A0843|34 45|% mortality
P10706513A0843|78 89|ventilation
P10706736A1091|168 176|epitopes
P10706736A1091|96 99|CD8
P10706736A1091|67 69|Ag
P10706736A1091|131 136|HLA-A
P10706887A1457|4 12|addition
P10706887A1457|36 40|ATIC
P10706887A1457|110 116|tumors
P10706887A1457|160 172|methotrexate
P10708424A0800|81 90|magnesium
P10708424A0800|11 15|ions
P10709705T0000|7 33|point feature registration
P10710742T0000|1 28|Serum leptin concentrations
P10710742T0000|45 76|gonadotropin stimulation cycles
P10711674A0000|1 8|PURPOSE
P10711674A0000|101 110|amaurosis
P10711674A0000|52 58|family
P10712599A0349|20 25|IRF-1
P10713083A0170|16 22|system
P10713083A0170|40 44|TraR
P10713155A0151|85 93|extracts
P10713155A0151|19 41|IIIa pre-mRNA splicing
P10713155A0151|188 196|extracts
P10713155A0151|133 138|cells
P10713175A1399|85 91|change
P10713175A1399|168 185|cell cycle arrest
P10713175A1399|40 51|ARF binding
P10713176A0885|118 122|cdk4
P10713176A0885|100 110|expression
P10713176A0885|39 57|Rb phosphorylation
P10713176A0885|177 190|DNA synthesis
P10713176A0885|195 213|cell proliferation
P10713453A0172|100 120|polytene chromosomes
P10713453A0172|5 12|protein
P10713453A0172|77 81|gene
P10715322A0000|82 92|eukaryotes
P10715322A0000|104 110|plants
P10715602A0149|1 8|Animals
P10715602A0149|20 24|dose
P10715602A0149|158 171|Wellcome GmbH
P10715602A0149|146 156|surfactant
P10715602A0149|28 41|dexamethasone
P10715602A0149|211 221|surfactant
P10720434A0291|138 141|UTR
P10720434A0291|89 99|repression
P10720434A0291|13 22|injection
P10721704A1155|114 130|promoter element
P10721704A1155|82 89|members
P10721704A1155|199 207|activity
P10721704A1155|41 45|mHuA
P10721714A1087|170 176|region
P10721714A1087|53 56|Sp1
P10721714A1087|104 112|promoter
P10721726T0000|11 18|cloning
P10722509A0392|136 138|kg
P10722509A0392|7 15|patients
P10722509A0392|29 31|mg
P10722509A0392|107 109|mg
P10722661A0406|17 21|CYC2
P10722661A0406|71 82|trypanosome
P10722661A0406|96 103|kinases
P10722661A0406|179 197|trypanosome genome
P10722661A0406|105 109|CRKs
P10722969A0510|41 45|area
P10723727A0713|19 25|region
P10723727A0713|89 121|polyadenylation signal sequences
P10724483A0540|97 108|HOG pathway
P10724483A0540|62 73|HEM13 genes
P10725017A0673|85 99|specialisation
P10725017A0673|6 11|paper
P10725017A0673|41 49|approach
P10725433A0543|102 114|B cell lines
P10725433A0543|154 158|site
P10725433A0543|32 39|binding
P10725433A0543|216 233|promoter function
P10725433A0543|126 134|mutation
P10727413A1244|252 258|action
P10727413A1244|279 286|insulin
P10727413A1244|114 122|vicinity
P10727413A1244|178 182|unit
P10727413A1244|72 86|hamster CYP7A1
P10727413A1244|211 221|expression
P10727428A0000|68 86|cell proliferation
P10727428A0000|33 40|protein
P10727428A0000|42 49|kinases
P10727428A0000|131 135|role
P10727428A0000|91 106|differentiation
P10727433T0000|87 107|macrophage cell line
P10727433T0000|200 208|receptor
P10727433T0000|111 121|macrophage
P10727433T0000|73 79|RAW264
P10727515A1202|1 13|Coactivation
P10727515A1202|86 94|receptor
P10727515A1202|144 153|responses
P10727515A1202|111 123|stimulations
P10727515A1202|41 42|G
P10728986A0000|58 76|animal development
P10729155A0653|21 32|MVMi capsid
P10729155A0653|39 47|sequence
P10729155A0653|58 69|carboxy end
P10729155A0653|89 102|beta-strand I
P10729220A1569|16 27|methylation
P10729220A1569|110 115|brain
P10730292T0000|34 51|Class II division
P10730292T0000|7 26|treatment mechanics
P10731411A0958|5 14|consensus
P10731411A0958|112 134|DEAD-box RNA helicases
P10731411A0958|208 212|DEAD
P10731411A0958|74 80|motifs
P10731411A0958|30 40|importance
P10732669A0510|53 58|cells
P10732669A0510|214 234|HD-Zip binding sites
P10732669A0510|28 32|rice
P10732669A0510|14 20|assays
P10733569A0364|23 27|HSF1
P10733569A0364|130 138|function
P10733569A0364|63 73|regulation
P10733591A0146|103 105|S6
P10733591A0146|99 102|p70
P10733591A0146|167 180|transcription
P10733591A0146|107 113|kinase
P10733591A0146|85 95|activation
P10733591A0146|153 163|regulation
P10733591A0146|28 35|targets
P10733880X1783|1 10|Copyright
P10735272A0649|100 111|alterations
P10735272A0649|162 172|expression
P10735272A0649|176 193|glioma cell lines
P10735272A0649|211 216|ANOVA
P10735272A0649|30 71|strand conformation polymorphism analyses
P10736161T0000|1 9|Enzyme I
P10737366A0280|87 96|threshold
P10737366A0280|144 148|rats
P10737366A0280|56 60|PTFL
P10739408A0896|64 77|relationships
P10739408A0896|79 92|substance use
P10740602A0141|1 13|STUDY DESIGN
P10740602A0141|48 54|smears
P10740602A0141|108 114|breast
P10740602A0141|63 68|cases
P10741947T0000|64 67|LAD
P10741947T0000|76 84|hemoclip
P10742216A0555|1 9|Schlegel
P10743719A0223|49 58|rejection
P10743719A0223|96 100|risk
P10743719A0223|11 13|dg
P10744749A0315|196 203|factors
P10744749A0315|145 157|MyoD protein
P10744749A0315|120 128|activity
P10744749A0315|30 40|mechanisms
P10744974T0000|1 16|Phosphorylation
P10744974T0000|59 65|Cdc15p
P10747053A1102|171 175|role
P10747053A1102|5 15|cell cycle
P10747053A1102|36 43|defects
P10747053A1102|222 225|MBF
P10747053A1102|112 122|modulators
P10747053A1102|214 217|SBF
P10747053A1102|60 66|slm7-1
P10747782A0390|69 75|extent
P10747782A0390|1 12|Proteolysis
P10747782A0390|42 51|complexes
P10747782A0390|160 180|DNA binding activity
P10747890A1096|87 106|groove interactions
P10747890A1096|172 179|lesions
P10747890A1096|128 150|base pair interactions
P10748054T0048|3 10|pathway
P10748054T0048|29 49|B lymphocyte antigen
P10748125A0000|68 105|protein serine/threonine phosphatases
P10748125A0000|36 39|I-2
P10748125A0000|107 110|PP1
P10748125A0000|14 17|I-1
P10748175A0000|154 166|transporters
P10748175A0000|5 15|substrates
P10748175A0000|57 62|Golgi
P10748204A0238|8 10|J.
P10749145T0000|59 81|diphosphatase activity
P10749145T0000|123 126|Ras
P10749849A0000|99 116|cell cycle arrest
P10749849A0000|76 85|stability
P10749849A0000|160 180|kinase inhibitor p21
P10749849A0000|14 23|mechanism
P10750020A0843|69 83|ER/Sp1 binding
P10750020A0843|35 37|ER
P10750020A0843|7 31|growth factor activation
P10750020A0843|124 131|pathway
P10750524A0724|19 29|thresholds
P10750524A0724|59 64|tests
P10750524A0724|88 98|proportion
P10752450A0288|136 142|market
P10752450A0288|3 10|variety
P10752807A1598|1 11|CONCLUSION
P10752807A1598|97 106|advantage
P10752807A1598|145 151|status
P10752807A1598|123 131|survival
P10752807A1598|13 22|Treatment
P10754312A0798|35 43|proteins
P10756007A1512|1 12|EM analysis
P10756007A1512|48 55|complex
P10756032A0599|81 88|regions
P10756032A0599|9 38|dimethyl sulfate footprinting
P10756032A0599|107 123|hypersensitivity
P10756100A0457|29 43|amino-terminus
P10756100A0457|13 21|mutation
P10758289A0141|1 8|METHODS
P10758289A0141|115 128|pisiform bone
P10758289A0141|26 39|muscle fibres
P10758726T0000|10 16|impact
P10760109A1050|103 104|%
P10760109A1050|141 144|CVD
P10760109A1050|67 70|CVD
P10760109A1050|165 169|tHcy
P10760109A1050|19 31|malnutrition
P10760109A1050|219 235|blood hemoglobin
P10760109A1050|177 189|plasma IGF-1
P10760169A1142|69 99|transcription initiation sites
P10760169A1142|31 41|CreA sites
P10761263A1108|54 66|T2 statistic
P10761263A1108|42 51|Hotelling
P10761263A1108|123 135|displacement
P10762348A0269|7 22|phosphorylation
P10762348A0269|63 70|nucleus
P10763827A1158|25 44|senescence pathways
P10763827A1158|106 124|TGFbeta1 secretion
P10763827A1158|164 182|senescence program
P10764574A0718|1 12|Application
P10764574A0718|20 26|method
P10764574A0718|129 148|prediction accuracy
P10764574A0718|47 50|set
P10764760T0000|1 16|Transactivation
P10764760T0000|75 96|JNK signaling pathway
P10764970A1009|217 222|class
P10764970A1009|162 170|isolates
P10764970A1009|27 52|quinupristin/dalfopristin
P10764970A1009|243 251|practice
P10764970A1009|13 23|resistance
P10766246A0000|68 82|cell functions
P10766246A0000|155 170|differentiation
P10766246A0000|175 183|survival
P10766246A0000|140 153|proliferation
P10766556T0000|5 25|somatoform conundrum
P10766556T0000|29 37|question
P10767251A1046|141 145|pigs
P10767251A1046|172 181|pressures
P10767251A1046|122 137|lung resections
P10767251A1046|30 35|study
P10767553A0100|139 147|HNF3beta
P10767553A0100|125 137|Factor 3beta
P10767553A0100|106 116|Hepatocyte
P10769144A0000|5 8|CRE
P10769144A0000|79 90|cis-element
P10770065A0264|69 90|lymph node dissection
P10770065A0264|92 93|R
P10770065A0264|27 33|T1N0M0
P10771528T0036|48 56|children
P10771528T0036|24 44|alkaline phosphatase
P10772856X1492|16 30|Academic Press
P10773351A0672|119 151|gamma-interferon activation site
P10773351A0672|1 10|Induction
P10773351A0672|48 58|U937 cells
P10773351A0672|64 73|IFN-gamma
P10773351A0672|14 29|CD86 expression
P10773458A0000|87 92|cells
P10773458A0000|40 50|regulation
P10773951A0000|1 4|IgM
P10773951A0000|64 79|O group mothers
P10773951A0000|9 12|IgG
P10775267A0363|171 181|pre-B-cell
P10775267A0363|141 144|T/T
P10775267A0363|97 119|bone marrow transplant
P10775267A0363|145 146|F
P10775267A0363|77 84|disease
P10775267A0363|28 31|T/T
P10775623A0120|48 51|gag
P10775623A0120|53 56|pol
P10777499A0883|1 8|Results
P10777499A0883|80 87|signals
P10777499A0883|67 70|DE1
P10777499A0883|43 50|mutants
P10777499A0883|176 183|element
P10777669A0582|66 90|chromosome 19qter region
P10777669A0582|95 105|RH mapping
P10778757A0000|33 39|nature
P10778757A0000|126 136|seed locus
P10778757A0000|95 101|allele
P10778757A0000|166 185|cell wall invertase
P10779329T0000|1 5|Slap
P10779329T0000|27 30|Src
P10779508A0452|51 55|SFRE
P10779508A0452|12 44|footprinting protection analysis
P10779508A0452|60 71|ERE regions
P10779508T0000|144 160|lactoferrin gene
P10779508T0000|27 41|receptor alpha
P10780518A1270|68 79|examination
P10780518A1270|5 12|effects
P10780883T0000|84 94|resistance
P10780883T0000|1 7|Kaposi
P10780883T0000|29 40|herpesvirus
P10780883T0000|120 126|effect
P10781423A0993|1 11|Comparison
P10781423A0993|55 78|consensus binding sites
P10781423A0993|15 24|sequences
P10781552A0000|139 140|H
P10781552A0000|23 31|bacteria
P10781552A0000|144 153|oxidation
P10781552A0000|122 133|respiration
P10781611A1023|99 109|efficiency
P10781611A1023|158 162|mice
P10781611A1023|131 142|macrophages
P10782640A0444|5 11|method
P10782640A0444|62 85|CM300 FEG/UT microscope
P10782640A0444|120 131|astigmatism
P10784367A0133|238 247|disorders
P10784367A0133|118 123|study
P10784367A0133|23 31|subjects
P10784367A0133|193 198|study
P10784367A0133|210 218|patients
P10785294A0720|110 114|ones
P10785294A0720|134 149|resin composite
P10785880A0947|1 11|CONCLUSION
P10785880A0947|48 61|complications
P10785880A0947|91 99|patients
P10786742A0670|52 53|h
P10786742A0670|60 67|surgery
P10787804T0000|1 5|AMDA
P10787804T0000|12 17|paper
P10788476A0891|51 78|Sec31A co-precipitate Sec13
P10788476A0891|144 164|stomatitis G protein
P10788476A0891|182 192|cell assay
P10790390X0000|103 106|mod
P10790390X0000|306 321|gene expression
P10790390X0000|235 238|PEV
P10790390X0000|283 293|regulation
P10790390X0000|41 81|position effect variegation modifier mod
P10790390X0000|107 111|mdg4
P10790390X0000|256 281|gypsy insulator sequences
P10790390X0000|158 165|variety
P10790390X0000|82 86|mdg4
P10791819A0771|6 14|tendency
P10791819A0771|147 153|codons
P10791819A0771|73 89|asparagus genome
P10792583A0000|1 11|Regulation
P10792583A0000|163 169|stress
P10792583A0000|126 130|ACTH
P10792583A0000|132 141|secretion
P10793143A1533|69 78|Abf1 ARS1
P10793143A1533|143 151|activity
P10793143A1533|126 130|Cdc6
P10793143A1533|91 99|activity
P10794405A0000|16 21|study
P10794405A0000|71 81|histone H1
P10794405A0000|25 33|peptides
P10794405A0000|121 134|understanding
P10794405A0000|60 67|domains
P10795098A0253|42 49|disease
P10795098A0253|74 84|phenomenon
P10796486A0817|1 19|SELECTION CRITERIA
P10796486A0817|32 38|trials
P10796486A0817|114 125|conjunction
P10796486A0817|131 148|asthma medication
P10797586A0402|99 106|bladder
P10797586A0402|5 11|models
P10797586A0402|42 50|response
P10799501A1391|37 46|component
P10799501A1391|59 70|environment
P10799590A0431|238 247|mechanism
P10799590A0431|168 175|EBNA-3C
P10799590A0431|53 63|activation
P10799590A0431|214 227|transcription
P10799590A0431|109 115|Jkappa
P10799590A0431|271 277|Jkappa
P10799863T0000|117 126|MHC class
P10799863T0000|24 41|metallopeptidases
P10799863T0000|12 20|cleavage
P10801244A0578|85 102|NONMEM population
P10801244A0578|67 72|model
P10801482A0968|19 22|p65
P10801482A0968|64 72|affinity
P10801482A0968|142 156|kappaB targets
P10801860A0000|137 142|acids
P10801860A0000|48 83|immunoglobulin superfamily proteins
P10801860A0000|5 12|Siglecs
P10802909A0478|1 12|PATIENTS OR
P10802909A0478|57 65|criteria
P10805286A0233|221 229|androgen
P10805286A0233|250 257|tissues
P10805286A0233|66 74|PCI gene
P10805286A0233|123 132|cell line
P10805286A0233|88 98|expression
P10805286A0233|134 145|HepG2 cells
P10805390A0340|32 44|measurements
P10805390A0340|48 65|photoluminescence
P10805737T0000|139 152|eIF5 function
P10805737T0000|67 71|eIF5
P10805737T0000|106 118|beta subunit
P10805737T0000|122 126|eIF2
P10805739A0343|32 49|complex formation
P10805739A0343|6 14|activity
P10805747A0633|98 103|Kcc4p
P10805747A0633|127 133|effect
P10805747A0633|62 69|kinases
P10807900A0933|204 216|hypertension
P10807900A0933|156 161|value
P10807900A0933|99 100|%
P10807900A0933|23 27|lack
P10807900A0933|7 21|non-cirrhotics
P10807900A0933|134 135|%
P10809233A0606|87 95|residues
P10809233A0606|115 117|H4
P10809233A0606|123 126|H11
P10809233A0606|62 69|absence
P10810294A0730|1 16|Stat activation
P10810294A0730|39 43|IL-6
P10810294A0730|62 85|reporter gene induction
P10811079A0555|1 8|RESULTS
P10811079A0555|129 146|epilepsy patients
P10811079A0555|91 113|vigabatrin monotherapy
P10811079A0555|60 77|epilepsy patients
P10811804A0000|19 26|protein
P10811804A0000|55 60|MKP-3
P10811804A0000|144 150|kinase
P10811804A0000|28 31|MAP
P10811908A0938|1 28|HPLC phosphopeptide mapping
P10811908A0938|99 103|NCLK
P10811908A0938|30 51|amino acid sequencing
P10814989T0000|1 28|Hepatitis C virus infection
P10814989T0000|53 61|diseases
P10815807A1271|62 76|c-Myb promoter
P10815807A1271|120 132|T-cell lines
P10819327T0000|49 70|sea urchin kinesin-II
P10819327T0000|19 24|OSM-3
P10819327T0000|25 30|KAP-1
P10820904A0000|21 35|encephalopathy
P10820904A0000|58 66|syndrome
P10820904A0000|89 102|liver failure
P10822117A1386|84 96|observations
P10822117A1386|53 58|model
P10823837A1213|34 38|idea
P10823837A1213|5 9|data
P10823837A1213|280 288|mannoses
P10823837A1213|135 140|group
P10823837A1213|117 124|mannose
P10823837A1213|250 258|alpha1-4
P10823837A1213|176 184|proteins
P10824485A0393|115 119|AIDS
P10824485A0393|129 138|illnesses
P10824485A0393|47 54|disease
P10825000A1245|5 29|gene amplification model
P10825293T0000|140 147|signals
P10825293T0000|93 105|contribution
P10826861A0000|119 133|hyperviscosity
P10826861A0000|188 195|failure
P10826861A0000|43 63|plasma cell neoplasm
P10826861A0000|148 164|cryoglobulinemia
P10826861A0000|135 146|amyloidosis
P10828022A0877|119 128|complexes
P10828022A0877|1 21|Endostatin treatment
P10828022A0877|43 48|hours
P10828022A0877|29 36|minutes
P10828591A0080|100 114|transcript map
P10828591A0080|5 15|transcript
P10828591A0080|193 197|gene
P10828591A0080|211 218|disease
P10829973T0000|1 28|Iodine deficiency disorders
P10831972A0744|1 8|RESULTS
P10831972A0744|18 29|CD23 levels
P10831972A0744|91 100|treatment
P10833461A0603|17 21|gene
P10833461A0603|143 145|kb
P10833461A0603|25 28|P-1
P10833461A0603|40 50|chromosome
P10833461A0603|90 109|length UGT2B7 probe
P10834707A1533|37 63|platelet activating factor
P10834707A1533|26 33|amounts
P10835355A0225|115 123|nutrient
P10835355A0225|76 86|suppressor
P10835355A0225|94 111|rim15Delta defect
P10835732A0911|66 74|mapuches
P10835732A0911|79 86|aymaras
P10836786A0516|116 134|hairpin structures
P10836786A0516|157 170|RNase MRP RNA
P10836786A0516|145 147|P3
P10836786A0516|78 99|substrate specificity
P10838139A1447|17 29|Ha-ras codon
P10838139A1447|81 87|tumors
P10838531A0675|49 50|%
P10838531A0675|71 79|patients
P10838531A0675|66 67|%
P10838531A0675|24 29|T3 N0
P10839547A0978|21 26|model
P10839547A0978|28 40|CTCF binding
P10840001A0188|71 79|diseases
P10840001A0188|95 102|cancers
P10841593A0780|33 44|% reduction
P10841593A0780|93 105|availability
P10843716A0406|85 91|mastin
P10843716A0406|113 117|dogs
P10843716A0406|95 99|gene
P10845522A0000|17 22|study
P10845522A0000|1 10|OBJECTIVE
P10845522A0000|218 229|examination
P10845522A0000|107 117|sonography
P10845522A0000|60 65|roles
P10846069T0000|34 41|domains
P10846069T0000|49 58|P protein
P10846069T0000|98 111|transcription
P10848848A0413|1 8|RESULTS
P10848848A0413|10 18|Fournier
P10850329A0248|1 5|IL-2
P10850329A0248|93 103|biotherapy
P10850329A0248|77 89|chemotherapy
P10850329A0248|60 71|combination
P10850453A1292|68 95|Ras/MAPK pathway activation
P10850453A1292|39 58|prostate carcinomas
P10850849A0730|103 108|hours
P10850849A0730|200 205|hours
P10850849A0730|10 24|administration
P10850849A0730|75 83|t1/2beta
P10850849A0730|257 272|bioavailability
P10850849A0730|212 227|absorption time
P10850849A0730|26 39|AUC0-infinity
P10850849A0730|60 73|microg x h/ml
P10850997A1016|4 12|contrast
P10850997A1016|14 18|H-NS
P10851267A0000|1 4|E2F
P10851267A0000|77 84|S-phase
P10852221A0422|175 182|neurons
P10852221A0422|142 150|survival
P10852221A0422|24 33|treatment
P10852221A0422|104 111|surgery
P10852485A0477|17 19|CS
P10852485A0477|118 121|5AL
P10852485A0477|113 114|%
P10852485A0477|9 15|Spring
P10853059X0751|1 10|Karger AG
P10853850A1103|50 54|rise
P10853850A1103|98 120|inhalation provocation
P10853850A1103|122 123|p
P10854699A0424|117 122|exons
P10854699A0424|83 98|splice variants
P10854699A0424|107 111|exon
P10855793A1418|33 37|TNRs
P10855793A1418|161 166|genes
P10855793A1418|124 138|identification
P10855793A1418|62 67|genes
P10856298A0798|221 227|enzyme
P10856298A0798|71 90|hamster ovary cells
P10856298A0798|110 115|level
P10856298A0798|126 132|growth
P10856298A0798|167 173|growth
P10856805T0000|71 76|level
P10857215A0806|86 96|population
P10857215A0806|5 11|MRS II
P10857751A0304|34 48|Mharp/Smarcal1
P10857751A0304|70 101|Caenorhabditis elegans ortholog
P10857751A0304|4 12|addition
P10858988A0786|1 4|ECP
P10858988A0786|79 88|challenge
P10860196A0876|34 39|costs
P10860196A0876|77 81|year
P10860827A0399|137 151|cardiomyocytes
P10860827A0399|1 9|Deletion
P10860827A0399|25 33|analyses
P10861080A0433|119 122|GBS
P10861080A0433|92 101|TNF-alpha
P10861080A0433|147 148|%
P10861080A0433|30 42|IkappaBalpha
P10861086A0904|39 44|a-Src
P10861086A0904|123 129|series
P10861086A0904|90 99|membranes
P10861906A1479|49 56|meiosis
P10861906A1479|179 191|alkalization
P10861906A1479|108 112|CCL1
P10861906A1479|195 201|medium
P10862289A0289|17 24|montoux
P10862289A0289|2 5|GUT
P10862289A0289|6 10|Sera
P10862289A0289|111 117|bodies
P10863352T0001|1 15|Franz Schubert
P10863352T0001|37 45|diseases
P10864496A0401|84 107|nrgAB promoter fragment
P10864496A0401|116 118|nM
P10864496A0401|5 37|equilibrium dissociation binding
P10864989A0484|34 38|PAIP
P10864989A0484|1 8|RESULTS
P10864989A0484|197 216|separation efficacy
P10864989A0484|133 140|numbers
P10864989A0484|14 26|introduction
P10864989A0484|220 221|%
P10864989A0484|151 154|FIP
P10865838A0000|117 125|division
P10865838A0000|53 60|agonist
P10865838A0000|22 35|growth factor
P10866323A0666|35 57|SIE-1 hypermethylation
P10866323A0666|24 31|effects
P10866689A0295|115 118|pRb
P10866689A0295|179 208|tal-1-E12-Lmo2-Ldb1 complexes
P10866689A0295|160 174|tal-1-E12-Lmo2
P10866689A0295|148 156|activity
P10866689A0295|15 31|SAOS-2 cell line
P10867199A0230|34 42|criteria
P10867199A0230|4 12|contrast
P10867199A0230|128 132|EPVs
P10868488A0921|87 105|testosterone level
P10868488A0921|38 48|aggression
P10869465A1054|186 196|cell types
P10869465A1054|236 241|cells
P10869465A1054|9 22|hybridization
P10869465A1054|132 139|changes
P10869465A1054|75 93|expression changes
P10870391T0034|1 11|Prevention
P10870391T0034|26 35|diagnosis
P10871347A0477|70 87|PyRo1 interaction
P10871412A0369|32 41|selection
P10871412A0369|22 28|rounds
P10871412A0369|45 66|focus formation assay
P10871842A0988|82 89|members
P10871842A0988|93 122|transcription factor families
P10871842A0988|26 47|proteasome inhibition
P10872535A0000|102 107|twins
P10872535A0000|1 5|AIMS
P10872535A0000|200 222|glucose tolerance test
P10872535A0000|319 332|abnormalities
P10872535A0000|254 265|association
P10872535A0000|23 27|role
P10872535A0000|178 187|responses
P10872827A0000|1 19|Penicillin acylase
P10872827A0000|21 23|PA
P10872827A0000|132 135|kDa
P10872827A0000|74 85|heterodimer
P10872851A0714|54 65|tachycardia
P10872851A0714|93 94|P
P10872851A0714|10 13|LCx
P10872851A0714|88 91|AoP
P10873286X0000|1 14|GAP JUNCTIONS
P10873286X0000|29 36|PREFACE
P10873387A0816|157 161|Xp11
P10873387A0816|43 46|end
P10873387A0816|135 141|region
P10873387A0816|30 34|gene
P10874044A0647|101 105|JNK2
P10874044A0647|141 157|pE1-luc activity
P10874044A0647|59 67|p38alpha
P10874044A0647|12 25|co-expression
P10878398A0542|50 63|leptin levels
P10878398A0542|43 48|group
P10878398A0542|122 125|Epo
P10878675A1278|35 54|antagonist idazoxan
P10878675A1278|138 146|subjects
P10878675A1278|93 101|activity
P10880486A0790|100 103|Ebr
P10880486A0790|93 99|zipper
P10881275T0000|62 70|practice
P10882213A0163|478 495|myositis patients
P10882213A0163|1 7|Topics
P10882213A0163|66 74|myositis
P10882213A0163|464 474|management
P10882213A0163|80 86|cancer
P10882213A0163|573 579|damage
P10882213A0163|389 397|entities
P10882213A0163|505 515|approaches
P10882213A0163|526 537|limitations
P10882213A0163|107 118|evaluations
P10882213A0163|190 198|patients
P10882213A0163|428 435|factors
P10882213A0163|176 186|assessment
P10882850A0000|103 127|pyrimidine base residues
P10882850A0000|49 64|DNA glycosylase
P10882850A0000|83 90|removal
P10885708T0000|80 87|abscess
P10885708T0000|10 28|bile duct blockage
P10885750A0236|49 57|function
P10885750A0236|96 112|organ physiology
P10887912A0740|143 154|muscle pain
P10887912A0740|57 65|masseter
P10887912A0740|192 196|side
P10887912A0740|164 176|subjects bit
P10888570A0678|55 60|Lopez
P10888570A0678|142 153|food safety
P10888570A0678|93 99|Puebla
P10888570A0678|72 80|Montsama
P10888570A0678|62 70|Marciana
P10890911A0470|137 150|transcription
P10890911A0470|158 184|Xenopus homeobox gene twin
P10890911A0470|76 80|LEF1
P10890911A0470|90 97|TGFbeta
P10891266A0421|39 45|H type
P10891399A1185|204 214|cell cycle
P10891399A1185|19 29|activation
P10891399A1185|175 180|c-fos
P10891399A1185|66 76|inhibition
P10891399A1185|226 231|genes
P10891399A1185|132 141|AP-1 site
P10891489A0152|170 178|proteins
P10891489A0152|38 54|HMG-I/Y proteins
P10891489A0152|143 150|cancers
P10891489A0152|202 212|malignancy
P10892300A0268|32 42|calcinosis
P10892300A0268|86 90|cows
P10892300A0268|11 19|symptoms
P10893243T0000|17 27|regulation
P10893243T0000|157 191|factor family zinc finger proteins
P10894149T0000|220 236|receptor alpha-1
P10894149T0000|203 211|estrogen
P10894149T0000|52 59|protein
P10894149T0000|192 201|ERRalpha1
P10894149T0000|91 101|activation
P10894886A0375|37 43|tumors
P10894886A0375|79 84|genes
P10895417A0669|102 118|food consumption
P10895417A0669|155 171|body temperature
P10895417A0669|40 56|DepoFoam vehicle
P10895417A0669|120 127|arousal
P10896008A0531|186 187|n
P10896008A0531|48 59|outpatients
P10896008A0531|114 115|n
P10896008A0531|176 184|controls
P10896008A0531|94 104|neuropathy
P10896008A0531|151 152|n
P10896859A0838|58 70|Na retention
P10897973T0001|35 45|substitute
P10897973T0001|52 59|heparin
P10897973T0001|61 75|Thrombosis ABC
P10899128A0661|189 204|gene expression
P10899128A0661|43 71|transcription factor complex
P10899128A0661|105 121|forkhead protein
P10900129A0138|68 83|CYP3A sequences
P10900129A0138|1 19|Degenerate primers
P10901133A0381|1 17|Methyllevamisole
P10903440A0515|103 110|puparia
P10903440A0515|54 59|ovary
P10903440A0515|82 88|adults
P10903440A0515|176 182|stages
P10903583T0000|51 57|OSI CA
P10903583T0000|1 12|Reliability
P10903583T0000|25 30|range
P10903837A1208|34 42|ortholog
P10903837A1208|11 20|RINX gene
P10903837A1208|88 92|VSX1
P10903877A0879|80 92|calphostin C
P10903877A0879|37 40|AMP
P10903877A0879|132 144|3TP activity
P10903877A0879|165 184|ERK kinase activity
P10903877A0879|120 128|decrease
P10905349A0329|34 40|motifs
P10905349A0329|54 82|XPF endonuclease superfamily
P10905352A0000|35 40|yeast
P10905352A0000|173 175|TP
P10905352A0000|182 188|primer
P10905352A0000|12 25|plasmid pCLU1
P10905352A0000|134 147|plasmid pGKL2
P10906317A0351|153 154|%
P10906317A0351|55 64|hemifield
P10906317A0351|66 70|left
P10906317A0351|160 161|%
P10906317A0351|122 127|shift
P10907348A0508|68 72|ions
P10907348A0508|99 110|blood serum
P10907348A0508|132 146|bone isoenzyme
P10907348A0508|150 152|AP
P10907971T0000|32 67|HMG-CoA reductase inhibitor therapy
P10907971T0000|94 106|CURVES study
P10908364A0000|1 6|G-DNA
P10908364A0000|73 78|roles
P10908478A0717|49 55|adults
P10908478A0717|156 161|drugs
P10908478A0717|36 42|trials
P10908478A0717|192 200|outcomes
P10909973A1508|153 162|substrate
P10909973A1508|117 141|consensus serine residue
P10909973A1508|64 78|cotransfection
P10909973A1508|96 103|isoform
P10909973A1508|28 33|GLP-1
P10910439A1196|84 87|GFR
P10910439A1196|49 61|protein load
P10910439A1196|130 139|treatment
P10913094A0424|118 147|gel mobility shift-PCR method
P10913094A0424|6 19|DNA fragments
P10913276A0510|70 81|interaction
P10913276A0510|46 50|SOS1
P10913304A0894|70 74|Elk1
P10913304A0894|80 83|PE1
P10913304A0894|41 45|Ets2
P10913304A0894|14 23|Ets mRNAs
P10915728A0216|17 25|patients
P10915728A0216|155 161|months
P10915728A0216|66 72|groups
P10915728A0216|77 85|patients
P10915728A0216|31 40|cirrhosis
P10917402T0000|25 39|administration
P10917402T0000|60 68|patients
P10918164A0878|200 201|P
P10918164A0878|158 179|% confidence interval
P10918164A0878|145 154|detectors
P10918164A0878|183 187|% CI
P10918572A0794|68 73|ErbB3
P10918572A0794|9 13|VaII
P10918572A0794|41 46|ErbB2
P10918596A0000|34 48|p53 C-terminus
P10918596A0000|65 69|role
P10918612A0000|118 126|patterns
P10918612A0000|5 29|transcription factor Jun
P10918612A0000|31 36|c-Jun
P10918948A0110|138 146|diseases
P10918948A0110|67 75|Debridat
P10918948A0110|77 80|CAS
P10920186A0528|18 27|formation
P10920186A0528|41 50|templates
P10920186A0528|107 111|loop
P10920186A0528|60 72|fusion point
P10921197A0179|1 13|Measurements
P10921197A0179|97 114|ADAC Pinnacle3 V4
P10925159A1353|116 124|extracts
P10925159A1353|126 132|MARTA2
P10925159A1353|47 54|lysates
P10926776A0731|70 81|amino acids
P10926776A0731|57 66|insertion
P10926776A0731|13 26|PDP1 isoforms
P10928337A0590|53 67|erythropoietin
P10928337A0590|9 19|correction
P10930526A0174|87 99|mouse origin
P10930526A0174|36 43|cloning
P10931927A0655|69 84|template-primer
P10931927A0655|281 293|template DNA
P10931927A0655|108 123|Klenow fragment
P10931927A0655|49 55|TAACCC
P10931927A0655|144 158|DNA polymerase
P10931927A0655|29 30|A
P10931927A0655|31 37|GGGTTA
P10931960A0630|118 126|addition
P10931960A0630|5 9|loss
P10931960A0630|182 194|protein VP16
P10931960A0630|44 53|mutations
P10932329A0597|114 123|ventralis
P10932329A0597|23 28|cecum
P10932329A0597|47 52|colon
P10932527T0000|5 18|effectiveness
P10932527T0000|73 86|wound healing
P10933154A1118|38 46|analysis
P10933154A1118|77 94|donor transplants
P10933732A0000|5 11|genome
P10933732A0000|203 206|IRF
P10933732A0000|74 88|reading frames
P10933732A0000|105 113|proteins
P10933732A0000|25 36|herpesvirus
P10933732A0000|58 65|cluster
P10933732A0000|90 94|ORFs
P10934310A0698|86 96|weaknesses
P10934310A0698|31 41|ultrasound
P10934751T0001|37 49|significance
P10935880A1049|1 8|Viruses
P10935880A1049|91 97|BVHV-1
P10935880A1049|30 35|lungs
P10936920A0105|98 108|prediction
P10936920A0105|36 40|cues
P10938102A1359|86 92|eIF4GI
P10938102A1359|158 162|mRNA
P10938102A1359|213 239|influenza virus messengers
P10938102A1359|73 76|NS1
P10938102A1359|194 205|translation
P10938105A0000|1 9|Splicing
P10938105A0000|178 189|splice site
P10938105A0000|47 80|fibroblast growth factor receptor
P10938113A0388|76 80|Vav3
P10938113A0388|146 155|receptors
P10938113A0388|135 142|classes
P10938130A0338|81 90|homodimer
P10938130A0338|24 28|data
P10938556A0248|35 39|rats
P10938556A0248|4 12|addition
P10938556A0248|89 99|ventricles
P10939785A0540|1 9|Patients
P10939785A0540|155 171|contraindication
P10939785A0540|55 80|ACE inhibitor perindopril
P10939785A0540|36 45|treatment
P10940553A0912|49 67|tissue-specificity
P10940553A0912|7 14|regions
P10940562A0379|1 18|Sequence analysis
P10940562A0379|77 87|pseudogene
P10940892A0573|48 58|vasculitis
P10940892A0573|24 43|susceptibility loci
P10940892A0573|108 116|D4Mit147
P10942599A1298|92 101|functions
P10942599A1298|176 189|embryogenesis
P10942599A1298|109 123|Hoxa-1 protein
P10944466A0451|24 33|structure
P10945781A0412|42 59|V cholerae non-O1
P10945781A0412|13 30|Aeromonas strains
P10947274A0839|33 36|NCS
P10947274A0839|96 101|157Gd
P10947274A0839|63 70|RBE-cGy
P10950398T0100|1 22|Losartan Intervention
P10950924A0393|1 4|RNA
P10950924A0393|110 115|areas
P10950924A0393|13 26|hybridization
P10950924A0393|30 44|brain sections
P10951579A1238|83 89|wt-p53
P10951579A1238|7 24|gamma-irradiation
P10951579A1238|42 50|F9 cells
P10951579A1238|120 135|gene expression
P10952828A2638|85 91|volume
P10952828A2638|71 80|technique
P10952828A2638|197 207|ventricles
P10952828A2638|167 178|3D approach
P10954525A1161|69 76|profile
P10954525A1161|97 102|TRE-2
P10954525A1161|46 52|extent
P10954913A0152|84 102|liver cDNA library
P10954913A0152|22 32|cDNA clone
P10955913A0827|27 34|heparin
P10958271A0365|1 8|METHODS
P10958271A0365|201 243|equilibrium radionuclide angiocardiography
P10958271A0365|173 178|Tc99m
P10958271A0365|257 265|patients
P10958271A0365|157 167|Technetium
P10958271A0365|297 305|function
P10958271A0365|124 131|volumes
P10958271A0365|62 74|measurements
P10958673A0142|71 74|UPR
P10958673A0142|53 69|protein response
P10958673A0142|107 133|ER stress response element
P10958698A0280|103 111|function
P10958698A0280|52 63|mutagenesis
P10959676A0200|5 10|bases
P10961046A0342|1 16|Platelet counts
P10961046A0342|21 29|function
P10961046A0342|56 77|von Willebrand factor
P10962564A0883|117 124|thymine
P10962564A0883|70 79|cytosines
P10962564A0883|142 146|loss
P10962564A0883|150 158|activity
P10962738A0000|33 42|attention
P10962738A0000|63 73|perception
P10963577T0016|13 18|smell
P10963735A0651|10 27|plasma parameters
P10963735A0651|47 52|thiol
P10964995A2152|66 68|ER
P10964995A2152|42 49|concern
P10964995A2152|72 79|cancers
P10965135A1207|137 147|MKK levels
P10965135A1207|100 119|cell transformation
P10965135A1207|57 61|gene
P10965135A1207|31 41|expression
P10965905A1618|68 73|cells
P10965905A1618|304 310|target
P10965905A1618|337 346|mediation
P10965905A1618|225 246|MAP kinase activation
P10965905A1618|392 397|cells
P10965905A1618|20 34|Akt activation
P10965905A1618|146 168|wortmannin sensitivity
P10965905A1618|329 333|PI3K
P10967361A0000|21 38|resonance imaging
P10967361A0000|40 44|fMRI
P10967890A1120|117 128|development
P10967890A1120|5 12|results
P10967890A1120|107 113|stages
P10972688A1272|68 77|incidence
P10972688A1272|81 97|hospitalizations
P10972980A0295|137 138|C
P10972980A0295|97 99|PI
P10972980A0295|111 128|protein kinases A
P10972980A0295|12 22|cell lines
P10972980A0295|75 95|phosphatidylinositol
P10972980A0295|187 193|kinase
P10972980A0295|24 28|mTOR
P10972990A0526|118 134|thymidine kinase
P10972990A0526|49 57|increase
P10972990A0526|219 224|locus
P10972990A0526|213 217|HPRT
P10972990A0526|31 33|E6
P10972990A1518|71 82|maintenance
P10972990A1518|25 30|model
P10972990A1518|40 51|p53 protein
P10973385A1423|239 247|patients
P10973385A1423|18 22|type
P10973385A1423|4 12|patients
P10973385A1423|59 65|spread
P10973385A1423|26 32|tumors
P10973385A1423|120 129|curvature
P10974541A0389|67 72|MZF1B
P10974541A0389|15 32|K562 cDNA library
P10976413A0514|96 106|predictors
P10976413A0514|203 212|FSH level
P10976413A0514|196 199|day
P10976413A0514|220 226|mIU/ml
P10976413A0514|156 165|FSH level
P10976413A0514|24 33|FSH level
P10981094A0779|184 193|magnitude
P10981094A0779|65 89|Joint National Committee
P10981094A0779|8 23|target BP goals
P10981094A0779|146 155|treatment
P10981094A0779|91 97|JNC VI
P10982143A0346|5 11|muskox
P10982825A0363|84 87|OpA
P10982825A0363|24 34|difference
P10983857A0923|85 89|loss
P10983857A0923|140 146|damage
P10983857A0923|82 83|H
P10983857A0923|9 20|application
P10983857A0923|194 198|rats
P10984122A0911|69 82|vector mU6-C1
P10984122A0911|4 11|control
P10987301A0332|373 384|development
P10987301A0332|175 187|herpes virus
P10987301A0332|283 296|growth factor
P10987301A0332|72 73|G
P10987301A0332|397 404|sarcoma
P10987301A0332|249 258|secretion
P10987301A0332|149 161|herpes virus
P10987301A0332|121 127|Kaposi
P10987301A0332|90 98|receptor
P10991383A0289|19 20|%
P10991383A0289|99 107|sublevel
P10991383A0289|59 64|atoms
P10991383A0289|28 33|sites
P10991383A0289|135 137|3D
P10992299A0745|136 155|tumor brain tissues
P10992299A0745|71 84|tumorigenesis
P10992299A0745|37 52|gene expression
P10992299A0745|192 199|U-87 MG
P10993773A0717|81 92|microm/mmHg
P10993773A0717|114 128|control values
P10993773A0717|6 11|slope
P10995121A0569|1 9|Analysis
P10995121A0569|157 166|variation
P10995121A0569|142 153|coefficient
P10995121A0569|47 61|Infant Formula
P10995121A0569|121 123|K1
P10997330A0361|119 127|PML gene
P10997330A0361|1 23|Northern blot analysis
P10997330A0361|74 81|pattern
P10997904A1258|116 123|binding
P10997904A1258|76 95|response regulators
P10997904A1258|46 51|patch
P10999205A0607|25 35|resolution
P10999205A0607|56 64|interest
P10999205A0607|164 171|spectra
P10999369A0192|81 91|N2/P2 peak
P10999369A0192|52 62|potentials
P10999369A0192|164 166|mA
P10999369A0192|120 126|microV
P11000250A0200|139 147|pathways
P11000250A0200|156 160|CD40
P11000250A0200|113 117|AP-1
P11000250A0200|26 41|plasma membrane
P11000521A0588|304 320|protein kinase B
P11000521A0588|169 184|phosphorylation
P11000521A0588|322 329|PKB/AKT
P11000521A0588|188 216|insulin receptor substrate-2
P11000521A0588|79 93|transformation
P11000521A0588|242 252|activation
P11003471A1149|82 87|group
P11003471A1149|132 137|India
P11003471A1149|14 22|analysis
P11003652A0961|140 144|role
P11003652A0961|59 77|pheromone response
P11003652A0961|41 45|fact
P11003669A0000|68 75|protein
P11003669A0000|138 152|kinase domains
P11003669A0000|5 12|product
P11003669A0000|92 98|screen
P11003807A0303|80 88|symptoms
P11003807A0303|122 140|oesophageal damage
P11005808A1082|52 71|ERK MAPK activation
P11005808A1082|27 30|Ras
P11006283A1180|64 67|DNA
P11006283A1180|80 92|homopolymers
P11006283A1180|37 44|binding
P11006283A1180|72 76|poly
P11006283A1180|135 139|role
P11006331A0319|31 46|allotetraploids
P11007777A0813|152 160|splicing
P11007777A0813|51 61|BAC clones
P11007777A0813|173 177|gene
P11007777A0813|88 96|junctate
P11007949A1607|77 81|PTEN
P11007949A1607|89 94|cells
P11007961A0930|1 10|Mutations
P11007961A0930|177 181|drug
P11007961A0930|29 44|PR65/A subunits
P11007961A0930|14 19|genes
P11008139T0000|12 20|learning
P11011139A0000|155 166|involvement
P11011139A0000|108 122|RNA polymerase
P11011139A0000|209 228|chromatin structure
P11011139A0000|75 91|mediator complex
P11012671A0576|100 110|C/EBPdelta
P11012671A0576|4 12|addition
P11012671A0576|189 211|reporter gene analysis
P11012671A0576|179 183|EMSA
P11012680A1020|237 257|ERK2 phosphorylation
P11012680A1020|168 179|PDGFR-FGFR1
P11012680A1020|36 43|peptide
P11012680A1020|228 232|GVBD
P11012680A1020|45 53|neomycin
P11012680A1020|123 134|stimulation
P11012680A1020|149 156|oocytes
P11014197A0339|71 81|inhibitors
P11014197A0339|10 29|inhibitor scaffolds
P11014215A1092|153 159|region
P11014215A1092|19 35|deletion studies
P11014215A1092|173 183|GnRHR gene
P11014215A1092|227 242|down-regulation
P11014821T0000|55 65|Drosophila
P11014821T0000|42 51|Doa locus
P11014821T0000|182 193|development
P11016724A0536|101 102|h
P11016724A0536|36 57|99mTc-HSA nanocolloid
P11016724A0536|26 32|microL
P11016724A0536|15 18|MBq
P11016850A0423|50 54|part
P11016850A0423|114 125|LysR family
P11016850A0423|145 155|regulators
P11016850A0423|60 67|protein
P11017876A0787|53 72|EGFP fusion protein
P11017876A0787|167 173|matrix
P11017876A0787|74 92|cell fractionation
P11018264A0397|1 34|Reporter gene expression analyses
P11018264A0397|127 137|cell lines
P11018264A0397|89 99|expression
P11020375A0134|3 8|total
P11020375A0134|65 81|treatment groups
P11020375A0134|197 203|ppb AF
P11020375A0134|164 167|ppb
P11020375A0134|221 224|CLI
P11020375A0134|127 131|g kg
P11020375A0134|176 182|ppb AF
P11020375A0134|209 215|ppb AF
P11023832A1038|101 104|PLD
P11023832A1038|55 63|TNFalpha
P11023832A1038|178 188|MAP kinase
P11023832A1038|43 53|KG1a cells
P11023832A1038|90 96|PC-PLC
P11023934A0855|70 73|chi
P11023934A0855|82 83|P
P11023934A0855|108 118|predictors
P11023934A0855|122 128|events
P11024036A0984|23 34|fibroblasts
P11024036A0984|73 97|reporter gene expression
P11024182A0781|101 123|pHbetaAPr-1-neo vector
P11024182A0781|54 63|reduction
P11024182A0781|142 143|%
P11024182A0781|161 170|reduction
P11024182A0781|183 191|ribozyme
P11024182A0781|15 16|I
P11025367A1009|18 40|plasma cholecystokinin
P11025367A1009|63 71|patients
P11027267A0752|1 9|Polysome
P11027267A0752|14 36|40S ribosome fractions
P11027280A0536|1 11|Cam kinase
P11027280A0536|91 96|Smad3
P11027280A0536|60 65|Smad4
P11027289A0321|115 116|S
P11027289A0321|6 12|result
P11027289A0321|56 60|ARM1
P11027724A0335|51 54|Ser
P11027724A0335|76 84|residues
P11027724A0335|13 20|BRI1-KD
P11027724A0335|60 69|threonine
P11028131A1374|67 79|modification
P11028131A1374|129 140|IFN beta-1b
P11028131A1374|40 65|measure treatment effects
P11028131A1374|120 125|costs
P11028944A1020|19 29|AUC values
P11029262T0000|1 6|Diary
P11029459A0000|81 95|tumor promoter
P11029459A0000|59 75|tumor suppressor
P11029459A0000|14 33|growth factor-beta1
P11029656A0640|55 65|activities
P11029656A0640|25 41|junction binding
P11029700A0746|103 112|rice CDKs
P11029700A0746|54 58|CycH
P11030066A0142|64 70|babies
P11030066A0142|42 54|brain injury
P11030744A0763|1 15|Overexpression
P11030744A0763|53 55|S.
P11030744A0763|40 49|his7/dpm1
P11030744A0763|90 98|increase
P11031366T0001|65 69|view
P11031366T0001|56 61|point
P11032599T0000|114 133|practice guidelines
P11032599T0000|40 43|use
P11034392A1072|21 25|data
P11034392A1072|161 174|proliferation
P11034392A1072|90 98|receptor
P11034547A1355|119 129|properties
P11034547A1355|23 28|study
P11035037A0183|33 45|yeast TAF145
P11035037A0183|22 29|segment
P11035037A0183|90 102|TBP function
P11036786A0628|59 73|target animals
P11036786A0628|89 113|Drinking Water Standards
P11036939A2149|35 43|pathways
P11036939A2149|49 60|Wnt pathway
P11037823A1134|50 67|ear malformations
P11037823A1134|197 204|hearing
P11037823A1134|145 151|gusher
P11037823A1134|121 129|deafness
P11037823A1134|181 185|SNHL
P11038118A0000|145 148|BSA
P11038118A0000|77 88|fabrication
P11038118A0000|130 143|serum albumin
P11038366A1322|22 33|methylation
P11038366A1322|95 102|subunit
P11038366A1322|14 18|loss
P11039341A0180|139 142|ICA
P11039341A0180|55 70|characteristics
P11039341A0180|114 124|components
P11040101A1180|17 24|results
P11040101A1180|139 148|IL-1 beta
P11040101A1180|234 243|VEGF gene
P11040101A1180|127 133|levels
P11040101A1180|264 269|sites
P11040101A1180|194 198|turn
P11041308A0156|5 13|subjects
P11041308A0156|109 116|Version
P11041308A0156|120 146|South Oaks Gambling Screen
P11042199A0572|68 77|treatment
P11042199A0572|35 41|levels
P11042199A0572|238 248|activation
P11042199A0572|142 144|Ca
P11042199A0572|131 138|removal
P11042199A0572|158 164|medium
P11042199A0572|124 129|MK801
P11042703A0875|117 119|mo
P11042703A0875|96 101|birth
P11042703A0875|79 89|increments
P11042703A0875|28 37|reference
P11044097A0422|84 89|sites
P11044097A0422|143 148|sites
P11044105A0616|87 89|nt
P11044105A0616|20 27|element
P11044105A0616|76 79|use
P11045607A0239|71 73|bp
P11045607A0239|37 66|transcription initiation site
P11046148A0716|137 152|destabilization
P11046148A0716|16 19|Lyn
P11046148A0716|96 116|Nedd4 family members
P11046148A0716|160 179|Lyn tyrosine kinase
P11046517A0619|5 12|results
P11046517A0619|63 64|Z
P11049241A0659|1 8|RESULTS
P11049241A0659|33 58|serum PP14 concentrations
P11049241A0659|143 148|group
P11049241A0659|26 31|group
P11049241A0659|209 210|p
P11050084A0000|58 72|receptor alpha
P11050084A0000|161 176|lipid oxidation
P11050084A0000|149 157|capacity
P11050168A1185|139 147|affinity
P11050168A1185|96 106|mRNA decay
P11050168A1185|56 70|susceptibility
P11050168A1185|30 38|evidence
P11051370A1906|65 77|HCV genotype
P11053263A0200|51 61|sequencing
P11053263A0200|69 72|end
P11054011A1685|1 12|CONCLUSIONS
P11054011A1685|206 214|hospital
P11054011A1685|106 107|%
P11054011A1685|225 232|Ecuador
P11054011A1685|218 223|Quito
P11054011A1685|57 61|MSGT
P11054011A1685|149 157|patients
P11054539A0114|33 38|exons
P11054539A0114|5 9|gene
P11054539A0114|145 156|polypeptide
P11054539A0114|165 184|amino acid residues
P11054571A0230|18 28|teneurin-1
P11054571A0230|111 121|locus Xq25
P11054571A0230|30 34|TEN1
P11055513A0564|113 120|testing
P11055513A0564|26 34|patients
P11056007A0224|138 141|SET
P11056007A0224|203 206|SID
P11056007A0224|78 86|sequence
P11056007A0224|195 201|domain
P11056007A0224|118 121|Phe
P11056007A0224|26 37|amino acids
P11056007A0224|211 215|rMTM
P11058008A0159|74 87|tip ischaemia
P11058008A0159|15 24|instances
P11058120A0256|70 81|counterpart
P11058120A0256|106 115|potential
P11058406A0447|19 22|SLN
P11058406A0447|93 97|i.v.
P11058406A0447|60 76|circulation time
P11059777A0813|207 217|expression
P11059777A0813|114 129|PAX3 repressors
P11059777A0813|179 194|down-regulation
P11059777A0813|198 203|BCL-X
P11059786T0000|187 193|kinase
P11059786T0000|163 183|phosphatidylinositol
P11059786T0000|228 235|hypoxia
P11059786T0000|120 138|glioblastoma cells
P11062067A0000|18 32|protein kinase
P11062067A0000|36 41|SAPK1
P11062067A0000|56 61|c-Jun
P11062067A0000|73 79|kinase
P11062257A0977|48 57|reactions
P11062257A0977|81 87|fusion
P11062257A0977|109 116|vacuole
P11062257A0977|91 99|vesicles
P11062705A0658|69 85|cancer cell line
P11062705A0658|29 33|role
P11063169T0000|93 101|outcomes
P11063169T0000|26 35|treatment
P11063742A0000|32 52|transcription factor
P11063742A0000|106 114|chemical
P11066245T0000|27 44|compliance review
P11066245T0000|73 77|SNFs
P11067928A0532|39 40|J
P11067928A0532|41 42|H
P11067928A0532|88 100|Jkappa genes
P11067928A0532|44 57|gene segments
P11069075T0000|119 136|vertebrate embryo
P11069075T0000|64 76|implications
P11069075T0000|95 111|cell development
P11069307A0546|1 11|Inhibition
P11069307A0546|175 178|p20
P11069307A0546|191 201|antagonist
P11069307A0546|97 108|translation
P11069307A0546|129 150|replication factor 1a
P11069788A0531|108 111|Pga
P11069788A0531|119 124|decay
P11069788A0531|190 197|dyn ref
P11069788A0531|158 159|O
P11069788A0531|126 130|mean
P11069788A0531|182 186|PEEP
P11069788A0531|211 215|cm H
P11069825A0530|65 74|follow-up
P11069825A0530|25 37|tuberculosis
P11069999A1602|21 24|U16
P11069999A1602|59 66|HIV LTR
P11070056A0704|48 61|RNaseH domain
P11070056A0704|5 21|Cili-2 sequences
P11070056A0704|94 109|retrotransposon
P11071651A1308|39 46|pathway
P11071651A1308|128 146|FR-beta expression
P11071852A0297|49 54|IGFIR
P11071852A0297|24 30|SOCS-3
P11071852A0297|150 161|muscle mRNA
P11071974A0155|68 75|disease
P11071974A0155|136 147|coagulation
P11071974A0155|178 204|plasma homocysteine levels
P11071974A0155|77 81|ESRD
P11071974A0155|28 31|HRT
P11071974A0155|211 220|treatment
P11072388T0000|66 73|smokers
P11072388T0000|7 18|feasibility
P11073218A0800|96 102|region
P11073218A0800|63 71|U.G pair
P11073870A0375|1 9|Patients
P11073870A0375|188 201|memory delays
P11073870A0375|37 40|PRC
P11073870A0375|111 114|PHC
P11073870A0375|57 60|PHC
P11073870A0375|15 22|lesions
P11073954A0337|5 14|Psc2 cDNA
P11074210A0623|5 16|QT interval
P11074210A0623|58 85|insulin resistance syndrome
P11074210A0623|104 123|insulin sensitivity
P11075929A1657|99 108|formation
P11075929A1657|5 9|data
P11075929A1657|25 33|evidence
P11075929A1657|63 73|metabolism
P11076860A0872|101 108|Kua-UEV
P11076860A0872|33 41|proteins
P11076860A0872|219 226|Kua-UEV
P11076860A0872|93 96|Kua
P11076860A0872|165 175|Kua domain
P11080796A0883|77 84|protein
P11080796A0883|28 37|cell line
P11081962T0000|13 17|AFLP
P11081962T0000|45 48|map
P11082587X0000|1 8|Effects
P11082587X0000|262 272|spot model
P11082587X0000|196 200|SBBS
P11082587X0000|106 117|model limit
P11082587X0000|135 155|laser beam smoothing
P11083154A0881|5 10|males
P11083154A0881|77 98|minute ventilation VE
P11083154A0881|26 41|test conditions
P11083432A0332|35 42|control
P11083432A0332|79 80|n
P11083432A0332|73 77|FK-3
P11083432A0332|44 45|n
P11084022A1178|143 157|cell processes
P11084022A1178|95 110|cell flattening
P11084022A1178|15 29|ALK7 signaling
P11084556T0000|1 12|Association
P11084556T0000|54 61|numbers
P11084556T0000|75 80|cells
P11085267A0562|1 15|Transformation
P11085267A0562|42 47|sconB
P11086872A0000|1 10|Influence
P11086872A0000|87 98|Kagzi limes
P11086872A0000|76 83|changes
P11088635A0200|142 156|usage patterns
P11088635A0200|61 69|coupling
P11088635A0200|105 111|source
P11090172A0612|20 36|RNA1 replication
P11090172A0612|67 72|yeast
P11090172A0612|41 55|RNA3 synthesis
P11090762A0527|137 139|Hz
P11090762A0527|154 161|alpha-1
P11090762A0527|168 170|Hz
P11090762A0527|114 122|increase
P11090762A0527|172 186|power increase
P11090762A0527|29 40|muscle pain
P11092809A0823|18 25|results
P11092809A0823|36 40|ERKs
P11092809A0823|90 98|mesoderm
P11092886A0341|52 61|CREMalpha
P11092886A0341|93 101|promoter
P11092886A0341|109 142|phosphoenolpyruvate carboxykinase
P11092886A0341|15 43|protein kinase A stimulation
P11094066A0505|66 103|forkhead transcription factor FKHR-L1
P11094066A0505|161 167|manner
P11094066A0505|109 113|IL-3
P11094072A0842|1 6|DNase
P11094072A0842|92 99|fashion
P11094073A0000|157 162|yeast
P11094073A0000|25 31|member
P11094073A0000|146 153|protein
P11094073A0000|60 64|Vav3
P11094087T0000|86 91|cells
P11094087T0000|9 19|expression
P11094109A0600|1 8|RESULTS
P11094109A0600|18 21|age
P11095248A0423|32 37|XFGF3
P11095248A0423|67 69|Mr
P11095248A0423|77 89|glycoprotein
P11095248A0423|182 186|gp27
P11095981A0254|80 91|bp promoter
P11095981A0254|27 39|cis-elements
P11095981A0254|150 159|mutations
P11097040A0000|138 146|freezing
P11097040A0000|76 81|Equex
P11097040A0000|131 136|steps
P11097040A0000|226 236|treatments
P11097040A0000|255 263|survival
P11097040A0000|184 189|rates
P11097040A0000|267 282|dog spermatozoa
P11097040A0000|31 36|study
P11098217A0674|77 90|hybridization
P11099377T0000|23 33|expression
P11099377T0000|56 107|proteoglycan core protein beta-d-xylosyltransferase
P11099377T0000|122 135|isoform XT-II
P11101008A0649|1 16|Chaperones/HSPs
P11102367A1170|205 210|masse
P11102367A1170|117 123|system
P11102367A1170|6 11|study
P11102367A1170|52 60|identity
P11102367A1170|229 238|mutations
P11102367A1170|90 101|development
P11103472A0802|1 9|Children
P11103472A0802|48 63|CNV-1 amplitude
P11103472A0802|104 109|CNV-2
P11103472A0802|15 18|ADD
P11103792A0755|1 15|Overexpression
P11103792A0755|188 197|apoptosis
P11103792A0755|82 91|apoptosis
P11103792A0755|281 292|fibroblasts
P11103792A0755|130 138|presence
P11103792A0755|225 233|bax-null
P11105716A0782|1 11|CONCLUSION
P11105716A0782|38 57|AIF peak saturation
P11105716A0782|92 97|error
P11105716A0782|122 125|CBV
P11106216A0918|99 100|%
P11106216A0918|8 21|COPD patients
P11106216A0918|88 95|FOT Rrs
P11106667A1061|85 100|Cox2p synthesis
P11106667A1061|7 14|Pet111p
P11106667A1061|31 36|roles
P11107637X0001|33 39|bounds
P11107637X0001|65 74|titration
P11107637X0001|315 328|use titration
P11107637X0001|166 176|definition
P11107637X0001|223 231|patients
P11107637X0001|80 85|ozone
P11107637X0001|266 281|atherosclerosis
P11107637X0001|247 255|diseases
P11107637X0001|208 219|blood serum
P11107637X0001|91 106|pathophysiology
P11108548A0710|34 43|psoralens
P11108548A0710|174 188|APcI interface
P11108548A0710|23 32|coumarins
P11108548A0710|89 110|substitution patterns
P11108720A0124|255 259|S6K2
P11108720A0124|185 192|nucleus
P11108720A0124|113 114|N
P11108720A0124|42 53|core kinase
P11108720A0124|131 138|regions
P11108720A0124|30 34|S6K1
P11108839A0401|116 128|localisation
P11108839A0401|21 29|isoforms
P11108839A0401|44 47|kDa
P11110528A0414|84 93|direction
P11110528A0414|23 25|2D
P11110528A0414|130 138|velocity
P11110528A0414|149 153|cm/s
P11112417A1126|5 9|data
P11112417A1126|127 141|melanoma cells
P11112417A1126|160 176|MLSN1 expression
P11112700A1936|1 8|Plectin
P11112700A1936|133 140|plectin
P11112700A1936|62 71|C-termini
P11112700A1936|150 161|desmoplakin
P11112790A0989|32 43|involvement
P11112790A0989|58 66|elements
P11113179A1020|87 99|LXXLL motifs
P11113179A1020|144 164|coactivator activity
P11113179A1020|108 118|AD1 region
P11113179A1020|15 24|construct
P11113201A1114|84 99|O mannosylation
P11113201A1114|23 41|six-protein family
P11113201A1114|11 17|member
P11113692A0169|103 106|PDR
P11113692A0169|5 8|aim
P11113692A0169|133 141|patients
P11113692A0169|44 56|risk factors
P11113692A0169|258 263|mm Hg
P11113692A0169|81 92|retinopathy
P11113692A0169|245 250|entry
P11113692A0169|209 217|mean age
P11113823A0197|6 11|cases
P11114521A0282|118 127|migration
P11114521A0282|99 113|cell spreading
P11114521A0282|44 52|adhesion
P11114924A0808|1 5|ORFA
P11114924A0808|10 14|ccdA
P11116131A0863|7 12|cells
P11116131A0863|30 34|mRNA
P11117263A0570|101 111|H. vulgare
P11117263A0570|202 206|acid
P11117263A0570|286 290|acid
P11117263A0570|251 261|H. vulgare
P11117263A0570|297 307|S. cereale
P11117263A0570|26 33|species
P11117263A0570|208 210|MA
P11117826A0788|99 102|PET
P11117826A0788|36 48|pretreatment
P11117826A0788|178 182|data
P11117826A0788|9 12|PET
P11117826A0788|208 212|data
P11118438A0411|70 89|plant species apple
P11118438A0411|23 32|isolation
P11118438A0411|163 184|substrate specificity
P11118438A0411|209 216|juglone
P11118619A0835|17 21|data
P11118619A0835|190 204|transformation
P11118619A0835|122 131|infection
P11118619A0835|45 48|TAg
P11119611A0428|1 7|ORFK10
P11119611A0428|67 72|LANA2
P11119611A0428|144 147|PEL
P11119611A0428|56 63|antigen
P11121043A0074|4 11|Xenopus
P11121043A0074|79 91|neurogenesis
P11121118T0000|35 64|phosphodiesterase PDE11A gene
P11121434A0915|171 175|HR12
P11121434A0915|19 34|Mek/Erk pathway
P11121434A0915|38 52|Rat1/ras cells
P11121434A0915|122 130|recovery
P11122381A0908|87 96|tyrosines
P11122381A0908|148 158|activation
P11122381A0908|47 55|peptides
P11123316T0000|1 21|Tec kinase signaling
P11123316T0000|49 78|phosphatidylinositol 3-kinase
P11123912A0306|155 164|T antigen
P11123912A0306|114 121|peptide
P11123912A0306|27 37|SH2 domain
P11123912A0306|135 147|polyomavirus
P11124902X1337|1 10|Copyright
P11125363A0525|102 104|m.
P11125363A0525|191 203|radiotherapy
P11125363A0525|97 99|mg
P11125363A0525|131 133|gm
P11125363A0525|106 115|cisplatin
P11125363A0525|164 168|days
P11125872A0133|6 16|philosophy
P11125872A0133|40 51|compound RP
P11125872A0133|192 206|administration
P11126353A0582|1 8|RESULTS
P11126353A0582|33 40|BMI SDS
P11126353A0582|92 94|3y
P11126353A0582|57 66|diagnosis
P11127161T0000|1 10|Bupropion
P11127250A1111|102 104|SB
P11127250A1111|49 51|SB
P11127250A1111|59 63|days
P11127250A1111|126 130|cure
P11127250A1111|149 151|VL
P11127250A1111|135 143|patients
P11128312A1238|207 210|FD2
P11128312A1238|130 133|BMD
P11128312A1238|115 116|%
P11128312A1238|82 88|groups
P11128312A1238|57 65|fracture
P11128312A1238|177 186|dimension
P11129515A0000|153 156|PMS
P11129515A0000|143 151|syndrome
P11129515A0000|41 49|efficacy
P11131321T0000|68 75|results
P11131321T0000|33 42|pregnancy
P11131321T0000|46 59|Yankasa sheep
P11132063A0250|136 147|hepatitis C
P11132063A0250|184 198|cardiomyopathy
P11132063A0250|113 122|cirrhosis
P11132063A0250|249 260|dysfunction
P11132195A0000|206 223|input/output data
P11132195A0000|106 112|memory
P11132195A0000|134 146|nonlinearity
P11132195A0000|190 202|measurements
P11132195A0000|249 256|systems
P11132195A0000|92 98|length
P11132195A0000|121 126|order
P11133741A0617|17 32|MCP-1 synthesis
P11133741A0617|115 123|promoter
P11133741A0617|42 52|activation
P11133741A0617|56 65|NF-kappaB
P11133927T0000|1 9|Validity
P11133927T0000|59 65|muscle
P11133927T0000|13 29|NIR spectroscopy
P11134033A0000|84 97|tumor viruses
P11134033A0000|70 75|mouse
P11134033A0000|135 169|translation initiation factor eIF3
P11134351A1405|65 70|MBP-1
P11134351A1405|15 21|MIP-2A
P11134822A0629|30 50|accelerations/30 min
P11137296A1216|49 56|tissues
P11137296A1216|81 92|PFK-C genes
P11137551A0437|26 30|acid
P11137551A0437|47 53|levels
P11138231T0000|25 31|nurses
P11139148A0421|186 195|fractions
P11139148A0421|25 32|protein
P11139148A0421|108 112|MARs
P11139469A0402|186 192|agents
P11139469A0402|169 171|Ca
P11139469A0402|72 76|Ang1
P11139469A0402|30 53|Ang2 mRNA accumulations
P11139567A1440|118 147|G protein beta gamma subunits
P11139567A1440|99 110|PI 3-kinase
P11139567A1440|30 34|ARNO
P11139974A0762|1 12|Termination
P11139974A0762|93 102|RV pacing
P11139974A0762|108 109|%
P11141003T0000|1 8|Changes
P11141003T0000|36 40|time
P11141003T0000|12 30|stimulation levels
P11143384A0267|85 101|microphone input
P11143384A0267|39 48|operating
P11143384A0267|57 78|conference situations
P11145562A0468|87 92|cells
P11145562A0468|5 18|P69 cell line
P11145563A0303|35 57|StAR promoter activity
P11145563A0303|98 120|granulosa-lutein cells
P11145563A0303|76 87|COS-1 cells
P11145571A0788|34 50|STAT1 homodimers
P11145571A0788|86 102|response element
P11145571A0788|145 152|element
P11145571A0788|104 108|ISRE
P11145717A0936|23 29|lysine
P11145717A0936|31 32|K
P11145813A0668|1 20|Regional blood blow
P11145813A0668|37 42|means
P11145813A0668|46 58|microspheres
P11145813A0668|73 80|regions
P11145955A0189|35 58|estrogen receptor alpha
P11145955A0189|5 14|mechanism
P11145955A0189|79 89|activation
P11145955A0189|254 256|E2
P11145955A0189|321 328|control
P11145955A0189|93 108|gene expression
P11145955A0189|180 188|analysis
P11145955A0189|60 67|ERalpha
P11148042A1258|23 25|LA
P11148042A1258|147 165|gel state bilayers
P11148042A1258|91 101|variations
P11149472A1257|51 62|osteoblasts
P11149472A1257|39 49|osteocytes
P11150315A0226|258 262|PC12
P11150315A0226|188 211|DNA recognition library
P11150315A0226|232 252|DNA binding proteins
P11150315A0226|271 279|extracts
P11150315A1126|1 4|NGF
P11150315A1126|77 82|Fra-2
P11151826T0000|1 9|Workload
P11152081A0413|68 88|metal solubilization
P11152081A0413|53 66|acidification
P11152081A0413|11 21|mmol SDS/l
P11152344A0416|32 39|animals
P11152344A0416|6 13|animals
P11152344A0416|77 91|arachnoid scar
P11152344A0416|160 166|sponge
P11152451A1580|255 270|TGF-beta effect
P11152451A1580|7 11|data
P11152451A1580|91 101|receptor I
P11152451A1580|194 219|target gene transcription
P11152963A0000|35 38|SH3
P11152963A0000|117 141|astrocyte transformation
P11152963A0000|19 31|src homology
P11152963A0000|93 97|gene
P11152963A0000|177 182|brain
P11154491A0322|187 194|needles
P11154491A0322|114 116|CT
P11154491A0322|128 135|EUS-FNA
P11154491A0322|43 51|patients
P11154491A0322|94 100|masses
P11156303A1098|35 43|shunting
P11156303A1098|199 208|infection
P11156303A1098|150 159|adhesions
P11156484A0223|1 13|TBARS levels
P11156484A0223|116 119|EPR
P11156484A0223|59 70|AFR release
P11156484A0223|146 155|existence
P11156484A0223|105 114|resonance
P11156789A1669|109 124|motion artifact
P11156789A1669|74 87|CSF pulsation
P11156789A1669|327 333|uptake
P11156789A1669|253 260|changes
P11156789A1669|294 310|propofol binding
P11156789A1669|146 166|oxygen concentration
P11156789A1669|91 99|children
P11157334A1107|1 10|Serum PTH
P11157334A1107|37 45|WL group
P11157774A0789|43 54|development
P11157774A0789|13 26|dSLBP alleles
P11157879A0192|1 8|METHODS
P11157879A0192|33 42|transport
P11157879A0192|14 21|passive
P11158288T0000|19 33|RNA polymerase
P11158288T0000|37 44|complex
P11158288T0000|121 141|CREB phosphorylation
P11158295A0158|6 14|function
P11158295A0158|37 50|kinase domain
P11158295A0158|88 91|SH3
P11158324A1073|231 239|increase
P11158324A1073|471 535|bile acid transporters sodium taurocholate cotransporter protein
P11158324A1073|160 176|apolipoprotein B
P11158324A1073|192 221|triglyceride transfer protein
P11158324A1073|14 24|phenotypes
P11158324A1073|324 344|lipoprotein receptor
P11158324A1073|430 445|down-regulation
P11158324A1073|92 113|lipoprotein secretion
P11158324A1073|61 71|disruption
P11158337A0000|235 242|element
P11158337A0000|197 201|GRAS
P11158337A0000|111 132|transcription factors
P11158337A0000|229 233|AP-1
P11158337A0000|187 195|sequence
P11158337A0000|266 274|factor-1
P11158337A0000|208 227|activator protein-1
P11159081A1155|118 128|reexcision
P11159081A1155|108 114|seroma
P11159081A1155|29 39|MR imaging
P11160096A1067|76 85|phenotype
P11160307A0394|255 261|region
P11160307A0394|16 25|wH22xeGFP
P11160307A0394|6 14|molecule
P11160307A0394|301 310|FcgammaRI
P11160307A0394|88 92|eGFP
P11160307A0394|269 272|Fab
P11160683A1220|100 118|CREB-1 recruitment
P11160683A1220|39 58|C/EBP dimer binding
P11160683A1220|162 166|CREB
P11160721A0932|129 141|T-cell lines
P11160721A0932|11 24|transfections
P11160721A0932|46 54|mutation
P11160732A1199|273 279|import
P11160732A1199|161 172|pseudotypes
P11160732A1199|14 25|PCR studies
P11160732A1199|289 292|DNA
P11160732A1199|113 124|macrophages
P11160732A1199|88 95|nucleus
P11160742A0696|68 73|cells
P11160742A0696|37 51|PML dispersion
P11160896A0713|1 27|Immunofluorescence studies
P11160896A0713|66 83|MEF2A co-localise
P11160896A0713|56 61|Smad2
P11160896A0713|31 45|C2C12 myotubes
P11160929T0000|7 16|evolution
P11160929T0000|44 53|LAGLIDADG
P11161720X1294|1 10|Copyright
P11161816A0851|159 163|mode
P11161816A0851|95 108|SH3GLB family
P11161816A0851|79 87|sequence
P11162576A0213|100 108|promoter
P11162576A0213|78 83|exons
P11162576A0213|60 71|alternative
P11162936A2727|16 27|development
P11162936A2727|138 156|tissue selectivity
P11162936A2727|66 75|estrogens
P11162936A2727|108 114|ERbeta
P11162936A2727|166 172|agents
P11162936A2727|224 233|treatment
P11163968A0152|16 20|work
P11163968A0152|117 122|genus
P11163968A0152|81 98|Pyrococcus abyssi
P11163968A0152|202 222|genome polymorphisms
P11163968A0152|104 111|species
P11166478T0000|70 80|pain model
P11167019A1249|48 57|GABPalpha
P11167019A1249|11 16|motif
P11167778T0000|37 43|sepsis
P11168422A0248|51 70|metal fluoride ions
P11168422A0248|80 89|phosphate
P11168422A0248|8 14|Nature
P11168588T0000|1 11|Expression
P11168588T0000|92 97|c-Jun
P11168588T0000|109 126|kinase activation
P11169113A0555|39 51|phi29 mutant
P11169113A0555|78 86|mutation
P11169113A0555|30 33|p16
P11170476A1546|19 28|stability
P11170476A1546|98 104|pocket
P11170476A1546|143 151|peptides
P11170476A1546|196 207|recognition
P11170476A1546|41 55|gp96 complexes
P11171320A0894|1 13|Coexpression
P11171320A0894|139 146|protein
P11171320A0894|161 184|amino acid substitution
P11171320A0894|186 194|tyrosine
P11171320A0894|21 25|p120
P11171320A0894|58 66|deletion
P11171320A0894|31 38|protein
P11172944A0548|1 8|RESULTS
P11172944A0548|36 41|Grade
P11172944A0548|44 55|pneumonitis
P11175333A0336|75 83|proteins
P11176290T0000|84 96|fibrillation
P11176290T0000|49 72|radiofrequency ablation
P11177686A0243|68 75|therapy
P11177686A0243|131 139|dilation
P11178696A0301|115 124|injection
P11178696A0301|95 96|s
P11178696A0301|182 187|PD US
P11179272T0000|1 16|Cytomegalovirus
P11179272T0000|18 27|Chlamydia
P11179272T0000|106 118|implantation
P11179664T0000|1 13|Architecture
P11179664T0000|18 25|anatomy
P11179687A0280|139 150|subfamilies
P11179687A0280|76 88|phosphatases
P11179687A0280|177 190|receptor PTPs
P11179687A0280|192 197|RPTPs
P11179687A0280|90 94|PTPs
P11179689A0000|5 20|Sox gene family
P11179689A0000|128 139|amino acids
P11179689A0000|183 194|DNA binding
P11179689A0000|31 43|HMG box gene
P11180027A1306|69 79|depression
P11180027A1306|13 23|parameters
P11180688A0000|204 208|test
P11180688A0000|97 108|association
P11180688A0000|192 199|shuttle
P11180688A0000|15 36|maximum oxygen uptake
P11180688A0000|252 257|years
P11180688A0000|126 135|illnesses
P11181525T0000|69 79|regulation
P11181525T0000|5 22|androgen receptor
P11181525T0000|24 26|AR
P11181548A0214|54 55|s
P11181548A0214|127 139|mE-RABP gene
P11181548A0214|46 53|element
P11181548A0214|150 162|DNA fragment
P11181995A1093|17 32|genome sequence
P11181995A1093|191 196|genes
P11181995A1093|202 215|mouse matches
P11182746A0872|17 25|patients
P11182746A0872|42 48|levels
P11187016T0000|27 47|A-bomb survivor data
P11187016T0000|12 18|models
P11188993A0298|1 8|Corneal
P11188993A0298|144 169|methenamine silver stains
P11188993A0298|123 129|Giemsa
P11191208A0000|113 134|membrane efflux pumps
P11191208A0000|212 219|control
P11191208A0000|92 97|genes
P11191208A0000|11 21|resistance
P11191208A0000|167 200|ABC binding cassette transporters
P11193045A1193|87 104|tumor suppression
P11193045A1193|33 41|gradient
P11193045A1193|65 68|p73
P11193045A1193|60 63|p53
P11193704A0000|19 34|pleuropneumonia
P11193704A0000|57 63|cattle
P11194147A1496|5 17|distribution
P11194147A1496|78 91|HIDD villages
P11195338A0494|43 53|Lg3 allele
P11195338A0494|79 88|phenotype
P11196191A1789|65 96|EGF receptor autocrine activity
P11196191A1789|52 59|synergy
P11196340A1046|51 59|antigens
P11196340A1046|114 128|aescin analogs
P11196340A1046|144 152|validity
P11197328T0000|1 8|Binding
P11197328T0000|67 73|region
P11197328T0000|148 161|transcription
P11197328T0000|165 180|mesophyll cells
P11197926A0000|1 11|BACKGROUND
P11197926A0000|80 88|versions
P11197926A0000|22 29|studies
P11197926A0000|199 204|times
P11198289T0000|11 30|serum ceruloplasmin
P11198424T0000|68 77|precursor
P11198424T0000|23 39|characterization
P11198424T0000|52 56|gene
P11198424T0000|11 18|cloning
P11201250A0849|48 53|ng/ml
P11201250A0849|83 91|PSA tape
P11201250A0849|109 113|skin
P11202705A1112|1 13|Implications
P11202705A1112|109 127|Posidonia oceanica
P11204897A0797|16 20|time
P11204897A0797|25 35|absorption
P11207216A0719|35 42|protein
P11207216A0719|101 106|cells
P11207216A0719|5 15|regulation
P11207216A0719|123 154|phorbol 12-myristate 13-acetate
P11207269A0745|16 19|mAb
P11207269A0745|73 86|p95 component
P11207288A0897|1 14|Substitutions
P11207288A0897|37 43|region
P11207288A0897|126 133|binding
P11207288A0897|45 48|ABR
P11207609A0994|4 12|contrast
P11207609A0994|172 176|HeLa
P11207609A0994|154 158|VSVG
P11207609A0994|48 53|TGN46
P11207609A0994|249 260|trafficking
P11207609A0994|123 152|stomatitis virus glycoprotein
P11208814A0673|103 121|sequence alignment
P11208814A0673|141 143|m5
P11208814A0673|166 180|consensus site
P11208814A0673|153 155|m8
P11208814A0673|21 32|specificity
P11208814A0673|218 227|subdomain
P11208814A0673|145 147|m7
P11209814A0243|206 217|bioceramics
P11209814A0243|21 34|investigation
P11209814A0243|66 81|characteristics
P11209814A0243|97 111|tissue capsule
P11209814A0243|147 173|aluminum calcium phosphate
P11210401A0544|21 29|profiles
P11210401A0544|105 119|administration
P11210988T0000|5 13|survival
P11210988T0000|31 39|patients
P11211936A1490|48 58|expression
P11211936A1490|77 94|JNK/SAPK activity
P11211936A1490|62 66|blr1
P11211936A1490|105 120|SAPK activation
P11212327A1564|185 195|regulation
P11212327A1564|261 264|PIG
P11212327A1564|131 144|p59Lyn kinase
P11212327A1564|208 219|interaction
P11212327A1564|225 233|caveolin
P11214177A1125|51 58|nt RNAs
P11214177A1125|122 131|satellite
P11215622A0949|1 9|Grippers
P11215622A0949|73 79|strain
P11218739A0811|49 54|cases
P11218739A0811|27 33|H-BPPV
P11220306A0911|98 102|HexA
P11220306A0911|129 135|strain
P11220306A0911|27 31|RpoS
P11220486A0686|2 3|%
P11220486A0686|9 14|IL-12
P11220857T0000|28 44|Veterans Affairs
P11221845A0295|169 177|Scanning
P11221845A0295|140 160|Restriction Landmark
P11221845A0295|182 193|Methylation
P11221845A0295|226 236|loci/spots
P11221845A0295|88 104|SV40 T/t antigen
P11221845A0295|28 46|methylation status
P11221845A1370|84 92|stom ach
P11221845A1370|1 23|Northern blot analysis
P11221845A1370|38 41|mlt
P11222387A1497|51 57|action
P11222387A1497|80 110|ABL tyrosine kinase inhibition
P11222387A1497|22 30|compound
P11222387A1497|131 138|promise
P11222720A1699|18 22|RPMS
P11222720A1699|65 79|Notch activity
P11222720A1699|92 104|interactions
P11223153A0533|175 187|color schema
P11223153A0533|99 109|constructs
P11223153A0533|5 15|BFA System
P11223153A0533|162 167|flows
P11223153A0533|72 93|microsphere technique
P11223186A1095|20 56|oIFNtau enhancer-reporter constructs
P11223186A1095|130 138|sequence
P11223186A1095|148 149|s
P11223186A1095|90 97|regions
P11223240A0655|52 73|polyadenylation sites
P11223255A1034|49 82|serine threonine receptor kinases
P11223255A1034|4 12|addition
P11223257A0404|169 180|cantharidin
P11223257A0404|201 203|EN
P11223257A0404|43 61|rice seedling leaf
P11223257A0404|315 318|CHX
P11223257A0404|224 228|time
P11223257A0404|262 271|induction
P11223257A0404|157 167|inhibitors
P11223257A0404|334 345|requirement
P11223257A0404|300 313|cycloheximide
P11223257A0404|151 155|PP2A
P11224226A0000|16 32|chlordiazepoxide
P11224226A0000|5 12|effects
P11224226A0000|42 47|mg/kg
P11224226A0000|94 104|bretazenil
P11226752A0750|186 192|manner
P11226752A0750|70 91|mouse deltex homologs
P11226752A0750|36 50|overexpression
P11226752A0750|172 179|protein
P11226752A0750|123 131|activity
P11226752A0750|14 34|tissue culture cells
P11227182A1475|65 75|parameters
P11227182A1475|83 89|lipids
P11227182A1475|126 131|serum
P11227182A1475|44 56|correlations
P11228700T0000|21 28|analyst
P11228700T0000|5 13|position
P11230169A0480|204 210|invdup
P11230169A0480|223 240|marker chromosome
P11230169A0480|138 148|DNA domain
P11230169A0480|74 93|array hybridization
P11230889A1151|5 10|cases
P11230889A1151|77 89|improvements
P11230889A1151|133 142|treatment
P11230889A1151|120 126|months
P11232947A1451|39 56|radiation therapy
P11232947A1451|147 155|survival
P11234223A1451|17 28|antibiotics
P11234223A1451|169 172|AMK
P11234223A1451|201 204|CAZ
P11234223A1451|174 177|IPM
P11234223A1451|111 116|class
P11234223A1451|120 131|antibiotics
P11235777A0878|18 26|syndrome
P11235777A0878|36 61|serum testosterone levels
P11235777A0878|79 82|end
P11235777A0878|28 33|47XXY
P11236056A0374|1 11|Conclusion
P11236056A0374|23 29|levels
P11237491A0000|71 89|tumour markers CEA
P11237491A0000|142 148|cancer
P11237491A0000|166 176|hypothesis
P11237491A0000|259 273|concentrations
P11237491A0000|223 235|fluctuations
P11237491A0000|182 202|serum concentrations
P11238105A0959|170 194|tyrosine phosphorylation
P11238105A0959|103 110|alpha-2
P11238105A0959|18 32|alpha subunits
P11238105A0959|212 222|substrates
P11238105A0959|62 68|term-3
P11238105A0959|151 158|ability
P11238402A0191|38 48|mechanisms
P11238447A0524|154 177|nucleoporins CAN/nup214
P11238447A0524|179 185|nup153
P11238447A0524|43 49|eIF-5A
P11238447A0524|198 203|nup62
P11238447A0524|91 98|Rev-NES
P11238882A0157|30 34|eIF6
P11238916A0838|169 175|domain
P11238916A0838|218 222|Pyk2
P11238916A0838|77 92|tyrosine kinase
P11238916A0838|94 98|Pyk2
P11238916A0838|13 20|complex
P11239184A1340|1 19|Baseline variables
P11239184A1340|64 67|use
P11239184A1340|144 155|mass effect
P11239184A1340|121 131|CT changes
P11240600A0523|65 73|duration
P11240600A0523|77 91|VGB medication
P11241215A0566|34 42|sBMPR-IA
P11241215A0566|154 165|performance
P11241215A0566|143 148|phase
P11241215A0566|219 231|enterokinase
P11241215A0566|12 21|receptors
P11241332A0393|118 137|bone anchor designs
P11241332A0393|64 82|fixation strengths
P11241332A0393|230 234|bone
P11241332A0393|10 17|purpose
P11241332A0393|90 100|variations
P11241672T0000|97 110|interleukin-4
P11241672T0000|37 48|murine beta
P11241672T0000|148 154|STAT-6
P11241672T0000|13 29|characterization
P11243336A0000|84 96|applications
P11243336A0000|129 152|brachytherapy dosimetry
P11243777A0000|12 26|CCAAT elements
P11244568A0506|119 125|larvae
P11244568A0506|96 102|amount
P11244568A0506|29 33|gene
P11245986T0000|32 39|protein
P11246887A0000|103 107|CETP
P11246887A0000|340 348|diabetes
P11246887A0000|6 11|study
P11246887A0000|283 291|subjects
P11246887A0000|315 329|sex difference
P11246887A0000|160 168|activity
P11246887A0000|154 158|PLTP
P11246887A0000|25 29|role
P11246887A0000|209 229|artery calcification
P11246887A0000|303 307|loss
P11248463A0187|5 17|blood levels
P11248463A0187|30 38|pyruvate
P11250196A0455|48 69|calcium binding sites
P11250196A0455|40 44|pair
P11251083T0000|119 138|MEK/ERK activations
P11251083T0000|87 100|growth factor
P11251083T0000|29 36|control
P11251252A0494|1 20|3D image-processing
P11251252A0494|128 136|3D views
P11251252A0494|148 152|mode
P11251697T0000|80 93|determination
P11251697T0000|8 38|superoxide scavenging activity
P11251697T0000|73 78|drugs
P11254134A0648|33 54|background activities
P11254134A0648|11 15|PTax
P11254134A0648|60 63|PTF
P11254713A1029|39 49|components
P11254713A1029|162 172|activation
P11254713A1029|131 142|alterations
P11254713A1029|26 29|Tat
P11254713A1029|151 158|complex
P11254864T0000|26 35|treatment
P11255252A0961|11 23|ER3 sequence
P11255252A0961|73 80|FXR HRE
P11256845A0340|36 70|Scotland Coronary Prevention Study
P11256845A0340|72 79|WOSCOPS
P11256845A0340|13 21|analysis
P11256845A0340|105 121|statin treatment
P11256845A0340|81 89|findings
P11256845A0340|179 189|population
P11256845A0340|28 32|West
P11256962A0233|255 262|portion
P11256962A0233|206 210|exon
P11256962A0233|200 204|exon
P11256962A0233|40 51|differences
P11256962A0233|270 284|GlyR beta mRNA
P11258906A0743|4 33|DNA strand exchange reactions
P11258906A0743|40 56|oligonucleotides
P11258906A0743|72 76|Rec2
P11259503A0212|87 97|luciferase
P11259503A0212|52 57|cells
P11260468A1179|156 168|protein H-NS
P11260468A1179|5 12|results
P11260468A1179|67 78|CAP subunit
P11263622A0683|1 8|RESULTS
P11263622A0683|138 139|r
P11263622A0683|37 38|p
P11263622A0683|89 105|vessel wall area
P11263622A0683|151 152|r
P11263664T0000|39 47|deltaEF1
P11263664T0000|7 31|Smad interacting protein
P11264177T0000|1 20|Nucleotide sequence
P11264177T0000|22 39|transcription map
P11264177T0000|106 112|B-cell
P11264177T0000|45 62|mutation analysis
P11264372T0000|86 106|herpes simplex virus
P11264372T0000|42 55|translocation
P11264561A0167|86 95|occlusion
P11264561A0167|56 63|anatomy
P11266184A0000|87 90|TOF
P11266184A0000|116 122|images
P11266184A0000|71 85|time-of-flight
P11266184A0000|189 191|SE
P11266184A0000|178 187|spin-echo
P11266184A0000|132 142|components
P11266227A0295|48 56|pH value
P11266227A0295|5 15|flux rates
P11266558A1470|32 53|transcription extract
P11266558A1470|189 209|SL RNA gene promoter
P11267679A0102|50 72|Southern hybridization
P11267679A0102|135 146|amino acids
P11267679A0102|90 103|reading frame
P11268887A1174|38 54|reference values
P11268887A1174|125 129|FEV1
P11268887A1174|107 113|regard
P11273995A1148|108 118|velocities
P11273995A1148|30 38|subjects
P11274149A0625|117 128|interaction
P11274149A0625|37 42|U-box
P11274149A0625|74 82|proteins
P11274184A0000|16 26|expression
P11274184A0000|115 129|detoxification
P11274184A0000|58 69|antioxidant
P11274184A0000|45 52|enzymes
P11274357A0724|205 243|nucleoside diphosphate kinase activity
P11274357A0724|142 146|Rac1
P11274357A0724|133 138|forms
P11274357A0724|54 58|type
P11274357A0724|249 255|nm23H1
P11274357A0724|148 153|Cdc42
P11274357A0724|91 97|mutant
P11274368A0818|1 9|Deletion
P11274368A0818|27 44|initiator element
P11274368A0818|61 71|repression
P11275986A0091|114 125|degradation
P11275986A0091|8 21|gene products
P11277913T0000|55 65|Hsp70 mRNA
P11277913T0000|39 45|region
P11278286A1083|68 73|MR/GR
P11278286A1083|77 88|combination
P11278286A1083|104 106|GR
P11278310A1516|36 42|mutant
P11278310A1516|123 134|cell number
P11278400A0668|82 93|OCT binding
P11278400A0668|144 164|mobility shift assay
P11278400A0668|95 115|homeodomain proteins
P11278461A0637|97 108|amino acids
P11278461A0637|46 50|part
P11278461A0637|183 216|chinook salmon HIF-1alpha protein
P11278461A0637|121 153|rainbow trout HIF-1alpha protein
P11278521A0849|170 178|promoter
P11278521A0849|48 55|nonamer
P11278521A0849|64 77|up-regulation
P11278521A0849|125 130|acids
P11278583A0873|305 310|motif
P11278583A0873|139 154|differentiation
P11278583A0873|200 211|recruitment
P11278583A0873|348 351|Sos
P11278583A0873|228 250|phosphotyrosine motifs
P11278583A0873|164 186|phosphotyrosine motifs
P11278583A0873|21 24|IRS
P11278583A0873|264 275|recruitment
P11278583A0873|215 219|Grb2
P11278604A0300|137 146|CHO cells
P11278604A0300|57 63|5Lec20
P11278604A0300|26 35|N-glycans
P11278604A0300|241 250|acceptors
P11278671T0000|64 67|Bak
P11278671T0000|46 60|splice variant
P11278819A0565|84 90|intron
P11278819A0565|115 131|mouse IRBP genes
P11278819A0565|197 209|MOK2 binding
P11278819A0565|149 162|half sequence
P11278855A0205|136 148|Western blot
P11278855A0205|38 41|TLS
P11278855A0205|46 49|p65
P11278855A0205|91 123|coimmunoprecipitation experiment
P11278928A1634|138 159|C/EBPepsilon isoforms
P11278928A1634|21 25|data
P11278928A1634|161 164|p32
P11278928A1634|91 105|mRNA structure
P11279086A1350|100 115|tumor processes
P11279086A1350|157 165|molecule
P11279086A1350|82 93|development
P11279086A1350|25 34|ADAM-TS12
P11279086A1350|44 49|roles
P11279207A0904|17 24|results
P11279207A0904|61 74|TCR signaling
P11279324A0710|50 65|creatine kinase
P11279324A0710|75 81|method
P11279720A0844|83 91|patients
P11279720A0844|144 151|disease
P11279720A0844|108 117|diagnosis
P11279720A0844|183 199|levodopa therapy
P11279720A0844|132 141|Parkinson
P11280799A1025|4 12|contrast
P11280799A1025|172 176|IL-8
P11280799A1025|43 51|peptides
P11280799A1025|192 197|PTHrP
P11281268A0000|155 190|sea anemone Anthopleurura japonicus
P11281268A0000|99 108|evolution
P11281268A0000|112 130|phosphagen kinases
P11281268A0000|132 135|AKs
P11282088A0837|17 24|females
P11282088A0837|44 45|P
P11282395A0530|38 53|RAG1/2 proteins
P11282395A0530|158 194|DNA repair proteins Nbs1/Mre11/Rad50
P11282433T0000|1 6|Phase
P11282433T0000|39 48|etoposide
P11282433T0000|10 15|study
P11283010A0701|6 16|activation
P11283168A0738|175 183|anthesis
P11283168A0738|83 91|Gus gene
P11283168A0738|129 144|mid-development
P11283168A0738|28 33|lines
P11283354A0548|7 11|data
P11283354A0548|58 79|histone modifications
P11283354A0548|151 175|heterochromatin assembly
P11285235A0466|97 109|GATA factors
P11286833A0959|185 190|years
P11286833A0959|65 75|leucovorin
P11286833A0959|172 177|range
P11286833A0959|79 103|maintenance chemotherapy
P11286833A0959|46 60|5-fluorouracil
P11286833A0959|104 111|RESULTS
P11287578A1311|171 173|E6
P11287578A1311|154 167|keratinocytes
P11287578A1311|37 47|macrophage
P11287578A1311|61 75|protein 1alpha
P11287611A0802|83 90|ligands
P11287611A0802|8 17|PPARgamma
P11287611A0802|160 174|cyclin D1 gene
P11287611A0802|47 54|15d-PGJ
P11287654A0150|1 5|PABP
P11287654A0150|86 96|C terminus
P11288930A0000|186 195|gestation
P11288930A0000|18 25|effects
P11288930A0000|156 162|mating
P11288930A0000|97 101|rats
P11288930A0000|129 140|generations
P11289149A0658|34 47|transcription
P11289149A0658|108 116|cofactor
P11289149A0658|130 137|protein
P11290906T0000|12 24|accumulation
P11290906T0000|74 84|infarction
P11292335A0852|71 92|sequence substitution
P11292335A0852|23 30|dnaE173
P11292335A0852|148 157|frequency
P11292844A0081|20 26|trimer
P11292844A0081|11 14|DNA
P11295470A0954|85 91|B cell
P11295470A0954|130 133|UTR
P11295470A0954|73 77|site
P11295760A1374|1 24|Specimen mass reduction
P11295760A1374|64 65|%
P11295760A1374|40 50|irradiance
P11296442A0565|16 25|tube size
P11296442A0565|200 209|tube size
P11296442A0565|176 183|formula
P11296442A0565|135 145|anesthesia
P11297514A0218|95 106|temperature
P11297514A0218|45 54|induction
P11297866A0484|4 12|contrast
P11297866A0484|22 34|I. argentina
P11297866A0484|73 75|BF
P11301189A1396|4 12|contrast
P11301189A1396|29 39|expression
P11301189A1396|47 52|INK4d
P11302566A1318|56 85|dopamine receptor sensitivity
P11303027A0954|97 106|effectors
P11303027A0954|76 86|ARF family
P11303027A0954|29 36|network
P11303027A0954|134 144|cross-talk
P11303890A0996|38 43|doses
P11303890A0996|52 58|values
P11306101A0000|100 114|dehydrogenases
P11306101A0000|146 154|alcohols
P11306101A0000|192 214|3alpha-hydroxysteroids
P11306511A1476|116 120|lack
P11306511A1476|99 109|mdm2 mRNAs
P11306511A1476|45 55|expression
P11308851A0333|64 68|GSER
P11308851A0333|128 147|material parameters
P11308851A0333|94 109|frequency range
P11309077A0953|87 91|ones
P11309077A0953|37 43|jejuni
P11309077A0953|31 35|Camp
P11309389A0273|289 304|down-regulation
P11309389A0273|32 43|proteolysis
P11309389A0273|145 169|metalloprotease activity
P11309389A0273|78 123|phorbol ester phorbol 12-myristate 13-acetate
P11309389A0273|194 198|GHBP
P11309677A0000|168 172|GV-H
P11309677A0000|99 102|GWI
P11309677A0000|36 43|battery
P11309677A0000|128 135|fatigue
P11310937A0548|1 8|RESULTS
P11310937A0548|168 175|tertile
P11310937A0548|108 115|tertile
P11310937A0548|243 251|tertiles
P11310937A0548|180 190|fibrinogen
P11311464A0362|34 38|pain
P11311464A0362|69 77|sciatica
P11311464A0362|7 16|disorders
P11311464A0362|135 145|paraplegia
P11311550A0253|221 236|rat cardiocytes
P11311550A0253|257 258|C
P11311550A0253|263 281|myoblast cell line
P11311550A0253|76 101|rat eIF4E promoter region
P11311550A0253|46 60|rat eIF4E gene
P11311550A0253|28 38|regulation
P11311687A0231|35 42|studies
P11311687A0231|5 11|JHRLSS
P11311687A0231|53 65|RLS severity
P11311687A0231|108 116|relation
P11311980A1049|1 5|GABA
P11311980A1049|6 7|B
P11312120A1311|1 29|NF-kappaB pathway activation
P11312120A1311|113 120|Bcr/Abl
P11312120A1311|130 133|Rac
P11312120A1311|122 125|Ras
P11312584X1846|16 30|Academic Press
P11313342A0224|113 125|depurinating
P11313342A0224|162 165|PAP
P11313342A0224|150 158|activity
P11313398A0687|1 23|Cross-linking FcalphaR
P11313398A0687|96 106|activation
P11313398A0687|27 34|wt-ITAM
P11313946T0000|87 101|gene induction
P11313946T0000|19 27|effector
P11313946T0000|106 117|cell growth
P11314030A1264|51 54|Crk
P11314030A1264|5 12|results
P11314030A1264|231 241|SH3 domain
P11314030A1264|209 212|SH3
P11314030A1264|164 172|paradigm
P11314030A1264|120 123|FAK
P11314373T0000|47 54|problem
P11315633A0920|170 183|sobemoviruses
P11315633A0920|35 38|RNA
P11315633A0920|5 18|cleavage site
P11315633A0920|27 30|VPg
P11317256A0361|137 144|abscess
P11317256A0361|48 56|isolates
P11317256A0361|12 20|isolates
P11317256A0361|60 75|S. constellatus
P11318608A0669|184 191|protein
P11318608A0669|96 106|DENTT cDNA
P11318608A0669|7 35|brain cDNA library screening
P11318608A0669|268 275|regions
P11319098A0164|100 112|protein NusG
P11319098A0164|22 39|tryptophanyl tRNA
P11319098A0164|167 171|PkwR
P11319098A0164|132 144|proteins L11
P11319098A0164|195 202|protein
P11321187A0355|84 86|C.
P11321187A0355|32 43|MS patients
P11321187A0355|156 157|%
P11321187A0355|107 110|IgG
P11323419T0000|190 195|tract
P11323419T0000|41 51|expression
P11323419T0000|28 35|mapping
P11324516A0159|158 177|potentiating effect
P11324516A0159|133 147|pain threshold
P11324516A0159|47 51|i.t.
P11324516A0159|181 183|AA
P11325391A0498|20 33|d-amphetamine
P11325391A0498|11 16|doses
P11325944A0511|169 173|UhpB
P11325944A0511|235 241|strain
P11325944A0511|36 40|UhpB
P11325944A0511|10 20|expression
P11325944A0511|73 79|GST-Bc
P11325944A0511|90 115|glutathione S-transferase
P11327698A0191|339 350|P4 activity
P11327698A0191|446 451|U0126
P11327698A0191|198 217|Sp1 phosphorylation
P11327698A0191|166 187|PKC expression vector
P11327698A0191|356 367|IGF-II mRNA
P11327698A0191|19 22|PKC
P11327698A0191|460 479|Sp1 phosphorylation
P11327698A0191|528 539|HepG2 cells
P11327698A0191|159 162|PMA
P11327698A0191|27 49|p44/p42MAPK signalings
P11327698A0191|122 130|activity
P11328699A0000|86 90|wall
P11328699A0000|59 63|time
P11328699A0000|73 78|close
P11331589A0113|84 94|expression
P11331589A0113|5 16|MSL complex
P11331604A0267|87 95|turnover
P11331604A0267|39 53|Gcn4 stability
P11331604A0267|26 35|regulator
P11333263A0240|49 55|middle
P11333263A0240|7 13|intron
P11333263A0240|133 150|promoter activity
P11334124A0903|69 73|FEV1
P11334124A0903|57 65|increase
P11334124A0903|104 108|FEV1
P11334124A0903|120 130|dose range
P11335710A0320|45 50|phase
P11336698A0075|71 98|yeast remodeler RSC complex
P11336698A0075|28 33|Rsc30
P11340048A0432|136 150|flux densities
P11340048A0432|174 181|sensors
P11340048A0432|27 38|correlation
P11340085A0211|171 181|C/EBPalpha
P11340085A0211|206 210|frog
P11340085A0211|197 204|species
P11340085A0211|287 309|transactivation domain
P11340085A0211|14 24|hypothesis
P11340525A0737|158 167|regimen C
P11340525A0737|8 16|patients
P11340525A0737|147 148|%
P11340525A0737|120 129|regimen B
P11340525A0737|45 61|study end points
P11341405A0146|20 23|MCB
P11341405A0146|8 18|POPULATION
P11341828A0744|95 104|molecules
P11341828A0744|31 41|D-peptides
P11344530A0320|1 12|Percentages
P11344530A0320|42 56|dilution tests
P11345445A0533|34 43|Cd levels
P11345445A0533|188 202|concentrations
P11345445A0533|147 153|levels
P11345445A0533|14 23|OECD soil
P11348318A0940|20 27|adjunct
P11348318A0940|89 96|breasts
P11348318A0940|134 140|masses
P11350038A0459|85 99|stem structure
P11350038A0459|155 169|export process
P11350038A0459|143 147|role
P11350038A0459|42 46|half
P11350175A0173|79 88|isomerase
P11350175A0173|44 58|protein family
P11350957A0457|71 76|cells
P11350957A0457|78 83|PACAP
P11352423A0084|68 76|arm flap
P11352423A0084|96 102|choice
P11352423A0084|88 92|flap
P11352671A0492|84 87|ACU
P11352671A0492|7 18|application
P11352671A0492|77 80|UCU
P11352671A0492|245 249|cDNA
P11352671A0492|225 231|rPIV2V
P11353770A0085|187 193|places
P11353770A0085|172 177|sites
P11353770A0085|111 118|removal
P11353770A0085|26 34|activity
P11354406A1373|68 78|compliance
P11354406A1373|14 37|CSF outflow conductance
P11355576A1125|206 210|part
P11355576A1125|5 12|cyclins
P11355576A1125|229 237|activity
P11355576A1125|288 306|cell proliferation
P11355576A1125|185 192|S phase
P11355576A1125|179 181|G1
P11355668T0000|129 143|syndrome virus
P11355668T0000|92 99|porcine
P11355668T0000|15 27|vasculopathy
P11356716A0372|18 23|clone
P11356853A0429|137 145|pHO15luc
P11356853A0429|35 45|expression
P11356853A0429|86 93|control
P11356853A0429|111 135|pair mouse ho-1 promoter
P11356853A0873|1 8|Members
P11356853A0873|77 81|StRE
P11357063A1053|59 65|region
P11357063A1053|108 121|TATA sequence
P11357063A1053|73 89|gpLH/CGbeta gene
P11358958A0878|1 11|Expression
P11358958A0878|82 86|HF7c
P11358958A0878|135 144|apoptosis
P11359568T0000|53 57|ParB
P11359568T0000|27 51|pRA2 partitioning region
P11359568T0000|72 91|parAB transcription
P11359568T0000|104 125|nucleoprotein complex
P11359907A0099|9 28|dozen HIF-1 targets
P11359907A0099|104 108|VEGF
P11361338A0093|6 11|yeast
P11361338A0093|24 39|matrix proteins
P11361338A0093|121 135|tripeptide SKL
P11361493T0000|65 84|security institutes
P11361493T0000|11 39|hepatitis B virus infections
P11367523A2624|85 99|concentrations
P11367523A2624|10 22|C4B proteins
P11368363A1103|143 160|repressor domains
P11368363A1103|128 138|activation
P11368363A1103|192 203|rat protein
P11368363A1103|60 66|domain
P11368901A0327|38 46|proteins
P11368901A0327|59 70|repeat unit
P11368914T0071|119 126|control
P11368914T0071|146 154|promoter
P11368914T0071|88 91|end
P11369106A0428|136 145|food webs
P11369106A0428|42 48|sulfur
P11369106A0428|92 116|transformation processes
P11369453A1083|71 88|peptide treatment
P11369453A1083|26 41|protein binding
P11369700A0616|68 91|mouse GL alpha promoter
P11369700A0616|155 159|site
P11369700A0616|232 249|GL alpha promoter
P11369700A0616|177 187|expression
P11369700A0616|133 137|PU.1
P11370174A0447|67 73|months
P11370174A0447|94 97|MMF
P11371160A0193|20 31|nucleotides
P11371160A0193|67 89|discriminator base A73
P11371160A0193|46 62|base-pair C1-G72
P11371343A0125|101 108|securin
P11371343A0125|20 30|cell cycle
P11372882A1143|22 37|beta-HCH levels
P11372882A1143|94 98|PCBs
P11372882A1143|12 13|p
P11373277A0812|239 256|corepressor CtBP1
P11373277A0812|4 11|summary
P11373277A0812|203 214|interaction
P11373277A0812|124 130|effect
P11373277A0812|105 119|AP-2alpha gene
P11374559A0103|1 13|SERS spectra
P11374559A0103|54 61|casting
P11374559A0103|111 137|colloidal silver solutions
P11375392T0000|190 194|gene
P11375392T0000|5 18|core promoter
P11375392T0000|92 97|Oct-1
P11375392T0000|78 86|activity
P11375392T0000|28 49|thioredoxin reductase
P11376119A0346|81 92|GHR 1A mRNA
P11376119A0346|11 15|exon
P11376119A0346|121 125|exon
P11376165T0000|1 4|FLP
P11376165T0000|9 33|Cre recombinase function
P11376687A0344|35 38|SNP
P11376687A0344|43 47|exon
P11376687A0344|10 33|nucleotide polymorphism
P11376687A0344|192 208|MTH1 polypeptide
P11376687A0344|90 101|GTG83/ATG83
P11377975A0898|142 152|conditions
P11377975A0898|107 117|substrates
P11379106A0372|96 100|flow
P11379106A0372|112 123|pilot plant
P11380370A0000|71 73|KS
P11380370A0000|53 59|Kaposi
P11380370A0000|62 69|sarcoma
P11381094A0797|4 12|addition
P11381094A0797|14 20|stonin
P11382948A0793|141 153|permeability
P11382948A0793|172 177|USPIO
P11382948A0793|209 220|tumor grade
P11384225A0634|17 36|expression cassette
P11384225A0634|116 119|end
P11384225A0634|93 96|GFP
P11384225A0634|161 170|sequences
P11384576A1132|21 32|vision loss
P11384576A1132|80 91|retinopathy
P11385840A1684|43 60|wastewater system
P11385840A1684|15 28|RTC algorithm
P11387351A0092|168 176|children
P11387351A0092|215 223|syndrome
P11387351A0092|122 127|2-CDA
P11387351A0092|135 143|children
P11387351A0092|31 35|June
P11387351A0092|45 53|December
P11387950X0001|205 226|tumor necrosis factor
P11387950X0001|101 113|pancreatitis
P11387950X0001|40 49|decoction
P11387950X0001|287 290|ANP
P11387950X0001|437 455|leukocyte adhesion
P11387950X0001|316 324|relation
P11387950X0001|14 19|study
P11387950X0001|424 433|Decoction
P11387950X0001|397 403|effect
P11387950X0001|334 341|changes
P11387950X0001|246 251|stage
P11389085A0290|1 9|TT cells
P11389085A0290|99 102|p65
P11389085A0290|94 98|RelA
P11390395A1018|105 120|transactivation
P11390395A1018|15 32|HMGI-C expression
P11390650A0562|113 119|SLP-76
P11390650A0562|72 78|domain
P11390684A1170|17 39|Northern hybridization
P11390684A1170|55 70|jadM expression
P11391303A1023|103 132|Tl-201 lung uptake evaluation
P11391303A1023|87 99|contribution
P11391303A1023|18 29|methodology
P11391793A0856|206 212|clones
P11391793A0856|189 199|chromosome
P11391793A0856|26 36|complexity
P11391793A0856|121 124|SRO
P11392772A0182|175 184|petroleum
P11392772A0182|143 147|Kyiv
P11392772A0182|135 139|city
P11392772A0182|164 171|content
P11392772A0182|188 193|water
P11392772A0182|24 37|biotechnology
P11392772A0182|209 216|Dnieper
P11393791A1153|49 62|mouse tissues
P11393791A1153|39 45|number
P11393791A1153|112 123|osteoclasts
P11393791A1153|76 81|Atp6i
P11393791A1153|146 156|expression
P11396685A0477|221 228|cheeses
P11396685A0477|190 196|groups
P11396685A0477|200 209|compounds
P11396685A0477|108 114|sample
P11396685A0477|15 22|results
P11398134A1565|138 151|hyperuricemia
P11398134A1565|25 39|alcohol intake
P11398134A1565|104 114|predictors
P11399064T0000|34 42|pathways
P11399064T0000|1 15|Autoregulation
P11399064T0000|91 101|C/EBP beta
P11400644A0435|141 150|g I-TEQ/y
P11400644A0435|20 33|uncertainties
P11400644A0435|6 16|reflection
P11401611A1703|1 12|CONCLUSIONS
P11401611A1703|67 70|HRT
P11401611A1703|57 63|trials
P11403173A0192|3 8|total
P11403173A0192|15 23|patients
P11403719A1257|5 12|results
P11403719A1257|27 31|Gab1
P11404016A1922|137 143|number
P11404016A1922|100 103|TEs
P11404016A1922|21 31|TE domains
P11404016A1922|203 207|NRPS
P11404016A1922|105 111|TE IIs
P11404312A0660|14 23|pmol/24 h
P11406025A0204|35 41|review
P11406025A0204|87 100|acceptability
P11406025A0204|108 117|diaphragm
P11406025A0204|61 74|effectiveness
P11406642A0792|53 58|genes
P11407448A0815|85 112|jejunum flap reconstruction
P11407448A0815|257 265|puncture
P11407448A0815|5 12|results
P11407448A0815|60 68|patients
P11408099A0518|71 80|pregnancy
P11408099A0518|98 104|kidney
P11408099A0518|128 133|heart
P11408099A0518|106 107|r
P11408099A0518|135 136|r
P11408575A0000|113 121|cyclin B
P11408575A0000|58 68|activation
P11408575A0000|123 126|Clb
P11408604A1440|187 195|pathways
P11408604A1440|217 241|receptor tyrosine kinase
P11408604A1440|5 12|results
P11408604A1440|163 173|activation
P11408604A1440|27 28|D
P11408604A1440|121 134|PDGF receptor
P11409425A0000|305 309|risk
P11409425A0000|207 221|apolipoprotein
P11409425A0000|40 48|patients
P11409425A0000|228 230|E2
P11409425A0000|104 110|Stroke
P11409425A0000|327 337|hemorrhage
P11409425A0000|155 167|Stroke Trial
P11409425A0000|293 299|stroke
P11409425A0000|56 74|National Institute
P11409425A0000|149 153|t-PA
P11409425A0000|91 99|Diseases
P11410563A0363|116 126|valve size
P11410563A0363|97 114|body surface area
P11410563A0363|128 152|shop order fracture rate
P11410563A0363|199 202|OSF
P11410563A0363|61 80|regression analysis
P11410679A0000|153 156|use
P11410679A0000|250 254|gene
P11410679A0000|217 220|cre
P11410679A0000|93 98|genes
P11410679A0000|46 61|Cre recombinase
P11410679A0000|15 25|alteration
P11411623T0000|98 106|exercise
P11411623T0000|61 74|tissue injury
P11413148A0573|50 61|SH3 domains
P11413148A0573|93 117|tyrosine phosphorylation
P11413148A0573|41 44|SH2
P11413310A0148|1 7|RANTES
P11413310A0148|179 189|cell types
P11413310A0148|145 156|lymphocytes
P11413310A0148|24 34|activation
P11413310A0148|134 143|monocytes
P11413641A0373|69 81|quadrat area
P11413641A0373|59 65|effect
P11414754X1099|16 30|Academic Press
P11415952A0369|1 7|Angina
P11415952A0369|98 104|angina
P11415952A0369|76 86|infarction
P11415952A0369|106 132|electrocardiogram ischemia
P11415952A0369|164 184|heart disease events
P11416012A1982|102 114|LDL receptor
P11416012A1982|39 48|mediation
P11416012A1982|52 54|LH
P11416012A1982|229 232|PKI
P11416012A1982|133 149|reporter plasmid
P11416012T0000|186 200|protein kinase
P11416012T0000|204 233|phosphatidylinositol 3-kinase
P11416012T0000|257 290|protein kinase signaling pathways
P11416012T0000|86 93|insulin
P11416012T0000|27 37|activation
P11416144A1324|103 112|mechanism
P11416144A1324|5 13|findings
P11416144A1324|26 39|understanding
P11416393A0000|340 343|day
P11416393A0000|614 633|tobacco consumption
P11416393A0000|336 337|g
P11416393A0000|79 101|lifestyle modification
P11416393A0000|155 171|weight reduction
P11416393A0000|266 275|morbidity
P11416393A0000|576 592|exercise program
P11416393A0000|506 525|alcohol consumption
P11416393A0000|432 438|dosage
P11416393A0000|492 502|moderation
P11416393A0000|541 546|ounce
P11416393A0000|126 150|blood pressure elevation
P11416393A0000|181 192|body weight
P11416737T0000|1 6|Ga-67
P11416737T0000|65 76|case report
P11418130A0499|25 39|loxP sequences
P11419938T0000|152 178|diphtheria toxin repressor
P11419938T0000|16 23|changes
P11419938T0000|109 117|evidence
P11419938T0000|90 101|DNA binding
P11422200A0000|100 118|defence mechanisms
P11422200A0000|127 136|infection
P11422200A0000|47 61|administration
P11423991A1393|137 146|responses
P11423991A1393|175 191|cancer therapies
P11423991A1393|43 48|yeast
P11423991A1393|28 39|p53 mutants
P11425076A0364|50 55|flows
P11425076A0364|110 116|values
P11425076A0364|124 139|Reynolds number
P11425076A0364|166 173|inertia
P11425076A0364|61 67|result
P11427329A1077|153 159|sample
P11427329A1077|117 120|CAS
P11427329A1077|5 13|validity
P11427329A1077|130 131|N
P11427329A1077|90 93|VAS
P11428276A0352|21 37|syndrome lesions
P11428276A0352|96 104|increase
P11428276A0352|13 18|Hoeve
P11428435A0446|117 125|December
P11428435A0446|25 37|chart review
P11428435A0446|47 55|patients
P11428897A0318|170 174|face
P11428897A0318|260 264|CopG
P11428897A0318|232 238|repeat
P11428897A0318|97 104|protein
P11428897A0318|41 45|CopG
P11428897A0318|105 115|DNA ratios
P11430042A0000|154 160|liquid
P11430042A0000|99 116|tetrafluoroborate
P11430042A0000|24 48|Stille coupling reaction
P11431348A0000|153 165|MAPK pathway
P11431348A0000|1 13|Interactions
P11431348A0000|190 197|variety
P11431348A0000|82 92|inhibitors
P11431348A0000|148 151|MEK
P11431857A0186|68 72|time
P11431857A0186|5 13|students
P11431857A0186|91 105|urine analysis
P11432748T0000|1 11|Regulation
P11432748T0000|15 50|laminin beta2 chain gene expression
P11433014A0683|96 100|tail
P11433014A0683|110 113|MCB
P11433014A0683|45 51|fusion
P11433024A0260|118 126|template
P11433024A0260|70 73|DNA
P11433024A0260|79 90|chromosomes
P11434084A0508|16 27|patients DD
P11435517A0396|34 36|CP
P11435517A0396|7 22|digestibilities
P11435517A0396|87 89|GE
P11435517A0396|156 161|fiber
P11435517A0396|52 57|fiber
P11435517A0396|126 131|diets
P11435517A0396|26 28|DM
P11435578A0760|154 162|AGACGTCA
P11435578A0760|174 182|TGACCTCA
P11435578A0760|52 55|CRE
P11435578A0760|42 50|elements
P11435578A0760|90 99|consensus
P11435605A0587|138 143|Tyr83
P11435605A0587|228 245|Ad41L fiber knobs
P11435605A0587|105 121|contact residues
P11435605A0587|48 66|CAR residues Leu73
P11435605A0587|179 198|binding interaction
P11435605A0587|208 211|Ad5
P11435983T0000|1 10|Tolerance
P11435983T0000|53 64|bone marrow
P11437660A1219|17 32|serine residues
P11437660A1219|66 70|loss
P11437660A1219|133 146|transcription
P11437660A1219|74 95|phosphorylation sites
P11438654A1237|100 132|c-Akt/Pak1 cell survival pathway
P11438654A1237|83 87|PI3K
P11438654A1237|59 74|c-Met signaling
P11438838A0788|76 88|RNA promoter
P11438838A0788|11 20|inhibitor
P11441163T0000|1 11|Foreigners
P11441952A0414|141 151|difference
P11441952A0414|167 182|months post-TBI
P11441952A0414|195 209|avoidance test
P11441952A0414|184 185|b
P11441952A0414|53 57|rats
P11441952A0414|25 31|months
P11443509A0293|68 89|First National Health
P11443509A0293|155 160|NHEFS
P11443509A0293|114 120|NHANES
P11443509A0293|56 62|period
P11443509A0293|44 45|y
P11444762A0373|101 107|action
P11444762A0373|56 64|analysis
P11447490A0598|50 55|fluid
P11447490A0598|5 11|amount
P11449014A0000|84 91|quality
P11449014A0000|158 171|participation
P11449014A0000|142 150|relation
P11449014A0000|125 131|trials
P11449014A0000|210 213|E/B
P11450776T0000|8 12|case
P11450776T0000|46 57|peritonitis
P11451682A0190|66 101|benzimidazole carbamate derivatives
P11451682A0190|111 122|mebendazole
P11451682A0190|13 25|chemotherapy
P11454004T0000|68 107|glycerol-3-phosphate dehydrogenase gene
P11454004T0000|33 42|promoters
P11454004T0000|109 123|identification
P11454239A0478|203 210|RESULTS
P11454239A0478|42 88|Pearson Product Moment Correlation Coefficient
P11454239A0478|196 201|alpha
P11454239A0478|13 21|Analysis
P11454239A0478|189 194|alpha
P11454239A0478|124 154|Discriminant Function Analysis
P11454239A0478|31 36|ANOVA
P11454239A0478|90 119|Principal Components Analysis
P11456259A0142|5 10|titer
P11456259A0142|77 78|%
P11456259A0142|14 50|TSH binding inhibitor immunoglobulin
P11459048A0485|34 47|uncertainties
P11459048A0485|158 173|rotation states
P11459048A0485|94 104|atmosphere
P11459794A1172|1 13|TE-671 cells
P11459794A1172|113 121|activity
P11459794A1172|41 62|cAMP response element
P11459962A0785|221 227|growth
P11459962A0785|116 135|rad27 Delta strains
P11459962A0785|174 188|semipermissive
P11459962A0785|193 202|degrees C
P11459962A0785|104 112|survival
P11461595A0000|20 37|reaction kinetics
P11461595A0000|57 66|particles
P11461595A0000|89 105|coalescence type
P11461595A0000|165 170|flows
P11462004A1500|206 209|Vp1
P11462004A1500|101 104|Vp3
P11462004A1500|163 169|signal
P11462004A1500|78 85|nucleus
P11462952A1040|32 37|range
P11462952A1040|9 23|gastrin levels
P11462952A1040|46 50|mU/L
P11463834A0606|138 144|region
P11463834A0606|43 54|amino acids
P11463834A0606|149 164|Tax interaction
P11465518A0000|1 11|BACKGROUND
P11465518A0000|223 228|risks
P11465518A0000|196 207|individuals
P11465518A0000|79 85|public
P11465518A0000|132 142|treatments
P11465844T0000|1 5|Lack
P11465844T0000|66 84|Rickettsia conorii
P11465844T0000|125 155|Ehrlichia phagocytophila group
P11465844T0000|104 121|Coxiella burnetii
P11467349A0452|58 69|ISF glucose
P11469701A0377|23 45|insulin administration
P11469701A0377|179 200|insulin concentration
P11469701A0377|11 19|approach
P11469701A0377|121 128|insulin
P11469853A0702|16 22|system
P11469853A0702|125 130|yeast
P11469853A0702|27 43|domain shuffling
P11469853A0702|61 69|function
P11469926T0000|52 64|crystal ball
P11470914A0305|98 113|gene expression
P11470914A0305|58 65|nucleus
P11471231A0964|68 79|differences
P11471231A0964|4 12|addition
P11471231A0964|188 198|procedures
P11472696A0387|24 29|CPIgG
P11472696A0387|94 97|ACS
P11472696A0387|31 34|CRP
P11473261A0587|80 83|GEF
P11478627A0573|5 26|desirability function
P11478627A0573|178 187|criterion
P11478627A0573|92 94|Yn
P11478627A0573|79 81|Y1
P11478627A0573|63 70|optimum
P11478627A0573|104 118|transformation
P11479501A0744|206 222|Omnicarbon valve
P11479501A0744|36 48|distribution
P11479501A0744|197 198|%
P11479501A0744|84 93|SD/mean x
P11479501A0744|114 125|valve sizes
P11479501A0744|58 69|coefficient
P11480497T0000|85 93|learning
P11480497T0000|98 104|memory
P11480497T0000|26 39|JP-8 jet fuel
P11481625A0202|189 198|microg/kg
P11481625A0202|145 147|QW
P11481625A0202|88 91|TIW
P11481625A0202|120 123|MIU
P11484578A1132|98 114|measurement data
P11484578A1132|26 37|differences
P11484578A1132|123 129|object
P11486141A0424|85 90|power
P11486141A0424|54 62|students
P11486141A0424|162 167|error
P11486141A0424|151 158|sources
P11486476A0147|111 116|value
P11486476A0147|162 172|CK-MB mass
P11486476A0147|317 328|information
P11486476A0147|81 89|patients
P11486476A0147|249 257|patients
P11486476A0147|95 105|chest pain
P11486476A0147|148 157|myoglobin
P11489597A0379|17 19|gd
P11489597A0379|101 107|status
P11489597A0379|66 71|group
P11489597A0379|124 131|outcome
P11490862A0141|68 82|Stamey-Pereyra
P11490862A0141|140 147|support
P11490862A0141|31 54|bladder neck suspension
P11495833T0000|16 22|impact
P11495833T0000|47 52|means
P11496495A0000|51 61|conditions
P11496495A0000|21 29|analysis
P11496495A0000|125 133|children
P11498795A0716|136 154|S phase transition
P11498795A0716|41 49|G1-phase
P11498795A0716|72 87|phosphorylation
P11500512A0000|68 71|ABC
P11500512A0000|32 38|member
P11500512A0000|11 21|ABCG1 gene
P11500512A0000|88 108|transporter proteins
P11500913A1238|1 14|C/EBPbeta LIP
P11500913A1238|57 73|beta-casein mRNA
P11500913A1238|149 157|hormones
P11502758A0869|52 56|role
P11502758A0869|78 92|FGFR signaling
P11504545A0393|1 12|Competition
P11504545A0393|157 164|BKV-MLP
P11504545A0393|82 93|NF1 factors
P11504545A0393|29 43|mobility shift
P11505407A0461|1 8|RESULTS
P11505407A0461|48 56|activity
P11505407A0461|145 153|TNFalpha
P11505407A0461|60 65|EpCAM
P11509615T0000|1 30|Phosphatidylinositol 3-kinase
P11511544T0000|20 51|heat shock transcription factor
P11511544T0000|104 115|heat stress
P11511544T0000|75 86|specificity
P11513121T0000|23 38|robustness test
P11513121T0000|145 154|compounds
P11513121T0000|13 18|study
P11513579A0372|22 28|system
P11513579A0372|57 61|Rac1
P11513579A0372|166 183|complex formation
P11517190A0352|17 34|promoter sequence
P11517190A0352|1 9|Analysis
P11517190A0352|145 153|elements
P11517190A0352|215 222|element
P11517190A0352|130 133|cis
P11517269A0472|155 161|degree
P11517269A0472|176 188|conservation
P11517269A0472|29 51|differentiation defect
P11517269A0472|107 117|phenotypes
P11517445A0221|43 57|V. cholerae O1
P11518868A0559|117 150|healthcare provider communication
P11518868A0559|77 86|knowledge
P11518868A0559|31 38|history
P11520436A0705|103 113|connection
P11520436A0705|159 165|asthma
P11520436A0705|79 86|studies
P11520436A0705|122 131|infection
P11522431A0673|141 152|nondrinkers
P11522431A0673|5 15|prevalence
P11522431A0673|163 171|drinkers
P11522431A0673|130 131|%
P11522626A1374|23 33|regulation
P11522626A1374|42 60|gene transcription
P11522626A1374|124 131|pathway
P11522658A0870|49 53|MAPK
P11522658A0870|158 173|kinase activity
P11522658A0870|23 38|phosphorylation
P11522658A0870|42 45|p27
P11524015A0937|49 60|H4 promoter
P11524015A0937|8 18|expression
P11524015A0937|62 64|nt
P11524823X0001|102 109|purpose
P11524823X0001|42 52|evaluation
P11524823X0001|162 178|OAE screener GSI
P11524823X0001|227 234|infants
P11524823X0001|87 96|emissions
P11524823X0001|26 29|GSI
P11524823X0001|147 154|ability
P11525486A0350|39 47|solution
P11525486A0350|27 29|N2
P11528127A1402|118 122|% GC
P11528127A1402|8 18|GC content
P11528127A1402|24 25|%
P11528127A1402|72 74|H1
P11528500A0571|4 12|mutation
P11528500A0571|57 65|families
P11530684A0667|37 46|responses
P11530684A0667|350 358|A-fibers
P11530684A0667|255 285|drive NMDA receptor-mechanisms
P11530684A0667|216 220|ones
P11530684A0667|364 394|drive NMDA-receptor mechanisms
P11530684A0667|208 212|type
P11530684A0667|62 69|neurons
P11530684A0667|91 99|C-fibers
P11532556A0000|116 123|thalami
P11532556A0000|89 97|etiology
P11533238A1137|17 32|octamer element
P11533238A1137|115 142|HLA-DRA promoter activation
P11533238A1137|91 101|repression
P11533863A0125|81 95|presupposition
P11533863A0125|58 65|routine
P11533863A0125|15 19|case
P11534900A0000|116 134|synergists MGK-264
P11534900A0000|156 158|PB
P11534900A0000|25 37|combinations
P11534900A0000|180 193|Embelia ribes
P11535140T0000|26 35|pregnancy
P11535832A0586|5 12|isoform
P11535832A0586|58 68|C terminus
P11535832A0586|74 79|HDAC9
P11538437A0568|207 208|C
P11538437A0568|283 304|% CH4 post-discharges
P11538437A0568|76 77|A
P11538437A0568|133 135|N2
P11538437A0568|259 260|X
P11538437A0568|256 258|N2
P11538437A0568|81 83|N2
P11538437A0568|144 145|B
P11538437A0568|264 266|CN
P11538437A0568|215 217|M2
P11538437A0568|271 272|V
P11538437A0568|269 270|A
P11538437A0568|237 239|N2
P11538437A0568|233 235|M2
P11538437A0568|111 113|N2
P11538437A0568|227 228|V
P11538437A0568|225 226|B
P11538437A0568|119 121|N2
P11538437A0568|114 115|A
P11538437A0568|189 192|CH4
P11538437A0568|242 243|V
P11538437A0568|240 241|X
P11540991A0127|4 9|order
P11540991A0127|189 218|Shuttle Atlantis mission 61-B
P11540991A0127|110 121|NASA KC-135
P11540991A0127|165 177|EASE program
P11540991A0127|135 141|flight
P11542780A0086|237 240|LET
P11542780A0086|178 193|track detectors
P11542780A0086|242 251|component
P11542780A0086|106 131|energy transfer component
P11542780A0086|195 199|PNTD
P11543317A0203|119 121|Tb
P11543317A0203|66 75|detectors
P11543317A0203|110 117|Mg2SiO4
P11543317A0203|149 163|track detector
P11543317A0203|14 18|dose
P11545594A1556|178 185|protein
P11545594A1556|92 102|Myb domain
P11545594A1556|30 41|Myb domains
P11548027A0163|221 231|indicators
P11548027A0163|69 75|groups
P11548027A0163|3 11|proposal
P11548027A0163|159 185|service quality indicators
P11552058A0235|87 91|days
P11552058A0235|6 9|ICP
P11552058A0235|46 56|herniation
P11552724A0527|255 262|failure
P11552724A0527|33 37|IVUS
P11552724A0527|218 231|interventions
P11552724A0527|83 95|vessel lumen
P11552724A0527|266 273|allergy
P11552724A0527|164 174|blood flow
P11553091A1472|139 144|Class
P11553091A1472|5 12|results
P11553091A1472|72 84|relationship
P11554469A1386|53 63|CesA genes
P11554469A1386|196 202|plants
P11554469A1386|183 192|synthases
P11554566A0833|126 135|locations
P11554566A0833|75 80|Tr104
P11555516A0639|126 140|artery disease
P11555516A0639|57 62|L/min
P11555516A0639|29 38|threshold
P11555669A0983|50 57|tissues
P11555669A0983|25 33|sections
P11555669A0983|14 17|mix
P11557127A0991|16 20|NF-Y
P11557127A0991|59 63|role
P11557127A0991|126 135|MRP2 gene
P11557127A0991|95 108|rat mrp2 gene
P11559547T0000|54 83|pS2 breast cancer marker gene
P11559547T0000|120 129|receptors
P11559789A0314|175 182|ASF/SF2
P11559789A0314|55 60|virus
P11559789A0314|263 270|absence
P11559789A0314|76 99|ASF/SF2 splicing factor
P11559789A0314|107 119|progesterone
P11560292A0557|79 102|dipslide urine cultures
P11560292A0557|61 74|prototype DSS
P11560990A0272|170 180|transition
P11560990A0272|127 133|levels
P11560990A0272|88 93|point
P11560992A0651|1 20|SAPK/JNK activation
P11560992A0651|64 68|MKK7
P11560992A0651|53 60|absence
P11560992A0651|129 133|mkk7
P11560992A0651|160 175|phosphorylation
P11561623A0897|168 176|increase
P11561623A0897|80 93|Tisbe furcata
P11561623A0897|214 220|spring
P11561623A0897|121 125|fall
P11562278A0169|23 28|genes
P11562278A0169|142 156|transformation
P11562278A0169|97 110|proliferation
P11562278A0169|45 58|G1 regulation
P11564871A1184|140 144|need
P11564871A1184|53 74|transcription systems
P11564871A1184|7 14|results
P11564871A1184|166 170|Pols
P11564871A1184|28 36|presence
P11564871A1184|91 101|eukaryotes
P11565747A1020|136 154|binding affinities
P11565747A1020|1 5|Data
P11565747A1020|20 35|splicing assays
P11565747A1020|112 123|correlation
P11565747A1020|196 203|ability
P11566948A1217|34 41|therapy
P11566948A1217|111 120|incidence
P11566948A1217|56 60|ACEI
P11566996A1391|35 69|nucleotide excision repair pathway
P11566996A1391|173 182|S. mutans
P11566996A1391|159 169|adaptation
P11566996A1391|90 96|repair
P11569800T0000|41 48|systems
P11569949A2087|1 6|Zarix
P11569949A2087|74 80|Spring
P11570820T0000|6 19|casein kinase
P11570820T0000|22 30|isoforms
P11572388A0000|115 120|LSERs
P11572388A0000|6 11|paper
P11572388A0000|129 139|prediction
P11572388A0000|161 170|compounds
P11572388A0000|61 72|application
P11572467T0000|48 58|hemorrhage
P11572467T0000|94 98|t-PA
P11572467T0000|104 110|volume
P11573891A0525|1 8|RESULTS
P11573891A0525|20 24|cent
P11573891A0525|122 128|whites
P11573891A0525|60 79|community outbreaks
P11574105A0727|374 389|antibody titers
P11574105A0727|234 241|outcome
P11574105A0727|161 178|disability scores
P11574105A0727|319 337|IgM antibody peaks
P11574105A0727|15 29|antibody peaks
P11574105A0727|352 360|patients
P11574105A0727|270 288|IgM antibody peaks
P11574105A0727|209 212|GBS
P11575977A1133|87 100|complications
P11575977A1133|10 18|patients
P11576776T0081|26 52|microcrystalline cellulose
P11578685A0077|55 57|GO
P11578685A0077|29 38|predictor
P11580173A0181|119 135|P3 approximation
P11580173A0181|49 52|use
P11580173A0181|180 185|paper
P11580757A0304|69 76|surgery
P11580757A0304|140 149|resonance
P11580757A0304|111 114|aim
P11580757A0304|198 202|zone
P11580757A0304|166 172|lesion
P11583428A0191|4 7|Exp
P11583880T0000|14 29|aneurysm repair
P11584328A0532|93 100|statins
P11584328A0532|72 89|CYP450 isoenzymes
P11586096A0699|113 121|patients
P11586096A0699|27 50|patient characteristics
P11587980A1039|171 188|resistance values
P11587980A1039|69 72|FOT
P11587980A1039|4 12|children
P11587980A1039|192 200|baseline
P11587980A1039|134 142|subgroup
P11587980A1039|60 61|n
P11589779T0000|49 57|patients
P11589779T0000|37 45|response
P11592315A0325|1 10|PROCEDURE
P11592315A0325|64 68|body
P11592315A0325|12 20|Cannulas
P11593394A0000|102 112|activities
P11593394A0000|69 74|cells
P11593394A0000|199 209|regulation
P11593394A0000|14 32|growth factor-beta
P11593394A0000|84 94|regulation
P11593394A0000|52 65|growth arrest
P11593394A0000|121 122|D
P11595176T0000|76 100|close promoter proximity
P11595176T0000|63 71|splicing
P11595813A0633|137 147|activities
P11595813A0633|197 205|presence
P11595813A0633|42 47|place
P11595813A0633|162 178|5alpha-reductase
P11595813A0633|12 22|metabolism
P11595813A0633|90 94|unit
P11596104A0614|1 23|Northern blot analysis
P11596104A0614|40 46|PARNAs
P11596104A0614|74 80|signal
P11597185A0477|155 178|metapopulation dynamics
P11597185A0477|144 151|regimes
P11599079A1040|102 105|API
P11599079A1040|19 35|orifice voltages
P11599079A1040|129 132|API
P11599079A1040|126 127|V
P11599840A0813|170 173|kPa
P11599840A0813|5 11|moduli
P11599840A0813|135 142|section
P11599840A0813|75 79|mean
P11599840A0813|118 121|kPa
P11599840A0813|250 257|section
P11599840A0813|93 102|deviation
P11600314A0000|16 28|polarography
P11600314A0000|138 146|analysis
P11600314A0000|162 164|B2
P11600314A0000|150 160|vitamin B1
P11600467A1436|67 79|permeability
P11603271T0001|10 17|vertigo
P11605207T0001|23 36|heart disease
P11606538A1002|115 129|neuropeptidase
P11606538A1002|94 97|Tpp
P11606538A1002|11 20|insertion
P11642687T0000|1 11|Comparison
P11642687T0000|58 63|SF-36
P11642687T0000|47 53|QWB-SA
P11669281A0653|71 79|evidence
P11669281A0653|83 94|competition
P11669281A0653|12 24|cytotoxicity
P11675912A0131|96 103|aspirin
P11675912A0131|127 138|alleviation
P11675912A0131|11 18|alcohol
P11677363A0775|100 109|deviation
P11677363A0775|144 147|SBP
P11677363A0775|125 132|measure
P11677363A0775|88 90|PP
P11677363A0775|151 165|PP variability
P11678437A0000|81 86|maize
P11678437A0000|5 11|effect
P11678437A0000|37 43|growth
P11678437A0000|62 77|nutrient uptake
P11678437A0000|151 166|manifold sample
P11680835A0756|102 113|pamidronate
P11680835A0756|84 88|acid
P11680835A0756|41 46|costs
P11684665A0000|140 158|nematode body plan
P11684665A0000|75 89|cell divisions
P11685284X0000|36 43|B37-B44
P11686378A0326|305 315|phenomenon
P11686378A0326|281 289|colonies
P11686378A0326|133 147|concentrations
P11686378A0326|81 85|LD50
P11686378A0326|92 98|values
P11686378A0326|62 71|discharge
P11686378A0326|181 194|E coli/cfu mL
P11687180A3209|84 90|speeds
P11687180A3209|117 125|dialysis
P11687180A3209|97 103|delays
P11687180A3209|13 17|term
P11687517A1619|37 51|mouse promoter
P11687869A0000|37 44|colitis
P11691585A1174|17 38|mobility shift assays
P11691585A1174|96 114|heterodimerization
P11691585A1174|130 150|cKrox family members
P11692004A1200|3 9|review
P11692004A1200|130 133|NF1
P11692004A1200|151 160|aneurysms
P11695481A0310|27 44|combination O3/UV
P11695481A0310|11 21|conditions
P11703464A0560|155 161|reward
P11703464A0560|178 191|reinforcement
P11703464A0560|25 38|subjects rCBF
P11704380A1608|5 15|event rate
P11704380A1608|108 116|Rev-rMFP
P11704380A1608|120 129|Sta-nrMFP
P11705093A2016|12 32|vitamin D3 analogues
P11706949T0000|1 15|Growth hormone
P11706949T0000|97 100|rat
P11708032A0183|70 82|levoforinate
P11708032A0183|4 12|addition
P11708032A0183|160 170|metastases
P11708032A0183|117 121|5-FU
P11708032A0183|127 129|mg
P11708032A0183|94 96|mg
P11708431A0904|51 59|category
P11708431A0904|140 154|patient groups
P11708431A0904|11 19|patients
P11709561T0000|1 6|Phase
P11709561T0000|10 15|trial
P11709561T0000|45 57|antibody 3F8
P11710233T0000|1 10|Hydrogels
P11710685A0994b|17 23|subset
P11710685A0994b|99 110|sensitivity
P11710685A0994b|45 60|ASCUS/SIL ratio
P11714429X0000|278 285|Aspirin
P11714429X0000|196 203|aspirin
P11714429X0000|72 79|disease
P11714429X0000|134 142|efficacy
P11714429X0000|289 297|Patients
P11714429X0000|221 231|prevention
P11714429X0000|146 161|thienopyridines
P11714429X0000|244 251|disease
P11714429X0000|28 35|aspirin
P11716043A0380|67 70|PTC
P11716043A0380|78 88|Department
P11716043A0380|28 36|patients
P11723500X0000|103 113|BACKGROUND
P11723500X0000|190 200|population
P11723500X0000|140 143|SCC
P11723500X0000|59 73|cell carcinoma
P11723500X0000|31 46|characteristics
P11723675A1022|136 138|.3
P11723675A1022|5 13|severity
P11723675A1022|143 148|point
P11723675A1022|227 234|group C
P11723675A1022|50 55|means
P11723675A1022|86 94|.3 point
P11723675A1022|250 255|point
P11723675A1022|59 69|SOFA score
P11723675A1022|242 244|.2
P11724510T0000|36 45|apheresis
P11726068A0539|1 5|Rind
P11726068A0539|75 79|data
P11726262A0692|1 26|Lactate accumulation peak
P11726262A0692|83 86|LEU
P11726262A0692|62 65|HMB
P11726262A0692|104 107|CON
P11726574A1304|7 14|results
P11726574A1304|45 65|baseline assumptions
P11727209A0502|99 103|test
P11727209A0502|76 87|examination
P11727209A0502|108 119|orthostasia
P11730182A0984|274 282|Ambrosia
P11730182A0984|202 207|Pinus
P11730182A0984|284 285|r
P11730182A0984|223 235|Cupressaceae
P11730182A0984|323 324|P
P11730182A0984|260 261|r
P11730182A0984|209 210|r
P11730182A0984|239 240|p
P11730182A0984|168 169|p
P11730182A0984|39 50|correlation
P11730182A0984|166 167|r
P11730182A0984|190 191|p
P11730182A0984|188 189|r
P11730182A0984|302 307|Rumex
P11730712A0416|35 40|weeks
P11730712A0416|76 81|edema
P11730712A0416|56 71|infarction size
P11732417A0571|117 130|serum samples
P11732417A0571|13 40|percentage positivity value
P11732417A0571|164 175|sample data
P11736792A0204|97 99|G2
P11736792A0204|11 24|semen samples
P11736792A0204|73 75|G1
P11737158A1517|69 79|Broca BA44
P11737158A1517|38 46|Wernicke
P11737158A1517|159 166|contact
P11737158A1517|95 100|gyrus
P11738404A0120|477 479|MS
P11738404A0120|236 252|furancarbonyloxy
P11738404A0120|97 116|alpha-benzoyloxy-13
P11738404A0120|349 354|alpha
P11738404A0120|198 203|alpha
P11738404A0120|153 190|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|256 297|alpha-benzoyloxy-13-isobutanoyloxy-4 beta
P11738404A0120|48 53|alpha
P11738404A0120|366 445|alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuran
P11738404A0120|301 338|beta-dihydroxy-beta-dihydroagarofuran
P11741554T0000|68 73|women
P11741554T0000|100 114|artery disease
P11741554T0000|122 125|men
P11743360A2491|19 23|rats
P11743360A2491|7 13|stress
P11743360A2491|58 62|IL-6
P11743360A2491|79 84|urine
P11744290T0045|2 11|Cactaceae
P11752821A1365|1 11|CONCLUSION
P11752821A1365|54 59|signs
P11752821A1365|77 96|Adamantiades-Behcet
P11760398A0553|51 59|patients
P11760398A0553|87 97|conditions
P11760398A0553|159 161|BS
P11760398A0553|147 155|features
P11760398A0553|227 239|ISG criteria
P11760398A0553|165 170|means
P11761601A0133|103 129|contaminant concentrations
P11761601A0133|21 31|ACCESS-IAQ
P11761601A0133|146 150|zone
P11761601A0133|62 77|airflow pattern
P11764062A0000|50 56|PSWQ-C
P11764062A0000|5 35|Penn State Worry Questionnaire
P11764062A0000|125 133|tendency
P11764062A0000|226 231|Behav
P11765448A0588|49 57|patients
P11768467A0000|68 78|households
P11768467A0000|44 55|agriculture
P11771979A1141|238 251|heterogeneity
P11771979A1141|35 46|variability
P11771979A1141|113 118|range
P11771979A1141|182 189|mapping
P11771979A1141|88 97|microflow
P11773921A0397|304 312|patients
P11773921A0397|168 172|days
P11773921A0397|233 238|group
P11773921A0397|142 146|dose
P11773921A0397|351 362|clopidogrel
P11773921A0397|10 31|P-selectin expression
P11773921A0397|316 321|group
P11773921A0397|254 256|mg
P11773921A0397|260 271|clopidogrel
P11773921A0397|82 86|flow
P11773921A0397|122 133|clopidogrel
P11775301A0797|18 30|intervention
P11777575A0363|102 106|PyMS
P11777575A0363|116 120|data
P11777575A0363|5 13|quantity
P11777575A0363|22 32|population
P11777575A0363|166 170|ANNs
P11778044A0000|259 279|climate observations
P11778044A0000|93 107|climate system
P11778044A0000|161 172|simulations
P11778044A0000|75 85|properties
P11781615A0000|36 41|cGVHD
P11781615A0000|27 34|disease
P11783457A0000|32 41|component
P11783457A0000|110 116|bottle
P11783457A0000|56 68|preparations
P11785827A0986|85 95|physiology
P11785827A0986|139 150|degradation
P11785827A0986|5 12|results
P11785827A0986|232 245|communication
P11785827A0986|183 201|selection pressure
P11786945A0958|84 85|%
P11786945A0958|58 67|follow-up
P11786945A0958|89 96|group A
P11787322X0001|1 10|Influence
P11787322X0001|238 245|records
P11787322X0001|99 107|V gypsum
P11787322X0001|167 181|prosthodontics
P11787322X0001|87 91|type
P11787322X0001|191 196|stone
P11787322X0001|331 339|diseases
P11787322X0001|211 222|impressions
P11787746A0374|1 11|Vitrectomy
P11787746A0374|101 109|glaucoma
P11787746A0374|129 137|patients
P11789216T0001|51 63|blood stasis
P11789216T0001|1 8|Effects
P11789216T0001|67 81|barrier action
P11791292A0193|86 93|problem
P11791292A0193|64 71|network
P11791585A0287|69 72|use
P11791585A0287|146 153|surface
P11792586A0290|19 23|bone
P11792586A0290|127 131|bone
P11792586A0290|79 90|microcracks
P11793614A0000|1 10|OBJECTIVE
P11793614A0000|101 118|phosphodiesterase
P11793614A0000|78 88|cilomilast
P11793614A0000|29 33|lack
P11793614A0000|211 226|anticoagulation
P11800119A0814|5 21|design principle
P11800878T0000|1 16|Dynamic imaging
P11800878T0000|28 42|wave functions
P11802580A0000|70 91|computerized database
P11802580A0000|5 39|General Practice Research Database
P11802580A0000|148 156|practice
P11803325A0868|68 70|DC
P11803325A0868|110 119|GIK group
P11803325A0868|10 26|DC cardioversion
P11804100A0365a|49 54|NH3-N
P11804100A0365a|23 36|disappearance
P11804100A0365a|95 103|kinetics
P11804510A0730|119 129|processing
P11804510A0730|32 44|chlozolinate
P11804510A0730|48 49|%
P11804510A0730|228 238|processing
P11804510A0730|56 67|etridiazole
P11804510A0730|133 139|apples
P11810685A0147|68 71|MRI
P11810685A0147|190 215|displacement distribution
P11810685A0147|159 165|limits
P11810685A0147|178 180|3D
P11810685A0147|227 233|DT-MRI
P11811825A0972|5 12|results
P11811825A0972|110 121|specificity
P11811825A0972|89 95|system
P11816458A0319|119 133|review article
P11816458A0319|81 89|examples
P11816458A0319|179 194|journal article
P11816458A0319|27 39|Explanations
P11816458A0319|14 22|Examples
P11816458A0319|105 113|sections
P11818675X0897|12 17|Basel
P11821098A0269|1 21|MAIN OUTCOME MEASURE
P11821098A0269|22 23|S
P11821098A0269|26 38|Serum levels
P11822811A0319|1 6|Group
P11822811A0319|27 34|Collies
P11822811A0319|62 87|microg/kg ivermectin p.o.
P11824801A0661|16 28|continuation
P11824801A0661|36 54|interferon therapy
P11824801A0661|176 193|organ involvement
P11824801A0661|62 70|presence
P11826141T0000|85 93|amygdala
P11826141T0000|101 112|maintenance
P11826141T0000|162 166|rats
P11826141T0000|13 20|effects
P11830544A0335|1 10|Herceptin
P11830544A0335|223 235|angiogenesis
P11830544A0335|33 38|HER-2
P11830544A0335|67 71|size
P11830544A0335|177 196|control MC-5 tumors
P11832019A0668|52 69|emergency disease
P11834476A1187|275 285|protection
P11834476A1187|139 161|hemoglobin transfusion
P11834476A1187|55 63|ischemia
P11834476A1187|23 35|animal model
P11834476A1187|73 84|transfusion
P11836046A0549|305 312|group B
P11836046A0549|97 104|calcium
P11836046A0549|133 138|times
P11836046A0549|164 181|calcium carbonate
P11836046A0549|255 278|mg medrogestone acetate
P11836046A0549|81 83|mg
P11836046A0549|52 54|mg
P11836046A0549|58 75|calcium carbonate
P11836046A0549|146 153|group A
P11836046A0549|240 248|estrogen
P11836303A1191|87 93|change
P11836303A1191|97 113|cytokine biology
P11838058A0084|1 8|METHODS
P11838058A0084|65 69|CITE
P11838058A0084|161 166|study
P11838058A0084|47 63|tissue expansion
P11840365A0949|35 45|hematocrit
P11840365A0949|53 73|General Health scale
P11840365A0949|88 89|P
P11842728X0001|38 52|Schistosomosis
P11842728X0001|67 75|diseases
P11844591A0329|69 72|APT
P11844591A0329|23 32|parameter
P11845547A0449|71 87|21-aminosteroids
P11845547A0449|11 21|treatments
P11846187A0894|5 24|GT-foreign-pictures
P11846187A0894|95 118|permeability directions
P11849417A0900|68 75|RESULTS
P11849417A0900|1 4|Age
P11849417A0900|98 118|dialysis PD patients
P11849417A0900|172 183|HD patients
P11851941A0372|169 187|reference solution
P11851941A0372|38 57|serumalbumin method
P11851941A0372|212 215|HES
P11851941A0372|151 161|comparison
P11853943A0122|55 78|R-R interval estimation
P11853943A0122|15 25|prediction
P11858548A0241|5 14|structure
P11858548A0241|94 111|mass spectrometry
P11859400A0229|17 25|efficacy
P11859400A0229|156 164|patients
P11859400A0229|66 82|HSV reactivation
P11859400A0229|226 241|HSV prophylaxis
P11859400A0229|150 154|APCT
P11859400A0229|30 35|costs
P11860097A1695|141 150|non-users
P11860097A1695|108 115|outcome
P11860097A1695|120 136|prosthesis users
P11860876A0409|20 24|IDUs
P11862350T0000|154 161|traffic
P11862350T0000|39 52|carbamazepine
P11862350T0000|28 35|effects
P11862350T0000|15 20|study
P11864173T0000|81 91|bronchitis
P11864173T0000|43 47|type
P11866130A0419|100 105|MS222
P11866130A0419|80 92|phagocytosis
P11866130A0419|56 75|complement activity
P11866130A0419|14 24|benzocaine
P11870646A0668|5 12|utility
P11870646A0668|93 103|resistance
P11870646A0668|47 80|ceramic/substrate bilayer systems
P11872570T0000|45 49|care
P11874637A0212|85 97|improvements
P11874637A0212|50 55|HAART
P11874637A0212|5 8|use
P11874637A0212|246 258|malignancies
P11874637A0212|161 170|incidence
P11874637A0212|211 230|deficiency syndrome
P11876937A0261|119 126|N group
P11876937A0261|100 106|saline
P11876937A0261|18 20|kg
P11876937A0261|79 86|H group
P11876937A0261|134 137|day
P11881268A0000|5 12|purpose
P11881268A0000|79 115|exercise self-efficacy questionnaire
P11882054A0568|153 157|ROIs
P11882054A0568|143 151|interest
P11882054A0568|72 83|FMZ binding
P11882054A0568|132 139|regions
P11882054A0568|60 70|structures
P11882747A0354|29 51|Farnsworth D-15 method
P11883763A1062|84 93|particles
P11883763A1062|71 80|transport
P11883763A1062|125 130|slope
P11883763A1062|28 30|Pu
P11885053A1897|136 143|objects
P11885053A1897|38 44|Volkan
P11885053A1897|165 180|memorial shrine
P11886473A0796|99 103|CagA
P11886473A0796|131 132|p
P11886473A0796|106 107|p
P11886473A0796|164 170|corpus
P11886473A0796|153 159|antrum
P11886473A0796|49 53|CagA
P11886473A0796|94 97|nod
P11888183A0541|87 95|duration
P11888183A0541|113 116|hrs
P11888183A0541|11 19|analysis
P11890354A0000|68 75|Neumega
P11890354A0000|59 66|rhIL-11
P11890354A0000|106 111|IL-11
P11893403A0252|1 9|Elements
P11893403A0252|86 94|exposure
P11893403A0252|59 77|flavor ingredients
P11893403A0252|149 159|toxicology
P11894605A1429|51 61|dissonance
P11894605A1429|222 229|content
P11894605A1429|100 107|smoking
P11894605A1429|196 203|changes
P11894605A1429|78 96|health information
P11895184A0000|69 81|object-place
P11895184A0000|49 56|lesions
P11895184A0000|83 93|odor-place
P11895184A0000|26 33|control
P11897888A0590|35 49|administration
P11897888A0590|59 70|supplements
P11898018T0000|1 16|Data management
P11899479A0122|70 76|palate
P11899479A0122|280 298|assimilation tests
P11899479A0122|14 20|smears
P11899479A0122|324 337|kit AuxaColor
P11899479A0122|116 133|cotton wool swabs
P11899479A0122|217 230|yeast species
P11899479A0122|62 68|cheeks
P11900770T0000|22 32|incentives
P11900770T0000|62 68|impact
P11902738A0185|87 93|cancer
P11902738A0185|115 126|institution
P11902738A0185|142 153|neutropenia
P11902738A0185|132 137|fever
P11902738A0185|28 33|study
P11902738A0185|224 230|period
P11904017A0000|178 184|system
P11904017A0000|131 135|flow
P11904017A0000|31 38|process
P11908529A0553|100 109|detectors
P11908529A0553|5 12|results
P11908529A0553|43 48|stars
P11908529A0553|78 88|comparison
P11908529A0553|184 191|objects
P11908529A0553|159 165|region
P11908529A0553|27 31|flux
P11910310A0279|1 7|DESIGN
P11911552A0776|103 112|remission
P11911552A0776|83 87|dose
P11911552A0776|125 130|range
P11911552A0776|28 38|quetiapine
P11912677A0281|34 44|hypotheses
P11912677A0281|11 19|analysis
P11915436A0491|77 87|population
P11915436A0491|14 29|incidence rates
P11917882A0326|85 92|dentine
P11917882A0326|53 62|interface
P11917882A0326|72 81|selection
P11920896A0298|169 170|%
P11920896A0298|39 41|DR
P11920896A0298|148 152|rate
P11920896A0298|62 66|test
P11921126A1196|87 95|patients
P11921126A1196|20 26|PDQ-39
P11921126A1196|28 35|STN-DBS
P11920455X1195|1 10|Copyright
P11920455X1195|56 62|.10318
P11917061A0922|23 31|response
P11917061A0922|144 158|remission rate
P11917061A0922|10 19|predictor
P11917061A0922|89 99|prednisone
P11917061A0922|61 69|response
P11913427A0290|5 13|subjects
P11913427A0290|76 89|accelerations
P11912261A0284|86 94|receptor
P11912261A0284|114 120|glands
P11912261A0284|14 20|agents
P11910344A1119|1 12|CONCLUSIONS
P11910344A1119|80 84|type
P11910344A1119|159 167|increase
P11910344A1119|46 51|study
P11909404A0000|19 26|regions
P11909404A0000|57 61|sign
P11907691A0214|5 17|orientations
P11907691A0214|52 61|locations
P11907691A0214|78 84|object
P11902781A0550|1 15|Concentrations
P11902781A0550|19 20|N
P11902781A0550|39 40|N
P11902781A0550|129 135|season
P11902781A0550|44 53|Deoprayag
P11902068T0000|5 16|CKD patient
P11899489A0119|32 41|treatment
P11899489A0119|93 101|dementia
P11899489A0119|126 131|stage
P11898797A0124|98 104|cortex
P11898797A0124|108 116|patients
P11898797A0124|47 81|choline acetyltransferase activity
P11897950A0617|1 12|CONCLUSIONS
P11897950A0617|154 161|pathway
P11897950A0617|40 65|cynomolgus monkey eyelids
P11897950A0617|14 32|Lymphoscintigraphy
P11897449A0566|141 145|rest
P11897449A0566|67 74|esmolol
P11897449A0566|163 168|state
P11897449A0566|195 204|beats/min
P11897449A0566|49 63|administration
P11897449A0566|127 137|heart rate
P11895024A1054|96 113|hospital searches
P11895024A1054|57 73|AFP surveillance
P11895024A1054|15 18|GBS
P11893767A0356|86 87|O
P11893767A0356|145 162|breathing pattern
P11893767A0356|198 201|day
P11893767A0356|47 48|E
P11890438A0838|71 77|wounds
P11890438A0838|39 45|clinic
P11888867A0000|1 11|BACKGROUND
P11888867A0000|206 214|survival
P11888867A0000|191 201|recurrence
P11888867A0000|218 226|patients
P11888867A0000|52 63|serum level
P11888867A0000|123 130|antigen
P11887803A1455|80 87|animals
P11887803A1455|203 210|animals
P11887803A1455|231 238|Balance
P11887803A1455|179 183|CAPD
P11887803A1455|149 159|peritoneum
P11887803A1455|224 228|CAPD
P11885737A1713|97 105|criteria
P11885737A1713|30 48|spermatozoa/microl
P11884014A0665|64 66|GI
P11884014A0665|75 82|effects
P11883682A0162|23 33|monitoring
P11883682A0162|92 98|metals
P11882054A1250|17 28|correlation
P11882054A1250|168 179|FMZ binding
P11882054A1250|133 143|epilepsies
P11882054A1250|210 220|mechanisms
P11882054A1250|194 202|relation
P11881923A1256|1 11|Neutrophil
P11881923A1256|54 64|CBG levels
P11881923A1256|131 134|PRE
P11881923A1256|79 80|P
P11881923A1256|30 48|plasma haptoglobin
P11879108A0719|1 21|MAIN OUTCOME MEASURE
P11879108A0719|23 24|A
P11879108A0719|92 119|ligase chain reaction assay
P11879108A0719|208 211|HIV
P11875695A0718|1 5|Time
P11875695A0718|39 45|months
P11875695A0718|95 101|months
P11875695A0718|61 69|survival
P11875695A0718|75 87|registration
P11873003X0000|168 185|progression times
P11873003X0000|140 150|OBJECTIVES
P11873003X0000|129 138|countries
P11873003X0000|286 291|death
P11873003X0000|45 55|difference
P11873003X0000|83 91|survival
P11873003X0000|26 32|Africa
P11873003X0000|210 224|seroconversion
P11872359A0000|170 175|cause
P11872359A0000|103 115|risk factors
P11872359A0000|98 101|CVD
P11872359A0000|142 150|syndrome
P11872359A0000|89 96|disease
P11872359A0000|47 49|IR
P11867388A0502|204 208|tone
P11867388A0502|234 235|%
P11867388A0502|96 113|fear conditioning
P11867388A0502|41 47|memory
P11867388A0502|16 27|suppression
P11867388A0502|117 124|context
P11867388A0502|53 66|concentration
P11867388A0502|150 151|%
P11865218A0069|1 10|Treatment
P11865218A0069|20 29|condition
P11865218A0069|45 48|use
P11863811A0259|98 108|experiment
P11863811A0259|27 41|Nusselt number
P11861092A0730|343 350|Bothell
P11861092A0730|306 321|HDI5000 scanner
P11861092A0730|276 290|inversion mode
P11861092A0730|193 196|FCD
P11861092A0730|326 336|C5-2 probe
P11861092A0730|152 157|scale
P11861092A0730|253 258|scale
P11861092A0730|292 295|Pim
P11861092A0730|260 263|HGS
P11861092A0730|177 191|colour Doppler
P11860723A0182|18 33|Georgia members
P11860723A0182|79 92|Gynecologists
P11860723A0182|61 74|Obstetricians
P11859943A0150|65 73|hospital
P11859943A0150|26 44|outpatient clinics
P11858635A0896|35 43|property
P11858635A0896|75 95|LOO cross-validation
P11858256A0102|55 61|effect
P11852907A0871|137 142|order
P11852907A0871|37 41|EPC0
P11852907A0871|146 155|magnitude
P11852907A0871|46 58|surface soil
P11849796A0452|1 8|RESULTS
P11849796A0452|80 92|improvements
P11849796A0452|123 134|IMRT fields
P11847580T0000|42 50|findings
P11846167A0000|1 9|Selenium
P11846167A0000|26 33|element
P11846167A0000|46 53|animals
P11844812A0915|103 113|percentage
P11844812A0915|138 144|PSA-TZ
P11844812A0915|200 201|P
P11844812A0915|161 172|PSA density
P11844812A0915|94 98|AUCs
P11844812A0915|183 198|prostate volume
P11843252A0907|68 69|%
P11843252A0907|98 106|survival
P11843252A0907|10 23|response rate
P11843252A0907|60 64|% CI
P11842037A0327|87 92|value
P11842037A0327|38 63|% urine-plasma difference
P11838102T0001|11 25|granulomatosis
P11837409A0584|103 117|symptomatology
P11837409A0584|25 52|National Longitudinal Study
P11836303A0518|1 9|TNFalpha
P11836303A0518|14 25|IL-6 levels
P11835109A0000|49 58|awareness
P11835109A0000|198 204|trials
P11835109A0000|167 176|disorders
P11835109A0000|107 114|quality
P11833863A0987|72 81|positions
P11833863A0987|14 24|difference
P11831512A0468|203 222|dextrose equivalent
P11831512A0468|160 167|lactose
P11831512A0468|46 47|d
P11831512A0468|224 226|DE
P11831512A0468|187 191|gram
P11831512A0468|93 103|treatments
P11831512A0468|240 247|lactose
P11828186A0239|69 74|years
P11828186A0239|140 161|Third National Health
P11828186A0239|5 15|population
P11828186A0239|93 106|heart disease
P11828186A0239|166 194|Nutrition Examination Survey
P11825801A1212|80 86|months
P11824701A0894|35 40|event
P11824701A0894|64 81|behavior patterns
P11824701A0894|93 107|Bortner scores
P11824701A0894|150 155|event
P11822790A0907|235 256|reproducibility noise
P11822790A0907|65 66|%
P11822790A0907|113 118|score
P11822790A0907|126 142|study population
P11822790A0907|198 203|items
P11819326A0000|171 180|cirrhosis
P11819326A0000|157 165|patients
P11819326A0000|249 259|volunteers
P11819326A0000|43 49|status
P11819326A0000|63 71|patients
P11819326A0000|120 123|PSE
P11816779A0343|62 77|chloramphenicol
P11816779A0343|44 57|acetaminophen
P11815644A0081|140 158|muscle recruitment
P11815644A0081|67 70|bat
P11815644A0081|56 63|species
P11815644A0081|14 29|characteristics
P11811743A0800|118 125|patient
P11811743A0800|5 14|procedure
P11811743A0800|31 40|retention
P11806132A0253|33 37|area
P11806132A0253|53 66|% TB patients
P11806132A0253|26 31|AIRIN
P11804100A0365b|113 121|kinetics
P11804100A0365b|125 135|TP removal
P11804100A0365b|40 44|BOD5
P11804081A0552|54 58|tons
P11804081A0552|24 28|ENRP
P11802601A0107|113 131|aldicarb sulfoxide
P11802601A0107|37 53|laboratory study
P11802601A0107|24 31|results
P11802601A0107|79 90|metabolites
P11801459T0000|49 59|management
P11801459T0000|63 79|atherothrombosis
P11800586A1090|153 162|diagnosis
P11800586A1090|128 132|tool
P11800586A1090|72 79|results
P11800586A1090|13 22|DPPD gene
P11796977T0000|31 46|mainland Europe
P11793172A0545|35 42|PE head
P11793172A0545|20 27|surface
P11793172A0545|88 108|friction coefficient
P11791853A0532|18 25|results
P11791853A0532|108 113|color
P11791853A0532|122 125|COD
P11791571T0000|3 54|high-efficiency cross-flow micronebulizer interface
P11790897T0000|69 78|potential
P11790897T0000|39 45|fluids
P11790897T0000|112 121|diagnosis
P11790897T0000|125 138|breast cancer
P11789206A1182|1 12|CONCLUSIONS
P11789206A1182|39 52|Qi deficiency
P11789206A1182|57 69|blood stasis
P11789206A1182|73 76|TCM
P11789206A1182|31 35|MIRI
P11787720A1313|138 139|%
P11787720A1313|141 142|P
P11787720A1313|66 69|C18
P11787720A1313|125 128|C20
P11787720A1313|79 80|%
P11787720A1313|15 19|milk
P11786248A1162|17 26|% sucrose
P11786248A1162|1 12|Consumption
P11786248A1162|141 150|% sucrose
P11786248A1162|59 66|lesions
P11786248A1162|74 78|PPTg
P11785085X0001|69 77|patients
P11785085X0001|33 43|techniques
P11785085X0001|306 317|prostatitis
P11785085X0001|13 21|analysis
P11785085X0001|190 203|Introl-4 unit
P11785085X0001|120 128|efficacy
P11782218A0349|34 43|perimetry
P11782218A0349|116 126|estimation
P11782218A0349|215 230|learning effect
P11782218A0349|148 164|media absorption
P11782218A0349|13 27|white-on-white
P11778804A0179|50 56|method
P11778804A0179|21 27|curves
P11777632A1678|186 199|AF expression
P11777632A1678|1 3|AF
P11777632A1678|39 46|pattern
P11777632A1678|178 182|loss
P11777632A1678|147 154|lesions
P11776922A0830|69 74|group
P11776922A0830|77 84|lesions
P11776922A0830|28 38|resorption
P11776922A0830|14 23|sclerosis
P11775180A0379|50 56|survey
P11775180A0379|22 33|exploration
P11773168A0915|101 106|arm A
P11773168A0915|65 68|PFS
P11773168A0915|85 86|%
P11773168A0915|115 116|%
P11773168A0915|95 96|%
P11773168A0915|150 151|P
P11769229A0357|69 76|process
P11769229A0357|5 24|sorption mechanisms
P11769229A0357|92 100|sorption
P11766747A0000|55 63|patients
P11764226A0798|1 15|Classification
P11764226A0798|81 89|patients
P11764226A0798|67 75|patients
P11764226A0798|122 128|months
P11763176A0918|101 111|experiment
P11763176A0918|20 28|decrease
P11760796A0698|1 9|Evidence
P11760796A0698|157 167|background
P11760796A0698|24 39|PHACES syndrome
P11760796A0698|56 67|association
P11755894A0466|168 173|ileus
P11755894A0466|140 150|management
P11755894A0466|8 17|treatment
P11755894A0466|198 202|time
P11755894A0466|221 235|bowel function
P11755894A0466|57 64|surgery
P11744953A0878|1 13|Skin cancers
P11744953A0878|67 73|system
P11743612A1179|136 149|CF population
P11743612A1179|98 111|survival rate
P11743612A1179|22 36|meconium ileus
P11743612A1179|15 17|CF
P11742432A0798|278 283|trial
P11742432A0798|9 16|results
P11742432A0798|316 337|macrolide prophylaxis
P11742432A0798|104 112|patients
P11742432A0798|85 100|MAC prophylaxis
P11742432A0798|189 198|incidence
P11742432A0798|297 312|discontinuation
P11742432A0798|62 70|efficacy
P11741259A1233|169 173|form
P11741259A1233|5 16|performance
P11741259A1233|131 140|intestine
P11740571A0114|152 159|toluene
P11740571A0114|170 197|chemiluminescence intensity
P11740571A0114|217 227|activation
P11740571A0114|6 12|toxins
P11740571A0114|244 253|processes
P11740571A0114|90 98|activity
P11737900A0700|33 43|plasma COP
P11737900A0700|72 75|age
P11737900A0700|13 24|correlation
P11737056A0680|100 101|%
P11737056A0680|25 35|leucocytes
P11737056A0680|43 45|ME
P11736254A0000|170 180|structures
P11736254A0000|4 12|analysis
P11736254A0000|92 99|glasses
P11736254A0000|62 68|models
P11732088A0471|71 90|sphincter manometry
P11732088A0471|190 198|response
P11732088A0471|249 258|diagnosis
P11732088A0471|111 119|secretin
P11730262A0874|239 256|calcium/vitamin D
P11730262A0874|190 200|etidronate
P11730262A0874|159 171|osteoporosis
P11730262A0874|264 268|days
P11730262A0874|123 126|men
P11730262A0874|105 116|pilot study
P11728771A0187|45 53|reaction
P11727073A0842|1 11|CONCLUSION
P11727073A0842|71 78|changes
P11727073A0842|82 87|skill
P11727073A0842|43 57|MIST-VR yields
P11726413A1756|43 50|infants
P11726413A1756|75 82|opioids
P11726164A0215|103 111|residues
P11726164A0215|21 36|food processors
P11726164A0215|56 69|cross-contact
P11726164A0215|164 173|reactions
P11726022A0909|51 62|penetration
P11726022A0909|38 47|estimates
P11726022A0909|110 127|time calculations
P11723928A0294|5 12|process
P11723928A0294|92 97|China
P11723928A0294|58 73|Yangpu District
P11723511A0780|35 40|drugs
P11723511A0780|98 108|category B
P11723511A0780|23 27|risk
P11723511A0780|92 93|%
P11723511A0780|147 148|%
P11723511A0780|121 122|%
P11722993A0276|53 63|thrombosis
P11722993A0276|130 139|locations
P11722993A0276|165 170|utero
P11716441A0585|19 29|physiology
P11716441A0585|42 59|health evaluation
P11715079A1016|118 131|perturbations
P11715079A1016|155 165|mismatches
P11715079A1016|21 35|proprioception
P11715079A1016|65 79|efference copy
P11715079A1016|299 305|organs
P11715079A1016|225 232|command
P11711701A0602|204 209|hours
P11711701A0602|278 307|pertechnetate thyroid imaging
P11711701A0602|111 141|Tc-99m MIBI image combinations
P11711701A0602|57 65|findings
P11711701A0602|166 173|minutes
P11711701A0602|180 185|hours
P11710685A0994a|118 135|Papanicolaou test
P11710685A0994a|27 32|ASCUS
P11709890T0000|51 58|Alberta
P11709890T0000|66 79|food facility
P11709890T0000|41 49|Edmonton
P11708761A1388|100 108|patients
P11708761A1388|64 67|use
P11708761A1388|40 49|arguments
P11708362A0889|33 40|payload
P11708362A0889|59 68|operation
P11707977A0750|37 53|infusion therapy
P11707977A0750|14 18|hand
P11706668A0000|114 126|intervention
P11706668A0000|72 81|treatment
P11704829A0312|152 166|melanoma cells
P11704829A0312|38 62|melanoma differentiation
P11704829A0312|95 99|gene
P11704829A0312|74 80|gene-7
P11703558A0000|81 87|tumors
P11703558A0000|14 17|DOX
P11697760A0000|86 88|E2
P11697760A0000|114 117|PTH
P11697760A0000|161 169|OVX rats
P11697760A0000|130 142|bone quality
P11693461A1649|117 119|RA
P11693461A1649|80 82|US
P11693461A1649|97 112|TNF antagonists
P11693461A1649|7 23|utilisation data
P11691585T0000|5 23|hcKrox gene family
P11689217T0000|68 76|subjects
P11689217T0000|80 85|study
P11689217T0000|104 115|angiography
P11687737A0000|1 11|BACKGROUND
P11687737A0000|144 147|age
P11687737A0000|90 99|diabetics
P11687352A0215|51 55|eyes
P11687352A0215|98 107|September
P11687352A0215|79 88|September
P11687083A0218|17 26|objective
P11687083A0218|1 11|OBJECTIVES
P11687083A0218|115 120|stage
P11687083A0218|60 67|effects
P11686239A0464|33 40|3B gene
P11686239A0464|83 86|G/C
P11686239A0464|58 59|T
P11686239A0464|150 169|sequence similarity
P11685047A0301|24 30|method
P11683558A0446|5 9|diet
P11683558A0446|13 21|migrants
P11683558A0446|44 58|macronutrients
P11679441A0429|1 15|NO metabolites
P11679441A0429|138 142|cGMP
P11679441A0429|54 69|nitrate/nitrite
P11679441A0429|113 136|guanosine monophosphate
P11679441A0429|76 100|micromol/mmol creatinine
P11677839A0876|85 86|p
P11677839A0876|28 36|patients
P11676899A0704|84 97|mononucleosis
P11676899A0704|20 32|risk factors
P11676899A0704|127 143|immunodeficiency
P11669476A0346|18 26|cytokine
P11669476A0346|57 66|TNF-alpha
P11669476A0346|149 153|role
P11669476A0346|91 98|tissues
P11653491T0000|14 20|action
P11639485A0478|112 119|benefit
P11639485A0478|79 83|Urdu
P11639485A0478|135 147|day students
P11614398T0000|39 46|aspects
P11605598A0785|17 39|C seroprevalence rates
P11605598A0785|81 88|El Paso
P11605598A0785|111 125|US populations
P11605598A0785|56 67|adolescents
P11604152A0526|204 207|CCF
P11604152A0526|33 41|bandpass
P11604152A0526|140 142|Hz
P11604152A0526|77 82|range
P11604152A0526|105 124|low-frequency range
P11604152A0526|84 87|VLF
P11604152A0526|216 223|purpose
P11604152A0526|126 128|LF
P11602353A0770|152 156|gene
P11602353A0770|16 26|HNF-3 beta
P11602353A0770|42 47|HFH-3
P11602353A0770|28 33|HFH-1
P11600365A0471|34 40|E-4767
P11600365A0471|23 32|organisms
P11600365A0471|45 51|E-5065
P11600252A0795|5 7|LA
P11600252A0795|132 138|change
P11599797A0732|1 8|RESULTS
P11597936A0570|236 244|controls
P11597936A0570|65 68|age
P11597936A0570|83 91|baseline
P11597936A0570|7 19|CAD patients
P11597936A0570|122 127|mg/dL
P11597936A0570|75 80|years
P11596838A1357|6 14|analysis
P11596838A1357|94 103|treatment
P11596838A1357|107 115|patients
P11596838A1357|61 67|microg
P11595840A0000|93 112|blood glucose level
P11595840A0000|72 77|tumor
P11595478A1014|34 40|cancer
P11595478A1014|101 114|Hp negativity
P11595478A1014|123 139|cancer relatives
P11595478A1014|13 22|relatives
P11595170A0582|50 54|gene
P11595170A0582|97 108|delineation
P11595170A0582|127 139|organization
P11595170A0582|24 29|cDNAs
P11595170A0582|72 80|sequence
P11592532A0188|152 158|method
P11592532A0188|86 93|degrees
P11592532A0188|52 59|program
P11592532A0188|45 48|HFA
P11590364A1056|14 35|beta5L splice variant
P11589568A0744|153 165|kinetochores
P11589568A0744|64 77|proteins Mad1
P11589568A0744|12 17|yeast
P11587514A0758|55 70|ABA suppression
P11587514A0758|14 33|abi1-1 gene product
P11585856A0285|186 200|backprojection
P11585856A0285|1 8|METHODS
P11585856A0285|157 160|PER
P11585856A0285|76 78|AC
P11585856A0285|61 63|RR
P11584107T0000|21 29|diseases
P11584107T0000|44 50|origin
P11583621A0301|80 88|cleavage
P11583621A0301|92 96|hTAF
P11583621A0301|166 173|complex
P11583621A0301|28 35|stimuli
P11583621A0301|121 126|delta
P11580941A0815|103 110|therapy
P11580941A0815|117 121|mean
P11580941A0815|38 46|UPDRS II
P11580941A0815|20 31|examination
P11580941A0815|149 153|time
P11580301A1161|35 43|patients
P11580301A1161|18 31|HCV arthritis
P11579100T0000|68 83|gene regulation
P11579100T0000|89 108|cell transformation
P11577094A1226|51 64|HSAL2 pathway
P11577094A1226|100 113|hematopoiesis
P11577094A1226|76 80|role
P11576158A1371|34 49|skin blood flow
P11576158A1371|89 97|controls
P11575109A0214|77 85|patients
P11575109A0214|108 115|surgery
P11575109A0214|29 40|examination
P11575109A0214|181 188|gingiva
P11574088A1687|18 22|time
P11574088A1687|5 9|mean
P11574088A1687|66 70|days
P11574088A1687|75 78|SPK
P11573771T0000|1 7|Effect
P11573771T0000|11 26|heat treatments
P11572467A0658|136 140|clot
P11572467A0658|81 85|t-PA
P11572467A0658|10 20|blood clot
P11572377T0000|1 4|Use
P11572377T0000|74 90|cavitation field
P11570735A1097|1 8|RESULTS
P11570735A1097|83 87|peak
P11570735A1097|97 118|ground reaction force
P11570735A1097|287 302|feedback groups
P11570735A1097|14 22|subjects
P11569900A0660|1 15|APC-resistance
P11569900A0660|66 77|sensitivity
P11568988A0960|71 75|time
P11568988A0960|125 136|Pa elastase
P11568988A0960|10 26|regression model
P11568988A0960|106 120|antibody titer
P11566961A0472|71 84|blood glucose
P11566961A0472|89 111|blood pressure control
P11566874T0000|9 21|motor domain
P11564893A1068|187 194|respond
P11564893A1068|71 75|MGMT
P11564893A1068|140 146|R-MGMT
P11564893A1068|162 166|cell
P11564893A1068|27 39|conformation
P11564893A1068|45 51|repair
P11562870A0892|35 46|lamotrigine
P11562870A0892|20 29|treatment
P11562870A0892|108 109|%
P11562870A0892|72 78|months
P11561626A0197|38 44|TMT-55
P11561626A0197|142 148|Zn-TMT
P11561626A0197|111 116|salts
P11561626A0197|199 205|Pb-TMT
P11561626A0197|259 260|n
P11561626A0197|54 63|solutions
P11561626A0197|94 101|cadmium
P11561626A0197|208 210|M3
P11561626A0197|240 243|Pb2
P11560992A1184|69 88|SAPK/JNK activation
P11560992A1184|175 188|proliferation
P11560992A1184|92 102|mast cells
P11560992A1184|133 146|growth factor
P11560992A1184|151 158|antigen
P11560992A0000|70 76|kinase
P11560992A0000|277 284|stimuli
P11560992A0000|196 201|SAPKs
P11560992A0000|78 81|MKK
P11560992A0000|106 115|molecules
P11560992A0000|48 62|protein kinase
P11560992A0000|147 161|stress kinases
P11560509T0000|1 16|DNA recognition
P11560509T0000|89 92|DNA
P11559821A1315|34 46|interference
P11559821A1315|1 19|DNA binding assays
P11559821A1315|129 152|repeat oligonucleotides
P11559821A1315|93 96|CBP
P11559564A0459|1 7|NB-506
P11559564A0459|98 113|splicing factor
P11559564A0459|128 143|splicing factor
P11559366T0000|49 85|plasminogen activator inhibitor type
P11559366T0000|31 41|inhibition
P11556809A2085|185 196|P450 enzyme
P11556809A2085|234 255|hydrocarbon substrate
P11556809A2085|212 226|hydroxylations
P11556809A2085|108 124|1-deoxycapsidiol
P11555669A0464|56 73|Vrinnevi Hospital
P11554727A0890|87 90|PTH
P11554727A0890|5 25|mutation experiments
P11554727A0890|56 64|sequence
P11554566A0668|136 145|company A
P11554566A0668|5 23|hatcher incubators
P11553704A0674|9 13|data
P11553704A0674|63 73|EGFR-CD533
P11552922A0361|1 17|CYP2C19 genotype
P11552058A0833|137 149|barbiturates
P11552058A0833|81 113|Tris-hydroxy-methyl-aminomethane
P11552058A0833|58 73|saline solution
P11550795A2583|1 15|Overexpression
P11550795A2583|157 168|interleukin
P11550795A2583|142 152|Fas-ligand
P11550795A2583|92 109|T cell hybridomas
P11547819A0532|343 354|examination
P11547819A0532|103 114|measurement
P11547819A0532|38 46|catheter
P11547819A0532|10 21|Experiments
P11547819A0532|193 210|matter generation
P11547819A0532|80 88|catheter
P11547819A0532|246 252|tissue
P11547819A0532|122 145|laser output beam sizes
P11543662A0562|18 25|mutants
P11543662A0562|93 100|ability
P11543662A0562|79 85|defect
P11543662A0562|12 16|gstC
P11543154T0000|55 60|glass
P11543154T0000|78 87|particles
P11543154T0000|14 25|TLD Mg2SiO4
P11542677A0411|83 95|alternatives
P11542677A0411|43 58|Generic Systems
P11539522A0612|34 43|knowledge
P11539522A0612|5 20|NAUSICAA system
P11539522A0612|47 58|LET spectra
P11536063A0178|27 47|lung transplantation
P11536063A0178|88 106|heart-lung-machine
P11535532A0189|49 57|response
P11535532A0189|22 34|enzyme DUB-2
P11535014A1157|16 23|results
P11535014A1157|80 89|frequency
P11535014A1157|173 177|P300
P11535014A1157|93 100|seizure
P11535014A1157|195 203|patients
P11534132A0219|72 78|domain
P11534132A0219|15 29|search engines
P11533340A1285|54 60|scores
P11533340A1285|89 100|PDF infants
P11533340A1285|122 137|point advantage
P11532856A1175|235 238|JNK
P11532856A1175|77 83|effect
P11532856A1175|195 206|involvement
P11532856A1175|87 90|HGF
P11532856A1175|126 140|p42/44 mitogen
P11532856A1175|94 118|stress kinase activities
P11532856A1175|151 157|kinase
P11530829A0000|118 129|maintenance
P11530829A0000|55 68|ECG simulator
P11530829A0000|82 85|use
P11530829A0000|93 100|testing
P11529914T0000|51 62|CD40 ligand
P11529914T0000|64 74|expression
P11529914T0000|44 49|CD154
P11528253X1211|16 18|S.
P11525640A0560|137 155|chemical inhibitor
P11525640A0560|222 237|GADD45 promoter
P11525640A0560|202 214|UV induction
P11525640A0560|110 119|treatment
P11525640A0560|56 66|expression
P11525640A0560|15 19|JNK1
P11525102A0970|141 142|%
P11525102A0970|67 68|n
P11525102A0970|9 15|sample
P11525102A0970|108 119|sensitivity
P11525102A0970|30 37|reviews
P11524815A0753|98 100|T1
P11524815A0753|92 93|%
P11524815A0753|74 85|lung cancer
P11524815A0753|45 56|lung cancer
P11523446A0523|101 103|LC
P11523446A0523|80 82|MS
P11523446A0523|59 73|time-of-flight
P11523446A0523|121 139|nitrogen detection
P11522658A0086|140 146|BT-474
P11522658A0086|72 79|process
P11522658A0086|151 157|SKBR-3
P11522584A0882|70 80|MMF lesion
P11522584A0882|9 17|myalgias
P11522584A0882|107 108|P
P11521191A0000|169 184|phosphorylation
P11521191A0000|111 115|p107
P11521191A0000|133 140|changes
P11521191A0000|192 214|retinoblastoma protein
P11519466A0196|14 18|diet
P11518505A0107|74 81|tissues
P11517399A0858|5 13|patterns
P11517399A0858|66 73|mutants
P11517399A0858|127 128|T
P11517399A0858|111 119|mutation
P11517399A0858|209 219|generation
P11517399A0858|135 148|acceptor site
P11517190T0000|32 49|rat ER alpha gene
P11517190T0000|107 115|receptor
P11516890A0236|113 119|extent
P11516890A0236|93 96|3A4
P11516890A0236|132 137|SSRIs
P11516890A0236|60 71|venlafaxine
P11513180A1257|110 115|bowel
P11513180A1257|12 17|cases
P11512925A0000|1 19|EXAFS measurements
P11512925A0000|80 86|alloys
P11512925A0000|131 140|structure
P11509673A0574|185 187|AA
P11509673A0574|251 260|apoptosis
P11509673A0574|203 212|apoptosis
P11509673A0574|161 165|acid
P11509673A0574|15 28|transfectants
P11509266A0955|70 81|development
P11509266A0955|4 7|Cox
P11509266A0955|197 205|survival
P11509266A0955|56 57|P
P11509266A0955|183 193|predictors
P11509266A0955|90 91|P
P11504709A0981|235 241|kinase
P11504709A0981|54 62|response
P11504709A0981|145 149|GPIX
P11504709A0981|40 50|expression
P11504709A0981|73 76|PMA
P11502778A0941|136 145|bone loss
P11502778A0941|19 22|men
P11502778A0941|127 132|rates
P11502778A0941|94 99|pg/ml
P11502778A0941|41 57|estradiol levels
P11502778A0941|211 227|estradiol levels
P11502738A1457|38 48|inhibitors
P11502738A1457|110 119|bp region
P11500571A0976|70 87|gPAL1 transcripts
P11500571A0976|18 28|expression
P11500571A0976|62 68|pollen
P11500377A0518|33 43|repressors
P11496617A0301|171 178|regimes
P11496617A0301|32 40|patients
P11496617A0301|338 343|group
P11496617A0301|312 321|induction
P11496617A0301|437 442|group
P11496617A0301|256 261|group
P11496617A0301|428 435|placebo
P11496617A0301|52 67|thyroid surgery
P11496617A0301|183 196|mg dolasetron
P11496617A0301|271 284|mg dolasetron
P11495920A0504|49 55|region
P11495920A0504|109 126|enhancer activity
P11494391A0579|50 72|artery-alone ALT graft
P11494391A0579|5 12|results
P11494391A0579|94 103|structure
P11489597A0561|54 65|weight gain
P11489597A0561|89 93|dose
P11489597A0561|135 136|%
P11489597A0561|105 120|pregnancy rates
P11486476A1512|87 96|diagnosis
P11486476A1512|9 27|markers troponin T
P11486476A1512|44 53|myoglobin
P11486399A0000|32 42|epirubicin
P11486399A0000|5 16|combination
P11486399A0000|79 94|salvage regimen
P11486032A1261|86 91|RUNX1
P11486032A1261|11 32|transcription factors
P11484028T0000|4 18|cross purposes
P11480555A0928|5 15|production
P11480555A0928|45 52|fixture
P11480490A0443|34 39|signs
P11480490A0443|114 124|occurrence
P11480490A0443|82 84|Kr
P11479104A0446|203 206|POF
P11479104A0446|53 61|antibody
P11479104A0446|179 186|disease
P11479104A0446|192 197|woman
P11479104A0446|91 99|criteria
P11474642A1451|35 45|resistance
P11474642A1451|57 70|hexamethonium
P11474642A1451|88 91|min
P11473254A0000|118 121|Leu
P11473254A0000|87 98|Lys residue
P11473254A0000|57 79|recombinase activities
P11472523A0535|68 71|DON
P11472523A0535|100 104|AFB1
P11472523A0535|52 64|inactivation
P11472523A0535|90 95|value
P11471077A0382|1 8|RESULTS
P11471077A0382|66 73|results
P11471077A0382|123 126|TRA
P11471077A0382|150 156|survey
P11469970A0873|1 9|Patients
P11469970A0873|115 140|botulinum toxin injection
P11469970A0873|24 27|SOD
P11469970A0873|62 67|trial
P11469970A0873|104 109|trial
P11469853A1053|50 61|interaction
P11469853A1053|36 44|evidence
P11469853A1053|134 139|yeast
P11469853A1053|75 81|GTPase
P11469737A1791|81 82|%
P11469737A1791|108 112|test
P11469737A1791|88 89|%
P11468958A0122|137 140|CJD
P11468958A0122|37 52|policy analysis
P11468958A0122|77 86|decisions
P11468958A0122|105 110|blood
P11468958A0122|187 198|individuals
P11468958A0122|296 299|CJD
P11468958A0122|214 228|travel history
P11466227A1665|68 78|activation
P11466227A1665|86 88|EB
P11466227A1665|41 47|effect
P11466227A1665|90 107|mTf-CAT construct
P11465655A0439|39 58|antagonist atenolol
P11465655A0439|94 100|mg/day
P11465655A0439|120 126|mg/day
P11464997A0566|6 15|knowledge
P11464997A0566|61 68|patient
P11464997A0566|30 39|diagnosis
P11463359A0167|110 125|luciferase gene
P11463359A0167|94 104|expression
P11463359A0167|151 166|G6Pase promoter
P11462024A0306|6 8|V.
P11462004A0886|69 78|advantage
P11462004A0886|114 116|N.
P11462004A0886|97 112|complementation
P11460035A0548|87 99|imputability
P11460035A0548|62 73|fluvoxamine
P11460035A0548|44 57|carbamazepine
P11459960A1109|40 50|components
P11459304T0078|1 22|Enantiomer separation
P11459304T0078|26 37|venlafaxine
P11457139A0604|81 87|GlcNAc
P11457139A0604|99 110|D1D3 isomer
P11457139A0604|66 78|affinity Man
P11457139A0604|120 126|GlcNAc
P11454703A0000|5 15|telomerase
P11454703A0000|52 63|maintenance
P11454703A0000|229 242|tumorigenesis
P11454703A0000|151 156|cells
P11454190A0000|1 16|BACKGROUND/AIMS
P11454190A0000|98 103|forms
P11454190A0000|107 120|liver disease
P11451995T0000|65 71|Ste14p
P11451995T0000|82 88|member
P11451447A0205|1 6|Gimpl
P11450490A0565|205 206|P
P11450490A0565|187 192|range
P11450490A0565|63 83|range hand motions/0
P11448051A0093|117 121|core
P11448051A0093|5 11|system
P11448051A0093|232 246|Eudragit RS100
P11448051A0093|176 181|agent
P11448051A0093|63 85|intestine transit time
P11445008A0816|39 49|comparison
P11445008A0816|107 115|RNA pool
P11445008A0816|135 151|RNA pool samples
P11443999A0573|1 23|Mean Hg concentrations
P11443999A0573|54 59|sites
P11443999A0573|41 45|mice
P11443999A0573|104 105|P
P11441974A0320|51 64|hemolymph PO2
P11441974A0320|190 198|mmol x l
P11441974A0320|97 107|hemocyanin
P11441974A0320|27 36|migration
P11441311X0001|102 109|results
P11441311X0001|69 78|lymphomas
P11441311X0001|80 90|BACKGROUND
P11441311X0001|24 31|MACOP-B
P11441311X0001|133 154|chemotherapy regimens
P11439343A0785|16 20|MPc3
P11439343A0785|83 86|AF9
P11439343A0785|45 59|Pc protein M33
P11438666A0555|99 105|finger
P11438666A0555|39 42|TAF
P11438666A0555|94 97|PHD
P11438666A0555|75 92|plant homeodomain
P11438651A1365|38 41|HML
P11438651A1365|147 156|component
P11438651A1365|61 67|origin
P11437439A0201|39 45|region
P11437439A0201|78 84|subset
P11435688A0262|69 79|N-terminus
P11435688A0262|55 61|domain
P11435688A0262|111 133|transmembrane segments
P11435578A2231|96 103|binding
P11435578A2231|76 85|enhancers
P11435578A2231|24 38|reconstitution
P11435578A2231|44 57|consensus CRE
P11435560A1322|16 20|data
P11435560A1322|95 99|fate
P11435428A0000|85 95|acetyl-CoA
P11435428A0000|100 115|lipid synthesis
P11435428A0000|11 32|acetyl-CoA synthetase
P11433379A0000|1 4|SIT
P11433379A0000|93 108|adaptor protein
P11433018A0756|137 146|stability
P11433018A0756|39 46|binding
P11433018A0756|93 101|assembly
P11433018A0756|164 174|components
P11432776A0421|84 91|tissues
P11432776A0421|54 59|Graf2
P11432776A0421|133 139|muscle
P11432112A0000|1 8|PURPOSE
P11432112A0000|32 37|study
P11432112A0000|157 181|embryo selection process
P11432112A0000|111 126|sperm injection
P11432112A0000|14 23|objective
P11431472A0540|81 86|Rab1B
P11431472A0540|54 55|K
P11431472A0540|25 34|Rab6A-GTP
P11431472A0540|106 107|A
P11430976X0000|9 15|issues
P11430976X0000|31 43|biosynthesis
P11429702A0917|98 104|levels
P11429702A0917|191 206|K650E receptors
P11429702A0917|212 220|addition
P11429702A0917|43 53|conditions
P11429702A0917|123 136|FGFR3 mutants
P11429702A0917|181 186|Y373C
P11428487T0000|11 21|vein varix
P11428283A0228|49 56|stridor
P11428283A0228|15 21|infant
P11427611A0000|5 19|susceptibility
P11427611A0000|337 342|assay
P11427611A0000|277 285|carbonyl
P11427611A0000|313 316|XTT
P11427611A0000|348 361|determination
P11427611A0000|288 311|H-tetrazolium hydroxide
P11427611A0000|392 402|microscopy
P11427611A0000|115 121|agents
P11425877A1026|1 6|Cells
P11425877A1026|138 161|fluid phase pinocytosis
P11425877A1026|130 134|rate
P11425877A1026|15 19|p116
P11425877A1026|87 97|structures
P11425877A1026|113 122|reduction
P11425877A1026|177 185|decrease
P11424992A0712|112 120|criteria
P11422757A0737|67 77|ACR levels
P11422757A0737|29 36|changes
P11420612A0303|32 39|mapping
P11420612A0303|143 150|regions
P11420612A0303|107 111|maps
P11418662A0917|16 23|portion
P11418662A0917|113 116|p65
P11418662A0917|27 32|Notch
P11418662A0917|120 129|NF-kappaB
P11416879A1589|10 28|blood gas tensions
P11416650T0000|36 42|Update
P11416260A0000|16 22|method
P11416260A0000|173 186|data analysis
P11416132A1351|85 110|repeat binding activities
P11416132A1351|82 83|n
P11416132A1351|76 77|d
P11416132A1351|46 57|recognition
P11416012A2511|440 445|U0124
P11416012A2511|238 266|phophatidylinositol 3-kinase
P11416012A2511|306 312|microM
P11416012A2511|173 178|cells
P11416012A2511|110 142|LDL receptor promoter expression
P11416012A2511|224 234|inhibitors
P11416012A2511|394 400|microM
P11416012A2511|428 438|derivative
P11416012A2511|384 389|U0126
P11416012A2511|362 364|PD
P11416012A2511|268 278|wortmannin
P11415958A0000|159 169|advantages
P11415958A0000|94 102|analysis
P11415958A0000|62 65|use
P11415958A0000|120 124|data
P11415633A1253|97 108|compression
P11415633A1253|24 34|force data
P11413760A0000|100 113|ACh receptors
P11413760A0000|77 87|antibodies
P11413760A0000|135 142|synapse
P11413319A0000|50 60|host cells
P11413319A0000|73 80|absence
P11413277A1121|64 69|ara-C
P11413277A1121|93 98|PCNSL
P11411961A0735|1 27|Keratoconjunctivitis sicca
P11411961A0735|144 151|battery
P11411961A0735|58 70|complication
P11411198A0711|174 182|lymphoma
P11411198A0711|12 18|cancer
P11411198A0711|62 76|Ashkenazi Jews
P11410664A0963|174 177|BER
P11410664A0963|9 15|report
P11410664A0963|166 170|step
P11410664A0963|252 260|reversal
P11410664A0963|21 30|technique
P11410664A0963|113 118|order
P11410664A0963|189 197|activity
P11410110A0190|51 59|muscle O
P11410110A0190|36 47|measurement
P11410110A0190|128 136|subjects
P11410110A0190|79 80|O
P11410110A0190|63 74|consumption
P11408774X0893|12 17|Basel
P11408591A0000|35 45|hyaluronan
P11408591A0000|21 31|production
P11408591A0000|107 120|v-src mutants
P11408338A1686|6 11|study
P11408338A1686|111 119|majority
P11408338A1686|123 128|cases
P11407650A0661|1 14|Hypercalcemia
P11407650A0661|83 102|hyperparathyroidism
P11407650A0661|40 63|serum PTH concentration
P11407650A0661|132 133|%
P11407289A1507|1 12|CONCLUSIONS
P11407289A1507|86 95|BIS index
P11406277A0598|35 43|elements
P11406277A0598|197 225|parent Hlx promoter sequence
P11406277A0598|167 175|elements
P11406277A0598|13 23|hypothesis
P11406277A0598|181 189|activity
P11406007A0292|100 114|contraceptives
P11406007A0292|80 85|forms
P11406007A0292|147 155|outcomes
P11406007A0292|181 186|years
P11404019A0532|89 104|promoter region
P11404010A0235|38 44|length
P11404010A0235|14 23|triplexes
P11403663A0359|39 47|bearings
P11403663A0359|23 27|drag
P11403663A0359|91 102|predictions
P11402674T0000|1 33|Newcastle disease antibody titre
P11401105T0000|43 58|cancer patients
P11399834T0000|19 37|HCV seroconversion
P11399834T0000|41 49|Portugal
P11399834T0000|60 72|introduction
P11398899A1183|49 58|locations
P11398899A1183|9 16|tunnels
P11398899A1183|26 33|windows
P11397652A0381|171 190|sample availability
P11397652A0381|117 124|variety
P11397652A0381|81 93|test methods
P11397652A0381|212 222|volatility
P11397652A0381|224 228|etc.
P11395469A1373|81 85|sid1
P11395469A1373|67 77|regulation
P11395469A1373|9 17|mutation
P11393463A0274|1 5|Data
P11393463A0274|128 137|occasions
P11393463A0274|41 56|student samples
P11393463A0274|72 77|group
P11393463A0274|254 263|relatives
P11393463A0274|296 310|month interval
P11393463A0274|243 250|friends
P11392306T0000|18 24|design
P11392306T0000|29 39|techniques
P11391531A1157|1 9|Mutation
P11391531A1157|39 53|Mdr1b promoter
P11391303A0807|55 84|intraobserver reproducibility
P11391303A0807|7 10|LHR
P11390663A1400|103 121|Gcn4p target genes
P11390663A1400|67 94|induction pathway operating
P11390663A1400|10 19|profiling
P11390581A1203|78 87|Cp region
P11390581A1203|11 18|finding
P11390581A1203|183 191|promoter
P11389085A1032|138 141|RET
P11389085A1032|145 158|NIH 3T3 cells
P11389085A1032|58 68|cell death
P11389085A1032|28 46|NF-kappaB activity
P11389077A0000|3 10|variety
P11387940A0647|68 78|percussion
P11387940A0647|5 13|severity
P11387208T0000|1 38|SKP1-SnRK protein kinase interactions
P11387208T0000|72 98|plant SCF ubiquitin ligase
P11384880A0719|5 14|mechanism
P11384880A0719|52 67|gene expression
P11384880A0719|111 130|breast cancer cells
P11384229A1669|138 144|factor
P11384229A1669|74 85|interaction
P11384229A1669|45 59|VP5 background
P11383860A0661|101 106|brain
P11383860A0661|5 11|images
P11383860A0661|161 170|excretion
P11383860A0661|61 80|99mTc ciprofloxacin
P11382701A0688|98 125|plasma sodium concentration
P11382701A0688|14 25|transection
P11380837A1505|1 14|Interventions
P11380837A1505|53 62|processes
P11380837A1505|151 169|access dysfunction
P11380028A0000|99 104|99mTc
P11380028A0000|203 216|blood samples
P11380028A0000|185 189|cats
P11380028A0000|156 172|plasma clearance
P11380028A0000|80 93|Technetium Tc
P11380028A0000|176 180|dogs
P11378898A0164|16 29|EMBL databank
P11378898A0164|12 14|bp
P11376946A0000|86 97|phosphatase
P11376946A0000|38 43|SHP-1
P11376946A0000|147 155|lineages
P11376946A0000|208 215|control
P11376946A0000|47 50|SH2
P11376279A0000|69 80|angiography
P11376279A0000|65 67|MR
P11376279A0000|94 105|extremities
P11376134A1506|34 43|sequences
P11376134A1506|98 103|sites
P11376007A0584|186 208|protein phosphatase 2A
P11376007A0584|143 150|subunit
P11376007A0584|230 242|reactivation
P11376007A0584|161 180|protein phosphatase
P11376007A0584|299 310|microcystin
P11376007A0584|210 214|PP2A
P11374866X0914|1 10|Copyright
P11374051A0437|170 174|risk
P11374051A0437|80 94|anticoagulants
P11374051A0437|37 40|age
P11374051A0437|12 19|factors
P11372959A1447|207 208|%
P11372959A1447|114 119|sites
P11372959A1447|92 101|abundance
P11372959A1447|146 161|R2 coefficients
P11372959A1447|72 79|factors
P11371417A0744|68 84|chord compliance
P11371417A0744|341 360|preventilation data
P11371417A0744|281 286|pg/ml
P11371417A0744|261 266|MIP-2
P11371417A0744|27 40|control lungs
P11371417A0744|89 97|increase
P11371417A0744|170 175|pg/ml
P11371417A0744|309 315|levels
P11371417A0744|226 236|macrophage
P11371417A0744|379 389|percentage
P11371417A0744|191 193|IL
P11371417A0744|178 189|interleukin
P11371417A0744|422 424|LA
P11371160A0854|35 49|anticodon loop
P11371160A0854|98 115|TyrRS interaction
P11371160A0854|76 80|acts
P11371160A0854|150 162|tyrosylation
P11371115A0962|81 82|%
P11371115A0962|23 31|biopsies
P11371115A0962|61 72|HBs antigen
P11369700A0074|152 153|C
P11369700A0074|35 49|chain isotypes
P11369700A0074|154 155|H
P11369700A0074|53 62|cytokines
P11369700A0074|67 84|B cell activators
P11369410A0949|138 148|processing
P11369410A0949|159 171|participants
P11369410A0949|11 21|hypothesis
P11369066A1210|1 12|CONCLUSIONS
P11369066A1210|172 192|radiation dermatitis
P11369066A1210|43 57|corticosteroid
P11368911T0000|70 80|C. elegans
P11368911T0000|11 25|identification
P11368787A0180|85 100|annexin A5 gene
P11368787A0180|64 71|portion
P11368787A0180|167 193|transcription start points
P11368363A0129|32 53|transcription factors
P11368363A0129|235 241|member
P11368363A0129|8 14|course
P11368363A0129|106 114|promoter
P11368363A0129|165 169|cDNA
P11368363A0129|84 99|myeloperoxidase
P11368363A0129|182 185|DNA
P11367523A1684|81 88|classes
P11367523A1684|92 100|proteins
P11367523A1684|60 69|allotypes
P11361338A0447|126 141|Pex5p chimaeras
P11361338A0447|40 47|tobacco
P11361338A0447|104 113|construct
P11360190A0178|69 80|G0/G1 phase
P11360190A0178|131 136|cells
P11360190A0178|29 32|Tax
P11359827T0000|94 99|SPE-I
P11359827T0000|91 92|J
P11359827T0000|75 84|exotoxins
P11358962A0344|102 118|Foxp2 expression
P11358962A0344|70 73|E12
P11358962A0344|53 57|lung
P11358962A0344|11 16|Foxp2
P11358801A1046|20 30|situations
P11358801A1046|131 138|studies
P11358801A1046|44 50|breaks
P11357063A0138|1 13|Descriptions
P11357063A0138|96 104|features
P11357063A0138|22 27|locus
P11357063A0138|134 138|loci
P11356853A0554|1 18|Mutation analyses
P11356853A0554|95 100|StREs
P11356835A0000|49 56|network
P11356835A0000|132 150|protein precursors
P11356835A0000|121 128|amounts
P11356214A0794|136 144|surfaces
P11356214A0794|33 37|time
P11356214A0794|80 107|Knoop hardness measurements
P11356214A0794|232 238|dentin
P11356214A0794|148 163|resin specimens
P11355615A0766|64 73|direction
P11355615A0766|95 108|incorporation
P11355615A0766|26 34|research
P11354975A0850|18 29|Euspondylus
P11354975A0850|54 60|female
P11354975A0850|128 137|Venezuela
P11354975A0850|108 113|Sucre
P11353774A0255|34 50|characterization
P11353774A0255|140 150|hepatocyte
P11353774A0255|20 29|isolation
P11353774A0255|212 228|hormone receptor
P11353774A0255|230 232|NR
P11353774A0255|58 76|forkhead homologue
P11353392A1127|114 127|ASIP mutation
P11353392A1127|29 34|ADEx2
P11352663A0138|101 108|COUP-TF
P11352663A0138|53 63|expression
P11352663A0138|120 127|binding
P11352663A0138|45 50|class
P11350982A0560|98 102|GCN2
P11350982A0560|27 35|evidence
P11350812A0829|153 175|stress fiber formation
P11350812A0829|19 42|Raf-1 target ERK kinase
P11350812A0829|106 120|ERK activation
P11350812A0829|44 47|MEK
P11350165A1606|1 8|Changes
P11350165A1606|91 97|losses
P11349796A0950|102 113|measurement
P11349796A0950|1 13|Measurements
P11349796A0950|80 84|days
P11349796A0950|58 66|exposure
P11347201X0001|69 79|BACKGROUND
P11347201X0001|98 109|vitamin B12
P11347201X0001|158 163|acids
P11347201X0001|111 120|vitamin D
P11347201X0001|132 135|n-3
P11345435A0199|22 36|RNA subdomains
P11342479A0430|153 164|evaporation
P11342479A0430|138 148|paclitaxel
P11342479A0430|64 74|paclitaxel
P11342479A0430|95 110|microgram/stent
P11341405A1154|1 12|CONCLUSIONS
P11341405A1154|99 105|MCB-IV
P11341405A1154|163 174|orientation
P11341405A1154|317 323|racing
P11341405A1154|116 126|Greyhounds
P11341405A1154|80 90|properties
P11341405A1154|218 221|MCB
P11341405A1154|26 35|RELEVANCE
P11341405A1154|150 158|turnover
P11341349T0000|37 68|breast cancer screening program
P11341349T0000|25 31|effect
P11340516A0509|106 115|Tisuacryl
P11340516A0509|44 57|Vicryl suture
P11340516A0509|75 81|ADAL-2
P11340080A0096|110 129|immunoprecipitation
P11340080A0096|63 67|Hus1
P11340080A0096|14 22|proteins
P11340080A0096|134 139|yeast
P11337859A0651|5 8|COD
P11337859A0651|247 252|mol/L
P11337859A0651|92 99|dosages
P11337859A0651|79 90|coagulation
P11337859A0651|13 27|color removals
P11336211A0132|34 43|Bengtsson
P11336211A0132|15 21|method
P11335116A1099|1 22|Bandshift experiments
P11335116A1099|136 145|sequences
P11335116A1099|203 207|role
P11335116A1099|283 297|vitellogenesis
P11335116A1099|153 162|promoters
P11335116A1099|212 218|BmHR3A
P11333268A1521|171 177|switch
P11333268A1521|206 209|Ras
P11333268A1521|96 103|regions
P11333268A1521|193 202|anchoring
P11333268A1521|74 80|switch
P11333268A1521|45 57|interactions
P11333268A1521|154 165|interaction
P11333268A1521|213 216|Sos
P11333268A1521|302 306|site
P11331613A0827|81 89|subclass
P11331613A0827|59 68|mutations
P11331596A0710|34 45|EVH1 domain
P11331596A0710|49 53|Mena
P11328853A0644|1 12|Examination
P11328853A0644|96 111|promoter region
P11328853A0644|125 143|promoter sequences
P11327858A0087|48 64|oncoprotein Hdm2
P11327858A0087|31 34|Arf
P11327292A0190|69 73|risk
P11327292A0190|87 91|loss
P11327292A0190|13 21|location
P11325685A1624|133 140|decline
P11325685A1624|13 34|L-carnitine treatment
P11325685A1624|45 76|plasma carnitine concentrations
P11325195A0661|16 19|MFI
P11325195A0661|78 94|pork longissimus
P11323716A0413|20 25|RAD23
P11323716A0413|58 70|interactions
P11323411A0505|68 72|SHP2
P11323411A0505|207 210|Tyr
P11323411A0505|100 111|orientation
P11323411A0505|81 85|Gab1
P11323411A0505|126 138|N-SH2 domain
P11323411A0505|165 168|Tyr
P11319880A1108|1 10|Rapamycin
P11319880A1108|41 63|4E-BP1 phosphorylation
P11319880A1108|121 125|band
P11318608A1155|1 13|Transfection
P11318608A1155|110 119|nucleolus
P11318363A0085|1 7|DESIGN
P11316127A0485|65 71|values
P11316127A0485|79 85|HCM-II
P11316127A0485|15 20|HCM-I
P11314428A0651|191 192|P
P11314428A0651|202 205|RHS
P11314428A0651|163 169|region
P11314428A0651|123 147|months width differences
P11314428A0651|30 37|ability
P11314046A0000|32 44|determinants
P11313961A1323|152 160|p53 gene
P11313961A1323|86 89|age
P11313961A1323|67 73|tumors
P11313961A1323|94 102|contrast
P11313946A0449|86 91|M-Ras
P11313946A0449|96 103|p21 Ras
P11313386A0704|84 108|B cell receptor ligation
P11313386A0704|43 61|CD40 cross-linking
P11313249T0000|28 37|zebrafish
P11312326A0169|34 42|HIV type
P11312326A0169|115 121|method
P11312326A0169|11 14|rev
P11312326A0169|208 214|genome
P11312326A0169|63 68|clone
P11312326A0169|180 188|elements
P11312108A2853|7 9|P.
P11311909A0938|66 69|end
P11311909A0938|28 36|aneurysm
P11311563A0423|54 72|promoter construct
P11311563A0423|74 86|OA induction
P11311480A0079|50 61|perineurium
P11311480A0079|190 196|fibers
P11311480A0079|127 138|perineurium
P11311153T0000|186 198|arthroplasty
P11311153T0000|5 17|relationship
P11311153T0000|25 49|factor V Leiden mutation
P11311153T0000|75 87|polymorphism
P11309678A0489|49 57|patients
P11309678A0489|9 35|transcription-PCR analysis
P11309400T0000|1 8|Effects
P11309400T0000|79 96|protein synthesis
P11309400T0000|15 37|terminus modifications
P11309373A0783|1 9|Analysis
P11309373A0783|200 207|lengths
P11309373A0783|140 144|gene
P11309373A0783|79 83|rise
P11308877A0213|85 97|input phases
P11308877A0213|174 207|orientation preserving circle map
P11308877A0213|36 41|input
P11306845A0168|65 82|blister formation
P11306845A0168|43 50|changes
P11306463A0383|35 40|L901Q
P11306463A0383|3 11|mutation
P11306463A0383|88 111|cdk4/D1 phosphorylation
P11305129T0000|69 76|courses
P11305129T0000|80 91|vaccination
P11305129T0000|127 135|globulin
P11305129T0000|14 26|booster dose
P11303638A0559|32 39|control
P11303638A0559|6 24|NEU overexpression
P11303638A0559|57 58|%
P11302704T0000|50 75|mouse histone deacetylase
P11302072A0508|184 196|significance
P11302072A0508|98 124|Word List Recognition Task
P11302072A0508|5 12|results
P11302072A0508|135 147|intervention
P11298326A0677|3 13|comparison
P11298326A0677|108 115|regions
P11298326A0677|134 139|genes
P11297545A0948|139 150|mitogenesis
P11297545A0948|175 185|protection
P11297545A0948|53 68|carcinoma cells
P11297545A0948|8 20|transfection
P11297545A0948|241 247|manner
P11297419A0894|4 9|F222W
P11297419A0894|10 24|W21F rGST A1-1
P11297419A0894|94 105|environment
P11296288A1107|81 84|pol
P11296288A1107|36 44|pCMVJS21
P11296288A1107|76 79|gag
P11296288A1107|149 153|foci
P11296288A1107|90 95|orf-x
P11295523A0218|7 14|numbers
P11294895A0292|173 178|yeast
P11294895A0292|107 112|Sec14
P11292839A0531|207 214|TBP-DR2
P11292839A0531|140 149|construct
P11292839A0531|229 232|TBP
P11292839A0531|194 197|TBP
P11292839A0531|57 64|factors
P11292839A0531|244 249|TBPwt
P11292839A0531|31 34|pol
P11291552A0156|53 56|MFH
P11290415A0288|16 21|study
P11290415A0288|92 100|placenta
P11290415A0288|46 67|ICBP90 gene structure
P11289135A0975|103 117|protein kinase
P11289135A0975|185 198|PMA treatment
P11289135A0975|261 282|protein kinase kinase
P11289135A0975|333 342|apoptosis
P11289135A0975|317 329|potentiation
P11289135A0975|285 300|inhibitor U0126
P11288208A0712|1 9|Children
P11288208A0712|80 85|rates
P11288208A0712|145 149|life
P11288208A0712|62 65|PCP
P11287623A0286|168 185|integrin subunits
P11287623A0286|143 153|expression
P11287623A0286|83 89|kinase
P11287623A0286|91 94|ERK
P11287579A1084|49 55|E4orf6
P11287579A1084|81 101|late-gene expression
P11287555A1057|102 109|CEMx174
P11287555A1057|114 123|MT4 cells
P11287555A1057|83 97|infectiousness
P11285329A0682|8 12|% CI
P11285329A0682|47 48|P
P11285054A0781|102 111|REM sleep
P11285054A0781|33 57|SOREMP dream occurrences
P11285054A0781|159 167|arousals
P11283256A0258|70 79|complexes
P11283014A0921|86 92|manner
P11283014A0921|5 12|results
P11283014A0921|41 54|transcription
P11283014A0921|120 124|role
P11282761A0531|112 125|NO production
P11282761A0531|25 35|L-arginine
P11282395A1073|103 125|kappaL chain gene loci
P11282395A1073|200 211|individuals
P11282395A1073|59 73|CDR3 sequences
P11282395A1073|88 98|Ig lambdaL
P11282394A0841|17 29|VH/VL-chains
P11282394A0841|101 105|mAbs
P11282029A0075|136 149|transcription
P11282029A0075|49 71|beta-receptor promoter
P11282029A0075|83 94|CCAAT motif
P11282029A0075|124 128|role
P11281201T0000|15 22|effects
P11280495A1330|128 132|AGEs
P11280495A1330|95 104|formation
P11279385A3917|68 74|M mode
P11279385A3917|169 177|pathways
P11279385A3917|25 34|technique
P11279385A3917|135 142|ability
P11279217A0273|1 5|Biol
P11279108T0000|100 115|gene expression
P11279108T0000|12 33|serum response factor
P11279038A0194|1 13|WRN helicase
P11279038A0194|80 83|DNA
P11278870A0123|1 9|Analysis
P11278870A0123|39 47|promoter
P11278870A0123|24 31|regions
P11278870A0123|226 251|transcription factor Cuf1
P11278870A0123|183 190|element
P11278848A1316|100 105|cells
P11278848A1316|125 132|plasmid
P11278848A1316|148 170|Sp1 consensus sequence
P11278848A1316|45 55|activation
P11278713A1054|129 140|transcripts
P11278713A1054|167 192|coding region determinant
P11278713A1054|45 49|exon
P11278610A0902|19 27|SOCS box
P11278610A0902|44 52|Cullin-2
P11278594A0618|185 196|interaction
P11278594A0618|114 123|secretion
P11278594A0618|215 231|MIC-1 propeptide
P11278594A0618|72 77|MIC-1
P11278563A0917|1 18|Deletion analyses
P11278563A0917|98 107|tankyrase
P11278563A0917|63 68|Grb14
P11278488T0000|85 100|adhesion kinase
P11278488T0000|36 40|cell
P11278440A0095|1 4|SV1
P11278440A0095|20 31|acid insert
P11278440A0095|124 136|S0-S1 linker
P11278390A0632|68 78|PKRDeltaE7
P11278390A0632|103 108|range
P11278390A0632|9 55|transcriptase-polymerase chain reaction assays
P11278290A1220|96 110|Agc expression
P11278290A1220|9 14|Smad2
P11278290A1220|131 147|Smad2 activation
P11278290A1220|45 53|TGF-beta
P11278286A0456|100 104|nGRE
P11278286A0456|140 150|regulation
P11278286A0456|198 213|corticosteroids
P11278286A0456|50 66|5-HT1A receptors
P11278286A0456|185 194|promoters
P11278286A0456|80 92|inactivation
P11278286A0456|299 307|promoter
P11276426A0501|118 122|gene
P11276426A0501|18 28|Mad member
P11276426A0501|97 105|products
P11276426A0501|11 16|Mmip1
P11274563T0000|34 36|MR
P11274563T0000|53 60|results
P11274368A0469|33 40|absence
P11274368A0469|52 69|protein synthesis
P11274184A1068|117 123|manner
P11274184A1068|155 159|Nrf2
P11274184A1068|142 149|complex
P11274184A1068|29 33|ATF4
P11274179A0610|81 91|activation
P11274179A0610|26 39|Rac/Cdc42/Pak
P11274179A0610|107 117|disruption
P11274109A0129|1 8|Acetoin
P11274109A0129|74 88|carbon sources
P11271297T0000|1 15|Nephrotoxicity
P11271297T0000|76 78|FK
P11271297T0000|91 99|patients
P11268459A0167|178 191|tissue tumors
P11268459A0167|93 96|%DB
P11268459A0167|147 159|tumor volume
P11268459A0167|72 91|DOX binding ability
P11268459A0167|135 143|decrease
P11266615A0258|38 45|domains
P11266615A0258|93 112|amino acid residues
P11266540A0328|40 62|Groucho family members
P11266540A0328|73 80|ability
P11266194A0743|10 22|distribution
P11265853A0000|155 168|configuration
P11265853A0000|66 73|Oakland
P11265853A0000|75 77|CA
P11265853A0000|30 43|Assist System
P11264375A0000|125 134|regulator
P11264375A0000|56 67|protein IE2
P11264375A0000|28 32|HCMV
P11264182A0000|37 43|HTLV-I
P11264182A0000|77 86|regulator
P11264182A0000|134 139|genes
P11264176A0181|1 6|B-myb
P11264176A0181|24 39|G1/S transition
P11263664A1085|5 9|data
P11263664A1085|24 28|SIP1
P11260662X0000|5 12|Slatkin
P11259593A1094|102 108|growth
P11259593A1094|64 79|cell separation
P11259593A1094|13 28|ace2Delta cells
P11259347A0000|49 59|literature
P11259347A0000|80 85|clues
P11259347A0000|148 157|chemicals
P11257870A0000|275 278|HRT
P11257870A0000|110 116|filter
P11257870A0000|13 18|study
P11257870A0000|152 155|ASP
P11257870A0000|259 273|retention time
P11257870A0000|81 88|reactor
P11257870A0000|63 69|hybrid
P11256944A1144|186 195|ER stress
P11256944A1144|48 64|G13 gene product
P11256944A1144|95 108|point mutants
P11255423A0211|1 10|OBJECTIVE
P11255423A0211|55 63|symptoms
P11255423A0211|95 102|decline
P11255423A0211|29 40|association
P11255035A0331|38 43|brain
P11255035A0331|131 140|phenotype
P11255035A0331|45 66|SVZa progenitor cells
P11254504A0766|236 242|gene A
P11254504A0766|231 234|Cdx
P11254504A0766|72 80|elements
P11254504A0766|119 138|activator protein-2
P11254504A0766|248 275|Cdx protein-2 binding sites
P11254504A0766|89 92|Sp1
P11251951A0000|103 115|skin lesions
P11251951A0000|81 89|accuracy
P11251951A0000|144 153|diagnosis
P11251951A0000|41 50|technique
P11251951A0000|224 232|melanoma
P11251276A0793|33 40|surgery
P11251104A0526|117 120|GA.
P11251104A0526|5 15|expression
P11250942A0626|102 106|AF-2
P11250942A0626|53 57|RAC3
P11250942A0626|77 100|VDR activation function
P11250942A0626|24 27|VDR
P11250942A0626|108 114|domain
P11248626T0000|84 90|nerves
P11248626T0000|169 177|surgeons
P11248626T0000|143 153|evaluation
P11248626T0000|62 70|function
P11247663A1447|71 82|individuals
P11247663A1447|45 58|DNAH9 alleles
P11246679A0000|84 88|CCHB
P11246679A0000|71 82|heart block
P11246679A0000|97 102|fetus
P11244733A0782|1 6|Cases
P11244733A0782|42 52|metastasis
P11243980A0510|64 82|staging procedures
P11243980A0510|13 21|patients
P11243494A0833|117 128|performance
P11243494A0833|83 88|rates
P11243494A0833|63 69|heroin
P11243306A0961|118 132|artery disease
P11243306A0961|81 93|hypertension
P11243306A0961|37 53|oxLDL antibodies
P11243306A0961|27 33|levels
P11241356T0000|143 157|stellate cells
P11241356T0000|58 63|Smad3
P11241356T0000|14 29|phosphorylation
P11241243A0693|51 60|pathology
P11241243A0693|39 47|analysis
P11241243A0693|66 80|quantification
P11241243A0693|88 98|percentage
P11241166A0677|100 106|amount
P11241166A0677|202 207|SOCS3
P11241166A0677|110 125|leptin receptor
P11241166A0677|224 243|cytokine signalling
P11241166A0677|185 200|STAT signalling
P11241166A0677|54 66|FA treatment
P11241166A0677|127 131|Ob-R
P11241166A0677|146 154|increase
P11239529A0981|1 9|IL-1beta
P11239529A0981|76 89|localizations
P11238947A0636|84 88|case
P11238947A0636|38 46|sequence
P11238947A0636|92 98|A2RE-2
P11238947A0636|109 122|RNA transport
P11238884A0892|1 5|Mice
P11238884A0892|80 90|hypoplasia
P11238884A0892|25 37|dlg mutation
P11238884A0892|130 135|cleft
P11238586A0000|36 41|class
P11238586A0000|128 131|TCR
P11238586A0000|12 19|studies
P11238586A0000|50 76|histocompatibility complex
P11238586A0000|260 272|interactions
P11238586A0000|298 305|binding
P11238586A0000|210 213|MHC
P11238405A0817|20 25|tup11
P11238405A0817|113 133|fbp1-lacZ expression
P11238405A0817|144 169|spc1 MAPK phosphorylation
P11238405A0817|209 219|activation
P11238405A0817|30 35|tup12
P11238375A0617|86 90|ERK6
P11238375A0617|42 56|kinase cascade
P11238375A0617|92 101|p38 gamma
P11238375A0617|15 19|RhoA
P11237598A0962|100 109|evolution
P11237598A0962|47 54|enzymes
P11237038A0889|3 9|subset
P11237038A0889|52 73|pressure flow studies
P11237038A0889|124 151|bladder outflow obstruction
P11235817A0000|5 38|histamine H1 receptor antagonists
P11235817A0000|189 197|children
P11235817A0000|40 54|antihistamines
P11235817A0000|107 113|relief
P11235817A0000|165 175|conditions
P11233643A0000|69 83|protoporphyrin
P11233643A0000|143 150|maximum
P11233643A0000|179 184|mg/kg
P11233643A0000|56 59|ALA
P11233643A0000|88 92|PPIX
P11231287A0158|86 98|thapsigargin
P11231287A0158|5 16|sensitivity
P11230534A0688|27 41|DEAH helicases
P11230534A0688|15 20|total
P11230145A0732|139 147|pathways
P11230145A0732|157 168|replication
P11230145A0732|93 112|cell fate decisions
P11230145A0732|61 89|RBP-Jkappa signaling pathway
P11227484T0000|99 107|presence
P11227484T0000|111 117|iodide
P11227484T0000|14 27|determination
P11227039A0953|55 58|PBF
P11227039A0953|41 42|P
P11227039A0953|13 18|women
P11226228A0899|32 37|yeast
P11226228A0899|44 48|gene
P11223938X1218|16 26|John Wiley
P11223938X1218|29 33|Sons
P11223256A1212|52 58|region
P11223246A0359|118 129|motif LxCxE
P11223246A0359|148 154|region
P11223199A0751|84 89|serum
P11223199A0751|117 123|horses
P11223199A0751|7 14|results
P11223199A0751|29 39|evaluation
P11223164A0000|1 10|Retinoids
P11223164A0000|56 65|apoptosis
P11223164A0000|74 84|inhibition
P11223164A0000|30 35|onset
P11223131A0000|1 18|Folate metabolism
P11223131A0000|87 95|activity
P11223131A0000|116 127|replication
P11223131A0000|160 165|class
P11222639A1273|36 40|role
P11222639A1273|88 102|L1 endocytosis
P11222639A1273|45 61|tyrosine residue
P11221845A1713|1 10|Treatment
P11221845A1713|172 183|methylation
P11221845A1713|133 143|repression
P11221845A1713|258 277|liver tumorigenesis
P11221845A1713|291 305|SV40 T antigen
P11221845A1713|92 102|expression
P11221845A1713|147 150|mlt
P11221845A0800|278 282|half
P11221845A0800|5 21|Genescan program
P11221845A0800|78 82|gene
P11221845A0800|228 256|C2H2-type zinc finger motifs
P11221836A0981|145 151|tumors
P11221836A0981|58 65|vaccine
P11220487T0000|51 65|trichomoniasis
P11220487T0000|12 18|review
P11220306A1753|140 144|hexA
P11220306A1753|10 16|copies
P11220306A1753|132 136|copy
P11220306A1753|44 48|hand
P11220166A0616|155 167|interactions
P11220166A0616|282 294|cortex loops
P11220166A0616|111 121|processing
P11220166A0616|41 52|stimulation
P11220166A0616|134 143|existence
P11220166A0616|60 77|motor performance
P11214354A1104|103 104|p
P11214354A1104|158 169|CON animals
P11214354A1104|52 58|levels
P11214354A1104|8 15|animals
P11213342A0492|1 8|RESULTS
P11213342A0492|41 51|efficiency
P11212249A0993|32 41|receptors
P11212249A0993|5 12|effects
P11212249A0993|63 73|antagonism
P11211759A0165|153 174|humidification system
P11211759A0165|32 37|group
P11211759A0165|66 75|hot-water
P11211759A0165|178 193|ANAMED HUMITUBE
P11211759A0165|108 115|group B
P11210839A0282|48 49|%
P11210839A0282|158 170|oprofloxacin
P11210839A0282|127 138|ethionamide
P11210839A0282|111 122|ethambutole
P11210839A0282|104 109|drugs
P11210401A0000|154 166|hemodialysis
P11210401A0000|108 125|hyperphosphatemia
P11210401A0000|26 33|Renagel
P11209100A0069|64 67|PMN
P11209100A0069|199 205|IL-1ra
P11209100A0069|124 131|release
P11209100A0069|135 155|cytokine antagonists
P11209100A0069|45 49|data
P11208017A0070|80 87|soybean
P11208017A0070|23 52|C2H2-type zinc finger protein
P11207308A0999|207 211|JAK1
P11207308A0999|96 117|STAT1 phosphorylation
P11207308A0999|131 139|activity
P11207308A0999|225 231|ERK1/2
P11207308A0999|22 39|diferuloylmethane
P11207308A0999|213 217|JAK2
P11207282A0729|85 91|Notch2
P11207282A0729|141 163|surface IgM expression
P11207282A0729|97 108|B cell line
P11207282A0729|59 63|form
P11207282A0729|122 137|down-regulation
P11207261A1421|207 212|SHP-1
P11207261A1421|101 132|Fc gamma RIIB1-PECAM-1 receptor
P11207261A1421|320 331|BCR complex
P11207261A1421|160 172|Src homology
P11207261A1421|46 63|DT40 B cell lines
P11207216A0296|40 51|combination
P11207216A0296|107 129|cDNA library screening
P11203702A1307|237 246|organizer
P11203702A1307|168 177|mechanism
P11203702A1307|55 72|activation domain
P11203702A1307|125 134|CT239-403
P11202434T0000|156 171|ankyrin repeats
P11202434T0000|143 150|protein
P11202434T0000|77 78|C
P11202434T0000|79 100|palmitoyl-CoA binding
P11200568A0830|103 117|IgG antibodies
P11200568A0830|80 91|measurement
P11200568A0830|59 63|time
P11200568A0830|40 51|inoculation
P11200568A0830|121 132|M. pulmonis
P11198385A0000|119 135|Culex pipiens L.
P11198385A0000|98 115|laboratory colony
P11198385A0000|75 81|larvae
P11198053T0000|138 141|rat
P11198053T0000|37 57|Hypericum perforatum
P11198053T0000|59 66|St John
P11198053T0000|121 130|responses
P11197549A0748|50 54|mean
P11197549A0748|86 97|arrhythmias
P11197549A0748|76 81|mm Hg
P11197549A0748|43 48|PaCO2
P11197288A0855|6 14|patients
P11197288A0855|131 139|regimens
P11196199T0000|84 99|element binding
P11196199T0000|101 105|CREB
P11196199T0000|20 41|yeast Rad23 protein A
P11196199T0000|107 122|binding protein
P11195401A1030|110 115|SIADH
P11195401A1030|63 68|SSRIs
P11194183A0866|375 379|mean
P11194183A0866|5 13|increase
P11194183A0866|336 338|SD
P11194183A0866|131 140|cm square
P11194183A0866|165 195|procyanidin B-2 group subjects
P11194183A0866|327 331|mean
P11194183A0866|398 399|P
P11194183A0866|83 89|microm
P11194183A0866|93 101|diameter
P11194183A0866|214 219|trial
P11194183A0866|148 156|cm2 area
P11194101A0532|1 20|Baseline BMD values
P11194101A0532|71 76|group
P11194101A0532|371 376|femur
P11194101A0532|283 294|user groups
P11194101A0532|146 150|view
P11194101A0532|107 112|level
P11193666A1269|44 67|Babesia carrier animals
P11191365A0682|68 77|diabetics
P11191365A0682|204 206|VF
P11191365A0682|101 107|hearts
P11191365A0682|143 145|VT
P11191365A0682|281 294|non-diabetics
P11191365A0682|166 174|episodes
P11191365A0682|154 155|%
P11191365A0682|190 202|fibrillation
P11191365A0682|265 267|VF
P11191365A0682|271 272|%
P11189314A1000|78 85|effects
P11189314A1000|91 95|GLCM
P11188971A0000|71 81|discussion
P11188971A0000|97 108|methodology
P11188971A0000|123 129|target
P11185475T0034|4 11|Caveman
P11182520A0889|19 27|genotype
P11181564A0733|49 59|region 8E1
P11181564A0733|8 13|mouse
P11181531A0464|102 125|NF-kappa B target genes
P11181531A0464|71 81|repression
P11181531A0464|9 18|mechanism
P11181531A0464|46 58|osteoporosis
P11181516A0119|258 263|A2/A3
P11181516A0119|252 256|Flat
P11181516A0119|100 116|INS-1 beta-cells
P11181516A0119|76 89|transfections
P11181516A0119|244 246|E2
P11180255A0776|81 96|UHF frequencies
P11180255A0776|42 55|improbability
P11180255A0776|146 152|energy
P11180255A0776|106 115|mechanism
P11179956A1818|97 115|nucleotide binding
P11179956A1818|177 184|domains
P11179956A1818|210 226|proton transport
P11179687A1118|35 41|module
P11179687A1118|25 33|metazoan
P11179687A1118|149 154|group
P11179668A0869|35 43|proteins
P11179400T0000|1 10|Responses
P11179400T0000|63 67|rats
P11178765A0642|87 97|metastasis
P11178765A0642|20 27|effects
P11178765A0642|148 153|colon
P11178248A1042|85 95|efficiency
P11178248A1042|39 59|screening techniques
P11178248A1042|63 68|terms
P11177538A0655|50 54|days
P11177538A0655|1 17|Tumor cell lines
P11176098A0342|1 8|METHODS
P11176098A0342|61 73|shock groups
P11172944A0826|4 12|contrast
P11172944A0826|46 57|correlation
P11172610A0508|79 88|promoters
P11171118A0836|34 39|PSE-B
P11171118A0836|52 57|PSE-A
P11171118A0836|125 142|NF-1 DNA elements
P11171118A0836|26 30|NF-1
P11169149A0097|20 29|knowledge
P11169080T0000|53 56|Bok
P11169080T0000|42 51|ignorance
P11168446T0000|115 128|haemodynamics
P11168446T0000|66 79|heart failure
P11168446T0000|11 35|erythropoietin synthesis
P11168366A0569|115 126|HepG2 cells
P11168366A0569|80 89|sequences
P11167111A0957|102 108|grafts
P11167111A0957|111 116|weeks
P11167111A0957|88 91|LPD
P11166863A0167|35 43|patients
P11166863A0167|86 90|RTOG
P11166863A0167|76 84|toxicity
P11166863A0167|15 16|%
P11164078A0833|22 30|dystonia
P11164078A0833|56 59|NAD
P11164078A0833|63 66|man
P11163932A0000|153 162|pulmonate
P11163932A0000|98 103|order
P11163932A0000|127 144|thermopreferendum
P11163932A0000|28 36|specimen
P11163932A0000|44 79|roman garden snail Helix pomatia L.
P11162666A0442|5 32|glucose/insulin stimulation
P11162278A0629|87 93|lobule
P11162278A0629|27 34|figures
P11162278A0629|46 56|activation
P11161793A1033|5 13|presence
P11161793A1033|27 44|receptor isoforms
P11161793A1033|123 128|roles
P11161455A1286|35 38|DNA
P11161455A1286|115 125|chromosome
P11160902A0962|85 95|expression
P11160902A0962|99 126|c-sis/PDGF-B proto-oncogene
P11160902A0962|177 187|expression
P11160902A0962|149 157|settings
P11160860A0662|32 46|IkappaB kinase
P11160860A0662|20 28|activity
P11160860A0662|92 112|NF-kappaB activation
P11160860A0662|121 144|IkappaB phosphorylation
P11160738A1414|40 46|vIRF-2
P11160738A1414|106 115|infection
P11160732A0464|99 118|T-lymphocyte tropic
P11160732A0464|143 160|macrophage tropic
P11160732A0464|26 43|envelope proteins
P11160732A0464|88 97|SIVmac239
P11160688A1726|92 105|translocation
P11160688A1726|72 81|cyclin D3
P11160688A1726|15 21|events
P11160656A0000|42 46|HCMV
P11160656A0000|227 232|cells
P11160656A0000|118 126|promoter
P11160656A0000|157 166|modulator
P11160656A0000|321 326|cells
P11160656A0000|25 40|cytomegalovirus
P11160656A0000|298 314|NTera2 carcinoma
P11160656A0000|181 185|lack
P11160280A1275|42 47|IRF-1
P11160280A1275|28 38|expression
P11159363A1251|21 38|cytosine residues
P11159363A1251|67 69|CG
P11159363A1251|46 57|E2F element
P11159363A1251|60 61|m
P11158456A0223|238 244|spells
P11158456A0223|71 83|consultation
P11158456A0223|142 151|frequency
P11158456A0223|196 210|family history
P11158456A0223|186 194|sequelae
P11158456A0223|155 161|spells
P11158456A0223|216 219|age
P11158326A1032|34 39|SHIP2
P11158326A1032|81 85|R47G
P11158326A1032|7 14|effects
P11158310A0993|101 105|ERSE
P11158310A0993|53 62|ATF6alpha
P11158310A0993|44 48|NF-Y
P11158290A0728|68 83|destruction box
P11158290A0728|5 11|region
P11158290A0728|28 35|serines
P11158236A0000|66 73|actions
P11158236A0000|77 87|PC12 cells
P11158236A0000|46 48|RA
P11157784A0141|159 164|locus
P11157784A0141|59 70|copy repeat
P11157784A0141|130 136|DGCR6L
P11157784A0141|79 83|sc11
P11157784A0141|15 25|DGCR6 gene
P11157763T0000|18 31|EMAPII domain
P11157763T0000|41 74|aminoacyl-tRNA synthetase complex
P11157035A1405|80 94|determinations
P11157035A1405|158 165|benefit
P11157035A1405|107 113|trials
P11156618T0000|169 178|sequences
P11156618T0000|36 50|mouse SCL loci
P11156618T0000|88 113|restriction endonucleases
P11156618T0000|62 69|regions
P11156413T0000|156 175|cancer therapeutics
P11156413T0000|109 118|T antigen
P11156413T0000|46 51|mouse
P11156413T0000|120 127|utility
P11155096A0222|1 8|METHODS
P11155096A0222|103 121|thyroid peroxidase
P11155096A0222|41 49|baseline
P11155096A0222|83 99|serum antibodies
P11155096A0222|212 216|mU/l
P11155096A0222|123 130|TPO-Abs
P11155096A0222|181 184|TSH
P11153302A0000|1 25|Naltrexone hydrochloride
P11153302A0000|41 67|opioid receptor antagonist
P11152521A0181|203 209|intron
P11152521A0181|110 129|ORF40/41 transcript
P11152451A0529|80 103|Sj26-GST fusion protein
P11152451A0529|66 74|bacteria
P11152451A0529|131 141|antibodies
P11152283A0223|99 104|order
P11152283A0223|142 147|genes
P11152283A0223|26 30|role
P11152070A0573|84 100|expression level
P11152070A0573|156 161|genes
P11152070A0573|114 118|pcbC
P11152070A0573|233 243|transcript
P11152070A0573|181 207|cephalosporin fermentation
P11150439A0701|68 71|NaH
P11150439A0701|169 180|application
P11150439A0701|83 89|breath
P11150439A0701|94 96|CO
P11150439A0701|195 214|regression equation
P11150315A0844|1 4|NGF
P11150315A0844|67 70|EGF
P11150114T0000|1 10|Chlamydia
P11150114T0000|24 30|cancer
P11148589A1124|1 12|CONCLUSIONS
P11148589A1124|188 191|HBV
P11148589A1124|199 205|future
P11148589A1124|28 50|immunization practices
P11146961T0000|75 81|PADCAB
P11145887A1393|1 11|Activation
P11145887A1393|115 131|c-Fos activation
P11145887A1393|54 66|Jurkat cells
P11145887A1393|82 87|Fra-2
P11145887A1393|194 197|Tax
P11145887A1393|15 28|transcription
P11145743A0170|170 175|Pax-8
P11145743A0170|49 54|genes
P11145743A0170|200 208|activity
P11145743A0170|77 83|effect
P11145743A0170|29 39|regulation
P11145590A0217|55 71|TGF-beta1 action
P11145590A0217|94 109|gene expression
P11145590A0217|180 201|transcription factors
P11145590A0217|75 88|thyroglobulin
P11145566A0000|169 182|understanding
P11145566A0000|64 71|element
P11145566A0000|127 133|target
P11145566A0000|75 98|cholesterol homeostasis
P11145563A0202|98 106|proteins
P11145563A0202|108 114|SREBPs
P11145562A0000|66 74|receptor
P11145562A0000|76 82|IGF-IR
P11145562A0000|10 18|decrease
P11145562A0000|26 30|type
P11145562A0000|61 64|IGF
P11142380A0389|117 126|structure
P11142380A0389|82 87|TE105
P11142380A0389|41 52|mutagenesis
P11140472A0497|51 58|results
P11140472A0497|170 179|algorithm
P11140472A0497|32 41|algorithm
P11140472A0497|83 93|algorithms
P11140472A0497|107 116|algorithm
P11139605A0811|152 173|mobility shift assays
P11139605A0811|1 18|Deletion analysis
P11139605A0811|189 200|interaction
P11139605A0811|94 111|promoter activity
P11139605A0811|44 52|sequence
P11139473A0696|98 101|CRE
P11139473A0696|126 140|SMemb promoter
P11139473A0696|89 96|element
P11139336A0257|38 53|INCENP behavior
P11139336A0257|15 27|associations
P11138694A0000|204 209|study
P11138694A0000|234 241|density
P11138694A0000|83 108|acetylcholine transporter
P11138694A0000|189 195|ligand
P11138694A0000|268 271|PET
P11138009A1032|32 41|mutations
P11138009A1032|66 67|G
P11138009A1032|43 54|Delta M1281
P11137367A0297|58 73|X-ray TV system
P11137367A0297|13 32|Toshiba IIDR system
P11137296A0923|206 232|transcription-PCR analysis
P11137296A0923|6 36|transcription initiation sites
P11137296A0923|254 259|PFK-B
P11137296A0923|157 159|bp
P11137296A0923|247 252|PFK-A
P11137296A0923|332 338|levels
P11134508A0317|24 30|plants
P11134508A0317|56 70|Arabidopsis HD
P11134033A0639|19 28|int6Delta
P11134033A0639|75 81|medium
P11133986A0350|204 212|enhancer
P11133986A0350|216 225|3T3 cells
P11133986A0350|59 80|transcription factors
P11133986A0350|161 166|c-Fos
P11133986A0350|10 17|studies
P11133986A0350|91 95|PU.1
P11133830A0174|1 11|Engagement
P11133830A0174|98 104|number
P11133830A0174|21 24|CD2
P11133830A0174|56 59|mAb
P11132790A0609|51 56|score
P11132790A0609|64 67|S-B
P11132790A0609|14 20|method
P11132148A0162|32 40|residues
P11132148A0162|5 13|presence
P11132148A0162|63 78|promoter region
P11131634A0955|54 65|roscovitine
P11131634A0955|44 50|extent
P11129724A0904|137 145|neonates
P11129724A0904|101 105|milk
P11129724A0904|37 43|source
P11129724A0904|47 60|contamination
P11128925A0000|1 11|BACKGROUND
P11128925A0000|200 202|RA
P11128925A0000|79 83|IL-6
P11128925A0000|17 20|aim
P11128925A0000|152 160|findings
P11128925A0000|189 198|arthritis
P11128925A0000|29 34|study
P11127955X0001|36 43|Surgery
P11127955X0001|22 34|colon cancer
P11127955X0001|109 122|colon cancers
P11127200A1024|307 314|peptide
P11127200A1024|110 136|AP-1 transcription factors
P11127200A1024|281 288|hormone
P11127200A1024|316 321|PTHrP
P11127200A1024|323 331|receptor
P11127200A1024|83 88|cells
P11127200A1024|177 187|expression
P11126806A0206|86 97|circulation
P11126806A0206|28 55|antiphospholipid-antibodies
P11126275A1068|21 53|anticardiolipin immunoglobulin G
P11125411A0857|17 25|patients
P11125411A0857|36 47|laparoscopy
P11125411A0857|133 139|testis
P11125151T0000|71 89|pineapple mealybug
P11125151T0000|59 67|analysis
P11124024A1098|34 39|sites
P11124024A1098|139 150|GAGA motifs
P11124024A1098|86 92|repeat
P11124024A1098|44 61|protein complexes
P11123701A0442|117 127|activities
P11123701A0442|261 275|DNA supercoils
P11123701A0442|9 17|evidence
P11123701A0442|131 140|promoters
P11123701A0442|27 31|type
P11123089A0362|118 130|vasculitides
P11123089A0362|48 57|frequency
P11123089A0362|178 193|tissue diseases
P11123089A0362|59 74|characteristics
P11122588A0549|1 22|MAIN OUTCOME MEASURES
P11122588A0549|168 171|SDB
P11122588A0549|200 206|events
P11122588A0549|76 88|apnea events
P11122588A0549|130 134|odds
P11122588A0549|187 190|AHI
P11122588A0549|219 224|sleep
P11122588A0549|91 106|hypopnea events
P11121490A0000|103 112|apoptosis
P11121490A0000|67 73|stress
P11121397A0587|137 147|initiation
P11121397A0587|40 53|rib-2 protein
P11121397A0587|13 21|findings
P11121118A0075|23 31|variants
P11120441A1193|71 81|activation
P11120441A1193|130 140|complexity
P11118712A1296|206 221|within-herd PTB
P11118712A1296|141 156|herd prevalence
P11118712A1296|279 295|herd specificity
P11118712A1296|67 75|accuracy
P11118712A1296|118 128|estimation
P11118712A1296|324 333|herd size
P11118712A1296|300 305|herds
P11118440T0000|113 124|mSin3/HDAC1
P11118440T0000|72 103|candidate tumor suppressor ING1
P11118440T0000|14 25|association
P11118062A1691|39 51|localization
P11118062A1691|59 67|mutation
P11118062A1691|28 33|model
P11117523A0650|119 132|cell cultures
P11117523A0650|19 38|COUP-TFI expression
P11117523A0650|4 12|contrast
P11117523A0650|60 75|differentiation
P11116148A0741|48 51|PKB
P11116148A0741|80 89|C/EBPbeta
P11116148A0741|36 43|insulin
P11116148A0741|61 76|transactivation
P11116084A0000|101 109|function
P11116084A0000|40 44|gene
P11114718A0349|17 34|mouse fibroblasts
P11114718A0349|112 121|cyclin D1
P11114718A0349|77 91|protein levels
P11114718A0349|57 62|v-Src
P11114294A0075|217 222|HT-29
P11114294A0075|97 113|interferon gamma
P11114294A0075|125 135|expression
P11114294A0075|227 236|T84 cells
P11114294A0075|150 194|fibrosis transmembrane conductance regulator
P11113822A0999|11 20|quadrants
P11113546A0728|51 54|end
P11113546A0728|37 46|beginning
P11113546A0728|133 145|Giardia cyst
P11113199A0800|68 83|MEK interaction
P11113199A0800|48 52|ERKs
P11113199A0800|174 179|cells
P11113199A0800|58 62|lack
P11113179A0541|17 25|contrast
P11113179A0541|64 81|estrogen receptor
P11113179A0541|53 56|CBP
P11113179A0541|29 33|SRC1
P11113179A0541|165 169|p300
P11112700T0000|1 17|Characterization
P11112700T0000|55 92|microtubule actin crosslinking factor
P11112700T0000|127 132|group
P11112700T0000|94 98|MACF
P11112438X0847|1 10|Copyright
P11111051A0051|32 37|Tip60
P11111051A0051|74 82|activity
P11110040A0000|1 11|Ketanserin
P11110040A0000|129 136|corneal
P11110040A0000|213 218|times
P11110040A0000|27 31|drug
P11110040A0000|149 161|applications
P11110040A0000|194 202|pressure
P11108720A1130|1 13|Pretreatment
P11108720A1130|109 124|inhibitor U0126
P11108720A1130|135 150|S6K2 activation
P11108720A1130|164 170|extent
P11108616A0000|155 157|hg
P11108616A0000|141 153|hypergravity
P11108616A0000|127 133|STS-84
P11108616A0000|13 36|Oreochromis mossambicus
P11108616A0000|74 75|g
P11108523A0326|103 107|axis
P11108523A0326|66 70|area
P11108523A0326|172 181|bulkiness
P11108523A0326|109 116|moments
P11108523A0326|72 81|perimeter
P11108523A0326|21 29|nostrils
P11108523A0326|149 152|I11
P11108151A0560|16 32|fibronectin mRNA
P11108151A0560|117 131|EGF-R function
P11108151A0560|71 84|PKC depletion
P11108151A0560|53 67|PKC inhibitors
P11108151A0560|213 229|fibronectin mRNA
P11106668A0875|99 107|function
P11106668A0875|126 136|BIR domain
P11106668A0875|45 63|spacer-RING domain
P11106428A0635|152 155|Ser
P11106428A0635|136 140|form
P11106428A0635|40 48|proteins
P11106428A0635|166 191|glutathione-S-transferase
P11106428A0635|13 16|end
P11105717A0123|1 8|METHODS
P11105717A0123|200 216|microvasculature
P11105717A0123|56 62|images
P11105717A0123|104 129|susceptibility difference
P11105129T0000|33 43|Klebsiella
P11105129T0000|99 103|ESBL
P11105129T0000|15 29|Susceptibility
P11102458A0000|171 173|nm
P11102458A0000|202 209|subunit
P11102458A0000|162 163|K
P11102458A0000|44 60|characterization
P11102458A0000|17 31|identification
P11102458A0000|213 229|protein kinase A
P11102458A0000|183 187|type
P11101847A0159|76 86|activation
P11101847A0159|58 71|stabilization
P11101847A0159|11 21|signalling
P11100515A0282|1 15|Thyrotoxicosis
P11100515A0282|163 169|effect
P11100515A0282|105 114|potential
P11098420A0175|138 145|suicide
P11098420A0175|125 134|mortality
P11098420A0175|88 99|development
P11097079A0525|6 11|study
P11097079A0525|62 71|clinician
P11096662T0000|1 10|Tranilast
P11096662T0000|38 52|Artery Disease
P11095248A1523|108 116|activity
P11095248A1523|73 85|prerequisite
P11094590A0617|99 112|Gram staining
P11094590A0617|283 288|value
P11094590A0617|196 197|%
P11094590A0617|199 210|specificity
P11094590A0617|221 222|%
P11094590A0617|157 160|PTC
P11094590A0617|127 136|diagnosis
P11094590A0617|244 249|value
P11094091A0000|21 46|transcription factor CREB
P11094091A0000|77 84|stimuli
P11094091A0000|104 119|phosphorylation
P11094075A0257|119 131|retroviruses
P11094075A0257|155 173|v-ras-Ki oncogenes
P11094075A0257|201 210|phenotype
P11094075A0257|145 150|v-mos
P11094072A1234|38 52|RAG-2 promoter
P11094072A1234|56 63|T cells
P11094066A1194|205 218|proliferation
P11094066A1194|50 60|inhibition
P11094066A1194|23 35|observations
P11094066A1194|192 200|survival
P11094066A1194|74 87|transcription
P11093745A0563|53 65|NF1/CTF site
P11093745A0563|110 117|element
P11092850A1023|50 57|species
P11092850A1023|145 149|copy
P11092850A1023|208 216|ancestor
P11092850A1023|181 188|lineage
P11092770A0238|84 91|class C
P11092770A0238|185 186|%
P11092770A0238|97 106|predictor
P11092770A0238|124 134|extraction
P11090272A1240|5 18|transcription
P11090272A1240|62 66|GAIP
P11089911A1267|20 29|sequences
P11089911A1267|112 130|retrotransposition
P11087141A0977|137 145|evidence
P11087141A0977|117 123|region
P11087141A0977|22 28|alpha1
P11087141A0977|128 131|UTR
P11087141A0977|30 44|GT transcripts
P11085600A0123|5 12|authors
P11085600A0123|95 101|region
P11084649A0497|187 195|mesoderm
P11084649A0497|100 105|onset
P11084649A0497|32 42|expression
P11084649A0497|215 221|streak
P11084649A0497|123 133|expression
P11084649A0497|150 158|epiblast
P11084334A0590|221 229|proteins
P11084334A0590|86 110|tetratricopeptide repeat
P11084334A0590|5 18|swa2-1 allele
P11084334A0590|112 115|TPR
P11084334A0590|146 153|auxilin
P11084334A0590|47 53|screen
P11083868A0386|1 12|DNA binding
P11083868A0386|77 84|binding
P11083868A0386|94 99|Elk-1
P11083358A1071|1 11|CONCLUSION
P11083358A1071|13 16|SPT
P11082715X0001|168 181|determination
P11082715X0001|99 113|chromatography
P11082715X0001|14 27|determination
P11082715X0001|185 197|theophylline
P11082715X0001|80 91|performance
P11082715X0001|31 43|theophylline
P11082715X0001|241 252|metabolites
P11082185A0415|55 61|domain
P11082185A0415|83 94|amino acids
P11082185A0415|148 156|activity
P11080796A1277|48 51|Tax
P11080796A1277|114 125|recruitment
P11080796A1277|203 206|IKK
P11080796A1277|83 91|IKKalpha
P11080796A1277|59 62|IKK
P11078726X0000|170 180|antibodies
P11078726X0000|48 54|Ser315
P11078726X0000|337 352|gene expression
P11078726X0000|95 115|p53 protein activity
P11078726X0000|41 44|p53
P11078726X0000|121 141|transcription factor
P11075944A0691|101 110|androgens
P11075944A0691|114 124|SC-3 cells
P11075944A0691|62 76|MMTV insertion
P11075678A0298|54 63|vibration
P11075678A0298|110 123|approximation
P11075678A0298|95 102|B3LYP/6
P11075678A0298|134 143|agreement
P11075678A0298|90 93|DFT
P11074003A0741|51 58|cycling
P11074003A0741|5 12|results
P11073919A0631|137 141|Y323
P11073919A0631|4 12|addition
P11073919A0631|143 147|Y331
P11073919A0631|77 81|D233
P11073919A0631|195 214|mouse ODC numbering
P11073919A0631|17 36|amino acid residues
P11073919A0631|83 87|G235
P11073919A0631|384 388|ODCs
P11073919A0631|89 93|G236
P11073919A0631|101 105|F238
P11073919A0631|173 177|G387
P11073919A0631|161 165|D361
P11073919A0631|107 111|E274
P11073919A0631|252 261|formation
P11073919A0631|53 57|D134
P11073919A0631|189 193|F397
P11073919A0631|297 303|domain
P11073919A0631|125 129|Y278
P11073539A0866|35 41|desmin
P11073539A0866|101 107|clumps
P11073539A0866|161 170|cytoplasm
P11073539A0866|12 20|analysis
P11073163A0131|156 169|cell survival
P11073163A0131|95 99|role
P11073163A0131|29 40|degradation
P11073163A0131|44 52|proteins
P11072155A0764|50 58|TGF beta
P11072155A0764|61 67|levels
P11071924A0588|100 103|SH2
P11071924A0588|3 10|protein
P11071924A0588|83 90|protein
P11071924A0588|58 66|activity
P11071924A0588|108 127|RING finger domains
P11071924A0588|164 171|domains
P11071789T0000|38 52|ACE inhibitors
P11070078A1153|50 53|p53
P11070078A1153|101 111|HeLa cells
P11070078A1153|58 86|Rb tumor suppressor pathways
P11070078A1153|240 245|cells
P11070078A1153|165 173|pathways
P11070078A1153|121 131|repression
P11070007A0136|136 138|Wp
P11070007A0136|1 14|Transcription
P11070007A0136|129 131|Cp
P11070007A0136|162 165|end
P11069897A1112|7 14|results
P11069897A1112|95 106|interaction
P11069897A1112|75 78|BTB
P11069791A0226|236 245|Regimen C
P11069791A0226|168 177|Regimen B
P11069791A0226|142 144|mg
P11069791A0226|134 137|IPT
P11069791A0226|17 25|subjects
P11069791A0226|217 219|mg
P11069791A0226|93 95|mo
P11069756A2618|479 481|PS
P11069756A2618|136 139|FAK
P11069756A2618|1 14|Abbreviations
P11069756A2618|546 584|growth factor receptor tyrosine kinase
P11069756A2618|77 80|CSK
P11069756A2618|463 470|partner
P11069756A2618|324 327|JNK
P11069756A2618|93 103|SRC kinase
P11069756A2618|330 333|PAK
P11069756A2618|239 272|G-protein-coupled-receptor kinase
P11069756A2618|234 237|GRK
P11069756A2618|524 539|phosphotyrosine
P11069756A2618|586 588|SH
P11069756A2618|109 134|Papillomavirus E6 protein
P11069756A2618|520 522|PY
P11069756A2618|498 500|PT
P11069756A2618|319 322|p38
P11069756A2618|105 107|E6
P11069756A2618|357 360|PBS
P11069756A2618|428 431|PKL
P11069756A2618|603 609|domain
P11069756A2618|483 496|phosphoserine
P11069223A0593|49 65|marrow functions
P11069011A0224|1 16|SSF experiments
P11069011A0224|101 106|traps
P11069011A0224|177 186|pesticide
P11069011A0224|121 128|mixture
P11067797A1306|103 111|function
P11067797A1306|124 134|assessment
P11067797A1306|192 202|components
P11064829T0058|50 59|treatment
P11063252A0437|35 37|kb
P11063252A0437|48 74|HSL translation start site
P11063127A0000|85 104|protein phosphatase
P11063127A0000|71 81|inhibition
P11063127A0000|158 162|acid
P11063127A0000|25 35|modulation
P11063127A0000|106 108|PP
P11062274T0000|100 106|stroke
P11062068T0000|117 121|role
P11062068T0000|144 150|domain
P11062068T0000|92 106|p38 MAP kinase
P11062068T0000|57 77|kinase phosphatase-1
P11062068T0000|167 177|regulation
P11062047A1208|35 47|densoviruses
P11062047A1208|55 76|genus Brevidensovirus
P11062047A1208|145 182|virus Penaeus stylirostris densovirus
P11059786A0682|1 23|VEGF promoter activity
P11059786A0682|168 174|kinase
P11059786A0682|37 50|transfections
P11059786A0682|130 150|phosphatidylinositol
P11059492A0376|1 10|Bacteriol
P11058132A0264|70 87|Bacillus subtilis
P11058132A0264|142 150|proteins
P11058132A0264|26 43|% match sequences
P11058132A0264|122 132|comparison
P11058119A0957|99 102|XPA
P11058119A0957|7 14|results
P11058119A0957|28 32|XAB1
P11056019A0926|69 83|ethenocytosine
P11056019A0926|87 97|metabolite
P11056019A0926|64 65|N
P11056019A0926|120 135|ethyl carbamate
P11055786A0306|14 23|algorithm
P11054970A0282|87 90|NF1
P11054565A0654|33 37|exon
P11054565A0654|202 214|conservation
P11054565A0654|78 84|length
P11054565A0654|41 47|p190-A
P11054565A0654|72 74|kb
P11054565A0654|132 140|residues
P11054341A0599|152 163|SWAP result
P11054341A0599|1 8|RESULTS
P11054341A0599|95 99|risk
P11054341A0599|106 124|SWAP abnormalities
P11053370A0708|119 122|GST
P11053370A0708|1 11|Expression
P11053370A0708|145 158|Uhp signaling
P11053370A0708|78 82|UhpB
P11053009A0000|23 29|ulcers
P11053009A0000|106 129|prostaglandin synthesis
P11053009A0000|88 91|COX
P11051364A0890|1 8|RESULTS
P11051364A0890|71 72|%
P11051364A0890|24 25|%
P11051364A0890|27 35|patients
P11050084A0888|32 41|PPARalpha
P11050084A0888|18 25|element
P11049889A1271|1 20|Thromboelastography
P11049889A1271|125 139|weight heparin
P11049889A1271|73 79|degree
P11048832A0271|16 20|test
P11048832A0271|70 78|analysis
P11046153A1052|70 80|expression
P11046153A1052|88 104|p300 coactivator
P11046146A1202|99 107|addition
P11046146A1202|66 73|binding
P11046146A1202|202 217|NFI-DNA binding
P11046146A1202|77 89|NFI proteins
P11046146A1202|118 132|concentrations
P11046146A1202|221 227|levels
P11045180A1892|1 12|Leptinaemia
P11045180A1892|131 145|classification
P11045180A1892|88 93|stage
P11044097T0000|55 76|transcription factors
P11044097T0000|146 154|promoter
P11044097T0000|44 51|binding
P11043469A0440|136 143|T-right
P11043469A0440|163 173|production
P11043469A0440|77 86|T-regions
P11043469A0440|181 194|Amadoriopines
P11042204A0186|70 91|p38 kinase activation
P11042204A0186|126 134|activity
P11042204A0186|30 50|phosphatidylinositol
P11042197A0386|53 56|end
P11042197A0386|14 17|Arg
P11040219A0548|1 8|Binding
P11040219A0548|20 23|RNA
P11040219A0548|52 53|N
P11040219A0548|12 16|NusA
P11039780A0770|34 41|studies
P11039780A0770|251 257|future
P11039780A0770|5 12|authors
P11039780A0770|188 199|development
P11039780A0770|82 95|animal models
P11039780A0770|120 132|gene therapy
P11038366A1417|118 131|PP2A function
P11038366A1417|7 18|methylation
P11038366A1417|46 55|formation
P11038317A0000|49 62|RAB subfamily
P11038317A0000|98 107|machinery
P11038317A0000|122 138|membrane traffic
P11038042A0948|1 11|Escalation
P11038042A0948|97 98|l
P11037759T0000|119 123|rats
P11037759T0000|1 16|Catch-up growth
P11037759T0000|92 109|agent vincristine
P11036938A1162|216 229|gonadotropins
P11036938A1162|111 123|augmentation
P11036938A1162|63 77|erbB receptors
P11036938A1162|135 152|steroid secretion
P11035867A0000|136 144|Kronberg
P11035867A0000|101 122|Braun PrecisionSensor
P11035867A0000|173 203|ANSI/AAMI SP10-1992 guidelines
P11035867A0000|224 228|data
P11035867A0000|247 256|selection
P11035867A0000|264 273|algorithm
P11034933A0389|1 8|METHODS
P11034933A0389|144 158|repolarization
P11034933A0389|13 20|RESULTS
P11034933A0389|60 77|guinea pig hearts
P11034547A0674|140 169|homeodomain recognition sites
P11034547A0674|112 119|element
P11034547A0674|82 89|binding
P11032677A0230|69 74|plugs
P11032677A0230|175 186|candidiasis
P11032677A0230|145 153|myopathy
P11032677A0230|166 173|atrophy
P11031773A0174|32 36|test
P11031773A0174|52 73|formalin induced-pain
P11031773A0174|10 17|purpose
P11031252A0646|32 50|PKC epsilon levels
P11031252A0646|5 14|LMW FGF-2
P11031252A0646|111 116|level
P11031252A0646|181 190|PKC delta
P11030476A0685|78 87|spores/mL
P11030476A0685|61 66|water
P11029704A0378|204 207|ABA
P11029704A0378|78 86|tetramer
P11029704A0378|287 292|G-box
P11029704A0378|14 22|analysis
P11029704A0378|53 74|tobacco leaf sections
P11029704A0378|94 104|distB ABRE
P11029704A0378|29 49|particle bombardment
P11029704A0378|149 164|transactivation
P11029700A0295|53 60|tissues
P11029700A0295|24 28|cycH
P11029700A0295|122 127|cells
P11029467T0000|102 114|factor-kappa
P11029467T0000|155 161|levels
P11029467T0000|127 142|gene activation
P11029467T0000|45 54|adenylate
P11029458A0000|58 65|stimuli
P11029045A0000|85 92|mitosis
P11029045A0000|49 54|cells
P11029045A0000|108 119|catastrophe
P11028131T0000|1 19|Cost-effectiveness
P11028131T0000|62 94|sclerosis disability progression
P11027833A0362|28 47|cell cycle analysis
P11027294A0483|96 105|reduction
P11027294A0483|159 178|chromatin structure
P11027294A0483|121 140|histone acetylation
P11027289A0000|119 120|S
P11027289A0000|49 53|gene
P11027289A0000|178 185|alleles
P11027289A0000|95 114|RNA binding protein
P11027289A0000|149 165|RNA accumulation
P11027289A0000|211 232|transposon insertions
P11027274A1682|83 90|extents
P11027274A1682|145 152|isoform
P11027027A0061|86 91|LC/MS
P11027027A0061|4 21|Sunset Yellow FCF
P11024300A1579|187 195|portions
P11024300A1579|216 229|reading frame
P11024300A1579|233 243|TIG-1 mRNA
P11024300A1579|144 163|chromatin structure
P11024300A1579|89 100|polypeptide
P11024300A1579|31 51|amino acid sequences
P11024047A0626|1 11|Expression
P11024047A0626|76 104|luciferase reporter activity
P11024026A0133|116 128|dissociation
P11024026A0133|25 34|arrestins
P11024026A0133|104 111|binding
P11023853A0188|305 313|activity
P11023853A0188|97 102|birds
P11023853A0188|193 202|estimates
P11023853A0188|259 266|verdins
P11023853A0188|188 191|TAL
P11023853A0188|212 230|energy expenditure
P11023853A0188|245 254|partition
P11023853A0188|268 281|energy budget
P11023074A1105|5 9|cost
P11023074A1105|46 50|kEIA
P11019257A0159|85 95|decay rate
P11019257A0159|140 146|extent
P11019257A0159|46 52|effect
P11019257A0159|14 21|3T1-3T2
P11019257A0159|60 70|line shape
P11018028A0263|84 99|phosphorylation
P11018028A0263|146 152|RasGEF
P11018028A0263|26 37|involvement
P11018028A0263|72 75|PKA
P11016954A0438|1 5|AGO1
P11016954A0438|20 25|QDE-2
P11016737A0275|27 34|outcome
P11016014A0181|68 82|susceptibility
P11016014A0181|153 161|patients
P11016014A0181|86 100|apolipoprotein
P11016014A0181|143 149|status
P11016014A0181|29 34|study
P11015197A0310|39 43|time
P11015197A0310|83 86|TMS
P11015197A0310|60 68|residues
P11014465A0479|140 144|days
P11014465A0479|110 113|PVL
P11014465A0479|10 13|day
P11014465A0479|89 93|days
P11014465A0479|46 59|echodensities
P11014213A1019|325 342|CAT reporter gene
P11014213A1019|262 268|domain
P11014213A1019|276 301|transcription factor GAL4
P11014213A1019|22 33|interaction
P11014213A1019|89 108|receptor activation
P11013079A0927|102 125|transfection constructs
P11013079A0927|223 236|SV40 promoter
P11013079A0927|188 196|activity
P11013079A0927|10 35|transcription start sites
P11012680A0676|51 61|SH2 domain
P11012680A0676|65 68|Src
P11012680A0676|89 98|inhibitor
P11012568A0192|51 58|obesity
P11012568A0192|37 47|ACTH drive
P11008420A0580|51 69|segment deviations
P11008420A0580|5 13|detector
P11008420A0580|128 144|characterization
P11007968A0255|32 35|dxr
P11007968A0255|143 150|regions
P11007968A0255|10 17|purpose
P11007954A0170|34 41|protein
P11007954A0170|143 149|signal
P11007954A0170|199 202|Ras
P11007954A0170|79 82|Sos
P11007954A0170|45 49|Grb2
P11007954A0170|84 87|Son
P11007954A0170|217 220|Sos
P11007954A0170|247 257|activation
P11007949A1395|50 54|PTEN
P11007949A1395|26 46|inactivation mutants
P11007949A1395|75 80|forms
P11007509A1271|116 129|wall segments
P11007509A1271|8 23|PMR target area
P11007509A1271|176 192|stress perfusion
P11006284T0000|113 142|phosphatidylinositol 3-kinase
P11006284T0000|59 68|complexes
P11005831A0242|50 54|type
P11005831A0242|188 211|element binding protein
P11005831A0242|148 153|AREB1
P11005831A0242|28 42|leucine zipper
P11005831A0242|104 109|yeast
P11004369A0000|85 109|color Doppler ultrasound
P11004369A0000|49 59|blood flow
P11004369A0000|67 72|tumor
P11004369A0000|193 202|carcinoma
P11003805A0443|85 96|acid reflux
P11003805A0443|65 73|symptoms
P11003805A0443|142 154|oesophagitis
P11003653A0198|137 158|beta-globin switching
P11003653A0198|234 240|switch
P11003653A0198|173 177|mice
P11003653A0198|127 132|gamma
P11003653A0198|74 101|beta-globin locus construct
P11003641A0811|251 259|promoter
P11003641A0811|199 212|transcription
P11003641A0811|109 119|phenotypes
P11003641A0811|72 77|TFIIF
P11003641A0811|28 39|motif KEFGK
P11003641A0811|181 186|Fcp1p
P11002236A0328|1 8|METHODS
P11002236A0328|81 101|retrospective search
P11002236A0328|143 163|Pediatric Hematology
P11002236A0328|126 138|Associations
P11000266T0000|1 15|Identification
P11000266T0000|22 30|enhancer
P11000203A0752|253 263|RNA export
P11000203A0752|7 16|mutations
P11000203A0752|59 69|properties
P11000203A0752|165 169|type
P10999301A0000|187 192|scale
P10999301A0000|71 76|order
P10999301A0000|159 168|magnetism
P10999301A0000|132 142|technology
P10999301A0000|44 54|parameters
P10998679A0500|102 110|scenario
P10998679A0500|48 55|illness
P10998679A0500|36 39|wth
P10997863A0753|34 40|ratios
P10997863A0753|25 28|NAA
P10997863A0753|89 101|FLE patients
P10995751A0093|127 147|IFN response element
P10995751A0093|58 70|protein-beta
P10995751A0093|195 202|element
P10993787A0369|155 159|MSNA
P10993787A0369|142 151|elevation
P10993787A0369|22 35|MSNA increase
P10993787A0369|43 46|SHG
P10993787A0369|14 17|MAP
P10993787A0369|75 78|PHI
P10992983T0000|40 51|orientation
P10992983T0000|73 75|A.
P10989777A1286|81 86|study
P10989777A1286|25 32|clients
P10989777A1286|13 21|subgroup
P10987280A0604|102 106|site
P10987280A0604|5 24|amino acid sequence
P10987280A0604|57 74|threonine residue
P10983979T0000|51 63|U5 tri-snRNP
P10983979T0000|94 98|step
P10983979T0000|45 50|U4/U6
P10983344A0000|68 76|ischemia
P10983344A0000|5 12|article
P10983344A0000|28 38|diagnosing
P10982391A0425|325 333|elements
P10982391A0425|189 202|membrane core
P10982391A0425|270 278|segments
P10982391A0425|135 139|site
P10982391A0425|30 37|leucine
P10982076A0000|171 181|indicators
P10982076A0000|36 55|morbidity recording
P10982076A0000|197 215|influenza activity
P10982076A0000|105 113|sampling
P10980416T0000|35 52|bone sialoprotein
P10980416T0000|143 148|Pit-1
P10980416T0000|59 77|gene transcription
P10980416T0000|150 155|motif
P10975465A0134|185 201|carboxy terminus
P10975465A0134|77 84|protein
P10975465A0134|148 149|D
P10975465A0134|165 177|BRCT domains
P10975465A0134|91 102|amino acids
P10973400A0664|1 8|RESULTS
P10973400A0664|157 164|flexion
P10973400A0664|79 104|flexion-distraction Stage
P10973151A0883|87 97|Pernambuco
P10973151A0883|5 15|importance
P10973151A0883|163 175|interference
P10973151A0883|183 194|environment
P10972990A0966|170 184|amplifications
P10972990A0966|251 257|mutant
P10972990A0966|199 213|translocations
P10972990A0966|94 105|aberrations
P10972990A0966|72 78|mosaic
P10972990A0196|69 78|stability
P10972894A0488|201 208|library
P10972894A0488|114 122|colonies
P10972894A0488|127 133|plates
P10972894A0488|41 49|cultures
P10970048A0352|35 43|RH level
P10970048A0352|19 27|increase
P10970048A0352|98 110|contrariwise
P10970048A0352|162 166|drop
P10970048A0352|63 69|values
P10967531A1025|220 224|type
P10967531A1025|100 110|leucocytes
P10967531A1025|55 60|edema
P10967531A1025|179 183|type
P10967531A1025|165 171|microm
P10965905T0000|1 17|Insulin receptor
P10965905T0000|39 50|enhancement
P10965830A0305|84 92|patients
P10965830A0305|110 119|fasciitis
P10965830A0305|29 39|tissue PO2
P10965830A0305|44 57|PCO2 tensions
P10965135A0735|207 224|MAP kinase kinase
P10965135A0735|155 163|activity
P10965135A0735|53 67|cotransfection
P10965135A0735|179 184|cells
P10965135A0735|226 229|MKK
P10964833A1696|16 28|participants
P10964833A1696|159 163|mmHg
P10964833A1696|106 107|%
P10963735A0193|222 253|polyacrylonitrile membrane AN69
P10963735A0193|116 127|HD patients
P10963735A0193|42 47|level
P10963735A0193|79 87|controls
P10963735A0193|61 67|stress
P10962881A0900|52 56|risk
P10962881A0900|30 36|effect
P10961585A0273|5 19|manifestations
P10961585A0273|45 61|thrombocytopenia
P10959838A0153|81 102|nitrilase superfamily
P10959838A0153|67 73|member
P10959838A0153|60 63|Nit
P10958698A0485|49 52|END
P10958698A0485|41 47|domain
P10958698A0485|123 129|effect
P10958688A0265|143 153|nucleotide
P10958688A0265|111 122|interaction
P10958688A0265|161 173|conformation
P10958456A0529|116 119|F10
P10958456A0529|97 99|F6
P10958456A0529|94 96|Cp
P10958456A0529|29 35|length
P10958456A0529|107 109|bp
P10955998A1124|116 129|DNA mutations
P10955998A1124|94 104|S120K MutY
P10955998A1124|31 51|glycosylase activity
P10955313A0000|66 74|children
P10955313A0000|45 51|speech
P10954564A1262|38 44|domain
P10954564A1262|59 66|protein
P10954093A0000|86 93|strains
P10954093A0000|57 64|genomes
P10954093A0000|30 33|Pat
P10951848A0230|154 171|quality autograft
P10951848A0230|217 233|megachemotherapy
P10951848A0230|110 120|cell shift
P10951848A0230|95 100|terms
P10951848A0230|104 108|CD34
P10950935A0111|71 77|method
P10950935A0111|147 152|yeast
P10950935A0111|123 134|chromosomes
P10950935A0111|45 54|sequences
P10950415A0866|51 66|Terson syndrome
P10950415A0866|37 47|hemorrhage
P10950415A0866|133 144|improvement
P10950415A0866|91 100|procedure
P10947840A0762|115 123|coupling
P10947840A0762|37 53|18S ribosome RNA
P10947840A0762|89 97|proteins
P10946303A0000|98 112|PGE2 formation
P10946303A0000|83 93|expression
P10946303A0000|76 81|COX-2
P10946303A0000|46 54|increase
P10945010T0001|71 79|leukemia
P10945010T0001|29 46|induction therapy
P10943891A1062|84 107|splice site recognition
P10943891A1062|185 189|site
P10943891A1062|190 191|s
P10943891A1062|65 76|branch site
P10943891A1062|127 137|nucleotide
P10942587A0981|102 117|HPV E6/E7 genes
P10942587A0981|256 266|antibodies
P10942587A0981|83 87|form
P10942587A0981|8 17|treatment
P10942587A0981|165 175|E7 protein
P10942587A0981|211 217|levels
P10940562T0000|141 162|cysteine biosynthesis
P10940562T0000|24 40|characterization
P10940562T0000|89 94|thiol
P10940562T0000|73 87|O-acetylserine
P10940557A1687|36 82|Broad Complex Z2 transcription factor elements
P10940557A1687|24 31|CF1/USP
P10940557A1687|121 124|MIH
P10940413A1153|141 149|strength
P10940413A1153|160 164|bone
P10940413A1153|44 50|effect
P10939030A0986|101 111|survival p
P10939030A0986|175 188|neutropenia p
P10939030A0986|82 83|p
P10939030A0986|94 95|%
P10939030A0986|46 61|response rate p
P10938135A0259|140 174|tyrosine kinase signaling pathways
P10938135A0259|218 240|growth factor receptor
P10938135A0259|90 100|repression
P10938120A1093|17 27|regulation
P10938120A1093|80 84|UAS2
P10938120A1093|147 152|sites
P10938120A1093|31 55|fbp1 promoter constructs
P10938109A1361|80 87|insulin
P10938109A1361|23 30|PKCbeta
P10938109A1361|133 140|signals
P10938102T0000|100 109|activator
P10938102T0000|113 128|influenza virus
P10938102T0000|60 66|target
P10938102A0265|55 82|NS1 influenza virus protein
P10938102A0265|44 51|targets
P10936051T0000|49 57|sequence
P10936051T0000|5 10|RS447
P10935488A1033|1 13|Troglitazone
P10935488A1033|98 118|acid binding protein
P10935488A1033|41 62|PPARgamma target gene
P10935488A1033|120 126|A-FABP
P10934640A1114|1 13|TB bone area
P10934640A1114|71 72|p
P10934640A1114|27 33|height
P10934640A1114|63 69|colony
P10934640A1114|15 16|p
P10934073A1433|128 132|home
P10934073A1433|31 44|CHIME monitor
P10933728A1398|274 288|responsiveness
P10933728A1398|71 92|EBNA2 transactivation
P10933728A1398|53 57|CBF2
P10933728A1398|112 130|hnRNP protein AUF1
P10933728A1398|230 250|CBF1 binding element
P10933728A1398|183 191|evidence
P10932679A0049|168 179|food intake
P10932679A0049|98 108|absorption
P10932679A0049|127 133|energy
P10932679A0049|160 164|role
P10932527A0947|69 86|epithelialization
P10932527A0947|28 35|healing
P10932196A0359|1 10|Mutations
P10932196A0359|67 68|%
P10932196A0359|31 37|Xp11.3
P10931950A0869|1 5|Cdk2
P10931950A0869|43 56|tumor lysates
P10931950A0869|94 97|p27
P10931524A0313|127 132|assay
P10931524A0313|88 96|sequence
P10928477A0764|87 104|platelet function
P10928477A0764|6 11|study
P10928477A0764|150 162|shear stress
P10928179A0101|81 85|SLNs
P10928179A0101|13 22|technique
P10925207A0634|16 21|exons
P10925207A0634|126 133|regions
P10924061A0588|1 11|Activation
P10924061A0588|42 45|min
P10920906A0759|17 24|authors
P10920906A0759|139 141|cm
P10920906A0759|74 77|STS
P10919971A0606|139 163|creatine kinase activity
P10919971A0606|4 12|addition
P10919971A0606|203 216|muscle repair
P10919971A0606|88 97|vitamin E
P10918943T0000|76 80|mice
P10918943T0000|31 36|class
P10918599A0071|136 142|levels
P10918599A0071|81 87|E2F-3B
P10918599A0071|66 79|G1/S boundary
P10918599A0071|177 179|Rb
P10918572A1547|171 191|TGF-alpha precursors
P10918572A1547|38 47|TGF-alpha
P10918572A1547|7 19|interactions
P10918572A1547|77 93|ErbB2 activation
P10918440T0000|1 32|Erythema exsudativum multiforme
P10918440T0000|44 55|granulocyte
P10918059A0569|17 27|RVH domain
P10918059A0569|48 50|Ca
P10918059A0569|40 44|loss
P10915780A1063|86 100|overexpression
P10915780A1063|58 72|cyclin D1 mRNA
P10915780A1063|182 198|cyclin D1 levels
P10915780A1063|104 109|Wnt-1
P10913304A1180|102 109|protein
P10913304A1180|154 157|PE1
P10913304A1180|140 150|Ets domain
P10913304A1180|37 42|brain
P10913304A1180|75 86|kDa protein
P10913276A0684|80 90|PLC-gamma1
P10913276A0684|112 123|association
P10913172A0442|102 108|lysine
P10913172A0442|114 121|residue
P10913172A0442|61 75|Rad24 function
P10910908A0767|98 104|effect
P10910908A0767|108 111|EPO
P10910073A0876|139 143|cDNA
P10910073A0876|81 85|exon
P10910073A0876|149 152|PCR
P10910073A0876|13 30|PDGFbetaR fusions
P10908822A0519|2 3|%
P10908822A0519|7 11|% CI
P10908462A3159|5 18|effectiveness
P10908462A3159|22 25|NRT
P10908317A1459|220 235|transactivation
P10908317A1459|207 216|magnitude
P10908317A1459|191 199|increase
P10908317A1459|83 94|replacement
P10908317A1459|162 183|estradiol sensitivity
P10907971A0806|1 13|Atorvastatin
P10906999T0000|51 68|chemiluminescence
P10906999T0000|5 16|measurement
P10906176A0000|16 19|ETn
P10906176A0000|39 45|family
P10906176A0000|88 95|mutagen
P10905349A0609|49 55|Mus81p
P10905349A0609|83 89|repair
P10905349A0609|67 74|pathway
P10905349A0609|15 23|analysis
P10904191A0000|200 210|void urine
P10904191A0000|79 85|AMP CT
P10904191A0000|87 109|Gen-Probe Incorporated
P10904191A0000|217 226|specimens
P10904191A0000|212 215|FVU
P10904191A0000|145 154|specimens
P10904191A0000|122 124|CA
P10903843A0447|17 29|localization
P10903843A0447|40 50|chromosome
P10903843A0447|132 137|Tapa1
P10903733A0540|115 121|factor
P10903733A0540|78 82|BCMA
P10903733A0540|132 137|TRAF2
P10903495A0533|34 39|HepG2
P10903495A0533|48 56|extracts
P10903495A0533|74 82|sequence
P10902348A0566|33 46|field strains
P10902348A0566|125 136|application
P10902348A0566|165 181|glass jar method
P10900269A0396|169 174|range
P10900269A0396|36 40|TFOs
P10900269A0396|110 118|TK genes
P10900269A0396|150 161|frequencies
P10899142A0000|220 224|gene
P10899142A0000|138 139|G
P10899142A0000|21 29|Berkeley
P10899142A0000|246 252|DLGR-2
P10899142A0000|166 169|LGR
P10899142A0000|241 244|LGR
P10898795A0527|76 80|BCoR
P10898795A0527|146 151|HDACs
P10898795A0527|47 52|HDACs
P10897233A1057|1 11|CONCLUSION
P10897233A1057|23 28|fever
P10896859A0000|51 63|Na excretion
P10896859A0000|155 166|aldosterone
P10896859A0000|143 151|infusion
P10896859A0000|40 41|h
P10896859A0000|15 32|water deprivation
P10895851A0696|1 19|Bailey Instruments
P10895851A0696|24 46|Owen Mumford filaments
P10895417A0000|102 131|DepoFoam drug delivery system
P10895417A0000|34 37|EPI
P10895417A0000|39 47|delivery
P10895417A0000|192 201|analgesia
P10894816A0836|17 33|reporter plasmid
P10894816A0836|141 145|IL-6
P10894816A0836|129 137|response
P10893258T0000|119 144|reticulum quality control
P10893258T0000|14 30|protein response
P10892823A1040|119 127|HBP care
P10892823A1040|42 49|alcohol
P10892823A1040|62 70|drug use
P10892823A1040|91 101|components
P10891632A0435|234 246|side-effects
P10891632A0435|97 116|withdrawal syndrome
P10891632A0435|146 164|treatment schedule
P10891441A0871|16 42|pTyr317 Shc phosphopeptide
P10891441A0871|143 153|mast cells
P10891441A0871|92 103|p85 subunit
P10891441A0871|78 82|SHIP
P10891441A0871|107 127|phosphatidylinositol
P10891286A0000|35 54|chain kinase family
P10891286A0000|1 8|Members
P10891286A0000|156 164|assembly
P10891286A0000|105 130|actin/myosin cytoskeleton
P10891093A0000|5 27|transmembrane topology
P10891093A0000|37 38|H
P10891093A0000|42 56|exchanger NHE3
P10891093A0000|229 242|NHE3 membrane
P10891093A0000|89 114|transcription/translation
P10891093A0000|31 33|Na
P10889399A0243|76 79|MEK
P10887921A0718|171 180|diagnosis
P10887921A0718|185 194|follow-up
P10887921A0718|67 78|field areas
P10887921A0718|41 51|topography
P10887921A0718|132 140|rim area
P10886067A0520|67 69|mm
P10886067A0520|11 19|diameter
P10886067A0520|45 50|rotor
P10885731A0915|48 68|synthesis conditions
P10885731A0915|112 118|impact
P10885731A0915|162 172|solubility
P10885731A0915|72 84|block length
P10884978A0633|85 90|males
P10884978A0633|5 13|duration
P10884978A0633|95 102|females
P10884978A0633|26 35|hyperemia
P10882462T0000|5 12|science
P10882163A1077|204 205|%
P10882163A1077|38 45|studies
P10882163A1077|106 123|aminoglutethimide
P10882163A1077|134 144|exemestane
P10882163A1077|179 199|aromatase inhibitors
P10882163A1077|149 155|mg/day
P10880702A0966|118 127|component
P10880702A0966|59 70|amphetamine
P10880702A0966|131 144|sensitization
P10880702A0966|47 55|exposure
P10878944A0000|55 60|agent
P10878944A0000|144 153|Institute
P10878944A0000|10 43|diphtheria toxin polymer particle
P10878944A0000|88 99|Switzerland
P10878606A0876|65 71|organs
P10878606A0876|112 124|interactions
P10874151A0000|1 11|BACKGROUND
P10874151A0000|83 90|surgery
P10874151A0000|13 37|Gamma knife radiosurgery
P10873388A0623|16 29|Rhotekin cDNA
P10873388A0623|175 182|tissues
P10873388A0623|232 244|lung tissues
P10873388A0623|123 128|level
P10873388A0623|88 98|transcript
P10873386A0000|72 82|C2 subunit
P10873158A0000|35 41|kappaB
P10873158A0000|116 121|cells
P10873158A0000|23 29|factor
P10873158A0000|73 88|gene expression
P10872831A0000|34 37|EST
P10872831A0000|114 126|EST database
P10872831A0000|47 55|homology
P10872756A1325|85 91|number
P10872756A1325|18 41|randomization imbalance
P10872756A1325|112 125|motor deficit
P10872756A1325|144 150|chance
P10872473A2286|50 58|XH2 gene
P10872473A2286|5 19|ATR-X syndrome
P10872473A2286|89 95|Xq13.3
P10872473A2286|75 87|X chromosome
P10871615A0368|9 13|Hyde
P10871379A0261|19 43|transactivation function
P10871379A0261|47 52|Luman
P10871045A1221|119 136|C/EBPbeta protein
P10871045A1221|141 158|C/EBPbeta binding
P10871045A1221|23 32|C/EBPbeta
P10871045A1221|232 238|effect
P10871045A1221|199 207|promoter
P10870043A0621|116 129|control group
P10870043A0621|99 100|%
P10870043A0621|52 72|bone mineral density
P10869076A1384|50 58|presence
P10869076A1384|139 148|rut sites
P10869076A1384|98 102|tnaC
P10869076A1384|110 113|Rho
P10869076A1384|27 37|hypothesis
P10869076A1384|62 72|tryptophan
P10867496T0001|1 18|Neurofibromatosis
P10867496T0001|26 32|breast
P10866886A1277|46 55|oxycodone
P10866886A1277|73 92|mu-receptor agonist
P10866677A1839|100 108|extracts
P10866677A1839|29 37|peptides
P10865940A0000|103 105|EC
P10865940A0000|52 56|PDTC
P10865422A0138|100 109|donations
P10865422A0138|21 35|serum ferritin
P10865422A0138|54 56|Hb
P10865422A0138|42 52|hemoglobin
P10864641A1400|84 95|HA molecule
P10864641A1400|32 41|N-glycans
P10864641A1400|198 204|Asn123
P10864641A1400|107 117|regulators
P10864641A1400|164 170|Asn149
P10864271A0504|138 142|role
P10864271A0504|99 105|nature
P10864271A0504|77 95|Trichinella larvae
P10864271A0504|194 202|behavior
P10864271A0504|60 73|dissemination
P10863048A0000|118 126|stimulus
P10863048A0000|168 169|s
P10863048A0000|159 163|mmHg
P10863048A0000|213 217|rats
P10863048A0000|151 154|CRD
P10861909A0502|372 377|sites
P10861909A0502|170 175|genes
P10861909A0502|234 237|81X
P10861909A0502|337 349|cloning site
P10861909A0502|226 229|41X
P10861909A0502|154 158|ura4
P10861909A0502|387 404|restriction sites
P10861909A0502|145 147|S.
P10861909A0502|121 123|S.
P10861906A0999|119 127|mutation
P10861906A0999|87 92|genes
P10861906A0999|253 260|meiosis
P10861906A0999|141 157|transcript level
P10861906A0999|213 220|defects
P10861906A0999|109 113|IME2
P10861086A0259|117 120|Csk
P10861086A0259|279 285|manner
P10861086A0259|4 30|reconstitution experiments
P10861086A0259|53 63|expression
P10861086A0259|165 185|gain-of-function Csk
P10860846A0480|186 190|role
P10860846A0480|39 47|mutation
P10860846A0480|126 147|AP2 expression vector
P10860846A0480|12 19|studies
P10860752A1601|33 36|RNA
P10860752A1601|38 52|binding domain
P10860752A1601|173 177|mRNA
P10860752A1601|91 105|autoregulation
P10860131A0847|99 103|% CI
P10860131A0847|89 91|RR
P10858355A0920|1 13|Sparfloxacin
P10858355A0920|18 31|clinafloxacin
P10857262A0186|87 101|type A protein
P10857262A0186|201 202|%
P10857262A0186|176 181|exons
P10857262A0186|28 43|fruA transcript
P10857215A0000|5 27|Menopause-Rating-Scale
P10857215A0000|29 34|MRS I
P10856491A0178|1 8|SETTING
P10856491A0178|114 125|pregnancies
P10856491A0178|43 50|Patient
P10856491A0178|10 20|University
P10855796A1160|171 182|development
P10855796A1160|18 43|RNA hybridization studies
P10855796A1160|128 134|region
P10855690A0870|71 85|hPL-B enhancer
P10855690A0870|110 117|pathway
P10854004A0788|81 94|noradrenaline
P10854004A0788|55 58|HRT
P10854004A0788|112 125|acetylcholine
P10854004A0788|42 43|%
P10854004A0788|47 50|ERT
P10853778A0316|8 26|surgery bone cysts
P10852953A0000|84 90|bursts
P10852953A0000|207 211|beta
P10852953A0000|159 161|Hz
P10852953A0000|130 151|gamma frequency range
P10852953A0000|106 122|field potentials
P10852460A0170|70 78|selenium
P10852460A0170|5 18|relationships
P10852460A0170|143 151|Northern
P10852460A0170|220 228|criteria
P10852460A0170|86 93|retinol
P10852460A0170|25 45|blood concentrations
P10851745A0624|17 24|fatigue
P10851745A0624|70 76|safety
P10851745A0624|63 68|sleep
P10851089A1248|7 10|SAG
P10851089A1248|109 119|cell cycle
P10851089A1248|56 61|yeast
P10851089A1248|30 52|cell cycle progression
P10850942A0989|100 104|rats
P10850942A0989|115 118|TPN
P10850942A0989|4 14|experiment
P10850942A0989|57 66|% peptone
P10850719A0680|153 165|Jbeta12-RSSs
P10850719A0680|1 15|Vbeta segments
P10850719A0680|80 85|Vbeta
P10850719A0680|135 148|Vbeta 23-RSSs
P10850453A0713|35 41|Ha-Ras
P10850453A0713|157 162|DU145
P10850453A0713|179 190|stimulation
P10850453A0713|133 153|TGF-beta1 inhibition
P10850453A0713|194 216|V12Ha-Ras transfection
P10848993A0000|188 192|gene
P10848993A0000|111 141|Amycolatopsis mediterranei U32
P10848993A0000|9 23|DNA sequencing
P10848993A0000|88 97|rifamycin
P10848993A0000|74 79|mutAB
P10848605T0000|137 150|Eph receptors
P10848605T0000|20 37|tyrosine residues
P10848605T0000|63 83|juxtamembrane region
P10846054A0573|171 174|RNA
P10846054A0573|216 236|LIYV RNA replication
P10846054A0573|126 142|progeny LIYV RNA
P10846054A0573|148 151|RNA
P10846054A0573|47 53|codons
P10843810A0802|98 118|tyrosine phosphatase
P10843810A0802|65 73|homology
P10843810A0802|162 171|direction
P10843810A0802|121 125|gene
P10841601T0000|1 12|Paper alert
P10841537A0669|131 141|structures
P10841537A0669|61 73|interactions
P10839593A0000|1 10|OBJECTIVE
P10839593A0000|139 150|candidiasis
P10839593A0000|52 66|amphotericin B
P10839593A0000|111 122|fluconazole
P10839593A0000|72 82|suspension
P10839470A1148|85 93|exercise
P10839470A1148|170 176|change
P10839470A1148|202 203|p
P10839470A1148|106 122|measure analysis
P10839470A1148|134 140|Malays
P10838399A0525|16 23|PET FDG
P10838399A0525|40 54|lung infection
P10837126A1004|7 12|genes
P10837126A1004|95 105|repertoire
P10837126A1004|45 51|Xwnt-8
P10836542A0363|55 68|UV-A waveband
P10836542A0363|9 10|%
P10835485A0941|16 19|SH3
P10835485A0941|21 28|segment
P10835485A0941|36 49|linker domain
P10835485A0941|160 166|cattle
P10835485A0941|120 139|amino acid residues
P10834781A0693|173 174|P
P10834781A0693|78 82|MRTs
P10834781A0693|166 171|group
P10834781A0693|61 76|residence times
P10833486A0598|1 4|Age
P10833486A0598|141 144|ALT
P10833486A0598|12 17|years
P10833486A0598|154 156|OR
P10833486A0598|115 139|alanine aminotransferase
P10833486A0598|95 101|mmol/L
P10833486A0598|31 33|OR
P10831972A1091|17 25|findings
P10831972A1091|71 82|CD23 levels
P10831972A1091|131 159|leuprolide acetate injection
P10830395A0408|5 22|network evolution
P10830395A0408|45 53|approach
P10828751A2258|10 19|challenge
P10828751A2258|28 34|future
P10828319A0342|102 111|psoriasis
P10828319A0342|23 33|vitamin D3
P10828319A0342|12 19|analogs
P10827952A0158|84 103|bromodomain modules
P10827952A0158|57 62|TFIID
P10827952A0158|149 168|histone H4 peptides
P10826946A1198|33 38|basis
P10826946A1198|158 159|V
P10826946A1198|160 161|H
P10826946A1198|46 57|interaction
P10826946A1198|165 168|Igs
P10825294A0473|136 146|mechanisms
P10825294A0473|82 85|LTR
P10825294A0473|77 80|MDR
P10825294A0473|14 25|OC promoter
P10825200T0000|103 107|Jak3
P10825200T0000|168 183|STAT activation
P10825200T0000|126 129|Syk
P10825200T0000|63 72|signaling
P10825200T0000|74 84|activation
P10825200T0000|134 137|Lck
P10824958A1109|69 71|CO
P10824958A1109|48 51|use
P10824958A1109|36 39|PAB
P10824958A1109|146 149|age
P10823961A0664|152 157|means
P10823961A0664|19 23|TRBP
P10823961A0664|5 15|C terminus
P10823961A0664|46 53|DRIP130
P10823961A0664|135 148|transcription
P10823630A1124|79 88|parameter
P10823630A1124|14 22|presence
P10821836A0842|25 38|S transcripts
P10820829T0000|17 37|Brosimum acutifolium
P10817754T0000|1 4|H19
P10817754T0000|66 70|ways
P10817754T0000|124 127|H19
P10817754T0000|105 111|region
P10815410A0000|190 196|system
P10815410A0000|159 166|effects
P10815410A0000|108 117|cytokines
P10815410A0000|12 18|system
P10812294X0000|17 21|diet
P10812294X0000|35 38|SBF
P10812294X0000|143 153|ingredient
P10811804A0800|156 161|MKP-3
P10811804A0800|83 106|target substrates Elk-1
P10811804A0800|142 152|activation
P10811804A0800|58 71|docking sites
P10811079A1277|64 70|groups
P10810745A0677|1 9|HFA 134a
P10810745A0677|24 32|tendency
P10810745A0677|44 52|moisture
P10810083A1283|22 33|kinase gene
P10807903A0362|143 155|D1 receptors
P10807903A0362|350 358|agonists
P10807903A0362|77 84|potency
P10807903A0362|14 20|D5/D1D
P10807903A0362|21 23|CT
P10807903A0362|25 50|tail substitution mutants
P10807903A0362|215 239|cAMP accumulation assays
P10807903A0362|89 107|agonist affinities
P10805823A1920|1 12|CONCLUSIONS
P10805823A1920|141 147|causes
P10805823A1920|26 32|pacing
P10805823A1920|74 80|pacing
P10805739A0640|69 81|eIF2Bepsilon
P10805739A0640|5 13|analysis
P10805739A0640|148 159|interaction
P10805739A0640|135 143|activity
P10805738A0799|375 380|mouse
P10805738A0799|310 314|MyoD
P10805738A0799|350 360|conversion
P10805738A0799|133 138|genes
P10805738A0799|154 163|induction
P10805738A0799|262 272|activation
P10805738A0799|430 437|embryos
P10805738A0799|297 306|reporters
P10805738A0799|63 82|p38 kinase activity
P10805729A0987|69 77|C strand
P10805729A0987|96 100|DDP1
P10805729A0987|180 201|acid binding surfaces
P10805286A0914|17 36|PCI mRNA expression
P10805286A0914|81 93|rat PCI cDNA
P10805286A0914|127 135|androgen
P10805286A0914|57 63|organs
P10804379T0001|53 56|HIV
P10804379T0001|26 36|infections
P10802669A1434|84 87|A-T
P10802669A1434|5 9|data
P10802669A1434|52 62|similarity
P10801809T0000|17 27|regulation
P10801809T0000|58 68|comparison
P10801330A1714|32 39|cytosol
P10801330A1714|128 148|platelet aggregation
P10801330A1714|192 200|fraction
P10801330A1714|44 75|membrane cytoskeleton fractions
P10799879T0000|1 8|Cloning
P10799879T0000|92 104|Src homology
P10799879T0000|107 114|domains
P10799879T0000|13 29|characterization
P10799595A1454|46 56|regulators
P10799595A1454|122 136|HPV life cycle
P10799576A0196|1 3|M.
P10798607A1359|5 9|data
P10798607A1359|145 153|immunity
P10798607A1359|47 59|meningococci
P10797125A0000|239 242|min
P10797125A0000|203 205|yr
P10797125A0000|160 168|estrogen
P10797125A0000|187 192|women
P10797125A0000|292 295|min
P10797125A0000|266 275|degrees C
P10797125A0000|125 139|sweating onset
P10797125A0000|94 120|core temperature threshold
P10796465A0373|1 19|SELECTION CRITERIA
P10796465A0373|56 62|trials
P10794936A0241|171 172|%
P10794936A0241|113 125|mycobacteria
P10794936A0241|247 248|%
P10794936A0241|57 62|media
P10794936A0241|192 215|M. tuberculosis complex
P10794936A0241|28 35|MB/BacT
P10793991A0569|80 88|position
P10793991A0569|37 40|Web
P10793991A0569|42 57|TIE researchers
P10792718T0000|1 15|Identification
P10792718T0000|38 42|BarX
P10792718T0000|111 137|autoregulator biosynthesis
P10791901A0609|69 91|MRP1-PG13 supernatants
P10791901A0609|115 124|MRP1 gene
P10791901A0609|260 274|concentrations
P10791901A0609|232 240|presence
P10791901A0609|149 166|target K562 cells
P10791251A0110|26 31|kinds
P10791251A0110|60 69|functions
P10788480T0000|113 128|DNA replication
P10788480T0000|132 142|drosophila
P10788320A1034|191 203|U4/U6 snRNPs
P10788320A1034|125 138|102kD protein
P10788320A1034|160 169|tri-snRNP
P10788320A1034|91 103|interactions
P10787437A1616|83 88|SRE-1
P10786671A0182|170 175|hTERT
P10786671A0182|19 23|step
P10786671A0182|64 74|expression
P10786671A0182|177 181|gene
P10786671A0182|28 47|telomerase activity
P10785668A0000|23 29|attack
P10785668A0000|37 42|range
P10785668A0000|176 186|ecologists
P10785668A0000|46 56|herbivores
P10785668A0000|134 142|research
P10784393A0000|87 90|MDS
P10784393A0000|148 157|anomalies
P10784393A0000|122 131|cytopenia
P10784393A0000|104 120|marrow blastosis
P10782989A0575|174 185|amino acids
P10782989A0575|40 48|presence
P10782989A0575|105 125|amino acid sequences
P10781990A0455|114 129|globus pallidus
P10781990A0455|13 16|MRI
P10781604A0827|54 66|CTD sequence
P10781604A0827|124 132|Rsp5 WW2
P10781604A0827|167 173|assays
P10781541A1063|116 120|role
P10781541A1063|159 169|regulation
P10781541A1063|27 36|sequences
P10781541A1063|75 84|promoters
P10781109T0000|32 44|interference
P10781109T0000|64 67|RNA
P10780764A0722|100 103|PM2
P10780764A0722|39 40|%
P10780764A0722|92 98|microm
P10780764A0722|160 165|x m-3
P10780764A0722|61 70|diameters
P10780018A0539|20 26|models
P10780018A0539|45 50|aging
P10779508A0897|33 38|SRC1a
P10779508A0897|42 47|GRIP1
P10779352T0000|1 15|Identification
P10779352T0000|77 88|specificity
P10779352T0000|106 117|Rb proteins
P10779313A1842|50 65|Xenopus oocytes
P10779313A1842|83 94|stimulation
P10779313A1842|178 193|phosphorylation
P10779313A1842|210 214|beta
P10778740A1493|103 111|activity
P10778740A1493|168 173|pho85
P10778740A1493|72 79|strains
P10778740A1493|132 138|region
P10777586A1022|1 23|Co-immunoprecipitation
P10777586A1022|117 133|silencer element
P10777586A1022|248 265|band shift assays
P10777586A1022|92 98|ZBP-89
P10777586A1022|224 228|HeLa
P10777217A0536|100 106|domain
P10777217A0536|66 74|contrast
P10777217A0536|78 81|p53
P10777217A0536|44 57|PIG3 promoter
P10775585A0754|1 15|Ab-MLV strains
P10775585A0754|201 204|MAP
P10775585A0754|27 33|P70/S2
P10775585A0754|192 199|protein
P10775038A0142|64 69|yeast
P10775038A0142|7 14|attempt
P10775038A0142|133 134|s
P10773667A0351|81 82|%
P10773667A0351|66 77|yeast NHP6A
P10773667A0351|88 89|%
P10773455A1268|262 272|importance
P10773455A1268|217 232|differentiation
P10773455A1268|80 86|region
P10773455A1268|124 144|mouse ALAS2 promoter
P10773455A1268|180 190|activation
P10772977A0222|32 45|PVX CP mutant
P10772977A0222|66 86|Nicotiana tabacum cv
P10771709A0291|5 15|physicians
P10771709A0291|96 104|presence
P10771709A0291|108 111|IgM
P10771709A0291|74 88|seroconversion
P10771709A0291|191 208|Coxiella burnetii
P10771709A0291|246 259|questionnaire
P10771709A0291|180 187|phase I
P10770471T0000|37 49|night sweats
P10770041A0731|100 109|thickness
P10770041A0731|52 57|right
P10770041A0731|124 125|p
P10767560A0105|71 83|organization
P10767560A0105|7 16|extension
P10767560A0105|91 105|mouse Pkr gene
P10767338T0000|80 84|pump
P10767338T0000|73 75|Ca
P10767091A0133|17 27|ultrasound
P10767091A0133|176 194|image obliteration
P10767091A0133|29 33|IOUS
P10767091A0133|62 69|attempt
P10766493T0000|16 27|replication
P10766493T0000|42 52|complexity
P10766493T0000|29 35|repair
P10765095A0308|236 249|PRL secretion
P10765095A0308|6 11|study
P10765095A0308|147 161|metoclopramide
P10765095A0308|106 116|conditions
P10764802A1258|258 272|family members
P10764802A1258|136 147|interaction
P10764802A1258|48 51|p57
P10764802A1258|248 251|p57
P10764802A1258|7 11|data
P10764802A1258|182 191|mechanism
P10764729A1846|85 101|accession number
P10764729A1846|37 51|betaV spectrin
P10764729A1846|14 27|cDNA sequence
P10764150A0000|20 29|abilities
P10764150A0000|109 128|cytokine dependency
P10764150A0000|62 67|forms
P10763823A0824|19 24|mcl-1
P10763823A0824|58 67|apoptosis
P10763823A0824|109 116|plasmid
P10762254A0954|137 159|TMA methyltransferases
P10762254A0954|19 41|TMA methyltransferases
P10762254A0954|5 8|MMA
P10762254A0954|110 115|genes
P10762254A0954|10 13|DMA
P10760950A1133|37 47|N-utrophin
P10760132A1169|86 105|protein prenylation
P10760132A1169|41 52|temperature
P10760132A1169|134 154|vesicle polarization
P10759693A0201|274 282|nonusers
P10759693A0201|235 245|famotidine
P10759693A0201|310 322|theophylline
P10759693A0201|110 121|interaction
P10759693A0201|286 294|warfarin
P10759693A0201|49 56|measure
P10759693A0201|250 260|nizatidine
P10759693A0201|27 37|odds ratio
P10758489A0206|114 125|Arabidopsis
P10758489A0206|23 32|isolation
P10758489A0206|74 81|Cdc2aAt
P10757983A0733|17 21|size
P10757983A0733|190 212|mouse ZBP-89 homologue
P10757983A0733|8 13|basis
P10757983A0733|27 39|CRS sequence
P10756225A1464|103 111|response
P10756225A1464|54 62|rhinitis
P10756225A1464|142 147|cells
P10756225A1464|25 26|%
P10756225A1464|176 191|ethmoid sinuses
P10756094A0671|69 86|marker resolution
P10756094A0671|33 41|interval
P10756094A0671|115 117|kb
P10756020A0571|141 160|electron microscopy
P10756020A0571|173 178|cells
P10756020A0571|42 66|vaccinia virus particles
P10756007A0575|21 34|RBE sequences
P10756007A0575|88 94|genome
P10753553T0000|1 10|Phenazone
P10753553T0000|45 51|effect
P10752475A1376|138 146|ligation
P10752475A1376|39 65|signal-transduction events
P10752475A1376|105 112|B cells
P10752475A1376|221 226|cells
P10752475A1376|82 91|apoptosis
P10752475A1376|334 346|mouse models
P10752475A1376|150 154|CD20
P10751398A1135|103 108|virus
P10751398A1135|116 132|membrane protein
P10751398A1135|4 12|addition
P10750021A0728|85 93|activity
P10750021A0728|124 130|region
P10750021A0728|14 22|analysis
P10749932A0000|1 9|Paxillin
P10749932A0000|41 59|integrin signaling
P10749166A0991|50 55|genes
P10749166A0991|189 203|A. tumefaciens
P10749166A0991|7 14|results
P10748672A0130|1 6|Bites
P10748672A0130|25 31|adders
P10748672A0130|14 21|species
P10748194T0000|40 62|density protein PSD-95
P10748164A1284|35 45|AC element
P10748164A1284|114 119|sites
P10748164A1284|146 148|AC
P10748164A1284|135 142|factors
P10748113A0187|118 123|brain
P10748113A0187|26 37|RIM protein
P10747987A0658|34 42|monomers
P10747879A0607|65 78|reading frame
P10747879A0607|22 26|CCR5
P10747879A0607|126 139|reading frame
P10747099A0507|136 143|c-CrkII
P10747099A0507|38 48|activation
P10747099A0507|231 240|apoptosis
P10747099A0507|194 207|cell invasion
P10747099A0507|116 125|substrate
P10747099A0507|127 130|CAS
P10747099A0507|264 279|collagen matrix
P10745563A0409|16 27|hyperplasia
P10745563A0409|43 56|complications
P10745563A0409|165 170|steel
P10744749T0000|152 156|p300
P10744749T0000|53 64|Tax protein
P10744749T0000|11 17|T cell
P10744026A0000|1 11|Invertases
P10744026A0000|36 45|breakdown
P10744026A0000|60 68|fructose
P10743608A1154|253 264|involvement
P10743608A1154|216 220|body
P10743608A1154|163 177|daughter cells
P10743608A1154|47 57|cell cycle
P10743608A1154|225 236|kinetoplast
P10742114A0486|51 56|pudgy
P10742114A0486|1 5|Dll3
P10742114A0486|99 106|defects
P10742114A0486|73 80|variety
P10741850A0452|86 90|GCSh
P10741850A0452|64 73|sequences
P10741850A0452|95 113|GCSl subunit genes
P10739671A0136|273 280|complex
P10739671A0136|368 372|IRFs
P10739671A0136|128 154|transcription pause region
P10739671A0136|382 390|proteins
P10739671A0136|225 230|cells
P10739671A0136|48 54|probes
P10739671A0136|82 90|segments
P10739671A0136|295 303|fragment
P10738139A0681|76 80|KSHV
P10738139A0681|11 18|mimicry
P10736223A1227|16 20|data
P10736223A1227|98 102|prgQ
P10736223A1227|83 94|Qa promoter
P10736223A1227|108 112|PrgX
P10736223A1227|181 192|readthrough
P10735848A1440|1 5|RegA
P10734312A0503|84 96|Shc function
P10734312A0503|23 39|Shc localization
P10734312A0503|43 57|membrane rafts
P10733591A0533|1 11|Expression
P10733591A0533|112 117|Cdc42
P10733591A0533|25 38|Cdc42 results
P10733591A0533|63 72|PKClambda
P10733591A0533|122 131|PKClambda
P10733581A1391|117 131|TTF-1 activity
P10733581A1391|109 113|loss
P10733581A1391|63 66|Raf
P10732669A1336|1 8|Results
P10732669A1336|23 29|assays
P10732669A1336|214 220|family
P10732669A1336|164 176|heterodimers
P10731926A0775|68 75|adenoma
P10731926A0775|101 110|component
P10731926A0775|36 43|adenoma
P10731926A0775|145 154|carcinoma
P10730763A1491|137 153|disease severity
P10730763A1491|24 56|Nottingham Eczema Severity Score
P10730763A1491|123 133|assessment
P10730763A1491|13 16|use
P10729221A0798|5 15|comparison
P10729221A0798|56 74|Kv4 family members
P10729220A0000|67 76|H19 genes
P10729220A0000|45 58|growth factor
P10729151A1160|39 45|HPV-11
P10728945A0233|1 9|Patients
P10728945A0233|98 107|IMPACT-II
P10728945A0233|109 114|trial
P10727511A0294|34 42|cultures
P10727511A0294|112 130|signaling pathways
P10727511A0294|10 11|s
P10727511A0294|75 80|GLT-1
P10727433A0560|153 160|element
P10727433A0560|168 180|uPA promoter
P10727433A0560|248 273|protein kinase C pathways
P10727433A0560|132 149|activator protein
P10727433A0560|240 243|ras
P10727426A1280|84 95|roscovitine
P10727426A1280|5 20|kinase activity
P10727426A1280|46 60|CDK inhibitors
P10727247A0461|112 126|TEF-1 isoforms
P10727247A0461|22 29|cloning
P10727247A0461|47 65|expression pattern
P10725382A0398|84 90|domain
P10725382A0398|22 26|sos2
P10725382A0398|121 127|domain
P10724519A1185|45 49|RNAs
P10724436A0085|23 27|U3O8
P10723723A0781|19 33|mouse promoter
P10723723A0781|58 89|CT dinucleotide repeat sequence
P10723723A0781|46 52|copies
P10722737A1726|55 58|Inr
P10722737A1726|7 15|findings
P10722737A1726|110 130|transcription factor
P10722737A1726|29 40|involvement
P10722737A1726|44 47|Sp1
P10722661A0146|65 88|Neurospora crassa PREG1
P10722661A0146|111 123|PHO80 cyclin
P10722063A0328|117 121|acid
P10722063A0328|5 16|HPLC method
P10722063A0328|58 67|degrees C
P10722063A0328|29 51|octadecylsilane column
P10722063A0328|134 137|v/v
P10721717A0676|38 55|sequence identity
P10721717A0676|10 14|FGD1
P10721704X0000|305 315|regulation
P10721704X0000|136 148|organization
P10721704X0000|279 292|proliferation
P10721704X0000|319 333|mRNA stability
P10721704X0000|105 113|evidence
P10721704X0000|51 55|gene
P10721704X0000|263 274|cell growth
P10721704X0000|93 100|element
P10721704X0000|150 154|mHuA
P10721698A1195|139 147|promoter
P10721698A1195|168 181|transcription
P10721698A1195|7 11|data
P10721698A1195|26 35|expansion
P10717612A0000|1 11|BACKGROUND
P10717612A0000|141 159|stimulating factor
P10717612A0000|230 238|patients
P10717612A0000|75 83|toxicity
P10717612A0000|217 226|treatment
P10717612A0000|189 202|interleukin-2
P10717612A0000|29 34|study
P10715325A0834|171 175|EIN2
P10715325A0834|101 109|wounding
P10715325A0834|203 211|pathways
P10715325A0834|122 130|salinity
P10715325A0834|74 91|stress conditions
P10714985A1057|87 97|AG repeats
P10714985A1057|83 86|G/U
P10714985A1057|72 78|number
P10713239A0988|1 11|CONCLUSION
P10713239A0988|26 35|mechanism
P10713176A0422|1 20|Cyclin A expression
P10713176A0422|263 281|mitogen withdrawal
P10713176A0422|144 149|v-Jun
P10713176A0422|56 59|E2F
P10713176A0422|47 52|cells
P10713176A0422|91 117|pocket protein partners Rb
P10713161A0985|17 21|Ulp2
P10713161A0985|55 62|defects
P10713161A0985|46 50|ulp1
P10713083A0560|161 181|DNA recognition site
P10713083A0560|123 143|transcription factor
P10713083A0560|73 77|TraM
P10712618A0181|186 196|aspartases
P10712618A0181|100 127|Bacillus subtilis aspartase
P10712618A0181|134 135|%
P10712512A0506|1 7|Ste18p
P10712512A0506|67 78|prenylation
P10712512A0506|28 43|plasma membrane
P10710985T0000|26 39|work practice
P10710985T0000|45 53|families
P10710499A0000|19 39|serotonin antagonist
P10710499A0000|76 92|wound blood flow
P10708769A0433|117 128|tunicamycin
P10708769A0433|22 28|region
P10708769A0433|104 113|induction
P10708243A0000|139 149|antibodies
P10708243A0000|98 110|preeclampsia
P10708243A0000|15 26|observation
P10706887A0281|17 18|%
P10706887A0281|64 65|t
P10706887A0281|41 44|ALK
P10706688A0376|37 49|AP-1 binding
P10706688A0376|130 147|NF-kappaB binding
P10706688A0376|15 28|TCR signaling
P10706475A0644|55 58|DSP
P10705380A0629|200 207|genesis
P10705380A0629|147 167|BMP-4 overexpression
P10705380A0629|195 198|way
P10704853T0000|1 18|Cooperative roles
P10704853T0000|55 63|proteins
P10704853T0000|108 117|zebrafish
P10704410T0000|35 41|export
P10704410T0000|49 86|replication initiator proteins Mcm2-7
P10704285A0536|81 99|AP-2alpha promoter
P10704285A0536|176 185|AP-2alpha
P10704196A1051|141 146|model
P10704196A1051|80 84|half
P10704196A1051|162 166|side
P10702926T0089|1 15|Cross-reaction
P10702926T0089|37 45|antibody
P10702389A1148|12 14|BL
P10702389A1148|75 82|protein
P10702253A0357|84 102|HIF-1alpha subunit
P10702253A0357|12 19|cloning
P10702253A0357|31 70|transcriptase-polymerase chain reaction
P10701534A0164|119 124|years
P10701534A0164|5 12|patient
P10701534A0164|63 75|hemidystonia
P10699896A0455|50 51|P
P10699896A0455|18 23|group
P10699896A0455|27 35|patients
P10699653A0967|35 41|access
P10699653A0967|49 56|bottles
P10699653A0967|21 25|rats
P10699653A0967|157 165|solution
P10699653A0967|126 133|ethanol
P10698974A0951|294 297|WBS
P10698974A0951|97 102|genes
P10698974A0951|299 307|deletion
P10698974A0951|227 238|breakpoints
P10698516T0000|1 4|KFC
P10698516T0000|55 65|capability
P10695685T0000|34 43|rationale
P10695685T0000|56 68|implications
P10694605A1327|139 145|months
P10694605A1327|113 124|double-lung
P10694605A1327|126 127|P
P10694210A0385|190 192|mg
P10694210A0385|128 142|administration
P10694210A0385|146 164|d-chlorpheniramine
P10694210A0385|182 186|dose
P10694210A0385|88 106|cingulate cortices
P10693314A0521|70 78|patients
P10693314A0521|67 68|%
P10693314A0521|109 117|patients
P10693314A0521|12 20|patients
P10692433A0000|49 53|role
P10692433A0000|5 29|transcription factor E2F
P10692433A0000|109 119|cell cycle
P10692167A0364|59 71|observations
P10690866A0783|50 76|TSH frequency distribution
P10690866A0783|5 15|variations
P10690866A0783|40 46|shifts
P10690702A0065|108 125|myasthenia gravis
P10690702A0065|10 43|Acetylcholine receptor antibodies
P10688663A0207|16 41|core histone tail domains
P10688663A0207|53 72|trypsin proteolysis
P10688663A0207|142 152|inhibition
P10688663A0207|95 113|core histone tails
P10688660A0992|68 78|T47D cells
P10688660A0992|168 197|progesterone response element
P10688660A0992|37 40|CBP
P10688660A0992|130 143|transcription
P10688660A0992|211 232|reporter DNA template
P10688639A1310|38 58|PU.1 transactivation
P10688639A1310|62 74|PEST domains
P10687862A1980|5 32|CCAAT core sequence mutants
P10687862A1980|47 51|CIII
P10687855A1197|86 91|Zn-16
P10687855A1197|66 71|cells
P10687855A1197|31 40|pituitary
P10684967A0000|186 200|lung phenotype
P10684967A0000|1 7|NKX2.1
P10684967A0000|115 120|mouse
P10684967A0000|27 37|NK2 family
P10684967A0000|13 19|member
P10684660A1266|136 143|enzymes
P10684660A1266|19 24|plant
P10684660A1266|111 121|activities
P10684534A0634|1 10|Protamine
P10684534A0634|36 39|sum
P10684534A0634|104 118|clotting times
P10684111A1411|84 92|MAPK p44
P10684111A1411|76 80|pair
P10684111A1411|56 63|factors
P10684069A0508|155 168|aminophylline
P10684069A0508|48 52|P0.1
P10684069A0508|36 39|FIC
P10684069A0508|77 79|Vr
P10684069A0508|41 46|Wimax
P10684069A0508|30 34|MMIF
P10683259A0774|81 87|thiols
P10683259A0774|110 130|maleimide derivative
P10683259A0774|162 172|difference
P10683259A0774|94 102|reaction
P10683259A0774|195 201|values
P10683244A1860|187 198|interaction
P10683244A1860|216 223|absence
P10683244A1860|233 244|nucleotides
P10683244A1860|57 61|NBF1
P10683244A1860|62 70|R region
P10683244A1860|150 160|propensity
P10683072T0000|83 110|bolus interleukin-2 therapy
P10683072T0000|132 146|cell carcinoma
P10681679A0220|48 53|tumor
P10681679A0220|98 108|tumor cyst
P10681679A0220|111 116|years
P10681679A0220|73 84|enlargement
P10681588A0899a|140 143|ATF
P10681588A0899a|40 44|PC12
P10681588A0899a|79 82|CRE
P10681588A0899a|255 264|CCAAT-box
P10681588A0899a|53 55|C6
P10681588A0899a|297 306|factor Y.
P10681588A0899a|270 277|complex
P10681588A0899a|88 95|complex
P10681520A0525|1 9|Ras-GRF1
P10681520A0525|114 117|Rac
P10681520A0525|127 130|Rho
P10681520A0525|135 140|Cdc42
P10679781A1183|66 90|glucocorticoid induction
P10679781A1183|40 43|GRU
P10679190A0693|59 63|uORF
P10679190A0693|12 20|evidence
P10679190A0693|44 57|reading frame
P10679065A0711|1 18|BCR cross-linking
P10679065A0711|207 224|peptide substrate
P10679065A0711|156 172|protein kinase-2
P10679065A0711|56 81|protein kinase-2 activity
P10679065A0711|180 189|complexes
P10678968A1096|34 47|I. scapularis
P10678968A1096|153 170|E. phagocytophila
P10678968A1096|101 111|proportion
P10678968A1096|199 207|activity
P10678968A1096|182 188|period
P10677297A0933|171 176|cells
P10677297A0933|10 20|expression
P10677297A0933|135 143|location
P10677214A1045|103 108|slope
P10677214A1045|236 238|pK
P10677214A1045|66 69|cat
P10677214A1045|10 19|type MutT
P10677214A1045|79 81|pH
P10677214A1045|399 406|complex
P10677214A1045|321 334|acid catalyst
P10677214A1045|297 301|base
P10677214A1045|177 184|maximum
P10677214A1045|209 216|plateau
P10677214A1045|60 63|log
P10675331A0600|101 115|Erk activation
P10675331A0600|4 12|contrast
P10675331A0600|82 85|Shc
P10675331A0600|166 171|Stat3
P10674484A0633|34 41|lesions
P10674484A0633|7 11|data
P10674484A0633|122 132|perception
P10673426A0168|220 224|site
P10673426A0168|204 212|receptor
P10673426A0168|96 102|domain
P10673426A0168|112 125|translocation
P10673426A0168|131 138|process
P10673426A0168|60 68|activity
P10671606A0884|152 153|%
P10671606A0884|169 172|BAH
P10671606A0884|81 87|images
P10671606A0884|110 118|patients
P10671606A0884|107 108|%
P10671520T0000|36 41|I-mfa
P10671520T0000|134 150|HIV-1 expression
P10671224A0254|16 21|study
P10671224A0254|72 88|CD95L expression
P10670358A0143|19 28|exception
P10669736A0903|36 39|CAT
P10669736A0903|132 135|PTB
P10669736A0903|60 71|transcripts
P10669596A0430|100 104|Abc2
P10669596A0430|294 300|enzyme
P10669596A0430|246 270|RecBCD nuclease activity
P10669596A0430|12 18|growth
P10669596A0430|164 181|nuclease activity
P10669594A0000|35 39|AgfA
P10669594A0000|25 33|fimbrins
P10669594A0000|160 163|PT3
P10669594A0000|44 48|SefA
P10668701A1311|85 87|AD
P10668701A1311|1 11|CONCLUSION
P10668701A1311|109 115|effect
P10668701A1311|63 67|risk
P10666509A0494|27 38|arrhythmias
P10666509A0494|63 74|zatebradine
P10666238A1322|65 69|E4-6
P10666238A1322|24 35|E2F binding
P10666238A1322|133 156|E2F-1 promoter activity
P10665949A1131|77 84|lesions
P10665949A1131|13 24|farm budget
P10665308T0001|1 11|Mechanisms
P10665308T0001|60 68|duration
P10663558T0000|138 143|chain
P10663558T0000|129 131|Ig
P10663558T0000|47 75|basement membrane reactivity
P10662614A0000|154 161|genomes
P10662614A0000|5 24|genome organization
P10662614A0000|110 117|members
P10662614A0000|125 136|Potyviridae
P10660676A0000|1 18|Zebrafish cyclops
P10660676A0000|20 23|cyc
P10660676A0000|77 93|signaling factor
P10660304A0522|255 262|context
P10660304A0522|16 30|JAK/Tyk family
P10660304A0522|87 93|Tyr705
P10660304A0522|172 184|STAT3 Tyr727
P10660304A0522|229 237|stimulus
P10660304A0522|130 136|kinase
P10658588A0304|34 61|didesmethylferrochloroquine
P10658588A0304|154 157|Dd2
P10658588A0304|93 107|schizontocides
P10658588A0304|146 149|HB3
P10658425A1567|42 43|%
P10658425A1567|63 67|dogs
P10657658A0165|169 193|ICAM-1 promoter activity
P10657658A0165|49 61|HA fragments
P10657658A0165|20 30|T-24 cells
P10657658A0165|9 16|studies
P10657658A0165|75 106|I kappa B alpha phosphorylation
P10656802A1724|31 62|cathepsin X amino acid sequence
P10656154A0722|17 18|%
P10656154A0722|37 40|PMS
P10655164A0546|84 96|Li abundance
P10655164A0546|141 143|Li
P10655164A0546|41 54|uncertainties
P10655164A0546|148 153|solm0
P10655164A0546|122 128|limits
P10653733A0596|57 65|peptides
P10653693A0903|85 95|KAP-1-RBCC
P10653693A0903|117 126|mutations
P10653693A0903|18 24|B2 box
P10653693A0903|5 16|RING finger
P10653693A0903|42 48|region
P10653550A1120|139 145|region
P10653550A1120|33 52|collagen remodeling
P10653359A1297|1 11|Scmh1 maps
P10653359A1297|15 23|4D1-D2.1
P10652362A0933|39 56|carboxyl terminus
P10652362A0933|228 236|vesicles
P10652362A0933|148 168|adaptor complex AP-2
P10652362A0933|60 64|CFTR
P10652228A0759|46 52|kinase
P10652228A0759|122 125|Dbl
P10652228A0759|15 25|activation
P10652093A0139|36 44|analyses
P10652093A0139|130 140|collection
P10651805A1600|71 97|mouse L1210 leukemia cells
P10651805A1600|8 20|transfection
P10651805A1600|146 156|leucovorin
P10651805A1600|109 128|folate accumulation
P10650958A1315|1 10|Element B
P10650958A1315|172 192|mobility shift assay
P10650958A1315|41 51|% homology
P10650939A0789|1 10|Induction
P10650939A0789|27 39|coexpression
P10650104X0284|1 10|Copyright
P10650104X0284|37 49|Radiologists
P10649456A1061|101 110|Frankfurt
P10649456A1061|76 88|stock centre
P10649456A1061|60 67|EUROFAN
P10648619A0000|168 171|Ala
P10648619A0000|308 310|SG
P10648619A0000|283 287|silk
P10648619A0000|78 95|TATA interactions
P10648619A0000|73 76|TBP
P10648619A0000|165 166|C
P10648619A0000|26 38|contribution
P10648619A0000|303 307|tRNA
P10648211A0000|10 30|signaling properties
P10648211A0000|74 85|combination
P10647859A0000|275 281|levels
P10647859A0000|136 145|diaphragm
P10647859A0000|99 103|IPPV
P10647859A0000|199 208|occasions
P10647859A0000|356 359|CO2
P10647859A0000|323 328|cmH2O
P10647859A0000|354 355|P
P10647859A0000|386 394|eucapnia
P10647859A0000|418 421|gas
P10647859A0000|120 128|activity
P10647633A1685|50 59|sphincter
P10647633A1685|5 10|study
P10647633A1685|110 116|stools
P10647633A1685|147 153|rectum
P10646863A0838|1 15|Overexpression
P10646863A0838|98 119|topoisomerase IIalpha
P10646863A0838|47 52|cells
P10645921A1320|137 138|P
P10645921A1320|191 192|P
P10645921A1320|53 54|P
P10645921A1320|63 73|odds ratio
P10645921A1320|120 122|SD
P10644760A0956|1 9|Analysis
P10644760A0956|24 31|domains
P10644753A0725|137 155|glycosaminoglycans
P10644753A0725|112 119|heparin
P10644753A0725|11 19|isoforms
P10644357A0935|139 142|VP2
P10644357A0935|67 74|nucleus
P10644357A0935|147 150|VP3
P10642889A0393|1 18|Sequence analysis
P10642889A0393|111 119|TATA box
P10642524A0156|17 28|interaction
P10642524A0156|141 144|TPR
P10642524A0156|66 67|N
P10642524A0156|162 169|regions
P10642524A0156|146 152|motifs
P10640701T0000|66 76|initiation
P10640701T0000|31 41|Engrailed2
P10640683A0204|1 13|NDRF/NeuroD2
P10640683A0204|39 42|PKN
P10640683A0204|52 58|lysate
P10640683A0204|62 73|COS-7 cells
P10638607A0000|187 190|SCC
P10638607A0000|32 39|results
P10638607A0000|99 108|treatment
P10638607A0000|112 120|patients
P10638607A0000|76 81|phase
P10637238A0291|1 47|Eastern Cooperative Oncology Group trial E3186
P10637149A0806|50 51|p
P10637149A0806|19 34|G-A anastomosis
P10637149A0806|48 49|E
P10637149A0806|56 66|loop areas
P10634007A0202|87 89|HD
P10634007A0202|23 45|acetaminophen overdose
P10634007A0202|73 85|hemodialysis
P10634007A0202|15 19|case
P10633075A1111|52 60|polymers
P10633075A1111|11 14|IgG
P10630471T0000|4 13|ASIC-chip
P10630471T0000|90 103|cell behavior
P10629176A0887|37 46|complexes
P10629176A0887|89 98|FBP1 gene
P10628971A1165|205 212|product
P10628971A1165|279 284|INP53
P10628971A1165|76 85|mutations
P10628971A1165|167 186|ribosome biogenesis
P10628971A1165|104 108|RIC1
P10628971A1165|188 192|LUV1
P10628971A1165|25 32|mutants
P10628971A1165|62 70|isolates
P10628755A0000|86 98|GH secretion
P10628755A0000|67 72|cycle
P10628755A0000|123 154|orphan GH-secretagogue receptor
P10628750A0298|32 36|APRE
P10628750A0298|189 201|x NF-kappaB1
P10628750A0298|42 50|cytokine
P10628750A0298|149 162|factor-kappaB
P10628748A0344|69 93|inhibin alpha expression
P10628748A0344|127 131|SF-1
P10628748A0344|28 40|cAMP pathway
P10627834A0178|101 105|G120
P10627834A0178|140 143|Rex
P10627834A0178|41 45|Vina
P10627834A0178|85 94|Esterhazy
P10627834A0178|154 159|Glory
P10627834A0178|145 151|Dublin
P10627834A0178|30 36|Tehama
P10627518A0544|103 116|contributions
P10627518A0544|41 52|cooperation
P10625683A0091|50 54|PTKs
P10625683A0091|64 79|phosphorylation
P10625683A0091|6 15|receptors
P10625683A0091|147 155|function
P10625438A1429|239 254|control samples
P10625438A1429|71 83|bp insertion
P10625438A1429|178 188|transcript
P10625438A1429|125 135|conditions
P10625438A1429|149 156|% level
P10623804A0808|136 150|decoy proteins
P10623804A0808|19 27|approach
P10623804A0808|99 103|SHIP
P10623804A0808|36 44|question
P10622576A0552|137 148|risk groups
P10622576A0552|113 122|attention
P10622576A0552|160 172|drug abusers
P10622576A0552|61 69|patients
P10620010A1155|16 20|Cdks
P10620010A1155|48 58|cell cycle
P10620010A1155|140 155|phosphorylation
P10620010A1155|176 182|T-loop
P10620010A1155|120 126|kinase
P10619254A1055|1 15|Animal studies
P10619254A1055|28 45|beam equalization
P10619062T0000|30 35|n. sp
P10617144A0386|35 40|Ser44
P10617144A0386|5 12|extents
P10617144A0386|120 121|%
P10616948A0998|35 39|dose
P10616948A0998|91 114|seizure threshold level
P10614676A0000|1 10|Objective
P10614676A0000|36 45|thickness
P10614676A0000|208 214|E+NETA
P10614676A0000|121 129|tibolone
P10614676A0000|134 136|mg
P10613863T0000|102 109|repeats
P10613863T0000|5 28|VirR response regulator
P10613816X0000|34 39|bones
P10613816X0000|16 22|lipids
P10613816X0000|175 179|bone
P10613816X0000|140 149|compounds
P10613816X0000|266 278|osteoporosis
P10613816X0000|244 257|bone diseases
P10612805A0716|21 31|alteration
P10612505A1317|170 171|%
P10612505A1317|19 24|error
P10612505A1317|38 43|study
P10612505A1317|163 164|%
P10612505A1317|12 16|type
P10611353A0458|223 225|kb
P10611353A0458|142 153|transcripts
P10611353A0458|129 135|retina
P10611353A0458|229 251|Northern blot analysis
P10611353A0458|63 75|mRNA samples
P10611242A0541|55 66|TBP binding
P10611242A0541|125 129|Spt8
P10611242A0541|104 108|SAGA
P10611228A1388|50 58|DAP5/p97
P10611228A1388|24 28|form
P10610716A1127|20 38|missense mutations
P10610716A1127|40 45|E138V
P10610716A1127|107 118|FD patients
P10608053A0923|1 13|Thrombolysis
P10608053A0923|232 238|groups
P10608053A0923|109 113|hour
P10608053A0923|185 186|p
P10608053A0923|52 69|platelet activity
P10608053A0923|215 219|p NS
P10608053A0923|150 155|Group
P10607899A0605|138 168|estrogen receptor binding site
P10607899A0605|110 114|CREB
P10607899A0605|26 41|promoter region
P10607899A0605|105 108|Sp1
P10606664A0000|117 122|roles
P10606664A0000|126 149|cell fate determination
P10606272A1241|1 10|Injection
P10606272A1241|157 165|metazoan
P10606272A1241|126 131|yeast
P10606272A1241|30 33|RNA
P10604945A0731|206 212|factor
P10604945A0731|172 187|promoter region
P10604945A0731|93 100|ethanol
P10604945A0731|106 112|others
P10604246A0523|139 158|AutoPBSC tubing set
P10604246A0523|64 74|collection
P10604246A0523|202 211|procedure
P10604246A0523|196 200|cell
P10604246A0523|78 83|PBPCs
P10604246A0523|119 126|version
P10604246A0523|251 259|patients
P10604246A0523|179 182|MNC
P10602838A0127|18 26|patients
P10602838A0127|31 38|females
P10602507A0652|16 24|increase
P10602507A0652|54 60|effect
P10602507A0652|42 45|p21
P10602507A0652|160 175|CSF-1 induction
P10602507A0652|28 37|cyclin D1
P10602419A1253|19 26|effects
P10601606A0152|97 98|h
P10601606A0152|121 131|degrees C.
P10601606A0152|105 114|degrees C
P10601344A1653|101 107|beta1A
P10601344A1653|143 153|GD25 cells
P10601344A1653|109 115|beta1D
P10601344A1653|87 97|expression
P10601344A1653|182 186|RhoA
P10601344A1653|61 68|GTPases
P10601290A0742|170 173|I1F
P10601290A0742|19 24|basis
P10601290A0742|43 65|cell surface stability
P10601290A0742|193 217|x-ray crystal structures
P10601290A0742|120 131|differences
P10600171A1432|64 73|3A23SiteA
P10600171A1432|113 153|bHLH/leucine zipper transcription factor
P10600171A1432|8 15|CYP3A23
P10599727A1567|51 56|girls
P10599727A1567|99 109|conformity
P10599727A1567|11 13|GH
P10598316A1534|1 4|GHB
P10598316A1534|8 10|CB
P10598101A0000|118 121|box
P10598101A0000|4 12|addition
P10598101A0000|128 151|kDa zein gene promoters
P10597232A0000|64 73|RET genes
P10597232A0000|5 27|RET/PTC3 rearrangement
P10597232A0000|41 47|fusion
P10597222A1371|53 61|molecule
P10597222A1371|28 31|p27
P10595315A0344|76 82|status
P10595315A0344|88 99|blood gases
P10594239T0000|83 87|Tih1
P10594239T0000|129 137|location
P10594239T0000|105 115|expression
P10594130A0652|16 22|hearts
P10594130A0652|48 55|infants
P10593939A0747|171 178|members
P10593939A0747|274 279|U-70K
P10593939A0747|250 261|Arabidopsis
P10593939A0747|180 185|SRZ21
P10593939A0747|91 103|SR33 protein
P10592791T0001|64 76|enterotoxins
P10592791T0001|15 31|immunoassay kits
P10591990A0178|114 117|PAS
P10591990A0178|93 97|SAPS
P10591990A0178|105 109|BPRS
P10591990A0178|15 21|DSM-IV
P10591933A0798|101 109|coracoid
P10591933A0798|180 188|distance
P10591933A0798|61 67|values
P10590368X0000|33 44|alternative
P10590368X0000|12 25|trachelectomy
P10590368X0000|192 207|stage carcinoma
P10590368X0000|87 107|stage IA-B carcinoma
P10590368X0000|248 262|survival rates
P10590368X0000|215 221|cervix
P10589711A1228|102 108|kidney
P10589711A1228|4 12|addition
P10589711A1228|214 220|milieu
P10589711A1228|120 125|cells
P10588946A0432|17 24|minimum
P10588946A0432|72 77|ORP-1
P10587461A0341|71 80|formation
P10587461A0341|115 119|site
P10587461A0341|30 38|contacts
P10586626A0607|139 147|patients
P10586626A0607|124 135|involvement
P10586626A0607|15 23|diseases
P10586107A0160|86 108|cell surface receptors
P10585808A0000|1 30|Mycoplasma hominis infections
P10585808A0000|92 101|detection
P10585480A0265|67 78|interaction
P10585463A0859|52 85|baculovirus-Sf9 expression system
P10585440A0204|103 106|arm
P10585440A0204|59 65|DFak56
P10585440A0204|44 57|FAK homologue
P10585311A1542|103 107|MPGN
P10585311A1542|96 100|type
P10584704A0913|221 229|sections
P10584704A0913|175 183|melanoma
P10584704A0913|200 205|block
P10584704A0913|62 67|cases
P10584704A0913|105 106|%
P10582831T0000|1 10|Syndromes
P10582831T0000|27 41|redistribution
P10580071A0436|52 56|list
P10580071A0436|61 76|transplantation
P10579331A1225|51 82|rat HDL receptor SR-BI promoter
P10579331A1225|5 12|results
P10579331A1225|22 29|studies
P10579331A1225|182 195|transcription
P10579331A1225|151 159|SREBP-1a
P10576545A0926|5 17|availability
P10576545A0926|132 142|expression
P10575642T0000|1 16|Skin pH changes
P10575231A0355|85 90|exons
P10575231A0355|97 104|introns
P10575231A0355|56 65|Cdc6 gene
P10574982A1075|55 63|factor-1
P10574982A1075|91 95|part
P10574913A1108|252 266|ERK activation
P10574913A1108|144 159|internalization
P10574913A1108|106 121|Src recruitment
P10572866A0481|70 80|phosphorus
P10572866A0481|59 68|potassium
P10572866A0481|8 17|hemolysis
P10572130A1623|138 142|role
P10572130A1623|7 14|results
P10572130A1623|95 103|subunits
P10572130A1623|107 121|RNA polymerase
P10571474A0571|54 61|atrophy
P10571474A0571|24 30|stress
P10570996A1213|34 44|TK domains
P10570996A1213|16 24|analysis
P10570996A1213|246 255|receptors
P10570996A1213|93 106|scavenger RTK
P10570996A1213|133 142|signature
P10568744A0728|136 140|role
P10568744A0728|80 85|genes
P10568744A0728|24 29|sites
P10568744A0728|46 55|promoters
P10568455A0000|175 177|CL
P10568455A0000|76 80|SRE2
P10568455A0000|160 173|corpora lutea
P10568455A0000|132 141|PGF2alpha
P10567589A1268|103 120|Pmt3p conjugation
P10567589A1268|27 32|Pmt3p
P10567581A0119|34 63|fork head homolog-11B protein
P10567581A0119|206 216|expression
P10567581A0119|65 72|HFH-11B
P10567581A0119|196 201|liver
P10567581A0119|149 175|head transcription factors
P10567581A0119|28 33|HNF-3
P10567533A0818|113 119|motifs
P10567533A0818|9 22|transcription
P10567533A0818|78 85|primers
P10567430A0785|171 177|Galpha
P10567430A0785|199 209|constructs
P10567430A0785|12 19|studies
P10567430A0785|132 138|Galpha
P10567430A0785|153 154|s
P10567430A0785|157 163|Galpha
P10567430A0785|213 217|GRK5
P10567430A0785|121 128|binding
P10566630A0371|1 6|Serum
P10566630A0371|37 42|IGF-I
P10566630A0371|165 171|months
P10566630A0371|44 52|SD score
P10564593A1618|49 56|absence
P10564593A1618|24 40|half-transporter
P10564593A1618|109 116|regions
P10564593A1618|72 80|evidence
P10564495A0444|138 141|CEA
P10564495A0444|233 238|CD66c
P10564495A0444|143 148|CD66e
P10564495A0444|40 44|C751
P10564495A0444|198 205|tropism
P10564495A0444|251 256|cells
P10564495A0444|24 36|Opa proteins
P10564495A0444|210 214|CGM1
P10564479A0384|136 143|formate
P10564479A0384|55 59|FdsR
P10564479A0384|178 185|formate
P10564479A0384|167 174|absence
P10564479A0384|13 17|fdsR
P10564479A0384|45 51|effect
P10564472A0853|77 83|system
P10564231A0315|1 12|N. van Hoek
P10563789A1951|4 12|addition
P10563789A1951|92 94|CG
P10563789A1951|14 19|media
P10563212A0514|25 44|SF-36 questionnaire
P10562456T0000|118 125|walbaum
P10562456T0000|83 96|rainbow trout
P10562456T0000|46 52|intron
P10562456T0000|60 79|growth hormone gene
P10561546A0000|42 49|protein
P10561546A0000|91 99|antibody
P10561251A0000|1 8|PURPOSE
P10561251A0000|39 47|survival
P10561251A0000|76 78|OS
P10561251A0000|286 311|stem-cell transplantation
P10561251A0000|49 52|DFS
P10561251A0000|92 99|factors
P10561251A0000|264 268|HDCT
P10561251A0000|123 132|mortality
P10561095A2141|50 55|group
P10561095A2141|10 21|reoperation
P10561095A2141|132 141|incidence
P10560014A0000|109 115|system
P10560014A0000|73 90|angioarchitecture
P10559324A0716|129 131|Ad
P10559324A0716|73 82|rat cells
P10559303A0000|33 49|membrane protein
P10559303A0000|21 24|EBV
P10559303A0000|89 103|transformation
P10557308A0000|50 57|protein
P10557308A0000|71 84|RAS signaling
P10557308A0000|28 31|CNK
P10557072A0418|1 5|ULKs
P10557072A0418|71 84|kinase domain
P10557072A0418|156 162|domain
P10557072A0418|10 16|UNC-51
P10557008T0000|1 10|Detection
P10557008T0000|72 77|child
P10557008T0000|14 23|poisoning
P10556595A0391|71 83|transversion
P10556595A0391|114 120|region
P10556595A0391|96 99|end
P10556595A0391|62 63|C
P10556145A1034|1 11|Gentamicin
P10556145A1034|81 82|p
P10556145A1034|106 111|order
P10556145A1034|61 79|sputum Psa density
P10556063A0092|56 69|Trk subfamily
P10556044A0913|1 8|Binding
P10556044A0913|12 23|sulphatides
P10556029A0852|1 14|WA constructs
P10556029A0852|117 127|precursors
P10556029A0852|62 82|cyclization kinetics
P10555964A0778|1 3|S.
P10555964A0778|10 12|S.
P10555079A0254|29 39|morphology
P10553959A0812|28 33|range
P10552357A1936|17 25|addition
P10552357A1936|252 264|echogenicity
P10552357A1936|117 133|LV opacification
P10552357A1936|236 243|effects
P10552357A1936|270 273|AIR
P10552357A1936|73 85|microspheres
P10551867A0350|84 99|splice variants
P10551867A0350|54 74|9-kilobase pair mRNA
P10551816A0162|7 13|LTBP-1
P10551788A0229|34 51|gonadotrope cells
P10551788A0229|56 62|CGbeta
P10550571A0000|1 8|PURPOSE
P10550571A0000|49 56|studies
P10550571A0000|168 175|WR-2721
P10550571A0000|157 164|effects
P10550571A0000|73 86|plasma levels
P10549912A0136|239 247|branches
P10549912A0136|155 159|lead
P10549912A0136|6 12|report
P10549912A0136|163 180|segment elevation
P10549912A0136|300 306|artery
P10549912A0136|75 85|infarction
P10549354A1782|3 13|proportion
P10549354A1782|131 137|result
P10549354A1782|224 238|downregulation
P10549354A1782|262 276|Axin/Conductin
P10549354A1782|247 256|GSK3 beta
P10549354A1782|31 47|colon carcinomas
P10549354A1782|181 193|beta-catenin
P10548622A0906|32 37|block
P10548622A0906|203 208|TUGOR
P10548622A0906|182 201|ultrasound guidance
P10548622A0906|72 83|conjunction
P10548622A0906|120 134|egg collection
P10545281A0836|93 106|coding region
P10545281A0836|46 72|purification tag sequences
P10545281A0836|14 26|introduction
P10545192T0000|138 159|agent vanadyl sulfate
P10545192T0000|97 114|signaling cascade
P10545192T0000|92 95|s6k
P10545192T0000|88 91|p70
P10544089A1208|98 115|hairpin structure
P10544089A1208|203 205|U1
P10544089A1208|163 165|MP
P10544089A1208|74 79|crTMV
P10544089A1208|185 188|UTR
P10544089A1208|246 253|MP gene
P10544089A1208|215 218|UTR
P10544089A1208|63 69|TMV U1
P10544037A0617|137 142|FZD10
P10544037A0617|32 37|FZD10
P10544037A0617|107 111|FZD4
P10544037A0617|51 70|amino acid identity
P10544037A0617|115 120|FZD10
P10544037A0617|126 127|%
P10544037A0617|148 149|%
P10543730A0000|18 37|cyclin Ume3p/Srb11p
P10543730A0000|163 170|meiosis
P10543730A0000|76 81|Ume5p
P10543730A0000|63 69|kinase
P10543727A0282|100 112|binding site
P10543727A0282|66 73|example
P10543727A0282|172 177|H2TF1
P10543727A0282|230 245|kappaB2 element
P10543727A0282|117 152|rel/NF-kappaB transcription factors
P10543727A0282|429 436|EnA-TRE
P10543727A0282|296 309|H2TF1 element
P10543727A0282|384 388|AP-1
P10543727A0282|181 196|kappaB1 element
P10542281A2021|5 12|results
P10542281A2021|42 49|absence
P10542281A2021|151 156|sites
P10542281A2021|30 38|presence
P10542277A0000|64 72|proteins
P10542277A0000|20 36|beta heterodimer
P10542269A0000|1 21|Amyloid beta-protein
P10542269A0000|217 220|APP
P10542269A0000|142 144|AD
P10542269A0000|42 53|constituent
P10542269A0000|133 140|disease
P10542269A0000|121 130|Alzheimer
P10542249A0415|1 19|Albumin expression
P10542249A0415|159 168|C/EBPbeta
P10542249A0415|82 103|transcription factors
P10542249A0415|41 46|liver
P10542249A0415|134 141|protein
P10541865A1301|50 56|CDKN2B
P10541865A1301|39 45|CDKN2A
P10541865A1301|149 155|tumors
P10541432A0185|117 129|Shc proteins
P10541432A0185|65 68|EGF
P10541432A0185|247 266|ERK MAPK activities
P10541432A0185|183 202|ERK MAPK activities
P10540553A0980|154 161|ability
P10540553A0980|98 106|activity
P10540553A0980|129 132|DNA
P10540553A0980|24 27|PNA
P10540553A0980|166 179|proliferation
P10540015A0664|85 106|stimulation intensity
P10540015A0664|1 14|C-SP duration
P10540015A0664|127 140|MEP threshold
P10536369A1280|38 48|mechanisms
P10536369A1280|63 71|response
P10536125A0093|119 148|influenzavirus neuraminidases
P10536125A0093|64 71|prodrug
P10536125A0093|14 20|GS4104
P10534691A0542|171 180|infection
P10534691A0542|49 55|grafts
P10534691A0542|159 167|evidence
P10534691A0542|144 154|procedures
P10534402A0126|16 20|cDNA
P10534402A0126|156 169|Spo11p family
P10534402A0126|65 72|protein
P10534402A0126|123 130|domains
P10533066A1197|25 38|abnormalities
P10533066A1197|72 90|missense mutations
P10533066A1197|104 108|TSC2
P10532805A1084|141 151|nrg-1 mRNA
P10532805A1084|44 69|protein kinase A activity
P10532354A1374|68 79|epsilon-COP
P10532354A1374|115 126|ER membrane
P10532354A1374|5 12|results
P10532354A1374|196 206|alteration
P10532354A1374|161 186|protein transport pathway
P10532354A1374|26 31|Anu2p
P10531360A0958|34 39|cells
P10531360A0958|157 164|hypoxia
P10531360A0958|106 115|induction
P10531342A0348|103 111|homology
P10531342A0348|16 22|domain
P10531342A0348|157 174|psa2/gp46 complex
P10531334A0525|4 10|assays
P10531334A0525|110 124|protein kinase
P10531334A0525|126 129|cGK
P10531334A0525|131 135|type
P10528035A1102|54 91|serum alanine aminotransferase levels
P10528035A1102|37 50|normalization
P10527426A0521|17 37|SBEI gene transcript
P10527426A0521|5 9|form
P10527426A0521|52 59|kernels
P10527426A0521|110 113|end
P10527426A0521|147 156|inclusion
P10527426A0521|74 99|exon I+II+III combination
P10527158T0000|24 52|generation staging container
P10527158T0000|79 97|USDOE Pantex Plant
P10526670A1828|21 32|ICE/caspase
P10526670A1828|162 173|suppression
P10526670A1828|94 103|apoptosis
P10525413A1408|70 74|LIM2
P10525413A1408|5 22|backbone dynamics
P10525413A1408|57 61|part
P10525413A1408|75 80|R122A
P10524258A0286|53 58|cek-1
P10524258A0286|78 86|cultures
P10524258A0286|90 109|immunocytochemistry
P10523663A0404|98 103|group
P10523663A0404|132 142|modulators
P10523647A0000|49 56|protein
P10523647A0000|5 30|transcription factor CHOP
P10523647A0000|92 99|variety
P10523647A0000|215 225|cell death
P10523634A1404|85 99|Cbf5p proteins
P10523634A1404|174 180|domain
P10523634A1404|203 214|interaction
P10523634A1404|13 22|mutations
P10523319A0209|70 77|domains
P10523319A0209|31 36|Rat7p
P10521544T0000|129 141|biosynthesis
P10521544T0000|77 88|Man9GlcNAc2
P10521544T0000|44 65|alpha 1,2-mannosidase
P10521450A0437|37 40|Syk
P10521450A0437|13 27|Akt activation
P10521450A0437|75 82|B cells
P10521447A0606|102 109|members
P10521447A0606|5 11|factor
P10521447A0606|77 87|core motif
P10521345A0202|69 92|sea surface temperature
P10521345A0202|33 47|Laurentian Fan
P10521345A0202|140 151|Gulf Stream
P10521345A0202|276 282|system
P10521345A0202|244 250|notion
P10518956A1212|1 9|ESS type
P10518956A1212|18 21|FT3
P10518956A1212|30 33|FT4
P10518937A0572|50 70|phosphate starvation
P10518937A0572|5 24|expression analysis
P10518937A0572|198 201|way
P10518937A0572|79 93|adenine supply
P10518937A0572|105 112|factors
P10518561A0885|56 58|PH
P10518561A0885|63 74|SH2 domains
P10518561A0885|30 35|BRDG1
P10518502T0000|1 6|nos-1
P10518502T0000|22 27|genes
P10518502T0000|11 16|nos-2
P10517675A0809|64 84|p21WAF1/CIP1 protein
P10517675A0809|176 183|p27kip1
P10517675A0809|151 174|kinase inhibitor family
P10517666A1069|38 40|GR
P10517666A1069|93 101|elements
P10517666A1069|15 28|binding sites
P10516738A0925|8 19|time-points
P10516738A0925|26 34|patients
P10516026A0270|26 32|clones
P10514808T0000|22 30|genetics
P10513922A1237|168 169|p
P10513922A1237|5 10|study
P10513922A1237|160 166|groups
P10513922A1237|106 117|repair site
P10512882A0137|1 9|Assembly
P10512882A0137|161 168|kinases
P10512882A0137|89 101|localization
P10512882A0137|31 34|FAK
P10512882A0137|15 22|complex
P10512699T0000|152 166|SECIS elements
P10512699T0000|108 120|gene fusions
P10512699T0000|12 22|expression
P10512699T0000|194 198|selA
P10511554T0000|42 58|polymorphism map
P10510379A0105|84 95|DNA element
P10510379A0105|40 47|process
P10509768A1118|34 46|acids intake
P10509768A1118|5 14|reduction
P10509768A1118|95 101|mmol/l
P10509768A1118|106 107|%
P10505694A0739|1 17|IL-12 production
P10505694A0739|82 94|hemodialyzer
P10505694A0739|131 132|P
P10505694A0739|121 122|r
P10504332A0701|1 23|Immunofluoresence data
P10504332A0701|141 148|pathway
P10504332A0701|248 255|markers
P10504332A0701|162 167|cells
P10504332A0701|193 201|receptor
P10503540A0602|48 64|banding patterns
P10503540A0602|125 144|polyacrylamide gels
P10503540A0602|73 74|%
P10502434A0604|21 31|stage IBG3
P10502434A0604|8 16|patients
P10502402A0533|137 160|T lymphocyte activation
P10502402A0533|65 93|signal transduction pathways
P10502402A0533|106 126|TRAIL gene induction
P10502216A0289|113 141|tissue plasminogen activator
P10502216A0289|67 80|streptokinase
P10502216A0289|40 48|efficacy
P10502216A0289|88 95|heparin
P10501965A0879|102 106|Rsk3
P10501965A0879|190 199|G-protein
P10501965A0879|9 14|genes
P10501965A0879|148 153|genes
P10501965A0879|74 77|end
P10501656A1415|95 111|tumor cell lines
P10499357A0439|1 13|SCOB testing
P10499357A0439|33 40|animals
P10499357A0439|96 104|schedule
P10499357A0439|72 74|FR
P10499357A0439|194 198|data
P10499357A0439|82 90|interval
P10499357A0439|92 94|FI
P10499357A0439|180 188|behavior
P10498717A1048|35 39|RsmC
P10498717A1048|61 79|rsmB transcription
P10498616A1280|154 169|signaling paths
P10498616A1280|23 45|Caenorhabditis elegans
P10498616A1280|128 138|activation
P10498616A1280|11 16|M-Ras
P10497874A0925|20 41|phosphatidyl inositol
P10497874A0925|112 128|tyrosine residue
P10497874A0925|46 58|bisphosphate
P10497874A0925|60 64|PIP2
P10497262A0000|65 73|U5 snRNA
P10497262A0000|163 175|cDNA cloning
P10497262A0000|45 50|trans
P10497117A0358|100 103|ORF
P10497117A0358|46 55|V protein
P10496388A1956b|68 72|dose
P10496388A1956b|80 85|J/cm2
P10496388A1956b|104 110|events
P10496303A1968|81 90|exposures
P10496303A1968|54 68|valganciclovir
P10496303A1968|172 177|mg/kg
P10496303A1968|107 112|AUC24
P10496161A0503|115 118|WPI
P10496161A0503|97 101|rats
P10496161A0503|46 47|%
P10493876A0000|64 71|bonding
P10493876A0000|612 623|combination
P10493876A0000|196 197|g
P10493876A0000|79 91|fjord region
P10493876A0000|221 222|g
P10493876A0000|325 328|dA6
P10493876A0000|219 220|B
P10493876A0000|575 586|information
P10493876A0000|639 647|dynamics
P10493876A0000|31 37|adduct
P10493876A0000|653 665|calculations
P10493876A0000|102 105|12R
P10493876A0000|306 316|trans-anti
P10493876A0000|512 513|B
P10493876A0000|97 100|11S
P10493876A0000|161 169|epoxy-11
P10493876A0000|522 524|dT
P10493876A0000|532 538|duplex
P10493876A0000|117 129|stereoisomer
P10493876A0000|353 373|thymine residue dT17
P10493876A0000|112 115|14S
P10493876A0000|600 608|NMR data
P10493876A0000|420 421|B
P10493575T0000|139 145|domain
P10493575T0000|92 99|peptide
P10493575T0000|41 44|Ca2
P10493575T0000|12 19|changes
P10492169A0939|156 163|EST-YD1
P10492169A0939|53 57|ESTs
P10492169A0939|112 118|PAPP-A
P10492169A0939|132 136|gene
P10491213A0263|71 82|osteocalcin
P10491213A0263|203 215|measurements
P10491213A0263|400 406|femurs
P10491213A0263|84 100|bone Gla protein
P10491213A0263|325 334|vertebrae
P10491213A0263|270 276|femurs
P10491213A0263|149 166|deoxypyridinoline
P10491213A0263|102 105|BGP
P10491213A0263|443 448|girls
P10491213A0263|39 59|alkaline phosphatase
P10491213A0263|187 197|tomography
P10491213A0263|116 122|levels
P10491213A0263|359 375|material density
P10491213A0263|126 138|pyridinoline
P10491133A0365|69 79|reactivity
P10491133A0365|100 110|NO species
P10491133A0365|123 132|NO donors
P10490843A0159|16 37|POZ/Zn finger protein
P10490843A0159|100 110|regulators
P10490843A0159|126 133|protein
P10490843A0159|180 184|PLZF
P10490826T0000|113 116|ALL
P10490826T0000|9 49|tyrosine kinase signal transduction gene
P10490826T0000|132 152|oncoprotein E2a-Pbx1
P10490816A0000|18 26|RET gene
P10490816A0000|133 139|MEN 2B
P10490662A0431|1 8|Mutants
P10490662A0431|97 107|appendages
P10490662A0431|109 121|compound eye
P10490609A0413|221 233|ARS activity
P10490609A0413|18 24|region
P10490609A0413|96 103|repeats
P10490609A0413|76 84|sequence
P10490609A0413|179 186|guanine
P10490609A0413|133 141|adenines
P10490065T0000|54 61|therapy
P10490065T0000|31 35|role
P10489680A0927|17 20|MPO
P10489680A0927|96 97|P
P10489680A0927|56 59|BPT
P10488337T0000|66 77|DNA binding
P10488337T0000|111 124|bZIP proteins
P10488148A1267|114 118|AP-1
P10488148A1267|53 57|AP-1
P10488148A1267|198 207|HIV-1 LTR
P10488148A1267|28 32|MAPK
P10488147A1176|1 15|Identification
P10488147A1176|86 108|eosinophil trafficking
P10488147A1176|144 153|phenomena
P10488088T0000|116 123|protein
P10488088T0000|65 85|transcription factor
P10487953A0765|5 13|patients
P10487953A0765|130 139|operation
P10487953A0765|90 99|specimens
P10487762A0252|1 5|NuA4
P10487762A0252|44 47|MDa
P10487759A0630|141 146|Xbra2
P10487759A0630|163 176|reporter gene
P10487759A0630|125 135|expression
P10487744T0000|18 32|sorting signal
P10487744T0000|67 73|domain
P10487744T0000|104 119|plasma membrane
P10487217A0735|116 127|amino acids
P10487217A0735|29 39|preprotein
P10487217A0735|135 145|N-terminus
P10486210A0126|54 77|aldehyde reductase gene
P10486210A0126|14 24|regulation
P10485470A0242|51 58|factors
P10485470A0242|190 203|TSA treatment
P10485470A0242|9 14|study
P10485470A0242|91 113|p21/WAF1/Cip1 promoter
P10485470A0242|30 33|Sp1
P10484818A0292|41 46|means
P10483945A0641|102 104|5x
P10483945A0641|84 88|3-5x
P10483945A0641|1 8|RESULTS
P10483945A0641|95 96|%
P10483945A0641|123 131|patients
P10483945A0641|60 61|%
P10482620A1009|185 198|transcription
P10482620A1009|65 68|LTR
P10482620A1009|57 61|MMTV
P10482620A1009|104 110|Stat5a
P10482516T0000|108 142|Bacillus subtilis trpEDCFBA operon
P10482516T0000|90 100|expression
P10480937A0000|85 93|DAKAP200
P10480937A0000|200 214|diacylglycerol
P10480937A0000|231 233|E.
P10480937A0000|9 43|Drosophila A kinase anchor protein
P10480937A0000|182 186|cAMP
P10479382A1098|18 25|results
P10479382A1098|131 138|fitness
P10479382A1098|57 61|time
P10479382A1098|29 34|terms
P10478848A0331|1 5|SF-1
P10478275A1230|190 200|technology
P10478275A1230|67 77|mechanisms
P10478275A1230|43 49|number
P10478275A1230|107 111|diet
P10477620A0580|51 55|RelA
P10477620A0580|64 77|translocation
P10477620A0580|197 215|curcumin treatment
P10477620A0580|108 124|I kappa B serine
P10477620A0580|167 170|IKK
P10477597A0126|1 6|TRAF2
P10477597A0126|19 28|activator
P10477597A0126|130 134|KHS1
P10477597A0126|104 108|GCKR
P10477583A0000a|19 37|B cell Ag receptor
P10477583A0000a|39 42|BCR
P10477583A0000a|123 132|mechanism
P10477583A0000a|72 75|IgG
P10476970A0542|141 147|family
P10476970A0542|114 128|alpha-subunits
P10476970A0542|27 34|isoform
P10476970A0542|61 68|protein
P10473623A0081|184 187|ARF
P10473623A0081|10 25|Xenopus embryos
P10473623A0081|44 77|growth factor-beta member activin
P10473623A0081|90 100|gene Mix.2
P10473589A0189|48 53|alpha
P10473589A0189|96 106|C terminus
P10473589A0189|63 79|integrase domain
P10472314A0717|69 74|women
P10472314A0717|32 36|PUNP
P10472314A0717|25 28|TTP
P10471743A0000|3 7|cDNA
P10471743A0000|28 31|RNA
P10471696A0734|17 21|SAS4
P10471696A0734|82 96|HMR-E silencer
P10471696A0734|109 113|role
P10471696A0734|26 30|SAS5
P10471696A0734|44 48|role
P10469656T0000|101 120|MAP kinase cascades
P10469656T0000|58 72|gene induction
P10469656T0000|122 126|MSK1
P10469140A0336|20 28|function
P10469140A0336|97 105|promoter
P10469140A0336|110 124|responsiveness
P10469140A0336|61 66|sites
P10468033T0000|83 91|solvents
P10467403A0000|5 37|Trk/Nerve Growth Factor receptor
P10467403A0000|97 115|signaling proteins
P10467403A0000|57 67|activation
P10467004A0116|33 44|nucleotides
P10467004A0116|114 129|sequence motifs
P10467004A0116|82 91|structure
P10466306A0000|65 74|technique
P10466306A0000|22 52|Technetium-99m sestamibi SPECT
P10464302A1109b|258 278|growth factor signal
P10464302A1109b|50 54|p185
P10464302A1109b|5 16|recruitment
P10464302A1109b|199 207|assembly
P10464302A1109b|286 298|cytoskeleton
P10464302A1109b|225 232|pathway
P10463242A0316|51 57|region
P10463242A0316|25 30|waves
P10460172A0823|1 23|Velocity sedimentation
P10460172A0823|25 38|cross-linking
P10460172A0823|44 72|immunoprecipitation analyses
P10460015A0465|50 58|estrogen
P10460015A0465|80 86|weight
P10460015A0465|142 150|bone age
P10460015A0465|94 105|improvement
P10458914A0674|17 32|mouse STAP gene
P10458914A0674|1 9|Analysis
P10458914A0674|59 66|library
P10458905A0000|70 90|YAC/BAC clone contig
P10458905A0000|15 27|construction
P10455189A0427|52 56|HEF1
P10455189A0427|72 76|time
P10455183A0930|117 128|determinant
P10455183A0930|21 28|results
P10455183A0930|209 223|U6 snRNA genes
P10455183A0930|181 193|Xenopus tRNA
P10455143T0000|39 47|fragment
P10454570A0846|275 284|induction
P10454570A0846|100 118|protein kinase-Jun
P10454570A0846|203 207|JunD
P10454570A0846|130 147|kinase activation
P10454570A0846|166 181|phosphorylation
P10454570A0846|346 362|ERK-2 activation
P10454570A0846|185 190|ATF-2
P10454570A0846|417 428|stimulation
P10454561A0594|16 21|study
P10454561A0594|81 125|phorbol myristate acetate-phytohemagglutinin
P10454561A0594|276 289|sequestration
P10454561A0594|43 53|expression
P10454561A0594|57 72|TD-IkappaBalpha
P10454561A0594|211 241|NF-kappaB DNA binding activity
P10454557A0000|49 60|replicators
P10454557A0000|190 194|ARSs
P10454557A0000|247 274|replication origin activity
P10454557A0000|125 133|sequence
P10454557A0000|135 138|ARS
P10454540A0392|5 29|amino acid changes D206A
P10454540A0392|61 72|combination
P10453721A0445|58 88|parameter estimation algorithm
P10453721A0445|11 28|sampling strategy
P10453248A0094|147 156|behaviour
P10453248A0094|12 16|Udry
P10453006A0000|201 214|beta subunits
P10453006A0000|108 123|clone fragments
P10453006A0000|15 24|zebrafish
P10453006A0000|185 189|loci
P10453006A0000|218 229|proteasomes
P10453006A0000|89 99|chromosome
P10452951A0000|116 123|species
P10452951A0000|54 75|transcription factors
P10452951A0000|28 31|NRs
P10451209A0000|102 106|dogs
P10451209A0000|1 10|OBJECTIVE
P10451209A0000|80 90|hemorrhage
P10451209A0000|134 169|methylprednisolone sodium succinate
P10449899A0881|60 69|PERV copy
P10448902A0921|70 90|superoxide dismutase
P10448902A0921|33 41|catalase
P10448902A0921|43 65|glutathione peroxidase
P10448285A1035|65 70|phase
P10448285A1035|26 34|response
P10448285A1035|12 21|durations
P10448285A1035|74 79|trial
P10448036A0748|204 212|affinity
P10448036A0748|237 244|protein
P10448036A0748|20 25|zf4-6
P10448036A0748|128 133|zf4-7
P10448036A0748|90 114|competitor concentration
P10447593A0144|85 103|specificity factor
P10447593A0144|138 151|sigma factors
P10447593A0144|110 122|similarities
P10447593A0144|62 64|T7
P10446998A0955|274 286|protein SP-1
P10446998A0955|231 258|DNA binding characteristics
P10446998A0955|109 117|junB SRE
P10446998A0955|167 181|mobility shift
P10446998A0955|90 93|SRF
P10446912A0883|141 144|Sp3
P10446912A0883|64 67|OF3
P10446912A0883|8 14|course
P10446912A0883|56 59|OF5
P10446912A0883|133 136|Sp1
P10446833T0000|34 42|shunting
P10446833T0000|57 62|shock
P10446149A0809|101 106|A-Raf
P10446149A0809|159 163|Rin1
P10446149A0809|92 99|c-Raf-1
P10446149A0809|147 153|RalGDS
P10446149A0809|30 35|yeast
P10445161A1565|50 55|study
P10445161A1565|191 194|ppm
P10445161A1565|128 132|rats
P10445161A1565|148 168|organ weight changes
P10444597A0586|136 141|Npl3p
P10444597A0586|169 176|nucleus
P10444597A0586|39 45|stress
P10444597A0586|112 123|mRNA export
P10444597A0586|75 82|ethanol
P10442493A0815|4 12|baseline
P10442493A0815|43 47|FLOP
P10442493A0815|73 83|serum FLOP
P10442493A0815|30 38|lycopene
P10441483A0454|1 23|Oligonucleotide probes
P10441483A0454|62 76|EpRE sequences
P10441243A0443|99 107|subjects
P10441243A0443|22 43|leptin concentrations
P10439040A0658|96 99|UTR
P10439040A0658|123 136|CAT reporters
P10439040A0658|88 94|region
P10438941A1197|139 144|genes
P10438941A1197|65 77|T cell lines
P10438941A1197|59 60|B
P10438924A1009|23 28|cells
P10438924A1009|30 33|Akt
P10438607A0330|21 26|SEBP2
P10438607A0330|14 19|SEBPs
P10438540A1185|103 121|transport activity
P10438540A1185|129 136|protein
P10438540A1185|61 63|Cd
P10436016A0337|1 15|Gel filtration
P10436016A0337|20 51|co-immunoprecipitation analyses
P10433970A0279|119 141|transactivation domain
P10433970A0279|1 7|Spfkh1
P10433970A0279|95 114|localization signal
P10430980A0465|15 18|men
P10430890A1059|7 16|elongin C
P10430890A1059|91 105|rearrangements
P10430883A0000|340 371|horseradish peroxidase reaction
P10430883A0000|42 47|gland
P10430883A0000|166 176|metaplasia
P10430883A0000|119 124|tract
P10430883A0000|55 60|cells
P10430883A0000|23 28|cells
P10430883A0000|299 327|sodium borohydride reduction
P10430883A0000|209 214|class
P10430883A0000|90 96|glands
P10430580A0000|33 37|DSBs
P10430580A0000|127 132|yeast
P10430580A0000|88 92|NHEJ
P10429946A0988|85 102|complex formation
P10429946A0988|14 22|addition
P10429740A0000|6 12|review
P10429740A0000|88 102|bowel syndrome
P10428862A0834|1 32|Immunoprecipitation experiments
P10428862A0834|53 63|antibodies
P10428862A0834|126 133|protein
P10428811A0628|1 6|Cat-1
P10428811A0628|155 163|activity
P10428811A0628|47 62|binding partner
P10428294A0227|85 90|years
P10428294A0227|113 118|women
P10428294A0227|105 108|men
P10427654A0000|70 81|laparoscopy
P10427654A0000|190 196|cancer
P10427654A0000|6 11|study
P10427654A0000|40 44|role
P10427654A0000|224 231|surgery
P10426450A1458|35 47|liver/spleen
P10426450A1458|99 113|contact chicks
P10426450A1458|127 130|ILK
P10426450A1458|72 86|contact poults
P10426450A1458|91 93|SG
P10425094A1006|32 39|complex
P10425094A1006|14 24|relaxivity
P10423193A1309|19 26|results
P10423193A1309|141 144|CTS
P10422468A0524|102 106|risk
P10422468A0524|169 173|rate
P10422468A0524|196 210|microdeletions
P10422468A0524|14 18|risk
P10422468A0524|152 155|NOA
P10422468A0524|218 230|Y chromosome
P10422468A0524|127 140|abnormalities
P10422468A0524|58 62|ICSI
P10422291A0572|16 26|IgA lambda
P10422291A0572|36 43|myeloma
P10419006A0378|39 67|estrogen replacement therapy
P10419006A0378|74 83|menopause
P10417331A1008|51 62|mM pantoate
P10417331A1008|5 11|enzyme
P10417331A1008|76 77|s
P10417331A1008|90 92|pH
P10416429A0221|33 38|women
P10416429A0221|99 105|number
P10416429A0221|59 64|years
P10416429A0221|72 88|NSW PKU database
P10416429A0221|44 47|PKU
P10413676A1193|34 38|FRNK
P10413676A1193|57 71|point mutation
P10413676A1193|106 123|FRNK localization
P10413676A0000|1 4|FAK
P10413676A0000|18 23|sites
P10413607A0085|171 181|cell types
P10413607A0085|34 42|contrast
P10413607A0085|66 82|matrix molecules
P10413607A0085|134 147|DNA synthesis
P10411160T0000|56 77|skin cancer incidence
P10411139A1344|98 104|Prp44p
P10411139A1344|125 136|U4/U6 helix
P10411139A1344|63 70|results
P10409755A1846|4 11|summary
P10409755A1846|67 76|apoptosis
P10409755A1846|44 57|NO production
P10409741A0382|70 77|cdc4-16
P10409741A0382|42 46|CDC4
P10409741A0382|57 64|cdc4-11
P10409741A0382|31 38|alleles
P10409724A1021|41 50|induction
P10409724A1021|15 21|ERK1/2
P10409656A1016|1 15|Overexpression
P10409656A1016|140 144|part
P10409656A1016|89 100|growth rate
P10409656A1016|183 186|LPS
P10409656A1016|132 136|H411
P10407269A0000b|82 85|arm
P10407269A0000b|8 10|bp
P10407269A0000b|63 68|cdc14
P10407269A0000b|151 165|European Union
P10407184A0520|229 232|URE
P10407184A0520|286 292|rhesus
P10407184A0520|135 144|phbetaE-B
P10407184A0520|187 202|promoter region
P10407184A0520|184 185|h
P10407184A0520|260 267|plasmid
P10407184A0520|125 128|CAT
P10407184A0520|89 123|chloramphenicol acetyl transferase
P10407184A0520|363 380|hbetaAPP promoter
P10406954A0715|1 25|Chemical stability tests
P10406954A0715|146 154|residues
P10406954A0715|88 91|D63
P10406954A0715|44 55|mutagenesis
P10406466A0000|87 100|acid receptor
P10406466A0000|52 76|thyroid hormone receptor
P10406464A0687|4 12|contrast
P10406464A0687|59 68|component
P10406464A0687|135 153|vitamin D receptor
P10406464A0687|90 97|TRAP220
P10406459A0000|117 126|forskolin
P10406459A0000|236 244|kinetics
P10406459A0000|64 68|PDGF
P10406459A0000|173 180|protein
P10406459A0000|182 205|Ser-133 phosphorylation
P10406459A0000|135 139|CREB
P10406047A1244|71 79|capacity
P10406047A1244|36 47|differences
P10406047A1244|286 290|PFTs
P10406047A1244|194 205|ILD infants
P10406047A1244|357 366|age group
P10406047A1244|93 99|weight
P10406047A1244|145 151|system
P10403839A1459|1 11|Comparison
P10403839A1459|21 42|bHLH/PAS family genes
P10403839A1459|131 135|mAhr
P10403839A1459|243 247|gene
P10403839A1459|61 87|intron/exon splice pattern
P10403690A0000|475 486|vinblastine
P10403690A0000|276 287|IEP regimen
P10403690A0000|468 471|day
P10403690A0000|221 224|BSC
P10403690A0000|456 461|mg/m2
P10403690A0000|386 391|mg/m2
P10403690A0000|29 34|study
P10403690A0000|373 382|cisplatin
P10403690A0000|98 108|stage IIIb
P10403690A0000|40 48|patients
P10403690A0000|316 335|mesna uroprotection
P10403690A0000|489 494|mg/m2
P10403690A0000|421 432|mitomycin-C
P10403690A0000|302 307|gm/m2
P10403690A0000|363 366|day
P10402467T0000|1 7|Myosin
P10402467T0000|98 109|plasminogen
P10402467T0000|131 136|cells
P10400794T0000|103 115|similarities
P10400794T0000|169 174|virus
P10400794T0000|67 78|herpesvirus
P10400794T0000|29 33|gene
P10400794T0000|90 97|protein
P10400757A1498|186 193|domains
P10400757A1498|238 252|fusion process
P10400757A1498|99 112|HIV-1 strains
P10400757A1498|7 11|data
P10400757A1498|63 75|requirements
P10400712A0577|136 146|SV5 genome
P10400712A0577|33 35|GE
P10400712A0577|197 209|GS sequences
P10400712A0577|111 116|cDNAs
P10400712A0577|160 183|gene junction sequences
P10400712A0577|316 337|counterpart sequences
P10400712A0577|45 57|GS sequences
P10400712A0577|20 29|functions
P10400712A0577|189 191|IG
P10400712A0577|91 99|plasmids
P10400593A1084|4 12|contrast
P10400593A1084|67 72|VirE2
P10400593A1084|14 19|PvirE
P10399136A0389|100 104|rCBF
P10399136A0389|38 45|dilazep
P10399136A0389|22 33|cinnarizine
P10398286A0678|17 26|procedure
P10398286A0678|33 45|illustration
P10398286A0678|77 96|sample size methods
P10398286A0678|47 58|comparisons
P10396793A0815|48 51|day
P10396793A0815|37 43|drinks
P10396793A0815|147 157|indicators
P10396793A0815|208 209|%
P10396793A0815|72 91|dependence criteria
P10396343A0754|152 153|%
P10396343A0754|32 45|blood samples
P10396343A0754|18 28|proportion
P10396343A0754|158 173|T. b. gambiense
P10396343A0754|182 183|%
P10396343A0754|60 66|sample
P10395911A0288|1 17|Characterisation
P10395827A1297|118 137|parallel beta sheet
P10395827A1297|93 105|beta strands
P10395283A0960|34 43|activin A
P10395283A0960|48 52|OP-1
P10395283A0960|129 146|signal transducer
P10395283A0960|73 78|Smad4
P10394919A1058|9 16|element
P10394919A1058|46 55|amplitude
P10394116T0000|52 59|remarks
P10394116T0000|63 75|oscillometry
P10393910A0705|84 89|motif
P10393910A0705|98 102|part
P10393910A0705|158 165|element
P10393910A0705|15 26|mutagenesis
P10393251T0000|70 79|gene HUG1
P10393251T0000|41 55|HOX11 oncogene
P10393201A0654|171 176|break
P10393201A0654|55 74|DNA polymerase beta
P10393201A0654|26 43|DNA repair system
P10393201A0654|209 220|exonuclease
P10393192A0792|49 53|trap
P10393192A0792|58 72|intron mutants
P10392903A0889|64 70|cdc25A
P10392903A0889|144 152|mimosine
P10392903A0889|75 92|cdc25B expression
P10392900A1020|5 15|activation
P10392900A1020|146 160|RNA polymerase
P10392900A1020|73 78|c-Abl
P10392669A0935|684 696|pantoprazole
P10392669A0935|142 176|prostaglandin analogue misoprostol
P10392669A0935|559 573|term treatment
P10392669A0935|73 80|lesions
P10392669A0935|626 632|ulcers
P10392669A0935|29 38|incidence
P10392669A0935|96 106|approaches
P10392669A0935|383 416|histamine H2 receptor antagonists
P10392669A0935|503 513|prevention
P10392669A0935|319 328|reduction
P10392669A0935|792 806|barrier agents
P10392669A0935|253 263|prevention
P10392669A0935|901 912|gastropathy
P10392669A0935|302 308|ulcers
P10391903T0000|85 94|signaling
P10391903T0000|1 5|Gab2
P10391903T0000|114 119|Elk-1
P10391246A0756|70 87|kinase activities
P10391246A0756|24 28|TAK1
P10390538T0000|68 77|sequences
P10388670A1976|117 124|storage
P10388670A1976|71 79|addition
P10388670A1976|5 16|percentages
P10388670A1976|44 56|storage time
P10385395A0000|68 79|cholesterol
P10385395A0000|36 44|receptor
P10385395A0000|144 156|HDL particle
P10385395A0000|10 29|density lipoprotein
P10385395A0000|104 114|substrates
P10384129A0000|1 10|TCR alpha
P10384129A0000|101 104|CD8
P10384129A0000|114 121|T cells
P10384129A0000|95 98|CD4
P10384129A0000|62 66|PBMC
P10383764A1809|272 279|channel
P10383764A1809|141 162|transenvelope channel
P10383764A1809|191 203|DNA transfer
P10383764A1809|295 309|export machine
P10383764A1809|127 135|assembly
P10383764A1809|40 45|model
P10381377T0000|80 84|role
P10381377T0000|22 25|rat
P10381377T0000|41 61|inositol phosphatase
P10381377T0000|106 123|insulin signaling
P10380890A0619|13 22|sequences
P10380800A0194|3 13|comparison
P10380800A0194|178 184|dsRNAs
P10380800A0194|106 128|RNA polymerase domains
P10380800A0194|150 156|dsRNAs
P10380232A0000|1 10|OBJECTIVE
P10380232A0000|198 205|control
P10380232A0000|184 188|TROP
P10380232A0000|114 127|dexamethasone
P10380232A0000|25 52|cost-effectiveness analysis
P10380232A0000|267 275|children
P10380232A0000|89 111|regimen-chlorpromazine
P10380232A0000|329 337|patients
P10379942A0956|31 39|residues
P10379547A0000|1 10|Molecules
P10379547A0000|53 62|radiation
P10377438A0647|16 23|protein
P10377438A0647|25 29|UBC9
P10376991A0977|32 40|tegument
P10376874A0759|222 230|presence
P10376874A0759|99 112|protein eRF3C
P10376874A0759|247 258|interaction
P10376874A0759|40 61|eRF1-eRF3 interaction
P10376446A0000|69 75|method
P10376446A0000|87 90|leg
P10376446A0000|99 102|PLR
P10376446A0000|29 34|years
P10376446A0000|166 171|cycle
P10376446A0000|60 66|2-hour
P10375718A0000|64 76|angiogenesis
P10375718A0000|111 118|methods
P10375718A0000|88 101|animal models
P10375640A0153|156 159|kDa
P10375640A0153|142 148|weight
P10375640A0153|24 43|nucleotide sequence
P10375107A1138|1 12|Progression
P10375107A1138|83 91|survival
P10375107A1138|30 42|chemotherapy
P10374632A0818|39 46|mg.kg-1
P10374632A0818|5 12|potency
P10374632A0818|30 33|Nim
P10373507A0680|1 10|SRFDelta5
P10373507A0680|112 123|alpha-actin
P10373507A0680|166 175|SM22alpha
P10372627A0530|35 44|snowboard
P10372627A0530|10 18|injuries
P10370778A0000|137 142|women
P10370778A0000|66 76|evaluation
P10370778A0000|231 240|letrozole
P10370778A0000|11 31|aromatase inhibitors
P10370778A0000|222 228|Zeneca
P10370778A0000|80 89|treatment
P10370778A0000|264 272|vorozole
P10370778A0000|242 248|FEMARA
P10370778A0000|180 197|tamoxifen therapy
P10369965A0000|49 76|basidiocarp differentiation
P10369775A0178|85 107|residues Lys438-Gln520
P10369775A0178|42 64|residues Arg183-His267
P10369775A0178|13 30|protein fragments
P10369625A0942|9 19|monitoring
P10367646A0569|71 82|mean values
P10367646A0569|234 241|protein
P10367646A0569|8 17|hemolysis
P10367646A0569|134 143|increases
P10367646A0569|216 223|albumin
P10367646A0569|56 63|changes
P10367385A0000|50 58|analysis
P10367385A0000|26 32|method
P10366722T0000|1 5|cDNA
P10366722T0000|99 106|subunit
P10366722T0000|60 88|mouse DNA polymerase epsilon
P10366503A1506|67 74|peptide
P10366503A1506|196 207|association
P10366503A1506|165 174|structure
P10366503A1506|87 95|antibody
P10366503A1506|55 59|gp20
P10366503A1506|247 264|terminase regions
P10366446A0893|84 101|interaction motif
P10366446A0893|106 113|FLI LRR
P10364523T0000|84 88|SOX9
P10364523T0000|115 129|control region
P10364523T0000|90 98|evidence
P10364425A0610|52 59|absence
P10364425A0610|108 118|activation
P10364425A0610|122 127|STAT3
P10364314A0919|7 17|subgenomes
P10364314A0919|74 78|part
P10364163A0092|1 4|Hrs
P10364163A0092|92 101|phosphate
P10364163A0092|130 138|proteins
P10364076A0429|32 37|E-box
P10364076A0429|7 14|regions
P10364076A0429|60 73|repeat motifs
P10362897A0545|1 8|RESULTS
P10362897A0545|163 169|effect
P10362897A0545|146 154|duration
P10362897A0545|91 100|intensity
P10362652A0350|21 27|microM
P10362652A0350|6 15|carbachol
P10360947A1113|186 193|domains
P10360947A1113|201 208|protein
P10360947A1113|99 104|ALG-2
P10360947A1113|11 36|fluorescence spectroscopy
P10360454A0916|152 153|p
P10360454A0916|86 100|pentoxifylline
P10360454A0916|178 191|control group
P10360454A0916|145 150|pg/ml
P10359673A0000|80 87|control
P10359673A0000|131 156|GCN4 transcription factor
P10359673A0000|30 53|lipoamide dehydrogenase
P10359663A1280|116 126|expression
P10359663A1280|4 27|co-transfection studies
P10359663A1280|77 92|transactivation
P10359663A1280|130 136|GATA-1
P10359663A1280|47 52|c-Jun
P10359603A0430|29 51|Sec1p homologue Vps45p
P10359014A1077|190 208|threonine residues
P10359014A1077|54 58|MAPK
P10359014A1077|23 50|Fra-2 phosphorylation sites
P10359014A1077|88 103|serine residues
P10358083A0263|17 25|analyses
P10358083A0263|65 73|F9 cells
P10358083A0263|232 237|sites
P10358083A0263|110 119|complexes
P10358083A0263|78 94|characterization
P10358080A1114|254 285|HSF1 monomer-trimer equilibrium
P10358080A1114|101 108|studies
P10358080A1114|10 24|linker regions
P10358080A1114|132 143|HSF1 linker
P10358080A1114|224 235|determinant
P10358075A0984|116 126|homologues
P10358075A0984|158 173|PtdIns 3-kinase
P10358075A0984|24 33|component
P10358075A0984|134 145|insulin/IGF
P10357751A0866|141 145|risk
P10357751A0866|312 318|weight
P10357751A0866|165 169|risk
P10357751A0866|366 370|risk
P10357751A0866|270 277|disease
P10357751A0866|302 307|score
P10357751A0866|90 93|FFM
P10355536A0172|42 47|years
P10355536A0172|30 35|range
P10353880A0257|116 119|HSV
P10353880A0257|121 122|P
P10350638A0000|1 8|Latexin
P10350638A0000|125 132|systems
P10350638A0000|12 40|carboxypeptidase A inhibitor
P10350454A0000|1 5|MutY
P10350454A0000|110 113|G.A
P10350454A0000|24 35|glycosylase
P10350454A0000|57 67|mismatches
P10349443A0358|119 120|%
P10349443A0358|20 23|lab
P10349443A0358|53 59|levels
P10349443A0358|63 74|infestation
P10349443A0358|90 96|values
P10348859A0292|96 99|ion
P10348859A0292|126 133|monomer
P10348859A0292|89 91|Hg
P10348859A0292|31 44|binding sites
P10347220A1477|101 104|RNA
P10347220A1477|320 342|methyltransferase Hcm1
P10347220A1477|351 353|p.
P10347220A1477|108 122|triphosphatase
P10347220A1477|271 311|triphosphatase-guanylyltransferase Mce1p
P10347220A1477|62 67|yeast
P10347197A0502|18 36|urokinase promoter
P10347197A0502|83 96|co-expression
P10347197A0502|40 46|HGF/SF
P10344736A0796|1 23|CDK4 kinase activities
P10344736A0796|53 59|levels
P10342829A1370|48 57|alphaT3-1
P10342829A1370|66 73|extract
P10342829A1370|89 101|SF-1 protein
P10342536A0954|51 59|formulae
P10342536A0954|173 185|whey formula
P10342536A0954|264 282|amino acid formula
P10342536A0954|130 134|milk
P10342536A0954|208 227|whey/casein formula
P10342536A0954|74 85|information
P10341219A0481|53 58|cells
P10341219A0481|82 99|YD-repeat protein
P10341219A0481|14 37|heparin lyase treatment
P10340447A0424|72 75|QMF
P10340447A0424|13 25|coefficients
P10339552A0361|157 161|gene
P10339552A0361|36 46|SRm160/300
P10339552A0361|77 80|ESE
P10334888A0960|4 17|reperfusion B
P10334888A0960|82 101|IL-8 concentrations
P10334888A0960|130 142|nondiabetics
P10333526A0459|62 67|exons
P10332733A0000|27 28|F
P10332733A0000|30 37|protein
P10331730A0504|1 8|RESULTS
P10331730A0504|39 44|cases
P10331730A0504|53 61|Sardinia
P10331730A0504|176 183|centres
P10331276A0298|41 50|structure
P10330168A0135|99 104|Cdc7p
P10330168A0135|53 56|Clb
P10330168A0135|182 197|DNA replication
P10330168A0135|132 144|factor Dbf4p
P10330168A0135|30 37|kinases
P10330146A0730|33 39|intron
P10330146A0730|127 148|luciferase expression
P10330146A0730|8 12|case
P10330146A0730|166 174|deletion
P10329736A1106|1 20|Insulin stimulation
P10329736A1106|71 74|Nck
P10329736A1106|65 69|SHP2
P10329625A0715|155 160|cells
P10329625A0715|55 60|cells
P10329625A0715|42 45|CD8
P10329625A0715|167 171|FTOC
P10329574A1733|64 67|RNA
P10329574A1733|96 99|RNA
P10329574A1733|14 19|RNA-7
P10329135A1326|7 14|results
P10329135A1326|73 81|mt-hsp70
P10327051A0688|33 64|Stress-Activated-Protein-Kinase
P10327051A0688|179 186|complex
P10327051A0688|72 84|target sites
P10327051A0688|135 144|formation
P10326654A0351|369 379|difference
P10326654A0351|231 233|VF
P10326654A0351|315 325|prevalence
P10326654A0351|14 31|pilot experiments
P10326654A0351|186 191|group
P10326654A0351|116 123|minutes
P10326654A0351|292 297|group
P10326654A0351|263 274|arrhythmias
P10326654A0351|57 66|durations
P10326654A0351|329 331|VF
P10325413A1211|34 74|DNA containing 5-methylcytosine residues
P10325413A1211|203 207|base
P10325413A1211|25 30|c-Abl
P10325413A1211|14 21|binding
P10323463T0000b|67 81|manifestations
P10323463T0000b|94 100|effect
P10323225A0244|1 10|Km values
P10323225A0244|41 45|NADH
P10323225A0244|61 64|NAD
P10322022A0263|1 7|Rep63A
P10322022A0263|278 286|plasmids
P10322022A0263|197 211|pAW63 replicon
P10322022A0263|167 175|pSM19035
P10322022A0263|13 24|amino acids
P10322022A0263|55 58|ORF
P10322022A0263|91 101|% identity
P10320579A1831|54 74|flagellar chaperones
P10320579A1831|144 151|domains
P10320579A1831|26 30|FliT
P10320177A0487|1 30|Baseline electrocorticography
P10320177A0487|64 68|lobe
P10320177A0487|162 165|min
P10320177A0487|228 238|alfentanil
P10320177A0487|107 115|amygdala
P10320177A0487|242 251|microg/kg
P10320177A0487|120 131|hippocampus
P10319327A1237|117 125|presence
P10319327A1237|178 193|protein E12/E47
P10319327A1237|72 80|extracts
P10318918A0824|33 37|NS5A
P10318918A0824|125 138|HCV genotypes
P10318918A0824|88 93|motif
P10318859A0535|71 95|tyrosine phosphorylation
P10318859A0535|112 120|paxillin
P10318806A0476|115 124|responses
P10318806A0476|77 88|MAP kinases
P10308312A0203|116 121|media
P10308312A0203|9 14|paper
P10308312A0203|89 99|ultrasound
P10308312A0203|28 34|status
P10281637A0000|1 10|Reporting
P10281637A0000|55 61|trials
P10281637A0000|92 99|complex
P10243927A0000|185 191|spread
P10243927A0000|201 206|smoke
P10243927A0000|144 155|fire origin
P10243927A0000|63 85|IIT Research Institute
P10243927A0000|30 40|fire tests
P10236651T0000|58 76|admission criteria
P10236651T0000|26 41|pharmacy school
P10234698A0728|34 41|effects
P10234698A0728|123 138|corticosteroids
P10234698A0728|225 234|treatment
P10234698A0728|164 169|brain
P10234698A0728|45 60|CNS development
P10233885A0899|155 158|p32
P10233885A0899|115 125|activation
P10233885A0899|163 175|p30 isoforms
P10232872A0081|84 94|population
P10232872A0081|61 69|subgroup
P10232078A0552|49 56|release
P10232078A0552|14 25|reperfusion
P10231581A1125|52 61|SP1 sites
P10231581A1125|74 78|exon
P10231485A0342|186 202|membrane protein
P10231485A0342|139 145|4Fe-4S
P10231485A0342|49 92|molybdopterin guanine dinucleotide cofactor
P10231485A0342|216 237|quinol oxidation site
P10231485A0342|147 155|clusters
P10231485A0342|122 126|TtrB
P10231026A0253|39 41|kb
P10231026A0253|23 27|Elk1
P10229668A0560|50 57|Cln3-1p
P10229668A0560|141 146|eIF4E
P10229668A0560|173 183|cell cycle
P10229668A0560|127 137|dependence
P10229668A0560|79 88|CLN3 mRNA
P10229084A0000|276 280|pp43
P10229084A0000|282 286|pp72
P10229084A0000|288 292|pp85
P10229084A0000|392 400|SLAP-130
P10229084A0000|52 70|immunoprecipitates
P10229084A0000|298 326|protein tyrosine kinase Pyk2
P10229084A0000|363 379|adaptor proteins
P10228561A0539|76 84|residues
P10228561A0539|92 99|contact
P10228561A0539|105 119|DNA phosphates
P10228155A1293|51 62|suppression
P10228155A1293|71 81|regulation
P10226838A1011|17 22|sperm
P10226838A1011|5 13|motility
P10226838A1011|107 110|60s
P10226029A0905|157 162|serum
P10226029A0905|146 153|absence
P10226029A0905|124 132|contacts
P10226029A0905|60 65|sites
P10225279A0450|154 158|gene
P10225279A0450|100 105|ORF-1
P10225279A0450|43 52|MDV2 UL54
P10225279A0450|57 67|UL55 genes
P10225279A0450|73 81|homology
P10224513A0240|99 104|films
P10224513A0240|36 47|arithmetics
P10224513A0240|108 118|videotapes
P10224513A0240|15 24|stressors
P10224293A0000|1 39|Receptor protein tyrosine phosphatases
P10224293A0000|59 65|family
P10224293A0000|132 142|ectodomain
P10224257A0079|170 176|intron
P10224257A0079|138 140|P2
P10224257A0079|4 12|XO males
P10224257A0079|126 132|region
P10224257A0079|31 37|her-1a
P10223498A0479|101 108|ability
P10223498A0479|191 195|IIEF
P10223498A0479|172 189|Erectile Function
P10223498A0479|89 97|question
P10223498A0479|75 83|erection
P10223338A1601|86 95|HIV-2 gag
P10223338A1601|4 12|addition
P10223338A1601|57 71|fusion protein
P10223338A1601|135 143|HIV-1SF2
P10221467T0000|114 123|Parkinson
P10221467T0000|126 133|disease
P10221467T0000|14 26|pericarditis
P10220275A0694|5 12|binding
P10220275A0694|58 71|preincubation
P10220275A0694|75 85|Gbetagamma
P10218357A0486|103 116|cuff-pressure
P10218357A0486|141 144|N2O
P10218357A0486|42 52|cuff-tubes
P10218357A0486|26 32|Brandt
P10218357A0486|91 99|increase
P10218109T0000|24 33|mechanism
P10216161A1530|170 174|type
P10216161A1530|1 20|Sequence comparison
P10216161A1530|49 57|homologs
P10216161A1530|24 38|cytochromes bd
P10216161A1530|193 195|bd
P10216161A1530|302 306|type
P10216052A0105|343 351|glaucoma
P10216052A0105|445 454|questions
P10216052A0105|203 218|factor analysis
P10216052A0105|413 424|reliability
P10216052A0105|128 145|glaucoma patients
P10216052A0105|400 408|validity
P10216052A0105|318 328|field loss
P10216052A0105|184 196|disabilities
P10216052A0105|55 64|frequency
P10216052A0105|299 307|severity
P10216052A0105|361 369|subgroup
P10215811A0635|92 95|EVL
P10215811A0635|78 86|sessions
P10215608A0161|86 94|rGST Yc1
P10215608A0161|9 14|study
P10215608A0161|75 84|rat GSTA3
P10215485A0837|118 120|NA
P10215485A0837|108 113|mI/Cr
P10215485A0837|41 47|status
P10212969A0470|1 13|Uroflowmetry
P10212969A0470|25 32|dysuria
P10212332T0000|38 45|disease
P10212278A0387|98 118|protein kinase/c-Jun
P10212278A0387|197 211|protein kinase
P10212278A0387|244 253|molecules
P10212278A0387|160 171|p38 members
P10212278A0387|56 72|c-jun expression
P10211422T0000|25 37|complication
P10210952A0261|64 72|criteria
P10210952A0261|20 29|diagnoses
P10209119A0594|78 82|pop1
P10209119A0594|227 236|functions
P10209119A0594|60 72|similarities
P10209031A0832|142 157|phosphorylation
P10209031A0832|59 70|interaction
P10209031A0832|161 180|zeta ITAM tyrosines
P10209031A0832|90 100|Fyn kinase
P10208893A0839|14 21|results
P10207115A0389|35 40|level
P10207115A0389|44 47|p21
P10207090A0801|38 41|GRR
P10207090A0801|22 30|presence
P10207049A1001|34 50|Glc7 phosphatase
P10207049A1001|97 102|roles
P10207049A1001|124 142|CUP1 transcription
P10207049A1001|75 87|subunit play
P10207041A0065|100 116|protein products
P10207041A0065|42 46|part
P10207041A0065|63 76|transcription
P10206698A2041|7 15|findings
P10206698A2041|131 138|ability
P10206698A2041|105 110|genes
P10205933A0699|1 9|Bacteria
P10205933A0699|173 184|spirochaete
P10205933A0699|111 122|spirochaete
P10205933A0699|88 107|Treponemas Pallidum
P10205176A0704|53 57|PSU1
P10205099A0377|239 248|groups I3
P10205099A0377|232 237|weeks
P10205099A0377|142 152|groups T12
P10205099A0377|72 78|groups
P10205099A0377|165 177|itraconazole
P10205099A0377|118 121|day
P10205099A0377|253 255|I4
P10205099A0377|113 115|mg
P10205099A0377|182 184|mg
P10202006A1266|237 241|role
P10202006A1266|132 146|autoantibodies
P10202006A1266|20 33|ssDNA binding
P10202006A1266|112 120|activity
P10202006A1266|95 97|Ab
P10202006A1266|210 225|polypyrimidines
P10201468A0297|1 15|Plasma glucose
P10201468A0297|93 103|time point
P10201468A0297|58 66|glucagon
P10201468A0297|72 84|GLP-1 levels
P10199539A1353|102 105|VO2
P10199539A1353|25 32|hypoxia
P10199539A1353|79 97|a3 oxidation level
P10199539A1353|135 142|hypoxia
P10198056A0000|81 109|glycosylphosphatidylinositol
P10198056A0000|111 114|GPI
P10197985A0145|10 34|RNase H protection assay
P10197985A0145|133 153|branchpoint sequence
P10197985A0145|252 257|sites
P10197985A0145|57 73|oligonucleotides
P10197985A0145|298 315|complex formation
P10197985A0145|88 99|recognition
P10196597A0510|100 113|drink drivers
P10196597A0510|39 46|studies
P10196316A0715|119 122|DNA
P10196316A0715|140 150|Oka strain
P10196316A0715|108 111|VZV
P10196316A0715|56 62|series
P10196248A0482|186 187|%
P10196248A0482|170 180|GC content
P10196248A0482|23 33|TTV genome
P10196248A0482|161 168|stretch
P10196248A0482|72 74|nt
P10195697A0456|10 24|F-SRC-1 mutant
P10195425T0000|118 130|conservation
P10195425T0000|70 80|pufferfish
P10195425T0000|82 95|Fugu rubripes
P10194762A0648|98 120|transactivation domain
P10194762A0648|10 23|precipitation
P10194762A0648|227 233|serine
P10194762A0648|166 172|ERK1/2
P10194762A0648|241 247|STAT5a
P10194230A0817|19 26|surgery
P10194230A0817|28 42|dialysate PGE2
P10193950A0478|34 38|June
P10193950A0478|67 69|T2
P10193950A0478|73 75|T3
P10193950A0478|18 24|August
P10193950A0478|158 180|lymph node involvement
P10193950A0478|208 217|pendetide
P10193950A0478|150 154|risk
P10192432A0214|3 7|list
P10192432A0214|112 119|experts
P10192432A0214|177 185|criteria
P10192432A0214|165 173|core set
P10191090A0000|34 43|PAX3 gene
P10191090A0000|72 83|development
P10187864A1372|51 61|KCC family
P10187864A1372|23 27|KCC3
P10187864A1372|7 14|results
P10187798A1098|50 59|apoptosis
P10187798A1098|1 15|Overexpression
P10187798A1098|77 102|L929 fibroblast cell line
P10184191T0045|1 7|Holger
P10171173A0955|136 145|hepatitis
P10171173A0955|174 189|research effort
P10171173A0955|247 253|bypass
P10171173A0955|12 20|concerns
P10171173A0955|31 36|blood
P10146207A0223|1 16|Ultrasonography
P10132730T0000|27 31|pact
P10132730T0000|62 66|Wis.
P10120952T0000|1 6|HANYS
P10103057A0251|152 159|studies
P10103057A0251|39 55|characterization
P10103057A0251|22 34|optimization
P10102627A0217|83 88|cells
P10102627A0217|14 34|DNA binding activity
P10102136A0220|48 59|cyst fluids
P10102136A0220|75 76|%
P10101744A0917|8 14|trials
P10101744A0917|45 46|h
P10101198A0632|49 56|protein
P10101198A0632|144 151|binding
P10100605A0392|141 150|rhodamine
P10100605A0392|97 113|dihydrorhodamine
P10100605A0392|79 93|transformation
P10099247A1051|216 218|MB
P10099247A1051|162 166|time
P10099247A1051|125 133|inoculum
P10099247A1051|41 55|retention time
P10098601A1320|86 90|site
P10098601A1320|36 39|DNA
P10098601A1320|129 142|SF-1 sequence
P10097120T0000|4 8|exon
P10097120T0000|45 49|mRNA
P10096469T0000|42 50|activity
P10096469T0000|14 24|modulation
P10095061A0592|187 197|structures
P10095061A0592|117 124|protein
P10095061A0592|112 115|DRS
P10095061A0592|147 158|nucleoplasm
P10094701A0000|51 55|gene
P10094701A0000|83 87|ackA
P10094701A0000|8 12|work
P10094701A0000|146 166|phosphate limitation
P10094314A0935|171 176|SRp20
P10094314A0935|20 33|RNA sequences
P10094314A0935|142 146|fact
P10094314A0935|58 82|zinc knuckle 9G8 variant
P10092847A0455|204 210|factor
P10092847A0455|21 33|distribution
P10092847A0455|58 73|promoter region
P10092847A0455|79 91|hMT-IIA gene
P10092847A0455|44 48|MREs
P10091619A0104|1 7|Schwab
P10091619A0104|87 92|state
P10091619A0104|12 30|England ADL scores
P10090943A1976|118 134|activation stage
P10090943A1976|37 44|variant
P10090943A1976|167 172|B-CLL
P10090943A1976|63 68|CD79b
P10090535A1194|69 71|Lp
P10090535A1194|5 14|algorithm
P10090535A1194|43 44|%
P10090535A1194|62 63|%
P10090125A0750|69 70|M
P10090125A0750|76 86|relaxation
P10087993A0782|98 108|expression
P10087993A0782|54 68|delta promoter
P10087993A0782|14 22|deletion
P10087213A0878|17 34|protein sequences
P10087213A0878|185 211|H. pylori plasmid proteins
P10087213A0878|99 137|H. pylori plasmid replication proteins
P10086544A0504|478 492|catecholamines
P10086544A0504|403 414|preejection
P10086544A0504|345 352|Doppler
P10086544A0504|15 19|data
P10086544A0504|269 281|urine output
P10086544A0504|239 267|oxygen saturation difference
P10086544A0504|508 517|enoximone
P10086544A0504|37 44|arrival
P10086544A0504|162 170|pressure
P10086544A0504|523 533|furosemide
P10086544A0504|494 505|epinephrine
P10086544A0504|122 132|heart rate
P10086544A0504|301 308|lactate
P10085605A0239|95 98|hCG
P10085605A0239|74 83|alpha hCG
P10085383A1367|68 87|Regulation schedule
P10085383A1367|5 10|WORDS
P10085383A1367|40 53|Littoral zone
P10085120A0000|81 84|PDT
P10085120A0000|72 79|therapy
P10085120A0000|91 100|hypericin
P10084294A0219|33 37|iron
P10084294A0219|24 28|need
P10084294A0219|183 195|microg/liter
P10082573A1015|153 164|holocomplex
P10082573A1015|55 58|HS2
P10082573A1015|39 49|hypothesis
P10082573A1015|249 260|holocomplex
P10082573A1015|226 231|DNase
P10082573A1015|211 220|formation
P10082554T0000|84 94|repression
P10082554T0000|23 53|c-myc promoter binding protein
P10080901A0271|51 59|elements
P10080901A0271|111 117|domain
P10080901A0271|73 82|structure
P10080436T0000|1 11|Comparison
P10080436T0000|37 49|fibrillation
P10080436T0000|132 138|bypass
P10078876A0000|32 39|changes
P10078876A0000|5 12|origins
P10078876A0000|83 90|signals
P10078876A0000|160 182|microspectrophotometry
P10078876A0000|271 282|oxygenation
P10078876A0000|151 158|imaging
P10077533A0976|54 68|identification
P10077533A0976|76 79|MKS
P10076007A0656|35 48|casein kinase
P10076007A0656|21 27|kinase
P10076007A0656|56 62|kinase
P10076007A0656|132 138|kinase
P10074921A1169|43 73|HepG2 hepatoblastoma cell line
P10074520T0000|51 57|IS2606
P10074520T0000|81 90|sequences
P10074520T0000|108 130|Mycobacterium ulcerans
P10074520T0000|40 46|IS2404
P10074282A0236|117 134|cGMPase inhibitor
P10074282A0236|66 88|NO-synthesis inhibitor
P10074282A0236|93 107|methylene blue
P10074282A0236|14 18|side
P10073947A1110|19 30|differences
P10073899A0740|102 105|CVS
P10073899A0740|12 32|culture failure rate
P10073899A0740|44 48|cent
P10072205A0167|4 9|order
P10072205A0167|53 55|ML
P10072205A0167|110 129|point approximation
P10072205A0167|133 147|density values
P10071761A2374|169 184|UCP2 expression
P10071761A2374|155 165|regulation
P10071761A2374|80 88|promoter
P10071761A2374|203 209|anyone
P10071761A2374|29 44|promoter region
P10071761A2374|14 21|mapping
P10071205A0833|94 104|AUG codons
P10071205A0833|61 65|STA2
P10069815A0285|16 24|evidence
P10069815A0285|53 64|interaction
P10068674A0644|51 58|Lyp RNA
P10068674A0644|60 64|Lyp2
P10068446A0124|136 153|cysteine residues
P10068446A0124|70 86|PKC preparations
P10068446A0124|38 46|presence
P10068446A0124|114 117|BPO
P10068040A0136|59 69|ubc-9 gene
P10066798A0391|1 7|Cyclin
P10066798A0391|22 37|kinase activity
P10066798A0391|110 126|tumor virus-pp60
P10066798A0391|149 153|mice
P10065684A0916|205 215|sarcomeres
P10065684A0916|98 99|%
P10065684A0916|311 312|p
P10065684A0916|230 238|subjects
P10065684A0916|14 18|hand
P10065684A0916|185 186|p
P10065684A0916|217 218|L
P10065684A0916|219 222|sar
P10065684A0916|303 309|microm
P10064604A0824|50 56|TFIIIA
P10064604A0824|81 87|repair
P10063122T0000|1 26|Two-Channel Kondo Lattice
P10055173T0000|1 23|Band structure effects
P10055173T0000|63 76|quasicrystals
P10053852T0000|42 73|Gerasimov-Drell-Hearn sum rules
P10053852T0000|28 37|Schwinger
P10052371A0171|168 177|cessation
P10052371A0171|157 161|days
P10052371A0171|92 101|occasions
P10052371A0171|209 212|day
P10052371A0171|181 188|smoking
P10051488A1293|117 140|mobility AP-1 complexes
P10051488A1293|99 108|discovery
P10051488A1293|83 87|HSCs
P10051488A1293|9 17|analysis
P10051030A1080|32 37|males
P10051030A1080|4 14|difference
P10051030A1080|41 57|semen production
P10049912T0000|1 15|Identification
P10049912T0000|42 52|suppressor
P10049912T0000|60 74|UV sensitivity
P10049742T0000|1 9|Analysis
P10049742T0000|74 77|ZF5
P10049357A0608|34 43|component
P10049357A0608|113 123|repression
P10049357A0608|25 28|Ski
P10046849T0000|7 12|scale
P10043466T0000|71 92|polydiacetylene 4BCMU
P10043466T0000|47 55|kinetics
P10037774A0366|36 64|signal transduction pathways
P10037774A0366|9 14|study
P10037576T0000|21 29|necrosis
P10037576T0000|88 96|melanoma
P10037378A0176|67 76|lidocaine
P10036191A0000|137 141|TFEC
P10036191A0000|5 23|microphthalmia-TFE
P10036191A0000|131 135|TFEB
P10036191A0000|25 28|MiT
P10036191A0000|125 129|TFE3
P10036191A0000|180 190|regulation
P10036191A0000|30 39|subfamily
P10035841T0000|44 52|hydrogen
P10033973T0000|25 30|atoms
P10033973T0000|13 21|exchange
P10032519T0000|26 36|beta decay
P10032519T0000|45 56|possibility
P10029917A0366|83 87|case
P10029917A0366|196 216|portal vein branches
P10029917A0366|91 95|case
P10029337A0406|170 174|days
P10029337A0406|109 117|increase
P10029337A0406|45 72|blood lactate concentration
P10029337A0406|189 190|U
P10029337A0406|95 96|l
P10029337A0406|88 92|mmol
P10029337A0406|181 183|SD
P10027498A0536|123 124|p
P10027498A0536|90 102|U.S. program
P10026784A2166|100 108|sequence
P10026784A2166|8 21|Oct-1 crystal
P10026784A2166|146 152|domain
P10026784A2166|60 74|GCAT half-site
P10026784A0331|141 146|roles
P10026784A0331|59 65|family
P10026784A0331|10 18|evidence
P10026229A0950|102 107|sites
P10026229A0950|4 12|addition
P10026229A0950|43 52|Engrailed
P10026229A0950|148 159|enhancement
P10026211A0136|1 9|Proteins
P10026211A0136|81 88|members
P10026211A0136|62 69|protein
P10026211A0136|135 141|family
P10025506A1078|12 24|Inr sequence
P10025050A1052|5 12|therapy
P10025050A1052|77 86|therapies
P10024498A0783|70 77|Y sites
P10024498A0783|101 106|sites
P10024498A0783|58 65|HNF-3 X
P10022978A1261|33 40|repeats
P10022978A1261|54 66|organization
P10022978A1261|123 127|base
P10022921A0608|85 99|cell viability
P10022921A0608|60 64|pst1
P10022880A0000|48 60|p120 Ras-GAP
P10022880A0000|110 118|effector
P10022880A0000|92 105|downregulator
P10022880A0000|122 134|Ras proteins
P10022867A1069b|16 20|ETH1
P10022867A1069b|64 78|mutation rates
P10022867A1069b|24 36|apn1 strains
P10022867A1069b|149 156|adenine
P10022858A0985|66 75|selection
P10022858A0985|107 114|protein
P10022210A0620|21 37|direct-immersion
P10022210A0620|43 55|SPME process
P10021350A0093|201 214|transcription
P10021350A0093|218 230|Wingless/Wnt
P10021350A0093|242 247|genes
P10021350A0093|104 110|nuclei
P10019841T0000|64 72|approach
P10019841T0000|9 16|gravity
P10009565T0000|54 68|semiconductors
P10009565T0000|28 50|electron self-energies
P10007564T0000|23 31|geometry
P10007564T0000|47 56|structure
P10006319T0000|66 76|anisotropy
P10001541T0000|1 11|Mechanisms
P10001541T0000|29 37|emission
P10000253T0000|21 44|spin-glass correlations
P09999256T0000|21 27|theory
P09995847T0000|1 27|Optical-absorption spectra
P09995847T0000|43 56|energy levels
P09995847T0000|91 98|holmium
P09990507A0763|116 140|F-box/WD-repeat proteins
P09990507A0763|47 51|Pop1
P09990315A0205|1 4|TPO
P09990315A0205|38 42|ERK2
P09990315A0205|174 182|thrombin
P09990315A0205|133 137|ERKs
P09990315A0205|225 239|PKC activation
P09990315A0205|187 201|phorbol esters
P09990315A0205|249 257|agonists
P09990060A0803|25 29|part
P09990060A0803|147 160|CD18 promoter
P09989339A0968|20 23|use
P09989339A0968|42 54|brain weight
P09988850A0000|70 77|SCIRFIR
P09988850A0000|370 387|autopsy materials
P09988850A0000|317 323|change
P09988850A0000|113 140|dementia rating instruments
P09988850A0000|25 35|Impairment
P09988850A0000|297 303|course
P09988850A0000|61 68|Records
P09988682T0033|98 102|core
P09988682T0033|11 18|cloning
P09987634A1265|34 37|age
P09987634A1265|101 111|PRK effect
P09987634A1265|25 30|weeks
P09986796A1761|80 87|effects
P09986796A1761|10 19|deletions
P09984526T0000|51 65|semiconductors
P09984526T0000|29 47|lattice parameters
P09982923T0000|34 39|NiSi2
P09982923T0000|43 54|CoSi2 layer
P09976626T0000|1 8|Erratum
P09976626T0000|99 107|Li metal
P09976626T0000|88 95|crystal
P09973607A0254|152 155|end
P09973607A0254|117 126|existence
P09973607A0254|163 173|Sp100 gene
P09973607A0254|41 57|characterization
P09971822A1542|34 38|role
P09971822A1542|43 45|U1
P09971806A1585|68 81|KSHV/Rta gene
P09971806A1585|53 60|control
P09971806A1585|11 16|cycle
P09971776A0838|238 244|region
P09971776A0838|1 10|Mutations
P09971776A0838|141 144|L58
P09971776A0838|92 99|binding
P09971776A0838|26 40|CD4 regulation
P09971776A0838|210 219|dipeptide
P09965234T0000|55 58|8CB
P09965234T0000|60 74|liquid crystal
P09964171T0000|18 23|atoms
P09964171T0000|59 67|presence
P09961326T0000|66 72|models
P09961326T0000|44 53|interface
P09952425A0893|205 211|lesion
P09952425A0893|259 265|degree
P09952425A0893|64 69|tasks
P09952425A0893|9 14|group
P09952425A0893|41 48|animals
P09952425A0893|121 125|type
P09950394A0336|71 80|physician
P09950394A0336|89 98|diagnosis
P09949312A0524|1 8|Airflow
P09949312A0524|53 64|vacuum pump
P09949160A0600|196 204|isoforms
P09949160A0600|73 81|activity
P09949160A0600|225 235|readdition
P09949160A0600|45 50|level
P09949160A0600|246 252|growth
P09949160A0600|94 104|expression
P09949160A0600|120 136|eta PKC isoforms
P09945838T0000|19 38|matching conditions
P09945838T0000|58 73|heterojunctions
P09943651T0000|21 28|soliton
P09938097T0000|69 78|acceptors
P09938097T0000|28 64|photoluminescence undulation spectra
P09935377T0108|1 6|Genoa
P09935377T0108|8 13|Italy
P09933848A1008|7 21|alloantibodies
P09933848A1008|44 52|analysis
P09933428A0351|68 76|controls
P09933428A0351|38 40|TB
P09931435A0357|86 91|ZIS-1
P09931435A0357|55 59|exon
P09931435A0357|129 134|ZIS-1
P09931435A0357|148 152|size
P09931435A0357|120 124|exon
P09931252A1055|136 155|scaffolding protein
P09931252A1055|23 47|amino acid substitutions
P09931252A1055|61 73|coat protein
P09931191A0434|32 40|subjects
P09931191A0434|110 125|muscle ischemia
P09931191A0434|59 72|Ecc arm curls
P09931191A0434|145 155|resistance
P09929811A0000|1 12|Experiments
P09929811A0000|143 149|agents
P09929811A0000|163 169|CM-251
P09929811A0000|287 296|occlusion
P09929811A0000|352 358|artery
P09929811A0000|54 65|derivatives
P09929811A0000|215 222|segment
P09927589T0000|118 121|DSX
P09927589T0000|163 173|mechanisms
P09927589T0000|147 150|sex
P09927589T0000|61 89|Caenorhabditis elegans MAB-3
P09927570A0507|220 232|kDa proteins
P09927570A0507|18 32|RNU2 fragility
P09927570A0507|173 185|E1A proteins
P09927570A0507|202 205|E1B
P09927570A0507|72 89|expression vector
P09927570A0507|135 144|E1 vector
P09927193A0107|38 43|LAZ-3
P09927193A0107|29 33|PLZF
P09927193A0107|75 86|oncogenesis
P09925372A1063|21 31|expression
P09925372A1063|89 98|HFHZ mRNA
P09925372A1063|45 50|heart
P09925120A0074|1 10|OBJECTIVE
P09925120A0074|130 136|fibers
P09924675A0412|153 167|rehabilitation
P09924675A0412|206 221|characteristics
P09924675A0412|114 122|mainstay
P09924675A0412|128 133|model
P09924675A0412|27 40|consideration
P09924675A0412|240 247|process
P09922856A0459|1 11|Trinipatch
P09922856A0459|142 149|mg/24 h
P09922856A0459|58 63|patch
P09922856A0459|72 91|absorption promoter
P09921179T0001|5 9|role
P09921179T0001|63 68|heart
P09920930A0959|187 201|co-stimulation
P09920930A0959|154 158|AP-1
P09920930A0959|48 62|growth factors
P09920930A0959|81 85|AP-1
P09920930A0959|159 162|Luc
P09920930A0959|226 236|Ro-31-8220
P09920903A1045|32 42|c-met gene
P09920903A1045|7 14|results
P09920882A0287|1 5|Chem
P09920539A0272|5 17|stimulations
P09920539A0272|43 49|GnRH-a
P09918720A0998|118 124|pocket
P09918720A0998|5 18|S229A variant
P09918720A0998|162 169|contact
P09918720A0998|44 49|bases
P09918715A0304|1 5|MotA
P09918715A0304|58 66|position
P09917555T0001|1 9|Analysis
P09917389A1239|16 33|RNase E digestion
P09917389A1239|98 109|finP305 RNA
P09917389A1239|37 48|finP305 RNA
P09917389A1239|73 81|GST-FinO
P09917064T0000|92 99|masking
P09917064T0000|24 41|clam CPEB homolog
P09916786A0811|137 144|markers
P09916786A0811|273 287|chromatography
P09916786A0811|99 119|X-ray absorptiometry
P09916786A0811|77 82|femur
P09916786A0811|148 163|bone remodeling
P09916786A0811|225 248|urine deoxypyridinoline
P09915860A0000|55 61|region
P09915860A0000|99 108|mdr genes
P09915860A0000|125 143|consensus Sp1 site
P09915118T0000|36 49|rat accessory
P09915118T0000|60 64|bulb
P09914518A1217|204 207|ICI
P09914518A1217|96 125|AF-1 transactivation function
P09914518A1217|129 131|ER
P09914518A1217|47 57|activation
P09914156A1496|171 188|promoter activity
P09914156A1496|19 26|regions
P09914156A1496|250 252|bp
P09914156A1496|67 73|series
P09914156A1496|269 283|RNA start site
P09911328T0000|22 32|scattering
P09903722T0000|1 21|Autoionization rates
P09903722T0000|77 79|H2
P09903722T0000|26 39|energy levels
P09897032T0000|30 42|self-pulsing
P09894962T0000|100 113|malformations
P09894962T0000|30 37|profile
P09893262A1272|39 46|schemes
P09893262A1272|82 93|restriction
P09892736A0343|141 157|cell replication
P09892736A0343|37 43|region
P09892736A0343|10 16|search
P09892736A0343|73 85|% similarity
P09892642A0172|1 3|E1
P09892642A0172|43 57|HPV E2 protein
P09892021A0712|171 177|factor
P09892021A0712|84 93|secretion
P09892021A0712|1 15|Overexpression
P09892021A0712|39 52|NIH 3T3 cells
P09891707A0000|16 24|subtypes
P09891707A0000|28 47|spondyloarthropathy
P09891085A0815|16 21|cells
P09891085A0815|41 48|defects
P09891061A1240|64 70|timing
P09891061A1240|28 32|SpHE
P09891061A1240|134 138|SpHE
P09891049A0761|102 107|Rnt1p
P09891049A0761|33 42|precursor
P09891049A0761|52 61|nucleases
P09891046A0269|85 95|disruption
P09891046A0269|66 75|apoptosis
P09891046A0269|11 17|manner
P09891046A0269|29 32|PKR
P09890778T0000|19 34|glycoconjugates
P09889202T0000|50 63|domain Zalpha
P09889202T0000|141 147|family
P09889202T0000|67 97|dsRNA adenosine deaminase type
P09889202T0000|108 118|similarity
P09888711A0781|1 23|Bioplastique granuloma
P09888711A0781|236 241|shape
P09888711A0781|64 70|spaces
P09888711A0781|143 149|bodies
P09888711A0781|227 231|size
P09886850A0145|70 84|ligand binding
P09886850A0145|21 29|activity
P09886850A0145|145 170|MEK/ERK signaling pathway
P09886602A0000|1 11|OBJECTIVES
P09886602A0000|138 149|tumor grade
P09886602A0000|97 100|PSA
P09886602A0000|313 316|PSA
P09886602A0000|164 168|race
P09886602A0000|223 238|prostate cancer
P09886602A0000|297 309|introduction
P09886602A0000|27 34|ability
P09886602A0000|88 95|antigen
P09886602A0000|151 162|Gleason sum
P09884747A0477|136 150|yeast antigens
P09884747A0477|184 193|allergens
P09884747A0477|94 112|skin prick testing
P09884747A0477|15 22|testing
P09884232A0286|152 157|place
P09884232A0286|1 11|Comparison
P09884232A0286|19 28|sequences
P09884232A0286|38 42|attB
P09884232A0286|111 124|core sequence
P09884232A0286|132 145|recombination
P09882638A0235|8 14|tissue
P09882638A0235|78 87|expansion
P09882499A0231|143 147|Pax6
P09882499A0231|88 96|elements
P09882451A0195|143 153|phenotypes
P09882451A0195|110 115|HEM15
P09882451A0195|161 174|transformants
P09882337A0000|51 55|type
P09882337A0000|98 107|component
P09882337A0000|25 28|VZV
P09882337A0000|132 154|gI Fc receptor complex
P09882321A0948|136 147|EBNA-3 gene
P09882321A0948|55 61|EBNA-3
P09882321A0948|4 12|contrast
P09882321A0948|160 171|EBNA-3 cDNA
P09882303A1984|103 124|signalling mechanisms
P09882303A1984|38 43|TRADD
P09882303A1984|7 11|data
P09882303A1984|89 93|LMP1
P09881692A1109|117 127|probe DNAs
P09881692A1109|168 175|rabbits
P09881692A1109|111 113|b9
P09881692A1109|46 51|genes
P09881692A1109|104 106|b6
P09881666A0535|3 8|motif
P09881666A0535|36 45|CREB site
P09881666A0535|10 18|TGATGTCA
P09880543A0570|77 88|yeast cells
P09880512A1251|5 9|data
P09880512A1251|88 91|Sp1
P09880103A0387|51 64|self-labeling
P09880103A0387|38 47|technique
P09880103A0387|72 80|presence
P09879766A0402|4 9|PAV-3
P09879766A0402|15 25|E1A region
P09878437A0967|54 58|site
P09878437A0967|12 16|site
P09878437A0967|90 94|Glu9
P09877417A0704|46 55|intervals
P09875541A0210|48 52|part
P09875541A0210|134 152|hand movement task
P09873291A0620|70 85|knowledge score
P09873291A0620|21 29|variance
P09872832A1262|136 141|IL-12
P09872832A1262|236 247|differences
P09872832A1262|36 45|cytokines
P09872832A1262|172 181|TNF-alpha
P09872832A1262|130 134|IL-8
P09872832A1262|188 204|interferon gamma
P09872832A1262|123 127|IL-6
P09872326A0566|127 135|promoter
P09872326A0566|105 123|heat shock protein
P09869528T0000|6 14|fixation
P09869356A0926|1 9|CAL gain
P09869356A0926|38 39|%
P09869356A0926|63 71|CAL gain
P09868412A1628|1 11|CONCLUSION
P09868412A1628|65 73|neck BMD
P09868412A1628|337 357|grip muscle strength
P09868412A1628|107 118|study group
P09868412A1628|224 227|BMD
P09868412A1628|189 206|swimming exercise
P09868412A1628|214 220|effect
P09867253A0229|6 20|c-Jun activity
P09867253A0229|37 42|c-Fos
P09867253A0229|92 97|c-Jun
P09866068A1058|32 35|OCs
P09866068A1058|55 66|suppression
P09866068A1058|183 194|recruitment
P09866068A1058|14 26|Pretreatment
P09864689A1408|34 39|MYO/M
P09864689A1408|97 106|treatment
P09864689A1408|110 123|heart failure
P09864689A1408|60 72|washout rate
P09864141A0528|16 21|Stat3
P09864141A0528|65 80|phosphopeptides
P09864141A0528|92 96|Y704
P09864141A0528|26 35|Stat3beta
P09864141A0528|135 152|peptide analogues
P09863624A2301|17 41|receptor internalization
P09863624A2301|155 158|Cos
P09863624A2301|161 166|cells
P09863624A2301|79 83|125I
P09863624A2301|183 187|time
P09863624A2301|194 197|min
P09862496A0187|140 160|betaGLU I expression
P09862496A0187|25 42|endosperm rupture
P09862343A0225|18 36|gp200-MR6 ligation
P09862343A0225|133 139|system
P09862343A0225|194 207|B lymphocytes
P09862343A0225|105 114|influence
P09861099A1011|141 152|differences
P09861099A1011|111 112|r
P09861099A1011|78 79|r
P09861099A1011|193 195|SD
P09861099A1011|119 120|P
P09861099A1011|62 76|protein intake
P09858883A1106|69 73|N-A3
P09858883A1106|100 103|M-1
P09858883A1106|25 29|Kaff
P09858883A1106|58 65|binding
P09858883A1106|123 127|N-A3
P09858745A1350|170 181|interaction
P09858745A1350|185 189|CatR
P09858745A1350|5 13|location
P09858745A1350|52 56|gene
P09858745A1350|208 221|binding sites
P09858745A1350|62 75|cooperativity
P09858713A1174|137 146|Wg signal
P09858713A1174|117 129|transduction
P09858713A1174|23 27|data
P09858713A1174|52 55|Pan
P09858713A1174|214 239|gain-of-function activity
P09858713A1174|195 206|enhancement
P09858599A0392|69 83|transformation
P09858599A0392|39 58|NIH 3T3 fibroblasts
P09858599A0392|97 110|HOXA9 domains
P09858588A1046|103 108|cells
P09858588A1046|117 121|G2/M
P09858588A1046|78 82|G1/S
P09858577A1186|139 144|Sko1p
P09858577A1186|5 9|loss
P09858577A1186|161 169|effector
P09858577A1186|177 188|HOG pathway
P09858571T0000|137 155|dolichol synthesis
P09858571T0000|98 119|cis-prenyltransferase
P09858571T0000|127 133|enzyme
P09858094A0583|52 54|O1
P09858094A0583|40 50|potentials
P09858094A0583|61 63|O4
P09857197A0289|1 6|Yap1p
P09857197A0289|38 49|crm1 mutant
P09857197A0289|97 100|NES
P09857197A0289|132 140|presence
P09856732A0114|101 110|lidocaine
P09856732A0114|91 97|effect
P09855111A0905|309 317|synthase
P09855111A0905|128 144|SREBP processing
P09855111A0905|379 385|manner
P09855111A0905|114 124|regulation
P09855111A0905|245 256|mRNA levels
P09855111A0905|28 42|overexpression
P09852752A0950|35 45|vasculitis
P09852752A0950|67 79|complication
P09852136A0174|172 179|protein
P09852136A0174|22 30|mutation
P09852136A0174|161 163|HA
P09852136A0174|57 63|domain
P09852136A0174|107 125|guanine nucleotide
P09852068A0150b|50 55|DNase
P09852068A0150b|159 167|promoter
P09852068A0150b|58 70|footprinting
P09852068A0150b|11 15|SHBG
P09852068A0150b|91 103|significance
P09851988A0085|87 94|pathway
P09851988A0085|22 30|arginine
P09851614A0109|171 176|mRNAs
P09851614A0109|19 27|features
P09851614A0109|110 113|nts
P09851614A0109|147 161|cap structures
P09849961A0387|1 16|Down-regulation
P09849961A0387|20 25|IRS-1
P09849961A0387|125 140|differentiation
P09849961A0387|79 99|PI 3-kinase activity
P09849421A0332|190 203|EORTC QLQ-C30
P09849421A0332|6 12|survey
P09849421A0332|147 166|Cancer Core Quality
P09849421A0332|104 116|Organization
P09849421A0332|134 143|Treatment
P09847397A0935|17 18|%
P09847397A0935|218 228|TATA boxes
P09847397A0935|178 189|CCAAT boxes
P09847397A0935|134 149|glucocorticoids
P09846927A0227|16 22|button
P09846927A0227|86 91|death
P09846927A0227|61 73|stomach wall
P09846033A0488|35 47|pretreatment
P09846033A0488|80 81|p
P09845662A0085|1 9|Collagen
P09845662A0085|138 157|gel electrophoresis
P09845662A0085|64 72|collagen
P09845662A0085|159 167|SDS-PAGE
P09845662A0085|91 96|means
P09844921A0000|115 139|differentiation messages
P09844921A0000|88 94|growth
P09843944A0976|153 172|UP element function
P09843944A0976|59 66|hexamer
P09843572A0944|118 130|cell lysates
P09843572A0944|53 68|Cdr2 associates
P09843572A0944|110 114|Wee1
P09843572A0944|150 154|Wee1
P09843378A0187|5 25|dopamine D4 receptor
P09840943A0144|32 38|cyclin
P09840943A0144|40 49|cyclin E2
P09840932A0365|83 96|cyclin A/Cdk2
P09840932A0365|40 45|B-Myb
P09840932A0365|72 78|target
P09840822A0462|5 11|method
P09840822A0462|28 35|tagging
P09837978T0093|82 90|JNK/SAPK
P09837978T0093|11 21|activation
P09837933T0000|69 84|peptidylglycine
P09837933T0000|101 114|monooxygenase
P09837933T0000|135 144|endosomes
P09837913A0000|1 5|Type
P09837913A0000|82 98|triiodothyronine
P09837913A0000|57 66|thyroxine
P09837824A0419|186 204|missense mutations
P09837824A0419|222 227|T274I
P09837824A0419|66 77|individuals
P09837824A0419|131 151|frameshift mutations
P09837824A0419|211 216|S262I
P09837824A0419|15 31|telSMN mutations
P09837714A1068|70 83|modifications
P09837714A1068|156 171|differentiation
P09837714A1068|23 34|possibility
P09837714A1068|40 42|pH
P09835615A0574|35 38|KS1
P09835615A0574|52 59|protein
P09835615A0574|13 21|analysis
P09834070A0793|140 165|protein kinase C activity
P09834070A0793|126 136|inhibition
P09834070A0793|26 36|activation
P09834070A0793|209 213|CD19
P09834070A0793|61 68|absence
P09833610A0626|34 50|affinity hormone
P09833610A0626|59 63|site
P09832511A0269|137 144|pattern
P09832511A0269|148 155|neurons
P09832511A0269|14 26|neurogenesis
P09832504A0596|103 120|cysteine residues
P09832504A0596|53 56|Tat
P09832504A0596|77 81|zinc
P09832436A0738|1 16|RT-PCR analysis
P09832436A0738|83 94|rat strains
P09832436A0738|46 51|PLP-C
P09832436A0738|121 134|PLP diversity
P09829916T0000|85 92|vectors
P09829916T0000|66 72|operon
P09829916T0000|29 37|promoter
P09829843A0119|205 211|cancer
P09829843A0119|216 227|neutropenia
P09829843A0119|191 199|patients
P09829843A0119|47 50|CSF
P09829843A0119|121 129|measures
P09829836A0000|155 159|CDKs
P09829836A0000|33 44|progression
P09829836A0000|128 134|cyclin
P09827993A0000|35 39|NCPs
P09827993A0000|167 184|RNA encapsidation
P09827993A0000|12 33|nucleocapsid proteins
P09827724A1362|4 13|mutations
P09826778A0943|1 16|Over-expression
P09826778A0943|129 136|COUP-TF
P09826778A0943|89 102|transcription
P09826434T0000|51 82|platelet cAMP phosphodiesterase
P09826434T0000|9 25|characterization
P09826434T0000|40 44|site
P09824021A1263|52 59|disease
P09824021A1263|40 48|features
P09824021A1263|150 160|parameters
P09823775A1122|102 108|Oct-2A
P09823775A1122|37 42|HMG I
P09823775A1122|43 44|Y
P09823775A1122|62 70|cofactor
P09823775A1122|75 98|HLA-DRA gene activation
P09823014T0000|139 144|NIDDM
P09823014T0000|53 65|carbohydrate
P09823014T0000|125 133|patients
P09823014T0000|31 39|products
P09822690A0000|70 100|protein phosphorylation events
P09822690A0000|11 25|sperm motility
P09822661T0073|17 23|domain
P09822661T0073|60 75|quinone binding
P09822647A0000|5 24|rat aldolase C gene
P09822602A0237|255 258|CBP
P09822602A0237|156 168|derepression
P09822602A0237|246 253|protein
P09822602A0237|43 53|activation
P09822602A0237|57 67|HIF-1alpha
P09822602A0237|133 139|import
P09820621A0067|119 128|influence
P09820621A0067|54 61|changes
P09820621A0067|132 145|leptin levels
P09820205A0000|118 136|gamete interaction
P09820205A0000|5 19|zona pellucida
P09820205A0000|44 54|glycocalyx
P09819507A0000|16 23|rabbits
P09819507A0000|191 194|use
P09819507A0000|58 72|wound reaction
P09819507A0000|78 83|Dexon
P09819507A0000|148 170|trabeculectomy surgery
P09819440A0000|99 114|RNA polymerases
P09819440A0000|131 135|ways
P09819440A0000|120 127|variety
P09819422A0768|101 116|coprecipitation
P09819422A0768|120 124|Cns1
P09819414A1103|52 59|isoform
P09819414A1103|15 21|nexins
P09819391A1123|35 39|Arfs
P09819391A1123|113 125|organization
P09819391A1123|150 176|membrane remodeling events
P09819288A0578|1 7|Levels
P09819288A0578|54 57|IgE
P09819288A0578|11 20|serum IgE
P09819110A0703|1 15|CD4 lymphocyte
P09819110A0703|59 67|response
P09819110A0703|90 97|time LD
P09817601T0000|1 17|Characterization
P09817601T0000|36 43|regions
P09817601T0000|57 66|aromatase
P09817190A0074|21 34|cyclosporin A
P09817190A0074|67 77|prevalence
P09815948A1065|21 31|parameters
P09815948A1065|94 99|curve
P09815948A1065|104 121|peak plasma level
P09814905A0598|55 66|environment
P09814905A0598|5 17|consequences
P09814905A0598|31 47|swine production
P09813635A0678|7 17|striations
P09813635A0678|126 133|complex
P09813635A0678|77 83|canine
P09813254A0000|69 86|family interferon
P09813254A0000|114 122|proteins
P09813254A0000|56 63|members
P09813203T0000|116 132|envelope protein
P09813203T0000|5 11|effect
P09813203T0000|27 47|serine substitutions
P09813098A0521|1 11|Paralemmin
P09813098A0521|44 48|mRNA
P09813063T0000|1 11|Expression
P09813063T0000|30 53|phospholipase D homolog
P09811730T0000|101 112|KCS element
P09811730T0000|174 197|protein kinase pkr gene
P09811730T0000|61 70|positions
P09811718A0979a|38 49|association
P09811718A0979a|96 103|TCRzeta
P09811718A0979a|7 14|results
P09810087A0379|1 8|RESULTS
P09810087A0379|143 148|humor
P09810087A0379|22 36|seroconversion
P09810087A0379|95 100|HSV I
P09808366A0828|154 161|animals
P09808366A0828|7 15|apneusis
P09808366A0828|106 123|KA microinjection
P09808366A0828|45 55|conditions
P09808155A0813|1 12|Examination
P09808155A0813|143 148|cells
P09808155A0813|162 174|DNA fragment
P09808155A0813|91 98|factors
P09806919A0447|39 52|instar larvae
P09806919A0447|149 167|puparium formation
P09806857A0854|34 41|protein
P09806857A0854|66 76|similarity
P09806857A0854|146 163|Pac25I R-M operon
P09806826A1773|204 215|lung injury
P09806826A1773|156 161|locus
P09806826A1773|82 88|region
P09806826A1773|166 180|susceptibility
P09806826A1773|134 142|syndrome
P09806546A1270|69 80|RFX complex
P09806546A1270|5 16|interaction
P09806546A1270|31 36|RFXAP
P09806516A1212|52 60|patients
P09805052A0119|1 5|Dose
P09805052A0119|42 48|scheme
P09805052A0119|167 171|dose
P09805052A0119|12 14|ig
P09804779A1163|21 29|pathways
P09804779A1163|210 216|Stat5a
P09803081T0000|42 55|childhood SLE
P09802206A1058|139 149|protein S7
P09802206A1058|114 118|RPS7
P09802206A1058|10 27|sequence homology
P09801156A0220|85 93|ecdysone
P09801156A0220|104 112|gene E75
P09799793T0000|48 63|chromosome 7q22
P09799793T0000|81 83|kb
P09799793T0000|145 150|genes
P09799793T0000|123 133|CUTL1 loci
P09799793T0000|31 38|regions
P09799362A1463|153 162|influence
P09799362A1463|33 43|yeast cell
P09799362A1463|67 83|expression level
P09799362A1463|166 171|Azf1p
P09799237A0624|89 93|term
P09799237A0624|15 22|embryos
P09798263T0000|141 145|mice
P09798263T0000|40 66|serotonin receptor ligands
P09798068A0290|1 8|RESULTS
P09798068A0290|207 213|acid B
P09798068A0290|38 42|cDNA
P09798068A0290|125 136|amino acids
P09798068A0290|215 220|GABAB
P09798068A0290|164 174|% homology
P09797456A0000|69 74|roles
P09797456A0000|115 129|transformation
P09797456A0000|78 96|cell proliferation
P09795341A0806|117 124|isoform
P09795341A0806|95 98|TR2
P09795170A0774|21 41|polyadenylation site
P09795170A0774|105 123|kb transcript size
P09794795A0183|1 15|Ligand binding
P09794795A0183|369 373|SHP2
P09794795A0183|78 88|activation
P09794795A0183|107 110|Jak
P09794795A0183|221 238|signal transducer
P09794795A0183|256 283|transcription factors STAT3
P09794795A0183|23 39|receptor complex
P09794795A0183|92 105|Janus kinases
P09794795A0183|243 252|activator
P09792714A1408|139 154|gene expression
P09792714A1408|99 108|mechanism
P09792714A1408|5 16|interaction
P09792714A1408|125 135|activation
P09792714A1408|30 38|proteins
P09792682A0713|39 45|number
P09792682A0713|62 64|F0
P09792627A0441|42 52|repression
P09790986A0689|50 90|glutathione S-transferase fusion protein
P09790986A0689|29 37|antibody
P09790771A0956|50 57|tissues
P09790771A0956|39 46|variety
P09790771A0956|73 78|brain
P09790767A0372|104 112|band q31
P09790767A0372|90 100|chromosome
P09789795A0607|70 84|concentrations
P09789795A0607|23 31|subjects
P09788739A1096|158 184|MDA231 breast cancer cells
P09788739A1096|77 85|molecule
P09788739A1096|27 40|serine kinase
P09786949A0114|1 3|J.
P09786926A1372|141 144|SRE
P09786926A1372|25 40|binding studies
P09786926A1372|57 63|SREBP2
P09786404A0541|35 36|P
P09786404A0541|30 33|rpm
P09785114A1026|46 57|CORT levels
P09784192A1027|21 32|MBP fusions
P09784192A1027|13 20|peptide
P09781874A1061|52 72|adenine substitution
P09781874A1061|76 86|nucleotide
P09781874A1061|149 154|cwg2p
P09781761A0384|119 124|fluid
P09781761A0384|101 106|urine
P09781761A0384|6 22|Ho Chi Minh City
P09781761A0384|73 78|blood
P09780228A0613|96 115|fatty-acid-synthase
P09780228A0613|126 133|domains
P09780228A0613|75 79|FkbA
P09780228A0613|15 32|domain structures
P09780002A0996|84 97|transcription
P09780002A0996|65 68|E2F
P09780002A0996|10 16|E2FBP1
P09778191A0000|64 68|rCBF
P09778191A0000|127 132|basis
P09778191A0000|25 31|method
P09778191A0000|181 184|MRI
P09778006A0718|275 280|value
P09778006A0718|200 225|carbon dioxide reactivity
P09778006A0718|128 130|SD
P09778006A0718|44 52|pressure
P09778006A0718|17 30|baseline Vmca
P09778006A0718|186 190|mmHg
P09778006A0718|248 249|s
P09778006A0718|113 117|mmHg
P09778006A0718|56 70|carbon dioxide
P09778006A0718|90 95|PaCO2
P09777600A0000|32 41|l-menthol
P09777600A0000|113 121|detector
P09776360A1781|50 58|activity
P09776360A1781|142 153|DLD-1 cells
P09776360A1781|79 87|promoter
P09776293A0777|85 86|%
P09776293A0777|34 41|1-HMPAO
P09776293A0777|1 8|RESULTS
P09776293A0777|25 32|99mTc d
P09776293A0777|94 95|%
P09776293A0777|14 21|binding
P09774641A0824|1 10|Forskolin
P09774641A0824|82 97|phosphorylation
P09774450A0000|51 79|gamma-glutamyl leukotrienase
P09774450A0000|116 120|LTC4
P09774450A0000|81 84|GGL
P09774450A0000|31 43|mouse enzyme
P09774403A0107|5 13|Mahasneh
P09774403A0107|29 31|G.
P09773975A1873|273 278|S335D
P09773975A1873|339 344|S338D
P09773975A1873|11 25|AT1A receptors
P09773975A1873|346 350|t1/2
P09773975A1873|327 331|Ymax
P09773975A1873|322 325|min
P09773975A1873|147 162|internalization
P09773975A1873|306 311|T336E
P09773975A1873|174 175|%
P09773975A1873|313 317|t1/2
P09773975A1873|164 168|Ymax
P09773975A1873|116 120|t1/2
P09773975A1873|294 298|Ymax
P09773975A1873|247 251|t1/2
P09773975A1873|360 364|Ymax
P09773975A1873|303 304|%
P09771967A1052|33 49|chromosome 13q14
P09771967A1052|53 59|region
P09770686A0484|49 61|hypertension
P09770415A0139|168 171|NLS
P09770415A0139|147 166|localization signal
P09770415A0139|72 92|amino acid positions
P09770241A0000|3 12|technique
P09770241A0000|25 32|imaging
P09770241A0000|40 46|animal
P09769209A0100|18 25|studies
P09769209A0100|144 169|antitermination mechanism
P09767593A0130|34 37|PTP
P09767593A0130|113 123|host cells
P09767593A0130|10 14|YopH
P09767504A1371|85 99|administration
P09767504A1371|80 81|h
P09767504A1371|57 70|concentration
P09765466A0231|1 3|J.
P09765394A1590|131 146|superactivation
P09765394A1590|150 164|CAT expression
P09765388T0000|17 20|p53
P09765388T0000|54 57|E1B
P09765388T0000|93 105|oncoproteins
P09765388T0000|29 32|p73
P09765285A1763|66 84|binding affinities
P09765285A1763|111 118|IRper-1
P09765285A1763|121 125|DR-4
P09765277A0000|139 151|trophoblasts
P09765277A0000|25 52|glucose transporter isoform
P09765261A0000|236 243|element
P09765261A0000|308 334|cAMP response element core
P09765261A0000|11 17|T cell
P09765261A0000|75 78|Tax
P09765261A0000|156 193|cAMP response element binding protein
P09765261A0000|112 139|basic-domain/leucine-zipper
P09765261A0000|147 154|protein
P09763607A0521|92 102|p38 kinase
P09763607A0521|43 58|phosphorylation
P09763607A0521|63 73|activation
P09763470A1756|139 143|CREB
P09763470A1756|20 25|study
P09763470A1756|110 131|transcription factors
P09763470A1756|145 148|AP2
P09763470A1756|89 98|synergism
P09763446A1234|71 80|fractions
P09763446A1234|13 27|GAP activities
P09763421A1199|37 62|Fab1p kinase inactivation
P09763421A1199|93 99|growth
P09763421A1199|11 21|phenotypes
P09761723A0226|1 7|GETS-1
P09761723A0226|29 36|tissues
P09760341T0000|70 74|FIO2
P09760341T0000|60 66|effect
P09759865A0673|96 99|p65
P09759865A0673|228 241|IkappaB-alpha
P09759865A0673|284 292|IL-1beta
P09759865A0673|16 24|IL-1beta
P09759865A0673|263 277|myofibroblasts
P09759865A0673|29 38|TNF-alpha
P09759865A0673|60 67|binding
P09759180A0000|1 11|BACKGROUND
P09759180A0000|58 66|children
P09759180A0000|31 33|FQ
P09756895A0322|18 24|chCTCF
P09756895A0322|57 61|exon
P09756895A0322|90 95|exons
P09755478A0366|137 153|trace expression
P09755478A0366|42 52|expression
P09755478A0366|120 126|larvae
P09755199A0373|34 41|lesions
P09755199A0373|96 108|requirements
P09755199A0373|61 68|alleles
P09754571A1257|64 69|10q26
P09754571A1257|42 45|arm
P09753775A0734|99 125|histone H1 kinase activity
P09753775A0734|10 14|ICK1
P09753774A1642|118 140|1,1,1-fructosylnystose
P09753774A1642|65 88|oligofructans 1-kestose
P09753774A1642|96 107|1,1-nystose
P09753774A1642|109 112|GF3
P09753730A0881|1 17|T7 transcription
P09753730A0881|83 93|expression
P09753730A0881|60 66|levels
P09751114A1987|103 113|conditions
P09751114A1987|83 96|MyoD function
P09751114A1987|57 61|role
P09751114A1987|28 34|Thr115
P09751061A0000|272 282|expression
P09751061A0000|71 78|members
P09751061A0000|140 151|development
P09751061A0000|295 300|genes
P09751061A0000|108 116|proteins
P09750325A0000|119 127|survival
P09750325A0000|206 208|H7
P09750325A0000|21 46|intensity light emissions
P09750325A0000|214 236|Listeria monocytogenes
P09750325A0000|105 109|PPET
P09749533A0764|16 23|homolog
P09749533A0764|48 52|gene
P09749533A0764|99 110|Arabidopsis
P09748513X1360|16 37|Elsevier Science B.V.
P09748261A0000|100 105|Faaps
P09748261A0000|74 98|acid activation proteins
P09747651A0000|1 15|Laser ablation
P09744095A1016|305 311|mutant
P09744095A1016|272 280|CAB gene
P09744095A1016|173 181|darkness
P09744095A1016|196 205|hypocotyl
P09744095A1016|119 127|phyA-201
P09744095A1016|216 234|inflorescence stem
P09744095A1016|248 264|level expression
P09744095A1016|112 118|fre1-1
P09743233A0526|99 103|SMCs
P09743233A0526|58 62|site
P09743233A0526|78 95|promoter activity
P09741391A0581|34 42|body box
P09741391A0581|81 87|effort
P09741391A0581|65 70|Pause
P09741391A0581|91 100|breathing
P09739401A0000|102 107|years
P09739401A0000|1 10|OBJECTIVE
P09739401A0000|53 72|balance instruments
P09739401A0000|132 138|clinic
P09738087A0583|118 127|illnesses
P09738087A0583|27 37|predictors
P09738087A0583|41 49|survival
P09737921T0000|33 49|tail fiber locus
P09737921T0000|111 123|motifs swaps
P09737921T0000|132 143|specificity
P09736770A0351|69 77|promoter
P09736770A0351|110 116|GC box
P09736770A0351|130 133|Sp1
P09736770A0351|90 98|activity
P09736697A1107|140 150|inhibition
P09736697A1107|10 14|ERKs
P09736697A1107|74 84|serine-727
P09736697A1107|105 127|serine phosphorylation
P09736697A1107|257 264|pathway
P09736697A1107|25 40|IL-6 activation
P09736697A1107|62 70|mutation
P09736239A0436|174 175|p
P09736239A0436|276 288|accumulation
P09736239A0436|106 114|striatum
P09736239A0436|51 60|aspartate
P09736239A0436|299 311|excitotoxins
P09736239A0436|243 244|%
P09735368A0636|103 111|activity
P09735368A0636|23 25|m8
P09735368A0636|79 90|transcripts
P09735286A0599|103 111|presence
P09735286A0599|115 118|ATP
P09735286A0599|5 11|defect
P09735286A0599|123 133|target DNA
P09733854A0198|53 60|latency
P09733854A0198|89 92|RNA
P09733794A1323|35 40|Bcl-2
P09733794A1323|143 152|treatment
P09733794A1323|58 66|proteins
P09733794A1323|121 126|cells
P09733493A0493|139 147|solution
P09733493A0493|5 12|results
P09733493A0493|47 57|standpoint
P09731704A1472|186 192|manner
P09731704A1472|1 13|Transfection
P09731704A1472|39 70|delta5ERalpha expression vector
P09731704A1472|107 119|potentiation
P09731513A1090|153 163|HTLV-I Tax
P09731513A1090|140 149|IL-8 gene
P09731513A1090|23 30|results
P09731513A1090|121 136|transactivation
P09730413A0642|116 127|TME surgery
P09730413A0642|188 195|cancers
P09730413A0642|63 67|role
P09729481A0000|153 170|Sp1 binding sites
P09729481A0000|100 108|promoter
P09729481A0000|126 135|sequences
P09729481A0000|180 204|transcription start site
P09727046A0000|190 193|Lam
P09727046A0000|95 101|region
P09727046A0000|132 135|HS2
P09727046A0000|150 182|beta-globin locus control region
P09726991T0000|16 34|DNA binding domain
P09726991T0000|60 85|transcription factor Mac1
P09726987T0000|61 85|transcription factor IID
P09726201T0000|15 29|interpretation
P09725651A0077|68 79|environment
P09725651A0077|91 99|versions
P09725651A0077|45 62|Microsoft Windows
P09724772A0840|101 117|ZiaR-DNA binding
P09724772A0840|151 165|metal-chelator
P09724772A0840|75 96|zia operator-promoter
P09724754A0173|65 72|nucleus
P09724754A0173|94 99|genes
P09724654A0761|97 108|Mcm protein
P09724654A0761|131 134|RPA
P09724654A0761|63 69|timing
P09722766A0706|116 120|rats
P09722766A0706|65 74|injection
P09722161A3065|1 11|Regulation
P09722161A3065|46 55|targeting
P09721798A1734|71 84|HCV hepatitis
P09721798A1734|25 33|children
P09721798A1734|56 66|transplant
P09721798A1734|14 21|percent
P09719636A1134|6 16|hypothesis
P09719636A1134|43 52|mutations
P09719636A1134|199 205|region
P09719636A1134|215 225|C terminus
P09718372T0000|1 9|Evidence
P09718372T0000|82 102|Sty1/Spc1 MAP kinase
P09718372T0000|106 119|fission yeast
P09717835A0941|38 44|xIRS-u
P09717835A0941|126 132|member
P09717835A0941|56 62|member
P09716435A1004|84 94|depression
P09716435A1004|96 103|decline
P09716435A1004|12 22|CR/PP diet
P09716435A1004|164 174|PR/CP diet
P09716179A0974|1 21|RXR-gamma expression
P09716179A0974|117 147|kinase inhibitors p21Cip1/WAF1
P09716179A0974|218 236|RB phosphorylation
P09716179A0974|56 62|levels
P09715384A0235|49 59|treatments
P09715384A0235|111 112|%
P09715384A0235|147 149|mm
P09715384A0235|73 78|J/cm2
P09715384A0235|91 98|results
P09715278A1079|153 159|manner
P09715278A1079|114 119|genes
P09715278A1079|127 147|G1 cell cycle arrest
P09715278A1079|180 192|NT2/D1 cells
P09714109A0785|117 125|increase
P09714109A0785|86 94|infusion
P09714109A0785|129 139|muscle SNA
P09713996T0000|171 179|patients
P09713996T0000|185 189|drug
P09713996T0000|156 166|cell lines
P09713996T0000|66 80|rearrangements
P09713990T0000|1 10|Isolation
P09713990T0000|46 68|colon cancer cell line
P09712919A0307|85 86|s
P09712919A0307|139 146|T cells
P09712919A0307|67 84|signaling pathway
P09712898T0000|69 73|SAPK
P09712898T0000|100 103|JNK
P09712898T0000|92 98|kinase
P09712898T0000|75 78|Jun
P09712859A1110|101 110|infection
P09712859A1110|53 61|enhancer
P09712859A1110|131 144|blood T-cells
P09712297T0000|114 125|individuals
P09712297T0000|67 75|patients
P09710641A0000|206 227|zeta-crystallin genes
P09710641A0000|235 239|lens
P09710641A0000|42 47|Pax-6
P09710641A0000|87 107|transcription factor
P09710641A0000|157 167|activation
P09710641A0000|58 64|domain
P09710615T0000|85 90|yeast
P09710615T0000|100 119|protein trafficking
P09710615T0000|23 31|molecule
P09710615T0000|46 62|syntaxin homolog
P09710599T0000|101 109|response
P09710599T0000|147 156|signaling
P09710599T0000|132 138|factor
P09710591A0981|1 10|Mutations
P09710591A0981|70 93|phosphorylation targets
P09710591A0981|190 200|MAP kinase
P09710591A0981|36 41|c-fos
P09710591A0981|148 163|transactivation
P09710582A0535|139 146|PD98059
P09710582A0535|114 117|MEK
P09710582A0535|67 89|protein kinase pathway
P09710582A0535|124 137|MEK inhibitor
P09708565A0000|71 80|selection
P09708565A0000|206 209|NHL
P09708565A0000|234 244|study site
P09708565A0000|173 176|RIT
P09708565A0000|196 204|lymphoma
P09708565A0000|84 94|antibodies
P09708565A0000|253 271|multicenter trials
P09708565A0000|123 130|methods
P09707577A1047|4 12|contrast
P09706643A0206|44 51|disease
P09705564T0000|69 73|E1E4
P09705564T0000|48 59|E5A protein
P09705564T0000|74 87|E5 transcript
P09705352A0879|10 14|Hsk1
P09705352A0879|41 45|Mcm2
P09705352A0879|47 54|subunit
P09705324A0213|169 178|consensus
P09705324A0213|42 65|mobility shift analyses
P09705324A0213|108 112|HNF1
P09705324A0213|258 260|bp
P09705324A0213|290 297|rat Std
P09705324A0213|144 151|protein
P09705324A0213|269 286|promoter sequence
P09704927A0479|115 126|box domains
P09704927A0479|40 44|E2Fs
P09704927A0479|72 83|DNA binding
P09704569T0000|98 126|steroid receptor superfamily
P09704569T0000|13 22|structure
P09704006A0224|1 11|Arnt3 mRNA
P09704006A0224|107 111|acid
P09704006A0224|75 84|P19 cells
P09703276A2346|69 84|carcinogenicity
P09703276A2346|7 14|results
P09703021A0000|204 212|function
P09703021A0000|216 227|vertebrates
P09703021A0000|4 11|insects
P09703021A0000|229 238|catalysis
P09703021A0000|13 48|arylalkylamine N-acetyltransferases
P09703021A0000|165 182|neurotransmitters
P09701821A1108|136 142|levels
P09701821A1108|98 108|osmolarity
P09701821A1108|54 61|sigma A
P09701821A1108|14 27|transcription
P09701609A0116|5 15|laboratory
P09701609A0116|59 74|orphan proteins
P09701609A0116|134 144|Gbetagamma
P09698512A0296|64 85|transplant recipients
P09698457A0778|115 119|hair
P09698457A0778|36 51|Cux/CDPDeltaCR1
P09696164A0000|34 43|detection
P09696164A0000|54 75|infant death syndrome
P09694897T0000|152 157|motif
P09694897T0000|82 91|U6 snRNAs
P09694897T0000|109 136|affinity RNA binding domain
P09694860A0498|16 22|region
P09694860A0498|92 100|homology
P09694860A0498|45 51|domain
P09694599A1355|54 62|IL-1beta
P09694599A1355|40 49|IL-1alpha
P09694599A1355|72 80|patients
P09694034A0713|102 106|mode
P09694034A0713|156 158|LI
P09694034A0713|20 29|clozapine
P09694034A0713|110 116|action
P09694034A0713|46 48|LI
P09694034A0713|164 174|test model
P09693134A0782|184 202|column neuroblasts
P09693134A0782|80 87|domains
P09693134A0782|295 303|position
P09693134A0782|93 104|neuroblasts
P09693134A0782|148 151|DER
P09692965A0904|38 45|helices
P09692965A0904|92 100|exposure
P09692965A0904|105 111|burial
P09691031A1050|79 94|myosin proteins
P09691031A1050|62 71|targeting
P09689047A0253|48 63|glycoconjugates
P09689047A0253|81 106|sugar-nucleotide cytidine
P09689047A0253|110 123|monophosphate
P09689047A0253|24 33|synthesis
P09689047A0253|149 159|CMP-Neu5Ac
P09687514A0521|9 14|study
P09687514A0521|107 115|proteins
P09687498A1173|50 59|mutations
P09687498A1173|71 77|v-erbA
P09687498A1173|38 42|role
P09687498A1173|5 12|results
P09686344T0000|43 80|ornithine transcarbamylase deficiency
P09685226A0000|35 43|agonists
P09685226A0000|5 9|role
P09685226A0000|162 166|gene
P09685226A0000|63 75|cAMP pathway
P09685226A0000|195 216|lung cancer cell line
P09683576A0542|22 35|cleavage site
P09683576A0542|107 117|processing
P09681822A0520|71 78|tissues
P09679750A0304|34 65|prostate cancer chemoprevention
P09679750A0304|138 144|NSAIDs
P09679750A0304|110 136|cyclo-oxygenase inhibitors
P09678837A0736|85 97|methacholine
P09678837A0736|101 109|subjects
P09678837A0736|5 8|aim
P09678837A0736|126 134|rhinitis
P09678837A0736|182 191|serum IgE
P09677410A1059|223 231|function
P09677410A1059|80 83|HBV
P09677410A1059|67 71|role
P09677410A1059|177 180|HBx
P09677410A1059|120 137|HBV core promoter
P09677330A0584|70 74|UCR2
P09677330A0584|177 181|exon
P09677330A0584|94 99|exons
P09677330A0584|61 65|UCR1
P09676349A0000|4 11|Level A
P09676349A0000|96 99|CAS
P09676349A0000|122 135|Bronchoretard
P09676349A0000|30 41|correlation
P09675154A0690|139 153|point mutation
P09675154A0690|200 217|missense mutation
P09675154A0690|163 192|consensus splicing donor site
P09675154A0690|41 49|families
P09673037A0358|19 26|changes
P09673037A0358|144 150|Gomori
P09673037A0358|134 140|method
P09671579A1168|84 94|integrator
P09671579A1168|55 74|signaling processes
P09671496A0557|33 38|c-Cbl
P09671496A0557|42 53|development
P09671496A0557|58 69|homeostasis
P09671496A0557|73 77|mice
P09671313A0334|34 46|MT Hartsough
P09671313A0334|55 57|J.
P09669641A0425|16 24|accuracy
P09669641A0425|61 68|amylase
P09668108A1017|55 72|cell cycle arrest
P09668108A1017|112 120|strategy
P09668108A1017|124 138|cancer therapy
P09668096A0806|73 81|partners
P09667795A0000|49 57|disorder
P09666114A0389|87 91|TATA
P09666114A0389|42 48|region
P09666114A0389|160 177|Sp1 binding sites
P09666114A0389|135 146|G-C content
P09665720A1145|22 25|Mg2
P09665720A1145|27 40|binding sites
P09665720A1145|134 144|polymerase
P09665503A0526|23 33|volunteers
P09664033A1204|187 193|bodies
P09664033A1204|81 90|nucleolus
P09664033A1204|142 148|import
P09662443A0402|48 60|organization
P09662443A0402|79 89|expression
P09661676T0000|25 39|protein levels
P09661676T0000|10 21|implication
P09660836A0983|171 180|S222D MEK
P09660836A0983|191 199|PD098059
P09660836A0983|39 53|state kinetics
P09660836A0983|57 71|MEK inhibition
P09660836A0983|14 24|evaluation
P09658769A0058|77 89|hepatitis C.
P09658403A1207|1 9|Addition
P09658403A1207|20 24|KN62
P09658403A1207|52 76|progesterone agonist Org
P09658403A1207|89 95|effect
P09658403A1207|31 39|exposure
P09658104T0000|115 139|repeat promoter activity
P09658104T0000|82 100|Rous sarcoma virus
P09656485A0351|17 23|copies
P09656485A0351|66 87|restriction digestion
P09655916A0415|33 39|finger
P09655916A0415|8 29|DNA recognition helix
P09655916A0415|125 134|histidine
P09655916A0415|89 93|side
P09653745A0180|51 56|1940s
P09653745A0180|143 151|thirties
P09653745A0180|67 80|paper queries
P09653745A0180|178 186|projects
P09653745A0180|245 252|malaria
P09653641A0471|66 77|start codon
P09652742A0455|39 42|p53
P09652742A0455|146 152|strain
P09652736A1205|184 192|activity
P09652736A1205|4 12|addition
P09652736A1205|43 52|apoptosis
P09652736A1205|56 59|p53
P09652736A1205|88 92|p300
P09651383A0967|99 110|HepG2 cells
P09651383A0967|197 204|control
P09651383A0967|259 270|apoCII gene
P09651383A0967|222 227|HNF-4
P09651383A0967|80 95|HNF-4 synthesis
P09651383A0967|27 45|HNF-4 binding site
P09651383A0967|242 251|regulator
P09651367T0000|3 7|role
P09651367T0000|12 18|RalGDS
P09650789A0185|137 143|degree
P09650789A0185|69 85|Overhauser shift
P09650789A0185|155 166|orientation
P09650299A1334|98 109|integration
P09650299A1334|58 64|domain
P09650275T0000|53 65|implications
P09650275T0000|30 48|weapons convention
P09650180A1130|58 59|V
P09650180A1130|107 116|mGy min-1
P09650180A1130|74 75|%
P09649501A0358|212 219|protein
P09649501A0358|95 120|protein interaction assay
P09649501A0358|300 319|HSF1 heptad repeats
P09649501A0358|269 276|repeats
P09649501A0358|30 37|repeats
P09649437A1140|53 59|C/EBPs
P09649437A1140|107 113|GATA-1
P09649315A0943|153 158|range
P09649315A0943|49 56|spectra
P09649315A0943|162 169|ability
P09649315A0943|62 68|series
P09649315A0943|134 142|proteins
P09649069A0490|40 60|laryngeal parameters
P09647233A0336|118 131|binding sites
P09647233A0336|4 15|macrophages
P09647233A0336|76 83|binding
P09647233A0336|31 52|HIV-1 gene expression
P09645942A1164|80 93|stoichiometry
P09645942A1164|57 59|8S
P09643548A0000|21 27|2Fe-2S
P09643548A0000|40 51|ferredoxins
P09643153T0000|21 23|T1
P09642276A0881|137 145|function
P09642276A0881|5 13|cleavage
P09642276A0881|89 104|suicide program
P09642276A0881|149 152|Fak
P09642238A0532|1 7|Intron
P09642214A0244|139 143|MAPK
P09642214A0244|9 15|report
P09642214A0244|123 137|protein kinase
P09642214A0244|91 101|activation
P09642042A0646|1 19|Binding affinities
P09642042A0646|158 175|substrate binding
P09642042A0646|94 101|analogs
P09640802A0467|117 128|flap choice
P09640802A0467|72 76|flap
P09639565A0225|112 125|SV40 promoter
P09639565A0225|47 64|enhancer activity
P09639410A3282|67 77|strategies
P09638793A1446|51 62|superiority
P09638793A1446|156 180|i.v. perflubron emulsion
P09638793A1446|197 204|carrier
P09638793A1446|76 78|LV
P09638793A1446|89 99|properties
P09638485A0111|55 94|leukocyte alkaline phosphatase activity
P09638485A0111|96 100|LAPA
P09638485A0111|126 139|car mechanics
P09638485A0111|13 20|benzene
P09637689A0150|175 183|promoter
P09637689A0150|83 97|RNA polymerase
P09637689A0150|144 155|recruitment
P09637689A0150|57 60|DNA
P09637689A0150|105 115|holoenzyme
P09636670T0000|18 22|gene
P09636670T0000|95 103|analysis
P09636119T0000|70 75|plant
P09636119T0000|22 31|generator
P09635149A1148|1 11|Hematocrit
P09633630A0740|102 105|v/v
P09633630A0740|20 30|hydrophila
P09633630A0740|52 67|lettuce extract
P09633630A0740|127 129|Ps
P09633630A0740|107 110|BMC
P09633630A0740|15 18|Aer
P09633171A0321|169 179|shear mode
P09633171A0321|127 132|hours
P09633171A0321|198 213|testing machine
P09633171A0321|90 99|tap water
P09632734A0943|66 69|p70
P09632734A0943|41 56|ERK2 activation
P09632734A0943|60 64|p126
P09632709A0464|5 15|cDNA clone
P09632709A0464|57 64|protein
P09632709A0464|91 95|BX42
P09632217A0477|102 108|heroin
P09632217A0477|156 162|effect
P09632217A0477|143 148|mg/kg
P09632217A0477|128 133|doses
P09632217A0477|44 49|mg/kg
P09630245A0903|1 15|Yeast U1 snRNP
P09630245A0903|48 56|proteins
P09630245A0903|146 154|proteins
P09629449A0540|48 59|spermatozoa
P09629449A0540|173 178|cells
P09629449A0540|128 134|number
P09629449A0540|90 103|concentration
P09628821A1194|23 39|KG1a EST dataset
P09628821A1194|128 139|progression
P09628821A1194|44 54|candidates
P09628375A0700|8 23|ePTFE specimens
P09627285A0554|71 83|oocyte yield
P09627285A0554|143 146|hMG
P09627285A0554|8 9|S
P09627285A0554|122 128|number
P09626662A1076|113 120|partner
P09626662A1076|58 64|RIP140
P09626662A1076|176 182|ligand
P09626662A1076|72 83|RXR subunit
P09625762A0426|51 66|transactivation
P09625762A0426|11 26|oncoprotein E1A
P09622121T0000|5 8|use
P09622121T0000|146 155|pre-mRNAs
P09622121T0000|88 106|protein components
P09622055A0207|20 30|Cbl family
P09622055A0207|67 72|c-Cbl
P09622055A0207|77 82|Cbl-b
P09622055A0207|104 109|Sli-1
P09621372A0369|34 46|leukocytosis
P09621372A0369|9 26|blood examination
P09621372A0369|75 78|CRP
P09620955A0370|65 78|program Mfold
P09620955A0370|22 31|structure
P09620955A0370|120 129|deletions
P09620606A0000|4 12|addition
P09620606A0000|40 48|ligation
P09620606A0000|61 68|T cells
P09619777A1583|103 108|Fluid
P09619777A1583|277 293|state conditions
P09619777A1583|172 177|hours
P09619777A1583|44 55|dissolution
P09619777A1583|153 166|% dissolution
P09619777A1583|188 193|state
P09619777A1583|125 130|SGFsp
P09618481T0000|100 103|Sp1
P09618481T0000|25 47|p21/WAF1/Cip1 promoter
P09618481T0000|79 91|interactions
P09618164A0709|100 113|mdx myoblasts
P09618164A0709|21 48|methyl oligoribonucleotides
P09618164A0709|52 58|OMeRNA
P09618150A0127|236 242|effect
P09618150A0127|72 79|insulin
P09618150A0127|45 60|growth factor I
P09618150A0127|18 23|doses
P09618150A0127|218 219|h
P09618150A0127|148 176|UCP1 gene transcription rate
P09618150A0127|180 181|h
P09617765A0174|116 118|nt
P09617765A0174|5 13|sequence
P09617765A0174|128 132|poly
P09617765A0174|31 44|reading frame
P09614065A0966|1 12|Elimination
P09614065A0966|127 131|EpRE
P09614065A0966|78 87|sequences
P09614065A0966|105 113|presence
P09613574A0905|84 92|transfer
P09613574A0905|200 209|degrees C
P09613574A0905|97 99|3H
P09613574A0905|162 170|activity
P09613574A0905|123 136|substrate DNA
P09612351A0386|64 72|ULF band
P09612351A0386|14 22|evidence
P09611234A0098|84 93|LAZ3/BCL6
P09611234A0098|32 53|Mad bHLH-zip proteins
P09611234A0098|22 27|Mxi-1
P09611016A0652|69 74|grade
P09611016A0652|1 11|CONCLUSION
P09611016A0652|77 85|prolapse
P09611016A0652|150 159|pessaries
P09609720A0357|65 71|halves
P09609720A0357|147 154|protein
P09609720A0357|167 173|region
P09609720A0357|120 129|proteases
P09609342A0000|33 44|turbo pumps
P09609342A0000|66 69|CFP
P09609342A0000|24 29|types
P09609342A0000|91 94|MFP
P09606633A0523|1 24|Interferon beta therapy
P09605930A1428|38 51|transfections
P09605930A1428|56 77|mobility shift assays
P09605930A1428|104 119|rat hepatocytes
P09604052A0166|110 116|sample
P09604052A0166|124 129|women
P09604052A0166|135 149|wrist fracture
P09602124A0127|10 12|M.
P09601921A0000|1 12|Tributyltin
P09601921A0000|21 39|breakdown products
P09601921A0000|178 188|west coast
P09601921A0000|126 137|Great Lakes
P09601921A0000|210 216|Canada
P09601510A0215|4 12|contrast
P09601510A0215|28 40|retroviruses
P09599897A0000|233 240|protein
P09599897A0000|319 322|HSP
P09599897A0000|84 87|HSP
P09599897A0000|18 37|laboratory features
P09599897A0000|216 221|serum
P09599897A0000|295 309|manifestations
P09599897A0000|247 253|levels
P09599897A0000|242 245|CRP
P09599664A0881|39 45|clones
P09599664A0881|59 69|expression
P09598894A0732|49 59|resorption
P09598894A0732|9 17|subjects
P09596738T0000|1 6|Roles
P09596738T0000|115 126|candidiasis
P09596738T0000|14 30|Candida albicans
P09596542A0542|18 26|surfaces
P09596542A0542|107 111|core
P09595496A0000|98 106|patients
P09595496A0000|126 133|surgery
P09595496A0000|89 94|fluid
P09593302A1165|87 95|A-domain
P09593302A1165|42 60|non-responsiveness
P09592208A0470|216 226|statistics
P09592208A0470|37 47|importance
P09592208A0470|166 179|possibilities
P09592208A0470|30 34|book
P09592125A0000|119 124|cells
P09592125A0000|49 53|role
P09592125A0000|76 83|complex
P09592125A0000|88 96|hybrid N
P09590540A0513|33 35|kb
P09590540A0513|5 14|bZP2 cDNA
P09590540A0513|199 204|frame
P09590540A0513|223 234|T5 promoter
P09590540A0513|159 168|Sac1-Sal1
P09590540A0513|245 265|lac operator control
P09590540A0513|180 188|fragment
P09588228A0370|112 123|MPM tissues
P09588228A0370|24 39|anticytokeratin
P09586832A0229|5 10|lines
P09585540A0440|26 32|enzyme
P09584194A1305|137 150|protein Dim1p
P09584194A1305|98 105|homolog
P09584194A1305|193 197|HEF1
P09584194A1305|17 21|role
P09584194A1305|217 221|HEF1
P09584194A1305|213 216|p55
P09584194A1305|183 189|region
P09584180A0701|101 119|NF-kappaB proteins
P09584180A0701|91 96|Stat6
P09584165T0000|1 6|RACK1
P09584165T0000|48 55|homolog
P09584165T0000|112 132|src tyrosine kinases
P09584165T0000|147 160|NIH 3T3 cells
P09584165T0000|63 75|beta subunit
P09583592A0263|21 31|Case study
P09583201A0759|1 5|None
P09582953A1097|1 8|RESULTS
P09582953A1097|101 121|protein C activities
P09582953A1097|53 77|fibrinogen concentration
P09582953A1097|163 169|horses
P09582953A1097|134 136|PT
P09582635A0523|1 8|Results
P09582635A0523|25 43|mean bond strength
P09582635A0523|107 125|mean bond strength
P09582343A0000|35 48|cell line SX9
P09582327A0295|171 181|base pairs
P09582327A0295|374 385|stimulation
P09582327A0295|143 154|fusion gene
P09582327A0295|318 327|LHbetaLUC
P09582327A0295|86 92|GGH3-1
P09582327A0295|113 123|expression
P09582327A0295|94 99|cells
P09582327A0295|389 397|activity
P09582308A1165|119 131|heterodimers
P09582308A1165|42 51|formation
P09582308A1165|72 82|homodimers
P09582267A0326|153 158|cells
P09582267A0326|222 231|induction
P09582267A0326|200 213|growth arrest
P09582267A0326|67 86|expression plasmids
P09582267A0326|57 65|proteins
P09581834A2578|184 201|signaling pathway
P09581834A2578|203 212|induction
P09581834A2578|123 129|effect
P09581834A2578|151 161|impairment
P09581834A2578|90 96|effect
P09581552A1323|80 86|bundle
P09581552A1323|40 62|tetramerization domain
P09580563A0331|170 171|%
P09580563A0331|118 119|%
P09580563A0331|42 43|%
P09580563A0331|73 79|dynein
P09579808A0000|85 87|EC
P09579808A0000|158 165|glycans
P09579808A0000|77 80|GnT
P09579808A0000|12 38|alpha-6-D-mannoside beta-1
P09579602A1720|103 112|reduction
P09579602A1720|53 68|reproducibility
P09579602A1720|72 91|CD34 determinations
P09578042A0363|35 43|patterns
P09578042A0363|154 167|lobe epilepsy
P09578042A0363|99 108|SEEG/ECoG
P09578042A0363|122 127|group
P09577365A0747|155 162|vessels
P09577365A0747|113 120|vessels
P09577365A0747|43 49|mucosa
P09577365A0747|210 215|level
P09577365A0747|194 202|staining
P09576230T0000|50 68|reperfusion injury
P09576230T0000|112 118|arrest
P09576230T0000|76 81|brain
P09575217A0000|64 68|Jaks
P09575217A0000|97 107|activators
P09575217A0000|126 131|Stats
P09575217A0000|74 92|signal transducers
P09575143A1189|21 27|ZAP-70
P09575143A1189|189 206|activation motifs
P09575143A1189|214 217|TCR
P09575143A1189|91 109|SRC-family kinases
P09573884A0392|85 94|retrusive
P09573884A0392|21 29|position
P09573884A0392|41 48|S-N-Pog
P09573884A0392|134 142|subjects
P09573374A0687|103 116|cosmid clones
P09573374A0687|87 97|chromosome
P09573374A0687|216 225|structure
P09573374A0687|65 68|YAC
P09573374A0687|176 185|IRF1 gene
P09573202A0900|50 63|alpha subunit
P09573202A0900|98 105|glycine
P09573202A0900|82 94|substitution
P09572990A0630|33 39|Stat-3
P09572990A0630|24 28|hSIE
P09572990A0630|46 60|MHC-I ligation
P09572990A0630|181 188|agarose
P09572511A0148|81 87|RBI-EM
P09572511A0148|9 18|algorithm
P09572511A0148|89 98|algorithm
P09572428A0526|1 5|Mean
P09572428A0526|97 101|PCOS
P09572428A0526|162 167|women
P09572428A0526|199 204|ng/ml
P09572428A0526|89 92|PCO
P09570952A0000|113 123|myofibrils
P09570952A0000|67 76|M-protein
P09570952A0000|91 98|protein
P09570133A0474|140 148|proteins
P09570133A0474|76 92|partner proteins
P09570133A0474|161 170|promoters
P09570030T0000|7 25|growth retardation
P09570030T0000|31 36|cause
P09568445T0000|111 123|thrombolysis
P09568445T0000|45 55|infarction
P09566882A0693|51 59|promoter
P09566882A0693|39 43|Pho2
P09566882A0693|7 15|function
P09566871T0000|33 55|Ty1 retrotransposition
P09566731A0458|170 176|clones
P09566731A0458|55 61|region
P09566731A0458|146 158|cell hybrids
P09565584A0770|171 180|targeting
P09565584A0770|223 243|mutagenesis analysis
P09565584A0770|3 10|cluster
P09565584A0770|67 76|sequences
P09565584A0770|105 109|exon
P09564917A0900|21 39|alpha2-antiplasmin
P09564917A0900|66 77|mediastinum
P09564860A2139|190 199|receptors
P09564860A2139|140 148|proteins
P09564860A2139|112 121|receptors
P09564860A2139|133 134|G
P09564860A2139|14 41|receptor/G protein coupling
P09562398A0848|207 209|.9
P09562398A0848|173 175|.1
P09562398A0848|93 95|.4
P09562398A0848|43 46|AUC
P09561560A0579|1 16|Rhesus macaques
P09561560A0579|21 32|BALB/c mice
P09561560A0579|260 269|positions
P09561560A0579|162 182|HIV-Nef recombinants
P09561560A0579|214 218|mice
P09560390A0771|64 68|sum1
P09560390A0771|26 44|checkpoint control
P09560390A0771|121 127|stress
P09560221A0282|170 181|animal CAKs
P09560221A0282|3 7|cDNA
P09560221A0282|108 132|fission yeast CAK mutant
P09560221A0282|151 158|protein
P09557708A1426|85 95|microvilli
P09557708A1426|1 24|Specialized actin tails
P09557708A1426|37 50|IEV particles
P09557708A1426|131 136|cells
P09557678A0140|116 120|HT-3
P09557678A0140|39 49|expression
P09557678A0140|213 237|G1/S phase growth arrest
P09557678A0140|130 150|carcinoma cell lines
P09556573A1062|85 89|acid
P09556573A1062|200 209|PPARalpha
P09556573A1062|232 236|SMRT
P09556573A1062|127 136|PPARalpha
P09556573A1062|9 16|studies
P09556561A0671|119 124|yeast
P09556561A0671|138 144|guides
P09556561A0671|76 81|group
P09556561A0671|11 24|H/ACA snoRNAs
P09555046A1617|136 144|sequence
P09555046A1617|168 175|mammals
P09555046A1617|54 84|branchpoint consensus sequence
P09555046A1617|91 97|intron
P09553143A0729|157 166|treatment
P09553143A0729|172 176|H2O2
P09553143A0729|12 28|ZAP-70 substrate
P09553040A0651|1 14|Cell survival
P09553040A0651|18 21|Epo
P09553040A0651|38 48|activation
P09553040A0651|124 129|Stats
P09551972A1033|119 124|CL-17
P09551972A1033|1 13|Fluorescence
P09551972A1033|22 35|hybridization
P09551972A1033|131 144|cosmid c101F1
P09551972A1033|180 188|telomere
P09551182A0212|139 153|fusion protein
P09551182A0212|33 50|zebrafish embryos
P09551182A0212|178 200|transactivation domain
P09551182A0212|10 29|retinoid signalling
P09551182A0212|122 129|embryos
P09550919A0365|102 104|mg
P09550919A0365|168 176|episodes
P09550919A0365|96 98|mg
P09550919A0365|199 200|%
P09550919A0365|161 162|%
P09550919A0365|187 195|episodes
P09550919A0365|112 114|mg
P09550919A0365|209 217|episodes
P09550919A0365|180 181|%
P09549783T0000|83 91|patients
P09549783T0000|57 65|saccades
P09549632A1189|84 98|predictability
P09549632A1189|67 68|%
P09549632A1189|42 43|%
P09549632A1189|135 140|trial
P09549179A0774|85 88|DDE
P09549179A0774|17 29|testosterone
P09549179A0774|1 13|Serum levels
P09549179A0774|80 81|p
P09549179A0774|57 64|changes
P09547349A0000|5 77|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09547349A0000|126 135|apoptosis
P09547349A0000|91 101|edelfosine
P09546424A1550|30 48|PDGF beta-receptor
P09545638A1181|23 30|HRMT1L1
P09545638A1181|14 19|roles
P09545638A0330b|67 71|HMT1
P09545353A1071|64 122|activating transcription factor/cAMP response element site
P09545353A1071|161 176|E-selectin gene
P09545353A1071|148 153|sites
P09545323T0000|82 97|yeast MSH2-MSH6
P09545323T0000|61 73|DNA mismatch
P09545293A0590|1 6|Sites
P09545293A0590|60 68|location
P09544991A0750|255 263|m-Stat5a
P09544991A0750|33 38|SHP-2
P09544991A0750|140 148|m-Stat5b
P09544991A0750|77 101|tyrosine phosphorylation
P09544991A0750|130 138|m-Stat5a
P09544991A0750|226 251|transactivation potential
P09544987A1583|66 70|NCoR
P09541721A0894|21 42|ischemia/angiotension
P09541721A0894|54 63|AHF model
P09541721A0894|120 125|LVEDP
P09541280A0404|48 55|NC mice
P09541280A0404|11 21|plasma IgE
P09539779A0621|153 163|expression
P09539779A0621|21 34|hybridization
P09539779A0621|167 171|All1
P09539779A0621|44 57|mouse embryos
P09539721A0599|66 80|RNA polymerase
P09539721A0599|29 33|DnaA
P09538258A0200|102 107|types
P09538258A0200|36 45|mechanism
P09538258A0200|77 88|stimulation
P09538258A0200|57 71|Ras activation
P09538156A0130|42 59|zinc finger motif
P09537378A1227|71 90|gcv-lacZ expression
P09537378A1227|43 53|chromosome
P09537378A1227|30 33|bcp
P09537361A0149|5 20|iron dependence
P09537361A0149|178 188|conditions
P09537361A0149|24 37|transcription
P09537361A0149|78 107|transporter accessory protein
P09537361A0149|192 203|iron excess
P09537295A0951|22 32|start site
P09537295A0951|199 211|cDNA cloning
P09537295A0951|177 193|primer extension
P09537295A0951|148 158|P1 primers
P09536440A0000|95 100|motor
P09536440A0000|45 53|myosin V
P09535908A0321|96 102|masses
P09535908A0321|131 136|LNX-b
P09535908A0321|62 70|proteins
P09535851A0591|85 102|P kinase activity
P09535851A0591|76 82|PtdIns
P09535851A0591|57 67|Vmax value
P09535851A0591|13 21|isoforms
P09535833A0228|38 44|m-Staf
P09535833A0228|91 129|selenocysteine tRNA gene transcription
P09535833A0228|15 34|amino acid sequence
P09535082A0537|170 174|CIII
P09535082A0537|207 209|bp
P09535082A0537|5 13|addition
P09535082A0537|161 168|complex
P09535082A0537|190 194|PrfA
P09535082A0537|214 226|DNA fragment
P09533030T0000|1 13|Cytochrome b
P09533030T0000|197 201|SDHD
P09533030T0000|73 85|cDNA cloning
P09533030T0000|224 229|11q23
P09533030T0000|159 164|genes
P09533030T0000|56 70|oxidoreductase
P09533030T0000|180 184|SDHC
P09531549A0658|169 174|actin
P09531549A0658|32 51|GST fusion proteins
P09531549A0658|157 162|Pan1p
P09531549A0658|127 135|clathrin
P09531549A0658|10 25|binding studies
P09531549A0658|105 112|yAP180A
P09530251A0766|49 52|min
P09530251A0766|99 107|duration
P09530251A0766|9 12|PBS
P09529649A0307|1 10|Jean Klig
P09529649A0307|26 36|literature
P09529156A1238|171 172|%
P09529156A1238|80 93|receptor tail
P09529156A1238|110 130|phorbol 12-myristate
P09529156A1238|150 165|desensitization
P09528950A0716|13 22|fragments
P09528792A0000|191 197|manner
P09528792A0000|25 58|fibroblast growth factor receptor
P09528792A0000|62 68|FGF-R2
P09528792A0000|211 221|cell types
P09528770A1379|258 265|acetate
P09528770A1379|71 83|UAS activity
P09528770A1379|232 238|repeat
P09528770A1379|246 254|presence
P09528770A1379|131 144|carbon source
P09528770A1379|211 223|UAS activity
P09528766A0915|69 77|pathways
P09528766A0915|33 40|ERK/RSK
P09528766A0915|10 20|inhibition
P09527921A1178|206 221|initiation site
P09527921A1178|101 116|WDV Rep protein
P09527921A1178|235 245|start site
P09527921A1178|128 140|core element
P09527921A1178|45 64|electron microscopy
P09525888A1482|13 24|FLAP clones
P09525105A0298|100 117|glycoside linarin
P09525105A0298|54 61|extract
P09524273A0205|34 46|organization
P09524273A0205|71 87|characterization
P09524273A0205|107 113|region
P09524259A0301|153 169|insulin receptor
P09524259A0301|101 116|mutant receptor
P09524259A0301|199 205|system
P09524259A0301|62 67|IGFIR
P09524229A0000|5 15|gene lac-1
P09524229A0000|231 236|lac-1
P09524229A0000|187 192|group
P09524229A0000|87 92|genes
P09524229A0000|218 229|mycoviruses
P09524229A0000|298 312|concentrations
P09524229A0000|30 44|enzyme laccase
P09524222A0769|101 109|sequence
P09524222A0769|5 18|COOH-terminus
P09524222A0769|78 88|amino acid
P09524222A0769|287 303|protein kinase C
P09524222A0769|59 63|beta
P09524222A0769|266 273|protein
P09524222A0769|328 342|beta 4-adducin
P09523551A0367|6 14|variants
P09523551A0367|94 103|receptors
P09522979T0000|85 95|population
P09522979T0000|42 52|prediction
P09521913A0400|84 90|factor
P09521913A0400|36 44|60A gene
P09521907A0190|86 105|expression patterns
P09521907A0190|43 52|Otx genes
P09519830A0282|289 310|thymidine kinase gene
P09519830A0282|324 330|genome
P09519830A0282|168 173|ICP34
P09519830A0282|4 9|order
P09519830A0282|202 212|expression
P09519830A0282|176 185|promoters
P09519757A0482|48 53|R835C
P09519757A0482|114 118|fold
P09519757A0482|161 165|SUR1
P09519757A0482|27 32|D811N
P09519757A0482|151 157|region
P09518383A0000|68 83|control program
P09518383A0000|168 176|syphilis
P09518383A0000|201 210|gonococci
P09518383A0000|220 230|medication
P09518383A0000|116 120|Lima
P09518383A0000|53 61|diseases
P09518383A0000|95 106|sex workers
P09518383A0000|63 66|STD
P09517646A0149|1 13|Azithromycin
P09517646A0149|82 98|pharmacokinetics
P09517646A0149|133 138|agent
P09515924A0553|115 127|gene regions
P09515924A0553|5 8|PDH
P09515924A0553|26 31|genes
P09515921A1662|17 25|mutation
P09515921A1662|91 101|pca operon
P09515665T0000|17 35|foscarnet efficacy
P09515665T0000|52 73|CMV polyradiculopathy
P09515031A1020|7 14|results
P09515031A1020|94 110|SRF binding site
P09514272A0482|85 88|kDa
P09514272A0482|1 13|Purification
P09514272A0482|96 99|kDa
P09514272A0482|77 81|mass
P09514159A0562|16 45|hormone-coding gene promoters
P09513759A0716|1 19|Calcitriol therapy
P09513759A0716|42 50|decrease
P09512550T0000|101 108|pathway
P09512550T0000|76 79|pRb
P09511760A0221|187 197|cHO-1 gene
P09511760A0221|262 266|ends
P09511760A0221|39 53|Southern blots
P09511760A0221|10 37|restriction enzyme analysis
P09511760A0221|227 229|kb
P09510925A0389|86 97|week course
P09510925A0389|109 117|sulphate
P09510398A1138|137 141|Post
P09510398A1138|55 67|hypouricemia
P09510398A1138|97 116|urate concentration
P09510398A1138|76 85|elevation
P09510398A1138|125 133|subtypes
P09509226A1235|1 12|CONCLUSIONS
P09509226A1235|138 142|unit
P09509226A1235|77 90|time patients
P09509226A1235|147 154|savings
P09509226A1235|31 37|method
P09509226A1235|60 69|reduction
P09508511A0588|4 11|ferrets
P09508511A0588|67 72|mg/kg
P09508511A0588|58 62|dose
P09508119A0498|35 47|presentation
P09508119A0498|55 59|case
P09508119A0498|72 79|Gardner
P09506990T0000|125 142|activator protein
P09506990T0000|75 106|transcription activation domain
P09506962A1000|34 43|targeting
P09506962A1000|107 115|elements
P09506439A2179|1 10|PKC-gamma
P09506439A2179|36 49|keratinocytes
P09506439A2179|75 90|gene expression
P09505135A0182|19 26|stimuli
P09504553T0000|20 28|cannabis
P09504423A0114|239 248|pGEX-4T-2
P09504423A0114|141 152|fusion gene
P09504423A0114|130 133|DE3
P09504423A0114|194 198|gene
P09504423A0114|322 330|protease
P09504423A0114|189 192|GST
P09504423A0114|332 346|alpha-thrombin
P09504423A0114|268 281|gene sequence
P09503017A1021|187 212|lung carcinoma cell lines
P09503017A1021|37 42|HYAL1
P09503017A1021|106 112|others
P09502720A0214|107 114|domains
P09501982A1178|275 285|transition
P09501982A1178|98 105|neurons
P09501982A1178|39 43|role
P09501982A1178|413 431|XNeuroD expression
P09501982A1178|383 398|differentiation
P09501982A1178|14 19|XCoe2
P09501982A1178|222 238|progenitor cells
P09501982A1178|352 356|fate
P09501982A1178|329 339|commitment
P09501093A0071|1 11|Activation
P09501093A0071|19 26|mitogen
P09501093A0071|71 82|consequence
P09501093A0071|46 49|MAP
P09499061A0000|1 9|Cleavage
P09499061A0000|96 105|integrase
P09499061A0000|58 85|immunodeficiency virus type
P09499061A0000|26 35|reactions
P09499061A0000|14 17|DNA
P09499031A0000|48 64|stomatitis virus
P09499031A0000|188 198|transcript
P09499031A0000|130 145|polyadenylation
P09499031A0000|226 239|transcription
P09499031A0000|150 175|transcription termination
P09498553T0000|115 117|I.
P09498553T0000|40 46|sterol
P09498553T0000|62 66|P450
P09495771A0379|112 116|FtsK
P09495771A0379|167 176|septation
P09495771A0379|74 94|midcell constriction
P09494078A1362|9 23|5HT5A receptor
P09494078A1362|28 36|addition
P09491074A0104|91 106|promoter region
P09491074A0104|30 39|mechanism
P09490676A0800|191 194|Myb
P09490676A0800|130 151|oligodeoxynucleotides
P09490676A0800|14 21|binding
P09490676A0800|45 58|Ets-2 protein
P09488725T0000|82 93|proton pump
P09488713A0886|92 106|overexpression
P09488713A0886|29 39|inhibition
P09488486A0906|152 165|transcription
P09488486A0906|139 142|Pol
P09488486A0906|65 73|activity
P09488486A0906|78 111|yeast U6 snRNA gene transcription
P09488466A0695|118 148|precursor-product relationship
P09488466A0695|76 87|actinomycin
P09488466A0695|56 60|mRNA
P09487841A0132|5 9|ESEM
P09487841A0132|105 112|changes
P09487130A0383|84 88|Cdc2
P09487130A0383|18 33|telomere length
P09487130A0383|158 167|telomeres
P09487130A0383|46 53|mutants
P09486531A0638|103 115|gut endoderm
P09486531A0638|23 39|HFH-8 expression
P09486531A0638|8 21|organogenesis
P09486531A0638|130 134|role
P09485790T0000|1 27|Alison Bell Memorial Award
P09484781A1233|21 32|association
P09484781A1233|90 100|activation
P09483596A0626|113 132|suxamethonium group
P09483596A0626|56 66|conditions
P09483596A0626|74 80|minute
P09482902A0423|1 9|C.D2-Chr
P09482902A0423|157 160|p15
P09482902A0423|113 120|alleles
P09482902A0423|95 100|DBA/2
P09481826T0000|1 8|Control
P09481826T0000|55 61|change
P09481826T0000|65 69|diet
P09481826T0000|104 117|somatotrophin
P09480843A0848|19 25|region
P09480843A0848|33 44|transcripts
P09480843A0848|97 107|nucleotide
P09479498A0000|84 91|protein
P09479498A0000|30 46|RING-finger gene
P09478976A0718|98 108|start site
P09478976A0718|42 50|deletion
P09478976A0718|135 138|OSM
P09478921A0126|1 11|Substrates
P09478921A0126|79 82|CML
P09476520A1326|153 163|complexity
P09476520A1326|80 88|profiles
P09476520A1326|178 187|existence
P09476520A1326|208 221|heterogeneity
P09476520A1326|30 41|interaction
P09475378A1449|21 60|transcription-polymerase chain reaction
P09475378A1449|133 147|splice variant
P09474001A0825|100 108|patients
P09474001A0825|55 61|groups
P09474001A0825|147 151|arms
P09474001A0825|182 183|%
P09474001A0825|192 194|SP
P09473483A0953|139 146|therapy
P09473483A0953|155 170|HIV-I infection
P09473483A0953|175 186|individuals
P09473483A0953|90 100|Rev mutant
P09473040A1303b|92 99|mutants
P09472616A1004|70 73|VP7
P09472616A1004|48 55|regions
P09472616A1004|59 60|B
P09472038T0000|87 97|activation
P09472038T0000|57 71|immunoreceptor
P09472038T0000|30 37|T cells
P09469933A1060|42 49|message
P09469933A1060|95 101|Restin
P09469820A0151|169 175|events
P09469820A0151|236 243|control
P09469820A0151|108 122|reading frames
P09469820A0151|280 290|mRNA decay
P09469820A0151|87 92|uORF2
P09469820A0151|20 25|genes
P09469820A0151|210 213|UTR
P09468515A0621|18 26|deletion
P09468515A0621|94 111|SF-1 binding site
P09468515A0621|164 168|SF-1
P09468509A0463|82 91|cytoplasm
P09468509A0463|26 36|F2771 cDNA
P09467955A0468|80 93|PEA3 promoter
P09467955A0468|6 16|hypothesis
P09467955A0468|40 50|occurrence
P09467707T0000|1 20|Sibling aggregation
P09467707T0000|96 106|A-I levels
P09467707T0000|46 69|lipoprotein cholesterol
P09466931T0000|102 122|ng-2 intermolt genes
P09466931T0000|1 14|Cross-talking
P09466931T0000|40 49|receptors
P09465783A0449|80 88|parallel
P09465783A0449|25 33|response
P09465783A0449|40 62|micrograms collagen/ml
P09464525T0000|16 32|characterization
P09464525T0000|113 123|antibodies
P09464525T0000|61 63|Fv
P09463560A0124|1 9|PATIENTS
P09463560A0124|14 20|METHOD
P09463174A0670|28 35|results
P09463174A0670|91 97|period
P09460171T0000|84 91|effects
P09460171T0000|32 44|implications
P09460171T0000|15 30|thyroid hormone
P09459685T0001|99 110|adolescents
P09459685T0001|40 54|stress factors
P09458030A0192|5 10|study
P09458030A0192|43 49|effect
P09456312A1064|33 39|domain
P09454735A1782|1 7|Levels
P09454735A1782|160 173|cell motility
P09454735A1782|60 71|mitogenesis
P09453689A0000|137 148|cord injury
P09453689A0000|71 74|PPS
P09453689A0000|5 12|purpose
P09453689A0000|97 101|S2-4
P09453689A0000|56 69|pin sensation
P09452444A0450|53 61|variants
P09452444A0450|159 180|transcription factors
P09452444A0450|107 120|reporter gene
P09452421A1042|1 11|Antibodies
P09452421A1042|121 124|Tyr
P09452421A1042|60 67|protein
P09451016A1037|1 7|GlcNAc
P09451016A1037|213 217|gene
P09451016A1037|13 45|GlcNAc2-PP-Dolichol biosynthesis
P09451016A1037|181 194|transcription
P09450932A0142|65 90|DNA structure checkpoints
P09450932A0142|9 17|analysis
P09448574A0964|5 13|findings
P09448574A0964|172 186|system atrophy
P09448574A0964|57 62|RACLO
P09448574A0964|91 99|measures
P09447994A0000|70 75|c-fos
P09447994A0000|141 158|response elements
P09447994A0000|9 16|studies
P09447994A0000|130 133|AMP
P09447994A0000|135 139|cAMP
P09447994A0000|60 66|region
P09447973A0168|119 132|NIH 3T3 cells
P09447973A0168|153 168|mSos C terminus
P09447973A0168|49 70|myristoylation signal
P09447973A0168|214 222|activity
P09447973A0168|74 79|mSos1
P09447962A1027|204 212|increase
P09447962A1027|158 167|half-life
P09447962A1027|22 36|interpretation
P09447962A1027|128 138|suppressor
P09447962A1027|47 51|form
P09447917A0000|5 15|hypothesis
P09446616A0780|84 94|cell lines
P09446616A0780|19 33|Raf-1 activity
P09446616A0780|57 63|kinase
P09445488A1169|102 106|SUR1
P09445488A1169|36 44|clusters
P09445488A1169|197 211|DNA binding/EF
P09445488A1169|73 77|ESTs
P09445488A1169|90 95|genes
P09445056A0215|32 54|chemical cross-linking
P09445056A0215|64 81|sulfosuccinimidyl
P09445056A0215|92 95|BS3
P09443978A0262|100 113|transcription
P09443978A0262|201 210|initiator
P09443978A0262|129 138|promoters
P09443978A0262|74 77|Sp1
P09443972A1145|51 71|transcription factor
P09443972A1145|23 27|GKLF
P09443972A1145|91 101|regulation
P09442172A0908|118 124|number
P09442172A0908|23 26|FSH
P09442172A0908|150 164|pregnancy rate
P09442072A0716|68 76|promoter
P09442072A0716|100 104|cell
P09442072A0716|279 282|DNA
P09442072A0716|10 15|DNase
P09442072A0716|18 30|footprinting
P09442072A0716|113 120|extract
P09442072A0716|265 271|region
P09442024A0708|171 185|Jacalin lectin
P09442024A0708|200 209|O-glycans
P09442024A0708|143 146|P47
P09442024A0708|89 111|fibroblasts MRC5 cells
P09442024A0708|44 50|fusion
P09441664A0377|70 75|HNF-6
P09441664A0377|99 127|HNF-3 beta promoter activity
P09441664A0377|163 169|region
P09440166A0857|1 8|RESULTS
P09440166A0857|99 105|region
P09440166A0857|192 198|region
P09440166A0857|87 91|mRNA
P09440166A0857|157 168|nucleotides
P09440166A0857|146 152|region
P09438427A0727|16 20|role
P09438427A0727|128 166|Hoxa1 beta-galactosidase reporter gene
P09438427A0727|199 210|CE2 element
P09438427A0727|183 191|mutation
P09437001A0769|86 97|temperature
P09437001A0769|53 67|sec61-2 strain
P09437001A0769|14 28|overproduction
P09436795A0350|154 162|children
P09436795A0350|70 81|risk factor
P09436795A0350|25 45|protein S deficiency
P09436795A0350|89 90|%
P09436657A0303|187 196|knowledge
P09436657A0303|98 102|ways
P09436657A0303|6 12|review
P09436657A0303|56 64|pathways
P09435789A0961a|76 83|S phase
P09435789A0961a|194 196|HU
P09435789A0961a|262 272|DNA damage
P09435789A0961a|53 70|cell cycle arrest
P09435789A0961a|144 153|viability
P09435789A0961a|182 190|presence
P09435056A0128|33 45|pediocin AcH
P09435056A0128|23 29|domain
P09435056A0128|127 136|periplasm
P09435056A0128|147 151|form
P09435056A0128|243 246|MBP
P09435056A0128|47 50|Lys
P09434185A0902|153 160|regions
P09434185A0902|48 59|replication
P09434185A0902|5 17|organization
P09434185A0902|79 102|phage assembly proteins
P09434185A0902|61 74|DNA packaging
P09434160A0767|63 85|bone marrow stem cells
P09431828A1472|113 118|range
P09431828A1472|92 97|l h-1
P09431828A1472|72 77|l h-1
P09430730A0374|1 3|S.
P09430661A0796|68 83|Nck recruitment
P09430661A0796|116 130|JNK activation
P09430661A0796|36 51|EphB1 receptors
P09430661A0796|11 25|overexpression
P09429913A0528|1 8|RESULTS
P09429913A0528|101 108|studies
P09429913A0528|125 133|efficacy
P09429913A0528|192 200|disorder
P09428787A0138|93 97|exon
P09428787A0138|72 78|region
P09427844A0739|71 82|association
P09427844A0739|157 163|affect
P09427844A0739|97 108|dCK subunit
P09427844A0739|167 171|dGuo
P09427627A0930|153 162|treatment
P09427627A0930|124 127|S6k
P09427627A0930|132 142|MAP kinase
P09427627A0930|13 20|variant
P09427551A0501|50 60|kb introns
P09427551A0501|114 130|linkage analysis
P09427551A0501|23 28|exons
P09426958A0110|82 102|corneal cDNA library
P09426958A0110|62 67|CO-Ag
P09426595T0000|68 88|Arabidopsis thaliana
P09426595T0000|36 62|saccharopine dehydrogenase
P09426595T0000|90 109|nucleotide sequence
P09426183A0000|16 36|Rel/NF-kappaB family
P09426183A0000|172 180|activity
P09426183A0000|40 72|vertebrate transcription factors
P09426183A0000|209 217|location
P09426068A0826|5 25|c-myc/TGF-alpha HCCs
P09426068A0826|196 206|c-myc HCCs
P09426068A0826|148 154|levels
P09426068A0826|122 127|index
P09425038A0752|1 3|A.
P09425038A0752|12 14|A.
P09424012A1774|114 123|isocenter
P09424012A1774|146 153|patient
P09424012A1774|227 233|errors
P09424012A1774|181 186|error
P09423856A1098|1 20|Protease activities
P09423856A1098|278 283|parts
P09423856A1098|54 61|strains
P09423856A1098|246 259|peptide bonds
P09423856A1098|145 148|kDa
P09423856A1098|214 229|autoproteolysis
P09423123A0000|48 58|oxygenator
P09422351A0000|1 4|Ca2
P09422351A0000|76 107|serine/threonine protein kinase
P09422351A0000|147 154|enzymes
P09422351A0000|46 50|CaMK
P09421516A1516|221 239|deadenylation step
P09421516A1516|19 24|decay
P09421516A1516|142 151|stability
P09421516A1516|162 178|beta-globin mRNA
P09421516A1516|28 44|beta-globin mRNA
P09421508A0696|32 37|TCF11
P09421508A0696|131 149|transfection assay
P09421508A0696|60 64|site
P09420671A1190|1 12|CONCLUSIONS
P09420671A1190|65 73|subjects
P09420671A1190|146 158|dipyridamole
P09420671A1190|29 35|uptake
P09420275A0682|68 74|series
P09420275A0682|37 49|CBF2 binding
P09420275A0682|162 175|core sequence
P09420275A0682|78 94|oligonucleotides
P09420252A0092|103 111|proteins
P09420252A0092|202 212|expression
P09420252A0092|42 50|promoter
P09420252A0092|29 35|repeat
P09420252A0092|135 143|promoter
P09420239A1937|101 103|TM
P09420239A1937|233 242|V2 region
P09420239A1937|108 128|Nef coding sequences
P09420239A1937|198 207|Sp1 sites
P09420239A1937|318 337|glycosylation sites
P09420239A1937|83 93|elongation
P09420239A1937|178 192|TATA box sites
P09420220A0070|1 5|Cell
P09420220A0070|33 45|interactions
P09420220A0070|106 110|HCMV
P09419680A1112|1 11|CONCLUSION
P09419680A1112|94 101|finding
P09419680A1112|132 150|irradiation injury
P09419415A0236|69 90|fibroblast cell lines
P09419415A0236|53 58|panel
P09419415A0236|9 14|study
P09418882A0760|72 78|Prp42p
P09418882A0760|61 68|version
P09418871A0620|33 37|E2F1
P09418871A0620|25 28|DDB
P09418057A0684|5 10|R-EST
P09418057A0684|28 36|sequence
P09417941A1287|119 130|strand beta
P09417941A1287|5 23|disulphide bridges
P09417941A1287|198 202|face
P09417941A1287|210 216|domain
P09417941A1287|150 152|LG
P09417870A0105|156 160|cell
P09417870A0105|179 192|melanogenesis
P09417870A0105|47 63|protein kinase C
P09417870A0105|90 114|B16 mouse melanoma cells
P09417108A0000|12 25|Htf9-a/RanBP1
P09416898A1798|5 16|mean values
P09416898A1798|36 46|components
P09415711A1348|84 93|rat liver
P09415711A1348|49 54|liver
P09415711A1348|36 42|assays
P09415711A1348|145 161|alpha 1B-AR gene
P09415711A1348|134 137|CRE
P09414287A0637|33 50|Sp1 binding sites
P09413375A1486|55 59|rise
P09413375A1486|96 100|rise
P09413375A1486|129 138|cytokines
P09413375A1486|104 125|plasma concentrations
P09411459A0729|175 182|success
P09411459A0729|114 123|selection
P09411459A0729|127 141|vowel deletion
P09411459A0729|43 56|deletion task
P09411459A0729|166 171|level
P09409774A0214|84 105|rat Rattus norvegicus
P09409774A0214|219 230|polypeptide
P09409774A0214|111 121|VCSA1 gene
P09409774A0214|44 51|members
P09408796A0648|103 118|Distractibility
P09408796A0648|172 184|CVLT indices
P09408796A0648|10 29|regression analyses
P09408796A0648|44 85|WAIS-R factor scores Verbal Comprehension
P09407642A0305|19 32|gel technique
P09407642A0305|56 74|antibody detection
P09407036T0000|1 12|Tcn1p/Crz1p
P09407036T0000|89 104|gene expression
P09407031A0557|87 93|timing
P09407031A0557|6 15|UV damage
P09407031A0557|97 112|phosphorylation
P09405685A0113|153 162|GPyPyPy-3
P09405685A0113|129 143|GPyPyPyPuPuPuC
P09405685A0113|92 107|consensus motif
P09405685A0113|24 56|DNA binding transcription factor
P09405685A0113|149 152|T/A
P09405380A0800|5 14|existence
P09405380A0800|130 140|retrovirus
P09405380A0800|91 101|properties
P09404725A0644|7 11|days
P09404725A0644|26 38|gangliosides
P09404725A0644|104 113|exception
P09402139A1121|39 65|phosphoenolpyruvate kinase
P09402139A1121|234 241|IGFBP-1
P09402139A1121|74 83|promoters
P09402139A1121|114 121|insulin
P09402139A1121|95 102|regions
P09402139A1121|123 137|glucocorticoid
P09402029A1632|84 90|probes
P09402029A1632|114 119|genes
P09402029A1632|243 255|strain H37Rv
P09402029A1632|30 42|strain H37Ra
P09400613A1209|7 36|GST-PKR fusion chromatography
P09400613A1209|94 106|PKR homologs
P09398855A0438|139 147|mutation
P09398855A0438|96 113|gamma-irradiation
P09398855A0438|8 9|D
P09398855A0438|229 237|response
P09398855A0438|118 127|bieomycin
P09398855A0438|294 297|p53
P09398855A0438|88 94|agents
P09398332A0732|1 10|Sequences
P09398332A0732|39 42|mu2
P09398332A0732|196 203|165YVKM
P09398332A0732|177 194|SH2 binding motif
P09398332A0732|72 80|residues
P09398332A0732|47 53|CTLA-4
P09397723T0001|46 53|council
P09396823T0000|83 106|RNA exonuclease domains
P09396823T0000|45 59|DNA polymerase
P09396722A0185|99 111|organization
P09396722A0185|11 16|ApxII
P09396427A1488|68 76|patients
P09396427A1488|144 147|AMI
P09396427A1488|11 18|absence
P09395525A0395|187 201|IGF-I promoter
P09395525A0395|81 90|component
P09395525A0395|217 221|site
P09395525A0395|161 171|C/EBPdelta
P09395525A0395|124 131|complex
P09395456A0424|76 84|variants
P09395456A0424|107 125|proenteropeptidase
P09395456A0424|44 65|substrate recognition
P09393966A0190|34 46|region genes
P09393966A0190|21 24|IgH
P09393771A1659|1 19|TNF-alpha exposure
P09393771A1659|71 79|proteins
P09393771A1659|129 136|protein
P09393706A1171|48 57|activator
P09391173A0811|34 54|plastid ACCase genes
P09391173A0811|87 98|cDNA clones
P09391173A0811|143 152|cDNA ends
P09390125A0379|1 8|RESULTS
P09390125A0379|64 65|%
P09390125A0379|22 25|FNF
P09390125A0379|57 58|%
P09389669A1009|32 52|dorsal leg cell fate
P09389669A1009|93 107|leg disc cells
P09389492A0520|117 124|phorbol
P09389492A0520|48 53|serum
P09389492A0520|82 95|dexamethasone
P09389492A0520|107 113|effect
P09389137A0763|55 59|L2-4
P09389137A0763|22 30|apoplexy
P09389137A0763|46 50|T1-9
P09388246A0903|122 132|cytomatrix
P09388246A0903|73 84|amphiphysin
P09388200A0639|35 44|titration
P09388200A0639|138 147|promoters
P09388200A0639|115 120|c-fos
P09388200A0639|166 179|transcription
P09388198A1396|18 26|evidence
P09388198A1396|38 65|signal transduction pathway
P09388198A1396|197 211|autoregulation
P09388198A1396|145 149|rhoB
P09388198A1396|215 219|rhoB
P09387333T0001|5 13|progress
P09387333T0001|60 67|nucleus
P09385169T0000|12 19|experts
P09383156A0691|76 104|polynucleotide phosphorylase
P09383156A0691|106 112|PNPase
P09382886A1061|49 58|apoptosis
P09382886A1061|138 141|SBM
P09382886A1061|146 149|p53
P09382886A1061|62 65|PKD
P09382498A0618|85 89|area
P09382498A0618|114 118|MCTs
P09382498A0618|97 102|tumor
P09382498A0618|199 203|area
P09382498A0618|12 16|MCTs
P09382498A0618|211 216|tumor
P09381261A0970|1 12|CONCLUSIONS
P09381261A0970|33 43|EPO levels
P09381261A0970|121 125|ones
P09380697T0000|102 110|response
P09380697T0000|71 98|caveolin gene transcription
P09380697T0000|5 11|sterol
P09380697T0000|36 45|sequences
P09380504A1255|39 50|transcripts
P09380504A1255|97 99|kb
P09380504A1255|56 80|thyroid cancer cell line
P09380504A1255|181 195|actinomycin D.
P09377374A0000|70 78|features
P09377374A0000|9 14|paper
P09377374A0000|120 130|narcomania
P09376782A0328|22 32|experience
P09376782A0328|56 64|practice
P09376782A0328|44 47|MMT
P09376325A0167|1 11|Comparison
P09376325A0167|47 55|ph locus
P09373651A0255|103 119|hydrogen cyanide
P09373651A0255|36 46|glycosides
P09373651A0255|79 98|acetone cyanohydrin
P09373140A0000|33 41|enhancer
P09373140A0000|97 112|gene regulation
P09372968A0532|1 18|Sequence analysis
P09372968A0532|132 138|dynein
P09372968A0532|44 55|cDNA clones
P09372950A1283|116 129|cleavage site
P09372950A1283|96 101|sides
P09372950A1283|58 67|structure
P09372950A1283|160 166|U2 RNA
P09372924A0758|19 34|rhHR23 proteins
P09372924A0758|96 104|proteins
P09372924A0758|161 180|DNA repair reaction
P09372924A0758|124 135|involvement
P09372451T0000|92 98|domain
P09372451T0000|122 129|subunit
P09371731A0627|50 68|eIF-2alpha kinases
P09371731A0627|6 13|inserts
P09371657A0165|66 70|R77A
P09371657A0165|56 59|R77
P09371657A0165|63 64|A
P09371622A0779|103 125|lac operator sequences
P09371622A0779|1 9|Chimeras
P09371622A0779|57 70|transcription
P09371596T0000|116 136|receptor superfamily
P09371596T0000|93 100|members
P09371596T0000|14 24|regulation
P09371564A0713|18 24|amount
P09371564A0713|66 69|RNA
P09371564A0713|28 32|tRNA
P09371431T0000|80 101|terminal oxidase cbb3
P09371431T0000|43 50|thiCOGE
P09371431T0000|105 119|Rhizobium etli
P09370307A0093|84 91|tissues
P09370307A0093|62 71|regulator
P09370307A0093|181 201|DNA binding proteins
P09369482A0690|137 159|G6Pase gene expression
P09369482A0690|86 90|HNF4
P09369482A0690|67 76|HNF1alpha
P09369451A0693|136 144|sequence
P09369451A0693|185 191|region
P09369451A0693|157 170|TTAAAAATAAAAA
P09369451A0693|214 225|OP-1 effect
P09369451A0693|124 127|MEF
P09368760A0665|136 145|oogenesis
P09368760A0665|33 66|Drosophila protein kinase DSTPK61
P09368760A0665|7 11|PDK1
P09368419A0000|119 139|protein biosynthesis
P09368419A0000|21 30|induction
P09368419A0000|65 69|rd22
P09368419A0000|59 63|gene
P09368100A1354|5 17|mHIF-1 alpha
P09368100A1354|29 33|gene
P09368058A0969|86 100|phosphopeptide
P09368058A0969|211 215|site
P09368026A0435|136 156|MC3T3-E1 osteoblasts
P09368026A0435|9 14|study
P09368026A0435|122 132|calcitriol
P09368026A0435|31 38|effects
P09368014A0740|46 48|PU
P09367676A1115|116 124|sequence
P09367676A1115|42 52|expression
P09367426A1354|118 132|interpretation
P09367426A1354|83 100|compartment cells
P09367426A1354|27 31|role
P09367288A0115|69 85|unit rest length
P09367288A0115|201 207|tendon
P09367288A0115|172 183|adaptations
P09367288A0115|108 122|immobilisation
P09366517A1828|50 58|function
P09366517A1828|5 13|findings
P09366517A1828|90 105|phosphorylation
P09366456A0234|99 100|n
P09366456A0234|167 174|persons
P09366456A0234|75 80|group
P09366456A0234|59 69|anesthesia
P09366456A0234|208 210|kg
P09366456A0234|183 197|body mas index
P09365272T0000|1 8|Xenopus
P09365272T0000|59 66|effects
P09365272T0000|78 86|assembly
P09364750T0000|17 27|regulation
P09364750T0000|31 36|SUP35
P09364211A0319|82 89|binding
P09364211A0319|73 76|DNA
P09362499A0000|138 146|enhancer
P09362499A0000|5 16|Fis protein
P09362473A1540|275 289|twist activity
P09362473A1540|33 39|tinman
P09362473A1540|203 226|repressor binding sites
P09362473A1540|78 95|enhancer elements
P09362473A1540|302 307|areas
P09362473A1540|15 22|results
P09361007A0922|3 8|DNase
P09360956A0840|119 126|binding
P09360956A0840|70 83|CKIalpha site
P09360956A0840|174 193|signal transduction
P09360956A0840|130 135|c-Raf
P09360422A0135|169 200|plasminogen activator-inhibitor
P09360422A0135|276 286|volunteers
P09360422A0135|202 207|pAI-1
P09360422A0135|73 78|limbs
P09360422A0135|152 159|D-dimer
P09360422A0135|116 118|TM
P09360422A0135|244 250|values
P09359844A0674|3 4|%
P09359844A0674|14 29|HSL transcripts
P09358069T0000|1 19|Codon optimization
P09358069T0000|55 69|erythropoietin
P09358045A0000|86 94|receptor
P09358045A0000|36 40|Type
P09358045A0000|10 30|length cDNA sequence
P09354757A1444|1 20|Amino acid residues
P09354757A1444|145 150|dsDNA
P09354757A1444|43 50|alpha B
P09354757A1444|124 137|primer strand
P09354757A1444|61 65|loop
P09354676A1714|50 53|q32
P09354676A1714|114 116|MM
P09354676A1714|7 15|findings
P09354676A1714|176 187|abnormality
P09354676A1714|228 230|MM
P09354349A0338|152 154|WS
P09354349A0338|136 150|Warthin-Starry
P09354349A0338|223 242|H. pylori antiserum
P09354349A0338|43 50|patient
P09354349A0338|192 195|IMM
P09354349A0338|14 20|slides
P09353343A0919|84 85|U
P09353343A0919|87 96|Sepharose
P09353343A0919|112 120|hnRNP A1
P09353343A0919|44 51|binding
P09353304A0732|69 74|Tiam1
P09353304A0732|79 96|membrane ruffling
P09353304A0732|44 65|membrane localization
P09353255A0159|95 116|FG-nucleoporin family
P09353255A0159|120 133|pore proteins
P09352127A0953|32 47|serum myoglobin
P09352127A0953|52 73|CA III concentrations
P09352127A0953|12 23|correlation
P09351823A0414|86 90|eggs
P09351823A0414|22 36|MAPK functions
P09349967A0653|84 96|organisation
P09349967A0653|41 53|blood supply
P09349967A0653|30 37|pattern
P09348931T0000|15 22|lottery
P09346953A0000|291 296|3-OST
P09346953A0000|66 73|HSPGact
P09346953A0000|299 306|Shworak
P09346953A0000|107 112|level
P09346953A0000|14 18|rate
P09346935A0927|168 175|pol IIo
P09346935A0927|40 47|domains
P09346935A0927|191 205|RNA polymerase
P09346935A0927|93 113|RNA binding activity
P09346935A0927|267 271|role
P09346935A0927|330 344|RNA processing
P09346935A0927|60 87|pre-mRNA maturating factors
P09346925A0660|141 148|binding
P09346925A0660|20 24|Grb2
P09346925A0660|160 164|HPK1
P09346925A0660|180 190|Cos1 cells
P09346238T0000|7 15|proteins
P09346238T0000|58 68|substrates
P09345037A0886|58 77|trans-factor GATA-1
P09343982A0890|85 95|difference
P09343982A0890|5 14|amplitude
P09343982A0890|57 62|hours
P09343433A0000|145 160|yeast telomeres
P09343433A0000|56 70|RNA polymerase
P09343426A0456|1 31|Alanine substitution mutations
P09343426A0456|39 60|Zta activation domain
P09343426A0456|92 95|Zta
P09343222A0415|5 8|AGM
P09343222A0415|94 101|protein
P09343208A1405|16 23|segment
P09343208A1405|216 221|virus
P09343208A1405|140 152|organization
P09343208A1405|93 102|segment W
P09343208A1405|198 207|functions
P09341192T0000|49 65|3T3L1 adipocytes
P09341192T0000|9 14|shock
P09341158A0167|102 110|assembly
P09341158A0167|39 42|mu1
P09341158A0167|178 189|recognition
P09341158A0167|208 223|sorting signals
P09341158A0167|47 50|mu2
P09341158A0167|164 173|complexes
P09340641T0001|1 7|Effect
P09340641T0001|11 18|alcohol
P09338414A0430|32 37|ratio
P09338414A0430|97 110|stroke volume
P09338414A0430|88 92|ESAP
P09336455A0000|136 147|ultraviolet
P09336455A0000|38 46|recovery
P09336455A0000|22 30|kinetics
P09336455A0000|109 117|exposure
P09336455A0000|121 132|yeast cells
P09335608T0000|70 78|splicing
P09335608T0000|97 103|myosin
P09335298A1227|137 151|MC1061K strain
P09335298A1227|257 279|stabilization activity
P09335298A1227|173 201|multimer resolution activity
P09335298A1227|213 219|parCBA
P09335298A1227|122 129|plasmid
P09335267A0142|137 144|effects
P09335267A0142|16 32|operon structure
P09335267A0142|111 115|risk
P09335267A0142|41 49|organism
P09335267A0142|91 102|mutagenesis
P09334331A0910|55 76|EGF receptor DER/Egfr
P09334331A0910|23 34|possibility
P09334331A0910|132 136|Vein
P09334264A0540|82 89|subunit
P09334264A0540|107 111|mass
P09333168A0310|1 23|Anti-hepatitis A virus
P09333168A0310|25 28|HAV
P09333168A0310|30 35|titer
P09333026A0397|57 67|boundaries
P09333026A0397|13 22|structure
P09333026A0397|105 123|PTK family members
P09331864A0848|1 24|Serum E2 concentrations
P09331864A0848|70 71|d
P09331864A0848|134 137|MGA
P09331119A0659|51 67|thrombocytopenia
P09331119A0659|38 49|neutropenia
P09331119A0659|107 113|cycles
P09328824A0000|85 92|version
P09328824A0000|100 132|chicken thyroid hormone receptor
P09328824A0000|250 264|acid receptors
P09328824A0000|22 32|properties
P09328824A0000|225 230|roles
P09328476A0068|1 12|U4/U6 snRNP
P09328476A0068|97 99|U5
P09328476A0068|93 95|U2
P09328476A0068|78 87|particles
P09328476A0068|104 109|U4/U6
P09328343A0181|158 165|members
P09328343A0181|178 184|family
P09328343A0181|108 111|E2A
P09327881T0000|103 111|primates
P09327881T0000|73 80|studies
P09326317A0372|85 89|EXT1
P09326317A0372|118 134|linkage analysis
P09326317A0372|94 104|EXT2 genes
P09326246A0567|1 18|Sequence analysis
P09326246A0567|162 181|bp reporter plasmid
P09326246A0567|130 149|luciferase activity
P09325322A1293|85 90|shift
P09325322A1293|5 15|inhibition
P09325322A1293|94 98|EC50
P09325322A1293|62 75|cooperativity
P09325278A0458|139 147|proteins
P09325278A0458|3 28|data base homology search
P09325278A0458|234 265|Caenorhabditis elegans sequence
P09325278A0458|96 103|regions
P09325278A0458|57 80|ER1 amino acid sequence
P09325278A0458|285 289|mta1
P09325135A0737|88 95|protein
P09324988X0000|34 42|proteins
P09324988X0000|1 11|Substrates
P09324988X0000|52 58|lamins
P09324988X0000|29 32|ras
P09324878A0952|136 153|type B dissection
P09324878A0952|45 67|ultrasound examination
P09323612A0374|136 145|dysphasia
P09323612A0374|32 39|studies
P09323612A0374|86 89|use
P09323612A0374|43 70|sleep electroencephalograms
P09323612A0374|227 233|speech
P09323612A0374|192 200|children
P09323366A0000|40 45|yeast
P09323366A0000|130 143|growth medium
P09322738A0510|85 95|chromosome
P09322738A0510|71 77|allele
P09322738A0510|22 26|gene
P09321657A0439|152 174|cox3 promoter activity
P09321657A0439|221 227|effect
P09321657A0439|83 97|cox3 promoters
P09321657A0439|9 14|study
P09317830T0000|34 41|CICADAS
P09317131A1332|100 105|STAT6
P09317131A1332|37 70|NF kappa B2 nucleoprotein complex
P09317131A1332|15 19|data
P09316937A0133|64 77|discrepancies
P09316937A0133|90 95|Vitek
P09315651T0000|1 12|Involvement
P09315651T0000|24 34|regulation
P09315632A1137|222 231|neoplasia
P09315632A1137|157 170|dysregulation
P09315632A1137|131 142|fibroblasts
P09315632A1137|208 212|role
P09314570A0153|68 82|gene promoters
P09314570A0153|39 45|motifs
P09314570A0153|106 116|activation
P09314570A0153|120 130|repression
P09314537A1600|26 31|EBP50
P09314306A0571|34 40|pl-ALB
P09314306A0571|53 57|g/dL
P09312087A0000|36 50|Src homology-2
P09312087A0000|8 15|studies
P09312087A0000|287 302|phosphopeptides
P09312087A0000|105 110|SHP-2
P09312087A0000|263 267|part
P09312087A0000|52 55|SH2
P09312087A0000|92 103|phosphatase
P09312028A0975|20 33|RXRalphaF318A
P09312028A0975|93 101|presence
P09312028A0975|73 85|heterodimers
P09312028A0975|151 167|RAR AF-2 domains
P09312025A0373|186 192|mutant
P09312025A0373|33 46|co-expression
P09312025A0373|80 90|inhibition
P09312025A0373|7 14|effects
P09312025A0373|94 137|phosphatidylinositol 3-kinase p85alpha-p110
P09311810A0814|160 165|virus
P09311810A0814|26 43|cyclin D3 protein
P09311810A0814|47 57|Vero cells
P09311810A0814|75 97|alpha0 deletion mutant
P09311796A0218|81 94|IEP86 binding
P09311796A0218|146 166|transcription factor
P09311796A0218|107 131|TATA-box binding protein
P09311164A0245|25 34|density J
P09309457A0680|1 7|Assays
P09309457A0680|198 201|ERT
P09309457A0680|44 47|HDL
P09309457A0680|17 28|cholesterol
P09309457A0680|55 58|LDL
P09309457A0680|146 154|baseline
P09309457A0680|60 73|triglycerides
P09308234A0225|84 92|promoter
P09308234A0225|5 18|Max complexes
P09307065A0553|171 188|dissociation rate
P09307065A0553|50 57|D10 TCR
P09307065A0553|157 160|sec
P09307065A0553|212 215|sec
P09307065A0553|230 251|dissociation constant
P09307065A0553|151 152|M
P09305870A0894|155 160|discs
P09305870A0894|5 28|recognition specificity
P09305870A0894|213 219|domain
P09305870A0894|89 100|PDZ domains
P09305631A0770|1 15|Overexpression
P09305631A0770|48 58|cell lines
P09305631A0770|83 93|cell death
P09304123A0079|71 86|tooth structure
P09304123A0079|7 20|discoloration
P09304123A0079|124 130|manner
P09303437A0875|256 275|CAT gene expression
P09303437A0875|188 191|p12
P09303437A0875|162 171|insertion
P09303437A0875|124 132|function
P09303437A0875|149 156|element
P09303437A0875|241 252|stimulation
P09301114A0573|12 14|H.
P09300697A0000|1 12|Proteasomes
P09300697A0000|95 104|MHC class
P09300697A0000|73 81|peptides
P09299696A1074|21 35|cryptosporidia
P09299696A1074|173 182|infection
P09299696A1074|112 115|DPI
P09299696A1074|196 201|model
P09299696A1074|43 52|intestine
P09299696A1074|149 165|characterization
P09296251A0163|82 86|data
P09296251A0163|61 69|patients
P09294453A0949|70 74|ORF3
P09294453A0949|5 16|ORF3 mutant
P09294453A0949|44 52|tabtoxin
P09294422A1376|185 195|production
P09294422A1376|217 221|form
P09294422A1376|199 202|POR
P09294262A0885|5 20|promoter region
P09294262A0885|76 86|CreA boxes
P09294262A0885|166 175|promoters
P09294161A0650|184 190|assays
P09294161A0650|4 12|contrast
P09294161A0650|39 49|expression
P09294161A0650|76 93|activation domain
P09294161A0650|30 37|protein
P09293006A1412|34 45|S. lividans
P09293006A1412|26 30|lipA
P09291098T0000|119 130|liver cells
P09291098T0000|19 27|promoter
P09291077T0000|11 26|hyperammonaemia
P09290571A0420|81 86|study
P09290571A0420|108 116|patients
P09290571A0420|88 91|EPS
P09288916T0000|153 165|kidney cells
P09288916T0000|99 105|meprin
P09288916T0000|11 21|expression
P09288916T0000|134 145|Madin-Darby
P09287362A0589|81 98|PPPLPERTPESFVLADM
P09287362A0589|132 140|PTP-PEST
P09287362A0589|73 79|region
P09287362A0589|45 48|p50
P09287036A0457|110 114|mass
P09287036A0457|125 130|ng/ml
P09287036A0457|135 140|women
P09287036A0457|45 50|women
P09286115T0000|1 4|S2F
P09286115T0000|112 122|RPL21 gene
P09285715A1257|19 23|data
P09285715A1257|189 196|factors
P09285715A1257|229 240|mRNA export
P09285715A1257|62 76|export pathway
P09282985A0961|32 37|males
P09282985A0961|39 40|p
P09282329A0527|239 255|progenitor cells
P09282329A0527|35 47|interactions
P09282329A0527|175 185|regulation
P09282329A0527|143 155|determinants
P09282329A0527|12 22|mechanisms
P09279889A1124|119 123|PG-7
P09279889A1124|1 5|Area
P09279889A1124|101 105|PG-2
P09279889A1124|64 67|MTX
P09279889A1124|40 46|curves
P09279379A0310|48 52|acid
P09279379A0310|54 57|DNA
P09279379A0310|59 68|sequences
P09279379A0310|24 30|pBR322
P09278494A0762|19 22|Sp1
P09278494A0762|4 12|contrast
P09278494A0762|73 90|promoter activity
P09278454A1261|140 144|YB-1
P09278454A1261|78 90|CTGCTGGGCAAG
P09278454A1261|62 76|Y-box sequence
P09278445T0000|48 68|yeast RNA polymerase
P09278441A1160|102 106|days
P09278441A1160|170 176|tinman
P09278441A1160|69 79|expression
P09278441A1160|206 210|gene
P09278441A1160|5 12|pattern
P09278441A1160|159 166|homolog
P09277629A0268|18 19|N
P09277629A0268|108 119|memory task
P09277629A0268|63 69|nature
P09276882A0479|17 24|culture
P09276882A0479|32 34|CC
P09276882A0479|86 87|P
P09276882A0479|191 193|pH
P09276882A0479|5 13|addition
P09276882A0479|42 56|SW by-products
P09275164A0000|119 137|RNA triphosphatase
P09275164A0000|139 162|RNA guanylyltransferase
P09275164A0000|5 26|m7GpppN cap structure
P09275164A0000|110 117|enzymes
P09275164A0000|41 45|mRNA
P09272138A1153|169 175|groups
P09272138A1153|39 40|%
P09272138A1153|14 22|response
P09272138A1153|48 52|CODE
P09272138A1153|24 26|CR
P09272138A1153|177 178|P
P09272108A1295a|1 9|Analysis
P09272108A1295a|96 110|CAAT sequences
P09272108A1295a|43 47|gene
P09271417A1011|102 113|COS-7 cells
P09271417A1011|5 9|MCAD
P09271417A1011|47 53|NRRE-1
P09271400A0475|54 62|sequence
P09271400A0475|9 15|assays
P09271400A0475|90 97|control
P09271394A0558|1 6|DNase
P09271394A0558|93 97|MURA
P09271394A0558|160 163|Mu1
P09269900A1035|85 95|activation
P09269900A1035|38 49|EGF/Ras/Raf
P09269900A1035|162 171|repressor
P09269900A1035|131 137|factor
P09269900A1035|180 188|response
P09268661A1405|5 12|results
P09268661A1405|133 145|CCA sequence
P09268638A0332|72 78|D8S260
P09268638A0332|90 96|D8S285
P09268578A0225|89 94|death
P09268578A0225|15 29|cDNA sequences
P09268298T0000|31 54|fungus Phaeosphaeria sp
P09267439A0000|1 6|Genes
P09267439A0000|127 134|variety
P09267306A0381|102 122|laboratory precision
P09267306A0381|163 175|introduction
P09267306A0381|59 64|apo B
P09267306A0381|44 55|measurement
P09265642A0668|114 122|membrane
P09265642A0668|41 48|vacuole
P09265642A0668|167 178|sop mutants
P09265642A0668|88 103|internalization
P09264466A0947|36 42|target
P09264466A0947|123 138|phosphorylation
P09264466A0947|73 81|function
P09263094A0799|137 145|pressure
P09263094A0799|32 46|Lung elastance
P09263094A0799|109 124|airway pressure
P09263094A0799|326 328|Hz
P09263094A0799|18 30|MAIN RESULTS
P09263094A0799|292 313|breathing frequencies
P09263094A0799|267 272|cmH2O
P09263094A0799|56 66|resistance
P09263094A0799|240 260|mean airway pressure
P09261397A0509|1 28|Gag protein sequence motifs
P09261397A0509|36 45|NC domain
P09261397A0509|63 70|viruses
P09261184A0170|20 47|gel mobility shift analysis
P09261184A0170|76 81|FIRE1
P09261155A0833|71 72|%
P09261155A0833|143 148|IRS-1
P09261155A0833|161 166|IRS-3
P09259320A0830|102 106|DSBP
P09259320A0830|23 37|chromatography
P09259320A0830|63 70|pattern
P09259313A0950|17 35|PI kinase activity
P09259313A0950|72 87|PRL stimulation
P09258606A0822|1 10|Crosstalk
P09258606A0822|106 116|malignancy
P09258606A0822|60 66|stress
P09257887A0457|100 109|apheresis
P09257887A0457|36 41|cycle
P09257887A0457|127 143|neutrophil count
P09256973A0673|1 8|RESULTS
P09256973A0673|168 173|hours
P09256973A0673|109 122|micrograms/ml
P09256973A0673|149 152|MRT
P09256973A0673|14 16|E1
P09255349A0836|43 51|proteins
P09255349A0836|63 67|IRA1
P09254678A0106|236 245|PLP mRNAs
P09254678A0106|43 47|RNAs
P09254678A0106|78 86|proteins
P09254678A0106|130 149|proteolipid protein
P09254678A0106|192 200|Gtx mRNA
P09254678A0106|321 329|PLP gene
P09254678A0106|214 222|parallel
P09254678A0106|120 123|MBP
P09252406A0511|68 88|Shc adaptor proteins
P09252406A0511|169 180|phosphatase
P09252406A0511|38 50|binding site
P09252406A0511|109 129|phosphatidylinositol
P09252406A0511|182 186|SHP2
P09251843A0189|118 125|disease
P09251843A0189|145 156|hyperplasia
P09251843A0189|56 61|cases
P09251843A0189|106 115|Castleman
P09251843A0189|47 52|cases
P09251843A0189|181 189|lymphoma
P09249710A0331|27 31|sera
P09249039A0124|96 111|differentiation
P09249039A0124|27 34|enzymes
P09249039A0124|88 94|growth
P09247645A0000|68 77|SEC genes
P09247645A0000|215 221|screen
P09247645A0000|135 143|vesicles
P09247645A0000|31 38|alleles
P09246343T0000|1 12|Proteinuria
P09244350A0000|1 6|BRCA1
P09244350A0000|141 160|breast cancer cells
P09244350A0000|38 64|cancer susceptibility gene
P09244100A0194|40 46|groups
P09243587A0000|187 224|abortion increases breast cancer risk
P09243587A0000|141 153|interruption
P09243587A0000|81 90|pregnancy
P09243587A0000|92 96|FFTP
P09243385A1314|19 32|presaturation
P09243385A1314|63 77|motion studies
P09242551A0653|1 11|EBER1 mRNA
P09242551A0653|71 80|PEL cases
P09242551A0653|189 203|lymphoma cells
P09242551A0653|42 49|latency
P09242551A0653|26 32|marker
P09242499A0505|84 95|application
P09242499A0505|37 42|backs
P09242499A0505|124 135|base lotion
P09242499A0505|61 63|UV
P09241232A1154|103 107|Ogg1
P09241232A1154|67 71|K120
P09241232A1154|75 87|endonuclease
P09241092A1108|86 96|trans-diol
P09241092A1108|66 82|carbamazepine-10
P09241092A1108|129 139|conversion
P09241092A1108|243 251|reaction
P09241092A1108|14 23|Valproate
P09238860A1974|34 41|signals
P09238860A1974|7 12|cells
P09238860A1974|126 130|IL-2
P09238860A1974|166 174|increase
P09238860A1974|135 143|response
P09238850A2042|16 27|oscillation
P09238850A2042|56 61|clock
P09238467A0763|33 44|propranolol
P09237695A0000|67 77|indicators
P09237695A0000|29 34|study
P09236441A0639|18 26|patients
P09236441A0639|97 101|SaO2
P09236441A0639|108 119|respiration
P09236118A1455|119 129|DNA target
P09236118A1455|191 223|nucleoprotein activation complex
P09236118A1455|58 62|site
P09236118A1455|151 157|dimers
P09235995A0339|2 7|1996a
P09235424A1200|54 58|ABPM
P09235424A1200|29 35|nurses
P09235424A1200|90 96|effect
P09234743A0475|49 53|pair
P09234743A0475|18 26|proteins
P09234743A0475|83 86|UTR
P09234727A0770|35 48|transcription
P09234727A0770|80 88|promoter
P09234727A0770|10 24|fusion protein
P09234723A0846|6 15|mechanism
P09234723A0846|22 30|contrast
P09234723A0846|72 75|PTB
P09234717A0000|205 208|SH2
P09234717A0000|8 15|studies
P09234717A0000|128 134|number
P09234717A0000|227 235|proteins
P09234717A0000|253 257|role
P09234717A0000|261 280|signal transduction
P09234717A0000|56 71|protein product
P09234703A0192|50 64|G proteins Rac
P09234690A0242|1 9|Upstream
P09234690A0242|21 30|sequences
P09234690A0242|159 162|PRE
P09234690A0242|176 188|binding site
P09233811A0072|117 132|protein Mat1-Mc
P09233811A0072|6 16|regulation
P09233811A0072|30 46|HMG-box proteins
P09233809A0381|236 241|Hnf3g
P09233809A0381|172 183|Hnf3g locus
P09233809A0381|162 164|kb
P09233809A0381|133 143|expression
P09233772A0136|510 538|E3 ubiquitin-protein ligases
P09233772A0136|64 70|weight
P09233772A0136|6 13|protein
P09233772A0136|203 228|cell cycle regulator RCC1
P09233772A0136|72 78|EMBO J
P09233772A0136|293 304|protein Ran
P09233772A0136|125 132|domains
P09233772A0136|26 30|p532
P09233772A0136|480 506|HECT domain characteristic
P09232593A0946|6 12|regard
P09232593A0946|88 100|repeat units
P09230945A0089|19 28|deformity
P09230384A1056|65 74|specimens
P09230384A1056|24 33|MB system
P09230384A1056|12 18|BACTEC
P09230384A1056|134 142|recovery
P09230307A0329|49 60|development
P09230307A0329|25 31|GATA-1
P09230129A0039|197 206|nucleases
P09230129A0039|108 114|purity
P09230129A0039|44 51|% yield
P09230129A0039|156 164|SDS/PAGE
P09230129A0039|261 267|enzyme
P09230129A0039|240 248|antibody
P09229420A0158|1 14|Re-evaluation
P09229420A0158|70 74|time
P09229420A0158|53 56|hip
P09229420A0158|146 156|background
P09229420A0158|90 99|operation
P09228092A1779|159 164|exons
P09228092A1779|7 15|analyses
P09228092A1779|105 116|transcripts
P09227799A0254|169 180|egg antigen
P09227799A0254|206 221|precipitin test
P09227799A0254|124 129|tests
P09227799A0254|182 185|SEA
P09227799A0254|31 35|tool
P09227099A0106|55 73|bar superstructure
P09227099A0106|197 207|angulation
P09227099A0106|228 236|accuracy
P09227099A0106|211 219|implants
P09226113A0857|55 63|borehole
P09226113A0857|30 49|source water sample
P09225686A0683|111 117|months
P09225686A0683|94 107|complications
P09225686A0683|14 38|radiofrequency lesioning
P09225506A0462|5 18|control group
P09225506A0462|59 78|coagulation factors
P09225506A0462|89 93|VIII
P09224811A0000|116 120|gene
P09224811A0000|141 148|thyroid
P09224811A0000|172 178|animal
P09224811A0000|231 239|pathways
P09224811A0000|109 114|P450R
P09223880A1147|22 37|injection speed
P09223880A1147|44 53|.2 ml.s-1
P09223647T0000|49 57|zymogens
P09223647T0000|83 91|analysis
P09223647T0000|126 138|implications
P09223479A1193|186 196|BHRF1 gene
P09223479A1193|1 7|ORF M1
P09223479A1193|33 49|poxvirus serpins
P09223479A1193|200 203|EBV
P09223479A1193|57 64|ORF M11
P09223479A1193|165 168|HVS
P09223229A0565|70 79|mb-1 gene
P09223229A0565|89 97|TATA box
P09223042A0000|85 90|drugs
P09223042A0000|1 6|Liver
P09223042A0000|30 34|LRBV
P09222057A0176|38 41|PDF
P09222057A0176|83 89|course
P09222057A0176|22 36|dialysis fluid
P09220158A0537|205 210|virus
P09220158A0537|136 141|ORF-2
P09220158A0537|98 106|sequence
P09220158A0537|147 176|baculovirus expression vector
P09218775A1229|68 78|strain PAO
P09218775A1229|99 102|use
P09218775A1229|124 140|algD-xylE fusion
P09218775A1229|13 18|palgD
P09218599A0184|38 48|mechanisms
P09218599A0184|90 97|effects
P09218459A0000|169 175|growth
P09218459A0000|53 59|family
P09218459A0000|125 145|transcription factor
P09218459A0000|75 83|proteins
P09216936T0000|64 77|leptin levels
P09216936T0000|9 18|editorial
P09215891A0000|102 109|pathway
P09215891A0000|52 56|CIN2
P09215891A0000|46 50|CIN1
P09214274T0001|35 43|approach
P09214274T0001|12 21|carcinoma
P09212059A1856|290 292|PR
P09212059A1856|97 100|LBD
P09212059A1856|215 224|sequences
P09212059A1856|167 174|regions
P09212059A1856|29 34|paper
P09211981A0526|68 71|p13
P09211981A0526|155 159|cell
P09211981A0526|212 216|cdc2
P09211981A0526|94 100|kinase
P09211981A0526|72 76|suc1
P09211981A0526|31 35|gar2
P09211913A0000|35 47|translocator
P09211913A0000|100 125|aryl hydrocarbon receptor
P09211913A0000|49 53|ARNT
P09211913A0000|223 237|erythropoietin
P09211913A0000|127 130|AhR
P09211913A0000|242 250|response
P09211913A0000|60 69|component
P09211605A0478|21 27|degree
P09210478A0000|100 106|number
P09210478A0000|78 88|expression
P09210478A0000|46 54|factor-1
P09209438A0994|32 39|extract
P09209438A0994|94 101|protein
P09209438A0994|134 141|complex
P09209372A0345|217 222|AML1b
P09209372A0345|82 91|regulator
P09209372A0345|161 166|AML1a
P09209372A0345|26 31|AML1a
P09209031A0350|59 83|serine carboxypeptidases
P09208214A0572|37 44|muscles
P09208214A0572|78 83|cases
P09206230A0000|17 22|study
P09206230A0000|67 77|asthenopia
P09205677A0577|1 5|Lung
P09205677A0577|41 51|indicators
P09205677A0577|60 67|outcome
P09204570A0110|67 71|nmh7
P09204570A0110|73 75|J.
P09203731A0497|78 103|Poliomyelitis Eradication
P09203731A0497|46 59|Certification
P09203731A0497|195 207|transmission
P09203731A0497|105 110|ICCPE
P09203585A0660|39 49|H19 allele
P09203585A0660|57 67|occurrence
P09202669A1530|85 89|gene
P09202669A1530|64 81|rat preproinsulin
P09202147A0866|155 161|result
P09202147A0866|5 9|data
P09202147A0866|58 67|subfamily
P09202147A0866|165 171|stress
P09201946A0000|254 274|termination sequence
P09201946A0000|233 238|trp t
P09201946A0000|182 201|nucleotide residues
P09201946A0000|73 109|transcription termination factor rho
P09200530A0411|53 65|Zorbax RX C8
P09200530A0411|24 34|separation
P09200029A0211|127 150|bone marrow examination
P09200029A0211|77 86|diagnosis
P09200029A0211|60 67|setting
P09199932A1357|1 32|Promoter recognition algorithms
P09199932A1357|185 197|ATM promoter
P09199932A1357|83 93|CpG island
P09199932A1357|126 140|E14/NPAT genes
P09199413A0518|80 81|%
P09199413A0518|127 131|days
P09199413A0518|15 28|inoculum size
P09199348A0156|145 153|Y domain
P09199348A0156|198 206|analysis
P09199348A0156|74 80|domain
P09199327A1250|184 191|complex
P09199327A1250|36 44|EM motif
P09199327A1250|212 219|binding
P09199327A1250|130 154|transactivation function
P09199327A1250|227 234|complex
P09199318A1147|14 18|p150
P09199286A0086|22 26|mkh1
P09199286A0086|89 96|protein
P09197408A0126|102 104|Zn
P09197408A0126|1 11|Sequencing
P09197408A0126|162 169|leucine
P09197408A0126|118 125|C6 zinc
P09197408A0126|251 258|regions
P09197408A0126|56 63|protein
P09197408A0126|149 160|DNA binding
P09197241A0770|141 146|c-fgr
P09197241A0770|53 73|hyperphosphorylation
P09197241A0770|37 41|CD45
P09197241A0770|26 33|absence
P09197241A0770|104 107|hck
P09194250A0708|152 164|inequalities
P09194250A0708|32 44|World Summit
P09194250A0708|96 100|year
P09194250A0708|121 128|targets
P09193080A0904|1 20|Sequence divergence
P09193080A0904|74 84|definition
P09193072A0199|63 72|nucleolus
P09192842A0988|256 270|carcinogenesis
P09192842A0988|39 52|FISH analysis
P09192842A0988|112 118|region
P09192842A0988|58 67|PE-2 gene
P09192842A0988|27 34|hybrids
P09192842A0988|150 159|deletions
P09192769T0000|51 57|CHEMR1
P09192769T0000|70 88|chemokine receptor
P09192769T0000|23 39|characterization
P09192769T0000|11 18|cloning
P09191052A0850|69 81|Hox proteins
P09191052A0850|11 14|PCE
P09190821A0707|68 76|position
P09190821A0707|58 64|change
P09189896A0611|114 126|instructions
P09189896A0611|27 38|ERP effects
P09188863A0954|25 31|CDC25B
P09188863A0954|75 93|cell proliferation
P09188094A0934|49 59|activation
P09188094A0934|20 24|mcs4
P09188094A0934|63 67|Spc1
P09187371A0450|21 33|mRNA species
P09187371A0450|111 117|kidney
P09187371A0450|79 86|species
P09187371A0450|122 127|brain
P09187136A0000|1 7|SSeCKS
P09187136A0000|116 119|src
P09187136A0000|43 69|protein kinase C substrate
P09187136A0000|194 205|fibroblasts
P09186430A0341|45 53|albinism
P09185645T0000|80 99|arbutamine infusion
P09185645T0000|108 117|detection
P09185645T0000|15 49|Tc-99m sestamibi perfusion imaging
P09185183T0000|85 96|MRI changes
P09185183T0000|38 47|dystrophy
P09185183T0000|60 70|deficiency
P09183406A0637|23 39|thrombocytopenia
P09183406A0637|62 77|incompatibility
P09182990A0245|103 113|approaches
P09182990A0245|207 230|translation termination
P09182990A0245|139 146|product
P09182990A0245|67 78|combination
P09182990A0245|176 180|eRF1
P09182990A0245|45 50|SUP45
P09182527A0443|21 25|role
P09182527A0443|29 47|p53 ubiquitination
P09182527A0443|105 111|Nedd-4
P09181130A1587a|69 80|populations
P09181130A1587a|39 47|analysis
P09181130A1587a|97 105|mutation
P09181130A1587a|195 207|consequences
P09181130A1587a|134 138|role
P09180687A0096|70 83|cell division
P09180687A0096|20 26|region
P09180687A0096|162 168|series
P09180687A0096|151 155|SulA
P09178494A1123|98 113|loop structures
P09178494A1123|143 155|flaviviruses
P09178494A1123|297 308|replication
P09178494A1123|77 85|patterns
P09178494A1123|89 93|stem
P09178494A1123|60 67|regions
P09177169A0935|103 111|bacteria
P09177169A0935|46 52|halves
P09176340A1194|85 96|mRNA levels
P09176340A1194|1 14|Transcription
P09176340A1194|59 63|lung
P09176340A1194|133 138|liver
P09175708A1526|101 112|possibility
P09175708A1526|7 12|PRL-R
P09175708A1526|57 64|regions
P09173733A0404|235 240|shape
P09173733A0404|280 289|densities
P09173733A0404|107 109|EA
P09173733A0404|17 27|techniques
P09173733A0404|245 260|factor analysis
P09173733A0404|121 125|band
P09173733A0404|60 65|study
P09172641A0181|86 95|subdomain
P09172641A0181|114 122|contacts
P09172641A0181|132 143|nucleotides
P09172641A0181|45 48|end
P09172312T0000|21 31|CR1 repeat
P09172312T0000|67 81|chicken genome
P09171468T0000|19 28|responses
P09171363A0149|19 29|mechanisms
P09171239A1118|50 55|helix
P09171239A1118|27 31|part
P09171239A1118|11 22|amino acids
P09171239A1118|166 190|transactivation function
P09171081T0000|1 8|Cloning
P09171081T0000|101 124|plant Chenopodium album
P09170159A0721|117 124|HLH-Zip
P09170159A0721|39 43|exon
P09170159A0721|128 141|Zip structure
P09169853A0000|1 6|Pax-3
P09169853A0000|24 37|homeobox gene
P09169593T0000|153 157|role
P09169593T0000|64 67|MEK
P09169593T0000|128 140|cell nucleus
P09169593T0000|107 120|casein kinase
P09169593T0000|165 175|regulation
P09169475A0272|67 77|gp130 gene
P09169475A0272|47 53|region
P09169127A0371|342 346|exon
P09169127A0371|170 178|sequence
P09169127A0371|32 61|neuropeptide Y receptor genes
P09169127A0371|248 255|y5 gene
P09169127A0371|228 236|sequence
P09168879A0219|137 147|TAAG sites
P09168879A0219|96 106|TAAG sites
P09168511A0640|154 162|argument
P09168511A0640|37 49|developments
P09168511A0640|27 33|number
P09168511A0640|120 133|dexamethasone
P09168134A0858|1 20|Sequence comparison
P09168134A0858|80 89|Sm-E gene
P09168134A0858|94 108|U1 snRNA genes
P09168134A0858|180 196|snRNP components
P09167421A0234|82 88|device
P09167421A0234|106 108|Gy
P09165039A1372|16 35|marmoset monkey LHR
P09165039A1372|80 84|exon
P09165039A1372|95 103|LHR gene
P09165035A0842|186 187|D
P09165035A0842|1 36|Serum alkaline phosphatase activity
P09165035A0842|250 257|animals
P09165035A0842|157 166|vertebrae
P09165035A0842|244 245|D
P09165035A0842|192 199|animals
P09164856A0980|139 147|promoter
P09164856A0980|97 113|glutaminase gene
P09164856A0980|46 58|TATA element
P09163332A0275|87 94|Ser/Thr
P09163332A0275|156 166|efficiency
P09163332A0275|78 85|hydroxy
P09162097A0776|119 137|leukocyte adhesion
P09162097A0776|156 164|adhesion
P09162097A0776|26 42|MAdCAM-1 variant
P09162097A0776|89 101|mucin domain
P09162084A0956|68 75|PECAM-1
P09162084A0956|6 17|association
P09160361A0858|68 69|%
P09160361A0858|77 78|%
P09160361A0858|12 21|mortality
P09159160A0000|77 82|genes
P09159160A0000|12 19|cloning
P09157760A0000|103 110|nucleus
P09157760A0000|207 218|individuals
P09157760A0000|93 100|Meynart
P09157760A0000|165 173|thalamus
P09157100A0583|17 24|signing
P09157100A0583|63 66|SIB
P09155024A0955|69 75|growth
P09155024A0955|100 112|pseudohyphae
P09155024A0955|116 122|liquid
P09155024A0955|27 38|C. albicans
P09154827A0158|172 178|subset
P09154827A0158|10 17|studies
P09154827A0158|72 86|point mutation
P09154827A0158|156 166|expression
P09154827A0158|59 63|ts13
P09154827A0158|123 127|gene
P09154827A0158|208 210|G1
P09154819A0501|76 79|REF
P09154819A0501|109 129|fibroblast cell line
P09154819A0501|29 34|c-Jun
P09154795A0628|59 67|analysis
P09154795A0628|120 128|beta-pol
P09154283A0307|1 12|Latanoprost
P09154283A0307|115 126|pilocarpine
P09154283A0307|128 141|acetazolamide
P09154283A0307|106 113|timolol
P09154283A0307|61 69|pressure
P09153348A0647|71 106|mineralocorticoid steroid secretion
P09153348A0647|39 44|shift
P09153348A0647|163 174|progression
P09153348A0647|10 18|increase
P09153348A0647|182 189|disease
P09153319A0844|86 93|ethanol
P09153319A0844|36 45|triplexes
P09152656A0149|129 134|study
P09152656A0149|10 18|patients
P09151837A0723|153 167|fusion protein
P09151837A0723|189 192|35S
P09151837A0723|9 28|protein interaction
P09151806A1125|69 82|mLAT pre-mRNA
P09151806A1125|20 28|evidence
P09151806A1125|7 11|data
P09151152A0174|153 163|factor VII
P09151152A0174|175 176|p
P09151152A0174|140 148|factor X
P09151152A0174|232 238|amount
P09151152A0174|242 259|serum lipoprotein
P09150728A0596|85 90|heart
P09150728A0596|20 24|gene
P09150728A0596|104 110|muscle
P09150595A0225|68 83|E. chrysanthemi
P09150595A0225|114 122|HarpinEa
P09150595A0225|144 151|protein
P09150595A0225|179 194|signal sequence
P09150595A0225|241 247|domain
P09150334A0559|79 82|min
P09149825A0151|17 23|cement
P09149825A0151|100 111|bone cement
P09149825A0151|47 52|resin
P09148929A0372|5 7|P1
P09148929A0372|41 58|plasmid subclones
P09148770A0977|99 113|Csk SH2 domain
P09148770A0977|10 13|Csk
P09147420A0623|35 47|HCMV IE1/IE2
P09146027A0809|50 60|spasticity
P09146027A0809|3 10|patient
P09146027A0809|88 93|trunk
P09144770A0906|34 43|beta-turn
P09144770A0906|92 114|FKBP12 binding surface
P09144770A0906|74 82|contacts
P09144165A1275|100 107|binding
P09144165A1275|27 35|NFAT RIR
P09143465A0838|71 73|IQ
P09143465A0838|56 69|image quality
P09143465A0838|91 96|scale
P09142146A0887|1 8|RESULTS
P09142146A0887|159 164|index
P09142146A0887|110 125|vehicle animals
P09142146A0887|79 95|WEB-2086 animals
P09142146A0887|47 56|mortality
P09140079A2528|54 57|TRE
P09140079A2528|41 44|TRs
P09139910A0350|1 18|Sequence analysis
P09139910A0350|236 239|kbp
P09139910A0350|188 208|clone XbaI fragments
P09139910A0350|92 105|DNA fragments
P09139910A0350|29 41|PCR products
P09139737A0000|275 286|cholesterol
P09139737A0000|39 46|release
P09139737A0000|229 234|genes
P09139737A0000|187 194|nucleus
P09139737A0000|20 28|protease
P09139737A0000|113 121|proteins
P09139737A0000|297 302|acids
P09139694A0789|1 10|CTF1alpha
P09139694A0789|206 216|palindrome
P09139694A0789|147 160|DNA fragments
P09139694A0789|182 189|binding
P09139694A0789|134 144|palindrome
P09138492A0806|222 242|epidermoid carcinoma
P09138492A0806|115 123|ORL exam
P09138492A0806|99 113|calcifications
P09138492A0806|145 149|foot
P09138492A0806|192 196|exam
P09136080A1469|187 191|gene
P09136080A1469|136 146|expression
P09136080A1469|5 12|results
P09136080A1469|91 99|Sp1 site
P09135928A0912|171 172|P
P09135928A0912|138 151|glibenclamide
P09135928A0912|160 169|metformin
P09135928A0912|47 59|BP responses
P09135928A0912|15 21|mmol/l
P09135149A0000|68 78|Cdc2/Cdc13
P09135149A0000|168 173|Cdc25
P09135149A0000|178 204|Pyp3 tyrosine phosphatases
P09133122A0656|52 61|sequences
P09133122A0656|77 92|video sequences
P09133122A0656|12 23|information
P09132057A0559|3 14|polypeptide
P09132057A0559|97 103|domain
P09132057A0559|42 55|reading frame
P09132057A0559|166 184|S-receptor kinases
P09132057A0559|115 139|receptor protein kinases
P09132057A0559|323 331|pathogen
P09132057A0559|145 151|plants
P09132057A0559|60 79|sequence similarity
P09131139T0000|1 12|Implication
P09131139T0000|24 39|acetylhydrolase
P09131139T0000|73 80|disease
P09130718A0497|1 10|Sequences
P09130718A0497|37 47|expression
P09130718A0497|110 112|kb
P09130595A0478|20 27|cloning
P09128730A0000|237 248|delta mu Na
P09128730A0000|111 119|acetyl-S
P09128730A0000|73 82|malonyl-S
P09128730A0000|250 260|generation
P09128730A0000|179 193|biotin protein
P09128730A0000|29 46|Malonomonas rubra
P09128730A0000|60 69|formation
P09123787A0486|68 79|R1 response
P09123787A0486|139 150|stimulation
P09123787A0486|191 193|R2
P09123787A0486|261 285|orbicularis oculi muscle
P09123787A0486|229 240|R3 response
P09122215A0335|117 125|interest
P09122215A0335|92 101|mutations
P09122176A0970|39 49|repression
P09122176A0970|97 104|RAR/RXR
P09122176A0970|125 144|RA response element
P09121998A0663|168 171|MTT
P09121998A0663|39 45|region
P09121998A0663|226 233|stomach
P09121998A0663|75 85|subjection
P09121998A0663|154 166|transit time
P09121998A0663|248 251|F90
P09121998A0663|243 246|min
P09121774A0611|39 50|stimulation
P09121774A0611|106 123|MAP kinase family
P09121454A1328|71 76|Bur6p
P09121454A1328|81 86|Mot1p
P09121454A1328|172 195|transcription machinery
P09121454A1328|27 31|bur6
P09121454A1328|13 23|phenotypes
P09121435A1183|1 8|Domains
P09121435A1183|93 113|protein footprinting
P09121435A1183|56 74|TFIIIB-DNA complex
P09121432A0000|5 16|Ras guanine
P09121432A0000|79 89|signalling
P09121430A0132|118 126|tyrosine
P09121430A0132|38 52|protein kinase
P09121430A0132|128 129|Y
P09121430A0132|78 85|complex
P09119391A0870|136 141|GPT-1
P09119391A0870|46 57|amino acids
P09119391A0870|31 38|protein
P09119031A1036|191 201|comparison
P09119031A1036|126 141|alpha2beta beta
P09119031A1036|209 215|enzyme
P09119031A1036|15 41|holoenzyme RNA polymerases
P09118664A1734|168 178|conditions
P09118664A1734|148 154|return
P09118664A1734|105 121|filling pressure
P09117345A0945|84 98|cell migration
P09117345A0945|1 11|Activation
P09117345A0945|133 148|phosphorylation
P09117345A0945|15 20|alpha
P09115395A0478|342 346|Cdc5
P09115395A0478|143 167|Elongation factor 1gamma
P09115395A0478|348 371|innercentrosome protein
P09115395A0478|223 231|proteins
P09115395A0478|260 267|mitosis
P09115395A0478|452 456|BRG1
P09115395A0478|269 291|epithelial-microtubule
P09115395A0478|169 173|BRG1
P09115395A0478|507 512|HoxD1
P09115395A0478|520 525|Vent2
P09115395A0478|535 543|isoforms
P09115395A0478|251 256|roles
P09115395A0478|485 490|Oct91
P09115395A0478|303 314|protein-115
P09115357A0073|263 270|process
P09115357A0073|97 125|immunoglobulin hypermutation
P09115357A0073|27 36|mechanism
P09115357A0073|46 58|availability
P09115357A0073|75 81|assays
P09115265A1160|23 34|CCCC module
P09115242A0934|206 219|collagenase-1
P09115242A0934|80 84|role
P09115242A0934|189 202|transcription
P09115242A0934|25 35|supershift
P09115242A0934|41 67|promoter deletion analyses
P09111863A0743|141 160|chromosome fragment
P09111863A0743|173 187|tumorigenicity
P09111863A0743|127 133|region
P09111863A0743|193 205|introduction
P09111863A0743|107 118|coincidence
P09111340A0240|223 239|beta-globin gene
P09111340A0240|116 127|C2C12 cells
P09111340A0240|260 293|chloramphenicol acetyltransferase
P09111340A0240|82 92|myogenesis
P09111340A0240|24 32|elements
P09111340A0240|60 74|downregulation
P09111314A1243|275 292|kinase activation
P09111314A1243|155 169|p15 transcript
P09111314A1243|37 47|regulation
P09111314A1243|245 270|cyclin D1-cdk association
P09111314A1243|132 140|184A1L5R
P09111309A0674|51 58|protein
P09111309A0674|154 164|deltaRaf-1
P09111309A0674|65 90|kinase expression vectors
P09111309A0674|112 138|HB-EGF promoter activation
P09111309A0674|165 167|ER
P09111048X0000|152 173|nitric-oxide synthase
P09111048X0000|175 179|nNOS
P09111048X0000|26 41|mRNA transcript
P09111048X0000|181 196|gene expression
P09110176A0890|288 293|locus
P09110176A0890|1 9|Northern
P09110176A0890|236 244|evidence
P09110176A0890|173 183|expression
P09110176A0890|267 277|expression
P09110176A0890|14 29|RT-PCR analysis
P09108279A0431|5 13|capacity
P09108279A0431|24 30|8-OxoG
P09108279A0431|109 127|34mer DNA fragment
P09108279A0431|88 100|ogg1 strains
P09108038A1128|49 56|Acan125
P09108038A1128|65 85|C. elegans homologue
P09108038A1128|41 47|domain
P09106057A0000|239 243|HPLC
P09106057A0000|273 282|detection
P09106057A0000|168 173|urine
P09106057A0000|51 59|N-methyl
P09106057A0000|250 267|chemiluminescence
P09106057A0000|112 117|EM523
P09106057A0000|61 70|N-ethyl-8
P09105363A0636|84 111|tissue silicon measurements
P09105363A0636|21 27|plasma
P09104816A0610|22 27|class
P09104816A0610|104 118|vaccinia virus
P09104816A0610|30 40|biogenesis
P09102113A0739|68 74|causes
P09102113A0739|158 159|%
P09102113A0739|107 114|disease
P09101085A0686|35 45|cell lines
P09101085A0686|115 126|cell growth
P09101085A0686|5 16|derivatives
P09099745A1446|68 77|complexes
P09099745A1446|236 249|cyclin E-Cdk2
P09099745A1446|174 189|phosphorylation
P09099745A1446|160 169|threonine
P09099745A1446|222 232|activation
P09099745A1446|113 116|p21
P09099745A1446|209 218|mechanism
P09099702A0692|117 123|region
P09099702A0692|188 193|stage
P09099702A0692|197 212|spermatogenesis
P09099702A0692|149 153|gene
P09099702A0692|14 22|sequence
P09099683A0000|85 90|cells
P09099683A0000|24 27|DGK
P09099683A0000|40 46|levels
P09099683A0000|123 132|messenger
P09098899A0000|187 204|zinc-finger motif
P09098899A0000|126 131|phage
P09098899A0000|31 43|acid protein
P09096958A0000|307 318|fibroblasts
P09096958A0000|263 276|cell motility
P09096958A0000|197 201|TD77
P09096958A0000|176 192|antibodies TA205
P09096958A0000|122 135|precipitation
P09096958A0000|240 249|adhesions
P09096229T0000|1 16|Excision repair
P09096229T0000|117 123|repair
P09096229T0000|143 149|strand
P09096229T0000|37 47|nucleotide
P09096229T0000|91 98|mapping
P09094315A0541|69 80|cyclin-Cdks
P09094315A0541|9 14|study
P09093867T0000|33 42|formation
P09093867T0000|44 53|structure
P09092636A0802|119 143|DYZ3 satellite sequences
P09092636A0802|49 63|rad54-3 allele
P09092636A0802|79 92|recombination
P09092493A0861|101 109|proteins
P09092493A0861|53 76|AP-1 signaling pathways
P09092493A0861|144 148|cell
P09092493A0861|40 48|Jak-Stat
P09091125A0161|55 63|activity
P09091125A0161|80 97|acid phosphatases
P09091125A0161|106 121|NBT-test values
P09090592A0175|43 64|activation fMR images
P09090592A0175|31 38|control
P09090050A0419|32 46|sugar carriers
P09089653A0615|155 160|times
P09089653A0615|54 57|UTR
P09089653A0615|125 144|luciferase activity
P09089653A0615|13 21|plasmids
P09089653A0615|105 113|sequence
P09088737T0000|67 77|microscopy
P09088371T0000|1 14|Plasma levels
P09088371T0000|64 72|patients
P09088371T0000|91 102|haemorrhage
P09086268A0611|85 87|P2
P09086268A0611|37 46|particles
P09086268A0611|109 111|P7
P09086268A0611|62 71|particles
P09085842A0181|136 143|domains
P09085842A0181|43 51|U1 snRNP
P09085842A0181|90 118|protein/protein interactions
P09084621A0374|1 14|Movement time
P09084621A0374|172 190|movement variables
P09084621A0374|77 86|magnitude
P09084621A0374|29 44|characteristics
P09084176A0601|102 106|lacZ
P09084176A0601|84 87|RNA
P09084176A0601|108 127|M. smegmatis clones
P09083563A0971|169 174|fluid
P09083563A0971|53 66|surface layer
P09083563A0971|209 215|toxins
P09083563A0971|15 22|lesions
P09083291A1378|136 148|cyclin E-cdk
P09083291A1378|7 16|TGF-beta1
P09083291A1378|230 233|pRb
P09083291A1378|119 122|MCs
P09083291A1378|80 98|G1 phase cyclin D1
P09083291A1378|264 271|S phase
P09083291A1378|151 159|activity
P09080517A0215|13 21|patients
P09079928A1319|98 108|expression
P09079928A1319|80 85|loops
P09079928A1319|112 116|oxyR
P09079928A1319|163 179|LysR superfamily
P09079915T0000|100 126|consensus sigma70 promoter
P09079915T0000|60 75|motility operon
P09079902A0713|101 108|complex
P09079902A0713|10 13|Pra
P09079902A0713|130 133|Ndk
P09079902A0713|135 137|Pk
P09079902A0713|194 197|Pra
P09079902A0713|212 219|complex
P09079902A0713|180 188|affinity
P09079817A0928|36 41|cells
P09079817A0928|94 107|NO synthetase
P09079650A0136|16 27|MAPK family
P09079650A0136|154 169|protein kinases
P09079650A0136|99 104|c-Jun
P09079650A0136|54 70|response kinases
P09079650A0136|129 133|JNKs
P09079650A0136|120 127|kinases
P09079625A0935|1 11|Syndecan-4
P09079625A0935|23 41|adhesion component
P09079625A0935|52 63|interaction
P09077437T0000|1 23|Recognition mechanisms
P09077437T0000|83 97|RNA polymerase
P09077076A0219|10 18|CRP test
P09075739A0827|1 5|Type
P09075739A0827|36 43|exon U3
P09075739A0827|79 84|ovary
P09073582A0444|70 82|SSO activity
P09073582A0444|106 109|Mol
P09073582A0444|90 97|Kataoka
P09072361A0357|35 40|SHRSP
P09072361A0357|80 87|tissues
P09072361A0357|25 33|fraction
P09072361A0357|95 104|elevation
P09072361A0357|62 71|magnesium
P09071308A0376|1 8|RESULTS
P09071308A0376|53 65|distribution
P09071308A0376|111 112|%
P09071308A0376|124 125|%
P09067577A0721|86 89|C3G
P09067577A0721|99 104|c-ABL
P09067577A0721|37 45|proteins
P09065768A0862|116 128|lactase mRNA
P09065768A0862|12 17|class
P09065463A1012|34 47|Rad51 protein
P09065463A1012|78 81|RPA
P09064868T0001|24 32|solution
P09062130A0116|68 69|V
P09062130A0116|70 73|max
P09062130A0116|218 231|PTPase domain
P09062130A0116|167 175|deletion
P09062130A0116|13 27|autoinhibition
P09061697T0000|70 80|comparison
P09061697T0000|88 91|day
P09061697T0000|30 47|99Tcm-tetrofosmin
P09060971A0982|170 174|neck
P09060971A0982|142 149|decline
P09060971A0982|226 236|trochanter
P09060971A0982|50 53|BMD
P09060971A0982|80 85|sites
P09060971A0982|265 266|p
P09060623A0961|54 63|SIV entry
P09060444A0557|51 75|luciferase reporter gene
P09060444A0557|114 124|initiation
P09060444A0557|162 180|EGF-responsiveness
P09060444A0557|132 140|reporter
P09059039A0850|1 12|99mTc-HMPAO
P09059039A0850|36 47|territories
P09059039A0850|199 208|territory
P09059039A0850|135 145|papaverine
P09059039A0850|155 165|C4 segment
P09059039A0850|216 219|ACA
P09059039A0850|63 66|MCA
P09058373A1620|187 195|receptor
P09058373A1620|159 167|function
P09058373A1620|26 39|reporter gene
P09058323A1287|170 174|beta
P09058323A1287|191 196|alpha
P09058323A1287|66 71|alpha
P09058323A1287|92 99|regions
P09058323A1287|131 135|part
P09058323A1287|30 42|cis elements
P09058002T0000|19 23|task
P09057840A0946|84 107|affinity chromatography
P09057840A0946|57 60|NH4
P09057840A0946|61 79|2SO4-precipitation
P09057648A0422|375 406|mol/L phorbol myristate acetate
P09057648A0422|443 448|% FCS
P09057648A0422|172 205|chloramphenicol acetyltransferase
P09057648A0422|41 58|sense orientation
P09057648A0422|107 121|c-fos promoter
P09057648A0422|256 268|Jurkat cells
P09057648A0422|320 323|FCS
P09057648A0422|212 216|gene
P09057648A0422|300 301|%
P09057648A0422|123 126|FC3
P09057648A0422|240 252|CAT activity
P09056761A0000|171 181|mRNA decay
P09056761A0000|223 244|splice site selection
P09056761A0000|116 123|variety
P09056761A0000|250 254|exon
P09056761A0000|147 153|events
P09056761A0000|105 110|cause
P09053973A1252|1 11|CONCLUSION
P09053973A1252|39 50|misoprostol
P09053973A1252|124 131|ascites
P09053494A0612|1 8|RESULTS
P09053494A0612|206 208|kg
P09053494A0612|99 101|CY
P09053494A0612|161 163|kg
P09053494A0612|45 56|cell yields
P09053494A0612|216 231|reference group
P09053494A0612|261 262|P
P09053494A0612|61 69|patients
P09051656A0390|1 15|Tissue samples
P09051656A0390|42 46|rats
P09051656A0390|79 89|withdrawal
P09050861A0903|21 35|identification
P09050861A0903|58 69|pets factor
P09050849A0000|16 23|protein
P09050849A0000|175 192|protein transport
P09050849A0000|36 41|cells
P09050689A0685|103 112|treatment
P09050689A0685|128 133|hours
P09050689A0685|120 124|J/cm
P09049306A0830|35 40|exons
P09049306A0830|55 57|kb
P09049306A0830|78 88|chromosome
P09049270A0488|136 149|tomato plants
P09049270A0488|39 43|LeMT
P09049270A0488|44 45|B
P09049270A0488|222 225|MTs
P09049270A0488|115 121|leaves
P09049270A0488|127 132|roots
P09049270A0488|27 31|LeMT
P09048617A0648|23 27|type
P09048617A0648|106 117|cAMP effect
P09047252A0209|1 8|METHODS
P09047252A0209|64 73|resection
P09047252A0209|126 131|ng/ml
P09047252A0209|105 115|AFP levels
P09046186A0189|55 63|fracture
P09046186A0189|37 50|fall distance
P09046013A0000|273 282|occlusion
P09046013A0000|97 104|SNX-111
P09046013A0000|244 258|carotid artery
P09046013A0000|193 201|ischemia
P09046013A0000|150 154|rats
P09045842T0000|49 63|RNA polymerase
P09045842T0000|18 23|alpha
P09045842T0000|89 99|mer operon
P09045636A0789|55 60|Sam68
P09045636A0789|75 82|T cells
P09043534A1600|23 32|decreases
P09042755T0000|17 36|sigma factor sigmaB
P09042755T0000|96 104|response
P09042755T0000|108 120|growth phase
P09042269A1007|55 67|chemotherapy
P09042269A1007|109 115|cancer
P09041123A0195|37 43|ligand
P09041123A0195|132 141|responses
P09039744T0000|34 56|electro-encephalograms
P09039744T0000|22 30|analysis
P09038192A0846|38 44|Dudley
P09038192A0846|46 48|D.
P09037163A1652|5 14|relevance
P09037163A1652|57 66|induction
P09037032T0000|136 147|Rb1 binding
P09037032T0000|5 18|proliferation
P09037032T0000|63 70|domains
P09037032T0000|164 174|expression
P09035612T0000|85 93|function
P09035612T0000|9 27|endothelin release
P09035612T0000|104 114|infarction
P09034337A0251|1 8|Studies
P09034337A0251|81 84|Y15
P09034337A0251|122 130|response
P09034337A0251|134 144|DNA damage
P09032304T0000|69 89|herpes simplex virus
P09032304T0000|101 113|protein ICP4
P09032267A0850|50 53|CBP
P09032267A0850|116 124|p45/NF-E
P09032267A0850|109 111|TR
P09032259A0150|139 157|Ras transformation
P09032259A0150|79 92|NIH 3T3 cells
P09032259A0150|104 113|functions
P09032259A0150|14 24|activation
P09032254A0724|66 75|sequences
P09032248A0239|48 77|Pcl1,2-Pho85 kinase complexes
P09032248A0239|112 119|absence
P09032248A0239|10 15|Pho85
P09031639A0474|51 54|ORF
P09031639A0474|96 107|amino acids
P09031639A0474|77 88|polypeptide
P09031639A0474|109 111|aa
P09031639A0474|63 65|bp
P09030688A0435|87 105|Rap1p localization
P09030688A0435|62 71|silencing
P09029956T0000|50 69|structure formation
P09029956T0000|26 36|management
P09029159A0000|51 56|dsRNA
P09029159A0000|5 15|interferon
P09029159A0000|160 163|IFN
P09029159A0000|149 156|effects
P09029091A0881|139 153|A2/HCP chimera
P09029091A0881|37 61|tyrosine phosphorylation
P09028942A0000|85 90|genes
P09028942A0000|99 104|c-fos
P09028942A0000|111 114|myc
P09028942A0000|57 64|hGM-CSF
P09028942A0000|150 155|egr-1
P09028089A0183|110 133|transplantation surgery
P09027346A1957|10 26|antibody binding
P09027346A1957|130 137|peptide
P09027346A1957|107 110|mAb
P09027346A1957|181 184|LHR
P09025122A0374|87 96|COWA task
P09025122A0374|72 79|aspects
P09025122A0374|44 49|tasks
P09024793A1325|100 108|myogenin
P09024793A1325|141 156|enhancer region
P09024793A1325|59 67|extracts
P09024793A1325|128 133|E-box
P09024793A1325|164 172|MCK gene
P09024039A0247|141 144|CCA
P09024039A0247|24 30|status
P09024039A0247|11 14|ASA
P09024039A0247|150 160|desflurane
P09024039A0247|45 53|patients
P09023197T0000|5 16|dnaK operon
P09022040A0263|253 273|nucleotide sequences
P09022040A0263|82 89|rodents
P09022040A0263|298 322|L-plastin gene promoters
P09022040A0263|183 188|cells
P09020856A0560|71 83|MCK promoter
P09020856A0560|15 21|effect
P09020169A0552|1 5|SIM1
P09020169A0552|10 14|SIM2
P09019302A0600|97 113|sodium bisulfite
P09019302A0600|128 133|phase
P09019302A0600|24 30|plasma
P09018122A1389|18 33|ORF-1 sequences
P09018122A1389|80 92|prerequisite
P09018122A1389|43 49|tumors
P09018122A1389|61 66|proof
P09016566A0655|23 28|motif
P09015757T0000|119 122|BSP
P09015757T0000|76 86|expression
P09015757T0000|124 128|gene
P09015757T0000|45 51|tissue
P09013760A0000|1 12|Cholesterol
P09013760A0000|99 112|gonadotropins
P09013760A0000|67 82|gene expression
P09013760A0000|58 65|P450scc
P09013760A0000|176 181|cells
P09012636A0723|152 162|fibrinogen
P09012636A0723|16 19|age
P09012636A0723|80 87|smoking
P09012636A0723|40 55|HDL cholesterol
P09012636A0723|167 182|atherosclerosis
P09011745T0000|17 28|chick brain
P09011745T0000|81 95|acid receptors
P09011745T0000|131 139|function
P09011745T0000|104 116|conservation
P09011591A0309|21 30|specimens
P09011591A0309|11 17|number
P09010223A0667|117 126|complexes
P09010223A0667|86 99|PU.1 proteins
P09010223A0667|55 63|EWS-FLI1
P09010223A0667|143 152|Egr1 SREI
P09010223A0667|42 47|SAP1a
P09010223A0667|132 135|SRF
P09008301A0193|8 20|enzyme forms
P09008301A0193|60 79|autoprocessing site
P09006935A0590|1 4|Sp1
P09006935A0590|82 98|consensus GC box
P09006935A0590|15 25|CTC repeat
P09006914A0812|1 4|JNK
P09006914A0812|80 85|ATF-2
P09006914A0812|9 12|p38
P09006902A0370|20 24|cDNA
P09006051A1162|1 5|PrpB
P09006051A1162|111 118|homolog
P09006051A1162|13 21|homology
P09006051A1162|253 258|yeast
P09006051A1162|263 289|Bacillus subtilis proteins
P09006051A1162|25 69|carboxyphosphonoenolpyruvate phosphonomutase
P09006051A1162|126 157|carnation Dianthus caryophyllus
P09006051A1162|210 227|citrate synthases
P09006010A0527|207 223|secretion signal
P09006010A0527|278 288|amino acid
P09006010A0527|77 83|effect
P09006010A0527|165 172|protein
P09006010A0527|190 194|RsaA
P09006010A0527|244 254|amino acid
P09006010A0527|122 132|amino acid
P09005979A0841|77 92|differentiation
P09005609A0299|1 20|Control examination
P09005609A0299|42 45|end
P09005273A0322|64 73|syndromes
P09005273A0322|96 117|chemical interactions
P09005273A0322|131 152|butyrylcholinesterase
P09005273A0322|79 91|risk factors
P09004504A0000|80 101|plasminogen activator
P09004504A0000|13 22|structure
P09004504A0000|121 132|replication
P09003617A0000|51 57|months
P09003617A0000|64 69|years
P09003617A0000|73 76|age
P09003462A0792|35 38|S61
P09003462A0792|115 128|self-splicing
P09003462A0792|40 43|SL1
P09003462A0792|91 102|nrdB intron
P09003312A0740|205 212|mutants
P09003312A0740|98 102|size
P09003312A0740|43 62|AT-PHH1 delta C-513
P09003312A0740|13 20|AT-PHH1
P09003312A0740|134 139|cDNAs
P09003001A1909|98 108|gel shifts
P09003001A1909|142 148|CANNTG
P09003001A1909|72 78|CATCTG
P09002672A0439|154 159|hTRF1
P09002672A0439|202 219|binding substrate
P09002672A0439|57 68|kDa protein
P09002672A0439|130 150|sequence specificity
P09002672A0439|29 39|mTRF1 cDNA
P09002672A0439|105 110|mTRF1
P09001828A0222|17 20|men
P09001828A0222|3 8|total
P09001828A0222|83 93|physicians
P09001828A0222|104 107|BPH
P09001313A0000|1 11|Prevalence
P09001313A0000|86 91|women
P09001213A1111|102 115|P. falciparum
P09001213A1111|21 40|level transcription
P09001213A1111|83 98|chromosome ends
P09000589A0000|34 41|malaria
P09000589A0000|59 69|evaluation
P09000108A0330|34 41|kb mRNA
P09000108A0330|5 26|transcription product
P09000108A0330|142 144|bp
P09000108A0330|197 201|CG30
P08999882T0000|1 11|Expression
P08999882T0000|45 55|beta cells
P08999414A0819|23 32|subgenera
P08997532A0116|139 154|ELISA technique
P08997532A0116|38 57|IgE immunoglobulins
P08997532A0116|111 114|TES
P08997532A0116|10 13|IgG
P08996730A1146|137 151|grinder wheels
P08996730A1146|1 5|Lack
P08996730A1146|55 75|employment durations
P08996730A1146|106 116|variations
P08996730A1146|120 135|tool conditions
P08995659A0563|16 39|region splice junctions
P08995659A0563|110 137|sequencing RNA-PCR products
P08995659A0563|47 51|MSRs
P08995614T0000|32 39|element
P08995614T0000|141 150|sequences
P08995614T0000|61 101|histocompatibility complex gene promoter
P08995410A0000|168 169|S
P08995410A0000|108 118|eIF2 x GTP
P08995410A0000|248 254|factor
P08995410A0000|126 129|Met
P08995410A0000|214 230|ribosome subunit
P08995410A0000|121 125|tRNA
P08995054A0618|84 93|gag genes
P08995054A0618|36 55|zinc knuckle region
P08995054A0618|124 137|retroelements
P08994832A0782|32 38|HEK293
P08994832A0782|42 52|HeLa cells
P08993836A0699|18 25|results
P08993836A0699|111 121|epithelium
P08993836A0699|62 71|induction
P08993393T0000|68 83|splice variants
P08993393T0000|158 166|hPACAP-R
P08993393T0000|44 59|gene activation
P08992115A0199|65 85|blood concentrations
P08992115A0199|189 194|humor
P08992115A0199|111 125|KKS activation
P08992115A0199|148 157|serotonin
P08992115A0199|89 109|acute-phase proteins
P08990194A0000|17 27|resistance
P08990194A0000|200 214|hormone action
P08990194A0000|76 81|serum
P08990194A0000|135 156|thyrotropin secretion
P08990194A0000|105 112|failure
P08989763A0605|49 62|visualization
P08988913A0821|169 178|processes
P08988913A0821|96 112|folate excretion
P08988913A0821|76 84|turnover
P08988913A0821|44 54|provisions
P08987225A0675|17 28|risk factor
P08987225A0675|207 217|Queensland
P08987225A0675|113 121|drug use
P08987225A0675|199 202|ACT
P08987225A0675|150 155|cases
P08986812A1214|92 102|cell lines
P08986812A1214|27 38|delta proAE
P08986812A1214|134 141|effects
P08986692A0306|95 101|IVF-ET
P08986692A0306|14 15|S
P08986214A0000|205 208|HGF
P08986214A0000|50 58|patients
P08986214A0000|233 236|AFP
P08986214A0000|214 231|alpha-fetoprotein
P08986214A0000|74 87|liver disease
P08986214A0000|134 143|hepatitis
P08985415A1096|5 29|STAT-1 signaling pathway
P08985415A1096|66 76|activation
P08985415A1096|109 118|monocytes
P08985115A1571|238 248|expression
P08985115A1571|190 200|mechanisms
P08985115A1571|159 172|understanding
P08985115A1571|146 150|gene
P08985115A1571|109 118|isolation
P08985115A1571|73 78|study
P08981371A2049b|40 51|kDa protein
P08980819A0193|1 10|Mortality
P08980819A0193|189 201|insemination
P08980819A0193|78 84|groups
P08980819A0193|88 95|turkeys
P08980819A0193|164 169|event
P08980533A1160|68 75|protein
P08980533A1160|81 84|rat
P08980533A1160|25 31|region
P08980413A0500|20 26|ppSEPs
P08980413A0500|96 99|PES
P08980413A0500|31 58|phase reversal relationship
P08979089A1197|51 61|constructs
P08979089A1197|206 224|Ig kappa enhancers
P08979089A1197|142 150|TATA box
P08979089A1197|125 133|Sp1 site
P08979089A1197|28 45|BL cell line Raji
P08978817A0620|70 96|endocytosis mutants end4-1
P08978817A0620|21 28|mutants
P08978817A0620|163 180|DIM gene products
P08978817A0620|41 51|dim1-delta
P08977401A0227|342 354|leader exons
P08977401A0227|140 142|kb
P08977401A0227|406 411|mRNAs
P08977401A0227|287 290|RNA
P08977401A0227|85 92|introns
P08977401A0227|155 162|cloning
P08977401A0227|178 197|RI alpha pseudogene
P08977401A0227|63 70|lengths
P08977401A0227|362 366|rise
P08977235A0134|70 82|JAK2 kinases
P08977235A0134|91 117|STAT transcription factors
P08976253A0637|51 56|serum
P08976253A0637|31 42|correlation
P08974103A0451|1 9|Patterns
P08974103A0451|108 111|PEM
P08974103A0451|94 104|likelihood
P08974103A0451|120 125|all-2
P08973917A0632|9 14|cDNAs
P08973527A0000|70 77|regions
P08973527A0000|81 103|Agropyron mosaic virus
P08973527A0000|105 109|AgMV
P08972232A0365|100 105|yGCN5
P08972232A0365|37 42|hGCN5
P08972232A0365|75 96|substrate specificity
P08972182A0527|1 4|Fas
P08972182A0527|116 123|studies
P08972182A0527|66 72|enzyme
P08972182A0527|232 270|tripeptide pan-ICE inhibitor Z-VAD-FMK
P08972182A0527|31 34|ICE
P08971835A1057|4 9|Group
P08971835A1057|67 72|BAEPs
P08971835A1057|125 133|Group II
P08971835A1057|150 168|reperfusion period
P08971009A0860|115 123|sequence
P08971009A0860|20 27|problem
P08971009A0860|47 55|strategy
P08970984A0765|185 212|tumor necrosis factor alpha
P08970984A0765|114 145|YY1 class transcription factors
P08970984A0765|176 181|serum
P08970984A0765|105 108|ETS
P08970951A0823|49 60|hepatitis B
P08970951A0823|147 168|HBV DNA intermediates
P08970951A0823|63 70|antigen
P08969777A0771|170 179|paralysis
P08969777A0771|54 65|differences
P08969777A0771|160 166|degree
P08967963A1735|136 139|rat
P08967963A1735|218 233|alpha2c-AR gene
P08967963A1735|91 94|rat
P08967963A1735|60 85|rat glioma cell line C6B4
P08964172A0221|161 171|background
P08964172A0221|109 119|aggregates
P08964172A0221|47 52|urine
P08962614A0000|205 223|outcome predictors
P08962614A0000|234 242|children
P08962614A0000|22 38|immunoglobulin E
P08962614A0000|40 43|IgE
P08962614A0000|74 90|laboratory tests
P08960827A1169|34 43|GG motifs
P08960827A1169|7 14|results
P08960827A1169|182 188|factor
P08960827A1169|120 131|association
P08959117A0708|290 300|hypoxaemia
P08959117A0708|250 253|REF
P08959117A0708|233 248|reference group
P08959117A0708|42 49|changes
P08958720A1204|100 102|CO
P08958720A1204|42 46|mPAP
P08958720A1204|10 16|degree
P08958720A1204|107 110|VO2
P08955928A0390|1 7|Damage
P08955928A0390|33 46|extravasation
P08955928A0390|133 137|MCAo
P08955928A0390|15 18|BBB
P08955306A0224|1 9|Northern
P08955306A0224|98 111|reading frame
P08955306A0224|77 85|subunits
P08955306A0224|11 14|RNA
P08955306A0224|132 140|function
P08955159A0000|25 27|AC
P08955159A0000|29 61|N-acylsphingosine amidohydrolase
P08955111A0989|155 181|activin betaA subunit gene
P08955111A0989|124 141|promoter activity
P08954725A1175|140 146|source
P08954725A1175|97 105|tail bud
P08954725A1175|77 85|mesoderm
P08954725A1175|150 158|mesoderm
P08952965A1182|1 11|Comparison
P08952965A1182|100 104|site
P08952965A1182|231 250|MHC contact regions
P08952965A1182|252 256|CDR1
P08952965A1182|48 50|pN
P08952965A1182|261 265|CDR2
P08952965A1182|212 214|pN
P08952483A0207|169 192|multisynthetase complex
P08952483A0207|67 96|hamster lysyl-tRNA synthetase
P08952483A0207|151 157|enzyme
P08950352A0525|175 187|significance
P08950352A0525|212 216|test
P08950352A0525|131 135|ones
P08950352A0525|107 112|rates
P08948440A0628|51 54|An3
P08948440A0628|5 27|ERH expression profile
P08948440A0628|79 96|animal hemisphere
P08946668A0077|71 86|organ rejection
P08946668A0077|94 102|toxicity
P08945810T0001|11 21|morphology
P08945810T0001|47 50|man
P08943928A1137|1 15|Administration
P08943928A1137|36 43|vaccine
P08943032A0000|206 215|selection
P08943032A0000|98 103|yeast
P08943032A0000|37 41|TetR
P08943032A0000|43 58|operator system
P08943032A0000|130 141|disruptions
P08940298A0962|138 146|receptor
P08940298A0962|59 70|AF-2 domain
P08940298A0962|107 124|estrogen receptor
P08940132A1120|170 182|contribution
P08940132A1120|188 193|CPP32
P08940132A1120|142 150|DEVD-CHO
P08940132A1120|127 138|sensitivity
P08940132A1120|29 47|fodrin proteolysis
P08940132A1120|211 219|protease
P08939891A0285|51 54|NRE
P08939891A0285|11 16|yeast
P08939891A0285|28 34|screen
P08938418A0099|1 5|Merr
P08937981A0840|153 160|nucleus
P08937981A0840|179 182|p54
P08937981A0840|106 109|p46
P08937981A0840|14 27|co-expression
P08937112A0561|69 74|years
P08937112A0561|55 59|mean
P08937112A0561|14 30|age distribution
P08936128A0611|116 128|disagreement
P08936128A0611|95 102|control
P08935931A0787|1 11|CONCLUSION
P08935931A0787|155 165|monitoring
P08935931A0787|25 48|diazepam administration
P08935931A0787|56 59|EGD
P08935931A0787|91 95|SpO2
P08934533A0784|81 90|chromatin
P08934533A0784|53 57|junB
P08933487A0325|61 64|run
P08933487A0325|30 31|W
P08932363A0807|100 110|activation
P08932363A0807|114 122|E2F1/DP1
P08932363A0807|10 24|E1A N-terminus
P08931388A0806|168 174|sample
P08931388A0806|36 38|bp
P08931388A0806|132 136|band
P08931388A0806|74 81|extract
P08929089A0231|95 101|demand
P08927612T0000|12 25|p53 mutations
P08925545T0001|77 84|myeloma
P08925545T0001|29 36|r-HuEPO
P08925545T0001|45 54|treatment
P08924211A0941|1 6|Exons
P08924211A0941|126 135|AST cDNAs
P08924211A0941|74 80|region
P08923469A1391|141 144|VDR
P08923469A1391|56 64|polarity
P08923469A1391|105 130|hormone response elements
P08923258A0353|1 8|Jerseys
P08923258A0353|28 45|Cu concentrations
P08922391A0304|53 61|entirety
P08922391A0304|29 38|structure
P08922391A0304|91 97|PDZ1-2
P08922390A0793|49 61|binding site
P08922390A0793|66 74|vinculin
P08922390A0793|111 114|FAK
P08922390A0793|28 36|presence
P08922385A0622|127 141|fusion subunit
P08922385A0622|176 184|lysosome
P08922385A0622|160 168|tetramer
P08922344A1539|204 210|effect
P08922344A1539|100 111|association
P08922344A1539|42 50|subjects
P08922344A1539|161 168|factors
P08922344A1539|195 200|cause
P08921667A0294|18 32|input function
P08921667A0294|54 73|distribution volume
P08921667A0294|177 187|volunteers
P08921667A0294|45 50|value
P08919907A0763|34 45|protoplasts
P08919907A0763|57 61|vs-1
P08919907A0763|11 21|expression
P08918934A0424|68 73|Nsplp
P08918934A0424|1 11|Comparison
P08918934A0424|36 56|xFxFG repeat regions
P08918934A0424|89 93|NTF2
P08918934A0424|60 63|p62
P08918885A1087|98 104|mutant
P08918885A1087|140 144|Dig2
P08918885A1087|196 210|growth pathway
P08918885A1087|14 29|dig1 dig2 cells
P08918810A0967|119 152|protection pattern characteristic
P08918810A0967|64 68|Pmom
P08918810A0967|97 103|strand
P08918810A0967|10 15|DNase
P08918456A0455|81 87|anchor
P08918456A0455|142 152|position Y
P08918456A0455|43 45|mu
P08918456A0455|57 61|AP-2
P08918456A0455|13 21|sequence
P08917449A0000|21 27|factor
P08917449A0000|39 51|neuropoietin
P08917449A0000|29 32|LIF
P08917270A0229|34 36|QT
P08917270A0229|154 165|QT syndrome
P08917270A0229|38 41|QTc
P08917270A0229|43 51|interval
P08917270A0229|107 114|disease
P08916960A0350|20 36|biopsy specimens
P08916960A0350|162 165|ORF
P08916960A0350|109 119|bcl-2 gene
P08916960A0350|167 174|regions
P08915559A0366|1 22|REM sleep deprivation
P08915051T0000|10 27|resonance imaging
P08914522A0118|191 206|G beta mutation
P08914522A0118|5 15|STE20 gene
P08914522A0118|56 85|pheromone signal transduction
P08913974A0533|153 164|salpingitis
P08913974A0533|50 51|%
P08913974A0533|178 184|others
P08913974A0533|28 31|EPs
P08913974A0533|135 136|%
P08913186A0431|139 171|convergence retraction nystagmus
P08913186A0431|71 79|downgaze
P08913186A0431|47 52|riMLF
P08913186A0431|60 67|control
P08912232A0260|64 72|children
P08912232A0260|77 81|boys
P08912232A0260|46 50|axis
P08910550A0501|101 105|EDTA
P08910550A0501|67 76|78C1 site
P08910550A0501|176 189|transcription
P08910550A0501|31 42|observation
P08910292T0000|1 10|Signaling
P08910292T0000|110 132|protein kinase pathway
P08906139A2935|118 134|vitamin D intake
P08906139A2935|50 57|calcium
P08906139A2935|173 180|periods
P08906139A2935|6 17|observation
P08905819A0531|32 35|0-I
P08905819A0531|65 71|cancer
P08905819A0531|5 13|majority
P08902988A0258|68 72|risk
P08902988A0258|83 93|thrombosis
P08902641A0930|84 90|inflow
P08902641A0930|144 147|DAo
P08902641A0930|8 19|VA-SMV mode
P08902641A0930|57 65|conduits
P08902641A0930|149 150|n
P08902214A1486|102 109|binding
P08902214A1486|21 35|administration
P08902214A1486|90 100|activation
P08901635A0000|18 24|effort
P08901635A0000|143 160|cell wall polymer
P08901635A0000|109 118|synthesis
P08901635A0000|122 131|cellulose
P08901635A0000|90 91|s
P08900296A0000|71 82|endothelium
P08900296A0000|143 151|response
P08900296A0000|22 32|E-selectin
P08900164A0188|1 3|T.
P08900164A0188|12 14|S.
P08898866A0458|257 263|domain
P08898866A0458|162 169|mutants
P08898866A0458|215 230|serine residues
P08898866A0458|151 158|annexin
P08898336A0268|34 48|rRNA fragments
P08898336A0268|55 60|genes
P08898336A0268|112 122|transcript
P08898336A0268|134 143|sequences
P08897663T0000|12 17|Tower
P08897663T0000|30 42|nomenclature
P08896795A0166|35 41|medium
P08896795A0166|173 181|specimen
P08896795A0166|7 12|Spurr
P08896795A0166|122 125|use
P08896795A0166|15 20|resin
P08896473A0282|5 14|objective
P08896473A0282|88 95|factors
P08896473A0282|120 123|VGS
P08896280A0860|171 186|yvh1 disruption
P08896280A0860|52 56|IME1
P08896280A0860|91 97|result
P08895997A0336|1 8|Physiol
P08895522T0000|99 121|cell adhesion molecule
P08895522T0000|11 21|activation
P08894144A1173|1 4|CsA
P08893822A0560|1 18|Northern analysis
P08893822A0560|125 132|tissues
P08892859A0563|170 182|c-myb allele
P08892859A0563|143 158|RAV integration
P08892859A0563|133 139|result
P08892859A0563|61 70|cell line
P08892755A0981|51 84|chloramphenicol acetyltransferase
P08892755A0981|86 89|CAT
P08892755A0981|128 145|carp CF cell line
P08892755A0981|193 198|times
P08892755A0981|91 104|reporter gene
P08891474A0667|33 39|F-wave
P08891474A0667|83 107|depolarization threshold
P08891474A0667|59 69|motoneuron
P08891345A0684|116 127|translation
P08891345A0684|230 235|uORFs
P08891345A0684|131 142|transcripts
P08891345A0684|160 163|UTR
P08891337A0614|136 140|p300
P08891337A0614|188 203|binding protein
P08891337A0614|160 181|cAMP response element
P08891337A0614|183 186|CRE
P08890537A0355|35 43|patients
P08890537A0355|62 71|bone cyst
P08887674A0920|159 169|mechanisms
P08887674A0920|9 17|settings
P08887667A0992|49 65|spindle assembly
P08887667A0992|20 44|Tyr-19 dephosphorylation
P08887667A0992|189 205|Cdc28/Clb kinase
P08887667A0992|109 126|spindle formation
P08887667A0992|209 223|SPB separation
P08887661A0138|1 6|IRF-1
P08887661A0138|66 75|repressor
P08887652A0341|256 260|gene
P08887652A0341|262 267|con10
P08887652A0341|52 64|DNA fragment
P08887652A0341|24 34|expression
P08887652A0341|107 113|region
P08887643A1167|34 41|signals
P08887643A1167|48 58|activation
P08887643A1167|62 65|Ras
P08885270A0428|50 56|strain
P08885270A0428|58 62|PAO1
P08884273A1413|101 108|studies
P08884273A1413|81 89|resource
P08884273A1413|112 130|telomere structure
P08884273A1413|135 143|function
P08884273A1413|181 196|map integration
P08882492A0000|219 228|organisms
P08882492A0000|129 135|queues
P08882492A0000|47 56|Hox genes
P08882492A0000|15 35|homeodomain proteins
P08881036A0351|48 51|CL2
P08879237A0744|137 138|R
P08879237A0744|49 57|sequence
P08879237A0744|76 100|consensus promoter motif
P08879237A0744|14 30|initiation sites
P08878573A1370|170 173|ATO
P08878573A1370|1 15|Administration
P08878573A1370|177 181|RIFA
P08878573A1370|61 64|ATO
P08878573A1370|31 40|mg/kg/day
P08878044A1390|139 145|Caco-2
P08878044A1390|39 48|virulence
P08878044A1390|110 121|replication
P08878044A1390|79 90|mouse model
P08878019A0357|156 160|case
P08878019A0357|142 147|tumor
P08878019A0357|28 33|cells
P08877103A0081|140 147|J7.V2-1
P08877103A0081|129 138|cell line
P08877103A0081|14 24|regulation
P08876167A0717|207 210|CDP
P08876167A0717|39 50|H4 promoter
P08876167A0717|13 20|CDP/cut
P08876167A0717|105 108|pRB
P08876167A0717|22 29|complex
P08876167A0717|179 188|gp91-phox
P08874631A1133|34 39|HIV-2
P08874631A1133|64 72|presence
P08874631A1133|24 29|HIV-1
P08873159A0791|33 38|group
P08873159A0791|63 75|chemotherapy
P08873063A0493|66 72|LvUSF1
P08873063A0493|13 32|amino acid sequence
P08872162A0884|6 13|alleles
P08872162A0884|73 76|CD8
P08871542A1352|51 61|mechanisms
P08871542A1352|19 28|potential
P08871542A1352|77 85|evidence
P08869825A0000|114 120|manner
P08869825A0000|10 17|studies
P08869358A0121|102 107|cells
P08869358A0121|128 135|T cells
P08869358A0121|74 83|apoptosis
P08868660A0087|238 245|methods
P08868660A0087|282 289|results
P08868660A0087|10 13|aim
P08868660A0087|50 55|arena
P08868660A0087|21 33|contribution
P08868660A0087|214 236|hypothesis formulation
P08868660A0087|91 101|Infermiere
P08867519A0557|87 101|administration
P08867519A0557|5 15|elevations
P08867519A0557|28 32|LDEE
P08864219A0178|191 201|techniques
P08864219A0178|24 38|concentrations
P08864219A0178|106 120|amphotericin B
P08864219A0178|63 73|miconazole
P08863824A0509|1 8|Cloning
P08863824A0509|155 175|transmembrane domain
P08863824A0509|67 75|deletion
P08863824A0509|13 30|sequence analyses
P08862522A0690|38 46|cdc28-P8
P08862522A0690|76 86|precursors
P08861963A0375b|153 170|rrnBP1 UP element
P08861963A0375b|50 71|mutant alpha subunits
P08861963A0375b|96 104|response
P08858463A0853|221 235|nephrotoxicity
P08858463A0853|70 77|ILd-AmB
P08858463A0853|22 35|AIDS patients
P08858463A0853|108 114|dosage
P08858463A0853|41 55|cryptococcosis
P08858211A0694|35 59|3T3-L1 adipocyte lysates
P08858211A0694|159 162|GDP
P08858211A0694|92 102|hydrolysis
P08858211A0694|121 124|GTP
P08856077T0000|95 100|cells
P08856077T0000|31 64|tryptophanyl-tRNA synthetase mRNA
P08854844A0637|17 24|finding
P08854844A0637|116 118|AC
P08854844A0637|53 55|GB
P08854844A0637|135 143|accuracy
P08853893A0158|110 121|fibroblasts
P08853893A0158|44 57|E2F complexes
P08851434A0383|86 90|mice
P08851434A0383|9 13|mice
P08850585A0602|5 22|enzyme activities
P08850585A0602|61 76|pathophysiology
P08849778A0598|33 50|initiator protein
P08849778A0598|93 104|translation
P08849778A0598|27 31|repA
P08849778A0598|72 75|tap
P08849569A0615|5 15|techniques
P08849569A0615|106 113|pattern
P08848052A0733|70 73|Rev
P08848052A0733|7 17|properties
P08848052A0733|43 60|RNA-export factor
P08848052A0733|120 128|function
P08847723A2351|173 185|replications
P08847723A2351|128 134|cancer
P08847723A2351|109 116|studies
P08847723A2351|44 49|study
P08847723A2351|75 82|results
P08847138A0609|5 20|detection ratio
P08847138A0609|31 35|ages
P08845378A0368|32 49|Southern analysis
P08845378A0368|111 115|gene
P08844577A0000|1 11|Tilmicosin
P08844577A0000|23 32|macrolide
P08843419A1290|55 67|interactions
P08843419A1290|111 123|interactions
P08843411A0801|101 113|dimerization
P08843411A0801|174 184|activation
P08843411A0801|25 34|receptors
P08840997A0765|1 11|MVR typing
P08840997A0765|125 136|resemblance
P08840501A0345|20 29|discovery
P08840501A0345|66 74|organism
P08839832A1220|80 88|labeling
P08839832A1220|95 98|32P
P08839498A0507|138 144|stages
P08839498A0507|175 178|fat
P08839498A0507|159 171|distribution
P08839498A0507|57 68|tissue mass
P08838585A0968|21 30|structure
P08838148A1218|137 155|L channel activity
P08838148A1218|86 98|transfection
P08838148A1218|23 32|cell line
P08837746A0951|64 75|postproline
P08837746A0951|7 10|use
P08836740A1025|18 22|CES4
P08836740A1025|9 13|CES1
P08836032T0000|1 16|Bifunctionality
P08836032T0000|59 62|hr1
P08836032T0000|24 30|AcMNPV
P08836032T0000|107 128|sequence requirements
P08835895A1292|5 14|CD4 count
P08835895A1292|109 118|infection
P08833653A0783|34 41|insulin
P08833653A0783|250 264|G9 islet cells
P08833653A0783|92 101|sequences
P08833653A0783|214 222|promoter
P08833653A0783|46 75|amylin gene promoter elements
P08833153A0628|137 142|exons
P08833153A0628|70 79|databases
P08833153A0628|200 206|region
P08833153A0628|167 174|domains
P08833153A0628|16 26|comparison
P08833153A0628|249 253|part
P08831364A1252|155 159|dose
P08831364A1252|20 31|propranolol
P08831364A1252|53 60|effects
P08831364A1252|202 207|block
P08831364A1252|130 139|verapamil
P08831364A1252|90 92|AV
P08828857A2423|84 89|study
P08828857A2423|20 28|GE cells
P08828857A2423|97 106|endocrine
P08828857A2423|133 140|factors
P08828152A1238|220 233|relationships
P08828152A1238|84 89|MCV-1
P08828152A1238|19 39|amino acid sequences
P08828152A1238|166 177|differences
P08828152A1238|74 78|LCDV
P08827783A0499|5 9|ewes
P08827783A0499|41 51|monitoring
P08825636T0000|86 90|p105
P08825636T0000|111 143|transcription factors NF-kappa B
P08825636T0000|56 66|gene NFKB1
P08825636T0000|182 190|NF-kappa
P08825636T0000|165 177|implications
P08825556A0522|87 90|CRE
P08825556A0522|22 29|CREsp-a
P08825556A0522|92 98|CREpal
P08825556A0522|31 39|TGACCTCA
P08825178A0071|38 49|individuals
P08825178A0071|110 123|participation
P08825178A0071|13 33|inpatient experience
P08824884A0000|186 190|form
P08824884A0000|17 27|expression
P08824884A0000|87 96|expansion
P08824884A0000|143 155|X chromosome
P08824884A0000|125 129|Xq28
P08824805A0832|50 60|boundaries
P08824805A0832|90 101|p55 protein
P08824798A0761|33 44|LIM domains
P08824798A0761|80 81|%
P08824798A0761|7 24|ESP1/CRP2 protein
P08824798A0761|126 133|protein
P08824798A0761|135 138|CRP
P08824201A0270|25 36|publication
P08823646A1012|1 15|Administration
P08823646A1012|72 76|SaO2
P08823187A1020|152 167|disulfide bonds
P08823187A1020|93 113|membrane dipeptidase
P08822399A0518|34 43|attitudes
P08822399A0518|55 69|susceptibility
P08822399A0518|14 21|factors
P08820648A0123|119 125|growth
P08820648A0123|178 185|species
P08820648A0123|40 64|ribonucleotide reductase
P08820648A0123|133 137|cell
P08820324A1699|33 36|DBS
P08820324A1699|41 54|TOF responses
P08818436A0557|103 111|diseases
P08818436A0557|54 60|gender
P08818436A0557|28 36|analysis
P08818436A0557|120 126|gender
P08817323A0714|118 122|ESTs
P08817323A0714|154 167|DXS6673E gene
P08817323A0714|143 146|end
P08817323A0714|60 63|end
P08816759A0000|140 149|subfamily
P08816759A0000|67 73|member
P08816759A0000|161 170|receptors
P08816759A0000|105 108|RAR
P08816759A0000|45 60|orphan receptor
P08816504T0000|169 181|Ras activity
P08816504T0000|144 152|proteins
P08816504T0000|56 85|phosphatidylinositol 3-kinase
P08816483A0869|32 36|SWI5
P08816483A0869|42 46|RIC3
P08816472T0000|1 15|Identification
P08816472T0000|71 87|response pathway
P08816472T0000|52 56|Byr2
P08816460A1769|144 149|Erk-2
P08816460A1769|29 39|inhibition
P08816460A1769|91 109|Ras transformation
P08816453A0000|5 14|elevation
P08816453A0000|25 28|AMP
P08816453A0000|73 81|activity
P08816443A1674|187 200|kinase domain
P08816443A1674|154 164|regulators
P08816443A1674|112 121|C termini
P08816443A1674|25 34|ROK alpha
P08816443A1674|106 107|N
P08816443A1674|61 75|reorganization
P08816052A0238|50 54|form
P08816052A0238|1 5|Data
P08816052A0238|81 89|validity
P08816052A0238|172 178|K-SNAP
P08813900A1088|154 166|P deficiency
P08813900A1088|64 78|mineralization
P08813900A1088|143 150|effects
P08813900A1088|36 47|orderliness
P08813900A1088|197 206|structure
P08813900A1088|214 220|tibias
P08812490A1509|82 86|loci
P08812490A1509|148 170|chromosome locus 12q13
P08812490A1509|105 110|AQP-2
P08812490A1509|45 54|structure
P08812490A0000|37 54|gene symbol AQP2L
P08812490A0000|10 20|cDNA clone
P08812490A0000|31 35|hKID
P08812020A0597|115 116|%
P08812020A0597|26 37|Chessmaster
P08812020A0597|12 22|experiment
P08810323A0735|16 36|polyglutamine motifs
P08810040A0955|103 114|replacement
P08810040A0955|125 134|frequency
P08810040A0955|29 33|loss
P08808939A0000|51 68|Bacillus subtilis
P08808939A0000|37 47|gnt operon
P08808939A0000|88 119|catabolite control protein CcpA
P08808939A0000|134 156|phosphocarrier protein
P08808924A0326|250 257|segment
P08808924A0326|5 23|hydropathy profile
P08808924A0326|113 121|residues
P08808924A0326|261 265|ProW
P08808924A0326|183 187|L-61
P08808707A0631|71 77|kinase
P08808707A0631|25 33|proteins
P08808707A0631|125 129|SAPK
P08808707A0631|79 82|ERK
P08808707A0631|210 225|gene expression
P08808120A0774|171 198|iron transferrin saturation
P08808120A0774|204 225|serum ferritin levels
P08808120A0774|308 329|serum aluminum levels
P08808120A0774|41 58|aluminum overload
P08808120A0774|19 30|probability
P08808120A0774|83 95|micrograms/L
P08808120A0774|246 254|patients
P08808120A0774|267 278|probability
P08808120A0774|362 374|micrograms/L
P08807288T0000|1 10|Isolation
P08807288T0000|65 80|ADH2 expression
P08806817A0716|65 69|gene
P08806817A0716|9 26|DNA hybridization
P08806693A0584|170 198|luciferase expression vector
P08806693A0584|141 149|promoter
P08806693A0584|96 100|ME26
P08806693A0584|228 245|mouse fibroblasts
P08806693A0584|46 61|GATA-1 promoter
P08806693A0584|107 114|protein
P08805824A1155|220 236|lens aberrations
P08805824A1155|48 59|combination
P08805824A1155|65 94|exit wavefront reconstruction
P08805824A1155|142 149|effects
P08805824A1155|199 209|microscope
P08804389A0893|49 54|probe
P08804389A0893|141 147|levels
P08804389A0893|189 191|pv
P08804389A0893|121 129|increase
P08804389A0893|151 160|Ltp4 mRNA
P08803845A0665|174 181|attempt
P08803845A0665|5 13|presence
P08803845A0665|128 132|line
P08803845A0665|149 155|lesion
P08801403T0001|21 29|effusion
P08798782A0976|1 4|Lck
P08798782A0976|57 68|SH3 domains
P08798700A0134|170 180|activation
P08798700A0134|117 123|relief
P08798700A0134|127 137|repression
P08798700A0134|226 229|UAS
P08798700A0134|62 70|response
P08798700A0134|74 80|oxygen
P08798643T0000|81 84|Cbl
P08798643T0000|125 131|ZAP-70
P08798635A0870|103 109|effect
P08798635A0870|33 43|hydrolysis
P08798635A0870|78 82|ARF3
P08798635A0870|94 98|ARF6
P08798635A0870|47 50|GTP
P08798512A1197|5 11|amount
P08798512A1197|44 53|GEO cells
P08798443A0660|1 7|Serine
P08798443A0660|65 77|substitution
P08798443A0660|49 59|cell lines
P08798443A0660|263 281|herpes tk promoter
P08798443A0660|95 102|alanine
P08798443A0660|180 188|promoter
P08797362T0037|1 7|Update
P08797362T0037|54 60|states
P08797362T0037|75 79|USSR
P08794869A0274|55 63|PKC-zeta
P08794869A0274|9 14|lines
P08794869A0274|88 112|integrin gene expression
P08794547A1403|86 89|SAH
P08794363A0259|85 104|jun-fos gene family
P08794363A0259|21 25|bZIP
P08794363A0259|8 13|basis
P08794363A0259|47 50|meq
P08794339A1162|233 246|CREB function
P08794339A1162|73 82|deltaCREB
P08794339A1162|153 160|protein
P08794339A1162|112 121|complexes
P08794339A1162|127 131|p300
P08794339A1162|95 98|IE2
P08794254A2957|84 94|graft loss
P08794254A2957|76 80|risk
P08794254A2957|8 11|SPK
P08793029A0246|1 8|Control
P08790387A0299|76 84|whn gene
P08790387A0299|41 58|nonsense mutation
P08790288A0068|84 90|barley
P08790288A0068|92 110|Hordeum vulgare cv
P08790288A0068|28 37|isolation
P08787110A0981|35 48|investigation
P08787110A0981|70 78|patients
P08787110A0981|142 156|investigations
P08787110A0981|180 199|function laboratory
P08783666A0957|18 22|time
P08783666A0957|94 101|cohorts
P08781144A1520|55 60|index
P08781144A1520|93 96|NPC
P08781144A1520|75 89|tumour hypoxia
P08780339A0142|32 33|x
P08780339A0142|36 54|Latin-square study
P08780339A0142|17 29|single-blind
P08780339A0142|222 225|RS2
P08780339A0142|115 122|females
P08780339A0142|260 270|cornstarch
P08780339A0142|210 220|cornstarch
P08778265A0422|116 127|Stroop test
P08778265A0422|157 161|test
P08778265A0422|22 34|test battery
P08778265A0422|176 192|recognition test
P08776901A0000|102 113|variegation
P08776901A0000|117 123|leaves
P08776901A0000|22 25|chm
P08776901A0000|30 41|Arabidopsis
P08776792A0626|48 52|days
P08776735A0000|273 283|regulation
P08776735A0000|37 42|cells
P08776735A0000|142 150|residues
P08776735A0000|191 200|rLHR-t631
P08776735A0000|26 32|kidney
P08776735A0000|123 128|tails
P08776735A0000|180 189|rLHR-t653
P08774732A0271|17 20|Sp1
P08774732A0271|25 35|zif268/egr
P08771781A1103|5 23|ORFII gene product
P08771781A1103|110 118|presence
P08771781A1103|122 135|PMSR activity
P08770981A0328|50 53|vWF
P08770981A0328|5 13|patients
P08770981A0328|110 116|weight
P08770981A0328|27 48|von Willebrand factor
P08770896A1121|168 171|14K
P08770896A1121|21 30|secretion
P08770896A1121|36 42|IGF-II
P08770896A1121|46 50|xz97
P08769568A0949|48 56|ancestor
P08769568A0949|24 29|genes
P08769409A0114|49 59|expression
P08769409A0114|217 223|Zimmer
P08769409A0114|163 177|reading frames
P08769409A0114|229 233|A.M.
P08769409A0114|209 215|region
P08769409A0114|134 139|level
P08768377A1387|144 151|cloning
P08768377A1387|57 69|centimorgans
P08768377A1387|13 25|hcf109 locus
P08766781A0322|50 60|hematocrit
P08766781A0322|76 77|%
P08766781A0322|13 19|period
P08764136A0000|51 61|expression
P08764136A0000|140 145|cells
P08764136A0000|97 111|transformation
P08764136A0000|25 30|genes
P08764136A0000|147 151|MECs
P08763953A0805|34 38|traB
P08763953A0805|18 22|traA
P08763953A0805|65 69|traC
P08763953A0805|24 28|traF
P08763311A0189|25 55|alpha-1 adrenoreceptor agonist
P08763311A0189|166 177|bradycardia
P08762472A0000|118 125|studies
P08762472A0000|43 46|LTH
P08762472A0000|15 41|ligustrazine hydrochloride
P08762021A0156|54 65|performance
P08761169T0000|35 40|child
P08761169T0000|55 61|damage
P08760889A0170|93 97|H2A1
P08760889A0170|41 46|probe
P08760776A1559|48 70|fluticasone propionate
P08760776A1559|191 197|asthma
P08760776A1559|92 102|micrograms
P08760776A1559|74 84|micrograms
P08759870A1128|19 41|fbpA operator sequence
P08759870A1128|110 117|binding
P08759870A1128|46 48|bp
P08757265A0466|57 64|effects
P08756642A0230|1 12|Alterations
P08756642A0230|92 100|leukemia
P08756617A1204|1 5|Biol
P08756597A0854|48 59|% reduction
P08756597A0854|76 85|psaB mRNA
P08756433A0282|35 50|promoter region
P08756433A0282|158 168|MAP1B gene
P08755898A0339|138 144|avrBs2
P08755898A0339|89 96|fitness
P08755898A0339|28 37|pathogens
P08754840A0793|59 64|Rho1p
P08754827A0231|1 7|Hoeben
P08754777A1214|87 89|T3
P08754777A1214|5 10|upTRE
P08754777A1214|142 144|dn
P08754777A1214|76 81|dnTRE
P08751635A0135|84 87|CA3
P08751635A0135|93 98|hilus
P08751635A0135|29 35|damage
P08750190A0000|175 180|CD44v
P08750190A0000|5 15|laboratory
P08750190A0000|147 157|generation
P08750190A0000|106 110|site
P08749394A0874|171 187|Drosophila Notch
P08749394A0874|154 166|mouse Notch1
P08749394A0874|113 114|H
P08749394A0874|110 112|Su
P08749394A0874|94 105|RBP-J kappa
P08748033A0874|155 159|DegP
P08748033A0874|112 119|effects
P08748033A0874|43 51|toxicity
P08747078T0000|32 43|miscarriage
P08746605A0377|48 57|incidence
P08746605A0377|109 121|pancreatitis
P08746605A0377|74 81|effects
P08742385A0211|19 25|causes
P08742385A0211|140 141|%
P08742385A0211|73 81|drainage
P08741280A0374|114 118|lobe
P08741280A0374|95 101|length
P08741280A0374|60 64|ones
P08740416A0919|51 58|protein
P08740416A0919|5 19|SEB1 homologue
P08740416A0919|61 62|%
P08739260T0000|1 6|Catha
P08738510A0254|32 39|Q-MRGlu
P08738510A0254|62 68|cortex
P08733881A0343|136 146|TSH levels
P08733881A0343|113 121|subjects
P08733881A0343|90 100|TSH values
P08733123A0951|55 61|length
P08733123A0951|110 117|protein
P08733123A0951|125 144|amino acid residues
P08732665A0000|1 14|Amplification
P08732665A0000|139 145|levels
P08732665A0000|41 54|c-erbB-2 gene
P08732665A0000|19 33|overexpression
P08732665A0000|188 198|p185erbB-2
P08732665A0000|82 104|breast carcinoma cells
P08732665A0000|247 260|growth factor
P08731222A0000|170 174|area
P08731222A0000|38 49|projections
P08731222A0000|166 168|Cu
P08731222A0000|284 291|laminae
P08731222A0000|194 197|rat
P08731222A0000|22 34|organization
P08731222A0000|149 164|Cuneate nucleus
P08731222A0000|90 121|subnucleus reticularis dorsalis
P08730470A0000|116 128|transmission
P08730470A0000|37 54|hepatitis C virus
P08730470A0000|145 151|babies
P08727992A0570|84 90|estrus
P08727992A0570|40 47|heifers
P08727992A0570|75 80|signs
P08726247A0175|51 63|measurements
P08726247A0175|24 45|concentration changes
P08726024A0244|53 58|study
P08726024A0244|26 35|H. pylori
P08723883A0823|70 82|modification
P08723883A0823|109 114|assay
P08723352A0084|82 86|cdks
P08723352A0084|125 162|retinoblastoma tumour suppressor gene
P08723352A0084|164 167|pRb
P08722011A0103|200 211|protein L12
P08722011A0103|6 13|complex
P08722011A0103|108 115|protein
P08722011A0103|31 44|GTPase domain
P08721999A0432|4 12|addition
P08721526A0000|80 91|pet animals
P08721526A0000|60 68|children
P08719832A0397|80 90|acromegaly
P08719832A0397|31 49|rhinotomy approach
P08719156A0953|33 37|gene
P08719156A0953|105 112|protein
P08717559A0223|66 70|ages
P08717559A0223|14 20|dosage
P08716757T0001|1 25|Microcomputer management
P08712799A0123|9 17|attempts
P08710504A0995|1 11|Activation
P08710504A0995|60 71|cat1 mutant
P08710371A0499|96 116|base pair mismatches
P08710371A0499|135 153|base pair deletion
P08710151A0782|32 37|value
P08710151A0782|99 100|%
P08710151A0782|54 61|episode
P08710151A0782|129 133|cost
P08710151A0782|149 156|class A
P08710151A0782|45 49|cost
P08709637A1471|84 94|activation
P08709637A1471|5 9|data
P08709637A1471|130 134|role
P08709637A1471|165 182|precursor B cells
P08709245A1521|169 177|assembly
P08709245A1521|5 12|studies
P08709245A1521|78 85|Ser-123
P08709245A1521|116 142|trans-suppression activity
P08709245A1521|52 67|phosphorylation
P08709245A1521|31 42|possibility
P08708984T0000|32 44|indomethacin
P08708984T0000|13 20|process
P08707846A2308|258 269|endocytosis
P08707846A2308|190 201|endocytosis
P08707846A2308|129 152|receptor ubiquitination
P08707846A2308|209 226|a-factor receptor
P08707825A0063|38 50|muscle cells
P08707825A0063|96 104|analysis
P08707825A0063|212 224|antibody R4A
P08707825A0063|242 246|cDNA
P08707424A0709|139 150|development
P08707424A0709|19 32|ERV3 env mRNA
P08706662A1125|33 40|absence
P08706662A1125|81 86|cells
P08706662A1125|124 133|induction
P08706662A1125|105 116|suppression
P08705056T0000|21 27|nurses
P08704124A0420|87 120|Vigna radiata lambda gt11 library
P08704124A0420|33 39|CPK3-8
P08704124A0420|61 68|bp cDNA
P08703908A1814|112 122|expression
P08703908A1814|62 66|role
P08703005A0645|16 24|elements
P08703005A0645|112 120|alphaCbf
P08703005A0645|131 136|CCAAT
P08703005A0645|149 156|protein
P08702936A0168|217 237|virus shuttle vector
P08702936A0168|142 147|cells
P08702936A0168|72 77|cDNAs
P08702826A0870|81 89|activity
P08702826A0870|108 116|promoter
P08702826A0870|120 130|MCF7 cells
P08702756A0000|110 121|cytokinesis
P08702756A0000|11 21|GTPase Rho
P08702756A0000|149 167|muscle contraction
P08702644A0499|49 55|apoB17
P08702644A0499|38 39|%
P08702644A0499|178 224|glycosylphosphatidylinositol anchor attachment
P08702644A0499|167 173|signal
P08702644A0499|134 140|factor
P08702556A0000|137 141|Imai
P08702556A0000|143 148|S.-i.
P08702556A0000|133 135|H.
P08702556A0000|86 89|PAP
P08702556A0000|126 131|Kanoh
P08702556A0000|182 184|J.
P08702517A0000|17 22|genes
P08702517A0000|72 79|B6SUtA1
P08698756A1240|1 12|CONCLUSIONS
P08698756A1240|218 224|damage
P08698756A1240|161 166|cross
P08698756A1240|94 98|role
P08698756A1240|195 201|degree
P08692924A0328|70 75|BCL-6
P08692924A0328|42 49|ability
P08692924A0328|12 24|DNA sequence
P08692885A0663|16 19|A20
P08692885A0663|79 97|zinc finger domain
P08691106A0733|102 106|cell
P08691106A0733|37 56|nuclease protection
P08691106A0733|62 72|lactotroph
P08690118A0845|41 54|manual method
P08690118A0845|14 33|regression analysis
P08690118A0845|120 130|predictors
P08688556A0242|153 158|yeast
P08688556A0242|76 87|suppressors
P08688556A0242|177 186|viability
P08688556A0242|166 172|scd1-i
P08688556A0242|15 25|laboratory
P08686381A0527|206 212|region
P08686381A0527|218 231|transcription
P08686381A0527|42 53|9765orfR013
P08686381A0527|26 37|9765orfR011
P08686381A0527|13 24|9765orfR002
P08684522A0415|50 60|deposition
P08684522A0415|116 123|laminin
P08684522A0415|83 91|matrices
P08683983A0785|5 12|complex
P08683983A0785|29 38|D protein
P08683108A0965|70 99|transcription factor proteins
P08683108A0965|22 36|interpretation
P08683108A0965|124 128|site
P08682868A0738|49 56|residue
P08682868A0738|130 146|Cdc31p stability
P08682868A0738|121 126|Dsk2p
P08682155A0902|137 148|differences
P08682155A0902|5 31|euglobulin clot lysis time
P08682155A0902|79 90|non-smokers
P08680702A0548|273 274|p
P08680702A0548|202 211|ml/kg/min
P08680702A0548|315 323|catheter
P08680702A0548|346 355|ml/kg/min
P08680702A0548|357 360|Day
P08680702A0548|392 395|Day
P08680702A0548|21 30|lethality
P08680702A0548|417 418|p
P08680702A0548|213 216|Day
P08680702A0548|149 160|differences
P08678959A0640|94 95|%
P08678959A0640|75 90|ultrasonography
P08677443A0238|6 28|Hoosier Oncology Group
P08677443A0238|40 45|study
P08677443A0238|286 287|%
P08677443A0238|134 140|regard
P08677443A0238|251 265|survival rates
P08677443A0238|89 92|VIP
P08677443A0238|151 155|time
P08676858A0309|171 180|sequences
P08676858A0309|87 92|apple
P08676858A0309|23 39|characterization
P08676858A0309|77 85|Rosaceae
P08676858A0309|94 111|Malus x domestica
P08676858A0309|132 146|Pyrus serotina
P08676456A0879|46 63|leucine mutations
P08676456A0879|107 117|comparison
P08676383A0518|34 52|disulfide linkages
P08676383A0518|62 74|cis peptides
P08675821A0657|83 93|malignancy
P08675821A0657|13 17|EMPD
P08675763A0788|1 14|Mean increase
P08675763A0788|18 36|milk protein yield
P08675763A0788|93 108|protein content
P08675763A0788|125 129|milk
P08675763A0788|44 47|g/d
P08675395A0751|23 28|model
P08675395A0751|61 64|fit
P08673026T0000|39 45|traits
P08673026T0000|26 37|schizotypal
P08670910A0156|100 119|polypeptide complex
P08670910A0156|40 43|DNA
P08670556A0425|18 19|p
P08670556A0425|93 105|infinity AUC
P08670556A0425|45 76|plasma concentration-time curve
P08669274T0000|32 38|choice
P08669274T0000|12 30|chain ossification
P08668209A0406|9 32|Cold Spring Harbor Symp
P08668201A1059|58 75|sequence boundary
P08668201A1059|10 21|mutagenesis
P08668201A1059|167 172|codon
P08668201A1059|180 187|element
P08668158A1252|139 157|biogenesis defects
P08668158A1252|94 103|mutations
P08668158A1252|14 21|strains
P08668142A1048|55 62|balance
P08668142A1048|5 17|introduction
P08666913A0000|1 6|Ly-49
P08666913A0000|27 49|transmembrane proteins
P08666913A0000|12 23|family type
P08666398T0000|1 4|YAC
P08666398T0000|37 51|Batten disease
P08666398T0000|9 23|cosmid contigs
P08666241A0930|55 68|24p3 promoter
P08666102A0820|1 5|ZIOS
P08666102A0820|59 66|methods
P08664667A0093|23 28|India
P08664347A0923|170 176|enzyme
P08664347A0923|18 49|proprotein processing proteases
P08664347A0923|151 161|maturation
P08663392A0215|84 94|regulation
P08663392A0215|41 50|DSG3 gene
P08663310A0157|54 61|members
P08663310A0157|10 13|SRF
P08663310A0157|41 50|regulator
P08663310A0157|123 128|genes
P08663172A0311|33 47|amino terminus
P08663172A0311|73 80|protein
P08663127A0697|155 174|glycosylation sites
P08663127A0697|24 28|KCC1
P08663127A0697|12 20|analysis
P08663127A0697|62 66|NKCC
P08663000A0000|154 163|TGF-beta1
P08663000A0000|18 28|hyaluronan
P08663000A0000|38 46|motility
P08663000A0000|95 108|fibrosarcomas
P08662936A0428|84 85|%
P08662936A0428|155 158|TEA
P08662936A0428|177 183|factor
P08662936A0428|106 120|chicken TEF-1A
P08662928A1153|6 16|regulation
P08662928A1153|63 73|expression
P08662789A0673|19 23|gene
P08662789A0673|46 65|GenBankTM data base
P08662499A0484|5 10|front
P08662499A0484|62 65|RNA
P08661613A0691|136 141|group
P08661613A0691|99 108|education
P08661613A0691|66 71|users
P08661613A0691|167 189|enforcement activities
P08661116A0963|1 18|Promoter activity
P08661116A0963|202 204|bp
P08661116A0963|62 68|levels
P08661104A0687|51 55|mRNA
P08661104A0687|5 9|gene
P08661104A0687|133 138|colon
P08661104A0687|122 127|liver
P08661100A0285|154 163|structure
P08661100A0285|81 89|App gene
P08661100A0285|128 135|domains
P08660998A0851|50 54|TATA
P08660998A0851|5 20|mMIWC1 promoter
P08660998A0851|172 178|mMIWC1
P08660998A0851|193 208|initiation site
P08660998A0851|62 66|GATA
P08660866A0504|171 177|sheath
P08660866A0504|200 209|trichogen
P08660866A0504|161 169|thecogen
P08660866A0504|51 65|loss phenotype
P08660866A0504|116 120|SOPs
P08660866A0504|149 156|neurons
P08660866A0504|90 97|progeny
P08660733X0000|33 38|aphid
P08660733X0000|62 73|Puerto Rico
P08657918A0360|1 10|MATERIALS
P08657918A0360|213 216|SLL
P08657918A0360|111 114|SLL
P08657918A0360|229 239|dissection
P08657918A0360|121 129|patients
P08657157A0000|171 182|recognition
P08657157A0000|136 146|POU domain
P08657157A0000|42 52|POU domain
P08657157A0000|194 219|octamer sequence elements
P08657135A1444|139 150|muscle gene
P08657135A1444|37 41|CKII
P08657135A1444|77 87|myogenesis
P08655555A1368|136 145|promoters
P08655555A1368|5 17|DNA sequence
P08655555A1368|75 84|TGn motif
P08655497A0000|113 123|resistance
P08655497A0000|25 28|cmr
P08655497A0000|79 90|K-12 genome
P08654972A0000|1 8|Defects
P08654972A0000|43 45|Sp
P08654972A0000|47 51|cell
P08654946A0475|48 54|region
P08654946A0475|5 7|aa
P08654946A0475|9 15|shares
P08654946A0475|104 111|product
P08654390A0000|1 15|Heme oxygenase
P08654390A0000|98 102|iron
P08654390A0000|73 77|heme
P08654200A0274|205 210|mg/kg
P08654200A0274|236 239|ICG
P08654200A0274|21 38|resonance imaging
P08654200A0274|129 138|clearance
P08654200A0274|182 187|mg/kg
P08654200A0274|166 175|lorazepam
P08651853T0000|17 26|sclerosis
P08650818A0000|157 162|spite
P08650818A0000|230 237|arrival
P08650818A0000|79 85|strain
P08650818A0000|166 175|isolation
P08650818A0000|13 19|spread
P08649773A1374|139 152|cell lymphoma
P08649773A1374|55 64|repressor
P08649773A1374|108 121|B lymphocytes
P08649428A1227|9 14|study
P08649428A1227|79 101|c-mos oncogene product
P08649428A1227|44 54|regulation
P08649425T0000|56 82|mouse immunoglobulin kappa
P08649424A0000|1 11|Expression
P08649424A0000|64 71|kidneys
P08649424A0000|53 59|livers
P08649424A0000|123 138|glucocorticoids
P08649424A0000|75 82|rodents
P08649403A0963|5 18|growth defect
P08649403A0963|24 33|reg1 reg2
P08649389A0692|116 120|CTCF
P08649389A0692|40 57|CTCF binding site
P08649389A0692|62 98|transient-cotransfection experiments
P08649386A1032|87 101|consensus Abf1
P08649386A1032|110 114|site
P08649372A0755|137 141|Mbp1
P08649372A0755|99 103|Swi6
P08649372A0755|5 21|carboxy terminus
P08649372A0755|79 95|carboxy terminus
P08648726A0713|1 8|Cloning
P08648726A0713|101 112|ZID domains
P08648726A0713|142 145|TPA
P08648726A0713|92 95|ZIC
P08648665A0956|100 105|cells
P08648665A0956|143 146|LE6
P08647884A0547|35 44|reticulum
P08647884A0547|111 120|transport
P08647884A0547|75 84|molecules
P08647802A0000|128 132|Grb2
P08647802A0000|90 101|arrangement
P08647434A1124|144 154|conditions
P08647434A1124|125 129|hTAF
P08647434A1124|95 99|hTAF
P08647434A1124|90 93|TBP
P08647091A0592|17 23|clones
P08647091A0592|92 98|region
P08647091A0592|122 129|introns
P08647091A0592|75 80|exons
P08647086A0720|98 102|SV40
P08647086A0720|173 183|HeLa cells
P08647086A0720|198 211|Cdk2-cyclin-E
P08647086A0720|81 91|H1 histone
P08647086A0720|188 196|contrast
P08647086A0720|93 96|pRB
P08647086A0720|61 71|substrates
P08645219A1377|16 19|Zn2
P08645219A1377|32 41|S100 beta
P08645219A1377|21 28|binding
P08645219A1377|110 122|binding site
P08645219A1377|105 108|Zn2
P08644734A0404|87 108|segment-polarity gene
P08643682A0268|174 188|fusion protein
P08643682A0268|130 143|NIH 3T3 cells
P08643682A0268|44 51|CBFbeta
P08643633A1187|50 57|deltaEC
P08643633A1187|6 23|immunoprecipitate
P08643633A1187|47 49|N1
P08643578A0000|1 10|RAS2val19
P08643578A0000|155 158|TyA
P08643578A0000|190 218|mating pathway reporter FUS1
P08643578A0000|66 70|Ras2
P08643578A0000|161 165|lacZ
P08643513A0361|1 18|Deletion analysis
P08643513A0361|115 123|sequence
P08643513A0361|22 25|rOC
P08643513A0361|144 152|promoter
P08643111A0855|342 357|antigen binding
P08643111A0855|153 157|cLL2
P08643111A0855|315 319|mLL2
P08643111A0855|56 76|region glycosylation
P08643111A0855|148 151|LL2
P08643111A0855|211 221|properties
P08642313T0000|85 92|I kappa
P08642313T0000|100 108|activity
P08642313T0000|65 80|Notch homologue
P08642285A1548|102 112|antibodies
P08642285A1548|131 136|STAT5
P08642285A1548|61 71|cell lines
P08641705A0986|17 29|observations
P08641705A0986|201 206|point
P08641705A0986|82 92|codon beta
P08641705A0986|40 54|heterozygosity
P08641705A0986|227 238|inheritance
P08641705A0986|62 63|A
P08639837A0268|99 109|Ets family
P08639837A0268|73 79|GATA-1
P08639561T0000|1 10|Adduction
P08639561T0000|175 179|SRSR
P08639561T0000|65 66|R
P08639561T0000|76 87|dihydroxy-9
P08639561T0000|198 199|S
P08639561T0000|195 196|R
P08639561T0000|223 238|tetrahydrobenzo
P08639561T0000|144 154|refinement
P08639561T0000|58 60|7S
P08639561T0000|62 63|R
P08639561T0000|241 248|pyrenyl
P08639310A0548|157 164|mg p.r.
P08639310A0548|97 100|MCP
P08639310A0548|179 180|h
P08639310A0548|150 153|MCP
P08639310A0548|30 45|mg tid prn days
P08637717A1231|3 14|p21 peptide
P08637717A1231|133 153|p21-PCNA interaction
P08637717A1231|62 66|PCNA
P08637711A1121|33 37|IL-6
P08637711A1121|67 83|response element
P08637711A1121|56 65|IFN gamma
P08637711A1121|148 152|site
P08637711A1121|91 105|IRF-1 promoter
P08636428A1363|21 28|results
P08636428A1363|72 99|smooth muscle proliferation
P08636149A0220|138 146|response
P08636149A0220|13 22|receptors
P08636149A0220|45 57|cell surface
P08636031A1413|1 12|Interaction
P08636031A1413|20 33|Fur repressor
P08636031A1413|74 87|pvdS promoter
P08634697A1155|5 13|sequence
P08634697A1155|93 98|Brca1
P08634697A1155|27 32|cDNAs
P08634697A1155|133 143|importance
P08634420A1784|1 11|HuEpo-R Ab
P08634420A1784|86 91|clone
P08634420A1784|43 59|UT-7 cell growth
P08634290A0000|19 31|retroviruses
P08634290A0000|5 11|genome
P08632779A0351|205 215|HeLa cells
P08632779A0351|48 50|AA
P08632779A0351|5 16|XPG regions
P08632779A0351|36 46|amino acid
P08632779A0351|72 74|AA
P08632779A0351|194 201|nucleus
P08632018A0587|86 97|UGT1A1 gene
P08632018A0587|113 125|MC induction
P08632018A0587|31 42|nucleotides
P08632015A0879|43 56|transcription
P08631958T0000|98 101|p53
P08631958T0000|7 22|cytomegalovirus
P08631934A0000|34 55|transcription factors
P08631934A0000|138 141|MBS
P08631934A0000|5 12|members
P08631934A0000|143 151|sequence
P08631934A0000|162 167|A/C/G
P08631934A0000|132 136|site
P08631934A0000|156 159|A/G
P08631822A0677|35 39|VEGF
P08631822A0677|70 85|heparin binding
P08631822A0677|163 179|cell mitogenesis
P08631822A0677|132 139|ability
P08631817T0000|1 15|Identification
P08631817T0000|98 102|form
P08631817T0000|112 157|deoxyuridine triphosphate nucleotidohydrolase
P08631760A0609|113 134|Crk-SH2 binding motif
P08631760A0609|6 17|interaction
P08631667A0851|1 15|Identification
P08631667A0851|83 98|complementation
P08631667A0851|144 150|mutant
P08631667A0851|199 214|kinase activity
P08631667A0851|46 54|tmk gene
P08631667A0851|104 121|yeast dTMP kinase
P08630583A1056|4 6|pH
P08630583A1056|11 13|Hb
P08630542A1421|85 93|increase
P08630542A1421|33 41|increase
P08630542A1421|97 98|Q
P08630542A1421|132 141|procedure
P08628681A0821|1 22|Sequence conservation
P08628681A0821|39 47|residues
P08628681A0821|72 79|centers
P08628302A0683|17 37|transcription factor
P08628302A0683|4 11|hnRNP K
P08628302A0683|44 56|interactions
P08628260A0895|21 41|transfection studies
P08628260A0895|196 213|promoter activity
P08628260A0895|149 156|results
P08628260A0895|105 123|promoter sequences
P08628254A0665|115 123|c-Ha-Ras
P08628254A0665|25 41|Jun/eb1 chimeras
P08628254A0665|134 138|foci
P08627719A0784|169 173|CstF
P08627719A0784|140 167|cleavage stimulation factor
P08627719A0784|230 237|classes
P08627719A0784|187 196|site RNAs
P08627719A0784|48 61|HSV infection
P08627719A0784|261 268|binding
P08627719A0784|179 183|poly
P08627667A0132|85 92|domains
P08627667A0132|1 6|ZEBRA
P08627667A0132|20 40|AP-1 bZip activators
P08627354A0000|87 97|regulation
P08627354A0000|54 62|proteins
P08626785A0674|306 313|mTGRRE1
P08626785A0674|233 239|region
P08626785A0674|427 430|RAR
P08626785A0674|398 411|DR7/DR5 motif
P08626785A0674|127 136|sequences
P08626785A0674|264 294|pair retinoid response element
P08626785A0674|180 219|mouse tissue transglutaminase promoters
P08626698A0989|137 145|antibody
P08626698A0989|202 218|gel kinase assay
P08626698A0989|22 30|increase
P08626698A0989|91 110|immunoprecipitation
P08626667A1372|100 107|binding
P08626667A1372|42 51|mutations
P08626667A1372|123 131|proteins
P08626610A0931|17 28|suppression
P08626610A0931|32 40|cleavage
P08626610A0931|182 188|result
P08626610A0931|135 148|COOH terminus
P08626540A1007|99 107|ceramide
P08626540A1007|131 147|lactosylceramide
P08626540A1007|62 70|turnover
P08626529A0799|340 348|granules
P08626529A0799|96 105|frequency
P08626529A0799|310 318|proteins
P08626529A0799|109 123|heptad repeats
P08626529A0799|187 197|structures
P08626529A0799|352 372|neuroendocrine cells
P08626529A0799|125 139|characteristic
P08626529A0799|243 254|amino acids
P08626493A1468|1 10|Mutations
P08626493A1468|159 172|transcription
P08626493A1468|144 155|stimulation
P08626493A1468|228 236|type E1A
P08626493A1468|89 116|retinoblastoma gene product
P08626493A1468|28 34|region
P08626325A0543|4 13|agreement
P08626325A0543|99 109|homodimers
P08626325A0543|144 155|heterodimer
P08626325A0543|131 135|UmuD
P08626325A0543|62 66|UmuD
P08626290T0000|98 102|OmpA
P08626290T0000|52 60|homologs
P08625987A1086|48 59|VpreB genes
P08625987A1086|214 221|B cells
P08625987A1086|11 39|bone marrow cells expression
P08625987A1086|135 147|state levels
P08625900T0000|96 110|protein kinase
P08625900T0000|215 222|hormone
P08625900T0000|122 129|pathway
P08624445A0257|153 158|wx-m9
P08624445A0257|138 140|Ac
P08624445A0257|36 55|sequencing analysis
P08624445A0257|160 169|Ac allele
P08624445A0257|224 228|gene
P08622893A0000|100 105|roles
P08622893A0000|231 237|family
P08622893A0000|161 172|development
P08622893A0000|11 20|subfamily
P08622893A0000|194 213|signalling pathways
P08622698T0000|21 27|Notch1
P08622698T0000|59 64|genes
P08622668A1155|51 59|function
P08622668A1155|196 203|protein
P08622668A1155|63 69|U6 RNA
P08622668A1155|134 150|C1 hnRNP protein
P08622596A0189|100 104|week
P08622596A0189|5 8|men
P08622596A0189|44 48|home
P08622030A0667|102 120|treatment protocol
P08622030A0667|175 178|LDH
P08622030A0667|52 62|age groups
P08622030A0667|122 140|performance status
P08621719A0568|80 91|interaction
P08621719A0568|108 124|Grb2 SH3 domains
P08621719A0568|15 23|fraction
P08621714A0361|80 85|Cys25
P08621714A0361|5 12|protein
P08621661A1035|159 165|intron
P08621661A1035|193 203|transcript
P08621661A1035|47 57|transcript
P08621628A1233|7 14|hGRbeta
P08621628A1233|60 69|inhibitor
P08621453A0815|4 12|addition
P08621453A0815|76 88|cell lysates
P08621448A0862|34 38|cDNA
P08621448A0862|113 120|protein
P08621448A0862|40 45|clone
P08621384A0935|1 10|Treatment
P08621384A0935|82 86|EGFR
P08621384A0935|58 80|growth factor receptor
P08621384A0935|135 138|min
P08620889A0771|48 67|aldolase C promoter
P08620889A0771|23 26|G+C
P08620889A0771|128 133|cells
P08620003T0000|35 57|N-O acyl rearrangement
P08620003T0000|19 27|evidence
P08619866A0000|84 94|infarction
P08619866A0000|53 61|patients
P08619866A0000|13 43|serum hepatocyte growth factor
P08618864A0754|70 74|core
P08618864A0754|9 17|analysis
P08618864A0754|26 32|domain
P08618433A0000|152 157|STK-1
P08618433A0000|86 90|FLT3
P08618433A0000|142 147|FLK-2
P08618433A0000|25 50|growth factor FLT3 ligand
P08617800A0675|1 6|DNase
P08617800A0675|42 63|mobility shift assays
P08617800A0675|95 104|half-site
P08617800A0675|133 165|core recognition sequence TGGGAG
P08617311A0979|52 66|membrane exons
P08617311A0979|95 99|mIgG
P08617311A0979|149 161|Xenopus mIgY
P08617238A0334|204 219|phosphorylation
P08617238A0334|86 101|phosphorylation
P08617238A0334|250 255|hsp27
P08617238A0334|128 138|activation
P08617238A0334|227 245|heat shock protein
P08617216A0584|48 52|DnaK
P08617216A0584|83 92|refolding
P08617216A0584|24 28|DnaJ
P08615183T0000|1 8|Effects
P08615183T0000|42 51|Parkinson
P08615012A0627|1 15|Cotransfection
P08615012A0627|128 133|cells
P08615012A0627|73 79|amount
P08614403A0989|102 103|E
P08614403A0989|139 161|GAL4 response elements
P08614403A0989|217 223|domain
P08614403A0989|265 273|silencer
P08614403A0989|225 228|LBD
P08614403A0989|105 111|region
P08612852A0553|16 35|plasma IGF-I levels
P08612852A0553|64 67|BMI
P08612852A0553|47 62|body mass index
P08610582A0150|34 41|lesions
P08610582A0150|95 105|MR imaging
P08610582A0150|12 20|patients
P08610272A0265|252 260|patients
P08610272A0265|200 214|growth factors
P08610272A0265|20 34|investigations
P08610272A0265|160 164|role
P08610272A0265|240 247|outcome
P08608447A0806|34 51|codon recognition
P08608447A0806|59 74|TPI transcripts
P08608126A0811|87 91|acid
P08608126A0811|141 153|medium-chain
P08608126A0811|202 206|acid
P08608126A0811|8 14|length
P08608126A0811|133 135|nM
P08608126A0811|180 191|short-chain
P08605931A0777|1 16|Epitope mapping
P08605931A0777|83 97|epitope domain
P08605931A0777|124 133|RNP motif
P08605302A1770|85 96|GATC motifs
P08605302A1770|115 119|exon
P08605302A1770|58 73|deoxyadenosines
P08605302A1770|161 175|rice CatA gene
P08604338A0885|34 51|EWS-FLI-1 binding
P08604338A0885|184 188|step
P08604338A0885|4 32|electromobility shift assays
P08604338A0885|231 236|FLI-1
P08604338A0885|111 118|binding
P08604338A0885|122 127|FLI-1
P08603921A1346|50 73|calmodulin binding site
P08603921A1346|18 37|Spc110p truncations
P08603921A1346|146 152|manner
P08602169A0484|50 62|endonuclease
P08602169A0484|86 90|type
P08602169A0484|8 20|point mutant
P08602169A0484|40 46|repair
P08601616A0726|102 115|G1/S boundary
P08601616A0726|126 130|time
P08601616A0726|74 78|step
P08601284A0000|158 167|U3 snoRNA
P08601284A0000|42 48|region
P08601284A0000|29 35|spacer
P08601284A0000|121 123|bp
P08600048T0000|18 32|conjunctivitis
P08600048T0000|43 70|bone marrow transplantation
P08599946A0999|239 246|complex
P08599946A0999|101 109|L1Hs RNA
P08599946A0999|200 220|example coiled-coils
P08599946A0999|172 182|structures
P08599946A0999|47 58|p40 complex
P08598449A0784|4 12|contrast
P08598449A0784|202 205|btk
P08598449A0784|43 64|surface Ig engagement
P08598449A0784|193 196|fyn
P08598449A0784|83 96|CD38 ligation
P08598449A0784|244 251|protein
P08598449A0784|303 306|CA2
P08598051T0000|77 99|RNP consensus-sequence
P08598051T0000|11 19|analysis
P08597596A0135|33 41|cassette
P08597596A0135|43 58|ABC transporter
P08597108A0642|98 103|NOAEL
P08597108A0642|36 42|QBMD05
P08597108A0642|14 22|% change
P08595836T0000|33 40|changes
P08595836T0000|8 17|shrinkage
P08595627A1513|17 21|KATP
P08595627A1513|83 95|consequences
P08595627A1513|52 59|channel
P08595627A1513|108 117|occlusion
P08595184A0407|87 99|correlations
P08595184A0407|64 71|effects
P08595184A0407|24 33|estimator
P08593813A0967|48 52|germ
P08593813A0967|113 123|efficiency
P08593813A0967|10 18|analysis
P08592590A0822|69 80|hepatitis C
P08592590A0822|139 147|response
P08592590A0822|97 117|interferon treatment
P08590465A0773|51 53|S.
P08590465A0773|22 32|regulation
P08590465A0773|60 77|URA1 gene product
P08589358A0841|21 35|erythropoietin
P08589358A0841|128 137|Hb levels
P08589358A0841|57 62|donor
P08589315A1029|221 229|syndrome
P08589315A1029|115 121|groups
P08589315A1029|157 176|lupus erythematosus
P08589315A1029|20 33|survival rate
P08589315A1029|247 248|%
P08589315A1029|123 143|tumor lysis syndrome
P08587075T0000|32 37|cases
P08587075T0000|41 58|hepatitis B virus
P08586643A0951|84 87|UMP
P08586643A0951|92 95|CMP
P08586643A0951|26 32|enzyme
P08585957A0101|116 128|zinc fingers
P08585957A0101|233 256|mobility group proteins
P08585957A0101|219 224|motif
P08585957A0101|93 101|proteins
P08585957A0101|56 63|regions
P08585639T0000|54 76|immunodeficiency virus
P08585639T0000|26 43|hepatitis B virus
P08585324A0467|35 44|SSC1 gene
P08584074A0000|154 160|period
P08584074A0000|110 123|lobe epilepsy
P08584074A0000|125 128|TLE
P08584074A0000|167 173|months
P08584074A0000|45 51|months
P08584026A0115|36 38|P1
P08584026A0115|43 45|P2
P08583846A0121|99 108|perilymph
P08583846A0121|88 94|marker
P08582633T0000|118 136|telomere structure
P08582633T0000|39 44|yeast
P08582633T0000|46 53|effects
P08582633T0000|91 100|HMR locus
P08581174A0472|51 63|qutA mutants
P08581174A0472|25 33|analysis
P08581174A0472|148 160|QUTA protein
P08580083A0259|223 230|HIV LTR
P08580083A0259|142 158|reporter plasmid
P08580083A0259|244 255|T cell line
P08580083A0259|29 41|significance
P08580083A0259|45 48|Fyn
P08576262A0160|5 18|IL-8 receptor
P08576262A0160|24 61|seven-transmembrane spanning receptor
P08576179A0126|102 115|alpha subunit
P08576179A0126|70 99|translation initiation factor
P08576179A0126|11 14|PKR
P08576131A0151|68 81|USF2 isoforms
P08576131A0151|184 192|splicing
P08576131A0151|142 149|subunit
P08576131A0151|109 116|subunit
P08575754T0000|20 38|expression pattern
P08575754T0000|108 114|cyclin
P08575754T0000|78 90|CDKN2D/INK4d
P08575754T0000|11 18|cloning
P08575614A0264|1 13|Rad6 mutants
P08575614A0264|155 173|retrotransposition
P08575614A0264|179 190|sporulation
P08575614A0264|104 115|mutagenesis
P08574583A0658|154 165|sim mutants
P08574583A0658|33 40|S phase
P08574583A0658|77 83|arrest
P08574583A0658|109 115|strain
P08573637A0434|51 64|determination
P08573637A0434|5 11|method
P08572616A0000|18 41|differentiation markers
P08572616A0000|75 84|neoplasms
P08569684A0000|35 40|basis
P08569684A0000|251 263|DNA fragment
P08569684A0000|113 119|domain
P08569684A0000|192 218|polymerase chain reactions
P08569684A0000|180 187|primers
P08569443A0123|100 106|tumors
P08569443A0123|5 12|purpose
P08569443A0123|67 78|differences
P08569443A0123|89 91|T2
P08569443A0123|135 146|differences
P08567717T0000|73 77|part
P08567717T0000|30 69|spindle pole body duplication gene MPS1
P08567556A0000|341 350|immersion
P08567556A0000|175 182|feature
P08567556A0000|277 288|differences
P08567556A0000|193 205|field diving
P08567556A0000|49 53|MbO2
P08567556A0000|246 264|lactate production
P08567556A0000|123 145|laboratory simulations
P08566756A0752|152 155|BPS
P08566756A0752|83 97|UV cross-links
P08566756A0752|129 135|region
P08566756A0752|29 32|SAP
P08566751A0788|6 14|approach
P08566751A0788|88 91|lab
P08566747A0756|1 4|SBF
P08566747A0756|18 26|promoter
P08566747A0756|96 112|Cln/Cdc28 kinase
P08566747A0756|76 78|G1
P08565330A1783|94 104|expression
P08565330A1783|28 36|features
P08564488A1359|6 23|fibrinogen levels
P08564488A1359|63 73|thrombosis
P08562688A0968|55 63|isolates
P08562688A0968|79 85|length
P08561893A0100|69 87|gene transcription
P08561893A0100|18 22|deal
P08561893A0100|92 121|E-box DNA consensus sequences
P08561893A0100|208 216|presence
P08561893A0100|165 175|eukaryotes
P08558187A0403|30 35|weeks
P08555753A0591|1 4|CBT
P08555753A0591|21 31|comparison
P08555753A0591|94 109|activation task
P08555498A0427|37 42|genes
P08555498A0427|56 63|chicken
P08555498A0427|46 51|mouse
P08555289A0207|84 92|purposes
P08555289A0207|10 26|storm indicators
P08555076A0333|119 120|n
P08555076A0333|139 140|n
P08555076A0333|130 137|Candida
P08555076A0333|106 117|Aspergillus
P08554540A1480|32 62|HIT protein similarity regions
P08553580A0102|29 33|ORF2
P08553580A0102|14 27|reading frame
P08552670A0665|85 86|d
P08552670A0665|1 5|Abp1
P08552670A0665|48 51|ARS
P08552387A0000|85 97|cell sarcoma
P08552387A0000|191 208|factor gene ATF-1
P08552387A0000|58 63|parts
P08552387A0000|11 27|characterization
P08552387A0000|164 167|EWS
P08552095A1115|1 6|Paf1p
P08552095A1115|78 85|subsets
P08552095A0686|51 56|Paf1p
P08552095A0686|77 84|nucleus
P08552092A1678|137 152|promoter region
P08552092A1678|35 44|sequences
P08552092A1678|87 100|transcription
P08552092A1678|172 186|protein factor
P08552092A1678|73 83|regulation
P08552082A0480|48 51|CAP
P08552082A0480|143 156|protein Abp1p
P08552082A0480|73 84|SH3 domains
P08552042A1497|254 265|generations
P08552042A1497|154 155|A
P08552042A1497|18 24|degree
P08552042A1497|9 13|case
P08552042A1497|123 132|reduction
P08552042A1497|149 153|poly
P08551572A0155|84 88|ICP4
P08551572A0155|1 22|Oligodeoxynucleotides
P08551572A0155|114 127|proliferation
P08551572A0155|161 165|CU91
P08551572A0155|167 188|reticuloendotheliosis
P08550476A0610|33 37|epiF
P08550476A0610|5 13|promoter
P08550476A0610|27 31|gene
P08550476A0610|56 78|activator protein EpiQ
P08550467A0863|100 102|OB
P08550467A0863|32 36|scrB
P08550467A0863|113 122|positions
P08550467A0863|56 64|deletion
P08550467A0863|90 98|sequence
P08550461A0284|12 14|S.
P08550425A1401|16 24|subunits
P08550425A1401|92 114|Halobacterium halobium
P08549706T0000|16 43|hepatitis B virus infection
P08549706T0000|62 72|drug users
P08547205A1060|64 75|zatebradine
P08547205A1060|43 59|agents alinidine
P08547205A1060|121 124|SVT
P08545502A0914|49 64|activation task
P08545502A0914|7 12|SPECT
P08543810A0000|101 107|clones
P08543810A0000|25 30|genes
P08543810A0000|199 203|ESTs
P08543275A0130|168 181|Arctic region
P08543275A0130|80 84|area
P08543275A0130|212 221|Japan Sea
P08543275A0130|132 141|sea lions
P08543275A0130|120 128|presence
P08542746T0000|1 14|Diabetes care
P08542746T0000|89 98|standards
P08542026A0792|1 4|DAF
P08542026A0792|163 175|gene cluster
P08542026A0792|13 28|kD glycoprotein
P08542026A0792|87 91|SCRs
P08542026A0792|179 189|chromosome
P08542026A0792|208 210|kb
P08541499A0306|32 49|Epifagus plastids
P08541499A0306|9 28|transcript patterns
P08538483A0207|96 121|body bone mineral content
P08538483A0207|76 81|TBBMC
P08538483A0207|161 174|GnRH agonists
P08538483A0207|192 205|endometriosis
P08538483A0207|13 33|consideration weight
P08538052A0000|96 103|THZif-1
P08538052A0000|336 343|protein
P08538052A0000|394 397|NHE
P08538052A0000|87 94|protein
P08538052A0000|178 197|leukemia HL60 cells
P08538052A0000|213 240|oligodeoxynucleotide probes
P08538052A0000|385 392|element
P08537388A0825|32 41|deletions
P08537388A0825|163 169|WNT-5A
P08537388A0825|149 159|base pairs
P08535537A0000|80 94|drug treatment
P08535537A0000|108 120|hypertension
P08534855A0000|98 110|desaturation
P08534855A0000|37 56|chloroplast omega-3
P08534848A0188a|40 42|cv
P08534217A0402|49 64|pollution level
P08534217A0402|5 13|subjects
P08534217A0402|27 34|regions
P08533473A0375|70 78|database
P08533473A0375|37 46|ADH1 gene
P08532967A0364|15 21|origin
P08532516A0000|9 14|paper
P08532516A0000|45 60|cdc10-C4 mutant
P08531373A0470|104 124|SS-A/SS-B antibodies
P08531373A0470|45 53|erythema
P08530432A0093|82 92|activation
P08530432A0093|9 15|series
P08530384A0559|68 75|binding
P08530384A0559|173 180|binding
P08530384A0559|199 203|Oct1
P08530384A0559|109 132|resolution footprinting
P08530384A0559|184 187|BOB
P08530384A0559|22 33|interaction
P08530384A0559|148 159|interaction
P08530345A0880|206 213|HD PPRE
P08530345A0880|140 151|DR2 element
P08530345A0880|66 79|TGACCT motifs
P08530345A0880|108 115|HD PPRE
P08530345A0880|194 202|response
P08530149A0689|1 11|Comparison
P08530149A0689|101 108|element
P08530149A0689|96 99|Inr
P08530149A0689|59 77|consensus sequence
P08530105A0308|137 140|map
P08530105A0308|173 182|deletions
P08530105A0308|144 152|analysis
P08530105A0308|94 102|analysis
P08530105A0308|194 203|endpoints
P08529654A0589|5 56|B. germanica cyclophilin amino acid sequence shares
P08529654A0589|89 108|cyclophilin isoform
P08529098A0549|206 212|domain
P08529098A0549|233 256|susceptibility mutation
P08529098A0549|10 31|sequence similarities
P08529098A0549|291 306|transport motif
P08529098A0549|262 266|exon
P08529098A0549|94 98|SMF1
P08529098A0549|183 196|transmembrane
P08528479A0000|1 19|Videonystagmoscopy
P08528479A0000|141 149|deficits
P08528479A0000|90 96|system
P08525186A0288|20 24|Lund
P08525186A0288|93 103|proportion
P08525186A0288|123 135|counterparts
P08524294A0652|5 9|skp1
P08524284A0309|19 28|isolation
P08524284A0309|76 85|PTF delta
P08524284A0309|109 116|studies
P08524284A0309|167 178|PTF complex
P08524284A0309|47 52|cDNAs
P08524267A1022|92 100|reporter
P08524267A1022|12 22|expression
P08524267A1022|149 154|genes
P08524241A0212|33 38|HSP82
P08524241A0212|20 29|induction
P08524229T0000|1 12|Degradation
P08524229T0000|20 38|soybean ribulose-1
P08524229T0000|123 131|cleavage
P08523566A1106|125 136|interaction
P08523566A1106|28 42|% Nonidet P-40
P08523031A0737|69 74|onset
P08523031A0737|86 94|seizures
P08523031A0737|25 29|data
P08522511A1578|152 181|beta-glucuronidase activities
P08522511A1578|33 37|pelA
P08522511A1578|189 202|transformants
P08522511A1578|42 46|pelB
P08522511A1578|135 140|f. sp
P08522175A0306|138 141|NAC
P08522175A0306|189 204|protein sorting
P08522175A0306|209 222|translocation
P08522175A0306|224 232|Wiedmann
P08521717A0126|137 145|biopsies
P08521717A0126|200 211|endothelium
P08521717A0126|172 180|activity
P08521717A0126|92 100|antibody
P08521717A0126|160 166|Factor
P08521717A0126|31 41|PAP method
P08520646A0000|1 24|Embryo coculture system
P08520646A0000|111 116|aging
P08519621A0150|101 107|stages
P08519621A0150|65 72|changes
P08519621A0150|111 118|illness
P08519621A0150|228 233|tract
P08519621A0150|150 161|association
P08517737A0889|7 15|findings
P08517737A0889|59 69|conditions
P08517737A0889|31 36|range
P08516308A0669|20 25|cells
P08516308A0669|45 58|microcolonies
P08515776A0971|100 106|region
P08515776A0971|58 65|regions
P08514766A0732|5 20|GTPase activity
P08514766A0732|24 31|CDC42Ce
P08513025A0000|119 128|bilirubin
P08513025A0000|35 44|thickness
P08513025A0000|52 63|correlation
P08513025A0000|72 77|serum
P08511994A0000|70 82|ichthiomycin
P08511994A0000|86 100|concentrations
P08510647A1347|84 106|utilization properties
P08510647A1347|117 133|barley globulins
P08510647A1347|73 80|storage
P08510320A0000|69 73|MRSA
P08510320A0000|175 181|agents
P08510320A0000|192 201|arbekacin
P08510320A0000|122 136|concentrations
P08509419A0785|1 11|Expression
P08509419A0785|129 143|TyrRS activity
P08509419A0785|57 65|tyrosine
P08509333A0843|117 126|ftsN gene
P08509333A0843|99 107|plasmids
P08509333A0843|78 87|minicells
P08509333A0843|44 61|membrane fraction
P08508861A0294|32 41|ischaemia
P08508861A0294|97 121|lactate extraction ratio
P08508861A0294|74 79|basis
P08508774A0242|17 24|binding
P08508774A0242|64 77|DNA fragments
P08508774A0242|110 113|Lrp
P08508774A0242|88 94|region
P08506384A0146|117 122|eIF-2
P08506384A0146|65 73|activity
P08506384A0146|40 51|eIF-2 alpha
P08506384A0146|14 19|cells
P08505605A0461|138 142|time
P08505605A0461|156 163|healing
P08505605A0461|76 97|wound characteristics
P08505605A0461|46 52|wounds
P08505340T0000|49 57|promoter
P08505340T0000|65 104|rat prostaglandin endoperoxide synthase
P08505340T0000|31 41|regulation
P08505075A0236|1 15|Maximum number
P08505075A0236|19 26|strains
P08505075A0236|123 131|S. typhi
P08504932A0123|170 175|cells
P08504932A0123|25 47|GATA factor expression
P08504932A0123|15 21|aspect
P08504707A0376|97 106|accidents
P08504707A0376|78 87|treatment
P08504707A0376|26 34|brain CT
P08501678A0498|71 98|immunoprophylactic strategy
P08501678A0498|43 54|development
P08500938A0408|119 123|part
P08500938A0408|131 141|metaphysis
P08500938A0408|28 32|BGCT
P08499916A0000|152 173|epidermolysis bullosa
P08499916A0000|5 16|COL7A1 gene
P08499916A0000|132 137|forms
P08499376A0000|82 93|corrections
P08497280T0000|84 94|cell cycle
P08497280T0000|36 44|elements
P08497280A0266|53 75|cell cycle progression
P08497280A0266|11 21|regulation
P08497280A0266|121 131|regulators
P08497269A0999|136 140|GCN2
P08497269A0999|54 58|GCN1
P08497269A0999|6 25|sequence similarity
P08497269A0999|199 221|translation elongation
P08497269A0999|165 176|tRNA levels
P08497248A0000|184 196|trophoblasts
P08497248A0000|5 9|gene
P08497248A0000|36 46|macrophage
P08497248A0000|76 81|CSF-1
P08496848A0692|20 40|contrast differences
P08496848A0692|62 75|FSE sequences
P08496599A0310|42 50|BGP gene
P08496599A0310|28 36|splicing
P08496185A0484|116 122|region
P08496185A0484|24 52|nucleotide sequence analysis
P08496185A0484|12 19|cloning
P08496157A0000|54 62|proteins
P08496157A0000|130 148|splicing mechanism
P08492290A0306|51 57|medium
P08492290A0306|67 78|strength mu
P08492290A0306|133 141|log beta
P08491683A0651|118 126|prostate
P08491683A0651|7 15|patients
P08491683A0651|61 69|patients
P08491383A0154|5 18|alpha-subunit
P08490002A0620|1 7|Xylose
P08490002A0620|73 82|cellulose
P08486705A0181|5 15|yeast gene
P08486705A0181|47 51|TIF5
P08486035T0000|1 8|Closure
P08486035T0000|67 82|minithoracotomy
P08484891A0000|32 44|conditioning
P08484891A0000|128 132|bulb
P08484891A0000|56 60|rats
P08484514A1536|82 93|stimulation
P08484514A1536|29 39|isoflurane
P08483412A0000|101 110|promoters
P08483412A0000|82 87|sigma
P08483412A0000|14 28|nifH promoters
P08481004A0321|9 14|clone
P08476854A0097|115 117|P7
P08476854A0097|9 21|footprinting
P08476854A0097|89 96|domains
P08476854A0097|151 161|base pairs
P08475104A0341|169 174|cells
P08475104A0341|87 102|G1-S activation
P08475104A0341|216 233|p33cdk2 complexes
P08475104A0341|199 207|cyclin A
P08475104A0341|134 137|htk
P08474456A1041|114 117|Ets
P08474456A1041|11 32|transfection analysis
P08474456A1041|44 53|mutations
P08474438A0000|203 227|pre-mRNA polyadenylation
P08474438A0000|22 40|ribonucleoproteins
P08474438A0000|167 191|RNA processing reactions
P08474438A0000|107 118|transcripts
P08473731A0149|1 2|B
P08473731A0149|109 113|sIgM
P08473731A0149|47 68|alpha/beta components
P08471796A1654|16 23|results
P08471796A1654|67 82|gene expression
P08471796A1654|45 55|regulation
P08471241T0000|76 81|women
P08471241T0000|47 54|removal
P08470021A0195|103 121|Instituto Nacional
P08470021A0195|157 168|Mexico City
P08470021A0195|83 95|blood donors
P08470021A0195|31 45|IgG antibodies
P08468475A1280|64 74|YT-1 cells
P08468475A1280|20 42|internalization assays
P08468475A1280|144 162|IL-2R beta subunit
P08468475A1280|317 338|F42A binding reaction
P08466864A0878|170 182|binding site
P08466864A0878|234 238|PU-1
P08466864A0878|43 53|importance
P08466864A0878|164 168|CREB
P08466864A0878|82 92|bp segment
P08466864A0878|124 127|AMP
P08466864A0878|271 288|promoter activity
P08464056A0510|221 234|hybridization
P08464056A0510|93 115|Southern blot analysis
P08464056A0510|9 17|evidence
P08464056A0510|133 154|restriction fragments
P08463485T0000|25 43|endotoxin infusion
P08463284A1531|17 20|PKC
P08463284A1531|111 121|cell cycle
P08463284A1531|27 41|p34cdc2 kinase
P08461946A0386|34 45|improvement
P08461946A0386|21 27|change
P08461946A0386|122 123|%
P08461946A0386|61 69|findings
P08459465A0257|255 279|energy expenditure times
P08459465A0257|307 320|stress factor
P08459465A0257|217 235|energy expenditure
P08459465A0257|72 80|patients
P08459465A0257|135 153|energy expenditure
P08458906A0827|32 37|urine
P08458906A0827|75 82|persons
P08458660A0855|44 52|variable
P08457205A0240|114 123|sequences
P08457205A0240|10 29|amino acid sequence
P08457205A0240|89 108|% sequence identity
P08456378A0134|118 123|model
P08456378A0134|6 11|study
P08456378A0134|61 77|lymphangiography
P08455623A0630|136 149|proteins NOP1
P08455623A0630|154 158|GAR1
P08455623A0630|9 16|results
P08455623A0630|88 97|depletion
P08455611A0000|118 125|element
P08455611A0000|127 132|HS-40
P08455611A0000|27 38|interaction
P08455611A0000|63 67|zeta
P08454858A0285|186 205|signal transduction
P08454858A0285|103 112|associate
P08454858A0285|130 139|effectors
P08454858A0285|14 21|Ig-beta
P08454591A0692|58 64|region
P08454591A0692|72 81|TSG6 gene
P08454591A0692|30 38|fragment
P08453950A0498|52 57|mm Hg
P08453950A0498|129 134|level
P08453950A0498|62 71|brain pHi
P08453950A0498|30 34|MABP
P08451331T0000|32 37|bulbs
P08451331T0000|127 131|mice
P08450015A0175|84 90|plasma
P08450015A0175|33 42|isolation
P08450015A0175|130 139|formation
P08450015A0175|46 56|oxiracetam
P08449978A0000|50 55|yeast
P08449978A0000|222 228|groups
P08449978A0000|232 239|cyclins
P08449978A0000|182 192|cell cycle
P08449978A0000|13 34|cell cycle regulation
P08449978A0000|269 274|times
P08449133A0578|36 51|tumor extension
P08449133A0578|94 103|T4 tumors
P08446579A1210|55 61|levels
P08446579A1210|73 75|hr
P08445792A0469|50 53|IIA
P08445792A0469|99 106|species
P08445792A0469|58 61|IIB
P08445792A0469|124 130|stages
P08445655A1009|21 36|insertion locus
P08445655A1009|61 84|complementation studies
P08444345A0403|39 41|aa
P08444345A0403|43 51|sequence
P08444345A0403|57 58|%
P08444345A0403|124 137|family member
P08444345A0403|72 80|rat EFIA
P08444345A0403|150 159|protein B
P08444184A0245|12 14|A.
P08443340A0522|35 54|expression patterns
P08443340A0522|4 9|order
P08443340A0522|197 207|expression
P08443340A0522|242 256|tobacco plants
P08443340A0522|165 168|GUS
P08443122A0657|116 119|CyA
P08443122A0657|80 86|signal
P08443122A0657|28 61|fibroblasts PILOT gene expression
P08442384A0430|153 171|amino acid peptide
P08442384A0430|81 94|reading frame
P08442384A0430|36 43|protein
P08441423A0145|81 89|products
P08441423A0145|40 44|GCD6
P08441394A1297|175 189|Ras activation
P08441394A1297|24 33|component
P08441394A1297|95 100|c-fos
P08441394A1297|133 138|c-myc
P08441394A1297|105 109|junB
P08440720A1404|139 146|protein
P08440720A1404|39 49|PfCPK cDNA
P08440238T0000|17 27|C-terminus
P08440238T0000|213 223|metastasis
P08440238T0000|162 169|T24-ras
P08440238T0000|46 57|E1a protein
P08440238T0000|74 85|association
P08439597A0000|87 91|FEIA
P08439597A0000|189 200|blood spots
P08439597A0000|125 142|fluoroimmunoassay
P08439597A0000|151 164|determination
P08438584T0000|21 42|coat protein promoter
P08438584T0000|62 74|mosaic virus
P08437737A0100|42 45|%BF
P08437737A0100|75 79|duty
P08435885A0787|42 73|pyridinium cross-link excretion
P08435755A1078|1 4|PNT
P08435755A1078|99 117|seizure parameters
P08435755A1078|52 65|kindling rate
P08435755A1078|214 219|group
P08435755A1078|89 97|seizures
P08435755A1078|74 81|stage-3
P08432696A1117|171 176|media
P08432696A1117|17 26|apeA gene
P08432696A1117|1 9|Deletion
P08432696A1117|82 90|protease
P08432696A1117|134 140|effect
P08432137A0000|200 206|P/SLYS
P08432137A0000|96 116|PADA/serum ADA ratio
P08432137A0000|282 289|ability
P08432137A0000|166 171|cases
P08432137A0000|327 336|effusions
P08432137A0000|118 124|P/SADA
P08432137A0000|81 89|patients
P08432137A0000|178 198|PLYS/serum LYS ratio
P08432137A0000|57 61|PADA
P08430095A0913|68 86|splicing apparatus
P08430095A0913|22 27|Smd1p
P08430095A0913|93 99|factor
P08430095A0913|124 133|stability
P08430087A0467|202 211|Sf9 cells
P08430087A0467|37 41|beta
P08430087A0467|144 161|membrane extracts
P08430087A0467|14 21|ability
P08429020A0495|114 126|glycoprotein
P08429020A0495|5 9|gene
P08429020A0495|159 163|exon
P08429020A0495|58 67|kilobases
P08429019A0735|175 200|GATA-1 consensus sequence
P08429019A0735|81 87|repeat
P08429019A0735|42 57|silencer region
P08429019A0735|108 113|motif
P08429019A0735|13 22|footprint
P08428953A1718|338 348|activation
P08428953A1718|277 288|fibroblasts
P08428953A1718|196 204|contrast
P08428953A1718|436 456|L-plastin expression
P08428953A1718|45 55|expression
P08428953A1718|364 372|colonies
P08428953A1718|63 90|reporter beta-galactosidase
P08428953A1718|211 219|promoter
P08428952A0399|155 168|tumorigenesis
P08428952A0399|93 99|origin
P08428952A0399|10 19|L-plastin
P08428907A0653|32 46|OBP transcript
P08428907A0653|14 26|stage larvae
P08428722A1123|237 242|ileus
P08428722A1123|21 29|analysis
P08428722A1123|198 209|peritonitis
P08428722A1123|211 214|age
P08425221A0000|154 159|cells
P08425221A0000|115 121|stages
P08425221A0000|57 60|BPK
P08423831A0523|17 22|model
P08423831A0523|5 8|use
P08423831A0523|148 158|parameters
P08421910A0599|84 87|p56
P08421910A0599|65 68|p37
P08421910A0599|8 18|components
P08421910A0599|150 172|uv cross-linking assay
P08421910A0599|75 78|p50
P08421823A1041|69 77|patients
P08421823A1041|19 39|protein S deficiency
P08421823A1041|91 98|absence
P08421295A0365|66 76|DNA duplex
P08421295A0365|43 52|complexes
P08421295A0365|91 95|CTGT
P08420571A1880|28 31|PC4
P08419376A0357|32 36|gene
P08419376A0357|5 24|nucleotide sequence
P08419376A0357|126 133|domains
P08419333A0126|21 31|expression
P08418183A0000|136 143|couples
P08418183A0000|236 243|husband
P08418183A0000|76 111|T cell leukemia/lymphoma virus type
P08418183A0000|13 20|factors
P08418183A0000|324 325|W
P08418183A0000|190 198|November
P08418183A0000|321 322|H
P08418183A0000|299 300|W
P08418183A0000|208 213|April
P08417331A0745|69 76|repeats
P08417331A0745|169 178|repressor
P08417331A0745|21 30|HIR1 gene
P08417331A0745|82 87|motif
P08417331A0745|147 152|yeast
P08417117A0592|57 66|abundance
P08417117A0592|30 32|kb
P08416952A0956|152 157|Leu99
P08416952A0956|86 104|protein substrates
P08416952A0956|203 212|acylation
P08416952A0956|108 113|Nmt1p
P08416952A0956|164 176|substitution
P08415643A0555|55 59|gene
P08415643A0555|95 100|onset
P08415643A0555|72 79|protein
P08414502A0244|85 96|p53 protein
P08414502A0244|64 73|regulator
P08414502A0244|146 155|promoters
P08413291A1473|69 77|reporter
P08413291A1473|107 113|muscle
P08413260A1437|85 89|cell
P08413260A1437|7 14|results
P08413260A1437|29 39|Rb protein
P08413260A1437|75 76|s
P08413223A0847|117 124|element
P08413223A0847|145 158|phorbol ester
P08413223A0847|192 207|gene expression
P08413209A0159|33 40|protein
P08413209A0159|108 116|proteins
P08413186A1199|38 42|copy
P08413186A1199|58 84|N. plumbaginifolia species
P08412665A0000|5 16|scr regulon
P08412665A0000|57 68|scr regulon
P08412665A0000|94 101|KAY2026
P08412620A0688|49 74|transcription start point
P08412620A0688|157 161|VirF
P08412620A0688|126 136|activation
P08412620A0688|28 30|bp
P08411276A0302|103 125|Trauma Score variables
P08411276A0302|311 312|A
P08411276A0302|314 315|B
P08411276A0302|357 365|injuries
P08411276A0302|21 32|PIC patient
P08411276A0302|190 194|rate
P08411276A0302|260 265|ASCOT
P08411276A0302|127 151|Glascow Coma Scale score
P08411276A0302|328 344|ASCOT components
P08410097A0356|140 144|beta
P08410097A0356|8 22|mean intensity
P08410097A0356|125 138|oxygen uptake
P08410097A0356|26 31|CLTPA
P08409593A0357|70 79|H. pylori
P08409593A0357|4 8|CFDN
P08409593A0357|97 101|AMPC
P08409593A0357|10 14|AMPC
P08408963A0048|11 13|L.
P08408825A0000|10 29|lupus erythematosus
P08408825A0000|60 74|autoantibodies
P08407784A0850|37 51|srjA mutations
P08407784A0850|28 35|strains
P08406419A0155|140 148|Westwood
P08406419A0155|110 138|Ortho Diagnostic Systems Inc
P08406419A0155|40 50|antibodies
P08406004A0691|101 115|JB cis-element
P08406004A0691|213 220|portion
P08406004A0691|125 135|activation
P08406004A0691|224 228|PU.1
P08403804A0754|184 194|transplant
P08403804A0754|173 177|time
P08403804A0754|97 121|cyclosporin trough level
P08403804A0754|29 48|regression analysis
P08403804A0754|210 221|cyclosporin
P08401614A0187|55 58|PAL
P08401614A0187|76 81|genes
P08401614A0187|92 96|PAL3
P08401614A0187|166 178|bean tissues
P08400928A0318|153 164|combination
P08400928A0318|1 14|INTERVENTIONS
P08400928A0318|38 47|treatment
P08400928A0318|177 190|bromocriptine
P08400928A0318|192 195|arm
P08399970T0000|49 59|inoculants
P08396913A1379|69 73|cell
P08396913A1379|106 114|DGK gene
P08396913A1379|15 22|element
P08396749A1112a|100 101|P
P08396749A1112a|116 121|apo B
P08396749A1112a|78 83|weeks
P08396749A1112a|164 165|P
P08396667T0000|19 28|oncogenes
P08396667T0000|93 111|lymphocyte subsets
P08396261A0388|100 104|cAMP
P08396261A0388|309 315|growth
P08396261A0388|413 425|cAMP binding
P08396261A0388|172 178|strain
P08396261A0388|196 212|cyclase activity
P08396261A0388|497 502|cells
P08396261A0388|49 66|growth inhibition
P08396261A0388|18 26|evidence
P08396261A0388|528 543|C alpha protein
P08396261A0388|83 95|PKA subunits
P08396261A0388|243 256|transformants
P08395681A0388|204 219|binding ability
P08395681A0388|229 237|products
P08395681A0388|85 93|HPV16 E7
P08395681A0388|325 346|adenovirus E1A mutant
P08395681A0388|188 198|activities
P08395681A0388|267 269|RB
P08395681A0388|243 265|retinoblastoma protein
P08395014A1364|9 21|interactions
P08395014A1364|106 120|pathway branch
P08395014A1364|45 63|pathway components
P08395004A0558|138 150|protein HMG1
P08395004A0558|26 55|protein sequence similarities
P08394862A0565|34 45|CMV disease
P08394862A0565|7 12|group
P08394862A0565|75 88|CMV hepatitis
P08394255A0000|101 126|polymerase chain reaction
P08394255A0000|3 8|sheep
P08394255A0000|82 87|probe
P08394255A0000|128 131|PCR
P08394255A0000|195 216|hormone receptor cDNA
P08393143A1281|64 67|TRE
P08392221A0449|1 7|Losses
P08392221A0449|279 288|genistein
P08392221A0449|111 116|steps
P08392221A0449|194 206|matairesinol
P08392221A0449|157 166|standards
P08392221A0449|208 218|enterodiol
P08392221A0449|268 273|equol
P08391534A0828|10 12|P.
P08390747A0586|33 41|genetics
P08390747A0586|9 15|report
P08390747A0586|148 151|syn
P08390120A0785|18 24|trials
P08390120A0785|96 103|quality
P08390120A0785|107 111|life
P08389365A1344|96 104|sequence
P08389365A1344|52 65|repair system
P08389365A1344|90 94|GATC
P08388600A0000|98 103|girls
P08388600A0000|28 33|doses
P08388510A0891|1 9|Analysis
P08388510A0891|132 139|surface
P08388510A0891|91 101|expression
P08387994A0980|5 23|orf61 gene product
P08387994A0980|122 131|attB site
P08387662A0302|16 29|patients self
P08387662A0302|7 14|surgery
P08387662A0302|163 167|pain
P08387662A0302|78 89|medications
P08387662A0302|106 113|placebo
P08387155A1248|51 56|c-Jun
P08387155A1248|99 104|c-Fos
P08387155A1248|79 83|topo
P08386592A0089|221 223|kd
P08386592A0089|184 190|region
P08386592A0089|233 245|Elk-1 kinase
P08386592A0089|144 159|phosphorylation
P08386592A0089|56 62|change
P08386318A1102|170 177|kinases
P08386318A1102|138 140|Ca
P08386318A1102|179 182|Ras
P08386318A1102|29 36|JRE-IL6
P08386318A1102|61 68|pathway
P08386318A1102|194 200|NF-IL6
P08386280T0000|1 9|Mutation
P08386280T0000|88 101|gag enhancers
P08385581A0126|153 160|mitosis
P08385581A0126|141 149|function
P08385581A0126|56 60|data
P08385581A0126|14 19|genes
P08385131A0000|5 10|alpha
P08385131A0000|126 134|proteins
P08385131A0000|88 97|pertussis
P08383850A0206|16 21|study
P08383850A0206|157 167|withdrawal
P08383850A0206|77 94|nonequilibrium mu
P08383850A0206|193 197|rats
P08383526A0591|17 22|genes
P08383526A0591|58 74|receptor protein
P08383323A0000|53 60|signals
P08383323A0000|9 19|activation
P08383217A0357|84 98|Bel-1 activity
P08383217A0357|33 44|amino acids
P08383129A0776|19 43|mass polypeptide complex
P08383129A0776|130 146|protein antigens
P08383129A0776|73 93|antigen presentation
P08382769A0924|100 104|role
P08382769A0924|38 49|nucleotides
P08382769A0924|128 147|recognition element
P08382303T0000|38 57|papillomavirus type
P08382303T0000|125 153|p34cdc2 phosphorylation site
P08382300A0341|139 143|VP23
P08382300A0341|36 43|ability
P08382300A0341|59 70|replication
P08382300A0341|149 156|mutants
P08380896A0938|84 95|replication
P08380896A0938|48 65|polymerase domain
P08378082A1031|71 77|p21ras
P08378082A1031|37 47|cross-talk
P08378082A1031|144 150|states
P08376796A0172|136 139|IgG
P08376796A0172|279 282|SLE
P08376796A0172|310 322|efficiencies
P08376796A0172|43 53|antibodies
P08376796A0172|166 169|mAb
P08376796A0172|16 26|VH regions
P08376796A0172|266 273|patient
P08376796A0172|177 184|B cells
P08376796A0172|362 364|Ag
P08375651T0000|93 101|organism
P08375651T0000|31 41|chain gene
P08371936T0000|16 36|Independence Measure
P08371936T0000|61 70|clinician
P08371650T0000|16 33|claudication pain
P08371650T0000|49 61|implications
P08370119A1521|152 160|elements
P08370119A1521|1 9|Deletion
P08370119A1521|191 206|luciferase cDNA
P08370119A1521|27 42|promoter region
P08369887A0781|69 72|EAD
P08369887A0781|1 12|Differences
P08369887A0781|56 65|subgroups
P08367388T0035|52 60|syndrome
P08365944A1537|1 11|CONCLUSION
P08365944A1537|32 40|analysis
P08365944A1537|172 184|radiotherapy
P08365944A1537|78 84|course
P08365944A1537|211 216|boost
P08361761A0174|372 375|LTR
P08361761A0174|237 242|v-Rel
P08361761A0174|66 82|reporter plasmid
P08361761A0174|230 235|sites
P08361761A0174|193 198|v-Rel
P08361761A0174|19 24|v-Rel
P08361761A0174|458 475|Sp1 binding sites
P08361761A0174|146 172|chicken embryo fibroblasts
P08361754A0733|48 54|domain
P08361754A0733|24 34|structures
P08360112T0036|1 4|XII
P08356944A0589|138 162|cyanmethemoglobin method
P08356944A0589|178 188|generation
P08356944A0589|198 204|wastes
P08356792A1275|55 59|Rex1
P08356792A1275|82 88|levels
P08356792A1275|41 51|N-terminus
P08356792A1275|148 152|mRNA
P08355697A0000|1 30|Protein tyrosine phosphatases
P08355697A0000|53 77|protein tyrosine kinases
P08355697A0000|106 116|regulation
P08355697A0000|120 135|cell activation
P08355680A0824|38 55|mRNA accumulation
P08355680A0824|189 222|glucose 6-phosphate dehydrogenase
P08355680A0824|160 164|gene
P08355680A0824|107 123|HIV-1 constructs
P08355063A0456|5 15|rCBF ratio
P08352268A0000|118 120|SC
P08352268A0000|19 33|erythropoietin
P08352268A0000|122 127|route
P08350398A1616|171 176|class
P08350398A1616|51 56|gp19K
P08350398A1616|21 23|ER
P08350398A1616|179 184|heavy
P08350398A1616|41 47|domain
P08349632A0679|68 77|PSG12 psi
P08349632A0679|84 85|%
P08349632A0679|155 165|stop codon
P08349632A0679|36 41|exons
P08349632A0679|58 63|PSG12
P08349104A0450|102 109|factors
P08349104A0450|234 252|operator sequences
P08349104A0450|277 284|defects
P08349104A0450|313 324|sporulation
P08349104A0450|162 167|yeast
P08349104A0450|119 133|tsf6 mutations
P08349104A0450|223 230|variety
P08349104A0450|176 192|hybrid promoters
P08348919T0000|1 16|Botulinum toxin
P08348919T0000|28 37|treatment
P08345191A1140|139 143|MCL1
P08345191A1140|5 21|peptide sequence
P08345191A1140|133 137|gene
P08343961A0000|1 22|Anterior body pattern
P08343961A0000|64 76|distribution
P08343961A0000|91 98|protein
P08343041A0000|51 62|infertility
P08343041A0000|20 30|antibodies
P08340400T0000|99 106|protein
P08340400T0000|37 42|RPE65
P08340400T0000|60 67|pigment
P08337828A0895|76 82|AcMNPV
P08337828A0895|47 74|Autographa californica MNPV
P08336698T0000|1 5|TFEC
P08336698T0000|98 122|transcription activation
P08336698T0000|47 59|heterodimers
P08336012A0632|54 64|blood cell
P08336012A0632|124 126|FN
P08336012A0632|31 35|lung
P08334989A0070|220 244|luciferase reporter gene
P08334989A0070|156 163|library
P08334989A0070|66 70|gene
P08334989A0070|267 285|NIH3T3 fibroblasts
P08334989A0070|120 128|sequence
P08334158A0660|97 110|Fe/S proteins
P08334158A0660|73 84|arrangement
P08332495A0408|86 92|A549-1
P08332495A0408|65 84|lung adenocarcinoma
P08332495A0408|162 177|pT7-EMC-CAT DNA
P08332495A0408|94 99|cells
P08332495A0408|132 139|complex
P08332033T0000|34 45|brain edema
P08332033T0000|16 30|quantification
P08332033T0000|97 101|mice
P08331067T0000|136 143|homolog
P08331067T0000|112 122|comparison
P08331067T0000|10 29|nucleotide sequence
P08331067T0000|74 98|endo-N-acylneuraminidase
P08327488A0839|48 51|p70
P08327488A0839|203 206|RNA
P08327488A0839|131 144|helper genome
P08325720A0840|220 242|muscle buffer capacity
P08325720A0840|152 173|lactate dehydrogenase
P08325720A0840|35 48|blood lactate
P08325720A0840|101 117|citrate synthase
P08325720A0840|8 15|deficit
P08325720A0840|176 182|number
P08325504A0226|18 37|RD21 mRNA synthesis
P08325504A0226|9 13|RD19
P08324280A0098|7 14|lesions
P08323294T0000|110 119|structure
P08323294T0000|134 144|expression
P08322117A1019|136 151|Sussett formula
P08322117A1019|66 75|pressures
P08322117A1019|97 102|cmH2O
P08322117A1019|180 187|centile
P08321227A0854|76 85|COS cells
P08321199T0000|49 52|cis
P08321199T0000|41 47|states
P08321199T0000|106 115|silencing
P08321199T0000|12 21|switching
P08319907A0754|71 93|telomere tract lengths
P08319907A0754|178 182|size
P08319907A0754|215 220|tract
P08319907A0754|47 52|cells
P08317094A0778|69 77|sequence
P08317094A0778|81 86|TAAAG
P08317094A0778|25 36|transcripts
P08317094A0778|56 57|A
P08317094A0778|120 128|promoter
P08316240A1068|84 99|hexamer element
P08316240A1068|49 54|CHL15
P08316240A1068|191 201|regulation
P08316240A1068|112 133|MluI restriction site
P08316240A1068|240 245|yeast
P08316100A0586|51 56|range
P08316100A0586|5 12|neglect
P08316100A0586|27 33|theory
P08316100A0586|60 67|factors
P08314163T0000|33 48|agranulocytosis
P08314163T0000|94 119|colony stimulating factor
P08309975A0662|1 10|Depletion
P08309975A0662|174 185|consumption
P08309975A0662|189 197|lab chow
P08309975A0662|162 170|increase
P08309975A0662|75 83|behavior
P08309953A0776|32 61|dopamine receptor stimulation
P08309953A0776|114 121|pattern
P08309953A0776|163 185|reaction time response
P08309953A0776|75 92|dopamine agonists
P08309726A0000|102 109|authors
P08309726A0000|341 345|ARDS
P08309726A0000|276 284|patients
P08309726A0000|377 385|patients
P08309726A0000|17 24|insight
P08309726A0000|221 236|cytokine levels
P08309726A0000|294 298|ARDS
P08309726A0000|246 254|severity
P08309726A0000|91 95|ARDS
P08307564A0233|66 72|contig
P08307564A0233|76 83|density
P08307564A0233|30 35|sites
P08306959A0278|78 86|affinity
P08306959A0278|122 147|IFN gamma activation site
P08306959A0278|62 69|element
P08306356A0000|68 72|dose
P08306356A0000|20 33|malformations
P08306356A0000|76 82|X-rays
P08306356A0000|88 91|cGy
P08304342A0605|274 279|HLA-A
P08304342A0605|154 160|probes
P08304342A0605|143 150|battery
P08304342A0605|108 119|chromosomes
P08304342A0605|227 237|HLA-F loci
P08303233A0313|22 29|priming
P08303233A0313|60 68|identity
P08301841A0000|38 43|serum
P08301841A0000|97 112|angina pectoris
P08301841A0000|79 82|AMI
P08300625A1352|158 163|lysis
P08300625A1352|130 143|slyD function
P08300611A0341|34 38|traI
P08300611A0341|117 123|assays
P08300611A0341|59 70|application
P08300611A0341|90 103|TraI proteins
P08300605A0432|119 129|silk gland
P08300605A0432|17 25|analysis
P08300605A0432|212 220|elements
P08300605A0432|265 280|initiation site
P08300605A0432|149 162|instar larvae
P08300527T0000|1 11|Inhibition
P08300527T0000|55 97|malonyl-coenzyme A decarboxylase gene eryM
P08300527T0000|15 37|erythromycin synthesis
P08299896A0880|71 79|patients
P08299896A0880|27 38|IBDQ scores
P08299725A0724|52 57|brain
P08299725A0724|42 48|intron
P08299725A0724|149 157|residues
P08299725A0724|14 20|region
P08299725A0724|90 106|tumor cell lines
P08299181A1148|96 100|eyes
P08299181A1148|56 60|eyes
P08299181A1148|46 49|eye
P08298129A0274|34 39|basis
P08298129A0274|79 83|gene
P08298129A0274|60 70|expression
P08296434A1141|59 66|adjunct
P08296434A1141|88 97|treatment
P08294865A0236|52 60|mutation
P08294865A0236|29 34|cells
P08294865A0236|91 100|formation
P08294459A0446|96 107|amino acids
P08294459A0446|177 183|domain
P08294459A0446|72 77|SAP-1
P08294386A0000|239 250|blood level
P08294386A0000|115 123|patients
P08294386A0000|83 90|authors
P08294386A0000|177 185|hospital
P08294386A0000|104 111|outcome
P08293992A0432|68 74|K/NPAG
P08293992A0432|58 66|sequence
P08291886T0024|17 26|expansion
P08291620A0372|23 41|locomotor behavior
P08291620A0372|60 76|torso morphology
P08290421A0165|19 23|type
P08290421A0165|112 120|syndrome
P08290421A0165|41 49|acidosis
P08289834A0341|102 109|protein
P08289834A0341|83 87|bone
P08289834A0341|25 35|test cells
P08289793A1226|53 61|COUP-TFs
P08289793A1226|43 49|effect
P08289793A1226|94 100|effect
P08289783A1476|51 58|RAREoct
P08289783A1476|116 124|promoter
P08289783A1476|219 227|EC cells
P08289783A1476|108 113|Oct-3
P08289593A1404|34 38|rats
P08289593A1404|278 285|cocaine
P08289593A1404|119 124|mg/kg
P08289593A1404|185 186|n
P08289593A1404|178 183|mg/kg
P08289593A1404|92 104|cocaine dose
P08289593A1404|56 62|MK-801
P08289342A0931|102 107|assay
P08289342A0931|70 85|DNA replication
P08289342A0931|47 50|trs
P08289339A0527|97 102|sides
P08289339A0527|12 23|exonuclease
P08289339A0527|151 160|sequences
P08288622A0725|16 24|analysis
P08288622A0725|201 205|exon
P08288622A0725|52 65|heterogeneity
P08288622A0725|166 188|splicing acceptor site
P08288596A0663|71 78|rGH-TRE
P08288596A0663|202 210|promoter
P08288596A0663|133 142|templates
P08288596A0663|15 17|T3
P08288596A0663|190 193|rGH
P08288596A0663|158 162|TREs
P08288596A0663|26 27|M
P08288596A0663|301 309|sequence
P08288240A1343|36 40|idea
P08288240A1343|147 166|stathmin/Lap18 gene
P08288240A1343|104 116|modification
P08286035A0587|16 36|sequence information
P08286035A0587|114 119|PMNLs
P08286035A0587|42 47|c11/1
P08286035A0587|131 144|transcription
P08286035A0587|193 196|PCR
P08286035A0587|151 162|combination
P08284337A0825|157 165|distress
P08284337A0825|22 31|screening
P08284337A0825|77 82|means
P08284337A0825|147 153|levels
P08283531A0700|48 72|Dornier HM3 lithotriptor
P08283531A0700|93 106|visualization
P08283531A0700|150 157|calculi
P08282749A1474|35 36|%
P08282749A1474|71 77|demand
P08282749A1474|95 105|myocardium
P08282749A1474|133 141|duration
P08282501A0358|170 176|agents
P08282501A0358|199 206|grade-3
P08282501A0358|215 221|events
P08282501A0358|41 63|angiography procedures
P08281634A1801|21 36|iron metabolism
P08281634A1801|94 98|risk
P08281153A0543|40 52|conservation
P08281153A0543|30 36|degree
P08280476A0602|82 93|Z2Z6 strain
P08280476A0602|29 39|HIV-1 HXB2
P08280476A0602|44 69|HIV-1 Z2Z6 core enhancers
P08278929A0866|206 214|controls
P08278929A0866|216 217|P
P08278929A0866|93 99|ml CRS
P08278929A0866|128 135|embryos
P08278929A0866|166 167|%
P08278929A0866|60 62|ml
P08277632A0997|100 101|%
P08277632A0997|80 93|R2b operation
P08277632A0997|41 49|patients
P08276871A1001|39 47|identity
P08276871A1001|93 103|% identity
P08276871A1001|60 61|%
P08276854A1894|217 235|gene transcription
P08276854A1894|5 12|results
P08276854A1894|27 36|structure
P08276854A1894|44 65|decorin gene promoter
P08276762T0000|87 91|gene
P08276762T0000|95 113|proline activation
P08276762T0000|61 84|gramicidin S synthetase
P08276336A0371|70 78|patients
P08276336A0371|20 28|analysis
P08275618A0457|1 12|Drug effect
P08275618A0457|308 316|subjects
P08275618A0457|203 210|measure
P08275618A0457|79 88|cirrhosis
P08275618A0457|134 145|effect area
P08275618A0457|156 161|curve
P08275618A0457|214 225|sensitivity
P08273122A0708|34 47|QA/QI process
P08273122A0708|1 8|RESULTS
P08273122A0708|206 228|component transfusions
P08273122A0708|138 165|blood administration policy
P08273122A0708|196 201|blood
P08270580A0155|77 90|cotrimoxazole
P08270580A0155|43 54|combination
P08269439X0000|35 40|niche
P08269439X0000|94 99|agent
P08269439X0000|13 22|analgesia
P08269439X0000|45 54|Talwin Nx
P08268912A0657|118 120|kD
P08268912A0657|100 108|mobility
P08268912A0657|124 147|SDS polyacrylamide gels
P08268718A0676|54 63|complexes
P08268718A0676|44 47|p50
P08267658A0391|173 175|hr
P08267658A0391|37 39|UW
P08267658A0391|57 58|K
P08267658A0391|62 74|lactobionate
P08267658A0391|150 165|rat hepatocytes
P08265602T0000|51 58|packing
P08265602T0000|66 87|transmembrane segment
P08265602T0000|91 113|phage M13 coat protein
P08264650A0925|118 124|growth
P08264650A0925|71 75|MDS1
P08264650A0925|13 20|strains
P08264628A0418|116 122|TFIIIB
P08264628A0418|97 103|TIF-IB
P08264628A0418|105 110|TFIID
P08264591A1190|71 76|TFIIB
P08264591A1190|7 11|data
P08264591A1190|242 250|proteins
P08264591A1190|91 103|determinants
P08264582A0750|170 189|amino acid residues
P08264582A0750|38 44|domain
P08264582A0750|213 219|region
P08264582A0750|125 140|point mutations
P08264582A0750|91 100|deletions
P08263933T0000|11 18|cloning
P08262054A0565|138 142|copy
P08262054A0565|81 86|LMP2A
P08262054A0565|219 240|B cell transformation
P08262054A0565|177 182|motif
P08262054A0565|211 215|role
P08261398A0838|171 187|P388/ADR/7 cells
P08261398A0838|70 75|cDNAs
P08261398A0838|156 166|P388/ADR/3
P08261398A0838|134 145|transcripts
P08260635A0926|68 74|intron
P08260635A0926|84 106|transit peptide region
P08260635A0926|144 148|GapB
P08260635A0926|122 133|GAPDH genes
P08258025A1131|1 12|CONCLUSIONS
P08258025A1131|21 29|patients
P08258025A1131|158 165|factors
P08258025A1131|127 134|disease
P08258025A1131|45 50|range
P08257666A0662|87 90|IHA
P08257666A0662|38 49|OPT complex
P08257666A0662|146 166|learning performance
P08257666A0662|121 127|effect
P08255341A0554|102 112|diloxanide
P08255341A0554|124 134|amoebicide
P08255341A0554|62 75|metronidazole
P08254738A0428|157 162|TS677
P08254738A0428|9 15|series
P08254738A0428|79 88|Sf9 cells
P08254738A0428|226 235|T antigen
P08254738A0428|107 113|origin
P08253777A0301|154 160|manner
P08253777A0301|83 89|region
P08253777A0301|130 134|gene
P08253777A0301|26 29|CRE
P08253777A0301|31 47|consensus signal
P08253387A0801|103 108|TCF-2
P08253387A0801|207 215|enhancer
P08253387A0801|159 168|sequences
P08253387A0801|195 199|site
P08252976A0467|1 6|Rinit
P08252976A0467|123 129|system
P08252976A0467|30 41|resistances
P08251622A0000|5 13|promoter
P08251622A0000|41 84|Brassica napus 2S storage protein napA gene
P08249390A0111|17 34|diabetes mellitus
P08249390A0111|5 13|duration
P08249390A0111|94 102|patients
P08249390A0111|44 52|patients
P08248688A0726|21 32|stimulation
P08248688A0726|52 59|nitrate
P08248688A0726|105 118|NO production
P08248246A0838|35 38|Sp1
P08248246A0838|113 117|role
P08248246A0838|146 164|R1 gene expression
P08247005A0584|21 42|drs2 mutation process
P08247005A0584|126 134|subunits
P08247005A0584|75 83|18S rRNA
P08246984A0923|54 74|PI 3-kinase isoforms
P08246984A0923|144 152|subunits
P08246984A0923|122 133|PI 3-kinase
P08246984A0923|31 40|existence
P08245933A0617|9 20|engorgement
P08245456A0501|86 103|O2-dibutyryl cAMP
P08245456A0501|36 40|IL-5
P08245456A0501|7 12|cells
P08245456A0501|198 202|mRNA
P08245456A0501|135 138|PMA
P08245456A0501|105 112|Bt2cAMP
P08245013A0000|174 187|understanding
P08245013A0000|97 106|receptors
P08245013A0000|27 32|basis
P08245013A0000|215 224|receptors
P08243476A1177|103 113|reductases
P08243476A1177|25 44|tryptophan residues
P08241656A0189|100 111|Wildervanck
P08241656A0189|114 122|syndrome
P08241656A0189|8 17|knowledge
P08240170A0000|68 77|transport
P08240170A0000|81 84|sea
P08240170A0000|15 28|salmonellosis
P08239164A0551|50 56|minute
P08239164A0551|70 73|VO2
P08239164A0551|95 103|patients
P08239164A0551|121 133|lung disease
P08239164A0551|211 223|lung disease
P08237578A0253|34 45|mean values
P08237578A0253|84 99|LDL-cholesterol
P08237578A0253|219 236|preinsertion mean
P08237578A0253|56 69|triglycerides
P08237578A0253|132 135|end
P08237578A0253|104 119|HDL-cholesterol
P08237112A0553|71 79|proteins
P08237112A0553|57 67|structures
P08234276A0556|21 31|activation
P08234276A0556|92 98|NF-IL6
P08232412A1342|184 190|levels
P08232412A1342|219 224|cells
P08232412A1342|92 104|L. enriettii
P08231816A1473|157 174|promoter fragment
P08231816A1473|58 89|penicillin producing conditions
P08231816A1473|121 129|activity
P08231398A0802|307 308|l
P08231398A0802|98 108|isolations
P08231398A0802|174 189|prison patients
P08231398A0802|287 290|CD4
P08231398A0802|19 30|moth period
P08231398A0802|260 277|immunosuppression
P08231398A0802|214 236|immunodeficiency virus
P08230452A0551|441 456|capsid proteins
P08230452A0551|226 236|processing
P08230452A0551|17 25|vaccinia
P08230452A0551|49 64|P1 polyproteins
P08230452A0551|358 374|capsid precursor
P08230452A0551|95 113|processing defects
P08230452A0551|390 407|poliovirus genome
P08230418A0812|169 194|acid phosphatase promoter
P08230418A0812|39 42|LTR
P08230418A0812|162 166|type
P08230418A0812|72 78|effect
P08230418A0812|15 18|nef
P08230418A0812|86 94|activity
P08230418A0812|247 257|frameshift
P08230418A0812|213 221|activity
P08229330A0000|35 42|smoking
P08228997A0866|81 92|oxygenation
P08228997A0866|5 12|results
P08227129T0000|26 32|domain
P08227129T0000|45 58|muscle MyBP-C
P08226798A1124|34 55|HIV envelope proteins
P08226798A1124|172 182|inhibition
P08226798A1124|94 101|effects
P08226798A1124|166 170|part
P08226780A0160|66 70|case
P08226780A0160|122 130|proteins
P08226776A0990|68 73|delta
P08226776A0990|43 50|process
P08225657A0000|5 11|effect
P08225657A0000|78 94|II heart failure
P08225657A0000|47 55|patients
P08225657A0000|61 73|NYHA Class I
P08224260A1248|17 22|study
P08224260A1248|114 127|endometriomas
P08224260A1248|178 179|%
P08224260A1248|77 87|efficiency
P08224260A1248|147 153|masses
P08223823T0000|54 76|Stroop Color-Word Test
P08223613A0105|103 131|synthase/phosphatase complex
P08223613A0105|169 173|glc6
P08223613A0105|157 161|fdp1
P08223613A0105|178 192|cif1 mutations
P08223613A0105|26 30|TPS1
P08223576A1261|16 25|H4PteGlun
P08223576A1261|140 149|T protein
P08223576A1261|5 12|absence
P08223425T0000|5 20|yeast SSS1 gene
P08223425T0000|121 130|reticulum
P08222556T0000|41 48|muscles
P08221251A0239|17 19|CT
P08221251A0239|55 61|tumors
P08220494A0231|153 170|promotor activity
P08220494A0231|81 97|bp cyt-1 element
P08220494A0231|203 217|tobacco plants
P08220494A0231|43 49|origin
P08220494A0231|63 69|planta
P08219081A0000|80 99|PR-1 protein family
P08219081A0000|42 51|component
P08218230A1920|235 240|cells
P08218230A1920|178 185|control
P08218230A1920|193 231|Xenopus fibrinogen B beta subunit gene
P08218230A1920|122 130|promoter
P08218056A0000|115 123|subjects
P08218056A0000|5 19|ultrastructure
P08218056A0000|61 65|eyes
P08216115A0158|171 177|labour
P08216115A0158|191 197|parity
P08216115A0158|67 75|oxytocin
P08216115A0158|109 119|percentile
P08213235A1024|16 20|SaO2
P08213235A1024|33 41|altitude
P08213235A1024|93 101|newborns
P08212571A0971|119 124|cells
P08212571A0971|1 9|Analysis
P08212571A0971|197 206|mutations
P08212571A0971|146 157|tat mutants
P08212571A0971|241 262|tat expression vector
P08209772A0167|32 45|reading frame
P08209772A0167|145 149|mass
P08209772A0167|47 50|ORF
P08209051T0000|70 74|home
P08209051T0000|42 50|fibrosis
P08208540A1114|159 178|repressor functions
P08208540A1114|11 33|co-transfection assays
P08208540A1114|73 78|kappa
P08208540A1114|120 129|NFKB2 p85
P08208540A0000|1 15|Rearrangements
P08208540A0000|23 33|NFKB2 gene
P08207805A0000|138 147|repressor
P08207805A0000|124 133|activator
P08207405A0372|221 232|HSP70 genes
P08207405A0372|1 4|BYV
P08207405A0372|70 79|carnation
P08207405A0372|193 202|fragments
P08207405A0372|29 32|CTV
P08207405A0372|47 58|stunt virus
P08207022T0000|1 20|Subunit composition
P08207022T0000|25 41|domain structure
P08206867A0874|1 27|Southern blotting analysis
P08206867A0874|40 50|occurrence
P08205827A0940|153 166|translocation
P08205827A0940|217 222|shock
P08205827A0940|43 52|endotoxin
P08205827A0940|94 105|bloodstream
P08205827A0940|31 39|bacteria
P08204426T0001|39 50|ventilation
P08204426T0001|58 74|diaphragm pacing
P08204426T0001|120 131|indications
P08204348T0000|1 6|VP-16
P08204348T0000|59 75|cell lung cancer
P08202546A1206|34 59|hUBF-promoter interaction
P08202546A1206|4 12|addition
P08201758A0125|54 65|obstruction
P08201758A0125|76 86|laparotomy
P08200528A0970|65 118|Rhodosporidium toruloides phenylalanine ammonia lyase
P08200528A0970|42 56|Tn903 neo gene
P08200528A0970|182 186|REP2
P08200528A0970|134 138|gene
P08199204A0746|1 4|H-7
P08199204A0746|115 121|PtdIns
P08199204A0746|76 82|effect
P08196624A0593|187 196|receptors
P08196624A0593|33 40|ActR-IB
P08196624A0593|179 183|type
P08196624A0593|26 31|cells
P08196624A0593|72 75|set
P08196616A1112|51 56|motif
P08196616A1112|35 41|ZAP-70
P08196616A1112|20 31|interaction
P08196616A1112|178 184|ZAP-70
P08196616A1112|78 86|presence
P08196616A1112|242 249|binding
P08195233A0147|19 25|kinase
P08195233A0147|179 192|tumorigenesis
P08195233A0147|125 135|chromosome
P08195216A1022|137 142|GCN4p
P08195216A1022|187 203|GCN4p activation
P08195216A1022|207 211|TRP3
P08195216A1022|80 89|sequences
P08195216A1022|120 131|conjunction
P08194970A0000|1 6|Women
P08194970A0000|32 36|work
P08194970A0000|127 138|Trudy Wynne
P08194970A0000|95 100|carer
P08194549A0000|152 156|OBLA
P08194549A0000|115 120|onset
P08194549A0000|66 78|relationship
P08194549A0000|124 150|blood lactate accumulation
P08193147A0831|71 80|Kissinger
P08193147A0831|174 182|elements
P08193147A0831|42 61|Desulfovibrio gigas
P08193147A0831|214 219|Dg Fd
P08193147A0831|63 65|Dg
P08192451A0885|35 43|decrease
P08192451A0885|96 106|NAO uptake
P08192451A0885|61 67|uptake
P08191910A0228|50 54|work
P08191910A0228|145 150|ruler
P08191910A0228|28 34|traits
P08190633A0000|85 94|HLA locus
P08190633A0000|63 73|chromosome
P08189533A0203|86 90|NS53
P08189533A0203|128 157|baculovirus expression system
P08189533A0203|176 193|vaccinia virus/T7
P08189533A0203|47 54|product
P08189498T0000|137 148|polypeptide
P08189498T0000|1 15|Identification
P08189498T0000|38 42|gene
P08188978A0822|34 44|ECG R-wave
P08188978A0822|115 116|s
P08188978A0822|124 129|sleep
P08188603A0230|186 191|CPS-A
P08188603A0230|71 79|homology
P08188603A0230|114 123|CPA2 gene
P08188603A0230|6 14|analysis
P08188603A0230|61 67|degree
P08188258A0000|99 110|synthetases
P08188258A0000|30 52|prolyl-tRNA synthetase
P08187088A0530|137 139|8p
P08187088A0530|10 14|loss
P08187088A0530|133 134|%
P08187088A0530|221 222|%
P08187088A0530|157 158|%
P08187088A0530|145 146|%
P08187088A0530|208 209|%
P08187088A0530|34 37|LOH
P08187088A0530|234 235|%
P08187088A0530|161 163|9q
P08187088A0530|46 47|%
P08187088A0530|186 189|13q
P08187088A0530|113 115|5q
P08187088A0530|242 245|19q
P08187088A0530|121 122|%
P08185288A0106|84 88|stay
P08185288A0106|203 208|kg m.
P08185288A0106|53 61|subjects
P08185288A0106|162 173|min cycling
P08185288A0106|148 157|afternoon
P08183915T0000|145 155|activities
P08183915T0000|63 83|p105 NF-kappa B gene
P08183552T0000|34 59|tyrosine kinase substrate
P08183552T0000|11 21|eps15 gene
P08182056A0695|50 72|NQO1 gene organization
P08182056A0695|20 32|conservation
P08182056A0695|146 161|NQO gene family
P08182056A0695|41 45|NQO2
P08181755A0989|1 18|Northern analysis
P08181755A0989|36 52|pcbAB transcript
P08179827T0000|1 8|Factors
P08179827T0000|55 82|hepatitis B virus infection
P08178490A0879|80 91|K SA domain
P08178490A0879|29 44|signal function
P08177143T0000|25 33|children
P08177143T0000|44 55|institution
P08175188A0685|3 16|concentration
P08175188A0685|92 93|%
P08175188A0685|57 72|baseline values
P08175188A0685|123 124|%
P08173814A0132|7 14|viruses
P08173814A0132|29 48|host cell machinery
P08173814A0132|74 86|interference
P08173532A0000|50 56|target
P08173532A0000|175 187|facilitation
P08173532A0000|23 25|RT
P08173532A0000|145 147|ms
P08173532A0000|125 136|S2 location
P08172653A1589|118 127|sequences
P08172653A1589|173 179|family
P08172653A1589|144 151|members
P08172653A1589|14 21|regions
P08172416A0860|1 11|Moxidectin
P08172416A0860|71 78|effects
P08172416A0860|99 110|performance
P08172416A0860|131 147|folliculogenesis
P08172416A0860|193 204|development
P08169709T0000|50 55|cases
P08169709T0000|29 33|jaws
P08167555A0972|84 94|treatments
P08167555A0972|207 208|p
P08167555A0972|37 45|patients
P08167555A0972|123 127|ones
P08166402A0631|1 20|Cerebral125 albumin
P08166402A0631|67 73|groups
P08164680A1086|100 105|cells
P08164680A1086|78 85|B cells
P08164661A0414|71 79|subunits
P08164661A0414|178 185|factors
P08164661A0414|58 63|yeast
P08164661A0414|15 27|TFIIIC alpha
P08163546A1230|19 23|data
P08163546A1230|81 90|transport
P08163546A1230|37 43|Ypt51p
P08163546A1230|57 63|Ypt53p
P08163546A1230|45 51|Ypt52p
P08163498A0789|141 155|trypsinization
P08163498A0789|66 69|32P
P08163498A0789|163 170|peptide
P08163498A0789|63 64|S
P08163498A0789|44 58|SGASGLLTSEHHSR
P08160905A0217|8 16|patients
P08160054A0224|19 33|deterioriation
P08160054A0224|67 75|increase
P08160054A0224|147 159|coagulopathy
P08160054A0224|79 92|liver enzymes
P08157674T0000|114 119|cells
P08157674T0000|63 96|protein tyrosine kinase substrate
P08157009T0000|119 127|evidence
P08157009T0000|71 78|subunit
P08157009T0000|96 117|clathrin AP-1 complex
P08157009T0000|160 168|clathrin
P08156332T0000|86 95|ischaemia
P08156332T0000|26 39|sympathectomy
P08154171A0649|140 149|treatment
P08154171A0649|159 167|patients
P08154171A0649|110 121|conjunction
P08154171A0649|26 29|use
P08154171A0649|90 100|infarction
P08153130T0000|1 8|Effects
P08153130T0000|25 36|worm burden
P08152800A0357|102 103|%
P08152800A0357|49 56|carboxy
P08152800A0357|188 191|Ets
P08152800A0357|142 146|ER81
P08152800A0357|11 21|ETS domain
P08152800A0357|88 95|protein
P08151790A0354|54 69|HIV replication
P08151790A0354|218 221|HIV
P08151790A0354|147 151|site
P08151790A0354|166 172|effect
P08151790A0354|121 133|Sp1 mutation
P08151790A0354|90 97|context
P08151787A0355|174 182|proteins
P08151787A0355|20 36|oligonucleotides
P08151787A0355|95 100|IE175
P08151787A0355|208 217|phenotype
P08151787A0355|303 315|localization
P08149484A1551|68 77|PKC delta
P08149484A1551|184 193|sequences
P08149484A1551|7 14|results
P08149484A1551|79 86|calcium
P08149484A1551|45 52|calcium
P08148756A0358|143 148|lungs
P08148756A0358|59 69|hemorrhage
P08148756A0358|15 31|lung destruction
P08145770A1078|156 181|differentiation processes
P08145770A1078|10 22|observations
P08145770A1078|46 50|link
P08144852A0000|168 176|response
P08144852A0000|97 110|corticotropin
P08144852A0000|40 48|cortisol
P08144852A0000|186 205|cortisol deficiency
P08144852A0000|252 262|metyrapone
P08144852A0000|23 38|stress hormones
P08144852A0000|121 127|factor
P08144631A0000|68 76|proteins
P08144631A0000|1 10|Signaling
P08144631A0000|98 101|SH2
P08144631A0000|124 148|tyrosine phosphorylation
P08144631A0000|14 30|tyrosine kinases
P08144572A0786|51 58|Ssb1/2p
P08144572A0786|64 69|level
P08144572A0786|122 140|Ssa Hsp70 proteins
P08144497T0000|51 55|zinc
P08144497T0000|124 131|GTP-ras
P08144497T0000|73 82|liposomes
P08144037A0000|85 93|bacteria
P08144037A0000|98 104|plants
P08144037A0000|14 16|TR
P08143667A0222|35 43|pressure
P08143667A0222|5 9|mean
P08143667A0222|166 171|ratio
P08143667A0222|90 94|MUCP
P08143667A0222|15 17|sd
P08143198T0001|1 12|Restoration
P08143198T0001|108 135|m. extensor hallucis brevis
P08140847X0001|1 6|Crohn
P08140847X0001|238 242|CDAI
P08140847X0001|278 289|body weight
P08140847X0001|197 213|disease patients
P08140847X0001|106 114|subjects
P08140847X0001|254 259|order
P08140847X0001|352 358|intake
P08140847X0001|121 124|aim
P08139914A0554|102 107|cells
P08139914A0554|83 89|muscle
P08139562A0404|118 123|uORF1
P08139562A0404|86 90|GCN4
P08139562A0404|9 15|report
P08139562A0404|133 141|scanning
P08139543A0427|82 100|suppression screen
P08139543A0427|15 20|genes
P08139542A1229|48 52|CPA1
P08139542A1229|56 64|arginine
P08139031A1168|154 159|C-426
P08139031A1168|178 201|transactivator function
P08139031A1168|57 68|mutagenesis
P08139031A1168|328 345|acid interactions
P08139031A1168|121 137|ORF4 polypeptide
P08139004A0278|8 11|UTR
P08139004A0278|31 39|hairpins
P08138364T0000|22 32|experience
P08136383A0359|41 49|patients
P08134108A0277|5 10|c-myc
P08134108A0277|24 50|alpha-actin gene promoters
P08132667T0000|1 11|Expression
P08132667T0000|27 61|proprotein processing enzyme furin
P08132541A0000|57 65|MAL gene
P08131545A0158|97 102|years
P08131545A0158|72 77|women
P08131545A0158|254 264|adenovirus
P08131545A0158|84 87|age
P08131545A0158|266 283|Coxiella burnetii
P08131545A0158|28 33|group
P08131545A0158|180 185|tests
P08129955A0572|101 111|unclamping
P08129955A0572|18 28|troponin T
P08129955A0572|8 14|levels
P08127950A0000|174 177|FT4
P08127950A0000|203 206|FT3
P08127950A0000|163 172|thyroxine
P08127950A0000|382 390|subjects
P08127950A0000|74 77|HPT
P08127950A0000|291 299|TSH-IRMA
P08127950A0000|250 255|means
P08127950A0000|213 240|thyroid stimulating hormone
P08127950A0000|242 245|TSH
P08126096A0478|71 76|alpha
P08126096A0478|54 63|functions
P08126096A0478|10 21|experiments
P08126096A0478|148 157|sequences
P08126096A0478|134 137|rat
P08125337A0940|1 16|Sterol analysis
P08125337A0940|58 70|accumulation
P08125337A0940|74 84|ignosterol
P08125258A0142|112 120|stresses
P08125258A0142|92 99|variety
P08125258A0142|41 51|conditions
P08124912A0456|116 123|glucose
P08124912A0456|77 84|lactate
P08124912A0456|12 23|correlation
P08124912A0456|45 54|SF levels
P08123787A0554|93 103|difference
P08123787A0554|160 167|enzymes
P08123787A0554|192 206|overexpression
P08122364A0954|1 18|Deletion analyses
P08122364A0954|53 72|promoter constructs
P08122364A0954|131 145|pCD41 sequence
P08122364A0954|46 49|use
P08120019A1500|103 116|sequestration
P08120019A1500|138 148|mechanisms
P08119958A0273|51 55|PKCs
P08119958A0273|17 26|C2 domain
P08119958A0273|64 72|presence
P08119958A0273|232 236|PKCs
P08119958A0273|197 203|member
P08119958A0273|124 138|signal peptide
P08119149A0000|1 28|Tumor necrosis factor-alpha
P08119149A0000|79 86|factors
P08119149A0000|30 39|TNF alpha
P08116245A0174|72 81|specimens
P08116245A0174|15 18|RNA
P08115744A0462|86 94|aperture
P08115744A0462|54 72|laser densitometer
P08114710A0137|85 92|binding
P08114710A0137|109 117|TATA box
P08114710A0137|31 36|LBP-1
P08113736A0309|222 225|ORF
P08113736A0309|64 70|clover
P08113736A0309|5 22|gene organization
P08113736A0309|160 169|exception
P08113736A0309|88 93|RCNMV
P08113736A0309|105 111|clover
P08112611A0404|5 13|sequence
P08112611A0404|73 84|amino acids
P08112526A0443|142 150|bladders
P08112526A0443|61 83|detrusor contractility
P08111974A1034|157 168|involvement
P08111974A1034|128 139|translation
P08111974A1034|44 46|CX
P08111974A1034|60 71|degradation
P08108413A0964|81 88|tissues
P08108413A0964|176 187|transcripts
P08108099T0000|1 11|Evaluation
P08108099T0000|39 50|extractions
P08108099T0000|15 27|desmopressin
P08107167A0222|1 7|Anti-B
P08107167A0222|113 118|assay
P08107167A0222|161 162|%
P08107167A0222|44 50|anti-B
P08107167A0222|30 39|turicatae
P08106398A1003|7 14|results
P08106398A1003|149 156|peptide
P08106398A1003|30 38|cleavage
P08106325A0000|116 135|nucleotide sequence
P08106325A0000|162 183|diphtheria toxin gene
P08106245A0325|273 279|Bq m-3
P08106245A0325|174 178|year
P08106245A0325|12 31|radon concentration
P08106245A0325|105 111|winter
P08106245A0325|153 159|Bq m-3
P08106245A0325|321 325|year
P08106245A0325|182 194|measurements
P08106245A0325|329 341|measurements
P08105994T0000|39 71|serum gamma-glutamyl transferase
P08105994T0000|10 17|aspects
P08104189A1168|173 179|ATPase
P08104189A1168|67 70|TGN
P08104189A1168|30 46|proSRIF cleavage
P08103379A0577|127 151|amino acid substitutions
P08103379A0577|25 36|amino acids
P08101843A0151|103 105|bp
P08101843A0151|64 77|consensus CRE
P08101843A0151|5 30|tyrosine hydroxylase gene
P08101843A0151|123 152|transcription initiation site
P08101171A0924|101 111|boundaries
P08101171A0924|145 148|gap
P08101171A0924|44 61|Pc group products
P08100843A0134|137 147|Cd22 locus
P08100843A0134|1 18|Southern analysis
P08100843A0134|175 184|copy gene
P08100843A0134|198 200|kb
P08100843A0134|60 70|cell lines
P08100057A0577|81 92|macrophages
P08100057A0577|52 63|populations
P08098914A0400|156 158|SD
P08098914A0400|8 16|exercise
P08098914A0400|160 167|mmHg/ml
P08098914A0400|62 66|left
P08098842A0660|69 93|transcription start site
P08098842A0660|1 10|Mutations
P08098842A0660|248 263|gene expression
P08098842A0660|110 118|homology
P08098842A0660|196 203|element
P08098842A0660|40 42|bp
P08097732A0000|204 221|Spec1/Spec2 genes
P08097732A0000|140 144|part
P08097732A0000|161 177|sequence element
P08097732A0000|74 92|sea urchin embryos
P08096944A0951|114 121|ovaries
P08096944A0951|159 170|stimulation
P08096944A0951|72 82|indication
P08095875T0000|1 8|Effects
P08095875T0000|21 32|hypercapnia
P08095875T0000|73 77|rats
P08095698T0000|1 11|Metabolism
P08095698T0000|93 98|study
P08095698T0000|41 49|patients
P08095698T0000|15 22|calcium
P08094498A0614|78 87|prognosis
P08094498A0614|31 37|spouse
P08094464A0869|10 14|tyrA
P08094464A0869|105 112|portion
P08093616T0000|204 211|antigen
P08093616T0000|86 100|binding factor
P08093616T0000|191 195|cell
P08093616T0000|7 27|8-base pair sequence
P08093450A0688|1 12|Mutagenesis
P08093450A0688|21 32|NRF-1 motif
P08093450A0688|145 156|mutagenesis
P08093450A0688|210 214|loss
P08093450A0688|91 135|chloramphenicol acetyltransferase expression
P08091665T0000|99 111|TNF receptor
P08091665T0000|79 83|form
P08091665T0000|91 95|type
P08090767A0000|202 224|DNA methylation damage
P08090767A0000|79 85|enzyme
P08090767A0000|12 20|evidence
P08090571T0001|1 12|Elimination
P08090571T0001|24 34|antibodies
P08089834A0561|7 14|mutants
P08089834A0561|78 96|amino acid residue
P08088818A1053|142 148|strain
P08088818A1053|107 111|host
P08088818A1053|45 54|deletions
P08088513A0419|155 161|snRNAs
P08088513A0419|26 34|evidence
P08088513A0419|104 122|DEAH protein Prp16
P08087887A1067|55 72|Volvox life cycle
P08087887A1067|145 159|post-inversion
P08087887A1067|78 83|peaks
P08086450A0467|158 172|binding motifs
P08086450A0467|123 125|GC
P08086450A0467|192 199|factors
P08086450A0467|28 32|gene
P08086450A0467|224 227|GCF
P08086450A0467|75 85|hATP1 gene
P08085609A0384|1 8|Results
P08085609A0384|23 29|KNM-LU
P08085609A0384|62 76|chimpanzee M1s
P08084592A0145|39 49|expression
P08084592A0145|11 34|fibroblast cell hybrids
P08083999A0501|187 200|transcription
P08083999A0501|48 54|HPV-16
P08083999A0501|160 161|M
P08083999A0501|134 136|Kd
P08083998A1723a|100 119|RNA-RNA interaction
P08083998A1723a|7 14|results
P08083220A0988|6 10|mode
P08083220A0988|196 210|serum response
P08083220A0988|146 153|complex
P08083220A0988|94 113|c-fos protooncogene
P08083220A0988|180 188|assembly
P08082440A0339a|2 6|LH P
P08082292T0000|55 58|HIV
P08082292T0000|104 116|tuberculosis
P08082292T0000|60 68|patients
P08082215A0230|42 57|cytomegalovirus
P08082215A0230|24 38|past-infection
P08079268T0028|1 4|Use
P08079268T0028|8 31|Medi-Jector EZ dermojet
P08078416A0581|50 63|biofilm cells
P08078416A0581|142 155|disinfectants
P08078416A0581|120 134|concentrations
P08077236A0243|86 96|COS7 cells
P08077236A0243|22 31|Epo cDNAs
P08076631A0000|119 134|promoter region
P08076631A0000|16 41|transcription factor AP-1
P08076631A0000|223 228|MG-63
P08076631A0000|143 147|VDRE
P08076631A0000|162 178|osteocalcin gene
P08076631A0000|46 64|vitamin D receptor
P08075421A0621a|50 60|C terminus
P08075421A0621a|13 16|ORF
P08073505T0000|69 76|example
P08073505T0000|53 63|biologists
P08072547A1009|68 73|c-Jun
P08072547A1009|115 132|activation domain
P08072547A1009|40 64|JNK phosphorylation site
P08072547A1009|90 95|c-Fos
P08072352A0567|64 83|aspirin sensitivity
P08072352A0567|22 28|polyps
P08072352A0567|43 49|asthma
P08072352A0567|57 58|%
P08072352A0567|91 92|%
P08071356A0232|35 40|sizes
P08071356A0232|48 61|DNA footprint
P08071356A0232|8 29|transcript elongation
P08070654A0000|1 5|KAR1
P08070654A0000|95 104|karyogamy
P08070654A0000|109 124|SPB duplication
P08070004A0782|38 55|PCZ plasma levels
P08070004A0782|65 70|ng/ml
P08070004A0782|144 147|min
P08070004A0782|91 107|plasma half-life
P08069427T0000|1 28|Roux-en-Y gastroenterostomy
P08069427T0000|47 55|emptying
P08067607A0568|83 98|baseline values
P08067607A0568|28 39|CBC results
P08067607A0568|44 67|serum CRP concentration
P08067123A0248|313 314|%
P08067123A0248|280 295|anti-HCV-C100-3
P08067123A0248|107 110|USA
P08067123A0248|165 177|blood donors
P08067123A0248|117 131|detection rate
P08067123A0248|54 57|use
P08067123A0248|268 274|donors
P08067123A0248|91 105|ABBOTT HCV EIA
P08067123A0248|181 187|Moscow
P08066094T0000|32 42|reactivity
P08065368A0839|8 15|Biochem
P08065365A0000|117 125|assembly
P08065365A0000|97 101|step
P08065365A0000|12 14|U2
P08065331A0279|68 81|DNA sequences
P08065331A0279|21 45|site selection procedure
P08065331A0279|172 173|t
P08065324A0458|23 33|expression
P08065324A0458|52 57|maize
P08065324A0458|78 83|plant
P08065324A0458|150 163|transcription
P08064351A1020|22 27|units
P08064351A1020|41 47|shocks
P08064351A1020|60 66|jitter
P08063791A1370|138 150|Ras proteins
P08063791A1370|7 14|results
P08063791A1370|105 118|modifications
P08063766A0595|117 124|kinases
P08063766A0595|22 25|PKC
P08063766A0595|147 154|lamin B
P08063766A0595|14 18|beta
P08062833A0000|70 87|mouse desmin gene
P08062833A0000|33 62|transcription initiation site
P08062833A0000|231 241|expression
P08062833A0000|209 214|level
P08062833A0000|14 16|nt
P08058948A0810|64 73|detection
P08058948A0810|52 56|role
P08058948A0810|108 111|CRF
P08057833A0573|68 90|translation initiation
P08057833A0573|9 22|ParA proteins
P08057833A0573|46 52|result
P08057421A1583|103 121|CBF1 binding sites
P08057421A1583|172 185|CD23 promoter
P08057421A1583|231 238|Cp site
P08057421A1583|194 218|EBV LMP-1 promoter sites
P08057356A0531|23 27|form
P08057356A0531|56 60|V88A
P08055941A1264|18 23|chain
P08055941A1264|39 52|beta subunits
P08055941A1264|113 118|alpha
P08055941A1264|121 125|beta
P08055939A0159|115 121|domain
P08055939A0159|143 160|hexapeptide motif
P08055939A0159|162 170|variants
P08055939A0159|75 87|H1 molecules
P08053697A0000|16 22|DESIGN
P08053697A0000|67 71|foci
P08053697A0000|215 225|correlates
P08053697A0000|47 51|nevi
P08053697A0000|75 92|hyperpigmentation
P08051102A0532|16 22|effect
P08051102A0532|26 39|rAC-st myosin
P08051102A0532|105 110|forms
P08051059A1000|5 13|sequence
P08051059A1000|66 73|repeats
P08049885T0000|23 42|multisystem disease
P08049444A0351|118 125|protein
P08049444A0351|232 239|regions
P08049444A0351|163 168|SATB1
P08049444A0351|76 83|protein
P08049444A0351|243 246|DNA
P08048916A0000|93 101|pathways
P08048916A0000|44 52|proteins
P08046923A0000|36 44|patients
P08046923A0000|105 114|resection
P08045431A0894|32 42|rubredoxin
P08045431A0894|63 71|proteins
P08044800A0550|65 73|entirety
P08044800A0550|124 129|sites
P08043523A0000|136 144|patients
P08043523A0000|87 92|nAChR
P08043523A0000|175 185|antibodies
P08043523A0000|63 85|acetylcholine receptor
P08041362T0000|24 46|cysteine synthase cDNA
P08041362T0000|11 18|cloning
P08041362T0000|62 70|vulgaris
P08040391T0000|1 7|Number
P08040391T0000|83 94|correlation
P08040391T0000|126 142|tumour behaviour
P08040391T0000|12 16|size
P08039422A0000|36 40|NGFB
P08039422A0000|89 99|chromosome
P08036004A0292|220 225|class
P08036004A0292|5 14|R2 region
P08036004A0292|228 238|expression
P08036004A0292|62 69|element
P08036004A0292|90 95|cells
P08035796A0890|1 14|32Pi labeling
P08035796A0890|139 150|eIF-2 alpha
P08035796A0890|39 47|analysis
P08035796A0890|266 283|growth conditions
P08035796A0890|193 204|eIF-2 alpha
P08035505A0586|1 11|Processing
P08035505A0586|25 38|B polyprotein
P08035498A0833|115 135|AAV promoter regions
P08035498A0833|46 55|sequences
P08034741A0000|34 50|characterization
P08034741A0000|54 57|myr
P08034741A0000|73 76|rat
P08034741A0000|15 29|identification
P08034682T0000|82 97|3T3 fibroblasts
P08034486A0579|152 157|areas
P08034486A0579|33 41|subjects
P08034486A0579|5 14|incidence
P08034486A0579|43 48|HSV-2
P08033490A0875|51 73|O-desmethylvenlafaxine
P08033490A0875|35 46|venlafaxine
P08033490A0875|157 165|patients
P08033490A0875|208 214|ml/min
P08030704A1503|1 11|CONCLUSION
P08030704A1503|27 32|birth
P08030704A1503|72 109|progesterone/17 beta-estradiol ratios
P08030239A0833|50 61|polypeptide
P08030239A0833|260 277|EHV-1 IE promoter
P08030239A0833|196 213|EHV-1 tk promoter
P08030239A0833|73 92|amino acid residues
P08029001A1020|34 39|class
P08029001A1020|7 14|results
P08029001A1020|56 74|activator proteins
P08025669A0724|5 13|proteins
P08025669A0724|36 40|rpoN
P08024139A0393|185 194|solutions
P08024139A0393|64 71|volumes
P08024139A0393|36 46|hypothesis
P08022212A0071|279 301|phase angle alpha pi/2
P08022212A0071|76 82|method
P08022212A0071|111 114|ALP
P08022212A0071|152 154|Hz
P08022212A0071|214 218|line
P08022212A0071|361 384|ion relaxation time tau
P08022212A0071|30 43|two-frequency
P08021177A0000|70 86|transport system
P08021177A0000|5 14|fepA-entD
P08021177A0000|43 65|enterobactin synthesis
P08021177A0000|132 141|promoters
P08020965A0465|101 103|kb
P08020965A0465|23 29|region
P08020806A0187|200 212|feeding tube
P08020806A0187|261 266|% fat
P08020806A0187|127 135|outcomes
P08020806A0187|162 166|diet
P08020806A0187|229 236|peptide
P08020806A0187|243 247|diet
P08020702A0000|1 12|Endotoxemia
P08020702A0000|38 46|bacteria
P08020702A0000|66 71|shock
P08017290A1347|49 56|lactate
P08017290A1347|82 86|PCO2
P08017290A1347|78 80|pH
P08017290A1347|91 112|potassium differences
P08016102A1238|5 13|presence
P08016102A1238|203 213|indication
P08016102A1238|46 53|binding
P08016102A1238|259 277|defense mechanisms
P08016102A1238|185 191|injury
P08016102A1238|158 166|response
P08016102A1238|242 246|HO-1
P08015672A1282|84 88|Type
P08015672A1282|4 20|control patients
P08015672A1282|112 116|Type
P08015672A1282|62 66|Type
P08014377A1277|153 164|interaction
P08014377A1277|203 212|divisions
P08014377A1277|76 84|outflows
P08014377A1277|15 25|conditions
P08013457A0342|19 25|domain
P08013457A0342|52 64|interactions
P08012566A0254|81 84|m/z
P08012566A0254|5 33|pentafluorobenzyl derivative
P08012566A0254|37 53|clonidine yields
P08012566A0254|132 137|ng/ml
P08011166A0207|119 135|characterization
P08011166A0207|77 85|sequence
P08011166A0207|183 191|segments
P08011166A0207|14 31|gene organization
P08007954A0374|1 17|Deletion studies
P08007954A0374|83 100|cytokine response
P08006773A0836|102 116|blood pressure
P08006773A0836|140 151|hypotension
P08006773A0836|14 24|difference
P08006773A0836|81 89|patients
P08006773A0836|261 265|TxA2
P08006773A0836|59 65|figure
P08006773A0836|123 135|preeclampsia
P08006773A0836|243 244|p
P08006101A1142|82 104|validation experiments
P08006101A1142|121 134|study samples
P08005412A0608|202 205|DNA
P08005412A0608|167 179|interactions
P08005412A0608|73 82|formation
P08004442A0265|153 157|axis
P08004442A0265|5 12|effects
P08004442A0265|23 32|isolation
P08004442A0265|94 101|animals
P08004442A0265|164 171|animals
P08002857A1070|154 160|reflux
P08002857A1070|116 126|protection
P08002857A1070|20 28|findings
P08002857A1070|210 214|bile
P08001966A0563|85 91|skin-1
P08001966A0563|38 46|homology
P08001966A0563|126 137|development
P08001966A0563|12 19|regions
P08001136T0000|32 38|kinase
P08001136T0000|61 83|CTD kinase TFIIH/TFIIK
P08000427A0000|191 193|pI
P08000427A0000|160 171|amino acids
P08000427A0000|75 100|tobacco cell cDNA library
P08000074A0162|33 34|%
P08000074A0162|113 127|reading frames
P08000074A0162|160 168|fragment
P07999982A0086|220 224|gene
P07999982A0086|206 212|search
P07999982A0086|38 42|FRDA
P07999982A0086|73 78|D9S15
P07999982A0086|164 184|recombination events
P07999363A0000|87 95|isoforms
P07999363A0000|113 123|ectodomain
P07999363A0000|8 18|variations
P07999363A0000|183 196|kinase domain
P07997174A0936|98 107|functions
P07997174A0936|52 59|His-304
P07995173A0585|1 9|Transfer
P07995173A0585|71 72|P
P07993559A0233|17 37|Fluorosis Risk Index
P07993559A0233|92 98|review
P07991582A1023b|80 86|motifs
P07991582A1023b|24 34|yeast CEG1
P07990136A1124|98 126|tRNA gene transcription unit
P07990136A1124|145 159|identification
P07990136A1124|229 238|complexes
P07990136A1124|26 55|selectivity arrest elongation
P07990136A1124|15 22|ability
P07988731A1301|83 102|GBF protein complex
P07988730A0220|32 42|constructs
P07988730A0220|233 240|absence
P07988730A0220|11 28|promoter strength
P07988730A0220|152 158|assays
P07988730A0220|185 195|HeLa cells
P07988730A0220|112 145|chloramphenicol acetyltransferase
P07988730A0220|92 95|LTR
P07987924A0670|69 95|USCI Tuohy-Borst Y adaptor
P07987924A0670|26 31|probe
P07984261A0536|81 87|centre
P07984261A0536|52 61|reduction
P07984261A0536|107 114|tissues
P07984088A0592|68 73|genes
P07984088A0592|48 58|expression
P07984088A0592|22 26|gene
P07984088A0592|31 43|ivanolysin O
P07983716A1082|172 181|Y88L RNAs
P07983716A1082|144 148|RNAs
P07983716A1082|56 74|transcriptase-PCRs
P07983716A1082|210 216|levels
P07983716A1082|30 43|blot analysis
P07983712A0914|86 97|replication
P07983712A0914|62 69|plasmid
P07983712A0914|15 21|domain
P07983011A0617|34 40|kinase
P07983011A0617|140 146|family
P07983011A0617|110 116|hybrid
P07983011A0617|499 521|domain binding regions
P07983011A0617|494 497|SH3
P07983011A0617|397 403|domain
P07983011A0617|355 362|segment
P07983011A0617|211 251|fibroblast growth factor receptor family
P07982964A1017|51 104|phosphodiesterase substrate p-nitrophenyl thymidine-5
P07982964A1017|11 15|PC-1
P07982964A1017|44 48|type
P07981143A0633|50 56|IL-4RE
P07981143A0633|3 10|stretch
P07981143A0633|72 89|IL-4 inducibility
P07979827A0722|50 58|increase
P07979827A0722|82 92|blood flow
P07978406A0998|118 122|PCO2
P07978406A0998|140 144|mmHg
P07978406A0998|22 29|pre-DEX
P07978406A0998|8 17|ISO group
P07978406A0998|73 81|mL.min-1
P07978406A0998|105 116|hypercapnia
P07977648A0880|19 35|TP53 transcripts
P07977648A0880|130 136|tumors
P07977648A0880|107 113|allele
P07975882T0000|7 22|adenovirus type
P07973825A0445|80 94|pulse pressure
P07973825A0445|67 75|pressure
P07973364A0325|16 23|article
P07973364A0325|39 44|death
P07973364A0325|163 174|Wistar rats
P07973364A0325|130 133|OFA
P07973364A0325|181 188|studies
P07972237A0665|64 67|DNA
P07972237A0665|79 84|N-myc
P07972237A0665|47 49|kb
P07971709A0907|83 91|activity
P07971709A0907|105 110|state
P07969954T0000|83 94|improvement
P07969954T0000|132 147|plasma exchange
P07969954T0000|164 180|cyclophosphamide
P07969152A0721|102 120|CUP1 transcription
P07969152A0721|306 318|hsp70 family
P07969152A0721|141 158|heat shock stress
P07969152A0721|188 194|region
P07969152A0721|124 132|response
P07969152A0721|224 245|heat shock activation
P07969135A0913|27 43|Cln2 PEST domain
P07969135A0913|89 96|protein
P07969116A0196|39 62|transcription activator
P07969116A0196|96 106|expression
P07969116A0196|121 126|genes
P07968409A0123|80 98|Outpatient Service
P07968409A0123|214 218|July
P07968409A0123|146 163|Ospedale Maggiore
P07968409A0123|135 142|Bologna
P07967360A1048|37 45|patients
P07967360A1048|135 153|glomerulonephritis
P07966602A0130|1 8|Roizman
P07965152A0764|1 9|Segments
P07965152A0764|59 70|mismatching
P07965152A0764|131 138|reserve
P07965152A0764|28 40|BMIPP uptake
P07964814T0000|19 33|hallucinations
P07964624A0491|138 146|P131 ORF
P07964624A0491|5 13|P131 ORF
P07964624A0491|177 178|r
P07964624A0491|109 130|UGA termination codon
P07964624A0491|90 101|readthrough
P07964458A0179|3 17|candidate gene
P07964458A0179|212 219|animals
P07964458A0179|88 93|Nramp
P07963782A0000|118 123|space
P07963782A0000|57 62|drugs
P07963782A0000|132 141|treatment
P07961755A0474|1 9|Homology
P07961755A0474|77 96|cysteine synthase C
P07960796A0154|1 12|Peter Elfer
P07960796A0154|46 52|ruling
P07959953A0423|1 6|IFI16
P07959953A0423|97 100|DNA
P07959953A0423|90 92|kb
P07959760A0763|71 77|orders
P07959760A0763|97 102|sites
P07959760A0763|104 108|STSs
P07959760A0763|17 27|YAC contig
P07959760A0763|358 360|CA
P07959760A0763|256 258|kb
P07959760A0763|190 195|Fli-1
P07959760A0763|178 183|c-ets
P07959760A0763|361 362|n
P07959760A0763|120 127|minimum
P07959015A0478|156 158|aa
P07959015A0478|5 12|results
P07959015A0478|163 172|nt levels
P07959015A0478|77 80|kDa
P07959015A0478|147 148|%
P07959011A0379a|1 12|C/EBP alpha
P07959011A0379a|32 40|promoter
P07959011A0379a|115 119|Arch
P07958915A1507|16 23|changes
P07958915A1507|189 192|Ca2
P07958915A1507|127 140|transcription
P07958915A1507|109 113|cAMP
P07958915A1507|180 185|forms
P07958898A1050|16 26|dTFIIA-L/S
P07958898A1050|81 91|activation
P07958898A1050|151 156|NTF-1
P07958446A0000|34 39|HNF-3
P07958446A0000|188 211|helix DNA binding motif
P07958446A0000|161 169|homology
P07958446A0000|41 49|forkhead
P07958446A0000|89 95|family
P07957559A1557|10 19|rapamycin
P07957559A1557|47 59|Ba/F3-EpoRgp
P07957559A1557|105 127|p70 S6 kinase activity
P07957158A1532|102 111|parameter
P07957158A1532|187 194|control
P07957158A1532|45 50|areas
P07957106A0471|79 104|glutathione-agarose beads
P07956869A0000|169 174|years
P07956869A0000|43 63|breast cancer tissue
P07956869A0000|130 133|Dar
P07956869A0000|150 157|storage
P07956869A0000|90 98|archives
P07954891T0000|39 44|cycle
P07954891T0000|82 89|genomes
P07953785A0648|23 29|chicks
P07953785A0648|146 156|resistance
P07953785A0648|122 132|H/L ratios
P07951410A1332|1 19|E1A autoactivation
P07951410A1332|38 43|sites
P07951235A0277|85 91|muscle
P07949551A0000|1 4|Use
P07949551A0000|57 80|cadaver transplantation
P07949164A0799|35 48|kappa B motif
P07949164A0799|140 145|cells
P07949164A0799|108 130|IL-6 promoter activity
P07949164A0799|94 104|abrogation
P07949137A0000|68 79|bone marrow
P07949137A0000|3 8|total
P07949137A0000|37 45|patients
P07949137A0000|127 133|period
P07949137A0000|95 106|mafosfamide
P07948129A0297|223 250|neomycin phosphotransferase
P07948129A0297|260 264|gene
P07948129A0297|176 186|SV40 virus
P07948129A0297|10 17|vectors
P07948129A0297|193 208|region promoter
P07948129A0297|45 51|repeat
P07945937A0358|103 106|rat
P07945937A0358|71 76|level
P07945937A0358|96 101|mouse
P07945937A0358|48 54|region
P07945937A0358|80 88|homology
P07945937A0358|146 155|exception
P07945134A0079|137 143|sounds
P07945134A0079|48 49|m
P07945134A0079|5 15|volunteers
P07945134A0079|165 180|head microphone
P07944461A0321|38 39|%
P07944461A0321|12 20|TG-night
P07942722T0000|1 13|Constipation
P07942722T0000|39 50|hemorrhoids
P07942722T0000|67 72|study
P07942076A0497|93 112|estradiol ingestion
P07942076A0497|145 148|age
P07942076A0497|135 142|patient
P07941739A0000|8 19|kb fragment
P07941739A0000|109 116|mapping
P07938137A0384|136 146|withdrawal
P07938137A0384|5 11|groups
P07938137A0384|120 125|signs
P07937954A0612|1 4|HBx
P07937954A0612|77 80|Raf
P07937954A0612|124 134|MAP kinase
P07937656A0182|342 349|minimum
P07937656A0182|69 82|Log-Rank-Test
P07937656A0182|174 189|NSE serum level
P07937656A0182|42 64|Kaplan-Meier-estimates
P07937656A0182|229 255|serum alkaline phosphatase
P07937656A0182|357 358|p
P07937656A0182|217 218|p
P07937656A0182|24 32|analysis
P07937656A0182|270 273|U/l
P07937132A0819|33 40|stretch
P07937132A0819|13 16|U21
P07937132A0819|45 47|nt
P07937112A0220|87 99|denaturation
P07937112A0220|73 78|cells
P07937106A0100|103 127|amino acid substitutions
P07937106A0100|201 206|v-ets
P07937106A0100|129 136|alanine
P07937106A0100|74 95|progenitor p68c-ets-1
P07937106A0100|191 197|valine
P07937106A0100|265 268|end
P07937106A0100|270 280|mutation C
P07936650A0656|168 176|sequence
P07936650A0656|141 151|Ets-1-beta
P07936650A0656|133 136|BEC
P07936635A1134|1 9|Mutation
P07936635A1134|92 99|protein
P07936635A1134|131 138|nucleus
P07935626A1249|16 24|presence
P07935626A1249|66 78|mitochondria
P07935626A1249|42 45|CCA
P07935491A1182|69 77|affinity
P07935491A1182|91 137|acid receptor-retinoid-X receptor heterodimers
P07935472A0790|87 96|complexes
P07935472A0790|42 47|Ets-1
P07935471A0613|136 151|mapping regions
P07935471A0613|216 221|state
P07935471A0613|36 44|activity
P07935471A0613|125 131|system
P07935451T0000|170 180|c-rel gene
P07935451T0000|139 142|p65
P07935451T0000|54 68|NF-kappa B/Rel
P07935451T0000|36 50|Tax activation
P07935451T0000|78 93|phosphorylation
P07935426A0714|17 25|isoforms
P07935426A0714|105 125|TdT promoter binding
P07935415T0000|114 126|localization
P07935415T0000|52 61|inhibitor
P07935415T0000|90 97|cloning
P07935383A0108|70 77|subunit
P07935383A0108|81 85|CstF
P07935383A0108|27 44|mapping technique
P07935383A0108|215 238|adenovirus L3 pre-mRNAs
P07935375A1197|35 43|ras gene
P07935375A1197|80 85|v-src
P07935094A0516|85 104|Tl-201 counterparts
P07935094A0516|116 132|liver background
P07935094A0516|25 32|quality
P07934331T0037|43 54|improvement
P07934331T0037|29 38|incentive
P07933107A0991|154 166|% similarity
P07933107A0991|3 13|comparison
P07933107A0991|21 40|nucleotide sequence
P07933107A0991|132 143|virus Ba71V
P07933095A0000|190 216|chicken embryo fibroblasts
P07933095A0000|218 220|S.
P07933095A0000|162 186|transcription factor Sp1
P07933095A0000|94 104|expression
P07933066T0000|136 140|DP-1
P07933066T0000|39 54|adenovirus E4-6
P07933066T0000|126 131|E2F-1
P07933066T0000|73 100|retinoblastoma gene product
P07932095A0000|51 58|VII-XII
P07932095A0000|48 49|V
P07932095A0000|109 113|XIII
P07932095A0000|105 107|VI
P07929560T0000|1 15|Identification
P07929560T0000|113 131|filament anchorage
P07929560T0000|43 49|domain
P07929431A0949|1 9|Plasmids
P07929431A0949|36 57|mouse promoter region
P07929431A0949|121 124|CAT
P07928954A0545|1 22|DNA sequence analysis
P07928954A0545|39 43|gene
P07928954A0545|163 189|lipoprotein signal peptide
P07928954A0545|194 234|consensus prolipoprotein processing site
P07927711A0698|99 106|regions
P07927711A0698|41 48|protein
P07927130A0625|70 78|ml/kg bw
P07927130A0625|203 213|myocardium
P07927130A0625|173 183|infiltrate
P07927130A0625|82 85|day
P07927130A0625|145 156|eradication
P07926775A0895|137 150|wg expression
P07926775A0895|206 208|hh
P07926775A0895|173 189|wg transcription
P07926775A0895|78 90|slp activity
P07926775A0895|122 133|maintenance
P07926749A0471|119 122|DNA
P07926749A0471|222 240|core motif PuGGTCA
P07926749A0471|191 199|sequence
P07926749A0471|126 134|monomers
P07926749A0471|9 23|site selection
P07926749A0471|105 113|isoforms
P07926739A0766|5 23|expression pattern
P07926739A0766|59 72|hybridization
P07926739A0766|147 153|stages
P07925282A0705|35 40|genes
P07925282A0705|100 111|cell growth
P07925282A0705|128 149|protein translocation
P07925022A0285|1 11|Expression
P07925022A0285|42 45|CNS
P07919540A1119|4 12|addition
P07919540A1119|23 27|exon
P07919540A1119|128 146|reporter construct
P07919540A1119|90 103|transcription
P07918494A1163|49 60|thioredoxin
P07918494A1163|142 151|formation
P07918494A1163|8 16|presence
P07918494A1163|89 94|NADPH
P07918494A1163|120 127|mutants
P07918097T0000|11 38|Notch homologue mouse Notch
P07917016A0581|28 63|zinc finger domain protein sequence
P07916729T0000|32 42|suppressor
P07916729T0000|99 116|enhancer function
P07916729T0000|89 95|effect
P07916689A0312|122 135|carbon source
P07916689A0312|14 25|POT1 clones
P07916588A0471|250 253|PWV
P07916588A0471|6 11|virus
P07916588A0471|52 81|passion fruit woodiness virus
P07916588A0471|196 200|part
P07916588A0471|215 223|subgroup
P07916588A0471|165 172|strains
P07916327A0250|20 27|cloning
P07916327A0250|77 84|library
P07916327A0250|41 55|goosecoid gene
P07916003A0688|16 26|mouse gene
P07916003A0688|135 148|octamer motif
P07916003A0688|105 121|mouse CD79 alpha
P07914700A0000|32 58|eIF-2 alpha protein kinase
P07914700A0000|83 88|mouse
P07914700A0000|60 63|PKR
P07914192A0844|222 229|binding
P07914192A0844|175 180|cells
P07914192A0844|196 200|HER2
P07914192A0844|44 69|oligonucleotide sequences
P07913926A0878|1 18|Northern analysis
P07913926A0878|138 145|absence
P07913926A0878|22 33|RNA samples
P07913926A0878|106 113|amounts
P07913080A0564|116 122|region
P07913080A0564|65 71|humans
P07913080A0564|130 140|horse gene
P07911736A1715|8 11|MTD
P07911736A1715|45 53|toxicity
P07910716A0359|35 43|patients
P07910716A0359|374 383|IU/m2/day
P07910716A0359|141 146|weeks
P07910716A0359|5 18|study cohorts
P07910716A0359|447 451|week
P07910716A0359|110 114|days
P07910716A0359|316 331|U/m2/day thrice
P07910716A0359|344 352|SC rIL-2
P07910716A0359|425 434|IU/m2/day
P07910716A0359|260 268|patients
P07910716A0359|246 251|weeks
P07910716A0359|95 104|IU/m2/day
P07908827A1200|255 258|RAR
P07908827A1200|71 79|RAR beta
P07908827A1200|5 8|use
P07908827A1200|178 187|COS cells
P07908827A1200|107 116|complexes
P07908012A0678|16 27|possibility
P07908012A0678|33 49|LNNB performance
P07908012A0678|115 125|medication
P07908012A0678|127 135|analyses
P07906265A0897|70 82|fasD mutants
P07906265A0897|130 136|export
P07906265A0897|90 98|products
P07905413A0585|32 53|plasma concentrations
P07905413A0585|277 281|time
P07905413A0585|132 150|segment depression
P07905413A0585|223 224|%
P07905413A0585|248 249|P
P07905413A0585|91 92|h
P07903099A0918|50 60|IVS2C beta
P07903099A0918|96 104|cleavage
P07903099A0918|73 81|terminus
P07902532A1655|1 18|Deletion analyses
P07902532A1655|98 105|BOX DNA
P07902532A1655|173 178|cells
P07902532A1655|26 35|construct
P07901125A0416|145 167|yeast Candida albicans
P07901125A0416|109 124|ARO3 homologues
P07901125A0416|31 37|degree
P07900915A0000|34 39|water
P07900915A0000|237 249|blood volume
P07900915A0000|200 216|min-1 hemorrhage
P07900915A0000|110 124|plasma protein
P07900915A0000|131 141|hemorrhage
P07900915A0000|222 233|restitution
P07900915A0000|22 26|food
P07900915A0000|93 105|blood volume
P07899581A0000|204 210|groups
P07899581A0000|19 48|Ca entry blocker nitrendipine
P07899581A0000|175 183|function
P07899581A0000|5 11|effect
P07899581A0000|212 213|n
P07899581A0000|88 91|SOD
P07898178A0849|138 161|cyclosporin maintenance
P07898178A0849|80 90|graft loss
P07898178A0849|53 65|azathioprine
P07898178A0849|22 32|graft loss
P07898178A0849|208 221|patient death
P07897359A0354|119 127|vaccinia
P07897359A0354|143 163|T7 polymerase system
P07897359A0354|40 49|F protein
P07897359A0354|79 92|HeLa T4 cells
P07896846T0000|67 74|protein
P07896846T0000|122 133|beta-myosin
P07896615A0554|119 128|skin flow
P07896615A0554|38 45|changes
P07896615A0554|5 17|contribution
P07896615A0554|132 150|laser flow Doppler
P07896615A0554|181 196|water immersion
P07896088A0720|32 36|tail
P07896088A0720|5 13|function
P07896088A0720|40 60|telomere maintenance
P07896088A0720|89 93|RAP1
P07896088A0720|224 239|telomere length
P07894359T0000|52 54|RU
P07894359T0000|12 24|hemodynamics
P07892353A0667|204 217|brain regions
P07892353A0667|39 51|correlations
P07892353A0667|112 118|cortex
P07892353A0667|57 61|rCBF
P07892353A0667|134 140|factor
P07891720A0818|84 96|calcium ions
P07891720A0818|67 80|concentration
P07891709A1542|53 63|mechanisms
P07891709A1542|124 137|deadenylation
P07891708A0690|6 9|Epo
P07891708A0690|41 46|liver
P07891708A0690|75 85|HeLa cells
P07891638T0000|57 74|chest radiographs
P07890680A1193|153 168|primer terminus
P07890680A1193|140 145|alpha
P07890680A1193|93 103|holoenzyme
P07890680A1193|10 18|addition
P07890599A0132|169 181|acid protein
P07890599A0132|234 240|rbSec1
P07890599A0132|143 147|cDNA
P07890599A0132|219 226|munc-18
P07890599A0132|242 270|Caenorhabditis elegans unc18
P07890599A0132|301 306|Sec1p
P07888828A0765|34 48|identification
P07888828A0765|79 87|primates
P07888629A0344|239 247|sequence
P07888629A0344|1 12|Translation
P07888629A0344|57 63|MsPRP2
P07888629A0344|148 163|signal sequence
P07888306A1659|1 11|Expression
P07888306A1659|278 283|WORDS
P07888306A1659|129 138|substrate
P07888306A1659|46 56|production
P07888306A1659|15 19|h6.1
P07888306A1659|187 190|CaM
P07888306A1659|23 34|COS-1 cells
P07888306A1659|147 155|activity
P07888306A1659|182 185|Ca2
P07888156A0169|87 93|Norway
P07888156A0169|115 130|section service
P07888156A0169|65 74|hospitals
P07888156A0169|219 229|discussion
P07888156A0169|198 206|findings
P07887859A0315|48 54|ulcers
P07887859A0315|59 64|tcPO2
P07887859A0315|24 32|patients
P07886610A0000|87 92|India
P07886610A0000|8 18|population
P07886610A0000|57 65|patients
P07883193A0000|49 60|amino acids
P07883193A0000|141 155|pGEX-KT vector
P07883193A0000|111 120|regulator
P07883193A0000|208 233|glutathione S-transferase
P07883167A0157|100 106|report
P07883167A0157|200 205|decay
P07883167A0157|142 158|characterization
P07883167A0157|40 50|UPF3 genes
P07883167A0157|73 86|decay pathway
P07883167A0157|15 23|products
P07880650A0493|204 228|crotoxin complex crystal
P07880650A0493|32 53|diffraction intensity
P07880650A0493|179 189|resolution
P07880650A0493|147 167|diffraction patterns
P07880442A0236|11 49|PKC beta transcription initiation site
P07878040A0505|103 107|loss
P07878040A0505|147 151|mice
P07878040A0505|26 35|sequences
P07877619A1284|71 93|zif268 gene expression
P07877619A1284|191 197|region
P07877619A1284|120 149|base pair nucleotide sequence
P07876562A1646|42 49|effects
P07876562A1646|13 20|outcome
P07876562A1646|74 88|responsiveness
P07876210A0751|118 122|gene
P07876210A0751|1 9|Mutation
P07876210A0751|203 210|protein
P07876210A0751|215 223|response
P07876210A0751|270 276|levels
P07876194T0000|50 73|growth factor receptors
P07876194T0000|99 108|sequences
P07876194T0000|27 36|targeting
P07876191A0808|71 76|liver
P07876191A0808|24 32|ADH mRNA
P07875595A0910|100 113|hybridization
P07875595A0910|115 119|FISH
P07875595A0910|143 148|genes
P07875595A0910|161 184|chicken microchromosome
P07873876A1035|170 177|cloning
P07873876A1035|5 15|NR2 hybrid
P07873876A1035|43 50|mapping
P07873876A1035|122 128|probes
P07873876A1035|30 34|tool
P07873631A0114|5 12|regions
P07872673A0332|157 178|SV40 promoter complex
P07872673A0332|58 60|Rb
P07872673A0332|27 39|relationship
P07871757A0846|17 25|sequence
P07871757A0846|86 103|promotor sequence
P07871757A0846|72 80|presence
P07871754A0857|54 63|mechanism
P07871754A0857|6 13|finding
P07871754A0857|73 92|HPV gene expression
P07871721A0000|16 29|reading frame
P07871721A0000|142 146|p223
P07871721A0000|73 79|genome
P07870305A1015|102 107|input
P07870305A1015|155 165|inhibition
P07870305A1015|203 204|P
P07870305A1015|199 201|ms
P07869913A1076|101 115|control values
P07869913A1076|8 23|ISO+AT infusion
P07867944A0365|152 161|promoters
P07867944A0365|19 44|transcription start point
P07867944A0365|54 73|nucleotide sequence
P07867944A0365|132 137|sigma
P07867604A1777|70 75|mRNAs
P07867604A1777|39 59|inhibin/activin beta
P07867604A1777|229 238|promoters
P07867604A1777|268 282|phorbol esters
P07867604A1777|134 143|promoters
P07865895A0896|97 101|rats
P07865895A0896|42 62|lung clearance assay
P07865895A0896|227 232|event
P07865895A0896|13 23|experiment
P07865895A0896|105 117|LGL/NK cells
P07865876A1292|153 162|phenotype
P07865876A1292|86 105|DP/E2F heterodimers
P07865876A1292|21 31|expression
P07865786A0457|1 16|Gene expression
P07865786A0457|39 45|rhythm
P07865786A0457|61 66|light
P07864709A0324|239 245|domain
P07864709A0324|103 113|amantadine
P07864709A0324|203 207|acid
P07864709A0324|14 25|influenza A
P07864709A0324|253 263|M2 protein
P07864709A0324|27 31|H3N2
P07864709A0324|61 70|outbreaks
P07864652A0753|68 72|E2L2
P07864652A0753|1 11|Constructs
P07864652A0753|129 136|numbers
P07864652A0753|161 180|amino acid sequence
P07864652A0753|104 108|E2L1
P07864652A0753|189 197|portions
P07864652A0753|112 114|L2
P07864652A0753|88 90|L2
P07863619A0098|19 24|shape
P07863619A0098|146 155|fragments
P07863619A0098|56 62|system
P07863619A0098|30 37|contour
P07862533A0000|187 204|growth response-1
P07862533A0000|206 211|EGR-1
P07862533A0000|39 42|WT1
P07862533A0000|213 220|protein
P07862165A0184|137 143|vector
P07862165A0184|99 108|mutations
P07862165A0184|131 135|SV40
P07862165A0184|13 29|monkey COS cells
P07862165A0184|121 126|virus
P07862154A0340|98 102|RAF1
P07862154A0340|12 27|complementation
P07862141A1412|20 26|family
P07862141A1412|96 101|genes
P07862141A1412|28 32|RFX1
P07862129A1391|141 152|target gene
P07862129A1391|123 133|expression
P07862129A1391|47 56|reduction
P07862092A0302|200 204|sdp1
P07862092A0302|284 291|vectors
P07862092A0302|115 121|sdp5-1
P07862092A0302|260 270|singlecopy
P07862092A0302|126 142|mutation pol3-11
P07862092A0302|176 191|haploid strains
P07862092A0302|209 223|pol3-11 sdp5-1
P07860208A0000|279 282|AGN
P07860208A0000|128 137|monocytes
P07860208A0000|259 277|glomerulonephritis
P07860208A0000|114 123|monocytes
P07860208A0000|22 29|release
P07860208A0000|299 307|controls
P07860208A0000|208 213|blood
P07859739T0000|1 5|Lack
P07859739T0000|47 52|cells
P07859371A1246|70 85|mouse fragments
P07859371A1246|10 17|binding
P07859238A1150|12 24|side effects
P07857762A0611|5 23|MAP kinase cascade
P07857163A0551|17 35|6-fluoroquinolones
P07857163A0551|61 72|derivatives
P07856102A1616|7 11|data
P07856102A1616|26 41|phosphorylation
P07854324A0281|76 86|expression
P07854324A0281|92 107|vertebrate wee1
P07854324A0281|27 39|conservation
P07854324A0281|164 173|mutations
P07854130A1387|5 16|requirement
P07854130A1387|132 150|twitching-motility
P07854130A1387|121 126|pilus
P07853488T0000|117 139|complementation system
P07853488T0000|159 176|P1 capsid protein
P07853488T0000|67 94|immunodeficiency virus type
P07853448A0601|69 75|nature
P07853448A0601|93 98|model
P07853448A0601|106 121|sport performer
P07852361A0868|1 8|Removal
P07852361A0868|66 84|cell cycle changes
P07852361A0868|12 16|PDMP
P07851758A0330|32 46|chromosome XVI
P07851758A0330|55 59|TPK2
P07848358A0254|3 12|reduction
P07848358A0254|78 88|mg/kg b.w.
P07846942T0001|8 20|fibrillation
P07846199A0000|32 55|sensorimotor reactivity
P07846199A0000|95 111|startle response
P07846153A0403|1 11|Chrispeels
P07844555A0406|137 142|birth
P07844555A0406|25 35|E mu pim-1
P07844555A0406|47 51|mice
P07844201T0000|19 34|albumin columns
P07844201T0000|39 44|years
P07844142A0640|39 43|cDNA
P07844142A0640|23 33|sequencing
P07844142A0640|145 151|member
P07844142A0640|133 138|SRP54
P07844142A0640|75 82|SR beta
P07841663A0685|64 69|sperm
P07841663A0685|23 26|SOD
P07841663A0685|110 120|comparison
P07841663A0685|28 36|activity
P07840643A1006|207 213|enzyme
P07840643A1006|21 56|Flavobacterium glycosylasparaginase
P07840643A1006|106 107|%
P07840643A1006|194 199|forms
P07836471A0375|36 37|%
P07836471A0375|13 29|protein sequence
P07836390A1152|49 66|cleavage reaction
P07836390A1152|202 213|conjugation
P07836390A1152|160 184|transfer DNA replication
P07836390A1152|105 116|relaxosomes
P07836228A1052|99 103|drop
P07836228A1052|121 129|pressure
P07835888A0402|81 97|mouse chromosome
P07835888A0402|144 158|backcross mice
P07835888A0402|73 77|part
P07835888A0402|44 46|Xd
P07835826A0195|1 9|Fraction
P07835826A0195|43 53|vitamin D3
P07835826A0195|29 41|2-vitamin D3
P07835826A0195|62 72|vitamin D3
P07835273A0411|51 56|level
P07835273A0411|21 31|conversion
P07835273A0411|7 16|selection
P07835273A0411|134 138|cell
P07835214A0603|49 52|GDM
P07835214A0603|72 73|%
P07835214A0603|15 26|prevalences
P07834582A0115|113 120|animals
P07834582A0115|162 174|hypertension
P07834582A0115|125 131|humans
P07832086A1023|35 45|vancomycin
P07832086A1023|71 74|IMP
P07832086A1023|96 100|MINO
P07832086A1023|79 80|%
P07832086A1023|47 50|VCM
P07832086A1023|85 94|minomycin
P07832086A1023|29 30|%
P07832086A1023|61 69|imipenam
P07831799T0000|1 20|Nucleotide sequence
P07831799T0000|80 86|Bombyx
P07831799T0000|41 49|analysis
P07830112A0532|33 36|PFR
P07830112A0532|4 12|contrast
P07830112A0532|202 203|p
P07830112A0532|133 143|PFR-to-PER
P07830112A0532|75 78|EDV
P07830112A0532|289 297|patients
P07830112A0532|252 262|mass index
P07830112A0532|27 31|rate
P07830112A0532|124 129|ratio
P07830112A0532|181 185|TPFR
P07829519A1251|33 53|polyadenylation site
P07829519A1251|6 17|utilization
P07829519A1251|106 115|mechanism
P07829519A1251|194 199|chain
P07829097A0000|20 25|DXS52
P07829097A0000|93 96|G+C
P07829097A0000|77 81|band
P07829097A0000|60 64|Xq28
P07829057A1097|5 18|marker orders
P07828824A0307|1 10|Mutations
P07828824A0307|22 50|photoreceptor cell structure
P07828600A0095|205 210|cells
P07828600A0095|1 8|Binding
P07828600A0095|23 45|stage selector element
P07828600A0095|176 197|stage erythroleukemia
P07828600A0095|47 50|SSE
P07826625X0000|236 245|threonine
P07826625X0000|7 17|components
P07826625X0000|349 354|parts
P07826625X0000|164 178|RNA polymerase
P07826625X0000|50 64|RNA polymerase
P07826625X0000|251 267|proline residues
P07826625X0000|25 48|transcription apparatus
P07826625X0000|421 444|polyglutamine stretches
P07826625X0000|148 154|domain
P07825888A0715|92 107|cortisol levels
P07825888A0715|13 22|subgroups
P07824657A1456|65 72|sulfite
P07824657A1456|14 32|cysteine formation
P07824325A0714|140 145|group
P07824325A0714|67 74|closure
P07824325A0714|128 136|patients
P07824325A0714|14 19|times
P07824325A0714|152 177|vancomycin concentrations
P07824325A0714|294 306|micrograms/g
P07824325A0714|211 214|MIC
P07823953A0777|138 144|region
P07823953A0777|200 207|binding
P07823953A0777|403 414|interaction
P07823953A0777|437 443|region
P07823953A0777|85 109|I kappa B alpha molecule
P07823953A0777|20 43|I kappa B alpha mutants
P07823953A0777|485 493|subunits
P07823953A0777|298 304|region
P07823953A0777|148 163|I kappa B alpha
P07823919A1422|102 110|COUP-TFI
P07823919A1422|118 123|ARP-1
P07823919A1422|96 101|EAR-3
P07823919A1422|47 50|RAR
P07822329A0773|119 125|factor
P07822329A0773|5 12|complex
P07822329A0773|63 68|cells
P07821790A1084|137 151|transactivator
P07821790A1084|202 224|co-transfection assays
P07821790A1084|104 109|UCRBP
P07821790A1084|15 20|UCRBP
P07819225A1094|223 231|ABSTRACT
P07819225A1094|53 57|site
P07819225A1094|76 87|suppression
P07819225A1094|198 221|tetracycline resistance
P07819225A1094|132 139|Gln-220
P07819225A1094|120 127|Lys-220
P07816808A1102|154 164|Arthropoda
P07816808A1102|142 146|rise
P07816808A1102|88 96|ancestor
P07816808A1102|47 52|genes
P07816619A0872|223 226|Dr1
P07816619A0872|110 117|protein
P07816619A0872|162 171|mechanism
P07816619A0872|47 54|protein
P07816617A0763|64 69|genes
P07816617A0763|28 32|HAC1
P07816049A0686|170 172|kb
P07816049A0686|252 265|transcription
P07816049A0686|222 232|initiation
P07816049A0686|9 15|Athyp1
P07816049A0686|123 130|regions
P07815811A1487b|119 133|concentrations
P07815811A1487b|65 85|ischemia-reperfusion
P07815811A1487b|93 107|norepinephrine
P07814717A0669|85 92|changes
P07814717A0669|49 52|fat
P07814717A0669|96 110|concentrations
P07814717A0669|58 76|AA supplementation
P07814717A0669|121 124|Met
P07814323A0313|1 10|Inclusion
P07814323A0313|116 134|flagellum assembly
P07814323A0313|29 37|proteins
P07814323A0313|61 65|FliR
P07813786A0641|13 18|cDNAs
P07812450A0849|71 80|nspC gene
P07812450A0849|14 17|ORF
P07811639A0222|115 119|gene
P07811639A0222|77 90|stage embryos
P07811639A0222|148 159|archenteron
P07809128T0000|27 36|E2F1 gene
P07807002A0500|114 138|luciferase reporter gene
P07807002A0500|25 28|DNA
P07807002A0500|13 21|segments
P07807002A0500|164 182|mouse B cell lines
P07806651A0097|137 143|MMPI-2
P07806651A0097|6 11|study
P07806651A0097|110 111|L
P07806651A0097|29 35|degree
P07806651A0097|120 129|MF scales
P07806507A0121|231 249|activation cascade
P07806507A0121|40 55|CD3-TCR complex
P07806507A0121|11 21|dissection
P07806507A0121|164 181|recognition event
P07803809A1852|49 57|increase
P07803809A1852|9 16|studies
P07803809A1852|104 139|tyrosine kinase inhibitor genistein
P07802355T0000|84 93|analyzers
P07802355T0000|95 107|Coulter STKS
P07802355T0000|13 18|study
P07800505T0000|51 54|kDa
P07800505T0000|65 86|phospholipase A2 gene
P07799950A0282|4 11|studies
P07799950A0282|54 59|cells
P07799950A0282|146 153|element
P07799950A0282|167 171|CREB
P07799939A0628|53 84|serine/threonine phosphoprotein
P07799939A0628|13 20|element
P07799931A0287|102 112|mechanisms
P07799931A0287|76 92|L7 gene insights
P07799931A0287|61 68|control
P07799437A0656|96 104|labeling
P07799437A0656|108 124|control plasmids
P07798217T0095|3 7|role
P07798217T0095|46 53|control
P07798207A0759|171 195|Paracoccus denitrificans
P07798207A0759|233 234|%
P07798207A0759|162 165|rat
P07798207A0759|130 138|subunits
P07798207A0759|13 33|amino acid sequences
P07797583A0222|304 312|activity
P07797583A0222|230 237|effects
P07797583A0222|256 260|DREF
P07797583A0222|83 86|DRE
P07797583A0222|126 133|respect
P07797583A0222|366 371|flies
P07797583A0222|245 252|binding
P07797346T0000|16 27|hepatitis A
P07797346T0000|52 61|Amsterdam
P07796935A0284|98 107|hTR alpha
P07796935A0284|110 117|mutants
P07796935A0284|192 197|hPPAR
P07796935A0284|257 259|DR
P07796935A0284|148 158|peroxisome
P07796935A0284|28 34|effect
P07796935A0284|241 245|TREs
P07795104T0000|1 6|Risks
P07795104T0000|10 20|chronicity
P07793783A0189|100 124|scalp flap transposition
P07793783A0189|41 46|point
P07793783A0189|134 141|closure
P07791776T0000|1 17|Characterization
P07791776T0000|105 116|conjugation
P07791769A0826|153 161|TATA box
P07791769A0826|163 165|C.
P07791769A0826|111 114|DNA
P07791769A0826|73 77|TATA
P07791764A0357|49 52|Cbl
P07791764A0357|97 117|adapter protein Grb2
P07791760A0424|103 116|MAPK activity
P07791760A0424|82 86|MAPK
P07791760A0424|145 165|complex kinase assay
P07790377A0561|1 11|Antibodies
P07790377A0561|64 70|monkey
P07790377A0561|72 75|rat
P07789971A0758|33 46|hybridization
P07789971A0758|22 29|regions
P07789971A0758|245 250|GSTT2
P07789971A0758|165 171|genome
P07789396A0504|1 9|Lipiodol
P07789275A0325|101 127|loss-of-function mutations
P07789275A0325|24 25|s
P07789275A0325|30 33|E74
P07786821A2292|17 20|MTD
P07786821A2292|100 118|patient population
P07786821A2292|25 31|CPT-11
P07784942T0001|37 46|knowledge
P07784942T0001|13 27|thrombomodulin
P07784199A0000|24 26|rp
P07784199A0000|146 166|gene regulator Rap1p
P07784199A0000|182 186|site
P07784199A0000|15 22|protein
P07784079A1018|138 155|expression vector
P07784079A1018|52 64|NIH3T3 cells
P07784079A1018|196 204|presence
P07784079A1018|130 134|form
P07784079A1018|105 113|activity
P07784061A0894|110 115|cells
P07784061A0894|125 138|kb transcript
P07783641A0591|42 52|data-bases
P07782775A0889|103 120|BBTV coat protein
P07782775A0889|22 32|components
P07782775A0889|61 69|proteins
P07782113A0726|86 98|blood levels
P07782113A0726|52 59|studies
P07780738A0091|129 144|DNA replication
P07780738A0091|12 16|Cdks
P07780738A0091|104 111|antigen
P07780738A0091|31 39|S phases
P07780525A0495|1 10|Schooling
P07780525A0495|42 48|health
P07779812A0000|49 60|tumor types
P07779812A0000|38 45|variety
P07779812A0000|127 133|number
P07779558T0000|50 58|training
P07779558T0000|64 88|selenium supplementation
P07776979A0702|35 41|effect
P07776979A0702|63 85|reporter gene activity
P07776711A0295|119 134|neuropathy type
P07776711A0295|69 74|years
P07776711A0295|101 106|motor
P07776711A0295|78 81|age
P07776711A0295|14 21|METHODS
P07775428A0172|23 28|Ash-m
P07775428A0172|77 87|Ash-l cDNA
P07775428A0172|15 21|clones
P07774807A0405|84 89|genes
P07774807A0405|54 64|activators
P07772036A1000|51 59|USF/MLTF
P07772036A1000|6 12|region
P07772036A1000|120 127|CTF/NF1
P07768953T0039|84 91|fingers
P07768953T0039|127 135|IQ motif
P07768953T0039|74 82|cysteine
P07768848A1880|35 40|sizes
P07768848A1880|136 147|cotJ operon
P07768848A1880|199 205|layers
P07768848A1880|213 217|coat
P07768848A1880|57 63|spores
P07768848A1880|265 269|coat
P07768824A0167|157 165|proteins
P07768824A0167|5 11|timing
P07768824A0167|42 52|cell cycle
P07768824A0167|91 105|RNA polymerase
P07766885A0405|171 177|domain
P07766885A0405|101 107|kinase
P07766885A0405|66 74|features
P07766885A0405|14 31|polypeptide chain
P07763727A1035|18 24|pAMS13
P07763727A1035|29 35|pAMS14
P07763727A1035|60 77|laboratory strain
P07762431A0356|84 90|yields
P07762431A0356|39 43|cDNA
P07762431A0356|110 115|litre
P07761434A1084|69 77|findings
P07761434A1084|7 11|AP-1
P07761434A1084|28 36|mediator
P07761216T0000|41 51|candidemia
P07760844A0413|84 89|c-jun
P07760844A0413|94 105|c-fos genes
P07760844A0413|14 30|AP-1 DNA binding
P07760841A0221|1 5|UAS1
P07760790A0327|103 129|MEF2 site binding activity
P07760790A0327|71 84|NIH 3T3 cells
P07760790A0327|63 67|line
P07759525A0417|140 148|isoforms
P07759525A0417|67 88|protein kinase domain
P07759525A0417|124 137|casein kinase
P07758837A1118|136 143|exon 1B
P07758837A1118|99 110|observation
P07758837A1118|281 285|exon
P07758837A1118|46 52|region
P07758837A1118|14 24|complexity
P07758246A0469|34 37|bps
P07758246A0469|5 12|protein
P07758246A0469|61 67|intron
P07757315A1227|17 28|aggregation
P07757315A1227|52 59|% value
P07757315A1227|125 143|observation period
P07757315A1227|62 63|h
P07755884A0000|128 149|sensorimotor deficits
P07755884A0000|195 210|dopamine system
P07755884A0000|15 21|grafts
P07753837A0724|38 48|desmoglein
P07753837A0724|6 9|RNA
P07753837A0724|126 138|accumulation
P07753796A0625|69 78|sequences
P07753796A0625|111 137|liver eIF-2B alpha subunit
P07753796A0625|15 34|amino acid sequence
P07753027A0240|72 79|strands
P07752644A1031|84 101|plasma drug level
P07752644A1031|7 9|VF
P07752223A0960|5 11|Myc LZ
P07752223A0960|45 57|interactions
P07750217T0000|32 40|F-18 FDG
P07749461A0632|87 93|region
P07749461A0632|25 31|region
P07749461A0632|133 146|sGTH alpha-G1
P07749461A0632|44 46|kb
P07748952A1329|35 39|miaA
P07748952A1329|7 14|results
P07748952A1329|123 138|cotranscription
P07748952A1329|209 225|RNase E activity
P07748952A1329|91 101|mechanisms
P07748848A0263|5 9|term
P07748493A1045|187 192|gland
P07748493A1045|117 124|hormone
P07748493A1045|80 84|role
P07748493A1045|92 102|processing
P07748493A1045|167 172|cells
P07747462A0332|87 93|motifs
P07747462A0332|173 187|tyrosine motif
P07747462A0332|37 51|RCR initiators
P07746794A0000|102 112|castor oil
P07746794A0000|114 126|Cremophor EL
P07746794A0000|43 54|formulation
P07745726A1496|51 61|palindrome
P07745726A1496|200 209|half site
P07745726A1496|82 113|nucleotide sequence information
P07745696A0932|1 29|Restriction mapping analysis
P07745696A0932|64 69|U1102
P07745696A0932|57 63|HHV-6A
P07745696A0932|79 95|BamHI G fragment
P07745696A0932|133 140|segment
P07745696A0932|45 49|cDNA
P07745685A1442|16 23|virions
P07745685A1442|132 134|SN
P07745685A1442|74 84|antibodies
P07745311A0264|54 62|findings
P07744954A0418|98 110|COOH termini
P07744954A0418|52 59|portion
P07744954A0418|192 197|stalk
P07744954A0418|120 127|epitope
P07744776A0617|1 20|Transcript analysis
P07744776A0617|41 62|B block substitutions
P07743697A0703|1 5|Data
P07743697A0703|260 279|vasodilator therapy
P07743697A0703|78 99|plasma norepinephrine
P07743697A0703|285 317|hydralazine/isosorbide dinitrate
P07743697A0703|121 135|treatment arms
P07743697A0703|15 21|V-HeFT
P07743472A0181|71 100|Roswell Park Cancer Institute
P07743472A0181|22 35|breast cancer
P07743472A0181|8 16|patients
P07743472A0181|211 220|diagnosis
P07743472A0181|120 128|New York
P07742550A0407|200 203|TFL
P07742550A0407|317 321|SNCL
P07742550A0407|155 164|lymphomas
P07742550A0407|248 269|mantle cell lymphomas
P07742550A0407|271 274|MCL
P07742550A0407|61 64|DAL
P07742363A0135|98 107|inhibitor
P07742363A0135|143 156|alpha subunit
P07742363A0135|199 210|nucleotides
P07742363A0135|109 112|dsI
P07742363A0135|44 53|repressor
P07742363A0135|15 22|enzymes
P07741255A0194|11 20|districts
P07741255A0194|44 47|km2
P07740487A0167|200 210|Fibrinogen
P07740487A0167|163 172|framework
P07740487A0167|115 125|affections
P07740487A0167|218 239|International Society
P07740487A0167|146 151|study
P07740487A0167|91 95|data
P07739544A0364|136 142|domain
P07739544A0364|42 59|SGC1 gene product
P07739544A0364|95 105|similarity
P07739544A0364|15 34|amino acid sequence
P07739520A1250|81 90|proximity
P07739520A1250|114 120|Surf-3
P07739520A1250|22 29|members
P07738026A0216|68 73|forms
P07738026A0216|14 19|mouse
P07737508A0649|103 107|gene
P07737508A0649|56 63|tRNAGln
P07737508A0649|44 54|tRNA genes
P07737024A1003|84 89|drugs
P07737024A1003|7 23|bowel irrigation
P07737024A1003|73 80|passage
P07735590A0990|5 18|concentration
P07735590A0990|213 218|homes
P07735590A0990|95 105|house dust
P07735590A0990|124 136|cat allergen
P07735590A0990|149 154|homes
P07735590A0990|60 70|micrograms
P07731898A0823|253 272|catalase activities
P07731898A0823|81 95|concentrations
P07731898A0823|173 177|ions
P07731898A0823|231 248|erythrocyte SOD-1
P07731898A0823|10 17|studies
P07730795A0104|80 87|species
P07730795A0104|113 120|regions
P07730795A0104|47 55|subunits
P07730337A1439|86 97|development
P07730337A1439|73 78|brain
P07730328A0000|116 120|cell
P07730328A0000|67 77|activation
P07730328A0000|88 98|expression
P07730328A0000|45 52|changes
P07729427A0942|34 37|TBP
P07729427A0942|1 18|Deletion analysis
P07729427A0942|159 167|hTAFII28
P07729427A0942|79 87|hTAFII28
P07723247A1161|49 55|IL-1Ra
P07723247A1161|10 25|hour incubation
P07721878A1163|152 176|Fc epsilon R1 beta chain
P07721878A1163|84 87|p33
P07721878A1163|101 108|protein
P07721878A1163|25 38|Fc epsilon R1
P07721074A0766|137 149|multiplicity
P07721074A0766|37 43|rashes
P07721074A0766|163 178|trigger factors
P07721074A0766|92 117|patient treatment program
P07720709A0755|139 157|cell proliferation
P07720709A0755|228 247|AP1 transrepression
P07720709A0755|26 35|3T3 cells
P07720709A0755|73 75|RA
P07720572A0701|117 125|sequence
P07720572A0701|141 149|position
P07720572A0701|39 52|myoD enhancer
P07720572A0701|89 95|humans
P07717823A0328|1 27|Standard reference sources
P07717823A0328|89 95|height
P07717823A0328|122 129|support
P07715602A1088|22 40|gene cluster codes
P07714758A1193|51 58|mg kg-1
P07714758A1193|38 47|lidocaine
P07713936A0393|1 8|Binding
P07713936A0393|111 124|transcription
P07713936A0393|12 17|meAda
P07713936A0393|165 170|meAda
P07713421A1435a|80 87|ability
P07713421A1435a|26 50|gain-of-function mutants
P07711667A0766|372 385|airflow rooms
P07711667A0766|140 151|FAB subtype
P07711667A0766|111 121|percentage
P07711667A0766|345 360|decontamination
P07711667A0766|45 52|relapse
P07711667A0766|16 24|analysis
P07711667A0766|157 163|number
P07711667A0766|297 300|sex
P07711667A0766|208 217|remission
P07711667A0766|28 40|risk factors
P07711667A0766|302 326|GVHD prophylaxis regimen
P07708488A0151|21 28|results
P07708488A0151|67 83|sequence variant
P07707544T0000|17 30|transcription
P07707544T0000|110 121|transcripts
P07707523A0704|33 53|NF-kappa B inhibitor
P07707523A0704|96 104|activity
P07707523A0704|108 111|LMP
P07706307A0914|102 104|S.
P07706307A0914|5 24|amino acid sequence
P07706307A0914|126 127|B
P07706307A0914|47 53|region
P07706291T0000|38 48|expression
P07706291T0000|80 89|homologue
P07706291T0000|56 66|ad4bp gene
P07706273T0000|17 27|regulation
P07706273T0000|91 102|THP-1 cells
P07705476A0292|103 115|urine volume
P07705476A0292|86 98|water intake
P07705476A0292|13 24|food intake
P07704273A0000|205 219|plasmid pNU305
P07704273A0000|64 75|strain HfrH
P07704273A0000|172 192|Citrobacter freundii
P07704273A0000|31 60|ampD ampE deletion derivative
P07702808A0427|16 30|BP differences
P07702808A0427|39 47|fish oil
P07702808A0427|88 95|Dinamap
P07702378A0668|49 59|dermatitis
P07702378A0668|89 92|VO2
P07701266A0808|1 8|RESULTS
P07701266A0808|139 143|days
P07701266A0808|57 60|TPN
P07701266A0808|26 34|fistulas
P07699845A0537|201 210|pneumonia
P07699845A0537|470 474|days
P07699845A0537|130 141|tonsillitis
P07699845A0537|104 115|pharyngitis
P07699845A0537|425 430|doses
P07699845A0537|48 56|patients
P07699845A0537|322 337|balanoposthitis
P07699845A0537|297 313|tract infections
P07699845A0537|215 224|pertussis
P07699845A0537|388 396|vulvitis
P07699845A0537|241 246|fever
P07699632A0522|17 29|race persons
P07699632A0522|90 99|arthritis
P07698219A0551|1 14|Cell adhesion
P07698219A0551|81 97|laminin receptor
P07698219A0551|149 157|PE cells
P07696878A0222|5 20|leader sequence
P07696878A0222|37 47|cDNA clone
P07696878A0222|76 90|reading frames
P07696183A0567|103 106|Rak
P07696183A0567|432 442|SH2 domain
P07696183A0567|76 83|kinases
P07696183A0567|40 43|Rak
P07696183A0567|496 502|p54rak
P07696183A0567|405 424|localization signal
P07696183A0567|532 539|nucleus
P07696183A0567|291 298|glycine
P07696183A0567|26 36|properties
P07696183A0567|89 99|expression
P07696183A0567|362 365|Rak
P07693975T0000|115 120|cells
P07693975T0000|27 46|protease activities
P07693967A0905|21 23|RV
P07693967A0905|67 73|effect
P07693967A0905|29 40|SL sequence
P07693699A0831|31 58|nucleotide binding function
P07693699A0831|120 124|urea
P07693372A0115|84 90|action
P07693372A0115|6 11|agent
P07693372A0115|31 37|fungus
P07692754T0000|55 82|hepatitis C virus infection
P07692754T0000|95 107|blood donors
P07692366A0000|139 147|features
P07692366A0000|109 120|correlation
P07692366A0000|13 24|Delineation
P07692366A0000|75 87|degeneration
P07691837A1359|37 52|K3 keratin gene
P07691837A1359|229 235|GC box
P07691837A1359|109 117|promoter
P07691837A1359|132 140|clusters
P07689154A0168|238 245|protein
P07689154A0168|192 200|uPA mRNA
P07689154A0168|154 163|pp60v-src
P07689154A0168|217 220|AMP
P07689154A0168|264 270|agents
P07689154A0168|300 315|uPA mRNA levels
P07689154A0168|60 79|uPA gene expression
P07687745T0000|23 28|FK506
P07687541A0200|50 63|fission yeast
P07687541A0200|143 158|mtr1/prp20/srm1
P07687541A0200|196 199|RNA
P07687541A0200|160 167|mutants
P07686619A0704|1 5|Chem
P07685823A1234|32 42|A promoter
P07685823A1234|67 85|base-pair sequence
P07685823A1234|91 96|DNase
P07683375A0000|35 49|growth factors
P07683375A0000|70 79|estradiol
P07683375A0000|164 166|ER
P07683375A0000|81 83|E2
P07683375A0000|188 195|studies
P07683375A0000|145 162|estrogen receptor
P07683375A0000|88 98|regulation
P07682842A0771|69 73|exon
P07682842A0771|53 61|sequence
P07682842A0771|11 15|exon
P07681539A0000|118 121|mSv
P07681539A0000|97 106|radiation
P07681539A0000|88 93|doses
P07681147A1420|137 144|ability
P07681147A1420|32 40|analyses
P07681147A1420|202 212|signalling
P07681147A1420|108 113|cells
P07680120A1008|1 7|RT-PCR
P07680120A1008|65 73|prostate
P07680120A1008|27 34|primers
P07680120A1008|149 155|source
P07680120A1008|121 126|brain
P07679836A0387|65 70|agent
P07679836A0387|28 30|FK
P07678695A0604|115 125|activation
P07678695A0604|27 32|Oct-3
P07678695A0604|13 23|expression
P07678593A0708|17 22|clone
P07678593A0708|52 55|DNA
P07678051A1303|103 113|production
P07678051A1303|49 58|PLC gamma
P07678006A0472|1 26|RNase protection analyses
P07678006A0472|55 67|CaM PDE mRNA
P07678006A0472|123 139|CaM PDE isoforms
P07677715A1076|58 61|OCD
P07676655A0214|38 46|dialysis
P07676655A0214|83 89|mmol/l
P07676655A0214|94 95|D
P07676492A1000|117 121|risk
P07676492A1000|83 104|transplant recipients
P07676492A1000|22 32|comparison
P07675445A0463|116 120|SSLP
P07675445A0463|66 75|n repeats
P07675445A0463|43 49|domain
P07675445A0463|61 62|p
P07673178A0982|5 12|results
P07673178A0982|212 219|factors
P07673178A0982|121 144|MDF/bH-L-H heterodimers
P07673128A0989|26 31|motif
P07673128A0989|60 63|CRE
P07672821A0763|98 109|relatedness
P07672821A0763|113 132|complement factor H
P07672821A0763|77 85|evidence
P07672821A0763|14 21|linkage
P07670504A0834|48 63|banding pattern
P07670504A0834|67 72|plant
P07670504A0834|180 183|GBF
P07667621T0001|1 27|Doppler ultrasound studies
P07667621T0001|41 50|follow-up
P07667097A0267|156 159|RNA
P07667097A0267|5 16|association
P07667097A0267|111 119|splicing
P07667097A0267|164 181|splicing products
P07666538A0000|1 11|Initiation
P07666538A0000|64 74|RNA genome
P07666538A0000|131 137|region
P07666538A0000|94 108|ribosome entry
P07666538A0000|15 26|translation
P07666415A0000|32 43|chloroplast
P07666415A0000|5 24|nucleotide sequence
P07666415A0000|45 47|cp
P07665948A0591|118 124|adults
P07665948A0591|156 165|infection
P07665948A0591|52 63|individuals
P07665948A0591|26 32|values
P07665605A1127|92 101|DD dimers
P07665477A0901|1 5|EsaR
P07665477A0901|67 77|expression
P07665187A0208|1 17|Primer extension
P07665187A0208|22 34|cDNA cloning
P07664278A0135|1 3|A.
P07663963A1588|144 156|cohabitation
P07663963A1588|208 223|control animals
P07663963A1588|12 29|system activation
P07663963A1588|91 95|time
P07663138A0835|16 26|heart rate
P07663138A0835|7 14|nadolol
P07663138A0835|47 48|%
P07659757A0191|50 59|gamma-32P
P07659757A0191|127 146|autophosphorylation
P07659757A0191|28 43|fusion proteins
P07659529A0135|96 126|transcription control elements
P07659529A0135|146 152|region
P07659529A0135|166 175|EpoR gene
P07659085A1520|16 58|transcription factor Oct-1 forms complexes
P07659085A1520|96 100|FPIV
P07659085A1520|196 207|partnership
P07659085A1520|128 133|liver
P07659085A1520|104 122|gel shift analysis
P07658471A0000|5 24|plant hormone auxin
P07657705A1181|64 68|HSPG
P07657705A1181|29 39|K-glypican
P07657162A1412|86 93|process
P07657162A1412|148 156|addition
P07657162A1412|121 144|trans-activation domain
P07655509T0000|115 118|pea
P07655509T0000|25 38|motif signals
P07655509T0000|120 133|Pisum sativum
P07655184A0852|175 186|ER sequence
P07655184A0852|52 73|transmembrane protein
P07654712A0774|171 173|pH
P07654712A0774|157 166|degrees C
P07654712A0774|142 150|analysis
P07653892A0306|49 54|birds
P07653892A0306|140 141|n
P07653892A0306|37 47|triplicate
P07653892A0306|78 85|agonist
P07653094A0169|275 279|CV-1
P07653094A0169|237 251|plasmid vector
P07653094A0169|71 74|d44
P07653094A0169|202 212|expression
P07653094A0169|13 18|amino
P07653094A0169|51 54|d20
P07653094A0169|223 228|genes
P07653094A0169|80 83|d73
P07653094A0169|176 186|attributes
P07653094A0169|28 44|deletion mutants
P07652575A0435|50 55|forms
P07652575A0435|67 72|Cdc42
P07652575A0435|14 28|microinjection
P07651835A0652|48 54|motifs
P07651424A0743|152 162|Ssm1p pool
P07651424A0743|21 38|SSM1b transcripts
P07651424A0743|63 68|level
P07651424A0743|14 19|cells
P07651400A0335|56 60|exon
P07651400A0335|135 153|consensus sequence
P07651398A0803|64 72|Tyr-1228
P07651398A0803|13 25|binding site
P07651386A0925|35 48|p53 induction
P07651386A0925|80 90|adenovirus
P07651141A0265|8 16|terminus
P07651141A0265|24 37|p-gvpF-M mRNA
P07650958A0123|139 149|indicators
P07650958A0123|54 70|electromyography
P07650958A0123|89 106|motor improvement
P07648338A0815|83 100|cytokine profiles
P07648338A0815|59 67|ischemia
P07648338A0815|149 168|SMA occlusion model
P07647303T0000|102 109|flowers
P07647303T0000|86 94|seedling
P07647303T0000|5 23|homeobox gene ATK1
P07647303T0000|27 47|Arabidopsis thaliana
P07644503A0729|33 41|RAR beta
P07644503A0729|124 134|activation
P07644503A0729|63 78|differentiation
P07644127A0000|33 41|neurones
P07644127A0000|279 300|acetylcholine agonist
P07644127A0000|167 178|stimulation
P07644127A0000|186 211|rat substantia innominata
P07644127A0000|263 270|effects
P07644127A0000|320 329|glutamate
P07644127A0000|94 100|fibres
P07642544A0868|82 87|cells
P07642544A0868|146 165|NF-kappa B activity
P07642544A0868|121 125|loss
P07642538A0138|70 74|RSK3
P07642538A0138|236 242|mutant
P07642538A0138|203 208|C-Lys
P07642538A0138|196 201|K444A
P07642538A0138|435 442|residue
P07642538A0138|288 293|C-Thr
P07642538A0138|357 361|VIII
P07642538A0138|187 193|mutant
P07642538A0138|295 301|mutant
P07642538A0138|245 252|N/C-Lys
P07642538A0138|149 153|K91A
P07640422A0649|136 148|hemodialysis
P07640422A0649|154 161|heparin
P07640422A0649|98 105|heparin
P07640422A0649|173 181|Wilcoxon
P07640422A0649|111 123|hemodialysis
P07639703A1703|169 195|islet cell differentiation
P07639703A1703|22 37|thyroid hormone
P07639703A1703|13 17|acid
P07638517A0000|102 126|individuals AIDS victims
P07638517A0000|65 86|Sao Paulo City Morgue
P07638517A0000|6 9|May
P07638517A0000|90 98|cadavers
P07636984A1349|63 71|extracts
P07636984A1349|30 34|role
P07636962A1288|36 47|determinant
P07636408T0000|34 54|Tesla field strength
P07636408T0000|19 24|Tesla
P07636408T0000|108 118|evaluation
P07636187A0585|21 44|protein expression data
P07636187A0585|57 73|gene transcripts
P07636187A0585|46 52|V beta
P07635572A1153|1 11|CIITA mRNA
P07635572A1153|138 144|effect
P07635572A1153|128 130|RB
P07635572A1153|148 175|CIITA mRNA induction levels
P07635140A0172|49 54|CYP19
P07635140A0172|5 15|expression
P07635140A0172|41 47|enzyme
P07635140A0172|73 77|part
P07633444T0000|69 96|mouse WD-repeat gene DMR-N9
P07633444T0000|12 24|organization
P07630934A0343|1 6|Harel
P07629196A0274|153 156|Jun
P07629196A0274|55 62|mutants
P07629196A0274|197 205|JNK/SAPK
P07629196A0274|24 34|expression
P07629196A0274|135 145|activation
P07629196A0274|181 195|protein kinase
P07629150A0155|205 213|elements
P07629150A0155|102 109|hormone
P07629150A0155|19 31|CYP11A1 gene
P07629150A0155|173 181|promoter
P07629150A0155|127 133|number
P07629122A0323|82 87|NIM-1
P07629122A0323|12 20|analysis
P07629122A0323|45 66|phosphorylation sites
P07629103T0000|50 55|delta
P07629103T0000|24 45|protein isoforms beta
P07628451A0114|19 21|RA
P07628451A0114|128 136|F9 cells
P07628451A0114|109 124|differentiation
P07628451A0114|26 29|E1A
P07628389A0145|95 118|testosterone production
P07628389A0145|60 68|cytokine
P07626806A1098|84 92|proteins
P07626806A1098|37 49|acid protein
P07626378T0000|1 20|Hepatitis B vaccine
P07624581A0312|305 308|T45
P07624581A0312|5 13|subjects
P07624581A0312|232 239|therapy
P07624581A0312|104 119|thyroid hormone
P07624581A0312|255 269|treatment days
P07624581A0312|291 303|days washout
P07624581A0312|126 133|glucose
P07624581A0312|271 274|T30
P07624581A0312|241 243|T0
P07623844A0639|17 22|Bcl-2
P07623844A0639|190 198|presence
P07623844A0639|125 135|expression
P07623844A0639|72 81|apoptosis
P07623844A0639|31 47|E1B 19K proteins
P07623838A1112|1 3|D.
P07623821T0000|52 63|combination
P07623821T0000|111 126|enhancer factor
P07623814A1040|51 69|estrogen receptors
P07623814A1040|16 30|cotransfection
P07623814A1040|156 167|ER activity
P07623814A1040|4 14|CV-1 cells
P07623814A1040|110 118|activity
P07622932T0000|40 47|leprosy
P07622060A0967|24 29|cells
P07620491T0000|1 10|Resources
P07620491T0000|40 47|smoking
P07618280A0550|63 94|density gradient centrifugation
P07616569A0168|205 209|atp9
P07616569A0168|100 103|cob
P07616569A0168|234 238|rrn5
P07616569A0168|128 154|NADH dehydrogenase complex
P07616569A0168|315 320|rpl16
P07616569A0168|167 172|nad4L
P07616569A0168|51 69|cytochrome oxidase
P07616569A0168|292 296|rps3
P07616569A0168|248 251|lrn
P07616569A0168|112 120|subunits
P07616569A0168|298 303|rps11
P07616056A0278|51 70|feedback inhibition
P07616056A0278|6 8|mu
P07616056A0278|13 21|gamma 2b
P07615541T0000|12 20|analysis
P07615541T0000|60 102|mouse porphobilinogen deaminase gene locus
P07612557A0635|50 59|pathology
P07612557A0635|72 77|pairs
P07610735A1471|58 66|response
P07610735A1471|75 85|conversion
P07610324A0319|203 210|centers
P07610324A0319|109 114|years
P07609372A0261|103 108|cases
P07609372A0261|49 60|HR patients
P07609372A0261|39 44|cases
P07609372A0261|129 140|LR patients
P07609372A0261|89 96|minutes
P07609037A0775|186 199|MMTV promoter
P07609037A0775|153 166|transcription
P07609037A0775|115 133|DNA affinity resin
P07609037A0775|82 91|antiserum
P07609037A0775|245 253|promoter
P07608649A1429|33 46|CyA treatment
P07608649A1429|11 25|blood pressure
P07607669A1112|33 35|GC
P07607669A1112|92 105|binding sites
P07607537A0954|17 27|phenotypes
P07607537A0954|117 139|VP16 activation domain
P07607537A0954|5 13|spectrum
P07607233A0186|119 138|nucleotide sequence
P07607233A0186|97 99|K7
P07607197A1048|100 108|controls
P07607197A1048|7 28|plasma renin activity
P07607197A1048|30 33|PRA
P07606548T0000|23 42|board certification
P07604794A0958|85 91|mg/day
P07604794A0958|101 105|week
P07604794A0958|39 43|week
P07604794A0958|7 18|cholesterol
P07604794A0958|76 77|%
P07604794A0958|60 66|mg/day
P07604047A0704|291 295|GA19
P07604047A0704|200 210|capability
P07604047A0704|158 168|cDNA clone
P07604047A0704|142 150|identity
P07604047A0704|108 132|transcription-PCR method
P07604047A0704|44 46|GA
P07603726T0000|37 45|recovery
P07603726T0000|74 91|neuroma resection
P07601827A0778|98 108|repression
P07601827A0778|10 22|lacZ fusions
P07601121A0153|118 123|start
P07601121A0153|86 92|region
P07601121A0153|178 187|sequences
P07600986A0605|117 122|sites
P07600986A0605|13 33|immunoprecipitations
P07600986A0605|164 183|transcription units
P07599653A0898|103 112|agreement
P07599653A0898|23 34|differences
P07599653A0898|93 98|roots
P07599653A0898|132 142|activities
P07599653A0898|74 80|shoots
P07598303A1728|68 95|bone marrow transplantation
P07598303A1728|53 64|prophylaxis
P07597804A1007|35 37|kb
P07597804A1007|5 16|transcripts
P07597030A0260|20 27|cloning
P07597030A0260|109 114|TFIID
P07597030A0260|106 107|h
P07597030A0260|88 95|subunit
P07596558A0824|50 59|IL-1 beta
P07596558A0824|7 14|results
P07596287A0183|85 89|ORF5
P07596287A0183|114 130|protein products
P07596287A0183|189 225|cassette membrane transport proteins
P07596287A0183|280 294|export systems
P07596287A0183|46 50|fimA
P07596287A0183|269 275|uptake
P07595857A0521|5 20|peak velocities
P07595857A0521|436 444|patients
P07595857A0521|107 108|A
P07595857A0521|393 406|cardioversion
P07595857A0521|458 472|cardiomyopathy
P07595857A0521|157 161|PVS1
P07595857A0521|189 198|durations
P07595857A0521|266 272|motion
P07595857A0521|57 68|transmitral
P07595857A0521|90 105|flow velocities
P07595221A0733|114 123|MHC class
P07595221A0733|127 136|promoters
P07595221A0733|73 78|genes
P07595221A0733|151 163|transfection
P07594047T0000|84 95|arrhythmias
P07594047T0000|138 149|QT syndrome
P07594047T0000|12 21|verapamil
P07594047T0000|47 67|afterdepolarizations
P07593266A1174|55 61|region
P07592946A0261|99 103|gene
P07592946A0261|42 56|p44 MAP kinase
P07592946A0261|130 152|intron/exon boundaries
P07592946A0261|89 95|kinase
P07592771A0258|5 15|mouse beta
P07592771A0258|67 72|exons
P07592771A0258|124 132|position
P07592771A0258|29 33|gene
P07592723A0814|1 15|Phorbol esters
P07592723A0814|157 171|PKC substrates
P07592723A0814|46 62|CSK 35H proteins
P07592711T0000|55 64|lethality
P07592711T0000|11 16|forms
P07592706A1465|85 97|lipase ratio
P07592706A1465|1 9|Exchange
P07592706A1465|139 145|region
P07592706A1465|126 130|role
P07592658A0309|33 40|complex
P07592647A0797|70 79|complexes
P07592467A0000|18 42|peroxisome proliferation
P07592337A0891|64 74|expression
P07592337A0891|78 82|nfxB
P07592072A0217|137 146|injection
P07592072A0217|4 9|Trial
P07592072A0217|58 59|d
P07592072A0217|40 46|farrow
P07592072A0217|105 111|farrow
P07590657A0624|116 124|patients
P07590657A0624|72 78|system
P07590283A0820|5 12|finding
P07590283A0820|337 342|Kumar
P07590283A0820|128 130|aa
P07590283A0820|164 184|template utilization
P07590283A0820|327 335|activity
P07590283A0820|294 302|Pol beta
P07590283A0820|31 34|TdT
P07590268A0350|65 76|polypeptide
P07590268A0350|133 142|MAPKAPK-2
P07589069A1245|171 184|reading frame
P07589069A1245|188 195|CD6-PB1
P07589069A1245|76 85|sequences
P07589069A1245|44 49|forms
P07588750T0061|1 8|Cloning
P07588750T0061|25 35|expression
P07588750T0061|10 20|sequencing
P07588628A0318|1 15|Overexpression
P07588628A0318|29 32|p53
P07588603A1054|84 89|sites
P07588603A1054|70 72|DH
P07588603A1054|5 12|results
P07588240A0000|170 173|ICE
P07588240A0000|55 60|ced-3
P07588240A0000|140 149|IL-1 beta
P07588240A0000|162 168|enzyme
P07588240A0000|120 138|interleukin-1 beta
P07585559A0000|49 65|2-hydroxyethoxyl
P07585559A0000|250 255|cells
P07585559A0000|67 72|ethyl
P07585559A0000|160 167|ability
P07585559A0000|73 78|amino
P07585559A0000|120 123|SCH
P07583562A1826|4 7|men
P07583562A1826|113 119|models
P07583562A1826|142 144|TG
P07583562A1826|27 29|OR
P07583562A1826|13 16|BMI
P07582592A0545|69 75|damage
P07582592A0545|223 232|achalasia
P07582592A0545|144 158|administration
P07582592A0545|177 202|botulinum toxin injection
P07581364A0500|51 54|SMA
P07581364A0500|87 91|copy
P07581364A0500|42 46|type
P07581364A0500|27 31|type
P07580330A0331|36 42|person
P07580330A0331|142 152|micrograms
P07580330A0331|73 76|HCH
P07580330A0331|191 194|HCB
P07580330A0331|83 92|microgram
P07580330A0331|127 135|dieldrin
P07580330A0331|177 186|microgram
P07579704A0085|21 33|actin cables
P07579704A0085|106 116|components
P07579704A0085|75 85|cell cycle
P07579695A0336|113 148|yeast centromere protein genes-CEP1
P07579695A0336|53 62|mutations
P07579695A0336|160 170|NDC10/CBF2
P07579695A0336|88 97|mutations
P07579328A1345|26 44|DNA binding domain
P07579328A1345|132 142|expression
P07579328A1345|62 86|reporter gene expression
P07579164A0409|35 44|sequences
P07579164A0409|4 14|comparison
P07577904A0141|17 22|years
P07577904A0141|32 43|persistence
P07577904A0141|168 182|microphthalmos
P07577904A0141|188 199|dislocation
P07577904A0141|108 121|camera aquosa
P07577904A0141|89 100|dislocation
P07576307A0144|156 176|enkephalin phenotype
P07576307A0144|59 67|cassette
P07576307A0144|79 81|bp
P07576307A0144|90 104|rat enkephalin
P07576178A0000|103 112|receptors
P07576178A0000|32 41|cytokines
P07575438A1409|67 77|E1 element
P07575416A0000|1 17|Protein kinase C
P07575416A0000|155 165|isoenzymes
P07575416A0000|129 135|family
P07575416A0000|182 201|tissue distribution
P07575416A0000|240 250|properties
P07574064A1416|186 191|shift
P07574064A1416|115 119|mmHg
P07574064A1416|199 220|response relationship
P07574064A1416|104 108|PCO2
P07571953T0000|31 43|mycobacteria
P07569770A0298|157 164|vaccine
P07569770A0298|23 37|non-responders
P07569770A0298|167 172|years
P07569770A0298|73 80|vaccine
P07569532T0001|1 10|Pediatric
P07569532T0001|67 73|locale
P07568865A0305|207 213|CFU/ml
P07568865A0305|81 86|range
P07568865A0305|5 14|carcasses
P07568865A0305|27 40|contamination
P07568865A0305|167 175|bacteria
P07568118A1267|157 166|mechanism
P07568118A1267|7 14|results
P07568118A1267|92 96|step
P07568118A1267|28 34|G beta
P07568026A0622|35 37|kb
P07568026A0622|23 27|size
P07568026A0622|52 59|protein
P07567979A1266|118 123|hERR1
P07567979A1266|96 111|testis receptor
P07567979A1266|60 66|assays
P07567300T0000|16 27|enterotoxin
P07567300T0000|80 87|patient
P07565797A0116|1 9|Deletion
P07565797A0116|77 86|CRY2 mRNA
P07565797A0116|13 25|inactivation
P07565775T0000|140 143|RNA
P07565775T0000|24 28|mRNA
P07565775T0000|109 118|formation
P07565775T0000|12 20|analysis
P07565740T0000|71 75|Pdr5
P07565740T0000|107 118|transporter
P07565740T0000|45 51|plasma
P07565731A1629|112 130|ribonucleoproteins
P07565731A1629|11 16|model
P07565720A0256|51 65|fusion protein
P07565720A0256|27 31|NirA
P07565720A0256|75 100|glutathione S-transferase
P07565712A0286|51 54|set
P07565712A0286|32 41|LYS2 gene
P07565712A0286|143 152|structure
P07565712A0286|72 79|inserts
P07565688T0000|1 11|Expression
P07565688T0000|113 121|evidence
P07565688T0000|106 111|cells
P07565688T0000|30 40|interferon
P07565685A0420|39 45|factor
P07565685A0420|58 68|GABP alpha
P07565685A0420|90 93|Ets
P07565669T0000|1 11|Ras p21Val
P07565669T0000|53 64|DNA binding
P07565104A0084|35 39|tcpA
P07565104A0084|23 33|pilin gene
P07565104A0084|73 77|ToxT
P07565031A0454|337 346|additives
P07565031A0454|128 145|apricot marmelade
P07565031A0454|198 207|empanadas
P07565031A0454|392 396|milk
P07565031A0454|147 150|hip
P07565031A0454|369 376|ricotta
P07565031A0454|310 324|milk confiture
P07565031A0454|167 177|mayonnaise
P07565031A0454|45 59|V. cholerae O1
P07565031A0454|358 367|tuna fish
P07565031A0454|251 266|spinach ravioli
P07565031A0454|61 66|Ogawa
P07564004A0292|66 67|%
P07564004A0292|8 15|minutes
P07563090A0624|1 17|Characterization
P07563090A0624|235 239|copy
P07563090A0624|260 279|primer binding site
P07563090A0624|52 65|DNA fragments
P07563090A0624|178 186|majority
P07563090A0624|125 129|PPT2
P07563076A0766|258 265|targets
P07563076A0766|273 290|splicing proteins
P07563076A0766|87 99|splice sites
P07563076A0766|212 215|bi4
P07563076A0766|131 139|activity
P07563076A0766|195 200|cores
P07562775A0596|35 36|%
P07562775A0596|5 10|range
P07562775A0596|89 94|nadir
P07562775A0596|14 25|eosinophils
P07560137T0000|62 71|subscales
P07559640A1230|171 181|core motif
P07559640A1230|54 61|element
P07559640A1230|111 122|UAS element
P07559640A1230|9 14|bases
P07559563A0282|11 19|residues
P07559524A0741|1 28|Cyclin D1 promoter activity
P07559524A0741|143 153|base pairs
P07559524A0741|111 118|c-Ets-2
P07559510A0000|169 171|L.
P07559510A0000|143 159|bacteriophage T4
P07559510A0000|10 44|Micrococcus luteus UV endonuclease
P07559510A0000|123 137|endonuclease V
P07559478A0389|25 27|T.
P07559402A0622|114 130|protein kinase A
P07559402A0622|27 34|peptide
P07559402A0622|88 91|PKC
P07559355A0066|155 160|genes
P07559355A0066|172 192|Proteus gene cluster
P07559355A0066|132 142|regulation
P07559233A0534|102 103|%
P07559233A0534|190 191|%
P07559233A0534|66 67|P
P07559233A0534|193 194|P
P07559233A0534|123 145|triceps brachii muscle
P07559233A0534|149 155|R rats
P07558263T0000|1 8|Closure
P07558263T0000|88 94|device
P07557446T0000|83 87|poly
P07557446T0000|9 20|transcripts
P07557446T0000|88 89|A
P07557446T0000|44 54|VCSA1 gene
P07557387A0241|114 124|C/EBP beta
P07557387A0241|9 14|study
P07557387A0241|88 95|program
P07557091A0314|87 97|volunteers
P07557091A0314|26 39|serum albumin
P07554541A0587|82 106|electrolyte disturbances
P07554541A0587|62 72|management
P07552974A0217|70 78|arginine
P07552974A0217|42 53|amino acids
P07550216A0195|32 39|latency
P07548858A0000|18 27|phosphate
P07548858A0000|97 105|pressure
P07548858A0000|37 43|saline
P07547510A0261|68 87|HNF-3 beta promoter
P07547510A0261|50 55|sites
P07547510A0261|237 243|factor
P07547510A0261|125 132|factors
P07547510A0261|182 186|site
P07547220A0229|71 77|slides
P07547220A0229|128 133|slide
P07546294A0000|138 149|sporulation
P07546294A0000|5 19|RAD6/UBC2 gene
P07546294A0000|121 132|mutagenesis
P07546256A0000|83 91|children
P07546256A0000|67 75|injuries
P07546256A0000|133 143|Casablanca
P07545510A0735|70 78|SDS-PAGE
P07545510A0735|5 17|gene product
P07545510A0735|59 66|Cot40-2
P07543868A0414|156 157|A
P07543868A0414|124 132|sequence
P07543868A0414|13 30|restriction sites
P07543592A0624|136 151|down-regulation
P07543592A0624|55 65|E5 protein
P07543592A0624|28 34|mutant
P07542698A0137|98 110|probe RH-414
P07542698A0137|27 34|signals
P07542616A0313|1 6|GCD10
P07542616A0313|72 76|GCN4
P07541912A0485|115 117|P1
P07541912A0485|66 73|exon 1a
P07541912A0485|28 35|regions
P07540866A1069|18 32|insulin effect
P07540866A1069|150 160|Y/F2 cells
P07540866A1069|45 62|ras GTP formation
P07540607A0709|65 73|response
P07540607A0709|24 28|dogs
P07539119A0985|83 98|target proteins
P07539119A0985|52 66|Abl SH3 domain
P07538818A0197|256 260|IL-3
P07538818A0197|272 277|Ba/F3
P07538818A0197|202 207|cDNAs
P07538818A0197|178 185|hG-CSFR
P07538818A0197|40 66|growth signal transduction
P07538818A0197|106 130|amino acid substitutions
P07538122A0800|32 41|isolation
P07538122A0800|93 101|affinity
P07538122A0800|124 126|nM
P07538122A0800|61 67|Fab A8
P07537851A0891|1 12|Experiments
P07537851A0891|51 58|p50/p65
P07537851A0891|253 260|protein
P07537851A0891|83 84|I
P07537851A0891|126 133|binding
P07537851A0891|182 187|IRF-1
P07537851A0891|150 159|VCAM1 IRF
P07537736A0453|119 125|region
P07537736A0453|101 109|membrane
P07537736A0453|197 226|cytokine receptor superfamily
P07537736A0453|56 60|PRLR
P07537736A0453|133 141|receptor
P07537267A2094|273 283|expression
P07537267A2094|156 164|enhancer
P07537267A2094|7 11|data
P07537267A2094|199 210|specificity
P07537267A2094|89 104|HPFH-3 deletion
P07537267A2094|224 242|gamma-globin genes
P07535593A0714|6 9|CD3
P07535593A0714|56 70|rearrangements
P07534297A0141|159 162|CAT
P07534297A0141|124 157|chloramphenicol acetyltransferase
P07534297A0141|61 67|region
P07534297A0141|90 110|AP endonuclease gene
P07534285A0155|81 91|BaF3 cells
P07534285A0155|9 14|paper
P07534285A0155|30 44|ligand binding
P07533858A1503|103 118|oligomerization
P07533858A1503|123 132|transport
P07533858A1503|44 51|proline
P07533527A0128|1 11|Cell lines
P07533527A0128|145 148|PCR
P07533527A0128|29 35|tumors
P07531321A0369|84 97|CI evaluation
P07531321A0369|76 79|PVC
P07531321A0369|60 72|distribution
P07530502T0000|53 79|tyrosine kinase activation
P07530502T0000|123 130|protein
P07530502T0000|91 100|life span
P07530128A0578|60 65|ng/ml
P07529504A0000|80 110|X-ray contrast agent iopromide
P07529504A0000|37 52|characteristics
P07528772A1539|17 25|tyrosine
P07528772A1539|125 131|ZAP-70
P07528746A1049|1 27|Phosphoamino acid analysis
P07528746A1049|229 230|P
P07528746A1049|74 75|P
P07528746A1049|254 258|RHL1
P07528746A1049|157 174|phosphoamino acid
P07528746A1049|113 114|%
P07528746A1049|124 125|P
P07528746A1049|120 123|Thr
P07528531A0904|174 177|CRP
P07528531A0904|10 20|infections
P07528531A0904|160 161|P
P07528531A0904|114 116|rs
P07528531A0904|179 181|rs
P07528531A0904|125 126|P
P07528531A0904|60 65|cells
P07528028A1192|250 255|WORDS
P07528028A1192|124 137|transfectants
P07528028A1192|192 205|transfectants
P07528028A1192|224 232|ABSTRACT
P07526609A0736|71 93|PKR activator sequence
P07526609A0736|37 39|S4
P07526609A0736|24 29|sigma
P07526609A0736|123 125|S4
P07525596A0584|142 157|PPIase activity
P07525596A0584|72 76|Fpr3
P07524265T0000|67 75|neonates
P07524265T0000|91 104|complications
P07523363A0440|81 91|base pairs
P07523363A0440|25 30|HpaII
P07521916T0000|1 8|Effects
P07521916T0000|66 93|immunodeficiency virus type
P07521916T0000|12 23|alterations
P07521285A1109|305 312|absence
P07521285A1109|279 288|amplitude
P07521285A1109|76 79|GBS
P07521285A1109|317 332|minimum latency
P07521285A1109|84 88|CIDP
P07521285A1109|262 269|latency
P07521285A1109|53 66|nerve lesions
P07521285A1109|31 40|frequency
P07520098A0211|139 147|sequence
P07520098A0211|48 54|strain
P07520098A0211|76 78|Db
P07520098A0211|56 60|part
P07520098A0211|120 125|class
P07519481A1275|131 144|KL expression
P07519481A1275|41 61|follicle development
P07519481A1275|195 208|oocyte growth
P07519481A1275|19 21|Sl
P07519481A1275|22 25|pan
P07519481A1275|177 181|role
P07519447T0000|1 13|Organization
P07519447T0000|28 32|gene
P07518561A0496|124 132|tyrosine
P07518561A0496|209 215|p56lck
P07518561A0496|165 184|receptor triggering
P07518426A0000|1 14|Interleukin-8
P07518426A0000|76 82|family
P07517869A0411|205 209|acid
P07517869A0411|18 35|dephosphorylation
P07517869A0411|144 152|presence
P07517869A0411|214 234|sodium orthovanadate
P07516866A0000|49 52|DNA
P07516866A0000|58 65|pigeons
P07516866A0000|133 146|transcription
P07516866A0000|15 27|PRL receptor
P07516469A1025|9 12|Src
P07516337A1119|128 140|Jurkat cells
P07516337A1119|11 14|Lck
P07516337A1119|90 97|binding
P07514295A0000|117 120|TCR
P07514295A0000|76 81|event
P07514295A0000|177 196|signaling machinery
P07512552A0270|1 5|Joys
P07512159A0992|1 12|Improvement
P07512159A0992|20 40|polypyrimidine tract
P07512159A0992|60 79|splicing efficiency
P07511496A1511|6 27|plasma concentrations
P07511496A1511|94 105|dysfunction
P07511444A0728|67 78|hepatitis C
P07511444A0728|108 119|hepatitis C
P07511444A0728|160 163|BMT
P07510635A0479|220 223|Pol
P07510635A0479|39 46|peptide
P07510635A0479|230 233|Pol
P07510635A0479|62 69|epitope
P07509811A1357|373 380|Jun/Fos
P07509811A1357|103 112|congeners
P07509811A1357|169 185|oligonucleotides
P07509811A1357|279 299|CRE oligonucleotides
P07509811A1357|7 10|TRE
P07509811A1357|436 457|transcription factors
P07509811A1357|358 365|members
P07509811A1357|459 467|CREB/ATF
P07509811A1357|213 216|TRE
P07509811A1357|481 502|transcription factors
P07509811A1357|122 137|protein binding
P07509472A1320|101 127|alpha interferon treatment
P07509472A1320|39 49|regression
P07509449A0000|119 132|Gag sequences
P07509449A0000|185 205|Src homology regions
P07509449A0000|81 91|p47gag-crk
P07509449A0000|36 54|sarcoma virus CT10
P07509449A0000|215 218|SH2
P07508954A0000|169 178|technique
P07508954A0000|101 108|results
P07508954A0000|72 91|Mycobacterium bovis
P07508954A0000|165 167|ZN
P07508250A0537|221 232|correlation
P07508250A0537|141 143|mo
P07508250A0537|83 111|liver selenium concentration
P07508250A0537|37 48|correlation
P07508250A0537|167 186|time liver selenium
P07508250A0537|63 78|selenium intake
P07508082A0821|72 81|bleaching
P07508082A0821|105 113|chlorine
P07507207A0991|96 106|IRF-2 gene
P07507207A0991|78 88|expression
P07506253A0742|51 60|promoters
P07506253A0742|64 74|HeLa cells
P07506253A0742|42 44|TK
P07505349A0702|53 54|%
P07505349A0702|77 85|survival
P07504171A1214|102 107|light
P07504171A1214|157 171|Src SH2 domain
P07504171A1214|47 65|binding properties
P07501992A0125|102 109|SEM-EDS
P07501992A0125|189 200|rat incisor
P07501992A0125|7 15|incisors
P07501992A0125|79 100|spectroscopy analysis
P07501992A0125|121 131|microscopy
P07501458A0578|53 56|LIP
P07501458A0578|75 81|Ig/EBP
P07500953A0305|81 89|proteins
P07500953A0305|6 22|ADR1 gene dosage
P07500953A0305|109 113|copy
P07500597A0212|71 76|years
P07500597A0212|36 39|age
P07500597A0212|58 62|days
P07500597A0212|91 93|SD
P07499848A0409|152 161|cytokines
P07499848A0409|93 108|germ-line gamma
P07499848A0409|75 84|Sf9 cells
P07499409A0367|1 5|TPBF
P07499409A0367|53 59|region
P07499409A0367|127 145|targeting sequence
P07499394A0187|1 3|J.
P07499242A0898|10 17|tissues
P07498727A0724|87 100|rad18 mutator
P07498727A0724|42 52|production
P07498727A0724|29 33|rev3
P07498727A0724|180 183|G.C
P07496184T0001|20 29|prospects
P07496184T0001|42 52|gynecology
P07496184T0001|60 67|Charite
P07495120A0260|35 40|trial
P07495120A0260|138 141|men
P07495120A0260|95 106|cryosurgery
P07495120A0260|72 78|safety
P07494314A1287|35 43|splicing
P07494314A1287|23 33|regulation
P07494314A1287|107 121|LMP2A homologs
P07494314A1287|45 69|kinase interaction sites
P07494303A0000|37 40|Vpr
P07494303A0000|76 83|protein
P07494274A1015|152 161|alpha TIF
P07494274A1015|170 179|infection
P07494274A1015|110 121|temperature
P07494274A1015|12 23|experiments
P07493627A0882|1 10|Treatment
P07493627A0882|80 90|expression
P07493627A0882|53 60|agonist
P07493627A0882|110 119|treatment
P07493627A0882|14 18|PCC4
P07491791A0263|84 106|helper adenovirus type
P07491791A0263|110 113|Ad5
P07491111A0221|22 34|DMS-79 cells
P07490766T0000|49 58|formation
P07490766T0000|80 101|c-Myc leucine zippers
P07490766T0000|176 187|specificity
P07490766T0000|28 36|parallel
P07490278A0799|68 86|mother cell cortex
P07490278A0799|12 18|domain
P07490083A0000|23 27|CA V
P07490083A0000|59 65|matrix
P07490079A0825|69 77|evidence
P07490079A0825|42 49|synteny
P07490079A0825|130 139|STEP gene
P07488959T0000|34 39|model
P07488959T0000|43 60|lymphocytopoiesis
P07488247T0000|58 83|translocator interactions
P07488247T0000|89 114|aryl hydrocarbon receptor
P07488247T0000|122 127|yeast
P07487811A0000|35 42|effects
P07487811A0000|5 16|experiments
P07487811A0000|83 96|bone turnover
P07487811A0000|57 68|spaceflight
P07487067A0592|34 40|clones
P07487067A0592|81 91|% identity
P07487067A0592|66 70|APS1
P07487067A0592|144 149|amino
P07487067A0592|180 196|transit peptides
P07483285A0322|153 162|induction
P07483285A0322|218 233|E7 gene product
P07483285A0322|78 86|MMTV LTR
P07483285A0322|134 148|transformation
P07482069A0606|32 39|mg/week
P07482069A0606|24 27|MTX
P07478525A1177|17 31|MHBst proteins
P07478525A1177|97 109|dimerization
P07478514A0237|32 35|rat
P07476975A0492|141 150|pituitary
P07476975A0492|5 11|number
P07476975A0492|42 53|thyrotropes
P07476975A0492|215 225|cell types
P07476975A0492|15 26|lactotropes
P07476963A0000|1 11|Peroxisome
P07476963A0000|143 148|acids
P07476963A0000|57 77|retinoid X receptors
P07476963A0000|46 51|PPARs
P07476164A1602|70 74|F17A
P07476164A1602|114 121|mutants
P07476164A1602|144 153|structure
P07476164A1602|47 64|resonance studies
P07475733T0000|1 8|Malaria
P07475733T0000|23 41|HIV-1 transmission
P07474617A1035|1 9|Patients
P07474617A1035|28 33|drugs
P07474140A1036|185 190|H-479
P07474140A1036|156 169|herpesviruses
P07474140A1036|178 183|E-358
P07474140A1036|199 204|C-483
P07474140A1036|132 146|ICP27 homologs
P07474140A1036|60 65|ICP27
P07474085A0932|41 47|codons
P07474085A0932|104 109|codon
P07473742A0187|68 79|GATA family
P07473742A0187|83 115|vertebrate transcription factors
P07473742A0187|45 49|gene
P07472736A0278|44 49|fossa
P07471210A0384|32 40|proteins
P07471210A0384|175 181|genome
P07471210A0384|124 138|messenger RNAs
P07467975A0316|304 312|approach
P07467975A0316|170 181|percentages
P07467975A0316|67 71|cent
P07467975A0316|43 47|role
P07467975A0316|79 87|patients
P07467975A0316|378 384|Europe
P07467975A0316|220 226|births
P07467975A0316|158 162|time
P07467975A0316|247 257|percentage
P07463465A0297|85 91|infant
P07463465A0297|7 16|infection
P07462481A0422|139 146|infarct
P07462481A0422|172 181|occlusion
P07462481A0422|128 135|regions
P07462481A0422|13 36|backscatter coefficient
P07462481A0422|60 67|regions
P07461226A0958|4 12|symptoms
P07461226A0958|58 69|correlation
P07461226A0958|75 93|plasma epinephrine
P07457931A0655|111 116|study
P07457931A0655|57 64|5-OH-DA
P07455521A0414|39 49|NEXT study
P07455521A0414|25 31|result
P07453919A0000|307 311|area
P07453919A0000|402 408|finger
P07453919A0000|315 319|pain
P07453919A0000|345 349|skin
P07453919A0000|357 361|head
P07453919A0000|53 67|investigations
P07453919A0000|333 337|area
P07453919A0000|271 288|blood neutrophils
P07453919A0000|150 166|acid phosphatase
P07453919A0000|181 189|esterase
P07450031A0691|190 194|NF20
P07450031A0691|8 25|sedative activity
P07450031A0691|109 113|NF19
P07449221A0086|100 106|tendon
P07449221A0086|5 14|operation
P07449221A0086|44 46|mm
P07440430A1074|69 72|end
P07440430A1074|236 261|hemoglobin concentrations
P07440430A1074|5 10|lambs
P07440430A1074|110 111|b
P07440430A1074|116 127|S x B lambs
P07440430A1074|80 90|experiment
P07440430A1074|149 158|Hb levels
P07438482A0145|102 110|oestrone
P07438482A0145|112 114|E1
P07438482A0145|132 134|E2
P07438482A0145|120 130|oestradiol
P07436794A0148|32 48|carotid arteries
P07436459A0245|68 78|acid ratio
P07436459A0245|200 206|stress
P07436459A0245|109 130|vitamin B6 deficiency
P07435185A0074|64 72|lymphoma
P07435185A0074|82 91|diagnosis
P07434431A0203|17 26|refeeding
P07434431A0203|89 99|infections
P07434431A0203|61 71|activation
P07431059A0000|239 243|vein
P07431059A0000|338 342|size
P07431059A0000|8 22|cadaver brains
P07431059A0000|43 44|X
P07431059A0000|104 111|anatomy
P07431059A0000|220 237|cerebellar artery
P07431059A0000|260 264|vein
P07431059A0000|247 252|Galen
P07431059A0000|328 332|vein
P07431059A0000|151 163|relationship
P07428037A0989|86 106|bp hairpin structure
P07428037A0989|113 121|sequence
P07428037A0989|27 38|nucleotides
P07428037A0989|208 215|systems
P07428037A0989|166 169|RNA
P07426604A0397|55 62|changes
P07426604A0397|5 10|C18:1
P07426604A0397|135 140|acids
P07425838A0182|80 89|pregnancy
P07425838A0182|13 17|case
P07419485A0158|50 55|waves
P07419485A0158|158 162|cost
P07419485A0158|9 14|study
P07418498A0217|103 112|infection
P07418498A0217|4 9|spite
P07418498A0217|182 194|lung abscess
P07418498A0217|166 174|excision
P07418498A0217|45 60|corticosteroids
P07415340A0280|49 64|pneumocytes typ
P07415340A0280|31 41|structures
P07413806T0000|39 48|pathology
P07413441T0070|18 30|localisation
P07413441T0070|47 59|distribution
P07413144T0018|24 34|population
P07408970A0706|99 102|mg%
P07408970A0706|52 54|Gf
P07408970A0706|59 66|Cv mice
P07408970A0706|26 40|administration
P07408970A0706|121 131|difference
P07405701T0000|38 64|platelet monoamine oxidase
P07405701T0000|24 33|responses
P07397066T0000|26 48|blood aspirin esterase
P07395750A0294|1 17|Underestimations
P07395750A0294|57 65|problems
P07393976A0000|157 171|discrimination
P07393976A0000|113 121|hr fluid
P07393976A0000|212 239|% sodium saccharin solution
P07393976A0000|92 106|taste aversion
P07393976A0000|41 46|mg/kg
P07393976A0000|243 248|water
P07392519T0001|46 54|children
P07386864T0000|22 30|dialysis
P07385933A0085|170 174|hour
P07385933A0085|79 84|mu Ci
P07385933A0085|149 158|intervals
P07385933A0085|31 42|g galactose
P07385543T0001|58 67|fractures
P07385543T0001|88 93|bones
P07379334A0503|1 8|Changes
P07379334A0503|114 122|subjects
P07379334A0503|57 72|transfer factor
P07377378A0143|1 21|Estrogen replacement
P07377378A0143|54 79|beta-estradiol-3-benzoate
P07377378A0143|178 187|heat loss
P07377378A0143|106 114|capsules
P07375864A0431|49 61|platelet MAO
P07375864A0431|190 198|findings
P07375864A0431|5 12|authors
P07375864A0431|128 141|schizophrenia
P07375864A0431|167 172|proof
P07372928A0105|152 159|cochlea
P07372928A0105|1 6|Tests
P07372928A0105|114 144|signal-transmission properties
P07372928A0105|173 179|source
P07369458A0606|139 155|amputation level
P07369458A0606|73 91|muscle temperature
P07365183A0000|116 124|efficacy
P07365183A0000|67 77|depression
P07365183A0000|8 16|patients
P07365183A0000|192 197|MMECT
P07365183A0000|240 244|SECT
P07365183A0000|105 111|safety
P07355527A0467|28 40|Lich-Gregoir
P07349416A0337|22 33|summer coat
P07345217A0000|12 25|complications
P07340196T0001|35 40|HBSAG
P07340196T0001|53 56|aid
P07340196T0001|75 89|infectiousness
P07330073T0000|69 80|blood cells
P07330073T0000|44 47|use
P07327097A0647|119 120|%
P07327097A0647|87 94|neurons
P07327097A0647|36 43|deficit
P07327097A0647|148 155|deficit
P07327097A0647|107 115|controls
P07323573A0644|10 14|zone
P07320153T0000|100 108|detector
P07320153T0000|142 156|catecholamines
P07320153T0000|160 171|body fluids
P07320153T0000|120 138|injection analysis
P07311881T0000|31 46|health director
P07309562T0000|41 54|determination
P07306839T0001|1 9|Electron
P07306839T0001|56 60|rats
P07306839T0001|74 83|degrees C
P07299857A0294|1 12|LD50 values
P07299857A0294|36 41|mg/kg
P07299857A0294|202 216|intrarectally.
P07299857A0294|282 287|mg/kg
P07299857A0294|166 172|female
P07299857A0294|50 54|rats
P07299857A0294|291 296|males
P07299857A0294|157 162|mg/kg
P07299857A0294|178 184|KP-T10
P07299857A0294|264 275|LD50 values
P07299857A0294|63 68|mg/kg
P07298259T0000|1 14|Determination
P07298259T0000|26 31|blood
P07297978A0570|100 102|C.
P07297978A0570|94 95|A
P07296997A0125|39 50|gallbladder
P07296997A0125|10 18|patients
P07295417A0092|118 131|phase imaging
P07295417A0092|55 64|ventricle
P07293327T0001|1 25|Fibrinogen determination
P07286057A0159|103 107|dose
P07286057A0159|141 143|i.
P07286057A0159|37 53|pharmacokinetics
P07286057A0159|10 31|AUC infinity analyses
P07286057A0159|134 136|mg
P07282943A0097|117 120|PO2
P07282943A0097|71 79|pressure
P07282943A0097|130 134|mmHg
P07282943A0097|107 115|aeration
P07282943A0097|44 62|superfusate oxygen
P07282444A0075|78 83|cases
P07282444A0075|12 17|cases
P07282444A0075|60 66|tumour
P07278578T0001|36 43|Hodgkin
P07278578T0001|46 53|disease
P07277222A1391|48 58|motor unit
P07277222A1391|9 14|waves
P07277222A1391|160 169|existence
P07274505A0660|26 37|differences
P07274428A0000|99 113|contrast agent
P07274428A0000|74 80|anions
P07274428A0000|115 118|RCA
P07274428A0000|159 170|Bengal pink
P07274428A0000|246 260|indigo-carmine
P07274428A0000|180 188|affinity
P07270991A0149|33 46|grass species
P07270991A0149|110 116|values
P07268828A0000|118 129|propranolol
P07268828A0000|3 20|fluoroimmunoassay
P07268828A0000|200 211|propranolol
P07268828A0000|72 83|propranolol
P07268828A0000|29 42|determination
P07266969A0246|51 60|Tamoxifen
P07266969A0246|5 17|relationship
P07263745T0000|11 32|Charnley arthroplasty
P07263374T0000|39 52|pneumonectomy
P07263374T0000|8 21|lung function
P07262239T0000|96 99|cat
P07262239T0000|43 54|development
P07260389A0221|35 42|blocker
P07260389A0221|19 24|mg/kg
P07260389A0221|81 92|development
P07260389A0221|46 65|serotonin receptors
P07256543A0814|69 77|presence
P07256543A0814|169 181|space injury
P07256543A0814|112 136|carboxyhemoglobin levels
P07256543A0814|266 272|injury
P07256543A0814|151 157|sputum
P07252346A0223|42 49|problem
P07249895A0177|136 143|animals
P07249895A0177|272 283|esophagitis
P07249895A0177|258 268|production
P07249895A0177|118 127|treatment
P07249895A0177|55 66|esophagitis
P07249895A0177|219 242|prostaglandin synthesis
P07249895A0177|149 161|indomethacin
P07249544A0343|83 91|patients
P07247059A0775|137 149|transit time
P07247059A0775|1 17|Catheter transit
P07247059A0775|223 225|N2
P07247059A0775|59 72|concentration
P07247059A0775|162 170|catheter
P07247059A0775|211 212|s
P07242929T0001|1 10|Recording
P07242929T0001|57 68|extremities
P07237817T0000|21 41|theophylline RIA kit
P07237123T0000|57 70|nerve volleys
P07237123T0000|104 108|bulb
P07235355A0462|111 117|change
P07235355A0462|57 65|sequence
P07235355A0462|135 153|density dependence
P07235355A0462|14 22|subjects
P07234974T0000|15 23|features
P07234308A0121|114 118|cure
P07234308A0121|126 133|disease
P07234308A0121|26 32|C-MOPP
P07234308A0121|61 76|remission rates
P07226440T0000|5 17|hemodynamics
P07225300A0968|117 128|sensitivity
P07225300A0968|83 89|nature
P07225300A0968|93 100|effects
P07225300A0968|63 70|respect
P07221179A0156|136 139|min
P07221179A0156|96 110|administration
P07221179A0156|82 85|min
P07221179A0156|124 129|nadir
P07219297T0000|27 42|standardization
P07219297T0000|46 55|allergens
P07217523A0364|16 32|recognition task
P07217523A0364|54 61|effects
P07217523A0364|123 134|recognition
P07214665A0000|84 95|vincristine
P07214665A0000|191 204|breast cancer
P07214665A0000|97 124|bis-chloroethyl nitrosourea
P07214665A0000|149 150|P
P07214665A0000|30 64|fluorouracil imidazole carboxamide
P07208984A0000|1 6|Brain
P07208984A0000|48 55|albumin
P07208984A0000|131 139|patients
P07208984A0000|106 108|CT
P07205120T0000|37 46|amplitude
P07202919A0142|1 6|Ulcer
P07202919A0142|23 30|angulus
P07202919A0142|58 62|week
P07202224A0452|33 42|vis-a-vis
P07202224A0452|5 16|preferences
P07202224A0452|97 106|castrates
P07202224A0452|108 122|attractiveness
P07195615A0087|119 131|accumulation
P07195615A0087|5 11|number
P07195615A0087|25 29|rats
P07195615A0087|192 197|brain
P07195615A0087|135 137|Cd
P07195615A0087|45 53|increase
P07192722A0682|185 189|PMNs
P07192722A0682|201 202|p
P07192722A0682|172 174|CL
P07192722A0682|27 44|parathyroidectomy
P07192722A0682|107 112|group
P07192722A0682|61 69|decrease
P07191972A0391|48 57|responses
P07191972A0391|104 109|phase
P07191183A0505|84 88|rate
P07191183A0505|39 40|s
P07191183A0505|108 114|lipids
P07191183A0505|30 31|V
P07190627T0000|20 49|plasminogen activator release
P07190627T0000|11 16|study
P07184774T0000|23 33|ED01 study
P07184375T0001|55 67|prednisolone
P07184375T0001|24 35|vincristine
P07184375T0001|72 73|P
P07184375T0001|15 20|study
P07182523A0462|6 12|groups
P07182523A0462|63 68|times
P07180901A0539|111 118|effects
P07180901A0539|31 41|blood flow
P07175474A0102|84 92|findings
P07175474A0102|5 10|cause
P07175474A0102|149 157|official
P07175474A0102|14 19|death
P07174122A0000|1 22|Serum creatine kinase
P07174122A0000|65 75|laboratory
P07174122A0000|97 108|performance
P07173729A0000|101 112|interaction
P07173729A0000|82 87|order
P07173729A0000|57 62|mucus
P07173729A0000|121 126|sperm
P07169630A0983|49 60|differences
P07169630A0983|123 127|task
P07169630A0983|105 115|complexity
P07160491A0547|16 22|effect
P07160491A0547|79 87|increase
P07155579T0001|34 43|fertility
P07149303T0000|68 76|behavior
P07149303T0000|55 63|activity
P07149303T0000|40 43|CNS
P07147622T0000|17 32|storage disease
P07141130A0615|70 76|number
P07141130A0615|54 62|increase
P07141130A0615|108 113|cells
P07141130A0615|166 183|cells/100 microns
P07141130A0615|210 221|mean height
P07141130A0615|14 24|evaluation
P07140060T0000|36 43|patella
P07136569A0000|4 9|Malmo
P07136569A0000|26 41|school children
P07136569A0000|122 126|ages
P07136569A0000|105 109|year
P07135112T0000|71 75|flap
P07135112T0000|42 45|leg
P07132408A0387|12 16|time
P07126413A0000|158 168|Eudragit S
P07126413A0000|82 87|colon
P07126413A0000|121 128|coating
P07125238T0000|34 39|entry
P07125238T0000|82 88|system
P07125238T0000|43 56|blood vessels
P07124743A1223|139 146|arsenic
P07124743A1223|101 108|arsenic
P07124743A1223|231 240|workshift
P07124743A1223|41 55|As2O3 exposure
P07124743A1223|439 444|lungs
P07124743A1223|292 314|microgram/g creatinine
P07124743A1223|114 127|determination
P07124743A1223|179 198|mouth contamination
P07124743A1223|367 373|intake
P07116962A0299|54 59|shock
P07116962A0299|74 82|patients
P07114083A0153|157 162|cells
P07114083A0153|53 60|disease
P07114083A0153|43 50|Hodgkin
P07114083A0153|130 143|disappearance
P07113365A0737|1 6|Ficat
P07113365A0737|80 90|Brattstrom
P07113365A0737|11 16|Bizou
P07113365A0737|28 39|depth index
P07112471A0639|93 102|factories
P07112471A0639|57 64|workers
P07110999A0160|42 54|tetraparesis
P07110999A0160|73 93|oculomotor paralysis
P07107773A0000|139 147|subjects
P07107773A0000|42 46|acid
P07107773A0000|283 311|resolution mass spectrometry
P07107773A0000|51 52|m
P07107773A0000|326 340|ion monitoring
P07107773A0000|80 84|acid
P07107773A0000|189 198|ingestion
P07107287A1083|34 41|drivers
P07107287A1083|13 18|doses
P07106323A0560|68 72|role
P07106323A0560|80 90|production
P07106323A0560|111 120|pregnancy
P07106323A0560|29 40|possibility
P07097182A0480|48 57|potential
P07097182A0480|157 161|ears
P07097182A0480|22 31|amplitude
P07094905A0644|34 44|injections
P07094905A0644|48 50|KA
P07094905A0644|79 83|loss
P07090151A0165|84 90|animal
P07090151A0165|38 51|release bolus
P07090151A0165|8 15|turnout
P07084814T0000|50 68|coagulation assays
P07084814T0000|25 45|phospholipid reagent
P07084198T0000|20 33|thoroughbreds
P07080496A0097|35 47|lipoproteins
P07080496A0097|87 98|lipoprotein
P07080496A0097|249 256|attacks
P07080496A0097|213 221|infarcts
P07080496A0097|182 194|lipoproteins
P07078263T0000|119 126|type I.
P07078263T0000|1 4|Use
P07078263T0000|39 44|child
P07075438T0000|13 35|serial xeroradiography
P07073520A0153|68 70|Na
P07073520A0153|93 98|mEq/L
P07073520A0153|128 140|fluid volume
P07073520A0153|72 85|concentration
P07068887A0000|201 215|symptomatology
P07068887A0000|127 161|Michigan Alcoholism Screening Test
P07068887A0000|62 68|scores
P07068887A0000|44 58|dimensionality
P07068493A0636|34 52|oxygen consumption
P07068493A0636|64 72|subjects
P07068493A0636|22 30|increase
P07065206A0398|101 106|ng/ml
P07065206A0398|126 132|bypass
P07065206A0398|72 87|ng/ml prebypass
P07064662A0222|96 103|muscles
P07064662A0222|146 158|dorsal roots
P07064662A0222|63 76|target fibres
P07062269A0798|163 172|mechanism
P07062269A0798|63 71|naloxone
P07062269A0798|75 84|tolerance
P07061350A0042|168 176|pressure
P07061350A0042|101 110|magnitude
P07061350A0042|9 16|Science
P07049690T0000|29 39|allografts
P07044842A2062|102 110|syndrome
P07044842A2062|5 17|relationship
P07044842A2062|73 88|pathophysiology
P07044389T0000|68 80|pathologists
P07044389T0000|14 39|Economic Recovery Tax Act
P07038684A1050|234 237|p62
P07038684A1050|59 72|sequence data
P07038684A1050|130 133|p62
P07038684A1050|122 125|p60
P07037479T0000|21 29|syndrome
P07026328A0369|138 139|%
P07026328A0369|8 17|diabetics
P07026328A0369|164 171|glucose
P07026328A0369|19 22|Ca2
P07026328A0369|52 62|plasma Ca2
P07026328A0369|189 190|p
P07026328A0369|95 99|fall
P07018810A0002|116 122|cortex
P07018810A0002|203 210|medulla
P07018810A0002|148 155|outflow
P07018810A0002|180 184|half
P07015262A0396|53 61|children
P07015262A0396|95 105|CRP values
P07015262A0396|134 146|microgram/ml
P07007591A0324|5 22|residue functions
P07007591A0324|336 347|transferrin
P07007591A0324|195 200|areas
P07007591A0324|263 265|RR
P07007591A0324|24 25|R
P07007591A0324|88 92|time
P07007591A0324|151 161|extraction
P07007591A0324|34 42|C-11 CPZ
P07007591A0324|306 323|residue functions
P07007591A0324|163 164|E
P07007591A0324|47 66|In-113m transferrin
P07007591A0324|165 166|t
P07007591A0324|115 123|interest
P07007591A0324|246 247|t
P07004236A0741|204 209|cases
P07004236A0741|80 88|methanol
P07004236A0741|53 73|formate accumulation
P07004236A0741|125 136|utilization
P07004236A0741|160 163|use
P07004236A0741|104 121|formate oxidation
P06994049T0001|25 39|hypothyroidism
P06993660A0000|67 68|K
P06993660A0000|42 51|serotonin
P06993660A0000|13 22|responses
P06993660A0000|327 335|controls
P06993660A0000|115 125|papaverine
P06993660A0000|26 40|norepinephrine
P06993660A0000|182 188|strips
P06986168A0304|123 134|V8 protease
P06986168A0304|105 113|peptides
P06981991A0756|119 132|bypass grafts
P06981991A0756|1 15|Aneurysmectomy
P06981991A0756|39 43|CABG
P06981991A0756|97 108|ECG changes
P06981991A0756|194 205|ECG changes
P06977605T0000|22 28|issues
P06973664A0000|20 37|cleavage syndrome
P06972443A0375|71 84|abnormalities
P06972443A0375|44 51|carrier
P06969638A0180|33 43|indicators
P06969638A0180|189 202|complications
P06969638A0180|47 64|CNS abnormalities
P06969638A0180|91 111|meningeal infections
P06963337T0000|45 56|hyperplasia
P06962492A0612|43 51|eruption
P06962492A0612|90 100|hypotrophy
P06957633T0001|101 108|history
P06957633T0001|64 80|erythroblastosis
P06957633T0001|27 35|leukemia
P06957633T0001|121 127|anemia
P06953957A0503|71 75|peak
P06953957A0503|9 33|creatine kinase activity
P06953957A0503|194 205|correlation
P06948868A0082|56 75|faculty evaluations
P06948868A0082|29 33|part
P06948398A0523|40 45|blood
P06946314T0000|1 17|Serum IgE levels
P06935514A0000|117 129|desametazone
P06935514A0000|156 167|alterations
P06935514A0000|5 12|Authors
P06935514A0000|215 224|component
P06928974T0000|5 22|electrocardiogram
P06916588A0304|5 19|infection rate
P06916588A0304|29 34|times
P06916588A0304|60 77|Hickman catheters
P06902722T0000|16 21|phase
P06895663A0810|101 113|significance
P06895663A0810|9 16|therapy
P06895663A0810|61 64|RBT
P06891270A0000|33 39|stress
P06891270A0000|78 91|contractility
P06891270A0000|60 73|extensibility
P06890935T0001|10 18|syndrome
P06886948A0750|83 84|%
P06886948A0750|8 13|rates
P06884450A0234|71 74|TBN
P06884450A0234|56 58|FB
P06884450A0234|12 19|tumours
P06882578A0464|137 142|ng/ml
P06882578A0464|33 52|testosterone levels
P06882578A0464|8 28|ultramarathon runner
P06882578A0464|198 203|hours
P06882578A0464|73 82|beginning
P06882578A0464|241 255|hours training
P06880604A0167|154 161|January
P06880604A0167|3 15|reassessment
P06880604A0167|23 38|prevalence data
P06880604A0167|133 147|prevalence day
P06876317T0033|1 14|Relationships
P06875478A0542|3 23|microU/l thyrotropin
P06875478A0542|39 40|%
P06872800T0000|33 41|patients
P06872800T0000|7 11|type
P06869215A0347|16 18|IC
P06869215A0347|43 61|hypocomplementemia
P06863087A0664|21 23|mg
P06863087A0664|77 86|parameter
P06863087A0664|41 43|mg
P06858805A0314|70 78|Candidin
P06858805A0314|80 91|Trycophytin
P06858805A0314|6 12|groups
P06858449A0335|1 13|Disturbances
P06856306T0000|69 81|significance
P06856306T0000|5 22|Tullio phenomenon
P06856306T0000|24 36|fistula test
P06853042A0282|16 29|acidification
P06853042A0282|114 119|urine
P06851280A0144|1 18|Plasma fibrinogen
P06851280A0144|53 59|method
P06848729A0000|22 35|neuroblastoma
P06848729A0000|47 50|St.
P06840803A0397|80 94|i.v. challenge
P06840803A0397|121 125|days
P06837312A0000|170 176|months
P06837312A0000|86 91|swine
P06837312A0000|219 226|lesions
P06837312A0000|109 122|vitamin D3/kg
P06837312A0000|180 201|vitamin D3 withdrawal
P06835516A0000|19 34|epidermoid cyst
P06835516A0000|54 61|cistern
P06833047A0000|71 81|inhibition
P06833047A0000|125 136|ventilation
P06830033A0661|48 60|pneumothorax
P06830033A0661|67 72|cmH2O
P06828396A0095|35 40|wound
P06828396A0095|74 99|biopsy fixation technique
P06825641A0076|86 95|knowledge
P06825641A0076|148 153|waste
P06822645T0039|1 5|Time
P06818113A0384|118 142|corticosteroid treatment
P06818113A0384|236 244|infusion
P06818113A0384|175 196|plasminogen activator
P06818113A0384|53 63|parameters
P06818113A0384|162 171|responses
P06816609A0639|119 120|%
P06816609A0639|6 32|% blood pressure reduction
P06816609A0639|59 67|decrease
P06816123A0526|136 141|roles
P06816123A0526|1 9|Selenium
P06816123A0526|110 114|body
P06816123A0526|63 67|role
P06815368A0203|54 62|patients
P06810694A1000|1 14|Apo A-I level
P06810694A1000|95 104|adiposity
P06810070A0502|64 78|control spores
P06810070A0502|7 17|properties
P06809474A1156|1 15|Bile bilirubin
P06809474A1156|94 107|investigation
P06809474A1156|47 60|haem infusion
P06808287T0001|14 35|hemophilia A carriers
P06807192A0312|71 90|glucose utilization
P06807192A0312|147 152|Duffy
P06807192A0312|135 145|conditions
P06807149A0222|100 103|EIB
P06807149A0222|6 11|study
P06805504A0629|85 91|weight
P06805504A0629|115 126|N excretion
P06805504A0629|162 170|mg/kg W0
P06805504A0629|24 32|N values
P06802500T0001|23 42|thyroid gammagraphy
P06798609A0000|87 103|gamma-vinyl GABA
P06798609A0000|143 147|days
P06798609A0000|105 108|GVG
P06796300A0759|87 112|oestradiol administration
P06796300A0759|42 55|nursing women
P06795900A0000|81 91|blood flow
P06795900A0000|93 96|CBF
P06795900A0000|125 131|oxygen
P06795900A0000|133 138|CMRO2
P06795654A0434|48 62|mg/kg/infusion
P06795654A0434|81 109|self-administration behavior
P06795654A0434|147 149|FR
P06794666A0208|103 112|intensity
P06794666A0208|48 58|myocardium
P06794666A0208|166 195|cardiomyocyte adrenoreceptors
P06794666A0208|120 149|neurotransmitter biosynthesis
P06793764T0001|28 37|infection
P06790572A0330|83 103|trimethoprim lactate
P06790572A0330|8 16|isolates
P06790572A0330|122 132|anisomycin
P06790572A0330|105 116|polymyxin B
P06786756T0000|5 9|role
P06786756T0000|47 61|RNA processing
P06784123T0000|1 12|Transcripts
P06784123T0000|53 62|structure
P06784123T0000|92 103|development
P06784123A0286|1 11|Production
P06784123A0286|99 101|JH
P06784123A0286|60 73|recombination
P06782612A0142|67 72|ratio
P06782612A0142|123 126|CLi
P06782612A0142|14 21|measure
P06782612A0142|30 40|impairment
P06781339A0501|99 107|patients
P06781339A0501|6 11|study
P06781339A0501|122 137|hypoventilation
P06777229A0243|21 26|study
P06777229A0243|42 50|subjects
P06775834A0000|1 6|HLA-A
P06775834A0000|127 131|form
P06775834A0000|135 142|relapse
P06775834A0000|105 111|regard
P06772370A0342|33 37|DMDZ
P06772370A0342|140 144|l/kg
P06772370A0342|11 23|distribution
P06772370A0342|106 121|protein binding
P06772370A0342|80 84|DMDZ
P06772370A0342|123 128|range
P06764669T0001|39 43|iron
P06764669T0001|14 27|determination
P06762321T0000|1 20|Nucleotide sequence
P06762321T0000|54 59|genes
P06762321T0000|95 108|Streptococcus
P06760394T0001|35 38|aid
P06760394T0001|89 95|type F
P06755468A0180|69 75|intron
P06755468A0180|1 8|Regions
P06755468A0180|83 91|cob gene
P06755468A0180|95 100|yeast
P06753902A0437|154 159|death
P06753902A0437|143 146|IIS
P06753902A0437|8 16|patients
P06750608A1442|1 10|Mutations
P06750608A1442|26 35|lts genes
P06748227A0423|34 41|maximum
P06748227A0423|5 9|maps
P06748227A0423|133 139|thorax
P06743061A0239|101 109|tinnitus
P06743061A0239|29 37|patients
P06740697A0318|5 12|results
P06740697A0318|29 40|sensitivity
P06738410T0000|19 27|children
P06734713T0000|33 42|poisoning
P06731302A0930|4 11|patient
P06731302A0930|42 45|SCD
P06726257T0000|1 8|Effects
P06726257T0000|140 171|serotonin autoreceptor function
P06726257T0000|128 136|relation
P06726257T0000|90 109|serotonin synthesis
P06723849A0197|49 58|Formation
P06723849A0197|15 20|tract
P06720371T0000|1 12|Pilot study
P06718064T0001|1 19|Plasma lactoferrin
P06718064T0001|28 39|blood count
P06715792A0295|59 71|accumulation
P06714298X0000|229 237|pressure
P06714298X0000|135 158|calcium channel blocker
P06714298X0000|318 319|%
P06714298X0000|53 60|preload
P06714298X0000|266 276|resistance
P06714298X0000|88 99|nisoldipine
P06714298X0000|241 242|%
P06713200A0630|49 56|laminae
P06713200A0630|109 120|projections
P06713200A0630|164 173|phenytoin
P06711642A0093|70 78|azotemia
P06711642A0093|55 66|development
P06711642A0093|218 220|gm
P06711642A0093|13 31|immunoglobulinuria
P06709310A0000|68 72|girl
P06709310A0000|27 36|nystagmus
P06705456A0346|35 39|time
P06705456A0346|54 57|min
P06702643A0000|87 94|carotid
P06702643A0000|115 123|arteries
P06702643A0000|177 183|artery
P06702643A0000|13 26|infant hearts
P06702643A0000|45 62|arch interruption
P06700469T0000|9 31|hospital accreditation
P06698047A0445|52 57|norms
P06698047A0445|63 72|responses
P06694380A1483|51 59|mg/liter
P06694380A1483|138 143|WORDS
P06694380A1483|112 120|ABSTRACT
P06694380A1483|91 92|P
P06692517T0000|80 90|assessment
P06692517T0000|96 123|indium-111 platelet imaging
P06692517T0000|40 48|patients
P06689513T0001|17 24|studies
P06689513T0001|28 39|retinopathy
P06687953T0000|13 29|defence capacity
P06685643A0179|71 78|disease
P06685643A0179|23 25|C4
P06685643A0179|120 126|stages
P06685177T0000|1 13|Dipetalonema
P06685177T0000|27 46|hydrochoerus subgen
P06684624A0736|97 103|groups
P06684624A0736|46 59|mg creatinine
P06683876A0244|36 44|diameter
P06683876A0244|25 32|microns
P06683876A0244|104 118|daughter cells
P06675047A0000|49 59|hemoglobin
P06675047A0000|162 166|urea
P06675047A0000|107 116|Berthelot
P06675047A0000|75 82|methods
P06674516A0350|49 55|dosage
P06674516A0350|140 145|field
P06672094A0390|5 13|subgroup
P06672094A0390|37 43|rectus
P06672094A0390|162 172|fasciculus
P06672094A0390|90 108|oculomotor nucleus
P06671385A0856|5 7|NA
P06671385A0856|46 67|plasma renin activity
P06671047A1124|171 174|DOM
P06671047A1124|341 348|factors
P06671047A1124|7 14|results
P06671047A1124|47 50|NOM
P06671047A1124|164 166|LD
P06671047A1124|115 121|states
P06671047A1124|144 153|responses
P06671047A1124|265 267|DA
P06671047A1124|208 217|sub-group
P06669864T0001|5 10|liver
P06667868T0001|18 24|status
P06667868T0001|55 60|blood
P06667868T0001|126 134|exposure
P06662623A0124|102 114|neutron flux
P06662623A0124|87 88|h
P06662623A0124|64 80|SLOWPOKE reactor
P06662623A0124|125 135|n cm-2 s-1
P06658586T0001|1 24|Angionephroscintigraphy
P06658586T0001|61 67|kidney
P06658029A0086|55 64|component
P06658029A0086|97 102|tests
P06658029A0086|72 79|battery
P06656249T0000|37 45|practice
P06654686T0001|1 12|Combination
P06654686T0001|18 36|Shwachman syndrome
P06653755A0192|100 109|AP levels
P06653755A0192|79 84|i. e.
P06634712A0557|84 93|secretion
P06634712A0557|97 100|PTH
P06634712A0557|43 52|phosphate
P06634712A0557|29 39|importance
P06629370A0252|16 21|group
P06629370A0252|175 181|Alport
P06629370A0252|6 14|patients
P06629370A0252|148 155|pattern
P06629370A0252|29 33|type
P06627123A0000|86 94|calories
P06627123A0000|38 42|diet
P06627123A0000|8 19|Wistar rats
P06615403A0718|51 57|series
P06615403A0718|71 82|microns TMs
P06615403A0718|142 153|microns TMs
P06615403A0718|42 49|minutes
P06615403A0718|61 62|n
P06612373A0000|87 99|prescription
P06612373A0000|6 11|paper
P06612373A0000|77 83|extent
P06612373A0000|28 32|data
P06612373A0000|61 68|sources
P06609166A0209|64 76|acetonitrile
P06609166A0209|53 60|volumes
P06609166A0209|89 98|injection
P06607427A0000|34 41|effects
P06607427A0000|71 78|lesions
P06607427A0000|112 118|dorsal
P06607427A0000|163 175|hypothalamus
P06607427A0000|133 144|projections
P06602600A0582|100 108|cannulas
P06602600A0582|58 64|system
P06600533T0000|69 81|lobe bronchi
P06600533T0000|36 40|wall
P06597709A0596|152 159|results
P06597709A0596|169 181|measurements
P06597709A0596|93 98|ratio
P06597709A0596|208 213|cases
P06593862T0001|1 20|Hepatitis B vaccine
P06585277A0000|188 197|existence
P06585277A0000|6 9|man
P06585277A0000|108 113|serum
P06585277A0000|122 130|presence
P06585277A0000|224 233|carcinoma
P06582285A0222|84 97|D&E abortions
P06582285A0222|39 42|U-P
P06582285A0222|29 35|safety
P06582285A0222|120 125|weeks
P06579147A0060|48 58|management
P06579147A0060|142 149|disease
P06579147A0060|92 106|reconstruction
P06568939A0000|119 128|integrity
P06568939A0000|100 111|information
P06568939A0000|156 165|brainstem
P06568939A0000|27 36|responses
P06548953T0001|35 51|thyroid diseases
P06548953T0001|27 30|HTS
P06545651A0346|1 22|Ammonia concentration
P06545651A0346|66 73|finding
P06545651A0346|52 62|treatments
P06542372A0159|118 123|terms
P06542372A0159|142 154|potentiation
P06542372A0159|128 138|additivity
P06542372A0159|13 18|paper
P06541019A0555|5 13|patients
P06535384A1115|19 26|subtest
P06535384A1115|172 180|ABSTRACT
P06535384A1115|146 153|success
P06535384A1115|198 203|WORDS
P06535384A1115|107 112|items
P06527872T0000|184 200|acid phosphatase
P06527872T0000|83 89|nerves
P06527872T0000|172 177|means
P06527872T0000|163 168|study
P06527872T0000|28 39|projections
P06524761A0596|101 109|hamsters
P06524761A0596|40 47|quality
P06524761A0596|195 205|T-1 strain
P06524761A0596|221 228|changes
P06524761A0596|22 32|difference
P06524761A0596|301 310|challenge
P06524761A0596|268 291|live-toxoplasma vaccine
P06524202A0167|101 107|method
P06524202A0167|22 36|EMG-BFB method
P06524202A0167|215 233|motor coordination
P06524202A0167|180 191|antagonists
P06521802A0251|205 209|CMEA
P06521802A0251|1 23|Scientific cooperation
P06521802A0251|110 135|Cancer Research Institute
P06521802A0251|192 201|framework
P06521802A0251|91 102|sponsorship
P06517816A0388|69 71|HR
P06517816A0388|155 173|saline experiments
P06517816A0388|129 142|g X m-2 X h-1
P06517816A0388|27 28|p
P06517816A0388|45 48|Tre
P06516847A0393|78 89|pneumococci
P06513456T0001|69 74|ulcer
P06513456T0001|36 42|mucosa
P06513456T0001|46 54|patients
P06507629A0717|4 12|contrast
P06507629A0717|92 95|NH3
P06507629A0717|14 21|kidneys
P06505014A1192|50 55|Vinca
P06505014A1192|41 45|Y-12
P06503329A0588|68 69|g
P06503329A0588|33 41|newborns
P06503329A0588|59 61|SD
P06503329A0588|123 124|g
P06501086A0165|273 305|sperm agglutinin antibody titers
P06501086A0165|138 161|vas deferens granulomas
P06501086A0165|55 64|sham rats
P06501086A0165|114 123|formation
P06501086A0165|13 24|alterations
P06495195A0536|118 126|patients
P06495195A0536|42 50|activity
P06495195A0536|61 64|U/l
P06494297A0939|138 149|stimulation
P06494297A0939|67 73|effect
P06494297A0939|77 88|acquisition
P06494297A0939|124 130|effect
P06493655A0415|114 122|patients
P06493655A0415|10 27|FHR decelerations
P06493655A0415|31 43|bradycardias
P06487290A0000|169 179|trimesters
P06487290A0000|260 265|cycle
P06487290A0000|59 60|P
P06487290A0000|130 137|females
P06487290A0000|210 218|controls
P06483863A0000|170 174|days
P06483863A0000|37 47|BALB/cCrgl
P06483863A0000|111 121|micrograms
P06483863A0000|51 70|BALB/cfC3HCrgl mice
P06483863A0000|294 304|Experiment
P06483863A0000|261 272|Experiments
P06483863A0000|213 217|days
P06483863A0000|125 139|beta-estradiol
P06482318A0117|1 21|Thrombocyte function
P06482318A0117|42 50|patients
P06480542A0000|59 67|patients
P06480542A0000|28 38|apalcillin
P06479362A0680|49 72|postdenervation changes
P06479362A0680|109 114|doses
P06479362A0680|122 129|hormone
P06473219T0000|51 55|type
P06473219T0000|37 47|management
P06473219T0000|10 29|urine glucose tests
P06468673A0358|26 43|E2 concentrations
P06468673A0358|121 126|group
P06468565A0000|119 133|time constants
P06468565A0000|5 24|response properties
P06468565A0000|213 215|Gm
P06468565A0000|43 58|canal afferents
P06468565A0000|135 138|tau
P06467241A0000|1 22|Modern cancer therapy
P06467241A0000|110 122|hyperthermia
P06467241A0000|92 105|immunotherapy
P06463429A0414|39 40|%
P06463429A0414|9 11|VE
P06460889A0111|155 165|blood flow
P06460889A0111|67 81|blood pressure
P06460889A0111|41 46|mg/kg
P06460889A0111|13 23|injections
P06454625A0000|188 213|magnification angiography
P06454625A0000|215 235|magnification factor
P06454625A0000|106 116|hemostasis
P06454625A0000|73 84|vasculature
P06452827T0001|19 28|recording
P06451557A0777|117 124|Ahlberg
P06451557A0777|131 138|Weseloh
P06451557A0777|104 110|Jordan
P06451557A0777|31 40|olecranon
P06444119A0340|16 24|organism
P06444119A0340|155 170|toxin formation
P06444119A0340|48 58|preference
P06444119A0340|131 145|growth factors
P06444119A0340|63 74|requirement
P06443639T0001|33 37|rate
P06443639T0001|20 28|motility
P06441624A0263|51 62|measurement
P06441624A0263|66 81|bone metabolism
P06439114A0677|1 12|Ceftazidime
P06439114A0677|19 26|promise
P06435565A0648|117 121|mmHg
P06435565A0648|48 57|afterload
P06435565A0648|36 44|decrease
P06435565A0648|163 173|resistance
P06435565A0648|215 223|dynes/cm
P06434572A0157|279 287|criteria
P06434572A0157|172 173|n
P06434572A0157|76 89|GH deficiency
P06434572A0157|128 129|n
P06434572A0157|152 170|growth retardation
P06434572A0157|249 250|n
P06434572A0157|91 92|n
P06434572A0157|211 217|growth
P06429992T0000|49 53|sets
P06429992T0000|57 65|DZ twins
P06426493A0331|232 239|mg kg-1
P06426493A0331|128 131|CVP
P06426493A0331|14 17|min
P06426493A0331|194 201|mg kg-1
P06426493A0331|216 227|pancuronium
P06426493A0331|178 188|atracurium
P06426493A0331|28 45|state anaesthesia
P06415299A0233|18 23|doses
P06415299A0233|27 38|doxorubicin
P06413492A0990|1 7|Commun
P06411659A0793|53 58|times
P06411659A0793|63 81|energy expenditure
P06407348A0516|171 176|beta1
P06407348A0516|1 4|New
P06407348A0516|217 222|beta2
P06407348A0516|199 215|muscle receptors
P06404842A0127|153 161|duration
P06404842A0127|169 174|years
P06404842A0127|65 74|treatment
P06404842A0127|132 137|weeks
P06402480A0373|220 235|recommendations
P06402480A0373|202 212|evaluation
P06402480A0373|176 186|infections
P06402480A0373|63 74|antibiotics
P06402480A0373|91 106|plasmid pattern
P06397009A0204|136 145|physician
P06397009A0204|117 126|invention
P06397009A0204|173 181|medicine
P06397009A0204|89 94|merit
P06394347A1024|35 43|increase
P06394347A1024|81 90|excretion
P06394347A1024|47 68|plasma renin activity
P06391496T0000|1 7|Effect
P06391496T0000|23 30|enzymes
P06391496T0000|75 83|almagate
P06388189T0001|20 27|kidneys
P06388189T0001|56 66|recipients
P06384983T0000|15 27|hypertension
P06376227A0217|1 4|EGV
P06376227A0217|23 29|effect
P06374369A1112|119 123|diet
P06374369A1112|33 37|part
P06374369A1112|58 69|food intake
P06374369A1112|45 54|reduction
P06373409A1163|23 32|technique
P06373409A1163|94 106|restorations
P06373409A1163|133 138|teeth
P06370553A0444|32 34|NE
P06370553A0444|232 237|ng/ml
P06370553A0444|40 51|epinephrine
P06370553A0444|187 192|ng/ml
P06370553A0444|112 122|withdrawal
P06370553A0444|124 134|guanfacine
P06370553A0444|88 95|therapy
P06369355A0834|65 70|forms
P06369355A0834|37 45|plasmids
P06369355A0834|109 119|A2 protein
P06369355A0834|150 169|replication protein
P06362239T0001|1 14|Martin Luther
P06361318A1127|137 142|cases
P06361318A1127|227 232|group
P06361318A1127|153 167|incidence rate
P06361318A1127|48 56|symptoms
P06361318A1127|212 213|%
P06361318A1127|125 130|group
P06361318A1127|88 93|cases
P06360426A0501|108 120|pH indicator
P06360426A0501|41 48|ammonia
P06354594A0114|16 24|mandarin
P06354594A0114|7 14|oranges
P06354594A0114|26 36|grapefruit
P06349364A1051|112 116|type
P06349364A1051|7 14|results
P06349364A1051|57 64|passive
P06345840A0348|34 36|CI
P06345840A0348|87 92|fiber
P06345840A0348|4 12|patients
P06345840A0348|66 70|mean
P06345840A0348|47 57|heart rate
P06341661T0001|10 13|use
P06341661T0001|41 52|acid suture
P06340703A0324|1 10|Grimelius
P06336045A0261b|153 156|TRP
P06336045A0261b|169 174|phase
P06336045A0261b|81 87|spikes
P06336045A0261b|188 193|spike
P06336045A0261b|127 151|threshold response phase
P06336045A0261b|62 64|SA
P06333878T0000|13 26|acid overdose
P06331684A0607|16 20|test
P06331684A0607|58 67|screening
P06331684A0607|94 108|stomach cancer
P06328485A0277|291 313|chicken proto-myc gene
P06328485A0277|98 101|end
P06328485A0277|145 150|order
P06328485A0277|78 87|delta gag
P06328485A0277|56 58|kb
P06328485A0277|133 140|MH2 DNA
P06328012A0549|85 92|BamHI-K
P06328012A0549|98 112|kilobase pairs
P06328012A0549|67 79|transfection
P06328012A0549|148 151|kbp
P06327638A0155|5 16|gene cat-86
P06327638A0155|108 120|1.1-kilobase
P06327039A0743|96 110|blood pressure
P06327039A0743|46 49|LVM
P06327039A0743|132 138|output
P06327039A0743|16 27|correlation
P06327039A0743|157 167|resistance
P06327039A0743|112 122|heart rate
P06327039A0743|298 299|r
P06324121A0256|16 19|12K
P06324121A0256|145 151|region
P06324121A0256|24 35|polypeptide
P06324121A0256|122 126|base
P06323556A0126|117 125|catheter
P06323556A0126|12 23|tomographic
P06321770A1353|119 124|virus
P06321770A1353|5 15|expression
P06321770A1353|83 92|infection
P06321770A1353|147 153|nature
P06321505A0401|152 171|S1 nuclease mapping
P06321505A0401|3 20|promoter sequence
P06321505A0401|67 77|base pairs
P06321505A0401|42 50|TATA box
P06321505A0401|210 223|transcription
P06319740A1331|102 126|erythroblast hyperplasia
P06319740A1331|172 188|Rauscher disease
P06319740A1331|163 168|phase
P06319740A1331|73 86|amplification
P06319072A0711|23 34|morning dip
P06319072A0711|58 66|patients
P06319072A0711|149 156|results
P06319072A0711|194 220|beta-adrenoceptor function
P06319040A1627|221 229|increase
P06319040A1627|66 87|carotid chemoreceptor
P06319040A1627|42 57|system activity
P06319040A1627|147 156|reduction
P06318091A0395|5 25|splice acceptor site
P06316623A0188|101 106|goats
P06316623A0188|93 97|cent
P06316623A0188|24 32|antibody
P06316623A0188|125 145|immunodiffusion test
P06314312A0359|275 281|levels
P06314312A0359|199 206|average
P06314312A0359|227 242|feed efficiency
P06314312A0359|51 55|diet
P06314312A0359|87 90|ppm
P06314312A0359|189 195|chicks
P06314312A0359|246 253|average
P06314312A0359|61 67|levels
P06310608A0749|69 79|M-MuLV DNA
P06310608A0749|168 181|sarcoma virus
P06310608A0749|5 12|mutants
P06310608A0749|126 138|Ableson MuLV
P06310608A0749|60 65|clone
P06310457A0000|68 72|carp
P06310457A0000|15 25|recordings
P06309020A0473|1 9|Naloxone
P06309020A0473|89 107|lipopolysaccharide
P06309020A0473|13 24|mg/kg bolus
P06308536T0001|5 31|hepatitis A virus antibody
P06306342A1156|4 14|conclusion
P06306342A1156|140 150|disruption
P06306342A1156|196 212|Heidenhain pouch
P06306342A1156|44 48|LiCl
P06300836A0285|207 227|constituent segments
P06300836A0285|55 67|RR1 colonies
P06300836A0285|132 157|DNA clones representative
P06300836A0285|120 128|presence
P06298720A0893|87 108|integration mechanism
P06298720A0893|131 146|MuLV proviruses
P06296833A0000|34 65|cuticle protein gene expression
P06296833A0000|109 115|strain
P06290899T0000|81 86|Japan
P06290899T0000|63 77|chicken flocks
P06287737A0477|103 112|type NANB
P06287737A0477|307 316|hepatitis
P06287737A0477|230 231|%
P06287737A0477|376 385|type NANB
P06287737A0477|258 272|liver diseases
P06287737A0477|50 59|hepatitis
P06287737A0477|291 299|jaundice
P06287737A0477|27 38|transfusion
P06287737A0477|90 99|carcinoma
P06287212A1352|4 8|fact
P06287212A1352|99 108|sequences
P06287212A1352|52 62|initiation
P06287212A1352|128 129|T
P06287212A1352|10 18|families
P06287212A1352|120 123|VP1
P06281891A0399|116 133|pain transmission
P06281891A0399|65 75|substances
P06281891A0399|26 34|pathways
P06281759A1086|19 31|host mutants
P06281759A1086|83 90|PL mRNA
P06281759A1086|161 174|int synthesis
P06281759A1086|133 147|int mRNA decay
P06278544T0027|16 31|Physiopathology
P06277159T0033|3 13|hypothesis
P06270347A0740|65 68|RNA
P06270347A0740|93 105|DNA fragment
P06259220A0464|136 141|shock
P06259220A0464|50 58|reaction
P06259220A0464|122 132|reexposure
P06258806A0963|50 57|element
P06258806A0963|97 101|gene
P06258806A0963|127 137|expression
P06254973A1757|138 140|dT
P06254973A1757|200 202|dT
P06254973A1757|76 91|polynucleotides
P06254973A1757|347 349|n.
P06254973A1757|344 346|dT
P06254973A1757|294 306|accumulation
P06254973A1757|189 191|dT
P06254973A1757|24 39|calf thymus DNA
P06254973A1757|210 212|dT
P06252883A0100|115 124|rotavirus
P06252883A0100|54 57|K88
P06252883A0100|58 61|H10
P06252883A0100|105 108|PWD
P06251469A0830|21 37|library isolates
P06251469A0830|126 132|others
P06251469A0830|148 158|occurrence
P06245672T0000|11 32|macrophage inhibition
P06245672T0000|60 69|reduction
P06242113T0001|26 45|Codonopsis pilosula
P06241900A0000|6 11|study
P06241900A0000|199 208|ischaemia
P06241900A0000|108 116|recovery
P06241900A0000|182 188|period
P06239545A0649|70 76|volume
P06239545A0649|89 95|output
P06239545A0649|134 142|activity
P06238540A0798|71 74|LVH
P06238540A0798|114 135|wall muscle stiffness
P06238540A0798|198 203|slope
P06238540A0798|13 29|volume stiffness
P06234786A0606|48 58|evaluation
P06234786A0606|78 89|cell tumors
P06233924T0000|1 12|Fibrin gels
P06233924T0000|48 68|surface hemorheology
P06233924T0000|72 78|health
P06229542T0045|82 103|template rescue assay
P06229542T0045|61 69|activity
P06225279A0498|100 106|tissue
P06223586A0460|170 174|mice
P06223586A0460|64 72|interval
P06223586A0460|29 40|mitomycin C
P06218005A0948|37 45|L-L size
P06218005A0948|13 21|patients
P06216125A0470|191 199|follicle
P06216125A0470|111 119|follicle
P06216125A0470|40 47|patient
P06216125A0470|123 125|mm
P06212776A0000|119 125|people
P06212776A0000|156 165|knowledge
P06212776A0000|54 63|incidence
P06212776A0000|25 29|town
P06212776A0000|177 185|diseases
P06209403A0562|11 18|repeats
P06209403A0562|47 57|U2/4 locus
P06208024A0168|57 65|RNase T1
P06208024A0168|31 41|digestions
P06203843A0757|137 143|agents
P06203843A0757|1 9|Products
P06203843A0757|20 25|cells
P06199132A0179|137 143|sepsis
P06199132A0179|118 126|patients
P06199132A0179|70 73|WBC
P06198241A0209|32 40|plasmids
P06198241A0209|110 117|markers
P06198241A0209|183 188|cells
P06198241A0209|75 94|replication origins
P06191243T0000|14 26|drawing size
P06185493A0468|3 20|polypeptide chain
P06185493A0468|27 35|residues
P06185493A0468|121 137|ADP binding site
P06184487A1485|171 183|30K proteins
P06184487A1485|116 119|31K
P06184487A1485|200 203|RNA
P06184487A1485|6 10|mRNA
P06184487A1485|25 29|cDNA
P06182979A0807|35 43|emphasis
P06182979A0807|110 119|analogues
P06182979A0807|123 154|cisplatinum diammine dichloride
P06175691T0000|1 32|Bacillus cereus cross-infection
P06173032T0000|71 79|pressure
P06173032T0000|83 93|dipivefrin
P06173032T0000|45 53|response
P06165551A0793|206 212|window
P06165551A0793|278 300|segmentation algorithm
P06165551A0793|9 26|inappropriateness
P06165551A0793|73 79|spikes
P06165551A0793|218 221|sec
P06165551A0793|145 153|duration
P06165551A0793|60 69|isolation
P06165068A0547|50 58|duodenum
P06162419A0118|64 69|doses
P06162419A0118|99 110|development
P06162419A0118|151 155|cent
P06158844A0000|119 127|patients
P06158844A0000|64 81|gamma irradiation
P06158844A0000|27 40|CM-Pf complex
P06153936A0784|51 69|gland examinations
P06153936A0784|128 137|occasions
P06153936A0784|12 17|cases
P06152670T0000|1 16|Plasma secretin
P06152670T0000|54 61|hormone
P06151518A0000|114 118|rats
P06151518A0000|66 70|form
P06151518A0000|10 14|acid
P06151518A0000|150 160|injections
P06151518A0000|164 172|dexazone
P06147504A0086|5 13|patients
P06147504A0086|91 95|mass
P06142279T0000|39 52|haemodialysis
P06142279T0000|27 35|patients
P06138313A0948|5 23|distribution phase
P06138313A0948|126 138|distribution
P06138313A0948|105 108|min
P06137028A0624|1 12|Propranolol
P06131378A0818|84 93|DHFR cDNA
P06131378A0818|53 62|sequences
P06131378A0818|11 15|mRNA
P06130348T0000|1 10|Isolation
P06130348T0000|14 23|Aeromonas
P06120429T0000|41 52|radioiodine
P06120429T0000|91 105|thyroid cancer
P06113443T0000|32 44|erythrocytes
P06113443T0000|63 66|use
P06111283T0032|1 16|Trial treatment
P06111283T0032|20 33|schizophrenia
P06109017A0000|32 38|beta-1
P06109017A0000|200 202|LV
P06109017A0000|280 290|blood flow
P06109017A0000|224 229|dP/dt
P06109017A0000|322 326|dogs
P06109017A0000|114 125|prenalterol
P06109017A0000|214 222|diameter
P06109017A0000|62 78|4-hydroxyphenoxy
P06101359T0000|46 53|tumours
P06098828A0352|69 78|sequences
P06098828A0352|5 12|results
P06098828A0352|107 121|RNA polymerase
P06097285A1077|112 127|motor behaviour
P06097285A1077|22 33|haloperidol
P06096863T0000|34 43|CYC1 gene
P06096863T0000|10 26|activation sites
P06096246T0000|41 47|stress
P06096246T0000|105 109|rats
P06095372A0435|5 9|drug
P06095372A0435|58 59|h
P06093363A0612|1 4|USA
P06093363A0612|66 85|amino acid sequence
P06093363A0612|28 36|proteins
P06092588T0000|1 18|Hepatitis B virus
P06091914A0000|139 149|expression
P06091914A0000|173 181|oncogene
P06091914A0000|189 194|int-1
P06091914A0000|46 57|tumor virus
P06091914A0000|120 126|genome
P06090369A0000|70 77|studies
P06090369A0000|59 64|Phase
P06088722A0171|1 8|Courses
P06088722A0171|36 44|recovery
P06084864T0001|42 53|oligoamnios
P06084279A0218|55 68|serum amylase
P06084279A0218|22 30|patients
P06074093T0001|1 5|Iron
P06074093T0001|31 40|pregnancy
P06072512T0000|38 44|action
P06054411T0000|35 53|gas chromatography
P06054411T0000|71 90|combination columns
P06054411T0000|61 67|series
P06048505T0000|1 12|Derivatives
P06027841T0000|32 51|hyperfine structure
P06027841T0000|9 13|spin
P05999607T0001|36 46|precursors
P05999607T0001|12 23|lipogenesis
P05994421T0045|70 78|Santiago
P05994421T0045|53 59|region
P05994421T0045|63 68|Nunoa
P05985275T0000|15 24|substance
P05969185T0001|26 30|cord
P05960999T0001|1 6|Value
P05960999T0001|24 48|passive hemagglutination
P05960999T0001|182 187|serum
P05960999T0001|14 20|method
P05949971T0000|16 25|toxaphene
P05949971T0000|37 42|lakes
P05938720T0000|1 6|Story
P05938720T0000|12 20|hospital
P05930797T0000|9 16|studies
P05917315T0026|3 14|case report
P05901778T0000|39 49|deposition
P05901778T0000|53 57|mice
P05893495T0001|1 8|Studies
P05893495T0001|31 40|infection
P05890351T0001|7 24|antitetanus serum
P05884183T0001|1 11|Experience
P05884183T0001|36 60|agglutination properties
P05884183T0001|131 137|method
P05879595T0094|1 11|Statistics
P05858571T0000|22 29|1,3-bis
P05858571T0000|47 58|nitrosourea
P05858571T0000|30 43|2-chloroethyl
P05850652T0001|64 78|I-131-triolein
P05850652T0001|93 97|body
P05850652T0001|109 112|rat
P05839844T0000|1 15|Histochemistry
P05839844T0000|20 39|electron microscopy
P05839844T0000|90 99|ducklings
P05836483T0000|39 48|childhood
P05826818T0098|1 3|I.
P05822499T0034|5 14|structure
P05810259T0001|24 41|solution mediator
P05806936T0000|66 73|colitis
P05806936T0000|89 97|subjects
P05806936T0000|15 27|electrolytes
P05805644T0001|35 47|distribution
P05805644T0001|126 140|colloidal ThO2
P05805644T0001|94 102|skeleton
P05805644T0001|61 66|224Ra
P05798063T0000|32 41|prototype
P05798063T0000|15 30|family practice
P05792911T0000|1 8|Effects
P05792911T0000|108 116|subjects
P05792911T0000|28 45|receptor blockade
P05789870T0001|52 70|hyperbilirubinemia
P05782943T0001|1 13|Relationship
P05782943T0001|60 64|skin
P05779953T0000|39 47|serum LH
P05779953T0000|52 55|FSH
P05769307T0000|1 19|Automatic view box
P05758469T0001|1 21|Hemodynamics changes
P05758469T0001|25 28|man
P05750950T0001|23 32|abilities
P05742879T0000|1 16|Transformations
P05734847T0000|1 8|Studies
P05734847T0000|30 55|Glossina morsitans colony
P05733952T0001|65 84|antibody production
P05733952T0001|5 17|significance
P05727222T0000|5 12|effects
P05727222T0000|40 45|pumps
P05722341T0000|34 49|monosaccharides
P05722341T0000|71 76|urine
P05722341T0000|20 30|estimation
P05719031T0000|16 22|method
P05719031T0000|54 63|compounds
P05718500T0001|34 41|decidua
P05718500T0001|56 60|half
P05715613T0000|1 8|Sterols
P05693602T0001|1 11|Evaluation
P05689427T0052|4 38|N-Alkyl-N-2-chloroethylaminomethyl
P05689427T0052|62 63|b
P05683809T0000|54 84|surface charge characteristics
P05683809T0000|95 108|blood vessels
P05672903T0001|1 24|Osteogenesis imperfecta
P05621339T0001|34 51|Cs137 irradiation
P05594277T0051|21 31|P32 uptake
P05594277T0051|78 86|peroxide
P05594277T0051|104 110|medium
P05574818T0000|5 8|Lab
P05574818T0000|11 30|computer programmes
P05574818T0000|122 128|muscle
P05560428T0001|78 86|reptiles
P05560428T0001|31 41|expression
P05555149T0001|24 30|method
P05552642T0000|17 35|hormone production
P05552642T0000|81 85|rats
P05544291T0031|1 3|V.
P05533214T0001|30 41|thyroiditis
P05529283T0000|48 54|health
P05529283T0000|59 66|disease
P05502054T0000|50 55|cases
P05502054T0000|13 18|twins
P05500957T0001|34 43|hydergine
P05500957T0001|5 16|association
P05500957T0001|63 72|treatment
P05500957T0001|45 54|Brinedine
P05496619T0000|9 17|profiles
P05488121T0000|49 61|filter paper
P05472485T0000|37 44|rodents
P05466177T0001|24 37|actinomycin D
P05466177T0001|13 20|effects
P05460466T0001|1 12|Elimination
P05460466T0001|63 80|drug preparations
P05451324T0000|70 83|CO saturation
P05451324T0000|33 38|blood
P05451324T0000|62 65|Po2
P05441564T0001|1 8|Studies
P05441564T0001|41 45|HILL
P05441564T0001|47 52|virus
P05425195T0001|119 125|course
P05425195T0001|1 9|Behavior
P05425195T0001|83 85|EC
P05425195T0001|41 43|EC
P05425195T0001|135 153|radiation syndrome
P05421537T0001|36 52|sputum viscosity
P05414186T0001|11 30|Hong Kong influenza
P05412687T0000|24 32|impulses
P05412687T0000|47 68|collateral inhibition
P05410641T0000|9 16|percent
P05394461T0001|1 15|Tolerance test
P05394461T0001|29 47|animal experiments
P05389125T0000|52 56|mice
P05379901T0000|18 32|flood channels
P05368978T0000|71 87|amine mechanisms
P05363816T0001|5 9|need
P05363816T0001|58 62|list
P05359464T0000|17 20|use
P05359464T0000|70 89|radiation dosimetry
P05357390T0001|1 5|Auto
P05357390T0001|11 18|isotopy
P05353667T0000|8 27|cord representation
P05340801T0000|25 30|foods
P05322558T0000|24 48|hemagglutinin production
P05309471T0000|17 30|determination
P05309471T0000|48 55|content
P05305671T0000|23 41|color deficiencies
P05299993T0000|84 93|mechanism
P05299993T0000|21 27|growth
P05299993T0000|31 42|Tetrahymena
P05284310T0000|87 90|rat
P05284310T0000|44 58|plasma calcium
P05274526T0000|37 46|remission
P05253274T0001|1 13|Osteosarcoma
P05203499T0001|54 57|BSP
P05203499T0001|22 35|scintillation
P05203499T0001|59 70|description
P05203499T0001|78 91|thyroid gland
P05174753T0001|15 25|dysostosis
P05172320T0001|93 101|triradii
P05172320T0001|42 48|prints
P05172320T0001|63 72|reference
P05162342T0001|11 17|tumors
P05154132T0000|5 10|value
P05154132T0000|47 52|diets
P05145925T0000|16 22|nature
P05145925T0000|60 69|potential
P05135168T0000|20 24|bark
P05132558T0000|64 92|monoamine oxidase inhibitors
P05132558T0000|5 16|interaction
P05132558T0000|30 42|theophylline
P05123884T0000|25 47|4-chlorophenoxyacetate
P05119546T0001|1 10|Treatment
P05110049T0001|35 42|therapy
P05110049T0001|46 57|scleroderma
P05101762T0000|19 27|syndrome
P05093030T0001|69 76|methods
P05093030T0001|80 107|medium-tension intophoresis
P05093030T0001|47 52|urine
P05081814T0000|1 12|Derivatives
P05068271T0000|1 10|Influence
P05068271T0000|30 43|VMA excretion
P05065548T0075|24 44|Dryopteris polylepis
P05049711T0000|9 23|session report
P05034373T0000|69 80|requirement
P05034373T0000|12 16|role
P05031074T0001|50 72|calcium administration
P05031074T0001|28 37|pregnancy
P05027799T0000|31 38|failure
P05025918T0000|27 36|bone cyst
P05020660T0000|53 67|chlorpromazine
P05020660T0000|37 49|phagocytosis
P05012220T0000|10 20|experience
P05000171T0000|51 73|horseradish peroxidase
P05000171T0000|99 105|spaces
P05000171T0000|23 27|flow
P04992478T0000|1 19|Plasma histaminase
P04992478T0000|23 31|patients
P04992478T0000|45 51|asthma
P04989251T0000|13 28|corticosteroids
P04975676T0000|67 86|allotransplantation
P04970918T0069|1 11|LA-3848-MS
P04967824T0000|71 75|newt
P04967824T0000|46 63|melanin synthesis
P04948325T0000|1 10|Isolation
P04948325T0000|42 51|carcinoma
P04948325T0000|73 79|effect
P04948325T0000|14 21|Proteus
P04942414T0000|5 15|metabolism
P04941419T0000|1 29|Yusuf Dawood Docrat L.R.C.P.
P04911925T0001|1 35|Electrocardiographic QRS complexes
P04890336T0001|33 50|Wassermann reagin
P04890336T0001|97 101|RPCF
P04890336T0001|106 120|FTA antibodies
P04878680T0000|85 91|survey
P04878680T0000|49 55|cavity
P04878680T0000|72 79|results
P04863895T0000|1 13|Relationship
P04863895T0000|57 66|serotypes
P04863895T0000|28 35|lesions
P04843031T0000|100 108|fibrosis
P04843031T0000|5 11|levels
P04843031T0000|79 87|patients
P04837183T0000|17 25|saccules
P04837183T0000|55 67|hypergravity
P04826272T0074|1 4|VII
P04820791T0001|22 26|acid
P04820791T0001|44 54|conditions
P04810131T0000|42 49|smoking
P04801663T0049|31 41|properties
P04796997T0000|117 122|bitch
P04796997T0000|22 29|effects
P04796997T0000|8 20|reproduction
P04791420T0000|40 41|S
P04791420T0000|74 80|possum
P04791420T0000|14 21|Barrels
P04788701T0001|70 77|breasts
P04788701T0001|56 62|tumors
P04787472T0001|64 70|action
P04787472T0001|95 100|field
P04787472T0001|15 21|makeup
P04782788T0001|31 39|patients
P04766888T0000|49 64|meningococcemia
P04766888T0000|29 37|children
P04760826T0000|43 57|undergraduates
P04758799T0000|1 13|Pneumothorax
P04753286T0000|35 38|rat
P04753286T0000|1 12|Suppression
P04752455T0000|35 43|security
P04733391T0000|1 29|Metal coordination compounds
P04729063T0000|32 42|investment
P04729063T0000|14 21|justice
P04718233T0000|32 43|rat kidneys
P04704186T0000|19 27|Hereford
P04704186T0000|76 83|heifers
P04704186T0000|29 37|Hereford
P04679807T0000|46 66|breathalyzer ampules
P04676734T0000|57 70|plasma levels
P04676734T0000|105 108|age
P04656185T0000|32 39|changes
P04656185T0000|43 59|plasma nutrients
P04653144T0000|51 61|population
P04653144T0000|33 45|heritability
P04645078T0001|31 43|cervix uteri
P04638365T0001|1 7|Effect
P04638365T0001|11 20|triftazin
P04627477T0001|51 52|H
P04627477T0001|81 92|lividomycin
P04627477T0001|56 58|Rv
P04622430T0000|52 65|Rhesus monkey
P04615828T0001|18 44|colonel prof. e.cerny m.d.
P04613073T0001|1 5|Role
P04613073T0001|27 40|manifestation
P04598670T0000|7 24|graft irradiation
P04598670T0000|31 38|adjunct
P04580044T0047|10 23|relationships
P04578686T0000|1 13|Pneumothorax
P04562038T0001|42 51|influence
P04562038T0001|73 84|lymphocytes
P04551650T0001|1 15|Cell viability
P04547933T0000|95 98|eye
P04547933T0000|73 81|junction
P04544704T0001|1 7|Method
P04544704T0001|39 45|factor
P04543036T0001|1 11|Directives
P04536964T0000|68 87|bullfrog toe muscle
P04536964T0000|19 29|H ion flux
P04524081T0000|17 25|response
P04524081T0000|38 45|tissues
P04524081T0000|62 89|aluminum chloride solutions
P04515631T0000|24 36|antithrombin
P04515631T0000|46 56|assessment
P04511139T0001|1 11|Composites
P04506738T0000|1 10|Junctions
P04506738T0000|38 50|enamel organ
P04488271T0001|55 59|coma
P04488271T0001|15 19|care
P04482661T0001|68 71|use
P04482661T0001|21 33|nursing care
P04482661T0001|37 45|patients
P04482661T0001|75 82|pillows
P04460692T0000|10 16|topics
P04445874T0001|14 22|neuritis
P04429269T0000|21 26|mucus
P04429269T0000|8 17|transport
P04428800T0001|1 7|Effect
P04428800T0001|52 64|GPT activity
P04428800T0001|72 78|plasma
P04428800T0001|31 40|increases
P04418687T0000|25 40|glucocorticoids
P04418687T0000|12 20|estrogen
P04394290T0000|48 54|rectum
P04394290T0000|96 99|cat
P04394290T0000|31 40|receptors
P04387103T0000|1 10|Particles
P04387103T0000|78 82|dogs
P04371279T0000|1 8|Absence
P04371279T0000|33 37|frog
P04371279T0000|12 29|action potentials
P04364369T0000|1 23|Pre-beta-1 lipoprotein
P04364369T0000|47 59|risk factors
P04335965T0000|38 41|lip
P04325736T0001|1 14|Serodiagnosis
P04325736T0001|18 28|ectromelia
P04321861T0001|10 42|glutathione reductase deficiency
P04321861T0001|47 55|disorder
P04308979T0000|102 113|quartz dust
P04308979T0000|1 7|Effect
P04308979T0000|25 38|time interval
P04308979T0000|11 21|variations
P04308979T0000|62 65|BCG
P04295031T0062|21 31|guinea pig
P04289156T0000|35 43|chickens
P04289156T0000|5 14|incidence
P04282315T0001|87 95|pancreas
P04282315T0001|18 33|hyperlactatemia
P04263748T0042|24 30|review
P04247966T0000|32 56|protein maintenance diet
P04246054T0028|1 7|Effect
P04246054T0028|18 29|lymphocytes
P04246054T0028|89 100|macrophages
P04226360T0001|51 60|leukemias
P04226360T0001|14 31|platelet function
P04213917T0001|6 13|dosages
P04194466T0000|1 17|Serotonin levels
P04179445T0036|1 3|D.
P04176268T0000|64 71|failure
P04176268T0000|25 34|treatment
P04175007T0001|67 73|tumors
P04175007T0001|8 15|problem
P04175007T0001|124 135|antibiotics
P04164669T0000|27 42|kinin formation
P04160980T0000|53 56|dog
P04145244T0000|1 11|Relaxation
P04145244T0000|15 20|catch
P04140567T0001|49 54|shock
P04139081T0001|6 16|antibodies
P04123662T0000|15 31|thyroid function
P04115870T0000|48 51|use
P04113011T0000|5 20|desensitization
P04102280T0000|1 10|Treatment
P04102280T0000|14 19|Paget
P04093211A0560|76 88|orientations
P04088733T0001|1 9|Activity
P04088733T0001|83 92|pneumonia
P04088733T0001|13 28|acid hydrolases
P04086657T0000|66 69|rat
P04086657T0000|22 33|development
P04085589A0264b|155 173|tract colonization
P04085589A0264b|109 130|serum lysozyme levels
P04085589A0264b|14 25|correlation
P04084896A0569|117 140|intervention strategies
P04084896A0569|42 52|sub-groups
P04082592T0000|1 18|Blood eosinophils
P04082592T0000|22 30|patients
P04081425T0016|10 17|aspects
P04075061A0355|21 26|total
P04075061A0355|5 12|runners
P04074214A0000|1 8|Factors
P04074214A0000|82 93|environment
P04071063A0863|137 143|levels
P04071063A0863|87 93|groups
P04071063A0863|43 51|decrease
P04071063A0863|198 203|group
P04069756T0025|35 54|leukoencephalopathy
P04068774A1292|119 123|bone
P04068774A1292|38 40|Zn
P04068774A1292|89 97|contents
P04068774A1292|44 46|Mg
P04067540A0413|327 334|victims
P04067540A0413|251 258|weekend
P04067540A0413|114 121|victims
P04067540A0413|188 193|crime
P04067540A0413|350 356|spouse
P04067540A0413|167 175|ex-lover
P04066194A0163|141 144|ear
P04066194A0163|191 194|ear
P04066194A0163|218 241|stimulation arrangement
P04066194A0163|160 168|material
P04062128T0028|1 20|National Institutes
P04058985A0000|98 114|plasma prolactin
P04058985A0000|61 66|women
P04056218A0463|51 56|dB/dB
P04056218A0463|6 11|slope
P04056218A0463|62 64|L1
P04052919A0205|171 176|phase
P04052919A0205|374 383|indicator
P04052919A0205|312 324|progesterone
P04052919A0205|281 284|use
P04052919A0205|195 214|progesterone levels
P04052919A0205|459 465|number
P04052919A0205|387 396|ovulation
P04052919A0205|484 491|results
P04052919A0205|265 275|thresholds
P04050821A0531|155 163|hospital
P04050821A0531|20 30|mechanisms
P04050821A0531|124 132|episodes
P04043489A0648|41 51|re-reading
P04041307A0614|50 59|diltiazem
P04041307A0614|5 12|results
P04041307A0614|76 83|effects
P04040339T0001|68 77|tocolysis
P04040339T0001|55 60|fetus
P04040339T0001|123 130|Pre-par
P04040083A0000|1 12|Rabbit eyes
P04040083A0000|60 68|chambers
P04039667T0000|32 52|Walker carcinoma-256
P04039667T0000|56 75|Sprague-Dawley rats
P04039439A0842|100 107|rodents
P04039439A0842|6 11|study
P04039307A0613|4 5|d
P04039307A0613|94 110|treatment groups
P04039307A0613|72 79|heifers
P04038702A0768|163 171|cortisol
P04038702A0768|348 353|gilts
P04038702A0768|153 159|rhythm
P04038702A0768|289 295|stalls
P04038702A0768|115 125|experience
P04038702A0768|94 101|penning
P04037809A0964|29 43|dose schedules
P04034666T0000|7 31|extremity weight bearing
P04034666T0000|94 102|patients
P04033402A1112|84 112|HDL2-cholesterol subfraction
P04033402A1112|29 37|hormones
P04032349A0000|33 43|occlusions
P04032349A0000|174 187|units/kg/hour
P04032349A0000|53 69|graft thromboses
P04032349A0000|193 208|Lys Plasminogen
P04031488A1091|18 29|correlation
P04031488A1091|37 42|sense
P04031488A1091|58 68|conception
P04027182T0000|1 9|Vitiligo
P04026903A0512|137 149|contractions
P04026903A0512|187 193|barium
P04026903A0512|38 47|stimulant
P04026903A0512|219 228|carbachol
P04026903A0512|77 93|guinea pig ileum
P04026903A0512|161 174|acetylcholine
P04025178A0126|139 144|ml/m2
P04025178A0126|113 125|volume index
P04025178A0126|95 97|LV
P04025178A0126|61 69|decrease
P04021437A0000|87 103|ear dysfunctions
P04021437A0000|7 17|infections
P04021305A0530|17 33|desympathization
P04021305A0530|218 232|catecholamines
P04021305A0530|209 214|cells
P04021305A0530|62 78|hyper-reactivity
P04021305A0530|91 101|pacemakers
P04021305A0530|105 118|noradrenaline
P04019066A0000|16 32|field potentials
P04019066A0000|141 144|SCX
P04019066A0000|178 187|halothane
P04019066A0000|133 139|cortex
P04017295A0139|5 15|comparison
P04017295A0139|56 64|dialyses
P04014861A0000|34 43|liposomes
P04014861A0000|154 162|catalase
P04014861A0000|67 73|agents
P04014861A0000|176 191|oxygen toxicity
P04014861A0000|124 144|superoxide dismutase
P04013604A0412|16 25|frequency
P04013604A0412|109 132|slow-release tablet use
P04013604A0412|74 79|cases
P04011466T0000|39 47|children
P04011466T0000|72 76|data
P04005190A1288|29 40|PCA content
P04002667A0181|39 46|results
P04002667A0181|113 125|localization
P04002667A0181|129 140|lung tissue
P04002667A0181|90 92|cm
P04001490T0001|21 35|Polyneuropathy
P04001490T0001|37 49|Organomegaly
P04001490T0001|89 93|Skin
P04000347A0442|66 73|persons
P04000347A0442|219 226|disease
P04000347A0442|95 101|groups
P04000347A0442|134 137|BEN
P03998813A0406|48 52|role
P03998813A0406|173 179|system
P03998813A0406|126 142|frequency tuning
P03998813A0406|150 155|mouse
P03997467A0000|5 11|effect
P03997467A0000|26 45|antagonist naloxone
P03992022A0330|118 146|aniline hydroxylase activity
P03992022A0330|257 274|enzyme activities
P03992022A0330|218 222|rats
P03992022A0330|23 33|cytochrome
P03992022A0330|63 70|enzymes
P03992022A0330|181 185|rats
P03988001A0227|105 109|ClO2
P03987818A0440|7 11|data
P03987818A0440|77 90|heart failure
P03984683A0000|21 32|hemiparesis
P03984683A0000|36 46|hemiplegia
P03984683A0000|7 17|appearance
P03981952T0000|92 103|salt intake
P03981952T0000|46 64|chloride titrators
P03981421A0246|66 72|volume
P03981421A0246|78 80|mL
P03981421A0246|56 64|receptor
P03979084A1019|69 78|functions
P03979084A1019|10 17|kidneys
P03978045A0857|175 183|syndrome
P03978045A0857|97 103|stages
P03978045A0857|47 53|stages
P03978045A0857|153 160|vessels
P03978045A0857|55 57|0T
P03978045A0857|59 61|0N
P03978045A0857|264 275|alterations
P03977577T0000|1 25|Shoulder forearm support
P03974790A0053|50 63|brain infarct
P03974790A0053|13 24|CT findings
P03972038A0000|84 90|region
P03972038A0000|5 15|topography
P03972038A0000|40 58|commissural fibers
P03965012A0163|119 133|heart diseases
P03965012A0163|33 38|years
P03965012A0163|5 12|results
P03965012A0163|135 146|ICD A83-A84
P03964489A1195|9 19|% decrease
P03959045A0000|100 130|Medical College Admission Test
P03959045A0000|20 32|relationship
P03959045A0000|132 136|MCAT
P03956647A1063|255 264|densities
P03956647A1063|291 296|A/cm2
P03956647A1063|64 92|scanning electron microscopy
P03956647A1063|127 142|microC/cm2 X ph
P03956647A1063|162 169|erosion
P03956647A1063|271 286|microC/cm2 X ph
P03952387A0336|100 113|oxyhemoglobin
P03952387A0336|64 72|reaction
P03952387A0336|9 20|compartment
P03944239A0780|141 143|T4
P03944239A0780|23 31|patients
P03944239A0780|176 178|T3
P03944239A0780|13 17|time
P03940818T0000|34 45|HBV carrier
P03940426A0618|1 8|Results
P03940426A0618|37 40|GLC
P03940426A0618|17 22|study
P03940426A0618|50 55|chain
P03940426A0618|189 192|fir
P03940426A0618|212 232|genus identification
P03940426A0618|62 67|acids
P03937481T0001|20 33|microanalysis
P03936828T0000|64 77|thyroid gland
P03936828T0000|41 56|B-cell lymphoma
P03935375A0414|119 126|medulla
P03935375A0414|86 98|biochemistry
P03935375A0414|6 13|article
P03935375A0414|213 217|rise
P03935375A0414|72 80|function
P03935375A0414|194 201|changes
P03934667A0124|35 40|crsA1
P03934667A0124|273 279|pUB110
P03934667A0124|231 237|factor
P03934667A0124|19 33|crsA mutations
P03934667A0124|86 101|gene conversion
P03934667A0124|53 59|crsA47
P03934667A0124|241 267|B. subtilis RNA polymerase
P03933232T0000|66 83|animal morphology
P03933232T0000|28 37|structure
P03931293A0437|48 55|sucrose
P03931293A0437|25 36|stabilizers
P03931293A0437|78 94|thermoresistance
P03930549A0209|5 11|sample
P03930549A0209|126 135|injection
P03930549A0209|63 67|acid
P03929486A0309|33 41|patients
P03929486A0309|235 242|mg/d SR
P03929486A0309|173 174|D
P03929486A0309|227 229|SR
P03929486A0309|107 124|ejection fraction
P03929486A0309|253 258|drugs
P03929486A0309|216 224|releases
P03929486A0309|53 64|NYHA II-III
P03929486A0309|148 149|%
P03928442A0463|97 106|phage SPR
P03928442A0463|25 33|homology
P03928442A0463|61 66|genes
P03928442A0463|15 21|degree
P03925712A0229|87 107|transport mechanisms
P03925712A0229|52 67|enzyme activity
P03923828A1031|21 36|cryoprecipitate
P03923828A1031|83 92|treatment
P03923828A1031|179 189|procedures
P03923828A1031|130 138|bleeding
P03921727A0523|35 43|apo A-II
P03921727A0523|5 19|concentrations
P03921727A0523|125 133|controls
P03915540A0863|69 79|efficiency
P03915540A0863|4 12|addition
P03915540A0863|110 114|gcn2
P03915540A0863|120 124|gcn3
P03913522A0000|36 51|function change
P03911965A0513|212 219|placebo
P03911965A0513|25 37|significance
P03911965A0513|106 117|superiority
P03911052A0909|49 51|CP
P03911052A0909|98 100|CP
P03911052A0909|127 139|CABG surgery
P03908493A0246|113 121|sections
P03908493A0246|37 42|resin
P03904952T0000|1 18|Nursing education
P03898382A0000|204 218|sulfur colloid
P03898382A0000|115 122|lesions
P03898382A0000|163 182|radiogallium survey
P03898382A0000|59 71|67Ga citrate
P03894482A0549|152 165|control serum
P03894482A0549|5 13|patients
P03894482A0549|127 132|times
P03894482A0549|88 102|binding values
P03890486A0000|87 104|imaging confusion
P03890486A0000|59 64|cause
P03890486A0000|151 161|malignancy
P03887769A0584|50 60|population
P03887769A0584|99 100|%
P03887769A0584|108 125|iodine deficiency
P03887085A0000|169 176|hypoxia
P03887085A0000|201 212|CBA X C57Bl
P03887085A0000|79 88|cystamine
P03887085A0000|134 144|conditions
P03887085A0000|117 122|mg/kg
P03887085A0000|213 220|F1 mice
P03887085A0000|181 182|%
P03883541A0200|5 28|H2 receptor antagonists
P03882029A0000|17 22|study
P03882029A0000|156 166|components
P03882029A0000|177 191|cat epithelium
P03882029A0000|107 108|%
P03882029A0000|121 125|cats
P03880838T0000|52 76|captopril administration
P03877298A0718|139 153|recovery times
P03877298A0718|5 12|results
P03877298A0718|110 121|variability
P03874921A0862|1 14|Documentation
P03874921A0862|172 181|procedure
P03874921A0862|144 155|anovulation
P03874921A0862|131 133|EP
P03874921A0862|44 57|fertilization
P03871445T0000|19 26|mapping
P03871445T0000|43 51|analysis
P03869442A0223|51 59|disorder
P03869442A0223|4 12|addition
P03869442A0223|148 167|vasopressin therapy
P03865743A0859|51 58|HDL2-C.
P03865743A0859|87 103|apo A-II/B ratio
P03865743A0859|7 14|results
P03865743A0859|148 161|heart disease
P03865743A0859|60 65|apo B
P03863231A0530|43 49|factor
P03861687A0000|101 110|treatment
P03861687A0000|74 78|care
P03861687A0000|30 35|males
P03857577A0413|138 148|HeLa cells
P03857577A0413|53 66|DNA sequences
P03843676A0381|53 57|data
P03843676A0381|108 112|risk
P03841627T0001|1 13|Chemotherapy
P03838797A0903|170 174|cDNA
P03838797A0903|111 115|mRNA
P03838797A0903|95 103|sequence
P03838797A0903|73 80|absence
P03836854T0000|1 11|Inhibition
P03836854T0000|63 65|RP
P03836777T0001|85 100|HBs Ag carriers
P03836777T0001|19 33|interpretation
P03836777T0001|120 135|hepatitis stage
P03830255A0074|65 77|distribution
P03829848T0001|116 125|extremity
P03829848T0001|26 38|vein segment
P03829848T0001|44 49|valve
P03828209T0000|16 23|changes
P03828209T0000|61 67|adults
P03826871A0000|53 59|Br ion
P03826871A0000|76 86|Greyhounds
P03820222A0203|143 148|group
P03818467A0180|186 194|activity
P03818467A0180|1 9|Selenium
P03818467A0180|23 24|E
P03818467A0180|59 63|diet
P03818467A0180|29 34|IU/kg
P03818467A0180|14 17|ppm
P03811852A0109|64 71|factors
P03811852A0109|20 33|complications
P03811852A0109|112 129|magnesium sulfate
P03811852A0109|82 91|gestation
P03811852A0109|150 157|agonist
P03810361A0576|175 184|diagnosis
P03810361A0576|110 136|plasma cortisol estimation
P03810361A0576|198 206|syndrome
P03805090A0645|35 43|patients
P03805090A0645|233 242|certainty
P03805090A0645|108 116|patients
P03805090A0645|17 25|analyses
P03805090A0645|246 254|patients
P03805090A0645|182 187|years
P03805090A0645|90 104|chondrosarcoma
P03799790A0146|103 108|light
P03799790A0146|49 52|eye
P03799790A0146|67 81|ophthalmoscopy
P03799790A0146|160 167|margins
P03795488A0487|100 113|response rate
P03795488A0487|89 91|PR
P03789052A0527|16 31|tissue response
P03789052A0527|48 66|cyanoacrylate site
P03789052A0527|141 156|tissue adhesive
P03789052A0527|95 103|chemical
P03785212A1128|36 49|Alu sequences
P03783160A0285|50 63|R1-barrigenol
P03783160A0285|96 109|R1-barrigenol
P03781000A0101|68 76|activity
P03781000A0101|6 10|lack
P03781000A0101|128 134|stages
P03781000A0101|14 25|correlation
P03780371A0792|52 59|introns
P03780371A0792|12 21|sequences
P03779205A0459|171 176|years
P03779205A0459|118 126|patients
P03779205A0459|99 111|presentation
P03779205A0459|12 20|patients
P03777398A0156|1 9|Examples
P03776438A0000|1 15|Glucocorticoid
P03776438A0000|81 83|Na
P03776438A0000|24 36|hypertension
P03776438A0000|73 79|sodium
P03774111T0000|1 9|Evidence
P03774111T0000|53 61|response
P03771749A0465|51 61|miconazole
P03771749A0465|207 240|microtiter broth dilution systems
P03771749A0465|81 95|amphotericin B
P03771749A0465|189 202|agar dilution
P03771749A0465|133 148|Candida species
P03771749A0465|180 185|media
P03771670T0058|1 11|Prevention
P03769224A0000|70 73|SLE
P03769224A0000|26 34|patients
P03769224A0000|13 17|data
P03766370A0546|42 52|deviations
P03766370A0546|13 21|r values
P03765552A0582|169 187|antibody synthesis
P03765552A0582|18 24|action
P03765552A0582|5 14|mechanism
P03765552A0582|45 51|detail
P03763241A0446|43 54|extremities
P03761122T0000|5 14|relations
P03761122T0000|23 38|type A behavior
P03761122T0000|60 68|behavior
P03759330A0713|86 88|G1
P03759330A0713|5 16|combination
P03759330A0713|27 29|F2
P03759330A0713|74 84|population
P03757294A0414|49 54|cysts
P03757294A0414|101 112|liver cysts
P03757294A0414|8 13|cases
P03757294A0414|61 62|%
P03755623A1233|99 103|DLIS
P03751308T0001|85 106|2-deoxyglucose method
P03751308T0001|1 6|Study
P03751308T0001|39 56|sensomotor cortex
P03751308T0001|61 72|hippocampus
P03749226A0506|6 19|phencyclidine
P03749226A0506|88 94|errors
P03746906A0000|119 134|Type A behavior
P03746906A0000|87 90|JAS
P03746906A0000|5 12|studies
P03746906A0000|26 31|types
P03746601A0299|32 45|extravasation
P03746601A0299|59 65|sepsis
P03746601A0299|94 99|total
P03746107A0192|51 58|tumours
P03745833A0258|102 110|increase
P03745833A0258|32 39|voltage
P03745833A0258|64 68|fall
P03745833A0258|231 239|cerebrum
P03745833A0258|81 89|pressure
P03745833A0258|144 149|brain
P03745833A0258|244 254|cerebellum
P03743702A0158|305 311|micron
P03743702A0158|237 241|mean
P03743702A0158|283 289|micron
P03743702A0158|130 137|lingual
P03743702A0158|17 18|%
P03743702A0158|261 267|micron
P03743702A0158|246 248|SD
P03743702A0158|331 337|micron
P03743702A0158|120 128|alveolar
P03738919A0000|85 94|vertebrae
P03738919A0000|32 37|aorta
P03738919A0000|148 158|tomography
P03734641A0203|71 76|force
P03734641A0203|5 12|results
P03734641A0203|97 104|failure
P03733563A0716|66 79|serum dextran
P03733563A0716|93 119|cholesterol concentrations
P03728230A0104|16 24|hospital
P03721666A0000|1 7|Nickel
P03721666A0000|141 142|%
P03721666A0000|67 76|Singapore
P03721666A0000|45 63|contact dermatitis
P03720966A1043|48 56|N intake
P03717936A0252|34 44|tobramycin
P03717936A0252|66 80|aminoglycoside
P03714473A0496|1 10|Induction
P03714473A0496|29 40|transcripts
P03713187A0691|222 231|frequency
P03713187A0691|80 89|frequency
P03713187A0691|93 103|occurrence
P03713187A0691|199 204|sites
P03713187A0691|10 17|lesions
P03713187A0691|150 156|muscle
P03712106A0000|51 62|utilization
P03712106A0000|5 11|effect
P03712106A0000|122 146|nitrogen balance studies
P03710973A0817|1 5|Mean
P03710973A0817|33 36|Tsk
P03710973A0817|158 177|Tre-to-Tsk gradient
P03710973A0817|106 117|acclimation
P03709191A0125|139 145|number
P03709191A0125|38 44|cortex
P03709191A0125|52 55|rat
P03709191A0125|75 81|volume
P03703493A0654|5 11|number
P03703493A0654|27 35|deposits
P03700952A0273|1 8|Infants
P03700952A0273|38 40|PL
P03700952A0273|89 97|McDonald
P03697971A0311|81 95|stomach mucosa
P03697971A0311|143 153|diet group
P03697971A0311|24 55|glutathione peroxidase activity
P03697587T0000|5 29|XXXXY chromosome anomaly
P03697587T0000|67 75|syndrome
P03694102A0000|152 157|leads
P03694102A0000|5 16|development
P03694102A0000|73 82|reference
P03692331A0000|35 45|antagonist
P03692331A0000|99 104|women
P03692331A0000|47 55|pindolol
P03690262A0428|204 206|T5
P03690262A0428|33 42|responses
P03690262A0428|99 101|T2
P03690262A0428|189 191|T1
P03690262A0428|213 217|rami
P03690262A0428|193 195|T3
P03688301A0129|100 105|cases
P03688301A0129|39 45|spread
P03688301A0129|72 78|type A
P03688301A0129|62 70|invasion
P03687313A0000|48 53|BAY o
P03687313A0000|99 108|diabetics
P03687313A0000|9 31|glucosidase inhibitors
P03687313A0000|91 95|type
P03687078T0001|1 11|References
P03687078T0001|57 65|diseases
P03687078T0001|29 36|fitness
P03684517A0462|87 91|type
P03684517A0462|11 19|training
P03684517A0462|75 83|decrease
P03682805A0375|1 13|Serum levels
P03682805A0375|93 102|postshock
P03682805A0375|161 164|Day
P03682805A0375|26 34|globulin
P03679756A0830|99 105|plexus
P03679756A0830|41 48|absence
P03679756A0830|62 74|architecture
P03678372A0170|137 142|weeks
P03678372A0170|55 60|weeks
P03678372A0170|5 11|number
P03678372A0170|123 130|pellets
P03676174A0730|4 10|calves
P03676174A0730|129 135|calves
P03676174A0730|61 68|g DM/kg
P03673881A0000|258 271|valve disease
P03673881A0000|68 94|pulse repetition frequency
P03673881A0000|49 53|wave
P03673881A0000|96 100|HPRF
P03673881A0000|146 164|pressure gradients
P03673881A0000|166 186|Doppler examinations
P03672532A1111|27 34|effects
P03668396A0171|7 28|equilibrium solutions
P03666957A0219|35 46|conjunctiva
P03666957A0219|168 172|cats
P03666957A0219|59 64|weeks
P03663789A0568|50 58|activity
P03663789A0568|87 91|test
P03663789A0568|125 135|conversion
P03663789A0568|62 66|RHAL
P03659805A0404|154 166|IMB computer
P03659805A0404|143 147|help
P03659805A0404|129 132|Cox
P03659805A0404|120 125|model
P03652083A0720|81 90|crosslink
P03652083A0720|28 47|vessel pyridinoline
P03651330T0000|25 32|lesions
P03635597A0377|102 109|passive
P03635597A0377|86 93|infants
P03635597A0377|4 12|addition
P03635597A0377|53 60|mothers
P03629974A1468|1 11|Comparison
P03629974A1468|19 38|amino acid sequence
P03629974A1468|92 102|Punta Toro
P03629974A1468|148 153|cases
P03629974A1468|46 59|M RNA product
P03629974A1468|241 244|end
P03628794A0648|43 50|disease
P03628794A0648|74 97|I-131 MIBG scintigraphy
P03628794A0648|105 116|examination
P03628596A0000|1 8|Samples
P03628596A0000|138 143|fluid
P03627720A0196|57 65|sac cyst
P03625762A0308|239 263|behaviour problem rating
P03625762A0308|1 11|Comparison
P03625762A0308|197 207|sub-groups
P03625762A0308|94 99|serum
P03625762A0308|134 143|phenytoin
P03622571A0208|1 19|Radionuclide study
P03622571A0208|66 78|degeneration
P03619249A0428|171 176|serum
P03619249A0428|234 236|Ag
P03619249A0428|276 281|serum
P03619249A0428|283 288|non-A
P03619249A0428|46 51|serum
P03619249A0428|15 22|markers
P03619249A0428|186 192|HBc Ag
P03619249A0428|53 57|skin
P03619249A0428|178 181|HBs
P03619249A0428|124 130|HBe Ag
P03619249A0428|241 249|antibody
P03616237T0001|37 45|infusion
P03615763A0170|205 208|age
P03615763A0170|273 281|diabetes
P03615763A0170|283 297|family history
P03615763A0170|316 339|Type A behavior pattern
P03615763A0170|104 116|associations
P03615763A0170|75 86|opportunity
P03615763A0170|223 235|hypertension
P03615763A0170|52 63|angiography
P03615763A0170|26 31|women
P03615763A0170|301 314|heart disease
P03615763A0170|120 128|relation
P03615550A0000|55 74|antagonist naloxone
P03615550A0000|142 145|FCN
P03615550A0000|147 155|schedule
P03612316A0102|140 144|days
P03612316A0102|65 69|diet
P03612316A0102|8 12|rats
P03612316A0102|89 95|saline
P03610663A0201|51 62|calculation
P03610663A0201|66 86|nutrient utilization
P03610663A0201|197 203|states
P03610663A0201|133 142|precision
P03608916A0790|137 145|increase
P03608916A0790|48 56|2D level
P03608916A0790|83 88|cases
P03608916A0790|90 91|P
P03608916A0790|15 26|degrees HPT
P03607109A0370|67 76|pregnancy
P03607109A0370|58 63|month
P03602261A0238|307 321|norepinephrine
P03602261A0238|338 352|growth hormone
P03602261A0238|129 143|blood pressure
P03602261A0238|73 85|correlations
P03602261A0238|87 88|p
P03602261A0238|250 262|correlations
P03602261A0238|354 355|r
P03602261A0238|295 296|r
P03602261A0238|148 156|dopamine
P03601275A0601|154 159|ratio
P03601275A0601|113 128|plasma dopamine
P03601275A0601|7 24|dopamine infusion
P03601275A0601|130 144|norepinephrine
P03601275A0601|28 33|women
P03600633A1069|1 5|Cell
P03597218A0901|201 207|shifts
P03597218A0901|161 175|concentrations
P03597218A0901|14 28|concentrations
P03597218A0901|48 57|inhibitor
P03597218A0901|263 273|inhibitors
P03597218A0901|298 299|P
P03597218A0901|211 223|plasma water
P03592297A0679|169 173|mmHg
P03592297A0679|115 124|degrees C
P03592297A0679|197 206|degrees C
P03592297A0679|26 38|quadriplegia
P03592297A0679|14 15|n
P03591464A0840b|70 78|efficacy
P03591464A0840b|82 110|calcium antagonist treatment
P03590911T0001|51 68|light sensitivity
P03584426A0706|116 117|%
P03584426A0706|235 243|material
P03584426A0706|173 174|%
P03584426A0706|144 152|activity
P03584426A0706|31 33|LT
P03584426A0706|60 74|stool isolates
P03582982A0000|18 23|genes
P03582982A0000|52 55|RNA
P03582149T0001|118 134|Jiangxi Province
P03582149T0001|20 26|survey
P03578948A0448|98 107|c X min-1
P03578948A0448|65 74|ml X kg-1
P03578948A0448|12 23|ventilation
P03577670A0102|33 40|atrophy
P03572706A0329|187 198|F-K indices
P03572706A0329|140 159|treatment condition
P03572706A0329|22 37|interpretations
P03572706A0329|181 182|F
P03570455A0433|1 8|Rabbits
P03570455A0433|95 100|mg/dl
P03570455A0433|47 53|levels
P03568311A0273|119 126|indexes
P03568311A0273|81 84|RAP
P03568311A0273|7 15|patients
P03568311A0273|90 93|IPP
P03563604A1075|65 66|%
P03563604A1075|93 94|%
P03563604A1075|106 123|drug intervention
P03563604A1075|30 39|villagers
P03561622A0659|100 127|DiaTAP button graft complex
P03561622A0659|52 59|patient
P03561622A0659|63 71|dialysis
P03559287T0000|50 61|consumption
P03559287T0000|23 30|ecology
P03559193A0000|96 101|scale
P03559193A0000|167 177|correlates
P03559193A0000|60 70|dimensions
P03555318T0000|5 17|pharmacology
P03553149A0299|65 69|MucA
P03553149A0299|96 109|cleavage site
P03550444T0000|51 62|specificity
P03550444T0000|1 12|Development
P03545955A1378|5 27|serum insulin response
P03544858A0374|154 159|males
P03544858A0374|142 149|females
P03544858A0374|57 64|insulin
P03544858A0374|107 117|metabolism
P03543485A0069|23 33|mechanisms
P03543485A0069|60 68|response
P03541263A0368|53 60|control
P03540591A0330|136 143|protein
P03540591A0330|77 91|P0 transcripts
P03540591A0330|57 62|cDNAs
P03537721A0876|137 150|yeast vacuole
P03537721A0876|64 83|precursor molecules
P03537721A0876|192 202|hydrolases
P03537711A0181|1 3|W.
P03534581A0976|69 74|group
P03534581A0976|5 14|incidence
P03534581A0976|179 180|%
P03534581A0976|88 102|5-fluorouracil
P03534581A0976|104 115|doxorubicin
P03528748A0414|24 31|protein
P03522105A1011|6 37|trough serum TOB concentrations
P03522105A1011|78 84|levels
P03517388A0763|54 56|BC
P03517388A0763|77 79|CC
P03517388A0763|27 38|CK-MB level
P03517388A0763|91 94|U/L
P03515840A0000|140 147|sarcoma
P03515840A0000|189 203|generalization
P03515840A0000|208 213|death
P03515840A0000|31 36|cases
P03513989A0580|21 29|estrogen
P03513989A0580|9 16|ethanol
P03508698A0535|4 9|order
P03508698A0535|59 68|adductors
P03508698A0535|46 49|jaw
P03508698A0535|30 44|finger flexors
P03504971A0000|116 133|% methylhexadiene
P03504971A0000|141 147|source
P03504971A0000|177 190|vulcanization
P03504971A0000|15 28|Goodyear Tire
P03499657A0000|1 12|Osteocalcin
P03499657A0000|38 42|sBGP
P03499657A0000|73 76|sAP
P03499657A0000|45 71|serum alkaline phosphatase
P03499657A0000|191 210|hyperparathyroidism
P03499657A0000|244 258|hypercalcaemia
P03499657A0000|90 121|hydroxyproline/creatinine ratio
P03494649A0472|98 102|MABP
P03494649A0472|88 94|change
P03494649A0472|62 65|CBF
P03491190A0233|82 87|scans
P03491190A0233|26 33|defects
P03491190A0233|61 62|%
P03487348A0000|70 92|afterhyperpolarization
P03487348A0000|25 32|Kernell
P03487348A0000|14 21|version
P03485064A0135|3 8|total
P03484075T0001|1 20|Emergency treatment
P03478354A0436|19 23|cows
P03478354A0436|37 49|d postpartum
P03478354A0436|12 17|herds
P03473379A0183|18 29|amyloidosis
P03466730A0210|49 55|pupils
P03463543A1613|69 72|UTI
P03463543A1613|44 53|treatment
P03459736A0184|70 77|variety
P03459736A0184|5 14|criterion
P03459736A0184|91 99|capsules
P03457330A0271|5 13|patients
P03457330A0271|56 60|week
P03451761A0215|103 107|base
P03451761A0215|115 125|ventricles
P03451761A0215|25 37|WPW syndrome
P03451761A0215|131 134|RNV
P03449358T0001|26 39|polyarteritis
P03446332A0831|49 51|LH
P03446332A0831|63 67|LHRH
P03443573A0329|53 71|longissimus muscle
P03443573A0329|148 154|tissue
P03443573A0329|121 123|mg
P03443144A0409|103 112|reactions
P03443144A0409|7 32|aspirin esterase activity
P03440780A0779|119 143|calcium entry mechanisms
P03440780A0779|163 174|differences
P03440780A0779|57 83|vasoconstrictor properties
P03440780A0779|12 19|results
P03436877A0950|171 181|% delta CT
P03436877A0950|1 3|Kf
P03436877A0950|4 5|c
P03436877A0950|110 111|c
P03436877A0950|40 49|lung mass
P03436877A0950|194 200|% mass
P03436877A0950|325 330|WORDS
P03436877A0950|89 109|lung mass % delta Kf
P03436877A0950|149 150|P
P03436119A0000|23 33|tomography
P03436119A0000|107 122|reproducibility
P03430221A1236|35 42|context
P03430221A1236|52 62|properties
P03429306T0000|50 56|cortex
P03429306T0000|28 33|layer
P03428084A0430|7 22|degrees stimuli
P03428084A0430|72 93|pattern reversal P100
P03428084A0430|44 63|scalp distributions
P03427474A0853|103 122|saccharin solutions
P03427474A0853|40 47|animals
P03421425A0878|84 98|determinations
P03421425A0878|7 15|patients
P03420324A0178|175 190|h/day beginning
P03420324A0178|42 51|following
P03420324A0178|129 138|pregnancy
P03420324A0178|10 14|rats
P03420324A0178|194 197|day
P03420324A0178|87 91|days
P03420324A0178|262 265|day
P03420324A0178|59 60|%
P03420324A0178|146 147|%
P03418727A0992|139 149|treatments
P03418727A0992|26 37|penetration
P03417588T0000|69 73|corn
P03417588T0000|1 7|Liquid
P03417588T0000|24 30|method
P03413890T0001|1 10|Prognosis
P03413890T0001|59 65|region
P03407843T0000|1 7|Papers
P03407843T0000|15 22|Society
P03406054A0351|1 5|Data
P03406054A0351|156 161|front
P03406054A0351|143 152|isocentre
P03406054A0351|167 178|polystyrene
P03406054A0351|13 33|line spread function
P03404334T0000|19 46|equilibrium water partition
P03403480A0299|68 81|configuration
P03403480A0299|173 184|alterations
P03403480A0299|197 201|area
P03403480A0299|11 21|suspension
P03403480A0299|225 248|collagen concentrations
P03403480A0299|134 142|diameter
P03403313A0298|196 204|excision
P03403313A0298|214 215|%
P03403313A0298|183 184|%
P03403313A0298|104 112|excision
P03403313A0298|134 142|excision
P03398823A0459|70 77|toluene
P03398823A0459|158 161|min
P03398823A0459|52 66|mg/kg p-xylene
P03398823A0459|128 136|p-xylene
P03398823A0459|165 172|removal
P03398433T0001|18 23|liver
P03398433T0001|5 10|state
P03396437A0321|11 19|problems
P03395164A0000|21 28|effects
P03395164A0000|60 62|FU
P03390074A0000|80 90|assessment
P03390074A0000|105 116|dysfunction
P03384272A0145|111 117|lesion
P03384272A0145|56 61|range
P03384272A0145|31 35|size
P03383897A0189|19 25|action
P03383897A0189|188 197|treatment
P03383897A0189|148 158|conditions
P03383897A0189|90 96|effect
P03382772A0319|116 119|man
P03382772A0319|73 83|parameters
P03382772A0319|135 141|trials
P03381039A0364|69 74|range
P03381039A0364|18 21|MAN
P03381039A0364|4 12|contrast
P03379058A0188|171 173|bp
P03379058A0188|71 81|base pairs
P03379058A0188|83 85|bp
P03379058A0188|43 62|E1 alpha cDNA clone
P03379058A0188|90 96|length
P03377891A0652|51 68|life stress group
P03377891A0652|233 244|sensitivity
P03377891A0652|246 256|depression
P03377891A0652|270 292|psychoticism subscales
P03377891A0652|122 136|severity index
P03375184A0000|152 164|n-1 CH2CH2OH
P03375184A0000|5 27|spermicide nonoxynol-9
P03375184A0000|144 151|CH2CH2O
P03375184A0000|122 142|formula C9H19-C6H6-O
P03372422A0558|69 74|phase
P03372422A0558|5 24|maximum deflections
P03372422A0558|146 171|tracer gas concentrations
P03372422A0558|41 43|Ar
P03372422A0558|28 33|phase
P03371806A0000|139 146|species
P03371806A0000|189 195|stains
P03371806A0000|29 32|EDP
P03371806A0000|151 171|organ identification
P03370815T0000|69 79|radioassay
P03370815T0000|7 16|detection
P03366864A0099|55 63|segments
P03366864A0099|95 100|blood
P03361653A0459|93 104|limitations
P03361653A0459|132 139|objects
P03360667A0000|232 233|n
P03360667A0000|280 288|subjects
P03360667A0000|17 23|effect
P03360667A0000|187 196|sea level
P03360667A0000|114 119|youth
P03360667A0000|261 269|altitude
P03360667A0000|27 35|altitude
P03360667A0000|61 72|development
P03355122A0238|35 56|plasma glucose levels
P03355122A0238|114 120|levels
P03355122A0238|27 33|potato
P03354295A0157|32 40|patients
P03354295A0157|63 71|serum Tg
P03354295A0157|44 45|%
P03352727T0000|6 19|biotechnology
P03352254A0203|19 28|structure
P03352254A0203|96 105|syllables
P03348382A0785|16 23|ouabain
P03348382A0785|55 64|secretion
P03346157A0000|237 242|order
P03346157A0000|43 52|ABCC/RERF
P03346157A0000|109 117|subjects
P03346157A0000|84 102|Adult Health Study
P03346157A0000|19 24|times
P03346157A0000|178 184|x-rays
P03346157A0000|301 306|doses
P03344812A0924|383 393|population
P03344812A0924|193 198|state
P03344812A0924|152 159|factors
P03344812A0924|327 334|ranking
P03344812A0924|48 63|HR measurements
P03344812A0924|355 357|BP
P03344812A0924|267 273|animal
P03344812A0924|362 371|HR levels
P03343730A0486|106 128|calcium stone patients
P03343730A0486|15 26|association
P03340726A1103|99 103|days
P03340726A1103|6 15|histology
P03340726A1103|123 125|Gy
P03338154T0000|6 20|concentrations
P03338154T0000|75 83|patients
P03335923A0257|206 212|ulcers
P03335923A0257|39 45|groups
P03335923A0257|229 233|bulb
P03335923A0257|107 117|volunteers
P03335923A0257|153 171|reflux gastropathy
P03335923A0257|248 256|patients
P03335923A0257|122 130|patients
P03335444A0000|34 38|male
P03335444A0000|78 80|Pu
P03335127A0176|70 79|procedure
P03335127A0176|52 57|order
P03332848A0000|72 80|analysis
P03332848A0000|28 42|Doppler probes
P03330711T0000|35 39|neem
P03330711T0000|41 62|Azadirachta indica A.
P03326381A0423|169 174|drugs
P03326381A0423|21 29|findings
P03326381A0423|197 205|pancreas
P03322829A0952|5 9|size
P03322829A0952|72 75|use
P03322829A0952|195 199|dose
P03322829A0952|17 22|group
P03322829A0952|251 263|prescription
P03322829A0952|126 131|group
P03319912A0000|1 11|Cephradine
P03319912A0000|103 111|mean age
P03319912A0000|235 242|dysuria
P03319912A0000|134 141|history
P03319912A0000|16 18|mg
P03319912A0000|218 227|frequency
P03319912A0000|57 77|prophylactic measure
P03319621A0707|85 94|myoblasts
P03319621A0707|21 25|mRNA
P03319621A0707|99 107|myotubes
P03319621A0707|44 60|beta actin mRNAs
P03315359A0732|1 12|Proctoscopy
P03315359A0732|96 104|patients
P03315359A0732|131 142|suppuration
P03315359A0732|62 66|part
P03312033A0501|1 12|Monotherapy
P03312033A0501|110 119|cefazolin
P03309892A0637|17 28|observation
P03309892A0637|87 92|yeast
P03309892A0637|111 132|actin gene transcript
P03309892A0637|149 160|nucleotides
P03306340A0537|68 76|invasion
P03306340A0537|35 44|carcinoma
P03306340A0537|21 27|spread
P03306340A0537|172 187|pancreaticogram
P03306340A0537|107 111|body
P03304866T0001|1 18|Revascularization
P03300118A0392|1 16|Oxygen delivery
P03300118A0392|66 70|pigs
P03297181A0127|153 157|dose
P03297181A0127|116 118|SR
P03297181A0127|18 26|subjects
P03297181A0127|78 95|quinidine sulfate
P03297181A0127|74 76|RR
P03297181A0127|120 139|quinidine bisulfate
P03296212A0603|5 11|future
P03296212A0603|66 71|areas
P03296212A0603|380 389|community
P03296212A0603|73 80|Efforts
P03296212A0603|288 295|disease
P03296212A0603|187 192|order
P03296212A0603|324 339|tumor debulking
P03296212A0603|431 439|diseases
P03296212A0603|177 182|terms
P03296212A0603|271 276|agent
P03293844T0000|17 23|eczema
P03292076A0820|137 148|circulation
P03292076A0820|223 235|hemodynamics
P03292076A0820|9 20|endotoxemia
P03292076A0820|183 197|refractoriness
P03286611A1198|1 5|Yang
P03283881A0216|55 63|evidence
P03283881A0216|29 43|hypersecretion
P03282232A0743|1 11|Antibodies
P03282232A0743|25 39|fusion protein
P03282232A0743|56 66|DP1A clone
P03280807A0000|137 140|GGX
P03280807A0000|1 10|Mutations
P03280807A0000|86 97|suppressors
P03280807A0000|179 182|UGA
P03280807A0000|146 153|proline
P03280807A0000|104 124|frameshift mutations
P03278829A0082|127 134|tension
P03278829A0082|145 154|deformity
P03278829A0082|94 104|tip grafts
P03276246A0037|98 108|evaluation
P03276246A0037|112 124|appendicitis
P03276246A0037|15 18|use
P03275867A0187|87 109|mating type loci HML E
P03275867A0187|114 119|HMR E
P03275867A0187|179 192|transcription
P03275867A0187|62 71|silencers
P03275867A0187|15 24|sequences
P03270085A0382|52 58|kidney
P03267732A0788|19 38|Ga-fbg scintigraphy
P03267732A0788|125 132|thrombi
P03267732A0788|180 187|therapy
P03264299A0679|33 41|activity
P03264299A0679|56 67|macrophages
P03264299A0679|14 18|mice
P03263465T0000|24 29|genes
P03263465T0000|89 94|H-2Ld
P03263465T0000|104 109|genes
P03261331A0563|34 43|diagnosis
P03261331A0563|23 26|aid
P03261331A0563|132 142|mechanisms
P03261331A0563|151 159|disorder
P03261005A0216|1 8|Records
P03261005A0216|126 133|failure
P03261005A0216|29 33|AIDS
P03258069A0000|51 57|effect
P03258069A0000|117 134|nerve stimulation
P03258069A0000|5 13|purposes
P03258069A0000|22 27|study
P03258069A0000|244 251|changes
P03258069A0000|148 166|acupuncture points
P03256150A1866|39 51|requirements
P03256150A1866|56 60|task
P03251210A0981|20 23|BGC
P03251210A0981|62 76|calcifications
P03251210A0981|45 56|development
P03249792A0241|51 65|symptomatology
P03249792A0241|98 102|role
P03249792A0241|10 17|factors
P03249792A0241|106 120|group dynamics
P03243920A0591|101 109|modeling
P03243920A0591|121 131|regression
P03239106A0856|76 83|calcium
P03239106A0856|88 97|magnesium
P03235487A0404|1 14|Incorporation
P03235487A0404|66 81|sugar solutions
P03235487A0404|126 135|diltiazem
P03233862T0000|1 21|Neuromyelitis optica
P03233862T0000|31 39|syndrome
P03229917A0099|31 40|resection
P03228518A0339|124 134|dimensions
P03228518A0339|45 52|samples
P03227288A0542|70 76|months
P03227288A0542|11 18|infants
P03220077A0274|12 20|survival
P03218714A0000|85 94|tetralogy
P03218714A0000|98 104|Fallot
P03218714A0000|37 62|Dandy-Walker malformation
P03214709A0559|51 79|plasma corticosterone levels
P03214709A0559|7 10|min
P03214709A0559|91 97|stress
P03214709A0559|30 36|stress
P03212551T0001|21 30|Dupuytren
P03208493A0849|51 68|lithium clearance
P03208493A0849|79 80|%
P03200844A1211|158 164|member
P03200844A1211|144 152|features
P03200844A1211|13 21|sequence
P03200844A1211|75 85|similarity
P03199436A1060|101 119|psbE-psbF clusters
P03199436A1060|73 92|psbB-psbH-petB-petD
P03198525A0164|138 141|d-1
P03198525A0164|130 137|mg.hd-1
P03198525A0164|164 172|DEPO-MGA
P03198525A0164|80 86|weight
P03198525A0164|144 151|control
P03198525A0164|56 61|light
P03198525A0164|122 125|MGA
P03195167A0104|168 171|PVC
P03195167A0104|191 193|PS
P03195167A0104|5 27|platelet adhesion rate
P03195167A0104|219 232|test chambers
P03195167A0104|178 189|polystyrene
P03195167A0104|88 106|haemocompatibility
P03192950A0566|49 54|women
P03192950A0566|63 73|TSH levels
P03192724A0000|39 51|drug abusers
P03192724A0000|72 76|Ryan
P03190914A0149|69 83|responsiveness
P03190914A0149|15 38|migration differentials
P03185540T0000|1 8|Factors
P03185540T0000|98 109|specificity
P03185540T0000|57 71|RNA polymerase
P03185540T0000|30 43|transcription
P03184267A0000|100 108|serotype
P03184267A0000|189 203|food poisoning
P03184267A0000|25 41|broiler chickens
P03183103A0000|98 106|h period
P03183103A0000|12 27|MR examinations
P03183103A0000|62 69|sinuses
P03180595A1040|101 111|indicators
P03180595A1040|52 69|ejection fraction
P03180595A1040|123 130|disease
P03178626A0137|1 9|Aviators
P03178626A0137|96 109|aircraft type
P03178097A0000|5 23|CHARGE association
P03178097A0000|43 54|multisystem
P03178097A0000|29 39|collection
P03172863T0000|19 33|undernutrition
P03172863T0000|91 95|rats
P03171221A0531|68 73|exons
P03171221A0531|5 16|variability
P03171221A0531|91 110|elastin transcripts
P03167060A0000|71 76|mRNAs
P03167060A0000|110 115|forms
P03167060A0000|150 154|gene
P03159903A0352|80 99|amino acid sequence
P03159903A0352|125 144|amino acid sequence
P03159903A0352|148 151|IHF
P03150296A0594|139 150|recognition
P03150296A0594|202 212|techniques
P03150296A0594|214 230|serum creatinine
P03150296A0594|109 112|GFR
P03150296A0594|123 130|caution
P03150296A0594|303 311|practice
P03149774A0173|113 124|enhancement
P03149774A0173|76 87|bicuculline
P03149774A0173|162 170|training
P03149774A0173|208 230|bicuculline methiodide
P03149774A0173|150 151|h
P03149774A0173|303 310|barrier
P03146784A0158|191 194|PSR
P03146784A0158|172 189|stretch receptors
P03146784A0158|43 54|ventilation
P03146784A0158|109 126|stretch receptors
P03146017A0983|103 111|presence
P03146017A0983|5 24|nucleotide sequence
P03146017A0983|53 55|M.
P03146017A0983|193 196|mol
P03146017A0983|63 70|ORFtrpA
P03143485A0366|5 12|Euglena
P03143485A0366|23 43|protein gene cluster
P03143485A0366|73 87|protein operon
P03143485A0366|181 186|genes
P03142875A0366|81 92|amino acids
P03142875A0366|29 53|6-kilobase cDNA sequence
P03138449A0759|33 38|delta
P03138449A0759|111 120|w6 supply
P03138449A0759|106 109|C18
P03137601A0212|129 133|mice
P03137601A0212|176 180|mice
P03137601A0212|78 80|NE
P03137601A0212|41 45|DOPS
P03137601A0212|135 139|DOPS
P03137105A0146|71 83|gonadotropin
P03137105A0146|99 102|end
P03137105A0146|261 278|embryo recipients
P03137105A0146|129 134|phase
P03137105A0146|243 256|oocyte donors
P03133360A1215|85 95|inhibition
P03133360A1215|114 123|trpE mRNA
P03133360A1215|5 13|findings
P03132498A0730|100 112|asthma score
P03132498A0730|188 193|hours
P03132498A0730|22 27|PaCO2
P03132498A0730|162 166|torr
P03132498A0730|131 136|PaCO2
P03132498A0730|60 64|torr
P03127034A0591|5 15|heart rate
P03125422A0202|70 89|activator sequences
P03125422A0202|112 121|induction
P03125422A0202|125 134|galactose
P03123983T0000|48 53|drugs
P03123983T0000|36 44|response
P03120334A0893|80 84|vein
P03120334A0893|53 59|origin
P03120334A0893|24 28|vein
P03119227A0079|139 153|amino terminus
P03119227A0079|5 17|DNA sequence
P03119227A0079|196 202|region
P03119227A0079|28 35|protein
P03119227A0079|44 55|amino acids
P03117147A1059|69 85|oesophageal EMGd
P03117147A1059|108 120|surface EMGd
P03117147A1059|147 151|tool
P03115787A0633|239 245|months
P03115787A0633|168 177|responses
P03115787A0633|66 76|adriamycin
P03115787A0633|92 98|CHAP-5
P03115787A0633|147 155|response
P03115787A0633|46 64|hexamethylmelamine
P03114995T0000|1 8|Effects
P03114995T0000|65 69|dogs
P03114188A0907|170 172|Gy
P03114188A0907|103 121|chest wall sarcoma
P03114188A0907|67 73|decade
P03114188A0907|79 87|patients
P03112028A0404|85 95|parameters
P03112028A0404|19 27|patients
P03110801A0532|26 51|plasma prolactin response
P03110746A0146|169 174|group
P03110746A0146|112 120|subjects
P03110746A0146|10 20|percentage
P03110746A0146|45 58|triglycerides
P03110678A0702|221 236|treatment modes
P03110678A0702|1 11|Comparison
P03110678A0702|201 210|diffusion
P03110678A0702|59 80|polysulphone membrane
P03110678A0702|182 192|convection
P03110678A0702|15 19|beta
P03109954A0945|311 320|influence
P03109954A0945|349 362|plasma lipids
P03109954A0945|285 292|balance
P03109954A0945|49 58|influence
P03109954A0945|367 380|atherogenesis
P03109954A0945|208 216|lowering
P03109147A0000|1 16|Ethylene glycol
P03109147A0000|21 38|diethylene glycol
P03109147A0000|144 147|und
P03109147A0000|92 98|groups
P03109147A0000|150 152|mg
P03104982A0690|140 145|years
P03104982A0690|7 10|age
P03104982A0690|149 152|age
P03104248A0322|55 60|tumor
P03104248A0322|22 30|patients
P03104248A0322|160 162|G3
P03104248A0322|62 64|G1
P03102289A0786|119 128|follicles
P03102289A0786|81 89|midcycle
P03102289A0786|203 218|serum E2 levels
P03102289A0786|144 146|cm
P03102289A0786|109 115|number
P03102289A0786|194 197|hCG
P03097643A1357|69 85|octamer sequence
P03097643A1357|179 189|expression
P03097643A1357|11 22|BALB/c gene
P03091849A0000|275 283|membrane
P03091849A0000|204 212|pressure
P03091849A0000|232 243|superfusion
P03091849A0000|132 142|experiment
P03091849A0000|49 63|ultrastructure
P03091849A0000|189 198|perfusion
P03091849A0000|89 102|rat mesentery
P03090237A0202|169 181|response key
P03090237A0202|108 120|response key
P03090237A0202|122 130|work key
P03090237A0202|194 197|key
P03083441T0000|1 14|Modifications
P03079276T0029|1 9|Analysis
P03079276T0029|25 33|patients
P03076124A0496|71 75|acid
P03076124A0496|5 27|bile acid sequestrants
P03076124A0496|77 88|fenofibrate
P03076124A0496|166 176|lovastatin
P03076124A0496|284 290|agents
P03076124A0496|48 58|colestipol
P03076124A0496|323 328|total
P03076124A0496|298 319|plasma concentrations
P03076124A0496|360 361|%
P03076124A0496|150 159|reductase
P03073192T0000|1 54|Mycobacterium avium-intracellulare complex infections
P03073091A0338|102 109|patient
P03073091A0338|112 120|glycemia
P03073091A0338|127 132|mg/dl
P03073091A0338|30 49|% dextrose solution
P03072021A0696|5 25|amino acid sequences
P03072021A0696|132 144|polypeptides
P03069046A0126|5 11|method
P03066625A0756|103 115|risk factors
P03066625A0756|162 169|studies
P03066625A0756|208 217|questions
P03066131A0000|186 192|author
P03066131A0000|169 181|hypothalamus
P03066131A0000|232 242|operations
P03066131A0000|247 254|control
P03066131A0000|285 299|aggressiveness
P03066131A0000|211 222|experiences
P03065610A0375|5 13|rci gene
P03065610A0375|29 33|lacZ
P03065140A0273|84 115|transcription activation domain
P03065140A0273|7 16|mutations
P03065140A0273|56 74|DNA binding domain
P03064524A0160|41 46|drugs
P03062370A0000|1 5|GCN4
P03062370A0000|45 55|amino acid
P03061301A1409|141 146|ng/gm
P03061301A1409|162 163|p
P03061301A1409|150 160|creatinine
P03060953A0481|34 45|vaccination
P03060953A0481|59 69|mechanisms
P03059171A1232|50 66|prostaglandin E1
P03059171A1232|19 33|anticoagulants
P03059171A1232|71 82|ticlopidine
P03059171A1232|120 128|symptoms
P03053713A0752|1 15|DNA sequencing
P03053713A0752|23 32|DPM1 gene
P03052327A1474|18 25|results
P03052327A1474|114 118|Type
P03052327A1474|130 138|patients
P03050147A0896|84 91|viruses
P03050147A0896|59 76|E1a-E1b functions
P03050147A0896|131 149|mRNA transcription
P03048024A0418|86 87|p
P03048024A0418|37 43|tissue
P03048024A0418|15 22|culture
P03046655A0000|115 124|keratitis
P03046655A0000|148 154|period
P03046655A0000|13 29|prevalence study
P03045117A0936|187 192|Asp27
P03045117A0936|143 147|type
P03045117A0936|131 136|order
P03045117A0936|243 248|Tyr29
P03045117A0936|44 51|methods
P03045117A0936|60 69|agreement
P03042778A0643|27 32|yeast
P03041046A0127|152 159|viruses
P03041046A0127|200 204|MuLV
P03041046A0127|173 179|BALB/c
P03041046A0127|59 71|Moloney MuLV
P03041046A0127|122 128|A-MuLV
P03040023A0113|36 47|bradycardia
P03039177A0503|68 78|transcript
P03039177A0503|5 10|group
P03039177A0503|124 153|restriction site polymorphism
P03038643A1374|71 82|duplication
P03038643A1374|7 11|data
P03038643A1374|45 59|alpha-spectrin
P03036933A0774|48 56|children
P03036415T0000|1 10|Influence
P03036415T0000|48 77|leukotriene receptor blockade
P03036415T0000|14 40|cyclo-oxygenase inhibition
P03035218T0000|116 122|repeat
P03035218T0000|73 99|T-cell leukemia virus type
P03034956A0666|4 12|contrast
P03034956A0666|163 164|P
P03034956A0666|107 115|subjects
P03033283A1415|156 164|strength
P03033283A1415|178 189|arrangement
P03033283A1415|72 87|repeat elements
P03033283A1415|302 312|host range
P03033283A1415|31 35|sets
P03032964T0000|49 57|promoter
P03032964T0000|14 22|function
P03031602A1001|32 40|elements
P03031602A1001|12 17|group
P03027905A0632|36 60|plasma aldosterone level
P03027661A0000|5 15|activities
P03027661A0000|40 53|miniF plasmid
P03025862A0860|48 59|amino acids
P03025862A0860|140 141|A
P03025862A0860|67 76|ssd chain
P03025862A0860|135 139|poly
P03025655T0000|16 22|domain
P03025655T0000|89 104|kinase function
P03024703A1036|138 152|hsp108 protein
P03024703A1036|113 119|weight
P03024703A1036|56 73|polypeptide chain
P03023970A0922|119 129|generation
P03023970A0922|95 102|protein
P03023970A0922|149 160|amino acids
P03023970A0922|30 48|termination signal
P03023859A0000|185 210|breakpoint cluster region
P03023859A0000|52 69|leukemia patients
P03023859A0000|89 99|breakpoint
P03023859A0000|180 183|bcr
P03023679A0624|41 49|proteins
P03023679A0624|104 112|proteins
P03022129A0842|17 23|arrays
P03022129A0842|86 90|loss
P03022129A0842|128 141|accessibility
P03022129A0842|94 100|detail
P03022129A0842|45 47|II
P03021050A0501|27 32|peaks
P03020001A0781|171 185|kilobase pairs
P03020001A0781|50 64|kilobase pairs
P03020001A0781|202 208|clones
P03020001A0781|95 108|DNA fragments
P03020001A0781|123 137|kilobase pairs
P03018491A0840|223 239|receptor binding
P03018491A0840|5 19|hexanucleotide
P03018491A0840|62 74|GRE activity
P03018491A0840|135 141|region
P03017225A0706|238 244|theory
P03017225A0706|101 113|II c portion
P03017225A0706|174 183|carcinoma
P03017225A0706|12 21|carcinoma
P03017225A0706|210 215|focus
P03016506A0611|118 130|B95-8 strain
P03016506A0611|262 273|marker gene
P03016506A0611|218 234|BamHI-C fragment
P03016506A0611|82 93|nucleotides
P03016506A0611|72 80|fragment
P03016506A0611|15 21|vector
P03015953T0000|41 54|cell variants
P03015953T0000|107 116|DNA clone
P03015611A0331|5 24|amino acid sequence
P03015611A0331|46 54|residues
P03014515T0000|86 92|enzyme
P03014515T0000|7 28|alpha-galactosidase A
P03013477A0000|343 350|group B
P03013477A0000|4 9|order
P03013477A0000|413 418|ng/ml
P03013477A0000|380 401|serum ferritin levels
P03013477A0000|75 84|leucocyte
P03013477A0000|153 169|superoxide anion
P03013477A0000|251 256|group
P03013477A0000|218 224|groups
P03013477A0000|125 137|hemodialysis
P03013477A0000|300 321|serum ferritin levels
P03013477A0000|363 374|individuals
P03010281A0220|51 61|activation
P03010281A0220|5 11|copies
P03009366A0438|103 109|target
P03009366A0438|70 74|Type
P03009366A0438|216 221|weeks
P03009366A0438|142 152|surfactant
P03009366A0438|131 138|release
P03008094A0697|16 19|end
P03008094A0697|72 81|sequences
P03006066A0653|32 34|Mr
P03006066A0653|65 70|c-myb
P03006066A0653|8 23|P135gag-myb-ets
P03006066A0653|72 80|P75c-myb
P03004982A1094|59 70|FeS protein
P03004982A1094|44 51|peptide
P03004739A0753|50 57|residue
P03004739A0753|113 121|activity
P03004739A0753|161 169|affinity
P03004739A0753|130 139|promoters
P03003695A0395|1 11|Comparison
P03003695A0395|158 168|c-sis exon
P03003695A0395|72 78|Nature
P03002501A1327|1 11|Comparison
P03002501A1327|158 165|regions
P03002501A1327|46 49|rat
P03001705T0000|50 75|herpes simplex virus type
P03001705T0000|93 99|region
P03001705T0000|78 81|DNA
P03001353A0146|32 46|transformation
P03001353A0146|115 125|RNA genome
P03001353A0146|174 178|mRNA
P03001353A0146|130 140|P85gag-mos
P03001086A0587|171 188|dnaK gene product
P03001086A0587|118 129|yeast hsp70
P03001086A0587|140 148|homology
P03001086A0587|90 101|trout hsp70
P03001054A0703|80 85|sites
P03000457A1554|119 123|beta
P03000457A1554|99 104|alpha
P03000457A1554|126 133|species
P03000457A1554|94 97|kDa
P03000457A1554|44 45|t
P02999267A0606|97 106|intensity
P02999267A0606|133 140|sternum
P02998016A0527|17 22|v-mil
P02998016A0527|103 109|region
P02998016A0527|157 171|nonsense codon
P02998016A0527|113 117|exon
P02998016A0527|125 136|nucleotides
P02998016A0527|60 64|exon
P02997622A0916|53 72|SCLC cell line DNAs
P02997622A0916|12 20|sequence
P02995967T0000|18 31|protooncogene
P02995967T0000|83 110|growth factor-receptor gene
P02994253A0482|216 233|days postexposure
P02994253A0482|159 174|hr postexposure
P02994253A0482|129 130|%
P02994253A0482|264 265|%
P02994253A0482|285 292|animals
P02994253A0482|90 91|%
P02991060A0465|101 106|cases
P02991060A0465|163 169|months
P02991060A0465|29 35|babies
P02991060A0465|122 128|months
P02989637A0671|102 117|renin secretion
P02989637A0671|38 48|regulation
P02989637A0671|311 326|renin secretion
P02989637A0671|7 11|data
P02989637A0671|265 291|metoclopramide stimulation
P02989637A0671|240 246|system
P02987777A0000|36 50|cell carcinoma
P02987777A0000|58 64|rectum
P02986279A0000|98 108|occurrence
P02986279A0000|54 60|months
P02986279A0000|67 75|delivery
P02986279A0000|44 48|days
P02985812A0984|67 71|mRNA
P02985812A0984|41 46|genes
P02983316A0310|102 107|genes
P02983316A0310|276 284|sequence
P02983316A0310|196 208|caiman genes
P02983316A0310|367 373|period
P02983316A0310|56 91|complementarity-determining regions
P02983316A0310|123 138|probe sequences
P02981840A0907|103 104|d
P02981840A0907|109 116|repeats
P02981840A0907|105 107|AC
P02979834T0000|1 8|Effects
P02979834T0000|32 68|maltose tetrapalmitate immunotherapy
P02979834T0000|104 116|radiotherapy
P02976332A1277|55 62|surface
P02976332A1277|22 26|PGI2
P02975680A0000|169 172|GAD
P02975680A0000|307 315|disorder
P02975680A0000|317 320|MDD
P02975680A0000|322 330|patients
P02975680A0000|263 266|GAD
P02975680A0000|249 257|patients
P02975680A0000|240 245|group
P02971957A0287|49 60|improvement
P02971957A0287|28 32|mesh
P02971957A0287|134 142|bleeding
P02971603A0883|36 45|injection
P02971603A0883|25 32|tablets
P02970061A0271|21 34|reading frame
P02970061A0271|60 71|amino acids
P02969316A0002|256 262|pacing
P02969316A0002|140 165|plasma ANP concentrations
P02969316A0002|110 113|ANP
P02969316A0002|57 78|plasma concentrations
P02969316A0002|30 35|atria
P02967915A0968|86 95|sequences
P02967915A0968|115 125|components
P02967915A0968|59 66|variety
P02967496A0182|50 64|reading frames
P02967496A0182|155 161|region
P02967496A0182|142 147|cpc-1
P02966671A0151|169 183|breathing rate
P02966671A0151|18 28|end points
P02966671A0151|38 42|time
P02966671A0151|82 87|times
P02966671A0151|229 234|weeks
P02966671A0151|242 251|treatment
P02964329A0000|5 17|pathogenesis
P02964329A0000|82 93|abnormality
P02964329A0000|150 165|microangiopathy
P02962859A0276|86 91|clone
P02962859A0276|42 75|beta-galactosidase fusion protein
P02962859A0276|14 24|antibodies
P02959089T0000|49 59|vasospasms
P02959089T0000|12 18|effect
P02958233A0123|26 47|laboratory parameters
P02957125A0601|87 101|cent reduction
P02957125A0601|29 36|failure
P02957125A0601|45 58|haemodialysis
P02949170A0184|6 11|study
P02949170A0184|232 250|testosterone index
P02949170A0184|133 142|prolactin
P02949170A0184|118 131|gonadotropins
P02949170A0184|188 192|SHBG
P02949170A0184|24 31|effects
P02949170A0184|57 85|micrograms ethinyl estradiol
P02943562T0000|1 25|Penicillinase production
P02940334A0141|68 76|globulin
P02940334A0141|49 60|hepatitis B
P02940334A0141|78 82|HBIG
P02938185A0223|154 163|degrees C
P02938185A0223|262 272|CREF cells
P02938185A0223|174 183|degrees C
P02938185A0223|57 74|E1b gene products
P02938185A0223|13 23|cell lines
P02936163T0000|1 18|Platelet function
P02936163T0000|76 84|patients
P02934891A0845|68 71|ner
P02934891A0845|201 203|Mu
P02934891A0845|56 64|extracts
P02934891A0845|166 177|nucleotides
P02934778A0702|98 105|species
P02934778A0702|5 9|data
P02934778A0702|82 88|artery
P02929056T0000|19 43|transureteroureterostomy
P02929056T0000|94 101|failure
P02928112T0000|66 73|protein
P02928112T0000|11 18|cloning
P02928112T0000|45 47|U2
P02926499A0340|233 238|blood
P02926499A0340|73 78|brain
P02926499A0340|222 229|density
P02926499A0340|262 266|heat
P02926499A0340|112 122|expression
P02926499A0340|244 245|c
P02926499A0340|149 152|CBF
P02925013A1112|82 88|tissue
P02925013A1112|47 55|aluminum
P02925013A1112|31 37|levels
P02920591A0251|76 83|digoxin
P02920591A0251|125 142|micrograms/kg/min
P02920591A0251|13 23|assessment
P02919530A0000|141 147|effect
P02919530A0000|95 111|artery occlusion
P02919530A0000|211 222|alterations
P02918474A0817|64 74|blood flow
P02918474A0817|42 52|collateral
P02918474A0817|150 163|subepicardium
P02914492A0183|237 243|mEq/dl
P02914492A0183|203 218|hypermagnesemia
P02914492A0183|161 167|mEq/dl
P02914492A0183|133 148|normomagnesemia
P02914492A0183|21 24|ICU
P02914492A0183|178 186|patients
P02914492A0183|56 70|hypomagnesemia
P02914492A0183|120 127|percent
P02913368A1037|1 21|Pharmacology studies
P02913368A1037|77 84|raveron
P02913368A1037|27 45|potassium chloride
P02910989T0000|1 8|Effects
P02910989T0000|22 46|beta-adrenergic-blockade
P02909528A1081|50 56|region
P02909528A1081|10 27|promoter activity
P02907533A0362|113 135|diazepam concentration
P02907533A0362|30 48|drug concentration
P02906673T0000|34 56|Bacillus thuringiensis
P02906673T0000|115 125|California
P02906673T0000|14 30|field evaluation
P02906027A1156|102 108|intron
P02906027A1156|71 80|sequences
P02904322A0002|58 72|model ruminant
P02904322A0002|89 96|studies
P02902927A0145|47 68|rat GHF-1 cDNA clones
P02902656A0481|68 77|sequences
P02902656A0481|108 110|TR
P02902656A0481|14 20|testes
P02902656A0481|222 227|cases
P02902656A0481|127 129|TE
P02902656A0481|149 161|hyperintense
P02902656A0481|91 106|repetition time
P02901763A0977|238 244|number
P02901763A0977|1 12|Codon usage
P02901763A0977|248 253|tRNAs
P02901763A0977|286 303|protein synthesis
P02901763A0977|120 125|genes
P02900760A0073|7 24|sequence elements
P02900760A0073|244 253|3T6 cells
P02900760A0073|198 210|transfection
P02900760A0073|106 122|RNA polymerase I
P02899177A0605|187 194|regions
P02899177A0605|82 87|model
P02899177A0605|147 152|drugs
P02897651A0000|50 61|infertility
P02897651A0000|76 84|abortion
P02895566A0187|153 176|pressure pain component
P02895566A0187|139 145|effect
P02895566A0187|66 90|pressure pain components
P02895566A0187|107 124|ischemia duration
P02894789A0954|50 55|times
P02894789A0954|79 84|T4/T1
P02894789A0954|14 30|recovery indexes
P02894689A0000|35 48|DNA fragments
P02894689A0000|56 61|bases
P02894689A0000|150 166|diiodosalicylate
P02890200T0001|71 88|neurofibromatosis
P02890200T0001|45 50|tumor
P02889352A0000|157 175|calcium antagonist
P02889352A0000|112 124|beta blocker
P02889352A0000|78 85|classes
P02889352A0000|89 98|compounds
P02884860A0329|1 10|Terazosin
P02884860A0329|59 64|alpha
P02884860A0329|123 130|therapy
P02883871A1075|139 147|contrast
P02883871A1075|114 135|drug hypersensitivity
P02883871A1075|166 169|ISA
P02883871A1075|151 157|agents
P02882893A0301|84 99|P. s. campbelli
P02882893A0301|30 41|conductance
P02879951T0000|1 8|Effects
P02879951T0000|42 50|SGB-1534
P02878100A0674|87 96|diltiazem
P02878100A0674|115 124|diltiazem
P02878100A0674|9 16|results
P02876899A0568|4 8|Days
P02876899A0568|42 50|subjects
P02876899A0568|88 120|bevantolol plasma concentrations
P02875967A0377|81 92|guinea pigs
P02875967A0377|40 50|adrenaline
P02874635T0000|10 18|exposure
P02874635T0000|106 110|mice
P02874635T0000|120 124|rats
P02874635T0000|75 85|ballooning
P02873593A0581|236 243|effects
P02873593A0581|172 178|reward
P02873593A0581|107 110|BZP
P02870851A0349|1 7|Output
P02870851A0349|27 40|parotid gland
P02870851A0349|74 98|parotid saliva flow rate
P02868848A0167|137 145|imipenem
P02868848A0167|25 35|fosfomycin
P02868848A0167|180 192|gas gangrene
P02868848A0167|120 132|penicillin G
P02865502T0000|115 125|infarction
P02865502T0000|46 79|tissue-type plasminogen activator
P02863492A0544|141 150|IgG index
P02863492A0544|108 112|mean
P02863492A0544|44 60|treatment groups
P02861067A0000|102 108|asthma
P02861067A0000|155 176|bronchodilator effect
P02861067A0000|112 117|order
P02861067A0000|67 78|ipratropium
P02861067A0000|46 53|effects
P02856622T0001|49 58|follow-up
P02856622T0001|77 87|carcinomas
P02853799T0001|33 42|hepatitis
P02853799T0001|20 25|non-A
P02853799T0001|72 86|transformation
P02852805A0216|16 22|solids
P02852805A0216|41 56|characteristics
P02850967T0000|1 10|Induction
P02850967T0000|59 84|adenylate cyclase pathway
P02850967T0000|14 46|proto-oncogene fos transcription
P02849759A0865|5 18|SV40 enhancer
P02848842A0643|3 9|family
P02848842A0643|42 56|kilobase range
P02848842A0643|13 26|RNA molecules
P02848842A0643|75 80|probe
P02846640A0643|29 37|bacteria
P02844797A1225|222 235|acid sequence
P02844797A1225|262 282|transmembrane domain
P02844797A1225|297 315|consensus sequence
P02844797A1225|148 154|length
P02844797A1225|166 177|replacement
P02844797A1225|44 55|amino acids
P02844767A0596|85 96|photosystem
P02844767A0596|54 63|psbB gene
P02844767A0596|166 183|chloroplast genes
P02843694T0001|65 76|case report
P02843694T0001|9 28|E-B virus infection
P02840376A0461|2 10|anti-IIa
P02839716A1907|5 14|mechanism
P02839716A1907|162 166|site
P02839716A1907|108 110|E2
P02839716A1907|194 199|WORDS
P02839488A1314|116 137|erythrocyte type-1 Gs
P02839488A1314|212 217|error
P02839488A1314|14 20|assays
P02838319A0527|1 5|RVEF
P02838319A0527|10 14|LVEF
P02838319A0527|44 45|p
P02837763A0259|1 20|Amino acid sequence
P02837763A0259|47 52|HL-14
P02837763A0259|75 81|rabbit
P02836623A1094|6 8|SV
P02836623A1094|161 183|months postinoculation
P02836623A1094|94 102|delta Mo
P02836623A1094|105 107|SV
P02834478A0000|52 60|interest
P02834478A0000|15 30|weight heparins
P02833101T0000|27 41|cell disorders
P02833101T0000|74 94|parvovirus infection
P02833049A0630|70 79|deletions
P02833049A0630|30 32|U3
P02833012A0428|157 159|MW
P02833012A0428|76 89|reading frame
P02833012A0428|15 21|L mRNA
P02832293T0000|5 8|use
P02832293T0000|12 18|CRF-41
P02832293T0000|75 82|obesity
P02831796A0000|86 98|similarities
P02831796A0000|191 195|AIDS
P02831796A0000|8 30|immunodeficiency virus
P02831796A0000|108 130|immunodeficiency virus
P02831398A0346|1 8|Irmiere
P02830265A0341|1 7|RPA190
P02830265A0341|80 93|reading frame
P02829183A0117|1 22|DNA sequence analysis
P02829183A0117|43 49|clones
P02826729A0790|51 53|WB
P02826729A0790|1 7|Growth
P02826729A0790|9 13|4-PA
P02826127A0709|221 231|cell lines
P02826127A0709|38 49|interaction
P02826127A0709|112 126|protein oct-B2
P02825139A0661|20 23|DNA
P02825139A0661|79 93|acid sequences
P02820128A1670|201 208|B chain
P02820128A1670|39 46|domains
P02820128A1670|78 89|coincidence
P02820128A1670|55 58|ORF
P02820128A1670|157 173|protein sequence
P02820128A1670|265 275|T2 protein
P02820128A1670|183 191|homology
P02817724A0075|69 75|planes
P02817724A0075|5 16|examination
P02817724A0075|30 32|T1
P02815229A0139|115 118|MBq
P02815229A0139|93 97|dose
P02815229A0139|24 33|mg t.i.d.
P02815229A0139|62 66|days
P02814182A1211|64 72|ABSTRACT
P02814182A1211|43 48|4-EPI
P02813369A0390|152 161|neighbors
P02813369A0390|76 87|territories
P02813369A0390|58 63|years
P02811378A0250|16 21|forms
P02811378A0250|55 62|infants
P02811378A0250|25 30|cases
P02811378A0250|130 137|maxilla
P02809831A0799|4 12|contrast
P02809831A0799|58 72|bone formation
P02809831A0799|47 54|amounts
P02809651A0492|87 100|policy makers
P02809651A0492|9 13|turn
P02809651A0492|47 60|meta-analysis
P02808232A0681|21 34|micrograms/kg
P02808232A0681|7 13|limits
P02806916A0000|96 100|rice
P02806916A0000|166 172|Sau3AI
P02806916A0000|45 47|Oc
P02806916A0000|248 253|probe
P02806916A0000|122 148|lambda EMBL3 phage library
P02806916A0000|30 43|oryzacystatin
P02802280A0495|51 53|TS
P02802280A0495|62 65|PTS
P02800417A0332|84 99|PC20 PGF2 alpha
P02800417A0332|8 13|group
P02800417A0332|122 123|r
P02798953A0307|184 193|stability
P02798953A0307|201 216|administrations
P02798953A0307|81 91|instrument
P02798953A0307|163 178|days postpartum
P02798953A0307|8 14|sample
P02798953A0307|134 145|consistency
P02796988A0735|5 29|transcription factor Sp1
P02796988A0735|95 113|gel shift analysis
P02795923A0000|190 197|surgery
P02795923A0000|178 185|autopsy
P02795923A0000|167 172|lungs
P02795923A0000|45 59|CT appearances
P02793753A0354|50 55|cmH2O
P02793753A0354|23 36|PA dispersion
P02793753A0354|59 62|CFV
P02793753A0354|107 112|sites
P02793216A0876|152 155|CgA
P02793216A0876|138 148|importance
P02793216A0876|20 24|lack
P02793216A0876|14 18|hand
P02792270A1220|92 101|responses
P02792270A1220|105 123|flexor motoneurons
P02790009A0375|1 20|Sequencing analysis
P02790009A0375|125 131|region
P02790009A0375|56 65|fragments
P02789180A0407|85 96|hypertrophy
P02789062A0000|38 43|chain
P02789062A0000|162 177|gene expression
P02789062A0000|198 215|T-cell activation
P02789062A0000|62 74|model system
P02789062A0000|45 50|4F2HC
P02784507A0000|117 125|provirus
P02784507A0000|42 47|HIV-1
P02784507A0000|11 38|immunodeficiency virus type
P02781567A0544|3 7|soap
P02781567A0544|29 37|solution
P02781567A0544|74 89|stratum corneum
P02780157A0576|173 177|part
P02780157A0576|77 80|VHA
P02780157A0576|41 59|spleen MP function
P02780157A0576|132 136|lack
P02780157A0576|20 27|feature
P02780157A0576|249 257|standing
P02780157A0576|331 336|HBsAg
P02780157A0576|181 190|spleen MP
P02779752A0000|115 123|receptor
P02779752A0000|4 14|1-Naphthyl
P02779752A0000|59 90|serotonin antagonist properties
P02779752A0000|15 25|piperazine
P02778237A0585|101 131|maintenance prednisone therapy
P02778237A0585|12 16|term
P02776823A0000|71 73|6S
P02776823A0000|99 139|carbamoyloxymethyl-2-penem-3-carboxylate
P02776823A0000|79 81|1R
P02776823A0000|221 228|mg.kg-1
P02776823A0000|83 95|hydroxyethyl
P02776823A0000|59 65|sodium
P02776823A0000|28 44|pharmacokinetics
P02776471A0235|33 40|animals
P02776471A0235|59 69|responders
P02775136A1151|70 88|breathing patterns
P02775136A1151|216 234|breathing patterns
P02775136A1151|97 105|altitude
P02775136A1151|28 36|HAPE-S-S
P02775136A1151|151 154|AMS
P02774271A0000|103 107|acid
P02774271A0000|190 191|F
P02774271A0000|128 130|Br
P02774271A0000|73 85|end products
P02774271A0000|151 159|pathways
P02773507A0750|171 180|clearance
P02773507A0750|3 8|value
P02773507A0750|104 109|value
P02773507A0750|117 121|l/kg
P02773507A0750|82 91|clearance
P02773507A0750|62 78|sample estimates
P02767733A0690|70 72|G3
P02767733A0690|114 119|cases
P02767733A0690|123 124|%
P02767733A0690|46 51|cases
P02766745T0000|86 96|dairy cows
P02766745T0000|74 82|mastitis
P02766745T0000|31 43|relationship
P02766330A0779|5 11|author
P02766330A0779|89 96|effects
P02765001A0105|220 224|rash
P02765001A0105|19 27|patients
P02765001A0105|247 256|psoriasis
P02765001A0105|229 243|family history
P02765001A0105|123 127|rash
P02765001A0105|44 53|arthritis
P02763467A0903|70 73|35S
P02763467A0903|263 268|point
P02763467A0903|93 101|proteins
P02763467A0903|161 168|viruses
P02762006A0071|1 5|Cord
P02762006A0071|65 72|lesions
P02761537A0168|1 14|Heating cells
P02761537A0168|206 217|nucleotides
P02761537A0168|73 77|rRNA
P02761537A0168|21 30|degrees C
P02761537A0168|188 194|region
P02761537A0168|246 254|28S rRNA
P02761537A0168|298 316|transcription unit
P02761150A0000|69 75|kidney
P02761150A0000|173 177|days
P02761150A0000|161 165|days
P02761150A0000|54 59|liver
P02761150A0000|61 67|spleen
P02761150A0000|90 98|duodenum
P02760922A0000|49 64|core protein A1
P02760922A0000|23 40|ribonucleoprotein
P02760922A0000|42 47|hnRNP
P02757862T0000|67 80|defibrillator
P02757862T0000|27 41|microprocessor
P02756878A0075|19 26|process
P02756878A0075|5 11|nature
P02756878A0075|72 82|arrhythmia
P02752651A0480|35 44|September
P02752651A0480|21 31|department
P02752651A0480|163 165|Th
P02752651A0480|133 143|modalities
P02752651A0480|181 192|disturbance
P02752303A0000|1 15|Lithium delays
P02752303A0000|76 97|plasma concentrations
P02752303A0000|135 146|weight loss
P02749215A0000|53 59|pyuria
P02749215A0000|10 21|proteinuria
P02748188A0091|137 139|PS
P02748188A0091|38 40|PT
P02748188A0091|77 81|test
P02748188A0091|46 48|Ss
P02748188A0091|83 88|means
P02748188A0091|179 182|sec
P02748188A0091|209 210|t
P02746099A0000|5 13|mobility
P02746099A0000|37 46|premolars
P02746099A0000|108 115|contact
P02745444A0391|5 34|transcription initiation site
P02744490A0894|68 79|S1 nuclease
P02744490A0894|84 108|primer extension studies
P02744490A0894|19 28|structure
P02744490A0894|142 152|PTHrP gene
P02744490A0894|122 132|hypothesis
P02743981A0347|84 109|L1e-L10e-L12e transcripts
P02743981A0347|207 210|ORF
P02743981A0347|142 150|NAB-L11e
P02743981A0347|225 235|transcript
P02740955A0333|36 50|mortality rate
P02740955A0333|14 22|patients
P02740627A0137|168 180|VE/VO2 ratio
P02740627A0137|5 18|oxygen uptake
P02740627A0137|140 155|oxygen pressure
P02740627A0137|79 97|minute ventilation
P02740627A0137|74 76|fR
P02740627A0137|49 53|VCO2
P02740627A0137|20 23|VO2
P02740627A0137|113 124|ventilation
P02740627A0137|264 266|VD
P02740196A0704|103 108|range
P02740196A0704|4 14|Experiment
P02740196A0704|89 95|center
P02736482A0550|50 66|brain metastases
P02736482A0550|31 48|radiation therapy
P02733690T0000|87 96|reductase
P02733690T0000|11 18|cloning
P02732341A0000|169 177|staining
P02732341A0000|141 149|lymphoma
P02732341A0000|92 96|year
P02732341A0000|182 204|chloroacetate esterase
P02731611A0134|171 196|Mental Research Institute
P02731611A0134|54 58|view
P02731611A0134|143 153|principles
P02731611A0134|74 78|case
P02727909A0383|71 80|threshold
P02727909A0383|55 63|decrease
P02727909A0383|146 155|types IIa
P02727909A0383|10 19|amplitude
P02727909A0383|133 140|persons
P02727909A0383|90 101|sensitivity
P02725495A0929|70 102|pre-mRNA branchpoint recognition
P02725495A0929|138 154|metazoan U2 RNAs
P02725495A0929|181 193|trypanosomes
P02723503T0000|56 67|spermatozoa
P02720966A0455|18 23|fluid
P02720966A0455|142 147|years
P02720966A0455|42 55|concentration
P02720966A0455|106 116|meningitis
P02720966A0455|28 31|ADA
P02717349A0311|1 4|Men
P02717349A0311|45 52|fitness
P02714852T0000|22 27|HLA-B
P02714852T0000|56 65|evolution
P02713994A0482|68 75|mothers
P02713994A0482|19 27|HSV type
P02713994A0482|39 47|HSV type
P02713310T0000|1 15|Fundus changes
P02713310T0000|77 83|drusen
P02713310T0000|105 111|report
P02711167A0818|32 41|PFB-group
P02711167A0818|114 120|degree
P02711167A0818|6 9|day
P02711167A0818|149 156|animals
P02709819A0495|10 13|ADR
P02708353A1452|80 91|transcripts
P02708353A1452|72 76|gene
P02708353A1452|121 139|polysome fractions
P02708288A0621|236 237|V
P02708288A0621|293 307|oxidation mode
P02708288A0621|277 285|detector
P02708288A0621|144 148|acid
P02708288A0621|126 132|column
P02707909A0209|70 78|fraction
P02707909A0209|26 29|UKM
P02707909A0209|121 129|dialyses
P02705296A0231|39 50|polyprotein
P02705296A0231|73 84|kilodaltons
P02704579A1078|139 140|P
P02704579A1078|64 71|disease
P02704579A1078|197 211|lung mechanics
P02704579A1078|125 136|a/AO2 ratio
P02704579A1078|91 114|gas exchange parameters
P02703121T0000|50 61|blood donor
P02703121T0000|22 44|sclerosing cholangitis
P02702566A0000|68 72|days
P02702566A0000|18 27|cisplatin
P02702566A0000|124 128|head
P02702566A0000|89 97|infusion
P02695914T0000|26 37|drug action
P02693593A0866|27 42|leader sequence
P02692881A0354|169 173|tone
P02692881A0354|4 14|comparison
P02692881A0354|36 41|women
P02692881A0354|110 120|heart rate
P02692881A0354|73 78|women
P02692881A0354|259 263|acid
P02692881A0354|323 340|calcium excretion
P02692881A0354|248 253|serum
P02692881A0354|268 277|reduction
P02692881A0354|211 219|function
P02691811A0355|70 75|spite
P02691811A0355|96 110|blood acidosis
P02691811A0355|27 35|recovery
P02689544A0456|19 28|abutments
P02689544A0456|88 97|abutments
P02689439A0000|49 51|EC
P02689439A0000|166 177|glutathione
P02689439A0000|121 132|conjugation
P02689439A0000|15 41|glutathione S-transferases
P02688772T0000|20 24|skin
P02686980A0000|4 9|order
P02686980A0000|163 168|yeast
P02686588A0592|18 26|analysis
P02686588A0592|42 52|hematocrit
P02686588A0592|57 67|hemoglobin
P02685461A0380|16 24|symptoms
P02685461A0380|32 39|disease
P02684585T0001|1 26|Agranulocytosis treatment
P02680843A0724|33 44|REM latency
P02680843A0724|79 92|investigation
P02680843A0724|11 22|application
P02677666A0356|115 123|mutation
P02677666A0356|78 85|mutants
P02677002A0205|152 155|C-P
P02677002A0205|65 68|14C
P02677002A0205|112 117|C-Asp
P02677002A0205|128 131|32P
P02677002A0205|132 150|carbamyl phosphate
P02675492A0806|16 24|patients
P02675492A0806|81 91|pain score
P02675492A0806|93 96|ESR
P02674674A1308|34 40|notion
P02674674A1308|5 12|results
P02674674A1308|77 89|OBF1 protein
P02674674A1308|134 140|origin
P02674327A0493|93 108|polyhedrin gene
P02674327A0493|29 45|codon usage bias
P02670457T0000|5 24|calcium requirement
P02668691A0570|99 103|nagC
P02668691A0570|37 41|nagA
P02668691A0570|108 112|nagD
P02666568A0000|67 82|protocol TCL821
P02666568A0000|29 37|patients
P02666034A1520|33 39|course
P02666034A1520|127 139|vasodilation
P02666034A1520|199 213|placebo course
P02657883T0001|1 8|Doppler
P02657883T0001|42 50|fistulae
P02657388A1011|33 44|termination
P02657388A1011|73 89|RNA polymerase I
P02655381A0000|6 13|studies
P02655381A0000|172 190|hyperprolactinemia
P02655381A0000|192 202|occlusions
P02655381A0000|117 122|means
P02655381A0000|158 170|hypogonadism
P02655381A0000|266 278|incompetence
P02651448A0000|153 163|bioerosion
P02651448A0000|174 190|depolymerization
P02651448A0000|41 50|diffusion
P02651448A0000|192 198|Type B
P02651448A0000|104 112|material
P02649811T0000|12 25|contraception
P02648646A0932|97 101|Vp30
P02648646A0932|179 205|platelet activating factor
P02648646A0932|89 93|fall
P02648646A0932|164 174|micrograms
P02648396A1033|27 31|foci
P02648396A1033|47 51|RECs
P02647937A0191|83 87|ways
P02647937A0191|108 116|problems
P02647918A0423|34 54|somatomedin-C levels
P02647918A0423|143 148|ng/ml
P02647918A0423|72 76|mean
P02647918A0423|91 96|error
P02646007T0000|87 107|protein C deficiency
P02646007T0000|33 41|leukemia
P02645276T0088|1 13|Construction
P02645276T0088|79 86|mutants
P02642976A1474|11 30|consensus sequences
P02641762T0001|117 121|bull
P02641762T0001|93 103|comparison
P02641762T0001|10 23|heart disease
P02641762T0001|107 112|SPECT
P02637597A0362|100 109|IgM level
P02637597A0362|142 144|C3
P02637597A0362|130 138|decrease
P02637597A0362|149 151|C4
P02637597A0362|13 20|studies
P02634872A0000|1 11|Retrograde
P02634872A0000|40 58|endodontics system
P02632904A0619|33 38|Q/VO2
P02632904A0619|82 83|r
P02632904A0619|93 94|p
P02631743A0275|115 121|plates
P02631743A0275|83 86|use
P02631743A0275|45 61|color deficiency
P02631505A0382|35 49|aminoglycoside
P02631505A0382|86 91|cases
P02631505A0382|13 16|AMP
P02629109A0000|246 257|1880 levels
P02629109A0000|14 31|fertility decline
P02623038A0632|84 101|saline injections
P02623038A0632|4 11|changes
P02620085A0656|34 46|applications
P02620085A0656|1 7|Animal
P02620085A0656|86 106|replacement implants
P02620085A0656|130 138|material
P02615078A0283|61 65|M.f.
P02609112A0000|1 15|Reagent strips
P02609112A0000|111 123|laboratories
P02605679A0306|51 73|isomerization rate k12
P02605679A0306|1 9|Analysis
P02605679A0306|201 206|delta
P02605679A0306|178 193|hydrolysis rate
P02605679A0306|209 218|ester k24
P02605160A0000|116 119|end
P02605160A0000|57 66|pregnancy
P02605160A0000|123 132|pregnancy
P02605160A0000|15 26|iron intake
P02603923A0220|155 160|ng/ml
P02603923A0220|21 35|skin incisions
P02603923A0220|53 57|back
P02603923A0220|229 236|fashion
P02603923A0220|182 198|lactate solution
P02603923A0220|120 122|ml
P02602150A0993|103 128|replication origin region
P02602150A0993|143 155|construction
P02602150A0993|179 186|vectors
P02602150A0993|240 254|virus replicon
P02602150A0993|74 91|sequence elements
P02600306A0140|141 148|channel
P02600306A0140|162 170|AM tones
P02598745A0251|51 56|cases
P02597549A0964|136 151|recovery period
P02597549A0964|100 107|aspirin
P02597549A0964|189 200|prothrombin
P02597549A0964|67 79|dipyridamole
P02597549A0964|213 233|thromboplastin times
P02595451T0000|68 85|J1 series hybrids
P02595451T0000|40 54|chromosome 11p
P02592961A0327|17 25|measures
P02592961A0327|74 97|psychomotor performance
P02592543A0106|96 112|plasmid profiles
P02592543A0106|62 90|Kanagawa hemolysin reactions
P02592543A0106|165 173|organism
P02591969A0961|116 122|region
P02591969A0961|60 82|ADH gene transcription
P02590869A0743|119 124|serum
P02590869A0743|139 146|SC dose
P02590869A0743|101 114|lavage fluids
P02590869A0743|38 47|serum IgG
P02590869A0743|82 92|LNA titers
P02590540A0741|49 50|%
P02590540A0741|33 42|diagnoses
P02590540A0741|8 13|women
P02590540A0741|63 69|levels
P02586513A0622|1 9|Analysis
P02586513A0622|169 186|zinc finger motif
P02586513A0622|310 317|Thr Ser
P02586513A0622|196 210|amino terminus
P02586513A0622|130 139|organisms
P02586513A0622|288 305|consensus Tyr Ser
P02586513A0622|322 325|Ser
P02585492A1005|101 113|parB mutants
P02585492A1005|53 64|P7 proteins
P02585492A1005|90 97|P1 parA
P02582918A0000|102 110|anti-HBs
P02582918A0000|232 235|T12
P02582918A0000|202 203|%
P02582918A0000|130 144|S/N Ratio Unit
P02582918A0000|195 196|%
P02582918A0000|217 219|T1
P02582918A0000|188 189|%
P02582918A0000|125 128|S/N
P02582918A0000|91 96|cases
P02580830A1131|102 114|% similarity
P02580830A1131|38 44|region
P02580830A1131|10 18|sequence
P02577458A0412|117 134|receptor blockers
P02577458A0412|140 159|calcium antagonists
P02577458A0412|58 69|angiotensin
P02575959A0643|65 71|values
P02575959A0643|95 103|training
P02575959A0643|105 107|T2
P02575490A1021|154 159|liver
P02575490A1021|144 150|weight
P02575490A1021|72 76|band
P02574551T0000|1 15|Antihistamines
P02574052A0910|16 27|differences
P02574052A0910|42 50|relation
P02573836A0244|204 210|GXGKST
P02573836A0244|156 179|core consensus sequence
P02573836A0244|124 148|amino acid substitutions
P02573836A0244|46 49|NBS
P02573336A0000|101 106|order
P02573336A0000|4 14|experiment
P02573336A0000|65 70|snake
P02573336A0000|212 215|ROF
P02573336A0000|195 204|magnitude
P02572928T0000|26 35|arthritis
P02571924A0000|18 31|mating type A
P02571924A0000|55 86|yeast Rhodosporidium toruloides
P02571924A0000|144 157|undecapeptide
P02571924A0000|9 14|cells
P02568930T0000|37 41|cDNA
P02568930T0000|62 70|cytokine
P02568930T0000|134 147|T lymphocytes
P02566680A0820|207 221|response rates
P02566680A0820|101 102|%
P02566680A0820|4 12|contrast
P02566680A0820|161 166|times
P02566680A0820|227 228|%
P02566613A0831|84 95|nucleotides
P02566613A0831|59 67|enhancer
P02566613A0831|74 82|TGACGTCA
P02565683A0841|98 107|reentrant
P02565683A0841|128 139|tachycardia
P02565683A0841|164 175|tachycardia
P02562825A0413|19 41|beta-2 agonist therapy
P02562825A0413|73 74|p
P02560415T0012|49 52|jaw
P02560415T0012|57 69|face regions
P02557350A0632|71 72|%
P02557350A0632|52 59|SRP54sp
P02557350A0632|27 35|proteins
P02557350A0632|79 80|%
P02557217A0000|1 15|Beta-endorphin
P02557217A0000|83 88|males
P02557217A0000|26 44|cortisol secretion
P02556269A0187|5 14|DNA helix
P02556269A0187|219 222|DNA
P02556269A0187|146 154|nuclease
P02556269A0187|183 190|plasmid
P02555703T0000|155 174|c-myc transcription
P02555703T0000|200 205|v-abl
P02555703T0000|93 111|signaling pathways
P02555703T0000|122 127|c-myc
P02555418A0973|77 85|sequence
P02554310A0419|4 12|contrast
P02554310A0419|24 32|fragment
P02552143A0748|1 4|VP5
P02552143A0748|30 44|capsid protein
P02550682A0411|95 96|%
P02550682A0411|72 75|IIc
P02550682A0411|14 23|incidence
P02549417A0000|61 83|acristate mitochondria
P02549417A0000|90 99|functions
P02549036A0000|223 233|properties
P02549036A0000|5 32|Bacillus subtilis phage phi
P02549036A0000|166 177|homogeneity
P02547778A0786|114 124|expression
P02547778A0786|42 46|ANT1
P02547778A0786|12 18|nature
P02547706A0928|118 124|CMV-IP
P02547706A0928|20 23|ISH
P02547706A0928|129 132|IIP
P02547079A0910|35 55|hyperparathyroidemia
P02547079A0910|157 164|calcium
P02547079A0910|14 29|calcium balance
P02545903A0639|1 11|Antibodies
P02545903A0639|140 162|BTV-10 virus particles
P02545903A0639|110 119|BHK cells
P02545903A0639|43 55|immunization
P02544059A0377|68 71|MPa
P02544059A0377|53 56|PHe
P02544059A0377|22 25|PN2
P02544059A0377|45 51|helium
P02543679A1291|17 25|evidence
P02543679A1291|43 51|lambda O
P02543679A1291|94 118|DnaK heat shock proteins
P02543679A1291|133 137|role
P02543226A1559|313 319|blocks
P02543226A1559|471 477|blocks
P02543226A1559|438 449|hyperplasia
P02543226A1559|50 59|carcinoma
P02543226A1559|416 425|carcinoma
P02543226A1559|146 161|breast biopsies
P02543226A1559|26 36|likelihood
P02543226A1559|331 341|parenchyma
P02542270A0000|70 78|relation
P02542270A0000|168 183|mesophyll cells
P02542270A0000|198 206|greening
P02542270A0000|224 229|maize
P02541882A0251|84 92|patients
P02541882A0251|60 70|metastasis
P02538720A0582|1 5|UbiA
P02538720A0582|110 118|sequence
P02538450A0000|18 29|cDNA clones
P02538450A0000|55 60|liver
P02537441A0231|102 109|disease
P02537441A0231|55 71|varicella-zoster
P02537441A0231|79 87|globulin
P02536096A0327|259 297|chloramphenicol acetyltransferase gene
P02536096A0327|4 14|HeLa cells
P02536096A0327|52 77|herpes simplex virus type
P02536096A0327|29 42|transcription
P02534067A0316|1 15|Administration
P02534067A0316|110 129|beta-desoxycortisol
P02534067A0316|131 144|DHEA sulphate
P02534067A0316|74 80|plasma
P02534067A0316|84 105|alpha OH progesterone
P02534067A0316|294 307|alpha OH DHEA
P02534067A0316|146 161|androstenedione
P02534067A0316|242 262|beta OH androsterone
P02532032A0385|1 22|Plasma concentrations
P02532032A0385|113 123|parameters
P02532032A0385|26 29|ANF
P02532032A0385|60 65|renin
P02530470A0604|82 94|blood donors
P02530470A0604|56 69|staff members
P02529378A0536|1 21|S1 nuclease analysis
P02529378A0536|277 287|activation
P02529378A0536|166 170|TATA
P02529378A0536|220 227|element
P02529378A0536|295 302|HIV LTR
P02529378A0536|178 185|portion
P02529378A0536|151 159|enhancer
P02528329A0000|142 149|plasmid
P02528329A0000|163 167|uncB
P02528329A0000|27 34|subunit
P02528329A0000|61 72|F1F0-ATPase
P02527365T0000|87 97|maturation
P02527365T0000|24 41|mos protooncogene
P02525044A1026|21 28|T25-T75
P02525044A1026|128 141|suxamethonium
P02525044A1026|94 104|mivacurium
P02522297A0000|35 39|TXA2
P02522297A0000|19 33|thromboxane A2
P02522297A0000|5 11|effect
P02522297A0000|89 91|SQ
P02521217A1035|65 83|membrane fractions
P02521217A1035|28 35|protein
P02519679T0000|44 49|ticks
P02518691A0251|221 231|regulation
P02518691A0251|76 94|DNA binding assays
P02518691A0251|181 197|kappa B enhancer
P02518691A0251|15 45|IL2R alpha promoter constructs
P02517008A0481|67 78|monotherapy
P02517008A0481|11 19|patients
P02514498A0000|234 237|use
P02514498A0000|143 150|persons
P02514498A0000|247 256|electrode
P02514498A0000|9 17|CO2/HCO3
P02514498A0000|74 88|acid secretion
P02514498A0000|60 70|inhibition
P02511898A0000|112 120|research
P02511898A0000|25 32|reasons
P02511207A0282|1 3|K.
P02511069A0532|18 27|mutations
P02511069A0532|53 60|failure
P02511069A0532|131 141|DRE region
P02511069A0532|89 98|lethality
P02509123A0371|102 121|baseline conditions
P02509123A0371|32 39|latency
P02509123A0371|8 16|sessions
P02508306A0528|42 54|plasma cells
P02508306A0528|26 37|lymphocytes
P02508306A0528|134 143|follicles
P02507523A0791|117 124|protein
P02507523A0791|53 57|ORF2
P02507523A0791|88 92|ORF1
P02506390T0001|20 31|anastomoses
P02504603T0000|1 10|Isolation
P02504603T0000|41 54|CDC group IIf
P02502602A0323|1 10|Tonometry
P02502602A0323|140 143|p50
P02502602A0323|66 79|determination
P02502602A0323|14 27|blood samples
P02500432A1416|117 120|end
P02500432A1416|141 148|segment
P02500432A1416|191 196|front
P02500432A1416|89 97|kilobase
P02498322A0226|118 139|oligonucleotide probe
P02498322A0226|55 77|gel retardation assays
P02498322A0226|165 171|region
P02496109A0754|308 314|region
P02496109A0754|336 341|genes
P02496109A0754|349 352|IF1
P02496109A0754|356 368|L17 interval
P02496109A0754|256 264|promoter
P02496109A0754|27 37|S1 mapping
P02496109A0754|62 78|gene disruptions
P02496090A0252|19 36|tracheostomy tube
P02496090A0252|8 11|CO2
P02493644A0588|23 28|jun-D
P02493644A0588|97 110|transcription
P02493644A0588|72 77|c-jun
P02492111A0670|35 51|bone lead values
P02492111A0670|6 7|%
P02492111A0670|149 155|adults
P02489753A0581|169 177|position
P02489753A0581|115 123|position
P02489753A0581|66 74|FB group
P02489753A0581|181 189|position
P02488148A1156|117 121|time
P02488148A1156|80 89|diagnosis
P02488148A1156|108 109|%
P02486634A0632|153 175|collateral development
P02486634A0632|143 149|degree
P02486634A0632|72 90|contrast injection
P02486634A0632|60 65|level
P02483438A0498|34 40|action
P02483438A0498|21 30|mechanism
P02483438A0498|56 67|inodilators
P02483438A0498|91 119|phosphodiesterase inhibitors
P02482511A0860|223 227|rats
P02482511A0860|7 35|phosphodiesterase inhibitors
P02482511A0860|76 84|syndrome
P02481779A0213|1 8|NIK-244
P02481779A0213|100 121|plasma concentrations
P02481779A0213|172 180|ligation
P02481779A0213|220 230|mg/kg i.v.
P02481779A0213|185 194|digitalis
P02481779A0213|292 302|mg/kg i.v.
P02481779A0213|332 336|mean
P02481779A0213|61 72|arrhythmias
P02481230A1258|93 97|mice
P02480419A0735|85 96|hepatitis B
P02480419A0735|16 25|cirrhosis
P02480419A0735|133 134|%
P02479635A0659|137 147|expression
P02479635A0659|112 119|phorbol
P02479635A0659|41 49|plasmids
P02476664A0563|70 72|D.
P02476664A0563|29 37|sequence
P02475717A0565|119 131|infarct size
P02475717A0565|1 16|Tissue necrosis
P02475717A0565|142 156|risk zone size
P02474356A0559|186 192|animal
P02474356A0559|5 10|ratio
P02474356A0559|59 65|tissue
P02474356A0559|124 136|microspheres
P02474356A0559|31 37|tumour
P02474110A1039|220 237|resonance imaging
P02474110A1039|101 119|inhibitor ramipril
P02474110A1039|4 12|addition
P02474110A1039|96 99|ACE
P02474110A1039|183 194|hypertrophy
P02474110A1039|45 59|blood pressure
P02473942A1207|116 138|transmembrane segments
P02473718A0000|340 346|female
P02473718A0000|142 146|OKT3
P02473718A0000|133 140|T-cells
P02473718A0000|193 200|B-cells
P02473718A0000|87 96|serotonin
P02473718A0000|265 269|male
P02473718A0000|150 158|T-helper
P02473718A0000|168 180|T-suppressor
P02473718A0000|370 375|years
P02473718A0000|315 323|subjects
P02473718A0000|357 360|age
P02473718A0000|116 122|5-HIAA
P02473718A0000|127 130|VMA
P02473718A0000|243 251|subjects
P02473619A0202|187 196|reactions
P02473619A0202|159 167|patients
P02473619A0202|214 222|blockers
P02473619A0202|74 89|control animals
P02473619A0202|45 54|chemicals
P02473156A0000|3 7|cDNA
P02473156A0000|111 117|member
P02469451A0239|55 62|fashion
P02469451A0239|144 152|subjects
P02469451A0239|107 131|MAO-B inhibitor deprenyl
P02466665A0202|61 66|fluid
P02464097T0000|138 149|arrhythmias
P02464097T0000|54 91|prostaglandin endoperoxide antagonist
P02464097T0000|96 104|ischemia
P02462523A0394|174 198|germ-line transformation
P02462523A0394|125 127|su
P02462523A0394|79 88|mutations
P02462523A0394|44 55|DNA changes
P02462047A0208|55 71|pedicle ligation
P02462047A0208|176 181|flaps
P02462047A0208|160 166|island
P02462047A0208|94 100|artery
P02462047A0208|134 151|flap replantation
P02459309T0000|136 144|dialysis
P02459309T0000|32 41|serotonin
P02459309T0000|213 222|detection
P02459309T0000|180 194|chromatography
P02458234T0000|7 13|method
P02458234T0000|90 104|EEG recordings
P02457922A0991|71 75|RNAs
P02457922A0991|140 142|kb
P02457922A0991|36 42|region
P02457922A0991|144 151|message
P02457922A0991|198 202|size
P02457922A0991|62 67|blots
P02455821A0099|143 155|EHV-1 genome
P02455821A0099|88 91|map
P02455821A0099|45 84|AccI-EcoRI restriction fragment mapping
P02454390T0000|1 9|Enhancer
P02454390T0000|57 82|glucocorticoid repression
P02454390T0000|90 114|alpha 1-fetoprotein gene
P02451872A0391|53 54|%
P02446871A1021|98 107|LSU rRNAs
P02446871A1021|179 188|molecules
P02446871A1021|166 169|end
P02446871A1021|135 144|structure
P02444507A0240|101 109|patients
P02443028A0695|84 95|reperfusion
P02443028A0695|4 10|reflow
P02438637T0000|1 19|Mucolipidosis type
P02438637T0000|54 61|history
P02437792T0000|65 81|immunoreactivity
P02437792T0000|40 46|lipase
P02437792T0000|31 38|amylase
P02436005A0707|85 95|inhibition
P02436005A0707|99 108|Ca influx
P02436005A0707|7 14|results
P02436005A0707|61 71|nicorandil
P02427869A0939|73 76|BHT
P02427797A0199|100 109|cessation
P02427797A0199|140 148|ischemia
P02427797A0199|7 11|dogs
P02427797A0199|40 48|pancreas
P02427797A0199|21 25|limb
P02427797A0199|113 123|blood flow
P02427797A0199|177 181|dogs
P02424743A0280|34 43|amplitude
P02424743A0280|78 85|periods
P02423773T0001|36 44|glycerin
P02423773T0001|14 20|method
P02423533A1314|52 57|mRNAs
P02423533A1314|160 174|rat PC12 cells
P02423533A1314|192 211|nerve growth factor
P02423533A1314|105 110|level
P02418701A0000|32 39|tissues
P02418701A0000|142 151|specimens
P02418701A0000|76 83|antigen
P02418701A0000|179 187|polypoid
P02418701A0000|229 243|diverticulitis
P02418701A0000|215 223|adenomas
P02417023T0001|1 5|Role
P02417023T0001|66 72|method
P02417023T0001|9 29|superoxide dismutase
P02409297A0984|119 134|virus particles
P02409297A0984|141 153|polypeptides
P02409297A0984|12 21|antiserum
P02406992A0192|175 193|laboratory studies
P02406992A0192|110 119|algorithm
P02406992A0192|124 134|evaluation
P02406992A0192|75 90|amaurosis fugax
P02406570A0466|99 112|test plasmids
P02406570A0466|61 64|UAS
P02405589A0000|62 73|pharmacists
P02405589A0000|31 48|drug interactions
P02404451A1532|187 202|Cys-118 residue
P02404451A1532|262 270|activity
P02404451A1532|81 87|region
P02404451A1532|227 240|glycosylation
P02404451A1532|106 113|Cys-118
P02403926A0000|236 244|sequence
P02403926A0000|276 286|Xiao-Chang
P02403926A0000|46 79|breast carcinoma cell line MDA-MB
P02403926A0000|259 266|Redmond
P02403926A0000|253 257|S.C.
P02403926A0000|321 326|Hynes
P02403926A0000|95 111|DNA-transfection
P02403926A0000|147 188|trk proto-oncogene receptor kinase domain
P02403926A0000|328 332|N.E.
P02403035A0621|81 89|fumarase
P02403035A0621|12 25|reading frame
P02400457A0469|255 268|Experiment I.
P02400457A0469|4 14|Experiment
P02400457A0469|42 56|supine cycling
P02400457A0469|78 85|minutes
P02400457A0469|60 69|% VO2 max
P02399053A1032|5 7|Lm
P02398897A0000|85 95|efficiency
P02398897A0000|99 109|elongation
P02398897A0000|12 33|transcription factors
P02395868A0322|51 58|ligands
P02395868A0322|97 103|ligand
P02395868A0322|148 155|ligands
P02394707A0789|1 18|Promoter elements
P02394707A0789|138 143|CCAAT
P02394707A0789|145 150|ATTGG
P02394707A0789|177 197|nucleotide stretches
P02394707A0789|60 69|CCAAT box
P02393001A0324|48 49|r
P02393001A0324|98 105|obesity
P02393001A0324|42 46|BMIs
P02393001A0324|130 142|densitometry
P02392032A0657|102 116|distance scale
P02392032A0657|5 12|results
P02392032A0657|128 140|architecture
P02392032A0657|56 73|relaxation curves
P02392032A0657|29 33|idea
P02390989A0745|86 101|point mutations
P02390989A0745|162 175|reading frame
P02390989A0745|46 50|exon
P02390989A0745|122 124|bp
P02390538A0000|48 57|gestation
P02390538A0000|173 187|Olympus PF18 S
P02390538A0000|161 171|fiberscope
P02390538A0000|193 195|mm
P02386895A0496|102 113|hypotension
P02386895A0496|71 72|%
P02386895A0496|98 99|%
P02386895A0496|45 53|headache
P02386895A0496|117 118|%
P02386895A0496|22 37|nausea/vomiting
P02386895A0496|125 137|hypertension
P02384389A0854|119 129|fed cattle
P02384389A0854|53 55|YG
P02384389A0854|10 15|trend
P02384389A0854|107 115|seam fat
P02383771A0544|136 148|distribution
P02383771A0544|112 122|epithelium
P02383771A0544|40 50|epithelium
P02378945A0487|71 77|effect
P02378945A0487|6 16|adaptation
P02376023A0307|68 69|P
P02376023A0307|223 228|level
P02376023A0307|156 159|IgE
P02376023A0307|52 58|levels
P02376023A0307|131 138|infants
P02376023A0307|62 66|IgG1
P02373810A1118|84 85|%
P02373810A1118|4 12|contrast
P02373810A1118|23 24|%
P02372712A0002|102 106|PCO2
P02372712A0002|86 100|carbon dioxide
P02372712A0002|5 12|effects
P02372712A0002|40 42|CW
P02372712A0002|62 64|pH
P02372712A0002|44 49|water
P02370571A0663|85 91|goiter
P02370571A0663|184 189|women
P02370571A0663|5 13|findings
P02370571A0663|76 81|cause
P02370571A0663|146 156|population
P02370571A0663|121 127|cohort
P02362803A0608|51 60|isolation
P02362803A0608|36 42|probes
P02362803A0608|13 22|fragments
P02361812A1110|140 142|EX
P02361812A1110|5 15|kg FFM SMR
P02361812A1110|176 180|cent
P02361812A1110|63 71|EX group
P02361812A1110|210 211|P
P02361812A1110|151 155|cent
P02361008T0000|12 21|prognosis
P02361008T0000|30 36|births
P02358975A0709|143 157|IgA deficiency
P02356823A0063|118 134|alarm properties
P02356823A0063|36 45|principle
P02356823A0063|15 21|method
P02355765A0220|82 87|weeks
P02355765A0220|30 51|benzathine penicillin
P02354381A0207|69 75|corner
P02354381A0207|14 24|treatments
P02354381A0207|255 256|N
P02354381A0207|216 220|back
P02354381A0207|83 87|cage
P02354381A0207|26 33|control
P02354381A0207|148 152|cage
P02353453A1249|69 79|RUB genome
P02353453A1249|156 169|rearrangement
P02353453A1249|112 129|alphavirus genome
P02353453A1249|213 220|viruses
P02353453A1249|194 203|evolution
P02351239A0693|67 74|removal
P02351239A0693|167 190|histamine concentration
P02351239A0693|107 110|rat
P02351239A0693|254 270|gastrin infusion
P02351239A0693|93 99|mucosa
P02351239A0693|215 231|hypergastrinemia
P02349942A0287|98 104|recall
P02349942A0287|15 22|factors
P02348728A1153|18 28|DNA ploidy
P02348728A1153|61 67|factor
P02348225A0192|143 155|distribution
P02348225A0192|72 81|mL/min/m2
P02348225A0192|227 235|patients
P02348225A0192|84 93|half-life
P02348225A0192|31 40|clearance
P02348225A0192|241 249|jaundice
P02347407A0217|37 44|animals
P02347407A0217|26 31|field
P02344529T0000|47 61|erythropoietin
P02342477A1292|233 252|sequence similarity
P02342477A1292|11 15|UfAP
P02342477A1292|258 262|UfAP
P02342477A1292|20 24|UTMP
P02342477A1292|296 304|function
P02342477A1292|94 106|biosynthesis
P02342477A1292|150 158|presence
P02340595A0124|110 120|tRNA genes
P02340595A0124|56 65|sequences
P02339005T0000|1 7|Effect
P02339005T0000|63 67|rats
P02335815A0530|86 96|C assembly
P02335815A0530|8 25|carboxyl terminus
P02335815A0530|124 132|activity
P02335521T0000|16 46|vitellogenin activator element
P02335521T0000|56 69|transcription
P02334972A0145|65 71|drusen
P02334972A0145|110 119|incidence
P02334972A0145|147 160|complications
P02334972A0145|56 61|types
P02334972A0145|165 169|loss
P02333545A0313|115 123|controls
P02333545A0313|27 44|fibrinogen levels
P02332798A0725|16 21|phase
P02332798A0725|25 33|response
P02331361A0268|21 29|increase
P02331361A0268|37 53|myocyte diameter
P02331361A0268|89 106|autopsy specimens
P02330110A1085|86 93|outcome
P02329840A0383|49 60|measurement
P02329840A0383|81 88|changes
P02329840A0383|26 41|microelectrodes
P02327159T0001|51 55|home
P02327159T0001|33 37|life
P02327159T0001|10 14|AIDS
P02326716A0139|1 8|Methods
P02326716A0139|140 157|angle differences
P02326716A0139|159 164|RVADs
P02326716A0139|196 208|displacement
P02326716A0139|91 118|concave rib-vertebra angles
P02326716A0139|120 124|RVAs
P02325208A0209|9 11|M.
P02324104A0929|98 104|region
P02324104A0929|142 150|splicing
P02324104A0929|28 39|CeCAT alpha
P02324104A0151|170 180|C. elegans
P02324104A0151|155 166|populations
P02324104A0151|47 74|phosphotransferase activity
P02323517A0557|138 172|prostaglandin generation technique
P02323517A0557|37 41|part
P02323517A0557|12 19|lesions
P02320999A0606|175 191|emission factors
P02320999A0606|80 92|gypsum board
P02320999A0606|113 120|plywood
P02320999A0606|126 146|polyurethane lacquer
P02320999A0606|193 203|mg m-2 h-1
P02319610A1527|152 157|route
P02319610A1527|33 41|findings
P02319610A1527|14 23|relevance
P02317554T0000|1 14|Determination
P02317554T0000|36 54|imaging properties
P02315472A0583|21 33|imaging time
P02315472A0583|39 49|parameters
P02315472A0583|123 124|%
P02312689A0360|48 60|Patho Dx Kit
P02312689A0360|26 35|agreement
P02311544A0086|100 107|disease
P02311544A0086|57 66|MSMR cyst
P02311544A0086|88 96|symptoms
P02310350A0221|99 103|ABRs
P02310350A0221|42 51|intensity
P02310350A0221|63 71|polarity
P02310350A0221|13 18|study
P02310261A0115|87 98|pericardium
P02310261A0115|67 72|layer
P02307850A1197|5 14|induction
P02307850A1197|43 46|Con
P02307850A1197|107 109|NK
P02307848T0042|68 73|genes
P02307848T0042|33 43|complexity
P02307613A0783|1 41|Erythrocyte protoporphyrin concentration
P02307613A0783|217 226|remainder
P02307613A0783|202 208|groups
P02307613A0783|176 180|dogs
P02307067A1348|184 195|adaptations
P02307067A1348|48 65|families Tydeidae
P02307067A1348|20 27|members
P02307067A1348|172 180|evidence
P02307067A1348|129 153|concentration treatments
P02305014A0226|24 35|experiments
P02305014A0226|95 109|guide cannulas
P02305014A0226|14 20|series
P02303470A0242|25 28|kbp
P02300759A0000|17 26|protocole
P02300759A0000|77 88|epithelioma
P02300759A0000|167 176|radiology
P02300759A0000|181 188|surgery
P02300541A0000|87 93|series
P02300541A0000|18 25|effects
P02300541A0000|43 50|barrier
P02300541A0000|62 69|surface
P02300541A0000|120 124|MDIs
P02298741A0809|204 207|kDa
P02298741A0809|70 74|beta
P02298741A0809|39 49|antibodies
P02298741A0809|266 280|alpha antibody
P02298741A0809|144 152|JK cells
P02298741A0809|123 126|PKC
P02295521A0922|102 112|complaints
P02295521A0922|70 75|level
P02295521A0922|232 243|development
P02295521A0922|264 274|complaints
P02295521A0922|11 20|relations
P02293664A0946|18 24|series
P02293664A0946|146 156|base pairs
P02293664A0946|28 37|deletions
P02293664A0946|45 62|vimentin promoter
P02292272T0000|39 49|locomotion
P02291144A0493|138 143|MCHCH
P02291144A0493|92 99|machine
P02291144A0493|11 19|accuracy
P02291144A0493|73 74|H
P02289639A0989|20 24|HbA1
P02289639A0989|66 67|%
P02289639A0989|120 121|p
P02287860T0001|34 39|study
P02287860T0001|96 110|X-ray exposure
P02284393A0751|49 62|coping styles
P02284393A0751|88 121|EE/low EE research classification
P02283378T0000|110 124|chromatography
P02283378T0000|8 14|method
P02283148T0000|17 36|cytokine production
P02283148T0000|41 59|adhesion molecules
P02281948A0245|64 68|milk
P02281948A0245|93 100|sucrose
P02281948A0245|14 35|mineral oil emulsions
P02281118A1191|118 121|use
P02281118A1191|141 151|situations
P02281118A1191|72 76|bone
P02278474A0000|68 83|cancer patients
P02278474A0000|98 109|individuals
P02278474A0000|131 140|treatment
P02277452A0116|137 145|ischemia
P02277452A0116|169 179|chest pain
P02277452A0116|21 36|angina pectoris
P02277452A0116|53 57|LVEF
P02277452A0116|59 64|LVESV
P02277452A0116|199 202|ECG
P02277005A0227|5 23|CT characteristics
P02274509A0623|1 18|Liver dysfunction
P02274509A0623|56 65|reactions
P02274509A0623|106 117|blood serum
P02274509A0623|90 98|activity
P02273690T0001|71 79|hormones
P02273690T0001|12 21|cisapride
P02270834A0123|10 16|method
P02270096T0000|11 19|activity
P02269281A1276|17 28|maintenance
P02269281A1276|42 53|involvement
P02269281A1276|148 156|relation
P02269281A1276|192 207|control signals
P02266679A0740|1 10|Plasma Al
P02266679A0740|36 44|baseline
P02264601A0000|1 23|Taste reactivity tests
P02264601A0000|127 129|NP
P02264601A0000|92 93|P
P02264601A0000|95 99|rats
P02264601A0000|104 125|alcohol nonpreferring
P02261254A0168|102 113|circulation
P02261254A0168|1 12|Experiments
P02261254A0168|148 156|ischemia
P02261254A0168|73 83|conditions
P02259334A0205|76 80|gene
P02259334A0205|111 114|kDa
P02259334A0205|14 22|promoter
P02257899T0000|17 28|interaction
P02257899T0000|36 46|generation
P02256678A1224|153 170|protein complexes
P02256678A1224|64 70|region
P02256678A1224|26 47|footprinting analysis
P02254418A0641|49 64|delta hemolysin
P02254418A0641|23 37|S. lugdunensis
P02254418A0641|107 110|CNS
P02253663A0687|98 105|maximum
P02253663A0687|76 83|minimum
P02253663A0687|57 67|difference
P02253663A0687|15 21|rhythm
P02252953A0300|206 222|eating behaviour
P02252953A0300|23 28|girls
P02252953A0300|56 65|EAT score
P02252953A0300|90 95|girls
P02251119A0319|58 61|U14
P02251119A0319|40 48|presence
P02251119A0319|132 137|mouse
P02249872A1051|137 142|phase
P02249872A1051|170 176|microC
P02249872A1051|67 81|charge density
P02249872A1051|126 132|charge
P02249872A1051|181 186|phase
P02247924A0078|77 88|nephrectomy
P02247924A0078|15 19|case
P02247072A0794|5 30|SUP44 suppressor mutation
P02247072A0794|110 121|alterations
P02247072A0794|45 51|region
P02246803A0692|127 133|output
P02246362T0000|102 108|traits
P02246362T0000|58 66|evidence
P02243093A0000|70 77|protein
P02243093A0000|140 142|bp
P02243093A0000|37 43|HTLV-I
P02243093A0000|144 151|repeats
P02243093A0000|134 138|pair
P02241892A0681|101 106|mRNAs
P02241892A0681|146 152|length
P02241892A0681|28 51|polyadenylation signals
P02237431A0833|87 94|T alpha
P02237431A0833|5 23|Ets-1 binding site
P02237431A0833|61 67|region
P02236276T0000|1 5|Rats
P02236276T0000|60 65|naris
P02236060A1671|64 70|amount
P02236060A1671|29 37|compound
P02236002A0958|97 106|diversity
P02236002A0958|29 49|nucleotide diversity
P02236002A0958|120 128|elements
P02234345A0215|64 74|epithelium
P02233715A0914|184 187|Dex
P02233715A0914|217 219|GR
P02233715A0914|112 121|initiator
P02233715A0914|95 109|RNA start site
P02233715A0914|73 86|IL-6 TATA box
P02233715A0914|151 161|MRE region
P02233626T0000|71 89|strabismus surgery
P02231162T0000|9 16|studies
P02229282A0454|1 9|Patients
P02229282A0454|127 133|levels
P02229068A0156|1 16|Gene constructs
P02229068A0156|66 75|env genes
P02229068A0156|46 49|rev
P02229068A0156|51 54|tat
P02229068A0156|146 148|SU
P02229068A0156|149 151|TM
P02229068A0156|180 191|rev protein
P02227438A0492|1 26|Primer extension analysis
P02227438A0492|163 174|start codon
P02227438A0492|125 127|nt
P02223928T0069|9 19|experience
P02223652A0939|87 89|UH
P02223652A0939|7 30|antithrombin unit basis
P02220102A0271|69 76|disease
P02220102A0271|31 36|grade
P02218094A0395|20 26|tissue
P02218094A0395|40 42|Ft
P02218094A0395|30 38|transfer
P02217307T0000|54 60|rhythm
P02217307T0000|73 90|emptying response
P02209811T0000|13 23|peroxidase
P02209811T0000|60 70|rat caudal
P02209540A1362|26 30|Ets2
P02209540A1362|46 59|transcription
P02209237A0239|168 183|liver cirrhosis
P02209237A0239|96 104|scanning
P02209237A0239|25 33|shunting
P02209237A0239|63 68|cases
P02206858A0000|67 71|girl
P02206858A0000|57 65|siblings
P02206858A0000|124 128|ages
P02206858A0000|107 116|diagnoses
P02206430A0197|85 90|level
P02206430A0197|1 5|Pups
P02206430A0197|28 39|environment
P02204810A1080|8 14|region
P02204623A0000|343 347|C.R.
P02204623A0000|33 49|insulin receptor
P02204623A0000|308 312|Dull
P02204623A0000|337 341|Kahn
P02204623A0000|276 280|J.N.
P02204623A0000|282 288|Backer
P02204623A0000|51 53|IR
P02204623A0000|290 294|J.M.
P02204623A0000|114 120|Tyr960
P02204623A0000|320 327|Ullrich
P02204623A0000|264 274|Livingston
P02204623A0000|329 331|A.
P02204029A0184|139 149|base pairs
P02204029A0184|48 51|unr
P02204029A0184|80 89|direction
P02204029A0184|42 46|gene
P02202496T0000|10 19|nutrition
P02201901A0229|71 83|SSN6 protein
P02200736A1003|85 89|MLTF
P02200736A1003|7 14|factors
P02200736A1003|108 122|CACCTGTC motif
P02200736A1003|134 143|sequences
P02200150A1381|154 169|plastic surgeon
P02200150A1381|25 33|decision
P02200150A1381|109 119|geneticist
P02200150A1381|134 149|psychotherapist
P02198289A0436|16 24|peptides
P02198289A0436|162 167|dimer
P02198289A0436|41 52|amino acids
P02196565T0000|50 67|activation signal
P02196565T0000|207 213|factor
P02196565T0000|106 110|Gal4
P02196450A0870|1 9|Analysis
P02196450A0870|257 265|promoter
P02196450A0870|21 37|deletion mutants
P02196450A0870|199 202|QBP
P02196450A0870|94 97|QBP
P02196176A0749|64 69|TREB5
P02196176A0749|96 102|repeat
P02196176A0749|11 17|TREB36
P02195715A0143|174 182|embolism
P02195715A0143|133 137|risk
P02195715A0143|149 159|thrombosis
P02195715A0143|61 69|newborns
P02194972T0000|81 102|Enterococcus faecalis
P02194972T0000|127 131|mice
P02194972T0000|13 20|effects
P02190122A0633|136 144|primates
P02190122A0633|6 18|emancipation
P02190122A0633|26 33|ability
P02190122A0633|60 69|influence
P02188096A0955|54 70|c-myb expression
P02188096A0955|83 97|c-myb function
P02187091A0721|168 169|P
P02187091A0721|20 30|resistance
P02185140A0000|204 233|yeast transcription promoters
P02185140A0000|235 240|pADC1
P02185140A0000|80 97|alpha-demethylase
P02185140A0000|242 246|pGPD
P02185140A0000|149 156|strains
P02185140A0000|30 39|14DM gene
P02182618A0168|51 61|expression
P02182618A0168|174 180|region
P02182618A0168|67 100|chloramphenicol acetyltransferase
P02182240A0355|34 46|anistreplase
P02182240A0355|86 92|period
P02182240A0355|64 71|heparin
P02182240A0355|107 110|min
P02180935A0535|102 113|HL-60 cells
P02180935A0535|9 20|experiments
P02180935A0535|122 124|Mr
P02179188A1223|70 78|presence
P02179188A1223|82 95|dinitrophenol
P02176822A0000|33 37|MFPK
P02176822A0000|99 101|BT
P02176822A0000|106 108|BS
P02176822A0000|17 31|protein kinase
P02176822A0000|188 205|glycogen synthase
P02176822A0000|92 97|sites
P02176822A0000|209 214|sites
P02176209A0954|98 106|extracts
P02176209A0954|114 121|variety
P02176209A0954|24 27|EFI
P02176209A0954|135 145|cell types
P02176021T0000|18 24|diquat
P02176021T0000|52 88|electron spin resonance spectroscopy
P02175433A0575|114 120|copies
P02175433A0575|77 97|Ylp vector sequences
P02174861A0736|1 11|Regulation
P02174861A0736|155 163|promoter
P02174861A0736|108 112|dyad
P02174861A0736|123 131|sequence
P02174861A0736|31 42|V. cholerae
P02174105A1232|87 92|cells
P02174105A1232|21 29|analysis
P02173399A0333|141 142|%
P02173399A0333|159 160|%
P02173399A0333|144 155|sensitivity
P02173399A0333|125 136|specificity
P02170687A0000|101 119|transforming genes
P02170687A0000|77 87|expression
P02168640A0268|153 159|ground
P02168640A0268|67 75|response
P02168640A0268|128 140|disturbances
P02168640A0268|13 25|correlations
P02167467T0000|32 50|protein equivalent
P02167467T0000|5 21|26S rRNA binding
P02166825A0198|186 189|set
P02166825A0198|237 252|promoter region
P02166825A0198|4 9|order
P02166825A0198|57 65|promoter
P02166825A0198|41 49|elements
P02166040A0385|411 419|leukemia
P02166040A0385|339 353|hepatoma cells
P02166040A0385|277 280|neo
P02166040A0385|73 79|series
P02166040A0385|379 388|infection
P02166040A0385|533 567|chloroamphenicol acetyltransferase
P02166040A0385|223 228|genes
P02166040A0385|396 403|Moloney
P02166040A0385|92 97|genes
P02166040A0385|486 500|neo expression
P02166040A0385|448 460|transfection
P02165589A0000|97 109|X-chromosome
P02165589A0000|62 67|2C1-3
P02165589A0000|120 126|member
P02164637A0515|1 11|Disruption
P02164637A0515|19 28|IRA2 gene
P02164637A0515|142 153|suppression
P02164637A0515|111 130|sporulation defects
P02164604A0399|5 12|studies
P02164604A0399|26 34|findings
P02164585A0814|102 113|amino acids
P02164585A0814|54 62|tra gene
P02164585A0814|24 28|orfD
P02164585A0814|88 89|%
P02163394T0000|5 14|sacT gene
P02163394T0000|78 86|homology
P02163394T0000|30 42|sacPA operon
P02163347A0472|141 152|amino acids
P02163347A0472|5 18|cDNA sequence
P02163347A0472|166 179|ets-1 protein
P02162754A0801|1 4|PAO
P02162754A0801|158 182|glucose-transport system
P02162754A0801|66 78|accumulation
P02162754A0801|12 20|turnover
P02162467A0311|106 122|cAMP/CAP complex
P02162467A0311|14 29|cytR expression
P02162049A0291|82 94|DNA sequence
P02162049A0291|28 32|gene
P02160622A0000|187 198|combination
P02160622A0000|21 31|properties
P02160622A0000|52 62|tail-flick
P02160622A0000|92 105|motor effects
P02159559A0779|27 39|interference
P02158927A0000|140 144|tRNA
P02158927A0000|128 132|UTR3
P02158927A0000|109 114|genes
P02158927A0000|154 158|RAD7
P02158927A0000|191 196|yeast
P02158927A0000|145 148|Gly
P02158927A0000|63 74|COR segment
P02157882T0000|17 25|function
P02157882T0000|86 100|transformation
P02157882T0000|53 56|abl
P02157141A0923|103 112|sequences
P02157141A0923|154 157|DNA
P02157141A0923|20 29|T antigen
P02157141A0923|173 180|changes
P02156828A0164|51 59|residues
P02156828A0164|36 43|destrin
P02156828A0164|88 89|%
P02154885A0153|169 175|enzyme
P02154885A0153|140 161|substrate recognition
P02154885A0153|37 45|residues
P02154602A0092|17 24|homolog
P02154602A0092|61 71|resistance
P02154599A0382|112 131|Zta fusion proteins
P02154599A0382|9 14|study
P02154599A0382|167 173|motifs
P02154467A0709|34 44|similarity
P02154467A0709|5 16|PC2 protein
P02154467A0709|161 169|molecule
P02153683A1579|64 71|ankyrin
P02153683A1579|6 12|result
P02153683A1579|76 82|fodrin
P02153683A1579|109 111|Na
P02151229A0921|1 19|Mean ROI-A/B ratio
P02151229A0921|36 37|%
P02151229A0921|123 128|group
P02149566A0478|55 57|Pi
P02149566A0478|113 117|rest
P02149566A0478|79 82|PCr
P02149566A0478|121 132|LVH baboons
P02149566A0478|181 182|P
P02148799A0000|87 104|Neurospora crassa
P02148799A0000|59 83|nitrogen control circuit
P02148799A0000|209 214|genes
P02148799A0000|47 51|gene
P02148508A0374|8 12|AVLF
P02148219A0508|114 122|extensor
P02148219A0508|127 133|flexor
P02148219A0508|74 79|facts
P02147223A1047|117 127|PC12 cells
P02147223A1047|18 21|CRE
P02147223A1047|96 99|E1a
P02146266A0000|16 38|BamHI-HindIII fragment
P02146266A0000|127 132|sod-1
P02146266A0000|247 276|N. crassa amino acid sequence
P02145268A0746|68 75|analogy
P02145268A0746|49 58|sequences
P02145268A0746|83 95|organization
P02145268A0746|110 124|collagen genes
P02144610A1306|1 10|TCR alpha
P02144610A1306|272 287|decamer element
P02144610A1306|108 114|T beta
P02144610A1306|135 138|set
P02144610A1306|224 231|element
P02144610A1306|117 124|element
P02144610A1306|178 186|proteins
P02144610A1306|245 263|TCR alpha enhancer
P02144290A1444|1 4|Sci
P02143768T0000|48 52|wall
P02143186A0867|103 109|region
P02143186A0867|53 57|AHA2
P02143186A0867|148 161|coding region
P02143186A0867|73 79|intron
P02142993A0176|118 128|L. tropica
P02142993A0176|154 162|patterns
P02142993A0176|231 237|France
P02142993A0176|29 36|disease
P02142921T0000|86 93|results
P02142921T0000|199 204|depot
P02142921T0000|148 157|goserelin
P02142921T0000|74 82|analysis
P02142240A0506|116 124|presence
P02142240A0506|128 149|progesteron receptors
P02142240A0506|94 112|estrogen receptors
P02142240A0506|45 59|response rates
P02139891A0532|190 201|orientation
P02139891A0532|114 124|TAGA motif
P02139891A0532|142 150|TATA box
P02139891A0532|210 223|ATF/CREB site
P02138992A0911|140 148|approach
P02138992A0911|92 104|modification
P02138992A0911|120 124|work
P02138707A0198|86 98|protein mXBP
P02138707A0198|148 151|end
P02138707A0198|47 77|lambda gt11 expression library
P02138707A0198|284 289|class
P02135343A0131|99 111|maloclusions
P02135343A0131|83 95|distribution
P02135343A0131|9 16|article
P02135343A0131|146 158|relationship
P02132636A0188|84 98|nonsuppressors
P02132636A0188|62 77|DST suppressors
P02131666A0483|18 23|group
P02131666A0483|73 82|anomalies
P02129338A0568|78 115|alga Scenedemus obliquus plastocyanin
P02129338A0568|13 32|amino acid sequence
P02126417A0408|142 151|advantage
P02126417A0408|8 16|controls
P02125016A0145|1 5|PBSX
P02125016A0145|44 56|SOS response
P02124710A0193|37 42|c-fos
P02124710A0193|47 67|c-jun protooncogenes
P02123877A1452|186 207|serum response factor
P02123877A1452|170 178|addition
P02123877A1452|113 118|fra-1
P02123877A1452|93 104|liver cells
P02123877A1452|124 129|egr-2
P02123877A1452|106 111|fos-B
P02123820A0000|51 60|inhibitor
P02123820A0000|1 8|Effects
P02123820A0000|43 46|MAO
P02123820A0000|198 208|aggression
P02123820A0000|133 146|MAO inhibitor
P02123820A0000|225 229|rats
P02123466A0272|49 54|motif
P02123466A0272|78 84|domain
P02123466A0272|12 19|members
P02123295A0645|1 11|Disruption
P02123295A0645|15 19|ARF2
P02123029A0478|190 197|regions
P02123029A0478|213 220|isotype
P02123029A0478|92 111|spleen cDNA library
P02123029A0478|47 58|chain genes
P02121371T0000|67 70|GAP
P02121371T0000|75 93|yeast IRA proteins
P02120707A0594|82 83|W
P02120707A0594|124 153|HLA-DRA X-box oligonucleotide
P02120707A0594|88 98|V elements
P02119626A0471|12 17|scars
P02118612A0629|100 104|rats
P02118612A0629|81 89|eminence
P02118612A0629|8 15|minutes
P02118612A0629|147 155|exposure
P02118519A0516|168 189|neurofilament protein
P02118519A0516|110 115|genes
P02118519A0516|124 152|nerve growth factor receptor
P02117799T0000a|58 67|induction
P02117799T0000a|94 116|kidney transplantation
P02117799T0000a|29 40|prophylaxis
P02116071A0000|205 208|IgE
P02116071A0000|312 319|antigen
P02116071A0000|161 168|antigen
P02116071A0000|51 65|stage children
P02116071A0000|18 23|study
P02116071A0000|81 88|potency
P02116071A0000|144 152|exposure
P02116071A0000|366 372|amount
P02116071A0000|390 393|IgG
P02115572A1323|50 62|psi V lambda
P02115572A1323|22 41|V lambda pseudogene
P02115121A0000|139 148|mutations
P02115121A0000|156 186|dihydrolipoyl transsuccinylase
P02115121A0000|129 135|result
P02115121A0000|210 217|complex
P02115116A1137|51 60|enhancers
P02115116A1137|73 90|promoter elements
P02115111T0000|69 83|reading frames
P02115111T0000|48 56|analysis
P02115111T0000|123 137|strain PCC7120
P02115111T0000|91 106|nif gene region
P02113699A0372|5 13|patients
P02113699A0372|108 110|IM
P02113699A0372|194 195|N
P02113699A0372|119 120|N
P02113699A0372|222 227|spots
P02113699A0372|54 62|patients
P02113699A0372|122 130|patients
P02113174A0957|1 8|Krox-24
P02113015A0295|39 48|pregnancy
P02113015A0295|10 18|seizures
P02110148A0423|304 308|gene
P02110148A0423|49 70|DNA sequence analysis
P02110148A0423|203 208|probe
P02110148A0423|212 217|clone
P02110148A0423|12 28|HindIII fragment
P02110148A0423|164 172|sequence
P02109544A0000|201 208|culture
P02109544A0000|17 21|cost
P02109544A0000|250 253|DFA
P02109544A0000|296 305|treatment
P02109544A0000|26 34|benefits
P02109544A0000|240 248|antibody
P02107073A0584|175 180|STE18
P02107073A0584|113 127|overexpression
P02107073A0584|131 135|STE4
P02107073A0584|89 107|pheromone response
P02107073A0584|165 171|levels
P02105497A1092|103 112|BiP genes
P02105497A1092|81 88|species
P02105497A1092|58 72|HSP70 proteins
P02105497A1092|31 51|amino acid sequences
P02103140A1088|174 191|retransplantation
P02103140A1088|126 132|grafts
P02103140A1088|46 53|failure
P02102823A0492|1 20|Promoter activities
P02102823A0492|96 117|reporter gene systems
P02095150T0000|115 122|canines
P02095150T0000|92 111|ingrowth components
P02095150T0000|9 26|strain adaptation
P02094221A0247|1 9|Diuresis
P02094221A0247|47 50|tea
P02093741A0211|33 47|query language
P02093741A0211|53 66|data analysis
P02093741A0211|125 129|tool
P02092131T0000|80 95|transfer factor
P02092131T0000|31 39|transfer
P02089054A0121|33 55|liquid-solid partition
P02089054A0121|145 155|conditions
P02089054A0121|194 205|UV detector
P02083546A0000|200 208|subjects
P02083546A0000|108 119|amine oxime
P02083546A0000|227 236|Alzheimer
P02083546A0000|251 259|patients
P02083546A0000|213 221|patients
P02083546A0000|63 69|uptake
P02083546A0000|121 132|99mTc-HMPAO
P02083230A0938|186 192|domain
P02083230A0938|161 167|domain
P02083230A0938|89 114|amino acid residue domain
P02083230A0938|13 21|sequence
P02081463A0110|34 52|Spec gene activity
P02081463A0110|20 30|regulation
P02081463A0110|58 64|region
P02079811A0407|68 73|ulcer
P02079811A0407|80 89|operation
P02079811A0407|97 104|stomach
P02079811A0407|177 185|bleeding
P02079811A0407|47 54|EMB AZS
P02078080T0040|20 30|Madagascar
P02078080T0040|47 60|disadvantages
P02076816T0000|21 28|pathway
P02076620A0548|101 112|gemfibrozil
P02076620A0548|66 67|%
P02076620A0548|14 38|plasma fibrinogen levels
P02075876A0408|57 66|variation
P02075876A0408|28 31|EER
P02072798A0330|38 42|goal
P02072798A0330|88 93|ulcer
P02070227T0000|13 25|cell seeding
P02069738A0000|27 43|stimulus control
P02066246A0258|50 55|files
P02066246A0258|97 102|cases
P02064119A1172|51 56|L/min
P02064119A1172|138 146|ABSTRACT
P02064119A1172|21 30|responses
P02064119A1172|57 63|% SaO2
P02064119A1172|164 169|WORDS
P02062116A0688|71 74|max
P02061333A0784|33 40|introns
P02061333A0784|4 12|evidence
P02060052A0954|51 59|radicals
P02060052A0954|7 11|data
P02060052A0954|94 106|mitochondria
P02055484A0538|49 53|ATG1
P02055484A0538|13 25|PCR products
P02053289A0701|103 117|nt differences
P02053289A0701|71 77|groups
P02052544A0641|137 144|complex
P02052544A0641|154 158|DPB2
P02052544A0641|18 32|DNA polymerase
P02052544A0641|192 203|replication
P02047597A0149|125 132|strains
P02047597A0149|57 72|field condition
P02045809A0331|137 146|reduction
P02045809A0331|100 111|concentrate
P02045809A0331|4 12|contrast
P02045809A0331|74 80|powder
P02045366A1149|1 24|Hydrophobicity analysis
P02045366A1149|109 125|KlaC polypeptide
P02045366A1149|181 188|domains
P02044950A0258|11 36|polymerase chain reaction
P02041088A1053|16 33|enhancer activity
P02041088A1053|93 97|DR60
P02041088A1053|208 220|39K promoter
P02041088A1053|45 61|reporter plasmid
P02038326A0538|168 197|translation initiation factor
P02038326A0538|201 212|eIF-2 alpha
P02038326A0538|217 234|43S-48S particles
P02038326A0538|144 152|subunits
P02038326A0538|108 120|accumulation
P02038326A0538|56 68|accumulation
P02036066A0000|38 47|perfusion
P02036066A0000|110 118|solution
P02036066A0000|151 161|rat hearts
P02034676A0267|5 15|homologues
P02034655T0000|1 17|Characterization
P02034655T0000|25 30|alpha
P02033062A1169|81 94|chicken IGF-I
P02033062A1169|129 145|reporter plasmid
P02033062A1169|107 110|DNA
P02030910A1070|39 48|ETS1 cDNA
P02030910A1070|78 86|products
P02029468A0296|43 52|diagnosis
P02029468A0296|88 104|reference limits
P02027839A0250|5 12|muscles
P02027839A0250|213 218|group
P02027839A0250|177 185|distance
P02027839A0250|62 63|P
P02026461A0760|50 61|individuals
P02026461A0760|9 14|cases
P02026144A0741|116 120|NRS2
P02026144A0741|21 35|GUS expression
P02026144A0741|161 172|domain UAS1
P02024816A0521|53 57|SP-A
P02024816A0521|10 15|ELISA
P02024625A0202|103 115|similarities
P02024625A0202|78 83|cases
P02024625A0202|29 41|presentation
P02024252A0000|85 97|municipality
P02024252A0000|58 77|disability pensions
P02024252A0000|123 129|Norway
P02024252A0000|28 33|total
P02023421A0343|76 84|increase
P02023421A0343|131 144|wound healing
P02023421A0343|10 23|proliferation
P02023421A0343|121 127|effect
P02022920A0334|5 20|C4BP alpha gene
P02022920A0334|107 110|UTR
P02022188A0112|214 218|HMGs
P02022188A0112|13 21|analysis
P02022188A0112|44 55|BJ1 protein
P02022188A0112|75 86|nucleosomes
P02020314A1290|84 100|thrombocytopenia
P02020314A1290|19 43|micrograms/kg/day GM-CSF
P02020314A1290|56 64|severity
P02020314A1290|183 195|chemotherapy
P02019572A0000|71 96|rat liver pyruvate kinase
P02019572A0000|472 481|CHO cells
P02019572A0000|104 109|genes
P02019572A0000|439 444|cells
P02019572A0000|17 30|DNA sequences
P02019572A0000|53 63|expression
P02019572A0000|455 466|C2C12 cells
P02019572A0000|365 385|hepatoma HepG2 cells
P02019572A0000|147 195|chloramphenicol acetyltransferase reporter genes
P02019572A0000|330 340|expression
P02017271A0502|103 107|none
P02017271A0502|113 121|controls
P02017271A0502|41 49|strength
P02016769A0720|81 89|contexts
P02016769A0720|45 54|promoters
P02015921A0523|71 75|node
P02015921A0523|99 104|nodes
P02015921A0523|11 22|subdivision
P02012789A0051|13 27|family history
P02011924A0729|19 25|number
P02011924A0729|127 136|treatment
P02011924A0729|161 174|cell leukemia
P02011924A0729|29 37|patients
P02008982A0463|1 6|ELISA
P02008982A0463|27 39|contribution
P02008982A0463|60 72|tuberculosis
P02006558A0000|64 70|vision
P02004705A0686|99 106|product
P02004705A0686|76 84|fragment
P02004705A0686|120 122|Mr
P02002511A0637|25 39|PB-PK modeling
P02002511A0637|57 65|problems
P02002051A0276|20 29|isolation
P02002051A0276|47 57|cDNA clone
P02000093A0794|22 24|cv
P01999459A0795|1 3|A.
P01997465A0276|19 26|changes
P01997465A0276|71 87|collagen content
P01997465A0276|113 124|irradiation
P01995951A0000|69 72|HIV
P01995951A0000|97 102|sites
P01995951A0000|27 30|LTR
P01993181T0000|1 29|Nucleotide sequence analysis
P01993181T0000|56 88|PpG7 salicylate hydroxylase gene
P01992953A0247|103 107|test
P01992953A0247|9 15|levels
P01992953A0247|28 39|abnormality
P01992459A0000|55 62|element
P01992459A0000|158 169|protein Rev
P01992459A0000|76 103|immunodeficiency virus mRNA
P01992459A0000|267 274|nucleus
P01992459A0000|14 25|interaction
P01990266A0678|187 195|proteins
P01990266A0678|237 241|site
P01990266A0678|82 90|mobility
P01990266A0678|214 222|promoter
P01990266A0678|13 37|UV cross-linking studies
P01989999A0000|169 172|AMP
P01989999A0000|99 118|purine biosynthesis
P01989999A0000|162 165|IMP
P01989999A0000|91 95|role
P01989999A0000|30 33|IMP
P01988041A0281|67 85|BAL cDNA structure
P01986254A0452|136 143|T cells
P01986254A0452|117 121|band
P01986254A0452|92 100|addition
P01986254A0452|45 53|E6 motif
P01986225A0250|38 41|HSF
P01985920T0000|84 89|cDNAs
P01985920T0000|49 81|rat liver sterol carrier protein
P01985920T0000|26 45|nucleotide sequence
P01985301T0000|49 59|protection
P01985301T0000|10 17|therapy
P01983026A0483|103 120|CA concentrations
P01983026A0483|66 69|min
P01983026A0483|145 157|study period
P01983026A0483|10 20|heart rate
P01982190T0001|43 52|evolution
P01982190T0001|62 71|hepatitis
P01982061A0615|61 90|transcription initiation site
P01978834A0076|10 43|abomasum lambda gt11 cDNA library
P01977585A0222|154 168|protein kinase
P01977585A0222|12 18|enzyme
P01975428A0151|1 10|Telomeres
P01975428A0151|99 111|DNA molecule
P01975428A0151|57 68|degradation
P01975428A0151|30 37|fusions
P01974876A1051|18 58|restriction fragment length polymorphism
P01974876A1051|122 134|enzyme BglII
P01973384A0206|35 48|binding sites
P01973384A0206|104 117|transcription
P01971191A1271|38 45|agonist
P01971191A1271|110 122|liver volume
P01971191A1271|95 106|capacitance
P01971191A1271|47 60|isoproterenol
P01970926A0000|70 89|concentration rises
P01970926A0000|8 18|exercise K
P01970560A1024|307 316|organisms
P01970560A1024|143 168|beta-Galactosidase assays
P01970560A1024|109 113|copy
P01970560A1024|15 22|fusions
P01970560A1024|289 298|operators
P01970560A1024|334 344|efficiency
P01970560A1024|30 34|aroF
P01968156T0000|25 40|botulinum toxin
P01968043A0908|24 35|cDNA clones
P01968043A0908|75 81|pASB-1
P01964989A0145|35 48|phencyclidine
P01964989A0145|113 123|9-THC-COOH
P01964989A0145|231 238|ammonia
P01964989A0145|147 162|sodium chloride
P01964989A0145|107 111|acid
P01964989A0145|164 170|bleach
P01963438T0000|80 89|methylene
P01963438T0000|95 111|polypyrrole film
P01963438T0000|15 32|electron transfer
P01961996A0522|18 19|R
P01961996A0522|46 56|preference
P01961213A0150|52 63|breast milk
P01958821T0000|10 33|fluorescence microscopy
P01956491A0095|258 262|rats
P01956491A0095|22 36|amphotericin B
P01956491A0095|110 113|GFR
P01956491A0095|9 18|treatment
P01956491A0095|228 238|comparison
P01956491A0095|135 144|clearance
P01954835A0000|54 73|aspiration cytology
P01954835A0000|109 115|female
P01952827A0215|33 40|patient
P01952827A0215|8 12|time
P01947449A1082|222 239|cylinder diameter
P01947449A1082|142 153|requirement
P01947449A1082|47 57|model sets
P01945430A0660|155 171|neuroma suspects
P01945430A0660|127 141|labyrinthotomy
P01945430A0660|14 23|technique
P01942033T0000|21 34|RNA structure
P01942033T0000|47 66|splicing inhibition
P01939899A2043|100 106|number
P01939899A2043|67 74|effects
P01939899A2043|144 152|ABSTRACT
P01939899A2043|9 14|model
P01939899A2043|120 126|amount
P01939827A0150|173 186|mmol/L KH2PO4
P01939827A0150|227 240|precipitation
P01939827A0150|14 26|pretreatment
P01939827A0150|75 90|titanium powder
P01939827A0150|51 70|oxide surface layer
P01939827A0150|115 128|precipitation
P01939827A0150|191 203|mmol/L Hepes
P01939827A0150|300 313|mmol/L KH2PO4
P01939131A0871|35 41|BW2001
P01939131A0871|58 70|strain cells
P01937989A0383|66 70|test
P01937989A0383|37 46|induction
P01936997A0795|1 20|RNA gel retardation
P01936997A0795|105 127|TAR RNA loop sequences
P01936213T0000|1 11|Evaluation
P01936213T0000|44 61|membrane fluidity
P01934378A1219|10 41|muscle metaboreceptor responses
P01932695A1155|5 16|suppression
P01931966A0490|1 7|Fusion
P01931966A0490|54 60|pADPRP
P01931966A0490|11 20|ubiquitin
P01930470A0337|171 178|markers
P01930470A0337|203 208|blood
P01930470A0337|126 133|testing
P01930470A0337|95 106|Blood Banks
P01930470A0337|194 199|units
P01927845A0107|82 87|Bowen
P01927845A0107|29 36|lesions
P01925092A0304|68 77|treatment
P01925092A0304|101 129|tissue plasminogen activator
P01925092A0304|13 18|hours
P01925092A0304|30 37|animals
P01924920A0115|70 83|Gram staining
P01924920A0115|23 36|Mobiluncus SP
P01924920A0115|107 120|microorganism
P01924920A0115|14 21|samples
P01923985A0111|21 27|action
P01923766A0485|1 18|Sequence analysis
P01923766A0485|64 71|variant
P01923766A0485|36 44|addition
P01923766A0485|125 133|splicing
P01923766A0485|151 160|exclusion
P01923167A0000|1 30|Blood flow velocity waveforms
P01923167A0000|55 74|Doppler examination
P01923167A0000|125 133|arteries
P01922734T0000|36 43|neurons
P01922734T0000|78 89|stimulation
P01921463T0000|54 63|averaging
P01921463T0000|42 49|display
P01918073A0150|1 11|Comparison
P01918073A0150|471 481|adaptation
P01918073A0150|678 685|absence
P01918073A0150|766 773|mammals
P01918073A0150|145 163|extension sequence
P01918073A0150|691 719|protein kinase C target site
P01918073A0150|582 588|domain
P01918073A0150|40 71|TnIcardiac amino acid sequences
P01918073A0150|642 662|TnIcardiac sequences
P01918073A0150|119 127|presence
P01918073A0150|293 300|feature
P01918073A0150|485 488|TnI
P01918073A0150|419 422|TnC
P01918073A0150|607 626|sequence divergence
P01918010A1730|84 92|fragment
P01918010A1730|100 112|LPL promoter
P01918010A1730|190 207|3T3-L1 adipocytes
P01918010A1730|56 63|plasmid
P01918010A1730|164 174|expression
P01917962A0152|187 194|control
P01917962A0152|5 17|cDNA segment
P01917962A0152|202 215|SV40 promoter
P01917943A0621a|49 58|sequences
P01917943A0621a|201 209|plasmids
P01917943A0621a|219 261|chloramphenicol acetyltransferase reporter
P01917943A0621a|126 150|transfection experiments
P01917943A0621a|26 31|sMtCK
P01916405A0242|136 142|stages
P01916405A0242|115 117|DB
P01916405A0242|111 113|PC
P01916405A0242|31 38|persons
P01915580A0889|117 133|airway responses
P01915580A0889|138 160|airway hyperreactivity
P01915580A0889|7 14|results
P01911767T0000|35 67|ribulosebisphosphate carboxylase
P01911767T0000|24 31|subunit
P01911767T0000|75 90|subunit binding
P01909960A0134|170 171|%
P01909960A0134|82 94|biosynthesis
P01909960A0134|145 160|normetanephrine
P01909960A0134|78 80|NA
P01909960A0134|63 76|noradrenaline
P01909960A0134|15 24|injection
P01909027A0922|170 187|protein fork head
P01909027A0922|223 230|factors
P01909027A0922|232 237|HNF-3
P01909027A0922|108 136|fork head DNA binding domain
P01909027A0922|194 200|family
P01907265A0670|127 148|DNA cleavage activity
P01907265A0670|29 35|result
P01906509A0072|9 14|study
P01906111A1295|136 152|toxicity profile
P01906111A1295|95 98|use
P01906111A1295|45 52|regimen
P01905199A0210|80 83|ADR
P01905199A0210|5 11|effect
P01905199A0210|133 144|alterations
P01905199A0210|31 49|antitumor response
P01905199A0210|15 23|ICRF-187
P01904437A0000|22 31|metH gene
P01904437A0000|131 150|DNA binding protein
P01903841A1449|65 69|gene
P01903841A1449|120 131|yeast cells
P01903404A0688|85 92|studies
P01903404A0688|154 155|%
P01903404A0688|277 293|perfusion status
P01903404A0688|129 135|patent
P01903404A0688|176 177|p
P01901946A0243|256 279|affinity chromatography
P01901946A0243|66 91|mouse c-fos gene promoter
P01901946A0243|144 149|probe
P01901946A0243|13 28|oligonucleotide
P01901946A0243|44 56|SRE sequence
P01901405A0694|51 57|AT-BP2
P01901405A0694|83 90|tissues
P01901405A0694|13 28|mRNA expression
P01899846A0862|78 87|condition
P01899287A0726|16 26|cell cycle
P01899287A0726|57 67|RNA levels
P01898928A0260|103 112|DNA locus
P01898928A0260|83 85|Y.
P01898928A0260|74 79|cells
P01898113A0265|36 50|clearance rate
P01898113A0265|13 24|uptake rate
P01896777T0000|1 18|Ivermectin uptake
P01896777T0000|23 35|distribution
P01896777T0000|108 127|Onchocerca volvulus
P01895393A0745|50 57|absence
P01895393A0745|156 170|RNA polymerase
P01895393A0745|104 112|TATA box
P01895393A0745|74 83|Sp1 sites
P01895370A0199|155 156|D
P01895370A0199|39 43|peak
P01895370A0199|77 111|maximum shifted-frequency envelope
P01895370A0199|29 33|flow
P01895370A0199|60 61|D
P01895370A0199|15 25|reductions
P01893195A0000|69 76|authors
P01893195A0000|25 32|monkeys
P01893195A0000|120 135|virus Issyk-Kul
P01890989A1392|118 128|amphibians
P01890989A1392|66 84|estrogen induction
P01890989A1392|105 113|chickens
P01889753A0441|38 43|exons
P01889753A0441|5 15|nucleotide
P01889753A0441|57 67|boundaries
P01886774A0000|81 97|characterization
P01886774A0000|28 35|domains
P01886774A0000|120 136|octamer sequence
P01886043A0380|52 54|pH
P01886043A0380|179 198|inclusion complexes
P01886043A0380|26 33|complex
P01886043A0380|89 99|solubility
P01886043A0380|122 125|SMX
P01885752A0198|1 22|Chlamydia trachomatis
P01885752A0198|27 45|Chlamydia psittaci
P01885006A0995|25 40|superactivation
P01885006A0995|105 115|activation
P01884435A0088|218 222|ptO2
P01884435A0088|6 11|study
P01884435A0088|159 173|microelectrode
P01884435A0088|108 120|tissue sites
P01884435A0088|227 230|ptH
P01882386A0000|65 68|MFA
P01882386A0000|112 115|NaB
P01882386A0000|163 172|excretion
P01882386A0000|126 137|combination
P01882386A0000|176 180|lead
P01882386A0000|74 110|N-benzyl-N-dithiocarboxy-D-glucamine
P01881671T0001|11 20|ofloxacin
P01878755A0496|49 62|disappearance
P01878755A0496|64 65|P
P01878755A0496|8 13|ileum
P01876836T0000|1 15|Identification
P01876836T0000|54 72|GA binding protein
P01874752A0948|48 67|conditions cdc2/p58
P01874752A0948|129 137|activity
P01873999A0000|136 151|gene expression
P01873999A0000|201 211|production
P01873999A0000|125 132|details
P01873999A0000|228 236|proteins
P01871971A0836|69 81|binding site
P01871971A0836|19 26|mutants
P01871971A0836|143 149|growth
P01871033A0434|119 134|clearing cement
P01871033A0434|139 153|testing cement
P01871033A0434|48 53|force
P01871033A0434|30 40|impression
P01870428A0677|48 54|HDL2-C
P01870428A0677|59 63|mass
P01870428A0677|74 91|LDL particle size
P01869968A0673|81 90|clearance
P01869968A0673|92 97|HMPAO
P01869968A0673|132 144|significance
P01869907A2146|152 157|WORDS
P01869907A2146|5 25|across-fiber pattern
P01869907A2146|56 70|NaCl solutions
P01867069A0000|169 180|development
P01867069A0000|155 161|effect
P01867069A0000|20 24|days
P01867069A0000|78 82|days
P01867069A0000|134 137|age
P01864837A1029|127 137|% homology
P01864837A1029|89 105|mouse contrapsin
P01864837A1029|44 52|proteins
P01864510A0946|35 45|starvation
P01864510A0946|72 77|cells
P01863768A0649|5 12|protein
P01863768A0649|56 62|domain
P01862027A0212|7 15|features
P01861034A0798|33 41|fragment
P01861034A0798|56 68|contact area
P01861034A0798|105 122|scaphoid fragment
P01857326A0160|1 11|Oculus-500
P01857326A0160|92 101|computers
P01857326A0160|31 56|resolution imaging boards
P01856021A0577|97 106|procedure
P01856021A0577|126 133|control
P01856021A0577|177 183|xylene
P01856021A0577|60 64|year
P01854339A0221|8 14|region
P01854339A0221|109 118|sequences
P01854339A0221|135 141|levels
P01852603A0000|41 54|fission yeast
P01852603A0000|14 31|DNA repair mutant
P01851876A0129|36 47|EMBL3 mouse
P01851876A0129|56 63|library
P01851386T0092|37 44|FONICAP
P01850127A0000|117 124|protein
P01850127A0000|8 19|association
P01850127A0000|41 61|branchpoint sequence
P01850127A0000|75 84|pre-mRNAs
P01850096A0662|1 13|Heterodimers
P01850096A0662|138 143|start
P01850096A0662|73 93|restriction fragment
P01850096A0662|30 33|E12
P01849675A0167|18 30|relationship
P01849675A0167|40 47|viruses
P01848871A0392|220 229|potential
P01848871A0392|98 107|potential
P01848871A0392|174 185|QRS complex
P01848871A0392|143 150|portion
P01848871A0392|6 11|study
P01848871A0392|63 68|drugs
P01847665A1079|85 97|glioma cells
P01847665A1079|38 42|idea
P01847665A1079|67 81|PDGF receptors
P01847665A1079|213 231|glia cell lineages
P01847665A1079|195 202|program
P01846803A0688|136 144|residues
P01846803A0688|6 12|result
P01846803A0688|76 99|p34cdc2 kinase activity
P01846803A0688|46 49|Thr
P01846803A0688|104 108|line
P01846489A1119|77 93|protease domains
P01845899A0000|34 42|rep gene
P01845899A0000|66 71|Rep78
P01845899A0000|111 130|AAV DNA replication
P01845899A0000|29 32|AAV
P01845899A0000|135 154|AAV gene regulation
P01845829A0158|119 126|factors
P01845829A0158|80 87|domains
P01845829A0158|10 18|analysis
P01844878A0000|154 167|DNA fragments
P01844878A0000|81 85|gene
P01844878A0000|105 123|promoter sequences
P01842867A0696|4 14|conclusion
P01842867A0696|78 84|injury
P01840902A1089|32 38|system
P01840902A1089|161 167|dicots
P01840608A0823|32 45|reading frame
P01840608A0823|99 103|nifB
P01840608A0823|107 137|amino acid sequence comparison
P01840513A1019|187 196|induction
P01840513A1019|138 180|chloramphenicol acetyltransferase activity
P01840513A1019|126 134|increase
P01840513A1019|46 58|pCAT plasmid
P01837842A1410|35 53|protein components
P01837842A1410|116 119|CRE
P01833716A0990|1 13|Deregulation
P01833716A0990|93 109|HTLV-1 infection
P01833185A0547|119 125|Thr161
P01833185A0547|140 144|acid
P01833185A0547|231 242|cytokinesis
P01833185A0547|40 49|phenotype
P01833185A0547|210 217|mitosis
P01832152A0902|64 68|ORF2
P01832152A0902|25 38|start signals
P01832019A0265|78 85|animals
P01830114A1587|64 78|P4 transcripts
P01830114A1587|20 26|effect
P01830114A1587|111 127|gene copy number
P01830114A1587|30 33|NS1
P01829060A0649|70 76|values
P01829060A0649|5 16|ED30 values
P01829060A0649|106 111|mg/kg
P01827203A0136|51 59|proteins
P01827203A0136|75 81|dimers
P01826043A0431|207 230|protein kinase C family
P01826043A0431|5 36|pp90rsk-protein kinase activity
P01826043A0431|192 199|members
P01826043A0431|241 244|Ca2
P01825027T0000|84 90|family
P01825027T0000|33 54|peroxisome biogenesis
P01825027T0000|9 19|yeast gene
P01824713A0964|5 20|12S E1A product
P01824713A0964|59 73|cotransfection
P01824713A0964|41 53|TRE sequence
P01823520A0183|42 71|haematofluorometer Buchler ZF
P01822581A0533|119 133|breath samples
P01822581A0533|99 114|microgram/100ml
P01822581A0533|31 48|alcohol responses
P01816655T0000|42 46|case
P01816655T0000|30 36|report
P01812690A0475|48 54|growth
P01812690A0475|12 15|SMF
P01811948A0289|85 87|bp
P01811948A0289|70 77|element
P01811948A0289|143 144|G
P01811948A0289|133 141|sequence
P01811948A0289|105 123|LpS1 beta promoter
P01809854A0106|1 9|Examples
P01809854A0106|25 33|subjects
P01809854A0106|107 120|meta-analysis
P01808602A0000|80 100|nifedipine treatment
P01808602A0000|148 152|acid
P01808602A0000|62 69|effects
P01808602A0000|45 57|hypertension
P01808136T0000|16 30|contrast media
P01806314A0322|6 11|cells
P01806314A0322|47 54|markers
P01798407A1011|70 80|hypothesis
P01798407A1011|173 190|laughing seizures
P01798407A1011|159 165|origin
P01798407A1011|90 96|cortex
P01797459A0103|1 11|Mycoplasma
P01797459A0103|67 74|patient
P01792580A0198|39 45|Serbia
P01792580A0198|93 103|percentage
P01792580A0198|27 35|Republic
P01792580A0198|72 87|blood donations
P01791363A0208|102 109|testing
P01791363A0208|7 14|results
P01787085A0331|48 60|control rats
P01787085A0331|75 82|colloid
P01785749A0695|7 14|changes
P01785749A0695|45 50|group
P01783375A1066|37 48|involvement
P01783375A1066|91 100|disorders
P01782982A0155|1 11|Felodipine
P01782982A0155|99 108|histamine
P01782982A0155|125 144|bronchoconstriction
P01782424A0278|101 105|role
P01782424A0278|64 73|phenomena
P01782424A0278|109 118|sentinels
P01780235A0094|5 15|EPO levels
P01779433A0694|35 52|Alu family repeat
P01779433A0694|278 287|insertion
P01779433A0694|12 19|finding
P01779433A0694|157 163|rhesus
P01779433A0694|125 130|alpha
P01779433A0694|360 377|Alu family repeat
P01779433A0694|149 153|unit
P01779433A0694|303 320|Alu family repeat
P01777841A0744|98 107|afferents
P01777841A0744|36 47|differences
P01777841A0744|77 83|muscle
P01777841A0744|14 24|mechanisms
P01776306A0572|13 20|patient
P01774093T0000|16 23|outcome
P01774093T0000|36 39|IgM
P01774062A0257|127 136|YAC B1D12
P01774062A0257|40 54|HLA-DQA1 locus
P01774062A0257|109 111|kb
P01772201T0001|41 53|subjectivity
P01772201T0001|61 67|period
P01771593A1232|18 24|adults
P01771593A1232|77 86|offspring
P01770651T0001|116 125|thyroxine
P01770651T0001|26 36|evaluation
P01770651T0001|105 110|serum
P01769189A0000|1 13|Plasma lipid
P01769189A0000|277 281|body
P01769189A0000|172 178|VO2max
P01769189A0000|161 170|km week-1
P01769189A0000|106 111|years
P01769189A0000|84 85|n
P01769189A0000|18 38|lipoprotein profiles
P01769189A0000|294 295|%
P01769189A0000|188 201|ml kg-1 min-1
P01769189A0000|212 214|SD
P01769189A0000|270 275|years
P01767899A0136|70 81|prothrombin
P01767899A0136|189 201|envenomation
P01767899A0136|8 24|thrombocytopenia
P01767899A0136|104 123|thromboplastin time
P01767060A0000|222 228|stages
P01767060A0000|83 95|radiotherapy
P01767060A0000|111 120|frequency
P01767060A0000|125 133|duration
P01767060A0000|182 190|patients
P01767060A0000|241 251|carcinomas
P01766876A0000|69 79|chain gene
P01766876A0000|114 125|co-exchange
P01766876A0000|46 52|events
P01766876A0000|165 171|marker
P01765407A0866|64 84|plasma concentration
P01765407A0866|23 33|mg DMEA/m3
P01765407A0866|8 16|exposure
P01765407A0866|131 138|mumol/l
P01765375A0290|64 78|clathrin clone
P01765375A0290|5 9|mRNA
P01765375A0290|182 188|weight
P01765375A0290|121 123|kb
P01765266A0000|4 18|Xenopus laevis
P01765266A0000|76 88|EF-1 alpha O
P01765266A0000|24 28|gene
P01765266A0000|133 140|oocytes
P01764899A0399|51 69|water fluoridation
P01764899A0399|115 121|caries
P01764899A0399|41 47|effect
P01763065A0913|1 3|P.
P01762914A1218|59 67|elements
P01762914A1218|12 24|uPA promoter
P01761736A0158|1 10|Diltiazem
P01761736A0158|251 263|distribution
P01761736A0158|230 237|changes
P01761736A0158|88 89|P
P01761736A0158|31 45|body clearance
P01759282A0000|35 41|energy
P01759282A0000|100 104|head
P01759282A0000|112 118|impact
P01759282A0000|11 23|distribution
P01759282A0000|75 94|contact interaction
P01758750A0000|100 111|ventilators
P01758750A0000|21 29|air flow
P01758750A0000|75 83|children
P01756539A0354|59 68|narrowing
P01756539A0354|120 130|infarction
P01754381A0000|171 182|Trypanozoon
P01754381A0000|257 266|pol alpha
P01754381A0000|251 255|core
P01754381A0000|158 169|Trypanosoma
P01754381A0000|198 202|gene
P01752792A0000|117 124|neurons
P01752792A0000|81 85|ITDs
P01752792A0000|42 48|coding
P01752792A0000|63 79|time differences
P01751970A0209|85 93|residues
P01751970A0209|56 64|sequence
P01751163A0000|5 12|authors
P01751163A0000|146 152|calves
P01751163A0000|124 136|Sarns/3M-VAD
P01748292A0000|85 108|Lycopersicon esculentum
P01748292A0000|18 23|cDNAs
P01748292A0000|77 83|tomato
P01748194A0767|144 160|cord transection
P01748194A0767|94 102|recovery
P01748194A0767|11 18|lesions
P01747972T0000|14 21|therapy
P01744042A1355|5 16|csbA fusion
P01744042A1355|130 141|% glutamine
P01744042A1355|74 79|cells
P01742879A0471|1 8|RESULTS
P01742879A0471|110 118|patients
P01742879A0471|10 30|Plasma AVP responses
P01742341A0499|103 111|stressor
P01742341A0499|6 11|study
P01742341A0499|42 50|reaction
P01740682A0703|1 9|Toxicity
P01740682A0703|174 175|%
P01740682A0703|162 170|patients
P01740682A0703|72 73|%
P01740682A0703|105 130|World Health Organization
P01740682A0703|153 154|%
P01740682A0703|217 218|%
P01740682A0703|183 190|courses
P01740682A0703|60 68|patients
P01740437A0851|156 167|fibroglycan
P01740437A0851|92 100|antibody
P01740121A0136|49 54|Kex2p
P01740121A0136|65 106|baculovirus/insect cell expression system
P01739439A0257|48 55|muscles
P01739439A0257|20 30|discharges
P01739439A0257|59 67|mdx mice
P01739439A0257|94 104|discharges
P01738653T0014|1 5|Bone
P01737789A0800|173 179|intron
P01737789A0800|77 97|acceptor splice site
P01737789A0800|62 69|repeats
P01736844T0000|118 142|testosterone measurement
P01736844T0000|20 32|testosterone
P01736844T0000|199 202|men
P01736844T0000|73 85|testosterone
P01736093A0731|16 28|CAT activity
P01736093A0731|112 123|CCAAT boxes
P01736093A0731|60 69|sequences
P01735447A0833|55 65|processing
P01735447A0833|95 104|precursor
P01735447A0833|11 31|active-site mutation
P01735347A0482|138 145|ascites
P01735347A0482|93 97|rise
P01735347A0482|123 134|development
P01735347A0482|181 189|necrosis
P01734283A0817|98 101|DNA
P01734283A0817|121 140|translation product
P01733358A0240|99 102|III
P01733358A0240|7 13|tumors
P01733358A0240|124 140|mucin production
P01733358A0240|104 118|adenocarcinoma
P01732752A0156|69 85|pre-B-cell lines
P01732752A0156|42 50|leukemia
P01732752A0156|15 22|B cells
P01732033A0000|70 77|infancy
P01732033A0000|5 20|pathophysiology
P01732033A0000|128 140|brain injury
P01731933T0000b|50 57|protein
P01731933T0000b|39 46|T4 gene
P01731107A0928|51 61|ICR2 motif
P01731107A0928|70 76|levels
P01731107A0928|80 96|pRNA replication
P01731107A0928|214 220|genome
P01731107A0928|194 200|strand
P01730412T0000|1 4|Max
P01730412T0000|29 40|interaction
P01727488A1146|96 111|gene expression
P01726211A0502|119 126|factors
P01726211A0502|7 19|risk factors
P01726211A0502|42 48|groups
P01725547A0354|103 113|blood flow
P01725547A0354|115 118|CBF
P01725547A0354|127 128|p
P01725547A0354|124 125|%
P01725547A0354|60 68|diameter
P01723962A0165|34 41|amylase
P01723962A0165|103 104|h
P01723962A0165|111 120|injection
P01723962A0165|89 96|maximum
P01722479A0302|35 38|HCG
P01722479A0302|72 83|specificity
P01722479A0302|45 56|sensitivity
P01721884A0962|32 37|match
P01721884A0962|225 232|RNase H
P01721884A0962|194 207|investigators
P01721884A0962|256 265|helices O
P01721884A0962|250 253|Pol
P01721884A0962|114 120|domain
P01721884A0962|270 271|P
P01720843A1506|33 49|sulfhydryl group
P01720843A1506|148 169|nitrovasodilator EDRF
P01720843A1506|61 72|angiotensin
P01719684A0494|172 190|sphincter function
P01719684A0494|11 18|results
P01718043A0384|51 52|n
P01718043A0384|4 12|patients
P01718043A0384|42 49|empyema
P01718043A0384|78 89|sensitivity
P01718043A0384|180 191|sensitivity
P01717925A0477|153 159|region
P01717925A0477|1 11|Comparison
P01717925A0477|123 125|bp
P01717833A1223|87 102|granulosa cells
P01717833A1223|5 27|alpha inhibin promoter
P01717833A1223|74 83|forskolin
P01716629A0000|61 88|matrix glycoprotein undulin
P01715975A0885|67 72|cells
P01714902A0221|119 127|CD3 zeta
P01714902A0221|222 248|histocompatibility complex
P01714902A0221|4 12|addition
P01714902A0221|105 117|cell surface
P01714358A0990|66 91|wheat etioplast membranes
P01714358A0990|109 112|ATP
P01713213A0488|21 31|pim-1 cDNA
P01713213A0488|65 79|vector pGEX-2T
P01713213A0488|88 101|Pim-1 protein
P01712296A0157|5 25|nucleotide sequences
P01712296A0157|61 70|positions
P01711041A0962|38 47|kilobases
P01711041A0962|126 131|exons
P01711041A0962|62 67|exons
P01710768A1172|101 108|pattern
P01710768A1172|5 12|results
P01710768A1172|146 157|HLA-B7 gene
P01710768A1172|166 173|ability
P01710768A1172|44 53|sequences
P01709933T0000|1 10|Isolation
P01709933T0000|39 42|rat
P01709933T0000|109 115|statin
P01709933T0000|15 31|characterization
P01708774A0203|5 17|DNA sequence
P01708098A0922|51 57|series
P01708098A0922|168 170|GR
P01708098A0922|182 193|control GRE
P01708098A0922|121 130|basepairs
P01707659A0458|65 69|gene
P01707659A0458|91 106|chimpanzee gene
P01703632T0000|51 62|polypeptide
P01703632T0000|36 40|gene
P01702972A0613|100 108|patterns
P01702972A0613|138 143|cDNAs
P01702972A0613|39 48|DNA blots
P01702972A0613|67 76|subfamily
P01702972A0613|195 200|genes
P01702426A1006|7 10|set
P01702426A1006|76 111|lambda-ZAP goose liver cDNA library
P01702426A1006|14 25|cDNA clones
P01702361A0621|65 75|deposition
P01702361A0621|42 60|collagen synthesis
P01700272A0838|152 163|recruitment
P01700272A0838|114 120|number
P01700272A0838|59 69|maturation
P01698772A0238|8 10|J.
P01697928A1214|260 269|promoters
P01697928A1214|27 44|sequence homology
P01697928A1214|94 103|consensus
P01697611A0738|71 78|growths
P01695905A0480|119 133|adipose tissue
P01695905A0480|80 86|levels
P01695905A0480|52 61|intestine
P01695905A0480|90 96|kidney
P01695322A0000|8 13|int-1
P01695322A0000|79 82|DNA
P01695322A0000|104 115|tumor virus
P01695314A0762|19 21|NS
P01695314A0762|12 17|mg/dl
P01695098A1116|39 47|patients
P01694280A0000|67 77|ventricles
P01694280A0000|28 43|ventriculoscope
P01694009A0112|117 128|polypeptide
P01694009A0112|6 10|exon
P01692837A0390|84 90|region
P01692837A0390|38 45|introns
P01692837A0390|6 11|genes
P01692837A0390|27 32|exons
P01691184A0995|1 7|Gap b3
P01691184A0995|24 42|polypeptide chains
P01691184A0995|44 46|Mr
P01690728A1166|84 86|kb
P01690728A1166|189 214|polymerase chain reaction
P01690728A1166|42 58|mRNA transcripts
P01690728A1166|151 179|S1 nuclease protection assay
P01688972A0803|45 52|patient
P01687050T0000|59 62|IgG
P01687050T0000|90 98|diseases
P01684791A0000|69 102|chicken glutamine synthetase gene
P01682509A0539|119 130|T-cell line
P01682509A0539|55 59|IE72
P01682509A0539|40 53|proteins IE86
P01682509A0539|132 138|HUT-78
P01681075A0429|16 36|dobutamine injection
P01681075A0429|141 154|tissue levels
P01681075A0429|158 169|metabolites
P01681075A0429|9 12|min
P01681075A0429|120 133|determination
P01679124A1368|201 215|MS/HSI animals
P01679124A1368|43 47|loss
P01679124A1368|13 20|studies
P01679124A1368|152 166|norepinephrine
P01679124A1368|217 225|ABSTRACT
P01679124A1368|243 248|WORDS
P01678392A0648|51 54|Ros
P01678392A0648|7 26|% confidence values
P01678392A0648|28 31|2SD
P01675763A1389|32 40|children
P01675763A1389|9 17|benefits
P01675763A1389|46 49|CD4
P01675424A0991|49 62|H-NR sequence
P01675424A0991|80 97|NADH-NR sequences
P01675424A0991|43 46|NAD
P01675424A0991|47 48|P
P01674817T0000|68 83|mRNA decay rate
P01674817T0000|1 10|Mutations
P01674817T0000|140 153|RNA15 protein
P01674662A0000|139 140|n
P01674662A0000|237 241|AIDS
P01674662A0000|229 232|ARC
P01674662A0000|74 81|disease
P01674662A0000|220 227|complex
P01674662A0000|289 298|relevance
P01674662A0000|122 137|lymphadenopathy
P01674242A0358|69 70|%
P01674242A0358|339 349|furosemide
P01674242A0358|351 360|frusemide
P01674242A0358|280 290|etintidine
P01674242A0358|407 418|allopurinol
P01674242A0358|395 405|viloxazine
P01674242A0358|327 337|nifedipine
P01674242A0358|217 226|ofloxacin
P01674242A0358|268 278|cimetidine
P01674242A0358|98 110|erythromycin
P01674242A0358|447 460|thiabendazole
P01674242A0358|167 175|enoxacin
P01674242A0358|522 530|caffeine
P01674242A0358|489 504|BCG-vaccination
P01674242A0358|112 126|troleandomycin
P01674242A0358|177 190|ciprofloxacin
P01673220A0578|81 92|bol3 allele
P01673220A0578|40 51|cDNA clones
P01671675A0483|220 229|amino end
P01671675A0483|50 54|pair
P01671675A0483|100 102|bp
P01671675A0483|56 58|bp
P01671675A0483|122 143|hybridization methods
P01671675A0483|15 26|clone pKB11
P01664192A1577|19 26|effects
P01662807A1182|5 11|factor
P01662807A1182|62 78|SV40 chromosomes
P01662609A0398|87 94|R.HgiCI
P01662609A0398|9 14|genes
P01662609A0398|74 85|amino acids
P01660925T0000|1 19|Transfer RNA genes
P01660925T0000|113 128|consensus boxes
P01660925T0000|92 100|elements
P01659685T0000|71 88|Dd ras expression
P01659685T0000|92 105|Dictyostelium
P01658468A0123|50 62|C. kutscheri
P01658468A0123|139 146|culture
P01658468A0123|37 46|isolation
P01658468A0123|77 83|cavity
P01658356T0000|138 145|viruses
P01658356T0000|59 60|C
P01658356T0000|30 55|leukemia virus subgroup B
P01657969A1420|141 147|change
P01657969A1420|10 21|alterations
P01657969A1420|89 113|amino acid substitutions
P01657415A0837|1 17|Intron K1 cox1.2
P01657246A0325|5 34|transcription initiation site
P01657246A0325|62 64|bp
P01656235A0946|99 110|CCAAT motif
P01656235A0946|27 34|element
P01656220T0000|21 25|gene
P01656220T0000|62 76|leukemia cells
P01655126T0000|101 104|HBr
P01655126T0000|92 99|toluene
P01655126T0000|45 63|butyltin compounds
P01653918A0286|85 92|corneas
P01653918A0286|39 47|pressure
P01653918A0286|128 150|corneal pain threshold
P01653238A1062|259 274|promoter region
P01653238A1062|188 206|growth factor beta
P01653238A1062|58 75|response elements
P01653238A1062|14 51|12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|105 110|sites
P01653173A0619|171 200|HPV-18 P105 promoter template
P01653173A0619|256 277|preinitiation complex
P01653173A0619|38 45|binding
P01653173A0619|53 55|E2
P01653173A0619|150 163|preincubation
P01652515A0379|102 117|microinjections
P01652515A0379|76 87|haloperidol
P01652515A0379|27 36|deviation
P01652515A0379|149 154|level
P01651918A0000|118 149|rat testis fructose-6-phosphate
P01651918A0000|172 186|bisphosphatase
P01651918A0000|95 114|amino acid sequence
P01650557T0000|59 69|assessment
P01650557T0000|12 19|results
P01649835A0822|85 93|increase
P01649835A0822|139 152|binding sites
P01649835A0822|32 44|PBR/IBP cDNA
P01649835A0822|101 108|density
P01649835A0822|127 129|3H
P01649318A1222|7 18|experiments
P01649318A1222|128 141|transcription
P01649318A1222|57 74|cell DNA fragment
P01649173A0160|85 96|nucleotides
P01649173A0160|175 185|attenuator
P01649173A0160|163 173|attenuator
P01649173A0160|60 70|attenuator
P01648142A1170|4 12|patients
P01648142A1170|67 70|arm
P01648142A1170|147 155|survival
P01648142A1170|26 33|disease
P01648142A1170|105 113|survival
P01647656A0000|49 57|receptor
P01647656A0000|5 13|relation
P01647656A0000|160 178|LV volume overload
P01647656A0000|135 140|years
P01646753A0336|216 218|V.
P01646753A0336|25 30|oxide
P01646753A0336|195 197|EO
P01646753A0336|105 123|reduction proceeds
P01646157A0414|103 113|nucleotide
P01646157A0414|230 234|cDNA
P01646157A0414|128 147|amino acid homology
P01645902A1462|137 139|TK
P01645902A1462|101 107|region
P01645902A1462|76 80|gene
P01645902A1462|44 47|Syn
P01645902A1462|18 25|results
P01645902A1462|144 146|UL
P01645902A1462|121 129|portions
P01644821A1259|85 97|fusion genes
P01644821A1259|118 127|sequences
P01644821A1259|174 183|sequences
P01644821A1259|10 18|butyrate
P01644796A0374|9 14|study
P01644796A0374|62 67|furin
P01643943A0300|67 70|TFR
P01643943A0300|15 34|lung cancer tissues
P01641628A0869|189 205|reference values
P01641628A0869|58 66|subjects
P01641628A0869|26 42|reference values
P01639724A0452|32 35|age
P01639724A0452|42 47|years
P01639724A0452|108 113|times
P01639724A0452|123 133|pill cycle
P01637758A0532|169 170|%
P01637758A0532|96 98|cm
P01637758A0532|128 139|examination
P01637758A0532|187 189|OR
P01637758A0532|23 33|proportion
P01637758A0532|59 64|group
P01637758A0532|183 184|%
P01636339A0200|1 8|Account
P01636339A0200|117 130|pollen grains
P01636339A0200|63 69|smears
P01636339A0200|47 55|elements
P01634464A0163|114 118|rise
P01634464A0163|128 139|haemorrhage
P01634464A0163|13 20|patient
P01634308A0191|59 69|techniques
P01633435A0743|19 26|protein
P01633435A0743|5 10|DRF-2
P01633435A0743|124 132|Hauschka
P01633435A0743|31 46|characteristics
P01630569A0605|36 45|remission
P01630569A0605|26 29|AmB
P01630454A0635|55 64|regulator
P01630454A0635|9 13|poly
P01628904A0386|66 72|insert
P01628904A0386|11 20|screening
P01628904A0386|31 36|clone
P01628201A0824|65 69|year
P01628201A0824|109 117|datasets
P01627828A0475|184 192|SmN gene
P01627828A0475|4 13|agreement
P01627828A0475|123 133|pseudogene
P01627828A0475|45 54|mouse DNA
P01626631A0557|172 181|elevation
P01626631A0557|145 151|system
P01626631A0557|75 85|brain stem
P01626430A1112|5 15|homologies
P01626430A1112|24 29|RAD16
P01626430A1112|31 36|RAD54
P01625527A0000|7 29|blood serotonin levels
P01625527A0000|108 124|failure patients
P01625527A0000|193 194|n
P01625527A0000|253 268|transplantation
P01625527A0000|126 127|n
P01625527A0000|182 191|treatment
P01624425A0907|58 71|substitutions
P01624425A0907|11 18|protein
P01624425A0907|45 52|mutants
P01621584A0183|19 27|solution
P01621584A0183|114 127|IOP reduction
P01621584A0183|41 42|%
P01621584A0183|75 79|eyes
P01620610A1070|38 40|TI
P01620610A1070|54 73|expression problems
P01620610A1070|202 206|rule
P01620610A1070|121 127|vector
P01620118A0470|69 74|kappa
P01620118A0470|206 213|chicken
P01620118A0470|163 169|repeat
P01620118A0470|14 22|proteins
P01619114A0383|25 36|performance
P01619114A0383|44 48|SMSP
P01618243T0000|13 32|amine pressor tests
P01617801A0088|118 127|captopril
P01617801A0088|99 106|minutes
P01617801A0088|9 26|Serum aldosterone
P01617801A0088|31 52|plasma renin activity
P01617242T0000|48 56|products
P01615493A0975|136 147|wall damage
P01615493A0975|50 60|conditions
P01615493A0975|83 93|inhibition
P01615493A0975|44 46|HC
P01615182A0206|69 74|amoxy
P01615182A0206|142 144|mg
P01615182A0206|76 82|levels
P01615182A0206|193 195|mg
P01615182A0206|13 18|study
P01615182A0206|90 108|combination tablet
P01613640A0158|96 100|Brij
P01613640A0158|28 38|poloxamine
P01613640A0158|60 70|poloxamine
P01611699A0000|7 29|pyridoxine derivatives
P01607223A0000|171 180|liposomes
P01607223A0000|53 70|release technique
P01607223A0000|8 22|investigations
P01607223A0000|91 102|laser light
P01603088A1121|7 14|results
P01603088A1121|94 104|repression
P01601181A0842|68 80|gastrulation
P01601181A0842|5 20|60A transcripts
P01601181A0842|25 32|protein
P01597462A0457|1 11|Disruption
P01597462A0457|30 35|CDC14
P01597170A0000|103 111|group Co
P01597170A0000|96 99|NO3
P01597170A0000|43 52|mg/m3 Co2
P01597170A0000|152 160|group Co
P01597170A0000|185 188|air
P01597170A0000|114 116|Cr
P01597170A0000|212 218|months
P01594554A0845|50 53|CCK
P01594554A0845|114 130|feedback control
P01594554A0845|7 14|results
P01589576A0170|152 154|T2
P01589576A0170|185 187|ns
P01589576A0170|55 68|superposition
P01589576A0170|5 17|decay curves
P01589576A0170|148 150|ps
P01589576A0170|135 137|T1
P01588963A1153|92 105|Cdc25 protein
P01588913A0000|154 163|P. putida
P01588913A0000|98 111|transcription
P01588270A1029|119 121|.9
P01588270A1029|16 30|blood pressure
P01588270A1029|157 160|DBP
P01588270A1029|130 134|mmHg
P01587267A1144|118 125|cloning
P01587267A1144|86 95|structure
P01587267A1144|160 164|gene
P01587267A1144|41 55|interpretation
P01587267A1144|195 206|mutagenesis
P01585014A0000|4 14|experiment
P01585014A0000|412 416|I.U.
P01585014A0000|78 85|hormone
P01585014A0000|393 404|combination
P01585014A0000|452 456|PMSG
P01585014A0000|91 106|micrograms GnRH
P01585014A0000|305 319|sponge removal
P01585014A0000|39 48|treatment
P01585014A0000|498 503|FSH-P
P01585014A0000|187 193|spring
P01585014A0000|426 450|mare serum gonadotrophin
P01585014A0000|294 298|days
P01585014A0000|177 183|autumn
P01583819A0377|69 71|Hz
P01583819A0377|55 57|HZ
P01583819A0377|78 91|Simson method
P01582413A0759|1 13|Dimerization
P01582413A0759|95 103|affinity
P01582413A0759|165 176|DNA binding
P01581965A0388|220 232|GAP activity
P01581965A0388|8 18|C-terminus
P01581965A0388|161 168|rho GAP
P01581965A0388|242 249|GTPases
P01581965A0388|60 69|sequences
P01581409A0398|1 12|Sensitivity
P01581409A0398|82 100|DPC AlaSTAT System
P01581409A0398|135 139|skin
P01581409A0398|120 127|results
P01579537A0000|39 43|uses
P01579537A0000|47 62|botulinum toxin
P01577819A0709|80 87|repeats
P01577819A0709|91 100|domain C.
P01577056A0178|203 217|washout period
P01577056A0178|163 170|periods
P01577056A0178|106 116|omeprazole
P01577056A0178|223 227|days
P01577056A0178|127 130|day
P01577056A0178|182 186|days
P01572549A0000|171 189|signal transducers
P01572549A0000|81 87|virtue
P01572549A0000|143 152|oncogenes
P01572549A0000|27 31|PTKs
P01572549A0000|106 116|appearance
P01572549A0000|120 128|products
P01569584A0672|34 39|6F6.2
P01569584A0672|1 19|Hybridization data
P01569584A0672|109 114|6F6.1
P01569344A0404|184 185|P
P01569344A0404|80 95|New Orleans age
P01569344A0404|67 70|age
P01569344A0404|27 37|prevalence
P01569015A0120|97 106|direction
P01569015A0120|24 32|analysis
P01569015A0120|61 75|reading frames
P01567649A0139|18 19|%
P01567649A0139|53 63|hemorrhage
P01567649A0139|105 110|palsy
P01565882A0737|307 315|RD image
P01565882A0737|66 76|ReI images
P01565882A0737|106 111|types
P01565882A0737|184 185|%
P01565882A0737|18 25|changes
P01565882A0737|59 61|RD
P01565882A0737|145 153|RD image
P01565882A0737|29 46|perfusion defects
P01565882A0737|269 271|Ia
P01564653A0307|9 18|companies
P01563343A0548|1 14|Lac operators
P01563343A0548|65 77|CAB promoter
P01563343A0548|44 53|positions
P01560774A0885|9 11|kb
P01559209T0000|1 14|Preceptorship
P01559209T0000|47 52|study
P01557411A1282|114 123|promoters
P01557411A1282|41 49|category
P01556111A0241|31 38|plasmid
P01555556A0565|34 43|degrees C
P01555556A0565|1 16|Control Tmuscle
P01555556A0565|61 64|max
P01553407T0000|39 43|area
P01552662A0398|17 27|blood flow
P01552662A0398|83 89|artery
P01552662A0398|91 94|LAD
P01552052A0139|16 21|study
P01552052A0139|138 147|mg/kg/day
P01552052A0139|54 63|frequency
P01552052A0139|67 78|alterations
P01551910A0313|137 158|transcription factors
P01551910A0313|25 59|gel mobility shift electrophoresis
P01551568A1476|1 23|Marker rescue analysis
P01551568A1476|96 106|Rif domain
P01551568A1476|74 78|rpoB
P01549465A0122|101 104|Ser
P01549465A0122|59 70|amino acids
P01549465A0122|109 112|Val
P01549129A0356|141 144|Src
P01549129A0356|27 34|domains
P01549123A0480|35 43|sequence
P01549123A0480|5 14|MET4 gene
P01549123A0480|128 138|activators
P01548891A0635|119 127|patients
P01548891A0635|155 156|P
P01548891A0635|59 67|patients
P01548891A0635|44 51|hormone
P01547957A1083|307 311|GL81
P01547957A1083|235 247|DNA fragment
P01547957A1083|20 44|oligodeoxyribonucleotide
P01547957A1083|320 323|DNA
P01547957A1083|177 181|CYP2
P01547957A1083|269 294|polymerase chain reaction
P01547787A0548|1 22|Proprotein processing
P01546522A0000|1 9|Probable
P01546522A0000|33 52|leukoencephalopathy
P01546522A0000|174 183|remission
P01546522A0000|54 57|PML
P01545806T0000|39 44|yeast
P01545806T0000|59 85|recombination genes REC102
P01545792A0492|102 126|MLC-2 gene transcription
P01545792A0492|1 21|Deletion mutagenesis
P01545787A0345|117 124|NFIL-2B
P01545787A0345|18 26|enhancer
P01545787A0345|94 104|footprints
P01544928A1252|186 200|cassette model
P01544928A1252|139 147|splicing
P01544928A1252|162 170|pre-mRNA
P01544928A1252|72 77|mRNAs
P01544854A0699|8 13|drugs
P01544854A0699|75 78|DMF
P01542730A1982|170 177|support
P01542730A1982|233 237|DDDR
P01542730A1982|129 139|DDD pacing
P01542730A1982|86 90|risk
P01542730A1982|293 301|patients
P01542730A1982|63 70|patient
P01542730A1982|303 311|ABSTRACT
P01542667A0125|5 9|gene
P01542667A0125|159 169|expression
P01542667A0125|73 89|enhancer element
P01542565A0220|71 85|protein L7/L12
P01541556A1040|85 103|lipid modification
P01541556A1040|63 70|protein
P01538403A1058|187 204|complex formation
P01538403A1058|139 144|TFIID
P01538403A1058|247 255|TATA-box
P01538403A1058|95 112|protein fractions
P01538403A1058|15 29|reconstitution
P01537845A0571|42 48|change
P01537845A0571|92 106|mRNA stability
P01537845A0571|56 60|rate
P01536575A1213|43 51|position
P01536575A1213|108 116|sequence
P01536575A1213|226 231|genes
P01536575A1213|293 305|hydrocarbons
P01536575A1213|208 214|CYPIA1
P01536575A1213|183 206|cytochrome P450IA1 gene
P01535242A0557|33 39|growth
P01535242A0557|115 116|h
P01535242A0557|52 58|GM-CSF
P01535242A0557|95 105|c-fms mRNA
P01535242A0557|123 139|factor switching
P01532914A0067|20 23|use
P01532914A0067|27 47|hepatitis B vaccines
P01532914A0067|74 86|immunization
P01532229A1264|69 74|HF-1a
P01532229A1264|97 102|HF-1b
P01532229A1264|146 153|pathway
P01532229A1264|208 220|muscle cells
P01532229A1264|61 67|factor
P01531214A0885|19 23|mice
P01531214A0885|27 33|RP-170
P01531214A0885|47 51|i.v.
P01529530T0000|68 74|effect
P01529530T0000|78 85|ouabain
P01529530T0000|89 99|activation
P01526690T0000|20 26|action
P01526690T0000|30 38|warfarin
P01524549A0241|119 130|association
P01524549A0241|6 19|GH deficiency
P01524549A0241|162 166|time
P01524549A0241|40 46|growth
P01524549A0241|181 191|GH therapy
P01522699A0092|1 8|Methods
P01522699A0092|60 75|recipe analysis
P01518849A0165|216 232|elastin peptides
P01518849A0165|173 211|alpha 1-proteinase inhibitor complexes
P01518849A0165|109 124|protein elastin
P01518849A0165|151 161|activities
P01516829A0113|137 144|complex
P01516829A0113|94 104|activation
P01516829A0113|44 57|SNF6 function
P01513213A0231|139 144|years
P01513213A0231|175 183|survival
P01513213A0231|53 72|survival experience
P01513213A0231|76 81|women
P01513213A0231|89 98|HIP trial
P01512941A0000|51 63|levofloxacin
P01512941A0000|71 78|DR-3355
P01512941A0000|157 166|ofloxacin
P01512941A0000|178 189|norfloxacin
P01512941A0000|135 148|ciprofloxacin
P01512259A0867|116 121|times
P01512259A0867|125 132|Dfurin2
P01511231A0085|51 55|year
P01511231A0085|21 35|smoking habits
P01511231A0085|76 99|smoking cessation trial
P01506746A0476|1 22|Greater rupture force
P01506746A0476|72 76|pigs
P01505516A0928|36 42|lysine
P01505516A0928|59 66|alanine
P01505516A0928|123 129|dimers
P01504853A0299|11 15|LHRH
P01502157A0000|85 118|P2 transcription initiation sites
P01502157A0000|1 6|ME1a1
P01502157A0000|31 50|factor binding site
P01499213A0185|141 149|fracture
P01499213A0185|54 64|ochronosis
P01499213A0185|109 114|spine
P01499213A0185|45 48|man
P01497582A0593|154 162|placenta
P01497582A0593|140 146|embryo
P01497582A0593|72 82|infections
P01497582A0593|105 114|pathogens
P01496348A0000|1 7|Caries
P01496348A0000|58 66|diseases
P01493864A0619|69 82|pre-treatment
P01493864A0619|21 29|subjects
P01493864A0619|44 50|6-OHDA
P01490493A0416|50 67|serum cholesterol
P01490493A0416|22 33|examination
P01486836A0774|1 9|Patients
P01486836A0774|203 214|differences
P01486836A0774|129 131|T1
P01486836A0774|46 55|attention
P01486836A0774|20 23|VPA
P01486836A0774|57 79|visuomotor performance
P01486836A0774|31 42|differences
P01483771A1335|57 84|plasma epinephrine response
P01483771A1335|47 53|change
P01482912A0617|5 8|CEM
P01482912A0617|123 142|relational database
P01482912A0617|72 89|data dependencies
P01480183A1689|119 124|mouse
P01480183A1689|26 36|mechanisms
P01478672A0795|5 16|phage clone
P01478672A0795|28 36|junction
P01476376T0000|1 6|Assay
P01476376T0000|63 71|pH-meter
P01474990A0000|18 23|pTt21
P01474990A0000|97 112|trypomastigotes
P01474990A0000|178 192|trypomastigote
P01474990A0000|11 16|clone
P01473207A0582|54 67|prematuration
P01473207A0582|40 48|placenta
P01471602A0362|17 20|use
P01471602A0362|84 89|acids
P01471602A0362|71 75|acid
P01471602A0362|246 257|conjunction
P01471602A0362|267 272|drugs
P01471602A0362|227 237|approaches
P01470243A0871|275 280|means
P01470243A0871|98 99|p
P01470243A0871|143 144|%
P01470243A0871|133 139|months
P01470243A0871|17 25|subgroup
P01470243A0871|49 52|l/l
P01470243A0871|262 271|viscosity
P01470243A0871|323 339|viscosity effect
P01470243A0871|219 220|%
P01470243A0871|361 366|group
P01470243A0871|211 212|%
P01469042A0355|173 184|interaction
P01469042A0355|126 135|satellite
P01469042A0355|226 245|centromere function
P01469042A0355|211 215|kind
P01468625A0282|20 24|LEU2
P01468625A0282|162 168|manner
P01468625A0282|29 39|HIS3 cDNAs
P01467088T0075|1 10|Abstracts
P01464329T0000|23 30|protein
P01460772T0001|19 30|hepatitis C
P01460772T0001|77 97|interferon treatment
P01460054A0478|184 198|amino terminus
P01460054A0478|86 89|ICS
P01460054A0478|128 146|DNA binding domain
P01459885A0705|49 56|changes
P01459885A0705|99 107|increase
P01459885A0705|126 134|decrease
P01459885A0705|10 14|days
P01459447A0484|84 91|library
P01459447A0484|70 75|yeast
P01459447A0484|57 62|genes
P01457695T0000b|53 67|hemofiltration
P01457695T0000b|76 80|year
P01457380A0000|119 133|ttk transcript
P01457380A0000|21 25|gene
P01457380A0000|66 74|proteins
P01454819A0000|1 22|Mono-ADP-ribosylation
P01454819A0000|55 63|proteins
P01454819A0000|39 51|modification
P01454819A0000|108 110|EC
P01454819A0000|74 106|arginine ADP-ribosyltransferases
P01452703A0782|102 106|case
P01452703A0782|154 160|bodies
P01452703A0782|231 237|bodies
P01452703A0782|180 190|ELISA kits
P01452037A0000|305 321|gap amber mutant
P01452037A0000|237 249|gene cluster
P01452037A0000|108 111|PGK
P01452037A0000|73 78|GAPDH
P01452037A0000|16 21|genes
P01452037A0000|188 214|Bacillus megaterium DSM319
P01452037A0000|31 71|glyceraldehyde-3-phosphate dehydrogenase
P01450815A0337|84 87|RPF
P01450815A0337|36 40|IPRK
P01450815A0337|92 95|GFR
P01450815A0337|134 142|increase
P01449183A0795|4 12|addition
P01449183A0795|29 33|beta
P01449183A0795|61 70|diagnosis
P01448917A0775|1 12|Comparisons
P01448917A0775|32 50|amino acid residue
P01448917A0775|312 319|protein
P01448917A0775|106 114|sequence
P01448917A0775|288 296|helicase
P01448917A0775|254 273|proteinase cofactor
P01448917A0775|52 54|aa
P01448917A0775|298 301|VPg
P01448917A0775|56 76|sequence information
P01448917A0775|361 364|87K
P01448107A0361|97 104|absence
P01448107A0361|108 129|amino acid starvation
P01448107A0361|30 44|GCN2 mutations
P01447189A1546|69 77|activity
P01447189A1546|130 141|lymphocytes
P01447189A1546|26 35|RNK-Met-1
P01446828A1088|32 55|consensus binding sites
P01446828A1088|18 22|ADH5
P01446828A1088|111 116|LF-A1
P01446828A1088|106 109|AP2
P01446828A1088|91 99|proteins
P01443748A1190|5 13|pressure
P01443748A1190|73 81|tadpoles
P01443047A0773|35 57|differentiation status
P01443047A0773|10 17|changes
P01441120T0000|1 4|Use
P01438224A0749|58 60|J.
P01436261A0145|1 28|Subcutaneous administration
P01436261A0145|139 148|diarrhoea
P01436261A0145|59 69|octreotide
P01436261A0145|124 135|improvement
P01433524A0788|48 59|amino acids
P01433524A0788|10 16|domain
P01433391A0594|69 76|neurons
P01433391A0594|49 56|density
P01433391A0594|6 17|consequence
P01433391A0594|26 33|rearing
P01431809T0000|102 120|polyhedrosis virus
P01431809T0000|76 93|Spodoptera exigua
P01431809T0000|41 49|analysis
P01431380A0244|38 48|tick fauna
P01431380A0244|203 211|antibody
P01431380A0244|197 201|SFGR
P01431380A0244|128 133|ticks
P01431380A0244|437 441|SFGR
P01431380A0244|462 468|organs
P01431380A0244|257 265|findings
P01431380A0244|293 305|patient sera
P01431380A0244|178 195|group rickettsiae
P01431380A0244|421 433|observations
P01431380A0244|241 255|tick emulsions
P01429836A0457|1 11|Disruption
P01429836A0457|113 127|Vps1p function
P01429836A0457|148 160|microtubules
P01429836A0457|15 27|microtubules
P01429740A1065|145 152|E2 gene
P01429740A1065|46 57|presequence
P01429596A1669|66 79|hemagglutinin
P01429596A1669|8 13|basis
P01429596A1669|30 40|properties
P01428490A0671|64 70|wheeze
P01428490A0671|96 102|breath
P01428490A0671|36 47|pet allergy
P01428490A0671|176 180|pets
P01428490A0671|72 79|attacks
P01427034A0440|50 63|protein genes
P01427034A0440|175 181|length
P01427034A0440|106 115|S13 genes
P01427034A0440|195 202|introns
P01425653T0000|5 12|effects
P01425653T0000|104 109|women
P01423738A0639|81 88|rabbits
P01423738A0639|142 149|rhythms
P01423738A0639|122 134|deceleration
P01423738A0639|151 165|mean delta tau
P01422265A0263|137 141|IgG4
P01422265A0263|5 25|IgG subclass profile
P01422265A0263|130 134|IgG3
P01422265A0263|123 127|IgG2
P01422265A0263|224 240|coeliac patients
P01421390T0000|233 241|lymphoma
P01421390T0000|159 186|bone marrow transplantation
P01421390T0000|14 19|trial
P01420579A0292|50 56|calves
P01420579A0292|32 40|antibody
P01420579A0292|113 118|month
P01420579A0292|79 80|%
P01420579A0292|61 62|%
P01420363A0818|152 163|AP1 factors
P01420363A0818|19 27|AP1 site
P01420363A0818|5 9|TIMP
P01420363A0818|133 140|binding
P01420363A0818|211 218|factors
P01420177A1065|34 37|Gly
P01420177A1065|1 13|Substitution
P01420177A1065|52 55|Ser
P01420177A1065|129 135|enzyme
P01420177A1065|24 29|Val33
P01418860A0797|87 96|diltiazem
P01418860A0797|163 172|diltiazem
P01418860A0797|130 135|cases
P01418860A0797|241 253|interactions
P01418542A0000|5 11|effect
P01418542A0000|25 43|beta-glycyrrhetate
P01418542A0000|15 21|sodium
P01418272A1072|49 52|CEA
P01418272A1072|59 60|%
P01413984A0737|169 181|antithrombin
P01413984A0737|66 77|cholesterol
P01413984A0737|128 133|HbA1C
P01413984A0737|135 142|glucose
P01413984A0737|187 218|plasminogen activator inhibitor
P01413984A0737|156 167|factor VIII
P01413984A0737|144 154|fibrinogen
P01413984A0737|24 30|effect
P01413984A0737|121 123|Lp
P01409643A0618|274 277|TMF
P01409643A0618|143 157|identification
P01409643A0618|266 272|factor
P01409643A0618|242 254|TATA element
P01409643A0618|46 62|oligonucleotides
P01408474A0531|1 15|PaO2 threshold
P01408474A0531|56 71|sensor catheter
P01408137A0974|138 143|% G+C
P01408137A0974|5 13|sequence
P01408137A0974|40 51|G+C content
P01407286A0427|171 191|tyrosine hydroxylase
P01407286A0427|158 166|reaction
P01407286A0427|27 35|survival
P01407286A0427|72 83|integration
P01406688A0898|1 20|Sequencing analysis
P01406688A0898|101 107|region
P01406688A0898|41 53|rap1t allele
P01406656A1075|84 86|kb
P01406656A1075|19 24|clone
P01406656A1075|158 169|fibroblasts
P01406656A1075|47 58|mouse alpha
P01406630A0545|84 91|binding
P01406630A0545|216 236|sequence specificity
P01406630A0545|27 36|sequences
P01406630A0545|193 206|DNA sequences
P01406630A0545|134 142|proteins
P01404401A0740|37 51|reading frames
P01403222A0391|118 129|transfusion
P01403222A0391|54 59|woman
P01403222A0391|42 46|care
P01400775A0435|76 94|N-methylsalsolinol
P01400775A0435|109 114|brain
P01400401A0065|51 57|muscle
P01400401A0065|71 73|E1
P01400401A0065|4 10|humans
P01400401A0065|163 171|criteria
P01400401A0065|63 68|liver
P01400401A0065|60 61|L
P01400217T0000|101 105|traF
P01400217T0000|77 81|traG
P01400217T0000|12 20|analysis
P01398140A0488|19 34|Xenopus U7 gene
P01398140A0488|124 127|PSE
P01398140A0488|150 158|location
P01398104A0834|38 46|CArG box
P01398104A0834|72 79|protein
P01398104A0834|121 127|factor
P01398074A1081|102 111|viability
P01398074A1081|5 23|RNase MRP RNA gene
P01398073A0986|65 78|TFIID protein
P01398073A0986|127 145|activation domains
P01398073A0986|104 115|stimulation
P01398068A0948|117 133|RGC DNA sequence
P01398068A0948|67 79|p53 proteins
P01396592A1113|34 42|SCL gene
P01396592A1113|156 165|regulator
P01396592A1113|52 58|target
P01396592A1113|77 104|transcription factor GATA-1
P01396572A0320|100 102|CG
P01396572A0320|24 37|plasmid pUC19
P01396572A0320|124 129|dG-dC
P01396432A0388|17 22|range
P01396432A0388|113 131|memory performance
P01396432A0388|75 82|seizure
P01394655A0615b|1 16|Urease activity
P01394655A0615b|96 98|ng
P01394655A0615b|42 60|ammonia production
P01394655A0615b|109 112|S/N
P01392358A0389|7 12|reply
P01392012A0228|152 162|van Dongen
P01392012A0228|38 54|oxytocin content
P01392012A0228|124 132|activity
P01392012A0228|73 87|pressor effect
P01389585A0825|23 33|Scotchbond
P01389585A0825|90 112|dentine bonding agents
P01389362T0000|21 34|bond strength
P01387105A0933|35 38|DNA
P01387105A0933|200 214|loci Cycb1-rs1
P01387105A0933|9 31|Southern blot analyses
P01387105A0933|286 287|X
P01387105A0933|218 227|Cycb1-rs9
P01387105A0933|178 187|sequences
P01387105A0933|91 98|strains
P01386210A0293|83 93|depression
P01386210A0293|63 72|treatment
P01386210A0293|105 108|man
P01384229A0175|70 85|oligonucleotide
P01384229A0175|234 268|chloramphenicol acetyl transferase
P01384229A0175|281 288|pBLCAT2
P01384229A0175|125 135|BF-IV gene
P01384229A0175|270 273|CAT
P01384040A1043|141 146|pCF10
P01384040A1043|21 31|activation
P01383690A1023|5 19|ARG SH2 domain
P01383690A1023|59 62|BCR
P01380716A0174|48 54|molars
P01380716A0174|12 19|tissues
P01380076A0165|84 99|docusate sodium
P01380076A0165|5 11|method
P01379150A0996|50 55|agent
P01379150A0996|168 175|therapy
P01379150A0996|7 18|cibenzoline
P01379150A0996|132 137|class
P01378526A0535|35 54|FK506 plasma levels
P01378526A0535|79 89|appearance
P01378431A0202|19 24|M.-Y.
P01378431A0202|55 57|S.
P01378431A0202|43 45|J.
P01378431A0202|26 41|Vallejo-Ramirez
P01378431A0202|47 53|Inouye
P01378052A0594|204 223|activator sequences
P01378052A0594|96 99|N11
P01378052A0594|128 131|N14
P01378052A0594|41 46|types
P01378052A0594|50 59|sequences
P01378052A0594|116 119|TGT
P01378052A0594|156 165|sequences
P01378052A0594|91 94|CAC
P01378052A0594|181 185|NtrC
P01377818A0468|96 107|C/EBP alpha
P01377818A0468|14 24|C/EBP beta
P01377696A0000|5 10|chick
P01377696A0000|27 59|surface glycoprotein neurofascin
P01375913A0484|169 176|plasmid
P01375913A0484|112 143|T7 RNA polymerase promoter site
P01374688A0471|116 131|micrograms/kg/0
P01374688A0471|97 102|hours
P01374688A0471|77 83|plasma
P01374688A0471|41 56|% pentafraction
P01374392A0341|71 76|NHE-2
P01374392A0341|28 33|NHE-3
P01373374A0735|1 11|Homodimers
P01373374A0735|79 83|GBF1
P01373374A0735|135 143|sequence
P01372900A0448|80 99|amino acid residues
P01372900A0448|7 12|exons
P01372900A0448|160 162|F.
P01372456A0426|1 9|Necrosis
P01372456A0426|20 21|h
P01372456A0426|128 138|% necrosis
P01372456A0426|56 62|extent
P01372456A0426|28 39|TA infusion
P01371863A0000|82 111|protozoan parasite Leishmania
P01371275T0000|33 34|B
P01371275T0000|36 43|subunit
P01371275T0000|14 24|expression
P01371181A0688|17 25|plasmids
P01371181A0688|66 70|pLB4
P01371181A0688|128 138|regulation
P01371181A0688|72 77|share
P01371181A0688|104 119|characteristics
P01370281A0461|1 11|Sequencing
P01363166T0001|1 17|Currents aspects
P01363166T0001|65 71|ulcers
P01360294A0000|70 78|subjects
P01360294A0000|21 28|October
P01360294A0000|97 103|levels
P01360294A0000|107 113|plasma
P01360180A0513|101 113|recombinants
P01360180A0513|141 147|kinase
P01360180A0513|10 17|efforts
P01360180A0513|165 171|domain
P01358880A0251|13 32|amino acid sequence
P01358592A0752|67 76|cell fate
P01358592A0752|148 154|embryo
P01358592A0752|105 110|state
P01357528A0084|251 265|enterobacteria
P01357528A0084|5 20|subunit protein
P01357528A0084|126 134|fimbriae
P01357528A0084|24 29|curli
P01357528A0084|167 176|strain 3b
P01354506T0000|119 126|history
P01354506T0000|27 35|diseases
P01354506T0000|44 52|advances
P01352113A0231|119 122|ppm
P01352113A0231|157 171|exposure times
P01352113A0231|126 133|ppm NO2
P01352113A0231|15 22|effects
P01350932A1123|138 155|disulphide bridge
P01350932A1123|20 33|glycosylation
P01350932A1123|128 132|part
P01350932A1123|12 16|site
P01349837T0000|70 86|chaperonin HSP60
P01349837T0000|22 42|Arabidopsis thaliana
P01349837T0000|135 145|heat shock
P01348508A0313|70 80|comparison
P01348508A0313|20 29|positions
P01348508A0313|246 253|introns
P01348508A0313|229 233|date
P01348508A0313|90 95|genes
P01347944A0964|12 19|studies
P01347944A0964|45 69|homeodomain binding site
P01347664A1026|6 14|mutation
P01347664A1026|73 80|protein
P01346534T0000|1 17|Characterization
P01346534T0000|25 32|regulon
P01341119A0450|84 97|H2 inhibitors
P01341119A0450|71 80|ingestion
P01341119A0450|41 45|kind
P01339815A1545|16 28|correlations
P01339773A0000|16 24|patients
P01339773A0000|112 123|capnography
P01339773A0000|125 135|spirometry
P01339773A0000|150 158|analysis
P01339391A0000|42 48|region
P01339125A0153|70 75|teeth
P01339125A0153|95 105|dentifrice
P01339125A0153|26 30|Ca45
P01337142A2043|17 52|glycoprotein alpha-subunit promoter
P01337142A2043|83 90|GH4 rat
P01337142A2043|108 116|ABSTRACT
P01334493A0289|32 37|sHGFr
P01334493A0289|26 30|HGFr
P01334493A0289|120 128|receptor
P01333317A1008|69 76|protein
P01333317A1008|114 119|PRF-I
P01333317A1008|108 109|s
P01333317A1008|45 48|Sp1
P01333053A0110|162 166|cAMP
P01333053A0110|27 65|steroid hydroxylase gene transcription
P01333053A0110|94 100|cortex
P01333035T0000|55 68|alpha subunit
P01333035T0000|13 47|cAMP receptor protein contact site
P01332589A0666|18 26|compound
P01332589A0666|37 38|%
P01332589A0666|151 164|micrograms/ml
P01331501A0397|35 43|peptides
P01331501A0397|144 148|p130
P01331501A0397|124 128|p107
P01331086T0000|71 75|gene
P01331086T0000|144 165|transcription factors
P01331086T0000|107 117|ets motifs
P01331057A0000|98 118|cytochrome c oxidase
P01331057A0000|30 35|COX12
P01330309A1134|38 42|MyoD
P01330309A1134|113 121|extracts
P01330309A1134|47 71|myogenin fusion proteins
P01329039A0951|138 155|Ig kappa E2 E-box
P01329039A0951|81 88|E-boxes
P01329039A0951|56 69|TnI enhancers
P01328884T0000|1 20|Truncation variants
P01328884T0000|78 93|sequence motifs
P01328884T0000|60 69|molecules
P01328681A0348|10 12|M.
P01328219A1397|49 59|cell lines
P01327967A0668|50 61|sensitivity
P01327967A0668|140 146|serine
P01327967A0668|124 135|requirement
P01327967A0668|13 25|inactivation
P01327280A0000|4 8|rats
P01327280A0000|77 78|K
P01327280A0000|150 160|electrodes
P01327280A0000|45 52|changes
P01326329A0703|234 266|glucocorticoid response elements
P01326329A0703|317 321|CREs
P01326329A0703|166 177|CACCC boxes
P01326329A0703|135 144|sequences
P01326329A0703|156 164|GC boxes
P01326329A0703|294 315|AMP response elements
P01326329A0703|179 190|CCAAT boxes
P01326329A0703|123 131|presence
P01325221A0870|158 172|chromatography
P01325221A0870|124 138|p41 MAP kinase
P01325221A0870|12 18|arrest
P01324406A1250|154 163|sequences
P01324406A1250|19 23|RAD5
P01324406A1250|65 75|DNA repair
P01324406A1250|10 15|roles
P01324404A0813|68 75|regions
P01324404A0813|24 41|activation domain
P01324404A0813|134 152|HNF-3 beta protein
P01324172A0880|34 41|protein
P01324172A0880|59 71|mitochondria
P01321337A0318|51 55|mass
P01321337A0318|103 110|ability
P01321337A0318|81 91|properties
P01321337A0318|173 180|subunit
P01321337A0318|59 62|kDa
P01321336A0000|35 49|leukemia virus
P01321336A0000|24 27|Akv
P01321280A0494|152 160|antisera
P01321280A0494|115 146|immunoprecipitation experiments
P01321280A0494|40 42|E6
P01321280A0494|193 201|BPV-1 E6
P01321280A0494|15 21|number
P01321277A0342|68 71|SRC
P01321277A0342|173 176|UR2
P01321277A0342|25 28|end
P01321277A0342|47 50|end
P01321277A0342|74 77|ROS
P01320255A0795|175 188|transcription
P01320255A0795|7 14|results
P01320255A0795|198 200|L1
P01320255A0795|90 101|L1 sequence
P01318310A0000|49 67|affinity receptors
P01318310A0000|158 169|cholesterol
P01318310A0000|77 96|density lipoprotein
P01316903A1040|1 19|RNA polymerase IIA
P01316903A1040|98 110|input enzyme
P01316903A1040|75 84|reactions
P01316900A0000|25 49|sulfate activation locus
P01316476A1428|50 53|ORF
P01316476A1428|129 138|induction
P01316476A1428|11 15|gene
P01316476A1428|75 84|induction
P01316461A1083|116 120|sera
P01316461A1083|52 60|peptides
P01316461A1083|78 80|S2
P01316461A1083|215 222|protein
P01316125A0382|139 143|YHPD
P01316125A0382|5 11|points
P01316125A0382|132 134|OH
P01316125A0382|225 229|BHPD
P01316125A0382|116 124|radicals
P01316125A0382|54 60|damage
P01316125A0382|294 299|yield
P01316125A0382|303 306|1O2
P01315706A0000|80 103|rat L6 muscle cell line
P01314841A0724|16 22|MK-801
P01314841A0724|33 50|burst suppression
P01314841A0724|111 115|mean
P01314841A0724|125 133|pressure
P01313909A0526|168 183|nonsense mutant
P01313909A0526|217 226|phenotype
P01313909A0526|23 44|ICP0 nonsense mutants
P01313846A0850|220 239|poliovirus receptor
P01313846A0850|153 171|melanoma Ag MUC-18
P01313846A0850|1 11|Comparison
P01313846A0850|115 125|similarity
P01313846A0850|173 180|members
P01313846A0850|63 69|member
P01312005A0600|32 41|mt genome
P01312005A0600|74 82|cleavage
P01312005A0600|154 166|target sites
P01312005A0600|116 117|H
P01312005A0600|266 276|structures
P01312005A0600|209 214|tract
P01312005A0600|329 335|origin
P01310899A0339|102 122|transmembrane domain
P01310899A0339|15 33|receptor structure
P01310178A0876|81 91|production
P01310178A0876|5 33|JS78 mutation changes Gln243
P01310178A0876|131 142|polypeptide
P01309910A0428|1 29|Nucleotide sequence analysis
P01309910A0428|56 63|protein
P01309860A0559|97 106|sequences
P01309860A0559|124 139|mouse L1 family
P01309860A0559|75 85|% identity
P01309593A1092|48 61|target motifs
P01309593A1092|159 179|immunoglobulin light
P01309593A1092|197 202|genes
P01309593A1092|215 223|elements
P01309593A1092|121 138|virus P5 promoter
P01309587A0715|141 154|c-myb protein
P01309587A0715|58 77|Z/c-myb combination
P01309587A0715|104 111|binding
P01309244A0798|102 112|cell types
P01309244A0798|54 58|acts
P01309244A0798|163 171|promoter
P01309244A0798|30 39|positions
P01304515A0178|41 54|control group
P01301171A0979|22 30|enhancer
P01301171A0979|47 70|c-myc bearing sequences
P01299489A0788|119 127|athletes
P01299489A0788|49 57|evidence
P01299489A0788|27 32|study
P01299489A0788|75 90|supplementation
P01298173A0153|101 105|part
P01298173A0153|172 182|modalities
P01298173A0153|198 205|measure
P01298173A0153|13 20|history
P01298173A0153|30 37|lesions
P01297332A0983|32 45|consideration
P01297332A0983|141 159|consensus sequence
P01297332A0983|53 57|SCBs
P01295500A0366|116 117|%
P01295500A0366|56 63|Attacks
P01295500A0366|104 112|Deficits
P01294345A0591|190 195|edema
P01294345A0591|52 66|administration
P01294345A0591|213 230|breast tenderness
P01294345A0591|29 40|improvement
P01294345A0591|181 188|tension
P01287197A0761|257 259|iv
P01287197A0761|261 263|po
P01287197A0761|46 62|plasma potassium
P01287197A0761|165 170|group
P01287197A0761|15 20|group
P01285807A0365|175 179|mmHg
P01285807A0365|53 57|mmHg
P01285807A0365|82 86|mmHg
P01285807A0365|107 108|P
P01285807A0365|15 17|SD
P01285358A0396|1 14|Serum gastrin
P01285358A0396|81 89|interest
P01285358A0396|104 110|course
P01284828T0001|69 81|fibrinolysis
P01284828T0001|1 29|Tissue plasminogen activator
P01284828T0001|140 148|prostate
P01284828T0001|121 132|hypertrophy
P01284032A0213|1 3|AP
P01284032A0213|92 96|acid
P01284032A0213|106 110|mmol
P01282014A0275|1 8|Animals
P01282014A0275|93 105|saline group
P01281472T0000|17 34|muscle glycogenin
P01280807A0575|98 124|ThrRS/CGU operator complex
P01280807A0575|24 50|MetRS/CAU operator complex
P01279696A0862|54 56|M.
P01279696A0862|67 69|E.
P01279696A0862|40 42|S.
P01279696A0862|72 81|Kishimoto
P01279696A0862|30 38|Hisanaga
P01279352A1197|159 191|beta-galactosidase reporter gene
P01279352A1197|58 64|tissue
P01279352A1197|131 146|promoter region
P01279352A1197|88 99|development
P01279352A0297|5 9|site
P01279352A0297|11 14|PAL
P01278251A0000|190 200|sensitizer
P01278251A0000|5 12|authors
P01278251A0000|128 148|tetraphenylbutadiene
P01278251A0000|88 97|materials
P01278251A0000|61 66|tests
P01275541A0405|154 162|delivery
P01275541A0405|142 147|weeks
P01272816A0000|119 123|47Ca
P01272816A0000|156 166|absorption
P01272816A0000|5 10|study
P01272816A0000|14 32|calcium metabolism
P01265887T0001|10 31|factor VIII inhibitor
P01264640T0028|20 26|Saigon
P01261005A0711|49 60|differences
P01261005A0711|109 136|bandpass spectrophotometers
P01256410T0001|3 13|activities
P01256410T0001|21 27|factor
P01256410T0001|31 39|molecule
P01252223A0347|71 89|trait correlations
P01252223A0347|5 12|authors
P01252223A0347|108 116|contrast
P01252223A0347|44 53|pugnacity
P01248124A0281|84 93|gestation
P01248124A0281|74 80|stages
P01246210A0648|68 71|men
P01246210A0648|19 29|mean ratio
P01246210A0648|5 18|calcium ratio
P01246210A0648|89 90|%
P01244236A1122|141 149|increase
P01244236A1122|173 180|vessels
P01244236A1122|163 169|number
P01244236A1122|195 215|vasomotor reactivity
P01244236A1122|289 298|thickness
P01244236A1122|323 330|vessels
P01244236A1122|302 308|muscle
P01242636A0678|5 12|results
P01241588A1470|85 95|conditions
P01241588A1470|54 61|regions
P01241588A1470|5 16|alterations
P01241588A1470|130 143|neurotoxicity
P01241588A1470|29 42|5-HIAA levels
P01237206A0199|1 14|Demonstration
P01237206A0199|98 105|methods
P01237206A0199|173 189|Coxiella content
P01237206A0199|22 27|agent
P01237206A0199|148 166|antibody technique
P01235347T0001|32 42|adriamycin
P01228882A0437|55 69|concentrations
P01228882A0437|159 168|component
P01228882A0437|130 138|response
P01228882A0437|14 25|correlation
P01225339A0590|22 32|occlusions
P01217450A0295|65 70|block
P01217450A0295|94 98|dogs
P01211754A0192|38 47|operation
P01211754A0192|91 99|patients
P01208811T0001|1 6|Study
P01208811T0001|40 53|plutonium-239
P01206772T0000|3 8|study
P01206772T0000|27 38|lymphocytes
P01206772T0000|44 52|patients
P01201977T0000|5 19|interpretation
P01193770T0000|19 27|bacteria
P01191964A0000|274 279|basis
P01191964A0000|7 13|groups
P01191964A0000|108 114|goitre
P01191964A0000|17 25|patients
P01191964A0000|80 87|disease
P01191964A0000|158 163|years
P01191964A0000|209 212|T-4
P01190251A0335|49 53|dyes
P01190251A0335|58 69|lymphograms
P01186344A0303|118 122|male
P01186344A0303|38 43|terms
P01186344A0303|5 15|attainment
P01186344A0303|212 219|process
P01186344A0303|26 34|maturity
P01186344A0303|180 190|end-points
P01176905A0094|52 60|mid-dark
P01176905A0094|72 81|mid-light
P01172917T0000|51 65|milk tolerance
P01172917T0000|38 47|predictor
P01171935A0313|204 212|striatum
P01171935A0313|81 84|use
P01171935A0313|158 192|dopamine receptor site sensitivity
P01171935A0313|88 96|levodopa
P01171935A0313|30 48|movement disorders
P01170143A0247|87 97|conditions
P01170143A0247|122 131|cylinders
P01168908A0000|118 125|tissues
P01168908A0000|169 174|cycle
P01168908A0000|19 22|PGF
P01168908A0000|208 234|plasma progesterone levels
P01159822A0353|136 140|axes
P01159822A0353|233 240|numbers
P01159822A0353|161 167|number
P01159822A0353|15 24|epithelia
P01159822A0353|83 97|ultrastructure
P01159822A0353|180 189|lysosomes
P01159822A0353|211 217|bodies
P01158512T0000|36 42|G-6-PD
P01157191A0536|184 191|tumours
P01157191A0536|36 52|sodium saccharin
P01157191A0536|131 146|bladder tumours
P01157191A0536|224 229|weeks
P01156631A0658|137 146|treatment
P01156631A0658|5 37|mean plasma sodium concentration
P01156631A0658|162 164|SD
P01156631A0658|60 62|SD
P01148868A0284|33 45|progesterone
P01148868A0284|15 29|clearance rate
P01147436T0000|14 39|Burkitt Lymphoma Registry
P01141114A0188|34 42|increase
P01141114A0188|69 73|mmHg
P01141114A0188|190 201|temperature
P01141114A0188|95 99|PH-v
P01141114A0188|104 115|degrees C-v
P01138330A0204|136 158|acetylcholine chloride
P01138330A0204|100 109|% peptone
P01138330A0204|64 69|N HC1
P01138330A0204|73 82|% glucose
P01131946T0001|1 7|Effect
P01131946T0001|78 84|organs
P01131946T0001|11 20|ingestion
P01130186A0568|55 70|insulin release
P01130186A0568|74 82|response
P01125117A0183|49 56|attacks
P01125117A0183|4 8|none
P01125117A0183|41 45|type
P01123658A0000|154 159|spine
P01123658A0000|5 12|authors
P01123658A0000|125 132|anatomy
P01123658A0000|26 35|technique
P01123658A0000|74 79|spine
P01119658A0000|236 238|N1
P01119658A0000|5 12|records
P01119658A0000|87 101|cell carcinoma
P01119658A0000|158 169|hypopharynx
P01119658A0000|147 153|larynx
P01119658A0000|271 285|neck treatment
P01118293A0150|34 45|suppression
P01118293A0150|5 9|data
P01118293A0150|73 80|rivalry
P01116254A0000|205 215|myocardium
P01116254A0000|236 237|%
P01116254A0000|110 121|rubidium-81
P01116254A0000|221 222|%
P01116254A0000|54 67|concentration
P01116254A0000|260 261|%
P01116254A0000|92 104|potassium-43
P01116254A0000|242 251|potassium
P01107226A0808|58 62|mice
P01107226A0808|45 50|feces
P01101272T0000|19 34|carcinogenicity
P01101272T0000|66 76|Cyclamates
P01098592A0567|103 108|onset
P01098592A0567|58 65|samples
P01097100A0217|5 13|patients
P01093847A0000|16 22|action
P01093847A0000|95 107|neuroleptics
P01093847A0000|26 51|tropatepine hydrochloride
P01093055T0000|46 52|uremia
P01090210A0417|288 294|cm H20
P01090210A0417|1 5|Mean
P01090210A0417|178 183|phase
P01090210A0417|162 168|volume
P01090210A0417|12 25|lung capacity
P01090210A0417|47 55|capacity
P01087288T0000|3 13|comparison
P01087288T0000|110 127|thyroid carcinoma
P01087288T0000|95 105|iodine-131
P01083784T0000|69 77|patients
P01083784T0000|48 65|eosinophil counts
P01083784T0000|28 37|serum IgE
P01083321X0000|137 149|productivity
P01083321X0000|115 120|rates
P01083321X0000|54 57|age
P01083321X0000|59 72|subalpine fir
P01082726A0248|40 48|response
P01082726A0248|56 62|DC-ERG
P01080374A0709|103 107|form
P01080374A0709|82 88|entity
P01080374A0709|28 33|Leber
P01075075T0038|1 3|I.
P01067493A0119|19 26|pattern
P01067493A0119|62 69|percent
P01057137A0192|82 88|groups
P01050144A0297|137 148|83A complex
P01050144A0297|82 93|antibiotics
P01050144A0297|122 129|strains
P01048020T0000|1 9|Critique
P01048020T0000|37 49|Test Anxiety
P01048020T0000|74 93|A-F Grade Condition
P01047417T0000|11 38|National Health Dis-service
P01036714A0072|119 127|increase
P01036714A0072|97 107|chrysotile
P01036714A0072|145 160|cell population
P01036714A0072|135 139|lung
P01021091T0000|116 127|vasopressin
P01021091T0000|5 14|influence
P01021091T0000|76 86|rabbit ear
P01021091T0000|29 35|nerves
P01012904A0333|16 35|interference effect
P01012904A0333|95 106|Stroop test
P01010638A0161|5 9|feed
P01009739T0001|1 7|Effect
P01009739T0001|36 47|circulation
P01009739T0001|11 23|indomethacin
P01004298A0744|6 16|up-grading
P01004298A0744|43 55|CA component
P01004298A0744|105 111|scores
P01000378T0000|1 7|Effect
P01000378T0000|67 72|sheep
P01000378T0000|11 17|trauma
P00993176A0066|139 149|hemoglobin
P00993176A0066|7 16|myoglobin
P00993176A0066|42 52|hemoglobin
P00993176A0066|95 102|portion
P00993176A0066|60 73|heme pigments
P00989973A0000|174 181|rabbits
P00989973A0000|113 122|injection
P00989973A0000|159 166|rabbits
P00989973A0000|126 135|endotoxin
P00987649T0001|1 6|State
P00987649T0001|57 64|rhythms
P00987649T0001|14 18|body
P00986800A0325|190 193|day
P00986800A0325|5 14|Cu values
P00986800A0325|67 83|saturation level
P00986800A0325|129 135|values
P00986800A0325|89 102|mug Cu/g diet
P00985276A0000|1 10|Preflight
P00985276A0000|83 93|astronauts
P00985276A0000|108 122|Skylab mission
P00985276A0000|26 60|postflight exercise response tests
P00985276A0000|12 20|inflight
P00984209A0614|1 21|Serum gastrin levels
P00984209A0614|47 52|group
P00984209A0614|134 146|V&P patients
P00975540T0000|87 109|high-accuracy analyses
P00975540T0000|37 46|chemistry
P00974901A0080|16 35|macrophage function
P00974901A0080|101 107|effect
P00974901A0080|46 72|Bordetella pertussis cells
P00970488A0105|201 212|development
P00970488A0105|25 33|increase
P00970488A0105|89 109|DA receptor blocking
P00970488A0105|61 70|indicator
P00968181A0264|68 77|challenge
P00968181A0264|109 118|infection
P00968181A0264|15 21|calves
P00964758T0001|36 49|parotid gland
P00962222A0633|82 109|erythrocyte characteristics
P00962222A0633|28 38|variations
P00959656A0250|49 61|antithrombin
P00959656A0250|39 45|levels
P00956554A0414|85 95|reactivity
P00956554A0414|55 76|solid-phase allergens
P00956554A0414|7 14|samples
P00954819A1041|153 166|AChE activity
P00954819A1041|69 77|function
P00954819A1041|37 45|recovery
P00954819A1041|111 116|Sarin
P00951909X0001|140 148|patients
P00951909X0001|162 185|Billroth-II gastrectomy
P00951909X0001|47 53|author
P00947327A0000|342 355|sulfanilamide
P00947327A0000|279 284|tests
P00947327A0000|469 474|Nevin
P00947327A0000|132 140|activity
P00947327A0000|256 262|agents
P00947327A0000|460 462|CN
P00947327A0000|390 413|3,4,5-trimethoxy-benzyl
P00947327A0000|268 275|results
P00947327A0000|169 181|trimethoprim
P00947327A0000|512 517|tests
P00947327A0000|313 315|N1
P00947327A0000|164 167|SMZ
P00947327A0000|427 439|trimethoprim
P00947327A0000|188 199|combination
P00947327A0000|183 186|TMP
P00938594A0149|152 171|laboratory features
P00938594A0149|4 13|cessation
P00938594A0149|197 199|RA
P00938594A0149|74 88|manifestations
P00933251T0000|23 29|plaque
P00933251T0000|9 19|meningioma
P00932738A0116|41 45|mmHg
P00932738A0116|31 33|BP
P00932738A0116|15 29|blood pressure
P00930947A0629|16 33|drug interactions
P00930947A0629|156 161|drugs
P00930947A0629|93 96|PZA
P00930947A0629|194 200|effect
P00928529T0001|1 17|Feeding behavior
P00928529T0001|78 86|hamsters
P00928529T0001|30 41|body weight
P00926751A0000|109 118|materials
P00926751A0000|74 84|evaluation
P00926751A0000|31 41|rat larynx
P00926272A0000|32 45|deterioration
P00926272A0000|73 80|patient
P00921032T0000|51 57|Beagle
P00921032T0000|12 22|evaluation
P00918965A0728|201 205|PAO2
P00918965A0728|23 31|patients
P00918965A0728|135 140|shunt
P00917721A0484|6 14|analysis
P00917721A0484|107 120|dream content
P00916099A0000|1 18|Self-emasculation
P00916099A0000|63 71|disorder
P00913623A0242|118 122|pass
P00913623A0242|81 85|EHDP
P00913623A0242|5 14|mechanism
P00913623A0242|146 150|bone
P00913623A0242|30 39|molecules
P00910823A0196|6 10|term
P00910823A0196|62 73|blood gases
P00910823A0196|75 77|pH
P00903772A0359|58 71|modifications
P00903772A0359|107 110|leg
P00903772A0359|90 99|ischaemia
P00892353A0686|68 73|fever
P00892353A0686|43 50|toxemia
P00890028A0507|171 188|Kolmogoroff scale
P00890028A0507|5 18|length scales
P00890028A0507|159 161|mm
P00890028A0507|94 104|macroscale
P00890028A0507|63 78|Reynolds number
P00881630A0000|19 26|effects
P00881630A0000|48 55|N. naja
P00881630A0000|202 219|cremaster vessels
P00881630A0000|110 125|Phospholipase-A
P00881630A0000|165 170|venom
P00881630A0000|60 73|A. piscivorus
P00879329A0176|118 122|mmHg
P00879329A0176|174 177|IIp
P00879329A0176|92 100|pressure
P00879329A0176|150 158|pressure
P00876722T0000|35 42|abscess
P00876722T0000|11 21|meningitis
P00874942T0000|29 40|prematurity
P00872442T0000|1 11|Estimation
P00872442T0000|37 43|plasma
P00872442T0000|15 24|L-alanine
P00870859A0121|5 9|data
P00870859A0121|58 65|account
P00868301A0043|139 148|condition
P00868301A0043|4 26|diethyl ether solution
P00868301A0043|52 84|2-benzylidenamio-1-phenylpropane
P00863773T0000|1 8|Dangers
P00863773T0000|12 15|use
P00857024A0888|1 11|Recurrence
P00857024A0888|93 109|properdin levels
P00851041A0000|49 56|anomaly
P00851041A0000|25 33|patients
P00846559A0000|207 215|capacity
P00846559A0000|117 140|F. sporotrichioides var
P00846559A0000|98 105|species
P00846559A0000|158 164|U.S.A.
P00846559A0000|142 152|tricinctum
P00846559A0000|8 15|strains
P00843232A0100|70 79|character
P00843232A0100|5 15|background
P00843232A0100|97 107|epithelium
P00842406A0771|19 24|tests
P00842406A0771|52 56|task
P00838152A0863|18 39|mean temperature rise
P00838152A0863|160 174|qualifications
P00838152A0863|270 276|groups
P00838152A0863|182 196|triplet groups
P00838152A0863|132 145|disappearance
P00837262A0000|136 147|stimulation
P00837262A0000|55 65|colliculus
P00837262A0000|5 19|responsiveness
P00837262A0000|131 134|OFF
P00837262A0000|123 125|ON
P00833472A0907|64 75|institution
P00833472A0907|174 178|drug
P00833472A0907|43 53|gallstones
P00833472A0907|91 101|saturation
P00830568A0000|239 247|patients
P00830568A0000|203 220|gastrojejunostomy
P00830568A0000|167 185|gastroduodenostomy
P00830568A0000|288 291|V&P
P00830568A0000|187 193|STG-BI
P00830568A0000|115 122|persons
P00830568A0000|127 135|patients
P00830568A0000|150 161|gastrectomy
P00822611A0467|25 33|patients
P00822611A0467|72 79|persons
P00819176T0001|118 139|Pontella mediterranea
P00819176T0001|141 162|Labidocera wollastoni
P00819176T0001|43 60|swimming activity
P00819176T0001|27 35|pressure
P00811852T0001|38 47|encounter
P00811852T0001|26 33|nursing
P00808266T0000|17 27|management
P00808266T0000|43 49|cancer
P00806295A0193|80 84|cent
P00806295A0193|41 45|cent
P00792847A0000|51 54|ALG
P00792847A0000|95 101|humans
P00779272T0001|51 56|virus
P00779272T0001|24 34|antibodies
P00771729X0000|34 44|variations
P00771729X0000|20 26|system
P00767161A0837|140 145|hours
P00767161A0837|125 128|day
P00767161A0837|149 152|day
P00767161A0837|13 22|increases
P00764737X0000|55 63|deficits
P00764737X0000|28 39|measurement
P00759400T0000|21 25|5-HT
P00759400T0000|56 62|plasma
P00759400T0000|31 35|5-HT
P00757244A0000|57 66|membranes
P00757244A0000|31 36|study
P00755869A0216|51 69|parents/caregivers
P00755869A0216|154 165|weight loss
P00755869A0216|113 128|self-monitoring
P00755869A0216|90 102|consequences
P00755245A0000|1 7|Effect
P00755245A0000|110 114|cats
P00755245A0000|11 20|indoramin
P00748978T0000|50 59|abortions
P00748978T0000|25 41|prostaglandin E2
P00745775A0170|153 155|M.
P00745775A0170|101 114|complications
P00745775A0170|126 135|injection
P00741476A0000|76 80|days
P00741476A0000|91 99|abortion
P00741476A0000|15 20|woman
P00737422A0832|170 178|patients
P00737422A0832|98 103|staff
P00737422A0832|113 120|numbers
P00733067A0188|343 351|stitches
P00733067A0188|277 288|anastomosis
P00733067A0188|109 116|section
P00733067A0188|132 137|stump
P00733067A0188|392 397|lumen
P00733067A0188|157 169|construction
P00733067A0188|177 188|anastomosis
P00733067A0188|63 68|steps
P00728718T0000|21 30|pregnancy
P00725752T0001|34 45|combination
P00725752T0001|64 87|beta receptor blockader
P00725752T0001|89 96|obsidan
P00725336T0000|1 37|Newcastle disease virus surveillance
P00725336T0000|73 80|poultry
P00722652A0118|81 91|micrometer
P00722652A0118|122 129|surface
P00716366T0001|1 6|Value
P00716366T0001|76 85|diagnosis
P00716366T0001|10 23|determination
P00715180T0074|50 60|inhalation
P00715180T0074|64 93|plutonium-239 dioxide aerosol
P00715180T0074|97 100|rat
P00715180T0074|28 39|alterations
P00712117A0521|116 123|variant
P00712117A0521|9 17|outbreak
P00712117A0521|147 156|prototpye
P00712117A0521|107 112|virus
P00710217T0001|23 32|hip joint
P00703932A0000|19 37|glomerulonephritis
P00703932A0000|5 13|patients
P00703932A0000|79 84|shunt
P00702773A0327|1 12|Althoug RBF
P00702773A0327|42 49|therapy
P00702773A0327|105 108|GFR
P00701144T0000|35 45|lens power
P00701144T0000|93 101|implants
P00701144T0000|11 19|analysis
P00696680A0000|141 147|cervix
P00696680A0000|59 64|cases
P00696680A0000|126 137|endometrium
P00686836A0000|85 103|gas chromatography
P00686836A0000|168 172|diet
P00686836A0000|140 145|weeks
P00686836A0000|40 58|lipid peroxidation
P00686836A0000|107 121|breath samples
P00686836A0000|210 230|IU vitamin E acetate
P00681550A0000|1 8|Procion
P00681550A0000|173 177|site
P00681550A0000|79 87|goldfish
P00681550A0000|209 215|macula
P00681550A0000|60 75|auditory fibers
P00676416A0320|28 33|years
P00668122A0414|55 64|hepatitis
P00668122A0414|97 114|mean iron content
P00668122A0414|122 146|liver ferritin molecules
P00665214A0374|55 65|physiology
P00665214A0374|79 84|cycle
P00664320T0000|9 18|detectors
P00659962T0000|61 75|acid ingestion
P00656008T0000|1 11|Prevention
P00656008T0000|42 46|rats
P00646023T0058|25 40|virus excretion
P00644314T0000|34 41|effects
P00644314T0000|9 25|hypersensitivity
P00640584A0250|21 30|principle
P00637637T0000|32 53|plasma renin activity
P00637637T0000|14 21|factors
P00635194A0093|78 95|dose distribution
P00633909A0000|21 29|patients
P00633909A0000|114 123|treatment
P00633909A0000|198 205|control
P00633909A0000|31 37|scores
P00628990A0000|175 179|loop
P00628990A0000|39 44|units
P00628990A0000|73 87|reconstruction
P00627129A0944|137 143|effect
P00627129A0944|206 224|beta-adrenoceptors
P00627129A0944|36 42|others
P00627129A0944|147 156|labetalol
P00626014T0001|5 14|malignity
P00622556A0111|38 44|tissue
P00622556A0111|79 85|tendon
P00619948A0000|278 288|detachment
P00619948A0000|72 78|tablet
P00619948A0000|195 205|heart rate
P00619948A0000|260 267|anxiety
P00619948A0000|332 340|diazepam
P00619948A0000|91 103|fluphenazine
P00619948A0000|238 244|scales
P00619948A0000|174 177|CNV
P00619948A0000|108 110|mg
P00619948A0000|115 128|nortriptyline
P00619948A0000|249 258|alertness
P00619948A0000|59 66|Motival
P00619948A0000|363 370|placebo
P00619305A0759|23 29|groups
P00617815A0215|15 30|L-R differences
P00614915T0001|22 34|traumatology
P00603783A0647|17 20|IgG
P00603783A0647|67 75|findings
P00602622A0362|139 147|activity
P00602622A0362|53 58|Roter
P00602622A0362|12 25|ulcer therapy
P00602622A0362|31 39|atropine
P00600943T0001|3 8|cases
P00598012A0174|4 26|girls prolactin levels
P00598012A0174|95 101|change
P00598012A0174|105 121|prolactin levels
P00594617A0192|129 140|nephropathy
P00594617A0192|116 125|incidence
P00594617A0192|292 299|disease
P00594617A0192|218 223|Godal
P00594617A0192|189 197|presence
P00594617A0192|208 216|monomers
P00594617A0192|271 276|signs
P00593119T0001|50 53|IgE
P00593119T0001|33 46|determination
P00593119T0001|106 120|IgE antibodies
P00593119T0001|14 29|asthma patients
P00587791T0054|1 8|Nursing
P00587791T0054|12 20|patients
P00583004A0445|156 169|inflammations
P00583004A0445|127 134|lesions
P00583004A0445|13 37|1,8-dihydroxy-9-anthrone
P00580106T0000|22 29|disease
P00577440A0298|50 54|dose
P00577440A0298|8 16|duodenum
P00574956A0304|233 241|dopamine
P00574956A0304|22 32|stereotypy
P00574956A0304|95 99|tone
P00574956A0304|301 314|manifestation
P00569989A0239|87 116|acceleration pneumocardiogram
P00569989A0239|33 54|flow pneumocardiogram
P00569989A0239|178 194|pneumotachograph
P00569989A0239|151 156|apnea
P00565136T0000|84 87|Br2
P00565136T0000|37 47|inhalation
P00565136T0000|9 18|mortality
P00565136T0000|72 78|SO2Cl2
P00564032A0724|18 25|content
P00564032A0724|83 91|pressure
P00564032A0724|121 126|gland
P00555583T0000|38 41|man
P00555583T0000|45 51|review
P00555492A1034|52 62|blood flow
P00555492A1034|8 15|changes
P00555492A1034|182 196|blood pressure
P00550399A0615|19 25|causes
P00550399A0615|62 68|groups
P00540707A0255|69 82|complications
P00540707A0255|131 147|tip displacement
P00540707A0255|225 231|method
P00540707A0255|255 271|PMK implantation
P00540707A0255|52 59|account
P00540707A0255|28 35|results
P00534613A0000|1 12|Irradiation
P00534613A0000|98 107|challenge
P00534613A0000|82 91|aggregate
P00534613A0000|43 47|UV-A
P00524451A0136|221 224|rat
P00524451A0136|48 52|mice
P00524451A0136|125 138|hexobarbitone
P00524451A0136|148 152|time
P00524451A0136|74 79|death
P00519173A0126|35 43|evidence
P00519173A0126|47 59|oesophagitis
P00516545T0001|96 104|function
P00516545T0001|57 79|peroxidation processes
P00516545T0001|12 27|characteristics
P00513284A0000|235 237|mg
P00513284A0000|128 141|drip infusion
P00513284A0000|225 229|DOTC
P00513284A0000|50 60|Vibramycin
P00513284A0000|262 264|ml
P00513284A0000|158 163|study
P00513284A0000|62 68|Pfizer
P00513284A0000|31 42|doxycycline
P00510341T0036|3 8|study
P00506649T0000|23 47|serum protein components
P00503336A0285|171 179|findings
P00503336A0285|38 40|CC
P00503336A0285|197 206|diagnosis
P00503336A0285|59 66|attacks
P00503336A0285|78 83|fever
P00503336A0285|45 49|CIEC
P00497494A0112|5 16|ventilation
P00494659A0391|39 54|3-carboxyphenyl
P00494659A0391|109 119|toloxatone
P00490336A0181|52 57|m/sec
P00490336A0181|59 66|group C
P00485615A0935|138 146|syndrome
P00485615A0935|261 268|surgery
P00485615A0935|7 11|data
P00485615A0935|107 117|importance
P00485615A0935|150 155|order
P00483716A0366|68 82|carotid artery
P00483716A0366|115 126|anastomosis
P00479246T0000|32 45|osteomyelitis
P00478714T0000|41 66|alcohol treatment program
P00476572A0139|27 33|lesion
P00476572A0139|149 154|cases
P00474064A0205|9 18|situation
P00474064A0205|166 174|fentanyl
P00474064A0205|154 155|R
P00474064A0205|80 89|pethidine
P00474064A0205|93 105|mg.kg-1 I.V.
P00474064A0205|215 219|I.V.
P00473229T0000|68 87|tetrachloroethylene
P00473229T0000|49 66|trichloroethylene
P00473229T0000|92 99|toluene
P00473229T0000|122 135|chick embryos
P00465681A0000|3 7|rise
P00465681A0000|76 80|iron
P00465681A0000|130 145|oxygen pressure
P00465681A0000|11 35|hemoglobin concentration
P00465681A0000|88 99|blood serum
P00465681A0000|211 216|state
P00464387A1185|8 20|measurements
P00464387A1185|72 88|disease activity
P00464387A1185|30 39|serum IgE
P00456424A0000|141 148|rabbits
P00456424A0000|66 80|microgram kg-1
P00456424A0000|42 48|i.c.i.
P00456424A0000|183 197|cisterna magna
P00456424A0000|31 40|injection
P00453780A0430|116 122|tissue
P00453780A0430|53 71|patient population
P00453780A0430|182 185|IgA
P00450760T0001|21 28|Raynaud
P00450367T0000|119 124|stage
P00450367T0000|139 148|carcinoma
P00450367T0000|91 97|radium
P00450367T0000|45 57|hysterectomy
P00445259T0000|34 57|bone marrow iron stores
P00439618T0001|1 18|Lethal Tachmalcor
P00439618T0001|67 76|poisoning
P00439618T0001|57 65|ajmaline
P00435187T0000|18 31|flowers bloom
P00431832T0001|1 19|Plasma ion changes
P00429893A0000|35 47|round window
P00429893A0000|129 142|scala tympani
P00429893A0000|196 207|stimulation
P00429893A0000|161 167|trauma
P00429893A0000|150 157|minimum
P00427715A0000|68 77|diaphragm
P00427715A0000|168 175|Florida
P00427715A0000|39 46|disease
P00427715A0000|123 140|radiation therapy
P00427715A0000|15 23|patients
P00423649A0259|70 75|claim
P00423649A0259|7 17|techniques
P00423649A0259|41 47|people
P00418341T0000|12 22|adaptation
P00417166T0000|42 56|rhesus monkeys
P00415543A0320|16 25|emphysema
P00415543A0320|156 168|lung disease
P00415543A0320|66 73|quality
P00415543A0320|40 51|radiographs
P00413854A0958|1 8|Changes
P00413854A0958|104 109|blood
P00411465A0142|35 42|section
P00411465A0142|53 57|cent
P00406585T0001|10 20|hematology
P00401521A0138|24 32|patients
P00401521A0138|13 20|percent
P00393598A0198|56 59|ALS
P00386251A0899|102 123|sulphonamide residues
P00386251A0899|5 24|IDF standard method
P00386251A0899|89 98|detection
P00386251A0899|60 64|milk
P00381783T0000|1 33|Bone marrow transplantation-1979
P00378735A0000|308 316|carriers
P00378735A0000|97 102|blood
P00378735A0000|135 146|amoxycillin
P00378735A0000|152 167|dosage schedule
P00378735A0000|80 85|fever
P00378735A0000|321 334|relapse rates
P00378735A0000|297 304|respect
P00377466A0188|35 42|hormone
P00377466A0188|201 208|disease
P00377466A0188|96 100|HPRL
P00377466A0188|79 82|FSH
P00377466A0188|44 46|LH
P00377466A0188|85 94|prolactin
P00377466A0188|155 156|T
P00377466A0188|179 192|healing phase
P00369397A0280|68 84|GnRH stimulation
P00369397A0280|53 60|addicts
P00369397A0280|160 168|controls
P00369397A0280|89 96|addicts
P00361059T0000|3 8|study
P00361059T0000|67 77|% ointment
P00361059T0000|40 63|diflucortolone valerate
P00354315T0000|38 59|ataxia telangiectasia
P00354315T0000|9 20|dysfunction
P00350465T0000|11 20|diagnosis
P00342623A0228|24 44|whole-virus vaccines
P00342623A0228|11 19|vaccines
P00339289T0049|49 57|proteins
P00339289T0049|36 45|chemistry
P00336547A0000|304 310|BALB/c
P00336547A0000|142 146|mice
P00336547A0000|312 319|CBA/LAC
P00336547A0000|229 233|mice
P00336547A0000|325 331|C3H/eB
P00336547A0000|251 264|mouse strains
P00336547A0000|150 153|ICR
P00331936T0000|1 10|Detection
P00330364A0132|274 286|laboratories
P00330364A0132|3 8|total
P00330364A0132|79 87|cultures
P00330364A0132|15 26|BCG strains
P00330364A0132|220 235|BCG-vaccination
P00330364A0132|189 196|strains
P00330364A0132|56 63|strains
P00330364A0132|91 94|BCG
P00316723A0558|38 46|behavior
P00304806A0760|17 44|serum alpha1AT quantitation
P00304806A0760|8 13|basis
P00304806A0760|160 163|mg%
P00304240A0369|23 28|tests
P00304240A0369|78 85|disease
P00300314A0132|139 149|drug death
P00300314A0132|116 131|hospitalization
P00300314A0132|20 30|infections
P00300314A0132|246 258|methotrexate
P00300314A0132|209 214|mg/m2
P00300314A0132|165 173|patients
P00267764A0651|38 45|reasons
P00267764A0651|110 120|management
P00264240A1843|186 209|X. laevis oocyte 5S DNA
P00264240A1843|5 14|sequences
P00264240A1843|29 47|X. borealis oocyte
P00264240A1843|60 68|5S genes
P00254537T0000|40 48|programs
P00254537T0000|60 72|state boards
P00240518A0000|40 53|determination
P00240518A0000|61 87|fungicide 5-fluorocytosine
P00239169T0000|1 27|Dopamine receptor blockade
P00234626T0036|1 4|XXI
P00234206T0000|64 75|arboviruses
P00234206T0000|37 53|Bunyamwera group
P00234206T0000|88 97|Sao Paulo
P00232354A0286|1 11|Serum ACTH
P00232354A0286|31 38|insulin
P00227610A1593|80 84|SV40
P00227610A1593|89 104|polyoma viruses
P00225352T0000|96 105|rat liver
P00225352T0000|42 52|metabolism
P00225352T0000|60 70|vitamin D3
P00222827A0000|69 74|depth
P00222827A0000|81 88|attempt
P00222827A0000|53 56|TDI
P00222827A0000|15 26|sensitivity
P00221725A0523|32 50|cytochrome oxidase
P00221725A0523|5 12|decline
P00221725A0523|52 62|peroxidase
P00221725A0523|74 87|lipid content
P00219674A0000|50 61|scintigrams
P00219674A0000|101 109|patients
P00219674A0000|131 136|range
P00219533T0001|34 49|serum uric-acid
P00219533T0001|70 81|populations
P00219533T0001|104 109|women
P00211881A0602|153 156|PBB
P00211881A0602|64 78|kidney lesions
P00211881A0602|36 42|amount
P00211881A0602|135 139|site
P00209664A0836|116 127|correlation
P00209664A0836|64 72|bone age
P00209664A0836|14 25|correlation
P00201881A0487|77 84|PI ACTH
P00201881A0487|89 101|MSH contents
P00198510T0000|1 12|Innervation
P00198510T0000|28 37|diaphragm
P00193587T0000|35 44|phenomena
P00193587T0000|48 54|review
P00188387A0975|1 8|Studies
P00188387A0975|67 75|families
P00188387A0975|12 24|lipoproteins
P00176742T0000|17 34|suture absorption
P00176742T0000|43 47|role
P00172199A0270|119 135|cross striations
P00172199A0270|88 98|appearance
P00172199A0270|60 70|morphology
P00168176A0000|1 8|Patulin
P00168176A0000|53 66|ethyl acetate
P00168176A0000|164 170|eluant
P00163384A0000|5 12|carcass
P00163384A0000|97 104|Ontario
P00163384A0000|31 34|owl
P00155973A0387|50 56|errors
P00155973A0387|184 187|vol
P00155973A0387|234 239|min-1
P00155973A0387|96 102|system
P00155973A0387|249 254|range
P00155973A0387|30 36|limits
P00150066A0554|41 51|prostheses
P00149899T0001|19 24|times
P00142718A0156|50 57|changes
P00142718A0156|112 122|99mTc-EHDP
P00142718A0156|13 21|patients
P00139624A0318|23 37|administration
P00139624A0318|57 82|serum ceruloplasmin level
P00139624A0318|135 139|rats
P00136175A1137|118 126|exercise
P00136175A1137|169 180|enlargement
P00136175A1137|113 114|h
P00136175A1137|88 96|exercise
P00131739T0001|21 28|indices
P00131739T0001|41 52|populations
P00129659T0000|71 86|sex differences
P00129659T0000|37 47|trisomy-21
P00129659T0000|90 93|IQs
P00119339A0400|116 122|strain
P00119339A0400|172 184|degeneration
P00119339A0400|145 156|myocarditis
P00118044A0000|34 40|monkey
P00118044A0000|69 74|peaks
P00118044A0000|138 150|EMG activity
P00118044A0000|43 48|wrist
P00118044A0000|106 114|M3 peaks
P00115974A0576|80 83|age
P00115974A0576|43 47|maze
P00113657A0628|1 8|Pb foil
P00113657A0628|15 20|gcm-2
P00111174A0351|87 94|neurons
P00111174A0351|53 60|neurons
P00111174A0351|213 220|stimuli
P00111174A0351|109 116|stimuli
P00105401A0635|239 242|FT4
P00105401A0635|65 88|thyroid hormone binding
P00105401A0635|23 26|DPH
P00105401A0635|247 250|FT3
P00105401A0635|92 95|TBG
P00105401A0635|47 59|interference
P00100791A0425|102 116|rhesus monkeys
P00100791A0425|7 14|results
P00100791A0425|29 47|cynomolgus monkeys
P00097989A0106|16 24|analysis
P00094639A0313|51 59|patients
P00094639A0313|33 39|volume
P00094639A0313|83 85|mg
P00089778A0000|5 18|concentration
P00089778A0000|79 92|C3-complement
P00089778A0000|228 233|Fuchs
P00089778A0000|187 193|humour
P00089778A0000|22 43|alpha 2-macroglobulin
P00089778A0000|127 130|FDP
P00089778A0000|214 222|patients
P00089778A0000|149 157|activity
P00086313A0000|117 122|basis
P00086313A0000|38 54|disease bacteria
P00086313A0000|24 36|Legionnaires
P00083846T0000|1 8|Albumin
P00083846T0000|59 64|child
P00073344A0367|50 61|lymphocytes
P00073344A0367|81 90|treatment
P00066874T0000|103 110|results
P00066874T0000|71 84|contamination
P00066874T0000|25 55|fluid alpha fetoprotein levels
P00063680T0000|10 19|diagnosis
P00060529A0695|34 50|acquisition-rate
P00060529A0695|16 29|control group
P00060529A0695|138 148|percentage
P00060529A0695|173 192|practice population
P00060529A0695|88 99|0acteriuria
P00056837A0000|8 25|mediastinoscopies
P00054900A0226|57 65|esterase
P00050628A0202|49 54|serum
P00050628A0202|86 97|proteinuria
P00050628A0202|113 120|patient
P00041512T0067|1 10|Abstracts
P00038408T0000|100 103|FLA
P00038408T0000|79 95|alpha-methyldopa
P00033873T0001|1 30|Gamma glutamyl transpeptidase
P00033873T0001|38 46|activity
P00030183T0000|1 9|Takayasu
P00030183T0000|21 32|association
P00029555A0861|39 51|quantitation
P00029555A0861|59 66|methods
P00029555A0861|123 158|shellfish microbiology laboratories
P00027739T0000|70 76|cattle
P00027739T0000|40 49|diagnosis
P00024600A0522|104 118|dosage regimen
P00022143T0000|51 57|rabbit
P00022143T0000|24 35|etoperidone
P00013683A0210|21 32|CO2 removal
P00013683A0210|46 60|CO2 production
P00010943A0733|84 87|use
P00010943A0733|117 119|mg
P00010943A0733|53 57|drug
P00010943A0733|75 79|dose
P00008171T0000|15 22|aspects
P00008171T0000|35 53|hyperbilirubinemia
P00010943A0733|123 128|night
P00010943A0733|99 107|practice
P00010943A0733|1 11|Flurazepam
P00013683A0210|62 66|VCO2
P00013683A0210|78 89|ventilation
P00022143T0000|15 20|study
P00022143T0000|43 46|rat
P00024600A0522|14 32|HMG dosage regimen
P00024600A0522|55 65|advantages
P00027739T0000|53 66|liver disease
P00027739T0000|1 32|Serum gamma glutamyltransferase
P00029555A0861|10 19|exception
P00029555A0861|23 34|virus assay
P00030183T0000|12 19|disease
P00030183T0000|38 44|HLA-B5
P00033873T0001|62 67|fluid
P00033873T0001|32 36|GGTP
P00038408T0000|11 22|stimulation
P00038408T0000|64 73|treatment
P00038408T0000|34 53|alpha-autoreceptors
P00050628A0202|60 68|patients
P00050628A0202|4 7|IgG
P00050628A0202|19 29|gammopathy
P00054900A0226|12 27|reaction stains
P00056837A0000|90 101|operability
P00056837A0000|117 126|carcinoma
P00060529A0695|111 112|%
P00060529A0695|116 122|figure
P00060529A0695|253 257|A.B.
P00060529A0695|204 208|year
P00060529A0695|152 157|women
P00063680T0000|23 36|galactosaemia
P00066874T0000|96 101|blood
P00066874T0000|117 127|experiment
P00073344A0367|6 14|subjects
P00073344A0367|19 42|phytomitogen reactivity
P00083846T0000|45 51|fluids
P00083846T0000|20 30|AMP levels
P00086313A0000|13 20|strains
P00086313A0000|126 134|findings
P00086313A0000|168 184|antibody testing
P00086313A0000|103 109|groups
P00089778A0000|94 125|fibrinogen degradation products
P00089778A0000|247 256|dystrophy
P00089778A0000|296 304|cataract
P00089778A0000|261 269|patients
P00089778A0000|45 64|alpha 1-antitrypsin
P00089778A0000|198 203|serum
P00089778A0000|66 77|plasminogen
P00089778A0000|343 360|cataract patients
P00094639A0313|65 69|dose
P00094639A0313|1 9|Prazosin
P00097989A0106|28 43|treatment plans
P00097989A0106|51 59|patients
P00100791A0425|148 155|effects
P00100791A0425|159 169|norcocaine
P00105401A0635|15 18|CBZ
P00105401A0635|215 235|premedication levels
P00105401A0635|145 159|clearance rate
P00105401A0635|163 179|thyroid hormones
P00105401A0635|5 11|effect
P00105401A0635|200 211|maintenance
P00111174A0351|31 41|properties
P00111174A0351|126 130|eyes
P00111174A0351|172 179|stimuli
P00111174A0351|185 192|neurons
P00111174A0351|136 143|neurons
P00113657A0628|48 59|improvement
P00115974A0576|72 76|days
P00115974A0576|5 11|groups
P00118044A0000|88 96|terms M1
P00118044A0000|78 86|activity
P00118044A0000|98 100|M2
P00118044A0000|168 175|muscles
P00118044A0000|17 30|displacements
P00119339A0400|9 15|animal
P00119339A0400|93 108|T. cruzi stocks
P00119339A0400|190 197|lesions
P00119339A0400|205 215|oesophagus
P00129659T0000|27 35|syndrome
P00129659T0000|20 24|Down
P00129659T0000|1 12|Variability
P00131739T0001|56 66|Uzbekistan
P00136175A1137|134 138|week
P00136175A1137|78 84|amount
P00136175A1137|5 16|maintenance
P00136175A1137|184 187|ECA
P00136175A1137|51 58|density
P00139624A0318|41 51|colchicine
P00139624A0318|7 12|hours
P00139624A0318|113 117|rats
P00142718A0156|82 92|metastases
P00142718A0156|138 155|chest radiographs
P00149899T0001|36 47|development
P00149899T0001|1 11|Prediction
P00150066A0554|19 31|haemorrhages
P00155973A0387|286 291|min-1
P00155973A0387|66 67|%
P00155973A0387|188 189|%
P00155973A0387|141 169|carbon dioxide concentration
P00155973A0387|207 221|gas flow rates
P00155973A0387|258 276|minute ventilation
P00163384A0000|124 132|necropsy
P00163384A0000|36 52|Bubo virginianus
P00168176A0000|75 82|extract
P00168176A0000|27 47|apple butter samples
P00168176A0000|141 148|acetate
P00168176A0000|102 119|silica gel column
P00172199A0270|28 36|clusters
P00172199A0270|5 11|matrix
P00176742T0000|60 67|enzymes
P00176742T0000|1 12|Polyglactin
P00188387A0975|90 92|FH
P00188387A0975|111 124|heart disease
P00188387A0975|53 61|children
P00193587T0000|59 67|analysis
P00193587T0000|1 16|EEG theta waves
P00198510T0000|45 51|locust
P00198510T0000|53 71|Locusta migratoria
P00201881A0487|12 19|finding
P00201881A0487|57 68|correlation
P00201881A0487|34 41|studies
P00209664A0836|160 178|parallel phenomena
P00209664A0836|81 90|age group
P00209664A0836|34 42|serum LH
P00211881A0602|46 50|time
P00211881A0602|143 149|action
P00211881A0602|1 8|Efforts
P00219533T0001|90 93|men
P00219533T0001|18 30|correlations
P00219533T0001|1 13|Distribution
P00219674A0000|124 129|weeks
P00219674A0000|25 38|pyrophosphate
P00219674A0000|1 15|Technetium-99m
P00219674A0000|170 180|infarction
P00221725A0523|132 140|decrease
P00221725A0523|159 167|activity
P00221725A0523|20 28|activity
P00221725A0523|102 113|neutrophils
P00222827A0000|126 141|hyperreactivity
P00222827A0000|39 51|diisocyanate
P00222827A0000|1 8|Workers
P00222827A0000|102 112|mechanisms
P00225352T0000|57 59|3H
P00225352T0000|23 34|alterations
P00227610A1593|15 23|respects
P00227610A1593|66 76|messengers
P00227610A1593|38 46|DBP mRNA
P00232354A0286|43 53|metyrapone
P00234206T0000|28 35|Anhembi
P00234206T0000|11 22|Guama group
P00234206T0000|99 105|Brazil
P00234206T0000|1 9|Bertioga
P00239169T0000|36 48|neuroleptics
P00239169T0000|69 74|study
P00240518A0000|91 96|serum
P00240518A0000|22 31|procedure
P00254537T0000|31 36|types
P00254537T0000|8 17|graduates
P00264240A1843|105 113|residues
P00264240A1843|176 182|region
P00264240A1843|138 148|T clusters
P00267764A0651|89 99|philosophy
P00267764A0651|6 12|report
P00267764A0651|50 68|treatment failures
P00300314A0132|180 198|calcium leucovorin
P00300314A0132|106 108|mm
P00300314A0132|66 89|degrees F. granulocytes
P00300314A0132|235 239|days
P00300314A0132|32 37|fever
P00300314A0132|273 289|treatment cycles
P00304240A0369|52 60|presence
P00304806A0760|88 94|groups
P00304806A0760|126 140|concentrations
P00304806A0760|54 61|infants
P00316723A0558|12 23|body weight
P00316723A0558|1 8|Changes
P00330364A0132|208 213|cases
P00330364A0132|244 251|strains
P00330364A0132|117 124|strains
P00330364A0132|152 160|children
P00330364A0132|167 182|BCG-vaccination
P00330364A0132|108 113|batch
P00330364A0132|139 148|abscesses
P00331936T0000|30 40|antibodies
P00331936T0000|51 88|immunoperoxidase antiglobulin technic
P00336547A0000|158 172|C3H/eB origins
P00336547A0000|54 73|Nocardia asteroides
P00336547A0000|285 302|New Zealand Black
P00336547A0000|78 110|Nocardia brasiliensis infections
P00336547A0000|42 50|features
P00336547A0000|5 19|mortality rate
P00336547A0000|274 283|C57/BL/6J
P00339289T0049|20 28|isotopes
P00339289T0049|1 4|Use
P00342623A0228|56 70|type B antigen
P00342623A0228|102 112|reactivity
P00350465T0000|39 48|disorders
P00354315T0000|24 32|patients
P00361059T0000|28 36|efficacy
P00361059T0000|108 118|% ointment
P00361059T0000|82 103|clobetasol propionate
P00369397A0280|15 24|LH levels
P00369397A0280|106 115|LH values
P00369397A0280|7 10|FSH
P00369397A0280|98 101|FSH
P00377466A0188|120 132|progesterone
P00377466A0188|115 117|E2
P00377466A0188|49 77|follicle stimulating hormone
P00377466A0188|134 135|P
P00377466A0188|165 174|catabolic
P00377466A0188|11 19|controls
P00377466A0188|141 153|testosterone
P00377466A0188|103 113|oestradiol
P00378735A0000|269 289|temperature response
P00378735A0000|246 252|regard
P00378735A0000|23 28|trial
P00378735A0000|48 56|patients
P00378735A0000|225 240|chloramphenicol
P00378735A0000|107 121|marrow culture
P00378735A0000|173 174|g
P00378735A0000|204 208|days
P00384744T0000|27 39|hypofunction
P00386251A0899|46 56|penicillin
P00386251A0899|127 131|milk
P00386251A0899|33 42|detection
P00393598A0198|15 30|endotoxin fever
P00393598A0198|5 11|course
P00401521A0138|46 57|ticarcillin
P00406585T0001|28 31|age
P00411465A0142|106 114|cavities
P00411465A0142|65 75|trabeculae
P00411465A0142|84 91|contact
P00413854A0958|12 23|tissue PCO2
P00415543A0320|105 110|films
P00415543A0320|125 133|patients
P00415543A0320|114 119|films
P00415543A0320|1 12|Recognition
P00417166T0000|28 38|clonazepam
P00417166T0000|17 24|profile
P00418341T0000|37 42|parts
P00423649A0259|57 62|years
P00423649A0259|98 108|innovation
P00423649A0259|117 123|regard
P00427715A0000|29 36|Hodgkin
P00427715A0000|79 85|Stages
P00427715A0000|3 8|total
P00427715A0000|154 164|University
P00427715A0000|102 103|B
P00429893A0000|57 69|implantation
P00429893A0000|92 98|system
P00429893A0000|25 30|array
P00429893A0000|116 118|mm
P00431832T0001|30 35|blood
P00431832T0001|51 73|beta receptor blockers
P00439618T0001|26 40|diethylamino-2
P00439618T0001|42 55|hydroxypropyl
P00439618T0001|80 89|childhood
P00445259T0000|1 29|Serum ferritin concentration
P00450367T0000|15 20|trail
P00450367T0000|31 43|hysterectomy
P00450367T0000|71 77|radium
P00450367T0000|103 115|hysterectomy
P00450760T0001|31 39|syndrome
P00450760T0001|1 17|Cryoglobulinemia
P00453780A0430|160 166|source
P00453780A0430|18 36|serum IgA response
P00453780A0430|139 143|lung
P00456424A0000|104 114|heart rate
P00456424A0000|167 175|catheter
P00456424A0000|53 62|clonidine
P00456424A0000|5 12|effects
P00456424A0000|85 99|blood pressure
P00464387A1185|63 68|index
P00464387A1185|92 96|ABPA
P00465681A0000|151 154|atm
P00465681A0000|195 198|atm
P00465681A0000|182 187|state
P00465681A0000|109 113|mice
P00465681A0000|162 166|hour
P00465681A0000|54 62|increase
P00473229T0000|107 118|development
P00473229T0000|12 30|methylene chloride
P00473229T0000|32 47|trichloroethane
P00473229T0000|1 8|Effects
P00474064A0205|123 131|morphine
P00474064A0205|178 188|sufentanil
P00474064A0205|23 43|convlusion threshold
P00474064A0205|54 64|substances
P00474064A0205|195 196|R
P00474064A0205|107 118|piritramide
P00474064A0205|137 150|phenoperidine
P00476572A0139|133 145|radiodensity
P00476572A0139|110 115|cases
P00478714T0000|1 9|Efficacy
P00483716A0366|4 8|case
P00483716A0366|49 56|carotid
P00485615A0935|60 66|crisis
P00485615A0935|210 221|performance
P00485615A0935|24 33|existence
P00485615A0935|189 201|pancreatitis
P00485615A0935|81 87|entity
P00485615A0935|169 179|occurrence
P00490336A0181|7 26|conduction velocity
P00494659A0391|94 105|glucuronide
P00494659A0391|58 87|hydroxymethyl-2-oxazolidinone
P00494659A0391|19 30|metabolites
P00497494A0112|39 44|PACO2
P00503336A0285|149 154|serum
P00503336A0285|128 141|transaminases
P00503336A0285|93 99|levels
P00503336A0285|22 26|CAEC
P00503336A0285|103 123|alkaline phosphatase
P00506649T0000|67 73|stress
P00506649T0000|1 8|Changes
P00510341T0036|16 26|E.O.R.T.C.
P00513284A0000|268 284|glucose solution
P00513284A0000|148 154|series
P00513284A0000|294 299|mg/kg
P00513284A0000|87 99|tetracycline
P00513284A0000|16 27|preparation
P00513284A0000|44 48|DOTC
P00513284A0000|197 204|results
P00513284A0000|171 187|pediatrics field
P00516545T0001|130 148|glomerulonephritis
P00516545T0001|108 116|children
P00516545T0001|35 55|erythrocyte membrane
P00519173A0126|8 16|patients
P00524451A0136|105 113|toxicity
P00524451A0136|166 175|depletion
P00524451A0136|26 44|locomotor activity
P00524451A0136|179 193|catecholamines
P00524451A0136|207 213|organs
P00524451A0136|85 96|amphetamine
P00534613A0000|22 37|blood platelets
P00534613A0000|113 121|collagen
P00534613A0000|71 78|ability
P00540707A0255|120 125|cases
P00540707A0255|242 250|approach
P00540707A0255|294 297|use
P00540707A0255|152 167|pouch haematoma
P00540707A0255|109 113|rate
P00540707A0255|196 203|Authors
P00540707A0255|305 319|vena cephalica
P00550399A0615|29 34|death
P00555492A1034|89 98|injection
P00555492A1034|146 150|flow
P00555492A1034|127 136|injection
P00555492A1034|102 112|cimetidine
P00555583T0000|21 34|Carbamazepine
P00555583T0000|1 17|Pharmacokinetics
P00564032A0724|109 113|duct
P00564032A0724|65 75|mechanisms
P00564032A0724|1 8|Changes
P00565136T0000|57 62|doses
P00565136T0000|22 26|mice
P00565136T0000|66 70|CH2O
P00569989A0239|120 126|dPn/dt
P00569989A0239|56 60|PnCG
P00569989A0239|7 27|halothane anesthesia
P00569989A0239|70 74|time
P00574956A0304|195 202|systems
P00574956A0304|270 281|development
P00574956A0304|59 63|case
P00574956A0304|142 153|equilibrium
P00577440A0298|74 96|3H-alpha-acetyldigoxin
P00577440A0298|25 29|part
P00580106T0000|14 20|Graves
P00580106T0000|1 10|Treatment
P00583004A0445|177 181|skin
P00583004A0445|39 65|1,8,9-triacetoxyanthracene
P00583004A0445|70 94|1,8-diacetoxy-9-anthrone
P00587791T0054|40 48|diseases
P00590594T0000|9 28|allotransplantation
P00593119T0001|61 74|comprehension
P00593119T0001|78 86|spectrum
P00593119T0001|1 10|Screening
P00594617A0192|151 164|insufficiency
P00594617A0192|301 306|fever
P00594617A0192|56 64|presence
P00594617A0192|22 33|correlation
P00594617A0192|320 323|ESR
P00594617A0192|81 101|degradation products
P00594617A0192|226 251|ethanol-gelification test
P00594617A0192|103 106|FDP
P00598012A0174|78 82|boys
P00598012A0174|65 73|menarche
P00598012A0174|35 40|stage
P00600943T0001|18 37|lymphomononucleosis
P00602622A0362|44 51|Vikalin
P00602622A0362|82 83|p
P00602622A0362|100 109|reduction
P00603783A0647|25 28|IgM
P00603783A0647|1 13|Serum levels
P00603783A0647|85 105|observers IgA levels
P00614915T0001|1 11|Vitrectomy
P00619305A0759|59 68|dimension
P00619305A0759|86 96|dimensions
P00619948A0000|180 193|reaction time
P00619948A0000|355 357|mg
P00619948A0000|293 303|depression
P00619948A0000|51 55|dose
P00619948A0000|163 172|variation
P00619948A0000|374 385|propranolol
P00619948A0000|269 276|tension
P00619948A0000|390 392|mg
P00619948A0000|25 33|subjects
P00619948A0000|344 346|mg
P00619948A0000|132 134|mg
P00619948A0000|7 14|effects
P00619948A0000|207 221|blood pressure
P00622556A0111|21 29|collagen
P00626014T0001|25 32|lentigo
P00627129A0944|79 89|conditions
P00627129A0944|7 16|responses
P00627129A0944|55 63|subjects
P00627129A0944|184 192|blockade
P00628990A0000|134 154|ureteroneocystostomy
P00628990A0000|7 15|patients
P00628990A0000|98 117|ureteroureterostomy
P00628990A0000|190 202|ureterostomy
P00633909A0000|41 47|Rotter
P00633909A0000|77 90|Control Scale
P00633909A0000|157 165|patients
P00633909A0000|50 73|Internal-External Locus
P00635194A0093|1 16|Kodak XV-2 film
P00637637T0000|67 79|hypertension
P00640584A0250|56 65|stability
P00644314T0000|29 32|man
P00644314T0000|54 69|anticoagulation
P00646023T0058|14 21|studies
P00646023T0058|59 71|transmission
P00656008T0000|21 38|paraquat toxicity
P00656008T0000|50 70|superoxide dismutase
P00659962T0000|19 39|riboflavin excretion
P00664320T0000|39 46|pathway
P00665214A0374|5 11|method
P00668122A0414|13 35|liver biopsy specimens
P00668122A0414|41 49|patients
P00668122A0414|80 89|variation
P00668122A0414|1 9|Analysis
P00676416A0320|51 65|liver biopsies
P00681550A0000|181 192|termination
P00681550A0000|133 146|response type
P00681550A0000|108 120|relationship
P00681550A0000|156 162|fibers
P00682762T0001|1 20|Silicosis mortality
P00686836A0000|13 19|ethane
P00686836A0000|148 155|vitamin
P00686836A0000|125 129|rats
P00686836A0000|235 237|kg
P00686836A0000|1 8|Pentane
P00696680A0000|74 79|women
P00696680A0000|42 50|findings
P00696680A0000|5 12|authors
P00696680A0000|85 102|rhabdomyosarcomas
P00701144T0000|78 85|results
P00701144T0000|66 76|emmetropia
P00702773A0327|90 96|change
P00702773A0327|121 127|output
P00702773A0327|100 103|RBF
P00703932A0000|41 52|association
P00703932A0000|124 131|therapy
P00703932A0000|115 120|modes
P00710217T0001|10 15|cysts
P00712117A0521|61 69|February
P00712117A0521|89 98|A/Texas/1
P00712117A0521|131 143|A/Victoria/3
P00712117A0521|21 32|influenza A
P00712117A0521|49 53|base
P00715180T0074|11 15|time
P00715180T0074|20 24|dose
P00715180T0074|1 7|Effect
P00716366T0001|122 137|liver cirrhosis
P00716366T0001|27 58|alkaline phosphatase isoenzymes
P00716366T0001|101 109|jaundice
P00722652A0118|14 38|2nd-generation schizonts
P00722652A0118|56 64|diameter
P00722652A0118|137 142|cecum
P00725336T0000|41 50|Hong Kong
P00725752T0001|14 26|hypertension
P00725752T0001|106 117|vasodilator
P00725752T0001|1 10|Treatment
P00725752T0001|119 127|apressin
P00728718T0000|1 16|Thyroid disease
P00733067A0188|215 223|creation
P00733067A0188|246 258|valve system
P00733067A0188|292 311|spiral introflexion
P00733067A0188|319 325|mucosa
P00733067A0188|13 19|reflux
P00733067A0188|43 49|number
P00733067A0188|35 39|loop
P00737422A0832|88 94|member
P00737422A0832|157 164|numbers
P00737422A0832|1 10|Pathogens
P00737422A0832|51 58|bacilli
P00741476A0000|31 50|Ergotamine Tartrate
P00741476A0000|109 114|birth
P00741476A0000|55 62|mg p.d.
P00745775A0170|54 67|arteriography
P00745775A0170|139 148|Urografin
P00745775A0170|17 25|patients
P00748978T0000|1 21|Serum relaxin levels
P00755245A0000|30 35|doses
P00755245A0000|147 152|sites
P00755245A0000|86 96|chloralose
P00755245A0000|51 65|vasomotor loci
P00755869A0216|146 152|intake
P00755869A0216|33 40|clients
P00755869A0216|1 24|Contingency contracting
P00755869A0216|171 179|exercise
P00757244A0000|74 83|placentas
P00757244A0000|5 12|results
P00759400T0000|46 52|factor
P00759400T0000|77 85|patients
P00759400T0000|1 19|Platelet serotonin
P00764737X0000|5 19|vigilance task
P00767161A0837|31 53|serum E2 concentration
P00767161A0837|107 121|administration
P00767161A0837|95 100|hours
P00767161A0837|66 71|pg/ml
P00771729X0000|61 69|hormones
P00771729X0000|48 57|responses
P00779272T0001|13 20|studies
P00779272T0001|71 84|mononucleosis
P00792847A0000|26 49|antilymphocyte globulin
P00792847A0000|86 91|agent
P00806295A0193|120 128|subjects
P00806295A0193|59 69|absorption
P00806295A0193|1 11|Absorption
P00808266T0000|1 9|Advances
P00808266T0000|51 68|radiation therapy
P00811852T0001|10 22|satisfaction
P00811852T0001|71 79|patients
P00819176T0001|95 116|Anomalocera patersoni
P00819176T0001|5 11|effect
P00819176T0001|84 93|crustacea
P00822611A0467|15 21|number
P00822611A0467|94 107|binephrectomy
P00825571T0031|1 4|III
P00830568A0000|24 33|secretion
P00830568A0000|261 269|vagotomy
P00830568A0000|222 229|STG-BII
P00830568A0000|84 87|LTM
P00830568A0000|73 82|test meal
P00830568A0000|46 60|emptying rates
P00830568A0000|274 286|pyloroplasty
P00833472A0907|105 121|gallbladder bile
P00833472A0907|79 89|colestipol
P00833472A0907|127 138|cholesterol
P00833472A0907|21 28|patient
P00837262A0000|30 36|cortex
P00837262A0000|109 121|conditioning
P00837262A0000|67 69|SC
P00837262A0000|38 40|VC
P00837262A0000|156 162|rabbit
P00838152A0863|75 84|degrees C
P00838152A0863|209 221|predominance
P00838152A0863|242 256|qualifications
P00838152A0863|94 103|selection
P00838152A0863|57 66|degrees C
P00842406A0771|60 64|test
P00842406A0771|99 115|recognition task
P00842406A0771|69 92|visuomotor coordination
P00843232A0100|83 89|lesion
P00843232A0100|55 61|factor
P00846559A0000|225 234|T-2 toxin
P00846559A0000|37 56|F. sporotrichioides
P00846559A0000|66 74|U.S.S.R.
P00846559A0000|81 88|strains
P00846559A0000|19 32|Fusarium poae
P00846559A0000|169 175|France
P00851041A0000|13 18|study
P00851041A0000|39 46|Ebstein
P00857024A0888|15 29|bladder tumors
P00857024A0888|129 135|median
P00857024A0888|51 56|cases
P00863773T0000|19 38|live-virus vaccines
P00868301A0043|121 128|minutes
P00868301A0043|36 40|peak
P00868301A0043|98 112|retention time
P00870859A0121|73 82|direction
P00870859A0121|128 134|factor
P00870859A0121|86 99|recirculation
P00872442T0000|28 33|serum
P00872442T0000|54 80|LKB reaction rate analyser
P00874942T0000|14 24|amnionitis
P00874942T0000|56 62|report
P00876722T0000|56 62|septum
P00879329A0176|134 141|colloid
P00879329A0176|166 172|plasma
P00879329A0176|8 27|control preparation
P00879329A0176|35 41|weight
P00879329A0176|102 105|Pci
P00881630A0000|151 158|N. naja
P00881630A0000|193 197|lung
P00881630A0000|127 136|compounds
P00881630A0000|99 105|Factor
P00881630A0000|223 227|rats
P00881630A0000|34 46|snake venoms
P00890028A0507|26 36|turbulence
P00890028A0507|127 144|Taylor microscale
P00890028A0507|203 205|mm
P00890028A0507|119 121|mm
P00892353A0686|29 37|patients
P00892353A0686|4 15|hypotension
P00892353A0686|85 95|degrees C.
P00903772A0359|14 18|site
P00903772A0359|26 50|conditioning stimulation
P00903772A0359|1 9|Wherever
P00910823A0196|31 41|conditions
P00910823A0196|79 86|uterine
P00910823A0196|101 112|blood flows
P00913623A0242|131 142|capillaries
P00913623A0242|53 66|diphosphonate
P00913623A0242|157 174|passive diffusion
P00913623A0242|103 116|pyrophosphate
P00916099A0000|107 116|treatment
P00916099A0000|26 36|end result
P00917721A0484|61 81|presleep suggestions
P00917721A0484|37 45|evidence
P00918965A0728|105 117|componenents
P00918965A0728|146 154|parallel
P00918965A0728|55 62|failure
P00918965A0728|84 95|ventilation
P00921032T0000|26 36|mibolerone
P00926272A0000|60 64|cord
P00926272A0000|112 118|reflux
P00926272A0000|17 22|cause
P00926751A0000|61 66|organ
P00926751A0000|88 97|irritancy
P00926751A0000|8 15|studies
P00928529T0001|46 65|hibernation rhythms
P00928529T0001|127 134|bundles
P00930947A0629|60 70|probenecid
P00930947A0629|209 213|drug
P00930947A0629|80 89|secretion
P00930947A0629|138 144|effect
P00930947A0629|50 56|effect
P00932738A0116|120 122|BP
P00932738A0116|47 65|C02 responsiveness
P00932738A0116|110 116|levels
P00933251T0000|59 68|ear tumor
P00938594A0149|105 121|osteoarthropathy
P00938594A0149|123 126|HOA
P00938594A0149|37 44|patient
P00938594A0149|17 32|steroid therapy
P00938594A0149|186 195|arthritis
P00947327A0000|298 309|combination
P00947327A0000|54 64|resistance
P00947327A0000|358 369|sulfamoxole
P00947327A0000|523 530|TMP/SMZ
P00947327A0000|446 451|ratio
P00947327A0000|375 388|2,4-diamino-5
P00947327A0000|30 39|situation
P00947327A0000|91 98|Bavaria
P00947327A0000|146 162|sulfamethoxazole
P00947327A0000|223 234|antibiotics
P00947327A0000|16 22|survey
P00947327A0000|72 78|region
P00947327A0000|415 425|pyrimidine
P00947327A0000|476 485|Supristol
P00951909X0001|15 28|loop syndrome
P00951909X0001|56 63|opinion
P00951909X0001|96 109|loop syndrome
P00951909X0001|69 78|diagnosis
P00954819A1041|7 11|data
P00954819A1041|143 149|return
P00954819A1041|84 96|intoxication
P00954819A1041|102 107|Soman
P00956554A0414|113 127|IgE antibodies
P00956554A0414|18 23|serum
P00959656A0250|10 15|women
P00959656A0250|19 23|term
P00962222A0633|121 139|progesterone phase
P00962222A0633|42 55|heme turnover
P00962222A0633|71 78|changes
P00964758T0001|16 28|plasmacytoma
P00968181A0264|88 92|days
P00968181A0264|38 46|immunity
P00970488A0105|45 56|DA turnover
P00970488A0105|180 192|neuroleptics
P00970488A0105|79 85|degree
P00970488A0105|234 242|symptoms
P00970488A0105|170 176|effect
P00974901A0080|124 138|susceptibility
P00974901A0080|1 12|Stimulation
P00975540T0000|63 83|mass fragmentography
P00975540T0000|48 59|application
P00975540T0000|17 24|methods
P00984209A0614|180 185|study
P00984209A0614|63 102|background serum gastrin concentrations
P00984209A0614|152 164|V&A patients
P00985276A0000|148 158|evaluation
P00985276A0000|124 130|Skylab
P00985276A0000|176 186|adaptation
P00985276A0000|200 214|weightlessness
P00985276A0000|137 141|part
P00986800A0325|161 165|dams
P00986800A0325|197 205|delivery
P00986800A0325|112 121|exception
P00986800A0325|140 147|body Cu
P00986800A0325|33 39|organs
P00987649T0001|79 90|hypokinesia
P00987649T0001|22 31|disorders
P00989973A0000|79 89|turpentine
P00989973A0000|230 238|busulfan
P00989973A0000|66 75|injection
P00989973A0000|5 13|response
P00989973A0000|21 44|plasma fibrinogen level
P00993176A0066|165 178|2SO4 solution
P00993176A0066|161 164|NH4
P00993176A0066|110 117|extract
P00993176A0066|158 159|%
P00996364X0000|1 2|E
P01000378T0000|41 63|insulin concentrations
P01000378T0000|21 36|plasma glucagon
P01004298A0744|30 35|score
P01004298A0744|91 99|students
P01004298A0744|127 132|level
P01004298A0744|71 72|%
P01009739T0001|59 62|ECG
P01009739T0001|49 55|effect
P01010638A0161|42 43|%
P01012904A0333|165 171|format
P01012904A0333|142 148|sample
P01012904A0333|68 79|populations
P01021091T0000|43 51|response
P01021091T0000|129 140|Octapressin
P01021091T0000|55 68|blood vessels
P01030985T0090|1 3|I.
P01036714A0072|78 85|animals
P01036714A0072|42 49|changes
P01036714A0072|1 8|Studies
P01036714A0072|186 192|levels
P01048020T0000|134 152|Course Information
P01048020T0000|26 33|Effects
P01048020T0000|54 70|Credit/No Credit
P01050144A0297|47 54|strains
P01050144A0297|37 43|number
P01050144A0297|21 29|decrease
P01057137A0192|31 44|acceptability
P01057137A0192|4 14|difference
P01067493A0119|93 100|methods
P01067493A0119|34 39|women
P01080374A0709|45 63|aneurysm retinitis
P01080374A0709|111 116|Coats
P01080374A0709|1 9|Evidence
P01080374A0709|118 125|disease
P01082726A0248|27 32|pupil
P01082726A0248|5 14|influence
P01083321X0000|22 31|dominance
P01083321X0000|4 10|stands
P01083321X0000|156 162|stands
P01083321X0000|186 191|years
P01083784T0000|93 99|asthma
P01083784T0000|1 26|Lymphocyte subpopulations
P01087288T0000|73 81|patients
P01087288T0000|42 51|estimates
P01087288T0000|55 69|radiation dose
P01090210A0417|135 146|lung volume
P01090210A0417|271 282|differences
P01090210A0417|227 233|cm H20
P01090210A0417|110 129|mean closing volume
P01090210A0417|70 76|volume
P01090210A0417|254 269|airway pressure
P01093055T0000|13 34|phosphorus metabolism
P01093055T0000|1 8|Calcium
P01093847A0000|147 153|states
P01093847A0000|76 83|effects
P01097100A0217|37 45|regimens
P01098592A0567|79 83|days
P01098592A0567|1 11|IgG levels
P01101272T0000|52 61|sweetners
P01101272T0000|81 96|cyclohexylamine
P01101272T0000|1 11|Assessment
P01107226A0808|10 24|amphotericin B
P01107226A0808|102 118|mg/ml dose level
P01116254A0000|147 155|thallium
P01116254A0000|266 274|rubidium
P01116254A0000|23 37|administration
P01116254A0000|184 197|concentration
P01116254A0000|281 288|minutes
P01116254A0000|141 145|mice
P01116254A0000|71 90|tracer thallium-201
P01118293A0150|104 108|eyes
P01118293A0150|22 28|notion
P01118293A0150|49 55|images
P01119658A0000|240 243|N2A
P01119658A0000|122 132|oropharynx
P01119658A0000|248 251|N2B
P01119658A0000|114 120|cavity
P01119658A0000|308 325|radiation therapy
P01119658A0000|64 72|patients
P01119658A0000|207 228|lymph node metastases
P01123658A0000|165 168|L-4
P01123658A0000|56 66|tomography
P01123658A0000|176 182|sacrum
P01123658A0000|100 111|description
P01125117A0183|26 33|attacks
P01125117A0183|93 100|changes
P01125117A0183|19 23|type
P01125117A0183|139 145|groups
P01130186A0568|25 32|patient
P01130186A0568|86 97|tolbutamide
P01131946T0001|56 62|period
P01131946T0001|24 34|Norbiogest
P01138330A0204|121 132|% solutions
P01138330A0204|8 15|pouches
P01138330A0204|86 92|% NaC1
P01138330A0204|35 44|solutions
P01138330A0204|51 58|% Na C1
P01141114A0188|124 130|Pv-CO2
P01141114A0188|162 169|effects
P01141114A0188|207 208|H
P01141114A0188|17 21|work
P01141114A0188|85 88|P50
P01147436T0000|43 58|progress report
P01148868A0284|62 66|S.E.
P01148868A0284|68 73|1/day
P01156631A0658|92 101|treatment
P01156631A0658|179 180|P
P01156631A0658|69 75|mEq/kg
P01156631A0658|171 177|mEq/kg
P01157191A0536|57 73|sodium cyclamate
P01157191A0536|93 104|carcinogens
P01157191A0536|18 29|dose levels
P01158512T0000|44 54|deficiency
P01158512T0000|21 34|dehydrogenase
P01159822A0353|120 124|tilt
P01159822A0353|145 153|increase
P01159822A0353|105 118|invaginations
P01159822A0353|46 53|animals
P01159822A0353|172 176|size
P01159822A0353|272 280|granules
P01168908A0000|63 69|artery
P01168908A0000|83 94|vein plasma
P01168908A0000|49 53|vein
P01168908A0000|1 17|Prostaglandins F
P01168908A0000|137 142|times
P01170143A0247|33 44|saline mice
P01170143A0247|1 7|Groups
P01171935A0313|121 134|manifestation
P01171935A0313|52 58|humans
P01171935A0313|5 15|appearance
P01171935A0313|100 111|amphetamine
P01172917T0000|9 32|Lactose tolerance tests
P01172917T0000|1 7|Letter
P01176905A0094|13 22|melatonin
P01176905A0094|24 39|serum melatonin
P01178637T0001|1 16|Atherosclerosis
P01186344A0303|148 155|pattern
P01186344A0303|161 168|release
P01186344A0303|172 175|ova
P01186344A0303|99 110|spermatozoa
P01186344A0303|64 79|characteristics
P01186344A0303|85 95|production
P01190251A0335|36 39|use
P01190251A0335|1 8|Caution
P01191964A0000|214 219|level
P01191964A0000|53 66|thyroidectomy
P01191964A0000|257 266|subgroups
P01191964A0000|192 207|serum thyroxine
P01191964A0000|142 148|goitre
P01191964A0000|71 77|Graves
P01191964A0000|304 336|serum thyrotrophin concentration
P01193770T0000|1 15|Air ion action
P01201977T0000|34 52|disc sensitivities
P01206772T0000|12 23|chromosomes
P01206772T0000|66 76|hycanthone
P01208811T0001|31 36|state
P01208811T0001|59 88|citrate solution-blood system
P01211754A0192|75 86|improvement
P01211754A0192|27 32|cases
P01211754A0192|138 146|deafness
P01217450A0295|5 23|Chemical occlusion
P01225339A0590|61 71|infarction
P01225339A0590|49 53|time
P01228882A0437|73 92|CSF immunoglobulins
P01228882A0437|97 103|degree
P01228882A0437|191 199|diseases
P01235347T0001|14 28|cardiotoxicity
P01237206A0199|107 112|Stamp
P01237206A0199|208 217|titration
P01237206A0199|67 75|day p.i.
P01237206A0199|233 236|hen
P01237206A0199|117 134|auramine staining
P01237206A0199|239 243|eggs
P01241588A1470|123 127|IDPN
P01241588A1470|178 186|neurones
P01241588A1470|20 24|5-HT
P01241588A1470|69 74|brain
P01242636A0678|95 114|beryllium retention
P01242636A0678|65 71|system
P01244236A1122|91 101|resistance
P01244236A1122|117 126|gestation
P01244236A1122|255 261|amount
P01244236A1122|47 57|blood flow
P01244236A1122|233 241|increase
P01244236A1122|5 12|results
P01244236A1122|272 278|muscle
P01246210A0648|59 63|TBCa
P01246210A0648|98 103|women
P01246210A0648|117 118|%
P01248124A0281|44 50|fluids
P01248124A0281|7 18|cholesterol
P01252223A0347|120 125|Winch
P01252223A0347|148 163|complementarity
P01252223A0347|128 137|principle
P01252223A0347|141 145|type
P01252223A0347|35 39|fear
P01256410T0001|65 69|term
P01256410T0001|55 61|infant
P01261005A0711|91 99|bandpass
P01261005A0711|64 75|performance
P01261005A0711|35 44|variation
P01264640T0028|3 7|case
P01265887T0001|50 58|patients
P01272816A0000|53 61|children
P01272816A0000|81 89|controls
P01272816A0000|101 115|administration
P01275541A0405|26 38|CPK activity
P01275541A0405|55 63|newborns
P01275541A0405|102 111|dystrophy
P01278251A0000|150 153|TPB
P01278251A0000|24 31|results
P01278251A0000|37 43|series
P01278251A0000|99 111|polyethylene
P01278251A0000|235 244|materials
P01279352A0297|37 59|bp sequence GGGGAGGAGG
P01279352A1197|74 80|manner
P01279352A1197|27 35|promoter
P01279352A1197|24 25|H
P01279352A1197|111 115|mice
P01279352A1197|21 23|NF
P01279696A0862|44 52|Kusubata
P01279696A0862|10 17|studies
P01279696A0862|58 65|Okumura
P01279696A0862|83 85|T.
P01280807A0575|14 16|Kd
P01280807A0575|58 73|order magnitude
P01281472T0000|1 7|Rabbit
P01282014A0275|60 74|motor recovery
P01282014A0275|23 28|DSP-4
P01284032A0213|31 39|infusion
P01284032A0213|57 71|concentrations
P01284032A0213|98 102|GDOC
P01284032A0213|118 122|mmol
P01284828T0001|94 102|patients
P01284828T0001|55 65|parameters
P01284828T0001|35 44|inhibitor
P01284828T0001|85 90|blood
P01285358A0396|43 52|evolution
P01285358A0396|19 29|AFP levels
P01285358A0396|118 125|disease
P01285807A0365|181 182|P
P01285807A0365|125 130|PaCO2
P01285807A0365|97 105|infusion
P01285807A0365|5 9|mean
P01285807A0365|19 23|PaO2
P01287197A0761|75 85|salbutamol
P01287197A0761|180 189|decrement
P01287197A0761|242 248|mmol/l
P01287197A0761|138 144|mmol/l
P01287197A0761|34 42|decrease
P01294345A0591|121 137|overreactiveness
P01294345A0591|148 164|prolactin levels
P01294345A0591|197 208|weight gain
P01294345A0591|96 104|symptoms
P01294345A0591|70 79|Bromergon
P01295500A0366|13 21|patients
P01295500A0366|67 68|%
P01297332A0983|6 14|analysis
P01297332A0983|99 104|genes
P01297332A0983|190 197|element
P01297332A0983|119 127|proposal
P01298173A0153|150 155|death
P01298173A0153|130 138|survival
P01298173A0153|52 62|efficiency
P01298173A0153|80 90|treatments
P01298173A0153|116 128|chemotherapy
P01299489A0788|150 154|RDIs
P01299489A0788|65 71|effect
P01299489A0788|103 114|performance
P01301171A0979|74 84|chromosome
P01301171A0979|11 16|cases
P01304515A0178|14 21|results
P01304515A0178|66 76|volunteers
P01309244A0798|76 87|orientation
P01309244A0798|5 11|target
P01309244A0798|117 124|species
P01309244A0798|137 144|context
P01309587A0715|13 28|transactivation
P01309587A0715|36 50|BMRF1 promoter
P01309587A0715|119 128|Z protein
P01309593A1092|89 98|UCR motif
P01309593A1092|25 30|UCRBP
P01309593A1092|7 14|studies
P01309593A1092|143 151|elements
P01309593A1092|237 250|protein genes
P01309860A0559|14 23|sequences
P01309860A0559|40 56|integration site
P01309860A0559|172 181|sequences
P01309910A0428|87 100|CREB2 protein
P01310178A0876|181 187|domain
P01310178A0876|37 40|gp0
P01310178A0876|191 218|host transcription shut-off
P01310178A0876|49 60|amber codon
P01310899A0339|73 79|domain
P01310899A0339|152 182|serine/threonine kinase domain
P01312005A0600|60 64|MDP1
P01312005A0600|296 301|bases
P01312005A0600|190 191|A
P01312005A0600|86 97|chick mtDNA
P01312005A0600|344 355|replication
P01312005A0600|337 339|OH
P01312005A0600|1 9|Analysis
P01313846A0850|77 108|immunoglobulin gene superfamily
P01313846A0850|21 39|sequence databanks
P01313846A0850|256 278|cell adhesion molecule
P01313846A0850|50 57|Tactile
P01313846A0850|205 214|Ag family
P01313909A0526|94 99|virus
P01313909A0526|5 15|phenotypes
P01313909A0526|138 146|sequence
P01314841A0724|78 82|drop
P01314841A0724|58 61|EEG
P01314841A0724|97 102|mm Hg
P01314841A0724|1 10|Treatment
P01315706A0000|10 25|differentiation
P01315706A0000|50 72|adenovirus E1a protein
P01316125A0382|148 154|second
P01316125A0382|354 356|OH
P01316125A0382|185 191|damage
P01316125A0382|255 261|damage
P01316125A0382|195 199|YHPD
P01316125A0382|97 100|1O2
P01316125A0382|64 68|YHPD
P01316461A1083|149 155|horses
P01316461A1083|27 37|S2 protein
P01316461A1083|196 206|expression
P01316461A1083|235 242|animals
P01316461A1083|184 192|evidence
P01316476A1428|91 96|genes
P01316476A1428|57 61|gene
P01316476A1428|5 8|ORF
P01316900A0000|72 76|K-12
P01316900A0000|5 17|DNA sequence
P01316903A1040|62 71|complexes
P01316903A1040|115 133|RNA polymerase IIA
P01318310A0000|30 35|cells
P01318310A0000|126 133|removal
P01318310A0000|98 101|HDL
P01318310A0000|1 17|Plasma membranes
P01320255A0795|47 54|element
P01320255A0795|163 167|role
P01320255A0795|140 147|element
P01320255A0795|118 132|factor binding
P01321277A0342|91 117|chicken embryo fibroblasts
P01321277A0342|56 59|ros
P01321277A0342|129 153|spindle shape morphology
P01321277A0342|34 37|src
P01321277A0342|119 122|CEF
P01321280A0494|47 63|E7 gene products
P01321280A0494|26 32|nature
P01321280A0494|95 100|cells
P01321280A0494|206 224|E7 fusion proteins
P01321336A0000|63 86|sequence motif ACAGATGG
P01321336A0000|5 20|enhancer region
P01321337A0318|194 205|calcineurin
P01321337A0318|231 240|antiserum
P01321337A0318|263 274|calcineurin
P01321337A0318|19 28|component
P01321337A0318|170 171|B
P01321337A0318|119 124|45Ca2
P01324172A0880|1 11|Antibodies
P01324172A0880|51 55|RIM1
P01324404A0813|109 126|carboxyl terminus
P01324404A0813|154 165|amino acids
P01324406A1250|121 132|instability
P01324406A1250|112 117|rates
P01324406A1250|33 61|ATPase/DNA helicase activity
P01324406A1250|87 98|maintenance
P01325221A0870|90 100|MBP kinase
P01325221A0870|56 65|detection
P01325221A0870|22 33|DU249 cells
P01326329A0703|268 272|GREs
P01326329A0703|213 217|Ap-2
P01326329A0703|219 224|sites
P01326329A0703|54 62|CAP site
P01326329A0703|87 91|lack
P01326329A0703|192 209|activator protein
P01326329A0703|106 114|TATA box
P01326329A0703|9 25|base pair region
P01327280A0000|30 40|chloralose
P01327280A0000|90 106|cord dorsal horn
P01327280A0000|133 134|K
P01327280A0000|126 128|pH
P01327280A0000|70 72|pH
P01327967A0668|29 32|sms
P01327967A0668|80 109|agent methylmethane sulfonate
P01327967A0668|156 167|metabolites
P01328219A1397|33 39|number
P01328219A1397|1 7|NSCL-1
P01328681A0348|1 8|Ruddell
P01328884T0000|47 56|MHC class
P01328884T0000|24 32|peptides
P01329039A0951|106 109|MCK
P01329039A0951|24 37|gene activity
P01329039A0951|115 125|E-box site
P01329039A0951|1 20|Intermediate levels
P01330309A1134|93 101|proteins
P01330309A1134|5 18|CANNTG motifs
P01330309A1134|136 144|myotubes
P01331057A0000|58 69|subunit VIb
P01331057A0000|49 53|gene
P01331086T0000|11 28|promoter elements
P01331086T0000|39 67|cytochrome c oxidase subunit
P01331501A0397|107 118|interaction
P01331501A0397|130 138|cyclin A
P01331501A0397|71 80|sequences
P01331501A0397|84 87|E1A
P01332589A0666|92 101|S. aureus
P01332589A0666|5 9|MICs
P01332589A0666|48 57|organisms
P01333035T0000|89 103|RNA polymerase
P01333035T0000|1 8|Mapping
P01333053A0110|124 139|peptide hormone
P01333053A0110|9 18|mechanism
P01333053A0110|141 145|ACTH
P01333317A1008|13 19|region
P01333317A1008|77 78|s
P01333317A1008|101 107|factor
P01334493A0289|45 48|HGF
P01334493A0289|14 18|form
P01334493A0289|57 65|affinity
P01337142A2043|134 139|WORDS
P01337142A2043|76 79|FSK
P01337142A2043|101 106|cells
P01339125A0153|134 146|bleach teeth
P01339125A0153|124 130|enamel
P01339125A0153|39 44|teeth
P01339125A0153|1 19|Laboratory studies
P01339391A0000|52 73|DNA surrounding HRAS1
P01339773A0000|78 87|diagnosis
P01339773A0000|43 49|groups
P01339773A0000|3 8|total
P01339815A1545|32 40|peak VO2
P01339815A1545|69 74|tests
P01341119A0450|6 22|research studies
P01341119A0450|49 55|tumors
P01341119A0450|102 116|others antacid
P01346534T0000|81 88|protein
P01347664A1026|60 68|CAD mRNA
P01347664A1026|88 94|mutant
P01347664A1026|50 56|levels
P01347944A0964|73 81|sequence
P01347944A0964|109 119|regulation
P01348508A0313|131 141|activities
P01348508A0313|179 188|TGM1 gene
P01348508A0313|159 169|literature
P01348508A0313|39 46|introns
P01349837T0000|91 106|gene expression
P01349837T0000|47 55|Zea mays
P01349837T0000|114 130|seed germination
P01349837T0000|1 12|cDNA clones
P01350932A1123|72 94|N-glycosylation sequon
P01350932A1123|96 107|Asn-Cys-Ser
P01350932A1123|54 64|C-terminus
P01350932A1123|118 121|Cys
P01352113A0231|72 90|NO2 concentrations
P01352113A0231|189 192|min
P01352113A0231|141 151|mg m-3 NO2
P01354506T0000|60 73|understanding
P01354506T0000|91 105|histopathology
P01354506T0000|77 89|cytogenetics
P01357528A0084|89 104|subunit protein
P01357528A0084|229 247|surface organelles
P01357528A0084|77 83|SEF-17
P01357528A0084|59 73|amino terminus
P01357528A0084|200 206|fibres
P01357528A0084|220 225|class
P01358592A0752|134 140|region
P01358592A0752|26 33|pathway
P01358880A0251|45 55|% identity
P01358880A0251|78 103|transglutaminase sequence
P01360180A0513|41 54|baculoviruses
P01360180A0513|78 84|kinase
P01360180A0513|175 183|mutation
P01360294A0000|151 159|activity
P01360294A0000|125 137|antithrombin
P01360294A0000|6 12|August
P01360294A0000|55 60|women
P01363166T0001|52 61|treatment
P01363166T0001|21 44|H2 receptor antagonists
P01370281A0461|36 49|reading frame
P01370281A0461|68 75|protein
P01371181A0688|46 51|pE194
P01371181A0688|148 160|copy numbers
P01371181A0688|53 60|pADB201
P01371181A0688|33 44|pLS1 family
P01371275T0000|60 61|H
P01371275T0000|82 89|tissues
P01371275T0000|65 71|ATPase
P01371863A0000|63 74|gene family
P01372456A0426|90 91|h
P01372456A0426|72 73|h
P01372456A0426|79 80|%
P01372456A0426|96 103|animals
P01372456A0426|116 120|area
P01372456A0426|51 52|%
P01372900A0448|111 136|alpha s1-casein variant A
P01372900A0448|36 41|exons
P01373374A0735|61 72|G-box motif
P01373374A0735|88 100|GBF3 binding
P01373374A0735|25 33|proteins
P01374392A0341|61 66|NHE-1
P01374392A0341|5 24|hydrophobicity plot
P01374688A0471|134 139|hr E.
P01374688A0471|24 29|ml/kg
P01374688A0471|59 72|% pentastarch
P01374688A0471|6 11|group
P01375913A0484|62 76|U14 snRNA gene
P01375913A0484|38 58|DNA oligonucleotides
P01377696A0000|124 157|antibody perturbation experiments
P01377696A0000|95 108|fasciculation
P01377696A0000|84 90|growth
P01377818A0468|29 40|C/EBP gamma
P01377818A0468|4 12|addition
P01378052A0594|121 124|N10
P01378052A0594|81 89|symmetry
P01378052A0594|190 194|NifA
P01378052A0594|18 25|acoXABC
P01378052A0594|133 136|ACA
P01378052A0594|108 111|GTG
P01378052A0594|9 13|acoR
P01378052A0594|103 106|N18
P01378431A0202|14 17|Hsu
P01378431A0202|63 69|Inouye
P01378431A0202|10 12|J.
P01378431A0202|5 8|Sun
P01378431A0202|71 73|M.
P01378431A0202|1 3|C.
P01378526A0535|98 104|effect
P01379150A0996|90 97|profile
P01379150A0996|149 157|patients
P01379150A0996|140 145|drugs
P01379150A0996|185 201|risk arrhythmias
P01380076A0165|111 121|components
P01380076A0165|38 44|column
P01380076A0165|51 71|paired-ion technique
P01380716A0174|92 107|calcium hydrate
P01383690A1023|46 54|affinity
P01383690A1023|127 141|ABL SH2 domain
P01384040A1043|96 107|orientation
P01384040A1043|55 62|regions
P01384229A0175|181 187|copies
P01384229A0175|108 117|sequences
P01384229A0175|199 217|herpes TK promoter
P01384229A0175|54 65|chicken ICS
P01384229A0175|32 36|role
P01384229A0175|275 279|gene
P01386210A0293|120 138|GM2 gangliosidosis
P01386210A0293|26 29|use
P01386210A0293|51 58|therapy
P01387105A0933|244 261|mouse chromosomes
P01387105A0933|112 124|cell hybrids
P01387105A0933|44 53|backcross
P01387105A0933|160 166|cyclin
P01387105A0933|66 70|mice
P01387105A0933|138 142|loci
P01389362T0000|42 57|dentin adhesive
P01389362T0000|1 10|Porcelain
P01389585A0825|40 61|Prisma Universal Bond
P01389585A0825|116 122|choice
P01392012A0228|167 171|Hays
P01392012A0228|22 33|vasopressin
P01392012A0228|98 106|Dekanski
P01392358A0389|27 44|telephone contact
P01392358A0389|48 59|home visits
P01394655A0615b|125 146|Jack bean meal urease
P01394655A0615b|66 70|urea
P01394655A0615b|32 38|amount
P01394655A0615b|103 107|tube
P01396432A0388|36 45|functions
P01396432A0388|99 109|assessment
P01396572A0320|132 139|segment
P01396572A0320|147 153|Z-form
P01396572A0320|86 99|plasmid pUC19
P01396572A0320|171 181|competitor
P01396592A1113|179 194|differentiation
P01396592A1113|5 16|experiments
P01396592A1113|118 134|SCL gene product
P01398068A0948|43 49|his175
P01398068A0948|53 59|his273
P01398068A0948|1 10|Complexes
P01398073A0986|167 175|promoter
P01398073A0986|7 14|results
P01398074A1081|143 147|role
P01398074A1081|51 62|replacement
P01398074A1081|152 161|RNase MRP
P01398104A0834|12 19|results
P01398104A0834|21 26|CBF-A
P01398104A0834|49 54|ssDNA
P01398140A0488|73 79|motifs
P01398140A0488|174 176|bp
P01398140A0488|103 105|bp
P01400217T0000|109 126|phage sensitivity
P01400217T0000|86 97|involvement
P01400217T0000|34 72|IncP alpha plasmid transfer genes traF
P01400401A0065|122 129|variety
P01400401A0065|79 81|E2
P01400401A0065|83 94|erythrocyte
P01400401A0065|48 49|M
P01400401A0065|17 39|AMP deaminase variants
P01400775A0435|60 70|salsolinol
P01400775A0435|43 56|N-methylation
P01400775A0435|7 14|results
P01403222A0391|6 13|article
P01403222A0391|86 100|blood donation
P01404401A0740|12 26|ATPase cluster
P01404401A0740|103 119|chloroplast gene
P01406630A0545|61 79|consensus sequence
P01406630A0545|160 176|binding analysis
P01406630A0545|244 252|proteins
P01406630A0545|1 10|Alignment
P01406656A1075|195 198|ras
P01406656A1075|148 154|levels
P01406656A1075|64 68|gene
P01406656A1075|100 102|kb
P01406656A1075|118 121|DNA
P01406688A0898|65 82|nonsense mutation
P01406688A0898|116 127|amino acids
P01407286A0427|120 126|traces
P01407286A0427|56 61|cells
P01407286A0427|93 98|brain
P01407286A0427|1 8|Autopsy
P01408137A0974|124 134|mRNA start
P01408137A0974|22 28|region
P01408137A0974|55 56|%
P01408137A0974|103 105|bp
P01408474A0531|42 52|indwelling
P01409643A0618|90 112|immunodeficiency virus
P01409643A0618|208 212|mass
P01409643A0618|10 32|lambda gt11 expression
P01409643A0618|172 179|protein
P01409643A0618|115 127|TATA element
P01409643A0618|220 223|kDa
P01413984A0737|302 306|time
P01413984A0737|335 349|blood pressure
P01413984A0737|113 119|apo A1
P01413984A0737|253 288|von Willebrand factor concentration
P01413984A0737|220 248|tissue plasminogen activator
P01413984A0737|79 94|HDL cholesterol
P01413984A0737|96 111|LDL cholesterol
P01413984A0737|38 56|FA supplementation
P01418272A1072|9 14|ng/mL
P01418272A1072|22 28|cutoff
P01418272A1072|34 45|sensitivity
P01418542A0000|45 48|SGA
P01418542A0000|66 76|arrhythmia
P01418860A0797|194 218|calcium channel blockade
P01418860A0797|227 231|role
P01418860A0797|57 69|potentiation
P01418860A0797|5 12|effects
P01418860A0797|16 25|diltiazem
P01420177A1065|42 47|Gly28
P01420177A1065|163 171|activity
P01420177A1065|100 115|protein kinases
P01420177A1065|84 92|residues
P01420363A0818|45 50|motif
P01420363A0818|62 77|c-Fos/c-Jun AP1
P01420363A0818|193 201|addition
P01420363A0818|250 263|consensus TRE
P01420363A0818|118 128|competitor
P01420363A0818|171 184|consensus TRE
P01420579A0292|28 30|SN
P01420579A0292|8 26|serum neutralizing
P01420579A0292|99 110|SN antibody
P01420579A0292|154 165|vaccination
P01421390T0000|211 219|leukemia
P01421390T0000|130 142|chemotherapy
P01421390T0000|83 89|factor
P01421390T0000|102 118|body irradiation
P01422265A0263|104 108|IgG1
P01422265A0263|94 102|controls
P01422265A0263|158 167|magnitude
P01422265A0263|39 54|coeliac disease
P01422265A0263|186 204|subclass responses
P01423738A0639|14 18|hand
P01423738A0639|26 38|pinealectomy
P01423738A0639|174 175|h
P01425653T0000|30 48|caffeine ingestion
P01425653T0000|72 90|oxygen consumption
P01425653T0000|20 26|levels
P01427034A0440|12 19|introns
P01427034A0440|142 155|DNA sequences
P01427034A0440|169 171|bp
P01428490A0671|13 23|prevalence
P01428490A0671|57 62|cough
P01428490A0671|159 167|children
P01428490A0671|83 92|shortness
P01428490A0671|188 192|past
P01428490A0671|139 145|asthma
P01429596A1669|104 140|18K agglutination-aggregation factor
P01429596A1669|142 149|18K-LAF
P01429714A0730|1 5|Clin
P01429740A1065|108 113|exons
P01429740A1065|81 87|domain
P01429836A0457|47 55|fidelity
P01429836A0457|59 67|kinetics
P01429836A0457|80 95|protein sorting
P01431380A0244|269 280|rickettsiae
P01431380A0244|363 378|hemolymph cells
P01431380A0244|215 219|mice
P01431380A0244|387 392|ticks
P01431380A0244|398 406|electron
P01431380A0244|18 32|field research
P01431380A0244|492 497|gland
P01431380A0244|79 83|area
P01431380A0244|501 506|ticks
P01431380A0244|351 355|JSFR
P01431380A0244|141 148|vectors
P01431380A0244|339 347|antibody
P01431809T0000|57 72|polyhedrin gene
P01431809T0000|1 20|Nucleotide sequence
P01433391A0594|120 125|value
P01433391A0594|199 203|area
P01433391A0594|80 84|area
P01433391A0594|154 161|kittens
P01433524A0788|63 66|IE1
P01433524A0788|111 121|activities
P01436261A0145|75 85|micrograms
P01436261A0145|177 189|incontinence
P01436261A0145|36 57|somatostatin analogue
P01436261A0145|207 224|calcitonin levels
P01436261A0145|153 166|disappearance
P01441120T0000|20 28|minerals
P01443047A0773|75 86|association
P01443047A0773|92 109|Id-SCL expression
P01443748A1190|31 38|atm abs
P01443748A1190|53 65|excitability
P01443748A1190|152 161|movements
P01446828A1088|135 140|NF-E1
P01446828A1088|124 129|NF-A2
P01446828A1088|8 14|region
P01446828A1088|101 104|Sp1
P01446828A1088|118 122|NF-1
P01447189A1546|41 56|serine protease
P01447189A1546|7 11|data
P01447189A1546|103 111|granules
P01448107A0361|74 89|GCN4 expression
P01448107A0361|58 70|derepression
P01448917A0775|240 248|proteins
P01448917A0775|147 170|clover mottle virus RNA
P01448917A0775|95 103|CPMV RNA
P01448917A0775|335 339|RNAs
P01448917A0775|221 224|set
P01448917A0775|186 195|CPSMV RNA
P01448917A0775|404 418|cleavage sites
P01448917A0775|131 139|sequence
P01448917A0775|374 384|polymerase
P01448917A0775|341 355|24K proteinase
P01448917A0775|275 278|58K
P01449183A0795|88 102|fluid otorrhea
P01449183A0795|36 53|transferrin assay
P01449183A0795|18 25|utility
P01450815A0337|74 80|change
P01450815A0337|178 186|decrease
P01450815A0337|5 13|addition
P01450815A0337|17 28|diatrizoate
P01452037A0000|266 281|complementation
P01452037A0000|251 261|gap operon
P01452037A0000|132 136|part
P01452037A0000|167 170|TIM
P01452037A0000|140 165|triosephosphate isomerase
P01452037A0000|100 106|kinase
P01452703A0782|165 167|ml
P01452703A0782|242 244|ml
P01452703A0782|64 68|kits
P01452703A0782|1 19|Laboratory studies
P01454819A0000|194 203|reactions
P01454819A0000|210 232|ADP-ribosylation cycle
P01454819A0000|145 155|hydrolases
P01454819A0000|157 159|EC
P01454819A0000|70 73|NAD
P01457380A0000|95 103|splicing
P01457380A0000|5 14|tramtrack
P01457380A0000|16 19|ttk
P01457695T0000b|12 32|beta 2-microglobulin
P01457695T0000b|36 48|hemodialysis
P01457695T0000b|1 8|Removal
P01459447A0484|7 16|sequences
P01459447A0484|35 40|clone
P01459885A0705|75 80|delta
P01459885A0705|111 116|alpha
P01459885A0705|143 147|beta
P01459885A0705|18 39|haloperidol treatment
P01460054A0478|11 16|ICSBP
P01460054A0478|53 64|amino acids
P01460054A0478|116 120|part
P01460772T0001|44 58|hypothyroidism
P01460772T0001|3 7|case
P01464329T0000|72 92|prophase chromosomes
P01464329T0000|53 60|regions
P01468625A0282|60 69|frequency
P01468625A0282|11 18|library
P01468625A0282|110 115|cases
P01469042A0355|45 52|species
P01469042A0355|88 118|mouse centromere satellite DNA
P01469042A0355|57 69|CENP-B boxes
P01469042A0355|7 18|CENP-B gene
P01470243A0871|151 152|%
P01470243A0871|303 310|albumin
P01470243A0871|245 254|reduction
P01470243A0871|54 55|n
P01470243A0871|115 124|mortality
P01470243A0871|87 96|reduction
P01470243A0871|187 199|independence
P01470243A0871|284 297|haemodilution
P01470243A0871|203 207|home
P01470243A0871|175 183|increase
P01470243A0871|38 40|Ht
P01471602A0362|165 173|probucol
P01471602A0362|130 137|HMG-CoA
P01471602A0362|25 33|benefits
P01471602A0362|37 59|bile acid sequestrants
P01471602A0362|139 159|reductase inhibitors
P01471602A0362|118 128|coenzyme A
P01473207A0582|72 82|hypoplasia
P01473207A0582|24 32|findings
P01474990A0000|165 172|library
P01474990A0000|79 90|Trypanosoma
P01474990A0000|197 214|epimastigote cDNA
P01474990A0000|36 39|DNA
P01476376T0000|30 36|urease
P01476376T0000|10 14|urea
P01478672A0795|45 64|alpha satellite DNA
P01478672A0795|95 103|sequence
P01480183A1689|44 59|estrogen action
P01480183A1689|76 103|lactoferrin gene expression
P01482912A0617|46 57|HL7 message
P01482912A0617|106 115|interface
P01482912A0617|93 98|rules
P01482912A0617|18 38|registration updates
P01483771A1335|26 28|NA
P01486836A0774|180 184|span
P01486836A0774|88 92|span
P01486836A0774|188 190|T3
P01486836A0774|105 125|discrimination tasks
P01486836A0774|162 164|T2
P01486836A0774|232 234|T4
P01486836A0774|136 158|visuomotor performance
P01490493A0416|75 80|lipid
P01490493A0416|6 10|part
P01490493A0416|85 104|triglyceride levels
P01493864A0619|88 97|GBR-12909
P01493864A0619|1 17|Dopamine neurons
P01496348A0000|12 24|parodontitis
P01496348A0000|70 77|mankind
P01497582A0593|90 96|mother
P01497582A0593|61 68|effects
P01497582A0593|25 34|disorders
P01497582A0593|38 47|pregnancy
P01497582A0593|16 21|group
P01499213A0185|120 124|fall
P01499213A0185|5 9|case
P01499213A0185|80 101|hyperextension injury
P01499213A0185|171 187|L2-L3 disk space
P01502157A0000|72 80|c-MYC P1
P01502157A0000|136 147|P2 activity
P01504853A0299|44 59|mating behavior
P01504853A0299|71 78|species
P01505516A0928|24 28|acid
P01505516A0928|93 102|formation
P01505516A0928|70 84|valine residue
P01506746A0476|49 53|pigs
P01511231A0085|106 114|nicotine
P01511231A0085|39 48|relapsers
P01511231A0085|118 133|placebo patches
P01512259A0867|74 88|cysteine motif
P01512259A0867|24 34|phenomenon
P01512259A0867|169 174|furin
P01512941A0000|150 154|CPFX
P01512941A0000|65 69|LVFX
P01512941A0000|191 195|NFLX
P01512941A0000|168 172|OFLX
P01512941A0000|119 129|comparison
P01513213A0231|27 33|accord
P01513213A0231|127 132|women
P01513213A0231|114 123|exception
P01513213A0231|155 163|HIP data
P01513213A0231|1 18|Model predictions
P01516829A0113|28 32|SNF2
P01516829A0113|34 38|SNF5
P01518396T0000|1 10|George T.
P01518849A0165|26 37|destruction
P01518849A0165|8 11|PR3
P01518849A0165|54 68|microorganisms
P01518849A0165|1 3|NE
P01522699A0092|42 54|menu weights
P01522699A0092|34 40|recall
P01524549A0241|88 98|occurrence
P01524549A0241|108 115|puberty
P01524549A0241|67 74|stature
P01524549A0241|136 149|GH deficiency
P01525966T0000|29 35|stones
P01526690T0000|42 53|lymphocytes
P01529530T0000|107 134|ISGF3 transcription complex
P01529530T0000|26 41|gene expression
P01529530T0000|43 51|evidence
P01531214A0885|74 78|g/kg
P01531214A0885|11 15|LD50
P01531214A0885|39 43|g/kg
P01531214A0885|87 101|administration
P01532229A1264|12 17|study
P01532229A1264|27 35|evidence
P01532229A1264|82 95|muscle factor
P01532229A1264|174 184|expression
P01532229A1264|103 108|MEF-2
P01532914A0067|123 131|strategy
P01532914A0067|144 151|studies
P01532914A0067|1 8|Expense
P01535242A0557|11 17|FDC-P1
P01535242A0557|43 48|M-CSF
P01535242A0557|80 91|degradation
P01535242A0557|18 27|MAC cells
P01536575A1213|31 39|presence
P01536575A1213|149 158|induction
P01536575A1213|244 269|detoxification/activation
P01536575A1213|15 22|finding
P01536575A1213|79 85|dioxin
P01536575A1213|162 175|transcription
P01536575A1213|97 104|element
P01537845A0571|131 141|cell cycle
P01537845A0571|25 37|c-myb clones
P01537845A0571|64 88|c-myb gene transcription
P01538403A1058|57 80|transcription complexes
P01538403A1058|213 234|H5 promoter mutations
P01538403A1058|33 37|eUSF
P01538403A1058|154 158|eUSF
P01541556A1040|15 24|palmitate
P01541556A1040|118 132|Cys-22 residue
P01542565A0220|8 27|tobacco L12 protein
P01542565A0220|34 55|% amino acid identity
P01542667A0125|126 134|activity
P01542667A0125|203 207|gene
P01542667A0125|19 28|IFN-gamma
P01542730A1982|329 334|WORDS
P01542730A1982|219 231|dual-chamber
P01542730A1982|116 124|AV block
P01542730A1982|45 51|pacing
P01542730A1982|277 283|number
P01542730A1982|101 112|development
P01542730A1982|239 246|devices
P01544854A0699|58 67|protector
P01544854A0699|35 44|WR-168643
P01544928A1252|27 39|DNA sequence
P01544928A1252|99 110|transcripts
P01544928A1252|1 11|Comparison
P01545787A0345|106 112|NFAT-1
P01545787A0345|38 43|sites
P01545787A0345|86 91|DNase
P01545792A0492|88 98|regulation
P01545792A0492|50 58|elements
P01545806T0000|90 101|REC107/MER2
P01545806T0000|23 31|analysis
P01546522A0000|203 211|lymphoma
P01546522A0000|80 85|basis
P01546522A0000|98 105|picture
P01546522A0000|154 157|man
P01546522A0000|119 136|resonance imaging
P01547957A1083|329 338|substrate
P01547957A1083|211 217|genome
P01547957A1083|296 299|PCR
P01547957A1083|157 164|portion
P01547957A1083|77 88|aa sequence
P01547957A1083|168 172|CYP1
P01547957A1083|139 145|region
P01548891A0635|73 90|thyroid carcinoma
P01548891A0635|5 10|level
P01548891A0635|136 153|thyroid carcinoma
P01549123A0480|107 111|bZIP
P01549123A0480|93 99|family
P01549123A0480|70 77|protein
P01549129A0356|88 100|interactions
P01549129A0356|126 137|functioning
P01549465A0122|88 94|region
P01549465A0122|10 37|transactivation experiments
P01549465A0122|96 99|Gly
P01549465A0122|152 166|discrimination
P01551568A1476|63 70|segment
P01551568A1476|38 41|ts8
P01551910A0313|92 103|interaction
P01551910A0313|1 21|Competition analysis
P01552052A0139|151 163|cyclosporine
P01552052A0139|82 98|serum creatinine
P01552052A0139|116 125|psoriasis
P01552052A0139|1 10|OBJECTIVE
P01552052A0139|102 110|patients
P01552662A0398|29 31|BF
P01552662A0398|33 38|probe
P01553407T0000|60 75|risk assessment
P01553407T0000|1 9|Problems
P01555556A0565|77 79|SD
P01555556A0565|50 60|control Wi
P01555556A0565|85 91|W.kg-1
P01556111A0241|16 23|regions
P01557411A1282|80 85|genes
P01557411A1282|17 25|D1A gene
P01559209T0000|18 30|CNS students
P01560774A0885|74 83|fliA gene
P01560774A0885|19 27|fragment
P01563343A0548|96 103|plasmid
P01563343A0548|116 123|control
P01564653A0307|40 44|lens
P01564653A0307|32 36|type
P01565882A0737|121 137|perfusion defect
P01565882A0737|213 222|subgroups
P01565882A0737|297 298|%
P01565882A0737|113 117|Type
P01565882A0737|291 293|Ib
P01565882A0737|187 191|Type
P01565882A0737|231 247|perfusion defect
P01565882A0737|175 180|image
P01565882A0737|275 276|%
P01567649A0139|133 143|evaluation
P01567649A0139|21 28|infants
P01567649A0139|153 160|infancy
P01569015A0120|131 140|direction
P01569015A0120|77 81|ORFs
P01569015A0120|17 22|FRAME
P01569344A0404|9 15|cities
P01569344A0404|173 182|Baltimore
P01569344A0404|114 134|HTLV-I/II prevalence
P01569584A0672|134 139|6F6.2
P01569584A0672|168 173|genes
P01569584A0672|84 99|m6F6 cDNA clone
P01569584A0672|119 124|6F6.3
P01572549A0000|225 235|components
P01572549A0000|198 221|growth factor receptors
P01572549A0000|66 77|cell growth
P01572549A0000|55 62|control
P01572549A0000|1 25|Protein tyrosine kinases
P01577056A0178|120 122|mg
P01577056A0178|144 151|placebo
P01577056A0178|52 60|subjects
P01577056A0178|85 92|mg.kg-1
P01577056A0178|41 46|study
P01577056A0178|97 100|day
P01577056A0178|70 82|theophylline
P01577819A0709|13 34|PRP-precursor alleles
P01577819A0709|70 76|number
P01579537A0000|73 83|neurotoxin
P01579537A0000|16 21|years
P01581409A0398|104 114|comparison
P01581409A0398|146 150|test
P01581409A0398|53 73|Pharmacia CAP System
P01581409A0398|17 28|specificity
P01581965A0388|105 143|breakpoint cluster region gene product
P01581965A0388|26 33|protein
P01581965A0388|145 155|n-chimerin
P01581965A0388|39 45|domain
P01582413A0759|60 71|protein E12
P01582413A0759|132 147|transactivation
P01582413A0759|108 111|DNA
P01582413A0759|17 22|Myf-5
P01583819A0377|37 44|filters
P01583819A0377|1 4|SEA
P01585014A0000|360 371|Merino ewes
P01585014A0000|127 153|progestagen sponge removal
P01585014A0000|54 67|gonadotrophin
P01585014A0000|253 259|autumn
P01585014A0000|119 120|h
P01585014A0000|166 175|treatment
P01585014A0000|237 248|lupin grain
P01585014A0000|328 332|time
P01585014A0000|28 35|effects
P01585014A0000|156 162|season
P01585014A0000|465 496|mg follicle stimulating hormone
P01585014A0000|336 345|ovulation
P01585014A0000|200 206|effect
P01585014A0000|274 278|days
P01587267A1144|63 68|X-ray
P01587267A1144|130 140|expression
P01587267A1144|5 18|sequence data
P01587267A1144|103 109|enzyme
P01588270A1029|56 59|end
P01588270A1029|67 72|study
P01588270A1029|3 12|reduction
P01588270A1029|136 137|P
P01588913A0000|43 52|dnaA gene
P01588913A0000|3 7|gene
P01588963A1153|13 23|antibodies
P01588963A1153|52 62|conditions
P01589576A0170|165 167|ps
P01589576A0170|172 174|T3
P01589576A0170|21 45|chlorophyll fluorescence
P01589576A0170|101 111|components
P01589576A0170|117 131|time constants
P01594554A0845|58 76|trypsin inhibitors
P01594554A0845|39 44|roles
P01594554A0845|154 162|function
P01597170A0000|57 62|CoCl2
P01597170A0000|93 95|Cr
P01597170A0000|190 203|control group
P01597170A0000|222 231|days/week
P01597170A0000|79 88|mg/m3 Cr3
P01597170A0000|7 14|rabbits
P01597170A0000|140 149|mg/m3 Co2
P01597170A0000|239 245|hr/day
P01597462A0457|52 56|gene
P01601181A0842|125 134|germ band
P01601181A0842|59 64|onset
P01601181A0842|99 107|mesoderm
P01603088A1121|79 89|activation
P01603088A1121|128 134|manner
P01603088A1121|51 53|TR
P01607223A0000|208 219|vasculature
P01607223A0000|82 87|pulse
P01607223A0000|115 122|release
P01611699A0000|77 104|Albizzia julibrissin DURAZZ
P01611699A0000|64 73|stem bark
P01613640A0158|44 54|poloxamine
P01613640A0158|77 86|poloxamer
P01613640A0158|5 22|coating materials
P01615182A0206|120 122|mg
P01615182A0206|183 188|amoxy
P01615182A0206|128 139|bromhexeine
P01615182A0206|110 115|amoxy
P01615182A0206|49 67|sputum amoxycillin
P01615182A0206|34 45|improvement
P01615493A0975|97 114|thrombin activity
P01615493A0975|1 11|Argatroban
P01615493A0975|118 123|sites
P01617242T0000|21 35|growth factors
P01617242T0000|1 16|FDA regulations
P01617801A0088|132 134|mg
P01617801A0088|67 73|supine
P01617801A0088|1 7|DESIGN
P01618243T0000|44 54|volunteers
P01619114A0383|15 20|study
P01619114A0383|107 110|MSP
P01619114A0383|84 105|Mini Speech Processor
P01620118A0470|126 148|immunodeficiency virus
P01620118A0470|36 43|ability
P01620118A0470|223 228|cells
P01620118A0470|102 112|activation
P01620610A1070|150 159|mutations
P01620610A1070|218 231|MTI subregion
P01620610A1070|4 14|conclusion
P01620610A1070|186 195|sequences
P01621584A0183|165 173|IOP rise
P01621584A0183|83 90|rabbits
P01621584A0183|140 144|mmHg
P01621584A0183|1 7|UF-021
P01624425A0907|121 130|azido-ATP
P01624425A0907|79 100|consensus amino acids
P01625527A0000|270 271|n
P01625527A0000|146 163|treatment regimen
P01625527A0000|53 66|control group
P01625527A0000|85 90|group
P01625527A0000|229 230|n
P01625527A0000|202 227|maintenance haemodialysis
P01625527A0000|68 69|n
P01626430A1112|41 45|SNF2
P01626430A1112|113 129|Drosophila genes
P01626430A1112|103 108|yeast
P01626631A0557|199 204|level
P01626631A0557|8 21|Rett syndrome
P01626631A0557|55 67|disturbances
P01627828A0475|60 70|SmN probes
P01627828A0475|79 84|bands
P01627828A0475|33 41|blotting
P01628201A0824|44 48|year
P01628201A0824|82 89|minimum
P01628201A0824|1 15|Incidence rate
P01628904A0386|62 64|kb
P01628904A0386|52 60|kilobase
P01630454A0635|14 19|dA-dT
P01630454A0635|21 27|region
P01630454A0635|68 90|Act1 promoter activity
P01630569A0605|10 24|amphotericin B
P01630569A0605|53 58|tumor
P01633435A0743|106 111|MEF-2
P01633435A0743|113 119|Buskin
P01633435A0743|98 104|factor
P01633435A0743|139 146|Gossett
P01634308A0191|1 28|Cardiovascular risk factors
P01634464A0163|79 104|penicillin administration
P01634464A0163|67 75|reaction
P01634464A0163|32 52|factor VII inhibitor
P01636339A0200|107 115|crystals
P01636339A0200|140 149|fragments
P01636339A0200|154 159|fungi
P01636339A0200|85 90|mucus
P01637758A0532|147 158|labour ward
P01637758A0532|218 219|P
P01637758A0532|80 90|dilatation
P01637758A0532|198 202|% CI
P01637758A0532|37 42|women
P01637758A0532|4 12|addition
P01639724A0452|73 84|Nordette-28
P01639724A0452|57 71|contraceptives
P01639724A0452|25 30|women
P01639724A0452|3 16|control group
P01641628A0869|121 127|points
P01641628A0869|131 139|research
P01641628A0869|82 88|groups
P01641628A0869|5 15|modalities
P01643943A0300|47 51|67Ga
P01644796A0374|105 110|cells
P01644796A0374|89 95|medium
P01644821A1259|215 222|regions
P01644821A1259|230 241|PSG1-I gene
P01644821A1259|69 81|CAT activity
P01644821A1259|259 276|butyrate response
P01645902A1462|150 155|genes
P01645902A1462|92 94|gH
P01645902A1462|217 225|activity
P01645902A1462|50 55|locus
P01645902A1462|229 231|TK
P01645902A1462|203 213|expression
P01645902A1462|170 182|syn mutation
P01646157A0414|194 215|alpha-galactosidase A
P01646157A0414|162 163|%
P01646157A0414|217 228|alpha-Gal A
P01646157A0414|34 60|alpha-GalNAc cDNA sequence
P01646753A0336|135 138|N2O
P01646753A0336|199 206|N2O/N2O
P01646753A0336|5 11|reason
P01646753A0336|48 65|hydroxyl radicals
P01647656A0000|208 221|regurgitation
P01647656A0000|111 119|patients
P01647656A0000|80 82|LV
P01647656A0000|84 92|function
P01648142A1170|121 128|CAV arm
P01648142A1170|130 131|P
P01648142A1170|163 169|PE arm
P01648142A1170|39 47|survival
P01648142A1170|171 172|P
P01649173A0160|128 152|transcription start site
P01649173A0160|4 12|addition
P01649173A0160|201 212|nucleotides
P01649318A1222|106 112|EBNA-2
P01649318A1222|92 100|evidence
P01649318A1222|145 155|cell genes
P01649835A0822|130 132|PK
P01649835A0822|172 180|affinity
P01649835A0822|185 193|Ro5-4864
P01649835A0822|117 125|affinity
P01649835A0822|50 61|COS-7 cells
P01650557T0000|73 104|cytomegalovirus antibody status
P01650557T0000|27 51|latex agglutination test
P01650557T0000|116 133|transplant donors
P01651918A0000|159 169|fructose-2
P01651918A0000|48 62|cDNA fragments
P01651918A0000|152 158|kinase
P01652515A0379|166 177|neostriatum
P01652515A0379|42 64|avoidance conditioning
P01652515A0379|4 12|contrast
P01652515A0379|137 139|DA
P01653173A0619|6 16|repression
P01653173A0619|218 225|extract
P01653173A0619|101 123|P105 promoter TATA box
P01653173A0619|68 72|site
P01653173A0619|239 248|formation
P01653238A1062|151 169|consensus sequence
P01653238A1062|210 218|TGF-beta
P01653238A1062|53 56|TPA
P01653238A1062|233 240|element
P01653238A1062|119 144|transcription factor AP-1
P01653918A0286|67 73|cornea
P01653918A0286|98 106|strength
P01655126T0000|30 41|measurement
P01655126T0000|78 85|tissues
P01655126T0000|110 119|tropolone
P01655126T0000|1 21|Extraction procedure
P01656220T0000|94 118|receptor tyrosine kinase
P01656220T0000|1 4|axl
P01656235A0946|76 82|region
P01656235A0946|55 63|analysis
P01657246A0325|92 95|Met
P01657415A0837|73 81|location
P01657415A0837|85 94|K. lactis
P01657969A1420|182 200|calmodulin binding
P01657969A1420|55 67|interactions
P01657969A1420|155 161|enzyme
P01658356T0000|120 130|activities
P01658356T0000|76 88|env elements
P01658356T0000|1 14|Recombination
P01658468A0123|179 184|sites
P01658468A0123|117 125|attempts
P01658468A0123|16 22|months
P01658468A0123|85 93|hamsters
P01659685T0000|54 61|regions
P01659685T0000|17 26|promoters
P01660925T0000|25 49|Dictyostelium discoideum
P01660925T0000|157 164|regions
P01662609A0398|44 55|amino acids
P01662609A0398|57 64|M.HgiCI
P01662609A0398|24 36|polypeptides
P01662807A1182|31 42|TR promoter
P01662807A1182|97 106|infection
P01664192A1577|64 74|vecuronium
P01664192A1577|51 60|ED90 dose
P01671675A0483|60 71|cDNA insert
P01671675A0483|148 165|sequence analysis
P01671675A0483|198 211|cDNA sequence
P01671675A0483|237 252|CAD polypeptide
P01671675A0483|85 92|pCAD142
P01673220A0578|15 24|isolation
P01673220A0578|77 79|Sn
P01674242A0358|420 431|ticlopidine
P01674242A0358|244 250|T-3262
P01674242A0358|292 303|propranolol
P01674242A0358|532 550|half-life increase
P01674242A0358|316 325|diltiazem
P01674242A0358|433 445|idrocilamide
P01674242A0358|506 516|interferon
P01674242A0358|305 314|verapamil
P01674242A0358|387 393|agents
P01674242A0358|262 266|acid
P01674242A0358|462 472|disulfiram
P01674242A0358|152 165|roxithromycin
P01674242A0358|192 202|pefloxacin
P01674242A0358|128 149|triacetyloleandomycin
P01674242A0358|5 14|clearance
P01674242A0358|474 483|influenza
P01674242A0358|204 215|norfloxacin
P01674662A0000|83 84|n
P01674662A0000|258 265|factors
P01674662A0000|165 170|study
P01674662A0000|192 203|progression
P01674662A0000|39 53|heroin addicts
P01674662A0000|207 211|AIDS
P01674817T0000|126 132|domain
P01674817T0000|18 29|yeast RNA14
P01674817T0000|34 45|RNA15 genes
P01674817T0000|85 102|sequence analysis
P01675424A0991|124 143|pyridine nucleotide
P01675424A0991|66 76|comparison
P01675424A0991|19 29|difference
P01675424A0991|152 156|site
P01675763A1389|89 94|entry
P01675763A1389|80 85|liter
P01678392A0648|120 131|cmH2O l-1 s
P01678392A0648|41 47|change
P01678392A0648|83 94|variability
P01679124A1368|91 101|hippocampi
P01679124A1368|179 197|dorsal hippocampus
P01679124A1368|114 121|animals
P01679124A1368|51 64|ChAT activity
P01679124A1368|72 78|dorsal
P01679124A1368|142 148|levels
P01679124A1368|168 170|NE
P01681075A0429|57 77|pimobendan injection
P01681075A0429|83 93|myocardium
P01681075A0429|173 179|energy
P01681075A0429|184 207|carbohydrate metabolism
P01681075A0429|50 53|min
P01682509A0539|106 113|HIV LTR
P01682509A0539|65 69|IE55
P01682509A0539|17 25|evidence
P01684791A0000|16 23|element
P01684791A0000|34 61|glucocorticoid inducibility
P01687050T0000|12 17|value
P01687050T0000|35 57|fluid immunoglobulin G
P01688972A0803|11 13|VT
P01690728A1166|122 149|Northern blot hybridization
P01690728A1166|97 108|fibroblasts
P01690728A1166|5 13|presence
P01690728A1166|68 82|kilobase pairs
P01691184A0995|130 145|disulfide bonds
P01691184A0995|99 116|cleavage products
P01691184A0995|153 170|precursor protein
P01692837A0390|128 132|mRNA
P01692837A0390|96 110|kilobase pairs
P01692837A0390|154 163|kilobases
P01694009A0112|94 109|signal sequence
P01694009A0112|23 27|exon
P01694009A0112|68 74|region
P01694280A0000|88 96|cisterns
P01694280A0000|48 59|observation
P01695098A1116|1 10|Serum IgG
P01695314A0762|24 38|glucose levels
P01695322A0000|90 95|mouse
P01695322A0000|29 37|oncogene
P01695322A0000|57 66|insertion
P01695322A0000|1 6|Wnt-1
P01695905A0480|107 113|muscle
P01695905A0480|36 42|levels
P01695905A0480|1 11|GLUT5 mRNA
P01697611A0738|25 31|tumors
P01697928A1214|134 150|response element
P01697928A1214|228 238|alpha/beta
P01697928A1214|58 64|region
P01697928A1214|68 73|Ly-6E
P01700272A0838|89 97|residues
P01700272A0838|20 26|B4 RNA
P01700272A0838|1 16|Polyadenylation
P01702361A0621|11 18|studies
P01702361A0621|22 28|agents
P01702361A0621|101 124|angiogenesis inhibitors
P01702426A1006|146 154|fragment
P01702426A1006|178 187|DNA clone
P01702426A1006|53 55|kb
P01702972A0613|9 27|cDNA hybridization
P01702972A0613|112 117|bands
P01702972A0613|80 91|G0S19 genes
P01702972A0613|155 165|G0S30 cDNA
P01703632T0000|108 116|proteins
P01703632T0000|16 26|suppressor
P01703632T0000|68 75|regions
P01707659A0458|108 112|Ch28
P01707659A0458|71 78|HLA-5.4
P01708098A0922|73 101|alpha promoter DNA sequences
P01708098A0922|21 47|complex DNA binding assays
P01708098A0922|207 215|receptor
P01708774A0203|29 42|AP-1 activity
P01708774A0203|71 86|promoter region
P01709933T0000|79 82|pS1
P01709933T0000|66 77|polypeptide
P01709933T0000|55 59|gene
P01710768A1172|31 40|existence
P01710768A1172|74 76|kb
P01710768A1172|182 186|gene
P01710768A1172|128 138|expression
P01710768A1172|201 217|gamma interferon
P01710985A0315|1 5|Chem
P01711041A0962|73 83|beta-chain
P01711041A0962|5 19|C5 alpha-chain
P01711041A0962|102 111|kilobases
P01712296A0157|91 113|amino acid differences
P01712296A0157|35 40|genes
P01713213A0488|147 172|glutathione S-transferase
P01713213A0488|174 177|GST
P01713213A0488|117 131|fusion product
P01714358A0990|8 23|kDa polypeptide
P01714358A0990|98 107|gamma 32P
P01714902A0221|46 97|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01714902A0221|156 180|interleukin-2 production
P01714902A0221|187 202|TCR stimulation
P01715975A0885|10 17|effects
P01715975A0885|21 25|CYP1
P01716629A0000|18 29|cDNA clones
P01717833A1223|124 136|CREB protein
P01717833A1223|49 52|CRE
P01717925A0477|89 108|sequence similarity
P01717925A0477|19 39|nucleotide sequences
P01717925A0477|69 72|DNA
P01718043A0384|194 195|%
P01718043A0384|148 178|erythrocyte sedimentation rate
P01718043A0384|95 96|%
P01718043A0384|59 71|PMN elastase
P01718043A0384|18 31|osteomyelitis
P01719684A0494|62 71|receptors
P01719684A0494|82 90|prostate
P01719684A0494|33 41|increase
P01720843A1506|123 129|effect
P01720843A1506|7 14|results
P01720843A1506|84 101|enzyme inhibitors
P01721884A0962|89 103|ribonuclease H
P01721884A0962|54 60|region
P01721884A0962|290 297|helices
P01721884A0962|153 159|region
P01721884A0962|105 112|RNase H
P01721884A0962|313 338|RNase H crystal structure
P01721884A0962|304 305|D
P01722479A0302|90 91|%
P01722479A0302|64 65|%
P01722479A0302|17 31|concentrations
P01723962A0165|124 129|Na-Tc
P01723962A0165|5 13|activity
P01723962A0165|17 29|serum lipase
P01723962A0165|68 69|h
P01725547A0354|73 74|%
P01725547A0354|76 77|p
P01725547A0354|37 45|increase
P01725547A0354|1 10|Diltiazem
P01726211A0502|56 62|vessel
P01726211A0502|76 83|factors
P01726211A0502|102 108|action
P01727488A1146|43 54|stimulation
P01727488A1146|19 24|cDNAs
P01730412T0000|46 51|c-Myc
P01730412T0000|17 24|domains
P01731107A0928|29 34|bases
P01731107A0928|129 140|maintenance
P01731107A0928|168 177|structure
P01731107A0928|1 14|Substitutions
P01731933T0000b|8 35|coordination domain mutants
P01731933T0000b|1 3|Zn
P01732033A0000|146 151|model
P01732033A0000|82 91|childhood
P01732033A0000|54 66|brain injury
P01732033A0000|34 44|management
P01732752A0156|27 34|Abelson
P01732752A0156|87 94|LT mRNA
P01733358A0240|75 93|cystadenocarcinoma
P01733358A0240|47 53|groups
P01733358A0240|58 69|cystadenoma
P01733358A0240|158 162|cyst
P01734283A0817|61 71|HeLa cells
P01734283A0817|159 164|RAP30
P01734283A0817|33 46|RAP74 protein
P01735347A0482|62 71|treatment
P01735347A0482|24 30|insult
P01735347A0482|101 114|plasma lipase
P01735347A0482|153 162|extension
P01735447A0833|124 135|kDa pro-PrB
P01735447A0833|108 111|PrB
P01735447A0833|155 164|reticulum
P01736093A0731|161 174|constructions
P01736093A0731|86 94|promoter
P01736093A0731|137 140|HSE
P01736844T0000|208 216|epilepsy
P01736844T0000|96 110|androgen index
P01736844T0000|1 13|Testosterone
P01736844T0000|187 195|function
P01737789A0800|26 36|breakpoint
P01737789A0800|111 145|down-stream alpha-delta breakpoint
P01738653T0014|10 15|bones
P01739439A0257|75 82|complex
P01739439A0257|145 152|muscles
P01739439A0257|163 175|control mice
P01739439A0257|114 127|abnormalities
P01739439A0257|1 8|Complex
P01740121A0136|18 25|problem
P01740437A0851|146 152|domain
P01740437A0851|38 60|liver HSPG preparation
P01740437A0851|18 30|core protein
P01740682A0703|91 101|leukopenia
P01740682A0703|246 253|courses
P01740682A0703|81 88|courses
P01740682A0703|51 52|%
P01740682A0703|226 234|patients
P01740682A0703|41 47|emesis
P01740682A0703|197 213|thrombocytopenia
P01740682A0703|237 238|%
P01740682A0703|137 142|grade
P01742341A0499|76 90|transportation
P01742341A0499|116 127|Beagle dogs
P01742879A0471|135 149|water drinking
P01742879A0471|42 53|stimulation
P01742879A0471|71 81|inhibition
P01742879A0471|85 93|drinking
P01744042A1355|89 100|Luria broth
P01744042A1355|113 122|% glucose
P01744042A1355|65 70|phase
P01747972T0000|46 63|artery dissection
P01748194A0767|41 53|hemisections
P01748194A0767|162 163|N
P01748292A0000|30 34|gene
P01748292A0000|110 112|cv
P01748292A0000|48 71|G protein alpha subunit
P01751163A0000|79 91|implantation
P01751163A0000|27 36|potential
P01751163A0000|52 65|complications
P01751163A0000|116 122|device
P01751970A0209|1 20|Amino acid residues
P01752792A0000|164 175|albino rats
P01752792A0000|26 34|evidence
P01752792A0000|96 103|stimuli
P01752792A0000|141 147|cortex
P01754381A0000|15 19|step
P01754381A0000|83 95|trypanosomes
P01754381A0000|140 150|expression
P01754381A0000|64 79|DNA polymerases
P01754381A0000|32 48|characterization
P01754381A0000|220 240|DNA polymerase alpha
P01756539A0354|11 23|hypertension
P01756539A0354|83 92|condition
P01758750A0000|89 96|variety
P01758750A0000|64 68|tube
P01758750A0000|1 16|Airway pressure
P01759282A0000|150 162|biomechanics
P01759282A0000|58 64|object
P01759282A0000|138 146|position
P01759282A0000|1 7|Issues
P01761736A0158|241 247|volume
P01761736A0158|180 185|hours
P01761736A0158|124 145|elimination half-life
P01761736A0158|80 86|mL/min
P01761736A0158|207 217|antipyrine
P01761736A0158|187 188|P
P01762914A1218|89 91|kb
P01762914A1218|102 124|translation start site
P01764899A0399|73 90|caries prevalence
P01764899A0399|5 10|model
P01764899A0399|138 150|cavity level
P01765266A0000|151 158|embryos
P01765266A0000|109 115|oocyte
P01765266A0000|42 67|elongation factor 1-alpha
P01765266A0000|96 97|O
P01765375A0290|211 216|chain
P01765375A0290|88 99|transcripts
P01765375A0290|196 204|clathrin
P01765375A0290|39 48|rat cells
P01765375A0290|168 171|kDa
P01765407A0866|146 165|mmol/mol creatinine
P01765407A0866|93 105|postexposure
P01765407A0866|114 123|excretion
P01766876A0000|60 62|mu
P01766876A0000|132 146|point mutation
P01766876A0000|96 109|co-conversion
P01766876A0000|3 9|method
P01766876A0000|187 205|replacement vector
P01767060A0000|268 272|neck
P01767060A0000|147 156|responses
P01767060A0000|43 63|c-DDP administration
P01767060A0000|6 11|study
P01767060A0000|169 177|survival
P01767060A0000|259 263|head
P01767899A0136|26 35|depletion
P01767899A0136|163 170|minutes
P01767899A0136|39 55|serum fibrinogen
P01769189A0000|242 247|women
P01769189A0000|297 303|VO2max
P01769189A0000|249 251|UT
P01769189A0000|113 117|body
P01769189A0000|80 82|RU
P01769189A0000|253 254|n
P01769189A0000|133 150|training distance
P01769189A0000|130 131|%
P01769189A0000|313 326|ml kg-1 min-1
P01769189A0000|203 207|mean
P01769189A0000|71 78|runners
P01770651T0001|90 101|measurement
P01770651T0001|62 85|radioimmunoassay system
P01770651T0001|40 60|equilibrium dialysis
P01771593A1232|28 33|weeks
P01771593A1232|53 62|genitalia
P01772201T0001|15 22|patient
P01772201T0001|28 32|work
P01774062A0257|15 21|A148A7
P01774062A0257|10 13|YAC
P01774062A0257|77 82|locus
P01774062A0257|67 74|Y3/Ring
P01774093T0000|49 80|Chlamydia trachomatis infection
P01774093T0000|84 93|pregnancy
P01776306A0572|25 27|VT
P01777841A0744|122 130|neonates
P01777841A0744|111 117|adults
P01777841A0744|64 71|effects
P01779433A0694|60 68|junction
P01779433A0694|243 251|position
P01779433A0694|89 96|block I
P01779433A0694|333 336|end
P01779433A0694|217 220|Alu
P01779433A0694|116 117|Y
P01779433A0694|198 215|Alu family repeat
P01779433A0694|101 109|homology
P01780235A0094|107 118|transfusion
P01780235A0094|49 60|transfusion
P01782424A0278|5 14|existence
P01782424A0278|18 42|threshold concentrations
P01782982A0155|30 43|baseline FEV1
P01782982A0155|113 116|AMP
P01782982A0155|87 93|effect
P01783375A1066|134 159|translocation breakpoints
P01783375A1066|57 61|gene
P01783375A1066|5 12|mapping
P01785749A0695|60 68|children
P01785749A0695|85 91|weight
P01787085A0331|14 25|experiments
P01791363A0208|44 52|patients
P01791363A0208|82 89|sutures
P01792580A0198|62 68|number
P01792580A0198|160 170|percentage
P01792580A0198|179 191|blood donors
P01792580A0198|7 19|blood donors
P01792580A0198|114 120|donors
P01797459A0103|53 58|fluid
P01798407A1011|45 53|patients
P01798407A1011|134 138|lobe
P01798407A1011|23 36|abnormalities
P01798407A1011|5 13|presence
P01806314A0322|91 99|antibody
P01806314A0322|108 120|muscle actin
P01808136T0000|5 12|effects
P01808136T0000|34 56|coagulation factor XII
P01808602A0000|104 109|serum
P01808602A0000|12 20|patients
P01808602A0000|130 139|excretion
P01808602A0000|115 119|acid
P01809854A0106|77 97|consensus statements
P01809854A0106|49 64|research design
P01810154A0491|11 19|children
P01811948A0289|194 196|bp
P01811948A0289|95 97|bp
P01811948A0289|174 185|cis-element
P01811948A0289|16 21|study
P01811948A0289|205 207|bp
P01812690A0475|4 8|case
P01816655T0000|15 25|literature
P01816655T0000|60 64|cyst
P01816655T0000|1 7|Review
P01822581A0533|8 17|instances
P01822581A0533|86 93|reading
P01823520A0183|108 125|haematocrit value
P01823520A0183|1 13|Measurements
P01824713A0964|79 84|c-jun
P01824713A0964|110 121|stimulation
P01824713A0964|102 106|lack
P01825027T0000|66 72|member
P01825027T0000|1 5|PAS1
P01825027T0000|103 110|ATPases
P01826043A0431|107 141|signal transducing protein kinases
P01826043A0431|53 63|rsk-kinase
P01826043A0431|175 190|protein kinases
P01826043A0431|258 273|protein kinases
P01827203A0136|22 43|transcription factors
P01827203A0136|68 71|DNA
P01829060A0649|92 94|ED
P01829060A0649|80 90|nifedipine
P01829060A0649|34 39|mg/kg
P01830114A1587|94 107|amplification
P01830114A1587|162 169|repeats
P01830114A1587|54 60|levels
P01830114A1587|136 145|integrity
P01832019A0265|103 108|weeks
P01832152A0902|55 59|ORF1
P01833185A0547|104 115|replacement
P01833185A0547|192 206|uncoordination
P01833185A0547|57 70|fission yeast
P01833185A0547|5 23|Thr161Val mutation
P01833185A0547|168 183|phosphorylation
P01833716A0990|62 76|transformation
P01833716A0990|23 33|expression
P01837842A1410|72 91|gel shift complexes
P01837842A1410|1 5|CREB
P01840513A1019|211 215|acid
P01840513A1019|94 100|region
P01840513A1019|76 78|bp
P01840513A1019|223 235|8-bromo-cAMP
P01840513A1019|34 44|SL-2 cells
P01840608A0823|5 15|N-terminus
P01840608A0823|64 68|nifA
P01840902A1089|148 156|monocots
P01840902A1089|114 133|transport machinery
P01840902A1089|69 75|plants
P01842867A0696|36 56|regeneration ability
P01842867A0696|98 104|mucosa
P01844878A0000|131 135|pool
P01844878A0000|3 9|vector
P01844878A0000|50 77|neomycin phosphotransferase
P01845829A0158|144 155|brain cells
P01845829A0158|32 40|sequence
P01845899A0000|91 96|Rep40
P01845899A0000|73 78|Rep68
P01845899A0000|56 64|proteins
P01845899A0000|22 27|virus
P01845899A0000|80 85|Rep52
P01846489A1119|41 56|protease domain
P01846803A0688|60 63|Tyr
P01846803A0688|165 181|ATP binding site
P01846803A0688|27 42|phosphorylation
P01846803A0688|189 195|kinase
P01846803A0688|118 126|location
P01847665A1079|134 139|genes
P01847665A1079|145 155|expression
P01847665A1079|52 57|genes
P01847665A1079|5 13|findings
P01847665A1079|115 122|concert
P01848871A0392|195 207|prolongation
P01848871A0392|125 141|amplitude signal
P01848871A0392|23 33|hypothesis
P01848871A0392|39 53|sodium channel
P01848871A0392|251 258|slowing
P01848871A0392|274 285|tachycardia
P01849675A0167|62 74|DNA sequence
P01849675A0167|78 80|KV
P01849675A0167|100 102|bp
P01850096A0662|47 50|E12
P01850096A0662|38 42|MyoD
P01850096A0662|155 180|alpha-actin transcription
P01850096A0662|17 25|myogenin
P01850127A0000|132 152|polypyrimidine tract
P01850127A0000|94 101|binding
P01850127A0000|23 31|U2 snRNP
P01851386T0092|13 35|Lung Cancer Task Force
P01851756A0743|1 5|Biol
P01851876A0129|6 13|element
P01852603A0000|120 129|radiation
P01852603A0000|104 106|UV
P01852603A0000|5 9|rad9
P01854339A0221|28 47|sequence similarity
P01854339A0221|145 155|expression
P01854339A0221|68 87|consensus promoters
P01856021A0577|150 158|exposure
P01856021A0577|43 53|laboratory
P01856021A0577|162 169|toluene
P01856021A0577|5 11|method
P01857326A0160|61 64|use
P01857326A0160|70 76|IBM-AT
P01857326A0160|17 22|group
P01861034A0798|73 81|pressure
P01861034A0798|7 16|resection
P01862027A0212|63 88|Rothmund-Thomson syndrome
P01862027A0212|50 59|diagnosis
P01863768A0649|24 30|ORF113
P01864510A0946|30 31|h
P01864510A0946|1 11|Dd PK1 RNA
P01864837A1029|151 181|rat alpha 1-protease inhibitor
P01864837A1029|13 22|structure
P01864837A1029|110 118|contrast
P01864837A1029|65 75|% homology
P01867069A0000|44 62|% nicotine sulfate
P01867069A0000|7 16|CD-1 mice
P01867069A0000|201 207|molars
P01867069A0000|117 121|pups
P01869907A2146|121 124|H2O
P01869907A2146|126 134|ABSTRACT
P01869907A2146|33 42|responses
P01869968A0673|60 66|result
P01869968A0673|146 147|p
P01869968A0673|8 27|regression analysis
P01869968A0673|115 119|rCBF
P01870428A0677|40 43|HDL
P01870428A0677|98 103|women
P01870428A0677|1 12|Thigh girth
P01871033A0434|180 186|method
P01871033A0434|87 108|laboratory simulation
P01871033A0434|1 6|Tests
P01871971A0836|57 66|NFIII/OCT
P01871971A0836|98 107|ATF motif
P01871971A0836|1 9|Analysis
P01873999A0000|160 177|secretion process
P01873999A0000|57 69|model system
P01873999A0000|188 192|host
P01873999A0000|257 265|interest
P01874752A0948|72 80|cdc2/p62
P01874752A0948|98 109|differences
P01876836T0000|42 50|subunits
P01876836T0000|19 22|Ets
P01878755A0496|15 26|enterotoxin
P01878755A0496|97 113|blood appearance
P01878755A0496|115 116|P
P01878755A0496|137 148|chloroquine
P01881671T0001|1 7|Uptake
P01882386A0000|146 158|mobilization
P01882386A0000|43 50|2-furyl
P01882386A0000|59 63|acid
P01882386A0000|22 41|alpha-mercapto-beta
P01882386A0000|5 18|effectiveness
P01882386A0000|201 205|rats
P01884435A0088|78 95|ptH distributions
P01884435A0088|25 32|effects
P01884435A0088|202 214|measurements
P01884435A0088|36 47|hypovolemia
P01884435A0088|69 73|ptO2
P01885006A0995|56 62|subset
P01885006A0995|5 12|domains
P01885752A0198|67 84|methanol fixation
P01886043A0380|75 81|effect
P01886043A0380|12 14|pH
P01886043A0380|208 212|HPCD
P01886043A0380|160 169|molecules
P01886043A0380|59 63|HPCD
P01886043A0380|5 8|SMX
P01886774A0000|61 76|Echerichia coli
P01886774A0000|39 43|Oct3
P01886774A0000|101 112|DNA binding
P01889753A0441|96 103|regions
P01889753A0441|21 30|sequences
P01889753A0441|17 19|nt
P01890989A1392|37 45|elements
P01890989A1392|96 101|genes
P01893195A0000|60 64|mice
P01893195A0000|41 49|hamsters
P01893195A0000|100 110|properties
P01894696A0301|1 3|J.
P01895370A0199|45 46|S
P01895370A0199|120 128|parallel
P01895370A0199|63 69|points
P01895370A0199|52 58|trough
P01895370A0199|141 148|fashion
P01895393A0745|61 70|Sp1 sites
P01895393A0745|91 98|absence
P01895393A0745|11 20|promoters
P01895393A0745|175 183|promoter
P01895393A0745|34 42|TATA box
P01896777T0000|43 49|plasma
P01896777T0000|54 60|tissue
P01896777T0000|85 93|patients
P01898113A0265|73 76|BCF
P01898113A0265|81 94|SWA killifish
P01898928A0260|148 156|fur gene
P01898928A0260|1 27|DNA hybridization analysis
P01899287A0726|134 139|cells
P01899287A0726|1 11|Expression
P01899846A0862|109 115|growth
P01899846A0862|16 31|rbcL-rbcS locus
P01901405A0694|40 46|AT-BP1
P01901405A0694|1 9|Analysis
P01901664T0064|3 8|cases
P01901946A0243|210 218|blotting
P01901946A0243|183 195|Southwestern
P01901946A0243|197 208|DNA-protein
P01901946A0243|158 178|mobility shift assay
P01903404A0688|60 61|%
P01903404A0688|230 247|ejection fraction
P01903404A0688|188 195|changes
P01903404A0688|18 35|ejection fraction
P01903404A0688|118 124|artery
P01903841A1449|105 112|failure
P01903841A1449|5 30|plasmid shuffle technique
P01903841A1449|86 90|form
P01904437A0000|110 127|metR gene product
P01904437A0000|1 14|Transcription
P01905199A0210|164 169|index
P01905199A0210|88 91|WBH
P01905199A0210|199 217|modality treatment
P01905199A0210|65 76|combination
P01905199A0210|117 122|order
P01906111A1295|109 115|marrow
P01906111A1295|6 11|study
P01906509A0072|47 53|region
P01906509A0072|67 79|nidogen gene
P01907265A0670|57 70|endonucleases
P01907265A0670|84 96|cell extract
P01909027A0922|73 81|homology
P01909027A0922|58 61|ILF
P01909027A0922|36 54|DNA binding domain
P01909027A0922|1 18|Sequence analysis
P01909027A0922|204 214|hepatocyte
P01909960A0134|44 49|mg/kg
P01909960A0134|106 107|%
P01909960A0134|128 141|concentration
P01909960A0134|162 165|NMN
P01909960A0134|200 201|%
P01909960A0134|187 196|NA levels
P01911767T0000|95 104|catalysis
P01911767T0000|1 10|Mutations
P01915580A0889|28 34|NZ-107
P01915580A0889|64 73|treatment
P01915580A0889|87 93|asthma
P01915580A0889|51 55|drug
P01916405A0242|11 27|mucosa tattooing
P01916405A0242|126 134|diseases
P01916405A0242|71 79|aerosols
P01916405A0242|102 107|forms
P01917943A0621a|77 86|TATAA box
P01917943A0621a|178 188|expression
P01917943A0621a|113 115|bp
P01917943A0621a|101 111|base pairs
P01917943A0621a|1 18|Sequence analysis
P01917962A0152|36 86|immunoglobulin gene recombination signal sequences
P01917962A0152|99 111|cDNA segment
P01917962A0152|137 150|IL-2R L chain
P01918010A1730|26 46|octanucleotide motif
P01918010A1730|212 229|HepG2 hepatocytes
P01918010A1730|155 160|level
P01918010A1730|1 9|Deletion
P01918010A1730|137 147|% decrease
P01918073A0150|180 224|protein kinase A phosphorylation target site
P01918073A0150|540 557|actin/TnC-binding
P01918073A0150|355 365|divergence
P01918073A0150|493 496|TnC
P01918073A0150|254 261|segment
P01918073A0150|520 530|TnIcardiac
P01918073A0150|432 445|site sequence
P01918073A0150|304 307|TnI
P01918073A0150|759 762|TnI
P01918073A0150|83 96|TnI sequences
P01918073A0150|407 417|troponin C
P01918073A0150|559 580|actomyosin-inhibitory
P01918073A0150|748 755|feature
P01921463T0000|95 108|microcomputer
P01921463T0000|67 71|data
P01921463T0000|4 21|ASSEMBLER routine
P01922734T0000|58 63|snail
P01922734T0000|1 12|Habituation
P01923167A0000|97 104|carotid
P01923167A0000|207 215|approach
P01923167A0000|171 176|route
P01923766A0485|227 231|exon
P01923766A0485|82 94|mRNA species
P01923766A0485|203 205|nt
P01923766A0485|190 201|nucleotides
P01923985A0111|31 50|mastocyte mediators
P01923985A0111|1 9|Symptoms
P01924920A0115|61 62|%
P01924920A0115|160 170|atmosphere
P01924920A0115|99 100|%
P01924920A0115|137 145|agar RLK
P01925092A0304|165 171|saline
P01925092A0304|143 149|volume
P01925092A0304|87 97|micrograms
P01927845A0107|90 97|disease
P01927845A0107|11 21|morphology
P01927845A0107|71 80|disorders
P01930470A0337|27 36|incidence
P01930470A0337|108 112|AABB
P01930470A0337|53 56|PTH
P01930470A0337|71 91|American Association
P01931966A0490|45 50|yield
P01931966A0490|24 30|pADPRP
P01931966A0490|115 121|enzyme
P01932695A1155|94 111|barley endosperms
P01932695A1155|54 70|expression assay
P01934378A1219|58 71|heart failure
P01936213T0000|29 40|drug effect
P01936997A0795|60 75|TRP-185 binding
P01936997A0795|25 45|competition analyses
P01937989A0383|78 80|R2
P01937989A0383|6 12|groups
P01939131A0871|43 49|xth-11
P01939131A0871|5 14|construct
P01939131A0871|51 56|nfo-2
P01939827A0150|332 334|pH
P01939827A0150|157 169|mmol/L CaCl2
P01939827A0150|257 266|solutions
P01939827A0150|134 143|solutions
P01939827A0150|318 330|mmol/L Hepes
P01939827A0150|346 356|degrees C.
P01939827A0150|282 294|mmol/L CaCl2
P01939827A0150|205 207|pH
P01939899A2043|130 142|perturbation
P01939899A2043|110 115|tones
P01939899A2043|52 59|account
P01939899A2043|87 96|variables
P01939899A2043|170 175|WORDS
P01942033T0000|88 92|exon
P01942033T0000|1 14|Determination
P01945430A0660|73 82|ear fluid
P01945430A0660|99 108|procedure
P01947449A1082|75 92|requirement value
P01947449A1082|193 199|models
P01947449A1082|5 25|Diffusion limitation
P01952827A0215|61 72|test phrase
P01952827A0215|20 27|seizure
P01954835A0000|79 88|lung cyst
P01954835A0000|127 135|Missouri
P01954835A0000|1 24|Echinococcus granulosus
P01956491A0095|149 169|creatinine clearance
P01956491A0095|40 49|mg/kg/day
P01956491A0095|93 108|filtration rate
P01956491A0095|296 302|ml/min
P01956491A0095|203 209|ml/min
P01958821T0000|44 56|cell biology
P01961213A0150|28 38|HCB-levels
P01961213A0150|80 85|years
P01961996A0522|78 89|opportunity
P01961996A0522|1 8|Adult H
P01963438T0000|121 131|electrodes
P01963438T0000|36 48|cytochrome c
P01963438T0000|64 75|polypyrrole
P01964989A0145|181 200|potassium hydroxide
P01964989A0145|209 213|soap
P01964989A0145|215 225|2-propanol
P01964989A0145|172 179|vinegar
P01964989A0145|1 16|Urine specimens
P01964989A0145|50 53|PCP
P01968043A0908|105 117|orientations
P01968043A0908|67 73|insert
P01968156T0000|1 21|Dose standardisation
P01970560A1024|57 61|lacZ
P01970560A1024|248 262|TyrR repressor
P01970560A1024|187 197|regulation
P01970560A1024|46 53|regions
P01970560A1024|131 141|chromosome
P01970560A1024|201 221|aroF-lacZ expression
P01970926A0000|60 68|plasma K
P01970926A0000|49 55|muscle
P01971191A1271|151 169|outflow resistance
P01971191A1271|73 82|influence
P01971191A1271|126 130|dogs
P01971191A1271|200 209|histamine
P01971191A1271|185 191|agents
P01973384A0206|146 153|embryos
P01973384A0206|85 92|ability
P01974876A1051|78 81|DNA
P01974876A1051|100 111|individuals
P01975428A0151|130 138|function
P01975428A0151|142 155|cell division
P01975428A0151|81 84|end
P01977585A0222|122 130|subunits
P01977585A0222|71 76|cells
P01978834A0076|75 83|antibody
P01978834A0076|103 133|rabbit H,K-ATPase beta subunit
P01982061A0615|13 21|TATA box
P01982190T0001|27 35|modality
P01982190T0001|7 16|cirrhosis
P01983026A0483|57 63|degree
P01983026A0483|76 86|intubation
P01983026A0483|35 43|pressure
P01985301T0000|72 84|brain damage
P01985301T0000|23 29|MK-801
P01985301T0000|34 44|nimodipine
P01985920T0000|10 20|expression
P01985920T0000|1 8|Cloning
P01986225A0250|20 34|identification
P01986225A0250|49 62|fission yeast
P01986254A0452|148 158|HeLa cells
P01986254A0452|81 88|complex
P01986254A0452|1 26|Gel mobility shift assays
P01988041A0281|22 28|clones
P01988041A0281|5 13|sequence
P01989999A0000|60 62|EC
P01989999A0000|148 158|conversion
P01989999A0000|54 57|GDP
P01989999A0000|18 28|synthetase
P01989999A0000|34 52|L-aspartate ligase
P01990266A0678|94 108|sodium dodecyl
P01990266A0678|128 132|gels
P01990266A0678|53 58|UHF-1
P01990266A0678|153 156|kDa
P01992459A0000|105 108|RRE
P01992459A0000|215 221|export
P01992459A0000|282 291|cytoplasm
P01992459A0000|197 207|regulation
P01992459A0000|114 134|Rev response element
P01992459A0000|253 257|mRNA
P01992953A0247|130 138|patients
P01992953A0247|84 95|specificity
P01993181T0000|90 94|nahG
P01993181T0000|116 122|region
P01995951A0000|45 67|immunodeficiency virus
P01995951A0000|127 137|factor Sp1
P01995951A0000|19 25|repeat
P01997465A0276|42 49|alveoli
P01997465A0276|54 59|septa
P01997465A0276|101 106|weeks
P01997465A0276|34 38|area
P02000093A0794|12 16|La-O
P02000093A0794|1 10|Landsberg
P02002051A0276|93 100|isoform
P02002051A0276|115 124|C-subunit
P02002511A0637|9 21|applications
P02002511A0637|87 95|examples
P02004705A0686|46 57|amino acids
P02004705A0686|5 18|cdr1 sequence
P02006558A0000|39 44|sites
P02006558A0000|1 24|Displacement thresholds
P02008982A0463|47 56|diagnosis
P02008982A0463|92 104|sputum smear
P02011924A0729|60 66|report
P02011924A0729|46 51|basis
P02011924A0729|92 98|MU/day
P02011924A0729|141 149|patients
P02011924A0729|102 111|alpha-IFN
P02015921A0523|44 48|pN1a
P02015921A0523|26 38|Category pN1
P02015921A0523|81 85|pN1b
P02015921A0523|50 60|metastasis
P02016769A0720|28 37|strengths
P02017271A0502|26 37|improvement
P02017271A0502|9 15|months
P02017271A0502|87 95|patients
P02019572A0000|423 437|fibroblast LTK
P02019572A0000|123 133|constructs
P02019572A0000|247 257|base pairs
P02019572A0000|387 402|rat hepatocytes
P02019572A0000|113 119|series
P02019572A0000|259 261|bp
P02019572A0000|284 297|gene cap site
P02019572A0000|225 234|fragments
P02019572A0000|347 359|introduction
P02019572A0000|414 421|culture
P02020314A1290|107 148|carboplatin-cyclophosphamide chemotherapy
P02020314A1290|208 214|cancer
P02020314A1290|3 7|dose
P02020314A1290|222 228|future
P02020314A1290|68 79|neutropenia
P02022188A0112|151 154|DNA
P02022188A0112|121 127|agents
P02022188A0112|108 117|chromatin
P02022188A0112|189 212|mobility group proteins
P02022920A0334|56 66|exon codes
P02022920A0334|85 96|nucleotides
P02023421A0343|198 204|agents
P02023421A0343|27 38|fibroblasts
P02023421A0343|43 61|collagen synthesis
P02023421A0343|99 107|strength
P02024252A0000|12 17|years
P02024252A0000|41 48|persons
P02024252A0000|101 110|Nordreisa
P02024625A0202|135 143|features
P02024625A0202|56 66|appearance
P02024625A0202|1 12|Differences
P02024816A0521|88 106|pneumonia patients
P02024816A0521|42 51|protein A
P02026144A0741|10 17|control
P02026144A0741|92 96|NRS1
P02026144A0741|81 90|sequences
P02026461A0760|90 95|panel
P02026461A0760|99 105|probes
P02027839A0250|31 36|group
P02027839A0250|79 85|values
P02027839A0250|125 136|fiber ratio
P02027839A0250|112 121|capillary
P02027839A0250|100 107|density
P02029468A0296|108 112|week
P02029468A0296|1 25|Serum TNF concentrations
P02030910A1070|111 119|splicing
P02030910A1070|1 35|Polymerase chain reaction analysis
P02033062A1169|9 26|promotor function
P02033062A1169|37 42|genes
P02033062A1169|68 77|fragments
P02034655T0000|33 55|integrin gene promoter
P02034676A0267|23 37|rhombotin gene
P02036066A0000|105 108|PHP
P02036066A0000|130 138|function
P02036066A0000|67 103|hemoglobin polyoxyethylene conjugate
P02036066A0000|17 24|effects
P02038326A0538|95 102|couples
P02038326A0538|247 252|shift
P02038326A0538|5 22|gcd2-503 mutation
P02038326A0538|81 84|80S
P02038326A0538|48 54|runoff
P02038326A0538|272 283|temperature
P02041088A1053|121 168|reporter chloramphenicol acetyltransferase gene
P02041088A1053|179 186|control
P02041088A1053|37 41|DR60
P02044950A0258|73 82|organisms
P02044950A0258|54 66|U6 RNA genes
P02045366A1149|44 48|KlaA
P02045366A1149|53 70|KlaB polypeptides
P02045809A0331|31 53|B. sphaericus products
P02045809A0331|22 27|rates
P02045809A0331|55 63|ABG-6184
P02045809A0331|85 90|BSP-2
P02047597A0149|27 35|vulvitis
P02047597A0149|78 86|bacteria
P02052544A0641|73 79|dpb2-1
P02052544A0641|36 43|complex
P02052544A0641|87 92|cells
P02052544A0641|119 133|DNA polymerase
P02053289A0701|21 35|nt differences
P02053289A0701|139 146|strains
P02055484A0538|61 65|ATG2
P02055484A0538|36 45|mutations
P02060052A0954|29 35|levels
P02060052A0954|78 89|hepatocytes
P02060052A0954|39 45|oxygen
P02061333A0784|52 61|acvA gene
P02061333A0784|21 29|presence
P02062116A0688|14 41|monoamine oxidase inhibitor
P02062116A0688|1 10|Pargyline
P02064119A1172|106 112|% SaO2
P02064119A1172|128 136|subjects
P02064119A1172|71 80|relatives
P02064119A1172|100 105|L/min
P02066246A0258|63 92|Massachusetts Cancer Registry
P02066246A0258|19 23|list
P02069738A0000|47 54|ethanol
P02069738A0000|3 9|method
P02072798A0330|73 79|chance
P02072798A0330|46 53|therapy
P02072798A0330|19 32|stabilization
P02075876A0408|72 81|amplitude
P02075876A0408|5 23|stimulus threshold
P02076620A0548|91 97|effect
P02076620A0548|54 58|mean
P02076816T0000|94 122|IME1 transcript accumulation
P02076816T0000|33 52|sporulation control
P02078080T0040|5 16|application
P02078080T0040|32 42|advantages
P02079811A0407|122 127|level
P02079811A0407|131 146|acid production
P02079811A0407|5 12|authors
P02079811A0407|35 43|efficacy
P02081463A0110|131 136|sites
P02081463A0110|76 81|Spec1
P02081463A0110|98 113|initiation site
P02081463A0110|152 163|interaction
P02083230A0938|122 143|N-glycosylation sites
P02083230A0938|41 55|signal peptide
P02083230A0938|199 210|amino acids
P02083546A0000|329 350|motor neurone disease
P02083546A0000|301 309|patients
P02083546A0000|265 273|dementia
P02083546A0000|22 28|method
P02083546A0000|285 294|lobe type
P02083546A0000|160 185|photon emission tomograms
P02083546A0000|315 323|dementia
P02083546A0000|239 246|disease
P02089054A0121|122 128|column
P02089054A0121|64 72|extracts
P02089054A0121|1 4|IdB
P02092131T0000|7 13|method
P02092131T0000|51 67|hypersensitivity
P02093741A0211|131 138|MAXITAB
P02093741A0211|173 191|analysis technique
P02093741A0211|1 16|Data collection
P02094221A0247|56 60|ml/h
P02094221A0247|35 43|drinking
P02095150T0000|58 68|comparison
P02095150T0000|39 54|hip replacement
P02102823A0492|42 60|beta-glucuronidase
P02102823A0492|65 92|neomycin phosphotransferase
P02103140A1088|14 22|patients
P02103140A1088|11 12|%
P02103140A1088|67 73|grafts
P02105497A1092|164 175|HSP70 genes
P02105497A1092|195 205|eukaryotes
P02105497A1092|128 136|ancestor
P02105497A1092|185 189|time
P02105497A1092|17 27|comparison
P02107073A0584|46 60|STE18 proteins
P02107073A0584|10 24|overexpression
P02107073A0584|37 41|STE4
P02107073A0584|143 151|presence
P02109544A0000|269 275|option
P02109544A0000|94 99|males
P02109544A0000|58 79|Chlamydia trachomatis
P02109544A0000|157 195|leukocyte esterase urine dipstick test
P02109544A0000|116 139|decision analysis model
P02109544A0000|282 291|screening
P02109544A0000|38 53|screening tests
P02110148A0423|241 245|ClaI
P02110148A0423|108 131|B. subtilis IF2 protein
P02110148A0423|96 100|half
P02110148A0423|140 142|kb
P02110148A0423|289 292|IF2
P02110148A0423|258 266|fragment
P02113015A0295|59 63|cent
P02113174A0957|58 67|activator
P02113699A0372|180 181|N
P02113699A0372|147 152|spots
P02113699A0372|81 86|spots
P02113699A0372|255 256|N
P02113699A0372|51 52|N
P02113699A0372|105 106|N
P02113699A0372|197 205|patients
P02113699A0372|34 43|subgroups
P02115111T0000|13 32|nucleotide sequence
P02115111T0000|110 121|Anabaena sp
P02115111T0000|1 11|Expression
P02115116A1137|28 42|sequence match
P02115116A1137|5 12|results
P02115121A0000|31 61|pet complementation group G104
P02115121A0000|193 202|component
P02115121A0000|188 191|KE2
P02115121A0000|101 123|dehydrogenase activity
P02115121A0000|1 14|Yeast mutants
P02115572A1323|87 103|U266 lambda gene
P02115572A1323|68 70|kb
P02116071A0000|182 187|titer
P02116071A0000|297 303|amount
P02116071A0000|218 222|sera
P02116071A0000|257 264|attacks
P02116071A0000|327 331|body
P02116071A0000|280 289|reduction
P02116071A0000|349 358|reduction
P02116071A0000|110 140|type hypersensitivity reaction
P02117799T0000a|44 53|rejection
P02117799T0000a|79 90|nonfunction
P02117799T0000a|9 24|orthoclone OKT3
P02117799T0000a|1 5|Uses
P02118519A0516|93 102|positions
P02118519A0516|38 54|consensus motifs
P02118612A0629|46 66|DOPAC concentrations
P02118612A0629|179 185|effect
P02118612A0629|159 164|ether
P02118612A0629|19 35|supine restraint
P02119626A0471|47 48|%
P02119626A0471|59 69|dimensions
P02120707A0594|46 50|Raji
P02120707A0594|59 67|proteins
P02120707A0594|20 26|assays
P02121371T0000|25 32|protein
P02121371T0000|5 14|NF1 locus
P02123029A0478|10 17|isotype
P02123029A0478|128 135|Raja VH
P02123029A0478|21 40|Raja immunoglobulin
P02123029A0478|154 160|probes
P02123295A0645|41 50|phenotype
P02123466A0272|28 34|family
P02123466A0272|40 44|AP-4
P02123466A0272|138 149|DNA binding
P02123820A0000|210 213|FIA
P02123820A0000|62 72|clorgyline
P02123820A0000|148 157|nialamide
P02123820A0000|24 41|monoamine oxidase
P02123820A0000|86 101|MAO-B inhibitor
P02123820A0000|103 111|deprenyl
P02123877A1452|72 78|levels
P02123877A1452|227 237|regulation
P02123877A1452|24 29|c-fos
P02123877A1452|159 166|factors
P02123877A1452|257 271|gene induction
P02123877A1452|34 45|egr-1 mRNAs
P02124710A0193|13 21|proteins
P02124710A0193|93 113|proliferation period
P02124710A0193|117 149|osteoblast phenotype development
P02125016A0145|20 26|agents
P02126417A0408|130 140|hemisphere
P02126417A0408|82 98|control subjects
P02126417A0408|114 117|VHF
P02129338A0568|62 63|%
P02129338A0568|50 58|homology
P02131666A0483|40 60|examinees class II/2
P02132636A0188|31 45|schizophrenics
P02132636A0188|1 9|Subjects
P02135343A0131|44 54|percentage
P02135343A0131|199 220|ANGLE3 classification
P02135343A0131|178 183|archs
P02135343A0131|65 74|occlusion
P02138707A0198|181 226|histocompatibility complex A alpha gene X box
P02138707A0198|240 261|transcription element
P02138707A0198|166 171|class
P02138707A0198|293 298|genes
P02138707A0198|117 125|sequence
P02138992A0911|63 69|tumors
P02138992A0911|20 29|treatment
P02139891A0532|61 75|activators EIA
P02139891A0532|11 19|promoter
P02139891A0532|80 83|EIV
P02139891A0532|156 166|EIIF sites
P02139891A0532|102 110|elements
P02142240A0506|167 175|patients
P02142240A0506|77 90|concentration
P02142240A0506|158 163|group
P02142240A0506|16 27|differences
P02142921T0000|13 53|hormone-releasing hormone analog therapy
P02142921T0000|108 117|buserelin
P02142921T0000|65 72|fibroid
P02142993A0176|14 21|picture
P02142993A0176|94 107|leishmaniasis
P02142993A0176|173 184|L. infantum
P02142993A0176|207 214|pattern
P02143186A0867|47 51|AHA3
P02143186A0867|123 129|intron
P02143186A0867|27 34|introns
P02143186A0867|4 14|comparison
P02143768T0000|14 30|gastrostomy tube
P02143768T0000|1 10|Impaction
P02144610A1306|149 161|AMP response
P02144610A1306|214 221|T alpha
P02144610A1306|334 352|TCR beta promoters
P02144610A1306|87 95|proteins
P02144610A1306|15 35|beta gene expression
P02144610A1306|72 78|T-cell
P02144610A1306|65 68|set
P02144610A1306|307 313|number
P02145268A0746|13 32|nucleotide sequence
P02145268A0746|172 183|COL3A1 gene
P02145268A0746|157 161|exon
P02145268A0746|103 107|type
P02146266A0000|162 169|library
P02146266A0000|59 107|Neurospora crassa CuZn superoxide dismutase gene
P02146266A0000|188 215|deoxyoligonucleotide probes
P02147223A1047|108 112|HeLa
P02147223A1047|4 12|contrast
P02147223A1047|87 91|cAMP
P02147223A1047|35 49|c-fos promoter
P02148219A0508|93 101|rigidity
P02148219A0508|23 33|hypothesis
P02148219A0508|155 162|muscles
P02148508A0374|1 6|Fluid
P02148799A0000|166 176|expression
P02148799A0000|147 152|genes
P02148799A0000|5 13|nmr gene
P02148799A0000|222 229|circuit
P02149566A0478|14 24|P-31 NMR-S
P02149566A0478|62 77|phosphocreatine
P02149566A0478|43 53|phosphates
P02149566A0478|5 10|ratio
P02150473T0067|10 15|study
P02151229A0921|130 131|p
P02151229A0921|54 59|group
P02151229A0921|102 103|%
P02153683A1579|95 105|uvomorulin
P02153683A1579|37 46|complexes
P02153683A1579|113 114|K
P02153683A1579|116 122|ATPase
P02154467A0709|76 84|sequence
P02154467A0709|98 116|furin gene product
P02154599A0382|181 184|DSL
P02154599A0382|41 72|gel mobility retardation assays
P02154599A0382|24 36|footprinting
P02154602A0092|75 90|influenza virus
P02154602A0092|32 48|mouse Mx protein
P02154885A0153|24 35|mutagenesis
P02154885A0153|5 10|sites
P02154885A0153|100 114|loop structure
P02156828A0164|13 32|amino acid sequence
P02156828A0164|112 119|cofilin
P02156828A0164|173 180|protein
P02157141A0923|37 45|presence
P02157141A0923|218 228|base pairs
P02157141A0923|49 62|topoisomerase
P02157141A0923|84 87|DNA
P02157882T0000|74 82|proteins
P02157882T0000|114 119|cells
P02157882T0000|1 13|Conservation
P02158927A0000|122 126|UTR1
P02158927A0000|94 101|cluster
P02158927A0000|24 34|nucleotide
P02158927A0000|116 120|CYC1
P02158927A0000|134 138|OSM1
P02158927A0000|40 48|sequence
P02158927A0000|36 38|nt
P02158927A0000|171 183|chromosome X
P02159559A0779|57 74|DNA amplification
P02160622A0000|230 234|rats
P02160622A0000|67 82|hot-plate tests
P02160622A0000|139 171|benzodiazepine agonist midazolam
P02160622A0000|204 212|morphine
P02162049A0291|37 45|factor Y
P02162049A0291|17 22|issue
P02162467A0311|62 74|CytR protein
P02162754A0801|28 44|phosphoryl group
P02162754A0801|142 150|receptor
P02162754A0801|113 132|signal transmission
P02162754A0801|48 52|pp15
P02163347A0472|74 93|amino acid sequence
P02163347A0472|53 56|ORF
P02163347A0472|38 51|reading frame
P02163347A0472|101 102|%
P02163394T0000|46 70|Bacillus subtilis shares
P02163394T0000|108 123|antiterminators
P02164585A0814|134 141|alanine
P02164585A0814|146 153|leucine
P02164585A0814|5 20|protein product
P02164585A0814|70 74|traX
P02164604A0399|104 113|promoters
P02164604A0399|53 76|E2 transactivation gene
P02164637A0515|161 170|lethality
P02164637A0515|178 190|cdc25 mutant
P02164637A0515|55 66|sensitivity
P02164637A0515|70 80|heat shock
P02164637A0515|85 104|nitrogen starvation
P02165589A0000|150 178|hormone receptor superfamily
P02165589A0000|82 89|portion
P02165589A0000|3 7|gene
P02166040A0385|150 172|carboxykinase promoter
P02166040A0385|366 373|methods
P02166040A0385|22 30|vanadate
P02166040A0385|257 275|phosphotransferase
P02166040A0385|117 126|deletions
P02166040A0385|45 69|PEPCK gene transcription
P02166040A0385|285 318|chloramphenicol acetyltransferase
P02166040A0385|432 442|retrovirus
P02166040A0385|472 481|selection
P02166040A0385|519 529|expression
P02166825A0198|209 218|mutations
P02166825A0198|79 82|way
P02166825A0198|127 133|number
P02166825A0198|116 123|signals
P02166825A0198|137 155|promoter mutations
P02167467T0000|111 116|genes
P02167467T0000|64 75|protein L11
P02168640A0268|90 98|presence
P02168640A0268|176 185|disorders
P02168640A0268|59 63|SSEP
P02168640A0268|48 55|changes
P02170687A0000|41 57|papillomaviruses
P02170687A0000|5 19|E6/E7 promoter
P02173399A0333|28 36|controls
P02173399A0333|77 95|tissue radiographs
P02173399A0333|97 101|STRs
P02173399A0333|54 60|blocks
P02174105A1232|41 51|rat organs
P02174105A1232|64 72|staining
P02174861A0736|15 19|irgA
P02174861A0736|73 78|level
P02174861A0736|198 203|sites
P02174861A0736|23 27|iron
P02174861A0736|139 147|vicinity
P02174861A0736|186 189|Fur
P02175433A0575|37 55|beta A-globin gene
P02175433A0575|68 72|gene
P02176021T0000|39 48|materials
P02176021T0000|1 14|Determination
P02176209A0954|29 33|NF-Y
P02176209A0954|52 56|rise
P02176209A0954|38 46|CBF DNAs
P02176209A0954|70 94|gel retardation patterns
P02176822A0000|149 158|inhibitor
P02176822A0000|127 133|serine
P02176822A0000|113 122|threonine
P02176822A0000|75 84|peptide B
P02176822A0000|66 71|lyase
P02176822A0000|175 182|residue
P02179188A1223|26 42|motile responses
P02179188A1223|99 114|cytochalasin B.
P02180935A0535|45 48|min
P02180935A0535|147 192|chondroitin sulfate proteoglycan intermediate
P02180935A0535|67 84|precursor protein
P02182240A0355|134 142|symptoms
P02182240A0355|125 130|onset
P02182240A0355|3 8|total
P02182240A0355|16 24|patients
P02182618A0168|107 111|gene
P02182618A0168|5 22|promoter activity
P02182618A0168|138 154|deletion mutants
P02182618A0168|102 105|CAT
P02185140A0000|269 276|control
P02185140A0000|167 174|control
P02185140A0000|248 253|pPHO5
P02185140A0000|99 103|14DM
P02185140A0000|50 76|cytochrome P450 lanosterol
P02185140A0000|288 296|promoter
P02187091A0721|48 65|ejection fraction
P02187091A0721|100 117|relaxation period
P02188096A0955|5 17|contribution
P02188096A0955|35 50|splicing events
P02190122A0633|90 100|motivation
P02190122A0633|126 132|mating
P02190122A0633|113 122|regulator
P02193033A0195|1 3|R.
P02194972T0000|24 33|cefpirome
P02194972T0000|65 75|infections
P02194972T0000|35 37|HR
P02195715A0143|104 115|individuals
P02195715A0143|12 23|individuals
P02195715A0143|40 57|purpura fulminans
P02195715A0143|84 91|protein
P02196176A0749|56 58|bp
P02196176A0749|38 45|repeats
P02196176A0749|1 6|TREB7
P02196450A0870|57 78|sequence requirements
P02196450A0870|83 90|binding
P02196450A0870|223 231|function
P02196450A0870|154 164|Q activity
P02196565T0000|134 197|factor I/repressor/activator site binding protein 1/translation
P02196565T0000|97 104|factors
P02196565T0000|1 20|Yeast Gal11 protein
P02198289A0436|121 129|solution
P02198289A0436|111 117|dimers
P02198289A0436|140 143|DNA
P02198289A0436|84 95|amino acids
P02200150A1381|121 132|pathologist
P02200150A1381|9 17|patients
P02200150A1381|97 107|oncologist
P02200150A1381|69 73|team
P02200736A1003|27 30|set
P02200736A1003|76 80|AP-4
P02200736A1003|55 64|molecules
P02201901A0229|29 37|antibody
P02202496T0000|29 35|horses
P02204029A0184|164 169|point
P02204029A0184|93 98|N-ras
P02204029A0184|115 118|end
P02204029A0184|185 198|transcription
P02204029A0184|1 24|RNase protection assays
P02204623A0000|240 249|responses
P02204623A0000|296 302|Lauris
P02204623A0000|251 256|White
P02204623A0000|55 67|beta-subunit
P02204623A0000|258 262|M.F.
P02204623A0000|314 318|T.J.
P02204623A0000|163 186|tyrosyl phosphorylation
P02204623A0000|97 112|tyrosyl residue
P02204623A0000|5 25|juxtamembrane region
P02204623A0000|206 216|substrates
P02204623A0000|304 306|V.
P02204810A1080|46 56|expression
P02204810A1080|16 19|GA2
P02206430A0197|94 105|DA turnover
P02206430A0197|51 58|mothers
P02206858A0000|150 155|years
P02206858A0000|12 21|protein C
P02206858A0000|27 37|deficiency
P02206858A0000|76 79|boy
P02206858A0000|23 25|PC
P02209237A0239|147 152|cause
P02209237A0239|110 119|99mTc-MAA
P02209237A0239|156 164|cyanosis
P02209237A0239|35 38|IPS
P02209540A1362|72 77|genes
P02209540A1362|17 21|Ets1
P02209811T0000|75 89|iliac arteries
P02209811T0000|29 48|permeability marker
P02217307T0000|27 38|alterations
P02217307T0000|1 9|Evidence
P02218094A0395|79 81|Fm
P02218094A0395|66 77|utilization
P02220102A0271|45 56|hygiene und
P02220102A0271|1 10|Incidence
P02223652A0939|43 45|CY
P02223652A0939|32 34|CY
P02223928T0069|27 44|serotonin agonist
P02227438A0492|31 45|RNA sequencing
P02227438A0492|146 155|A residue
P02227438A0492|97 109|rat ODC mRNA
P02227438A0492|68 93|transcription start point
P02229068A0156|121 136|precursor SU-TM
P02229068A0156|56 59|rev
P02229068A0156|153 160|gp120 x
P02229068A0156|106 117|COS-1 cells
P02229068A0156|41 44|tat
P02229068A0156|138 143|gp160
P02229282A0454|26 42|serum TNF levels
P02229282A0454|67 90|serum T3 concentrations
P02231162T0000|31 39|movement
P02231162T0000|51 64|tooth contact
P02233626T0000|35 43|symptoms
P02233715A0914|195 203|presence
P02233715A0914|130 137|element
P02233715A0914|43 57|IL-6 construct
P02233715A0914|5 14|induction
P02233715A0914|18 36|pseudorabies virus
P02234345A0215|11 20|cyst wall
P02234345A0215|34 38|part
P02236002A0958|132 154|chicken TCR beta cDNAs
P02236002A0958|7 14|mammals
P02236002A0958|70 79|junctions
P02236060A1671|110 117|protein
P02236060A1671|1 13|Modification
P02236276T0000|25 29|bulb
P02236276T0000|84 89|odors
P02237431A0833|57 59|bp
P02237431A0833|80 83|end
P02237431A0833|51 55|pair
P02241892A0681|122 124|kb
P02241892A0681|178 185|regions
P02241892A0681|1 12|Utilization
P02243093A0000|79 82|Tax
P02243093A0000|7 33|T-cell leukemia virus type
P02243093A0000|159 168|U3 region
P02243093A0000|101 114|transcription
P02246362T0000|95 99|type
P02246362T0000|5 28|Jenkins Activity Survey
P02246803A0692|44 54|TTD method
P02246803A0692|5 11|result
P02247072A0794|59 66|protein
P02247072A0794|97 106|positions
P02247072A0794|136 149|ram mutations
P02247924A0078|58 72|amphotericin B
P02247924A0078|37 44|abscess
P02249872A1051|106 116|microC/cm2
P02249872A1051|37 42|range
P02249872A1051|6 17|interaction
P02249872A1051|51 61|parameters
P02251119A0319|105 112|introns
P02251119A0319|79 86|regions
P02251119A0319|146 167|hsc70 heat shock gene
P02251119A0319|1 8|Results
P02252953A0300|165 172|effects
P02252953A0300|129 143|susceptibility
P02252953A0300|185 196|mood states
P02252953A0300|119 126|mothers
P02253663A0687|91 92|h
P02253663A0687|145 146|%
P02253663A0687|113 114|h
P02253663A0687|116 136|serum concentrations
P02254418A0641|6 13|strains
P02254418A0641|96 103|species
P02254418A0641|17 18|%
P02256678A1224|126 134|presence
P02256678A1224|103 113|HSC82 gene
P02257899T0000|62 65|man
P02257899T0000|50 58|saccades
P02259334A0205|105 107|Mr
P02259334A0205|94 101|protein
P02259334A0205|126 134|function
P02259334A0205|52 60|sequence
P02261254A0168|133 144|development
P02261254A0168|55 66|circulation
P02261254A0168|35 41|arrest
P02261254A0168|186 192|tissue
P02264601A0000|72 79|alcohol
P02264601A0000|131 135|rats
P02264601A0000|59 68|responses
P02264601A0000|143 148|taste
P02264601A0000|152 159|alcohol
P02266679A0740|49 60|drug course
P02269281A1276|166 174|location
P02269281A1276|72 81|sequences
P02269281A1276|182 188|region
P02269281A1276|5 15|occurrence
P02269281A1276|119 129|structures
P02270096T0000|42 53|nitrosamine
P02270834A0123|27 37|HML method
P02273690T0001|48 56|motility
P02273690T0001|1 8|Effects
P02274509A0623|121 144|indicator liver enzymes
P02274509A0623|26 34|presence
P02274509A0623|178 186|function
P02277005A0227|53 63|literature
P02277452A0116|107 116|detection
P02277452A0116|42 49|changes
P02277452A0116|7 15|patients
P02277452A0116|188 195|changes
P02277452A0116|155 165|appearance
P02277452A0116|69 78|PSP/LVESV
P02278474A0000|123 127|kind
P02278474A0000|36 39|FDP
P02278474A0000|1 34|Serum Fibrin Degradation Products
P02281118A1191|61 68|healing
P02281118A1191|97 108|limitations
P02281118A1191|1 35|Prostaglandin synthesis inhibitors
P02281948A0245|105 106|M
P02281948A0245|123 132|ingestion
P02281948A0245|5 9|corn
P02283148T0000|72 87|immunopathology
P02283148T0000|1 13|Significance
P02283378T0000|40 61|cephalosporin DQ-2556
P02283378T0000|76 82|fluids
P02283378T0000|19 32|determination
P02284393A0751|9 17|research
P02287860T0001|75 79|mice
P02287860T0001|55 71|parenchyma cells
P02289639A0989|105 118|control group
P02289639A0989|10 16|change
P02289639A0989|96 97|%
P02289639A0989|51 56|value
P02291144A0493|148 162|basophil count
P02291144A0493|108 125|reference methods
P02291144A0493|21 22|r
P02292272T0000|66 69|cat
P02292272T0000|1 23|Interlimb coordination
P02293664A0946|90 99|sequences
P02293664A0946|106 116|base pairs
P02293664A0946|173 186|mRNA cap site
P02295521A0922|46 57|correlation
P02295521A0922|79 97|trapezius activity
P02295521A0922|163 187|muscle activity patterns
P02295521A0922|216 227|risk factor
P02295521A0922|139 149|individual
P02298741A0809|63 68|alpha
P02298741A0809|79 88|gamma PKC
P02298741A0809|163 173|JKPE cells
P02298741A0809|233 240|protein
P02298741A0809|114 119|types
P02298741A0809|1 9|Analysis
P02300541A0000|105 118|dose inhalers
P02300541A0000|151 155|dose
P02300541A0000|215 224|rat lungs
P02300541A0000|77 83|agents
P02300541A0000|168 178|surfactant
P02300541A0000|186 193|airways
P02300759A0000|104 110|cervix
P02300759A0000|130 135|forms
P02300759A0000|39 63|Gustave Roussy Institute
P02300759A0000|137 143|T1B-T2
P02303470A0242|5 12|introns
P02305014A0226|57 61|rats
P02305014A0226|131 140|ventricle
P02307067A1348|127 128|%
P02307067A1348|67 81|Nanorchestidae
P02307067A1348|5 16|persistence
P02307067A1348|217 225|habitats
P02307067A1348|86 98|Tarsonemidae
P02307613A0783|91 95|days
P02307613A0783|67 68|P
P02307613A0783|99 103|dogs
P02307613A0783|234 239|study
P02307613A0783|118 122|diet
P02307848T0042|51 55|Crry
P02307850A1197|135 163|killer lymphocyte activities
P02307850A1197|89 98|increases
P02307850A1197|58 70|spleen cells
P02307850A1197|18 35|RNKP-1 expression
P02310261A0115|5 12|abscess
P02310261A0115|34 40|septum
P02310350A0221|88 95|content
P02310350A0221|125 133|subjects
P02310350A0221|53 57|rate
P02310350A0221|32 38|effect
P02311544A0086|79 84|signs
P02311544A0086|32 44|relationship
P02311544A0086|1 8|Studies
P02312689A0360|5 22|kappa coefficient
P02312689A0360|69 84|standard method
P02315472A0583|93 96|C/A
P02315472A0583|80 84|RASE
P02315472A0583|101 110|unit time
P02317554T0000|66 83|microscope system
P02319610A1527|90 97|results
P02319610A1527|65 76|observation
P02319610A1527|117 122|P.HCl
P02320999A0606|72 78|carpet
P02320999A0606|41 50|materials
P02320999A0606|52 66|particle board
P02320999A0606|5 14|procedure
P02320999A0606|98 107|wallpaper
P02320999A0606|216 225|compounds
P02323517A0557|9 10|h
P02323517A0557|81 107|prostaglandin E2 synthesis
P02323517A0557|49 56|stomach
P02324104A0151|116 127|homogenates
P02324104A0151|103 112|fractions
P02324104A0151|17 18|%
P02324104A0929|46 54|residues
P02324104A0929|158 168|C pre-mRNA
P02324104A0929|17 26|C subunit
P02325208A0209|1 7|French
P02326716A0139|61 67|T7-T12
P02326716A0139|177 185|rotation
P02326716A0139|22 32|Cobb angle
P02326716A0139|80 86|convex
P02326716A0139|49 59|evaluation
P02326716A0139|187 191|tilt
P02327159T0001|43 47|care
P02327159T0001|1 5|Lars
P02329840A0383|104 105|o
P02329840A0383|5 16|application
P02329840A0383|101 102|K
P02330110A1085|20 38|laboratory studies
P02330110A1085|49 54|value
P02331361A0268|78 84|biopsy
P02331361A0268|67 70|age
P02332798A0725|63 78|EVS stimulation
P02332798A0725|5 14|afferents
P02333545A0313|88 100|distribution
P02333545A0313|5 17|distribution
P02334972A0145|181 187|vision
P02334972A0145|123 135|risk factors
P02334972A0145|94 105|development
P02334972A0145|76 86|evaluation
P02334972A0145|5 16|examination
P02334972A0145|32 42|assessment
P02335521T0000|98 134|Xenopus laevis vitellogenin promoter
P02335815A0530|46 53|residue
P02335815A0530|27 35|deletion
P02335815A0530|82 85|TRF
P02339005T0000|28 42|pain threshold
P02339005T0000|11 24|hyperglycemia
P02340595A0124|28 33|genes
P02340595A0124|126 144|plant mitochondria
P02340595A0124|1 18|Sequence analysis
P02342477A1292|271 275|UTMP
P02342477A1292|127 144|P4-responsiveness
P02342477A1292|114 125|endometrium
P02342477A1292|86 90|site
P02342477A1292|166 173|mannose
P02342477A1292|196 214|recognition marker
P02342477A1292|64 72|features
P02344529T0000|16 23|anaemia
P02347407A0217|59 68|SE-sector
P02348225A0192|269 277|controls
P02348225A0192|121 126|hours
P02348225A0192|185 189|L/m2
P02348225A0192|15 27|measurements
P02348225A0192|133 139|volume
P02348225A0192|11 13|SE
P02348225A0192|1 5|Mean
P02348728A1153|112 121|carcinoma
P02348728A1153|84 95|determinant
P02349942A0287|56 63|cohorts
P02351239A0693|30 46|hypergastrinemia
P02351239A0693|124 131|effects
P02351239A0693|153 165|HDC activity
P02351239A0693|195 211|ECL cell density
P02351239A0693|287 296|treatment
P02351239A0693|312 329|antisecretagogues
P02351239A0693|7 15|findings
P02353453A1249|41 61|nsP3 homology region
P02353453A1249|97 104|respect
P02353453A1249|5 10|order
P02353453A1249|18 32|helicase motif
P02354381A0207|183 186|H/S
P02354381A0207|89 90|S
P02354381A0207|95 114|fiberglass rollaway
P02354381A0207|191 199|nest box
P02354381A0207|154 155|H
P02354381A0207|134 140|corner
P02354381A0207|228 232|cage
P02354381A0207|35 36|C
P02355765A0220|63 71|U weekly
P02355765A0220|5 12|patient
P02356823A0063|110 114|time
P02356823A0063|53 67|sets technique
P02358975A0709|109 122|gluten intake
P02358975A0709|71 79|symptoms
P02361008T0000|45 50|years
P02361008T0000|1 8|Changes
P02361812A1110|164 166|DE
P02361812A1110|132 138|values
P02361812A1110|160 161|D
P02361812A1110|199 208|treatment
P02361812A1110|39 54|baseline values
P02361812A1110|100 108|subjects
P02362803A0608|109 120|Arabidopsis
P02362803A0608|98 105|library
P02362803A0608|68 82|U3 snRNA genes
P02370571A0663|215 221|factor
P02370571A0663|176 179|men
P02370571A0663|37 54|iodine deficiency
P02370571A0663|98 108|immigrants
P02370571A0663|222 223|s
P02371517A0747|12 20|patients
P02372712A0002|74 82|pressure
P02372712A0002|160 168|broilers
P02372712A0002|112 126|plasma lactate
P02372712A0002|21 23|TW
P02372712A0002|16 19|tap
P02373810A1118|42 54|risk factors
P02373810A1118|96 101|weeks
P02373810A1118|64 68|risk
P02373810A1118|103 104|p
P02376023A0307|26 29|age
P02376023A0307|93 97|IgG4
P02376023A0307|99 100|P
P02376023A0307|190 194|kU/l
P02376023A0307|16 22|months
P02378945A0487|112 122|vagal tone
P02378945A0487|36 42|stress
P02383771A0544|15 26|examination
P02383771A0544|161 167|nuclei
P02383771A0544|65 73|membrane
P02383771A0544|186 195|cytoplasm
P02384389A0854|41 48|heifers
P02384389A0854|93 103|deposition
P02384389A0854|34 36|YG
P02386895A0496|61 67|chills
P02386895A0496|57 58|%
P02386895A0496|83 94|tumor sites
P02386895A0496|75 79|pain
P02386895A0496|41 42|%
P02386895A0496|141 142|%
P02386895A0496|1 11|Toxicities
P02390538A0000|12 19|infants
P02390538A0000|95 104|anomalies
P02390538A0000|112 119|airways
P02390538A0000|39 44|weeks
P02390989A0745|60 68|GPE gene
P02390989A0745|132 142|stop codon
P02390989A0745|106 115|insertion
P02390989A0745|36 44|GPB gene
P02390989A0745|17 28|counterpart
P02392032A0657|148 158|pore space
P02392032A0657|43 52|structure
P02392032A0657|83 94|information
P02392032A0657|206 217|ambiguities
P02393001A0324|123 126|%BF
P02393001A0324|10 13|%BF
P02393001A0324|83 94|definitions
P02393001A0324|115 119|BMIs
P02393001A0324|170 177|results
P02394707A0789|123 134|compliments
P02394707A0789|92 107|initiation site
P02394707A0789|39 47|TATA box
P02394707A0789|49 53|GTTA
P02395868A0322|122 135|hydrogen bond
P02395868A0322|27 37|zinc sites
P02395868A0322|5 12|pattern
P02395868A0322|68 76|sequence
P02398897A0000|148 158|RNA chains
P02398897A0000|49 63|RNA polymerase
P02399053A1032|26 37|alveoli/mm2
P02399053A1032|50 65|recoil pressure
P02400457A0469|182 189|manners
P02400457A0469|131 136|women
P02400457A0469|212 223|adjustments
P02400457A0469|100 115|LBNP conditions
P02400457A0469|239 245|phases
P02403035A0621|54 63|precursor
P02403926A0000|268 274|S.M.S.
P02403926A0000|300 304|S.M.
P02403926A0000|214 224|amino acid
P02403926A0000|246 251|Kozma
P02403926A0000|292 298|Saurer
P02403926A0000|117 129|NIH3T3 cells
P02403926A0000|288 290|F.
P02403926A0000|314 316|B.
P02403926A0000|5 20|trk-2h oncogene
P02403926A0000|306 312|Groner
P02404451A1532|123 130|Cys-118
P02404451A1532|92 100|activity
P02404451A1532|156 164|activity
P02404451A1532|19 45|scanning-deletion analysis
P02404451A1532|274 280|GM-CSF
P02405589A0000|91 109|drug-use decisions
P02405589A0000|1 12|Information
P02406570A0466|39 45|origin
P02406570A0466|18 23|sites
P02406992A0192|211 233|carotid artery studies
P02406992A0192|162 173|examination
P02406992A0192|39 48|disorders
P02409297A0984|181 199|HBsAg determinants
P02409297A0984|39 53|fusion protein
P02409297A0984|101 113|polypeptides
P02417023T0001|108 117|materials
P02417023T0001|52 61|processes
P02417023T0001|80 93|determination
P02418701A0000|122 138|antigen staining
P02418701A0000|280 289|technique
P02418701A0000|92 101|intensity
P02418701A0000|196 204|adenomas
P02418701A0000|163 171|adenomas
P02418701A0000|18 28|likelihood
P02419588A0284|1 3|A.
P02423533A1314|180 188|exposure
P02423533A1314|94 99|brain
P02423533A1314|128 132|mRNA
P02423533A1314|5 11|levels
P02423773T0001|52 57|blood
P02424743A0280|12 14|P2
P02424743A0280|5 7|N1
P02427797A0199|243 250|lactate
P02427797A0199|27 31|tail
P02427797A0199|190 200|time point
P02427797A0199|87 93|cavity
P02427797A0199|281 288|vessels
P02427797A0199|234 241|Ringers
P02427797A0199|169 172|min
P02427869A0939|14 18|beta
P02427869A0939|34 45|sensitivity
P02436005A0707|127 139|mobilization
P02436005A0707|143 145|Ca
P02436005A0707|51 57|action
P02437792T0000|15 25|elastase-1
P02437792T0000|89 98|diagnosis
P02437792T0000|108 120|pancreatitis
P02437792T0000|1 11|Comparison
P02438637T0000|33 41|spectrum
P02443028A0695|40 47|percent
P02443028A0695|55 78|muscle microvasculature
P02444507A0240|78 82|sera
P02444507A0240|1 18|Lysozyme activity
P02446871A1021|13 22|structure
P02446871A1021|57 63|region
P02446871A1021|112 120|contrast
P02451872A0391|26 41|methoxydextrane
P02451872A0391|5 13|recovery
P02454390T0000|14 31|promoter elements
P02454390T0000|42 52|activation
P02454390T0000|118 129|hepatocytes
P02455821A0099|180 185|right
P02455821A0099|126 135|UL region
P02455821A0099|5 9|gene
P02457922A0991|192 194|kb
P02457922A0991|126 138|2.8-kilobase
P02457922A0991|97 104|tissues
P02457922A0991|20 25|probe
P02457922A0991|174 179|bands
P02457922A0991|1 14|Hybridization
P02458234T0000|47 61|sleep spindles
P02458234T0000|35 43|analysis
P02459309T0000|12 19|release
P02459309T0000|80 95|caudate-putamen
P02459309T0000|103 106|rat
P02459309T0000|68 72|acid
P02462047A0208|104 108|vein
P02462047A0208|124 127|day
P02462047A0208|78 85|vessels
P02462047A0208|8 18|flap areas
P02462523A0394|75 77|Hw
P02462523A0394|72 74|su
P02462523A0394|10 28|KpnI-SalI fragment
P02462523A0394|128 130|Hw
P02462523A0394|139 148|phenotype
P02464097T0000|5 12|effects
P02464097T0000|38 49|thromboxane
P02464097T0000|16 20|L655
P02466665A0202|23 30|protein
P02469451A0239|92 99|mg dose
P02469451A0239|5 18|investigation
P02473156A0000|29 61|lymphocyte cell surface molecule
P02473156A0000|143 149|family
P02473156A0000|153 170|adhesion proteins
P02473619A0202|60 70|proportion
P02473619A0202|13 26|sensitization
P02473619A0202|142 155|sensitization
P02473619A0202|232 240|exposure
P02473619A0202|254 268|IgE antibodies
P02473718A0000|182 186|OKT8
P02473718A0000|295 301|stress
P02473718A0000|255 261|female
P02473718A0000|160 164|OKT4
P02473718A0000|43 55|relationship
P02473718A0000|101 114|catecholamine
P02473718A0000|328 336|subjects
P02473718A0000|271 274|age
P02473718A0000|222 227|cells
P02473718A0000|284 289|years
P02473718A0000|72 83|metabolites
P02473718A0000|351 355|male
P02473718A0000|5 18|investigation
P02473942A1207|77 85|segments
P02473942A1207|19 24|plots
P02474110A1039|88 94|enzyme
P02474110A1039|242 258|echocardiography
P02474110A1039|65 76|angiotensin
P02474110A1039|141 151|regression
P02474110A1039|32 41|reduction
P02474356A0559|14 27|radioactivity
P02474356A0559|166 177|circulation
P02474356A0559|146 152|portal
P02474356A0559|67 68|T
P02474356A0559|69 76|N ratio
P02475717A0565|37 66|triphenyltetrazolium staining
P02475717A0565|96 115|baseline predictors
P02475717A0565|170 185|collateral flow
P02476664A0563|45 49|gene
P02476664A0563|65 68|K14
P02479635A0659|26 35|construct
P02479635A0659|59 62|PKI
P02479635A0659|1 15|Cotransfection
P02480419A0735|105 114|infection
P02480419A0735|77 78|%
P02480419A0735|51 52|%
P02481230A1258|30 52|bovine alpha transgene
P02481230A1258|70 78|placenta
P02481779A0213|29 37|ligation
P02481779A0213|126 137|arrhythmias
P02481779A0213|253 263|mg/kg i.v.
P02481779A0213|357 358|n
P02481779A0213|351 355|mean
P02481779A0213|341 343|SD
P02481779A0213|304 316|microgram/ml
P02482511A0860|122 133|weight loss
P02482511A0860|110 117|stimuli
P02482511A0860|190 200|naltrexone
P02482511A0860|154 173|withdrawal syndrome
P02483438A0498|46 52|groups
P02483438A0498|8 13|basis
P02483438A0498|141 147|agents
P02484994T0001|13 28|gamma globulins
P02486634A0632|12 21|perfusion
P02486634A0632|128 138|morphology
P02486634A0632|100 105|level
P02488148A1156|12 19|program
P02488148A1156|22 25|use
P02488148A1156|33 45|RSNA meeting
P02488148A1156|51 58|program
P02489753A0581|148 156|GF group
P02489753A0581|5 12|results
P02489753A0581|141 143|CG
P02489753A0581|50 62|EMG activity
P02492111A0670|25 33|children
P02492111A0670|64 68|LXRF
P02493644A0588|12 21|3T3 cells
P02493644A0588|82 87|jun-B
P02493644A0588|142 162|serum growth factors
P02493644A0588|54 59|level
P02496090A0252|127 145|sampling technique
P02496090A0252|68 85|mass spectrometry
P02496109A0754|182 191|promoters
P02496109A0754|86 98|alpha region
P02496109A0754|49 60|transcripts
P02496109A0754|134 147|fusion vector
P02496109A0754|10 21|experiments
P02496109A0754|233 239|growth
P02496109A0754|273 285|alpha operon
P02498322A0226|26 35|complexes
P02498322A0226|84 93|HeLa cell
P02498322A0226|102 110|extracts
P02500432A1416|176 187|orientation
P02500432A1416|38 52|CAT expression
P02500432A1416|101 104|DNA
P02500432A1416|204 212|CAT gene
P02502602A0323|126 134|affinity
P02502602A0323|83 103|acid-base quantities
P02502602A0323|33 41|patients
P02504603T0000|14 30|Weeksella virosa
P02504603T0000|71 77|sample
P02506390T0001|43 50|animals
P02506390T0001|1 7|Growth
P02507523A0791|132 143|amino acids
P02507523A0791|5 17|ORF1 product
P02507523A0791|35 45|competence
P02508306A0528|88 97|carcinoma
P02508306A0528|10 22|infiltration
P02509123A0371|47 61|P100 component
P02509123A0371|23 26|IFN
P02509123A0371|69 72|VEP
P02511069A0532|105 107|3L
P02511069A0532|108 111|RR2
P02511069A0532|161 186|polytene chromosome bands
P02511069A0532|115 123|deletion
P02511069A0532|102 104|Df
P02511898A0000|56 70|Chagas disease
P02511898A0000|37 46|countries
P02511898A0000|6 11|paper
P02514498A0000|211 215|pCO2
P02514498A0000|176 184|equation
P02514498A0000|92 97|intra
P02514498A0000|36 43|absence
P02514498A0000|188 209|Henderson-Hasselbalch
P02514498A0000|116 136|pCO2/pH measurements
P02517008A0481|58 63|doses
P02517008A0481|34 39|trial
P02518691A0251|120 129|sequences
P02518691A0251|59 71|transfection
P02518691A0251|235 261|IL2R alpha gene expression
P02519679T0000|15 35|phosphine fumigation
P02519679T0000|1 11|Inefficacy
P02521217A1035|52 60|ribosome
P02521217A1035|87 99|mitochondria
P02522297A0000|41 87|prostaglandin endoperoxide receptor antagonist
P02522297A0000|168 172|dogs
P02522297A0000|117 125|ischemia
P02525044A1026|72 80|patients
P02525044A1026|40 48|infusion
P02525044A1026|5 19|recovery index
P02527365T0000|63 74|fibroblasts
P02527365T0000|101 116|Xenopus oocytes
P02527365T0000|1 16|Xenopus homolog
P02528329A0000|180 184|gene
P02528329A0000|111 136|hydroxylamine mutagenesis
P02528329A0000|7 23|missense mutants
P02528329A0000|169 176|subunit
P02529378A0536|121 131|adenovirus
P02529378A0536|25 28|RNA
P02529378A0536|86 96|HeLa cells
P02529378A0536|44 56|transfection
P02529378A0536|161 164|SP1
P02529378A0536|66 80|HIV constructs
P02530470A0604|13 23|prevalence
P02530470A0604|27 38|HBV markers
P02530470A0604|102 106|area
P02532032A0385|31 35|pANF
P02532032A0385|67 70|PRC
P02532032A0385|38 49|aldosterone
P02532032A0385|51 54|PAC
P02534067A0316|264 279|etiocholanolone
P02534067A0316|212 221|excretion
P02534067A0316|19 32|dexamethasone
P02534067A0316|225 237|androsterone
P02534067A0316|166 178|testosterone
P02534067A0316|281 285|DHEA
P02534067A0316|65 70|rises
P02536096A0327|120 158|chloramphenicol acetyltransferase gene
P02536096A0327|212 237|thymidine kinase promoter
P02536096A0327|80 105|thymidine kinase promoter
P02536096A0327|184 195|orientation
P02536096A0327|305 313|sequence
P02537441A0231|36 42|duties
P02537441A0231|1 5|None
P02538450A0000|96 120|Na,K-ATPase beta subunit
P02538450A0000|81 88|isoform
P02538450A0000|35 44|rat brain
P02538720A0582|33 52|polyubiquitin genes
P02538720A0582|84 91|introns
P02541882A0251|1 18|Radiation therapy
P02542270A0000|105 115|expression
P02542270A0000|150 163|bundle sheath
P02542270A0000|5 16|methylation
P02542270A0000|32 48|chloroplast DNAs
P02542270A0000|119 142|C4 photosynthesis genes
P02543226A1559|299 306|maximum
P02543226A1559|214 220|method
P02543226A1559|386 392|tissue
P02543226A1559|248 263|breast biopsies
P02543226A1559|224 232|sampling
P02543226A1559|72 83|hyperplasia
P02543226A1559|351 355|case
P02543226A1559|103 127|adipose tissue component
P02543679A1291|56 68|P initiators
P02543679A1291|160 178|lambda replication
P02543679A1291|145 156|propagation
P02543679A1291|85 89|DnaJ
P02544059A0377|12 20|nitrogen
P02544059A0377|36 39|MPa
P02544059A0377|1 8|Effects
P02545903A0639|78 81|NS3
P02545903A0639|59 63|mice
P02545903A0639|36 39|NS3
P02545903A0639|86 90|NS3A
P02547079A0910|105 107|Cd
P02547079A0910|144 153|excretion
P02547079A0910|87 101|administration
P02547706A0928|28 31|IHC
P02547706A0928|5 16|application
P02547706A0928|84 98|classification
P02547706A0928|102 112|pneumonias
P02547778A0786|63 79|control elements
P02547778A0786|23 34|arrangement
P02549036A0000|181 186|order
P02549036A0000|37 46|repressor
P02549036A0000|99 106|protein
P02549036A0000|50 56|lambda
P02549417A0000|14 20|stages
P02549417A0000|43 52|parasites
P02550682A0411|29 47|type IIc carcinoma
P02550682A0411|56 57|%
P02550682A0411|82 86|type
P02552143A0748|64 102|chloramphenicol acetyltransferase gene
P02554310A0419|89 95|effect
P02554310A0419|58 64|region
P02555418A0973|44 53|sequences
P02555418A0973|1 8|Insert2
P02555703T0000|79 84|cells
P02555703T0000|36 60|interleukin-3 dependence
P02555703T0000|141 151|regulation
P02555703T0000|1 26|Tyrosine kinase oncogenes
P02556269A0187|41 55|13mer sequence
P02556269A0187|283 294|topoisomers
P02556269A0187|260 279|gel electrophoresis
P02556269A0187|103 119|hypersensitivity
P02557217A0000|126 146|IU salmon calcitonin
P02557217A0000|101 121|spray administration
P02557217A0000|17 21|ACTH
P02557350A0632|94 102|SRP54mam
P02557350A0632|40 47|SRP54sc
P02557350A0632|5 18|DNA sequences
P02560415T0012|28 38|metastasis
P02560415T0012|42 47|mouth
P02560415T0012|17 22|tumor
P02562825A0413|65 71|agents
P02562825A0413|1 15|Responsiveness
P02565683A0841|12 22|heart rate
P02565683A0841|54 59|state
P02565683A0841|85 94|instances
P02566613A0831|11 19|sequence
P02566613A0831|69 72|CRE
P02566680A0820|62 73|I-methadone
P02566680A0820|78 89|levorphanol
P02566680A0820|52 60|morphine
P02566680A0820|33 50|agonists fentanyl
P02566680A0820|138 143|doses
P02568930T0000|15 31|characterization
P02568930T0000|91 102|stimulation
P02568930T0000|111 124|CD2 structure
P02568930T0000|1 10|Isolation
P02571924A0000|196 212|carboxy terminus
P02571924A0000|97 113|mating pheromone
P02571924A0000|115 130|rhodotorucine A
P02571924A0000|169 188|S-farnesyl cysteine
P02572928T0000|1 11|Monitoring
P02573336A0000|89 97|subjects
P02573336A0000|173 179|retest
P02573336A0000|140 145|event
P02573336A0000|38 41|ROF
P02573836A0244|104 108|mdr1
P02573836A0244|26 36|importance
P02573836A0244|65 90|drug resistance phenotype
P02573836A0244|184 202|nucleotide binding
P02574052A0910|75 101|beta-adrenoceptor blockade
P02574052A0910|54 70|Type A behaviour
P02574551T0000|19 25|asthma
P02575490A1021|90 101|nucleotides
P02575490A1021|42 60|oIGF-I transcripts
P02575490A1021|112 123|transcripts
P02575490A1021|1 23|Northern blot analysis
P02575959A0643|26 47|lactate concentration
P02575959A0643|5 17|latency time
P02577458A0412|47 52|drugs
P02577458A0412|5 15|discussion
P02577458A0412|81 98|enzyme inhibitors
P02580830A1131|61 69|cap site
P02580830A1131|83 91|AFP gene
P02580830A1131|138 144|region
P02580830A1131|152 166|mouse AFP gene
P02582918A0000|149 151|T0
P02582918A0000|212 213|%
P02582918A0000|80 84|type
P02582918A0000|221 223|T2
P02582918A0000|225 227|T0
P02582918A0000|41 64|serum antibody response
P02582918A0000|7 39|hepatitis B vaccine immunization
P02582918A0000|175 179|rate
P02585492A1005|15 36|complementation tests
P02585492A1005|123 134|P1 proteins
P02585492A1005|158 170|P7 mutations
P02586513A0622|269 278|heptamers
P02586513A0622|155 163|presence
P02586513A0622|74 82|identity
P02586513A0622|40 53|ama-1 product
P02586513A0622|111 115|RNAP
P02586513A0622|236 242|domain
P02586513A0622|100 107|subunit
P02590540A0741|73 79|excess
P02590540A0741|56 58|CA
P02590540A0741|99 100|%
P02590540A0741|86 90|U/ml
P02590540A0741|118 122|U/ml
P02590869A0743|157 165|bacteria
P02590869A0743|64 67|IgA
P02590869A0743|49 59|lavage IgG
P02590869A0743|17 23|calves
P02591969A0961|30 56|glucocorticoid stimulation
P02591969A0961|5 13|elements
P02592543A0106|45 60|characteristics
P02592543A0106|13 20|studies
P02592543A0106|149 157|isolates
P02592543A0106|119 126|patient
P02592961A0327|1 7|COGLAB
P02595451T0000|56 64|analysis
P02595451T0000|18 30|deletion map
P02597549A0964|162 166|days
P02597549A0964|42 46|days
P02597549A0964|112 118|mg/day
P02597549A0964|21 29|patients
P02597549A0964|84 94|mg X 3/day
P02598745A0251|31 46|Sylvius fissure
P02600306A0140|56 65|detection
P02600306A0140|114 124|processing
P02600306A0140|69 93|envelope phase disparity
P02602150A0993|165 175|generation
P02602150A0993|62 70|analysis
P02602150A0993|213 219|plants
P02602150A0993|191 209|gene amplification
P02602150A0993|17 23|plants
P02603923A0220|167 169|ml
P02603923A0220|108 112|days
P02603923A0220|97 100|day
P02603923A0220|173 179|Ringer
P02603923A0220|71 75|pigs
P02603923A0220|136 149|growth factor
P02605160A0000|30 45|59Fe absorption
P02605160A0000|94 103|Fe status
P02605160A0000|5 11|effect
P02605160A0000|154 158|rats
P02605679A0306|146 156|ester kdeg
P02605679A0306|114 130|degradation rate
P02605679A0306|138 143|delta
P02605679A0306|17 31|rate constants
P02609112A0000|43 51|practice
P02609112A0000|55 74|laboratory medicine
P02615078A0283|15 25|antibodies
P02615078A0283|43 56|actinomycetes
P02620085A0656|58 64|screws
P02620085A0656|155 162|results
P02620085A0656|50 56|plates
P02623038A0632|40 51|performance
P02623038A0632|55 63|controls
P02629109A0000|45 55|population
P02629109A0000|63 80|Mississippi Delta
P02629109A0000|168 178|population
P02631505A0382|64 73|treatment
P02631505A0382|1 11|Ampicillin
P02631505A0382|51 54|AMI
P02631743A0275|90 95|H-R-R
P02631743A0275|21 30|incidence
P02631743A0275|68 75|Koreans
P02632904A0619|22 28|VE/VO2
P02632904A0619|5 13|relation
P02632904A0619|69 80|correlation
P02634872A0000|82 86|zone
P02634872A0000|102 110|approach
P02637597A0362|122 125|IgG
P02637597A0362|56 63|disease
P02637597A0362|92 95|IgA
P02637597A0362|81 90|serum ANA
P02637597A0362|34 47|relapse stage
P02641762T0001|124 135|eye display
P02641762T0001|77 89|scintigraphy
P02641762T0001|37 65|exercise stress thallium-201
P02642976A1474|61 69|elements
P02645276T0088|44 53|isolation
P02645276T0088|19 39|RIP1 deletion strain
P02646007T0000|57 65|leukemia
P02646007T0000|71 81|thrombosis
P02647918A0423|14 19|group
P02647918A0423|104 108|mean
P02647918A0423|27 29|GH
P02647918A0423|185 189|U/ml
P02647937A0191|15 23|sequence
P02647937A0191|36 44|planning
P02648396A1033|14 23|formation
P02648396A1033|109 160|tumor promoter phorbol 12-tetradecanoate 13-acetate
P02648396A1033|69 80|combination
P02648646A0932|46 72|baseline PC40 methacholine
P02648646A0932|26 37|correlation
P02648646A0932|129 139|micrograms
P02648646A0932|155 159|dose
P02649811T0000|29 50|family planning study
P02651448A0000|121 137|depolymerization
P02651448A0000|26 30|drug
P02651448A0000|67 78|dissolution
P02651448A0000|139 145|Type A
P02655381A0000|126 151|laboratory investigations
P02655381A0000|249 257|arteries
P02655381A0000|292 304|neuropathies
P02655381A0000|87 96|impotence
P02655381A0000|230 234|site
P02655381A0000|67 74|factors
P02655381A0000|35 46|possibility
P02657388A1011|5 22|terminator region
P02657388A1011|48 59|transcripts
P02657883T0001|55 63|dialysis
P02666034A1520|15 23|patients
P02666034A1520|43 50|therapy
P02666034A1520|217 224|therapy
P02666034A1520|68 98|vasodilator calcium antagonist
P02666568A0000|58 63|study
P02668691A0570|28 32|nagB
P02668691A0570|92 97|genes
P02668691A0570|6 10|mRNA
P02670457T0000|41 48|storage
P02670457T0000|64 71|explant
P02674327A0493|11 15|gene
P02674327A0493|5 8|p34
P02674674A1308|63 68|sites
P02674674A1308|144 155|replication
P02674674A1308|115 127|ARS function
P02675492A0806|41 52|improvement
P02675492A0806|66 79|Ritchie-Index
P02675492A0806|101 104|CRP
P02677002A0205|45 48|ATP
P02677002A0205|160 184|equilibrium Pi exchanges
P02677002A0205|76 110|equilibrium N-carbamyl-L-aspartate
P02677002A0205|36 43|enzymes
P02677002A0205|69 72|Asp
P02677666A0356|104 112|ag alpha
P02677666A0356|36 57|complementation group
P02677666A0356|1 8|Mapping
P02680843A0724|26 28|RS
P02680843A0724|66 72|groups
P02684585T0001|32 40|rhGM-CSF
P02685461A0380|61 66|group
P02685461A0380|70 78|patients
P02686588A0592|90 110|alkaline phosphatase
P02686588A0592|126 131|group
P02686588A0592|82 85|BUN
P02686980A0000|145 155|components
P02686980A0000|80 89|nucleolus
P02686980A0000|49 61|organization
P02688772T0000|1 11|Psychiatry
P02689439A0000|91 101|isoenzymes
P02689439A0000|150 160|substrates
P02689439A0000|43 47|GSTs
P02689439A0000|68 79|superfamily
P02689544A0456|46 53|incisor
P02689544A0456|1 6|Model
P02691811A0355|37 53|plasma potassium
P02691811A0355|20 23|min
P02691811A0355|152 165|concentration
P02692881A0354|363 379|sodium excretion
P02692881A0354|302 307|total
P02692881A0354|354 359|level
P02692881A0354|190 201|derangement
P02692881A0354|84 87|PIH
P02692881A0354|281 297|sodium excretion
P02692881A0354|66 71|women
P02692881A0354|98 106|increase
P02692881A0354|236 244|increase
P02693593A0866|13 20|protein
P02693593A0866|49 60|amino acids
P02695914T0000|5 22|stereoselectivity
P02702566A0000|133 144|neck cancer
P02702566A0000|3 14|combination
P02702566A0000|32 46|5-fluorouracil
P02703121T0000|76 106|serum alanine aminotransferase
P02703121T0000|1 10|Diagnosis
P02704579A1078|15 27|relationship
P02704579A1078|47 56|evolution
P02704579A1078|162 174|gas exchange
P02704579A1078|80 86|CRS/BW
P02704579A1078|116 120|FIO2
P02705296A0231|62 66|ORF1
P02705296A0231|25 31|weight
P02705296A0231|86 89|kDa
P02707909A0209|88 102|dialysate flow
P02707909A0209|4 22|alternative method
P02708288A0621|40 45|phase
P02708288A0621|179 188|compounds
P02708288A0621|97 109|PRP-1 liquid
P02708288A0621|5 20|dichloromethane
P02708288A0621|216 225|potential
P02708288A0621|68 76|aliquots
P02708353A1452|165 176|utilization
P02708353A1452|20 45|polymerase chain reaction
P02708353A1452|185 191|tissue
P02709819A0495|40 61|ciprofloxacin therapy
P02711167A0818|133 139|damage
P02711167A0818|66 89|serum pepsinogen levels
P02711167A0818|19 26|turnout
P02712246T0042|34 49|characteristics
P02713310T0000|47 65|glomerulonephritis
P02713310T0000|20 24|type
P02713994A0482|5 10|titer
P02713994A0482|81 91|cord blood
P02713994A0482|50 60|antibodies
P02714852T0000|73 86|HLA-B alleles
P02714852T0000|9 18|variation
P02714852T0000|32 47|HLA-C sequences
P02717349A0311|58 63|women
P02720966A0455|120 128|patients
P02720966A0455|149 160|sensitivity
P02720966A0455|167 178|specificity
P02720966A0455|67 75|mu kat/L
P02720966A0455|188 198|efficiency
P02723503T0000|15 33|alternative method
P02723503T0000|1 10|Swim-over
P02725495A0929|106 111|yeast
P02725495A0929|32 45|U2 RNA region
P02725495A0929|16 24|sequence
P02727909A0383|105 108|ADP
P02727909A0383|160 167|IIb HLP
P02727909A0383|27 38|aggregation
P02727909A0383|42 48|plates
P02727909A0383|175 178|CHD
P02727909A0383|187 190|HLP
P02731611A0134|23 32|rationale
P02731611A0134|5 11|author
P02731611A0134|102 109|hiccups
P02732341A0000|75 83|neoplasm
P02732341A0000|229 238|diagnosis
P02732341A0000|53 60|studies
P02732341A0000|101 106|woman
P02733690T0000|62 67|genes
P02733690T0000|23 39|characterisation
P02733690T0000|100 107|tobacco
P02736482A0550|4 12|contrast
P02740196A0704|62 70|standard
P02740196A0704|112 126|target numbers
P02740196A0704|32 46|classification
P02740627A0137|26 47|carbon dioxide output
P02740627A0137|126 128|VA
P02740627A0137|157 161|PAO2
P02740627A0137|257 262|space
P02740627A0137|222 228|volume
P02740627A0137|287 293|horses
P02740627A0137|230 232|VT
P02740627A0137|99 101|VE
P02740627A0137|200 204|cows
P02740627A0137|68 72|rate
P02740955A0333|79 87|patients
P02740955A0333|103 113|deliveries
P02743981A0347|62 66|L11e
P02743981A0347|169 184|NAB transcripts
P02743981A0347|1 12|Transcripts
P02744490A0894|44 55|cDNA clones
P02744490A0894|243 250|domains
P02744490A0894|175 206|mRNA transcription start points
P02744490A0894|1 9|Evidence
P02744490A0894|34 40|number
P02745444A0391|53 72|S1 nuclease mapping
P02746099A0000|78 86|relation
P02746099A0000|129 135|facets
P02746099A0000|53 57|load
P02748188A0091|31 36|group
P02748188A0091|265 272|studies
P02748188A0091|145 147|Ss
P02748188A0091|220 221|P
P02748188A0091|130 135|group
P02748188A0091|203 207|test
P02748188A0091|101 104|sec
P02749215A0000|75 82|finding
P02749215A0000|36 45|hematuria
P02752303A0000|30 36|rhythm
P02752303A0000|109 111|mM
P02752303A0000|64 72|hamsters
P02752651A0480|90 101|paraparesis
P02752651A0480|107 117|impairment
P02752651A0480|56 63|patient
P02752651A0480|4 13|admission
P02752651A0480|154 159|level
P02756878A0075|150 152|AF
P02756878A0075|52 63|occurrences
P02756878A0075|116 123|history
P02756878A0075|100 108|patients
P02757862T0000|9 19|experience
P02760922A0000|108 119|S particles
P02760922A0000|76 85|component
P02760922A0000|99 104|hnRNP
P02761150A0000|181 190|pregnancy
P02761150A0000|150 154|rats
P02761150A0000|123 130|control
P02761150A0000|15 30|zinc deficiency
P02761150A0000|77 85|pancreas
P02761150A0000|5 11|effect
P02761150A0000|34 46|trace metals
P02761537A0168|92 93|%
P02761537A0168|261 272|readthrough
P02761537A0168|157 182|transcription termination
P02761537A0168|45 51|amount
P02761537A0168|141 153|% inhibition
P02761537A0168|101 114|control level
P02761537A0168|239 242|end
P02762006A0071|33 41|patients
P02763467A0903|57 65|patterns
P02763467A0903|298 305|N1L ORF
P02763467A0903|22 40|polyacrylamide gel
P02763467A0903|116 121|cells
P02763467A0903|186 190|spot
P02765001A0105|132 141|arthritis
P02765001A0105|10 14|JPsA
P02765001A0105|179 189|dactylitis
P02765001A0105|191 195|nail
P02765001A0105|169 177|criteria
P02766330A0779|105 124|calcium antagonists
P02766330A0779|145 156|application
P02766330A0779|21 28|account
P02766745T0000|61 69|placenta
P02766745T0000|18 23|study
P02767733A0690|88 94|spread
P02767733A0690|63 65|G2
P02767733A0690|56 58|G1
P02767733A0690|18 25|grading
P02773507A0750|151 167|sample estimates
P02773507A0750|93 95|CL
P02773507A0750|184 190|plasma
P02773507A0750|16 20|l/kg
P02773507A0750|199 203|drug
P02773507A0750|205 210|CLunb
P02773507A0750|34 35|V
P02774271A0000|180 188|fluoride
P02774271A0000|109 113|TFAA
P02774271A0000|42 49|pathway
P02774271A0000|1 10|Halothane
P02774271A0000|119 126|bromide
P02775136A1151|241 246|cause
P02775136A1151|7 14|results
P02775136A1151|263 266|AMS
P02775136A1151|253 259|effect
P02775136A1151|136 147|development
P02776471A0235|113 121|response
P02776471A0235|87 94|pattern
P02776823A0000|148 153|penem
P02776823A0000|249 259|volunteers
P02776823A0000|48 51|FCE
P02776823A0000|14 23|tolerance
P02776823A0000|67 69|5R
P02776823A0000|206 215|i.v. dose
P02778237A0585|88 90|IA
P02778237A0585|42 44|IA
P02778237A0585|69 76|problem
P02779752A0000|27 31|1-NP
P02779752A0000|191 201|5-HT1 site
P02779752A0000|98 111|5-HT2 subtype
P02779752A0000|168 183|agonist actions
P02780157A0576|31 36|liver
P02780157A0576|63 71|patients
P02780157A0576|157 165|reaction
P02780157A0576|262 271|depletion
P02780157A0576|316 327|stimulation
P02780157A0576|230 240|overstrain
P02780157A0576|97 114|HBsAg carriership
P02780157A0576|279 288|MP system
P02781567A0544|12 17|water
P02781567A0544|24 27|v/v
P02784507A0000|72 75|CD4
P02784507A0000|77 90|T lymphocytes
P02784507A0000|158 165|periods
P02784507A0000|139 144|cells
P02789062A0000|28 31|4F2
P02789062A0000|122 128|events
P02789062A0000|78 85|studies
P02789062A0000|52 56|gene
P02789180A0407|40 51|hypertrophy
P02789180A0407|102 110|patients
P02790009A0375|95 106|nucleotides
P02790009A0375|146 154|fragment
P02792270A1220|15 30|EPSP components
P02792270A1220|150 159|amplitude
P02792270A1220|171 184|flexion phase
P02793216A0876|28 40|conservation
P02793216A0876|48 76|membrane attachment sequence
P02793216A0876|103 107|acid
P02793753A0354|13 17|lobe
P02793753A0354|146 156|dispersion
P02793753A0354|97 99|PA
P02793753A0354|81 85|flow
P02793753A0354|69 74|l/min
P02795923A0000|122 127|study
P02795923A0000|76 85|pneumonia
P02795923A0000|4 9|order
P02796988A0735|45 50|sites
P02796988A0735|128 131|Sp1
P02796988A0735|71 90|footprinting assays
P02798953A0307|56 65|subscales
P02798953A0307|93 98|WPL-R
P02798953A0307|37 44|infants
P02798953A0307|115 121|levels
P02798953A0307|18 25|mothers
P02800417A0332|104 120|histamine values
P02800417A0332|133 134|p
P02800417A0332|54 65|correlation
P02800417A0332|17 27|asthmatics
P02802280A0495|16 27|differences
P02806916A0000|181 188|digests
P02806916A0000|209 212|DNA
P02806916A0000|52 81|cysteine proteinase inhibitor
P02806916A0000|83 91|cystatin
P02806916A0000|192 196|rice
P02806916A0000|11 20|DNA clone
P02806916A0000|235 242|oc cDNA
P02808232A0681|83 84|%
P02808232A0681|68 79|reliability
P02809651A0492|72 82|clinicians
P02809651A0492|39 43|role
P02809651A0492|117 126|questions
P02809831A0799|78 82|bone
P02809831A0799|25 33|DBP side
P02809831A0799|18 22|PPSF
P02811378A0250|145 153|mandible
P02811378A0250|80 86|mucosa
P02811378A0250|117 122|ridge
P02813369A0390|29 34|males
P02813369A0390|128 133|years
P02813369A0390|114 120|harems
P02814182A1211|90 95|WORDS
P02814182A1211|4 8|rats
P02815229A0139|120 123|14C
P02815229A0139|124 133|diltiazem
P02815229A0139|42 51|mg t.i.d.
P02815229A0139|5 15|treatments
P02815229A0139|68 77|treatment
P02817724A0075|37 49|T2 sequences
P02817724A0075|54 59|scans
P02818260T0000|11 17|glioma
P02820128A1670|300 305|units
P02820128A1670|212 219|insulin
P02820128A1670|115 125|palindrome
P02820128A1670|135 138|end
P02820128A1670|97 100|end
P02820128A1670|5 17|significance
P02820128A1670|238 249|palindromes
P02825139A0661|43 51|homology
P02826127A0709|62 80|SV40 octamer motif
P02826127A0709|157 166|component
P02826127A0709|190 198|extracts
P02826729A0790|89 93|rats
P02826729A0790|18 35|14C turnover data
P02826729A0790|69 79|B-6 intake
P02829183A0117|79 90|translocase
P02829183A0117|70 75|forms
P02830265A0341|47 54|daltons
P02830265A0341|18 35|polypeptide chain
P02831398A0346|14 16|W.
P02831796A0000|164 189|immunodeficiency syndrome
P02831796A0000|146 151|agent
P02831796A0000|42 52|lentivirus
P02831796A0000|200 206|humans
P02831796A0000|32 35|SIV
P02832293T0000|62 70|syndrome
P02832293T0000|52 59|Cushing
P02832293T0000|39 48|diagnosis
P02833012A0428|31 42|nucleotides
P02833012A0428|110 119|L protein
P02833012A0428|138 149|amino acids
P02833049A0630|55 65|insertions
P02833049A0630|1 11|Variations
P02833101T0000|10 16|crisis
P02833101T0000|43 63|bone marrow necrosis
P02834478A0000|104 110|action
P02834478A0000|114 123|Xa factor
P02836623A1094|62 84|months postinoculation
P02836623A1094|27 34|animals
P02836623A1094|126 133|animals
P02836623A1094|1 3|Mo
P02837763A0259|91 117|muscle phosphatase 2A cDNA
P02837763A0259|126 147|% nucleotide identity
P02837763A0259|34 45|liver clone
P02838319A0527|41 42|%
P02838319A0527|65 66|p
P02839488A1314|60 69|alpha s-1
P02839488A1314|162 170|products
P02839488A1314|202 208|margin
P02839488A1314|34 42|activity
P02839716A1907|91 102|competition
P02839716A1907|24 28|E2-C
P02839716A1907|52 69|enhancer activity
P02839716A1907|168 176|ABSTRACT
P02840376A0461|16 22|Holmer
P02843694T0001|53 61|lymphoma
P02844767A0596|132 139|introns
P02844767A0596|5 23|Nostoc petBD genes
P02844767A0596|100 111|polypeptide
P02844797A1225|194 205|amino acids
P02844797A1225|13 27|muscle isoform
P02844797A1225|133 144|amino acids
P02844797A1225|332 350|glycosylation site
P02844797A1225|80 104|sequence Ala-Ile-Leu-Glu
P02844797A1225|117 124|isoform
P02846640A0643|45 64|indoxyl phosphatase
P02846640A0643|72 74|pI
P02848842A0643|91 95|gene
P02848842A0643|131 136|cells
P02848842A0643|39 41|.2
P02849759A0865|29 40|replication
P02849759A0865|48 52|fold
P02850967T0000|124 131|element
P02850967T0000|86 102|characterization
P02852805A0216|90 100|treatments
P02852805A0216|67 76|influence
P02853799T0001|105 114|carcinoma
P02853799T0001|5 16|progression
P02853799T0001|54 62|diseases
P02856622T0001|95 102|thyroid
P02856622T0001|8 41|serum thyroglobulin determination
P02856622T0001|1 4|Use
P02861067A0000|182 199|beta agonist drug
P02861067A0000|82 90|patients
P02861067A0000|5 8|aim
P02861067A0000|17 22|study
P02861238T0000|9 14|virus
P02863492A0544|228 238|responders
P02863492A0544|83 93|responders
P02863492A0544|16 27|differences
P02865502T0000|25 30|trial
P02865502T0000|87 94|placebo
P02868848A0167|165 169|mode
P02868848A0167|10 20|vancomycin
P02868848A0167|85 93|activity
P02870249T0000|14 26|chemotherapy
P02870851A0349|11 19|99mTcO-4
P02870851A0349|58 70|fluctuations
P02873593A0581|14 18|rats
P02873593A0581|196 216|5-HT uptake blockers
P02873593A0581|99 105|reward
P02873593A0581|139 148|frequency
P02874635T0000|90 102|cleft palate
P02874635T0000|62 73|torticollis
P02874635T0000|26 43|fungicide dinocap
P02874635T0000|128 136|hamsters
P02875967A0377|5 16|sensitivity
P02875967A0377|116 130|fertility rate
P02876899A0568|77 84|decline
P02876899A0568|127 143|absorption phase
P02878100A0674|46 56|inhibition
P02878100A0674|159 167|activity
P02878100A0674|71 83|transmission
P02878100A0674|204 216|transmission
P02879951T0000|55 79|rat platelet aggregation
P02879951T0000|35 40|agent
P02882893A0301|1 17|Body temperature
P02882893A0301|119 121|sp
P02883871A1075|13 16|ISA
P02883871A1075|65 69|drug
P02883871A1075|3 7|drug
P02883871A1075|34 48|beta receptors
P02884860A0329|25 31|analog
P02884860A0329|67 80|adrenoceptors
P02884860A0329|35 43|prazosin
P02889352A0000|41 43|BP
P02889352A0000|25 39|blood pressure
P02889352A0000|6 14|patients
P02889352A0000|137 153|enzyme inhibitor
P02890200T0001|54 68|Recklinghausen
P02894689A0000|90 94|help
P02894689A0000|106 126|extraction procedure
P02894689A0000|65 80|chromatin loops
P02894689A0000|136 145|lithium-3
P02894789A0954|107 108|%
P02894789A0954|100 101|%
P02894789A0954|69 74|T1/T0
P02895566A0187|36 45|intensity
P02895566A0187|20 28|increase
P02895566A0187|1 4|DPA
P02897651A0000|40 46|causes
P02897651A0000|1 16|Hyperthyroidism
P02899177A0605|105 112|effects
P02899177A0605|160 172|excitability
P02899177A0605|21 30|technique
P02899177A0605|34 56|low-frequency kindling
P02900760A0073|124 129|pol I
P02900760A0073|214 238|rDNA minigene constructs
P02900760A0073|77 102|transcription termination
P02900760A0073|159 179|transcription system
P02901763A0977|73 79|codons
P02901763A0977|148 159|codon usage
P02901763A0977|191 211|C. reinhardtii mtDNA
P02901763A0977|16 43|C. reinhardtii mitochondria
P02902656A0481|121 125|time
P02902656A0481|61 64|fat
P02902656A0481|179 182|fat
P02902656A0481|191 206|TR/TE sequences
P02902656A0481|165 175|isointense
P02902656A0481|46 57|hypointense
P02902656A0481|138 143|cases
P02902656A0481|34 40|testes
P02902927A0145|23 32|isolation
P02904322A0002|26 34|antelope
P02906027A1156|15 23|features
P02906027A1156|50 51|G
P02906673T0000|90 111|floodwater mosquitoes
P02906673T0000|58 62|H-14
P02906673T0000|1 9|Efficacy
P02906673T0000|68 81|B. sphaericus
P02907533A0362|6 10|loss
P02907533A0362|55 72|correction factor
P02909528A1081|95 106|start sites
P02910989T0000|12 17|aging
P02910989T0000|67 81|QT/QS2 changes
P02913368A1037|130 136|influx
P02913368A1037|95 113|calcium antagonist
P02913368A1037|154 161|calcium
P02913368A1037|50 63|acetylcholine
P02914492A0183|30 38|patients
P02914492A0183|95 101|mEq/dl
P02914492A0183|190 197|percent
P02914492A0183|107 115|patients
P02914492A0183|72 80|serum Mg
P02914492A0183|43 50|percent
P02914492A0183|4 13|admission
P02918474A0817|134 142|ml/min/g
P02918474A0817|9 18|verapamil
P02918474A0817|23 33|nifedipine
P02918474A0817|101 115|subendocardium
P02919530A0000|56 66|myocardium
P02919530A0000|172 183|wall motion
P02919530A0000|32 43|reperfusion
P02920591A0251|107 115|dopamine
P02920591A0251|58 72|administration
P02920591A0251|87 100|micrograms/kg
P02925013A1112|104 116|accumulation
P02925013A1112|132 146|citrate ligand
P02926499A0340|211 214|rho
P02926499A0340|176 179|tau
P02926499A0340|127 130|CBF
P02926499A0340|52 61|heat flow
P02926499A0340|155 157|Cb
P02926499A0340|195 200|decay
P02926499A0340|167 168|c
P02926499A0340|36 48|analog model
P02928112T0000|63 64|A
P02928112T0000|26 30|cDNA
P02929056T0000|12 15|use
P02929056T0000|55 75|ureterosigmoidostomy
P02934778A0702|24 32|presence
P02934778A0702|36 41|5-HT2
P02934778A0702|55 64|receptors
P02934891A0845|15 21|method
P02934891A0845|209 212|end
P02934891A0845|140 145|sites
P02934891A0845|86 91|cells
P02936163T0000|61 72|interaction
P02936163T0000|100 130|platelet lipoxygenase activity
P02938185A0223|211 223|architecture
P02938185A0223|94 101|viruses
P02938185A0223|42 45|E1a
P02938185A0223|141 147|growth
P02938185A0223|49 52|E1a
P02940334A0141|40 45|doses
P02940334A0141|110 119|schedules
P02940334A0141|1 8|Group A
P02943562T0000|71 81|importance
P02943562T0000|51 58|strains
P02949170A0184|92 114|mg cyproterone acetate
P02949170A0184|144 156|testosterone
P02949170A0184|158 186|sex hormone binding globulin
P02949170A0184|195 210|androstenedione
P02949170A0184|282 291|treatment
P02949170A0184|37 48|preparation
P02949170A0184|272 278|months
P02957125A0601|105 129|plasma ANP concentration
P02957125A0601|9 17|patients
P02958233A0123|14 21|picture
P02958233A0123|71 94|serum sickness reaction
P02959089T0000|22 30|ONO-3708
P02959089T0000|34 44|thrombosis
P02962859A0276|109 111|U1
P02962859A0276|127 136|A antigen
P02964329A0000|45 48|LJM
P02964329A0000|29 43|Joint Mobility
P02964329A0000|53 61|diabetes
P02964329A0000|137 146|incidence
P02966671A0151|94 108|treatment size
P02966671A0151|126 136|stem cells
P02966671A0151|114 122|survival
P02966671A0151|64 70|tumors
P02966671A0151|206 211|weeks
P02966671A0151|153 159|crypts
P02967496A0182|113 127|leader segment
P02967496A0182|19 29|transcript
P02967915A0968|149 156|signals
P02967915A0968|4 12|addition
P02967915A0968|18 41|calbindin-D28K promoter
P02969316A0002|15 22|ability
P02969316A0002|227 228|h
P02969316A0002|213 217|dogs
P02969316A0002|129 136|changes
P02969316A0002|101 108|peptide
P02970061A0271|45 52|protein
P02970061A0271|5 15|RAD18 gene
P02970061A0271|101 107|weight
P02971603A0883|6 14|patients
P02971603A0883|54 57|day
P02971957A0287|74 79|cases
P02971957A0287|101 111|techniques
P02975680A0000|151 167|anxiety disorder
P02975680A0000|93 99|nights
P02975680A0000|219 222|age
P02975680A0000|191 201|depression
P02975680A0000|117 127|inpatients
P02975680A0000|11 30|accommodation night
P02975680A0000|273 278|group
P02975680A0000|32 52|sleep EEG recordings
P02976332A1277|5 18|concentration
P02979834T0000|120 135|ethyl carbamate
P02979834T0000|156 167|lung cancer
P02979834T0000|70 99|cyclophosphamide chemotherapy
P02979834T0000|171 179|A/J mice
P02981840A0907|12 25|pair sequence
P02981840A0907|71 82|nucleotides
P02983316A0310|390 394|time
P02983316A0310|330 349|nucleotide sequence
P02983316A0310|314 326|preservation
P02983316A0310|162 170|analysis
P02983316A0310|42 51|framework
P02983316A0310|17 25|segments
P02985812A0984|12 19|feature
P02985812A0984|126 130|mRNA
P02985812A0984|98 111|reading frame
P02986279A0000|129 132|CMV
P02986279A0000|112 127|cytomegalovirus
P02986279A0000|4 16|milk samples
P02986279A0000|35 41|donors
P02987777A0000|7 12|cases
P02989637A0671|60 91|zona glomerulosa corticosteroid
P02989637A0671|330 333|men
P02989637A0671|131 139|patients
P02989637A0671|295 306|aldosterone
P02989637A0671|157 174|cord transections
P02989637A0671|206 214|pathways
P02991060A0465|61 69|delivery
P02991060A0465|132 136|ages
P02991060A0465|147 153|babies
P02991060A0465|7 21|IgG antibodies
P02994253A0482|30 47|mean NTE activity
P02994253A0482|134 148|control values
P02994253A0482|198 212|cord pathology
P02994253A0482|58 62|cord
P02994253A0482|7 14|dosages
P02994253A0482|96 101|brain
P02995967T0000|148 168|gland adenocarcinoma
P02995967T0000|64 72|c-erbB-1
P02995967T0000|33 41|c-erbB-2
P02997622A0916|127 134|patient
P02997622A0916|84 104|SCLC tumour specimen
P02998016A0527|228 233|c-mil
P02998016A0527|199 212|reading frame
P02998016A0527|5 13|homology
P02998016A0527|48 56|sequence
P02998016A0527|238 243|v-mil
P02999267A0606|28 39|amyloidosis
P02999267A0606|11 14|FAP
P02999267A0606|80 87|uptakes
P03000457A1554|72 82|processing
P03000457A1554|9 22|kDa precursor
P03000457A1554|54 55|h
P03000457A1554|114 117|kDa
P03001054A0703|31 36|nicks
P03001086A0587|15 34|amino acid sequence
P03001086A0587|83 88|hsp70
P03001086A0587|103 116|Xenopus hsp70
P03001086A0587|51 59|homology
P03001353A0146|105 107|kb
P03001353A0146|66 72|P58gag
P03001353A0146|4 16|temperatures
P03001353A0146|48 57|6m2 cells
P03001705T0000|11 25|transformation
P03001705T0000|108 120|gene product
P03001705T0000|37 46|fragments
P03002501A1327|15 24|sequences
P03002501A1327|110 118|homology
P03002501A1327|54 86|guinea-pig alpha s1-casein mRNAs
P03003695A0395|122 136|kbp DNA region
P03003695A0395|56 63|Collins
P03003695A0395|38 54|c-sis cDNA clone
P03003695A0395|186 188|bp
P03004739A0753|177 196|CAT binding protein
P03004739A0753|22 36|G transversion
P03004739A0753|65 84|CAT pentanucleotide
P03004739A0753|17 18|C
P03004982A1094|109 127|fbcF reading frame
P03004982A1094|16 24|sequence
P03006066A0653|111 119|P54c-ets
P03006066A0653|42 61|translation product
P03006066A0653|101 109|proteins
P03008094A0697|28 39|polypeptide
P03008094A0697|54 59|types
P03009366A0438|78 89|pneumocytes
P03009366A0438|42 49|studies
P03009366A0438|113 122|radiation
P03009366A0438|185 193|exposure
P03009366A0438|207 211|days
P03010281A0220|25 31|repeat
P03010281A0220|65 80|gene expression
P03013477A0000|241 249|patients
P03013477A0000|91 101|metabolism
P03013477A0000|333 338|ng/ml
P03013477A0000|179 182|PMN
P03013477A0000|23 32|influence
P03013477A0000|86 89|PMN
P03013477A0000|105 113|patients
P03013477A0000|192 197|blood
P03013477A0000|283 294|individuals
P03013477A0000|36 49|iron overload
P03013477A0000|139 149|generation
P03014515T0000|30 49|nucleotide sequence
P03014515T0000|55 65|cDNA clone
P03015611A0331|73 87|lysine residue
P03015611A0331|126 130|site
P03015953T0000|13 27|glucocorticoid
P03015953T0000|63 92|mouse glucocorticoid receptor
P03015953T0000|1 9|Analysis
P03016506A0611|303 315|animal cells
P03016506A0611|283 299|G-418 resistance
P03016506A0611|23 27|p410
P03016506A0611|200 208|sequence
P03016506A0611|168 182|antigen EBNA-1
P03017225A0706|121 128|stomach
P03017225A0706|149 155|glands
P03017225A0706|227 235|Nakamura
P03017225A0706|81 88|stomach
P03017225A0706|35 49|leather bottle
P03017225A0706|51 72|linitis plastica type
P03018491A0840|180 183|end
P03018491A0840|23 31|TGTCCT-3
P03018491A0840|191 195|gene
P03018491A0840|103 111|sequence
P03020001A0781|215 225|insertions
P03020001A0781|244 258|kilobase pairs
P03020001A0781|21 37|mini-Mu elements
P03020001A0781|84 91|cloning
P03021050A0501|56 65|sulbactam
P03021050A0501|40 52|quantitation
P03022129A0842|195 213|transcription rate
P03022129A0842|147 153|extent
P03022129A0842|36 44|MPE X Fe
P03022129A0842|222 226|gene
P03023679A0624|15 21|weight
P03023679A0624|150 162|modification
P03023859A0000|165 170|probe
P03023859A0000|122 136|Ph1 chromosome
P03023859A0000|8 12|DNAs
P03023859A0000|81 85|date
P03023859A0000|103 113|chromosome
P03023970A0922|135 146|p53 product
P03023970A0922|11 17|insert
P03023970A0922|76 87|termination
P03024703A1036|12 18|region
P03024703A1036|27 38|nucleotides
P03024703A1036|81 92|amino acids
P03025655T0000|134 168|Fujinami sarcoma virus P130gag-fps
P03025655T0000|109 130|transforming activity
P03025655T0000|68 75|kinases
P03025862A0860|10 14|exon
P03025862A0860|143 156|addition site
P03025862A0860|115 119|mRNA
P03025862A0860|101 107|region
P03027661A0000|23 32|D protein
P03027905A0632|79 89|lisinopril
P03027905A0632|1 22|Plasma renin activity
P03031602A1001|83 88|genes
P03031602A1001|68 74|region
P03032964T0000|94 102|activity
P03032964T0000|70 79|sequences
P03033283A1415|240 245|sites
P03033283A1415|331 340|SCMV IE94
P03033283A1415|317 327|expression
P03033283A1415|355 364|HCMV IE68
P03034956A0666|151 161|prednisone
P03034956A0666|128 131|day
P03034956A0666|143 146|day
P03034956A0666|34 49|androgen levels
P03035218T0000|46 55|sequences
P03035218T0000|1 15|Identification
P03036415T0000|165 169|dogs
P03036415T0000|100 136|pressure/cardiac index relationships
P03036933A0774|73 87|ACTH treatment
P03036933A0774|1 13|ACTH release
P03038643A1374|93 103|divergence
P03038643A1374|140 144|gene
P03039177A0503|94 112|IR2 repeat element
P03039177A0503|162 173|enzyme SmaI
P03039177A0503|18 29|cDNA clones
P03040023A0113|60 71|tachycardia
P03040023A0113|1 9|Morphine
P03041046A0127|9 15|A-MuLV
P03041046A0127|249 258|potential
P03041046A0127|260 262|N.
P03041046A0127|38 45|viruses
P03042778A0643|44 50|growth
P03042778A0643|5 9|gene
P03045117A0936|269 274|Leu47
P03045117A0936|226 229|Thr
P03045117A0936|79 86|species
P03045117A0936|161 166|Glu24
P03045117A0936|100 113|growth factor
P03045117A0936|17 23|values
P03046655A0000|72 75|eye
P03046655A0000|92 100|patients
P03046655A0000|49 55|acuity
P03048024A0418|76 84|NIB rats
P03048024A0418|64 66|IB
P03050147A0896|107 114|amounts
P03050147A0896|24 29|cells
P03050147A0896|7 16|infection
P03052327A1474|90 99|treatment
P03052327A1474|40 71|pancreas-kidney transplantation
P03052327A1474|4 8|view
P03052327A1474|103 109|choice
P03053713A0752|71 76|bases
P03053713A0752|50 63|reading frame
P03059171A1232|41 48|heparin
P03059171A1232|155 168|deterioration
P03059171A1232|1 15|Administration
P03060953A0481|94 103|outbreaks
P03060953A0481|1 8|Animals
P03061301A1409|44 52|F1 alpha
P03061301A1409|10 19|excretion
P03061301A1409|80 87|smokers
P03061301A1409|102 116|contraceptives
P03062370A0000|32 41|activator
P03062370A0000|69 74|genes
P03064524A0160|5 13|efficacy
P03065140A0273|27 34|regions
P03065140A0273|38 50|GAL4 protein
P03065610A0375|73 94|Western blot analysis
P03065610A0375|42 54|gene product
P03066131A0000|120 127|lesions
P03066131A0000|135 143|amygdala
P03066131A0000|9 15|survey
P03066131A0000|52 57|basis
P03066131A0000|71 80|treatment
P03066131A0000|84 103|behaviour disorders
P03066625A0756|30 37|studies
P03066625A0756|77 90|contributions
P03066625A0756|144 156|risk factors
P03069046A0126|58 69|sensitivity
P03069046A0126|35 44|precision
P03072021A0696|67 86|targeting sequences
P03072021A0696|33 38|yeast
P03073091A0338|8 24|insulin infusion
P03073091A0338|67 76|Biostator
P03073091A0338|80 85|order
P03073192T0000|71 96|immunodeficiency syndrome
P03076124A0496|180 191|simvastatin
P03076124A0496|29 43|cholestyramine
P03076124A0496|333 348|LDL-cholesterol
P03076124A0496|93 103|inhibitors
P03076124A0496|216 221|drugs
P03076124A0496|255 276|hypercholesterolaemia
P03076124A0496|226 229|use
P03076124A0496|107 139|hydroxymethylglutaryl coenzyme A
P03076124A0496|233 241|patients
P03076124A0496|141 148|HMG CoA
P03079276T0029|15 21|groups
P03079276T0029|86 95|flare-ups
P03083441T0000|62 68|people
P03083441T0000|34 49|postcontraction
P03090237A0202|13 22|schedules
P03090237A0202|95 100|times
P03090237A0202|37 49|response run
P03091849A0000|123 128|kinds
P03091849A0000|219 224|mm Hg
P03091849A0000|81 85|beds
P03091849A0000|16 30|glutaraldehyde
P03091849A0000|162 170|fixative
P03091849A0000|5 12|effects
P03091849A0000|34 44|dimensions
P03097643A1357|148 154|region
P03097643A1357|41 53|substitution
P03097643A1357|113 124|nucleotides
P03102289A0786|164 173|cycle day
P03102289A0786|150 160|ultrasound
P03102289A0786|59 77|hCG administration
P03102289A0786|249 257|follicle
P03102289A0786|5 9|data
P03102289A0786|238 244|pmol/l
P03104248A0322|105 110|tumor
P03104248A0322|124 132|patients
P03104248A0322|8 16|Stage IA
P03104248A0322|112 114|G2
P03104982A0690|105 119|sex difference
P03104982A0690|42 45|men
P03104982A0690|20 37|hemoglobin levels
P03104982A0690|81 86|women
P03109147A0000|160 164|dose
P03109147A0000|128 135|dosages
P03109147A0000|113 122|NMRI mice
P03109147A0000|169 174|mouse
P03109954A0945|328 340|relationship
P03109954A0945|123 133|inhibition
P03109954A0945|146 168|artery atherosclerosis
P03109954A0945|220 256|plasma HDL cholesterol concentration
P03109954A0945|79 86|ethinyl
P03109954A0945|108 110|OC
P03109954A0945|5 12|results
P03110678A0702|268 282|urea clearance
P03110678A0702|130 150|beta 2-microglobulin
P03110678A0702|36 43|removal
P03110678A0702|253 263|blood flow
P03110678A0702|103 118|haemofiltration
P03110678A0702|85 98|haemodialysis
P03110746A0146|79 93|adipose tissue
P03110746A0146|95 101|PLASAT
P03110746A0146|33 37|acid
P03110801A0532|60 70|micrograms
P03112028A0404|52 53|n
P03112028A0404|70 71|n
P03114188A0907|31 39|problems
P03114188A0907|176 182|breast
P03114188A0907|202 207|areas
P03114188A0907|136 144|patients
P03114995T0000|46 61|gastrin release
P03114995T0000|33 42|nutrition
P03115787A0633|28 44|cyclophosphamide
P03115787A0633|193 199|months
P03115787A0633|214 223|responses
P03115787A0633|6 14|patients
P03115787A0633|81 90|cisplatin
P03115787A0633|118 125|disease
P03117147A1059|165 178|investigation
P03117147A1059|57 64|surface
P03117147A1059|39 48|agreement
P03117147A1059|17 22|study
P03119227A0079|61 78|sequence homology
P03119227A0079|92 120|c-abl proto-oncogene product
P03119227A0079|172 183|amino acids
P03119227A0079|217 241|tyrosine kinase activity
P03120334A0893|123 128|veins
P03120334A0893|6 7|%
P03120334A0893|96 102|system
P03123983T0000|13 28|neuroplasticity
P03123983T0000|5 9|role
P03125422A0202|91 94|UAS
P03125422A0202|22 33|experiments
P03125422A0202|5 12|results
P03127034A0591|29 33|rate
P03127034A0591|69 79|resistance
P03132498A0730|149 153|mean
P03132498A0730|176 180|mean
P03132498A0730|7 15|patients
P03132498A0730|66 71|range
P03132498A0730|81 85|torr
P03133360A1215|31 42|mtr product
P03133360A1215|99 110|translation
P03133360A1215|55 80|transcription attenuation
P03137105A0146|192 209|oocyte collection
P03137105A0146|41 50|pregnancy
P03137105A0146|178 183|cycle
P03137105A0146|233 239|cycles
P03137105A0146|3 25|prostaglandin analogue
P03137601A0212|211 229|NE neurotoxin DSP4
P03137601A0212|62 76|norepinephrine
P03137601A0212|10 39|L-threo-dihydroxyphenylserine
P03137601A0212|108 118|immobility
P03137601A0212|162 172|immobility
P03137601A0212|82 91|precursor
P03138449A0759|41 64|desaturation activities
P03138449A0759|21 26|delta
P03138449A0759|85 95|conditions
P03142875A0366|67 72|chain
P03142875A0366|117 126|structure
P03143485A0366|194 201|tobacco
P03143485A0366|111 128|gene organization
P03143485A0366|158 163|order
P03143485A0366|206 235|liverwort chloroplast genomes
P03146017A0983|167 189|amino acid polypeptide
P03146017A0983|130 141|nucleotides
P03146017A0983|143 150|ORFtrpB
P03146017A0983|32 38|region
P03146017A0983|118 121|ORF
P03146784A0158|244 258|chemoreceptors
P03146784A0158|7 16|receptors
P03146784A0158|260 263|IPC
P03146784A0158|32 37|phase
P03149774A0173|61 71|picrotoxin
P03149774A0173|47 57|injections
P03149774A0173|128 137|retention
P03149774A0173|8 15|IA task
P03149774A0173|178 187|retention
P03149774A0173|234 258|GABA receptor antagonist
P03150296A0594|44 64|creatinine clearance
P03150296A0594|26 29|use
P03150296A0594|177 183|method
P03150296A0594|92 107|filtration rate
P03150296A0594|158 169|limitations
P03150296A0594|255 275|creatinine clearance
P03159903A0352|26 32|region
P03159903A0352|8 11|end
P03167060A0000|14 27|growth factor
P03167060A0000|125 135|derivation
P03167060A0000|54 65|polypeptide
P03167060A0000|32 37|IGFII
P03171221A0531|56 64|splicing
P03171221A0531|34 40|result
P03172863T0000|60 66|stress
P03172863T0000|37 51|susceptibility
P03172863T0000|1 7|Effect
P03178097A0000|94 101|atresia
P03178097A0000|66 75|anomalies
P03178626A0137|25 36|Attack Wing
P03178626A0137|38 45|Pacific
P03178626A0137|68 75|results
P03180595A1040|9 34|gallbladder visualization
P03180595A1040|39 48|reduction
P03182802A0278|1 4|Sci
P03183103A0000|122 132|volunteers
P03183103A0000|41 47|cavity
P03184267A0000|176 184|chickens
P03184267A0000|142 152|infections
P03184267A0000|5 9|feed
P03184267A0000|207 213|humans
P03185540T0000|149 154|TFIID
P03185540T0000|76 88|purification
P03185540T0000|115 145|TATA box-promoter interactions
P03186270T0001|14 23|diagnosis
P03190914A0149|123 128|group
P03192724A0000|15 32|style differences
P03192724A0000|108 129|FIRO-B interpretation
P03192724A0000|98 104|system
P03192950A0566|92 97|range
P03192950A0566|1 5|Sera
P03195167A0104|149 166|polyvinylchloride
P03195167A0104|37 43|layers
P03195167A0104|143 146|PUR
P03195167A0104|114 141|basic-polymers polyurethane
P03195167A0104|71 80|valuation
P03198525A0164|31 38|heifers
P03198525A0164|63 69|medium
P03198525A0164|176 177|d
P03198525A0164|218 227|mg MGA/hd
P03198525A0164|156 159|MGA
P03198525A0164|12 25|feedlot trial
P03198525A0164|198 203|ml/hd
P03198525A0164|102 112|treatments
P03199436A1060|12 25|gene clusters
P03199436A1060|35 60|photosynthesis components
P03200844A1211|44 61|pore glycoprotein
P03200844A1211|109 117|proteins
P03200844A1211|172 178|family
P03200844A1211|190 208|pore glycoproteins
P03208493A0849|16 31|filtration rate
P03212551T0001|5 17|pathogenesis
P03212551T0001|33 44|contracture
P03214709A0559|164 169|group
P03214709A0559|122 127|group
P03214709A0559|17 24|release
P03218714A0000|106 109|TOF
P03218714A0000|64 67|DWM
P03218714A0000|17 21|girl
P03220077A0274|60 64|time
P03220077A0274|72 77|years
P03227288A0542|37 41|loss
P03227288A0542|87 90|age
P03228518A0339|74 97|Personal Responsibility
P03228518A0339|64 72|Academic
P03229917A0099|66 83|remnant infection
P03233862T0000|62 71|sclerosis
P03235487A0404|29 58|M sodium dihydrogen phosphate
P03235487A0404|112 122|shelf-life
P03235487A0404|96 104|decrease
P03239106A0856|60 72|reabsorption
P03239106A0856|42 46|diet
P03239106A0856|16 34|phosphorus content
P03243920A0591|25 66|plasma concentration-effect relationships
P03249792A0241|73 89|group activities
P03249792A0241|26 37|development
P03249792A0241|131 145|stress factors
P03249792A0241|201 215|manifestations
P03249792A0241|171 180|psychoses
P03251210A0981|134 145|dysfunction
P03251210A0981|6 14|children
P03251210A0981|114 119|forms
P03256150A1866|5 12|results
P03258069A0000|183 197|pain threshold
P03258069A0000|214 219|wrist
P03258069A0000|267 271|time
P03258069A0000|66 75|intensity
P03258069A0000|81 90|frequency
P03258069A0000|255 261|effect
P03261005A0216|15 23|children
P03261005A0216|94 103|care unit
P03261005A0216|156 162|period
P03261005A0216|50 57|complex
P03261331A0563|47 68|AIDS dementia complex
P03261331A0563|92 105|understanding
P03261331A0563|1 6|SPECT
P03263465T0000|31 36|H-2Dq
P03263465T0000|12 21|MHC class
P03263465T0000|41 46|H-2Lq
P03263465T0000|144 152|antigens
P03264299A0679|107 119|ip injection
P03264299A0679|96 100|days
P03264299A0679|87 90|day
P03267732A0788|56 62|method
P03267732A0788|156 162|effect
P03270085A0382|27 44|magnesium wasting
P03270085A0382|1 15|Hypomagnesemia
P03275867A0187|151 159|sequence
P03275867A0187|161 164|UAS
P03275867A0187|52 60|elements
P03275867A0187|200 215|MAT alpha genes
P03275867A0187|1 5|GRFI
P03276246A0037|77 84|TAC-WBC
P03276246A0037|65 75|blood cell
P03276246A0037|51 58|colloid
P03278829A0082|77 86|candidate
P03278829A0082|25 28|use
P03278829A0082|5 16|indications
P03280807A0000|160 166|codons
P03280807A0000|128 135|glycine
P03280807A0000|18 29|suf12 locus
P03280807A0000|155 158|CCX
P03280807A0000|187 209|UAG nonsense mutations
P03280912T0000|1 24|Antituberculosis agents
P03282232A0743|109 120|immunoblots
P03282232A0743|93 97|DP-I
P03283881A0216|73 85|inflammation
P03283881A0216|8 16|patients
P03286611A1198|10 12|H.
P03292076A0820|240 263|eicosanoid biosynthesis
P03292076A0820|106 114|tendency
P03292076A0820|173 179|degree
P03292076A0820|87 99|permeability
P03293844T0000|1 5|Diet
P03296212A0603|538 544|agents
P03296212A0603|29 39|interferon
P03296212A0603|487 493|agents
P03296212A0603|216 225|potential
P03296212A0603|461 470|potential
P03296212A0603|357 366|diagnosis
P03296212A0603|15 23|research
P03296212A0603|229 232|IFN
P03296212A0603|142 149|synergy
P03296212A0603|234 242|research
P03296212A0603|415 422|history
P03297181A0127|181 185|food
P03297181A0127|107 114|release
P03297181A0127|65 72|release
P03297181A0127|48 53|doses
P03297181A0127|168 175|product
P03297181A0127|187 191|SR-F
P03300118A0392|21 32|base excess
P03304866T0001|59 68|osteotomy
P03306340A0537|91 99|hardness
P03306340A0537|122 133|obstruction
P03306340A0537|80 89|carcinoma
P03306340A0537|116 120|tail
P03306340A0537|153 157|duct
P03309892A0637|45 47|S.
P03309892A0637|177 198|initiation start site
P03309892A0637|54 59|genes
P03309892A0637|222 227|yeast
P03312033A0501|124 134|tobramycin
P03312033A0501|18 29|ceftazidime
P03312033A0501|85 104|combination therapy
P03315359A0732|160 168|fissures
P03315359A0732|144 150|masses
P03315359A0732|70 80|evaluation
P03315359A0732|34 41|studies
P03319621A0707|29 30|%
P03319621A0707|4 12|contrast
P03319621A0707|34 39|alpha
P03319912A0000|91 99|patients
P03319912A0000|22 27|night
P03319912A0000|117 122|years
P03319912A0000|194 200|median
P03319912A0000|162 168|months
P03319912A0000|206 214|episodes
P03319912A0000|35 41|months
P03322829A0952|214 223|deviation
P03322829A0952|83 97|digoxin marker
P03322829A0952|116 120|size
P03322829A0952|45 64|compliance category
P03322829A0952|135 143|patients
P03322829A0952|173 174|%
P03322829A0952|238 239|%
P03326381A0423|54 73|C-peptide excretion
P03326381A0423|155 161|action
P03326381A0423|103 110|effects
P03330711T0000|23 31|activity
P03331933T0048|4 18|Felix Lagrange
P03332848A0000|107 130|carotid artery stenosis
P03335127A0176|43 48|BASIC
P03335127A0176|5 12|program
P03335444A0000|57 64|mixture
P03335444A0000|3 8|study
P03335444A0000|68 73|241Am
P03335923A0257|182 190|patients
P03335923A0257|262 270|Moynihan
P03335923A0257|74 86|presentation
P03335923A0257|12 20|patients
P03335923A0257|173 176|DRG
P03335923A0257|235 238|RUD
P03335923A0257|273 280|disease
P03338154T0000|41 58|trypsin inhibitor
P03340726A1103|31 41|injections
P03340726A1103|112 116|dose
P03340726A1103|20 25|Evans
P03340726A1103|55 74|barrier alterations
P03343730A0486|73 75|pH
P03343730A0486|37 51|family history
P03344812A0924|298 307|influence
P03344812A0924|213 215|BP
P03344812A0924|257 262|cycle
P03344812A0924|18 22|data
P03344812A0924|220 229|HR values
P03344812A0924|107 114|factors
P03344812A0924|41 43|BP
P03344812A0924|342 352|individual
P03346157A0000|270 282|examinations
P03346157A0000|157 166|exposures
P03346157A0000|259 266|numbers
P03346157A0000|104 107|AHS
P03346157A0000|229 233|RERF
P03346157A0000|66 78|examinations
P03346157A0000|205 217|institutions
P03348382A0785|49 53|HCO3
P03352254A0203|77 83|vowels
P03352254A0203|39 49|prediction
P03352727T0000|28 39|specialists
P03352727T0000|1 3|UK
P03354295A0157|88 100|micrograms/l
P03354295A0157|9 15|spread
P03355122A0238|11 15|meal
P03355122A0238|128 129|h
P03355122A0238|87 90|min
P03360667A0000|241 249|subjects
P03360667A0000|271 272|n
P03360667A0000|145 151|status
P03360667A0000|218 230|mid-altitude
P03360667A0000|80 86|groups
P03360667A0000|50 56|growth
P03360667A0000|198 199|n
P03360667A0000|163 171|grouping
P03360667A0000|207 215|subjects
P03361653A0459|41 61|contour digitization
P03361653A0459|22 28|system
P03366864A0099|5 14|skin site
P03366864A0099|71 79|catheter
P03370815T0000|83 94|vitamin B12
P03370815T0000|51 61|test serum
P03371806A0000|12 27|data processing
P03371806A0000|77 93|acid phosphatase
P03371806A0000|113 118|serum
P03371806A0000|34 51|latex immunoassay
P03372422A0558|183 188|lungs
P03372422A0558|79 85|slopes
P03372422A0558|112 120|position
P03372422A0558|48 50|N2
P03375184A0000|91 109|polyethoxyethanols
P03375184A0000|56 62|series
P03375184A0000|66 89|alkylphenol-ethoxylates
P03375184A0000|33 39|member
P03377891A0652|15 26|disturbance
P03377891A0652|183 195|somatization
P03377891A0652|144 164|Symptom Checklist-90
P03377891A0652|97 107|elevations
P03377891A0652|169 179|elevations
P03377891A0652|258 265|anxiety
P03379058A0188|132 134|bp
P03379058A0188|110 123|reading frame
P03379058A0188|157 163|region
P03379058A0188|1 22|Nucleotide sequencing
P03381039A0364|130 136|micron
P03381039A0364|115 122|maximum
P03381039A0364|48 60|distribution
P03381039A0364|102 108|micron
P03382772A0319|28 35|studies
P03382772A0319|127 132|phase
P03382772A0319|1 19|Practical interest
P03383897A0189|166 174|patients
P03383897A0189|178 184|course
P03383897A0189|33 50|radiation therapy
P03383897A0189|100 112|leukopoiesis
P03384272A0145|74 87|presentations
P03384272A0145|43 47|mass
P03384272A0145|18 26|location
P03390074A0000|47 56|technique
P03390074A0000|1 20|Electroglottography
P03395164A0000|42 54|compound WEB
P03396437A0321|44 51|strains
P03398433T0001|62 71|infection
P03398433T0001|39 44|forms
P03398823A0459|30 44|administration
P03398823A0459|182 190|exposure
P03398823A0459|110 116|effect
P03398823A0459|96 98|hr
P03398823A0459|5 12|effects
P03401060A0000|6 15|melanomas
P03403313A0298|61 77|treatment groups
P03403313A0298|122 123|%
P03403313A0298|41 46|years
P03403313A0298|162 179|radiation therapy
P03403313A0298|21 34|control rates
P03403480A0299|44 50|change
P03403480A0299|89 107|femur middiaphysis
P03403480A0299|146 147|%
P03403480A0299|212 219|mineral
P03403480A0299|203 210|density
P03404334T0000|59 68|cartilage
P03404334T0000|1 14|Water content
P03406054A0351|63 68|image
P03406054A0351|78 80|mm
P03406054A0351|99 107|tungsten
P03406054A0351|86 90|slit
P03406054A0351|35 38|LSF
P03407843T0000|45 52|Surgery
P03413890T0001|14 19|Bowen
P03413890T0001|22 29|disease
P03417588T0000|78 82|rice
P03417588T0000|52 65|citreoviridin
P03417588T0000|35 48|determination
P03418727A0992|91 98|insight
P03418727A0992|108 118|myelopathy
P03418727A0992|68 80|chemotherapy
P03420324A0178|213 214|%
P03420324A0178|250 253|day
P03420324A0178|154 156|N2
P03420324A0178|221 223|N2
P03420324A0178|105 108|day
P03420324A0178|163 164|%
P03420324A0178|76 77|%
P03420324A0178|67 69|N2
P03421425A0878|41 55|hypothyroidism
P03421425A0878|21 28|percent
P03427474A0853|61 69|aversion
P03427474A0853|18 30|control rats
P03427474A0853|85 99|concentrations
P03428084A0430|135 142|striate
P03428084A0430|176 183|origins
P03428084A0430|102 118|pattern onset C1
P03429306T0000|3 14|Golgi study
P03430221A1236|79 88|detectors
P03430221A1236|5 13|findings
P03436119A0000|91 102|sensitivity
P03436119A0000|58 78|bone mineral content
P03436877A0950|210 211|r
P03436877A0950|123 129|% mass
P03436877A0950|299 307|ABSTRACT
P03436877A0950|220 221|P
P03436877A0950|75 85|reductions
P03436877A0950|10 12|CT
P03436877A0950|277 297|blocker pretreatment
P03436877A0950|139 140|r
P03436877A0950|238 251|relationships
P03440780A0779|209 214|EDLFs
P03440780A0779|182 205|vasoconstrictor effects
P03440780A0779|42 46|EDLF
P03440780A0779|250 254|beds
P03440780A0779|220 227|respect
P03443144A0409|55 61|factor
P03443144A0409|85 92|aspirin
P03443573A0329|89 92|fat
P03443573A0329|9 22|least-squares
P03443573A0329|143 144|g
P03446332A0831|41 45|rise
P03446332A0831|1 14|Nitrofurazone
P03449358T0001|17 22|study
P03451761A0215|9 23|baseline study
P03451761A0215|55 66|stimulation
P03451761A0215|86 91|sites
P03457330A0271|29 34|assay
P03457330A0271|22 24|CA
P03457330A0271|86 95|operation
P03459736A0184|37 45|sessions
P03459736A0184|81 86|pills
P03459736A0184|50 64|generalization
P03463543A1613|1 9|Enoxacin
P03466730A0210|11 23|dysfunctions
P03473379A0183|5 14|diagnosis
P03473379A0183|68 80|gland biopsy
P03478354A0436|57 70|corpus luteum
P03478354A0436|80 102|prostaglandin F2 alpha
P03484075T0001|56 64|injuries
P03485064A0135|52 60|patients
P03485064A0135|16 30|EVS treatments
P03487348A0000|94 97|AHP
P03487348A0000|48 53|model
P03491190A0233|44 54|LAD region
P03491190A0233|91 105|stress studies
P03491190A0233|37 40|RCA
P03491190A0233|5 18|detectability
P03494649A0472|73 80|absence
P03494649A0472|24 33|challenge
P03494649A0472|50 58|increase
P03499657A0000|123 142|uOH-Prol/creatinine
P03499657A0000|212 216|PHPT
P03499657A0000|262 272|malignancy
P03499657A0000|14 36|serum bone-Gla protein
P03499657A0000|230 238|patients
P03499657A0000|169 177|patients
P03499657A0000|274 276|HM
P03504971A0000|167 172|bonds
P03504971A0000|64 81|polyolefin rubber
P03504971A0000|33 57|Rubber Company tradename
P03504971A0000|1 7|Hexsyn
P03508698A0535|74 90|triceps reflexes
P03508698A0535|24 28|rate
P03508698A0535|129 135|groups
P03513989A0580|73 80|animals
P03513989A0580|54 69|UROD-deficiency
P03515840A0000|164 170|months
P03515840A0000|73 82|granuloma
P03515840A0000|176 181|years
P03515840A0000|113 126|histiocytosis
P03515840A0000|50 58|symptoms
P03517388A0763|72 75|U/L
P03517388A0763|58 60|BC
P03517388A0763|96 97|p
P03522105A1011|90 98|recovery
P03522105A1011|59 64|death
P03528748A0414|62 68|weight
P03528748A0414|6 21|maxicell system
P03534581A0976|121 137|cyclophosphamide
P03534581A0976|161 174|control group
P03534581A0976|59 60|%
P03534581A0976|35 44|neoplasms
P03536864A0000|13 17|work
P03537721A0876|14 26|observations
P03537721A0876|41 46|model
P03537721A0876|102 125|PEP4 gene self-activate
P03540591A0330|10 21|translation
P03540591A0330|176 189|reading frame
P03540591A0330|25 28|RNA
P03541263A0368|13 23|techniques
P03541263A0368|64 72|diabetes
P03543485A0069|72 92|space flight effects
P03543485A0069|49 56|changes
P03544858A0374|122 137|HDL-cholesterol
P03544858A0374|7 16|component
P03544858A0374|86 91|sexes
P03544858A0374|69 76|VO2 max
P03550444T0000|18 30|yeast system
P03550444T0000|34 39|assay
P03553149A0299|57 61|site
P03553149A0299|113 117|LexA
P03553149A0299|34 45|mutagenesis
P03555318T0000|21 30|carnitine
P03559193A0000|13 26|investigation
P03559193A0000|78 93|Framingham Type
P03559193A0000|103 107|FTAS
P03559287T0000|1 11|Legionella
P03561622A0659|195 209|blood cultures
P03561622A0659|11 17|resort
P03561622A0659|86 92|health
P03561622A0659|221 244|term vancomycin therapy
P03563604A1075|75 88|parasite rate
P03563604A1075|43 45|RK
P03563604A1075|5 16|spleen rate
P03568311A0273|75 78|PWP
P03568311A0273|59 73|wedge pressure
P03568311A0273|38 47|tamponade
P03568311A0273|139 147|function
P03570455A0433|28 40|hypocalcemia
P03570455A0433|124 130|TSST-1
P03570455A0433|111 120|influence
P03572706A0329|164 173|elevation
P03572706A0329|212 224|MMPI profile
P03572706A0329|53 62|protocols
P03572706A0329|100 110|therapists
P03577670A0102|5 10|study
P03577670A0102|69 89|matter hypodensities
P03578948A0448|52 58|volume
P03578948A0448|81 85|rate
P03582149T0001|40 53|valve disease
P03582149T0001|99 114|school students
P03582149T0001|68 73|fever
P03582982A0000|3 8|study
P03582982A0000|35 37|U4
P03584426A0706|105 113|isolates
P03584426A0706|78 79|%
P03584426A0706|202 209|strains
P03584426A0706|156 169|suckling mice
P03584426A0706|18 29|enterotoxin
P03590911T0001|25 35|dermatosis
P03591464A0840b|46 62|disease activity
P03591464A0840b|18 22|test
P03592297A0679|90 101|cord trauma
P03592297A0679|63 67|tone
P03592297A0679|129 147|vasodilation index
P03592297A0679|4 12|subjects
P03592297A0679|185 190|TcpO2
P03592297A0679|103 108|TcpO2
P03597218A0901|245 253|quantity
P03597218A0901|59 80|alpha 2-macroglobulin
P03597218A0901|86 98|antithrombin
P03597218A0901|118 126|exercise
P03597218A0901|132 133|P
P03597218A0901|231 239|exercise
P03597218A0901|32 37|alpha
P03601275A0601|211 217|groups
P03601275A0601|56 64|syndrome
P03601275A0601|163 186|dopamine/norepinephrine
P03601275A0601|97 109|state levels
P03601275A0601|80 88|controls
P03602261A0238|271 280|melatonin
P03602261A0238|212 213|r
P03602261A0238|158 159|r
P03602261A0238|323 324|r
P03602261A0238|185 186|r
P03602261A0238|285 293|dopamine
P03602261A0238|199 210|epinephrine
P03602261A0238|37 46|condition
P03602261A0238|169 183|norepinephrine
P03607109A0370|11 20|processes
P03607109A0370|111 119|controls
P03607109A0370|96 103|picture
P03608916A0790|45 47|OH
P03608916A0790|122 129|pattern
P03608916A0790|4 9|cases
P03608916A0790|32 38|plasma
P03610663A0201|123 129|effect
P03610663A0201|27 34|sources
P03610663A0201|6 14|approach
P03610663A0201|38 43|error
P03612316A0102|31 35|diet
P03612316A0102|41 52|low-protein
P03612316A0102|127 131|g BW
P03612316A0102|99 108|thyroxine
P03615550A0000|31 39|agonists
P03615550A0000|92 96|rats
P03615550A0000|5 12|effects
P03615550A0000|116 140|fixed-consecutive-number
P03615763A0170|210 213|sex
P03615763A0170|215 221|income
P03615763A0170|265 271|angina
P03615763A0170|156 163|measure
P03615763A0170|256 263|smoking
P03615763A0170|15 18|men
P03615763A0170|345 354|hostility
P03615763A0170|167 182|atherosclerosis
P03615763A0170|237 254|serum cholesterol
P03615763A0170|1 5|Data
P03616237T0001|12 30|status epilepticus
P03616237T0001|49 58|cisplatin
P03619249A0428|62 67|liver
P03619249A0428|297 299|Ag
P03619249A0428|113 119|HBs Ag
P03619249A0428|262 268|non-Bc
P03619249A0428|75 83|patients
P03619249A0428|132 140|anti-HBs
P03619249A0428|108 111|HBV
P03619249A0428|97 106|hepatitis
P03619249A0428|200 205|liver
P03619249A0428|307 312|liver
P03622571A0208|82 92|myocardium
P03622571A0208|39 45|biopsy
P03625762A0308|15 23|patients
P03625762A0308|224 235|vitamin B12
P03625762A0308|213 220|respect
P03625762A0308|174 184|difference
P03625762A0308|34 43|phenytoin
P03627720A0196|31 39|features
P03628596A0000|75 80|value
P03628596A0000|32 40|patients
P03628596A0000|84 109|acid alpha 1-glycoprotein
P03628794A0648|120 126|choice
P03628794A0648|56 60|data
P03628794A0648|5 13|patients
P03629974A1468|107 132|Rift Valley fever viruses
P03629974A1468|63 78|Uukuniemi virus
P03629974A1468|161 169|homology
P03629974A1468|203 211|proteins
P03629974A1468|252 261|precursor
P03635597A0377|151 152|P
P03635597A0377|39 44|scale
P03635597A0377|21 27|Cohler
P03635597A0377|138 145|mothers
P03645733T0001|1 16|Hyperthyroidism
P03652083A0720|14 20|region
P03652083A0720|94 102|collagen
P03658866A0081|10 29|lupus erythematosus
P03659805A0404|94 101|methods
P03659805A0404|37 54|prognosis factors
P03659805A0404|70 73|uni
P03659805A0404|17 29|significance
P03663789A0568|147 150|HAL
P03663789A0568|7 14|results
P03663789A0568|139 143|RHAL
P03666957A0219|150 159|infection
P03666957A0219|110 119|infection
P03666957A0219|1 10|Organisms
P03668396A0171|62 70|vertices
P03668396A0171|87 104|convex polyhedron
P03672532A1111|49 54|doses
P03673881A0000|26 34|accuracy
P03673881A0000|197 204|devices
P03673881A0000|55 57|CW
P03673881A0000|237 245|patients
P03673881A0000|102 109|Doppler
P03676174A0730|120 123|day
P03676174A0730|107 108|%
P03676174A0730|37 42|diets
P03676174A0730|70 82|milk intakes
P03678372A0170|167 172|weeks
P03678372A0170|21 28|pellets
P03678372A0170|69 80|pellets/day
P03678372A0170|152 159|pellets
P03679756A0830|12 31|nerve fiber defects
P03679756A0830|127 136|terminals
P03682805A0375|120 124|days
P03682805A0375|40 68|coagulation protein activity
P03682805A0375|126 143|skin lymph levels
P03682805A0375|83 91|preshock
P03682805A0375|17 24|albumin
P03684517A0462|47 56|stiffness
P03684517A0462|95 101|fibers
P03684517A0462|35 43|increase
P03687078T0001|40 51|adolescents
P03687078T0001|95 100|lungs
P03687078T0001|85 90|tract
P03687313A0000|123 133|conditions
P03687313A0000|76 86|volunteers
P03687313A0000|33 38|BAY m
P03688301A0129|165 175|carcinomas
P03688301A0129|183 190|bladder
P03688301A0129|125 134|extension
P03688301A0129|18 23|cases
P03688301A0129|136 142|type B
P03690262A0428|108 113|ramus
P03690262A0428|197 199|T4
P03690262A0428|5 22|maximum amplitude
P03690262A0428|174 185|stimulation
P03690262A0428|71 76|trunk
P03692331A0000|75 81|muscle
P03692331A0000|5 11|effect
P03692331A0000|155 160|women
P03692331A0000|85 89|term
P03694102A0000|22 31|data base
P03694102A0000|87 108|ECG computer programs
P03697587T0000|42 49|variant
P03697587T0000|53 64|Klinefelter
P03697971A0311|63 68|blood
P03697971A0311|179 189|diet group
P03697971A0311|5 19|selenium level
P03697971A0311|70 75|liver
P03700952A0273|110 128|laboratory setting
P03700952A0273|48 56|acuities
P03700952A0273|17 23|sample
P03703493A0654|82 110|RPE-choriocapillaris complex
P03703493A0654|69 74|areas
P03709191A0125|149 156|neurons
P03709191A0125|96 105|asymmetry
P03709191A0125|115 131|side differences
P03710973A0817|15 31|skin temperature
P03710973A0817|77 88|acclimation
P03710973A0817|140 141|P
P03710973A0817|49 50|P
P03712106A0000|15 43|L-methionine supplementation
P03712106A0000|89 92|SPI
P03712106A0000|156 161|women
P03712106A0000|68 87|soy protein isolate
P03713187A0691|167 177|carcinomas
P03713187A0691|40 54|lamina propria
P03713187A0691|297 304|lesions
P03713187A0691|266 276|comparison
P03713187A0691|116 123|lesions
P03713187A0691|255 262|lesions
P03714473A0496|49 59|heat shock
P03717936A0252|91 101|conditions
P03717936A0252|1 9|Amikacin
P03720966A1043|43 44|%
P03720966A1043|19 36|acid N absorption
P03721666A0000|27 32|cause
P03721666A0000|113 124|patch tests
P03721666A0000|100 109|reactions
P03728230A0104|49 53|cyst
P03733563A0716|15 40|herd X period interaction
P03733563A0716|53 61|liver TG
P03734641A0203|122 134|biomechanics
P03734641A0203|23 28|nerve
P03734641A0203|33 38|roots
P03738919A0000|45 50|level
P03738919A0000|114 119|women
P03738919A0000|1 15|Calcifications
P03738919A0000|102 105|men
P03743702A0158|88 98|structures
P03743702A0158|177 182|range
P03743702A0158|22 33|cell bodies
P03743702A0158|158 164|nerves
P03743702A0158|45 52|neurons
P03743702A0158|231 235|area
P03743702A0158|203 209|micron
P03743702A0158|69 74|intra
P03745833A0258|125 126|%
P03745833A0258|92 93|%
P03745833A0258|114 118|flow
P03745833A0258|131 136|areas
P03745833A0258|201 210|formation
P03745833A0258|4 14|transition
P03745833A0258|171 183|arborization
P03746107A0192|30 34|cent
P03746601A0299|73 81|hematoma
P03746601A0299|109 113|days
P03746601A0299|22 30|problems
P03746601A0299|117 125|exposure
P03746906A0000|94 115|questionnaire measure
P03746906A0000|54 85|student Jenkins Activity Survey
P03746906A0000|35 46|reliability
P03749226A0506|121 126|doses
P03749226A0506|52 65|response rate
P03751308T0001|14 31|energy metabolism
P03751308T0001|145 151|states
P03751308T0001|81 84|14C
P03751308T0001|118 129|development
P03755623A1233|9 23|investigations
P03755623A1233|85 95|properties
P03757294A0414|26 27|%
P03757294A0414|81 85|APCD
P03757294A0414|19 22|PLD
P03757294A0414|70 75|cases
P03759330A0713|62 65|CHD
P03759330A0713|125 140|trunk adiposity
P03759330A0713|20 22|F1
P03759330A0713|49 58|predictor
P03761122T0000|79 90|achievement
P03761122T0000|96 98|IQ
P03761122T0000|102 110|children
P03763241A0446|21 29|weakness
P03765552A0582|111 114|RES
P03765552A0582|141 152|suppression
P03765552A0582|116 136|Fc receptor blockade
P03765552A0582|103 109|system
P03766370A0546|77 79|LV
P03766370A0546|112 119|regions
P03769224A0000|89 97|biopsies
P03769224A0000|49 68|Lupus Erythematosus
P03771670T0058|42 53|combination
P03771670T0058|17 37|heparin-antithrombin
P03771749A0465|63 75|ketoconazole
P03771749A0465|25 31|agents
P03771749A0465|113 121|isolates
P03771749A0465|33 49|5-fluorocytosine
P03771749A0465|1 5|MICs
P03774111T0000|22 31|addiction
P03774111T0000|38 42|part
P03776438A0000|150 152|Na
P03776438A0000|89 97|contrast
P03776438A0000|127 139|hypertension
P03776438A0000|101 118|mineralocorticoid
P03777398A0156|38 50|therapy unit
P03777398A0156|17 20|use
P03779205A0459|144 155|secondaries
P03779205A0459|81 86|years
P03779205A0459|51 58|disease
P03780371A0792|105 110|exons
P03780371A0792|130 136|region
P03780371A0792|67 92|cytochrome P-450PBc2 gene
P03781000A0101|40 50|variations
P03781000A0101|142 149|disease
P03781000A0101|98 106|implants
P03783160A0285|22 35|21-O-angeloyl
P03783160A0285|1 9|Compound
P03783160A0285|68 80|21-O-tigloyl
P03785212A1128|1 14|RPS14 introns
P03789052A0527|115 123|reaction
P03789052A0527|175 183|evidence
P03789052A0527|206 213|effects
P03795488A0487|121 122|%
P03795488A0487|22 29|lesions
P03799790A0146|11 19|examiner
P03799790A0146|129 139|light pipe
P03799790A0146|33 41|interior
P03799790A0146|87 99|point source
P03799790A0146|186 192|plaque
P03805090A0645|208 220|degeneration
P03805090A0645|264 281|Maffucci syndrome
P03805090A0645|157 161|cent
P03805090A0645|133 140|disease
P03805090A0645|67 76|incidence
P03805090A0645|169 172|age
P03810361A0576|160 167|adjunct
P03810361A0576|93 97|mean
P03810361A0576|188 195|Cushing
P03810361A0576|34 60|plasma cortisol estimation
P03811852A0109|167 170|use
P03811852A0109|97 108|combination
P03811852A0109|5 9|risk
P03811852A0109|174 196|adrenocortico-steroids
P03811852A0109|223 231|maturity
P03818467A0180|107 124|Se concentrations
P03818467A0180|147 176|plasma glutathione peroxidase
P03818467A0180|178 184|GSH-Px
P03818467A0180|36 51|supplementation
P03818467A0180|85 102|plasma tocopherol
P03820222A0203|28 35|potency
P03826871A0000|24 30|method
P03826871A0000|67 72|urine
P03826871A0000|4 7|ion
P03828209T0000|47 57|intubation
P03829848T0001|75 79|vein
P03829848T0001|89 102|insufficiency
P03829848T0001|57 66|treatment
P03829848T0001|1 20|Autotransplantation
P03836777T0001|75 81|biopsy
P03836777T0001|43 62|hepatitis B markers
P03836777T0001|1 14|Practical use
P03836854T0000|107 112|agent
P03836854T0000|43 52|secretion
P03838797A0903|151 155|rise
P03838797A0903|40 55|oligonucleotide
P03838797A0903|131 143|cDNA library
P03838797A0903|1 18|Northern blotting
P03841627T0001|31 44|breast cancer
P03843676A0381|120 125|doses
P03843676A0381|8 21|extrapolation
P03857577A0413|178 191|transcription
P03857577A0413|115 134|level transcription
P03857577A0413|1 25|Deletion mapping studies
P03861687A0000|151 159|response
P03861687A0000|193 211|system stimulation
P03861687A0000|136 147|alterations
P03863231A0530|5 16|M-3 subtype
P03865743A0859|29 33|T.C.
P03865743A0859|43 49|HDL-C.
P03865743A0859|67 82|apo A-I/B ratio
P03865743A0859|35 41|LDL-C.
P03865743A0859|119 131|risk factors
P03869442A0223|97 109|hypertension
P03869442A0223|21 33|hypertension
P03869442A0223|68 81|abnormalities
P03871445T0000|64 91|positron emission tomograms
P03871445T0000|1 9|Computer
P03874921A0862|63 71|delivery
P03874921A0862|77 86|term baby
P03874921A0862|112 123|feasibility
P03874921A0862|206 214|drawback
P03877298A0718|125 134|induction
P03877298A0718|173 193|emulsion formulation
P03877298A0718|71 92|Cremophor formulation
P03880838T0000|31 45|artery lesions
P03880838T0000|1 10|Diagnosis
P03882029A0000|73 90|granuloma complex
P03882029A0000|46 50|cats
P03882029A0000|142 152|antibodies
P03882029A0000|33 37|sera
P03883541A0200|82 89|effects
P03883541A0200|33 48|sucralfate cost
P03887085A0000|62 77|pharmaceuticals
P03887085A0000|93 98|mg/kg
P03887085A0000|49 54|doses
P03887085A0000|104 112|mexamine
P03887085A0000|8 16|efficacy
P03887085A0000|33 36|use
P03887769A0584|134 135|%
P03887769A0584|8 14|region
P03887769A0584|64 81|iodine deficiency
P03890486A0000|120 130|propensity
P03890486A0000|77 83|source
P03890486A0000|21 43|lymph node enlargement
P03890486A0000|184 195|obstruction
P03894482A0549|27 33|levels
P03894482A0549|37 57|serum IgE antibodies
P03894482A0549|71 86|soybean extract
P03898382A0000|46 52|spleen
P03898382A0000|76 81|99mTc
P03898382A0000|232 237|image
P03898382A0000|19 38|subtraction imaging
P03904952T0000|24 43|computer obligation
P03908493A0246|15 24|advantage
P03908493A0246|66 92|immunoperoxidase technique
P03911052A0909|108 116|patients
P03911052A0909|55 67|CABG surgery
P03911052A0909|18 24|DIL-CP
P03911965A0513|121 133|Galphimia D6
P03911965A0513|92 97|trend
P03911965A0513|144 162|Galphimia dilution
P03913522A0000|6 11|aging
P03913522A0000|18 25|aspects
P03915540A0863|126 131|cells
P03915540A0863|83 97|GCN4-lacZ mRNA
P03915540A0863|18 35|gcd1-101 mutation
P03921727A0523|47 57|abstainers
P03921727A0523|23 30|apo A-I
P03921727A0523|114 121|changes
P03923828A1031|41 46|DDAVP
P03923828A1031|111 119|reversal
P03923828A1031|142 150|patients
P03923828A1031|5 17|availability
P03925712A0229|25 31|mucosa
P03925712A0229|71 83|deficiencies
P03925712A0229|1 9|Biopsies
P03928442A0463|75 85|Mtase gene
P03928442A0463|149 173|modification specificity
P03928442A0463|127 133|enzyme
P03929486A0309|208 209|P
P03929486A0309|126 131|LV-EF
P03929486A0309|23 28|trial
P03929486A0309|185 189|mg/d
P03929486A0309|192 199|placebo
P03929486A0309|47 51|COCM
P03929486A0309|282 287|doses
P03929486A0309|201 205|PLAC
P03929486A0309|71 83|sinus rhythm
P03930549A0209|75 86|supernatant
P03930549A0209|111 115|form
P03930549A0209|145 162|gas chromatograph
P03930549A0209|39 53|centrifugation
P03931293A0437|8 15|absence
P03931293A0437|114 123|% albumin
P03931293A0437|102 107|virus
P03933232T0000|7 17|classicism
P03933232T0000|54 62|pathways
P03934667A0124|181 185|rpoD
P03934667A0124|114 140|B. subtilis plasmid pRPD11
P03934667A0124|222 227|sigma
P03934667A0124|193 201|sequence
P03934667A0124|42 47|crsA4
P03934667A0124|103 110|process
P03935375A0414|60 70|morphology
P03935375A0414|135 144|pathology
P03935375A0414|161 164|RPN
P03935375A0414|230 242|degeneration
P03935375A0414|48 52|data
P03935375A0414|257 266|carcinoma
P03936828T0000|26 37|risk factor
P03936828T0000|9 20|thyroiditis
P03937481T0001|63 67|acid
P03937481T0001|86 98|preparations
P03940426A0618|95 104|anaerobes
P03940426A0618|127 132|tests
P03940426A0618|80 91|agar medium
P03940426A0618|254 266|agar culture
P03940426A0618|167 177|morphology
P03940426A0618|141 145|Gram
P03940818T0000|11 22|hepatitis A
P03944239A0780|150 152|T4
P03944239A0780|106 124|amiodarone therapy
P03944239A0780|59 89|plasma thyroid hormone changes
P03944239A0780|158 161|rT3
P03952387A0336|79 84|place
P03952387A0336|42 49|tissues
P03952387A0336|115 119|HbO2
P03956647A1063|183 206|iridium microelectrodes
P03956647A1063|146 151|A/cm2
P03956647A1063|25 47|%Ir microelectrode tip
P03956647A1063|96 112|charge densities
P03956647A1063|236 242|charge
P03956647A1063|1 12|Dissolution
P03959045A0000|61 76|coaching course
P03959045A0000|5 12|studies
P03959045A0000|81 92|performance
P03964489A1195|29 33|NADH
P03964489A1195|23 27|PaO2
P03965012A0163|195 213|paper mill workers
P03965012A0163|175 191|reference cohort
P03965012A0163|85 94|mortality
P03967144T0001|1 14|Hypersplenism
P03972038A0000|92 95|STR
P03972038A0000|20 32|trajectories
P03972038A0000|136 145|technique
P03974790A0053|78 84|tumour
P03977577T0000|43 51|shoulder
P03978045A0857|122 137|hyperreactivity
P03978045A0857|92 95|VWF
P03978045A0857|82 88|stages
P03978045A0857|221 227|origin
P03978045A0857|165 172|Raynaud
P03978045A0857|197 206|disorders
P03978045A0857|7 15|findings
P03979084A1019|109 113|IBPK
P03979084A1019|101 105|IMPK
P03979084A1019|34 36|hr
P03981421A0246|27 31|mL/h
P03981421A0246|95 102|results
P03981421A0246|3 12|flow rate
P03981952T0000|72 82|estimation
P03981952T0000|5 13|efficacy
P03984683A0000|67 77|spasticity
P03984683A0000|96 111|stroke patients
P03987818A0440|63 73|management
P03987818A0440|25 29|AP-A
P03988001A0227|90 99|treatment
P03988001A0227|27 54|rat blood chloroform levels
P03992022A0330|165 177|pretreatment
P03992022A0330|79 90|aminopyrine
P03992022A0330|96 113|TMO N-demethylase
P03992022A0330|191 201|cimetidine
P03992022A0330|1 11|Activities
P03992022A0330|239 249|ranitidine
P03997467A0000|77 85|patients
P03997467A0000|100 108|ischemia
P03998813A0406|94 102|activity
P03998813A0406|76 83|pattern
P03998813A0406|114 122|ontogeny
P03998813A0406|16 27|experiments
P04000347A0442|182 193|individuals
P04000347A0442|202 207|signs
P04000347A0442|23 31|criteria
P04000347A0442|169 172|BEN
P04001490T0001|78 87|component
P04001490T0001|5 19|POEMS syndrome
P04001490T0001|51 65|Endocrinopathy
P04002667A0181|179 194|lung parenchyma
P04002667A0181|66 81|tumor diameters
P04002667A0181|20 28|patients
P04002667A0181|157 166|cm tumors
P04005190A1288|5 12|extract
P04011466T0000|8 17|diameters
P04011466T0000|21 28|infants
P04013604A0412|47 57|ulceration
P04013604A0412|92 105|patient-years
P04014861A0000|13 24|feasibility
P04014861A0000|146 149|SOD
P04014861A0000|92 98|effect
P04014861A0000|81 86|lungs
P04014861A0000|207 211|rats
P04017295A0139|29 36|heparin
P04017295A0139|77 85|patients
P04019066A0000|91 94|MRF
P04019066A0000|111 113|CG
P04019066A0000|80 89|formation
P04019066A0000|169 174|doses
P04019066A0000|205 209|rats
P04021305A0530|164 174|regulation
P04021305A0530|47 58|development
P04021305A0530|149 156|changes
P04021305A0530|123 131|dopamine
P04021305A0530|191 199|activity
P04021437A0000|59 65|agents
P04021437A0000|71 77|number
P04025178A0126|15 23|analyses
P04025178A0126|148 149|%
P04025178A0126|127 131|EDVI
P04025178A0126|32 37|death
P04026903A0512|195 214|5-hydroxytryptamine
P04026903A0512|176 185|histamine
P04026903A0512|97 107|rat uterus
P04026903A0512|249 255|manner
P04026903A0512|1 12|Polysorbate
P04026903A0512|51 66|relaxant effect
P04027182T0000|13 30|diabetes mellitus
P04031488A1091|72 90|brain localization
P04031488A1091|8 14|degree
P04031488A1091|113 122|syndromes
P04032349A0000|148 155|therapy
P04032349A0000|109 117|ischemia
P04032349A0000|157 166|Urokinase
P04032349A0000|4 12|patients
P04033402A1112|45 75|HDL-cholesterol concentrations
P04033402A1112|144 172|triglyceride lipase activity
P04034666T0000|46 65|standing conditions
P04034666T0000|108 119|hemiparesis
P04037809A0964|47 54|KW-2083
P04038702A0768|211 217|estrus
P04038702A0768|321 344|cortisol concentrations
P04038702A0768|55 64|tethering
P04038702A0768|259 263|type
P04038702A0768|224 235|disruptions
P04038702A0768|43 51|response
P04038702A0768|5 12|results
P04039307A0613|11 23|progesterone
P04039307A0613|36 37|P
P04039439A0842|40 45|quail
P04039439A0842|80 94|Mn3O4 exposure
P04039667T0000|15 28|visualisation
P04039667T0000|79 84|means
P04039667T0000|103 112|monocytes
P04040083A0000|88 94|saline
P04040339T0001|107 118|partusisten
P04040339T0001|27 37|heart rate
P04040339T0001|1 19|Monitoring changes
P04041307A0614|30 48|calcium antagonist
P04041307A0614|112 120|function
P04041307A0614|87 97|isoflurane
P04043489A0648|29 36|storage
P04043489A0648|1 8|Visidex
P04050821A0531|78 91|oxygen demand
P04050821A0531|55 63|increase
P04052919A0205|182 190|subjects
P04052919A0205|297 308|measurement
P04052919A0205|25 47|progesterone secretion
P04052919A0205|82 94|luteal phase
P04052919A0205|426 432|nmol/l
P04052919A0205|109 118|frequency
P04052919A0205|400 409|threshold
P04052919A0205|7 11|data
P04052919A0205|343 348|phase
P04052919A0205|137 142|phase
P04056218A0463|67 69|L2
P04056218A0463|86 88|dB
P04058985A0000|15 20|doses
P04058985A0000|24 34|vitamin B6
P04062128T0028|24 73|Health Consensus Development Conference Statement
P04066194A0163|28 33|N1-P2
P04066194A0163|67 76|probe EPs
P04066194A0163|99 113|probe stimulus
P04066194A0163|38 59|baseline-P2 amplitude
P04066194A0163|1 20|Greater attenuation
P04067540A0413|227 239|suicide note
P04067540A0413|158 163|lover
P04067540A0413|5 16|comparisons
P04067540A0413|140 145|homes
P04067540A0413|55 67|perpetrators
P04068774A1292|75 81|effect
P04068774A1292|107 115|elements
P04068774A1292|10 23|relationships
P04068774A1292|32 33|F
P04069756T0025|1 10|Diagnosis
P04071063A0863|13 24|differences
P04071063A0863|95 112|fibrinogen levels
P04071063A0863|55 70|platelet counts
P04071063A0863|117 122|alpha
P04074214A0000|52 57|boars
P04074214A0000|21 42|semen characteristics
P04075061A0355|56 60|race
P04075061A0355|39 44|water
P04075061A0355|34 35|L
P04081425T0016|22 29|therapy
P04082592T0000|36 42|Taenia
P04084896A0569|56 66|attempters
P04084896A0569|5 19|recommendation
P04085589A0264b|134 139|rates
P04085589A0264b|63 69|status
P04085589A0264b|71 94|spirometry measurements
P04085589A0264b|34 49|secretor status
P04086657T0000|52 58|cortex
P04088233A0309|5 17|transit time
P04088733T0001|43 59|blood leukocytes
P04088733T0001|96 104|children
P04093211A0560|62 71|attitudes
P04093211A0560|38 45|ability
P04102280T0000|22 29|disease
P04113011T0000|26 43|ragweed hay fever
P04115870T0000|55 74|Urat-I lithotriptor
P04115870T0000|1 12|Experiences
P04123662T0000|1 11|Evaluation
P04139081T0001|35 43|patients
P04140567T0001|1 21|Histamine metabolism
P04145244T0000|43 49|muscle
P04160980T0000|14 21|control
P04160980T0000|34 45|circulation
P04164669T0000|52 56|skin
P04175007T0001|77 84|animals
P04175007T0001|42 48|growth
P04175007T0001|23 34|stimulation
P04176268T0000|42 54|hyperkalamia
P04176268T0000|1 16|Aluminium resin
P04194466T0000|21 42|infant hypothyroidism
P04213917T0001|46 54|fibroses
P04213917T0001|17 32|D-penicillamine
P04226360T0001|1 10|Disorders
P04246054T0028|122 144|incubation temperature
P04246054T0028|37 68|rabbit-anti-lymphocyte globulin
P04246054T0028|70 75|RAMLG
P04247966T0000|14 21|baboons
P04247966T0000|1 10|Lactation
P04282315T0001|45 55|phenformin
P04282315T0001|71 79|ablation
P04282315T0001|1 14|Sensitization
P04289156T0000|18 25|tumours
P04295031T0062|7 13|effect
P04308979T0000|47 56|treatment
P04308979T0000|123 128|lungs
P04308979T0000|147 158|lymph nodes
P04308979T0000|70 81|quartz dust
P04308979T0000|85 98|translocation
P04315233T0128|23 33|experiment
P04321861T0001|88 99|erythrocyte
P04321861T0001|59 80|glutathione synthesis
P04325736T0001|32 47|laboratory mice
P04335965T0000|15 30|colon carcinoma
P04335965T0000|1 11|Metastasis
P04364369T0000|73 86|heart disease
P04364369T0000|34 43|detection
P04371279T0000|43 56|muscle fibres
P04371279T0000|70 85|botulinum toxin
P04377328T0027|1 3|I.
P04387103T0000|22 33|microbodies
P04387103T0000|68 74|glands
P04394290T0000|79 88|sphincter
P04394290T0000|3 8|study
P04418687T0000|75 80|fetus
P04418687T0000|56 67|development
P04418687T0000|1 8|Effects
P04428800T0001|44 47|LAP
P04428800T0001|11 16|noise
P04428800T0001|82 86|rats
P04429269T0000|45 54|simulants
P04429269T0000|67 74|systems
P04445874T0001|45 50|horse
P04445874T0001|1 10|Pathology
P04460692T0000|20 46|laboratory animal medicine
P04482661T0001|10 16|course
P04482661T0001|96 111|buckwheat chaff
P04482661T0001|51 66|decubitus ulcer
P04487920T0001|10 40|Icelandic Red Cross activities
P04488271T0001|29 46|diabetes mellitus
P04488271T0001|1 10|Treatment
P04506738T0000|19 24|cells
P04511139T0001|15 36|restoration materials
P04515631T0000|60 74|liver function
P04515631T0000|10 19|Normotest
P04515631T0000|1 6|Value
P04524081T0000|93 122|tissue displacement materials
P04524081T0000|49 57|hemodent
P04536964T0000|15 17|pH
P04536964T0000|34 64|H ion permeability coefficient
P04543036T0001|31 35|care
P04544704T0001|11 20|synthesis
P04544704T0001|71 78|studies
P04547933T0000|15 31|fibril formation
P04547933T0000|46 51|cells
P04551650T0001|30 37|enzymes
P04562038T0001|62 69|hormone
P04562038T0001|9 22|investigation
P04578686T0000|24 36|lung abscess
P04578686T0000|50 68|transplant patient
P04580044T0047|32 49|development phase
P04598670T0000|56 73|immunosuppression
P04613073T0001|44 62|Shigella virulence
P04613073T0001|9 19|biocenosis
P04615828T0001|6 14|birthday
P04622430T0000|10 19|afferents
P04622430T0000|38 44|cortex
P04627477T0001|23 49|Mycobacterium tuberculosis
P04627477T0001|1 19|Resistance pattern
P04638365T0001|61 69|activity
P04638365T0001|25 33|aminazin
P04645078T0001|14 23|processes
P04653144T0000|75 82|parents
P04653144T0000|1 17|General formulae
P04656185T0000|88 95|glucose
P04656185T0000|144 152|newborns
P04656185T0000|1 27|Glucose disappearance rate
P04676734T0000|74 89|corticosteroids
P04676734T0000|5 17|relationship
P04679807T0000|10 28|acid concentration
P04704186T0000|40 48|Holstein
P04704186T0000|53 61|Holstein
P04704186T0000|1 15|Range behavior
P04718233T0000|1 28|Methyl mercury intoxication
P04729063T0000|72 79|Koreans
P04733391T0000|33 46|thiabendazole
P04752455T0000|1 21|Disability insurance
P04753286T0000|42 50|tung oil
P04753286T0000|16 27|food intake
P04758799T0000|37 54|steroid treatment
P04760826T0000|10 17|anxiety
P04760826T0000|21 38|Vietnam returnees
P04766888T0000|7 22|heparin therapy
P04782788T0001|15 27|examinations
P04782788T0001|53 73|kidney insufficiency
P04787472T0001|29 34|blood
P04787472T0001|114 118|body
P04787472T0001|1 7|Change
P04788701T0001|82 88|uterus
P04788701T0001|1 12|Combination
P04791420T0000|44 53|neocortex
P04791420T0000|26 36|somatotopy
P04791420T0000|1 12|Proceedings
P04796997T0000|42 51|injection
P04796997T0000|55 82|medroxyprogesterone acetate
P04796997T0000|103 109|organs
P04810131T0000|9 37|Aryl hydrocarbon hydroxylase
P04810131T0000|1 7|Letter
P04820791T0001|76 84|children
P04820791T0001|64 72|diseases
P04837183T0000|29 33|rats
P04837183T0000|1 13|Observations
P04843031T0000|15 45|galactosyltransferase activity
P04843031T0000|66 74|children
P04843031T0000|49 53|sera
P04863895T0000|90 97|disease
P04863895T0000|107 114|poultry
P04863895T0000|99 102|CRD
P04878680T0000|60 70|oropharynx
P04878680T0000|21 30|radiation
P04878680T0000|1 8|Effects
P04890336T0001|73 88|appearance time
P04890336T0001|22 29|pattern
P04890336T0001|55 65|comparison
P04911925T0001|60 68|QRS loop
P04921762T0000|9 21|preservation
P04942414T0000|36 50|5-fluorouracil
P04942414T0000|20 32|pharmacology
P04948325T0000|31 36|MC-63
P04948325T0000|107 124|Ehrlich carcinoma
P04948325T0000|83 98|Crocker sarcoma
P04967824T0000|12 23|temperature
P04967824T0000|37 42|cycle
P04967824T0000|1 8|Effects
P04975676T0000|30 41|alterations
P04975676T0000|54 60|baboon
P04989251T0000|1 9|Analysis
P04992478T0000|60 66|effect
P04992478T0000|83 97|administration
P05000171T0000|109 132|toad bladder epithelium
P05000171T0000|5 11|effect
P05000171T0000|35 47|distribution
P05012220T0000|61 70|ileostomy
P05012220T0000|36 51|proctocolectomy
P05020660T0000|23 33|inhibition
P05020660T0000|1 8|Factors
P05025918T0000|1 12|Angiography
P05027799T0000|1 19|Sodium restriction
P05031074T0001|1 20|Serum lipid changes
P05034373T0000|31 61|function oxidase enzyme system
P05034373T0000|101 104|rat
P05034373T0000|85 93|selenium
P05049711T0000|42 51|screening
P05065548T0075|8 20|constituents
P05068271T0000|14 18|diet
P05081814T0000|26 31|acids
P05087496T0000|10 18|arteries
P05093030T0001|112 136|partition chromatography
P05093030T0001|1 11|Separation
P05093030T0001|34 43|compounds
P05101762T0000|1 15|Spasmus nutans
P05110049T0001|5 9|data
P05119546T0001|22 31|neoplasms
P05123884T0000|11 21|metabolism
P05124972T0042|1 3|I.
P05132558T0000|47 58|theobromine
P05132558T0000|20 28|caffeine
P05135168T0000|28 50|Erythrophleum ivorense
P05135168T0000|1 14|New alkaloids
P05145925T0000|82 94|spleen cells
P05154132T0000|74 78|calf
P05154132T0000|24 31|sources
P05154132T0000|35 43|nitrogen
P05162342T0001|21 30|childhood
P05172320T0001|27 33|nature
P05172320T0001|76 88|interdigital
P05172320T0001|1 8|Studies
P05203499T0001|104 110|spleen
P05203499T0001|128 136|131-I-RB
P05203499T0001|93 99|kidney
P05203499T0001|112 122|comparison
P05253274T0001|24 39|3,4-benzopyrene
P05274526T0000|12 20|leukemia
P05274526T0000|1 8|Relapse
P05284310T0000|33 40|control
P05284310T0000|17 25|fluoride
P05299993T0000|46 55|compounds
P05299993T0000|1 13|Modification
P05305671T0000|9 19|discussion
P05309471T0000|59 77|influenza vaccines
P05309471T0000|1 9|Problems
P05322558T0000|94 98|mice
P05322558T0000|1 19|Homograft response
P05340801T0000|1 11|Mycotoxins
P05353667T0000|35 46|micturition
P05357390T0001|26 37|conjunctiva
P05359464T0000|24 54|chromosome aberration analysis
P05359464T0000|1 9|Pitfalls
P05363816T0001|41 50|expertise
P05363816T0001|96 103|actions
P05368978T0000|22 33|anesthetics
P05368978T0000|1 12|CNS effects
P05379901T0000|1 14|Midge control
P05389125T0000|17 26|behaviour
P05394461T0001|19 21|HB
P05410641T0000|46 60|airway disease
P05410641T0000|18 30|Venturi mask
P05412687T0000|12 20|invasion
P05412687T0000|82 96|tract neurones
P05414186T0001|38 49|Netherlands
P05421537T0001|1 13|Difficulties
P05425195T0001|13 39|aspartate aminotransferase
P05425195T0001|57 81|alanine aminotransferase
P05425195T0001|98 107|rat serum
P05425195T0001|170 188|body X-irradiation
P05441564T0001|61 68|mutants
P05441564T0001|73 86|suckling mice
P05441564T0001|33 37|ECHO
P05441564T0001|16 29|pathogenicity
P05451324T0000|42 49|content
P05451324T0000|19 29|correction
P05451324T0000|1 12|Calibration
P05460466T0001|42 51|oxidation
P05460466T0001|16 33|gamma-irradiation
P05466177T0001|41 45|rats
P05472485T0000|9 33|cochlear response curves
P05488121T0000|21 33|chloroplasts
P05488121T0000|1 17|CO2 assimilation
P05496619T0000|21 53|air pollution control activities
P05500957T0001|107 116|pregnancy
P05500957T0001|94 103|syndromes
P05500957T0001|20 29|clopamide
P05502054T0000|31 37|review
P05502054T0000|1 9|Leukemia
P05529283T0000|26 29|IgA
P05529283T0000|39 44|serum
P05529283T0000|1 13|Quantitation
P05533214T0001|1 18|Iodine metabolism
P05552642T0000|66 77|trophoblast
P05552642T0000|1 12|Propagation
P05555149T0001|47 49|SH
P05555149T0001|55 65|S-S-groups
P05560428T0001|63 74|wakefulness
P05560428T0001|53 58|sleep
P05574818T0000|46 51|study
P05574818T0000|82 109|contractile characteristics
P05574818T0000|35 38|use
P05594277T0051|41 55|Jensen sarcoma
P05594277T0051|5 17|modification
P05621339T0001|25 30|doses
P05642051T0000|20 41|department management
P05683809T0000|41 46|drugs
P05683809T0000|131 138|studies
P05683809T0000|1 7|Effect
P05689427T0052|73 87|hydrochlorides
P05693602T0001|25 44|blood cell counters
P05715613T0000|12 18|pollen
P05718500T0001|14 26|observations
P05718500T0001|64 73|pregnancy
P05719031T0000|26 40|size reduction
P05719031T0000|1 8|Studies
P05722341T0000|91 105|chromatography
P05722341T0000|54 67|disaccharides
P05722341T0000|1 15|Identification
P05727222T0000|75 91|Callionymus lyra
P05727222T0000|53 71|oxygen consumption
P05733952T0001|88 95|culture
P05733952T0001|54 60|tissue
P05733952T0001|32 41|integrity
P05734847T0000|59 65|Lisbon
P05742879T0000|24 39|morphine series
P05750950T0001|56 60|rats
P05750950T0001|1 7|Estrus
P05758469T0001|36 42|flight
P05763287T0063|1 3|I.
P05779953T0000|11 21|castration
P05779953T0000|83 87|rats
P05779953T0000|1 7|Effect
P05782943T0001|31 52|sarcoidosis granuloma
P05782943T0001|17 27|mast cells
P05789870T0001|1 43|Phosphate glucose dehydrogenase deficiency
P05792911T0000|72 83|lung volume
P05792911T0000|49 67|airway conductance
P05796272T0000|14 38|chlorpromazine cataracts
P05798063T0000|47 53|doctor
P05798063T0000|1 11|Specialist
P05805644T0001|74 77|RES
P05805644T0001|109 122|incorporation
P05805644T0001|1 10|Variation
P05805644T0001|51 56|228Ra
P05806936T0000|46 51|cases
P05806936T0000|37 42|colon
P05806936T0000|1 11|Absorption
P05810259T0001|1 18|Polyvinyl alcohol
P05822499T0034|18 30|digiprogenin
P05836483T0000|30 35|liver
P05836483T0000|18 26|teratoma
P05839844T0000|74 86|Aflatoxin B1
P05839844T0000|49 62|liver lesions
P05850652T0001|14 25|alterations
P05850652T0001|40 50|absorption
P05850652T0001|55 60|means
P05850652T0001|1 6|Study
P05858571T0000|60 70|NSC-409962
P05858571T0000|10 16|trials
P05879595T0094|26 31|years
P05884183T0001|94 102|cultures
P05884183T0001|112 115|use
P05884183T0001|21 32|restoration
P05884183T0001|119 128|Rzhaninov
P05890351T0001|36 42|wealth
P05893495T0001|44 51|rabbits
P05901778T0000|23 31|patterns
P05901778T0000|5 11|effect
P05917315T0026|43 48|study
P05930797T0000|56 73|Australia antigen
P05930797T0000|34 54|isoprecipitin system
P05938720T0000|37 65|employee orientation program
P05942953T0049|1 3|I.
P05949971T0000|1 12|Persistence
P05960999T0001|151 167|slide latex test
P05960999T0001|135 146|capillaries
P05960999T0001|95 102|protein
P05960999T0001|54 70|polysaccharide C
P05960999T0001|118 131|precipitation
P05969185T0001|1 11|Concussion
P05985275T0000|42 55|acorn extract
P05994421T0045|36 45|marriages
P05994421T0045|19 28|migration
P05994421T0045|1 14|Consanguinity
P05999607T0001|63 66|rat
P05999607T0001|1 8|Studies
P06027841T0000|59 76|emission spectrum
P06027841T0000|17 22|249Bk
P06048505T0000|16 24|fluorene
P06054411T0000|23 31|steroids
P06054411T0000|1 19|Retention behavior
P06072512T0000|10 20|evaluation
P06072512T0000|48 52|urea
P06074093T0001|10 27|folate deficiency
P06084279A0218|79 83|ERCP
P06084279A0218|37 41|rise
P06084864T0001|61 70|prognosis
P06084864T0001|19 37|alpha fetoproteins
P06088722A0171|48 64|myelosuppression
P06090369A0000|25 33|patients
P06090369A0000|48 55|WR-2721
P06091914A0000|75 83|provirus
P06091914A0000|14 20|tumors
P06091914A0000|59 63|MMTV
P06091914A0000|96 102|region
P06091914A0000|32 37|mouse
P06092588T0000|23 31|hepatoma
P06093363A0612|44 56|% identities
P06093363A0612|93 102|alignment
P06093363A0612|117 121|gaps
P06095372A0435|74 93|radiation treatment
P06095372A0435|36 40|dose
P06095372A0435|48 52|g/m2
P06096246T0000|88 96|hormones
P06096246T0000|1 7|Effect
P06096863T0000|136 144|TATA box
P06097285A1077|58 64|animal
P06097285A1077|67 75|capacity
P06098828A0352|31 37|report
P06098828A0352|149 157|elements
P06098828A0352|55 59|SV40
P06101359T0000|15 24|treatment
P06101359T0000|1 10|Diagnosis
P06109017A0000|264 272|pressure
P06109017A0000|295 305|heart rate
P06109017A0000|80 105|isopropylamino-2-propanol
P06109017A0000|50 57|agonist
P06109017A0000|166 178|measurements
P06109017A0000|231 239|velocity
P06109017A0000|5 12|effects
P06109017A0000|204 212|pressure
P06111283T0032|39 62|des-Tyr-gamma-endorphin
P06113443T0000|105 125|separation technique
P06113443T0000|56 61|blood
P06113443T0000|1 11|Separation
P06120429T0000|62 70|patients
P06120429T0000|5 24|thyroglobulin assay
P06130348T0000|29 35|faeces
P06131378A0818|73 76|end
P06131378A0818|110 133|polyadenylation signals
P06131378A0818|154 163|DHFR cDNA
P06137028A0624|54 60|tremor
P06138313A0948|90 100|mean value
P06138313A0948|79 88|half-life
P06138313A0948|42 59|elimination phase
P06138313A0948|116 122|volume
P06142279T0000|9 23|HTLV infection
P06142279T0000|1 5|Risk
P06147504A0086|28 35|therapy
P06147504A0086|54 61|reasons
P06151518A0000|74 85|sodium salt
P06151518A0000|41 45|LD50
P06151518A0000|125 129|days
P06151518A0000|20 24|dose
P06152670T0000|79 95|failure patients
P06152670T0000|18 30|pancreozymin
P06153936A0784|30 33|SjS
P06153936A0784|92 105|year interval
P06153936A0784|178 185|changes
P06158844A0000|106 112|series
P06158844A0000|140 144|pain
P06158844A0000|1 12|Thalamotomy
P06158844A0000|152 162|malignancy
P06162419A0118|46 53|maximum
P06162419A0118|114 133|lymphadenosis NK/Li
P06165068A0547|23 28|juice
P06165551A0793|90 95|waves
P06165551A0793|176 184|relation
P06165551A0793|127 131|view
P06165551A0793|192 198|length
P06165551A0793|162 172|transients
P06165551A0793|39 51|segmentation
P06165551A0793|236 251|autocorrelation
P06173032T0000|15 28|echothiophate
P06173032T0000|57 63|rabbit
P06173032T0000|5 11|effect
P06175691T0000|38 52|maternity-unit
P06182979A0807|15 23|category
P06182979A0807|94 105|doxorubicin
P06182979A0807|67 90|anthracycline analogues
P06184487A1485|124 136|30K proteins
P06184487A1485|163 166|31K
P06184487A1485|80 89|AcNPV map
P06184487A1485|48 72|HindIII-P/EcoRI-B region
P06184487A1485|103 112|synthesis
P06184487A1485|220 249|HindIII-A/EcoRI-C/SstI-G cDNA
P06185493A0468|148 170|muscle pyruvate kinase
P06185493A0468|97 113|peptide sequence
P06185493A0468|51 76|yeast amino acid sequence
P06191243T0000|54 66|brain damage
P06198241A0209|166 171|yeast
P06198241A0209|57 62|yeast
P06198241A0209|7 14|fusions
P06199132A0179|38 43|cases
P06199132A0179|1 9|Toxicity
P06199132A0179|51 59|patients
P06203843A0757|109 114|group
P06203843A0757|54 65|lymphokines
P06203843A0757|34 49|transfer factor
P06208024A0168|45 50|DNase
P06208024A0168|104 114|hydrolysis
P06208024A0168|6 14|fraction
P06209403A0562|29 39|pseudogene
P06212776A0000|12 20|Oristano
P06212776A0000|199 209|prevention
P06212776A0000|67 79|thalassaemia
P06212776A0000|4 10|Cabras
P06212776A0000|84 99|G6PD deficiency
P06216125A0470|62 64|ET
P06216125A0470|26 32|chance
P06216125A0470|161 166|cycle
P06216125A0470|82 87|cycle
P06216125A0470|4 12|addition
P06218005A0948|59 71|A-P diameter
P06223586A0460|107 110|SPG
P06223586A0460|89 103|administration
P06223586A0460|139 148|life-span
P06225279A0498|15 22|surface
P06225279A0498|69 74|layer
P06229542T0045|12 28|characterization
P06229542T0045|34 42|fraction
P06233924T0000|83 90|disease
P06233924T0000|32 43|implication
P06234786A0606|41 44|use
P06234786A0606|93 97|bone
P06234786A0606|1 21|Radiogallium imaging
P06238540A0798|177 180|LVH
P06238540A0798|144 173|mean wall stress relationship
P06238540A0798|38 67|mean wall stress relationship
P06239545A0649|30 38|pressure
P06239545A0649|44 52|decrease
P06239545A0649|114 118|fall
P06239545A0649|1 12|Weight loss
P06241900A0000|41 48|effects
P06241900A0000|146 156|rat hearts
P06241900A0000|52 63|hypothermia
P06241900A0000|68 89|chemical cardioplegia
P06242113T0001|1 21|Cultivation technics
P06245672T0000|73 83|metastasis
P06251469A0830|62 71|IAP units
P06251469A0830|78 95|restriction sites
P06251469A0830|163 171|position
P06252883A0100|30 36|strain
P06252883A0100|147 153|number
P06252883A0100|92 99|piglets
P06252883A0100|157 166|occasions
P06252883A0100|49 53|O149
P06254973A1757|331 339|residues
P06254973A1757|261 273|binding site
P06254973A1757|112 124|accumulation
P06254973A1757|289 292|HDP
P06254973A1757|192 193|n
P06254973A1757|131 134|HDP
P06254973A1757|6 8|dT
P06254973A1757|175 184|molecules
P06254973A1757|1 5|Poly
P06258806A0963|22 31|insertion
P06258806A0963|70 78|terminus
P06258806A0963|170 176|enzyme
P06259220A0464|1 11|Experiment
P06259220A0464|84 98|administration
P06259220A0464|102 112|naltrexone
P06270347A0740|37 56|translation product
P06270347A0740|3 18|22K polypeptide
P06278544T0027|1 11|Physiology
P06281759A1086|106 122|endoribonuclease
P06281759A1086|94 97|sib
P06281759A1086|9 14|RNase
P06281759A1086|65 75|processing
P06281759A1086|49 63|sib regulation
P06281891A0399|94 112|complex modulation
P06281891A0399|81 86|roles
P06286443A0498|15 32|serum ACTH levels
P06287212A1352|147 153|result
P06287212A1352|244 248|AUGs
P06287212A1352|22 34|polypeptides
P06287212A1352|66 77|translation
P06287212A1352|157 188|transcription initiation events
P06287212A1352|81 91|AUG codons
P06287737A0477|61 70|cirrhosis
P06287737A0477|396 410|type B disease
P06287737A0477|184 209|posttransfusion hepatitis
P06287737A0477|327 339|transfusions
P06287737A0477|165 174|incidence
P06287737A0477|280 287|history
P06287737A0477|5 14|frequency
P06287737A0477|136 137|%
P06290899T0000|28 56|egg drop syndrome-1976 virus
P06290899T0000|11 19|antibody
P06290899T0000|1 7|Survey
P06296833A0000|5 14|mutations
P06298720A0893|12 24|conservation
P06298720A0893|113 126|VL30 elements
P06298720A0893|50 65|repeat sequence
P06300836A0285|91 102|genome RNAs
P06300836A0285|176 189|reovirus RNAs
P06300836A0285|235 251|rotavirus genome
P06300836A0285|1 14|Hybridization
P06306342A1156|92 106|acid secretion
P06306342A1156|22 29|studies
P06306342A1156|174 181|barrier
P06308536T0001|62 76|liver diseases
P06308536T0001|33 41|anti-HAV
P06309020A0473|29 44|mg X kg-1 X h-1
P06309020A0473|76 81|doses
P06309969T0055|1 3|I.
P06310457A0000|54 60|tectum
P06310608A0749|30 42|substitution
P06310608A0749|183 188|M-MSV
P06310608A0749|83 86|DNA
P06310608A0749|140 147|Ab-MuLV
P06310608A0749|117 124|viruses
P06310608A0749|153 160|Moloney
P06314312A0359|123 130|sources
P06314312A0359|212 213|%
P06314312A0359|155 163|purities
P06314312A0359|259 260|%
P06314312A0359|17 32|soybean protein
P06314312A0359|287 288|P
P06314312A0359|174 185|weight gain
P06316623A0188|45 49|cent
P06316623A0188|9 20|prevalences
P06316623A0188|76 81|sheep
P06316623A0188|53 59|cattle
P06316623A0188|68 72|cent
P06319040A1627|242 250|pressure
P06319040A1627|95 105|activation
P06319040A1627|129 137|reflexly
P06319040A1627|169 179|blood flow
P06319040A1627|205 208|dog
P06319072A0711|132 140|affinity
P06319072A0711|108 128|cell receptor number
P06319072A0711|97 104|changes
P06319072A0711|175 181|groups
P06319740A1331|59 69|initiation
P06319740A1331|22 26|gp54
P06319740A1331|38 42|gene
P06321505A0401|105 115|initiation
P06321505A0401|227 239|rat PTH mRNA
P06321505A0401|22 38|Goldberg-Hogness
P06321505A0401|96 101|point
P06321505A0401|119 132|transcription
P06321770A1353|75 76|h
P06321770A1353|161 170|promoters
P06321770A1353|96 101|cells
P06321770A1353|19 52|chloramphenicol acetyltransferase
P06323556A0126|44 59|EOE-13 infusion
P06323556A0126|82 99|perfusion pattern
P06324121A0256|47 55|IEmRNA-5
P06324121A0256|12 14|MW
P06324121A0256|92 105|reading frame
P06324121A0256|81 86|codon
P06327039A0743|91 94|age
P06327039A0743|219 223|CD25
P06327039A0743|53 67|wall thickness
P06327039A0743|252 266|catecholamines
P06327039A0743|288 296|patients
P06327039A0743|72 89|body surface area
P06327039A0743|198 209|wall stress
P06327039A0743|309 310|p
P06327638A0155|128 131|DNA
P06327638A0155|55 88|chloramphenicol acetyltransferase
P06328012A0549|127 142|I1f subfragment
P06328012A0549|114 117|kbp
P06328012A0549|16 28|EBNA protein
P06328485A0277|29 48|nucleotide sequence
P06328485A0277|193 198|virus
P06328485A0277|228 231|mht
P06328485A0277|176 185|structure
P06328485A0277|263 270|viruses
P06328485A0277|71 74|end
P06330082A0329|1 3|A.
P06331684A0607|27 34|stomach
P06331684A0607|39 53|tumor antigens
P06331684A0607|85 89|risk
P06336045A0261b|14 18|Ft I
P06336045A0261b|24 33|frog type
P06336045A0261b|66 71|units
P06336045A0261b|38 40|Ft
P06336045A0261b|100 117|indentation phase
P06336045A0261b|1 10|Frog type
P06340703A0324|31 45|Masson Fontana
P06341661T0001|74 83|operation
P06341661T0001|56 71|Blalock-Taussig
P06345840A0348|104 112|velocity
P06345840A0348|43 45|CI
P06345840A0348|114 118|mVCF
P06345840A0348|141 144|TPR
P06345840A0348|16 23|group A
P06349364A1051|121 150|group B Streptococcus antigen
P06349364A1051|199 208|infection
P06349364A1051|82 96|serum globulin
P06349364A1051|98 108|antibodies
P06354594A0114|77 87|processing
P06354594A0114|49 53|lime
P06360426A0501|13 23|hydrolysis
P06360426A0501|27 31|urea
P06360426A0501|87 100|colour change
P06361318A1127|182 183|%
P06361318A1127|95 106|KS-R1 group
P06361318A1127|113 118|cases
P06361318A1127|255 265|difference
P06361318A1127|192 203|KS-R1 group
P06361318A1127|1 12|Side effect
P06362239T0001|23 33|physicians
P06364265T0062|9 31|gamma-ray spectroscopy
P06369355A0834|13 21|proteins
P06369355A0834|78 89|trfA region
P06369355A0834|173 184|plasmid RK2
P06369355A0834|1 9|Analysis
P06370553A0444|148 157|plasma NE
P06370553A0444|56 62|levels
P06370553A0444|53 54|E
P06370553A0444|194 202|plasma E
P06370553A0444|9 30|plasma norepinephrine
P06370553A0444|139 146|control
P06370553A0444|103 105|wk
P06373409A1163|41 50|placement
P06373409A1163|77 84|amalgam
P06373409A1163|1 10|Lauciello
P06374369A1112|150 156|events
P06374369A1112|7 11|data
P06374369A1112|85 89|rats
P06376227A0217|72 82|conditions
P06376227A0217|33 45|PP secretion
P06381438A1280|1 29|Lung prostacyclin production
P06384983T0000|1 11|Management
P06388189T0001|40 46|donors
P06388189T0001|1 16|Transplantation
P06391496T0000|94 102|antacids
P06391496T0000|55 71|antacid activity
P06391496T0000|35 47|polypeptides
P06394347A1024|94 107|noradrenaline
P06394347A1024|1 13|Hydrallazine
P06397009A0204|44 55|explanation
P06397009A0204|7 18|description
P06397009A0204|32 36|life
P06397009A0204|69 86|conductor Bozzini
P06397009A0204|204 217|possibilities
P06402480A0373|149 161|surveillance
P06402480A0373|27 39|PPNG strains
P06402480A0373|126 135|necessity
P06402480A0373|5 19|susceptibility
P06402480A0373|254 263|treatment
P06404842A0127|10 18|patients
P06404842A0127|80 98|depot testosterone
P06404842A0127|103 105|mg
P06407348A0516|160 169|receptors
P06407348A0516|93 103|situations
P06407348A0516|19 24|drugs
P06407348A0516|136 144|blockade
P06411659A0793|90 98|N intake
P06411659A0793|25 38|energy intake
P06411659A0793|113 122|mg/kg/day
P06415299A0233|62 64|mg
P06415299A0233|66 68|m.
P06426493A0331|151 156|group
P06426493A0331|89 97|pressure
P06426493A0331|59 71|measurements
P06426493A0331|117 122|FE'CO
P06426493A0331|75 78|IOP
P06426493A0331|160 168|patients
P06426493A0331|111 115|FIO2
P06426493A0331|99 109|heart rate
P06429992T0000|24 31|mothers
P06429992T0000|1 20|Gonadotropin levels
P06434572A0157|240 247|stature
P06434572A0157|335 345|GH reserve
P06434572A0157|50 60|categories
P06434572A0157|326 331|tests
P06434572A0157|111 126|hypopituitarism
P06434572A0157|202 207|delay
P06434572A0157|7 15|children
P06435565A0648|123 124|p
P06435565A0648|24 30|result
P06435565A0648|7 14|changes
P06435565A0648|235 236|p
P06435565A0648|71 79|pressure
P06439114A0677|43 50|therapy
P06439114A0677|87 97|infections
P06441624A0263|27 36|serum BGP
P06441624A0263|5 12|results
P06443639T0001|41 49|movement
P06443639T0001|65 83|circuit television
P06443639T0001|1 6|Study
P06444119A0340|79 90|temperature
P06444119A0340|92 100|salinity
P06444119A0340|116 125|nutrients
P06444119A0340|206 213|factors
P06444119A0340|102 104|pH
P06451557A0777|61 68|process
P06451557A0777|89 97|De Palma
P06451557A0777|20 23|tip
P06451557A0777|1 12|Deformities
P06452827T0001|32 50|Huntington choreas
P06454625A0000|89 99|parenchyma
P06454625A0000|130 158|Infrared-Contact-Coagulation
P06454625A0000|25 42|animal experiment
P06454625A0000|48 59|alterations
P06460889A0111|167 170|PBF
P06460889A0111|27 32|SG-75
P06460889A0111|83 86|SBP
P06463429A0414|26 31|phase
P06463429A0414|77 82|phase
P06467241A0000|45 57|radiotherapy
P06467241A0000|59 71|chemotherapy
P06467241A0000|36 43|surgery
P06468565A0000|60 61|N
P06468565A0000|28 31|cat
P06468565A0000|145 169|frequency gain constants
P06468565A0000|96 106|parameters
P06468565A0000|187 211|frequency gain constants
P06468565A0000|171 173|G1
P06468673A0358|63 75|mucus scores
P06468673A0358|128 129|P
P06473219T0000|59 76|diabetes mellitus
P06473219T0000|1 6|Value
P06479362A0680|164 179|muscle membrane
P06479362A0680|149 156|changes
P06479362A0680|80 95|muscle membrane
P06479362A0680|1 15|Hydrocortisone
P06480542A0000|89 93|unit
P06480542A0000|19 24|study
P06482318A0117|82 103|platelet shape change
P06483863A0000|150 153|oil
P06483863A0000|95 105|injections
P06483863A0000|178 182|life
P06483863A0000|248 259|concretions
P06483863A0000|221 224|age
P06483863A0000|286 292|silica
P06483863A0000|8 19|experiments
P06483863A0000|235 239|time
P06487290A0000|45 57|progesterone
P06487290A0000|29 39|E2-17 beta
P06487290A0000|10 19|estradiol
P06487290A0000|23 27|beta
P06487290A0000|87 114|radioimmunoassay techniques
P06487290A0000|237 242|phase
P06493655A0415|88 89|%
P06493655A0415|67 82|nonstress tests
P06493655A0415|102 103|%
P06494297A0939|24 32|kindling
P06494297A0939|92 98|HPC SS
P06494297A0939|5 12|results
P06495195A0536|30 35|tests
P06495195A0536|165 177|liver damage
P06495195A0536|69 89|alkaline phosphatase
P06501086A0165|45 49|rats
P06501086A0165|179 192|serum protein
P06501086A0165|217 223|levels
P06501086A0165|101 112|hypertrophy
P06501086A0165|236 257|serum electrophoresis
P06503329A0588|13 23|birth mass
P06503329A0588|126 127|P
P06503329A0588|114 116|SD
P06503329A0588|86 99|control group
P06505014A1192|28 37|dosimetry
P06505014A1192|7 20|uncertainties
P06507629A0717|134 153|mumol X min-1 X g-1
P06507629A0717|27 31|rats
P06507629A0717|112 118|groups
P06507629A0717|55 63|acidosis
P06513456T0001|92 101|treatment
P06513456T0001|1 24|Adenyl cyclase activity
P06516847A0393|63 72|mortality
P06516847A0393|38 49|pneumococci
P06517816A0388|121 124|Msw
P06517816A0388|76 85|b X min-1
P06517816A0388|54 63|degrees C
P06517816A0388|1 3|HA
P06517816A0388|103 104|p
P06521802A0251|165 179|Czechoslovakia
P06521802A0251|27 48|CMEA member countries
P06521802A0251|155 163|Sciences
P06521802A0251|137 151|Slovak Academy
P06524202A0167|121 129|training
P06524202A0167|160 170|spasticity
P06524202A0167|7 14|variant
P06524202A0167|38 50|multichannel
P06524202A0167|139 146|muscles
P06524761A0596|61 66|fever
P06524761A0596|249 257|hamsters
P06524761A0596|324 333|RH strain
P06524761A0596|51 59|immunity
P06524761A0596|130 155|killed-toxoplasma vaccine
P06524761A0596|172 181|challenge
P06524761A0596|71 87|body weight loss
P06527872T0000|133 137|cord
P06527872T0000|97 118|substantia gelatinosa
P06527872T0000|202 205|ACP
P06527872T0000|141 145|rats
P06527872T0000|207 213|method
P06535384A1115|63 73|difficulty
P06535384A1115|131 142|possibility
P06535384A1115|162 170|subjects
P06535384A1115|38 43|items
P06541019A0555|52 60|response
P06541019A0555|33 41|toxicity
P06542372A0159|43 56|discrepancies
P06542372A0159|82 93|terminology
P06542372A0159|169 179|similarity
P06545651A0346|166 169|NH3
P06545651A0346|112 140|protein nitrogen degradation
P06545651A0346|156 164|nitrogen
P06545651A0346|102 108|effect
P06548953T0001|7 25|thyroid stimulator
P06568939A0000|132 140|pathways
P06568939A0000|38 43|BAERs
P06568939A0000|71 91|eye movement studies
P06568939A0000|1 10|Brainstem
P06579147A0060|74 84|approaches
P06579147A0060|22 30|features
P06579147A0060|36 44|problems
P06579147A0060|117 128|deformities
P06582285A0222|47 50|D&E
P06582285A0222|127 136|gestation
P06582285A0222|70 73|U-P
P06585277A0000|30 38|leukemia
P06585277A0000|44 55|association
P06585277A0000|79 104|acid phosphatase activity
P06585277A0000|142 154|bone lesions
P06585277A0000|158 173|roentgenography
P06588501T0059|27 32|study
P06597709A0596|72 84|lung volumes
P06597709A0596|43 53|asbestosis
P06597709A0596|140 146|volume
P06597709A0596|102 117|transfer factor
P06600533T0000|92 102|CT variant
P06600533T0000|1 12|Azygos vein
P06602600A0582|26 33|cannula
P06602600A0582|5 14|Sarns 51F
P06607427A0000|180 186|cortex
P06607427A0000|244 253|behaviour
P06607427A0000|7 18|experiments
P06607427A0000|261 264|rat
P06607427A0000|207 226|body weight changes
P06609166A0209|104 115|microliters
P06609166A0209|36 43|samples
P06609166A0209|5 11|method
P06609166A0209|152 177|C18 reversed-phase column
P06612373A0000|104 107|use
P06612373A0000|124 129|drugs
P06612373A0000|142 147|1960s
P06612373A0000|158 163|1970s
P06612373A0000|50 57|variety
P06615403A0718|180 187|minutes
P06615403A0718|129 137|ligation
P06615403A0718|115 122|minutes
P06615403A0718|17 30|LAD occlusion
P06627123A0000|44 52|Sustacal
P06627123A0000|110 117|sucrose
P06627123A0000|81 82|%
P06627123A0000|70 77|ethanol
P06629370A0252|106 117|lamellation
P06629370A0252|125 142|basement membrane
P06629370A0252|36 65|basement membrane nephropathy
P06629370A0252|184 192|syndrome
P06634712A0557|105 107|CT
P06634712A0557|57 64|calcium
P06634712A0557|111 117|uremia
P06634712A0557|5 12|results
P06648156T0034|14 21|remarks
P06653755A0192|7 30|clofelin administration
P06653755A0192|35 57|autoregulation borders
P06654686T0001|86 90|girl
P06654686T0001|51 80|granulocyte function disorder
P06656249T0000|1 24|Nursing home discharges
P06658029A0086|111 128|hazard evaluation
P06658029A0086|5 24|carcinogen bioassay
P06658586T0001|45 53|diseases
P06658586T0001|32 41|diagnosis
P06662623A0124|40 47|samples
P06662623A0124|7 11|MISO
P06662623A0124|2 6|82Br
P06662623A0124|51 58|Br-MISO
P06667868T0001|92 100|variants
P06667868T0001|39 47|elements
P06667868T0001|64 68|rats
P06667868T0001|138 150|BR-1 benzene
P06671047A1124|62 66|test
P06671047A1124|391 397|states
P06671047A1124|297 308|possibility
P06671047A1124|157 162|CD/LD
P06671047A1124|221 234|Prolactinomas
P06671047A1124|74 83|diagnosis
P06671047A1124|193 202|existence
P06671047A1124|276 281|tonus
P06671047A1124|35 43|validity
P06671385A0856|12 13|A
P06671385A0856|77 79|PA
P06671385A0856|138 157|body sodium content
P06672094A0390|78 82|face
P06672094A0390|127 134|neurons
P06672094A0390|202 209|mammals
P06674516A0350|107 115|diseases
P06674516A0350|33 36|AMK
P06674516A0350|16 29|drip infusion
P06675047A0000|135 148|determination
P06675047A0000|29 41|interference
P06675047A0000|5 12|authors
P06675047A0000|85 94|Berthelot
P06683876A0244|63 70|fission
P06683876A0244|7 12|cells
P06683876A0244|80 88|clusters
P06684624A0736|9 41|N-acetylglucosaminidase activity
P06685177T0000|15 25|Alafilaria
P06685177T0000|55 57|n.
P06685643A0179|30 36|C1-INH
P06685643A0179|62 67|stage
P06685643A0179|5 19|concentrations
P06685643A0179|101 112|mean values
P06687953T0000|50 67|leukocyte enzymes
P06689513T0001|53 60|infants
P06692517T0000|31 36|drugs
P06692517T0000|144 160|echocardiography
P06692517T0000|5 12|effects
P06692517T0000|71 78|thrombi
P06694380A1483|40 45|group
P06694380A1483|71 73|SD
P06694380A1483|1 10|Plasma NE
P06698047A0445|120 125|cases
P06698047A0445|76 79|TRH
P06698047A0445|5 21|Prolactin levels
P06702643A0000|30 31|%
P06702643A0000|135 142|Celoria
P06702643A0000|147 153|Patton
P06702643A0000|125 131|type B
P06702643A0000|185 187|SA
P06705456A0346|43 47|peak
P06705456A0346|1 11|Absorption
P06709310A0000|45 50|onset
P06709310A0000|3 7|case
P06711642A0093|104 124|creatinine clearance
P06711642A0093|179 187|dipstick
P06711642A0093|233 249|urine collection
P06711642A0093|138 149|proteinuria
P06711642A0093|255 263|oliguria
P06713200A0630|91 96|layer
P06713200A0630|67 72|layer
P06713200A0630|1 22|Epileptiform activity
P06714298X0000|183 193|nifedipine
P06714298X0000|332 338|output
P06714298X0000|82 86|pigs
P06714298X0000|292 302|maxLVdP/dt
P06714298X0000|105 130|micrograms X kg-1 X min-1
P06714298X0000|280 281|%
P06715792A0295|26 33|fetuses
P06715792A0295|1 18|HBB concentration
P06718064T0001|55 66|neutrophils
P06720371T0000|37 50|gout patients
P06720371T0000|16 33|blood coagulation
P06723849A0197|60 63|MRF
P06723849A0197|102 113|transection
P06726257T0000|12 24|methiothepin
P06726257T0000|59 76|serotonin release
P06726257T0000|38 55|acid diethylamide
P06731302A0930|92 104|branch block
P06731302A0930|76 81|block
P06731302A0930|17 32|bradyarrhythmia
P06734713T0000|1 11|Diclofenac
P06738410T0000|1 15|Blood pressure
P06740697A0318|56 74|guinea pig strains
P06743061A0239|12 19|percent
P06743061A0239|53 60|disease
P06748227A0423|13 17|Case
P06748227A0423|111 115|side
P06748227A0423|70 75|right
P06750608A1442|62 71|phenotype
P06750608A1442|57 60|mak
P06753902A0437|122 131|class IIM
P06753902A0437|42 51|captopril
P06753902A0437|33 38|month
P06753902A0437|84 90|months
P06755468A0180|111 130|amino acid homology
P06755468A0180|32 46|reading frames
P06755468A0180|50 54|cobA
P06760394T0001|46 49|ITI
P06760394T0001|8 25|tooth replacement
P06760394T0001|51 87|International Team fur Implantologie
P06762321T0000|24 50|DNA controlling expression
P06762321T0000|64 91|maltosaccharide utilization
P06764669T0001|90 97|reagent
P06764669T0001|59 73|deferoxamine B
P06772370A0342|91 101|correction
P06772370A0342|59 63|l/kg
P06772370A0342|185 189|ages
P06772370A0342|160 165|women
P06772370A0342|174 177|men
P06772370A0342|39 44|range
P06772370A0342|1 7|Volume
P06775834A0000|31 39|patients
P06775834A0000|11 23|B phenotypes
P06775834A0000|65 74|melanomas
P06777229A0243|58 66|patients
P06777229A0243|5 13|subjects
P06777229A0243|87 94|disease
P06781339A0501|78 82|mode
P06781339A0501|53 62|follow-up
P06781339A0501|86 95|treatment
P06782612A0142|90 91|V
P06782612A0142|104 121|lithium clearance
P06782612A0142|76 88|urine volume
P06784123A0286|15 24|C mu RNAs
P06784123A0286|91 97|region
P06784123A0286|33 41|mu mRNAs
P06784123A0286|103 108|locus
P06784123T0000|67 75|splicing
P06784123T0000|20 44|immunoglobulin C mu gene
P06786756T0000|13 30|DNA rearrangement
P06786756T0000|83 109|immunoglobulin delta genes
P06786756T0000|69 79|expression
P06790572A0330|47 55|colistin
P06790572A0330|57 65|nystatin
P06790572A0330|67 81|amphotericin B
P06790572A0330|35 45|lincomycin
P06793764T0001|1 12|Host lipids
P06794666A0208|88 95|measure
P06794666A0208|64 68|ATCI
P06794666A0208|154 162|function
P06794666A0208|17 40|neuroeffector influence
P06795654A0434|126 145|minimum requirement
P06795654A0434|18 23|doses
P06795654A0434|1 13|Fenfluramine
P06795900A0000|193 197|rats
P06795900A0000|25 68|acid cyclo-oxygenase inhibitor indomethacin
P06795900A0000|5 11|effect
P06795900A0000|116 120|rate
P06796300A0759|22 38|prolactin levels
P06798609A0000|60 68|protocol
P06798609A0000|127 135|mg/kg IP
P06798609A0000|32 36|rats
P06798609A0000|170 177|periods
P06802500T0001|1 19|Thyreoliberin VUFB
P06805504A0629|77 79|kg
P06805504A0629|144 145|N
P06805504A0629|50 58|mg/kg W0
P06807149A0222|78 83|forms
P06807149A0222|87 90|DSG
P06807149A0222|51 58|ability
P06807192A0312|28 35|puppies
P06807192A0312|92 96|LCGU
P06807192A0312|1 5|LCBF
P06808287T0001|1 10|Detection
P06809474A1156|63 70|finding
P06809474A1156|39 40|h
P06810070A0502|29 38|Cd-spores
P06810070A0502|21 23|Hg
P06810694A1000|56 75|ethanol consumption
P06810694A1000|32 35|age
P06815368A0203|22 30|mannitol
P06816123A0526|31 53|glutathione peroxidase
P06816123A0526|146 154|selenium
P06816123A0526|87 102|defense systems
P06816123A0526|16 27|constituent
P06816609A0639|105 113|CBF fall
P06816609A0639|52 55|kPa
P06816609A0639|34 38|PCO2
P06818113A0384|11 19|patients
P06818113A0384|67 77|adrenaline
P06818113A0384|83 91|controls
P06818113A0384|201 216|clotting factor
P06818113A0384|35 44|responses
P06822645T0039|13 44|increase growth hormone release
P06825641A0076|15 34|landfill operations
P06825641A0076|129 140|containment
P06828396A0095|14 27|contamination
P06828396A0095|5 10|level
P06830033A0661|9 21|observations
P06830033A0661|80 83|min
P06833047A0000|41 50|mechanism
P06833047A0000|6 11|study
P06833047A0000|138 142|HFOV
P06835516A0000|3 7|case
P06837312A0000|15 22|intimal
P06837312A0000|73 78|aorta
P06837312A0000|126 130|diet
P06837312A0000|141 156|months duration
P06837312A0000|103 105|IU
P06840803A0397|14 19|signs
P06840803A0397|36 44|reaction
P06840803A0397|71 73|hr
P06848729A0000|8 16|children
P06851280A0144|63 68|timol
P06851280A0144|83 88|units
P06853042A0282|134 142|capacity
P06853042A0282|38 47|threshold
P06853042A0282|69 93|bicarbonate reabsorption
P06856306T0000|42 51|Hennebert
P06856306T0000|54 58|sign
P06858449A0335|27 37|maturation
P06858805A0314|31 36|tests
P06858805A0314|96 106|Tuberculin
P06858805A0314|48 64|hypersensitivity
P06863087A0664|29 31|DB
P06863087A0664|10 11|D
P06863087A0664|92 99|control
P06864955T0000|16 20|MMWR
P06869215A0347|6 12|levels
P06872800T0000|14 23|hepatitis
P06872800T0000|55 68|HBV infection
P06875478A0542|27 28|%
P06875478A0542|54 55|%
P06876317T0033|40 59|deficiency syndrome
P06880604A0167|122 127|Vaasa
P06880604A0167|110 118|province
P06880604A0167|83 90|Uusimaa
P06880604A0167|71 79|province
P06882578A0464|90 106|training session
P06882578A0464|210 215|ng/ml
P06882578A0464|122 127|ng/ml
P06882578A0464|228 231|end
P06882578A0464|262 267|ng/ml
P06882578A0464|153 161|training
P06884450A0234|62 63|%
P06884450A0234|29 36|results
P06884450A0234|93 94|%
P06886948A0750|88 100|requirements
P06886948A0750|53 67|energy intakes
P06886948A0750|17 28|weight gain
P06890935T0001|1 7|Behcet
P06891270A0000|41 44|EPS
P06891270A0000|5 11|effect
P06891270A0000|119 129|rat atrium
P06895663A0810|41 52|association
P06895663A0810|115 116|P
P06895663A0810|69 72|RLF
P06902722T0000|51 61|infarction
P06916588A0304|105 114|catheters
P06916588A0304|46 54|patients
P06916588A0304|116 117|p
P06935514A0000|134 139|order
P06935514A0000|43 51|research
P06935514A0000|64 75|preparation
P06935514A0000|175 189|dentinogenesis
P06946314T0000|21 38|Tauranga children
P06948398A0523|26 36|management
P06948398A0523|77 87|importance
P06948868A0082|41 52|reliability
P06948868A0082|5 11|scores
P06953957A0503|108 116|episodes
P06953957A0503|77 86|myoglobin
P06953957A0503|154 164|peak value
P06957633T0001|41 48|trisomy
P06957633T0001|131 136|years
P06957633T0001|86 93|patient
P06957633T0001|1 12|Development
P06962492A0612|10 16|growth
P06962492A0612|114 124|bone bases
P06963337T0000|62 74|hypertension
P06969638A0180|150 157|therapy
P06969638A0180|130 142|determinants
P06969638A0180|6 18|examinations
P06969638A0180|171 180|prognosis
P06972443A0375|18 28|evaluation
P06973664A0000|62 69|patient
P06973664A0000|3 7|case
P06977605T0000|1 11|Endorphins
P06981991A0756|24 35|performance
P06981991A0756|232 246|artery disease
P06981991A0756|169 174|group
P06981991A0756|274 279|group
P06981991A0756|137 144|patient
P06986168A0304|63 71|peptides
P06986168A0304|10 19|sequences
P06993660A0000|56 65|potassium
P06993660A0000|249 253|days
P06993660A0000|223 227|rats
P06993660A0000|75 93|relaxant responses
P06993660A0000|229 232|AHR
P06993660A0000|97 110|isoproterenol
P06994049T0001|58 65|infants
P06994049T0001|1 10|Detection
P07004236A0741|183 192|treatment
P07004236A0741|27 43|folate compounds
P07004236A0741|219 237|methanol poisoning
P07004236A0741|5 12|results
P07004236A0741|168 175|folates
P07007591A0324|243 245|RT
P07007591A0324|251 253|RR
P07007591A0324|254 255|t
P07007591A0324|226 233|formula
P07007591A0324|106 111|areas
P07007591A0324|235 236|E
P07007591A0324|237 238|t
P07007591A0324|211 215|msec
P07007591A0324|328 331|CPZ
P07007591A0324|26 27|t
P07007591A0324|266 267|t
P07007591A0324|284 286|RR
P07007591A0324|133 136|CPZ
P07007591A0324|277 279|RT
P07015262A0396|75 90|tract infection
P07015262A0396|13 31|cefadroxil therapy
P07015262A0396|161 166|group
P07015262A0396|5 9|days
P07018810A0002|192 198|cortex
P07018810A0002|78 85|outflow
P07018810A0002|218 228|cat kidney
P07018810A0002|1 27|Plasma renin concentration
P07026328A0369|24 33|infusions
P07026328A0369|82 88|mmol/1
P07026328A0369|115 123|glucagon
P07026328A0369|186 187|%
P07026328A0369|44 48|rise
P07026328A0369|141 142|p
P07037479T0000|6 19|cracked-tooth
P07038684A1050|194 218|p60 initiator methionine
P07038684A1050|149 169|amino acid sequences
P07038684A1050|10 34|peptide map similarities
P07038684A1050|93 99|origin
P07038684A1050|220 227|residue
P07044389T0000|1 6|Facts
P07044389T0000|85 97|audiologists
P07044842A2062|92 99|Bartter
P07044842A2062|35 48|complications
P07049690T0000|12 19|lesions
P07061350A0042|72 78|bundle
P07061350A0042|80 84|COCB
P07061350A0042|138 143|f2-f1
P07061350A0042|118 136|distortion product
P07062269A0798|105 116|l-methadone
P07062269A0798|40 48|receptor
P07062269A0798|140 147|effects
P07064662A0222|27 34|lesions
P07064662A0222|128 138|neurolysis
P07064662A0222|49 59|occurrence
P07065206A0398|26 51|plasma TXB2 concentration
P07065206A0398|7 20|control sheep
P07065206A0398|119 122|min
P07068493A0636|99 108|pressures
P07068493A0636|115 118|SIP
P07068887A0000|31 39|validity
P07068887A0000|180 188|lifetime
P07068887A0000|111 112|N
P07068887A0000|99 109|inpatients
P07068887A0000|18 29|reliability
P07073520A0153|177 189|fluid volume
P07073520A0153|42 60|substitution fluid
P07073520A0153|21 35|hemofiltration
P07073520A0153|102 110|decrease
P07078263T0000|111 117|anemia
P07078263T0000|21 33|deferoxamine
P07078263T0000|50 65|hemochromatosis
P07080496A0097|105 114|fractions
P07080496A0097|196 199|LDL
P07080496A0097|159 166|respect
P07080496A0097|18 31|investigation
P07080496A0097|100 103|HDL
P07084198T0000|41 55|United Kingdom
P07084198T0000|1 16|Selenium status
P07084814T0000|1 12|Preparation
P07090151A0165|108 116|category
P07090151A0165|53 57|MSRB
P07090151A0165|19 27|morantel
P07094905A0644|133 144|hippocampus
P07094905A0644|97 102|cells
P07094905A0644|116 125|CA3 field
P07097182A0480|110 120|overgrowth
P07097182A0480|5 13|duration
P07097182A0480|200 204|ears
P07097182A0480|100 104|ears
P07106323A0560|94 101|E3-16-G
P07106323A0560|7 14|results
P07106323A0560|50 55|fetus
P07107287A1083|75 90|99Mo generators
P07107287A1083|64 71|numbers
P07107773A0000|180 184|meal
P07107773A0000|113 119|plasma
P07107773A0000|221 237|amine precursors
P07107773A0000|258 276|gas chromatography
P07107773A0000|350 397|trifluoroethyl-pentafluoropropionyl derivatives
P07107773A0000|163 174|consumption
P07107773A0000|202 211|deuterium
P07110999A0160|31 40|disorders
P07110999A0160|56 68|incontinence
P07112471A0639|120 126|worker
P07112471A0639|161 168|factory
P07112471A0639|1 21|Histamine reactivity
P07113365A0737|63 76|surface angle
P07113365A0737|130 137|methods
P07113365A0737|141 152|measurement
P07114083A0153|30 39|remission
P07114083A0153|147 154|Gaucher
P07114083A0153|7 19|MOPP therapy
P07114083A0153|80 93|normalization
P07114083A0153|101 125|glucocerebrosidase level
P07116962A0299|5 22|COP-PAWP gradient
P07116962A0299|98 103|edema
P07124743A1223|419 429|absorption
P07124743A1223|22 39|glassware factory
P07124743A1223|156 166|evaluation
P07124743A1223|392 397|hands
P07124743A1223|280 286|levels
P07124743A1223|11 16|study
P07124743A1223|202 209|arsenic
P07124743A1223|71 82|measurement
P07124743A1223|170 174|hand
P07125238T0000|22 26|site
P07125238T0000|5 14|pia mater
P07126413A0000|151 156|resin
P07126413A0000|13 28|delivery system
P07126413A0000|113 117|site
P07126413A0000|69 74|drugs
P07132408A0387|37 59|magnesium cardioplegia
P07135112T0000|22 28|defect
P07135112T0000|1 7|Repair
P07136569A0000|88 97|scoliosis
P07136569A0000|11 17|Sweden
P07136569A0000|54 59|years
P07136569A0000|139 144|years
P07140060T0000|17 28|dislocation
P07141130A0615|195 201|mucosa
P07141130A0615|240 245|cells
P07141130A0615|270 276|groups
P07141130A0615|145 151|number
P07141130A0615|115 116|p
P07147622T0000|36 42|cattle
P07149303T0000|27 36|lidocaine
P07149303T0000|80 84|cats
P07149303T0000|17 23|action
P07155579T0001|14 29|bacteriospermia
P07160491A0547|91 98|LD50/30
P07160491A0547|108 129|dose reduction factor
P07165767T0000|1 13|Mastocytosis
P07169630A0983|135 139|type
P07169630A0983|27 34|absence
P07169630A0983|69 79|conditions
P07173729A0000|10 27|penetration tests
P07173729A0000|37 42|sperm
P07173729A0000|140 145|mucus
P07174122A0000|24 27|SCK
P07174122A0000|112 129|bicycle ergometry
P07174122A0000|49 57|subjects
P07174122A0000|136 148|lifting task
P07175474A0102|107 113|manner
P07175474A0102|163 173|difficulty
P07175474A0102|117 122|death
P07180901A0539|75 99|prostaglandin synthetase
P07180901A0539|122 131|ibuprofen
P07180901A0539|153 161|necrosis
P07182523A0462|72 89|SOA concentration
P07182523A0462|38 41|SOA
P07184375T0001|75 99|combination chemotherapy
P07184375T0001|133 141|lymphoma
P07184375T0001|37 49|methotrexate
P07184375T0001|69 71|VM
P07184774T0000|1 15|Re-examination
P07190627T0000|96 103|dog leg
P07190627T0000|64 70|agents
P07191183A0505|14 25|meat muscle
P07191183A0505|92 104|autoxidation
P07191183A0505|1 10|Treatment
P07191972A0391|15 26|temperature
P07191972A0391|33 42|degrees C
P07191972A0391|68 75|cooling
P07192722A0682|73 90|serum iPTH levels
P07192722A0682|147 151|sera
P07192722A0682|128 135|ability
P07192722A0682|115 119|PMNs
P07192722A0682|101 103|CL
P07192722A0682|139 144|group
P07195615A0087|61 69|duration
P07195615A0087|73 90|Cd administration
P07195615A0087|94 105|association
P07195615A0087|178 184|region
P07195615A0087|155 159|bulb
P07202224A0452|130 137|females
P07202224A0452|67 77|injections
P07202224A0452|53 58|males
P07202224A0452|81 83|TP
P07202919A0142|79 89|ulcer scar
P07202919A0142|97 106|42nd week
P07202919A0142|38 45|stomach
P07205120T0000|15 22|overlay
P07205120T0000|50 64|ECG wave forms
P07208984A0000|57 66|MAA brain
P07208984A0000|158 166|diseases
P07208984A0000|86 104|tomography studies
P07214665A0000|15 26|combination
P07214665A0000|74 82|triazeno
P07214665A0000|130 140|prednisone
P07214665A0000|142 146|FIVB
P07214665A0000|169 174|women
P07217523A0364|75 82|voicing
P07217523A0364|97 110|vowel context
P07217523A0364|1 8|Results
P07217523A0364|84 92|position
P07219297T0000|11 19|approach
P07221179A0156|26 38|GABA content
P07221179A0156|163 170|minutes
P07221179A0156|53 66|GABA decrease
P07221179A0156|18 22|fall
P07225300A0968|29 36|neonate
P07225300A0968|108 112|drug
P07225300A0968|7 14|results
P07225300A0968|54 59|adult
P07226440T0000|66 69|rat
P07226440T0000|51 58|failure
P07234308A0121|89 94|cases
P07234308A0121|43 48|BACOP
P07234308A0121|7 20|drug regimens
P07234308A0121|34 38|CHOP
P07234974T0000|27 40|Jat dentition
P07235355A0462|121 131|flow rates
P07235355A0462|28 32|COPD
P07235355A0462|95 96|%
P07235355A0462|69 74|tests
P07237123T0000|29 43|unit responses
P07237123T0000|87 93|turtle
P07237817T0000|1 17|Cross reactivity
P07242929T0001|117 124|methods
P07242929T0001|35 43|activity
P07247059A0775|28 36|response
P07247059A0775|42 55|step increase
P07247059A0775|114 118|cent
P07247059A0775|87 88|s
P07247059A0775|102 109|cent-90
P07249544A0343|10 21|temperature
P07249544A0343|35 63|serum creatine kinase levels
P07249895A0177|24 38|prostaglandins
P07249895A0177|294 302|recovery
P07249895A0177|86 101|LES hypotension
P07249895A0177|16 20|role
P07249895A0177|167 180|micrograms/kg
P07249895A0177|206 215|inhibitor
P07252346A0223|12 21|technique
P07256543A0814|105 110|burns
P07256543A0814|9 14|study
P07256543A0814|37 45|criteria
P07256543A0814|219 232|airway injury
P07256543A0814|50 67|inhalation injury
P07256543A0814|205 213|patients
P07260389A0221|126 135|serotonin
P07260389A0221|116 122|effect
P07260389A0221|1 13|Methisergide
P07262239T0000|28 39|deprivation
P07262239T0000|77 88|projections
P07262239T0000|1 8|Effects
P07263374T0000|25 32|puppies
P07263745T0000|45 54|procedure
P07266969A0246|37 47|properties
P07266969A0246|65 89|breast cancer management
P07268828A0000|104 114|antibodies
P07268828A0000|46 51|serum
P07268828A0000|215 221|tracer
P07268828A0000|55 68|plasma levels
P07268828A0000|154 175|solid-phase particles
P07270991A0149|72 79|results
P07270991A0149|6 21|pollen allergen
P07274428A0000|120 129|bilignost
P07274428A0000|298 309|liver cells
P07274428A0000|212 225|RCA triombrin
P07274428A0000|22 33|experiments
P07274428A0000|291 293|PM
P07274428A0000|280 289|membranes
P07274428A0000|138 154|cholecystography
P07274505A0660|4 12|controls
P07277222A1391|78 88|oscillator
P07277222A1391|112 122|occurrence
P07277222A1391|187 199|interactions
P07278578T0001|9 15|status
P07278578T0001|19 31|chemotherapy
P07282444A0075|44 52|approach
P07282444A0075|109 114|shunt
P07282943A0097|31 40|decreases
P07282943A0097|91 98|control
P07282943A0097|166 173|changes
P07282943A0097|81 84|PO2
P07282943A0097|206 213|tension
P07282943A0097|102 103|%
P07286057A0159|147 156|injection
P07286057A0159|57 67|buflomedil
P07286057A0159|172 174|mg
P07286057A0159|184 198|administration
P07293327T0001|36 47|KZM-1 meter
P07295417A0092|107 116|technique
P07295417A0092|35 42|regions
P07296997A0125|56 59|OCG
P07296997A0125|77 105|Tc-99m-PyG cholescintigraphy
P07297978A0570|12 16|data
P07297978A0570|36 48|case history
P07297978A0570|50 64|smoking habits
P07298259T0000|18 22|lead
P07299857A0294|89 95|KP-CMC
P07299857A0294|333 335|KP
P07299857A0294|145 149|male
P07299857A0294|25 27|KP
P07299857A0294|250 256|KP-CMC
P07299857A0294|324 329|terms
P07299857A0294|16 21|terms
P07299857A0294|79 83|rats
P07299857A0294|313 320|females
P07299857A0294|232 246|administration
P07299857A0294|136 141|mg/kg
P07299857A0294|304 309|mg/kg
P07306839T0001|46 52|cortex
P07306839T0001|22 29|picture
P07309562T0000|91 96|acids
P07309562T0000|67 71|acid
P07311881T0000|1 13|MSMS Council
P07320153T0000|47 53|system
P07320153T0000|24 30|liquid
P07320153T0000|65 74|precolumn
P07320153T0000|1 6|Micro
P07323573A0644|32 44|dissociation
P07327097A0647|122 123|p
P07327097A0647|163 176|granule cells
P07327097A0647|4 11|PB mice
P07327097A0647|51 57|number
P07330073T0000|15 36|transfusion reactions
P07330073T0000|1 11|Prevention
P07330073T0000|51 57|saline
P07340196T0001|93 119|hepatitis B virus carriers
P07340196T0001|18 31|determination
P07345217A0000|60 69|treatment
P07345217A0000|87 97|malignancy
P07355527A0467|15 24|procedure
P07355527A0467|69 75|adults
P07365183A0000|134 142|response
P07365183A0000|183 190|therapy
P07365183A0000|43 52|diagnosis
P07365183A0000|231 238|therapy
P07365183A0000|96 101|terms
P07369458A0606|45 54|technique
P07369458A0606|115 122|adjunct
P07372928A0105|14 20|method
P07372928A0105|203 211|membrane
P07372928A0105|38 54|Mossbauer source
P07372928A0105|84 92|membrane
P07375864A0431|107 115|disorder
P07375864A0431|27 41|nonspecificity
P07375864A0431|76 85|correlate
P07375864A0431|157 163|burden
P07375864A0431|206 218|platelet MAO
P07377378A0143|225 233|controls
P07377378A0143|145 150|rates
P07377378A0143|36 50|beta-estradiol
P07377378A0143|154 169|heat production
P07379334A0503|133 140|placebo
P07379334A0503|24 34|reactivity
P07379334A0503|38 46|subjects
P07385543T0001|31 54|blood sulfhydryl groups
P07385543T0001|109 118|infection
P07385543T0001|1 11|Importance
P07385933A0085|47 61|kg body weight
P07385933A0085|11 23|iv injection
P07385933A0085|108 117|galactose
P07385933A0085|119 124|14CO2
P07392519T0001|31 42|retinopathy
P07392519T0001|9 16|changes
P07393976A0000|72 77|mg/kg
P07393976A0000|131 135|rats
P07393976A0000|179 205|bottle taste aversion task
P07393976A0000|52 67|sodium barbital
P07393976A0000|5 12|ability
P07393976A0000|16 36|sodium phenobarbital
P07395750A0294|82 95|methodologies
P07395750A0294|34 35|%
P07397066T0000|1 16|Drug inhibition
P07405701T0000|92 102|alcoholism
P07405701T0000|68 76|patients
P07408970A0706|72 78|weight
P07408970A0706|42 48|uterus
P07408970A0706|163 164|p
P07408970A0706|5 10|hours
P07408970A0706|85 88|mg%
P07413144T0018|1 9|Analysis
P07413441T0070|67 73|kidney
P07413806T0000|52 56|rats
P07413806T0000|18 26|amygdala
P07415340A0280|12 16|size
P07415340A0280|1 7|Number
P07418498A0217|28 41|complications
P07418498A0217|123 132|treatment
P07418498A0217|78 86|recovery
P07418498A0217|138 152|amphotericin B
P07419485A0158|89 97|solution
P07419485A0158|22 32|transition
P07419485A0158|174 188|simplification
P07419485A0158|68 73|waves
P07425838A0182|67 76|trimester
P07425838A0182|21 37|pheochromocytoma
P07426604A0397|12 21|C10 value
P07426604A0397|38 45|measure
P07428037A0989|44 61|mouse mt 12S rRNA
P07428037A0989|193 200|subunit
P07428037A0989|242 259|mRNA binding site
P07428037A0989|261 267|ACCUCC
P07428037A0989|140 151|nucleotides
P07428037A0989|290 312|corn chloroplast rRNAs
P07431059A0000|268 277|Rosenthal
P07431059A0000|360 365|notch
P07431059A0000|297 301|vein
P07431059A0000|53 66|magnification
P07431059A0000|119 132|pineal region
P07431059A0000|404 410|nerves
P07431059A0000|312 317|sinus
P07431059A0000|203 209|artery
P07431059A0000|70 75|order
P07431059A0000|171 182|pineal body
P07434431A0203|47 56|mechanism
P07434431A0203|125 131|famine
P07435185A0074|28 36|findings
P07435185A0074|5 13|symptoms
P07435185A0074|115 127|drill biopsy
P07436459A0245|163 171|response
P07436459A0245|175 196|tryptophan metabolism
P07436794A0148|6 19|control group
P07436794A0148|50 53|CCA
P07438482A0145|14 19|right
P07438482A0145|52 65|blood samples
P07438482A0145|85 98|determination
P07440430A1074|210 211|P
P07440430A1074|52 61|Hb levels
P07440430A1074|185 192|B lambs
P07440430A1074|16 26|B breeding
P07440430A1074|140 141|P
P07440430A1074|168 179|D x B lambs
P07440430A1074|100 108|NB lambs
P07449221A0086|30 38|excision
P07449221A0086|58 62|slip
P07449221A0086|86 92|repair
P07450031A0691|181 188|dioxide
P07450031A0691|162 178|benzothiazepin-6
P07450031A0691|81 97|benzothiazepin-6
P07450031A0691|100 107|dioxide
P07453919A0000|30 38|headache
P07453919A0000|121 135|determinations
P07453919A0000|88 104|blood cell count
P07453919A0000|213 218|tests
P07453919A0000|21 27|Horton
P07453919A0000|220 223|IgM
P07453919A0000|228 239|IgG binding
P07453919A0000|383 387|side
P07453919A0000|7 15|patients
P07453919A0000|137 145|alkaline
P07455521A0414|5 9|ESEG
P07457931A0655|44 53|injection
P07457931A0655|9 15|series
P07457931A0655|19 23|mice
P07461226A0958|28 33|flush
P07461226A0958|97 118|norepinephrine levels
P07462481A0422|45 49|time
P07462481A0422|105 114|occlusion
P07462481A0422|160 165|weeks
P07462481A0422|93 98|weeks
P07462481A0422|71 78|infarct
P07463465A0297|43 56|control women
P07463465A0297|66 71|birth
P07467975A0316|147 154|periods
P07467975A0316|261 275|multigravidity
P07467975A0316|185 195|primiparae
P07467975A0316|356 374|behaviour patterns
P07467975A0316|316 328|reproduction
P07467975A0316|280 290|parameters
P07467975A0316|110 124|contraceptives
P07467975A0316|200 212|secundiparae
P07467975A0316|1 16|Family planning
P07471210A0384|63 70|daltons
P07471210A0384|5 16|87K protein
P07471210A0384|190 199|positions
P07472736A0278|14 23|component
P07472736A0278|71 79|eminence
P07473742A0187|165 172|element
P07473742A0187|5 18|protein ELT-1
P07474085A0932|15 24|R protein
P07474085A0932|89 98|V protein
P07474085A0932|66 81|frameshift site
P07474140A1036|210 215|C-488
P07474140A1036|192 197|C-400
P07474140A1036|77 96|amino acid residues
P07474140A1036|251 259|activity
P07474140A1036|18 29|mutagenesis
P07474140A1036|171 176|D-357
P07474617A1035|62 72|PRL levels
P07475733T0000|10 17|anaemia
P07475733T0000|53 59|Africa
P07476164A1602|91 95|F27Y
P07476164A1602|76 80|K13Q
P07476164A1602|82 86|F15Y
P07476164A1602|4 12|addition
P07476164A1602|171 183|CspB protein
P07476963A0000|79 83|RXRs
P07476963A0000|97 114|hormone receptors
P07476963A0000|168 172|acid
P07476963A0000|35 44|receptors
P07476975A0492|28 40|somatotropes
P07476975A0492|199 211|distribution
P07476975A0492|59 71|gonadotropes
P07476975A0492|157 165|products
P07476975A0492|102 110|controls
P07478514A0237|50 55|clone
P07478525A1177|6 13|classes
P07478525A1177|51 57|dimers
P07482069A0606|48 54|months
P07482069A0606|70 89|vasculitis symptoms
P07483285A0322|47 69|SV40 enhancer/promoter
P07483285A0322|7 24|HPV16 E6/E7 cDNAs
P07483285A0322|175 188|DNA synthesis
P07483285A0322|102 112|activities
P07487067A0592|125 132|lengths
P07487067A0592|159 168|sequences
P07487067A0592|5 25|translation products
P07487067A0592|201 221|plastid localization
P07487811A0000|151 156|PSE-1
P07487811A0000|129 149|Systems Experiment-1
P07487811A0000|173 184|spaceflight
P07487811A0000|190 195|PSE-2
P07487811A0000|204 210|flight
P07488247T0000|12 20|analysis
P07488247T0000|24 49|aryl hydrocarbon receptor
P07488247T0000|139 145|system
P07488959T0000|4 12|approach
P07490079A0825|15 22|regions
P07490079A0825|108 115|homolog
P07490079A0825|93 97|STEP
P07490083A0000|10 21|anhydrase V
P07490083A0000|93 100|tissues
P07490083A0000|69 74|liver
P07490278A0799|55 60|Num1p
P07490766T0000|105 116|description
P07490766T0000|72 75|Max
P07490766T0000|143 155|interactions
P07490766T0000|191 209|heterodimerization
P07491111A0221|77 93|cell lung cancer
P07491111A0221|16 18|GR
P07491791A0263|5 22|promoter mutation
P07491791A0263|51 63|E1A products
P07493627A0882|94 103|EC-1 mRNA
P07493627A0882|142 149|agonist
P07493627A0882|158 173|EC-1 expression
P07493627A0882|19 30|aza1R cells
P07494274A1015|195 212|virion maturation
P07494274A1015|77 88|virus yield
P07494274A1015|64 73|reduction
P07494274A1015|137 148|disfunction
P07494303A0000|121 132|replication
P07494303A0000|7 34|immunodeficiency virus type
P07494303A0000|136 157|monocytes/macrophages
P07494314A1287|75 99|tyrosine phosphorylation
P07494314A1287|162 185|sequences heterogeneity
P07494314A1287|256 260|EBVs
P07494314A1287|205 219|repeat regions
P07495120A0260|26 31|Phase
P07495120A0260|83 91|efficacy
P07495120A0260|117 134|radiation therapy
P07495120A0260|153 163|recurrence
P07496184T0001|8 15|history
P07496184T0001|76 100|Vienna University Clinic
P07498727A0724|14 25|requirement
P07498727A0724|62 79|T.A transversions
P07498727A0724|56 59|G.C
P07498727A0724|127 140|substitutions
P07498727A0724|186 202|T.A transversion
P07499242A0898|59 75|RAFTK expression
P07499409A0367|76 82|region
P07499409A0367|36 43|regions
P07499409A0367|101 111|N terminus
P07499848A0409|45 52|B cells
P07499848A0409|14 25|stimulation
P07499848A0409|115 134|epsilon transcripts
P07500597A0212|30 34|BPVs
P07500597A0212|78 82|mean
P07500597A0212|8 12|time
P07500597A0212|98 103|years
P07500953A0305|121 130|ADR1 gene
P07500953A0305|37 50|transcription
P07500953A0305|54 59|genes
P07501458A0578|45 51|Ig/EBP
P07501458A0578|61 68|CHOP-10
P07501458A0578|20 43|C/EBP family inhibitors
P07501992A0125|208 214|dentin
P07501992A0125|163 168|lines
P07501992A0125|172 181|strontium
P07501992A0125|32 49|scanning electron
P07504171A1214|91 98|results
P07504171A1214|122 148|crystal structure solution
P07504171A1214|21 36|Src SH2 mutants
P07505349A0702|11 20|lethality
P07505349A0702|92 98|months
P07505349A0702|39 47|resectio
P07506253A0742|6 14|enhancer
P07506253A0742|34 37|K19
P07507207A0991|149 165|IRF-1 expression
P07507207A0991|58 72|IRF-2 promoter
P07507207A0991|20 36|IRF binding site
P07508082A0821|13 21|decrease
P07508082A0821|35 43|activity
P07508250A0537|123 124|p
P07508250A0537|147 156|treatment
P07508250A0537|276 289|investigation
P07508250A0537|113 114|r
P07508250A0537|207 211|time
P07508954A0000|150 163|Ziehl-Neelsen
P07508954A0000|46 52|method
P07508954A0000|39 44|ABC-P
P07508954A0000|19 37|complex peroxidase
P07509449A0000|151 160|sequences
P07509449A0000|95 100|v-Crk
P07509449A0000|65 79|fusion protein
P07509449A0000|18 22|gene
P07509449A0000|223 236|SH3 sequences
P07509472A1320|63 81|neovascularization
P07509472A1320|18 33|study documents
P07509472A1320|1 11|CONCLUSION
P07509811A1357|270 273|TRE
P07509811A1357|264 268|GTRE
P07509811A1357|335 343|proteins
P07509811A1357|222 242|CRE oligonucleotides
P07509811A1357|16 36|CRE oligonucleotides
P07509811A1357|469 477|families
P07509811A1357|507 523|chromaffin cells
P07509811A1357|207 211|GTRE
P07509811A1357|70 85|protein binding
P07509811A1357|1 5|GTRE
P07510635A0479|15 21|mAb1C2
P07510635A0479|160 169|promoters
P07510635A0479|5 13|antibody
P07510635A0479|101 114|transcription
P07511444A0728|148 153|years
P07511444A0728|40 43|BMT
P07511444A0728|127 134|patient
P07511444A0728|1 14|HCV infection
P07511496A1511|110 115|death
P07511496A1511|39 49|E-selectin
P07512159A0992|90 96|degree
P07512159A0992|139 159|branchpoint mutation
P07512552A0270|10 12|F.
P07514295A0000|122 133|stimulation
P07514295A0000|92 115|T-cell antigen receptor
P07514295A0000|38 46|proteins
P07514295A0000|1 25|Tyrosine phosphorylation
P07516337A1119|73 86|stoichiometry
P07516337A1119|57 63|p95Vav
P07516469A1025|73 78|cells
P07516469A1025|25 33|proteins
P07516866A0000|29 33|PRLR
P07516866A0000|160 185|polymerase chain reaction
P07516866A0000|92 117|pigeon crop sac libraries
P07517869A0411|165 187|phosphatase inhibitors
P07517869A0411|127 136|increases
P07517869A0411|81 92|C/EBP-delta
P07517869A0411|70 77|ability
P07518426A0000|47 55|mediator
P07518426A0000|86 102|C-X-C chemokines
P07518426A0000|16 20|IL-8
P07518561A0496|28 58|p72syk protein tyrosine kinase
P07518561A0496|193 200|T cells
P07518561A0496|93 108|TCR/CD3 complex
P07519447T0000|65 79|oxide synthase
P07519481A1275|148 162|follicle cells
P07519481A1275|27 31|mice
P07519481A1275|113 119|result
P07519481A1275|186 191|c-kit
P07519481A1275|14 17|pan
P07519481A1275|11 13|Sl
P07519481A1275|102 107|stage
P07520098A0211|29 40|B6.CH-2bm13
P07520098A0211|42 46|bm13
P07520098A0211|98 104|groove
P07520098A0211|19 21|Db
P07520098A0211|68 73|class
P07521285A1109|183 193|assessment
P07521285A1109|293 301|addition
P07521285A1109|358 372|F wave studies
P07521285A1109|134 164|motor conduction abnormalities
P07521285A1109|349 354|yield
P07521285A1109|5 13|findings
P07521285A1109|206 223|F wave parameters
P07521285A1109|239 255|chronodispersion
P07521916T0000|42 56|site sequences
P07521916T0000|96 107|replication
P07523363A0440|107 139|USF2 translation initiation site
P07523363A0440|36 51|fragment island
P07524265T0000|30 48|stimulating factor
P07524265T0000|57 63|levels
P07524265T0000|50 55|G-CSF
P07525596A0584|108 114|domain
P07526609A0736|165 167|S4
P07526609A0736|10 20|expression
P07526609A0736|43 49|UTR/S1
P07526609A0736|99 101|S1
P07526609A0736|116 119|UTR
P07528028A1192|166 171|FGF-1
P07528028A1192|46 74|FGF-1 cell surface receptors
P07528028A1192|27 37|cell lines
P07528028A1192|101 108|studies
P07528531A0904|149 151|rs
P07528531A0904|95 112|blood cell counts
P07528531A0904|22 27|G-CSF
P07528531A0904|190 191|P
P07528531A0904|78 79|P
P07528531A0904|67 69|rs
P07528531A0904|136 147|neutrophils
P07528746A1049|183 194|polypeptide
P07528746A1049|213 221|presence
P07528746A1049|248 249|%
P07528746A1049|154 155|%
P07528746A1049|225 228|Tyr
P07528746A1049|44 58|ASGPR subunits
P07528746A1049|70 73|Ser
P07528772A1539|41 53|TAM peptides
P07528772A1539|110 121|SH2 domains
P07529504A0000|123 126|CAS
P07529504A0000|112 121|Ultravist
P07529504A0000|169 176|studies
P07530128A0578|42 51|serum PSA
P07530502T0000|104 109|c-kit
P07530502T0000|148 152|form
P07530502T0000|16 28|Steel factor
P07531321A0369|29 41|PVC/24 hours
P07531321A0369|1 9|Patients
P07533527A0128|73 86|hybridization
P07533527A0128|95 101|status
P07533527A0128|127 137|chromosome
P07533527A0128|153 164|marker loss
P07533858A1503|74 87|substitutions
P07533858A1503|19 40|alanine substitutions
P07533858A1503|136 144|GP64 EFP
P07534285A0155|125 137|Mpl receptor
P07534285A0155|53 77|tyrosine phosphorylation
P07534285A0155|139 148|BaF3/mMpl
P07534297A0141|164 168|gene
P07534297A0141|26 51|pair HindIII DNA fragment
P07534297A0141|112 115|APE
P07535593A0714|11 28|T-cell precursors
P07535593A0714|37 53|V delta 2D delta
P07535593A0714|1 4|CD7
P07537267A2094|31 40|sequences
P07537267A2094|123 132|structure
P07537267A2094|297 301|life
P07537267A2094|141 149|function
P07537267A2094|71 81|breakpoint
P07537736A0453|47 51|Jak2
P07537736A0453|182 189|members
P07537736A0453|27 38|interaction
P07537736A0453|5 12|results
P07537736A0453|85 93|sequence
P07537851A0891|30 38|proteins
P07537851A0891|88 95|protein
P07537851A0891|215 218|p50
P07537851A0891|248 249|I
P07537851A0891|250 251|Y
P07537851A0891|85 86|Y
P07537851A0891|168 172|site
P07537851A0891|137 142|IRF-1
P07538122A0800|47 59|Fab fragment
P07538122A0800|9 15|report
P07538122A0800|110 118|receptor
P07538818A0197|241 254|interleukin-3
P07538818A0197|79 88|deletions
P07538818A0197|282 297|FDCP cell lines
P07538818A0197|22 29|regions
P07538818A0197|168 174|domain
P07538818A0197|70 77|hG-CSFR
P07539119A0985|37 44|binding
P07539119A0985|6 15|mutations
P07539119A0985|119 124|assay
P07540607A0709|83 97|immunoglobulin
P07540607A0709|1 12|Retreatment
P07540866A1069|105 118|A/K1018 cells
P07540866A1069|67 86|MAP kinase activity
P07541912A0485|45 53|CAAT box
P07541912A0485|122 124|P2
P07541912A0485|83 102|G-C content regions
P07541912A0485|1 18|Sequence analysis
P07542616A0313|59 68|repressor
P07542698A0137|12 17|noise
P07542698A0137|53 65|preparations
P07542698A0137|1 8|Sources
P07543592A0624|77 85|receptor
P07543592A0624|98 131|receptor tyrosine phosphorylation
P07543868A0414|151 155|poly
P07543868A0414|73 86|cDNA fragment
P07543868A0414|159 163|tail
P07545510A0735|162 173|cotS region
P07545510A0735|83 97|immunoblotting
P07545510A0735|21 25|cotS
P07545510A0735|139 146|plasmid
P07546256A0000|125 129|care
P07546256A0000|112 116|unit
P07546256A0000|33 38|study
P07546294A0000|82 88|enzyme
P07546294A0000|101 111|DNA repair
P07547220A0229|13 33|screening programmes
P07547220A0229|39 54|Haemoccult test
P07547220A0229|84 88|test
P07547510A0261|245 255|LF-H3 beta
P07547510A0261|320 331|hepatocytes
P07547510A0261|290 316|HNF-3 beta gene expression
P07547510A0261|204 216|binding site
P07548858A0000|77 85|function
P07548858A0000|52 58|dermis
P07548858A0000|5 14|flow rate
P07550216A0195|24 30|limits
P07552974A0217|10 22|requirements
P07552974A0217|55 64|glutamine
P07554541A0587|13 17|care
P07554541A0587|46 57|recognition
P07554541A0587|21 32|CHF patient
P07557091A0314|10 14|rHb1
P07557091A0314|1 8|METHODS
P07557387A0241|40 44|role
P07557387A0241|143 162|NIH-3T3 fibroblasts
P07557387A0241|48 58|C/EBP beta
P07557446T0000|91 101|processing
P07557446T0000|109 112|rat
P07557446T0000|127 132|gland
P07557446T0000|70 78|splicing
P07558263T0000|36 63|guillotine amputation wound
P07559233A0534|105 106|P
P07559233A0534|63 64|%
P07559233A0534|182 186|head
P07559233A0534|94 98|head
P07559233A0534|55 59|head
P07559233A0534|1 26|Citrate synthase activity
P07559355A0066|47 62|urease activity
P07559355A0066|27 32|genes
P07559355A0066|115 127|organization
P07559355A0066|222 228|detail
P07559402A0622|132 135|PKA
P07559402A0622|23 25|VT
P07559402A0622|70 86|protein kinase C
P07559478A0389|16 23|O'Neill
P07559510A0000|79 85|enzyme
P07559510A0000|161 167|Gordon
P07559510A0000|100 108|homology
P07559524A0741|47 61|overexpression
P07559524A0741|83 97|protein kinase
P07559524A0741|99 106|p41MAPK
P07559563A0282|62 70|activity
P07559563A0282|43 46|Ca2
P07559640A1230|43 46|end
P07559640A1230|97 105|function
P07559640A1230|138 143|bases
P07560137T0000|14 25|sensitivity
P07560137T0000|33 57|MMPI-2 depression scales
P07562775A0596|44 50|number
P07562775A0596|97 98|%
P07562775A0596|71 82|blood cells
P07563076A0766|44 53|sequences
P07563076A0766|62 70|elements
P07563076A0766|161 169|portions
P07563076A0766|7 22|intron chimeras
P07563076A0766|237 242|cores
P07563076A0766|204 207|ai4
P07563090A0624|28 32|ends
P07563090A0624|214 227|DNA fragments
P07563090A0624|283 292|agreement
P07563090A0624|96 104|fragment
P07563090A0624|311 316|model
P07563090A0624|339 364|RNA reverse transcription
P07564004A0292|40 46|FEV1.0
P07564004A0292|22 38|Cr2O3 inhalation
P07565031A0454|303 308|cocoa
P07565031A0454|242 246|meat
P07565031A0454|114 126|cream cheese
P07565031A0454|187 192|pasta
P07565031A0454|105 112|yoghurt
P07565031A0454|228 240|meat sausage
P07565031A0454|96 103|strains
P07565031A0454|268 277|margarine
P07565031A0454|156 165|marmelade
P07565031A0454|326 332|starch
P07565031A0454|349 356|lettuce
P07565031A0454|8 21|food products
P07565031A0454|279 291|milk dessert
P07565104A0084|59 63|ToxR
P07565104A0084|5 15|expression
P07565669T0000|134 141|factors
P07565669T0000|21 31|myogenesis
P07565669T0000|84 94|activities
P07565685A0420|73 82|GABP beta
P07565685A0420|5 22|peptide sequences
P07565685A0420|98 110|Notch motifs
P07565688T0000|75 94|adenosine deaminase
P07565688T0000|130 135|forms
P07565688T0000|143 152|deaminase
P07565688T0000|16 26|regulation
P07565712A0286|94 101|inserts
P07565712A0286|168 184|quasipalindromes
P07565712A0286|1 10|Deletions
P07565712A0286|119 128|potential
P07565720A0256|104 125|Schistosoma japonicum
P07565720A0256|5 23|DNA binding domain
P07565731A1629|73 77|role
P07565731A1629|147 155|proteins
P07565731A1629|34 50|mRNA degradation
P07565740T0000|88 96|cassette
P07565740T0000|26 37|degradation
P07565740T0000|1 12|Endocytosis
P07565775T0000|79 90|GTP binding
P07565775T0000|124 136|GMP transfer
P07565775T0000|37 43|enzyme
P07565775T0000|55 66|amino acids
P07565797A0116|29 33|CRY1
P07565797A0116|67 73|levels
P07567300T0000|30 41|involvement
P07567300T0000|49 56|illness
P07567979A1266|45 56|development
P07567979A1266|31 36|basis
P07567979A1266|5 13|findings
P07567979A1266|85 92|ligands
P07568026A0622|67 78|amino acids
P07568026A0622|5 16|Stat5b mRNA
P07568118A1267|104 111|pathway
P07568118A1267|123 140|p21ras activation
P07568118A1267|179 218|growth factor tyrosine kinase receptors
P07568118A1267|52 71|Shc phosphorylation
P07568865A0305|181 190|threshold
P07568865A0305|215 221|Figure
P07568865A0305|145 146|%
P07568865A0305|65 73|bacteria
P07568865A0305|117 123|CFU/ml
P07569532T0001|45 53|hospital
P07569532T0001|19 30|emergencies
P07569770A0298|104 116|immunization
P07569770A0298|123 135|booster dose
P07569770A0298|56 60|dose
P07569770A0298|83 89|months
P07569770A0298|1 8|METHODS
P07571953T0000|66 72|smears
P07574064A1416|29 53|concentration anesthesia
P07574064A1416|96 98|VE
P07574064A1416|153 160|l.min-1
P07575416A0000|104 113|processes
P07575416A0000|46 52|enzyme
P07575416A0000|215 227|localization
P07575416A0000|71 81|regulation
P07575416A0000|19 22|PKC
P07575438A1409|46 53|factors
P07575438A1409|6 12|action
P07576178A0000|1 27|Polypeptide growth factors
P07576178A0000|68 77|functions
P07576307A0144|106 110|rENK
P07576307A0144|24 28|role
P07576307A0144|112 116|gene
P07576307A0144|138 148|regulation
P07577904A0141|160 163|eye
P07577904A0141|67 71|body
P07577904A0141|235 239|body
P07577904A0141|253 256|eye
P07577904A0141|136 147|buphthalmos
P07579164A0409|88 98|atp9 genes
P07579164A0409|18 22|cDNA
P07579164A0409|50 68|RNA editing events
P07579328A1345|107 117|cell lines
P07579328A1345|46 51|MZF-1
P07579328A1345|160 170|cell lines
P07579695A0336|149 158|CBF1/CPF1
P07579695A0336|176 186|CEP3/CBF3B
P07579695A0336|66 70|MIF2
P07579695A0336|34 44|phenotypes
P07579704A0085|132 137|sites
P07579704A0085|142 153|cell growth
P07579704A0085|38 45|patches
P07580330A0331|26 30|EDIs
P07580330A0331|113 122|microgram
P07580330A0331|53 62|microgram
P07580330A0331|17 24|intakes
P07580330A0331|163 166|DDT
P07580330A0331|97 106|gamma-HCH
P07581364A0500|106 110|C212
P07581364A0500|95 101|Ag1-CA
P07581364A0500|65 74|deletions
P07581364A0500|16 21|cases
P07582592A0545|210 219|treatment
P07582592A0545|129 132|LES
P07582592A0545|96 106|dilatation
P07582592A0545|1 5|HRES
P07583562A1826|60 61|P
P07583562A1826|56 58|TG
P07583562A1826|146 151|LDL-C
P07583562A1826|96 98|RP
P07583562A1826|157 169|hypertension
P07583562A1826|100 101|P
P07585559A0000|194 230|muscle alpha-actin promoter activity
P07585559A0000|109 118|quinoline
P07585559A0000|22 30|compound
P07585559A0000|82 101|methyl-1M-pyrazo lo
P07585559A0000|32 43|6-methoxy-4
P07585559A0000|103 108|3,4-b
P07588240A0000|78 86|homologs
P07588240A0000|5 53|Caenorhabditis elegans death susceptibility gene
P07588240A0000|191 196|CPP32
P07588240A0000|101 108|species
P07588240A0000|68 74|number
P07588603A1054|54 61|spacing
P07588603A1054|35 46|flexibility
P07588628A0318|62 65|LCL
P07588628A0318|46 55|apoptosis
P07588750T0061|62 73|kinase gene
P07588750T0061|77 94|Pyrococcus woesei
P07588750T0061|143 150|protein
P07588750T0061|119 135|characterization
P07589069A1245|59 67|CD6 cDNA
P07589069A1245|113 120|regions
P07589069A1245|140 146|domain
P07590268A0350|45 47|Dm
P07590268A0350|96 115|sequence similarity
P07590268A0350|49 53|cDNA
P07590283A0820|94 113|polymerase activity
P07590283A0820|250 257|finding
P07590283A0820|284 290|domain
P07590283A0820|196 219|polymerization reaction
P07590283A0820|351 353|J.
P07590283A0820|36 52|Pol beta protein
P07590283A0820|139 147|Pol beta
P07590657A0624|38 43|cases
P07590657A0624|1 16|Cholangiography
P07592072A0217|150 172|prostaglandin F2 alpha
P07592072A0217|176 177|d
P07592072A0217|65 67|NF
P07592072A0217|185 194|gestation
P07592337A0891|30 34|NfxB
P07592337A0891|7 14|results
P07592467A0000|5 14|mechanism
P07592647A0797|21 54|DNA Pur alpha recognition element
P07592658A0309|63 82|p50/p65 heterodimer
P07592706A1465|47 55|reversal
P07592706A1465|25 32|HL lids
P07592706A1465|169 180|specificity
P07592706A1465|17 20|LPL
P07592711T0000|28 41|yeast protein
P07592711T0000|129 141|beta subunit
P07592711T0000|70 104|G protein alpha subunit deficiency
P07592723A0814|27 42|phosphorylation
P07592723A0814|86 95|sequences
P07592723A0814|118 138|PKC binding activity
P07592771A0258|41 50|kilobases
P07592771A0258|92 102|homologues
P07592771A0258|159 163|gene
P07592771A0258|140 145|alpha
P07592946A0261|109 122|determination
P07592946A0261|162 178|characterization
P07592946A0261|20 27|cloning
P07592946A0261|186 194|promoter
P07593266A1174|87 106|pair stem structure
P07594047T0000|107 118|epinephrine
P07594047T0000|26 37|propranolol
P07594047T0000|1 8|Effects
P07595221A0733|60 69|MHC class
P07595221A0733|211 216|cells
P07595221A0733|42 47|CIITA
P07595221A0733|7 12|cells
P07595857A0521|151 155|wave
P07595857A0521|183 187|flow
P07595857A0521|386 389|day
P07595857A0521|334 347|cardioversion
P07595857A0521|113 116|PVA
P07595857A0521|323 327|days
P07595857A0521|223 228|waves
P07595857A0521|44 49|waves
P07595857A0521|287 294|systole
P07595857A0521|234 243|amplitude
P07595857A0521|414 422|patients
P07596287A0183|149 156|members
P07596287A0183|94 98|ORF1
P07596287A0183|162 173|superfamily
P07596287A0183|5 24|nucleotide sequence
P07596287A0183|69 83|reading frames
P07596558A0824|90 99|treatment
P07596558A0824|32 46|concentrations
P07596558A0824|118 128|hemorrhage
P07597030A0260|29 39|expression
P07597030A0260|123 131|hTAFII32
P07597030A0260|57 73|characterization
P07597804A1007|24 26|kb
P07597804A1007|86 108|glycoprotein gene EUS4
P07598303A1728|120 136|survival benefit
P07598303A1728|18 25|studies
P07599653A0898|61 68|factors
P07599653A0898|150 158|promoter
P07599653A0898|42 49|binding
P07599653A0898|172 178|organs
P07599653A0898|4 12|addition
P07600986A0605|90 98|affinity
P07600986A0605|74 81|classes
P07600986A0605|38 54|gel shift assays
P07601121A0153|127 140|transcription
P07601121A0153|18 26|sequence
P07601121A0153|1 9|Analysis
P07601827A0778|56 69|DNA sequences
P07601827A0778|140 146|region
P07601827A0778|116 119|pfl
P07603726T0000|12 32|adaptation exercises
P07603726T0000|53 58|stage
P07604047A0704|299 303|GA20
P07604047A0704|282 286|GA44
P07604047A0704|66 74|sequence
P07604047A0704|218 232|fusion protein
P07604047A0704|3 13|cDNA clone
P07604047A0704|274 278|GA53
P07604794A0958|145 146|%
P07604794A0958|129 135|mg/day
P07604794A0958|158 164|mg/day
P07604794A0958|54 55|%
P07604794A0958|116 117|%
P07606548T0000|46 61|pharmacotherapy
P07606548T0000|1 9|Benefits
P07607197A1048|74 75|P
P07607197A1048|64 72|training
P07607233A0186|52 64|epilancin K7
P07607233A0186|16 20|gene
P07607537A0954|44 53|mutations
P07607537A0954|101 108|adaptor
P07607537A0954|84 93|mutations
P07607669A1112|56 68|CpG doublets
P07607669A1112|110 113|Sp1
P07607669A1112|16 22|region
P07608649A1429|78 89|ET-1 levels
P07609037A0775|14 23|depletion
P07609037A0775|27 32|Oct-1
P07609037A0775|4 12|addition
P07609037A0775|50 57|extract
P07609037A0775|289 298|sequences
P07609037A0775|205 210|level
P07609372A0261|25 32|minutes
P07609372A0261|113 124|HR patients
P07609372A0261|65 76|LR patients
P07609372A0261|1 7|M.M.C.
P07610324A0319|41 48|aspects
P07610324A0319|143 157|reconstruction
P07610735A1471|30 38|decrease
P07610735A1471|89 101|sinus rhythm
P07610735A1471|1 10|Diltiazem
P07612557A0635|16 24|children
P07612557A0635|103 111|children
P07615541T0000|47 52|sites
P07615541T0000|24 31|DNase-I
P07616056A0278|28 39|chain genes
P07616056A0278|80 104|chain gene rearrangement
P07616569A0168|240 243|srn
P07616569A0168|179 194|ATPase subunits
P07616569A0168|83 98|apocytochrome b
P07616569A0168|156 160|nad1
P07616569A0168|257 262|tRNAs
P07616569A0168|14 19|genes
P07616569A0168|228 232|RNAs
P07616569A0168|196 200|atp6
P07616569A0168|282 290|proteins
P07616569A0168|71 75|cox1
P07616569A0168|35 43|subunits
P07616569A0168|305 310|rps12
P07618280A0550|27 37|structures
P07620491T0000|23 31|patients
P07622060A0967|106 122|thyroid hormones
P07622060A0967|50 61|ME activity
P07622932T0000|19 27|features
P07623814A1040|142 152|inhibition
P07623814A1040|38 46|retinoid
P07623814A1040|184 203|breast cancer cells
P07623814A1040|84 94|inhibition
P07623821T0000|15 46|Gax homeobox gene transcription
P07623821T0000|76 83|factors
P07623821T0000|1 11|Regulation
P07623844A0639|164 182|cell proliferation
P07623844A0639|104 117|growth arrest
P07623844A0639|227 230|p53
P07623844A0639|146 159|DNA synthesis
P07623844A0639|207 213|levels
P07624581A0312|181 192|cholesterol
P07624581A0312|121 124|PRL
P07624581A0312|147 155|nitrogen
P07624581A0312|157 179|glutamine transaminase
P07624581A0312|49 77|blood pressure determination
P07624581A0312|135 145|creatinine
P07624581A0312|197 224|triglycerides plasma levels
P07624581A0312|99 102|TSH
P07624581A0312|32 35|ECG
P07626378T0000|36 44|problems
P07626806A1098|58 68|similarity
P07626806A1098|5 14|RAT3 gene
P07628389A0145|30 39|TNF alpha
P07628389A0145|122 140|mouse Leydig cells
P07628389A0145|1 28|Tumor necrosis factor-alpha
P07628451A0114|79 90|kDa protein
P07628451A0114|92 96|p300
P07628451A0114|37 52|phosphorylation
P07629103T0000|132 157|beta-casein gene promoter
P07629103T0000|92 97|cells
P07629103T0000|119 124|sites
P07629122A0323|134 138|NIMA
P07629122A0323|76 80|NIMA
P07629122A0323|101 116|protein kinases
P07629150A0155|66 85|adrenocorticotropin
P07629150A0155|48 56|hormones
P07629150A0155|1 11|Expression
P07629150A0155|137 151|growth factors
P07629150A0155|239 267|signal transduction pathways
P07629196A0274|104 117|alpha 13Q226L
P07629196A0274|94 99|alpha
P07629196A0274|76 89|alpha 12Q229L
P07629196A0274|66 71|alpha
P07629196A0274|207 214|pathway
P07630934A0343|8 12|E.M.
P07633444T0000|134 149|dystrophy locus
P07633444T0000|43 61|expression pattern
P07635140A0172|120 123|use
P07635140A0172|148 158|mechanisms
P07635140A0172|23 27|gene
P07635140A0172|98 107|promoters
P07635572A1153|105 109|line
P07635572A1153|111 124|re-expression
P07635572A1153|37 46|IFN-gamma
P07635572A1153|87 92|lines
P07635572A1153|50 55|class
P07636187A0585|133 141|promoter
P07636187A0585|108 113|lines
P07636408T0000|133 156|intervertebral foramina
P07636408T0000|64 81|resonance imaging
P07636408T0000|1 11|Comparison
P07636962A1288|77 90|HSV-alpha TIF
P07636962A1288|137 145|activity
P07636984A1349|91 96|cells
P07636984A1349|38 41|SP1
P07638517A0000|163 184|police investigations
P07638517A0000|143 149|deaths
P07638517A0000|32 42|necropsies
P07639703A1703|90 99|processes
P07639703A1703|126 133|element
P07639703A1703|158 165|process
P07640422A0649|208 212|test
P07640422A0649|163 164|p
P07640422A0649|55 60|pg/ml
P07640422A0649|190 195|pairs
P07640422A0649|1 15|Thromboxane B2
P07642538A0138|60 68|RSK cDNA
P07642538A0138|29 43|RSK activation
P07642538A0138|387 392|N-Ser
P07642538A0138|155 160|N-Lys
P07642538A0138|16 25|mechanism
P07642538A0138|394 400|mutant
P07642538A0138|318 343|MAPK phosphorylation site
P07642538A0138|281 286|T570A
P07642538A0138|380 385|S218A
P07642538A0138|369 377|C-domain
P07642538A0138|273 279|mutant
P07642538A0138|136 147|RSK mutants
P07642544A0868|13 22|treatment
P07642544A0868|93 111|phenylarsine oxide
P07642544A0868|49 60|phosphatase
P07644127A0000|213 215|SI
P07644127A0000|248 257|carbachol
P07644127A0000|18 29|stimulation
P07644127A0000|107 112|study
P07644127A0000|230 244|microinjection
P07644127A0000|64 75|cell bodies
P07644503A0729|14 29|over-expression
P07644503A0729|106 115|RAR gamma
P07644503A0729|4 12|contrast
P07644503A0729|138 150|target genes
P07647303T0000|144 150|plants
P07647303T0000|114 127|inflorescence
P07647303T0000|68 78|shoot apex
P07648338A0815|120 132|TNF response
P07648338A0815|193 203|laparotomy
P07648338A0815|7 14|results
P07648338A0815|38 44|models
P07650958A0123|5 12|changes
P07650958A0123|19 28|treatment
P07651141A0265|78 84|p-gvpF
P07651141A0265|92 98|p-gvpE
P07651141A0265|54 65|nucleotides
P07651386A0925|19 26|element
P07651386A0925|102 110|promoter
P07651398A0803|76 79|DER
P07651398A0803|34 49|dShc PTB domain
P07651400A0335|72 83|splice site
P07651400A0335|6 16|inhibition
P07651424A0743|107 112|SSM1b
P07651424A0743|72 89|SSM1a transcripts
P07651424A0743|136 144|majority
P07651835A0652|23 39|binding affinity
P07652575A0435|134 147|DNA synthesis
P07652575A0435|59 62|Rac
P07652575A0435|83 111|Rho inhibitor C3 transferase
P07653094A0169|61 64|d31
P07653094A0169|56 59|d27
P07653094A0169|144 155|maintenance
P07653094A0169|115 138|cell surface expression
P07653094A0169|253 270|pcDL-SR alpha-296
P07653094A0169|284 294|HeLa cells
P07653094A0169|46 49|d10
P07653094A0169|66 69|d40
P07653094A0169|3 9|series
P07653094A0169|103 113|processing
P07653892A0306|122 129|agonist
P07653892A0306|131 138|U50488H
P07653892A0306|97 98|n
P07653892A0306|19 33|isoflurane MAC
P07653892A0306|87 95|morphine
P07654712A0774|5 17|yeast enzyme
P07654712A0774|55 62|enzymes
P07655184A0852|92 110|ER leader sequence
P07655184A0852|5 14|transport
P07655184A0852|152 159|protein
P07655509T0000|47 56|targeting
P07655509T0000|82 90|proteins
P07657162A1412|164 174|HMG domain
P07657162A1412|46 51|LEF-1
P07657162A1412|18 42|transcription activation
P07657705A1181|91 102|development
P07657705A1181|7 14|results
P07658471A0000|59 64|genes
P07659085A1520|211 230|androgen regulation
P07659085A1520|182 191|candidate
P07659085A1520|162 167|Oct-1
P07659085A1520|67 80|octamer motif
P07659085A1520|138 153|kidney extracts
P07659529A0135|31 50|transfection assays
P07659529A0135|56 80|reporter gene constructs
P07659529A0135|9 26|deletion analysis
P07659757A0191|60 63|ATP
P07659757A0191|79 84|assay
P07659757A0191|1 11|Incubation
P07659757A0191|102 110|proteins
P07663138A0835|62 65|PBV
P07663138A0835|70 73|PBF
P07663963A1588|44 74|metanephrine/epinephrine ratio
P07663963A1588|135 140|month
P07663963A1588|106 111|males
P07663963A1588|179 185|levels
P07663963A1588|158 166|turnover
P07665187A0208|72 75|end
P07665187A0208|83 94|Nramp1 mRNA
P07665477A0901|26 36|expression
P07665477A0901|81 85|esaI
P07665605A1127|47 54|product
P07665605A1127|21 22|D
P07665948A0591|94 109|children groups
P07665948A0591|143 152|intensity
P07665948A0591|1 11|IgE levels
P07665948A0591|68 78|IgE levels
P07666415A0000|58 63|maize
P07666415A0000|65 73|Zea mays
P07666415A0000|49 52|DNA
P07666538A0000|167 173|manner
P07666538A0000|40 57|hepatitis C virus
P07666538A0000|59 62|HCV
P07666538A0000|141 144|NCR
P07667097A0267|30 48|splicing complexes
P07667097A0267|124 141|immunoprecipitate
P07667097A0267|82 89|mAb CC3
P07667097A0267|20 24|p255
P07667097A0267|69 76|finding
P07667621T0001|54 62|children
P07667621T0001|85 93|syndrome
P07670504A0834|111 116|G-box
P07670504A0834|81 89|proteins
P07670504A0834|139 152|binding assay
P07672821A0763|29 33|FHR2
P07672821A0763|42 56|factor H genes
P07672821A0763|158 166|proteins
P07672821A0763|141 147|factor
P07673128A0989|11 17|domain
P07673128A0989|37 58|cAMP response element
P07673178A0982|109 117|spectrum
P07673178A0982|37 56|muscle gene E-boxes
P07673178A0982|155 173|MCK-L type E-boxes
P07675445A0463|63 65|CA
P07675445A0463|7 13|clones
P07675445A0463|86 114|sequence length polymorphism
P07676492A1000|134 137|IHD
P07676492A1000|36 43|reports
P07676492A1000|55 62|regions
P07676655A0214|28 30|iP
P07676655A0214|127 131|mmol
P07676655A0214|5 24|serum concentration
P07676655A0214|48 50|HD
P07677715A1076|5 15|TAF factor
P07678006A0472|92 103|transcripts
P07678006A0472|175 181|manner
P07678051A1303|5 18|PDGFR mutants
P07678051A1303|117 136|inositol phosphates
P07678593A0708|26 39|V. vulnificus
P07678593A0708|71 93|V. cholerae fur mutant
P07678695A0604|150 158|promoter
P07678695A0604|72 80|promoter
P07678695A0604|38 50|hybrid cells
P07679836A0387|74 96|kidney transplantation
P07679836A0387|7 14|results
P07680120A1008|91 97|D mRNA
P07680120A1008|47 53|kidney
P07680120A1008|160 172|aFGF protein
P07680120A1008|110 116|kidney
P07680120A1008|55 60|brain
P07681147A1420|74 80|Ser-12
P07681147A1420|162 171|pp60c-src
P07681147A1420|55 70|phosphorylation
P07681147A1420|85 91|Ser-48
P07681539A0000|13 20|studies
P07681539A0000|56 72|hospital workers
P07681539A0000|39 50|lymphocytes
P07682842A0771|88 94|coding
P07682842A0771|27 29|bp
P07682842A0771|115 124|sequences
P07683375A0000|121 126|genes
P07683375A0000|299 301|ER
P07683375A0000|24 31|effects
P07683375A0000|54 58|cAMP
P07683375A0000|224 234|activators
P07683375A0000|283 291|activity
P07683375A0000|238 253|protein kinases
P07683375A0000|102 112|expression
P07685823A1234|125 135|start site
P07685823A1234|99 108|digestion
P07685823A1234|1 15|RNA polymerase
P07687541A0200|192 193|A
P07687541A0200|108 112|gene
P07687541A0200|83 91|mutation
P07687541A0200|206 216|degrees C.
P07687541A0200|187 191|poly
P07687745T0000|38 55|amino acid import
P07689154A0168|89 94|cells
P07689154A0168|124 138|phorbol esters
P07689154A0168|52 56|role
P07689154A0168|222 226|cAMP
P07689154A0168|286 290|cAMP
P07689154A0168|96 110|protein kinase
P07689154A0168|1 24|Protein phosphorylation
P07691837A1359|166 172|motifs
P07691837A1359|10 12|bp
P07691837A1359|25 33|sequence
P07691837A1359|186 209|NFkB consensus sequence
P07692366A0000|44 51|aspects
P07692366A0000|89 93|ARMD
P07692366A0000|188 200|pathogenesis
P07692366A0000|1 11|BACKGROUND
P07692754T0000|37 51|seroprevalence
P07692754T0000|1 13|Risk factors
P07693372A0115|110 122|cyclosporine
P07693372A0115|71 80|mechanism
P07693699A0831|105 116|sensitivity
P07693699A0831|14 23|stability
P07693699A0831|70 78|proteins
P07693967A0905|77 88|translation
P07693967A0905|5 13|presence
P07693975T0000|56 94|leukosis virus Gag-Pol fusion proteins
P07693975T0000|9 22|transcriptase
P07696183A0567|211 221|cell lines
P07696183A0567|331 352|membrane localization
P07696183A0567|147 157|cell lines
P07696183A0567|189 194|liver
P07696183A0567|460 481|fractionation studies
P07696183A0567|254 257|Rak
P07696183A0567|225 231|breast
P07696183A0567|199 205|kidney
P07696183A0567|162 169|tissues
P07696183A0567|313 326|myristylation
P07696183A0567|236 248|colon origin
P07696878A0222|107 123|initiation codon
P07696878A0222|144 157|reading frame
P07696878A0222|173 192|homeodomain protein
P07698219A0551|61 65|beta
P07698219A0551|53 58|alpha
P07698219A0551|19 35|migration assays
P07698219A0551|118 126|F9 cells
P07699632A0522|101 104|PsA
P07699632A0522|34 48|Chukcha-Eskimo
P07699845A0537|363 376|lymphadenitis
P07699845A0537|150 169|lacunar tonsillitis
P07699845A0537|453 459|t.i.d.
P07699845A0537|189 199|bronchitis
P07699845A0537|81 89|diseases
P07699845A0537|255 274|impetigo contagiosa
P07699845A0537|378 386|S.S.S.S.
P07699845A0537|407 414|colitis
P07699845A0537|10 24|studies SY5555
P07699845A0537|446 451|mg/kg
P07701266A0808|63 75|somatostatin
P07701266A0808|10 22|Closure time
P07701266A0808|38 46|patients
P07701266A0808|169 172|TPN
P07702378A0668|28 36|children
P07702378A0668|19 24|sleep
P07702808A0427|121 126|mm Hg
P07702808A0427|52 70|corn oil treatment
P07702808A0427|141 144|ABP
P07702808A0427|170 175|mm Hg
P07704273A0000|149 168|beta-lactamase gene
P07704273A0000|114 124|expression
P07704273A0000|18 24|JRG582
P07704689T0000|10 24|thyroid nodule
P07705476A0292|71 84|protein level
P07705476A0292|154 161|protein
P07706273T0000|44 45|H
P07706273T0000|49 71|ATPase B2 subunit gene
P07706291T0000|149 160|development
P07706291T0000|93 104|ftz-f1 gene
P07706291T0000|4 17|E box element
P07706307A0914|61 79|specificity pocket
P07706307A0914|133 135|C.
P07706307A0914|113 122|proteases
P07706307A0914|32 39|protein
P07707523A0704|15 25|expression
P07707523A0704|8 13|cells
P07707523A0704|55 70|I kappa B-alpha
P07707544T0000|40 68|channel catfish virus genome
P07707544T0000|70 86|characterization
P07708488A0151|89 92|ref
P07708488A0151|4 12|contrast
P07711667A0766|240 261|consolidation therapy
P07711667A0766|62 65|age
P07711667A0766|331 340|isolation
P07711667A0766|125 138|marrow blasts
P07711667A0766|219 238|maintenance therapy
P07711667A0766|263 279|marrow cell dose
P07711667A0766|85 96|blast count
P07711667A0766|74 83|diagnosis
P07711667A0766|167 194|remission induction courses
P07711667A0766|67 70|WBC
P07711667A0766|100 109|diagnosis
P07713421A1435a|133 138|SxlM4
P07713421A1435a|163 168|SxlM1
P07713421A1435a|102 126|sex determination signal
P07713936A0393|73 87|response genes
P07713936A0393|43 56|transcription
P07713936A0393|128 132|aidB
P07713936A0393|153 161|presence
P07714758A1193|1 15|Blood pressure
P07715602A1088|46 51|parts
P07715602A1088|71 94|cytochrome c haem lyase
P07717823A0328|149 158|functions
P07717823A0328|111 117|kcal/d
P07717823A0328|69 74|child
P07720572A0701|20 33|myoD promoter
P07720572A0701|4 12|contrast
P07720572A0701|100 104|mice
P07720572A0701|68 80|conservation
P07720709A0755|192 209|growth inhibition
P07720709A0755|41 53|model system
P07720709A0755|99 108|retinoids
P07721074A0766|26 30|itch
P07721074A0766|8 18|dermatitis
P07721074A0766|197 204|itching
P07721074A0766|54 58|rash
P07721878A1163|134 140|report
P07721878A1163|5 17|beta subunit
P07721878A1163|185 193|identity
P07721878A1163|51 74|tyrosine phosphoprotein
P07723247A1161|60 69|IL-1 beta
P07723247A1161|96 112|radioimmunoassay
P07729427A0942|89 97|hTAFII18
P07729427A0942|42 50|hTAFII18
P07729427A0942|172 180|hTAFII30
P07729427A0942|118 121|TBP
P07729427A0942|68 75|domains
P07730328A0000|104 112|spectrum
P07730328A0000|22 27|cells
P07730328A0000|143 148|genes
P07730337A1439|47 65|expression pattern
P07730337A1439|5 11|Ng/RC3
P07730337A1439|16 31|PKC-gamma genes
P07730795A0104|59 64|DdRPs
P07730795A0104|5 25|amino acid sequences
P07731898A0823|61 77|bicarbonate ions
P07731898A0823|131 143|hemodialysis
P07731898A0823|23 34|blood cells
P07731898A0823|277 316|erythrocyte membrane lipid peroxidation
P07731898A0823|201 229|superoxide anions generation
P07731898A0823|50 57|acetate
P07735590A0990|75 87|p milligrams
P07735590A0990|227 230|cat
P07735590A0990|27 35|allergen
P07735590A0990|162 165|cat
P07735590A0990|172 199|micrograms Fel d milligrams
P07735590A0990|236 263|micrograms Fel d milligrams
P07737024A1003|109 116|pylorus
P07737024A1003|48 57|technique
P07737508A0649|31 35|gene
P07737508A0649|11 13|U6
P07737508A0649|7 9|Tb
P07737508A0649|68 75|tRNAIle
P07738026A0216|77 80|ADH
P07739520A1250|121 131|rpL7a gene
P07739520A1250|37 57|Surfeit gene cluster
P07739520A1250|4 12|homologs
P07739520A1250|98 100|D.
P07739544A0364|150 160|Myc family
P07739544A0364|176 184|proteins
P07739544A0364|71 77|region
P07740487A0167|180 196|SSC Subcommittee
P07740487A0167|243 253|Thrombosis
P07740487A0167|25 36|association
P07740487A0167|54 71|dysfibrinogenemia
P07740487A0167|258 269|Haemostasis
P07740487A0167|76 89|thrombophilia
P07740487A0167|99 104|cases
P07741255A0194|29 33|area
P07741255A0194|59 69|population
P07742363A0135|181 189|exchange
P07742363A0135|242 247|eIF-2
P07742363A0135|228 237|recycling
P07742363A0135|129 135|Ser-51
P07742363A0135|55 58|HCR
P07742550A0407|240 242|FL
P07742550A0407|301 315|cell lymphomas
P07742550A0407|189 198|lymphomas
P07742550A0407|83 93|mixed-cell
P07742550A0407|50 59|lymphomas
P07742550A0407|229 238|lymphomas
P07742550A0407|5 10|cases
P07743472A0181|164 189|cigarette smoking history
P07743472A0181|111 118|Buffalo
P07743472A0181|197 201|time
P07743472A0181|143 154|information
P07743472A0181|102 106|RPCI
P07743697A0703|45 54|follow-up
P07743697A0703|180 189|treatment
P07743697A0703|228 244|enzyme inhibitor
P07743697A0703|246 255|enalapril
P07743697A0703|70 74|rise
P07743697A0703|153 160|disease
P07744776A0617|70 86|U6 RNA synthesis
P07744954A0418|90 93|NH2
P07744954A0418|74 81|domains
P07744954A0418|146 154|antibody
P07744954A0418|5 12|protein
P07745311A0264|14 18|FHCS
P07745311A0264|1 10|Diagnosis
P07745685A1442|47 55|proteins
P07745685A1442|139 158|CAT fusion partners
P07745685A1442|102 120|accessory proteins
P07745696A0932|166 172|SalI L
P07745696A0932|148 154|genome
P07745696A0932|177 193|SalI O fragments
P07745696A0932|110 113|end
P07745696A0932|236 250|repeat regions
P07745696A0932|205 209|left
P07745726A1496|158 178|E1 recognition motif
P07745726A1496|118 128|E1 binding
P07746794A0000|73 82|Sandimmun
P07746794A0000|58 71|Cyclosporin A
P07746794A0000|154 159|agent
P07747462A0332|120 143|metal coordination site
P07747462A0332|67 70|set
P07747462A0332|235 254|replicator proteins
P07747462A0332|1 21|Sequence comparisons
P07748493A1045|40 52|candidate PC
P07748493A1045|126 129|ELH
P07748493A1045|19 34|Aplysia Afurin2
P07748493A1045|139 149|precursors
P07748848A0263|23 44|papillary haemangioma
P07748952A1329|45 59|hfq expression
P07748952A1329|183 200|promoter strength
P07748952A1329|29 33|mutL
P07748952A1329|160 170|modulation
P07748952A1329|113 119|degree
P07748952A1329|153 158|genes
P07749461A0632|61 79|sGTH alpha subunit
P07749461A0632|126 131|clone
P07749461A0632|7 9|kb
P07750217T0000|67 88|carcinoma recurrences
P07750217T0000|1 27|Indium-111 OncoScint CR/OV
P07752223A0960|75 88|Myc inability
P07752644A1031|127 137|conduction
P07752644A1031|23 37|defibrillation
P07753027A0240|30 39|psbH-psbN
P07753027A0240|5 25|gene pairs psbB-psbT
P07753796A0625|44 51|regions
P07753796A0625|82 90|peptides
P07753837A0724|107 113|effect
P07753837A0724|142 153|plakoglobin
P07753837A0724|23 34|tail domain
P07753837A0724|69 84|plakoglobin RNA
P07755884A0000|44 51|tissues
P07755884A0000|166 173|lesions
P07755884A0000|118 123|motor
P07757315A1227|108 113|level
P07757315A1227|145 153|ABSTRACT
P07757315A1227|70 86|drug application
P07757315A1227|171 176|WORDS
P07758246A0469|77 82|exons
P07758246A0469|20 26|region
P07758837A1118|60 76|GH receptor gene
P07758837A1118|226 235|sequences
P07758837A1118|265 276|P1 promoter
P07758837A1118|162 177|intron boundary
P07758837A1118|116 122|probes
P07759525A0417|30 31|%
P07759525A0417|161 167|region
P07759525A0417|5 13|proteins
P07759525A0417|103 104|%
P07760790A0327|22 40|MEF2 reporter gene
P07760790A0327|1 16|Serum induction
P07760841A0221|13 25|binding site
P07760841A0221|50 65|regulator Adr1p
P07760844A0413|61 80|GH trans-activation
P07760844A0413|1 10|Induction
P07761216T0000|14 36|amphotericin B therapy
P07761216T0000|65 73|patients
P07761434A1084|40 61|tumor promoter action
P07761434A1084|115 123|activity
P07761434A1084|136 148|antioxidants
P07762431A0356|5 12|protein
P07762431A0356|65 79|culture medium
P07762431A0356|103 105|mg
P07763727A1035|164 182|wine yeast strains
P07763727A1035|115 121|pAMS15
P07763727A1035|1 16|Plasmids pAMS12
P07766885A0405|89 99|plant CDPK
P07766885A0405|188 203|junction region
P07766885A0405|118 127|sequences
P07768824A0167|15 34|fla gene expression
P07768824A0167|132 142|activation
P07768824A0167|82 87|forms
P07768824A0167|114 124|appearance
P07768848A1880|120 128|products
P07768848A1880|176 185|formation
P07768848A1880|247 257|components
P07768848A1880|79 85|mutant
P07768848A1880|96 101|basis
P07768848A1880|69 73|cotE
P07768848A1880|1 13|Polypeptides
P07768953T0039|46 62|membrane protein
P07768953T0039|1 5|EEA1
P07771671T0000|51 68|carbon electrodes
P07772036A1000|42 49|factors
P07772036A1000|81 116|transcription factor/nuclear factor
P07774807A0405|10 18|proteins
P07774807A0405|101 113|heterodimers
P07774807A0405|153 167|family members
P07775428A0172|41 61|nucleotide sequences
P07775428A0172|110 116|region
P07775428A0172|34 35|s
P07776711A0295|44 49|women
P07776711A0295|33 36|men
P07776711A0295|1 9|MATERIAL
P07776711A0295|170 184|polyneuropathy
P07776979A0702|14 21|COUP-TF
P07776979A0702|4 12|contrast
P07779558T0000|40 48|exercise
P07779558T0000|1 23|Muscle GSH-Px activity
P07779812A0000|94 98|role
P07779812A0000|5 15|c-myc gene
P07779812A0000|115 121|growth
P07779812A0000|137 147|cell types
P07780525A0495|76 87|differences
P07780525A0495|102 115|health inputs
P07780738A0091|91 95|cell
P07780738A0091|47 57|cell cycle
P07780738A0091|24 26|G1
P07780738A0091|113 117|PCNA
P07782113A0726|5 24|roxithromycin doses
P07782775A0889|14 18|ORFs
P07782775A0889|91 95|size
P07782775A0889|82 85|kDa
P07783641A0591|24 34|homologues
P07783641A0591|1 5|CodY
P07784061A0894|25 35|G proteins
P07784061A0894|70 73|TTF
P07784079A1018|29 46|expression vector
P07784079A1018|214 217|FGF
P07784079A1018|76 87|acquisition
P07784079A1018|175 183|activity
P07784079A1018|1 13|Transfection
P07784199A0000|28 42|gene promoters
P07784199A0000|125 130|sites
P07784199A0000|214 219|Abf1p
P07784199A0000|206 212|factor
P07784942T0001|58 67|prospects
P07786821A2292|126 135|mg/m2/day
P07786821A2292|52 91|consecutive-days-every-3 weeks schedule
P07786821A2292|1 11|CONCLUSION
P07789275A0325|15 23|function
P07789275A0325|41 54|metamorphosis
P07789275A0325|145 163|transcription unit
P07789396A0504|41 45|EDTB
P07789971A0758|90 99|sequences
P07789971A0758|210 215|genes
P07789971A0758|127 138|pseudogenes
P07789971A0758|5 12|absence
P07790377A0561|46 53|protein
P07790377A0561|25 30|PTS1R
P07790377A0561|81 94|hamster cells
P07791760A0424|61 78|tyrosine residues
P07791760A0424|42 57|phosphorylation
P07791760A0424|1 15|GnRH treatment
P07791764A0357|76 84|antibody
P07791764A0357|33 47|Jurkat T cells
P07791769A0826|90 97|protein
P07791769A0826|40 49|complexes
P07791769A0826|129 146|ICP4 binding site
P07791769A0826|1 5|ICP4
P07791769A0826|102 107|TFIIB
P07791776T0000|21 25|fus1
P07791776T0000|85 93|function
P07793783A0189|149 159|donor site
P07793783A0189|82 87|weeks
P07793783A0189|1 12|Scalp flaps
P07795104T0000|37 64|hepatitis B virus infection
P07795104T0000|68 74|review
P07796935A0284|268 275|TRE-LAP
P07796935A0284|182 190|receptor
P07796935A0284|248 255|TRE-PAL
P07796935A0284|119 131|c-erbA alpha
P07796935A0284|231 239|elements
P07796935A0284|65 73|hTR beta
P07797346T0000|45 48|men
P07797346T0000|4 12|outbreak
P07797583A0222|88 108|nucleotide positions
P07797583A0222|27 45|base substitutions
P07797583A0222|179 188|PCNA gene
P07797583A0222|59 68|deletions
P07797583A0222|325 344|Drosophila Kc cells
P07797583A0222|286 295|PCNA gene
P07797583A0222|141 170|transcription initiation site
P07797583A0222|274 280|factor
P07798207A0759|208 213|group
P07798207A0759|146 149|ETF
P07798207A0759|96 106|% identity
P07798207A0759|49 66|W3A1 ETF subunits
P07798217T0095|12 38|glycogen synthase kinase-3
P07798217T0095|57 72|gene expression
P07799437A0656|63 73|pNeo.Myc-2
P07799437A0656|7 13|assays
P07799437A0656|48 59|replication
P07799931A0287|146 158|organization
P07799931A0287|174 180|system
P07799931A0287|137 141|fate
P07799939A0628|142 151|3T3 cells
P07799939A0628|118 125|nucleus
P07799950A0282|108 117|prototype
P07799950A0282|76 102|somatostatin gene promoter
P07799950A0282|65 68|CRE
P07800505T0000|25 33|promoter
P07800505T0000|1 17|Characterization
P07802355T0000|45 61|blood cell count
P07802355T0000|109 118|Sysmex NE
P07802355T0000|128 141|Technicon H-1
P07803809A1852|61 77|beta-globin mRNA
P07803809A1852|148 183|protein kinase C inhibitor Compound
P07803809A1852|213 218|WORDS
P07803809A1852|187 195|ABSTRACT
P07806507A0121|121 132|CD3 epsilon
P07806507A0121|94 106|polypeptides
P07806507A0121|108 116|CD3 zeta
P07806507A0121|200 206|events
P07806651A0097|91 102|performance
P07806651A0097|72 89|Mexican-Americans
P07806651A0097|52 60|identity
P07806651A0097|113 114|K
P07807002A0500|75 95|germline epsilon RNA
P07807002A0500|225 228|IgE
P07807002A0500|41 46|flank
P07807002A0500|54 70|initiation sites
P07809128T0000|11 19|capacity
P07811639A0222|183 189|midgut
P07811639A0222|95 109|gastrula stage
P07811639A0222|59 64|plate
P07811639A0222|1 19|Endo16 transcripts
P07812450A0849|44 50|strand
P07813786A0641|45 53|proteins
P07813786A0641|73 90|XMyoDa TATA motif
P07814323A0313|88 102|export pathway
P07814323A0313|52 56|FliQ
P07814323A0313|19 25|family
P07814403A0433|1 5|Chem
P07814717A0669|13 23|blood NEFA
P07814717A0669|128 133|blood
P07814717A0669|114 117|Lys
P07814717A0669|1 9|Increase
P07815811A1487b|10 26|vasoconstriction
P07815811A1487b|37 49|endothelin-1
P07815811A1487b|184 190|bypass
P07816049A0686|91 99|polarity
P07816049A0686|193 201|elements
P07816049A0686|32 35|ORF
P07816049A0686|237 248|termination
P07816049A0686|1 7|Atcys1
P07816049A0686|17 23|AKin10
P07816617A0763|7 14|results
P07816619A0872|135 141|genera
P07816619A0872|58 68|A.thaliana
P07816619A0872|93 101|ubiquity
P07816619A0872|18 32|identification
P07816619A0872|184 208|transcription initiation
P07816808A1102|73 81|nematode
P07816808A1102|7 11|data
P07816808A1102|33 43|STR family
P07816808A1102|169 177|Chordata
P07819225A1094|31 38|residue
P07819225A1094|167 181|Asn-285 mutant
P07819225A1094|95 111|Asn-285 mutation
P07819225A1094|249 254|WORDS
P07819225A1094|5 17|introduction
P07819225A1094|152 159|mutants
P07821790A1084|75 84|repressor
P07821790A1084|176 188|UCR elements
P07821790A1084|157 165|reporter
P07822329A0773|88 95|binding
P07822329A0773|178 181|kDa
P07822329A0773|153 157|mass
P07823919A1422|13 23|activation
P07823919A1422|27 32|Oct-3
P07823919A1422|35 43|promoter
P07823919A1422|51 67|RXR heterodimers
P07823953A0777|362 372|inhibition
P07823953A0777|265 270|dimer
P07823953A0777|335 346|DNA binding
P07823953A0777|321 331|inhibition
P07823953A0777|221 225|mask
P07823953A0777|464 470|region
P07823953A0777|9 16|battery
P07823953A0777|501 506|dimer
P07823953A0777|64 69|dimer
P07823953A0777|238 257|localization signal
P07824325A0714|247 258|microgram/g
P07824325A0714|48 62|thorax opening
P07824325A0714|119 120|%
P07824325A0714|193 200|tissues
P07824325A0714|76 82|period
P07824325A0714|36 46|procedures
P07824325A0714|102 108|bypass
P07824657A1456|94 104|leaf discs
P07824657A1456|38 50|pCSK4F plant
P07825888A0715|26 44|dementia disorders
P07825888A0715|71 82|differences
P07826625X0000|300 318|activation domains
P07826625X0000|212 219|Regions
P07826625X0000|82 89|protein
P07826625X0000|156 159|CTD
P07826625X0000|194 209|enhancer domain
P07826625X0000|228 234|serine
P07826625X0000|381 389|proteins
P07826625X0000|99 117|activation domains
P07828600A0095|121 130|silencing
P07828600A0095|12 15|SSP
P07828600A0095|199 203|K562
P07828600A0095|143 156|beta-promoter
P07828600A0095|68 89|gamma-globin promoter
P07828824A0307|111 120|deletions
P07828824A0307|55 66|development
P07829057A1097|40 47|RH maps
P07829097A0000|30 36|Factor
P07829097A0000|125 130|genes
P07829097A0000|42 46|gene
P07829097A0000|5 11|region
P07829097A0000|102 110|isochore
P07829519A1251|74 84|exon usage
P07829519A1251|231 236|locus
P07829519A1251|157 162|forms
P07829519A1251|170 187|immunoglobulin mu
P07830112A0532|303 313|acromegaly
P07830112A0532|176 179|PFR
P07830112A0532|157 158|p
P07830112A0532|84 97|stroke volume
P07830112A0532|326 333|normals
P07830112A0532|14 18|peak
P07830112A0532|67 73|volume
P07830112A0532|99 101|SV
P07830112A0532|168 172|time
P07830112A0532|275 276|p
P07831799T0000|57 76|DNA polymerase gene
P07831799T0000|100 118|polyhedrosis virus
P07832086A1023|121 124|AMK
P07832086A1023|150 153|FOM
P07832086A1023|55 56|%
P07832086A1023|105 106|%
P07832086A1023|132 133|%
P07832086A1023|111 119|amikacin
P07832086A1023|5 21|drug sensitivity
P07832086A1023|138 148|fosfomycin
P07834582A0115|46 54|n-3 EFAs
P07834582A0115|9 19|supplement
P07834582A0115|25 33|fish oil
P07834582A0115|101 109|property
P07835214A0603|62 63|%
P07835214A0603|36 44|diabetes
P07835273A0411|60 75|EGFR expression
P07835273A0411|179 196|3T3-L1 adipocytes
P07835273A0411|200 209|5000/cell
P07835273A0411|35 45|adipocytes
P07835273A0411|102 112|adipocytes
P07835826A0195|88 100|3-vitamin D3
P07835826A0195|26 28|OH
P07835826A0195|58 60|OH
P07835826A0195|85 87|OH
P07835888A0402|104 122|haplotype analysis
P07835888A0402|24 31|XD gene
P07835888A0402|5 10|locus
P07836228A1052|44 54|impairment
P07836228A1052|58 69|LV function
P07836228A1052|16 29|communication
P07836390A1152|120 133|IncP plasmids
P07836390A1152|146 156|initiation
P07836390A1152|5 20|characteristics
P07836471A0375|60 64|hNUC
P07836471A0375|88 106|osteosarcoma cells
P07840643A1006|134 135|%
P07840643A1006|74 94|glycosylasparaginase
P07840643A1006|144 154|similarity
P07840643A1006|3 13|comparison
P07840643A1006|119 127|identity
P07841663A0685|128 135|control
P07841663A0685|178 184|medium
P07841663A0685|143 149|sample
P07841663A0685|1 21|Superoxide dismutase
P07844142A0640|120 128|SR alpha
P07844142A0640|11 18|cloning
P07844142A0640|159 177|GTPase superfamily
P07844142A0640|53 60|SR beta
P07844142A0640|102 109|protein
P07844201T0000|48 55|results
P07844201T0000|1 14|Sex selection
P07844555A0406|77 97|lymphoma development
P07844555A0406|127 133|M-MuLV
P07846153A0403|19 25|EMBO J
P07846199A0000|15 22|ethanol
P07846199A0000|5 11|effect
P07846942T0001|47 53|system
P07848358A0254|89 98|d onwards
P07848358A0254|20 55|aspartate aminotransferase activity
P07851758A0330|10 28|analysis maps SAL6
P07851758A0330|64 69|spt14
P07852361A0868|91 96|cells
P07852361A0868|26 37|cell medium
P07852361A0868|113 120|S phase
P07852361A0868|50 58|reversal
P07853448A0601|9 13|task
P07853448A0601|18 35|sports scientists
P07853488T0000|180 185|trans
P07853488T0000|97 105|gag gene
P07853488T0000|18 38|poliovirus replicons
P07853488T0000|1 14|Encapsidation
P07854130A1387|28 44|pilus biogenesis
P07854130A1387|93 115|pilE insertion mutants
P07854130A1387|20 24|PilE
P07854324A0281|177 182|yeast
P07854324A0281|43 70|cell cycle control elements
P07854324A0281|111 123|mik1 homolog
P07856102A1616|45 54|M protein
P07856102A1616|76 81|sites
P07856102A1616|103 117|virus assembly
P07857163A0551|5 13|activity
P07857762A0611|96 105|responses
P07857762A0611|51 61|eukaryotes
P07859371A1246|63 66|rat
P07859371A1246|108 116|extracts
P07859739T0000|74 80|levels
P07859739T0000|9 31|cyclin D-Cdk complexes
P07859739T0000|84 127|p16INK4/MTS1 tumour suppressor gene product
P07860208A0000|63 91|tumour necrosis factor-alpha
P07860208A0000|93 96|TNF
P07860208A0000|53 57|IL-1
P07860208A0000|154 172|lipopolysaccharide
P07860208A0000|221 229|patients
P07860208A0000|174 177|LPS
P07860208A0000|33 51|interleukin-1 beta
P07862092A0302|94 110|mutation pol3-14
P07862092A0302|247 256|libraries
P07862092A0302|22 27|clone
P07862092A0302|53 64|suppressors
P07862092A0302|85 89|sdp1
P07862092A0302|73 83|ts mutants
P07862129A1391|60 82|HNF-3 alpha expression
P07862129A1391|107 115|decrease
P07862129A1391|158 166|TTR gene
P07862129A1391|16 22|livers
P07862141A1412|66 73|variety
P07862141A1412|5 11|member
P07862141A1412|39 59|transcription factor
P07862154A0340|64 72|analysis
P07862154A0340|1 8|Cloning
P07862165A0184|165 170|cells
P07862165A0184|62 70|psoralen
P07862165A0184|196 211|helix formation
P07862165A0184|35 51|oligonucleotides
P07862533A0000|12 37|tumour suppressor protein
P07862533A0000|5 10|Wilms
P07862533A0000|156 173|sequence homology
P07862533A0000|103 115|zinc fingers
P07862533A0000|85 92|protein
P07863619A0098|90 99|fragments
P07863619A0098|125 131|object
P07863619A0098|4 9|order
P07863619A0098|171 178|objects
P07864652A0753|57 59|H1
P07864652A0753|52 56|E2L1
P07864652A0753|83 87|E2H1
P07864652A0753|109 111|H1
P07864652A0753|40 44|E2L1
P07864652A0753|140 151|parentheses
P07864652A0753|238 247|construct
P07864652A0753|205 217|E2 component
P07864709A0324|89 99|resistance
P07864709A0324|145 163|enzyme immunoassay
P07864709A0324|118 129|rimantadine
P07864709A0324|133 138|means
P07864709A0324|33 40|viruses
P07864709A0324|1 8|METHODS
P07864709A0324|171 181|sequencing
P07865786A0457|93 99|plants
P07865786A0457|70 76|leaves
P07865876A1292|122 131|DRTF1/E2F
P07865876A1292|71 82|combination
P07865876A1292|35 52|DP family members
P07865876A1292|170 174|cell
P07865895A0896|151 163|LGL/NK cells
P07865895A0896|192 197|event
P07865895A0896|213 220|absence
P07865895A0896|76 79|mAb
P07865895A0896|137 146|rationale
P07867604A1777|195 203|elements
P07867604A1777|108 124|initiation sites
P07867604A1777|5 12|results
P07867604A1777|293 303|conditions
P07867604A1777|256 260|cAMP
P07867944A0365|46 49|tsp
P07867944A0365|99 123|consensus sequence motif
P07867944A0365|1 9|Upstream
P07869913A1076|134 142|subjects
P07869913A1076|39 49|blood flow
P07870305A1015|31 82|thalami-nucleus ventralis lateralis thalami neurons
P07870305A1015|113 137|nucleus entopeduncularis
P07870305A1015|4 21|nucleus ventralis
P07870305A1015|223 244|haloperidol influence
P07871721A0000|47 64|scorch carlavirus
P07871721A0000|122 129|protein
P07871721A0000|66 71|BBScV
P07871721A0000|137 140|kDa
P07871754A0857|129 134|model
P07871754A0857|143 148|study
P07871754A0857|168 181|cooperativity
P07871757A0846|43 59|initiation codon
P07871757A0846|1 9|Analysis
P07872673A0332|75 93|expression plasmid
P07872673A0332|125 135|c-fos gene
P07872673A0332|142 149|control
P07872673A0332|48 53|c-fos
P07873631A0114|20 34|tooth fracture
P07873876A1035|73 79|region
P07873876A1035|146 154|deletion
P07873876A1035|58 64|probes
P07873876A1035|185 191|region
P07875595A0910|121 133|localization
P07875595A0910|6 12|humans
P07875595A0910|38 46|chickens
P07875595A0910|18 34|PITSLRE PK genes
P07876191A0808|15 20|class
P07876191A0808|55 62|stomach
P07876191A0808|1 11|Expression
P07876194T0000|128 150|tyrosine kinase domain
P07876194T0000|1 12|Endocytosis
P07876210A0751|241 250|induction
P07876210A0751|147 160|P450BM-3 gene
P07876210A0751|97 102|Bm3P1
P07876210A0751|65 75|expression
P07876210A0751|84 92|P450BM-3
P07876210A0751|17 36|P450BM-3 Barbie box
P07876562A1646|150 165|HIV-1 infection
P07876562A1646|122 133|stimulation
P07876562A1646|101 108|T cells
P07877619A1284|42 53|suppression
P07877619A1284|4 12|addition
P07877619A1284|205 216|zif268 gene
P07878040A0505|56 70|mouse enhancer
P07878040A0505|111 119|activity
P07880442A0236|89 111|S1 nuclease protection
P07880442A0236|68 84|primer extension
P07880650A0493|57 65|function
P07880650A0493|112 123|possibility
P07880650A0493|16 24|analysis
P07880650A0493|85 98|electron dose
P07883167A0157|31 35|UPF1
P07883167A0157|123 137|identification
P07883167A0157|229 234|mRNAs
P07883167A0157|173 180|factors
P07883167A0157|4 9|yeast
P07883193A0000|194 198|gene
P07883193A0000|41 47|domain
P07883193A0000|173 178|frame
P07883193A0000|3 15|DNA fragment
P07886610A0000|104 114|prevalence
P07886610A0000|128 138|population
P07886610A0000|71 83|hemophilia A
P07887859A0315|121 124|TBI
P07887859A0315|126 133|indices
P07887859A0315|98 101|ABI
P07888156A0169|150 167|video conferences
P07888156A0169|176 182|review
P07888156A0169|39 45|Tromso
P07888156A0169|140 146|access
P07888156A0169|250 256|issues
P07888156A0169|16 35|University Hospital
P07888306A1659|242 250|rolipram
P07888306A1659|113 117|cGMP
P07888306A1659|252 260|ABSTRACT
P07888306A1659|194 198|cGMP
P07888306A1659|224 238|concentrations
P07888306A1659|78 90|PDE activity
P07888306A1659|99 103|cAMP
P07888306A1659|70 74|type
P07888629A0344|104 124|Da cell wall protein
P07888629A0344|27 34|segment
P07888629A0344|191 199|sequence
P07888629A0344|274 297|lipid transfer proteins
P07888828A0765|60 65|genes
P07888828A0765|6 13|concept
P07890599A0132|47 61|MIN6 cell line
P07890599A0132|227 233|n-Sec1
P07890599A0132|22 40|mouse cDNA library
P07890599A0132|113 120|isoform
P07890599A0132|203 213|% identity
P07890599A0132|87 97|beta cells
P07890680A1193|63 70|complex
P07890680A1193|131 136|gamma
P07890680A1193|22 41|core DNA polymerase
P07890680A1193|116 127|replacement
P07891638T0000|14 23|detection
P07891638T0000|36 45|asymmetry
P07891708A0690|11 16|HNF-4
P07891708A0690|52 63|Hep3B cells
P07891708A0690|33 39|kidney
P07891709A1542|7 19|observations
P07891709A1542|87 97|transcript
P07891720A0818|23 30|binding
P07891720A0818|34 37|C1F
P07892353A0667|164 172|patterns
P07892353A0667|176 188|correlations
P07892353A0667|6 13|factors
P07892353A0667|87 93|cortex
P07894359T0000|73 77|rats
P07894359T0000|63 69|sepsis
P07894359T0000|32 40|abortion
P07896088A0720|165 169|tail
P07896088A0720|106 117|factor RIF1
P07896088A0720|213 220|effects
P07896088A0720|174 198|RIF1 interaction domains
P07896088A0720|119 131|rap1 alleles
P07896615A0554|104 115|measurement
P07896615A0554|57 70|nm absorption
P07896615A0554|21 30|skin flow
P07896615A0554|155 169|NIR recordings
P07896846T0000|91 108|suppressor region
P07896846T0000|25 33|isoforms
P07896846T0000|140 150|chain gene
P07897359A0354|27 32|forms
P07897359A0354|96 99|use
P07897359A0354|68 74|BHK-21
P07898178A0849|14 18|risk
P07898178A0849|111 123|azathioprine
P07898178A0849|97 107|conversion
P07898178A0849|39 49|conversion
P07898178A0849|200 204|risk
P07898589T0000|6 19|tobacco issue
P07899581A0000|132 152|superoxide dismutase
P07899581A0000|66 86|superoxide dismutase
P07899581A0000|115 127|nitrendipine
P07899581A0000|223 227|rats
P07899581A0000|100 111|combination
P07900915A0000|297 307|hematocrit
P07900915A0000|266 271|Evans
P07900915A0000|188 197|ml.kg-1 x
P07900915A0000|285 293|dilution
P07900915A0000|78 89|restitution
P07900915A0000|143 146|fed
P07900915A0000|64 69|tract
P07900915A0000|169 173|rats
P07901125A0416|90 97|species
P07901125A0416|41 61|aa sequence homology
P07901125A0416|9 18|advantage
P07901125A0416|70 76|DAHPSs
P07902532A1655|142 150|EC cells
P07902532A1655|54 67|transcription
P07902532A1655|71 81|BOXF1 gene
P07903099A0918|28 38|transcript
P07903099A0918|112 127|splice acceptor
P07903099A0918|5 13|presence
P07905413A0585|181 189|workload
P07905413A0585|267 273|points
P07905413A0585|114 115|h
P07905413A0585|16 25|treatment
P07905413A0585|78 85|ng.ml-1
P07905413A0585|100 107|ng.ml-1
P07905413A0585|239 246|placebo
P07906265A0897|13 24|experiments
P07906265A0897|141 149|assembly
P07908012A0678|179 196|medication levels
P07908012A0678|158 170|relationship
P07908012A0678|201 212|LNNB scores
P07908012A0678|71 77|groups
P07908827A1200|44 58|identification
P07908827A1200|270 277|element
P07908827A1200|158 162|RARs
P07908827A1200|21 31|antibodies
P07908827A1200|136 145|sequences
P07910716A0359|151 159|patients
P07910716A0359|57 65|SC rIL-2
P07910716A0359|387 391|days
P07910716A0359|119 123|week
P07910716A0359|284 300|SC rIFN-alpha 2b
P07910716A0359|438 442|days
P07910716A0359|130 135|total
P07910716A0359|470 475|weeks
P07910716A0359|173 186|rIFN-alpha 2b
P07910716A0359|235 240|total
P07910716A0359|206 221|U/m2/day thrice
P07910716A0359|69 74|doses
P07911736A1715|15 24|mg/m2/day
P07911736A1715|62 67|agent
P07911736A1715|71 87|myelosuppression
P07913080A0564|76 80|mice
P07913080A0564|3 35|decanucleotide promoter sequence
P07913926A0878|63 71|cultures
P07913926A0878|79 90|ntcA mutant
P07913926A0878|158 168|transcript
P07913926A0878|117 129|glnA message
P07914192A0844|31 39|extracts
P07914192A0844|92 107|promoter region
P07914192A0844|246 269|GAGGAA response element
P07914192A0844|139 146|complex
P07914192A0844|1 17|Gel-shift assays
P07914700A0000|97 100|DNA
P07914700A0000|5 9|gene
P07916003A0688|60 70|CD79 alpha
P07916003A0688|44 50|region
P07916003A0688|79 87|TATA box
P07916003A0688|186 190|gene
P07916327A0250|57 60|GSC
P07916327A0250|93 101|sequence
P07916327A0250|117 124|protein
P07916588A0471|227 238|potyviruses
P07916588A0471|176 179|PWV
P07916588A0471|42 48|strain
P07916588A0471|142 145|CPs
P07916588A0471|83 86|PWV
P07916588A0471|101 112|CP sequence
P07916689A0312|107 113|oleate
P07916689A0312|46 60|kb RNA species
P07916729T0000|57 64|protein
P07916729T0000|3 24|leucine zipper domain
P07917016A0581|15 26|DNA-binding
P07918097T0000|122 137|neuroepithelium
P07918097T0000|66 87|growth factor-repeats
P07918494A1163|62 83|thioredoxin reductase
P07918494A1163|41 47|system
P07918494A1163|178 182|mole
P07918494A1163|168 173|dCTPs
P07918494A1163|186 192|enzyme
P07919540A1119|160 165|level
P07919540A1119|52 57|forms
P07919540A1119|65 78|c-Myc protein
P07919540A1119|35 39|exon
P07925022A0285|64 70|stages
P07925282A0705|161 172|ER membrane
P07925282A0705|71 83|SRP proteins
P07925282A0705|1 11|Disruption
P07926739A0766|123 139|progenitor cells
P07926739A0766|27 30|GL2
P07926739A0766|93 97|gene
P07926739A0766|170 190|trichome development
P07926749A0471|242 246|RORE
P07926749A0471|77 86|ROR alpha
P07926749A0471|93 102|ROR alpha
P07926749A0471|138 163|hormone response elements
P07926749A0471|51 59|proteins
P07926775A0895|61 68|embryos
P07926775A0895|106 117|requirement
P07926775A0895|163 167|time
P07926775A0895|21 28|stripes
P07926775A0895|50 53|slp
P07927130A0625|46 53|Biotest
P07927130A0625|110 114|days
P07927130A0625|36 44|Cytotect
P07927130A0625|188 195|CMV-DNA
P07927130A0625|101 106|ml/kg
P07927130A0625|1 34|CMV hyperimmunoglobulin treatment
P07927711A0698|59 61|Da
P07927711A0698|1 4|ORF
P07928954A0545|89 96|protein
P07928954A0545|52 54|bp
P07928954A0545|114 120|weight
P07929238A0734|8 16|Genomics
P07929431A0949|72 119|reporter gene chloramphenicol acetyltransferase
P07929431A0949|173 184|INS-1 cells
P07929560T0000|72 76|role
P07929560T0000|53 63|desmoglein
P07929560T0000|80 95|plaque assembly
P07932095A0000|30 39|compounds
P07932095A0000|151 172|Oroxylum indicum Vent
P07932095A0000|10 21|naphthalene
P07932095A0000|138 147|root bark
P07932095A0000|85 94|compounds
P07933066T0000|57 64|protein
P07933066T0000|20 31|interaction
P07933066T0000|115 122|domains
P07933095A0000|63 79|retrovirus Rev-T
P07933095A0000|27 32|v-Rel
P07933095A0000|110 119|promoters
P07933095A0000|38 49|oncoprotein
P07933095A0000|139 144|sites
P07933107A0991|95 98|E70
P07933107A0991|81 93|ASFV strains
P07933107A0991|48 56|p54 gene
P07933107A0991|103 106|E75
P07934331T0037|10 22|registration
P07935094A0516|148 157|FDG study
P07935094A0516|36 46|FDG images
P07935094A0516|1 8|RESULTS
P07935375A1197|56 76|TIS10/PGS2 induction
P07935375A1197|1 11|Expression
P07935383A0108|135 142|regions
P07935383A0108|10 15|RNase
P07935383A0108|197 202|virus
P07935383A0108|115 124|pre-mRNAs
P07935383A0108|169 182|cleavage site
P07935415T0000|134 138|gene
P07935415T0000|99 108|structure
P07935415T0000|17 27|expression
P07935426A0714|49 67|zinc finger domain
P07935451T0000|133 137|RelA
P07935451T0000|7 33|T-cell leukemia virus type
P07935451T0000|113 128|I kappa B alpha
P07935451T0000|98 109|degradation
P07935451T0000|153 162|induction
P07935471A0613|95 106|Xenopus HSF
P07935471A0613|67 75|antibody
P07935471A0613|20 23|HSF
P07935471A0613|155 160|hHSF1
P07935471A0613|187 198|maintenance
P07935472A0790|116 137|mobility shift assays
P07935472A0790|17 33|binding activity
P07935491A1182|22 39|response elements
P07935626A1249|47 62|gene transcript
P07935626A1249|37 40|trp
P07935626A1249|32 36|tRNA
P07936635A1134|13 17|KRKR
P07936635A1134|58 69|compartment
P07936635A1134|21 25|NGER
P07936635A1134|34 38|MO15
P07936650A0656|82 99|activating region
P07936650A0656|18 27|subdomain
P07936650A0656|103 113|p58c-ets-2
P07937106A0100|208 217|mutations
P07937106A0100|145 155|isoleucine
P07937106A0100|224 225|B
P07937106A0100|163 170|c-ets-1
P07937106A0100|5 19|v-ets oncogene
P07937106A0100|33 47|retrovirus E26
P07937112A0220|28 30|Ku
P07937112A0220|147 149|Ku
P07937112A0220|16 24|subunits
P07937132A0819|91 99|sequence
P07937132A0819|53 68|complementarity
P07937132A0819|103 111|28S rRNA
P07937656A0182|147 160|disease stage
P07937656A0182|294 307|serum albumin
P07937656A0182|324 338|activity index
P07937656A0182|130 137|factors
P07937656A0182|162 163|p
P07937656A0182|203 215|micrograms/l
P07937656A0182|309 310|p
P07937656A0182|1 11|Univariate
P07937656A0182|275 276|p
P07937954A0612|43 46|Ras
P07937954A0612|23 29|levels
P07938137A0384|60 65|mg/kg
P07938137A0384|46 54|naloxone
P07938137A0384|86 97|environment
P07941739A0000|73 79|region
P07941739A0000|27 39|yeast genome
P07941739A0000|83 97|chromosome XIV
P07942076A0497|182 186|type
P07942076A0497|59 77|estradiol valerate
P07942076A0497|19 43|estradiol concentrations
P07942722T0000|23 34|risk factor
P07942722T0000|98 104|agents
P07944461A0321|61 64|mm3
P07944461A0321|53 54|%
P07944461A0321|1 7|TG-day
P07945134A0079|89 91|ft
P07945134A0079|38 40|ft
P07945134A0079|117 118|m
P07945937A0358|26 40|zebrafish egr1
P07945937A0358|260 272|Egr1 protein
P07945937A0358|216 222|region
P07945937A0358|118 128|Egr1 genes
P07945937A0358|174 208|triplet nucleotide repeat sequence
P07945937A0358|238 252|amino terminus
P07945937A0358|1 18|Sequence analysis
P07948129A0297|89 123|chloramphenicol acetyl transferase
P07948129A0297|130 143|reporter gene
P07948129A0297|125 128|CAT
P07948129A0297|53 58|chLTR
P07948129A0297|71 81|expression
P07948129A0297|255 258|NEO
P07949137A0000|108 114|ASTA Z
P07949137A0000|22 30|leukemia
P07949137A0000|81 83|BM
P07949137A0000|153 160|January
P07949137A0000|137 144|January
P07949164A0799|57 68|CAT plasmid
P07949164A0799|52 56|IL-6
P07949164A0799|19 27|mutation
P07949551A0000|12 21|vena cava
P07949551A0000|48 52|vein
P07951235A0277|5 9|gene
P07951410A1332|125 137|E1A promoter
P07951410A1332|87 97|activation
P07953785A0648|107 111|food
P07953785A0648|160 191|marble spleen disease infection
P07953785A0648|8 21|heat exposure
P07953785A0648|65 78|% restriction
P07954891T0000|53 64|maintenance
P07954891T0000|1 5|ERV1
P07956869A0000|194 208|flow cytometry
P07956869A0000|106 126|Pathology laboratory
P07956869A0000|228 244|S-phase fraction
P07956869A0000|213 223|DNA ploidy
P07957106A0471|47 69|GST-POU fusion protein
P07957106A0471|9 20|interaction
P07957158A1532|202 217|Starling forces
P07957158A1532|17 32|filtration rate
P07957559A1557|30 43|proliferation
P07957559A1557|91 101|inhibition
P07957559A1557|73 82|MEL cells
P07957559A1557|136 141|cells
P07958446A0000|133 148|gene regulators
P07958446A0000|56 64|proteins
P07958446A0000|24 32|factor-3
P07958446A0000|5 15|hepatocyte
P07958446A0000|51 54|fkh
P07958898A1050|104 125|transcription factors
P07958898A1050|141 145|VP16
P07958898A1050|136 139|Sp1
P07958915A1507|41 44|Ca2
P07958915A1507|215 230|protein kinases
P07958915A1507|159 167|presence
P07958915A1507|98 105|ability
P07959011A0379a|92 98|manner
P07959011A0379a|48 68|rat class-I ADH gene
P07959011A0379a|100 106|Potter
P07959015A0478|122 132|identities
P07959015A0478|27 30|ORF
P07959015A0478|111 116|rAMPK
P07959015A0478|52 63|amino acids
P07959015A0478|65 67|aa
P07959015A0478|34 39|hAMPK
P07959760A0763|62 66|YACs
P07959760A0763|333 347|microsatellite
P07959760A0763|216 226|ets family
P07959760A0763|399 409|Fli-1 gene
P07959760A0763|290 296|contig
P07959760A0763|152 176|Ewing sarcoma breakpoint
P07959760A0763|135 137|Mb
P07959760A0763|349 356|D11S912
P07959760A0763|201 208|members
P07959760A0763|274 277|DNA
P07959953A0423|79 88|kilobases
P07959953A0423|23 28|exons
P07959953A0423|50 57|introns
P07960796A0154|26 38|implications
P07961755A0474|131 147|leader sequences
P07961755A0474|49 73|transit peptide sequence
P07961958T0000|1 28|Rat kidney carboxylesterase
P07963782A0000|27 36|stability
P07963782A0000|42 53|combination
P07963782A0000|153 157|pain
P07964458A0179|162 178|membrane protein
P07964458A0179|22 25|Bcg
P07964458A0179|68 86|macrophage protein
P07964624A0491|47 50|ORF
P07964624A0491|160 171|polypeptide
P07964624A0491|188 192|P191
P07964624A0491|175 176|M
P07964814T0000|37 45|migraine
P07964814T0000|50 58|epilepsy
P07965152A0764|46 57|MIBI uptake
P07965152A0764|146 168|dobutamine stimulation
P07965152A0764|93 104|wall motion
P07966602A0130|10 12|J.
P07967360A1048|91 106|IgA nephropathy
P07967360A1048|13 17|data
P07967360A1048|51 67|TGBM nephropathy
P07968409A0123|165 181|General Hospital
P07968409A0123|199 203|days
P07968409A0123|5 11|sample
P07968409A0123|117 125|Diseases
P07969116A0196|130 138|response
P07969116A0196|5 18|Nur77 protein
P07969116A0196|156 163|stimuli
P07969135A0913|11 19|presence
P07969152A0721|30 33|HSF
P07969152A0721|88 98|activation
P07969152A0721|163 181|glucose starvation
P07969152A0721|277 284|members
P07969152A0721|262 267|genes
P07969152A0721|50 67|activation domain
P07969954T0000|105 118|immunotherapy
P07969954T0000|14 35|motor neuron syndrome
P07969954T0000|52 61|serum IgM
P07969954T0000|71 81|antibodies
P07971709A0907|67 74|rhG-CSF
P07971709A0907|19 27|response
P07972237A0665|107 122|subcloning YACs
P07972237A0665|128 135|cosmids
P07972237A0665|19 34|restriction map
P07973364A0325|29 35|causes
P07973364A0325|199 202|OF1
P07973364A0325|112 119|studies
P07973364A0325|207 216|NMRI mice
P07973364A0325|85 108|carcinogenicity studies
P07973825A0445|5 19|recovery value
P07973825A0445|32 40|pressure
P07975882T0000|39 45|fibers
P07977648A0880|41 46|exons
P07977648A0880|80 89|mutations
P07977648A0880|1 11|Sequencing
P07978406A0998|31 34|CBF
P07978406A0998|147 155|ABSTRACT
P07978406A0998|93 101|response
P07978406A0998|173 178|WORDS
P07978406A0998|86 89|g-1
P07979827A0722|13 23|cromakalim
P07979827A0722|1 8|KRN2391
P07980468A0298|1 5|Acta
P07981143A0633|143 150|factors
P07981143A0633|101 124|nucleoprotein complexes
P07981143A0633|17 28|nucleotides
P07982964A1017|106 119|monophosphate
P07982964A1017|1 4|ATX
P07983011A0617|329 333|acid
P07983011A0617|125 132|members
P07983011A0617|456 463|domains
P07983011A0617|81 105|serine/threonine kinases
P07983011A0617|51 57|domain
P07983011A0617|283 304|leucine zipper motifs
P07983011A0617|173 202|protein kinase kinase kinases
P07983011A0617|1 18|Sequence analysis
P07983011A0617|478 490|src homology
P07983712A0914|28 34|domain
P07983712A0914|76 82|levels
P07983716A1082|15 23|Northern
P07983716A1082|91 103|transfection
P07983716A1082|107 112|COS-7
P07983716A1082|25 28|RNA
P07983716A1082|163 167|Y88S
P07983716A1082|116 126|HeLa cells
P07984088A0592|107 118|L. ivanovii
P07984088A0592|81 103|virulence gene cluster
P07984088A0592|1 14|Transcription
P07984088A0592|137 141|PrfA
P07984261A0536|27 33|cortex
P07984261A0536|5 9|ICBF
P07987924A0670|133 147|probe hypotube
P07987924A0670|5 18|inflation hub
P07988730A0220|147 150|CAT
P07988730A0220|58 67|deletions
P07988730A0220|250 276|transactivator tax protein
P07988730A0220|221 229|presence
P07988730A0220|75 84|U5 region
P07988730A0220|199 213|Jurkat T-cells
P07988730A0220|169 181|transfection
P07988731A1301|13 20|protein
P07988731A1301|32 36|GF14
P07990136A1124|183 193|properties
P07990136A1124|214 220|polIII
P07990136A1124|77 86|positions
P07990136A1124|59 65|polIII
P07991582A1023b|12 20|analysis
P07991582A1023b|113 128|enzyme function
P07993559A0233|10 15|index
P07993559A0233|52 59|Pendrys
P07995173A0585|59 60|r
P07995173A0585|49 57|juice pH
P07997174A0936|111 129|A. vinelandii NifL
P07997174A0936|5 9|data
P07997174A0936|33 48|phosphorylation
P07999363A0000|43 69|transmembrane FGF receptor
P07999363A0000|22 27|genes
P07999363A0000|71 75|FGFR
P07999363A0000|139 159|juxtamembrane domain
P07999982A0086|47 51|D9S5
P07999982A0086|11 29|maximum lod scores
P07999982A0086|64 68|FRDA
P07999982A0086|119 141|recombination fraction
P08000074A0162|60 68|sequence
P08000074A0162|145 151|kb DNA
P08000074A0162|3 11|sequence
P08000074A0162|85 96|translation
P08000427A0000|31 40|kb insert
P08000427A0000|143 154|kDa protein
P08000427A0000|3 18|cDNA clone pCZ1
P08001136T0000|43 57|RNA polymerase
P08001136T0000|1 13|Relationship
P08001966A0563|77 80|CNC
P08001966A0563|67 75|proteins
P08001966A0563|169 191|Caenorhabditis elegans
P08002857A1070|60 82|oesophageal surfactant
P08002857A1070|106 112|degree
P08002857A1070|200 206|attack
P08002857A1070|49 56|barrier
P08002857A1070|1 12|CONCLUSIONS
P08004442A0265|148 151|HPA
P08004442A0265|196 220|corticosterone secretion
P08004442A0265|53 71|locomotor activity
P08004442A0265|236 249|adrenalectomy
P08005412A0608|47 48|P
P08005412A0608|88 103|protein complex
P08005412A0608|26 41|gene expression
P08005412A0608|140 148|PS sites
P08006101A1142|109 117|analysis
P08006101A1142|1 40|Standard curve correlation coefficients
P08006773A0836|28 49|plasma concentrations
P08006773A0836|213 217|PGI2
P08006773A0836|189 209|plasma concentration
P08006773A0836|53 57|PGI2
P08006773A0836|288 289|p
P08006773A0836|73 77|TxA2
P08006773A0836|171 183|preeclampsia
P08007954A0374|109 119|properties
P08007954A0374|38 54|response element
P08007954A0374|152 160|enhancer
P08011166A0207|62 69|results
P08011166A0207|95 101|clones
P08011166A0207|139 155|polymerase chain
P08012566A0254|104 109|limit
P08012566A0254|149 162|plasma sample
P08012566A0254|113 122|detection
P08012566A0254|65 77|ion fragment
P08013457A0342|15 17|SH
P08013457A0342|82 126|tyrosine kinase receptor signal transduction
P08013457A0342|1 13|Src homology
P08014377A1277|27 42|activity levels
P08014377A1277|129 137|subjects
P08014377A1277|54 59|vagal
P08015672A1282|151 155|Type
P08015672A1282|22 37|baseline images
P08015672A1282|159 167|baseline
P08015672A1282|48 52|Type
P08016102A1238|28 37|sequences
P08016102A1238|57 78|transcription factors
P08016102A1238|114 124|activation
P08016102A1238|87 97|NF-kappa B
P08016102A1238|286 299|tissue injury
P08016102A1238|231 235|role
P08016102A1238|174 178|cell
P08016102A1238|102 106|AP-2
P08017290A1347|29 45|sinus difference
P08017290A1347|126 131|group
P08017290A1347|141 147|pacing
P08020702A0000|149 157|lipid A.
P08020702A0000|143 147|wall
P08020702A0000|116 125|component
P08020806A0187|74 79|Crohn
P08020806A0187|26 31|trial
P08020806A0187|145 155|amino acid
P08020806A0187|179 184|% fat
P08020806A0187|82 89|disease
P08020806A0187|53 61|patients
P08020965A0465|127 131|ends
P08020965A0465|140 150|transcript
P08020965A0465|85 95|transcript
P08021177A0000|214 224|conditions
P08021177A0000|173 194|Fur repressor protein
P08021177A0000|19 35|fes-entF operons
P08022212A0071|303 314|conductance
P08022212A0071|88 109|admittance locus plot
P08022212A0071|123 143|low-frequency region
P08022212A0071|267 277|parameters
P08022212A0071|45 58|AC excitation
P08022212A0071|351 355|1/R0
P08022212A0071|336 348|frequency G0
P08024139A0393|213 223|impairment
P08024139A0393|4 12|addition
P08024139A0393|116 127|differences
P08025669A0724|74 79|sigma
P08025669A0724|83 91|activity
P08029001A1020|183 189|target
P08029001A1020|79 93|RNA polymerase
P08029001A1020|140 149|component
P08029001A1020|205 228|transcription machinery
P08030239A0833|149 166|activation domain
P08030239A0833|231 238|ability
P08030239A0833|35 39|form
P08030704A1503|135 148|preterm labor
P08030704A1503|124 129|women
P08030704A1503|162 166|term
P08033490A0875|122 139|dosage adjustment
P08033490A0875|20 31|disposition
P08033490A0875|4 14|conclusion
P08033490A0875|103 110|disease
P08033490A0875|171 198|creatinine clearance values
P08034486A0579|110 120|population
P08034486A0579|18 23|HSV-2
P08034486A0579|49 69|HSV-1 antibody ratio
P08034682T0000|8 18|expression
P08034682T0000|32 78|inositol 1,4,5-trisphosphate receptor subunits
P08034741A0000|61 67|myosin
P08034741A0000|145 161|border myosin I.
P08034741A0000|99 107|myosin I
P08035498A0833|14 31|computer analysis
P08035498A0833|4 12|addition
P08035498A0833|71 85|A stem element
P08035505A0586|19 22|NS3
P08035796A0890|120 135|phosphorylation
P08035796A0890|229 236|strains
P08035796A0890|97 104|mutants
P08035796A0890|80 93|casein kinase
P08035796A0890|184 189|forms
P08035796A0890|51 62|eIF-2 alpha
P08036004A0292|120 136|binding activity
P08036004A0292|26 31|class
P08036004A0292|188 193|cells
P08036004A0292|34 42|enhancer
P08039422A0000|74 79|group
P08039422A0000|106 122|mouse Chromosome
P08039422A0000|5 34|nerve growth factor beta gene
P08040391T0000|72 81|seminomas
P08040391T0000|52 60|clusters
P08040391T0000|113 121|features
P08041362T0000|134 137|Cys
P08041362T0000|72 82|watermelon
P08041362T0000|95 110|complementation
P08041362T0000|139 148|auxotroph
P08043523A0000|158 168|dyskinesia
P08043523A0000|19 31|serum levels
P08043523A0000|35 45|antibodies
P08043523A0000|239 247|patients
P08044800A0550|6 38|DNA containing promoter activity
P08045431A0894|88 96|bacteria
P08045431A0894|20 28|identity
P08045431A0894|1 5|HupI
P08046923A0000|74 86|osteomalacia
P08046923A0000|4 15|examination
P08048916A0000|11 28|insulin receptors
P08048916A0000|1 6|IGF I
P08049444A0351|9 17|cleavage
P08049444A0351|144 159|binding protein
P08049444A0351|22 47|peptide sequence analysis
P08049444A0351|248 257|MARs/SARs
P08049885T0000|7 19|pancreatitis
P08051059A1000|30 43|rhlA promoter
P08051059A1000|96 109|binding sites
P08051059A1000|118 132|RhlR regulator
P08051102A0532|46 72|chain phosphatase activity
P08051102A0532|1 8|Heparin
P08051102A0532|84 85|B
P08053697A0000|150 158|diameter
P08053697A0000|106 110|dots
P08053697A0000|144 146|mm
P08053697A0000|1 11|BACKGROUND
P08053697A0000|238 242|dots
P08055939A0159|56 63|regions
P08055939A0159|22 28|domain
P08055939A0159|200 212|H1 molecules
P08055941A1264|60 76|artifactual beta
P08055941A1264|129 135|enzyme
P08055941A1264|5 13|topology
P08055941A1264|80 86|capsid
P08057356A0531|105 111|region
P08057356A0531|42 54|substitution
P08057356A0531|85 103|response regulator
P08057421A1583|8 15|binding
P08057421A1583|52 74|oligonucleotide probes
P08057421A1583|20 38|competition assays
P08057421A1583|137 141|CBF1
P08057833A0573|108 120|start codons
P08057833A0573|142 155|reading frame
P08058948A0810|94 102|patients
P08058948A0810|25 36|angiography
P08058948A0810|83 90|nodules
P08058948A0810|1 11|CONCLUSION
P08062833A0000|122 134|binding site
P08062833A0000|106 111|E box
P08062833A0000|113 115|E1
P08062833A0000|168 178|regulators
P08063766A0595|75 80|times
P08063766A0595|166 171|rates
P08063766A0595|93 102|alpha PKC
P08063766A0595|49 65|envelope lamin B
P08063766A0595|85 89|rate
P08063791A1370|42 45|set
P08063791A1370|67 82|sequence motifs
P08063791A1370|154 159|yeast
P08064351A1020|90 92|ms
P08064351A1020|76 83|latency
P08064351A1020|1 13|Long-latency
P08065324A0458|89 92|USE
P08065324A0458|37 48|snRNA genes
P08065324A0458|97 110|TATA elements
P08065331A0279|133 149|E2A-HLF proteins
P08065331A0279|189 198|leukemias
P08065331A0279|116 119|HLF
P08065365A0000|62 70|pre-mRNA
P08065365A0000|29 46|ribonucleoprotein
P08065365A0000|48 53|snRNP
P08065365A0000|1 8|Binding
P08065368A0839|1 6|Ariga
P08066094T0000|1 12|Marine oils
P08067123A0248|303 308|blood
P08067123A0248|61 86|assay systems ORTHO ELISA
P08067123A0248|29 35|assays
P08067123A0248|18 25|results
P08067123A0248|255 256|%
P08067123A0248|135 150|anti-HCV-C100-3
P08067123A0248|317 318|p
P08067123A0248|196 197|%
P08067123A0248|236 250|HBsAg carriers
P08067607A0568|13 24|alterations
P08067607A0568|128 141|control group
P08067607A0568|116 120|dogs
P08069427T0000|63 74|gallbladder
P08070004A0782|151 159|patients
P08070004A0782|109 119|t1/2 alpha
P08070004A0782|20 29|variation
P08070004A0782|174 183|mg/m2 PCZ
P08070654A0000|44 49|yeast
P08070654A0000|27 36|component
P08070654A0000|58 67|pole body
P08070654A0000|69 72|SPB
P08071356A0232|127 150|transcription complexes
P08071356A0232|86 106|transcription bubble
P08071356A0232|171 189|template positions
P08072352A0567|121 122|%
P08072352A0567|9 17|patients
P08072352A0567|144 154|IgE levels
P08072352A0567|36 37|%
P08072352A0567|98 110|eosinophilia
P08072547A1009|150 155|c-Fos
P08072547A1009|9 17|sequence
P08072547A1009|103 107|part
P08073505T0000|7 17|generation
P08073505T0000|21 48|information retrieval tools
P08073505T0000|84 101|ExPASy WWW server
P08075421A0621a|64 69|HrpJ2
P08076631A0000|88 92|AP-1
P08076631A0000|270 293|osteosarcoma cell lines
P08076631A0000|66 69|VDR
P08076631A0000|5 12|binding
P08076631A0000|256 262|SaOs-2
P08076631A0000|136 140|AP-1
P08077236A0243|77 81|COS1
P08077236A0243|67 73|levels
P08077236A0243|1 10|Wild type
P08078416A0581|28 41|disinfectants
P08078416A0581|18 24|effect
P08079268T0028|56 63|surgery
P08079268T0028|36 46|anesthesia
P08082215A0230|12 20|response
P08082215A0230|77 81|RTID
P08082215A0230|65 73|patients
P08082292T0000|44 51|disease
P08082292T0000|9 20|NK activity
P08082440A0339a|15 23|LH/FSH P
P08083220A0988|121 130|formation
P08083220A0988|46 54|contrast
P08083220A0988|78 86|promoter
P08083220A0988|229 236|complex
P08083220A0988|22 39|complex formation
P08083998A1723a|28 46|leader-mRNA fusion
P08083998A1723a|142 151|sequences
P08083998A1723a|50 75|coronavirus transcription
P08083999A0501|122 132|affinities
P08083999A0501|59 76|BPV-1 E2 proteins
P08083999A0501|1 9|Vaccinia
P08083999A0501|85 102|consensus E2 site
P08084592A0145|66 80|tumorigenicity
P08084592A0145|4 8|HeLa
P08085609A0384|89 98|distances
P08085609A0384|138 159|crown fissure termini
P08085609A0384|118 128|dimensions
P08086450A0467|105 121|guanine-cytosine
P08086450A0467|61 67|region
P08086450A0467|132 138|region
P08086450A0467|209 212|Sp1
P08086450A0467|214 218|AP-2
P08086450A0467|1 11|Comparison
P08087887A1067|131 139|cleavage
P08087887A1067|5 23|polyubiquitin gene
P08087887A1067|98 109|mRNA levels
P08088513A0419|132 134|U6
P08088513A0419|80 91|interaction
P08088513A0419|139 141|U2
P08088818A1053|165 175|RAD52 gene
P08088818A1053|10 15|level
P08088818A1053|68 72|YACs
P08089834A0561|59 67|residues
P08089834A0561|19 28|deletions
P08090571T0001|49 59|xenografts
P08090767A0000|134 145|replication
P08090767A0000|26 46|DNA polymerase delta
P08090767A0000|108 117|viability
P08090767A0000|168 188|base excision repair
P08091665T0000|46 50|gene
P08091665T0000|27 33|copies
P08091665T0000|1 13|Cowpox virus
P08093450A0688|165 177|NRF-1 motifs
P08093450A0688|40 53|ALAS promoter
P08093450A0688|218 228|expression
P08093450A0688|81 87|levels
P08093616T0000|40 43|DNA
P08093616T0000|142 147|genes
P08093616T0000|64 71|element
P08093616T0000|117 127|expression
P08093616T0000|152 172|DNA polymerase alpha
P08094464A0869|61 69|promoter
P08094464A0869|116 120|aroF
P08094498A0614|47 52|truth
P08094498A0614|64 73|diagnosis
P08095698T0000|105 113|patients
P08095698T0000|27 37|vitamin D3
P08095698T0000|80 89|nephritis
P08095698T0000|119 141|nephropathia epidemica
P08095875T0000|36 47|hypothermia
P08095875T0000|64 69|He-O2
P08096944A0951|132 137|women
P08096944A0951|27 38|stimulation
P08096944A0951|96 106|assessment
P08097732A0000|44 55|Spec2a gene
P08097732A0000|125 131|region
P08097732A0000|179 182|RSR
P08097732A0000|1 11|Activation
P08098842A0660|124 132|sequence
P08098842A0660|146 150|exon
P08098842A0660|230 238|increase
P08098842A0660|283 293|regulation
P08098842A0660|154 159|c-fos
P08098842A0660|16 22|region
P08098914A0400|75 80|slope
P08098914A0400|106 109|Ees
P08098914A0400|95 104|elastance
P08098914A0400|22 38|Pes-Ves relation
P08098914A0400|169 170|P
P08100057A0577|112 123|dendrocytes
P08100843A0134|30 33|DNA
P08100843A0134|104 114|mCD22 cDNA
P08100843A0134|157 162|mCD22
P08100843A0134|48 55|tissues
P08100843A0134|84 97|mouse strains
P08101171A0924|14 21|results
P08101171A0924|77 83|memory
P08101171A0924|163 173|regulators
P08101171A0924|34 38|idea
P08101843A0151|92 101|base pair
P08101843A0151|54 58|copy
P08101843A0151|32 34|TH
P08103379A0577|11 18|stretch
P08103379A0577|76 84|proteins
P08103379A0577|55 66|MADS domain
P08104189A1168|7 11|data
P08104189A1168|113 115|pH
P08104189A1168|85 93|reaction
P08105994T0000|27 35|increase
P08105994T0000|84 94|infarction
P08106245A0325|243 249|period
P08106245A0325|215 221|Bq m-3
P08106245A0325|53 59|period
P08106245A0325|84 90|Bq m-3
P08106245A0325|287 293|winter
P08106245A0325|229 235|summer
P08106245A0325|39 45|summer
P08106325A0000|57 64|protein
P08106325A0000|83 95|tox operator
P08106325A0000|1 5|DtxR
P08106398A1003|73 77|step
P08106398A1003|46 60|leader peptide
P08106398A1003|81 97|nisin maturation
P08107167A0222|120 123|IFA
P08107167A0222|209 216|IFA-ABS
P08107167A0222|52 70|parkeri antibodies
P08107167A0222|236 237|%
P08107167A0222|170 183|serum samples
P08108099T0000|79 88|disorders
P08108099T0000|54 62|patients
P08108413A0964|107 122|PANG expression
P08108413A0964|59 69|cell lines
P08108413A0964|138 143|brain
P08111974A1034|75 87|tubulin mRNA
P08111974A1034|183 195|trans-factor
P08111974A1034|25 34|mechanism
P08112526A0443|30 51|calcium concentration
P08112526A0443|104 110|manner
P08112526A0443|119 126|control
P08112611A0404|58 65|protein
P08112611A0404|33 46|reading frame
P08113736A0309|121 127|mosaic
P08113736A0309|26 36|CRSV RNA-1
P08113736A0309|129 134|SCNMV
P08113736A0309|80 86|mosaic
P08113736A0309|175 185|CRSV RNA-1
P08113736A0309|136 150|dianthoviruses
P08114710A0137|47 66|HIV-1 transcription
P08114710A0137|96 101|TFIID
P08115744A0462|5 10|films
P08115744A0462|33 41|scanning
P08115744A0462|103 110|microns
P08116245A0174|29 38|reactions
P08116245A0174|94 105|infant rats
P08119149A0000|120 127|effects
P08119149A0000|131 135|bone
P08119958A0273|211 219|subgroup
P08119958A0273|179 185|PKC mu
P08119958A0273|159 165|domain
P08119958A0273|5 9|lack
P08119958A0273|98 106|sequence
P08119958A0273|34 36|Ca
P08120019A1500|74 85|PI turnover
P08120019A1500|16 27|Hm1 mutants
P08122364A0954|166 175|synthesis
P08122364A0954|26 37|pCD41 ORF-A
P08122364A0954|111 119|promoter
P08122364A0954|200 207|protein
P08123787A0554|14 33|amino acid sequence
P08123787A0554|56 68|HemB protein
P08123787A0554|111 137|metal cofactor requirement
P08123787A0554|223 231|analysis
P08124912A0456|91 111|beta 2-microglobulin
P08124912A0456|58 62|IL-8
P08124912A0456|86 89|LDH
P08125258A0142|167 180|perturbations
P08125258A0142|57 66|CHOP gene
P08125258A0142|22 27|cells
P08125258A0142|141 152|deprivation
P08125337A0940|107 122|Erg24p activity
P08125337A0940|99 103|loss
P08125337A0940|34 40|mutant
P08126096A0478|91 97|domain
P08126096A0478|208 224|domain antiserum
P08126096A0478|111 121|homologies
P08126096A0478|174 181|studies
P08126096A0478|259 264|forms
P08127950A0000|26 34|function
P08127950A0000|112 119|authors
P08127950A0000|185 201|triiodothyronine
P08127950A0000|135 154|0800h plasma levels
P08127950A0000|79 83|axis
P08127950A0000|315 323|controls
P08127950A0000|283 289|assays
P08127950A0000|96 106|depression
P08127950A0000|4 9|order
P08129955A0572|37 45|activity
P08129955A0572|86 87|h
P08129955A0572|49 54|CK-MB
P08131545A0158|62 65|men
P08131545A0158|213 235|Legionella pneumophila
P08131545A0158|190 200|Mycoplasma
P08131545A0158|289 298|Chlamydia
P08131545A0158|104 110|living
P08131545A0158|40 57|community members
P08131545A0158|237 252|cytomegalovirus
P08132541A0000|9 19|DNA clones
P08132667T0000|86 95|promoters
P08134108A0277|134 142|elements
P08134108A0277|59 76|YY1 binding sites
P08136383A0359|11 16|hours
P08136383A0359|23 36|MR tomography
P08138364T0000|1 10|Varieties
P08139004A0278|77 80|A/U
P08139004A0278|81 94|UGC sequences
P08139031A1168|225 242|cysteine residues
P08139031A1168|287 299|interactions
P08139031A1168|144 149|C-421
P08139031A1168|96 113|cysteine residues
P08139031A1168|357 374|ORF4 inducibility
P08139542A1229|5 14|mutations
P08139542A1229|34 44|repression
P08139543A0427|44 61|SLK1-SLT2 pathway
P08139562A0404|166 181|GCN4 start site
P08139562A0404|41 49|evidence
P08139562A0404|59 68|ribosomes
P08139562A0404|32 37|lines
P08139914A0554|37 54|dnHLH protein Id1
P08139914A0554|64 79|differentiation
P08140847X0001|30 39|remission
P08140847X0001|189 194|Crohn
P08140847X0001|153 158|study
P08140847X0001|227 236|remission
P08140847X0001|9 16|disease
P08140847X0001|76 82|intake
P08140847X0001|409 417|controls
P08140847X0001|136 140|year
P08143198T0001|63 96|composites dorsal pedal skin flap
P08143198T0001|39 54|transplantation
P08143198T0001|16 24|opponens
P08143667A0222|45 48|IVP
P08143667A0222|180 184|MUCP
P08143667A0222|189 192|IVP
P08143667A0222|71 88|closure pressures
P08143667A0222|137 142|cmH2O
P08144037A0000|58 64|enzyme
P08144037A0000|1 12|Thioredoxin
P08144497T0000|105 112|segment
P08144497T0000|29 41|raf-1 kinase
P08144497T0000|19 25|region
P08144572A0786|28 47|polypeptide binding
P08144572A0786|160 164|DnaK
P08144572A0786|1 4|ATP
P08144572A0786|152 155|BiP
P08144631A0000|47 59|associations
P08144631A0000|82 94|Src homology
P08144631A0000|115 120|sites
P08144631A0000|103 110|domains
P08144852A0000|241 250|inhibitor
P08144852A0000|159 164|males
P08144852A0000|87 90|AVP
P08144852A0000|50 66|11-deoxycortisol
P08144852A0000|74 85|vasopressin
P08144852A0000|129 132|CRF
P08144852A0000|5 14|responses
P08144852A0000|68 72|ACTH
P08145770A1078|63 66|PKC
P08145770A1078|142 152|activities
P08145770A1078|71 88|retinoid pathways
P08148756A0358|122 127|fluid
P08148756A0358|96 114|hemoglobin content
P08148756A0358|5 11|degree
P08149484A1551|166 170|AP-1
P08149484A1551|147 152|genes
P08149484A1551|116 129|transcription
P08149484A1551|34 43|PKC alpha
P08151787A0355|105 120|500-VRPRKRR-506
P08151787A0355|243 249|motifs
P08151787A0355|56 89|amino acid motifs 726-GRKRKSP-732
P08151787A0355|126 131|IE110
P08151787A0355|157 162|forms
P08151787A0355|1 10|Insertion
P08151790A0354|104 107|LTR
P08151790A0354|135 143|deletion
P08151790A0354|193 204|infectivity
P08151790A0354|42 50|kinetics
P08151790A0354|5 25|revertant TATA boxes
P08152800A0357|180 186|member
P08152800A0357|133 137|PEA3
P08152800A0357|110 111|%
P08152800A0357|66 72|region
P08152800A0357|200 218|Molecule PEA3-like
P08152800A0357|221 224|ERM
P08153130T0000|12 21|estradiol
P08153130T0000|52 62|leukocytes
P08153130T0000|103 107|rats
P08154171A0649|183 191|embolism
P08154171A0649|42 50|patients
P08154171A0649|7 13|issues
P08154171A0649|65 75|thrombosis
P08154171A0649|33 38|LMWHs
P08156332T0000|52 61|treatment
P08157009T0000|30 39|APS1 gene
P08157009T0000|176 189|Golgi complex
P08157009T0000|143 154|interaction
P08157009T0000|50 57|homolog
P08157674T0000|13 29|characterization
P08157674T0000|52 59|protein
P08160054A0224|44 50|status
P08160054A0224|94 103|aspartate
P08160054A0224|108 134|alanine aminotransaminases
P08160054A0224|5 13|patients
P08160905A0217|41 68|hepatitis B surface antigen
P08160905A0217|70 75|HBsAg
P08163498A0789|121 136|phosphorylation
P08163498A0789|40 43|32P
P08163498A0789|36 38|RS
P08163498A0789|5 20|phosphopeptides
P08163498A0789|70 84|SGASGLLTSEHHSR
P08163546A1230|132 139|sorting
P08163546A1230|108 115|pathway
P08163546A1230|233 248|sorting pathway
P08163546A1230|185 197|intersection
P08163546A1230|152 162|hydrolases
P08164661A0414|121 127|degree
P08164661A0414|144 154|divergence
P08164661A0414|159 173|RNA polymerase
P08164661A0414|35 43|homology
P08164680A1086|22 39|protease activity
P08166402A0631|46 57|proportions
P08166402A0631|87 102|hyperosmolality
P08167555A0972|13 22|treatment
P08167555A0972|56 68|pretreatment
P08167555A0972|155 163|relation
P08167555A0972|1 9|Response
P08169709T0000|12 21|bone cyst
P08169709T0000|35 43|analysis
P08172416A0860|149 158|ovulation
P08172416A0860|40 44|dose
P08172416A0860|82 85|cow
P08172416A0860|18 23|times
P08172416A0860|184 189|phase
P08172653A1589|45 57|TnT isoforms
P08172653A1589|94 106|modification
P08172653A1589|159 162|TnT
P08172653A1589|81 89|addition
P08172653A1589|136 140|rise
P08173532A0000|58 60|S2
P08173532A0000|8 21|reaction time
P08173532A0000|98 101|cue
P08173532A0000|155 167|target onset
P08173532A0000|103 105|S1
P08173814A0132|150 165|host physiology
P08173814A0132|59 68|existence
P08173814A0132|98 107|processes
P08175188A0685|133 136|CBF
P08175188A0685|43 51|decrease
P08175188A0685|25 32|ppm SO2
P08175188A0685|102 105|MCA
P08177143T0000|58 68|experience
P08177143T0000|7 21|cell carcinoma
P08178490A0879|54 69|anchor function
P08179827T0000|39 51|transmission
P08179827T0000|86 91|Korea
P08181755A0989|73 83|transcript
P08181755A0989|116 120|mRNA
P08182056A0695|132 138|member
P08182056A0695|10 16|degree
P08182056A0695|77 85|sequence
P08182056A0695|101 110|NQO2 gene
P08183552T0000|91 95|maps
P08183552T0000|77 86|evolution
P08183915T0000|13 21|splicing
P08183915T0000|94 118|I kappa B gamma isoforms
P08183915T0000|25 40|RNA transcripts
P08185288A0106|27 31|male
P08185288A0106|189 193|work
P08185288A0106|96 116|respiration chambers
P08185288A0106|5 15|experiment
P08185288A0106|136 143|morning
P08187088A0530|182 183|%
P08187088A0530|125 127|6p
P08187088A0530|251 252|%
P08187088A0530|225 228|18q
P08187088A0530|109 110|%
P08187088A0530|173 176|11p
P08187088A0530|169 170|%
P08187088A0530|149 151|9p
P08187088A0530|89 103|chromosomes 3p
P08187088A0530|212 215|17q
P08187088A0530|18 32|heterozygosity
P08187088A0530|195 196|%
P08187088A0530|199 202|17p
P08187088A0530|67 72|cases
P08188258A0000|15 25|synthetase
P08188258A0000|73 80|classes
P08188258A0000|175 183|pathways
P08188603A0230|40 44|arg4
P08188603A0230|143 150|subunit
P08188603A0230|174 184|synthetase
P08188603A0230|34 38|gene
P08188978A0822|63 78|MSNA burst peak
P08188978A0822|147 166|pulse-synchronicity
P08188978A0822|16 23|latency
P08189498T0000|58 71|disease virus
P08189498T0000|86 99|repeat region
P08189498T0000|50 55|Marek
P08189533A0203|195 201|vTF7-3
P08189533A0203|40 44|gene
P08189533A0203|77 82|forms
P08189533A0203|203 220|expression system
P08190633A0000|47 51|gene
P08190633A0000|5 30|transcription factor AP-2
P08191910A0228|120 130|strategist
P08191910A0228|107 116|abilities
P08191910A0228|1 11|San Martin
P08191910A0228|68 74|lodges
P08192451A0885|11 20|treatment
P08192451A0885|71 76|Rh123
P08192451A0885|84 92|increase
P08193147A0831|199 201|Pf
P08193147A0831|126 134|topology
P08193147A0831|67 69|Fd
P08193147A0831|21 38|crystal structure
P08193147A0831|1 11|Comparison
P08194549A0000|27 35|kayakers
P08194549A0000|96 101|power
P08194549A0000|103 105|CP
P08194970A0000|79 83|role
P08194970A0000|9 22|opportunities
P08194970A0000|112 118|family
P08194970A0000|49 53|home
P08195216A1022|60 66|subset
P08195216A1022|25 29|case
P08195216A1022|169 178|sequences
P08195216A1022|103 116|transcription
P08195216A1022|34 38|HIS3
P08195233A0147|107 115|position
P08195233A0147|92 97|genes
P08195233A0147|4 12|addition
P08195233A0147|169 175|stages
P08196616A1112|130 147|tyrosine residues
P08196616A1112|95 113|ZAP-70 SH2 domains
P08196616A1112|261 272|SH2 domains
P08196616A1112|155 160|motif
P08196616A1112|204 228|phosphotyrosine residues
P08196624A0593|45 62|T beta R-I signal
P08196624A0593|167 174|ligands
P08196624A0593|130 141|association
P08196624A0593|4 14|Mv1Lu lung
P08196624A0593|117 126|responses
P08199204A0746|126 139|P2 production
P08199204A0746|53 67|PKC activation
P08199204A0746|86 110|tyrosine phosphorylation
P08200528A0970|120 123|PAL
P08200528A0970|165 172|control
P08200528A0970|176 180|pPGK
P08200528A0970|6 14|strategy
P08201758A0125|15 22|patient
P08201758A0125|93 98|times
P08202546A1206|125 132|adducts
P08202546A1206|100 107|effects
P08204348T0000|8 18|ifosfamide
P08204348T0000|23 32|cisplatin
P08204348T0000|34 37|VIP
P08204426T0001|78 87|childhood
P08204426T0001|93 115|implantation technique
P08205827A0940|14 27|Translocation
P08205827A0940|79 84|tract
P08205827A0940|124 142|animal experiments
P08205827A0940|191 199|patients
P08205827A0940|1 12|CONCLUSIONS
P08206867A0874|63 74|COXVb genes
P08206867A0874|82 92|rat genome
P08207022T0000|91 108|Bacillus subtilis
P08207022T0000|49 87|Spo0A sporulation transcription factor
P08207405A0372|60 64|BYSV
P08207405A0372|122 147|kb amplification products
P08207405A0372|89 110|fleck virus templates
P08207405A0372|6 27|citrus tristeza virus
P08207405A0372|169 179|sequencing
P08207405A0372|35 39|beet
P08207805A0000|72 79|protein
P08207805A0000|5 38|p53 tumor suppressor gene product
P08208540A0000|63 75|malignancies
P08208540A0000|96 108|significance
P08208540A0000|118 129|alterations
P08208540A1114|44 68|NFKB2 expression vectors
P08208540A1114|88 105|reporter plasmids
P08208540A1114|197 206|NFKB2 p52
P08209051T0000|24 31|therapy
P08209051T0000|55 63|hospital
P08209772A0167|91 98|protein
P08209772A0167|106 117|amino acids
P08209772A0167|5 13|ns2 gene
P08209772A0167|87 89|ns
P08212571A0971|57 62|cells
P08212571A0971|25 37|rev proteins
P08212571A0971|87 95|proteins
P08212571A0971|17 20|gag
P08213235A1024|105 112|infants
P08213235A1024|64 68|care
P08213235A1024|1 12|Measurement
P08216115A0158|44 53|catheters
P08216115A0158|131 139|activity
P08216115A0158|5 13|patients
P08216115A0158|21 26|group
P08218056A0000|31 38|vessels
P08218056A0000|97 101|eyes
P08218056A0000|80 88|patients
P08218230A1920|28 31|GRE
P08218230A1920|63 90|glucocorticoid inducibility
P08218230A1920|146 158|determinants
P08218230A1920|98 108|HNF-1 site
P08218230A1920|253 265|liver tissue
P08219081A0000|5 16|PRB-1b gene
P08220494A0231|180 184|stem
P08220494A0231|11 19|promoter
P08220494A0231|189 199|root cells
P08220494A0231|174 178|leaf
P08220494A0231|118 124|region
P08221251A0239|42 51|diagnosis
P08221251A0239|70 74|area
P08222556T0000|11 16|aging
P08222556T0000|1 7|Effect
P08223425T0000|94 101|protein
P08223425T0000|48 69|protein translocation
P08223576A1261|39 48|T protein
P08223576A1261|98 107|H4PteGlun
P08223576A1261|69 79|conditions
P08223613A0105|163 167|byp1
P08223613A0105|66 73|subunit
P08223613A0105|18 22|gene
P08223613A0105|1 5|GGS1
P08223823T0000|22 35|aging effects
P08223823T0000|1 20|Stroop interference
P08224260A1248|161 172|specificity
P08224260A1248|93 94|%
P08224260A1248|54 69|ultrasonography
P08224260A1248|1 11|CONCLUSION
P08225657A0000|15 24|ibopamine
P08225657A0000|180 185|trial
P08225657A0000|29 39|furosemide
P08225657A0000|113 121|parallel
P08226776A0990|91 100|delta Hva
P08226776A0990|59 64|ratio
P08226780A0160|74 81|ankyrin
P08226780A0160|6 11|motif
P08226780A0160|38 58|protein interactions
P08226798A1124|209 218|functions
P08226798A1124|111 120|mechanism
P08226798A1124|19 30|CaM binding
P08226798A1124|137 149|cytotoxicity
P08227129T0000|60 69|C protein
P08227129T0000|101 124|immunoglobulin C2 motif
P08228997A0866|39 57|lipid accumulation
P08229330A0000|6 13|smokers
P08230418A0812|61 64|nef
P08230418A0812|126 157|urokinase plasminogen activator
P08230418A0812|294 305|amino acids
P08230418A0812|119 124|c-fms
P08230418A0812|47 57|expression
P08230418A0812|109 114|virus
P08230418A0812|313 320|protein
P08230418A0812|5 11|action
P08230452A0551|241 257|assembly defects
P08230452A0551|333 349|vaccinia viruses
P08230452A0551|458 460|D.
P08230452A0551|117 122|cells
P08230452A0551|153 167|vaccinia virus
P08230452A0551|194 217|poliovirus 3CD protease
P08230452A0551|169 173|VVP3
P08230452A0551|275 297|complementation system
P08231398A0802|125 135|bacteremia
P08231398A0802|113 121|episodes
P08231398A0802|44 49|total
P08231398A0802|66 80|blood cultures
P08231398A0802|279 283|mean
P08231398A0802|139 154|M. tuberculosis
P08231398A0802|1 8|RESULTS
P08231816A1473|24 32|extracts
P08231816A1473|218 226|IPNS tsp
P08232412A1342|135 140|cells
P08232412A1342|159 170|vinblastine
P08232412A1342|5 16|lemdr1 gene
P08232412A1342|35 60|expression vector pALTNEO
P08234276A0556|52 65|IL-8 promoter
P08234276A0556|103 127|NF-kappa B binding sites
P08237112A0553|4 12|homology
P08237112A0553|35 46|36K protein
P08237578A0253|180 186|months
P08237578A0253|12 28|lipid metabolism
P08237578A0253|144 149|years
P08237578A0253|71 82|cholesterol
P08237578A0253|153 171|Norplant-2 rod use
P08239164A0551|60 68|exercise
P08239164A0551|14 21|isotime
P08239164A0551|78 85|dyspnea
P08239164A0551|145 151|values
P08239164A0551|1 5|CPAP
P08239164A0551|187 195|patients
P08240170A0000|6 11|forms
P08240170A0000|48 56|feedlots
P08241656A0189|61 72|association
P08241656A0189|36 40|case
P08241656A0189|81 95|cholelithiasis
P08243476A1177|132 149|Paracoccus enzyme
P08243476A1177|7 15|cysteine
P08245013A0000|72 76|mRNA
P08245013A0000|228 235|agonist
P08245013A0000|127 151|receptor down-regulation
P08245013A0000|53 68|destabilization
P08245013A0000|201 211|regulation
P08245456A0501|211 225|protein levels
P08245456A0501|62 65|PMA
P08245456A0501|27 32|level
P08245456A0501|82 84|N6
P08245456A0501|175 190|IL-5 production
P08245456A0501|118 129|combination
P08245933A0617|39 49|treatments
P08246984A0923|88 94|family
P08246984A0923|177 180|p85
P08246984A0923|7 14|results
P08246984A0923|98 103|genes
P08247005A0584|47 60|20S precursor
P08247005A0584|112 115|40S
P08247005A0584|1 8|Strains
P08248246A0838|52 59|complex
P08248246A0838|5 12|complex
P08248246A0838|84 91|binding
P08248688A0726|88 92|rate
P08248688A0726|5 9|rate
P08248688A0726|136 144|molecule
P08249390A0111|133 143|infarction
P08249390A0111|76 81|years
P08249390A0111|64 70|months
P08251622A0000|121 130|sequences
P08251622A0000|27 33|region
P08251622A0000|171 181|expression
P08252976A0467|46 51|Rdiff
P08252976A0467|94 115|pressure dissipations
P08253387A0801|15 31|enhancer mutants
P08253387A0801|46 62|trans-activation
P08253387A0801|66 75|hLEF/GAL4
P08253387A0801|1 11|Inspection
P08253387A0801|137 144|protein
P08253777A0301|91 95|cAMP
P08253777A0301|124 127|Kv1
P08253777A0301|110 120|expression
P08253777A0301|3 24|cAMP response element
P08254738A0428|62 75|baculoviruses
P08254738A0428|192 208|T-antigen kinase
P08254738A0428|26 36|T antigens
P08254738A0428|124 134|activities
P08254738A0428|143 148|TS677
P08255341A0554|47 58|combination
P08255341A0554|79 96|tissue amoebicide
P08255341A0554|5 13|patients
P08257666A0662|74 83|afferents
P08257666A0662|95 97|HD
P08257666A0662|23 30|lesions
P08257666A0662|64 70|source
P08257666A0662|16 21|study
P08258025A1131|88 103|Karnofsky index
P08258025A1131|83 86|age
P08258025A1131|54 73|treatment variables
P08258025A1131|185 194|mortality
P08260635A0926|135 139|GapA
P08260635A0926|160 166|plants
P08260635A0926|6 12|intron
P08260635A0926|34 42|position
P08261398A0838|45 53|strategy
P08261398A0838|96 103|termini
P08261398A0838|18 31|amplification
P08261398A0838|35 39|cDNA
P08262054A0565|60 79|membrane protein 2A
P08262054A0565|150 161|Tyr-X-X-Leu
P08262054A0565|108 113|virus
P08262054A0565|39 45|domain
P08262054A0565|115 118|EBV
P08263933T0000|31 42|ATPase gene
P08263933T0000|52 83|cyanobacterium Synechocystis sp
P08264582A0750|193 197|LIFR
P08264582A0750|111 120|deletions
P08264582A0750|234 243|signaling
P08264582A0750|49 56|mutants
P08264591A1190|181 189|function
P08264591A1190|107 141|transcription start site selection
P08264591A1190|212 223|interaction
P08264591A1190|38 45|subunit
P08264591A1190|49 63|RNA polymerase
P08264628A0418|89 93|site
P08264628A0418|55 68|accessibility
P08264628A0418|1 28|Oligonucleotide competitors
P08264650A0925|156 163|meiosis
P08264650A0925|1 9|Analysis
P08264650A0925|34 52|mds1 null mutation
P08265602T0000|7 20|Ala mutations
P08265602T0000|1 4|Val
P08267658A0391|134 146|preservation
P08267658A0391|180 202|drug transport studies
P08267658A0391|94 103|raffinose
P08267658A0391|76 82|KH2PO4
P08267658A0391|23 31|solution
P08267658A0391|84 89|MgSO4
P08268718A0676|7 19|bcl3 protein
P08268912A0657|63 66|RNA
P08268912A0657|10 33|translation experiments
P08268912A0657|50 54|cDNA
P08268912A0657|85 92|protein
P08269439X0000|135 139|pain
P08269439X0000|56 67|Pentazocine
P08269439X0000|108 118|management
P08270580A0155|14 22|response
P08270580A0155|58 72|amphotericin B
P08273122A0708|63 93|blood administration practices
P08273122A0708|110 118|variance
P08273122A0708|185 192|percent
P08273122A0708|49 59|monitoring
P08273122A0708|17 26|beginning
P08275618A0457|268 276|patients
P08275618A0457|125 130|ratio
P08275618A0457|194 199|curve
P08275618A0457|165 183|concentration area
P08275618A0457|282 291|cirrhosis
P08275618A0457|65 73|patients
P08275618A0457|101 109|subjects
P08276336A0371|150 156|polyps
P08276336A0371|49 62|colonoscopies
P08276336A0371|100 112|relationship
P08276762T0000|40 57|glycine-870 codon
P08276762T0000|18 36|base substitutions
P08276762T0000|1 7|Effect
P08276854A1894|167 182|pur/pyr segment
P08276854A1894|203 213|regulation
P08276854A1894|191 195|role
P08276854A1894|102 123|proteoglycan promoter
P08276871A1001|128 141|transmembrane
P08276871A1001|158 165|domains
P08277632A0997|28 34|months
P08277632A0997|5 18|survival rate
P08277632A0997|55 65|N2 disease
P08278480T0002|1 3|G.
P08278929A0866|13 31|SPF type V embryos
P08278929A0866|78 81|CRS
P08278929A0866|145 158|VSD incidence
P08278929A0866|65 74|% ethanol
P08278929A0866|101 109|controls
P08278929A0866|187 198|% incidence
P08280476A0602|107 121|point mutation
P08280476A0602|8 15|studies
P08280476A0602|153 157|site
P08281153A0543|56 72|intron sequences
P08281153A0543|99 106|species
P08281634A1801|7 17|parameters
P08281634A1801|48 56|ferritin
P08282501A0358|94 105|conclusions
P08282501A0358|131 142|differences
P08282501A0358|22 28|number
P08282501A0358|187 194|grade-2
P08282749A1474|41 46|% CO2
P08282749A1474|9 26|Hospital solution
P08282749A1474|1 7|Thomas
P08282749A1474|153 159|arrest
P08283531A0700|183 189|gantry
P08283531A0700|5 31|Stryker frame modification
P08283531A0700|118 130|localization
P08284337A0825|95 108|cardiologists
P08284337A0825|178 186|patients
P08284337A0825|113 123|internists
P08284337A0825|35 47|IHD patients
P08286035A0587|166 191|polymerase chain reaction
P08286035A0587|198 205|methods
P08286035A0587|92 96|poly
P08286035A0587|97 98|A
P08286035A0587|100 103|RNA
P08286035A0587|68 72|cDNA
P08288240A1343|88 99|duplication
P08288240A1343|7 11|data
P08288240A1343|66 76|SCG10 gene
P08288596A0663|177 182|front
P08288596A0663|52 65|transcription
P08288596A0663|113 119|F2-TRE
P08288596A0663|84 90|TREpal
P08288596A0663|284 299|binding protein
P08288596A0663|231 255|TATA box binding protein
P08288596A0663|101 107|ME-TRE
P08288622A0725|73 81|HDC mRNA
P08288622A0725|123 138|intron sequence
P08288622A0725|98 107|insertion
P08288622A0725|155 158|use
P08289339A0527|120 122|E1
P08289339A0527|28 38|protection
P08289339A0527|63 74|core region
P08289342A0931|30 45|resolution site
P08289342A0931|3 9|mutant
P08289342A0931|17 20|AAV
P08289593A1404|209 215|MK-801
P08289593A1404|126 127|n
P08289593A1404|266 274|toxicity
P08289593A1404|157 161|rats
P08289593A1404|289 297|urethane
P08289593A1404|311 315|rats
P08289593A1404|138 145|vehicle
P08289783A1476|94 104|activation
P08289783A1476|128 137|P19 cells
P08289783A1476|21 32|mutagenesis
P08289783A1476|187 197|repression
P08289793A1226|123 127|stem
P08289793A1226|108 112|Oct4
P08289793A1226|142 150|enhancer
P08289834A0341|61 69|TGF-beta
P08289834A0341|37 42|Atr-I
P08289834A0341|71 78|activin
P08290421A0165|133 140|patient
P08290421A0165|8 17|knowledge
P08290421A0165|86 97|association
P08290421A0165|103 109|Alport
P08291620A0372|11 19|patterns
P08291620A0372|96 107|anthropoids
P08293992A0432|28 30|nt
P08293992A0432|6 12|repeat
P08294386A0000|30 40|predictors
P08294386A0000|135 145|depression
P08294386A0000|67 77|depression
P08294386A0000|203 214|desipramine
P08294386A0000|1 11|BACKGROUND
P08294459A0446|15 34|amino acid sequence
P08294459A0446|133 136|PTP
P08294459A0446|42 52|SAP-1 cDNA
P08294459A0446|203 209|region
P08294865A0236|104 124|peptide/DR complexes
P08294865A0236|9 17|features
P08296434A1141|74 83|diagnosis
P08296434A1141|123 132|condition
P08296434A1141|5 22|Harleco apparatus
P08298129A0274|104 117|gene promoter
P08298129A0274|97 101|beta
P08299181A1148|12 17|fluid
P08299181A1148|106 107|%
P08299181A1148|66 67|%
P08299181A1148|87 90|eye
P08299725A0724|120 131|readthrough
P08299725A0724|62 68|muscle
P08299725A0724|133 137|form
P08299725A0724|178 181|end
P08299896A0880|130 131|b
P08299896A0880|141 142|P
P08299896A0880|1 23|Regression line slopes
P08300527T0000|41 51|disruption
P08300527T0000|101 128|Saccharopolyspora erythraea
P08300605A0432|31 37|series
P08300605A0432|41 57|deletion mutants
P08300605A0432|176 184|presence
P08300605A0432|65 69|gene
P08300605A0432|85 93|extracts
P08300611A0341|15 26|mutagenesis
P08300611A0341|182 201|amino acid residues
P08300611A0341|158 168|importance
P08300611A0341|50 54|gene
P08300625A1352|72 88|peptide sequence
P08300625A1352|22 28|codons
P08300625A1352|32 36|slyD
P08301841A0000|67 77|infarction
P08301841A0000|114 117|UAP
P08301841A0000|19 34|enzyme activity
P08303233A0313|90 94|text
P08303233A0313|4 12|addition
P08304342A0605|27 51|hemochromatosis families
P08304342A0605|202 209|markers
P08304342A0605|65 92|hemochromatosis chromosomes
P08304342A0605|16 22|report
P08304342A0605|258 260|kb
P08306356A0000|124 133|gestation
P08306356A0000|112 116|days
P08306356A0000|51 55|rats
P08306959A0278|15 37|IFN gamma inducibility
P08306959A0278|107 114|version
P08306959A0278|149 152|GAS
P08306959A0278|1 10|IFN alpha
P08307564A0233|111 113|kb
P08307564A0233|37 41|STSs
P08309726A0000|151 168|activation status
P08309726A0000|215 218|PMN
P08309726A0000|127 140|relationships
P08309726A0000|399 403|ARDS
P08309726A0000|258 269|lung injury
P08309726A0000|72 89|distress syndrome
P08309726A0000|314 323|pneumonia
P08309726A0000|202 213|neutrophils
P08309726A0000|408 417|pneumonia
P08309726A0000|34 46|pathogenesis
P08309953A0776|125 132|effects
P08309953A0776|7 14|results
P08309953A0776|140 155|characteristics
P08309975A0662|30 47|nucleus accumbens
P08309975A0662|14 22|dopamine
P08309975A0662|129 134|lever
P08309975A0662|66 71|shift
P08309975A0662|117 125|decrease
P08314163T0000|121 129|rhGM-CSF
P08314163T0000|131 145|administration
P08314163T0000|1 9|Recovery
P08316100A0586|147 156|influence
P08316100A0586|189 195|theory
P08316100A0586|16 24|Richards
P08316240A1068|165 175|expression
P08316240A1068|209 228|DNA synthesis genes
P08316240A1068|39 45|region
P08316240A1068|101 107|ACGCGT
P08316240A1068|1 9|Analysis
P08316240A1068|68 76|presence
P08317094A0778|91 93|nt
P08317094A0778|8 12|ends
P08317094A0778|157 173|initiation codon
P08317094A0778|16 19|F3R
P08317094A0778|136 138|nt
P08319907A0754|11 24|rap1t alleles
P08319907A0754|163 170|changes
P08319907A0754|113 138|telomere position effects
P08319907A0754|187 196|structure
P08321199T0000|89 102|establishment
P08321199T0000|123 132|HMR locus
P08321199T0000|71 78|factors
P08321227A0854|41 55|culture medium
P08322117A1019|121 126|cmH2O
P08322117A1019|9 16|methods
P08322117A1019|189 195|cutoff
P08322117A1019|35 43|patients
P08323294T0000|60 72|cDNA cloning
P08323294T0000|94 106|conservation
P08323294T0000|1 58|Chicken sterol carrier protein 2/sterol carrier protein x
P08324280A0098|84 94|ulceration
P08325504A0226|67 78|heat stress
P08325720A0840|210 216|fibres
P08325720A0840|77 99|muscle enzyme activity
P08325720A0840|67 75|exercise
P08325720A0840|206 207|%
P08325720A0840|119 150|3-hydroxyacyl-CoA-dehydrogenase
P08325720A0840|186 204|muscle capillaries
P08327488A0839|15 18|RNA
P08327488A0839|59 65|region
P08327488A0839|233 236|p70
P08327488A0839|32 40|deletion
P08331067T0000|147 165|bacteriophage PK1E
P08331067T0000|37 64|bacteriophage K1F tail gene
P08331067T0000|100 106|endo-N
P08332033T0000|79 93|micro-infarcts
P08332033T0000|117 135|neurotropin effect
P08332033T0000|103 113|assessment
P08332495A0408|30 42|CAT activity
P08332495A0408|182 189|DC-chol
P08332495A0408|199 208|liposomes
P08332495A0408|143 160|T7 RNA polymerase
P08332495A0408|21 26|level
P08334158A0660|28 35|protein
P08334158A0660|11 21|gene codes
P08334158A0660|50 66|cystein residues
P08334989A0070|47 57|expression
P08334989A0070|25 34|mechanism
P08334989A0070|96 107|mouse B-myb
P08334989A0070|201 214|transcription
P08336012A0632|15 23|bacteria
P08336012A0632|106 120|administration
P08336012A0632|5 11|number
P08336012A0632|69 83|BAL fluid cell
P08336698T0000|65 69|TFE3
P08336698T0000|32 39|protein
P08337828A0895|30 43|Western blots
P08337828A0895|9 16|results
P08337828A0895|93 120|Spodoptera frugiperda cells
P08340400T0000|11 18|cloning
P08340400T0000|23 33|expression
P08343041A0000|113 123|antibodies
P08343041A0000|69 90|hospital laboratories
P08343961A0000|134 139|genes
P08343961A0000|161 168|domains
P08343961A0000|100 103|bcd
P08345191A1140|46 57|amino acids
P08345191A1140|83 88|bcl-2
P08345191A1140|33 39|region
P08345191A1140|69 79|similarity
P08348919T0000|53 58|spasm
P08349104A0450|301 307|mating
P08349104A0450|146 156|expression
P08349104A0450|19 26|results
P08349104A0450|288 299|cell growth
P08349104A0450|111 115|tsf1
P08349104A0450|67 76|TSF genes
P08349104A0450|203 207|lacZ
P08349104A0450|38 49|experiments
P08349632A0679|45 46|L
P08349632A0679|129 143|PSG12 psi gene
P08349632A0679|113 121|L/N exon
P08349632A0679|1 20|Sequence comparison
P08349632A0679|51 54|L/N
P08350398A1616|193 199|chains
P08350398A1616|160 167|domains
P08350398A1616|140 145|alpha
P08350398A1616|81 90|structure
P08350398A1616|152 157|alpha
P08350398A1616|186 191|alpha
P08352268A0000|95 99|i.v.
P08352268A0000|35 42|epoetin
P08355063A0456|46 51|lobes
P08355063A0456|55 56|%
P08355680A0824|29 34|rises
P08355680A0824|131 140|increases
P08355680A0824|174 185|gamma-actin
P08355680A0824|1 5|2-AP
P08355697A0000|149 164|differentiation
P08355697A0000|79 83|PTKs
P08355697A0000|32 36|PTPs
P08355697A0000|137 143|growth
P08356792A1275|193 203|proviruses
P08356792A1275|94 98|data
P08356792A1275|113 117|p21X
P08356792A1275|16 28|p21X protein
P08356944A0589|76 100|hemoglobin concentration
P08356944A0589|33 61|sodium lauryl sulfate method
P08356944A0589|119 130|alternative
P08361754A0733|14 18|hand
P08361754A0733|98 106|proteins
P08361761A0174|390 411|kappa B binding sites
P08361761A0174|364 370|repeat
P08361761A0174|48 58|expression
P08361761A0174|258 268|expression
P08361761A0174|312 339|immunodeficiency virus type
P08361761A0174|276 292|reporter plasmid
P08361761A0174|174 178|CEFs
P08361761A0174|103 120|Sp1 binding sites
P08361761A0174|343 348|HIV-1
P08365944A1537|62 70|efficacy
P08365944A1537|145 156|association
P08365944A1537|101 112|Mitomycin-C
P08365944A1537|117 131|5-fluorouracil
P08367388T0035|29 37|syndrome
P08369887A0781|28 47|viscosity variables
P08369887A0781|76 87|RA patients
P08369887A0781|16 24|profiles
P08370119A1521|132 139|ability
P08370119A1521|58 82|transcription start site
P08370119A1521|98 106|TATA box
P08370119A1521|170 183|transcription
P08371650T0000|76 84|training
P08371650T0000|1 12|Dissipation
P08371936T0000|75 87|self ratings
P08371936T0000|52 57|study
P08373972A0335|1 5|SvO2
P08375651T0000|43 60|clathrin function
P08376796A0172|211 218|patient
P08376796A0172|242 259|diabetes mellitus
P08376796A0172|147 151|IgG1
P08376796A0172|325 331|number
P08376796A0172|345 349|self
P08376796A0172|160 164|IgG3
P08376796A0172|110 116|status
P08376796A0172|200 207|subject
P08376796A0172|71 80|attention
P08378082A1031|56 66|RB protein
P08378082A1031|7 15|findings
P08378082A1031|98 112|cell phenotype
P08380896A0938|112 131|preinitiation stage
P08380896A0938|1 9|Kinetics
P08380896A0938|17 27|inhibition
P08382300A0341|131 134|VP5
P08382300A0341|7 17|cell lines
P08382300A0341|98 108|VP5 mutant
P08382303T0000|89 108|localization signal
P08382303T0000|5 27|E1 replication protein
P08382769A0924|79 90|consequence
P08382769A0924|22 34|conservation
P08382769A0924|156 169|SRP54 protein
P08383129A0776|194 207|T-lymphocytes
P08383129A0776|106 114|peptides
P08383129A0776|215 227|cell surface
P08383217A0357|173 177|VP16
P08383217A0357|48 53|Bel-1
P08383217A0357|152 169|activation domain
P08383323A0000|23 30|T cells
P08383526A0591|95 99|exon
P08383526A0591|38 47|structure
P08383850A0206|44 52|beta-FNA
P08383850A0206|58 69|naltrindole
P08383850A0206|23 42|beta-funaltrexamine
P08383850A0206|71 74|NTI
P08385131A0000|74 83|effectors
P08385131A0000|63 70|variety
P08385131A0000|25 33|receptor
P08385131A0000|35 45|alpha 2AAR
P08385581A0126|74 80|REC114
P08385581A0126|21 27|REC114
P08385581A0126|103 121|recombination gene
P08386280T0000|44 62|Rous sarcoma virus
P08386280T0000|77 83|repeat
P08386280T0000|17 36|C/EBP binding sites
P08386318A1102|14 18|IL-6
P08386318A1102|91 107|protein kinase C
P08386318A1102|130 136|kinase
P08386318A1102|202 212|C/EBP beta
P08386318A1102|184 189|Raf-1
P08386592A0089|167 172|Elk-1
P08386592A0089|110 117|complex
P08386592A0089|202 212|activation
P08386592A0089|86 94|mobility
P08386592A0089|1 26|Growth factor stimulation
P08387155A1248|150 155|assay
P08387155A1248|126 130|topo
P08387155A1248|18 24|effect
P08387662A0302|134 143|ibuprofen
P08387662A0302|148 150|mg
P08387662A0302|126 128|mg
P08387662A0302|197 206|intensity
P08387662A0302|115 122|codeine
P08387994A0980|91 102|integration
P08387994A0980|58 66|promoter
P08388510A0891|61 70|UL28 gene
P08388510A0891|13 44|cell surface immunofluorescence
P08388510A0891|111 124|glycoproteins
P08388510A0891|152 157|cells
P08388600A0000|65 72|stature
P08388600A0000|1 19|Estrogen treatment
P08389365A1344|88 89|d
P08389365A1344|6 17|observation
P08389365A1344|115 125|correction
P08390120A0785|43 51|question
P08390120A0785|80 87|options
P08390747A0586|106 115|syncytial
P08390747A0586|131 141|phenotypes
P08390747A0586|66 81|hep syn gB gene
P08390747A0586|49 55|region
P08391534A0828|1 8|Elledge
P08392221A0449|28 37|procedure
P08392221A0449|245 266|O-desmethylangolensin
P08392221A0449|220 233|enterolactone
P08392221A0449|74 93|estrogen conjugates
P08392221A0449|174 183|compounds
P08392221A0449|235 243|daidzein
P08393143A1281|5 15|Sp1 region
P08393143A1281|81 91|tat factor
P08394255A0000|160 171|kb fragment
P08394255A0000|179 182|rat
P08394255A0000|20 32|cDNA library
P08394255A0000|48 61|pcDNA1 vector
P08394862A0565|15 23|patients
P08394862A0565|57 64|patient
P08394862A0565|49 54|group
P08395004A0558|75 92|SPT2/SIN1 protein
P08395004A0558|9 21|localization
P08395014A1364|30 34|BCK2
P08395014A1364|135 139|PPZ2
P08395014A1364|79 93|BCK2 functions
P08395014A1364|126 130|PPZ1
P08395681A0388|125 139|reading frames
P08395681A0388|25 36|differences
P08395681A0388|55 59|HPV5
P08395681A0388|117 119|E7
P08395681A0388|281 305|complementation activity
P08395681A0388|64 72|HPV8 E7s
P08396261A0388|389 399|RI protein
P08396261A0388|487 491|BL21
P08396261A0388|458 467|phenotype
P08396261A0388|115 124|phenotype
P08396261A0388|222 233|growth rate
P08396261A0388|492 495|DE3
P08396261A0388|282 286|cAMP
P08396261A0388|9 14|lines
P08396261A0388|370 377|RI cDNA
P08396261A0388|338 345|RI cDNA
P08396261A0388|141 145|cAMP
P08396667T0000|45 53|patterns
P08396667T0000|64 72|lymphoma
P08396667T0000|1 8|BCR-ABL
P08396749A1112a|63 69|mmol/l
P08396749A1112a|157 162|mg/dl
P08396749A1112a|87 98|simvastatin
P08396749A1112a|1 16|LDL cholesterol
P08396913A1379|88 98|expression
P08396913A1379|40 44|part
P08399970T0000|7 34|bioencapsulation technology
P08400928A0318|166 169|arm
P08400928A0318|106 149|levodopa/decarboxylase inhibitor/selegiline
P08400928A0318|53 90|levodopa/dopa decarboxylase inhibitor
P08400928A0318|98 101|arm
P08400928A0318|16 24|Patients
P08401614A0187|30 36|family
P08401614A0187|40 45|genes
P08401614A0187|8 12|bean
P08401614A0187|83 87|PAL2
P08401614A0187|152 162|mRNA level
P08403804A0754|132 143|cholesterol
P08403804A0754|58 67|magnesium
P08403804A0754|202 206|dose
P08403804A0754|155 171|serum creatinine
P08406004A0691|45 49|PU.1
P08406004A0691|182 190|sequence
P08406004A0691|24 43|transfection assays
P08406004A0691|66 85|reporter constructs
P08406419A0155|150 152|MA
P08406419A0155|93 100|testing
P08406419A0155|54 71|hepatitis C virus
P08406419A0155|102 106|RIBA
P08407784A0850|22 26|recJ
P08407784A0850|97 107|phenotypes
P08408825A0000|90 101|La antigens
P08408825A0000|83 85|Ro
P08409593A0357|151 155|time
P08409593A0357|131 139|activity
P08409593A0357|53 61|activity
P08409593A0357|19 22|MNZ
P08410097A0356|193 210|plasma fibrinogen
P08410097A0356|95 96|p
P08410097A0356|244 254|covariates
P08410097A0356|59 86|regression coefficient beta
P08410097A0356|153 154|p
P08411276A0302|212 215|age
P08411276A0302|321 322|C
P08411276A0302|251 257|Trauma
P08411276A0302|55 64|mechanism
P08411276A0302|222 247|Severity Characterization
P08411276A0302|85 91|coding
P08411276A0302|162 176|blood pressure
P08411276A0302|3 10|patient
P08411276A0302|68 74|injury
P08412620A0688|78 82|virB
P08412620A0688|145 153|promoter
P08412620A0688|3 9|region
P08412665A0000|72 82|Klebsiella
P08412665A0000|147 156|repressor
P08412665A0000|158 162|ScrR
P08412665A0000|20 26|pUR400
P08413186A1199|5 14|Ntl1 gene
P08413209A0159|72 92|motif characteristic
P08413209A0159|20 25|third
P08413223A0847|15 21|copies
P08413223A0847|29 54|IL-1 beta NF-kappa B site
P08413223A0847|93 98|virus
P08413223A0847|102 110|promoter
P08413260A1437|107 116|machinery
P08413260A1437|124 132|G2 phase
P08413260A1437|65 74|component
P08413291A1473|31 54|rat TnI-CAT fusion gene
P08413291A1473|12 16|mice
P08414502A0244|121 134|transcription
P08414502A0244|21 31|hypothesis
P08414502A0244|103 106|DNA
P08415643A0555|104 111|mitosis
P08415643A0555|41 47|intron
P08415643A0555|5 12|E1 gene
P08415643A0555|64 68|RCC1
P08416952A0956|11 27|labeling studies
P08416952A0956|66 72|nmt72p
P08416952A0956|233 251|protein substrates
P08416952A0956|49 62|co-expression
P08416952A0956|186 195|reduction
P08417117A0592|10 14|mRNA
P08417331A0745|180 184|Tup1
P08417331A0745|127 137|transducin
P08417331A0745|5 13|sequence
P08417331A0745|101 115|G beta subunit
P08417331A0745|50 57|protein
P08418183A0000|269 273|wife
P08418183A0000|265 266|H
P08418183A0000|296 297|H
P08418183A0000|54 66|transmission
P08418183A0000|115 121|HTLV-I
P08418183A0000|288 289|W
P08418183A0000|160 181|Miyazaki Cohort Study
P08418183A0000|309 310|W
P08418183A0000|306 307|H
P08419333A0126|40 57|DNA repair enzyme
P08419333A0126|102 107|clone
P08419376A0357|67 78|amino acids
P08419376A0357|48 59|polypeptide
P08419376A0357|85 88|kDa
P08420571A1880|18 23|PACE4
P08421295A0365|131 145|LexA repressor
P08421295A0365|6 21|fusion proteins
P08421295A0365|99 123|4ACAG consensus sequence
P08421823A1041|128 137|condition
P08421823A1041|1 12|CONCLUSIONS
P08421910A0599|60 63|p30
P08421910A0599|121 128|TAR RNA
P08421910A0599|28 37|complexes
P08421910A0599|53 58|TRBPs
P08421910A0599|70 73|p46
P08423831A0523|74 80|issues
P08423831A0523|96 104|diseases
P08423831A0523|140 144|sets
P08425221A0000|62 86|B cell progenitor kinase
P08425221A0000|129 138|B lineage
P08425221A0000|33 48|tyrosine kinase
P08428722A1123|90 115|blood urea nitrogen level
P08428722A1123|227 232|score
P08428722A1123|80 88|survival
P08428722A1123|117 155|serum aspartate aminotransferase level
P08428722A1123|35 44|variables
P08428907A0653|109 112|RNA
P08428952A0399|120 130|expression
P08428952A0399|43 48|types
P08428952A0399|178 185|tissues
P08428952A0399|68 73|cells
P08428953A1718|148 153|cells
P08428953A1718|124 132|colonies
P08428953A1718|258 266|colonies
P08428953A1718|167 176|L-plastin
P08428953A1718|312 321|frequency
P08428953A1718|402 413|fibroblasts
P08428953A1718|6 14|promoter
P08428953A1718|99 108|frequency
P08429019A0735|160 165|bases
P08429019A0735|146 152|shares
P08429019A0735|5 10|DNase
P08429019A0735|115 122|epsilon
P08429019A0735|136 138|bp
P08429020A0495|25 30|exons
P08429020A0495|96 109|reading frame
P08429020A0495|39 46|introns
P08429020A0495|71 74|DNA
P08430087A0467|107 126|beta gamma activity
P08430087A0467|178 187|fractions
P08430087A0467|97 103|assays
P08430087A0467|49 61|gamma chains
P08430095A0913|42 51|component
P08430095A0913|7 11|data
P08430095A0913|103 119|snRNA maturation
P08432137A0000|146 154|lysozyme
P08432137A0000|212 217|cases
P08432137A0000|156 160|PLYS
P08432137A0000|250 253|IFN
P08432137A0000|259 264|cases
P08432137A0000|17 27|parameters
P08432137A0000|130 135|cases
P08432137A0000|232 248|interferon gamma
P08432137A0000|36 55|adenosine deaminase
P08432137A0000|342 348|others
P08432696A1117|144 155|cell growth
P08432696A1117|98 114|aminopeptidase N
P08432696A1117|69 80|proteinases
P08432696A1117|51 59|deletion
P08435755A1078|14 17|BSS
P08435755A1078|180 186|values
P08435755A1078|131 138|stage-3
P08435755A1078|42 50|kindling
P08435755A1078|6 9|ADD
P08435755A1078|33 38|stage
P08435885A0787|78 108|thyroid hormone concentrations
P08435885A0787|22 33|correlation
P08437737A0100|28 37|standards
P08437737A0100|1 16|Naval personnel
P08438584T0000|5 13|activity
P08438584T0000|102 121|C1-C2 gene products
P08439597A0000|12 25|communication
P08439597A0000|67 85|enzyme immunoassay
P08439597A0000|168 179|thyrotropin
P08440238T0000|31 41|adenovirus
P08440238T0000|195 208|tumorigenesis
P08440238T0000|148 158|modulation
P08440238T0000|179 193|transformation
P08440238T0000|3 9|region
P08440238T0000|102 116|phosphoprotein
P08440720A1404|100 105|level
P08440720A1404|1 11|Constructs
P08441394A1297|12 18|PC-PLC
P08441394A1297|78 91|transcription
P08441394A1297|161 170|PKC-delta
P08441394A1297|39 66|signal transduction pathway
P08441423A0145|151 161|conditions
P08441423A0145|114 130|GCN4 translation
P08441423A0145|49 59|GCD7 genes
P08442384A0430|96 100|uORF
P08442384A0430|116 122|leader
P08442384A0430|51 62|amino acids
P08443122A0657|88 91|PMA
P08443122A0657|4 12|contrast
P08443122A0657|16 23|T cells
P08443340A0522|123 137|glucanase gene
P08443340A0522|145 163|beta-glucuronidase
P08443340A0522|217 227|constructs
P08443340A0522|81 97|promoter regions
P08443340A0522|170 183|reporter gene
P08444184A0245|1 10|Sudomoina
P08444345A0403|88 89|%
P08444345A0403|109 121|EFIA/DbpB/YB
P08444345A0403|27 37|amino acid
P08444345A0403|161 165|DbpB
P08444345A0403|20 24|EFIA
P08445655A1009|44 56|yeast genome
P08445655A1009|145 154|mutations
P08445655A1009|1 13|Localization
P08445792A0469|43 48|forms
P08445792A0469|143 150|species
P08445792A0469|1 5|Type
P08446579A1210|15 23|fos gene
P08446579A1210|79 96|estrogen addition
P08449133A0578|73 82|T3 tumors
P08449133A0578|59 68|T2 tumors
P08449133A0578|1 15|Endosonography
P08449978A0000|150 157|changes
P08449978A0000|133 138|Cdc28
P08449978A0000|161 169|activity
P08449978A0000|117 131|protein kinase
P08449978A0000|1 9|Analysis
P08450015A0175|149 179|n-propyl carbamate derivatives
P08450015A0175|94 116|solid-phase extraction
P08450015A0175|5 11|method
P08450015A0175|70 78|standard
P08451331T0000|72 84|hypothalamus
P08451331T0000|113 123|aggression
P08451331T0000|1 9|Pathways
P08453950A0498|104 107|min
P08453950A0498|11 28|seizure induction
P08453950A0498|144 145|P
P08453950A0498|141 142|h
P08454591A0692|107 121|CAAT sequences
P08454591A0692|131 155|transcription start site
P08454591A0692|1 11|Sequencing
P08454858A0285|72 83|amino acids
P08454858A0285|1 9|Ig-alpha
P08454858A0285|51 60|structure
P08455611A0000|164 168|zeta
P08455611A0000|94 106|alpha globin
P08455611A0000|145 147|kb
P08455611A0000|70 85|globin promoter
P08455611A0000|171 182|globin gene
P08455623A0630|182 188|strain
P08455623A0630|36 48|23S pre-rRNA
P08455623A0630|169 174|snr10
P08455623A0630|68 75|species
P08456378A0134|26 37|feasibility
P08456378A0134|96 105|technique
P08457205A0240|62 69|protein
P08457205A0240|160 167|G alpha
P08457205A0240|145 152|G alpha
P08457205A0240|170 175|cDNAs
P08458660A0855|1 9|Air lead
P08458906A0827|3 15|micrograms/l
P08459465A0257|284 299|activity factor
P08459465A0257|46 65|energy expenditures
P08459465A0257|96 107|calorimetry
P08459465A0257|18 23|study
P08459465A0257|187 195|equation
P08460346A0350|72 77|study
P08461946A0386|88 102|split function
P08461946A0386|110 118|patients
P08461946A0386|71 80|t1/2 time
P08463284A1531|94 103|stability
P08463284A1531|9 13|beta
P08463284A1531|76 82|lamina
P08463485T0000|63 79|oxytocin release
P08463485T0000|1 8|Effects
P08464056A0510|245 256|chromosomes
P08464056A0510|179 204|field gel electrophoresis
P08464056A0510|50 77|FAX-ZFP transcription units
P08464056A0510|34 46|organization
P08466864A0878|243 260|Sp1 binding sites
P08466864A0878|57 66|sequences
P08466864A0878|187 195|TGF-beta
P08466864A0878|12 20|analyses
P08466864A0878|202 220|PMA responsiveness
P08466864A0878|139 162|element binding protein
P08468475A1280|301 309|affinity
P08468475A1280|179 190|IL-2R alpha
P08468475A1280|261 274|alpha-subunit
P08468475A1280|80 97|IL-2R alpha chain
P08468475A1280|221 244|F42A-IL-2R beta complex
P08470021A0195|125 136|Cardiologia
P08470021A0195|54 71|Trypanosoma cruzi
P08470021A0195|138 152|Ignacio Chavez
P08470021A0195|17 27|prevalence
P08471241T0000|58 62|milk
P08471241T0000|16 25|synthesis
P08471796A1654|31 36|model
P08471796A1654|86 100|A. caulinodans
P08473731A0149|91 98|complex
P08473731A0149|26 35|B29 genes
P08473731A0149|115 122|B cells
P08473731A0149|17 21|mb-1
P08474438A0000|89 103|RNA polymerase
P08474438A0000|270 284|mRNA transport
P08474438A0000|232 240|splicing
P08474438A0000|3 10|variety
P08474456A1041|167 178|D' activity
P08474456A1041|131 150|LyF-1 binding sites
P08474456A1041|81 87|region
P08475104A0341|29 45|promoter element
P08475104A0341|189 195|target
P08475104A0341|116 132|thymidine kinase
P08475104A0341|139 147|promoter
P08476854A0097|45 53|extracts
P08476854A0097|104 106|P1
P08476854A0097|27 36|rat liver
P08476854A0097|127 149|base pair DNA fragment
P08476854A0097|1 6|DNase
P08481004A0321|35 47|endonuclease
P08483412A0000|148 160|NifA protein
P08483412A0000|5 9|nifJ
P08483412A0000|32 42|Klebsiella
P08484514A1536|52 74|baseline vein diameter
P08484891A0000|225 233|memories
P08484891A0000|176 184|circuits
P08484891A0000|141 149|evidence
P08484891A0000|103 110|changes
P08486035T0000|48 56|Ligaclip
P08486035T0000|16 40|patent ductus arteriosus
P08486705A0181|29 34|eIF-5
P08486705A0181|137 150|eIF-5 protein
P08490002A0620|92 98|breads
P08490002A0620|34 42|polymers
P08491383A0154|48 51|DNA
P08491683A0651|29 37|patients
P08491683A0651|96 110|adenocarcinoma
P08492290A0306|90 109|stability constants
P08492290A0306|111 119|log beta
P08492290A0306|32 38|method
P08496157A0000|89 103|carboxyl tails
P08496157A0000|5 15|bcl-2 gene
P08496185A0484|60 62|S.
P08496185A0484|130 141|nucleotides
P08496185A0484|92 96|adk1
P08496185A0484|69 90|adenylate kinase gene
P08496599A0310|95 107|mRNA species
P08496599A0310|6 12|result
P08496848A0692|110 124|SE counterpart
P08497248A0000|88 107|c-fms protooncogene
P08497248A0000|23 31|receptor
P08497248A0000|66 72|factor
P08497248A0000|169 179|phagocytes
P08497269A0999|74 83|ribosomes
P08497269A0999|106 115|functions
P08497269A0999|37 48|possibility
P08497269A0999|188 195|process
P08497269A0999|87 101|tRNA molecules
P08497269A0999|119 130|conjunction
P08497280A0266|135 153|SWI4 transcription
P08497280A0266|25 29|SWI4
P08497280A0266|99 102|cis
P08497280T0000|53 71|SWI4 transcription
P08499376A0000|11 14|PRK
P08499376A0000|50 64|predictability
P08499916A0000|76 90|candidate gene
P08499916A0000|32 49|type VII collagen
P08500938A0408|74 82|excision
P08500938A0408|106 114|surfaces
P08500938A0408|18 23|grade
P08501678A0498|10 19|knowledge
P08501678A0498|115 126|Hib disease
P08504707A0376|15 24|pathology
P08504707A0376|40 48|features
P08504707A0376|59 73|manifestations
P08504707A0376|5 13|etiology
P08504932A0123|123 139|site specificity
P08504932A0123|64 77|GATA proteins
P08505075A0236|107 108|%
P08505075A0236|53 73|S. bareilly serotype
P08505075A0236|32 33|%
P08505075A0236|137 138|%
P08505340T0000|107 111|gene
P08505340T0000|115 130|granulosa cells
P08505340T0000|1 17|Characterization
P08505605A0461|126 133|healing
P08505605A0461|64 71|patient
P08505605A0461|116 122|extent
P08505605A0461|1 24|Patient characteristics
P08506384A0146|89 112|GDP-GTP exchange factor
P08506384A0146|77 83|eIF-2B
P08506384A0146|21 36|phosphorylation
P08508774A0242|28 31|Lrp
P08508774A0242|122 125|DNA
P08508774A0242|37 40|set
P08508774A0242|1 9|Analysis
P08508861A0294|60 66|groups
P08508861A0294|129 146|balloon inflation
P08508861A0294|5 13|patients
P08508861A0294|87 93|change
P08509333A0843|10 17|protein
P08509333A0843|144 148|FtsN
P08509333A0843|155 171|membrane protein
P08509419A0785|90 101|suppression
P08509419A0785|111 116|yeast
P08509419A0785|20 27|protein
P08510320A0000|13 20|strains
P08510320A0000|149 154|total
P08510320A0000|203 206|ABK
P08510320A0000|138 142|MICs
P08510647A1347|60 69|variation
P08510647A1347|10 14|Beg1
P08510647A1347|1 5|Beg2
P08511994A0000|37 42|carps
P08511994A0000|116 130|micrograms/dm3
P08513025A0000|135 143|readings
P08513025A0000|130 133|TcB
P08513025A0000|16 22|effect
P08513025A0000|84 99|bilirubin level
P08514766A0732|123 131|p21 rac1
P08514766A0732|66 77|n-chimaerin
P08514766A0732|99 106|protein
P08515776A0971|22 28|domain
P08516308A0669|15 18|RAD
P08516308A0669|110 115|cells
P08516308A0669|65 70|cells
P08517737A0889|92 105|water systems
P08517737A0889|127 138|populations
P08517737A0889|142 150|bacteria
P08519621A0150|183 191|bacteria
P08519621A0150|199 206|pharynx
P08519621A0150|6 16|conclusion
P08519621A0150|33 45|observations
P08520646A0000|58 68|mechanisms
P08520646A0000|96 105|fertility
P08520646A0000|84 92|decrease
P08521717A0126|242 252|LNG-IUD-20
P08521717A0126|229 238|insertion
P08521717A0126|52 61|antiserum
P08521717A0126|65 71|Factor
P08521717A0126|21 29|reaction
P08522175A0306|30 35|BTF3b
P08522175A0306|241 247|Nature
P08522175A0306|129 136|complex
P08522175A0306|64 76|beta subunit
P08522175A0306|1 6|Egd1p
P08522511A1578|125 127|F.
P08522511A1578|142 146|pisi
P08522511A1578|81 104|beta-glucuronidase gene
P08522511A1578|17 24|regions
P08523031A0737|61 65|time
P08523031A0737|127 137|recurrence
P08523031A0737|116 122|stroke
P08523566A1106|14 23|detergent
P08523566A1106|63 74|interaction
P08523566A1106|111 117|nature
P08524229T0000|41 84|bisphosphate carboxylase small-subunit mRNA
P08524229T0000|86 90|SRS4
P08524241A0212|73 82|IME1-IME2
P08524241A0212|99 106|cascade
P08524267A1022|62 84|prothymosin alpha gene
P08524267A1022|166 169|myc
P08524267A1022|123 133|repertoire
P08524267A1022|212 223|myc mutants
P08524284A0309|62 71|PTF gamma
P08524284A0309|182 195|HeLa extracts
P08524284A0309|130 140|antibodies
P08524284A0309|33 43|expression
P08524294A0652|11 15|gene
P08525186A0288|44 49|Chile
P08525186A0288|145 155|odds ratio
P08525186A0288|67 73|health
P08525186A0288|1 9|Refugees
P08528479A0000|62 71|responses
P08528479A0000|116 124|patients
P08528479A0000|102 112|population
P08529098A0549|147 154|domains
P08529098A0549|214 218|site
P08529098A0549|156 160|exon
P08529098A0549|84 92|proteins
P08529098A0549|42 43|%
P08529098A0549|64 69|yeast
P08529098A0549|103 107|SMF2
P08529654A0589|59 69|% identity
P08529654A0589|139 144|Cyp-1
P08530105A0308|13 19|region
P08530105A0308|109 117|patients
P08530105A0308|158 166|patients
P08530105A0308|34 67|Langer-Giedion syndrome deletions
P08530149A0689|15 24|promoters
P08530149A0689|110 113|TCA
P08530149A0689|38 43|c-myc
P08530149A0689|117 122|YYYNY
P08530149A0689|85 94|initiator
P08530345A0880|132 135|DR1
P08530345A0880|37 45|mutation
P08530345A0880|83 93|truncation
P08530345A0880|217 241|peroxisome proliferators
P08530345A0880|1 22|Transfection analyses
P08530384A0559|95 98|DNA
P08530384A0559|248 251|DNA
P08530384A0559|193 195|.1
P08530384A0559|79 91|Oct proteins
P08530384A0559|231 242|interaction
P08530384A0559|207 211|Oct2
P08530432A0093|26 34|proteins
P08530432A0093|58 65|domains
P08530432A0093|96 106|repression
P08531373A0470|90 93|SjS
P08531373A0470|68 86|skin manifestation
P08532516A0000|27 37|properties
P08532516A0000|68 81|fission yeast
P08532967A0364|73 80|therapy
P08533473A0375|98 111|EST sequences
P08534217A0402|75 78|FVC
P08534217A0402|83 94|FEV1 values
P08534217A0402|115 129|Viskovo region
P08534848A0188a|11 22|NR isoforms
P08534855A0000|63 78|acid desaturase
P08534855A0000|5 26|Arabidopsis FAD7 gene
P08534855A0000|141 146|acids
P08535537A0000|42 53|backgrounds
P08535537A0000|3 9|survey
P08537388A0825|193 210|promoter activity
P08537388A0825|66 74|promoter
P08537388A0825|117 125|activity
P08538052A0000|298 306|peptides
P08538052A0000|266 286|amino acid sequences
P08538052A0000|21 31|cDNA clone
P08538052A0000|49 69|amino acids residues
P08538052A0000|131 143|cDNA library
P08538052A0000|412 422|c-myc gene
P08538483A0207|181 187|months
P08538483A0207|47 54|changes
P08538483A0207|209 220|leiomyomata
P08538483A0207|58 67|bone mass
P08538483A0207|142 147|women
P08538483A0207|69 74|total
P08541499A0306|93 108|tobacco operons
P08542026A0792|121 131|regulation
P08542026A0792|214 218|size
P08542026A0792|158 161|RCA
P08542026A0792|135 156|complement activation
P08542026A0792|40 50|complement
P08542026A0792|98 102|gene
P08542026A0792|68 85|consensus repeats
P08542746T0000|18 27|guideline
P08542746T0000|35 45|facilities
P08543275A0130|44 49|burst
P08543275A0130|247 256|host fish
P08543275A0130|53 71|pseudoterranovosis
P08543275A0130|18 31|investigation
P08543810A0000|167 170|set
P08543810A0000|58 70|coelomocytes
P08543810A0000|141 153|cDNA library
P08543810A0000|184 197|sequence tags
P08545502A0914|37 40|PET
P08547205A1060|104 112|efficacy
P08547205A1060|160 170|infarction
P08547205A1060|5 12|results
P08547205A1060|184 188|dogs
P08549706T0000|76 83|Iceland
P08550425A1401|60 63|POR
P08550425A1401|82 90|archaeon
P08550425A1401|118 128|% identity
P08550461A0284|1 7|Cheung
P08550467A0863|151 155|scrB
P08550467A0863|172 182|start site
P08550467A0863|18 28|regulation
P08550467A0863|70 72|bp
P08550476A0610|107 115|sequence
P08550476A0610|198 202|EpiQ
P08550476A0610|131 148|EpiQ binding site
P08550476A0610|156 169|epiA promoter
P08551572A0155|150 159|MDCC-CU91
P08551572A0155|131 141|MSB1 cells
P08551572A0155|93 103|pp38 mRNAs
P08551572A0155|207 212|cells
P08551572A0155|50 80|translation initiation regions
P08552042A1497|28 48|promoter methylation
P08552042A1497|226 238|reactivation
P08552042A1497|214 221|meiosis
P08552042A1497|158 169|mRNA levels
P08552042A1497|86 93|borders
P08552042A1497|184 189|state
P08552082A0480|120 125|yeast
P08552082A0480|96 104|proteins
P08552082A0480|38 44|region
P08552092A1678|224 230|intron
P08552092A1678|110 122|footprinting
P08552092A1678|4 12|addition
P08552092A1678|16 31|protein binding
P08552092A1678|238 247|rep3 gene
P08552095A0686|28 32|role
P08552095A0686|36 49|transcription
P08552095A1115|89 100|yeast genes
P08552095A1115|64 74|regulation
P08552387A0000|120 144|chromosome translocation
P08552387A0000|72 78|tissue
P08552387A0000|41 49|melanoma
P08552387A0000|111 112|t
P08552387A0000|154 160|fusion
P08552670A0665|39 44|sites
P08552670A0665|87 90|A.T
P08552670A0665|68 84|DNA polymer poly
P08553580A0102|75 87|FIV isolates
P08553580A0102|47 55|function
P08554540A1480|7 14|regions
P08555076A0333|91 100|infection
P08555076A0333|11 25|Amphotericin-B
P08555076A0333|40 48|patients
P08555076A0333|69 76|mycosis
P08555289A0207|44 52|medicine
P08555289A0207|57 67|geophysics
P08555498A0427|88 99|gene family
P08555498A0427|133 153|vertebrate evolution
P08555498A0427|7 12|LAF-4
P08555753A0591|41 55|Wisconsin Card
P08555753A0591|125 137|neuroimaging
P08555753A0591|64 68|Test
P08555753A0591|153 158|lobes
P08558187A0403|1 7|Cycles
P08561893A0100|123 130|studies
P08561893A0100|229 243|family members
P08561893A0100|52 59|factors
P08561893A0100|139 154|factor function
P08562688A0968|90 98|sequence
P08562688A0968|38 47|sequences
P08562688A0968|1 9|Upstream
P08564488A1359|40 44|risk
P08565330A1783|75 82|control
P08565330A1783|56 63|control
P08566747A0756|40 50|activation
P08566747A0756|127 134|ability
P08566747A0756|54 67|transcription
P08566747A0756|155 158|SBF
P08566747A0756|171 184|transcription
P08566751A0788|22 29|gHoxb-1
P08566751A0788|71 78|context
P08566756A0752|63 81|SF3a/SF3b subunits
P08566756A0752|6 14|analysis
P08566756A0752|101 109|pre-mRNA
P08567556A0000|149 155|diving
P08567556A0000|215 227|measurements
P08567556A0000|55 61|stores
P08567556A0000|14 25|consumption
P08567556A0000|231 241|heart rate
P08567556A0000|65 77|seal muscles
P08567556A0000|307 322|diving response
P08567556A0000|103 115|seal muscles
P08567717T0000|91 101|checkpoint
P08569443A0123|120 131|consequence
P08569443A0123|165 171|volume
P08569443A0123|193 204|compartment
P08569443A0123|82 84|T1
P08569443A0123|20 25|study
P08569684A0000|134 150|protein kinase C
P08569684A0000|285 310|fungus Trichoderma reesei
P08569684A0000|63 91|amino acid sequence segments
P08569684A0000|157 165|proteins
P08569684A0000|1 17|Oligonucleotides
P08569684A0000|152 155|PKC
P08572616A0000|10 14|loss
P08573637A0434|126 132|fluids
P08573637A0434|98 110|formulations
P08573637A0434|68 79|paracetamol
P08574583A0658|125 133|activity
P08574583A0658|5 16|Clb5 kinase
P08574583A0658|87 92|cells
P08575614A0264|74 81|protein
P08575614A0264|47 56|phenotype
P08575614A0264|141 151|repression
P08575614A0264|117 139|postreplication repair
P08575614A0264|85 88|DNA
P08575754T0000|56 68|localization
P08575754T0000|95 104|inhibitor
P08575754T0000|127 134|kinases
P08576131A0151|151 156|USF2b
P08576131A0151|25 32|cloning
P08576131A0151|48 64|characterization
P08576131A0151|118 123|USF2a
P08576179A0126|30 35|dimer
P08576179A0126|141 169|polypeptide chain initiation
P08576179A0126|117 128|cIF-2 alpha
P08576262A0160|125 128|G16
P08576262A0160|97 107|G proteins
P08576262A0160|118 120|Gi
P08580083A0259|104 125|Fyn-expression vector
P08580083A0259|56 66|expression
P08580083A0259|76 85|promoters
P08580083A0259|174 212|chloramphenicol acetyltransferase gene
P08580083A0259|257 263|Jurkat
P08581174A0472|128 132|half
P08581174A0472|83 92|mutations
P08581174A0472|102 105|map
P08582633T0000|73 83|repression
P08582633T0000|26 35|silencing
P08582633T0000|1 12|Suppressors
P08582633T0000|102 113|cell growth
P08583846A0121|8 18|literature
P08583846A0121|38 56|beta-2 transferrin
P08584026A0115|25 34|promoters
P08584026A0115|5 16|hIGF-I gene
P08584074A0000|12 20|patients
P08584074A0000|177 199|Bethel Epilepsy Center
P08584074A0000|59 64|years
P08584074A0000|37 42|years
P08585324A0467|46 51|Smith
P08585639T0000|14 22|exposure
P08585639T0000|92 105|risk analysis
P08585957A0101|30 50|transcription factor
P08585957A0101|198 205|AT-hook
P08585957A0101|67 75|homology
P08585957A0101|6 10|gene
P08585957A0101|175 187|gene product
P08585957A0101|139 146|domains
P08586643A0951|77 80|ATP
P08586643A0951|52 71|phosphoryl transfer
P08587075T0000|12 26|microaneurysms
P08587075T0000|67 87|polyarteritis nodosa
P08589315A1029|88 89|%
P08589315A1029|182 190|patients
P08589315A1029|42 50|survival
P08589315A1029|39 40|%
P08589315A1029|200 201|%
P08589315A1029|235 243|patients
P08589358A0841|10 17|regimen
P08589358A0841|92 109|blood transfusion
P08589358A0841|65 69|need
P08589358A0841|153 163|milligrams
P08590465A0773|120 137|URA2 gene product
P08590465A0773|5 17|organization
P08592590A0822|7 15|findings
P08592590A0822|33 55|haemodialysis patients
P08592590A0822|184 192|patients
P08592590A0822|170 180|proportion
P08593813A0967|67 76|Sp1 mRNAs
P08593813A0967|141 151|transcript
P08595184A0407|133 137|LFPs
P08595184A0407|6 11|study
P08595184A0407|115 131|field potentials
P08595627A1513|210 212|VF
P08595627A1513|129 141|KATP opening
P08595627A1513|6 13|opening
P08595627A1513|173 175|VF
P08595627A1513|34 44|inhibition
P08595836T0000|59 72|glass ionomer
P08595836T0000|85 94|materials
P08597108A0642|26 34|response
P08597108A0642|66 73|average
P08597108A0642|1 6|QBMDs
P08597596A0135|5 9|gene
P08598051T0000|31 50|schizosaccharomyces
P08598051T0000|57 61|gene
P08598051T0000|112 119|domains
P08598449A0784|122 146|tyrosine phosphorylation
P08598449A0784|213 216|vav
P08598449A0784|20 29|signaling
P08598449A0784|282 289|changes
P08598449A0784|163 191|protein tyrosine kinases lyn
P08598449A0784|308 322|concentrations
P08598449A0784|68 81|B lymphocytes
P08599946A0999|110 111|s
P08599946A0999|5 13|evidence
P08599946A0999|64 89|ribonucleoprotein complex
P08599946A0999|138 150|interactions
P08600048T0000|124 128|case
P08600048T0000|111 116|study
P08601284A0000|104 112|sequence
P08601284A0000|135 150|complementarity
P08601284A0000|56 64|pre-rRNA
P08601284A0000|37 40|ETS
P08601616A0726|134 150|spindle assembly
P08601616A0726|24 36|pds1 mutants
P08601616A0726|6 20|spindle defect
P08602169A0484|123 132|MAT alpha
P08602169A0484|111 115|CPDs
P08602169A0484|67 71|site
P08602169A0484|100 107|removal
P08602169A0484|137 151|HML alpha loci
P08603921A1346|126 130|cell
P08603921A1346|86 92|growth
P08604338A0885|210 227|complex formation
P08604338A0885|95 98|SRF
P08604338A0885|59 62|SRE
P08604338A0885|173 176|DNA
P08604338A0885|156 167|interaction
P08604338A0885|84 91|absence
P08605302A1770|147 153|intron
P08605302A1770|264 269|assay
P08605302A1770|213 235|CatA promoter activity
P08605302A1770|1 16|DNA methylation
P08605326A0772|13 24|cDNA clones
P08605931A0777|43 49|clones
P08605931A0777|141 152|U1A protein
P08608126A0811|164 168|acid
P08608126A0811|28 32|acid
P08608126A0811|213 219|lipids
P08608126A0811|112 113|K
P08608126A0811|114 115|d
P08608126A0811|48 64|binding affinity
P08608447A0806|105 113|splicing
P08608447A0806|81 86|place
P08610272A0265|105 113|duration
P08610272A0265|271 278|disease
P08610272A0265|177 195|response modifiers
P08610272A0265|65 73|approach
P08610272A0265|117 141|maintenance chemotherapy
P08610272A0265|84 91|control
P08610582A0150|56 64|CT scans
P08610582A0150|113 115|T.
P08612852A0553|120 128|controls
P08612852A0553|95 103|patients
P08612852A0553|1 8|RESULTS
P08614403A0989|30 58|GAL4-REV-erbA alpha chimeras
P08614403A0989|181 190|8-Br-cAMP
P08614403A0989|122 135|transcription
P08614403A0989|77 79|AB
P08614403A0989|81 87|region
P08614403A0989|169 177|presence
P08615012A0627|91 98|enzymes
P08615012A0627|57 65|increase
P08615012A0627|25 33|ie1 gene
P08615183T0000|27 38|pallidotomy
P08615183T0000|54 61|disease
P08617216A0584|74 78|GrpE
P08617216A0584|111 121|luciferase
P08617216A0584|65 72|protein
P08617238A0334|105 119|p38 MAP kinase
P08617238A0334|146 179|substrate protein MAPKAP kinase-2
P08617238A0334|37 59|p38 MAP kinase pathway
P08617238A0334|18 22|cell
P08617238A0334|1 14|TNF Treatment
P08617311A0979|104 107|IgE
P08617311A0979|133 143|similarity
P08617311A0979|76 80|mIgY
P08617311A0979|20 39|sequence similarity
P08617800A0675|78 81|PBP
P08617800A0675|9 21|footprinting
P08617800A0675|113 123|palindrome
P08618433A0000|92 116|tyrosine kinase receptor
P08618433A0000|52 54|FL
P08618433A0000|71 77|ligand
P08618433A0000|118 119|R
P08618864A0754|45 56|mutagenesis
P08618864A0754|130 138|activity
P08618864A0754|101 109|residues
P08619866A0000|45 48|HGF
P08619866A0000|123 137|heart diseases
P08619866A0000|96 111|angina pectoris
P08620003T0000|73 77|step
P08620003T0000|1 17|Protein splicing
P08620003T0000|85 101|splicing process
P08620889A0771|76 89|transcription
P08620889A0771|33 40|element
P08621384A0935|14 27|keratinocytes
P08621384A0935|147 180|PKCdelta tyrosine phosphorylation
P08621384A0935|93 101|TGFalpha
P08621384A0935|115 128|growth factor
P08621448A0862|29 32|DNA
P08621448A0862|97 99|C1
P08621448A0862|54 79|RL95-2 expression library
P08621453A0815|128 139|fibroblasts
P08621453A0815|65 70|80K-H
P08621453A0815|35 45|antibodies
P08621628A1233|73 90|hGRalpha activity
P08621661A1035|61 75|Northern blots
P08621661A1035|123 127|cDNA
P08621661A1035|94 101|tissues
P08621661A1035|6 23|P5CDh cDNA clones
P08621714A0361|65 76|thiol group
P08621714A0361|38 53|disulfide bonds
P08621719A0568|27 30|Cbl
P08621719A0568|66 70|Grb2
P08622030A0667|180 185|level
P08622030A0667|146 173|serum lactate dehydrogenase
P08622030A0667|66 90|baseline characteristics
P08622030A0667|16 27|differences
P08622596A0189|90 93|fat
P08622596A0189|36 40|diet
P08622596A0189|71 74|fat
P08622668A1155|75 85|modulation
P08622668A1155|91 130|phosphorylation-dephosphorylation cycle
P08622668A1155|208 216|pre-mRNA
P08622668A1155|7 14|results
P08622668A1155|171 187|binding affinity
P08622698T0000|112 123|virus EBNA2
P08622698T0000|70 79|mechanism
P08622893A0000|123 136|communication
P08622893A0000|78 87|prototype
P08622893A0000|24 49|receptor tyrosine kinases
P08622893A0000|67 70|EPH
P08622893A0000|51 55|RTKs
P08624445A0257|63 92|cytosine methylation patterns
P08624445A0257|177 179|Ac
P08624445A0257|201 211|tenth exon
P08624445A0257|100 125|transposase binding sites
P08625900T0000|62 89|prolactin promoter activity
P08625900T0000|11 20|adenylate
P08625900T0000|40 51|polypeptide
P08625900T0000|173 180|pathway
P08625987A1086|107 112|cells
P08625987A1086|124 127|RNA
P08625987A1086|76 88|pro-B/pre-BI
P08626290T0000|37 42|genes
P08626290T0000|80 96|membrane protein
P08626290T0000|1 22|Aeromonas salmonicida
P08626325A0543|125 129|UmuD
P08626325A0543|111 120|UmuD-UmuD
P08626325A0543|37 41|data
P08626325A0543|157 166|UmuD-UmuD
P08626325A0543|71 75|UmuD
P08626493A1468|46 49|E1A
P08626493A1468|182 196|PEPCK promoter
P08626493A1468|78 81|E1A
P08626493A1468|67 74|binding
P08626493A1468|38 41|CR2
P08626493A1468|118 121|pRb
P08626529A0799|29 36|regions
P08626529A0799|267 272|motif
P08626529A0799|222 241|sequence ESLALEELEL
P08626529A0799|286 299|granin family
P08626529A0799|199 203|p230
P08626529A0799|143 156|alpha-helices
P08626529A0799|38 49|amino acids
P08626529A0799|70 74|p230
P08626540A1007|109 125|glucosylceramide
P08626540A1007|43 57|concentrations
P08626610A0931|44 51|SREBP-1
P08626610A0931|107 113|region
P08626610A0931|115 122|residue
P08626610A0931|204 212|splicing
P08626610A0931|171 176|forms
P08626667A1372|148 168|type oligonucleotide
P08626667A1372|70 77|repeats
P08626667A1372|1 29|EMSA competition experiments
P08626698A0989|56 77|PKC beta transfectant
P08626698A0989|172 192|complex kinase assay
P08626698A0989|34 47|ERK3 activity
P08626785A0674|329 354|hexanucleotide half-sites
P08626785A0674|452 466|RXR homodimers
P08626785A0674|296 303|mTGRRE1
P08626785A0674|431 447|RXR heterodimers
P08626785A0674|20 30|activation
P08626785A0674|109 115|region
P08626785A0674|38 70|tissue transglutaminase promoter
P08627354A0000|12 21|synapsins
P08627354A0000|101 125|neurotransmitter release
P08627354A0000|35 41|family
P08627667A0132|116 129|specificities
P08627667A0132|50 55|c-Fos
P08627719A0784|89 104|protein factors
P08627719A0784|127 136|component
P08627719A0784|292 296|IE63
P08627719A0784|184 185|A
P08627719A0784|78 85|binding
P08627719A0784|202 213|virus genes
P08627719A0784|278 288|expression
P08627719A0784|1 29|UV cross-linking experiments
P08628254A0665|72 81|AP1 sites
P08628254A0665|53 68|transactivators
P08628260A0895|45 56|HepG2 cells
P08628260A0895|134 144|nucleotide
P08628260A0895|77 85|deletion
P08628260A0895|93 99|factor
P08628260A0895|184 192|increase
P08628302A0683|66 80|RNA polymerase
P08628302A0683|84 107|transcription apparatus
P08628681A0821|121 135|DNA polymerase
P08628681A0821|95 106|pol domains
P08628681A0821|87 90|exo
P08630542A1421|45 46|V
P08630542A1421|7 15|findings
P08630542A1421|66 77|consequence
P08630542A1421|116 124|response
P08630583A1056|60 66|effect
P08630583A1056|43 54|CO2 content
P08630583A1056|70 71|Q
P08631667A0851|271 279|plasmids
P08631667A0851|167 179|enzyme assay
P08631667A0851|24 30|region
P08631667A0851|246 249|use
P08631667A0851|218 231|cell extracts
P08631760A0609|37 47|SH2 domain
P08631760A0609|83 97|phosphopeptide
P08631760A0609|51 54|Crk
P08631817T0000|21 30|consensus
P08631817T0000|48 75|kinase phosphorylation site
P08631822A0677|14 31|plasmin fragments
P08631822A0677|59 66|respect
P08631822A0677|112 126|VEGF receptors
P08631822A0677|87 98|interaction
P08631934A0000|20 30|Myb family
P08631934A0000|153 155|YG
P08631934A0000|160 161|C
P08631934A0000|172 175|G/A
P08631934A0000|99 105|domain
P08631934A0000|168 171|GTT
P08631934A0000|71 79|homology
P08631958T0000|77 94|repression domain
P08631958T0000|39 58|protein IE2 tethers
P08632015A0879|60 89|DNA polymerase alpha promoter
P08632015A0879|5 15|antibodies
P08632018A0587|72 78|region
P08632018A0587|3 15|DNA fragment
P08632779A0351|90 95|NLS-C
P08632779A0351|31 34|NLS
P08632779A0351|97 99|AA
P08632779A0351|158 166|beta-gal
P08632779A0351|65 70|NLS-B
P08632779A0351|184 185|%
P08634290A0000|58 62|RNAs
P08634290A0000|98 101|end
P08634420A1784|148 171|UT-7 cell proliferation
P08634420A1784|77 82|cells
P08634420A1784|116 123|muEpo-R
P08634697A1155|106 111|mouse
P08634697A1155|79 89|expression
P08634697A1155|176 183|domains
P08634697A1155|53 61|reagents
P08636031A1413|120 139|Fur titration assay
P08636031A1413|166 193|gel retardation experiments
P08636031A1413|48 56|fragment
P08636031A1413|220 235|Fur preparation
P08636149A0220|150 157|insulin
P08636149A0220|115 134|autophosphorylation
P08636149A0220|68 75|insulin
P08636428A1363|172 180|mitogens
P08636428A1363|136 146|expression
P08637711A1121|107 113|IR/IRF
P08637711A1121|208 225|binding complexes
P08637711A1121|178 182|site
P08637711A1121|38 54|interferon gamma
P08637711A1121|237 248|JRE-IL6-BCs
P08637717A1231|72 92|filter binding assay
P08637717A1231|24 35|amino acids
P08637717A1231|102 109|peptide
P08639310A0548|74 85|mg qds days
P08639310A0548|128 135|mg i.v.
P08639310A0548|7 18|mg tid days
P08639310A0548|143 145|CT
P08639310A0548|1 4|OND
P08639561T0000|91 98|epoxy-7
P08639561T0000|125 131|pyrene
P08639561T0000|24 35|N-ras codon
P08639561T0000|191 193|7S
P08639561T0000|254 274|deoxyadenosyl adduct
P08639561T0000|106 121|tetrahydrobenzo
P08639561T0000|280 286|1H NMR
P08639561T0000|202 203|R
P08639561T0000|39 47|sequence
P08639561T0000|69 70|S
P08639837A0268|45 52|factors
P08639837A0268|6 14|fragment
P08639837A0268|84 91|members
P08641705A0986|167 195|beta-globin gene duplication
P08641705A0986|242 255|Hb Costa Rica
P08641705A0986|110 118|deletion
P08641705A0986|141 151|Hbs Lepore
P08641705A0986|155 160|Kenya
P08641705A0986|68 78|G mutation
P08642285A1548|121 126|STAT1
P08642285A1548|1 19|DNA-STAT complexes
P08642313T0000|147 170|factor-kappa B proteins
P08642313T0000|174 181|T cells
P08642313T0000|1 7|T cell
P08643111A0855|15 18|LL2
P08643111A0855|88 106|immunoreactivities
P08643111A0855|41 46|chain
P08643111A0855|244 255|counterpart
P08643111A0855|20 24|hLL2
P08643111A0855|289 305|oligosaccharides
P08643513A0361|167 169|nt
P08643513A0361|197 202|level
P08643513A0361|188 189|%
P08643513A0361|206 233|osteocalcin gene expression
P08643513A0361|51 79|acetyltransferase constructs
P08643578A0000|111 121|expression
P08643578A0000|143 154|reporter FG
P08643578A0000|33 37|form
P08643578A0000|100 106|growth
P08643578A0000|220 224|lacZ
P08643633A1187|63 67|CBF1
P08643633A1187|36 43|complex
P08643682A0268|60 88|CBFbeta-SMMHC fusion protein
P08643682A0268|13 26|localizations
P08643682A0268|108 126|immunofluorescence
P08644734A0404|15 24|isolation
P08644734A0404|34 39|cDNAs
P08645219A1377|78 83|MRP14
P08645219A1377|173 188|binding domains
P08645219A1377|168 171|Ca2
P08645219A1377|1 4|Ca2
P08647086A0720|120 123|p53
P08647086A0720|125 130|E2F-1
P08647086A0720|159 167|proteins
P08647086A0720|251 259|proteins
P08647086A0720|216 229|Cdk2-cyclin-A
P08647086A0720|109 118|T antigen
P08647086A0720|5 27|Cdk2-cyclin-D1 complex
P08647086A0720|136 147|preparation
P08647091A0592|47 57|Adh-2 gene
P08647091A0592|109 118|placement
P08647091A0592|172 181|ADH genes
P08647434A1124|45 55|antibodies
P08647434A1124|74 77|TBP
P08647434A1124|108 112|hTAF
P08647434A1124|161 171|holo-TFIID
P08647434A1124|7 16|T antigen
P08647802A0000|105 124|SH3-SH2-SH3 domains
P08647802A0000|21 38|signaling protein
P08647884A0547|63 72|MHC class
P08647884A0547|128 140|cell surface
P08648665A0956|11 24|LE6 deletions
P08648665A0956|49 74|transformation efficiency
P08648726A0713|56 64|promoter
P08648726A0713|126 136|ZIB domain
P08648726A0713|23 33|ZI domains
P08648726A0713|87 90|ZIA
P08649372A0755|120 131|interaction
P08649372A0755|25 29|Mbp1
P08649372A0755|65 69|Swi6
P08649372A0755|48 59|interaction
P08649386A1032|60 68|analysis
P08649386A1032|7 30|UASH consensus sequence
P08649389A0692|165 175|c-myc gene
P08649389A0692|12 20|analysis
P08649389A0692|142 151|repressor
P08649403A0963|41 47|mutant
P08649403A0963|113 127|protein kinase
P08649403A0963|84 92|mutation
P08649424A0000|150 153|AMP
P08649424A0000|161 166|liver
P08649424A0000|99 104|birth
P08649424A0000|19 49|phenylalanine hydroxylase gene
P08649425T0000|29 48|chromatin structure
P08649425T0000|86 94|enhancer
P08649428A1227|62 71|synthesis
P08649428A1227|130 140|activation
P08649428A1227|144 148|Cdc2
P08649773A1374|5 12|ability
P08649773A1374|87 94|ability
P08649773A1374|16 21|BCL-6
P08650818A0000|149 153|ward
P08650818A0000|106 114|patients
P08650818A0000|245 253|hospital
P08650818A0000|261 279|Mediterranean area
P08650818A0000|87 91|MRSA
P08654200A0274|61 73|liver volume
P08654200A0274|148 164|model substrates
P08654200A0274|245 250|mg/kg
P08654200A0274|217 228|indocyanine
P08654200A0274|190 200|antipyrine
P08654200A0274|102 110|patients
P08654390A0000|44 59|heme catabolism
P08654390A0000|108 123|carbon monoxide
P08654390A0000|86 96|biliverdin
P08654390A0000|34 40|enzyme
P08654946A0475|148 152|gene
P08654946A0475|58 77|Xenopus laevis FGF3
P08654946A0475|18 28|% identity
P08654946A0475|84 94|% identity
P08654972A0000|88 110|cell cycle progression
P08654972A0000|70 75|genes
P08655497A0000|182 188|vector
P08655497A0000|9 13|gene
P08655497A0000|127 142|chloramphenicol
P08655497A0000|51 54|min
P08655555A1368|53 60|hexamer
P08655555A1368|114 120|region
P08657135A1444|24 31|studies
P08657135A1444|162 170|elements
P08657135A1444|64 73|regulator
P08657135A1444|102 122|E protein homodimers
P08657157A0000|109 118|complexes
P08657157A0000|65 70|motif
P08657157A0000|17 27|regulators
P08657918A0360|15 22|METHODS
P08657918A0360|88 103|dorsal portions
P08657918A0360|24 46|Coronal 3D GRE imaging
P08657918A0360|162 165|SLL
P08657918A0360|188 194|wrists
P08660733X0000|13 24|populations
P08660733X0000|77 82|April
P08660866A0504|211 216|shaft
P08660866A0504|240 245|cells
P08660866A0504|179 184|cells
P08660866A0504|222 230|tormogen
P08660866A0504|14 23|positions
P08660866A0504|232 238|socket
P08660866A0504|39 42|Brd
P08660998A0851|151 153|bp
P08660998A0851|72 85|AP-2 elements
P08660998A0851|56 60|CAAT
P08660998A0851|113 143|mMIWC transcription initiation
P08660998A0851|87 103|primer extension
P08661100A0285|177 182|parts
P08661100A0285|97 104|regions
P08661100A0285|33 38|Cdebp
P08661100A0285|17 29|distribution
P08661104A0687|106 114|prostate
P08661104A0687|82 95|cells/tissues
P08661104A0687|116 120|lung
P08661116A0963|31 41|cell lines
P08661116A0963|108 130|Northern blot analyses
P08661116A0963|83 90|D3 mRNA
P08661116A0963|171 179|promoter
P08661613A0691|6 11|users
P08661613A0691|39 58|management measures
P08661613A0691|87 95|response
P08662499A0484|15 26|interaction
P08662499A0484|12 13|F
P08662499A0484|55 58|end
P08662789A0673|99 105|RPS30A
P08662789A0673|69 87|sequence alignment
P08662928A1153|77 90|STAT proteins
P08662936A0428|122 133|mouse TEF-1
P08662936A0428|94 102|identity
P08662936A0428|27 52|FR-19 amino acid sequence
P08662936A0428|139 144|mouse
P08663000A0000|133 152|growth factor-beta1
P08663000A0000|5 13|receptor
P08663000A0000|55 70|gene expression
P08663000A0000|48 53|RHAMM
P08663127A0697|210 217|regions
P08663127A0697|192 193|N
P08663127A0697|95 102|domains
P08663127A0697|126 130|loop
P08663127A0697|50 58|homology
P08663172A0311|6 13|protein
P08663310A0157|209 224|differentiation
P08663310A0157|193 204|cell growth
P08663310A0157|130 134|IEGs
P08663310A0157|67 72|class
P08663310A0157|85 99|response genes
P08663392A0215|9 14|study
P08663392A0215|102 112|expression
P08664347A0923|88 95|pro-LPH
P08664347A0923|1 5|None
P08664667A0093|10 15|Delhi
P08666102A0820|72 75|Ptc
P08666102A0820|117 121|FEV1
P08666241A0930|41 47|region
P08666241A0930|86 104|Dex responsiveness
P08666398T0000|59 65|region
P08666398T0000|53 57|CLN3
P08666398T0000|69 82|16p12.1-p11.2
P08666913A0000|63 75|gene cluster
P08666913A0000|86 96|chromosome
P08668142A1048|105 116|Sec7p pools
P08668142A1048|21 26|hARF4
P08668142A1048|34 39|cells
P08668158A1252|61 76|precursor Rpm1r
P08668158A1252|114 118|gene
P08668158A1252|34 44|RPM1 genes
P08668201A1059|29 36|element
P08668201A1059|124 136|MATalpha1 IE
P08668201A1059|108 116|activity
P08668201A1059|201 209|interval
P08668209A0406|1 7|Merlie
P08669274T0000|55 63|approach
P08670556A0425|30 34|area
P08670556A0425|108 118|0-infinity
P08670556A0425|6 16|micromol/1
P08670910A0156|63 85|endonuclease co-purify
P08670910A0156|19 29|DNA ligase
P08670910A0156|1 17|DNA polymerase E
P08673026T0000|5 21|factor structure
P08673026T0000|55 72|replication study
P08675395A0751|72 91|acuity outcome data
P08675395A0751|1 8|RESULTS
P08675763A0788|62 65|Lys
P08675763A0788|76 84|increase
P08675763A0788|53 56|Met
P08675763A0788|117 121|g/kg
P08675821A0657|31 42|glans penis
P08675821A0657|63 69|search
P08675821A0657|55 59|area
P08676383A0518|6 19|half molecule
P08676456A0879|135 157|VP16 activation domain
P08676456A0879|12 30|VP16-Tat construct
P08676456A0879|84 103|AP-1 responsiveness
P08676858A0309|11 18|cloning
P08676858A0309|43 56|S-RNase genes
P08676858A0309|126 130|pear
P08676858A0309|66 73|species
P08676858A0309|222 228|RNases
P08677443A0238|269 270|%
P08677443A0238|182 188|months
P08677443A0238|159 170|progression
P08677443A0238|224 230|months
P08677443A0238|74 87|SCLC patients
P08677443A0238|198 212|survival times
P08677443A0238|281 282|%
P08677443A0238|274 275|%
P08678959A0640|41 49|patients
P08678959A0640|1 23|Sestamibi scintigraphy
P08680702A0548|122 129|animals
P08680702A0548|179 183|cart
P08680702A0548|248 251|Day
P08680702A0548|86 90|Days
P08680702A0548|50 61|dysfunction
P08680702A0548|194 200|Vo2DIR
P08680702A0548|382 383|p
P08680702A0548|77 82|group
P08680702A0548|336 344|Vo2INDIR
P08680702A0548|238 239|p
P08682155A0902|59 66|smokers
P08682155A0902|117 127|situations
P08682868A0738|14 29|DSK2-1 mutation
P08682868A0738|106 117|differences
P08682868A0738|64 69|Dsk2p
P08682868A0738|85 91|domain
P08683108A0965|110 114|junB
P08683108A0965|174 178|site
P08683108A0965|50 54|CREB
P08683983A0785|109 123|leukemia cells
P08684522A0415|95 99|type
P08684522A0415|140 144|wall
P08684522A0415|1 30|Immunofluorescence microscopy
P08684522A0415|103 111|collagen
P08686381A0527|243 255|protein Swi3
P08686381A0527|199 202|BCR
P08686381A0527|7 11|ORFs
P08686381A0527|114 143|polyadenylate binding protein
P08686381A0527|184 191|protein
P08688556A0242|122 130|clathrin
P08688556A0242|160 163|Chc
P08688556A0242|111 118|strains
P08688556A0242|38 44|screen
P08690118A0845|90 94|IVOS
P08690118A0845|134 147|fertilization
P08690118A0845|74 84|morphology
P08690118A0845|56 66|percentage
P08691106A0733|10 20|D8 binding
P08691106A0733|115 122|protein
P08692885A0663|29 49|NF-kappaB activation
P08692885A0663|5 12|ability
P08692924A0328|104 109|BCL-6
P08692924A0328|179 191|B-cell lines
P08692924A0328|157 165|extracts
P08692924A0328|136 145|complexes
P08698756A1240|123 133|procedures
P08698756A1240|40 53|pre-treatment
P08698756A1240|59 71|coenzyme Q10
P08698756A1240|18 26|findings
P08702517A0000|88 108|progenitor cell line
P08702517A0000|6 12|screen
P08702556A0000|150 156|Yamada
P08702556A0000|29 41|purification
P08702556A0000|158 160|K.
P08702556A0000|165 171|Sakane
P08702556A0000|173 175|F.
P08702556A0000|100 124|porcine thymus membranes
P08702556A0000|68 84|acid phosphatase
P08702644A0499|72 76|cDNA
P08702644A0499|43 47|apoB
P08702644A0499|142 145|DAF
P08702644A0499|3 7|cDNA
P08702644A0499|100 111|amino acids
P08702756A0000|123 136|cell motility
P08702756A0000|79 101|actin-myosin filaments
P08702756A0000|53 62|functions
P08702826A0870|40 62|GSTP1 silencer element
P08702826A0870|23 32|insertion
P08702936A0168|165 171|signal
P08702936A0168|124 129|blood
P08702936A0168|189 197|CD4 cDNA
P08702936A0168|4 22|expression library
P08703005A0645|72 77|sites
P08703005A0645|82 107|transcription factors Sp1
P08703005A0645|38 55|promoter activity
P08703908A1814|45 49|SF-1
P08703908A1814|130 139|StAR gene
P08703908A1814|19 27|findings
P08704124A0420|22 31|fragments
P08704124A0420|70 78|VrCDPK-1
P08705056T0000|31 35|risk
P08705056T0000|1 19|Workplace violence
P08706662A1125|44 63|perforin expression
P08706662A1125|5 12|results
P08706662A1125|175 187|factor NF-P2
P08707424A0709|5 15|expression
P08707424A0709|87 97|expression
P08707424A0709|119 125|stages
P08707825A0063|131 141|smoothelin
P08707825A0063|159 178|muscle cDNA library
P08707825A0063|54 71|Northern blotting
P08707825A0063|254 261|protein
P08707846A2308|63 71|receptor
P08707846A2308|97 111|ubiquitination
P08707846A2308|34 40|uptake
P08708984T0000|74 77|rat
P08708984T0000|64 70|lesion
P08709245A1521|90 97|Ser-210
P08709245A1521|245 250|HDAgs
P08709245A1521|156 160|HDAg
P08709245A1521|198 211|HDAg particle
P08709245A1521|232 241|transport
P08709245A1521|71 76|Ser-2
P08709245A1521|103 108|roles
P08709637A1471|107 112|STATs
P08709637A1471|36 54|IL-7R alpha chains
P08709637A1471|98 102|JAKs
P08709637A1471|152 161|signaling
P08710151A0782|75 82|class A
P08710151A0782|183 191|class B.
P08710151A0782|113 120|class B
P08710151A0782|65 71|pnx s.
P08710151A0782|138 145|patient
P08710371A0499|61 84|consensus binding sites
P08710371A0499|27 38|bp sequence
P08710371A0499|1 10|Site S-II
P08710504A0995|24 29|Cat8p
P08712799A0123|26 33|smoking
P08716757T0001|37 54|hepatitis B virus
P08716757T0001|68 76|patients
P08717559A0223|76 83|ampoule
P08717559A0223|99 109|micrograms
P08719156A0953|14 21|introns
P08719156A0953|69 82|reading frame
P08719832A0397|5 15|experience
P08719832A0397|69 76|surgery
P08721526A0000|29 38|allergens
P08721999A0432|80 90|snoRNA U14
P08721999A0432|34 42|features
P08722011A0103|88 100|binding site
P08722011A0103|58 70|subunit rRNA
P08722011A0103|174 185|protein L15
P08722011A0103|136 147|counterpart
P08723352A0084|73 80|kinases
P08723352A0084|110 117|product
P08723352A0084|6 16|transition
P08723883A0823|43 60|spectrophotometer
P08723883A0823|1 22|Blood GSH-Px activity
P08726024A0244|7 11|cats
P08726247A0175|73 84|attenuation
P08726247A0175|98 109|path length
P08727992A0570|15 24|injection
P08727992A0570|28 38|PGF2 alpha
P08727992A0570|112 115|min
P08730470A0000|134 141|mothers
P08730470A0000|179 196|household contact
P08730470A0000|18 27|agreement
P08730470A0000|102 106|data
P08731222A0000|303 311|C7 level
P08731222A0000|123 126|SRD
P08731222A0000|262 267|PHA-L
P08731222A0000|75 86|enlargement
P08731222A0000|226 260|Phaseolus vulgaris leucoagglutinin
P08731222A0000|5 17|distribution
P08731222A0000|207 222|microinjections
P08732665A0000|330 337|culture
P08732665A0000|58 64|21MT-2
P08732665A0000|294 307|growth factor
P08732665A0000|262 265|IGF
P08732665A0000|314 326|independence
P08732665A0000|309 312|EGF
P08732665A0000|69 75|21MT-1
P08733123A0951|12 22|chromosome
P08733123A0951|25 40|FRG1 transcript
P08733123A0951|80 85|exons
P08733123A0951|49 51|bp
P08733881A0343|6 30|thyroid function testing
P08733881A0343|70 77|samples
P08738510A0254|14 30|tumor FDG-uptake
P08738510A0254|77 88|meningiomas
P08739260T0000|32 51|amphetamine effects
P08739260T0000|17 22|plant
P08740416A0919|76 81|Seb1p
P08740416A0919|35 39|SEB2
P08741280A0374|45 49|lobe
P08741280A0374|28 32|size
P08741280A0374|7 11|ones
P08742385A0211|121 132|head injury
P08742385A0211|114 115|%
P08742385A0211|33 43|meningitis
P08742385A0211|87 88|%
P08746605A0377|28 42|ACE inhibitors
P08746605A0377|21 24|use
P08747078T0000|10 17|aspirin
P08748033A0874|14 18|cpxA
P08748033A0874|127 136|cytoplasm
P08748033A0874|20 29|mutations
P08748033A0874|69 93|LamB-LacZ hybrid protein
P08749394A0874|10 29|interaction studies
P08749394A0874|37 45|proteins
P08749394A0874|55 80|glutathione-S-transferase
P08749394A0874|137 150|RAM23 regions
P08750190A0000|72 77|exons
P08750190A0000|182 190|isoforms
P08750190A0000|161 173|CD44 variant
P08750190A0000|20 26|others
P08750190A0000|50 58|splicing
P08751635A0135|57 82|hippocampus subfields CA1
P08751635A0135|49 53|loss
P08754777A1214|46 66|T3R-RXR heterodimers
P08754777A1214|22 36|T3R homodimers
P08754777A1214|158 163|upTRE
P08754777A1214|115 134|heterodimer binding
P08754827A0231|9 13|F.J.
P08754840A0793|11 35|glucan synthase activity
P08754840A0793|99 115|deltabem4 mutant
P08755898A0339|46 65|Bs2 host resistance
P08755898A0339|5 12|classes
P08756433A0282|11 27|characterization
P08756433A0282|140 150|expression
P08756433A0282|84 92|elements
P08756597A0854|67 72|level
P08756597A0854|1 8|Mutants
P08756642A0230|29 37|interval
P08756642A0230|65 79|myelodysplasia
P08757265A0466|26 28|mV
P08757265A0466|1 8|Neurons
P08759870A1128|125 145|Fur repressor dimers
P08759870A1128|5 11|extent
P08759870A1128|69 90|footprinting analysis
P08760776A1559|161 170|treatment
P08760776A1559|25 34|treatment
P08760776A1559|141 153|theophylline
P08760776A1559|1 11|CONCLUSION
P08760889A0170|78 83|clone
P08760889A0170|5 15|cDNA clone
P08761169T0000|18 29|dysfunction
P08762021A0156|30 38|measures
P08762021A0156|136 143|rabbits
P08762472A0000|72 91|artery hypertension
P08762472A0000|5 11|effect
P08763311A0189|121 133|hypertension
P08763311A0189|89 105|vasoconstriction
P08763311A0189|1 14|Phenylephrine
P08763953A0805|5 9|unit
P08763953A0805|81 85|traG
P08763953A0805|71 75|traD
P08764136A0000|208 222|MEC strain 76N
P08764136A0000|179 192|hybridization
P08764136A0000|7 13|effort
P08764136A0000|276 282|76R-30
P08764136A0000|69 79|mRNA level
P08766781A0322|90 92|Hb
P08766781A0322|111 115|g/dl
P08766781A0322|38 46|increase
P08766781A0322|69 70|%
P08768377A1387|79 97|phytochrome C gene
P08768377A1387|42 50|distance
P08768377A1387|113 129|characterization
P08769409A0114|225 227|A.
P08769409A0114|78 82|gene
P08769409A0114|179 184|uORFs
P08769409A0114|67 75|RAR beta
P08769409A0114|86 99|mouse embryos
P08769568A0949|73 83|PLA2 genes
P08769568A0949|5 14|structure
P08770896A1121|150 155|appMr
P08770896A1121|160 163|17K
P08770896A1121|96 102|medium
P08770896A1121|55 64|G11 cells
P08770896A1121|137 144|species
P08770981A0328|145 165|weight vWF multimers
P08770981A0328|173 184|circulation
P08770981A0328|55 68|fragmentation
P08771781A1103|90 94|data
P08771781A1103|43 54|chloroplast
P08771781A1103|143 154|chloroplast
P08774732A0271|57 62|motif
P08774732A0271|64 86|gel retardation assays
P08776735A0000|240 250|importance
P08776735A0000|88 92|rLHR
P08776735A0000|63 86|type rat LH/CG receptor
P08776735A0000|296 310|responsiveness
P08776735A0000|259 265|region
P08776735A0000|97 106|receptors
P08776735A0000|206 215|rLHR-t628
P08776792A0626|59 64|hours
P08776792A0626|1 6|Sleep
P08776901A0000|160 167|fashion
P08776901A0000|65 73|mutation
P08776901A0000|1 20|Chloroplast mutator
P08778265A0422|63 77|Wisconsin card
P08778265A0422|92 114|Street completion test
P08778265A0422|140 146|memory
P08778265A0422|86 90|test
P08780339A0142|60 71|corrections
P08780339A0142|176 182|starch
P08780339A0142|80 97|carryover effects
P08780339A0142|155 162|glucose
P08780339A0142|184 186|RS
P08780339A0142|132 143|supplements
P08780339A0142|272 275|RS3
P08780339A0142|102 107|males
P08781144A1520|10 20|FMISO TMRR
P08781144A1520|6 9|18F
P08783666A0957|26 37|engraftment
P08783666A0957|4 12|addition
P08783666A0957|71 85|amifostine arm
P08787110A0981|56 66|management
P08787110A0981|18 22|CPET
P08787110A0981|100 107|disease
P08790288A0068|61 78|Spinacia oleracea
P08790288A0068|41 46|cDNAs
P08790288A0068|52 59|spinach
P08790387A0299|62 66|exon
P08790387A0299|8 22|rat rnu allele
P08793029A0246|63 69|groups
P08793029A0246|16 20|rats
P08794254A2957|42 49|therapy
P08794254A2957|16 28|PTA category
P08794339A1162|177 181|turn
P08794339A1162|212 228|adaptor proteins
P08794339A1162|25 28|IE2
P08794339A1162|190 194|CREB
P08794339A1162|14 21|binding
P08794339A1162|162 165|CBP
P08794339A1162|65 69|CREB
P08794363A0259|125 131|origin
P08794363A0259|37 45|homology
P08794363A0259|71 77|member
P08794547A1403|57 64|vessels
P08794547A1403|16 23|vessels
P08794869A0274|72 76|role
P08794869A0274|80 85|alpha
P08794869A0274|18 26|evidence
P08797362T0037|9 19|diphtheria
P08797362T0037|81 88|January
P08798443A0660|241 248|element
P08798443A0660|147 150|Myb
P08798443A0660|219 225|mim-1A
P08798443A0660|81 87|serine
P08798443A0660|104 109|S528A
P08798443A0660|136 143|ability
P08798443A0660|205 211|copies
P08798512A1197|67 77|u-PAR gene
P08798512A1197|21 28|factors
P08798635A0870|72 76|ARF1
P08798635A0870|10 20|spleen GAP
P08798635A0870|126 140|myristoylation
P08798635A0870|84 88|ARF5
P08798643T0000|135 142|T cells
P08798643T0000|58 77|transforming region
P08798643T0000|33 39|domain
P08798700A0134|104 108|part
P08798700A0134|149 154|Rox1p
P08798700A0134|162 166|part
P08798700A0134|5 18|transcription
P08798700A0134|84 99|heme deficiency
P08798700A0134|205 224|activation sequence
P08798782A0976|49 52|SH2
P08801403T0001|63 70|myeloma
P08801403T0001|33 50|presentation form
P08803845A0665|57 65|clusters
P08803845A0665|202 210|excision
P08803845A0665|80 85|cells
P08803845A0665|136 145|insertion
P08804389A0893|211 219|decrease
P08804389A0893|193 201|japonica
P08804389A0893|98 109|translucens
P08804389A0893|71 96|Xanthomonas campestris pv
P08804389A0893|1 23|Northern blot analysis
P08805824A1155|25 34|zero-loss
P08805824A1155|249 258|technique
P08805824A1155|18 21|use
P08805824A1155|184 194|scattering
P08806693A0584|268 274|GATA-1
P08806693A0584|29 38|sequences
P08806693A0584|124 133|deletions
P08806693A0584|78 88|activation
P08806693A0584|4 9|order
P08806693A0584|216 224|activity
P08806817A0716|41 47|SpSHR2
P08806817A0716|77 97|S. purpuratus genome
P08807288T0000|15 29|identification
P08807288T0000|33 38|genes
P08808120A0774|60 77|serum iron levels
P08808120A0774|149 155|values
P08808120A0774|335 347|micrograms/L
P08808120A0774|159 169|serum iron
P08808120A0774|352 355|DAI
P08808120A0774|289 306|aluminum overload
P08808120A0774|110 122|micrograms/L
P08808120A0774|100 103|DAI
P08808120A0774|1 9|Patients
P08808707A0631|134 137|Jun
P08808707A0631|149 155|kinase
P08808707A0631|109 123|protein kinase
P08808707A0631|162 170|cascades
P08808707A0631|157 160|JNK
P08808707A0631|1 10|Ha-RasV12
P08808924A0326|77 91|amino terminus
P08808924A0326|53 58|spans
P08808924A0326|143 151|presence
P08808924A0326|191 195|F-97
P08808924A0326|206 215|proximity
P08808939A0000|164 189|phosphotransferase system
P08808939A0000|127 130|HPr
P08808939A0000|1 29|Carbon catabolite repression
P08810040A0955|14 20|screen
P08810040A0955|63 82|target locus marker
P08810040A0955|139 140|%
P08810323A0735|70 77|regions
P08812020A0597|62 68|number
P08812020A0597|72 78|boards
P08812020A0597|125 133|accuracy
P08812020A0597|168 174|pieces
P08812490A0000|61 69|homology
P08812490A0000|77 87|aquaporins
P08812490A0000|114 133|kidney cDNA library
P08812490A1509|90 94|hKID
P08812490A1509|121 144|MIP family gene cluster
P08812490A1509|10 27|sequence homology
P08812490A1509|96 99|MIP
P08813900A1088|8 15|phytase
P08813900A1088|112 122|bone cells
P08813900A1088|83 94|arrangement
P08813900A1088|20 22|nP
P08813900A1088|98 107|cartilage
P08813900A1088|51 62|development
P08816052A0238|20 27|brevity
P08816052A0238|117 170|Kaufman Short Neuropsychological Assessment Procedure
P08816052A0238|35 43|WISC-III
P08816052A0238|102 108|K-FAST
P08816443A1674|268 286|adhesion complexes
P08816443A1674|244 257|stress fibers
P08816443A1674|231 240|formation
P08816443A1674|83 95|cytoskeleton
P08816443A1674|207 215|activity
P08816453A0000|30 34|cAMP
P08816453A0000|89 101|Raf-1 kinase
P08816453A0000|36 42|levels
P08816453A0000|50 54|cell
P08816460A1769|122 130|presence
P08816460A1769|43 64|Jun kinase activation
P08816460A1769|7 14|results
P08816472T0000|39 48|regulator
P08816472T0000|19 23|Ste4
P08816483A0869|26 30|SIC1
P08816483A0869|20 24|loci
P08816483A0869|1 10|Mutations
P08816504T0000|42 52|activation
P08816504T0000|18 24|growth
P08816504T0000|102 118|receptor binding
P08816759A0000|90 103|acid receptor
P08816759A0000|31 39|RZR beta
P08816759A0000|110 134|thyroid hormone receptor
P08816759A0000|5 29|retinoid Z receptor beta
P08816759A0000|136 138|TR
P08817323A0714|180 184|EST.
P08817323A0714|71 84|DXS6673E gene
P08817323A0714|103 116|sequence tags
P08817323A0714|17 34|sequence identity
P08818436A0557|165 170|death
P08818436A0557|77 84|history
P08818436A0557|49 52|age
P08820324A1699|15 24|agreement
P08820324A1699|5 11|limits
P08820648A0123|13 21|presence
P08820648A0123|208 216|presence
P08820648A0123|162 169|mutants
P08820648A0123|84 90|enzyme
P08820648A0123|220 226|oxygen
P08822399A0518|73 82|pregnancy
P08822399A0518|98 105|factors
P08823187A1020|28 44|porcine proteins
P08823187A1020|1 10|Titration
P08823646A1012|91 103|measurements
P08823646A1012|19 29|adrenaline
P08823646A1012|50 64|overestimation
P08824201A0270|1 9|Chernoff
P08824798A0761|92 100|residues
P08824798A0761|144 152|rat CRIP
P08824798A0761|66 67|%
P08824798A0761|55 61|shares
P08824805A0832|75 82|domains
P08824805A0832|16 31|exon boundaries
P08824884A0000|60 64|site
P08824884A0000|66 71|FRAXE
P08824884A0000|201 209|handicap
P08824884A0000|35 41|folate
P08824884A0000|102 112|GCC repeat
P08825178A0071|135 142|TB care
P08825178A0071|92 102|acceptance
P08825178A0071|67 69|TB
P08825556A0522|134 138|CREB
P08825556A0522|57 67|nucleotide
P08825556A0522|144 153|homodimer
P08825556A0522|6 13|element
P08825556A0522|100 108|TGACGTCA
P08825636T0000|148 163|I kappa B-gamma
P08825636T0000|26 35|structure
P08825636T0000|95 107|p50 proteins
P08825636T0000|202 221|signal transduction
P08827783A0499|72 74|h.
P08827783A0499|27 35|normoxia
P08828152A1238|181 202|amino acid similarity
P08828152A1238|47 64|RPO1 polypeptides
P08828152A1238|148 156|proteins
P08828152A1238|1 11|Comparison
P08828152A1238|68 72|IIV6
P08828857A2423|164 179|gene expression
P08828857A2423|108 117|paracrine
P08828857A2423|5 8|use
P08828857A2423|65 71|system
P08828857A2423|187 196|pregnancy
P08831364A1252|193 195|AV
P08831364A1252|163 172|adenosine
P08831364A1252|6 15|verapamil
P08831364A1252|66 75|adenosine
P08831364A1252|99 114|conduction time
P08833153A0628|120 125|genes
P08833153A0628|216 224|proteins
P08833153A0628|318 329|chromosomes
P08833153A0628|282 297|repeat sequence
P08833153A0628|4 12|addition
P08833153A0628|103 110|portion
P08833153A0628|34 54|hCHLR gene sequences
P08833653A0783|10 15|isl-1
P08833653A0783|244 248|InR1
P08833653A0783|163 173|properties
P08833653A0783|117 128|differences
P08835895A1292|60 76|immunodeficiency
P08835895A1292|24 33|remission
P08835895A1292|87 91|risk
P08836032T0000|78 91|ori functions
P08836032T0000|42 57|region sequence
P08836032T0000|65 73|enhancer
P08836740A1025|40 51|cell growth
P08836740A1025|66 81|deletion mutant
P08837746A0951|133 144|specificity
P08837746A0951|82 104|postglutamate cleavage
P08837746A0951|32 46|BrAAP activity
P08838148A1218|48 66|mouse TRH receptor
P08838148A1218|119 124|cells
P08838585A0968|46 64|backbone deviation
P08838585A0968|87 94|ras-p21
P08839498A0507|76 81|trunk
P08839498A0507|36 48|distribution
P08839498A0507|86 90|legs
P08839832A1220|14 29|phosphorylation
P08839832A1220|37 50|CD30v protein
P08840501A0345|53 57|gene
P08840501A0345|96 100|ACT4
P08840997A0765|27 34|alleles
P08840997A0765|158 165|alleles
P08840997A0765|85 94|sequences
P08843411A0801|5 12|classes
P08843411A0801|86 96|activation
P08843419A1290|9 20|calyculin A
P08843419A1290|37 42|OCFRE
P08843419A1290|1 4|OKA
P08844577A0000|86 94|medicine
P08844577A0000|68 71|use
P08845378A0368|83 93|MZF-1 gene
P08845378A0368|1 27|Restriction enzyme mapping
P08847138A0609|95 98|age
P08847138A0609|86 91|years
P08847723A2351|31 35|size
P08847723A2351|195 203|findings
P08847723A2351|58 71|inconsistency
P08847723A2351|159 171|associations
P08847723A2351|1 13|IMPLICATIONS
P08848052A0733|132 136|Gle1
P08848052A0733|92 102|RNA export
P08848052A0733|32 36|Gle1
P08849569A0615|47 56|variation
P08849569A0615|25 43|assay coefficients
P08849569A0615|117 125|cortisol
P08849778A0598|10 14|work
P08849778A0598|77 91|leader peptide
P08849778A0598|52 62|expression
P08850585A0602|45 53|elements
P08850585A0602|123 140|virulence factors
P08850585A0602|87 93|caries
P08851434A0383|66 70|half
P08851434A0383|19 44|fat/water intensity ratio
P08853893A0158|9 14|study
P08854844A0637|61 77|h post injection
P08854844A0637|28 45|non-visualization
P08854844A0637|157 158|%
P08854844A0637|103 112|diagnosis
P08854844A0637|85 94|criterion
P08856077T0000|13 23|processing
P08858211A0694|134 142|GST-Rab4
P08858211A0694|149 158|alpha-32P
P08858211A0694|111 120|alpha-32P
P08858211A0694|6 18|GAP activity
P08858463A0853|132 137|mg/kg
P08858463A0853|57 66|tolerance
P08858463A0853|213 217|rate
P08858463A0853|158 163|mg/kg
P08858463A0853|170 176|dosage
P08861963A0375b|108 132|transcription activation
P08861963A0375b|19 34|RNA polymerases
P08861963A0375b|136 144|cAMP-CRP
P08862522A0690|106 117|temperature
P08862522A0690|22 32|similarity
P08863824A0509|135 139|loop
P08863824A0509|183 191|5-HT2C-R
P08863824A0509|83 89|region
P08863824A0509|49 53|cDNA
P08864219A0178|75 87|itraconazole
P08864219A0178|89 100|fluconazole
P08864219A0178|40 44|MICs
P08864219A0178|158 171|inoculum size
P08864219A0178|49 61|ketoconazole
P08867519A0557|124 131|periods
P08867519A0557|39 43|s.c.
P08868660A0087|60 70|discussion
P08868660A0087|268 278|discussion
P08868660A0087|250 261|instruments
P08868660A0087|184 191|novelty
P08868660A0087|78 90|Rivista dell
P08868660A0087|196 206|weaknesses
P08868660A0087|138 146|research
P08868660A0087|170 179|strengths
P08869358A0121|12 19|viruses
P08869358A0121|49 59|strategies
P08869825A0000|74 77|FMO
P08869825A0000|58 72|monooxygenases
P08871542A1352|105 108|Mtx
P08871542A1352|156 177|Thbs3 gene expression
P08871542A1352|117 125|promoter
P08871567A0629|1 5|Gene
P08872162A0884|78 92|T cell subsets
P08872162A0884|68 71|CD4
P08873063A0493|36 42|LvUSF2
P08873063A0493|87 96|amino end
P08873159A0791|21 29|patients
P08874631A1133|47 55|evidence
P08874631A1133|76 81|HIV-1
P08874631A1133|1 15|Discrimination
P08876167A0717|215 230|p107 antibodies
P08876167A0717|93 100|CDP/cut
P08876167A0717|117 121|p107
P08876167A0717|74 84|antibodies
P08876167A0717|143 150|complex
P08876167A0717|5 11|HiNF-D
P08876167A0717|169 177|promoter
P08877103A0081|28 43|mdr2 expression
P08877103A0081|65 74|mdr2 gene
P08877103A0081|49 57|promoter
P08878019A0357|47 56|sinusoids
P08878019A0357|64 75|lymph nodes
P08878044A1390|150 160|J774 cells
P08878044A1390|213 219|strain
P08878044A1390|129 135|mutant
P08878044A1390|4 24|InlC deletion mutant
P08878573A1370|151 155|mice
P08878573A1370|44 55|combination
P08878573A1370|72 81|mg/kg/day
P08878573A1370|19 23|RIFA
P08878573A1370|103 115|prolongation
P08878573A1370|119 127|survival
P08879237A0744|147 148|G
P08879237A0744|157 175|rice mitochondrion
P08879237A0744|119 129|CRTA motif
P08881036A0351|23 33|VL element
P08881036A0351|16 19|PCR
P08882492A0000|75 79|role
P08882492A0000|93 104|development
P08882492A0000|163 173|identities
P08882492A0000|200 204|axis
P08884273A1413|44 57|polymorphisms
P08884273A1413|150 155|means
P08884273A1413|5 21|TYAC/P1 resource
P08884273A1413|201 208|closure
P08884273A1413|34 38|STSs
P08885270A0428|7 14|mutants
P08887643A1167|90 115|TC21 controls cell growth
P08887643A1167|156 174|signaling pathways
P08887643A1167|70 74|TC21
P08887652A0341|165 178|reading frame
P08887652A0341|270 273|hph
P08887652A0341|213 244|hygromycin B phosphotransferase
P08887652A0341|188 193|frame
P08887652A0341|138 145|segment
P08887652A0341|1 10|Selection
P08887661A0138|33 42|activator
P08887661A0138|50 55|IRF-2
P08887667A0992|89 99|conditions
P08887667A0992|145 152|mitosis
P08887667A0992|5 16|requirement
P08887667A0992|174 185|involvement
P08887674A0920|47 53|cyclin
P08887674A0920|111 119|activity
P08887674A0920|66 73|kinases
P08890537A0355|6 15|technique
P08891337A0614|30 33|E1A
P08891337A0614|63 78|weight proteins
P08891337A0614|112 132|coactivator function
P08891337A0614|20 26|region
P08891345A0684|88 99|translation
P08891345A0684|177 193|beta-globin mRNA
P08891345A0684|58 68|c-mos mRNA
P08891345A0684|20 38|UTR characteristic
P08891474A0667|183 197|depolarization
P08891474A0667|7 15|findings
P08891474A0667|143 155|nerve fibers
P08891474A0667|170 179|threshold
P08892755A0981|166 175|synthesis
P08892755A0981|11 23|DNA fragment
P08892755A0981|179 189|CAT enzyme
P08892755A0981|238 248|pCAT-Basic
P08892859A0563|14 21|example
P08892859A0563|72 74|T9
P08892859A0563|92 98|levels
P08892859A0563|114 127|C-MYB protein
P08893822A0560|73 83|transcript
P08893822A0560|33 43|PWP2H cDNA
P08894144A1173|32 45|bone turnover
P08895522T0000|29 51|tyrosine kinase domain
P08895522T0000|65 83|trk proto-oncogene
P08895522T0000|87 93|fusion
P08896280A0860|61 70|IME2 mRNA
P08896280A0860|42 48|levels
P08896280A0860|141 156|acid metabolism
P08896473A0282|105 116|development
P08896473A0282|61 65|HHCA
P08896473A0282|23 28|study
P08896473A0282|48 57|influence
P08896795A0166|105 109|lens
P08896795A0166|129 139|coverslips
P08896795A0166|66 75|specimens
P08896795A0166|81 94|oil immersion
P08896795A0166|152 163|air bubbles
P08897663T0000|47 58|suicidology
P08897663T0000|21 26|Babel
P08898336A0268|181 185|RNAs
P08898336A0268|83 91|evidence
P08898336A0268|1 26|RNase protection analysis
P08898866A0458|120 127|annexin
P08898866A0458|88 105|expression system
P08898866A0458|24 51|serine phosphorylation site
P08898866A0458|141 147|series
P08898866A0458|186 199|substitutions
P08900164A0188|5 10|Patel
P08900296A0000|45 63|adhesion molecules
P08900296A0000|113 122|mediation
P08900296A0000|5 18|up-regulation
P08900296A0000|100 105|event
P08901635A0000|164 170|plants
P08901635A0000|29 32|one
P08901635A0000|83 89|enzyme
P08901635A0000|4 9|spite
P08902214A1486|60 63|PRL
P08902214A1486|13 19|period
P08902214A1486|118 130|Stat factors
P08902641A0930|75 82|LV apex
P08902641A0930|109 114|aorta
P08902641A0930|126 127|n
P08902641A0930|25 35|connection
P08902641A0930|116 123|outflow
P08902988A0258|30 38|disorder
P08902988A0258|1 16|Factor V Leiden
P08905819A0531|61 63|sm
P08905819A0531|39 55|0-III components
P08905819A0531|21 26|cases
P08906139A2935|62 89|alkaline phosphatase values
P08906139A2935|36 46|monitoring
P08906139A2935|140 150|fortifiers
P08906139A2935|103 114|adjustments
P08910292T0000|56 61|Cdc42
P08910292T0000|38 51|proteins Rac1
P08910292T0000|69 74|c-Jun
P08910550A0501|122 138|cation chelators
P08910550A0501|92 96|EGTA
P08910550A0501|48 59|CBF binding
P08912232A0260|13 17|role
P08912232A0260|89 94|girls
P08912232A0260|21 23|ML
P08913186A0431|30 38|evidence
P08913186A0431|120 131|development
P08913186A0431|6 12|report
P08913186A0431|87 97|synkinesis
P08913974A0533|91 98|changes
P08913974A0533|13 20|percent
P08913974A0533|59 64|tubes
P08913974A0533|168 169|%
P08913974A0533|118 129|salpingitis
P08914522A0118|28 42|protein kinase
P08914522A0118|129 135|screen
P08914522A0118|157 168|suppressors
P08915051T0000|44 53|arthritis
P08915559A0366|47 65|platform technique
P08916960A0350|62 64|FL
P08916960A0350|79 90|alterations
P08916960A0350|147 160|reading frame
P08916960A0350|127 137|breakpoint
P08916960A0350|48 56|patients
P08917270A0229|131 140|substrate
P08917270A0229|59 67|exercise
P08917270A0229|87 93|marker
P08917270A0229|1 11|BACKGROUND
P08917449A0000|73 88|differentiation
P08917449A0000|97 105|survival
P08917449A0000|114 124|cell types
P08917449A0000|154 165|populations
P08918456A0455|26 37|interaction
P08918456A0455|131 138|leucine
P08918456A0455|112 122|position Y
P08918456A0455|66 74|tyrosine
P08918456A0455|100 108|arginine
P08918810A0967|43 53|OxyR-C199S
P08918810A0967|174 178|OxyR
P08918810A0967|18 30|footprinting
P08918885A1087|75 90|dig1 dig2 ste12
P08918885A1087|131 135|Dig1
P08918885A1087|52 63|agar medium
P08918885A1087|4 12|contrast
P08918885A1087|153 157|role
P08918934A0424|211 218|linkers
P08918934A0424|167 174|repeats
P08918934A0424|19 28|sequences
P08918934A0424|153 157|core
P08919907A0763|72 82|activation
P08919907A0763|109 117|promoter
P08919907A0763|25 30|VSF-1
P08920499A0164|1 26|Blood sampling procedures
P08921667A0294|75 77|Vd
P08921667A0294|92 108|rCBF measurement
P08921667A0294|157 162|study
P08921667A0294|117 123|method
P08922344A1539|57 61|acid
P08922344A1539|214 226|hypertension
P08922344A1539|66 82|xanthine oxidase
P08922344A1539|117 131|blood pressure
P08922385A0622|73 84|proteolysis
P08922385A0622|146 152|detour
P08922385A0622|92 119|beta-galactosidase tetramer
P08922385A0622|37 47|inhibition
P08922390A0793|167 178|amino acids
P08922390A0793|7 11|data
P08922390A0793|101 106|sites
P08922390A0793|152 159|stretch
P08922391A0304|132 136|site
P08922391A0304|112 119|protein
P08922391A0304|70 81|PDZ repeats
P08923258A0353|55 64|Holsteins
P08923258A0353|68 69|d
P08923469A1391|164 176|half-element
P08923469A1391|7 14|results
P08923469A1391|68 91|RXR heterodimer binding
P08924211A0941|43 49|region
P08924211A0941|110 115|types
P08924211A0941|119 122|PST
P08925545T0001|13 27|erythropoietin
P08925545T0001|58 64|anemia
P08927612T0000|47 61|adenocarcinoma
P08929089A0231|14 24|ratio M/Pc
P08929089A0231|43 48|index
P08931388A0806|104 110|sample
P08931388A0806|52 60|fragment
P08931388A0806|5 25|mobility shift assay
P08932363A0807|135 145|E1A mutant
P08932363A0807|52 74|squelshing experiments
P08932363A0807|38 48|competitor
P08932363A0807|154 173|CBP binding ability
P08933487A0325|14 28|occasion water
P08934533A0784|40 49|structure
P08934533A0784|20 29|mutations
P08934533A0784|70 73|DNA
P08935931A0787|107 116|procedure
P08935931A0787|196 199|EGD
P08935931A0787|83 87|fall
P08935931A0787|169 173|SpO2
P08936128A0611|62 66|G Hb
P08936128A0611|20 34|cost dimension
P08936128A0611|1 12|Discordance
P08937112A0561|44 49|years
P08937112A0561|1 8|RESULTS
P08937981A0840|90 102|distribution
P08937981A0840|44 56|p54 subunits
P08937981A0840|124 127|p46
P08937981A0840|36 39|p46
P08938418A0099|8 22|embryo library
P08939891A0285|75 79|bait
P08939891A0285|123 126|Nrl
P08939891A0285|97 102|clone
P08939891A0285|68 71|DNA
P08940132A1120|240 245|CPP32
P08940132A1120|72 80|activity
P08940132A1120|7 15|findings
P08940132A1120|249 268|DEVD-CHO inhibition
P08940132A1120|103 112|proteases
P08940298A0962|31 39|delta419
P08940298A0962|11 19|residues
P08940298A0962|80 99|vitamin D3 receptor
P08940298A0962|185 193|activity
P08943032A0000|161 173|interactions
P08943032A0000|22 35|tet-repressor
P08943032A0000|81 90|variation
P08943032A0000|115 120|assay
P08943928A1137|28 32|dose
P08943928A1137|55 63|outbreak
P08944755A0211|1 5|Biol
P08945810T0001|73 80|mammals
P08945810T0001|39 43|bulb
P08946668A0077|43 56|cyclosporin A
P08946668A0077|1 6|FK506
P08948440A0628|143 149|embryo
P08948440A0628|100 107|oocytes
P08950352A0525|150 154|area
P08950352A0525|46 53|samples
P08950352A0525|77 82|areas
P08950352A0525|189 190|p
P08952483A0207|134 142|assembly
P08952483A0207|37 57|polypeptide fragment
P08952483A0207|20 28|features
P08952965A1182|180 197|framework regions
P08952965A1182|112 119|tamarin
P08952965A1182|157 166|reduction
P08952965A1182|19 29|proportion
P08952965A1182|72 85|substitutions
P08952965A1182|129 141|region genes
P08952965A1182|170 172|pN
P08952965A1182|68 70|pS
P08954725A1175|10 21|development
P08954725A1175|126 132|streak
P08954725A1175|23 38|Tbx6 expression
P08955111A0989|47 63|enhancer regions
P08955111A0989|5 12|results
P08955111A0989|34 42|promoter
P08955159A0000|63 65|EC
P08955159A0000|7 22|acid ceramidase
P08955306A0224|166 172|growth
P08955306A0224|176 183|acetate
P08955306A0224|113 117|ORF1
P08955306A0224|49 58|cdh genes
P08955306A0224|16 29|blot analyses
P08955928A0390|62 64|EB
P08955928A0390|124 129|onset
P08955928A0390|116 117|h
P08955928A0390|50 60|Evans Blue
P08958720A1204|63 66|SVI
P08958720A1204|78 80|HR
P08958720A1204|20 28|exercise
P08959117A0708|126 136|influences
P08959117A0708|173 185|measurements
P08959117A0708|156 167|ICU setting
P08959117A0708|70 80|hypoxaemia
P08959117A0708|103 110|disease
P08960827A1169|104 116|insulin gene
P08960827A1169|77 90|transcription
P08960827A1169|141 148|binding
P08962614A0000|45 55|antibodies
P08962614A0000|130 150|challenge procedures
P08962614A0000|95 111|skin-prick tests
P08962614A0000|5 18|determination
P08962614A0000|187 198|individuals
P08964172A0221|74 79|cases
P08964172A0221|12 39|cytocentrifuge preparations
P08964172A0221|130 141|tumor cells
P08964172A0221|1 7|Filter
P08967963A1735|151 173|beta cell line RIN-5AH
P08967963A1735|109 126|cell line RSMT-A5
P08967963A1735|5 21|promoter segment
P08969777A0771|109 135|serum 25-OHD concentration
P08969777A0771|24 30|scores
P08969777A0771|69 77|patients
P08970951A0823|30 36|levels
P08970951A0823|109 113|core
P08970951A0823|99 105|levels
P08970951A0823|118 130|Pol proteins
P08970984A0765|91 103|Rel/NFkappaB
P08970984A0765|5 19|SCMV SNE sites
P08970984A0765|86 89|SRF
P08970984A0765|50 81|core recognition binding motifs
P08971009A0860|166 170|loci
P08971009A0860|98 103|sites
P08971009A0860|186 197|DNA genomes
P08971835A1057|13 17|dogs
P08971835A1057|110 111|%
P08971835A1057|54 65|reperfusion
P08971835A1057|32 41|alpha-MSH
P08972182A0527|74 90|family proteases
P08972182A0527|36 49|interleukin-1
P08972182A0527|101 110|apoptosis
P08972182A0527|138 171|cowpox ICE inhibitor protein CrmA
P08972182A0527|187 222|tetrapeptide ICE inhibitor YVAD-CMK
P08972232A0365|9 15|report
P08972232A0365|54 57|HAT
P08973527A0000|15 19|DNAs
P08973527A0000|37 49|coat protein
P08973527A0000|115 135|Hordeum mosaic virus
P08973527A0000|137 141|HoMV
P08973917A0632|42 51|PWP2 gene
P08974103A0451|135 142|pattern
P08974103A0451|57 75|laboratory results
P08974103A0451|21 33|combinations
P08975532T0001|1 15|Liver injuries
P08976253A0637|69 86|plasma PSA levels
P08977235A0134|61 65|JAK1
P08977235A0134|36 45|molecules
P08977235A0134|1 6|G-CSF
P08977401A0227|390 404|messenger RNAs
P08977401A0227|264 272|RI alpha
P08977401A0227|218 224|region
P08977401A0227|118 124|length
P08977401A0227|105 109|gene
P08977401A0227|46 51|exons
P08977401A0227|310 323|RI alpha gene
P08977401A0227|5 18|RI alpha gene
P08978817A0620|224 231|pathway
P08978817A0620|127 141|growth defects
P08978817A0620|4 12|addition
P08978817A0620|55 61|dim2-1
P08978817A0620|100 106|act1-1
P08979089A1197|73 96|core promoter mutations
P08979089A1197|8 20|transfection
P08979089A1197|173 183|activation
P08979089A1197|187 198|promoter P1
P08980413A0500|75 77|N2
P08980413A0500|13 16|N22
P08980413A0500|5 8|P13
P08980413A0500|68 70|P2
P08980533A1160|54 62|homology
P08980533A1160|35 40|ENBP1
P08980533A1160|119 132|testis tissue
P08980819A0193|135 140|birds
P08980819A0193|124 129|birds
P08980819A0193|110 114|toms
P08980819A0193|23 28|ranch
P08981371A2049b|14 26|PIP2 content
P08981371A2049b|78 93|CSF-1 treatment
P08985115A1571|11 25|identification
P08985115A1571|40 54|37LRP/p40 gene
P08985115A1571|93 97|step
P08985115A1571|217 230|up-regulation
P08985115A1571|256 270|tumor invasion
P08985115A1571|275 285|metastasis
P08985415A1096|52 61|mechanism
P08985415A1096|96 105|IFN-gamma
P08985415A1096|84 92|CAEV LTR
P08986214A0000|151 160|cirrhosis
P08986214A0000|89 93|sera
P08986214A0000|179 203|hepatocyte growth factor
P08986214A0000|38 46|response
P08986214A0000|103 111|patients
P08986692A0306|75 83|patients
P08986692A0306|29 50|hemostasis parameters
P08986692A0306|1 13|INTERVENTION
P08986812A1214|46 50|cDNA
P08986812A1214|78 83|tumor
P08986812A1214|18 21|p53
P08987225A0675|166 173|history
P08987225A0675|92 99|history
P08987225A0675|191 193|NT
P08987225A0675|136 146|proportion
P08987225A0675|68 85|hepatitis C cases
P08988913A0821|145 154|excretion
P08988913A0821|36 42|models
P08988913A0821|4 12|contrast
P08989763A0605|9 18|artifacts
P08989763A0605|70 79|diaphragm
P08990194A0000|31 46|thyroid hormone
P08990194A0000|182 196|refractoriness
P08990194A0000|5 13|syndrome
P08990194A0000|87 103|thyroid hormones
P08992115A0199|224 227|air
P08992115A0199|133 138|blood
P08992115A0199|26 36|bronchitis
P08992115A0199|162 181|lactic acid content
P08992115A0199|5 16|progression
P08993393T0000|14 23|signaling
P08993393T0000|107 116|adenylate
P08993393T0000|136 156|polypeptide receptor
P08993836A0699|31 38|respect
P08993836A0699|79 95|HNF-3 alpha gene
P08993836A0699|129 142|embryogenesis
P08994832A0782|9 19|expression
P08994832A0782|23 28|Apo-3
P08994832A0782|68 77|apoptosis
P08995054A0618|59 65|region
P08995054A0618|1 11|Similarity
P08995410A0000|180 187|subunit
P08995410A0000|63 70|complex
P08995410A0000|145 157|mRNA binding
P08995410A0000|189 193|eIF3
P08995410A0000|12 29|initiation factor
P08995410A0000|99 106|complex
P08995410A0000|33 37|eIF3
P08995614T0000|47 52|class
P08995614T0000|116 126|activation
P08995614T0000|1 15|Identification
P08995659A0563|179 192|splice region
P08995659A0563|81 90|infection
P08995659A0563|153 160|primers
P08996730A1146|28 50|vibration measurements
P08996730A1146|20 24|data
P08996730A1146|87 98|uncertainty
P08996730A1146|187 198|measurement
P08996730A1146|171 183|difficulties
P08997532A0116|24 27|IgE
P08997532A0116|66 74|Toxocara
P08997532A0116|101 109|antigens
P08999414A0819|40 57|genus Dermacentor
P08999414A0819|5 16|differences
P08999882T0000|24 30|traits
P09000108A0330|163 192|translation termination codon
P09000108A0330|82 91|consensus
P09000108A0330|66 70|site
P09000108A0330|103 126|polyadenylation signals
P09000589A0000|90 96|agents
P09000589A0000|5 15|resurgence
P09001213A1111|209 218|var genes
P09001213A1111|188 204|expression sites
P09001213A1111|51 55|gene
P09001313A0000|43 46|SDB
P09001313A0000|32 41|breathing
P09001828A0222|75 79|time
P09001828A0222|172 177|study
P09001828A0222|141 150|treatment
P09001828A0222|35 40|years
P09002672A0439|90 103|repeat arrays
P09002672A0439|225 231|TTAGGC
P09002672A0439|182 196|TTAGGG repeats
P09002672A0439|10 21|translation
P09002672A0439|172 178|arrays
P09002672A0439|236 250|TTGGGG repeats
P09003001A1909|47 67|transferrin promoter
P09003001A1909|27 39|SE2 fragment
P09003001A1909|5 19|E-box sequence
P09003001A1909|116 140|consensus E-box elements
P09003312A0740|31 38|AT-PHH1
P09003312A0740|243 248|light
P09003312A0740|178 183|yeast
P09003312A0740|116 132|photolyase genes
P09003462A0792|45 48|S29
P09003462A0792|56 61|SL196
P09003462A0792|66 71|SL126
P09003462A0792|19 33|mutation sites
P09003462A0792|50 54|SL11
P09003617A0000|21 29|children
P09003617A0000|3 9|cohort
P09004504A0000|61 69|pla gene
P09004504A0000|150 180|Yersinia pestis plasmid pYP358
P09004504A0000|111 117|origin
P09004504A0000|33 48|bp DNA fragment
P09005273A0322|40 46|factor
P09005273A0322|24 36|Associations
P09005273A0322|157 183|neuropathy target esterase
P09005273A0322|1 22|MAIN OUTCOME MEASURES
P09005609A0299|54 60|period
P09005979A0841|14 29|GHBP mRNA ratio
P09005979A0841|5 13|GHR mRNA
P09006010A0527|148 157|secretion
P09006010A0527|54 64|amino acid
P09006010A0527|87 105|S-layer biogenesis
P09006010A0527|230 231|C
P09006010A0527|37 52|RsaA C terminus
P09006010A0527|5 29|linker-peptide insertion
P09006051A1162|241 249|homology
P09006051A1162|301 309|function
P09006051A1162|335 364|acetyl coenzyme A synthetases
P09006051A1162|159 163|PrpC
P09006051A1162|323 331|homology
P09006051A1162|187 195|archaeal
P09006051A1162|229 233|PrpD
P09006051A1162|311 315|PrpE
P09006902A0370|40 45|MEKK3
P09006914A0812|47 54|nucleus
P09006914A0812|110 113|JNK
P09006914A0812|70 75|c-JUN
P09006914A0812|118 121|p38
P09006935A0590|44 46|KD
P09006935A0590|54 56|nM
P09006935A0590|34 42|affinity
P09008301A0193|148 155|studies
P09008301A0193|117 124|protein
P09010223A0667|77 81|PEA3
P09010223A0667|36 40|ELK1
P09010223A0667|65 69|ETS1
P09010223A0667|71 75|ETS2
P09010223A0667|49 53|FLI1
P09011591A0309|47 57|nonsmokers
P09011591A0309|65 72|smokers
P09011745T0000|120 129|structure
P09011745T0000|165 174|processes
P09011745T0000|6 13|cloning
P09011745T0000|190 199|receptors
P09012636A0723|132 143|association
P09012636A0723|27 38|cholesterol
P09012636A0723|57 70|triglycerides
P09012636A0723|1 11|Adjustment
P09012636A0723|102 110|pressure
P09013760A0000|151 155|cAMP
P09013760A0000|24 48|cleavage cytochrome P450
P09013760A0000|129 134|ovary
P09013760A0000|142 146|ACTH
P09013760A0000|117 121|cAMP
P09013760A0000|50 56|CYP11A
P09015757T0000|12 20|analysis
P09015757T0000|25 41|characterization
P09015757T0000|100 117|bone sialoprotein
P09016566A0655|75 84|BiP mRNAs
P09016566A0655|55 61|number
P09018122A1389|122 139|tumor development
P09018122A1389|5 14|detection
P09018122A1389|114 118|role
P09019302A0600|9 15|method
P09019302A0600|77 91|derivatization
P09019302A0600|59 70|sensitivity
P09019302A0600|17 20|PLP
P09020169A0552|27 37|homodimers
P09020169A0552|69 72|AHR
P09020856A0560|33 37|TIS1
P09022040A0263|240 248|function
P09022040A0263|147 162|gene expression
P09022040A0263|9 29|L-plastin expression
P09022040A0263|71 77|humans
P09022040A0263|117 127|mechanisms
P09023197T0000|20 37|Bacillus subtilis
P09024039A0247|164 174|isoflurane
P09024039A0247|180 191|ventilation
P09024039A0247|95 105|procedures
P09024039A0247|67 74|variety
P09024039A0247|84 85|h
P09024793A1325|91 95|MyoD
P09024793A1325|8 44|electrophoresis mobility shift assay
P09024793A1325|197 202|BMP-2
P09024793A1325|185 193|presence
P09024793A1325|84 89|cells
P09025122A0374|12 23|experiments
P09025122A0374|142 153|performance
P09027346A1957|30 39|site IIIa
P09027346A1957|47 69|hCG-ectodomain complex
P09027346A1957|166 170|pE x
P09027346A1957|160 164|exon
P09028089A0183|79 89|blood flow
P09028089A0183|39 51|hypertension
P09028942A0000|106 109|jun
P09028942A0000|78 81|set
P09028942A0000|126 146|growth response gene
P09028942A0000|49 55|factor
P09029091A0881|111 123|Jurkat cells
P09029091A0881|65 86|phospholipase C gamma
P09029159A0000|105 109|role
P09029159A0000|46 49|RNA
P09029159A0000|92 95|PKR
P09029159A0000|17 20|IFN
P09029159A0000|68 90|Ser/Thr protein kinase
P09029956T0000|8 17|relations
P09030688A0435|28 37|chromatin
P09030688A0435|4 16|rlf2 mutants
P09031639A0474|149 157|position
P09031639A0474|11 18|kb cDNA
P09031639A0474|177 189|U1-C protein
P09031639A0474|36 49|reading frame
P09031639A0474|139 147|position
P09032248A0239|123 143|Cln1,2-Cdc28 kinases
P09032248A0239|37 46|viability
P09032248A0239|99 104|Start
P09032254A0724|37 46|AP-1 site
P09032254A0724|1 18|Enhancer activity
P09032259A0150|61 75|transformation
P09032259A0150|28 32|Rac1
P09032259A0150|37 41|RhoA
P09032267A0850|90 100|cross talk
P09032267A0850|23 46|bZip interaction domain
P09032267A0850|1 15|Overexpression
P09032304T0000|39 61|transactivation domain
P09032304T0000|1 15|Identification
P09034337A0251|105 112|p34cdc2
P09034337A0251|44 53|induction
P09034337A0251|22 27|cells
P09034337A0251|86 101|phosphorylation
P09034337A0251|68 76|tyrosine
P09035612T0000|57 67|blood flow
P09035612T0000|32 44|infarct size
P09035612T0000|119 130|reperfusion
P09037032T0000|46 51|P2P-R
P09037032T0000|53 57|gene
P09037032T0000|191 206|differentiation
P09037032T0000|102 131|ribonucleoprotein association
P09037163A1652|24 32|elements
P09037163A1652|70 90|gpc4 gene expression
P09038192A0846|27 35|PD098059
P09038192A0846|16 25|inhibitor
P09039744T0000|70 83|sinc function
P09041123A0195|14 20|action
P09041123A0195|163 170|complex
P09041123A0195|71 78|factors
P09042269A1007|7 15|findings
P09042755T0000|63 73|regulation
P09042755T0000|125 135|heat shock
P09042755T0000|81 92|sigB operon
P09043534A1600|40 54|alkalinization
P09043534A1600|71 78|minutes
P09045636A0789|27 51|tyrosine phosphorylation
P09045636A0789|1 18|CD3 cross-linking
P09045842T0000|37 45|subunits
P09045842T0000|71 81|expression
P09045842T0000|1 10|Mutations
P09046013A0000|72 95|calcium channel blocker
P09046013A0000|215 223|ligation
P09046013A0000|312 318|artery
P09046013A0000|21 29|efficacy
P09046013A0000|171 174|min
P09046186A0189|5 14|protector
P09046186A0189|71 81|trochanter
P09047252A0209|78 81|HCC
P09047252A0209|22 30|patients
P09047252A0209|156 161|study
P09048617A0648|31 55|tyrosine kinase receptor
P09048617A0648|92 98|nature
P09049270A0488|182 192|metal ions
P09049270A0488|214 218|type
P09049270A0488|59 70|transcripts
P09049270A0488|87 92|genes
P09049270A0488|164 172|addition
P09049270A0488|196 210|characteristic
P09049270A0488|32 33|A
P09049270A0488|1 23|Northern blot analysis
P09049306A0830|5 13|HBP gene
P09049306A0830|71 74|arm
P09050689A0685|45 50|SnET2
P09050689A0685|77 91|administration
P09050689A0685|22 30|ablation
P09050849A0000|56 62|system
P09050849A0000|96 103|homolog
P09050849A0000|1 12|Cytohesin-1
P09050849A0000|136 153|Sec7 gene product
P09050861A0903|39 42|DEK
P09051656A0390|133 137|sham
P09051656A0390|108 129|day morphine infusion
P09051656A0390|154 162|subjects
P09053494A0612|120 125|G-CSF
P09053494A0612|246 248|CY
P09053494A0612|83 93|paclitaxel
P09053494A0612|254 259|G-CSF
P09053494A0612|14 21|medians
P09053494A0612|111 114|CEP
P09053494A0612|39 43|CD34
P09053494A0612|103 105|CE
P09053973A1252|90 96|effect
P09053973A1252|110 118|patients
P09053973A1252|21 35|administration
P09056761A0000|15 20|cells
P09056761A0000|47 58|translation
P09056761A0000|189 198|cytoplasm
P09056761A0000|71 77|codons
P09056761A0000|206 213|nucleus
P09056761A0000|32 43|termination
P09057648A0422|60 65|tat/S
P09057648A0422|149 154|front
P09057648A0422|29 37|tat cDNA
P09057648A0422|330 362|micrograms/mL phytohemagglutinin
P09057648A0422|417 427|U937 cells
P09057648A0422|459 468|mol/L PMA
P09057648A0422|84 91|plasmid
P09057648A0422|286 294|addition
P09057648A0422|11 25|cotransfection
P09057648A0422|308 318|calf serum
P09057648A0422|207 210|CAT
P09057648A0422|408 411|PMA
P09057840A0946|41 52|homogeneity
P09057840A0946|114 127|AMP-Sepharose
P09057840A0946|17 24|protein
P09058002T0000|50 61|lobe damage
P09058323A1287|78 82|beta
P09058323A1287|199 217|gene transcription
P09058323A1287|178 183|alpha
P09058323A1287|5 12|results
P09058323A1287|154 166|CNS patterns
P09058373A1620|12 17|tests
P09058373A1620|109 113|form
P09058373A1620|66 74|elements
P09059039A0850|123 131|infusion
P09059039A0850|321 327|ml/min
P09059039A0850|55 58|ACA
P09059039A0850|285 295|papaverine
P09059039A0850|228 236|patients
P09059039A0850|78 86|patients
P09059039A0850|273 281|infusion
P09059039A0850|305 315|C1 segment
P09060444A0557|215 219|gene
P09060444A0557|6 22|promoter segment
P09060444A0557|35 45|expression
P09060623A0961|11 21|coreceptor
P09060971A0982|183 190|g/cm2/y
P09060971A0982|244 247|hip
P09060971A0982|256 263|g/cm2/y
P09060971A0982|16 21|women
P09060971A0982|192 193|p
P09060971A0982|39 46|decline
P09060971A0982|1 8|RESULTS
P09061697T0000|60 68|practice
P09061697T0000|12 24|SPET imaging
P09061697T0000|100 120|day imaging protocol
P09062130A0116|183 194|SH2 domains
P09062130A0116|56 64|increase
P09062130A0116|99 122|N-SH2 domain engagement
P09062130A0116|1 7|Relief
P09062130A0116|137 158|phosphotyrosyl ligand
P09064868T0001|3 15|miracle cure
P09065463A1012|1 20|DNA strand exchange
P09065768A0862|45 58|kb transcript
P09065768A0862|21 25|cDNA
P09067577A0721|91 94|SOS
P09067577A0721|66 70|CRKL
P09067577A0721|18 23|cells
P09071308A0376|88 95|finding
P09071308A0376|130 138|patients
P09071308A0376|144 147|MTB
P09071308A0376|18 27|opacities
P09071308A0376|152 156|NTMB
P09072361A0357|123 138|magnesium ratio
P09072361A0357|176 181|SHRSR
P09072361A0357|112 119|calcium
P09072361A0357|168 171|WKY
P09072361A0357|50 58|decrease
P09073582A0444|12 18|report
P09073582A0444|43 62|BglII-SmaI fragment
P09073582A0444|84 88|ori2
P09075739A0827|9 23|splice pattern
P09075739A0827|48 49|S
P09075739A0827|68 74|kidney
P09077437T0000|44 50|origin
P09077437T0000|54 62|phage f1
P09079625A0935|131 140|adhesions
P09079625A0935|82 85|PKC
P09079625A0935|114 119|sites
P09079625A0935|102 110|activity
P09079650A0136|72 76|ERKs
P09079650A0136|144 151|p38/Hog
P09079650A0136|80 86|p42/44
P09079650A0136|87 91|MAPK
P09079650A0136|1 8|Members
P09079817A0928|13 26|NO production
P09079817A0928|76 80|mRNA
P09079817A0928|66 72|levels
P09079902A0713|57 72|pyruvate kinase
P09079902A0713|86 89|Pra
P09079902A0713|164 166|Pk
P09079902A0713|74 76|Pk
P09079902A0713|79 81|Pk
P09079902A0713|143 146|Pra
P09079902A0713|236 239|Ndk
P09079915T0000|11 27|characterization
P09079928A1319|128 136|bacteria
P09079928A1319|22 26|OxyR
P09079928A1319|5 17|binding site
P09079928A1319|38 44|P1oxyR
P09079928A1319|141 155|characteristic
P09081392A0174|37 53|salvage regimens
P09083291A1378|214 226|inactivation
P09083291A1378|52 62|expression
P09083291A1378|250 260|transition
P09083291A1378|194 209|phosphorylation
P09083291A1378|67 76|abundance
P09083291A1378|237 245|G1 phase
P09083291A1378|103 107|cdks
P09083563A0971|107 124|arachnoid vessels
P09083563A0971|243 248|fluid
P09083563A0971|71 92|leptomeningeal tissue
P09083563A0971|256 265|B. cereus
P09084176A0601|42 65|slot-blot hybridization
P09084176A0601|17 25|activity
P09084621A0374|122 127|areas
P09084621A0374|131 159|brain activity proportionate
P09084621A0374|163 167|task
P09084621A0374|99 109|blood flow
P09085842A0181|75 86|splice site
P09085842A0181|151 165|U1-70K protein
P09085842A0181|8 15|studies
P09085842A0181|170 177|SF2/ASF
P09086268A0611|89 103|RNA polymerase
P09086268A0611|10 12|P7
P09086268A0611|55 57|P7
P09088371T0000|44 56|antithrombin
P09088371T0000|29 38|protein S
P09088371T0000|18 27|protein C
P09088737T0000|24 46|thickness measurements
P09088737T0000|96 100|CMTF
P09089653A0615|61 65|exon
P09089653A0615|79 89|nt segment
P09089653A0615|188 203|control plasmid
P09089653A0615|48 50|nt
P09090050A0419|59 64|mouse
P09090592A0175|181 192|orientation
P09090592A0175|10 17|methods
P09090592A0175|103 108|error
P09091125A0161|67 75|alkaline
P09091125A0161|21 26|cells
P09092493A0861|130 139|mechanism
P09092493A0861|24 32|VIP CyRE
P09092493A0861|172 181|signaling
P09092493A0861|5 16|integration
P09092636A0802|181 185|DYZ5
P09092636A0802|5 12|results
P09092636A0802|207 216|YAC clone
P09093867T0000|14 31|Ac/Ds transposons
P09093867T0000|58 62|fate
P09094315A0541|57 65|activity
P09094315A0541|37 47|regulation
P09096229T0000|241 258|control sequences
P09096229T0000|24 29|level
P09096229T0000|202 207|rad16
P09096229T0000|80 89|MFA2 gene
P09096229T0000|169 183|identification
P09096958A0000|210 229|actin stress fibers
P09096958A0000|47 57|antibodies
P09096958A0000|79 93|platelet talin
P09096958A0000|25 30|panel
P09096958A0000|97 113|Western blotting
P09096958A0000|141 159|immunofluorescence
P09098899A0000|15 16|B
P09098899A0000|61 71|Ogr family
P09098899A0000|1 10|Coliphage
P09098899A0000|85 106|transcription factors
P09099683A0000|147 151|acid
P09099683A0000|57 81|messenger diacylglycerol
P09099683A0000|1 22|Diacylglycerol kinase
P09099702A0692|30 37|conRTRE
P09099702A0692|61 65|RTRE
P09099702A0692|131 146|mouse protamine
P09099702A0692|82 87|P2-RE
P09099702A0692|216 219|RTR
P09099745A1446|121 124|p27
P09099745A1446|334 349|phosphorylation
P09099745A1446|353 357|Cdk2
P09099745A1446|47 53|weight
P09099745A1446|8 17|complexes
P09099745A1446|140 144|Cdk2
P09099745A1446|273 298|CDK inhibitor association
P09101085A0686|63 73|expression
P09101085A0686|81 96|p27Kip1 protein
P09101085A0686|101 111|inhibition
P09102113A0739|15 31|failure patients
P09102113A0739|131 136|death
P09102113A0739|84 93|frequency
P09104816A0610|15 18|Vpu
P09104816A0610|120 122|VV
P09104816A0610|62 68|detail
P09104816A0610|5 11|effect
P09105363A0636|35 56|emission spectroscopy
P09106057A0000|269 271|CL
P09106057A0000|31 44|determination
P09106057A0000|157 163|plasma
P09106057A0000|223 237|chromatography
P09106057A0000|74 93|anhydroerythromycin
P09106057A0000|3 9|method
P09106057A0000|136 147|metabolites
P09108038A1128|11 21|LRR domain
P09108038A1128|124 140|binding proteins
P09108038A1128|101 107|family
P09108279A0431|62 70|extracts
P09108279A0431|148 162|8-OxoG residue
P09108279A0431|177 185|cytosine
P09108279A0431|202 211|substrate
P09108279A0431|187 195|8-OxoG/C
P09110176A0890|72 79|animals
P09110176A0890|53 66|mouse tissues
P09110176A0890|33 49|Ube3a expression
P09110176A0890|117 123|disomy
P09110176A0890|204 211|animals
P09111048X0000|134 139|theme
P09111048X0000|208 221|cells/tissues
P09111048X0000|77 98|nitric-oxide synthase
P09111048X0000|100 114|mRNA diversity
P09111309A0674|60 63|MAP
P09111309A0674|29 32|p44
P09111309A0674|142 150|response
P09111309A0674|19 24|Ets-2
P09111309A0674|1 15|Cotransfection
P09111314A1243|181 197|p15INK4B protein
P09111314A1243|63 71|TGF-beta
P09111314A1243|93 104|observation
P09111314A1243|5 15|importance
P09111314A1243|51 59|p15INK4B
P09111340A0240|45 55|c-myc mRNA
P09111340A0240|300 304|gene
P09111340A0240|162 167|genes
P09111340A0240|295 298|CAT
P09111340A0240|140 149|myc genes
P09111340A0240|185 198|myc sequences
P09111863A0743|30 36|region
P09111863A0743|209 220|tumor cells
P09111863A0743|40 49|deletions
P09111863A0743|66 82|tumor suppressor
P09111863A0743|5 15|likelihood
P09112589A0078|33 40|pattern
P09115242A0934|126 136|C/EBP-beta
P09115242A0934|112 124|protein-beta
P09115242A0934|233 238|cells
P09115242A0934|138 150|binding site
P09115265A1160|78 84|domain
P09115265A1160|102 129|transcription factor GATA-1
P09115357A0073|183 204|hypermutating B cells
P09115357A0073|148 159|development
P09115357A0073|163 178|culture systems
P09115357A0073|234 245|individuals
P09115357A0073|220 229|screening
P09115395A0478|123 134|protein-115
P09115395A0478|188 200|protein L18A
P09115395A0478|429 450|transcription factors
P09115395A0478|492 494|S.
P09115395A0478|501 505|Cdc5
P09115395A0478|514 518|Sox3
P09115395A0478|373 377|BRG1
P09115395A0478|89 111|epithelial-microtubule
P09115395A0478|386 402|RNA helicase WM6
P09115395A0478|80 87|mitosis
P09115395A0478|467 483|co-factor 2alpha
P09115395A0478|10 18|proteins
P09115395A0478|547 552|Xbr1b
P09115395A0478|136 141|Oct91
P09117345A0945|122 129|pattern
P09117345A0945|23 27|beta
P09117345A0945|35 41|TS2/16
P09117345A0945|68 79|protrusions
P09118664A1734|61 75|oxide synthase
P09118664A1734|27 36|inhibitor
P09118664A1734|1 13|L-canavanine
P09119031A1036|105 124|core RNA polymerase
P09119031A1036|78 85|mutants
P09119031A1036|179 187|activity
P09119031A1036|237 249|sigma factor
P09119391A0870|12 20|sequence
P09119391A0870|110 126|protein sequence
P09121430A0132|91 95|Grb2
P09121430A0132|131 138|residue
P09121430A0132|54 58|MAPK
P09121430A0132|1 4|Shc
P09121432A0000|121 128|kinases
P09121432A0000|36 43|protein
P09121432A0000|69 75|switch
P09121435A1183|40 48|assembly
P09121435A1183|21 22|B
P09121454A1328|120 129|functions
P09121454A1328|148 156|activity
P09121454A1328|42 46|mot1
P09121454A1328|36 40|bur3
P09121454A1328|48 57|mutations
P09121774A0611|91 98|members
P09121774A0611|7 17|activities
P09121774A0611|54 65|cell growth
P09121998A0663|112 122|procedures
P09121998A0663|184 192|fraction
P09121998A0663|49 57|interest
P09121998A0663|15 21|curves
P09121998A0663|200 209|test meal
P09121998A0663|141 145|mean
P09122176A0970|57 66|hMGP gene
P09122176A0970|77 84|binding
P09122176A0970|5 12|results
P09122215A0335|109 113|gene
P09122215A0335|21 27|method
P09123787A0486|131 135|side
P09123787A0486|212 214|Rc
P09123787A0486|36 45|responses
P09123787A0486|87 123|orbicularis oculi muscle ipsilateral
P09123787A0486|169 177|response
P09126487A1399|8 11|Hum
P09128730A0000|121 141|acyl-carrier protein
P09128730A0000|147 155|malonate
P09128730A0000|157 173|carboxyltransfer
P09128730A0000|84 104|acyl-carrier protein
P09128730A0000|10 25|decarboxylation
P09128730A0000|202 217|decarboxylation
P09130595A0478|57 70|enhancer site
P09130595A0478|35 42|protein
P09130718A0497|129 132|ATG
P09130718A0497|80 89|bp region
P09130718A0497|51 55|sid1
P09131139T0000|41 47|PAF-AH
P09131139T0000|49 57|activity
P09131139T0000|16 19|PAF
P09132057A0559|30 33|NTS
P09132057A0559|297 307|resistance
P09132057A0559|216 227|self-pollen
P09132057A0559|256 272|Pto gene product
P09132057A0559|231 247|Brassica species
P09132057A0559|276 282|tomato
P09132057A0559|203 212|rejection
P09133122A0656|149 156|program
P09133122A0656|94 108|x-ray analysis
P09133122A0656|110 120|angiograms
P09135149A0000|128 149|Mik1 tyrosine kinases
P09135149A0000|96 102|kinase
P09135149A0000|35 43|activity
P09135149A0000|119 123|Wee1
P09135928A0912|75 89|norepinephrine
P09135928A0912|94 105|angiotensin
P09135928A0912|23 24|P
P09135928A0912|184 185|P
P09136080A1469|44 63|chromatin structure
P09136080A1469|27 42|DNA methylation
P09136080A1469|69 84|transactivation
P09136080A1469|170 177|lineage
P09138492A0806|132 137|tumor
P09138492A0806|29 39|tuberculin
P09138492A0806|59 76|chest radiography
P09138492A0806|157 167|epiglottis
P09138492A0806|18 21|IDR
P09138492A0806|1 16|Laboratory exam
P09139694A0789|74 84|palindrome
P09139694A0789|193 202|CTF1alpha
P09139694A0789|111 121|palindrome
P09139694A0789|87 99|DNA fragment
P09139737A0000|123 129|SREBPs
P09139737A0000|212 225|transcription
P09139737A0000|251 257|uptake
P09139737A0000|262 271|synthesis
P09139737A0000|79 85|sterol
P09139737A0000|67 75|segments
P09139737A0000|136 150|cell membranes
P09139910A0350|241 246|pOST2
P09139910A0350|56 64|presence
P09139910A0350|163 169|probes
P09139910A0350|216 219|kbp
P09139910A0350|139 143|nifV
P09139910A0350|221 226|pOST4
P09140079A2528|10 16|effect
P09142146A0887|194 195|p
P09142146A0887|63 69|trauma
P09142146A0887|24 36|PAF blockade
P09142146A0887|127 128|p
P09142146A0887|172 180|delivery
P09142146A0887|187 192|hours
P09143465A0838|13 27|dual-T1 images
P09143465A0838|6 8|T1
P09144165A1275|60 64|role
P09144165A1275|111 144|AP-1 family transcription factors
P09144165A1275|68 83|DNA recognition
P09144770A0906|27 31|Type
P09144770A0906|6 15|conformer
P09146027A0809|14 21|Group B
P09146027A0809|98 102|neck
P09146027A0809|33 44|athetoid CP
P09147420A0623|80 89|HIV-1 LTR
P09147788A0458|13 34|chain enzyme activity
P09148770A0977|42 57|phosphoproteins
P09148929A0372|106 118|organization
P09148929A0372|126 136|Ctpct gene
P09148929A0372|16 21|clone
P09149825A0151|25 39|4-META/MMA-TBB
P09149825A0151|84 94|properties
P09150334A0559|89 97|sampling
P09150334A0559|6 12|sample
P09150595A0225|10 19|elicitors
P09150595A0225|42 50|reaction
P09150595A0225|52 54|HR
P09150595A0225|100 112|E. amylovora
P09150595A0225|85 94|HarpinEch
P09150728A0596|5 9|mRNA
P09150728A0596|33 37|HES1
P09151152A0174|121 133|hemodialysis
P09151152A0174|25 43|protein C activity
P09151152A0174|203 217|heparinization
P09151152A0174|64 65|p
P09151152A0174|185 186|p
P09151806A1125|45 48|LAT
P09151806A1125|97 109|branch point
P09151806A1125|55 61|intron
P09151837A0723|60 93|coimmunoprecipitation experiments
P09151837A0723|212 217|Rep78
P09151837A0723|252 284|transcription-translation system
P09151837A0723|171 182|combination
P09152656A0149|24 56|New York Heart Association class
P09152656A0149|71 84|heart failure
P09153319A0844|113 118|water
P09153348A0647|151 158|markers
P09153348A0647|193 201|patients
P09153348A0647|58 66|androgen
P09153348A0647|22 32|plasma TBG
P09153348A0647|115 133|cortisol secretion
P09153348A0647|207 220|HIV-infection
P09154283A0307|89 100|combination
P09154283A0307|146 156|dipivefrin
P09154283A0307|36 45|reduction
P09154283A0307|71 74|IOP
P09154795A0628|15 25|techniques
P09154795A0628|130 143|gene promoter
P09154795A0628|99 118|DNA polymerase beta
P09154819A0501|11 25|overexpression
P09154819A0501|43 64|tenascin-C expression
P09154819A0501|87 92|FR3T3
P09154827A0158|182 187|genes
P09154827A0158|94 97|TAF
P09154827A0158|219 229|degrees C.
P09154827A0158|192 199|arrests
P09154827A0158|40 57|hamster cell line
P09154827A0158|111 114|TAF
P09154827A0158|101 109|250/CCG1
P09155024A0955|83 87|form
P09155024A0955|19 23|EFG1
P09155024A0955|1 15|Overexpression
P09155024A0955|136 141|media
P09157100A0583|94 104|extinction
P09157760A0000|134 138|part
P09157760A0000|76 89|peculiarities
P09157760A0000|154 161|nucleus
P09157760A0000|35 43|analysis
P09159160A0000|45 54|sequences
P09159160A0000|108 116|diseases
P09160361A0858|134 135|p
P09160361A0858|29 38|CPB group
P09160361A0858|55 60|group
P09162084A0956|44 58|Src-SH2 domain
P09162084A0956|101 128|GST-Src-SH2 affinity matrix
P09162097A0776|192 202|L-selectin
P09162097A0776|182 190|receptor
P09162097A0776|141 147|LPAM-1
P09162097A0776|69 73|exon
P09163332A0275|30 50|mutagenesis approach
P09163332A0275|96 115|amino acid residues
P09163332A0275|70 73|Xaa
P09163332A0275|119 126|sequons
P09164856A0980|76 89|transcription
P09164856A0980|6 12|region
P09165035A0842|107 122|mineral density
P09165035A0842|95 103|analysis
P09165035A0842|67 79|energy x-ray
P09165035A0842|38 60|bone mass measurements
P09165035A0842|139 153|testing values
P09165035A0842|171 177|femora
P09165039A1372|123 130|species
P09165039A1372|54 62|sequence
P09165039A1372|4 14|conclusion
P09167421A0234|15 26|irradiation
P09167421A0234|128 137|fractions
P09167421A0234|50 68|microSelectron HDR
P09168134A0858|63 72|promoters
P09168134A0858|161 166|genes
P09168134A0858|33 53|kb promoter sequence
P09168134A0858|137 143|motifs
P09168511A0640|73 76|use
P09168511A0640|92 110|steroid budesonide
P09168511A0640|173 181|steroids
P09168879A0219|36 60|transcription initiation
P09168879A0219|20 29|Sf9 cells
P09169127A0371|11 20|proximity
P09169127A0371|355 362|y1 gene
P09169127A0371|101 123|gene duplication event
P09169127A0371|139 145|intron
P09169127A0371|289 297|sequence
P09169127A0371|186 193|y1 gene
P09169475A0272|8 15|studies
P09169475A0272|99 129|transcription initiation sites
P09169593T0000|88 102|protein kinase
P09169593T0000|41 62|protein kinase kinase
P09169593T0000|179 194|gene expression
P09169593T0000|1 19|Insulin regulation
P09169853A0000|104 108|tube
P09169853A0000|76 82|dorsal
P09170159A0721|29 35|codons
P09170159A0721|7 16|mutations
P09170159A0721|100 108|proteins
P09171081T0000|13 29|characterization
P09171081T0000|70 84|RNA polymerase
P09171081T0000|35 39|cDNA
P09171239A1118|192 196|AF-2
P09171239A1118|130 141|core domain
P09171239A1118|95 112|hormone receptors
P09171363A0149|4 12|ciliates
P09171468T0000|57 76|breathing apparatus
P09171468T0000|1 6|Diver
P09172312T0000|39 50|PCR markers
P09172312T0000|1 17|Characterization
P09172641A0181|28 36|evidence
P09172641A0181|12 19|studies
P09172641A0181|71 82|side chains
P09173733A0404|181 190|expansion
P09173733A0404|268 270|EA
P09173733A0404|31 42|EA analysis
P09173733A0404|158 164|method
P09173733A0404|75 97|Fourier transformation
P09173733A0404|198 208|EEG curves
P09173733A0404|99 102|FFT
P09175708A1526|79 87|receptor
P09175708A1526|126 134|fragment
P09175708A1526|188 195|nucleus
P09176340A1194|106 113|tissues
P09176340A1194|24 29|genes
P09176340A1194|71 79|freezing
P09176340A1194|51 54|gut
P09177169A0935|60 68|molecule
P09177169A0935|11 18|chimera
P09178269A0107|9 14|genes
P09178494A1123|285 292|control
P09178494A1123|193 205|preservation
P09178494A1123|179 188|selection
P09178494A1123|219 222|RNA
P09178494A1123|233 243|structures
P09180687A0096|30 34|SulA
P09180687A0096|56 66|inhibition
P09180687A0096|172 200|alanine substitution mutants
P09180687A0096|138 147|deletions
P09180687A0096|102 108|series
P09181130A1587a|121 126|light
P09181130A1587a|215 227|inactivation
P09181130A1587a|142 149|Krox-20
P09181130A1587a|157 169|segmentation
P09182527A0443|90 97|cytosol
P09182527A0443|134 141|cytosol
P09182527A0443|78 85|nucleus
P09182527A0443|49 55|mE6-AP
P09182990A0245|166 172|Sup45p
P09182990A0245|52 59|sup45-2
P09182990A0245|234 239|yeast
P09182990A0245|154 164|SUP45 gene
P09182990A0245|35 41|allele
P09182990A0245|187 193|factor
P09183406A0637|56 60|Baka
P09183406A0637|48 54|HPA-3a
P09185183T0000|72 80|epilepsy
P09185183T0000|1 8|Merosin
P09185183T0000|119 125|matter
P09185645T0000|130 144|artery disease
P09185645T0000|54 70|echocardiography
P09185645T0000|1 11|Comparison
P09187136A0000|75 85|expression
P09187136A0000|148 159|fibroblasts
P09187136A0000|20 25|essex
P09187136A0000|207 209|X.
P09187371A0450|104 109|heart
P09187371A0450|149 155|muscle
P09187371A0450|57 62|heart
P09187371A0450|159 164|liver
P09188094A0934|91 96|forms
P09188094A0934|26 31|cells
P09188094A0934|71 79|response
P09188094A0934|100 106|stress
P09188863A0954|13 21|splicing
P09188863A0954|64 71|control
P09189896A0611|5 13|findings
P09189896A0611|51 67|memory processes
P09190821A0707|82 87|P243L
P09191052A0850|61 66|Class
P09191052A0850|23 40|Pbx dimer partner
P09192769T0000|45 49|cDNA
P09192769T0000|142 147|CCR-4
P09192769T0000|96 104|homology
P09192769T0000|118 140|C-C chemokine receptor
P09192842A0988|90 108|chromosome 19q13.2
P09192842A0988|226 236|ETS factor
P09192842A0988|131 145|translocations
P09192842A0988|163 172|leukemias
P09192842A0988|248 252|role
P09192842A0988|191 197|tumors
P09193072A0199|13 17|data
P09193072A0199|35 45|transgenes
P09193080A0904|49 56|regions
P09193080A0904|102 108|probes
P09194250A0708|179 188|mortality
P09194250A0708|71 87|mortality target
P09194250A0708|49 57|Children
P09197241A0770|120 123|lyn
P09197241A0770|13 24|macrophages
P09197241A0770|78 93|hyperactivation
P09197241A0770|97 103|p56/59
P09197241A0770|113 119|p53/56
P09197241A0770|137 140|p58
P09197408A0126|182 202|heptad repeat motifs
P09197408A0126|320 329|activator
P09197408A0126|19 28|facB gene
P09197408A0126|108 113|2Cys6
P09197408A0126|278 286|function
P09197408A0126|137 144|cluster
P09199286A0086|12 18|region
P09199286A0086|56 60|exon
P09199318A1147|30 44|actin gelation
P09199318A1147|73 93|muscle alpha-actinin
P09199327A1250|242 250|EM motif
P09199327A1250|162 171|TEF-1-Max
P09199327A1250|6 12|effect
P09199327A1250|70 79|construct
P09199348A0156|44 60|U14 interactions
P09199348A0156|94 102|activity
P09199348A0156|131 139|U14 RNAs
P09199348A0156|8 12|view
P09199413A0518|105 112|animals
P09199413A0518|66 75|CFU/mouse
P09199932A1357|264 268|exon
P09199932A1357|213 219|intron
P09199932A1357|54 71|promoter elements
P09199932A1357|154 162|evidence
P09199932A1357|118 121|ATM
P09200029A0211|29 34|signs
P09200029A0211|110 118|features
P09200530A0411|90 106|gradient elution
P09200530A0411|77 83|column
P09200530A0411|1 7|Liquid
P09201946A0000|29 48|helicase activities
P09201946A0000|147 160|RNA molecules
P09201946A0000|205 211|length
P09202147A0866|31 36|yeast
P09202147A0866|41 47|plants
P09202147A0866|143 151|proteins
P09202147A0866|71 74|UBC
P09202147A0866|119 130|degradation
P09202669A1530|35 55|gene transfer system
P09203585A0660|12 19|feature
P09203585A0660|82 89|imprint
P09203585A0660|101 125|neo replacement cassette
P09203731A0497|135 167|Pan American Health Organization
P09203731A0497|13 37|International Commission
P09203731A0497|63 74|Eradication
P09204570A0110|28 41|MADS box gene
P09204570A0110|43 48|nmhC5
P09204570A0110|6 11|study
P09205677A0577|88 95|disease
P09205677A0577|23 29|damage
P09206230A0000|58 63|cause
P09206230A0000|1 10|OBJECTIVE
P09206230A0000|85 96|astigmatism
P09208214A0572|22 26|neck
P09208214A0572|1 20|Sternocleidomastoid
P09209031A0350|23 29|region
P09209372A0345|131 141|activation
P09209372A0345|145 150|AML1b
P09209372A0345|53 60|effects
P09209372A0345|187 195|affinity
P09209438A0994|62 68|GATA-4
P09209438A0994|155 164|GATA site
P09209438A0994|16 23|ATL-16T
P09210478A0000|56 61|HIF-1
P09210478A0000|127 132|genes
P09211605A0478|31 44|extensibility
P09211605A0478|1 7|Tendon
P09211913A0000|301 314|concentration
P09211913A0000|212 218|CYP1A1
P09211913A0000|190 202|target genes
P09211913A0000|154 160|factor
P09211913A0000|77 98|transcription factors
P09211913A0000|274 286|hydrocarbons
P09211913A0000|1 26|Aryl hydrocarbon receptor
P09211981A0526|132 140|extracts
P09211981A0526|208 211|p34
P09211981A0526|176 184|activity
P09211981A0526|217 223|kinase
P09211981A0526|17 25|evidence
P09212059A1856|13 20|results
P09212059A1856|133 148|PR dimerization
P09212059A1856|270 286|homodimerization
P09212059A1856|59 69|conclusion
P09212059A1856|190 195|hinge
P09214274T0001|47 55|patients
P09214274T0001|77 97|metastasis resection
P09215891A0000|61 71|CIN4 genes
P09215891A0000|130 150|microtubule function
P09215891A0000|5 13|products
P09216936T0000|41 48|effects
P09216936T0000|52 60|exercise
P09216936T0000|81 87|humans
P09218459A0000|194 199|genes
P09218459A0000|24 27|SRF
P09218459A0000|32 38|member
P09218459A0000|1 22|Serum response factor
P09218599A0184|9 14|study
P09218599A0184|101 105|IL-4
P09218775A1229|26 37|cysB mutant
P09218775A1229|42 45|CHA
P09218775A1229|1 9|Activity
P09220158A0537|63 73|processing
P09220158A0537|110 121|amino acids
P09220158A0537|18 25|protein
P09220158A0537|221 230|Sf9 cells
P09222057A0176|62 67|assay
P09222057A0176|97 102|study
P09222057A0176|113 117|days
P09222057A0176|1 6|Serum
P09223042A0000|58 72|disease states
P09223042A0000|16 28|blood volume
P09223229A0565|30 40|mb-1 genes
P09223229A0565|49 55|region
P09223479A1193|134 152|gammaherpesviruses
P09223479A1193|107 116|molecules
P09223479A1193|173 177|KSHV
P09223479A1193|21 29|homology
P09223479A1193|154 158|gene
P09223479A1193|85 92|homolog
P09223647T0000|149 159|activation
P09223647T0000|25 33|oligomer
P09223647T0000|114 121|complex
P09223647T0000|1 18|Crystal structure
P09223880A1147|78 88|anesthesia
P09224811A0000|13 18|study
P09224811A0000|77 107|cytochrome P450 oxidoreductase
P09224811A0000|283 299|P450R mRNA level
P09224811A0000|158 164|status
P09224811A0000|71 76|NADPH
P09224811A0000|50 63|transcription
P09225506A0462|111 122|index group
P09225506A0462|83 84|V
P09225506A0462|49 55|levels
P09225686A0683|46 55|hamartoma
P09225686A0683|124 131|surgery
P09225686A0683|68 85|seizure remission
P09226113A0857|91 99|borehole
P09227099A0106|15 24|technique
P09227099A0106|106 117|convenience
P09227099A0106|92 102|advantages
P09227099A0106|37 49|modification
P09227099A0106|119 127|security
P09227799A0254|150 155|ELISA
P09227799A0254|56 68|surveillance
P09227799A0254|131 148|stool examination
P09227799A0254|223 227|COPT
P09227799A0254|85 95|comparison
P09228092A1779|78 82|gene
P09228092A1779|37 53|dUTPase isoforms
P09228092A1779|137 140|use
P09229420A0158|107 112|areas
P09229420A0158|22 37|biopsy specimen
P09229420A0158|116 130|chondrosarcoma
P09229420A0158|169 183|chondromatosis
P09230129A0039|211 221|production
P09230129A0039|89 102|DNA-cellulose
P09230129A0039|23 34|homogeneity
P09230129A0039|55 78|affinity chromatography
P09230129A0039|166 170|lack
P09230129A0039|128 139|preparation
P09230129A0039|174 187|contamination
P09230307A0329|97 102|cells
P09230307A0329|1 4|FOG
P09230384A1056|211 216|sites
P09230384A1056|146 158|mycobacteria
P09230384A1056|173 182|specimens
P09230945A0089|67 71|slip
P09232593A0946|121 126|roles
P09232593A0946|57 67|DJ protein
P09232593A0946|35 53|expression pattern
P09233772A0136|147 154|regions
P09233772A0136|385 395|G proteins
P09233772A0136|354 366|beta subunit
P09233772A0136|324 331|domains
P09233772A0136|232 266|guanine nucleotide exchange factor
P09233772A0136|173 180|repeats
P09233772A0136|412 429|SH3 binding sites
P09233772A0136|442 456|leucine-zipper
P09233809A0381|47 61|Hnf3g-lacZ YAC
P09233809A0381|9 20|mouse lines
P09233809A0381|196 204|elements
P09233809A0381|86 90|copy
P09233809A0381|222 232|regulation
P09233811A0072|63 89|Ste11 transcription factor
P09233811A0072|98 99|M
P09234690A0242|74 79|genes
P09234690A0242|142 146|PREs
P09234690A0242|202 209|protein
P09234690A0242|32 36|UASs
P09234703A0192|1 4|JNK
P09234703A0192|69 74|Cdc42
P09234717A0000|176 191|forms complexes
P09234717A0000|113 122|substrate
P09234717A0000|155 171|tyrosine kinases
P09234717A0000|79 99|c-cbl proto-oncogene
P09234717A0000|197 200|SH3
P09234717A0000|39 42|Cbl
P09234723A0846|90 97|protein
P09234723A0846|40 45|cases
P09234723A0846|112 123|splice site
P09234723A0846|49 68|splicing regulation
P09234727A0770|54 67|reporter gene
P09234727A0770|116 128|DNA elements
P09234743A0475|144 160|binding proteins
P09234743A0475|141 142|C
P09234743A0475|168 181|alpha-complex
P09234743A0475|68 80|alpha-globin
P09235424A1200|12 20|measures
P09235424A1200|63 68|women
P09235995A0339|9 21|Biochemistry
P09236118A1455|105 111|groove
P09236118A1455|26 29|Lrp
P09236118A1455|5 12|results
P09236118A1455|175 180|sites
P09236441A0639|78 95|oxygen saturation
P09236441A0639|37 47|recordings
P09236441A0639|159 168|breathing
P09236441A0639|51 54|ECG
P09237695A0000|94 109|virus infection
P09238467A0763|7 14|lesions
P09238467A0763|48 60|phentolamine
P09238850A2042|94 101|nucleus
P09238850A2042|103 106|SCN
P09238860A1974|210 227|protein kinase C.
P09238860A1974|147 153|agents
P09238860A1974|59 63|CREB
P09238860A1974|189 192|Ca2
P09238860A1974|102 124|cytokine Interleukin-2
P09241092A1108|47 62|glucuronidation
P09241092A1108|179 200|trans-diol derivative
P09241092A1108|163 170|epoxide
P09241092A1108|143 159|carbamazepine-10
P09241092A1108|1 12|CONCLUSIONS
P09241232A1154|95 99|K241
P09241232A1154|3 21|consensus sequence
P09241232A1154|51 65|lysine residue
P09242499A0505|149 154|sites
P09242499A0505|76 77|d
P09242499A0505|1 11|Volunteers
P09242499A0505|103 113|sunscreens
P09242551A0653|179 185|subset
P09242551A0653|127 135|controls
P09242551A0653|143 159|EBER1 expression
P09242551A0653|100 106|levels
P09243385A1314|12 15|use
P09243385A1314|89 105|PC velocity data
P09243587A0000|161 170|pregnancy
P09243587A0000|36 44|question
P09243587A0000|115 128|breast cancer
P09243587A0000|1 19|PURPOSE/OBJECTIVES
P09244100A0194|12 16|rats
P09244350A0000|114 131|tumor suppressors
P09244350A0000|81 96|phosphoproteins
P09244350A0000|19 25|breast
P09246343T0000|24 27|man
P09247645A0000|151 166|plasma membrane
P09247645A0000|104 110|fusion
P09247645A0000|301 307|sec4-8
P09247645A0000|42 46|SEC3
P09247645A0000|258 265|mutants
P09249039A0124|122 132|metabolism
P09249039A0124|77 84|control
P09249039A0124|136 147|vertebrates
P09249710A0331|70 109|plaque reduction neutralization testing
P09251843A0189|91 102|hyperplasia
P09251843A0189|271 276|cases
P09251843A0189|208 213|cases
P09251843A0189|229 237|lymphoma
P09251843A0189|19 30|hyperplasia
P09252406A0511|133 139|kinase
P09252406A0511|94 105|p85 subunit
P09252406A0511|59 63|Grb2
P09252406A0511|141 161|phospholipase Cgamma
P09252406A0511|1 9|Tyrosine
P09254678A0106|151 154|PLP
P09254678A0106|299 313|point mutation
P09254678A0106|25 33|parallel
P09254678A0106|253 259|brains
P09254678A0106|228 231|MBP
P09254678A0106|280 284|rats
P09254678A0106|111 118|protein
P09254678A0106|173 190|brain development
P09254678A0106|1 9|Gtx mRNA
P09255349A0836|72 76|IRA2
P09255349A0836|25 31|GTPase
P09256973A0673|73 77|time
P09256973A0673|133 147|residence time
P09256973A0673|18 56|itraconazole plasma drug concentration
P09256973A0673|87 91|dose
P09257887A0457|45 58|microg/kg/day
P09257887A0457|22 25|day
P09257887A0457|80 83|day
P09257887A0457|1 6|G-CSF
P09258606A0822|89 100|development
P09258606A0822|21 29|pathways
P09258606A0822|51 56|forms
P09259313A0950|5 13|majority
P09259320A0830|74 89|O-glycosylation
P09259320A0830|93 97|SSBP
P09259320A0830|39 50|discordance
P09261155A0833|150 155|IRS-2
P09261155A0833|25 36|PTB domains
P09261155A0833|18 20|PH
P09261155A0833|102 129|insulin receptor substrates
P09261184A0170|52 74|supershift experiments
P09261184A0170|141 145|NF-Y
P09261397A0509|97 117|genome encapsidation
P09261397A0509|139 143|FeFV
P09263094A0799|151 162|airway flow
P09263094A0799|360 367|volumes
P09263094A0799|332 341|intervals
P09263094A0799|93 105|measurements
P09263094A0799|48 50|EL
P09263094A0799|394 396|mL
P09263094A0799|195 199|dogs
P09263094A0799|283 288|range
P09263094A0799|1 13|MEASUREMENTS
P09263094A0799|68 70|RL
P09264466A0947|106 118|interactions
P09264466A0947|58 61|APC
P09264466A0947|5 17|Cut9 subunit
P09265642A0668|133 142|marker FM
P09265642A0668|26 33|pathway
P09265642A0668|79 86|pathway
P09267306A0381|90 98|standard
P09267306A0381|25 29|case
P09267306A0381|127 138|reliability
P09267306A0381|188 200|laboratories
P09267439A0000|24 39|ras superfamily
P09267439A0000|138 147|organisms
P09267439A0000|84 92|proteins
P09268298T0000|1 21|Ent-kaurene synthase
P09268578A0225|61 68|message
P09268578A0225|96 99|mud
P09268638A0332|31 57|chromosome walking studies
P09268661A1405|31 43|retroplasmid
P09268661A1405|52 65|transcriptase
P09268661A1405|98 112|cDNA synthesis
P09269900A1035|147 151|JunD
P09269900A1035|58 71|transcription
P09269900A1035|99 109|ATF3/c-Jun
P09269900A1035|17 24|results
P09271394A0558|56 78|MURA-Mu1 TIR complexes
P09271394A0558|40 52|footprinting
P09271394A0558|139 145|region
P09271394A0558|153 156|TIR
P09271400A0475|28 45|promoter activity
P09271400A0475|126 144|growth stimulation
P09271400A0475|101 116|E2F2 expression
P09271417A1011|79 88|ERR alpha
P09271417A1011|18 43|receptor response element
P09272108A1295a|29 35|region
P09272108A1295a|66 74|presence
P09272108A1295a|87 91|TATA
P09272138A1153|28 32|rate
P09272138A1153|58 71|rhG-CSF group
P09272138A1153|116 124|survival
P09272138A1153|87 91|CODE
P09272138A1153|78 79|%
P09272138A1153|98 103|group
P09272138A1153|139 144|weeks
P09275164A0000|94 100|action
P09275164A0000|173 182|guanine-7
P09275164A0000|168 171|RNA
P09275164A0000|184 201|methyltransferase
P09276882A0479|126 129|Day
P09276882A0479|144 168|% carbohydrate treatment
P09276882A0479|39 41|CC
P09276882A0479|115 122|culture
P09276882A0479|206 220|% carbohydrate
P09276882A0479|69 78|pH values
P09277629A0268|73 89|ERP negativities
P09277629A0268|147 158|memory task
P09277629A0268|5 16|experiments
P09278441A1160|27 47|CARP mRNA expression
P09278441A1160|143 146|Csx
P09278441A1160|235 246|development
P09278441A1160|87 93|tongue
P09278441A1160|136 140|Nkx2
P09278441A1160|17 23|timing
P09278445T0000|30 44|RNase activity
P09278445T0000|1 22|Substrate specificity
P09278454A1261|148 184|DMS protection footprinting analysis
P09278454A1261|20 38|MMP-2 RE1 sequence
P09278454A1261|1 12|Examination
P09278494A0762|27 39|ETS proteins
P09278494A0762|98 114|Surf-1 direction
P09279379A0310|131 137|spacer
P09279379A0310|145 161|H2B histone gene
P09279379A0310|113 119|spacer
P09279379A0310|98 104|region
P09279889A1124|107 114|% Azone
P09279889A1124|125 140|% Azone systems
P09279889A1124|48 58|AUC0-24 hr
P09279889A1124|87 89|ng
P09279889A1124|16 20|drug
P09282329A0527|88 114|cell cycle control element
P09282329A0527|193 214|G1/S phase transition
P09282329A0527|218 224|FDC-P1
P09282329A0527|70 77|factors
P09282329A0527|51 55|Site
P09282985A0961|12 23|differences
P09282985A0961|65 80|characteristics
P09285715A1257|44 47|Rev
P09285715A1257|106 110|RNAs
P09285715A1257|128 131|RNA
P09285715A1257|115 117|5S
P09285715A1257|137 140|CTE
P09286115T0000|71 78|element
P09286115T0000|35 41|factor
P09287036A0457|91 102|differences
P09287036A0457|56 59|men
P09287036A0457|76 86|adjustment
P09287036A0457|1 29|Plasma leptin concentrations
P09287362A0589|31 41|SH3 region
P09287362A0589|122 128|region
P09287362A0589|6 17|interaction
P09287362A0589|49 52|csk
P09288916T0000|107 112|alpha
P09288916T0000|77 91|acid hydrolase
P09288916T0000|117 130|beta subunits
P09290571A0420|44 47|VTs
P09290571A0420|10 18|patients
P09290571A0420|97 100|VTs
P09291077T0000|46 58|shepherd dog
P09291098T0000|37 82|gamma-glutamyl transpeptidase gene expression
P09291098T0000|103 106|rat
P09293006A1412|12 22|expression
P09293006A1412|86 100|aphII promoter
P09293006A1412|51 55|gene
P09294161A0650|111 120|cell line
P09294161A0650|53 62|p45 NF-E2
P09294161A0650|157 170|transcription
P09294161A0650|100 105|NF-E2
P09294262A0885|31 49|consensus TATA box
P09294262A0885|145 155|regulation
P09294262A0885|66 71|CCAAT
P09294262A0885|116 122|stress
P09294422A1376|5 13|por gene
P09294422A1376|48 52|time
P09294422A1376|154 166|tac promoter
P09294453A0949|94 115|T beta L biosynthesis
P09294453A0949|86 90|role
P09294453A0949|34 40|levels
P09296251A0163|24 31|reports
P09296251A0163|51 57|number
P09299696A1074|57 63|number
P09299696A1074|92 98|villus
P09299696A1074|67 81|cryptosporidia
P09299696A1074|219 236|cryptosporidiosis
P09299696A1074|5 17|distribution
P09299696A1074|186 190|kids
P09300697A0000|107 116|molecules
P09300697A0000|59 69|generation
P09300697A0000|34 42|protease
P09301114A0573|1 10|Takahashi
P09303437A0875|31 34|Fp1
P09303437A0875|72 84|CAT activity
P09303437A0875|198 206|promoter
P09303437A0875|42 53|hCRBP1 gene
P09303437A0875|19 27|deletion
P09304123A0079|134 139|order
P09304123A0079|162 166|bulk
P09304123A0079|191 199|material
P09304123A0079|49 53|ways
P09305631A0770|64 68|heat
P09305631A0770|19 24|BAG-1
P09305870A0894|104 108|hDlg
P09305870A0894|167 183|tumor suppressor
P09305870A0894|36 50|p55 PDZ domain
P09305870A0894|116 136|lymphocyte homologue
P09305870A0894|223 237|glycophorin C.
P09307065A0553|89 103|enterotoxin C2
P09307065A0553|8 15|absence
P09307065A0553|112 128|association rate
P09307065A0553|19 28|MHC class
P09307065A0553|259 265|microM
P09308234A0225|59 69|activation
P09308234A0225|1 4|Mnt
P09309457A0680|120 123|FSH
P09309457A0680|89 100|lipoprotein
P09309457A0680|188 194|months
P09309457A0680|49 53|HDL2
P09309457A0680|75 87|endothelin-1
P09309457A0680|106 115|estradiol
P09309457A0680|172 175|ERT
P09311164A0245|60 66|volume
P09311164A0245|82 92|motor unit
P09311796A0218|133 136|TBP
P09311796A0218|42 52|activation
P09311796A0218|17 24|studies
P09311810A0814|210 226|alpha0 sequences
P09311810A0814|183 188|virus
P09311810A0814|130 135|cells
P09311810A0814|10 22|accumulation
P09312025A0373|196 204|p85alpha
P09312025A0373|67 75|PKC zeta
P09312025A0373|141 151|wortmannin
P09312025A0373|153 161|LY294002
P09312028A0975|105 111|BMS614
P09312028A0975|47 55|activity
P09312028A0975|125 134|integrity
P09312028A0975|143 146|RXR
P09312087A0000|367 392|tyrosine residues Tyr-663
P09312087A0000|144 150|domain
P09312087A0000|396 403|Tyr-686
P09312087A0000|154 161|PECAM-1
P09312087A0000|346 353|PECAM-1
P09312087A0000|231 238|process
P09312087A0000|336 342|domain
P09312087A0000|207 227|platelet aggregation
P09314306A0571|1 16|Supplementation
P09314537A1600|62 83|ezrin binding protein
P09314537A1600|7 15|findings
P09314570A0153|150 160|activities
P09314570A0153|6 12|family
P09314570A0153|16 24|proteins
P09315632A1137|74 93|FGFR3 kinase domain
P09315632A1137|41 51|expression
P09315632A1137|24 35|observation
P09315632A1137|174 179|FGFR3
P09315651T0000|72 84|chick retina
P09315651T0000|42 53|R-FABP gene
P09315651T0000|16 20|AP-2
P09316937A0133|22 30|organism
P09316937A0133|100 130|API 20E identification systems
P09317131A1332|132 142|activation
P09317131A1332|156 173|IgE germline gene
P09317830T0000|16 30|SONG FREQUENCY
P09321657A0439|122 134|core element
P09321657A0439|67 75|elements
P09321657A0439|185 202|element mutations
P09321657A0439|34 43|mutations
P09322738A0510|28 35|rpoCHIS
P09322738A0510|99 112|S. coelicolor
P09322738A0510|117 128|S. lividans
P09323366A0000|109 122|carbon source
P09323366A0000|27 31|MLS1
P09323366A0000|5 25|malate synthase gene
P09323612A0374|72 75|EEG
P09323612A0374|108 116|children
P09323612A0374|93 103|medication
P09323612A0374|168 188|treatment strategies
P09323612A0374|1 5|Lack
P09323612A0374|238 256|language disorders
P09324878A0952|98 107|diagnosis
P09324878A0952|34 38|wall
P09324988X0000|24 27|p21
P09324988X0000|66 72|series
P09324988X0000|84 92|proteins
P09325135A0737|60 61|%
P09325135A0737|12 26|fusion protein
P09325278A0458|107 117|similarity
P09325278A0458|125 128|rat
P09325278A0458|191 195|mta1
P09325278A0458|216 226|similarity
P09325278A0458|185 189|gene
P09325278A0458|205 212|regions
P09325322A1293|29 32|Ca2
P09325322A1293|113 133|InsP3 concentrations
P09325322A1293|50 58|decrease
P09326246A0567|120 126|levels
P09326246A0567|27 33|region
P09326246A0567|83 91|deletion
P09326246A0567|69 77|elements
P09326317A0372|19 24|study
P09326317A0372|34 52|mutation screening
P09327881T0000|47 68|dopamine transporters
P09327881T0000|1 42|Positron emission tomography radioligands
P09328343A0181|60 75|protein complex
P09328343A0181|129 137|proteins
P09328343A0181|22 29|element
P09328343A0181|1 11|Expression
P09328476A0068|89 91|U1
P09328476A0068|126 137|spliceosome
P09328476A0068|52 69|ribonucleoprotein
P09328476A0068|71 76|snRNP
P09328824A0000|134 136|TR
P09328824A0000|193 203|repression
P09328824A0000|234 236|TR
P09328824A0000|138 143|alpha
P09328824A0000|51 66|v-erbA oncogene
P09331119A0659|73 85|parasthesias
P09331119A0659|25 33|toxicity
P09331119A0659|17 22|grade
P09331119A0659|102 103|%
P09331864A0848|98 101|MGA
P09331864A0848|117 125|controls
P09331864A0848|85 93|controls
P09333026A0397|44 49|exons
P09333026A0397|26 29|brk
P09333026A0397|170 180|divergence
P09333168A0310|106 109|men
P09333168A0310|42 53|vaccination
P09334264A0540|15 31|calf thymus CstF
P09334264A0540|63 67|form
P09334264A0540|118 121|kDa
P09334331A0910|94 103|EMA cells
P09334331A0910|5 12|results
P09334331A0910|119 127|receptor
P09335267A0142|63 70|methods
P09335267A0142|214 220|genome
P09335267A0142|159 164|genes
P09335267A0142|187 196|mutations
P09335298A1227|91 97|region
P09335298A1227|298 304|operon
P09335298A1227|59 70|RK2 plasmid
P09335298A1227|18 27|insertion
P09335298A1227|35 49|ColE1 cer site
P09335608T0000|110 131|chain gene transcript
P09335608T0000|39 48|sequences
P09335608T0000|17 25|elements
P09336455A0000|149 151|UV
P09336455A0000|92 102|RNR3 genes
P09336455A0000|82 87|GAL10
P09336455A0000|50 64|mRNA synthesis
P09336455A0000|153 162|radiation
P09338414A0430|78 86|pressure
P09338414A0430|112 126|thermodilution
P09338414A0430|1 9|Ea value
P09340641T0001|40 54|nCPAP pressure
P09341158A0167|120 125|beta1
P09341158A0167|28 37|complexes
P09341158A0167|89 100|interaction
P09341158A0167|130 142|beta2 chains
P09341158A0167|5 18|medium chains
P09341158A0167|80 85|types
P09341192T0000|26 45|GLUT4 translocation
P09341192T0000|77 100|tyrosine kinase pathway
P09343208A1405|61 72|copy number
P09343208A1405|76 81|genes
P09343208A1405|277 282|wasps
P09343208A1405|156 160|PDVs
P09343208A1405|250 261|association
P09343222A0415|13 42|NIH/Swiss mouse CCR5 proteins
P09343222A0415|59 60|%
P09343222A0415|69 70|%
P09343426A0456|113 124|D-A complex
P09343426A0456|81 88|ability
P09343433A0000|75 79|RNAP
P09343433A0000|108 126|effect variegation
P09343433A0000|35 40|genes
P09343982A0890|113 121|controls
P09343982A0890|18 39|detrusor contractions
P09345037A0886|11 16|roles
P09345037A0886|92 121|progenitor cell proliferation
P09346238T0000|76 104|SCF ubiquitin-ligase complex
P09346238T0000|20 29|receptors
P09346925A0660|79 88|HPK1 tail
P09346925A0660|5 16|SH3 domains
P09346925A0660|65 71|motifs
P09346925A0660|152 156|Grb2
P09346935A0927|240 255|mRNA processing
P09346935A0927|147 158|interaction
P09346935A0927|179 183|form
P09346935A0927|295 326|KRAB multifinger protein family
P09346935A0927|281 287|member
P09346935A0927|7 28|ZNF74 sublocalization
P09346953A0000|75 85|generation
P09346953A0000|150 158|activity
P09346953A0000|160 185|HSact conversion activity
P09346953A0000|36 64|heparan sulfate proteoglycan
P09346953A0000|308 310|N.
P09346953A0000|238 289|heparan sulfate D-glucosaminyl 3-O-sulfotransferase
P09348931T0000|4 7|end
P09349967A0653|107 120|lamellar bone
P09349967A0653|5 12|results
P09351823A0414|128 139|development
P09351823A0414|48 58|maturation
P09352127A0953|75 77|rs
P09352127A0953|127 135|patients
P09352127A0953|155 162|failure
P09352127A0953|87 88|P
P09353255A0159|47 61|pore complexes
P09353255A0159|1 6|Rip1p
P09353304A0732|28 35|regions
P09353304A0732|1 10|Deletions
P09353343A0919|60 73|AUBP activity
P09353343A0919|79 83|poly
P09353343A0919|19 29|inhibition
P09353343A0919|1 15|RNA polymerase
P09353343A0919|136 152|hnRNP A1 binding
P09354349A0338|28 34|biopsy
P09354349A0338|244 253|DAKO B471
P09354349A0338|127 129|MG
P09354349A0338|184 190|method
P09354349A0338|119 125|Giemsa
P09354676A1714|211 224|tumorigenesis
P09354676A1714|161 167|target
P09354676A1714|43 48|p16.3
P09354676A1714|97 110|translocation
P09354676A1714|139 149|FGFR3 gene
P09354676A1714|34 35|t
P09354757A1444|91 105|RNase H domain
P09354757A1444|24 28|beta
P09354757A1444|77 83|His539
P09354757A1444|33 40|alpha A
P09358045A0000|56 74|growth factor-beta
P09358045A0000|76 84|TGF-beta
P09358045A0000|141 164|nematode Brugia pahangi
P09358069T0000|89 94|cells
P09358069T0000|71 74|EPO
P09358069T0000|35 45|expression
P09359844A0674|52 62|adipocytes
P09360422A0135|121 140|betathromboglobulin
P09360422A0135|83 96|plasma levels
P09360422A0135|18 26|patients
P09360422A0135|45 59|arteriopathies
P09360422A0135|161 163|DD
P09360422A0135|142 149|beta-TG
P09360422A0135|6 11|group
P09360422A0135|100 114|thrombomodulin
P09360956A0840|58 62|zeta
P09360956A0840|32 47|phosphorylation
P09360956A0840|85 92|Thr-233
P09361007A0922|26 30|site
P09361007A0922|68 88|pair enhancer region
P09362473A1540|60 65|array
P09362473A1540|319 342|twist expression domain
P09362473A1540|189 198|activator
P09362473A1540|250 258|enhancer
P09362473A1540|152 158|inputs
P09362499A0000|41 54|DNA inversion
P09362499A0000|80 94|DNA invertases
P09362499A0000|70 76|family
P09364211A0319|26 50|transcription factor E2F
P09364211A0319|5 9|cell
P09364750T0000|41 46|SUP45
P09365272T0000|90 110|Xenopus egg extracts
P09365272T0000|42 54|interactions
P09365272T0000|21 28|protein
P09366456A0234|90 97|persons
P09366456A0234|149 154|group
P09366456A0234|176 177|n
P09366456A0234|16 32|muscle paralysis
P09366456A0234|132 134|kg
P09366456A0234|106 121|body mass index
P09366456A0234|1 8|METHODS
P09366517A1828|62 65|WT1
P09366517A1828|32 40|evidence
P09367288A0115|10 13|aim
P09367288A0115|43 51|decrease
P09367288A0115|191 197|muscle
P09367288A0115|138 146|position
P09367426A1354|160 172|polarization
P09367426A1354|53 61|polarity
P09367426A1354|35 37|hh
P09367676A1115|56 62|Tbxas1
P09367676A1115|157 165|elements
P09367676A1115|1 22|Transfection analyses
P09368014A0740|5 22|lysozyme FEF site
P09368026A0435|61 83|OC promoter activation
P09368026A0435|109 117|FGF2/FSK
P09368026A0435|42 57|Msx2 expression
P09368026A0435|85 104|luciferase reporter
P09368058A0969|33 58|phosphopeptide comigrates
P09368058A0969|169 172|CAK
P09368100A1354|52 57|exons
P09368419A0000|95 99|acid
P09368419A0000|158 173|gene expression
P09368419A0000|4 15|Arabidopsis
P09368419A0000|101 104|ABA
P09368760A0665|150 165|spermatogenesis
P09368760A0665|115 134|sex differentiation
P09368760A0665|101 111|regulation
P09369451A0693|12 20|analysis
P09369451A0693|40 44|AP-1
P09369451A0693|99 122|myocyte enhancer factor
P09369451A0693|71 81|TGAATCATCA
P09369451A0693|50 58|sequence
P09369482A0690|27 48|cotransfection assays
P09369482A0690|113 117|site
P09369482A0690|1 22|Electromobility shift
P09370307A0093|120 138|barley gibberellin
P09370307A0093|150 157|element
P09370307A0093|18 28|AACA motif
P09370307A0093|102 112|similarity
P09371431T0000|56 66|production
P09371431T0000|36 41|genes
P09371431T0000|1 11|Expression
P09371564A0713|146 151|virus
P09371564A0713|81 88|viruses
P09371564A0713|33 37|3Lys
P09371596T0000|72 89|hepatitis B virus
P09371596T0000|53 62|promoters
P09371596T0000|32 37|pre-C
P09371622A0779|21 33|IE1 peptides
P09371622A0779|84 92|promoter
P09371657A0165|29 54|alanine cluster mutations
P09371657A0165|72 76|K79A
P09371657A0165|128 152|triphosphatase component
P09371657A0165|81 92|E192A-E194A
P09371731A0627|36 46|homologues
P09372451T0000|44 54|antibodies
P09372451T0000|106 119|integrin beta
P09372451T0000|1 9|Epitopes
P09372924A0758|57 67|NER system
P09372924A0758|202 205|XPC
P09372924A0758|185 196|interaction
P09372924A0758|139 153|hHR23 proteins
P09372950A1283|78 87|sequences
P09372950A1283|7 14|results
P09372950A1283|140 150|processing
P09372968A0532|151 158|protein
P09372968A0532|107 114|homolog
P09372968A0532|59 64|Dlc-1
P09372968A0532|68 76|sequence
P09373140A0000|5 21|mouse M-lysozyme
P09373140A0000|87 93|levels
P09373651A0255|8 15|cassava
P09373651A0255|48 58|processing
P09374541A0277|13 34|protein binding sites
P09376325A0167|23 31|sequence
P09376325A0167|118 137|transcription units
P09376782A0328|89 92|HCV
P09376782A0328|94 103|infection
P09376782A0328|70 87|hepatitis C virus
P09377374A0000|106 116|background
P09377374A0000|82 93|VH B course
P09377374A0000|16 32|characterization
P09380504A1255|122 145|cycloheximide treatment
P09380504A1255|161 162|h
P09380504A1255|5 15|ZnF20 cDNA
P09380504A1255|169 177|addition
P09380697T0000|143 154|cholesterol
P09380697T0000|54 67|up-regulation
P09380697T0000|118 137|density lipoprotein
P09381261A0970|60 68|newborns
P09381261A0970|77 81|area
P09381261A0970|48 55|mothers
P09382498A0618|30 39|electrode
P09382498A0618|149 153|size
P09382498A0618|130 139|electrode
P09382498A0618|43 45|cm
P09382498A0618|143 145|cm
P09382498A0618|49 53|size
P09382886A1061|91 94|p53
P09382886A1061|122 129|matings
P09382886A1061|8 13|proof
P09382886A1061|155 159|mice
P09383156A0691|45 51|pSok-6
P09383156A0691|11 35|RNase E cleavage product
P09385169T0000|30 53|productivity indicators
P09385169T0000|5 9|AONE
P09387333T0001|31 39|research
P09388198A1396|132 141|induction
P09388198A1396|95 109|p38 MAP kinase
P09388198A1396|163 169|stress
P09388198A1396|5 9|data
P09388198A1396|81 84|JNK
P09388198A1396|86 89|ERK
P09388200A0639|56 77|transcription factors
P09388200A0639|86 105|MDM2 overexpression
P09388200A0639|1 11|Inhibition
P09388246A0903|28 67|electron microscopy immunocytochemistry
P09388246A0903|107 112|nerve
P09388246A0903|176 189|intermediates
P09389137A0763|40 44|C1-7
P09389137A0763|5 17|prescription
P09389492A0520|14 21|fashion
P09389492A0520|41 46|cells
P09389492A0520|142 150|activity
P09389492A0520|70 78|response
P09389669A1009|15 18|omb
P09389669A1009|7 10|dpp
P09390125A0379|79 80|%
P09390125A0379|43 44|%
P09390125A0379|96 104|quarters
P09390125A0379|70 71|%
P09391173A0811|126 139|amplification
P09391173A0811|114 118|RACE
P09391173A0811|1 26|Transcription start sites
P09393706A1171|7 10|Fis
P09393706A1171|69 77|promoter
P09393771A1659|39 47|activity
P09393771A1659|100 102|Mr
P09393966A0190|56 59|CHB
P09393966A0190|48 51|CHA
P09395456A0424|14 18|role
P09395456A0424|28 40|chain motifs
P09395456A0424|160 180|transmembrane domain
P09395456A0424|188 202|signal peptide
P09395525A0395|57 62|C/EBP
P09395525A0395|142 146|HS3D
P09395525A0395|64 69|delta
P09395525A0395|48 55|protein
P09396427A1488|31 53|infarct-zone viability
P09396427A1488|196 204|geometry
P09396427A1488|118 126|dilation
P09396722A0185|46 77|ascorbate peroxidase isoenzymes
P09396722A0185|5 9|gene
P09396722A0185|119 123|gene
P09396823T0000|72 75|DNA
P09396823T0000|18 24|domain
P09397723T0001|1 23|Responsibility matters
P09398332A0732|107 115|sequence
P09398332A0732|94 100|CTLA-4
P09398332A0732|24 35|interaction
P09398332A0732|82 90|161TTGVY
P09398332A0732|217 233|CTLA-4 signaling
P09398855A0438|241 251|DNA damage
P09398855A0438|266 275|apoptosis
P09398855A0438|155 163|p53 gene
P09398855A0438|51 64|T-lymphocytes
P09398855A0438|10 25|J recombination
P09398855A0438|283 290|absence
P09398855A0438|206 225|DNA repair activity
P09398855A0438|1 7|SCID V
P09400613A1209|78 83|mouse
P09400613A1209|54 65|interaction
P09402029A1632|194 206|copy numbers
P09402029A1632|161 167|strain
P09402029A1632|55 68|hybridization
P09402139A1121|271 289|glucose metabolism
P09402139A1121|26 34|hIGFBP-1
P09402139A1121|218 228|hypothesis
P09402139A1121|257 267|regulation
P09402139A1121|67 72|PEPCK
P09402139A1121|174 183|responses
P09402139A1121|1 13|Similarities
P09404725A0644|63 70|females
P09404725A0644|79 84|males
P09404725A0644|16 22|amount
P09405380A0800|28 38|categories
P09405380A0800|42 49|strains
P09405380A0800|71 77|system
P09405685A0113|125 128|T/A
P09405685A0113|58 61|p53
P09405685A0113|111 118|PuPuPuC
P09405685A0113|144 147|A/T
P09405685A0113|119 122|A/T
P09407031A0557|159 174|Cdc2 activation
P09407031A0557|116 127|Chk1 kinase
P09407031A0557|17 21|Crb2
P09407036T0000|38 58|transcription factor
P09407642A0305|46 51|assay
P09407642A0305|79 93|identification
P09408796A0648|90 97|Freedom
P09408796A0648|150 158|variance
P09408796A0648|162 167|WMS-R
P09408796A0648|141 142|%
P09409774A0214|60 66|family
P09409774A0214|27 36|sequences
P09409774A0214|178 188|VCSB1 gene
P09409774A0214|16 21|level
P09409774A0214|152 168|polypeptide SMR1
P09411459A0729|229 242|CVCC material
P09411459A0729|76 87|puppet game
P09411459A0729|203 211|children
P09411459A0729|98 109|pretraining
P09411459A0729|19 29|experiment
P09413375A1486|63 73|IL-6 level
P09413375A1486|22 25|LIS
P09413375A1486|4 16|ICU patients
P09414287A0637|63 70|element
P09414287A0637|1 17|Gel-shift assays
P09415711A1348|63 71|extracts
P09415711A1348|97 111|DDT1MF-2 cells
P09415711A1348|168 187|CRE binding protein
P09415711A1348|1 19|Gel mobility shift
P09416898A1798|109 117|subjects
P09416898A1798|83 96|ARVD patients
P09417108A0000|30 42|Htf9-c genes
P09417108A0000|95 103|promoter
P09417870A0105|120 138|phorbol dibutyrate
P09417870A0105|77 86|treatment
P09417870A0105|140 144|PDBu
P09417870A0105|34 43|depletion
P09417941A1287|180 185|edges
P09417941A1287|107 114|loop LA
P09417941A1287|52 74|spermadhesin molecules
P09417941A1287|84 95|CUB domains
P09417941A1287|137 145|loops LE
P09418057A0684|56 65|locations
P09418871A0620|62 95|coimmunoprecipitation experiments
P09418871A0620|5 16|interaction
P09418882A0760|15 25|antibodies
P09418882A0760|104 112|U1 snRNA
P09418882A0760|118 132|yeast extracts
P09419415A0236|127 139|oncoproteins
P09419415A0236|32 47|STAT activation
P09419680A1112|105 120|single-fraction
P09419680A1112|46 64|barrier disruption
P09419680A1112|20 32|animal model
P09420220A0070|88 98|expression
P09420220A0070|144 146|J.
P09420220A0070|138 142|gene
P09420239A1937|246 248|SU
P09420239A1937|218 225|changes
P09420239A1937|262 294|consensus neutralization epitope
P09420239A1937|14 23|mutations
P09420239A1937|130 137|changes
P09420239A1937|162 176|acceptor sites
P09420239A1937|141 157|RNA splice donor
P09420239A1937|341 343|SU
P09420252A0092|226 244|auxiliary proteins
P09420252A0092|179 187|env gene
P09420252A0092|37 40|LTR
P09420252A0092|168 171|end
P09420252A0092|68 78|expression
P09420275A0682|111 133|transversion mutations
P09420275A0682|197 206|sequences
P09420275A0682|20 32|requirements
P09420671A1190|164 180|adenosine stress
P09420671A1190|78 86|patients
P09420671A1190|39 54|99mTc sestamibi
P09420671A1190|101 115|artery disease
P09420671A1190|136 144|exercise
P09421508A0696|88 96|presence
P09421508A0696|20 28|activity
P09421508A0696|100 104|MafG
P09421516A1516|182 192|K562 cells
P09421516A1516|97 110|NIH 3T3 cells
P09421516A1516|48 58|K562 cells
P09421516A1516|1 14|Deadenylation
P09422351A0000|192 213|transcription factors
P09422351A0000|123 135|ion channels
P09422351A0000|27 41|protein kinase
P09422351A0000|169 177|proteins
P09423123A0000|22 29|acronym
P09423123A0000|1 5|IVOX
P09423856A1098|24 32|cultures
P09423856A1098|179 189|processing
P09423856A1098|83 90|species
P09423856A1098|114 120|masses
P09423856A1098|291 300|molecules
P09423856A1098|204 210|result
P09424012A1774|13 35|field placement errors
P09424012A1774|41 49|patients
P09424012A1774|163 169|degree
P09424012A1774|69 81|mm distances
P09425038A0752|5 10|Swift
P09426068A0826|75 85|expression
P09426068A0826|89 98|TGF-alpha
P09426068A0826|131 139|contrast
P09426068A0826|158 167|apoptosis
P09426068A0826|184 191|tissues
P09426183A0000|148 151|DNA
P09426183A0000|129 137|proteins
P09426183A0000|155 161|dimers
P09426183A0000|85 91|number
P09426595T0000|22 31|reductase
P09426595T0000|114 130|characterization
P09426958A0110|47 52|clone
P09426958A0110|123 128|clone
P09426958A0110|5 16|study goals
P09427551A0501|5 9|gene
P09427551A0501|98 108|chromosome
P09427627A0930|120 123|p70
P09427627A0930|28 35|protein
P09427627A0930|56 76|transphosphorylation
P09427627A0930|168 174|FK1012
P09427844A0739|90 93|dGK
P09427844A0739|26 37|dAK subunit
P09427844A0739|202 209|subunit
P09427844A0739|175 179|dCyd
P09428787A0138|105 132|p69/71 2-5A synthetase gene
P09428787A0138|11 16|clone
P09428787A0138|50 52|kb
P09429913A0528|41 49|benefits
P09429913A0528|25 33|question
P09429913A0528|138 142|EMDR
P09429913A0528|153 162|disorders
P09430661A0796|144 169|cell attachment responses
P09430661A0796|53 58|Y594F
P09430661A0796|87 92|EphB1
P09430730A0374|9 15|Walter
P09430730A0374|17 19|P.
P09431828A1472|24 32|increase
P09431828A1472|36 53|cyclosporine DR/C
P09431828A1472|54 63|SS trough
P09434160A0767|9 16|PTPases
P09434185A0902|133 138|genes
P09434185A0902|198 208|DNA phages
P09434185A0902|21 31|SPP1 genes
P09434185A0902|117 129|organization
P09435056A0128|210 217|protein
P09435056A0128|166 171|frame
P09435056A0128|56 59|Cys
P09435056A0128|179 192|COOH terminus
P09435056A0128|97 106|machinery
P09435056A0128|234 241|protein
P09435789A0961a|241 247|repair
P09435789A0961a|27 31|MEC3
P09435789A0961a|113 115|HU
P09435789A0961a|157 168|yeast cells
P09435789A0961a|17 22|RAD24
P09435789A0961a|10 15|RAD17
P09435789A0961a|100 111|hydroxyurea
P09436657A0303|130 142|risk factors
P09436657A0303|36 43|disease
P09436657A0303|169 174|basis
P09436657A0303|68 82|carcinogenesis
P09436795A0350|94 102|patients
P09436795A0350|112 113|%
P09436795A0350|117 125|patients
P09436795A0350|1 21|Protein C deficiency
P09437001A0769|104 114|degrees C.
P09437001A0769|4 12|contrast
P09437001A0769|32 37|Der3p
P09438427A0727|29 40|CE2 element
P09438427A0727|92 96|mice
P09438427A0727|55 71|Hoxa1 expression
P09440166A0857|210 211|A
P09440166A0857|213 217|tail
P09440166A0857|21 41|cDNA insert sequence
P09440166A0857|50 61|nucleotides
P09440166A0857|111 122|nucleotides
P09440166A0857|65 71|length
P09440166A0857|205 209|poly
P09441664A0377|202 207|genes
P09441664A0377|48 68|transcription factor
P09442017A0435|8 15|Science
P09442024A0708|132 139|amounts
P09442024A0708|59 68|CEMLAI/NP
P09442024A0708|20 23|7H1
P09442024A0708|3 18|hybridoma clone
P09442072A0716|91 95|Hepa
P09442072A0716|188 190|bp
P09442072A0716|54 60|region
P09442072A0716|153 159|region
P09442072A0716|232 245|liver factors
P09442072A0716|138 147|footprint
P09442072A0716|205 214|fVII gene
P09442172A0908|31 34|age
P09442172A0908|128 135|oocytes
P09442172A0908|86 104|gonadotrophin dose
P09443972A1145|105 115|expression
P09443972A1145|130 135|genes
P09443972A1145|5 12|results
P09443978A0262|224 232|TATA box
P09443978A0262|150 160|TATA boxes
P09443978A0262|175 184|promoters
P09443978A0262|33 38|cells
P09445056A0215|60 63|bis
P09445056A0215|82 90|suberate
P09445056A0215|116 128|architecture
P09445056A0215|136 149|gp41 oligomer
P09445488A1169|134 140|region
P09445488A1169|58 71|sequence tags
P09445488A1169|97 100|BIR
P09445488A1169|1 20|PowerBLAST analysis
P09445488A1169|186 195|gene NEFA
P09446616A0780|71 75|Jak1
P09446616A0780|1 15|Reconstitution
P09447917A0000|28 37|Brain Res
P09447917A0000|19 26|Geisler
P09447962A1027|229 240|mRNA levels
P09447962A1027|267 282|HIS4 mRNA level
P09447962A1027|83 94|exonuclease
P09447962A1027|55 59|XRN1
P09447962A1027|171 181|rhis4 mRNA
P09447973A0168|26 33|reports
P09447973A0168|81 88|MyrSos1
P09447973A0168|35 43|addition
P09447973A0168|170 184|MyrSos1-deltaC
P09447973A0168|137 145|deletion
P09447994A0000|211 219|response
P09447994A0000|225 232|variety
P09447994A0000|160 164|CREs
P09447994A0000|188 207|c-fos transcription
P09447994A0000|250 257|stimuli
P09447994A0000|103 111|elements
P09448574A0964|149 157|patients
P09448574A0964|112 120|function
P09448574A0964|36 39|FDG
P09450932A0142|46 57|subpathways
P09450932A0142|127 140|DNA synthesis
P09450932A0142|117 123|arrest
P09451016A1037|135 142|plasmid
P09451016A1037|88 97|membranes
P09451016A1037|156 163|glucose
P09451016A1037|103 108|cells
P09452421A1042|74 77|kDa
P09452421A1042|27 37|GST mSH2-B
P09452444A0450|75 93|IL-6 gene promoter
P09452444A0450|26 34|deletion
P09452444A0450|6 14|analysis
P09453689A0000|150 153|SCI
P09453689A0000|111 114|BCR
P09453689A0000|173 198|bladder function recovery
P09453689A0000|80 95|bulbocavernosus
P09453689A0000|50 54|S4-5
P09454735A1782|15 36|MEK inhibitor PD98059
P09454735A1782|135 155|adhesion disassembly
P09454735A1782|76 102|MAP kinase phosphorylation
P09456312A1064|43 50|RanGAP1
P09456312A1064|86 105|localization signal
P09458030A0192|53 56|MMF
P09458030A0192|68 91|bone mineral metabolism
P09459685T0001|9 23|configurations
P09459685T0001|86 94|children
P09460171T0000|95 121|thyroid hormone disruptors
P09460171T0000|1 11|Resistance
P09460171T0000|68 76|research
P09463174A0670|104 110|months
P09463174A0670|51 59|patients
P09463560A0124|37 45|patients
P09463991T0000|14 19|audit
P09464525T0000|96 99|set
P09464525T0000|1 11|Expression
P09464525T0000|68 80|Fv fragments
P09465783A0449|95 104|treatment
P09465783A0449|110 113|ASA
P09465783A0449|1 21|Platelet aggregation
P09466931T0000|93 97|ng-1
P09466931T0000|69 85|response element
P09467707T0000|74 91|apolipoproteins B
P09467707T0000|126 134|children
P09467707T0000|140 160|Bogalusa Heart Study
P09467955A0468|107 114|ability
P09467955A0468|145 153|promoter
P09467955A0468|54 72|PEA3 binding sites
P09467955A0468|118 122|PEA3
P09468509A0463|52 61|COS cells
P09468509A0463|5 12|protein
P09468515A0621|132 139|ability
P09468515A0621|53 63|nucleotide
P09468515A0621|34 49|promoter region
P09469820A0151|52 61|YAP1 uORF
P09469820A0151|256 267|translation
P09469820A0151|72 82|YAP2 uORF1
P09469820A0151|199 205|region
P09469820A0151|5 10|mRNAs
P09469820A0151|138 148|modulation
P09469933A1060|31 36|brain
P09469933A1060|8 15|tissues
P09469933A1060|54 62|CLIP-170
P09472038T0000|14 26|polarization
P09472038T0000|114 123|mechanism
P09472616A1004|120 128|lineages
P09472616A1004|65 66|C
P09472616A1004|19 30|amino acids
P09473040A1303b|12 21|alcR gene
P09473040A1303b|55 84|siderophore system activities
P09473483A0953|42 46|care
P09473483A0953|216 222|HTLV-1
P09473483A0953|206 211|HIV-I
P09474001A0825|166 171|MMFCV
P09474001A0825|123 128|MMFCV
P09474001A0825|130 131|p
P09474001A0825|5 14|frequency
P09474001A0825|18 21|SPs
P09475378A1449|91 102|RUSH-1alpha
P09475378A1449|65 78|HPLC analysis
P09475898T0000|15 28|amnioinfusion
P09476520A1326|135 142|hybrids
P09476520A1326|8 14|models
P09476520A1326|231 240|molecules
P09476520A1326|116 126|antibodies
P09478921A0126|63 75|pathogenesis
P09478921A0126|21 28|bcr-abl
P09478921A0126|16 20|p210
P09478976A0718|145 154|induction
P09478976A0718|54 63|sequences
P09478976A0718|1 21|Transfection studies
P09479498A0000|48 52|RNF4
P09480843A0848|63 78|triplet repeats
P09480843A0848|80 83|GCT
P09480843A0848|168 176|rat RL14
P09480843A0848|85 92|alanine
P09481826T0000|78 81|use
P09481826T0000|38 49|Jersey herd
P09481826T0000|18 32|liver syndrome
P09482902A0423|73 84|Pctr1 locus
P09482902A0423|128 152|CDK4/CDK6 inhibitors p16
P09482902A0423|39 52|DBA/2 alleles
P09482902A0423|21 28|strains
P09483596A0626|164 180|rocuronium group
P09483596A0626|89 100|excellent/5
P09483596A0626|27 37|difference
P09483596A0626|140 151|excellent/3
P09484781A1233|104 111|PKB/Akt
P09484781A1233|38 63|D3 phosphatidylinositides
P09486531A0638|183 200|gut morphogenesis
P09486531A0638|161 170|induction
P09486531A0638|67 75|mesoderm
P09486531A0638|174 178|lung
P09486531A0638|85 95|apposition
P09487130A0383|110 128|DNA repair mutants
P09487130A0383|4 14|difference
P09487130A0383|70 80|regulation
P09487130A0383|186 190|type
P09487841A0132|36 39|SEM
P09487841A0132|51 69|sample preparation
P09488466A0695|8 16|fragment
P09488466A0695|98 103|cells
P09488486A0906|30 35|R235E
P09488486A0906|22 27|R231E
P09488486A0906|38 43|R239S
P09488486A0906|17 20|TBP
P09488713A0886|122 126|SCAP
P09488713A0886|43 58|Site-1 cleavage
P09488725T0000|11 27|characterization
P09488725T0000|50 58|subunits
P09490676A0800|211 216|sites
P09490676A0800|104 110|excess
P09490676A0800|37 40|Myb
P09490676A0800|68 77|fragments
P09491074A0104|74 85|temperature
P09491074A0104|56 66|expression
P09494078A1362|40 49|yohimbine
P09494078A1362|84 90|effect
P09495771A0379|47 52|cells
P09495771A0379|11 23|fluorescence
P09495771A0379|158 163|stage
P09498553T0000|29 36|studies
P09498553T0000|95 113|P450 monooxygenase
P09498553T0000|68 73|CYP51
P09499031A0000|210 222|reinitiation
P09499031A0000|89 106|sequence elements
P09499031A0000|66 69|VSV
P09499031A0000|20 34|gene junctions
P09499031A0000|254 264|transcript
P09499061A0000|89 94|HIV-1
P09499061A0000|176 187|host genome
P09499061A0000|144 153|insertion
P09499061A0000|157 166|HIV-1 DNA
P09501093A0071|135 158|Ras signal transduction
P09501093A0071|37 44|protein
P09501093A0071|86 100|Ras activation
P09501093A0071|117 121|role
P09501093A0071|51 57|kinase
P09501982A1178|301 311|competence
P09501982A1178|252 260|X-ngnr-1
P09501982A1178|165 170|XCoe2
P09501982A1178|109 124|Xenopus embryos
P09501982A1178|67 74|cascade
P09501982A1178|200 209|potential
P09501982A1178|141 163|Delta-Notch signalling
P09501982A1178|1 12|CONCLUSIONS
P09502720A0214|74 87|specification
P09502720A0214|1 20|CyIIa transcription
P09503017A1021|78 82|gene
P09503017A1021|118 135|chromosome 3p21.3
P09503017A1021|17 25|evidence
P09504423A0114|125 129|BL21
P09504423A0114|219 237|gene fusion vector
P09504423A0114|293 306|cleavage site
P09504423A0114|85 89|gene
P09504423A0114|14 24|expression
P09504423A0114|162 187|glutathione-S-transferase
P09504423A0114|32 43|4E-BP1 gene
P09504553T0000|13 16|use
P09505135A0182|71 78|targets
P09505135A0182|50 57|stimuli
P09506439A2179|112 118|manner
P09506439A2179|141 151|SVHK cells
P09506962A1000|47 54|calpain
P09506962A1000|66 76|proteasome
P09506962A1000|119 122|YY1
P09506990T0000|41 50|repressor
P09506990T0000|7 19|ZFM1 protein
P09508119A0498|82 90|syndrome
P09508119A0498|1 12|CONCLUSIONS
P09508511A0588|78 80|os
P09508511A0588|129 135|urease
P09508511A0588|36 47|H. mustelae
P09508511A0588|85 97|fluorofamide
P09509226A1235|14 17|Use
P09509226A1235|107 110|ICU
P09509226A1235|229 237|outcomes
P09509226A1235|158 170|nursing time
P09509226A1235|184 191|methods
P09509226A1235|118 126|transfer
P09510398A1138|146 155|Secretion
P09510398A1138|22 31|hematuria
P09510398A1138|5 17|risk factors
P09510398A1138|35 43|patients
P09510925A0389|56 62|g dL-1
P09510925A0389|8 33|haemoglobin concentration
P09510925A0389|35 37|Hb
P09511760A0221|94 108|DNA sequencing
P09511760A0221|246 253|regions
P09511760A0221|55 89|polymerase chain reaction analysis
P09511760A0221|154 160|clones
P09512550T0000|15 50|apolipoprotein AI enhancer activity
P09512550T0000|54 65|liver cells
P09512550T0000|1 4|E1A
P09513759A0716|54 71|serum iPTH levels
P09514159A0562|63 67|Ptx1
P09514272A0482|120 123|P16
P09514272A0482|112 115|P15
P09514272A0482|39 51|polypeptides
P09514272A0482|17 21|MvaT
P09515031A1020|29 38|TGF-betaf
P09515031A1020|78 81|PKC
P09515031A1020|55 64|c-fos SRE
P09515665T0000|1 12|Ganciclovir
P09515921A1662|74 82|promoter
P09515921A1662|35 54|pca gene expression
P09515924A0553|135 141|genome
P09515924A0553|145 155|Z. mobilis
P09515924A0553|81 98|sequence analysis
P09515924A0553|51 76|hybridization experiments
P09517646A0149|162 177|pylori regimens
P09517646A0149|23 43|generation macrolide
P09518383A0000|122 126|Peru
P09518383A0000|242 249|condoms
P09518383A0000|158 163|tests
P09518383A0000|190 196|smears
P09518383A0000|16 26|OBJECTIVES
P09518383A0000|108 111|FSW
P09518383A0000|235 238|STD
P09518383A0000|1 11|BACKGROUND
P09519757A0482|120 123|NBF
P09519757A0482|193 206|heterozygotes
P09519757A0482|57 61|exon
P09519757A0482|36 40|exon
P09519757A0482|174 181|patient
P09519757A0482|16 25|mutations
P09519830A0282|59 68|silencing
P09519830A0282|218 265|chloramphenicol acetyltransferase reporter gene
P09519830A0282|116 123|viruses
P09519830A0282|87 102|HSV-1 infection
P09519830A0282|35 39|role
P09521907A0190|27 30|otd
P09521907A0190|77 82|terms
P09521907A0190|117 127|phenotypes
P09521913A0400|19 28|mutations
P09522979T0000|56 70|preterm labour
P09522979T0000|23 34|fibronectin
P09523551A0367|47 55|topology
P09523551A0367|76 77|G
P09524222A0769|31 38|isoform
P09524222A0769|214 220|region
P09524222A0769|246 257|actin-cross
P09524222A0769|224 230|MARCKS
P09524222A0769|377 402|calmodulin binding domain
P09524222A0769|308 326|calcium/calmodulin
P09524222A0769|168 176|subunits
P09524222A0769|139 149|cell alpha
P09524229A0000|124 148|Cryphonectria parasitica
P09524229A0000|334 357|inhibitor cycloheximide
P09524229A0000|359 362|CHX
P09524229A0000|393 407|cyclosporin A.
P09524229A0000|77 83|number
P09524229A0000|172 183|hypoviruses
P09524229A0000|100 122|chestnut blight fungus
P09524259A0301|182 187|yeast
P09524259A0301|5 23|hp55 gamma protein
P09524259A0301|118 128|hp55 gamma
P09524259A0301|171 173|IR
P09524273A0205|6 11|paper
P09524273A0205|50 62|mouse gC1qBP
P09525105A0298|29 39|activities
P09525105A0298|65 81|Buddleia cordata
P09525888A1482|61 80|muscle cDNA library
P09525888A1482|46 51|mouse
P09527921A1178|270 283|transcription
P09527921A1178|93 97|site
P09527921A1178|292 300|TATA box
P09527921A1178|185 187|bp
P09527921A1178|32 41|complexes
P09528766A0915|111 139|CREB Ser-133 phosphorylation
P09528766A0915|49 66|p38/MAPKAP kinase
P09528770A1379|30 57|protein kinase cAPK pathway
P09528770A1379|193 198|Msn4p
P09528770A1379|111 118|glucose
P09528770A1379|172 188|activators Msn2p
P09528770A1379|99 107|presence
P09528770A1379|87 91|IREu
P09528792A0000|134 144|exons IIIb
P09528792A0000|13 21|splicing
P09528792A0000|149 153|IIIc
P09528792A0000|76 83|example
P09528792A0000|116 124|splicing
P09528950A0716|50 74|luciferase reporter gene
P09529156A1238|26 38|Ser residues
P09529156A1238|54 72|PKC consensus site
P09529156A1238|1 9|Deletion
P09529649A0307|61 76|tract infection
P09529649A0307|80 88|children
P09530251A0766|60 68|ischemia
P09530251A0766|111 122|reperfusion
P09530251A0766|33 34|h
P09530251A0766|1 5|SNAC
P09531549A0658|56 70|yeast extracts
P09531549A0658|199 206|patches
P09531549A0658|96 101|sites
P09531549A0658|217 232|plasma membrane
P09531549A0658|117 122|Pan1p
P09531549A0658|137 152|yAP180 proteins
P09533030T0000|215 219|1q21
P09533030T0000|93 103|components
P09533030T0000|23 30|complex
P09533030T0000|107 125|liver mitochondria
P09533030T0000|130 151|chromosome assignment
P09533030T0000|203 211|subunits
P09535082A0537|271 273|CI
P09535082A0537|262 269|complex
P09535082A0537|104 120|target sequences
P09535082A0537|128 135|absence
P09535082A0537|71 86|protein binding
P09535082A0537|139 143|PrfA
P09535082A0537|34 41|extract
P09535833A0228|151 165|Xenopus laevis
P09535833A0228|77 81|Staf
P09535833A0228|141 147|factor
P09535851A0591|27 39|beta isoform
P09535851A0591|111 124|gamma isoform
P09535851A0591|169 173|acid
P09535908A0321|30 42|LNX messages
P09535908A0321|109 112|kDa
P09535908A0321|126 129|kDa
P09535908A0321|114 117|LNX
P09536440A0000|123 131|movement
P09536440A0000|8 15|studies
P09537295A0951|160 174|primer walking
P09537295A0951|95 134|transcriptase-polymerase chain reaction
P09537295A0951|76 80|site
P09537295A0951|51 53|bp
P09537361A0149|56 60|cvaA
P09537361A0149|131 157|colicin V immunity protein
P09537361A0149|42 52|expression
P09537361A0149|113 116|cvi
P09537361A0149|207 216|depletion
P09537378A1227|61 67|effect
P09537378A1227|18 26|deletion
P09538156A0130|90 96|region
P09538156A0130|1 14|BRCA1 protein
P09538258A0200|9 15|report
P09538258A0200|111 120|receptors
P09538258A0200|138 143|cells
P09539721A0599|88 98|activation
P09539721A0599|106 117|pR promoter
P09539721A0599|50 62|beta subunit
P09539779A0621|106 121|Arp1 expression
P09539779A0621|95 102|pattern
P09539779A0621|70 74|days
P09541280A0404|61 70|treatment
P09541280A0404|76 90|FK506 ointment
P09541280A0404|103 119|plasma IgE level
P09541721A0894|110 118|pressure
P09541721A0894|65 68|NIC
P09544987A1583|29 39|RU486-PR-B
P09544991A0750|268 276|m-Stat5b
P09544991A0750|193 209|m-Stat5adelta749
P09544991A0750|176 184|deletion
P09544991A0750|23 29|mutant
P09544991A0750|64 73|induction
P09544991A0750|118 126|activity
P09545293A0590|30 39|keratocan
P09545293A0590|18 25|lumican
P09545323T0000|15 23|assembly
P09545323T0000|37 44|complex
P09545323T0000|102 129|MLH1-PMS1 protein complexes
P09545353A1071|227 237|expression
P09545353A1071|199 208|TNF-alpha
P09545353A1071|34 49|kappaB elements
P09545638A0330b|36 65|yeast hnRNP methyltransferase
P09545638A1181|52 59|disease
P09545638A1181|35 42|HRMT1L2
P09546424A1550|71 83|Crk proteins
P09547349A0000|79 89|ET-18-OCH3
P09547349A0000|145 156|tumor cells
P09547349A0000|115 122|inducer
P09549179A0774|82 83|p
P09549179A0774|99 109|conditions
P09549179A0774|118 123|study
P09549179A0774|68 76|exposure
P09549632A1189|74 80|regard
P09549632A1189|25 36|sensitivity
P09549632A1189|7 10|use
P09549632A1189|50 61|specificity
P09549632A1189|102 112|ALT levels
P09549783T0000|9 17|accuracy
P09550919A0365|90 92|mg
P09550919A0365|149 157|episodes
P09550919A0365|125 133|episodes
P09550919A0365|54 62|response
P09550919A0365|221 222|%
P09550919A0365|78 87|adenosine
P09550919A0365|42 48|manner
P09550919A0365|6 10|data
P09550919A0365|137 141|PSVT
P09551182A0212|73 79|method
P09551182A0212|215 228|acid receptor
P09551182A0212|161 167|ligand
P09551182A0212|248 266|DNA binding domain
P09551182A0212|101 110|retinoids
P09551972A1033|60 70|chromosome
P09551972A1033|192 198|8q24.3
P09551972A1033|162 172|gene close
P09551972A1033|39 56|metaphase spreads
P09551972A1033|85 114|hybrid cell line 706-B6 clone
P09553040A0651|106 115|PLC-gamma
P09553040A0651|93 104|PI-3 kinase
P09553040A0651|64 82|signaling pathways
P09553040A0651|117 120|Ras
P09553143A0729|30 36|SLP-76
P09553143A0729|52 66|Erk activation
P09553143A0729|140 150|P116 cells
P09553143A0729|115 127|Jurkat cells
P09555046A1617|5 12|results
P09555046A1617|114 121|disease
P09555046A1617|35 46|base change
P09556561A0671|149 172|pseudouridine synthesis
P09556561A0671|41 46|Gar1p
P09556561A0671|191 199|molecule
P09556561A0671|85 92|snoRNAs
P09556573A1062|146 166|co-activator RIP-140
P09556573A1062|58 59|S
P09556573A1062|112 123|interaction
P09556573A1062|39 55|PPARalpha ligand
P09556573A1062|185 196|interaction
P09557678A0140|107 111|HeLa
P09557678A0140|176 189|proliferation
P09557678A0140|93 103|E2 protein
P09557678A0140|64 83|papillomavirus type
P09557678A0140|87 91|BPV1
P09557708A1426|58 67|periphery
P09557708A1426|173 182|vA33delta
P09557708A1426|153 158|cells
P09560221A0282|134 140|cak1At
P09560221A0282|74 79|yeast
P09560221A0282|9 15|cak1At
P09560221A0282|50 62|CAK mutation
P09560390A0771|90 109|cell cycle response
P09560390A0771|46 60|overexpression
P09560390A0771|4 12|addition
P09561560A0579|198 210|CTL response
P09561560A0579|126 143|SIV gene products
P09561560A0579|53 81|Mengo virus SIV recombinants
P09561560A0579|234 250|HIV1 Nef peptide
P09561560A0579|100 113|CTL responses
P09562398A0848|149 157|n-hexane
P09562398A0848|58 60|.4
P09562398A0848|23 27|turn
P09562398A0848|138 144|values
P09562398A0848|1 18|Trichloroethylene
P09564860A2139|135 138|i/o
P09564860A2139|79 94|loop 3i domains
P09564860A2139|65 75|expression
P09564860A2139|4 12|contrast
P09564917A0900|11 17|levels
P09564917A0900|96 100|U/mL
P09564917A0900|102 103|p
P09565584A0770|133 137|exon
P09565584A0770|20 31|amino acids
P09565584A0770|33 37|KKKR
P09565584A0770|187 188|H
P09566731A0458|11 16|genes
P09566731A0458|111 127|mouse chromosome
P09566731A0458|71 95|chromosome 16p12.1-p11.2
P09566871T0000|77 96|protein kinase Fus3
P09566871T0000|19 29|regulation
P09566882A0693|96 100|Pho4
P09566882A0693|115 119|Pho2
P09566882A0693|85 92|binding
P09568445T0000|11 17|angina
P09568445T0000|84 104|contractile recovery
P09570030T0000|57 68|development
P09570133A0474|28 40|interactions
P09570133A0474|58 70|interactions
P09570133A0474|110 115|roles
P09570133A0474|4 12|addition
P09570952A0000|26 38|organization
P09570952A0000|53 57|gene
P09572428A0526|180 187|ovaries
P09572428A0526|78 83|women
P09572428A0526|128 133|ng/ml
P09572428A0526|8 36|SD serum VEGF concentrations
P09572428A0526|64 65|P
P09572511A0148|61 66|block
P09572511A0148|27 34|RBI-MAP
P09572511A0148|77 79|EM
P09572990A0630|151 161|hSIE probe
P09572990A0630|104 110|Stat-3
P09572990A0630|124 132|extracts
P09572990A0630|4 15|association
P09573202A0900|123 135|acid residue
P09573202A0900|36 42|levels
P09573202A0900|139 147|position
P09573202A0900|171 177|domain
P09573374A0687|7 29|Southern blot analysis
P09573374A0687|156 158|kb
P09573374A0687|70 75|yeast
P09573374A0687|139 147|RIL gene
P09573374A0687|34 53|restriction mapping
P09573884A0392|31 36|S-N-B
P09573884A0392|126 131|Class
P09573884A0392|98 103|Class
P09575143A1189|134 141|ability
P09575143A1189|79 87|activity
P09575143A1189|159 173|immunoreceptor
P09575143A1189|5 17|localization
P09575143A1189|35 46|cell cortex
P09575217A0000|111 124|transcription
P09575217A0000|145 154|signaling
P09575217A0000|6 24|cytokine receptors
P09575217A0000|32 62|Janus protein tyrosine kinases
P09576230T0000|22 46|oxide synthase inhibitor
P09576230T0000|5 11|effect
P09577365A0747|75 88|collagen type
P09577365A0747|180 185|cases
P09577365A0747|28 35|vessels
P09577365A0747|128 137|submucosa
P09577365A0747|4 18|angiodysplasia
P09577365A0747|223 241|muscularis mucosae
P09578042A0363|131 139|patients
P09578042A0363|71 86|seizure outcome
P09578042A0363|169 172|TLE
P09579602A1720|151 158|results
P09579602A1720|7 20|modifications
P09579602A1720|116 131|sample handling
P09579602A1720|136 147|calculation
P09579808A0000|41 72|N-acetylglucosaminyltransferase
P09579808A0000|127 135|assembly
P09579808A0000|1 11|UDP-GlcNAc
P09580563A0331|15 34|amino acid sequence
P09580563A0331|95 112|Neurospora crassa
P09580563A0331|86 91|chain
P09580563A0331|153 161|nidulans
P09581552A1323|11 20|modelling
P09581552A1323|143 154|amino acids
P09581552A1323|102 114|interactions
P09581834A2578|105 108|PCA
P09581834A2578|44 53|silymarin
P09581834A2578|23 30|results
P09581834A2578|216 221|CDKIs
P09581834A2578|239 248|G1 arrest
P09582267A0326|163 185|GM701 fibroblast cells
P09582267A0326|96 103|Siah-1A
P09582267A0326|235 244|apoptosis
P09582267A0326|16 24|function
P09582267A0326|51 55|Siah
P09582308A1165|109 113|homo
P09582308A1165|96 105|formation
P09582327A0295|31 40|GH3 cells
P09582327A0295|62 84|rat GnRH receptor cDNA
P09582327A0295|213 221|sequence
P09582327A0295|185 200|rat LHbeta gene
P09582327A0295|290 309|luciferase reporter
P09582327A0295|346 358|GnRH agonist
P09582327A0295|272 278|region
P09582327A0295|238 248|base pairs
P09582343A0000|62 86|carcinoma cell line FM3A
P09582635A0523|47 63|H.T.V. specimens
P09582635A0523|89 95|kg/cm2
P09582635A0523|129 145|R.T.V. specimens
P09582635A0523|171 177|kg/cm2
P09582953A1097|10 16|Horses
P09582953A1097|22 27|colic
P09582953A1097|141 145|APTT
P09582953A1097|87 96|alpha 2AP
P09583201A0759|13 21|patients
P09583592A0263|12 19|METHODS
P09583592A0263|1 7|DESIGN
P09584165T0000|79 89|G proteins
P09584165T0000|10 18|receptor
P09584165T0000|33 41|C kinase
P09584165T0000|100 108|activity
P09584165T0000|137 143|growth
P09584180A0701|25 38|reporter gene
P09584180A0701|139 162|I.29mu B lymphoma cells
P09584194A1305|29 36|spindle
P09584194A1305|113 117|G2/M
P09584194A1305|49 66|library screening
P09584194A1305|165 175|interactor
P09584194A1305|72 76|HEF1
P09584194A1305|4 11|support
P09585540A0440|62 70|dialysis
P09585540A0440|102 127|agent 1,10-phenanthroline
P09586832A0229|70 79|receptors
P09588228A0370|43 51|antibody
P09588228A0370|68 76|staining
P09590540A0513|271 284|pQE-30 vector
P09590540A0513|25 27|nt
P09590540A0513|80 95|signal sequence
P09590540A0513|48 57|sequences
P09590540A0513|129 135|domain
P09590540A0513|141 144|PCR
P09592125A0000|61 72|elaboration
P09592125A0000|9 30|alpha1,2-mannosidases
P09592125A0000|98 105|glycans
P09592125A0000|1 6|Class
P09592208A0470|15 24|qualities
P09592208A0470|60 64|fact
P09592208A0470|109 121|construction
P09592208A0470|141 145|data
P09593302A1165|122 129|ability
P09593302A1165|138 144|phenol
P09593302A1165|17 29|implications
P09595496A0000|26 32|levels
P09595496A0000|36 48|endothelin-1
P09595496A0000|50 54|ET-1
P09596542A0542|39 55|cartilage matrix
P09596738T0000|90 101|development
P09596738T0000|73 78|Cek1p
P09596738T0000|49 71|protein kinase homolog
P09598894A0732|30 44|bone formation
P09598894A0732|19 26|markers
P09599664A0881|73 82|RXR alpha
P09599664A0881|5 19|DNA sequencing
P09599664A0881|87 95|RXR beta
P09599897A0000|265 268|PLT
P09599897A0000|58 82|Henoch-Schonlein purpura
P09599897A0000|191 201|blood cell
P09599897A0000|155 173|laboratory indices
P09599897A0000|255 263|platelet
P09599897A0000|44 52|children
P09599897A0000|130 142|associations
P09599897A0000|203 206|WBC
P09601510A0215|46 58|FV pol genes
P09601510A0215|85 96|transcripts
P09601921A0000|192 208|British Columbia
P09601921A0000|110 120|Lake Huron
P09601921A0000|83 94|water birds
P09601921A0000|155 168|United States
P09601921A0000|51 62|di-butyltin
P09602124A0127|1 8|Fregnac
P09604052A0166|26 30|data
P09604052A0166|93 98|women
P09604052A0166|52 65|control group
P09605930A1428|11 18|results
P09605930A1428|144 152|ALS gene
P09606633A0523|48 53|weeks
P09609342A0000|60 64|pump
P09609342A0000|121 124|AFP
P09609342A0000|110 119|flow pump
P09609342A0000|80 89|flow pump
P09609342A0000|155 166|performance
P09609720A0357|47 48|N
P09609720A0357|79 87|nuclease
P09609720A0357|24 33|fragments
P09611016A0652|120 127|pessary
P09611016A0652|133 142|placement
P09611016A0652|55 65|management
P09611016A0652|16 21|women
P09611234A0098|62 79|oncoproteins PLZF
P09611234A0098|113 131|corepressors N-CoR
P09611234A0098|1 19|Rev-erbAalpha/beta
P09611234A0098|136 140|SMRT
P09612351A0386|41 52|oscillation
P09613574A0905|226 229|min
P09613574A0905|26 33|protein
P09613574A0905|144 156|MGMT protein
P09613574A0905|54 69|enzyme activity
P09613574A0905|100 113|methyl groups
P09614065A0966|30 38|response
P09614065A0966|61 69|mutation
P09614065A0966|145 154|AP-1 site
P09614065A0966|172 181|induction
P09617765A0174|75 81|strand
P09617765A0174|133 134|A
P09617765A0174|53 55|nt
P09617765A0174|101 107|region
P09617765A0174|136 140|tail
P09618150A0127|62 67|IGF-I
P09618150A0127|126 132|dbcAMP
P09618150A0127|292 294|h.
P09618150A0127|252 260|increase
P09618150A0127|192 214|UCP1 mRNA accumulation
P09618150A0127|110 124|dibutyryl cAMP
P09618150A0127|275 284|treatment
P09618164A0709|82 88|nuclei
P09618164A0709|18 19|O
P09618164A0709|117 124|culture
P09618481T0000|108 127|Smad family members
P09618481T0000|59 64|cells
P09618481T0000|1 11|Regulation
P09619777A1583|218 228|conditions
P09619777A1583|117 123|pepsin
P09619777A1583|258 263|hours
P09619777A1583|10 27|base ketoconazole
P09619777A1583|142 149|minutes
P09619777A1583|70 81|formulation
P09619777A1583|239 252|% dissolution
P09620606A0000|56 59|TCR
P09620606A0000|20 27|signals
P09620606A0000|101 108|signals
P09620955A0370|40 51|leader mRNA
P09620955A0370|172 182|lac operon
P09620955A0370|85 96|combination
P09621372A0369|104 111|enzymes
P09621372A0369|48 64|thrombocytopenia
P09622055A0207|134 139|D-Cbl
P09622055A0207|58 65|mammals
P09622055A0207|92 102|C. elegans
P09622055A0207|5 12|members
P09622121T0000|30 66|polypyrimidine tract binding protein
P09622121T0000|12 22|antibodies
P09622121T0000|173 186|branch points
P09622121T0000|68 71|PTB
P09625762A0426|87 93|manner
P09626662A1076|46 54|affinity
P09626662A1076|26 28|TR
P09626662A1076|9 20|experiments
P09626662A1076|128 146|TR/RXR heterodimer
P09627285A0554|15 23|patients
P09627285A0554|132 139|ampules
P09627285A0554|52 61|cycle day
P09627285A0554|38 48|FSH levels
P09627285A0554|1 7|RESULT
P09628375A0700|25 40|tissue coverage
P09628821A1194|89 94|roles
P09628821A1194|144 162|lineage commitment
P09628821A1194|69 74|genes
P09629449A0540|107 119|PMN elastase
P09629449A0540|23 37|ROS production
P09629449A0540|5 12|results
P09630245A0903|74 93|snRNP core proteins
P09630245A0903|179 196|U1 snRNP proteins
P09630245A0903|101 111|homologues
P09630245A0903|119 130|metazoan U1
P09632217A0477|12 33|antagonist naltrexone
P09632217A0477|82 98|stimulus effects
P09632217A0477|114 124|naltrexone
P09632217A0477|185 201|stimulus effects
P09632217A0477|205 212|cocaine
P09632709A0464|27 34|NCoA-62
P09632709A0464|131 138|protein
P09632709A0464|171 186|gene expression
P09632734A0943|31 37|effect
P09632734A0943|9 23|p82 expression
P09632734A0943|96 104|activity
P09633171A0321|79 86|storage
P09633171A0321|58 66|incisors
P09633171A0321|5 13|brackets
P09633171A0321|103 119|room temperature
P09633630A0740|181 184|v/v
P09633630A0740|131 142|fluorescens
P09633630A0740|178 179|%
P09633630A0740|5 11|growth
P09633630A0740|99 100|%
P09633630A0740|186 189|BMC
P09635149A1148|16 20|PaO2
P09636119T0000|81 88|pulleys
P09636670T0000|107 120|breast cancer
P09636670T0000|59 79|kinase inhibitor p18
P09636670T0000|1 10|Structure
P09637689A0150|11 15|type
P09637689A0150|25 43|activator proteins
P09637689A0150|163 167|RNAP
P09637689A0150|99 103|RNAP
P09638485A0111|44 49|tt-MA
P09638485A0111|183 190|workers
P09638485A0111|144 163|road tanker drivers
P09638485A0111|38 42|acid
P09638793A1446|29 41|hemodilution
P09638793A1446|43 46|Hct
P09638793A1446|127 138|oxygenation
P09638793A1446|66 71|LV MC
P09638793A1446|48 49|%
P09639410A3282|7 12|genes
P09639410A3282|39 46|targets
P09639565A0225|78 83|cells
P09640802A0467|44 56|consequences
P09640802A0467|96 109|possibilities
P09642042A0646|120 141|beta-phosphate moiety
P09642042A0646|59 72|triphosphates
P09642042A0646|33 48|nucleotide mono
P09642214A0244|31 35|role
P09642214A0244|180 191|COS-7 cells
P09642214A0244|56 73|phosphatase SHP-2
P09642214A0244|163 176|SHP-2 mutants
P09642238A0532|47 64|enhancer activity
P09642276A0881|60 64|role
P09642276A0881|72 81|execution
P09642276A0881|24 32|caspases
P09642276A0881|17 20|Fak
P09643153T0000|30 48|T2N breast cancers
P09643153T0000|2 11|Treatment
P09643548A0000|5 10|genes
P09643548A0000|84 120|cyanobacterium Synechocystis PCC6803
P09645942A1164|9 13|pool
P09645942A1164|17 42|Dsg-plakoglobin complexes
P09647233A0336|165 171|repeat
P09647233A0336|173 176|LTR
P09647233A0336|87 97|NF-kappa B
P09647233A0336|68 72|part
P09649069A0490|114 126|examinations
P09649315A0943|44 47|NMR
P09649315A0943|95 114|MIP-1 beta variants
P09649315A0943|33 42|resonance
P09649315A0943|1 12|Examination
P09649437A1140|73 91|Ets family members
P09649437A1140|133 165|eosinophil lineage determination
P09649437A1140|32 44|interactions
P09649501A0358|45 70|HSF1 trimerization domain
P09649501A0358|133 166|heat shock factor binding protein
P09649501A0358|78 83|yeast
P09649501A0358|247 253|arrays
P09649501A0358|170 175|HSBP1
P09650180A1130|13 26|recombination
P09650180A1130|43 50|voltage
P09650180A1130|80 90|dose-rates
P09650275T0000|92 114|biotechnology industry
P09650299A1334|46 51|VirD2
P09650299A1334|23 27|data
P09650789A0185|28 39|spin system
P09650789A0185|1 12|Orientation
P09650789A0185|103 116|energy levels
P09651367T0000|31 43|Ras effector
P09651367T0000|64 74|inhibition
P09651367T0000|87 97|myogenesis
P09651383A0967|124 140|HNF-4 constructs
P09651383A0967|188 189|%
P09651383A0967|155 179|apoCII promoter activity
P09651383A0967|49 61|element CIIB
P09651383A0967|10 19|mutations
P09651383A0967|66 76|inhibition
P09652736A1205|120 132|co-activator
P09652736A1205|63 75|tumour cells
P09652736A1205|27 32|E2F-1
P09652736A1205|196 201|E2F-1
P09652736A1205|141 159|E2F/DP heterodimer
P09652742A0455|89 95|glands
P09652742A0455|111 117|tumors
P09653641A0471|7 15|isoforms
P09653745A0180|94 103|reduction
P09653745A0180|199 204|model
P09653745A0180|266 279|problem today
P09653745A0180|232 237|world
P09653745A0180|1 8|Malaria
P09653745A0180|119 135|control projects
P09655916A0415|160 163|Gln
P09655916A0415|58 61|Arg
P09655916A0415|65 73|position
P09655916A0415|153 156|Leu
P09656485A0351|32 40|elements
P09658104T0000|13 49|transcription start site core region
P09658104T0000|54 78|transcription factor YY1
P09658104T0000|1 5|Role
P09658403A1207|13 16|Rap
P09658403A1207|43 48|cells
P09658403A1207|112 124|CAT activity
P09658403A1207|99 108|induction
P09658769A0058|56 65|diagnosis
P09658769A0058|33 45|IFN alpha-2b
P09660836A0983|104 109|U0126
P09660836A0983|144 152|affinity
P09660836A0983|157 170|deltaN3-S218E
P09660836A0983|81 90|compounds
P09661676T0000|79 87|patients
P09661676T0000|43 47|IL-5
P09661676T0000|59 65|sputum
P09662443A0402|97 117|caveolin gene family
P09664033A1204|120 127|snoRNAs
P09664033A1204|6 18|distribution
P09664033A1204|50 59|precursor
P09664033A1204|152 170|processing pathway
P09665503A0526|48 53|study
P09665720A1145|91 107|exonuclease site
P09665720A1145|57 72|primer terminus
P09665720A1145|152 156|site
P09666114A0389|12 20|analysis
P09666114A0389|95 108|CAAT elements
P09666114A0389|66 80|c-met promoter
P09667795A0000|7 19|pancreatitis
P09668096A0806|14 18|site
P09668096A0806|50 60|preference
P09668108A1017|77 86|apoptosis
P09668108A1017|21 42|checkpoint regulators
P09668108A1017|1 13|Manipulation
P09669641A0425|28 38|serum PE-1
P09670912T0000|19 27|seizures
P09671313A0334|1 6|Chem.
P09671496A0557|90 100|disruption
P09671496A0557|108 119|c-Cbl locus
P09671496A0557|25 29|role
P09671496A0557|188 198|appearance
P09671496A0557|137 141|mice
P09671579A1168|117 137|boundary development
P09671579A1168|17 25|noi/pax2
P09673037A0358|104 132|reticulin fiber impregnation
P09673037A0358|37 48|bone marrow
P09673037A0358|1 8|METHODS
P09675154A0690|126 135|insertion
P09675154A0690|219 224|W118R
P09675154A0690|55 61|GSD-Ib
P09675154A0690|85 94|mutations
P09676349A0000|74 94|release theophylline
P09676349A0000|109 120|preparation
P09676349A0000|143 156|investigation
P09677330A0584|30 47|linker region LR1
P09677330A0584|148 152|unit
P09677330A0584|109 112|LR2
P09677330A0584|126 130|UCR2
P09677410A1059|45 48|p53
P09677410A1059|13 17|time
P09677410A1059|161 169|enhancer
P09677410A1059|23 30|results
P09677410A1059|235 238|p53
P09678837A0736|61 79|bronchoprovocation
P09678837A0736|43 57|responsiveness
P09678837A0736|196 213|blood eosinophils
P09678837A0736|157 170|pollen season
P09678837A0736|16 21|study
P09679750A0304|166 175|attention
P09679750A0304|20 29|potential
P09679750A0304|103 108|drugs
P09681822A0520|11 30|c-erbB3 transcripts
P09683576A0542|62 77|protease domain
P09683576A0542|79 94|Gln2526-Asp2527
P09685226A0000|91 104|transcription
P09685226A0000|13 23|calcitonin
P09685226A0000|146 153|protein
P09685226A0000|218 221|BEN
P09685226A0000|155 160|PTHrP
P09686344T0000|31 39|spectrum
P09687498A1173|108 114|c-ErbA
P09687498A1173|191 205|overexpression
P09687498A1173|156 168|conformation
P09687498A1173|116 123|TRalpha
P09687498A1173|84 92|oncogene
P09687514A0521|148 157|complexes
P09687514A0521|50 70|transcription system
P09689047A0253|193 217|Golgi sialyltransferases
P09689047A0253|179 188|substrate
P09689047A0253|143 147|acid
P09689047A0253|3 15|prerequisite
P09691031A1050|14 19|model
P09691031A1050|29 42|Sro7 function
P09691031A1050|114 122|pathways
P09692965A0904|72 80|patterns
P09692965A0904|6 14|cysteine
P09693134A0782|31 38|markers
P09693134A0782|227 245|column neuroblasts
P09693134A0782|159 166|embryos
P09693134A0782|260 270|identities
P09693134A0782|323 334|neuroblasts
P09693134A0782|119 130|neuroblasts
P09694034A0713|226 231|drugs
P09694034A0713|147 152|value
P09694034A0713|7 14|results
P09694034A0713|65 79|antipsychotics
P09694034A0713|207 216|potential
P09694599A1355|121 130|hematuria
P09694599A1355|26 36|elevations
P09694599A1355|96 104|cystitis
P09694599A1355|1 12|CONCLUSIONS
P09694860A0498|124 131|protein
P09694860A0498|76 82|region
P09694897T0000|74 76|U2
P09694897T0000|27 63|ribonucleoprotein C protein tetramer
P09694897T0000|70 72|U1
P09696164A0000|77 81|SIDS
P09696164A0000|19 25|system
P09698457A0778|63 72|phenotype
P09698457A0778|96 105|vibrissae
P09698457A0778|19 23|mice
P09698512A0296|1 8|METHODS
P09701609A0116|109 116|ability
P09701609A0116|76 82|PhLOP1
P09701609A0116|87 93|PhLOP2
P09701821A1108|44 52|opuE P-1
P09701821A1108|4 12|contrast
P09701821A1108|71 81|proportion
P09703021A0000|104 113|processes
P09703021A0000|268 290|melatonin biosynthesis
P09703021A0000|125 139|sclerotization
P09703021A0000|260 264|step
P09703021A0000|141 153|inactivation
P09703021A0000|50 56|AANATs
P09703276A2346|30 43|hydroquinones
P09703276A2346|52 64|mutagenicity
P09704006A0224|45 51|muscle
P09704006A0224|62 69|embryos
P09704006A0224|29 34|brain
P09704569T0000|61 80|TR2 orphan receptor
P09704569T0000|39 47|location
P09704569T0000|84 90|member
P09704927A0479|26 34|homology
P09704927A0479|7 13|shares
P09704927A0479|85 103|heterodimerization
P09705324A0213|246 256|base pairs
P09705324A0213|191 224|thyroid hormone response elements
P09705324A0213|153 158|C/EBP
P09705324A0213|79 89|hepatocyte
P09705324A0213|9 21|footprinting
P09705324A0213|98 106|factor-1
P09705324A0213|1 6|DNase
P09705352A0879|73 115|minichromosome maintenance protein complex
P09705352A0879|130 143|fission yeast
P09705352A0879|34 39|Cdc19
P09705564T0000|25 44|papillomavirus type
P09705564T0000|1 11|Expression
P09706643A0206|31 36|agent
P09707577A1047|44 51|markers
P09707577A1047|18 30|distribution
P09708565A0000|21 28|article
P09708565A0000|153 171|radioimmunotherapy
P09708565A0000|47 54|factors
P09708565A0000|276 293|commercialization
P09708565A0000|96 109|radionuclides
P09708565A0000|5 12|purpose
P09708565A0000|138 149|development
P09710582A0535|15 18|Rho
P09710582A0535|22 26|AP-1
P09710582A0535|5 11|effect
P09710582A0535|175 188|AP-1 activity
P09710591A0981|45 60|serine residues
P09710591A0981|22 32|C terminus
P09710591A0981|98 112|growth factors
P09710591A0981|168 186|block potentiation
P09710591A0981|117 127|MAP kinase
P09710599T0000|44 63|protein kinases p42
P09710599T0000|12 22|activation
P09710599T0000|76 97|ets-2 phosphorylation
P09710599T0000|68 71|p44
P09710615T0000|37 42|Vam3p
P09710615T0000|64 72|function
P09710615T0000|1 6|Vam7p
P09710641A0000|121 136|eye development
P09710641A0000|83 85|HD
P09710641A0000|184 190|alphaA
P09710641A0000|193 199|delta1
P09710641A0000|66 68|PD
P09710641A0000|175 181|alphaB
P09710641A0000|70 81|homeodomain
P09712297T0000|5 38|prothrombin gene G20210A mutation
P09712297T0000|86 101|vein thrombosis
P09712859A1110|37 43|NF-AT4
P09712859A1110|5 12|binding
P09712859A1110|16 22|NF-ATp
P09712898T0000|109 112|p38
P09712898T0000|53 67|protein kinase
P09712898T0000|1 32|Tumor necrosis factor signaling
P09712919A0307|8 15|studies
P09712919A0307|113 128|CREB activation
P09712919A0307|34 40|report
P09713990T0000|107 129|TP53 expression system
P09713990T0000|22 38|TP53 target gene
P09713996T0000|27 43|characterization
P09713996T0000|96 116|drug resistance gene
P09713996T0000|201 204|ALL
P09713996T0000|118 137|MDR1/P-glycoprotein
P09714109A0785|10 33|blood pressure increase
P09714109A0785|37 45|response
P09714109A0785|49 56|smoking
P09715278A1079|90 97|changes
P09715278A1079|78 88|maturation
P09715278A1079|23 36|transfectants
P09715278A1079|1 13|RA-treatment
P09715384A0235|45 47|mm
P09715384A0235|13 20|vessels
P09715384A0235|29 37|diameter
P09715384A0235|131 138|vessels
P09715384A0235|162 163|%
P09716179A0974|193 213|cdk2 kinase activity
P09716179A0974|43 52|reduction
P09716179A0974|80 85|genes
P09716179A0974|184 188|cdc2
P09716179A0974|152 159|p27Kip1
P09716435A1004|107 113|vigour
P09716435A1004|76 80|rise
P09716435A1004|32 43|HS subjects
P09716435A1004|118 136|cortisol elevation
P09717835A0941|95 110|Xenopus homolog
P09717835A0941|7 24|sequence analyses
P09717835A0941|70 80|IRS family
P09718372T0000|41 48|pathway
P09718372T0000|65 71|stress
P09719636A1134|74 89|histidine pairs
P09719636A1134|95 112|H382-X2-H385 pair
P09719636A1134|229 233|gp17
P09719636A1134|144 161|H430-X5-H436 pair
P09719636A1134|118 135|H411-X2-H414 pair
P09721798A1734|106 116|recurrence
P09721798A1734|147 152|death
P09721798A1734|129 142|liver failure
P09722161A3065|73 86|Igf2/Mpr gene
P09722161A3065|25 31|growth
P09722766A0706|5 25|micturition pressure
P09722766A0706|80 85|BUP-4
P09724654A0761|121 127|timing
P09724654A0761|79 90|recruitment
P09724654A0761|37 44|origins
P09724654A0761|137 148|recruitment
P09724754A0173|25 30|STATs
P09724754A0173|1 9|Tyrosine
P09724772A0840|134 143|treatment
P09724772A0840|48 57|complexes
P09724772A0840|1 23|Gel retardation assays
P09725651A0077|14 18|RTPS
P09725651A0077|106 115|computers
P09725651A0077|137 155|Pentium processors
P09726201T0000|1 6|JCAHO
P09726987T0000|9 46|SPT3-TAFII31-GCN5-L acetylase complex
P09726991T0000|1 8|Mapping
P09727046A0000|44 51|protein
P09727046A0000|195 197|L.
P09727046A0000|124 128|site
P09727046A0000|53 59|HS2NF5
P09727046A0000|184 187|LCR
P09729481A0000|56 67|kinase mRNA
P09729481A0000|5 48|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A0000|50 54|BCOD
P09730413A0642|12 26|investigations
P09730413A0642|148 164|treatment option
P09730413A0642|81 90|treatment
P09730413A0642|169 180|Stage T1-T3
P09731513A1090|63 94|transcription factors NF-kappaB
P09731513A1090|99 103|AP-1
P09731513A1090|48 59|cooperation
P09731704A1472|28 35|amounts
P09731704A1472|77 84|ERalpha
P09731704A1472|86 94|OS cells
P09731704A1472|137 152|ERELuc activity
P09733493A0493|91 108|hydroxyl radicals
P09733493A0493|59 68|melatonin
P09733493A0493|117 123|vacuum
P09733794A1323|75 78|Bax
P09733794A1323|24 31|changes
P09733794A1323|92 99|control
P09733794A1323|158 160|Tg
P09733794A1323|68 73|Bcl-x
P09733854A0198|25 35|transcript
P09733854A0198|85 87|LR
P09735286A0599|83 95|Mu B protein
P09735286A0599|21 29|proteins
P09735286A0599|70 73|Mn2
P09735368A0636|29 32|UTR
P09735368A0636|130 145|K box sequences
P09735368A0636|50 62|accumulation
P09736239A0436|211 224|resuscitation
P09736239A0436|330 343|resuscitation
P09736239A0436|145 158|resuscitation
P09736239A0436|15 35|resuscitation period
P09736239A0436|160 161|p
P09736239A0436|232 233|%
P09736239A0436|65 89|glutamate concentrations
P09736697A1107|208 212|Jak2
P09736697A1107|185 203|Janus kinases Jak1
P09736697A1107|164 169|Stat3
P09736697A1107|225 230|Stat3
P09736697A1107|44 49|Stat3
P09736697A1107|96 100|site
P09736697A1107|1 5|MEKs
P09736770A0351|61 66|HEFT1
P09736770A0351|27 42|binding studies
P09736770A0351|1 13|Transfection
P09736770A0351|137 140|Sp3
P09737921T0000|79 92|recombination
P09737921T0000|64 77|bacteriophage
P09737921T0000|1 18|Genome plasticity
P09738087A0583|94 104|adjustment
P09738087A0583|5 11|effect
P09738087A0583|68 88|Cox regression model
P09739401A0000|142 158|home environment
P09739401A0000|32 39|article
P09739401A0000|16 23|purpose
P09741391A0581|44 54|PenH units
P09741391A0581|127 132|pause
P09741391A0581|157 167|expiration
P09741391A0581|141 152|inspiration
P09742129A0491|1 3|W.
P09743233A0526|24 28|AP-1
P09743233A0526|36 49|ets component
P09743233A0526|1 9|Mutation
P09744095A1016|22 29|mutants
P09744095A1016|83 94|mutants hy2
P09744095A1016|290 297|shy2-1D
P09744095A1016|161 169|response
P09744095A1016|37 51|shy2-1D mutant
P09744095A1016|96 99|hy3
P09744095A1016|100 106|phyB-1
P09747651A0000|81 90|emphysema
P09747651A0000|51 58|measure
P09748261A0000|46 66|acyl-CoA synthetases
P09748513X1360|1 10|Copyright
P09749533A0764|27 35|CONSTANS
P09749533A0764|81 95|flowering time
P09749533A0764|1 6|Clone
P09750325A0000|75 103|power energization technique
P09750325A0000|192 200|serotype
P09750325A0000|5 12|effects
P09750325A0000|141 152|populations
P09750325A0000|238 249|serotype 4b
P09751061A0000|209 237|signal-transduction pathways
P09751061A0000|197 205|response
P09751061A0000|53 65|factor Pit-1
P09751061A0000|156 167|homeostasis
P09751061A0000|86 104|homeodomain family
P09751061A0000|1 20|POU-domain proteins
P09751114A1987|122 133|mitogenesis
P09751114A1987|7 14|results
P09751114A1987|69 79|regulation
P09751458A0845|1 21|desmethyltrimebutine
P09753730A0881|107 110|use
P09753730A0881|114 132|promoter mutations
P09753774A1642|90 93|GF2
P09753774A1642|142 145|GF4
P09753774A1642|39 48|construct
P09753774A1642|1 7|Plants
P09753775A0734|30 33|ABA
P09753775A0734|77 85|decrease
P09753775A0734|50 64|ICK1 induction
P09754571A1257|5 15|hBRAG gene
P09754571A1257|49 59|chromosome
P09755199A0373|122 129|domains
P09755199A0373|50 53|Scm
P09755478A0366|60 70|transcript
P09755478A0366|74 82|diapause
P09755478A0366|1 18|Northern analysis
P09755478A0366|171 176|pupae
P09756895A0322|106 112|intron
P09756895A0322|9 14|locus
P09759180A0000|90 106|cartilage damage
P09759180A0000|13 29|Fluoroquinolones
P09759180A0000|82 86|risk
P09759865A0673|211 226|NF-kappaB-alpha
P09759865A0673|183 194|degradation
P09759865A0673|145 161|gel shift assays
P09759865A0673|250 259|cytoplasm
P09759865A0673|75 91|Rel proteins p50
P09759865A0673|106 141|NF-kappaB consensus oligonucleotide
P09759865A0673|198 207|inhibitor
P09759865A0673|305 316|PDGF-Ralpha
P09760341T0000|46 54|exercise
P09760341T0000|1 27|Phosphocreatine hydrolysis
P09761723A0226|57 63|retina
P09761723A0226|68 73|brain
P09763421A1199|146 155|increases
P09763421A1199|110 131|acidification defects
P09763421A1199|168 172|size
P09763446A1234|5 8|GEF
P09763446A1234|32 37|Ypt1p
P09763470A1756|56 62|Phox2a
P09763470A1756|196 204|DBH gene
P09763470A1756|178 188|activation
P09763470A1756|48 52|role
P09763470A1756|154 157|Sp1
P09763607A0521|24 35|Ngo strains
P09763607A0521|77 80|JNK
P09765261A0000|31 46|retrovirus type
P09765261A0000|58 73|trans-activator
P09765261A0000|355 364|sequences
P09765261A0000|50 56|HTLV-I
P09765261A0000|195 199|CREB
P09765261A0000|282 294|pair repeats
P09765261A0000|141 145|bZip
P09765277A0000|56 60|Glut
P09765277A0000|127 134|neurons
P09765285A1763|15 30|transactivation
P09765285A1763|92 109|response elements
P09765285A1763|128 135|IRhsp-1
P09765285A1763|5 11|levels
P09765388T0000|76 78|E4
P09765388T0000|36 51|adenovirus type
P09765388T0000|1 13|Inactivation
P09765394A1590|91 108|activation domain
P09765394A1590|40 48|proteins
P09765394A1590|1 15|Cotransfection
P09767504A1371|28 33|mg/kg
P09767504A1371|128 130|h.
P09767504A1371|17 21|dose
P09767593A0130|135 142|p130Cas
P09767593A0130|67 73|subset
P09767593A0130|101 109|proteins
P09769209A0100|73 82|induction
P09769209A0100|37 47|conclusion
P09769209A0100|86 108|nasF operon expression
P09770241A0000|57 69|brain cortex
P09770241A0000|96 102|system
P09770415A0139|45 50|motif
P09770415A0139|26 33|THOV NP
P09770415A0139|52 67|KRxxxxxxxxxKTKK
P09770686A0484|19 30|risk factor
P09771967A1052|14 22|LB1 gene
P09771967A1052|114 118|DLBL
P09771967A1052|100 110|breakpoint
P09773975A1873|240 245|T332E
P09773975A1873|125 128|min
P09773975A1873|355 358|min
P09773975A1873|48 67|hamster ovary cells
P09773975A1873|289 292|min
P09773975A1873|225 238|substitutions
P09773975A1873|96 114|Ang II stimulation
P09773975A1873|369 370|%
P09773975A1873|270 271|%
P09773975A1873|261 265|Ymax
P09773975A1873|256 259|min
P09773975A1873|192 201|receptors
P09773975A1873|280 284|t1/2
P09773975A1873|336 337|%
P09773975A1873|138 143|level
P09774403A0107|15 17|A.
P09774403A0107|23 27|Cote
P09774403A0107|1 3|T.
P09774450A0000|125 139|leukotriene D4
P09774450A0000|141 145|LTD4
P09774450A0000|100 114|leukotriene C4
P09774641A0824|105 132|retinoblastoma gene product
P09774641A0824|55 65|expression
P09774641A0824|69 77|cyclin D
P09776293A0777|123 131|solution
P09776293A0777|111 113|ml
P09776293A0777|76 77|%
P09776293A0777|103 104|%
P09776293A0777|51 59|placenta
P09776360A1781|72 75|NOS
P09776360A1781|124 132|effector
P09776360A1781|1 10|NF-kappaB
P09776360A1781|136 138|CM
P09777600A0000|21 27|method
P09777600A0000|69 83|chromatography
P09778006A0718|243 245|cm
P09778006A0718|296 314|baseline Vmca/mmHg
P09778006A0718|83 88|blood
P09778006A0718|256 260|mmHg
P09778006A0718|119 123|mean
P09778006A0718|165 169|PaCO
P09778006A0718|133 145|measurements
P09778006A0718|282 292|percentage
P09778006A0718|236 241|value
P09778191A0000|90 106|reserve capacity
P09778191A0000|162 179|resonance imaging
P09778191A0000|59 62|CBF
P09778191A0000|36 46|estimation
P09778191A0000|136 141|means
P09780002A0996|27 49|transactivation domain
P09780002A0996|101 112|cooperation
P09780002A0996|118 123|E2F-1
P09780228A0613|45 49|FkbC
P09780228A0613|148 155|modules
P09780228A0613|36 40|FkbB
P09780228A0613|116 119|FAS
P09781761A0384|94 99|fluid
P09781761A0384|38 45|culture
P09781761A0384|50 69|latex agglutination
P09781874A1061|105 111|region
P09781874A1061|41 48|guanine
P09781874A1061|129 141|change A202T
P09781874A1061|5 20|cwg2-1 mutation
P09784192A1027|58 83|surface plasmon resonance
P09785114A1026|13 16|PND
P09785114A1026|72 78|groups
P09786404A0541|11 24|aggregates/ml
P09786926A1372|132 139|element
P09786926A1372|146 150|site
P09786926A1372|114 120|sterol
P09786926A1372|85 104|ADD1/SREBP1 binding
P09788739A1096|91 108|signaling cascade
P09788739A1096|125 132|variety
P09788739A1096|145 154|responses
P09789795A0607|44 45|A
P09789795A0607|66 68|NA
P09789795A0607|51 64|noradrenaline
P09790767A0372|74 80|contig
P09790767A0372|37 56|sequence tag clones
P09790771A0956|83 89|testes
P09790771A0956|1 19|Gng3lg transcripts
P09790986A0689|122 133|amino acids
P09790986A0689|143 149|NRAMP2
P09792627A0441|56 67|GR activity
P09792627A0441|1 6|SRC-1
P09792682A0713|7 14|results
P09792682A0713|49 58|subunit c
P09792714A1408|62 67|steps
P09792714A1408|158 162|AF-1
P09792714A1408|20 24|AF-1
P09792714A1408|71 84|transcription
P09794795A0183|302 321|src homology domain
P09794795A0183|182 193|recruitment
P09794795A0183|113 128|phosphorylation
P09794795A0183|323 326|SH2
P09794795A0183|49 73|tyrosine phosphorylation
P09794795A0183|288 293|STAT1
P09794795A0183|198 213|phosphorylation
P09794795A0183|339 367|protein tyrosine phosphatase
P09794795A0183|136 168|signal transducing subunit gp130
P09795170A0774|75 80|codon
P09795170A0774|66 69|TGA
P09795341A0806|75 91|binding property
P09795341A0806|20 40|mobility shift assay
P09797456A0000|134 143|apoptosis
P09797456A0000|98 113|differentiation
P09797456A0000|1 11|BACKGROUND
P09797456A0000|17 37|c-myc proto-oncogene
P09798068A0290|56 69|reading frame
P09798068A0290|78 80|bp
P09798068A0290|110 117|protein
P09798068A0290|184 187|rat
P09798068A0290|222 230|receptor
P09798263T0000|124 137|swimming test
P09798263T0000|21 31|properties
P09798263T0000|71 98|calcium channel antagonists
P09799237A0624|47 66|gastrulation defect
P09799362A1463|105 131|transcription factor Mtf1p
P09799362A1463|179 190|suppression
P09799362A1463|20 25|Azf1p
P09799362A1463|1 16|Over-expression
P09799362A1463|220 241|RNA polymerase mutant
P09799793T0000|13 23|sequencing
P09799793T0000|95 103|sequence
P09799793T0000|65 73|analysis
P09799793T0000|115 118|EPO
P09801156A0220|14 23|fragments
P09801156A0220|42 70|amino acid sequence homology
P09802206A1058|72 109|translation elongation factor-1 alpha
P09802206A1058|58 61|TEF
P09802206A1058|33 38|genes
P09803081T0000|31 38|outcome
P09803081T0000|7 16|pathology
P09804779A1163|39 67|Stat5 serine phosphorylation
P09805052A0119|73 78|order
P09805052A0119|63 69|months
P09805052A0119|92 106|immunogenicity
P09805052A0119|144 150|months
P09806516A1212|88 98|recurrence
P09806516A1212|6 17|association
P09806546A1270|22 26|RFX5
P09806546A1270|54 61|binding
P09806546A1270|84 100|MHC-II promoters
P09806826A1773|104 108|gene
P09806826A1773|7 11|data
P09806826A1773|54 66|disease loci
P09806826A1773|32 44|localization
P09806857A0854|95 105|resolvases
P09806857A0854|9 22|reading frame
P09806857A0854|80 90|invertases
P09806919A0447|120 134|ecdysone pulse
P09806919A0447|9 12|usp
P09806919A0447|103 112|responses
P09808155A0813|195 197|bp
P09808155A0813|59 67|analysis
P09808155A0813|20 45|protein binding complexes
P09808155A0813|16 19|DNA
P09808366A0828|72 77|apnea
P09808366A0828|131 135|side
P09808366A0828|143 150|VRG-Apa
P09810087A0379|73 93|herpes simplex virus
P09810087A0379|110 115|acids
P09810087A0379|66 70|type
P09810087A0379|54 62|presence
P09811718A0979a|61 70|HIV-2 nef
P09811718A0979a|53 56|SIV
P09811718A0979a|80 89|HIV-1 nef
P09811730T0000|14 31|interferon action
P09811730T0000|142 152|activation
P09811730T0000|33 47|identification
P09811730T0000|1 10|Mechanism
P09813063T0000|83 94|development
P09813063T0000|102 111|forebrain
P09813098A0521|126 132|manner
P09813203T0000|94 108|immunogenicity
P09813203T0000|66 86|HIV-1 gp120 IIIB/LAI
P09813203T0000|55 62|V3 loop
P09813254A0000|88 91|IFN
P09813254A0000|40 51|synthetases
P09813254A0000|18 32|oligoadenylate
P09813254A0000|34 38|2-5A
P09813635A0678|92 94|P3
P09813635A0678|59 63|edge
P09813635A0678|33 40|contact
P09814905A0598|93 98|means
P09814905A0598|80 89|solutions
P09814905A0598|102 111|nutrition
P09815948A1065|79 83|area
P09815948A1065|59 69|toxicities
P09817190A0074|14 17|use
P09817190A0074|97 125|kidney transplant recipients
P09817190A0074|81 93|hypertension
P09817601T0000|78 82|gene
P09817601T0000|113 123|expression
P09817601T0000|68 76|P450arom
P09819110A0703|26 37|load levels
P09819110A0703|71 82|ARV therapy
P09819288A0578|89 92|end
P09819288A0578|78 84|height
P09819288A0578|100 106|season
P09819391A1123|44 60|tyrosine kinases
P09819391A1123|127 132|ASAP1
P09819391A1123|188 197|processes
P09819391A1123|84 95|cell growth
P09819414A1103|110 125|medium isoforms
P09819414A1103|67 82|leptin receptor
P09819422A0768|10 39|protein retention experiments
P09819422A0768|49 70|Hsp90 heterocomplexes
P09819440A0000|13 26|transcription
P09819440A0000|39 46|factors
P09819440A0000|70 91|transcription factors
P09819507A0000|198 209|mitomycin-C
P09819507A0000|9 14|study
P09819507A0000|113 117|flap
P09819507A0000|87 92|nylon
P09819507A0000|137 141|days
P09820205A0000|74 80|oocyte
P09820205A0000|21 23|ZP
P09820621A0067|88 104|body composition
P09820621A0067|23 39|thyroid function
P09820621A0067|65 83|energy expenditure
P09822602A0237|30 39|mechanism
P09822602A0237|177 199|transactivation domain
P09822602A0237|214 225|recruitment
P09822602A0237|144 154|activation
P09822602A0237|260 276|p300 coactivator
P09822602A0237|84 91|process
P09822647A0000|46 52|enzyme
P09822647A0000|81 86|brain
P09822661T0073|28 47|amino acid residues
P09822690A0000|44 51|cascade
P09822690A0000|113 130|protein kinase A.
P09823014T0000|105 121|lipid metabolism
P09823014T0000|88 100|carbohydrate
P09823014T0000|77 84|indices
P09823014T0000|70 73|fat
P09823014T0000|1 7|Effect
P09823775A1122|121 129|insights
P09823775A1122|27 31|view
P09823775A1122|7 14|studies
P09823775A1122|139 148|mechanism
P09823775A1122|152 158|action
P09824021A1263|109 117|response
P09824021A1263|129 139|NO therapy
P09824021A1263|1 11|CONCLUSION
P09826434T0000|108 119|mutagenesis
P09826434T0000|84 89|PDE3A
P09826778A0943|60 71|coactivator
P09826778A0943|24 37|cofactor p300
P09826778A0943|115 125|repression
P09827724A1362|39 47|adenomas
P09827993A0000|135 154|retrovirus assembly
P09827993A0000|89 118|virion RNA binding activities
P09827993A0000|55 75|zinc finger proteins
P09829836A0000|146 153|kinases
P09829836A0000|96 108|oscillations
P09829836A0000|116 124|activity
P09829836A0000|68 78|cell cycle
P09829843A0119|150 159|incidence
P09829843A0119|174 187|complications
P09829843A0119|38 45|factors
P09829843A0119|87 95|practice
P09829916T0000|15 19|lacZ
P09829916T0000|106 110|W205
P09829916T0000|1 11|Expression
P09829916T0000|119 125|fusion
P09832436A0738|29 34|PLP-H
P09832436A0738|56 61|PLP-D
P09832436A0738|156 167|differences
P09832504A0596|61 67|hCycT1
P09832504A0596|129 137|proteins
P09832504A0596|33 44|interaction
P09832511A0269|90 101|neuroblasts
P09832511A0269|28 39|Vnd protein
P09832511A0269|65 85|column neuroectoderm
P09833610A0626|106 112|signal
P09833610A0626|5 14|exodomain
P09834070A0793|224 239|B cell function
P09834070A0793|192 199|pathway
P09834070A0793|72 79|changes
P09834070A0793|40 44|ERK2
P09834070A0793|97 100|Ca2
P09835615A0574|91 108|repressor domains
P09835615A0574|110 112|R1
P09835615A0574|117 119|R2
P09837714A1068|109 115|events
P09837714A1068|126 144|cell proliferation
P09837714A1068|5 12|results
P09837714A1068|175 188|Dictyostelium
P09837714A1068|87 92|DdRPA
P09837824A0419|105 111|telSMN
P09837824A0419|166 174|542delGT
P09837824A0419|97 101|copy
P09837824A0419|206 209|A2G
P09837824A0419|153 161|800ins11
P09837913A0000|41 53|deiodination
P09837913A0000|8 18|deiodinase
P09837913A0000|20 22|D2
P09837914A0844|1 5|Biol
P09837933T0000|59 65|domain
P09837933T0000|1 7|P-CIP1
P09837933T0000|17 24|protein
P09837978T0093|25 30|c-Jun
P09837978T0093|66 80|protein kinase
P09840822A0462|56 63|concern
P09840822A0462|81 111|magnetization transfer effects
P09840932A0365|26 34|evidence
P09840932A0365|9 14|study
P09840943A0144|89 98|cyclin E.
P09840943A0144|77 85|homology
P09843378A0187|66 75|receptors
P09843378A0187|101 120|SH3 binding domains
P09843572A0944|28 39|experiments
P09843572A0944|6 11|model
P09843572A0944|100 106|domain
P09843944A0976|91 95|turn
P09843944A0976|1 9|A-tracts
P09844921A0000|14 45|serine-threonine protein kinase
P09844921A0000|72 84|transmission
P09844921A0000|1 4|Raf
P09845662A0085|47 51|lack
P09845662A0085|55 59|type
P09845662A0085|33 37|skin
P09845662A0085|100 114|sodium dodecyl
P09846033A0488|22 29|changes
P09846033A0488|1 8|RESULTS
P09846033A0488|51 64|posttreatment
P09846927A0227|5 8|tip
P09846927A0227|32 43|perforation
P09847397A0935|90 97|viruses
P09847397A0935|26 34|residues
P09847397A0935|112 129|response elements
P09847397A0935|65 74|sequences
P09849421A0332|45 55|Norwegians
P09849421A0332|74 77|age
P09849421A0332|121 129|Research
P09849421A0332|212 216|mail
P09849421A0332|65 70|years
P09849421A0332|170 188|Life Questionnaire
P09849961A0387|228 246|myoblast cell line
P09849961A0387|43 65|serine phosphorylation
P09849961A0387|154 159|IRS-1
P09851614A0109|133 140|absence
P09851614A0109|78 85|regions
P09851614A0109|97 108|nucleotides
P09851614A0109|87 90|UTR
P09851988A0085|10 18|presence
P09851988A0085|70 79|induction
P09851988A0085|35 47|anaerobiosis
P09852068A0150b|121 128|regions
P09852068A0150b|130 137|FP1-FP6
P09852068A0150b|25 33|promoter
P09852068A0150b|189 215|HepG2 hepatoblastoma cells
P09852136A0174|91 98|ability
P09852136A0174|183 192|COS cells
P09852136A0174|146 159|hemagglutinin
P09852136A0174|42 45|Asn
P09852136A0174|67 71|p190
P09852136A0174|32 37|Ser36
P09852752A0950|83 85|RA
P09855111A0905|331 341|cell lines
P09855111A0905|300 307|HMG CoA
P09855111A0905|212 222|regulation
P09855111A0905|288 298|coenzyme A
P09855111A0905|162 172|disruption
P09855111A0905|234 239|genes
P09855111A0905|64 71|domains
P09856732A0114|13 20|studies
P09857197A0289|107 115|sequence
P09857197A0289|144 150|RanGTP
P09857197A0289|80 95|export sequence
P09857197A0289|55 60|Crm1p
P09857197A0289|119 124|Yap1p
P09858094A0583|11 20|amplitude
P09858094A0583|58 60|O3
P09858094A0583|118 124|period
P09858571T0000|5 20|yeast RER2 gene
P09858571T0000|48 88|reticulum protein localization mutations
P09858577A1186|13 17|SKO1
P09858577A1186|108 126|stress sensitivity
P09858577A1186|59 70|hog1 mutant
P09858577A1186|38 53|ENA1 expression
P09858588A1046|45 48|p68
P09858588A1046|37 41|form
P09858588A1046|69 74|cells
P09858599A0392|131 146|PBX interaction
P09858599A0392|6 26|NUP98-HOXA9 chimeras
P09858599A0392|115 126|DNA binding
P09858713A1174|60 63|CiD
P09858713A1174|243 246|CiD
P09858713A1174|163 166|ciD
P09858713A1174|261 268|mutants
P09858713A1174|87 90|Arm
P09858713A1174|169 176|animals
P09858745A1350|121 128|studies
P09858745A1350|88 108|footprinting studies
P09858745A1350|146 149|IBS
P09858745A1350|36 40|catB
P09858745A1350|21 24|IBS
P09858745A1350|253 256|DNA
P09858883A1106|46 49|M-1
P09858883A1106|131 134|T84
P09858883A1106|77 82|T84.1
P09858883A1106|112 119|binding
P09858883A1106|1 17|BIAcore analysis
P09861099A1011|180 191|kcal/kg/day
P09861099A1011|86 87|P
P09861099A1011|45 57|measurements
P09861099A1011|160 166|g/kg/d
P09861099A1011|10 22|correlations
P09861099A1011|96 109|energy intake
P09861099A1011|168 170|SD
P09862343A0225|181 190|molecules
P09862343A0225|149 162|up-regulation
P09862343A0225|52 56|IL-4
P09862496A0187|58 78|betaGLU I expression
P09862496A0187|129 136|pattern
P09862496A0187|1 9|Ethylene
P09863624A2301|61 68|percent
P09863624A2301|72 77|total
P09863624A2301|131 139|fraction
P09863624A2301|246 251|oCRF1
P09863624A2301|204 213|degrees C
P09863624A2301|85 94|Tyr0-oCRF
P09864141A0528|195 199|Y764
P09864141A0528|41 49|affinity
P09864141A0528|159 174|phosphopeptides
P09864141A0528|101 105|Y744
P09864141A0528|186 190|Y729
P09864689A1408|131 134|DCM
P09864689A1408|7 15|findings
P09864689A1408|87 93|effect
P09866068A1058|151 157|effect
P09866068A1058|91 96|phase
P09866068A1058|198 213|pregnancy rates
P09866068A1058|115 129|cyst formation
P09866068A1058|1 12|CONCLUSIONS
P09867253A0229|110 135|transcription factor AP-1
P09867253A0229|52 68|protooncoprotein
P09868412A1628|149 158|exercises
P09868412A1628|246 254|swimming
P09868412A1628|17 22|study
P09868412A1628|44 52|body BMD
P09868412A1628|317 325|shoulder
P09868412A1628|278 286|exercise
P09868412A1628|175 183|subjects
P09869356A0926|47 54|defects
P09869356A0926|80 82|mm
P09869356A0926|32 34|mm
P09869528T0000|37 46|RF energy
P09869528T0000|18 22|dogs
P09872326A0566|42 50|CBF/cdc2
P09872326A0566|69 72|CBF
P09872832A1262|249 250|p
P09872832A1262|87 92|lungs
P09872832A1262|108 121|interleukin-6
P09872832A1262|143 170|tumor necrosis factor-alpha
P09872832A1262|5 23|BAL concentrations
P09872832A1262|206 215|IFN-gamma
P09873291A0620|9 17|analysis
P09873291A0620|101 115|patient groups
P09875541A0210|60 81|dorsal premotor areas
P09875541A0210|5 18|orbitofrontal
P09875541A0210|154 158|SELF
P09877417A0704|1 18|Plasma CCK levels
P09878437A0967|62 77|phosphorylation
P09878437A0967|37 48|triad Asp53
P09878437A0967|80 85|Asp10
P09879766A0402|57 66|map units
P09880103A0387|91 110|M hydrogen peroxide
P09880103A0387|24 32|mCi 125I
P09880103A0387|1 4|MPO
P09880512A1251|74 83|receptors
P09880512A1251|24 28|Bmp2
P09880543A0570|27 37|MA protein
P09880543A0570|1 5|HEED
P09881666A0535|67 76|AP-1 site
P09881666A0535|96 99|ER2
P09881692A1109|15 20|order
P09881692A1109|149 151|T.
P09881692A1109|79 95|oligonucleotides
P09881692A1109|179 196|Southern blotting
P09881692A1109|100 102|b5
P09882303A1984|29 33|role
P09882303A1984|57 71|JNK activation
P09882303A1984|188 198|activities
P09882303A1984|48 53|TRAF2
P09882303A1984|137 161|TNF receptor/CD40 family
P09882321A0948|93 118|EBNA-3 protein expression
P09882321A0948|38 43|cells
P09882321A0948|81 89|increase
P09882337A0000|30 45|glycoprotein gI
P09882337A0000|58 84|transmembrane glycoprotein
P09882337A0000|129 131|gE
P09882337A0000|1 23|Varicella-zoster virus
P09882451A0195|89 108|ferrochelatase gene
P09882451A0195|58 64|mutant
P09882451A0195|7 12|genes
P09882499A0231|31 47|mouse technology
P09882499A0231|129 139|expression
P09882638A0235|27 42|collagen fibers
P09882638A0235|95 103|erection
P09882638A0235|50 66|tunica albuginea
P09884232A0286|182 196|integrase gene
P09884232A0286|65 79|junctions attL
P09884232A0286|101 103|bp
P09884232A0286|32 36|attP
P09884232A0286|84 88|attR
P09884232A0286|171 174|end
P09884747A0477|44 59|brewery workers
P09884747A0477|124 130|barley
P09884747A0477|69 87|control volunteers
P09884747A0477|220 236|serum IgE levels
P09886602A0000|209 219|recurrence
P09886602A0000|125 136|tumor stage
P09886602A0000|179 193|radiation dose
P09886602A0000|322 334|tumor marker
P09886602A0000|258 280|beam radiation therapy
P09886602A0000|282 285|XRT
P09886602A0000|351 362|care center
P09886602A0000|38 50|pretreatment
P09886602A0000|170 173|age
P09886602A0000|102 114|measurements
P09886850A0145|113 128|phosphorylation
P09886850A0145|33 42|PPARgamma
P09888711A0781|192 206|round vacuoles
P09888711A0781|82 86|size
P09888711A0781|158 176|Artecoll granuloma
P09888711A0781|322 328|bodies
P09888711A0781|252 257|round
P09889202T0000|135 139|beta
P09889202T0000|127 132|alpha
P09889202T0000|20 28|analysis
P09889202T0000|168 176|proteins
P09890778T0000|47 54|methods
P09890778T0000|1 14|Carbohydrates
P09891046A0269|106 119|PKR signaling
P09891046A0269|42 53|cell growth
P09891046A0269|143 154|cell growth
P09891049A0761|79 94|rRNA processing
P09891049A0761|112 117|Rat1p
P09891049A0761|1 11|Processing
P09891061A1240|120 130|expression
P09891061A1240|74 96|SpEts4 gene expression
P09891061A1240|157 176|sea urchin blastula
P09891061A1240|49 58|regulator
P09891085A0815|67 72|cells
P09891085A0815|103 117|27S precursors
P09891707A0000|49 52|SpA
P09892021A0712|147 152|tumor
P09892021A0712|19 23|PTTG
P09892021A0712|69 79|expression
P09892021A0712|103 127|fibroblast growth factor
P09892642A0172|75 86|replication
P09892642A0172|7 19|DNA helicase
P09892736A0343|47 56|CDED/LIOR
P09892736A0343|167 171|ORC1
P09892736A0343|176 179|KSR
P09892736A0343|97 105|proteins
P09892736A0343|117 136|signal transduction
P09893262A1272|97 115|TGF-beta responses
P09893262A1272|17 24|variety
P09894962T0000|3 13|comparison
P09894962T0000|51 64|malformations
P09897032T0000|58 67|resonator
P09903722T0000|43 53|triplet nf
P09903722T0000|59 73|Rydberg states
P09911328T0000|10 18|approach
P09911328T0000|54 61|problem
P09914156A1496|77 107|tenascin-C promoter constructs
P09914156A1496|216 228|pair element
P09914156A1496|116 125|deletions
P09914156A1496|34 42|promoter
P09914518A1217|61 69|COUP-TFI
P09914518A1217|177 195|4-hydroxytamoxifen
P09914518A1217|159 167|presence
P09914518A1217|16 27|enhancement
P09914518A1217|171 173|E2
P09915118T0000|12 27|naris occlusion
P09915860A0000|63 69|pgp2GC
P09915860A0000|5 13|promoter
P09915860A0000|21 40|rat pgp2/mdr1b gene
P09916786A0811|165 170|serum
P09916786A0811|209 220|immunoassay
P09916786A0811|58 63|spine
P09916786A0811|23 43|bone mineral density
P09916786A0811|185 205|alkaline phosphatase
P09916786A0811|1 13|Measurements
P09917064T0000|15 18|p82
P09917064T0000|58 73|polyadenylation
P09917064T0000|6 11|roles
P09917389A1239|63 67|FinP
P09917389A1239|5 12|pattern
P09917389A1239|115 123|cleavage
P09917555T0001|27 54|growth factor prescriptions
P09917555T0001|68 82|cancer centers
P09918715A0304|19 31|DNA sequence
P09918715A0304|35 43|MotA box
P09918720A0998|88 92|base
P09918720A0998|142 148|Ser229
P09918720A0998|185 192|adenine
P09920539A0272|63 66|day
P09920539A0272|96 120|gonadotropin stimulation
P09920539A0272|80 88|protocol
P09920903A1045|63 82|p53 gene regulation
P09920903A1045|53 59|target
P09920930A0959|31 42|combination
P09920930A0959|10 18|C3 toxin
P09920930A0959|140 150|activation
P09920930A0959|175 183|response
P09920930A0959|86 98|Luc activity
P09920930A0959|207 221|growth factors
P09921179T0001|28 44|echocardiography
P09921179T0001|79 86|vessels
P09921179T0001|48 55|surgery
P09922856A0459|109 123|dose-strengths
P09922856A0459|127 134|mg/24 h
P09922856A0459|154 177|Laboratoires Synthelabo
P09924675A0412|14 19|point
P09924675A0412|271 283|intervention
P09924675A0412|77 82|ICIDH
P09924675A0412|261 266|basis
P09924675A0412|138 149|diagnostics
P09924675A0412|50 61|conceptions
P09925120A0074|106 112|effect
P09925120A0074|48 54|trials
P09925120A0074|17 30|meta-analysis
P09925372A1063|134 145|development
P09925372A1063|123 130|process
P09925372A1063|69 74|heart
P09927193A0107|44 49|BCL-6
P09927193A0107|4 8|date
P09927193A0107|19 27|proteins
P09927570A0507|209 212|kDa
P09927570A0507|111 114|kDa
P09927570A0507|158 169|E1 products
P09927570A0507|99 107|Ad12 E1B
P09927570A0507|51 63|transfection
P09927589T0000|15 26|DNA binding
P09927589T0000|47 57|regulation
P09927589T0000|131 143|conservation
P09927589T0000|1 11|Similarity
P09929811A0000|183 189|CM-345
P09929811A0000|27 31|cats
P09929811A0000|262 273|electrogram
P09929811A0000|324 330|branch
P09929811A0000|108 118|properties
P09929811A0000|202 211|mean rise
P09929811A0000|238 243|leads
P09929811A0000|171 177|CM-266
P09931191A0434|162 170|protocol
P09931191A0434|76 83|fatigue
P09931191A0434|4 12|protocol
P09931191A0434|51 54|Con
P09931252A1055|6 15|mutations
P09931252A1055|103 112|abilities
P09931435A0357|15 26|transcripts
P09931435A0357|106 110|exon
P09931435A0357|179 182|UTR
P09931435A0357|66 71|ZIS-2
P09931435A0357|48 53|exons
P09933428A0351|105 114|treatment
P09933428A0351|1 10|IFN-gamma
P09933848A1008|90 104|autoantibodies
P09933848A1008|73 77|drug
P09933848A1008|65 69|role
P09935377T0108|21 27|August
P09938097T0000|15 23|transfer
P09938097T0000|82 86|ZnTe
P09943651T0000|10 15|modes
P09945838T0000|43 47|GaAs
P09945838T0000|52 54|Ga
P09945838T0000|49 51|Al
P09949160A0600|268 273|cells
P09949160A0600|213 218|betaI
P09949160A0600|54 62|bulk PKC
P09949160A0600|15 29|32D Epo1 cells
P09949160A0600|166 178|upregulation
P09949160A0600|108 115|epsilon
P09949160A0600|239 242|Epo
P09949312A0524|21 30|dust trap
P09950394A0336|29 53|carboxyhemoglobin levels
P09950394A0336|5 12|history
P09950394A0336|16 24|exposure
P09952425A0893|227 231|role
P09952425A0893|176 186|structures
P09952425A0893|80 86|lesion
P09952425A0893|18 22|HIPP
P09952425A0893|102 113|impairments
P09952425A0893|239 250|hippocampus
P09961326T0000|12 24|fluctuations
P09964171T0000|45 51|medium
P09964171T0000|93 98|field
P09964171T0000|1 4|NMR
P09965234T0000|13 27|heat transport
P09965234T0000|35 53|octylcyanobiphenyl
P09971776A0838|133 136|W57
P09971776A0838|177 192|dileucine motif
P09971776A0838|115 123|receptor
P09971776A0838|252 259|protein
P09971776A0838|103 106|Nef
P09971776A0838|51 59|residues
P09971806A1585|110 128|tumor pathogenesis
P09971806A1585|20 24|KSHV
P09971822A1542|62 81|splicing inhibition
P09971822A1542|7 11|data
P09973607A0254|90 98|proteins
P09973607A0254|130 141|elucidation
P09973607A0254|22 36|identification
P09973607A0254|69 81|Sp100 splice
P09976626T0000|61 75|transformation
P09976626T0000|10 17|Absence
P09976626T0000|21 38|precursor effects
P09982923T0000|12 21|structure
P09982923T0000|58 65|bulk Si
P09984526T0000|12 25|point defects
P09984526T0000|1 8|Effects
P09986796A1761|47 58|amino acids
P09986796A1761|27 28|C
P09987634A1265|47 58|retreatment
P09987634A1265|83 93|regression
P09987634A1265|16 19|PRK
P09988682T0033|28 32|cDNA
P09988682T0033|109 113|core
P09988682T0033|50 89|beta1,6-N-acetylglucosaminyltransferase
P09988850A0000|245 252|purpose
P09988850A0000|213 235|schizophrenia patients
P09988850A0000|82 89|battery
P09988850A0000|327 340|schizophrenia
P09988850A0000|160 167|records
P09988850A0000|5 11|Scales
P09989339A0968|31 38|product
P09989339A0968|59 68|clearance
P09990060A0803|14 20|motifs
P09990060A0803|125 138|IL-2 enhancer
P09990060A0803|66 87|dyad symmetry element
P09990315A0205|155 163|agonists
P09990315A0205|119 129|activation
P09990315A0205|47 63|protein kinase C
P09990315A0205|79 82|TPO
P09990315A0205|65 68|PKC
P09990315A0205|32 36|ERK1
P09990507A0763|14 31|Fission yeast SCF
P09990507A0763|56 60|Pop2
P09990507A0763|1 12|CONCLUSIONS
P09995847T0000|62 87|transition line strengths
P09995847T0000|111 114|Na3
P09999256T0000|42 61|transport phenomena
P10000253T0000|80 88|XY model
P10000253T0000|1 16|Chirality-glass
P10001541T0000|67 74|silicon
P10006319T0000|25 47|Heisenberg ferrimagnet
P10006319T0000|1 19|Surface spin waves
P10007564T0000|62 63|W
P10007564T0000|69 76|surface
P10009565T0000|73 83|insulators
P10009565T0000|1 23|GW Gamma approximation
P10019841T0000|42 47|order
P10021350A0093|164 185|transcription factors
P10021350A0093|121 144|TCF/LEF family proteins
P10021350A0093|36 42|signal
P10021350A0093|54 76|Armadillo/beta-catenin
P10021350A0093|16 21|model
P10022210A0620|39 41|DI
P10022210A0620|1 8|Factors
P10022858A0985|23 49|splicing enhancer sequence
P10022858A0985|4 12|addition
P10022867A1069b|160 178|lysine prototrophy
P10022867A1069b|114 118|type
P10022867A1069b|1 12|Elimination
P10022867A1069b|136 145|reversion
P10022880A0000|11 40|Ras GTPase-activating protein
P10022880A0000|42 45|GAP
P10022880A0000|173 201|signal transduction pathways
P10022880A0000|152 156|role
P10022921A0608|21 30|SIN3 gene
P10022978A1261|106 113|regions
P10022978A1261|5 17|distribution
P10022978A1261|141 156|chromosome arms
P10024498A0783|130 140|HNF-3alpha
P10024498A0783|145 154|HNF-3beta
P10024498A0783|32 38|assays
P10025050A1052|106 118|lansoprazole
P10025050A1052|92 102|omeprazole
P10025050A1052|32 42|antagonist
P10025506A1078|4 8|TATA
P10026211A0136|28 37|PEPCK CRE
P10026211A0136|128 133|C/EBP
P10026211A0136|71 75|CREB
P10026211A0136|119 126|protein
P10026229A0950|57 67|Pbx1 sites
P10026229A0950|23 34|mutagenesis
P10026229A0950|187 195|fragment
P10026784A0331|160 171|development
P10026784A0331|42 51|functions
P10026784A0331|112 133|POU DNA binding motif
P10026784A0331|69 90|transcription factors
P10026784A2166|40 46|domain
P10026784A2166|179 185|strand
P10026784A2166|127 132|Pit-1
P10026784A2166|154 158|GTAT
P10027498A0536|12 22|end points
P10027498A0536|52 57|death
P10029337A0406|121 142|serum creatine kinase
P10029337A0406|148 156|activity
P10029337A0406|144 146|CK
P10029337A0406|80 82|SD
P10029337A0406|193 194|l
P10029337A0406|5 21|fatigue exercise
P10029917A0366|31 39|presence
P10029917A0366|43 57|myofibroblasts
P10029917A0366|129 151|muscle cell dispersion
P10029917A0366|1 8|Results
P10032519T0000|11 22|corrections
P10032519T0000|69 79|generation
P10033973T0000|56 72|Bose condensates
P10033973T0000|39 44|traps
P10035841T0000|10 18|trapping
P10036191A0000|210 225|gene expression
P10036191A0000|147 151|Mitf
P10036191A0000|92 113|transcription factors
P10036191A0000|82 90|bHLH-ZIP
P10036191A0000|66 80|leucine zipper
P10036191A0000|237 250|cell lineages
P10037378A0176|26 31|penis
P10037378A0176|5 18|dorsal nerves
P10037576T0000|36 42|iodine
P10037576T0000|49 68|plaque radiotherapy
P10037774A0366|97 115|LDLR transcription
P10043466T0000|15 22|effects
P10043466T0000|59 67|excitons
P10046849T0000|24 46|structure calculations
P10049357A0608|73 76|Ski
P10049357A0608|7 14|results
P10049357A0608|141 148|complex
P10049357A0608|51 63|HDAC complex
P10049742T0000|64 70|domain
P10049742T0000|17 43|consensus binding sequence
P10049912T0000|105 131|DNA exonuclease deficiency
P10049912T0000|19 26|RNase T
P10051030A1080|107 115|regimens
P10051030A1080|76 83|strains
P10051030A1080|18 28|percentage
P10051030A1080|85 94|CP levels
P10051488A1293|142 148|HMAP-1
P10051488A1293|65 72|culture
P10051488A1293|21 48|AP-1 DNA binding activities
P10052371A0171|120 127|subject
P10052371A0171|62 70|subjects
P10052371A0171|24 47|immunoglobulin A levels
P10052371A0171|219 228|cessation
P10052371A0171|138 145|smoking
P10052371A0171|1 13|STUDY DESIGN
P10053852T0000|9 11|g2
P10053852T0000|1 5|Role
P10055173T0000|27 47|transport properties
P10063122T0000|42 47|Metal
P10064604A0824|21 26|sites
P10064604A0824|1 5|CPDs
P10065684A0916|90 93|TLC
P10065684A0916|57 63|volume
P10065684A0916|20 28|subjects
P10065684A0916|263 274|abnormality
P10065684A0916|75 88|lung capacity
P10065684A0916|131 134|mit
P10065684A0916|129 130|n
P10065684A0916|65 67|RV
P10065684A0916|168 179|mt x microm
P10065684A0916|34 46|air trapping
P10066798A0391|42 56|protein levels
P10066798A0391|127 136|c-src527F
P10066798A0391|83 89|tumors
P10068040A0136|45 51|copies
P10068040A0136|18 30|mouse genome
P10068446A0124|157 160|PKC
P10068446A0124|19 26|studies
P10068446A0124|50 62|thiol agents
P10068446A0124|102 110|reaction
P10068674A0644|43 47|form
P10069815A0285|73 77|Doa4
P10069815A0285|86 96|proteasome
P10071205A0833|15 20|genes
P10071205A0833|121 128|cistron
P10071205A0833|50 53|ORF
P10071761A2374|122 129|insight
P10071761A2374|53 67|identification
P10071761A2374|233 240|factors
P10071761A2374|4 12|addition
P10071761A2374|100 109|sequences
P10072205A0167|60 73|MAP estimates
P10072205A0167|167 179|distribution
P10072205A0167|37 49|distribution
P10072205A0167|188 197|estimates
P10072205A0167|86 96|conditions
P10073899A0740|91 95|cent
P10073899A0740|65 68|EAF
P10073947A1110|44 49|PAI-1
P10073947A1110|34 39|FVIIa
P10074282A0236|59 64|L-NNA
P10074282A0236|36 40|ring
P10074282A0236|141 148|changes
P10074520T0000|134 137|PCR
P10074520T0000|95 104|detection
P10074520T0000|20 36|characterization
P10074520T0000|1 15|Identification
P10074921A1169|9 16|results
P10074921A1169|86 89|p53
P10076007A0656|89 96|mRNP3+4
P10076007A0656|5 9|MSY2
P10076007A0656|100 107|oocytes
P10077533A0976|88 97|MUL genes
P10077533A0976|7 11|data
P10077533A0976|34 39|tools
P10078876A0000|225 232|changes
P10078876A0000|242 266|hemoglobin concentration
P10078876A0000|202 211|flowmetry
P10078876A0000|113 137|rat somatosensory cortex
P10078876A0000|65 73|activity
P10080436T0000|15 26|frequencies
P10080436T0000|109 112|use
P10080436T0000|65 78|artery bypass
P10080901A0271|135 145|protein L9
P10080901A0271|10 18|peptides
P10080901A0271|3 6|set
P10082554T0000|12 19|domains
P10082554T0000|99 121|cell growth regulation
P10082573A1015|60 63|HS3
P10082573A1015|122 147|globin gene transcription
P10082573A1015|7 14|results
P10082573A1015|310 335|globin gene transcription
P10082573A1015|99 103|unit
P10082573A1015|69 72|HS4
P10084294A0219|104 118|serum ferritin
P10084294A0219|123 152|transferrin saturation levels
P10084294A0219|202 203|%
P10084294A0219|70 81|progenitors
P10085120A0000|29 47|signaling pathways
P10085120A0000|9 14|study
P10085383A1367|12 21|Melaleuca
P10085383A1367|23 38|Lake Okeechobee
P10085383A1367|55 66|Water level
P10085605A0239|60 67|estriol
P10085605A0239|28 45|alpha-fetoprotein
P10085605A0239|1 10|Specimens
P10086544A0504|62 71|care unit
P10086544A0504|191 213|temperature difference
P10086544A0504|117 120|CPB
P10086544A0504|439 452|ejection time
P10086544A0504|313 339|neutrophil elastase levels
P10086544A0504|371 378|factors
P10086544A0504|102 113|termination
P10086544A0504|90 95|hours
P10086544A0504|390 398|fraction
P10086544A0504|134 148|blood pressure
P10086544A0504|469 474|doses
P10086544A0504|283 299|serum creatinine
P10087213A0878|176 181|class
P10087213A0878|48 58|replicases
P10087213A0878|1 9|Analysis
P10087213A0878|152 161|formation
P10087993A0782|39 46|portion
P10087993A0782|4 12|contrast
P10087993A0782|86 94|decrease
P10090125A0750|19 45|alpha1 antagonist prazosin
P10090535A1194|28 30|TG
P10090535A1194|46 50|apoB
P10090535A1194|112 118|groups
P10090535A1194|87 88|%
P10090943A1976|149 155|B cell
P10090943A1976|89 99|regulation
P10090943A1976|11 18|B cells
P10090943A1976|50 59|mechanism
P10091619A0104|44 49|state
P10091619A0104|97 103|scores
P10091619A0104|117 118|%
P10091619A0104|69 70|%
P10092847A0455|122 150|mouse metallothionein-I gene
P10092847A0455|215 231|metal regulation
P10092847A0455|6 13|respect
P10092847A0455|168 183|MRE arrangement
P10094314A0935|123 132|agreement
P10094314A0935|163 166|9G8
P10094314A0935|113 118|SRp20
P10094314A0935|156 159|RBD
P10094701A0000|134 142|response
P10094701A0000|92 114|Sinorhizobium meliloti
P10094701A0000|67 81|acetate kinase
P10094701A0000|21 31|laboratory
P10095061A0592|74 77|kDa
P10095061A0592|37 49|MEMA protein
P10095061A0592|87 93|domain
P10095061A0592|1 18|Sequence analysis
P10095061A0592|102 109|serines
P10096469T0000|73 80|neurons
P10096469T0000|54 63|cat motor
P10097120T0000|23 32|transport
P10098601A1320|12 20|analysis
P10098601A1320|52 57|JEG-3
P10098601A1320|66 74|proteins
P10099247A1051|62 66|days
P10099247A1051|198 201|SRB
P10099247A1051|77 85|presence
P10099247A1051|8 18|reactor pH
P10099247A1051|103 117|SRB population
P10100605A0392|25 30|burst
P10100605A0392|159 173|flow cytometry
P10101198A0632|106 121|leucine zippers
P10101198A0632|3 29|deletion mutation analysis
P10101198A0632|87 93|region
P10101744A0917|62 71|treatment
P10101744A0917|16 33|antigen challenge
P10102136A0220|21 24|PSA
P10102136A0220|87 91|sera
P10102627A0217|36 58|AP-1 reporter activity
P10103057A0251|73 81|fragment
P10103057A0251|113 117|AML1
P10103057A0251|98 109|Runt domain
P10120952T0000|31 54|gall bladder guidelines
P10132730T0000|45 58|teacher union
P10132730T0000|10 21|CareNetwork
P10146207A0223|72 83|cord injury
P10146207A0223|51 61|evaluation
P10171173A0955|209 219|hemorrhage
P10171173A0955|123 128|non-A
P10171173A0955|99 118|deficiency syndrome
P10171173A0955|70 77|disease
P10171173A0955|274 285|circulation
P10187798A1098|26 31|DAP-1
P10187798A1098|129 151|osteosarcoma cell line
P10187798A1098|35 42|sentrin
P10187798A1098|153 157|U2OS
P10187864A1372|37 43|member
P10187864A1372|101 105|KCC1
P10187864A1372|85 95|regulation
P10191090A0000|16 26|expression
P10192432A0214|14 19|names
P10192432A0214|28 35|disease
P10192432A0214|82 97|Consensus Panel
P10192432A0214|54 62|criteria
P10192432A0214|139 144|order
P10193950A0478|88 91|TNM
P10193950A0478|93 111|prostate carcinoma
P10193950A0478|113 117|bone
P10193950A0478|49 52|men
P10193950A0478|232 255|staging lymphadenectomy
P10193950A0478|1 8|METHODS
P10194230A0817|105 107|nM
P10194230A0817|47 71|adenosine concentrations
P10194762A0648|151 162|association
P10194762A0648|31 71|glutathione-S-transferase-fusion protein
P10194762A0648|182 196|fusion protein
P10194762A0648|124 130|STAT5a
P10194762A0648|263 270|alanine
P10195425T0000|25 51|transcription factor MTF-1
P10195425T0000|140 161|metal stress response
P10195425T0000|1 17|Characterization
P10195697A0456|72 90|enhancing activity
P10195697A0456|49 55|domain
P10196248A0482|130 134|arms
P10196248A0482|52 60|sequence
P10196248A0482|191 193|nt
P10196248A0482|68 70|nt
P10196316A0715|30 36|VZV gK
P10196316A0715|40 52|virus growth
P10196316A0715|66 85|gK deletion mutants
P10196316A0715|18 26|function
P10196597A0510|13 21|findings
P10196597A0510|81 96|characteristics
P10197985A0145|180 190|U12 snRNPs
P10197985A0145|265 283|pre-mRNA substrate
P10197985A0145|125 127|ss
P10197985A0145|155 158|BPS
P10197985A0145|222 235|cooperativity
P10197985A0145|160 168|elements
P10197985A0145|172 175|U11
P10198056A0000|59 72|lipid bilayer
P10198056A0000|17 38|cell surface proteins
P10199539A1353|73 76|cyt
P10199539A1353|43 54|correlation
P10199539A1353|144 146|r2
P10201468A0297|47 56|C-peptide
P10201468A0297|41 44|IRI
P10201468A0297|111 115|OGTT
P10201468A0297|32 39|insulin
P10202006A1266|269 281|immunization
P10202006A1266|245 261|B cell selection
P10202006A1266|178 185|binding
P10202006A1266|191 197|ligand
P10202006A1266|50 59|VH domain
P10202006A1266|287 292|Z-DNA
P10202006A1266|1 15|Polypyrimidine
P10205099A0377|213 218|weeks
P10205099A0377|157 160|T16
P10205099A0377|187 190|day
P10205099A0377|16 30|Study patients
P10205099A0377|135 140|weeks
P10205099A0377|197 201|week
P10205099A0377|97 108|terbinafine
P10205099A0377|1 14|INTERVENTIONS
P10205176A0704|45 51|domain
P10205176A0704|71 84|transcription
P10205933A0699|27 40|labyrinthitis
P10205933A0699|197 209|Lyme Disease
P10205933A0699|70 73|ear
P10205933A0699|136 144|syphilis
P10206698A2041|74 82|approach
P10206698A2041|161 166|tract
P10206698A2041|50 61|mutagenesis
P10207041A0065|177 184|kinases
P10207041A0065|80 92|cyclin genes
P10207041A0065|16 26|cell cycle
P10207049A1001|106 120|HSF activation
P10207049A1001|59 63|Gac1
P10207049A1001|5 12|results
P10207090A0801|106 114|molecule
P10207090A0801|66 77|degradation
P10207090A0801|81 84|p50
P10207115A0389|96 105|mechanism
P10208893A0839|45 54|genotypes
P10208893A0839|71 90|WAD goat population
P10209031A0832|105 116|SH2 domains
P10209031A0832|196 222|zeta ITAM phosphotyrosines
P10209031A0832|76 80|zeta
P10209031A0832|5 21|Fyn NH2 terminus
P10209119A0594|240 251|proteolysis
P10209119A0594|130 149|deletion phenotypes
P10209119A0594|87 97|pop2 genes
P10210952A0261|4 14|retrospect
P10211422T0000|41 61|polyarteritis nodosa
P10211422T0000|7 19|pancreatitis
P10212278A0387|130 144|protein kinase
P10212278A0387|146 154|SAPK/JNK
P10212278A0387|213 217|MAPK
P10212278A0387|219 230|superfamily
P10212278A0387|18 33|protein kinases
P10212332T0000|1 19|Chronotherapeutics
P10212969A0470|87 95|subjects
P10215485A0837|13 25|correlations
P10215485A0837|79 96|State Examination
P10215485A0837|101 106|NA/mI
P10215608A0161|30 39|isolation
P10215608A0161|44 60|characterization
P10215608A0161|96 108|subunit gene
P10215811A0635|45 56|eradication
P10215811A0635|9 16|control
P10215811A0635|20 28|bleeding
P10216052A0105|89 99|disability
P10216052A0105|267 277|difficulty
P10216052A0105|18 23|study
P10216052A0105|284 291|measure
P10216052A0105|109 114|tasks
P10216052A0105|162 175|interrelation
P10216052A0105|433 441|subgroup
P10216052A0105|233 241|relation
P10216052A0105|5 9|aims
P10216052A0105|68 72|self
P10216052A0105|373 382|questions
P10216161A1530|226 230|type
P10216161A1530|245 273|B. stearothermophilus enzyme
P10216161A1530|71 80|organisms
P10216161A1530|139 150|subfamilies
P10216161A1530|103 111|proteins
P10218109T0000|41 66|MutT pyrophosphohydrolase
P10218109T0000|1 19|Solution structure
P10218357A0486|13 24|CONCLUSIONS
P10218357A0486|124 135|anaesthesia
P10218357A0486|54 56|G2
P10218357A0486|1 8|RESULTS
P10220275A0694|30 40|Gbetagamma
P10220275A0694|135 142|Gialpha
P10220275A0694|127 131|form
P10220275A0694|16 26|PH domains
P10221467T0000|47 54|disease
P10221467T0000|97 108|cabergoline
P10221467T0000|71 95|dopamine agonist therapy
P10223338A1601|148 155|HIV-1RF
P10223338A1601|126 133|HIV-1MN
P10223338A1601|115 124|HIV-1IIIB
P10223338A1601|101 111|V3 domains
P10223498A0479|28 37|responses
P10223498A0479|124 132|erection
P10223498A0479|53 60|ability
P10223498A0479|141 168|15-item International Index
P10223498A0479|1 9|Efficacy
P10224257A0079|95 97|P1
P10224257A0079|42 48|her-1b
P10224257A0079|18 29|her-1 mRNAs
P10224257A0079|84 93|promoters
P10224293A0000|105 124|phosphatase domains
P10224293A0000|41 46|RPTPs
P10224293A0000|172 178|motifs
P10224293A0000|69 77|proteins
P10224513A0240|123 133|interviews
P10224513A0240|67 78|Stroop test
P10224513A0240|80 97|videogame playing
P10224513A0240|49 61|speech tasks
P10225279A0450|26 30|gene
P10225279A0450|95 98|ORF
P10225279A0450|173 191|pseudorabies virus
P10225279A0450|117 133|herpesvirus type
P10226029A0905|15 20|cells
P10226029A0905|26 35|PH domain
P10226029A0905|95 102|contact
P10226029A0905|39 46|Akt/PKB
P10226838A1011|91 102|stimulation
P10226838A1011|58 68|electrodes
P10226838A1011|138 144|energy
P10228155A1293|29 46|tumor development
P10228155A1293|1 8|SCFFWD1
P10228155A1293|85 115|beta-catenin protein stability
P10228561A0539|41 60|DNA polymerase beta
P10228561A0539|25 37|organization
P10228561A0539|143 150|modules
P10229084A0000|177 192|protein complex
P10229084A0000|145 159|identification
P10229084A0000|115 128|T lymphocytes
P10229084A0000|259 274|phosphoproteins
P10229084A0000|17 36|gel electrophoresis
P10229084A0000|381 387|SKAP55
P10229084A0000|232 235|Fyn
P10229668A0560|43 48|Cln3p
P10229668A0560|96 107|translation
P10229668A0560|64 75|hybrid UBI4
P10229668A0560|3 17|cdc33-1 strain
P10231026A0253|78 85|introns
P10231026A0253|5 19|gene structure
P10231026A0253|64 69|exons
P10231485A0342|166 170|TtrC
P10231485A0342|108 115|cluster
P10231485A0342|33 37|TtrA
P10231485A0342|100 106|4Fe-4S
P10231485A0342|1 18|Sequence analysis
P10231581A1125|15 26|mutagenesis
P10231581A1125|124 141|promoter activity
P10232078A0552|60 77|6-keto-PGF1 alpha
P10232078A0552|82 86|TXB2
P10232078A0552|1 9|Ischemia
P10232872A0081|41 43|CD
P10233885A0899|133 147|mim-1 promoter
P10233885A0899|22 32|prediction
P10233885A0899|71 87|cell line Jurkat
P10233885A0899|34 47|transfections
P10234698A0728|105 117|pretreatment
P10234698A0728|74 88|animal studies
P10234698A0728|192 198|injury
P10234698A0728|64 70|number
P10236651T0000|15 22|success
P10236651T0000|43 47|PCAT
P10236651T0000|1 11|Predictors
P10243927A0000|211 216|gases
P10243927A0000|42 55|investigators
P10243927A0000|6 12|series
P10243927A0000|116 128|door control
P10243927A0000|136 140|room
P10281637A0000|22 28|events
P10281637A0000|81 86|drugs
P10281637A0000|118 123|issue
P10308312A0203|63 85|interaction mechanisms
P10308312A0203|130 137|factors
P10308312A0203|42 55|understanding
P10308312A0203|171 178|effects
P10318806A0476|59 63|role
P10318806A0476|16 21|study
P10318859A0535|38 59|tyrosine phosphatases
P10318859A0535|19 28|calpeptin
P10318918A0824|63 69|region
P10318918A0824|21 29|analysis
P10319327A1237|13 58|SRE oligonucleotide gel mobility shift assays
P10319327A1237|94 99|cells
P10319327A1237|138 141|SRF
P10319327A1237|1 9|Analysis
P10320177A0487|268 277|microg/kg
P10320177A0487|256 264|fentanyl
P10320177A0487|73 99|depth electrode recordings
P10320177A0487|40 47|surface
P10320177A0487|200 219|i.v. administration
P10320177A0487|169 178|recording
P10320579A1831|88 103|oligomerization
P10320579A1831|111 115|HAPs
P10320579A1831|159 165|export
P10320579A1831|17 21|FlgN
P10322022A0263|26 28|aa
P10322022A0263|155 161|pIP501
P10322022A0263|227 242|pAMbeta1 family
P10322022A0263|77 87|similarity
P10322022A0263|110 130|replication proteins
P10322022A0263|136 153|plasmids pAMbeta1
P10323225A0244|15 23|ammonium
P10323225A0244|47 56|glutamate
P10323225A0244|25 39|2-oxoglutarate
P10323225A0244|102 104|mM
P10323463T0000b|144 152|activity
P10323463T0000b|1 17|Interferon-alpha
P10325413A1211|104 114|propensity
P10325413A1211|129 134|helix
P10325413A1211|217 228|interaction
P10325413A1211|186 195|reduction
P10326654A0351|177 184|minutes
P10326654A0351|387 395|duration
P10326654A0351|217 229|fibrillation
P10326654A0351|399 407|ischemia
P10326654A0351|255 259|form
P10326654A0351|85 93|ischemia
P10326654A0351|167 172|study
P10326654A0351|283 290|minutes
P10326654A0351|129 138|durations
P10327051A0688|104 109|Thr71
P10327051A0688|88 92|ATF2
P10327051A0688|94 99|Thr69
P10327051A0688|66 70|SAPK
P10327051A0688|152 164|p300/CBP-ATF
P10329135A1326|42 54|presequences
P10329135A1326|112 126|protein import
P10329574A1733|149 158|deletions
P10329574A1733|114 127|OnuMV4-Ld RNA
P10329574A1733|1 3|O.
P10329625A0715|77 86|TCR genes
P10329625A0715|23 39|cell surface CD4
P10329625A0715|48 51|CD3
P10329736A1106|60 63|p85
P10329736A1106|80 83|Shc
P10329736A1106|49 54|mIRS3
P10329736A1106|34 45|association
P10330146A0730|41 51|repression
P10330146A0730|110 119|sequences
P10330146A0730|55 76|luciferase expression
P10330146A0730|184 189|sites
P10330168A0135|75 81|kinase
P10330168A0135|167 169|G1
P10330168A0135|43 51|cyclin B
P10330168A0135|83 93|Cdk/Cdc28p
P10331276A0298|12 20|elements
P10331730A0504|15 19|year
P10331730A0504|127 139|study period
P10331730A0504|83 84|%
P10331730A0504|98 106|patients
P10331730A0504|34 35|%
P10332733A0000|47 62|membrane fusion
P10332733A0000|5 25|paramyxovirus fusion
P10333526A0459|5 15|hTERT gene
P10334888A0960|37 42|group
P10334888A0960|114 117|min
P10334888A0960|70 78|increase
P10339552A0361|110 118|pre-mRNA
P10339552A0361|96 104|splicing
P10339552A0361|16 21|study
P10340447A0424|29 40|correlation
P10340447A0424|84 94|QIT system
P10341219A0481|41 49|extracts
P10341219A0481|142 157|mass aggregates
P10341219A0481|114 121|protein
P10342536A0954|28 43|protein content
P10342536A0954|124 127|cow
P10342536A0954|229 254|soy/pork collagen formula
P10342536A0954|7 20|determination
P10342536A0954|87 107|RAST/EAST inhibition
P10342829A1370|13 34|mobility shift assays
P10342829A1370|125 129|SF-1
P10342829A1370|173 184|GSE element
P10344736A0796|67 88|CDK inhibitor p21Cip1
P10344736A0796|100 124|cyclin E immunocomplexes
P10347197A0502|120 124|Grb2
P10347197A0502|129 154|Sos1 expression construct
P10347197A0502|55 67|Met receptor
P10347197A0502|1 10|Induction
P10347220A1477|132 155|RNA guanylyltransferase
P10347220A1477|124 129|Cet1p
P10347220A1477|76 85|apparatus
P10347220A1477|232 241|apparatus
P10347220A1477|157 162|Ceg1p
P10347220A1477|169 174|Abd1p
P10348859A0292|149 155|Cys126
P10348859A0292|111 116|Cys82
P10348859A0292|59 73|MerR homodimer
P10348859A0292|138 144|Cys117
P10349443A0358|28 39|field tests
P10349443A0358|78 84|larvae
P10349443A0358|5 12|results
P10349443A0358|138 139|%
P10350454A0000|41 52|specificity
P10350454A0000|78 90|8-oxoguanine
P10350454A0000|92 94|oG
P10350454A0000|101 108|guanine
P10350638A0000|60 64|cell
P10350638A0000|79 85|manner
P10350638A0000|140 143|rat
P10353880A0257|90 96|births
P10353880A0257|65 72|infants
P10353880A0257|103 112|diagnosis
P10355536A0172|12 15|age
P10355536A0172|23 28|years
P10357751A0866|60 65|score
P10357751A0866|149 154|death
P10357751A0866|244 252|children
P10357751A0866|75 81|weight
P10357751A0866|14 19|group
P10357751A0866|173 177|% CI
P10357751A0866|32 40|children
P10358075A0984|148 156|receptor
P10358075A0984|178 181|PKB
P10358075A0984|39 56|signaling pathway
P10358075A0984|1 6|DAF16
P10358080A1114|28 49|transcription factors
P10358080A1114|72 95|DNA binding specificity
P10358080A1114|173 197|HSF1 binding preferences
P10358080A1114|153 157|role
P10358083A0263|149 171|sequence motifs GTGACT
P10358083A0263|176 181|ATTGT
P10358083A0263|172 173|C
P10358083A0263|203 223|transcription factor
P10358083A0263|187 191|GATA
P10359014A1077|135 140|means
P10359014A1077|125 131|region
P10359014A1077|158 169|mutagenesis
P10359014A1077|234 238|MAPK
P10359014A1077|68 77|threonine
P10359603A0430|1 6|Vac1p
P10359663A1280|148 154|GATA-3
P10359663A1280|58 63|c-Fos
P10359663A1280|96 107|oIFNtau-CAT
P10359663A1280|33 43|expression
P10359663A1280|138 144|GATA-2
P10359673A0000|91 114|amino acid biosynthesis
P10359673A0000|5 20|yeast LPD1 gene
P10360454A0916|14 39|serum TNF-a concentration
P10360454A0916|129 134|month
P10360454A0916|67 75|patients
P10360454A0916|118 123|pg/ml
P10360947A1113|91 94|Ca2
P10360947A1113|80 87|binding
P10360947A1113|140 147|changes
P10360947A1113|50 59|dichroism
P10362652A0350|41 43|nM
P10362652A0350|53 67|Ras activation
P10362652A0350|33 36|EGF
P10362897A0545|108 122|Doppler signal
P10362897A0545|25 32|passage
P10362897A0545|36 44|contrast
P10362897A0545|68 75|amounts
P10364076A0429|106 116|affinities
P10364076A0429|83 90|SREBP-1
P10364163A0092|11 15|FYVE
P10364163A0092|161 168|traffic
P10364163A0092|23 41|zinc finger domain
P10364163A0092|68 88|phosphatidylinositol
P10364314A0919|42 53|nucleotides
P10364314A0919|86 94|NS2 gene
P10364425A0610|63 71|tyrosine
P10364425A0610|7 18|indications
P10364425A0610|34 44|signalling
P10364523T0000|12 47|dysplasia translocation breakpoints
P10364523T0000|69 71|Mb
P10366446A0893|15 21|domain
P10366446A0893|53 60|protein
P10366503A1506|211 215|gp20
P10366503A1506|115 122|peptide
P10366503A1506|290 307|packasome complex
P10366503A1506|220 224|gp17
P10366503A1506|14 23|terminase
P10366503A1506|276 282|portal
P10366503A1506|141 147|access
P10366722T0000|41 51|gene Pole1
P10366722T0000|21 33|organization
P10367385A0000|62 75|beta-carotene
P10367385A0000|87 91|food
P10367646A0569|243 244|P
P10367646A0569|145 169|alanine aminotransferase
P10367646A0569|184 199|serum globulins
P10367646A0569|108 116|addition
P10367646A0569|96 104|analytes
P10367646A0569|201 202|P
P10367646A0569|171 178|calcium
P10369625A0942|23 26|ODA
P10369775A0178|78 80|ER
P10369775A0178|115 121|rat GR
P10369965A0000|5 17|Aa-Pri2 gene
P10369965A0000|84 110|mushroom Agrocybe aegerita
P10370778A0000|149 156|disease
P10370778A0000|56 61|phase
P10370778A0000|212 220|ARIMIDEX
P10370778A0000|250 258|Novartis
P10370778A0000|104 117|breast cancer
P10370778A0000|199 210|anastrozole
P10370778A0000|283 290|Janssen
P10370778A0000|274 281|RIVIZOR
P10372627A0530|61 66|cases
P10372627A0530|24 29|cases
P10373507A0680|181 224|SRF promoter-luciferase reporter activities
P10373507A0680|133 144|alpha-actin
P10373507A0680|70 76|mutant
P10373507A0680|153 164|alpha-actin
P10374632A0818|76 79|NBP
P10374632A0818|20 26|effect
P10374632A0818|84 91|mg.kg-1
P10375107A1138|110 120|metastasis
P10375107A1138|96 104|patients
P10375640A0153|57 62|CBS-1
P10375640A0153|112 123|amino acids
P10375640A0153|80 93|reading frame
P10375640A0153|51 55|cDNA
P10375718A0000|122 136|administration
P10375718A0000|7 31|fibroblast growth factor
P10375718A0000|33 37|bFGF
P10376446A0000|135 137|LP
P10376446A0000|12 17|women
P10376446A0000|127 133|luteal
P10376446A0000|19 22|age
P10376446A0000|139 145|phases
P10376446A0000|119 121|FP
P10376874A0759|179 186|protein
P10376874A0759|25 32|defects
P10376874A0759|206 213|support
P10376874A0759|137 150|eRF1 proteins
P10376991A0977|1 4|Ras
P10377438A0647|59 62|TEL
P10379547A0000|14 17|NH3
P10379547A0000|64 69|MASER
P10379942A0956|90 94|part
P10379942A0956|102 119|MDV2 UL10 protein
P10380232A0000|302 314|perspectives
P10380232A0000|215 221|emesis
P10380232A0000|145 182|5-HT3 receptor antagonist-tropisetron
P10380232A0000|251 263|chemotherapy
P10380232A0000|54 57|CEA
P10380232A0000|316 324|hospital
P10380232A0000|129 136|CPM-DEX
P10380800A0194|44 64|amino acid sequences
P10380800A0194|72 84|core regions
P10380800A0194|228 238|host plant
P10380800A0194|21 31|nucleotide
P10380800A0194|253 261|ancestor
P10380890A0619|103 105|IR
P10381377T0000|11 18|cloning
P10381377T0000|92 102|regulation
P10381377T0000|65 70|SHIP2
P10383764A1809|107 118|information
P10383764A1809|230 238|activity
P10383764A1809|22 29|studies
P10383764A1809|5 12|results
P10383764A1809|55 67|VirB4 dimers
P10383764A1809|71 84|homomultimers
P10384129A0000|45 56|RNA samples
P10384129A0000|12 16|TCRA
P10384129A0000|80 91|populations
P10384129A0000|18 28|expression
P10384129A0000|138 149|individuals
P10385395A0000|31 34|HDL
P10385395A0000|182 188|gonads
P10385395A0000|58 64|uptake
P10385395A0000|172 177|gland
P10385395A0000|84 102|cholesteryl esters
P10385395A0000|119 134|steroidogenesis
P10388670A1976|83 93|dispersant
P10388670A1976|20 28|recovery
P10388670A1976|155 163|adhesion
P10390538T0000|24 43|zinc-finger protein
P10391246A0756|14 19|MOM-4
P10391246A0756|42 50|proteins
P10391903T0000|13 32|pleckstrin homology
P10391903T0000|100 110|ERK kinase
P10391903T0000|51 66|adapter protein
P10392669A0935|363 376|complications
P10392669A0935|418 432|H2 antagonists
P10392669A0935|540 546|ulcers
P10392669A0935|668 678|omeprazole
P10392669A0935|590 600|prevention
P10392669A0935|640 662|proton pump inhibitors
P10392669A0935|856 875|prophylactic agents
P10392669A0935|704 712|efficacy
P10392669A0935|440 450|ranitidine
P10392669A0935|452 462|cimetidine
P10392669A0935|467 477|famotidine
P10392669A0935|131 134|use
P10392669A0935|7 14|attempt
P10392669A0935|200 204|drug
P10392669A0935|744 750|ulcers
P10392900A1020|57 69|localization
P10392900A1020|23 35|HIV promoter
P10392900A1020|118 142|tyrosine phosphorylation
P10392903A0889|106 139|cell cycle inhibitors hydroxyurea
P10392903A0889|36 47|cell growth
P10392903A0889|1 17|E2 point mutants
P10393192A0792|98 104|defect
P10393192A0792|1 25|Neurospora crassa CYT-18
P10393201A0654|193 201|addition
P10393201A0654|79 99|DNA ligase III-XRCC1
P10393201A0654|139 151|base residue
P10393251T0000|13 24|10q24 locus
P10393251T0000|95 110|T-ALL cell line
P10393251T0000|1 9|Sequence
P10393910A0705|129 141|endonuclease
P10393910A0705|65 73|evidence
P10393910A0705|117 121|site
P10393910A0705|34 44|R2 protein
P10394116T0000|22 36|blood pressure
P10394116T0000|1 18|Wrist measurement
P10394919A1058|63 74|oscillation
P10395283A0960|14 25|competition
P10395283A0960|57 69|availability
P10395283A0960|202 211|responses
P10395283A0960|100 113|concentration
P10395827A1297|62 66|coil
P10395827A1297|23 48|parallel beta helix model
P10395911A0288|25 56|chicken apolipoprotein A-I gene
P10395911A0288|69 75|region
P10396343A0754|74 78|rest
P10396343A0754|143 146|PCR
P10396343A0754|188 205|T. b. rhodesiense
P10396343A0754|86 94|suspects
P10396343A0754|136 139|DNA
P10396793A0815|13 16|men
P10396793A0815|106 116|reductions
P10396793A0815|124 134|prevalence
P10396793A0815|161 179|alcohol dependence
P10396793A0815|200 201|%
P10396793A0815|1 8|Results
P10398286A0678|146 149|S2p
P10398286A0678|7 14|Scheffe
P10398286A0678|136 142|nature
P10399136A0389|10 20|ifenprodil
P10399136A0389|112 115|HPC
P10399136A0389|71 85|pentoxifylline
P10399136A0389|1 8|Ozagrel
P10400593A1084|108 113|virE2
P10400593A1084|23 47|Plac promoter constructs
P10400593A1084|81 86|virE1
P10400712A0577|61 74|transcription
P10400712A0577|260 262|HN
P10400712A0577|185 187|GE
P10400712A0577|284 285|L
P10400712A0577|287 292|genes
P10400712A0577|349 363|gene junctions
P10400712A0577|231 258|hemagglutinin-neuraminidase
P10400712A0577|37 39|IG
P10400712A0577|272 282|polymerase
P10400757A1498|46 51|CXCR4
P10400757A1498|197 202|CXCR4
P10400757A1498|219 224|HIV-1
P10400757A1498|35 41|detail
P10400757A1498|137 156|mutagenesis efforts
P10400774A0240|1 3|y.
P10400794T0000|150 152|2A
P10400794T0000|126 143|membrane proteins
P10400794T0000|39 45|Kaposi
P10400794T0000|1 15|Identification
P10402467T0000|14 26|chain kinase
P10402467T0000|162 168|manner
P10402467T0000|70 79|migration
P10402467T0000|51 58|Ras/ERK
P10403690A0000|120 143|ECOG performance status
P10403690A0000|240 244|care
P10403690A0000|250 274|combination chemotherapy
P10403690A0000|289 299|ifosfamide
P10403690A0000|435 440|mg/m2
P10403690A0000|501 505|days
P10403690A0000|442 451|cisplatin
P10403690A0000|91 96|NSCLC
P10403690A0000|215 219|care
P10403690A0000|145 147|PS
P10403690A0000|398 401|day
P10403690A0000|73 89|cell lung cancer
P10403690A0000|351 356|mg/m2
P10403690A0000|337 347|epirubicin
P10403690A0000|408 419|MVP regimen
P10403839A1459|91 97|mBMAL1
P10403839A1459|167 170|Ahr
P10403839A1459|157 162|BMAL1
P10403839A1459|190 198|subclass
P10406047A1244|242 249|infants
P10406047A1244|335 348|lung function
P10406047A1244|115 125|compliance
P10406047A1244|258 262|PPHN
P10406047A1244|165 171|weight
P10406047A1244|230 238|controls
P10406047A1244|175 186|lung volume
P10406047A1244|103 109|height
P10406459A0000|107 110|TPA
P10406459A0000|9 14|study
P10406459A0000|248 261|NIH 3T3 cells
P10406459A0000|71 105|12-O-tetradecanoyl-phorbol-acetate
P10406459A0000|49 62|growth factor
P10406459A0000|222 231|magnitude
P10406464A0687|14 37|mTRAP100 coprecipitates
P10406464A0687|176 182|manner
P10406464A0687|76 88|TRAP complex
P10406464A0687|115 126|contacts TR
P10406466A0000|36 45|receptors
P10406466A0000|118 127|receptors
P10406954A0715|104 108|RegR
P10406954A0715|95 99|RegS
P10406954A0715|67 83|amino acids H219
P10407184A0520|151 158|plasmid
P10407184A0520|243 253|prhbetaE-B
P10407184A0520|29 45|promoter regions
P10407184A0520|298 313|promoter region
P10407184A0520|294 296|rh
P10407184A0520|324 327|URE
P10407184A0520|16 23|studies
P10407184A0520|74 87|reporter gene
P10407184A0520|346 355|bp region
P10407269A0000b|45 58|markers cdc18
P10407269A0000b|192 217|genome sequencing project
P10407269A0000b|89 113|fission yeast chromosome
P10407269A0000b|25 28|DNA
P10407269A0000b|139 143|part
P10409656A1016|166 179|cell response
P10409656A1016|46 66|macrophage cell line
P10409656A1016|36 39|RAW
P10409656A1016|19 28|H411 cDNA
P10409656A1016|118 128|expression
P10409724A1021|74 88|response genes
P10409724A1021|1 11|Activation
P10409741A0382|106 121|division defect
P10409741A0382|125 138|cdc20-1 cells
P10409741A0382|48 55|cdc4-10
P10409755A1846|30 40|activation
P10409755A1846|13 15|Ca
P10409755A1846|83 94|TG exposure
P10409755A1846|98 110|JT/Neo cells
P10411139A1344|89 93|role
P10411139A1344|5 12|results
P10411160T0000|29 40|variability
P10411160T0000|5 14|mysteries
P10413607A0085|227 246|signal transduction
P10413607A0085|115 118|CVI
P10413607A0085|102 113|collagen VI
P10413676A0000|27 69|transmembrane integrin receptor clustering
P10413676A0000|100 116|signaling events
P10413676A1193|73 81|Leu-1034
P10413676A1193|133 146|contact sites
P10413676A1193|24 30|effect
P10413676A1193|85 88|Ser
P10416429A0221|121 127|number
P10416429A0221|9 19|Comparison
P10416429A0221|23 29|number
P10416429A0221|141 156|population data
P10416429A0221|1 7|DESIGN
P10417331A1008|29 37|activity
P10417331A1008|66 69|cat
P10417331A1008|64 65|k
P10419006A0378|15 23|evidence
P10419006A0378|94 112|breast cancer risk
P10422291A0572|60 71|involvement
P10422291A0572|3 12|diagnosis
P10422468A0524|177 191|sex chromosome
P10422468A0524|144 148|case
P10422468A0524|22 34|malformation
P10422468A0524|262 271|mutations
P10422468A0524|258 260|OA
P10422468A0524|286 299|fibrosis gene
P10422468A0524|38 46|children
P10422468A0524|239 243|case
P10423193A1309|65 76|involvement
P10423193A1309|116 126|neuropathy
P10423193A1309|1 11|CONCLUSION
P10425094A1006|55 57|mM
P10425094A1006|49 50|s
P10426450A1458|62 68|tonsil
P10426450A1458|11 19|recovery
P10426450A1458|23 25|SA
P10426450A1458|185 199|contact poults
P10426450A1458|204 210|chicks
P10427654A0000|149 158|esophagus
P10427654A0000|127 141|adenocarcinoma
P10427654A0000|113 121|patients
P10427654A0000|168 174|cancer
P10427654A0000|102 109|staging
P10428294A0227|59 70|individuals
P10428294A0227|1 26|Preheparin LPL mass level
P10428811A0628|104 111|betaARK
P10428811A0628|115 120|GRK-2
P10428811A0628|87 102|receptor kinase
P10428862A0834|107 111|DokR
P10428862A0834|76 87|interaction
P10428862A0834|184 195|BaF/3 cells
P10429740A0000|104 107|IBS
P10429740A0000|37 45|evidence
P10429740A0000|65 74|therapies
P10429946A0988|26 74|B-Myb-glutathionine S-transferase fusion protein
P10430580A0000|75 86|end-joining
P10430580A0000|11 31|double-strand breaks
P10430580A0000|54 57|DNA
P10430580A0000|1 7|Repair
P10430883A0000|329 334|Con A
P10430883A0000|62 69|Brunner
P10430883A0000|219 224|mucin
P10430883A0000|251 254|Con
P10430883A0000|257 265|staining
P10430883A0000|288 297|oxidation
P10430883A0000|72 78|glands
P10430883A0000|141 146|ducts
P10430890A1059|44 52|solution
P10430890A1059|111 118|binding
P10430890A1059|136 152|partner proteins
P10430980A0465|27 32|women
P10433970A0279|67 85|DNA binding domain
P10433970A0279|35 48|reading frame
P10436016A0337|132 137|Mad1p
P10436016A0337|64 69|Mad2p
P10436016A0337|102 130|spindle checkpoint component
P10438540A1185|92 98|strain
P10438540A1185|37 51|domain mutants
P10438540A1185|68 77|tolerance
P10438607A0330|72 86|gene fork head
P10438607A0330|48 55|product
P10438924A1009|121 126|GSK-3
P10438924A1009|69 119|serine/threonine kinase glycogen synthase kinase-3
P10438941A1197|7 27|recombination events
P10438941A1197|98 118|switch recombination
P10439040A0658|44 60|c-myc expression
P10439040A0658|166 176|constructs
P10439040A0658|66 71|c-myc
P10439040A0658|19 29|role eIF4E
P10441243A0443|82 87|ng/ml
P10441243A0443|1 8|RESULTS
P10441483A0454|116 124|analyses
P10441483A0454|137 145|proteins
P10442493A0815|14 26|serum levels
P10442493A0815|146 147|r
P10442493A0815|157 158|p
P10442493A0815|118 144|plasma cyclosporine levels
P10444597A0586|26 35|induction
P10444597A0586|66 70|salt
P10444597A0586|49 59|heat shock
P10444597A0586|84 94|conditions
P10445161A1565|106 117|weight gain
P10445161A1565|177 182|sexes
P10445161A1565|82 85|ppm
P10445161A1565|4 11|summary
P10445945T0000|1 20|John leonard dawson
P10446149A0809|47 52|assay
P10446149A0809|108 113|B-Raf
P10446149A0809|67 80|Ras effectors
P10446149A0809|115 145|phosphoinositol-3 kinase delta
P10446833T0000|46 52|sepsis
P10446833T0000|18 29|oxygenation
P10446912A0883|123 126|OF3
P10446912A0883|148 159|JEG-3 cells
P10446912A0883|78 99|CYP11A1 transcription
P10446912A0883|36 46|mechanisms
P10446912A0883|115 118|OF5
P10446998A0955|45 50|cells
P10446998A0955|123 132|c-fos SRE
P10446998A0955|79 86|ability
P10446998A0955|144 148|SREs
P10446998A0955|1 26|Adipocyte differentiation
P10446998A0955|186 207|gel supershift assays
P10447593A0144|43 60|bacteriophages T3
P10447593A0144|5 16|core enzyme
P10447593A0144|69 72|SP6
P10448036A0748|45 50|S RNA
P10448036A0748|245 260|RNA interaction
P10448036A0748|5 16|interaction
P10448036A0748|217 228|specificity
P10448036A0748|136 153|S RNA interaction
P10448036A0748|171 177|finger
P10448285A1035|104 110|months
P10448285A1035|89 95|months
P10448285A1035|39 52|survival time
P10448902A0921|24 31|enzymes
P10448902A0921|111 115|rats
P10448902A0921|155 159|rats
P10449899A0881|15 22|results
P10449899A0881|74 90|integration site
P10451209A0000|125 130|doses
P10451209A0000|33 47|administration
P10451209A0000|51 62|misoprostol
P10451209A0000|171 175|MPSS
P10452951A0000|9 26|hormone receptors
P10452951A0000|98 107|functions
P10453006A0000|60 70|chromosome
P10453006A0000|26 37|Danio rerio
P10453006A0000|158 172|identification
P10453006A0000|75 77|P1
P10453006A0000|131 142|cDNA clones
P10453006A0000|231 235|PSMB
P10453006A0000|1 11|Sequencing
P10453248A0094|29 40|perspective
P10453248A0094|102 108|models
P10453721A0445|109 134|ADAPT II software package
P10453721A0445|97 101|part
P10454540A0392|77 97|exonuclease activity
P10454540A0392|34 39|D208A
P10454557A0000|166 176|chromosome
P10454557A0000|229 243|HML locus show
P10454557A0000|140 148|elements
P10454557A0000|86 96|chromosome
P10454557A0000|16 21|yeast
P10454561A0594|165 196|IkappaBalpha gene transcription
P10454561A0594|298 301|p65
P10454561A0594|129 150|tumor necrosis factor
P10454561A0594|293 297|RelA
P10454561A0594|306 321|TD-IkappaBalpha
P10454570A0846|335 340|ERK-1
P10454570A0846|325 331|kinase
P10454570A0846|48 71|protein kinase pathways
P10454570A0846|192 197|c-Jun
P10454570A0846|436 448|uPA enhancer
P10454570A0846|382 385|TPA
P10454570A0846|5 13|analysis
P10454570A0846|238 242|IL-1
P10455143T0000|61 84|glucocorticoid receptor
P10455143T0000|1 22|Interdomain signaling
P10455183A0930|194 197|Sec
P10455183A0930|56 67|utilization
P10455183A0930|71 87|Staf zinc finger
P10455183A0930|152 172|activation mechanism
P10455189A0427|24 48|tyrosine phosphorylation
P10455189A0427|97 103|manner
P10458905A0000|94 102|8p22-p23
P10458914A0674|121 123|kb
P10458914A0674|144 149|exons
P10458914A0674|103 109|region
P10458914A0674|85 94|STAP gene
P10460015A0465|10 16|months
P10460015A0465|20 29|treatment
P10460015A0465|117 137|bone mineral density
P10460015A0465|69 75|height
P10460172A0823|167 182|heterotetramers
P10460172A0823|98 107|rat brain
P10460172A0823|136 152|kDa polypeptides
P10463242A0316|4 7|EEG
P10464250A0275|8 16|FASEB J.
P10464302A1109b|88 104|pathway proteins
P10464302A1109b|242 254|transmission
P10464302A1109b|173 178|model
P10464302A1109b|55 58|neu
P10464302A1109b|136 152|interaction site
P10466306A0000|111 119|function
P10466306A0000|97 106|perfusion
P10467004A0116|147 154|introns
P10467004A0116|5 15|intron RNA
P10467004A0116|156 162|Michel
P10467403A0000|73 79|number
P10467403A0000|127 156|phosphatidylinositol 3-kinase
P10467403A0000|158 169|PI 3-kinase
P10468033T0000|28 43|stratum corneum
P10468033T0000|1 16|Chemical uptake
P10469140A0336|128 136|TNFalpha
P10469140A0336|82 87|PAI-2
P10469140A0336|143 200|chloramphenicol acetyl transferase reporter gene deletion
P10469140A0336|205 222|mutation analyses
P10469656T0000|160 166|kinase
P10469656T0000|142 156|histone H3/HMG
P10469656T0000|17 25|response
P10471696A0734|121 124|ACS
P10471696A0734|56 74|Abf1p binding site
P10471696A0734|128 146|Rap1p binding site
P10471696A0734|6 13|alleles
P10471743A0000|75 110|Arabidopsis thaliana cDNA libraries
P10471743A0000|39 51|DNA helicase
P10472314A0717|14 21|Periods
P10472314A0717|54 57|men
P10472314A0717|1 8|RESULTS
P10473589A0189|28 31|kDa
P10473589A0189|111 114|kDa
P10473589A0189|5 15|N terminus
P10473589A0189|19 23|beta
P10473623A0081|120 129|formation
P10473623A0081|148 155|complex
P10473623A0081|176 182|factor
P10475610A1289|1 6|Natl.
P10476970A0542|166 176|G-proteins
P10476970A0542|77 86|rap1GAPII
P10476970A0542|38 42|Rapl
P10476970A0542|136 137|G
P10477583A0000a|106 117|progression
P10477583A0000a|77 87|Fc gamma R
P10477583A0000a|55 67|Fc receptors
P10477597A0126|151 161|activation
P10477597A0126|41 64|serine/threonine kinase
P10477597A0126|81 94|center kinase
P10477597A0126|169 181|SAPK pathway
P10477620A0580|149 165|I kappa B kinase
P10477620A0580|79 106|I kappa B alpha degradation
P10477620A0580|128 143|phosphorylation
P10477620A0580|172 180|activity
P10477620A0580|18 49|NF-kappa B DNA binding activity
P10478275A1230|165 170|foods
P10478275A1230|10 16|issues
P10478275A1230|25 29|need
P10478275A1230|142 146|risk
P10478275A1230|222 230|contrast
P10478848A0331|34 44|AF1 domain
P10479382A1098|106 126|development patterns
P10479382A1098|78 89|constraints
P10479382A1098|42 51|influence
P10480937A0000|224 229|Rossi
P10480937A0000|56 79|A kinase anchor protein
P10480937A0000|163 170|signals
P10480937A0000|188 190|Ca
P10480937A0000|216 218|Li
P10480937A0000|220 222|Z.
P10482516T0000|40 75|transcription attenuation mechanism
P10482516T0000|6 19|RNA stem-loop
P10482620A1009|208 216|MMTV LTR
P10482620A1009|93 100|absence
P10482620A1009|114 134|transcription factor
P10482620A1009|34 47|transcription
P10483945A0641|46 54|patients
P10483945A0641|10 25|CK-MB elevation
P10483945A0641|81 82|%
P10483945A0641|69 73|1-3x
P10483945A0641|118 119|%
P10484818A0292|11 16|areas
P10484818A0292|50 76|cross-correlation analysis
P10485470A0242|74 83|Sp1 sites
P10485470A0242|225 243|binding activities
P10485470A0242|38 41|Sp3
P10485470A0242|117 127|MG63 cells
P10485470A0242|152 173|mobility shift assays
P10486210A0126|82 90|promoter
P10486210A0126|32 42|expression
P10487217A0735|47 58|amino acids
P10487217A0735|5 12|C2C-Prx
P10487217A0735|103 109|signal
P10487744T0000|40 54|beta2 integrin
P10487744T0000|157 166|migration
P10487744T0000|87 96|recycling
P10487759A0630|59 68|integrity
P10487759A0630|82 91|sequences
P10487759A0630|18 33|Xenopus embryos
P10487762A0252|32 36|mass
P10487953A0765|45 62|S-phase fractions
P10487953A0765|29 35|tumors
P10487953A0765|111 115|time
P10488088T0000|14 29|growth factor-I
P10488088T0000|38 52|bcl-2 promoter
P10488147A1176|75 82|control
P10488147A1176|54 67|understanding
P10488147A1176|19 28|eotaxin-3
P10488148A1267|150 157|complex
P10488148A1267|124 133|NF-kappaB
P10488148A1267|7 14|studies
P10488148A1267|99 110|interaction
P10488337T0000|27 36|chaperone
P10488337T0000|52 64|dimerization
P10488337T0000|99 107|activity
P10489680A0927|77 94|grain dust-asthma
P10489680A0927|1 12|Sputum IL-8
P10489680A0927|68 71|TDI
P10490065T0000|23 29|angina
P10490065T0000|1 10|Treatment
P10490609A0413|145 153|thymines
P10490609A0413|42 51|sequences
P10490609A0413|163 175|interruption
P10490609A0413|190 198|cytosine
P10490609A0413|1 14|Substitutions
P10490662A0431|47 53|adults
P10490662A0431|77 89|morphologies
P10490662A0431|19 31|lace alleles
P10490816A0000|105 128|cancer syndromes MEN 2A
P10490816A0000|39 63|receptor tyrosine kinase
P10490816A0000|1 10|Mutations
P10490826T0000|89 90|t
P10490826T0000|97 103|subset
P10490826T0000|1 5|EB-1
P10490843A0159|41 50|structure
P10490843A0159|168 178|malignancy
P10490843A0159|1 5|BCL6
P10491133A0365|30 47|activity analyses
P10491133A0365|83 94|HO isozymes
P10491133A0365|1 11|Optical CD
P10491213A0263|61 65|BALP
P10491213A0263|430 434|boys
P10491213A0263|291 298|density
P10491213A0263|252 261|vertebrae
P10491213A0263|313 317|bone
P10491213A0263|168 172|Dpyr
P10491213A0263|239 244|areas
P10491213A0263|388 392|bone
P10491213A0263|450 454|ages
P10491213A0263|25 29|bone
P10491213A0263|460 465|years
P10491213A0263|344 350|volume
P10491213A0263|199 201|CT
P10491213A0263|140 143|Pyr
P10491213A0263|1 21|Serum concentrations
P10492169A0939|94 110|plasma protein-A
P10492169A0939|6 13|cluster
P10492169A0939|66 71|genes
P10493575T0000|149 152|p53
P10493575T0000|63 72|beta beta
P10493575T0000|27 37|C-terminus
P10493575T0000|52 61|rat S100B
P10493876A0000|422 423|g
P10493876A0000|245 246|N
P10493876A0000|249 260|amino group
P10493876A0000|490 497|A21-G22
P10493876A0000|426 445|A6-C7-T8-T9-C10-C11
P10493876A0000|424 425|C
P10493876A0000|319 320|B
P10493876A0000|107 110|13R
P10493876A0000|381 403|DNA sequence context d
P10493876A0000|514 515|g
P10493876A0000|649 651|MD
P10493876A0000|518 520|dA
P10493876A0000|516 517|C
P10493876A0000|448 449|d
P10493876A0000|450 485|G12-G13-A14-A15-G16-T17-G18-A19-G20
P10493876A0000|145 157|dihydroxy-13
P10493876A0000|321 322|g
P10493876A0000|323 324|C
P10493876A0000|223 226|CDE
P10493876A0000|404 418|C1-T2-C3-T4-C5
P10493876A0000|198 206|chrysene
P10493876A0000|276 287|residue dA6
P10493876A0000|5 23|solution structure
P10493876A0000|342 350|opposite
P10496161A0503|89 92|WPI
P10496161A0503|64 75|guinea pigs
P10496161A0503|1 17|Serum antibodies
P10496303A1968|94 105|ganciclovir
P10496303A1968|20 27|results
P10496303A1968|157 168|ganciclovir
P10496303A1968|1 12|CONCLUSIONS
P10496388A1956b|12 24|nonperfusion
P10496388A1956b|49 56|vessels
P10496388A1956b|119 126|concern
P10497117A0358|5 11|P mRNA
P10497117A0358|34 37|ORF
P10497262A0000|133 158|U5 RNA affinity selection
P10497262A0000|83 125|trypanosomatid species Leptomonas seymouri
P10497262A0000|32 36|gene
P10497874A0925|14 18|hand
P10497874A0925|93 108|phosphorylation
P10497874A0925|66 76|hydrolysis
P10497874A0925|136 154|PLC-gamma1 isozyme
P10498616A1280|57 64|exhibit
P10498616A1280|219 226|p21 Ras
P10498616A1280|86 94|features
P10498616A1280|187 195|parallel
P10498717A1048|7 19|observations
P10498717A1048|103 118|RsmA production
P10499357A0439|147 155|exposure
P10499357A0439|246 254|evidence
P10499357A0439|258 271|neurotoxicity
P10499357A0439|106 110|FR20
P10499357A0439|111 116|FI120
P10499357A0439|65 70|ratio
P10499357A0439|204 209|Weeks
P10501656A1415|14 24|expression
P10501656A1415|42 64|Northern blot analysis
P10501965A0879|91 100|s6 kinase
P10501965A0879|208 216|receptor
P10501965A0879|159 164|Gpr31
P10501965A0879|34 39|units
P10502216A0289|181 183|MI
P10502216A0289|160 171|reperfusion
P10502216A0289|52 61|efegatran
P10502216A0289|6 11|study
P10502216A0289|143 146|TPA
P10502402A0533|26 36|inhibitors
P10502402A0533|3 8|panel
P10502434A0604|40 44|ICG1
P10502434A0604|52 56|ICG2
P10502434A0604|68 80|ICG3 disease
P10503540A0602|107 114|alleles
P10503540A0602|3 8|total
P10503540A0602|16 28|primer pairs
P10504332A0701|94 97|RAP
P10504332A0701|203 219|RAP fluorescence
P10504332A0701|64 72|receptor
P10504332A0701|116 123|markers
P10505694A0739|104 107|min
P10505694A0739|72 78|outlet
P10505694A0739|111 119|dialysis
P10505694A0739|38 55|C3a concentration
P10506160A0297|1 3|J.
P10509768A1118|109 118|reduction
P10509768A1118|128 151|serum cholesterol level
P10509768A1118|69 74|group
P10510379A0105|11 31|transcription factor
P10510379A0105|101 120|cytokine activation
P10510379A0105|51 56|STAT6
P10511554T0000|67 101|clone Caenorhabditis elegans cdf-1
P10512699T0000|209 219|selC genes
P10512699T0000|72 97|rat thioredoxin reductase
P10512699T0000|200 204|selB
P10512699T0000|171 184|co-expression
P10512882A0137|120 128|activity
P10512882A0137|132 139|members
P10512882A0137|147 157|Src family
P10512882A0137|39 50|Src kinases
P10513922A1237|121 131|comparison
P10513922A1237|41 50|increases
P10513922A1237|58 64|number
P10513922A1237|86 92|fibers
P10514808T0000|10 20|dysplasias
P10514808T0000|36 51|epileptogenesis
P10516026A0270|6 17|HERV-K type
P10516738A0925|41 42|%
P10516738A0925|59 74|irbesartan/HCTZ
P10517666A1069|45 64|AP-1 nucleoproteins
P10517666A1069|113 117|nGRE
P10517675A0809|120 126|member
P10517675A0809|94 108|protein levels
P10517675A0809|52 60|increase
P10517675A0809|1 22|Western blot analysis
P10518502T0000|77 98|germ cell development
P10518502T0000|115 137|Caenorhabditis elegans
P10518502T0000|103 111|survival
P10518561A0885|90 103|kinase domain
P10518561A0885|11 26|phosphorylation
P10518561A0885|39 42|Tec
P10518937A0572|122 126|Bas1
P10518937A0572|130 134|Bas2
P10518937A0572|158 165|control
P10518937A0572|32 43|KlHIS4 gene
P10518937A0572|205 214|K. lactis
P10518956A1212|38 41|TSH
P10518956A1212|71 75|form
P10521345A0202|106 132|surface slope waters north
P10521345A0202|59 64|proxy
P10521345A0202|218 227|centuries
P10521345A0202|190 197|Ice Age
P10521345A0202|19 23|data
P10521447A0606|58 73|sequence TGTGGT
P10521447A0606|23 24|B
P10521447A0606|117 157|AML/CBFalpha transcription factor family
P10521450A0437|60 70|DT40 cells
P10521450A0437|31 34|Lyn
P10521450A0437|88 91|Lyn
P10521450A0437|97 101|mice
P10521544T0000|13 23|expression
P10521544T0000|92 112|Man8GlcNAc2 isomer B
P10521544T0000|1 8|Cloning
P10523319A0209|21 26|Dbp5p
P10523634A1404|30 49|Psi synthase domain
P10523634A1404|58 69|association
P10523634A1404|114 131|box H/ACA snoRNAs
P10523634A1404|3 9|subset
P10523647A0000|177 188|cell growth
P10523647A0000|131 147|stress responses
P10523647A0000|66 78|bZIP protein
P10523647A0000|32 37|C/EBP
P10523647A0000|103 110|stimuli
P10523663A0404|6 11|motif
P10523663A0404|48 73|homeobox activator DEAF-1
P10524258A0286|40 51|FGFR-1 gene
P10524258A0286|22 32|regulation
P10524258A0286|114 136|Northern blot analysis
P10525413A1408|26 34|residues
P10525413A1408|127 145|N NMR spectroscopy
P10525413A1408|65 69|CRP2
P10526670A1828|120 123|PKB
P10526670A1828|177 195|Ras transformation
P10526670A1828|52 57|N1445
P10526670A1828|35 44|inhibitor
P10527158T0000|57 71|plutonium pits
P10527158T0000|5 13|AL-R8 SI
P10527426A0521|193 202|sequences
P10527426A0521|160 166|intron
P10527426A0521|129 134|forms
P10527426A0521|172 181|exclusion
P10527426A0521|185 189|exon
P10528035A1102|13 14|P
P10528035A1102|96 103|percent
P10528035A1102|4 11|percent
P10531334A0525|77 86|substrate
P10531334A0525|25 32|enzymes
P10531334A0525|52 61|PTPS-S19A
P10531342A0348|43 46|kDa
P10531342A0348|115 149|promastigote surface glycoproteins
P10531342A0348|69 87|amino acid repeats
P10531360A0958|135 145|conditions
P10531360A0958|59 68|construct
P10531360A0958|17 26|infection
P10531360A0958|119 128|VEGF mRNA
P10532354A1374|95 107|accumulation
P10532354A1374|244 255|yeast cells
P10532354A1374|218 228|morphology
P10532354A1374|39 54|yeast homologue
P10532354A1374|139 147|blockage
P10532805A1084|105 111|agents
P10532805A1084|6 22|PC12 cell mutant
P10532805A1084|71 73|AB
P10533066A1197|46 49|PTT
P10533066A1197|8 16|patients
P10534402A0126|90 109|sequence similarity
P10534402A0126|43 53|mouse gene
P10534402A0126|140 148|proteins
P10534402A0126|33 36|DNA
P10534691A0542|29 34|weeks
P10534691A0542|112 119|culture
P10534691A0542|21 26|death
P10534691A0542|1 8|Animals
P10536125A0093|75 81|GS4071
P10536125A0093|106 115|inhibitor
P10536125A0093|1 12|Oseltamivir
P10536369A1280|14 24|importance
P10536369A1280|89 95|manner
P10540015A0664|44 56|ALS patients
P10540015A0664|156 157|%
P10540015A0664|69 77|controls
P10540553A0980|181 185|i.g.
P10540553A0980|11 20|synthesis
P10540553A0980|58 62|wall
P10540553A0980|191 197|growth
P10540553A0980|116 125|synthesis
P10540553A0980|35 40|cells
P10541432A0185|78 102|tyrosine phosphorylation
P10541432A0185|212 230|glioblastoma cells
P10541432A0185|18 31|erbB proteins
P10541432A0185|50 63|growth factor
P10541865A1301|23 35|co-deletions
P10541865A1301|100 111|transcripts
P10541865A1301|69 78|mutations
P10542249A0415|149 154|alpha
P10542249A0415|52 63|combination
P10542249A0415|112 116|CAAT
P10542249A0415|143 148|C/EBP
P10542269A0000|164 175|proteolysis
P10542269A0000|89 96|plaques
P10542269A0000|57 72|amyloid fibrils
P10542269A0000|110 117|vessels
P10542269A0000|23 28|Abeta
P10542269A0000|185 215|beta-amyloid precursor protein
P10542277A0000|5 19|importin alpha
P10542277A0000|54 60|import
P10542277A0000|102 122|localization signals
P10542281A2021|60 75|keratan sulfate
P10542281A2021|124 135|atrolysin C
P10542281A2021|112 120|activity
P10542281A2021|86 91|G1-G2
P10543727A0282|389 413|ATF recognition sequence
P10543727A0282|213 224|kappaB site
P10543727A0282|21 26|sites
P10543727A0282|359 369|HLA system
P10543727A0282|424 427|end
P10543727A0282|163 166|end
P10543727A0282|337 345|p65/relA
P10543727A0282|39 60|transcription factors
P10543730A0000|122 127|genes
P10543730A0000|108 118|repression
P10543730A0000|144 159|stress response
P10543730A0000|5 10|yeast
P10543730A0000|71 74|Cdk
P10544037A0617|94 98|FZD9
P10544037A0617|23 27|FZD9
P10544037A0617|86 90|FZD4
P10544037A0617|104 105|%
P10544037A0617|129 133|FZD9
P10544037A0617|1 5|FZD4
P10544089A1208|149 151|MP
P10544089A1208|177 184|MP-CP-3
P10544089A1208|144 148|IRES
P10544089A1208|53 59|sgRNAs
P10544089A1208|117 118|H
P10544089A1208|196 198|MP
P10544089A1208|173 175|CR
P10544089A1208|5 20|RNA transcripts
P10544089A1208|207 214|MP-CP-3
P10545192T0000|46 56|activation
P10545192T0000|76 83|MEK/ERK
P10545192T0000|64 73|ras/C-raf
P10545192T0000|1 42|Phosphatidylinositol 3-kinase requirement
P10545281A0836|149 169|protein accumulation
P10545281A0836|131 144|bop gene mRNA
P10545281A0836|5 12|example
P10548622A0906|224 228|pain
P10548622A0906|89 112|i.v. sedation/analgesia
P10548622A0906|43 53|lignocaine
P10548622A0906|236 245|procedure
P10548622A0906|170 175|route
P10549354A1782|150 159|mutations
P10549354A1782|242 245|APC
P10549354A1782|52 61|melanomas
P10549354A1782|17 20|APC
P10549354A1782|167 177|N terminus
P10549354A1782|97 102|Tcf-4
P10549354A1782|103 125|beta-catenin complexes
P10549912A0136|182 187|V1-V4
P10549912A0136|25 32|patient
P10549912A0136|266 277|angioplasty
P10549912A0136|203 207|loss
P10549912A0136|118 128|infarction
P10550571A0000|90 98|patients
P10550571A0000|124 133|compounds
P10550571A0000|190 196|thiols
P10550571A0000|19 26|WR-2721
P10550571A0000|139 143|none
P10551788A0229|89 106|trophoblast cells
P10551788A0229|1 7|LHbeta
P10551816A0162|45 50|forms
P10551867A0350|132 150|rat cDNA libraries
P10551867A0350|21 40|amino acid residues
P10552357A1936|151 155|OCTA
P10552357A1936|193 204|LV function
P10552357A1936|33 44|superiority
P10552357A1936|100 112|microspheres
P10552357A1936|139 147|efficacy
P10552357A1936|1 12|CONCLUSIONS
P10553959A0812|61 67|levels
P10553959A0812|5 20|Ishasha samples
P10555079A0254|1 3|Ti
P10555964A0778|5 8|Kim
P10556029A0852|45 56|topoisomers
P10556029A0852|98 113|interconversion
P10556029A0852|139 150|topoisomers
P10556044A0913|104 114|LG modules
P10556044A0913|32 59|alpha-dystroglycan receptor
P10556063A0092|31 40|subfamily
P10556063A0092|7 14|kinases
P10556145A1034|29 32|SVN
P10556145A1034|21 24|DPI
P10556145A1034|115 124|magnitude
P10556595A0391|60 61|G
P10556595A0391|67 68|T
P10556595A0391|39 48|recN gene
P10556595A0391|4 12|analysis
P10556595A0391|16 24|sequence
P10557008T0000|61 67|mother
P10557008T0000|27 33|Impila
P10557072A0418|121 127|domain
P10557072A0418|96 110|proline/serine
P10557072A0418|33 49|domain structure
P10557072A0418|117 119|PS
P10557072A0418|153 154|C
P10557308A0000|23 26|KSR
P10557308A0000|1 19|Connector enhancer
P10559303A0000|14 19|virus
P10559303A0000|53 57|LMP1
P10559303A0000|115 128|B lymphocytes
P10559324A0716|60 69|apoptosis
P10559324A0716|25 27|Ad
P10559324A0716|39 51|Ad5 E4orf6/7
P10560014A0000|148 158|myocardium
P10560014A0000|27 48|heart vascularization
P10561095A2141|41 48|disease
P10561095A2141|155 173|hypoparathyroidism
P10561095A2141|84 101|calcitonin levels
P10561251A0000|147 157|stage IIIB
P10561251A0000|213 229|modality therapy
P10561251A0000|250 262|chemotherapy
P10561251A0000|186 189|IBC
P10561251A0000|231 234|CMT
P10561251A0000|66 74|survival
P10561251A0000|136 141|women
P10561251A0000|171 184|breast cancer
P10561546A0000|161 182|NF-kappaB p65 subunit
P10561546A0000|138 157|localization signal
P10562456T0000|12 19|regions
P10562456T0000|27 35|promoter
P10562456T0000|98 110|Oncorhynchus
P10563212A0514|124 132|controls
P10563212A0514|55 58|QoL
P10563789A1951|31 51|F beta alpha/CG beta
P10563789A1951|99 112|FSH receptors
P10564231A0315|18 20|M.
P10564472A0853|47 58|TraR fusion
P10564472A0853|7 14|mutants
P10564479A0384|150 159|repressor
P10564479A0384|107 116|activator
P10564479A0384|124 132|presence
P10564479A0384|67 77|fds operon
P10564479A0384|1 9|Deletion
P10564495A0444|151 159|subgroup
P10564495A0444|94 98|cDNA
P10564495A0444|217 222|CD66d
P10564495A0444|167 178|CD66 family
P10564495A0444|228 231|NCA
P10564495A0444|129 136|antigen
P10564495A0444|66 76|HeLa cells
P10564495A0444|4 12|addition
P10564593A1618|183 203|MXR half-transporter
P10564593A1618|133 140|partner
P10564593A1618|229 243|drug transport
P10564593A1618|5 13|MXR gene
P10564593A1618|84 99|coamplification
P10566630A0371|135 141|months
P10566630A0371|93 98|women
P10566630A0371|20 35|growth factor I
P10566630A0371|85 88|men
P10567430A0785|146 152|Galpha
P10567430A0785|93 102|construct
P10567430A0785|54 58|q/11
P10567430A0785|221 225|GRK6
P10567430A0785|106 110|GRK2
P10567430A0785|41 53|brain Galpha
P10567430A0785|139 143|q/11
P10567533A0818|28 40|PCR products
P10567533A0818|131 147|tyrosine kinases
P10567533A0818|24 26|RT
P10567581A0119|241 257|hepatocyte entry
P10567581A0119|88 95|Trident
P10567581A0119|280 287|S phase
P10567581A0119|110 123|family member
P10567581A0119|263 278|DNA replication
P10567581A0119|100 103|Win
P10567589A1268|14 23|functions
P10567589A1268|77 85|proteins
P10568455A0000|45 74|slow-release estradiol-17beta
P10568455A0000|182 197|pseudopregnancy
P10568455A0000|95 110|pseudopregnancy
P10568455A0000|114 119|gilts
P10568455A0000|32 41|injection
P10568744A0728|160 169|direction
P10568744A0728|173 194|mating type switching
P10568744A0728|100 105|sites
P10570996A1213|151 159|TK class
P10570996A1213|56 65|sequences
P10570996A1213|163 172|receptors
P10570996A1213|112 119|domains
P10570996A1213|221 228|insulin
P10571474A0571|40 43|CA3
P10571474A0571|66 76|tianeptine
P10571474A0571|1 8|Results
P10572130A1623|166 178|DNA geometry
P10572130A1623|146 155|formation
P10572130A1623|33 57|transcription activators
P10572866A0481|88 95|protein
P10572866A0481|42 55|plasma values
P10572866A0481|101 127|aspartate aminotransferase
P10574913A1108|88 97|processes
P10574913A1108|198 212|ERK activation
P10574913A1108|39 63|receptor phosphorylation
P10574982A1075|105 114|complexes
P10574982A1075|72 77|USF-1
P10574982A1075|1 17|Supershift EMSAs
P10575231A0355|25 31|region
P10575231A0355|1 9|Analysis
P10575642T0000|33 46|iontophoresis
P10576545A0926|74 91|D1A gene promoter
P10576545A0926|146 156|transgenes
P10576545A0926|39 52|DNA cassettes
P10579331A1225|122 126|pSRE
P10579331A1225|131 135|dSRE
P10579331A1225|96 120|sterol response elements
P10579331A1225|204 208|gene
P10580071A0436|120 130|transplant
P10580071A0436|10 18|patients
P10582831T0000|56 69|complications
P10582831T0000|86 94|patients
P10584704A0913|90 96|HMB-45
P10584704A0913|47 52|S-100
P10584704A0913|132 143|cytokeratin
P10584704A0913|21 29|staining
P10584704A0913|153 158|cases
P10585311A1542|82 86|type
P10585311A1542|18 31|abnormalities
P10585311A1542|68 76|patients
P10585440A0204|121 131|chromosome
P10585440A0204|81 89|band 56D
P10585463A0859|13 33|prenylcysteine lyase
P10585480A0265|30 40|SH3 domain
P10585480A0265|1 16|Point mutations
P10585808A0000|70 77|methods
P10586107A0160|30 35|types
P10586107A0160|50 71|transduction pathways
P10586626A0607|91 99|presence
P10586626A0607|43 49|matter
P10586626A0607|153 157|ADEM
P10587461A0341|93 109|transition state
P10587461A0341|48 57|anticodon
P10587461A0341|19 28|mechanism
P10588946A0432|81 86|ORP-6
P10588946A0432|51 59|proteins
P10589711A1228|14 29|narZ expression
P10589711A1228|83 94|Madin-Darby
P10589711A1228|155 167|salts medium
P10590368X0000|123 133|BACKGROUND
P10590368X0000|56 68|hysterectomy
P10590368X0000|115 121|cervix
P10590368X0000|165 175|lymph node
P10590368X0000|73 81|patients
P10590368X0000|278 279|%
P10590368X0000|139 148|prognosis
P10591933A0798|91 96|angle
P10591933A0798|24 37|configuration
P10591933A0798|17 21|Type
P10591990A0178|45 56|in-patients
P10591990A0178|77 82|times
P10591990A0178|99 103|SANS
P10591990A0178|3 8|group
P10592791T0001|36 45|detection
P10592791T0001|1 11|Comparison
P10593939A0747|135 147|SR45 protein
P10593939A0747|190 195|SRZ22
P10593939A0747|207 213|family
P10593939A0747|51 74|interaction experiments
P10594130A0652|91 99|staining
P10594130A0652|71 78|degrees
P10594239T0000|60 69|Ipl/Tssc3
P10594239T0000|9 19|pleckstrin
P10594239T0000|37 48|gene family
P10594239T0000|71 77|TDAG51
P10595315A0344|29 36|effects
P10595315A0344|54 64|parameters
P10597222A1371|107 110|p21
P10597222A1371|65 79|HMBA signaling
P10597232A0000|145 163|thyroid carcinomas
P10597232A0000|55 59|ELE1
P10598101A0000|63 78|maize endosperm
P10598101A0000|20 40|bZIP protein Opaque2
P10598101A0000|87 95|proteins
P10598316A1534|12 15|HMB
P10598316A1534|42 52|substances
P10599727A1567|62 64|TS
P10599727A1567|129 134|peers
P10599727A1567|18 44|estrogen treatment regimen
P10600171A1432|94 98|USF1
P10600171A1432|22 30|activity
P10600171A1432|55 60|E-box
P10601290A0742|90 97|peptide
P10601290A0742|135 153|T cell recognition
P10601290A0742|229 234|class
P10601290A0742|162 165|I1Y
P10601290A0742|237 258|MHC-peptide complexes
P10601344A1653|120 131|IL2R-beta1A
P10601344A1653|208 213|Cdc42
P10601344A1653|191 195|Rac1
P10601344A1653|135 139|GE11
P10601344A1653|163 173|activation
P10601344A1653|4 12|addition
P10601344A1653|32 47|activity assays
P10601606A0152|61 73|WAG/Rij rats
P10601606A0152|47 52|flank
P10601606A0152|5 25|rhabdomyosarcoma R1H
P10602507A0652|105 113|activity
P10602507A0652|133 136|p53
P10602507A0652|179 182|p21
P10602507A0652|219 233|p53 expression
P10602507A0652|117 131|cyclin D1/cdk4
P10602838A0127|45 50|males
P10602838A0127|9 14|study
P10604246A0523|29 34|study
P10604246A0523|213 215|V4
P10604246A0523|18 25|METHODS
P10604246A0523|109 117|AutoPBSC
P10604246A0523|229 244|cell tubing set
P10604246A0523|128 129|V
P10604246A0523|97 103|device
P10604246A0523|272 278|donors
P10604246A0523|1 13|STUDY DESIGN
P10604945A0731|57 66|Sp1 sites
P10604945A0731|231 247|ethanol response
P10604945A0731|143 155|organization
P10604945A0731|17 36|promoter constructs
P10606272A1241|92 100|SF1 gene
P10606272A1241|39 49|C. elegans
P10606272A1241|71 80|lethality
P10606664A0000|27 38|zinc finger
P10606664A0000|55 65|regulators
P10606664A0000|1 22|Snail family proteins
P10607899A0605|120 130|half sites
P10607899A0605|76 100|consensus binding motifs
P10607899A0605|52 60|TATA box
P10607899A0605|1 18|Sequence analysis
P10608053A0923|122 128|groups
P10608053A0923|176 181|Group
P10608053A0923|83 89|values
P10608053A0923|192 210|001versus baseline
P10608053A0923|40 48|increase
P10608053A0923|141 146|IU/ml
P10610716A1127|47 52|R254G
P10610716A1127|94 101|AC gene
P10610716A1127|58 63|P362R
P10611228A1388|79 85|assays
P10611228A1388|5 13|DAP5/p86
P10611242A0541|74 87|HIS3 promoter
P10611242A0541|41 45|SAGA
P10611242A0541|22 29|finding
P10611242A0541|117 121|Spt3
P10611353A0458|27 53|transcription-PCR analyses
P10611353A0458|93 96|RNR
P10611353A0458|197 199|kb
P10611353A0458|175 177|kb
P10611353A0458|1 14|Northern blot
P10612505A1317|95 112|group differences
P10612505A1317|83 84|%
P10612505A1317|116 132|treatment effect
P10612505A1317|50 55|power
P10612805A0716|59 66|cancers
P10613816X0000|164 171|effects
P10613816X0000|212 222|treatments
P10613816X0000|114 119|study
P10613816X0000|98 103|drugs
P10613816X0000|1 8|Statins
P10613816X0000|50 57|statins
P10613863T0000|134 147|pfoA promoter
P10613863T0000|34 57|Clostridium perfringens
P10614676A0000|75 83|bleeding
P10614676A0000|181 206|mg norethisterone acetate
P10614676A0000|225 252|hormone replacement therapy
P10614676A0000|162 174|mg estradiol
P10614676A0000|54 63|incidence
P10614676A0000|102 107|women
P10616948A0998|8 20|BF ECT group
P10617144A0386|45 50|Ser64
P10617144A0386|93 98|sites
P10617144A0386|16 31|phosphorylation
P10617613A1192|1 5|Chem
P10619062T0000|1 28|Haycocknema perplexum n. g.
P10619254A1055|99 112|image quality
P10620010A1155|60 84|tyrosine phosphorylation
P10620010A1155|106 116|activation
P10620010A1155|159 168|threonine
P10620010A1155|200 210|activation
P10620010A1155|1 11|CONCLUSION
P10620777A1399|1 9|AB004534
P10622576A0552|89 99|prevention
P10622576A0552|27 38|information
P10622576A0552|80 85|means
P10623804A0808|105 110|SHP-1
P10623804A0808|66 73|effects
P10623804A0808|115 120|SHP-2
P10623804A0808|154 178|Fc gamma RIIB1 signaling
P10625438A1429|30 41|transcripts
P10625438A1429|160 166|insert
P10625438A1429|8 15|tissues
P10625438A1429|55 61|insert
P10625438A1429|87 93|repeat
P10625683A0091|164 173|receptors
P10625683A0091|24 48|protein tyrosine kinases
P10625683A0091|114 121|process
P10625683A0091|101 110|molecules
P10627518A0544|135 139|UTRs
P10627518A0544|92 95|sum
P10627518A0544|17 23|effect
P10627834A0178|180 187|Stanley
P10627834A0178|116 138|New Zealand selections
P10627834A0178|19 28|cultivars
P10627834A0178|74 83|cultivars
P10627834A0178|161 167|Meyric
P10627834A0178|5 7|US
P10627834A0178|169 178|McKinster
P10628748A0344|10 20|activation
P10628748A0344|116 123|actions
P10628750A0298|164 173|NF-kappaB
P10628750A0298|183 186|Rel
P10628750A0298|52 79|tumor necrosis factor-alpha
P10628750A0298|81 89|TNFalpha
P10628750A0298|103 111|enhancer
P10628755A0000|11 18|ligands
P10628755A0000|156 161|GHS-R
P10628971A1165|121 128|product
P10628971A1165|93 102|following
P10628971A1165|249 273|microtubule organization
P10628971A1165|50 57|defects
P10628971A1165|13 21|spectrum
P10628971A1165|315 351|inositol polyphosphate 5-phosphatase
P10628971A1165|38 41|TGN
P10628971A1165|237 244|vacuole
P10629176A0887|14 20|CaMig1
P10629176A0887|56 67|URS1 region
P10629176A0887|4 12|addition
P10630471T0000|31 45|depth analysis
P10633075A1111|75 94|N-acetylglucosamine
P10633075A1111|26 39|Fab fragments
P10633075A1111|102 108|effect
P10634007A0202|135 149|drug clearance
P10634007A0202|95 98|NAC
P10634007A0202|113 125|intoxication
P10637149A0806|44 46|CC
P10637149A0806|40 42|RD
P10637149A0806|101 104|REF
P10637149A0806|139 142|A-A
P10637238A0291|78 86|question
P10638607A0000|151 161|esophageal
P10638607A0000|7 15|articles
P10638607A0000|142 149|N0-1 M0
P10638607A0000|206 220|adenocarcinoma
P10638607A0000|84 90|trials
P10638607A0000|171 185|cell carcinoma
P10640683A0204|122 134|NDRF/NeuroD2
P10640683A0204|96 117|expression constructs
P10640683A0204|139 142|PKN
P10640701T0000|105 115|expression
P10640701T0000|22 27|sites
P10641037A1371|1 9|AF154055
P10642524A0156|43 48|hsp70
P10642524A0156|53 58|hsp90
P10642524A0156|115 139|tetratricopeptide repeat
P10642524A0156|32 37|mSTI1
P10642889A0393|47 53|region
P10642889A0393|70 79|ATG codon
P10644357A0935|28 31|VP1
P10644357A0935|7 14|results
P10644357A0935|116 123|regions
P10644753A0725|44 68|antibody affinity column
P10644753A0725|92 107|heparan sulfate
P10644753A0725|81 88|sulfate
P10644760A0956|62 79|activation domain
P10644760A0956|97 114|repression domain
P10644760A0956|35 39|Arix
P10645921A1320|14 24|predictors
P10645921A1320|41 51|remodeling
P10645921A1320|99 116|ejection fraction
P10645921A1320|201 211|odds ratio
P10645921A1320|171 189|circumflex disease
P10646863A0838|73 83|expression
P10646863A0838|19 25|ICBP90
P10647633A1685|134 139|colon
P10647633A1685|24 32|presence
P10647633A1685|67 70|RSJ
P10647633A1685|99 106|passage
P10647859A0000|303 308|Pappl
P10647859A0000|183 191|subjects
P10647859A0000|247 256|breathing
P10647859A0000|396 399|CO2
P10647859A0000|293 301|pressure
P10647859A0000|258 260|QB
P10647859A0000|224 229|rates
P10647859A0000|77 97|pressure ventilation
P10647859A0000|39 45|effect
P10647859A0000|342 352|hypocapnia
P10648211A0000|61 69|quantity
P10648211A0000|89 101|ion channels
P10648619A0000|151 164|silkworm tRNA
P10648619A0000|210 214|lack
P10648619A0000|260 277|promoter activity
P10648619A0000|226 247|interactions accounts
P10648619A0000|317 321|gene
P10648619A0000|312 315|Ala
P10648619A0000|173 177|gene
P10648619A0000|64 71|protein
P10648619A0000|103 120|promoter activity
P10649456A1061|90 99|EUROSCARF
P10649456A1061|5 11|clones
P10649456A1061|16 23|strains
P10650104X0284|20 33|Royal College
P10650939A0789|73 77|AP-1
P10650939A0789|43 48|A-Fos
P10650958A1315|106 115|complexes
P10650958A1315|57 80|consensus c-myb element
P10650958A1315|143 148|c-myb
P10651805A1600|167 191|acid growth requirements
P10651805A1600|228 240|methotrexate
P10651805A1600|213 224|sensitivity
P10651805A1600|53 65|carrier cDNA
P10652093A0139|63 74|A118 genome
P10652093A0139|160 173|DNA molecules
P10652093A0139|1 9|Electron
P10652228A0759|90 98|proteins
P10652228A0759|29 34|c-Jun
P10652228A0759|67 77|Rho family
P10652362A0933|91 113|internalization signal
P10652362A0933|193 198|entry
P10652362A0933|202 206|CFTR
P10652362A0933|17 21|data
P10653359A1297|27 31|mice
P10653550A1120|108 116|meniscus
P10653550A1120|71 77|region
P10653550A1120|1 21|Hyaluronan treatment
P10653693A0903|66 81|oligomerization
P10653693A0903|174 183|functions
P10653693A0903|100 112|KRAB binding
P10653693A0903|136 143|domains
P10653733A0596|10 17|domains
P10655164A0546|135 140|parl0
P10655164A0546|166 167|p
P10655164A0546|182 188|x10-10
P10655164A0546|160 165|parr0
P10655164A0546|154 155|H
P10656154A0722|24 32|criteria
P10656154A0722|6 11|women
P10656802A1724|14 23|insertion
P10656802A1724|114 118|site
P10657658A0165|124 129|kappa
P10657658A0165|111 122|degradation
P10657658A0165|200 208|NF-kappa
P10657658A0165|139 163|reporter gene expression
P10657658A0165|221 227|manner
P10658425A1567|26 35|infection
P10658425A1567|5 10|level
P10658588A0304|162 183|Plasmodium falciparum
P10658588A0304|113 115|CQ
P10658588A0304|1 29|Desmethylferrochloroquine 1a
P10658588A0304|137 144|strains
P10660304A0522|78 83|STAT3
P10660304A0522|59 74|phosphorylation
P10660304A0522|101 115|CNTF signaling
P10660304A0522|1 8|Members
P10660304A0522|153 168|phosphorylation
P10660304A0522|34 50|tyrosine kinases
P10660676A0000|113 124|mouse Nodal
P10660676A0000|48 66|Growth Factor beta
P10660676A0000|68 75|TGFbeta
P10662614A0000|76 80|WSMV
P10662614A0000|189 215|amino acid dissimilarities
P10662614A0000|49 74|wheat streak mosaic virus
P10662614A0000|237 249|polyproteins
P10663558T0000|93 97|mice
P10663558T0000|20 32|light chains
P10665308T0001|15 28|tachyphylaxis
P10665308T0001|41 51|anesthesia
P10665949A1131|90 97|feedlot
P10665949A1131|41 51|importance
P10666238A1322|72 79|protein
P10666238A1322|11 20|induction
P10666238A1322|43 57|E2F-1 promoter
P10666238A1322|114 129|transactivation
P10666509A0494|79 97|propranolol groups
P10668701A1311|13 21|Presence
P10668701A1311|72 80|dementia
P10668701A1311|25 38|APOE epsilon4
P10668701A1311|136 149|atherogenesis
P10668701A1311|119 131|dyslipidemia
P10669594A0000|182 221|16-amino acid Leishmania T-cell epitope
P10669594A0000|78 92|fimbriae SEF17
P10669594A0000|97 102|SEF14
P10669594A0000|239 259|metalloprotease gp63
P10669596A0430|88 96|presence
P10669596A0430|208 214|change
P10669596A0430|22 31|phage P22
P10669596A0430|141 146|level
P10669596A0430|222 228|nature
P10669736A0903|75 85|HeLa cells
P10669736A0903|22 32|difference
P10669736A0903|119 128|abundance
P10670358A0143|1 12|Dermatology
P10671224A0254|58 67|mechanism
P10671520T0000|60 67|protein
P10671520T0000|11 18|cloning
P10671520T0000|101 127|T-cell leukemia virus type
P10671606A0884|124 127|APA
P10671606A0884|6 28|chemical shift imaging
P10671606A0884|155 163|patients
P10671606A0884|34 50|signal intensity
P10672899A0078|1 5|Acad
P10673426A0168|14 15|R
P10673426A0168|93 94|T
P10673426A0168|232 244|cytotoxicity
P10673426A0168|173 179|domain
P10673426A0168|17 23|domain
P10674484A0633|74 81|neurons
P10674484A0633|89 98|rat brain
P10674484A0633|157 163|memory
P10675331A0600|14 19|c-Src
P10675331A0600|125 149|tyrosine phosphorylation
P10675331A0600|54 78|tyrosine phosphorylation
P10675331A0600|33 46|isoproterenol
P10675331A0600|153 162|cortactin
P10677214A1045|28 32|E53D
P10677214A1045|242 248|values
P10677214A1045|147 151|hump
P10677214A1045|387 394|dGTP-Mg
P10677214A1045|190 192|pH
P10677214A1045|51 56|plots
P10677214A1045|131 135|limb
P10677214A1045|37 49|E44D mutants
P10677214A1045|64 65|k
P10677214A1045|375 382|MutT-Mg
P10677297A0933|151 158|protein
P10677297A0933|72 90|missense mutations
P10677297A0933|59 67|nonsense
P10678968A1096|74 80|summer
P10678968A1096|56 64|activity
P10678968A1096|22 26|mice
P10678968A1096|1 9|Immunity
P10678968A1096|221 227|season
P10678968A1096|119 135|mouse population
P10679065A0711|240 251|CREB serine
P10679065A0711|131 139|p38 MAPK
P10679065A0711|86 92|enzyme
P10679065A0711|256 277|phosphoacceptor motif
P10679190A0693|120 133|reading frame
P10679190A0693|135 139|mORF
P10679190A0693|79 90|translation
P10679781A1183|107 121|dibutyryl-cAMP
P10679781A1183|7 38|bp Glucocorticoid Response Unit
P10679781A1183|137 151|phorbol esters
P10681520A0525|94 106|GEF activity
P10681520A0525|37 42|v-Src
P10681520A0525|184 194|Gbetagamma
P10681588A0899a|151 156|CCAAT
P10681588A0899a|208 215|C6 cell
P10681588A0899a|26 34|proteins
P10681588A0899a|59 69|Rat2 cells
P10681588A0899a|118 138|transcription factor
P10681588A0899a|224 232|extracts
P10681588A0899a|199 203|PC12
P10681588A0899a|174 186|protein beta
P10681588A0899a|1 5|EMSA
P10681679A0220|9 19|resolution
P10681679A0220|55 65|serial MRI
P10681679A0220|33 40|portion
P10681679A0220|136 145|diagnosis
P10683072T0000|23 34|tachycardia
P10683072T0000|54 65|prophylaxis
P10683244A1860|268 283|phosphorylation
P10683244A1860|79 90|NBF2 domain
P10683244A1860|129 134|units
P10683244A1860|21 32|experiments
P10683244A1860|50 54|CFTR
P10683259A0774|134 140|biotin
P10683259A0774|209 218|cysteines
P10683259A0774|27 40|iodoacetamide
P10683259A0774|230 246|splice junctions
P10683259A0774|189 191|pK
P10683259A0774|1 21|Sulfhydryl titration
P10684069A0508|134 150|methylphenidatum
P10684069A0508|57 75|minute ventilation
P10684069A0508|25 28|MIP
P10684069A0508|5 12|results
P10684069A0508|116 130|administration
P10684111A1411|31 38|variety
P10684111A1411|109 128|MAPK family members
P10684111A1411|97 105|MAPK p42
P10684534A0634|15 28|heparin doses
P10684534A0634|41 51|Sigma-dose
P10684534A0634|83 88|doses
P10684660A1266|41 58|processing enzyme
P10684660A1266|33 37|tRNA
P10684660A1266|1 11|Comparison
P10684660A1266|68 73|plant
P10684967A0000|147 161|thyroid tissue
P10684967A0000|64 85|transcription factors
P10684967A0000|101 111|disruption
P10684967A0000|136 143|absence
P10687855A1197|105 109|role
P10687855A1197|123 134|development
P10687855A1197|156 171|differentiation
P10687855A1197|1 11|Expression
P10687862A1980|56 62|CI/CII
P10687862A1980|98 115|promoter activity
P10688639A1310|6 16|repression
P10688639A1310|101 116|p300 expression
P10688660A0992|56 64|extracts
P10688660A0992|199 202|PRE
P10688660A0992|99 111|progesterone
P10688660A0992|16 24|addition
P10688663A0207|164 170|TFIIIA
P10688663A0207|76 87|acetylation
P10688663A0207|219 222|DNA
P10688663A0207|1 8|Removal
P10690702A0065|61 75|electromyogram
P10690702A0065|95 104|diagnosis
P10690702A0065|1 8|OUTCOME
P10690866A0783|92 100|neonates
P10690866A0783|80 87|mothers
P10692167A0364|75 86|M. synoviae
P10692167A0364|17 26|mechanism
P10692433A0000|57 58|G
P10692433A0000|65 83|S phase transition
P10693314A0521|30 43|CK-MB results
P10693314A0521|106 107|%
P10693314A0521|93 96|AMI
P10693314A0521|80 83|ECG
P10694210A0385|14 22|blockade
P10694210A0385|209 210|%
P10694210A0385|26 29|H1R
P10694210A0385|214 217|H1R
P10694210A0385|233 241|cortices
P10694605A1327|130 132|NS
P10694605A1327|37 60|events/100 patient-days
P10694605A1327|20 35|infection rates
P10695685T0000|13 20|therapy
P10695685T0000|83 95|consequences
P10698516T0000|82 98|SAPK/JNK pathway
P10698516T0000|19 25|kinase
P10698974A0951|284 292|syndrome
P10698974A0951|26 36|STAG3 gene
P10698974A0951|59 69|chromosome
P10698974A0951|158 162|gene
P10698974A0951|49 55|region
P10699653A0967|144 151|sucrose
P10699653A0967|4 14|experiment
P10699653A0967|81 90|tap water
P10699653A0967|154 155|%
P10699653A0967|136 137|%
P10699896A0455|42 48|gender
P10699896A0455|1 8|RESULTS
P10701534A0164|91 102|head trauma
P10701534A0164|128 131|age
P10701534A0164|38 58|low-frequency tremor
P10702253A0357|120 131|cDNA clones
P10702253A0357|166 174|splicing
P10702253A0357|182 197|HIF-1alpha gene
P10702389A1148|60 65|cases
P10702389A1148|104 113|cytoplasm
P10702389A1148|20 33|RB2/p130 gene
P10702926T0089|54 81|alpha beta T cell receptors
P10704196A1051|92 107|plasma membrane
P10704196A1051|20 37|sulfhydryl groups
P10704196A1051|174 181|helices
P10704285A0536|30 49|reporter expression
P10704285A0536|7 14|AP-2rep
P10704285A0536|119 133|AP-2alpha gene
P10704410T0000|1 18|Clb/Cdc28 kinases
P10704853T0000|88 104|dorsal organizer
P10704853T0000|22 36|Bozozok/Dharma
P10704853T0000|71 80|formation
P10705380A0629|105 112|regions
P10705380A0629|41 60|Xretpos transcripts
P10705380A0629|128 142|UV-irradiation
P10706475A0644|63 66|DPP
P10706475A0644|34 38|DSPP
P10706688A0376|109 116|fashion
P10706688A0376|58 62|site
P10706688A0376|81 103|fasl promoter function
P10706887A0281|22 27|ALCLs
P10706887A0281|139 153|ALK expression
P10706887A0281|102 115|abnormalities
P10708243A0000|79 93|pregnancy loss
P10708243A0000|116 120|role
P10708243A0000|51 61|antibodies
P10708769A0433|72 79|element
P10708769A0433|5 9|Mif1
P10708769A0433|51 53|ER
P10710499A0000|97 112|edema formation
P10710499A0000|1 13|Methysergide
P10710985T0000|61 82|strengths perspective
P10710985T0000|9 17|families
P10712512A0506|56 63|absence
P10712512A0506|82 95|thioacylation
P10712618A0181|15 34|sequence comparison
P10712618A0181|49 74|Bacillus YM55-1 aspartase
P10712618A0181|84 94|% homology
P10713083A0560|60 71|DNA binding
P10713083A0560|88 101|TraR function
P10713083A0560|26 31|assay
P10713161A0985|151 157|mutant
P10713161A0985|108 131|Smt3-protein conjugates
P10713161A0985|1 13|Inactivation
P10713161A0985|51 53|ts
P10713176A0422|165 172|control
P10713176A0422|227 245|E2F-p107 complexes
P10713176A0422|129 133|p130
P10713176A0422|197 199|Rb
P10713176A0422|70 81|conjunction
P10713176A0422|119 123|p107
P10713239A0988|93 102|IOL optic
P10713239A0988|50 67|capsulorhexis rim
P10714985A1057|127 149|leader RNA association
P10714985A1057|4 28|RNA boundary experiments
P10714985A1057|50 59|structure
P10715325A0834|135 142|drought
P10715325A0834|148 169|ETHYLENE-INSENSITIVE2
P10715325A0834|5 16|AtERF genes
P10715325A0834|50 58|ethylene
P10717612A0000|91 99|regimens
P10717612A0000|56 70|response rates
P10717612A0000|261 275|cell carcinoma
P10717612A0000|17 20|aim
P10717612A0000|161 167|GM-CSF
P10717612A0000|172 183|combination
P10717612A0000|204 208|IL-2
P10721698A1195|123 131|function
P10721698A1195|43 59|dodecamer repeat
P10721698A1195|96 100|CSTB
P10721698A1195|185 189|CSTB
P10721698A1195|84 92|promoter
P10721704X0000|31 43|mouse Elavl1
P10721704X0000|20 23|end
P10721704X0000|156 162|Elavl1
P10721704X0000|194 200|family
P10721704X0000|45 49|mHuA
P10721704X0000|231 239|proteins
P10721704X0000|204 209|genes
P10721704X0000|1 9|Analysis
P10721717A0676|28 34|degree
P10721717A0676|83 102|amino acid residues
P10721717A0676|1 5|Fgd3
P10722063A0328|149 154|phase
P10722063A0328|176 178|nm
P10722063A0328|159 168|detection
P10722063A0328|71 78|mixture
P10722661A0146|40 57|sequence identity
P10722661A0146|23 30|protein
P10722661A0146|1 5|CYC2
P10722737A1726|135 138|Sp1
P10722737A1726|160 170|regulation
P10722737A1726|178 181|LTC
P10722737A1726|80 90|regulation
P10722737A1726|184 190|S gene
P10723723A0781|125 129|exon
P10723723A0781|116 118|bp
P10724436A0085|37 56|reference materials
P10724436A0085|84 90|system
P10724519A1185|78 86|elements
P10725382A0398|131 135|SOS2
P10725382A0398|1 18|Sequence analyses
P10725382A0398|34 41|alleles
P10727247A0461|128 137|TEF-1beta
P10727247A0461|82 98|characterization
P10727247A0461|142 152|TEF-1gamma
P10727426A1280|24 29|PfPK6
P10727426A1280|69 79|olomoucine
P10727433A0560|91 109|signalling pathway
P10727433A0560|73 83|activation
P10727433A0560|123 130|Ets/AP1
P10727433A0560|21 46|CSF-1R expression plasmid
P10727433A0560|1 13|Transfection
P10727433A0560|220 226|target
P10727511A0294|62 71|induction
P10727511A0294|146 156|regulation
P10727511A0294|1 9|Molecule
P10728945A0233|26 36|Integrilin
P10728945A0233|83 96|Thrombosis-II
P10728945A0233|49 69|Platelet Aggregation
P10729151A1160|6 14|mutation
P10729151A1160|84 103|reporter expression
P10729220A0000|122 127|mouse
P10729220A0000|20 24|IGF2
P10729221A0798|23 42|expression patterns
P10729221A0798|81 100|subtype specificity
P10730763A1491|192 199|studies
P10730763A1491|79 90|development
P10730763A1491|96 109|research tool
P10731926A0775|123 132|dysplasia
P10731926A0775|59 61|mm
P10731926A0775|83 87|size
P10731926A0775|1 17|Advanced adenoma
P10732669A1336|105 113|proteins
P10732669A1336|193 201|proteins
P10732669A1336|144 154|homodimers
P10732669A1336|117 125|families
P10732669A1336|50 71|mobility shift assays
P10733581A1391|26 36|expression
P10733581A1391|71 81|V12N38 Ras
P10733591A0533|150 165|plasma membrane
P10733591A0533|46 59|translocation
P10733591A0533|177 186|cytoplasm
P10733591A0533|82 89|nucleus
P10733591A0533|99 106|cytosol
P10734312A0503|181 191|C-terminus
P10734312A0503|142 173|Ras membrane localization motif
P10734312A0503|115 126|Shc chimera
P10735848A1440|37 46|regulator
P10735848A1440|50 69|tol-oprL expression
P10736223A1227|56 60|prgX
P10736223A1227|131 144|transcription
P10736223A1227|39 52|transcription
P10736223A1227|207 221|mRNA stability
P10738139A0681|28 36|cytokine
P10738139A0681|41 72|cytokine response pathway genes
P10739671A0136|208 221|fibroblast WI
P10739671A0136|189 200|leukemia HL
P10739671A0136|113 125|c-myb intron
P10739671A0136|359 366|factors
P10739671A0136|167 175|extracts
P10739671A0136|315 328|binding sites
P10739671A0136|337 347|interferon
P10739671A0136|4 41|electrophoresis mobility shift assays
P10741850A0452|198 206|exposure
P10741850A0452|162 176|gene induction
P10741850A0452|33 38|EpREs
P10741850A0452|1 31|Electrophile Response Elements
P10742114A0486|58 60|pu
P10742114A0486|38 43|mouse
P10742114A0486|118 131|SD phenotypes
P10743608A1154|194 200|manner
P10743608A1154|268 280|microtubules
P10743608A1154|59 66|TbRAB31
P10743608A1154|98 107|structure
P10743608A1154|138 145|mitosis
P10743608A1154|1 18|TbRAB31 behaviour
P10744026A0000|73 80|glucose
P10744026A0000|49 56|sucrose
P10744749T0000|90 103|transcription
P10744749T0000|40 50|virus type
P10744749T0000|138 148|KIX domain
P10745563A0409|151 159|capacity
P10745563A0409|198 213|neo-endothelium
P10745563A0409|117 128|gold stents
P10747099A0507|63 71|coupling
P10747099A0507|145 148|Crk
P10747099A0507|25 31|kinase
P10747099A0507|220 225|cells
P10747099A0507|79 100|adaptor proteins p130
P10747099A0507|173 181|pathways
P10747099A0507|33 36|ERK
P10747879A0607|106 113|domains
P10747879A0607|42 48|region
P10747879A0607|5 14|evolution
P10747987A0658|17 24|enzymes
P10748113A0187|46 50|RIM2
P10748113A0187|81 85|RIM1
P10748164A1284|194 201|factors
P10748164A1284|62 71|induction
P10748164A1284|163 169|probes
P10748164A1284|1 19|Scanning mutations
P10748194T0000|10 19|targeting
P10748194T0000|92 110|trafficking signal
P10748672A0130|111 118|failure
P10748672A0130|33 45|Vipera aspis
P10748672A0130|50 62|Vipera berus
P10749166A0991|172 180|bacteria
P10749166A0991|86 97|arrangement
P10749166A0991|136 147|B. henselae
P10749932A0000|21 37|adaptor molecule
P10750021A0728|134 136|P2
P10750021A0728|26 63|deletion promoter-reporter constructs
P10750021A0728|97 99|P2
P10751398A1135|82 86|CD40
P10751398A1135|18 31|transcription
P10751398A1135|35 50|c-IAP2 promoter
P10752475A1376|240 244|goat
P10752475A1376|360 366|trials
P10752475A1376|261 271|antibodies
P10752475A1376|251 259|mouse Ig
P10752475A1376|186 194|presence
P10752475A1376|7 14|studies
P10752475A1376|168 178|antibodies
P10752475A1376|304 321|tumor regressions
P10753553T0000|55 64|lidocaine
P10753553T0000|68 72|mice
P10756007A0575|65 74|locations
P10756020A0571|109 116|virions
P10756020A0571|76 85|membranes
P10756020A0571|5 12|protein
P10756094A0671|47 49|Mb
P10756094A0671|3 8|total
P10756094A0671|16 20|STSs
P10756225A1464|30 38|patients
P10756225A1464|92 99|surgery
P10756225A1464|67 70|CRS
P10756225A1464|159 168|IL-5 mRNA
P10756225A1464|1 11|CONCLUSION
P10757983A0733|167 186|zinc finger protein
P10757983A0733|77 91|identification
P10757983A0733|97 116|zinc finger protein
P10757983A0733|118 128|Adx factor
P10758489A0206|105 108|CDK
P10758489A0206|127 134|Cdc2bAt
P10758489A0206|36 40|ICK2
P10759693A0201|264 269|users
P10759693A0201|296 305|phenytoin
P10759693A0201|216 233|agents ranitidine
P10759693A0201|73 77|risk
P10759693A0201|160 170|antagonist
P10759693A0201|172 182|cimetidine
P10759693A0201|39 41|OR
P10759693A0201|1 8|METHODS
P10759693A0201|137 140|use
P10760132A1169|73 78|level
P10760132A1169|5 9|data
P10760950A1133|12 28|staining pattern
P10760950A1133|112 131|actin stress fibers
P10762254A0954|78 104|MMA methyltransferase gene
P10762254A0954|129 132|DMA
P10762254A0954|191 202|amber codon
P10762254A0954|50 58|homologs
P10763823A0824|75 87|transfection
P10763823A0824|124 134|cell death
P10763823A0824|93 98|mcl-1
P10763823A0824|1 15|Overexpression
P10764150A0000|132 144|FDC-P1 cells
P10764150A0000|9 14|study
P10764150A0000|81 92|Raf kinases
P10764729A1846|78 80|TM
P10764729A1846|70 77|GenBank
P10764802A1258|225 233|activity
P10764802A1258|300 315|differentiation
P10764802A1258|52 56|Kip2
P10764802A1258|38 44|domain
P10764802A1258|252 256|Kip2
P10764802A1258|85 101|Cip/Kip proteins
P10765095A0308|226 231|tests
P10765095A0308|124 132|response
P10765095A0308|67 91|prostate cancer patients
P10765095A0308|39 52|PRL secretion
P10765095A0308|136 142|L-Dopa
P10766493T0000|56 63|harmony
P10766493T0000|1 14|Recombination
P10767091A0133|224 234|techniques
P10767091A0133|88 100|difficulties
P10767091A0133|148 170|inter-user variability
P10767091A0133|140 146|nature
P10767338T0000|15 22|disease
P10767338T0000|36 45|mutations
P10767338T0000|49 55|ATP2C1
P10767560A0105|150 175|mouse Pkr promoter region
P10767560A0105|203 216|transcription
P10767560A0105|35 51|characterization
P10770041A0731|77 89|kidney width
P10770041A0731|114 118|size
P10770041A0731|1 14|Kidney length
P10770471T0000|1 12|Benztropine
P10771709A0291|124 131|Q fever
P10771709A0291|158 176|IgG antibody titer
P10771709A0291|19 25|charge
P10771709A0291|47 55|evidence
P10771709A0291|143 150|disease
P10771709A0291|65 72|Q fever
P10771709A0291|33 41|patients
P10772977A0222|20 28|movement
P10773455A1268|44 49|sites
P10773455A1268|316 321|ALAS2
P10773455A1268|297 308|specificity
P10773455A1268|114 116|bp
P10773455A1268|338 348|activation
P10773455A1268|236 245|MEL cells
P10773667A0351|24 38|HMG20 proteins
P10773667A0351|5 15|HMG domain
P10775038A0142|29 44|Wee1 regulation
P10775038A0142|125 132|protein
P10775038A0142|52 62|cell cycle
P10775038A0142|81 90|screening
P10775585A0754|123 139|signaling events
P10775585A0754|54 67|NIH 3T3 cells
P10775585A0754|206 220|kinase pathway
P10775585A0754|103 111|capacity
P10777217A0536|166 179|PIG3 promoter
P10777217A0536|110 117|p73beta
P10777217A0536|5 24|p53-homolog p73beta
P10777217A0536|119 127|residues
P10777586A1022|28 55|DNA affinity chromatography
P10777586A1022|67 70|Sp1
P10777586A1022|157 164|complex
P10777586A1022|237 244|extract
P10777586A1022|171 179|mobility
P10778740A1493|192 197|locus
P10778740A1493|175 179|HIS3
P10778740A1493|16 32|Cdk2 truncations
P10778740A1493|119 124|pho85
P10779313A1842|122 135|GIRK channels
P10779313A1842|142 149|pathway
P10779313A1842|217 219|AR
P10779313A1842|34 42|myocytes
P10779352T0000|27 39|E2F3 product
P10779352T0000|92 102|repression
P10779352T0000|51 60|mechanism
P10779508A0897|20 31|coactivator
P10779508A0897|100 108|activity
P10780018A0539|59 72|response time
P10780018A0539|34 41|effects
P10780764A0722|12 18|levels
P10780764A0722|78 82|PM10
P10780764A0722|22 31|particles
P10780764A0722|140 145|range
P10780764A0722|117 122|range
P10781109T0000|71 91|Arabidopsis thaliana
P10781541A1063|60 66|region
P10781541A1063|198 207|promoters
P10781541A1063|131 140|sequences
P10781541A1063|173 186|transcription
P10781604A0827|150 155|yeast
P10781604A0827|26 34|peptides
P10781604A0827|108 122|Rsp5 WW domain
P10781604A0827|4 12|analysis
P10781990A0455|43 46|day
P10781990A0455|86 106|hyperintense lesions
P10782989A0575|79 97|DNA binding domain
P10782989A0575|5 16|interaction
P10782989A0575|138 156|DNA binding domain
P10784393A0000|47 55|patients
P10784393A0000|29 43|characteristic
P10784393A0000|77 85|syndrome
P10784393A0000|1 17|Marrow dysplasia
P10785668A0000|61 70|pathogens
P10785668A0000|161 171|biologists
P10785668A0000|110 117|subject
P10785668A0000|97 102|field
P10785668A0000|5 11|plants
P10786671A0182|107 113|enzyme
P10786671A0182|92 99|subunit
P10786671A0182|155 168|transcriptase
P10786671A0182|136 146|telomerase
P10787437A1616|14 21|element
P10787437A1616|38 62|transcription start site
P10788320A1034|227 236|particles
P10788320A1034|27 39|TPR elements
P10788320A1034|7 15|proteins
P10788320A1034|184 186|U5
P10788480T0000|57 86|protein gene expression links
P10788480T0000|1 11|Regulation
P10791251A0110|91 97|humans
P10791251A0110|42 48|things
P10791901A0609|144 145|%
P10791901A0609|36 50|cell line K562
P10791901A0609|278 287|etoposide
P10791901A0609|1 13|Transduction
P10792718T0000|89 98|regulator
P10792718T0000|22 36|AfsA homologue
P10792718T0000|139 165|virginiamycin biosynthesis
P10792718T0000|170 197|virginiamycin M1 resistance
P10793991A0569|110 122|telemedicine
P10793991A0569|20 29|longevity
P10793991A0569|100 106|trends
P10794936A0241|88 89|%
P10794936A0241|287 299|mycobacteria
P10794936A0241|131 145|recovery rates
P10794936A0241|37 41|MGIT
P10794936A0241|5 19|recovery rates
P10796465A0373|90 96|asthma
P10796465A0373|113 121|symptoms
P10796465A0373|69 80|acupuncture
P10797125A0000|299 307|exercise
P10797125A0000|213 227|degrees C rest
P10797125A0000|246 261|passive heating
P10797125A0000|48 57|increases
P10797125A0000|13 23|hypothesis
P10797125A0000|314 324|degrees C.
P10797125A0000|69 85|core temperature
P10798607A1359|90 95|assay
P10798607A1359|183 191|patients
P10798607A1359|36 43|killing
P10798607A1359|101 122|antibody titer levels
P10799595A1454|88 105|HPV-6 E1 promoter
P10799595A1454|12 15|YY1
P10799595A1454|20 23|CDP
P10799879T0000|47 62|adaptor protein
P10799879T0000|132 149|T cell activation
P10799879T0000|39 42|Lnk
P10799879T0000|68 87|pleckstrin homology
P10801330A1714|91 96|state
P10801330A1714|10 13|Cas
P10801330A1714|155 158|FAK
P10801809T0000|88 101|PHO5 promoter
P10801809T0000|35 54|yeast PHO8 promoter
P10802669A1434|92 95|NBS
P10802669A1434|66 75|phenotype
P10802669A1434|32 43|explanation
P10804379T0001|61 76|cytomegalovirus
P10804379T0001|40 51|hepatitis C
P10804379T0001|1 7|Update
P10805286A0914|8 13|study
P10805286A0914|143 162|PCI mRNA expression
P10805286A0914|117 123|effect
P10805729A0987|121 131|KH domains
P10805729A0987|26 35|complexes
P10805729A0987|5 18|stoichiometry
P10805738A0799|30 33|p38
P10805738A0799|391 402|fibroblasts
P10805738A0799|416 424|p38alpha
P10805738A0799|53 57|MyoD
P10805738A0799|216 240|Gal4-MyoD fusion protein
P10805738A0799|167 170|p38
P10805738A0799|40 49|activator
P10805738A0799|202 210|activity
P10805738A0799|6 14|evidence
P10805738A0799|103 113|expression
P10805739A0640|165 169|eIF2
P10805739A0640|83 91|residues
P10805739A0640|55 65|C terminus
P10805739A0640|17 35|nonsense mutations
P10805823A1920|89 99|prevention
P10805823A1920|113 118|death
P10805823A1920|49 56|benefit
P10805823A1920|103 109|stroke
P10807903A0362|63 73|rank order
P10807903A0362|176 190|ligand binding
P10807903A0362|260 272|D1 receptors
P10807903A0362|324 338|responsiveness
P10807903A0362|282 298|exhibit receptor
P10807903A0362|312 320|activity
P10807903A0362|7 9|CT
P10807903A0362|1 6|D5/D1
P10810083A1283|68 85|zinc finger motif
P10810745A0677|62 73|environment
P10810745A0677|83 86|HFA
P10811079A1277|8 27|SPP2 screening test
P10811079A1277|35 41|plates
P10811804A0800|111 114|p90
P10811804A0800|36 44|peptides
P10811804A0800|115 118|rsk
P10812294X0000|91 94|SBF
P10812294X0000|116 122|ponies
P10812294X0000|50 61|feed intake
P10815410A0000|132 136|IL-6
P10815410A0000|95 104|increases
P10815410A0000|126 130|IL-1
P10815410A0000|141 144|TNF
P10815410A0000|50 71|neuroendocrine system
P10817754T0000|26 36|expression
P10817754T0000|9 13|Igf2
P10817754T0000|83 86|cis
P10820829T0000|1 11|Flavonoids
P10821836A0842|75 94|sense S transcripts
P10823630A1124|120 130|prediction
P10823630A1124|26 36|effacement
P10823961A0664|74 95|DRIP/TRAP/ARC complex
P10823961A0664|166 178|interactions
P10823961A0664|57 66|component
P10823961A0664|33 41|CBP/p300
P10823961A0664|117 121|TRBP
P10824958A1109|105 121|broiler breeders
P10824958A1109|97 101|PSHL
P10824958A1109|140 142|wk
P10824958A1109|19 25|energy
P10824958A1109|84 86|PF
P10825200T0000|14 38|protein tyrosine kinases
P10825200T0000|88 91|syk
P10825200T0000|57 61|IL-2
P10825200T0000|42 55|interleukin-2
P10825200T0000|1 10|Hierarchy
P10825294A0473|90 103|BSP promoters
P10825294A0473|44 54|C terminus
P10825294A0473|246 264|pentapeptide VWRPY
P10825294A0473|65 71|manner
P10825294A0473|187 201|AML C terminus
P10826946A1198|107 116|gp120 SAg
P10826946A1198|72 75|Igs
P10826946A1198|142 148|subset
P10826946A1198|80 85|gp120
P10826946A1198|1 14|Investigation
P10827952A0158|46 53|subunit
P10827952A0158|24 32|TAFII250
P10828319A0342|62 68|number
P10828319A0342|72 78|trials
P10828319A0342|87 98|improvement
P10828751A2258|61 69|patients
P10828751A2258|47 57|management
P10828751A2258|103 112|treatment
P10830395A0408|67 78|Flory model
P10831972A1091|120 127|danazol
P10831972A1091|39 52|endometriosis
P10831972A1091|1 11|CONCLUSION
P10833486A0598|150 152|2N
P10833486A0598|63 65|OR
P10833486A0598|54 58|kg/m
P10833486A0598|19 29|odds ratio
P10833486A0598|73 86|triglycerides
P10833486A0598|43 46|BMI
P10833486A0598|103 105|OR
P10833486A0598|205 213|fibrosis
P10834781A0693|135 141|period
P10834781A0693|94 110|plasma clearance
P10834781A0693|22 27|group
P10834781A0693|114 123|lidocaine
P10835485A0941|148 155|factors
P10835485A0941|179 184|mouse
P10835485A0941|54 62|contrast
P10835485A0941|87 104|sequence identity
P10836542A0363|78 80|nm
P10836542A0363|24 35|UV exposure
P10837126A1004|30 41|pMesogenin1
P10837126A1004|109 121|marker genes
P10837126A1004|145 154|phenotype
P10837126A1004|55 71|signaling factor
P10838399A0525|87 110|reconstruction artifact
P10838399A0525|69 81|bone disease
P10839470A1148|12 22|comparison
P10839470A1148|26 47|percentage reductions
P10839470A1148|65 71|supine
P10839470A1148|51 61|heart rate
P10839593A0000|29 37|efficacy
P10839593A0000|167 180|HIV infection
P10839593A0000|42 48|safety
P10839593A0000|98 107|treatment
P10839593A0000|154 161|persons
P10839593A0000|84 88|ABOS
P10841537A0669|27 34|regions
P10841537A0669|38 42|RPB5
P10843810A0802|14 18|part
P10843810A0802|41 46|clone
P10843810A0802|197 200|LTR
P10843810A0802|80 84|exon
P10846054A0573|90 94|ORFs
P10846054A0573|12 20|analyses
P10846054A0573|193 201|proteins
P10846054A0573|110 122|accumulation
P10846054A0573|84 87|RNA
P10848605T0000|45 58|kinase domain
P10848605T0000|123 133|activities
P10848605T0000|1 16|Phosphorylation
P10848993A0000|31 39|vicinity
P10848993A0000|210 241|serine/threonine protein kinase
P10848993A0000|243 246|amk
P10848993A0000|43 72|methylmalonyl-CoA mutase gene
P10848993A0000|163 171|sequence
P10848993A0000|156 161|clone
P10850453A0713|63 68|Raf-1
P10850453A0713|11 21|expression
P10850453A0713|93 99|effect
P10850453A0713|116 123|TSU-Pr1
P10850453A0713|103 112|TGF-beta1
P10850719A0680|89 94|Jbeta
P10850719A0680|32 53|DJbeta rearrangements
P10850719A0680|118 131|compatibility
P10850942A0989|72 81|% glucose
P10850942A0989|43 51|emptying
P10850942A0989|21 31|difference
P10850942A0989|175 179|days
P10850942A0989|152 161|nutrition
P10851089A1248|75 89|ubiquitination
P10851089A1248|94 105|degradation
P10851089A1248|131 139|proteins
P10851745A0624|90 98|capacity
P10851745A0624|55 61|health
P10851745A0624|35 40|moods
P10852460A0170|181 190|age range
P10852460A0170|80 84|zinc
P10852460A0170|49 65|thyroid hormones
P10852460A0170|199 201|yr
P10852460A0170|99 115|alpha-tocopherol
P10852460A0170|236 252|SENIEUR protocol
P10852460A0170|171 179|subjects
P10852953A0000|227 229|Hz
P10852953A0000|214 219|range
P10852953A0000|188 199|oscillation
P10852953A0000|1 15|Investigations
P10852953A0000|34 40|slices
P10853778A0316|54 65|bone grafts
P10854004A0788|130 143|nitroprusside
P10854004A0788|7 10|FVR
P10854004A0788|96 107|angiotensin
P10854004A0788|64 77|FVR responses
P10855690A0870|45 55|MAP kinase
P10855690A0870|23 30|results
P10855796A1160|147 153|tectum
P10855796A1160|80 101|EphA8 gene expression
P10855796A1160|69 76|pattern
P10856491A0178|60 65|women
P10856491A0178|24 42|Paris VII hospital
P10856491A0178|99 104|myoma
P10856491A0178|70 82|embolization
P10856491A0178|51 52|s
P10857215A0000|57 65|practice
P10857262A0186|120 123|BTB
P10857262A0186|148 154|domain
P10857262A0186|5 12|protein
P10857262A0186|71 73|D.
P10858355A0920|55 82|Enterococcus faecium SF2149
P10858355A0920|87 114|Enterococcus faecalis WH245
P10860131A0847|28 33|times
P10860131A0847|83 87|drug
P10860131A0847|1 18|Tolterodine users
P10860752A1601|109 150|bacteriophage T4 DNA polymerase synthesis
P10860752A1601|5 13|presence
P10860752A1601|64 73|mechanism
P10860846A0480|90 116|cotransfection experiments
P10860846A0480|198 224|HGF gene promoter activity
P10860846A0480|162 165|AP2
P10860846A0480|55 78|AP2 core binding region
P10861086A0259|105 115|Src kinase
P10861086A0259|244 256|phagocytosis
P10861086A0259|200 208|Fc gamma
P10861086A0259|81 90|cell line
P10861086A0259|71 74|RAW
P10861086A0259|220 229|signaling
P10861906A0999|161 165|IME1
P10861906A0999|5 25|delta srb10 mutation
P10861906A0999|235 248|DNA synthesis
P10861906A0999|49 66|transcript levels
P10861906A0999|100 104|IME1
P10861906A0999|186 190|IME2
P10861909A0502|91 94|LEU
P10861909A0502|58 64|marker
P10861909A0502|222 224|3X
P10861909A0502|164 168|his3
P10861909A0502|97 101|gene
P10861909A0502|5 16|pJR vectors
P10861909A0502|207 220|nmt1 promoter
P10861909A0502|136 140|gene
P10861909A0502|275 299|transcription efficiency
P10863048A0000|78 86|activity
P10863048A0000|42 54|cord lesions
P10863048A0000|5 11|effect
P10863048A0000|139 149|distension
P10864271A0504|30 34|role
P10864271A0504|120 130|comparison
P10864271A0504|166 175|scavenger
P10864271A0504|5 12|results
P10864271A0504|38 52|S. argyrostoma
P10864271A0504|153 160|mammals
P10864641A1400|121 143|influenza virus growth
P10864641A1400|72 76|site
P10864641A1400|7 14|results
P10864641A1400|154 160|glycan
P10865422A0138|58 63|level
P10865422A0138|37 39|SF
P10865422A0138|114 134|iron supplementation
P10865422A0138|87 96|histories
P10865940A0000|161 181|NF-kappaB activation
P10865940A0000|96 101|cells
P10865940A0000|17 50|agent pyrrolidine dithiocarbamate
P10866677A1839|64 69|mouse
P10866677A1839|1 4|Phd
P10866886A1277|29 40|conjunction
P10866886A1277|6 12|effect
P10867496T0001|38 45|patient
P10867496T0001|51 76|Morbus von Recklinghausen
P10869076A1384|130 134|boxA
P10869076A1384|77 85|ribosome
P10869076A1384|7 14|results
P10869076A1384|116 122|access
P10869076A1384|169 194|transcription termination
P10870043A0621|27 39|GnRH agonist
P10870043A0621|5 19|administration
P10870043A0621|86 91|femur
P10871045A1221|242 254|acetaldehyde
P10871045A1221|52 65|C/EBP isoform
P10871045A1221|6 11|study
P10871045A1221|173 191|C/EBP binding site
P10871045A1221|85 99|stellate cells
P10871379A0261|74 77|HCF
P10871379A0261|9 13|VP16
P10871615A0368|15 17|C.
P10871615A0368|1 3|G.
P10872473A2286|149 164|gene expression
P10872473A2286|126 132|factor
P10872473A2286|33 42|mutations
P10872756A1325|95 103|patients
P10872756A1325|178 196|dose control group
P10872756A1325|4 14|NASCIS III
P10872756A1325|155 163|recovery
P10872831A0000|61 84|erythropoietin receptor
P10872831A0000|20 32|sequence tag
P10872831A0000|86 90|EPOR
P10873158A0000|31 33|NF
P10873158A0000|149 155|stress
P10873158A0000|98 104|airway
P10873158A0000|1 11|Activation
P10873386A0000|90 104|20S proteasome
P10873386A0000|53 63|mouse gene
P10873388A0623|132 140|prostate
P10873388A0623|42 64|Northern hybridization
P10873388A0623|157 162|level
P10873388A0623|222 227|liver
P10873388A0623|35 40|probe
P10874151A0000|108 115|lesions
P10874151A0000|39 42|GKR
P10874151A0000|68 79|alternative
P10878606A0876|36 46|structures
P10878944A0000|181 184|St.
P10878944A0000|130 140|laboratory
P10878944A0000|77 86|DiaMed AG
P10878944A0000|157 177|Childhood Infections
P10880702A0966|74 85|apomorphine
P10880702A0966|148 159|amphetamine
P10880702A0966|196 204|behavior
P10880702A0966|16 23|results
P10882163A1077|211 221|exemestane
P10882163A1077|95 102|failure
P10882163A1077|127 128|%
P10882163A1077|225 231|mg/day
P10882163A1077|78 88|exemestane
P10882163A1077|71 74|use
P10882163A1077|1 20|Objective responses
P10882462T0000|16 34|tissue engineering
P10884978A0633|130 133|age
P10884978A0633|66 76|difference
P10884978A0633|51 56|aging
P10885731A0915|180 188|polymers
P10885731A0915|89 102|crystallinity
P10885731A0915|144 157|crystallinity
P10885731A0915|38 44|impact
P10885731A0915|19 24|study
P10886067A0520|28 37|thickness
P10886067A0520|58 60|mm
P10887921A0718|91 95|SWAP
P10887921A0718|208 216|glaucoma
P10887921A0718|25 33|relation
P10887921A0718|159 163|role
P10887921A0718|1 12|CONCLUSIONS
P10889399A0243|57 64|markers
P10889399A0243|5 27|detection success rate
P10891093A0000|122 127|types
P10891093A0000|131 145|fusion vectors
P10891093A0000|196 210|cDNA sequences
P10891093A0000|163 192|membrane insertion properties
P10891093A0000|261 265|msds
P10891093A0000|252 259|domains
P10891286A0000|73 77|role
P10891286A0000|169 177|function
P10891286A0000|16 28|titin/myosin
P10891286A0000|85 97|organization
P10891441A0871|72 76|Sos1
P10891441A0871|131 137|kinase
P10891441A0871|66 70|Grb2
P10891441A0871|175 192|mass spectrometry
P10891632A0435|72 82|resolution
P10891632A0435|199 218|withdrawal symptoms
P10891632A0435|5 38|naltrexone/lofexidine combination
P10891632A0435|186 195|increases
P10892823A1040|28 37|treatment
P10892823A1040|12 22|counseling
P10892823A1040|1 10|Screening
P10893258T0000|75 102|membrane protein biogenesis
P10893258T0000|50 57|aspects
P10894816A0836|91 94|SRE
P10894816A0836|82 89|element
P10894816A0836|1 8|Studies
P10895417A0000|91 100|liposomes
P10895417A0000|167 175|morphine
P10895417A0000|154 163|clearance
P10895417A0000|51 59|morphine
P10895851A0696|78 79|%
P10895851A0696|111 113|g.
P10895851A0696|103 104|g
P10896859A0000|194 207|steroid sheep
P10896859A0000|95 98|ADX
P10896859A0000|5 11|effect
P10896859A0000|100 105|sheep
P10896859A0000|171 179|cortisol
P10897233A1057|36 49|Nazareth area
P10898795A0527|135 142|classes
P10898795A0527|10 15|class
P10898795A0527|25 45|histone deacetylases
P10898795A0527|98 102|BCoR
P10899142A0000|269 273|cDNA
P10899142A0000|41 64|Genome Project database
P10899142A0000|188 194|DLGR-1
P10899142A0000|156 164|receptor
P10899142A0000|70 79|sequences
P10900269A0396|120 133|recombination
P10900269A0396|179 180|%
P10900269A0396|6 11|cells
P10900269A0396|203 213|background
P10900269A0396|69 84|polypurine site
P10902348A0566|79 88|R5 strain
P10902348A0566|59 69|comparison
P10902348A0566|1 18|Resistance ratios
P10903495A0533|6 27|gel retardation assay
P10903495A0533|116 120|band
P10903733A0540|60 65|cells
P10903733A0540|123 127|TRAF
P10903733A0540|143 165|TRAF3 adaptor proteins
P10903733A0540|1 34|Coimmunoprecipitation experiments
P10903843A0447|89 94|genes
P10903843A0447|142 153|Kcnq1 genes
P10903843A0447|68 75|cluster
P10904191A0000|245 253|patients
P10904191A0000|126 129|USA
P10904191A0000|178 186|patients
P10904191A0000|48 59|sensitivity
P10904191A0000|13 18|study
P10904191A0000|111 120|San Diego
P10904191A0000|64 75|specificity
P10905349A0609|122 132|DNA damage
P10905349A0609|97 106|tolerance
P10905349A0609|38 44|Rad54p
P10906176A0000|104 116|mouse genome
P10906176A0000|27 37|transposon
P10906176A0000|49 58|sequences
P10906999T0000|37 44|systems
P10906999T0000|20 22|NO
P10907971A0806|42 69|HMG-CoA reductase inhibitor
P10908317A1459|131 142|counterpart
P10908317A1459|25 34|E domains
P10908317A1459|113 117|rtER
P10908317A1459|48 57|receptors
P10908317A1459|103 109|domain
P10908462A3159|91 98|support
P10908462A3159|67 76|intensity
P10908462A3159|115 121|smoker
P10908822A0519|20 23|.3%
P10910073A0876|60 68|splicing
P10910073A0876|122 135|amplification
P10910073A0876|94 98|gene
P10910073A0876|156 167|patient RNA
P10910908A0767|72 76|role
P10910908A0767|6 13|finding
P10910908A0767|33 60|PI3K-Akt activation pathway
P10913172A0442|130 135|motif
P10913172A0442|38 43|motif
P10913276A0684|129 133|SOS1
P10913276A0684|66 76|SH3 domain
P10913276A0684|16 34|expression studies
P10913304A1180|181 187|domain
P10913304A1180|5 18|kb transcript
P10913304A1180|223 226|ERF
P10913304A1180|204 212|homology
P10915780A1063|44 49|cells
P10915780A1063|165 177|ILK activity
P10915780A1063|125 130|gland
P10915780A1063|145 149|mice
P10915780A1063|1 21|Wnt-1 overexpression
P10918059A0569|65 75|activation
P10918059A0569|1 9|Deletion
P10918440T0000|75 81|factor
P10918440T0000|110 131|blood stem cell donor
P10918572A1547|57 62|ErbBs
P10918572A1547|129 141|consequences
P10918572A1547|23 25|WT
P10918572A1547|216 230|ErbB signaling
P10918599A0071|28 33|E2F-3
P10918599A0071|146 148|GO
P10918599A0071|4 12|contrast
P10918599A0071|115 125|cell cycle
P10918943T0000|15 23|toxicity
P10918943T0000|56 72|agent almokalant
P10919971A0606|45 64|neutrophil response
P10919971A0606|78 86|exercise
P10919971A0606|20 26|effect
P10919971A0606|115 123|increase
P10920906A0759|120 126|margin
P10920906A0759|52 62|management
P10920906A0759|1 11|CONCLUSION
P10924061A0588|61 70|treatment
P10924061A0588|53 54|h
P10925207A0634|135 139|UTRs
P10925207A0634|38 51|kb transcript
P10928179A0101|44 55|examination
P10928179A0101|59 79|sentinel lymph nodes
P10928179A0101|102 108|debate
P10928477A0764|122 138|platelet defects
P10928477A0764|174 193|patient populations
P10928477A0764|34 50|PFA-100 analyzer
P10931524A0313|27 35|activity
P10931524A0313|39 42|Gtx
P10931950A0869|10 14|MAPK
P10931950A0869|110 122|T187A mutant
P10932196A0359|105 120|linkage studies
P10932196A0359|72 85|XLRP patients
P10932196A0359|18 27|RP2 locus
P10932527A0947|15 17|HD
P10932527A0947|109 121|inflammation
P10932679A0049|26 34|evidence
P10932679A0049|40 56|diet composition
P10932679A0049|112 123|expenditure
P10932679A0049|86 90|role
P10933728A1398|44 48|role
P10933728A1398|208 216|sequence
P10933728A1398|7 14|results
P10933728A1398|142 151|component
P10933728A1398|292 297|EBNA2
P10933728A1398|155 159|CBF2
P10934073A1433|15 26|limitations
P10934073A1433|57 68|opportunity
P10934073A1433|93 97|data
P10934640A1114|46 51|years
P10934640A1114|94 95|p
P10934640A1114|114 120|TB BMC
P10934640A1114|86 92|menses
P10934640A1114|35 36|p
P10935488A1033|133 143|expression
P10935488A1033|66 75|T24 cells
P10935488A1033|169 199|bladder cancer differentiation
P10936051T0000|91 97|enzyme
P10936051T0000|116 124|promoter
P10936051T0000|17 30|megasatellite
P10938102A0265|22 28|effect
P10938102A0265|98 117|translation factors
P10938102T0000|12 45|translation initiation factor 4GI
P10938102T0000|71 82|NS1 protein
P10938109A1361|62 66|role
P10938109A1361|109 122|growth factor
P10938109A1361|96 99|EGF
P10938109A1361|16 21|cells
P10938120A1093|72 76|UAS1
P10938120A1093|111 126|MAPK regulation
P10938120A1093|103 106|PKA
P10938135A0259|45 66|transcription factors
P10938135A0259|126 136|activation
P10938135A0259|5 12|ability
P10938135A0259|16 20|SMRT
P10939030A0986|133 151|granulocytopenia p
P10939030A0986|124 129|grade
P10939030A0986|5 16|differences
P10939030A0986|71 76|power
P10940413A1153|75 84|stiffness
P10940413A1153|89 117|stress concentration effects
P10940413A1153|5 12|results
P10940413A1153|185 191|defect
P10940557A1687|135 140|genes
P10940557A1687|110 117|regions
P10940562T0000|104 111|enzymes
P10940562T0000|166 186|Arabidopsis thaliana
P10940562T0000|133 137|step
P10940562T0000|96 102|lyases
P10940562T0000|48 63|oas gene family
P10942587A0981|150 157|changes
P10942587A0981|89 93|mRNA
P10942587A0981|23 44|phosphorylation state
P10942587A0981|48 50|Rb
P10942587A0981|221 223|Rb
P10943891A1062|161 170|formation
P10943891A1062|5 12|ability
P10943891A1062|200 211|spliceosome
P10943891A1062|48 56|fidelity
P10943891A1062|16 30|U6-U57 mutants
P10945010T0001|13 25|daunorubicin
P10945010T0001|5 9|role
P10946303A0000|122 130|NCI-H292
P10946303A0000|58 74|cyclooxygenase-2
P10946303A0000|142 147|cells
P10946303A0000|21 25|dose
P10946303A0000|1 10|TNF-alpha
P10947840A0762|24 33|formation
P10947840A0762|80 85|level
P10947840A0762|1 5|Mis3
P10950415A0866|13 23|Vitrectomy
P10950415A0866|148 154|vision
P10950415A0866|1 11|CONCLUSION
P10950935A0111|15 27|manipulation
P10950935A0111|164 175|chromosomes
P10950935A0111|109 111|P1
P10950935A0111|177 181|YACs
P10950935A0111|136 140|PACs
P10951848A0230|135 140|blood
P10951848A0230|59 77|stimulating factor
P10951848A0230|202 210|recovery
P10951848A0230|19 35|cyclophosphamide
P10951848A0230|1 13|Mobilization
P10954093A0000|14 28|DNA transposon
P10954093A0000|113 138|fungus Podospora anserina
P10954564A1262|126 129|ORF
P10954564A1262|52 55|ORF
P10954564A1262|87 99|gene product
P10955313A0000|25 33|protocol
P10955313A0000|1 7|PLUS-3
P10955998A1124|13 23|efficiency
P10955998A1124|83 90|ability
P10958456A0529|88 90|bp
P10958456A0529|149 171|polyadenylation signal
P10958456A0529|72 79|regions
P10958456A0529|7 12|cDNAs
P10958456A0529|113 115|Cp
P10958688A0265|57 68|interaction
P10958688A0265|77 89|Sls1p mutant
P10958688A0265|128 133|Sls1p
P10958688A0265|3 29|Y. lipolytica Kar2p mutant
P10958698A0485|133 147|Cse4p function
P10958698A0485|5 12|spacing
P10958698A0485|70 73|HFD
P10959838A0153|40 54|fusion protein
P10959838A0153|4 17|invertebrates
P10959838A0153|19 23|Fhit
P10961585A0273|82 91|hemolysis
P10962593A0580|19 27|AFP rate
P10962881A0900|60 64|% CI
P10962881A0900|1 12|Multiparity
P10963735A0193|89 92|CTL
P10963735A0193|108 111|CRF
P10963735A0193|5 8|aim
P10963735A0193|168 184|dialysis session
P10963735A0193|16 21|study
P10964833A1696|142 145|IOP
P10964833A1696|33 34|%
P10964833A1696|50 54|POAG
P10965135A0735|106 125|oncogene inhibition
P10965135A0735|231 248|inhibitor PD98059
P10965135A0735|80 83|ras
P10965135A0735|87 100|mos oncogenes
P10965135A0735|1 18|Promoter activity
P10965830A0305|135 145|volunteers
P10965830A0305|179 189|conditions
P10965830A0305|1 14|INTERVENTIONS
P10965905T0000|95 120|protein kinase activation
P10965905T0000|54 60|growth
P10967531A1025|120 138|muscle fibre areas
P10967531A1025|88 96|adhesion
P10967531A1025|25 30|aorta
P10967531A1025|206 212|microm
P10967531A1025|68 82|fibre necrosis
P10970048A0352|151 156|times
P10970048A0352|77 83|orders
P10970048A0352|174 176|RH
P10970048A0352|116 130|voltage values
P10970048A0352|87 96|magnitude
P10972894A0488|63 69|format
P10972894A0488|9 18|libraries
P10972894A0488|144 151|library
P10972894A0488|174 181|library
P10972990A0196|22 33|protein p53
P10972990A0966|13 21|analysis
P10972990A0966|148 168|chromosome deletions
P10972990A0966|40 59|chromosome painting
P10972990A0966|25 36|LOH mutants
P10972990A0966|116 126|chromosome
P10973151A0883|44 51|profile
P10973151A0883|78 83|State
P10973151A0883|112 116|fact
P10973151A0883|55 70|schistosomiasis
P10973400A0664|107 115|injuries
P10973400A0664|25 36|deformation
P10973400A0664|139 144|range
P10973400A0664|50 61|artery flow
P10975465A0134|135 139|mass
P10975465A0134|106 112|length
P10975465A0134|11 27|cDNA clone NFBD1
P10975465A0134|203 222|amino acid residues
P10975465A0134|51 59|KIAA0170
P10980416T0000|13 31|hormone regulation
P10980416T0000|163 184|rat BSP gene promoter
P10980416T0000|54 57|BSP
P10980416T0000|119 141|transcription factor-1
P10982076A0000|74 81|illness
P10982076A0000|142 147|value
P10982076A0000|83 86|ILI
P10982391A0425|15 26|NPF repeats
P10982391A0425|45 51|repeat
P10982391A0425|72 80|residues
P10982391A0425|228 247|transmembrane spans
P10982391A0425|158 164|domain
P10982391A0425|117 119|WW
P10983344A0000|43 53|correction
P10983344A0000|84 93|intestine
P10983979T0000|30 41|splice site
P10983979T0000|12 23|recognition
P10983979T0000|108 128|spliceosome assembly
P10987280A0604|28 40|matrilysin-2
P10987280A0604|143 150|feature
P10987280A0604|154 164|matrilysin
P10989777A1286|104 114|assignment
P10989777A1286|162 167|group
P10989777A1286|53 56|URD
P10991648T0000|46 60|half syndromes
P10992983T0000|56 67|penile size
P10992983T0000|16 24|relation
P10993787A0369|194 201|factors
P10993787A0369|124 127|MAP
P10993787A0369|111 120|reduction
P10993787A0369|52 62|transition
P10993787A0369|174 184|separation
P10993787A0369|68 71|SHG
P10995751A0093|72 82|C/EBP-beta
P10995751A0093|92 110|gene transcription
P10997863A0753|61 74|seizure focus
P10997863A0753|8 20|TLE patients
P10997863A0753|138 151|seizure focus
P10998679A0500|159 163|pain
P10998679A0500|66 75|prognoses
P10998679A0500|17 24|factors
P10999301A0000|14 24|evaluation
P10999301A0000|150 155|study
P10999301A0000|126 130|SNOM
P10999301A0000|114 124|microscope
P10999301A0000|86 94|scanning
P11000203A0752|211 221|activities
P11000203A0752|107 117|RNA export
P11000203A0752|127 140|K-Rev mutants
P11000203A0752|20 25|K-Rev
P11000266T0000|72 78|intron
P11000266T0000|86 108|alpha-fetoprotein gene
P11000266T0000|50 58|promoter
P11002236A0328|25 30|study
P11002236A0328|55 64|PPB cases
P11002236A0328|168 184|Oncology centers
P11002236A0328|35 42|authors
P11003641A0811|61 68|subunit
P11003641A0811|47 52|RAP74
P11003641A0811|148 155|mutants
P11003641A0811|131 140|fcp1 tfg1
P11003641A0811|54 59|Tfg1p
P11003641A0811|170 177|ability
P11003653A0198|199 210|PYR complex
P11003653A0198|53 60|complex
P11003653A0198|39 43|site
P11003653A0198|1 9|Deletion
P11003805A0443|26 30|DGOR
P11003805A0443|39 50|acid reflux
P11003805A0443|1 8|Studies
P11004369A0000|28 40|relationship
P11004369A0000|111 130|microvessel density
P11004369A0000|157 177|growth factor levels
P11004369A0000|1 10|OBJECTIVE
P11005831A0242|44 48|bZIP
P11005831A0242|121 127|system
P11005831A0242|166 171|AREB3
P11005831A0242|7 12|cDNAs
P11005831A0242|155 160|AREB2
P11005831A0242|68 76|proteins
P11006284T0000|22 32|kinase fer
P11006284T0000|80 108|insulin receptor substrate-1
P11007509A1271|58 69|improvement
P11007509A1271|93 105|flow reserve
P11007509A1271|50 54|area
P11007949A1395|90 96|tumors
P11007949A1395|66 67|%
P11007954A0170|126 129|Ras
P11007954A0170|261 264|Ras
P11007954A0170|187 195|receptor
P11007954A0170|51 58|adaptor
P11007954A0170|107 122|exchange factor
P11007954A0170|228 236|membrane
P11007954A0170|161 169|tyrosine
P11007954A0170|5 18|growth factor
P11007968A0255|94 97|DNA
P11007968A0255|112 128|oligonucleotides
P11007968A0255|21 28|segment
P11007968A0255|102 105|PCR
P11008420A0580|22 31|advantage
P11008420A0580|86 101|complex changes
P11008420A0580|171 177|events
P11012568A0192|17 33|hypersensitivity
P11012680A0676|73 76|PP2
P11012680A0676|27 31|FGF1
P11012680A0676|1 15|Src activation
P11012680A0676|102 105|Src
P11013079A0927|53 78|primer extension analysis
P11013079A0927|86 96|mouse gene
P11013079A0927|153 161|promoter
P11014213A1019|224 230|domain
P11014213A1019|110 121|COS-1 cells
P11014213A1019|37 45|arsenite
P11014213A1019|234 241|ERalpha
P11014213A1019|71 77|domain
P11014213A1019|171 187|receptors GAL-ER
P11014465A0479|72 76|days
P11014465A0479|123 127|days
P11014465A0479|78 83|range
P11014465A0479|129 134|range
P11014465A0479|17 26|diagnosis
P11015197A0310|88 91|TM4
P11015197A0310|20 28|cysteine
P11016014A0181|211 226|angina pectoris
P11016014A0181|182 191|syndromes
P11016014A0181|114 126|lipoproteins
P11016014A0181|1 11|HYPOTHESIS
P11016014A0181|17 20|aim
P11016737A0275|74 80|status
P11016954A0438|52 57|RDE-1
P11016954A0438|71 75|RNAi
P11018028A0263|192 201|membranes
P11018028A0263|167 178|mouse brain
P11018028A0263|56 70|protein kinase
P11018028A0263|114 125|fibroblasts
P11018028A0263|103 110|CDC25Mm
P11019257A0159|211 222|distortions
P11019257A0159|183 192|magnitude
P11019257A0159|99 107|emission
P11019257A0159|117 126|3T2 state
P11023074A1105|14 18|test
P11023074A1105|42 44|CC
P11023074A1105|55 60|PACE2
P11023853A0188|28 46|weather conditions
P11023853A0188|176 186|laboratory
P11023853A0188|144 148|rate
P11023853A0188|324 334|components
P11023853A0188|107 122|laboratory data
P11023853A0188|232 235|DEE
P11023853A0188|70 81|budget data
P11024026A0133|74 82|receptor
P11024026A0133|10 21|selectivity
P11024026A0133|66 70|form
P11024047A0626|122 131|treatment
P11024047A0626|67 72|level
P11024047A0626|35 40|Smad2
P11024300A1579|165 168|ARC
P11024300A1579|123 131|proteins
P11024300A1579|112 119|complex
P11024300A1579|55 72|peptide fragments
P11024300A1579|1 7|Nature
P11027027A0061|52 84|chromatography/mass spectrometry
P11027027A0061|98 121|electrospray ionization
P11027274A1682|57 65|activity
P11027274A1682|127 136|structure
P11027274A1682|35 46|PI 3-kinase
P11027289A0000|195 200|genes
P11027289A0000|29 39|suppressor
P11027289A0000|58 59|s
P11027289A0000|116 118|SU
P11027289A0000|255 261|region
P11027294A0483|31 65|histone acetyltransferase activity
P11027294A0483|145 155|alteration
P11027294A0483|6 17|interaction
P11027294A0483|69 73|p300
P11027833A0362|1 14|Flow cytomery
P11028131T0000|23 41|interferon beta-1b
P11029045A0000|28 41|fission yeast
P11029045A0000|20 24|Cdc2
P11029045A0000|1 16|Hyperactivation
P11029458A0000|24 32|response
P11029458A0000|1 6|Cells
P11029467T0000|74 85|polypeptide
P11029467T0000|23 30|peptide
P11029467T0000|185 200|cell line THP-1
P11029700A0295|75 86|transcripts
P11029700A0295|10 14|cycH
P11029700A0295|7 9|Pt
P11029700A0295|21 23|Os
P11029704A0378|270 280|RY repeats
P11029704A0378|245 257|RY/G complex
P11029704A0378|219 227|tetramer
P11029704A0378|324 339|transactivation
P11029704A0378|192 200|response
P11029704A0378|131 138|element
P11029704A0378|168 172|ABI3
P11029704A0378|343 347|ABI3
P11030476A0685|13 32|Rhizopus stolonifer
P11030476A0685|1 7|Spores
P11031252A0646|125 136|PKC isotype
P11031252A0646|67 75|contrast
P11031252A0646|80 91|HMW isoform
P11031252A0646|171 177|amount
P11031773A0174|77 81|mice
P11031773A0174|38 47|capsaicin
P11032677A0230|121 130|steatitis
P11032677A0230|11 19|findings
P11032677A0230|213 222|glossitis
P11032677A0230|33 45|pancreatitis
P11034547A0674|11 15|Arix
P11034547A0674|97 100|DB1
P11034547A0674|20 26|NBPhox
P11034547A0674|48 57|multimers
P11034933A0389|120 132|prolongation
P11034933A0389|166 184|nmol/L domperidone
P11034933A0389|22 29|Studies
P11035867A0000|124 134|Braun GmbH
P11035867A0000|146 153|Germany
P11035867A0000|291 312|blood pressure values
P11035867A0000|336 357|blood pressure curves
P11035867A0000|36 47|performance
P11035867A0000|71 99|wrist blood pressure monitor
P11035867A0000|1 10|OBJECTIVE
P11036938A1162|29 39|expression
P11036938A1162|177 180|day
P11036938A1162|4 12|increase
P11036938A1162|207 212|surge
P11037759T0000|55 69|administration
P11037759T0000|34 44|dimensions
P11038042A0948|56 78|blood cell nadir count
P11038042A0948|19 24|mg/m2
P11038042A0948|103 123|platelet nadir count
P11038317A0000|82 90|elements
P11038317A0000|33 41|proteins
P11038317A0000|153 158|cells
P11038366A1417|59 63|PP2A
P11038366A1417|22 28|Pph21p
P11038366A1417|85 94|complexes
P11039780A0770|149 157|overview
P11039780A0770|219 243|osteoarthritis treatment
P11039780A0770|203 215|gene therapy
P11039780A0770|99 113|osteoarthritis
P11039780A0770|169 179|strategies
P11040219A0548|31 39|presence
P11040219A0548|43 48|alpha
P11040219A0548|142 146|NusA
P11040219A0548|81 99|S1 homology region
P11042197A0386|60 62|HD
P11042197A0386|82 94|dimerization
P11042197A0386|1 4|Lys
P11042204A0186|13 18|study
P11042204A0186|144 155|neutrophils
P11042204A0186|102 121|Akt phosphorylation
P11043469A0440|107 115|T-region
P11043469A0440|145 147|TR
P11043469A0440|16 32|border sequences
P11043469A0440|119 127|pTiChry5
P11044097T0000|107 134|immunodeficiency virus type
P11044097T0000|21 28|protein
P11044097T0000|84 93|U5 region
P11045180A1892|56 78|blood pressure reading
P11045180A1892|97 109|hypertension
P11046146A1202|255 260|cells
P11046146A1202|187 192|cells
P11046146A1202|162 170|extracts
P11046146A1202|231 239|extracts
P11046146A1202|7 24|diamide treatment
P11046146A1202|36 44|extracts
P11046146A1202|136 150|dithiothreitol
P11046153A1052|23 32|apoptosis
P11048832A0271|24 31|Pearson
P11048832A0271|1 7|Fisher
P11048832A0271|34 43|chi2 test
P11049889A1271|26 30|test
P11049889A1271|83 98|anticoagulation
P11050084A0888|46 55|PPARgamma
P11050084A0888|71 77|nuclei
P11051364A0890|94 114|variceal eradication
P11051364A0890|40 43|PHG
P11051364A0890|52 59|group A
P11051364A0890|116 123|group B
P11051364A0890|84 87|PHG
P11053009A0000|72 86|cyclooxygenase
P11053009A0000|93 101|activity
P11053009A0000|1 8|Aspirin
P11053370A0708|92 117|glutathione S-transferase
P11053370A0708|70 74|half
P11053370A0708|17 31|hybrid protein
P11054341A0599|134 138|risk
P11054341A0599|10 27|Glaucoma suspects
P11054341A0599|76 80|SWAP
P11054341A0599|50 56|groups
P11054565A0654|105 111|GTPase
P11054565A0654|226 235|structure
P11054565A0654|123 130|domains
P11054565A0654|10 21|p190-B exon
P11054565A0654|172 182|GAP domain
P11054565A0654|248 258|p190 genes
P11054970A0282|5 27|plexiform neurofibroma
P11054970A0282|51 64|neurofibromas
P11055786A0306|44 49|steps
P11056019A0926|55 61|adduct
P11056019A0926|101 115|vinyl chloride
P11056019A0926|1 5|MED1
P11056019A0926|17 37|glycosylase activity
P11058119A0957|56 62|GTPase
P11058119A0957|83 95|localization
P11058132A0264|47 55|proteins
P11058132A0264|183 193|B.subtilis
P11058132A0264|162 171|organisms
P11058132A0264|96 97|%
P11058132A0264|17 21|CDSs
P11059786A0682|122 125|Ras
P11059786A0682|162 164|PI
P11059786A0682|116 120|EGFR
P11059786A0682|154 160|kinase
P11059786A0682|102 112|inhibition
P11062047A1208|7 12|IHHNV
P11062047A1208|184 190|PstDNV
P11062047A1208|84 103|family Parvoviridae
P11062068T0000|11 21|activation
P11062068T0000|43 50|protein
P11062068T0000|129 132|p38
P11062068T0000|52 55|MAP
P11062274T0000|53 81|tissue plasminogen activator
P11063127A0000|164 166|OA
P11063127A0000|177 184|effects
P11063127A0000|142 146|role
P11063127A0000|39 54|phosphorylation
P11063127A0000|1 20|Signal transduction
P11063127A0000|119 123|PP2A
P11063252A0437|1 7|Exon A
P11064829T0058|1 28|Cardiovascular risk factors
P11067797A1306|14 29|EBCT technology
P11067797A1306|56 66|evaluation
P11067797A1306|1 12|CONCLUSIONS
P11067797A1306|152 167|BV distribution
P11069011A0224|148 157|materials
P11069011A0224|76 79|CO2
P11069011A0224|49 60|bioreactors
P11069223A0593|31 36|liver
P11069223A0593|1 9|Patients
P11069756A2618|298 312|protein kinase
P11069756A2618|541 544|RTK
P11069756A2618|185 189|GPCR
P11069756A2618|224 232|receptor
P11069756A2618|164 167|GIT
P11069756A2618|379 388|subdomain
P11069756A2618|47 49|CH
P11069756A2618|314 317|ERK
P11069756A2618|502 518|phosphothreonine
P11069756A2618|433 455|paxillin kinase linker
P11069756A2618|36 45|substrate
P11069756A2618|169 183|GRK interacter
P11069756A2618|390 393|PIX
P11069756A2618|147 162|adhesion kinase
P11069756A2618|457 461|POR1
P11069756A2618|16 19|CAS
P11069756A2618|349 355|kinase
P11069756A2618|474 477|Rac
P11069756A2618|274 278|MAPK
P11069756A2618|69 75|domain
P11069756A2618|411 426|exchange factor
P11069791A0226|209 212|IPT
P11069791A0226|59 63|dose
P11069791A0226|50 53|IPT
P11069791A0226|164 166|mo
P11069791A0226|232 234|mo
P11069791A0226|97 106|Regimen A
P11069791A0226|71 73|mg
P11069897A1112|30 36|BACH1t
P11069897A1112|46 51|BACH1
P11069897A1112|59 66|nucleus
P11070007A0136|26 36|EBNA genes
P11070007A0136|179 185|genome
P11070007A0136|86 93|B cells
P11070007A0136|118 127|promoters
P11070078A1153|14 22|response
P11070078A1153|135 141|HPV E6
P11070078A1153|225 232|signals
P11070078A1153|146 148|E7
P11070078A1153|188 195|fashion
P11070078A1153|207 213|growth
P11071789T0000|23 34|dose levels
P11071789T0000|64 77|heart failure
P11071924A0588|31 50|RING finger domains
P11071924A0588|131 136|SLI-1
P11071924A0588|23 26|SH2
P11071924A0588|175 180|c-Cbl
P11071924A0588|185 193|activity
P11072155A0764|30 41|correlation
P11072155A0764|79 100|cell radiosensitivity
P11072155A0764|102 116|lymphocyte SF2
P11073163A0131|107 117|proteasome
P11073163A0131|133 151|cell proliferation
P11073163A0131|66 84|cell cycle control
P11073539A0866|45 49|SW13
P11073539A0866|57 62|cells
P11073539A0866|127 135|material
P11073539A0866|70 81|aggregation
P11073539A0866|51 54|vim
P11073919A0631|179 183|Y389
P11073919A0631|59 63|R154
P11073919A0631|113 117|G276
P11073919A0631|48 51|E94
P11073919A0631|119 123|R277
P11073919A0631|167 171|D364
P11073919A0631|43 46|D88
P11073919A0631|38 41|K69
P11073919A0631|149 153|D332
P11073919A0631|330 336|domain
P11073919A0631|95 99|G237
P11073919A0631|155 159|C360
P11073919A0631|344 363|dimer stabilization
P11073919A0631|131 135|K294
P11073919A0631|413 431|S. ruminantium LDC
P11073919A0631|65 69|K169
P11073919A0631|71 75|H197
P11074003A0741|27 30|Shh
P11074003A0741|86 91|CGNPs
P11075678A0298|45 50|modes
P11075678A0298|105 106|G
P11075678A0298|210 221|force field
P11075678A0298|162 168|values
P11075678A0298|5 16|wavenumbers
P11075944A0691|14 18|npm3
P11075944A0691|54 58|fgf8
P11075944A0691|4 12|addition
P11078726X0000|303 307|role
P11078726X0000|285 291|domain
P11078726X0000|228 234|domain
P11078726X0000|260 267|enzymes
P11078726X0000|80 93|transcription
P11078726X0000|16 31|phosphorylation
P11080796A1277|73 81|subunits
P11080796A1277|172 175|Tax
P11080796A1277|96 103|IKKbeta
P11080796A1277|5 29|Tax/IKKgamma interaction
P11080796A1277|191 199|activity
P11080796A1277|153 162|mechanism
P11082185A0415|36 40|type
P11082185A0415|4 12|addition
P11082185A0415|98 103|IRF-1
P11082715X0001|121 127|method
P11082715X0001|52 63|metabolites
P11082715X0001|115 119|HPLC
P11082715X0001|224 232|caffeine
P11082715X0001|67 71|HPLC
P11082715X0001|206 217|metabolites
P11083358A1071|60 68|patients
P11083358A1071|37 40|WST
P11083358A1071|84 94|aspiration
P11083868A0386|130 152|transactivation domain
P11083868A0386|53 59|assays
P11083868A0386|17 42|glutathione S-transferase
P11084334A0590|193 204|interaction
P11084334A0590|127 132|motif
P11084334A0590|173 181|proteins
P11084334A0590|64 78|point mutation
P11084334A0590|117 123|domain
P11084649A0497|61 65|side
P11084649A0497|73 79|embryo
P11084649A0497|109 121|gastrulation
P11084649A0497|19 26|embryos
P11084649A0497|87 89|E6
P11084649A0497|169 177|endoderm
P11085600A0123|74 80|cortex
P11085600A0123|161 172|information
P11085600A0123|49 55|inputs
P11087141A0977|10 18|analysis
P11087141A0977|76 93|splicing patterns
P11087141A0977|156 173|splicing activity
P11087141A0977|207 213|manner
P11089911A1267|91 104|transcription
P11089911A1267|53 60|regions
P11089911A1267|138 151|ATLN elements
P11090272A1240|53 57|ORL1
P11090272A1240|35 43|splicing
P11092770A0238|160 171|sensitivity
P11092770A0238|5 15|extraction
P11092770A0238|154 155|%
P11092770A0238|136 147|specificity
P11092850A1023|121 128|species
P11092850A1023|10 41|16S rRNA gene sequence analysis
P11092850A1023|97 105|ancestor
P11092850A1023|69 78|tuf genes
P11093745A0563|37 47|apposition
P11093745A0563|18 27|HNF3 site
P11094066A1194|150 159|mechanism
P11094066A1194|109 132|FKHR-L1 phosphorylation
P11094066A1194|64 67|p27
P11094066A1194|68 72|KIP1
P11094072A1234|107 111|site
P11094072A1234|83 98|consensus c-Myb
P11094072A1234|18 23|c-Myb
P11094075A0257|52 65|r-PTPeta gene
P11094075A0257|86 103|rat thyroid cells
P11094075A0257|32 44|reexpression
P11094091A0000|134 148|serine residue
P11094091A0000|150 156|Ser133
P11094091A0000|5 13|activity
P11094590A0617|149 152|PSB
P11094590A0617|298 299|%
P11094590A0617|260 261|%
P11094590A0617|87 95|bacteria
P11094590A0617|75 83|presence
P11094590A0617|40 52|relationship
P11094590A0617|9 15|fields
P11094590A0617|140 143|VAP
P11094590A0617|175 186|sensitivity
P11095248A1523|26 33|Xenopus
P11095248A1523|48 53|FGF3s
P11096662T0000|18 25|Therapy
P11097079A0525|44 54|validation
P11097079A0525|78 88|NIMH-LCM-p
P11098420A0175|13 22|disorders
P11098420A0175|26 34|children
P11098420A0175|39 50|adolescents
P11098420A0175|70 79|morbidity
P11100515A0282|176 197|amiodarone withdrawal
P11100515A0282|23 33|amiodarone
P11100515A0282|118 132|thyrotoxicosis
P11101847A0159|94 115|tumour suppressor p53
P11101847A0159|25 29|E2F1
P11101847A0159|117 121|refs
P11102458A0000|123 126|kDa
P11102458A0000|156 160|site
P11102458A0000|164 165|d
P11102458A0000|108 115|protein
P11102458A0000|231 238|PKA RII
P11102458A0000|64 76|neurobeachin
P11103601T0025|7 12|UMDNJ
P11105129T0000|130 136|Brazil
P11105129T0000|55 97|Producing Extended-Spectrum beta-lactamase
P11105129T0000|117 126|Hospitals
P11105717A0123|166 176|hemoglobin
P11105717A0123|10 12|T2
P11105717A0123|184 195|vasculature
P11106428A0635|75 81|domain
P11106428A0635|107 118|amino acids
P11106428A0635|193 196|GST
P11106428A0635|142 149|Cys2408
P11106428A0635|85 90|FAP-1
P11106668A0875|30 35|cells
P11106668A0875|14 26|transfection
P11106668A0875|159 168|apoptosis
P11106668A0875|140 146|c-IAP1
P11108151A0560|172 189|tyrphostin AG1478
P11108151A0560|200 209|induction
P11108151A0560|155 167|EGF-R mutant
P11108151A0560|1 4|Ang
P11108151A0560|103 113|inhibition
P11108523A0326|83 91|centroid
P11108523A0326|154 157|I22
P11108523A0326|160 170|anisometry
P11108523A0326|199 217|internostril angle
P11108523A0326|143 147|axes
P11108523A0326|234 239|angle
P11108523A0326|1 13|Video images
P11108616A0000|165 169|days
P11108616A0000|89 93|days
P11108616A0000|54 66|microgravity
P11108616A0000|101 122|space missions STS-55
P11108616A0000|1 11|Young fish
P11108720A1130|104 107|MEK
P11108720A1130|89 102|kinase kinase
P11108720A1130|176 180|S6K1
P11108720A1130|17 22|cells
P11110040A0000|224 232|activity
P11110040A0000|242 252|metabolite
P11110040A0000|111 125|% w/v solution
P11110040A0000|93 101|infusion
P11110040A0000|37 62|5-HT2 receptor antagonism
P11110040A0000|254 266|ketanserinol
P11111051A0051|42 67|histone acetyltransferase
P11111051A0051|69 72|HAT
P11112438X0847|16 30|Academic Press
P11112700T0000|25 51|microtubule binding domain
P11112700T0000|159 167|proteins
P11112700T0000|101 115|identification
P11112700T0000|136 147|microtubule
P11113179A0541|107 121|SRC1 functions
P11113179A0541|42 49|binding
P11113179A0541|157 160|CBP
P11113179A0541|138 145|adaptor
P11113199A0800|133 156|ERK2-Delta19-25 mutants
P11113199A0800|7 10|MEK
P11113199A0800|33 39|anchor
P11113199A0800|117 129|localization
P11113546A0728|63 75|trial period
P11113546A0728|7 14|samples
P11113546A0728|115 128|nematode eggs
P11113822A0999|91 103|jaw pathoses
P11113822A0999|37 45|controls
P11114294A0075|208 212|CFTR
P11114294A0075|10 17|studies
P11114294A0075|196 200|CFTR
P11114294A0075|202 206|gene
P11114294A0075|55 92|cytokines tumor necrosis factor alpha
P11114718A0349|95 98|p21
P11114718A0349|127 135|cyclin E
P11114718A0349|100 109|WAF1/CIP1
P11114718A0349|68 72|mRNA
P11116084A0000|82 89|protein
P11116084A0000|1 13|Mouse Impact
P11116148A0741|131 154|transactivation domains
P11116148A0741|158 167|C/EBPbeta
P11116148A0741|99 109|C/EBPalpha
P11116148A0741|1 21|Coexpression studies
P11117523A0650|79 88|P19 cells
P11117523A0650|141 148|neurons
P11117523A0650|102 104|RA
P11118062A1691|75 85|K-ras gene
P11118062A1691|122 136|aggressiveness
P11118062A1691|113 118|level
P11118062A1691|157 166|phenotype
P11118440T0000|29 37|products
P11118440T0000|41 64|alternative transcripts
P11118440T0000|141 160|corepressor complex
P11118712A1296|53 59|limits
P11118712A1296|255 261|reason
P11118712A1296|227 237|prevalence
P11118712A1296|6 26|sensitivity analysis
P11118712A1296|175 192|confidence limits
P11118712A1296|98 102|test
P11120441A1193|106 115|asymmetry
P11120441A1193|18 27|believers
P11121118A0075|82 88|region
P11121118A0075|50 63|GAF sequences
P11121397A0587|166 181|heparan sulfate
P11121397A0587|67 107|alpha1,4-N-acetylglucosaminyltransferase
P11121397A0587|152 162|elongation
P11121490A0000|5 43|transcription factor CHOP/GADD153 gene
P11122588A0549|211 215|hour
P11122588A0549|24 41|Percentage change
P11122588A0549|253 259|weight
P11122588A0549|119 124|sleep
P11122588A0549|111 115|hour
P11122588A0549|232 239|respect
P11122588A0549|64 69|index
P11122588A0549|71 74|AHI
P11123089A0362|29 40|information
P11123089A0362|144 152|patients
P11123089A0362|6 13|article
P11123089A0362|100 110|mechanisms
P11123701A0442|165 179|DNA constructs
P11123701A0442|78 86|coupling
P11123701A0442|199 220|transcription complex
P11123701A0442|297 306|diffusion
P11123701A0442|322 332|DNA duplex
P11123701A0442|35 38|DNA
P11124024A1098|65 75|palindrome
P11124024A1098|100 112|C+T sequence
P11124024A1098|170 176|strand
P11125151T0000|106 113|virus-2
P11125151T0000|22 41|genome organization
P11125151T0000|1 20|Nucleotide sequence
P11125411A0857|110 116|testes
P11125411A0857|156 161|canal
P11126275A1068|11 17|levels
P11126275A1068|69 77|bleeding
P11126806A0206|12 20|sequelae
P11127200A1024|60 68|activity
P11127200A1024|146 155|TGF-beta1
P11127200A1024|251 261|expression
P11127200A1024|290 293|PTH
P11127200A1024|72 75|ROS
P11127200A1024|196 202|alpha1
P11127200A1024|39 43|AP-1
P11127200A1024|204 219|collagen I gene
P11127955X0001|10 17|therapy
P11127955X0001|82 88|number
P11128925A0000|122 125|GCF
P11128925A0000|214 227|periodontitis
P11128925A0000|115 120|fluid
P11128925A0000|85 91|levels
P11128925A0000|164 172|patients
P11128925A0000|229 231|AP
P11128925A0000|64 77|interleukin-6
P11129724A0904|75 79|role
P11129724A0904|129 133|MRSA
P11129724A0904|113 125|transmission
P11129724A0904|1 8|Studies
P11131634A0955|90 98|Y8 cells
P11131634A0955|76 81|cells
P11131634A0955|1 11|NF kappa B
P11132148A0162|126 130|loci
P11132148A0162|114 123|HLA class
P11132790A0609|181 194|risk children
P11132790A0609|80 88|subtests
P11132790A0609|100 105|score
P11133830A0174|122 130|proteins
P11133830A0174|147 165|kDa phosphoprotein
P11133830A0174|38 43|pairs
P11133830A0174|190 210|proto-oncogene c-Cbl
P11133830A0174|68 92|tyrosine phosphorylation
P11133986A0350|195 202|kappaE3
P11133986A0350|131 139|function
P11133986A0350|126 129|PIP
P11133986A0350|172 177|c-Jun
P11133986A0350|100 124|PU.1 interaction partner
P11134033A0639|30 36|mutant
P11134033A0639|4 17|int6 deletion
P11134508A0317|72 77|AtHD1
P11134508A0317|79 83|gene
P11137296A0923|299 312|mouse tissues
P11137296A0923|264 275|PFK-C genes
P11137296A0923|127 135|RLM-RACE
P11137296A0923|116 125|cDNA ends
P11137296A0923|73 76|RNA
P11137296A0923|99 112|amplification
P11137296A0923|169 197|translation initiation codon
P11137367A0297|88 93|image
P11137367A0297|103 110|circuit
P11138009A1032|59 64|IVS51
P11138009A1032|4 12|addition
P11138009A1032|85 97|USH1 patient
P11138694A0000|12 34|fluorobenzyltrozamicol
P11138694A0000|36 39|FBT
P11138694A0000|140 146|neuron
P11138694A0000|2 5|18F
P11138694A0000|255 262|ganglia
P11139336A0257|61 68|mitosis
P11139473A0696|63 72|consensus
P11139473A0696|41 49|sequence
P11139473A0696|158 176|Hex responsiveness
P11139473A0696|1 18|Promoter analysis
P11139605A0811|227 233|region
P11139605A0811|215 218|Sp1
P11139605A0811|116 131|auto-activation
P11139605A0811|204 210|C/EBPs
P11140472A0497|121 132|monochannel
P11140472A0497|148 153|noise
P11140472A0497|206 211|noise
P11140472A0497|16 23|results
P11140472A0497|238 255|cases improvement
P11142380A0389|180 187|regions
P11142380A0389|78 80|TE
P11142380A0389|143 150|helices
P11142380A0389|1 9|Nuclease
P11145562A0000|46 59|growth factor
P11145562A0000|94 102|prostate
P11145562A0000|176 181|state
P11145562A0000|127 141|transformation
P11145562A0000|114 119|cells
P11145563A0202|64 70|sterol
P11145563A0202|33 46|StAR promoter
P11145566A0000|26 46|lipoprotein receptor
P11145566A0000|159 164|drugs
P11145566A0000|48 53|HDL-R
P11145566A0000|186 202|HDL-R regulation
P11145590A0217|90 92|TG
P11145590A0217|41 51|mechanisms
P11145590A0217|126 135|attention
P11145590A0217|139 159|TGF-beta1 regulation
P11145743A0170|58 71|thyroid cells
P11145743A0170|159 166|protein
P11145743A0170|216 236|deiodinase promoters
P11145743A0170|87 115|thyroid transcription factor
P11145743A0170|119 124|TTF-1
P11145887A1393|105 109|JunB
P11145887A1393|41 50|AP-1 site
P11145887A1393|158 163|level
P11145887A1393|98 103|c-Jun
P11145887A1393|70 74|JunD
P11146961T0000|60 73|artery bypass
P11146961T0000|1 20|Perfusion technique
P11148589A1124|56 63|authors
P11148589A1124|142 161|United States today
P11148589A1124|234 256|liver carcinoma deaths
P11148589A1124|102 127|Pacific Islander children
P11150114T0000|39 50|association
P11150315A0844|42 61|ERK phosphorylation
P11150315A0844|97 104|reports
P11150439A0701|75 77|CO
P11150439A0701|56 64|infusion
P11150439A0701|128 159|isotope ratio mass spectroscopy
P11150439A0701|100 124|enrichment determination
P11150439A0701|1 19|Energy expenditure
P11152070A0573|60 74|A. chrysogenum
P11152070A0573|123 142|cefEF cephalosporin
P11152070A0573|5 14|actA gene
P11152070A0573|38 42|copy
P11152070A0573|50 56|genome
P11152283A0223|74 78|PC12
P11152283A0223|52 70|gene transcription
P11152283A0223|83 94|INS-1 cells
P11152283A0223|34 37|NGF
P11152451A0529|36 43|SmSmad2
P11152451A0529|5 34|Schistosoma mansoni homologue
P11152521A0181|77 95|expression vectors
P11152521A0181|158 167|component
P11152521A0181|20 36|protein products
P11153302A0000|117 131|detoxification
P11153302A0000|85 92|efforts
P11155096A0222|242 244|T4
P11155096A0222|146 151|IU/ml
P11155096A0222|219 240|serum thyroxin levels
P11155096A0222|154 170|serum TSH levels
P11155096A0222|10 24|Thyroid status
P11155096A0222|69 79|assessment
P11156413T0000|60 75|tumor cell line
P11156413T0000|135 146|development
P11156413T0000|89 101|polyomavirus
P11156413T0000|24 40|characterization
P11156413T0000|1 11|Derivation
P11156618T0000|73 84|sensitivity
P11156618T0000|12 22|comparison
P11156618T0000|140 145|peaks
P11157035A1405|31 36|study
P11157035A1405|126 138|IFN alpha-2b
P11157035A1405|5 14|utilities
P11157035A1405|169 176|therapy
P11157763T0000|96 109|dimer mimicry
P11157763T0000|1 10|Structure
P11157784A0141|29 45|chromosome 22q11
P11157784A0141|124 128|gene
P11157784A0141|179 181|b.
P11157784A0141|112 116|copy
P11157784A0141|173 177|sc11
P11158236A0000|40 44|acid
P11158236A0000|22 25|NGF
P11158236A0000|1 20|Nerve growth factor
P11158290A0728|113 120|epsilon
P11158290A0728|87 99|IkappaBalpha
P11158290A0728|102 106|beta
P11158310A0993|29 33|ERSF
P11158310A0993|141 144|UPR
P11158310A0993|70 74|beta
P11158326A1032|53 61|mutation
P11158326A1032|69 79|SH2 domain
P11158456A0223|23 32|interview
P11158456A0223|55 59|time
P11158456A0223|223 234|termination
P11158456A0223|109 118|intervals
P11158456A0223|129 133|type
P11158456A0223|174 184|phenomenon
P11158456A0223|1 8|METHODS
P11158456A0223|137 140|BHS
P11159363A1251|62 64|CG
P11159363A1251|123 130|complex
P11159363A1251|65 66|m
P11159363A1251|1 12|Methylation
P11160280A1275|56 63|binding
P11160280A1275|71 82|IRF element
P11160656A0000|89 94|MIERR
P11160656A0000|145 151|region
P11160656A0000|189 205|HCMV replication
P11160656A0000|260 270|cell types
P11160656A0000|81 87|region
P11160656A0000|316 319|NT2
P11160656A0000|128 136|enhancer
P11160656A0000|1 11|Inactivity
P11160688A1726|121 130|cytoplasm
P11160688A1726|109 113|ICP0
P11160688A1726|48 57|structure
P11160732A0464|132 141|SIVmac316
P11160732A0464|178 188|SIVmac1A11
P11160732A0464|65 78|SIVmac clones
P11160732A0464|1 14|Vector stocks
P11160738A1414|27 36|functions
P11160738A1414|69 82|establishment
P11160860A0662|208 236|IkappaBalpha phosphorylation
P11160860A0662|189 194|cells
P11160860A0662|48 56|IKK-beta
P11160860A0662|84 88|role
P11160902A0962|46 55|potential
P11160902A0962|196 200|gene
P11160902A0962|17 21|TFOs
P11161455A1286|52 64|cell hybrids
P11161455A1286|1 23|Southern blot analysis
P11161455A1286|102 111|cDNA maps
P11161793A1033|56 63|species
P11161793A1033|143 156|EGFR activity
P11161793A1033|84 92|proteins
P11162278A0629|123 128|gyrus
P11162278A0629|8 16|rotation
P11162666A0442|88 93|acids
P11162666A0442|54 62|addition
P11163932A0000|13 18|tests
P11163932A0000|193 204|temperature
P11163932A0000|212 222|substratum
P11163932A0000|235 250|air temperature
P11164078A0833|47 52|model
P11164078A0833|89 107|treatment-response
P11164078A0833|76 85|viewpoint
P11164078A0833|6 18|animal model
P11166863A0167|62 67|grade
P11166863A0167|21 25|% CI
P11166863A0167|32 33|%
P11167111A0957|74 84|recipients
P11167111A0957|123 125|TX
P11167111A0957|22 46|lung function parameters
P11168366A0569|41 49|fragment
P11168366A0569|4 12|addition
P11168366A0569|103 111|GGT mRNA
P11168446T0000|94 105|alterations
P11168446T0000|39 47|patients
P11169080T0000|14 23|education
P11169080T0000|59 62|Law
P11169149A0097|31 36|SNTCS
P11171118A0836|15 22|binding
P11171118A0836|147 157|antibodies
P11171118A0836|76 87|competition
P11171118A0836|103 115|interactions
P11172610A0508|14 17|p73
P11172610A0508|50 56|number
P11172944A0826|66 81|plasma TNFalpha
P11172944A0826|86 107|radiation pneumonitis
P11176098A0342|18 22|pigs
P11177538A0655|65 91|% gene transfer efficiency
P11177538A0655|35 38|MOI
P11178248A1042|120 129|positives
P11178248A1042|72 83|sensitivity
P11178248A1042|100 110|occurrence
P11178765A0642|62 73|development
P11178765A0642|52 56|acid
P11178765A0642|157 162|cells
P11178765A0642|117 137|mouse adenocarcinoma
P11179400T0000|26 53|carotid body chemoreceptors
P11179668A0869|64 75|PLTP family
P11179687A1118|134 140|member
P11179687A1118|63 73|disulphide
P11179687A1118|82 92|Ig members
P11179956A1818|61 68|effects
P11179956A1818|13 20|results
P11179956A1818|144 156|interactions
P11179956A1818|87 93|domain
P11180255A0776|167 172|space
P11180255A0776|24 33|arguments
P11180255A0776|158 162|time
P11180255A0776|70 77|effects
P11181516A0119|230 238|elements
P11181516A0119|173 195|rat insulin I promoter
P11181516A0119|154 161|regions
P11181516A0119|17 62|deletion insulin promoter-reporter constructs
P11181531A0464|28 37|estrogens
P11181531A0464|161 184|cytokines interleukin-6
P11181531A0464|189 202|interleukin-1
P11181531A0464|85 98|transcription
P11181564A0733|63 73|chromosome
P11181564A0733|20 25|genes
P11182520A0889|75 80|assay
P11182520A0889|50 61|restriction
P11188971A0000|47 54|disease
P11188971A0000|56 58|PD
P11188971A0000|23 30|surgery
P11188971A0000|35 44|Parkinson
P11189314A1000|29 33|BACM
P11189314A1000|7 14|results
P11191365A0682|242 243|%
P11191365A0682|296 297|P
P11191365A0682|223 225|VT
P11191365A0682|87 88|%
P11191365A0682|130 141|tachycardia
P11191365A0682|230 231|%
P11191365A0682|36 47|arrhythmias
P11191365A0682|236 238|VF
P11191365A0682|1 15|Susceptibility
P11193666A1269|31 40|outbreaks
P11193666A1269|99 103|herd
P11194101A0532|123 128|spine
P11194101A0532|93 99|others
P11194101A0532|336 340|bone
P11194101A0532|234 235|P
P11194101A0532|222 228|g x cm
P11194183A0866|121 125|area
P11194183A0866|384 386|SD
P11194183A0866|419 425|t test
P11194183A0866|295 310|procyanidin B-2
P11194183A0866|263 293|placebo control group subjects
P11194183A0866|393 396|cm2
P11194183A0866|17 23|number
P11194183A0866|345 348|cm2
P11194183A0866|350 357|placebo
P11194183A0866|36 41|hairs
P11194183A0866|64 69|hairs
P11195401A1030|44 49|cases
P11195401A1030|79 92|AVP secretion
P11195401A1030|6 23|plasma AVP levels
P11196199T0000|7 16|homologue
P11196199T0000|156 164|activity
P11196199T0000|168 171|p53
P11197288A0855|105 109|rate
P11197288A0855|25 38|metronidazole
P11197288A0855|69 76|strains
P11197549A0748|59 61|SD
P11197549A0748|21 41|stabilization period
P11197549A0748|1 8|RESULTS
P11198053T0000|90 102|constituents
P11198053T0000|26 33|extract
P11198053T0000|7 14|effects
P11198053T0000|18 20|LI
P11198053T0000|69 73|wort
P11198385A0000|26 39|algerae Vavra
P11198385A0000|86 92|adults
P11198385A0000|152 171|Gharbia Governorate
P11200568A0830|12 16|dams
P11200568A0830|95 98|IgM
P11200568A0830|67 75|necropsy
P11200568A0830|1 6|Blood
P11202434T0000|104 109|ACBP2
P11202434T0000|57 63|domain
P11202434T0000|8 32|amino acid substitutions
P11202434T0000|114 125|Arabidopsis
P11203702A1307|211 219|activity
P11203702A1307|7 13|Xlim-1
P11203702A1307|115 121|domain
P11203702A1307|223 229|Xlim-1
P11207216A0296|88 102|chain reaction
P11207216A0296|12 23|PGHS-2 cDNA
P11207261A1421|12 20|analysis
P11207261A1421|193 205|phosphatases
P11207261A1421|348 356|receptor
P11207261A1421|217 222|SHP-2
P11207261A1421|306 316|coligation
P11207261A1421|290 300|regulation
P11207282A0729|193 202|reduction
P11207282A0729|67 81|chicken Notch1
P11207282A0729|21 31|expression
P11207282A0729|206 226|IgH gene transcripts
P11207308A0999|63 68|agent
P11207308A0999|219 223|JAK3
P11207308A0999|154 159|c-Jun
P11207308A0999|12 20|curcumin
P11207308A0999|143 148|STAT1
P11207308A0999|237 256|p38 phosphorylation
P11207308A0999|171 188|kinase activation
P11208017A0070|54 60|SCOF-1
P11208017A0070|3 13|cDNA clone
P11209100A0069|164 197|interleukin-1 receptor antagonist
P11209100A0069|26 36|properties
P11209100A0069|108 119|stimulation
P11209100A0069|97 104|effects
P11210401A0000|135 143|patients
P11210401A0000|95 104|treatment
P11210401A0000|70 77|polymer
P11210401A0000|1 24|Sevelamer hydrochloride
P11210839A0282|58 66|patients
P11210839A0282|8 26|PO3 administration
P11210839A0282|142 153|ethambutole
P11210839A0282|38 42|half
P11211759A0165|88 94|system
P11211759A0165|127 148|transtracheal heating
P11211759A0165|219 235|cancer operation
P11211759A0165|39 54|Control group A
P11211759A0165|1 9|Patients
P11212249A0993|104 112|activity
P11212249A0993|77 94|activator protein
P11212249A0993|98 102|AP-1
P11213342A0492|14 28|parameters SF2
P11213342A0492|86 97|test period
P11214354A1104|73 91|lipid peroxidation
P11214354A1104|42 43|p
P11214354A1104|113 127|protein thiols
P11214354A1104|138 141|I-R
P11216247T0000|5 10|child
P11220166A0616|90 97|aspects
P11220166A0616|318 327|behaviour
P11220166A0616|298 303|motor
P11220166A0616|230 242|intervention
P11220166A0616|197 221|brain dopamine receptors
P11220166A0616|17 24|effects
P11220306A1753|107 114|effects
P11220306A1753|26 29|DNA
P11220306A1753|20 24|rsmB
P11220306A1753|70 80|production
P11220487T0000|33 38|tests
P11221836A0981|24 30|fusion
P11221836A0981|92 99|potency
P11221845A0800|133 155|493-amino acid protein
P11221845A0800|40 53|reading frame
P11221845A0800|212 218|region
P11221845A0800|99 108|B236 spot
P11221845A0800|171 191|SNAG repressor motif
P11221845A1713|56 75|5-aza-deoxycytidine
P11221845A1713|190 193|mlt
P11221845A1713|49 54|agent
P11221845A1713|14 27|N18TG-2 cells
P11221845A1713|106 109|mlt
P11221845A1713|207 218|target gene
P11221845A1713|239 250|methylation
P11222639A1273|74 84|regulation
P11222639A1273|7 14|results
P11223131A0000|181 187|agents
P11223131A0000|202 205|use
P11223131A0000|32 70|malaria parasite Plasmodium falciparum
P11223131A0000|100 111|cell growth
P11223131A0000|137 143|target
P11223164A0000|105 112|variety
P11223164A0000|88 94|growth
P11223164A0000|39 54|differentiation
P11223164A0000|137 142|cells
P11223199A0751|43 51|exposure
P11223199A0751|55 65|S. neurona
P11223199A0751|69 80|WB analysis
P11223246A0359|90 98|proteins
P11223246A0359|1 18|Sequence analysis
P11223246A0359|34 55|RBP21 shares homology
P11223256A1212|66 80|pea 33RNP gene
P11223938X1218|1 10|Copyright
P11223938X1218|35 39|Ltd.
P11226228A0899|10 18|plasmids
P11227039A0953|60 61|P
P11227039A0953|107 113|groups
P11227039A0953|36 39|BMI
P11227039A0953|84 89|primi
P11227484T0000|31 44|methylmercury
P11227484T0000|80 91|rhodamine B
P11227484T0000|51 74|ion-association complex
P11230145A0732|183 193|conversion
P11230145A0732|5 12|results
P11230145A0732|38 42|role
P11230145A0732|50 60|Notch-CBF1
P11230534A0688|56 63|species
P11231287A0158|26 53|neuroblastoma cells SK-N-SH
P11231287A0158|65 74|apoptosis
P11233643A0000|120 123|PDT
P11233643A0000|166 174|ALA dose
P11233643A0000|111 118|therapy
P11233643A0000|25 28|use
P11233643A0000|50 54|acid
P11235335T0000|10 13|HIV
P11235817A0000|73 78|class
P11235817A0000|124 132|symptoms
P11235817A0000|82 93|medications
P11235817A0000|202 208|adults
P11237038A0889|13 21|patients
P11237038A0889|111 115|HIFU
P11237038A0889|23 24|n
P11237598A0962|28 37|framework
P11237598A0962|132 141|mechanism
P11237598A0962|69 79|structures
P11238375A0617|72 82|activation
P11238375A0617|126 132|member
P11238375A0617|140 150|p38 family
P11238375A0617|154 159|MAPKs
P11238405A0817|105 109|role
P11238405A0817|41 50|atf1-pcr1
P11238405A0817|67 76|activator
P11238405A0817|173 177|atf1
P11238405A0817|4 11|strains
P11238586A0000|177 183|alpha1
P11238586A0000|159 167|contacts
P11238586A0000|188 202|alpha2 helices
P11238586A0000|133 144|alpha/betas
P11238586A0000|78 81|MHC
P11238586A0000|111 126|T cell receptor
P11238884A0892|46 64|growth retardation
P11238884A0892|146 152|palate
P11238884A0892|113 121|mandible
P11238884A0892|98 108|premaxilla
P11238884A0892|68 73|utero
P11238947A0636|10 21|base change
P11238947A0636|23 26|A8G
P11238947A0636|55 71|hnRNP A2 binding
P11239529A0981|59 66|lesions
P11239529A0981|38 50|endometrioma
P11241166A0677|209 220|suppressors
P11241166A0677|267 275|sequence
P11241166A0677|248 256|cytokine
P11241166A0677|20 35|gene expression
P11241166A0677|84 92|decrease
P11241166A0677|133 137|mRNA
P11241166A0677|8 16|analysis
P11241166A0677|277 280|CIS
P11241166A0677|171 181|regulators
P11241243A0693|130 135|% PSC
P11241243A0693|5 12|authors
P11241243A0693|141 155|p53 expression
P11241243A0693|119 128|component
P11241356T0000|94 121|collagen gene transcription
P11241356T0000|42 54|localization
P11243306A0961|151 159|presence
P11243306A0961|163 175|hypertension
P11243306A0961|203 209|levels
P11243306A0961|1 12|CONCLUSIONS
P11243494A0833|29 35|groups
P11243494A0833|76 79|CRF
P11243494A0833|19 23|days
P11243494A0833|1 8|RESULTS
P11243980A0510|36 52|PET examinations
P11244733A0782|10 21|lung cancer
P11244733A0782|97 102|death
P11246679A0000|31 42|association
P11246679A0000|113 120|disease
P11246679A0000|1 10|OBJECTIVE
P11247663A1447|30 41|inheritance
P11247663A1447|5 13|families
P11248626T0000|30 38|Cavermap
P11248626T0000|106 119|prostatectomy
P11248626T0000|49 57|location
P11248626T0000|1 9|Efficacy
P11250942A0626|12 20|analyses
P11250942A0626|176 183|regions
P11250942A0626|43 48|GRIP1
P11250942A0626|129 140|interaction
P11250942A0626|191 194|VDR
P11251104A0526|62 88|transcription factor GAMyb
P11251104A0526|19 32|alpha-amylase
P11251276A0793|11 19|patients
P11251951A0000|181 189|melanoma
P11251951A0000|13 23|Dermoscopy
P11251951A0000|199 203|CMIS
P11251951A0000|157 165|patients
P11251951A0000|1 11|BACKGROUND
P11254504A0766|183 204|zinc finger protein-1
P11254504A0766|146 150|p300
P11254504A0766|221 229|homeobox
P11254504A0766|14 29|promoter region
P11254504A0766|160 173|factor-kappaB
P11254504A0766|140 144|MyoD
P11254504A0766|100 117|growth response-1
P11255035A0331|14 30|progenitor cells
P11255035A0331|76 84|capacity
P11255423A0211|134 139|women
P11255423A0211|106 120|CD4 lymphocyte
P11255423A0211|145 148|HIV
P11255423A0211|81 90|mortality
P11256944A1144|26 31|forms
P11256944A1144|127 153|ER stress response element
P11256944A1144|35 39|ATF6
P11257870A0000|208 211|TCE
P11257870A0000|189 206|trichloroethylene
P11257870A0000|48 57|potential
P11257870A0000|118 120|TF
P11257870A0000|224 235|temperature
P11257870A0000|167 177|wastewater
P11257870A0000|136 150|sludge process
P11259347A0000|122 129|ability
P11259347A0000|11 23|observations
P11259347A0000|114 120|humans
P11259347A0000|100 110|variations
P11259593A1094|42 47|Ace2p
P11259593A1094|1 9|Analysis
P11260662X0000|14 16|D.
P11260662X0000|1 3|A.
P11263664A1085|52 72|XBra gene expression
P11263664A1085|80 88|mesoderm
P11264176A0181|87 109|cyclin A2/cdk2 complex
P11264182A0000|45 48|Tax
P11264182A0000|208 223|T-cell leukemia
P11264182A0000|7 33|T-cell leukemia virus type
P11264182A0000|184 198|leukemogenesis
P11264375A0000|11 26|cytomegalovirus
P11264375A0000|160 170|infections
P11264375A0000|81 95|phosphoprotein
P11265853A0000|45 49|LVAS
P11265853A0000|52 64|Novacor Corp
P11265853A0000|5 12|Novacor
P11266194A0743|60 70|tomography
P11266194A0743|1 5|Body
P11266540A0328|122 144|Tcf/Lef family members
P11266615A0258|73 86|linker region
P11266615A0258|5 12|protein
P11268459A0167|211 223|chemotherapy
P11268459A0167|47 59|relationship
P11268459A0167|26 31|study
P11268459A0167|228 237|prognosis
P11268459A0167|127 131|rate
P11268459A0167|117 125|response
P11271297T0000|58 71|cyclosporin A
P11271297T0000|33 54|liver transplantation
P11274109A0129|30 38|bacteria
P11274109A0129|57 62|phase
P11274179A0610|45 51|module
P11274179A0610|11 18|studies
P11274179A0610|64 69|Raf-1
P11274184A1068|88 97|ho-1 gene
P11274184A1068|7 14|results
P11274184A1068|54 58|CdCl
P11274184A1068|70 80|expression
P11274368A0469|93 121|histone deacetylase activity
P11274368A0469|6 12|effect
P11274563T0000|7 18|lung volume
P11274563T0000|20 30|estimation
P11276426A0501|61 66|share
P11276426A0501|41 48|protein
P11276426A0501|4 9|mouse
P11276426A0501|69 88|% sequence identity
P11278286A0456|270 280|inhibition
P11278286A0456|158 168|rat 5-HT1A
P11278286A0456|115 118|GRE
P11278286A0456|19 24|cells
P11278286A0456|227 236|inclusion
P11278286A0456|42 44|GR
P11278286A0456|38 40|MR
P11278286A0456|68 76|deletion
P11278290A1220|124 129|cells
P11278290A1220|199 213|Agc expression
P11278290A1220|82 92|activation
P11278290A1220|190 195|level
P11278390A0632|138 144|levels
P11278390A0632|118 125|tissues
P11278440A0095|94 108|hydrophobicity
P11278440A0095|83 85|S1
P11278440A0095|39 62|S1 transmembrane domain
P11278488T0000|62 73|association
P11278488T0000|5 21|v-Src SH3 domain
P11278563A0917|73 88|ankyrin repeats
P11278563A0917|128 139|interaction
P11278563A0917|48 59|amino acids
P11278594A0618|243 250|peptide
P11278594A0618|41 48|chimera
P11278594A0618|22 32|propeptide
P11278594A0618|81 101|TGF-beta1 propeptide
P11278594A0618|154 161|chimera
P11278610A0902|66 80|ubiquitination
P11278610A0902|84 92|TEL-JAK2
P11278713A1054|90 110|instability elements
P11278713A1054|25 31|region
P11278713A1054|68 72|site
P11278848A1316|14 22|SB203580
P11278848A1316|79 96|promoter activity
P11278848A1316|59 62|Sp1
P11278870A0123|90 103|fission yeast
P11278870A0123|192 196|CuSE
P11278870A0123|63 86|copper transporter gene
P11278870A0123|142 150|identity
P11278870A0123|55 59|ctr4
P11279038A0194|89 107|Holliday junctions
P11279038A0194|33 47|DNA structures
P11279108T0000|135 147|muscle cells
P11279108T0000|37 55|CArG box sequences
P11279108T0000|1 8|Binding
P11279385A3917|104 111|Doppler
P11279385A3917|88 90|2D
P11279385A3917|190 200|conduction
P11279385A3917|222 228|method
P11280495A1330|62 71|PD fluids
P11280495A1330|108 123|Amadori albumin
P11280495A1330|1 12|CONCLUSIONS
P11282029A0075|28 41|growth factor
P11282029A0075|43 47|PDGF
P11282029A0075|5 10|mouse
P11282029A0075|100 104|NF-Y
P11282394A0841|128 146|cross-reactivities
P11282394A0841|70 90|antigen reactivities
P11282395A1073|44 55|differences
P11282395A1073|149 166|blood lymphocytes
P11282395A1073|173 184|NBS patient
P11282395A1073|4 12|addition
P11282761A0531|60 79|plasma L-citrulline
P11282761A0531|97 108|enhancement
P11282761A0531|6 21|supplementation
P11283014A0921|26 30|WASP
P11283014A0921|144 164|actin polymerization
P11283014A0921|65 80|TCR stimulation
P11283256A0258|33 37|MRCK
P11285054A0781|92 98|amount
P11285054A0781|173 183|NREM sleep
P11285054A0781|1 20|Regression analyses
P11285054A0781|119 142|NREMP dream occurrences
P11285329A0682|40 45|women
P11285329A0682|23 33|micromol/L
P11287555A1057|5 20|Delta6CCI virus
P11287555A1057|49 69|replication capacity
P11287579A1084|9 15|mutant
P11287579A1084|33 40|ability
P11287579A1084|17 22|T255A
P11287623A0286|212 228|mouse cell lines
P11287623A0286|96 113|signaling pathway
P11287623A0286|191 198|variety
P11288208A0712|135 141|months
P11288208A0712|89 96|decline
P11288208A0712|42 58|tract infections
P11288208A0712|100 115|CD4 cell counts
P11289135A0975|15 17|FP
P11289135A0975|209 219|disruption
P11289135A0975|228 235|pathway
P11289135A0975|67 77|activation
P11289135A0975|156 178|protein kinase cascade
P11289135A0975|1 11|Coexposure
P11290415A0288|121 133|PCR analysis
P11290415A0288|109 116|library
P11290415A0288|71 80|screening
P11291552A0156|14 22|patients
P11291552A0156|1 8|METHODS
P11292839A0531|123 131|TATA-box
P11292839A0531|95 104|exception
P11292839A0531|185 192|protein
P11292839A0531|72 79|U6 gene
P11292839A0531|199 205|mutant
P11292839A0531|5 18|transcription
P11294895A0292|30 35|spo20
P11294895A0292|124 161|phosphatidylinositol transfer protein
P11294895A0292|39 51|gene product
P11295523A0218|50 59|mid-1970s
P11296288A1107|104 113|sequences
P11296288A1107|46 61|pCMVJS21DeltaGP
P11296288A1107|22 32|derivative
P11296288A1107|4 12|addition
P11297419A0894|79 86|changes
P11297419A0894|124 131|residue
P11297419A0894|57 75|fluorescence probe
P11297545A0948|30 39|CHOP cDNA
P11297545A0948|213 216|hGH
P11297545A0948|112 120|mediator
P11297545A0948|191 200|apoptosis
P11297545A0948|87 91|CHOP
P11297545A0948|222 225|p38
P11298326A0677|63 72|selection
P11298326A0677|143 158|point mutations
P11298326A0677|32 44|Vkappa genes
P11302072A0508|73 91|Boston Naming Test
P11302072A0508|54 65|performance
P11302072A0508|33 44|stimulation
P11302704T0000|1 21|Homo-oligomerisation
P11302704T0000|34 46|localisation
P11303638A0559|67 68|p
P11303638A0559|64 65|%
P11305129T0000|30 44|tetanus toxoid
P11305129T0000|93 105|implications
P11305129T0000|113 116|use
P11305129T0000|1 8|Effects
P11306463A0383|31 33|Rb
P11306463A0383|128 136|C domain
P11306463A0383|19 27|C domain
P11306845A0168|14 25|examination
P11306845A0168|97 110|keratinocytes
P11308877A0213|47 50|map
P11308877A0213|113 128|discharge times
P11308877A0213|68 76|relation
P11309373A0783|13 23|mCTR mRNAs
P11309373A0783|126 132|region
P11309373A0783|174 181|regions
P11309373A0783|64 73|promoters
P11309373A0783|102 115|mCTR isoforms
P11309400T0000|41 45|mRNA
P11309400T0000|57 62|decay
P11309678A0489|88 97|mutations
P11309678A0489|39 43|mRNA
P11309678A0489|118 126|splicing
P11311153T0000|95 106|angiotensin
P11311153T0000|142 163|thromboembolic events
P11311153T0000|118 124|enzyme
P11311480A0079|72 83|alterations
P11311480A0079|7 19|nerve biopsy
P11311480A0079|155 159|loss
P11311480A0079|102 119|cell infiltration
P11311563A0423|11 20|CCAAT box
P11311563A0423|114 123|CCAAT box
P11311909A0938|88 103|A1 fenestration
P11311909A0938|18 22|case
P11312108A2853|1 5|Raes
P11312326A0169|46 51|HIV-1
P11312326A0169|72 99|complementation experiments
P11312326A0169|242 259|virus replication
P11312326A0169|232 238|rescue
P11312326A0169|136 145|isolation
P11313249T0000|61 68|protein
P11313249T0000|99 116|activation domain
P11313386A0704|1 22|SH2D1A protein levels
P11313946A0449|29 34|Nore1
P11313946A0449|20 24|AF-6
P11313946A0449|1 9|RPM/RGL3
P11313961A1323|127 134|strains
P11313961A1323|5 9|mice
P11313961A1323|117 120|p53
P11314046A0000|56 78|cell cycle progression
P11314046A0000|1 8|Cyclins
P11314428A0651|45 59|hydroxyapatite
P11314428A0651|182 185|LHS
P11314428A0651|67 74|sockets
P11314428A0651|99 111|significance
P11314428A0651|171 172|P
P11316127A0485|90 104|Control groups
P11316127A0485|5 11|%SVend
P11318363A0085|23 28|study
P11318608A1155|29 58|DENTT NLS deletion constructs
P11318608A1155|81 86|NLS-1
P11319880A1108|74 86|predominance
P11319880A1108|12 31|FRAP/mTOR inhibitor
P11319880A1108|94 99|alpha
P11323411A0505|211 212|P
P11323411A0505|148 163|phosphotyrosine
P11323411A0505|53 64|SH2 domains
P11323411A0505|185 197|C-SH2 domain
P11323411A0505|169 170|P
P11323411A0505|1 26|Far Western blot analysis
P11323716A0413|30 34|DDI1
P11323716A0413|5 16|UBA domains
P11325195A0661|40 46|muscle
P11325195A0661|5 7|R2
P11325195A0661|69 73|lamb
P11325685A1624|104 111|fatigue
P11325685A1624|149 166|exercise capacity
P11325685A1624|170 191|hemodialysis patients
P11327292A0190|99 105|vision
P11327292A0190|35 47|malformation
P11327858A0087|90 93|p53
P11327858A0087|77 86|regulator
P11327858A0087|19 29|mechanisms
P11328853A0644|24 49|promoter deletion mutants
P11328853A0644|65 69|SF-1
P11331596A0710|88 95|protein
P11331596A0710|1 5|Prrp
P11331613A0827|12 19|effects
P11331613A0827|23 36|pVHL function
P11333268A1521|61 64|Sos
P11333268A1521|265 275|disruption
P11333268A1521|247 253|switch
P11333268A1521|87 93|switch
P11333268A1521|15 23|analysis
P11333268A1521|107 110|Ras
P11333268A1521|230 241|interaction
P11333268A1521|311 327|GDP dissociation
P11333268A1521|136 148|consequences
P11335116A1099|266 275|ESP genes
P11335116A1099|251 261|BmGATAbeta
P11335116A1099|40 46|BmHR3A
P11335116A1099|97 129|Orphan receptor Response Element
P11335116A1099|237 247|expression
P11335116A1099|69 73|RORE
P11335116A1099|171 176|genes
P11336211A0132|45 49|Appl
P11337859A0651|181 221|hydrogen peroxide oxidation pretreatment
P11337859A0651|227 238|H2O2 dosage
P11337859A0651|57 62|FeCl3
P11337859A0651|145 150|mol/L
P11337859A0651|112 123|coagulation
P11337859A0651|50 51|%
P11340080A0096|151 158|studies
P11340080A0096|73 77|Rad9
P11340080A0096|57 61|Rad1
P11340080A0096|35 55|checkpoint signaling
P11340516A0509|14 20|ADAL-2
P11340516A0509|62 71|tolerance
P11340516A0509|1 10|Tolerance
P11341349T0000|7 17|indicators
P11341349T0000|84 89|women
P11341405A1154|56 65|thickness
P11341405A1154|178 185|osteons
P11341405A1154|294 301|loading
P11341405A1154|250 259|responses
P11341405A1154|193 209|dorsal quadrants
P11341405A1154|111 112|V
P11341405A1154|336 342|tracks
P11341405A1154|307 313|result
P11342479A0430|13 20|RESULTS
P11342479A0430|22 42|Palmaz-Schatz stents
P11342479A0430|115 124|immersion
P11342479A0430|1 8|METHODS
P11345435A0199|108 120|localization
P11345435A0199|49 51|P3
P11347201X0001|63 67|diet
P11347201X0001|23 29|adults
P11347201X0001|81 91|Plant food
P11347201X0001|1 19|Nutritional status
P11349796A0950|133 137|days
P11349796A0950|145 148|D30
P11349796A0950|115 117|D3
P11349796A0950|68 70|D0
P11350165A1606|61 75|stem structure
P11350165A1606|101 123|translation efficiency
P11350165A1606|16 27|DB sequence
P11350812A0829|122 147|caldesmon phosphorylation
P11350812A0829|80 88|Rp-cAMPS
P11350812A0829|1 11|Inhibition
P11350982A0560|44 55|involvement
P11350982A0560|59 80|GCN1-GCN2 interaction
P11350982A0560|84 94|activation
P11352663A0138|90 97|binding
P11352663A0138|131 140|NF-kappaB
P11352663A0138|4 14|comparison
P11352663A0138|34 43|Ad5 cells
P11353392A1127|5 15|frameshift
P11353392A1127|68 83|coding sequence
P11353774A0255|126 132|member
P11353774A0255|247 254|protein
P11353774A0255|159 176|factor 3/forkhead
P11353774A0255|80 96|rhabdomyosarcoma
P11353774A0255|98 102|FKHR
P11353774A0255|186 197|gene family
P11354975A0850|77 86|bromeliad
P11354975A0850|7 14|species
P11354975A0850|99 106|El Humo
P11355615A0766|12 21|education
P11355615A0766|78 90|intervention
P11355615A0766|114 122|practice
P11356214A0794|195 205|dimensions
P11356214A0794|213 219|cavity
P11356214A0794|5 15|difference
P11356214A0794|174 185|Teflon mold
P11356214A0794|19 27|hardness
P11356214A0794|51 60|specimens
P11356835A0000|73 80|control
P11356835A0000|158 179|amino acid starvation
P11356835A0000|100 104|cell
P11356853A0554|52 61|sequences
P11356853A0554|85 93|elements
P11357063A0138|40 50|comparison
P11357063A0138|202 234|LHbeta-CGbeta gene cluster locus
P11357063A0138|114 121|species
P11357063A0138|171 185|LH/CGbeta gene
P11358801A1046|104 113|agreement
P11358801A1046|52 67|NHEJ deficiency
P11358801A1046|85 99|rearrangements
P11358962A0344|79 96|mouse development
P11358962A0344|39 45|levels
P11358962A0344|1 6|Foxp1
P11358962A0344|137 154|airway epithelium
P11359827T0000|31 47|characterization
P11359827T0000|104 109|SPE-J
P11360190A0178|90 101|G2/M phases
P11360190A0178|41 63|cell cycle progression
P11360190A0178|111 126|T-cell line Kit
P11360190A0178|84 85|S
P11361338A0447|11 27|PEX5-TPR domains
P11361338A0447|92 97|yeast
P11361338A0447|53 61|nematode
P11367523A1684|31 34|C4A
P11367523A1684|39 42|C4B
P11367523A1684|1 27|Immunofixation experiments
P11368363A0129|296 304|proteins
P11368363A0129|254 268|mobility group
P11368363A0129|133 137|time
P11368363A0129|196 200|HBP1
P11368363A0129|202 228|HMG-Box containing protein
P11368363A0129|101 104|MPO
P11368787A0180|107 109|bp
P11368787A0180|26 34|activity
P11368787A0180|1 9|Promoter
P11368911T0000|29 34|smg-4
P11368911T0000|49 66|mRNA surveillance
P11369066A1210|75 80|cream
P11369066A1210|142 147|cream
P11369066A1210|21 24|MMF
P11369410A0949|88 97|behaviour
P11369410A0949|43 48|sense
P11369410A0949|54 74|stimulus differences
P11369700A0074|147 149|GL
P11369700A0074|97 110|transcription
P11369700A0074|157 169|region genes
P11369700A0074|1 4|CSR
P11369700A0074|137 145|germline
P11369759A0605|1 5|Cell
P11371115A0962|108 111|MGN
P11371115A0962|5 15|proportion
P11371115A0962|115 127|MPGN pattern
P11371160A0854|57 65|tyrosine
P11371160A0854|6 12|domain
P11371160A0854|87 93|anchor
P11371160A0854|136 146|efficiency
P11371417A0744|123 144|tumor necrosis factor
P11371417A0744|54 64|% decrease
P11371417A0744|250 259|protein-2
P11371417A0744|319 328|cytokines
P11371417A0744|369 375|change
P11371417A0744|101 119|lung lavage levels
P11371417A0744|151 156|alpha
P11371417A0744|214 219|pg/ml
P11371417A0744|146 149|TNF
P11371417A0744|12 23|ventilation
P11371417A0744|196 200|beta
P11371417A0744|410 420|aggregates
P11372959A1447|132 144|relationship
P11372959A1447|10 29|regression analysis
P11372959A1447|229 243|tick abundance
P11372959A1447|173 189|habitat category
P11372959A1447|216 225|variation
P11374051A0437|61 76|corticosteroids
P11374051A0437|178 186|bleeding
P11374051A0437|54 57|use
P11374051A0437|136 144|diseases
P11374051A0437|102 121|ulcer complications
P11374866X0914|16 30|Academic Press
P11376007A0584|268 297|protein phosphatase inhibitor
P11376007A0584|108 116|addition
P11376007A0584|43 47|loss
P11376007A0584|82 88|DNA-PK
P11376007A0584|55 78|protein kinase activity
P11376134A1506|7 18|corrections
P11376134A1506|69 89|transcription factor
P11376279A0000|121 139|volume acquisition
P11376279A0000|54 63|resonance
P11376279A0000|3 9|method
P11376946A0000|14 21|studies
P11376946A0000|192 197|cells
P11376946A0000|124 129|cells
P11376946A0000|260 262|P1
P11376946A0000|250 258|promoter
P11378898A0164|31 44|Accession No.
P11378898A0164|1 5|ORF1
P11380028A0000|120 138|orthoiodohippurate
P11380028A0000|146 154|131I-OIH
P11380028A0000|54 61|methods
P11380028A0000|21 26|study
P11380028A0000|106 115|pentetate
P11380028A0000|66 76|estimation
P11380028A0000|5 12|purpose
P11380837A1505|133 138|costs
P11380837A1505|39 48|mediators
P11382701A0688|90 94|rise
P11382701A0688|39 50|vasopressin
P11382701A0688|69 77|response
P11383860A0661|108 112|lung
P11383860A0661|144 156|liver uptake
P11383860A0661|48 57|excretion
P11383860A0661|117 135|bone marrow uptake
P11384229A1669|14 27|N63S mutation
P11384229A1669|104 131|beta-galactosidase activity
P11384229A1669|171 183|PR7 mutation
P11384880A0719|22 31|induction
P11384880A0719|97 104|ZR-75-1
P11384880A0719|35 49|3beta-HSD type
P11387208T0000|59 66|binding
P11387940A0647|28 35|changes
P11387940A0647|55 64|magnitude
P11389077A0000|110 120|regulators
P11389077A0000|32 50|signaling pathways
P11389085A1032|72 80|TT cells
P11389085A1032|92 107|focus formation
P11389085A1032|129 134|forms
P11389085A1032|1 11|Inhibition
P11390581A1203|167 175|activity
P11390581A1203|26 40|identification
P11390581A1203|54 62|sequence
P11390663A1400|25 34|gcn4Delta
P11390663A1400|143 148|cells
P11391303A0807|12 17|R-LHR
P11391303A0807|37 50|interobserver
P11391531A1157|67 76|induction
P11391531A1157|80 89|TNF-alpha
P11391531A1157|17 31|NF-kappaB site
P11392306T0000|8 16|teaching
P11393463A0274|269 278|occasions
P11393463A0274|182 197|informant group
P11393463A0274|221 228|ratings
P11393463A0274|166 174|interval
P11393463A0274|79 80|n
P11393463A0274|199 200|n
P11393463A0274|101 122|NEO-PI-R self-ratings
P11395469A1373|134 138|iron
P11395469A1373|126 130|sid2
P11395469A1373|112 122|regulation
P11395469A1373|34 40|motifs
P11397652A0381|192 208|sample viscosity
P11397652A0381|37 49|spiral assay
P11397652A0381|138 150|difficulties
P11397652A0381|1 11|Guidelines
P11398899A1183|90 100|likelihood
P11398899A1183|109 127|PH3 concentrations
P11398899A1183|140 145|areas
P11398899A1183|1 5|Fans
P11399834T0000|11 15|case
P11399834T0000|76 93|HCV NAT screening
P11401105T0000|30 39|myoclonus
P11401105T0000|1 11|Gabapentin
P11402674T0000|50 77|serum calcium concentration
P11403663A0359|112 122|2-D theory
P11403663A0359|5 9|lift
P11403663A0359|64 72|impeller
P11404010A0235|52 58|repeat
P11404019A0532|12 25|understanding
P11404019A0532|33 50|mGSTM2 regulation
P11406007A0292|47 53|trials
P11406007A0292|159 164|women
P11406007A0292|64 68|IUSs
P11406007A0292|1 19|SELECTION CRITERIA
P11406277A0598|61 78|promoter activity
P11406277A0598|148 157|mutations
P11406277A0598|128 136|segments
P11406277A0598|96 124|reporter expression activity
P11407289A1507|44 54|anesthesia
P11407289A1507|184 190|agents
P11407650A0661|181 195|thyroid cancer
P11407650A0661|167 175|patients
P11407650A0661|142 146|none
P11407650A0661|158 163|women
P11407650A0661|118 129|BC patients
P11408338A1686|26 29|PSP
P11408338A1686|159 171|neurologists
P11408591A0000|47 49|HA
P11408591A0000|59 65|effect
P11408591A0000|86 91|cells
P11408591A0000|69 82|cell motility
P11408774X0893|1 10|Karger AG
P11410110A0190|89 107|forearm blood flow
P11410110A0190|109 112|FBF
P11410110A0190|76 78|mV
P11410110A0190|1 5|NIRS
P11410664A0963|268 285|repair activities
P11410664A0963|52 84|breast carcinoma MDA-MB231 cells
P11410664A0963|216 219|BER
P11410664A0963|262 266|MGMT
P11410664A0963|221 226|hOGG1
P11410664A0963|106 109|MPG
P11410664A0963|231 238|APE/ref
P11410664A0963|137 150|up-regulation
P11411198A0711|107 111|risk
P11411198A0711|140 154|stomach cancer
P11411961A0735|79 87|children
P11411961A0735|93 96|JRA
P11411961A0735|155 160|tests
P11413277A1121|24 36|chemotherapy
P11413277A1121|4 14|conclusion
P11413277A1121|51 59|dose MTX
P11413319A0000|1 15|Reovirus mRNAs
P11413319A0000|102 107|tails
P11413760A0000|63 73|production
P11413760A0000|36 43|disease
P11413760A0000|1 11|Myasthenia
P11415633A1253|67 72|model
P11415633A1253|38 43|input
P11415958A0000|13 19|decade
P11415958A0000|46 54|advances
P11415958A0000|78 89|methodology
P11415958A0000|186 194|approach
P11416012A2511|31 35|role
P11416012A2511|450 456|microM
P11416012A2511|95 106|stimulation
P11416012A2511|292 294|LY
P11416012A2511|284 286|nM
P11416012A2511|43 73|insulin/IGF-I effector pathway
P11416012A2511|202 205|min
P11416012A2511|339 360|protein kinase kinase
P11416012A2511|375 381|microM
P11416012A2511|410 416|latter
P11416132A1351|134 143|silencing
P11416132A1351|78 80|GA
P11416132A1351|7 14|studies
P11416132A1351|65 72|bxd PRE
P11416260A0000|109 117|patients
P11416260A0000|48 53|point
P11416260A0000|68 76|activity
P11416650T0000|19 31|Hypertension
P11416879A1589|53 70|ventilation modes
P11418662A0917|47 62|p50 DNA binding
P11418662A0917|96 107|p50 subunit
P11418662A0917|33 35|IC
P11420612A0303|44 62|sequencing efforts
P11420612A0303|6 16|complement
P11420612A0303|116 129|sequence data
P11420612A0303|154 162|interest
P11422757A0737|7 18|individuals
P11422757A0737|81 89|baseline
P11424992A0712|34 43|diagnoses
P11425877A1026|219 230|aggregation
P11425877A1026|53 62|formation
P11425877A1026|259 274|F-actin content
P11425877A1026|193 203|efficiency
P11425877A1026|39 45|defect
P11425877A1026|238 246|decrease
P11427611A0000|264 276|phenyl-amino
P11427611A0000|48 61|mulundocandin
P11427611A0000|84 92|compound
P11427611A0000|377 388|alterations
P11427611A0000|196 201|NCCLS
P11427611A0000|142 160|National Committee
P11427611A0000|203 215|M38-P method
P11427611A0000|174 194|Laboratory Standards
P11427611A0000|35 44|fumigatus
P11428283A0228|79 87|distress
P11428487T0000|62 75|vein stenosis
P11428487T0000|25 36|association
P11429702A0917|271 295|receptor phosphorylation
P11429702A0917|228 239|aFGF ligand
P11429702A0917|163 173|activation
P11429702A0917|66 77|OPM-2 cells
P11429702A0917|55 61|KMS-11
P11429702A0917|262 267|level
P11430976X0000|47 70|woody plant biopolymers
P11430976X0000|83 93|substances
P11431472A0540|56 57|d
P11431472A0540|5 21|affinity binding
P11431472A0540|64 70|microm
P11432112A0000|75 78|FEC
P11432112A0000|58 73|embryo cleavage
P11432112A0000|128 132|ICSI
P11432112A0000|86 87|h
P11432112A0000|139 148|parameter
P11432776A0421|14 35|Western blot analyses
P11432776A0421|110 120|expression
P11432776A0421|1 9|Northern
P11433018A0756|105 118|H/ACA snoRNPs
P11433018A0756|59 72|H/ACA snoRNAs
P11433018A0756|7 11|data
P11433018A0756|50 55|Nhp2p
P11433379A0000|132 143|lymphocytes
P11433379A0000|37 52|adaptor protein
P11435428A0000|74 79|cells
P11435428A0000|52 59|acetate
P11435428A0000|34 40|AceCS1
P11435560A1322|61 68|nucleus
P11435560A1322|36 48|HFV R region
P11435560A1322|103 118|target HFV mRNA
P11435578A2231|107 124|CREB/ATF proteins
P11435578A2231|145 155|repression
P11435578A2231|172 185|transcription
P11435688A0262|104 107|set
P11435688A0262|6 15|subfamily
P11435688A0262|19 24|genes
P11437439A0201|88 102|prestalk cells
P11437439A0201|5 22|promoter activity
P11438651A1365|164 185|replication initiator
P11438651A1365|91 113|replication initiation
P11438651A1365|7 32|replication fork movement
P11438651A1365|138 143|Orc2p
P11438666A0555|132 151|immunoprecipitation
P11438666A0555|24 37|mouse protein
P11438666A0555|65 68|HFD
P11438666A0555|170 185|TFIID component
P11439343A0785|22 26|data
P11439343A0785|4 12|contrast
P11441311X0001|195 204|lymphomas
P11441311X0001|11 18|results
P11441311X0001|36 53|radiation therapy
P11441311X0001|206 209|NHL
P11441311X0001|170 177|factors
P11441974A0320|150 157|reserve
P11441974A0320|8 11|end
P11441974A0320|20 23|day
P11441974A0320|84 87|kPa
P11443999A0573|31 37|livers
P11443999A0573|63 74|Isle Royale
P11443999A0573|202 213|consumption
P11443999A0573|156 175|government agencies
P11443999A0573|119 136|Hg concentrations
P11445008A0816|62 84|FGFR expression levels
P11445008A0816|5 10|assay
P11448051A0093|183 187|NaCl
P11448051A0093|146 152|matrix
P11448051A0093|189 197|mannitol
P11448051A0093|203 208|Emdex
P11448051A0093|223 230|polymer
P11450490A0565|47 53|acuity
P11450490A0565|111 116|lines
P11450490A0565|171 177|acuity
P11451447A0205|8 10|F.
P11451995T0000|28 36|analysis
P11451995T0000|96 147|isoprenylcysteine carboxyl methyltransferase family
P11454190A0000|47 66|fatty liver disease
P11454190A0000|128 141|United States
P11454190A0000|18 29|Hepatitis C
P11454190A0000|68 72|NAFL
P11454703A0000|28 35|complex
P11454703A0000|77 80|DNA
P11454703A0000|202 217|immortalization
P11454703A0000|84 99|chromosome ends
P11457139A0604|23 26|CVN
P11457139A0604|5 12|results
P11457139A0604|114 117|Man
P11459304T0078|74 80|plasma
P11459304T0078|42 64|O-desmethylvenlafaxine
P11459960A1109|56 60|heat
P11459960A1109|82 93|heat labile
P11460035A0548|13 17|case
P11460035A0548|24 42|hydroxychloroquine
P11462004A0886|82 85|NLS
P11462004A0886|5 9|role
P11462004A0886|32 41|infection
P11462004A0886|17 24|Vp1 DBD
P11462024A0306|1 4|Zhu
P11463359A0167|194 214|H4IIE hepatoma cells
P11463359A0167|24 41|phorbol ester PMA
P11463359A0167|136 143|control
P11464997A0566|44 53|treatment
P11464997A0566|73 83|counseling
P11464997A0566|100 106|family
P11465655A0439|13 17|week
P11465655A0439|83 87|dose
P11465655A0439|136 140|week
P11466227A1665|134 144|activation
P11466227A1665|5 13|presence
P11466227A1665|17 25|AS-oligo
P11468958A0122|268 276|concerns
P11468958A0122|95 101|recall
P11468958A0122|154 162|decision
P11468958A0122|118 123|donor
P11468958A0122|15 22|results
P11468958A0122|172 181|donations
P11468958A0122|236 238|UK
P11469737A1791|28 32|test
P11469737A1791|132 140|recovery
P11469737A1791|4 9|visit
P11469737A1791|49 73|muscle function recovery
P11469853A1053|105 113|function
P11469853A1053|121 130|C1 domain
P11469853A1053|20 24|data
P11469970A0873|15 19|type
P11469970A0873|150 157|ampulla
P11469970A0873|46 58|hyperalgesia
P11469970A0873|213 220|therapy
P11469970A0873|71 86|antidepressants
P11471077A0382|44 53|variation
P11471077A0382|107 114|results
P11471077A0382|77 81|TRA1
P11471077A0382|86 90|TRA2
P11471077A0382|34 40|amount
P11472523A0535|13 30|Extrusion cooking
P11472523A0535|114 128|metabisulphite
P11472523A0535|1 11|CONCLUSION
P11473254A0000|15 31|DNA endonuclease
P11473254A0000|39 52|topoisomerase
P11473254A0000|1 5|NaeI
P11474642A1451|75 83|mm Hg ml
P11474642A1451|109 116|control
P11474642A1451|5 15|decrements
P11479104A0446|134 144|CONCLUSION
P11479104A0446|150 158|presence
P11479104A0446|281 286|cause
P11479104A0446|231 240|clinician
P11479104A0446|113 132|lupus erythematosis
P11480490A0443|128 138|arrhythmia
P11480490A0443|80 81|I
P11480490A0443|86 93|current
P11480490A0443|68 76|blockade
P11480555A0928|67 77|cell death
P11480555A0928|19 27|ceramide
P11486032A1261|72 79|protein
P11486032A1261|125 132|E2A-HLF
P11486399A0000|47 56|etoposide
P11486399A0000|58 61|IEV
P11486399A0000|20 30|ifosfamide
P11486399A0000|119 126|disease
P11486476A1512|29 39|CK-MB mass
P11486476A1512|126 129|ECG
P11486476A1512|100 110|chest pain
P11489597A0561|14 19|death
P11489597A0561|29 40|body weight
P11489597A0561|146 151|group
P11494391A0579|151 165|bile secretion
P11494391A0579|124 129|month
P11494391A0579|33 34|%
P11495920A0504|63 74|CYP3A4 gene
P11495920A0504|10 23|pair mismatch
P11496617A0301|388 397|induction
P11496617A0301|243 254|anaesthesia
P11496617A0301|213 220|minutes
P11496617A0301|354 360|mg DHB
P11496617A0301|325 336|anaesthesia
P11496617A0301|13 19|female
P11496617A0301|401 412|anaesthesia
P11496617A0301|230 239|induction
P11496617A0301|414 419|group
P11496617A0301|1 8|METHODS
P11500377A0518|4 11|mammals
P11500377A0518|51 62|Wnt pathway
P11500571A0976|111 117|pollen
P11500571A0976|32 51|NtmybAS transcripts
P11502738A1457|11 18|effects
P11502738A1457|127 145|cyclin D1 promoter
P11502738A1457|71 78|mutants
P11502778A0941|150 156|levels
P11502778A0941|79 89|pmol/liter
P11502778A0941|160 183|bone resorption markers
P11502778A0941|189 192|men
P11502778A0941|237 247|pmol/liter
P11502778A0941|68 74|median
P11504709A0981|133 141|promoter
P11504709A0981|108 116|Ets site
P11504709A0981|6 11|study
P11504709A0981|80 83|TPO
P11504709A0981|185 195|activation
P11509266A0955|150 151|P
P11509266A0955|106 109|age
P11509266A0955|111 112|P
P11509266A0955|143 148|stage
P11509266A0955|21 54|hazards regression adenocarcinoma
P11509266A0955|85 88|BPF
P11509673A0574|30 39|BM3 cells
P11509673A0574|92 100|F87V BM3
P11509673A0574|174 183|14,15-EET
P11509673A0574|71 90|P450 AA epoxygenase
P11512925A0000|150 157|Ge atom
P11512925A0000|36 40|edge
P11512925A0000|101 105|time
P11513180A1257|31 40|polyposis
P11513180A1257|42 46|none
P11513180A1257|69 71|CT
P11516890A0236|47 50|CYP
P11516890A0236|29 45|cytochrome P-450
P11516890A0236|52 58|system
P11516890A0236|81 88|CYP 2D6
P11517190T0000|80 93|transcription
P11517190T0000|16 24|promoter
P11517399A0858|165 176|utilization
P11517399A0858|227 228|T
P11517399A0858|230 237|species
P11517399A0858|23 27|mRNA
P11517399A0858|188 200|splice sites
P11517399A0858|32 50|protein expression
P11518505A0107|86 92|organs
P11519466A0196|44 50|impact
P11521191A0000|46 61|12S E1A protein
P11521191A0000|148 158|cell cycle
P11521191A0000|76 98|phosphorylation status
P11521191A0000|102 106|p130
P11522584A0882|40 48|patients
P11522584A0882|92 105|muscle biopsy
P11522658A0086|30 51|ErbB1/ErbB2 signaling
P11522658A0086|164 183|breast cancer cells
P11522658A0086|93 123|ErbB kinase inhibitor AG1478in
P11523446A0523|75 78|TOF
P11523446A0523|12 30|reference solution
P11523446A0523|52 54|LC
P11523446A0523|141 148|LC-CLND
P11523446A0523|1 4|ICA
P11524815A0753|60 61|%
P11524815A0753|28 29|%
P11524815A0753|7 20|control rates
P11524815A0753|102 113|2N0M0 cases
P11525102A0970|134 135|%
P11525102A0970|125 126|%
P11525102A0970|128 130|CI
P11525102A0970|81 96|PubMed strategy
P11525102A0970|49 65|ACP Journal Club
P11525640A0560|164 172|PD098059
P11525640A0560|24 45|ERK kinase activities
P11525640A0560|159 162|ERK
P11525640A0560|99 103|JNK1
P11525640A0560|1 11|Inhibition
P11528253X1211|1 10|Copyright
P11529914T0000|30 40|regulation
P11529914T0000|92 99|T cells
P11529914T0000|1 10|NF-kappaB
P11530829A0000|26 32|design
P11530829A0000|37 48|development
P11530829A0000|6 13|article
P11530829A0000|154 163|equipment
P11530829A0000|102 113|calibration
P11532856A1175|30 34|data
P11532856A1175|244 252|p38 MAPK
P11532856A1175|159 163|MAPK
P11532856A1175|256 272|HIF-1 activation
P11532856A1175|227 233|kinase
P11532856A1175|36 52|N-acetylcysteine
P11532856A1175|1 6|Third
P11533340A1285|72 78|months
P11533340A1285|26 36|difference
P11533340A1285|141 166|Bayley motor score scales
P11534132A0219|88 95|experts
P11534132A0219|59 66|results
P11535014A1157|160 169|latencies
P11535014A1157|127 146|precipitate factors
P11535014A1157|65 68|TLE
P11535014A1157|49 61|seizure type
P11535532A0189|61 65|IL-2
P11535532A0189|81 89|function
P11536063A0178|61 72|indications
P11536063A0178|11 22|embolectomy
P11536063A0178|81 84|use
P11539522A0612|73 77|time
P11539522A0612|81 96|space dosimetry
P11542677A0411|130 137|control
P11542677A0411|6 13|article
P11542677A0411|99 125|composting facility design
P11543154T0000|26 28|Tb
P11543154T0000|92 107|space radiation
P11543154T0000|1 10|Responses
P11543662A0562|63 64|C
P11543662A0562|109 118|L protein
P11543662A0562|55 59|half
P11547819A0532|150 161|divergences
P11547819A0532|297 321|tissue penetration rates
P11547819A0532|218 226|ablation
P11547819A0532|258 269|measurement
P11547819A0532|167 177|evaluation
P11547819A0532|380 398|vessel wall injury
P11547819A0532|273 292|ablation hole sizes
P11547819A0532|1 8|METHODS
P11550795A2583|79 88|apoptosis
P11550795A2583|129 138|induction
P11550795A2583|54 60|T cell
P11550795A2583|19 27|RORgamma
P11552058A0833|75 79|THAM
P11552058A0833|7 16|therapies
P11552058A0833|115 121|buffer
P11552922A0361|40 113|polymerase chain reaction-restriction fragment length polymorphism method
P11553704A0674|122 137|MAPK activation
P11553704A0674|95 102|Ras N17
P11554566A0668|181 191|company B.
P11554566A0668|32 41|companies
P11554727A0890|73 83|repression
P11554727A0890|129 134|PTHSR
P11554727A0890|98 112|GGGGGAGGGGAG-3
P11555669A0464|29 37|sections
P11555669A0464|1 11|Experience
P11556809A2085|128 137|capsidiol
P11556809A2085|37 52|enzyme activity
P11556809A2085|168 174|notion
P11556809A2085|84 103|5-epi-aristolochene
P11559366T0000|88 92|gene
P11559564A0459|44 57|topoisomerase
P11559564A0459|145 152|SF2/ASF
P11559564A0459|32 40|capacity
P11559821A1315|79 92|CREB-Tax-p300
P11559821A1315|110 119|complexes
P11559821A1315|67 75|assembly
P11559821A1315|50 53|p30
P11560509T0000|62 69|binding
P11560509T0000|20 35|F factor TraI36
P11560992A0000|88 92|MKK4
P11560992A0000|179 194|protein kinases
P11560992A0000|220 227|kinases
P11560992A0000|229 233|JNKs
P11560992A0000|10 29|specificity kinases
P11560992A0000|203 208|c-Jun
P11560992A0000|64 68|MAPK
P11560992A0000|238 246|response
P11560992A1184|107 111|MKK7
P11560992A1184|41 50|regulator
P11560992A1184|7 11|MKK7
P11560992A1184|206 211|cells
P11561626A0197|211 217|S3C3N3
P11561626A0197|88 92|zinc
P11561626A0197|177 183|Cd-TMT
P11561626A0197|25 34|solutions
P11561626A0197|250 253|Zn2
P11561626A0197|220 224|nH2O
P11561626A0197|315 318|air
P11561626A0197|232 233|M
P11561626A0197|234 237|Cd2
P11562870A0892|132 133|%
P11562870A0892|124 129|years
P11562870A0892|5 16|probability
P11562870A0892|99 105|months
P11562870A0892|85 86|%
P11564893A1068|198 206|mutagens
P11564893A1068|92 109|DNA repair factor
P11564893A1068|59 69|6RG lesion
P11564893A1068|115 138|transcription regulator
P11564893A1068|170 175|sense
P11564893A1068|17 23|change
P11566874T0000|39 45|dynein
P11566961A0472|33 52|insulin sensitivity
P11566961A0472|1 22|Body weight reduction
P11568988A0960|94 101|culture
P11568988A0960|57 61|WCXR
P11568988A0960|42 49|changes
P11569900A0660|82 93|specificity
P11569900A0660|49 55|method
P11569900A0660|102 126|factor V Leiden mutation
P11570735A1097|209 218|reduction
P11570735A1097|40 54|feedback group
P11570735A1097|276 283|control
P11570735A1097|168 177|reduction
P11570735A1097|137 147|conditions
P11572377T0000|21 33|lithotripter
P11572467A0658|47 53|cavity
P11572467A0658|113 120|plasmin
P11572467A0658|98 109|plasminogen
P11572467A0658|68 77|injection
P11573771T0000|49 56|cheeses
P11573771T0000|34 45|meltability
P11574088A1687|112 113|P
P11574088A1687|96 110|PAK recipients
P11574088A1687|38 57|pancreas transplant
P11574088A1687|87 91|days
P11575109A0214|135 141|grafts
P11575109A0214|11 19|baseline
P11575109A0214|146 155|treatment
P11575109A0214|65 72|therapy
P11576158A1371|8 20|TVD-patients
P11577094A1226|46 50|WT-1
P11577094A1226|7 15|findings
P11577094A1226|84 95|development
P11579100T0000|46 66|DNA binding activity
P11579100T0000|1 24|Phosphotyrosyl peptides
P11580301A1161|5 14|diagnosis
P11580301A1161|101 114|polyarthritis
P11580301A1161|69 75|factor
P11580941A0815|124 135|% reduction
P11580941A0815|80 81|%
P11580941A0815|86 97|stimulation
P11580941A0815|1 8|RESULTS
P11580941A0815|51 61|III scores
P11583621A0301|135 139|hTAF
P11583621A0301|47 57|expression
P11583621A0301|182 186|hTAF
P11583621A0301|110 114|hTAF
P11583621A0301|103 108|delta
P11584107T0000|79 84|field
P11584107T0000|55 65|assessment
P11585856A0285|133 155|photon energy recovery
P11585856A0285|113 131|scatter correction
P11585856A0285|87 107|scanning line source
P11585856A0285|34 41|benefit
P11587514A0758|90 108|alpha-amylase gene
P11587514A0758|41 47|effect
P11589568A0744|31 50|checkpoint response
P11589568A0744|94 98|Bub3
P11589568A0744|117 129|counterparts
P11589568A0744|85 89|Bub1
P11590364A1056|58 64|retina
P11592532A0188|10 39|Humphrey Field Analyzer model
P11592532A0188|98 110|degrees grid
P11592532A0188|1 8|METHODS
P11595170A0582|44 48|hB1F
P11595170A0582|214 221|introns
P11595170A0582|162 164|kb
P11595170A0582|37 42|NR5A2
P11595170A0582|1 10|Alignment
P11595170A0582|187 192|exons
P11595478A1014|63 73|prevalence
P11595478A1014|77 84|atrophy
P11595478A1014|1 3|Hp
P11595840A0000|47 55|F-18 FDG
P11595840A0000|27 45|fluorodeoxyglucose
P11595840A0000|5 11|uptake
P11596838A1357|28 31|use
P11596838A1357|132 138|asthma
P11596838A1357|176 189|beta2-agonist
P11596838A1357|35 57|fluticasone propionate
P11597936A0570|134 147|triglycerides
P11597936A0570|213 218|drugs
P11597936A0570|52 60|patients
P11597936A0570|96 115|density lipoprotein
P11597936A0570|155 160|mg/dL
P11599797A0732|18 22|gene
P11600252A0795|75 81|series
P11600252A0795|142 151|mortality
P11600252A0795|39 43|data
P11600365A0471|107 119|tosufloxacin
P11600365A0471|153 172|reference compounds
P11602353A0770|60 70|C/EBP beta
P11602353A0770|125 144|expression profiles
P11602353A0770|49 54|C/EBP
P11602353A0770|35 40|HFH-2
P11604152A0526|240 246|effect
P11604152A0526|260 270|bandwidths
P11604152A0526|184 186|Hz
P11604152A0526|288 297|mean CCFs
P11604152A0526|14 27|MCBFV signals
P11604152A0526|163 168|range
P11604152A0526|5 9|MABP
P11604152A0526|100 102|Hz
P11604152A0526|170 172|HF
P11605598A0785|147 154|climate
P11605598A0785|159 178|prevention programs
P11605598A0785|1 12|Hepatitis B
P11614398T0000|12 18|people
P11614398T0000|50 59|Mormonism
P11639485A0478|13 17|work
P11639485A0478|94 103|languages
P11639485A0478|152 160|scholars
P11653491T0000|25 38|DNA violation
P11669476A0346|28 55|tumor necrosis factor-alpha
P11669476A0346|166 184|insulin resistance
P11669476A0346|108 116|subjects
P11676899A0704|161 169|exposure
P11676899A0704|66 71|virus
P11676899A0704|175 188|wood industry
P11677839A0876|45 53|controls
P11677839A0876|5 15|difference
P11679441A0429|180 185|urine
P11679441A0429|144 164|nmol/mmol creatinine
P11679441A0429|39 50|measurement
P11679441A0429|71 74|NOx
P11679441A0429|169 175|plasma
P11683558A0446|90 101|differences
P11683558A0446|74 88|micronutrients
P11683558A0446|125 129|diet
P11685047A0301|78 94|substrate S-2238
P11685047A0301|50 69|thrombin inhibition
P11686239A0464|177 184|G boxes
P11686239A0464|92 101|stretches
P11686239A0464|235 254|Dictyostelium genes
P11686239A0464|17 25|sequence
P11687083A0218|124 130|labour
P11687083A0218|71 101|prophylactic prostaglandin use
P11687083A0218|35 41|review
P11687352A0215|29 35|review
P11687352A0215|65 70|LASIK
P11687352A0215|1 8|METHODS
P11687737A0000|60 69|morbidity
P11687737A0000|74 83|mortality
P11687737A0000|22 35|heart disease
P11687737A0000|51 56|cause
P11689217T0000|40 55|atherosclerosis
P11689217T0000|1 35|Cholesteryl ester transfer protein
P11691585T0000|57 69|matrix genes
P11693461A1649|134 144|population
P11693461A1649|37 47|drug costs
P11693461A1649|65 67|US
P11693461A1649|55 60|range
P11697760A0000|105 112|hormone
P11697760A0000|57 64|ability
P11697760A0000|6 11|study
P11697760A0000|33 38|boron
P11697760A0000|68 84|17beta-estradiol
P11703558A0000|44 53|treatment
P11703558A0000|1 12|Doxorubicin
P11704829A0312|135 142|changes
P11704829A0312|82 87|mda-7
P11704829A0312|1 26|Subtraction hybridization
P11706668A0000|61 66|areas
P11706668A0000|25 28|men
P11706668A0000|1 11|Hydrocoele
P11707977A0750|79 90|H3 patients
P11707977A0750|67 75|survival
P11708362A0889|5 19|astronaut crew
P11708761A1388|30 36|number
P11708761A1388|114 131|diabetes mellitus
P11708761A1388|71 85|ACE inhibitors
P11709890T0000|88 116|health protection strategies
P11709890T0000|22 34|food handler
P11709890T0000|1 12|Hepatitis A
P11710685A0994a|45 60|ASCUS/SIL ratio
P11710685A0994a|99 110|sensitivity
P11710685A0994a|17 23|subset
P11711701A0602|13 32|medicine physicians
P11711701A0602|148 155|minutes
P11711701A0602|92 98|images
P11711701A0602|218 225|minutes
P11711701A0602|190 197|minutes
P11711701A0602|238 243|hours
P11715079A1016|106 114|response
P11715079A1016|248 254|motion
P11715079A1016|174 198|eye movement information
P11715079A1016|262 265|eye
P11715079A1016|87 98|development
P11716441A0585|61 67|APACHE
P11716441A0585|86 95|admission
P11716441A0585|1 4|ISS
P11722993A0276|28 40|epidemiology
P11722993A0276|95 101|system
P11722993A0276|1 13|Paul Monagle
P11723511A0780|182 193|category X.
P11723511A0780|176 177|%
P11723511A0780|127 137|category C
P11723511A0780|64 79|category A risk
P11723511A0780|49 50|%
P11723511A0780|153 163|category D
P11723928A0294|77 90|Shanghai City
P11723928A0294|37 54|river reclamation
P11726022A0909|167 172|model
P11726022A0909|7 14|results
P11726022A0909|81 93|calculations
P11726022A0909|102 106|root
P11726164A0215|73 86|food products
P11726164A0215|10 17|concern
P11726164A0215|190 202|food allergy
P11726413A1756|15 24|clearance
P11726413A1756|57 65|contrast
P11727073A0842|29 36|novices
P11727073A0842|127 131|task
P11727073A0842|190 198|training
P11727073A0842|155 162|results
P11727073A0842|17 25|training
P11728771A0187|62 79|contrast material
P11730262A0874|225 233|fluoride
P11730262A0874|208 212|days
P11730262A0874|76 88|osteoporosis
P11730262A0874|23 28|study
P11730262A0874|35 54|etidronate/fluoride
P11732088A0471|41 49|readings
P11732088A0471|142 152|ultrasound
P11732088A0471|4 9|order
P11732088A0471|216 222|method
P11732088A0471|154 159|SSEUS
P11736254A0000|148 157|landscape
P11736254A0000|20 28|dynamics
P11736254A0000|116 128|partitioning
P11737056A0680|9 18|timepoint
P11737056A0680|77 81|BrdU
P11737056A0680|113 120|subsets
P11737056A0680|50 59|ET mucosa
P11737900A0700|88 89|P
P11737900A0700|77 79|r2
P11737900A0700|48 59|body weight
P11740571A0114|46 53|maximum
P11740571A0114|128 140|brain tissue
P11740571A0114|66 79|concentration
P11740571A0114|18 22|dose
P11740571A0114|102 124|glutathione peroxidase
P11741259A1233|89 93|drug
P11741259A1233|66 73|ability
P11741259A1233|33 42|particles
P11741259A1233|119 123|part
P11742432A0798|264 269|tract
P11742432A0798|365 375|CD4 counts
P11742432A0798|397 409|cells/microL
P11742432A0798|135 146|combination
P11742432A0798|345 358|AIDS patients
P11742432A0798|162 169|therapy
P11742432A0798|232 244|colonization
P11742432A0798|38 44|trials
P11743612A1179|76 85|diagnosis
P11743612A1179|66 72|status
P11743612A1179|1 9|Patients
P11744953A0878|44 49|tract
P11744953A0878|96 108|age patients
P11755894A0466|123 125|mg
P11755894A0466|253 266|hospital stay
P11755894A0466|107 110|ADL
P11755894A0466|78 85|opioids
P11755894A0466|96 100|pain
P11755894A0466|175 178|POI
P11755894A0466|34 42|patients
P11760796A0698|79 91|phakomatosis
P11760796A0698|129 134|light
P11760796A0698|101 108|studies
P11763176A0918|147 148|%
P11763176A0918|81 92|experiments
P11763176A0918|32 53|antithrombin activity
P11764226A0798|166 180|EULAR criteria
P11764226A0798|96 112|disease duration
P11764226A0798|33 46|ILAR criteria
P11766747A0000|40 46|review
P11766747A0000|86 94|teratoma
P11769229A0357|52 61|partition
P11769229A0357|38 48|adsorption
P11773168A0915|30 32|OS
P11773168A0915|125 126|%
P11773168A0915|20 28|survival
P11773168A0915|55 63|survival
P11773168A0915|131 136|arm B
P11773168A0915|138 139|P
P11773168A0915|70 75|rates
P11775180A0379|64 85|gamma-detecting probe
P11776922A0830|60 65|cases
P11776922A0830|91 96|group
P11776922A0830|46 56|skull base
P11776922A0830|100 107|lesions
P11777632A1678|105 114|component
P11777632A1678|129 135|breast
P11777632A1678|260 266|stroma
P11777632A1678|234 247|breast cancer
P11777632A1678|50 60|expression
P11778804A0179|73 76|FDT
P11778804A0179|1 10|Frequency
P11782218A0349|45 49|SWAP
P11782218A0349|29 32|W-W
P11782218A0349|130 139|threshold
P11782218A0349|176 196|examination duration
P11782218A0349|84 95|variability
P11785085X0001|241 249|PVM-R-01
P11785085X0001|57 65|drainage
P11785085X0001|221 239|pneumovibromassage
P11785085X0001|142 150|drainage
P11785085X0001|272 280|patients
P11785085X0001|103 114|prostatitis
P11785085X0001|171 188|vacuum aspiration
P11786248A1162|133 134|%
P11786248A1162|98 102|rats
P11786248A1162|156 169|sham controls
P11786248A1162|84 88|PPTg
P11787041A0167|8 19|development
P11787720A1313|60 64|acid
P11787720A1313|130 132|n6
P11787720A1313|92 93|P
P11787720A1313|39 47|decrease
P11787720A1313|71 73|n6
P11787720A1313|119 123|acid
P11789206A1182|91 101|principles
P11789206A1182|122 124|Qi
P11789206A1182|142 154|blood stasis
P11789206A1182|18 27|mechanism
P11790897T0000|11 19|patterns
P11790897T0000|58 67|SELDI-TOF
P11790897T0000|23 29|nipple
P11790897T0000|87 97|biomarkers
P11791571T0000|109 133|plasma mass spectrometry
P11791571T0000|69 84|electrophoresis
P11791853A0532|149 159|wastewater
P11791853A0532|42 78|coagulation-electrooxidation process
P11793172A0545|75 78|THA
P11793172A0545|161 168|PE head
P11793172A0545|64 68|time
P11796977T0000|15 23|hardship
P11796977T0000|1 9|Postdocs
P11800586A1090|166 178|tuberculosis
P11800586A1090|57 64|bacilli
P11800586A1090|98 106|molecule
P11801459T0000|14 20|safety
P11801459T0000|24 31|aspirin
P11801459T0000|1 9|Efficacy
P11802601A0107|57 65|aldicarb
P11802601A0107|92 108|aldicarb sulfone
P11802601A0107|6 11|paper
P11804081A0552|62 64|TP
P11804081A0552|7 13|August
P11804081A0552|103 113|Everglades
P11804100A0365b|95 103|kinetics
P11804100A0365b|23 36|disappearance
P11804100A0365b|49 54|NH3-N
P11806132A0253|95 99|rate
P11806132A0253|5 17|TB incidence
P11811743A0800|134 143|clinician
P11811743A0800|88 94|manner
P11811743A0800|70 82|Class III FI
P11815644A0081|105 111|timing
P11815644A0081|166 178|echolocation
P11815644A0081|76 86|variations
P11815644A0081|39 44|calls
P11815644A0081|116 124|patterns
P11816779A0343|28 42|acetyl aspirin
P11816779A0343|5 17|drug packets
P11819326A0000|104 118|encephalopathy
P11819326A0000|125 132|METHODS
P11819326A0000|189 192|PSE
P11819326A0000|23 27|role
P11819326A0000|1 4|AIM
P11822790A0907|89 96|example
P11822790A0907|176 177|%
P11822790A0907|23 32|SIP score
P11822790A0907|5 13|instance
P11822790A0907|216 227|improvement
P11822790A0907|50 57|patient
P11824701A0894|57 61|Type
P11824701A0894|113 121|patients
P11824701A0894|1 9|Patients
P11825801A1212|28 37|mortality
P11825801A1212|64 73|follow-up
P11828186A0239|196 206|NHANES III
P11828186A0239|52 57|women
P11828186A0239|39 42|men
P11828186A0239|116 132|CRP measurements
P11831512A0468|121 128|lactose
P11831512A0468|178 182|gram
P11831512A0468|262 267|DE-42
P11831512A0468|51 54|age
P11831512A0468|13 17|pigs
P11831512A0468|198 201|CSS
P11831512A0468|108 115|control
P11831512A0468|136 155|carbohydrate source
P11833863A0987|28 42|apnea duration
P11833863A0987|55 61|supine
P11835109A0000|133 141|patients
P11835109A0000|124 128|HRQL
P11835109A0000|66 76|importance
P11835109A0000|118 122|life
P11836303A0518|49 69|culture supernatants
P11837409A0584|56 73|Adolescent Health
P11837409A0584|81 88|measure
P11837409A0584|136 144|interval
P11838102T0001|1 8|Wegener
P11842037A0327|19 29|precisions
P11843252A0907|30 31|%
P11843252A0907|72 73|%
P11843252A0907|114 120|months
P11843252A0907|35 56|% confidence interval
P11844812A0915|122 125|PSA
P11844812A0915|46 59|ANN ROC curve
P11844812A0915|146 147|P
P11844812A0915|127 128|P
P11844812A0915|18 29|ng/mL model
P11844812A0915|35 38|AUC
P11846167A0000|74 88|microorganisms
P11846167A0000|63 70|species
P11846167A0000|38 44|humans
P11847580T0000|15 28|cholecystitis
P11849796A0452|14 25|target dose
P11849796A0452|59 69|IMRT plans
P11849796A0452|48 54|3D-CRT
P11852907A0871|104 118|drainage water
P11852907A0871|89 100|SRP content
P11852907A0871|127 131|farm
P11852907A0871|5 35|equilibrium phosphorus content
P11858256A0102|22 30|research
P11858256A0102|35 46|explanation
P11858635A0896|47 58|QSAR models
P11859943A0150|91 95|days
P11859943A0150|5 11|adults
P11859943A0150|119 147|General Health Questionnaire
P11860723A0182|41 57|American College
P11860723A0182|3 14|mail survey
P11861092A0730|211 224|power Doppler
P11861092A0730|159 162|FGS
P11861092A0730|53 59|lesion
P11861092A0730|352 354|WA
P11861092A0730|19 30|enhancement
P11861092A0730|119 133|scanning modes
P11861092A0730|226 229|FPD
P11861092A0730|8 15|plateau
P11861092A0730|338 341|ATL
P11861092A0730|68 75|patient
P11863811A0259|60 61|%
P11863811A0259|80 82|Pr
P11863811A0259|71 76|range
P11865218A0069|82 87|agent
P11865218A0069|54 67|wax softening
P11867388A0502|90 91|%
P11867388A0502|183 200|fear conditioning
P11867388A0502|217 218|%
P11867388A0502|153 157|mean
P11867388A0502|133 134|%
P11867388A0502|78 84|memory
P11867388A0502|5 7|EC
P11867388A0502|169 172|SEM
P11867388A0502|238 239|P
P11872359A0000|63 70|cluster
P11872359A0000|27 45|insulin resistance
P11872359A0000|189 198|mortality
P11872359A0000|216 227|Australians
P11872359A0000|153 156|CVD
P11873003X0000|240 245|death
P11873003X0000|301 307|Uganda
P11873003X0000|189 204|HIV-1 infection
P11873003X0000|251 255|time
P11873003X0000|74 78|AIDS
P11873003X0000|228 232|AIDS
P11873003X0000|66 70|time
P11873003X0000|278 282|AIDS
P11873003X0000|1 16|HIV-1 infection
P11875695A0718|105 109|% CI
P11875695A0718|27 33|months
P11875695A0718|9 20|progression
P11875695A0718|115 121|months
P11879108A0719|75 84|infection
P11879108A0719|131 146|outcome measure
P11879108A0719|162 173|test result
P11879108A0719|184 206|immunodeficiency virus
P11879108A0719|34 45|test result
P11881923A1256|12 28|lymphocyte ratio
P11881923A1256|108 114|period
P11881923A1256|178 188|treatments
P11881923A1256|138 150|POST periods
P11882054A1250|75 91|spiking activity
P11882054A1250|224 239|epileptogenesis
P11882054A1250|46 55|decreases
P11882054A1250|59 70|FMZ binding
P11882054A1250|255 265|epilepsies
P11883682A0162|106 125|estuarine sediments
P11883682A0162|52 57|spill
P11883682A0162|70 82|distribution
P11884014A0665|10 29|treatment protocols
P11884014A0665|34 47|diet delivery
P11885737A1713|77 87|compromise
P11885737A1713|5 10|range
P11887803A1455|240 241|p
P11887803A1455|123 131|fibrosis
P11887803A1455|163 167|rats
P11887803A1455|36 46|peritoneum
P11887803A1455|5 19|mean thickness
P11887803A1455|70 76|groups
P11888867A0000|246 255|melanomas
P11888867A0000|67 74|TA90-IC
P11888867A0000|174 185|correlation
P11888867A0000|86 93|complex
P11888867A0000|139 147|antibody
P11890438A0838|90 99|dressings
P11890438A0838|54 58|days
P11890438A0838|1 9|Patients
P11893767A0356|132 136|ages
P11893767A0356|27 45|minute ventilation
P11893767A0356|82 84|VE
P11893767A0356|70 80|equivalent
P11895024A1054|31 33|TM
P11895024A1054|6 11|cases
P11897449A0566|27 42|activation site
P11897449A0566|114 121|RESULTS
P11897449A0566|221 230|beats/min
P11897449A0566|109 112|RFA
P11897449A0566|97 102|shift
P11897449A0566|5 10|shift
P11897449A0566|206 210|mean
P11897950A0617|135 142|eyelids
P11897950A0617|93 110|drainage pathways
P11897950A0617|184 190|eyelid
P11898797A0124|134 145|head injury
P11898797A0124|177 181|loss
P11898797A0124|37 43|levels
P11898797A0124|206 217|innervation
P11899489A0119|59 63|care
P11899489A0119|5 12|effects
P11899489A0119|68 75|support
P11902068T0000|19 26|journey
P11902781A0550|26 27|N
P11902781A0550|96 100|mg/L
P11902781A0550|21 23|O3
P11902781A0550|32 33|N
P11902781A0550|34 36|H3
P11907691A0214|25 41|contact surfaces
P11907691A0214|97 101|mass
P11907691A0214|87 93|center
P11909404A0000|7 14|domains
P11909404A0000|35 43|function
P11910344A1119|128 136|function
P11910344A1119|66 74|patients
P11910344A1119|87 90|HRS
P11910344A1119|171 179|survival
P11912261A0284|135 145|experience
P11912261A0284|38 51|PTH secretion
P11913427A0290|134 136|g.
P11913427A0290|67 72|value
P11913427A0290|116 121|error
P11917061A0922|73 84|cyclosporin
P11917061A0922|133 142|remission
P11917061A0922|161 162|%
P11917061A0922|172 173|P
P11917061A0922|35 45|tacrolimus
P11920455X1195|40 43|DOI
P11920455X1195|16 39|American Cancer Society
P11921126A1196|110 112|PD
P11921126A1196|80 83|QoL
P11921126A1196|69 76|aspects
P11920896A0298|122 127|women
P11920896A0298|9 14|study
P11920896A0298|154 157|FPR
P11920896A0298|85 95|population
P11917882A0326|26 31|study
P11917882A0326|141 158|adhesion-strategy
P11917882A0326|102 109|systems
P11915436A0491|56 61|rates
P11912677A0281|75 86|variability
P11912677A0281|55 64|structure
P11912677A0281|102 110|data set
P11911552A0776|40 47|therapy
P11911552A0776|145 149|mg/d
P11911552A0776|4 12|patients
P11910310A0279|59 64|trial
P11908529A0553|121 134|AgCl crystals
P11908529A0553|58 64|charge
P11908529A0553|53 56|cm3
P11908529A0553|72 76|ions
P11908529A0553|111 119|plastics
P11908529A0553|142 153|energy loss
P11908529A0553|33 39|number
P11908529A0553|136 139|LiF
P11904017A0000|148 154|region
P11904017A0000|58 68|blood flow
P11904017A0000|103 106|bed
P11902738A0185|14 21|METHODS
P11902738A0185|73 81|children
P11902738A0185|178 194|neutrophil count
P11902738A0185|53 65|cohort study
P11902738A0185|201 210|cells/mm3
P11902738A0185|1 9|PATIENTS
P11900770T0000|76 104|dopamine receptor antagonism
P11900770T0000|34 45|attenuation
P11899479A0122|26 33|lesions
P11899479A0122|54 60|tongue
P11899479A0122|252 261|germ tube
P11899479A0122|187 204|CHROMagar Candida
P11899479A0122|46 52|mucosa
P11899479A0122|97 112|denture surface
P11899479A0122|170 182|glucose agar
P11898018T0000|35 43|research
P11897888A0590|1 14|Urine samples
P11895184A0000|150 176|cheeseboard maze apparatus
P11895184A0000|127 131|task
P11895184A0000|5 12|ability
P11895184A0000|16 20|rats
P11894605A1429|211 217|amount
P11894605A1429|176 182|result
P11894605A1429|233 244|advertising
P11894605A1429|139 149|motivation
P11894605A1429|1 15|INTERPRETATION
P11893403A0252|107 114|analogy
P11893403A0252|128 144|pharmacokinetics
P11893403A0252|38 55|safety evaluation
P11893403A0252|116 126|metabolism
P11890354A0000|47 57|oprelvekin
P11890354A0000|92 96|form
P11890354A0000|1 19|Genetics Institute
P11888183A0541|135 141|maxima
P11888183A0541|59 76|maximum intensity
P11888183A0541|49 55|series
P11886473A0796|124 128|CagA
P11886473A0796|55 63|children
P11886473A0796|84 85|p
P11886473A0796|119 122|nod
P11886473A0796|44 47|nod
P11886473A0796|72 75|nod
P11886473A0796|77 81|CagA
P11886473A0796|1 16|Gastritis score
P11885053A1897|66 73|objects
P11885053A1897|48 54|groups
P11883763A1062|150 155|layer
P11883763A1062|11 17|fluxes
P11883763A1062|251 265|East China Sea
P11883763A1062|206 218|Pu transport
P11883763A1062|238 243|slope
P11882747A0354|1 3|CD
P11882054A0568|105 110|pairs
P11882054A0568|192 198|slices
P11882054A0568|232 245|lesion volume
P11882054A0568|19 26|lesions
P11882054A0568|254 267|mirror region
P11881268A0000|143 148|women
P11881268A0000|21 26|study
P11876937A0261|14 15|U
P11876937A0261|27 30|day
P11876937A0261|71 75|rats
P11876937A0261|1 8|Heparin
P11874637A0212|105 114|treatment
P11874637A0212|41 48|therapy
P11874637A0212|145 153|decrease
P11874637A0212|232 236|AIDS
P11874637A0212|175 183|severity
P11874637A0212|118 131|HIV infection
P11872570T0000|30 33|NHS
P11872570T0000|1 9|Dementia
P11870646A0668|128 134|damage
P11870646A0668|37 43|design
P11870646A0668|21 29|analyses
P11866130A0419|29 45|2-phenoxyethanol
P11866130A0419|110 129|quinaldine sulphate
P11866130A0419|4 12|addition
P11864173T0000|56 69|exacerbations
P11864173T0000|20 29|pathogens
P11864173T0000|33 39|causes
P11862350T0000|61 96|NMDA receptor antagonist remacemide
P11862350T0000|132 143|performance
P11862350T0000|100 113|road tracking
P11860876A0409|43 44|%
P11860876A0409|1 16|HIV-1 C subtype
P11860097A1695|62 67|study
P11860097A1695|9 23|prosthesis use
P11860097A1695|1 5|Data
P11859400A0229|181 189|controls
P11859400A0229|210 219|acyclovir
P11859400A0229|89 92|HSV
P11859400A0229|39 51|valacyclovir
P11859400A0229|117 148|progenitor cell transplantation
P11858548A0241|41 46|study
P11858548A0241|78 89|NMR spectra
P11858548A0241|54 58|mono
P11853943A0122|41 50|algorithm
P11851941A0372|90 103|haemodilution
P11851941A0372|135 146|haemoglobin
P11851941A0372|191 210|hydroxyethyl starch
P11851941A0372|71 83|blood volume
P11849417A0900|31 37|groups
P11849417A0900|140 145|years
P11849417A0900|155 156|P
P11849417A0900|84 94|initiation
P11846187A0894|41 49|judgment
P11846187A0894|59 67|subjects
P11845547A0449|30 40|dobutamine
P11845547A0449|42 65|KATP channel activators
P11844591A0329|56 67|peak torque
P11844591A0329|39 44|angle
P11842728X0001|106 123|Schistosoma genus
P11842728X0001|21 36|schistosomiasis
P11842728X0001|86 98|blood flukes
P11840365A0949|25 31|effect
P11840365A0949|81 86|SF-36
P11838058A0084|135 139|CPTE
P11838058A0084|12 17|cases
P11838058A0084|77 82|cases
P11838058A0084|117 133|tissue expansion
P11836303A1191|163 168|stage
P11836303A1191|54 65|disturbance
P11836303A1191|17 22|study
P11836046A0549|122 126|meal
P11836046A0549|298 303|month
P11836046A0549|212 218|mg/day
P11836046A0549|113 116|end
P11836046A0549|155 156|n
P11836046A0549|194 200|manner
P11836046A0549|284 287|day
P11836046A0549|314 315|n
P11836046A0549|141 144|day
P11834476A1187|105 113|ischemia
P11834476A1187|95 98|min
P11834476A1187|174 190|oxygen transport
P11834476A1187|223 231|increase
P11834476A1187|207 213|cortex
P11832019A0668|14 18|AMVT
P11832019A0668|1 12|CONCLUSIONS
P11830544A0335|76 78|nm
P11830544A0335|39 50|neu antigen
P11830544A0335|138 151|WIBC-9 tumors
P11830544A0335|87 94|1B4M-Gd
P11826141T0000|150 158|behavior
P11826141T0000|24 46|lidocaine inactivation
P11826141T0000|54 61|rostral
P11826141T0000|117 130|reinstatement
P11824801A0661|150 158|patients
P11824801A0661|109 120|sarcoidosis
P11824801A0661|93 105|exacerbation
P11824801A0661|138 146|minority
P11822811A0319|121 126|hours
P11822811A0319|133 145|intoxication
P11822811A0319|114 118|VMTH
P11821098A0269|47 49|LH
P11821098A0269|42 45|FSH
P11821098A0269|55 64|inhibin A
P11821098A0269|69 71|B.
P11818675X0897|1 10|Karger AG
P11816458A0319|164 174|experiment
P11816458A0319|135 150|journal article
P11816458A0319|43 51|APA Form
P11816458A0319|64 75|help system
P11816458A0319|216 227|experiments
P11811825A0972|29 57|cross-validation experiments
P11811825A0972|76 83|average
P11811825A0972|159 176|sensitivity level
P11810685A0147|90 102|displacement
P11810685A0147|127 142|long-wavelength
P11810685A0147|22 47|displacement distribution
P11810685A0147|156 157|q
P11810685A0147|116 117|r
P11804510A0730|28 29|%
P11804510A0730|11 24|dichlofluanid
P11804510A0730|198 199|%
P11804510A0730|176 182|levels
P11804510A0730|71 72|%
P11804510A0730|1 7|Losses
P11804100A0365a|40 44|BOD5
P11804100A0365a|125 135|TP removal
P11804100A0365a|113 121|kinetics
P11803325A0868|47 56|HBS group
P11803325A0868|78 87|CBC group
P11803325A0868|100 102|DC
P11802580A0000|180 200|health research tool
P11802580A0000|41 45|GPRD
P11802580A0000|54 59|world
P11802580A0000|119 134|patient records
P11800878T0000|48 74|ultrashort UV laser pulses
P11800119A0814|41 55|vibration mode
P11793614A0000|60 74|concentrations
P11793614A0000|121 130|inhibitor
P11793614A0000|182 189|disease
P11793614A0000|37 43|effect
P11793614A0000|139 148|treatment
P11792586A0290|44 52|activity
P11792586A0290|8 15|loading
P11792586A0290|66 75|formation
P11792586A0290|102 115|tissue matrix
P11791585A0287|5 15|electrodes
P11791292A0193|42 53|application
P11791292A0193|18 28|laboratory
P11789216T0001|93 97|wall
P11789216T0001|23 40|blood circulation
P11789216T0001|118 127|gastritis
P11787746A0374|72 78|acuity
P11787746A0374|36 50|lens fragments
P11787746A0374|117 125|majority
P11787746A0374|16 23|removal
P11787322X0001|122 133|instruments
P11787322X0001|24 31|methods
P11787322X0001|292 300|vehicles
P11787322X0001|73 83|properties
P11787322X0001|277 287|literature
P11787322X0001|138 147|materials
P11787322X0001|35 56|chemical disinfection
P11787322X0001|304 316|transmission
P11786945A0958|11 18|freedom
P11786945A0958|36 47|arrhythmias
P11785827A0986|30 38|relation
P11785827A0986|160 166|forest
P11785827A0986|53 59|models
P11785827A0986|206 222|transmissibility
P11785827A0986|69 80|propagation
P11783457A0000|132 145|decomposition
P11783457A0000|94 102|activity
P11783457A0000|156 160|drug
P11783457A0000|1 14|Preservatives
P11781615A0000|95 115|cell transplantation
P11781615A0000|54 66|complication
P11778044A0000|192 216|complexity climate model
P11778044A0000|126 149|fingerprinting approach
P11778044A0000|237 248|diagnostics
P11778044A0000|17 50|probability density distributions
P11777575A0363|92 98|pellet
P11777575A0363|37 47|bulgaricus
P11777575A0363|156 164|networks
P11777575A0363|49 64|S. thermophilus
P11775301A0797|4 10|effect
P11775301A0797|34 51|depression scores
P11773921A0397|179 187|patients
P11773921A0397|396 400|dose
P11773921A0397|221 229|patients
P11773921A0397|284 296|implantation
P11773921A0397|407 409|mg
P11773921A0397|434 440|groups
P11773921A0397|202 216|artery disease
P11773921A0397|413 424|clopidogrel
P11773921A0397|371 375|dose
P11773921A0397|1 8|METHODS
P11773921A0397|68 77|platelets
P11771979A1141|133 140|methods
P11771979A1141|162 165|LDF
P11771979A1141|154 160|organs
P11771979A1141|50 61|LDF signals
P11771979A1141|275 286|vasculature
P11768467A0000|1 24|Pyrethroid insecticides
P11765448A0588|11 27|X-ray projection
P11764062A0000|209 217|Chorpita
P11764062A0000|40 48|Children
P11764062A0000|202 207|worry
P11764062A0000|71 96|self-report questionnaire
P11764062A0000|137 145|children
P11761601A0133|160 180|inhalation exposures
P11761601A0133|83 95|time history
P11761601A0133|3 19|computer program
P11760398A0553|120 128|presence
P11760398A0553|132 139|absence
P11760398A0553|26 34|patients
P11760398A0553|40 42|BS
P11760398A0553|185 189|form
P11760398A0553|1 8|METHODS
P11752821A1365|13 16|MMF
P11752821A1365|22 27|g/day
P11752821A1365|99 106|disease
P11744290T0045|13 25|waste matter
P11743360A2491|134 136|pg
P11743360A2491|43 54|mean amount
P11743360A2491|92 93|%
P11743360A2491|138 140|ml
P11741554T0000|28 49|lipoprotein particles
P11741554T0000|140 154|artery disease
P11741554T0000|1 11|Comparison
P11740806X0810|1 17|Saunders Company
P11738404A0120|56 93|alpha-diacetoxy-8 beta-isobutanoyloxy
P11738404A0120|489 493|data
P11738404A0120|460 472|analyses NMR
P11738404A0120|358 362|beta
P11738404A0120|118 130|alpha-methyl
P11738404A0120|131 149|butanoyloxy-4 beta
P11738404A0120|230 234|beta
P11738404A0120|7 26|chemical structures
P11738404A0120|206 228|alpha-diacetoxy-8 beta
P11737158A1517|192 202|dimensions
P11737158A1517|127 139|computations
P11737158A1517|53 67|fusiform gyrus
P11737158A1517|19 24|areas
P11736792A0204|47 52|study
P11736792A0204|209 217|criteria
P11736792A0204|110 144|World Health Organization criteria
P11736792A0204|157 167|morphology
P11732417A0571|195 204|ELISA kit
P11732417A0571|147 156|reference
P11730712A0416|107 108|P
P11730712A0416|92 105|MCA occlusion
P11730712A0416|1 19|Treadmill training
P11730182A0984|180 186|Betula
P11730182A0984|124 135|Cherry Hill
P11730182A0984|251 258|Poaceae
P11730182A0984|104 116|Philadelphia
P11730182A0984|311 312|p
P11730182A0984|309 310|r
P11730182A0984|237 238|r
P11730182A0984|211 212|p
P11730182A0984|145 146|p
P11730182A0984|157 164|Quercus
P11730182A0984|262 263|p
P11730182A0984|87 100|pollen levels
P11730182A0984|286 287|p
P11730182A0984|143 144|r
P11730182A0984|137 141|Acer
P11727209A0502|24 32|families
P11727209A0502|5 13|patients
P11726574A1304|30 37|changes
P11726574A1304|73 78|model
P11726262A0692|45 60|supplementation
P11726262A0692|121 123|mM
P11726262A0692|79 81|mM
P11726262A0692|100 102|mM
P11726068A0539|15 20|study
P11726068A0539|28 39|conclusions
P11724510T0000|10 20|principles
P11723675A1022|123 130|group C
P11723675A1022|26 32|course
P11723675A1022|191 196|point
P11723675A1022|116 121|point
P11723675A1022|154 169|APACHE II score
P11723675A1022|220 225|point
P11723675A1022|198 205|group B
P11723675A1022|96 103|group B
P11723675A1022|71 78|group A
P11723675A1022|171 178|group A
P11723500X0000|124 138|cell carcinoma
P11723500X0000|96 101|women
P11723500X0000|157 163|cavity
P11723500X0000|86 92|cavity
P11718197A1282|5 14|procedure
P11716043A0380|47 54|surgery
P11716043A0380|92 99|Surgery
P11716043A0380|101 137|Helsinki University Central Hospital
P11714429X0000|301 305|Risk
P11714429X0000|176 187|ticlopidine
P11714429X0000|49 59|prevention
P11714429X0000|259 270|Clopidogrel
P11714429X0000|85 96|cornerstone
P11714429X0000|319 331|Events trial
P11714429X0000|109 117|evidence
P11714429X0000|163 174|clopidogrel
P11714429X0000|4 15|clopidogrel
P11710685A0994b|27 32|ASCUS
P11710685A0994b|118 135|Papanicolaou test
P11710233T0000|15 33|tissue engineering
P11709561T0000|30 32|D2
P11709561T0000|104 110|factor
P11709561T0000|115 128|neuroblastoma
P11708431A0904|88 93|onset
P11708431A0904|24 36|introduction
P11708431A0904|70 84|oligoarthritis
P11708032A0183|215 226|medications
P11708032A0183|58 66|infusion
P11708032A0183|253 258|hours
P11708032A0183|84 88|l-LV
P11708032A0183|197 200|day
P11708032A0183|101 115|5-fluorouracil
P11708032A0183|274 286|infuser pump
P11706949T0000|33 58|growth factor I receptors
P11706949T0000|84 89|joint
P11705093A2016|66 72|effect
P11704380A1608|41 49|Irr-rMFP
P11704380A1608|53 61|Un-nrMFP
P11704380A1608|19 27|patients
P11703464A0560|129 137|response
P11703464A0560|52 59|regions
P11703464A0560|117 125|circuits
P11695481A0310|94 103|ozonation
P11695481A0310|65 81|degradation rate
P11692004A1200|109 121|relationship
P11692004A1200|64 71|studies
P11692004A1200|17 27|literature
P11691585A1174|43 72|coimmunoprecipitation studies
P11691585A1174|86 90|homo
P11687869A0000|15 20|woman
P11687869A0000|68 79|sarcoidosis
P11687517A1619|4 9|ISREs
P11687180A3209|108 113|onset
P11687180A3209|19 28|questions
P11687180A3209|69 76|rHu EPO
P11686378A0326|388 393|cells
P11686378A0326|331 336|cells
P11686378A0326|247 255|Pn decay
P11686378A0326|22 29|reactor
P11686378A0326|155 160|range
P11686378A0326|401 404|EHD
P11686378A0326|370 377|numbers
P11685284X0000|26 31|Suppl
P11685284X0000|2 14|Diabetologia
P11684665A0000|52 60|sequence
P11684665A0000|1 25|C. elegans embryogenesis
P11680835A0756|18 26|analysis
P11680835A0756|51 58|patient
P11678437A0000|45 57|productivity
P11678437A0000|224 231|gravity
P11678437A0000|88 99|Zea mays L.
P11678437A0000|172 201|petroleum development company
P11678437A0000|21 33|oil spillage
P11678437A0000|119 133|pot experiment
P11677363A0775|47 57|IMT values
P11677363A0775|79 84|h SBP
P11677363A0775|111 112|P
P11677363A0775|20 27|finding
P11675912A0131|72 83|preparation
P11675912A0131|108 121|acetaminophen
P11675912A0131|142 151|headaches
P11675912A0131|35 39|week
P11669281A0653|37 48|antibiotics
P11669281A0653|98 107|synergism
P11642687T0000|75 83|outcomes
P11642687T0000|88 96|patients
P11642687T0000|22 39|language versions
P11642687T0000|102 118|prostate disease
P11606538A1002|41 44|Nrk
P11606538A1002|64 88|receptor tyrosine kinase
P11606538A1002|34 39|genes
P11605207T0001|1 10|Treatment
P11603271T0001|22 39|vertigo syndromes
P11600467A1436|36 46|alteration
P11600314A0000|46 51|pulse
P11600314A0000|66 73|methods
P11600314A0000|169 171|B6
P11599840A0813|212 215|kPa
P11599840A0813|189 196|section
P11599840A0813|48 54|matter
P11599840A0813|152 155|kPa
P11599840A0813|15 25|elasticity
P11599840A0813|230 233|kPa
P11599840A0813|70 73|kPa
P11599079A1040|79 82|API
P11599079A1040|76 77|V
P11599079A1040|99 100|V
P11599079A1040|50 61|instruments
P11597185A0477|59 65|models
P11597185A0477|36 50|metapopulation
P11597185A0477|70 90|computer simulations
P11596104A0614|132 142|cell lines
P11596104A0614|113 115|kb
P11596104A0614|102 111|kilobases
P11595813A0633|151 160|aromatase
P11595813A0633|26 35|androgens
P11595813A0633|213 231|androgen receptors
P11595813A0633|59 64|areas
P11595813A0633|118 129|differences
P11595176T0000|13 22|structure
P11595176T0000|108 131|AF1q translocation gene
P11595176T0000|36 46|SPEC1 gene
P11593394A0000|213 216|p15
P11593394A0000|217 222|Ink4b
P11593394A0000|135 158|cyclin kinase complexes
P11593394A0000|228 231|p27
P11593394A0000|232 236|Kip1
P11593394A0000|238 262|cyclin kinase inhibitors
P11593394A0000|34 42|TGF-beta
P11592315A0325|96 100|calf
P11592315A0325|81 87|antrum
P11589779T0000|63 79|strongyloidiasis
P11589779T0000|18 26|Th2 type
P11589779T0000|1 7|HTLV-1
P11587980A1039|90 111|interrupter technique
P11587980A1039|74 82|contrary
P11587980A1039|233 248|bronchodilation
P11587980A1039|49 58|maneuvers
P11587980A1039|152 160|children
P11586096A0699|12 23|differences
P11586096A0699|52 72|control measurements
P11586096A0699|99 105|muscle
P11584328A0532|40 45|drugs
P11584328A0532|1 18|Drug interactions
P11583880T0000|39 57|AneuRx stent-graft
P11580757A0304|151 153|MR
P11580757A0304|41 54|TFCD patients
P11580757A0304|244 254|recordings
P11580757A0304|93 101|epilepsy
P11580757A0304|1 8|METHODS
P11580173A0181|61 68|results
P11580173A0181|77 81|work
P11580173A0181|1 20|Plane wave geometry
P11580173A0181|152 160|geometry
P11578685A0077|46 51|onset
P11578685A0077|1 7|ICAM-1
P11576776T0081|16 22|moduli
P11575977A1133|33 52|office hypertension
P11574105A0727|61 69|increase
P11574105A0727|301 307|damage
P11574105A0727|145 148|GBS
P11574105A0727|252 255|IgG
P11574105A0727|135 141|course
P11574105A0727|73 87|antibody titer
P11574105A0727|111 125|antibody titer
P11574105A0727|200 205|weeks
P11574105A0727|1 9|Patients
P11573891A0525|150 159|exposures
P11573891A0525|36 45|Americans
P11573891A0525|117 118|%
P11573891A0525|85 88|TST
P11572467T0000|135 144|exchanger
P11572467T0000|64 92|tissue plasminogen activator
P11572467T0000|1 11|Management
P11572388A0000|26 33|results
P11572388A0000|213 217|RPLC
P11572388A0000|219 237|method development
P11572388A0000|83 113|solvation energy relationships
P11572388A0000|48 53|study
P11570820T0000|82 91|cytoplasm
P11570820T0000|70 77|nucleus
P11569949A2087|56 61|sites
P11569949A2087|16 34|patient enrollment
P11569800T0000|1 24|Temperature measurement
P11566996A1391|22 26|uvrA
P11566996A1391|113 123|DNA damage
P11566996A1391|190 193|pH.
P11566948A1217|73 84|combination
P11566948A1217|130 136|events
P11566948A1217|17 32|nephrosclerosis
P11565747A1020|228 242|P element IVS3
P11565747A1020|37 52|UV crosslinking
P11565747A1020|158 161|PSI
P11565747A1020|216 224|splicing
P11565747A1020|69 92|competition experiments
P11565747A1020|170 185|SELEX sequences
P11564871A1184|180 190|eukaryotes
P11564871A1184|149 152|TBP
P11564871A1184|209 222|TATA elements
P11564871A1184|232 241|promoters
P11564871A1184|114 121|insight
P11564871A1184|201 205|lack
P11562278A0169|89 93|role
P11562278A0169|112 127|differentiation
P11562278A0169|172 182|cell death
P11562278A0169|184 193|apoptosis
P11561623A0897|11 46|copepod Pseudonychocamptus proximus
P11561623A0897|97 109|sand filters
P11561623A0897|191 198|biomass
P11560992A0651|226 240|stress stimuli
P11560992A0651|179 183|MKK4
P11560992A0651|82 92|expression
P11560992A0651|96 100|MKK4
P11560992A0651|139 154|mast cell lines
P11560992A0651|205 213|response
P11560990A0272|72 77|stage
P11560990A0272|1 19|E47 protein levels
P11560990A0272|204 209|stage
P11560292A0557|46 58|domain model
P11560292A0557|33 42|structure
P11559789A0314|214 219|level
P11559789A0314|231 249|producer cell line
P11559789A0314|21 25|work
P11559789A0314|141 154|gene cassette
P11559789A0314|274 281|inducer
P11559547T0000|91 101|ERR family
P11559547T0000|17 27|regulation
P11557127A0991|77 87|expression
P11557127A0991|25 42|Sp1 binding sites
P11557127A0991|4 14|conclusion
P11555669A0983|90 95|pairs
P11555669A0983|62 68|stains
P11555669A0983|38 45|samples
P11555516A0639|151 155|risk
P11555516A0639|40 44|COAT
P11555516A0639|9 15|output
P11555516A0639|76 88|cutoff value
P11554566A0833|9 24|companies sites
P11554469A1386|28 36|question
P11554469A1386|124 131|members
P11554469A1386|7 15|analyses
P11554469A1386|71 90|cellulose synthases
P11553091A1472|125 135|correction
P11553091A1472|49 58|diagnosis
P11553091A1472|154 166|relationship
P11552724A0527|61 71|blood flow
P11552724A0527|295 309|contrast media
P11552724A0527|143 150|disease
P11552724A0527|235 243|patients
P11552724A0527|1 12|CONCLUSIONS
P11552724A0527|288 291|use
P11552058A0235|27 33|values
P11552058A0235|39 44|mm Hg
P11548027A0163|149 154|water
P11548027A0163|113 123|indicators
P11548027A0163|18 40|performance indicators
P11548027A0163|187 207|personnel indicators
P11548027A0163|137 147|indicators
P11545594A1556|75 83|function
P11545594A1556|162 169|surface
P11545594A1556|118 137|amino acid residues
P11543317A0203|165 169|PNTD
P11543317A0203|123 127|TDMS
P11543317A0203|97 106|dosemeter
P11543317A0203|35 46|combination
P11542780A0086|75 87|contribution
P11542780A0086|29 38|detectors
P11542780A0086|133 136|LET
P11542780A0086|40 43|TLD
P11542780A0086|142 156|keV/micrometer
P11542780A0086|221 235|energy tranfer
P11540991A0127|150 155|space
P11540991A0127|28 35|effects
P11540991A0127|37 42|tests
P11540991A0127|65 101|NASA MSFC Neutral Buoyancy Simulator
P11538437A0568|181 183|N2
P11538437A0568|122 123|X
P11538437A0568|124 125|V
P11538437A0568|249 251|CN
P11538437A0568|184 185|A
P11538437A0568|104 106|N2
P11538437A0568|107 108|X
P11538437A0568|43 52|reactions
P11538437A0568|96 97|B
P11538437A0568|98 99|V
P11538437A0568|211 212|N
P11538437A0568|91 93|N2
P11538437A0568|94 95|C
P11538437A0568|146 147|V
P11538437A0568|267 268|B
P11538437A0568|158 176|N2 post-discharges
P11538437A0568|222 224|CN
P11538437A0568|84 85|A
P11538437A0568|73 75|N2
P11538437A0568|9 19|conditions
P11538437A0568|197 205|products
P11538437A0568|141 143|N2
P11538437A0568|136 137|X
P11535832A0586|40 42|aa
P11535832A0586|25 31|HDAC9a
P11535140T0000|14 22|findings
P11534900A0000|164 176|fruit powder
P11534900A0000|92 110|Cedrus deodara oil
P11534900A0000|55 87|molluscicides Azadirachta indica
P11534900A0000|216 233|Lymnaea acuminata
P11534900A0000|136 154|piperonyl butoxide
P11533863A0125|24 35|restoration
P11533863A0125|112 119|therapy
P11533238A1137|75 80|HDAC1
P11533238A1137|64 71|ability
P11533238A1137|1 9|Mutation
P11532556A0000|44 48|SDAE
P11532556A0000|23 42|angioencephalopathy
P11532556A0000|70 77|disease
P11530684A0667|302 306|ones
P11530684A0667|242 250|C-fibers
P11530684A0667|144 161|pain transmission
P11530684A0667|293 297|type
P11530684A0667|55 59|type
P11530684A0667|104 133|drive NK1-receptor mechanisms
P11530684A0667|197 204|changes
P11530684A0667|7 19|nerve injury
P11528500A0571|20 28|NRL gene
P11528127A1402|90 97|segment
P11528127A1402|146 151|L1/L2
P11528127A1402|126 131|mouse
P11528127A1402|101 105|% GC
P11528127A1402|34 41|segment
P11525486A0350|76 78|pH
P11525486A0350|17 26|CaCO3-CO2
P11524823X0001|56 74|distortion product
P11524823X0001|217 225|neonates
P11524823X0001|118 123|study
P11524823X0001|12 24|OAE screener
P11524823X0001|197 213|cochlea function
P11524823X0001|1 8|Utility
P11524823X0001|239 245|adults
P11524015A0937|77 103|CAT reporter gene activity
P11524015A0937|22 28|BZAP45
P11522658A0870|126 139|stoichiometry
P11522658A0870|67 76|stability
P11522658A0870|113 117|Cdk2
P11522658A0870|80 83|p27
P11522626A1374|135 153|estrogen receptors
P11522626A1374|95 105|activation
P11522626A1374|37 38|G
P11522626A1374|113 121|Mek-Erk1
P11522431A0673|177 178|%
P11522431A0673|113 124|individuals
P11522431A0673|65 80|ICD-10 criteria
P11522431A0673|19 37|tobacco dependence
P11520436A0705|63 67|mice
P11520436A0705|7 18|BALB/c mice
P11520436A0705|53 59|strain
P11520436A0705|137 145|T. canis
P11518868A0559|94 111|hepatitis C virus
P11518868A0559|52 65|risk behavior
P11517445A0221|11 16|cases
P11517445A0221|20 27|cholera
P11517269A0472|226 231|genes
P11517269A0472|78 91|axon guidance
P11517269A0472|128 135|mutants
P11517269A0472|1 6|Pitx2
P11517190A0352|177 187|expression
P11517190A0352|108 116|TATA box
P11517190A0352|48 56|presence
P11517190A0352|84 94|start site
P11513579A0372|151 162|interaction
P11513579A0372|89 96|Rho-GDI
P11513579A0372|126 130|role
P11513121T0000|105 108|BCF
P11513121T0000|62 89|quantum chemical parameters
P11513121T0000|42 52|QSAR model
P11513121T0000|156 161|PCOCs
P11511544T0000|91 100|responses
P11511544T0000|5 16|loop domain
P11509615T0000|66 86|T cell proliferation
P11509615T0000|103 116|IL-2 receptor
P11505407A0461|75 80|cells
P11505407A0461|23 31|fragment
P11505407A0461|116 143|tumor necrosis factor alpha
P11504545A0393|134 144|CV-1 cells
P11504545A0393|125 129|HeLa
P11504545A0393|113 121|extracts
P11504545A0393|48 66|immunoshift assays
P11502758A0869|61 66|LAD-1
P11502758A0869|7 15|findings
P11500913A1238|30 40|HC11 cells
P11500913A1238|94 121|cell differentiation marker
P11500913A1238|126 134|response
P11500512A0000|73 84|superfamily
P11500512A0000|167 177|oxysterols
P11500512A0000|58 66|cassette
P11500512A0000|136 147|macrophages
P11498795A0716|121 126|delay
P11498795A0716|11 22|progression
P11498795A0716|95 105|RB protein
P11496495A0000|75 88|possibilities
P11496495A0000|5 12|authors
P11496495A0000|117 121|care
P11495833T0000|105 115|properties
P11495833T0000|79 84|model
P11490862A0141|105 117|bone anchors
P11490862A0141|88 91|use
P11490862A0141|16 27|development
P11489597A0379|44 51|females
P11489597A0379|197 210|malformations
P11489597A0379|4 15|termination
P11489597A0379|138 145|fetuses
P11486476A0147|62 77|characteristics
P11486476A0147|215 225|chest pain
P11486476A0147|332 341|admission
P11486476A0147|263 266|ACS
P11486476A0147|15 20|trial
P11486476A0147|281 288|markers
P11486476A0147|128 146|markers troponin T
P11486476A0147|235 245|proportion
P11486141A0424|43 50|outcome
P11486141A0424|6 13|factors
P11486141A0424|100 113|meta analysis
P11484578A1132|45 61|measurement data
P11484578A1132|167 181|design program
P11484578A1132|80 86|method
P11484578A1132|1 11|CONCLUSION
P11481625A0202|28 36|subjects
P11481625A0202|149 170|peginterferon alfa-2b
P11481625A0202|93 116|interferon alfa-2b dose
P11480497T0000|72 79|battery
P11480497T0000|112 115|rat
P11480497T0000|1 8|Effects
P11479501A0744|148 149|%
P11479501A0744|157 178|St Jude Medical valve
P11479501A0744|190 191|%
P11479501A0744|73 82|variation
P11479501A0744|97 98|%
P11479501A0744|141 142|%
P11479501A0744|1 8|RESULTS
P11478627A0573|135 143|property
P11478627A0573|72 73|D
P11478627A0573|43 49|search
P11478627A0573|163 168|scale
P11478627A0573|83 85|Y2
P11473261A0587|44 78|guanine nucleotide exchange factor
P11473261A0587|1 5|Mss4
P11472696A0387|61 69|patients
P11472696A0387|40 57|fibrinogen levels
P11472696A0387|5 16|differences
P11471231A0964|20 28|patients
P11471231A0964|116 124|spectrum
P11470914A0305|31 50|STAT3 translocation
P11470914A0305|5 13|activity
P11470914A0305|17 21|Rac1
P11469926T0000|1 30|Breast cancer risk assessment
P11469853A0702|73 83|C1 domains
P11469853A0702|95 105|Raf kinase
P11469853A0702|110 121|rat PKC eta
P11469701A0377|105 110|CIIIT
P11469701A0377|88 103|insulin therapy
P11469701A0377|215 219|vein
P11469701A0377|144 151|fashion
P11467349A0452|46 54|measures
P11467349A0452|23 27|task
P11465844T0000|29 46|Kawasaki syndrome
P11465844T0000|9 20|association
P11465844T0000|86 102|Rickettsia typhi
P11465844T0000|51 60|infection
P11465518A0000|106 110|ways
P11465518A0000|57 70|investigators
P11465518A0000|33 41|interest
P11465518A0000|49 53|part
P11463834A0606|107 113|region
P11463834A0606|9 29|deletion mutagenesis
P11463834A0606|71 74|CBP
P11463834A0606|117 120|CR2
P11462952A1040|95 99|mU/L
P11462952A1040|83 87|mean
P11462952A1040|70 74|mU/L
P11462004A1500|93 96|Vp2
P11462004A1500|190 202|localization
P11462004A1500|138 142|NLS1
P11462004A1500|34 38|Vp1s
P11461595A0000|72 79|inertia
P11461595A0000|109 117|reaction
P11461595A0000|125 126|B
P11461595A0000|119 122|B+B
P11459962A0785|46 51|Rad52
P11459962A0785|159 168|degrees C
P11459962A0785|33 38|genes
P11459962A0785|204 216|temperatures
P11459962A0785|68 82|repair pathway
P11459794A1172|129 145|GnRH-II promoter
P11459794A1172|70 80|constructs
P11459048A0485|75 82|planets
P11459048A0485|110 115|Venus
P11459048A0485|55 61|models
P11456259A0142|90 102|presentation
P11456259A0142|123 128|weeks
P11456259A0142|52 56|TBII
P11456259A0142|116 117|%
P11454239A0478|268 277|Chronbach
P11454239A0478|300 305|scale
P11454239A0478|178 186|Cronbach
P11454239A0478|217 228|Sensitivity
P11454239A0478|280 285|alpha
P11454239A0478|163 174|calculation
P11454239A0478|233 244|specificity
P11454004T0000|180 191|promoter B.
P11454004T0000|10 20|regulation
P11454004T0000|50 53|rat
P11454004T0000|137 161|hormone-response element
P11451682A0190|29 31|AE
P11451682A0190|127 138|albendazole
P11451682A0190|48 62|administration
P11450776T0000|24 29|group
P11449014A0000|61 68|aspects
P11449014A0000|133 137|CCTs
P11449014A0000|178 208|epidemiologist/biostatistician
P11449014A0000|23 28|study
P11449014A0000|1 16|STUDY OBJECTIVE
P11447490A0598|23 31|effusion
P11447490A0598|80 90|assessment
P11444762A0373|26 35|proposals
P11444762A0373|92 97|onset
P11444762A0373|68 72|data
P11443509A0293|148 153|Study
P11443509A0293|94 112|Examination Survey
P11443509A0293|21 33|cohort study
P11443509A0293|1 7|DESIGN
P11441952A0414|246 249|TBI
P11441952A0414|113 121|controls
P11441952A0414|216 220|test
P11441952A0414|84 94|percentage
P11441952A0414|13 14|D
P11441952A0414|7 11|days
P11441952A0414|98 107|avoidance
P11438838A0788|90 94|U6-P
P11438838A0788|59 61|U6
P11438838A0788|34 43|TAR decoy
P11438654A1237|7 15|findings
P11438654A1237|33 45|adapter Gab1
P11437660A1219|151 162|replication
P11437660A1219|123 129|effect
P11437660A1219|40 50|C-terminus
P11437660A1219|1 13|Substitution
P11435983T0000|88 97|follow-up
P11435983T0000|20 35|transplantation
P11435605A0587|30 33|CAR
P11435605A0587|213 216|Ad9
P11435605A0587|218 222|Ad12
P11435605A0587|85 91|Lys123
P11435605A0587|15 26|mutagenesis
P11435605A0587|128 133|Tyr80
P11435605A0587|71 77|Lys121
P11435578A0760|164 172|TGACGGCA
P11435578A0760|7 11|TxRE
P11435578A0760|80 88|TGACGTCA
P11435578A0760|141 147|strain
P11435517A0396|30 32|OM
P11435517A0396|176 180|dogs
P11435517A0396|59 62|TDF
P11435517A0396|189 201|control diet
P11435517A0396|117 121|dogs
P11435517A0396|79 85|energy
P11435517A0396|103 104|P
P11434084A0508|86 93|d-dimer
P11434084A0508|51 67|microlatex tests
P11433024A0260|101 114|RNA component
P11433024A0260|1 11|Telomerase
P11433024A0260|17 42|ribonucleoprotein complex
P11433014A0683|75 78|H2B
P11433014A0683|163 170|protein
P11433014A0683|55 71|core histone H2A
P11432748T0000|60 77|cancer cell lines
P11431857A0186|31 46|urine screening
P11431857A0186|150 164|urine analysis
P11431857A0186|115 119|days
P11431348A0000|134 138|MAPK
P11431348A0000|26 53|checkpoint abrogator UCN-01
P11431348A0000|140 146|kinase
P11431348A0000|207 226|leukemia cell lines
P11431348A0000|118 132|protein kinase
P11430042A0000|14 18|text
P11430042A0000|162 166|RTIL
P11430042A0000|2 8|figure
P11430042A0000|118 126|BMIM BF4
P11428897A0318|13 24|experiments
P11428897A0318|79 89|target DNA
P11428897A0318|189 194|helix
P11428897A0318|203 213|directions
P11428897A0318|273 279|target
P11428897A0318|152 157|turns
P11428435A0446|94 108|period January
P11428435A0446|76 86|procedures
P11428435A0446|1 7|DESIGN
P11428276A0352|108 118|phosphates
P11428276A0352|5 8|Van
P11428276A0352|70 82|calcium salt
P11427329A1077|122 123|r
P11427329A1077|95 96|r
P11427329A1077|21 26|FPS-R
P11427329A1077|103 104|N
P11427329A1077|68 80|correlations
P11425076A0364|195 222|perturbation theory results
P11425076A0364|226 236|comparison
P11425076A0364|76 81|alpha
P11425076A0364|278 283|model
P11425076A0364|254 265|integration
P11423991A1393|11 17|screen
P11423991A1393|114 117|p53
P11423991A1393|68 80|p53 variants
P11422200A0000|150 158|microbes
P11422200A0000|40 45|G-CSF
P11422200A0000|32 38|factor
P11422200A0000|1 12|Granulocyte
P11419938T0000|132 142|homologies
P11419938T0000|38 63|uptake regulation protein
P11419938T0000|69 85|metal activation
P11418130A0499|75 88|recombination
P11416737T0000|11 30|Tl-201 scintigraphy
P11416737T0000|49 61|plasmacytoma
P11416393A0000|482 487|drugs
P11416393A0000|302 320|sodium restriction
P11416393A0000|601 610|cessation
P11416393A0000|353 362|assurance
P11416393A0000|106 113|control
P11416393A0000|37 47|approaches
P11416393A0000|443 450|numbers
P11416393A0000|211 215|risk
P11416393A0000|219 231|hypertension
P11416393A0000|395 403|pressure
P11416393A0000|280 289|mortality
P11416393A0000|6 16|modalities
P11416393A0000|549 552|day
P11416144A1324|47 53|ZBP-89
P11416144A1324|126 137|p53 protein
P11416144A1324|64 82|cell proliferation
P11416012T0000|130 137|porcine
P11416012T0000|110 117|hormone
P11416012T0000|155 160|cells
P11416012T0000|49 82|density lipoprotein receptor gene
P11416012T0000|171 182|convergence
P11416012A1982|91 96|drive
P11416012A1982|57 69|contribution
P11416012A1982|129 131|bp
P11416012A1982|189 227|rabbit muscle protein kinase inhibitor
P11416012A1982|234 242|minigene
P11416012A1982|275 297|sarcoma virus promoter
P11415952A0369|12 23|persistence
P11415952A0369|9 10|Q
P11415952A0369|38 50|associations
P11415952A0369|190 192|Q5
P11414754X1099|1 10|Copyright
P11413641A0373|24 37|scale matters
P11413641A0373|1 9|Analyses
P11413310A0148|45 51|T-cell
P11413310A0148|245 258|RSV infection
P11413310A0148|92 104|CC chemokine
P11413310A0148|162 173|eosinophils
P11413310A0148|223 233|infiltrate
P11413310A0148|205 209|lung
P11413148A0573|25 37|Src homology
P11413148A0573|1 17|STAT5A mutations
P11411623T0000|14 33|compression therapy
P11411623T0000|37 45|symptoms
P11411623T0000|1 10|Influence
P11410679A0000|181 191|constructs
P11410679A0000|76 89|rearrangement
P11410679A0000|110 135|LOX recognition sequences
P11410679A0000|278 287|LOX sites
P11410679A0000|33 39|genome
P11410679A0000|258 266|interest
P11410563A0363|182 194|risk factors
P11410563A0363|92 95|age
P11410563A0363|22 28|factor
P11410563A0363|158 178|manufacturing period
P11410563A0363|32 36|risk
P11409425A0000|183 195|relationship
P11409425A0000|270 277|outcome
P11409425A0000|112 117|NINDS
P11409425A0000|223 226|Apo
P11409425A0000|16 30|plasma samples
P11409425A0000|119 147|tissue plasminogen activator
P11409425A0000|347 355|response
P11409425A0000|280 286|months
P11409425A0000|371 383|t-PA therapy
P11409425A0000|237 253|Apo E4 phenotype
P11408604A1440|104 113|signaling
P11408604A1440|177 183|ERK1/2
P11408604A1440|42 51|receptors
P11408604A1440|36 37|D
P11408604A1440|65 83|ERK kinase cascade
P11408604A1440|38 40|2L
P11408575A0000|30 35|entry
P11408575A0000|41 48|mitosis
P11408575A0000|93 105|kinase Cdc28
P11408575A0000|139 143|form
P11408099A0518|62 67|weeks
P11408099A0518|26 38|correlations
P11408099A0518|144 145|P
P11408099A0518|115 116|P
P11408099A0518|85 94|Se levels
P11407448A0815|144 167|tract voice restoration
P11407448A0815|201 217|voice prosthesis
P11407448A0815|290 305|speech training
P11406642A0792|24 34|expression
P11406642A0792|17 22|cases
P11406025A0204|135 145|spermicide
P11406025A0204|76 82|safety
P11406025A0204|1 11|OBJECTIVES
P11406025A0204|17 26|objective
P11404312A0660|25 26|P
P11404016A1922|47 51|PKSs
P11404016A1922|5 17|co-existence
P11404016A1922|155 165|polyketide
P11404016A1922|184 201|peptide synthases
P11403719A1257|62 78|egr-1 expression
P11403719A1257|92 99|insulin
P11403719A1257|51 58|control
P11403173A0192|39 52|brain tumours
P11401611A1703|105 114|reduction
P11401611A1703|131 140|fractures
P11401611A1703|18 31|meta-analysis
P11400644A0435|41 50|estimates
P11400644A0435|66 73|sources
P11400644A0435|99 114|PCDD/F releases
P11400644A0435|84 95|percentiles
P11399064T0000|54 89|CCAAT/enhancer binding protein beta
P11399064T0000|103 116|transcription
P11398134A1565|60 69|disorders
P11398134A1565|123 134|development
P11398134A1565|4 14|conclusion
P11398134A1565|16 23|obesity
P11396685A0477|133 135|mg
P11396685A0477|163 174|information
P11396685A0477|98 104|amount
P11396685A0477|33 36|DTD
P11393791A1153|27 31|RNAs
P11393791A1153|196 221|polymerase chain reaction
P11393791A1153|231 236|assay
P11393791A1153|261 269|analysis
P11393791A1153|223 229|RT-PCR
P11393791A1153|1 23|Northern blot analysis
P11392772A0182|56 65|treatment
P11392772A0182|249 254|times
P11392772A0182|114 127|zone Telychka
P11392772A0182|45 51|plants
P11392772A0182|73 93|surface storm waters
P11392772A0182|5 16|application
P11391793A0856|104 107|map
P11391793A0856|72 78|tumors
P11391793A0856|52 58|region
P11391793A0856|201 204|PAC
P11391793A0856|153 166|bacteriophage
P11391303A1023|33 48|LHR measurement
P11391303A1023|1 12|CONCLUSIONS
P11390684A1170|90 111|jadomycin B synthesis
P11390684A1170|1 9|Evidence
P11390650A0562|12 30|deletion mutations
P11390650A0562|146 156|P-1 domain
P11390650A0562|103 109|region
P11390395A1018|75 85|repression
P11389085A0290|44 59|MEN 2A type RET
P11389085A0290|111 118|nucleus
P11389085A0290|19 32|MTC cell line
P11387950X0001|360 363|ANP
P11387950X0001|178 200|leukocyte adhesiveness
P11387950X0001|23 34|ta chengchi
P11387950X0001|460 473|TNF secretion
P11387950X0001|119 129|objectives
P11387950X0001|345 356|lung injury
P11387950X0001|407 418|ta chengchi
P11387950X0001|167 174|changes
P11387950X0001|228 231|TNF
P11387950X0001|64 75|lung injury
P11387950X0001|273 285|pancreatitis
P11387950X0001|137 142|study
P11387351A0092|14 21|METHODS
P11387351A0092|91 120|analog 2-chlorodeoxyadenosine
P11387351A0092|225 228|MDS
P11387351A0092|192 195|AML
P11387351A0092|157 160|AML
P11387351A0092|1 9|PATIENTS
P11385840A1684|135 156|optimization routines
P11385840A1684|80 90|parameters
P11384576A1132|4 12|addition
P11384576A1132|50 60|interferon
P11384225A0634|9 12|end
P11384225A0634|55 59|gene
P11384225A0634|84 91|protein
P11382948A0793|31 39|MRI data
P11382948A0793|106 125|breast cancer model
P11382948A0793|4 14|conclusion
P11382948A0793|69 97|tumor microvessel properties
P11381094A0797|36 47|C2B domains
P11381094A0797|51 65|synaptotagmins
P11380370A0000|29 41|skin lesions
P11380370A0000|3 10|patient
P11379106A0372|8 16|meantime
P11379106A0372|53 79|deammonification processes
P11377975A0898|31 41|COS1 cells
P11377975A0898|161 166|study
P11377975A0898|64 83|proteinase activity
P11376687A0344|210 213|p26
P11376687A0344|147 150|AUG
P11376687A0344|161 171|MTH1 mRNAs
P11376687A0344|257 273|targeting signal
P11376687A0344|85 88|SNP
P11376165T0000|37 52|Xenopus embryos
P11376119A0346|104 106|bp
P11376119A0346|135 143|GHR gene
P11376119A0346|67 73|region
P11376119A0346|17 24|exon 1A
P11375392T0000|147 155|promoter
P11375392T0000|108 119|Sp3 binding
P11375392T0000|53 60|cloning
P11375392T0000|99 102|Sp1
P11374559A0103|31 49|vacuum evaporation
P11374559A0103|83 95|island films
P11374559A0103|65 70|p-NTP
P11373277A0812|45 60|oncoprotein E1A
P11373277A0812|181 199|AP-2alpha promoter
P11373277A0812|161 173|derepression
P11373277A0812|218 221|E1A
P11373277A0812|71 84|transcription
P11372882A1143|14 17|DDE
P11372882A1143|72 78|levels
P11372882A1143|10 11|p
P11372882A1143|84 90|levels
P11371343A0125|86 93|protein
P11371343A0125|32 40|separase
P11371160A0193|131 139|molecule
P11371160A0193|97 102|amino
P11371160A0193|117 123|branch
P11370174A0447|10 32|serum creatinine level
P11370174A0447|80 90|withdrawal
P11369700A0616|193 217|luciferase reporter gene
P11369700A0616|9 19|manuscript
P11369700A0616|101 128|transcription factors Elf-1
P11369700A0616|51 60|Ets sites
P11369453A1083|14 22|increase
P11369453A1083|52 59|element
P11369106A0428|75 87|interactions
P11369106A0428|8 16|advances
P11369106A0428|54 60|result
P11368914T0071|105 108|ORF
P11368914T0071|40 64|complement C3 gene locus
P11368914T0071|23 28|exons
P11368901A0327|27 32|mouse
P11368901A0327|4 12|contrast
P11368901A0327|98 105|portion
P11368363A1103|91 99|rat HBP1
P11368363A1103|11 27|protein sequence
P11368363A1103|110 118|homology
P11367523A2624|121 130|C4A genes
P11367523A2624|52 57|genes
P11361493T0000|88 100|Buenos Aires
P11361493T0000|43 54|adolescents
P11361493T0000|1 6|HIV-1
P11361338A0093|79 95|targeting signal
P11361338A0093|97 101|PTS1
P11361338A0093|50 54|type
P11359907A0099|89 102|growth factor
P11359907A0099|54 58|gene
P11359568T0000|135 157|plasmid partition site
P11359568T0000|11 19|analysis
P11359568T0000|159 163|parS
P11358958A0878|61 78|growth inhibition
P11358958A0878|106 117|tumor cells
P11358958A0878|21 26|RACK1
P11357063A1053|30 41|LHbeta gene
P11357063A1053|10 19|consensus
P11357063A1053|125 127|bp
P11357063A1053|144 167|translation start codon
P11356853A0873|36 64|basic-leucine zipper factors
P11356853A0873|16 32|AP-1 superfamily
P11356853A0429|4 14|Ka13 cells
P11356853A0429|16 20|CoCl
P11356853A0429|51 75|luciferase reporter gene
P11356716A0372|65 79|GHS-R variants
P11356716A0372|34 43|sequences
P11355668T0000|57 73|porcine neonates
P11355668T0000|42 53|hemorrhages
P11355576A1125|245 270|E2F transcription factors
P11355576A1125|58 73|phosphorylation
P11355576A1125|84 94|inhibition
P11355576A1125|134 157|pRb controls commitment
P11355576A1125|129 132|pRb
P11355576A1125|38 41|CDK
P11355576A1125|103 127|tumor suppressor protein
P11354406A1373|113 125|ICP waveform
P11353770A0085|122 143|8-oxoguanine residues
P11353770A0085|147 150|DNA
P11353770A0085|59 61|S3
P11353770A0085|80 102|N-glycosylase activity
P11352671A0492|30 38|genetics
P11352671A0492|132 136|site
P11352671A0492|58 75|nucleotide change
P11352671A0492|144 150|V gene
P11352671A0492|216 223|viruses
P11352671A0492|170 180|hPIV2 cDNA
P11352423A0084|12 24|forearm flap
P11352423A0084|114 124|situations
P11350957A0457|47 54|tissues
P11350957A0457|115 124|cytoplasm
P11350957A0457|1 11|PACAP mRNA
P11350175A0173|28 35|members
P11350175A0173|93 111|chaperone activity
P11350038A0459|113 120|hY RNAs
P11350038A0459|48 52|Stem
P11350038A0459|17 25|evidence
P11348318A0940|105 121|characterization
P11348318A0940|31 42|mammography
P11348318A0940|52 60|patients
P11345445A0533|164 166|Zn
P11345445A0533|109 120|springtails
P11345445A0533|78 95|Cd concentrations
P11345445A0533|157 159|Cu
P11344530A0320|29 37|overload
P11344530A0320|80 81|%
P11344530A0320|16 24|recovery
P11341828A0744|74 80|domain
P11341405A0146|31 48|racing Greyhounds
P11341405A0146|66 73|reasons
P11341405A0146|87 104|MCB abnormalities
P11340525A0737|75 76|%
P11340525A0737|109 110|%
P11340525A0737|176 203|treatment success criterion
P11340525A0737|25 32|regimen
P11340525A0737|86 95|regimen A
P11340085A0211|148 167|amino acid sequence
P11340085A0211|267 274|CR1-CR4
P11340085A0211|55 62|regions
P11340085A0211|118 130|coactivators
P11340085A0211|258 265|regions
P11340048A0432|96 103|sensors
P11340048A0432|117 128|differences
P11340048A0432|51 65|flux densities
P11336698A0075|43 53|components
P11336698A0075|19 23|Rsc3
P11335710A0320|54 68|Erk activation
P11334124A0903|14 27|dose-response
P11334124A0903|147 155|Respimat
P11334124A0903|82 83|h
P11334124A0903|85 93|AUC0-6 h
P11333263A0240|79 94|leader sequence
P11333263A0240|21 31|base pairs
P11331604A0267|122 135|srb10 mutants
P11331604A0267|67 82|phosphorylation
P11331604A0267|99 103|Gcn4
P11331604A0267|1 6|Srb10
P11331589A0113|50 67|male X chromosome
P11328699A0000|31 40|test mice
P11328699A0000|146 160|test situation
P11328699A0000|98 107|container
P11327698A0191|271 285|PKC inhibition
P11327698A0191|481 492|P4 activity
P11327698A0191|387 398|HepG2 cells
P11327698A0191|428 442|MEK activation
P11327698A0191|253 264|HepG2 cells
P11327698A0191|222 233|P4 activity
P11327698A0191|289 309|PKC inhibitor Go6976
P11327698A0191|318 337|Sp1 phosphorylation
P11327698A0191|497 508|IGF-II mRNA
P11327698A0191|96 105|IGF-II P4
P11327698A0191|141 155|PKC activation
P11327698A0191|414 424|inhibition
P11325944A0511|195 203|blockage
P11325944A0511|228 231|uhp
P11325944A0511|57 71|hybrid protein
P11325944A0511|158 165|portion
P11325944A0511|117 120|GST
P11325944A0511|207 222|uhpT expression
P11325391A0498|92 101|schedules
P11325391A0498|70 80|saline key
P11324516A0159|31 45|administration
P11324516A0159|88 122|D1/D2 receptor agonist apomorphine
P11324516A0159|56 84|D2 receptor agonist LY171555
P11323419T0000|91 115|fucosyltransferase genes
P11323419T0000|11 18|cloning
P11323419T0000|144 168|mouse uterine epithelium
P11323419T0000|68 85|blood group alpha
P11321187A0355|143 151|controls
P11321187A0355|71 80|synthesis
P11321187A0355|49 50|%
P11319098A0164|45 79|protein translocase component SecE
P11319098A0164|210 226|LacI-GalR family
P11319098A0164|149 151|L1
P11319098A0164|7 12|genes
P11319098A0164|155 163|addition
P11318608A0669|134 147|reading frame
P11318608A0669|242 246|NLSs
P11318608A0669|66 70|cDNA
P11318608A0669|49 62|amplification
P11318608A0669|220 240|localization signals
P11317256A0361|88 89|%
P11317256A0361|24 38|S. intermedius
P11317256A0361|102 114|S. anginosus
P11315633A0920|107 135|amino acid sequence analysis
P11315633A0920|143 154|polyprotein
P11315633A0920|49 63|RNA polymerase
P11315633A0920|84 93|E445-T446
P11314373T0000|28 35|formula
P11314373T0000|16 20|care
P11314030A1264|134 149|signal pathways
P11314030A1264|195 201|region
P11314030A1264|41 47|region
P11314030A1264|112 115|Abl
P11314030A1264|84 92|elements
P11313946T0000|31 36|M-Ras
P11313946T0000|41 48|p21 Ras
P11313946T0000|70 73|p21
P11313398A0687|74 76|PI
P11313398A0687|110 118|PKBalpha
P11313398A0687|38 52|IIA-ITAM cells
P11313342A0224|30 51|alanine substitutions
P11313342A0224|130 138|ribosome
P11313342A0224|66 87|center cleft residues
P11312584X1846|1 10|Copyright
P11312120A1311|44 58|transformation
P11312120A1311|72 78|number
P11312120A1311|92 101|oncogenes
P11312120A1311|174 183|potential
P11311980A1049|8 11|R1g
P11311980A1049|55 62|tissues
P11311980A1049|34 39|brain
P11311687A0231|127 135|measures
P11311687A0231|143 152|morbidity
P11311687A0231|169 172|RLS
P11311550A0253|121 133|contribution
P11311550A0253|209 217|cultures
P11311550A0253|146 154|elements
P11311550A0253|66 68|kB
P11311550A0253|253 254|C
P11311550A0253|169 182|transcription
P11311464A0362|151 170|bladder dysfunction
P11311464A0362|40 57|saddle anesthesia
P11311464A0362|112 123|extremities
P11311464A0362|84 98|motor weakness
P11310937A0548|120 123|CRP
P11310937A0548|195 204|TNF-alpha
P11310937A0548|57 61|time
P11310937A0548|128 132|IL-6
P11310937A0548|19 28|mortality
P11310937A0548|68 74|months
P11309677A0000|67 75|veterans
P11309677A0000|158 166|veterans
P11309677A0000|81 97|Gulf War Illness
P11309677A0000|137 141|GV-F
P11309389A0273|225 228|GHR
P11309389A0273|125 128|PMA
P11309389A0273|308 321|GHR abundance
P11309389A0273|255 269|domain remnant
P11309389A0273|326 338|GH signaling
P11309077A0953|95 105|biotype I.
P11309077A0953|6 13|strains
P11309077A0953|51 57|jejuni
P11308851A0333|160 164|bead
P11308851A0333|173 180|network
P11308851A0333|18 35|response function
P11306511A1476|124 145|progesterone receptor
P11306511A1476|4 15|association
P11306101A0000|164 187|17beta-hydroxy-steroids
P11306101A0000|63 76|hamster liver
P11306101A0000|7 22|RACE techniques
P11303890A0996|8 12|time
P11303890A0996|80 88|microg/l
P11303027A0954|120 129|potential
P11303027A0954|61 68|GTPases
P11303027A0954|40 52|interactions
P11303027A0954|7 11|data
P11302566A1318|90 109|psychomotor slowing
P11302566A1318|20 30|flattening
P11301189A1396|107 122|B-lineage cells
P11301189A1396|43 46|p19
P11297866A0484|90 100|propulsion
P11297866A0484|63 69|effect
P11297866A0484|39 50|I. theezans
P11297514A0218|15 28|hos1 mutation
P11297514A0218|62 87|CBF transcription factors
P11297514A0218|154 159|genes
P11296442A0565|46 53|formula
P11296442A0565|39 43|Cole
P11296442A0565|4 14|conclusion
P11296442A0565|103 112|tube size
P11295760A1374|96 100|W/cm
P11295760A1374|81 85|mass
P11295470A0954|14 22|evidence
P11295470A0954|26 48|linkage disequilibrium
P11295470A0954|101 109|promoter
P11292844A0081|60 63|DNA
P11292844A0081|43 50|trimers
P11292844A0081|1 4|HSF
P11292335A0852|41 57|mutator mutation
P11292335A0852|174 193|frameshift mutation
P11292335A0852|116 126|frameshift
P11290906T0000|28 40|Tl-201 SPECT
P11289149A0658|11 22|EWS protein
P11289149A0658|78 100|transactivation domain
P11289149A0658|139 142|CBP
P11288930A0000|88 92|MCPA
P11288930A0000|82 86|acid
P11288930A0000|200 209|lactation
P11288930A0000|175 181|mating
P11288930A0000|33 47|administration
P11287654A0150|61 68|domains
P11287654A0150|19 26|protein
P11287611A0802|105 117|troglitazone
P11287611A0802|62 65|PGD
P11287611A0802|92 100|BRL49653
P11287611A0802|142 152|expression
P11287578A1311|14 27|interleukin-8
P11287578A1311|29 35|RANTES
P11287578A1311|112 119|protein
P11287578A1311|1 10|Secretion
P11286833A0959|120 125|males
P11286833A0959|165 170|years
P11286833A0959|133 140|females
P11286833A0959|7 15|patients
P11286833A0959|36 42|cycles
P11286833A0959|155 158|age
P11285235A0466|10 15|TRPS1
P11285235A0466|68 78|activation
P11283354A0548|31 38|pathway
P11283354A0548|93 105|histone code
P11283354A0548|136 147|inheritance
P11283168A0738|167 168|d
P11283168A0738|112 121|endosperm
P11283168A0738|65 75|expression
P11283010A0701|37 47|CGS 12066A
P11282433T0000|107 123|cell lung cancer
P11282433T0000|52 60|patients
P11282433T0000|19 29|paclitaxel
P11282395A0530|135 150|protein complex
P11282395A0530|65 77|DNA hairpins
P11282395A0530|101 109|activity
P11282088A0837|1 13|Baseline MBF
P11282088A0837|68 73|males
P11281268A0000|76 81|times
P11281268A0000|20 36|arginine kinases
P11281268A0000|38 41|AKs
P11281268A0000|204 236|clam Pseudocardium sachalinensis
P11280799A1025|24 33|PTHrP1-34
P11280799A1025|127 137|antibodies
P11280799A1025|158 168|production
P11280799A1025|81 96|IL-8 production
P11279720A0844|166 179|complications
P11279720A0844|72 79|placebo
P11279720A0844|43 49|trials
P11279720A0844|53 64|cabergoline
P11279720A0844|1 19|SELECTION CRITERIA
P11279324A0710|5 9|size
P11279324A0710|17 24|infarct
P11279207A0904|48 57|component
P11279207A0904|34 38|HPK1
P11279086A1350|63 68|cells
P11279086A1350|7 11|data
P11279086A1350|140 148|activity
P11279086A1350|190 200|regulation
P11279086A1350|204 217|cell adhesion
P11278928A1634|109 120|translation
P11278928A1634|39 53|mRNA structure
P11278928A1634|81 87|effect
P11278928A1634|169 172|p30
P11278855A0205|165 169|cell
P11278855A0205|67 72|assay
P11278855A0205|18 29|interaction
P11278819A0565|180 192|core element
P11278819A0565|25 40|binding studies
P11278819A0565|67 72|sites
P11278819A0565|1 20|Sequence comparison
P11278671T0000|132 137|cells
P11278671T0000|89 96|neurons
P11278671T0000|17 31|Bcl-2 homology
P11278604A0300|195 202|ability
P11278604A0300|215 218|Gal
P11278604A0300|115 122|species
P11278604A0300|152 171|Lec20 cell extracts
P11278583A0873|56 71|effector motifs
P11278583A0873|25 27|CX
P11278583A0873|16 20|SNT1
P11278583A0873|45 52|classes
P11278583A0873|79 82|SNT
P11278583A0873|111 125|ERK activation
P11278583A0873|279 283|Shp2
P11278583A0873|1 12|Mutagenesis
P11278521A0849|11 31|pair oligonucleotide
P11278521A0849|93 103|inhibition
P11278521A0849|81 88|hypoxia
P11278521A0849|184 207|lacZ reporter construct
P11278461A0637|91 95|part
P11278461A0637|165 178|rainbow trout
P11278461A0637|12 22|antibodies
P11278461A0637|52 63|amino acids
P11278461A0637|220 241|Western blot analysis
P11278400A0668|77 80|POU
P11278400A0668|67 73|number
P11278400A0668|32 42|cell lines
P11278310A1516|111 119|decrease
P11278310A1516|70 91|caspase-3 stimulation
P11278286A1083|41 51|inhibition
P11278286A1083|98 100|MR
P11277913T0000|90 98|enhancer
P11277913T0000|4 11|element
P11277913T0000|102 118|mRNA translation
P11275986A0091|23 25|E6
P11275986A0091|51 79|p53 tumor suppressor protein
P11274368A0818|79 91|p21 promoter
P11274368A0818|95 100|c-Myc
P11274357A0724|303 307|form
P11274357A0724|183 188|forms
P11274357A0724|27 41|overexpression
P11274357A0724|159 163|RhoA
P11274357A0724|14 18|hand
P11274357A0724|317 324|GTPases
P11274357A0724|101 107|nm23H1
P11274184A0000|30 35|genes
P11274184A0000|94 98|HO-1
P11274184A0000|76 92|heme oxygenase-1
P11274184A0000|1 5|Nrf2
P11274149A0625|134 144|E2 enzymes
P11274149A0625|12 20|analysis
P11274149A0625|53 64|RING finger
P11274149A0625|103 108|basis
P11273995A1148|47 59|TOF patients
P11273995A1148|143 158|relaxation time
P11268887A1174|10 28|misinterpretations
P11268887A1174|77 91|preadolescents
P11268887A1174|117 120|FVC
P11267679A0102|120 127|protein
P11267679A0102|9 26|bp EcoRI fragment
P11266558A1470|107 124|initiator element
P11266558A1470|65 81|binding activity
P11266558A1470|153 178|recruiting RNA polymerase
P11266227A0295|64 78|donor solution
P11266227A0295|19 30|p-toluidine
P11266184A0000|193 199|images
P11266184A0000|112 114|MR
P11266184A0000|156 174|signal intensities
P11266184A0000|101 110|resonance
P11266184A0000|32 53|signal intensity area
P11266184A0000|1 9|Atheroma
P11264561A0167|33 37|RSTD
P11264561A0167|1 10|OBJECTIVE
P11264372T0000|59 80|infected-cell protein
P11264372T0000|1 13|Requirements
P11264177T0000|88 94|region
P11264177T0000|133 141|leukemia
P11264177T0000|70 75|13q14
P11263664T0000|132 142|repressors
P11263664T0000|66 89|enhancer binding factor
P11263664T0000|1 5|SIP1
P11263622A0683|122 136|histopathology
P11263622A0683|24 35|correlation
P11263622A0683|114 117|MRI
P11263622A0683|70 84|wall thickness
P11260468A1179|128 135|absence
P11260468A1179|96 115|papBA transcription
P11260468A1179|38 41|AR1
P11259503A0212|25 31|microM
P11259503A0212|67 68|h
P11259503A0212|1 20|Forskolin treatment
P11258906A0743|89 101|pairing bias
P11258906A0743|127 131|RecA
P11256962A0233|121 128|regions
P11256962A0233|147 171|GlyR alpha subunit genes
P11256962A0233|67 73|region
P11256962A0233|81 98|beta subunit gene
P11256962A0233|1 18|Sequence analysis
P11256845A0340|209 216|WOSCOPS
P11256845A0340|147 153|events
P11256845A0340|263 268|event
P11256845A0340|322 328|pounds
P11256845A0340|165 173|patients
P11256845A0340|286 290|cost
P11256845A0340|229 230|%
P11256845A0340|238 242|risk
P11255252A0961|122 136|yeast extracts
P11255252A0961|27 30|DNA
P11254864T0000|39 52|breast cancer
P11254713A1029|11 22|interaction
P11254713A1029|78 85|complex
P11254713A1029|58 65|rel/AP1
P11254713A1029|212 235|IL-2 gene transcription
P11254713A1029|200 208|decrease
P11254134A0648|122 128|region
P11254134A0648|143 160|background levels
P11254134A0648|85 93|sequence
P11251697T0000|131 147|spin trap method
P11251697T0000|97 120|electron spin resonance
P11251252A0494|90 96|planes
P11251252A0494|40 55|ultrasound data
P11251252A0494|98 110|section mode
P11251083T0000|60 73|S phase entry
P11251083T0000|40 55|cell morphology
P11251083T0000|1 10|Mechanism
P11250196A0455|167 177|Protein S.
P11250196A0455|126 165|betagamma-crystallin fold family member
P11250196A0455|17 28|domain fold
P11248463A0187|43 54|amino acids
P11248463A0187|21 28|lactate
P11246887A0000|61 64|CET
P11246887A0000|333 336|CAC
P11246887A0000|248 256|subjects
P11246887A0000|186 196|prevalence
P11246887A0000|109 117|activity
P11246887A0000|231 234|CAC
P11246887A0000|67 101|cholesteryl ester transfer protein
P11246887A0000|33 59|cholesteryl ester transfer
P11246887A0000|136 152|transfer protein
P11245986T0000|59 87|rat aldolase B gene promoter
P11244568A0506|75 86|development
P11244568A0506|59 63|mRNA
P11244568A0506|5 11|Gap69C
P11243777A0000|62 78|promoter regions
P11243336A0000|13 20|MD-55-2
P11243336A0000|35 39|film
P11241672T0000|134 144|regulation
P11241672T0000|122 129|element
P11241672T0000|76 90|identification
P11241672T0000|52 74|integrin gene promoter
P11241672T0000|1 8|Cloning
P11241332A0393|148 154|anchor
P11241332A0393|161 173|screw anchor
P11241332A0393|251 260|densities
P11241332A0393|206 211|foams
P11241215A0566|62 77|fusion proteins
P11241215A0566|189 196|RP-HPLC
P11241215A0566|83 94|thioredoxin
P11241215A0566|173 187|chromatography
P11241215A0566|204 213|digestion
P11240600A0523|12 24|drug history
P11240600A0523|54 60|amount
P11239184A1340|181 192|artery sign
P11239184A1340|135 140|edema
P11239184A1340|36 38|CD
P11239184A1340|81 88|aspirin
P11239184A1340|102 111|incidence
P11238916A0838|41 49|paxillin
P11238916A0838|131 149|macrophage lysates
P11238916A0838|179 186|PTP phi
P11238916A0838|32 39|PTP phi
P11238916A0838|205 213|paxillin
P11238882A0157|73 77|gene
P11238447A0524|104 118|CRM1/exportin1
P11238447A0524|10 25|binding studies
P11238447A0524|128 134|eIF-5A
P11238447A0524|76 87|interaction
P11238447A0524|187 192|nup98
P11238402A0191|69 92|DAN/TIR gene expression
P11238105A0959|241 245|CD86
P11238105A0959|198 203|Jak-2
P11238105A0959|54 60|domain
P11238105A0959|1 6|Cells
P11238105A0959|118 124|domain
P11237491A0000|91 93|CA
P11237491A0000|22 30|baseline
P11237491A0000|289 300|individuals
P11237491A0000|51 63|fluctuations
P11237491A0000|111 119|patients
P11237491A0000|101 103|CA
P11237491A0000|1 5|AIMS
P11236056A0374|39 47|children
P11236056A0374|17 19|Lp
P11235777A0878|107 133|dihydrotestosterone levels
P11235777A0878|97 102|range
P11235777A0878|4 15|Klinefelter
P11234223A1451|75 83|activity
P11234223A1451|182 186|PAPM
P11234223A1451|232 239|killing
P11234223A1451|38 44|groups
P11234223A1451|206 210|MEPM
P11234223A1451|153 160|killing
P11232947A1451|14 35|lymph node dissection
P11232947A1451|95 105|recurrence
P11232947A1451|70 75|chain
P11230889A1151|31 46|arm lymphoedema
P11230889A1151|148 152|HBO2
P11230889A1151|93 103|arm volume
P11230169A0480|15 21|method
P11230169A0480|212 215|20p
P11230169A0480|185 197|20p12 region
P11230169A0480|32 61|chromatin immunoprecipitation
P11228700T0000|40 49|yesterday
P11228700T0000|54 59|today
P11228700T0000|32 38|expert
P11227182A1475|109 122|leptin levels
P11227182A1475|93 104|bone marrow
P11227182A1475|5 12|authors
P11227182A1475|136 147|bone marrow
P11226752A0750|135 138|E47
P11226752A0750|246 252|Notch1
P11226752A0750|232 236|form
P11226752A0750|262 266|DTX1
P11226752A0750|204 215|suppression
P11224226A0000|132 163|benzodiazepine receptor agonist
P11224226A0000|57 88|benzodiazepine receptor agonist
P11224226A0000|212 220|paradigm
P11224226A0000|114 119|mg/kg
P11223257A0404|211 221|light/dark
P11223257A0404|182 184|CN
P11223257A0404|127 149|protein phosphatase 2A
P11223257A0404|249 255|manner
P11223257A0404|190 199|endothall
P11223257A0404|358 375|protein synthesis
P11223257A0404|107 109|JA
P11223257A0404|383 392|induction
P11223257A0404|65 73|response
P11223257A0404|101 105|acid
P11223257A0404|1 7|OsBBPI
P11223255A1034|18 44|consensus amino acid motif
P11223240A0655|12 35|Menin1 gene transcripts
P11223240A0655|100 108|messages
P11223186A1095|120 124|GATA
P11223186A1095|109 118|AP-1 site
P11223186A1095|143 147|site
P11223186A1095|1 16|Transactivation
P11223153A0533|24 33|text file
P11223153A0533|143 149|pixels
P11223153A0533|39 44|flows
P11223153A0533|114 126|lung anatomy
P11222720A1699|130 149|corepressor complex
P11222720A1699|42 51|regulator
P11222720A1699|55 60|EBNA2
P11222387A1497|147 156|treatment
P11222387A1497|176 184|leukemia
P11222387A1497|112 124|FTI SCH66336
P11222387A1497|38 47|mechanism
P11221845A1370|76 82|spleen
P11221845A1370|98 103|liver
P11221845A1370|69 74|brain
P11221845A0295|195 201|RLGS-M
P11221845A0295|62 67|liver
P11221845A0295|122 132|MT-D2 mice
P11221845A0295|72 84|liver tumors
P11221845A0295|282 294|liver tumors
P11221845A0295|116 120|mice
P11220857T0000|14 24|Department
P11220857T0000|1 5|CHAP
P11220486A0686|20 21|%
P11220306A0911|123 127|HexA
P11220306A0911|40 46|levels
P11220306A0911|67 79|sigma factor
P11220306A0911|1 7|HexA71
P11218739A0811|20 21|P
P11218739A0811|1 11|Transition
P11215622A0949|41 54|force sensors
P11214177A1125|14 19|sense
P11214177A1125|77 83|satRNA
P11212327A1564|31 45|rat adipocytes
P11212327A1564|73 86|PIG compounds
P11212327A1564|160 170|cross-talk
P11212327A1564|8 15|studies
P11212327A1564|96 127|IRS1/3 tyrosine phosphorylation
P11212327A1564|152 156|site
P11211936A1490|13 17|data
P11211936A1490|183 196|growth arrest
P11211936A1490|163 178|differentiation
P11211936A1490|100 103|JNK
P11210988T0000|63 78|prostate cancer
P11210401A0544|45 53|warfarin
P11210401A0544|123 132|sevelamer
P11210401A0544|33 40|digoxin
P11209814A0243|131 143|implantation
P11209814A0243|202 204|HA
P11209814A0243|5 12|purpose
P11209814A0243|175 180|ALCAP
P11209814A0243|186 200|hydroxyapetite
P11208814A0673|93 101|proteins
P11208814A0673|250 258|proteins
P11208814A0673|185 200|phosphorylation
P11208814A0673|50 61|interaction
P11208814A0673|65 76|DmCKIIalpha
P11208814A0673|204 208|CKII
P11207609A0994|181 190|NRK cells
P11207609A0994|94 109|ER localization
P11207609A0994|218 229|differences
P11207609A0994|18 25|failure
P11207609A0994|160 168|chimeras
P11207609A0994|66 70|tail
P11207609A0994|33 43|QKTT motif
P11207288A0897|94 102|residues
P11207288A0897|22 25|YFV
P11207288A0897|155 173|class Ia molecules
P11207288A0897|137 147|peptide-Ag
P11207269A0745|54 64|properties
P11207216A0719|165 167|nM
P11207216A0719|66 74|cultures
P11207216A0719|156 159|PMA
P11207216A0719|19 30|PGHS-2 mRNA
P11204897A0797|62 83|bridge simulator task
P11204897A0797|37 49|participants
P11202705A1112|47 68|accumulation patterns
P11202705A1112|98 105|tissues
P11202705A1112|17 30|biomonitoring
P11201250A0849|126 129|rat
P11201250A0849|64 75|application
P11201250A0849|1 25|Plasma DHE concentration
P11198424T0000|43 48|OsPSK
P11198424T0000|82 102|phytosulfokine-alpha
P11198424T0000|117 140|rice cell proliferation
P11198289T0000|61 69|dystonia
P11198289T0000|35 48|copper levels
P11197926A0000|126 129|GHQ
P11197926A0000|96 124|General Health Questionnaire
P11197926A0000|216 225|intervals
P11197926A0000|152 159|effects
P11197328T0000|12 16|cell
P11197328T0000|77 122|maize C4 phosphoenolpyruvate carboxylase gene
P11197328T0000|39 47|proteins
P11196340A1046|28 42|identification
P11196340A1046|80 91|variability
P11196340A1046|19 26|methods
P11196191A1789|10 37|T47D breast carcinoma cells
P11196191A1789|39 43|IL-6
P11196191A1789|119 137|MAPK/PI3K pathways
P11195338A0494|9 19|expression
P11194147A1496|45 54|Sri Lanka
P11194147A1496|25 41|rice cultivation
P11193704A0000|46 52|threat
P11193704A0000|67 73|Africa
P11193045A1193|45 53|function
P11193045A1193|108 119|development
P11193045A1193|3 10|picture
P11193045A1193|70 73|p63
P11191208A0000|74 88|overexpression
P11191208A0000|227 251|transcription regulators
P11191208A0000|146 158|facilitators
P11191208A0000|267 271|PDR1
P11191208A0000|276 286|PDR3 genes
P11188993A0298|135 141|Gomori
P11188993A0298|110 121|acid-Schiff
P11188993A0298|36 42|biopsy
P11188993A0298|85 95|evaluation
P11187016T0000|79 89|mechanisms
P11187016T0000|49 61|implications
P11182746A0872|65 77|drug therapy
P11181995A1093|241 249|evidence
P11181995A1093|66 77|transcripts
P11181995A1093|1 9|Analysis
P11181995A1093|119 127|evidence
P11181548A0214|73 79|tissue
P11181548A0214|109 119|expression
P11181548A0214|82 88|region
P11181525T0000|28 42|amino-terminus
P11181525T0000|83 101|AR gene expression
P11181525T0000|116 124|enhancer
P11180688A0000|179 182|MFT
P11180688A0000|219 233|schoolchildren
P11180688A0000|51 60|Hong Kong
P11180688A0000|165 177|Fitness Test
P11180688A0000|43 46|max
P11180688A0000|38 39|V
P11180688A0000|69 77|children
P11180027A1306|39 42|M6G
P11180027A1306|85 93|morphine
P11179689A0000|165 173|sequence
P11179689A0000|77 89|DNA sequence
P11179689A0000|22 25|Sry
P11179689A0000|101 107|domain
P11179687A0280|164 168|PTPs
P11179687A0280|46 53|enzymes
P11179687A0280|9 14|paper
P11179687A0280|19 27|tyrosine
P11179664T0000|41 46|locus
P11179664T0000|86 117|transcription factor RUNX1/AML1
P11179272T0000|44 78|Helicobacter pylori IgG antibodies
P11179272T0000|83 93|restenosis
P11179272T0000|154 170|ultrasound study
P11178696A0301|135 149|contrast agent
P11178696A0301|130 131|g
P11178696A0301|8 17|US images
P11177686A0243|46 53|options
P11177686A0243|1 10|Treatment
P11176290T0000|29 42|vein stenosis
P11176290T0000|1 15|Identification
P11176290T0000|103 106|MRI
P11175333A0336|22 46|co-precipitation methods
P11172944A0548|76 87|pneumonitis
P11172944A0548|20 28|patients
P11172944A0548|68 73|Grade
P11171320A0894|26 29|ctn
P11171320A0894|251 262|aggregation
P11171320A0894|291 305|EalphaCL cells
P11171320A0894|284 286|EL
P11171320A0894|235 243|increase
P11171320A0894|100 130|tyrosine phosphorylation sites
P11171320A0894|205 218|phenylalanine
P11170476A1546|126 131|relay
P11170476A1546|172 181|molecules
P11170476A1546|64 74|plasticity
P11170476A1546|155 158|MHC
P11170476A1546|32 39|peptide
P11169113A0555|90 94|gene
P11169113A0555|22 26|role
P11168588T0000|15 40|herpes simplex virus type
P11168588T0000|43 46|US3
P11168588T0000|59 76|Cdc42/Rac pathway
P11168422A0248|126 138|iron protein
P11168422A0248|113 118|sites
P11168422A0248|140 143|Kp2
P11167778T0000|10 33|antithrombin deficiency
P11167019A1249|61 96|ATPsynCF6 transcription start sites
P11167019A1249|5 9|TATA
P11166478T0000|55 60|mouse
P11166478T0000|34 49|antinociception
P11163968A0152|144 152|archaeon
P11163968A0152|55 76|Pyrococcus horikoshii
P11163968A0152|235 273|restriction-modification gene homologs
P11163968A0152|154 169|archaebacterium
P11163968A0152|35 51|genome sequences
P11162936A2727|31 38|ligands
P11162936A2727|79 92|antiestrogens
P11162936A2727|97 104|ERalpha
P11162936A2727|188 215|hormone replacement therapy
P11162936A2727|252 265|breast cancer
P11162936A2727|238 248|prevention
P11162576A0213|122 132|PDE5A gene
P11162576A0213|22 36|identification
P11161816A0851|167 173|action
P11161816A0851|130 134|fold
P11161816A0851|42 61|endophilin proteins
P11161816A0851|20 32|similarities
P11161720X1294|16 30|Academic Press
P11160929T0000|61 74|endonucleases
P11160929T0000|36 40|site
P11160896A0713|91 98|nucleus
P11160896A0713|131 146|differentiation
P11160896A0713|115 123|myotubes
P11160742A0696|12 24|R expression
P11160742A0696|6 7|Z
P11160732A1199|210 229|SIVmac239 infection
P11160732A1199|247 260|transcription
P11160732A1199|55 64|transport
P11160732A1199|194 205|restriction
P11160732A1199|41 50|synthesis
P11160732A1199|143 148|clone
P11160732A1199|68 78|vector DNA
P11160721A0932|72 94|TBLV enhancer activity
P11160721A0932|56 60|556M
P11160683A1220|122 136|ATF/CREB sites
P11160683A1220|6 17|interaction
P11160683A1220|71 81|C/EBP site
P11160307A0394|75 82|mAb H22
P11160307A0394|195 201|region
P11160307A0394|209 215|Fc end
P11160307A0394|129 132|end
P11160307A0394|141 151|CH3 domain
P11160307A0394|153 162|wH22xeGFP
P11160096A1067|45 60|fliF background
P11160096A1067|7 16|mutations
P11159081A1155|10 15|cases
P11159081A1155|21 22|%
P11159081A1155|85 90|tumor
P11158337A0000|58 71|GnRH receptor
P11158337A0000|81 85|gene
P11158337A0000|73 79|GnRH-R
P11158337A0000|40 50|expression
P11158337A0000|282 294|binding site
P11158337A0000|276 280|SF-1
P11158337A0000|169 175|GnRH-R
P11158324A1073|145 150|genes
P11158324A1073|417 422|liver
P11158324A1073|251 269|cholesterol uptake
P11158324A1073|393 409|bile acid uptake
P11158324A1073|346 367|scavenger receptor BI
P11158324A1073|287 297|expression
P11158324A1073|131 141|expression
P11158324A1073|381 389|decrease
P11158324A1073|548 573|anion transporter protein
P11158295A0158|72 84|Src homology
P11158295A0158|97 108|SH2 regions
P11158295A0158|54 57|Csk
P11158288T0000|77 94|activation domain
P11158288T0000|98 102|CREB
P11158288T0000|1 12|Recruitment
P11157879A0192|46 57|fluorescein
P11157879A0192|70 73|BRB
P11157879A0192|102 113|fluorometry
P11157774A0789|72 81|sterility
P11157334A1107|61 69|WM group
P11157334A1107|71 72|P
P11156789A1669|180 188|propofol
P11156789A1669|264 282|CSF protein levels
P11156789A1669|126 133|changes
P11156789A1669|21 32|observation
P11156789A1669|49 55|causes
P11156789A1669|220 226|oxygen
P11156789A1669|314 322|proteins
P11156789A1669|339 342|CSF
P11156484A0223|40 54|capacity assay
P11156484A0223|179 187|diabetes
P11156484A0223|83 91|electron
P11156484A0223|169 175|stress
P11156303A1098|120 128|children
P11156303A1098|108 116|drainage
P11156303A1098|82 93|alternative
P11156303A1098|170 177|history
P11154491A0322|160 173|echoendoscope
P11154491A0322|58 61|age
P11154491A0322|65 70|years
P11154491A0322|1 8|METHODS
P11152963A0000|75 85|astrocytes
P11152963A0000|145 152|culture
P11152963A0000|157 163|tumors
P11152963A0000|87 91|SETA
P11152963A0000|1 11|Expression
P11152451A1580|30 37|SmSmad2
P11152451A1580|74 85|interaction
P11152451A1580|163 170|nucleus
P11152451A1580|54 70|TGF-beta signals
P11152344A0416|124 133|placement
P11152344A0416|95 100|C1-C2
P11152344A0416|52 59|animals
P11152344A0416|206 210|cord
P11152344A0416|184 191|surface
P11152081A0413|93 109|sulfur oxidation
P11152081A0413|39 49|inhibition
P11151826T0000|11 15|UAPs
P11150315A1126|14 17|EGF
P11150315A1126|38 43|bands
P11150315A0226|134 143|signaling
P11150315A0226|9 17|approach
P11150315A0226|158 180|oligonucleotide clones
P11150315A0226|48 79|transcription factor activities
P11149472A1257|13 35|NP/NMP4/CIZ expression
P11149472A1257|84 92|rat bone
P11149472A1257|68 80|chondrocytes
P11148042A1258|47 56|chain PEs
P11148042A1258|10 18|mixtures
P11148042A1258|114 135|peptide immiscibility
P11145955A0189|210 224|protein kinase
P11145955A0189|121 124|SRE
P11145955A0189|296 305|TGF-alpha
P11145955A0189|154 162|analysis
P11145955A0189|226 230|MAPK
P11145955A0189|232 250|pathway activation
P11145955A0189|170 178|promoter
P11145955A0189|275 294|growth factor alpha
P11145813A0668|88 90|C6
P11145813A0668|92 95|T11
P11145813A0668|101 113|L6 vertebrae
P11145717A0936|90 100|sequencing
P11145717A0936|57 69|TPO fragment
P11145717A0936|118 122|K713
P11145571A0788|130 138|sequence
P11145571A0788|140 143|GAS
P11145571A0788|16 29|gene factor-3
P11145563A0303|15 23|SREBP-1a
P11145563A0303|65 72|context
P11145563A0303|1 11|Expression
P11145562A0468|67 75|prostate
P11145562A0468|114 123|T antigen
P11145562A0468|34 49|immortalization
P11143384A0267|25 35|capability
P11143384A0267|1 10|Tele-Talk
P11141003T0000|44 51|nucleus
P11141003T0000|72 77|users
P11141003T0000|55 63|cochlear
P11139974A0762|40 47|attempt
P11139974A0762|24 26|VT
P11139974A0762|83 84|%
P11139974A0762|68 77|BV pacing
P11139567A1440|54 64|activation
P11139567A1440|1 26|LH/CG receptor activation
P11139567A1440|68 97|phosphatidylinositol 3-kinase
P11139469A0402|120 147|protein kinase C inhibitors
P11139469A0402|80 95|Tie2 expression
P11139469A0402|1 7|Ang II
P11139148A0421|45 54|homologue
P11139148A0421|58 63|SAF-A
P11139148A0421|154 162|activity
P11138231T0000|12 20|resource
P11138231T0000|1 8|Closeup
P11137551A0437|89 94|limit
P11137551A0437|10 17|sardine
P11137296A1216|71 76|PFK-B
P11137296A1216|1 11|PFK-A mRNA
P11134822A0629|13 14|P
P11134351A1405|57 61|role
P11134351A1405|34 45|cell growth
P11134033A0000|12 23|int-6 locus
P11134033A0000|50 66|integration site
P11134033A0000|118 131|eIF3e subunit
P11133927T0000|94 102|exercise
P11133927T0000|86 90|rate
P11133741A0617|72 80|mutation
P11133741A0617|145 149|loss
P11133741A0617|163 180|promoter activity
P11133741A0617|1 5|NiCl
P11133741A0617|102 107|sites
P11132195A0000|148 155|methods
P11132195A0000|178 184|models
P11132195A0000|23 33|parameters
P11132195A0000|48 63|Volterra series
P11132195A0000|13 19|number
P11132195A0000|279 287|memories
P11132063A0250|14 33|treatment exposures
P11132063A0250|96 103|effects
P11132063A0250|48 58|population
P11132063A0250|222 229|effects
P11131321T0000|12 29|Trypanosoma vivax
P11131321T0000|79 108|homidum chloride chemotherapy
P11131321T0000|1 8|Effects
P11129515A0000|31 36|trial
P11129515A0000|56 87|Vitex agnus castus L extract Ze
P11129515A0000|115 123|patients
P11128312A1238|148 154|radius
P11128312A1238|214 215|%
P11128312A1238|24 35|differences
P11128312A1238|157 158|%
P11128312A1238|194 205|radiographs
P11128312A1238|37 38|p
P11128312A1238|102 111|femur BMD
P11127250A1111|13 18|mg/kg
P11127250A1111|41 45|dose
P11127250A1111|162 167|India
P11127250A1111|155 160|Bihar
P11127250A1111|1 3|PM
P11127161T0000|18 35|smoking cessation
P11126353A0582|10 20|Prevalence
P11126353A0582|24 31|obesity
P11126353A0582|52 53|%
P11126353A0582|87 88|%
P11125872A0133|91 100|inhibitor
P11125872A0133|182 188|routes
P11125872A0133|146 154|delivery
P11125872A0133|70 87|phosphodiesterase
P11125363A0525|135 137|m.
P11125363A0525|57 70|tumor mapping
P11125363A0525|146 160|5-fluorouracil
P11125363A0525|20 43|pretreatment cystoscopy
P11125363A0525|1 9|Patients
P11125363A0525|119 122|day
P11124902X1337|16 30|Academic Press
P11123912A0306|166 168|MT
P11123912A0306|5 14|structure
P11123912A0306|71 74|SH2
P11123316T0000|25 32|T cells
P11123316T0000|87 117|Tec pleckstrin homology domain
P11123054T0000|26 35|syndromes
P11122381A0908|106 124|GM-CSF stimulation
P11122381A0908|162 167|STAT5
P11122381A0908|1 9|Addition
P11121434A0915|79 86|PD98059
P11121434A0915|64 77|Mek inhibitor
P11121434A0915|1 11|Inhibition
P11121118T0000|9 21|organization
P11121043A0074|13 17|BMPs
P11121043A0074|65 75|regulators
P11121043A0074|35 43|inducers
P11119611A0428|125 132|tissues
P11119611A0428|163 173|KS lesions
P11119611A0428|20 27|protein
P11119611A0428|152 154|CD
P11118619A0835|61 92|host cell transcription factors
P11118619A0835|53 59|models
P11118619A0835|155 160|event
P11118438A0411|91 106|Malus domestica
P11118438A0411|46 60|Pin1 homologue
P11118438A0411|246 250|Pin1
P11118438A0411|36 42|MdPin1
P11118438A0411|237 241|case
P11117826A0788|79 82|use
P11117826A0788|144 154|comparison
P11117826A0788|112 120|patients
P11117826A0788|53 73|follow-up evaluation
P11117263A0570|243 249|epiHMA
P11117263A0570|123 130|cereale
P11117263A0570|92 97|roots
P11117263A0570|178 181|DMA
P11117263A0570|292 295|HMA
P11117263A0570|42 57|Ids3 expression
P11117263A0570|172 176|acid
P11117263A0570|237 241|acid
P11116131A0863|42 49|culture
P11116131A0863|22 25|P2Y
P11114924A0808|66 91|primer extension analysis
P11114521A0282|15 19|RhoA
P11114521A0282|67 72|cells
P11114521A0282|1 11|Regulation
P11113823A0197|24 38|chondromatosis
P11113692A0169|61 71|background
P11113692A0169|94 97|BDR
P11113692A0169|159 163|type
P11113692A0169|17 22|study
P11113692A0169|195 200|years
P11113692A0169|166 174|diabetes
P11113692A0169|227 241|blood pressure
P11113692A0169|204 207|age
P11113201A1114|45 50|yeast
P11113201A1114|76 80|step
P11113201A1114|1 5|Pmt2
P11113201A1114|103 118|target proteins
P11113179A1020|122 126|SRC1
P11113179A1020|42 50|residues
P11113179A1020|172 178|assays
P11112790A0989|74 77|UPR
P11112790A0989|7 14|results
P11112700A1936|45 52|domains
P11112700A1936|13 24|desmoplakin
P11112700A1936|123 129|domain
P11112700A1936|175 178|MTs
P11112417A1126|29 46|MLSN1 transcripts
P11112417A1126|215 228|transcription
P11112417A1126|233 248|mRNA processing
P11112417A1126|201 206|level
P11110528A0414|46 63|velocity encoding
P11110528A0414|110 116|region
P11110528A0414|32 40|sequence
P11108839A0401|60 66|kinase
P11108839A0401|77 88|kDa isoform
P11108839A0401|33 37|S6k1
P11108839A0401|1 8|T cells
P11108720A0124|225 244|localization signal
P11108720A0124|58 64|linker
P11108720A0124|76 83|domains
P11108720A0124|101 105|S6K1
P11108720A0124|1 5|S6K2
P11108548A0710|134 139|basis
P11108548A0710|147 155|response
P11108548A0710|65 73|flavones
P11108548A0710|1 19|MS characteristics
P11108374A1466|1 7|Acoust
P11107637X0001|122 134|significance
P11107637X0001|332 337|ozone
P11107637X0001|144 151|article
P11107637X0001|295 308|heart disease
P11107637X0001|156 162|method
P11107637X0001|187 194|binders
P11107637X0001|198 204|lipids
P11107637X0001|43 61|blood serum lipids
P11107637X0001|5 18|determination
P11106667A1061|45 66|membrane localization
P11106667A1061|108 120|mitochondria
P11106667A1061|71 81|regulation
P11106216A0918|60 61|%
P11106216A0918|27 38|variability
P11106216A0918|53 56|Rrs
P11105716A0782|105 118|determination
P11105716A0782|130 140|CBF values
P11105716A0782|178 185|account
P11105716A0782|216 236|MR perfusion studies
P11105716A0782|17 24|results
P11103792A0755|167 172|serum
P11103792A0755|265 270|mouse
P11103792A0755|67 72|cells
P11103792A0755|142 148|growth
P11103792A0755|19 24|c-Myc
P11103792A0755|51 56|mouse
P11103472A0802|120 130|amplitudes
P11103472A0802|94 99|CNV-1
P11103472A0802|70 75|trend
P11102367A1170|30 41|conclusions
P11102367A1170|177 185|approach
P11102367A1170|127 137|Drosophila
P11102367A1170|261 268|screens
P11102367A1170|64 72|proteins
P11102367A1170|154 161|example
P11101008A0649|37 42|roles
P11101008A0649|50 70|cell cycle processes
P11099377T0000|11 18|cloning
P11099377T0000|43 55|UDP-d-Xylose
P11098217A0674|30 53|mouse chromosome 7A2-A3
P11098217A0674|5 15|Aie1 locus
P11097040A0000|58 65|effects
P11097040A0000|115 120|semen
P11097040A0000|87 100|TRIS-extender
P11097040A0000|289 299|degrees C.
P11097040A0000|199 211|interactions
P11097040A0000|162 169|methods
P11097040A0000|5 15|objectives
P11095981A0254|164 173|deletions
P11095981A0254|124 132|plasmids
P11095981A0254|53 64|replication
P11095248A0423|91 95|gp31
P11095248A0423|125 133|cleavage
P11095248A0423|22 30|proteins
P11095248A0423|173 180|product
P11094109A0600|25 38|symptom onset
P11094109A0600|48 53|years
P11094087T0000|47 61|transformation
P11094087T0000|23 27|Rnd3
P11094087T0000|138 152|kinase pathway
P11094073A0000|90 126|Ros receptor protein tyrosine kinase
P11094073A0000|128 132|RPTK
P11094073A0000|39 58|Vav family proteins
P11094073A0000|174 183|screening
P11094072A0842|48 58|c-Myb site
P11094072A0842|17 29|footprinting
P11094066A0505|124 140|FKHR-L1 activity
P11094066A0505|22 32|regulation
P11094066A0505|48 58|modulation
P11092886A0341|151 155|gene
P11092886A0341|78 85|complex
P11092886A0341|144 149|PEPCK
P11092809A0823|45 50|PI3Ks
P11092809A0823|76 84|ectoderm
P11092809A0823|4 12|addition
P11090762A0527|210 224|parietal locus
P11090762A0527|126 131|delta
P11090762A0527|66 77|stimulation
P11090762A0527|141 146|power
P11090762A0527|19 25|effect
P11090762A0527|1 8|RESULTS
P11090172A0612|123 137|FHV virion RNA
P11090172A0612|92 97|yeast
P11090172A0612|5 16|time course
P11088635A0200|75 83|computer
P11088635A0200|164 170|system
P11088635A0200|11 42|Kubo-Martin-Schwinger condition
P11086872A0000|14 27|oil emulsions
P11086872A0000|32 40|diphenyl
P11086872A0000|100 119|Citrus aurantifolia
P11085267A0562|72 81|phenotype
P11085267A0562|23 36|sconC3 mutant
P11084556T0000|30 38|delivery
P11084556T0000|129 139|cord blood
P11084556T0000|99 115|progenitor cells
P11084556T0000|16 22|stress
P11084022A1178|62 77|cell morphology
P11084022A1178|52 58|change
P11084022A1178|115 126|elaboration
P11083432A0332|62 63|n
P11083432A0332|56 60|FK-1
P11083432A0332|9 15|groups
P11083154A0881|46 63|oxygen uptake VO2
P11083154A0881|130 139|shrinkage
P11083154A0881|110 118|exertion
P11083154A0881|65 75|heart rate
P11082587X0000|122 131|influence
P11082587X0000|57 77|brillouin scattering
P11082587X0000|233 238|limit
P11082587X0000|33 42|smoothing
P11082587X0000|170 194|Brillouin backscattering
P11081962T0000|60 65|Avena
P11080796A0883|44 54|expression
P11080796A0883|62 65|IKK
P11080796A0883|86 94|IKKgamma
P11076860A0872|133 143|structures
P11076860A0872|52 57|UEV1A
P11076860A0872|203 215|localization
P11076860A0872|71 78|protein
P11076860A0872|1 12|Experiments
P11075929A1657|148 152|ThlB
P11075929A1657|82 86|acid
P11075929A1657|39 43|ThlA
P11075929A1657|136 144|function
P11074210A0623|40 50|components
P11074210A0623|97 99|BP
P11073954A0337|61 80|CP2 family proteins
P11073954A0337|33 46|reading frame
P11073870A0375|148 161|response task
P11073870A0375|214 216|s.
P11073870A0375|129 139|oculomotor
P11073870A0375|66 74|patients
P11073870A0375|80 87|lesions
P11073870A0375|103 106|PRC
P11073218A0800|11 21|nucleotide
P11072388T0000|79 92|schizophrenia
P11072388T0000|23 29|safety
P11072388T0000|35 61|smoking reduction strategy
P11071974A0155|121 134|lipid profile
P11071974A0155|41 48|factors
P11071974A0155|110 117|changes
P11071974A0155|83 91|patients
P11071974A0155|17 24|effects
P11071974A0155|152 172|fibrinolysis markers
P11071852A0297|72 78|SOCS-3
P11071852A0297|115 129|chain reaction
P11071651A1308|106 124|retinoid induction
P11071651A1308|67 82|differentiation
P11070056A0704|30 40|similarity
P11070056A0704|77 85|mosquito
P11070056A0704|65 73|Lian-Aa1
P11069999A1602|26 39|gene products
P11069999A1602|5 12|U17/U16
P11069825A0530|89 98|incidence
P11069825A0530|59 61|yr
P11069825A0530|16 21|cases
P11069788A0531|151 155|cm H
P11069788A0531|29 31|SB
P11069788A0531|218 219|O
P11069788A0531|83 98|difference PEEP
P11069788A0531|55 63|patients
P11069788A0531|135 137|SD
P11069307A0546|15 31|RNA2 translation
P11069307A0546|82 93|translation
P11069307A0546|112 115|BMV
P11069307A0546|55 61|effect
P11069307A0546|222 233|translation
P11069307A0546|205 218|DED1 function
P11069075T0000|23 60|Xenopus laevis CXC chemokine receptor
P11069075T0000|1 17|Characterization
P11067928A0532|30 31|V
P11067928A0532|73 74|D
P11067928A0532|11 15|mAbs
P11067928A0532|76 82|Vkappa
P11067928A0532|32 33|H
P11066245T0000|56 64|mistakes
P11063742A0000|88 94|stress
P11063742A0000|130 140|reductants
P11063742A0000|1 10|NF-kappaB
P11063169T0000|58 67|foot drop
P11063169T0000|1 18|Botulinum toxin A
P11062705A0658|52 57|ATF-2
P11062257A0977|194 211|transport process
P11062257A0977|11 30|class C-Vps complex
P11062257A0977|159 170|specificity
P11062257A0977|175 185|efficiency
P11062257A0977|69 76|docking
P11062067A0000|167 175|stresses
P11062067A0000|145 154|cytokines
P11062067A0000|81 84|JNK
P11062067A0000|116 124|response
P11059786T0000|11 33|growth factor receptor
P11059786T0000|145 152|pathway
P11059786T0000|86 110|growth factor expression
P11059777A0813|148 157|apoptosis
P11059777A0813|10 26|deoxynucleotidyl
P11059777A0813|96 106|activation
P11059777A0813|48 72|nick end labeling assays
P11059777A0813|204 205|L
P11058406A0447|111 130|tobramycin solution
P11058406A0447|36 40|i.v.
P11058120A0256|14 21|factors
P11058120A0256|23 28|IRF-2
P11058120A0256|85 90|IRF-1
P11058008A0159|61 66|flaps
P11058008A0159|34 47|flap necrosis
P11056007A0224|61 68|stretch
P11056007A0224|153 170|Enhancer-of-zeste
P11056007A0224|105 108|Gln
P11056007A0224|41 48|FVVLNLQ
P11056007A0224|172 181|Trithorax
P11056007A0224|143 151|Suvar3-9
P11055513A0564|12 20|lookback
P11055513A0564|78 89|hepatitis C
P11055513A0564|48 53|blood
P11054571A0230|63 73|PAC clones
P11054571A0230|36 40|gene
P11054571A0230|87 91|part
P11054539A0114|107 117|base pairs
P11054539A0114|76 89|reading frame
P11054539A0114|54 61|introns
P11054539A0114|119 121|bp
P11054011A1685|125 133|survival
P11054011A1685|82 102|locoregional control
P11054011A1685|115 116|%
P11054011A1685|44 53|treatment
P11054011A1685|173 192|oncology department
P11054011A1685|139 145|series
P11053263A0200|3 8|total
P11053263A0200|17 23|clones
P11051370A1906|40 49|Americans
P11051370A1906|1 9|Response
P11050168A1185|165 172|protein
P11050168A1185|7 14|results
P11050168A1185|188 210|stability determinants
P11050084A0000|74 83|PPARalpha
P11050084A0000|106 109|fat
P11050084A0000|24 34|peroxisome
P11050084A0000|6 16|expression
P11049241A0659|89 91|ET
P11049241A0659|111 121|difference
P11049241A0659|190 194|days
P11049241A0659|169 174|group
P11049241A0659|205 207|ET
P11046517A0619|41 42|Z
P11046148A0716|56 63|fashion
P11046148A0716|24 42|Syk ubiquitination
P11046148A0716|1 6|LMP2A
P11046148A0716|84 92|activity
P11045607A0239|106 116|start site
P11045607A0239|4 17|RACE analysis
P11044105A0616|59 63|ESS1
P11044105A0616|36 55|splicing suppressor
P11044105A0616|98 109|splice site
P11044097A0422|28 31|HMG
P11044097A0422|114 134|transcription factor
P11042703A0875|105 110|girls
P11042703A0875|123 127|boys
P11042703A0875|6 10|BFDS
P11042703A0875|39 51|W/A Z scores
P11042199A0572|28 30|Ca
P11042199A0572|112 122|nifedipine
P11042199A0572|252 256|CREB
P11042199A0572|202 219|calcium elevation
P11042199A0572|169 179|dantrolene
P11042199A0572|103 110|protein
P11042199A0572|1 10|Elevation
P11041308A0156|45 51|DSM-IV
P11041308A0156|148 152|SOGS
P11041308A0156|36 41|basis
P11041308A0156|65 82|gambling criteria
P11040101A1180|57 77|VEGF gene expression
P11040101A1180|213 226|transcription
P11040101A1180|39 48|IL-1 beta
P11040101A1180|156 164|p38 MAPK
P11040101A1180|169 183|JNK signalings
P11039341A0180|5 12|purpose
P11039341A0180|21 26|study
P11039341A0180|87 94|mapping
P11039341A0180|186 190|task
P11038366A1322|104 109|Rts1p
P11038366A1322|59 70|association
P11038366A1322|82 87|yeast
P11038118A0000|57 68|oligoesters
P11038118A0000|92 104|microspheres
P11038118A0000|1 15|Methyl formate
P11037823A1134|14 31|LSCC malformation
P11037823A1134|176 179|CHL
P11037823A1134|93 101|aqueduct
P11037823A1134|1 12|CONCLUSIONS
P11036939A2149|65 88|planar polarity pathway
P11036939A2149|1 4|Dsh
P11036786A0628|15 22|results
P11036786A0628|40 51|experiments
P11036786A0628|118 125|Animals
P11035037A0183|47 54|yTAF145
P11035037A0183|65 68|TBP
P11034547A1355|43 49|NBPhox
P11034547A1355|34 38|Arix
P11034547A1355|137 149|DBH promoter
P11034392A1072|108 121|NF-kappaB/Rel
P11034392A1072|126 131|PI-3K
P11034392A1072|49 66|survival pathways
P11032599T0000|80 87|factors
P11032599T0000|16 31|recommendations
P11031366T0001|25 41|stomach diseases
P11031366T0001|1 20|Helicobacter pylori
P11030744A0763|31 35|dpm1
P11030744A0763|111 132|DPM synthase activity
P11030744A0763|19 25|Trdpm1
P11030066A0142|24 38|manifestations
P11030066A0142|83 97|motor deficits
P11029700A0746|83 85|R2
P11029700A0746|33 38|assay
P11029700A0746|51 53|Os
P11029656A0640|80 88|proteins
P11029656A0640|1 4|Mn2
P11029459A0000|146 150|cell
P11029459A0000|113 128|characteristics
P11029459A0000|35 44|TGF-beta1
P11028944A1020|10 14|Cmax
P11028944A1020|68 72|dose
P11028131A1374|94 101|history
P11028131A1374|9 17|research
P11028131A1374|144 148|RRMS
P11028131A1374|83 85|MS
P11027724A0335|90 95|p-Ser
P11027724A0335|43 49|serine
P11027724A0335|71 74|Thr
P11027289A0321|88 108|RNA binding activity
P11027289A0321|112 114|SU
P11027289A0321|65 69|ARM2
P11027289A0321|48 54|motifs
P11027280A0536|31 46|phosphorylation
P11027280A0536|83 89|extent
P11027280A0536|50 55|Smad2
P11027267A0752|99 104|cells
P11027267A0752|68 79|krr1 mutant
P11025367A1009|93 101|emptying
P11025367A1009|1 14|Abnormalities
P11024182A0781|75 77|IR
P11024182A0781|215 218|pCI
P11024182A0781|8 14|alpha1
P11024182A0781|219 229|neo vector
P11024182A0781|18 31|collagen mRNA
P11024182A0781|69 71|AR
P11024036A0984|42 71|C/EBP alpha expression vector
P11024036A0984|137 147|constructs
P11023934A0855|12 15|chi
P11023934A0855|25 26|P
P11023934A0855|53 68|filling pattern
P11023934A0855|1 4|L/H
P11023832A1038|194 214|NF-kappaB signalling
P11023832A1038|162 176|protein kinase
P11023832A1038|112 126|lipid products
P11023832A1038|18 25|results
P11023832A1038|139 143|turn
P11020375A0134|26 45|Ross broiler chicks
P11020375A0134|145 150|parts
P11020375A0134|188 191|CLI
P11020375A0134|119 122|CLI
P11020375A0134|135 139|diet
P11020375A0134|110 117|control
P11020375A0134|234 238|days
P11020375A0134|169 171|AF
P11018264A0397|79 85|levels
P11018264A0397|54 68|WASP promoters
P11017876A0787|15 35|localization studies
P11017876A0787|46 52|mDAP-3
P11017876A0787|97 128|protease protection experiments
P11017876A0787|139 145|mDAP-3
P11016850A0423|13 25|DNA fragment
P11016850A0423|99 106|members
P11016850A0423|157 162|LTTRs
P11016850A0423|85 95|similarity
P11016724A0536|123 131|aliquots
P11016724A0536|110 117|surgery
P11016724A0536|4 11|group B
P11015200A0156|8 10|J.
P11014821T0000|162 170|isoforms
P11014821T0000|5 26|LAMMER protein kinase
P11014821T0000|98 112|germline cells
P11014215A1092|110 132|translation start site
P11014215A1092|65 77|DNA fragment
P11014215A1092|252 275|GnRHR promoter activity
P11014197A0339|124 135|subfamilies
P11014197A0339|97 104|kinases
P11012680A1020|91 98|oocytes
P11012680A1020|62 87|calcium chelator BAPTA-AM
P11012680A1020|16 24|PLCgamma
P11012680A1020|195 216|PLCgamma binding site
P11012680A1020|110 115|FGFR1
P11012680A1020|5 8|use
P11012680A1020|138 145|PDGF-BB
P11012671A0576|43 47|site
P11012671A0576|59 79|Gadd45gamma promoter
P11012671A0576|157 177|mobility shift assay
P11012671A0576|86 95|C/EBPbeta
P11011139A0000|60 69|component
P11011139A0000|135 142|studies
P11011139A0000|182 192|alteration
P11011139A0000|37 54|SIN4 gene product
P11011139A0000|170 174|Sin4
P11008139T0000|27 54|pattern discrimination task
P11007961A0930|132 142|fostriecin
P11007961A0930|109 123|PP2A inhibitor
P11007961A0930|93 100|cancers
P11007949A1607|31 39|activity
P11007949A1607|43 46|ILK
P11007777A0813|13 35|intron/exon boundaries
P11007777A0813|79 86|junctin
P11007777A0813|1 9|Analysis
P11007777A0813|102 127|aspartyl beta-hydroxylase
P11006331A0319|14 23|phenotype
P11006331A0319|85 98|abnormalities
P11006283A1180|13 21|AROM-p64
P11006283A1180|77 78|A
P11006283A1180|143 169|mRNA maturation/metabolism
P11006283A1180|114 121|protein
P11005808A1082|107 117|heat shock
P11005808A1082|7 14|results
P11005808A1082|82 96|cell viability
P11003807A0303|52 64|oesophagitis
P11003807A0303|1 9|Symptoms
P11003669A0000|113 133|ErbB-2 juxtamembrane
P11003669A0000|156 160|bait
P11003669A0000|16 24|rat gene
P11003652A0961|28 34|Cdc42p
P11003652A0961|108 118|PAK Ste20p
P11003652A0961|7 14|results
P11003652A0961|87 98|interaction
P11003471A1149|91 98|viruses
P11003471A1149|59 68|Bangalore
P11003471A1149|39 53|ToLCV isolates
P11000521A0588|287 298|PI 3-kinase
P11000521A0588|24 42|signaling pathways
P11000521A0588|218 223|IRS-2
P11000521A0588|116 128|NIH3T3 cells
P11000521A0588|256 285|phosphatidylinositol 3-kinase
P11000250A0200|75 88|JAK molecules
P11000250A0200|58 62|TRAF
P11000250A0200|64 69|TRADD
P11000250A0200|101 110|NF-kappaB
P11000250A0200|1 6|LMP-1
P10999369A0192|151 157|microV
P10999369A0192|132 134|mA
P10999369A0192|64 73|amplitude
P10999369A0192|19 28|amplitude
P10999205A0607|132 143|acquisition
P10999205A0607|92 96|area
P10999205A0607|118 121|VOI
P10997904A1258|182 213|response regulator-kinase pairs
P10997904A1258|5 19|Spo0F residues
P10997904A1258|154 162|residues
P10997330A0361|46 56|STORP gene
P10997330A0361|85 95|expression
P10995121A0569|75 80|value
P10995121A0569|13 45|Standard Reference Material 1846
P10995121A0569|127 128|n
P10995121A0569|99 114|mg vitamin K/kg
P10995121A0569|116 117|K
P10993773A0717|172 184|min ischemia
P10993773A0717|53 65|min ischemia
P10993773A0717|200 211|microm/mmHg
P10993773A0717|155 165|myocardium
P10992299A0745|167 190|brain cancer cell lines
P10992299A0745|23 30|members
P10992299A0745|86 101|PI12 expression
P10992299A0745|204 206|H4
P10991383A0289|150 155|state
P10991383A0289|8 15|lattice
P10991383A0289|83 89|energy
P10991383A0289|115 116|%
P10991383A0289|50 51|%
P10987301A0332|388 394|Kaposi
P10987301A0332|331 341|stimulator
P10987301A0332|298 302|VEGF
P10987301A0332|218 230|angiogenesis
P10987301A0332|357 364|mitogen
P10987301A0332|9 15|regard
P10987301A0332|163 167|KSHV
P10987301A0332|100 104|GPCR
P10984122A0911|45 57|DNA mixtures
P10984122A0911|86 92|mU6-C2
P10984122A0911|17 22|cells
P10983857A0923|57 69|PD reduction
P10983857A0923|24 32|NCX-4016
P10983857A0923|113 122|hyperemia
P10983857A0923|154 161|stomach
P10982825A0363|63 80|Mot3 binding site
P10982825A0363|49 57|presence
P10982143A0346|37 46|T. gondii
P10982143A0346|21 32|host record
P10981094A0779|133 142|intensity
P10981094A0779|43 55|Sixth Report
P10981094A0779|197 214|pretreatment risk
P10981094A0779|116 123|premise
P10976413A0514|150 153|day
P10976413A0514|251 260|pregnancy
P10976413A0514|49 58|FSH level
P10976413A0514|135 142|patient
P10976413A0514|110 121|IVF success
P10976413A0514|173 179|mIU/ml
P10976413A0514|1 8|RESULTS
P10974541A0389|77 82|MZF1C
P10974541A0389|54 65|transcripts
P10973385A1423|148 160|artery nodes
P10973385A1423|162 175|esophagectomy
P10973385A1423|218 229|gastrectomy
P10973385A1423|38 45|pattern
P10973385A1423|187 203|survival benefit
P10972990A1518|94 103|integrity
P10972990A1518|128 134|repair
P10972990A1518|7 14|results
P10972990A0526|15 27|p53 function
P10972990A0526|77 97|mutation frequencies
P10972990A0526|172 211|hypoxanthine phosphoribosyl transferase
P10972990A0526|140 145|locus
P10972990A0526|1 11|Abrogation
P10972990A0526|136 138|TK
P10972980A0295|155 165|G-proteins
P10972980A0295|220 231|amino acids
P10972980A0295|47 54|targets
P10972980A0295|130 131|B
P10972980A0295|197 204|calcium
P10972980A0295|101 109|3-kinase
P10972688A1272|14 23|follow-up
P10972688A1272|50 60|difference
P10967890A1120|31 43|relationship
P10967890A1120|52 65|comprehension
P10967890A1120|70 80|production
P10967361A0000|91 105|brain function
P10967361A0000|129 136|feature
P10967361A0000|154 164|resolution
P10965905A1618|361 382|MAP kinase activation
P10965905A1618|263 271|activity
P10965905A1618|86 99|concentration
P10965905A1618|119 127|findings
P10965905A1618|317 325|addition
P10965905A1618|311 312|s
P10965905A1618|103 111|LY294002
P10965135A1207|45 53|Cktsf1b1
P10965135A1207|182 212|transcription factor complexes
P10965135A1207|5 12|results
P10965135A1207|84 95|development
P10964995A2152|166 171|HER-2
P10964995A2152|125 134|treatment
P10964995A2152|142 148|tumors
P10964995A2152|55 60|women
P10963735A0651|62 73|acid levels
P10963735A0651|36 45|vitamin E
P10963577T0016|1 8|Picture
P10962738A0000|52 58|memory
P10962738A0000|1 14|Consciousness
P10962564A0883|195 201|manner
P10962564A0883|3 32|beta2 RARE reporter construct
P10962564A0883|87 99|sense strand
P10961046A0342|41 51|fibrinogen
P10961046A0342|79 82|vWF
P10961046A0342|115 121|sample
P10961046A0342|84 90|levels
P10959676A0200|19 29|comparison
P10958698A0280|71 87|Cse4p N terminus
P10958673A0142|135 139|ERSE
P10958673A0142|144 151|mammals
P10958673A0142|20 29|signaling
P10958271A0365|180 195|perfusion SPECT
P10958271A0365|245 249|ERNA
P10958271A0365|95 112|ejection fraction
P10958271A0365|334 342|patients
P10958271A0365|114 118|LVEF
P10958271A0365|13 20|RESULTS
P10958271A0365|311 327|echocardiography
P10958271A0365|274 284|assessment
P10955913A0827|61 69|heparins
P10955913A0827|6 12|HIT II
P10954913A0152|39 63|Atlantic halibut Mx gene
P10954525A1161|14 22|presence
P10954525A1161|26 29|Tax
P10954525A1161|80 88|proteins
P10952828A2638|44 53|resonance
P10952828A2638|128 150|heart failure patients
P10952828A2638|96 124|ejection fraction estimation
P10952828A2638|221 234|image quality
P10951579A1238|30 38|majority
P10951579A1238|151 156|cells
P10951579A1238|59 68|apoptosis
P10951579A1238|97 105|triggers
P10951579A1238|139 142|DNA
P10950924A0393|61 68|embryos
P10950924A0393|132 138|cortex
P10950924A0393|87 95|labeling
P10950398T0100|27 35|Endpoint
P10947274A0839|121 124|10B
P10947274A0839|78 83|times
P10947274A0839|5 17|therapy time
P10947274A0839|49 53|dose
P10945781A0412|78 98|enterotoxin activity
P10944466A0451|41 52|WNT-2B gene
P10942599A1298|44 63|Hoxa-1 target genes
P10942599A1298|131 156|differentiation processes
P10942599A1298|9 25|characterization
P10940892A0573|74 84|chromosome
P10940892A0573|125 134|progenies
P10940892A0573|96 103|D4Mit89
P10940892A0573|86 89|Chr
P10940562A0379|53 63|oasA2 gene
P10940553A0912|111 135|hPer1 gene transcription
P10940553A0912|86 96|regulation
P10939785A0540|214 221|placebo
P10939785A0540|99 109|indapamide
P10939785A0540|175 184|treatment
P10939785A0540|222 223|s
P10939785A0540|137 147|indication
P10938556A0248|67 72|cells
P10938556A0248|49 56|neurons
P10938130A0338|108 117|interface
P10938130A0338|43 62|PLZF BTB/POZ domain
P10938130A0338|1 6|X-ray
P10938113A0388|227 237|activities
P10938113A0388|58 71|isoforms Vav2
P10938113A0388|185 197|Vav isoforms
P10938105A0000|123 136|sequence IAS1
P10938105A0000|83 87|gene
P10938105A0000|35 39|exon
P10938102A1359|61 66|model
P10938102A1359|46 50|data
P10938102A1359|129 135|region
P10938102A1359|140 143|UTR
P10936920A0105|10 20|experience
P10936920A0105|55 63|elements
P10936920A0105|71 81|generation
P10935880A1049|44 49|PI-3V
P10935880A1049|58 71|NCP BVDV type
P10935880A1049|102 106|BVDV
P10934751T0001|1 15|CREST syndrome
P10934310A0698|109 120|angiography
P10934310A0698|1 15|DATA SYNTHESIS
P10933732A0000|208 214|family
P10933732A0000|144 165|transcription factors
P10933732A0000|119 127|homology
P10933732A0000|195 201|factor
P10933732A0000|40 45|HHV-8
P10933732A0000|173 183|interferon
P10933154A1118|109 118|rejection
P10933154A1118|7 15|findings
P10932527T0000|90 96|horses
P10932527T0000|26 51|haemodialysate Solcoseryl
P10932527T0000|101 107|ponies
P10932329A0597|82 109|sulcus cecocolicus dorsalis
P10932329A0597|5 10|limit
P10931960A0630|134 151|activation domain
P10931960A0630|13 32|avirulence activity
P10931960A0630|161 175|herpes simplex
P10931960A0630|84 101|activation domain
P10931927A0655|269 273|size
P10931927A0655|243 251|products
P10931927A0655|177 190|transcriptase
P10931927A0655|59 62|T-3
P10931927A0655|165 168|HIV
P10931927A0655|10 25|oligomer duplex
P10931927A0655|204 226|telomere DNA sequences
P10930526A0174|73 81|HuPLSCR1
P10930526A0174|49 62|PL scramblase
P10928337A0590|109 115|volume
P10928337A0590|23 29|anemia
P10928337A0590|100 104|mass
P10926776A0731|41 53|substitution
P10926776A0731|115 122|protein
P10925159A1353|90 99|fractions
P10925159A1353|9 15|MARTA1
P10925159A1353|174 195|salt-wash preparation
P10921197A0179|88 92|VO5B
P10921197A0179|116 118|b.
P10921197A0179|50 76|treatment planning systems
P10920186A0528|120 123|use
P10920186A0528|89 99|transcript
P10920186A0528|127 138|MLL primers
P10920186A0528|152 155|PCR
P10918948A0110|37 47|metabolite
P10918948A0110|6 14|compound
P10918948A0110|51 62|trimebutine
P10918612A0000|130 145|gene expression
P10918612A0000|80 94|growth signals
P10918596A0000|89 97|activity
P10918596A0000|115 123|molecule
P10918572A0794|61 66|ErbB1
P10918572A0794|78 83|ErbB4
P10918572A0794|1 4|VaI
P10918164A0878|44 54|physicians
P10918164A0878|10 29|regression analysis
P10918164A0878|97 104|lesions
P10918164A0878|114 116|mm
P10918164A0878|64 69|times
P10917402T0000|43 56|amitriptyline
P10917402T0000|80 90|depression
P10915728A0216|109 114|units
P10915728A0216|126 134|IFN-beta
P10915728A0216|143 147|week
P10915728A0216|169 177|patients
P10915728A0216|186 197|IFN therapy
P10913304A0894|47 51|Fli1
P10913304A0894|53 62|GABPalpha
P10913304A0894|64 68|SAP1
P10913276A0510|91 112|PLC-gamma1 SH3 domain
P10913276A0510|36 42|domain
P10913094A0424|106 112|cycles
P10913094A0424|84 88|AdpA
P10910439A1196|72 80|decrease
P10910439A1196|27 39|hypertension
P10910439A1196|1 12|CONCLUSIONS
P10909973A1508|180 195|phosphorylation
P10909973A1508|41 44|CRE
P10909973A1508|4 12|contrast
P10909973A1508|18 24|action
P10909973A1508|84 91|M1-CREB
P10908478A0717|61 74|schizophrenia
P10908478A0717|127 134|placebo
P10908478A0717|115 125|quetiapine
P10908478A0717|86 95|illnesses
P10908478A0717|1 19|SELECTION CRITERIA
P10908364A0000|26 39|DNA structure
P10907971T0000|72 80|analysis
P10907971T0000|18 28|assessment
P10907348A0508|120 128|activity
P10907348A0508|13 25|examinations
P10907348A0508|77 95|PTH concentrations
P10907348A0508|48 58|metabolism
P10906317A0351|74 79|right
P10906317A0351|89 99|proportion
P10906317A0351|27 36|variables
P10906317A0351|140 149|hemifield
P10906317A0351|103 109|trials
P10905352A0000|120 126|helper
P10905352A0000|164 171|protein
P10905352A0000|89 98|cytoplasm
P10905352A0000|109 112|aid
P10905352A0000|55 61|lactis
P10905349A0329|20 28|homology
P10905349A0329|1 7|Mus81p
P10903877A0879|15 18|PKA
P10903877A0879|44 53|forskolin
P10903877A0879|73 76|PKC
P10903877A0879|59 69|inhibition
P10903877A0879|188 192|CRAC
P10903877A0879|1 11|Activation
P10903837A1208|106 133|Gene Nomenclature Committee
P10903837A1208|50 68|goldfish Vsx1 gene
P10903583T0000|63 84|spine motion analyser
P10903583T0000|117 125|subjects
P10903583T0000|34 40|motion
P10903440A0515|31 37|TSGF-2
P10903440A0515|126 130|gene
P10903440A0515|6 17|transcripts
P10903440A0515|64 78|testes tissues
P10901133A0381|43 51|standard
P10900129A0138|106 113|RT-PCRs
P10900129A0138|51 58|regions
P10899128A0661|90 98|MADS-box
P10899128A0661|165 175|regulation
P10899128A0661|144 156|implications
P10899128A0661|19 26|example
P10897973T0001|92 104|antithrombin
P10897973T0001|1 28|Antithrombin III deficiency
P10897973T0001|84 88|role
P10896859A0838|23 28|cause
P10896008A0531|106 110|type
P10896008A0531|27 33|sample
P10896008A0531|76 81|motor
P10896008A0531|140 149|dystrophy
P10896008A0531|1 13|PARTICIPANTS
P10895417A0669|30 36|saline
P10895417A0669|11 20|EPI-C0401
P10895417A0669|129 149|hindlimb muscle tone
P10895417A0669|85 87|hr
P10894886A0375|62 69|changes
P10894886A0375|27 33|subset
P10894149T0000|30 38|receptor
P10894149T0000|122 131|receptors
P10894149T0000|178 184|factor
P10894149T0000|142 162|orphan receptors SF1
P10894149T0000|1 5|PNRC
P10893243T0000|107 145|selenocysteine tRNA gene transcription
P10893243T0000|35 40|mouse
P10893243T0000|51 101|chaperonin subunit gene Ccta/t-complex polypeptide
P10892300A0268|57 62|March
P10892300A0268|101 124|locomotor abnormalities
P10891489A0152|109 123|transformation
P10891489A0152|83 96|proliferation
P10891489A0152|20 30|expression
P10891489A0152|156 160|role
P10891489A0152|186 198|pathogenesis
P10891399A1185|166 170|role
P10891399A1185|193 200|control
P10891399A1185|80 83|p21
P10891399A1185|33 40|c-fosER
P10891399A1185|84 93|Cip1/WAF1
P10891266A0421|25 35|C terminus
P10891266A0421|1 6|ACE-2
P10890911A0470|58 72|HMG box domain
P10890911A0470|22 27|Smad3
P10890911A0470|102 114|Wnt pathways
P10890911A0470|186 190|Xtwn
P10888570A0678|46 53|Atzimba
P10888570A0678|11 20|alkaloids
P10888570A0678|82 87|Murca
P10888570A0678|38 42|peel
P10888570A0678|119 125|limits
P10887912A0740|88 106|temporalis muscles
P10887912A0740|10 14|MVBF
P10887912A0740|23 43|maximum EMG activity
P10885750A0236|61 67|CREB-2
P10885750A0236|81 92|development
P10885708T0000|30 35|entry
P10885708T0000|53 58|agent
P10882850A0000|133 136|DNA
P10882850A0000|19 22|Nth
P10882850A0000|1 13|Endonuclease
P10882213A0163|123 133|malignancy
P10882213A0163|354 362|myositis
P10882213A0163|293 308|classifications
P10882213A0163|51 62|association
P10882213A0163|160 168|approach
P10882213A0163|312 322|discussion
P10882213A0163|239 249|usefulness
P10882213A0163|31 35|data
P10882213A0163|334 343|childhood
P10882213A0163|552 568|disease activity
P10882213A0163|401 407|review
P10882213A0163|139 155|myositis patient
P10882213A0163|204 233|dermatomyositis sine myositis
P10881275T0000|13 30|serum IgM binding
P10881275T0000|34 49|GM1 ganglioside
P10880486A0790|36 45|mutations
P10880486A0790|118 128|RhoA locus
P10878675A1278|110 128|energy expenditure
P10878675A1278|1 11|CONCLUSION
P10878398A0542|107 120|CAPD patients
P10878398A0542|27 30|Epo
P10878398A0542|138 143|group
P10878398A0542|17 25|patients
P10874044A0647|92 96|JNK1
P10874044A0647|80 84|ERK1
P10874044A0647|86 90|ERK2
P10874044A0647|49 55|mutant
P10873387A0816|105 129|mouse synaptophysin gene
P10873387A0816|94 97|end
P10873387A0816|54 71|Cacna1f gene maps
P10873387A0816|81 83|kb
P10873286X0000|22 27|BRAIN
P10872851A0714|165 166|P
P10872851A0714|130 131|P
P10872851A0714|126 128|SV
P10872851A0714|144 149|LVEDP
P10872827A0000|105 108|kDa
P10872827A0000|47 56|ATCC11105
P10872827A0000|142 149|subunit
P10872827A0000|115 122|subunit
P10872535A0000|123 137|susceptibility
P10872535A0000|59 66|factors
P10872535A0000|86 98|birthweights
P10872535A0000|224 228|OGTT
P10872535A0000|281 304|birthweight differences
P10872535A0000|141 149|diabetes
P10872535A0000|342 346|life
P10871842A0988|164 177|proliferation
P10871842A0988|57 69|upregulation
P10871842A0988|144 159|stress response
P10871842A0988|5 12|results
P10871412A0369|93 98|Rz007
P10871412A0369|83 91|ribozyme
P10871347A0477|41 53|motif TCCCCT
P10871347A0477|1 18|Mutation analysis
P10870391T0034|40 47|therapy
P10870391T0034|51 66|travel diarrhea
P10869465A1054|107 113|clones
P10869465A1054|198 205|Sertoli
P10869465A1054|42 52|RNA probes
P10869465A1054|152 168|germ cell stages
P10868488A0921|30 34|rate
P10868488A0921|18 24|period
P10867199A0230|79 86|studies
P10867199A0230|52 56|data
P10867199A0230|153 166|insect orders
P10867199A0230|102 107|level
P10866689A0295|63 79|reporter plasmid
P10866689A0295|227 248|tal-1-E12 heterodimer
P10866689A0295|95 113|tal-1 binding site
P10866689A0295|8 11|pRb
P10866323A0666|61 78|p21WAF1 induction
P10866323A0666|82 97|STAT activation
P10865838A0000|150 155|cells
P10865838A0000|37 41|VEGF
P10865838A0000|87 92|cells
P10865838A0000|103 112|migration
P10864989A0484|156 162|median
P10864989A0484|75 84|reduction
P10864989A0484|227 242|separation time
P10864989A0484|108 114|median
P10864989A0484|66 67|p
P10864989A0484|102 106|WBCs
P10864496A0401|129 139|conditions
P10864496A0401|55 66|interaction
P10864496A0401|70 74|TnrA
P10863352T0001|27 32|music
P10863352T0001|21 25|life
P10862289A0289|121 132|A60 antigen
P10862289A0289|42 48|adults
P10862289A0289|81 88|control
P10862289A0289|50 57|age/sex
P10862289A0289|102 105|IgG
P10861906A1479|124 143|nitrogen starvation
P10861906A1479|77 94|transcript levels
P10861906A1479|98 103|KIN28
P10861906A1479|34 44|conditions
P10861086A0904|28 37|construct
P10861086A0904|133 155|phagocytosis signaling
P10861086A0904|4 12|contrast
P10861080A0433|44 71|IkappaBalpha overexpression
P10861080A0433|78 88|production
P10861080A0433|18 26|transfer
P10860827A0399|88 94|region
P10860827A0399|71 79|elements
P10860827A0399|118 133|CSX1 expression
P10860196A0876|109 114|years
P10860196A0876|21 28|program
P10858988A0786|28 33|serum
P10858988A0786|9 24|tryptase levels
P10857751A0304|133 149|GenBank database
P10857751A0304|18 32|mouse ortholog
P10857751A0304|103 109|CEHARP
P10857215A0806|40 48|standard
P10857215A0806|55 65|instrument
P10856805T0000|47 58|preparation
P10856805T0000|1 34|Improving fissure sealant quality
P10856298A0798|40 47|enzymes
P10856298A0798|179 184|level
P10856298A0798|144 149|T339I
P10856298A0798|1 13|Transfection
P10856298A0798|17 22|cDNAs
P10855793A1418|94 98|cord
P10855793A1418|146 156|candidates
P10855793A1418|197 206|disorders
P10855793A1418|1 17|Characterization
P10854699A0424|7 19|FGF-AS cDNAs
P10854699A0424|138 153|FGF-AS sequence
P10854699A0424|51 62|FGF-AS mRNA
P10853850A1103|9 13|LTE4
P10853850A1103|35 45|challenges
P10853059X0751|12 17|Basel
P10852485A0477|95 97|q5
P10852485A0477|83 85|CS
P10852485A0477|55 79|chromosome deletion line
P10852485A0477|136 142|Q gene
P10852485A0477|34 40|Q gene
P10852221A0422|41 46|graft
P10852221A0422|128 134|effect
P10852221A0422|80 86|period
P10851267A0000|13 33|transcription factor
P10851267A0000|49 71|cell cycle progression
P10850997A1016|60 67|absence
P10850997A1016|28 38|regulation
P10850997A1016|71 74|Fur
P10850849A0730|177 181|Cmax
P10850849A0730|246 251|hours
P10850849A0730|158 167|microg/ml
P10850849A0730|288 289|%
P10850849A0730|133 137|Cmax
P10850849A0730|110 131|maximum concentration
P10850849A0730|169 173|time
P10850453A1292|149 169|TGF-beta1 production
P10850453A1292|21 25|data
P10850453A1292|119 135|growth advantage
P10850329A0248|166 180|cell carcinoma
P10850329A0248|111 121|management
P10850329A0248|32 41|treatment
P10850329A0248|136 144|melanoma
P10848848A0413|21 29|gangrene
P10846069T0000|9 11|NH
P10846069T0000|116 127|replication
P10846069T0000|1 5|Role
P10846069T0000|68 92|parainfluenza virus type
P10845522A0000|194 205|mammography
P10845522A0000|125 135|evaluation
P10845522A0000|139 153|breast lesions
P10845522A0000|69 102|99mTc-sestamibi scintimammography
P10843716A0406|62 73|pseudogenes
P10843716A0406|129 135|humans
P10843716A0406|5 19|tryptase locus
P10841593A0780|109 125|nicotine patches
P10841593A0780|5 10|model
P10841593A0780|48 69|cigarette consumption
P10840001A0188|127 132|tract
P10840001A0188|1 22|Mucin gene expression
P10839547A0978|57 72|DNA methylation
P10838531A0675|56 60|IIIB
P10838531A0675|36 37|%
P10838531A0675|39 43|IIIA
P10838531A0675|19 22|IIB
P10838531A0675|1 13|Tumor stages
P10838139A1447|33 42|mutations
P10836786A0516|30 34|role
P10836786A0516|58 73|enzyme function
P10836786A0516|42 54|RNA subunits
P10836786A0516|175 186|RNase P RNA
P10836786A0516|136 140|MRP3
P10835732A0911|25 43|cholesterol levels
P10835732A0911|4 15|differences
P10835355A0225|24 48|zinc finger protein Gis1
P10835355A0225|159 171|derepression
P10835355A0225|175 179|SSA3
P10834707A1533|111 125|treatment time
P10834707A1533|85 92|sorbent
P10833461A0603|149 155|length
P10833461A0603|57 64|library
P10833461A0603|52 55|PAC
P10833461A0603|116 121|clone
P10831972A0744|120 128|controls
P10831972A0744|59 64|women
P10831972A0744|70 83|endometriosis
P10829973T0000|32 42|Bangladesh
P10828591A0080|75 81|course
P10828591A0080|122 128|region
P10828591A0080|158 169|uteroglobin
P10828591A0080|54 67|cDNA sequence
P10828591A0080|137 153|markers D11S1765
P10828022A0877|57 81|tyrosine phosphorylation
P10828022A0877|93 102|formation
P10828022A0877|85 88|Shb
P10827885T0059|34 39|trial
P10826861A0000|166 176|neuropathy
P10826861A0000|94 108|manifestations
P10826861A0000|83 90|variety
P10826861A0000|16 39|immunoglobulin products
P10825293T0000|13 19|dimers
P10825293T0000|23 44|N-cadherin-Fc chimera
P10825293T0000|69 91|cell contact formation
P10825000A1245|33 41|Coquelle
P10824485A0393|73 92|T lymphocyte counts
P10824485A0393|5 13|patients
P10824485A0393|68 71|CD4
P10823837A1213|296 306|GPI anchor
P10823837A1213|156 172|GPI lipid anchor
P10823837A1213|194 199|Mcd4p
P10823837A1213|44 61|YLL031c transfers
P10823837A1213|66 87|ethanolaminephosphate
P10823837A1213|204 240|Gpi7p transfer ethanolaminephosphate
P10822117A1386|13 23|adjustment
P10822117A1386|115 126|information
P10822117A1386|136 150|subject-models
P10820904A0000|124 137|liver disease
P10820904A0000|157 168|anastomosis
P10820904A0000|1 11|BACKGROUND
P10819327T0000|76 115|mouse KIF3A/KIFB/KAP3 kinesin complexes
P10819327T0000|32 41|orthologs
P10819327T0000|1 18|C. elegans KLP-11
P10815807A1271|28 41|transcription
P10815807A1271|101 107|HTLV-I
P10814989T0000|65 71|France
P10814989T0000|84 89|study
P10811908A0938|130 133|I-1
P10811908A0938|71 82|mutagenesis
P10811908A0938|119 122|Ser
P10811804A0000|72 95|specificity phosphatase
P10811804A0000|157 168|MAP kinases
P10811804A0000|33 53|kinase phosphatase-3
P10811804A0000|152 155|ERK
P10811079A0555|120 121|%
P10811079A0555|160 185|carbamazepine monotherapy
P10811079A0555|19 35|color perception
P10811079A0555|51 52|%
P10810294A0730|20 28|response
P10810294A0730|32 34|GH
P10809233A0606|105 109|loop
P10809233A0606|73 76|H12
P10809233A0606|43 50|surface
P10809233A0606|101 103|H3
P10809233A0606|1 9|Modeling
P10807900A0933|121 126|value
P10807900A0933|82 95|% specificity
P10807900A0933|65 78|% sensitivity
P10807900A0933|38 56|vein visualisation
P10807900A0933|169 178|diagnosis
P10805747A0633|14 23|mutations
P10805747A0633|88 93|Hsl1p
P10805747A0633|4 12|contrast
P10805747A0633|137 156|septin organization
P10805739A0343|65 79|eIF2B subunits
P10805737T0000|74 78|role
P10805737T0000|12 20|analysis
P10805737T0000|131 135|eIF5
P10805737T0000|82 93|interaction
P10805737T0000|34 63|translation initiation factor
P10805390A0340|19 30|performance
P10805390A0340|69 97|GaAs/AlGaAs heterostructures
P10805286A0233|211 217|effect
P10805286A0233|166 189|rat PCI mRNA expression
P10805286A0233|40 52|cis-elements
P10805286A0233|233 236|rat
P10805286A0233|16 21|study
P10802909A0478|40 48|children
P10802909A0478|19 31|PARTICIPANTS
P10801860A0000|94 100|sugars
P10801860A0000|39 46|lectins
P10801860A0000|19 28|subfamily
P10801482A0968|92 100|residues
P10801482A0968|38 45|targets
P10801482A0968|115 120|roles
P10801244A0578|78 81|use
P10801244A0578|1 16|Vancomycin data
P10801244A0578|119 127|software
P10799863T0000|46 57|proteasomes
P10799863T0000|129 149|antigen presentation
P10799863T0000|84 101|HIV-1 ENV epitope
P10799590A0431|193 200|EBNA-3C
P10799590A0431|78 93|EBNA-3C protein
P10799590A0431|126 139|transcription
P10799590A0431|20 25|sites
P10799590A0431|1 7|Jkappa
P10799501A1391|106 111|Cdc42
P10799501A1391|7 14|studies
P10799501A1391|87 102|SPRK activation
P10797586A0402|83 89|signal
P10797586A0402|54 66|disturbances
P10796486A0817|104 110|family
P10796486A0817|80 87|therapy
P10796486A0817|155 163|children
P10796486A0817|49 57|children
P10796486A0817|171 188|asthma medication
P10795098A0253|10 20|vasculitis
P10795098A0253|34 39|Crohn
P10794405A0000|105 109|step
P10794405A0000|160 169|chromatin
P10794405A0000|142 150|function
P10794405A0000|154 156|H1
P10793143A1533|105 112|results
P10793143A1533|183 193|initiation
P10793143A1533|197 212|DNA replication
P10793143A1533|33 44|DNA binding
P10793143A1533|171 175|role
P10792583A0000|149 159|adaptation
P10792583A0000|25 50|vasopressin V1b receptors
P10792583A0000|117 124|hormone
P10792583A0000|68 72|role
P10791819A0771|124 133|selection
P10791819A0771|43 65|nucleotide composition
P10790390X0000|245 252|control
P10790390X0000|188 202|gene silencing
P10790390X0000|23 33|complexity
P10790390X0000|134 139|3-93D
P10790390X0000|130 133|var
P10790390X0000|128 129|E
P10790390X0000|338 348|cell death
P10790390X0000|206 233|position effect variegation
P10790390X0000|169 178|processes
P10788476A0891|91 109|ER-Golgi transport
P10788476A0891|40 47|portion
P10788476A0891|1 11|Antibodies
P10787804T0000|60 64|care
P10787804T0000|29 33|ways
P10787804T0000|68 72|SNFs
P10786742A0670|8 21|control group
P10786742A0670|23 39|platelet markers
P10785880A0947|108 113|class
P10785880A0947|116 130|HELLP syndrome
P10785880A0947|17 28|probability
P10785294A0720|29 42|inlays/onlays
P10785294A0720|66 78|restorations
P10784367A0133|13 19|sample
P10784367A0133|146 154|subjects
P10784367A0133|1 7|METHOD
P10784367A0133|170 179|disorders
P10784367A0133|51 87|Suffolk County Mental Health Project
P10782640A0444|91 101|correction
P10782640A0444|36 56|aberration constants
P10781611A1023|14 18|bone
P10781611A1023|113 123|comparison
P10781611A1023|65 69|mice
P10781611A1023|34 45|macrophages
P10781552A0000|106 120|photosynthesis
P10781552A0000|67 73|energy
P10781552A0000|87 94|sources
P10781552A0000|1 7|Purple
P10781423A0993|41 43|bp
P10781423A0993|87 150|homeodomain transcription factor thyroid transcription factor-1
P10781423A0993|152 157|TTF-1
P10780883T0000|47 57|interferon
P10780883T0000|130 146|interferon-alpha
P10780883T0000|69 75|factor
P10780518A1270|22 31|mutations
P10780518A1270|35 51|protein function
P10779508T0000|104 130|estrogen response elements
P10779508T0000|59 70|coactivator
P10779508T0000|1 9|Estrogen
P10779508A0452|90 140|glutathione S-transferase-ERRalpha1 fusion protein
P10779508A0452|4 9|DNase
P10779329T0000|41 49|function
P10779329T0000|82 105|cell morphology changes
P10778757A0000|121 124|Mn1
P10778757A0000|109 119|Miniature1
P10778757A0000|58 64|mutant
P10778757A0000|66 72|mn1-89
P10778757A0000|187 192|INCW2
P10777669A0582|37 50|marker RP S28
P10777669A0582|5 16|ZNF274 gene
P10777499A0883|24 30|assays
P10777499A0883|93 105|phytochromes
P10777499A0883|112 113|B
P10777499A0883|139 146|element
P10775623A0120|62 71|env genes
P10775623A0120|5 16|codon usage
P10775267A0363|121 124|BMT
P10775267A0363|12 24|transduction
P10775267A0363|126 131|model
P10775267A0363|196 204|lymphoma
P10775267A0363|157 169|long-latency
P10775267A0363|32 33|L
P10773951A0000|29 46|B antibody status
P10773951A0000|93 109|O group husbands
P10773951A0000|18 19|A
P10773458A0000|28 32|role
P10773458A0000|54 73|vesicle trafficking
P10773458A0000|1 8|SNAP-23
P10773351A0672|114 117|GAS
P10773351A0672|33 44|stimulation
P10773351A0672|87 95|presence
P10773351A0672|153 161|elements
P10772856X1492|1 10|Copyright
P10771528T0036|12 20|increase
P10771528T0036|3 8|cause
P10770065A0264|14 19|stage
P10770065A0264|40 63|S2 sleeve segmentectomy
P10770065A0264|96 97|b
P10769144A0000|13 23|TGACGTCA-3
P10769144A0000|52 70|consensus sequence
P10769144A0000|119 134|gene expression
P10767553A0100|78 104|helix transcription factor
P10767553A0100|36 41|liver
P10767553A0100|1 4|Hex
P10767251A1046|47 55|Vivostat
P10767251A1046|63 70|sealant
P10767251A1046|98 109|air leakage
P10767251A1046|1 12|CONCLUSIONS
P10766556T0000|53 59|valves
P10766246A0000|39 46|signals
P10766246A0000|115 130|gene expression
P10766246A0000|101 111|regulation
P10766246A0000|1 28|Integrin adhesion receptors
P10764970A1009|104 109|cases
P10764970A1009|88 91|PCR
P10764970A1009|182 194|introduction
P10764970A1009|125 134|existence
P10764970A1009|5 9|mode
P10764760T0000|60 67|repeats
P10764760T0000|40 45|HIV-1
P10764574A0718|74 94|Arabidopsis thaliana
P10764574A0718|63 68|genes
P10764574A0718|178 195|alignment methods
P10764574A0718|114 125|improvement
P10763827A1158|90 102|inactivation
P10763827A1158|62 70|response
P10763827A1158|128 136|response
P10763827A1158|76 88|ras oncogene
P10762348A0269|24 37|STAT proteins
P10762348A0269|99 107|activity
P10761263A1108|146 163|prostate patients
P10761263A1108|6 15|Newcastle
P10761263A1108|17 22|model
P10760169A1142|23 27|pair
P10760109A1050|209 212|SCr
P10760109A1050|127 135|patients
P10760109A1050|191 207|serum creatinine
P10760109A1050|50 58|patients
P10760109A1050|106 107|P
P10760109A1050|5 15|prevalence
P10760109A1050|38 39|%
P10760109A1050|171 175|SAlb
P10758726T0000|33 45|arrangements
P10758289A0141|145 154|specimens
P10758289A0141|70 84|finger flexors
P10757975A0509|1 5|Biol
P10756100A0457|47 50|IB1
P10756100A0457|71 79|diabetes
P10756032A0599|46 63|cyclin E promoter
P10756032A0599|92 102|protection
P10756032A0599|153 158|cells
P10756007A1512|70 86|ch-19 target DNA
P10754312A0798|5 15|solubility
P10752807A1598|165 173|function
P10752807A1598|62 86|factor antagonist BB-882
P10752807A1598|26 32|sepsis
P10752807A1598|178 198|organ failure scores
P10752807A1598|112 119|placebo
P10752450A0288|44 61|fluoride products
P10752450A0288|84 109|fluoride delivery systems
P10750524A0724|104 107|age
P10750524A0724|147 148|p
P10750524A0724|140 145|group
P10750524A0724|1 8|RESULTS
P10750020A0843|95 100|sites
P10750020A0843|155 164|ER action
P10750020A0843|50 65|transactivation
P10749849A0000|181 190|WAF1/Cip1
P10749849A0000|192 196|gene
P10749849A0000|125 135|activation
P10749849A0000|37 57|tumor suppressor p53
P10749145T0000|30 43|PCPH proteins
P10749145T0000|95 106|oncoprotein
P10749145T0000|172 183|kinase ERK1
P10748175A0000|44 49|lumen
P10748175A0000|78 84|sugars
P10748175A0000|20 36|glycan synthesis
P10748175A0000|119 126|cytosol
P10748125A0000|61 65|type
P10748125A0000|23 34|inhibitor-2
P10748125A0000|1 12|Inhibitor-1
P10748054T0048|15 25|regulation
P10748054T0048|67 79|calcium flux
P10747890A1096|29 36|residue
P10747890A1096|7 14|results
P10747890A1096|54 68|protein sensor
P10747782A0390|122 131|molecules
P10747782A0390|25 29|Swi4
P10747782A0390|197 209|core domains
P10747782A0390|16 20|Mbp1
P10747782A0390|85 94|sequences
P10747053A1102|180 185|TAF17
P10747053A1102|92 96|role
P10747053A1102|54 59|taf17
P10747053A1102|142 152|activation
P10747053A1102|200 210|activation
P10747053A1102|100 103|TAF
P10744974T0000|111 116|yeast
P10744974T0000|21 51|spindle pole body localization
P10744974T0000|85 99|protein kinase
P10744749A0315|90 96|effect
P10744749A0315|62 72|inhibition
P10744749A0315|179 187|paradigm
P10743719A0223|74 84|management
P10743719A0223|124 145|rejection nephropathy
P10743719A0223|18 27|rejection
P10742216A0555|11 13|J.
P10741947T0000|41 49|stenosis
P10741947T0000|7 16|technique
P10740602A0141|15 37|Fine needle aspiration
P10740602A0141|89 98|carcinoma
P10740602A0141|158 166|analysis
P10740602A0141|100 103|ILC
P10739408A0896|105 112|support
P10739408A0896|37 46|influence
P10739408A0896|1 19|Family environment
P10737366A0280|127 140|formalin test
P10737366A0280|112 119|stimuli
P10736161T0000|37 68|sugar phosphotransferase system
P10736161T0000|17 36|phosphoenolpyruvate
P10735272A0649|120 124|gene
P10735272A0649|228 271|chromosome 19q glioma tumor suppressor gene
P10735272A0649|128 135|gliomas
P10735272A0649|140 154|RT-PCR studies
P10735272A0649|1 18|Southern blotting
P10733880X1783|16 30|Academic Press
P10733591A0146|185 203|cell proliferation
P10733591A0146|118 123|c-jun
P10733591A0146|135 141|kinase
P10733591A0146|47 57|remodeling
P10733591A0146|143 146|JNK
P10733591A0146|65 83|actin cytoskeleton
P10733569A0364|150 165|stress response
P10733569A0364|94 116|stress gene expression
P10733569A0364|142 146|HSF2
P10733569A0364|17 21|HSFs
P10732669A0510|74 94|particle bombardment
P10732669A0510|122 128|Oshox1
P10732669A0510|163 171|activity
P10732669A0510|175 199|reporter gene constructs
P10731411A0958|44 52|residues
P10731411A0958|166 176|importance
P10731411A0958|214 219|motif
P10731411A0958|188 195|residue
P10731411A0958|185 186|A
P10730292T0000|54 66|malocclusion
P10729220A1569|78 81|H19
P10729220A1569|64 74|disruption
P10729155A0653|104 109|betaI
P10729155A0653|130 138|residues
P10729155A0653|203 210|subunit
P10729155A0653|174 178|face
P10728986A0000|88 107|cell fate decisions
P10728986A0000|5 26|Wnt signaling pathway
P10727515A1202|43 44|q
P10727515A1202|127 134|PLCbeta
P10727515A1202|54 63|receptors
P10727515A1202|184 199|pertussis toxin
P10727433T0000|15 65|urokinase plasminogen activator gene transcription
P10727433T0000|149 154|CSF-1
P10727433T0000|178 183|level
P10727433T0000|141 147|factor
P10727433T0000|1 11|Regulation
P10727428A0000|10 13|MAP
P10727428A0000|162 173|hypertrophy
P10727428A0000|115 125|cell types
P10727428A0000|139 150|MAP kinases
P10727413A1244|15 28|binding sites
P10727413A1244|226 244|tissue restriction
P10727413A1244|145 152|species
P10727413A1244|96 104|promoter
P10727413A1244|262 270|hormones
P10727413A1244|48 55|factors
P10725433A0543|164 173|consensus
P10725433A0543|65 85|Wp reporter activity
P10725433A0543|3 11|mutation
P10725433A0543|49 56|factors
P10725433A0543|187 195|sequence
P10725017A0673|61 68|CEN ENV
P10725017A0673|145 152|CEN ENV
P10725017A0673|118 135|healthcare record
P10725017A0673|171 201|Healthcare Record Architecture
P10724483A0540|25 37|cAMP control
P10724483A0540|53 57|SRP1
P10723727A0713|38 44|intron
P10722969A0510|28 32|date
P10722969A0510|16 24|progress
P10722661A0406|229 236|control
P10722661A0406|36 43|complex
P10722661A0406|143 157|TY epitope tag
P10722661A0406|116 125|CYC2 gene
P10722509A0392|44 53|dipivoxil
P10722509A0392|122 131|dipivoxil
P10722509A0392|58 60|kg
P10722509A0392|64 75|body weight
P10722509A0392|85 93|patients
P10721726T0000|22 50|mouse thioredoxin reductases
P10721714A1087|124 132|Sp1 site
P10721714A1087|80 87|regions
P10721714A1087|17 38|mobility shift assays
P10721704A1155|161 178|sequence analysis
P10721704A1155|25 37|organization
P10721704A1155|97 108|Elav family
P10721704A1155|222 232|cell types
P10720434A0291|63 72|sequences
P10720434A0291|36 41|mRNAs
P10720434A0291|103 117|cyclin B1 mRNA
P10715602A0149|121 134|phospholipids
P10715602A0149|46 51|mg/kg
P10715602A0149|199 204|rSP-C
P10715602A0149|173 182|Burgwedel
P10715602A0149|184 191|Germany
P10715602A0149|84 114|surfactant preparation Exosurf
P10715322A0000|41 54|DNA sequences
P10715322A0000|1 15|Gene silencing
P10713453A0172|93 96|57A
P10713453A0172|48 60|antibody Q18
P10713453A0172|153 159|Hrb57A
P10713176A0885|79 84|cells
P10713176A0885|142 155|inhibitor p16
P10713176A0885|156 161|INK4A
P10713176A0885|1 22|D-cyclin-cdk activity
P10713175A1399|133 149|ARF-Mdm2 complex
P10713175A1399|55 59|Mdm2
P10713175A1399|19 26|results
P10713175A1399|119 125|import
P10713155A0151|198 205|HeLa-NE
P10713155A0151|140 145|Ad-NE
P10713155A0151|170 179|HeLa cell
P10713083A0170|28 36|activity
P10713083A0170|96 100|TraM
P10712599A0349|67 74|pathway
P10711674A0000|134 145|keratoconus
P10711674A0000|112 115|LCA
P10711674A0000|117 120|MIM
P10711674A0000|84 89|Leber
P10710742T0000|32 37|women
P10709705T0000|47 58|information
P10708424A0800|47 66|autophosphorylation
P10708424A0800|109 117|activity
P10708424A0800|70 75|BGLF4
P10706887A1457|146 151|drugs
P10706887A1457|23 32|decreases
P10706887A1457|83 92|lymphomas
P10706887A1457|51 59|function
P10706736A1091|7 15|patients
P10706736A1091|83 92|detection
P10706736A1091|101 108|T cells
P10706736A1091|32 40|melanoma
P10706513A0843|16 25|prognosis
P10706513A0843|51 57|months
P10705783A0433|46 54|chemical
P10705783A0433|66 81|labyrinthectomy
P10705783A0433|86 91|means
P10704975A0479|73 76|min
P10704975A0479|95 100|NOC-5
P10704975A0479|158 171|neurotoxicity
P10704975A0479|186 194|controls
P10704499A0682|122 132|inhibitors
P10704499A0682|215 218|PKC
P10704499A0682|112 120|receptor
P10704499A0682|81 105|fibroblast growth factor
P10704499A0682|253 256|PMA
P10704499A0682|152 171|tyrosine kinase p59
P10704499A0682|107 110|FGF
P10704499A0682|172 175|fyn
P10704338A0354|243 252|structure
P10704338A0354|148 164|proline residues
P10704338A0354|112 123|replication
P10704338A0354|87 89|CA
P10704338A0354|230 233|p24
P10704338A0354|4 9|order
P10704338A0354|69 75|domain
P10704283A0649a|15 17|Mb
P10704283A0649a|31 39|sequence
P10704283A0649a|179 205|IL-4 cytokine gene cluster
P10704283A0649a|49 55|region
P10704283A0649a|69 76|synteny
P10703633A0747|208 211|SEM
P10703633A0747|213 216|min
P10703633A0747|48 58|comparison
P10703633A0747|117 125|duration
P10703633A0747|133 153|irritation sensation
P10703633A0747|201 205|mean
P10703633A0747|237 238|p
P10703633A0747|1 18|Strontium nitrate
P10702794A1495|31 35|ERK2
P10702794A1495|145 158|ERK2 activity
P10702794A1495|172 190|feedback mechanism
P10702794A1495|103 108|model
P10702794A1495|17 21|data
P10702285A0855|244 245|G
P10702285A0855|266 290|GLUT4-EGFP translocation
P10702285A0855|186 206|wortmannin treatment
P10702285A0855|15 27|relationship
P10702285A0855|47 55|function
P10702285A0855|36 37|G
P10702285A0855|38 39|q
P10702241A0357|144 150|kidney
P10702241A0357|54 59|brain
P10702241A0357|118 123|heart
P10702241A0357|14 24|a1 isoform
P10702241A0357|77 82|liver
P10702241A0357|64 69|heart
P10700262A0000|45 54|interplay
P10700262A0000|18 27|attention
P10699684A0661|14 19|Zelen
P10699684A0661|124 126|M.
P10699684A0661|111 122|institution
P10699684A0661|52 58|number
P10699354A0557|1 14|Reaction time
P10698937T0000|72 78|subset
P10698937T0000|92 97|genes
P10698937T0000|1 6|TIP30
P10696007A1325|89 97|response
P10694609A0309|104 114|filtration
P10694609A0309|63 73|anesthesia
P10694609A0309|188 197|care unit
P10694609A0309|206 211|hours
P10694609A0309|222 231|operation
P10694511A0570|90 99|phenotype
P10694511A0570|125 133|increase
P10694511A0570|144 159|uptake activity
P10694511A0570|5 15|expression
P10694511A0570|137 139|Ca
P10694189A0469|40 45|curve
P10694189A0469|68 81|noradrenaline
P10693246A0252|125 135|dissection
P10693246A0252|158 180|laryngeal nerve chains
P10692374A1873|74 89|20S proteasomes
P10692374A1873|196 204|proteins
P10692374A1873|296 304|reaction
P10692374A1873|232 251|amino acid residues
P10692374A1873|100 120|nucleotidase complex
P10691972T0000|151 169|resistance protein
P10691972T0000|89 93|MRP2
P10691972T0000|108 118|regulation
P10691972T0000|37 43|region
P10691972T0000|173 177|MRP3
P10690725A1037|30 34|PRFR
P10688666A1010|14 23|mechanism
P10688666A1010|56 60|part
P10688661A0237|30 39|REST/NRSF
P10688661A0237|210 215|genes
P10688661A0237|88 97|mutations
P10688661A0237|155 162|mutants
P10688646A0535|193 212|expression analysis
P10688646A0535|176 188|footprinting
P10688646A0535|66 83|HS-40 mutants cis
P10687945A0000|45 52|infants
P10687855T0000|106 125|zinc finger domains
P10687855T0000|142 151|rat Zn-15
P10687366A0000|45 53|abortion
P10687366A0000|133 138|weeks
P10687366A0000|1 23|National abortion laws
P10684941A0722|133 137|side
P10684941A0722|145 149|nick
P10684941A0722|5 16|requirement
P10684646A0224|73 79|growth
P10684646A0224|25 34|mechanism
P10684646A0224|98 108|expression
P10684304A1242|25 26|U
P10684265T0000|30 60|transactivator protein IE2-p86
P10684265T0000|89 100|conjugation
P10684265T0000|129 144|proteins SUMO-1
P10684097A0175|120 131|ovariectomy
P10684097A0175|107 118|ovariectomy
P10684097A0175|66 72|groups
P10684097A0175|81 95|sham operation
P10683989A0251|60 69|increases
P10683989A0251|73 77|PaO2
P10683989A0251|128 142|Qs/Q tau ratio
P10683989A0251|82 86|SaO2
P10683989A0251|116 124|decrease
P10683244X2359|16 30|Academic Press
P10683244A0939|208 209|R
P10683244A0939|58 65|mixture
P10683244A0939|213 217|NBF2
P10683244A0939|203 207|NBF1
P10683244A0939|18 22|NBF1
P10682570A0453|42 48|points
P10682570A0453|1 4|LPO
P10681588A0899b|88 95|complex
P10681588A0899b|270 277|complex
P10681588A0899b|297 306|factor Y.
P10681588A0899b|53 55|C6
P10681588A0899b|255 264|CCAAT-box
P10681588A0899b|79 82|CRE
P10681588A0899b|40 44|PC12
P10681588A0899b|140 143|ATF
P10681562A0263|108 123|mutant receptor
P10681562A0263|16 37|PPARgamma antagonists
P10679922A1110|12 21|mutations
P10679922A1110|127 138|neck cancer
P10679922A1110|118 122|head
P10679649A0311|210 215|years
P10679649A0311|55 66|outpatients
P10679649A0311|118 134|cyclophosphamide
P10679649A0311|72 88|breast carcinoma
P10679649A0311|231 236|years
P10679649A0311|136 148|methotrexate
P10679065A1217|31 78|junB promoter/chloramphenicol acetyltransferase
P10679065A1217|130 138|SB203580
P10679065A1217|1 11|Activation
P10679015A0216|14 18|view
P10679015A0216|106 114|proteins
P10679015A0216|67 74|snoRNPs
P10679015A0216|99 102|set
P10677214A2842|195 206|site region
P10677214A2842|12 19|changes
P10677214A2842|128 140|loop I-helix
P10677214A2842|143 148|motif
P10675610A0279|79 101|cell cycle progression
P10675610A0279|64 74|apopotosis
P10675610A0279|49 62|transcription
P10675154T0000|9 16|potency
P10674395A0262|56 60|gene
P10674395A0262|82 94|neuropeptide
P10674395A0262|96 100|GnRH
P10674395A0262|38 48|expression
P10674395A0262|204 218|protein kinase
P10673335X0782|16 30|Academic Press
P10672433A0199|247 253|person
P10672433A0199|21 26|diary
P10672433A0199|154 165|sleep onset
P10672433A0199|187 196|awakening
P10672433A0199|74 83|wake time
P10672433A0199|167 171|WASO
P10672433A0199|110 120|efficiency
P10672433A0199|143 147|wake
P10672433A0199|174 183|alertness
P10672433A0199|235 240|alarm
P10671554A0492|198 215|Edman degradation
P10671554A0492|53 59|bovine
P10671554A0492|175 183|sequence
P10671519A0641|198 209|polypeptide
P10671519A0641|131 141|LEM module
P10671519A0641|216 222|emerin
P10671519A0641|1 26|Protein sequence analysis
P10669751T0000|28 61|protein kinase signaling pathways
P10669751T0000|97 111|c-jun promoter
P10669633A0391|46 56|mechanisms
P10669633A0391|82 92|expression
P10669633A0391|136 147|THP-1 cells
P10669594A0969|11 19|contrast
P10669594A0969|23 27|AgfA
P10669319A1722|104 109|trial
P10669319A1722|95 100|phase
P10669319A1722|69 77|patients
P10667597A0668|80 84|gene
P10667597A0668|1 4|ZK7
P10666253A1291|65 76|tRNA primer
P10666253A1291|101 104|PBS
P10666222A0330|111 128|survivin proteins
P10666222A0330|87 96|existence
P10665798A0598|150 177|D. russelli venom injection
P10665798A0598|122 143|lactate dehydrogenase
P10665798A0598|76 96|alkaline phosphatase
P10665798A0598|218 231|tissue damage
P10665798A0598|4 12|increase
P10664876A0000|149 173|corticosteroid molecules
P10664876A0000|264 274|acetonides
P10664876A0000|334 340|esters
P10664876A0000|87 108|corticosteroid series
P10664876A0000|224 231|group A
P10664876A0000|131 145|classification
P10664876A0000|233 252|hydrocortisone type
P10664876A0000|1 11|Patch test
P10662614A0972|72 78|HC-Pro
P10662614A0972|59 64|genes
P10662614A0972|116 128|interactions
P10662614A0972|84 86|P3
P10662550A0679|94 109|ATR-16 patients
P10662550A0679|22 36|candidate gene
P10660604A0748|10 26|CARbeta/RXRalpha
P10660604A0748|37 50|transcription
P10660069A0819|73 77|PBS2
P10660069A0819|5 23|rrd1,2delta mutant
P10660069A0819|49 61|inactivation
P10658445A0208|122 138|treatment cycles
P10658445A0208|214 228|prostaglandins
P10658445A0208|143 147|year
P10658445A0208|21 26|group
P10658445A0208|85 109|PGE1 alpha-ciclodestrina
P10657899A0685|72 79|PKCzeta
P10657899A0685|52 68|oligonucleotides
P10657899A0685|114 118|AP-1
P10657899A0685|1 13|Pretreatment
P10657238A0541|60 66|region
P10657238A0541|89 99|mStaf gene
P10657238A0541|176 184|fragment
P10657238A0541|1 25|Transfection experiments
P10656161A0316|132 142|AUC values
P10656161A0316|9 13|MMBI
P10656161A0316|1 4|MBI
P10655230A0685|122 128|domain
P10655230A0685|77 86|sequences
P10654032A1133|25 42|compression ratio
P10654032A1133|1 5|JPEG
P10653697A0133|88 96|sequence
P10653697A0133|1 7|Actins
P10653693A0429|78 100|KAP-1-RBCC interaction
P10653693A0429|116 126|components
P10653400A0000|5 18|applicability
P10653400A0000|35 52|donor nephrectomy
P10652800A0984|126 129|age
P10652800A0984|144 152|duration
P10652800A0984|172 186|insulin dosage
P10652800A0984|65 73|patients
P10652800A0984|156 164|diabetes
P10652800A0984|222 225|BMI
P10652324A0177|31 47|collagen binding
P10652102A0620|26 32|dosage
P10652102A0620|86 103|Ty1 transposition
P10651805T0000|95 114|folate accumulation
P10651805T0000|127 141|leukemia cells
P10651076T0000|44 49|lungs
P10651076T0000|78 87|arthritis
P10651076T0000|53 61|patients
P10650939A1542|105 115|activation
P10650939A1542|41 62|progesterone receptor
P10650939A1542|129 133|luc3
P10650939A1542|119 128|PGDH-2368
P10650938T0000|24 26|ER
P10650938T0000|97 110|trout ER gene
P10649738A0953|73 82|episode/3
P10649738A0953|65 69|CAPD
P10649738A0953|17 28|peritonitis
P10649449A0413|164 171|binding
P10649449A0413|107 116|organisms
P10649449A0413|129 152|amino acid conservation
P10649449A0413|48 71|squalene synthase genes
P10649449A0413|186 193|domains
P10648489A1117|79 97|segment depression
P10648489A1117|52 61|reduction
P10648489A1117|1 10|Treatment
P10648020A0151|244 252|patients
P10648020A0151|59 95|factors tissue plasminogen activator
P10648020A0151|115 127|tPA capacity
P10648020A0151|133 164|plasminogen activator inhibitor
P10648020A0151|97 100|tPA
P10648020A0151|168 173|PAI-1
P10648020A0151|1 8|METHODS
P10647817T0000|14 19|cDNAs
P10647817T0000|89 93|PTA1
P10647817T0000|1 10|Isolation
P10647177A0599|163 167|base
P10647177A0599|5 16|RNA aptamer
P10647177A0599|70 76|bulges
P10646820T0000|122 131|carcinoma
P10646820T0000|59 70|lymph nodes
P10646820T0000|5 9|case
P10645921A0000|61 69|disorder
P10645921A0000|84 96|morphologies
P10644760A0000|25 36|maintenance
P10644760A0000|5 20|differentiation
P10644760A0000|139 148|machinery
P10644414T0000|29 39|regulation
P10644414T0000|65 96|mosquito ultraspiracle isoforms
P10643313A0345|91 107|micrograms rt-PA
P10643313A0345|7 26|i.v. administration
P10643313A0345|115 117|ml
P10643313A0345|119 122|BSS
P10642531A2322|86 107|RGD recognition sites
P10641688A0341|44 57|abnormalities
P10641688A0341|27 32|spine
P10640734A0190|91 103|phosphatases
P10640734A0190|6 30|tyrosine phosphorylation
P10640734A0190|38 43|ITIMs
P10640734A0190|51 60|molecules
P10640683A0670|61 71|expression
P10640683A0670|125 153|rat insulin promoter element
P10640683A0670|248 252|form
P10640683A0670|256 259|PKN
P10640683A0670|75 87|NDRF/NeuroD2
P10640683A0670|11 30|transfection assays
P10640683A0670|102 117|transactivation
P10639585A0157|58 67|mechanism
P10639585A0157|1 8|Studies
P10637337A0545|62 71|mutations
P10637230A0332|60 73|proliferation
P10637230A0332|109 113|IFNs
P10637230A0332|97 105|response
P10635209A0419|11 23|conditioning
P10635209A0419|34 38|coat
P10633499A1306|159 169|transition
P10633499A1306|87 98|distinction
P10633499A1306|51 58|synonym
P10630630A0614|79 87|increase
P10630630A0614|48 51|PKC
P10629938A1352|95 104|apparatus
P10629938A1352|43 59|GFP-POLO protein
P10629938A1352|23 35|distribution
P10629938A1352|170 181|development
P10629035A0827|181 188|defects
P10629035A0827|77 83|strand
P10629035A0827|53 62|extension
P10629035A0827|154 172|cdc17/pol1 mutants
P10628971A0824|167 193|dynamin family member VPS1
P10628971A0824|147 150|VPS
P10628971A0824|5 15|collection
P10628971A0824|38 41|TGN
P10628971A0824|50 57|defects
P10628750T0000|73 122|angiotensinogen gene acute-phase response element
P10628750T0000|144 151|pathway
P10628750T0000|32 38|factor
P10628748A0746|74 81|element
P10628748A0746|131 152|cAMP-response element
P10628748A0746|83 93|TCA GGGCCA
P10628748A0746|1 9|Deletion
P10628490T0000|1 8|Anatomy
P10627532A0739|151 161|activation
P10627532A0739|26 27|R
P10627532A0739|130 145|phosphorylation
P10627532A0739|179 204|transcription factor ATF2
P10627532A0739|81 88|protein
P10625721T0101|41 52|Study Group
P10625721T0101|1 12|Hypothermia
P10625494A1059|90 104|HL60/VCR cells
P10625494A1059|29 40|CAAT-region
P10624787A0432|147 148|P
P10624787A0432|54 62|patients
P10624787A0432|118 133|blood pressures
P10624787A0432|186 188|DM
P10624787A0432|135 136|P
P10624787A0432|237 252|waist-hip ratio
P10624787A0432|171 175|case
P10623758A0947|28 29|%
P10623758A0947|177 183|months
P10623758A0947|33 40|neurons
P10623758A0947|118 124|number
P10622574A0000|74 83|childhood
P10622574A0000|126 127|%
P10622574A0000|5 15|prevalence
P10622574A0000|38 41|HCV
P10620335A0749|63 73|CV-1 cells
P10620335A0749|21 24|AHR
P10619353T0000|151 158|COUP-TF
P10619353T0000|76 87|interaction
P10619353T0000|38 72|estrogen response element sequence
P10619169A0411|52 62|orchimetry
P10619169A0411|71 82|time period
P10618645A0750|75 79|CalC
P10618645A0750|22 26|AP-1
P10618645A0750|1 18|Maximum induction
P10617232A0393|78 93|liver histology
P10617232A0393|36 49|liver enzymes
P10617232A0393|1 14|Serum HBV-DNA
P10617126A1005|73 78|group
P10617126A1005|124 127|CA1
P10617126A1005|141 145|rats
P10617126A1005|48 52|loss
P10617126A1005|187 191|area
P10617126A1005|255 260|group
P10614857A0584|241 242|P
P10614857A0584|61 69|children
P10614857A0584|115 118|IFN
P10614857A0584|105 111|yields
P10614857A0584|193 194|P
P10614857A0584|204 215|coronavirus
P10614857A0584|1 19|Leukocyte cultures
P10613874A0663|13 23|sequencing
P10613874A0663|177 181|GlnR
P10613874A0663|146 154|proteins
P10613874A0663|50 54|pepX
P10613874A0663|68 76|presence
P10613843A0107|90 95|genes
P10613843A0107|130 142|ion channels
P10613843A0107|17 25|products
P10612918A0318|5 13|problems
P10612773A1210|14 26|Serum levels
P10612773A1210|53 60|markers
P10612773A1210|84 92|outcomes
P10612044A1180|107 136|transcription initiation site
P10612044A1180|145 154|Aal-rpL34
P10612044A1180|50 67|AP-4 binding site
P10611320A0816|122 135|Cak1p protein
P10611320A0816|84 88|CAK1
P10611235A1927|166 181|plasma membrane
P10611235A1927|41 46|model
P10611235A1927|97 106|betagamma
P10611235A1927|140 158|Ste5p-MAPK cascade
P10611225A1127|30 41|interaction
P10611225A1127|167 173|region
P10611225A1127|77 83|eIF4GI
P10611225A1127|7 11|data
P10611225A1127|141 146|eIF4A
P10608893A0727|28 32|Hp55
P10608893A0727|124 127|DNA
P10608893A0727|76 87|specificity
P10607900T0000|47 57|regulation
P10607566A0880|31 43|beta-catenin
P10607566A0880|161 164|RXR
P10607566A0880|22 29|finding
P10607566A0880|140 159|retinoid X receptor
P10607566A0880|86 89|RAR
P10606515A0389|74 95|acid receptor element
P10606515A0389|109 114|DNase
P10606515A0389|117 126|footprint
P10606245A0906|30 33|ROS
P10606245A0906|41 59|osteosarcoma cells
P10606245A0906|71 81|repression
P10606245A0906|1 15|Overexpression
P10604583T0000|75 89|Wilson disease
P10604583T0000|166 177|elimination
P10604583T0000|40 46|copper
P10604583T0000|52 59|patient
P10604583T0000|1 17|Albumin dialysis
P10603349A1667|124 130|somite
P10603349A1667|5 30|signalling molecules Wnt1
P10603349A1667|174 196|Myf5 expression domain
P10603349A1667|69 79|activation
P10602516A0182|14 17|SLK
P10602516A0182|88 93|M-NAP
P10602516A0182|79 86|protein
P10602516A0182|4 12|addition
P10602502A0422|79 87|S phases
P10602502A0422|23 27|Tob2
P10602502A0422|70 75|G0/G1
P10601747A0482|22 35|control words
P10601747A0482|156 160|msec
P10601410A0977|63 76|remyelination
P10601410A0977|96 113|sclerosis lesions
P10601410A0977|4 14|conclusion
P10601410A0977|137 152|conduction time
P10601335A0892|54 59|cells
P10601335A0892|1 15|Redistribution
P10601280A0674|71 92|ST3 promoter activity
P10600171A1066|61 67|result
P10600171A1066|29 43|responsiveness
P10600171A1066|110 129|CYP3A2 DexRE-1 site
P10599013A0505|15 21|deaths
P10598101A0754|106 110|site
P10598101A0754|246 267|maize endosperm cells
P10598101A0754|5 20|mEmBP-1 protein
P10598101A0754|114 125|yeast cells
P10598101A0754|34 47|transcription
P10597317A1156|244 248|LMP1
P10597317A1156|114 126|HD-MyZ cells
P10597317A1156|257 265|RS cells
P10597317A1156|152 158|masses
P10597317A1156|77 81|LMP1
P10597317A1156|69 72|JBD
P10597223A0339|151 180|transcription initiation site
P10597223A0339|132 134|bp
P10597223A0339|76 79|p21
P10597223A0339|23 37|Ras-expression
P10597223A0339|102 108|region
P10596955A1032|123 131|microg/l
P10596955A1032|65 73|microg/l
P10596955A1032|138 144|Immuno
P10594903A0000|135 152|warfare agents GA
P10594903A0000|198 208|laboratory
P10594903A0000|158 160|HD
P10594903A0000|154 156|GB
P10594903A0000|50 53|RNP
P10594239A0614|43 51|Chr 1q31
P10594239A0614|142 146|Tih1
P10594239A0614|21 30|mouse Chr
P10594239A0614|187 194|alleles
P10593950A1113|13 16|WT1
P10593950A1113|77 79|U5
P10593950A1113|42 56|chromatography
P10593950A1113|4 11|summary
P10592824A1157|120 124|dose
P10592824A1157|213 221|children
P10592824A1157|18 27|frequency
P10592824A1157|154 155|%
P10592824A1157|199 200|%
P10592824A1157|282 283|P
P10592824A1157|67 72|rates
P10592824A1157|308 318|trend test
P10592791A0370|95 103|SET-RPLA
P10592791A0370|263 275|SET-RPLA kit
P10592791A0370|20 29|TECRA kit
P10592791A0370|81 88|strains
P10592791A0370|192 196|lack
P10592791A0370|401 405|lack
P10592791A0370|471 480|screening
P10592791A0370|232 236|time
P10592791A0370|174 182|SE types
P10592791A0370|409 416|ability
P10592791A0370|68 70|SE
P10591976A0317|79 84|total
P10591976A0317|21 29|LWS p.a.
P10591976A0317|48 52|Ward
P10591976A0317|1 13|Measurements
P10591633A0138|46 57|recognition
P10591633A0138|197 208|recognition
P10591633A0138|112 116|view
P10591633A0138|174 178|role
P10591633A0138|216 231|membrane fusion
P10590092A0124|10 20|mechanisms
P10589562A1208|14 20|result
P10589562A1208|4 8|part
P10589562A1208|70 82|BB resonator
P10587576A0596|106 122|SH3GL pseudogene
P10587576A0596|7 11|REPs
P10587576A0596|16 24|clusters
P10587460A0302|215 223|bacteria
P10587460A0302|58 62|hVDR
P10587460A0302|53 56|VDR
P10587460A0302|114 122|Delta134
P10587460A0302|134 142|Delta102
P10587460A0302|67 73|series
P10587460A0302|100 112|hVDR mutants
P10586115A0477|121 125|IL-6
P10586115A0477|246 251|% FCS
P10586115A0477|234 242|cultures
P10586115A0477|156 162|PKCeta
P10586115A0477|86 94|IL-1beta
P10586074A0129|90 113|envelope glycoprotein E
P10586074A0129|29 35|series
P10586074A0129|77 82|forms
P10586074A0129|39 57|plasmid constructs
P10585491A0945|421 430|cytokinin
P10585491A0945|398 407|seedlings
P10585491A0945|55 58|CBF
P10585491A0945|184 192|extracts
P10585491A0945|226 235|seedlings
P10585491A0945|348 356|extracts
P10585491A0945|4 29|gel mobility shift assays
P10585491A0945|139 145|tissue
P10585480A0157|29 39|SH3 domain
P10585480A0157|95 98|Ras
P10585480A0157|103 106|Rac
P10585453A1029|166 170|role
P10585453A1029|78 93|gene activation
P10585453A1029|175 180|Pit-1
P10585417A1412|149 157|function
P10585417A1412|127 131|PRLr
P10585417A1412|100 104|PRLr
P10585311A0494|15 20|types
P10585311A0494|121 126|onset
P10585311A0494|77 80|age
P10585311A0494|54 57|age
P10585311A0494|70 75|onset
P10585311A0494|84 93|diagnosis
P10584138T0001|73 77|head
P10584138T0001|21 31|amifostine
P10584138T0001|35 47|radiotherapy
P10580438A0508|104 109|bands
P10580438A0508|123 131|extracts
P10580438A0508|42 46|EMSA
P10580438A0508|54 77|GLUT4 repressor element
P10579722T0000|44 47|MBS
P10579722T0000|52 70|myosin phosphatase
P10579722T0000|35 42|subunit
P10578528A0730|146 160|symptomatology
P10578528A0730|58 61|EEG
P10578528A0730|81 90|character
P10576177A0308|91 100|prognoses
P10576177A0308|82 87|range
P10575545A0147|29 40|CAAT motifs
P10574992A0901|13 24|E1A binding
P10574992A0901|56 64|increase
P10574992A0901|33 41|p300/CBP
P10574992A0901|68 88|PARP enzyme activity
P10574929A0583|48 62|P-CIP2 protein
P10573781A0631|72 83|chromosomes
P10573781A0631|101 112|chromosomes
P10573781A0631|1 8|Studies
P10572131A0000|87 103|nasFEDCBA operon
P10572087A0326|76 81|FANCC
P10572087A0326|20 35|binding partner
P10572087A0326|103 112|screening
P10571047A1009|9 12|7SL
P10571047A1009|141 143|kb
P10570262A0000|15 22|T cells
P10570262A0000|31 34|TCR
P10570262A0000|80 86|number
P10568728A1445|14 35|serum creatine kinase
P10568728A1445|72 77|ESWIB
P10568728A1445|101 105|week
P10568275A0679|13 22|transport
P10568275A0679|43 51|Kara Sea
P10568275A0679|5 9|role
P10567582A1334|15 20|CtBP1
P10567582A1334|8 13|mouse
P10567582A1334|39 45|embryo
P10567538A1028|108 127|activation function
P10567538A1028|4 12|addition
P10567538A1028|48 52|p300
P10567524T0000|5 26|elm1 kinase functions
P10566862A0000|13 24|Measurement
P10566862A0000|166 175|imbalance
P10566862A0000|179 189|strabismus
P10566862A0000|142 150|patients
P10566862A0000|84 108|depth stereoacuity tests
P10564939A0981|63 67|data
P10564939A0981|48 53|study
P10564593A0428|61 75|rearrangements
P10564593A0428|20 30|chromosome
P10564593A0428|86 96|chromosome
P10564593A0428|102 116|MCF-7 AdVp3000
P10564484A0859|181 185|site
P10564484A0859|148 156|function
P10564484A0859|52 56|gene
P10564484A0859|32 44|binding site
P10564474T0000|75 102|outer-membrane protein OprH
P10564474T0000|11 21|homologues
P10564280A0140|62 69|YT521-B
P10564280A0140|228 233|Sam68
P10564280A0140|53 60|protein
P10563836A1234|14 35|AP-2 binding activity
P10563836A1234|65 75|T47D cells
P10563836A1234|81 94|Western blots
P10563605A0773|13 18|trend
P10563605A0773|110 111|p
P10563605A0773|64 69|nerve
P10563605A0773|100 101|r
P10562495A0188|30 38|homologs
P10562495A0188|56 72|Chordopoxvirinae
P10562495A0188|161 166|virus
P10562418A0238|19 25|events
P10561460A0615|109 113|cDNA
P10561460A0615|5 22|GPI anchor moiety
P10561460A0615|157 177|GPI signal sequences
P10561153A0225|75 78|SSc
P10561153A0225|22 31|carcinoma
P10561153A0225|154 159|month
P10560997A1072|60 66|method
P10560997A1072|83 92|ovulation
P10560997A1072|34 43|LH levels
P10559364A0846|92 120|DNA replication compartments
P10559364A0846|216 219|SSB
P10559364A0846|221 225|UL57
P10559364A0846|195 214|DNA binding protein
P10559364A0846|9 14|Towne
P10559364A0846|4 8|HCMV
P10559364A0846|136 166|polymerase processivity factor
P10559320A0080|28 30|1a
P10559320A0080|80 92|protein nsP1
P10559320A0080|137 141|RNAs
P10559207A0207|47 67|APS kinase reactions
P10559207A0207|94 101|enzymes
P10559207A0207|126 131|genes
P10559207A0207|234 240|enzyme
P10559207A0207|187 193|course
P10557072A1218|108 113|cells
P10557072A1218|7 14|results
P10557072A0127|74 80|kinase
P10557072A0127|82 86|ULK1
P10556751A0758|62 65|HGV
P10556751A0758|40 58|transmission rates
P10556751A0758|157 163|hazard
P10556751A0758|187 192|staff
P10556263A1035|90 92|AC
P10556263A1035|99 104|space
P10556089A0901|150 166|muscle component
P10556089A0901|47 65|muscle development
P10556089A0901|131 141|processing
P10556089A0901|24 29|etr-1
P10556089A0901|69 79|C. elegans
P10556046A0328|104 108|side
P10556046A0328|116 130|Xenopus embryo
P10556033A0000|133 139|domain
P10556033A0000|5 23|RFX protein family
P10556033A0000|33 40|members
P10556028A0292|31 37|region
P10556028A0292|176 180|BD-1
P10556028A0292|126 130|Prep
P10556028A0292|96 105|structure
P10556028A0292|156 174|RepA binding sites
P10555285A1065|177 186|mechanism
P10555285A1065|234 248|globin cluster
P10555285A1065|84 106|FUT3-FUT5-FUT6 cluster
P10554946A0082|29 47|clomiphene citrate
P10554946A0082|162 169|actions
P10554946A0082|22 27|SERMS
P10554946A0082|112 122|raloxifene
P10554946A0082|189 193|bone
P10554946A0082|103 108|drugs
P10553551A0000|1 21|Factor XI deficiency
P10551879T0000|79 91|living cells
P10551879T0000|22 44|protein kinase binding
P10551879T0000|155 178|protein fusion proteins
P10551848A0000|30 32|Y.
P10551848A0000|77 79|D.
P10551848A0000|52 56|Tada
P10551848A0000|48 50|K.
P10551796T0000|15 34|HIV-1 transcription
P10550574A1038|31 41|toxicities
P10550574A1038|43 51|diarrhea
P10550574A1038|76 102|serum alkaline phosphatase
P10550574A1038|53 62|infection
P10550139A0191|14 21|METHODS
P10550139A0191|142 150|patients
P10550139A0191|116 121|crest
P10550139A0191|50 63|prostatectomy
P10549354A2371|31 43|deregulation
P10549354A2371|9 19|mechanisms
P10549354A2371|101 109|melanoma
P10548722A0099|72 86|TcP2beta genes
P10548722A0099|246 250|gene
P10548722A0099|158 162|SIRE
P10548722A0099|50 54|H1.8
P10548434A1549|27 34|ability
P10548434A1549|97 112|differentiation
P10548434A1549|38 45|polyoma
P10545248A0567|176 191|muscle lineages
P10545248A0567|65 78|binding sites
P10545248A0567|18 26|enhancer
P10544113A0293|61 68|portion
P10544113A0293|96 106|U3 segment
P10544113A0293|1 30|EIAV LTR sequence variability
P10544088A0308|47 52|PRDII
P10544088A0308|57 60|CAT
P10544088A0308|82 95|transcription
P10543949A0686|74 80|cavity
P10543949A0686|20 22|S1
P10543728A0358|142 147|cells
P10543728A0358|80 102|DNA binding activities
P10543728A0358|156 165|E1A cells
P10543270A1054|89 92|ppb
P10543270A1054|109 118|discharge
P10543270A1054|9 29|i.v. steroid therapy
P10543270A1054|136 137|p
P10542281A0382|15 20|G1-G2
P10542281A0382|113 125|proteoglycan
P10542281A0382|50 62|link protein
P10542281A0382|153 162|G1 domain
P10542274A1376|131 148|promoter activity
P10542274A1376|33 49|protein kinase A
P10542274A1376|51 54|PKA
P10542260A0832|97 106|receptors
P10542260A0832|33 41|activity
P10542237A0357|135 153|lipopolysaccharide
P10542237A0357|93 101|response
P10542237A0357|190 204|IL-6 secretion
P10542237A0357|118 125|stimuli
P10541550A0487|165 179|follicle cells
P10541550A0487|43 47|ACE3
P10541550A0487|7 25|immunolocalization
P10540915A0697|91 95|n.s.
P10540915A0697|10 22|transsection
P10540915A0697|53 58|TL&PL
P10540292A1179|166 174|response
P10540292A1179|79 87|regulons
P10540292A1179|95 99|cell
P10540292A1179|113 124|possibility
P10536788A0931|15 26|overfeeding
P10536788A0931|104 118|control livers
P10536788A0931|36 47|PL profiles
P10536788A0931|139 141|PL
P10536369A0662|56 86|VDR-TR heterodimer interaction
P10536369A0662|4 29|gel mobility shift assays
P10535715A0268|151 157|phases
P10535715A0268|67 68|F
P10535715A0268|142 149|kJ/24 h
P10535715A0268|5 8|RMR
P10534402A0659|72 90|testis development
P10534402A0659|20 42|hybridization analyses
P10534402A0659|237 252|pachytene stage
P10534402A0659|204 216|accumulation
P10534402A0659|220 224|mRNA
P10534048A0297|183 195|transmission
P10534048A0297|11 20|algorithm
P10534048A0297|83 94|calculation
P10534048A0297|138 141|ACF
P10533066A0758|75 91|splice mutations
P10533066A0758|53 63|insertions
P10532805A0792|97 102|nrg-1
P10532805A0792|83 93|expression
P10532805A0792|16 35|nerve growth factor
P10531446A0203|63 74|ErbB family
P10531446A0203|78 103|receptor tyrosine kinases
P10531446A0203|48 55|members
P10531342A1111|149 174|promastigote cell surface
P10531342A1111|67 84|ppg1 gene product
P10531340A1275|30 32|J.
P10531340A1275|5 16|Fleischmann
P10531340A1275|1 3|R.
P10529354A0375|104 117|P28 complexes
P10529354A0375|27 34|complex
P10529354A0375|82 85|20S
P10529354A0375|5 15|proteasome
P10529198A0068|89 96|ras-GRF
P10529198A0068|102 105|Sos
P10527475A0643|36 46|inclusions
P10527475A0643|51 58|grooves
P10527180A0869|182 203|% confidence interval
P10527180A0869|430 447|survival interval
P10527180A0869|114 122|analysis
P10527180A0869|291 298|absence
P10527180A0869|595 601|system
P10527180A0869|492 498|months
P10527180A0869|166 172|hazard
P10527180A0869|97 100|Cox
P10527180A0869|369 381|chemotherapy
P10527180A0869|508 512|% CI
P10527180A0869|150 155|years
P10527180A0869|695 700|sites
P10527180A0869|628 651|approaches significance
P10527180A0869|262 263|%
P10527180A0869|463 472|treatment
P10527180A0869|132 135|age
P10527180A0869|559 563|% CI
P10527180A0869|66 70|risk
P10527180A0869|273 277|% CI
P10527180A0869|611 615|% CI
P10527106A0384|132 139|deficit
P10527106A0384|25 38|preponderance
P10527106A0384|143 147|need
P10527106A0384|1 10|OBJECTIVE
P10526670A0236|12 21|uncapping
P10526670A0236|58 67|plus-ends
P10526670A0236|25 40|actin filaments
P10526670A0236|116 120|PIP2
P10526670A0236|102 114|bisphosphate
P10524258T0000|66 81|gene expression
P10524258T0000|98 120|muscle differentiation
P10523674A0000|107 122|DNA replication
P10523674A0000|138 155|S rRNA processing
P10523674A0000|16 50|ribonucleoprotein endoribonuclease
P10523647A1001|62 80|C/EBP target genes
P10523647A1001|7 11|CHOP
P10523640A0367|90 100|activation
P10523640A0367|149 157|tyrosine
P10523640A0367|188 193|Stat3
P10523640A0367|55 76|Stat3 phosphorylation
P10523520A0986|73 78|phyla
P10523520A0986|39 47|homologs
P10521796A0872|120 130|metaplasia
P10521796A0872|29 32|age
P10521796A0872|214 221|atrophy
P10521796A0872|288 291|DYS
P10521796A0872|226 242|neck hyperplasia
P10521796A0872|132 134|IM
P10521796A0872|347 349|SG
P10521796A0872|196 198|IM
P10521796A0872|310 318|subjects
P10521796A0872|371 380|gastritis
P10521509A0000|211 215|RGS7
P10521509A0000|63 66|DEP
P10521509A0000|217 221|RGS9
P10521509A0000|15 34|G protein signaling
P10521509A0000|192 209|RGS proteins RGS6
P10521509A0000|109 124|G protein gamma
P10521509A0000|36 39|RGS
P10521509A0000|1 11|Regulators
P10521447A1190|64 83|AML1-ETO repression
P10521443A0486|211 217|A32/36
P10521443A0486|161 175|overexpression
P10521443A0486|6 12|effect
P10521443A0486|114 134|NF-kappaB activation
P10521443A0486|235 249|overexpression
P10520800A0307|131 147|echocardiography
P10520800A0307|36 44|patients
P10520800A0307|70 73|age
P10520800A0307|50 54|HOCM
P10520800A0307|152 169|electrocardiogram
P10518956A0137|90 99|mediators
P10518956A0137|58 67|cytokines
P10518956A0137|197 214|deiodinase system
P10518956A0137|115 120|level
P10518956A0137|50 54|part
P10518822A1037|127 135|activity
P10518822A1037|143 170|CCR3 receptor ligand system
P10518822A1037|19 27|findings
P10518822A1037|204 210|asthma
P10518561A0261|140 147|enzymes
P10518561A0261|19 29|regulators
P10518496A0952|79 86|embryos
P10518496A0952|190 201|development
P10518496A0952|1 12|Aggregation
P10517672A1417|41 77|alpha1-globin promoter-CAT construct
P10517672A1417|131 135|CTF1
P10517672A1417|235 247|CAT activity
P10517672A1417|16 24|fragment
P10517672A1417|205 213|proteins
P10516878T0000|104 107|PET
P10516878T0000|95 100|study
P10516878T0000|50 59|pergolide
P10516072A0146|11 13|F.
P10516011A0471|90 101|mutagenesis
P10516011A0471|8 12|work
P10516011A0471|53 70|mass spectrometry
P10514493A0199|45 72|N1E-115 neuroblastoma cells
P10514493A0199|26 41|differentiation
P10514493A0199|92 102|expression
P10513756A0584|120 139|selection criterion
P10513756A0584|27 31|bias
P10513756A0584|5 8|EPV
P10512857A0000|73 80|nucleus
P10512857A0000|58 65|signals
P10512857A0000|4 17|Wnt signaling
P10512857A0000|19 31|beta-catenin
P10512699A0364|209 220|translation
P10512699A0364|109 133|selenocysteine insertion
P10512699A0364|93 97|mRNA
P10512699A0364|6 15|machinery
P10512699A0364|156 160|opal
P10511216A0654|43 47|kink
P10511216A0654|1 12|CONCLUSIONS
P10510295A0606|149 158|GLK1 gene
P10510295A0606|126 141|promoter region
P10510295A0606|66 75|TA repeat
P10508522A1598|58 66|EWS-FLI1
P10508522A1598|5 12|results
P10506143A0610|148 158|activators
P10506143A0610|261 268|Cdc42Hs
P10506143A0610|20 45|JNKK2-JNK1 fusion protein
P10506143A0610|198 212|UV irradiation
P10506143A0610|65 77|JNK activity
P10506143A0610|4 14|HeLa cells
P10506143A0610|136 143|stimuli
P10505694A0000|104 120|interferon-gamma
P10505694A0000|29 37|cytokine
P10505694A0000|148 159|enhancement
P10505694A0000|177 189|cytotoxicity
P10505694A0000|1 15|Interleukin-12
P10503812A1450|30 35|study
P10503812A1450|160 163|age
P10503812A1450|39 50|cyclosporin
P10503812A1450|99 119|allograft recipients
P10503812A1450|138 141|age
P10502522A0000|147 157|cell lines
P10502522A0000|37 63|T-cell leukemia virus type
P10502434A0367|133 152|vault brachytherapy
P10502434A0367|6 14|February
P10502434A0367|66 75|carcinoma
P10502402A0129|134 139|TRAIL
P10502402A0129|161 162|T
P10502402A0129|117 128|possibility
P10502402A0129|204 214|regulation
P10501969A1329|26 32|GATA-5
P10501969A1329|146 159|cardiogenesis
P10501936T0000|128 135|defects
P10501936T0000|172 182|morphology
P10501936T0000|116 119|RIP
P10501936T0000|1 13|Inactivation
P10501034A0839|135 141|manner
P10501034A0839|46 50|hmg1
P10501034A0839|217 224|embryos
P10501034A0839|1 31|Ribonuclease protection assays
P10499121A0542|56 75|Class D instruments
P10499121A0542|22 39|hearing aid users
P10499121A0542|115 119|time
P10498706A1219|124 128|KdgR
P10498706A1219|21 25|data
P10498706A1219|64 79|pelE expression
P10498616A0157|215 219|IL-4
P10498616A0157|178 185|absence
P10498616A0157|18 23|M-Ras
P10498616A0157|106 139|mast cell/megakaryocyte cell line
P10498616A0157|234 251|expression levels
P10498616A0157|275 281|growth
P10497800A0000|120 127|bulimia
P10497800A0000|107 115|anorexia
P10497800A0000|5 11|MMPI-A
P10497800A0000|68 76|McKinley
P10497199A0559|11 17|screen
P10497199A0559|176 185|COUP-TFII
P10497199A0559|115 132|chicken ovalbumin
P10496553A1004|135 143|patients
P10496553A1004|198 205|percent
P10496553A1004|158 183|immunodeficiency syndrome
P10496553A1004|81 88|percent
P10496553A1004|50 57|percent
P10496388A1956a|104 110|events
P10496388A1956a|80 85|J/cm2
P10496388A1956a|68 72|dose
P10496284A0115|28 36|episodes
P10496284A0115|72 75|IgG
P10496284A0115|54 70|immunoglobulin G
P10496284A0115|119 128|IgG index
P10495573A0365|164 165|%
P10495573A0365|195 205|acceptance
P10495573A0365|133 143|sildenafil
P10495573A0365|7 17|sildenafil
P10495573A0365|157 158|%
P10495573A0365|101 108|studies
P10493580A1126|26 30|part
P10493580A1126|77 90|stabilization
P10493580A1126|98 114|transition state
P10493203T0000|12 17|value
P10493203T0000|94 107|abnormalities
P10493203T0000|119 122|ECG
P10492127A0914|150 153|min
P10492127A0914|72 109|cholecystokinin-A receptor antagonist
P10492127A0914|128 136|mg/kg/hr
P10492127A0914|116 120|dose
P10491187T0000|109 145|histidine phosphocarrier protein HPr
P10491187T0000|161 170|gene ptsH
P10491187T0000|64 78|identification
P10490955T0000|134 150|thrombospondin-1
P10490955T0000|106 130|protein kinase signaling
P10490955T0000|59 83|T lymphoma cell adhesion
P10490955T0000|1 5|Beta
P10490835T0000|94 103|crosstalk
P10490835T0000|52 62|inhibition
P10490822A1167|25 34|targeting
P10490822A1167|38 45|Ras-GAP
P10490662A0819|30 33|fly
P10490662A0819|10 22|SPT activity
P10490662A0819|98 106|antibody
P10490639A0000|63 77|protein kinase
P10490639A0000|94 101|subunit
P10490639A0000|127 132|roles
P10490639A0000|204 208|Pcls
P10490604A0601|57 62|forms
P10490604A0601|66 69|Fyn
P10490604A0601|71 74|Lck
P10489822T0000|41 53|inflammation
P10489822T0000|21 27|airway
P10488875A0000|105 108|ITW
P10488875A0000|29 37|patients
P10488875A0000|92 103|toe walking
P10488148T0000|132 141|NF-kappaB
P10488148T0000|123 127|AP-1
P10488148T0000|42 52|activation
P10488148A0111|75 84|cytokines
P10488148A0111|192 201|infection
P10488148A0111|112 140|signal transduction pathways
P10488148A0111|36 46|activation
P10488148A0111|50 71|HIV-1 gene expression
P10488129T0058|78 84|intron
P10488129T0058|32 33|S
P10488129T0058|50 57|binding
P10488087A0340|27 32|sites
P10488087A0340|143 171|acetyltransferase constructs
P10488087A0340|101 109|activity
P10488087A0340|34 37|TBE
P10487921A0132|65 70|acids
P10487760A0336|13 19|screen
P10487760A0336|92 105|Xenopus MEF2D
P10487760A0336|128 134|screen
P10487760A0336|4 9|order
P10487753A0788|5 14|injection
P10487753A0788|48 60|Xenopus eggs
P10487307A0768|122 127|order
P10487307A0768|65 79|hydrocortisone
P10487040A0453|45 59|p53 antibodies
P10487040A0453|91 99|reaction
P10487040A0453|35 40|MIB-1
P10485585A0175|43 52|discovery
P10485585A0175|69 82|neurohormones
P10485353T0000|164 174|serosurvey
P10485353T0000|9 38|Haemophilus influenzae type b
P10485353T0000|81 88|infants
P10485353T0000|138 144|France
P10484695A0791|73 81|patients
P10484695A0791|57 68|baseline IQ
P10484695A0791|98 107|disorders
P10483124T0000|147 158|combination
P10483124T0000|127 143|Ac/Ds transposon
P10483124T0000|83 114|Arabidopsis thaliana chromosome
P10483124T0000|1 9|Regional
P10482565A0469|29 38|mutations
P10482516A1158|10 31|transcription results
P10482516A1158|126 135|stem-loop
P10482516A1158|158 183|transcription readthrough
P10482516A1158|81 102|attenuation mechanism
P10479492A0000|62 66|SEER
P10479492A0000|98 111|survival rate
P10479492A0000|49 60|End Results
P10479492A0000|17 29|Surveillance
P10479025A0528|30 37|sources
P10479025A0528|47 65|TF-MUSIC algorithm
P10479025A0528|84 97|target region
P10478844A1604|165 171|effect
P10478844A1604|233 245|coactivators
P10478844A1604|114 125|PPARalphatr
P10478844A1604|48 55|protein
P10478844A1604|1 15|Cotransfection
P10477748A1076|14 18|p193
P10477748A1076|3 10|portion
P10477599T0000|26 33|element
P10477599T0000|179 185|T cell
P10477599T0000|54 75|lymphotactin promoter
P10477583A0000b|72 75|IgG
P10477583A0000b|123 132|mechanism
P10477583A0000b|39 42|BCR
P10477583A0000b|19 37|B cell Ag receptor
P10477545T0000|82 87|entry
P10477545T0000|19 34|pertussis toxin
P10475972A0269|8 12|face
P10475972A0269|20 28|outbreak
P10475972A0269|84 90|deaths
P10474898A0629|132 140|analysis
P10474898A0629|208 216|primates
P10474898A0629|198 204|series
P10474898A0629|126 130|FISH
P10473598A0691|164 170|Skn-1a
P10473598A0691|54 77|transactivation ability
P10473598A0691|174 192|competition assays
P10473598A0691|1 7|Skn-1a
P10472836A0189|42 43|P
P10472836A0189|17 25|BW gains
P10471746A1102|29 45|tryptophan motif
P10471746A1102|83 100|Myogenin promoter
P10471746A1102|117 139|Myogenin transcription
P10471721A0141|147 160|pollen S gene
P10471721A0141|113 116|SLG
P10471721A0141|49 56|S locus
P10471721A0141|118 121|SRK
P10471587A0239|10 17|strains
P10471587A0239|159 173|antimicrobials
P10471587A0239|21 35|C. trachomatis
P10471587A0239|71 84|RT-PCR method
P10471587A0239|290 301|amoxicillin
P10470220A1011|26 39|cutoff-levels
P10470220A1011|159 160|%
P10470220A1011|75 86|specificity
P10470220A1011|128 131|RIA
P10470220A1011|142 153|sensitivity
P10470220A1011|98 110|Protein S100
P10469174A0678|12 29|sequence analysis
P10469174A0678|178 182|MBF1
P10469174A0678|168 174|domain
P10469174A0678|184 191|MBF1CTD
P10468585A0980|148 153|Hap46
P10468585A0980|6 17|DNA binding
P10468585A0980|35 46|enhancement
P10467465T0000|61 73|alternatives
P10467465T0000|5 16|controversy
P10467004A0683|47 51|fact
P10467004A0683|147 155|splicing
P10467004A0683|5 11|intron
P10467004A0683|84 109|EBS2/IBS2 sequence motifs
P10466825T0000|29 35|region
P10466825T0000|39 59|baculovirus p10 mRNA
P10464310A0218|46 63|fibroblast growth
P10464310A0218|11 35|tyrosine phosphorylation
P10464310A0218|229 236|Tyr-463
P10464310A0218|96 101|cells
P10464310A0218|39 42|Crk
P10464310A0218|256 273|complex formation
P10464291A0597|14 19|ng/ml
P10464291A0597|145 151|manner
P10464291A0597|48 58|PDGFalphaR
P10464291A0597|101 111|C/EBPdelta
P10464185T0000|91 123|Streptococcus agalactiae type Ia
P10464185T0000|54 87|polysaccharide biosynthesis genes
P10463057A0534|10 27|expression levels
P10460171A0842|97 116|phosphoryl transfer
P10460171A0842|1 22|Viscosity experiments
P10460171A0842|137 141|rate
P10459809A1262|11 30|matrix distribution
P10458907A0543|63 78|repair proteins
P10458907A0543|108 114|testis
P10457075A1198|151 152|%
P10457075A1198|131 144|peak decrease
P10457075A1198|127 129|Rn
P10457075A1198|65 73|increase
P10457075A1198|55 58|max
P10457075A1198|1 41|Independent protrudor muscle stimulation
P10455189A0104|95 112|integrin ligation
P10455189A0104|64 73|mechanism
P10455183A0530|29 33|gene
P10455183A0530|92 97|Oct-1
P10455183A0530|65 82|Staf zinc fingers
P10455183A0530|18 23|xtRNA
P10455087A1400|25 36|individuals
P10455087A1400|1 12|CONCLUSIONS
P10454568A0815|107 114|PDGF-BB
P10454568A0815|228 235|fashion
P10454568A0815|128 135|insulin
P10454568A0815|203 211|ecdysone
P10454568A0815|117 122|IGF-I
P10454557A0975|74 80|ARS302
P10454557A0975|62 68|ARS320
P10454557A0975|7 14|results
P10454557A0975|97 104|origins
P10454557A0975|54 60|ARS303
P10454557A0975|168 175|origins
P10454550A0960|108 127|Snf1 kinase complex
P10454550A0960|69 73|Glc7
P10454550A0960|85 95|substrates
P10454533A0859|109 113|acid
P10454533A0859|52 66|transformation
P10454533A0859|70 73|HRI
P10454533A0859|1 12|Interaction
P10453371A0640|12 27|height z-scores
P10453371A0640|1 7|Weight
P10453006A0478|75 80|genes
P10453006A0478|40 51|genes PSMB5
P10453006A0478|82 88|PSMB11
P10453006A0478|169 175|humans
P10452991A0331|7 12|cells
P10452991A0331|34 59|influenza virus particles
P10452306A0502|91 95|LVEF
P10452306A0502|107 112|x-ray
P10452306A0502|128 133|ratio
P10452306A0502|36 47|MIBG uptake
P10452306A0502|1 9|Patients
P10450815A0180|148 160|relationship
P10450815A0180|288 295|hygiene
P10450815A0180|75 86|individuals
P10450815A0180|13 26|investigation
P10450815A0180|42 52|population
P10450815A0180|309 321|inflammation
P10450815A0180|275 281|gender
P10449072A0560|76 78|PD
P10449072A0560|69 72|GPi
P10448440T0020|25 35|psychiatry
P10448440T0020|5 9|role
P10448095A0865|104 114|conversion
P10448095A0865|133 143|adipocytes
P10448095A0865|219 229|adipocytes
P10448095A0865|118 129|fibroblasts
P10447597A1004|37 42|motif
P10446998T0000|61 95|serum response factor interactions
P10446998T0000|101 124|serum response elements
P10446998A0375|123 141|c-fos inducibility
P10446998A0375|4 12|contrast
P10446998A0375|115 119|junB
P10446910A0147|88 105|E2-responsiveness
P10446910A0147|277 292|transactivation
P10446910A0147|155 181|deletion/mutation analysis
P10446910A0147|1 9|Analysis
P10446910A0147|119 138|transfection assays
P10446206A0000|31 43|presenilin-1
P10446206A0000|193 214|neuroblastoma SK-N-SH
P10446206A0000|219 239|hepatoma HepG2 cells
P10446206A0000|116 124|relation
P10446206A0000|50 58|promoter
P10446131A0132|89 93|ATII
P10446131A0132|51 70|smooth muscle cells
P10445506A0073|31 36|sperm
P10444813A0448|60 83|metastases interferon-a
P10444813A0448|88 110|somatostatin analogues
P10444813A0448|17 23|relief
P10443990A0000|1 11|BACKGROUND
P10441506A0098|94 101|repeats
P10441506A0098|223 229|domain
P10441506A0098|256 274|amino acid stretch
P10441506A0098|161 170|sequences
P10441506A0098|276 288|D region/HR2
P10441506A0098|141 155|leucine-zipper
P10441506A0098|71 74|PKN
P10441506A0098|1 8|PKNbeta
P10441449X1212|16 30|Academic Press
P10440923A0684|122 128|levels
P10440923A0684|264 270|levels
P10440923A0684|294 316|retinoblastoma protein
P10440923A0684|48 49|h
P10440923A0684|105 114|elevation
P10440923A0684|13 32|cell cycle proteins
P10440923A0684|200 208|cyclin E
P10440923A0684|1 9|Analysis
P10438950A0580|96 117|fibroblast cell lines
P10438950A0580|85 90|nurse
P10438924T0000|66 110|glycogen synthase kinase-3 signaling pathway
P10438924T0000|115 144|phosphatidylinositol 3-kinase
P10438627A0885|31 35|mono
P10438627A0885|123 137|T7 transcripts
P10438627A0885|144 152|variants
P10438627A0885|174 177|Phe
P10438627A0885|156 160|tRNA
P10438627A0885|1 18|Identity elements
P10438593A0000|11 40|immunodeficiency virus type-1
P10438593A0000|71 84|transcription
P10438593A0000|100 127|RNA polymerase processivity
P10437043A0164|52 60|biopsies
P10437043A0164|35 37|SS
P10435595A0203|41 57|trans-activation
P10433729A1559|22 30|Matthews
P10433729A1559|32 34|C.
P10430944A1298|46 50|role
P10430944A1298|21 39|JAK/STAT signaling
P10430886A0838|88 103|heteromultimers
P10430886A0838|52 56|TraR
P10430583A0000|59 67|homology
P10430583A0000|71 75|RecA
P10430421T0000|53 65|AD increases
P10430421T0000|86 104|Cache County Study
P10429946A0473|30 35|alpha
P10429946A0473|132 136|exon
P10429946A0473|109 117|promoter
P10429946A0473|179 187|elements
P10429946A0473|38 39|V
P10429946A0473|16 22|region
P10429184A0000|27 35|proteins
P10429184A0000|1 10|Expansins
P10429184A0000|17 23|family
P10428811A1067|108 111|Src
P10428811A1067|84 103|adhesion kinase Fak
P10428759A0743|94 103|receptors
P10428091A0322|104 113|mortality
P10428091A0322|6 12|report
P10428091A0322|138 143|women
P10426878A0367|192 202|prevention
P10426878A0367|79 92|Collaboration
P10426878A0367|163 173|infarction
P10426878A0367|20 32|ISIS-2 trial
P10425445T0000|15 25|expression
P10425445T0000|1 10|Structure
P10423292A0782|14 16|bp
P10423292A0782|36 41|Spam1
P10423292A0782|155 162|element
P10423156A0265|30 37|density
P10423156A0265|56 60|CsCl
P10423156A0265|80 95|capsid proteins
P10422342A0535|245 250|201Tl
P10422342A0535|261 266|111In
P10422342A0535|54 66|examinations
P10422342A0535|221 233|preparations
P10422342A0535|42 50|majority
P10422342A0535|203 217|administration
P10422342A0535|239 243|131I
P10419521A0136|88 106|interaction domain
P10419521A0136|178 191|transcription
P10419521A0136|4 12|addition
P10419521A0136|137 156|polymerase activity
P10417703A1326|130 140|eukaryotes
P10417703A1326|52 54|RP
P10417703A1326|233 242|functions
P10416558A0000|63 70|effects
P10416558A0000|246 257|individuals
P10416558A0000|259 260|N
P10416558A0000|285 291|degree
P10416558A0000|192 205|health status
P10416558A0000|143 151|function
P10416558A0000|1 8|PURPOSE
P10414451A0093|89 97|presence
P10414451A0093|27 30|age
P10414451A0093|59 62|DVT
P10414451A0093|186 196|antibodies
P10414451A0093|165 167|LA
P10414451A0093|201 213|deficiencies
P10414451A0093|136 141|APC-R
P10414451A0093|239 255|ATIII activities
P10413676A0595|150 168|SH3 binding region
P10413676A0595|23 34|FAK mutants
P10413676A0595|293 309|paxillin binding
P10413676A0595|252 255|FAK
P10413676A0595|47 52|cells
P10413676A0595|313 316|FAK
P10413676A0595|98 108|SH2 domain
P10413676A0595|275 277|FN
P10413662A0193|167 176|virulence
P10413662A0193|95 99|pJM1
P10413662A0193|218 226|pathogen
P10413662A0193|239 248|vibriosis
P10413604A0063|57 61|PKAs
P10413604A0063|158 171|DNA synthesis
P10411140A0499|121 131|terminator
P10411140A0499|27 30|RNA
P10411140A0499|51 67|RNase E cleavage
P10411139A0887|21 33|U4/U6 duplex
P10411139A0887|50 64|overexpression
P10409749T0000|19 28|structure
P10409749T0000|1 5|Role
P10409730A0597|123 136|transcription
P10409730A0597|109 119|initiation
P10409730A0597|5 18|transcription
P10409699A0292|56 75|sequence similarity
P10409699A0292|228 239|combination
P10409699A0292|93 98|yeast
P10409699A0292|190 209|mannosidase homolog
P10409699A0292|290 315|polymerase chain reaction
P10407985A0574|12 22|micrograms
P10407985A0574|66 72|GM-CSF
P10407985A0574|1 6|G-CSF
P10407269A0000a|45 58|markers cdc18
P10407269A0000a|192 217|genome sequencing project
P10407269A0000a|89 113|fission yeast chromosome
P10407269A0000a|25 28|DNA
P10407269A0000a|139 143|part
P10407184A0149|26 38|betaAPP gene
P10407184A0149|110 116|factor
P10407184A0149|4 18|overexpression
P10406843A1265|15 29|GlcNAc-TI mRNA
P10406843A1265|33 40|tobacco
P10406465A0589|28 31|VDR
P10406465A0589|6 14|sequence
P10406462A1127|94 106|OR1/RXRalpha
P10406462A1127|80 90|activation
P10406462A1127|50 55|SRC-1
P10406122T0000|147 163|methyl jasmonate
P10406122T0000|59 87|tobacco retrotransposon Tto1
P10406122T0000|175 184|elicitors
P10405635A0374|182 187|cells
P10405635A0374|87 106|deletion constructs
P10403839A0140|134 139|cDNAs
P10403839A0140|199 203|gene
P10403839A0140|7 27|sequence information
P10403839A0140|54 59|cDNAs
P10403839A0140|155 170|splice variants
P10403575A1401|46 51|DAX-1
P10403575A1401|80 93|transcription
P10403575A1401|19 42|StAR gene transcription
P10402022A0432|44 45|s
P10402022A0432|33 37|rate
P10400785A0912|133 155|nucleoporin CAN/Nup214
P10400785A0912|54 64|components
P10400785A0912|1 3|SM
P10400760A0663|22 30|analyses
P10400760A0663|5 12|results
P10400760A0663|71 100|amino acid residues E960-A961
P10400760A0663|102 113|E1071-S1072
P10400757A0000|12 30|chemokine receptor
P10400757A0000|93 97|R5X4
P10400757A0000|143 151|isolates
P10400757A0000|136 141|HIV-1
P10400712A0000|41 50|prototype
P10400712A0000|8 27|parainfluenza virus
P10400032A0304|120 130|management
P10400032A0304|77 88|hypotension
P10398682A0365|30 39|VP16 core
P10398682A0365|69 79|resolution
P10397257A1142|225 230|cells
P10397257A1142|41 50|Sp1 sites
P10397257A1142|161 166|cells
P10397257A1142|20 36|CDE/CHR elements
P10397257A1142|1 12|Mutagenesis
P10396343T0000|48 66|agglutination test
P10396343T0000|16 26|evaluation
P10395920A1424|28 35|members
P10395920A1424|176 179|CRE
P10395920A1424|7 14|results
P10395920A1424|156 163|stimuli
P10395920A1424|118 126|KGF gene
P10395908A0236|88 95|regions
P10395908A0236|144 154|R7G family
P10395908A0236|191 200|receptors
P10395378A1198|5 9|data
P10395378A1198|156 171|fusion activity
P10395199A0792|240 242|O.
P10395199A0792|244 254|Kenigsberg
P10395199A0792|292 298|Multon
P10395199A0792|356 362|Tocque
P10395199A0792|160 171|Ras pathway
P10395199A0792|232 238|Cochet
P10395199A0792|33 40|control
P10395199A0792|321 334|Schweighoffer
P10395199A0792|260 268|Delumeau
P10395199A0792|85 94|Y259 scFv
P10395199A0792|192 208|tumor regression
P10395199A0792|350 354|J.L.
P10395199A0792|6 10|scFv
P10395199A0792|274 286|Virone-Oddos
P10394900A1166|90 114|cauliflower mosaic virus
P10394900A1166|65 80|enhancer region
P10394900A1166|16 26|expression
P10393969A0000|14 30|cell protein no.
P10393969A0000|133 138|genes
P10393969A0000|178 190|transfection
P10393969A0000|156 161|cells
P10393969A0000|119 129|expression
P10393422A0476|108 114|LAMB2L
P10393422A0476|42 46|gene
P10393251A0283|23 34|insert size
P10393251A0283|38 43|120kb
P10393197A0543|24 39|heterochromatin
P10393197A0543|71 82|neuroblasts
P10392914A0000|75 80|AAPBD
P10392914A0000|123 133|dilatation
P10392914A0000|1 19|BACKGROUND/PURPOSE
P10392903A0000|107 126|carcinoma cell line
P10392903A0000|178 181|DNA
P10392903A0000|71 81|HT-3 cells
P10392710A1000|30 38|compleat
P10392710A1000|40 47|inducer
P10392710A1000|51 69|lung morphogenesis
P10392266A0111|129 143|immunoglobulin
P10392266A0111|49 67|serum lipid levels
P10391277A0000|94 106|fibrillation
P10391277A0000|55 61|choice
P10391277A0000|17 25|MAZE-III
P10391075A0000|63 72|sclerosis
P10391075A0000|117 128|brain tumor
P10390158A1150|24 28|site
P10390158A1150|1 16|Point mutations
P10385915A1341|132 140|distance
P10385915A1341|146 150|side
P10385915A1341|64 71|D3S2465
P10385915A1341|1 8|D3S1261
P10385384A0654|36 43|xylitol
P10385384A0654|48 57|activator
P10383966A0000|63 76|peptidoglycan
P10383966A0000|5 32|penicillin binding proteins
P10381570A1355|105 114|repressor
P10381570A1355|88 92|role
P10381570A1355|39 51|binding site
P10381570A1355|175 188|embryogenesis
P10381570A1355|16 29|transcription
P10381257A0000|134 147|mitochondrion
P10381257A0000|108 116|membrane
P10381257A0000|54 63|component
P10380878A0542|45 51|region
P10380878A0542|111 114|DNA
P10380878A0542|55 59|Bin1
P10380659A0545|37 43|adults
P10379942T0000|45 67|disease virus serotype
P10379942T0000|107 127|glycoprotein M genes
P10379942T0000|37 42|Marek
P10379942T0000|70 89|glycoprotein M gene
P10379899A0446|11 19|findings
P10379899A0446|27 34|studies
P10379899A0446|131 155|theca cell layer markers
P10378989A0000|166 171|Italy
P10378989A0000|198 205|January
P10378989A0000|158 164|Sicily
P10378989A0000|217 225|December
P10378989A0000|87 101|drug reactions
P10378989A0000|17 22|study
P10377345A0740|127 134|regions
P10377345A0740|1 6|Green
P10376877A0611|176 183|protein
P10376877A0611|162 168|region
P10376877A0611|97 106|formation
P10376877A0611|113 120|Ss rRNA
P10376877A0611|139 143|part
P10376873A0706|7 13|sgRNA2
P10376065A0881|134 145|RF02 filter
P10376065A0881|63 71|pressure
P10376065A0881|37 46|elevation
P10376065A0881|116 129|spring filter
P10375694T0000|104 110|monkey
P10375694T0000|167 177|motor area
P10375694T0000|78 88|motor area
P10375638A0859|75 79|mRNA
P10375638A0859|94 104|efficiency
P10375638A0859|145 163|translation system
P10375638A0859|1 10|Mutations
P10374632A0897|13 30|NBP pre-treatment
P10374632A0897|71 75|rCBF
P10373523A0924|15 20|media
P10373523A0924|53 62|apoptosis
P10373029A0204|13 24|artery/vein
P10373029A0204|102 112|volunteers
P10371097A0963|104 115|improvement
P10371097A0963|56 64|patients
P10371097A0963|66 74|training
P10371097A0963|1 12|CONCLUSIONS
P10370675A0649|91 92|%
P10370675A0649|124 135|combination
P10370675A0649|112 113|%
P10370675A0649|20 33|liver disease
P10370675A0649|164 165|%
P10370675A0649|10 16|causes
P10370675A0649|139 142|HCV
P10369926A0251|10 26|intron structure
P10369926A0251|86 89|IL8
P10369757A0000|182 183|l
P10369757A0000|334 339|genes
P10369757A0000|216 225|complexes
P10369757A0000|45 64|arginine metabolism
P10369757A0000|108 112|ArgR
P10369757A0000|163 171|proteins
P10369757A0000|341 345|AhrC
P10369418A0644|90 99|induction
P10369418A0644|25 33|extracts
P10369418A0644|52 63|stimulation
P10369418A0644|1 5|EMSA
P10369418A0644|103 122|NF-kappaB complexes
P10369418A0644|205 209|RelB
P10367460A0191|165 169|time
P10367460A0191|147 159|microseconds
P10367460A0191|5 20|FCMS conditions
P10367460A0191|85 112|V maximum capacitor voltage
P10367240A1354|150 161|spermatozoa
P10367240A1354|243 258|sperm injection
P10367240A1354|77 79|SP
P10367240A1354|34 45|spermatozoa
P10366559A0605|72 78|plants
P10366559A0605|53 59|levels
P10366503A0812|120 131|gp17 column
P10366503A0812|88 94|phages
P10366503A0812|41 47|phages
P10366503A0812|231 238|protein
P10366503A0812|100 107|His-tag
P10366503A0812|69 78|retention
P10365883A1355|165 174|pathogens
P10365883A1355|198 207|infection
P10365883A1355|36 48|VRE patients
P10364523A0826|94 100|region
P10364523A0826|53 58|exons
P10364523A0826|169 180|breakpoints
P10364523A0826|68 78|YAC 946E12
P10364319A0109|25 33|promoter
P10364319A0109|38 58|EBNA mRNA initiation
P10364202A0646|226 237|coactivator
P10364202A0646|199 210|involvement
P10364202A0646|158 182|GAL4-DBP fusion proteins
P10364202A0646|80 95|leukemia factor
P10364202A0646|33 54|expression constructs
P10364159A0813|121 134|kinase assays
P10364159A0813|67 94|FRAP/mTOR immunoprecipitate
P10364159A0813|152 158|4E-BP1
P10363517A0401|9 14|paper
P10363517A0401|21 28|lesions
P10362652A1456|63 70|HA-ERK2
P10362652A1456|38 59|carbachol stimulation
P10362652A1456|19 22|Sos
P10361038A0281|28 37|locations
P10360839A1338|31 41|expression
P10360839A1338|147 160|cell lineages
P10360839A1338|71 80|subfamily
P10359792A0610|91 98|Groucho
P10359792A0610|180 200|histone deacetylases
P10359792A0610|21 28|defects
P10359664A0579|46 52|MARCKS
P10359664A0579|71 89|lysyl endoprotease
P10359663A0425|75 82|oIFNtau
P10359663A0425|240 272|oIFNtau-SV40-CAT transactivation
P10359663A0425|146 153|regions
P10359663A0425|162 167|bases
P10359663A0425|116 121|virus
P10359663A0425|35 41|system
P10359575A0317|108 113|bIgG2
P10359575A0317|54 63|FcalphaRI
P10359575A0317|141 146|bIgG2
P10359575A0317|102 106|IgG2
P10358138A0672|75 84|signaling
P10358138A0672|7 14|results
P10358138A0672|168 193|signaling adaptor protein
P10358138A0672|102 106|SLAM
P10358080T0000|21 52|heat shock factor trimerization
P10358079A0391|45 57|heterodimers
P10358079A0391|10 29|neu differentiation
P10358079A0391|87 92|Stat5
P10358031A0303|133 144|cytokinesis
P10358031A0303|20 25|cells
P10358031A0303|81 91|G2/M delay
P10358031A0303|152 167|cell separation
P10355910A0369|28 31|age
P10355085A1119|73 76|ISS
P10355085A1119|125 139|injury pattern
P10355085A1119|162 174|nonsurvivors
P10355085A1119|65 71|trauma
P10353073A0118|56 63|factors
P10353073A0118|34 38|risk
P10350484A0346|166 170|Vmax
P10350484A0346|106 116|% decrease
P10350484A0346|131 134|ATP
P10350484A0346|17 32|kinase activity
P10350027A0942|40 47|effects
P10350027A0942|1 12|Amisulpride
P10350027A0942|17 19|mg
P10349084T0000|90 98|globulin
P10349084T0000|59 67|efficacy
P10349084T0000|140 147|purpura
P10347839A0434|29 32|dog
P10347839A0434|67 68|M
P10347839A0434|21 24|rat
P10347203A0832|120 122|PD
P10347203A0832|57 79|somatostatin treatment
P10347203A0832|172 185|proliferation
P10347203A0832|1 23|Serine phosphorylation
P10347144A0516|26 33|protein
P10347144A0516|143 148|AVQGP
P10347144A0516|51 69|baculovirus system
P10343189A0911|37 44|patient
P10342829A0236|151 156|issue
P10342829A0236|180 192|reproduction
P10342829A0236|94 104|regulation
P10342829A0236|52 62|mechanisms
P10342829A0236|118 123|GnRHR
P10342511A0909|52 58|scores
P10342511A0909|20 33|determination
P10340883A1266|62 67|stage
P10340883A1266|56 57|%
P10340883A1266|19 29|stage IIIB
P10339566A0602|112 118|Spc42p
P10339566A0602|86 98|Spc94p/Nud1p
P10339566A0602|1 7|Spc42p
P10336495A0547|105 109|NCoR
P10336495A0547|147 156|complexes
P10336495A0547|114 123|PPARalpha
P10336495A0547|170 175|cells
P10333529A0277|6 18|betaAPP mRNA
P10333529A0277|53 60|trisomy
P10333481A1102|224 226|bp
P10333481A1102|40 44|UCP2
P10333481A1102|97 103|region
P10333481A1102|237 252|promoter region
P10331875A0523|73 84|specificity
P10331875A0523|89 97|affinity
P10331875A0523|114 118|form
P10331875A0523|153 166|cooperativity
P10331646A0595|264 279|signal sequence
P10331646A0595|58 64|family
P10331646A0595|158 164|testis
P10331646A0595|326 333|protein
P10331646A0595|287 304|carboxyl terminus
P10331646A0595|350 356|export
P10331646A0595|4 12|contrast
P10330396A0387|160 170|Can/Nup214
P10330396A0387|144 155|p62 complex
P10330396A0387|36 48|accumulation
P10330396A0387|115 118|NPC
P10330159A1258|63 73|activation
P10330159A1258|82 99|promoter/enhancer
P10330159A1258|190 197|Jun-Fos
P10330159A1258|153 157|site
P10330134A0765|30 34|RFX2
P10330134A0765|227 233|manner
P10330134A0765|198 204|tissue
P10330134A0765|161 169|promoter
P10330134A0765|144 149|front
P10329736A0681|29 34|yeast
P10329736A0681|82 93|p85 subunit
P10329736A0681|54 59|mIRS3
P10329586A0414|29 31|FN
P10329586A0414|124 138|overexpression
P10329586A0414|142 144|FN
P10329566A0610|72 81|structure
P10329566A0610|161 175|aminoacyl stem
P10329566A0610|179 186|feature
P10329566A0610|93 109|valine anticodon
P10329566A0610|202 208|genera
P10328351A0443|90 91|d
P10328351A0443|76 77|d
P10326856T0000|15 37|pancreaticojejunostomy
P10326221A0531|44 54|amputation
P10326221A0531|12 20|mutation
P10326221A0531|58 62|legs
P10323863A0852|144 170|ribonucleoprotein assembly
P10323863A0852|38 48|production
P10323863A0852|103 129|rabbit reticulocyte lysate
P10323463T0000a|144 152|activity
P10323463T0000a|1 17|Interferon-alpha
P10322629A0198|52 65|Xenopus Pax-5
P10322629A0198|81 92|orthologues
P10322629A0198|70 75|Pax-8
P10321158T0000|41 47|canals
P10321158T0000|10 26|core fabrication
P10321158T0000|1 5|Post
P10320480A0451|61 65|role
P10320480A0451|23 29|system
P10320480A0451|81 91|C-terminus
P10319955A0941|58 62|chi2
P10319955A0941|76 80|test
P10319955A0941|98 109|differences
P10319320A1022|183 195|angiogenesis
P10319320A1022|42 50|16K hPRL
P10319320A1022|23 31|findings
P10319320A1022|154 163|mechanism
P10318900A0637|44 67|electron cryomicroscopy
P10318900A0637|240 248|particle
P10318900A0637|182 197|mRNA production
P10318900A0637|168 178|efficiency
P10318900A0637|152 158|capsid
P10318806A0918|208 220|Src homology
P10318806A0918|360 363|p38
P10318806A0918|188 195|protein
P10318806A0918|135 164|phosphatidylinositol 3-kinase
P10318806A0918|346 356|activation
P10318806A0918|199 202|Ras
P10318806A0918|311 315|role
P10318806A0918|1 9|Analyses
P10318806A0000|212 218|signal
P10318806A0000|155 161|kinase
P10318806A0000|184 192|elements
P10318806A0000|119 135|protein kinase-1
P10318806A0000|43 46|MAP
P10318806A0000|273 279|agents
P10318806A0000|1 8|Members
P10304090T0000|1 22|Medicare SNF benefits
P10271171A0458|29 34|shift
P10271171A0458|8 13|LATCH
P10271171A0458|38 52|identification
P10240361T0000|58 68|physicians
P10235265A0197|148 162|cyclin subunit
P10235265A0197|143 146|Clb
P10235265A0197|98 119|proteolysis machinery
P10233946A0000|72 79|repeats
P10233946A0000|10 14|work
P10233946A0000|219 226|SNV RNA
P10233946A0000|295 303|proteins
P10233946A0000|203 213|hypothesis
P10233147A0218|88 106|filamentation MAPK
P10233147A0218|108 126|Cdc42p/Ste20p/MAPK
P10233147A0218|158 172|protein kinase
P10233147A0218|64 82|signaling pathways
P10233147A0218|1 6|Ras2p
P10232600T0000|109 135|prostate cancer cell lines
P10232600T0000|19 26|antigen
P10231862A1117|107 111|week
P10231862A1117|213 217|pool
P10231862A1117|129 141|contribution
P10231862A1117|115 119|life
P10231513T0000|15 26|differences
P10231513T0000|89 92|rat
P10231454A0731|60 67|calcium
P10231454A0731|125 145|alkaline phosphatase
P10231454A0731|37 42|mg/dl
P10231454A0731|114 119|mg/dl
P10229682A1151|226 232|region
P10229682A1151|161 169|sequence
P10229682A1151|23 38|gene expression
P10229682A1151|171 183|NF-IL-6 site
P10229668A0190|49 51|G1
P10228795A0842|78 93|nerve responses
P10228795A0842|97 100|EFS
P10228795A0842|1 8|RESULTS
P10228157T0000|19 45|spindle checkpoint pathway
P10228009A0600|60 63|TNF
P10228009A0600|94 99|TRAF6
P10228009A0600|18 31|CINC promoter
P10228009A0600|35 40|IL-17
P10226074A0637|128 132|exon
P10226074A0637|64 69|exons
P10225945A0436|194 206|kinetochores
P10225945A0436|132 139|measure
P10225945A0436|43 50|meiosis
P10225945A0436|143 150|tension
P10225945A0436|156 164|distance
P10224758A0202|30 48|afterbirth samples
P10224758A0202|5 18|control group
P10224293A2021|82 101|RPTP-kappa function
P10224293A2021|71 78|studies
P10224289T0000|56 67|interaction
P10224289T0000|71 74|Nef
P10224289T0000|84 110|T cell receptor zeta chain
P10224244T0000|91 101|regulation
P10224244T0000|67 83|Snf1-Snf4 kinase
P10224244T0000|1 9|Evidence
P10223338A2186|5 12|results
P10223338A2186|64 69|HIV-1
P10223338A2186|118 134|HIV/AIDS vaccine
P10221820A0902|14 18|type
P10221820A0902|57 60|AMT
P10221820A0902|22 26|APBD
P10220364A0087|72 82|hypernovae
P10220364A0087|36 46|supernovae
P10219091A0246|33 42|gene CTL1
P10218200A0534|133 136|hrs
P10218200A0534|48 58|micrograms
P10217683A0509|43 52|treatment
P10216052A1682|150 158|severity
P10216052A1682|88 89|r
P10216052A1682|113 124|correlation
P10216052A1682|18 26|validity
P10216052A1682|49 58|questions
P10216052A1682|97 98|p
P10216052A1682|39 45|subset
P10215850A0754|62 72|TrxR2 gene
P10215850A0754|159 175|position 22q11.2
P10215850A0754|143 155|localization
P10215803T0000|40 48|infusion
P10215594A1728|94 103|induction
P10215594A1728|177 180|pO2
P10215594A1728|112 116|CRE1
P10215594A1728|1 9|Glucagon
P10215594A1728|119 123|CRE2
P10214610A0900|40 51|percentiles
P10212426A1067|150 155|study
P10212426A1067|125 130|delta
P10212426A1067|20 29|functions
P10212426A1067|49 61|hearing loss
P10212426A1067|34 43|listeners
P10212284A0000|62 79|matrix deposition
P10212284A0000|113 118|cells
P10212284A0000|34 39|beta1
P10211919A0846|135 156|CGI Improvement scale
P10211919A0846|176 181|weeks
P10211919A0846|23 34|improvement
P10211919A0846|53 69|sertraline group
P10211919A0846|169 172|end
P10211329A0457|105 115|malignancy
P10211329A0457|93 101|evidence
P10211329A0457|159 167|disorder
P10211329A0457|32 44|serum lipase
P10211329A0457|139 150|involvement
P10209759T0000|81 85|rats
P10209759T0000|50 77|ischemia reperfusion injury
P10209119A0076|56 69|member Cdc53p
P10209119A0076|196 199|Cdk
P10209119A0076|188 194|kinase
P10209119A0076|118 151|SCFCdc4p ubiquitin ligase complex
P10209021A0212|15 24|mechanism
P10209021A0212|86 97|mRNA export
P10208865A1246|29 48|osteoclast cultures
P10208865A1246|82 91|formation
P10208865A1246|50 57|mrIhh-N
P10207092A0924|86 109|protein kinase activity
P10207087A0956|105 124|activating activity
P10207087A0956|63 95|promoter reporter gene construct
P10207087A0956|9 14|AML1B
P10207087A0956|49 60|interleukin
P10207049A0693|104 108|Glc7
P10207049A0693|52 56|type
P10207049A0693|38 45|subunit
P10206152A1024|60 67|mitosis
P10206152A1024|131 144|messenger RNA
P10206152A1024|83 85|G1
P10206152A1024|19 29|expression
P10205588A0000|53 62|arthritis
P10205588A0000|39 47|patients
P10205588A0000|100 112|streptococci
P10205588A0000|69 78|infection
P10205588A0000|152 160|emphasis
P10205176A0000|134 142|features
P10205176A0000|95 106|yeast cells
P10205176A0000|162 169|control
P10205176A0000|201 210|evolution
P10203611T0000|1 57|Technetium-99m methylene diphosphonate scintimammography
P10202006A0546|92 95|SPA
P10202006A0546|81 90|protein A
P10202006A0546|32 46|fusion protein
P10200473A0171|88 95|aliases
P10200473A0171|130 135|CLARP
P10200473A0171|43 50|process
P10200473A0171|25 34|regulator
P10200473A0171|100 107|Usurpin
P10200473A0171|152 159|I-FLICE
P10198061A0339|130 137|ATP/GTP
P10198061A0339|18 30|import assay
P10198061A0339|101 109|addition
P10198003A1505|13 17|lacZ
P10198003A1505|98 108|expression
P10198003A1505|1 9|Analysis
P10197763A0580|31 40|mutations
P10197763A0580|93 119|nerve growth factor effect
P10196318T0000|90 92|E6
P10196318T0000|1 27|CCAAT displacement protein
P10196318T0000|102 114|E1 promoters
P10196266A0000|47 56|infection
P10196266A0000|11 30|mouse Mus castaneus
P10196266A0000|143 148|MuLVs
P10196127A1059|15 19|site
P10196127A1059|98 118|pyroglutamyl residue
P10195690A0000|61 68|members
P10195690A0000|39 48|receptors
P10195690A0000|84 112|hormone receptor superfamily
P10194769A0146|52 55|rat
P10194769A0146|66 89|cDNA expression library
P10194769A0146|157 172|element binding
P10194769A0146|98 123|417-amino acid WD protein
P10194769A0146|136 140|PREB
P10194451A0000|192 201|expansion
P10194451A0000|179 182|CML
P10194451A0000|66 70|p210
P10194451A0000|71 78|bcr/abl
P10194451A0000|117 131|manifestations
P10194451A0000|239 254|p210 substrates
P10194225A1132|77 90|pyruvate Gneo
P10194225A1132|103 114|glycerol Ra
P10192638T0000|88 96|efficacy
P10192638T0000|27 30|MSF
P10192638T0000|140 154|Alzheimer type
P10192638T0000|68 73|study
P10192134A1088|129 143|turkey rations
P10192134A1088|81 99|micrograms/kg feed
P10192134A1088|1 9|25-OH-D3
P10190324A0000|22 34|elastin gene
P10190324A0000|39 48|mutations
P10190324A0000|86 94|stenosis
P10187842A1155|12 20|contrast
P10187842A1155|24 34|PPARgamma2
P10187842A1155|96 100|site
P10187317T0000|1 9|Hospital
P10181397A0641|120 130|population
P10181397A0641|25 34|fertility
P10181397A0641|64 82|gender differences
P10153759A0360|22 34|organization
P10153759A0360|1 5|UPMC
P10134977T0000|1 6|JCAHO
P10125354T0000|46 49|gas
P10125354T0000|1 14|Groups dicker
P10119827T0000|1 15|Judge OKs docs
P10103002A0705|167 184|type glycan chain
P10103002A0705|10 30|N-glycosylation site
P10103002A0705|145 153|presence
P10103002A0705|127 131|gp42
P10102136A0646|31 33|Na
P10102136A0646|77 81|Type
P10102136A0646|1 5|Type
P10102136A0646|68 71|PSA
P10102000A1206|14 22|patients
P10102000A1206|97 111|mortality rate
P10102000A1206|118 119|%
P10101198A0946|104 136|transcription termination factor
P10101198A0946|208 223|leucine zippers
P10101198A0946|247 259|interactions
P10101198A0946|3 18|database search
P10101198A0946|69 74|match
P10101159A0742|93 108|cbp1 ts alleles
P10101159A0742|3 11|mutation
P10099576A0666|15 21|valves
P10099576A0666|72 81|parameter
P10099576A0666|142 152|conditions
P10099576A0666|51 57|effect
P10098744A0630|181 194|proliferation
P10098744A0630|208 222|tumorigenicity
P10098744A0630|127 145|proliferation rate
P10098744A0630|115 125|parameters
P10098744A0630|44 53|phenotype
P10098744A0630|160 176|serum-dependence
P10098744A0630|4 12|contrast
P10097932A0915|89 105|microalbuminuria
P10097932A0915|59 63|UAER
P10097932A0915|143 151|patients
P10097932A0915|191 196|years
P10097932A0915|18 26|patients
P10096573A0207|73 79|factor
P10096573A0207|10 17|studies
P10096573A0207|141 147|region
P10096573A0207|85 109|kappaB consensus element
P10095062A0558|122 124|kb
P10095062A0558|102 107|exons
P10095059A1003|22 42|nucleotide positions
P10094396A0000|75 81|PK CK2
P10094396A0000|43 71|protein kinase casein kinase
P10092856A0798|90 118|phosphate isomerase promoter
P10092856A0798|77 82|yeast
P10092132A0285|91 96|cases
P10092132A0285|12 17|gains
P10092132A0285|78 83|11q13
P10092132A0285|39 58|gene amplifications
P10092132A0285|153 160|7q21-22
P10092132A0285|171 181|12p11.2-12
P10091594A0284|44 65|structure predictions
P10091594A0284|150 160|propensity
P10091594A0284|214 225|recognition
P10091594A0284|67 69|CD
P10091594A0284|16 23|studies
P10090943A1426|123 125|SD
P10090943A1426|129 134|B-CLL
P10090943A1426|36 41|CD79b
P10090943A1426|136 137|P
P10090146T0000|14 24|expression
P10090146T0000|125 129|AP-2
P10090146T0000|97 121|R-FABP promoter activity
P10090146T0000|69 81|chick retina
P10087993A1352|165 173|increase
P10087993A1352|177 194|promoter activity
P10087993A1352|99 106|portion
P10087993A1352|140 146|region
P10087549A0720|211 213|ms
P10087549A0720|62 71|JTc delta
P10087549A0720|95 97|ms
P10087549A0720|113 122|JTc delta
P10087549A0720|221 224|ms.
P10087549A0720|130 139|PVC group
P10087549A0720|173 182|JTc delta
P10086725A0000|179 186|tissues
P10086725A0000|36 44|band q26
P10086725A0000|141 146|cells
P10085697T0000|1 46|FASEB Federal Funding Consensus Conference FY
P10085505A1184|88 93|cases
P10085505A1184|32 36|vein
P10085140A1004|29 34|ATF-2
P10085140A1004|108 114|target
P10085140A1004|7 14|results
P10085088A0918|104 121|protein synthesis
P10085088A0918|147 153|domain
P10085088A0918|7 14|results
P10085088A0918|48 52|eIF3
P10082585A0512|91 97|screen
P10082585A0512|144 154|expression
P10082585A0512|158 172|reporter genes
P10082585A0512|118 127|mutations
P10082137A0262|210 226|skin fibroblasts
P10082137A0262|176 177|I
P10082137A0262|93 99|factor
P10082137A0262|250 256|donors
P10082137A0262|72 82|interferon
P10082137A0262|5 12|results
P10082137A0262|169 175|alpha1
P10080875A0772|244 257|AP-1 proteins
P10080875A0772|266 271|C-Jun
P10080875A0772|259 264|c-Fos
P10080875A0772|51 61|antibodies
P10080875A0772|229 234|c-Rel
P10080875A0772|173 176|p65
P10080875A0772|236 241|Rel B
P10080875A0772|204 222|NF-kappaB proteins
P10079173A0000|26 34|proteins
P10079173A0000|82 86|RRMs
P10078734A0480|74 79|nerve
P10078734A0480|48 59|stimulation
P10078734A0480|87 92|elbow
P10077188A1172|164 174|heat shock
P10077188A1172|229 236|protein
P10077188A1172|87 92|acids
P10077188A1172|34 39|genes
P10075415A1178|106 119|UV resistance
P10075415A1178|9 19|sequencing
P10075415A1178|65 73|homology
P10075415A1178|48 55|ORF-Pto
P10074903A0915|72 84|p202 protein
P10074903A0915|162 166|part
P10074903A0915|23 30|results
P10074425A0729|15 27|inactivation
P10074425A0729|72 90|mitogen starvation
P10074425A0729|138 146|deletion
P10074425A0729|35 56|cyclin E-Cdk2 complex
P10074135T0000|56 65|synthesis
P10074135T0000|69 75|barley
P10073940A0335|9 19|expression
P10073940A0335|49 58|signaling
P10072774A0537|59 82|oligonucleotide primers
P10072774A0537|113 116|LBD
P10072774A0537|1 7|RT-PCR
P10071806A0377|13 26|resectability
P10071212A0399|23 39|O. australiensis
P10070158A0573|129 149|transmembrane domain
P10068834A0713|74 77|MR.
P10068834A0713|52 54|VR
P10068834A0713|5 10|costs
P10068834A0713|16 18|DM
P10068418A1194|164 183|alendronate therapy
P10068418A1194|72 76|body
P10068418A1194|4 12|increase
P10068418A1194|16 36|bone mineral density
P10066815T0000|27 35|inositol
P10066815T0000|5 8|SH2
P10066815T0000|141 151|inhibition
P10066815T0000|86 111|phosphoinositide 3-kinase
P10066790A0497|45 76|immunoprecipitation experiments
P10066790A0497|242 249|mu-ARP2
P10066790A0497|168 186|sigma4 polypeptide
P10066790A0497|139 143|AP-4
P10066790A0497|1 15|Gel filtration
P10066790A0497|17 39|sedimentation velocity
P10065176A0657|14 24|difference
P10065176A0657|113 134|lymph node metastases
P10065176A0657|153 168|macrometastases
P10063739A0601|120 128|controls
P10063739A0601|193 196|EVL
P10063739A0601|95 97|SD
P10063739A0601|110 114|mmHg
P10063739A0601|152 160|pressure
P10059496T0000|10 30|transmission spectra
P10054976T0000|26 30|ions
P10054976T0000|1 13|Spectroscopy
P10052878A0135|37 52|reproducibility
P10051488A1610|107 115|activity
P10051488A1610|97 103|% loss
P10051488A1610|141 145|HSCs
P10051488A1610|1 10|Mutations
P10051400A0000|79 82|NTD
P10051400A0000|5 13|Lp mouse
P10051400A0000|85 104|cranio-rachischisis
P10050883A0967|135 141|effect
P10050883A0967|82 98|p53 conformation
P10050883A0967|1 11|Inhibition
P10049775T0000|1 8|Mapping
P10049359A1073|72 83|translation
P10049359A1073|101 116|rhinovirus IRES
P10044519T0000|29 34|flows
P10044519T0000|38 46|polymers
P10041728T0000|28 35|feature
P10041728T0000|65 73|Analysis
P10037681A0494|90 98|fragment
P10037681A0494|12 23|interaction
P10037681A0494|27 30|ARF
P10037681A0494|155 161|mutant
P10037681A0494|50 54|PLD1
P10037460A0221|44 49|motor
P10037460A0221|26 35|receptors
P10037460A0221|96 116|ligand acetylcholine
P10037004A0000|150 157|therapy
P10037004A0000|73 76|ALL
P10037004A0000|198 203|study
P10037004A0000|97 108|bone marrow
P10037004A0000|32 37|years
P10036181A0603|59 81|GPR34 mRNA transcripts
P10036181A0603|103 120|rat brain regions
P10034615T0000|79 80|x
P10034615T0000|84 88|H/Ni
P10032581T0000|18 47|grazing-incidence diffraction
P10031854T0000|81 84|top
P10029860A0605|105 112|filling
P10029860A0605|67 71|type
P10027904A0768|62 68|region
P10026824A0309|268 276|coupling
P10026824A0309|108 120|V1a receptor
P10026824A0309|213 217|loop
P10026824A0309|96 100|loop
P10026824A0309|35 58|V1a/V2 hybrid receptors
P10026784A0929|29 40|DNA binding
P10026275A0549|19 37|structure elements
P10026211A0543|74 78|CREB
P10026211A0543|24 38|pDeltaCREC/EBP
P10026211A0543|113 136|glucocorticoid response
P10026146A0680|300 314|protein kinase
P10026146A0680|176 190|protein kinase
P10026146A0680|247 257|holoenzyme
P10026146A0680|23 38|RIalpha subunit
P10026146A0680|154 158|type
P10026146A0680|76 90|concentrations
P10026146A0680|100 102|Ka
P10025506A0079|4 10|humans
P10024882A0541|121 137|promoter opening
P10024882A0541|76 82|domain
P10024882A0541|4 12|addition
P10024882A0541|84 87|CTD
P10024383T0000|53 65|hyperostosis
P10024383T0000|1 11|Calcitonin
P10022925A0870|5 26|Nmd3 protein sequence
P10022925A0870|81 89|function
P10022905A0446|192 201|germ line
P10022905A0446|214 221|tissues
P10022905A0446|7 20|mog-1 alleles
P10022905A0446|99 116|missense mutation
P10022875A1265|110 113|Pak
P10022875A1265|66 77|PI 3-kinase
P10022867A1069a|160 178|lysine prototrophy
P10022867A1069a|114 118|type
P10022867A1069a|1 12|Elimination
P10022867A1069a|136 145|reversion
P10022850A0929|131 152|reactivation function
P10022850A0929|32 40|fragment
P10022850A0929|103 120|Zta transcription
P10022032A0000|281 293|interactions
P10022032A0000|36 43|studies
P10022032A0000|116 148|receptor antagonists propranolol
P10022032A0000|169 172|ATN
P10022032A0000|187 220|calcium channel blocker diltiazem
P10021333A0674|27 34|mutants
P10021333A0674|112 117|genes
P10013227T0000|30 55|pion mass difference m pi
P10013227T0000|1 22|Precision measurement
P10008261T0000|54 67|magnetization
P10008261T0000|1 23|Temperature dependence
P10007469T0000|55 58|C60
P10002245T0000|72 81|YBa2Cu3O7
P10002245T0000|22 34|conductivity
P10001333T0038|25 30|YAlO3
P10001333T0038|1 16|Echo modulation
P09999742T0000|29 31|Si
P09999742T0000|1 4|NH3
P09995897T0000|24 36|interactions
P09995897T0000|1 12|Observation
P09994942T0000|38 54|antiferromagnets
P09990507A0000|130 136|timing
P09990507A0000|114 125|selectivity
P09990507A0000|81 83|E3
P09990060A0937|134 155|dyad symmetry element
P09990060A0937|122 126|beta
P09990060A0937|96 103|binding
P09990060A0937|4 11|concert
P09990060A0937|81 90|GABPalpha
P09990057T0000|60 71|chain locus
P09990057T0000|143 150|absence
P09990057T0000|115 135|enhancer core region
P09990057T0000|100 105|chain
P09990057T0000|51 53|Ig
P09989334A0964|105 125|polyadenylation site
P09989334A0964|78 96|donor splice sites
P09988767A1496|15 40|mouse back-cross analysis
P09988767A1496|130 137|isologs
P09988767A1496|95 106|assignments
P09988767A1496|201 213|site markers
P09987961A0093|73 86|proliferation
P09987961A0093|11 18|lesions
P09987961A0093|55 67|vasculopathy
P09987176A0260|79 88|follow-up
P09987176A0260|7 13|months
P09987176A0260|49 58|vaccinees
P09985302T0000|9 26|electron dynamics
P09983871T0000|1 20|Raman investigation
P09980944T0000|28 54|superconductor Y2Ba4Cu7O15
P09980944T0000|1 20|Interplane coupling
P09974642T0000|42 49|magnets
P09974642T0000|1 10|Crossover
P09973351A1522|24 40|DcuS-DcuR system
P09971815A2094|126 133|latency
P09971815A2094|248 255|latency
P09971815A2094|83 92|gammaHV68
P09971815A2094|49 72|candidate latency genes
P09971815A2094|288 294|genome
P09971815A2094|164 170|organs
P09971815A2094|197 213|latency programs
P09971815A2094|99 109|expression
P09971790A0856|135 149|D40A-D42A-D44A
P09971790A0856|167 199|AAV hairpin DNA binding activity
P09971790A0856|126 133|protein
P09971790A0856|50 69|helicase activities
P09965909T0000|8 16|approach
P09964770T0000|20 32|conductivity
P09964770T0000|1 15|Microstructure
P09961682T0000|37 54|stick-slip motion
P09959737T0000|14 23|neutrinos
P09959737T0000|5 9|case
P09952378A0529|146 156|covariates
P09952378A0529|36 57|% confidence interval
P09952378A0529|20 23|CHD
P09950213A1660|53 60|TbetaRI
P09950213A1660|65 73|TbetaRII
P09950213A1660|155 164|TbetaRIII
P09949178A0264|91 97|growth
P09949178A0264|40 53|interleukin-6
P09949178A0264|128 133|1A9-M
P09949178A0264|103 113|pre-B-cell
P09947191T0000|45 54|exponents
P09947191T0000|80 95|antiferromagnet
P09947191T0000|69 71|Z2
P09940132T0000|44 66|charge-transfer solids
P09940132T0000|77 87|properties
P09936001T0000|12 21|structure
P09936001T0000|92 101|plutonium
P09936001T0000|32 41|plutonium
P09936001T0000|85 90|delta
P09934611A1054|88 92|mean
P09934611A1054|54 60|extent
P09933641A0241|193 202|cDNA ends
P09933641A0241|52 65|amplification
P09933641A0241|140 149|sequences
P09933641A0241|101 105|NHE5
P09933641A0241|69 78|cDNA ends
P09932288A0378|26 30|gene
P09932288A0378|127 139|cDNA library
P09932288A0378|1 11|Expression
P09931391A0944|22 36|liver function
P09931216A0566|45 52|turbine
P09931216A0566|59 64|45-ft
P09931216A0566|1 8|Airflow
P09931118A1072|13 19|p42/44
P09931118A1072|70 78|IL-1beta
P09929088A0000|97 101|cost
P09929088A0000|114 130|cancer screening
P09929088A0000|33 39|Papnet
P09929088A0000|50 62|technologies
P09927585A0796|117 120|KCS
P09927585A0796|84 111|bandshift complex formation
P09927449A0421|111 121|CLN2 genes
P09927449A0421|19 23|POG1
P09927449A0421|84 94|repression
P09925777A1195|15 32|affinity hnRNP A1
P09925777A1195|151 156|mRNAs
P09925777A1195|131 137|levels
P09925777A1195|68 88|beta-globin reporter
P09925372A0458|122 125|box
P09925372A0458|127 131|KRAB
P09925372A0458|64 73|heart ZFP
P09924987A0000|122 127|A4324
P09924987A0000|29 32|PAP
P09924987A0000|20 27|protein
P09924987A0000|153 161|23S rRNA
P09924987A0000|193 203|eukaryotes
P09924987A0000|39 59|Phytolacca americana
P09924987A0000|1 9|Pokeweed
P09923245A0482|5 9|RMRI
P09922230A1482|120 131|C. albicans
P09922230A1482|76 86|resistance
P09922230A1482|101 116|stress response
P09920982A0253|160 172|acne lesions
P09920982A0253|126 133|strains
P09920982A0253|113 119|agents
P09920982A0253|137 139|P.
P09920930A0521|31 44|RhoA function
P09920930A0521|66 69|SRE
P09920930A0521|1 9|C3 toxin
P09920896A1230|195 205|structures
P09920896A1230|156 166|disruption
P09920896A1230|16 27|differences
P09920775A0075|148 163|differentiation
P09920775A0075|95 119|reporter gene expression
P09920775A0075|5 13|sequence
P09918842A0184|132 147|RNA replication
P09918842A0184|92 100|proteins
P09918842A0184|33 41|terminus
P09918715A1158|74 94|TATA binding protein
P09918715A1158|176 199|core promoter sequences
P09918715A1158|112 119|factors
P09918715A1158|138 149|TBP results
P09918715A1158|17 21|MotA
P09918096A0520|15 19|case
P09917391A0380|45 52|repeats
P09917391A0380|64 70|effect
P09917387T0000|59 67|DNA bend
P09917387T0000|5 19|RNA polymerase
P09917387T0000|35 48|factor TFIIIB
P09916809A0405|58 65|protein
P09916809A0405|53 56|ECM
P09916809A0405|119 147|transmembrane signal peptide
P09915860A0119|7 11|role
P09915860A0119|38 57|pgp2/mdr1b promoter
P09915798A1077|47 65|chaperone activity
P09915798A1077|6 12|region
P09915798A1077|154 182|steroid receptor interaction
P09914525A0890|31 36|point
P09914525A0890|40 42|tm
P09914500A0000|209 214|alpha
P09914500A0000|242 252|conditions
P09914500A0000|25 34|NF-kappaB
P09914500A0000|112 120|proteins
P09914500A0000|154 177|cytokines interleukin-1
P09913308T0000|90 102|laser pulses
P09913308T0000|12 18|lasing
P09913308T0000|27 29|nm
P09904139T0000|15 23|approach
P09900679T0000|28 33|model
P09900679T0000|1 17|Wave cybernetics
P09895323T0000|74 79|Hoxa3
P09895323T0000|33 41|kreisler
P09893913A0656|14 25|anaesthesia
P09893913A0656|72 83|thiopentone
P09893913A0656|95 105|atracurium
P09893913A0656|87 92|mg/kg
P09893060A0767|52 62|expression
P09893060A0767|1 23|Northern blot analysis
P09892662A0334|122 131|regulator
P09892662A0334|20 40|mutant alpha subunit
P09892422A1096|31 44|tissue sheath
P09892422A1096|167 179|transmission
P09892422A1096|128 134|spread
P09892422A1096|138 148|conduction
P09892422A1096|187 194|impulse
P09892017A2151|9 20|experiments
P09892017A2151|87 107|receptor functioning
P09891092A1000|92 105|end formation
P09891092A1000|38 47|stem-loop
P09891065A1493|76 83|mutants
P09891065A1493|100 111|PKC-epsilon
P09891061A0373|150 154|bait
P09891061A0373|113 121|elements
P09891061A0373|69 82|SpHE promoter
P09891046A0554|57 60|PKR
P09891009T0000|11 18|cloning
P09889306A0321|90 102|gene therapy
P09889306A0321|74 86|applications
P09889306A0321|195 208|gene delivery
P09889306A0321|4 12|addition
P09889306A0321|32 54|Glvr-1 gene expression
P09888994A0858|109 115|embryo
P09888994A0858|86 99|somitogenesis
P09887544A0000|13 21|Diazepam
P09887544A0000|149 158|treatment
P09887544A0000|58 71|tranquilizers
P09887544A0000|98 102|drug
P09887544A0000|34 54|benzodiazepine group
P09886843A0339|107 115|elements
P09886843A0339|56 71|thyroid hormone
P09886843A0339|139 148|fragments
P09885431A0000|28 36|accuracy
P09885431A0000|58 63|crown
P09885431A0000|139 159|impression materials
P09885431A0000|103 106|mix
P09885431A0000|68 87|bridge restorations
P09884275T0000|66 74|disorder
P09884275T0000|1 27|Interferon-alpha treatment
P09883639A0000|11 19|patients
P09883639A0000|1 7|Number
P09882593A0996|15 25|experiment
P09882593A0996|150 156|groups
P09882593A0996|110 115|women
P09882593A0996|36 50|nickel isotope
P09882593A0996|71 85|drinking water
P09882489A0451|151 158|modules
P09882489A0451|77 92|mef2 expression
P09882489A0451|16 24|evidence
P09882348A0611|9 12|end
P09882348A0611|169 177|oncogene
P09882348A0611|68 93|tyrosine kinase substrate
P09882334A0822|146 154|mutation
P09882334A0822|53 58|cells
P09882334A0822|233 244|propagation
P09882334A0822|48 51|FLK
P09882334A0822|35 46|lamb kidney
P09882334A0822|119 131|transfection
P09882303T0000|100 110|C terminus
P09882303T0000|35 51|membrane protein
P09882303T0000|137 142|TRADD
P09882303A1413|90 111|deletion TRAF2 mutant
P09882303A1413|156 170|JNK activation
P09882303A1413|34 39|TRADD
P09881692A0094|40 48|variants
P09881692A0094|54 56|b5
P09881692A0094|50 52|b4
P09880544A0693|225 236|DT-40 cells
P09880544A0693|196 207|DT-40 cells
P09880544A0693|168 180|Fas ligation
P09880544A0693|119 141|recombination knockout
P09880513A1013|63 70|tubulin
P09880327A0322|104 111|protein
P09880327A0322|124 131|docking
P09880327A0322|58 66|proteins
P09880029A0703|270 277|SCSV-C2
P09880029A0703|148 162|FBNYV proteins
P09880029A0703|49 52|Rep
P09880029A0703|228 229|%
P09880029A0703|206 212|MDV-C2
P09880029A0703|70 78|proteins
P09880029A0703|103 122|amino acid identity
P09878542A1151|23 31|findings
P09878542A1151|116 132|osteopontin VDRE
P09878256A0000|195 200|death
P09878256A0000|146 159|abnormalities
P09878256A0000|38 42|PBDs
P09878256A0000|50 53|set
P09876794T0000|33 44|anaesthesia
P09874803A0000|135 139|SpeB
P09874803A0000|161 177|virulence factor
P09874803A0000|80 97|cysteine protease
P09873060A0901|123 127|FosB
P09873060A0901|95 110|phosphorylation
P09873060A0901|55 60|ERK-1
P09872337A0000|148 153|% w/v
P09872337A0000|295 304|Dalacin T
P09872337A0000|112 123|clindamycin
P09872337A0000|18 28|absorption
P09872337A0000|72 82|volunteers
P09872337A0000|172 199|clindamycin phosphate ester
P09872337A0000|204 219|clindamycin HCl
P09871353A0174|132 136|loch
P09871353A0174|85 97|furunculosis
P09869400A0203|30 37|germins
P09869400A0203|83 110|Arabidopsis GLP subfamilies
P09869400A0203|1 12|Comparisons
P09869297A1807|42 54|CE2 elements
P09869297A1807|69 90|Hoxb1 gene expression
P09867855T0000|62 118|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
P09867855T0000|1 20|Dorsal root ganglia
P09867159A1444|28 44|threshold values
P09867159A1444|144 145|%
P09867159A1444|86 87|%
P09867159A1444|132 133|%
P09867159A1444|128 129|%
P09867159A1444|140 141|%
P09865775A0162|104 114|properties
P09865775A0162|43 51|couplers
P09865775A0162|83 88|ALGO2
P09864335A1226|47 56|FCR1 gene
P09864335A1226|148 156|evidence
P09864335A1226|92 107|drug resistance
P09864335A1226|162 176|FCZ resistance
P09864335A1226|21 28|results
P09863720T0000|58 78|protein S deficiency
P09863624A0629|134 139|amino
P09863624A0629|192 200|residues
P09863624A0629|163 171|receptor
P09863624A0629|5 15|divergence
P09863624A0629|49 59|sheep CRF1
P09862481A0000|25 44|zinc finger protein
P09862481A0000|5 19|Mig1 repressor
P09861365A0000|122 127|serum
P09861365A0000|112 118|microL
P09861365A0000|5 10|Og4C3
P09860979A0521|15 19|p130
P09860979A0521|26 29|Cas
P09860979A0521|93 107|JNK activation
P09860979A0521|64 78|Crk SH2-domain
P09858745A2033|62 74|intermediate
P09858745A2033|125 134|formation
P09858745A2033|142 157|clcA transcript
P09858714A1171|14 19|dda.2
P09858714A1171|9 12|ORF
P09858714A1171|36 40|modA
P09858619A0356|8 15|studies
P09858619A0356|66 81|ZAP-70 function
P09858593A0334|20 40|amino acid sequences
P09858593A0334|103 126|insulin gene expression
P09858581A0183|150 152|Ts
P09858581A0183|10 20|expression
P09858581A0183|59 65|SPP381
P09858572A0000|62 69|regions
P09858572A0000|80 89|chromatin
P09858531A1017|73 94|proto-oncogenes c-jun
P09858531A1017|55 65|expression
P09857265A0669|150 164|dairy products
P09857265A0669|114 118|meat
P09857265A0669|16 25|vitamin A
P09857265A0669|72 77|women
P09857265A0669|198 199|%
P09857265A0669|97 110|contributions
P09857265A0669|64 67|men
P09857265A0669|1 12|Mean intake
P09857038A1374|5 10|Scott
P09856397A0099|29 53|nutrient digestibilities
P09856397A0099|114 125|persistency
P09856397A0099|81 108|sphingolipid concentrations
P09856397A0099|136 143|tissues
P09854034A0536|62 69|exon 1b
P09854034A0536|110 122|mRNA species
P09852136A0507|29 38|phenotype
P09852136A0507|140 156|ADP-ribosylation
P09852136A0507|50 55|cells
P09852109A1475|241 248|regions
P09852109A1475|10 21|translation
P09852109A1475|93 94|E
P09852109A1475|138 150|efficiencies
P09852005A1287|29 60|MADS box consensus binding site
P09852005A1287|131 140|gene PEP1
P09852005A1287|142 146|SAP1
P09852005A1287|70 78|promoter
P09852005A1287|255 264|complexes
P09851700A0000|25 58|tissue-type plasminogen activator
P09851700A0000|103 109|manner
P09849965A0000|135 138|hPR
P09849965A0000|76 82|ligand
P09849965A0000|6 11|study
P09849722A0797|183 189|cortex
P09849722A0797|8 20|presentation
P09849722A0797|277 301|emotion processing tasks
P09849722A0797|115 130|cingulate gyrus
P09849722A0797|152 166|cingulate gyri
P09848653A0597|82 90|proteins
P09848653A0597|51 57|family
P09847371A0000|108 130|immunodeficiency virus
P09847371A0000|59 69|lentivirus
P09846482A0441|90 104|protein kinase
P09846482A0441|10 18|assembly
P09846482A0441|58 68|activation
P09845856A0560|28 34|period
P09845856A0560|1 8|RESULTS
P09845043A0000|60 65|NIAAA
P09845043A0000|166 184|alcohol dependence
P09845043A0000|202 210|disorder
P09845043A0000|48 58|Alcoholism
P09845043A0000|103 111|drinking
P09844106A0835|59 64|cells
P09844106A0835|6 21|phosphorylation
P09844106A0835|87 90|ST2
P09844106A0835|68 79|fibronectin
P09843577A0000|77 99|G2/M cell size control
P09843412A0130|45 50|Abeta
P09843412A0130|128 130|AD
P09843412A0130|52 59|Abeta42
P09842517A0497|9 19|experience
P09842517A0497|59 67|SieScape
P09842517A0497|118 121|MRI
P09840934A0435|240 245|cells
P09840934A0435|93 99|Ha-Ras
P09840934A0435|113 125|Ha-RasV12G37
P09840934A0435|190 197|effects
P09840934A0435|106 110|E37G
P09840934A0435|65 87|Rafl signaling pathway
P09840928A0884|133 146|kinase assays
P09840928A0884|77 79|H4
P09840928A0884|32 35|Dlk
P09840928A0884|51 67|core histones H3
P09838122A0489|60 75|mouse homologue
P09838122A0489|32 52|coding cDNA sequence
P09837945A0820|122 130|fraction
P09837945A0820|52 64|distribution
P09837945A0820|23 28|Sop1p
P09837945A0820|69 95|cell fractionation studies
P09837920A0222|42 54|requirements
P09837920A0222|110 121|interaction
P09837920A0222|86 101|phosphorylation
P09837913A0419|46 65|sequence tag clones
P09837913A0419|129 133|cDNA
P09837907A0857|89 99|activities
P09837907A0857|147 156|NF-kappaB
P09837907A0857|161 176|AP-1 activation
P09837907A0857|58 73|down-regulation
P09837907A0857|5 13|decrease
P09837907A0857|34 38|IL-4
P09837715A0581|77 110|chloramphenicol acetyltransferase
P09837715A0581|37 43|amount
P09837715A0581|172 177|HIV-1
P09837715A0581|206 209|MLV
P09837715A0581|153 158|cells
P09836881A0441|14 23|BCH group
P09836881A0441|99 116|Motor Proficiency
P09836881A0441|118 127|Bruininks
P09834521A0000|18 30|hydatid cyst
P09833740A1112|78 81|LTR
P09833740A1112|199 208|mechanism
P09833740A1112|218 228|cell types
P09833740A1112|262 278|provirus latency
P09833740A1112|1 28|Pyrrolidine dithiocarbamate
P09832518A0615|148 153|yeast
P09832518A0615|131 138|homolog
P09832518A0615|114 119|Cdc68
P09832518A0615|168 174|lactis
P09832505A0903|58 67|activator
P09832505A0903|69 74|Oct-1
P09832436T0000|63 66|rat
P09832436T0000|77 86|prolactin
P09832436T0000|110 120|protein H.
P09832436T0000|49 55|member
P09832099A0000|105 114|tetralogy
P09832099A0000|126 129|TOF
P09832099A0000|118 124|Fallot
P09829843A0819|120 139|neutrophil recovery
P09829843A0819|300 316|neutrophil count
P09829843A0819|94 104|occurrence
P09829843A0819|321 340|neutrophil function
P09829843A0819|156 165|rHu G-CSF
P09829843A0819|44 54|initiation
P09829843A0819|202 210|microg m
P09829843A0819|5 15|injections
P09829836A0815|47 66|cyclin/CDK function
P09829836A0815|18 28|selections
P09828137A0000|31 35|rad1
P09828137A0000|132 142|DNA damage
P09828137A0000|158 173|DNA replication
P09828137A0000|100 111|G2/M arrest
P09827878A0091|31 34|GPX
P09827878A0091|94 105|erythrocyte
P09827878A0091|7 29|glutathione peroxidase
P09827878A0091|169 177|activity
P09827446T0001|21 30|hepatitis
P09826658A0691|105 116|suppression
P09826658A0691|145 153|splicing
P09826658A0691|66 77|nucleotides
P09824158A1336|75 80|N-CoR
P09824158A1336|108 121|transcription
P09824158A1336|85 89|SMRT
P09824001A1665|107 117|techniques
P09824001A1665|4 12|contrast
P09824001A1665|50 60|predictors
P09823561T0001|37 60|helicobacter heilmannii
P09822825A0141|45 55|expression
P09822825A0141|63 72|BAP3 gene
P09822825A0141|9 14|paper
P09822825A0141|35 39|BAP2
P09822685A0596|164 177|size proteins
P09822685A0596|47 65|Lu-ECAM-1 peptides
P09822685A0596|23 31|antisera
P09822652A1118|25 46|HCK promoter activity
P09822652A1118|68 82|concentrations
P09822602A1172|63 74|recruitment
P09822602A1172|78 81|CBP
P09822602A1172|156 175|signal transduction
P09821978A1255|44 51|animals
P09821978A1255|65 71|MK-801
P09820611T0000|105 116|predialysis
P09820611T0000|74 88|erythropoietin
P09820611T0000|124 132|patients
P09820163A0565|5 12|mapping
P09820163A0565|32 49|Southern blotting
P09819440A0783|72 76|RPB5
P09819440A0783|80 94|RNA polymerase
P09819430A0000|65 70|cycle
P09819430A0000|50 58|proteins
P09819421A0000|44 54|isomerases
P09819421A0000|126 129|CsA
P09819411A0897|104 116|CTTCCCTGGAAG
P09819411A0897|97 102|sites
P09819411A0897|4 9|DNase
P09819377A1209|120 132|accumulation
P09819377A1209|41 58|underaccumulation
P09819377A1209|146 150|RNAs
P09819377A1209|22 33|C2U4 repeat
P09819377A1209|3 11|mutation
P09819038A0448|104 120|body temperature
P09819038A0448|63 67|days
P09819038A0448|99 100|h
P09817373A0000|150 161|muscle tone
P09817373A0000|27 34|effects
P09817373A0000|38 58|hypercholesterolemia
P09817373A0000|235 258|constrictor eicosanoids
P09817373A0000|170 184|oxide synthase
P09817131A0296|64 83|translation process
P09815578A1245|30 40|alteration
P09815578A1245|6 11|study
P09815578A1245|86 99|abnormalities
P09814637A1214|89 91|CT
P09814637A1214|5 19|PbrO2 readings
P09813259A1097|107 113|injury
P09813259A1097|130 133|IBG
P09813259A1097|5 13|findings
P09813207A0434|91 101|transcript
P09813207A0434|245 256|nucleotides
P09813207A0434|223 233|TTGT motif
P09813207A0434|117 127|TAAG motif
P09813207A0434|326 329|ATG
P09813207A0434|308 315|respect
P09813207A0434|1 33|Transcription start site mapping
P09813110A0982|61 71|similarity
P09813110A0982|145 151|region
P09813110A0982|85 92|protein
P09813093A0624|92 96|GIN4
P09813093A0624|16 22|effect
P09813041A1122|72 78|kinase
P09813041A1122|57 60|Jun
P09813041A1122|43 53|activation
P09811730A1396|192 219|transfection reporter assay
P09811730A1396|157 174|promoter activity
P09811730A1396|1 17|Competition EMSA
P09811695A1146|29 48|HIV-1 Gag sequences
P09811695A1146|7 14|results
P09811695A1146|85 95|processing
P09808441A0320|164 177|lymphotropism
P09808441A0320|150 158|melanoma
P09808441A0320|110 114|case
P09808441A0320|66 75|melanomas
P09808216A0000|121 127|ratios
P09808216A0000|29 32|men
P09808216A0000|43 53|regulation
P09808216A0000|97 109|manipulation
P09808216A0000|86 88|FB
P09807755A0146|25 31|supply
P09807755A0146|68 79|muscle flap
P09806858T0000|1 15|Identification
P09806858T0000|51 63|plasmid pLS1
P09806830X1174|16 30|Academic Press
P09806826A0244|91 100|Vwf locus
P09806826A0244|41 48|RIIIS/J
P09806516A1689|44 49|Preop
P09806516A1689|94 101|disease
P09806516A1689|53 61|patients
P09806516A1689|19 26|control
P09805977A0143|183 196|xenoestrogens
P09805977A0143|23 27|data
P09805977A0143|71 77|origin
P09804836A0000|298 303|phase
P09804836A0000|325 339|chromatography
P09804836A0000|87 95|response
P09804836A0000|166 170|pp37
P09804836A0000|227 250|affinity chromatography
P09804836A0000|37 44|protein
P09804836A0000|99 125|mouse BAC1.2F5 macrophages
P09804779A0000|30 41|Stat family
P09804779A0000|1 22|Transcription factors
P09802902A0225|53 68|plasma membrane
P09801333A0174|41 54|reading frame
P09801333A0174|87 97|PRRS virus
P09800187A0100|210 230|mouse lymphoma cells
P09800187A0100|125 134|responses
P09800187A0100|43 47|TP53
P09800187A0100|20 33|mouse homolog
P09800187A0100|157 176|DNA damaging agents
P09800187A0100|238 247|mutations
P09799634A0161|95 112|crystal structure
P09799634A0161|54 60|domain
P09799634A0161|137 144|protein
P09799362A0507|33 41|features
P09799086A0725|60 71|frame shift
P09799086A0725|143 152|HPRT exon
P09799086A0725|19 35|hotspot mutation
P09799086A0725|84 106|G nucleotide insertion
P09798100A0705|15 21|CIDR-B
P09798100A0705|76 78|IM
P09797456A0883|90 97|nucleus
P09797456A0883|121 137|c-myc expression
P09797456A0883|28 37|cytoplasm
P09797456A0883|58 63|c-myc
P09797456A0883|1 6|AMY-1
P09797189A0559|56 67|CCAAT motif
P09795213A0129|209 211|L.
P09795213A0129|219 227|hTAFII68
P09795213A0129|190 197|Chambon
P09795213A0129|117 131|sub-population
P09795213A0129|152 165|Bertolotti A.
P09795213A0129|284 310|proto-oncoproteins TLS/FUS
P09795213A0129|167 171|Lutz
P09795213A0129|199 201|P.
P09795213A0129|97 103|factor
P09795213A0129|203 207|Tora
P09795213A0129|1 14|RBP56 protein
P09795130A0742|31 39|distance
P09795130A0742|19 27|increase
P09794414T0000|13 39|protein kinase C signaling
P09794414T0000|5 9|role
P09792702A0754|121 142|HSP70 gene expression
P09792702A0754|66 73|glucose
P09792702A0754|35 41|mutant
P09792630A1127|147 164|initiator element
P09792630A1127|113 117|NTCT
P09792630A1127|250 255|genes
P09792630A1127|13 21|sequence
P09792630A1127|110 112|+1
P09792630A1127|71 75|TTCC
P09792439T0000|88 107|40S hnRNP complexes
P09792439T0000|19 48|apolipoprotein B mRNA editing
P09790771A1032|24 39|backcross panel
P09790771A1032|96 106|chromosome
P09790771A1032|68 74|Gng3lg
P09790768A0621|108 114|kidney
P09790768A0621|1 12|Htra2-beta3
P09790499A0545|82 89|tissues
P09790499A0545|1 23|Northern blot analyses
P09789025A0149|60 63|SRF
P09789025A0149|10 18|Galpha12
P09789025A0149|42 49|Galphai
P09787323A0000|14 32|role interleukin-6
P09787323A0000|71 88|thrombocytopenias
P09787323A0000|34 38|IL-6
P09786932A1042|47 52|IRF-3
P09786932A1042|148 152|IFNA
P09786932A1042|7 12|IRF-7
P09786932A1042|80 90|expression
P09786932A1042|33 43|similarity
P09786926A0095|224 232|promoter
P09786926A0095|162 166|gene
P09786926A0095|197 205|activity
P09786926A0095|157 160|FAS
P09786926A0095|136 155|fatty-acid synthase
P09786197A0322|225 232|systems
P09786197A0322|109 123|reading frames
P09786197A0322|25 37|DNA sequence
P09786197A0322|136 140|csrR
P09784245T0000|44 58|identification
P09784245T0000|24 33|protein C
P09784245T0000|35 41|MyBP-C
P09784063A0621|62 70|promoter
P09784063A0621|83 114|ORF5/deltaX transcript promoter
P09781871A0404|241 263|response elicitor HrpN
P09781871A0404|264 267|Ecc
P09781871A0404|24 34|catabolism
P09781871A0404|220 225|plant
P09781871A0404|166 176|production
P09781871A0404|197 214|virulence factors
P09781871A0404|65 73|motility
P09781871A0404|103 112|adherence
P09780336A0771|104 114|germ cells
P09780336A0771|132 142|expression
P09780336A0771|59 71|mouse testes
P09780336A0771|202 209|amounts
P09780336A0771|1 9|Analysis
P09780228A0122|42 60|FK506 gene cluster
P09780228A0122|1 11|Sequencing
P09778197A0415|244 264|reductase inhibitors
P09778197A0415|294 309|atherosclerosis
P09778197A0415|115 125|comparison
P09778197A0415|194 230|beta-hydroxy-beta-methylglutaryl-CoA
P09778197A0415|346 357|cholesterol
P09778197A0415|77 98|health care resources
P09778197A0415|1 28|Cost-effectiveness analysis
P09778068A1129|14 35|Cox survival analysis
P09778068A1129|208 216|ablation
P09778068A1129|196 201|month
P09778068A1129|143 150|failure
P09778068A1129|255 260|death
P09778068A1129|102 115|regurgitation
P09777999A0796|95 106|hypercapnia
P09777999A0796|92 93|%
P09777999A0796|22 27|index
P09777477A0000|161 171|peppermint
P09777477A0000|66 80|vigilance task
P09777477A0000|117 123|whiffs
P09777477A0000|16 28|brain injury
P09776360A0620|44 69|transcription factor AP-1
P09776360A0620|1 3|CM
P09774662A0958|5 17|ARF promoter
P09774662A0958|102 109|results
P09774484T0000|80 104|glutathione peroxidase-1
P09774484T0000|1 19|UGA codon position
P09774444A0351|74 88|Cys2-His2 type
P09774444A0351|23 30|portion
P09774444A0351|115 126|CACCC motif
P09773981A0415b|15 38|glucocorticoid receptor
P09773981A0415b|47 54|complex
P09771985A0238|74 83|solutions
P09771985A0238|128 139|glutathione
P09771985A0238|36 57|ethylmercury chloride
P09771985A0238|4 12|subjects
P09771555A0499|27 52|anthraquinone sennoside B
P09771555A0499|5 12|results
P09770493A0499|56 77|cell cycle regulation
P09770493A0499|82 105|cell fate determination
P09770493A0499|4 8|PP2A
P09770493A0499|18 23|range
P09769910A1700|122 129|effects
P09769910A1700|42 47|cells
P09769910A1700|5 15|activation
P09769910A1700|139 148|mediators
P09767687T0000|14 22|position
P09767687T0000|108 122|rbcL sequences
P09767687T0000|83 91|analysis
P09767575A0657|42 46|edge
P09767575A0657|6 12|domain
P09767575A0657|84 100|ribosome binding
P09765754A1727|13 18|trend
P09765411A0991|61 70|ubiquitin
P09765411A0991|166 180|hybrid protein
P09765411A0991|111 117|CP Rit
P09765411A0991|48 52|S27a
P09765411A0991|1 21|Sequence comparisons
P09765394A0000|95 106|replication
P09765394A0000|128 134|oriLyt
P09765372A0669|167 177|C. armatus
P09765372A0669|77 89|distribution
P09765372A0669|52 56|half
P09765372A0669|64 68|body
P09765372A0669|32 38|spines
P09765285A0998|122 129|IRhsp-1
P09765285A0998|147 151|time
P09765285A0998|253 260|binding
P09765285A0998|165 175|stringency
P09765285A0998|40 65|consensus sequence AGGTCA
P09765285A0998|67 74|IRper-1
P09765271A1108|134 141|insulin
P09765271A1108|165 198|phosphoenolpyruvate carboxykinase
P09765271A1108|244 250|growth
P09765271A1108|6 14|sequence
P09765271A1108|38 63|insulin response sequence
P09764741A0092|41 49|elements
P09764741A0092|9 14|beams
P09764741A0092|96 103|beating
P09763522A2545|57 63|Ox-LDL
P09763522A2545|174 181|animals
P09763522A2545|87 96|apoptosis
P09763470A0000|61 69|dopamine
P09763470A0000|47 57|conversion
P09763470A0000|148 155|neurons
P09763470A0000|1 26|Dopamine beta-hydroxylase
P09763446A0000|7 14|GTPases
P09763446A0000|81 90|transport
P09761791A0489|5 16|interaction
P09761791A0489|87 105|blot overlay assay
P09761711A0000|125 131|nuclei
P09761711A0000|112 120|electron
P09761711A0000|86 94|coupling
P09760243A0970|79 94|transactivation
P09760243A0970|32 57|HNF-4 expression plasmids
P09760243A0970|102 118|apoCIII promoter
P09759691A1051|120 130|microg/min
P09759691A1051|94 111|albumin excretion
P09759691A1051|59 63|risk
P09759691A1051|190 195|mm Hg
P09759691A1051|357 364|smokers
P09759691A1051|135 138|men
P09759691A1051|143 148|women
P09759691A1051|278 279|L
P09759691A1051|4 12|analyses
P09759691A1051|68 84|microalbuminuria
P09757012A0942|128 139|information
P09757012A0942|25 36|SAM domains
P09757012A0942|5 13|presence
P09756687A0981|13 29|characterization
P09756687A0981|65 70|setup
P09756687A0981|34 44|discussion
P09755199A0559|130 133|Scm
P09755199A0559|139 146|alleles
P09755191A0553|60 66|allele
P09755191A0553|89 99|chain gene
P09755191A0553|179 192|reading frame
P09755191A0553|158 161|end
P09755191A0553|169 173|CHC1
P09754571A0169|108 128|RAG1 mRNA expression
P09754571A0169|50 70|display amplicon 3G1
P09753774A2246|160 179|plant fructan genes
P09753774A2246|42 62|amino acid sequences
P09753774A2246|66 71|1-sst
P09753769A0362|73 93|amino acid sequences
P09753769A0362|37 53|oligonucleotides
P09753769A0362|101 115|PBAN precursor
P09753241A0524|72 78|assays
P09753241A0524|131 143|colon mucosa
P09753241A0524|199 204|weeks
P09753241A0524|82 106|myeloperoxidase activity
P09753241A0524|116 127|homogenates
P09753241A0524|207 218|% DSS model
P09751166A1460|44 47|CRE
P09751166A1460|112 120|promoter
P09751166A1460|139 145|manner
P09751114A0967|89 95|vector
P09751114A0967|48 53|cells
P09750540A0000|42 50|syndrome
P09750540A0000|32 35|MCS
P09749988A0000|302 311|repulsion
P09749988A0000|244 258|repulsion zone
P09749988A0000|87 91|line
P09749988A0000|107 112|zones
P09749988A0000|13 23|Westheimer
P09749988A0000|229 236|extents
P09749988A0000|33 39|Vision
P09748669A0414|11 15|time
P09748669A0414|52 54|AD
P09748286A0000|134 150|characterization
P09748286A0000|107 111|gene
P09748286A0000|42 50|enhancer
P09748286A0000|101 105|LIFR
P09747873T0000|57 64|BCR-ABL
P09745797A0943|91 96|tasks
P09745797A0943|26 42|underpredictions
P09745797A0943|69 79|disruption
P09743720A0268|1 8|ANIMALS
P09743128A0969|23 30|Bis-GMA
P09741783A0000|149 162|breast cancer
P09741783A0000|129 134|women
P09741783A0000|68 86|survival advantage
P09739913A0194|78 83|trunk
P09739913A0194|1 12|CASE REPORT
P09738693T0000|12 19|rhG-CSF
P09738693T0000|48 56|survival
P09738693T0000|84 88|rats
P09738010A0305|130 148|base pair position
P09738010A0305|5 17|FAS promoter
P09737453A0557|121 127|factor
P09737453A0557|59 66|surgery
P09737453A0557|53 57|days
P09737453A0557|71 85|IgG antibodies
P09737453A0557|1 7|Plasma
P09736715A0729|167 169|Pi
P09736715A0729|95 98|ILK
P09736715A0729|172 173|K
P09736715A0729|116 124|addition
P09736697A0783|47 53|kinase
P09736697A0783|126 142|Stat3 activation
P09736697A0783|37 41|MEK1
P09736697A0783|1 11|Expression
P09735371A0227|95 106|touch cells
P09735371A0227|42 61|homeodomain protein
P09735371A0227|114 119|mec-3
P09735371A0227|139 158|homeodomain protein
P09735366A1180|195 201|humans
P09735366A1180|162 184|Caenorhabditis elegans
P09735366A1180|7 34|homology cloning techniques
P09735366A1180|71 72|E
P09735366A1180|152 156|ESTs
P09734808A0000|12 27|test efficiency
P09734808A0000|67 91|contrast/color card test
P09734808A0000|117 130|test stimulus
P09733815T0000|61 92|protein tyrosine kinase loading
P09733815T0000|24 43|membrane protein 2A
P09733815T0000|1 9|Tyrosine
P09733647A1960|149 154|algae
P09733647A1960|159 173|archeabacteria
P09733647A1960|71 77|B-loop
P09733647A1960|139 147|bacteria
P09731705A2126|36 42|system
P09731705A2126|64 72|evidence
P09731705A2126|19 24|yeast
P09731705A2126|119 130|interaction
P09731704A0000|56 79|estrogen receptor-alpha
P09731704A0000|111 113|E2
P09731704A0000|6 11|study
P09731704A0000|81 88|ERalpha
P09731354A0963|44 59|surface density
P09731354A0963|143 145|hr
P09731354A0963|18 27|degrees C
P09731354A0963|34 35|%
P09729481A1177|226 232|region
P09729481A1177|124 127|Sp1
P09729481A1177|160 177|promoter activity
P09729481A1177|59 77|promoter construct
P09727046A0784|90 95|NF-E2
P09727046A0784|22 25|HS2
P09727046A0784|5 14|CBF1 site
P09727046A0784|101 105|TAL1
P09727045A0817|41 51|activation
P09727045A0817|176 197|ligand binding domain
P09727045A0817|71 80|receptors
P09727045A0817|137 145|presence
P09726988A0275|39 51|M-CPT I mRNA
P09726979T0000|61 79|sphingosine kinase
P09726979T0000|34 50|characterization
P09725854A1060|228 256|urf209 processing activities
P09725854A1060|189 199|capability
P09725854A1060|54 60|action
P09725854A1060|154 161|alleles
P09725854A1060|119 137|IS1112C Rf3 allele
P09725292A1473|98 100|CT
P09725292A1473|51 59|criteria
P09724763T0000|31 64|abalone sperm fertilization genes
P09724763T0000|89 96|introns
P09724654A1120|14 22|presence
P09724654A1120|104 111|loading
P09724654A1120|115 118|RPA
P09724654A1120|69 76|origins
P09723896A0000|46 50|PPAR
P09723896A0000|131 139|elements
P09723896A0000|98 108|peroxisome
P09723896A0000|155 173|heterodimerization
P09723896A0000|35 44|receptors
P09722508A0953|148 161|HEK-293 cells
P09722508A0953|35 49|Galpha11 Q209L
P09722043A2070|15 25|TPN groups
P09722043A2070|54 64|activities
P09722043A2070|68 73|liver
P09721207A0637|67 73|region
P09721207A0637|84 94|Chromosome
P09718671A0000|31 34|AIS
P09718671A0000|161 169|patients
P09718671A0000|37 58|Injury Severity Scale
P09718671A0000|140 148|injuries
P09717887A0239|61 68|VO2peak
P09717887A0239|40 48|equation
P09717887A0239|111 115|PAOD
P09717887A0239|200 207|VO2peak
P09717887A0239|117 125|patients
P09717246A0526|181 185|ILVF
P09717246A0526|132 144|lipid weight
P09717246A0526|57 70|exposure time
P09717246A0526|19 30|ILVF values
P09717246A0526|171 176|day-1
P09716183A1036|147 173|ERK kinase consensus sites
P09716183A1036|39 47|extracts
P09716183A1036|100 104|ERK2
P09716183A1036|51 61|U937 cells
P09715278A1526|78 94|xenograft tumors
P09715278A1526|24 42|neovascularization
P09715278A1526|136 157|control transfectants
P09714835A0345|12 18|report
P09714835A0345|213 217|Song
P09714835A0345|219 221|L.
P09714835A0345|20 38|carboxypeptidase D
P09714835A0345|223 230|Fricker
P09714835A0345|152 158|enzyme
P09714109A0000|89 95|muscle
P09714109A0000|108 122|nerve activity
P09714109A0000|1 11|BACKGROUND
P09713996A0262|148 154|agents
P09713996A0262|54 61|cancers
P09713996A0262|19 23|MDR1
P09713584A1193|30 44|spouse/partner
P09713584A1193|106 112|people
P09713584A1193|1 12|Respondents
P09712915A0672|107 132|transcription factors Sp1
P09712915A0672|89 99|activities
P09712915A0672|5 13|activity
P09712898A0911|88 91|GCK
P09712898A0911|23 27|SAPK
P09712898A0911|71 86|protein kinases
P09712644T0000|63 73|expression
P09712644T0000|35 45|GluR2 gene
P09712644T0000|17 27|regulation
P09712037A0470|107 115|sequence
P09712037A0470|163 179|Fyn interactions
P09712037A0470|219 236|activation motifs
P09712037A0470|39 50|amino acids
P09712037A0470|1 16|Tctex-1 binding
P09710621A0598|73 95|cysteine substitutions
P09710621A0598|167 173|series
P09710621A0598|131 136|order
P09710621A0598|21 32|possibility
P09710614T0000|131 141|activation
P09710614T0000|66 72|domain
P09710614T0000|1 15|Identification
P09710614T0000|118 126|adhesion
P09710599A0310|15 20|cells
P09710599A0310|122 123|h
P09710599A0310|22 27|ets-2
P09710599A0310|155 168|ets-2 protein
P09710589A1111|15 26|mutagenesis
P09710589A1111|61 65|K85A
P09710589A1111|95 103|proteins
P09710589A1111|67 71|K88A
P09710589A1111|55 59|R82A
P09710131A0374|95 116|laser printer formats
P09710131A0374|51 60|distances
P09708450A0648|67 78|study group
P09708450A0648|155 160|G-CSF
P09708450A0648|1 9|Toxicity
P09707498A0262|58 73|seizure latency
P09706565A1072|45 48|min
P09706565A1072|52 66|immobilization
P09706565A1072|17 20|M/K
P09705497A0227|108 121|mms2-1 mutant
P09705497A0227|39 46|ability
P09705324A1602|390 395|C/EBP
P09705324A1602|24 49|rat Std promoter function
P09705324A1602|158 168|repression
P09705324A1602|250 259|positions
P09705324A1602|425 443|DNA-AR interaction
P09705324A1602|285 287|AR
P09705324A1602|227 241|C/EBP elements
P09705324A1602|77 82|C/EBP
P09705324A1602|103 120|liver specificity
P09705258A0837|79 85|copies
P09705258A0837|96 100|gene
P09705258A0837|118 127|insertion
P09704857T0000|75 83|HIV/AIDS
P09704857T0000|36 50|CD4 lymphocyte
P09704857T0000|16 30|skin disorders
P09704296T0000|124 131|patient
P09704296T0000|97 109|eosinophilia
P09703816A0139|74 85|shot method
P09703816A0139|12 21|cisplatin
P09703816A0139|25 27|mg
P09703816A0139|1 6|IA-CT
P09703213A0280|25 42|D1 antagonist SCH
P09703213A0280|4 15|experiments
P09701895A0119|72 78|period
P09701895A0119|23 31|children
P09701895A0119|86 90|year
P09701616A0108|9 48|transcriptase-polymerase chain reaction
P09701616A0108|101 104|DNA
P09700644T0000|59 70|measurement
P09700644T0000|5 13|spectrum
P09698457A0976|240 244|date
P09698457A0976|167 175|affinity
P09698457A0976|129 136|protein
P09698457A0976|263 273|cut repeat
P09698457A0976|34 40|levels
P09696819A0450|15 22|mutants
P09696819A0450|149 158|transport
P09696819A0450|76 89|vTF7-3 system
P09696819A0450|55 63|vaccinia
P09696819A0450|136 138|ER
P09695194T0000|59 63|data
P09694869A0932|214 222|mutation
P09694869A0932|295 310|cytokine effect
P09694869A0932|115 120|Stat3
P09694869A0932|259 267|promoter
P09694869A0932|160 172|p21 promoter
P09694869A0932|202 207|Stat3
P09694869A0932|65 75|activation
P09694869A0932|137 152|cytokine effect
P09694725A0500|77 82|LILRE
P09694725A0500|175 192|IL-1beta promoter
P09694725A0500|103 130|gamma interferon activation
P09694514A0000|75 84|G-protein
P09694514A0000|44 48|C3aR
P09694514A0000|247 265|muscle contraction
P09694514A0000|93 117|chemoattractant receptor
P09694514A0000|138 156|C3a peptide ligand
P09694514A0000|205 222|histamine release
P09693306T0000|22 32|potentials
P09693035T0000|73 95|Caenorhabditis elegans
P09693035T0000|111 121|expression
P09693035T0000|97 109|cDNA cloning
P09693035T0000|139 149|assignment
P09691037A0355|10 19|sequences
P09691037A0355|36 45|insertion
P09689919A1192|82 99|PEDF glycoprotein
P09688264A1029|47 50|spi
P09688264A1029|58 77|UTR silencer action
P09687511A1091|104 110|growth
P09687511A1091|148 159|restoration
P09687511A1091|130 146|colony formation
P09687511A1091|190 205|differentiation
P09687511A1091|1 15|Downregulation
P09686603A0124|46 54|elements
P09686603A0124|27 31|role
P09686603A0124|171 193|TCR beta gene segments
P09685346A0419|96 106|activation
P09685346A0419|20 25|Pitx2
P09685346A0419|38 57|homeodomain protein
P09685021A0127|183 189|microm
P09685021A0127|89 114|model lenticule materials
P09685021A0127|366 370|cats
P09685021A0127|156 162|microm
P09685021A0127|288 298|collagen I
P09685021A0127|10 45|Millipore ultrafiltration membranes
P09685021A0127|446 457|persistence
P09685021A0127|65 75|pore sizes
P09685021A0127|235 240|order
P09685021A0127|1 8|METHODS
P09682897A0218|105 116|QRS changes
P09682897A0218|143 157|injury pattern
P09682897A0218|19 24|years
P09680994A0169|56 61|jaf13
P09680994A0169|127 144|sequence homology
P09680994A0169|6 11|study
P09680994A0169|216 231|Z. mays r genes
P09680994A0169|187 208|P. hybrida orthologue
P09679066A1352|7 14|results
P09679066A1352|33 46|demonstration
P09678579A0768|44 54|AtCP1 gene
P09678579A0768|9 16|insight
P09677405A0856|29 41|antimutators
P09677405A0856|1 19|Pol32Delta strains
P09676419A0158|58 63|years
P09676419A0158|127 134|patient
P09676419A0158|257 279|serum immunoglobulin E
P09676419A0158|220 227|CAP SX1
P09676419A0158|109 123|questionnaires
P09676419A0158|234 247|determination
P09676419A0158|169 184|screening tests
P09676419A0158|1 7|METHOD
P09675896A0959|1 8|Removal
P09673436A0898|210 211|%
P09673436A0898|29 41|ANP infusion
P09673436A0898|213 214|n
P09673436A0898|160 168|infusion
P09673436A0898|128 129|%
P09673436A0898|141 142|n
P09673436A0898|170 174|FENA
P09671791T0000|89 101|intermediate
P09671791T0000|20 30|activation
P09671576A0900|62 82|streak morphogenesis
P09671464A0316|105 112|glucose
P09671464A0316|10 14|SNF1
P09671464A0316|142 146|Snf1
P09671464A0316|51 56|steps
P09670943T0000|40 49|formation
P09670943T0000|83 93|inhibition
P09670943T0000|1 24|B cell antigen receptor
P09670034A0340|77 88|interaction
P09670034A0340|98 104|Rad17p
P09668119A0496|108 123|point mutations
P09668119A0496|144 163|binding nucleotides
P09668119A0496|17 38|mobility shift assays
P09668098A0868|57 74|deletion analysis
P09668098A0868|23 38|FGF-BP promoter
P09668098A0868|140 150|base pairs
P09668063A0274|26 30|role
P09668063A0274|126 133|variety
P09668063A0274|184 189|cells
P09668063A0274|34 46|Ets proteins
P09667482A0978|74 81|context
P09667482A0978|177 184|context
P09667482A0978|36 48|contribution
P09667482A0978|115 122|disease
P09667482A0978|85 92|therapy
P09666103A0496|109 114|E225K
P09666103A0496|126 131|E274K
P09666103A0496|172 181|phenotype
P09666103A0496|5 20|missense allele
P09666103A0496|84 100|missense alleles
P09666103A0496|102 107|L173F
P09665720A0325|95 105|possession
P09665720A0325|113 128|primer terminus
P09665720A0325|19 22|Mg2
P09665361T0000|25 40|thyroid nodules
P09663062A0175|88 95|systems
P09663062A0175|189 196|scatter
P09663062A0175|216 224|dentists
P09663062A0175|72 78|dentin
P09663062A0175|97 119|Clearfil Liner Bond II
P09663062A0175|32 37|resin
P09662339A0744|151 158|protein
P09662339A0744|123 133|expression
P09662339A0744|93 101|activity
P09662339A0744|137 146|CD44 mRNA
P09660838A0920|214 233|heat shock response
P09660838A0920|188 194|growth
P09660838A0920|138 153|serine residues
P09660838A0920|69 92|protein kinase cascades
P09660823A0934|10 33|Ser/Thr phosphorylation
P09660823A0934|48 61|molecules Akt
P09658405A0000|66 73|members
P09658405A0000|5 15|Dax-1 gene
P09658122T0000|57 67|alpha-SNAP
P09658122T0000|36 44|homologs
P09658122T0000|1 14|Fowlpox virus
P09657003T0000|14 27|relationships
P09657003T0000|57 72|RNA polymerases
P09657003T0000|111 114|RNA
P09657003T0000|179 186|viruses
P09657003T0000|218 229|Arabidopsis
P09656414A0220|1 7|Dosage
P09655248A0000|60 92|lipoprotein receptor gene family
P09655248A0000|192 199|ligands
P09655248A0000|5 22|gp330/Megalin/LRP
P09655248A0000|137 145|receptor
P09653648A0445|151 159|end exon
P09653648A0445|57 68|ZNF189 gene
P09653648A0445|92 94|kb
P09653648A0445|184 202|zinc finger domain
P09653182A1298|47 51|BSMV
P09653182A1298|7 11|data
P09653182A1298|66 79|primer donors
P09653182A1298|84 93|MStV mRNA
P09652737A1244|88 93|Fra-1
P09652737A1244|159 185|Jun family member proteins
P09652737A1244|98 103|Fra-2
P09652737A1244|50 76|Fos family member proteins
P09651375T0000|44 63|binding specificity
P09651375T0000|92 95|PDZ
P09651375T0000|114 120|domain
P09651375T0000|1 7|GTPase
P09651321A0000|15 44|cysteine proteinase inhibitor
P09651321A0000|165 193|keratinocyte differentiation
P09651321A0000|92 105|cell envelope
P09651321A0000|1 11|Cystatin A
P09650403A0868|92 97|group
P09650403A0868|110 113|BMD
P09650299A0000|78 88|processing
P09650299A0000|93 101|transfer
P09650186A1043|9 15|number
P09650186A1043|83 94|radiologist
P09650186A1043|116 123|regions
P09649537A0000|73 78|yGCN2
P09649438A0182|73 84|CDK9 kinase
P09649438A0182|203 210|extract
P09649438A0182|190 194|HeLa
P09649438A0182|116 123|factors
P09649438A0182|19 57|transcription elongation factor P-TEFb
P09649426A0636|64 69|Msn2p
P09649426A0636|16 28|PKA activity
P09649265A1575|183 186|men
P09649265A1575|92 100|prostate
P09649265A1575|76 84|biopsies
P09649265A1575|1 12|CONCLUSIONS
P09649265A1575|258 267|serum PSA
P09647240A0000|5 14|influence
P09647240A0000|18 21|p53
P09647240A0000|204 207|p53
P09645961A1158|130 139|nTPH gene
P09645961A1158|67 76|CCAAT box
P09645961A1158|5 12|results
P09645576A0148|36 37|%
P09645576A0148|55 58|BMT
P09643546A0436|144 161|stress conditions
P09643546A0436|116 121|cells
P09642764A0469|15 19|mass
P09642764A0469|91 95|mass
P09642764A0469|145 155|techniques
P09642764A0469|39 51|QCM response
P09642764A0469|257 260|QCM
P09642238A1285|211 217|factor
P09642238A1285|72 75|Sp1
P09642238A1285|162 173|Sp1 protein
P09642238A1285|5 11|intron
P09642238A1285|137 148|involvement
P09642227A0000|38 55|bone proteoglycan
P09642200A0956|60 72|proteolipids
P09642200A0956|134 138|ahaK
P09642200A0956|280 287|archaea
P09642200A0956|248 264|chemical natures
P09642200A0956|292 300|bacteria
P09641167A1359|13 22|TNF alpha
P09641167A1359|24 32|TGF beta
P09641167A1359|144 162|gene transcription
P09641167A1359|34 38|PDGF
P09640162A0242|131 149|ventricle teratoma
P09640162A0242|83 108|growth hormone deficiency
P09640162A0242|51 65|growth hormone
P09639558A0957|37 47|haemolysis
P09639074A0707|13 25|Sp3 isoforms
P09639074A0707|64 76|constituents
P09639074A0707|137 141|site
P09638650A0169|271 275|ORF4
P09638650A0169|179 199|kDa movement protein
P09638650A0169|213 233|kDa movement protein
P09638650A0169|112 120|proteins
P09638650A0169|325 336|nucleotides
P09638650A0169|135 138|kDa
P09638650A0169|281 297|kDa coat protein
P09638650A0169|128 129|r
P09638650A0169|36 39|NCR
P09638650A0169|70 84|reading frames
P09638342T0000|44 48|link
P09638342T0000|79 109|membrane cytoskeleton assembly
P09638342T0000|66 74|adhesion
P09636708A0460|230 241|degradation
P09636708A0460|5 17|YccA protein
P09636708A0460|64 70|manner
P09636358A0000|73 76|RNA
P09636358A0000|146 151|mRNAs
P09636358A0000|112 123|translation
P09636358A0000|33 43|adenovirus
P09635276A1608|104 114|mechanisms
P09635276A1608|52 59|changes
P09633879A0246|44 54|resurgence
P09633879A0246|147 149|L1
P09633879A0246|96 104|patients
P09633879A0246|20 30|compliance
P09633274A0000|60 69|treatment
P09633274A0000|1 18|Exercise training
P09632785A0000|123 127|role
P09632785A0000|53 79|ribonucleoprotein particle
P09632785A0000|81 86|snRNP
P09632734A0081|105 110|group
P09632734A0081|24 32|proteins
P09632734A0081|82 99|sequence homology
P09632734A0081|169 189|GTP binding proteins
P09632637A0361|183 203|carbon tetrachloride
P09632637A0361|167 171|rats
P09632637A0361|232 241|stimulant
P09632637A0361|100 133|M6P/IGFIIR mRNA transcript levels
P09631366A0951|88 93|cases
P09631366A0951|78 83|cycle
P09631366A0951|49 59|dose level
P09630245A0102|120 125|yeast
P09630245A0102|130 137|metazoa
P09630245A0102|100 111|differences
P09628890A0455|14 23|following
P09628890A0455|65 87|carbohydrate structure
P09628419A0812|30 49|Kristofferson model
P09628419A0812|21 25|Wing
P09627598A0384|121 128|measure
P09627598A0384|132 156|otolith system imbalance
P09627598A0384|37 38|%
P09627598A0384|87 100|preponderance
P09627598A0384|17 25|patients
P09627285A0160|10 20|University
P09625807A0000|135 148|cell cultures
P09625807A0000|173 193|carcinoma cell lines
P09625807A0000|21 25|mRNA
P09623830A0000|24 39|botulinum toxin
P09623830A0000|17 20|use
P09622121A0525|41 48|binding
P09622121A0525|59 62|RNA
P09621893A0000|10 17|studies
P09621893A0000|55 64|increases
P09621062A0810|164 213|chloramphenicol acetyltransferase reporter system
P09621062A0810|149 156|mutants
P09621062A0810|5 15|importance
P09621062A0810|51 61|activation
P09620873A1710|39 68|luteal HSP-27 phosphorylation
P09620873A1710|190 217|sHSP phosphorylation events
P09620873A1710|102 111|PKC-delta
P09620273A0189|63 70|cyclins
P09620273A0189|4 11|mammals
P09620273A0189|85 103|cell proliferation
P09619631A0344|127 139|p120 Ras-GAP
P09619631A0344|1 8|RESULTS
P09618475A0747|37 42|motif
P09618475A0747|100 108|function
P09618150A1464|30 55|AP-1 DNA binding activity
P09618150A1464|62 68|effect
P09618150A1464|4 12|addition
P09617807A0929|164 176|relationship
P09617807A0929|40 60|transcriptase domain
P09617807A0929|111 118|Cyclops
P09617807A0929|216 224|elements
P09617807A0929|16 24|analysis
P09614106T0000|128 138|expression
P09614106T0000|80 91|Col2a1 gene
P09613946A0194|96 103|mm I.D.
P09613946A0194|3 29|deproteinization procedure
P09612775A0726|91 99|patients
P09612775A0726|48 68|serum antigen levels
P09611877A0455|90 94|ECHO
P09611877A0455|62 66|ECHO
P09611229A1664|47 72|nmt1-451Dino2 Delta cells
P09611229A1664|132 139|factors
P09611229A1664|199 205|levels
P09611229A1664|218 243|protein N-myristoy-lation
P09611229A1664|39 43|FAS1
P09610755A1731|62 65|EXT
P09610755A1731|5 28|side-to-side difference
P09610755A1731|69 78|degrees/s
P09609705A0895|76 81|Huang
P09609705A0895|65 70|Zhang
P09609705A0895|100 102|V.
P09609705A0895|34 63|bc1 complex crystal structure
P09606924T0000|24 30|method
P09606924T0000|1 7|Liquid
P09606924T0000|84 101|retinyl palmitate
P09605934A0801|107 113|member
P09605934A0801|22 28|CACGTG
P09605934A0801|96 102|factor
P09605934A0801|70 73|USF
P09605137A0677|105 124|reporter constructs
P09605137A0677|133 138|LFA-3
P09605137A0677|24 29|c-Jun
P09605137A0677|55 68|transcription
P09603345A1257|61 80|genome organization
P09603345A1257|107 112|group
P09603345A1257|114 117|BYV
P09603345A1257|190 209|genus Closterovirus
P09601940A0280|31 39|CD1 gene
P09601940A0280|96 117|transcription factors
P09601940A0280|17 23|region
P09601516A0695|90 105|fusion activity
P09601516A0695|57 65|residues
P09601516A0695|141 151|processing
P09601516A0695|1 13|Substitution
P09601007A0223|104 121|coral reef waters
P09601007A0223|62 69|changes
P09601007A0223|209 222|calcification
P09601007A0223|228 245|CaCO3 dissolution
P09601007A0223|141 150|processes
P09599724A0193|209 222|PCDF exposure
P09599724A0193|321 327|cohort
P09599724A0193|292 307|cancer findings
P09599724A0193|185 191|extent
P09599724A0193|41 50|employees
P09599724A0193|231 237|cohort
P09599724A0193|140 154|PCDF congeners
P09599102A1191|15 27|Mac1p mutant
P09599102A1191|121 128|pattern
P09599102A1191|29 39|refractile
P09599102A1191|82 83|I
P09599102A1191|85 100|transport genes
P09598205A0430|13 21|reaction
P09598205A0430|110 116|maltol
P09598205A0430|49 62|disaccharides
P09596638T0000|60 68|homeolog
P09596638T0000|28 51|Brassica S locus region
P09596536A0219|109 131|cartilage degeneration
P09596536A0219|35 55|knee loading changes
P09594299A0468|120 129|reduction
P09594299A0468|63 67|time
P09594299A0468|21 26|index
P09592219A0652|26 39|effectiveness
P09592219A0652|5 12|results
P09592168T0000|12 20|features
P09592168T0000|36 54|DNA binding domain
P09591221A0137|111 113|P1
P09591221A0137|140 144|site
P09591221A0137|101 109|ms range
P09590294A0453|91 104|Notch pathway
P09590294A0453|73 83|components
P09587549T0001|44 60|interferon alpha
P09587549T0001|29 38|treatment
P09586285A0551|75 80|years
P09586285A0551|5 13|patients
P09585253A1147|63 73|activation
P09585253A1147|40 55|raf-ERK pathway
P09585253A1147|22 32|activation
P09585253A1147|190 203|TF expression
P09585253A1147|207 223|MDA-MB-231 cells
P09584194A0000|43 49|family
P09584194A0000|7 11|p130
P09584194A0000|142 155|cell adhesion
P09584194A0000|1 5|HEF1
P09584179A0673|58 84|transcription factor Adf-1
P09583823A0238|151 158|holmium
P09583823A0238|213 214|n
P09583823A0238|188 191|YAG
P09583823A0238|251 256|group
P09583823A0238|48 56|ligation
P09583823A0238|258 259|n
P09583823A0238|12 17|total
P09583823A0238|200 211|laser group
P09583823A0238|1 8|METHODS
P09583208A0171|91 101|complement
P09583208A0171|8 17|elevation
P09583208A0171|71 85|immunoglobulin
P09582953A1670|36 45|alpha 2AP
P09582953A1670|87 107|acute-phase proteins
P09582953A0000|209 210|X
P09582953A0000|390 397|changes
P09582953A0000|212 215|F.X
P09582953A0000|59 65|F.VIII
P09582953A0000|295 305|population
P09582953A0000|218 237|hemostasis proteins
P09582953A0000|186 191|F.VII
P09582953A0000|198 200|F.
P09582953A0000|96 102|C1-INH
P09582953A0000|309 315|horses
P09582350A0165|166 176|activities
P09582350A0165|57 72|E1alpha subunit
P09582350A0165|4 12|patients
P09582350A0165|103 107|loss
P09582331A0506|104 110|GATA-1
P09582331A0506|82 92|CAAT boxes
P09582331A0506|156 164|elements
P09582326A0151|9 16|Fanning
P09582326A0151|1 3|N.
P09582306T0000|66 75|regulator
P09582306T0000|3 17|point mutation
P09582306T0000|49 60|interaction
P09581872A0000|60 79|collagen expression
P09581872A0000|53 57|type
P09581775A0185|131 135|U937
P09581775A0185|172 180|PLB-IIIB
P09581775A0185|16 21|study
P09581775A0185|137 144|U9-IIIB
P09580700A0841|41 63|repressor preparations
P09580700A0841|110 119|CIR3-CIR6
P09580700A0841|83 92|fragments
P09580700A0841|156 165|templates
P09580062A0100|148 157|mg/kg/day
P09580062A0100|138 142|dose
P09580062A0100|70 78|steroids
P09579789A0974|91 95|bulb
P09579789A0974|13 20|results
P09579789A0974|65 73|remnants
P09579789A0974|38 42|rats
P09578570A0200|45 54|protein Z
P09578570A0200|209 216|library
P09578570A0200|108 119|combination
P09578570A0200|77 86|structure
P09578570A0200|144 157|leukocyte DNA
P09578570A0200|175 187|phage clones
P09577395A0000|73 81|impulses
P09577395A0000|145 155|degrees/s2
P09577395A0000|158 171|low-amplitude
P09577395A0000|84 89|brief
P09576915A0269|56 61|rings
P09576915A0269|86 95|silencers
P09575217A0971|135 161|Stat5 hyperphosphorylation
P09575217A0971|39 55|Stat5 SH2 domain
P09575217A0971|70 85|phosphorylation
P09575217A0971|17 31|R618K mutation
P09575187A1558|105 109|data
P09575187A1558|12 16|role
P09575187A1558|177 183|effect
P09575187A1558|66 84|ER calcium release
P09574799A1072|120 126|market
P09574799A1072|149 164|food inspection
P09574799A1072|130 134|lack
P09574799A1072|48 55|factors
P09574799A1072|187 197|sanitation
P09573378A0761|14 15|C
P09573378A0761|23 31|D' boxes
P09573378A0761|1 4|U73
P09573244A0523|11 23|mRNA species
P09573187T0000|83 96|binding sites
P09573187T0000|17 27|repression
P09572965A1235|14 18|ORF5
P09572965A1235|40 49|gene agrB
P09572965A1235|162 169|species
P09572965A1235|103 112|mechanism
P09572491A1044|72 77|codon
P09572491A1044|112 119|alanine
P09572491A1044|19 24|cells
P09571563A0000|74 85|keratectomy
P09571563A0000|165 174|condition
P09571563A0000|182 188|cornea
P09571563A0000|48 54|cornea
P09571563A0000|1 8|PURPOSE
P09570944T0000|79 101|resistance gene region
P09570944T0000|20 25|exons
P09570944T0000|1 13|Localization
P09570107A0355|64 70|boiler
P09568549A0188|120 124|rats
P09568549A0188|9 14|study
P09568549A0188|128 140|serum levels
P09568549A0188|36 50|administration
P09568549A0188|71 80|malathion
P09566918A1115|105 110|IRF-3
P09566918A1115|193 197|ISRE
P09566918A1115|144 153|activator
P09566918A1115|97 101|form
P09566918A1115|21 34|Ser-Thr sites
P09566876A0000|120 144|transcription activation
P09566876A0000|96 108|promoter DNA
P09566876A0000|65 85|TATA binding protein
P09566871A0343|165 168|TyA
P09566871A0343|41 58|protein synthesis
P09566871A0343|76 86|processing
P09566871A0343|4 16|fus3 mutants
P09566871A0343|32 39|Ty1 RNA
P09566871A0343|220 228|Ty1 cDNA
P09565606A0520|26 35|structure
P09565606A0520|52 55|end
P09565606A0520|113 117|repZ
P09565576T0000|13 19|domain
P09564860A2315|105 121|protein coupling
P09564860A2315|88 98|receptor G
P09564860A2315|162 171|cell line
P09564860A2315|178 182|loop
P09564860A2315|203 222|signal transduction
P09564860A2315|50 54|loop
P09562558T0000|45 51|domain
P09562558T0000|27 32|IRF-2
P09562558T0000|1 19|Solution structure
P09561616A0142|73 84|% mortality
P09561616A0142|92 111|culicifacies adults
P09561616A0142|1 13|Deltamethrin
P09560430A0000|75 80|cells
P09560430A0000|22 26|role
P09560430A0000|1 5|Ime1
P09560325A1285|60 75|phosphorylation
P09560325A1285|128 149|protein heterogeneity
P09560325A1285|20 33|modifications
P09557912A0699|361 372|respiration
P09557912A0699|26 28|SD
P09557912A0699|251 253|SD
P09557912A0699|87 91|mmHg
P09557912A0699|259 263|mmHg
P09557912A0699|165 167|SD
P09557912A0699|12 15|IOP
P09557912A0699|131 140|injection
P09557912A0699|312 316|mmHg
P09557912A0699|283 293|convulsion
P09557912A0699|98 102|loss
P09557912A0699|34 38|mmHg
P09557682A0490|120 129|splicings
P09557682A0490|193 196|LTR
P09557682A0490|25 36|hGli2 alpha
P09557682A0490|143 151|isoforms
P09557682A0490|55 60|delta
P09556861A1018|208 223|tRNA-synthetase
P09556861A1018|22 32|literature
P09556861A1018|185 188|ATP
P09556861A1018|285 303|lipid peroxidation
P09556861A1018|172 181|depletion
P09556861A1018|65 73|toxicity
P09556861A1018|101 108|effects
P09556566A0174|77 85|RXRalpha
P09556566A0174|33 36|VDR
P09556557A1238|25 32|regions
P09553686A0000|240 260|absorption enhancers
P09553686A0000|21 29|patterns
P09553686A0000|44 47|CAS
P09553686A0000|287 299|applications
P09553686A0000|110 115|women
P09553686A0000|64 71|estrone
P09553686A0000|139 148|menopause
P09553134A0596|26 43|neurite outgrowth
P09553134A0596|64 103|tyrosine kinase inhibitors herbimycin A
P09552469A0225|106 118|spectroscopy
P09552469A0225|144 152|analysis
P09552469A0225|5 16|interaction
P09552469A0225|64 84|x-ray diffractometry
P09552469A0225|154 157|DTA
P09551938A0318|92 110|CCR5 gene promoter
P09551096A0108|29 39|components
P09551096A0108|115 133|particle formation
P09551096A0108|1 5|RNAs
P09550591A0454|12 21|treatment
P09550591A0454|82 87|cmH2O
P09550591A0454|156 160|OSAS
P09549660A0782|40 48|subjects
P09549660A0782|86 99|data scenario
P09549398A1463|198 207|viability
P09549398A1463|27 64|rest/postnitroglycerin technetium-99m
P09549398A1463|77 89|SPET studies
P09549398A1463|223 224|%
P09548481A0000|74 83|existence
P09548481A0000|53 55|P1
P09548481A0000|4 12|addition
P09547311A1394|14 26|interactions
P09547311A1394|62 72|E-cadherin
P09547311A1394|129 135|domain
P09547311A1394|81 88|chimera
P09547311A1394|238 250|interactions
P09547311A1394|254 264|E-cadherin
P09545638T0000|59 86|arginine methyltransferases
P09545638T0000|100 107|HRMT1L2
P09545638A0836|13 28|HRMT1L2 protein
P09545638A0330a|67 71|HMT1
P09545332A0137|150 158|response
P09545332A0137|162 166|IL-4
P09545332A0137|82 108|insulin receptor substrate
P09545332A0137|1 9|Mutation
P09545332A0137|50 74|tyrosine phosphorylation
P09545312A1197|46 58|HMG-I family
P09545312A1197|128 134|effect
P09545312A1197|5 17|observations
P09545146A0884|151 155|Cl/F
P09545146A0884|210 224|concentrations
P09545146A0884|40 44|data
P09545146A0884|80 87|changes
P09545146A0884|139 147|decrease
P09545146A0884|239 253|validation set
P09544991A0483|48 68|tyrosine phosphatase
P09543227A0815|90 95|years
P09543227A0815|41 49|patients
P09543227A0815|76 77|B
P09543227A0815|142 147|years
P09543227A0815|1 8|Group A
P09541636T0000|62 70|patients
P09541636T0000|86 92|tumors
P09540062A0755|75 83|proteins
P09540062A0755|224 234|cell types
P09540062A0755|177 210|H4 promoter/CAT fusion constructs
P09540062A0755|7 14|mutants
P09540062A0755|153 161|activity
P09539746A0781|63 72|caspase-9
P09539746A0781|86 91|cells
P09539746A0781|51 57|Apaf-1
P09539421A0970|25 34|K. lactis
P09539421A0970|7 19|Sir proteins
P09539421A0970|68 95|telomere length maintenance
P09538220A0000|75 88|tRNAPro genes
P09538220A0000|165 178|transcription
P09538220A0000|63 70|tRNAPhe
P09538220A0000|111 116|mtDNA
P09538220A0000|38 41|mrr
P09537651A0366|149 188|phorbol ester phorbol myristate acetate
P09537651A0366|26 30|STAT
P09537651A0366|59 68|induction
P09537651A0366|101 109|elements
P09537375A0198|60 64|gntT
P09537375A0198|146 155|regulator
P09537375A0198|6 26|gntR deletion mutant
P09537375A0198|32 42|expression
P09537295T0000|46 55|sequences
P09537295T0000|77 90|transcription
P09537295T0000|1 9|Analysis
P09536901A0362|15 23|occasion
P09536901A0362|44 46|T2
P09536901A0362|56 64|sagittal
P09536901A0362|87 96|sequences
P09536028A0945|73 95|cyclooxygenase product
P09536028A0945|52 56|acid
P09536028A0945|114 126|contractions
P09536028A0945|18 36|contractile action
P09535892A0000|183 188|units
P09535892A0000|147 154|segment
P09535892A0000|196 198|WD
P09535892A0000|5 17|beta subunit
P09535892A0000|251 259|proteins
P09535835A0279|75 80|Cdc42
P09535835A0279|9 17|Kinectin
P09535835A0279|66 70|RhoA
P09535835A0279|1 7|ROCK-I
P09535579A1105|89 103|interpretation
P09535579A1105|56 62|uptake
P09535579A1105|21 32|assumptions
P09533109A0449|194 206|significance
P09533109A0449|208 209|p
P09533109A0449|67 71|days
P09533109A0449|49 61|distribution
P09533109A0449|118 129|chloroquine
P09531559A1153|132 140|occludin
P09531559A1153|97 101|ZO-1
P09531559A1153|155 159|ZO-2
P09531538A0983|80 97|dU2AF38 RS domain
P09529721A0000|242 248|weight
P09529721A0000|219 227|hospital
P09529721A0000|48 63|classifications
P09529721A0000|11 21|indicators
P09529721A0000|142 159|childhood illness
P09529721A0000|207 215|referral
P09529721A0000|102 112|guidelines
P09529216A0644|72 83|connections
P09529216A0644|92 99|vessels
P09529216A0644|117 124|pedicle
P09528987A1348|74 97|T/EBP expression vector
P09528987A1348|109 120|HepG2 cells
P09528987A1348|143 148|T/EBP
P09528987A1348|32 66|T/EBP promoter-reporter constructs
P09528858A0205|44 48|CpGs
P09528858A0205|29 40|methylation
P09528858A0205|9 14|cases
P09528784A0000|88 103|complementation
P09528784A0000|23 36|fission yeast
P09528768A0000|75 84|reticulum
P09528768A0000|108 121|transcription
P09528768A0000|22 34|accumulation
P09528768A0000|86 88|ER
P09528758T0000|107 120|Oct-6 binding
P09528758T0000|10 14|gene
P09528758T0000|161 166|Rox-1
P09528758T0000|191 195|site
P09528758T0000|1 6|Rex-1
P09525891T0000|106 110|CRS1
P09525891T0000|124 129|CYP17
P09525891T0000|1 8|Members
P09525598A0325|121 124|Raf
P09525598A0325|111 117|domain
P09525598A0325|54 62|findings
P09525598A0325|33 40|T cells
P09525598A0325|70 77|variety
P09525598A0325|153 161|activity
P09524276A0939|193 199|damage
P09524276A0939|53 73|Klebsiella aerogenes
P09524276A0939|1 14|LysR proteins
P09524276A0939|85 93|catalase
P09524267A1023|147 162|helicase motifs
P09524267A1023|283 294|plant cells
P09524267A1023|201 205|part
P09524267A1023|253 279|nucleotide excision repair
P09524267A1023|136 142|domain
P09524250A0767|48 51|AP1
P09524222A1113|182 189|tissues
P09524222A1113|81 86|brain
P09524222A1113|115 119|NT-2
P09524222A1113|1 13|PCR analysis
P09524122A0336|26 30|GPA2
P09524122A0336|59 65|strain
P09523478A0572|60 73|toxoplasmosis
P09523478A0572|77 85|subjects
P09523478A0572|101 113|reactivation
P09522297A0744|72 76|mice
P09522297A0744|108 117|karyotype
P09522297A0744|1 11|Cell lines
P09521909A0081|125 135|expression
P09521909A0081|93 98|petal
P09521909A0081|1 21|APETALA3 transcripts
P09521909A0081|204 210|organs
P09520398A0124|58 76|acetylation levels
P09520398A0124|7 14|changes
P09519828A0809|82 92|activation
P09519828A0809|100 118|BPV-4 LCR promoter
P09518808T0000|33 42|component
P09517989A0476|56 59|HIV
P09517989A0476|24 30|people
P09517989A0476|5 10|study
P09516472A0292|78 88|TATA motif
P09516472A0292|103 124|Id4 promoter activity
P09515924A0104|10 11|g
P09515924A0104|42 53|PDH complex
P09515924A0104|70 78|activity
P09515858A0000|44 63|neutrophil peptides
P09515858A0000|107 125|azurophil granules
P09515858A0000|83 91|peptides
P09515032A1230|23 31|p21 mRNA
P09515032A1230|1 7|RT-PCR
P09514962A0841|60 75|T-cell lymphoma
P09514962A0841|47 51|MMTV
P09514962A0841|1 5|M-66
P09514260A1083|247 252|roles
P09514260A1083|52 65|pseudo intein
P09514260A1083|115 122|inteins
P09514260A1083|220 228|findings
P09514260A1083|98 110|architecture
P09514260A1083|273 282|EN motifs
P09514156A1147|24 34|reactivity
P09514156A1147|97 106|complexes
P09514156A1147|200 205|state
P09514156A1147|1 12|Alterations
P09514156A1147|137 143|manner
P09512559T0000|22 32|expression
P09512559T0000|118 135|chromosome vector
P09512416A0460|63 76|sequence tags
P09512416A0460|188 195|domains
P09512416A0460|141 148|protein
P09512416A0460|1 8|RESULTS
P09512416A0460|35 49|dbEST database
P09511724A0483|123 125|mM
P09511724A0483|8 13|cells
P09511724A0483|19 31|accumulation
P09510582A0157|165 170|agent
P09510582A0157|149 151|mg
P09510582A0157|130 136|geG-50
P09510582A0157|126 128|mg
P09510582A0157|118 121|geG
P09510189A0192|108 117|kilobases
P09510189A0192|138 141|DNA
P09510189A0192|119 121|kb
P09508775A0293|90 115|protein kinase activation
P09508775A0293|208 244|protooncogenes/transcription factors
P09508775A0293|157 165|pathways
P09508377A0863|123 128|point
P09508377A0863|176 194|chemical parameter
P09508377A0863|7 14|results
P09508377A0863|80 92|phaeomelanin
P09508377A0863|136 164|eumelanin/phaeomelanin ratio
P09508377A0863|258 269|skin cancer
P09507032A1144|135 144|apoptosis
P09507032A1144|19 35|CSF1R/IRDelta960
P09506983A0304|24 30|rounds
P09506983A0304|65 69|ends
P09506983A0304|34 38|RACE
P09506959T0000|82 89|members
P09506959T0000|20 36|characterization
P09506959T0000|136 146|regulators
P09505733A0246|123 131|distress
P09505733A0246|158 169|limitations
P09505733A0246|3 9|review
P09505733A0246|184 192|patients
P09504906A0099|106 122|cysteine residue
P09504906A0099|142 148|domain
P09504906A0099|51 59|function
P09504514T0000|90 102|chemotherapy
P09504514T0000|121 130|leukaemia
P09504514T0000|26 34|addition
P09504514T0000|173 178|trial
P09504514T0000|49 76|bone-marrow transplantation
P09503526A0614|27 34|Raynaud
P09503526A0614|76 104|diseases WFAg concentrations
P09503526A0614|4 12|patients
P09502720T0000|30 53|cell type specification
P09502720T0000|133 151|sea urchin embryos
P09502720T0000|119 129|CyIIa gene
P09502627A0705|125 141|ventriculography
P09502627A0705|189 216|peak creatine kinase levels
P09502627A0705|258 275|ejection fraction
P09502627A0705|286 304|hospital discharge
P09502627A0705|43 52|incidence
P09502627A0705|98 99|p
P09502627A0705|306 307|p
P09501169A0000|31 36|cells
P09501169A0000|59 70|equilibrium
P09501169A0000|1 27|Histone acetylation levels
P09499254A1309|194 207|investigation
P09499254A1309|148 155|regimen
P09499254A1309|97 117|islet-cell carcinoma
P09499048A1003|105 107|gK
P09499048A1003|82 87|cells
P09499048A1003|19 32|virus progeny
P09498769A0095|27 41|representative
P09498769A0095|66 74|proteins
P09498769A0095|100 118|B cell development
P09498769A0095|204 216|plasma cells
P09498553A0702|159 165|nature
P09498553A0702|39 54|promoter region
P09498553A0702|100 109|cap sites
P09498553A0702|69 77|GC boxes
P09495283A0000|132 142|HeLa cells
P09495283A0000|123 127|HSF2
P09495283A0000|114 118|HSF1
P09495283A0000|33 41|beta-gal
P09492038A0352|91 97|region
P09492038A0352|27 32|roles
P09492038A0352|114 131|promoter activity
P09492038A0352|153 164|mutagenesis
P09490727A1041|61 67|bodies
P09490727A1041|6 29|structure interconnects
P09489670A1157|208 213|yeast
P09489670A1157|58 64|levels
P09489670A1157|110 116|hyphae
P09489670A1157|320 331|C. albicans
P09489670A1157|156 174|HST6 transcription
P09489670A1157|17 21|HST6
P09488725A0904|74 86|polypeptides
P09488491A0000|30 34|part
P09488491A0000|67 92|tumor suppressor proteins
P09488486A0000|31 34|TBP
P09488486A0000|109 124|RNA polymerases
P09488486A0000|22 29|protein
P09488486A0000|55 59|role
P09488486A0000|139 142|Pol
P09488441A0615|244 254|expression
P09488441A0615|262 269|concert
P09488441A0615|18 31|transcription
P09488441A0615|79 114|P-selectin promoter NF-kappaB sites
P09488441A0615|67 75|enhancer
P09488441A0615|1 4|Sp1
P09487590A0657|42 47|weeks
P09487590A0657|5 18|mean duration
P09486890A0234|72 88|carcinoma spread
P09486890A0234|92 97|areas
P09486890A0234|129 142|visualization
P09486035A0051|12 29|population survey
P09486035A0051|110 116|causes
P09486035A0051|55 66|individuals
P09485308A1165|91 99|reaction
P09485308A1165|37 44|cluster
P09485308A1165|5 15|FMN moiety
P09484463T0000|31 36|genes
P09484463T0000|13 23|expression
P09482902A0942|120 127|ability
P09482902A0942|388 397|candidate
P09482902A0942|56 61|G232A
P09482902A0942|333 355|plasmacytoma induction
P09482902A0942|253 259|allele
P09482902A0942|192 214|retinoblastoma protein
P09482902A0942|317 328|BALB/c mice
P09482902A0942|78 86|variants
P09482902A0942|143 151|activity
P09482902A0942|279 283|role
P09482107A0551|88 95|effects
P09482107A0551|133 142|C3G cells
P09482107A0551|162 170|survival
P09482107A0551|99 113|cell viability
P09482107A0551|19 34|focus formation
P09482107A0551|51 59|presence
P09480929T0000|122 152|baculovirus/insect cell system
P09480929T0000|9 13|FasR
P09480929T0000|69 75|fusion
P09480831A0272|29 38|mechanism
P09480831A0272|162 167|cells
P09480831A0272|169 173|HAEC
P09480831A0272|51 66|gene expression
P09478976T0000|25 30|c-Fos
P09478976T0000|70 82|AP-1 element
P09478971A1896|44 50|manner
P09478971A1896|130 140|expression
P09478971A1896|86 89|AhR
P09478971A1896|1 20|Reporter constructs
P09477316A0140|227 234|signals
P09477316A0140|99 117|Hox gene regulator
P09477316A0140|48 66|Hox gene induction
P09476399A0141|32 46|tea plantation
P09475724T0000|61 72|cell growth
P09475724T0000|9 13|part
P09474648A0298|89 97|controls
P09474648A0298|78 81|Paf
P09474648A0298|32 36|time
P09473755A0318|14 21|METHODS
P09473755A0318|61 64|St.
P09473755A0318|1 9|PATIENTS
P09473317X2131|16 30|Academic Press
P09473040A1303a|92 99|mutants
P09472608A0253|134 143|cell line
P09472608A0253|198 203|cells
P09472608A0253|176 183|SK-N-MC
P09472608A0253|76 89|transcription
P09472608A0253|216 234|transfection assay
P09472608A0253|205 211|Jurkat
P09471984A0000|13 22|Chemicals
P09471984A0000|1 11|BACKGROUND
P09469833A0533|28 34|nature
P09469833A0533|96 107|bp sequence
P09469415A1337|128 141|possibilities
P09469415A1337|22 29|beta 2m
P09469415A1337|158 167|induction
P09469415A1337|5 16|observation
P09469415A1337|86 107|CTL target structures
P09468514A1065|56 62|tissue
P09468514A1065|42 52|expression
P09468514A1065|1 18|Northern analysis
P09468386A0594|148 154|manner
P09468386A0594|55 60|motif
P09468386A0594|34 42|PEA3 ETS
P09467900A0701|95 114|amino acid residues
P09467900A0701|5 19|CAPLC1 protein
P09467900A0701|50 58|features
P09467900A0701|220 234|binding domain
P09467044A0973|67 71|PALP
P09466267A1192|7 19|himA mutants
P09466267A1192|83 93|regulation
P09466267A1192|51 55|role
P09465035A1032|12 21|inhibitor
P09465035A1032|22 23|s
P09465035A1032|87 88|L
P09463964A0243|30 35|range
P09463964A0243|167 176|antiserum
P09463964A0243|110 124|micrograms l-1
P09463964A0243|81 89|antibody
P09463380A1050|11 18|xTAK1KN
P09463380A1050|35 45|expression
P09461594A0000|121 129|tyrosine
P09461594A0000|147 157|activation
P09461594A0000|96 101|field
P09461594A0000|18 26|evidence
P09461594A0000|184 194|PLC-gamma2
P09459835A0297|30 36|dosage
P09459835A0297|43 60|mg/kg body weight
P09459835A0297|67 71|cats
P09459835A0297|20 24|PMEA
P09459241A0707|73 76|kPa
P09459241A0707|97 98|P
P09459241A0707|50 55|mm Hg
P09458021A1373|40 50|AZA groups
P09458021A1373|25 28|MMF
P09455695A0762|15 25|responders
P09455695A0762|44 45|%
P09455695A0762|99 118|vitamin E treatment
P09455695A0762|50 60|AST levels
P09454719A0181|13 24|termination
P09454719A0181|197 229|polyadenylation signal sequences
P09454719A0181|174 180|effect
P09454719A0181|119 148|AAUAAA polyadenylation signal
P09453537A0863|123 126|SP1
P09453537A0863|83 91|GC boxes
P09453537A0863|34 44|CCAATC box
P09452444A0000|94 103|responses
P09452444A0000|39 47|cytokine
P09452444A0000|16 20|IL-6
P09451857T0001|66 79|determination
P09451857T0001|18 32|tissue lesions
P09451857T0001|102 107|blood
P09451003A0894|166 174|Esigma54
P09451003A0894|72 90|sigma54 activators
P09451003A0894|146 157|interaction
P09451003A0894|100 110|repression
P09449018T0000|31 35|risk
P09449018T0000|1 22|Childhood misbehavior
P09448268A0186|80 83|nmo
P09448268A0186|48 55|homolog
P09447979A1430|122 126|GNEF
P09447979A1430|6 15|mutations
P09447979A1430|86 120|guanine nucleotide exchange factor
P09447963A0223|65 69|SC35
P09447963A0223|48 59|interaction
P09447963A0223|34 40|virtue
P09447962A0452|24 30|rhis4l
P09446815A1021|36 42|region
P09446600A0260|30 48|beta-galactosidase
P09446600A0260|108 115|nucleus
P09446600A0260|3 17|fusion protein
P09445488A0230|30 48|USH1C disease gene
P09445488A0230|132 136|YACs
P09445488A0230|161 180|STS content mapping
P09445488A0230|185 206|Alu-PCR hybridization
P09445488A0230|102 107|yeast
P09444316A0388|88 98|F1 animals
P09444316A0388|22 27|signs
P09444316A0388|51 59|toxicity
P09443973A1028|21 28|plasmid
P09443948A0000|15 20|study
P09443948A0000|130 144|trichinellosis
P09443948A0000|111 120|diagnosis
P09443948A0000|213 222|outbreaks
P09443948A0000|203 207|sera
P09443948A0000|187 190|IIF
P09442080A0856|14 27|binding assay
P09442080A0856|94 105|association
P09442080A0856|124 129|SHP-1
P09442080A0856|138 170|glutathione S-transferase fusion
P09442080A0856|70 75|SHP-2
P09442080A0856|34 44|IM-9 cells
P09442031A0586|133 157|TSHR ectodomain variants
P09442031A0586|189 197|vicinity
P09442031A0586|80 87|subunit
P09442031A0586|51 55|size
P09442024A0236|13 15|J.
P09442024A0236|1 3|P.
P09441746A0546|67 72|GPR39
P09440616A0422|15 20|phase
P09438427T0000|27 34|element
P09438427T0000|84 94|expression
P09438165A0405|45 46|%
P09438165A0405|94 98|time
P09438165A0405|161 162|%
P09438165A0405|25 34|PC levels
P09438165A0405|102 119|VOD manifestation
P09436989A1011|165 194|spindle pole body duplication
P09436989A1011|147 157|initiation
P09436989A1011|80 84|MOB1
P09436989A1011|103 128|cell cycle reset function
P09436706A0168|44 66|sperm injection cycles
P09436706A0168|122 132|pharmacist
P09436706A0168|5 12|patient
P09436706A0168|253 269|leuprolide depot
P09436706A0168|275 289|gonadotrophins
P09435806T0001|94 99|CA125
P09435806T0001|10 15|value
P09435806T0001|23 33|estimation
P09435116A0437|42 52|MS-MS data
P09434979A0790|194 195|%
P09434979A0790|230 236|filter
P09434979A0790|143 149|filter
P09434979A0790|81 95|photon fluence
P09434979A0790|49 63|photon fluence
P09434160A2078|15 20|PTPRO
P09434160A2078|54 71|bone marrow cells
P09434160A2078|1 11|Expression
P09432752A0109|167 174|patient
P09432752A0109|20 29|relatives
P09432752A0109|1 9|Patients
P09431812A0576|26 28|Hh
P09431812A0576|65 81|Ci binding sites
P09431812A0576|33 40|Patched
P09430668A0172a|104 112|proteins
P09430668A0172a|5 13|promoter
P09430668A0172a|18 34|HMG-CoA synthase
P09430461A0742|28 39|defect size
P09430461A0742|298 306|patients
P09430461A0742|419 438|threshold technique
P09430461A0742|386 397|defect size
P09430461A0742|460 465|phase
P09430461A0742|49 62|BMIPP imaging
P09430461A0742|259 263|data
P09430461A0742|225 235|CONCLUSION
P09430461A0742|496 502|amount
P09430461A0742|401 406|means
P09430461A0742|506 516|myocardium
P09430461A0742|475 488|determination
P09428799A0897|14 18|gene
P09428799A0897|89 96|enzymes
P09428799A0897|102 126|intron/exon organization
P09428389A1805|165 170|doses
P09428389A1805|28 32|dose
P09428389A1805|77 88|combination
P09428389A1805|36 48|bicalutamide
P09428389A1805|174 186|bicalutamide
P09427627T0000|79 98|membrane attachment
P09427627T0000|39 62|PDGF receptor signaling
P09427627T0000|16 23|control
P09427627A0802|36 57|PDGF receptor protein
P09427627A0802|4 19|Xenopus embryos
P09427627A0802|70 79|formation
P09427544A0000|47 60|pectate lyase
P09427544A0000|22 34|Amycolata sp
P09427544A0000|156 160|TK24
P09426907A0391|72 91|silver sulfadiazine
P09426907A0391|111 114|gel
P09426907A0391|5 12|purpose
P09426907A0391|116 125|poloxamer
P09426239A0386|83 88|genes
P09426239A0386|115 134|restriction enzymes
P09426143A1358|240 254|RNA polymerase
P09426143A1358|263 273|occupation
P09426143A1358|87 97|expression
P09426143A1358|75 79|KdgR
P09426143A1358|226 235|repressor
P09426143A1358|67 70|CRP
P09426143A1358|200 210|regulators
P09425676A0000|134 141|monkeys
P09425676A0000|56 68|associations
P09425676A0000|32 49|stimulus-response
P09425676A0000|51 54|S-R
P09425036A0649|145 158|Csk substrate
P09425036A0649|54 71|Src family member
P09425036A0649|87 98|cell kinase
P09423968A0039|31 40|analgesia
P09423968A0039|227 238|nociception
P09423968A0039|144 151|systems
P09423968A0039|283 291|ontogeny
P09423968A0039|5 14|mechanism
P09423968A0039|205 211|course
P09423310A0251|31 43|lymphangioma
P09423310A0251|124 133|stainings
P09423310A0251|146 152|Factor
P09423310A0251|87 95|features
P09423310A0251|137 141|CD34
P09422727A0196|133 142|induction
P09422727A0196|167 186|CRE binding protein
P09422727A0196|43 51|TGACGTGA
P09422727A0196|53 70|promoter sequence
P09422727A0196|233 238|ATF-2
P09421521T0000|101 120|CCE1 homologue YDC2
P09421511A0827|195 209|telomerase RNA
P09421511A0827|100 129|telomerase RNA-gene promoters
P09421511A0827|50 59|evolution
P09421511A0827|17 28|comparisons
P09421507A0000|8 22|protein family
P09420275A1111|74 88|CD23 promoters
P09420275A1111|56 61|LMP-1
P09420275A1111|18 28|affinities
P09420269A0000|240 243|RNA
P09420269A0000|328 335|strands
P09420269A0000|27 30|RNA
P09420269A0000|216 219|end
P09420269A0000|49 52|RUB
P09420269A0000|186 196|complement
P09420269A0000|163 165|SL
P09420269A0000|168 170|nt
P09420269A0000|34 47|rubella virus
P09420234A0654|104 124|chaperonin-60 family
P09420234A0654|89 96|members
P09420234A0654|48 49|%
P09420219A0284|241 252|tumor virus
P09420219A0284|320 326|genome
P09420219A0284|285 288|end
P09420219A0284|227 232|mouse
P09420219A0284|36 46|parameters
P09420219A0284|206 223|enhancer-promoter
P09420219A0284|69 75|export
P09419421A0385|43 51|NF-Y/CBF
P09419421A0385|21 26|cells
P09419421A0385|32 39|binding
P09418905A1396|72 75|Ras
P09418905A1396|128 131|EGF
P09418905A1396|97 111|DAG production
P09418905A1396|216 219|PKC
P09418905A1396|32 40|addition
P09418861A0623|126 152|pleckstrin homology domain
P09418861A0623|99 110|n-chimaerin
P09418040T0000|151 156|yeast
P09418040T0000|26 40|identification
P09418040T0000|267 273|CHL I.
P09418040T0000|250 255|CHL D
P09418040T0000|221 234|co-expression
P09418040T0000|133 141|subunits
P09418040T0000|108 119|interaction
P09418040T0000|168 174|system
P09417928A0980|61 70|Gln155Lys
P09417928A0980|79 94|reading helices
P09417928A0980|42 51|His128Asn
P09417928A0980|139 146|binding
P09417928A0980|16 24|residues
P09417493A0823|89 101|inflammation
P09417493A0823|52 60|decrease
P09417493A0823|114 121|protein
P09417493A0823|64 85|laboratory indicators
P09417082A0127|48 66|urokinase receptor
P09416467A0959|210 214|role
P09416467A0959|7 14|results
P09416467A0959|142 159|scavenging action
P09416467A0959|169 174|drugs
P09414319A1442|63 69|Y15172
P09414319A1442|9 15|Surf-2
P09414319A1442|71 77|Surf-5
P09414319A1442|50 56|Surf-6
P09414319A1442|34 40|Surf-3
P09414074A0827|58 67|direction
P09414074A0827|144 149|power
P09414074A0827|32 43|power curve
P09414074A0827|119 124|loads
P09412079T0001|19 31|soy proteins
P09409821T0000|30 40|RAD30 gene
P09409821T0000|74 78|dinB
P09409821T0000|92 102|DNA damage
P09409821T0000|117 126|functions
P09409416A0111|61 69|approach
P09409416A0111|110 122|TC-2 64B EME
P09408516T0000|14 27|pyrimethamine
P09408516T0000|76 82|months
P09407090T0000|15 27|localization
P09407090T0000|55 64|SR-BI/CLA
P09407031A0974|72 76|cut5
P09407031A0974|20 34|overexpression
P09407031A0974|81 93|crb2 mutants
P09407026A0426|334 341|factors
P09407026A0426|81 92|positioning
P09407026A0426|222 227|steps
P09407026A0426|109 117|majority
P09407026A0426|96 101|nuc-1
P09407026A0426|1 14|TSA treatment
P09405536A0777|105 112|fashion
P09405536A0777|12 34|conditioning procedure
P09405536A0777|40 47|C-fiber
P09405536A0777|262 269|plateau
P09405536A0777|137 144|animals
P09405195A0320|74 87|recombination
P09405195A0320|227 230|DNA
P09405195A0320|129 138|stretches
P09405195A0320|248 261|recombination
P09403059A0209|13 19|repeat
P09403059A0209|40 52|DNA elements
P09403059A0209|80 116|medium reiteration frequency repeats
P09402088A2250|47 60|configuration
P09402088A2250|82 92|processing
P09402088A2250|100 118|AVP gene precursor
P09400738A1046|88 92|ufCB
P09400738A1046|108 123|CB instillation
P09400613A0594|328 342|lacZ reporters
P09400613A0594|125 137|K296R mutant
P09400613A0594|114 117|PKR
P09400613A0594|220 229|mouse PKR
P09400613A0594|319 323|HIS3
P09400613A0594|1 13|Coexpression
P09398598A0256|44 57|hamster ovary
P09398598A0256|59 62|CHO
P09398598A0256|64 73|cell line
P09398598A0256|206 215|multimers
P09398267A0440|74 98|chick embryo fibroblasts
P09398267A0440|57 60|DNA
P09398267A0440|100 103|CEF
P09397261A0940|1 21|Interleukin-1 levels
P09396796A1173|75 81|points
P09396796A1173|94 105|differences
P09396796A1173|53 70|E2F family member
P09396796A1173|21 31|conclusion
P09396437A0878|79 87|subjects
P09396437A0878|126 127|P
P09396437A0878|39 51|NE spillover
P09396402A0264|194 206|radiotherapy
P09396402A0264|73 79|stages
P09396402A0264|59 67|patients
P09396402A0264|23 37|Semen analyses
P09396402A0264|115 127|chemotherapy
P09396402A0264|1 9|PATIENTS
P09395470A0294|113 132|glycosylation sites
P09395470A0294|80 83|kDa
P09394650A0121|123 125|US
P09394650A0121|80 91|lymph nodes
P09393875A0873|29 43|papillomavirus
P09393875A0873|196 203|factors
P09393875A0873|157 168|c-fos mRNAs
P09393875A0873|291 296|cells
P09393875A0873|100 112|virus genome
P09393717A1517|181 191|mutC cells
P09393717A1517|150 159|phenotype
P09393717A1517|82 86|tRNA
P09393717A1517|100 117|mutator phenotype
P09393717A1517|51 55|idea
P09392979T0000|60 70|California
P09390183A1027|60 80|NMT peptide antibody
P09390183A1027|125 129|band
P09390183A1027|157 161|mass
P09390183A1027|1 22|Western blot analysis
P09389982A1383|122 138|prothrombin time
P09389982A1383|20 34|INR correction
P09389982A1383|68 75|methods
P09389666A0538|211 220|asymmetry
P09389666A0538|148 152|axis
P09389666A0538|7 21|Hex expression
P09389666A0538|250 266|endoderm lineage
P09389198A0363|134 139|state
P09389198A0363|12 21|aftermath
P09389198A0363|43 47|skin
P09389198A0363|76 87|arithmetics
P09388271A1243|62 71|treatment
P09388271A1243|77 87|inhibitors
P09388271A1243|5 19|mobility shift
P09388201A1027|11 13|PD
P09388201A1027|4 6|PU
P09388199A0948|180 187|regions
P09388199A0948|161 165|LexA
P09388199A0948|7 13|effort
P09388199A0948|191 195|FadR
P09388199A0948|86 100|ligand binding
P09388199A0948|68 80|dimerization
P09387999A1053|53 59|extent
P09387999A1053|19 24|DPOAE
P09386074A0694|91 92|%
P09386074A0694|5 9|pigs
P09383188A0654|89 93|site
P09383188A0654|43 48|match
P09383188A0654|83 87|rocD
P09382924A0131|60 76|interferon-gamma
P09382924A0131|177 191|20S proteasome
P09382924A0131|260 265|PSMB5
P09382924A0131|13 21|evidence
P09382924A0131|106 114|subunits
P09382924A0131|43 54|stimulation
P09382924A0131|143 149|PSMB10
P09382850A0000|52 63|progression
P09382850A0000|71 76|event
P09381950A0209|65 68|min
P09381950A0209|49 57|mL min-1
P09381950A0209|102 113|reperfusion
P09380707A0714|24 33|LAZ3/BCL6
P09380707A0714|80 88|proteins
P09380507A0514|41 63|GST-DP fusion proteins
P09380507A0514|112 121|E2F sites
P09380507A0514|1 26|Glutathione S-transferase
P09379301A2036|42 49|microns
P09379301A2036|54 62|A. wedli
P09379301A2036|17 33|A. microcephalum
P09377355A0362|125 136|impairement
P09377355A0362|174 179|tools
P09377355A0362|71 79|features
P09377355A0362|35 39|data
P09376626A0737|47 48|h
P09376626A0737|107 121|h postexposure
P09376626A0737|25 31|levels
P09376626A0737|93 100|group B
P09376626A0737|1 10|Radiation
P09374541T0000|14 24|protection
P09374541T0000|67 92|thymidine kinase promoter
P09374082A0504|180 188|betaPGF2
P09374082A0504|95 113|hydrolysis product
P09374082A0504|296 303|airways
P09374082A0504|159 161|PG
P09374082A0504|259 263|risk
P09374082A0504|194 203|PGF2alpha
P09374082A0504|316 330|characteristic
P09374082A0504|163 166|PGD
P09374082A0504|276 288|inflammation
P09374082A0504|65 74|phthalate
P09373155T0000|121 132|dynein gene
P09373155T0000|67 79|mouse testis
P09373155T0000|32 43|chain genes
P09372968A0996|30 35|cells
P09372968A0996|66 78|kappaB alpha
P09372960A0456|46 59|fal1-1 mutant
P09372960A0456|97 105|decrease
P09372960A0456|81 87|strain
P09372960A0456|137 145|subunits
P09372937T0000|5 10|yeast
P09372908A1068|120 135|gene repression
P09372908A1068|88 97|mechanism
P09372908A1068|162 178|Polycomb protein
P09372908A1068|218 227|silencing
P09372287A0296|90 95|tract
P09372287A0296|130 135|tract
P09372287A0296|97 101|LVST
P09372287A0296|17 27|electrodes
P09371698A1254|224 229|sites
P09371698A1254|46 56|constructs
P09371698A1254|179 194|pseudo-TATA box
P09371698A1254|115 125|definition
P09371698A1254|17 22|HepG2
P09371626A1345|241 250|synthesis
P09371626A1345|180 187|protein
P09371626A1345|72 80|deletion
P09371626A1345|5 12|results
P09371626A1345|190 197|ability
P09371626A1345|16 32|replicase assays
P09371566A1384|46 54|extracts
P09371566A1384|59 72|S100 extracts
P09371566A1384|33 37|HeLa
P09371455A0000|107 122|metalloprotease
P09371455A0000|32 38|region
P09371431A1172|56 72|Tn5mob insertion
P09371431A1172|21 35|R. etli mutant
P09371431A1172|103 123|thiCOGE gene cluster
P09370276A0781|9 22|reading frame
P09369453A0273|192 200|membrane
P09369453A0273|77 91|death promoter
P09369453A0273|53 63|Bcl-xL/Bcl
P09369453A0273|48 51|BAD
P09369453A0273|34 46|Bcl-2 family
P09369450A1358|231 252|transcription factors
P09369450A1358|52 54|GR
P09369450A1358|83 100|promoter activity
P09369450A1358|206 218|interactions
P09369450A1358|34 43|HNF-1beta
P09368419A0628|147 154|rd22BP1
P09368419A0628|67 95|DNA-ligand binding screening
P09368419A0628|3 7|cDNA
P09368190A1053|210 219|IFN-alpha
P09368190A1053|43 51|sequence
P09368190A1053|143 152|IFN-gamma
P09368190A1053|69 73|EMSA
P09368057A1083|165 175|inhibition
P09368057A1083|67 85|repressor activity
P09368057A1083|114 121|element
P09368026A0000|14 16|OC
P09368026A0000|46 53|protein
P09368026A0000|23 29|matrix
P09368026A0000|1 12|Osteocalcin
P09368006A1332|135 140|E2F-1
P09368006A1332|126 133|protein
P09368006A1332|5 12|results
P09367676A0275|45 68|DNA sequencing analysis
P09367676A0275|29 39|subcloning
P09367676A0275|189 191|kb
P09367676A0275|101 110|P1 clones
P09367676A0275|84 96|phage lambda
P09367392A0567|120 124|RdRp
P09367392A0567|180 186|levels
P09367392A0567|82 86|RNA3
P09367392A0567|5 13|presence
P09367392A0567|154 158|RNA3
P09366628T0000|20 29|direction
P09366628T0000|1 3|Re
P09366517A0835|82 87|sites
P09366517A0835|39 46|Ser-393
P09366517A0835|98 113|phosphorylation
P09366517A0835|152 155|WT1
P09365431A0314|36 51|benzodiazepines
P09365201A2018|28 33|basis
P09365201A2018|128 141|breast cancer
P09365201A2018|98 118|aromatase expression
P09365201A2018|85 94|mechanism
P09364440A2206|36 45|structure
P09364440A2206|5 10|study
P09364440A2206|100 108|coupling
P09363759A0000|94 113|signal transduction
P09363759A0000|1 21|Protein phosphatases
P09362480A0452|12 28|cysteine triplet
P09362480A0452|59 69|TB domains
P09362480A0452|102 106|core
P09362105X0422|145 148|HPV
P09362105X0422|83 84|%
P09362105X0422|21 31|resistance
P09360993T0000|75 91|serine proteases
P09360993T0000|37 43|member
P09360993T0000|1 25|Mouse mast cell protease
P09360953A1057|45 48|end
P09360953A1057|107 114|portion
P09360953A1057|79 85|Tyr318
P09360953A1057|66 71|helix
P09360953A1057|175 189|PTH-1 receptor
P09359887A1168|104 110|region
P09359887A1168|76 79|NPC
P09359887A1168|21 25|data
P09358837T0000|73 85|hypertension
P09358837T0000|50 59|treatment
P09358055A0590|109 114|mouse
P09358055A0590|25 33|homology
P09358055A0590|81 85|Enh2
P09356645A0672|91 108|nerve enlargement
P09356645A0672|33 40|sarcoma
P09354684A1158|30 38|Sp1 site
P09354684A1158|66 83|promoter activity
P09354644A0124|75 102|beta1,6-GlcNAc transferases
P09354644A0124|121 124|Gal
P09354644A0124|111 117|GlcNAc
P09353343T0000|15 45|AUUUA response element binding
P09353343T0000|101 114|T lymphocytes
P09353328A0736|130 138|proteins
P09353328A0736|110 118|homology
P09353328A0736|39 45|domain
P09353296A0510|194 202|cistrons
P09353296A0510|76 93|moaA gene product
P09353296A0510|101 105|CNXC
P09353247A0922|112 131|cyclin/CDK activity
P09353247A0922|18 44|over-replication phenotype
P09353247A0922|69 77|p65cdc18
P09352016A1110|72 75|CAM
P09352016A1110|59 68|predictor
P09351242A0719|14 39|AtP5CS1 mRNA accumulation
P09351242A0719|208 218|deficiency
P09351242A0719|110 118|response
P09351242A0719|172 185|cycloheximide
P09351242A0719|1 10|Induction
P09349501A0196|210 214|role
P09349501A0196|77 89|MLL products
P09349501A0196|218 232|leukemogenesis
P09348226A0852|91 102|association
P09348226A0852|108 114|Crk-II
P09348226A0852|49 73|tyrosine phosphorylation
P09346938A1680|61 75|protein levels
P09346938A1680|93 122|cysteine protease cathepsin B
P09346935A0459|105 123|zinc finger domain
P09346935A0459|29 58|coimmunoprecipitation studies
P09346935A0459|173 187|RNA polymerase
P09346935A0459|237 241|form
P09346621A1181|104 112|patients
P09346621A1181|149 152|OSF
P09346621A1181|126 133|failure
P09346621A1181|19 43|liver allograft shortage
P09345495A0000|60 74|brain function
P09344650A0967|40 48|Casr-rs2
P09344650A0967|83 91|Casr-rs1
P09344650A0967|68 69|%
P09343433A0360|11 21|rad6-delta
P09343433A0360|64 68|RNAP
P09343432A0209|74 80|length
P09343432A0209|56 66|% identity
P09343432A0209|159 168|C termini
P09343432A0209|33 48|homology domain
P09343398A1193|45 55|holoenzyme
P09343398A1193|93 97|poly
P09343398A1193|67 74|pcna-79
P09343398A1193|156 164|template
P09343398A1193|17 30|DNA synthesis
P09343210A1112|195 210|NF-kappaB sites
P09343210A1112|27 44|mutation analyses
P09343210A1112|52 67|VCAM-1 promoter
P09343210A1112|83 127|chloramphenicol acetyltransferase constructs
P09343210A1112|222 224|bp
P09341193A0362|122 140|Tax responsiveness
P09341193A0362|20 23|Sp1
P09341193A0362|103 107|TRE1
P09341182A0605|90 94|PLZF
P09341182A0605|70 84|BTB/POZ domain
P09341139A0690|74 79|Y326A
P09341139A0690|58 72|beta2AR mutant
P09341139A0690|4 12|contrast
P09339900A0939|210 218|activity
P09339900A0939|147 150|AP2
P09339900A0939|158 163|c-Myc
P09339900A0939|152 156|NF-Y
P09339900A0939|12 20|analysis
P09339900A0939|71 80|cyclin D2
P09339900A0939|100 106|region
P09337861T0000|104 124|inhibitor wortmannin
P09337861T0000|20 45|phosphoinositide 3-kinase
P09337861T0000|85 96|sensitivity
P09335619A0583|180 183|Zea
P09335619A0583|125 137|RU cytoplasm
P09335619A0583|48 60|similarities
P09335619A0583|194 202|teosinte
P09335619A0583|230 234|gene
P09335619A0583|33 34|R
P09335619A0583|1 29|Nucleotide sequence analysis
P09335298A2129|104 111|strains
P09335298A2129|199 206|strains
P09335298A2129|178 191|sensitivities
P09335298A2129|39 50|differences
P09335298A0529|31 44|parCBA operon
P09335298A0529|84 86|M.
P09334475A0327|147 157|chest pain
P09334475A0327|267 274|infarct
P09334475A0327|321 333|thrombolysis
P09334475A0327|224 231|CK rise
P09334475A0327|14 21|METHODS
P09334475A0327|106 116|Infarction
P09334475A0327|283 286|EKG
P09334475A0327|1 9|PATIENTS
P09334330A0252|149 154|daf-3
P09334330A0252|114 147|Smad signal transduction proteins
P09334330A0252|254 265|development
P09334330A0252|165 177|Smad protein
P09334330A0252|315 332|dauer development
P09334330A0252|67 82|TGF-beta signal
P09334330A0252|34 43|mutations
P09333231T0018|5 10|skull
P09333026A0851|149 158|anchorage
P09333026A0851|77 82|mouse
P09333026A0851|65 73|brk cDNA
P09333026A0851|50 56|tumour
P09333026A0851|171 177|growth
P09333018A0000|77 83|growth
P09333018A0000|116 136|transcription factor
P09331864A0230|121 128|heifers
P09331864A0230|242 247|mg E2
P09331864A0230|265 268|MGA
P09331864A0230|191 193|mg
P09331864A0230|156 166|treatments
P09331864A0230|289 295|mg TBA
P09331864A0230|198 204|heifer
P09331864A0230|32 36|TBOH
P09331864A0230|1 21|Serum concentrations
P09331864A0230|305 315|Finaplix-H
P09328833A0588|22 26|cDNA
P09328833A0588|32 34|kb
P09328476A0374|1 7|Hprp3p
P09328349A1679|105 123|alpha-subunit gene
P09328349A1679|11 20|CCAAT box
P09328349A1679|87 97|expression
P09328341A1449|94 121|TR alpha DNA binding mutant
P09328341A1449|22 42|vit A2 consensus ERE
P09326727T0000|37 47|injections
P09326263A0410|270 272|1B
P09326263A0410|26 43|transcription-PCR
P09326263A0410|53 66|methodologies
P09326263A0410|45 51|RT-PCR
P09326263A0410|133 141|material
P09326263A0410|9 13|RACE
P09326263A0410|99 104|brain
P09326163A0942|27 42|mortality ratio
P09326163A0942|87 91|% CI
P09325284A0469|15 19|cDNA
P09325284A0469|56 57|%
P09325273A1240|28 33|UBP41
P09325273A1240|330 338|proteins
P09325273A1240|56 60|role
P09325273A1240|156 162|action
P09325273A1240|117 138|poly-ubiquitin chains
P09325273A1240|283 304|poly-ubiquitin chains
P09325273A1240|169 181|S proteasome
P09325273A1240|68 77|recycling
P09325022A0192|90 102|C57BL/6 mice
P09325022A0192|41 48|studies
P09325022A0192|52 61|CD-1 mice
P09325022A0192|1 8|Ovaries
P09324922T0065|28 43|supplementation
P09324922T0065|97 101|acid
P09324720A0317|10 15|meals
P09324720A0317|23 28|times
P09323366A0299|75 79|UAS1
P09323366A0299|4 21|deletion analysis
P09323366A0299|84 88|UAS2
P09323366A0299|137 141|gene
P09322872A0745|13 21|deletion
P09322872A0745|79 84|cells
P09322872A0745|35 42|TK gene
P09321930A0567|176 190|heterozygosity
P09321930A0567|24 46|tumor suppressor genes
P09321930A0567|218 221|LOE
P09321930A0567|263 278|binding protein
P09321930A0567|224 232|mutation
P09321930A0567|192 195|LOH
P09321930A0567|64 67|APC
P09321930A0567|206 216|expression
P09321930A0567|238 250|inactivation
P09321406T0000|59 79|Ty5 retrotransposons
P09321406T0000|102 111|chromatin
P09317757T0000|29 74|CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALIS
P09317757T0000|1 9|EXERCISE
P09317131A0000|10 31|chain class switching
P09317131A0000|98 106|CH genes
P09315678A0278|74 77|rat
P09315678A0278|88 101|protein NAP57
P09315678A0278|218 220|U.
P09315633A0333|61 69|homology
P09315633A0333|40 44|gene
P09315633A0333|77 87|interferon
P09315631A1064|111 121|POR2 genes
P09315631A1064|154 162|glycerol
P09315631A1064|222 229|mutants
P09315631A1064|204 214|delta por1
P09315631A1064|51 60|phenotype
P09315631A1064|102 106|POR1
P09314554A0149|209 223|reading frames
P09314554A0149|76 79|AUG
P09314554A0149|98 111|reading frame
P09314487T0000|72 97|polymerase chain reaction
P09314487T0000|53 67|air filtration
P09313755A0816|62 69|factors
P09313755A0816|16 26|clustering
P09312032A0165|131 145|intron lariats
P09312032A0165|93 100|release
P09312032A0165|35 47|snoRNA genes
P09312025T0000|106 107|t
P09312025T0000|38 47|regulator
P09312025T0000|51 82|protein kinase C zeta signaling
P09311835A0147|91 103|SV40 mutants
P09311835A0147|182 200|ATP binding pocket
P09311835A0147|154 162|residues
P09311568A0595|60 61|G
P09311568A0595|56 57|S
P09311568A0595|53 54|E
P09311568A0595|51 52|Q
P09310836A1019|27 36|P element
P09310836A1019|131 139|elements
P09308738A1216|30 33|HES
P09308738A1216|8 21|United States
P09308738A1216|154 194|factor VIII/von Willebrand factor levels
P09307312A0172|120 129|responses
P09307312A0172|209 240|membrane vibration measurements
P09307312A0172|178 185|cochlea
P09307312A0172|53 62|responses
P09307312A0172|139 149|hair cells
P09305944A0621|73 97|rna1p mutant derivatives
P09305944A0621|172 186|yeast proteins
P09305944A0621|39 45|series
P09305944A0621|18 33|RanGAP activity
P09305755A0540|146 156|hepatocyte
P09305755A0540|188 192|HNF5
P09305755A0540|17 23|region
P09305755A0540|74 81|protein
P09305755A0540|106 109|NF1
P09305755A0540|43 56|binding sites
P09305755A0540|96 102|factor
P09305592A0000|122 133|p210bcr/abl
P09305592A0000|77 89|bcr/abl gene
P09305592A0000|54 57|CML
P09303635A0000|39 47|disorder
P09303635A0000|1 8|Gaucher
P09301350A0946|211 212|%
P09301350A0946|121 123|CI
P09301350A0946|362 368|favour
P09301350A0946|89 94|pg/ml
P09301350A0946|145 151|favour
P09301350A0946|54 81|treatment median difference
P09301350A0946|290 307|percentage points
P09301350A0946|316 320|% CI
P09301350A0946|5 25|sputum interleukin-8
P09301350A0946|309 311|pp
P09301350A0946|372 379|placebo
P09300698A1219|20 34|interpretation
P09300698A1219|55 59|MQ9b
P09300323A1182|47 63|blood flow ratio
P09300323A1182|215 218|NTG
P09300323A1182|6 12|result
P09297698A0933|134 142|distance
P09297698A0933|108 114|region
P09297698A0933|155 167|enolase gene
P09297698A0933|34 38|ends
P09294471A1198|121 126|model
P09294471A1198|41 51|150/microL
P09294471A1198|97 99|I1
P09294471A1198|64 74|200/microL
P09294452A2107|77 99|reporter enzyme levels
P09294452A2107|64 73|reduction
P09294422A1223|172 180|activity
P09294422A1223|99 115|disulfide bridge
P09294422A1223|136 154|activation process
P09294161A1103|92 99|regions
P09294161A1103|7 15|findings
P09294161A1103|137 146|promoters
P09294139A0729|110 117|homolog
P09294139A0729|334 340|motifs
P09294139A0729|233 241|segments
P09294139A0729|138 144|motifs
P09294139A0729|84 85|%
P09292499A0887|151 185|UV crosslinking/competition assays
P09292499A0887|27 37|pyrimidine
P09292499A0887|7 22|repressor sites
P09292499A0887|66 102|polypyrimidine tract binding protein
P09291098A0452|164 176|rat GGT gene
P09291098A0452|148 156|promoter
P09291098A0452|115 125|transcript
P09290571A0799|29 31|VT
P09290571A0799|5 17|cycle length
P09290207A0731|26 38|derepression
P09288848A0780|15 17|Gy
P09287352A0930|28 43|STAT activation
P09287352A0930|246 256|expression
P09287352A0930|296 306|% increase
P09287352A0930|260 265|SHP-1
P09287352A0930|185 188|Ser
P09287352A0930|132 154|protein kinase pathway
P09287352A0930|200 208|activity
P09287352A0930|170 175|SHP-1
P09286981A0147|90 92|Da
P09286981A0147|43 51|subunits
P09285789A0712|63 69|domain
P09285789A0712|108 127|pleckstrin homology
P09285789A0712|129 131|PH
P09285789A0712|22 56|guanine nucleotide exchange factor
P09283828A0484|57 61|cues
P09282911A0277|132 134|T3
P09282911A0277|5 9|goal
P09282911A0277|155 164|mechanism
P09282911A0277|49 62|cell cultures
P09280747A0195|198 212|ACE inhibitors
P09280747A0195|143 151|evidence
P09280747A0195|20 45|hydralazine hydrochloride
P09280747A0195|50 70|isosorbide dinitrate
P09278758A1636|60 64|N1-3
P09278758A1636|13 25|Patients wit
P09278758A1636|46 58|neck disease
P09278758A1636|109 116|disease
P09278758A1636|232 237|sites
P09278758A1636|1 11|CONCLUSION
P09278475A0465|44 56|ts phenotype
P09278475A0465|8 13|scs32
P09278450A1338|79 85|site A
P09278450A1338|17 38|mobility shift assays
P09278441A1777|27 41|cardiomyocytes
P09278441A1777|19 23|CARP
P09278441A0163|1 5|Biol
P09277472A1070|25 30|edema
P09277472A1070|81 92|dysfunction
P09275990A0938|14 18|part
P09275990A0938|104 114|activation
P09275990A0938|143 166|mutagenicity prevalence
P09275159T0000|92 117|mouse hepatitis virus RNA
P09275159T0000|23 43|ribonucleoprotein A1
P09272108A1295b|43 47|gene
P09272108A1295b|96 110|CAAT sequences
P09272108A1295b|1 9|Analysis
P09271496T0000|21 36|HIV-1 integrase
P09271496T0000|70 90|target DNA molecules
P09271496T0000|51 56|sites
P09271417A0585|59 65|kidney
P09271417A0585|142 147|acids
P09271417A0585|21 30|ERR alpha
P09271397A1596|75 81|copies
P09271397A1596|41 50|construct
P09271397A1596|96 119|LDL receptor SREBP site
P09271393A1333|47 62|Tax anchors CBP
P09271393A1333|160 170|activities
P09271393A1333|115 125|activation
P09271393A1333|32 37|model
P09271393A1333|17 21|data
P09269879A0266|7 17|absorption
P09269879A0266|35 50|bioavailability
P09268652A0116|78 96|expression library
P09268652A0116|21 40|zinc finger protein
P09268631A0316|15 40|transcription orientation
P09268631A0316|97 102|Igf2r
P09268631A0316|70 75|genes
P09268387A0293|9 15|report
P09268387A0293|101 112|interaction
P09268387A0293|152 170|elongation complex
P09267542A0126|83 92|treatment
P09267542A0126|55 74|Drug Administration
P09267431A0000|61 76|protein kinases
P09267431A0000|36 41|SPK-4
P09265932A0575|29 31|mg
P09265932A0575|67 76|injection
P09265932A0575|84 99|L2-3 interspace
P09265534A0455|17 40|Gy/20 fractions/5 weeks
P09263856A0563|134 144|structures
P09263856A0563|29 35|models
P09263856A0563|112 120|factor X
P09263010T0000|60 63|sIg
P09263010T0000|122 127|bcl-2
P09263010T0000|96 101|c-myc
P09263010T0000|51 55|CD23
P09261200T0001|25 38|head injuries
P09261178T0000|42 48|kinase
P09261178T0000|51 55|gene
P09259328A0440|268 270|bp
P09259328A0440|248 250|bp
P09259328A0440|291 298|regions
P09259328A0440|281 283|bp
P09259328A0440|237 239|bp
P09259328A0440|1 29|Deletion mapping experiments
P09259328A0440|137 147|start site
P09259315A0809|44 52|enhanson
P09259315A0809|209 213|BeWo
P09259315A0809|172 205|CSEn enhancer/silencer activities
P09259315A0809|138 154|GT-IIC enhansons
P09259315A0809|102 119|silencer activity
P09259052A0568|225 229|cJun
P09259052A0568|133 141|extracts
P09259052A0568|215 219|JunB
P09259052A0568|113 124|AtT-20 cell
P09259052A0568|1 18|Supershift assays
P09259052A0568|85 102|protein complexes
P09258439A1001|10 27|expression system
P09258439A1001|87 98|mutagenesis
P09257651T0000|11 22|U4/U6 snRNP
P09257651T0000|93 121|yeast splicing factors Prp4p
P09256973A0455|45 46|G
P09256973A0455|62 64|mg
P09256973A0455|113 118|weeks
P09256973A0455|38 43|group
P09256973A0455|85 93|capsules
P09254709T0000|58 70|protein CcpA
P09254709T0000|1 9|Contacts
P09252879A0470|72 81|functions
P09252879A0470|20 33|HRCT findings
P09252879A0470|139 151|significance
P09252397A0081|181 190|sequences
P09252397A0081|28 40|repair rates
P09252397A0081|200 229|transcription initiation site
P09252397A0081|256 264|promoter
P09252397A0081|239 245|repair
P09250554A0402|26 38|diltiazem CD
P09250554A0402|49 65|placebo once/day
P09250554A0402|69 80|combination
P09248639A0152|147 158|contraction
P09248639A0152|92 105|blister fluid
P09248639A0152|197 214|collagen lattices
P09248639A0152|114 120|effect
P09248639A0152|139 143|rate
P09246585T0000|8 16|blockade
P09244430A0693|120 125|exons
P09244430A0693|88 93|donor
P09244430A0693|98 112|acceptor sites
P09244282A1371|72 77|sites
P09244282A1371|36 42|region
P09244282A1371|20 24|pecT
P09244282A1371|1 12|Mutagenesis
P09243840A0663|13 20|studies
P09243840A0663|133 158|DNA Laboratory structures
P09243840A0663|100 103|DNA
P09243505A1194|151 162|specificity
P09243505A1194|74 86|MADS domains
P09243505A1194|92 97|dimer
P09243505A1194|4 12|addition
P09243505A1194|325 333|proteins
P09243505A1194|187 196|sequences
P09243267A0401|29 37|patients
P09243267A0401|126 135|treatment
P09243267A0401|139 165|Roswell Park Cancer Center
P09243267A0401|69 83|cell carcinoma
P09242506A1033|46 64|E2F family members
P09242506A1033|1 4|E2F
P09242375A1313|72 98|gain-of-function mutations
P09242375A1313|193 202|mutations
P09242375A1313|249 264|MEN2B mutations
P09242375A1313|16 24|findings
P09242375A1313|239 244|MEN2A
P09241232A0653|108 112|AP/C
P09241232A0653|98 106|cytosine
P09239635A0477|15 19|dogs
P09239635A0477|72 82|littermate
P09239635A0477|100 109|serum IgA
P09238860A0175|195 212|protein kinase A.
P09238860A0175|22 29|nucleus
P09238860A0175|114 156|AMP response element binding proteins CREB
P09238850A0785|60 68|promoter
P09238850A0785|88 101|feedback loop
P09237862A0782|78 85|absence
P09237862A0782|21 25|eyes
P09236656A0124|75 76|L
P09236656A0124|78 80|SD
P09236656A0124|116 119|day
P09236656A0124|102 103|L
P09236224A0939|90 98|activity
P09236224A0939|126 144|PC12 growth arrest
P09236224A0939|102 105|NGF
P09235998A0788|134 151|HMG-CoA reductase
P09235998A0788|46 59|beta subunits
P09235998A0788|76 87|cholesterol
P09235618A0000|60 83|Guillain Barre syndrome
P09235618A0000|271 289|sedimentation rate
P09235618A0000|126 134|epilepsy
P09235618A0000|293 305|erythrocytes
P09235618A0000|16 24|patients
P09235618A0000|46 58|Lyme disease
P09235618A0000|6 12|series
P09235618A0000|238 245|factors
P09235073A0000|66 81|Weaver syndrome
P09235073A0000|35 42|patient
P09234736A0999|224 234|lung cells
P09234736A0999|193 198|cells
P09234736A0999|41 51|rat tissue
P09234736A0999|65 76|correlation
P09234736A0999|217 221|type
P09234725A1892|60 79|interaction surface
P09234725A1892|127 140|AP-1 activity
P09234720A1015|60 65|v-Src
P09234720A1015|43 46|MEK
P09234720A1015|191 208|neurite outgrowth
P09234720A1015|48 54|MEK-2E
P09234713A0754|164 168|DSBs
P09234713A0754|121 125|gene
P09234713A0754|127 130|RAG
P09234713A0754|202 209|Jdelta1
P09234713A0754|173 177|RSSs
P09234713A0754|184 191|Ddelta3
P09234696A0238|11 34|protein kinase cascades
P09234696A0238|86 89|MAP
P09234677A0770|67 75|proteins
P09234677A0770|102 113|transcripts
P09233809A0815|150 154|gene
P09233809A0815|193 217|reporter gene expression
P09233809A0815|40 54|gene targeting
P09233809A0815|256 265|intestine
P09233809A0815|221 226|liver
P09233801A1180|107 115|receptor
P09233801A1180|57 58|V
P09233801A1180|100 104|type
P09233487A1386|30 46|outcome measures
P09233487A1386|8 16|analysis
P09233487A1386|50 61|performance
P09230986A0000|44 49|cause
P09230986A0000|25 28|AIN
P09230986A0000|1 23|Autoimmune neutropenia
P09230384A0725|73 79|BACTEC
P09230384A0725|36 48|mycobacteria
P09230384A0725|54 60|BACTEC
P09230384A0725|19 28|detection
P09230216T0000|88 102|heterozygosity
P09230216T0000|65 71|region
P09230216T0000|114 120|cancer
P09229595A0618|60 68|electron
P09229595A0618|81 88|studies
P09228202A0581|215 223|SC-53116
P09228202A0581|191 210|cisapride mosapride
P09228202A0581|258 266|emptying
P09228202A0581|79 90|granisetron
P09228202A0581|277 281|rats
P09228202A0581|169 189|receptor antagonists
P09228042A0109|183 195|ion-exchange
P09228042A0109|230 233|Zn2
P09228042A0109|52 61|epiphycan
P09228042A0109|21 50|dermatan sulfate proteoglycan
P09228042A0109|138 158|epiphyseal cartilage
P09228042A0109|68 75|decorin
P09227332A1798|47 52|panel
P09227332A1798|56 65|cytokines
P09227332A1798|113 115|DC
P09227332A1798|86 95|cytokines
P09226345A0436|15 26|food intake
P09226345A0436|130 139|SEP group
P09226345A0436|76 77|p
P09226345A0436|65 74|ACT group
P09226345A0436|156 163|amounts
P09225998A0000|150 172|cell surface receptors
P09225998A0000|80 85|genes
P09225998A0000|139 148|cytokines
P09225998A0000|204 218|phase proteins
P09225682A0579|74 91|syndrome patients
P09225682A0579|178 195|syndrome patients
P09225682A0579|36 51|antibody titers
P09225682A0579|156 164|syndrome
P09225682A0579|204 207|PEN
P09225151T0000|27 32|types
P09225151T0000|67 77|prostheses
P09225151T0000|96 112|scarring process
P09224655T0000|13 21|splicing
P09224655T0000|25 30|ClC-6
P09224655T0000|48 75|CIC chloride-channel family
P09224655T0000|34 40|member
P09223667A0139|164 166|bp
P09223667A0139|176 200|transcription start site
P09223667A0139|143 149|region
P09223667A0139|35 58|NIH3T3 fibroblast cells
P09223506T0000|90 114|transcription start site
P09223506T0000|1 35|Transcription factor binding sites
P09223475A0898|56 63|ability
P09223475A0898|83 91|activity
P09223475A0898|217 226|integrity
P09223475A0898|115 123|promoter
P09223475A0898|101 105|HCMV
P09223475A0898|1 41|Chloramphenicol acetyltransferase assays
P09223122A0774|10 29|matter NAA/mI ratio
P09222115A0545|111 123|binding site
P09222115A0545|21 31|hypothesis
P09222115A0545|235 247|surroundings
P09222115A0545|207 212|phase
P09220177A0564|61 64|CPK
P09220177A0564|167 180|cardioversion
P09220177A0564|145 151|number
P09220177A0564|155 163|attempts
P09220177A0564|119 124|shock
P09219526A0383|179 187|fragment
P09219526A0383|22 33|specificity
P09219526A0383|217 223|region
P09218775A0000|63 71|fibrosis
P09218775A0000|24 31|strains
P09218775A0000|42 50|patients
P09218520A0075|121 126|IL-1R
P09218520A0075|39 67|candidate signal transducers
P09218520A0075|102 108|domain
P09218436A0443|124 129|sites
P09218436A0443|37 41|Pint
P09218436A0443|23 31|TATA box
P09216017A0621|61 66|holes
P09216017A0621|1 11|Vitrectomy
P09215525A0581|24 31|effects
P09215525A0581|83 91|activity
P09215525A0581|51 58|changes
P09212063A0425|125 133|VDR gene
P09212063A0425|33 40|A-phage
P09212059A1356|62 78|self-association
P09212059A1356|25 60|metal affinity chromatography assay
P09212059A1356|139 144|DhLBD
P09211934A0722|1 6|DNase
P09211675A0392|210 216|visits
P09211675A0392|218 227|protocols
P09211675A0392|48 57|personnel
P09211675A0392|117 129|measurements
P09211675A0392|326 333|records
P09211675A0392|160 177|protein excretion
P09211675A0392|307 314|reviews
P09211675A0392|375 391|hospitalizations
P09211354A0000|44 49|MMP-3
P09211354A0000|115 120|cells
P09211354A0000|16 42|matrix metalloproteinase-3
P09210012A0000|63 70|couples
P09210012A0000|37 50|relationships
P09209406A1021|56 91|guanine nucleotide exchange factors
P09209406A1021|129 139|c-cbl gene
P09209312A0968|74 76|nt
P09209312A0968|121 124|RNA
P09209312A0968|148 159|nucleotides
P09209312A0968|5 18|RNA construct
P09209312A0968|64 66|nt
P09208930T0000|28 33|genes
P09208930T0000|58 75|interleukin-1beta
P09208930T0000|1 15|Identification
P09206968A0000|92 106|tunica propria
P09206968A0000|162 173|homeostasis
P09206968A0000|140 147|support
P09206968A0000|1 12|Disturbance
P09205965A1249|120 127|pathway
P09205965A1249|91 97|L-dopa
P09205965A1249|5 12|results
P09205965A1249|169 197|spinal alpha 1-adrenoceptors
P09205113A0587|165 180|mouse germ line
P09205113A0587|123 135|transmission
P09205113A0587|146 155|frequency
P09205113A0587|83 92|HPRT gene
P09204566T0000|61 75|fixNOQP operon
P09204566T0000|79 114|Rhizobium leguminosarum strain VF39
P09203586A1197|42 51|T antigen
P09203586A1197|76 79|SL1
P09203586A1197|21 32|recruitment
P09202859A0091|75 95|alkaline phosphatase
P09202859A0091|42 54|gonadotropin
P09202859A0091|5 17|serum levels
P09202669A0614|29 32|AAV
P09202669A0614|79 90|replication
P09202669A0614|5 11|pWP-19
P09202669A0614|175 179|neoR
P09202669A0614|51 58|repeats
P09201980A0910|5 19|p20-CGGBP gene
P09201980A0910|87 94|species
P09200811T0000|63 70|protein
P09200498T0000|47 54|control
P09200498T0000|67 76|stability
P09199970A1101|89 106|cofactor activity
P09199970A1101|110 122|C3b cleavage
P09199970A1101|21 25|pMCP
P09199970A1101|68 75|domains
P09199626A0613|23 29|change
P09199626A0613|17 18|%
P09199353A1924|177 183|access
P09199353A1924|36 41|Cdc68
P09199353A1924|191 199|template
P09199353A1924|206 213|origins
P09199353A1924|119 135|polymerase alpha
P09199328T0000|76 79|HCF
P09199328T0000|50 54|VP16
P09199328T0000|85 88|DNA
P09199322T0000|47 58|replication
P09199322T0000|37 43|origin
P09199292A0536|28 39|association
P09199292A0536|43 47|p107
P09199292A0536|51 55|p130
P09199292A0536|85 98|cyclin A-cdk2
P09199167A0942|58 63|Vti1p
P09199167A0942|19 24|Sed5p
P09197342T0000|14 18|milk
P09197342T0000|96 103|rabbits
P09197342T0000|1 10|Secretion
P09197342T0000|68 79|Lipiodol UF
P09195923A0125|244 250|region
P09195923A0125|5 17|immunophilin
P09195923A0125|101 125|tetratricopeptide repeat
P09195923A0125|49 76|cyclosporin A-binding class
P09195923A0125|154 178|receptor heterocomplexes
P09193671A0347|12 17|state
P09193671A0347|55 58|GTP
P09193077A0000|91 101|activation
P09193077A0000|109 126|chalcone synthase
P09193077A0000|141 149|promoter
P09193077A0000|153 173|Petroselinum crispum
P09192998A0356|208 218|CJ signals
P09192998A0356|59 69|terminator
P09192998A0356|83 86|phi
P09192998A0356|200 203|PTH
P09192998A0356|139 156|termination sites
P09192786T0000|62 64|Lu
P09192786T0000|71 72|b
P09192786T0000|1 13|Organization
P09192732A1384|31 38|portion
P09192732A1384|92 100|membrane
P09190940A0127|78 91|switch region
P09190940A0127|114 123|switching
P09190940A0127|1 10|Induction
P09190202A0166|31 36|Sar1p
P09190202A0166|76 82|Sec23p
P09190202A0166|173 177|p150
P09190202A0166|103 125|Sec13p protein complex
P09189783A0000|104 116|carbohydrate
P09189783A0000|183 200|insulin responses
P09189783A0000|145 150|bolus
P09189783A0000|80 88|feedings
P09189783A0000|118 121|CHO
P09188699A1388|92 104|SP-A species
P09187637A1199|61 64|OP1
P09187637A1199|1 19|Taurine deficiency
P09187277A0118|63 66|V I
P09187277A0118|8 33|position-vestibular-pause
P09187277A0118|98 104|number
P09187277A0118|35 40|PVP I
P09187277A0118|68 75|neurons
P09186507A0882|193 204|G+C content
P09186507A0882|161 171|CAAT boxes
P09186507A0882|97 110|cDNA sequence
P09186507A0882|223 240|CpG dinucleotides
P09186056A0514|75 88|transcription
P09186056A0514|94 106|CAT-reporter
P09186056A0514|139 147|enhancer
P09186056A0514|51 62|C2C12 cells
P09185586A0000|63 72|mechanism
P09185183A0089|45 48|age
P09185183A0089|71 80|worsening
P09183145T0001|26 35|perfusion
P09183145T0001|57 62|SPECT
P09183145T0001|1 11|Evaluation
P09182707A0254|62 77|adhesion kinase
P09182707A0254|189 205|protein paxillin
P09182707A0254|1 4|SPP
P09182707A0254|103 118|tyrosine kinase
P09182281A0197|38 51|Cyclosporin A
P09181130A1067|95 103|mutation
P09181130A1067|129 131|r3
P09181130A1067|117 125|deletion
P09178752A0574|23 28|means
P09178752A0574|32 59|transactivation domain AF-1
P09178752A0574|69 73|cAMP
P09178491A0262|125 142|initiator element
P09178491A0262|71 86|HBV adw subtype
P09178491A0262|17 24|regions
P09177857A0000|56 89|substrates titanium tetrachloride
P09177857A0000|189 222|chemical vapour deposition method
P09177857A0000|173 179|plasma
P09177857A0000|156 160|type
P09176837A0211|131 133|Ca
P09176837A0211|38 42|CSAO
P09176837A0211|138 154|P administration
P09175858A1449|270 276|mutant
P09175858A1449|110 117|effects
P09175858A1449|154 164|inspection
P09175858A1449|186 196|structures
P09174049A1788|129 133|role
P09174049A1788|143 150|protein
P09174049A1788|16 50|p34CDC2 histone H1 kinase activity
P09172812A0660|22 33|fludarabine
P09172414A0000|148 163|liver esterases
P09172414A0000|97 116|cocaine metabolites
P09172414A0000|80 93|determination
P09171969A1165|45 57|oxygen pulse
P09171969A1165|122 132|evaluation
P09171969A1165|159 167|patients
P09171969A1165|20 24|time
P09171969A1165|1 12|Measurement
P09171389A0549|14 24|occurrence
P09171389A0549|209 221|Bacillus sp.
P09171389A0549|247 256|mechanism
P09171389A0549|283 294|attenuation
P09171389A0549|65 92|Thermus pyr promoter region
P09171389A0549|306 325|pyr gene expression
P09171239A2146|122 133|heterodimer
P09171239A2146|67 74|binding
P09171239A2146|32 38|ligand
P09171235A0851|41 54|concentration
P09171235A0851|58 66|COUP-TFI
P09171235A0851|110 128|silencing activity
P09171038A0219|122 131|treatment
P09171038A0219|9 13|case
P09171038A0219|96 106|complaints
P09170159A0348|90 100|tyrosinase
P09170159A0348|66 81|marker proteins
P09169852A0235|134 151|missense mutation
P09169852A0235|25 38|pag-3 alleles
P09169852A0235|86 103|nonsense mutation
P09169852A0235|1 11|Sequencing
P09169852A0235|221 229|tyrosine
P09169475A0772|89 100|mutagenesis
P09169475A0772|53 70|deletion analysis
P09169475A0772|1 13|Localization
P09169420A0000|61 65|beta
P09169420A0000|172 175|PIK
P09169420A0000|71 94|delta form heterodimers
P09169420A0000|168 171|p55
P09169420A0000|139 147|adaptors
P09168892A1016|75 81|effect
P09168892A1016|41 45|AP-1
P09168892A1016|1 9|Mutation
P09168623A0614|47 60|mxbD promoter
P09168623A0614|78 88|expression
P09168623A0614|24 30|fusion
P09168623A0614|175 180|cells
P09168623A0614|3 7|xylE
P09168623A0614|102 107|cells
P09168218A0216|181 195|ganglion block
P09168218A0216|41 46|woman
P09168218A0216|1 8|METHODS
P09168083A0987|15 20|group
P09168083A0987|38 39|P
P09168083A0987|33 36|HAT
P09165118A0311|148 152|loss
P09165118A0311|108 120|sister cells
P09165118A0311|126 142|VB motor neurons
P09165118A0311|212 227|movement defect
P09165118A0311|19 35|VA motor neurons
P09165039A0728|89 98|LHR cDNAs
P09165039A0728|5 20|monkey LHR cDNA
P09165004A1700|79 93|complex factor
P09165004A1700|141 146|Elk-1
P09165004A1700|50 65|phosphorylation
P09164543A0219|47 54|persons
P09164543A0219|106 112|months
P09164543A0219|27 34|authors
P09164543A0219|219 227|drainage
P09164543A0219|1 9|MATERIAL
P09162097A1258|123 137|mouse MAdCAM-1
P09162097A1258|196 206|structures
P09162097A1258|67 80|MAdCAM-1 cDNA
P09162097A1258|153 168|dissimilarities
P09162092A0675|30 40|activation
P09162092A0675|122 127|MEKK2
P09162092A0675|76 88|coexpression
P09162092A0675|102 107|MEKK3
P09160881A0491|110 122|interactions
P09160881A0491|71 77|screen
P09159183A0119|109 113|bZIP
P09159183A0119|162 168|number
P09159183A0119|80 107|basic-region leucine zipper
P09159183A0119|71 76|class
P09159111A0437|74 89|NMR experiments
P09159111A0437|97 107|Skn domain
P09159111A0437|21 29|proposal
P09157337A0545|128 133|years
P09157337A0545|5 12|husband
P09157337A0545|35 42|couples
P09156883A0294|10 20|parameters
P09156883A0294|97 101|SaO2
P09156883A0294|48 62|blood pressure
P09156883A0294|154 163|procedure
P09156883A0294|85 95|saturation
P09155015A0140|121 129|promoter
P09155015A0140|23 43|protein kinase MEKK1
P09155015A0140|141 147|marker
P09154822T0000|62 71|apoptosis
P09154822T0000|93 98|cells
P09154822T0000|1 11|Inhibition
P09154797A0777|11 31|spermidine transport
P09154797A0777|143 149|strain
P09154797A0777|35 39|stk2
P09154621A1475|92 98|layers
P09154621A1475|112 131|liver triglycerides
P09154621A1475|174 181|effects
P09153795A0298|12 19|studies
P09153795A0298|67 75|validity
P09153795A0298|51 62|reliability
P09153319A1332|91 117|collagen promoter sequence
P09153319A1332|59 75|reporter plasmid
P09153319A1332|137 147|inhibition
P09153010A0499|241 245|MUPs
P09153010A0499|145 149|site
P09153010A0499|191 205|threshold MUPs
P09153010A0499|155 166|possibility
P09153010A0499|228 237|selection
P09153010A0499|10 20|advantages
P09153010A0499|350 362|laboratories
P09153010A0499|101 111|collection
P09151925A0479|74 79|C-LIP
P09151925A0479|92 106|gelatin sponge
P09151925A0479|55 67|embolization
P09151925A0479|34 45|transcather
P09151828A0919|104 111|regions
P09151828A0919|215 223|residues
P09151828A0919|53 71|9ORF1 polypeptides
P09151828A0919|157 163|region
P09151828A0919|137 145|residues
P09151376A0000|60 67|patient
P09151376A0000|74 83|diagnosis
P09151376A0000|22 26|type
P09150774A0616|44 47|ISO
P09150774A0616|32 42|isoflurane
P09150774A0616|1 11|Anesthesia
P09150595T0000|131 139|reaction
P09150595T0000|100 108|elicitor
P09150566A0316|28 34|grains
P09150566A0316|20 24|role
P09150566A0316|55 72|complex molecules
P09149929A0750|26 37|predictions
P09149929A0750|93 105|homesickness
P09149929A0750|80 87|control
P09148935A0805|150 183|c-Src binding site Phe-397 mutant
P09148935A0805|112 116|ERK2
P09148935A0805|98 108|activation
P09148903A1715|44 54|activation
P09148903A1715|285 292|pathway
P09148903A1715|11 18|studies
P09148903A1715|127 157|NF-kappaB transcription factor
P09147832A0174|62 63|n
P09147832A0174|12 23|temperament
P09147832A0174|37 50|socialization
P09147832A0174|80 85|years
P09147832A0174|103 113|predictors
P09147420T0000|62 68|repeat
P09147420T0000|25 40|transactivation
P09147420T0000|113 136|cytomegalovirus IE1/IE2
P09146071T0001|47 51|case
P09146071T0001|37 41|limb
P09144958A0047|28 34|region
P09144958A0047|57 68|Arabidopsis
P09144958A0047|6 13|protein
P09144958A0047|116 121|Lhcb1
P09144195A1051|75 108|phosphorylation/dephosphorylation
P09144195A1051|26 39|PS1 fragments
P09144195A1051|116 123|PS1 CTF
P09144165A0614|27 34|complex
P09144165A0614|184 191|members
P09144165A0614|135 151|hypervariability
P09144165A0614|199 230|Rel transcription factor family
P09144165A0614|76 93|Rel insert region
P09144165A0614|64 68|AP-1
P09143328A1002|27 34|example
P09143328A1002|96 110|RNA polymerase
P09143328A1002|70 89|dinucleotide primer
P09140474T0000|43 50|Minorca
P09140474T0000|52 57|Spain
P09140474T0000|98 103|years
P09139910A1572|72 85|nifV mutation
P09139910A1572|39 48|leuA gene
P09139910A1572|18 33|Anabaena strain
P09139892A1150|148 161|crp promoters
P09139892A1150|25 29|orfX
P09139892A1150|34 47|vfr promoters
P09139721A0183|148 156|deletion
P09139721A0183|127 136|selection
P09139721A0183|1 10|Cyclin G2
P09139665A0784|23 37|PhLP complexes
P09138076A1099|31 38|factors
P09138076A1099|95 105|osteoblast
P09138076A1099|173 181|elements
P09138076A1099|115 137|oligonucleotide probes
P09136015A0529|105 120|diversification
P09136015A0529|94 101|pattern
P09136015A0529|5 15|sequencing
P09135772T0000|89 97|subjects
P09135772T0000|10 18|response
P09135066A0653|78 85|absence
P09135066A0653|99 102|Ras
P09132061A0828|30 44|cDNA sequences
P09132061A0828|92 106|isoperoxidases
P09132061A0828|21 26|types
P09132011A0298|181 184|cdc
P09132011A0298|112 119|protein
P09132011A0298|48 56|proteins
P09132011A0298|1 11|Comparison
P09130720A0417|105 121|TACTAAC sequence
P09130720A0417|29 36|mutants
P09130720A0417|78 87|positions
P09130700A0676|30 41|interaction
P09130700A0676|104 124|SPC97 overexpression
P09130700A0676|148 165|co-overexpression
P09130700A0676|9 16|support
P09130700A0676|169 173|TUB4
P09129147A0644|107 124|ATF/CREB proteins
P09129147A0644|146 167|phosphorylation sites
P09129147A0644|5 25|Jem peptide sequence
P09129147A0644|35 49|leucine-zipper
P09126622A0466|41 49|colonies
P09126622A0466|54 65|appressoria
P09124054A1164|46 51|ABSCT
P09124054A1164|128 135|therapy
P09124054A1164|5 14|prognosis
P09123055T0000|52 58|livers
P09123055T0000|71 83|HTK solution
P09122198A0478|29 46|tyrosine residues
P09122198A0478|66 72|domain
P09122198A0478|1 16|Point mutations
P09122168A1427|210 221|interaction
P09122168A1427|183 202|isoform specificity
P09122168A1427|123 127|GRK2
P09122168A1427|231 241|components
P09122168A1427|6 11|study
P09121774T0000|75 85|activation
P09121774T0000|93 115|serum response element
P09121774T0000|36 48|polyomavirus
P09121476T0000|46 69|DEAD-box protein family
P09121476T0000|32 38|member
P09121452A0538|164 176|2D5 promoter
P09121452A0538|265 275|C/EBP site
P09121452A0538|39 58|C/EBP beta proteins
P09121452A0538|1 26|Domain switch experiments
P09121433A0463|123 126|T/A
P09121433A0463|127 131|4TAG
P09121433A0463|23 27|Smp1
P09121433A0463|119 122|CTA
P09121433A0463|14 18|Rlm1
P09121433A0463|73 77|Rlm1
P09121433A0463|98 109|specificity
P09121430A1075|14 27|Y239/240F Shc
P09121430A1075|37 46|Y317F Shc
P09121424A0296|104 111|complex
P09121424A0296|124 131|homolog
P09121424A0296|39 51|Swi3 homolog
P09119112A1350|146 150|lung
P09119112A1350|7 11|data
P09119112A1350|136 141|heart
P09118704A0771|89 110|% confidence interval
P09118704A0771|129 130|%
P09118704A0771|53 65|chemotherapy
P09118704A0771|70 75|G-CSF
P09118704A0771|84 85|%
P09118196A0281|121 162|Wechsler Adult Intelligence Scale-Revised
P09118196A0281|77 83|NART-R
P09118196A0281|93 111|Vocabulary subtest
P09118196A0281|204 209|level
P09115989A0993|89 107|initiation process
P09115989A0993|76 81|steps
P09115365A0000|105 114|oncogenes
P09115365A0000|47 51|gene
P09115365A0000|82 87|kinds
P09115365A0000|1 11|Expression
P09115279A0345|27 31|Pch1
P09115279A0345|116 127|Pch1 kinase
P09115279A0345|35 37|S.
P09115247A2069|31 56|11-aminoundecanoyl-SH-NH2
P09115247A2069|287 306|epsilon-amino group
P09115247A2069|147 155|elements
P09115247A2069|313 322|imidazole
P09115247A2069|250 261|amino group
P09115247A2069|1 26|11-Aminoundecanoyl-SK-NH2
P09114972A1366|24 33|viability
P09114972A1366|19 22|SOS
P09112400A1155|47 55|addition
P09112400A1155|59 68|forskolin
P09111367A1098|240 246|effect
P09111367A1098|125 136|temperature
P09111367A1098|352 361|oncogenes
P09111367A1098|376 387|experiments
P09111367A1098|309 318|host cell
P09111367A1098|578 583|cells
P09111367A1098|31 34|32D
P09111367A1098|262 271|integrity
P09111367A1098|620 627|protein
P09111367A1098|469 495|heterodimerization domains
P09111367A1098|545 547|M3
P09111367A1098|279 301|cell cycle checkpoints
P09111331A0119|77 86|functions
P09111331A0119|5 17|Rlm1 protein
P09111331A0119|21 27|member
P09111331A0119|35 50|MADS box family
P09111314A0970|39 43|cdk4
P09111059A0327|88 99|specificity
P09111059A0327|36 47|homeodomain
P09111004A0732|45 56|Xaa residue
P09111004A0732|192 195|L12
P09111004A0732|128 167|L12 influence p38 substrate specificity
P09111004A0732|69 102|phosphorylation motif Thr-Xaa-Tyr
P09111004A0732|17 24|effects
P09108451A0160|28 40|laboratories
P09108451A0160|128 144|tumor cell lines
P09108207A0306|14 27|participation
P09108029A0399|151 168|DNA repair enzyme
P09108029A0399|28 36|activity
P09108029A0399|84 101|DNA repair enzyme
P09108029A0399|170 185|AP endonuclease
P09105530A0000|75 93|cheese preparation
P09105530A0000|17 25|lysozyme
P09105042A1497|31 40|phenotype
P09105042A1497|74 86|HCM patients
P09105042A1497|280 286|effect
P09105042A1497|196 209|chain protein
P09105042A1497|323 329|stress
P09105042A1497|343 360|beta MHC function
P09103382T0000|9 24|FIGO definition
P09101910A0394|72 80|patients
P09101910A0394|108 109|%
P09101910A0394|52 53|%
P09101910A0394|19 28|mortality
P09100202A0000|109 131|tissue graft procedure
P09100202A0000|20 39|Class II recessions
P09099743A0585|104 111|mRNP3+4
P09099743A0585|132 144|polypeptides
P09099743A0585|20 32|purification
P09099743A0585|48 52|form
P09099743A0585|205 212|doublet
P09099702A0000|47 51|germ
P09099702A0000|109 115|factor
P09099702A0000|117 121|GCNF
P09098899A0435|182 195|acidification
P09098899A0435|59 73|characteristic
P09098899A0435|219 228|mM-1 cm-1
P09098899A0435|258 260|Cd
P09098899A0435|77 84|CysS-Cd
P09098899A0435|142 175|difference absorption coefficient
P09098899A0435|5 27|UV absorption spectrum
P09098066A0119|148 152|loss
P09098066A0119|267 272|locus
P09098066A0119|6 11|locus
P09098066A0119|206 215|phenotype
P09098066A0119|35 38|kbp
P09098066A0119|119 129|insertions
P09096234T0000|123 148|phage lambda cI repressor
P09096234T0000|22 33|interaction
P09094671A1192|61 69|p15INK4b
P09094671A1192|41 49|p16INK4a
P09094671A1192|112 134|Southern blot analysis
P09094671A1192|184 188|gene
P09094671A1192|35 39|Mts1
P09094093A0578|6 10|site
P09092675A0283|30 40|OcRNA site
P09092675A0283|109 116|strains
P09092675A0283|42 49|P22 R17
P09092675A0283|51 52|A
P09092580A1354|47 65|MAP kinase pathway
P09092580A1354|110 124|transmigration
P09092580A1354|97 102|cells
P09091403T0001|105 109|site
P09091403T0001|114 132|microsatellite DNA
P09091403T0001|1 9|Analysis
P09091403T0001|85 95|mts1 genes
P09091010A1003|54 62|cytology
P09090054A0186|194 198|MAL1
P09090054A0186|63 68|genes
P09090054A0186|131 135|gene
P09090054A0186|98 115|alpha-glucosidase
P09090054A0186|238 243|genes
P09089653A1112|91 97|region
P09089653A1112|127 129|nt
P09089653A1112|1 9|Analysis
P09089093A0373|39 47|CA genes
P09089093A0373|1 10|Sequences
P09088416A0000|194 210|artery occlusion
P09088416A0000|56 65|occlusion
P09088416A0000|67 74|IBRBRAO
P09088416A0000|142 149|vertigo
P09088416A0000|32 38|branch
P09087430A1046|76 79|PAP
P09087430A1046|51 54|BSA
P09085842A1559|147 168|phosphorylation state
P09085842A1559|184 201|pre-mRNA splicing
P09084621A2567|100 106|sulcus
P09084621A2567|1 6|Areas
P09084227A0833|62 73|ingredients
P09084227A0833|212 216|rats
P09084227A0833|191 208|muscle relaxation
P09084227A0833|116 124|medicine
P09084174A0667|120 161|aspartate-beta-semialdehyde dehydrogenase
P09084174A0667|106 109|asd
P09084174A0667|58 62|leuB
P09084174A0667|6 14|fragment
P09084174A0667|218 230|Asd proteins
P09084174A0667|185 192|product
P09083345A0851|60 64|need
P09083345A0851|23 29|values
P09083345A0851|80 89|districts
P09083345A0851|117 122|SYPLR
P09083345A0851|107 113|values
P09083345A0851|143 162|inter-relationships
P09083345A0851|205 213|duration
P09082335A0730|70 75|means
P09081389A1088|47 53|cycles
P09081389A1088|38 39|%
P09080250A0212|62 86|p15E cDNA gene fragments
P09080250A0212|179 188|P815/DTIC
P09080250A0212|190 202|tumour cells
P09080250A0212|16 21|study
P09079928A0525|91 97|region
P09079928A0525|101 110|M. leprae
P09079928A0525|1 15|M. leprae OxyR
P09079904A0995|132 141|virulence
P09079904A0995|29 44|sodA expression
P09079904A0995|96 109|coumermycin A
P09079878A0000|107 121|reading frames
P09079878A0000|10 12|kb
P09079878A0000|178 180|S.
P09079689A0472|61 71|C terminus
P09079689A0472|97 101|cDNA
P09079689A0472|35 45|PAS domain
P09079638A0883|132 138|domain
P09079638A0883|242 258|ligand challenge
P09079638A0883|40 48|mutation
P09079638A0883|96 104|mutation
P09079638A0883|5 17|3ASubE cells
P09079638A0883|117 123|serine
P09077438A0076|27 35|subunits
P09077438A0076|5 12|minimum
P09077108A0458|28 39|pleocytosis
P09077108A0458|20 26|period
P09077108A0458|80 84|IL-6
P09077108A0458|101 105|PGE2
P09076336A0281|91 104|constellation
P09076336A0281|57 66|diagnosis
P09076336A0281|206 218|GH secretion
P09074508A0397|11 20|CD38 gene
P09074508A0397|66 68|kb
P09073074T0000|11 24|transcription
P09073074T0000|68 80|developement
P09071407T0000|13 21|oxytocin
P09071407T0000|65 77|cohabitation
P09068989T0000|11 29|Azadirachta indica
P09068989T0000|1 7|Effect
P09067577A0307|79 82|CRK
P09067577A0307|4 14|cell lines
P09065690A0463|60 65|genes
P09065690A0463|129 137|function
P09065690A0463|32 42|expression
P09065690A0463|103 111|sequence
P09065170A0853|5 13|addition
P09065170A0853|51 59|transfer
P09064659A1055|56 66|yeast UPF1
P09064659A1055|161 166|HUPF1
P09064659A1055|178 185|homolog
P09064659A1055|70 77|protein
P09061698A0177|90 94|RBCs
P09061698A0177|77 88|blood cells
P09061698A0177|155 172|blood pool agents
P09061697A0629|121 124|mCi
P09061697A0629|240 244|days
P09061697A0629|147 159|day protocol
P09061697A0629|176 177|%
P09061697A0629|82 86|rest
P09061697A0629|262 265|MBq
P09061697A0629|325 337|day protocol
P09061697A0629|15 16|%
P09061697A0629|133 139|stress
P09061697A0629|98 99|h
P09061697A0629|309 317|occasion
P09060676A1634|89 99|properties
P09060676A1634|53 66|coronaviruses
P09060622A1679|88 92|tail
P09060622A1679|80 84|poly
P09060622A1679|19 25|report
P09060622A1679|152 158|genome
P09060045A0576|34 46|interactions
P09060045A0576|102 119|endotoxin release
P09058378A1134|121 124|p53
P09058378A1134|23 47|glucocorticoid receptors
P09058373A0670|60 76|GHR1-279 variant
P09058373A0670|80 90|IM-9 cells
P09058373A0670|1 29|RNase protection experiments
P09058250A0128|10 23|complications
P09058250A0128|59 61|NO
P09057841T0000|75 96|isocitrate lyase gene
P09057841T0000|160 168|pathways
P09057841T0000|1 13|Derepression
P09057703A1389|1 16|Snail mortality
P09057325A0177|15 27|plasmid pCM2
P09057325A0177|5 11|region
P09057325A0177|139 162|Bg/II/SmaI DNA fragment
P09055221A0288|125 132|effects
P09055221A0288|77 81|MSEs
P09055221A0288|5 14|intensity
P09055221A0288|34 39|order
P09053835A0865|11 23|p53 activity
P09053835A0865|35 37|OP
P09053309A1103|52 63|oep mutants
P09053309A1103|85 92|absence
P09050867A0542|151 169|TN control element
P09050867A0542|88 101|octamer motif
P09050867A0542|7 15|elements
P09050849A1459|9 15|regard
P09050849A1459|96 102|domain
P09050847A0180|89 94|class
P09050847A0180|8 13|class
P09050847A0180|35 52|TBP-TAF complexes
P09049313A0116|121 144|initiation factor eIF4G
P09049313A0116|9 18|instances
P09049313A0116|51 61|expression
P09049304A1193|82 104|VPF/VEGF transcription
P09049304A1193|48 71|Egr-1 expression vector
P09049304A1193|169 172|TGF
P09049198A0289|198 212|liver diseases
P09049198A0289|95 105|regulation
P09049198A0289|9 16|insight
P09049198A0289|113 121|p21 gene
P09049198A0289|156 174|liver regeneration
P09049198A0289|50 53|p21
P09047344A0000|126 136|calmodulin
P09047344A0000|110 114|MLCK
P09047344A0000|96 108|chain kinase
P09047344A0000|51 62|amino acids
P09046384A0403|60 66|counts
P09046384A0403|80 94|amylase levels
P09046384A0403|1 24|Marinol/marijuana usage
P09046090T0000|24 53|transcription factor yTAFII60
P09046090T0000|159 162|arm
P09046090T0000|191 205|chromosome VII
P09045919A1250|61 70|activator
P09045919A1250|28 36|evidence
P09045919A1250|261 285|B lymphocyte development
P09045919A1250|86 97|combination
P09045919A1250|135 139|part
P09045919A1250|72 75|NFE
P09045919A1250|196 213|enhancer activity
P09045805A0945|159 183|transactivating function
P09045805A0945|140 144|acoK
P09045805A0945|19 29|expression
P09043768A0139|36 39|BLM
P09043768A0139|65 71|In-111
P09042911A0626|75 85|regulation
P09042911A0626|9 26|promoter elements
P09042911A0626|188 196|sequence
P09042683A0492|147 155|disorder
P09042683A0492|5 22|FBF questionnaire
P09042683A0492|100 108|disorder
P09042078A0202|29 37|incisors
P09042078A0202|110 118|subjects
P09042078A0202|65 75|dimensions
P09040011A1316|13 16|p56
P09040011A1316|42 57|G1/S transition
P09040011A1316|22 30|activity
P09040011A1316|4 11|summary
P09040011A1316|70 81|thymoblasts
P09038202A1951|61 70|NRSF/REST
P09038202A1951|24 28|idea
P09038202A1951|143 151|proteins
P09038202A1951|38 57|repression activity
P09038166A0818|15 18|A1b
P09038166A0818|69 75|intron
P09037064A0183|164 170|number
P09037064A0183|109 119|volunteers
P09037064A0183|8 19|application
P09037064A0183|35 54|canarypox ALVAC/HIV
P09036529A0343|91 100|serum IgE
P09036529A0343|212 217|venom
P09036529A0343|191 195|wasp
P09036529A0343|21 31|skin tests
P09036529A0343|166 169|bee
P09036529A0343|106 114|RAST-CAP
P09036529A0343|197 209|Vespula spec
P09036529A0343|5 11|workup
P09035307A0000|44 47|man
P09035307A0000|22 26|case
P09035307A0000|158 168|99mTc-MIBI
P09032328A0650|27 34|segment
P09032328A0650|77 82|locus
P09032328A0650|98 103|ORF11
P09032328A0650|50 66|gammaherpesvirus
P09032328A0650|170 183|gene products
P09032275A1133|17 23|domain
P09032275A1133|102 106|date
P09032259A0972|61 73|lamellipodia
P09032259A0972|33 36|JNK
P09032259A0972|116 142|Rac1 transforming activity
P09032258A0395|40 53|transfectants
P09032258A0395|1 8|Studies
P09032250A0257|151 168|HeLa cDNA library
P09032250A0257|11 16|yeast
P09032250A0257|38 44|screen
P09032250A0257|100 109|B subunit
P09032233T0000|30 59|POU-homeodomain protein GHF-1
P09032233T0000|99 114|gene expression
P09032233T0000|16 21|Ets-1
P09030781A0734|62 75|cdc2/cyclin B
P09030781A0734|92 105|cdk2/cyclin E
P09030781A0734|290 294|IC50
P09030781A0734|153 164|IC50 values
P09030781A0734|110 118|cdk5/p35
P09030781A0734|233 247|cdk6/cyclin D2
P09030581A0990|45 55|activation
P09030581A0990|59 70|MAP kinases
P09030581A0990|98 101|p38
P09030581A0990|32 37|MKP-4
P09029713A1120|150 163|transcription
P09029713A1120|78 92|activator SF-1
P09029713A1120|101 118|repressor COUP-TF
P09029104A0226|40 47|lineage
P09029104A0226|17 21|gene
P09028998A0143|135 138|BCT
P09028998A0143|36 43|control
P09028998A0143|87 93|amount
P09028308A0590|165 178|micrograms/kg
P09028308A0590|79 102|bone marrow suppression
P09028308A0590|228 233|cycle
P09028308A0590|156 161|G-CSF
P09028308A0590|35 38|AZQ
P09027506T0000|15 34|expression analysis
P09027506T0000|129 135|eIF-4G
P09027506T0000|97 106|wheat eIF
P09027506T0000|70 74|gene
P09027506T0000|85 93|homology
P09025549A0000|12 17|nurse
P09025549A0000|43 48|level
P09025549A0000|202 212|colleagues
P09025549A0000|191 198|network
P09025549A0000|251 255|home
P09025549A0000|117 122|field
P09024805A0905b|125 128|ZII
P09024805A0905b|219 245|phorbol ester inducibility
P09024805A0905b|158 172|BZLF1 promoter
P09024805A0905b|141 148|element
P09024805A0905b|136 139|AP1
P09024097A0000|121 131|postpartum
P09024097A0000|101 114|complications
P09024097A0000|1 10|OBJECTIVE
P09024097A0000|85 89|rate
P09023378A0959|11 21|expression
P09023378A0959|108 120|C-repeat/DRE
P09023378A0959|33 38|yeast
P09023378A0959|170 178|versions
P09022632T0000|43 50|surgery
P09021684A1418|91 98|nucleus
P09021684A1418|130 149|repressor functions
P09021684A1418|205 229|transactivation activity
P09020172A0964|14 20|qTBP42
P09020172A0964|89 94|forms
P09020172A0964|245 254|Kd values
P09020172A0964|65 68|DNA
P09020172A0964|115 121|strand
P09020138A0833|15 18|Cas
P09020138A0833|73 88|tyrosine kinase
P09020138A0833|58 66|adhesion
P09020138A0833|141 162|adapter molecule CrkL
P09018133A0244|14 22|analysis
P09018133A0244|62 74|relationship
P09018133A0244|94 101|members
P09018133A0244|83 89|PhHV-1
P09017443A0734|56 66|occurrence
P09017443A0734|113 120|regimen
P09017443A0734|80 88|syndrome
P09017443A0734|103 109|effect
P09015799T0000|1 20|Serotonin receptors
P09015543A0210|14 22|solution
P09015543A0210|53 57|flap
P09013499A0198|208 212|time
P09013499A0198|129 134|mg/kg
P09013499A0198|4 14|Experiment
P09013499A0198|184 196|conditioning
P09013499A0198|152 155|min
P09012405A0785|135 145|DNA repair
P09012405A0785|73 78|TFIIH
P09012405A0785|123 131|function
P09011744A0790|180 188|subunits
P09011744A0790|300 311|F1xC57BL/6J
P09011744A0790|93 99|Grin2a
P09011744A0790|82 89|epsilon
P09011744A0790|291 298|spretus
P09011744A0790|165 169|zeta
P09011744A0790|46 76|NMDA receptor channel subunits
P09011744A0790|313 317|mice
P09011744A0790|173 178|Grinl
P09011744A0790|102 109|epsilon
P09010223A1850|214 223|Egr1 gene
P09010223A1850|144 152|function
P09010223A1850|6 14|R-domain
P09010223A1850|32 43|interaction
P09010223A1850|100 104|FLI1
P09009208A0337|59 64|bases
P09009208A0337|5 11|primer
P09006936T0000|95 115|glycoprotein IBalpha
P09006936T0000|1 15|Identification
P09006914A1127|93 103|activation
P09006914A1127|113 120|kinases
P09006914A1127|154 180|E-selectin gene expression
P09006910A0000|74 93|retinoid X receptor
P09006910A0000|133 139|region
P09006910A0000|20 30|mechanisms
P09006910A0000|153 170|RXRgamma2 isoform
P09006555A0738|150 174|neutrophil oxidant burst
P09006555A0738|47 59|hemodynamics
P09006555A0738|176 204|lung myeloperoxidase content
P09006555A0738|70 93|blood gas determination
P09006022A0252|88 95|control
P09006022A0252|99 125|T7 RNA polymerase promoter
P09006007A0997|62 71|UGA codon
P09006007A0997|271 278|complex
P09006007A0997|5 12|results
P09006007A0997|184 195|specificity
P09006007A0997|288 296|ribosome
P09005836A0977|39 45|horses
P09005836A0977|4 15|correlation
P09005273A1558|124 133|chemicals
P09005273A1558|108 120|combinations
P09005273A1558|173 199|neuropathy target esterase
P09005273A1558|1 11|CONCLUSION
P09004987T0001|67 72|fever
P09004987T0001|1 24|Serotonin concentration
P09004304A0000|62 68|number
P09004304A0000|41 56|reproducibility
P09004304A0000|83 100|clearance methods
P09004304A0000|5 8|aim
P09004304A0000|17 22|study
P09003463A0198|26 35|isolation
P09003463A0198|76 82|region
P09003463A0198|96 100|exon
P09003410A0000|11 23|p100 protein
P09003410A0000|99 106|antigen
P09003311A0478|61 71|porin gene
P09003311A0478|10 22|DNA fragment
P09003001A1593|28 31|E12
P09003001A1593|37 44|protein
P09002648A0202|121 131|cell death
P09002648A0202|24 33|apoptosis
P09002648A0202|1 6|BCL-2
P09001667A0312|64 84|day post-vaccination
P09001245A0187|70 76|screen
P09000632A2341|120 127|complex
P09000632A2341|25 42|Cys181 side-chain
P09000632A2341|85 102|Tyr181 side-chain
P09000146T0000|36 40|type
P09000146T0000|85 105|sequence alterations
P09000049A1341|105 123|cell proliferation
P09000049A1341|21 24|Max
P09000049A1341|17 20|Mnt
P08999857A0801|27 34|context
P08999857A0801|129 137|activity
P08999857A0801|98 109|enhancement
P08999857A0801|152 153|I
P08998115A0114|124 146|lymph node dissections
P08998115A0114|100 111|controversy
P08998115A0114|85 90|years
P08997490A1127|140 148|contexts
P08997490A1127|81 90|DBP sites
P08997490A1127|168 201|cholesterol hydroxylase promoters
P08997490A1127|1 13|C/EBP beta V
P08995681A0518|67 74|protein
P08995681A0518|50 55|forms
P08995652A0812|480 491|amino acids
P08995652A0812|359 373|UL80.5 protein
P08995652A0812|591 608|scaffold proteins
P08995652A0812|44 51|capsids
P08995652A0812|311 318|capsids
P08995652A0812|269 280|amino acids
P08995652A0812|456 464|sequence
P08995652A0812|701 716|UL80.5 proteins
P08995652A0812|567 583|self-interaction
P08995652A0812|130 141|amino acids
P08995652A0812|403 411|assembly
P08995652A0812|5 12|results
P08995652A0812|548 560|RRIFVAAMMKLE
P08995410A1109|183 186|p35
P08995410A1109|159 162|p47
P08995410A1109|81 85|eIF3
P08995410A1109|164 167|p44
P08995410A1109|46 56|co-workers
P08995410A1109|143 147|p110
P08995410A1109|174 177|p36
P08995410A1109|34 41|Hershey
P08995054A1368|59 65|region
P08995054A1368|116 134|nucleotide changes
P08995054A1368|1 3|D.
P08994968A0926|15 18|arm
P08994968A0926|135 139|NADP
P08994968A0926|127 131|ring
P08994825A0000|91 117|Cdc2/28-cyclin B complexes
P08994825A0000|63 69|factor
P08994825A0000|37 40|MPF
P08994825A0000|1 11|BACKGROUND
P08993831A0000|56 69|muscle fibers
P08993831A0000|141 154|gene products
P08993393A0498|26 38|implications
P08993393A0498|66 76|physiology
P08990397A1437|104 112|evidence
P08990397A1437|133 147|RNA processing
P08990397A1437|86 89|H13
P08990168A0688|94 98|GATE
P08990168A0688|55 59|JAK1
P08989025A0359|28 36|channels
P08989025A0359|112 118|microM
P08989025A0359|38 41|VOC
P08989025A0359|153 162|responses
P08988257A1256|30 38|creation
P08988257A1256|44 52|telomere
P08988257A1256|59 61|kb
P08988257A1256|114 116|bp
P08988257A1256|185 195|truncation
P08988257A1256|136 151|repeat sequence
P08987009A0400|66 73|freedom
P08987009A0400|38 51|prerequisites
P08986770A0268|130 135|I-POU
P08986770A0268|113 124|development
P08986770A0268|21 31|expression
P08986228A0000|123 136|malformations
P08986228A0000|38 45|mothers
P08986190A0927|45 63|lactate production
P08986190A0927|82 90|increase
P08986190A0927|1 12|Reperfusion
P08985122A0501|52 57|group
P08985122A0501|114 124|CAAT boxes
P08985122A0501|325 330|genes
P08985122A0501|105 109|TATA
P08985122A0501|142 155|binding sites
P08985122A0501|274 283|promoters
P08985109A1285|39 45|margin
P08985109A1285|116 120|cone
P08985109A1285|68 73|crest
P08981371A2049a|40 51|kDa protein
P08980536A1196|30 35|G-box
P08980536A1196|40 45|H-box
P08980536A1196|5 17|conservation
P08980522A0280|60 63|kDa
P08980522A0280|13 17|cpm7
P08979828A1561|55 63|behavior
P08978996A0000|224 238|patient groups
P08978996A0000|27 44|hepatitis C virus
P08978996A0000|58 63|cause
P08978996A0000|67 80|liver disease
P08978996A0000|114 133|transplant patients
P08978996A0000|205 214|infection
P08978690A0262|122 141|yeast model systems
P08978690A0262|50 57|protein
P08977235A0588|58 64|domain
P08977235A0588|80 87|ability
P08977235A0588|21 38|tyrosine residues
P08977235A0588|100 105|STAT5
P08977235A0588|136 141|STAT3
P08977013A0788|44 57|magnification
P08977013A0788|131 137|vision
P08977013A0788|5 17|implications
P08975713A0454|209 223|p53p2 promoter
P08975713A0454|36 41|probe
P08975713A0454|55 64|sequences
P08975713A0454|136 140|cDNA
P08974135A0052|91 101|stomatitis
P08974135A0052|42 52|deficiency
P08974135A0052|114 131|vitamin B1 levels
P08974135A0052|171 181|stomatitis
P08973917T0000|44 51|homolog
P08973917T0000|59 64|yeast
P08973917T0000|96 100|PWP2
P08973917T0000|118 125|21q22.3
P08973630A0923|31 45|Rac activation
P08973630A0923|9 14|cases
P08973630A0923|174 181|changes
P08973185T0061|5 11|effect
P08973185T0061|19 37|arginine mutations
P08972211A0059|15 25|expression
P08972211A0059|44 48|gene
P08972211A0059|73 77|mice
P08972211A0059|267 271|gene
P08972211A0059|138 146|sequence
P08972182A0000|29 47|signalling cascade
P08972182A0000|111 133|receptor cross-linking
P08972182A0000|84 93|apoptosis
P08971721A1314|61 67|domain
P08971721A1314|111 117|domain
P08971721A1314|71 75|HspA
P08970991A0747|109 114|cells
P08970991A0747|6 22|serum withdrawal
P08970979A1246|14 22|extracts
P08970979A1246|77 90|transcription
P08970979A1246|4 12|contrast
P08970979A1246|68 73|level
P08970352A0880|75 79|MSOF
P08970352A0880|7 11|data
P08970352A0880|83 89|sepsis
P08969495A0256|210 214|role
P08969495A0256|177 181|nrdF
P08969495A0256|76 88|nrdE cistron
P08969495A0256|5 15|sequencing
P08969495A0256|168 172|nrdE
P08967870A0000|13 22|protocols
P08967870A0000|55 73|Moscow hospitals N
P08964067A0188|64 71|failure
P08961873T0000|104 126|immunodeficiency virus
P08961873T0000|64 81|hepatitis C virus
P08959778A0292|149 167|retransplantations
P08959778A0292|108 111|DGF
P08959778A0292|129 145|transplantations
P08959778A0292|65 71|groups
P08959062A0372|13 17|case
P08959062A0372|123 126|EBV
P08959062A0372|21 31|vasculitis
P08959062A0372|139 146|Purtilo
P08958137A0534|42 45|LDL
P08958137A0534|1 27|Lipid hydroperoxide levels
P08955402A0288|241 253|Hol1 protein
P08955402A0288|125 135|histidinol
P08955402A0288|5 12|classes
P08955402A0288|223 233|expression
P08955402A0288|85 89|HOL1
P08955189A1198|130 133|Sp1
P08955189A1198|43 59|PMA inducibility
P08955189A1198|138 165|EGR-1 transcription factors
P08955136A0606|111 128|PIP5KI antibodies
P08955071T0000|15 37|re-replication control
P08955071T0000|41 55|overexpression
P08955071T0000|1 11|Disruption
P08953340A0000|79 95|body composition
P08953340A0000|5 12|effects
P08953340A0000|38 43|VOSO4
P08953340A0000|101 112|performance
P08952796A0743|30 37|relapse
P08951815A0465|15 19|ASN1
P08951815A0465|58 70|lacZ fusions
P08951815A0465|80 85|genes
P08951815A0465|154 183|transcription activator Gcn4p
P08950144A0172|45 57|CNV paradigm
P08950144A0172|129 132|ISI
P08950144A0172|70 88|reaction time task
P08950144A0172|1 9|Waves N1
P08947028A0992|28 33|Rho1p
P08947028A0992|57 71|reorganization
P08947028A0992|99 104|Pkc1p
P08946166A0568|12 19|results
P08945479T0000|12 17|basis
P08945479T0000|22 32|activation
P08943934A0604|29 41|improvements
P08943934A0604|114 122|findings
P08943354A0295|210 225|motheaten cells
P08943354A0295|56 64|function
P08943354A0295|126 137|association
P08943354A0295|8 15|studies
P08943354A0295|191 202|Jak kinases
P08942999T0000|135 159|hamster ovary cell lines
P08942999T0000|78 85|protein
P08942999T0000|52 57|SREBP
P08940134A0705|105 108|Cas
P08940134A0705|89 90|%
P08940134A0705|127 136|membranes
P08940134A0705|71 76|PTP1B
P08940134A0705|34 45|fibroblasts
P08939966A0816|56 69|embryogenesis
P08939966A0816|81 86|SEC-1
P08939966A0816|16 33|protein synthesis
P08938420A0862|224 241|mRNA accumulation
P08938420A0862|176 184|mannitol
P08938420A0862|5 17|accumulation
P08938420A0862|156 166|metabolism
P08938420A0862|139 151|sugar uptake
P08938420A0862|102 111|induction
P08937989A1365|120 127|regions
P08937989A1365|135 142|protein
P08937989A1365|96 106|properties
P08937989A1365|85 90|actin
P08937631A1223|14 21|changes
P08937631A1223|42 57|cell involution
P08937631A1223|155 165|remodeling
P08936640A0105|29 36|studies
P08936640A0105|77 95|government reports
P08936640A0105|110 122|epidemiology
P08936640A0105|1 13|DATA SOURCES
P08935991A0844|132 142|boundaries
P08935991A0844|43 48|mouse
P08935991A0844|5 34|nucleotide sequence alignment
P08935991A0844|98 104|region
P08934540A0673|13 25|nm23-H2 gene
P08934540A0673|5 12|nm23-H1
P08933640A0000|120 127|rabbits
P08933640A0000|97 100|KBL
P08933640A0000|101 110|JW strain
P08932385T0000|44 81|transcription factor TCF11/Nrf1/LCR-F
P08931991A1026|63 83|transcription factor
P08931991A1026|27 35|evidence
P08931991A1026|7 11|data
P08929563T0000|107 124|Ser-Lys-Leu motif
P08929563T0000|33 44|peroxisomes
P08927841A0053|121 131|occurrence
P08927841A0053|57 62|death
P08927169A0178|120 144|Community Health Service
P08927169A0178|148 155|Utrecht
P08927169A0178|93 99|clinic
P08927169A0178|37 46|body lice
P08924381T0000|47 54|regimen
P08924381T0000|1 14|Growth factor
P08923470A0458|81 83|h.
P08923470A0458|51 73|nM TNF alpha treatment
P08923460A0565|89 97|splicing
P08923460A0565|138 145|cloning
P08923460A0565|35 42|version
P08922488A0187|9 15|agents
P08922390A2076|211 222|determinant
P08922390A2076|226 233|protein
P08922390A2076|57 66|adhesions
P08922390A2076|7 11|data
P08922390A2076|157 170|demonstration
P08922390A2076|116 119|FAK
P08922390A0361|31 39|vinculin
P08922390A0361|13 18|study
P08922390A0361|125 133|adhesion
P08922390A0361|144 149|motif
P08922384A0466|97 108|08L epitope
P08922384A0466|70 82|08L antibody
P08922384A0466|136 143|protein
P08921865A1293|109 116|T4 gp17
P08921865A1293|162 175|ssDNA regions
P08921865A1293|207 212|T4DNA
P08921387A1182|198 204|domain
P08921387A1182|129 138|mechanism
P08921387A1182|157 169|EZH1 protein
P08921387A1182|17 21|cDNA
P08919986A1262|12 16|mind
P08919986A1262|46 53|dosages
P08919986A1262|38 41|age
P08919986A1262|138 145|results
P08919289A0402|44 53|resection
P08919289A0402|97 103|tissue
P08919289A0402|136 145|vena cava
P08918918T0000|29 47|HIV-1 LTR promoter
P08918918T0000|129 133|cell
P08918885A0811|30 45|GST-Dig1 fusion
P08918885A0811|53 60|absence
P08918464A0225|88 91|STK
P08918464A0225|108 136|mouse erythroleukaemia cells
P08918464A0225|20 25|Ba/F3
P08918464A0225|138 141|MEL
P08918464A0225|170 179|apoptosis
P08917696A0485|245 248|SRE
P08917696A0485|251 255|cAMP
P08917696A0485|398 406|promoter
P08917696A0485|290 294|AhRE
P08917696A0485|85 99|mobility shift
P08917696A0485|344 359|luciferase gene
P08917696A0485|193 230|12-O-tetradecanoyl-phorbol-13-acetate
P08917696A0485|232 235|TRE
P08917696A0485|370 377|control
P08917696A0485|171 188|response elements
P08917435A0481|14 18|role
P08917435A0481|229 244|PAI-1 synthesis
P08917435A0481|22 27|c-Jun
P08917435A0481|32 37|c-Fos
P08917435A0481|154 181|c-fos oligodeoxynucleotides
P08916960A1331|14 19|cases
P08916960A1331|131 143|conservation
P08916960A1331|36 45|DLL cells
P08916960A1331|96 113|breakpoint region
P08916960A1331|236 244|FL cells
P08916960A1331|68 88|bcl-2 gene sequences
P08916928A0950|111 120|PAE cells
P08916928A0950|81 83|3H
P08916928A0950|136 155|PDGF beta-receptors
P08915508A0000|331 334|tat
P08915508A0000|146 159|transcription
P08915508A0000|127 142|trans-activator
P08915508A0000|355 369|coding regions
P08915508A0000|16 30|leukemia virus
P08915508A0000|379 408|immunodeficiency virus type-1
P08915508A0000|72 79|vectors
P08915508A0000|350 353|Env
P08915508A0000|340 348|envelope
P08915508A0000|1 8|Moloney
P08915508A0000|410 415|HIV-1
P08914532A0598|6 12|enzyme
P08914388A1645|183 195|levofloxacin
P08914388A1645|176 180|CPFX
P08914388A1645|216 222|NM-394
P08914388A1645|118 130|sparfloxacin
P08914388A1645|106 113|CS-940*
P08914388A1645|161 174|ciprofloxacin
P08914388A1645|5 15|assessment
P08914388A1645|204 214|OPC-17116*
P08913387A1010|27 35|efficacy
P08912807A0411|165 185|beta-casein promoter
P08912807A0411|24 37|deer receptor
P08912807A0411|102 108|domain
P08910567A2269|48 78|rat liver glucokinase promoter
P08910567A2269|119 149|hepatocyte transfection system
P08910373A0315|27 36|mouse PP2
P08910373A0315|1 19|Percent identities
P08909546A0810|66 73|pattern
P08909546A0810|139 145|domain
P08906056A1290|122 128|degree
P08906056A1290|57 65|function
P08906056A1290|82 88|status
P08903339A0264|92 103|spliceosome
P08903339A0264|19 32|determination
P08902847A1946|300 305|rehCG
P08902847A1946|179 188|hCG alpha
P08902847A1946|191 195|beta
P08902847A1946|54 58|fact
P08902847A1946|325 330|min-1
P08902847A1946|225 227|pH
P08902847A1946|197 199|km
P08902847A1946|307 309|kw
P08902847A1946|68 76|affinity
P08902548A0144|131 135|mice
P08902548A0144|70 75|doses
P08902548A0144|35 56|L-5-hydroxytryptophan
P08901658A0498|123 142|glyceryl trinitrate
P08901658A0498|95 103|dilation
P08901658A0498|173 181|dilation
P08901658A0498|32 41|hyperemia
P08901135A1132|5 17|NIT2 protein
P08901135A1132|98 103|cells
P08901135A1132|86 94|fraction
P08901135A1132|34 40|nuclei
P08900190A0430|109 114|c-Fos
P08900190A0430|101 106|MKP-1
P08900190A0430|119 124|c-Jun
P08899719A0318|29 34|total
P08899719A0318|11 18|contigs
P08899719A0318|140 149|certainty
P08898893A0202|226 231|U-937
P08898893A0202|96 141|phorbol ester phorbol 12-myristate 13-acetate
P08898893A0202|5 15|PAI-2 gene
P08898893A0202|201 221|HT-1080 fibrosarcoma
P08898893A0202|187 191|acid
P08898365A0274|181 190|cytoplasm
P08898365A0274|110 116|domain
P08898365A0274|48 59|amino acids
P08897721A0000|107 112|group
P08897721A0000|140 149|immunogen
P08897721A0000|1 10|Infection
P08896804A0000|303 307|rats
P08896804A0000|300 301|P
P08896804A0000|147 152|mg/kg
P08896804A0000|95 98|BDZ
P08896804A0000|189 224|BDZ receptor antagonists flumazenil
P08896804A0000|253 258|mg/kg
P08896804A0000|359 363|EtOH
P08896804A0000|226 228|ZK
P08896804A0000|79 93|benzodiazepine
P08896804A0000|350 357|ethanol
P08896804A0000|168 179|combination
P08896804A0000|32 47|dose dependence
P08896590T0000|83 89|domain
P08896590T0000|18 28|adenovirus
P08896402A0587|180 182|kD
P08896402A0587|9 19|FL protein
P08896402A0587|53 62|cell line
P08896402A0587|119 131|glycoprotein
P08896272A0000|57 67|chromosome
P08896272A0000|35 37|bp
P08895579A0583|31 35|MDMX
P08895579A0583|42 46|MDM2
P08895579A0583|1 18|Northern blotting
P08894826A0228|122 135|HIV infection
P08894826A0228|145 150|warts
P08894826A0228|252 257|study
P08894826A0228|49 64|Royal Infirmary
P08894826A0228|109 118|diagnosis
P08894826A0228|207 217|gonorrhoea
P08894826A0228|68 77|Edinburgh
P08894144A0330|271 276|mg/kg
P08894144A0330|145 148|CsA
P08894144A0330|246 251|mg/kg
P08894144A0330|189 205|CsA vehicle p.o.
P08894144A0330|48 52|rats
P08894144A0330|153 158|mg/kg
P08894144A0330|226 228|sc
P08894144A0330|278 280|sc
P08894144A0330|170 183|FB vehicle sc
P08893779A0229|177 184|failure
P08893779A0229|24 60|digitorum longus muscle tendon units
P08893779A0229|113 114|p
P08893779A0229|255 256|p
P08893779A0229|152 153|p
P08893779A0229|104 111|failure
P08893779A0229|380 385|units
P08893779A0229|96 100|load
P08892757T0000|11 18|cloning
P08892757T0000|22 27|Elk-3
P08892757T0000|49 59|Ets family
P08892755A0186|120 127|domains
P08892755A0186|107 113|kinase
P08892755A0186|37 54|sequence homology
P08892755A0186|98 101|JH2
P08892755A0186|68 72|JAK1
P08891346A1217|27 33|effect
P08891346A1217|66 78|NIH3T3 cells
P08891346A1217|114 131|expression vector
P08891346A1217|152 157|FGF8a
P08891341A0724|150 161|between-247
P08891341A0724|133 141|sequence
P08891341A0724|245 255|cell lines
P08891341A0724|37 61|reporter gene constructs
P08891341A0724|170 172|bp
P08891131A0000|215 216|%
P08891131A0000|157 164|species
P08891131A0000|49 72|glycopeptide resistance
P08891131A0000|133 138|feces
P08891131A0000|173 179|horses
P08891131A0000|1 29|Enterococcus faecium strains
P08887678A0000|67 81|GAL10 promoter
P08887678A0000|54 61|control
P08887678A0000|1 11|Expression
P08887674A0630|3 9|subset
P08887674A0630|118 126|elements
P08887661A1061|165 171|manner
P08887661A1061|110 129|promoter activation
P08887661A1061|96 106|repression
P08887661A1061|32 37|TFIIB
P08887659A0753|37 43|serine
P08887659A0753|83 89|effect
P08887647T0000|37 59|chromosome segregation
P08886845A1274|122 141|expression activity
P08886845A1274|53 61|presence
P08886845A1274|101 108|vectors
P08886845A1274|34 51|myogenin promoter
P08884757A0653|149 154|scale
P08884757A0653|179 183|help
P08884757A0653|295 300|score
P08884757A0653|220 228|patients
P08884757A0653|14 24|statistics
P08884757A0653|230 274|Beurteilungsskala fur geriatrische Patienten
P08884757A0653|276 279|BGP
P08884757A0653|200 206|rating
P08884757A0653|342 358|Syndrom-Kurztest
P08882710A0000|151 155|IFNs
P08882710A0000|59 79|transcription factor
P08882710A0000|144 148|type
P08882710A0000|38 43|ISGF3
P08882710A0000|117 133|interferon-alpha
P08881542T0000|44 60|lithium toxicity
P08881542T0000|73 103|serum potassium concentrations
P08880405A1170|88 95|puberty
P08880405A1170|99 108|daughters
P08880405A1170|1 10|Selection
P08879080A0265|105 115|LISREL VII
P08879080A0265|78 82|data
P08879080A0265|65 70|model
P08879080A0265|86 99|path analysis
P08878045A0606|11 24|N-Nus complex
P08878045A0606|95 109|RNA polymerase
P08878045A0606|67 70|CTD
P08878045A0606|139 147|proteins
P08878037A0000|28 59|catabolite control protein CcpA
P08877818A0184|95 110|Lys/Arg-Arg-Gln
P08877818A0184|42 49|primers
P08877818A0184|5 18|amplification
P08876701A0177|45 49|DinB
P08876167A0322|47 53|HiNF-D
P08874399A0277|106 109|Ca2
P08874399A0277|111 124|concentration
P08874399A0277|7 11|days
P08874399A0277|55 63|tensions
P08874399A0277|154 156|B.
P08873063A0875|111 112|%
P08873063A0875|190 191|%
P08873063A0875|19 37|Lytechinus embryos
P08873063A0875|1 15|ECM disruption
P08872671A0573|91 97|oxygen
P08872671A0573|57 62|Qs/QT
P08872671A0573|159 162|air
P08872671A0573|5 10|model
P08871635A0000|56 85|WEHI-231 B lymphoma cell line
P08871635A0000|115 119|CD40
P08871567A0000|45 52|binding
P08871567A0000|1 14|MSSP proteins
P08870266A0651|151 157|domain
P08870266A0651|127 133|region
P08870266A0651|99 113|NodO secretion
P08869763A0378|44 53|phenomena
P08869763A0378|176 184|migraine
P08869763A0378|113 123|expression
P08869763A0378|155 172|receptor subtypes
P08868954A0648|61 66|drugs
P08868954A0648|199 211|hemodynamics
P08868954A0648|115 134|calcium antagonists
P08868954A0648|102 108|agents
P08868473A1287|147 151|type
P08868473A1287|112 123|development
P08868473A1287|16 19|p28
P08866485A0125|125 130|order
P08866485A0125|112 121|molecules
P08866485A0125|64 76|interactions
P08866485A0125|152 161|functions
P08864061A0000|75 85|cell cycle
P08864061A0000|1 11|Expression
P08862743A0603|72 73|p
P08862743A0603|3 11|decrease
P08861963T0000|93 100|contact
P08861963T0000|49 77|RNA polymerase alpha subunit
P08861955A0927|226 232|R-Ras2
P08861955A0927|219 222|Ran
P08861955A0927|233 237|TC21
P08861955A0927|71 75|p619
P08861955A0927|87 114|guanine nucleotide exchange
P08861955A0927|153 165|Rab proteins
P08858268A1307|135 146|improvement
P08858268A1307|28 37|treatment
P08858268A1307|56 64|response
P08858268A1307|1 11|CONCLUSION
P08856132T0000|75 86|development
P08856132T0000|28 32|role
P08856132T0000|1 9|Evidence
P08855804A1528|106 109|SLT
P08855804A1528|7 14|results
P08855804A1528|49 54|study
P08854459A0000|151 159|February
P08854459A0000|130 139|September
P08854459A0000|21 29|overview
P08854459A0000|116 122|period
P08853303A0431|151 154|min
P08853303A0431|213 215|C1
P08853303A0431|250 253|min
P08853303A0431|118 138|bolus MMC injections
P08853303A0431|17 27|parameters
P08853303A0431|229 231|kg
P08853303A0431|233 243|T1/2 alpha
P08853303A0431|64 74|literature
P08853303A0431|207 211|1/kg
P08851337A1092|31 36|means
P08851337A1092|40 51|prophylaxis
P08851337A1092|1 14|Tonsillectomy
P08849834A0000|56 61|blood
P08849834A0000|36 52|volume flow rate
P08849778A0226|56 66|plasmid R1
P08849778A0226|111 114|RNA
P08849778A0226|19 39|toeprinting analyses
P08849208A1022|41 48|measure
P08849208A1022|1 9|Demispan
P08848013A1469|72 89|promoter activity
P08848013A1469|99 107|TATA box
P08848013A1469|18 26|TATA box
P08847403T0000|53 56|IVF
P08846775A0110|28 47|Swi6 cell viability
P08846775A0110|132 136|CLN1
P08846775A0110|125 130|genes
P08846775A0110|140 144|CLN2
P08844712A0000|121 125|rats
P08844712A0000|63 73|C-reflexes
P08844712A0000|56 57|A
P08844712A0000|19 24|oxide
P08844448A0000|56 71|crossover study
P08844448A0000|158 164|effect
P08844448A0000|130 135|years
P08844448A0000|311 321|absorption
P08844448A0000|340 342|E.
P08844448A0000|139 142|age
P08844448A0000|239 249|absorption
P08843412A0543|211 222|interaction
P08843412A0543|73 76|RXR
P08843412A0543|78 81|RAR
P08843412A0543|65 69|LBDs
P08843412A0543|118 147|promoter transcription factor
P08842143A0000|37 49|determinants
P08842143A0000|65 68|hup
P08842143A0000|1 15|Plasmid pAL618
P08842143A0000|137 142|genes
P08840506A0544|93 98|G2850
P08839911A0716|10 16|cycles
P08839832A0729|121 128|domains
P08839832A0729|21 34|CD30v protein
P08838805T0000|54 60|CTNNB1
P08838314A0129|60 64|V1aR
P08838314A0129|27 37|expression
P08838314A0129|42 52|regulation
P08838314A0129|190 199|V1aR gene
P08838314A0129|169 176|mapping
P08838144A0107|63 74|PRL binding
P08838144A0107|27 39|significance
P08838144A0107|100 116|deletion mutants
P08837503A0392|11 24|repeat motifs
P08837503A0392|196 202|groups
P08837503A0392|206 221|dicot extensins
P08837503A0392|68 75|pattern
P08836172A1382|14 22|function
P08836172A1382|148 162|myogenin mRNAs
P08836172A1382|24 31|studies
P08836172A1382|48 63|over-expression
P08836172A1382|169 185|serum withdrawal
P08835969A0000|120 123|use
P08835969A0000|219 231|beta subunit
P08835969A0000|251 263|gonadotropin
P08835969A0000|21 32|laparoscopy
P08835969A0000|104 113|pregnancy
P08835969A0000|199 211|serum assays
P08835969A0000|66 75|reference
P08835393A2829|146 149|SRE
P08835393A2829|52 78|signal transduction events
P08835393A2829|86 106|calcium mobilization
P08833653A0304|99 109|fibroblast
P08833653A0304|71 90|rat amylin promoter
P08832146A0959|10 13|CBD
P08832146A0959|82 83|p
P08832146A0959|103 106|PTH
P08829393A0083|14 31|dipole estimation
P08829393A0083|46 60|SEP components
P08828152A1825|13 17|LCDV
P08828152A1825|89 99|similarity
P08828152A1825|5 9|RPO1
P08828152A1825|174 181|subunit
P08828142A0000|26 31|FeLVs
P08828142A0000|66 82|oncoretroviruses
P08828142A0000|152 164|environments
P08825639A0827|94 100|region
P08825639A0827|59 66|repeats
P08825633A0304|27 30|DNA
P08825633A0304|53 61|sequence
P08825633A0304|102 106|cDNA
P08825554A0000|45 50|group
P08825554A0000|18 21|TTP
P08825554A0000|119 136|CCCH zinc fingers
P08825087A0213|97 101|ORFs
P08825087A0213|33 55|bp BamHI-ClaI fragment
P08824881A0133|28 47|locus heterogeneity
P08824881A0133|108 115|16p13.3
P08824881A0133|1 16|Linkage studies
P08824800A0808|51 78|agarose gel electrophoresis
P08824585A0260|161 177|progenitor cells
P08824585A0260|82 86|HPK1
P08823709A0220|106 113|parotid
P08823709A0220|130 137|patient
P08823709A0220|22 34|modification
P08823709A0220|1 8|Therapy
P08823260A1161|147 156|infection
P08823260A1161|70 74|GVHD
P08823163T0000|123 129|domain
P08823163T0000|76 82|cobalt
P08823163T0000|87 96|manganese
P08823163T0000|17 26|structure
P08822208A1364|74 83|responses
P08822208A1364|100 111|differences
P08822208A1364|17 24|results
P08820642A0173|286 293|tobacco
P08820642A0173|280 282|HR
P08820642A0173|21 30|hrpZ gene
P08820642A0173|168 181|cosmid pHIR11
P08820642A0173|136 143|cluster
P08818718A1229|131 139|delivery
P08818718A1229|143 147|MDR1
P08818718A1229|185 191|organs
P08818718A1229|152 160|GC cDNAs
P08817324A1070|28 56|Xq28 duplication breakpoints
P08817324A1070|19 22|16p
P08817324A1070|1 11|Sequencing
P08816792A0000|31 37|DNA-PK
P08816792A0000|76 78|Ku
P08816792A0000|102 109|subunit
P08816507A1125|151 159|activity
P08816507A1125|135 142|13S E1A
P08816507A1125|192 199|element
P08816507A1125|97 104|12S E1A
P08816507A1125|223 224|%
P08816498A0000|123 130|stimuli
P08816498A0000|163 170|nucleus
P08816498A0000|140 155|plasma membrane
P08816482A0234|40 46|Stat5a
P08816482A0234|21 29|variants
P08816482A0234|51 57|Stat5b
P08816461A0892|28 33|Upf1p
P08816461A0892|78 88|activities
P08816461A0892|55 62|protein
P08816459A0090|57 79|orphan receptor RevErb
P08816459A0090|176 179|RAR
P08816459A0090|4 22|interaction screen
P08816459A0090|118 142|thyroid hormone receptor
P08816452A0936|60 63|p54
P08816452A0936|144 152|splicing
P08816452A0936|37 56|tissue distribution
P08816452A0936|190 196|manner
P08816438A0316|14 22|analysis
P08816438A0316|133 139|defect
P08816438A0316|97 116|replication origins
P08816438A0316|48 64|cdc28-1N strains
P08814651A0000|28 35|factors
P08814651A0000|125 137|rating scale
P08814651A0000|5 15|importance
P08814651A0000|100 103|rat
P08814651A0000|68 92|ethanol withdrawal signs
P08813766A0605|62 69|protein
P08813766A0605|217 222|Cre-A
P08813766A0605|119 137|consensus sequence
P08813766A0605|106 111|match
P08813766A0605|11 14|ORF
P08813766A0605|143 166|C2H2 zinc finger domain
P08812490A0542|134 138|mRNA
P08812490A0542|149 160|transcripts
P08812490A0542|193 197|exon
P08812490A0542|37 48|kidney cDNA
P08812490A0542|200 209|deletions
P08812490A0542|1 27|PCR/Southern blot analysis
P08812106T0000|43 55|crescent RNA
P08812106T0000|1 10|PCNA mRNA
P08812012T0000|27 37|variations
P08812012T0000|5 12|effects
P08810278A0682|61 68|BCR/ABL
P08810278A0682|248 251|CML
P08810278A0682|81 96|CRKL-SH2 domain
P08810278A0682|256 268|ALL patients
P08810278A0682|226 233|samples
P08810278A0682|111 115|p130
P08810278A0682|100 104|p130
P08809680T0000|15 26|seasonality
P08809680T0000|1 10|Melatonin
P08808927A0417|26 34|fragment
P08808927A0417|48 57|vspA gene
P08808756A0587|132 140|presence
P08808756A0587|109 114|cells
P08808756A0587|53 57|cDNA
P08808756A0587|1 18|Sequence analysis
P08808275A1193|14 31|RAD23 equivalents
P08808275A1193|58 67|evolution
P08808275A1193|141 158|yeast counterpart
P08807408A0524|57 59|AV
P08807408A0524|76 87|tachycardia
P08807408A0524|156 182|radiofrequency application
P08807408A0524|1 8|METHODS
P08807245A0843|8 28|retrospective review
P08806817A0244|94 109|orphan receptor
P08806817A0244|67 85|DNA binding domain
P08806817A0244|1 18|Sequence analysis
P08806491A0542|22 29|ODV-E18
P08806491A0542|1 12|Transcripts
P08806491A0542|34 42|ODV-EC27
P08805338A1061|28 37|OGG1 gene
P08805338A1061|177 179|OG
P08805338A1061|113 117|Ogg2
P08805338A1061|138 142|Ogg1
P08804012A0662|13 23|categories
P08804012A0662|126 130|rest
P08804012A0662|116 121|sleep
P08804012A0662|85 93|pastimes
P08803710A0701|72 78|stages
P08803710A0701|57 58|%
P08803710A0701|36 37|%
P08803710A0701|99 102|IVB
P08798893A0611|30 38|presence
P08798893A0611|14 22|freezing
P08798893A0611|129 147|CCCD heterogeneity
P08798893A0611|168 173|cells
P08798762A1279|59 67|activity
P08798762A1279|100 103|PKC
P08798648A1816|45 51|domain
P08798648A1816|21 26|Fe4S4
P08798641A0400|1 5|Biol
P08798610A0843|224 231|Cdc42Hs
P08798610A0843|270 285|Dbl oncoprotein
P08798610A0843|161 165|form
P08798610A0843|117 121|form
P08798443A1218|88 106|S528A substitution
P08798443A1218|270 278|proteins
P08798443A1218|246 258|interactions
P08798443A1218|5 16|DNA binding
P08798443A1218|184 222|transcription transactivating activity
P08798443A1218|51 56|c-Myb
P08798420A0207|215 219|pp60
P08798420A0207|172 180|CAAT box
P08798420A0207|115 132|AP-1 binding site
P08798420A0207|86 94|elements
P08798420A0207|137 140|TRE
P08795304T0000|1 22|Plasma thrombomodulin
P08795304T0000|68 85|diabetes mellitus
P08794601A0000|27 37|nizatidine
P08794601A0000|59 77|bismuth subcitrate
P08794601A0000|158 159|%
P08794601A0000|117 118|%
P08794547A0648|42 65|laser-doppler fluxmetry
P08794348A1067|151 163|NIa proteins
P08794348A1067|61 64|NIa
P08794348A1067|126 133|genomes
P08794326A0405|124 132|pol gene
P08794326A0405|64 67|TRE
P08794326A0405|69 71|GP
P08793693A0237|27 32|study
P08792217A1407|241 258|TIMP-2 mRNA level
P08792217A1407|199 207|increase
P08792217A1407|173 178|cells
P08792217A1407|223 227|cell
P08792217A1407|102 115|up-regulation
P08790291A1022|28 32|work
P08790291A1022|76 96|DNA damage tolerance
P08790291A1022|100 111|plant cells
P08789441A0339|121 133|sex reversal
P08789441A0339|214 228|cosmid markers
P08789441A0339|7 19|fluorescence
P08789441A0339|172 173|t
P08789441A0339|87 94|patient
P08784787A0383|105 120|ligand sequence
P08784787A0383|136 153|receptor cleavage
P08783180A0000|107 129|Carollia perspicillata
P08783180A0000|10 17|methods
P08781119A0723|31 51|mouse Met-ase-1 gene
P08781119A0723|132 150|rat Met-ase-1 gene
P08781119A0723|118 124|region
P08778700A0476|92 96|ARVD
P08778700A0476|64 75|involvement
P08777374A1471|8 22|concentrations
P08777374A1471|64 78|concentrations
P08776793A0811|36 41|males
P08776748T0000|27 33|marker
P08776748T0000|38 51|schizophrenia
P08775674A0000|62 77|characteristics
P08775674A0000|79 88|treatment
P08775674A0000|93 100|outcome
P08775674A0000|17 20|aim
P08771787T0000|41 47|repeat
P08771787T0000|54 61|protein
P08771787T0000|49 52|LRR
P08771781A0103|72 79|oleosin
P08771781A0103|197 202|ORFII
P08771781A0103|53 59|region
P08771781A0103|158 166|promoter
P08771781A0103|257 274|leaf cDNA library
P08771781A0103|204 215|cDNA clones
P08770920A1220|199 214|transactivation
P08770920A1220|184 195|enhancement
P08770920A1220|238 261|TAAT-1 element reporter
P08770021T0000|11 27|PTHRP production
P08770021T0000|80 101|Ras signaling pathway
P08770021T0000|68 72|role
P08769566A0000|31 35|cDNA
P08769566A0000|78 83|Zfhep
P08769566A0000|213 216|DNA
P08769566A0000|159 178|zinc finger domains
P08769566A0000|85 108|zinc finger homeodomain
P08769132A0000|122 137|mismatch repair
P08769132A0000|487 502|chromosome 2p16
P08769132A0000|190 194|MutS
P08769132A0000|289 294|sites
P08769132A0000|438 443|HNPCC
P08769132A0000|233 247|MSH-2 proteins
P08769132A0000|445 467|tumor suppressor genes
P08769132A0000|64 70|family
P08769132A0000|35 41|member
P08769132A0000|373 379|hMSH-2
P08768374A0765|63 70|regions
P08766049A0000|194 202|Amikacin
P08766049A0000|167 176|injection
P08766049A0000|42 61|corneal perforation
P08766049A0000|97 104|chamber
P08766049A0000|190 192|mg
P08766049A0000|1 12|CASE REPORT
P08764015A0284|1 3|A.
P08763925A0588|72 78|c-gvpE
P08763925A0588|143 151|antisera
P08763925A0588|5 15|expression
P08763925A0588|33 38|genes
P08763925A0588|102 114|Western blot
P08763207A0402|61 66|media
P08763207A0402|128 140|accumulation
P08763207A0402|144 155|clenbuterol
P08763207A0402|34 41|product
P08762172A0178|75 85|proportion
P08762172A0178|110 114|time
P08762172A0178|99 104|males
P08762172A0178|154 160|number
P08761480A0331|208 216|met26RD1
P08761480A0331|360 366|RPDE-6
P08761480A0331|247 250|PDE
P08761480A0331|326 335|v-Src-SH3
P08761480A0331|74 80|RPDE-6
P08761480A0331|160 170|N-terminus
P08761480A0331|197 206|v-Src-SH3
P08761480A0331|371 380|v-Src-SH3
P08761480A0331|138 144|RPDE-6
P08761480A0331|440 453|splice region
P08760889A0531|209 213|H2A2
P08760889A0531|27 47|amino acid sequences
P08760889A0531|53 70|protein sequences
P08760889A0531|119 130|differences
P08760889A0531|281 288|species
P08760889A0531|234 239|genes
P08760872A0696|62 72|repression
P08760872A0696|40 43|E2F
P08760872A0696|23 28|model
P08760872A0696|155 167|CHR elements
P08760286A0696|215 225|Rho family
P08760286A0696|49 84|guanine nucleotide exchange factors
P08760286A0696|192 199|members
P08760286A0696|314 336|Vav signaling pathways
P08760286A0696|172 178|routes
P08760286A0696|277 280|JNK
P08760286A0696|35 38|Vav
P08757943A0876|62 87|thymidine kinase promoter
P08757943A0876|6 10|site
P08756712A0227|46 56|amino acid
P08756712A0227|76 79|RPA
P08756712A0227|81 84|RPA
P08756636T0000|31 50|yeast Rad51 protein
P08756636T0000|84 97|Srs2 helicase
P08756609A0498|104 117|invertebrates
P08756609A0498|79 89|eukaryotes
P08756609A0498|126 132|plants
P08756609A0498|119 124|fungi
P08756556A0406|27 34|protein
P08756556A0406|76 96|acid signal sequence
P08756332A0000|104 111|variety
P08756332A0000|197 231|guanine nucleotide exchange factor
P08756332A0000|155 175|protein kinase c-Raf
P08756332A0000|16 29|Ras subfamily
P08754852A0960|31 34|RCS
P08754852A0960|133 145|chondrocytes
P08754852A0960|163 171|sequence
P08754852A0960|49 56|protein
P08754834A1097|132 139|NN-84AG
P08754834A1097|162 168|detail
P08754834A1097|84 102|transcription unit
P08754802T0000|74 95|acid oxidation enzyme
P08754802T0000|110 114|mice
P08754802T0000|116 120|role
P08752714A0000|28 38|malignancy
P08752714A0000|58 66|patients
P08752714A0000|84 96|malignancies
P08750702A0183|104 114|mg/kg i.v.
P08750702A0183|83 98|blockers WB4101
P08750702A0183|1 13|Study groups
P08750173A0000|151 166|D-galactosamine
P08750173A0000|127 139|liver injury
P08750173A0000|207 230|% liver resection model
P08750173A0000|35 50|system function
P08749393A0783|44 47|kDa
P08749393A0783|180 188|sequence
P08749393A0783|29 36|protein
P08749393A0783|246 255|C2 domain
P08749393A0783|114 134|p85 adaptor proteins
P08747343A0790|94 103|materials
P08747343A0790|1 14|Protein films
P08746981A0154|6 16|treatments
P08745669A0000|121 128|disease
P08745669A0000|193 203|methyl GAG
P08745669A0000|111 118|Hodgkin
P08745669A0000|66 74|lymphoma
P08745669A0000|171 178|regimen
P08742135A0000|15 22|analogs
P08742135A0000|109 120|head injury
P08742135A0000|163 165|CS
P08742135A0000|1 10|Fragments
P08742135A0000|137 143|levels
P08741206A1551|61 69|settings
P08741206A1551|124 135|hypotension
P08740416A0239|46 57|amino acids
P08740416A0239|24 29|Seb1p
P08740416A0239|103 109|region
P08739209A0700|107 118|arrhythmias
P08739209A0700|161 162|h
P08739209A0700|173 181|ligation
P08739209A0700|1 12|Zatebradine
P08734538A0613|12 22|experiment
P08734538A0613|24 33|crossover
P08733874A0000|164 177|body scanning
P08733874A0000|29 42|thyroidectomy
P08733874A0000|93 100|periods
P08733874A0000|1 9|Patients
P08733874A0000|119 133|hypothyroidism
P08733123A0000|30 39|dystrophy
P08733123A0000|177 180|arm
P08733123A0000|158 166|shoulder
P08733123A0000|137 144|muscles
P08731511A0625|15 25|fibrinogen
P08731511A0625|144 151|animals
P08731511A0625|66 82|heparin cofactor
P08731511A0625|55 60|ATIII
P08731155A0499|82 88|nerves
P08731155A0499|50 56|nerves
P08728040T0000|14 24|activation
P08728040T0000|63 69|kinase
P08728040T0000|71 81|Jun kinase
P08728040T0000|116 128|oncostatin M
P08727192A0000|1 13|STUDY DESIGN
P08726024A0532|209 219|weeks p.t.
P08726024A0532|27 30|PCR
P08726024A0532|93 97|cats
P08726024A0532|261 270|H. pylori
P08726024A0532|81 89|majority
P08726024A0532|68 75|product
P08723883A1684|133 144|alfalfa hay
P08723883A1684|110 116|levels
P08723883A1684|23 43|vitamin A precursors
P08723883A1684|203 204|E
P08723883A1684|65 68|hay
P08723365T0000|31 47|hyperinsulinemia
P08723365T0000|10 22|relationship
P08722568A1001|120 148|replacement H3 histone genes
P08722568A1001|106 116|expression
P08722568A1001|152 158|plants
P08721999A0727|25 27|nt
P08721999A0727|33 50|complementarities
P08721989A1012|105 123|signaling pathways
P08721989A1012|195 212|signal transducer
P08721989A1012|5 12|results
P08721989A1012|51 58|domains
P08720407A1386|94 103|cytokines
P08720407A1386|112 131|interleukin-1 alpha
P08720407A1386|49 53|site
P08720407A1386|17 24|results
P08719697A0221|94 102|subjects
P08719697A0221|77 80|eye
P08719697A0221|113 121|patients
P08719697A0221|35 38|eye
P08719155A0105|61 69|molecule
P08719155A0105|270 276|extent
P08719155A0105|75 88|P. falciparum
P08719155A0105|106 114|sequence
P08719155A0105|161 177|surface molecule
P08719155A0105|238 245|protein
P08717391A0466|60 67|surface
P08717391A0466|195 207|antigenicity
P08717391A0466|230 235|HBcAg
P08717391A0466|7 13|fusion
P08717391A0466|21 31|N-terminus
P08717391A0466|152 169|particle assembly
P08713933A0606|39 51|neuroimaging
P08713933A0606|1 22|Laboratory evaluation
P08711631A0989|45 61|cyclophosphamide
P08710377A0577|150 165|BCR stimulation
P08710377A0577|67 77|preference
P08710377A0577|54 58|Grb2
P08710377A0577|101 107|domain
P08710371A0000|211 230|p53 transactivation
P08710371A0000|79 82|BKV
P08710371A0000|110 121|protein p53
P08710371A0000|140 147|biology
P08709831A0599|29 40|Dacarbacine
P08709831A0599|48 57|treatment
P08709251A0000|122 134|DNA fragment
P08709251A0000|89 94|AcNPV
P08709251A0000|265 277|AcNPV mutant
P08709251A0000|231 240|eh2-AcNPV
P08709251A0000|96 102|genome
P08709251A0000|279 281|S.
P08709224T0000|14 19|virus
P08709224T0000|57 66|component
P08709224T0000|39 44|EBNA2
P08707922A0334|46 50|beta
P08707922A0334|147 175|translation initiation codon
P08707922A0334|199 224|primer extension analysis
P08707922A0334|112 122|base pairs
P08707922A0334|39 42|rat
P08707922A0334|1 31|Transcription initiation sites
P08707840A0753|131 134|p62
P08707840A0753|53 60|p58/p45
P08707840A0753|18 37|electron microscopy
P08707516A0194|40 46|people
P08707516A0194|9 18|estimates
P08706731A1303|195 215|ginseng ribonuclease
P08706731A1303|72 91|expression patterns
P08706731A1303|245 266|ribonuclease function
P08706731A1303|229 239|hypothesis
P08706731A1303|42 54|similarities
P08706731A1303|168 187|sequence similarity
P08706368A1024|149 159|brightness
P08706368A1024|40 44|area
P08706368A1024|203 204|p
P08706368A1024|190 201|correlation
P08706368A1024|103 104|p
P08704240A1111|47 57|starvation
P08704240A1111|110 129|PIXY321 stimulation
P08704240A1111|33 39|GM-CSF
P08703959A0659|145 155|assignment
P08703959A0659|219 232|adduct duplex
P08703959A0659|185 195|C7 residue
P08703959A0659|103 114|lesion site
P08703010A0905|240 244|site
P08703010A0905|82 104|GAP-43 promoter region
P08703010A0905|174 185|GAP-43 gene
P08702936A0984|26 30|TARC
P08702936A0984|113 125|granulocytes
P08702936A0984|100 109|monocytes
P08702845A0000|209 220|COS-7 cells
P08702845A0000|123 126|DAT
P08702845A0000|178 205|CFT binding characteristics
P08702845A0000|75 86|recognition
P08702845A0000|175 177|3H
P08702845A0000|101 121|dopamine transporter
P08702807A0964|91 95|MKK1
P08702807A0964|193 199|growth
P08702807A0964|219 225|manner
P08702807A0964|158 186|cyclin D1 protein expression
P08702728A1325|61 64|Shc
P08702728A1325|48 53|Y317F
P08702633A0164|150 161|recruitment
P08702633A0164|122 144|Grb2 complex formation
P08702633A0164|52 61|increases
P08702633A0164|5 14|mechanism
P08702633A0164|118 121|Shc
P08702543A0000|165 167|P.
P08702543A0000|23 29|member
P08702543A0000|140 155|binding protein
P08702543A0000|55 63|proteins
P08702543A0000|1 5|Gap1
P08700531A1420|121 141|chemical carcinogens
P08700531A1420|92 105|hamster cells
P08700531A1420|189 198|cph locus
P08700531A1420|290 300|conversion
P08700531A1420|9 21|chromosome X
P08700531A1420|207 217|chromosome
P08697728A1199|36 40|flag
P08697728A1199|16 21|value
P08692892A0330|151 156|cells
P08692892A0330|56 74|receptor signaling
P08692892A0330|173 185|alpha-factor
P08692892A0330|20 25|P258L
P08691962T0000|75 80|blood
P08691962T0000|41 48|Whipple
P08691962T0000|93 98|cells
P08690198A0346|194 206|fermentation
P08690198A0346|111 137|Lactobacillus reuteri R2LC
P08690198A0346|143 170|Lactobacillus plantarum DSM
P08690198A0346|234 239|study
P08690198A0346|70 74|diet
P08690198A0346|102 109|oatbase
P08689520T0000|70 75|goats
P08688190A0000|164 186|Lysionotus pauciflorus
P08688190A0000|9 27|flavone glucosides
P08688190A0000|155 160|parts
P08684742A0000|94 99|weeks
P08684742A0000|147 152|weeks
P08684742A0000|71 84|amniocentesis
P08684742A0000|1 10|OBJECTIVE
P08683983A1163|180 190|activation
P08683983A1163|166 176|mechanisms
P08683983A1163|213 228|differentiation
P08683983A1163|42 48|intron
P08683983A1163|70 80|regulation
P08683108A1501|60 94|protein kinase A signaling pathway
P08683108A1501|42 52|components
P08683108A1501|21 28|results
P08683106A0374|104 113|IFN-alpha
P08683106A0374|10 14|IL-2
P08683106A0374|55 60|STAT5
P08683106A0374|19 28|IFN-alpha
P08682317A0900|120 125|cells
P08682317A0900|97 105|extracts
P08682317A0900|1 16|HS inducibility
P08680706A0889|164 178|Control groups
P08680706A0889|121 140|Recipient Instilled
P08680706A0889|27 41|PO2/FlO2 ratio
P08680706A0889|82 89|Therapy
P08680706A0889|216 222|values
P08680706A0889|153 158|mm Hg
P08679131T0000|26 44|hypersensitivities
P08677678A0258|94 107|consolidation
P08677678A0258|37 64|immunomodulator neurotropin
P08677678A0258|66 69|NSP
P08677678A0258|19 33|administration
P08677678A0258|137 155|avoidance behavior
P08676858A1084|39 61|T2/S-RNase superfamily
P08676858A1084|16 20|tree
P08676495A0129|41 51|nucleotide
P08676495A0129|53 55|nt
P08676495A0129|175 180|times
P08676495A0129|17 28|splice site
P08676454A0731|132 139|virions
P08676454A0731|111 121|precursors
P08676454A0731|22 25|Pra
P08676454A0731|34 36|Nb
P08676266A0838|112 120|baseline
P08676266A0838|20 37|protease activity
P08675769A0158|132 144|calving rate
P08675769A0158|229 238|fertility
P08675769A0158|92 102|efficiency
P08675769A0158|66 74|measures
P08675769A0158|256 267|performance
P08675608T0000|30 44|hypothyroidism
P08675026A0420|132 144|Oryza sativa
P08675026A0420|63 76|sequence tags
P08675026A0420|78 81|EST
P08672242A0517|62 71|sequences
P08672242A0517|133 143|expression
P08672242A0517|10 34|reporter gene constructs
P08670853A0000|40 52|cell surface
P08670853A0000|80 90|importance
P08669676A1644|60 68|propofol
P08669676A1644|124 132|propofol
P08669676A1644|95 96|P
P08669676A1644|49 58|Q wave MI
P08669676A1644|134 135|n
P08669676A1644|41 46|group
P08669676A1644|77 86|midazolam
P08669676A1644|5 14|incidence
P08668210A0000|150 164|transformation
P08668210A0000|73 78|Raf-1
P08668210A0000|55 65|activation
P08668203A1230|104 115|sublineages
P08668203A1230|41 49|pancreas
P08668203A1230|64 89|differentiation functions
P08668190A1364|60 61|H
P08668190A1364|63 80|antiport activity
P08668190A1364|10 27|membrane vesicles
P08668190A1364|55 58|Ca2
P08668190A1364|33 45|hum1 mutants
P08668190A1364|171 179|membrane
P08668158A0765|245 249|tRNA
P08668158A0765|177 184|portion
P08668158A0765|256 260|gene
P08668158A0765|109 117|promoter
P08668158A0765|142 146|tRNA
P08668158A0765|36 41|Rpm1r
P08668124A0744|30 43|TDH3 promoter
P08668124A0744|95 99|sun2
P08668124A0744|5 15|Dox-A2 ORF
P08666404A0311|57 75|brain cDNA library
P08666404A0311|189 192|PP5
P08666404A0311|33 37|cDNA
P08666404A0311|1 10|Isolation
P08666383A1252|165 168|map
P08666383A1252|76 89|hybridization
P08666383A1252|36 48|cDNA mapping
P08666383A1252|137 147|definition
P08666238T0000|94 99|cells
P08665853A0228|75 88|ErbB proteins
P08665853A0228|161 169|activity
P08665853A0228|179 185|ErbB-1
P08665853A0228|190 196|ErbB-2
P08664462A1404|26 32|result
P08664462A1404|199 215|plasma clearance
P08664462A1404|7 14|changes
P08664462A1404|48 52|hand
P08664462A1404|100 112|transmission
P08664229T0000|28 45|Allergan Humphrey
P08664229T0000|10 20|evaluation
P08663326A0000|75 85|dmp operon
P08663326A0000|130 136|methyl
P08663326A0000|115 125|catabolism
P08663326A0000|137 144|phenols
P08663219A0246|47 51|CAAT
P08663219A0246|146 151|PGS-2
P08663219A0246|5 13|promoter
P08663219A0246|69 91|protein consensus site
P08663141T0000|14 25|DNA element
P08663141T0000|42 50|TATA box
P08663141T0000|55 84|transcription initiation site
P08663120T0000|11 16|Raf-1
P08663120T0000|92 99|pathway
P08662980A0762|179 187|receptor
P08662980A0762|66 74|receptor
P08662980A0762|155 159|form
P08662928T0000|15 26|interleukin
P08662928T0000|28 30|IL
P08662928T0000|71 91|signaling mechanisms
P08662928T0000|1 10|Receptors
P08662852A1297|26 30|GRK2
P08662852A1297|5 13|location
P08662852A1297|35 61|GRK5 phosphoacceptor sites
P08662617A2051|105 112|surface
P08662617A2051|129 146|uterine epithelia
P08662617A2051|21 25|data
P08662193A0404|63 69|region
P08662193A0404|133 139|region
P08662193A0404|16 37|activation subdomains
P08661119A0085|74 83|structure
P08661119A0085|96 105|EP4R cDNA
P08661114A0564|89 97|proteins
P08661114A0564|66 69|SIM
P08661101A0396|55 62|protein
P08661101A0396|84 92|rat CRP1
P08661007T0000|28 34|member
P08661007T0000|83 87|exon
P08661007T0000|51 67|anhydrase family
P08660892A1044|124 134|expression
P08660892A1044|42 58|co-transfections
P08660892A1044|170 174|MyoD
P08660748X0000|95 114|population patterns
P08660748X0000|5 10|model
P08660748X0000|49 57|dynamics
P08659545A0000|146 159|exon trapping
P08659545A0000|59 69|chromosome
P08659545A0000|172 181|fragments
P08659545A0000|185 195|chromosome
P08659545A0000|102 117|pathophysiology
P08657183A0145|27 33|repair
P08657183A0145|37 50|DNA fragments
P08657183A0145|113 117|DHFR
P08657150A1049|148 158|activators
P08657150A1049|22 32|regulators
P08657150A1049|113 133|promoter specificity
P08656672A0678|74 93|leukemia cell lines
P08656672A0678|136 145|subclones
P08655555A0772|47 49|bp
P08655555A0772|66 91|transcription start point
P08655555A0772|4 12|addition
P08655555A0772|17 26|deletions
P08654983A0000|148 157|homologue
P08654983A0000|66 69|Srb
P08654983A0000|217 224|DNA Res
P08654983A0000|175 201|SRP receptor alpha-subunit
P08654983A0000|71 77|system
P08654983A0000|119 130|Bs srb gene
P08654946A0986|74 91|mouse promoter P3
P08654946A0986|130 138|sequence
P08654435A0540|13 19|analog
P08654435A0540|125 133|activity
P08654435A0540|93 103|wortmannin
P08654435A0540|23 33|wortmannin
P08654435A0540|137 141|Erk2
P08654375A0544|150 172|DNA binding POU domain
P08654375A0544|176 181|Oct-1
P08654375A0544|67 78|amino acids
P08654375A0544|38 44|region
P08652081A1953|75 85|toxicities
P08652081A1953|198 205|lesions
P08652081A1953|125 133|headache
P08652081A1953|23 29|events
P08652081A1953|137 146|skin rash
P08651853A0607|180 188|patients
P08651853A0607|109 125|CA1/prosubiculum
P08651853A0607|162 175|dentate gyrus
P08651853A0607|234 235|%
P08651853A0607|207 217|CA4 region
P08651853A0607|84 91|gliosis
P08649841A0956|120 137|CAT reporter gene
P08649841A0956|95 103|promoter
P08649841A0956|55 70|Kozak sequences
P08649841A0956|18 22|uORF
P08649841A0956|171 193|CAT protein production
P08649440T0000|5 18|heterogeneity
P08649427A0689|105 108|GAP
P08649427A0689|40 44|cDNA
P08649427A0689|96 103|protein
P08649427A0689|64 70|member
P08649425A0373|56 60|core
P08649425A0373|19 21|bp
P08649405T0000|15 20|sites
P08649405T0000|28 42|CD11c promoter
P08649405T0000|117 130|transcription
P08649393A0000|183 204|kinetochore integrity
P08649393A0000|42 48|mutant
P08649393A0000|3 35|chromosome transmission fidelity
P08649393A0000|50 54|s138
P08649389A0000|164 171|protein
P08649389A0000|115 126|factor CTCF
P08649389A0000|220 240|amino acid sequences
P08649373T0000|92 102|c-myc gene
P08649372A0501|104 106|G2
P08649372A0501|92 100|activity
P08649372A0501|1 18|Clb2/Cdc28 kinase
P08648665A1320|121 126|cells
P08648665A1320|94 101|segment
P08648665A1320|67 74|protein
P08648408A0792|44 54|Hyp levels
P08648408A0792|122 127|group
P08648408A0792|96 101|group
P08648408A0792|18 28|CSA groups
P08647822T0000|10 14|role
P08647822T0000|64 74|activation
P08647822T0000|19 25|sterol
P08647451A0663|79 84|range
P08647451A0663|1 28|Northern blot hybridization
P08647264T0000|62 79|calcium ionophore
P08647264T0000|112 121|apoptosis
P08647264T0000|154 182|cysteine protease CPP32/Yama
P08647264T0000|136 146|activation
P08647264T0000|85 92|antigen
P08647086T0000|52 59|complex
P08647086T0000|81 85|Cdk2
P08647086T0000|102 111|cyclin D1
P08647086A0622|15 22|complex
P08647086A0622|46 52|system
P08645214A1052|60 67|plasmid
P08645214A1052|28 33|plysS
P08645214A1052|126 132|amount
P08645214A1052|190 196|enzyme
P08645214A1052|136 144|proteins
P08643759A0338|84 89|group
P08643646A0479|132 143|transcripts
P08643646A0479|176 178|kb
P08643646A0479|6 12|region
P08643646A0479|155 159|size
P08643578A0532|15 39|Rho family protein Cdc42
P08643578A0532|134 137|TyA
P08643578A0532|131 133|FG
P08643578A0532|140 155|lacZ expression
P08643557A0259|66 70|sets
P08643557A0259|34 46|HOX proteins
P08643382A0752|78 82|tail
P08643382A0752|127 146|chloroplast protein
P08643382A0752|54 60|region
P08642693T0000|46 60|identification
P08642693T0000|27 44|Southampton virus
P08642693T0000|1 23|Polyprotein processing
P08642313A0770|192 197|Bcl-3
P08642313A0770|113 133|reporter gene assays
P08642313A0770|49 55|TAN-1C
P08642313A0770|84 99|transactivation
P08642282A1009|39 48|knowledge
P08642282A1009|86 96|expression
P08642282A1009|118 120|B7
P08640866A0473|151 154|MEK
P08640866A0473|165 173|activity
P08640866A0473|129 138|increases
P08640866A0473|101 111|antibodies
P08640866A0473|1 9|Exposure
P08639742T0000|23 33|cDNA clone
P08639742T0000|55 65|similarity
P08639742T0000|1 10|Isolation
P08639521A1032|13 23|properties
P08639521A1032|113 119|models
P08638435A0522|31 52|agar diffusion method
P08638435A0522|57 74|Y. enterocolitica
P08638435A0522|84 103|inhibition activity
P08637717A0817|10 17|peptide
P08637717A0817|55 67|p21-activity
P08637717A0817|19 30|amino acids
P08637006A0000|75 80|array
P08637006A0000|225 233|ATF site
P08637006A0000|182 193|orientation
P08637006A0000|20 30|adenovirus
P08637006A0000|1 14|Transcription
P08636124A0410|30 34|cDNA
P08636124A0410|147 154|nucleus
P08636124A0410|6 13|protein
P08635771A0000|75 113|gas chromatographic/mass spectrometric
P08635771A0000|122 130|analysis
P08635771A0000|174 181|samples
P08635771A0000|115 120|GC/MS
P08635771A0000|49 69|EMIT II immunoassays
P08634423A0498|192 203|neutrophils
P08634423A0498|131 132|%
P08634423A0498|97 98|%
P08634423A0498|174 183|32D cells
P08634423A0498|18 30|integrations
P08634357A0527|28 42|Amphotericin B
P08634357A0527|66 71|fluid
P08634357A0527|114 119|range
P08633855A1064|125 140|S. thermophilus
P08633855A1064|97 121|lacS deletion derivative
P08633855A1064|32 68|E. coli-Streptococcus shuttle vector
P08632463A1508|26 34|argument
P08632463A1508|6 12|result
P08632463A1508|101 109|progress
P08632015A1226|211 221|expression
P08632015A1226|225 228|DNA
P08632015A1226|46 54|presence
P08632015A1226|264 277|DRE sequences
P08632015A1226|110 124|division cycle
P08632015A1226|20 28|analysis
P08632009A1067|75 90|characteristics
P08632009A1067|215 240|DNA binding specificities
P08632009A1067|199 207|addition
P08632009A1067|20 26|action
P08632009A1067|174 183|cofactors
P08631944A0663|210 220|regulation
P08631944A0663|128 143|J558L cell line
P08631944A0663|96 106|IgE grande
P08631944A0663|190 194|cell
P08631908A0224|27 32|VDREs
P08631908A0224|78 98|mobility shift assay
P08631908A0224|1 8|VDR/RXR
P08631820A0755|150 158|Lacroute
P08631820A0755|160 162|F.
P08631820A0755|96 108|yeast strain
P08631820A0755|175 177|F.
P08631820A0755|136 144|Delourme
P08631797A0982|164 170|effect
P08631797A0982|61 85|tyrosine phosphorylation
P08631797A0982|39 55|receptor subunit
P08631797A0982|17 23|ErbB-2
P08631685A0000|146 149|min
P08631685A0000|80 84|maoA
P08631685A0000|101 119|amine oxidase gene
P08630599A0534|104 112|subjects
P08630599A0534|142 155|micrograms/ml
P08630599A0534|189 202|micrograms/ml
P08630599A0534|114 118|mean
P08630599A0534|251 262|coal miners
P08630599A0534|18 47|elastin peptide concentration
P08630548A0000|123 150|tumor necrosis factor-alpha
P08630548A0000|53 63|regulation
P08630548A0000|101 114|interleukin-1
P08630548A0000|34 40|degree
P08629348A0237|94 101|changes
P08629348A0237|246 259|hydrocephalus
P08629348A0237|236 244|epilepsy
P08629348A0237|49 51|BI
P08628681A0364|76 86|oocyte RNA
P08628681A0364|33 40|kb mRNA
P08628284A0181|90 103|CYC1 promoter
P08628284A0181|55 64|lacZ gene
P08628284A0181|136 141|TRE-1
P08628255A0932|29 39|expression
P08628255A0932|161 165|site
P08628255A0932|82 91|beginning
P08628255A0932|17 27|HeLa cells
P08628251A1455|66 73|stimuli
P08627688A1520|67 75|activity
P08627688A1520|35 39|I299
P08627649A0734|90 97|binding
P08627649A0734|263 269|GC box
P08627649A0734|186 197|interaction
P08627649A0734|17 38|mobility shift assays
P08627649A0734|163 169|P4 EBS
P08627649A0734|232 235|Sp1
P08627649A0734|103 109|member
P08626809A0729|133 157|eIF-2alpha kinase family
P08626809A0729|64 69|Ser51
P08626809A0729|85 103|eIF-2alpha peptide
P08626777A0537|131 137|region
P08626777A0537|67 82|sequence motifs
P08626777A0537|1 18|Sequence analysis
P08626667A1517|63 70|repeats
P08626667A1517|172 191|GPT gene expression
P08626667A1517|1 14|Transcription
P08626612A1040|1 3|Am
P08626596A0000|194 202|pathways
P08626596A0000|56 70|protein kinase
P08626596A0000|86 90|role
P08626596A0000|136 149|ATP depletion
P08626539T0000|43 67|ApoA-I promoter activity
P08626539T0000|81 93|heterodimers
P08626539T0000|1 20|Binding specificity
P08626529A0000|195 197|B.
P08626529A0000|108 124|membrane protein
P08626529A0000|39 55|syndrome patient
P08626529A0000|155 159|face
P08626437A0332|182 190|tyrosine
P08626437A0332|36 43|lysates
P08626437A0332|87 112|glutathione S-transferase
P08626437A0332|119 129|Lyn fusion
P08626313A1037|15 18|Msp
P08626313A1037|1 11|Expression
P08626065A0000|63 75|DNA fragment
P08626065A0000|59 61|Bs
P08626065A0000|144 154|chromosome
P08625924A0411|93 97|size
P08625924A0411|64 75|amino acids
P08625924A0411|117 145|polyadenylation signal usage
P08625924A0411|16 19|34B
P08625806A0263|78 80|r3
P08625806A0263|142 155|mouse embryos
P08625806A0263|64 74|expression
P08625806A0263|85 87|r5
P08623554A1058|12 19|protein
P08622887A1026|134 139|GRE-2
P08622887A1026|62 104|glucocorticoid receptor DNA binding domain
P08622887A1026|147 153|motifs
P08622887A1026|176 215|oligonucleotide competition experiments
P08622887A1026|17 38|mobility shift assays
P08622675A0587|27 37|N terminus
P08622675A0587|67 74|protein
P08622675A0587|1 10|Inclusion
P08622645A1026|40 50|vitamin D3
P08622645A1026|68 80|RA induction
P08622070A0889|10 18|patients
P08622070A0889|39 47|response
P08622070A0889|32 34|CA
P08621730T0000|95 112|promoter activity
P08621730T0000|77 85|collagen
P08621730T0000|67 73|alpha2
P08621730T0000|87 93|COL1A2
P08621719A0000|135 162|T cell receptor stimulation
P08621719A0000|8 14|others
P08621664A1430|88 111|neurofilament L protein
P08621664A1430|19 42|neurofilament L protein
P08621664A1430|69 84|phosphorylation
P08621659A0189|31 41|Gla domain
P08621659A0189|117 118|G
P08621659A0189|69 75|growth
P08621542A0535|47 54|kinases
P08621542A0535|56 60|JNKs
P08621542A0535|129 133|IL-1
P08621542A0535|118 127|TNF-alpha
P08621420A1166|45 53|antibody
P08621420A1166|57 60|p50
P08621420A1166|19 24|bands
P08621420A1166|84 87|p65
P08621017A1186|29 52|uPA promoter activation
P08621017A1186|109 117|proteins
P08621017A1186|65 72|phorbol
P08621017A1186|139 170|tetradecanoylphorbol 13-acetate
P08620856A1172|181 185|size
P08620856A1172|330 341|spermatozoa
P08620856A1172|296 311|spermatogenesis
P08620856A1172|25 29|data
P08620856A1172|248 258|c-kit cDNA
P08620856A1172|161 172|polypeptide
P08620856A1172|4 13|agreement
P08619910A0000|180 192|observations
P08619910A0000|332 351|nigra zona compacta
P08619910A0000|353 356|SNc
P08619910A0000|256 263|disease
P08619910A0000|12 21|mechanism
P08619910A0000|200 206|effect
P08619910A0000|70 76|tremor
P08618882A0343|13 30|RAR alpha mutants
P08618882A0343|123 137|BZLF1 activity
P08618882A0343|1 9|Analysis
P08618433A1720|30 40|expression
P08618433A1720|125 144|leukemia cell lines
P08618433A1720|111 121|cell types
P08618433A1720|48 56|receptor
P08617802A0993|128 131|Ras
P08617802A0993|112 120|activity
P08617802A0993|32 41|sequences
P08617800A0150|61 72|determinant
P08617800A0150|76 95|receptor expression
P08617800A0150|1 8|Control
P08617243A0336|58 66|extracts
P08617243A0336|117 123|region
P08617237A0489|109 133|tyrosine phosphopeptides
P08617237A0489|65 88|DNA binding specificity
P08617237A0489|35 40|STAT5
P08616743T0000|17 20|Dr.
P08615025A1214|177 193|immunoreactivity
P08615025A1214|264 268|gp41
P08615025A1214|95 118|glycosylation phenotype
P08615025A1214|219 224|gp160
P08615025A1214|49 56|mutants
P08615025A1214|326 331|gp120
P08615025A1214|132 142|quantities
P08615025A1214|197 199|V3
P08615025A1214|411 416|cells
P08614410A0000|45 66|gonadotroph cell line
P08614410A0000|89 100|oncogenesis
P08614410A0000|157 191|glycoprotein hormone alpha-subunit
P08614410A0000|139 149|regulation
P08614403A0557|22 28|levels
P08614403A0557|64 79|C2C12 myoblasts
P08611280A0820|90 96|cm3/m2
P08611280A0820|183 189|cm3/m2
P08611280A0820|247 248|p
P08611280A0820|117 118|p
P08611280A0820|164 170|cm3/m2
P08611280A0820|130 135|onset
P08611280A0820|239 245|cm3/m2
P08610328A0228|94 105|experiences
P08610328A0228|59 66|studies
P08610328A0228|1 8|SUMMARY
P08608448A0353|15 23|residues
P08608448A0353|189 199|reactivity
P08608448A0353|217 225|residues
P08608448A0353|168 173|S RNA
P08608448A0353|238 243|loops
P08608222T0000|112 117|STAT3
P08608222T0000|33 39|region
P08606267A0740|181 217|Tc-99m 2-methoxy isobutyl isonitrile
P08606267A0740|167 177|evaluation
P08606267A0740|245 254|variables
P08606267A0740|219 223|MIBI
P08606267A0740|1 10|Variables
P08606267A0740|51 57|events
P08605705A0676|94 110|disease activity
P08605705A0676|49 52|CIC
P08605324A0434|31 39|promoter
P08604708A1086|12 19|studies
P08604708A1086|147 153|change
P08604708A1086|129 136|minutes
P08604338A0198|47 68|transcription factors
P08604338A0198|6 15|EWS-FLI-1
P08604338A0198|114 123|ets boxes
P08602608A1056|74 78|STKS
P08602608A1056|146 165|reference procedure
P08602608A1056|39 51|performances
P08601806A0875|25 30|RPF-1
P08601806A0875|7 11|data
P08601806A0875|65 70|steps
P08601283A0875|90 104|selenoproteins
P08601283A0875|240 254|SECIS function
P08601283A0875|143 153|deiodinase
P08601283A0875|55 69|reading frames
P08601283A0875|184 197|SECIS element
P08601283A0875|136 140|type
P08600028A1129|61 76|intron enhancer
P08600028A1129|122 132|properties
P08600028A1129|5 9|data
P08599945T0000|150 161|transitions
P08599945T0000|76 96|yeast RNA polymerase
P08599945T0000|18 32|alpha-amanitin
P08599945T0000|1 10|Mutations
P08598359X0000|28 38|field size
P08598359X0000|265 270|T1-T2
P08598359X0000|134 140|larynx
P08598359X0000|12 26|treatment time
P08598359X0000|77 84|control
P08598359X0000|142 149|PURPOSE
P08598359X0000|237 244|control
P08598359X0000|103 118|cell carcinomas
P08597636A0000|79 98|expression patterns
P08597636A0000|142 157|gene regulation
P08597636A0000|113 124|involvement
P08597177T0000|21 30|exposures
P08597177T0000|71 74|EEG
P08597177T0000|34 51|hydrogen sulphide
P08595878A0201|79 83|Ras1
P08595878A0201|127 130|RTK
P08595878A0201|101 125|receptor tyrosine kinase
P08595878A0201|220 234|Drosophila eye
P08595658A0961|129 133|ends
P08595658A0961|53 61|homology
P08595658A0961|65 101|plant mitochondrial-processing sites
P08595414A0000|226 232|clones
P08595414A0000|67 79|construction
P08595414A0000|191 197|extent
P08595414A0000|170 183|determination
P08595414A0000|17 25|sequence
P08595012A0817|4 16|nondiabetics
P08595012A0817|33 38|tcPO2
P08595012A0817|50 53|LDF
P08592713T0001|26 31|drugs
P08591700A0972|72 77|kg/m2
P08591700A0972|5 25|mean body mass index
P08591700A0972|49 54|kg/m2
P08589735A0577|151 161|rice actin
P08589735A0577|127 142|maize ubiquitin
P08589735A0577|163 167|Act1
P08589735A0577|173 187|CaMV 35S genes
P08589735A0577|85 118|Arabidopsis alcohol dehydrogenase
P08589358A0235|43 57|erythropoietin
P08589358A0235|93 98|times
P08589358A0235|101 105|week
P08588852A0236|150 156|thumbs
P08588852A0236|182 188|tibiae
P08588852A0236|22 31|pregnancy
P08588852A0236|87 91|week
P08586874T0000|30 48|Haplorchis pumilio
P08586874T0000|94 107|redescription
P08586874T0000|1 8|Studies
P08586874T0000|50 55|Looss
P08585994A0567|214 251|segmentation gene expression patterns
P08585994A0567|172 182|chromosome
P08585994A0567|64 86|ost transcription unit
P08585994A0567|259 265|embryo
P08585883A0381|165 168|day
P08585883A0381|130 146|copulation plugs
P08585883A0381|76 87|LNG pellets
P08585883A0381|174 177|day
P08585883A0381|117 120|day
P08585883A0381|51 64|breeder males
P08585324A0823|72 79|remnant
P08585324A0823|6 12|region
P08584530A0545|165 177|test results
P08584530A0545|79 82|Raw
P08584530A0545|145 156|differences
P08584530A0545|69 75|values
P08584035A0740|134 141|ability
P08584035A0740|218 220|R4
P08584035A0740|156 172|beta I-A element
P08584035A0740|1 26|Gel mobility shift assays
P08583846A0807|14 44|methodology beta-2 transferrin
P08583846A0807|98 107|perilymph
P08583783A0870|60 64|calf
P08583783A0870|94 97|ANP
P08583783A0870|66 76|filtration
P08582143A0614|90 114|cephalosporin substrates
P08582143A0614|212 219|species
P08582143A0614|139 141|S1
P08580671A0137|60 70|metoprolol
P08580671A0137|243 251|bleeding
P08580671A0137|101 111|prevention
P08580671A0137|84 96|beta-blocker
P08580671A0137|51 56|trial
P08576546A0975|13 19|series
P08576546A0975|52 62|PDC/HDC Ac
P08576245A0000|94 101|protein
P08576245A0000|59 68|reticulum
P08576245A0000|20 29|chaperone
P08576245A0000|1 6|GRP78
P08576131A0685|149 161|USF proteins
P08576131A0685|40 52|USF subunits
P08576131A0685|18 36|heterodimerization
P08576042A0765|149 169|heat shock induction
P08576042A0765|177 181|dnaK
P08576042A0765|297 308|temperature
P08576042A0765|54 58|hrcA
P08576042A0765|186 198|groE operons
P08576042A0765|46 50|copy
P08576042A0765|206 211|level
P08576042A0765|1 15|Overproduction
P08575618A1138|89 104|skin expression
P08575618A1138|36 47|correlation
P08575618A1138|1 24|RNase protection assays
P08575609A0526|108 112|eyes
P08575609A0526|5 14|C/D ratio
P08575609A0526|70 76|values
P08574414A1037|57 63|length
P08574414A1037|76 95|Xanthomonas species
P08574414A1037|100 109|pathovars
P08573083A0645|135 141|factor
P08573083A0645|43 51|identity
P08573083A0645|6 12|region
P08573083A0645|174 190|insulin promoter
P08570615T0000|46 61|point mutations
P08570615T0000|65 70|E2F-1
P08570615T0000|98 107|apoptosis
P08569680A0636|60 67|residue
P08569680A0636|10 22|areA product
P08569680A0636|111 117|domain
P08567847A1005|147 160|semen samples
P08567847A1005|111 121|instrument
P08567847A1005|8 15|opinion
P08567847A1005|21 34|SM-CMA system
P08567683A0401|29 39|base pairs
P08567683A0401|43 49|length
P08566773A1023|26 30|CTS2
P08566773A1023|147 153|fungus
P08566773A1023|65 72|classes
P08566773A1023|17 21|CTS1
P08566754A0783|195 202|ASF/SF2
P08566754A0783|160 191|splicing factor/splicing factor
P08566754A0783|99 101|U1
P08566754A0783|136 142|snRNPs
P08566751A0455|149 157|function
P08566751A0455|46 66|vertebrate Hox genes
P08566751A0455|87 94|control
P08565548A0196|41 50|potential
P08565548A0196|6 11|study
P08565548A0196|99 107|collagen
P08564588A1318|91 114|management expenditures
P08564588A1318|124 132|ABSTRACT
P08564588A1318|1 22|Strontium chloride Sr
P08563483A0094|92 102|TSH levels
P08563483A0094|116 119|hCG
P08563483A0094|136 144|activity
P08561897A0604|14 31|supershift assays
P08561897A0604|193 208|CRE/TRE element
P08561897A0604|124 147|competition experiments
P08561897A0604|111 119|elements
P08561897A0604|71 77|factor
P08561607A1443|46 61|transplantation
P08561607A1443|25 35|infections
P08556707A1390|57 81|transactivation activity
P08556707A1390|7 11|data
P08556707A1390|188 196|presence
P08556707A1390|87 99|p53 promoter
P08556707A1390|103 108|yeast
P08555597A0808|76 82|months
P08555597A0808|50 54|g/dl
P08555446A0000|28 33|ppa-1
P08555446A0000|78 93|pyrophosphatase
P08555446A0000|157 163|sugars
P08555168A0390|10 13|Mn2
P08555168A0390|1 4|Mg2
P08554723A0187|14 18|rats
P08554723A0187|192 207|sodium appetite
P08554723A0187|280 284|chow
P08554723A0187|218 238|furosemide treatment
P08554723A0187|263 269|sodium
P08554723A0187|253 259|access
P08554069A0743|47 55|mutation
P08554069A0743|179 191|RNA splicing
P08554069A0743|140 146|intron
P08554069A0743|153 157|exon
P08552670T0000|45 52|cloning
P08552670T0000|98 105|protein
P08552670T0000|17 29|purification
P08552643A0261|57 66|phenotype
P08552643A0261|161 174|IFN treatment
P08552643A0261|96 104|activity
P08552643A0261|1 7|Clones
P08552096A0151|62 72|yeast gene
P08552096A0151|95 105|expression
P08552096A0151|19 39|suppression strategy
P08552095A0758|133 143|expression
P08552095A0758|37 54|yeast transcripts
P08552095A0758|81 85|paf1
P08552093A0657|121 132|selectivity
P08552093A0657|80 85|forms
P08552093A0657|101 106|alpha
P08552093A0657|154 164|G proteins
P08552086A0150|40 66|vitamin D response element
P08552086A0150|81 89|promoter
P08552045A0973|120 137|binding sequences
P08552045A0973|11 30|consensus sequences
P08552045A0973|173 186|transcription
P08552045A0973|65 76|GCACGTGGG-3
P08552045A0973|35 57|phosphatase regulation
P08551577A0000|12 23|replication
P08551577A0000|40 47|portion
P08551577A0000|163 181|Rous sarcoma virus
P08551577A0000|185 193|src mRNA
P08550564T0000|31 35|sets
P08550564T0000|1 15|CXC chemokines
P08550564T0000|153 178|interleukin-8 receptor B.
P08550470A1021|73 84|kinase CheA
P08550470A1021|40 48|coupling
P08550462A0815|1 9|Upstream
P08550462A0815|34 47|reading frame
P08550460A0374|28 32|gene
P08550460A0374|99 116|protein precursor
P08549859A1604|53 66|chromosome 3p
P08549859A1604|70 118|Centre d'Etude du Polymorphisme Humain pedigrees
P08548291A1059|132 154|serum response element
P08548291A1059|76 83|complex
P08548291A1059|185 198|transcription
P08548291A1059|51 60|formation
P08546707T0000|60 73|NF-kappa Bp65
P08546707T0000|35 56|chicken lysozyme gene
P08546707T0000|17 27|activation
P08544820T0000|24 55|EcR/USP heterodimer target site
P08544820T0000|70 93|ecdysone responsiveness
P08543595A1093|40 51|carboplatin
P08543595A1093|69 81|radiotherapy
P08543173A0314|13 21|TATA box
P08543173A0314|86 111|primer extension analysis
P08542027A1471|107 111|CD44
P08542027A1471|5 13|XS2 gene
P08542027A1471|50 60|expression
P08541793A0796|39 42|min
P08538702A0214|104 111|protein
P08538702A0214|13 24|polypeptide
P08538702A0214|130 144|Brugia pahangi
P08538702A0214|39 47|sequence
P08538702A0214|115 128|Brugia malayi
P08538702A0214|184 191|antigen
P08538382A1012|39 46|infants
P08538382A1012|70 76|breast
P08538382A1012|102 108|levels
P08537403A0336|31 36|LIMK1
P08537403A0336|180 194|subdomains VII
P08537403A0336|199 203|VIII
P08537403A0336|5 27|protein kinase domains
P08536694A0000|43 50|control
P08536694A0000|68 77|processes
P08535138A0857|159 164|onset
P08535138A0857|115 135|cycMs4 transcription
P08535138A0857|168 181|DNA synthesis
P08534848A0188b|11 22|NR isoforms
P08534367A0984|40 48|deletion
P08534367A0984|55 66|amino acids
P08534367A0984|84 91|exon E1
P08533757A0204|124 131|markers
P08533757A0204|159 161|kb
P08533757A0204|55 72|185delAG mutation
P08533472A0777|15 31|protein products
P08533472A0777|95 103|proteins
P08533472A0777|82 89|domains
P08533472A0777|188 199|interleukin
P08533472A0777|64 76|similarities
P08533472A0777|50 55|N2403
P08532536A0925|53 61|TGF-beta
P08532536A0925|96 101|BMP-2
P08532536A0925|158 161|EGF
P08532536A0925|190 214|growth factors/cytokines
P08532536A0925|85 94|protein-2
P08531669A0950|133 140|control
P08531669A0950|70 86|Caribean islands
P08531669A0950|154 161|species
P08531669A0950|50 65|Central America
P08530503A1004|8 11|ARF
P08530503A1004|54 70|plasma membranes
P08530418A1182|15 19|data
P08530418A1182|177 209|acid signal transduction pathway
P08530418A1182|37 56|TR2 orphan receptor
P08530418A1182|143 150|CRBPIIp
P08530369A0099|13 32|autophosphorylation
P08530369A0099|36 42|Tyr397
P08530369A0099|68 102|consensus autophosphorylation site
P08530107A1003|73 80|finding
P08530107A1003|95 118|histidase transcription
P08530107A1003|145 152|factors
P08529662A0507|66 82|Western blotting
P08529662A0507|51 62|ERp57/GRP58
P08529630A0840|63 68|level
P08528796A1470|13 25|UA PI values
P08528796A1470|78 87|parameter
P08526620A1344|90 96|marker
P08526620A1344|27 37|importance
P08526620A1344|6 11|study
P08526620A1344|118 139|complement activation
P08524314A0216|107 119|zinc cluster
P08524314A0216|124 142|dimerization motif
P08524314A0216|5 9|TEA1
P08524314A0216|168 174|family
P08524314A0216|85 95|N terminus
P08524292A1022|147 150|YY1
P08524292A1022|76 91|transactivation
P08524292A1022|53 56|YY1
P08524292A1022|18 33|mechanism study
P08524272T0000|14 24|regulation
P08524272T0000|111 138|tyrosine phosphatase SHPTP1
P08524272T0000|32 42|alpha/beta
P08524260A0835|150 157|repeats
P08524260A0835|299 305|LTBP-1
P08524260A0835|76 82|LTBP-2
P08524260A0835|5 21|domain structure
P08524260A0835|236 244|examples
P08524260A0835|259 265|motifs
P08524235A0695|109 113|loop
P08524235A0695|196 203|max RNA
P08524235A0695|82 88|region
P08524235A0695|38 42|dMax
P08524235A0695|184 192|splicing
P08524036A0747|194 199|level
P08524036A0747|62 71|variation
P08524036A0747|79 85|stripe
P08524036A0747|203 212|variation
P08524036A0747|236 243|regions
P08524036A0747|170 175|sites
P08523545T0000|104 119|transactivation
P08523545T0000|167 170|ATF
P08523545T0000|147 152|genes
P08523545T0000|175 201|Oct-1 DNA binding activity
P08522530A1342|47 63|primer extension
P08522530A1342|25 31|points
P08522530A1342|212 215|box
P08522530A1342|113 115|bp
P08522530A1342|98 99|s
P08522530A1342|186 188|bp
P08522511A1250|29 43|lyase activity
P08521780A0485|1 11|Umweltchem
P08521414A1384|240 254|p16INK4A locus
P08521414A1384|47 57|CpG island
P08521414A1384|183 187|exon
P08521414A1384|7 17|cell lines
P08521414A1384|80 84|exon
P08519862T0001|61 64|kit
P08519862T0001|1 12|Measurement
P08518797T0000|47 56|isolation
P08518797T0000|10 28|liver glycogenosis
P08516324A0000|104 109|tumor
P08516324A0000|176 183|portion
P08516324A0000|191 199|EWS gene
P08516324A0000|259 268|FLI1 gene
P08516301A0080|62 69|introns
P08516301A0080|20 22|kb
P08515619A0184|215 226|B type COPD
P08515619A0184|114 120|counts
P08515619A0184|230 252|Burrows classification
P08515619A0184|201 210|emphysema
P08515619A0184|101 110|ventricle
P08515619A0184|171 175|COPD
P08514757A1100|90 98|category
P08514757A1100|146 162|protein function
P08514757A1100|39 44|roles
P08514757A1100|102 108|ligand
P08512728A0991|214 218|msec
P08512728A0991|178 195|accessory pathway
P08512728A0991|36 47|differences
P08512728A0991|70 75|group
P08512728A0991|1 8|RESULTS
P08510924A0490|88 100|Myb proteins
P08510924A0490|70 84|HSP70 promoter
P08510320A1249|46 51|MRSAs
P08510320A1249|99 109|resistance
P08510320A1249|118 123|drugs
P08509430A0372|145 154|psaB gene
P08509430A0372|59 65|mutant
P08509430A0372|188 201|transformants
P08509430A0372|69 82|Chlamydomonas
P08509430A0372|118 137|frameshift mutation
P08509335T0000|9 13|gene
P08509051A0316|61 62|%
P08509051A0316|17 25|patients
P08508778A0112|121 127|growth
P08508778A0112|36 45|NOP1 gene
P08508778A0112|153 163|processing
P08507921A1021|77 88|MI patients
P08507921A1021|22 34|observations
P08507921A1021|4 14|conclusion
P08507921A1021|206 210|risk
P08507921A1021|186 197|individuals
P08506317A0000|54 58|bZip
P08506317A0000|32 52|basic-leucine zipper
P08506317A0000|1 8|Members
P08506317A0000|152 167|enhancer motifs
P08505495A0253|18 26|75SeHCAT
P08504933A0000|28 45|POU domain factor
P08504933A0000|65 75|appearance
P08504933A0000|85 100|cell phenotypes
P08504928T0000|47 54|homolog
P08504928T0000|161 166|TFIID
P08504928T0000|19 32|TFIID subunit
P08503348A0226|78 84|agents
P08501030A0456|105 109|M.H.
P08501030A0456|96 103|strains
P08501030A0456|17 26|induction
P08500524A0424|10 15|study
P08500524A0424|144 163|intron organization
P08499903A0883|45 51|origin
P08499903A0883|21 30|deletions
P08498570A1118|60 70|blood flow
P08498570A1118|27 52|carotid sinus stimulation
P08498570A1118|95 102|changes
P08498570A1118|4 14|conclusion
P08497280A1397|104 108|SWI6
P08497280A1397|93 100|absence
P08497273T0000|73 87|alpha enhancer
P08497273T0000|43 57|immunoglobulin
P08497273T0000|97 103|stages
P08497273T0000|1 6|NF-HB
P08497259A0452|99 103|type
P08497259A0452|68 81|tap1-1 mutant
P08497190T0079|60 67|mutants
P08497190T0079|1 18|Sequence analysis
P08496601A1153|52 65|muMIP-1 alpha
P08496601A1153|114 132|expression studies
P08496601A1153|21 30|promoters
P08496601A1153|259 309|growth hormone reporter gene link LPS-inducibility
P08496601A1153|196 208|muMIP-1 beta
P08496601A1153|233 241|promoter
P08496601A1153|136 139|RAW
P08496475T0000|31 44|Streptococcus
P08496475T0000|83 94|matruchotii
P08496475T0000|69 81|Bacterionema
P08496184A0772|74 84|chromosome
P08496184A0772|38 43|clone
P08496184A0772|17 30|reading frame
P08495786A0085|79 86|surface
P08495786A0085|1 24|Cryopreservation straws
P08492164T0000|13 25|burst firing
P08492164T0000|108 128|interaction measures
P08492164T0000|66 82|depth dependence
P08491383A1291|60 67|protein
P08491383A1291|79 100|transcription factors
P08491124A0517|15 27|construction
P08491124A0517|78 82|need
P08491124A0517|111 116|costs
P08491124A0517|35 51|mouth protectors
P08488700A0283|41 52|hepatitis D
P08488700A0283|229 240|hepatitis B
P08488700A0283|25 36|hepatitis B
P08488700A0283|158 163|blood
P08488700A0283|136 144|exposure
P08486276A0419|150 152|TM
P08486276A0419|267 282|symport protein
P08486276A0419|54 70|protein database
P08486276A0419|135 148|transmembrane
P08486276A0419|228 230|Tc
P08486276A0419|99 121|% aa sequence homology
P08486276A0419|1 20|Sequence comparison
P08485317A0000|109 123|protein kinase
P08485317A0000|25 29|gene
P08484689T0000|61 66|women
P08484689T0000|26 35|arthritis
P08484689T0000|51 57|factor
P08483479A1056|30 34|cAMP
P08483479A1056|253 277|collagen gene expression
P08483479A1056|47 73|collagen promoter activity
P08483479A1056|77 86|calvariae
P08483479A1056|7 11|data
P08483479A1056|234 249|cAMP repression
P08483479A1056|140 157|collagen promoter
P08482539A0913|61 65|xylP
P08482539A0913|83 93|transcript
P08482539A0913|1 23|Northern blot analysis
P08479742A0985|31 35|part
P08479742A0985|66 69|p53
P08476087A0814|75 84|pressures
P08476087A0814|58 63|range
P08474464A0348|46 53|Rev-Erb
P08474464A0348|22 34|relationship
P08474439A0877|90 103|site mutation
P08474439A0877|176 180|MEF1
P08474439A0877|159 168|mutations
P08474439A0877|20 25|sites
P08474439A0877|262 271|mutations
P08474439A0877|195 199|site
P08474439A0877|227 237|expression
P08474439A0877|38 45|effects
P08474439A0877|71 76|cells
P08473967T0000|15 34|Jungian type theory
P08473967T0000|1 11|Bipolarity
P08472750A0999|133 135|pH
P08472750A0999|8 24|oxide inhalation
P08472750A0999|71 94|porcine endotoxin shock
P08471629A0816|42 52|C-terminus
P08471629A0816|110 123|nPKC activity
P08471629A0816|69 81|PKC isotypes
P08471629A0816|137 149|Histone IIIS
P08470895A1617|30 38|sequence
P08470895A1617|76 84|TATA box
P08470895A1617|1 12|Examination
P08469831T0001|107 112|hyper
P08469831T0001|146 151|shock
P08469831T0001|22 30|dynamics
P08469831T0001|34 50|prostaglandin E1
P08464924A0243|25 30|eIF-5
P08464924A0243|3 11|rat cDNA
P08464056A0000|90 104|C2H2 type ZFPs
P08464056A0000|108 122|Xenopus laevis
P08464056A0000|68 77|subfamily
P08463320A1219|146 159|SSB tetramers
P08463320A1219|58 90|gel shift assembly intermediates
P08463320A1219|188 196|addition
P08463320A1219|205 218|SSB tetramers
P08461981A0882|122 126|rats
P08461981A0882|81 103|regeneration phenomena
P08461981A0882|16 20|need
P08460918A0252|124 134|impairment
P08460918A0252|214 242|gamma-glutamyltranspeptidase
P08460918A0252|261 266|group
P08460918A0252|248 258|IU liter-1
P08460918A0252|51 56|group
P08460918A0252|161 174|mumol liter-1
P08460918A0252|97 105|patients
P08460270A0205|25 35|infections
P08459012T0000|40 45|tibia
P08459012T0000|22 32|deficiency
P08458849A0364|72 77|sigma
P08458849A0364|98 110|ftr elements
P08458849A0364|32 50|flaN transcription
P08458849A0364|137 161|transcription start site
P08457291A0170|30 40|expression
P08457291A0170|141 155|c-fos oncogene
P08457291A0170|1 10|Estradiol
P08456879A0000|76 90|serum cotinine
P08456879A0000|16 23|purpose
P08455629A0335|12 14|L.
P08455611A0154|79 87|enhancer
P08455611A0154|199 205|origin
P08455611A0154|163 172|cell line
P08455611A0154|49 54|HS-40
P08455598A0000|210 220|repression
P08455598A0000|177 183|result
P08455598A0000|199 207|a1-alpha
P08455598A0000|189 195|defect
P08455598A0000|64 77|alpha * cells
P08454591A1322|128 132|AP-1
P08454591A1322|96 109|binding sites
P08454591A1322|54 63|positions
P08454591A1322|138 145|NF-IL-6
P08454077A0956|302 305|GMV
P08454077A0956|250 258|controls
P08454077A0956|378 380|NS
P08454077A0956|40 59|mg/kg i.v. infusion
P08454077A0956|237 238|p
P08454077A0956|329 336|muscles
P08454077A0956|214 217|min
P08454077A0956|263 270|normals
P08454077A0956|154 156|PI
P08454077A0956|74 77|min
P08454077A0956|400 411|h ischaemia
P08454077A0956|338 339|p
P08454077A0956|4 12|contrast
P08453101A0128|60 79|c-jun messenger RNA
P08453101A0128|81 85|mRNA
P08453101A0128|87 93|levels
P08451187A0267|61 74|ars sequences
P08449986A0455|45 50|cDNAs
P08449986A0455|55 64|MMI alpha
P08449943A0225|60 66|action
P08449943A0225|107 122|kinase isozymes
P08449943A0225|70 79|8-Cl-cAMP
P08449943A0225|16 21|study
P08447005T0001|28 56|influenzae type b meningitis
P08447005T0001|79 90|vaccination
P08446579A0784|90 94|cell
P08446579A0784|13 40|transcription factor Gal-ER
P08446579A0784|199 209|C terminus
P08445729A0657|105 116|RNA binding
P08445729A0657|52 56|ARMs
P08445729A0657|20 35|spacer sequence
P08445299T0000|58 72|ozone toxicity
P08445299T0000|36 48|deferoxamine
P08445299T0000|1 7|Effect
P08444344A0000|43 48|motif
P08444344A0000|84 92|proteins
P08443341A0384|120 139|MA type myrosinases
P08443341A0384|77 88|B. napus MA
P08443341A0384|232 237|genes
P08443341A0384|184 203|MB type myrosinases
P08443341A0384|171 176|genes
P08443339A1374|120 126|cortex
P08443339A1374|44 61|promoter function
P08443339A1374|65 79|leaf epidermis
P08443339A1374|81 90|mesophyll
P08442384T0000|74 87|reading frame
P08442384T0000|49 55|leader
P08441869A0334|5 22|plateau MO2 value
P08441411A1260|271 281|transition
P08441411A1260|213 224|interaction
P08441411A1260|23 34|splenocytes
P08441411A1260|116 122|levels
P08441411A1260|74 75|h
P08441411A1260|316 326|cell cycle
P08441411A1260|36 52|Gfi-1 expression
P08441379A0912|52 58|region
P08441379A0912|99 111|proIL-1 beta
P08441379A0912|185 194|monocytes
P08441379A0912|136 153|enhancer elements
P08440688A1509|47 52|genes
P08440688A1509|7 14|studies
P08440688A1509|82 95|LLC-PK1 cells
P08439597A0176|78 91|blood samples
P08439597A0176|5 15|evaluation
P08439564A0883|134 153|porcine haptocorrin
P08439564A0883|63 83|Cbl binding proteins
P08439564A0883|5 34|amino acid sequence alignment
P08439564A0883|38 40|TC
P08439564A0883|171 172|%
P08438584A0524|61 63|C1
P08438584A0524|6 23|promoter activity
P08438584A0524|117 123|V1 ORF
P08437521A0000|107 116|areA gene
P08437521A0000|128 158|nitrogen metabolite repression
P08437521A0000|82 91|activator
P08437521A0000|216 223|ability
P08437521A0000|256 266|expression
P08437521A0000|275 280|genes
P08435755A0938|134 137|rat
P08435755A0938|111 122|stimulation
P08435755A0938|55 60|mg/kg
P08435755A0938|17 41|scopolamine hydrobromide
P08432526A0580|73 112|polymerase chain reaction amplification
P08432526A0580|118 141|fibroblast cDNA library
P08431100A0108|40 57|motor performance
P08431100A0108|92 100|children
P08431100A0108|6 11|study
P08431100A0108|222 225|sex
P08431100A0108|137 150|consciousness
P08430095A0161|47 51|gene
P08430095A0161|63 71|function
P08430095A0161|6 12|report
P08429568A0000|26 42|plasmid pRmeGR4b
P08429568A0000|112 133|nodulation efficiency
P08429568A0000|175 188|alfalfa roots
P08429019A2022|14 24|competitor
P08429019A2022|40 62|YY1 consensus sequence
P08429019A2022|175 183|ABSTRACT
P08429019A2022|103 113|competitor
P08428965A1868|95 103|ABSTRACT
P08428965A1868|36 59|CBP/tk binding activity
P08428952A1957|63 78|plastin isoform
P08428952A1957|139 148|intestine
P08428952A1957|119 125|levels
P08428940A1763|194 203|merR mRNA
P08428940A1763|180 190|initiation
P08428940A1763|142 148|result
P08428940A1763|87 96|occupancy
P08428750T0000|64 75|protein CLP
P08428750T0000|1 13|Localization
P08427501A0221|75 90|enzyme activity
P08427501A0221|31 37|groups
P08427501A0221|108 123|enzyme activity
P08427501A0221|174 180|polyps
P08425050A0898|62 69|repeats
P08425050A0898|23 29|repeat
P08425050A0898|141 149|sequence
P08422975A1205|24 33|necessity
P08422975A1205|38 45|editing
P08421897A0000|164 174|DNA probes
P08421897A0000|129 153|stringency hybridization
P08421897A0000|201 224|animal retrovirus genes
P08421897A0000|17 23|decade
P08420230A0544|29 49|thallium-201 imaging
P08420230A0544|8 24|echocardiography
P08420230A0544|1 6|SAECG
P08419338A0273|92 94|H.
P08419338A0273|51 53|X.
P08419338A0273|85 90|Murer
P08419338A0273|77 79|M.
P08419338A0273|39 41|J.
P08419338A0273|64 66|A.
P08419338A0273|1 3|L.
P08419318A1695|1 5|Biol
P08417349A1633|58 67|templates
P08417349A1633|32 43|replication
P08417330A0149|126 149|CYC1-lacZ reporter gene
P08417330A0149|54 64|oligo31/32
P08417330A0149|35 52|promoter fragment
P08416977A0892|41 46|CTDK2
P08416977A0892|86 93|Mono Q.
P08415712A1153|107 112|genes
P08415712A1153|124 135|chromosomes
P08415712A1153|67 72|GPRK6
P08415712A1153|233 243|chromosome
P08415637A0000|30 33|ARF
P08415637A0000|57 68|subfamilies
P08415637A0000|76 91|RAS superfamily
P08415637A0000|138 148|G proteins
P08414410A0270|134 147|field defects
P08414410A0270|28 32|eyes
P08414410A0270|111 115|eyes
P08414410A0270|82 88|fields
P08414410A0270|1 8|METHODS
P08413274A0452|11 15|HeLa
P08413274A0452|20 30|Raji cells
P08413274A0452|1 5|MDBP
P08413239A0490|230 238|mutation
P08413239A0490|189 199|vertebrate
P08413239A0490|98 111|U snRNA genes
P08413239A0490|154 168|U2 transcripts
P08413239A0490|50 61|3-10AGTNNAA
P08413215A0327|41 60|NF-kappa B subunits
P08413215A0327|22 29|ability
P08413205A0733|181 201|recognition sequence
P08413205A0733|11 35|transfection experiments
P08413205A0733|110 123|transcription
P08413205A0733|71 72|b
P08413205A0733|50 64|Pax-8 isoforms
P08413186A0077|196 211|reductase genes
P08413186A0077|158 168|expression
P08413186A0077|237 244|enzymes
P08412662A0333|74 94|transposon insertion
P08412662A0333|66 70|site
P08412662A0333|38 41|DNA
P08412662A0333|138 155|kb EcoRI fragment
P08412120A0839|53 54|P
P08412120A0839|1 5|Skin
P08411024T0000|41 47|option
P08410042T0000|62 68|report
P08410042T0000|76 81|cases
P08409284A0262|90 96|system
P08409284A0262|225 232|cholera
P08409284A0262|192 197|stage
P08409284A0262|11 21|absorption
P08409284A0262|110 121|amino acids
P08409284A0262|69 80|amino acids
P08408841A0281|104 113|mutations
P08408841A0281|42 53|mutagenesis
P08408194T0000|29 50|membrane-cytoskeleton
P08408194T0000|159 168|epithelia
P08408194T0000|55 63|cadherin
P08408194T0000|16 21|roles
P08406497A0000|95 110|Marfan syndrome
P08406497A0000|23 27|FBN1
P08406497A0000|1 8|Defects
P08406352A0172|90 98|controls
P08406352A0172|180 206|Veterans Affairs hospitals
P08406352A0172|122 127|study
P08406352A0172|245 252|receipt
P08406352A0172|138 146|veterans
P08406352A0172|220 228|controls
P08405433A0000|95 97|P4
P08405433A0000|42 48|IGF-II
P08405433A0000|50 54|gene
P08405433A0000|84 86|P2
P08403245A1234|1 29|Plasma thromboxane B2 levels
P08401570A0828|164 169|sites
P08401570A0828|46 70|transcription factor Sp1
P08401570A0828|143 152|enhancers
P08400240A0166|72 75|LCR
P08400240A0166|11 32|hypersensitivity site
P08400240A0166|36 39|HS2
P08400240A0166|84 101|gamma-globin gene
P08397123T0000|11 19|activity
P08397123T0000|161 172|transcripts
P08397123T0000|69 105|corticotropin-releasing hormone gene
P08396749A1112b|63 69|mmol/l
P08396749A1112b|157 162|mg/dl
P08396749A1112b|87 98|simvastatin
P08396749A1112b|1 16|LDL cholesterol
P08396713A0305|104 109|cells
P08396713A0305|227 245|heat shock protein
P08396713A0305|92 100|extracts
P08396713A0305|7 18|experiments
P08396713A0305|49 53|form
P08396657A0452|1 4|Liu
P08396120A0690|5 34|rhaB transcription start site
P08395654T0000|15 21|factor
P08395654T0000|67 77|expression
P08395654T0000|85 103|rat aromatase gene
P08395010T0000|126 137|heterodimer
P08395010T0000|71 85|acid receptors
P08395010T0000|103 112|responses
P08395004A0141|150 158|increase
P08395004A0141|172 188|HIS4 mRNA levels
P08395004A0141|16 30|spt2 mutations
P08394464A1080|93 97|p2/2
P08394464A1080|114 117|p20
P08394464A1080|51 57|masses
P08394019A0695|151 154|Fyn
P08394019A0695|52 59|Fyn SH2
P08394019A0695|70 85|SH2/SH3 domains
P08394019A0695|1 14|Precipitation
P08392623A1374|135 146|amino acids
P08392623A1374|108 118|C terminus
P08392623A1374|1 21|IE2-IE2 interactions
P08391748A0452|120 136|QRS prolongation
P08391748A0452|247 248|%
P08391748A0452|190 198|patients
P08391748A0452|84 92|patients
P08391748A0452|163 178|QT prolongation
P08391748A0452|337 353|QRS prolongation
P08391748A0452|64 76|contractions
P08390831A0143|126 130|risk
P08390831A0143|23 32|leukaemia
P08390831A0143|71 80|leukaemia
P08390831A0143|1 11|Recipients
P08390665A0000|57 67|generation
P08390665A0000|197 215|resonance oximetry
P08390665A0000|113 125|crystallites
P08390665A0000|1 23|Lithium phthalocyanine
P08389453A0193|46 50|step
P08389453A0193|58 72|repair pathway
P08389074A1227|63 74|RNA binding
P08389074A1227|79 106|activation domain functions
P08389074A1227|1 10|Mutations
P08389074A1227|152 161|structure
P08388543A1263|226 235|cell line
P08388543A1263|148 168|calcium mobilization
P08388543A1263|93 96|Ras
P08388543A1263|197 210|GDP/GTP state
P08388543A1263|113 123|activation
P08388543A1263|33 44|Y977F/Y989F
P08388496A1117|214 221|B cells
P08388496A1117|126 133|passage
P08388496A1117|163 182|BamHI-A transcripts
P08388496A1117|352 357|mRNAs
P08388496A1117|1 11|Expression
P08387743A0624|44 50|region
P08387743A0624|156 179|Mn-superoxide dismutase
P08387743A0624|70 77|mutants
P08387519A0000|91 95|pair
P08387519A0000|203 212|myoblasts
P08387519A0000|184 199|gene expression
P08387519A0000|152 160|myotubes
P08387507A1015|29 42|MyoD function
P08387507A1015|124 129|serum
P08387507A1015|5 15|regulation
P08387507A1015|19 24|Myf-5
P08387507A1015|259 283|myoblast differentiation
P08386637A1220|88 89|h
P08386637A1220|145 146|%
P08386637A1220|20 29|situation
P08386637A1220|115 125|regulation
P08386319A1229|44 52|tyrosine
P08386319A1229|160 174|Mpk1p function
P08386319A1229|101 114|phenylalanine
P08386319A1229|119 126|alanine
P08386317T0000|9 31|protein phosphatase 2A
P08386317T0000|49 63|protein kinase
P08386279A1621|164 189|HIV-1 promoter activation
P08386279A1621|144 149|cells
P08386279A1621|80 89|cell line
P08386279A1621|33 38|EBNA2
P08385337A0282|74 93|consensus sequences
P08385337A0282|124 139|leucine zippers
P08385337A0282|67 72|C/EBP
P08385337A0282|3 22|sequence comparison
P08385337A0282|35 65|CCAAT/enhancer binding protein
P08384309A0000|56 71|dioxin receptor
P08384309A0000|231 243|target genes
P08384309A0000|81 100|signal transduction
P08384309A0000|258 282|dioxin response elements
P08383622T0000|120 140|ETS domain activator
P08383622T0000|13 17|GABP
P08383622T0000|58 87|cytochrome oxidase expression
P08383622T0000|1 9|Identity
P08383492A1205|176 195|cytochrome oxidases
P08383492A1205|65 75|aa stretch
P08383492A1205|207 225|c-type cytochromes
P08383287A0611|44 52|estrogen
P08383287A0611|57 87|thyroid hormone responsiveness
P08383214A0389|29 44|Trp-595-Tyr-596
P08383214A0389|23 25|RT
P08383214A0389|48 51|Pol
P08382778A0891|126 131|TFIIE
P08382778A0891|76 82|region
P08382778A0891|86 97|Raf kinases
P08382778A0891|138 159|transcription factors
P08382359A0469|45 56|interaction
P08382359A0469|77 92|tumor induction
P08382359A0469|249 260|experiments
P08382359A0469|140 155|point mutations
P08382359A0469|33 39|extent
P08382359A0469|100 105|virus
P08382303A0507|121 127|region
P08382303A0507|76 92|papillomaviruses
P08382303A0507|5 7|E1
P08382296A0766|13 15|F.
P08381121A0773|62 68|domain
P08380736A0895|94 108|amino terminus
P08380736A0895|38 46|splicing
P08377199A1432|105 116|recognition
P08377199A1432|25 30|patch
P08376397A0788|83 89|number
P08376397A0788|5 24|binding specificity
P08376397A0788|71 74|E2F
P08374753A0335|75 80|water
P08374753A0335|16 31|relaxation time
P08373274A0546|60 65|doses
P08373274A0546|101 112|endotoxemia
P08371713T0000|74 83|rat brain
P08371713T0000|49 68|endothelin receptor
P08370275A0290|62 69|testing
P08370275A0290|89 93|pair
P08370275A0290|5 15|chimpanzee
P08370119A0642|54 56|bp
P08370119A0642|87 96|sequences
P08370119A0642|184 215|muscle cell AT1a receptor cDNAs
P08367487A1014|88 110|HeLa splicing extracts
P08367487A1014|196 206|antibodies
P08367487A1014|70 83|12S U2 snRNPs
P08367487A1014|136 145|U2 snRNPs
P08366034A0637|29 46|cysteine residues
P08366034A0637|159 164|cells
P08366034A0637|48 66|carboxymethylation
P08363332A0365|105 109|apex
P08363332A0365|151 156|sinus
P08363332A0365|271 276|heart
P08363332A0365|42 50|activity
P08363332A0365|18 27|recording
P08361755A0734|13 23|conditions
P08361755A0734|182 190|CArG box
P08361755A0734|25 38|transfections
P08361755A0734|158 173|NF-kappa B site
P08361755A0734|115 121|factor
P08360180A1041|211 221|progenitor
P08360180A1041|109 115|degree
P08360180A1041|20 32|barley PSI-K
P08360180A1041|169 173|gene
P08357834A0285|31 51|amino acid sequences
P08357834A0285|209 215|degree
P08357834A0285|176 186|% homology
P08357834A0285|219 240|sequence conservation
P08357834A0285|3 13|comparison
P08357834A0285|69 85|PKC-delta clones
P08356792T0000|63 74|T-cell line
P08356792T0000|1 23|HTLV-1 gene expression
P08355857A1293|26 34|patients
P08355857A1293|67 74|patient
P08355857A1293|4 13|elevation
P08355696A0236|46 66|UV response elements
P08355696A0236|5 17|UV induction
P08355539A0133|62 70|etiology
P08355539A0133|260 265|study
P08355539A0133|185 188|EAA
P08355539A0133|84 89|study
P08355539A0133|105 115|antibodies
P08355539A0133|233 236|EAT
P08355539A0133|136 143|disease
P08355062A0000|15 23|emission
P08355062A0000|166 174|patients
P08355062A0000|95 100|HMPAO
P08355062A0000|126 133|changes
P08355062A0000|33 43|tomography
P08352066A0000|27 41|beta-estradiol
P08352066A0000|67 82|bone resorption
P08352066A0000|136 140|bone
P08350061A0209|106 132|T cell development program
P08350061A0209|65 73|CD8 gene
P08349499A1169|14 21|variate
P08349499A1169|58 63|width
P08349499A1169|67 73|muzzle
P08349104A0000|30 34|GAL1
P08349104A0000|212 216|UASG
P08349104A0000|39 50|GAL10 genes
P08349104A0000|101 110|galactose
P08349104A0000|85 97|availability
P08347677A0308|62 68|number
P08347677A0308|265 273|peptides
P08347677A0308|83 100|arginine residues
P08347677A0308|235 244|substrate
P08347677A0308|169 175|serine
P08347677A0308|119 134|arginyl cluster
P08344248A0910|63 69|growth
P08343216A0883|14 36|IgG subclass responses
P08342703A0966|91 107|outflow pressure
P08342703A0966|130 139|flow rate
P08342703A0966|59 68|flow rate
P08342703A0966|20 24|mu W
P08337841A0612|243 244|A
P08337841A0612|260 271|nucleotides
P08337841A0612|157 162|AACAG
P08337841A0612|184 190|G gene
P08337841A0612|99 103|mRNA
P08337841A0612|171 176|start
P08337841A0612|34 39|ARV G
P08336738A1273|46 50|T-47
P08336738A1273|37 41|H-87
P08336543A0243|60 61|F
P08336543A0243|22 30|families
P08336543A0243|55 56|A
P08336543A0243|69 70|V
P08336543A0243|34 45|L1 elements
P08335710A0338|47 57|resolution
P08334304A0473|46 56|activation
P08334304A0473|110 118|addition
P08334304A0473|64 71|pathway
P08334304A0473|33 41|capacity
P08333643A0000|56 66|discussion
P08333643A0000|25 34|condition
P08332492A0145|30 36|family
P08332492A0145|121 148|immunodeficiency virus type
P08332492A0145|159 168|infection
P08332492A0145|5 11|member
P08332492A0145|152 157|HIV-1
P08331728A0686|29 46|ribonucleoprotein
P08331064A0440|27 35|pressure
P08331064A0440|1 8|Release
P08331064A0440|51 54|way
P08325883A0368|193 206|alpha-helixes
P08325883A0368|162 168|region
P08325883A0368|5 13|sequence
P08325883A0368|136 142|region
P08325639A0129|10 17|studies
P08325639A0129|37 51|20S proteasome
P08325639A0129|142 161|proteinase activity
P08325639A0129|237 246|ubiquitin
P08324792T0000|45 51|pacing
P08324792T0000|22 28|period
P08324107A0000|15 36|albumin concentration
P08324107A0000|71 72|%
P08322823A0839|44 47|MFA
P08322823A0839|56 64|severity
P08321741A0396|211 212|%
P08321741A0396|31 34|BMB
P08321741A0396|11 16|group
P08321741A0396|245 248|CML
P08321741A0396|292 293|%
P08321741A0396|220 228|patients
P08321203A0840|58 69|C/EBP alpha
P08321203A0840|87 98|C/EBP delta
P08321203A0840|17 20|p50
P08320120A0361|126 135|diffusion
P08320120A0361|191 195|area
P08320120A0361|139 157|sodium fluorescein
P08319396A0448|211 215|limb
P08319396A0448|122 131|tegmentum
P08319396A0448|28 43|intensity areas
P08319396A0448|253 257|part
P08319396A0448|51 59|thalamus
P08319396A0448|232 239|capsule
P08319396A0448|4 6|T2
P08319396A0448|274 282|peduncle
P08317092A0304|241 247|tobamo
P08317092A0304|197 220|RNA replication complex
P08317092A0304|116 136|RNA polymerase motif
P08317092A0304|70 84|helicase motif
P08316209A0000|28 34|sulfur
P08316209A0000|95 105|expression
P08316209A0000|159 166|enzymes
P08316209A0000|64 81|Neurospora crassa
P08316209A0000|170 187|sulfur catabolism
P08314922A0941|58 75|perfusion changes
P08314922A0941|85 98|brain surface
P08312243A0177|194 199|diets
P08312243A0177|77 83|levels
P08312243A0177|127 131|rats
P08312243A0177|99 101|Zn
P08312243A0177|139 152|Zn-sufficient
P08309957A0000|134 149|agent reserpine
P08309957A0000|92 106|administration
P08309957A0000|5 16|experiments
P08309912A0306|39 48|treatment
P08308008A0201|121 125|unit
P08308008A0201|176 190|COXIV promoter
P08308008A0201|36 43|binding
P08308008A0201|80 99|ets sequence motifs
P08307338A0227|74 85|degradation
P08307338A0227|26 35|gene CBP1
P08307338A0227|127 130|cob
P08307338A0227|64 70|result
P08306834A0866|44 51|benefit
P08306834A0866|68 79|irradiation
P08305058T0000|1 13|Pneumothorax
P08304301A0331|123 127|HCCs
P08304301A0331|54 61|nodules
P08304301A0331|21 26|cases
P08302589A1132|88 102|protein kinase
P08302589A1132|142 145|Ca2
P08302589A1132|17 30|cell motility
P08301702A1083|181 186|heron
P08301702A1083|14 24|antibodies
P08301702A1083|78 85|protein
P08300611T0000|104 108|TraI
P08300611T0000|11 17|action
P08300611T0000|125 136|plasmid RP4
P08300611T0000|51 54|DNA
P08300605A0671|92 102|regulation
P08300601A0745|29 39|activation
P08300601A0745|58 62|MyoD
P08300601A0745|6 12|region
P08300463A0581|147 152|cases
P08300463A0581|202 207|cases
P08300463A0581|18 29|Albendazole
P08300463A0581|1 13|Praziquantel
P08299896A0626|53 61|subjects
P08299896A0626|16 27|IBDQ scores
P08299568A1401|26 36|activation
P08299568A1401|86 97|stimulation
P08298129T0000|15 31|characterization
P08298129T0000|77 90|integrin gene
P08298129T0000|1 10|Isolation
P08297376A0236|123 159|rat uncoupling protein gene promoter
P08297376A0236|43 73|CCAAT/enhancer binding protein
P08297376A0236|196 202|region
P08297376A0236|20 38|expression vectors
P08294906A1315|121 132|amino acids
P08294906A1315|41 68|neurotransmitters glutamate
P08294906A1315|138 147|substrate
P08294511A0639|15 23|evidence
P08294511A0639|97 104|protein
P08294511A0639|136 156|snRNP core particles
P08294429A0153|91 124|chloramphenicol acetyltransferase
P08294429A0153|161 165|cAMP
P08294429A0153|128 144|luciferase genes
P08294429A0153|36 39|hGH
P08294429A0153|187 208|hGH promoter activity
P08293993A0948|123 148|invertase signal sequence
P08293993A0948|1 4|ENV
P08293412T0000|47 55|efficacy
P08293412T0000|182 192|prevention
P08293412T0000|95 120|5-HT3 receptor antagonist
P08293412T0000|76 87|tropisetron
P08291761A0416|39 46|effects
P08291761A0416|1 11|Animal age
P08291761A0416|50 65|CSF composition
P08291233A0000|141 163|Rous sarcoma virus LTR
P08291233A0000|101 106|probe
P08290278A0374|12 16|Mxi1
P08290278A0374|42 54|Myc function
P08289831A0290|30 40|constructs
P08289831A0290|13 20|mig/CAT
P08289831A0290|158 168|gamma RE-1
P08289831A0290|1 9|Analysis
P08289784A0381|20 22|M.
P08289783A0000|62 83|transcription factors
P08289783A0000|128 153|differentiation decisions
P08289783A0000|48 58|POU family
P08289357A0724|53 61|function
P08289357A0724|101 104|LTR
P08289341A1202|44 46|E2
P08289341A1202|96 101|E2-RS
P08289341A1202|1 11|Repression
P08288633A0144|195 202|segment
P08288633A0144|97 116|amino acid residues
P08288633A0144|295 308|Rho subfamily
P08288633A0144|279 287|proteins
P08288633A0144|222 236|protein region
P08288633A0144|17 20|DNA
P08288606A0240|72 85|pair fragment
P08288606A0240|95 105|sialymotif
P08288606A0240|157 162|probe
P08288606A0240|185 200|coding sequence
P08288606A0240|222 226|gene
P08288554A0295|40 55|mouse HO-1 gene
P08288554A0295|80 83|p32
P08288240A0304|44 49|SCG10
P08288240A0304|5 24|sequence similarity
P08285710A0634|104 112|position
P08285710A0634|145 155|initiation
P08285710A0634|159 176|protein synthesis
P08285710A0634|116 118|bp
P08285710A0634|17 32|transcript mRNA
P08284227A0336|107 126|cell types Id1 mRNA
P08284227A0336|77 80|Id1
P08284227A0336|158 171|cycling cells
P08284227A0336|205 213|cultures
P08283292A0779|144 150|groups
P08283292A0779|188 193|fiber
P08283292A0779|1 7|Plasma
P08283292A0779|221 234|control group
P08283292A0779|119 126|control
P08282576A0297|31 41|oropharynx
P08282576A0297|1 8|Tumours
P08281740A0000|73 79|cattle
P08281740A0000|111 121|production
P08281740A0000|178 189|ELISA assay
P08281740A0000|83 89|Uganda
P08281740A0000|1 10|Responses
P08281536A0626|39 49|metastasis
P08280925A0261|183 186|IgM
P08280925A0261|148 159|differences
P08280925A0261|125 129|mice
P08280925A0261|191 194|IgG
P08280925A0261|204 214|antibodies
P08279098T0001|32 43|dystrophies
P08278548A0597|11 15|psaF
P08278548A0597|158 170|psaE product
P08278548A0597|114 148|polyacrylamide gel electrophoresis
P08278548A0597|50 58|isoforms
P08278423A0147|126 151|disaccharide intolerances
P08278423A0147|55 58|HIV
P08278423A0147|32 45|abnormalities
P08276900A0543|5 7|K.
P08276865A1188|122 128|p21ras
P08276865A1188|177 191|protein kinase
P08276865A1188|5 35|kinase inhibitor staurosporine
P08276865A1188|204 216|LPA receptor
P08276865A1188|220 237|p21ras activation
P08276851A0347|93 106|relationships
P08276851A0347|293 303|regulation
P08276851A0347|138 146|proteins
P08276851A0347|170 179|processes
P08276732A0799|60 71|time period
P08276732A0799|13 22|decrement
P08276732A0799|26 41|DPOAE amplitude
P08276732A0799|101 115|susceptibility
P08276234A0119|107 121|c-fos promoter
P08276234A0119|26 29|YY1
P08276234A0119|153 166|DNA structure
P08274774A0958|151 157|TMV-U5
P08274774A0958|14 26|REP21 plants
P08274774A0958|73 86|tobamoviruses
P08274774A0958|97 116|tomato mosaic virus
P08274774A0958|64 69|range
P08274774A0958|137 149|mosaic virus
P08270257A0551|60 72|homolog gene
P08270257A0551|44 51|nm23-H1
P08270257A0551|3 29|sequence homology analysis
P08270257A0551|85 95|NDP-K beta
P08269424A0339|54 65|ACTH levels
P08269424A0339|18 32|administration
P08269424A0339|117 125|patients
P08268833T0000|58 69|application
P08268833T0000|84 93|arthritis
P08267667A0748|209 210|F
P08267667A0748|28 32|GRg2
P08267667A0748|366 384|h memory retention
P08267667A0748|386 387|F
P08267667A0748|187 207|learning acquisition
P08267667A0748|496 497|p
P08267667A0748|400 401|p
P08267667A0748|36 41|mg/kg
P08267667A0748|100 108|deficits
P08265955T0000|11 17|change
P08264664A0128|12 22|expression
P08264664A0128|96 105|promoters
P08264664A0128|1 9|TGF beta
P08264631A0746|66 69|TAD
P08264631A0746|87 103|ADR1 DNA binding
P08264631A0746|118 141|ADH2 promoter sequences
P08264617A0000|13 23|expression
P08264617A0000|143 169|ErbB-3 signal transduction
P08264617A0000|175 192|ligand activation
P08264583A0520|150 157|ability
P08264583A0520|62 70|extracts
P08264583A0520|41 44|end
P08264583A0520|118 128|cell lines
P08264579A1209|108 130|peptide transport gene
P08264579A1209|5 12|cloning
P08262067A1608|28 32|Cwg2
P08262067A1608|78 85|control
P08262067A1608|161 174|establishment
P08262067A1608|178 191|cell polarity
P08262067A1608|115 119|link
P08262041A0727|107 117|cell cycle
P08262041A0727|53 59|extent
P08262041A0727|33 47|phosphoprotein
P08261398A0392|133 143|transcript
P08261398A0392|110 118|addition
P08261398A0392|174 190|P388/4 cell line
P08259650A0640|58 65|mutants
P08259650A0640|80 82|HA
P08259650A0640|84 93|phenotype
P08257754A0711|149 162|HB antibodies
P08257754A0711|72 85|HB antibodies
P08257754A0711|127 131|ones
P08257754A0711|55 66|individuals
P08257754A0711|136 137|%
P08255758A0000|106 109|LTR
P08255758A0000|142 152|regulation
P08255758A0000|156 169|homeoproteins
P08255022A0827|74 77|V25
P08255022A0827|147 164|blood cell counts
P08255022A0827|5 11|degree
P08255022A0827|115 127|blood volume
P08253958A0000|45 53|presence
P08253958A0000|25 30|tests
P08253958A0000|3 9|number
P08253387A1291|224 232|enhancer
P08253387A1291|109 127|TCR alpha enhancer
P08253387A1291|199 206|factors
P08253387A1291|64 68|cell
P08253387A1291|168 172|hLEF
P08253386A0800|199 210|interaction
P08253386A0800|232 253|branch site sequences
P08253386A0800|98 108|SE element
P08253386A0800|35 41|action
P08252067A0917|60 72|COOH termini
P08252067A0917|133 145|conservation
P08252067A0917|52 55|NH2
P08252067A0917|100 110|similarity
P08251506A0503|104 107|kDa
P08251506A0503|127 135|proteins
P08251506A0503|65 74|complexes
P08249319A0578|105 110|field
P08249319A0578|71 75|peak
P08248253A1785|54 62|enhancer
P08248253A1785|71 89|chicken L-CAM gene
P08247043T0000|1 12|Hepatitis B
P08246987A0260|91 94|SH2
P08246987A0260|37 50|kinase domain
P08246987A0260|143 149|region
P08246987A0260|4 12|addition
P08246984A0512|89 99|cell lines
P08246984A0512|58 69|PI 3-kinase
P08246984A0512|38 48|expression
P08246984A0512|16 24|analysis
P08245461A0700|123 128|stage
P08245461A0700|37 43|number
P08245461A0700|1 25|Hu-Met-1 mRNA expression
P08245125A0822|88 95|ability
P08245125A0822|115 125|degrees C.
P08245125A0822|35 49|F-actin nuclei
P08244034T0000|111 128|metalloproteinase
P08242861A0368|22 31|A alpha C
P08242861A0368|50 56|p.p.b.
P08241139A0378|74 80|MgdTDP
P08241139A0378|124 135|nucleotides
P08241139A0378|113 120|absence
P08239586T0000|44 58|nephrotoxicity
P08239586T0000|12 21|diltiazem
P08238626A0248|91 101|blood flow
P08238626A0248|24 42|baseline brain pHi
P08238626A0248|6 11|PaCO2
P08238626A0248|119 121|ml
P08237171A0000|72 79|patient
P08237171A0000|33 44|enlargement
P08234308T0000|11 21|retraction
P08234166A0425|108 114|humans
P08234166A0425|67 77|conditions
P08234166A0425|99 103|dogs
P08234166A0425|118 126|capsules
P08232304A1166|44 52|fragment
P08232304A1166|93 110|promoter activity
P08232304A1166|3 9|series
P08231577A1027|106 111|apnea
P08231577A1027|23 29|larynx
P08230452A1489|14 29|capsid proteins
P08230452A1489|209 216|virions
P08230452A1489|144 160|capsid particles
P08230452A1489|112 115|VP1
P08230452A1489|117 126|VP1-G001V
P08230445A0000|29 42|reading frame
P08230445A0000|144 151|virions
P08230445A0000|83 88|HIV-1
P08230445A0000|20 23|vpr
P08229826A1145|104 112|activity
P08229826A1145|132 139|muscles
P08229826A1145|16 24|response
P08229102A0768|106 114|patients
P08229102A0768|66 76|instrument
P08228805A0540|63 97|guanine nucleotide binding protein
P08228805A0540|20 28|molecule
P08228805A0540|140 163|protein tyrosine kinase
P08228805A0540|32 55|TCR signal transduction
P08226956A1397|82 91|fad7 mRNA
P08226956A1397|33 51|growth temperature
P08226794A0501|8 10|Dk
P08226794A0501|2 7|Ala85
P08226777A0936|3 29|Dictyostelium transformant
P08226616A0000|124 128|step
P08226616A0000|5 15|nit-3 gene
P08226616A0000|35 59|fungus Neurospora crassa
P08224907A0000|106 118|band pattern
P08224907A0000|9 31|Southern blot analysis
P08224907A0000|35 43|rat EFIA
P08223875A0711|88 92|CD45
P08223875A0711|177 182|cells
P08223875A0711|114 119|cells
P08223875A0711|17 19|3H
P08223875A0711|108 112|CD45
P08223875A0711|1 12|Stimulation
P08223613A0519|134 142|subunits
P08223613A0519|88 98|genes TPS2
P08223613A0519|22 30|sequence
P08223613A0519|103 107|TSL1
P08223613A0519|221 229|function
P08223592A0424|177 181|gene
P08223592A0424|127 133|leader
P08223592A0424|81 105|transcription start site
P08223554A0574|29 46|polypeptide chain
P08223554A0574|66 72|enzyme
P08223554A0574|81 96|transit peptide
P08222618A0000|64 72|analysis
P08222618A0000|85 91|curves
P08222384A0455|47 57|parameters
P08222384A0455|65 90|surface electrocardiogram
P08222384A0455|118 121|ECG
P08220621T0000|48 54|system
P08219227A0830|73 78|level
P08219227A0830|145 153|sequence
P08219227A0830|159 170|replacement
P08219227A0830|38 42|copy
P08219227A0830|1 12|Replacement
P08219072A0287|1 5|Acad
P08218230A1505|58 70|binding site
P08218230A1505|143 148|HNF-1
P08218230A1505|154 163|positions
P08218230A1505|34 42|sequence
P08217862A1336|180 186|number
P08217862A1336|95 102|ability
P08217862A1336|157 165|subjects
P08217862A1336|256 262|states
P08213747A0000|91 100|infection
P08213747A0000|215 222|factors
P08213747A0000|159 162|men
P08213747A0000|352 381|baseline HIV-1 seroprevalence
P08213747A0000|256 264|diseases
P08213747A0000|84 89|HIV-1
P08213747A0000|104 106|US
P08213747A0000|496 503|centers
P08213747A0000|33 43|prevalence
P08213747A0000|511 524|United States
P08213747A0000|304 311|authors
P08213747A0000|137 140|men
P08212897A0404|65 73|presence
P08212897A0404|35 52|methyltransferase
P08212571A0597|166 173|effects
P08212571A0597|56 63|viruses
P08212571A0597|126 142|virus production
P08212571A0597|37 44|plasmid
P08212571A0597|1 16|Co-transfection
P08209423T0000|31 50|nucleotide sequence
P08209423T0000|58 84|MDV-1 BamHI-D DNA fragment
P08209423T0000|99 107|splicing
P08208618A1334|25 32|HR21Xap
P08208618A1334|55 65|inhibition
P08208540A0417|45 50|cDNAs
P08208540A0417|149 151|kD
P08208540A0417|127 135|proteins
P08208540A0417|83 91|splicing
P08208540A0417|257 273|carboxy-terminus
P08208540A0417|153 159|p84/85
P08208247T0030|12 20|analysis
P08208247T0030|36 48|segment 64AB
P08207795A0409|41 61|phosphorylation site
P08207795A0409|76 83|protein
P08207232A0503|90 97|members
P08207232A0503|56 63|NF-IL-6
P08207232A0503|139 151|NF-IL-6 site
P08206991A0466|132 145|palmitylation
P08206991A0466|56 61|Gly-2
P08206991A0466|163 168|Cys-3
P08206991A0466|20 36|palmitate analog
P08206991A0466|1 10|Acylation
P08206848A0296|72 78|masses
P08206848A0296|5 9|pyrR
P08204824A0000|121 129|cultures
P08204824A0000|133 143|periwinkle
P08204824A0000|95 105|cell cycle
P08204824A0000|25 35|cyc07 gene
P08204403A0000|121 144|radioimmunoscintigraphy
P08204403A0000|192 202|antibodies
P08204403A0000|106 117|sensitivity
P08204403A0000|38 46|patients
P08204403A0000|169 175|CEA/CA
P08203260A1204|22 26|SIMV
P08203260A1204|48 56|neonates
P08201932A0355|13 24|examination
P08201352A0239|109 113|risk
P08201352A0239|8 12|case
P08201352A0239|117 130|skin necrosis
P08199878T0000|5 12|effects
P08199878T0000|50 66|brain metabolism
P08198524A1134|4 7|kDa
P08196618A0473|126 134|activity
P08196618A0473|1 6|PRL-1
P08196607A0280|122 132|CATTCATCCG
P08196607A0280|92 108|sequence element
P08196607A0280|178 184|carbon
P08196607A0280|202 212|regulation
P08196607A0280|51 65|identification
P08195217A0799|182 186|gels
P08195217A0799|144 158|sodium dodecyl
P08195186A0000|211 220|RNA blots
P08195186A0000|297 303|Finley
P08195186A0000|257 270|T lymphocytes
P08195186A0000|195 204|ecoR/CAT1
P08195186A0000|44 56|T lymphocyte
P08195186A0000|11 24|cDNA sequence
P08195186A0000|142 152|retrovirus
P08195186A0000|275 280|liver
P08195186A0000|171 193|amino acid transporter
P08194753A0157|72 77|boxes
P08194753A0157|56 60|MluI
P08194753A0157|38 43|rhp51
P08194753A0157|139 145|region
P08194139A0498|62 72|variations
P08194139A0498|1 12|CONCLUSIONS
P08192795T0000|29 36|purpura
P08192140A0209|120 133|San Francisco
P08192140A0209|135 136|n
P08192140A0209|41 67|hepatitis B vaccine trials
P08192140A0209|5 17|participants
P08192140A0209|34 37|men
P08190633A0273|89 92|DNA
P08190633A0273|78 80|kb
P08189533A0919|164 171|cytosol
P08189533A0919|179 190|association
P08189533A0919|33 52|immunoblot analyses
P08189533A0919|139 143|NS53
P08189533A0919|102 107|cells
P08189503A0000|104 107|RNA
P08189503A0000|122 142|cassette mutagenesis
P08189503A0000|109 116|pMIDI-C
P08189503A0000|169 180|coronavirus
P08189174A0148|94 117|breast cancer screening
P08189174A0148|22 27|study
P08189174A0148|49 54|women
P08189174A0148|136 140|city
P08188606A1034|62 70|presence
P08188606A1034|213 223|chromosome
P08188606A1034|1 21|Restriction analysis
P08188606A1034|187 205|cadmium resistance
P08188290A0544|88 104|polymerase chain
P08188290A0544|142 152|expression
P08188290A0544|171 190|TCRAJ gene segments
P08187177A0405|77 88|interaction
P08187177A0405|35 38|CPY
P08187085A0086|124 137|end sequences
P08187085A0086|76 98|tyrosine kinase domain
P08187085A0086|36 45|formation
P08184923A0829|107 115|exposure
P08184923A0829|92 93|%
P08184923A0829|76 80|CeBF
P08184923A0829|70 71|%
P08183915A0000|46 55|precursor
P08183915A0000|148 163|I kappa B gamma
P08183915A0000|78 109|transcription factor NF-kappa B
P08183915A0000|5 9|gene
P08183915A0000|221 225|p105
P08182171A0000|5 13|efficacy
P08182171A0000|19 50|Propionibacterium acnes product
P08182041A1067|56 65|induction
P08182041A1067|78 81|PKA
P08182041A1067|5 12|results
P08182041A1067|86 96|inhibition
P08182041A1067|100 107|insulin
P08180129A1256|53 60|content
P08180129A1256|70 81|transcripts
P08178572A1118|61 71|base pairs
P08178572A1118|98 105|protein
P08178446A1160|104 108|role
P08178446A1160|76 86|TM segment
P08178446A1160|5 9|data
P08176742A0190|29 45|assay conditions
P08176742A0190|71 92|transposition pathway
P08173693A0390|72 80|patients
P08173693A0390|43 54|innervation
P08172905A0000|31 54|alanine tRNA synthetase
P08172905A0000|125 137|alanine tRNA
P08172905A0000|5 10|class
P08172905A0000|69 85|RNA miniduplexes
P08172598A0237|27 31|mRNA
P08172598A0237|50 64|N. patriciarum
P08170400T0000|14 25|orientation
P08170400T0000|43 49|region
P08170400T0000|1 9|Location
P08169201A0291|31 39|sequence
P08169201A0291|107 126|nucleotide sequence
P08167396A0154|74 104|substantia nigra pars compacta
P08164684A1266|105 112|complex
P08164684A1266|36 40|acid
P08164684A1266|16 19|RXR
P08164679A0809|1 23|Transactivation domain
P08164302A0547|120 132|energy level
P08164302A0547|158 165|glucose
P08164302A0547|69 89|nutrient composition
P08163183T0000|90 100|sequencing
P08163183T0000|31 35|gene
P08163183T0000|37 41|xylA
P08163183T0000|81 88|cloning
P08160387T0000|60 66|cortex
P08160387T0000|90 100|experience
P08160387T0000|41 44|rat
P08160387T0000|22 33|development
P08159174A0581|5 13|presence
P08157663A0882|181 187|family
P08157663A0882|77 92|vertebrate gene
P08157663A0882|7 14|results
P08157663A0882|191 203|polypeptides
P08157663A0882|169 175|member
P08157009A0264|67 80|sigma subunit
P08157009A0264|38 43|Aps1p
P08157009A0264|1 21|Sequence comparisons
P08154182A0955|43 69|lambda AD5 cloning vectors
P08154182A0955|5 15|usefulness
P08153146A0327|104 114|resistance
P08153146A0327|175 186|artery mean
P08153146A0327|70 81|circulation
P08153146A0327|136 147|artery flow
P08152800A0709|98 113|oligonucleotide
P08152800A0709|187 199|Ets proteins
P08151980T0001|12 21|emphysema
P08151787T0000|26 46|localization domains
P08151787T0000|114 119|IE175
P08151787T0000|155 175|herpes simplex virus
P08151787T0000|51 59|evidence
P08150970A0434|8 20|cutoff level
P08150970A0434|59 66|samples
P08150970A0434|84 92|patients
P08149484A0151|88 99|PKC alpha K
P08149484A0151|63 72|PKC alpha
P08149484A0151|1 20|Expression plasmids
P08148463A0000|176 187|interleukin
P08148463A0000|111 126|granulocyte CSF
P08148463A0000|97 106|monocytes
P08148463A0000|156 170|macrophage CSF
P08145646T0000|15 25|expression
P08145646T0000|106 115|relevance
P08145646T0000|1 10|Structure
P08145646T0000|68 90|Rhodobacter capsulatus
P08144668A0802|74 81|exon VI
P08144668A0802|183 191|sequence
P08144668A0802|109 122|reading frame
P08144668A0802|196 214|membrane anchoring
P08144615A0533|14 20|NF-IL6
P08144615A0533|26 44|endoprotease Asp-N
P08144615A0533|126 132|domain
P08144615A0533|173 181|presence
P08144615A0533|185 188|DNA
P08144615A0533|85 104|NF-IL6 bZIP domains
P08144504T0064|22 33|requirement
P08144470A0711|148 163|protein product
P08144470A0711|5 13|mutation
P08144470A0711|68 78|transition
P08144035A0387|26 33|regions
P08143236A1055|132 138|trials
P08143236A1055|9 24|ethanol regimen
P08143236A1055|86 99|day-1 regimen
P08142875A0877|112 124|intervention
P08142875A0877|81 85|lens
P08139928T0000|13 35|ribonucleoprotein gene
P08139928T0000|1 5|RNP1
P08139577T0000|106 110|TATA
P08139577T0000|25 56|yeast transcription factor IIIB
P08139543A1520|24 32|analysis
P08139543A1520|48 53|NHP6A
P08139542T0000|14 18|mRNA
P08139542T0000|113 134|yeast gene transcript
P08139542T0000|3 10|segment
P08139542T0000|32 46|leader peptide
P08139539A0446|73 77|rise
P08139539A0446|160 170|activation
P08139539A0446|126 130|cAMP
P08139539A0446|174 191|protein kinase A.
P08139539A0446|18 33|m1R stimulation
P08139017A1465|134 150|Ets-1 cDNA clone
P08139017A1465|198 204|tumors
P08139017A1465|188 193|cells
P08139017A1465|21 25|site
P08139017A1465|101 103|bp
P08139001A1235|94 103|cysteines
P08139001A1235|42 57|carboxy termini
P08139001A1235|65 85|NS1 protein molecule
P08138180A0593|44 55|suppressors
P08138180A0593|107 120|SPT10 protein
P08138180A0593|9 14|spt10
P08134115A1161|149 152|myc
P08134115A1161|131 138|ACT-ATT
P08134115A1161|217 219|TT
P08134115A1161|33 47|fusion protein
P08134115A1161|1 7|MSSP-1
P08134115A1161|102 108|TCTTAT
P08133502T0105|33 66|Disease Collaborative Study Group
P08132574A0831|12 15|SVA
P08132574A0831|124 146|cytochrome CYP1A1 gene
P08132574A0831|76 85|kilobases
P08132574A0831|1 8|Members
P08131746A0140|108 118|MEK kinase
P08131746A0140|64 81|activator kinases
P08131746A0140|1 4|MEK
P08130942A0051|49 55|method
P08130942A0051|1 16|Regionalization
P08128629A1164|91 97|p60CRS
P08128629A1164|33 54|gene expression assay
P08128629A1164|102 108|p40CRS
P08126096A1071|78 84|B form
P08126096A1071|159 173|reading frames
P08126096A1071|99 112|coding region
P08125949A1162|121 132|rpl12 genes
P08125949A1162|87 97|AUG codons
P08125949A1162|35 46|translation
P08125949A1162|136 147|Arabidopsis
P08125949A1162|288 298|eubacteria
P08125319A1085|5 15|ipiO genes
P08125319A1085|84 92|homology
P08124956T0000|47 59|pancreatitis
P08124956T0000|84 95|oxygenation
P08124785A0445|13 20|RESULTS
P08124785A0445|53 57|dogs
P08124785A0445|71 97|circumflex artery stenosis
P08124785A0445|252 253|P
P08124785A0445|118 126|decrease
P08122370A0331|134 139|EHV-1
P08122370A0331|40 42|US
P08122370A0331|97 100|PRV
P08122370A0331|114 130|herpesvirus type
P08120029A0864|75 95|sense RNA transcript
P08120029A0864|125 135|R2 message
P08119995A0814|44 64|T3R-RXR heterodimers
P08119995A0814|160 171|nucleotides
P08119995A0814|32 40|function
P08119995A0814|68 85|response elements
P08119995A0814|220 228|sequence
P08119907A0000|26 30|role
P08119907A0000|110 128|signaling pathways
P08119907A0000|103 108|IGF-I
P08118044A0318|39 45|levels
P08118044A0318|98 110|FDC-P1 cells
P08115744A0846|121 146|quality assurance program
P08115744A0846|72 80|analysis
P08114745A0953|90 97|ability
P08114745A0953|132 137|class
P08114745A0953|111 128|termination sites
P08114745A0953|142 151|templates
P08114745A0953|39 43|role
P08114745A0953|48 50|La
P08114702A0000|124 132|sequence
P08114702A0000|66 72|family
P08114702A0000|184 189|genes
P08114702A0000|50 56|factor
P08112870A0484|147 153|masses
P08112870A0484|66 69|SOD
P08112870A0484|19 33|immunoblotting
P08112601T0000|12 24|organization
P08112601T0000|115 122|protein
P08112601T0000|32 36|gene
P08112341A1128|25 27|G.
P08112341A1128|1 3|L.
P08111035A0098|241 247|fusion
P08111035A0098|150 160|expression
P08111035A0098|125 143|beta-glucuronidase
P08111035A0098|113 121|analysis
P08111035A0098|48 68|bp promoter fragment
P08108343A0000|208 213|signs
P08108343A0000|297 318|gonadotropin reserves
P08108343A0000|251 260|diagnosis
P08108343A0000|225 238|insufficiency
P08108343A0000|162 174|hypogonadism
P08108343A0000|142 146|ones
P08108343A0000|100 108|subjects
P08107208A0673|127 129|B.
P08107208A0673|48 56|strategy
P08107208A0673|68 80|recombinants
P08106512A0522|195 201|factor
P08106512A0522|57 70|reporter gene
P08106512A0522|127 138|interferons
P08106512A0522|140 156|interferon-alpha
P08106369A0000|192 195|V1a
P08106369A0000|58 69|nonapeptide
P08106369A0000|197 200|V1b
P08106369A0000|99 100|G
P08106369A0000|236 246|messengers
P08106313A1492|121 125|hrpL
P08106313A1492|27 32|hrpRS
P08106313A1492|84 88|HrpR
P08106313A1492|46 50|part
P08106313A1492|199 204|genes
P08106313A1492|37 41|hrpL
P08106313A1492|169 179|expression
P08106087A0139|72 81|sequences
P08106087A0139|162 183|polyadenylation sites
P08106087A0139|20 26|region
P08105727A0099|61 79|animal experiments
P08105727A0099|1 11|Fenoldopam
P08103935T0000|1 10|Isolation
P08102364A0000|31 38|tobacco
P08102364A0000|1 8|Tobacco
P08101839A0000|89 102|mdr1 promoter
P08101839A0000|58 67|mdr1 gene
P08101839A0000|20 30|regulation
P08101134A0376|63 64|%
P08101134A0376|23 34|plasma ACTH
P08101134A0376|39 47|cortisol
P08100765A0361|30 59|transgene expression patterns
P08100765A0361|140 152|compartments
P08099443A0359|45 62|yeast eIF-2 alpha
P08099443A0359|162 167|yeast
P08099443A0359|142 158|GCN4 translation
P08098882T0001|14 29|desensitization
P08098228A0625|3 13|transcript
P08097666A1135|62 71|potential
P08097666A1135|108 117|frequency
P08097666A1135|141 147|spikes
P08096066A0623|26 34|isolates
P08096066A0623|161 176|drug resistance
P08096066A0623|53 61|patients
P08096066A0623|98 105|strains
P08095872A1672|65 72|timolol
P08095872A1672|185 205|contraction efficacy
P08095872A1672|136 151|LONG/CIRC ratio
P08094927A0311|30 39|mutations
P08094927A0311|47 57|6K protein
P08094927A0311|118 125|virions
P08094464A2014|124 147|base-residue divergence
P08094464A2014|67 77|structures
P08094464A2014|20 37|attenuator region
P08094464A2014|115 120|spots
P08093642A0600|209 221|D10S94 locus
P08093642A0600|78 79|%
P08093642A0600|312 319|testing
P08093642A0600|87 96|RET locus
P08093642A0600|103 143|restriction fragment length polymorphism
P08093642A0600|171 172|%
P08093616A1214|46 50|DREF
P08093616A1214|140 149|sequences
P08093616A1214|1 6|DNase
P08091669A0828|94 107|reading frame
P08091669A0828|129 136|control
P08091669A0828|22 25|P35
P08091669A0828|85 88|p35
P08091655A0000|47 50|MDV
P08091655A0000|24 29|Marek
P08091655A0000|32 45|Disease Virus
P08090746A1288|90 108|promoter sequences
P08090746A1288|9 17|sequence
P08090746A1288|155 184|tomato fruit-ripening E4 gene
P08090746A1288|50 63|region shares
P08089887A0742|11 26|OUTCOME MEASURE
P08089184A0825|18 33|megabase region
P08088777A0754|151 153|Hc
P08088777A0754|123 127|Fpgs
P08088777A0754|94 100|Col5a1
P08088777A0754|81 84|Dbh
P08088777A0754|119 122|Ak1
P08088777A0754|107 117|Spna2-Ab l
P08088777A0754|47 51|data
P08088777A0754|5 25|consensus gene order
P08088777A0754|137 141|Pbx3
P08088022A1417|126 131|heart
P08088022A1417|172 180|ischemia
P08086453T0000|12 29|promoter analysis
P08086453T0000|70 79|APEX gene
P08085782A0164|47 49|cm
P08085782A0164|16 21|cases
P08085228A0000|13 28|characteristics
P08085228A0000|198 216|testing facilities
P08085228A0000|229 233|Tex.
P08085228A0000|33 49|risk factor data
P08085228A0000|118 127|infection
P08085228A0000|220 227|Houston
P08084339A0907|57 70|reading frame
P08084339A0907|112 118|region
P08084339A0907|99 106|J alpha
P08084339A0907|221 243|amino acid polypeptide
P08083998A1723b|7 14|results
P08083998A1723b|100 119|RNA-RNA interaction
P08083963A0795|31 34|VBP
P08083963A0795|63 78|extract protein
P08083963A0795|144 175|methylation interference assays
P08083963A0795|48 54|B-cell
P08083963A0795|17 27|activities
P08083011A0584|88 104|R-L brain weight
P08083011A0584|208 215|females
P08083011A0584|127 131|cats
P08083011A0584|173 185|testosterone
P08083011A0584|137 153|R-L brain weight
P08082360A0411|27 44|oxygen saturation
P08082286A0748|61 66|point
P08082286A0748|88 92|area
P08082286A0748|1 19|Acupuncture effect
P08078473A1107|29 31|S.
P08078473A1107|1 11|Expression
P08078167A0000|26 30|risk
P08078167A0000|1 10|OBJECTIVE
P08076937A0851|162 184|Tru9I restriction site
P08076937A0851|7 16|detection
P08076937A0851|49 70|restriction digestion
P08076937A0851|137 151|point mutation
P08075421A0621b|64 69|HrpJ2
P08075070A1632|105 122|repressor domains
P08075070A1632|74 81|contact
P08075070A1632|183 189|motifs
P08075070A1632|131 150|sequence homologies
P08075070A1632|53 56|DNA
P08075070A1632|85 99|operator sites
P08072547T0000|62 76|protein kinase
P08072547T0000|99 102|ERK
P08072547A0690|151 159|activity
P08072547A0690|97 106|positions
P08072547A0690|69 74|c-Jun
P08071982T0000|37 45|syndrome
P08070654A0574|131 138|protein
P08070654A0574|159 172|Chlamydomonas
P08070654A0574|1 6|CDC31
P08070393A0631|74 76|h.
P08070393A0631|36 45|ng/ml EGF
P08069481A0736|14 25|experiments
P08069481A0736|51 63|calf muscles
P08069298A0492|78 85|sources
P08069298A0492|176 179|LMC
P08069298A0492|19 34|splice variants
P08067546A0000|46 65|vasomotor responses
P08067546A0000|193 198|oxide
P08067546A0000|214 230|vasodilator tone
P08067546A0000|294 297|dog
P08067546A0000|200 202|NO
P08067546A0000|255 279|vasoconstrictor activity
P08067013T0001|120 128|diseases
P08067013T0001|32 65|creatine phosphokinase antibodies
P08065901A0997|31 42|KRAB domain
P08065901A0997|244 253|apparatus
P08065901A0997|5 12|results
P08065901A0997|69 75|region
P08065901A0997|103 116|transcription
P08065366A0918|39 44|Dbf8p
P08065366A0918|64 68|role
P08065338T0000|95 105|duplicates
P08065338T0000|5 10|Oct-2
P08065327A0000|47 58|development
P08065327A0000|131 141|protozoans
P08065310A1144|28 34|heptad
P08065310A1144|57 75|heterodimerization
P08065310A1144|196 216|receptor gene family
P08063836A0904|104 109|c-Abl
P08063836A0904|89 100|DNA binding
P08063836A0904|34 53|c-myc transcription
P08063775T0000|59 74|gene expression
P08063775T0000|1 11|Regulation
P08063108A0109|5 14|acfD gene
P08063108A0109|85 92|protein
P08062824A0626|87 105|isomerase activity
P08062824A0626|16 22|domain
P08058326A0463|44 54|mechanisms
P08058326A0463|130 134|gene
P08058326A0463|16 24|insights
P08057762A0878|30 45|reproducibility
P08057762A0878|73 74|%
P08057762A0878|56 58|T1
P08057762A0878|142 143|%
P08057762A0878|87 102|reproducibility
P08057356A1824|74 88|NarL heptamers
P08057356A1824|25 47|operon control regions
P08057356A1824|1 12|Comparisons
P08056474A0438|61 62|%
P08056474A0438|46 47|%
P08056474A0438|97 98|%
P08055939A0707|30 36|length
P08055939A0707|44 50|intron
P08055939A0707|198 204|domain
P08055939A0707|145 151|region
P08055939A0707|116 122|intron
P08055939A0707|139 143|nose
P08054281A0731|72 81|potential
P08054281A0731|146 153|insight
P08054281A0731|163 175|relationship
P08054281A0731|201 211|malignancy
P08054281A0731|184 196|201Tl uptake
P08051151A0347|110 124|chain reaction
P08051151A0347|54 58|mRNA
P08051074A0000|30 42|footprinting
P08051074A0000|123 131|promoter
P08051074A0000|162 167|DNase
P08051074A0000|84 106|immunodeficiency virus
P08051019A0365|61 70|mechanism
P08049521T0000|124 129|yeast
P08049521T0000|37 45|tyrosine
P08049521T0000|87 93|action
P08049401A0428|127 143|thyroid hormones
P08049401A0428|116 123|changes
P08049401A0428|1 17|Immunodepression
P08048582A0821|126 129|g-1
P08048582A0821|66 69|CFX
P08048582A0821|19 23|MVO2
P08048582A0821|184 201|ml O2.min-1 times
P08045834A0783|27 28|P
P08045834A0783|100 101|P
P08044802A0462|28 46|karyotype analyses
P08044802A0462|89 100|copy number
P08044802A0462|10 23|Southern blot
P08044802A0462|110 124|rearrangements
P08044794A0000|73 80|protein
P08044794A0000|5 21|tumor suppressor
P08041793A0242|12 19|studies
P08041793A0242|53 61|elements
P08041793A0242|141 146|genes
P08040468A0303|82 93|necrobiosis
P08040468A0303|173 182|reactions
P08040336A0435|26 33|element
P08040336A0435|80 88|homology
P08040336A0435|155 157|bp
P08037338A0000|151 158|infants
P08037338A0000|176 180|year
P08037338A0000|112 123|prematurity
P08037338A0000|38 52|erythropoietin
P08037338A0000|184 188|life
P08037338A0000|102 108|anemia
P08035833A1556|28 35|homolog
P08035833A1556|82 87|yeast
P08035833A1556|65 74|component
P08035517A0753|15 23|promoter
P08035517A0753|79 87|addition
P08035499A0941|105 122|dissociation rate
P08035499A0941|130 146|A stem substrate
P08035499A0941|22 32|difference
P08035499A0941|66 75|complexes
P08035499A0941|238 240|TR
P08034742A0307|1 3|M.
P08034708A0000|121 126|genes
P08034708A0000|162 177|differentiation
P08034708A0000|39 50|progenitors
P08034680A0180|105 121|I kappa B kinase
P08034680A0180|199 209|I kappa B.
P08034680A0180|23 31|zeta PKC
P08034680A0180|80 90|activation
P08034318A0724|44 51|species
P08034318A0724|124 130|motifs
P08034318A0724|5 17|availability
P08034318A0724|141 148|members
P08034318A0724|171 192|transcription factors
P08031424T0000|61 72|ventilation
P08031424T0000|17 26|treatment
P08030243A1011|53 62|multimers
P08030243A1011|138 142|NS35
P08029334T0000|19 32|plant omega-3
P08028671A0687|90 103|transcription
P08028671A0687|127 135|promoter
P08028671A0687|21 35|microinjection
P08025074A0000|28 33|nylon
P08025074A0000|77 97|laser energy density
P08025074A0000|178 185|prolene
P08025074A0000|16 21|study
P08023662T0000|109 116|monitor
P08023662T0000|16 27|measurement
P08021225A0000|40 54|EcoRI-fragment
P08021225A0000|162 171|DNA probe
P08021225A0000|1 18|Sequence analysis
P08021175A0486|93 102|consensus
P08021175A0486|65 74|sequences
P08021175A0486|19 25|region
P08021175A0486|171 176|sites
P08020962A1226|122 125|MER
P08020962A1226|112 114|L1
P08020962A1226|101 104|Alu
P08020962A1226|84 96|DNA elements
P08020702A0137|60 70|antibodies
P08020702A0137|94 106|disturbances
P08020702A0137|172 197|antibodies administration
P08020702A0137|114 125|endotoxemia
P08018361A0636|36 51|neutron fluency
P08016189A0741|74 86|intervention
P08016189A0741|22 28|saline
P08016189A0741|114 121|regimen
P08015850A1076|194 202|efficacy
P08015850A1076|44 48|time
P08015850A1076|29 42|dose response
P08015850A1076|93 103|postinjury
P08015850A1076|53 57|mode
P08015850A1076|17 25|analysis
P08014919A0530|166 172|length
P08014919A0530|146 155|direction
P08014919A0530|128 135|rostral
P08014919A0530|82 88|fields
P08014228A0278|63 73|extraction
P08014228A0278|117 129|racemization
P08014228A0278|35 40|order
P08013348A0143|105 112|species
P08013348A0143|73 91|binding properties
P08013348A0143|20 25|SHBGs
P08012448T0000|28 33|yeast
P08012448T0000|77 88|segregation
P08012448T0000|20 24|gene
P08011017A0169|31 35|SaO2
P08011017A0169|12 29|oxygen saturation
P08011017A0169|124 146|repeat polysomnography
P08011017A0169|4 8|drop
P08007975A0000|83 88|yeast
P08007835A0538|182 190|response
P08007835A0538|10 18|analysis
P08007835A0538|126 136|importance
P08007835A0538|71 82|FB memories
P08007835A0538|117 122|level
P08006772A0000|44 49|fetus
P08006772A0000|121 127|labour
P08006772A0000|57 63|labour
P08005438A1185|147 156|regulator
P08005438A1185|59 64|spp43
P08005230A0222|90 104|c-fos promoter
P08005230A0222|12 32|reporter gene system
P08005230A0222|173 192|luciferase activity
P08003700T0000|122 143|genome rearrangements
P08003700T0000|147 151|atp6
P08003700T0000|103 113|sugar-beet
P08002564A0249|167 176|rpoAL290H
P08002564A0249|93 106|alpha subunit
P08002564A0249|138 146|position
P08002564A0249|119 134|leucine residue
P08001792A0284|11 15|git3
P08001792A0284|23 27|git7
P08001792A0284|5 9|git1
P08001792A0284|17 21|git5
P08000497A0179|122 128|volume
P08000497A0179|145 148|VTG
P08000497A0179|87 91|test
P08000497A0179|102 109|airways
P08000112T0000|20 28|syndrome
P08000112T0000|1 12|Goodpasture
P07999995A0000|33 39|OsPK10
P07999995A0000|68 80|Oryza sativa
P07999604A0139|81 88|lesions
P07999066A0238|260 264|IL-2
P07999066A0238|184 197|phorbol ester
P07999066A0238|13 20|HIV tat
P07999066A0238|40 56|enhancing factor
P07999066A0238|202 209|calcium
P07999066A0238|67 70|LTR
P07995910A0119|94 97|way
P07995910A0119|22 33|sensitivity
P07995910A0119|65 66|%
P07995910A0119|116 127|involvement
P07994021A1223|13 21|splicing
P07994021A1223|110 125|phosphorylation
P07994021A1223|157 176|affinity modulation
P07992027A0485|15 16|%
P07992027A0485|80 95|transplantation
P07992027A0485|34 43|morbidity
P07991437A1032|38 46|majority
P07988945T0000|31 51|lupus anticoagulants
P07988945T0000|1 4|New
P07988731A0002|79 88|promoters
P07988731A0002|142 150|elements
P07988731A0002|168 185|promoter activity
P07988731A0002|16 22|number
P07988559A0836|11 18|element
P07985305T0001|36 44|children
P07985305T0001|18 32|hydronephrosis
P07984105A1509|77 98|yersiniabactin uptake
P07984105A1509|66 75|fyuA gene
P07983744A0920|208 227|punctate structures
P07983744A0920|145 150|IE110
P07983744A0920|23 28|forms
P07983744A0920|71 75|form
P07983744A0920|187 192|IE175
P07983715A0996|90 93|arm
P07983715A0996|106 114|activity
P07983715A0996|57 61|NF-Y
P07983715A0996|230 247|expression assays
P07983715A0996|1 16|Point mutations
P07983704A0330|77 86|structure
P07983704A0330|8 15|genomes
P07983704A0330|156 169|HERV-K family
P07983704A0330|32 40|sequence
P07983704A0330|1 5|Type
P07982995A0000|180 185|gland
P07982995A0000|125 127|Na
P07982995A0000|84 88|PDGF
P07982995A0000|107 117|activation
P07982995A0000|198 203|NMuMG
P07982995A0000|232 235|CHO
P07982995A0000|237 242|cells
P07981246A0112|151 164|hormones/IBMX
P07981246A0112|14 19|study
P07981246A0112|121 128|process
P07981246A0112|79 86|protein
P07981246A0112|87 88|s
P07980669A0373|29 40|AVP release
P07980669A0373|126 133|samples
P07980669A0373|82 99|plasma NPY levels
P07980440A0138|72 75|AMP
P07980440A0138|125 132|insulin
P07980440A0138|83 116|increase PEPCK gene transcription
P07980440A0138|170 176|effect
P07979810A0340|61 65|test
P07979810A0340|42 50|motility
P07979810A0340|21 31|parameters
P07978229T0000|12 24|complication
P07977239A1283|148 155|papilla
P07977239A1283|264 272|drainage
P07977239A1283|58 66|stenosis
P07977239A1283|80 87|papilla
P07977239A1283|287 292|juice
P07977239A1283|231 243|pancreatitis
P07977239A1283|307 315|pressure
P07977239A1283|1 20|Outflow obstruction
P07975763A0000|43 52|infection
P07975763A0000|5 15|importance
P07975763A0000|115 127|introduction
P07975763A0000|19 36|hepatitis C virus
P07973397T0001|18 34|potassium iodide
P07972831A0563|63 70|iohexol
P07972831A0563|101 110|ioxaglate
P07972012A0956|15 25|cDNA clone
P07972012A0956|195 201|domain
P07972012A0956|92 99|protein
P07972012A0956|42 58|rat lung library
P07972012A0956|170 182|ANP-receptor
P07971282A0000|71 103|pre-mRNA splicing characteristic
P07969181A0313|78 83|study
P07969181A0313|42 50|CKB mRNA
P07969181A0313|54 64|HeLa cells
P07969181A0313|153 164|p53 protein
P07969136A0273|176 180|gene
P07969136A0273|96 106|mobilities
P07969136A0273|81 90|complexes
P07969132A0268|14 22|plasmids
P07969132A0268|73 84|suppression
P07969132A0268|214 222|gcn2-507
P07969132A0268|5 10|class
P07969132A0268|33 37|tRNA
P07969115A0000|133 140|binding
P07969115A0000|10 38|organello footprint analysis
P07969115A0000|112 117|level
P07969115A0000|191 197|region
P07967725A0262|13 22|receptors
P07967725A0262|109 115|domain
P07967725A0262|66 73|domains
P07966873A0693|30 43|heart disease
P07966873A0693|91 101|infarction
P07966873A0693|113 120|disease
P07966583A1268|30 39|construct
P07966583A1268|11 24|transfections
P07966583A1268|199 202|kDa
P07966583A1268|188 192|mass
P07966583A1268|81 89|clone B1
P07966565A0901|120 137|replication cycle
P07966565A0901|13 19|length
P07966565A0901|161 167|stages
P07966565A0901|39 50|nucleotides
P07964918A0000|60 71|variability
P07964918A0000|79 89|evaluation
P07964918A0000|34 41|factors
P07964770A0172|58 70|arthroplasty
P07964459A0845|129 136|regions
P07964459A0845|6 11|motif
P07964162A0941|12 22|mechanisms
P07964162A0941|36 46|activation
P07964162A0941|119 132|specification
P07963540A0795|135 137|UV
P07963540A0795|13 28|I-kappa B alpha
P07963540A0795|89 93|RelA
P07963540A0795|39 60|kappa B motif binding
P07961957A1565|42 50|addition
P07961957A1565|54 59|TEF-1
P07961957A1565|18 22|data
P07961545A1314|107 115|sweating
P07961545A1314|93 105|constipation
P07961545A1314|143 154|ejaculation
P07961545A1314|69 76|placebo
P07960608A0228|34 39|weeks
P07959952A1446|107 146|polymerase chain reaction amplification
P07959952A1446|66 90|mouse mast cell chymases
P07959952A1446|154 159|mouse
P07959734A0194|70 88|peptide sequencing
P07959734A0194|17 26|contactin
P07959011A0379b|92 98|manner
P07959011A0379b|48 68|rat class-I ADH gene
P07959011A0379b|100 106|Potter
P07958920A1157|95 103|extracts
P07958920A1157|33 45|SNM1 protein
P07958920A1157|1 11|Antibodies
P07958911A0500|62 70|location
P07958911A0500|78 92|fork head gene
P07958865A1152|40 53|abnormalities
P07958865A1152|176 187|development
P07958865A1152|96 106|conclusion
P07958865A1152|17 24|embryos
P07957632A0000|253 261|pmol/rat
P07957632A0000|152 156|rats
P07957632A0000|45 46|R
P07957632A0000|41 42|R
P07957632A0000|76 83|glycine
P07957632A0000|201 221|halothane anesthesia
P07957632A0000|103 110|agonist
P07957243A1316|50 57|domains
P07957106A0875|121 134|VP16 contacts
P07957106A0875|7 16|mutations
P07957085A0207|21 29|proteins
P07957085A0207|48 53|Cbf3c
P07956578A0851|132 139|removal
P07956578A0851|67 81|configurations
P07956578A0851|1 17|Lesion diameters
P07954475A0714|122 138|C3H/HeJ x A/J F1
P07954475A0714|24 30|tumors
P07954475A0714|157 162|C3AF1
P07954475A0714|76 92|A/J x C3H/HeJ F1
P07954475A0714|67 74|crosses
P07954475A0714|174 182|evidence
P07951874A0320|105 112|hamster
P07951874A0320|88 97|radiation
P07951874A0320|1 17|Cestode invasion
P07951410A0647|62 66|DP-1
P07951410A0647|144 157|participation
P07951410A0647|55 60|E2F-1
P07951410A0647|16 20|U937
P07951410A0647|193 197|DP-1
P07951410A0647|5 9|HeLa
P07951410A0647|201 207|others
P07951410A0647|68 76|cyclin A
P07949770T0000|47 63|prostaglandin E1
P07949770T0000|99 103|pigs
P07949205A0286|12 26|testololactone
P07949137A0532|62 67|mg/kg
P07949137A0532|40 56|cyclophosphamide
P07948921A0051|90 95|probe
P07948921A0051|1 7|Optima
P07947930A0499|89 90|%
P07947930A0499|93 94|%
P07947930A0499|5 15|fibrinogen
P07947930A0499|101 102|%
P07947930A0499|17 31|serum proteins
P07945330A0103|42 44|RA
P07945330A0103|36 40|acid
P07944542T0000|25 33|Calcutta
P07943556A0694|8 15|persons
P07943556A0694|69 80|Og4C3 assay
P07942448A1227|14 22|patients
P07942448A1227|86 91|WORDS
P07941750A0344|30 34|half
P07941750A0344|42 48|length
P07941750A0344|68 85|hydantoinase HyuA
P07941174T0001|1 14|Laser therapy
P07937965T0000|89 113|3T3-L1 mouse fibroblasts
P07937965T0000|9 14|c-myc
P07937965T0000|1 5|Role
P07937841A0790|128 147|myb oncogene family
P07937841A0790|37 43|bypass
P07937841A0790|114 120|member
P07937147A0205|90 92|IR
P07937147A0205|44 62|pi protein mutants
P07937147A0205|11 17|system
P07937147A0205|97 99|DR
P07937147A0205|101 105|York
P07937127A0645|12 18|method
P07937127A0645|108 115|regions
P07937127A0645|64 82|activation domains
P07937108A0325|61 78|RNA polymerase I.
P07936650A1752|90 94|time
P07936650A1752|26 31|model
P07936650A1752|59 68|evolution
P07936650A1752|6 10|work
P07936640A0900|94 115|footprinting analysis
P07936640A0900|27 34|protein
P07936640A0900|53 58|cells
P07936640A0900|139 157|TGF alpha promoter
P07936640A0900|16 23|binding
P07935997A0000|122 127|group
P07935997A0000|82 91|complexes
P07935997A0000|39 47|immunity
P07935997A0000|153 169|cervix carcinoma
P07935997A0000|171 181|Stages IIB
P07935577A0305|73 81|symptoms
P07935577A0305|108 123|micro-organisms
P07935577A0305|154 157|CSF
P07935577A0305|16 30|amphotericin B
P07935491A0495|30 37|members
P07935491A0495|72 81|receptors
P07935491A0495|117 132|gene expression
P07935472A0276|148 159|LVb element
P07935472A0276|259 266|phorbol
P07935472A0276|109 124|T-cell line EL4
P07935472A0276|230 233|LVb
P07935472A0276|129 140|alterations
P07935472A0276|207 215|mutation
P07935472A0276|1 10|Enhancers
P07935468T0000|1 11|Activation
P07935447A0972|28 36|evidence
P07935447A0972|263 275|alpha-myosin
P07935447A0972|252 258|MLC-2v
P07935447A0972|118 122|MLE1
P07935447A0972|288 293|genes
P07935447A0972|42 45|USF
P07935447A0972|6 11|study
P07935418A0447|88 93|RLD-1
P07935418A0447|147 156|receptors
P07935418A0447|128 135|domains
P07935395A0094|105 113|clusters
P07935395A0094|126 130|ends
P07935395A0094|138 146|molecule
P07935379A0347|27 32|cells
P07935379A0347|113 122|apoptosis
P07935370A0000|31 34|CD4
P07935370A0000|97 113|maturation state
P07935370A0000|50 68|T-cell development
P07934666A0158|90 93|T2f
P07934666A0158|67 77|components
P07934666A0158|115 124|component
P07934666A0158|16 29|magnetization
P07933116A0412|57 69|T-cell lines
P07933116A0412|5 13|p55 mRNA
P07933101A0131|45 57|TATA element
P07933101A0131|96 117|HIV-1 gene expression
P07933076A0211|77 94|membrane proteins
P07932943A0113|62 80|awareness strategy
P07932943A0113|20 25|study
P07932943A0113|118 145|Five-Step Approach strategy
P07931490A0237|14 21|METHODS
P07931490A0237|95 104|cisplatin
P07931490A0237|66 74|patients
P07931490A0237|116 121|mg/m2
P07929559A0000|13 19|dynein
P07929559A0000|124 131|variety
P07929559A0000|189 198|transport
P07929411A0087|31 51|polypeptide sequence
P07929411A0087|240 255|enzyme activity
P07929411A0087|59 77|Drosophila protein
P07929411A0087|98 106|subunits
P07929165T0000|121 123|A3
P07929165T0000|81 93|gene cluster
P07929165T0000|1 13|DNA sequence
P07927838A0000|151 157|finger
P07927838A0000|10 16|groups
P07927838A0000|67 72|tools
P07927838A0000|96 101|years
P07927838A0000|168 176|numbness
P07927838A0000|220 231|extremities
P07927267T0000|104 113|rat liver
P07927267T0000|76 88|regeneration
P07926789A0960|161 168|fusions
P07926789A0960|5 17|DNA sequence
P07926789A0960|34 43|lacZ gene
P07926774A0652|5 29|p73pct1/p85cdc10 complex
P07926774A0652|84 93|E2F sites
P07926748A0383|90 94|NOT4
P07926748A0383|82 86|NOT3
P07926748A0383|21 25|NOT1
P07926748A0383|115 129|not2 mutations
P07926729A0000|135 145|activation
P07926729A0000|161 179|gene transcription
P07926729A0000|24 32|elements
P07926729A0000|100 106|events
P07925097A1205|42 53|COS-1 cells
P07925097A1205|16 26|AR content
P07922709T0000|40 54|growth factors
P07919540A0240|15 26|alterations
P07919540A0240|79 82|p64
P07919540A0240|64 77|c-myc protein
P07918128A0000|90 95|5-HT3
P07918128A0000|47 50|MDL
P07918128A0000|57 59|EF
P07918128A0000|154 166|chemotherapy
P07918128A0000|69 86|hydroxytryptamine
P07917540A0000|90 109|interferon-alpha 2b
P07917540A0000|44 49|study
P07917540A0000|130 134|week
P07917540A0000|113 117|U/m2
P07917540A0000|139 148|vindesine
P07917540A0000|220 228|melanoma
P07916983A0623|57 65|patients
P07916983A0623|71 89|N1-N3 neck disease
P07916689A1407|128 151|Y. lipolytica LEU2 gene
P07916689A1407|5 18|Y. lipolytica
P07916689A1407|68 70|bp
P07916685A0455|30 53|arogenate dehydrogenase
P07916685A0455|5 10|ratio
P07916685A0455|18 26|activity
P07916577A0190|30 45|candidate genes
P07916577A0190|162 166|zinc
P07916577A0190|4 9|order
P07916577A0190|185 190|cDNAs
P07916326A0000|40 46|coding
P07916326A0000|71 78|regions
P07915144A0000|120 125|hours
P07915144A0000|46 57|hippocampus
P07915144A0000|70 78|increase
P07914507A1029|15 29|cDNA sequences
P07914507A1029|111 125|addition sites
P07914507A1029|52 64|mRNA species
P07914507A1029|1 11|Comparison
P07914192A0211|225 233|TATA box
P07914192A0211|193 201|CAAT box
P07914192A0211|146 152|GAGGAA
P07914192A0211|76 80|site
P07914192A0211|1 26|HER2 overexpressing cells
P07913891A0174|106 118|relationship
P07913891A0174|81 93|interactions
P07913891A0174|153 162|Hox genes
P07912123A0711|17 41|lymphocyte proliferation
P07910946A0323|125 133|activity
P07910946A0323|22 41|deletion constructs
P07910946A0323|233 241|L2 cells
P07910946A0323|98 111|reporter gene
P07910946A0323|1 9|Analysis
P07909936A0672|13 31|treatment strategy
P07909936A0672|94 100|effect
P07909936A0672|231 238|factors
P07909936A0672|187 190|use
P07908187T0000|1 5|ISIS
P07907846A0623|67 93|cholinesterase degradation
P07907846A0623|159 170|combination
P07907846A0623|174 200|physostigmine pretreatment
P07907846A0623|19 32|physostigmine
P07907846A0623|1 6|Group
P07906616A0191|107 112|goats
P07906616A0191|77 79|Hz
P07905453A0281|62 82|maxicell experiments
P07905453A0281|23 57|transcription-translation analysis
P07903670A1202|62 68|tua1-1
P07903670A1202|26 46|alpha 1-tubulin gene
P07902583A0545|89 98|half-life
P07902583A0545|53 75|Grf10-Swi5-DNA complex
P07902583A0545|1 9|Analysis
P07902532A0312|94 96|TK
P07902532A0312|76 92|thymidine kinase
P07902532A0312|53 66|transcription
P07902532A0312|118 126|EC cells
P07901121T0000|36 55|class homeo domains
P07899634A0000|14 17|aim
P07899634A0000|57 66|anchorage
P07899634A0000|99 113|surface effect
P07899634A0000|119 133|alloy Ti Al Va
P07898840X0000|302 305|FGR
P07898840X0000|420 429|waveforms
P07898840X0000|213 217|test
P07898840X0000|461 469|analysis
P07898840X0000|220 225|power
P07898840X0000|166 177|circulation
P07898840X0000|128 143|Doppler studies
P07898840X0000|340 351|combination
P07898840X0000|1 20|Pregnancy screening
P07898275A0254|296 303|systems
P07898275A0254|87 107|31P MRS measurements
P07898275A0254|350 358|31P MRS.
P07898275A0254|172 183|test object
P07898275A0254|71 82|test object
P07898275A0254|139 148|sequences
P07897696A0000|150 163|concentration
P07897696A0000|58 66|activity
P07897696A0000|52 56|ALAD
P07897696A0000|319 327|subjects
P07897696A0000|130 144|coproporphyrin
P07897696A0000|197 207|indicators
P07897696A0000|101 104|ZPP
P07897696A0000|68 99|erythrocyte zinc protoporphyrin
P07896852T0000|22 50|growth response factor Egr-1
P07896852T0000|1 12|Involvement
P07896817A0204|151 189|SDS-polyacrylamide gel electrophoresis
P07896817A0204|209 220|Immobilon-P
P07896817A0204|1 9|Proteins
P07896817A0204|34 41|lysates
P07896291A0693|61 64|map
P07896291A0693|79 87|resource
P07896291A0693|116 121|genes
P07894761A0000|72 77|cases
P07894761A0000|199 206|surgery
P07894761A0000|113 116|ECH
P07894761A0000|101 111|hemorrhage
P07894021A1130|60 70|protection
P07894021A1130|95 106|desiccation
P07894021A1130|86 89|DNA
P07892076A0578|77 94|transmission mode
P07892076A0578|1 9|Survival
P07891713T0000|89 115|NF-E2 transcription factor
P07891713T0000|7 19|Maf proteins
P07891708A1192|60 68|Epo gene
P07891708A1192|100 111|Hep3B cells
P07891685A1051|42 47|genes
P07891685A1051|129 134|Cat4p
P07891685A1051|80 85|Cat8p
P07891685A1051|118 125|release
P07891685A1051|152 165|CAT8 promoter
P07890740A0997|47 56|infection
P07890740A0997|131 139|increase
P07890740A0997|5 14|PSD2 gene
P07890674A0916|75 85|E-cadherin
P07890674A0916|145 152|absence
P07890674A0916|67 70|APC
P07890674A0916|54 61|fashion
P07890485A0827|13 25|illumination
P07890485A0827|182 186|cats
P07890485A0827|161 163|ml
P07890485A0827|97 102|g.min
P07890485A0827|86 88|ml
P07888788A1010|24 40|hypersensitivity
P07888788A1010|5 13|presence
P07888788A1010|174 182|response
P07888788A1010|117 124|disease
P07888788A1010|186 197|Aspergillus
P07888623A0721|146 169|plant MAP kinase MsERK1
P07888623A0721|25 35|% identity
P07888623A0721|175 182|alfalfa
P07888156T0000|9 15|status
P07887859A0998|44 53|technique
P07887859A0998|1 18|TcPO2 measurement
P07887226A0858|281 288|disease
P07887226A0858|20 34|serum ferritin
P07887226A0858|263 269|anemia
P07887226A0858|70 102|serum transferrin receptor assay
P07887226A0858|186 193|measure
P07885999A0000|73 79|region
P07885999A0000|146 177|methylation interference assays
P07885999A0000|17 24|factors
P07883754A0993|128 140|NRE fragment
P07883754A0993|101 108|protein
P07883754A0993|35 40|HepG2
P07883168A0090|122 133|decay rates
P07883168A0090|41 54|stabilization
P07883168A0090|81 99|nonsense mutations
P07881077A0195|67 76|sequences
P07881077A0195|100 108|patients
P07880449A0091|73 76|ICR
P07880449A0091|8 14|course
P07880449A0091|20 25|study
P07880449A0091|33 52|dose X-rays effects
P07880449A0091|136 144|behavior
P07879204T0000|43 57|graft survival
P07879204T0000|1 17|OKT3 prophylaxis
P07879204T0000|171 181|US studies
P07878029A0721|132 137|CBF-C
P07878029A0721|123 128|CBF-A
P07878029A0721|24 29|CBF-C
P07877308A1175|10 18|protocol
P07877308A1175|65 71|cohort
P07876300A0994|64 78|protein import
P07876210A0275|150 158|proteins
P07876210A0275|70 75|genes
P07876192A0443|27 37|propeptide
P07876192A0443|112 120|catalyst
P07876192A0443|4 13|ICE gamma
P07876134A0348|127 129|bp
P07876134A0348|116 125|base pair
P07876134A0348|68 72|form
P07874060A0810|61 77|xanthine oxidase
P07874060A0810|79 81|XO
P07874060A0810|83 91|activity
P07874060A0810|1 6|TDEYA
P07873831T0000|22 33|involvement
P07872788A1717|107 113|region
P07872788A1717|41 42|%
P07872788A1717|52 63|hydrolase B
P07872788A1717|203 213|divergence
P07872788A1717|236 240|gene
P07872788A1717|68 69|C
P07871891A0227|71 82|protein S13
P07871755A0521|12 18|method
P07871755A0521|76 92|characterization
P07871721A0392|75 86|tymoviruses
P07871721A0392|195 208|histidine1075
P07871721A0392|56 63|viruses
P07871721A0392|6 25|sequence alignments
P07871718A1132|88 106|factors GABP alpha
P07871718A1132|10 19|inclusion
P07871718A1132|39 52|CGGAAR motifs
P07869937A1142|95 96|%
P07869937A1142|127 135|decrease
P07869937A1142|20 40|kilogram body weight
P07869937A1142|154 155|%
P07869937A1142|68 76|dF group
P07869721A0000|109 131|heart valve prosthesis
P07869721A0000|19 27|analysis
P07869721A0000|51 64|closing phase
P07867622X0000|209 216|protein
P07867622X0000|130 147|alpha 1-chimaerin
P07867622X0000|199 205|p21rac
P07867622X0000|55 72|alpha 1-chimaerin
P07867622X0000|187 194|protein
P07865917A0191|24 28|FSGS
P07865917A0191|52 60|steroids
P07865917A0191|86 89|CSA
P07865917A0191|1 10|Treatment
P07865888A1309|57 68|pre-protein
P07865888A1309|25 36|cells PBP74
P07865888A1309|83 91|membrane
P07865787A1086|182 203|wheat histone H3 gene
P07865787A1086|82 86|role
P07865787A1086|48 62|octamer motifs
P07865787A1086|87 88|s
P07865129A0293|20 27|ATF/CRE
P07864652A1901|31 48|domain constructs
P07864652A1901|112 116|E2L2
P07864652A1901|103 107|E2L1
P07863992A0908|124 138|mean follow-up
P07863992A0908|9 14|group
P07863992A0908|261 269|exercise
P07863992A0908|173 181|episodes
P07863992A0908|86 94|evidence
P07863992A0908|17 25|patients
P07863047A0229|29 47|serum ACE activity
P07863047A0229|245 254|parameter
P07863047A0229|65 69|COPD
P07863047A0229|1 11|OBJECTIVES
P07862168A0000|105 113|response
P07862168A0000|94 101|T cells
P07862168A0000|5 16|interleukin
P07862168A0000|19 39|receptor alpha-chain
P07862162A0408|94 107|transcription
P07862162A0408|8 16|presence
P07862162A0408|20 28|inositol
P07862150A0429|107 118|cell clones
P07862150A0429|214 223|responses
P07862150A0429|67 73|vector
P07862150A0429|86 95|mink lung
P07862141A0317|44 49|genes
P07862141A0317|108 123|differentiation
P07862141A0317|33 40|alleles
P07862108A0987|95 98|kDa
P07862108A0987|1 29|UV cross-linking experiments
P07860646A1363|57 66|treatment
P07860646A1363|93 101|diseases
P07859777A0000|61 73|fermentation
P07859777A0000|107 120|microcapsules
P07859777A0000|146 154|diameter
P07859777A0000|203 212|reduction
P07859777A0000|19 32|serum albumin
P07859665A0498|73 76|day
P07859665A0498|145 157|microseconds
P07859665A0498|93 105|microseconds
P07859301A0325|41 47|domain
P07859301A0325|80 101|leucine-zipper motifs
P07859301A0325|103 111|features
P07858986A0310|122 132|BioImplant
P07858986A0310|58 65|porcine
P07858986A0310|172 178|valves
P07858986A0310|80 86|valves
P07857344A0591|62 66|data
P07857344A0591|25 33|compound
P07857344A0591|143 144|h
P07857344A0591|86 92|change
P07857086A0949|104 111|H White
P07857086A0949|114 119|Class
P07857086A0949|101 102|F
P07857086A0949|68 89|Non Insulin Dependent
P07854324A0742|24 29|clone
P07854324A0742|5 15|expression
P07854130T0000|63 79|pilus biogenesis
P07854130T0000|126 135|N-termini
P07854130T0000|81 116|shares amino acid sequence identity
P07853524A1944|61 64|Tax
P07853524A1944|128 136|ABSTRACT
P07853524A1944|97 126|Tax-CREB-21-bp-repeat complex
P07853524A1944|154 159|WORDS
P07853524A1944|16 26|GST domain
P07853476A0159|1 8|Schnell
P07852400A0519|67 71|RhoA
P07852400A0519|33 40|Rho GDI
P07852037A0548|46 50|data
P07852037A0548|19 36|DCT method yields
P07851643A1365|47 54|isoform
P07851643A1365|78 91|proliferation
P07847036A0353|75 84|inhibitor
P07847036A0353|53 66|haemophiliacs
P07846942A0717|90 94|form
P07846942A0717|74 81|therapy
P07846942A0717|126 131|class
P07846942A0717|1 21|Digitalis glycosides
P07846163A0422|73 80|introns
P07846163A0422|18 27|GRF genes
P07845672A0368|143 149|domain
P07845672A0368|32 45|blk sequences
P07845672A0368|153 163|% identity
P07844425A0289|5 13|students
P07844425A0289|54 59|urine
P07844155A0327|224 232|splicing
P07844155A0327|167 173|system
P07844155A0327|79 90|development
P07844155A0327|19 27|function
P07841663A0845|61 72|stimulation
P07841663A0845|192 201|viability
P07841663A0845|140 144|part
P07841663A0845|117 129|SOD activity
P07841230T0000|18 30|complexation
P07838156A0789|47 50|RVR
P07838156A0789|10 32|cotransfection studies
P07838156A0789|200 218|ROR alpha function
P07838156A0789|187 196|repressor
P07836406A0884|83 94|cdc2 kinase
P07836406A0884|114 128|phosphopeptide
P07836406A0884|169 180|performance
P07836364A0000|26 34|proteins
P07836364A0000|147 171|antigen presenting cells
P07836364A0000|43 51|peptides
P07836364A0000|173 176|APC
P07836364A0000|136 143|surface
P07836218A0128|107 115|evidence
P07836218A0128|42 64|beta-endorphin release
P07836218A0128|80 95|exertion levels
P07836218A0128|168 182|beta-endorphin
P07835886A0894|224 232|globulin
P07835886A0894|107 119|serpin genes
P07835886A0894|129 153|alpha 1-antichymotrypsin
P07835886A0894|155 174|protein C inhibitor
P07835710T0000|30 47|porcine I kappa B
P07835710T0000|63 67|gene
P07835273A0000|20 37|glucose transport
P07835088A0238|135 148|hybridization
P07835088A0238|59 78|beta-HSD isoenzymes
P07835088A0238|156 180|chromosome 1p13.1 region
P07832779A0719|63 72|receptors
P07832779A0719|97 119|oligosaccharide chains
P07831829A1324|30 34|PMTV
P07831829A1324|97 110|heterogeneity
P07831829A1324|114 133|genome organization
P07831829A1324|19 26|genomes
P07831310A0000|121 127|plants
P07831310A0000|94 97|NIb
P07831310A0000|131 142|protoplasts
P07831310A0000|178 189|TEV mutants
P07829554A0257|60 75|system response
P07829554A0257|149 162|wear products
P07829554A0257|250 256|method
P07829554A0257|291 299|immunity
P07829554A0257|186 193|devices
P07829554A0257|236 241|assay
P07829554A0257|304 310|metals
P07829102T0000|91 100|infection
P07829102T0000|23 40|sequence analysis
P07829102T0000|1 18|Haplotype mapping
P07829057T0000|36 58|Werner syndrome region
P07828852A0153|46 52|nuclei
P07828852A0153|68 77|functions
P07828811A0556|111 118|ability
P07828811A0556|35 46|G1/S arrest
P07828584A0681|65 85|AP1 bearing promoter
P07828584A0681|1 12|Mutagenesis
P07826412T0112|104 114|holoenzyme
P07826412T0112|57 65|subunits
P07826412T0112|21 31|mechanisms
P07826412T0112|118 128|transducin
P07824726A0454|164 181|fatty replacement
P07824726A0454|183 189|type b
P07824726A0454|213 230|fatty replacement
P07824726A0454|115 132|fatty replacement
P07824726A0454|49 54|basis
P07824464A0169|60 65|lumen
P07824464A0169|88 95|thrombi
P07824464A0169|144 156|fissurations
P07824464A0169|261 276|artery stenosis
P07824464A0169|21 27|images
P07824464A0169|238 248|mechanisms
P07823964A0922|121 126|trans
P07823964A0922|52 58|domain
P07823951A1100|56 80|transactivation function
P07823951A1100|196 209|transcription
P07823951A1100|7 14|results
P07823951A1100|223 228|cells
P07823951A1100|139 143|EKLF
P07822333A0376|1 5|Chem
P07822161A1172|165 173|residues
P07822161A1172|93 110|amino acid levels
P07822161A1172|5 13|sequence
P07820057A0000|78 92|growth control
P07820057A0000|143 153|properties
P07820057A0000|34 42|cytokine
P07818416A0895|150 153|g/L
P07818416A0895|73 78|group
P07818416A0895|178 190|revision THR
P07818416A0895|136 139|THR
P07816630A1333|165 174|H4-I gene
P07816630A1333|29 31|bp
P07816630A1333|96 108|beta-tubulin
P07816630A1333|118 122|gene
P07816619A0000|130 141|pde1 mutant
P07816619A0000|87 96|phenotype
P07816049A1157|77 83|Atcys1
P07816049A1157|178 183|genes
P07816049A1157|96 102|AKin10
P07816049A1157|1 40|Southern blot hybridization experiments
P07816049A1157|85 91|Athyp1
P07816025A0196|126 130|Coix
P07816025A0196|96 111|gamma-prolamins
P07816025A0196|115 120|maize
P07816025A0196|50 63|gamma-kafirin
P07814405A1170|15 19|time
P07814405A1170|72 94|plasma membrane family
P07814405A1170|98 124|guanylyl cyclase receptors
P07814405A1170|32 40|deletion
P07814388A0662|44 48|type
P07814388A0662|59 66|M6P/IGF
P07814388A0662|84 90|nM IGF
P07814321A0850|27 31|ponA
P07814321A0850|18 22|prfA
P07814321A0850|85 107|sporulation efficiency
P07813466A0074|40 47|hamster
P07813466A0074|159 171|protein gene
P07813466A0074|5 14|U14 genes
P07813466A0074|35 38|rat
P07811964A1252|120 124|role
P07811964A1252|77 83|domain
P07811964A1252|87 93|EmBP-1
P07809410A0606|224 231|therapy
P07809410A0606|176 187|differences
P07809410A0606|42 58|serum TSH levels
P07809410A0606|16 21|cases
P07808210A1510|44 45|%
P07808210A1510|36 37|%
P07806820A0091|121 132|fascia flap
P07806820A0091|85 91|artery
P07806532A0659|58 79|half-saturation value
P07806532A0659|1 14|Protein cHMGI
P07806492A1162|19 28|cucumisin
P07802655T0000|107 109|L1
P07802655T0000|99 103|exon
P07802655T0000|21 29|FIII/YY1
P07802655T0000|70 85|protein binding
P07801180A0197|26 36|advantages
P07801180A0197|6 11|paper
P07800479A0201|47 51|gene
P07800479A0201|11 15|gene
P07800479A0201|93 107|RNA maturation
P07800479A0201|17 21|NSR1
P07799948A0777|14 22|deletion
P07799948A0777|122 125|Ras
P07799948A0777|95 98|Src
P07799948A0777|65 75|activation
P07799948A0777|4 12|contrast
P07799931A1232|28 35|protein
P07799931A1232|37 40|Nrl
P07799925A0526|167 170|p62
P07799925A0526|109 126|complex formation
P07799925A0526|52 76|src family kinase p59fyn
P07799925A0526|200 203|SH3
P07799925A0526|19 28|complexes
P07799925A0526|1 15|Reconstitution
P07798271A0330|31 36|sites
P07798271A0330|79 84|liver
P07798271A0330|93 101|extracts
P07798217T0000|95 110|gene expression
P07798217T0000|32 39|CREB341
P07798134T0000|45 52|cloning
P07798134T0000|73 83|expression
P07798134T0000|97 104|mapping
P07798134T0000|54 71|sequence analysis
P07797476A1001|107 118|stimulation
P07797476A1001|22 27|TFIIF
P07797476A1001|85 91|region
P07797077A0842|209 220|ISGF3 gamma
P07797077A0842|126 136|interferon
P07797077A0842|156 159|IRF
P07797077A0842|72 80|homology
P07797077A0842|161 167|family
P07797077A0842|42 45|Pip
P07797077A0842|32 38|domain
P07795576A0126|106 127|plasma renin activity
P07795576A0126|80 86|system
P07794556A0000|120 127|service
P07794556A0000|72 82|Huntington
P07794556A0000|162 173|DNA-linkage
P07794556A0000|25 33|Genetics
P07794556A0000|203 220|mutation analysis
P07791783A0000|151 184|rainbow trout testis cDNA library
P07791783A0000|29 36|protein
P07791783A0000|65 68|HMG
P07791783A0000|70 73|box
P07791771A0183|1 5|Otte
P07791768A0930|148 157|mutations
P07791768A0930|198 211|establishment
P07791768A0930|161 165|SIR1
P07791768A0930|5 11|effect
P07791768A0930|175 179|gene
P07791768A0930|119 133|clb5 mutations
P07791763T0000|78 89|involvement
P07791763T0000|142 167|Xenopus oocyte maturation
P07791763T0000|69 73|cDNA
P07790719A0098|55 63|patients
P07790271A1185|14 23|lens dose
P07790271A1185|79 89|techniques
P07789809A1246|105 108|Ypt
P07789809A1246|72 74|Cr
P07789809A1246|79 81|Vc
P07789809A1246|201 216|differentiation
P07789342A1352|91 94|TSH
P07789342A1352|176 187|TSH binding
P07789342A1352|144 164|transmembrane domain
P07789342A1352|117 129|hyt mutation
P07787179A0312|151 164|reporter gene
P07787179A0312|6 17|bp fragment
P07787179A0312|70 79|positions
P07786820A0284|92 94|ml
P07786820A0284|71 76|mg/m2
P07786820A0284|1 7|CPT-11
P07784870A0119|180 194|histochemistry
P07784870A0119|208 227|electron microscopy
P07784870A0119|145 159|investigations
P07784870A0119|168 178|microscopy
P07784870A0119|87 94|reports
P07784197A0827|60 71|monkey Cos7
P07784197A0827|27 34|variety
P07784197A0827|189 201|cell extract
P07784197A0827|81 100|mouse fibrosarcomas
P07784197A0827|48 58|cell lines
P07784078A1064|77 83|levels
P07784078A1064|4 15|explanation
P07784078A1064|100 103|PML
P07784078A1064|119 134|APL cell growth
P07783822A0000|31 40|incidence
P07783822A0000|115 132|district hospital
P07783064A0452|73 90|creatinine kinase
P07783064A0452|37 45|patients
P07783064A0452|17 30|strength data
P07782302A0479|91 97|domain
P07782302A0479|58 61|GDP
P07782302A0479|168 180|HTF9A/RanBP1
P07782087A0559|73 82|positions
P07782087A0559|146 169|ribonuclease protection
P07782087A0559|25 55|transcription initiation sites
P07782087A0559|171 187|primer extension
P07780148A1153|15 18|PML
P07780148A1153|56 58|G2
P07780148A1153|53 54|S
P07780148A1153|103 108|level
P07779811A0901|95 112|reporter activity
P07779811A0901|1 9|Mutation
P07777518A0483|107 112|genes
P07777518A0483|64 75|cDNA clones
P07776882A0000|13 18|study
P07776882A0000|64 74|rat hearts
P07776882A0000|102 113|reperfusion
P07776685A0000|62 75|immunotherapy
P07776685A0000|41 49|toxicity
P07776685A0000|25 36|feasibility
P07776685A0000|81 86|tumor
P07776685A0000|100 111|lymphocytes
P07774925A0084|121 129|placenta
P07774925A0084|9 23|cosmid contigs
P07774925A0084|172 176|head
P07774925A0084|70 81|cDNA clones
P07774925A0084|1 4|YAC
P07774137A0000|15 21|impact
P07774137A0000|56 67|Strep A OIA
P07774137A0000|144 155|pharyngitis
P07774137A0000|86 95|treatment
P07774137A0000|137 142|GABHS
P07771745A0442|97 103|region
P07771745A0442|18 25|tissues
P07771745A0442|1 10|Elevation
P07770033A0978|61 65|cap3
P07770033A0978|193 233|Neurospora crassa copper metallothionein
P07770033A0978|156 163|peptide
P07770033A0978|1 21|Nucleotide sequences
P07770033A0978|85 98|reading frame
P07768898A0492|198 205|protein
P07768898A0492|24 30|values
P07768898A0492|141 145|site
P07768898A0492|69 74|terms
P07768836A1126|82 84|bp
P07768836A1126|48 77|transcription initiation site
P07767011A0689|123 131|mutation
P07767011A0689|67 75|activity
P07767011A0689|115 119|site
P07767011A0689|16 25|insertion
P07765118A0967|78 86|excision
P07765118A0967|98 121|maximum enzyme activity
P07765118A0967|70 71|h
P07762504A0648|131 132|g
P07762504A0648|5 10|study
P07762504A0648|84 88|days
P07762504A0648|102 107|doses
P07761467A0666|12 19|complex
P07761420A0909|27 33|assays
P07761420A0909|69 72|Ca2
P07761091A0294|1 13|Inactivation
P07761091A0294|51 62|phosphatase
P07760841A0647|111 128|promoter elements
P07760841A0647|8 15|context
P07760841A0647|23 27|ADH2
P07760841A0647|83 90|concert
P07760841A0647|48 54|region
P07760819A0731|121 127|effect
P07760819A0731|57 66|molecules
P07760819A0731|153 168|differentiation
P07759529A0288|45 52|CDP/cut
P07759529A0288|78 103|gp91-phox gene expression
P07759094A0634|15 27|dinucleotide
P07759094A0634|29 34|GT/CA
P07759094A0634|35 43|n repeat
P07758459A1277|57 63|motifs
P07758459A1277|5 8|UAS
P07758459A1277|205 236|ABF1 consensus binding sequence
P07758167A1488|47 56|clone CA9
P07758167A1488|64 72|presence
P07758167A1488|103 104|%
P07755914A0000|29 35|impact
P07755914A0000|160 187|Mycobacterium avium complex
P07755914A0000|43 55|introduction
P07755914A0000|112 120|survival
P07755914A0000|98 107|treatment
P07755914A0000|1 10|OBJECTIVE
P07754713A0227|91 102|protein S24
P07754713A0227|63 67|gene
P07754713A0227|142 149|protein
P07754713A0227|20 25|PRP21
P07754713A0227|157 168|amino acids
P07753796A0743|97 120|SDS/polyacrylamide gels
P07753796A0743|81 93|eIF-2B alpha
P07753030A0173|61 87|Rhizobium leguminosarum bv
P07753030A0173|161 186|Xanthomonas campestris pv
P07753030A0173|188 198|campestris
P07753030A0173|1 22|Hybridization signals
P07752886A0595|21 36|FecR derivative
P07752886A0595|50 69|amino acid residues
P07752454A0341|88 93|DMPPC
P07752454A0341|55 71|resistance rates
P07751848A0222|126 131|value
P07751848A0222|37 40|CPT
P07751848A0222|81 100|nmol/min/mg protein
P07749461A1022|121 129|plasmids
P07749461A1022|28 55|sGTH alpha subunit promoter
P07749461A1022|12 20|analysis
P07749461A1022|159 164|cells
P07749088A0119|29 35|images
P07749088A0119|17 19|T2
P07748952A0462|96 107|nucleotides
P07748952A0462|38 43|PmiaA
P07748952A0462|137 160|translation start sites
P07748502A0794|82 96|discrimination
P07748502A0794|1 5|Rats
P07748451A0343|105 110|stone
P07748451A0343|131 145|vinyl siloxane
P07748451A0343|76 88|restorations
P07748451A0343|174 188|vinyl siloxane
P07748451A0343|152 173|medium-viscosity poly
P07746937A0100|22 25|EFR
P07746937A0100|1 20|Lung function tests
P07746397A0233|240 245|value
P07746397A0233|159 164|hours
P07746397A0233|21 29|patients
P07746397A0233|226 231|times
P07746397A0233|40 55|anticoagulation
P07746397A0233|141 148|heparin
P07746397A0233|170 175|onset
P07745726A0960|134 144|half sites
P07745726A0960|43 45|E1
P07745726A0960|189 202|relationships
P07745726A0960|5 36|replication reporter constructs
P07745693A0914|124 135|proteolysis
P07745693A0914|163 164|s
P07745693A0914|18 27|inhibitor
P07745693A0914|69 80|stimulation
P07745684T0000|73 87|protein kinase
P07745684T0000|7 26|papillomavirus type
P07745684T0000|99 106|changes
P07745008A0892|1 20|Radioligand binding
P07744846A1006|62 76|binding assays
P07744846A1006|177 199|Bcl-2 homodimerization
P07744846A1006|354 365|combination
P07744846A1006|19 41|Bcl-2 homodimerization
P07744846A1006|135 142|support
P07744846A1006|13 18|Bcl-2
P07744846A1006|277 286|structure
P07744846A1006|1 9|Analysis
P07744846A1006|305 313|presence
P07744763A0514|63 79|orphan receptors
P07744763A0514|199 206|element
P07744763A0514|143 150|results
P07744763A0514|21 30|rat liver
P07744763A0514|1 17|Binding activity
P07743515A0223|104 109|cells
P07743515A0223|22 41|tissue distribution
P07743515A0223|191 201|lymphatics
P07742917T0001|13 29|beta-thalassemia
P07742917T0001|55 66|Brazzaville
P07742363A0941|132 156|casein kinase activities
P07742363A0941|27 31|form
P07742363A0941|16 19|Ala
P07742024A0121|14 22|symptoms
P07742024A0121|107 117|directions
P07742024A0121|176 182|sellar
P07742024A0121|24 29|signs
P07742024A0121|49 67|operation findings
P07742024A0121|184 190|clival
P07740490T0000|47 54|uraemia
P07740490T0000|67 71|role
P07739566A1076|74 92|amino acid stretch
P07739566A1076|13 39|Pax-6-BSAP fusion proteins
P07739566A1076|111 115|part
P07739542A1419|120 151|retinoblastoma protein function
P07739542A1419|25 33|cyclin E
P07739542A1419|38 46|contrast
P07739382A0457|14 22|analyses
P07739382A0457|29 49|amino acid sequences
P07739382A0457|198 206|proteins
P07739382A0457|128 136|gelsolin
P07738839A0173|40 50|VC breaths
P07738839A0173|54 58|rest
P07738839A0173|70 82|CO2 pressure
P07738839A0173|118 122|mmHg
P07737944A0000|134 157|blood cell transfusions
P07737944A0000|241 255|erythropoietin
P07737944A0000|229 237|decrease
P07737944A0000|163 170|variety
P07737118A0317|15 28|reading frame
P07737118A0317|142 147|yeast
P07737118A0317|69 81|LexA protein
P07735833A1078|105 116|synthetases
P07735833A1078|80 85|seryl
P07735833A1078|16 26|comparison
P07735833A1078|137 141|core
P07733075A1200|177 186|H. pylori
P07733075A1200|249 259|omeprazole
P07733075A1200|263 267|mg/d
P07733075A1200|87 91|mg/q
P07733075A1200|285 287|wk
P07733075A1200|7 14|therapy
P07733075A1200|200 219|ulcer healing rates
P07733075A1200|69 73|i.d.
P07731686A0000|63 77|translocations
P07731686A0000|43 47|site
P07731686A0000|87 102|T-cell leukemia
P07730337T0000|107 118|RC3 protein
P07730337T0000|67 83|protein kinase C
P07730337T0000|1 10|Structure
P07730336A0606|91 99|sequence
P07730336A0606|9 14|ATF-1
P07730336A0606|19 23|CREM
P07730273A1309|14 27|NarQ proteins
P07730273A1309|81 99|histidine position
P07730273A1309|136 150|NarL-phosphate
P07728201A0660|135 140|years
P07728201A0660|144 147|age
P07728201A0660|112 120|asplenia
P07728201A0660|21 29|evidence
P07724452A0344|62 68|chicks
P07724452A0344|39 42|pen
P07723247A0187|14 24|mechanisms
P07723247A0187|89 97|products
P07723247A0187|196 214|pressure recording
P07723247A0187|53 75|transmembrane transfer
P07723247A0187|155 169|dialysis model
P07721422A0241|90 92|bp
P07721422A0241|56 86|transcription initiation sites
P07721422A0241|119 132|receptor gene
P07720710A0861|5 8|Oct
P07720572A1584|44 53|myoblasts
P07720572A1584|93 103|cell types
P07720572A1584|112 131|chromatin structure
P07720572A1584|191 204|myoD enhancer
P07719527T0000|6 19|allergenicity
P07719527T0000|81 91|volunteers
P07715922A0188|134 140|months
P07715922A0188|41 47|number
P07715922A0188|9 14|paper
P07715922A0188|112 120|patients
P07715922A0188|18 28|comparison
P07715200A0000|109 123|blood pressure
P07715200A0000|53 60|patient
P07714608A1252|63 65|pH
P07714608A1252|131 145|glucose levels
P07714608A1252|67 72|PaCO2
P07714608A1252|87 95|pressure
P07713421A1435b|133 138|SxlM4
P07713421A1435b|163 168|SxlM1
P07713421A1435b|102 126|sex determination signal
P07711730A0000|93 109|lipid metabolism
P07711730A0000|81 89|disorder
P07711730A0000|1 31|Carnitine palmitoyltransferase
P07708497A0000|31 46|thyroid hormone
P07708497A0000|107 127|T3 response elements
P07708497A0000|161 170|sequences
P07708497A0000|99 101|TR
P07708497A0000|86 97|T3 receptor
P07708058A0178|121 136|c-jun homodimer
P07708058A0178|12 22|nucleotide
P07708058A0178|5 8|GRE
P07708058A0178|141 164|c-jun/c-fos heterodimer
P07708058A0178|101 105|AP-1
P07707531A0550|62 74|displacement
P07707531A0550|126 131|alpha
P07707531A0550|82 87|alpha
P07707531A0550|156 160|ICP4
P07706396T0000|95 107|accumulation
P07706396T0000|67 74|protein
P07706396T0000|18 28|VPS45 gene
P07706396T0000|1 10|Mutations
P07706299A0563|145 151|detail
P07706299A0563|101 110|compounds
P07706287A0698|14 23|inability
P07706287A0698|47 54|nucleus
P07706287A0698|117 136|cell division cycle
P07705627A1107|75 87|dpp pathways
P07705627A1107|52 62|components
P07705627A1107|17 20|Mad
P07704730T0000|21 26|ideas
P07704456A1014|28 40|acceleration
P07704456A1014|63 73|conditions
P07704456A1014|128 138|conditions
P07704040A0000|211 213|EC
P07704040A0000|124 140|quinone acceptor
P07704040A0000|115 118|NAD
P07704040A0000|119 120|P
P07704040A0000|73 74|P
P07704040A0000|77 101|menadione oxidoreductase
P07704040A0000|69 72|NAD
P07702752A0545|181 191|base pairs
P07702752A0545|107 125|gene transcription
P07702752A0545|37 57|rat P450c17 promoter
P07702752A0545|20 29|sequences
P07702752A0545|253 261|plasmids
P07702752A0545|327 343|mouse cell lines
P07702327T0000|14 34|adhesion prophylaxis
P07700361A0125|74 83|molecules
P07700361A0125|24 36|interactions
P07699632A0715|94 105|prevalences
P07699632A0715|27 34|studies
P07699632A0715|117 124|HLA-B27
P07699632A0715|137 148|populations
P07698727A0386|77 90|HIV infection
P07698727A0386|34 43|infection
P07697294A0329|53 58|roots
P07696450A0271|213 224|Switzerland
P07696450A0271|190 204|Nestle-Clintec
P07696450A0271|184 188|Diet
P07696450A0271|254 259|weeks
P07696450A0271|37 47|experience
P07696450A0271|206 211|Vevey
P07696450A0271|238 247|nutrition
P07695629A0489|39 49|disruptant
P07695629A0489|17 31|mck1 mds1 mrk1
P07693975A1418|112 114|PR
P07693975A1418|4 12|contrast
P07693975A1418|18 26|proteins
P07693708A0000|14 20|growth
P07693708A0000|47 55|IGF-BP-2
P07693708A0000|110 113|age
P07693708A0000|118 125|fasting
P07693672A0259|72 82|protection
P07693672A0259|38 46|promoter
P07693132A0100|74 89|Zm-ERabp5 genes
P07693132A0100|59 68|Zm-ERabp4
P07693132A0100|32 40|analysis
P07692668A0326|127 129|kb
P07692668A0326|212 234|transcription strategy
P07692668A0326|250 261|arrangement
P07691885T0000|91 119|mast cell leukemia cell line
P07691885T0000|161 174|c-kit product
P07691885T0000|59 79|proto-oncogene c-kit
P07691885T0000|1 15|Identification
P07688112A0274|62 72|correction
P07688112A0274|48 53|cases
P07688112A0274|1 9|Prostate
P07687541A0992|105 113|homologs
P07687541A0992|7 12|RCC1p
P07687541A0992|21 25|GNRP
P07687541A0992|117 120|Ran
P07687320A0526|61 68|ability
P07687320A0526|13 27|plasmid pFV100
P07685874A0258|31 55|magnesium concentrations
P07685874A0258|192 208|amylase activity
P07685874A0258|10 16|sodium
P07685874A0258|247 255|controls
P07685874A0258|116 135|lupus erythematosus
P07685263A0503|76 86|base pairs
P07685263A0503|129 149|Tropheryma whippelii
P07685263A0503|55 68|DNA fragments
P07683131A0885|13 22|structure
P07683131A0885|127 133|domain
P07683131A0885|83 105|exon/intron boundaries
P07682842A0294|14 20|origin
P07682842A0294|215 227|organization
P07682842A0294|267 278|fMLF-R gene
P07682842A0294|66 73|linkage
P07682842A0294|169 180|copy number
P07681513A0000|43 52|inhibitor
P07681513A0000|81 103|vasodilator properties
P07680629T0000|120 131|cell fusion
P07680629T0000|47 52|genes
P07680629T0000|11 18|cloning
P07680629T0000|71 96|cell surface glycoprotein
P07680035A0221|61 74|GnRH response
P07680035A0221|5 10|roles
P07679390A0721|135 159|transcription start site
P07679390A0721|214 229|splice junction
P07679390A0721|1 17|RNase protection
P07679390A0721|238 242|exon
P07678602A0153|56 64|controls
P07678602A0153|76 84|patients
P07678242A0473|74 83|acc genes
P07678242A0473|43 49|levels
P07678242A0473|53 66|transcription
P07678006A0901|14 24|protection
P07678006A0901|110 122|T-lymphocyte
P07678006A0901|52 58|cortex
P07678006A0901|84 97|kidney cortex
P07677836A1356|15 28|matter injury
P07677836A1356|107 126|leukoencephalopathy
P07677836A1356|50 59|radiation
P07677573A0000|15 26|correlation
P07677573A0000|58 68|parameters
P07677573A0000|37 43|number
P07677573A0000|157 165|patients
P07677573A0000|137 143|mucosa
P07676587T0000|12 25|certification
P07675449A0848|86 91|PDGFR
P07674649A0508|28 32|ABAB
P07674649A0508|83 106|treatment effectiveness
P07673154A0688|133 144|fibronectin
P07673154A0688|38 46|CAK beta
P07673154A0688|118 127|3Y1 cells
P07672822T0000|35 43|location
P07672822T0000|68 87|receptor alpha gene
P07670943A0308|161 164|CAD
P07670943A0308|55 58|CAD
P07670943A0308|35 43|patients
P07669351A1278|23 26|phi
P07668009A0172|15 25|cumlations
P07667195A0146|24 36|sulfate salt
P07667195A0146|127 138|Beagle dogs
P07667195A0146|64 74|suspension
P07667195A0146|16 20|base
P07666966A0207|19 28|extension
P07666966A0207|1 5|Mean
P07666523T0000|22 29|control
P07666523T0000|33 44|coronavirus
P07666414A0614|183 200|anti-tropomyosins
P07666414A0614|35 45|tmy-1 gene
P07666414A0614|17 27|expression
P07665633A0284|14 22|isolates
P07665633A0284|52 66|disk diffusion
P07665633A0284|71 95|agar dilution procedures
P07665567A0495|333 337|gene
P07665567A0495|52 61|CD69 gene
P07665567A0495|254 264|NF-kappa B
P07665567A0495|314 324|expression
P07665567A0495|231 252|transcription factors
P07665567A0495|38 44|region
P07665567A0495|1 18|Sequence analysis
P07665187A0824|78 107|transcription initiation site
P07665187A0824|22 53|S1 nuclease mapping experiments
P07665187A0824|1 17|Primer extension
P07665172A0000|66 71|motif
P07665172A0000|115 120|genes
P07665172A0000|85 95|expression
P07663998T0000|59 68|aneurysms
P07663160A0287|15 27|DNA sequence
P07663160A0287|245 256|preferences
P07663160A0287|114 117|RNA
P07663160A0287|201 219|protein expression
P07663160A0287|100 103|16S
P07660712A0118|60 68|children
P07660712A0118|106 116|risk group
P07660712A0118|79 85|adults
P07660712A0118|34 42|response
P07659746A1464|5 35|CVA16.4 proteolipid transcript
P07659746A1464|103 109|ovules
P07659515T0000|40 48|evidence
P07659515T0000|85 93|elements
P07658777A0400|36 44|patients
P07658262A0944|61 70|admission
P07658262A0944|189 196|factors
P07658262A0944|96 105|infusions
P07658262A0944|138 148|correction
P07657668A0642|94 107|Btk TH domain
P07657668A0642|115 129|Fyn SH3 domain
P07656588A0101|151 158|cluster
P07656588A0101|125 129|FUT1
P07656588A0101|189 193|FUT1
P07656588A0101|222 224|cM
P07656588A0101|290 299|lod score
P07656588A0101|46 77|Genethon microsatellite D19S596
P07656588A0101|281 288|D19S571
P07655505A0527|72 78|tissue
P07655505A0527|27 39|GT-2 protein
P07655505A0527|9 15|shoots
P07655505A0527|129 140|development
P07655505A0527|20 25|roots
P07654740A0563|104 115|composition
P07654740A0563|123 141|transplant work-up
P07654740A0563|83 98|transplantation
P07654740A0563|18 35|selection process
P07654740A0563|204 211|factors
P07654239A0698|52 57|level
P07654239A0698|1 4|Max
P07653812T0000|89 97|morphine
P07653812T0000|115 119|rats
P07652582A0000|36 47|development
P07652582A0000|1 18|INF-alpha therapy
P07652066A0677|31 38|concept
P07652066A0677|280 288|contours
P07652066A0677|247 256|migration
P07652066A0677|203 212|incisions
P07652066A0677|99 108|anchoring
P07652066A0677|116 124|arm flap
P07651734A0961|135 142|tissues
P07651734A0961|37 47|expression
P07651734A0961|98 108|expression
P07651734A0961|84 89|brain
P07651424A0487|74 78|part
P07651424A0487|108 115|subunit
P07651424A0487|55 62|protein
P07651424A0487|33 38|Ssm1p
P07651398T0000|18 30|gene product
P07651398A0257|15 27|dShc protein
P07651398A0257|122 125|DER
P07651398A0257|174 177|DER
P07651398A0257|69 79|Drosophila
P07651340A0286|130 132|UV
P07651340A0286|53 60|cosmids
P07651340A0286|1 17|Retransformation
P07651340A0286|137 151|MMS resistance
P07651131A1407|74 95|kDa repressor isoform
P07651131A1407|111 115|CIRs
P07651131A1407|140 147|targets
P07651131A1407|152 159|binding
P07649098A0676|607 621|cotransfection
P07649098A0676|724 743|reporter expression
P07649098A0676|297 301|exon
P07649098A0676|531 534|PKA
P07649098A0676|191 210|reporter expression
P07649098A0676|118 120|nt
P07649098A0676|377 422|IGF-I promoter-luciferase-reporter constructs
P07649098A0676|583 597|PGE2 treatment
P07649098A0676|235 254|reporter expression
P07649098A0676|451 464|alpha-isoform
P07649098A0676|629 636|plasmid
P07649098A0676|698 702|cAMP
P07649098A0676|280 282|nt
P07649098A0676|545 552|results
P07649098A0676|5 13|evidence
P07647570A0713|46 50|gold
P07647570A0713|123 128|cells
P07647570A0713|82 95|Kupffer cells
P07646439A0535|105 136|mAb F11 affinity chromatography
P07646439A0535|38 56|platelet membranes
P07644466A0578|30 35|assay
P07644466A0578|120 128|residues
P07644466A0578|46 64|NS3-4A polyprotein
P07644466A0578|214 230|trans-processing
P07644466A0578|66 69|NS3
P07642633T0000|13 21|promoter
P07642633T0000|130 134|gene
P07642633T0000|112 122|regulation
P07642633T0000|33 46|binding sites
P07642538A0744|29 34|C-Thr
P07642538A0744|59 74|kinase activity
P07642538A0744|19 24|C-Lys
P07642490A0318|15 22|pHBK280
P07642490A0318|7 13|vector
P07640309A0000|72 86|mobility group
P07640309A0000|200 202|X.
P07640309A0000|16 33|peptide sequences
P07639106A0678|14 17|age
P07639106A0678|56 61|TBBMD
P07639106A0678|76 82|weight
P07639106A0678|114 117|fit
P07639106A0678|48 51|fit
P07637718A0218|75 82|repeats
P07637718A0218|19 33|messenger RNAs
P07637718A0218|102 115|epimastigotes
P07636962A1883b|72 80|activity
P07636962A1883b|22 29|fusions
P07636962A1883b|140 156|carboxyl termini
P07636962A1883b|170 178|activity
P07636648A1229|181 199|pertussis antigens
P07636648A1229|148 162|concentrations
P07636648A1229|231 239|children
P07636648A1229|5 10|month
P07636337A0687|60 68|hormones
P07636337A0687|128 133|women
P07636337A0687|86 107|serum estradiol level
P07636179A0000|104 114|G1 cyclins
P07636179A0000|12 22|cell cycle
P07636179A0000|87 98|protein pRb
P07635312A0692|133 141|interest
P07635312A0692|7 18|mutagenesis
P07635312A0692|115 129|act1 mutations
P07633756A0690|54 57|sum
P07633756A0690|84 107|background EEG activity
P07633756A0690|281 287|signal
P07633756A0690|67 74|signals
P07633756A0690|5 26|ARX2 procedure models
P07633756A0690|139 146|process
P07631267T0001|24 35|orchiectomy
P07631267T0001|39 47|stage D1
P07630687A0010|180 191|involvement
P07630687A0010|267 287|lupus anticoagulants
P07630687A0010|53 56|sex
P07630687A0010|48 51|age
P07630687A0010|326 331|event
P07630687A0010|193 203|prevalence
P07630687A0010|67 77|conditions
P07630687A0010|5 14|objective
P07630687A0010|207 219|antithrombin
P07629163A0770|181 195|transformation
P07629163A0770|24 41|deletion analysis
P07629163A0770|81 123|guanine nucleotide exchange factor domains
P07629123A0885|88 98|alteration
P07629123A0885|53 61|arginine
P07629123A0885|65 73|position
P07629123A0885|34 49|leucine residue
P07629113A0726|44 52|aspartyl
P07629113A0726|22 32|inhibitors
P07629113A0726|100 116|N-ethylmaleimide
P07628456A0000|107 114|variety
P07628456A0000|41 46|dsRBD
P07628456A0000|231 237|kinase
P07628456A0000|71 87|amino acid motif
P07628456A0000|239 242|PKR
P07628438T0000|73 84|development
P07628438T0000|97 114|receptor isoforms
P07627317A1502|30 35|mg/m3
P07627317A1502|47 52|shift
P07627317A1502|124 146|microgram/g creatinine
P07627317A1502|5 7|Al
P07626469A1341|107 111|MLTC
P07626469A1341|53 62|M1 domain
P07626469A1341|139 148|CHO cells
P07624615A0267|94 99|mEq/L
P07624615A0267|178 183|ratio
P07624615A0267|296 298|Pi
P07624615A0267|80 84|HCO3
P07624615A0267|19 35|body temperature
P07624615A0267|285 294|phosphate
P07624615A0267|228 232|Atot
P07624615A0267|7 15|decrease
P07624615A0267|168 170|OH
P07624119A0528|89 103|test fragments
P07624119A0528|214 224|cell types
P07624119A0528|141 147|domain
P07624119A0528|16 20|PAX3
P07623840A0352|45 54|sequences
P07623840A0352|77 85|activity
P07623840A0352|168 189|amino acid limitation
P07623825T0000|97 103|stress
P07623825T0000|49 66|heat shock factor
P07623821A0649|43 54|cis element
P07623821A0649|23 28|HRF-1
P07623807A0162|94 100|system
P07623807A0162|18 28|mechanisms
P07623807A0162|51 65|Raf-1 proteins
P07622521A0418|89 97|residues
P07622521A0418|188 196|beta ARK
P07622521A0418|19 26|mapping
P07622521A0418|167 184|carboxyl terminus
P07622521A0418|229 237|residues
P07622521A0418|200 205|order
P07622521A0418|34 61|G beta gamma binding region
P07622058A0411|52 54|aa
P07622058A0411|5 25|PEBP2 alpha proteins
P07616802A0315|135 141|return
P07616802A0315|88 96|patients
P07616802A0315|110 117|heparin
P07616802A0315|157 162|value
P07616802A0315|169 186|heparin cessation
P07616563A0532|79 84|DNase
P07616563A0532|108 110|bp
P07616563A0532|174 187|GATC sequence
P07615634A0535|104 111|protein
P07615634A0535|7 18|transcripts
P07615634A0535|119 121|kD
P07614762A0224|18 30|antigen test
P07612174A1064|92 96|PCBs
P07612174A1064|102 108|humans
P07610716A0117|5 13|analysis
P07610716A0117|69 81|MS-frequency
P07610052A1064|89 99|rat cortex
P07610052A1064|108 116|extracts
P07610052A1064|199 211|observations
P07610052A1064|23 32|complexes
P07610052A1064|173 182|relevance
P07610052A1064|48 51|C25
P07609079A0387|302 305|LTR
P07609079A0387|177 203|transcription factor TFIIB
P07609079A0387|59 75|receptor mutants
P07609079A0387|1 16|Transactivation
P07609079A0387|119 129|A/B region
P07608968A0836|21 32|Tat mutants
P07608968A0836|175 178|TBP
P07608968A0836|1 9|Analysis
P07608268A0194|208 209|n
P07608268A0194|198 206|controls
P07608268A0194|83 111|melatonin secretion profiles
P07608268A0194|141 150|males IGD
P07607607T0000|47 64|fructose infusion
P07607607T0000|33 40|oxalate
P07607342A0703|181 192|drug trials
P07607342A0703|123 131|patients
P07607342A0703|40 48|evidence
P07607342A0703|6 11|paper
P07607213A0140|105 114|evolution
P07607213A0140|146 156|mechanisms
P07607213A0140|76 82|issues
P07606587A0266|45 54|treatment
P07606587A0266|58 68|infections
P07605990A1110|225 231|levels
P07605990A1110|72 77|PEBP2
P07605990A1110|146 156|importance
P07605990A1110|64 68|role
P07605990A1110|85 109|GM-CSF promoter activity
P07604783A0952|27 34|changes
P07604783A0952|83 91|lecithin
P07604783A0952|102 123|bile acid composition
P07603956A0115|126 129|RSB
P07603956A0115|54 65|arrangement
P07603956A0115|18 24|design
P07603956A0115|153 161|chickens
P07601828A0095|63 68|class
P07601828A0095|9 15|report
P07601445A0207|145 152|Ce08102
P07601445A0207|54 61|homolog
P07601445A0207|156 178|Caenorhabditis elegans
P07601445A0207|184 191|members
P07601445A0207|204 218|protein family
P07601078A1003|212 216|% CI
P07601078A1003|154 156|OR
P07601078A1003|132 140|subjects
P07601078A1003|167 171|% CI
P07601078A1003|108 116|hypoergy
P07601078A1003|67 72|pg/m3
P07601078A1003|1 9|Subjects
P07600111A0000|268 281|Guinea-Bissau
P07600111A0000|113 124|virus types
P07600111A0000|84 89|HIV-2
P07600111A0000|162 172|infections
P07600111A0000|39 67|immunodeficiency virus types
P07600111A0000|207 217|infections
P07599449A0445|90 104|control groups
P07599449A0445|5 20|fracture groups
P07598106A0709|121 134|malocclusions
P07598106A0709|29 34|Class
P07598106A0709|113 118|Class
P07598106A0709|174 184|similarity
P07598106A0709|201 212|development
P07597488T0000|11 19|jaundice
P07597488T0000|51 62|kernicterus
P07596697A0971|134 147|control group
P07596697A0971|101 109|children
P07596697A0971|68 72|meal
P07596287A1724|41 54|bp transcript
P07596287A1724|5 15|ORF3 probe
P07596283A0396|77 80|oil
P07596283A0396|32 40|activity
P07596283A0396|117 126|emulsions
P07595374A1215|45 56|amino acids
P07595374A1215|131 140|promoters
P07595374A1215|112 122|activation
P07595374A1215|33 41|deletion
P07595374A1215|187 195|residues
P07594592A0755|109 117|proteins
P07594592A0755|17 50|NF-IL6 beta leucine zipper domain
P07593896A1053|123 132|equipment
P07593896A1053|27 48|measurement technique
P07592946A0997|28 38|TATA boxes
P07592946A0997|299 305|NF-IL6
P07592946A0997|144 148|half
P07592946A0997|188 201|binding sites
P07592946A0997|325 330|Zeste
P07592946A0997|166 173|element
P07592946A0997|130 138|GAGA box
P07592946A0997|64 82|start sites region
P07592946A0997|342 352|hepatocyte
P07592946A0997|275 278|p53
P07592790A1457|148 156|activity
P07592790A1457|55 63|subgroup
P07592790A1457|16 20|data
P07592730A0204|211 227|TSG-14 synthesis
P07592730A0204|242 250|organism
P07592730A0204|125 143|lipopolysaccharide
P07592730A0204|152 160|contrast
P07592730A0204|78 82|mice
P07592730A0204|39 44|PTX-3
P07592730A0204|69 74|serum
P07592721A0827|94 97|DNA
P07592721A0827|16 24|mutation
P07592710T0000|75 85|activation
P07592710T0000|26 44|protein kinase PKR
P07592676A0466|42 51|complexes
P07592676A0466|143 161|repressor activity
P07592647T0000|110 143|DNA Pur alpha recognition element
P07592647T0000|65 67|Rb
P07592485A0734|61 68|pathway
P07592485A0734|143 153|expression
P07592485A0734|18 33|gene expression
P07592485A0734|136 140|gene
P07592439A0000|1 5|A511
P07592220A0846|74 80|VE/VO2
P07592220A0846|11 14|PO2
P07592220A0846|23 28|ratio
P07592220A0846|99 105|PETCO2
P07590744A0829|93 99|clones
P07590744A0829|53 61|analysis
P07590744A0829|114 123|GAR1 gene
P07590525A0811|58 68|hamburgers
P07590525A0811|37 49|revertants/g
P07590268A0740|110 112|kb
P07590268A0740|83 94|transcripts
P07590264A0373|209 227|end RNA processing
P07590264A0373|92 98|levels
P07590264A0373|52 67|polyadenylation
P07590264A0373|191 202|differences
P07590264A0373|258 262|poly
P07590264A0373|37 48|differences
P07590264A0373|169 174|sense
P07590264A0373|102 106|DHFR
P07588777A1524|58 61|CTD
P07588777A1524|82 88|target
P07588777A1524|50 54|RNAP
P07588633A0362|181 191|efficiency
P07588633A0362|195 208|NIH 3T3 cells
P07588633A0362|25 52|c-fos protooncogene product
P07588608A1687|95 100|genes
P07588608A1687|232 239|effects
P07588608A1687|173 191|cell proliferation
P07588608A1687|81 91|ets family
P07588608A1687|1 12|Obstruction
P07588245T0000|15 29|glucocorticoid
P07588245T0000|89 113|thyroid hormone receptor
P07588245T0000|115 117|TR
P07586403A0765|72 77|range
P07586403A0765|127 134|weights
P07586403A0765|23 32|relations
P07586403A0765|65 69|RFSS
P07585246T0000|81 112|Caenorhabditis elegans pre-mRNA
P07585246T0000|51 54|RNA
P07583190A0306|125 141|brain potentials
P07583190A0306|267 276|area lead
P07583190A0306|96 106|hemisphere
P07583190A0306|320 330|assignment
P07583190A0306|152 156|area
P07582316A0696|24 29|pairs
P07582316A0696|80 103|IS6110 banding patterns
P07582316A0696|136 147|MTB strains
P07580782T0000|29 44|epidermoid cyst
P07580058A0000|148 154|plasma
P07580058A0000|41 47|liquor
P07580058A0000|58 91|tissue-type plasminogen activator
P07580058A0000|5 12|effects
P07580058A0000|49 53|CPOL
P07580058A0000|103 134|plasminogen activator inhibitor
P07579695A0693|45 57|Mif2 protein
P07579695A0693|110 126|yeast centromere
P07579695A0693|86 96|centromere
P07579695A0693|171 178|complex
P07579683A0660|13 38|hGMR beta subunit mutants
P07579683A0660|1 9|Analyses
P07579683A0660|102 116|c-myc promoter
P07579328A0653|1 6|MZF-1
P07579328A0653|17 45|CAT reporter gene expression
P07579023A0214|90 97|patient
P07579023A0214|131 137|levels
P07579023A0214|71 81|medication
P07576307A1654|151 155|HeLa
P07576307A1654|110 118|extracts
P07576307A1654|87 96|complexes
P07576179A0781|44 61|CpG dinucleotides
P07575947T0000|17 26|electives
P07575416A1970|95 106|cDNA probes
P07575416A1970|6 10|work
P07575416A1970|116 129|PKC zeta mRNA
P07574682T0000|1 5|cDNA
P07572582A0000|133 148|calcium channel
P07572582A0000|66 80|chemical class
P07571766A0122|47 55|patients
P07571766A0122|130 134|pain
P07571766A0122|159 181|ST-segment depressions
P07571766A0122|20 30|percentage
P07569640A0539|42 56|albumin levels
P07569640A0539|1 24|Protein electrophoresis
P07569075A0585|181 190|histology
P07569075A0585|165 173|cytology
P07569075A0585|11 16|stage
P07569075A0585|22 42|lung cancer patients
P07569075A0585|156 158|CT
P07569075A0585|103 111|response
P07568576A0074|28 40|relationship
P07568576A0074|81 99|emotion dimensions
P07568116A0902|62 68|region
P07568116A0902|5 20|hydropathy plot
P07567980T0000|22 37|domain peptides
P07567980T0000|64 72|elements
P07567830A0072|165 170|years
P07567830A0072|128 133|males
P07567830A0072|138 145|females
P07567830A0072|1 8|METHODS
P07567079A0014|181 188|oocysts
P07567079A0014|53 60|oocysts
P07567079A0014|18 28|separation
P07567079A0014|192 201|C. parvum
P07567079A0014|8 14|method
P07567079A0014|66 71|feces
P07567079A0014|170 177|numbers
P07565776A0612|28 38|PBS2 genes
P07565776A0612|228 246|salt concentration
P07565776A0612|59 67|decrease
P07565776A0612|212 217|shift
P07565776A0612|168 176|increase
P07565776A0612|1 11|Disruption
P07565775A1265|182 188|enzyme
P07565775A1265|127 136|catalysis
P07565775A1265|45 46|V
P07565775A1265|12 21|mutations
P07565775A1265|78 86|affinity
P07565775A1265|173 176|GMP
P07565775A1265|101 104|GTP
P07565736A2134|62 92|GM-CSF receptor alpha promoter
P07565723A0200|44 59|phosphorylation
P07565723A0200|97 112|differentiation
P07565723A0200|86 92|growth
P07565713A0634|83 94|suppression
P07565713A0634|19 23|SCS1
P07565709A0000|94 104|activation
P07565709A0000|20 30|thymocytes
P07565709A0000|117 132|T-cell receptor
P07565688A0797|172 181|cytoplasm
P07565688A0797|140 147|protein
P07565688A0797|1 30|Immunofluorescence microscopy
P07565688A0797|186 193|nucleus
P07565672A0798|146 156|components
P07565672A0798|82 92|expression
P07565672A0798|4 9|cells
P07565113A0000|195 203|plasmids
P07565113A0000|80 88|deletion
P07565113A0000|32 49|transposon Tn4451
P07565049A1032|105 107|NB
P07565049A1032|46 53|outline
P07565049A1032|138 141|age
P07564210A0557|73 82|analgesia
P07564210A0557|57 68|anaesthesia
P07564210A0557|86 90|pigs
P07563994A0488|183 186|OLB
P07563994A0488|177 179|ml
P07563994A0488|146 156|blood loss
P07563994A0488|25 29|VTLB
P07563994A0488|73 77|VTLB
P07563994A0488|66 71|times
P07563994A0488|206 207|p
P07563090A0124|240 248|sequence
P07563090A0124|133 141|boundary
P07563090A0124|109 114|sites
P07563090A0124|250 254|PPT2
P07563090A0124|223 232|integrase
P07563090A0124|50 63|DNA synthesis
P07563072A0773|148 153|ppGpp
P07563072A0773|128 144|hypersensitivity
P07563072A0773|1 12|Comparisons
P07560662A0496|30 46|saline challenge
P07559650A0558|7 14|results
P07559650A0558|33 42|PCNA gene
P07559639A0996|79 89|activation
P07559639A0996|112 116|HSE2
P07559639A0996|18 40|R206S HSF substitution
P07559555A0557|53 60|EBS-CRE
P07559555A0557|17 22|c-Jun
P07559524A0000|33 47|growth factors
P07559488A0440|90 107|estradiol-17 beta
P07559488A0440|144 157|reporter gene
P07559488A0440|64 85|affinity binding site
P07559488A0440|187 194|type ER
P07559356T0000|135 144|fnrN gene
P07559356T0000|94 102|promoter
P07559356T0000|116 127|mutagenesis
P07559347A0000|5 15|expression
P07559347A0000|48 65|Bacillus subtilis
P07559347A0000|87 91|bglP
P07558583A0562|215 225|inhibitors
P07558583A0562|82 87|order
P07558583A0562|253 260|enzymes
P07558583A0562|70 78|sequence
P07558583A0562|50 61|derivatives
P07557717A0184|104 113|morbidity
P07557717A0184|10 18|division
P07557717A0184|59 68|diathermy
P07557424A0124|41 53|fusion clone
P07557424A0124|1 5|XYL1
P07557276A0526|27 30|ALT
P07557276A0526|110 119|infection
P07557276A0526|32 38|levels
P07555373A0000|90 98|controls
P07555373A0000|23 31|patients
P07555373A0000|1 16|Serum magnesium
P07553942A0810|72 82|Marchantia
P07553942A0810|97 103|genome
P07553942A0810|39 46|introns
P07553942A0810|50 55|rrn26
P07551787A0917|97 104|results
P07551787A0917|20 32|optimization
P07551787A0917|152 174|radiotherapy technique
P07549005A0530|93 98|place
P07549005A0530|65 78|Epon sections
P07548425A0000|109 112|Sur
P07548425A0000|78 84|nerves
P07548425A0000|235 245|S2-3 level
P07548425A0000|17 21|cats
P07547500A0066|45 53|GAL4-p40
P07547500A0066|167 172|yeast
P07547500A0066|82 88|domain
P07547500A0066|101 110|sequences
P07547500A0066|153 159|growth
P07546794A0100|88 93|signs
P07546794A0100|55 63|collapse
P07546293A0968|26 41|protein binding
P07546293A0968|5 12|results
P07545920A1336|28 38|hsiggll150
P07545920A1336|10 15|genes
P07544357A0808|91 102|LNCap cells
P07544357A0808|56 68|invasiveness
P07544357A0808|128 137|phenotype
P07544357A0808|219 242|prostate tumor behavior
P07544357A0808|38 51|tumorigenesis
P07544357A0808|152 163|correlation
P07543684A1027|60 69|regulator
P07543684A1027|132 136|CFTR
P07543684A1027|39 42|PKA
P07543684A1027|119 128|induction
P07542616A0486|120 145|yeast initiation factor-3
P07542616A0486|109 116|subunit
P07542616A0486|179 186|complex
P07542616A0486|155 160|eIF-3
P07542616A0486|1 6|GCD10
P07542577A0438|95 100|order
P07542577A0438|36 41|ELISA
P07542577A0438|64 69|panel
P07542577A0438|87 91|sera
P07541589A0652|13 22|variables
P07541589A0652|58 63|grade
P07541589A0652|117 138|lymph node metastasis
P07540773A0576|23 26|MBP
P07540773A0576|69 72|PVB
P07539314T0000|91 99|exposure
P07539314T0000|127 133|P-7138
P07539314T0000|117 125|Furanace
P07539314T0000|50 56|chanos
P07539119A0291|60 79|c-abl kinase domain
P07539119A0291|124 138|transformation
P07539119A0291|83 95|NH2-terminus
P07539119A0291|101 115|G128R mutation
P07538173A0307|61 75|ATP hydrolysis
P07538173A0307|96 99|Mg2
P07538173A0307|138 146|strength
P07538173A0307|84 92|presence
P07538068A1094|97 111|Hox expression
P07538068A1094|53 55|AX
P07538068A1094|85 93|boundary
P07537851A0000|31 53|cell adhesion molecule
P07537851A0000|145 173|cytokines interleukin-1 beta
P07537851A0000|65 69|gene
P07537851A0000|1 14|Transcription
P07537362A1112|29 58|Shb-SH3 domain proteins v-Src
P07537362A1112|9 20|association
P07535768A1076|128 151|MAP kinase phosphatases
P07535768A1076|96 100|PAC1
P07535768A1076|80 90|mouse MKP1
P07535768A1076|1 10|HVH2 mRNA
P07534306A0444|31 47|GrsA derivatives
P07534306A0444|317 325|D-isomer
P07534306A0444|247 254|ability
P07534306A0444|307 308|L
P07534306A0444|288 301|phenylalanine
P07534286A0842|115 124|paxil-lin
P07534286A0842|70 77|protein
P07533880T0000|56 59|RNA
P07533880T0000|5 17|FinO protein
P07533880T0000|100 116|duplex formation
P07533758A1038|91 92|%
P07533758A1038|106 116|similarity
P07533758A1038|43 47|RfbA
P07533758A1038|52 65|RfbB homologs
P07533758A1038|98 99|%
P07532278A0833|10 12|I.
P07530549A0956|224 232|portions
P07530549A0956|122 128|clones
P07530549A0956|93 101|evidence
P07530549A0956|36 41|BLAST
P07530549A0956|174 180|clones
P07530549A0956|17 26|sequences
P07530502A0974|46 63|SI4-h220 cultures
P07530502A0974|39 42|SLF
P07530502A0974|1 9|Addition
P07529516A0474|80 89|mg/m2/day
P07529516A0474|16 24|patients
P07529124A0119|160 163|kDa
P07529124A0119|129 137|subunits
P07529124A0119|36 38|RT
P07529124A0119|206 226|amino acid sequences
P07528772A0616|363 371|TCR zeta
P07528772A0616|335 347|TCR zeta cyt
P07528772A0616|259 267|peptides
P07528772A0616|319 333|TCR zeta chain
P07528772A0616|79 82|TCR
P07528772A0616|131 172|glutathione S-transferase fusion proteins
P07528772A0616|99 112|binding assay
P07528772A0616|34 46|requirements
P07528667A0834|38 47|positions
P07528325A0165|182 189|nucleus
P07528325A0165|79 84|Stat1
P07528325A0165|53 64|GH receptor
P07528325A0165|100 120|transcription factor
P07527168A0524|78 90|angiogenesis
P07527168A0524|1 13|Microvessels
P07525843A0859|120 132|target cells
P07525843A0859|210 214|H-2d
P07525843A0859|331 340|H-2b mice
P07525843A0859|22 38|H-2d NP peptides
P07525843A0859|221 257|histocompatibility complex molecules
P07525843A0859|284 291|account
P07525843A0859|317 323|NP CTL
P07525843A0859|201 205|H-2b
P07525843A0859|306 313|removal
P07525843A0859|68 83|H-2b NP peptide
P07525548A1380|150 170|fibronectin variants
P07525548A1380|24 33|hierarchy
P07525548A1380|5 12|results
P07525548A1380|137 140|CS1
P07523710T0000|124 139|ultrasonography
P07523710T0000|96 107|examination
P07523710T0000|48 62|serum prostate
P07522163T0000|105 108|MHC
P07522163T0000|123 130|C57BL/6
P07522163T0000|77 103|histocompatibility complex
P07522163T0000|158 171|T lymphocytes
P07522163T0000|251 266|CTL recognition
P07522163T0000|1 13|Presentation
P07521601A0000|75 87|myelopoiesis
P07521601A0000|124 139|cancer patients
P07521009A0377|31 35|pms3
P07521009A0377|178 184|Kramer
P07521009A0377|159 162|G/G
P07521009A0377|154 157|A/C
P07521009A0377|164 168|etc.
P07521009A0377|133 147|DNA mismatches
P07521009A0377|7 14|mutants
P07519606A1269|97 112|lamellar bodies
P07519606A1269|117 128|homogenates
P07519463A0000|60 81|segment work/regional
P07519463A0000|140 146|inflow
P07518578A0000|29 47|Rous sarcoma virus
P07518578A0000|321 330|pp60c-src
P07518578A0000|203 218|binding ability
P07518578A0000|49 58|pp60v-src
P07518578A0000|220 229|pp60v-src
P07518460A0771|14 18|hand
P07518460A0771|39 44|PTP1C
P07518460A0771|68 72|site
P07518257A0351|121 123|P2
P07518257A0351|111 115|gene
P07518257A0351|5 14|promoters
P07518257A0351|34 53|S1 nuclease mapping
P07517544A0515|224 228|time
P07517544A0515|29 39|regression
P07517544A0515|161 169|function
P07517544A0515|9 13|days
P07517544A0515|59 70|alterations
P07516597A1017|44 54|processing
P07516597A1017|122 136|proteinase NS3
P07516597A1017|163 175|presentation
P07516597A1017|80 99|polyprotein segment
P07516597A1017|204 222|T cell determinant
P07516466A1054|14 23|injection
P07516466A1054|193 214|phosphorylation state
P07516466A1054|179 185|effect
P07516466A1054|218 222|CREB
P07516466A1054|253 266|NIH 3T3 cells
P07516466A1054|68 77|t antigen
P07514301A0000|94 98|role
P07514301A0000|54 57|PKR
P07514301A0000|115 122|defense
P07514301A0000|137 146|infection
P07513703T0000|64 71|SH-PTP2
P07513703T0000|103 111|peptides
P07512258A0441|30 37|patient
P07512258A0441|133 144|neutropenia
P07512258A0441|162 167|G-CSF
P07512258A0441|119 125|status
P07511818A0485|211 225|control vector
P07511818A0485|133 137|rate
P07511818A0485|184 189|cells
P07511818A0485|85 95|production
P07511444T0000|98 125|bone marrow transplantation
P07511444T0000|50 63|liver failure
P07511444T0000|34 45|risk factor
P07510724A1208|163 174|sarcoidosis
P07510724A1208|5 16|lymph nodes
P07510724A1208|33 41|patients
P07510724A1208|100 111|granulomata
P07510461A0731|5 12|patient
P07509624T0000|151 161|chromosome
P07509624T0000|12 19|mapping
P07509624T0000|52 74|chromosome aberrations
P07509450A0705|15 34|methylation pattern
P07509450A0705|42 54|inactivation
P07509450A0705|81 92|methylation
P07509450A0705|185 205|HSV tk gene activity
P07509053A0139|47 55|function
P07509053A0139|95 108|establishment
P07509053A0139|5 9|role
P07508441A0487|242 261|amino acid sequence
P07508441A0487|354 364|annexin XI
P07508441A0487|118 135|HeLa cell extract
P07508441A0487|74 81|protein
P07508441A0487|382 384|Ca
P07508441A0487|97 112|56K autoantigen
P07508441A0487|368 374|member
P07508441A0487|341 350|homologue
P07508441A0487|1 11|Antibodies
P07508441A0487|137 152|cDNA sequencing
P07508140A0448|71 97|hepatitis C virus antibody
P07507458A0250|44 52|patients
P07507458A0250|123 133|antibodies
P07507458A0250|99 116|hepatitis C virus
P07507458A0250|118 121|HCV
P07507187T0000|14 25|enhancement
P07507187T0000|58 75|cointernalization
P07507187T0000|1 10|Mechanism
P07505798A0000|75 88|hemagglutinin
P07505798A0000|120 125|class
P07505798A0000|195 208|T lymphocytes
P07505798A0000|27 32|sites
P07505798A0000|162 165|MHC
P07504712A0843|60 83|cell substrate adhesion
P07504712A0843|7 19|observations
P07504171A0715|160 179|PDGF-R binding site
P07504171A0715|52 66|phosphopeptide
P07504171A0715|184 187|Src
P07501700A0000|90 108|micrograms/kg i.v.
P07501700A0000|214 218|dogs
P07501700A0000|82 85|MLA
P07501700A0000|32 52|pretreatment regimen
P07501016T0000|16 26|giga-maser
P07500950A0000|36 45|rolC gene
P07500950A0000|3 20|tobacco homologue
P07500386A0870|41 51|constructs
P07500386A0870|126 131|yeast
P07500386A0870|16 39|GapIII protein activity
P07499421A0237|150 200|chloramphenicol acetyltransferase reporter plasmid
P07499421A0237|110 116|CYP3A1
P07499421A0237|71 95|rat hepatocytes plasmids
P07499401A0444|60 61|F
P07499401A0444|79 80|H
P07499401A0444|22 30|hnRNPs H
P07499401A0444|54 55|H
P07499401A0444|86 87|F
P07499252A0150|47 65|consensus sequence
P07499252A0150|22 26|hGMR
P07499252A0150|158 168|activation
P07499252A0150|81 92|PI 3-kinase
P07499252A0150|119 128|mechanism
P07498791A0680|165 190|osmolarity stress pathway
P07498791A0680|123 137|protein kinase
P07498791A0680|86 90|gene
P07496400A0525|123 128|plant
P07496400A0525|94 100|levels
P07496400A0525|108 115|tissues
P07496400A0525|232 237|roots
P07496400A0525|4 12|contrast
P07496400A0525|171 177|levels
P07495726A1189|24 33|Chi motif
P07495726A1189|178 189|T-ALL lines
P07495726A1189|142 147|close
P07495726A1189|49 56|element
P07495059T0078|1 8|Results
P07494306A0240|182 193|polypeptide
P07494306A0240|244 256|protein VP22
P07494306A0240|21 30|potential
P07494306A0240|35 39|VP16
P07494293A0585|121 124|Lck
P07494293A0585|53 58|stage
P07494293A0585|157 167|activation
P07494244A0335|72 77|c-fos
P07494244A0335|27 30|YY1
P07494244A0335|144 147|CRE
P07494244A0335|19 25|E1A243
P07493327A0507|63 65|U2
P07493327A0507|50 59|integrity
P07491305A0102|6 11|study
P07491305A0102|33 45|localization
P07491305A0102|118 129|QRS complex
P07491305A0102|102 110|polarity
P07490770A0267|182 198|DNA endonuclease
P07490770A0267|58 64|intron
P07490770A0267|21 31|coxI genes
P07490770A0267|50 55|group
P07490742A0636|37 43|notion
P07490742A0636|53 74|dsRNA binding domains
P07490156A0647|75 79|mass
P07490156A0647|92 99|modulus
P07490156A0647|1 11|Vitamin D3
P07490079T0000|135 139|loci
P07490079T0000|11 18|cloning
P07490079T0000|82 86|gene
P07490079T0000|103 110|mapping
P07489502A0000|88 98|activities
P07489502A0000|178 195|pre-mRNA splicing
P07489502A0000|65 74|regulator
P07489502A0000|154 159|mRNAs
P07488291A0934|47 59|somatostatin
P07488291A0934|113 118|signs
P07488291A0934|153 176|triamcinolone acetonide
P07487908A0230|105 108|CAT
P07487908A0230|146 152|AR-42J
P07487908A0230|197 200|Rat
P07487908A0230|189 195|origin
P07487908A0230|71 103|chloramphenicol acetyltranferase
P07487908A0230|207 210|IEC
P07487363A0447|30 35|asIgE
P07487363A0447|5 17|serum levels
P07487363A0447|64 78|food allergens
P07483857A0350|180 205|connective-tissue-protein
P07483857A0350|115 158|connective-tissue-protein frei meat protein
P07483857A0350|103 110|protein
P07483276A0139|90 93|UL1
P07483276A0139|240 262|varicella-zoster virus
P07483276A0139|208 211|PRV
P07483276A0139|144 152|proteins
P07483276A0139|156 178|herpes simplex virus-1
P07483276A0139|17 25|sequence
P07483276A0139|130 138|homology
P07483276A0139|100 103|UL3
P07479004A0421|47 51|PERE
P07479004A0421|148 153|cells
P07479004A0421|82 84|P1
P07479004A0421|71 80|complexes
P07479004A0421|136 140|HeLa
P07478523A0551|41 57|amino acid forms
P07478523A0551|4 12|addition
P07477245A0625|90 94|ones
P07477245A0625|126 140|concentrations
P07477245A0625|112 114|G1
P07477245A0625|50 72|aflatoxins B1 B2 G1 G2
P07477245A0625|171 176|mg/kg
P07476971A0381|67 93|transcription factor Pit-1
P07476701A0654|77 84|pollens
P07476701A0654|103 117|correspondence
P07475793T0000|1 4|BSE
P07474772A0274|128 138|appearance
P07474772A0274|5 34|Laser Scanning Ophthalmoscope
P07474451A0000|29 32|MRI
P07474451A0000|95 106|differences
P07474451A0000|82 91|pathology
P07474124A1360|133 144|differences
P07474124A1360|7 14|results
P07474124A1360|113 120|viruses
P07474124A1360|217 231|F glycoprotein
P07474124A1360|205 209|tail
P07474078A0838|111 126|CA dinucleotide
P07474078A0838|55 74|integration studies
P07474078A0838|171 172|%
P07473169A0133|94 114|superoxide dismutase
P07473169A0133|1 6|EUK-8
P07472582A0993|30 40|myocardium
P07472582A0993|130 138|severity
P07472582A0993|5 19|identification
P07472582A0993|155 163|activity
P07472582A0993|51 68|99mTc-tetrofosmin
P07469692A0000|129 136|members
P07469692A0000|155 163|families
P07466831A0714|105 124|porphyrin excretion
P07466831A0714|166 183|porphyrin pattern
P07466831A0714|1 18|Pentachlorophenol
P07466831A0714|68 73|words
P07463294A1216|105 110|group
P07463294A1216|131 136|group
P07463294A1216|6 8|wk
P07463294A1216|168 173|group
P07463294A1216|84 89|group
P07461848A0230|92 95|ppm
P07461848A0230|179 192|micrograms/m3
P07461848A0230|119 122|ppb
P07461848A0230|166 172|matter
P07461848A0230|110 113|NO2
P07461848A0230|5 16|mean values
P07461848A0230|139 152|micrograms/m3
P07458171A0086|20 27|species
P07458171A0086|35 49|Platyhelmintha
P07455042A0457|62 70|machines
P07455042A0457|27 34|imaging
P07455042A0457|142 160|density resolution
P07455042A0457|250 254|vein
P07455042A0457|222 228|atrium
P07450388A0406|133 150|duodenofiberscope
P07450388A0406|109 124|pressure sensor
P07450388A0406|67 71|part
P07450388A0406|18 24|effect
P07449253A0411|145 157|blood volume
P07449253A0411|76 77|h
P07449253A0411|55 59|mmHg
P07449253A0411|33 41|pressure
P07445971A0241|10 18|response
P07445971A0241|34 44|acrylamide
P07438346A0381|91 92|%
P07438346A0381|95 101|action
P07438346A0381|144 145|%
P07438346A0381|4 6|pH
P07436702A0156|46 50|DNFB
P07436702A0156|34 42|reaction
P07436187A0147|161 168|factors
P07436187A0147|172 182|disability
P07436187A0147|81 87|entity
P07434456A0286|208 213|index
P07434456A0286|218 227|osmometry
P07434456A0286|141 153|measurements
P07434456A0286|71 79|glycerol
P07432288A0218|99 108|infection
P07432288A0218|87 95|duration
P07429009T0121|13 20|anatomy
P07426745A0177|15 21|growth
P07426745A0177|130 134|dose
P07426745A0177|25 58|blood erythrocyte membrane injury
P07426101A0124|9 15|plasma
P07426101A0124|196 213|bicycle ergometer
P07426101A0124|249 264|training period
P07426101A0124|54 96|adipose tissue lipoprotein lipase activity
P07426101A0124|98 117|anthropometric data
P07423803T0001|26 37|peritonitis
P07418829A0191|22 33|observation
P07418829A0191|1 13|Implications
P07416204A0437|93 95|t0
P07416204A0437|185 197|potentiation
P07416204A0437|105 111|timing
P07416204A0437|167 169|t1
P07416204A0437|41 53|potentiation
P07416204A0437|142 144|t0
P07414817T0001|32 40|glaucoma
P07413781A0169|120 131|stimulation
P07413781A0169|149 161|conditioning
P07413781A0169|101 111|inhibition
P07413781A0169|49 69|stimulus preexposure
P07413242A0000|59 66|lesions
P07413242A0000|33 44|paraplegics
P07410037A0752|198 205|calcium
P07410037A0752|10 23|stone-formers
P07410037A0752|66 86|magnesium metabolism
P07410037A0752|54 62|features
P07410037A0752|186 194|relation
P07406527A0212|160 161|%
P07406527A0212|42 61|porphyrin excretion
P07406527A0212|141 148|animals
P07406527A0212|70 87|porphyrin content
P07401318A0823|44 53|staircase
P07401318A0823|113 115|Hz
P07396545A0217|52 58|course
P07396545A0217|1 13|Chemotherapy
P07394364A0738|240 244|lung
P07394364A0738|147 153|levels
P07394364A0738|191 196|rates
P07394364A0738|255 258|VO2
P07393856A0314|77 95|reference standard
P07393856A0314|6 12|result
P07393856A0314|55 61|apo-EE
P07387242A0236|126 136|hemoglobin
P07387242A0236|159 177|clotting functions
P07387242A0236|1 16|Blood variables
P07386500A0174|10 32|clotting factor assays
P07386500A0174|66 74|factor X
P07386500A0174|100 104|cent
P07385920A0189|150 154|acid
P07385920A0189|5 12|results
P07385920A0189|32 48|blood lead level
P07380615A0478|193 208|work efficiency
P07380615A0478|40 51|possibility
P07380615A0478|297 311|collar workers
P07380615A0478|283 287|jobs
P07377954A0117|363 371|subjects
P07377954A0117|301 311|volunteers
P07377954A0117|249 270|gastrocnemius muscles
P07377954A0117|321 356|postexercise ankle pressure changes
P07377954A0117|184 201|health volunteers
P07377954A0117|75 81|system
P07377954A0117|227 235|tibialis
P07377954A0117|278 286|exercise
P07377954A0117|207 219|emg activity
P07377954A0117|170 178|exercise
P07376165T0001|1 8|Ecthyma
P07375836T0000|27 34|patient
P07375836T0000|53 63|metastasis
P07372433A0000|44 61|guinea pig ureter
P07372433A0000|27 40|relationships
P07372433A0000|97 102|weeks
P07369183T0000|9 18|artifacts
P07356273T0022|28 43|cell carcinomas
P07354367A0162|29 33|head
P07354367A0162|1 12|Hypotension
P07341346A0174|74 82|arteries
P07341346A0174|20 33|shunt vessels
P07337609A0531|209 221|immunization
P07337609A0531|124 132|chickens
P07337609A0531|157 166|intervals
P07337609A0531|185 197|immunization
P07328000T0000|1 22|Nutritional cataracts
P07326596A0061|5 19|IgA deficiency
P07323063A0000|106 110|SHRs
P07323063A0000|177 199|mg/kg dl-isoproterenol
P07323063A0000|264 271|failure
P07323063A0000|64 68|rats
P07312707T0000|24 28|cord
P07312707T0000|34 42|F344 rat
P07310206A0154|5 17|architecture
P07310206A0154|21 37|microvasculature
P07308849A0817|15 26|differences
P07308849A0817|126 132|weight
P07308849A0817|49 71|sham operation animals
P07304905A0336|58 69|Heparin-DPD
P07304905A0336|1 16|Autotransfusion
P07298523T0000|11 23|indomethacin
P07298523T0000|1 7|Effect
P07298209A0291|31 51|performance capacity
P07298209A0291|93 100|VO2 max
P07298209A0291|65 69|W170
P07298209A0291|154 171|bicycle ergometer
P07297576A0454|92 106|drinking water
P07296303A0418|14 23|brainstem
P07296303A0418|43 51|dorsalis
P07296303A0418|101 108|latency
P07295033A0513|28 29|%
P07295033A0513|8 14|period
P07295033A0513|96 101|urine
P07295033A0513|87 88|%
P07293100T0001|56 71|system diseases
P07283110A0000|11 13|B1
P07283110A0000|50 56|values
P07282552A0990|104 110|tissue
P07282552A0990|130 143|subepicardium
P07282552A0990|4 11|Group V
P07282552A0990|87 91|zone
P07280654A0000|20 23|HBE
P07280654A0000|4 14|literature
P07278104T0001|80 90|bronchitis
P07276210T0000|31 38|trypsin
P07276210T0000|94 102|fibrosis
P07276210T0000|48 59|blood spots
P07274482A0000|90 105|afterdischarges
P07274482A0000|121 126|sound
P07274482A0000|132 140|velocity
P07274482A0000|148 156|movement
P07274482A0000|69 80|selectivity
P07274042A0249|62 67|group
P07274042A0249|86 94|patients
P07270163A0684|28 39|projections
P07270163A0684|131 136|layer
P07270163A0684|189 196|vessels
P07270163A0684|81 84|CNF
P07270163A0684|100 109|structure
P07267675A0000|29 42|cephalosporin
P07267675A0000|108 116|patients
P07264787A0351|73 84|thyroiditis
P07264787A0351|12 20|patients
P07264787A0351|53 61|evidence
P07263421A0351|15 18|So2
P07263421A0351|57 58|%
P07263421A0351|64 71|control
P07262625A0000|265 280|corticosteroids
P07262625A0000|332 338|course
P07262625A0000|114 140|host parasite relationship
P07262625A0000|155 163|steroids
P07262625A0000|254 261|effects
P07262625A0000|315 324|intestine
P07262625A0000|204 222|protozoal parasite
P07260987A0336|30 57|disposition phase t1/2 beta
P07260987A0336|79 83|hour
P07260987A0336|113 121|function
P07260987A0336|87 94|rabbits
P07259325A0394|74 83|diagnosis
P07259325A0394|66 70|date
P07259325A0394|1 9|Survival
P07253335T0000|12 36|prostaglandin inhibitors
P07253335T0000|53 64|proteinuria
P07253335T0000|69 75|stroke
P07251564A0569|14 15|%
P07251564A0569|70 79|diagnosis
P07249660T0000|25 39|distensibility
P07249660T0000|71 83|hypertension
P07249497A0688|45 57|estrogen PPI
P07249497A0688|198 205|courses
P07249497A0688|173 181|patients
P07249497A0688|86 91|women
P07243380A0327|44 45|P
P07243380A0327|13 21|acidosis
P07243380A0327|7 9|hr
P07240343A0000|44 48|rats
P07240343A0000|59 74|post conception
P07240343A0000|52 55|day
P07237560A1038|75 85|inactivity
P07237560A1038|11 20|deletions
P07237560A1038|108 120|substitution
P07237560A1038|32 40|sequence
P07237560A1038|136 143|portion
P07236351A0812|105 108|CA4
P07236351A0812|41 44|EEG
P07236351A0812|20 28|recovery
P07235317T0000|45 63|Phadebas RAST test
P07234755A0838|56 57|%
P07234755A0838|35 43|Hematrak
P07228955A0000|40 52|interference
P07228955A0000|131 141|metabolite
P07228955A0000|145 153|caffeine
P07225540A0193|135 145|techniques
P07225540A0193|37 70|electron capture detection method
P07221354T0000|44 51|summary
P07221354T0000|12 24|applications
P07221354T0000|1 7|Theory
P07218008T0000|31 38|neurons
P07218008T0000|196 201|areas
P07218008T0000|127 137|comparison
P07218008T0000|80 90|owl monkey
P07217329A0000|243 257|chromatography
P07217329A0000|292 303|UV detector
P07217329A0000|44 57|determination
P07217329A0000|108 119|metabolites
P07217329A0000|140 159|dinoracetylmethadol
P07217329A0000|64 84|alpha-acetylmethadol
P07217329A0000|3 9|method
P07214230T0000|15 39|Fusarium moniliforme var
P07214230T0000|66 71|agent
P07214230T0000|101 131|soil bacterium Arthrobacter sp
P07205967T0000|44 51|partner
P07205967T0000|9 17|reaction
P07205967T0000|55 63|response
P07203410T0000|47 55|patients
P07203410T0000|1 14|Family visits
P07202525A0200|74 81|stimuli
P07202525A0200|25 30|light
P07202525A0200|6 11|trial
P07202525A0200|35 41|buzzer
P07195880A0621|44 49|means
P07195880A0621|6 10|test
P07194905A0332|46 56|indication
P07194905A0332|109 119|hemorrhage
P07192369T0000|94 116|l-alpha-acetylmethadol
P07192369T0000|127 131|rats
P07192369T0000|48 56|toxicity
P07191804A0000|14 22|response
P07191804A0000|41 62|bicycle exercise test
P07191804A0000|86 92|cadets
P07190869A0316|28 33|agent
P07190869A0316|51 59|lymphoma
P07184795A0517|47 65|serum CPK activity
P07184795A0517|87 92|liter
P07184598T0001|10 19|secretion
P07183576A0157|144 146|SD
P07183576A0157|20 33|concentration
P07183576A0157|184 186|SD
P07183576A0157|220 232|micrograms/g
P07183576A0157|130 142|micrograms/g
P07183576A0157|234 236|SD
P07183576A0157|64 73|operation
P07183576A0157|170 182|micrograms/g
P07181985A0107|123 131|catheter
P07181985A0107|40 45|water
P07181985A0107|52 60|mg/40 ml
P07179412A1131|29 33|head
P07179412A1131|37 47|population
P07179412A1131|20 24|cost
P07174437A0181|38 45|bobcats
P07174046T0000|38 49|Maharashtra
P07174046T0000|1 17|Vibrio fluvialis
P07172690A0547|301 311|blood flow
P07172690A0547|146 152|ATPase
P07172690A0547|24 36|disturbances
P07172690A0547|54 70|energy transport
P07172690A0547|259 269|myocardium
P07172690A0547|72 90|creatine phosphate
P07172690A0547|173 182|reticulum
P07172690A0547|275 288|% restriction
P07168531T0001|29 37|parasite
P07168531T0001|50 56|cattle
P07162146A0000|126 144|gas chromatography
P07162146A0000|5 16|application
P07162146A0000|39 57|sample preparation
P07162146A0000|116 122|plasma
P07158726T0001|1 8|Triumph
P07154928T0001|1 13|Modification
P07149047A0260|13 24|dog vessels
P07149047A0260|70 78|Torr/cm2
P07143347T0000|26 35|disorders
P07140493A1045|120 134|acid secretion
P07140493A1045|109 110|%
P07140493A1045|6 11|study
P07140493A1045|84 88|rate
P07137927A0000|61 69|serology
P07137927A0000|78 87|diagnosis
P07137927A0000|110 118|diseases
P07136524A0180|58 65|tumours
P07136524A0180|98 105|tumours
P07136524A0180|18 28|literature
P07134924A0640|26 39|malformations
P07134924A0640|17 22|types
P07130335A1081|132 152|plasma 18-OHB levels
P07130335A1081|76 79|day
P07130335A1081|86 90|days
P07130335A1081|187 192|ng/dl
P07126067T0000|14 26|reproduction
P07126067T0000|50 55|fever
P07125064T0000|55 62|monkeys
P07125064T0000|102 121|Schistosoma mansoni
P07119890T0000|5 6|A
P07119890T0000|55 66|blood cells
P07119890T0000|16 22|method
P07116298A1079|330 338|patients
P07116298A1079|219 225|months
P07116298A1079|22 26|type
P07116298A1079|294 300|months
P07116298A1079|116 124|patients
P07116298A1079|135 157|Corynebacterium parvum
P07116298A1079|317 321|DTIC
P07116298A1079|174 180|months
P07116298A1079|39 46|therapy
P07113897A0285|61 68|studies
P07113897A0285|302 303|p
P07113897A0285|122 124|NS
P07113897A0285|27 38|differences
P07113897A0285|212 223|correlation
P07113897A0285|260 266|values
P07113897A0285|250 256|groups
P07113897A0285|135 143|exercise
P07113897A0285|42 44|EF
P07113897A0285|97 98|%
P07112654A0388|148 156|patients
P07112654A0388|48 58|difference
P07112320A0086|65 69|time
P07112320A0086|35 38|ADA
P07109788A0333|55 63|vagotomy
P07109788A0333|68 80|pyloroplasty
P07107462A0202|97 105|increase
P07107462A0202|80 95|training period
P07107462A0202|34 52|dissociation curve
P07106534A0160|79 84|curve
P07106534A0160|9 12|way
P07106534A0160|112 115|man
P07106534A0160|155 158|rat
P07106534A0160|137 141|mass
P07105635A0412|60 68|majority
P07105635A0412|122 128|effect
P07105635A0412|140 147|beating
P07096587A0267|106 111|month
P07096587A0267|21 29|patients
P07096587A0267|186 194|material
P07094856A0115|38 45|fetuses
P07094856A0115|87 92|weeks
P07088195T0019|45 50|birds
P07088195T0019|32 41|UV vision
P07084617A0204|27 36|parasites
P07084617A0204|77 81|drug
P07084617A0204|99 101|wk
P07081327A0546|91 102|differences
P07081327A0546|79 83|zinc
P07081327A0546|64 74|phosphorus
P07079595A0848|124 145|diameter measurements
P07079595A0848|196 212|sperm production
P07079595A0848|53 61|diameter
P07079595A0848|81 82|P
P07076222A0543|48 54|issues
P07075024A0540|107 112|cases
P07075024A0540|71 75|CMIR
P07072635A0000|10 16|method
P07072635A0000|76 91|desferrioxamine
P07072635A0000|39 43|iron
P07068496A0000|147 159|rabbit lungs
P07068496A0000|99 117|sucrose indicators
P07068496A0000|17 23|volume
P07068493A0414|177 180|SIP
P07068493A0414|157 161|Torr
P07068493A0414|169 173|runs
P07068493A0414|17 21|rate
P07064923T0000|14 50|phenylalanine hydroxylase deficiency
P07064923T0000|1 10|Diagnosis
P07063606T0000|1 10|Microwave
P07062036A0072|41 55|sham operation
P07061263A0293|15 23|pressure
P07061263A0293|25 29|Pvas
P07061263A0293|96 99|min
P07053251A0666|73 78|tract
P07053251A0666|113 118|study
P07053251A0666|34 41|effects
P07045156A0204|37 42|assay
P07045156A0204|71 81|GBS sepsis
P07044562T0000|13 17|ApUp
P07040659A0212|135 146|improvement
P07040659A0212|95 103|patients
P07040659A0212|5 13|patients
P07040659A0212|119 124|group
P07038189A2301|46 54|efficacy
P07038189A2301|129 134|field
P07038189A2301|33 36|CXD
P07034479A1050|93 94|p
P07034479A1050|35 48|placebo group
P07021505A0510|28 34|supine
P07021505A0510|62 63|P
P07016141A0238|14 24|blood flow
P07016141A0238|43 53|blood flow
P07016141A0238|55 58|NBF
P07015018A0395|44 64|migration inhibition
P07015018A0395|79 85|assays
P07007181T0000|5 11|effect
P07007181T0000|54 64|microflora
P06997203A0325|181 182|%
P06997203A0325|63 67|test
P06997203A0325|52 54|HI
P06997203A0325|4 20|rubella patients
P06997203A0325|117 125|patients
P06994035T0001|24 46|steroid concentrations
P06994035T0001|50 66|radioimmunoassay
P06992600A0405|5 28|extraction measurements
P06984225A0367|28 29|%
P06984225A0367|46 58|patent graft
P06978566A0197|62 74|lung lesions
P06978566A0197|97 109|maximum dose
P06978566A0197|140 145|units
P06978566A0197|117 118|X
P06975206A0279|29 42|betamethasone
P06975206A0279|11 25|administration
P06975206A0279|131 142|growth rate
P06975206A0279|80 90|absorption
P06972501A0615|33 44|involvement
P06972179A0556|10 20|IgE levels
P06966678A0523|210 217|changes
P06966678A0523|29 38|clearance
P06966678A0523|246 256|injections
P06966678A0523|21 25|rate
P06966678A0523|118 128|metabolism
P06966678A0523|345 346|r
P06966678A0523|42 48|tracer
P06966678A0523|279 280|r
P06966678A0523|101 106|curve
P06966678A0523|304 310|atrium
P06962634A0190|14 21|methods
P06962634A0190|113 132|porphyrin transport
P06962634A0190|137 146|clearance
P06959130A0996|146 159|Arg180-Val181
P06959130A0996|5 26|arginyl peptide bonds
P06959130A0996|71 77|factor
P06957125T0000|46 50|beta
P06957125T0000|66 83|stimulating drugs
P06950004T0047|26 31|metal
P06950004T0047|10 22|distribution
P06950004T0047|87 96|specimens
P06948493T0026|8 18|variations
P06948493T0026|34 43|potential
P06946693T0000|8 30|prostaglandin F2 alpha
P06946693T0000|1 4|Use
P06938948T0001|11 14|IgA
P06938948T0001|92 98|mucosa
P06938948T0001|19 40|serum immunoglobulins
P06931124A0109|91 96|water
P06931124A0109|29 46|complex formation
P06931124A0109|66 67|n
P06919347T0001|56 62|School
P06919347T0001|9 13|year
P06919347T0001|81 90|education
P06919347T0001|17 25|planning
P06911559T0000|16 30|nurse managers
P06897114A0240|88 91|CAP
P06895559A0000|120 131|combination
P06895559A0000|46 58|aminophyllin
P06895559A0000|33 40|agonist
P06895559A0000|136 150|rabbit fetuses
P06891051A0587|44 53|platelets
P06891051A0587|86 96|correction
P06891051A0587|1 9|Survival
P06890622A0067|182 195|pre-eclampsia
P06890622A0067|126 138|hypertension
P06890622A0067|153 164|coagulation
P06886031A0898|120 129|test dose
P06886031A0898|145 148|day
P06886031A0898|7 17|PGE levels
P06883385A0509|105 111|values
P06883385A0509|4 12|patients
P06883385A0509|55 60|tumor
P06880650A0316|5 12|results
P06880563A0516|57 65|diabetes
P06880563A0516|82 87|women
P06880563A0516|96 99|men
P06880563A0516|39 43|type
P06880563A0516|184 198|administration
P06876006A0930|106 111|cases
P06876006A0930|40 49|diagnosis
P06876006A0930|1 16|Echosismography
P06873504T0000|63 92|sodium metabolism alterations
P06873504T0000|50 58|acidosis
P06869986A0000|94 101|lesions
P06869986A0000|118 127|ruminants
P06868345A0000|64 68|time
P06868345A0000|17 28|visna-maedi
P06864837T0000|1 9|Efficacy
P06858967A0167|33 51|haptoglobin levels
P06858640A0262|105 116|fibroblasts
P06858640A0262|59 66|amyloid
P06858640A0262|35 43|findings
P06856669A1004|111 117|output
P06856669A1004|7 14|results
P06856669A1004|65 69|5-HT
P06854957T0066|31 39|asynergy
P06854957T0066|50 66|echocardiography
P06851327A0000|74 91|Neisseria species
P06851327A0000|6 14|patients
P06849842T0000|52 66|granulopoiesis
P06842629A0446|61 77|treatment groups
P06842629A0446|47 52|shock
P06838388A0896|172 181|structure
P06838388A0896|143 156|normalization
P06838388A0896|80 85|place
P06838388A0896|50 62|tissue scars
P06835914A0192|106 117|differences
P06835914A0192|127 138|feed intake
P06835914A0192|154 162|practice
P06835914A0192|69 82|copper intake
P06833422T0000|62 72|dien-3-one
P06833422T0000|76 82|plasma
P06833422T0000|1 14|Determination
P06830351A0397|14 21|Sugiura
P06830351A0397|124 125|%
P06830351A0397|58 65|Type Ia
P06830351A0397|71 72|%
P06830351A0397|103 104|%
P06829082A0187|74 82|increase
P06829082A0187|226 230|rats
P06829082A0187|25 36|hypothermia
P06829082A0187|217 221|rats
P06826813A0264|46 55|exposures
P06826813A0264|1 9|Vesicles
P06823837A0562|111 117|groove
P06821147A0468|72 78|flours
P06821147A0468|1 20|Sulphur amino acids
P06817410A0982|60 72|epidemiology
P06817410A0982|135 143|increase
P06817410A0982|177 186|hepatitis
P06817410A0982|19 25|months
P06817410A0982|50 56|change
P06816442T0001|12 17|value
P06816442T0001|40 45|cases
P06816053A0849|63 67|cent
P06816053A0849|101 115|mast cell test
P06816053A0849|85 93|response
P06812389A0658|37 47|teratogens
P06810694A0328|128 135|apo A-I
P06810694A0328|116 124|decrease
P06810694A0328|17 32|HDL-cholesterol
P06809586T0000|1 29|Autoimmune manipulation aids
P06808529A0167|107 113|mmol/l
P06808529A0167|80 98|EDTA concentration
P06807659T0001|26 33|bacilli
P06807659T0001|1 13|Phagocytosis
P06807149T0000|47 68|disodium cromoglycate
P06807149T0000|76 86|prevention
P06807149T0000|136 141|study
P06805537T0001|52 58|factor
P06805537T0001|1 9|Advances
P06803634A0810|106 130|blood gas determinations
P06803634A0810|147 156|responses
P06803634A0810|27 40|relationships
P06803634A0810|4 13|silicosis
P06803634A0810|168 173|Paco2
P06801778T0001|31 52|gas exchange reaction
P06801778T0001|65 72|loading
P06801778T0001|1 13|Significance
P06797063A0000|62 85|von Willebrand activity
P06797063A0000|133 138|times
P06797063A0000|159 162|DIC
P06797063A0000|1 7|Factor
P06795971A0000|64 75|amelgenesis
P06795832A0148|90 104|HBe-antibodies
P06795832A0148|62 65|HBc
P06795832A0148|66 69|IgM
P06795832A0148|18 29|Hepatitis A
P06795119T0000|1 22|Lens aldose reductase
P06794480A0785|79 80|p
P06794480A0785|49 58|age group
P06791500A0622|94 104|management
P06791500A0622|70 81|cornerstone
P06788388A0000|27 33|action
P06788388A0000|158 167|compounds
P06788388A0000|139 146|studies
P06785113A0337|105 113|patients
P06784123A0771|73 81|mu chain
P06784123A0771|37 60|sequence characteristic
P06784123A0771|102 109|species
P06782869A0263|151 155|SGPT
P06782869A0263|89 92|BUN
P06782869A0263|145 149|SGOT
P06782869A0263|172 198|serum alkaline phosphatase
P06782869A0263|1 17|Nitrogen balance
P06781728A0690|148 162|bone formation
P06781728A0690|179 200|fluorochrome labeling
P06781728A0690|20 35|differentiation
P06781728A0690|80 87|failure
P06776918T0000|1 18|Trypanosoma cruzi
P06772612A0000|72 81|responses
P06772612A0000|43 50|blocker
P06772612A0000|52 63|haloperidol
P06772612A0000|1 8|Effects
P06767648A0734|60 66|values
P06767648A0734|1 13|Measurements
P06763897A0216|88 94|analog
P06763897A0216|67 78|angiotensin
P06763897A0216|96 100|Sar1
P06763897A0216|32 35|PRA
P06762025A0171|42 46|PGE2
P06762025A0171|5 38|13,14-dihydro-15-keto-metabolites
P06755986A0382|121 128|strains
P06755986A0382|95 99|mice
P06755986A0382|141 160|hospital infections
P06754662T0001|40 52|eosinophilia
P06751455A0117|31 41|gallstones
P06751455A0117|80 88|patients
P06751455A0117|98 106|glucagon
P06749072A0116|165 180|water immersion
P06749072A0116|58 67|excretion
P06749072A0116|71 76|urate
P06744024A0000|94 107|formalin test
P06744024A0000|145 149|pain
P06744024A0000|53 56|rat
P06740919A0162|108 112|calf
P06740919A0162|53 57|goat
P06740919A0162|38 44|nymphs
P06740373A0891|47 57|cynomolgus
P06740373A0891|9 14|study
P06740373A0891|34 41|captive
P06735247A0803|150 151|p
P06735247A0803|129 138|excretion
P06735247A0803|140 141|r
P06732946A0281|183 188|scale
P06732946A0281|24 29|areas
P06732946A0281|129 142|magnification
P06732946A0281|5 16|measurement
P06732946A0281|156 170|image analyser
P06728580A0291|122 130|students
P06728580A0291|108 114|result
P06728580A0291|55 62|records
P06726257A1179|211 243|autoreceptor antagonist activity
P06726257A1179|180 188|striatum
P06726257A1179|270 278|ABSTRACT
P06726257A1179|247 259|methiothepin
P06726257A1179|55 67|accumulation
P06726257A1179|134 146|hypothalamus
P06726257A1179|106 116|inhibition
P06726257A1179|71 74|LSD
P06721188A0200|72 85|contrast test
P06721188A0200|17 25|analysis
P06719057A0181|132 139|urogram
P06719057A0181|86 95|hematuria
P06719057A0181|35 52|vein phlebography
P06716977A0136|36 57|ethanol concentration
P06716977A0136|5 12|samples
P06714354A0194|73 80|removal
P06714354A0194|102 108|cortex
P06713204A0867|95 107|V1 component
P06713204A0867|65 70|state
P06712314A0148|9 15|number
P06709700A0230|12 23|compartment
P06709700A0230|40 48|severity
P06709700A0230|199 214|outcome measure
P06709700A0230|233 242|treatment
P06709700A0230|81 106|Hamilton Depression Scale
P06707357A0180|15 27|observations
P06707357A0180|196 211|volume overload
P06707357A0180|136 147|differences
P06707357A0180|68 81|regurgitation
P06704467A0539|54 58|bats
P06704467A0539|32 43|photoperiod
P06702257T0001|21 32|hip surgery
P06700231A0259|15 30|tumor resection
P06700231A0259|131 135|year
P06700231A0259|116 122|months
P06694778A0000|93 100|imaging
P06694778A0000|54 81|redistribution thallium-201
P06692631A0129|10 19|interface
P06692631A0129|112 116|bone
P06692631A0129|50 74|microstress distribution
P06691304A0284|122 127|males
P06691304A0284|41 47|values
P06691304A0284|77 87|deviations
P06691304A0284|5 10|range
P06689413A0174|30 36|Am-241
P06689413A0174|46 52|source
P06689413A0174|57 60|mCi
P06689413A0174|112 119|K alpha
P06689413A0174|71 82|Ge detector
P06689413A0174|153 156|KeV
P06686454A0585|145 164|Serratia marcescens
P06686454A0585|64 71|bacilli
P06686454A0585|169 176|Proteus
P06685536A0502|11 16|years
P06685536A0502|39 46|control
P06685004A0000|72 75|age
P06685004A0000|77 92|body mass index
P06685004A0000|113 120|fitness
P06685004A0000|65 69|SHBG
P06684624A0298|72 76|rats
P06684624A0298|21 32|mortalities
P06683807A0160|63 74|alcohol use
P06674977A1181|105 113|table VI
P06674977A1181|94 103|diagnosis
P06674977A1181|42 51|pregnancy
P06674977A1181|68 69|%
P06674374T0000|38 57|health-care workers
P06674374T0000|1 33|Hepatitis B vaccination strategy
P06671925T0000|63 73|volunteers
P06671925T0000|81 89|patients
P06671925T0000|1 24|Amikacin concentrations
P06671065A0000|37 44|insulin
P06671065A0000|18 30|lipoproteins
P06671065A0000|137 145|patients
P06670732A0000|30 38|patients
P06670732A0000|88 95|effects
P06670732A0000|178 185|Innovar
P06670732A0000|113 115|mg
P06670732A0000|257 267|parameters
P06670732A0000|17 22|study
P06670732A0000|173 175|mg
P06670732A0000|99 107|Fentanyl
P06670732A0000|137 145|Fentanyl
P06668316A0178|240 250|phenacetin
P06668316A0178|230 238|standard
P06668316A0178|96 115|baseline separation
P06668316A0178|274 277|min
P06668316A0178|119 129|antipyrine
P06667015A0832|72 76|wall
P06667015A0832|97 104|surgery
P06667015A0832|38 49|sensitivity
P06659982A0231|124 126|DS
P06659982A0231|364 368|life
P06659982A0231|21 30|structure
P06659982A0231|185 194|increases
P06659982A0231|254 260|change
P06659982A0231|227 232|sleep
P06659982A0231|234 236|PS
P06659982A0231|98 101|age
P06659982A0231|304 310|months
P06658445A0140|9 16|effects
P06658445A0140|80 87|amounts
P06657559A0489|88 91|age
P06657559A0489|244 258|blood pressure
P06657559A0489|45 57|control feed
P06657559A0489|229 239|heart rate
P06657559A0489|129 133|feed
P06657559A0489|279 288|half hour
P06657559A0489|207 223|ppm ochratoxin A
P06657559A0489|171 183|control feed
P06655634A0195|132 133|%
P06655634A0195|162 171|morbidity
P06655634A0195|22 30|patients
P06655634A0195|117 125|delivery
P06654047A0694|107 116|apoptosis
P06654047A0694|6 16|phenomenon
P06654047A0694|70 80|cell death
P06652293A0353|44 53|responses
P06652293A0353|24 29|point
P06652293A0353|85 86|%
P06643612A0000|106 111|urine
P06643612A0000|81 91|imipramine
P06630319A0244|104 111|animals
P06630319A0244|126 137|barbiturate
P06630319A0244|22 23|h
P06630319A0244|1 9|Brain pH
P06627569T0001|1 3|HL
P06625058A0666|5 15|population
P06615053A0202|165 171|RVEDVI
P06615053A0202|41 46|hours
P06615053A0202|157 163|volume
P06615053A0202|50 63|resuscitation
P06610347A0581|79 89|conduction
P06610347A0581|68 75|fashion
P06607714T0000|47 61|cyclosporin A.
P06607714T0000|1 16|Limb allografts
P06606043A0598|129 137|decrease
P06606043A0598|38 49|6-positions
P06606043A0598|101 109|position
P06602580A0664|14 21|history
P06602580A0664|107 118|individuals
P06602580A0664|57 69|otitis media
P06602580A0664|170 177|normals
P06599282T0001|67 74|gingiva
P06594105A0560|63 79|cent haematocrit
P06594105A0560|179 186|gingiva
P06594105A0560|223 232|lambda tp
P06594105A0560|16 22|values
P06594105A0560|194 197|dog
P06594105A0560|199 208|lambda cp
P06594105A0560|99 103|pulp
P06591992A0569|51 59|solution
P06588306A0076|82 85|AIL
P06588306A0076|87 102|AIEOP protocols
P06584416A0157|60 69|treatment
P06584416A0157|28 37|knowledge
P06584416A0157|126 129|PGF
P06584416A0157|82 92|angiograms
P06579152A1061|104 107|way
P06579152A1061|77 100|velopharyngeal activity
P06579152A1061|54 58|tool
P06571587T0000|12 20|ketamine
P06571587T0000|54 77|body tissue oxygenation
P06571587T0000|115 125|conditions
P06555107A1227|89 94|value
P06555107A1227|40 68|calcium antagonist Verapamil
P06555107A1227|18 32|administration
P06546392A0542|28 50|protein concentrations
P06546392A0542|9 18|respect C
P06546392A0542|141 155|concentrations
P06542918A1131|31 45|discrimination
P06542918A1131|65 69|time
P06541932A0000|96 103|effects
P06541932A0000|141 151|analgesics
P06539738T0000|56 59|CFC
P06539738T0000|19 29|evaluation
P06531286A0382|12 27|lipid fractions
P06531286A0382|99 110|HPLC column
P06531286A0382|85 91|damage
P06527379T0044|41 56|beta B1 subunit
P06524727A0601|73 81|prelabel
P06524727A0601|24 31|species
P06524727A0601|112 129|incubation period
P06524727A0601|1 12|Lymphocytes
P06521999A0677|28 35|results
P06521999A0677|55 64|melanomas
P06520418A0325|104 112|patients
P06520418A0325|5 12|results
P06520418A0325|70 73|MVA
P06520418A0325|50 68|valve orifice area
P06516977T0000|31 39|exercise
P06516977T0000|1 9|Reaction
P06516369T0001|1 12|Proteinuria
P06508393T0000|47 53|camels
P06508393T0000|18 33|trypanosomiasis
P06506074A0456|62 63|X
P06506074A0456|57 58|C
P06506074A0456|24 37|hen plasma TG
P06506074A0456|105 106|C
P06506074A0456|41 42|X
P06506074A0456|76 85|plasma TG
P06506074A0456|1 14|E2 treatments
P06503885A0342|61 66|water
P06503885A0342|244 266|xenon/CT rCBF protocol
P06503885A0342|6 19|machine drift
P06503885A0342|292 297|scans
P06503885A0342|137 152|x-ray tube heat
P06503132A0784|39 40|s
P06503132A0784|35 37|Hn
P06497671T0001|52 61|responses
P06494766A0241|91 97|septum
P06494766A0241|124 135|explanation
P06494215A0248|28 37|component
P06494215A0248|94 102|schedule
P06492188A0615|12 13|d
P06492188A0615|42 48|effect
P06486932A0000|165 170|death
P06486932A0000|29 38|occurring
P06486932A0000|79 94|Malumfashi area
P06486932A0000|116 120|data
P06486932A0000|16 22|deaths
P06482665A0735|211 220|increases
P06482665A0735|121 125|peak
P06482665A0735|89 95|height
P06482665A0735|283 288|state
P06482665A0735|5 13|findings
P06482179A0497|62 70|children
P06482179A0497|97 102|years
P06482179A0497|50 56|period
P06479976A0386|46 54|patients
P06479976A0386|213 221|patients
P06479976A0386|142 143|P
P06479976A0386|80 83|AMB
P06479976A0386|186 197|nerve signs
P06473252A1073|106 114|ABSTRACT
P06473252A1073|65 79|egg production
P06473252A1073|51 54|sex
P06468694A0441|195 205|components
P06468694A0441|56 62|system
P06468694A0441|66 70|dogs
P06468694A0441|20 35|caudate nucleus
P06468694A0441|115 125|micrograms
P06468694A0441|1 12|Stimulation
P06468632A0135|109 112|ear
P06468632A0135|58 64|rabbit
P06468632A0135|1 12|Endothelium
P06467797A0233|180 186|Swedes
P06467797A0233|146 148|rs
P06467797A0233|188 190|rs
P06467797A0233|19 30|correlation
P06467797A0233|109 117|D/4-OH-D
P06467797A0233|39 55|plasma clearance
P06467797A0233|102 107|ratio
P06466804A0686|13 24|endothelium
P06466804A0686|174 184|denudation
P06466804A0686|38 52|shear stresses
P06466804A0686|1 9|Exposure
P06466804A0686|220 228|dyne/cm2
P06460889A0512|133 141|pressure
P06460889A0512|4 9|doses
P06460889A0512|69 83|pulse pressure
P06460889A0512|85 95|heart rate
P06459831T0001|67 84|tobacco poisoning
P06459831T0001|1 15|Cardiovascular
P06453290A0000|133 138|weeks
P06453290A0000|5 16|development
P06452461A0930|58 65|pre-AVR
P06452461A0930|38 44|LVM/M2
P06452461A0930|70 86|post AVR studies
P06446048A0356|58 66|solution
P06443714T0001|45 63|babassu palm trees
P06443550T0000|5 15|management
P06439135A0250|45 50|xenon
P06439135A0250|61 69|patients
P06439135A0250|32 41|clearance
P06437579A0727|28 33|night
P06437579A0727|147 156|treatment
P06437579A0727|1 11|Cimetidine
P06437579A0727|84 96|dose regimen
P06434587A0551|94 96|LH
P06434587A0551|36 46|FSH levels
P06434587A0551|70 79|secretion
P06433442T0000|13 19|plasma
P06433442T0000|58 60|C.
P06433442T0000|1 9|Freezing
P06428116T0000|79 90|thyroiditis
P06419251T0000|61 73|requirements
P06419251T0000|1 21|Movement programming
P06414990A0057|29 33|data
P06414990A0057|124 130|limits
P06414990A0057|37 45|TRH test
P06414990A0057|17 25|analysis
P06412385A0356|28 40|lung disease
P06412385A0356|300 310|dependence
P06412385A0356|53 68|muscle weakness
P06412385A0356|154 161|maximum
P06412385A0356|119 127|capacity
P06412385A0356|135 148|lung capacity
P06412385A0356|11 19|patients
P06412385A0356|172 183|ventilation
P06412385A0356|100 109|decreases
P06411659A0264|38 49|consumption
P06411659A0264|70 74|rate
P06406060A0000|43 45|iv
P06406060A0000|64 68|mice
P06406060A0000|50 52|ip
P06402859A0000|88 96|thrombin
P06402859A0000|32 46|plasma protein
P06402859A0000|1 17|Antithrombin III
P06401749T0000|30 44|osmoregulation
P06401749T0000|48 78|arginine vasopressin secretion
P06395804A0382|33 42|organisms
P06395804A0382|68 71|min
P06394228T0073|1 8|Results
P06388818A0000|195 198|HDC
P06388818A0000|129 150|chemotherapy regimens
P06388818A0000|246 266|bone marrow infusion
P06388818A0000|5 13|patients
P06385474T0001|10 19|treatment
P06385474T0001|49 56|allergy
P06382374A0206|78 92|glucose levels
P06382374A0206|212 220|disorder
P06382374A0206|157 165|disorder
P06382374A0206|18 21|min
P06382374A0206|68 74|change
P06379363A0415|122 139|diabetes mellitus
P06379363A0415|93 100|therapy
P06374418A0877|74 80|amount
P06374418A0877|5 13|aspirate
P06373855A0000|31 38|papules
P06373855A0000|176 194|immunofluorescence
P06373855A0000|145 150|PLEVA
P06373855A0000|97 119|pityriasis lichenoides
P06373855A0000|64 71|lesions
P06372563T0000|104 116|hyponatremia
P06372563T0000|92 100|reversal
P06372563T0000|7 15|response
P06372563T0000|54 58|role
P06369954T0000|29 37|pressure
P06369954T0000|1 8|Effects
P06367414A0000|133 148|crossover trial
P06367414A0000|39 48|half-life
P06367414A0000|69 74|hours
P06362602T0001|124 129|swine
P06362602T0001|59 76|vaccine additives
P06362602T0001|49 55|action
P06362143A0565|61 65|tilt
P06362143A0565|98 106|patients
P06362143A0565|69 90|isoprenaline infusion
P06361318A0440|183 184|%
P06361318A0440|198 203|group
P06361318A0440|126 143|committee members
P06361318A0440|53 64|KS-R1 group
P06361318A0440|114 122|criteria
P06361318A0440|153 154|%
P06355483A0134|5 10|genes
P06355483A0134|19 24|locus
P06355483A0134|68 77|sequences
P06350092A0916|121 128|degrees
P06350092A0916|227 232|death
P06350092A0916|21 26|phase
P06350092A0916|49 53|CCHD
P06346427A0000|26 40|insulin levels
P06346427A0000|81 85|rats
P06342141A0226|423 435|consequences
P06342141A0226|605 610|study
P06342141A0226|189 199|modalities
P06342141A0226|292 297|needs
P06342141A0226|165 173|efficacy
P06342141A0226|42 55|understanding
P06342141A0226|507 524|literature review
P06342141A0226|305 311|family
P06342141A0226|390 400|importance
P06342141A0226|213 231|family health care
P06342141A0226|262 266|care
P06342141A0226|132 142|techniques
P06341139A0213|180 185|bread
P06341139A0213|56 60|time
P06341139A0213|191 192|g
P06341139A0213|221 229|g apples
P06341139A0213|106 115|ingestion
P06341139A0213|199 203|rice
P06341139A0213|96 99|min
P06341139A0213|237 246|g carrots
P06340643A0598|36 49|possibilities
P06340643A0598|19 28|extension
P06336045A0261a|14 18|Ft I
P06336045A0261a|24 33|frog type
P06336045A0261a|66 71|units
P06336045A0261a|38 40|Ft
P06336045A0261a|100 117|indentation phase
P06336045A0261a|1 10|Frog type
P06333433A0000|74 82|outbreak
P06333433A0000|95 123|H. influenzae type b disease
P06333433A0000|32 49|influenzae type b
P06333433A0000|204 207|LPS
P06330478A0304|23 33|cimetidine
P06330478A0304|99 104|doses
P06328504A0161|104 109|locus
P06328504A0161|114 137|phosphoglycerate kinase
P06328504A0161|139 142|PGK
P06328002A0000|60 67|passage
P06328002A0000|24 37|sarcoma virus
P06328002A0000|39 43|MPSV
P06327292A0846|93 105|start codons
P06325415A0757|45 53|Ad5 DBPs
P06325415A0757|61 68|absence
P06325415A0757|37 40|Ad7
P06325415A0757|143 150|domains
P06325415A0757|171 182|amino acids
P06324089A0453|13 22|structure
P06324089A0453|63 71|features
P06322183A1070|31 48|agar plate assays
P06322183A1070|144 152|presence
P06322183A1070|188 195|absence
P06322183A1070|156 164|cysteine
P06321634A0123|91 97|intron
P06321634A0123|161 178|TRs/IRs sequences
P06321634A0123|49 64|leader sequence
P06320380T0001|33 43|metastases
P06319421A0937|15 26|desipramine
P06319421A0937|107 125|mianserin blockade
P06319421A0937|163 186|alpha 2-adrenoreceptors
P06319421A0937|138 144|uptake
P06319071A0173|164 174|difference
P06319071A0173|40 48|subjects
P06319071A0173|114 124|AMP levels
P06319071A0173|251 261|creatinine
P06319071A0173|141 153|counterparts
P06318322A0350|135 140|virus
P06318322A0350|27 32|model
P06318322A0350|48 51|SSV
P06318322A0350|100 103|DNA
P06318078T0000|15 40|herpes simplex virus beta
P06318078T0000|97 106|induction
P06318078T0000|81 86|cells
P06316347A0852|72 80|proteins
P06316347A0852|5 14|dnaQ-lacZ
P06316347A0852|86 113|beta-galactosidase activity
P06314276T0000|72 77|cDNAs
P06314276T0000|18 25|cloning
P06314276T0000|84 91|control
P06310553T0000|62 79|muscle actin gene
P06310553T0000|38 44|origin
P06310159A0000|7 10|RNA
P06310159A0000|81 95|retrovirus MH2
P06309855T0000|44 58|porcelain frit
P06308607A0375|124 136|p30 sequence
P06308607A0375|42 51|sequences
P06308607A0375|71 92|DNA sequence analysis
P06308607A0375|103 114|nucleotides
P06307099A1005|1 13|Lung density
P06304771A1284|88 100|adenoviruses
P06304771A1284|199 211|JCV sequence
P06304771A1284|55 60|times
P06304771A1284|19 27|GGGXGGAG
P06300662T0000|76 81|cells
P06300662T0000|3 22|cDNA cloning vector
P06298014A0647|47 52|forms
P06298014A0647|109 114|units
P06298014A0647|5 14|ensembles
P06295429A0412|149 154|doses
P06295429A0412|123 136|sensitization
P06295429A0412|5 16|combination
P06295429A0412|201 206|doses
P06291369A0000|30 58|equilibrium ventriculography
P06291369A0000|198 215|ejection fraction
P06291369A0000|113 125|day interval
P06291369A0000|71 86|catheterization
P06290859A0426|63 88|hepatitis Bs antigenaemia
P06290859A0426|92 93|%
P06290859A0426|157 171|liver function
P06290859A0426|117 127|antibodies
P06287231A0914|14 32|TRP1 RI Circle DNA
P06287231A0914|78 85|spacing
P06287231A0914|69 73|size
P06286549A0000|56 60|acid
P06286549A0000|126 132|testis
P06286549A0000|159 162|FSa
P06286549A0000|186 191|lungs
P06286549A0000|164 177|tumor nodules
P06286549A0000|10 13|S-2
P06286549A0000|1 8|WR-2721
P06286191T0000|32 41|functions
P06286191T0000|51 58|animals
P06281786A1222|124 127|RNA
P06281786A1222|161 167|length
P06281786A1222|65 78|histone genes
P06281786A1222|49 57|addition
P06279309A0000|89 93|loci
P06279309A0000|160 171|oncogenesis
P06279309A0000|179 184|virus
P06279309A0000|21 43|erythroblastosis virus
P06278424A0145|46 60|CH gene switch
P06278424A0145|95 109|gamma 2b genes
P06278424A0145|136 149|mouse myeloma
P06272844A0000|165 174|digestion
P06272844A0000|126 132|extent
P06272844A0000|36 47|chromosomes
P06272844A0000|20 25|virus
P06272844A0000|237 251|SV40 chromatin
P06259389A0000|75 88|mouth disease
P06259389A0000|31 37|August
P06259389A0000|108 123|Gifu prefecture
P06259389A0000|66 70|foot
P06259220A0000|31 40|influence
P06259220A0000|128 136|exposure
P06259220A0000|96 104|reaction
P06259220A0000|118 121|min
P06259220A0000|51 62|antagonists
P06259220A0000|186 194|reaction
P06258699T0000|39 50|Polybactrin
P06258699T0000|84 94|cystoscopy
P06254403A0000|5 19|antibody titer
P06254403A0000|101 115|blocking assay
P06252520T0000|41 47|review
P06246254A0676|61 70|sequences
P06246254A0676|135 146|FeSV genome
P06246254A0676|173 187|kilobase pairs
P06246254A0676|81 85|FeSV
P06246254A0676|1 19|Restriction enzyme
P06244732T0000|92 102|infarction
P06244732T0000|1 17|Radioimmunoassay
P06241980A0855|36 47|Krogh model
P06241980A0855|1 16|Oxygen profiles
P06240448A0652|180 190|resistance
P06240448A0652|242 250|increase
P06240448A0652|262 268|output
P06240448A0652|118 127|reduction
P06240448A0652|104 111|LV mass
P06240448A0652|227 234|LV mass
P06240448A0652|78 83|phase
P06240448A0652|5 11|effect
P06240448A0652|205 210|phase
P06238704T0001|1 10|Synthesis
P06237518A0117|164 174|chloramine
P06237518A0117|122 126|flow
P06237518A0117|92 96|acid
P06237518A0117|156 159|KCN
P06230499A0128|62 66|form
P06230499A0128|214 225|irradiation
P06230499A0128|191 198|surgery
P06230499A0128|116 118|Gy
P06230499A0128|74 87|fractionation
P06230499A0128|131 134|day
P06230499A0128|276 282|course
P06230499A0128|174 178|days
P06230499A0128|304 310|period
P06227570A0523|36 39|ENL
P06227570A0523|17 28|LL patients
P06224974A0833|113 118|agent
P06224974A0833|1 5|Data
P06223586A0000|40 43|SPG
P06223586A0000|76 82|agents
P06223586A0000|114 123|tumor-C3H
P06217859T0000|47 51|flap
P06217859T0000|1 11|Experience
P06214605A0123|56 69|configuration
P06214605A0123|87 93|series
P06214605A0123|102 113|experiments
P06209499A0682|12 19|effects
P06209499A0682|92 106|pressor effect
P06209499A0682|156 167|tachycardia
P06208477A0000|91 98|Pietras
P06208477A0000|40 45|mouse
P06208477A0000|5 17|construction
P06204120T0001|60 73|enteroviruses
P06204120T0001|77 90|cell cultures
P06204120T0001|1 4|Use
P06200300A0409|58 63|skull
P06200300A0409|38 52|VEP amplitudes
P06198532A0982|75 83|patients
P06198532A0982|183 192|incidence
P06198532A0982|215 225|comparison
P06198532A0982|235 238|RHD
P06193351A1010|42 47|drugs
P06193351A1010|82 84|VF
P06193351A1010|100 107|release
P06189698A0246|73 83|components
P06189698A0246|131 143|task demands
P06189698A0246|5 19|P165 component
P06185014A0642|128 129|%
P06185014A0642|22 43|complement factor C3c
P06185014A0642|68 87|alpha 1-antitrypsin
P06184276T0001|19 32|plasmocytosis
P06181216A0070|94 99|years
P06173860A0000|9 14|cases
P06173860A0000|65 84|segment depressions
P06173860A0000|153 171|segment elevations
P06167806A0000|78 87|induction
P06167806A0000|53 62|treatment
P06167806A0000|248 258|infarction
P06167806A0000|206 217|stimulation
P06167806A0000|221 225|days
P06165132A0000|192 196|RIHA
P06165132A0000|43 48|fowls
P06165132A0000|53 61|broilers
P06165132A0000|80 85|farms
P06165132A0000|156 164|immunity
P06163433T0000|14 28|p-chlorophenyl
P06163433T0000|83 109|monoamine oxidase activity
P06163433T0000|65 78|concentration
P06161823A0129|44 46|mg
P06161823A0129|129 140|hypertrophy
P06161823A0129|103 106|men
P06155967A1132|177 181|time
P06155967A1132|118 131|abnormalities
P06155967A1132|152 158|effort
P06152844T0000|74 82|subjects
P06152844T0000|25 39|growth hormone
P06151942A0235|105 117|risk factors
P06151942A0235|177 186|gamma-GTP
P06151942A0235|163 175|triglyceride
P06151942A0235|80 94|blood pressure
P06151942A0235|1 6|Serum
P06150069A0422|31 36|mg/m2
P06150069A0422|23 26|VCR
P06150069A0422|5 13|patients
P06143734T0000|62 68|testis
P06143734T0000|24 36|progesterone
P06141764A0339|57 60|RNA
P06141764A0339|138 149|information
P06138015T0114|7 13|report
P06136374A0151|9 27|water temperatures
P06131038A0000|107 114|rabbits
P06131038A0000|12 36|erthrocyte lipid profile
P06131038A0000|41 68|lipoprotein lipase activity
P06131038A0000|154 169|atherosclerosis
P06121577A0280|15 25|reductions
P06121577A0280|109 110|%
P06121577A0280|125 126|%
P06121577A0280|144 145|%
P06121577A0280|49 63|blood pressure
P06121577A0280|136 138|mg
P06119262T0000|31 38|toxemia
P06119262T0000|5 19|roll-over test
P06113084T0000|40 64|calcium binding activity
P06110026T0000|31 36|death
P06110026T0000|1 11|Endorphins
P06108610A0518|1 9|Theories
P06099656T0000|23 33|cell lines
P06099656T0000|1 13|Construction
P06098719A0369|14 20|effect
P06098719A0369|34 53|laboratory findings
P06097027A0000|122 142|myeloblastosis virus
P06097027A0000|144 147|AMV
P06097027A0000|18 26|provirus
P06096380A0662|166 172|enzyme
P06096380A0662|8 12|mRNA
P06096380A0662|96 102|length
P06096380A0662|68 75|chicken
P06095774T0001|37 45|nephroma
P06094591A0000|225 229|gp37
P06094591A0000|57 61|gp85
P06094591A0000|66 70|gp37
P06094591A0000|5 27|envelope glycoproteins
P06094591A0000|115 119|acid
P06094591A0000|205 221|carboxy terminus
P06093354A0000|81 94|DNA sequences
P06093354A0000|19 29|DNA clones
P06093354A0000|152 168|Balb/c mouse DNA
P06092048A1111|10 15|cases
P06092048A1111|17 25|asbestos
P06090458A0407|5 28|PEPCK promoter fragment
P06090458A0407|81 94|transcription
P06089575A0464|121 124|min
P06089575A0464|94 104|fmol/gland
P06089575A0464|18 21|MCh
P06089575A0464|69 79|cGMP level
P06085839A0721|75 83|etiology
P06084810A0169|121 128|library
P06084810A0169|21 25|mRNA
P06084810A0169|70 74|cDNA
P06074640T0001|1 10|Symposium
P06073427T0001|79 84|urine
P06073427T0001|17 33|characteriaztion
P06070204T0025|1 4|XXI
P06065507T0000|20 31|hypertrophy
P06051644T0000|57 67|creatinine
P06051644T0000|16 22|method
P06035001T0000|61 71|injections
P06035001T0000|25 35|resorption
P06012827T0000|47 53|system
P06012827T0000|17 24|studies
P05995140T0001|66 72|tumors
P05995140T0001|49 62|glucose level
P05992157T0001|22 44|Achromobacter puntatum
P05992157T0001|54 61|blooded
P05982700T0000|29 51|Cysticercus pisiformis
P05967610T0000|28 47|noradrenaline level
P05967610T0000|12 26|nerve function
P05967610T0000|76 79|cat
P05959588T0000|31 47|virus infections
P05959588T0000|1 8|Studies
P05947377T0001|46 53|thyroid
P05947377T0001|25 30|I-132
P05947377T0001|32 38|uptake
P05933228T0000|12 19|rhythms
P05933228T0000|23 33|indicators
P05919308T0001|52 80|monoamine oxidase inhibitors
P05919308T0001|35 47|adrenolytics
P05909034T0000|1 8|Studies
P05902458T0001|1 12|Naphthalene
P05896996T0001|46 49|age
P05896996T0001|18 30|aminoketones
P05890093T0000|122 136|mother animals
P05890093T0000|10 21|micromelias
P05890093T0000|64 71|hypoxia
P05890093T0000|1 6|Study
P05890093T0000|85 94|injection
P05881833T0001|28 36|leucosis
P05881833T0001|65 77|Lower Saxony
P05859016T0000|1 27|Hydroxypropyl methacrylate
P05857301T0000|58 63|CC1-4
P05857301T0000|37 46|responses
P05857301T0000|1 9|Chemical
P05847772T0001|12 21|disorders
P05847772T0001|58 65|surgery
P05837169T0001|1 15|Methoxyflurane
P05833022T0001|59 71|brain tissue
P05833022T0001|21 28|changes
P05823624T0031|23 31|hospital
P05819249T0000|23 31|iron ore
P05807222T0052|1 14|Ion injection
P05806615T0001|11 22|degradation
P05806615T0001|130 136|solute
P05806615T0001|48 53|study
P05799686T0001|30 42|chemotherapy
P05799686T0001|95 98|aid
P05799686T0001|144 155|idoxuridine
P05799686T0001|102 115|cytodiagnosis
P05794247T0000|74 79|liver
P05794247T0000|26 38|inactivation
P05794247T0000|98 102|dogs
P05792868T0000|42 51|transport
P05792868T0000|1 38|Evidence forthe electroosmosis theory
P05787318T0000|22 32|clofibrate
P05787318T0000|48 60|serum lipids
P05781385T0000|25 56|phenolphthalein sulphatase test
P05781385T0000|65 80|differentiation
P05781385T0000|85 99|identification
P05774062T0000|42 54|conductivity
P05763347T0000|26 36|inhibition
P05763347T0000|10 22|applications
P05760665T0000|33 39|office
P05751819T0000|63 67|male
P05751819T0000|5 12|bearing
P05751819T0000|98 110|Hariana cows
P05751819T0000|16 22|season
P05749438T0001|14 25|anesthetics
P05749438T0001|29 43|o-chlorophenyl
P05740389T0001|30 40|mechanisms
P05740389T0001|1 10|Relations
P05733953T0001|5 11|effect
P05733953T0001|35 40|field
P05732641T0001|1 7|Trials
P05725509T0000|13 21|germfree
P05725509T0000|1 9|Steroids
P05719746T0001|1 9|Children
P05718994T0000|37 49|incompetence
P05718994T0000|55 66|coarctation
P05718386T0001|41 53|complication
P05718386T0001|24 33|skin flap
P05693605T0001|40 52|autoanalyzer
P05693605T0001|1 14|Determination
P05692759T0001|1 12|Nephrectomy
P05684081T0001|1 13|Measurements
P05684081T0001|51 67|chamber VA-K-254
P05683363T0001|22 30|exchange
P05683363T0001|1 14|Investigation
P05671267T0000|31 47|dihydro-5H-benzo
P05671267T0000|65 72|azepine
P05627251T0000|26 41|skin potentials
P05627251T0000|55 60|sleep
P05595036T0001|41 50|disorders
P05595036T0001|1 9|Students
P05572662T0000|57 74|electrocardiogram
P05572662T0000|16 24|catheter
P05567721T0000|18 33|thromboplastins
P05556977T0001|73 101|phasmid Carausius morosus Br
P05556977T0001|53 65|regeneration
P05553261T0000|24 33|reticulum
P05552149T0000|9 25|85Sr scintimetry
P05552149T0000|1 4|18F
P05536803T0001|75 81|effect
P05536803T0001|53 58|space
P05536803T0001|85 95|furosemide
P05532854T0001|18 32|manifestations
P05501347T0001|92 100|ischemia
P05501347T0001|39 49|metabolism
P05501347T0001|19 35|dosage radiation
P05497793T0000|105 109|rats
P05497793T0000|131 143|environments
P05497793T0000|1 8|Effects
P05492285T0000|16 36|Hyostrongylus ruidus
P05474466T0001|7 28|hemagglutination test
P05471866T0000|5 40|plasma growth hormone concentration
P05463837T0023|14 27|configuration
P05463837T0023|51 55|acid
P05456002T0000|1 9|Mae West
P05445187T0000|80 92|heat balance
P05445187T0000|50 58|passages
P05437405T0000|31 47|dilator capacity
P05437405T0000|12 19|forearm
P05424220T0001|78 82|rats
P05424220T0001|93 97|food
P05424220T0001|48 57|epiphysis
P05417431T0001|7 17|disagnosis
P05417431T0001|21 27|cancer
P05413428T0000|75 92|combat casualties
P05413428T0000|58 71|resuscitation
P05413428T0000|21 32|body fluids
P05412122T0000|26 46|8-phenyl derivatives
P05412122T0000|4 10|Methyl
P05410590T0000|22 26|acid
P05410590T0000|48 71|bladder tumor formation
P05394352T0000|29 35|states
P05388567T0000|31 44|aminophylline
P05388567T0000|70 76|muscle
P05372511T0105|1 19|Diethylene benzene
P05364951T0001|1 15|Histopathology
P05362866T0000|46 58|hypertension
P05356107T0001|12 18|action
P05356107T0001|39 50|elimination
P05356107T0001|71 75|dogs
P05344097T0000|1 8|Factors
P05322747T0034|13 18|study
P05322747T0034|98 106|subjects
P05322747T0034|48 59|tolbutamide
P05316745T0000|42 47|Skuse
P05316745T0000|1 14|Aedes aegypti
P05308271T0000|1 4|BIM
P05285978T0076|8 14|report
P05276380T0000|14 31|cigarette smoking
P05276380T0000|1 10|Influence
P05274128T0001|32 45|galactosamine
P05274128T0001|16 27|glucosamine
P05210791T0001|1 10|Pneumonia
P05177935T0001|43 49|nurses
P05177935T0001|1 10|Proposals
P05172970T0001|45 57|tuberculosis
P05172970T0001|109 114|cases
P05172970T0001|78 86|analysis
P05172970T0001|66 71|basis
P05172970T0001|16 27|disablement
P05170106T0034|149 151|NF
P05170106T0034|131 136|means
P05170106T0034|155 162|methods
P05170106T0034|103 115|chymotrypsin
P05152314T0001|12 24|oscillations
P05138738T0001|3 7|case
P05133723T0000|25 40|gluconeogenesis
P05133723T0000|1 7|Effect
P05128149T0001|1 19|Surgical treatment
P05124707T0001|13 26|hospital stay
P05124707T0001|1 9|Dynamics
P05120197T0000|14 26|pancreatitis
P05114515T0000|58 63|drugs
P05114515T0000|84 97|polyarthritis
P05095988T0001|43 58|system injuries
P05083872T0000|15 24|education
P05083872T0000|5 11|status
P05083872T0000|50 66|speech pathology
P05075857T0000|71 83|sweep speeds
P05066316T0001|25 30|ratio
P05066316T0001|67 75|products
P05066316T0001|96 112|aluminosilicates
P05066316T0001|1 9|Relation
P05060388T0000|55 60|ovary
P05045351T0000|41 48|infants
P05045351T0000|24 29|apnea
P05031659T0000|25 36|candidiasis
P05028628T0001|27 39|examinations
P05028628T0001|85 93|arteries
P05021912T0000|75 85|pigeon eye
P05015678T0000|19 30|tautomerism
P05015678T0000|34 44|porphyrins
P05005311T0000|107 114|species
P05005311T0000|27 39|mycobacteria
P04999086T0001|15 20|study
P04999086T0001|57 65|analyzer
P04999086T0001|83 94|ontogenesis
P04990556T0000|39 47|globulin
P04990556T0000|17 22|horse
P04976988T0000|1 14|Heterogeneity
P04973523T0000|16 23|studies
P04970131T0001|6 24|reflexions apropos
P04959816T0000|42 51|component
P04959816T0000|16 21|fluid
P04947347T0000|18 22|rats
P04947347T0000|51 70|homograft rejection
P04925617T0000|8 11|bar
P04919613T0001|22 36|autoantibodies
P04919613T0001|1 6|Study
P04884060T0000|5 26|Twentieth Anniversary
P04871589T0001|75 79|flap
P04871589T0001|21 26|elbow
P04852635T0000|9 15|effect
P04852635T0000|23 51|appetite stimulant pizotifen
P04852635T0000|1 5|Lack
P04839176T0001|45 69|blood coagulation system
P04839176T0001|1 7|Effect
P04828587T0000|44 49|virus
P04828587T0000|51 59|strain T
P04824747T0000|52 61|compounds
P04824747T0000|1 18|Nonteratogenicity
P04813394T0000|40 47|reagent
P04813394T0000|1 11|Evaluation
P04803629T0001|39 46|allergy
P04789916T0001|13 28|clearance curve
P04789916T0001|1 9|Analysis
P04787716T0000|21 38|flight activities
P04784432T0001|29 43|administration
P04784432T0001|1 14|Possibilities
P04778129T0000|33 57|estradiol 3-methyl ether
P04764049T0001|19 35|nephronophthisis
P04757217T0000|60 75|LCAT deficiency
P04757217T0000|27 31|LP-X
P04757217T0000|1 8|Studies
P04753073T0000|1 7|Choice
P04746559T0053|46 57|plasma flow
P04746559T0053|84 101|vein renin levels
P04730467T0000|107 111|rats
P04730467T0000|23 33|starvation
P04730467T0000|81 101|epiphyseal cartilage
P04727344T0000|57 71|isotope method
P04727344T0000|1 19|Microdetermination
P04712626T0000|75 100|Swertia chirata Buch.-Ham
P04712626T0000|1 22|Chemical constituents
P04704137T0001|65 74|abortions
P04704137T0001|1 5|Role
P04679438T0001|26 29|mud
P04661961T0001|44 55|bone marrow
P04661961T0001|8 14|values
P04654249T0000|75 79|bulb
P04654249T0000|83 86|cat
P04654249T0000|50 61|stimulation
P04646045T0001|19 25|tumors
P04640155T0045|1 10|Sex ratio
P04632967T0000|97 114|aminorex fumarate
P04632967T0000|33 42|structure
P04624863T0001|14 27|immunogenesis
P04624863T0001|82 93|salmonellae
P04624863T0001|71 78|mutants
P04621188T0000|15 29|bacteriophages
P04621188T0000|1 11|Morphology
P04615525T0001|5 11|effect
P04615525T0001|98 102|mice
P04615525T0001|51 66|transplantation
P04600603T0001|1 7|Letter
P04583791T0000|42 49|Nigeria
P04583791T0000|35 40|Lagos
P04579436T0000|27 41|colour changes
P04563045T0000|91 97|review
P04563045T0000|9 22|2-chloroethyl
P04563045T0000|55 67|nitrosoureas
P04563045T0000|1 8|1,3-bis
P04552263T0000|36 40|R.N.
P04548483T0001|96 110|rhesus monkeys
P04548483T0001|18 37|coagulation factors
P04548483T0001|1 16|Blood platelets
P04546974T0000|52 69|bundle recordings
P04546974T0000|1 11|Variations
P04544430T0001|78 91|heart defects
P04544430T0001|34 45|heart block
P04539552T0001|26 32|SF-837
P04533208T0083|1 8|Changes
P04518624T0000|57 64|disease
P04518624T0000|1 23|Glutathione peroxidase
P04512496T0000|1 8|Hodgkin
P04510102T0000|1 19|Electrocardiograms
P04495034T0000|29 36|toluene
P04495034T0000|43 52|treatment
P04488232T0001|12 22|alcoholism
P04487835T0001|4 11|parents
P04468264T0053|1 9|Problems
P04446923T0001|30 44|verticillation
P04446923T0001|48 69|Platynothrus peltifer
P04437406T0000|120 128|exchange
P04437406T0000|71 82|application
P04428981T0000|13 31|calcium metabolism
P04423347T0001|12 33|ceruloplasmin content
P04423347T0001|92 100|diseases
P04423347T0001|1 7|Copper
P04407649T0000|74 97|99mTc brainscintigraphy
P04392584T0000|41 59|hemisphere monkeys
P04385060T0000|44 52|motility
P04385060T0000|1 11|Disulfiram
P04377003A0000|58 79|polyamines putrescine
P04377003A0000|217 223|tumors
P04377003A0000|253 259|tumors
P04377003A0000|14 20|method
P04377003A0000|42 50|analysis
P04377003A0000|174 182|patients
P04377003A0000|204 210|system
P04369884T0000|24 34|inhibitors
P04369884T0000|69 72|CSF
P04350410T0000|62 70|Cloforex
P04350410T0000|24 29|study
P04350410T0000|1 8|Genesis
P04328746T0073|1 18|Ultrasound effect
P04323641T0000|1 8|Studies
P04316696T0001|66 71|horse
P04316696T0001|1 7|Enzyme
P04311951T0001|88 95|otology
P04311951T0001|50 61|association
P04305850T0000|1 10|Androgens
P04291759T0048|66 73|control
P04291759T0048|1 19|Laboratory aspects
P04284435T0000|1 11|Vitamin D3
P04281856T0001|9 22|sex structure
P04281856T0001|38 48|population
P04262268T0001|40 52|ear ossicles
P04262268T0001|1 8|Studies
P04247472T0001|8 13|cycle
P04247472T0001|48 57|mountains
P04239041T0045|61 67|ATPase
P04239041T0045|5 11|effect
P04239041T0045|69 75|sodium
P04214345T0000|9 17|relation
P04214345T0000|54 61|glucose
P04196986T0000|15 32|fluid transferrin
P04196986T0000|56 65|disorders
P04189158T0000|57 65|globulin
P04189158T0000|1 11|Prevention
P04176625T0000|40 54|cardiomyopathy
P04176625T0000|82 90|myopathy
P04176249T0001|24 29|media
P04176249T0001|1 11|Assessment
P04172166T0000|22 29|vaccine
P04164595T0020|75 80|types
P04164595T0020|84 93|infection
P04152725T0001|1 8|Studies
P04139943T0001|60 65|Corti
P04139943T0001|40 56|guinea pig organ
P04139943T0001|23 32|structure
P04138224T0095|60 74|gamma-globulin
P04138224T0095|5 11|effect
P04138224T0095|17 32|tissue emulsion
P04123217T0000|14 20|hyphae
P04123217T0000|25 39|chlamydospores
P04114211T0000|57 65|subjects
P04114211T0000|20 34|sulphadimidine
P04103248T0000|38 46|averager
P04101003T0001|104 110|rabbit
P04101003T0001|83 86|man
P04101003T0001|71 79|activity
P04088936T0001|45 50|level
P04088936T0001|28 40|antithrombin
P04088936T0001|55 85|plasminogen activator activity
P04088396A0145|134 135|%
P04088396A0145|11 32|patients grades 1-2-3
P04088396A0145|83 94|abnormality
P04086993T0000|20 31|rhythmicity
P04086993T0000|54 60|pineal
P04086993T0000|1 6|Daily
P04086403A1016|75 76|P
P04086403A1016|44 59|feed conversion
P04086403A1016|72 73|%
P04086403A1016|23 24|P
P04086403A1016|141 156|feed conversion
P04086403A1016|102 105|fed
P04085589A0264a|14 25|correlation
P04085589A0264a|109 130|serum lysozyme levels
P04085589A0264a|155 173|tract colonization
P04084607A0663|60 65|O6meG
P04084607A0663|31 36|O6meG
P04084607A0663|112 129|modification site
P04084607A0663|248 251|ppm
P04084607A0663|50 52|G3
P04084607A0663|193 206|imino protons
P04084607A0663|66 67|N
P04082267A0720|45 54|degrees C
P04082267A0720|62 71|degrees C
P04082267A0720|77 83|vexans
P04082267A0720|17 21|days
P04079738A0677|41 43|SD
P04079738A0677|5 10|rates
P04079738A0677|138 147|degrees C
P04079738A0677|87 88|P
P04075021T0000|7 26|beta-phenethylamine
P04075021T0000|101 108|effects
P04075021T0000|32 44|distribution
P04075021T0000|51 65|administration
P04073848T0000|42 51|diagnosis
P04073848T0000|1 8|Failure
P04070725A0442|89 99|hypothesis
P04070725A0442|1 15|Component P100
P04068969A0300|60 67|anatomy
P04068969A0300|47 52|model
P04068969A0300|19 23|load
P04068663A0452|11 18|rabbits
P04068663A0452|25 40|mouse CRF-flora
P04068663A0452|141 156|mouse CRF flora
P04068663A0452|101 111|parameters
P04066274A0265|90 103|parotidectomy
P04066274A0265|120 121|%
P04066274A0265|41 50|neoplasms
P04066274A0265|27 28|%
P04066274A0265|141 142|%
P04063732A0509|26 32|output
P04063732A0509|42 49|conduit
P04063732A0509|4 12|controls
P04061342A0512|121 122|p
P04061342A0512|58 64|uptake
P04061342A0512|99 100|%
P04061342A0512|50 54|mean
P04056256A0416|109 122|concentration
P04056256A0416|58 76|nifedipine aerosol
P04056256A0416|218 219|p
P04056256A0416|207 216|histamine
P04055593A0523|134 141|effects
P04055593A0523|46 48|N2
P04055593A0523|145 152|changes
P04055593A0523|96 108|compensation
P04055593A0523|156 171|gas composition
P04051521T0001|43 58|cancer patients
P04051521T0001|100 104|5-FU
P04051521T0001|84 88|dose
P04050771A0474|22 35|hazards model
P04050771A0474|5 8|Cox
P04050771A0474|119 127|survival
P04048245A0331|38 52|hydrocortisone
P04048245A0331|16 33|oxyphenylbutazone
P04041346T0000|43 52|quinidine
P04040858A0000|25 29|June
P04040858A0000|7 16|September
P04040307A0145|56 62|nerves
P04040307A0145|8 13|birth
P04039744A0141|121 140|i.u. vitamin D3/day
P04039744A0141|177 181|days
P04039744A0141|7 14|results
P04039744A0141|53 62|D mothers
P04039525A0475|12 42|bladder platinum concentration
P04039525A0475|146 157|blood count
P04039525A0475|162 177|blood chemistry
P04039525A0475|112 123|examination
P04039525A0475|1 7|Plasma
P04039439A0000|15 20|quail
P04039439A0000|121 125|diet
P04039439A0000|146 150|days
P04039439A0000|154 157|age
P04039109A0139|133 140|seconds
P04039109A0139|146 159|power density
P04039109A0139|53 65|fluid medium
P04039109A0139|168 173|W/cm2
P04039109A0139|87 94|vessels
P04038454A0984|26 46|plasma retinol level
P04038454A0984|266 273|mg dl-1
P04038454A0984|232 238|cancer
P04038454A0984|50 61|conjunction
P04038454A0984|119 134|micrograms dl-1
P04036838A0918|88 89|r
P04036838A0918|182 183|p
P04036838A0918|7 13|factor
P04036838A0918|71 86|pressure ratios
P04034220A0205|195 211|tract infections
P04034220A0205|133 151|tolerance Cefaclor
P04034220A0205|95 108|H. influenzae
P04034220A0205|33 41|activity
P04034220A0205|170 179|treatment
P04032716A0299|215 221|cervix
P04032716A0299|230 240|myometrium
P04032716A0299|5 25|mean transfer ratios
P04032716A0299|33 37|drug
P04032268A0358|151 155|drug
P04032268A0358|109 125|Ag/AgCl/3 M NaCl
P04032268A0358|59 61|EC
P04032268A0358|81 90|potential
P04028871A0133|30 42|tetracycline
P04028871A0133|72 85|blister fluid
P04028871A0133|126 140|mg lymecycline
P04028871A0133|5 21|pharmacokinetics
P04026972T0000|12 37|alcohol reaction profiles
P04025179A0955|4 9|group
P04024685A0650|56 64|increase
P04024685A0650|247 250|EDV
P04024685A0650|320 322|ml
P04024685A0650|115 116|p
P04024685A0650|224 226|ml
P04024685A0650|165 167|cm
P04024685A0650|228 229|p
P04024685A0650|10 11|%
P04024685A0650|66 74|RS index
P04024685A0650|169 170|p
P04024685A0650|205 207|ml
P04021431A0000|105 120|blood pressures
P04021431A0000|61 73|pulse curves
P04021431A0000|243 253|dilatation
P04021431A0000|229 233|eyes
P04021431A0000|261 267|pupils
P04021431A0000|1 5|OODG
P04021281T0001|63 70|infarct
P04021281T0001|1 15|Ultrastructure
P04018444A0000|57 61|urso
P04018444A0000|98 101|man
P04018444A0000|51 55|acid
P04015988T0000|25 41|anorexia nervosa
P04014833A0400|88 105|blood lymphocytes
P04014833A0400|109 127|phytohemagglutinin
P04014833A0400|23 34|lymphopenia
P04014833A0400|1 15|Hydrocortisone
P04013576A0981|150 160|Leptospira
P04013576A0981|89 113|Leptospira phospholipids
P04013576A0981|80 85|acids
P04013576A0981|216 220|acid
P04013576A0981|49 61|distribution
P04011338A0620|210 217|placebo
P04011338A0620|177 183|extent
P04011338A0620|113 125|relationship
P04011338A0620|81 85|loss
P04011338A0620|226 234|decrease
P04011338A0620|197 206|acid loss
P04011338A0620|65 73|decrease
P04011338A0620|137 138|r
P04004168A0000|194 202|evidence
P04004168A0000|46 82|triosephosphate isomerase deficiency
P04004168A0000|177 188|tract signs
P04004168A0000|159 165|tremor
P04002131A0506|120 121|P
P04002131A0506|72 77|urine
P04002131A0506|10 27|disease remission
P04001413A0093|91 98|patient
P04001413A0093|110 124|breath-holding
P04001413A0093|48 54|device
P03999219A0463|150 159|chromatin
P03999219A0463|212 227|alum irrigation
P03999219A0463|64 73|resection
P03999219A0463|34 41|patient
P03998071T0000|62 72|vitamin K1
P03998071T0000|52 58|levels
P03995513T0000|14 25|dacarbazine
P03995513T0000|107 121|leiomyosarcoma
P03995513T0000|1 12|Doxorubicin
P03989827T0000|40 55|Aymara children
P03989827T0000|18 36|lactase phenotypes
P03987857A0733|13 20|muscles
P03987857A0733|144 155|stimulation
P03985849A0221|61 69|patients
P03985849A0221|149 153|CVID
P03985849A0221|79 90|development
P03985849A0221|231 245|IgA deficiency
P03985849A0221|51 57|groups
P03982288T0000|23 30|members
P03982288T0000|34 48|union pitfalls
P03981640A0168|59 64|mRNAs
P03980386A0000|90 100|blood flow
P03980386A0000|47 58|angiotensin
P03980386A0000|108 112|lung
P03980386A0000|35 42|hypoxia
P03978132A0108|120 139|distribution curves
P03978132A0108|26 41|source emission
P03978132A0108|4 18|MCCP functions
P03977603A0326|72 77|doses
P03977603A0326|49 55|ulcers
P03976323A0821|15 26|correlation
P03976323A0821|35 56|blood pressure change
P03972185A0137|88 89|%
P03972185A0137|93 101|controls
P03972185A0137|172 177|times
P03972185A0137|143 164|plasma glucose levels
P03970191A0275|104 106|DC
P03970191A0275|129 134|sites
P03970191A0275|81 85|ECoG
P03966687A0000|120 127|Allergy
P03966687A0000|25 41|childhood asthma
P03966687A0000|80 86|Taylor
P03966687A0000|102 106|data
P03964855A0254|41 51|rCBF study
P03964855A0254|100 110|angiograms
P03963860A0137|15 23|patients
P03963860A0137|61 65|MY-1
P03956695A0617|61 67|season
P03956695A0617|83 90|factors
P03953361A0000|28 39|propranolol
P03953361A0000|144 146|CK
P03953361A0000|93 112|serial measurements
P03953361A0000|54 64|metabolism
P03953361A0000|152 159|calcium
P03953361A0000|165 173|contents
P03953361A0000|161 163|Ca
P03953361A0000|202 216|concentrations
P03946125T0000|10 31|nutrient interactions
P03944212A0166|28 41|water content
P03944212A0166|147 148|h
P03944212A0166|112 118|margin
P03944212A0166|18 22|rCBF
P03944212A0166|1 16|Tissue pressure
P03940733A0755|12 18|method
P03940733A0755|59 68|vitamin A
P03940733A0755|139 152|malabsorption
P03939317A0352|135 141|region
P03939317A0352|92 116|soybean HS-protein genes
P03939317A0352|3 13|comparison
P03937294A0404|127 132|onset
P03937294A0404|112 116|hour
P03937294A0404|1 23|Plasma secretin levels
P03935797A0183|150 155|sites
P03935797A0183|5 9|data
P03935797A0183|263 268|alpha
P03935797A0183|71 89|sry messenger RNAs
P03935797A0183|273 278|delta
P03935117T0000|11 17|effect
P03935117T0000|78 86|rat lung
P03933784A0420|25 29|role
P03931797A0134|45 46|%
P03931797A0134|62 63|%
P03931797A0134|67 72|women
P03930894T0000|61 65|lung
P03930894T0000|78 83|aging
P03930894T0000|112 126|administration
P03930894T0000|141 149|vagotomy
P03930894T0000|85 95|inhalation
P03929610A0268|14 24|discomfort
P03928678T0000|75 81|muscle
P03928678T0000|54 62|urethral
P03928357A0340|88 102|chlorobenzenes
P03928357A0340|77 82|PCDFs
P03928357A0340|113 118|PCDFs
P03923976T0001|55 76|factor XII deficiency
P03923976T0001|1 17|Thrombophlebitis
P03922116A0197|268 289|iliac lymphadenectomy
P03922116A0197|63 76|gamma-therapy
P03922116A0197|179 198|radiation treatment
P03922116A0197|81 86|cases
P03922116A0197|106 119|gamma-therapy
P03922116A0197|228 232|beam
P03922116A0197|162 167|group
P03922116A0197|204 212|megavolt
P03920700A0491|54 68|responsiveness
P03914875T0001|6 17|candidiasis
P03912247A0282|60 82|collateral circulation
P03912247A0282|28 32|flap
P03912247A0282|52 58|ml/min
P03912247A0282|5 11|volume
P03911702A0530|90 112|microembolism syndrome
P03911702A0530|41 46|model
P03911702A0530|235 245|conditions
P03911702A0530|205 215|anesthesia
P03910310A0666|55 64|pathology
P03908196T0000|36 41|resin
P03908196T0000|1 20|Shear bond strength
P03904004A1577|209 223|energy photons
P03904004A1577|42 67|medium energy collimation
P03904004A1577|185 200|Compton scatter
P03904004A1577|239 243|124I
P03896991T0000|53 61|products
P03891766A1473|30 36|factor
P03891766A1473|111 127|latex adsorbents
P03891766A1473|1 13|Interference
P03888621A0185|25 36|hydrogenase
P03888621A0185|87 89|Da
P03887769A0093|61 78|micrograms J/g Cr
P03887769A0093|5 9|Mean
P03885983A0254|47 56|Class III
P03885983A0254|7 14|results
P03883052T0001|4 10|memory
P03881260A0000|80 127|arginine pathway carbamoyl-phosphate synthetase
P03881260A0000|35 45|gene CP A1
P03878585A0507|329 330|r
P03878585A0507|264 269|blood
P03878585A0507|87 99|CPB duration
P03878585A0507|44 47|CPB
P03878585A0507|167 191|bubble oxygenator/m2 bsa
P03878585A0507|37 40|end
P03878585A0507|5 29|percentage RFR reduction
P03878585A0507|139 143|OFRI
P03875231A0627|240 253|abnormalities
P03875231A0627|176 184|hematoma
P03875231A0627|67 68|%
P03875231A0627|190 200|hemorrhage
P03875231A0627|84 91|kidneys
P03873141A0304|45 53|bleeding
P03873141A0304|78 85|therapy
P03873141A0304|87 93|Visick
P03873141A0304|118 132|mortality rate
P03871298A0217|132 139|promise
P03871298A0217|37 47|tomography
P03871298A0217|117 123|Tl-201
P03871298A0217|153 165|localization
P03866085A0795|165 173|children
P03866085A0795|148 157|disorders
P03866085A0795|219 227|vomiting
P03866085A0795|96 106|infections
P03863561A0405|12 17|Strep
P03863561A0405|89 101|mutans/Strep
P03863561A0405|113 114|p
P03863561A0405|103 111|cricetus
P03863561A0405|152 162|clump size
P03862898A0563|73 89|tumor E2R status
P03862898A0563|53 63|IgE scores
P03862898A0563|1 10|Serum IgM
P03860162A0000|41 55|amphotericin B
P03860162A0000|57 60|AMB
P03860162A0000|108 121|drug toxicity
P03860162A0000|65 74|liposomes
P03848527T0020|61 69|industry
P03848527T0020|86 91|years
P03843496A0919|181 196|risk assessment
P03843496A0919|11 16|years
P03843496A0919|76 83|variety
P03843496A0919|156 170|extrapolations
P03840480T0000|17 25|families
P03837609T0000|23 28|study
P03836853A0204|46 47|%
P03836853A0204|64 65|%
P03836853A0204|51 52|%
P03835413A0616|150 172|duration space flights
P03835413A0616|25 32|effects
P03835413A0616|39 51|irradiations
P03830147A0000|63 80|lactate threshold
P03830147A0000|299 302|VO2
P03830147A0000|290 293|LT2
P03830147A0000|356 361|value
P03830147A0000|104 131|blood lactate concentration
P03830147A0000|432 445|blood lactate
P03830147A0000|507 515|capacity
P03830147A0000|579 587|students
P03830147A0000|372 377|onset
P03830147A0000|30 41|descriptors
P03830147A0000|213 216|LT1
P03830147A0000|82 84|LT
P03830147A0000|222 225|VO2
P03830147A0000|197 210|exercise test
P03830147A0000|5 18|relationships
P03830147A0000|409 413|OBLA
P03828500T0001|37 57|contractile activity
P03827071T0040|1 3|II
P03824908A0116|122 154|arginine amino acid substitution
P03824908A0116|112 118|lysine
P03824908A0116|201 211|M proteins
P03824908A0116|69 79|nucleotide
P03818866A0116|95 96|p
P03818866A0116|1 16|Framingham Type
P03818866A0116|85 86|r
P03814493T0000|37 42|grade
P03814493T0000|1 13|Chlorambucil
P03810867A0305|13 21|patients
P03810867A0305|43 50|lesions
P03810867A0305|65 66|%
P03806696A0000|180 189|adulthood
P03806696A0000|12 20|toxicity
P03806696A0000|108 122|Japanese quail
P03806696A0000|234 244|injections
P03806696A0000|64 80|mercury chloride
P03806696A0000|156 160|ages
P03802195A0481|91 110|DNA binding domains
P03802195A0481|76 86|activation
P03802195A0481|173 180|portion
P03799323A0501|60 86|oxygen saturation decrease
P03799323A0501|31 46|flow conditions
P03799323A0501|52 56|rate
P03791645A1124|90 100|narcolepsy
P03791645A1124|106 109|OSA
P03791645A1124|69 81|pathogenesis
P03788231A0802|62 70|survival
P03788231A0802|147 152|heart
P03788231A0802|244 249|chest
P03788231A0802|112 124|implantation
P03785212A0091|66 71|cDNAs
P03781948T0000|13 23|adaptation
P03781948T0000|35 42|hypoxia
P03780704A0573|135 146|utilization
P03780704A0573|148 150|WW
P03780704A0573|9 17|increase
P03780704A0573|54 64|conditions
P03780704A0573|119 127|increase
P03780248A0274|72 77|group
P03780248A0274|10 21|differences
P03780248A0274|159 168|transport
P03780248A0274|143 151|settings
P03780248A0274|138 141|IMV
P03780248A0274|184 191|infants
P03779182A0370|62 68|number
P03779182A0370|113 119|deaths
P03776779A0238|27 36|treatment
P03776080A0400|61 68|animals
P03776080A0400|127 139|CWE antigens
P03776080A0400|119 122|E/S
P03772471A1054|134 138|time
P03772471A1054|41 47|tumors
P03772471A1054|142 149|surgery
P03772471A1054|171 175|case
P03771703A0000|81 84|gas
P03771703A0000|68 76|reagents
P03770143A1209|79 94|fibre structure
P03770143A1209|5 16|possibility
P03768208A0879|132 136|mass
P03768208A0879|110 119|increases
P03768208A0879|36 45|pregnancy
P03765731A0918|24 30|stroke
P03765731A0918|92 103|hypertrophy
P03765731A0918|1 11|Incidences
P03763836T0001|52 57|sites
P03763836T0001|1 8|Results
P03761523A0000|41 48|effects
P03761523A0000|52 58|sepsis
P03761523A0000|5 9|rats
P03759731A0992|40 48|ml/min/1
P03759731A0992|7 16|clearance
P03759731A0992|96 101|group
P03758250A0000|30 39|movements
P03758250A0000|59 68|extremity
P03758250A0000|155 162|muscles
P03753022A0000|45 50|terms
P03753022A0000|69 77|behavior
P03750700T0001|43 57|endoprosthesis
P03750700T0001|1 14|Possibilities
P03747493A0000|16 24|patients
P03746896A0890|62 73|possibility
P03746896A0890|128 142|susceptibility
P03746896A0890|170 185|Type A behavior
P03746508A0390|26 36|additivity
P03746053A0670|45 47|N1
P03746053A0670|132 134|N2
P03746053A0670|22 32|potentials
P03746053A0670|87 93|matter
P03744168T0001|91 116|methano-1H-4-benz azonine
P03744168T0001|77 88|hexahydro-1
P03744168T0001|17 23|action
P03743683A0000|90 101|individuals
P03743683A0000|111 116|years
P03743683A0000|32 41|autopsies
P03736081A0465|210 216|ml/min
P03736081A0465|390 391|%
P03736081A0465|246 250|rise
P03736081A0465|218 219|p
P03736081A0465|399 400|%
P03736081A0465|75 83|decrease
P03736081A0465|131 139|L/min/m2
P03736081A0465|141 142|p
P03736081A0465|374 384|difference
P03736081A0465|238 242|rate
P03733563A0820|14 39|serum NEFA concentrations
P03732252A0556|269 279|m run time
P03732252A0556|121 122|r
P03732252A0556|113 119|VO2max
P03732252A0556|322 331|delta VO2
P03732252A0556|72 73|r
P03732252A0556|351 361|m run time
P03732252A0556|64 67|VO2
P03732252A0556|169 187|m race performance
P03732252A0556|34 38|data
P03722016A0797|5 15|FFA levels
P03721594A0000|146 162|fibrinogen level
P03721594A0000|48 57|migration
P03721594A0000|85 94|reduction
P03721594A0000|133 144|macrophages
P03721594A0000|11 23|phagocytosis
P03721594A0000|202 233|dilution protamine sulfate test
P03721594A0000|69 80|tetrazolium
P03721594A0000|342 347|colon
P03720615A0434|95 102|infants
P03720615A0434|36 41|trend
P03717475A0208|44 61|immunodiagnostics
P03717475A0208|131 142|infertility
P03717475A0208|20 25|steps
P03714348A0833|164 189|peak expiratory flow rate
P03714348A0833|147 158|patient age
P03714348A0833|126 135|NIH score
P03714348A0833|86 93|portion
P03714348A0833|1 8|Factors
P03712153T0000|76 86|assessment
P03712050T0000|58 67|arthritis
P03712050T0000|1 29|Indium-111 leukocyte imaging
P03709627A0247|47 65|acetaminophen i.v.
P03709627A0247|132 137|urine
P03709627A0247|172 182|production
P03709627A0247|5 13|subjects
P03709627A0247|117 124|minutes
P03704087A0394|75 85|components
P03704087A0394|89 94|anger
P03704087A0394|41 52|instruments
P03704087A0394|161 183|Anger Expression Scale
P03704087A0394|99 106|anxiety
P03701640A1178|7 14|results
P03701640A1178|175 183|ABSTRACT
P03701640A1178|33 39|effect
P03698251T0000|44 52|patients
P03698251T0000|21 32|consumption
P03697798T0001|44 52|activity
P03697798T0001|56 73|stretch receptors
P03697798T0001|1 12|Contraction
P03696899T0001|58 65|indices
P03696899T0001|1 33|Blood serum erythropoietin level
P03693543A0405|122 135|elution times
P03693543A0405|199 214|N. brasiliensis
P03693543A0405|295 301|genera
P03693543A0405|174 193|N. otitidiscaviarum
P03693543A0405|272 282|separation
P03693543A0405|259 266|species
P03691316A0560|22 37|contact allergy
P03688676A0487|10 21|conversions
P03688676A0487|66 72|result
P03688202A0377|75 77|CN
P03688202A0377|67 70|PBB
P03687148T0187|1 9|Salzburg
P03685073A0200|45 75|acetylcholinesterase inhibitor
P03685073A0200|27 40|physostigmine
P03685073A0200|113 118|range
P03684378A0653|15 19|milk
P03684378A0653|73 84|cholesterol
P03684378A0653|215 219|milk
P03684378A0653|59 69|vitamin K1
P03684378A0653|113 118|lipid
P03684378A0653|86 87|r
P03680791A0230|62 68|hearts
P03680791A0230|116 121|heart
P03679407A0556|28 47|N-nitroso compounds
P03679407A0556|7 14|results
P03679407A0556|153 163|infections
P03679407A0556|119 130|association
P03678269A0633|127 136|childhood
P03678269A0633|155 158|age
P03678269A0633|100 112|modification
P03676054A0865|13 16|Paw
P03676054A0865|27 31|PaO2
P03676054A0865|144 152|diameter
P03676054A0865|18 25|delta V
P03676054A0865|87 95|pressure
P03673640A0533|243 261|suicide attempters
P03673640A0533|95 98|KSP
P03673640A0533|55 72|KSP Impulsiveness
P03673640A0533|152 169|KSP Socialization
P03673640A0533|288 309|platelet MAO activity
P03673640A0533|74 89|EPQ Neuroticism
P03673640A0533|226 237|psychopaths
P03673640A0533|174 178|line
P03668736A0177|60 68|elements
P03668736A0177|13 23|deviations
P03668736A0177|78 84|series
P03668736A0177|163 168|block
P03668003T0000|49 61|skin lesions
P03664038A0000|149 162|reliabilities
P03664038A0000|110 113|GSS
P03664038A0000|65 69|form
P03664038A0000|115 119|Form
P03659994A0150|109 125|signal intensity
P03659994A0150|129 131|T1
P03659994A0150|22 26|site
P03659994A0150|203 209|images
P03659994A0150|141 147|images
P03659603A0797|63 66|CO2
P03659603A0797|97 112|CO2 sensitivity
P03659603A0797|38 47|responses
P03653226A0833|104 108|fate
P03653226A0833|112 123|perhexiline
P03651840A0266|9 28|MAO inhibition data
P03651840A0266|145 154|pargyline
P03651840A0266|55 64|inhibitor
P03649340A1119|74 80|choice
P03649340A1119|110 124|exon sequences
P03649340A1119|84 96|splice sites
P03637037T0000|16 32|teaching booklet
P03632739T0000|1 23|Cyclosporine treatment
P03628713A0961|181 192|tumor cells
P03628713A0961|104 118|Gy irradiation
P03628713A0961|56 68|36B-10 cells
P03628713A0961|196 204|trap AIB
P03628713A0961|39 52|86RbCl uptake
P03628713A0961|169 177|capacity
P03628532A0000|28 44|taste perception
P03628532A0000|67 73|series
P03626129T0001|61 67|embryo
P03626129T0001|25 35|laser beam
P03625688A0372|94 101|methods
P03625688A0372|23 31|fracture
P03625688A0372|1 15|Immobilization
P03622423A0000|27 34|Fischer
P03622423A0000|117 131|concentrations
P03622423A0000|106 108|hr
P03622423A0000|162 169|control
P03622423A0000|202 207|vapor
P03622423A0000|1 7|Groups
P03618039A0126|121 152|catecholamine biotransformation
P03618039A0126|63 76|noradrenaline
P03618039A0126|5 13|presence
P03618039A0126|34 44|antibodies
P03616174A1069|134 144|blood flow
P03616174A1069|161 168|tissues
P03616174A1069|55 64|degrees C
P03615550A1094|45 51|U50488
P03615550A1094|95 105|mg/kg dose
P03615550A1094|32 40|morphine
P03612648A0085|28 47|lupus anticoagulant
P03612648A0085|80 99|thromboplastin time
P03610674T0000|52 70|fiber zinc content
P03610674T0000|5 11|effect
P03608989A0668|112 130|filament formation
P03608989A0668|138 148|rod region
P03607961T0001|14 20|action
P03607961T0001|71 88|diabetes mellitus
P03605895A0888|61 62|%
P03605895A0888|21 45|carboxyhemoglobin levels
P03605895A0888|84 109|carbon monoxide poisoning
P03601533T0001|12 22|importance
P03601533T0001|42 65|complement constituents
P03600705T0000|11 19|symptoms
P03600705T0000|1 7|Timing
P03597269A0409|88 92|cVO2
P03597269A0409|67 74|form La
P03597269A0409|84 87|exp
P03597269A0409|51 59|constant
P03595418A0688|130 137|regions
P03595418A0688|50 79|ornithine decarboxylase mRNAs
P03592297A0138|244 253|degrees C
P03592297A0138|266 278|vasodilation
P03592297A0138|116 125|degrees C
P03592297A0138|72 92|surface temperatures
P03592297A0138|130 136|theory
P03592297A0138|161 169|activity
P03592297A0138|99 108|degrees C
P03592297A0138|1 18|Dorsal foot TcpO2
P03591464A0840a|82 110|calcium antagonist treatment
P03591464A0840a|70 78|efficacy
P03586925T0001|129 145|Medinform system
P03586925T0001|1 12|Development
P03583001A0111|47 60|gas injection
P03583001A0111|178 188|vitrectomy
P03583001A0111|64 70|bubble
P03582184A0448|74 91|dosage adjustment
P03582184A0448|32 37|phase
P03581160A0583|91 123|artery pulse amplitude responses
P03581160A0583|21 42|heart rate reactivity
P03577670A0236|74 81|finding
P03577670A0236|89 104|arylsulfatase A
P03577670A0236|130 141|fibroblasts
P03577670A0236|5 14|diagnosis
P03577670A0236|32 46|leukodystrophy
P03575656A0120|46 50|90Sr
P03575656A0120|146 152|period
P03575656A0120|81 85|lung
P03571135T0000|91 99|children
P03571135T0000|8 13|value
P03568311A1361|14 23|tamponade
P03568311A1361|121 126|TMFP1
P03568311A1361|148 149|r
P03568311A1361|141 146|TMFP2
P03568311A1361|170 175|TMFP3
P03567017A0000|63 65|mg
P03567017A0000|10 16|dosing
P03567017A0000|146 163|drug accumulation
P03567017A0000|48 58|indoprofen
P03567017A0000|119 128|half-life
P03563399A0534|121 131|difference
P03563399A0534|5 21|signal durations
P03561036T0000|28 32|rats
P03561036T0000|19 24|aorta
P03561036T0000|1 11|Lymphatics
P03559232T0000|33 42|arthritis
P03556834T0000|47 51|mice
P03553439A0404|105 116|tumor cells
P03553439A0404|194 198|Type
P03553439A0404|212 223|tumor cells
P03553439A0404|5 11|latter
P03553439A0404|118 122|Type
P03552363A0568|13 33|serum insulin levels
P03552363A0568|56 68|correlations
P03552363A0568|187 199|correlations
P03549045A0878|30 39|verapamil
P03549045A0878|105 110|group
P03549045A0878|81 86|group
P03545955A0751|210 216|apples
P03545955A0751|242 252|mmol X h/l
P03545955A0751|92 97|juice
P03545955A0751|144 152|fructose
P03545955A0751|263 270|glucose
P03545955A0751|116 123|glucose
P03545955A0751|254 259|Study
P03545955A0751|226 237|apple juice
P03545955A0751|277 286|ice cream
P03545955A0751|71 78|glucose
P03545955A0751|306 313|lactose
P03545955A0751|103 110|sucrose
P03543936A0000|76 84|homology
P03543936A0000|5 14|rho genes
P03542945T0000|19 27|overview
P03540853A0652|47 64|sequence homology
P03540853A0652|70 90|DNA binding proteins
P03537727A0243|105 112|protein
P03537727A0243|28 31|RNA
P03537727A0243|92 99|protein
P03537721A0491|91 95|GAL4
P03537721A0491|8 16|analysis
P03537721A0491|69 78|PEP4 gene
P03537686A0099|121 127|vector
P03537686A0099|281 290|mutations
P03537686A0099|213 225|transfection
P03537686A0099|336 346|background
P03537686A0099|250 261|plasmid DNA
P03537686A0099|239 244|cells
P03536682A0572|33 34|%
P03531317A0930|104 109|model
P03531317A0930|113 119|Fisher
P03531317A0930|70 84|hypergeometric
P03526279T0000|16 23|schools
P03520729A0381|89 114|aldosterone concentration
P03520729A0381|36 47|body weight
P03520729A0381|70 84|renin activity
P03516189A0406|46 58|mg kg-1 i.v.
P03513989A1149|135 142|insight
P03513989A1149|160 172|pathogenesis
P03513989A1149|112 121|countries
P03513989A1149|201 208|effects
P03510185A0187|1 6|Natl.
P03507689A0000|151 167|bacteriophage f1
P03507689A0000|10 42|phage-plasmid expression vectors
P03507689A0000|65 82|pUC18/19 plasmids
P03507689A0000|184 209|bacteriophage T7 promoter
P03499822A0182|120 131|hepatitis B
P03499822A0182|106 116|prevalence
P03499822A0182|58 72|seropositivity
P03499822A0182|175 178|age
P03499608A1054|56 78|heterozygote detection
P03499608A1054|43 51|reagents
P03499608A1054|162 167|cause
P03499608A1054|190 201|hyperplasia
P03493240T0000|42 48|agents
P03488532A0235|23 29|report
P03488532A0235|86 94|symptoms
P03488532A0235|51 61|resolution
P03486405A0341|120 130|IL-1 alpha
P03486405A0341|24 31|portion
P03486405A0341|39 60|precursor polypeptide
P03484894A0782|79 86|biotype
P03484894A0782|126 128|V.
P03484894A0782|7 12|cases
P03479897A0961|109 118|Class III
P03479897A0961|97 105|relation
P03476002A0148|106 115|intervals
P03476002A0148|42 51|vitamin C
P03476002A0148|1 5|Hair
P03473253A0000|78 94|chemical workers
P03473253A0000|185 199|U.S. companies
P03465957A1008|1 22|Mean fluorosis scores
P03463537T0001|10 16|method
P03463537T0001|76 80|bite
P03459385T0000|13 21|Tourette
P03459385T0000|1 8|Allergy
P03452920T0001|1 4|Man
P03450438A0446|15 31|Yates correction
P03450438A0446|1 8|X2 test
P03448035T0000|9 15|tumors
P03443609A0000|27 47|fluid chromatography
P03443609A0000|66 75|technique
P03443609A0000|49 52|SFC
P03443566A0675|45 63|gain-to-feed ratio
P03443566A0675|9 20|experiments
P03443566A0675|81 83|TR
P03441587A0000|210 219|reference
P03441587A0000|161 168|results
P03441587A0000|97 102|tests
P03441587A0000|200 206|method
P03441587A0000|1 9|Research
P03439248A0000|36 48|dipyridamole
P03439248A0000|173 181|patients
P03439248A0000|206 220|artery disease
P03439248A0000|137 152|artery stenosis
P03436529A1066|94 115|oligodeoxynucleotides
P03436529A1066|22 30|enhancer
P03436529A1066|138 144|region
P03436529A1066|153 165|nt positions
P03434347A0358|42 47|weeks
P03434347A0358|81 85|side
P03429371A1051|60 64|site
P03429371A1051|144 148|site
P03428274A0000|224 240|recognition site
P03428274A0000|183 189|origin
P03428274A0000|215 221|factor
P03428274A0000|77 87|initiation
P03428274A0000|21 26|NFIII
P03428274A0000|156 175|nucleotide sequence
P03427613A0659|90 102|pineal organ
P03427613A0659|36 42|system
P03427613A0659|113 121|portions
P03423732A0341|46 56|increments
P03423732A0341|27 33|De-Nol
P03423732A0341|173 177|PGE2
P03423732A0341|101 102|%
P03423732A0341|68 82|HCO3 secretion
P03420466A0000|91 100|specimens
P03420466A0000|5 14|incidence
P03420466A0000|117 124|Kinyoun
P03420266A0000|5 16|interaction
P03420266A0000|81 95|Dunning R3327G
P03420266A0000|34 46|hyperthermia
P03417668A1233|30 49|autophosphorylation
P03417668A1233|121 131|transition
P03417668A1233|88 100|beta subunit
P03417668A1233|53 59|Thr286
P03417668A1233|80 86|Thr287
P03417104A0536|92 108|stimulus effects
P03417104A0536|112 119|animals
P03413681A0659|45 50|years
P03413681A0659|74 81|patient
P03413681A0659|10 23|heart disease
P03413681A0659|25 28|age
P03407676A0585|9 18|infection
P03404495A0172|1 23|Thyroid function tests
P03403826T0000|124 134|comparison
P03403826T0000|213 225|flow reserve
P03403826T0000|87 99|measurements
P03403412A0000|148 161|grain content
P03403412A0000|25 33|implants
P03403412A0000|83 89|growth
P03403412A0000|116 125|fed diets
P03403412A0000|137 143|forage
P03402183A0171|124 127|MVC
P03402183A0171|179 191|contractions
P03402183A0171|36 41|forms
P03402183A0171|114 117|MVC
P03402183A0171|64 76|contractions
P03402183A0171|100 112|contractions
P03400694A0245|47 59|scintigraphy
P03400694A0245|97 102|mg/kg
P03400694A0245|140 147|minutes
P03400694A0245|168 179|sarcoidosis
P03400694A0245|1 9|PATIENTS
P03398714A0594|126 154|propagation transition state
P03398714A0594|59 73|peroxy radical
P03398714A0594|16 18|RH
P03396628A0207|62 67|spots
P03396628A0207|178 187|incidence
P03396628A0207|158 159|%
P03396628A0207|256 257|%
P03396628A0207|12 30|observation period
P03396628A0207|232 237|weeks
P03395249A1044|132 137|cells
P03395249A1044|167 178|development
P03395249A1044|78 89|pneumocytes
P03395249A1044|53 66|proliferation
P03395249A1044|19 30|examination
P03395249A1044|102 115|proliferation
P03395009A1750|29 36|degrees
P03395009A1750|57 73|cord compression
P03395009A1750|267 270|T11
P03395009A1750|290 292|L2
P03395009A1750|13 21|analysis
P03395009A1750|280 284|L1-2
P03395009A1750|172 181|diameters
P03395009A1750|207 220|cord sections
P03387665A0000|73 81|T brucei
P03387665A0000|126 133|animals
P03387665A0000|97 102|goats
P03387665A0000|5 16|development
P03384033A0155|164 169|input
P03384033A0155|11 16|units
P03384033A0155|78 79|%
P03384033A0155|42 48|motion
P03384033A0155|103 116|otolith input
P03382855A0368|121 128|picture
P03382855A0368|50 54|wrap
P03382310A0903|150 170|management decisions
P03382310A0903|123 134|arthropathy
P03382310A0903|10 23|technetium Tc
P03382310A0903|84 99|polyarthralgias
P03380547A0169|40 48|aversion
P03378994T0000|75 79|dogs
P03378994T0000|9 23|administration
P03377864A0000|72 81|solutions
P03377864A0000|59 68|particles
P03377864A0000|35 44|diffusion
P03373755T0001|46 53|factors
P03373755T0001|24 29|drugs
P03373755T0001|98 106|problems
P03373755T0001|85 93|efficacy
P03371894A0355|1 20|Vimentin positivity
P03371139A0829|12 17|group
P03368701A0113|73 78|place
P03368701A0113|22 33|reliability
P03368701A0113|48 61|arteriography
P03366720A1335|121 128|glucose
P03366720A1335|107 117|metabolism
P03366720A1335|8 14|change
P03360948A0477|13 16|CAP
P03360948A0477|26 35|variables
P03360948A0477|144 178|Behavioral/Emotional Control scale
P03359860A0000|211 238|New York Longitudinal Study
P03359860A0000|107 122|undercompliance
P03359860A0000|145 155|adjustment
P03359860A0000|5 14|relations
P03359860A0000|86 96|aggression
P03354341A0177|133 141|infusion
P03354341A0177|145 151|inulin
P03354341A0177|175 179|acid
P03352947T0001|47 60|health worker
P03352947T0001|3 7|case
P03352439T0000|58 69|anastomosis
P03351478A0371|45 48|% C
P03351478A0371|11 18|regions
P03346210A0000|15 28|growth factor
P03346210A0000|178 192|EGF activation
P03346210A0000|70 102|protein tyrosine kinase activity
P03345706A0561|44 47|RDS
P03345706A0561|82 91|judgement
P03345706A0561|35 40|PtcO2
P03344586T0000|21 30|diagnosis
P03344586T0000|35 49|classification
P03340774A0328|72 75|rad
P03340774A0328|126 134|estimate
P03340774A0328|32 38|organs
P03340548A1018|120 138|lipopolysaccharide
P03340548A1018|8 21|chicken liver
P03340548A1018|23 29|levels
P03340548A1018|33 48|chicken MT mRNA
P03340548A1018|100 115|glucocorticoids
P03337024A0000|121 126|mg/kg
P03337024A0000|41 58|pharmaco-dynamics
P03337024A0000|110 114|dose
P03337024A0000|136 140|rate
P03335651A0000|120 127|concept
P03335651A0000|166 174|approach
P03335651A0000|228 246|hydrogen weighting
P03335651A0000|83 90|imaging
P03335651A0000|216 218|T1
P03335651A0000|68 77|resonance
P03335398A0568|12 18|levels
P03335398A0568|108 136|passive transfer experiments
P03335398A0568|69 76|surface
P03334950A0000|180 187|control
P03334950A0000|208 217|radiation
P03334950A0000|23 41|Pediatric Oncology
P03334950A0000|99 103|CESS
P03334950A0000|141 153|chemotherapy
P03332022A1094|105 124|nucleotide sequence
P03332022A1094|12 38|cysteine clustering region
P03332022A1094|229 235|region
P03332022A1094|80 87|product
P03332022A1094|239 255|protein kinase C
P03331525T0001|12 17|study
P03331525T0001|40 49|adhesives
P03331525T0001|21 36|dentin adhesion
P03329716A0187|79 98|receptor RNA levels
P03329716A0187|112 123|stimulation
P03329716A0187|21 42|EGF receptor promoter
P03325081A0524|134 139|cause
P03325081A0524|44 50|origin
P03325081A0524|9 20|keratopathy
P03320875A2090|30 38|Supramid
P03320875A2090|93 103|resistance
P03320875A2090|68 88|tissue compatibility
P03319646T0000|73 87|chlorthalidone
P03317796A0853|57 71|osteoarthritis
P03317796A0853|39 46|picture
P03312514A0756|126 147|preischemia amplitude
P03312514A0756|20 24|SSEP
P03312514A0756|85 93|recovery
P03312514A0756|109 110|%
P03312514A0756|202 203|%
P03312514A0756|238 239|%
P03311954A0000|15 20|study
P03311954A0000|123 132|mg b.i.d.
P03311954A0000|108 118|ranitidine
P03311954A0000|168 177|treatment
P03311954A0000|137 147|ranitidine
P03308909A0485|11 18|enzymes
P03305875T0000|8 16|orthoses
P03305875T0000|39 50|microstomia
P03298134A0000|73 88|Schering-Plough
P03298134A0000|131 134|HCL
P03298134A0000|97 106|treatment
P03298134A0000|33 37|work
P03296254A0556|130 140|depression
P03296254A0556|7 18|differences
P03296254A0556|71 80|elevation
P03296254A0556|84 100|prothrombin time
P03296019T0000|1 19|Time delay effects
P03292082A0486|31 45|concentrations
P03292082A0486|167 176|neurinoma
P03292082A0486|58 66|patients
P03292082A0486|4 12|contrast
P03287597T0000|11 19|function
P03285764A0675|31 43|hypogonadism
P03285764A0675|111 119|leakages
P03285764A0675|82 90|stenoses
P03285764A0675|191 203|consequences
P03285764A0675|1 20|Hyperprolactinaemia
P03282813A0794|192 197|slope
P03282813A0794|147 148|r
P03282813A0794|25 30|range
P03282813A0794|39 56|oxygen extraction
P03282813A0794|138 145|failure
P03282813A0794|103 111|patients
P03280946A0375|224 231|control
P03280946A0375|195 213|expression vectors
P03280946A0375|55 58|35S
P03280946A0375|237 262|bacteriophage T7 promoter
P03280946A0375|119 122|cni
P03280807A1447|194 202|proteins
P03280807A1447|247 252|SUF12
P03280807A1447|64 69|suf12
P03280807A1447|35 48|heterozygotes
P03280807A1447|137 148|suppression
P03280021A1615|14 16|dT
P03280021A1615|79 85|M NaCl
P03280021A1615|188 193|value
P03280021A1615|18 26|affinity
P03280021A1615|153 157|NaBr
P03276924A0090|37 50|rearrangement
P03276924A0090|17 23|tumors
P03275873A0379|92 99|ability
P03275873A0379|22 31|mutations
P03275873A0379|158 170|transfection
P03275873A0379|141 151|resistance
P03274204A0642|112 131|cent alkaline fuxin
P03274204A0642|50 55|index
P03268555T0000|28 44|biocompatibility
P03268555T0000|55 64|materials
P03264886A0000|30 38|children
P03264886A0000|56 59|age
P03264886A0000|212 222|physicians
P03264886A0000|144 149|croup
P03264886A0000|135 140|cases
P03264886A0000|47 52|years
P03264886A0000|76 81|towns
P03264073A0224|130 141|albino mice
P03264073A0224|158 166|activity
P03264073A0224|170 181|albino rats
P03263357A0112|107 117|variations
P03263357A0112|146 150|iron
P03263357A0112|36 48|relationship
P03263357A0112|71 77|rhythm
P03263357A0112|152 156|zinc
P03261223A0644|10 18|patients
P03261223A0644|42 55|disease group
P03259437A0140|105 106|%
P03259437A0140|183 191|neonates
P03259437A0140|270 274|IU/l
P03259437A0140|247 252|value
P03259437A0140|218 219|p
P03259437A0140|17 51|neonates serum alpha-amylase value
P03257146A1037|148 153|types
P03257146A1037|111 139|marrow neutrophil precursors
P03257146A1037|157 166|childhood
P03257146A1037|48 65|neutrophil counts
P03253219T0000|90 95|study
P03253219T0000|8 15|voltage
P03249840A0411|151 162|% reduction
P03249840A0411|121 125|dose
P03249840A0411|56 57|s
P03249840A0411|59 63|FEV1
P03249840A0411|187 198|% reduction
P03249840A0411|44 50|volume
P03249840A0411|129 138|carbachol
P03249840A0411|172 176|PD35
P03249840A0411|1 22|Baseline measurements
P03246999A0483|123 131|controls
P03246999A0483|5 13|increase
P03246999A0483|17 27|amplitudes
P03243027T0000|77 88|development
P03243027T0000|22 32|regulation
P03237446A0377|42 52|infections
P03237446A0377|17 24|history
P03234790T0001|36 50|administration
P03234790T0001|1 7|Effect
P03232410A1467|41 46|cases
P03232410A1467|50 61|lung cancer
P03228785A1047|192 195|cm2
P03228785A1047|176 181|weeks
P03228785A1047|231 239|ABSTRACT
P03228785A1047|99 103|week
P03228785A1047|257 262|WORDS
P03228785A1047|221 228|control
P03227568T0001|12 16|cows
P03227568T0001|95 101|mirror
P03227568T0001|21 26|sires
P03227568T0001|1 8|Variety
P03223123T0001|10 20|evaluation
P03223123T0001|55 62|markers
P03219107A0212|56 62|babies
P03219107A0212|81 87|births
P03216131A0559|61 72|enterotoxin
P03216131A0559|21 41|Aeromonas hydrophila
P03212929A0000|78 82|dogs
P03212929A0000|86 115|Dirofilaria immitis infection
P03209019A0662|133 140|acetone
P03209019A0662|199 212|test material
P03209019A0662|189 193|week
P03209019A0662|234 239|weeks
P03209019A0662|18 36|promotion bioassay
P03207975A0709|13 18|hours
P03207975A0709|25 39|administration
P03207975A0709|84 91|vitamin
P03200488A0439|52 65|turnover rate
P03200488A0439|5 12|results
P03200488A0439|87 103|dopamine neurons
P03199043A0248|15 25|uniqueness
P03199043A0248|150 165|transport rates
P03199043A0248|29 38|solutions
P03199043A0248|228 237|constants
P03199043A0248|58 81|boundary value problems
P03198436T0000|14 23|treatment
P03198436T0000|27 44|bladder carcinoma
P03194410A0771|73 91|tissue specificity
P03194410A0771|57 60|rat
P03194410A0771|114 125|UOxase gene
P03192799T0000|38 55|Implant Dentistry
P03192799T0000|1 10|Statement
P03192537A0370|180 191|amino acids
P03192537A0370|24 34|amino acid
P03192537A0370|42 50|sequence
P03192537A0370|140 145|HMG-I
P03190481A0292|29 37|esterase
P03190481A0292|199 210|macrophages
P03190481A0292|92 114|infiltration area unit
P03190481A0292|189 195|number
P03190481A0292|232 239|capsule
P03190481A0292|80 86|number
P03186091T0000|75 84|gestation
P03186091T0000|121 133|hypertension
P03186091T0000|41 52|oxytocinase
P03186091T0000|68 73|weeks
P03185322A1305|192 201|dysplasia
P03185322A1305|8 19|correlation
P03185322A1305|83 89|result
P03183127A0068|121 143|CT myelocisternography
P03183127A0068|83 94|myelography
P03183127A0068|1 11|Comparison
P03182872A1122|1 5|Chem
P03181276A0422|58 64|cavity
P03181276A0422|22 29|placebo
P03181276A0422|4 18|micrograms PAF
P03179496T0000|80 85|fluid
P03179496T0000|1 11|Evaluation
P03178161A0000|209 217|Transkei
P03178161A0000|59 79|blood concentrations
P03178161A0000|83 97|micronutrients
P03178161A0000|222 228|Ciskei
P03178161A0000|12 17|brush
P03178161A0000|230 245|Southern Africa
P03178161A0000|202 204|EC
P03178161A0000|171 175|risk
P03175942A0706|128 133|doses
P03175942A0706|6 12|effect
P03175942A0706|21 25|fact
P03171279A0158|131 137|artery
P03171279A0158|168 174|grafts
P03171279A0158|154 161|toe PIP
P03171279A0158|17 27|conclusion
P03168709A0000|104 127|suprathreshold strategy
P03168709A0000|86 95|threshold
P03166458A1356|47 61|GC box element
P03166458A1356|3 20|protein footprint
P03154072A0862|42 55|soybean flour
P03150015T0001|10 18|research
P03150015T0001|52 61|hepatitis
P03147912A0422|13 29|hyperventilators
P03147912A0422|147 153|PETCO2
P03147912A0422|43 49|number
P03147912A0422|137 141|time
P03146150T0000|59 68|urokinase
P03146150T0000|1 13|Potentiation
P03144705A0859|160 161|%
P03144705A0859|248 266|Alu family repeats
P03144705A0859|114 133|sequence divergence
P03144705A0859|50 60|resolution
P03144705A0859|220 221|X
P03143048A1091|23 24|P
P03143048A1091|20 21|%
P03143048A1091|1 16|HDL-cholesterol
P03139750A0000|13 18|basis
P03139750A0000|50 61|VH allotype
P03138190A0347|74 87|Kupffer cells
P03138190A0347|93 105|target cells
P03138190A0347|34 44|ampicillin
P03137346A0319|96 115|amino acid residues
P03137346A0319|38 48|base-pairs
P03134872T0029|14 18|case
P03133250A0000|150 157|hormone
P03133250A0000|198 213|embryo transfer
P03133250A0000|27 32|study
P03133250A0000|66 77|stimulation
P03133250A0000|223 230|program
P03127463A1017|165 171|marrow
P03127463A1017|56 68|CSF activity
P03127463A1017|7 12|rIL-3
P03127463A1017|202 210|cultures
P03127463A1017|141 154|proliferation
P03126531T0000|105 135|dopamine agonist pretreatments
P03126531T0000|97 101|rats
P03126531T0000|49 59|stereotypy
P03126531T0000|17 25|increase
P03123310A0000|29 38|Gart gene
P03123310A0000|108 117|synthesis
P03123310A0000|81 88|pathway
P03119485A0476|46 51|acids
P03119485A0476|129 137|interest
P03119485A0476|158 169|development
P03119485A0476|174 183|prognosis
P03119485A0476|86 95|nutrition
P03119485A0476|187 192|shock
P03118631A0140|104 112|cochleas
P03118631A0140|140 149|perfusion
P03118631A0140|19 35|fixation quality
P03117046T0000|37 50|vinculin cDNA
P03117046T0000|69 80|fibroblasts
P03115087A0515|56 57|%
P03115087A0515|65 73|standard
P03114829T0000|25 35|correlates
P03112412A0985|26 32|strain
P03112412A0985|196 203|mutants
P03112412A0985|82 101|synthetase mutation
P03112412A0985|184 188|none
P03111946A0309|4 10|effect
P03110794A0991|22 35|g fluvoxamine
P03110794A0991|4 13|overdoses
P03110692A0156|244 252|patients
P03110692A0156|332 340|dialysis
P03110692A0156|216 217|P
P03110692A0156|21 23|SD
P03110692A0156|258 268|bone cysts
P03110692A0156|425 428|day
P03110692A0156|42 43|P
P03110692A0156|415 420|litre
P03110692A0156|141 145|mg/l
P03110692A0156|101 109|patients
P03110119A0267|166 177|cm cephalad
P03110119A0267|108 118|side ports
P03110119A0267|8 10|BH
P03110119A0267|64 65|%
P03110119A0267|49 58|bias flow
P03109147T0127|33 50|diethylene glycol
P03109147T0127|68 75|effects
P03108171A0088|91 95|5-HT
P03108171A0088|21 30|substance
P03108171A0088|119 125|system
P03104914T0000|65 73|analysis
P03104914T0000|18 19|t
P03104245A0402|211 216|range
P03104245A0402|91 92|p
P03104245A0402|43 51|addition
P03104245A0402|7 15|patients
P03104245A0402|64 73|radiation
P03104245A0402|171 176|range
P03098018A0139|106 116|micropenis
P03098018A0139|40 46|weight
P03098018A0139|36 38|cm
P03098018A0139|64 70|length
P03098018A0139|50 52|kg
P03097509A0654|11 15|rise
P03097509A0654|19 32|RNA molecules
P03090372A0607|59 68|operation
P03090372A0607|102 107|weeks
P03088643A0000|33 43|preference
P03088643A0000|17 21|rats
P03080793T0000|91 100|workplace
P03080793T0000|66 83|AIDS transmission
P03080793T0000|33 43|guidelines
P03078268A0529|135 142|maleate
P03078268A0529|192 202|mechanisms
P03078268A0529|52 65|acidification
P03078268A0529|235 243|steroids
P03078268A0529|255 268|acidification
P03075154T0000|45 55|transplant
P03075154T0000|1 11|Recurrence
P03073091A0449|61 82|hour insulin infusion
P03073091A0449|215 221|mmol/l
P03073091A0449|321 326|drugs
P03073091A0449|358 367|mg/kg/min
P03073091A0449|152 158|mmol/l
P03073091A0449|47 50|min
P03073091A0449|173 182|mg/kg/min
P03073091A0449|337 343|mmol/l
P03073091A0449|206 207|K
P03073091A0449|1 8|Amounts
P03072580A0455|1 13|Van der Ende
P03069980T0000|89 96|dentine
P03069980T0000|25 38|bond strength
P03069980T0000|68 75|ionomer
P03067505A0688|48 56|property
P03066208A0310|14 25|examination
P03066208A0310|83 97|cell carcinoma
P03065621T0000|146 154|ribosome
P03065621T0000|39 43|gene
P03065621T0000|117 124|subunit
P03065141A0448|120 129|citB gene
P03065141A0448|39 43|citA
P03065141A0448|48 52|citB
P03065141A0448|87 95|location
P03065141A0448|68 77|promoters
P03064811A0485|63 79|phosphoryl group
P03064811A0485|32 49|S. aureus peptide
P03062370A0384|30 42|GCN3 product
P03062370A0384|62 72|repression
P03062370A0384|7 14|results
P03061383A0000|164 168|type
P03061383A0000|135 140|TEM-1
P03061383A0000|26 36|mecillinam
P03061383A0000|112 127|beta-lactamases
P03061383A0000|202 225|agar dilution technique
P03061301A0624|284 294|cigarettes
P03061301A0624|229 241|participants
P03061301A0624|129 134|means
P03061301A0624|71 111|metabolite 6-keto-prostaglandin F1 alpha
P03061301A0624|1 23|Prostacyclin formation
P03060846T0000|28 43|L1 binding site
P03060846T0000|12 20|analysis
P03057259A0514|44 52|lymphoma
P03057259A0514|80 91|thyroiditis
P03052641A0204|18 27|compounds
P03050147A1520|45 59|scanning model
P03050147A1520|177 196|initiator AUG codon
P03050147A1520|103 112|ribosomes
P03050147A1520|205 214|C protein
P03049570A1242|39 50|E2 proteins
P03046931A0247|36 46|retroposon
P03046931A0247|18 24|eIF-4A
P03045725A0872|89 111|breast cancer patients
P03045725A0872|22 33|suppression
P03041802A0975|134 153|platelet activation
P03041802A0975|62 68|levels
P03041802A0975|72 88|fibrinopeptide A
P03041802A0975|92 108|cleavage product
P03041802A0975|187 191|role
P03040403A0155|75 87|YEp13 vector
P03040403A0155|42 50|fragment
P03039387A0920|74 85|enhancement
P03039387A0920|56 59|BCG
P03039387A0920|145 156|combination
P03039387A0920|103 109|effect
P03039387A0920|186 202|cyclophosphamide
P03038891A0935|22 26|RNAs
P03038891A0935|1 18|Northern analyses
P03037334A0932|109 124|sequence motifs
P03037334A0932|64 80|yeast RP39A gene
P03036817A0213|26 37|mutagenesis
P03036817A0213|97 100|ATG
P03035658A0355|209 212|VO2
P03035658A0355|182 191|ml/kg/min
P03035658A0355|22 32|anesthesia
P03035658A0355|164 169|ng/ml
P03035658A0355|44 47|VO2
P03035658A0355|202 207|ng/ml
P03035056T0000|104 114|cell lines
P03035056T0000|8 14|lambda
P03035056T0000|19 52|kappa antibody gene rearrangement
P03034570A0943|149 159|hygromycin
P03034570A0943|42 46|code
P03034570A0943|189 208|papillomavirus type
P03034570A0943|114 118|gene
P03034570A0943|169 175|ORF E7
P03033283A0837|107 111|case
P03033283A0837|26 30|loci
P03033283A0837|213 236|consensus binding sites
P03033283A0837|65 74|IE68 gene
P03033283A0837|272 278|region
P03032143A0218|45 51|region
P03032143A0218|78 80|bp
P03032143A0218|3 13|centromere
P03032143A0218|84 90|length
P03032143A0218|205 214|chromatin
P03029111A0155|5 12|mutants
P03029111A0155|19 33|representative
P03027779A0000|149 156|normals
P03027779A0000|40 46|Tc-MDP
P03027779A0000|115 126|dislocation
P03026915A1024|56 65|sequences
P03026915A1024|126 145|lacZ fusion vectors
P03026915A1024|36 41|parts
P03025661A0260|1 8|Gluzman
P03025606T0000|150 154|mRNA
P03025606T0000|97 102|bases
P03025606T0000|81 89|gene lie
P03024343A0372|40 54|neuroendocrine
P03024343A0372|5 11|tumors
P03023887A0470|46 69|glucocorticoid receptor
P03023887A0470|97 102|sites
P03023887A0470|1 22|Nuclease footprinting
P03023682A0271|57 90|chloramphenicol acetyltransferase
P03023682A0271|97 107|expression
P03023682A0271|16 18|bp
P03023067A0779|1 12|Translation
P03021088A0135|120 128|Billroth
P03021088A0135|12 19|periods
P03021088A0135|198 205|average
P03021088A0135|213 218|years
P03021088A0135|36 45|exclusion
P03021088A0135|139 153|reconstruction
P03020513T0000|27 47|T4 DNA topoisomerase
P03020513T0000|69 81|gyrA-protein
P03019505A0390|6 14|patients
P03019505A0390|68 73|tumor
P03017996A0731|12 24|biosynthesis
P03017996A0731|133 140|protein
P03017996A0731|172 174|X3
P03016883A0000|15 22|history
P03016883A0000|150 157|urethra
P03016883A0000|162 177|virus isolation
P03016883A0000|80 89|infection
P03016883A0000|116 121|weeks
P03016301A0605|94 104|c-myc exon
P03016301A0605|71 79|terminus
P03016301A0605|152 158|region
P03015628A1078|72 92|hyperphosphatasaemia
P03015628A1078|110 120|mechanisms
P03015628A1078|1 12|Osteocalcin
P03014593A0681|105 110|mg/kg
P03014593A0681|79 88|Ro 5-4864
P03014593A0681|1 9|Diazepam
P03013841A0207|15 17|J.
P03011793A0582|44 48|rbsC
P03011793A0582|56 64|proteins
P03011793A0582|86 105|amino acid residues
P03009826A0201|15 21|clones
P03009826A0201|47 67|base-pair dimer unit
P03008405A0532|29 36|disease
P03008405A0532|51 62|deer calves
P03007281A0905|52 54|2L
P03007281A0905|5 17|Dox-A2 locus
P03007281A0905|55 70|OD15 breakpoint
P03007281A0905|49 51|Df
P03005231A0649|61 70|sequences
P03005231A0649|111 122|termination
P03005231A0649|96 106|initiation
P03004982A0199|121 125|fbcB
P03004982A0199|46 60|R. sphaeroides
P03004982A0199|130 134|fbcC
P03004982A0199|33 35|bp
P03004364A0775|63 66|ADM
P03004364A0775|78 84|FAMLIP
P03004364A0775|71 74|MMC
P03004364A0775|118 124|MMCLIP
P03002786A0143|41 50|midazolam
P03002786A0143|5 10|group
P03002786A0143|69 77|atropine
P03001952A0958|165 174|acyclovir
P03001952A0958|72 76|type
P03001952A0958|25 33|patients
P03001952A0958|207 218|recurrences
P03001645A0785|15 25|his3 genes
P03001645A0785|59 75|initiation sites
P03001110A0546|210 213|mol
P03001110A0546|196 205|phosphate
P03001110A0546|6 21|phosphorylation
P03001110A0546|115 139|tyrosine kinase activity
P03001110A0546|84 113|receptor self-phosphorylation
P03001084A0406|134 143|psi alpha
P03001084A0406|110 115|alpha
P03001084A0406|55 62|segment
P03001084A0406|51 53|bp
P03000489A0822|121 125|mean
P03000489A0822|116 119|CGL
P03000489A0822|72 76|AIDS
P03000489A0822|109 110|%
P03000489A0822|10 21|lymphocytes
P03000489A0822|172 182|activation
P03000489A0822|99 104|range
P03000489A0822|204 221|blood lymphopenia
P02999267A0885|286 288|GS
P02999267A0885|270 281|hypertrophy
P02999267A0885|53 61|patients
P02999267A0885|39 49|Tc-99m-PYP
P02999267A0885|187 197|appearance
P02998043A1199|74 82|presence
P02998043A1199|182 184|G2
P02998043A1199|36 61|Punta Toro M gene product
P02998043A1199|174 180|region
P02998043A1199|1 12|Examination
P02997777A0609|333 351|delta top1 top2 ts
P02997777A0609|315 325|cell death
P02997777A0609|203 210|killing
P02997777A0609|19 30|experiments
P02997777A0609|252 263|temperature
P02997777A0609|68 83|delta top1 top2
P02995999A0000|31 39|products
P02995999A0000|158 161|att
P02995999A0000|115 128|recombination
P02995999A0000|227 235|position
P02995999A0000|282 300|base-pair deletion
P02995999A0000|202 208|joints
P02995999A0000|369 392|base-pair substitutions
P02994336A0864|57 68|plasma ACTH
P02994336A0864|113 119|CB-154
P02994336A0864|98 111|bromocriptine
P02994336A0864|85 90|level
P02993630A1190|108 122|enzyme attacks
P02993630A1190|52 58|events
P02993630A1190|6 14|analysis
P02993630A1190|188 194|strand
P02993630A1190|152 155|G-A
P02989786A0328|8 15|absence
P02989786A0328|19 37|enhancer sequences
P02988457A0650|53 65|potentiality
P02988457A0650|98 103|types
P02987220A0472|15 28|DNA fragments
P02987220A0472|160 166|region
P02987220A0472|52 54|kb
P02987220A0472|87 99|DNA fragment
P02987220A0472|136 140|gene
P02985820A1287|125 142|retroviruses CMII
P02985820A1287|52 59|vectors
P02985820A1287|153 156|MH2
P02983331T0000|75 80|ether
P02983331T0000|82 96|immobilization
P02983331T0000|1 9|Evidence
P02982332T0001|44 50|tumors
P02982332T0001|10 15|study
P02982332T0001|1 6|Phase
P02979426T0000|26 33|Denmark
P02975753A1333|104 114|regulation
P02975753A1333|38 53|binding domains
P02975753A1333|1 28|Oligonucleotide mutagenesis
P02973304A0000|88 92|vein
P02973304A0000|167 182|cardiosclerosis
P02973304A0000|128 145|patient suffering
P02971710A0734|150 159|viscosity
P02971710A0734|25 34|2A weight
P02971710A0734|74 85|inflections
P02971710A0734|132 136|role
P02971710A0734|193 203|hematocrit
P02971710A0734|43 53|hematocrit
P02971710A0734|1 6|Plots
P02970640A0341|166 178|acid protein
P02970640A0341|8 36|absorption spectrophotometry
P02970640A0341|70 82|E1A proteins
P02969819A0814|125 140|Cmu transcripts
P02969819A0814|1 23|Ig D-JH recombinations
P02968055A0984|5 8|HOI
P02967915A0000|90 113|calcium binding protein
P02967915A0000|121 135|calbindin-D28K
P02967915A0000|18 50|hormone 1,25-dihydroxyvitamin D3
P02966671A0551|148 164|radiation effect
P02966671A0551|26 37|mg/kg c-DDP
P02966671A0551|191 197|factor
P02966671A0551|253 264|mg/kg c-DDP
P02966671A0551|74 79|X-ray
P02966671A0551|281 282|h
P02966671A0551|1 9|Schedule
P02965149A0727|30 32|C.
P02963517A0453|14 22|analysis
P02963517A0453|199 202|mm2
P02963517A0453|162 166|area
P02963517A0453|118 126|increase
P02960012A0838|65 66|%
P02960012A0838|49 50|%
P02958660A1094|131 141|experiment
P02958660A1094|5 9|data
P02958660A1094|100 111|flow values
P02958204A0175|90 96|HDL-PL
P02958204A0175|148 154|HDL2-C
P02958204A0175|159 165|HDL3-C
P02958204A0175|20 27|effects
P02958204A0175|187 195|patients
P02958204A0175|47 50|HDL
P02958204A0175|128 146|HDL-C subfractions
P02958204A0175|64 69|HDL-C
P02958204A0175|71 88|HDL phospholipids
P02950216A0084|12 16|flow
P02950216A0084|37 60|laser Doppler flowmetry
P02950216A0084|97 112|blood cell flux
P02950216A0084|136 141|terms
P02947866A1416|83 91|evidence
P02947866A1416|141 152|angioplasty
P02947866A1416|32 51|thallium-201 uptake
P02941237A0160|180 200|alkaline phosphatase
P02941237A0160|299 304|roles
P02941237A0160|115 123|hormones
P02941237A0160|165 172|enzymes
P02941237A0160|40 53|serum calcium
P02941237A0160|101 113|blood supply
P02939260A1553|150 162|DNA sequence
P02939260A1553|243 249|cycles
P02939260A1553|110 118|residues
P02939260A1553|20 48|amino acid sequence analysis
P02939260A1553|175 185|methionine
P02936284A0357|13 24|degradation
P02936284A0357|62 67|route
P02936284A0357|159 162|min
P02936284A0357|86 89|man
P02935638A0000|77 117|sea urchin Strongylocentrotus purpuratus
P02935638A0000|59 69|Spec1 gene
P02934889A0558|63 67|days
P02934889A0558|177 191|cent reduction
P02934889A0558|142 160|Ostertagia species
P02934889A0558|48 52|time
P02934889A0558|1 12|Oxfendazole
P02930623A0404|75 84|direction
P02930623A0404|8 24|flexion whiplash
P02930623A0404|54 61|condyle
P02928376A0312|59 66|mixture
P02928376A0312|101 112|heat defect
P02928376A0312|17 21|work
P02927391A0238|194 205|integration
P02927391A0238|226 235|germ line
P02927391A0238|27 37|proviruses
P02927391A0238|59 82|founder SWR/J-RF/J mice
P02925568A0460|11 18|effects
P02925568A0460|117 124|effects
P02925568A0460|51 61|conditions
P02923687A0218|47 51|side
P02923687A0218|22 34|relationship
P02923687A0218|55 64|sinusitis
P02919832A0144|9 16|disease
P02919832A0144|86 110|Doppler echocardiography
P02919483A0091|46 49|age
P02919483A0091|64 74|half years
P02916764A0253|41 53|hypertension
P02916764A0253|36 39|sex
P02916764A0253|5 17|risk factors
P02916764A0253|141 155|family history
P02914422A0409|165 172|notches
P02914422A0409|109 114|order
P02914422A0409|36 45|averaging
P02911540A0478|60 65|hands
P02911540A0478|73 77|face
P02911540A0478|82 90|perineum
P02911540A0478|3 10|patient
P02910496A0583|104 117|cleavage site
P02910496A0583|172 186|RNAase MRP RNA
P02910496A0583|139 152|RNA substrate
P02907533T0000|78 85|albumin
P02907533T0000|32 48|blood substitute
P02907308T0001|12 16|type
P02907308T0001|3 8|cases
P02906249A1195|14 19|group
P02906249A1195|41 46|mg/kg
P02906249A1195|129 139|PGF2 alpha
P02906249A1195|119 125|Oxy-Hb
P02906027A0553|78 84|region
P02906027A0553|4 23|sequence comparison
P02906027A0553|154 171|CpG dinucleotides
P02903500A0278|121 127|domain
P02903500A0278|131 134|neu
P02903500A0278|191 196|chain
P02903500A0278|156 163|portion
P02902844A1219|15 19|gene
P02902844A1219|73 80|protein
P02902844A1219|163 176|cyanobacteria
P02902615A0000|121 132|hepatitis B
P02902615A0000|26 35|treatment
P02902615A0000|93 102|treatment
P02901498A0354|162 188|chicken embryo fibroblasts
P02901498A0354|52 60|proteins
P02901498A0354|141 148|ability
P02899792T0000|19 27|overdose
P02898752A0683|41 48|numbers
P02898752A0683|78 82|rate
P02898752A0683|86 98|granulocytes
P02895754A0000|11 32|percent isoproterenol
P02895754A0000|40 48|presence
P02895754A0000|189 196|chamber
P02895754A0000|157 167|humor flow
P02895754A0000|116 123|ability
P02895472A0178|121 137|mRNA translation
P02895472A0178|82 86|cDNA
P02895472A0178|98 101|BiP
P02894741A0000|27 32|doses
P02894741A0000|98 116|NLA II anaesthesia
P02892762A0296|63 74|nucleotides
P02892762A0296|21 36|repeat elements
P02889495A0000|151 154|end
P02889495A0000|183 198|mg flupenthixol
P02889495A0000|92 104|flupenthixol
P02889495A0000|117 122|weeks
P02885517T0000|26 31|non-A
P02885517T0000|39 48|hepatitis
P02883963A0000|90 93|HAM
P02883963A0000|78 88|myelopathy
P02883963A0000|59 65|HTLV-I
P02883327A0413|90 93|DNA
P02883327A0413|129 130|L
P02883327A0413|112 115|end
P02883327A0413|49 52|end
P02880841A0313|90 93|TF1
P02880841A0313|209 217|sequence
P02880841A0313|297 309|chloroplasts
P02880841A0313|254 264|categories
P02880841A0313|74 78|gene
P02880841A0313|11 20|stability
P02880841A0313|162 181|nucleotide sequence
P02880841A0313|111 120|structure
P02879906A0000|47 52|veins
P02879906A0000|89 101|relationship
P02879906A0000|190 207|nerve innervation
P02879906A0000|1 8|Studies
P02877124A0000|486 489|end
P02877124A0000|179 194|trifluoperazine
P02877124A0000|430 432|Tc
P02877124A0000|292 298|agents
P02877124A0000|164 174|H1 blocker
P02877124A0000|437 440|MDP
P02877124A0000|111 140|H1 receptor blocking activity
P02877124A0000|445 454|indicator
P02877124A0000|92 105|phenothiazine
P02877124A0000|398 400|Tc
P02877124A0000|220 240|H1 blocking activity
P02877124A0000|552 558|sacrum
P02877124A0000|198 211|phenothiazine
P02877124A0000|275 282|effects
P02876820A0841|42 53|stimulation
P02875224A1059|90 96|damage
P02875224A1059|193 194|p
P02875224A1059|157 165|instance
P02875224A1059|55 61|hearts
P02875224A1059|136 149|contractility
P02874078A0252|62 63|%
P02874078A0252|16 39|luteal phase deficiency
P02872786A0147|134 144|blood flow
P02872786A0147|73 82|parasites
P02872786A0147|53 60|effects
P02870720A0188|105 117|isoprenaline
P02870720A0188|41 69|beta-adrenoceptor antagonist
P02870720A0188|1 11|Bisoprolol
P02869125A0120|91 99|syndrome
P02869125A0120|138 159|locomotor stimulation
P02869125A0120|1 9|Fentanyl
P02869125A0120|171 182|tachycardia
P02868446A0184|74 86|dnaG protein
P02868446A0184|208 213|alpha
P02868446A0184|176 187|RPase alpha
P02868446A0184|296 303|primase
P02868446A0184|16 23|domains
P02863747T0000|55 64|sequences
P02862656T0000|45 51|humans
P02862656T0000|64 78|alcohol intake
P02861144A0242|74 91|encoding proteins
P02861144A0242|56 61|genes
P02861144A0242|115 119|kDal
P02859434T0000|53 66|serum lithium
P02859434T0000|1 14|Poor response
P02853922A0596|60 65|study
P02853922A0596|43 47|eyes
P02852894T0000|61 69|chickens
P02852894T0000|11 16|death
P02850971A0180|104 123|hybridization probe
P02850971A0180|197 217|cosmid vector pVK102
P02850971A0180|157 164|library
P02850971A0180|51 57|region
P02850472A0112|19 30|origin core
P02849100A0441|134 149|plasma membrane
P02849100A0441|66 75|extremity
P02846852A1459|15 26|polymerases
P02846852A1459|5 11|number
P02846852A1459|87 93|number
P02845654A0510|62 70|position
P02845654A0510|261 271|processing
P02845654A0510|87 100|cleavage site
P02845654A0510|194 213|amino acid position
P02845654A0510|229 242|cleavage site
P02845654A0510|43 58|alanine residue
P02845654A0510|169 190|phenylalanine residue
P02844767A1022|61 74|cytochrome b6
P02844767A1022|148 155|subunit
P02844767A1022|127 131|mRNA
P02844767A1022|1 24|RNA blot hybridizations
P02844767A0191|182 184|T.
P02844767A0191|118 131|apocytochrome
P02844767A0191|186 193|Spiller
P02844767A0191|75 85|Rieske-FeS
P02844767A0191|13 22|structure
P02844767A0191|203 209|Malkin
P02843495A0544|30 35|CSF-1
P02843495A0544|82 101|factor independence
P02843495A0544|139 148|mechanism
P02843495A0544|17 22|v-fms
P02840034A1266|62 82|lung cancer patients
P02840034A1266|128 135|account
P02839716A0673|104 133|HPV-11 enhancer-SV40 promoter
P02839716A0673|10 15|cells
P02839716A0673|17 28|E2 proteins
P02838710A0299|29 32|rat
P02838710A0299|102 111|treatment
P02838246A0225|62 73|T4/T8 ratio
P02838246A0225|116 117|%
P02838246A0225|85 96|sensitivity
P02838246A0225|45 54|inversion
P02838246A0225|99 100|%
P02838246A0225|1 23|Herpes virus infection
P02837575A0979|90 96|enzyme
P02837575A0979|131 134|end
P02837575A0979|33 41|cleavage
P02834843A0000|150 153|CGP
P02834843A0000|89 92|F22
P02834843A0000|242 246|test
P02834843A0000|125 128|C29
P02834843A0000|114 117|CGP
P02834843A0000|18 26|activity
P02834843A0000|72 75|RBU
P02834843A0000|108 111|RPE
P02834843A0000|161 164|C27
P02834843A0000|141 144|C70
P02834843A0000|309 335|Mycobacterium tuberculosis
P02833517A0467|30 39|sequences
P02833517A0467|52 60|cleavage
P02833049A1041|344 354|cell types
P02833049A1041|27 43|state RNA levels
P02833049A1041|58 68|cell lines
P02833049A1041|4 12|analysis
P02833021A1185|30 42|organization
P02833021A1185|76 82|repeat
P02833021A1185|5 12|results
P02833021A1185|137 145|promoter
P02832744A0403|47 55|analyses
P02832744A0403|89 102|quail ovaries
P02832744A0403|42 45|RNA
P02832744A0403|32 40|Northern
P02832149A1009|13 19|change
P02832149A1009|146 155|insertion
P02832149A1009|5 9|lack
P02832149A1009|200 215|myb transcripts
P02832149A1009|273 291|mouse myb oncogene
P02831556A0173|73 77|pain
P02831556A0173|24 33|alpha-MSH
P02831556A0173|7 16|offspring
P02831556A0173|119 127|response
P02830282A0155|162 173|amino acids
P02830282A0155|115 127|V-8 protease
P02830282A0155|17 27|A1 protein
P02830214A0000|30 33|ACZ
P02830214A0000|52 62|activities
P02830214A0000|38 42|HCO3
P02830214A0000|116 138|microelectrode methods
P02828926A1870|148 169|actin gene expression
P02828926A1870|136 144|programs
P02826717A0179|111 115|gill
P02826717A0179|1 7|Anoxia
P02826717A0179|68 74|oxygen
P02825750A0260|71 79|response
P02825750A0260|17 25|patients
P02824334A0972|94 105|chromosomes
P02821340A0434|30 33|DCR
P02821340A0434|74 79|value
P02821340A0434|182 187|speed
P02821340A0434|177 180|kph
P02821340A0434|97 117|mm Hg X ml-1 X min-1
P02821340A0434|191 192|%
P02820128A1333|73 94|hexanucleotide ATTGTT
P02820128A1333|161 168|ORF T3C
P02820128A1333|114 121|regions
P02818122A0000|180 186|cortex
P02818122A0000|148 161|relationships
P02818122A0000|9 13|deal
P02818122A0000|67 76|claustrum
P02818122A0000|17 28|information
P02816251A0397|114 121|network
P02816251A0397|153 160|surface
P02814820A0967|182 190|Billroth
P02814820A0967|112 116|rate
P02814820A0967|262 268|solids
P02814820A0967|74 82|emptying
P02814820A0967|12 21|Roux limb
P02814820A0967|173 180|minutes
P02813404T0000|15 27|antigen gene
P02813404T0000|80 86|stages
P02811378A0379|47 55|staining
P02811378A0379|93 104|cell tumors
P02811378A0379|21 28|studies
P02810911A0372|78 95|131I-MIBG imaging
P02810911A0372|42 55|neuroblastoma
P02810911A0372|19 27|presence
P02809722A0926|20 27|patient
P02809116A0237|30 37|effects
P02809116A0237|122 134|satisfaction
P02809116A0237|96 106|retirement
P02807780A0143|123 128|areas
P02807780A0143|27 35|solution
P02807780A0143|67 73|M NaCl
P02807780A0143|39 53|methylene blue
P02807780A0143|98 106|staining
P02805945A0000|181 186|years
P02805945A0000|27 32|cysts
P02805945A0000|256 266|view point
P02805945A0000|107 114|cosinor
P02805945A0000|193 214|laboratory conditions
P02805945A0000|37 49|growth rates
P02805945A0000|5 16|percentages
P02800435A0000|105 106|T
P02800435A0000|133 136|PMF
P02800435A0000|93 99|effect
P02800435A0000|53 58|mg/kg
P02800435A0000|169 172|leg
P02799892A0154|42 47|cells
P02799892A0154|87 96|hemolysis
P02799892A0154|118 126|patients
P02797877A0475|123 134|antibiotics
P02797877A0475|24 34|micrograms
P02797877A0475|37 40|PEF
P02797877A0475|86 94|regrowth
P02796216A0063|29 35|course
P02796216A0063|97 107|appearance
P02796216A0063|48 65|jaundice syndrome
P02794828A0214|43 48|heart
P02794828A0214|64 77|microcomputer
P02793620A0214|125 133|pastures
P02793620A0214|93 107|Red Poll bulls
P02792430A0000|149 160|development
P02792430A0000|214 218|rats
P02792430A0000|37 48|guinea pigs
P02792430A0000|174 180|oedema
P02792430A0000|1 12|Experiments
P02792430A0000|205 210|serum
P02790009A1052|12 19|protein
P02790009A1052|70 76|region
P02789217A1323|95 103|distance
P02789217A1323|111 120|kilobases
P02789062A1420|167 194|NF-4FB recognition sequence
P02789062A1420|21 52|NF-4FB enhancer binding protein
P02789062A1420|84 108|lambda gt11 cDNA library
P02787430A0124|42 58|biopsy specimens
P02783181A0000|181 184|rat
P02783181A0000|125 135|blood flow
P02783181A0000|140 156|mucus secretions
P02783181A0000|34 44|activities
P02781495T0001|41 49|patients
P02781495T0001|1 8|Changes
P02779752A0776|151 162|5-HT1 sites
P02779752A0776|95 100|TFMPP
P02779752A0776|83 93|piperazine
P02779752A0776|221 233|methysergide
P02779752A0776|45 50|mg/kg
P02779752A0776|110 115|mg/kg
P02778873A0761|123 128|DR-A2
P02778873A0761|9 16|segment
P02778873A0761|20 24|CRL3
P02777797A0720|79 83|gene
P02777797A0720|93 116|PtdIns transfer protein
P02776742A0000|151 158|firemen
P02776742A0000|329 348|breathing apparatus
P02776742A0000|182 184|yr
P02776742A0000|25 36|temperature
P02776742A0000|186 193|VO2 max
P02776742A0000|165 168|age
P02776742A0000|13 15|HR
P02776742A0000|228 240|fire fighter
P02776742A0000|350 352|FE
P02776742A0000|272 276|fire
P02776742A0000|205 218|ml kg-1 min-1
P02775333A1137|195 199|dose
P02775333A1137|208 213|mg/kg
P02775333A1137|144 152|decrease
P02775333A1137|175 183|increase
P02775333A1137|1 11|Buflomedil
P02774808A0194|62 68|summer
P02774808A0194|5 11|values
P02774808A0194|119 125|winter
P02773930T0000|14 20|kidney
P02773930T0000|24 29|model
P02772495A0641|79 81|AT
P02772495A0641|66 67|%
P02772495A0641|101 111|INTR group
P02767166A0368|134 140|damage
P02767166A0368|182 190|diabetes
P02767166A0368|21 39|lipid peroxidation
P02767166A0368|170 178|cataract
P02767166A0368|205 211|myopia
P02766508A0421|54 64|similarity
P02766508A0421|101 115|mean IQRST map
P02765214A0486|72 81|arguments
P02765214A0486|54 64|importance
P02764797A0182|151 169|imaging parameters
P02764797A0182|192 210|gradient waveforms
P02764797A0182|109 114|gates
P02764797A0182|126 140|sampling times
P02764797A0182|116 124|rf phase
P02764797A0182|85 87|rf
P02762198T0001|44 50|period
P02762198T0001|18 25|reports
P02761540A0873|43 49|NF-4FB
P02761540A0873|98 115|enhancer activity
P02761540A0873|35 41|NF-4FA
P02761492A0124|26 30|view
P02761492A0124|5 13|findings
P02761008X0000|210 226|organophosphorus
P02761008X0000|63 69|egrets
P02761008X0000|116 136|brain cholinesterase
P02761008X0000|187 195|exposure
P02761008X0000|230 250|carbamate pesticides
P02761008X0000|138 141|ChE
P02761008X0000|102 112|inhibition
P02758382A0478|133 161|sex hormone binding globulin
P02758382A0478|42 53|proportions
P02758382A0478|169 175|levels
P02758382A0478|1 8|Obesity
P02757033A0905|79 82|arm
P02757033A0905|25 31|effect
P02757033A0905|51 56|genes
P02756731T0001|20 30|gallstones
P02752629A0163|125 133|fracture
P02752629A0163|113 118|weeks
P02752629A0163|1 8|Dynamic
P02751080A0176|25 32|bullets
P02751080A0176|93 95|dB
P02748595A0492|92 100|ADH-beta
P02748595A0492|21 39|baboon liver class
P02747653A0910|60 68|staining
P02747653A0910|131 136|stage
P02747653A0910|114 127|metamorphosis
P02747653A0910|101 110|beginning
P02745666A0000|13 21|biopsies
P02745666A0000|26 43|plasma oestradiol
P02745666A0000|53 65|progesterone
P02745666A0000|84 92|patients
P02745280A0276|151 165|concentrations
P02745280A0276|242 264|resonance spectroscopy
P02745280A0276|9 14|level
P02745280A0276|127 134|changes
P02745280A0276|190 205|phosphocreatine
P02745280A0276|48 56|measures
P02744123A0237|210 230|background luminance
P02744123A0237|52 59|species
P02744123A0237|20 27|results
P02744123A0237|84 87|man
P02743842A0000|361 365|acid
P02743842A0000|56 67|cytoprotect
P02743842A0000|335 341|mucosa
P02743842A0000|323 326|rat
P02743842A0000|115 132|stress ulceration
P02743842A0000|13 18|study
P02743842A0000|40 54|prostaglandins
P02743842A0000|278 279|H
P02743842A0000|236 252|lesion formation
P02743842A0000|205 209|PGE2
P02740874A0957|43 51|controls
P02740874A0957|86 89|SO2
P02740347A0644|67 86|restriction mapping
P02740347A0644|118 120|kb
P02739739T0000|32 38|member
P02735364A1330|14 19|model
P02735364A1330|28 29|p
P02735364A1330|130 133|age
P02735364A1330|218 226|survival
P02735364A1330|21 26|grade
P02735364A1330|84 112|progesterone receptor status
P02733116T0000|33 39|Health
P02731671A0000|148 159|B6C3F1 mice
P02731671A0000|81 84|H2O
P02731671A0000|74 79|NiSO4
P02731671A0000|192 198|hr/day
P02731671A0000|132 143|F344/N rats
P02731671A0000|40 43|NiO
P02731671A0000|202 211|days/week
P02729666A0267|93 117|tissue profile variables
P02725513A0617|121 130|promoters
P02725513A0617|142 151|G residue
P02725513A0617|32 51|CHO spacer promoter
P02724227T0000|52 66|flap tolerance
P02724227T0000|1 18|Perfusion washout
P02721169A0171|115 128|relationships
P02721169A0171|1 10|NERVTRACK
P02718683A0142|1 21|Handgrip dynamometry
P02717133T0001|3 9|method
P02714525A0529|90 100|dose level
P02714525A0529|159 164|weeks
P02714525A0529|168 176|exposure
P02714525A0529|34 46|weight ratio
P02713520T0000|57 71|cholinesterase
P02713520T0000|25 41|methyl parathion
P02712450A0989|210 217|changes
P02712450A0989|25 30|mm Hg
P02712450A0989|117 125|response
P02712450A0989|75 76|p
P02712450A0989|14 19|PACO2
P02712450A0989|162 168|others
P02712450A0989|100 108|subjects
P02711601A0601|62 69|control
P02711601A0601|33 58|acid phosphatase activity
P02711601A0601|19 29|inhibition
P02711145T0000|28 32|AIDS
P02709081T0000|44 59|profile measure
P02709081T0000|67 91|type A behaviour pattern
P02709081T0000|1 11|Validation
P02708353A1080|176 187|P-450e gene
P02708353A1080|1 29|Primer extension experiments
P02708288A0139|90 94|acid
P02708288A0139|41 50|detection
P02708288A0139|127 142|base hydrolysis
P02708288A0139|52 57|LC/AD
P02708288A0139|1 22|Liquid chromatography
P02705556A1049|29 31|RC
P02705556A1049|66 78|flow reserve
P02705072A0464|60 70|infarction
P02705072A0464|76 80|rate
P02705072A0464|85 90|death
P02703925A0359|361 366|areas
P02703925A0359|487 496|inversion
P02703925A0359|179 203|proteoglycan aggregation
P02703925A0359|905 920|sedimentability
P02703925A0359|253 257|sign
P02703925A0359|425 430|areas
P02703925A0359|643 663|S value distribution
P02703925A0359|106 129|polydispersity profiles
P02703925A0359|315 328|proteoglycans
P02703925A0359|446 453|finding
P02703925A0359|171 175|loss
P02703925A0359|809 824|cartilage layer
P02703925A0359|208 223|sedimentability
P02703925A0359|868 878|aggregates
P02703925A0359|405 411|weight
P02703925A0359|620 625|areas
P02703925A0359|349 351|HW
P02703925A0359|413 415|LW
P02702849A0418|63 71|patients
P02702849A0418|140 170|patients plasma concentrations
P02702849A0418|115 117|mg
P02702849A0418|1 32|Metformin plasma concentrations
P02700977A0444|1 11|Scotchbond
P02700977A0444|102 113|combination
P02694731A0241|180 187|profile
P02694731A0241|110 120|hypotheses
P02694731A0241|53 62|Parkinson
P02694731A0241|65 72|disease
P02693208A0166|90 95|rad52
P02693208A0166|22 26|role
P02693208A0166|70 79|mutations
P02693208A0166|34 47|recombination
P02691998A0672|13 17|data
P02691998A0672|103 106|bed
P02691557A0273|123 137|concentrations
P02691557A0273|24 43|breathing movements
P02691557A0273|200 209|gestation
P02691557A0273|141 151|plasma PGE
P02689439A0402|45 51|pmGT10
P02689439A0402|147 152|pmGT2
P02689439A0402|213 225|rat Yb2 gene
P02689439A0402|98 104|region
P02689439A0402|69 75|degree
P02689439A0402|137 143|region
P02689136A1851|42 46|time
P02686985A0811|160 177|complex formation
P02686985A0811|111 124|transcription
P02686985A0811|3 39|transcription factor exclusion assay
P02686985A0811|220 229|component
P02686749A0000|121 129|exposure
P02686749A0000|192 212|beta 2-microglobulin
P02686749A0000|179 188|excretion
P02686749A0000|276 280|year
P02686749A0000|216 239|retinol binding protein
P02686749A0000|290 295|years
P02685565A0165|93 98|cells
P02685565A0165|138 149|c-myb genes
P02685331A0523|210 215|sigma
P02685331A0523|57 70|nifH promoter
P02685331A0523|229 238|promoters
P02685331A0523|97 119|methylation protection
P02684159A0870|40 44|size
P02684159A0870|70 79|kilobases
P02679804A2000|73 83|channeling
P02679804A2000|33 37|ura3
P02679804A2000|17 28|genes ura10
P02677429A0366|121 136|treatment group
P02677429A0366|58 59|%
P02677429A0366|251 259|subjects
P02677429A0366|152 153|%
P02677429A0366|167 173|months
P02677429A0366|197 198|%
P02677429A0366|278 279|%
P02677429A0366|33 48|treatment group
P02677429A0366|1 15|Survival rates
P02674679A1237|181 192|specificity
P02674679A1237|196 218|start site utilization
P02674679A1237|52 68|RNA preparations
P02674679A1237|142 148|levels
P02674679A1237|102 106|dhfr
P02674671A0601|45 46|%
P02674671A0601|89 102|met2 mutation
P02674671A0601|24 41|DNA transformants
P02674141A1202|13 29|cysteine residue
P02674141A1202|33 37|CTSE
P02669199A0000|95 104|endotoxin
P02669199A0000|52 66|shock syndrome
P02667259A0331|121 125|flow
P02667259A0331|79 85|nausea
P02667259A0331|66 70|case
P02667259A0331|51 55|ADRs
P02666404A0220|212 238|liver glucose transporters
P02666404A0220|261 267|xylose
P02666404A0220|165 192|muscle glucose transporters
P02666404A0220|315 322|glucose
P02666404A0220|337 359|galactose transporters
P02666404A0220|38 46|sequence
P02666404A0220|137 154|HepG2-erythrocyte
P02664229A0138|165 169|ease
P02664229A0138|286 305|hypospadias repairs
P02664229A0138|109 118|treatment
P02664229A0138|246 255|operation
P02664229A0138|20 29|extension
P02664229A0138|50 58|problems
P02657883A0000|59 65|method
P02657883A0000|32 41|attention
P02657883A0000|85 95|evaluation
P02656257A0000|59 75|bacteriophage P1
P02656257A0000|116 135|crossing-over sites
P02651487A0000|151 182|excitation contraction coupling
P02651487A0000|244 260|glucagon release
P02651487A0000|200 206|glands
P02651487A0000|71 82|contraction
P02651487A0000|102 108|muscle
P02650663A0178|211 219|dementia
P02650663A0178|7 13|rating
P02650663A0178|116 130|Alzheimer type
P02650663A0178|169 175|degree
P02649445A0412|43 47|OGTT
P02649445A0412|127 130|men
P02649445A0412|82 88|medium
P02648646A0216|45 50|doses
P02648646A0216|106 112|change
P02648646A0216|57 73|minute intervals
P02648646A0216|145 146|%
P02648646A0216|1 27|Platelet activating factor
P02648396A0565|41 51|c-jun mRNA
P02648396A0565|113 124|form tumors
P02648396A0565|21 31|expression
P02648396A0565|87 92|clone
P02647918A0588|300 313|disappearance
P02647918A0588|333 344|GH response
P02647918A0588|125 126|%
P02647918A0588|113 121|patients
P02647918A0588|85 94|GH levels
P02647918A0588|164 172|patients
P02647918A0588|286 294|criteria
P02647918A0588|348 361|TRH/GnRH test
P02647918A0588|38 42|cure
P02647918A0588|103 108|ng/ml
P02647403A0000|14 28|hallucinations
P02647403A0000|98 103|years
P02645431A1562|43 47|type
P02645431A1562|7 11|data
P02645431A1562|115 123|function
P02644735A0427|40 49|insertion
P02644735A0427|53 70|S. frugiperda DNA
P02644735A0427|96 107|transcripts
P02644735A0427|117 128|S1 analysis
P02642466T0000|1 18|Sequence analysis
P02638964A0372|62 71|composite
P02638964A0372|43 54|examination
P02638964A0372|5 19|maximum stress
P02636920T0001|15 20|study
P02634490A0186|135 148|ATB treatment
P02634490A0186|193 200|therapy
P02634490A0186|96 110|CT examination
P02634490A0186|18 27|diagnosis
P02631887A0000|8 16|patients
P02631566A0151|181 190|chlorides
P02631566A0151|76 96|3,4-dimethylpyridine
P02631566A0151|18 46|dimethylpyridinium chlorides
P02631566A0151|221 245|1-ethyloxymethylimidazol
P02630543A0210|75 87|tissue cells
P02630543A0210|209 215|volume
P02630543A0210|124 125|T
P02630543A0210|173 189|cell populations
P02630543A0210|115 116|T
P02630543A0210|156 163|numbers
P02627159A0899|22 35|IgG4 antibody
P02627159A0899|51 56|index
P02621983T0001|64 69|tests
P02617623A0740|75 84|altitudes
P02617623A0740|12 20|isolates
P02617623A0740|23 29|LON-73
P02617623A0740|35 41|LON-71
P02614668A0971|45 50|ng/ml
P02614668A0971|23 36|concentration
P02607766A0000|420 422|Cd
P02607766A0000|124 137|concentration
P02607766A0000|176 180|lead
P02607766A0000|50 66|characterization
P02607766A0000|288 290|Hg
P02607766A0000|317 319|Pb
P02607766A0000|98 101|QCM
P02607766A0000|150 152|Cd
P02607766A0000|159 170|microgram/L
P02607766A0000|256 258|Cd
P02607766A0000|192 205|micrograms/dL
P02607766A0000|279 286|mercury
P02607766A0000|3 11|protocol
P02605182A0936|13 29|protein sequence
P02605182A0936|87 101|signal peptide
P02604420A0234|107 109|.0
P02604420A0234|8 17|challenge
P02604420A0234|96 101|range
P02604420A0234|136 146|year study
P02603374A0383|72 89|patient morbidity
P02603374A0383|114 127|complications
P02601707A0986|46 58|footprinting
P02601707A0986|147 158|C2 myotubes
P02601707A0986|212 220|sequence
P02601707A0986|201 202|A
P02601707A0986|254 260|region
P02599995A1031|133 146|staphylococci
P02599995A1031|55 64|times MBC
P02599995A1031|102 110|activity
P02598034A0000|44 49|MAEPs
P02598034A0000|101 108|lesions
P02598034A0000|1 24|Middle-latency auditory
P02598034A0000|68 76|controls
P02597484A0624|27 38|diffusivity
P02597484A0624|6 13|respect
P02597484A0624|65 83|surface reactivity
P02597484A0624|155 164|materials
P02595451A1136|129 134|sides
P02595451A1136|23 36|aniridia gene
P02595451A1136|138 142|MIC1
P02595451A1136|100 115|marker sequence
P02592640A0466|242 247|cream
P02592640A0466|21 28|retinol
P02592640A0466|153 154|g
P02592640A0466|281 294|beta-carotene
P02592640A0466|110 116|cheese
P02592640A0466|33 46|beta-carotene
P02591078A0000|124 140|Langerhans cells
P02591078A0000|8 22|investigations
P02591078A0000|39 49|Grenz rays
P02591078A0000|216 225|epidermis
P02590615A0636|121 137|pharmacokinetics
P02590615A0636|56 60|meal
P02590615A0636|110 116|manner
P02590615A0636|141 151|nifedipine
P02590391A0442|209 227|phospholipid class
P02590391A0442|261 268|grading
P02590391A0442|184 200|acid composition
P02590391A0442|160 173|sphingomyelin
P02590391A0442|276 283|lesions
P02590391A0442|1 5|None
P02590097A0093|62 68|mucosa
P02590097A0093|42 54|infiltration
P02590097A0093|159 169|Type Kappa
P02590097A0093|87 100|lobe bronchus
P02586485A0511|8 15|YC819-9
P02586485A0511|1 6|GN101
P02584969A0119|78 88|treatments
P02584969A0119|128 143|protection time
P02584969A0119|49 65|regression model
P02582240A1009|120 130|initiation
P02582240A1009|6 20|ATP/GTP ratios
P02582240A1009|71 82|dCTTT sites
P02577867T0000|20 27|homolog
P02576405A0223|194 195|%
P02576405A0223|26 29|VAD
P02576405A0223|147 152|VP-16
P02576405A0223|173 182|responses
P02576405A0223|81 96|CBV combination
P02576405A0223|154 162|platinum
P02575567T0001|1 26|Materials science studies
P02575174A0229|105 112|blocker
P02575174A0229|56 65|doxazosin
P02575174A0229|140 152|hypertension
P02575174A0229|117 125|patients
P02574193A0663|181 199|withdrawal periods
P02574193A0663|213 221|subjects
P02574193A0663|159 167|baseline
P02574193A0663|21 26|items
P02574193A0663|43 90|Institute Withdrawal Assessment-Benzodiazepines
P02574193A0663|234 242|symptoms
P02574193A0663|139 150|differences
P02574016A0428|165 173|children
P02574016A0428|79 90|neostigmine
P02574016A0428|125 131|adults
P02574016A0428|64 77|control value
P02574016A0428|153 160|infants
P02573829T0000|106 124|transcription unit
P02573829T0000|143 160|segmentation gene
P02573303A0000|94 98|PEEP
P02573303A0000|158 175|contractile state
P02573303A0000|39 52|stroke volume
P02573303A0000|84 92|pressure
P02572777T0000|1 23|Tumour necrosis factor
P02569411A0151|7 18|termination
P02569411A0151|37 44|animals
P02567030A0482|36 50|discrimination
P02567030A0482|116 124|reversal
P02566613T0000|122 130|proteins
P02566613T0000|85 105|DNA control elements
P02565807A1198|144 152|ABSTRACT
P02565807A1198|4 12|contrast
P02565807A1198|50 65|kinase activity
P02565807A1198|119 125|levels
P02565405T0000|1 9|Drug use
P02562787A0637|42 45|NBP
P02559630A0270|148 186|fibrin/fibrinogen degradation products
P02559630A0270|127 142|platelet counts
P02559630A0270|99 113|thrombin times
P02559630A0270|18 24|values
P02557217A0398|24 34|calcitonin
P02557217A0398|5 9|data
P02556603A0606|24 35|improvement
P02556603A0606|84 102|gallbladder cancer
P02556264A0278|6 20|TC-II enhanson
P02556264A0278|71 91|kappa chain enhancer
P02556264A0278|223 236|kappa B motif
P02555519A0798|131 139|H-chains
P02555519A0798|53 61|sequence
P02555519A0798|20 30|variations
P02555519A0798|153 165|conservation
P02555519A0798|34 40|length
P02555177A0488|180 198|COX1 mRNA splicing
P02555177A0488|10 15|pet54
P02555177A0488|118 126|aI5 beta
P02555177A0488|68 74|genome
P02552316A0526|74 78|days
P02552316A0526|123 142|seroconversion rate
P02552316A0526|83 88|woman
P02551886A0332|106 115|fragments
P02551886A0332|1 17|Restriction maps
P02550118A0610|38 51|infiltrations
P02549343A1008|58 62|mO74
P02549343A1008|320 325|virus
P02549343A1008|80 95|characteristics
P02549343A1008|116 119|gpI
P02549343A1008|167 194|immunoprecipitation pattern
P02549343A1008|234 245|polypeptide
P02549343A1008|4 15|consequence
P02549343A1008|138 143|cells
P02548683T0001|40 48|Shanghai
P02548683T0001|58 69|hepatitis A
P02547706T0001|13 28|immunohistology
P02547706T0001|41 54|hybridization
P02547706T0001|168 195|bone marrow transplantation
P02547611A0318|61 70|clone 22c
P02547611A0318|98 104|intron
P02547611A0318|1 9|Clone 4c
P02546234A1382|29 40|tachycaydia
P02546234A1382|115 122|outcome
P02545357A0000|5 35|mustard chloroplast gene rps16
P02543734A0414|165 175|expression
P02543734A0414|127 148|cotransfection assays
P02543734A0414|100 123|IE1/2 enhancer/promoter
P02543621A0788|60 65|Wilms
P02543621A0788|29 34|cases
P02543621A0788|67 72|tumor
P02543621A0788|170 174|gene
P02542612A0530|74 84|Vero cells
P02542612A0530|133 134|Z
P02542612A0530|179 184|level
P02542612A0530|53 64|B95-8 cells
P02542612A0530|1 21|S1 nuclease analysis
P02542194A1496|131 142|ependymomas
P02542194A1496|7 14|results
P02542194A1496|64 75|irradiation
P02541251A1327|165 168|end
P02541251A1327|122 137|CCAAT sequences
P02541251A1327|231 238|T1 gene
P02541251A1327|81 105|transcription factor SP1
P02538656A0172|209 215|genome
P02538656A0172|93 99|mutant
P02538656A0172|173 189|mouse C127 cells
P02538656A0172|33 43|E1 mutants
P02537485A0841|160 164|dose
P02537485A0841|8 21|formalin test
P02537485A0841|32 40|naloxone
P02537485A0841|84 89|doses
P02536160A0518|72 89|sense orientation
P02536160A0518|56 64|sequence
P02536160A0518|27 36|condition
P02536160A0518|197 208|orientation
P02536160A0518|171 179|sequence
P02535460A1443|1 16|RNA transcripts
P02532210A0000|5 24|adenovirus E1A gene
P02531203A0241|14 25|predictions
P02531203A0241|115 125|SSTS model
P02530413A0195|91 96|level
P02530413A0195|114 119|pg/ml
P02530413A0195|21 38|plasma ANP levels
P02528730A1073|45 53|sequence
P02528730A1073|11 19|exons 2a
P02528730A1073|27 32|share
P02528730A1073|131 133|bp
P02527745A0865|126 137|vertebrates
P02527745A0865|110 116|domain
P02527745A0865|1 23|Southern blot analyses
P02526165X0000|46 50|sign
P02526165X0000|111 117|marker
P02526165X0000|54 66|Leser-Trelat
P02523800A1178|44 53|CHS1 gene
P02523800A1178|83 90|repeats
P02523800A1178|200 202|J.
P02523800A1178|190 198|Kronstad
P02521674T0000|58 63|virus
P02521674T0000|39 46|mutants
P02521674T0000|1 8|Mapping
P02520622A0200|75 88|transit times
P02520622A0200|132 151|cimetropium bromide
P02520622A0200|182 187|month
P02520622A0200|155 164|mg t.d.s.
P02519327T0001|13 23|rheumatism
P02518645T0001|26 46|laboratory diagnosis
P02518645T0001|64 68|year
P02515953A0459|26 27|%
P02515953A0459|51 64|effectiveness
P02512010A0801|79 93|defibrillation
P02512010A0801|5 23|PETCO2 measurement
P02512010A0801|68 75|success
P02511430A0000|22 28|region
P02511430A0000|36 46|mouse MOPC
P02511430A0000|50 55|kappa
P02511150T0025|27 39|perspectives
P02510242A0313|104 110|search
P02510242A0313|11 16|cases
P02510242A0313|37 46|hepatitis
P02510242A0313|233 240|viruses
P02510242A0313|252 255|CMV
P02508726A0498|90 99|treatment
P02508726A0498|300 306|agents
P02508726A0498|155 167|brain injury
P02508726A0498|72 82|medication
P02508726A0498|7 19|case reports
P02508726A0498|36 44|evidence
P02507815A0000|74 82|amygdala
P02507815A0000|86 90|cats
P02507815A0000|1 9|Kindling
P02506740A0742|99 106|hypoxia
P02506740A0742|35 40|hours
P02505087A1037|79 93|leucine zipper
P02505087A1037|20 44|dimerization specificity
P02502960A0762|12 14|p.
P02502096A0462|68 87|excretion processes
P02498652A0460|110 113|GH3
P02498652A0460|136 149|cell cultures
P02497340A0989|57 59|JH
P02497340A0989|111 123|chain probes
P02497340A0989|64 66|VH
P02496100T0000|29 34|assay
P02496100T0000|65 84|cottonseed products
P02496100T0000|49 61|aflatoxin B1
P02495745T0000|36 69|tissue-type plasminogen activator
P02495745T0000|71 77|AK-124
P02492111A0868|224 239|U.S. guidelines
P02492111A0868|106 113|results
P02492111A0868|161 167|margin
P02492111A0868|82 90|exposure
P02492111A0868|71 77|levels
P02489895T0001|106 112|adults
P02489895T0001|93 101|children
P02489895T0001|1 14|Muscle action
P02489032A0000|150 163|gene segments
P02489032A0000|146 148|JL
P02489032A0000|22 27|chain
P02489032A0000|1 15|Immunoglobulin
P02489032A0000|221 230|VL region
P02489032A0000|119 127|variable
P02487898A0315|6 24|NGF administration
P02485188A0415|271 291|chondroitin sulfates
P02485188A0415|57 66|reactions
P02485188A0415|159 160|p
P02485188A0415|326 327|p
P02485188A0415|319 324|group
P02485188A0415|11 28|chondroitinase AC
P02485188A0415|199 200|p
P02485188A0415|304 312|diabetes
P02484714T0000|12 24|organization
P02483210A0000|106 128|relapsing pancreatitis
P02483210A0000|25 36|blood serum
P02483210A0000|49 56|amylase
P02483210A0000|16 21|value
P02482293A1518|195 203|receptor
P02482293A1518|128 141|phorbol ester
P02482293A1518|213 218|cells
P02482293A1518|18 45|T24 bladder carcinoma cells
P02481429T0000|9 27|staining technique
P02480959A0470|181 194|gonadotropins
P02480959A0470|62 67|surge
P02480959A0470|228 237|prolactin
P02480959A0470|6 19|P-450scc mRNA
P02480959A0470|114 119|cells
P02480959A0470|170 177|absence
P02479823A0727|62 70|GC boxes
P02479823A0727|1 18|Sequence analysis
P02477373A0930|36 46|base pairs
P02476030A0000|43 46|eye
P02476030A0000|70 76|states
P02475506A0878|27 31|cDNA
P02475506A0878|5 9|mRNA
P02474204A0105|73 87|immunostaining
P02474204A0105|92 104|chromogranin
P02474204A0105|33 38|means
P02474204A0105|136 141|cells
P02474093T0000|24 41|enzyme inhibitors
P02474093T0000|71 79|efficacy
P02473907A1338|28 32|site
P02473907A1338|129 133|site
P02473907A1338|80 92|Fc epsilon R
P02473907A1338|184 196|Fc epsilon R
P02473907A1338|205 209|site
P02473693A0174|6 14|approach
P02473198A0613|29 45|potassium efflux
P02473198A0613|58 62|86Rb
P02473198A0613|64 70|efflux
P02473198A0613|84 90|glands
P02470955A0101|56 71|CSF AP activity
P02470955A0101|115 127|meningitides
P02468795A1086|88 101|cancer volume
P02468795A1086|71 82|correlation
P02468795A1086|103 104|r
P02466414A0000|31 47|plasma viscosity
P02466414A0000|149 169|exchange transfusion
P02466414A0000|177 179|ml
P02466414A0000|25 29|dogs
P02466414A0000|49 51|Ep
P02466414A0000|195 201|plasma
P02466414A0000|140 145|steps
P02463050A0514|148 153|males
P02463050A0514|5 50|corticosterone synthesis inhibitor metyrapone
P02463050A0514|102 116|corticosterone
P02462305A1071|112 120|sequence
P02462305A1071|36 49|glycosylation
P02462305A1071|5 21|size discrepancy
P02461368A0162|107 114|cloning
P02461368A0162|9 15|report
P02461368A0162|81 96|type X collagen
P02461368A0162|119 129|sequencing
P02458080T0000|36 43|myeloma
P02456827A0899|41 49|decrease
P02456827A0899|5 9|4-AP
P02456827A0899|65 73|activity
P02456827A0899|103 106|TEA
P02454976A0944|225 230|areas
P02454976A0944|27 35|relation
P02454976A0944|112 115|cat
P02454976A0944|263 268|gyrus
P02454976A0944|272 280|primates
P02452313A0114|60 77|blocking activity
P02452313A0114|120 123|pA2
P02452313A0114|246 247|X
P02452313A0114|158 166|activity
P02452313A0114|216 224|ASL-8123
P02452313A0114|255 257|M.
P02449431A1121|77 83|araATP
P02449431A1121|48 62|concentrations
P02449431A1121|1 23|ATP gamma S inhibition
P02445751A0925|73 80|subunit
P02445751A0925|147 151|type
P02445751A0925|129 138|F1 ATPase
P02445751A0925|20 32|measurements
P02443924A0083|105 113|survival
P02443924A0083|82 88|cancer
P02442837A0060|176 183|minutes
P02442837A0060|92 101|verapamil
P02442837A0060|129 152|calcium channel blocker
P02442837A0060|202 205|end
P02442837A0060|18 24|groups
P02437895A0000|242 253|dysarthrics
P02437895A0000|261 271|hemisphere
P02437895A0000|325 333|subjects
P02437895A0000|118 131|language task
P02437895A0000|197 199|LH
P02437895A0000|97 108|hemispheres
P02437895A0000|3 8|probe
P02437895A0000|69 79|engagement
P02437625A0197|105 117|degeneration
P02437625A0197|5 10|study
P02437625A0197|119 122|AMD
P02431314A0834|75 89|eosinophiluria
P02431314A0834|18 24|Hansel
P02427812A0865|27 31|view
P02427812A0865|37 46|clonidine
P02427812A0865|113 116|rat
P02427812A0865|152 158|action
P02427024X0000|14 35|fenfluramine anorexia
P02427024X0000|104 113|tolerance
P02427024X0000|198 208|phenomenon
P02427024X0000|37 41|fact
P02427024X0000|168 178|generality
P02427024X0000|1 10|Tolerance
P02423850A0292|122 137|yeast CYC1 gene
P02423850A0292|83 91|homology
P02423850A0292|68 74|region
P02423533A1790|40 49|sequences
P02423533A1790|125 135|sea urchin
P02423533A1790|5 10|cDNAs
P02420432A1060|15 26|conjunction
P02420432A1060|43 57|pregnancy test
P02420432A1060|66 73|patient
P02420432A1060|85 92|history
P02419327A0998|208 212|side
P02419327A0998|25 28|DNA
P02419327A0998|65 72|enzymes
P02417669A0218|75 79|acid
P02417669A0218|129 139|metabolite
P02417669A0218|4 28|maximum photosensitivity
P02417669A0218|207 214|animals
P02411513A0667|134 151|dorsal negativity
P02411513A0667|122 128|dipole
P02411513A0667|26 33|N22/P22
P02408248A0414|63 80|enzyme inhibitors
P02406570A0898|78 89|possibility
P02406570A0898|146 150|ARS1
P02406570A0898|127 142|DNA replication
P02406570A0898|23 33|properties
P02406570A0898|4 15|examination
P02405818A0550|31 37|artery
P02405818A0550|42 53|perforators
P02405818A0550|100 108|arteries
P02405818A0550|1 17|Branch occlusion
P02405393T0000|26 42|characterization
P02405393T0000|50 58|promoter
P02403926A0307|180 188|extracts
P02403926A0307|110 127|kd phosphoprotein
P02403926A0307|154 163|threonine
P02403926A0307|50 93|beta gal-trk receptor kinase fusion protein
P02403634A0788|303 333|muscle-CAAT consensus sequence
P02403634A0788|89 96|domains
P02403634A0788|52 55|ATA
P02403634A0788|191 193|bp
P02403634A0788|73 79|region
P02403634A0788|37 45|addition
P02403634A0788|237 243|factor
P02403634A0788|342 344|bp
P02402678A0463|24 36|formulations
P02402678A0463|116 138|aerosol space-spraying
P02402678A0463|225 232|g ai/ha
P02402678A0463|198 215|application rates
P02402678A0463|97 102|water
P02402678A0463|272 288|housefly control
P02400070T0000|15 23|propofol
P02400070T0000|55 61|agents
P02400070T0000|84 91|therapy
P02399053A0153|123 125|RA
P02399053A0153|24 28|rats
P02399053A0153|67 75|room air
P02399053A0153|50 58|% oxygen
P02396415T0001|78 90|hypertension
P02396415T0001|55 63|patients
P02394718A0130|45 54|libraries
P02394718A0130|58 81|hybridization screening
P02394718A0130|191 197|enzyme
P02393895A0918|285 289|ones
P02393895A0918|124 125|p
P02393895A0918|113 114|r
P02393895A0918|98 111|insufficiency
P02393895A0918|70 75|scale
P02392511T0000|74 80|marker
P02392511T0000|37 52|blood platelets
P02392511T0000|1 33|Serotonin 5-HT2 receptor binding
P02391344T0000|24 28|cDNA
P02391344T0000|38 70|rat NADH-cytochrome b5 reductase
P02390633T0000|7 19|encephalitis
P02388685A0577|88 117|alkaline phosphatase activity
P02388685A0577|215 217|CV
P02388685A0577|246 247|%
P02388685A0577|290 295|femur
P02388685A0577|119 138|bone mineralization
P02388685A0577|39 67|oyster shell supplementation
P02388685A0577|204 213|variation
P02386485A0554|105 107|bp
P02386485A0554|40 42|bp
P02386485A0554|162 166|tail
P02386485A0554|159 160|A
P02386485A0554|64 70|region
P02384265A0947|106 125|prophylactic effect
P02384265A0947|129 140|polypectomy
P02384265A0947|36 40|risk
P02384265A0947|68 82|polyp patients
P02383693A0301|122 136|M KOH solution
P02383693A0301|21 27|column
P02383693A0301|98 110|Triton X-100
P02378615A0807|164 176|carbohydrate
P02378615A0807|132 136|site
P02378615A0807|5 21|protein sequence
P02374886A0305|89 101|productivity
P02374886A0305|41 53|outcome data
P02374886A0305|129 142|relationships
P02374886A0305|200 205|years
P02374886A0305|69 77|subjects
P02374886A0305|186 193|average
P02373686T0000|134 138|mRNA
P02373686T0000|109 119|initiation
P02373686T0000|35 65|chicken progesterone receptors
P02372496A0782|75 81|artery
P02372496A0782|123 134|compartment
P02372496A0782|93 106|drug exposure
P02372496A0782|22 25|5FU
P02372496A0782|1 18|Co-administration
P02371273A0144|46 52|region
P02371273A0144|21 25|unit
P02368931A0587|4 37|addition serum IgE concentrations
P02362161T0000|1 7|MK-927
P02361575T0000|62 71|diepoxide
P02361575T0000|8 16|toxicity
P02360336A0574|75 90|multidose vials
P02360336A0574|44 63|batch manufacturing
P02360336A0574|1 5|Drug
P02357537A0451|135 142|animals
P02357537A0451|23 32|latencies
P02357537A0451|5 12|effects
P02355920A0681|105 144|proenkephalin germ cell cap site region
P02355920A0681|3 25|consensus binding site
P02355293A0749|225 232|modulus
P02355293A0749|192 199|tissues
P02355293A0749|144 148|drip
P02355293A0749|22 33|differences
P02355293A0749|49 58|responses
P02353875A0800|41 52|eosinophils
P02353875A0800|162 167|cases
P02353875A0800|21 31|followings
P02353875A0800|136 147|eosinophils
P02351297A0000|24 41|toxicity research
P02351297A0000|128 132|cent
P02351297A0000|206 213|percent
P02351297A0000|186 191|level
P02349998A0297|1 22|Dopamine SERS spectra
P02349827A0193|25 31|system
P02348408A0126|95 102|samples
P02348408A0126|1 10|Attitudes
P02347655A0193|159 170|temperature
P02347655A0193|252 263|consumption
P02347655A0193|118 140|blood inlet conditions
P02347655A0193|225 247|blood tissue perfusion
P02347655A0193|106 116|parameters
P02347655A0193|142 157|blood flow rate
P02347102A0000|78 83|fever
P02347102A0000|54 63|condition
P02347102A0000|85 100|lymphadenopathy
P02343033A0000|43 52|placentae
P02343033A0000|84 91|infants
P02341669A0000|75 80|BAERs
P02341669A0000|165 168|MLS
P02341669A0000|112 137|pseudorandom pulse trains
P02341669A0000|64 73|responses
P02341669A0000|1 12|Experiments
P02339447A0162|183 184|A
P02339447A0162|22 29|7,7-2H2
P02339447A0162|86 93|7,7-2H2
P02339447A0162|154 159|assay
P02339447A0162|119 121|E1
P02339447A0162|110 117|estrone
P02339447A0162|203 267|gas chromatography/mass spectrometry-mass fragmentography method
P02339447A0162|34 37|OHA
P02336338A0931|64 74|expression
P02336338A0931|16 30|mean luminance
P02335713A0905|46 49|PbB
P02335713A0905|54 67|ALAD activity
P02335034A0584|97 101|LBNP
P02335034A0584|68 73|suits
P02333749A0411|47 50|SPT
P02333749A0411|24 43|regression analysis
P02333749A0411|168 174|eczema
P02333749A0411|84 104|serum IgE antibodies
P02333239T0000|20 27|problem
P02332018A0538|13 20|absence
P02332018A0538|41 47|asthma
P02332018A0538|159 167|subjects
P02332018A0538|70 76|WH air
P02330333A0325|60 62|Ga
P02330333A0325|24 35|202Tl label
P02330333A0325|76 81|brain
P02330333A0325|86 93|muscles
P02330333A0325|102 107|times
P02330041A0335|269 275|manner
P02330041A0335|92 96|hUBF
P02330041A0335|246 253|binding
P02330041A0335|48 69|transcription studies
P02330041A0335|184 188|core
P02328328A0419|75 91|tumour detection
P02328328A0419|24 59|tumour progesterone receptor status
P02328328A0419|65 71|season
P02328328A0419|117 125|survival
P02326946T0000|134 155|liver transplantation
P02326946T0000|89 98|predictor
P02326946T0000|52 60|activity
P02326946T0000|102 121|allograft viability
P02325895T0000b|121 125|skin
P02325895T0000b|129 136|raccoon
P02325895T0000b|55 63|function
P02325895T0000b|17 21|type
P02324104A1195|173 181|residues
P02324104A1195|71 94|translation stop signal
P02324104A1195|139 147|sequence
P02324104A0516|89 100|development
P02324104A0516|6 12|levels
P02324102A1157|91 95|48K5
P02324102A1157|125 132|Marynen
P02324102A1157|178 180|H.
P02324102A1157|186 191|David
P02324102A1157|45 52|domains
P02324102A1157|107 123|lung fibroblasts
P02324102A1157|77 89|proteoglycan
P02324102A1157|138 143|Zhang
P02322535A0658|90 92|kb
P02322535A0658|1 7|Intron
P02322535A0658|51 58|introns
P02320008A0651|124 130|region
P02320008A0651|1 7|TMBr-1
P02318208A0817|135 148|core sequence
P02318208A0817|66 68|bp
P02318208A0817|87 116|transcription initiation site
P02318208A0817|186 192|Ad2MLP
P02317413A0364|79 98|neutrophil elastase
P02317413A0364|218 231|heart disease
P02317413A0364|156 160|acid
P02317413A0364|1 9|Patients
P02317413A0364|137 143|isomer
P02315151T0020|8 15|systems
P02315151T0020|54 57|age
P02312470A0774|210 212|Na
P02312470A0774|28 36|activity
P02312470A0774|113 116|ELF
P02312470A0774|153 154|s
P02312470A0774|40 44|urea
P02312470A0774|201 205|urea
P02312470A0774|69 71|Na
P02310496X0000|148 171|nucleus basalis lesions
P02310496X0000|335 356|place navigation task
P02310496X0000|249 264|nucleus basalis
P02310496X0000|321 328|MS-VDBB
P02310496X0000|87 102|nucleus basalis
P02310496X0000|314 319|Broca
P02310496X0000|9 27|memory impairments
P02310496X0000|237 245|function
P02310300A0298|46 48|CT
P02308496A0000|210 216|GHM-10
P02308496A0000|81 84|TSH
P02308496A0000|86 94|cortisol
P02308496A0000|109 118|C-peptide
P02308496A0000|76 79|STH
P02308496A0000|5 10|paper
P02308496A0000|138 145|session
P02308496A0000|100 107|insulin
P02307850A0000|105 111|RNKP-1
P02307850A0000|148 164|serine proteases
P02307850A0000|76 101|cDNA rat NK cell protease
P02307848A0347|88 97|sequences
P02307848A0347|29 38|Crry gene
P02307848A0347|57 59|kb
P02307371A0263|53 86|transcription elongation blockage
P02307371A0263|262 276|Xenopus oocyte
P02307371A0263|252 257|cells
P02307371A0263|45 49|loss
P02307371A0263|286 294|vesicles
P02307371A0263|101 119|c-myc deregulation
P02306539T0000|61 74|Daphnia pulex
P02306539T0000|52 56|food
P02306539T0000|1 4|Use
P02303874A1643|135 139|mean
P02303874A1643|39 49|adjustment
P02303874A1643|116 133|micrograms/24 hrs
P02303158T0000|58 65|protein
P02303158T0000|21 31|expression
P02300577A0852|74 99|endoglycosidase digestion
P02300577A0852|5 15|beta chain
P02300577A0852|170 181|side chains
P02299543A0317|55 62|outlook
P02296509A0997|96 113|serum p24 antigen
P02294048A0881|111 130|Bacillus megaterium
P02294048A0881|81 86|hsp70
P02293019A0000|150 170|proteinases elastase
P02293019A0000|133 139|serine
P02293019A0000|36 39|mol
P02293019A0000|1 20|Antileukoproteinase
P02291628A0264|135 145|literature
P02291628A0264|12 16|part
P02291628A0264|76 83|aspects
P02291628A0264|97 101|help
P02291628A0264|50 62|applications
P02290216T0001|1 7|Effect
P02290216T0001|50 68|serum SPan-1 level
P02289102A0114|64 78|hallucinations
P02289102A0114|48 56|duration
P02284573A0943|92 112|methenamine staining
P02284573A0943|18 22|MoAB
P02284573A0943|32 41|BAL fluid
P02283873A0308|76 89|parents smoke
P02283873A0308|115 133|smoking prevention
P02283873A0308|152 160|enhancer
P02283378A0385|115 135|ultrafiltration tube
P02282815T0000|33 51|basement membranes
P02281330A0556|60 77|Horowitz quotient
P02281330A0556|46 50|FiO2
P02281330A0556|139 142|day
P02280777T0000|5 25|uteroglobin promoter
P02280777T0000|50 58|estrogen
P02278217A0372|121 129|delivery
P02278217A0372|9 15|groups
P02278217A0372|51 58|therapy
P02277319A0211|76 82|assays
P02277319A0211|101 118|product sterility
P02276891T0000|42 48|demand
P02274343A0064|105 110|corns
P02274343A0064|89 103|hallux rigidus
P02274343A0064|125 141|nail pathologies
P02274343A0064|143 152|arthritis
P02274343A0064|80 87|bunions
P02274343A0064|115 123|calluses
P02272095A0832|27 38|involvement
P02272095A0832|7 14|results
P02272095A0832|87 95|patients
P02270587A0000|59 64|order
P02270587A0000|68 77|magnitude
P02269426A0428|28 31|TAR
P02269426A0428|244 259|mRNA expression
P02269426A0428|129 132|IST
P02269426A0428|37 57|Tat trans-activation
P02269426A0428|16 26|RNA target
P02268461A0224|61 66|years
P02268461A0224|21 25|case
P02265055A0417|150 161|laudanosine
P02265055A0417|41 52|laudanosine
P02265055A0417|173 180|ng ml-1
P02265055A0417|1 22|Plasma concentrations
P02262439A0508|47 55|increase
P02262439A0508|59 76|airway resistance
P02259795A0570|13 24|consumption
P02259795A0570|41 45|skin
P02259795A0570|99 108|water PO2
P02259795A0570|139 140|%
P02258918A0242|31 37|slices
P02258918A0242|109 126|sampling fraction
P02257251T0000|43 50|animals
P02257251T0000|1 16|Pathophysiology
P02254749A0133|188 193|codon
P02254749A0133|51 63|170K protein
P02254749A0133|11 16|cDNAs
P02254749A0133|231 239|sequence
P02254749A0133|42 46|110K
P02254749A0133|71 80|sequences
P02254282T0000|40 70|Zymomonas mobilis gene cluster
P02254282T0000|22 34|organization
P02254282T0000|103 121|glucose metabolism
P02253274A0000|180 188|elements
P02253274A0000|89 93|DNAs
P02253274A0000|22 28|Varkud
P02253274A0000|154 167|mtDNA introns
P02252891T0000|41 52|interleukin
P02252891T0000|55 66|stimulation
P02250919A0404|74 86|muscle cramp
P02250919A0404|195 204|headaches
P02250919A0404|1 12|Perceptions
P02250919A0404|137 157|assessment intervals
P02248732A1113|183 185|NA
P02248732A1113|25 29|data
P02248732A1113|112 120|LC cells
P02248732A1113|81 89|increase
P02247081A0223|180 199|growth temperatures
P02247081A0223|156 162|growth
P02247081A0223|16 26|disruption
P02247069A0261|44 49|genes
P02247069A0261|5 14|TUP1 gene
P02247069A0261|33 39|screen
P02246447A0460|11 19|evidence
P02246447A0460|82 95|portion sizes
P02246447A0460|34 51|regression slopes
P02243386A0113|126 133|virions
P02243386A0113|84 89|DIssF
P02243386A0113|51 59|passages
P02242222T0000|47 51|cold
P02241742A0766|43 53|reductions
P02241742A0766|19 29|resistance
P02237431A0000|148 150|kb
P02237431A0000|162 182|C alpha gene segment
P02237431A0000|42 45|TCR
P02237431A0000|1 11|Expression
P02236064A1178|31 43|displacement
P02236064A1178|126 141|phosphorylation
P02236022A0000|105 111|manner
P02236022A0000|131 144|transcription
P02236022A0000|5 24|protooncogene c-myb
P02234731A0503|67 79|inflammation
P02234731A0503|140 149|dysplasia
P02234731A0503|18 23|class
P02233729A1065|47 53|manner
P02233729A1065|179 195|Dhfr transcripts
P02233729A1065|110 126|Dhfr transcripts
P02233729A1065|152 161|abundance
P02233680A1115|7 14|results
P02233680A1115|99 123|HaG3-A helianthinin gene
P02233680A1115|48 56|elements
P02231479A0585|149 162|task activity
P02231479A0585|52 55|son
P02231479A0585|83 96|conversations
P02229541T0000|29 35|report
P02229541T0000|54 64|literature
P02229541T0000|1 6|Giant
P02229072A1012|92 97|cells
P02229072A1012|6 19|growth arrest
P02228615A0974|150 169|metal-oxyhydroxides
P02228615A0974|79 101|desorption experiments
P02228615A0974|32 57|distribution coefficients
P02228615A0974|137 146|formation
P02225687A0546|54 63|teratogen
P02225687A0546|115 125|procedures
P02225687A0546|136 164|pregnancy management options
P02223773A0000|79 94|actin filaments
P02223773A0000|59 66|protein
P02220304A0501|45 66|medium MS risk region
P02220304A0501|94 100|Kurzke
P02220304A0501|188 194|Europe
P02220304A0501|116 124|MS areas
P02220304A0501|34 39|Alcoy
P02219751A0517|76 81|basis
P02219751A0517|85 90|speed
P02217741T0001|26 32|levels
P02217741T0001|36 51|glucocorticoids
P02217741T0001|71 76|blood
P02213566A0000|90 98|survival
P02213566A0000|63 71|capacity
P02213566A0000|39 48|captopril
P02213566A0000|16 28|coenzyme Q10
P02212540A0473|46 50|area
P02212540A0473|143 175|transmission electron microscopy
P02212540A0473|119 135|light microscopy
P02209605A0510|13 21|sequence
P02209605A0510|141 143|Da
P02209605A0510|117 128|amino acids
P02209243A0237|45 48|SCr
P02209243A0237|13 20|protein
P02209243A0237|37 40|BUN
P02208762A0228|162 172|appendages
P02208762A0228|5 16|grandfather
P02208762A0228|48 56|microtia
P02208762A0228|68 75|atresia
P02206789A0002|143 154|environment
P02206789A0002|18 24|safety
P02204625A1130|30 35|genes
P02204625A1130|89 96|insulin
P02204625A1130|42 49|members
P02204625A1130|21 26|group
P02204621T0000|122 149|tRNA nucleotidyltransferase
P02204621T0000|93 100|cloning
P02204621T0000|38 44|mutant
P02203672A1542|25 39|cytocentrifuge
P02201905A1004|61 73|RAP1 protein
P02201905A1004|147 162|gene expression
P02201905A1004|81 90|sequences
P02201770A0188|13 24|flea larvae
P02201770A0188|112 116|form
P02201770A0188|68 82|Anomiopsyllini
P02200315A0278|9 30|IgM antibody activity
P02200315A0278|64 72|dilution
P02200315A0278|85 91|plates
P02199311A0620|10 32|transcription extracts
P02199311A0620|156 163|variety
P02199311A0620|136 146|RET1 cells
P02198259A0685|176 184|activity
P02198259A0685|67 73|codons
P02198259A0685|115 128|reading frame
P02198259A0685|51 55|repA
P02196565A0606|242 255|GRFI/RAP1/TUF
P02196565A0606|147 156|activator
P02196565A0606|281 295|gal11 mutation
P02196565A0606|42 82|repressor/activator site binding protein
P02196565A0606|36 40|GRFI
P02196565A0606|86 90|RAP1
P02196311A1034|58 65|regimen
P02196311A1034|81 99|antitumor immunity
P02195715T0000|10 16|stroke
P02195025T0000|15 25|yeast LEU2
P02194273A0913|10 31|hyperimmune globulins
P02194273A0913|80 93|Streptococcus
P02190134A0572|164 173|membranes
P02190134A0572|225 236|hemorrhages
P02190134A0572|197 210|complications
P02190134A0572|80 89|exception
P02190134A0572|35 46|progression
P02188168A0000|28 34|levels
P02188168A0000|191 206|lymphadenopathy
P02188168A0000|154 162|carriers
P02188168A0000|66 78|drug addicts
P02188168A0000|279 288|community
P02188168A0000|238 246|patients
P02187871T0000|56 98|protein synthesis initiation factor eIF-4D
P02185250A0726|88 106|reticulum membrane
P02185250A0726|1 12|Truncations
P02183467A0668|180 192|lentiviruses
P02183467A0668|265 270|exons
P02183467A0668|157 160|tat
P02183467A0668|50 53|BIV
P02183467A0668|224 228|ORFs
P02183467A0668|78 86|location
P02183467A0668|281 286|genes
P02183467A0668|102 112|similarity
P02182323A0121|43 47|tRNA
P02182323A0121|53 56|UAC
P02182323A0121|18 29|transcripts
P02182323A0121|103 120|growth conditions
P02181760A0311|88 96|diastole
P02181760A0311|124 133|direction
P02181760A0311|16 24|velocity
P02179815A0582|62 80|immunofluorescence
P02179815A0582|213 221|p68c-rel
P02179815A0582|8 16|p59v-rel
P02179815A0582|178 183|cells
P02179815A0582|159 168|cytoplasm
P02179815A0582|322 330|p59v-rel
P02179052A1044|31 48|sequence families
P02179052A1044|73 79|system
P02179052A1044|19 20|Y
P02176232T0001|52 63|lung cancer
P02176232T0001|69 74|stage
P02176152A0896|108 124|AP1 binding site
P02176152A0896|52 60|activity
P02176152A0896|19 21|RA
P02175908A0805|61 76|Ulysses element
P02175908A0805|13 22|mutations
P02175908A0805|49 53|copy
P02174974A0000|134 151|xylR gene product
P02174974A0000|159 167|presence
P02174974A0000|80 91|TOL plasmid
P02174974A0000|171 179|m-xylene
P02174427A1574|110 111|%
P02174427A1574|65 79|carbon sources
P02173405A0270|59 65|period
P02172672T0001|11 22|Goodpasture
P02172672T0001|3 7|case
P02169887A0360|124 129|mRNAs
P02169887A0360|101 109|EMCV-RNA
P02167784A0109|62 63|%
P02167784A0109|37 40|air
P02167784A0109|158 173|CO2 measurement
P02167784A0109|19 27|subjects
P02167321T0000|44 51|element
P02167321T0000|3 12|DNA motif
P02167321T0000|100 104|site
P02167321T0000|118 165|tissue-type plasminogen activator gene promoter
P02167321T0000|239 243|cAMP
P02166416A0419|94 100|origin
P02166416A0419|5 14|diagnosis
P02165589A0888|57 74|c-jun oncoprotein
P02165589A0888|77 91|leucine zipper
P02165589A0888|140 163|heterodimerization site
P02165589A0888|184 200|fos oncoproteins
P02165181A0299|45 50|basis
P02165181A0299|6 12|cohort
P02164604A1574|30 41|E2 proteins
P02164604A1574|14 22|analysis
P02164604A1574|91 104|BPV-1 mutants
P02164604A1574|173 186|E2 expression
P02164588A0266|57 61|role
P02164588A0266|188 203|HN glycoprotein
P02164588A0266|101 107|domain
P02164588A0266|171 180|transport
P02164585A0416|57 64|regions
P02164585A0416|115 121|region
P02163382A0169|72 79|pJHCV32
P02163382A0169|128 136|Tn3HoHo1
P02163382A0169|21 34|O7-LPS region
P02163382A0169|205 209|lacZ
P02162835A0989|72 84|architecture
P02162835A0989|23 44|sequence similarities
P02162835A0989|153 160|enzymes
P02162754A0339|65 98|3T3-L1 adipocyte insulin receptor
P02162754A0339|19 24|sites
P02162103A0000|270 278|proteins
P02162103A0000|59 63|mRNA
P02162103A0000|294 305|amino acids
P02162103A0000|184 190|length
P02162103A0000|84 85|P
P02162103A0000|132 142|cDNA clone
P02162103A0000|201 205|poly
P02162103A0000|169 180|nucleotides
P02160955A0899|90 99|distances
P02160955A0899|57 63|region
P02160955A0899|34 40|AATAAA
P02160502A0471|69 88|recombination point
P02159470A1432|243 258|phosphorylation
P02159470A1432|77 89|Mt sequences
P02159470A1432|25 40|protein factors
P02159470A1432|48 53|sites
P02159470A1432|136 146|regulation
P02158099A0487|61 64|CCL
P02158099A0487|132 142|expression
P02158099A0487|70 77|pM1 DNA
P02157764A1115|90 97|portion
P02157764A1115|3 19|rabbit antiserum
P02157067A0610|10 18|Virology
P02155017A1106|60 68|bleeding
P02155017A1106|47 56|frequency
P02155017A1106|26 37|LMW heparin
P02155017A1106|197 206|incidence
P02155017A1106|222 235|complications
P02154686A0185|58 66|enhancer
P02154686A0185|173 201|polyomavirus enhancer region
P02154686A0185|114 142|beta-galactosidase synthesis
P02154686A0185|222 228|levels
P02154599T0000|134 138|AP-1
P02154599T0000|176 192|enhancer regions
P02154599T0000|143 152|ZRE sites
P02154599T0000|55 76|cycle gene expression
P02154474A1504|47 66|cAMP responsiveness
P02154474A1504|92 100|P-450scc
P02153977A0364|40 45|hours
P02153977A0364|7 12|genes
P02153977A0364|53 63|initiation
P02153977A0364|86 91|mRNAs
P02153243A0965|57 67|int-2 gene
P02153243A0965|93 124|fibroblast growth factor family
P02153243A0965|178 184|tumors
P02151229A0000|181 198|diabetes mellitus
P02151229A0000|146 154|patients
P02151229A0000|294 302|subjects
P02151229A0000|49 81|N-isopropyl-123I-iodoamphetamine
P02151229A0000|119 129|tomography
P02151229A0000|131 133|CT
P02151229A0000|309 314|years
P02151229A0000|1 9|Regional
P02149570T0000|11 19|necrosis
P02149487A0348|135 144|reduction
P02149487A0348|62 75|% suppression
P02149487A0348|148 160|testosterone
P02149487A0348|7 42|days dexamethasone suppression test
P02148508A1478|66 74|patients
P02148508A1478|5 12|results
P02148291A0173|181 190|screening
P02148291A0173|29 49|HSE oligonucleotides
P02148291A0173|129 166|tomato lambda gt11 expression library
P02147422A0000|60 80|U1-70K snRNP protein
P02146495A0706|167 170|CRE
P02146495A0706|67 73|region
P02146495A0706|137 143|dimers
P02145268A1454|44 59|EDS-IV collagen
P02145268A1454|94 115|collagenase digestion
P02145195A0253|41 50|structure
P02145195A0253|8 17|stem-loop
P02145195A0253|119 130|Sm proteins
P02144558A1022|3 19|needs assessment
P02143961A0400|6 21|antidepressants
P02143961A0400|65 77|pretreatment
P02143186A1306|76 79|RNA
P02143186A1306|39 48|AHA2 mRNA
P02143186A1306|117 123|levels
P02143023A0729|164 180|repeat sequences
P02143023A0729|125 141|octamer elements
P02143023A0729|100 113|transcription
P02142955A0248|90 95|basis
P02142955A0248|25 32|infants
P02142955A0248|39 45|adults
P02142955A0248|154 163|exemplars
P02142486A0367|56 61|fever
P02142486A0367|127 132|cases
P02142486A0367|1 12|Teicoplanin
P02141425A0175|194 199|level
P02141425A0175|73 78|stool
P02141425A0175|53 61|patients
P02141425A0175|168 173|floor
P02141425A0175|207 212|floor
P02139473A1603|143 149|region
P02139473A1603|99 117|Fur concentrations
P02138915A1060|121 125|gene
P02138915A1060|59 67|sequence
P02138915A1060|112 113|%
P02138915A1060|87 89|kb
P02138915A1060|153 158|WORDS
P02137704A0000|240 254|blood pressure
P02137704A0000|600 610|mass index
P02137704A0000|488 496|diameter
P02137704A0000|533 547|wall thickness
P02137704A0000|224 231|morning
P02137704A0000|315 327|office visit
P02137704A0000|508 522|wall thickness
P02137704A0000|92 103|association
P02137704A0000|80 88|strength
P02137704A0000|152 153|h
P02137704A0000|558 572|wall thickness
P02137704A0000|474 477|end
P02137704A0000|201 202|h
P02135536A0621|28 42|brush abrasion
P02135536A0621|106 109|MPa
P02135536A0621|229 239|degrees C.
P02135536A0621|143 159|water absorption
P02135536A0621|19 24|ratio
P02133731A1572|30 33|CBF
P02133731A1572|130 131|p
P02133731A1572|43 47|%WTh
P02133731A1572|110 124|control levels
P02133731A1572|20 21|%
P02133731A1572|49 54|1/TPC
P02131902A0000|164 168|S-LV
P02131902A0000|95 105|transducer
P02131902A0000|136 140|view
P02131652A0883|76 82|ng.l-1
P02131652A0883|127 135|AUC0-120
P02131652A0883|16 43|serum gastrin concentration
P02131652A0883|220 227|VTP-Cas
P02126504A0602|56 65|mechanism
P02125153A0410|90 91|%
P02125153A0410|74 75|%
P02125153A0410|110 111|%
P02125153A0410|159 171|streptomycin
P02125153A0410|98 100|R5
P02125153A0410|136 145|organisms
P02124710A1624|90 100|type alpha
P02124710A1624|6 11|model
P02124710A1624|103 120|collagen promoter
P02124710A1624|171 175|VDRE
P02124433A0235|149 156|group B
P02124433A0235|94 101|Group A
P02124433A0235|22 27|cases
P02124433A0235|113 116|MMC
P02124433A0235|223 230|group C
P02124433A0235|195 213|immunochemotherapy
P02124433A0235|8 16|patients
P02124433A0235|67 77|background
P02124433A0235|174 178|5-FU
P02124433A0235|103 110|surgery
P02123875A0223|330 336|region
P02123875A0223|267 271|core
P02123875A0223|24 32|features
P02123875A0223|398 407|delta pro
P02123875A0223|167 180|translocation
P02123875A0223|36 44|residues
P02123875A0223|200 224|amino acid substitutions
P02123875A0223|408 415|apoA-II
P02123467A0811|14 24|expression
P02123467A0811|210 213|Sp1
P02123467A0811|177 185|presence
P02123467A0811|143 148|sites
P02123467A0811|32 40|promoter
P02123300T0000|46 52|factor
P02123300T0000|54 60|factor
P02123293A0227|12 14|S.
P02122454A1042|164 172|molecule
P02122454A1042|27 33|Phe-62
P02122454A1042|66 77|determinant
P02122454A1042|100 105|chain
P02120833A0000|131 136|units
P02120833A0000|114 118|case
P02120833A0000|21 26|cases
P02119946T0000|10 19|dysphagia
P02119946T0000|50 62|introduction
P02119530T0000|55 65|activation
P02119530T0000|69 81|fibrinolysis
P02118525A0737|46 58|CCK promoter
P02118525A0737|191 199|position
P02118525A0737|86 94|enhancer
P02118525A0737|139 185|herpes simplex virus thymidine kinase promoter
P02117799T0000b|29 40|prophylaxis
P02117799T0000b|94 116|kidney transplantation
P02117799T0000b|58 67|induction
P02116537A1237|40 54|concentrations
P02116537A1237|64 67|MIC
P02115889A0436|56 60|gene
P02115889A0436|37 46|structure
P02115889A0436|100 109|kilobases
P02115122A0562|95 100|c-Fos
P02115122A0562|129 140|truncations
P02115122A0562|80 91|amino acids
P02115118A0565|45 57|smg p25A GDI
P02115118A0565|109 128|gel electrophoresis
P02115118A0565|71 85|sodium dodecyl
P02115115A1053|79 87|CAR1 URS
P02115115A1053|55 60|sites
P02113901A0000|105 112|tension
P02113901A0000|10 13|CO2
P02113901A0000|114 118|PaO2
P02113901A0000|35 39|hypo
P02113455A0207|112 128|threshold levels
P02113455A0207|21 32|variability
P02113174A0064|33 45|zinc fingers
P02111015A0574|135 155|IFN response factors
P02111015A0574|97 116|sequence similarity
P02111015A0574|157 162|IRF-1
P02110145T0000|150 180|Bacillus cereus beta-lactamase
P02110145T0000|78 89|Bacteroides
P02110145T0000|67 71|CfiA
P02110145T0000|141 145|CfiA
P02110145T0000|16 20|gene
P02107548A0727|61 65|poly
P02107548A0727|125 132|psi ARF
P02107548A0727|66 67|A
P02107548A0727|157 160|ARF
P02106287A0478|60 66|0.5-in
P02106287A0478|1 14|Spore inocula
P02103403A0149|36 50|alcohol intake
P02103403A0149|4 11|patient
P02103403A0149|87 92|drugs
P02102831A1282|29 48|soybean actin genes
P02102831A1282|111 120|stretches
P02102831A1282|140 143|DNA
P02099622A1046|29 37|antisera
P02099622A1046|182 191|structure
P02099622A1046|93 101|staining
P02099622A1046|203 220|Campylobacter spp
P02094257T0000|12 17|value
P02094257T0000|21 49|adenosine deaminase activity
P02093888A0293|1 6|ARPIA
P02093033T0001|44 57|plutonium-239
P02093033T0001|125 129|rats
P02093033T0001|83 101|tributyl phosphate
P02093033T0001|1 7|Effect
P02091890A0614|74 81|profile
P02091890A0614|209 217|sedation
P02091890A0614|9 14|model
P02091890A0614|16 27|eltoprazine
P02088781A0653|47 51|base
P02088781A0653|126 134|accuracy
P02088781A0653|76 89|density units
P02088781A0653|5 12|results
P02088781A0653|38 43|level
P02083253A1512|165 176|TCF-1 alpha
P02083253A1512|198 218|transcription factor
P02083253A1512|52 79|TCR alpha enhancer activity
P02083253A1512|137 147|HeLa cells
P02083199A1175|42 67|autophosphorylation sites
P02083199A1175|1 23|Phosphopeptide mapping
P02080902A0183|65 83|avoidance response
P02080902A0183|4 13|adulthood
P02078570A0287|26 36|expression
P02077560T0000|29 38|profiling
P02077560T0000|5 9|role
P02076620T0000|66 73|disease
P02076620T0000|1 12|Gemfibrozil
P02075876T0001|82 89|pathway
P02075876T0001|33 41|response
P02075876T0001|51 59|relation
P02073222A0269|46 59|moclobemide n
P02073222A0269|138 148|conditions
P02072238T0000|24 29|child
P02069873X0000|14 24|activation
P02069873X0000|66 71|locus
P02069873X0000|32 49|vav protooncogene
P02069873X0000|1 10|Mechanism
P02068085A1273|79 85|region
P02068085A1273|93 96|Mlu
P02068085A1273|17 25|evidence
P02065022A0747|43 49|region
P02065022A0747|96 99|dbl
P02065022A0747|71 92|transforming activity
P02062933A0738|88 105|flutamide females
P02062933A0738|42 48|female
P02062933A0738|71 75|male
P02062933A0738|118 126|controls
P02061333A1359|218 232|ACV tripeptide
P02061333A1359|65 100|phosphopantetheine-attachment sites
P02061333A1359|116 133|thioesterase site
P02061333A1359|171 188|reaction sequence
P02061282A0447|107 109|bp
P02061282A0447|176 203|recombination junction site
P02061282A0447|144 154|pilin gene
P02061282A0447|21 34|pMxL1 plasmid
P02056553T0000|13 18|shock
P02056553T0000|33 46|translocation
P02054754A0919|78 89|Sandostatin
P02054754A0919|99 107|patients
P02052592A0000|301 328|tumor necrosis factor alpha
P02052592A0000|330 339|TNF-alpha
P02052592A0000|263 272|secretion
P02052592A0000|291 295|IL-1
P02052592A0000|184 191|effects
P02052592A0000|49 57|products
P02052592A0000|195 207|oophorectomy
P02052592A0000|468 473|blood
P02052592A0000|381 390|secretion
P02052592A0000|444 450|GM-CSF
P02046202A0625|5 14|remainder
P02046202A0625|32 47|IgA nephropathy
P02045524A0000|73 77|Food
P02045524A0000|202 214|end-of-phase
P02045524A0000|115 124|mid-1970s
P02045524A0000|19 31|availability
P02045524A0000|103 106|FDA
P02044975A0380|192 196|flow
P02044975A0380|109 121|instillation
P02044975A0380|145 148|min
P02044975A0380|64 65|P
P02044975A0380|101 102|h
P02044975A0380|184 185|%
P02044785A0000|79 83|cyst
P02044785A0000|21 35|adenocarcinoma
P02038784A0317|7 15|patients
P02038784A0317|35 42|failure
P02038293A0919|13 27|inlet type VSD
P02038293A0919|70 78|features
P02038293A0919|152 163|VSD closure
P02035805T0000|50 61|obstruction
P02034669A0293|69 79|expression
P02034669A0293|137 143|system
P02034655A1224|60 79|transfection assays
P02034655A1224|5 10|alpha
P02033038A0309|29 44|E3 polypeptides
P02033038A0309|156 164|fraction
P02033038A0309|51 56|bands
P02030910A0000|39 48|ETS1 gene
P02028125A0101|105 120|tumour response
P02028125A0101|198 207|functions
P02028125A0101|59 72|AIDS patients
P02028125A0101|81 92|probability
P02026491A0399|74 81|seizure
P02026491A0399|36 43|effects
P02026491A0399|49 52|NMF
P02026147A0000|120 130|properties
P02026147A0000|63 73|CaM kinase
P02026147A0000|20 30|calmodulin
P02026147A0000|84 89|yeast
P02025515A0979|42 51|doses/day
P02025515A0979|4 8|view
P02024791A0582|124 136|L atropine/0
P02024791A0582|78 83|study
P02024791A0582|140 156|L metaproterenol
P02024791A0582|100 117|FEV1 measurements
P02024488A0506|41 49|nef gene
P02024488A0506|111 122|coselection
P02024488A0506|64 76|CMV promoter
P02024488A0506|84 93|HIV-1 LTR
P02023904A0120|55 78|translation start sites
P02023904A0120|32 42|AUG codons
P02023097A0000|95 104|regulator
P02023097A0000|42 47|HIV-1
P02023097A0000|49 60|Rev protein
P02022188A1463|149 164|gene expression
P02022188A1463|99 114|order structure
P02021630A1104|90 93|DNA
P02021630A1104|135 141|groove
P02021630A1104|145 148|DNA
P02021630A1104|7 18|differences
P02021630A1104|154 165|alterations
P02020082A0356|30 42|gas exchange
P02020082A0356|225 235|difference
P02020082A0356|244 258|plasma colloid
P02020082A0356|267 275|pressure
P02020082A0356|5 16|disturbance
P02020082A0356|117 128|dysfunction
P02017414A0307|8 11|POI
P02017414A0307|16 25|asymptote
P02017414A0307|69 76|Line F.
P02017159A0646|1 7|Grasso
P02016053A0752|40 52|E74A protein
P02016053A0752|1 32|Amino acid sequence comparisons
P02014928T0000|14 20|asthma
P02014928T0000|83 103|serum albumin powder
P02012097T0000|12 24|fluctuations
P02012097T0000|52 81|Plasmodium falciparum malaria
P02010912A0366|148 153|pulAp
P02010912A0366|9 14|paper
P02010912A0366|158 173|pulCp promoters
P02007045A0092|22 26|case
P02007045A0092|65 75|brain cyst
P02007045A0092|119 127|distress
P02005547A0121|107 118|development
P02005547A0121|266 273|illness
P02005547A0121|20 33|understanding
P02005547A0121|187 199|practitioner
P02004521A0266|79 86|disease
P02004521A0266|1 9|Patients
P02002051T0000|59 66|subunit
P02002051T0000|85 99|protein kinase
P02001033A1907|47 57|desflurane
P02001033A1907|243 251|decrease
P02001033A1907|177 187|desflurane
P02001033A1907|127 134|absence
P02001033A1907|216 224|activity
P02001033A1907|102 109|effects
P01999999T0001|71 80|treatment
P01999035A0383|90 95|years
P01999035A0383|62 67|years
P01999035A0383|11 20|follow-up
P01999035A0383|71 81|Caerphilly
P01996312A0454|110 121|Dd kinase-2
P01996312A0454|1 4|DNA
P01993656A1860|112 120|proteins
P01992953T0000|38 46|practice
P01992742A0000|89 95|period
P01992742A0000|32 40|patients
P01991521A0481|28 38|conclusion
P01991521A0481|126 133|muscles
P01991521A0481|5 12|results
P01990254A0791|91 102|cell origin
P01990254A0791|1 18|Immunophenotyping
P01989561A0100|72 77|aorta
P01989561A0100|95 112|perfusion cannula
P01989561A0100|158 163|heart
P01989561A0100|205 212|venting
P01986360A0000|146 149|32P
P01986360A0000|93 134|mouse fibroblast lambda gt11 cDNA library
P01986360A0000|23 66|interferon response element binding factors
P01986360A0000|169 175|trimer
P01986241A0117|67 72|sites
P01986241A0117|1 10|Induction
P01985924A0554|30 37|complex
P01985924A0554|72 80|subunits
P01985924A0554|130 144|chromatography
P01985924A0554|96 99|pol
P01985924A0554|103 113|holoenzyme
P01985924A0554|220 223|pol
P01985920A0156|94 119|rat SCP2 protein sequence
P01985920A0156|24 46|rat liver cDNA library
P01985920A0156|141 156|pair cDNA clone
P01984665T0000|13 22|secretion
P01984665T0000|130 135|cells
P01984665T0000|48 55|carboxy
P01982997A1104|75 86|MDI regimen
P01982997A1104|150 160|c-Jun mRNA
P01982997A1104|101 103|RA
P01982997A1104|1 12|Examination
P01982997A1104|187 197|expression
P01982061T0000|63 79|hamster CAD gene
P01978857A0504|62 77|CD4 cell counts
P01978857A0504|18 36|laboratory testing
P01977856A1036|91 99|location
P01977856A1036|26 31|BSPMs
P01977856A1036|6 11|study
P01977856A1036|64 67|AMI
P01977856A1036|50 60|assessment
P01976638A1135|48 54|region
P01975157A0836|13 27|transformation
P01974550A0362|74 93|ipratropium bromide
P01974550A0362|133 141|mg/kg iv
P01974550A0362|99 114|microgram/kg iv
P01974550A0362|117 129|indomethacin
P01972379T0042|60 67|hamster
P01972379T0042|1 13|DNA sequence
P01972379T0042|84 95|protein CAD
P01970984A0668|11 20|treatment
P01970984A0668|22 44|serum estradiol levels
P01970984A0668|87 95|group C.
P01970801A0925|61 65|OSBP
P01970801A0925|124 134|chromosome
P01970801A0925|99 104|group
P01970801A0925|175 185|chromosome
P01970801A0925|117 120|arm
P01968224A0119|219 222|rat
P01968224A0119|285 292|leucine
P01968224A0119|109 119|base pairs
P01968224A0119|311 317|region
P01968224A0119|96 102|intron
P01968224A0119|138 139|%
P01968061A0371|1 4|Sci
P01967130A0645|123 143|DNA binding proteins
P01963858T0001|11 21|activation
P01963858T0001|97 110|microdialysis
P01963858T0001|68 83|neuroglycopenia
P01963419A0501|125 128|16O
P01963419A0501|58 69|MeV protons
P01963419A0501|188 200|18F reaction
P01963419A0501|155 158|18F
P01963419A0501|132 137|alpha
P01963419A0501|10 31|silver liquid chamber
P01963419A0501|138 150|13N reaction
P01961747A0000|114 129|substrate genes
P01961747A0000|103 109|enzyme
P01960974A0000|52 57|cases
P01960974A0000|16 24|chemical
P01958368A0556|89 95|stages
P01958368A0556|1 10|Evolution
P01956285A0000|128 159|choline-glycine betaine pathway
P01956285A0000|66 75|bet genes
P01954355A0997|45 49|IL-1
P01954355A0997|146 154|episodes
P01954355A0997|54 64|TNF levels
P01954355A0997|32 40|leukemia
P01948783A0000|74 80|period
P01948783A0000|101 109|patients
P01947449A0191|15 35|diffusion limitation
P01947449A0191|76 97|uptake/O2 requirement
P01947449A0191|67 72|ratio
P01947449A0191|5 11|effect
P01947449A0191|101 109|fraction
P01947449A0191|171 182|requirement
P01943184A1050|105 112|% cells
P01943184A1050|13 18|cells
P01943184A1050|122 123|p
P01939906A0233|225 244|optimization method
P01939906A0233|130 141|environment
P01939906A0233|24 27|MFP
P01939906A0233|110 122|search space
P01939906A0233|294 301|minimum
P01939906A0233|184 197|wave equation
P01939878A0765|127 135|patients
P01939878A0765|18 32|solidification
P01939199A0588|122 136|TFIID fraction
P01939199A0588|177 182|level
P01939199A0588|19 24|TFIID
P01939199A0588|186 199|transcription
P01938178T0000|1 13|Applications
P01937790A0292|56 64|children
P01937790A0292|69 75|adults
P01936348A0155|72 76|resp
P01936348A0155|5 17|examinations
P01934378T0000|69 82|heart failure
P01933614A0406|5 11|effect
P01933614A0406|48 53|women
P01932650A0435|15 23|patients
P01932650A0435|147 151|MBRS
P01932650A0435|4 9|group
P01932650A0435|87 92|hours
P01930660T0000|31 36|IGF-1
P01928923A0000|211 217|horses
P01928923A0000|24 45|yeast cell derivative
P01928923A0000|141 150|treatment
P01928923A0000|103 119|wound medicament
P01927421A0181|61 70|nystagmus
P01927421A0181|18 30|examinations
P01925092A0000|73 79|retina
P01925092A0000|83 87|part
P01925092A0000|116 124|meshwork
P01924315A0158|40 53|copper levels
P01924315A0158|82 87|level
P01923803A0609|46 69|SsoL12 protein sequence
P01923803A0609|19 29|isoleucine
P01923628T0001|14 22|analysis
P01923628T0001|89 94|cases
P01923628T0001|26 29|DNA
P01922739A0336|389 394|level
P01922739A0336|182 191|operation
P01922739A0336|92 102|directions
P01922739A0336|23 27|ROSP
P01922739A0336|326 336|dura mater
P01922739A0336|131 140|amplitude
P01922739A0336|313 318|level
P01922739A0336|351 357|values
P01922739A0336|232 238|values
P01922082A0149|74 79|mRNAs
P01922082A0149|116 122|region
P01922082A0149|1 11|Expression
P01918070A0281|194 201|potency
P01918070A0281|149 157|rGH T3RE
P01918070A0281|229 240|T3R binding
P01918070A0281|218 225|changes
P01918010A0000|88 95|pattern
P01918010A0000|99 109|regulation
P01918010A0000|33 39|enzyme
P01918010A0000|50 72|lipoprotein metabolism
P01917943A0621b|77 86|TATAA box
P01917943A0621b|178 188|expression
P01917943A0621b|113 115|bp
P01917943A0621b|101 111|base pairs
P01917943A0621b|1 18|Sequence analysis
P01916632A0431|10 20|production
P01916168A0969|88 100|ulcer margin
P01916168A0969|128 134|mucosa
P01916168A0969|54 71|ISO2 measurements
P01916168A0969|4 9|study
P01913955A0177|268 279|muscle cell
P01913955A0177|299 303|wall
P01913955A0177|417 425|collagen
P01913955A0177|83 89|number
P01913955A0177|359 371|muscle cells
P01913955A0177|16 23|changes
P01913955A0177|160 169|pericytes
P01913955A0177|383 395|accumulation
P01913955A0177|337 348|hyperplasia
P01913955A0177|442 446|type
P01910505A0000|60 76|cyclophosphamide
P01910505A0000|99 103|mice
P01910505A0000|85 95|leukopenia
P01909621A0119|58 66|lithemia
P01907941A0275|15 29|I kappa B beta
P01907941A0275|97 109|kappa B site
P01907941A0275|86 89|Rel
P01906692A0321|54 61|aspirin
P01906692A0321|16 24|Patients
P01906166A0119|30 38|necrosis
P01906166A0119|91 95|skin
P01906166A0119|126 145|drug administration
P01905517A1076|47 55|features
P01905517A1076|65 84|sequence data bases
P01904546A0671|31 40|AAR1 gene
P01904546A0671|92 101|phenotype
P01904546A0671|54 67|a/alpha cells
P01904154A0164|134 160|gene rearrangement process
P01904154A0164|41 57|characterization
P01904154A0164|82 89|Ig loci
P01904154A0164|16 20|case
P01903841A0125|12 27|lysine residues
P01903841A0125|92 104|modification
P01901950T0000|75 81|intron
P01901950T0000|37 57|transcription arrest
P01901859A0000|151 158|species
P01901859A0000|130 137|variety
P01901859A0000|9 17|Gal beta
P01901859A0000|23 36|4GlcNAc alpha
P01901859A0000|190 193|man
P01901859A0000|205 222|Old World monkeys
P01901443A0297|210 218|O stains
P01901443A0297|176 185|steatosis
P01901443A0297|34 55|maintenance valproate
P01900194T0000|36 61|NADH-ubiquinone reductase
P01899409T0000a|106 134|tissue plasminogen activator
P01899409T0000a|27 36|ischaemia
P01899409T0000a|155 164|occlusion
P01899209A0883|89 98|decreases
P01899209A0883|18 32|perfusate PCO2
P01899209A0883|1 10|Increases
P01899209A0883|136 154|oxygen consumption
P01898164A0839|159 171|arch indices
P01898164A0839|87 94|infants
P01898164A0839|136 157|aorta diameter ratios
P01897515A0348|40 47|disease
P01897515A0348|111 121|mechanisms
P01897515A0348|1 26|Bone marrow abnormalities
P01895555T0001|32 40|function
P01895555T0001|84 95|Tc-99m-MIBI
P01895384A0746|78 88|expression
P01895384A0746|102 110|promoter
P01895358A0000|106 111|limit
P01895358A0000|130 148|training programme
P01895358A0000|113 120|changes
P01895358A0000|169 183|energy balance
P01895358A0000|51 62|performance
P01893927A0704|109 112|NNA
P01893927A0704|38 60|phenylephrine infusion
P01893927A0704|101 104|NMA
P01892680A0907|90 95|arm B
P01892680A0907|53 61|sedation
P01892680A0907|34 42|regimens
P01890362A0305|123 128|years
P01890362A0305|48 65|eye complications
P01888896A0505|62 70|position
P01888896A0505|3 18|deletion series
P01888896A0505|169 176|tobacco
P01886368A0000|130 138|normoxia
P01886368A0000|143 152|hyperoxia
P01886368A0000|1 17|PO2 measurements
P01885915A0000|91 103|endocarditis
P01885915A0000|16 26|infections
P01885613A1298|74 84|regulation
P01885613A1298|92 101|pro alpha
P01885613A1298|36 45|sequences
P01884998A1135|110 114|site
P01884998A1135|5 12|members
P01883992A0922|28 34|beta-1
P01883992A0922|95 105|expression
P01883992A0922|142 157|maize endosperm
P01882240A0526|89 97|research
P01882240A0526|41 47|issues
P01882240A0526|22 31|attention
P01882240A0526|101 105|AIDS
P01881595A0476|25 31|SNO NS
P01881595A0476|127 135|activity
P01881595A0476|142 154|NnS neurones
P01881595A0476|36 48|NnS neurones
P01881595A0476|1 9|Formalin
P01878489A0959|15 23|response
P01878489A0959|27 38|neutrophils
P01878489A0959|95 117|NADPH oxidase activity
P01878489A0959|43 52|monocytes
P01875922A0770|39 47|segments
P01875922A0770|1 18|Mutation analysis
P01874195A0139|94 103|receptors
P01874195A0139|191 215|tyrosine kinase activity
P01874195A0139|71 90|sequence similarity
P01872856A0277|27 29|BA
P01872856A0277|188 195|animals
P01872856A0277|47 48|%
P01872856A0277|111 124|radioactivity
P01872856A0277|173 174|%
P01872856A0277|38 43|urine
P01872856A0277|1 9|Recovery
P01871135A0295|28 41|reading frame
P01871135A0295|124 127|kDa
P01871135A0295|113 117|mass
P01871135A0295|70 77|protein
P01871135A0295|85 96|amino acids
P01870500A0276|243 262|reciprocity theorem
P01870500A0276|40 62|target volume elements
P01870500A0276|20 25|pairs
P01870500A0276|222 232|host organ
P01870500A0276|103 108|tumor
P01870194A0302|38 43|HIV-1
P01869968A0000|72 77|HMPAO
P01869968A0000|93 101|subjects
P01869565A1254|32 45|transcription
P01869565A1254|1 4|USF
P01869565A1254|118 121|MLP
P01865010A0000|286 289|rat
P01865010A0000|246 254|auditory
P01865010A0000|172 178|manner
P01865010A0000|272 278|cortex
P01865010A0000|1 9|Patterns
P01864821A0000|134 141|hypoxia
P01864821A0000|29 41|cell disease
P01864821A0000|82 94|globin chain
P01864821A0000|174 185|blood cells
P01864821A0000|190 201|obstruction
P01863887A0174|164 178|growth hormone
P01863887A0174|89 107|tissue plasminogen
P01863887A0174|130 138|hormones
P01863887A0174|197 213|clotting factors
P01863887A0174|64 79|pharmaceuticals
P01863887A0174|1 18|Space limitations
P01862455T0000|26 36|management
P01861188A0000|90 95|plate
P01861188A0000|104 108|bone
P01861188A0000|133 144|screw heads
P01861188A0000|266 271|bones
P01861188A0000|292 303|osteotomies
P01861188A0000|153 158|plate
P01860846A0663|45 72|tumor necrosis factor-alpha
P01860846A0663|11 15|cDNA
P01857143A0351|31 35|male
P01857143A0351|83 96|myelofibrosis
P01857143A0351|70 79|diagnosis
P01855255T0000|11 21|initiation
P01855255T0000|36 41|yeast
P01853796T0000|26 43|glucose tolerance
P01853796T0000|58 62|role
P01853796T0000|49 52|age
P01852438A0928|5 14|MVV-value
P01852438A0928|38 43|level
P01851862A0273|58 63|SFV-1
P01851862A0273|34 42|env gene
P01851527T0000|30 34|gene
P01851527T0000|130 139|sequences
P01851527T0000|5 22|promoter activity
P01850893A0286|57 64|rabbits
P01850893A0286|84 89|farms
P01850105A1093|79 94|differentiation
P01850105A1093|112 114|Id
P01850105A1093|140 162|muscle differentiation
P01849734A1063|45 47|kb
P01849734A1063|11 31|PR55 beta transcript
P01849734A1063|127 132|level
P01849734A1063|140 144|mRNA
P01849509T0000|120 131|transposase
P01849509T0000|192 197|IS256
P01849509T0000|202 232|Thiobacillus ferrooxidans IST2
P01849509T0000|20 39|nucleotide sequence
P01848300A0910|12 20|evidence
P01848300A0910|39 43|cstA
P01847464A0856|240 245|c-myc
P01847464A0856|77 82|sites
P01847464A0856|196 207|amino acids
P01847464A0856|175 194|EBNA-1 construction
P01847464A0856|254 273|localization signal
P01846491A0459|285 293|ancestor
P01846491A0459|40 48|VV genes
P01846491A0459|232 239|viruses
P01846491A0459|260 270|divergence
P01846491A0459|201 207|genome
P01846491A0459|50 69|genus Orthopoxvirus
P01846206A0665|57 68|replication
P01846206A0665|35 42|CMV dbp
P01845885A1003|284 311|methionine initiation codon
P01845885A1003|345 349|UL26
P01845885A1003|160 164|mRNA
P01845885A1003|126 134|proteins
P01845885A1003|323 331|position
P01845885A1003|222 256|UL26 transcription initiation site
P01844982A0324|63 78|schistosomiasis
P01844982A0324|27 40|leishmaniasis
P01844982A0324|55 61|factor
P01844017A0410|134 138|hand
P01844017A0410|160 169|poisoning
P01844017A0410|25 37|relationship
P01844017A0410|175 189|sodium nitrite
P01842498A0000|27 29|R2
P01842498A0000|58 71|hybridization
P01842498A0000|93 111|phytohemagglutinin
P01842498A0000|189 201|cDNA library
P01842498A0000|155 167|Jurkat cells
P01840711A0000|53 57|RHDV
P01840711A0000|38 51|disease virus
P01840607A0294|30 34|UTRs
P01840607A0294|58 62|type
P01840607A0294|82 84|bp
P01839414T0000|5 13|spectrum
P01837787T0000|12 23|Mov-34 gene
P01837787T0000|54 66|organization
P01833637A0531|90 95|cells
P01833637A0531|130 141|temperature
P01833637A0531|219 226|fashion
P01833637A0531|5 14|abundance
P01833637A0531|102 110|transfer
P01832197T0001|1 8|Imaging
P01832152A0000|52 90|Agrobacterium tumefaciens oncogenicity
P01830928A0361|134 152|attachment domains
P01830928A0361|24 42|microtubule motors
P01830928A0361|48 55|dyneins
P01829460A0329|1 27|Southwestern blot analysis
P01828248A0189|132 135|DNA
P01828248A0189|147 160|UvrAB complex
P01828248A0189|99 107|solution
P01828248A0189|18 30|UvrA protein
P01827068T0000|94 120|T cell receptor alpha gene
P01827068T0000|7 13|GATA-3
P01826003A0694|31 33|bp
P01826003A0694|72 82|SIG family
P01826003A0694|5 9|gene
P01826003A0694|119 124|exons
P01824944A0988|22 33|tunicamycin
P01824944A0988|84 96|polypeptides
P01823524A0238|75 82|variety
P01823524A0238|210 221|differences
P01823524A0238|243 263|xenobiotics toxicity
P01823524A0238|23 29|number
P01823524A0238|155 162|factors
P01822995T0000|72 92|dicot rbcS promoters
P01822995T0000|1 29|Maize rbcS promoter activity
P01817497A0715|46 54|decrease
P01817497A0715|126 136|population
P01817497A0715|102 103|%
P01814182A0000|90 97|oestrus
P01814182A0000|11 16|doses
P01814182A0000|20 40|15-methyl-PGF2 alpha
P01814182A0000|51 53|mg
P01812102A0101|121 126|women
P01812102A0101|131 138|changes
P01812102A0101|142 149|latency
P01812102A0101|190 199|responses
P01812102A0101|51 60|responses
P01812102A0101|220 225|state
P01811243A0000|192 197|study
P01811243A0000|127 130|age
P01811243A0000|112 120|patients
P01811243A0000|138 143|years
P01811243A0000|19 29|blood flow
P01811243A0000|170 175|years
P01810108A0000|130 134|milk
P01810108A0000|7 22|phase slug flow
P01810108A0000|87 109|Listeria monocytogenes
P01808829A0510|1 5|TPTA
P01808186A0984|72 74|kg
P01808186A0984|54 58|diet
P01808049A0262|151 152|%
P01808049A0262|27 38|term babies
P01808049A0262|155 166|hypodensity
P01808049A0262|186 187|%
P01808049A0262|172 182|hemorrhage
P01808049A0262|201 208|atrophy
P01808049A0262|139 140|%
P01804671A1001|46 53|results
P01804671A1001|265 271|mmHg-1
P01804671A1001|112 122|air spaces
P01804671A1001|168 202|ventilation/perfusion distribution
P01804671A1001|237 243|CDCSF6
P01804671A1001|35 40|QS/QC
P01797467A0000|90 99|pregnancy
P01797467A0000|22 33|combination
P01792914T0000|27 45|childhood leukemia
P01791754T0000|61 69|features
P01791754T0000|12 20|analysis
P01791754T0000|32 36|role
P01788002T0001|19 30|hepatitis A
P01788002T0001|35 36|B
P01786094T0001|9 17|contents
P01784589A0000|93 101|behavior
P01784589A0000|50 73|5-HT2 receptor activity
P01783088A1136|134 148|micrograms.l-1
P01783088A1136|41 48|disease
P01783088A1136|281 289|ABSTRACT
P01783088A1136|53 63|mast cells
P01783088A1136|237 245|patients
P01783088A1136|153 164|fibronectin
P01782669A0496|37 49|temperatures
P01781923A0744|61 74|concentration
P01781923A0744|94 98|loss
P01781923A0744|146 150|rate
P01781923A0744|114 116|LS
P01781923A0744|19 30|sensitivity
P01781923A0744|102 110|righting
P01779769A0000|127 140|reading frame
P01779769A0000|21 36|repressor locus
P01779769A0000|48 60|Streptomyces
P01779769A0000|155 166|kDa protein
P01779299A0000|24 35|alterations
P01779299A0000|116 141|Moniliformis moniliformis
P01776715A0489|164 168|PCO2
P01776715A0489|121 127|sample
P01776715A0489|192 203|measurement
P01776715A0489|54 65|measurement
P01776715A0489|175 178|kPa
P01776715A0489|100 113|equilibration
P01774822A0289|27 35|computer
P01774063A0161|15 33|backcross analysis
P01774063A0161|135 154|thrombospondin gene
P01774063A0161|73 95|C57BL/6J x Mus spretus
P01774063A0161|40 47|progeny
P01774063A0161|202 210|B2M loci
P01774063A0161|102 115|C57BL/6J mice
P01772341A0852|94 125|thromboxane receptor antagonist
P01772341A0852|163 183|digoxin intoxication
P01772341A0852|38 47|treatment
P01772341A0852|201 206|agent
P01771959A0442|246 255|deviation
P01771959A0442|263 267|PTCA
P01771959A0442|286 290|PTCA
P01771959A0442|193 197|PTCA
P01771959A0442|7 11|PTCA
P01771959A0442|101 109|function
P01771593A1152|58 60|GD
P01771593A1152|39 47|decrease
P01771593A1152|51 54|AGD
P01769919A0393|123 126|kHz
P01768648A0853|30 50|LexA fusion proteins
P01768648A0853|96 103|domains
P01768648A0853|16 26|properties
P01767592A0682|147 161|nucleotide-154
P01767592A0682|93 99|region
P01767592A0682|207 221|nucleotide-136
P01766999A0000|12 20|activity
P01766999A0000|24 57|allergen extract Ambrosia elatior
P01766999A0000|85 95|volunteers
P01766666A0788|24 28|rE12
P01766666A0788|33 40|rNFIL-6
P01766666A0788|1 11|Antibodies
P01765386A0305|74 76|bp
P01765386A0305|26 28|kb
P01765386A0305|9 15|report
P01765386A0305|159 163|gene
P01765386A0305|87 91|gene
P01765269A0308|29 34|class
P01765269A0308|133 141|features
P01765269A0308|7 14|introns
P01765095A0680|128 143|regulators CMD1
P01765095A0680|1 37|12-O-Tetradecanoylphorbol 13-acetate
P01763106A0070|43 47|hole
P01763106A0070|21 29|behavior
P01762917A0615|88 94|finger
P01762917A0615|124 128|loss
P01762917A0615|43 46|Lys
P01762917A0615|101 107|TFIIIA
P01762917A0615|35 38|Glu
P01762053A0557|5 13|granules
P01762053A0557|33 41|material
P01760166A0963|24 28|SpO2
P01760166A0963|97 108|finger site
P01759052A0786|1 5|Appl
P01757341A0591|111 116|brain
P01757341A0591|22 24|Vv
P01757341A0591|5 20|volume fraction
P01757341A0591|152 172|alkaline phosphatase
P01756195A1117|77 91|concentrations
P01756195A1117|4 12|addition
P01756195A1117|102 103|p
P01753317A0879|135 147|bone defects
P01753317A0879|77 81|FDBA
P01753317A0879|53 56|TTC
P01752441A0000|215 226|transcripts
P01752441A0000|71 79|residues
P01752441A0000|87 106|hexanucleotide loop
P01752441A0000|17 27|activation
P01751255A0529|47 48|p
P01751255A0529|17 19|CO
P01748630A0125|215 217|E.
P01748630A0125|92 109|activation domain
P01748630A0125|219 228|Northwood
P01748630A0125|194 204|Myc family
P01748630A0125|230 234|I.C.
P01748630A0125|206 213|Alvarez
P01748630A0125|70 75|c-Myc
P01748287T0000|41 51|properties
P01748287T0000|19 27|proteins
P01748067A0000|150 153|hip
P01748067A0000|55 63|patients
P01748067A0000|87 92|years
P01748067A0000|15 20|trial
P01748067A0000|160 171|replacement
P01748067A0000|110 113|age
P01748067A0000|68 71|men
P01744119A0757|128 157|oligoribonucleotide synthesis
P01744119A0757|212 221|templates
P01744119A0757|233 241|sequence
P01744119A0757|20 49|primase recognition sequences
P01744119A0757|51 84|nucleotide substrate requirements
P01744039A0511|134 159|conformation polymorphism
P01744039A0511|5 14|fragments
P01742606A0000|61 91|lambda Gt11 expression library
P01742606A0000|3 28|mouse brain beta-spectrin
P01742606A0000|32 36|cDNA
P01740448A1735|211 221|precursors
P01740448A1735|197 207|attachment
P01740448A1735|156 162|region
P01740330A0329|1 3|J.
P01739956A0638|94 99|drugs
P01739956A0638|37 52|calcium channel
P01739956A0638|1 11|Management
P01738936A0292|18 34|plasma C-peptide
P01738936A0292|85 93|analysis
P01738470A0441|58 67|positions
P01738470A0441|103 121|recognition memory
P01737741A0000|149 154|study
P01737741A0000|64 69|MAOIs
P01737741A0000|17 30|effectiveness
P01736651A0104|30 46|Children clinics
P01736651A0104|10 15|Women
P01736651A0104|17 24|Infants
P01735721A0185|181 203|B. subtilis TyrTS gene
P01735721A0185|109 119|% identity
P01735721A0185|216 220|tyrZ
P01735721A0185|69 102|Bacillus stearothermophilus TyrTS
P01735447A0271|122 135|sec61 mutants
P01735447A0271|24 32|molecule
P01735447A0271|142 155|translocation
P01735447A0271|87 104|pre-super-pro-PrB
P01734570T0000|78 88|resistance
P01734570T0000|142 155|porcine model
P01734570T0000|1 8|Effects
P01734020A1318|48 58|constructs
P01734020A1318|117 124|mutants
P01734020A1318|1 15|Immunostaining
P01733105A0127|43 51|segments
P01733105A0127|81 90|sense RNA
P01732736A1076|72 78|levels
P01732736A1076|82 89|oocytes
P01732736A1076|100 107|embryos
P01731979A1408|94 128|CaMV 35S domain B enhancer element
P01731979A1408|5 23|tissue specificity
P01731933T0000a|39 46|T4 gene
P01731933T0000a|50 57|protein
P01730747A0205|42 44|C.
P01730747A0205|34 40|Reilly
P01727494A0000|62 73|VV proteins
P01727494A0000|52 58|nature
P01727494A0000|33 42|immunogen
P01727494A0000|17 19|VV
P01726631T0001|59 76|Local Health Unit
P01726631T0001|80 87|Sassari
P01726631T0001|155 160|usage
P01726631T0001|139 145|agents
P01725622A0292|62 67|Gpt/l
P01725622A0292|37 55|platelet increment
P01724982A0237|77 90|North Chicago
P01724982A0237|64 75|Abbott Lab.
P01723619A0766|45 49|rise
P01723619A0766|195 207|F absorption
P01723619A0766|128 135|passage
P01723619A0766|53 75|plasma F concentration
P01723619A0766|156 165|intestine
P01722319A0849|104 111|domains
P01722319A0849|59 73|CHIP28 protein
P01722319A0849|184 193|C termini
P01722319A0849|137 158|N-glycosylation sites
P01721261T0000|21 23|FK
P01720555A1087|29 42|B2 transcript
P01718983A1640|28 37|Griffiths
P01718983A1640|24 26|D.
P01718983A1640|55 61|Newman
P01718983A1640|86 90|Lobb
P01718983A1640|14 16|C.
P01718983A1640|43 49|Tizard
P01718983A1640|39 41|B.
P01718983A1640|1 3|E.
P01717994T0000|88 93|yeast
P01717994T0000|20 24|cDNA
P01717994T0000|100 108|mutation
P01717833T0000|64 77|monophosphate
P01717833T0000|19 37|alpha inhibin gene
P01717833T0000|84 96|transfection
P01717718A1255|15 30|point mutations
P01717718A1255|183 195|prerequisite
P01717718A1255|159 168|PR domain
P01717718A1255|66 76|activation
P01717718A1255|200 210|activation
P01717718A1255|139 151|conformation
P01716292A0000|135 145|cell lines
P01716292A0000|192 200|Eb genes
P01716292A0000|113 119|series
P01716292A0000|65 87|T cell allorecognition
P01716292A0000|185 190|DRB/H
P01715593A0838|44 64|fluoxetine injection
P01715593A0838|6 17|desipramine
P01715593A0838|34 37|hrs
P01714452A0559|89 101|conservation
P01714452A0559|25 32|protein
P01714452A0559|156 179|carbohydrate attachment
P01714452A0559|117 127|threonines
P01714322A0969|77 85|products
P01714322A0969|67 72|maize
P01714322A0969|55 63|kDa hsps
P01713213A0000|90 98|homology
P01713213A0000|162 174|Pim-1 enzyme
P01713213A0000|52 79|pim-1 proto-oncogene shares
P01711048T0000|30 31|G
P01711048T0000|46 52|intron
P01711048T0000|78 82|gene
P01711048T0000|84 90|COL1A2
P01711048T0000|137 160|osteogenesis imperfecta
P01711041A0348|7 13|clones
P01711041A0348|81 95|C5 alpha-chain
P01710979T0000|91 104|proteins p130
P01710979T0000|28 35|pp60src
P01710979T0000|67 75|tyrosine
P01710979T0000|50 61|association
P01710766A0349|40 47|absence
P01710766A0349|67 75|sequence
P01710766A0349|87 109|amino acids C terminal
P01709486A0000|12 20|mutation
P01709486A0000|59 73|proto-oncogene
P01708771A1215|122 131|molecules
P01708771A1215|36 44|peptides
P01708771A1215|155 160|Asn72
P01708771A1215|84 89|Asn65
P01707800A0354|14 40|N13-N20 interpeak interval
P01707800A0354|145 160|onset latencies
P01707800A0354|96 101|peaks
P01703335T0000|45 62|immunosuppression
P01703335T0000|21 30|disorders
P01703335T0000|68 70|FK
P01702432A1296|61 66|genes
P01702432A1296|112 125|pollen tissue
P01702426A0196|164 182|acid synthase gene
P01702426A0196|92 102|expression
P01702426A0196|38 42|gene
P01701088A1335|76 88|AP-2 element
P01701088A1335|1 13|Co-existence
P01699944A1538|192 203|c-fos genes
P01699944A1538|7 14|results
P01699944A1538|70 95|CArG box binding proteins
P01698761A1059|130 139|structure
P01698761A1059|76 83|repeats
P01698761A1059|173 180|strains
P01698761A1059|18 36|DNA rearrangements
P01698761A1059|50 56|region
P01697683T0000|44 52|promoter
P01697683T0000|20 36|characterization
P01695378A1406|30 37|T cells
P01695378A1406|79 88|ionomycin
P01695378A1406|43 74|phorbol 12-myristate 13-acetate
P01695378A1406|1 10|Induction
P01695314T0000|36 43|control
P01695314T0000|64 92|calcium antagonist treatment
P01695116A0078|75 87|chemotherapy
P01695116A0078|109 115|months
P01695116A0078|5 12|patient
P01694525A0000|124 134|N-terminus
P01694525A0000|1 26|Isopenicillin N isomerase
P01694014A0716|161 170|LD78 cDNA
P01694014A0716|59 90|phorbol 12-myristate 13-acetate
P01694014A0716|141 157|RNA hybridizable
P01694014A0716|49 53|U937
P01692962A0980|47 60|s polypeptide
P01692962A0980|92 97|cells
P01692962A0980|162 185|protein kinase activity
P01692962A0980|87 90|CHO
P01692135A0783|14 43|rtFc gamma R alpha cDNA clone
P01692135A0783|93 98|mRNAs
P01692135A0783|219 231|killer cells
P01692135A0783|205 210|mouse
P01690812A0000|132 147|gene insertions
P01690812A0000|41 45|rDNA
P01690812A0000|36 39|DNA
P01690812A0000|17 18|%
P01690703A0285|17 19|D.
P01688841A0430|44 48|invG
P01688841A0430|26 30|ipaB
P01688841A0430|19 24|genes
P01688841A0430|1 11|Expression
P01686909A0299|14 22|increase
P01686909A0299|79 90|elimination
P01686909A0299|136 142|kidney
P01682542A0690|28 42|HIV prevalence
P01682542A0690|99 110|counselling
P01682542A0690|86 94|location
P01682484A0680|133 144|dysfunction
P01682484A0680|162 170|LCX flow
P01682484A0680|81 85|dose
P01682484A0680|17 25|stenosis
P01679749A1171|164 187|HSPG2 proteoglycan gene
P01679749A1171|26 44|proteoglycan locus
P01679749A1171|111 116|tools
P01679749A1171|145 153|diseases
P01679749A1171|5 17|localization
P01679068A0000|11 18|infants
P01679068A0000|199 215|Enterobacter spp
P01679068A0000|156 163|strains
P01679068A0000|34 44|care units
P01678287A1308|93 98|cells
P01678287A1308|219 224|cells
P01675637T0033|10 31|amino acid difference
P01675637T0033|86 94|activity
P01675154T0000|12 22|infarction
P01675154T0000|49 63|bypass surgery
P01674817A0862|74 82|proteins
P01674817A0862|58 63|RNA14
P01674817A0862|4 12|homology
P01674369A0417|22 29|element
P01674177T0001|25 34|psoriasis
P01671675A0905|90 98|CAD gene
P01671675A0905|80 86|region
P01669611A0142|30 35|fever
P01669611A0142|57 65|aneurysm
P01669611A0142|87 102|pleuropneumonia
P01662884A1029|124 135|prostatitis
P01662884A1029|55 59|days
P01662884A1029|1 13|Temafloxacin
P01662794A0640|42 54|transfection
P01662794A0640|19 27|wt1 gene
P01662794A0640|84 95|kDa protein
P01661369A0825|111 119|capacity
P01661369A0825|86 94|presence
P01661369A0825|16 20|strD
P01660486A1756|123 129|marker
P01660486A1756|202 213|PKC pathway
P01660486A1756|81 106|aminoglycoside resistance
P01660486A1756|171 189|control mechanisms
P01658741A1047|45 54|kilobases
P01658741A1047|110 113|ADE
P01658741A1047|116 121|locus
P01658375A0854|57 64|introns
P01658375A0854|43 47|ends
P01658375A0854|5 25|nucleotide sequences
P01658375A0854|168 178|difference
P01658375A0854|204 214|LAT intron
P01658356A1369|24 36|coexpression
P01658356A1369|5 12|results
P01658356A1369|140 155|3201B cell line
P01658356A1369|103 109|FeLV-C
P01657594A0472|93 97|cgs2
P01657594A0472|48 70|complementation groups
P01657249A1019|79 81|CA
P01657249A1019|23 25|CA
P01657249A1019|115 118|VH4
P01656675A0236|106 114|controls
P01656675A0236|80 90|complaints
P01656675A0236|51 59|patients
P01656221A1319|151 158|members
P01656221A1319|78 85|regions
P01656221A1319|18 38|amino acid sequences
P01656221A1319|51 58|Tyr-766
P01655713A0294|132 135|Tn1
P01655713A0294|9 14|study
P01655713A0294|96 102|strain
P01655713A0294|33 39|region
P01654349A0327|120 121|K
P01654349A0327|158 164|NaHCO3
P01654349A0327|1 12|Feed intake
P01653238A1715|9 17|TGF-beta
P01653238A1715|1 4|TPA
P01653236A0895|146 165|hamster ovary cells
P01653236A0895|111 134|glucocorticoid receptor
P01653236A0895|50 73|glucocorticoid receptor
P01652755A1492|180 184|IL-6
P01652755A1492|62 76|overexpression
P01652755A1492|93 135|retinoblastoma susceptibility gene product
P01652755A1492|200 205|c-fos
P01652755A1492|50 60|HeLa cells
P01652755A1492|326 329|MHC
P01652372A0153|56 59|NLS
P01652372A0153|20 24|SWI5
P01652372A0153|118 123|entry
P01651232A0152|42 58|uridine residues
P01651232A0152|6 10|mRNA
P01650524A0837|164 170|BW A4C
P01650524A0837|13 18|phase
P01650524A0837|41 53|permeability
P01650524A0837|83 98|LTB4 production
P01650524A0837|207 220|dexamethasone
P01650524A0837|137 162|5-LO inhibitors phenidone
P01649539T0000|25 31|lipids
P01649539T0000|1 17|Plasma vitamin E
P01649318A0734|89 146|herpes simplex virus TK promoter transcription start site
P01649318A0734|1 7|EBNA-2
P01648530A0000|67 86|actin gene promoter
P01648530A0000|18 26|M region
P01648530A0000|51 58|Xenopus
P01647813A0512|12 22|transcript
P01647813A0512|157 167|expression
P01647813A0512|50 57|protein
P01647070A0232|44 56|SV40 origins
P01647070A0232|36 39|JCV
P01646487A0874|61 69|decrease
P01646487A0874|28 36|activity
P01646487A0874|218 226|activity
P01646487A0874|109 122|B lymphocytes
P01646487A0874|43 44|X
P01646487A0874|98 101|IgM
P01646487A0874|1 9|Patients
P01645905A0341|160 170|C-terminus
P01645905A0341|98 102|mass
P01645905A0341|49 63|vaccinia virus
P01645905A0341|16 17|N
P01644831A0824|90 98|activity
P01644831A0824|230 238|activity
P01644831A0824|23 27|role
P01644831A0824|174 182|portions
P01644831A0824|190 207|carboxyl terminus
P01644831A0824|35 52|carboxyl terminus
P01644814A0068|37 40|tax
P01644814A0068|87 94|T cells
P01644751A0590|11 24|reading frame
P01644751A0590|118 135|msgB gene product
P01642060A0471|129 138|carcinoma
P01642060A0471|51 65|Phthalocyanine
P01640778A0485|90 99|screening
P01640778A0485|42 51|MLPA test
P01639092A0776|1 6|Lewis
P01636714A0845|89 95|spleen
P01636714A0845|131 134|MBF
P01636714A0845|5 12|results
P01636714A0845|118 124|serosa
P01636714A0845|68 73|liver
P01634861A1336|88 99|oxygen debt
P01634861A1336|41 63|oxygen debt hypothesis
P01634400A1101|42 51|operating
P01634400A1101|1 17|Production costs
P01633816A0667|192 217|primer extension analysis
P01633816A0667|167 177|start site
P01633816A0667|222 241|S1 nuclease mapping
P01633816A0667|69 74|exons
P01631229T0000|1 14|Cutis aplasia
P01630455A0448|193 208|IL-1 beta genes
P01630455A0448|33 46|NFIL-1 beta A
P01630455A0448|17 24|protein
P01629768A0131|22 40|pressure injection
P01629768A0131|1 8|Lesions
P01628806A1347|120 135|helicase region
P01628806A1347|93 96|ORF
P01628806A1347|64 65|Y
P01627830A0000|92 96|CKI1
P01627830A0000|20 35|casein kinase-1
P01627106A0320|14 24|experiment
P01627106A0320|124 135|differences
P01627106A0320|139 141|S.
P01626440A0449|94 97|day
P01626440A0449|34 58|instrument disinfectants
P01626372T0000|91 99|presence
P01626372T0000|41 50|thymidine
P01626372T0000|114 120|levels
P01626372T0000|1 8|Tissues
P01625131A0452|57 61|risk
P01625131A0452|35 45|stoma site
P01623900A0670|183 187|drop
P01623900A0670|159 167|Pl group
P01623900A0670|225 240|blood pressures
P01623900A0670|40 48|activity
P01623900A0670|7 21|blood pressure
P01623900A0670|371 388|dF administration
P01623900A0670|275 295|norepinephrine level
P01620781A0611|93 98|words
P01620781A0611|20 28|subjects
P01620781A0611|50 59|sequences
P01620781A0611|254 259|class
P01620781A0611|130 132|A5
P01620781A0611|203 211|position
P01620781A0611|141 149|reversal
P01620129A0417|107 120|H4-FO108 gene
P01620129A0417|124 134|cell cycle
P01620129A0417|23 34|interaction
P01620129A0417|170 172|J.
P01618256A0521|60 67|regimen
P01618256A0521|72 86|micrograms.l-1
P01618256A0521|128 134|regime
P01618256A0521|139 153|micrograms.l-1
P01618027A1108|124 136|E10 fragment
P01618027A1108|80 87|profile
P01618027A1108|156 162|probes
P01617776A0343|147 152|heart
P01617776A0343|128 139|innervation
P01617776A0343|174 178|role
P01617776A0343|206 212|system
P01617776A0343|32 38|system
P01617776A0343|85 95|infarction
P01616475A0756|88 96|patients
P01616475A0756|58 73|CP/NCA patients
P01616475A0756|7 14|results
P01616475A0756|50 54|NFPD
P01615493A0408|46 47|%
P01615493A0408|79 87|daughter
P01615493A0408|112 118|levels
P01615493A0408|54 55|%
P01615049A0000|43 48|goats
P01615049A0000|53 59|ad lib
P01615049A0000|16 33|drinking patterns
P01612085A0624|131 147|distance runners
P01612085A0624|162 163|P
P01612085A0624|5 25|serum erythropoietin
P01612085A0624|154 160|U.ml-1
P01605038T0001|62 66|GABA
P01605038T0001|70 74|rats
P01605038T0001|51 58|effects
P01601869A1389|125 131|region
P01601869A1389|203 218|BC3H1 myoblasts
P01601869A1389|71 76|E-box
P01600531A0483|41 56|phosphocreatine
P01600531A0483|66 67|%
P01597272A0077|28 37|methadone
P01597272A0077|49 68|withdrawal symptoms
P01596007A0908|13 19|events
P01596007A0908|130 131|%
P01596007A0908|57 60|REM
P01596007A0908|36 42|Stages
P01596007A0908|237 245|gamma OH
P01596007A0908|102 116|gamma OH study
P01592545A0726|149 157|patients
P01592545A0726|25 39|blood pressure
P01592545A0726|48 55|average
P01588965A0000|58 73|gene expression
P01588961A0000|74 83|sequences
P01588961A0000|24 34|yeast gene
P01588961A0000|51 58|removal
P01588315A0356|240 244|maps
P01588315A0356|12 37|Orgyia pseudotsugata MNPV
P01588315A0356|131 146|polyhedrin gene
P01588315A0356|113 121|sequence
P01588315A0356|200 209|direction
P01588315A0356|155 162|viruses
P01587763A0402|131 135|days
P01587763A0402|7 23|body irradiation
P01587763A0402|116 118|hr
P01586901A0000|11 23|interactions
P01586901A0000|80 91|medications
P01586901A0000|138 144|window
P01584812T0000|114 141|transcription factor NGFI-C
P01584812T0000|84 88|gene
P01582500A0178|15 26|rhythmicity
P01582413A0192|15 26|mutagenesis
P01582413A0192|63 74|amino acids
P01582413A0192|159 165|domain
P01582413A0192|218 240|hetero-oligomerization
P01581577A1186|46 62|gene duplication
P01581577A1186|79 83|gene
P01580738T0001|13 21|syndrome
P01580738T0001|1 10|Allagille
P01579472A1018|43 49|region
P01577740A1111|75 105|transcription initiation sites
P01577740A1111|22 31|mung bean
P01577740A1111|1 17|Primer extension
P01573270A0000|160 163|LAK
P01573270A0000|108 117|HLA class
P01573270A0000|36 42|series
P01573270A0000|85 97|immunization
P01569945A0529|90 97|protein
P01569945A0529|109 113|mass
P01569945A0529|119 122|kDa
P01569581A0482|131 135|fold
P01569581A0482|112 123|start codon
P01569581A0482|18 26|evidence
P01569581A0482|48 52|mRNA
P01569102A0708|91 103|conservation
P01569102A0708|39 51|LDL receptor
P01569102A0708|1 7|Domain
P01568960A1129|148 160|VA/Q regions
P01568960A1129|112 126|corner vessels
P01568960A1129|48 56|pressure
P01566576A0605|1 5|Keck
P01565093A0179|210 228|Alabama Department
P01565093A0179|247 251|ADPH
P01565093A0179|232 245|Public Health
P01565093A0179|83 100|blood lead levels
P01565093A0179|119 127|hospital
P01563635T0000|54 79|M.HinfI methyltransferase
P01563635T0000|17 29|purification
P01562659A0676|122 136|administration
P01562659A0676|213 223|C. immitis
P01562659A0676|52 66|administration
P01562659A0676|198 209|association
P01562659A0676|174 184|situations
P01562659A0676|70 84|amphotericin B
P01562659A0676|1 12|Institution
P01560021A0379|130 138|rat gene
P01560021A0379|76 94|brain AE3 variants
P01558942A1369|58 63|genes
P01557217A0272|40 47|lesions
P01556068A0000|134 143|compounds
P01556068A0000|109 117|tyramine
P01556068A0000|173 196|ammonium ion repression
P01554334A0000|74 83|diagnosis
P01554334A0000|182 185|use
P01554334A0000|24 40|gamma-interferon
P01554334A0000|110 116|cattle
P01554334A0000|53 65|assay system
P01552853A1377|7 18|temperature
P01552853A1377|54 63|induction
P01552457T0000|109 114|PT-01
P01552457T0000|98 107|ofloxacin
P01552457T0000|35 48|periodontitis
P01551910A0978|51 59|sequence
P01551898A1084|73 83|expression
P01551898A1084|6 12|vector
P01551898A1084|139 149|LAPP/liter
P01551898A1084|34 39|yeast
P01551176A0000|41 52|mitoquidone
P01551176A0000|68 82|pyrroloquinone
P01549346A0000|5 24|c-Ets-1 oncoprotein
P01549125A0140|62 79|beta GK promoters
P01549125A0140|43 50|insulin
P01549125A0140|52 56|IAPP
P01549125A0140|5 14|functions
P01549118A0000|147 170|hermaphrodite intestine
P01549118A0000|5 46|Caenorhabditis elegans vitellogenin genes
P01548756A1102|28 33|EHS-1
P01548756A1102|130 142|band pattern
P01548756A1102|58 61|DNA
P01548756A1102|175 180|locus
P01548756A1102|85 95|EHS-1 loci
P01547942A0120|134 141|protein
P01547942A0120|92 97|clone
P01547942A0120|35 54|dimerization domain
P01547775A1024|62 72|frameshift
P01547775A1024|146 149|RNA
P01547775A1024|42 54|significance
P01547775A1024|201 231|ORF2a/ORF2b transframe protein
P01545818A0696|106 111|v-Src
P01545818A0696|42 50|proteins
P01545818A0696|66 75|v-Src SH2
P01545818A0696|5 9|p130
P01545797A0587|62 66|slk1
P01545797A0587|98 107|degrees C
P01545797A0587|118 123|cells
P01545792A0000|13 33|myosin light chain-2
P01545792A0000|42 55|gene promoter
P01545792A0000|141 151|regulation
P01545523A0000|120 138|antistreptolysin O
P01545523A0000|109 115|factor
P01545523A0000|78 79|C
P01544918A1240|245 258|subunit sizes
P01544918A1240|27 37|R subunits
P01544918A1240|293 316|RII alpha dephosphoform
P01544918A1240|352 355|kDa
P01544918A1240|224 232|SDS-PAGE
P01544918A1240|47 82|8-azido-cAMP photoaffinity labeling
P01544918A1240|339 347|RI alpha
P01544918A1240|275 278|kDa
P01543909A0787|214 218|gene
P01543909A0787|168 178|pseudogene
P01543909A0787|35 45|K562 cells
P01542686A0000|73 98|p75 nucleoprotein complex
P01542686A0000|26 47|polypeptide component
P01542686A0000|142 145|p65
P01542686A0000|116 124|identity
P01542565T0000|147 158|cDNA clones
P01542565T0000|112 121|isolation
P01542565T0000|54 71|Nicotiana tabacum
P01542565T0000|184 193|precursor
P01541577A0000|72 89|Stanford Hypnotic
P01541577A0000|126 128|J.
P01541577A0000|4 13|volunteer
P01541577A0000|19 21|Ss
P01539996A0588|335 345|C terminus
P01539996A0588|178 189|Ser residue
P01539996A0588|158 170|conservation
P01539996A0588|21 40|amino acid sequence
P01539996A0588|105 111|enzyme
P01539996A0588|3 13|comparison
P01539996A0588|137 147|similarity
P01538401A1244|73 83|S RNA gene
P01538401A1244|142 148|latter
P01538401A1244|188 201|DNA fragments
P01537334A0507|61 67|region
P01537334A0507|33 49|mouse chromosome
P01536153A0574|151 161|skin tests
P01536153A0574|182 192|fish flour
P01536153A0574|53 63|prevalence
P01536153A0574|87 95|symptoms
P01536153A0574|171 175|dust
P01533760T0000|57 64|results
P01533760T0000|1 29|Estrogen replacement therapy
P01532796A0107|164 172|Ackerman
P01532796A0107|127 139|mitochondria
P01532796A0107|174 176|S.
P01532796A0107|86 91|alpha
P01532796A0107|1 10|Mutations
P01532796A0107|152 162|aggregates
P01531632A0000|164 169|motif
P01531632A0000|130 134|NSR1
P01531632A0000|42 51|nucleolus
P01531632A0000|175 185|GAR domain
P01531632A0000|87 95|proteins
P01531086A0127|43 54|amino acids
P01531086A0127|5 9|cDNA
P01527020A0511|13 22|junctions
P01527020A0511|40 70|rat AdoMet decarboxylase genes
P01527020A0511|159 163|exon
P01527020A0511|171 179|rat gene
P01526658A0454|108 118|B lineages
P01526658A0454|66 71|cells
P01526658A0454|102 103|T
P01525153A0359|14 15|d
P01525153A0359|165 167|W.
P01525153A0359|145 148|Sen
P01525153A0359|4 12|contrast
P01525153A0359|98 120|K cation concentration
P01525153A0359|16 22|T2AG3T
P01523111A0769|25 34|afterdrop
P01523111A0769|98 107|body mass
P01518926T0000|30 45|ultrasonography
P01518833A0397|58 61|RNA
P01518833A0397|54 55|A
P01518833A0397|49 53|poly
P01516829A0460|14 23|LexA-GAL4
P01516829A0460|40 55|fusion proteins
P01516829A0460|157 171|lexA operators
P01516829A0460|84 88|SNF5
P01516427T0000|44 53|diagnosis
P01516427T0000|65 77|tuberculosis
P01513114A1133|10 33|serum creatinine levels
P01513114A1133|110 115|WORDS
P01513114A1133|69 72|KTA
P01512654A0503|14 18|hand
P01512654A0503|47 63|saline injection
P01512654A0503|88 102|KLH challenges
P01512654A0503|110 112|ES
P01511950T0000|60 68|Hisayama
P01511950T0000|46 56|population
P01511950T0000|114 141|hepatitis B surface antigen
P01511950T0000|1 9|Exposure
P01511950T0000|102 110|antibody
P01509798A0520|41 43|UT
P01509798A0520|65 67|AT
P01509798A0520|71 72|%
P01506705A0282|8 18|V-A bypass
P01505488A0231|27 35|patients
P01505488A0231|76 82|August
P01505488A0231|49 52|EVL
P01504178T0000|26 36|prevention
P01504178T0000|67 74|complex
P01499616A0136|107 108|%
P01499616A0136|177 180|tip
P01499616A0136|78 79|g
P01499616A0136|207 220|foreskin flap
P01499616A0136|119 128|induction
P01498607A0000|12 32|nucleotide sequences
P01498607A0000|34 39|boxes
P01496784A0939|5 12|results
P01496784A0939|69 74|cause
P01495069A0392|62 67|value
P01495069A0392|111 115|DFAT
P01492463T0001|62 66|trip
P01492463T0001|78 83|ocean
P01492463T0001|1 6|Alena
P01487144A0505|60 67|signals
P01487144A0505|47 56|mu m poly
P01487144A0505|57 58|A
P01487144A0505|110 118|sequence
P01487144A0505|84 86|bp
P01485648A0000|149 160|measurement
P01485648A0000|182 196|IgE antibodies
P01485648A0000|110 117|Uppsala
P01485648A0000|216 220|RAST
P01485648A0000|32 37|value
P01485648A0000|119 125|Sweden
P01483755A0000|43 50|imaging
P01483755A0000|82 92|techniques
P01483755A0000|101 106|study
P01483755A0000|34 37|MRS
P01480470A0323|31 40|ionophore
P01480470A0323|58 68|activities
P01480183A0000|37 53|lactoferrin gene
P01480183A0000|17 23|region
P01477021A0394|111 120|gestation
P01477021A0394|1 8|RESULTS
P01477021A0394|17 26|AGA group
P01473234A1001|107 111|acid
P01473234A1001|1 13|Green pepper
P01473196A1016|25 37|reabsorption
P01470741T0062|1 13|Distribution
P01469047A1606|63 69|shares
P01469047A1606|130 141|mouse brain
P01469047A1606|33 44|tail domain
P01469047A1606|117 124|protein
P01468625A1080|59 64|times
P01468625A1080|48 52|NSR1
P01467828A0542|61 76|opioid peptides
P01467828A0542|92 99|effects
P01467828A0542|189 199|antagonism
P01467828A0542|118 127|ischaemia
P01464606A0344|12 19|amounts
P01464606A0344|123 134|fibronectin
P01464606A0344|177 184|elution
P01464606A0344|99 117|detergent extracts
P01464606A0344|81 95|chromatography
P01462786T0000|43 58|complex systems
P01462786T0000|1 24|Dynamic decision making
P01460054A0968|125 130|cells
P01460054A0968|102 107|genes
P01459921A0000|226 231|C18:2
P01459921A0000|94 104|experiment
P01459921A0000|42 59|Hampshire wethers
P01459921A0000|234 241|cis C18
P01459451A0478|78 94|co-antirepressor
P01459451A0478|141 148|embryos
P01458170A0155|244 250|cortex
P01458170A0155|218 222|beta
P01458170A0155|55 64|amplitude
P01458170A0155|255 264|hippocamp
P01458170A0155|160 169|hippocamp
P01458170A0155|99 113|theta-activity
P01458170A0155|138 141|EEG
P01457695T0000a|12 32|beta 2-microglobulin
P01457695T0000a|36 48|hemodialysis
P01457695T0000a|1 8|Removal
P01456888A0074|330 360|myristylation consensus signal
P01456888A0074|214 227|baculoviruses
P01456888A0074|158 176|expression systems
P01456888A0074|51 62|derivatives
P01456888A0074|200 208|vaccinia
P01456888A0074|306 314|sequence
P01454518A0336|14 26|significance
P01454518A0336|73 85|conservation
P01454518A0336|93 97|gene
P01454518A0336|103 110|homolog
P01452584T0000|63 76|wound healing
P01452584T0000|24 34|exotoxin A
P01452584T0000|87 101|Lindberg Award
P01451771A0619|160 176|scaling analysis
P01451771A0619|113 132|components analysis
P01451771A0619|80 84|data
P01451771A0619|221 229|husbands
P01451771A0619|34 50|family variables
P01449301A0710|42 47|mm Hg
P01449301A0710|1 18|Cold cardioplegia
P01448806A0135|74 89|bone maturation
P01448806A0135|1 15|Administration
P01447189T0000|74 82|granules
P01447189T0000|37 52|serine protease
P01447189T0000|18 25|cloning
P01447189T0000|1 13|Purification
P01446132A0328|75 87|complication
P01446132A0328|5 17|air embolism
P01443745T0000|67 76|midazolam
P01443745T0000|38 48|anesthesia
P01441818T0001|33 47|body reactions
P01438287T0000|66 71|genes
P01437562A0462|47 55|extracts
P01437562A0462|95 99|size
P01437562A0462|76 85|agreement
P01437562A0462|153 157|gene
P01435698A0000|75 78|AVG
P01435698A0000|63 73|vein graft
P01435698A0000|133 143|harvesting
P01435698A0000|112 122|production
P01435698A0000|4 9|order
P01433502A1163|134 140|levels
P01433502A1163|165 171|factor
P01433502A1163|46 63|enhancer activity
P01433502A1163|38 43|class
P01432453T0000|25 32|systems
P01432453T0000|34 51|system definition
P01431602A0229|75 96|micrograms phosphorus
P01431602A0229|25 30|macro
P01431602A0229|32 37|assay
P01429836A1205|55 61|domain
P01429836A1205|116 121|cells
P01429768T0000|41 49|exposure
P01429768T0000|53 57|F-75
P01429724A0664|46 52|domain
P01429724A0664|56 61|Nmt1p
P01429724A0664|5 9|data
P01429724A0664|81 86|Ile59
P01429624A0328|66 70|loss
P01429624A0328|114 129|adenylylcyclase
P01429624A0328|102 110|activity
P01427457A0000|61 69|efficacy
P01427457A0000|208 218|thrombosis
P01427457A0000|39 44|trial
P01427457A0000|154 168|sodium heparin
P01427457A0000|220 223|DVT
P01426635A0496|13 20|profile
P01426635A0496|78 81|DDC
P01426635A0496|24 29|ZFH-2
P01425921A1286|121 139|consensus sequence
P01425921A1286|83 98|lysine deletion
P01425921A1286|187 191|V1J1
P01424674A0000|96 109|cicatrization
P01423454A0309|47 59|contribution
P01423454A0309|127 136|indicator
P01423454A0309|219 228|treatment
P01423454A0309|1 12|Examination
P01423454A0309|84 93|diagnosis
P01421609A1067|29 33|DMVA
P01421609A1067|128 135|support
P01421609A1067|65 71|trauma
P01421145A1190|44 74|heparin-agarose chromatography
P01421145A1190|32 40|extracts
P01421145A1190|118 126|extracts
P01420363T0000|121 134|transcription
P01420363T0000|113 119|TIMP-1
P01420363T0000|1 12|Involvement
P01420363T0000|50 60|regulation
P01420223T0000|21 32|biopsy site
P01420223T0000|68 80|fiber typing
P01419945A1386|91 103|interscalene
P01419945A1386|46 62|nerve stimulator
P01418834A0987|15 34|hematocrit decrease
P01418834A0987|79 83|fall
P01418834A0987|156 161|mm Hg
P01418834A0987|51 52|P
P01418494T0000|10 16|spikes
P01414219A0319|133 136|OXC
P01414219A0319|66 69|AUC
P01414219A0319|71 97|peak plasma concentrations
P01414219A0319|51 62|differences
P01410071T0000|92 98|rhythm
P01410071T0000|66 74|relation
P01410071T0000|1 13|Blood levels
P01410071T0000|102 127|platelet serotonin uptake
P01409581A0206|42 47|v-ets
P01409581A0206|117 121|site
P01408219A0670|14 22|patients
P01408219A0670|78 87|nontender
P01408219A0670|51 67|lymph-adenopathy
P01408090A0572|22 39|TEE visualization
P01408090A0572|65 73|arteries
P01406703A1435|89 110|hormone receptor cDNA
P01406703A1435|126 130|cDNA
P01406703A1435|16 36|Y1 cell cDNA library
P01406677A0000|27 43|control elements
P01406677A0000|76 86|expression
P01406677A0000|140 148|analysis
P01406677A0000|100 114|myoglobin gene
P01406630A0965|94 101|respect
P01406630A0965|81 88|binding
P01406630A0965|16 19|p50
P01404612A0303|30 33|Ads
P01404612A0303|108 126|vaccine candidates
P01403391T0000|41 49|children
P01402647A0114|94 111|peptide sequences
P01402647A0114|1 14|DR1 molecules
P01400401A0854|120 130|expression
P01400401A0854|146 156|AMPD3 cDNA
P01400401A0854|84 92|extracts
P01400396A1265|42 56|phorbol esters
P01400396A1265|5 13|promoter
P01399206A0375|29 36|reports
P01399206A0375|42 64|collagenase inhibitors
P01398106A0754|148 155|strands
P01398106A0754|40 46|I-CreI
P01398106A0754|125 128|top
P01398106A0754|66 68|bp
P01398106A0754|32 38|enzyme
P01398106A0754|137 143|bottom
P01398098A0770|57 68|translation
P01398098A0770|1 21|Clone pSRc200 hybrid
P01398074A0697|91 120|RNase MRP enzyme preparations
P01398074A0697|5 18|gene sequence
P01398071A0526|90 103|BRF1 activity
P01398071A0526|7 18|temperature
P01398071A0526|140 148|activity
P01398071A0526|152 167|RNA polymerases
P01396601A0986|120 128|homology
P01396601A0986|37 43|Sec12p
P01396601A0986|4 12|contrast
P01396583A0204|53 64|interleukin
P01396583A0204|3 15|cDNA library
P01396444A0934|194 200|degree
P01396444A0934|89 91|AM
P01396444A0934|37 48|micromilieu
P01396444A0934|115 132|activation states
P01396444A0934|204 212|recovery
P01395755A1023|215 221|ml/min
P01395755A1023|267 272|L/min
P01395755A1023|144 150|ml/min
P01395755A1023|223 224|p
P01395755A1023|152 153|p
P01395755A1023|75 82|methods
P01395755A1023|97 110|oxygen uptake
P01394200A0592|182 190|receptor
P01394200A0592|147 166|subset markers CD25
P01394200A0592|213 218|cells
P01394200A0592|5 20|treatment group
P01394200A0592|168 179|interleukin
P01392277A0000|194 197|No.
P01392277A0000|77 91|swimming pools
P01392277A0000|189 192|DIN
P01392277A0000|113 123|connection
P01392277A0000|35 41|status
P01391001A0583|60 61|%
P01391001A0583|81 91|ATB method
P01391001A0583|118 125|methods
P01389573A1071|108 110|A1
P01389573A1071|22 30|quotient
P01389573A1071|38 48|difference
P01389573A1071|1 5|TBPf
P01388160A1102|166 173|choices
P01388160A1102|177 184|Ser-106
P01388160A1102|128 144|peptide sequence
P01388160A1102|66 73|residue
P01388160A1102|186 193|Ser-107
P01386897A0000|146 150|CLN1
P01386897A0000|127 134|cyclins
P01386897A0000|81 93|CDC28 kinase
P01386897A0000|1 6|Entry
P01386897A0000|51 56|Start
P01385462A0151|174 184|monoamines
P01385462A0151|153 166|determination
P01384165A0000|26 32|effect
P01384165A0000|158 163|stage
P01384165A0000|4 8|rats
P01384165A0000|86 93|trachea
P01383695A0100|110 120|IgM lambda
P01383695A0100|16 32|EBV B-cell clone
P01383695A0100|34 39|E29.1
P01380825A0622|194 202|function
P01380825A0622|88 92|cDNA
P01380825A0622|1 23|Northern blot analyses
P01380454A0451|148 171|Hela cell AP-1 proteins
P01380454A0451|125 143|Jun-Jun homodimers
P01380454A0451|53 63|ref-1 gene
P01380454A0451|272 287|ATF/CREB family
P01380454A0451|103 123|Fos-Jun heterodimers
P01380062A0097|134 137|Y-3
P01380062A0097|52 64|T lymphocyte
P01380062A0097|113 127|CTL clones Y-1
P01380062A0097|71 91|recognition epitopes
P01380062A0097|1 10|T antigen
P01379032A0495|95 100|group
P01379032A0495|8 15|percent
P01379032A0495|19 27|patients
P01379032A0495|137 147|prednisone
P01378506A0884|56 61|block
P01378506A0884|65 78|virus release
P01378506A0884|19 39|full-deletion mutant
P01378127A0841|29 47|calcium supplement
P01378127A0841|51 69|calcium antagonist
P01377962A1012|42 50|subunits
P01377962A1012|4 12|contrast
P01377764A0309|72 77|layer
P01377764A0309|41 51|epithelium
P01376319T0000|28 33|mouse
P01376319T0000|1 5|Gene
P01375224A0152|150 158|proteins
P01375224A0152|129 137|activity
P01375224A0152|65 79|transformation
P01375224A0152|171 188|growth regulation
P01374398A0951|165 184|amino acid residues
P01374398A0951|132 136|acid
P01374398A0951|95 117|amino acid composition
P01374331A0636|74 94|nuclease S1 analysis
P01374331A0636|51 61|start site
P01372900A1017|65 104|goat alpha s1-casein transcription unit
P01372802A1481|180 192|C3 fragments
P01372802A1481|125 127|C3
P01372802A1481|430 437|protein
P01372802A1481|223 243|fluid-phase fragment
P01372802A1481|318 319|D
P01372802A1481|315 317|C3
P01372802A1481|128 129|D
P01372802A1481|4 11|summary
P01372802A1481|275 283|residues
P01372365A1202|88 96|sites %T
P01372365A1202|9 14|sites
P01372365A1202|70 71|M
P01371413A0742|61 83|Southern blot analysis
P01371413A0742|125 149|rodent-human hybrid DNAs
P01371413A0742|4 12|addition
P01371413A0742|116 121|panel
P01371272A1167|1 13|Perturbation
P01371272A1167|85 111|yeast DNA polymerase alpha
P01370446A0818|32 64|keratan sulfate attachment sites
P01364100A0377|23 42|subrepeat structure
P01363080A0710|45 52|changes
P01363080A0710|8 14|acuity
P01363080A0710|112 131|agent metronidazole
P01363080A0710|83 95|sulfonamides
P01360180A1568|146 156|properties
P01360180A1568|98 103|dsRNA
P01359588A0375|45 52|network
P01359588A0375|86 94|elements
P01358758A0000|12 19|portion
P01358758A0000|215 223|enhancer
P01358758A0000|58 61|DNA
P01358758A0000|98 101|Far
P01358190A0654|41 52|H-2E beta k
P01358190A0654|92 116|alpha chain substitution
P01358190A0654|71 75|loss
P01357190A0726|47 69|membrane anchor domain
P01357190A0726|133 139|fusion
P01357190A0726|23 30|mutants
P01357190A0726|155 160|cells
P01353478T0000|57 79|A20/2J B cell lymphoma
P01353478T0000|16 21|H-2Eb
P01352113A0002|63 65|NO
P01352113A0002|159 167|measures
P01352113A0002|115 131|inhalation model
P01350780A0184|74 79|yeast
P01350780A0184|141 148|lengths
P01350780A0184|1 31|Amino acid sequence comparison
P01349705T0000|23 39|thyroid function
P01349705T0000|51 57|babies
P01348590A0000|124 129|stage
P01348590A0000|82 88|cohort
P01348590A0000|217 223|agents
P01348590A0000|45 50|cases
P01348590A0000|133 144|HIV-disease
P01348590A0000|110 118|patients
P01348590A0000|168 172|time
P01348504A0757|11 36|pol alpha-primase complex
P01347908T0000|72 81|Parkinson
P01347908T0000|58 66|patients
P01347908T0000|84 91|disease
P01347476T0000|1 8|Mapping
P01346262A0377|15 20|study
P01346262A0377|64 82|S. entomophila UC9
P01346262A0377|34 50|protein profiles
P01340470A0000|30 34|rbp1
P01340470A0000|107 114|Arg-Ser
P01340470A0000|125 131|domain
P01339773A0778|88 97|gradients
P01339773A0778|59 62|CO2
P01339773A0778|39 48|pressures
P01339468A0272|134 143|analogues
P01339468A0272|5 17|ORF1 protein
P01339468A0272|154 159|potex
P01339468A0272|68 93|potexvirus RNA replicases
P01339373T0000|31 35|gene
P01339373T0000|41 61|Arabidopsis thaliana
P01339373T0000|1 10|Structure
P01338867A0503|57 66|treatment
P01338867A0503|199 209|activation
P01338867A0503|83 93|antagonist
P01338867A0503|154 167|fatiguability
P01338867A0503|220 226|system
P01334518T0000|40 57|hepatitis C virus
P01334518T0000|1 11|Strategies
P01334428A1102|45 52|peptide
P01334428A1102|88 90|mM
P01334428A1102|125 127|mM
P01334428A1102|67 70|Tyr
P01334428A1102|21 31|substrates
P01334428A1102|136 152|mumol min-1 mg-1
P01333125A0000|193 205|rhinoviruses
P01333125A0000|111 129|structure elements
P01333125A0000|175 188|enteroviruses
P01333125A0000|86 98|conservation
P01333047A0404|164 172|tyrosine
P01333047A0404|29 42|growth factor
P01333047A0404|130 145|phosphorylation
P01333047A0404|115 120|cells
P01332964A0247|13 21|promoter
P01332964A0247|83 91|elements
P01331516A0103|7 14|mutants
P01331516A0103|32 58|3T6 mouse fibroblast cells
P01331292A1425|28 37|instances
P01331292A1425|76 83|repeats
P01331292A1425|53 68|oligonucleotide
P01331060A0768|89 103|cDNA sequences
P01331060A0768|22 40|calcineurin A gene
P01330975T0000|12 26|polyneuropathy
P01330077A0000|106 115|leukemias
P01330077A0000|23 31|TCR beta
P01330077A0000|117 121|ALLs
P01329039A0239|75 86|nucleotides
P01329039A0239|126 131|genes
P01329039A0239|101 108|E-boxes
P01328854T0000|73 86|transcription
P01328854T0000|131 159|phosphoglycerate mutase gene
P01328854T0000|52 59|element
P01328681A0149|151 159|proteins
P01328681A0149|193 203|inhibition
P01328681A0149|125 135|activities
P01328681A0149|207 224|protein synthesis
P01328197A0985|94 104|components
P01328197A0985|7 15|findings
P01327758A0000|90 100|E1 protein
P01327758A0000|41 46|BPV-1
P01327758A0000|48 51|DNA
P01327758A0000|1 12|Replication
P01326557T0000|21 30|structure
P01326557T0000|34 42|neurocan
P01325386A0766|30 36|defect
P01325386A0766|40 49|synthesis
P01324639T0000|60 71|amoxicillin
P01324639T0000|73 88|amoxicillin-BRL
P01324639T0000|49 56|bacilli
P01324639T0000|1 17|Susceptibilities
P01324404A1208|109 115|region
P01324404A1208|58 64|region
P01324404A1208|141 154|participation
P01324404A1208|119 127|activity
P01324385A0329|28 33|HHV-6
P01324385A0329|114 126|seronegative
P01324385A0329|258 261|age
P01324385A0329|79 97|immunofluorescence
P01324385A0329|196 201|IV-C1
P01324385A0329|35 49|anti-HHV-6-IgG
P01324385A0329|205 208|CDC
P01321337A1161|150 163|growth arrest
P01321337A1161|54 61|mutants
P01321336A0731|72 81|insertion
P01321336A0731|127 138|amino acids
P01321336A0731|103 111|proteins
P01321332A0970|11 30|transfection assays
P01321332A0970|199 201|RA
P01321332A0970|82 85|RXR
P01321332A0970|141 149|promoter
P01321332A0970|101 116|transactivation
P01321332A0970|259 266|amounts
P01321277A0664|106 109|ros
P01321277A0664|7 10|SRC
P01321277A0664|1 4|ROS
P01320640A0336|79 87|glucagon
P01320640A0336|70 77|insulin
P01318739A0410|57 67|teniposide
P01318739A0410|20 40|patients vincristine
P01317376A0981|132 140|increase
P01317376A0981|144 159|frk mRNA levels
P01317376A0981|98 105|glucose
P01316903A0296|30 44|RNA polymerase
P01316903A0296|94 98|form
P01316903A0296|113 116|IIO
P01316680A0643|123 150|consensus zinc finger motif
P01316680A0643|110 115|match
P01316680A0643|20 27|IR5 ORF
P01316680A0643|49 57|sequence
P01316680A0643|152 168|C-X2-4-C-X2-15-C
P01316476A0842|83 94|start sites
P01316459A0311|1 5|Acad
P01316125A0176|123 127|YHPD
P01316125A0176|248 252|BHPD
P01316125A0176|116 119|aid
P01316125A0176|45 48|1O2
P01316125A0176|230 234|YHPD
P01316125A0176|5 15|experiment
P01316125A0176|169 172|1O2
P01314953A1266|72 76|HAP2
P01314953A1266|111 125|hap3 mutations
P01314953A1266|4 12|contrast
P01314457T0000|60 79|herpesvirus saimiri
P01314457T0000|167 172|virus
P01314457T0000|146 149|HVS
P01314457T0000|81 84|HVS
P01314457T0000|101 113|conservation
P01313894A1179|29 36|results
P01313894A1179|94 105|transcripts
P01313894A1179|66 87|LMP2B mRNA expression
P01313894A1179|55 62|respect
P01313715A0461|151 161|cell lines
P01313715A0461|126 130|U937
P01313715A0461|52 63|feasibility
P01313715A0461|87 97|expression
P01313715A0461|228 235|EBV-BCL
P01313715A0461|5 9|goal
P01313715A0461|204 226|B-lymphocyte cell line
P01310935T0000|67 73|enzyme
P01310879A0000|45 61|thrombocytopenia
P01310879A0000|79 96|arteriothromboses
P01310879A0000|114 121|failure
P01310879A0000|152 159|heparin
P01310154A0879|146 155|mutations
P01310154A0879|52 61|mutations
P01310154A0879|216 231|gene regulation
P01310154A0879|86 101|transrepression
P01309894A0807|6 11|Rep78
P01309894A0807|64 68|site
P01309894A0807|16 21|Rep68
P01309815A0972|47 65|signal recognition
P01309815A0972|83 89|arrest
P01309815A0972|152 165|AEP synthesis
P01309593A0095|91 101|regulation
P01309593A0095|24 33|CGCCATTTT
P01304809T0001|14 23|dentistry
P01304809T0001|5 10|years
P01302765A0999|120 122|ad
P01302765A0999|7 17|components
P01302765A0999|36 38|R2
P01300914A1066|301 309|criteria
P01300914A1066|126 133|dangers
P01300914A1066|597 608|sensitivity
P01300914A1066|227 231|ACRV
P01300914A1066|525 542|amplification ECG
P01300914A1066|714 730|RV abnormalities
P01300914A1066|373 375|VT
P01300914A1066|214 223|diagnosis
P01300914A1066|456 467|stimulation
P01300914A1066|562 566|sign
P01300914A1066|262 271|existence
P01300914A1066|622 627|froms
P01300914A1066|77 81|view
P01300914A1066|203 208|walls
P01298398A0461|73 79|change
P01298398A0461|32 45|determination
P01297332T0000|12 20|analysis
P01297332T0000|59 74|gene expression
P01296815A0059|72 89|sequence analysis
P01296815A0059|27 31|gene
P01296815A0059|53 63|LD78 gamma
P01295373A0651|28 36|response
P01295373A0651|148 149|p
P01295373A0651|125 126|%
P01295373A0651|144 145|%
P01295373A0651|5 14|magnitude
P01295373A0651|51 52|%
P01292230A0283|9 14|drugs
P01286732A0572|30 39|elevation
P01286732A0572|108 119|involvement
P01286732A0572|43 50|enzymes
P01286732A0572|159 178|liver cell necrosis
P01286732A0572|84 94|proportion
P01286732A0572|220 241|P. falciparum malaria
P01285554T0000|35 42|systems
P01285009A0000|58 62|gene
P01285009A0000|158 161|vTK
P01285009A0000|248 257|cytoplasm
P01285009A0000|185 189|rCCK
P01285009A0000|164 183|rat cholecystokinin
P01285009A0000|195 213|chicken beta-actin
P01285009A0000|37 51|growth hormone
P01285009A0000|272 283|medaka eggs
P01284595A0102|45 59|identification
P01284595A0102|67 79|Y-231 cosmid
P01284595A0102|5 14|isolation
P01284595A0102|140 146|insert
P01282638A0934|91 103|chemotherapy
P01282638A0934|332 347|life expectancy
P01282638A0934|212 216|life
P01282638A0934|82 87|cycle
P01282638A0934|250 262|continuation
P01282638A0934|226 234|patients
P01282638A0934|108 117|agreement
P01282638A0934|5 21|prophylactic use
P01281771T0000|45 56|cytokeratin
P01281771T0000|1 17|Characterization
P01281322A0604|60 80|percent area density
P01281322A0604|106 120|percent change
P01281322A0604|137 146|flow rate
P01280413T0001|27 33|smears
P01280413T0001|64 78|microorganisms
P01280413T0001|51 60|detection
P01279374A0396|124 134|truncation
P01279374A0396|138 144|PET122
P01279352A0473|148 152|PROX
P01279352A0473|9 17|extracts
P01279352A0473|157 170|PAL sequences
P01279352A0473|71 82|mouse brain
P01279197T0000|12 20|analysis
P01279197T0000|82 85|use
P01279197T0000|34 49|homology region
P01276105A0313|99 109|puerperium
P01276105A0313|18 34|insulin response
P01275335A0158|12 18|agents
P01275335A0158|42 47|semen
P01267446A0210|30 34|acid
P01267446A0210|1 17|Biohydrogenation
P01265443A0159|94 104|inhibition
P01265443A0159|129 143|acid secretion
P01265443A0159|200 206|saline
P01265443A0159|51 72|Heidenhain pouch dogs
P01259027A0416|319 333|design problem
P01259027A0416|183 187|data
P01259027A0416|244 251|concept
P01259027A0416|5 12|concept
P01259027A0416|290 298|approach
P01253191T0000|15 51|phase-plane technique representation
P01253191T0000|3 7|note
P01249198A1097|97 109|GTD patients
P01249198A1097|64 70|ranges
P01247475A0000|121 128|outlook
P01247475A0000|78 84|growth
P01247475A0000|21 35|retinoblastoma
P01245162A0262|14 20|dosage
P01245162A0262|78 82|drug
P01245162A0262|1 10|Reduction
P01243628A0286|57 80|blood carboxyhemoglobin
P01243628A0286|82 86|COHb
P01243628A0286|23 26|end
P01241866A0682|105 112|phase-2
P01241866A0682|8 16|increase
P01241866A0682|20 36|leukocyte-counts
P01241437A0152|74 84|nalorphine
P01241437A0152|98 105|Micoren
P01241437A0152|34 40|groups
P01236224T0001|10 19|pathology
P01228258A0000|15 26|preparation
P01228258A0000|150 154|5-FU
P01228258A0000|63 68|agent
P01228258A0000|110 116|cancer
P01228258A0000|87 95|patients
P01224116A0576|105 112|Barbeau
P01224116A0576|88 93|Russe
P01224116A0576|24 32|patients
P01224116A0576|153 159|family
P01215067A0000|88 101|conductometry
P01215067A0000|79 84|means
P01215067A0000|108 113|cases
P01215067A0000|25 35|resistance
P01215067A0000|173 178|cases
P01209618A0409|15 17|mg
P01209618A0409|46 52|effect
P01209618A0409|130 144|d-tubocurarine
P01209618A0409|93 112|potentiating effect
P01206896T0001|52 74|emergency lung surgery
P01206896T0001|1 16|Characteristics
P01202616A0466|104 118|lamina propria
P01202616A0466|160 166|detail
P01202616A0466|50 56|lining
P01194673A0652|4 12|evidence
P01193458T0001|61 70|detection
P01193458T0001|9 28|isotope cystography
P01191955A0077|45 57|incompetence
P01191955A0077|125 131|reflux
P01191955A0077|80 84|cent
P01190120A0832|96 103|storage
P01190120A0832|87 92|hours
P01185956A0722|39 59|Doppler-cardiography
P01185956A0722|114 127|stroke volume
P01174873T0000|36 43|history
P01174873T0000|48 57|prognosis
P01174873T0000|1 15|Retinoblastoma
P01172734T0035|1 12|Association
P01171020A0711|32 55|nucleus accumbens septi
P01168956A0552|146 169|maximum weight decrease
P01168956A0552|126 129|day
P01168956A0552|52 63|weight gain
P01168956A0552|96 104|placenta
P01168607A0672|13 27|administration
P01168607A0672|148 157|intervals
P01168607A0672|143 144|E
P01158838A0438|75 81|ml/min
P01157614T0000|89 97|children
P01157614T0000|39 62|matrix task performance
P01156814T0000|58 80|thromboembolic disease
P01156814T0000|21 28|heparin
P01150658A0683|75 81|Sairam
P01150658A0683|66 73|hormone
P01147502T0000|32 49|instrument system
P01145884T0028|40 45|study
P01140184A0342|104 105|%
P01140184A0342|127 135|capacity
P01140184A0342|1 17|Liver microsomes
P01138215T0001|26 35|treatment
P01138215T0001|39 48|fractures
P01130531A0224|27 35|cycles/s
P01130531A0224|80 83|CBF
P01130531A0224|1 18|Nerve stimulation
P01130531A0224|137 146|frequency
P01128985A0000|32 38|method
P01128985A0000|119 127|patients
P01124944A0830|19 27|attitude
P01122015A0467|15 16|%
P01122015A0467|52 59|mumol/1
P01122015A0467|66 75|mg/100 ml
P01122015A0467|85 92|mumol/1
P01119586A0337|41 54|tissue levels
P01119586A0337|58 76|creatine phosphate
P01119586A0337|87 94|lactate
P01116466A0185|30 49|thromboplastin time
P01116466A0185|89 104|clot retraction
P01116466A0185|110 126|clotting factors
P01116466A0185|81 87|fibrin
P01116466A0185|1 20|Thromboplastin time
P01113908A0475|74 80|values
P01113908A0475|110 120|experiment
P01113908A0475|20 28|increase
P01103390A0149|45 49|mice
P01103390A0149|124 132|increase
P01103390A0149|140 151|parasitemia
P01103390A0149|84 91|animals
P01099693T0000|25 52|bone marrow transplantation
P01098179A0167|195 203|activity
P01098179A0167|176 183|release
P01098179A0167|86 104|dissolution curves
P01098179A0167|1 8|Results
P01098179A0167|119 125|assays
P01096741X0000|97 112|supplementation
P01096741X0000|35 42|animals
P01093845A0208|150 158|cannabis
P01093845A0208|126 139|modifications
P01093845A0208|174 179|dream
P01093845A0208|87 97|comparison
P01092248T0000|107 116|disorders
P01092248T0000|42 54|pathogenesis
P01088654T0001|53 57|mass
P01088654T0001|1 10|Technique
P01084413A0271|52 55|EMI
P01083375T0000|32 51|childhood cirrhosis
P01082833A0000|46 52|Y-8004
P01082833A0000|131 139|response
P01082833A0000|110 112|IM
P01082833A0000|96 108|indomethacin
P01082833A0000|185 202|carrageenin edema
P01082833A0000|239 248|pleuritis
P01081904A0198|72 94|pull-out arteriography
P01081904A0198|27 35|catheter
P01078982A0227|107 110|ALG
P01078982A0227|167 173|dosage
P01078982A0227|128 146|ALG administration
P01078982A0227|112 121|treatment
P01071715A0903|18 27|technique
P01064124A0560|10 11|d
P01064124A0560|50 56|lesion
P01050400T0000|82 86|ward
P01050400T0000|101 108|infants
P01050400T0000|16 35|nursing instruction
P01048968A0152|7 14|studies
P01048968A0152|86 98|penicillin G
P01048968A0152|35 43|majority
P01047895T0001|76 84|Patients
P01047895T0001|86 95|criticism
P01047895T0001|17 29|patient care
P01044338A0240|10 22|measurements
P01044338A0240|50 59|estimates
P01035457A0623|89 98|treatment
P01035457A0623|56 66|importance
P01027644T0001|12 16|test
P01019207A0232|120 125|range
P01019207A0232|58 68|dependence
P01019207A0232|137 151|mug ruscogenin
P01012640T0001|57 73|pheochromocytoma
P01012640T0001|43 51|patients
P01012640T0001|84 90|Sipple
P01009841T0001|6 17|innervation
P01009841T0001|53 67|lamprey larvae
P01009451A0728|13 21|controls
P01009451A0728|107 119|nocturnality
P01009451A0728|35 43|OCS rats
P01003819A0498|67 78|axis length
P01003819A0498|20 32|nomogram one
P00999494A0000|109 126|agent propranolol
P00999494A0000|23 32|diagnosis
P00999494A0000|71 76|doses
P00996272A0397|75 88|investigation
P00996272A0397|48 59|variability
P00992316A0178|56 66|activities
P00992316A0178|145 154|gravidity
P00988572A0000|211 217|source
P00988572A0000|29 42|lymph vessels
P00988572A0000|146 175|catheter-tip oxygen electrode
P00988572A0000|235 240|lymph
P00988572A0000|118 125|chamber
P00986925A0002|15 25|calcitonin
P00986925A0002|132 140|subjects
P00986925A0002|96 128|plasma 47Ca radioactivity curves
P00986925A0002|157 161|47Ca
P00986925A0002|84 92|glucagon
P00985279A0493|67 68|h
P00985279A0493|18 43|hemoglobin concentrations
P00985279A0493|137 145|decrease
P00985110T0001|126 132|cortex
P00985110T0001|52 59|putamen
P00985110T0001|98 105|regions
P00980255T0000|88 98|blood flow
P00980255T0000|20 44|2-deoxy-D-glucose method
P00975314T0001|9 20|amenorrhoea
P00975314T0001|66 75|karyotype
P00970839A0118|75 80|water
P00970839A0118|109 116|pellets
P00970839A0118|1 14|Rainbow trout
P00970320A0000|75 78|SO2
P00970320A0000|106 116|conditions
P00970320A0000|5 16|performance
P00962277T0000|73 80|priming
P00962277T0000|1 14|Haemodilution
P00961711T0000|27 32|month
P00961711T0000|1 19|Hematology problem
P00958550T0001|46 53|Britain
P00958550T0001|1 7|Crisis
P00956364A0138|66 74|MSB agar
P00956364A0138|1 15|Batch cultures
P00952734T0000|28 34|damage
P00952734T0000|93 103|cutis laxa
P00952734T0000|1 7|Letter
P00947834X0000|1 8|RESULTS
P00941050T0000|15 19|food
P00941050T0000|5 11|effect
P00935526A0000|29 43|prostaglandins
P00935526A0000|108 119|sensitivity
P00935526A0000|189 199|resolution
P00935526A0000|100 104|lack
P00932817A0499|60 79|pinhole collimators
P00932817A0499|147 152|99mTc
P00932817A0499|1 11|Iodine-123
P00931089T0001|13 19|arrest
P00929418T0001|75 84|incidence
P00929418T0001|101 109|diseases
P00927633T0001|31 45|investigations
P00927633T0001|77 82|fiber
P00927633T0001|66 74|Reissner
P00926604A0504|14 21|Inderal
P00926604A0504|79 88|apparatus
P00926604A0504|233 243|myocardium
P00926604A0504|175 180|doses
P00926604A0504|1 12|Propranolol
P00921911A0159|148 153|onset
P00921911A0159|128 130|cm
P00921911A0159|157 163|labour
P00921911A0159|16 19|PGF
P00920381T0000|108 112|rats
P00920381T0000|49 58|injection
P00918556A0000|179 193|liver diseases
P00918556A0000|5 15|prevalence
P00918556A0000|157 165|patients
P00918556A0000|19 46|hepatitis B surface antigen
P00917572T0001|43 52|detection
P00917572T0001|1 12|Possibility
P00915090A0536|13 17|days
P00915090A0536|95 101|number
P00915090A0536|24 33|injection
P00915090A0536|48 54|Tc-99m
P00915090A0536|136 143|control
P00911590T0000|63 91|atropine-neostigmine mixture
P00911590T0000|27 37|antagonism
P00909114A0000|105 109|rats
P00909114A0000|180 188|hamsters
P00909114A0000|92 101|neoplasms
P00909114A0000|197 199|sc
P00909114A0000|235 243|compound
P00909114A0000|1 19|Diallylnitrosamine
P00898500A0246|132 136|test
P00898500A0246|172 193|IgE antibody activity
P00898500A0246|20 30|secretions
P00898500A0246|138 142|RAST
P00891370A0000|134 142|arm vein
P00891370A0000|166 174|patients
P00891370A0000|37 42|limbs
P00891370A0000|17 29|arteriograms
P00885562A0281|94 108|osteoarthrosis
P00885562A0281|7 11|GAGs
P00885562A0281|143 156|GAG synthesis
P00885562A0281|34 50|cartilage matrix
P00879829A0564|46 49|IVH
P00879829A0564|76 90|birth asphyxia
P00879829A0564|34 39|hours
P00877857A0763|70 79|serum FFA
P00877857A0763|1 14|Serum amylase
P00875778T0000|1 11|Evaluation
P00872922A0204|28 38|hydrolysis
P00872922A0204|5 10|acids
P00871237A0601|26 33|patient
P00868903A0000|26 35|treatment
P00868903A0000|81 89|patients
P00866577A0579|180 187|therapy
P00866577A0579|25 47|plasminogen activators
P00866577A0579|156 160|term
P00866577A0579|16 23|heparin
P00863184T0043|28 45|transport maximum
P00863184T0043|1 11|Adaptation
P00851286A0375|90 98|distress
P00851286A0375|73 76|ppm
P00851286A0375|81 86|signs
P00851286A0375|19 24|hours
P00847967T0000|41 51|tomography
P00847967T0000|64 72|medicine
P00843670T0000|5 10|sense
P00842522T0000|21 31|intubation
P00839378A0649|14 20|Viso V
P00839378A0649|28 37|RDS group
P00839378A0649|103 110|disease
P00837811A0675|106 119|abnormalities
P00837811A0675|55 60|signs
P00837811A0675|16 18|MS
P00836637A0000|14 24|experiment
P00836637A0000|130 152|arithmetic performance
P00836637A0000|76 91|music-listening
P00836637A0000|156 168|EMR children
P00832096T0000|47 58|sarcoidosis
P00827364A0000|72 80|material
P00827364A0000|95 101|vacuum
P00827364A0000|84 89|ultra
P00823087A0608|35 43|patients
P00821833A0000|47 57|repertoire
P00821833A0000|25 33|analysis
P00821833A0000|6 12|report
P00818380A0239|150 161|populations
P00818380A0239|93 105|gold therapy
P00818380A0239|35 49|antibody tests
P00808898A0000|91 95|IPRF
P00808898A0000|82 89|failure
P00807356T0001|46 67|hydroxy-9 ellipticine
P00803867A0315|74 80|cancer
P00803867A0315|46 52|groups
P00803867A0315|175 181|months
P00803867A0315|152 159|disease
P00799988A0554|89 99|imipramine
P00799988A0554|8 13|basis
P00799988A0554|136 143|therapy
P00780639X0000|27 30|CEA
P00780639X0000|32 42|procedures
P00775582T0000|26 35|sumithion
P00767155T0001|30 36|Moscow
P00767155T0001|5 13|December
P00762763A0253|13 22|incidence
P00762763A0253|55 61|births
P00759049A0185|22 35|microcuvettes
P00759049A0185|5 16|micromethod
P00756511T0036|14 23|childhood
P00756511T0036|1 10|Dietetics
P00755671A0485|18 25|heparin
P00755671A0485|117 126|hematomas
P00753237A0000|301 311|traumatism
P00753237A0000|124 128|role
P00753237A0000|58 62|ends
P00753237A0000|288 299|body weight
P00753237A0000|45 50|level
P00753237A0000|109 113|PAIN
P00753237A0000|433 444|compression
P00753237A0000|313 320|effects
P00753237A0000|569 572|fig
P00753237A0000|452 456|ends
P00753237A0000|212 223|combination
P00753237A0000|260 261|C
P00753237A0000|564 567|PPU
P00753237A0000|132 141|outsentry
P00753237A0000|78 82|arcs
P00753237A0000|472 476|arcs
P00747722A0486|107 111|drop
P00747722A0486|145 148|sec
P00747722A0486|33 41|reaction
P00747722A0486|86 95|injection
P00743335T0001|59 68|diabetics
P00743335T0001|1 15|Reaction times
P00740409A0000|52 71|cerebellar deposits
P00740409A0000|85 90|Tonge
P00736376A0371|105 114|operation
P00736376A0371|9 14|stage
P00736376A0371|34 43|mortality
P00729003A1182|38 46|splicing
P00726581T0122|1 7|Orthop
P00725534A0888|270 277|leprosy
P00725534A0888|145 154|tolerance
P00725534A0888|65 73|antigens
P00725534A0888|115 125|epithelium
P00725534A0888|35 44|challenge
P00725257A0452|40 41|E
P00725257A0452|16 26|pD2 values
P00722298A0619|122 138|field dependence
P00722298A0619|58 61|men
P00722298A0619|23 31|variance
P00722298A0619|161 164|rho
P00722298A0619|111 117|groups
P00722298A0619|66 71|women
P00722298A0619|206 212|famale
P00715753A0241|125 135|% fraction
P00715753A0241|65 83|total-CPK activity
P00715753A0241|48 51|CPK
P00715753A0241|102 109|muscles
P00713525A0268|26 42|disfluency rates
P00713525A0268|9 18|decreases
P00713525A0268|163 168|model
P00710372A0302|72 80|function
P00710372A0302|95 108|GH deficiency
P00704675A0199|13 16|UO2
P00704675A0199|57 68|bifurcation
P00704675A0199|5 9|mass
P00704675A0199|101 102|d
P00703350A0418|1 14|99mTc phytate
P00703350A0418|35 40|99mTc
P00701462A0722|57 62|cases
P00696858A0000|28 44|porcine secretin
P00696858A0000|5 11|effect
P00696858A0000|137 153|porcine pancreas
P00693987T0001|79 89|intralipid
P00693987T0001|93 96|men
P00693987T0001|33 41|activity
P00693987T0001|1 15|Thromboplastic
P00693987T0001|152 156|life
P00685922A0451|32 42|strictures
P00681571T0028|28 37|epidermis
P00681571T0028|64 88|eccrine sweat duct units
P00676790T0000|1 19|Angiotensin effect
P00669800A0579|65 70|males
P00665336A0908|13 17|time
P00665053A0276|46 51|06a6b
P00665053A0276|58 60|H1
P00665053A0276|81 96|group affection
P00663166A0000|94 106|particulates
P00663166A0000|196 199|PDA
P00663166A0000|156 164|patients
P00663166A0000|170 194|patent ductus arteriosus
P00657551T0000|57 61|26Mg
P00657551T0000|1 12|Measurement
P00646193T0000|31 41|comparison
P00646193T0000|47 56|halothane
P00646193T0000|25 29|dogs
P00644539A0783|134 141|subject
P00644539A0783|40 42|ml
P00644539A0783|24 34|inhalation
P00644539A0783|82 83|%
P00644539A0783|50 56|saline
P00641395A0441|78 89|measurement
P00641395A0441|93 96|ZPP
P00641395A0441|6 19|blood samples
P00641395A0441|175 192|extraction method
P00639410T0000|52 73|lipid clearing agents
P00639410T0000|1 10|Cortisone
P00636526T0033|1 10|Diagnosis
P00635143T0001|11 23|strontium-90
P00635143T0001|1 7|Action
P00630713T0000|1 11|Evaluation
P00627202T0000|27 39|pharmacology
P00627039T0000|30 73|Louisiana paper manufacturing plant workers
P00627039T0000|16 26|bagassosis
P00623361A0221|1 8|Smoking
P00621626T0000|73 77|type
P00621626T0000|19 42|affiliation preferences
P00621626T0000|1 15|Stress effects
P00619782A0058|111 115|UV-A
P00619782A0058|67 75|exposure
P00619782A0058|33 38|backs
P00618078A0367|65 76|improvement
P00618078A0367|19 36|lysozyme activity
P00616575A0000|104 119|decimeter waves
P00616575A0000|166 179|unit activity
P00616575A0000|128 130|DW
P00616575A0000|142 155|investigation
P00606849T0000|23 36|heart disease
P00606849T0000|48 62|thromboxane A2
P00602702A0309|41 62|estriol concentration
P00602702A0309|8 15|patient
P00602702A0309|66 71|serum
P00601401A0181|57 65|affinity
P00601401A0181|70 76|oxygen
P00601401A0181|118 146|delta log Po2/delta pH ratio
P00599601A0260|46 56|procedures
P00599601A0260|78 90|pinealectomy
P00597715A0256|151 157|others
P00597715A0256|97 110|FSH elevation
P00597715A0256|18 21|men
P00597715A0256|185 194|prognosis
P00597715A0256|119 129|experience
P00594466T0001|79 90|combination
P00594466T0001|54 66|allylglycine
P00594466T0001|116 127|stimulation
P00592887T0000|22 40|Patent Blue Violet
P00589073A0000|121 128|control
P00589073A0000|195 202|history
P00589073A0000|55 62|samples
P00589073A0000|19 50|plasma prolactin concentrations
P00589073A0000|153 158|group
P00583522T0001|34 42|problems
P00580151A0706|242 247|doses
P00580151A0706|131 136|range
P00580151A0706|142 153|convenience
P00580151A0706|221 228|effects
P00578648T0048|39 53|administration
P00575231A0422|48 69|detrusor contractions
P00574222T0000|9 17|kindling
P00574222T0000|36 47|development
P00565314A0293|44 45|g
P00564943A0444|45 62|blood cholesterol
P00564943A0444|79 80|T
P00564943A0444|68 74|calves
P00557559A0170|26 31|alpha
P00557559A0170|8 17|compounds
P00557559A0170|172 181|organisms
P00555495T0000|75 84|treatment
P00555495T0000|46 57|termination
P00555495T0000|157 165|delivery
P00555495T0000|1 6|Study
P00553858A0000|134 146|publications
P00553858A0000|160 169|technique
P00553858A0000|76 83|account
P00553858A0000|232 242|principles
P00553858A0000|18 27|operation
P00541752A1032|105 111|values
P00541752A1032|148 152|mean
P00541752A1032|57 63|plasma
P00541752A1032|92 99|October
P00541752A1032|157 159|SD
P00535520A0239|29 35|method
P00528144T0000|45 52|gallium
P00528144T0000|8 12|role
P00528144T0000|35 41|uptake
P00521732T0000|9 18|excretion
P00521732T0000|67 78|pregnancies
P00521732T0000|32 50|oestradiol-17 beta
P00517890A0468|61 72|hepatitis A
P00517890A0468|13 18|route
P00517890A0468|96 123|hepatitis A virus excretion
P00517890A0468|86 92|levels
P00513284A1255|45 61|laboratory tests
P00513284A1255|66 71|liver
P00513284A1255|19 23|days
P00512215A0000|179 181|L2
P00512215A0000|134 139|f2/f1
P00512215A0000|13 18|study
P00512215A0000|130 132|f1
P00512215A0000|96 106|parameters
P00512215A0000|141 143|f2
P00512215A0000|32 42|dependence
P00509703A0581|7 18|differences
P00506559A0000|15 34|inhalation toxicity
P00506559A0000|38 46|furfural
P00499588T0000|33 46|semen profile
P00499588T0000|70 83|sperm studies
P00495097A0663|72 87|fiber synthesis
P00495097A0663|96 102|matrix
P00495097A0663|118 124|tissue
P00493818A0422|41 60|patient intolerance
P00493818A0422|5 13|failures
P00493818A0422|114 118|days
P00488534A0308|27 57|Treatment X Strain interaction
P00488534A0308|80 98|defecation numbers
P00484177A0242|60 70|expiration
P00484177A0242|109 114|range
P00484177A0242|32 52|laminar flow regimen
P00481612A1121|29 38|receptors
P00481612A1121|69 78|ventricle
P00479222A0682|164 168|PECF
P00479222A0682|176 185|degrees C
P00479222A0682|157 162|fluid
P00479222A0682|117 132|immersion times
P00479222A0682|1 11|Resistance
P00477794T0000|96 114|nuclei principalis
P00477794T0000|70 77|neurons
P00477794T0000|119 125|oralis
P00476020T0000|52 58|growth
P00473249T0000|28 42|administration
P00473249T0000|92 99|rabbits
P00473249T0000|68 88|electroencephalogram
P00465829T0000|9 32|Planck analog equations
P00465829T0000|1 7|Nernst
P00465223A0373|10 18|patients
P00465223A0373|113 115|SD
P00465223A0373|117 121|mmHg
P00463973A0000|88 93|women
P00463973A0000|72 81|pregnancy
P00463973A0000|177 184|infants
P00463973A0000|59 68|trimester
P00463973A0000|21 30|life span
P00463973A0000|1 16|Platelet number
P00454780A0340|72 87|titanium alloys
P00454780A0340|97 99|Ta
P00454780A0340|1 20|Ultimate strengthes
P00451192A0248|94 99|curve
P00451192A0248|117 138|LV region-of-interest
P00450559A0269|29 35|report
P00450559A0269|97 105|accuracy
P00450559A0269|114 125|thermometer
P00445720A0263|14 31|pressure gradient
P00445720A0263|109 143|high-fidelity pressure transducers
P00445720A0263|55 64|ventricle
P00445720A0263|87 89|LA
P00439716T0001|22 32|evaluation
P00437749A0242|91 101|physiology
P00437749A0242|9 29|treatment modalities
P00437749A0242|50 57|context
P00432615A0541|194 198|RIST
P00432615A0541|67 89|heterophile antibodies
P00432615A0541|175 190|Sephadex system
P00430889T0001|17 25|fistulas
P00429949A0000|240 249|prolactin
P00429949A0000|226 229|IRP
P00429949A0000|22 47|World Health Organization
P00429949A0000|53 69|Expert Committee
P00429949A0000|254 265|immunoassay
P00429151T0000|72 84|Glasgow area
P00429151T0000|1 5|Year
P00425547A0000|26 39|osteomyelitis
P00425547A0000|131 136|weeks
P00420460A0291|133 135|SQ
P00420460A0291|179 180|P
P00420460A0291|97 103|change
P00420460A0291|4 12|patients
P00417301T0001|13 23|mechanisms
P00417301T0001|50 56|humans
P00416758T0001|54 64|adaptation
P00416758T0001|1 10|Isolation
P00414575T0000|12 22|evaluation
P00409927A0570|76 88|streptococci
P00409927A0570|38 51|staphylococci
P00401676A0414|40 48|patients
P00401676A0414|21 28|staging
P00390932T0001|10 18|antigens
P00385457A0187|11 21|inhibition
P00385457A0187|25 31|pepsin
P00385457A0187|87 96|influence
P00383169A0000|182 187|basis
P00383169A0000|94 105|apomorphine
P00383169A0000|9 16|article
P00383169A0000|114 125|derivatives
P00383169A0000|138 159|rye-ergot derivatives
P00378492A0475|44 52|patients
P00378492A0475|147 171|plasma aldosterone level
P00378492A0475|1 14|Renin studies
P00378492A0475|238 253|artery stenosis
P00369683T0000|13 23|comparison
P00369683T0000|59 67|schedule
P00369683T0000|1 11|Adriamycin
P00361340A0529|135 164|1,25-dihydroxycholecalciferol
P00361340A0529|183 195|significance
P00361340A0529|110 119|condition
P00361340A0529|36 50|osteodystrophy
P00358945A0225|13 19|period
P00358945A0225|84 89|weeks
P00352569A0000|9 22|oxygen supply
P00352569A0000|36 52|blood parameters
P00340692T0033|12 43|John Henri Roosegaarde Bisschop
P00337102T0058|13 19|August
P00336354A0543|29 46|arginine infusion
P00336354A0543|5 13|response
P00331128A0000|75 82|failure
P00331128A0000|6 12|levels
P00321261A0104|121 127|routes
P00321261A0104|160 166|phases
P00321261A0104|25 41|prostaglandin E2
P00321261A0104|184 189|cycle
P00313766A0666|123 124|%
P00313766A0666|126 127|p
P00313766A0666|96 97|%
P00313766A0666|64 74|depression
P00304310A0000|31 36|phase
P00304310A0000|63 74|retinopathy
P00304310A0000|106 112|vision
P00304310A0000|5 14|end-stage
P00303189A0247|149 156|process
P00303189A0247|99 107|efficacy
P00303189A0247|32 37|drugs
P00294502T0001|47 55|division
P00294502T0001|1 10|Diagnosis
P00265964A0562|6 15|mechanism
P00261981A0434|21 40|serum somatomedin A
P00242427T0001|15 21|stress
P00242427T0001|6 11|field
P00239014A0000|30 36|method
P00239014A0000|89 93|CPIB
P00239014A0000|103 115|blood plasma
P00234264A0164|124 135|aminopyrine
P00234264A0164|144 149|weeks
P00234264A0164|1 39|Gamma glutamyl transpeptidase activity
P00232456T0000|41 45|MC29
P00232456T0000|24 37|gene products
P00232456T0000|116 125|carcinoma
P00232456T0000|1 8|Anatomy
P00232456T0000|50 53|MH2
P00231555T0001|92 111|cortisol production
P00231555T0001|1 7|Effect
P00227393T0000|15 50|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|71 108|cytochrome P-450 monooxygenase system
P00224013A0661|456 460|part
P00224013A0661|354 371|extraction ratios
P00224013A0661|115 125|beta-Block
P00224013A0661|258 269|utilization
P00224013A0661|468 482|vasodilatation
P00224013A0661|282 290|delivery
P00224013A0661|402 428|beta-Vasodilator receptors
P00224013A0661|336 340|body
P00224013A0661|200 207|hypoxia
P00224013A0661|140 144|fall
P00224013A0661|304 308|limb
P00222102A0227|181 194|normalisation
P00222102A0227|198 211|serum-calcium
P00222102A0227|1 10|Treatment
P00222102A0227|153 161|response
P00221136A0984|11 21|phenomenon
P00219565A0172|78 82|cent
P00219565A0172|18 37|hepatitis B antigen
P00216939T0001|90 95|brain
P00216939T0001|27 36|intensity
P00216939T0001|54 82|acid dehydrogenase reactions
P00216939T0001|1 7|Effect
P00210220X0000|39 44|drugs
P00205074A0000|9 25|hypophosphatemia
P00199012T0000|9 22|ACTH syndrome
P00196255A0000|134 147|verbalization
P00196255A0000|195 203|salience
P00196255A0000|94 104|hemisphere
P00196255A0000|117 120|ego
P00196255A0000|34 44|categories
P00193088A0196|63 72|responses
P00193088A0196|22 30|subjects
P00183063A0300|210 215|Stage
P00183063A0300|80 88|patinets
P00183063A0300|118 123|Stage
P00183063A0300|44 48|cent
P00183063A0300|128 134|cancer
P00183063A0300|98 102|cent
P00183063A0300|139 147|patients
P00173860A0475|134 143|magnitude
P00173860A0475|31 41|percentage
P00173860A0475|167 178|elimination
P00173860A0475|93 111|excretion patterns
P00168431T0000|43 47|term
P00168431T0000|34 39|fluid
P00167544A0067|11 15|ears
P00167544A0067|32 47|microdissection
P00159600A0871|147 152|shift
P00159600A0871|22 25|SHR
P00159600A0871|99 102|SHR
P00159600A0871|1 3|SV
P00154430A0906|42 54|localization
P00154430A0906|127 135|fragment
P00154430A0906|87 100|transcription
P00150066A0100|62 70|thrombin
P00146327A0147|46 54|cavities
P00146327A0147|77 87|incidences
P00146327A0147|5 13|majority
P00146327A0147|119 126|trachea
P00139827A0000|22 34|pregnenolone
P00139827A0000|156 158|ml
P00139827A0000|50 72|dehydroepiandrosterone
P00139827A0000|198 204|course
P00139827A0000|36 48|progesterone
P00139827A0000|169 175|plasma
P00137671A0896|61 71|VIII-ratio
P00137671A0896|7 19|observations
P00133214T0064|5 13|concepts
P00133214T0064|32 40|function
P00122718A0500|90 94|case
P00122718A0500|5 13|majority
P00122718A0500|102 110|activity
P00117748T0000|44 71|Corynebacterium diphtheriae
P00117748T0000|18 40|clindamycin resistance
P00114144A0189|163 187|glycogen storage disease
P00114144A0189|200 207|disease
P00114144A0189|155 159|Type
P00114144A0189|259 272|enzyme defect
P00114144A0189|137 149|similarities
P00112627A0542|123 128|mg/kg
P00112627A0542|147 152|mg/kg
P00112627A0542|131 142|anileridine
P00112627A0542|155 167|alphaprodine
P00112627A0542|1 14|Pentobarbital
P00112627A0542|103 116|normeperidine
P00105903A0288|78 81|PEG
P00105903A0288|53 72|polyethylene glycol
P00101300A0257|44 46|T1
P00101300A0257|56 58|N0
P00101300A0257|78 86|followup
P00101300A0257|52 54|T3
P00101300A0257|48 50|T2
P00100540T0000|78 88|inhibition
P00100540T0000|32 46|susceptibility
P00100540T0000|50 74|platelet cyclo-oxygenase
P00096241A0087|31 38|courses
P00096241A0087|94 100|values
P00096241A0087|163 166|EGA
P00096241A0087|156 161|weeks
P00096241A0087|139 146|infants
P00092689A0352|45 50|times
P00092689A0352|17 25|patients
P00088391A0181|88 95|antigen
P00088391A0181|78 84|factor
P00084275T0063|1 8|Preface
P00074758T0000|21 35|hypothyroidism
P00072928T0000|19 28|diagnosis
P00072928T0000|1 15|Serum-ferritin
P00064414A1098|1 6|Sings
P00061478T0000|23 38|catheterisation
P00056901A0308|29 30|%
P00056901A0308|20 27|albumin
P00056901A0308|70 78|solution
P00055040A0000|120 130|deposition
P00055040A0000|182 192|FR-antigen
P00055040A0000|23 42|pustulosis palmaris
P00055040A0000|221 225|skin
P00055040A0000|134 144|fibrinogen
P00055040A0000|160 180|degradation products
P00055040A0000|5 17|out-patients
P00052597T0000|12 28|immunoglobulin E
P00052597T0000|59 75|Professor Dan H.
P00052597T0000|34 40|impact
P00048373A0377|93 103|epithelium
P00048373A0377|1 8|Removal
P00039271T0000|14 20|action
P00039271T0000|24 32|diazepam
P00034935A0545|60 69|incidence
P00034935A0545|73 82|psychoses
P00034935A0545|111 112|%
P00030937A0119|7 11|SGOT
P00030937A0119|84 92|subjects
P00029953T0045|20 35|lipase activity
P00027967A0207|150 160|antibodies
P00027967A0207|177 183|levels
P00027967A0207|213 220|illness
P00027967A0207|67 72|onset
P00027967A0207|98 106|patients
P00027967A0207|204 209|onset
P00025557A0100|41 48|animals
P00025557A0100|35 36|%
P00015731A0090|121 130|sulthiame
P00015731A0090|208 216|increase
P00015731A0090|266 271|blood
P00015731A0090|251 253|pH
P00015731A0090|51 71|anhydrase inhibitors
P00015731A0090|13 27|administration
P00015731A0090|32 37|mg/kg
P00015731A0090|239 247|decrease
P00012653T0045|1 5|Beta
P00008997A0472|122 130|controls
P00008997A0472|57 61|data
P00008997A0472|6 9|CSF
P00008997A0472|170 175|slope
P00001606T0076|1 11|Comparison
